<SEC-DOCUMENT>0000950170-23-005118.txt : 20230228
<SEC-HEADER>0000950170-23-005118.hdr.sgml : 20230228
<ACCEPTANCE-DATETIME>20230228162213
ACCESSION NUMBER:		0000950170-23-005118
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		113
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230228
DATE AS OF CHANGE:		20230228

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Vir Biotechnology, Inc.
		CENTRAL INDEX KEY:			0001706431
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				812730369
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39083
		FILM NUMBER:		23685790

	BUSINESS ADDRESS:	
		STREET 1:		499 ILLINOIS STREET
		STREET 2:		SUITE 500
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
		BUSINESS PHONE:		415-906-4324

	MAIL ADDRESS:	
		STREET 1:		499 ILLINOIS STREET
		STREET 2:		SUITE 500
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>vir-20221231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2023-02-28T15:30:33.5717+00:00 --><!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:vir="http://www.vir.bio/20221231" xmlns:srt="http://fasb.org/srt/2022" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_8818a887-324c-4500-a98b-191605dee51d" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_62304650-1cd7-4013-b062-3aa4e9d5ad9f">P3Y</ix:nonNumeric><ix:nonNumeric id="F_eea247aa-b454-4118-bb33-6d0a7452daf1" name="dei:DocumentFiscalPeriodFocus" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68">FY</ix:nonNumeric><ix:nonNumeric id="F_0ef0daab-8a05-4fa7-ae0c-27cd8627c533" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf">http://fasb.org/us-gaap/2022#AccruedLiabilitiesAndOtherLiabilities</ix:nonNumeric><ix:nonFraction id="F_c96f0ebc-77ee-4fcb-8f17-f5159dfe676a" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" contextRef="C_cff30d28-1ec5-4dba-ae19-25ca903d9e22" unitRef="U_pure" decimals="9" scale="0" format="ixt:numdotdecimal">0.222222222</ix:nonFraction><ix:nonFraction id="F_f8694a50-65fb-4c52-8533-1d35751b0dcd" name="us-gaap:CommitmentsAndContingencies" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_63d71f7a-f5e8-43cd-b54e-054d6fece2b0" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" format="ixt:booleantrue">true</ix:nonNumeric><ix:nonNumeric id="F_b8b36721-3cb4-433a-80d0-34cd8d9386fc" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3">http://fasb.org/us-gaap/2022#AccruedLiabilitiesAndOtherLiabilities</ix:nonNumeric><ix:nonNumeric id="F_5e71ec6a-22b0-4059-a89c-67344cbf8a96" name="dei:CurrentFiscalYearEndDate" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68">--12-31</ix:nonNumeric><ix:nonFraction id="F_51add2ca-9313-4a69-901e-884acd814211" name="us-gaap:CommitmentsAndContingencies" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_42ecc27d-dd4e-4bd9-a1b3-ab9d1b0e44c1" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" contextRef="C_d1b3ce8b-0ec8-4d9b-ab94-b0c5e209d62d">P7Y</ix:nonNumeric><ix:nonNumeric id="F_e5972bc8-c341-44f2-a1e7-401190923bbf" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="C_62304650-1cd7-4013-b062-3aa4e9d5ad9f">P7Y</ix:nonNumeric><ix:nonNumeric id="F_6e3bf6bc-7e1c-4d4c-81d7-17386f7ad6b8" name="us-gaap:LesseeOperatingLeaseRenewalTerm" contextRef="C_2cb7e32a-2474-4d3b-85d8-13557d0b4572">P1Y</ix:nonNumeric><ix:nonNumeric id="F_04e7e692-80a4-4a41-b1fc-41a7859e5462" name="dei:AmendmentFlag" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68">false</ix:nonNumeric><ix:nonNumeric id="F_5dac47e7-0c9b-40b2-b070-76af35962042" name="vir:RoyaltiesPaymentRangeOnNetSalesOfLicensedProduct" contextRef="C_8accf173-e6d5-4267-8c30-3f78db2b46fa">mid-single-digits to sub-teen double-digits</ix:nonNumeric><ix:nonNumeric id="F_9eaad379-f48b-4dc1-9088-41247d137fea" name="dei:EntityCentralIndexKey" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68">0001706431</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="vir-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_2af6ea14-ac98-4568-81e0-3bef718e3542"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9a41c817-24ee-4d06-ab61-6c839a61c843"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d3f945e7-1296-4c70-9ecd-08b3a017a4df"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1e2fb995-8c8f-44b9-a52f-67b970d66f9a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_440e7984-bced-4ce9-9125-e4710cb5f43b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:InfluenzaAAndInfluenzaBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:MedImmuneAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:MedImmuneLimitedLiabilityCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_720cbd98-e278-45a4-979c-db878614348b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vir:TwoThousandSixteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-09-01</xbrli:startDate><xbrli:endDate>2016-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ad4974d2-db54-4104-9b56-2ebf05ffda38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cafcd678-0319-424b-834a-70769b2cb74b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:Vir2218Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBioParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">vir:Vir3434Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_57d6ead3-d03e-4250-b98c-0c50109e7cfe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:ContractRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6b24e017-0f8a-429b-817a-9ef0927b8433"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBioParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_896e4988-6bb1-4c02-8cd3-19e59ff58b81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vir:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d876049e-5055-4f47-995e-2fbfc3f91f50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vir:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8ea58521-d0a7-4461-a025-c44f108acb5b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5cf7a8d0-261c-43e4-b66c-26e9b9c2e5b8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5996e992-06fd-457c-9ae0-b6c5639ae79b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:GlaxoSmithKlineTradingServiceLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:AntibodyProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_46218237-5c98-4a62-bcee-3c18140a4029"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandAndTwentyOneGSKAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:ContractRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cff30d28-1ec5-4dba-ae19-25ca903d9e22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-16</xbrli:startDate><xbrli:endDate>2019-09-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f3bae72e-0345-4ef5-af24-752bbadb5f0b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:PreliminaryCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c80ea697-a368-4975-9736-adb7c05cefbd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vir:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_083fe6a6-b404-46c5-8780-c18507a330b4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandAndTwentyOneGSKAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-12</xbrli:startDate><xbrli:endDate>2021-02-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_59d1854c-78da-4bb2-8d89-3e539c321e00"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:SARSCoV2ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ab10cbf0-1e01-4fdf-9b82-e97488c8af01"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8d7f14bb-4690-4c57-9bee-e30534233b77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a0ca781f-26e8-4b49-94e4-3f01a982fe52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3e754139-9f86-457e-a6d3-61f2f6892dbf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBioParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1e3fe30c-1972-4e8c-8649-eeb82a737029"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2ec7ad16-c1b2-49f2-9adb-7d795c32364a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:DevelopmentProgramsExercisedByVirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ef53fffe-7284-4da2-ade0-6081e04aa2dd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e4a53be8-c056-44f1-b563-47390cc21dad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-02-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bdb11187-f9e0-4206-b870-fc0fe6a80046"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a055c3a3-3329-46bd-a235-0271e1908c6b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:SARSCoV2ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bbef5af8-652f-4bae-a181-e9df48dc51ea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1b0ce50f-5b97-4517-8931-808c3219617e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:GlaxoGroupLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b1fed0e5-7cc7-463c-bdd6-e6e1458d55b5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ae08f4b9-a601-42cb-8ece-21e5e2b7b3f0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:GlaxoGroupLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandTwentyOneStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_34578bdd-5e64-44f6-8af5-ed7833cd36ba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:VaccinalAntibodyGrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e5b7cf6a-c235-492c-a434-ae21534824b2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:LetterAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4afe2d0e-b9a0-4c40-9bbf-4330eabe88fe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vir:DevelopedTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ef41dda9-45c7-47f2-94ae-8f41c2af548c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">vir:MeasurementInputProbabilityRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">vir:ClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5d48d11c-c737-4016-a687-853508a51066"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AmendmentNumberOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bc722d93-c8c5-4bb5-99b0-064fd7628401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:PreliminaryCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_87139d89-e3fd-445f-b6c1-4593f57a1d30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vir:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e422f02f-6b34-4d0a-8361-270372955b88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_04175337-eb05-48c1-8aac-bc7c29d50097"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_44ac39fd-62b7-430a-9b57-c2cfeb3f1006"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:RockefellerAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:RockefellerUniversityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_904cd630-0ecd-4275-ad9e-ee81b3b5999d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:LetterAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-09-01</xbrli:startDate><xbrli:endDate>2016-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_946bca5b-a819-49fc-a9eb-3deae58d8824"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ab50ccb4-8ce1-479d-85a9-8614fa9f9f31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c00e1b15-1ac9-46ef-8ed8-c2ca882b705b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">vir:CommercialMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b67fb883-45a1-44e2-8338-3440f618fc44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2aa5b5ab-23ab-4d0b-881f-3bccc42774eb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ef38c128-b6f9-4268-8e29-dbff882abc57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandAndTwentyOneGSKAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_64b0a6fe-b0bf-4dcf-a49e-f88368c52dbd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8accf173-e6d5-4267-8c30-3f78db2b46fa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:InfluenzaAAndInfluenzaBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:MedImmuneAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_95d1c581-2af9-4924-b965-78baf570226f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ef2dbdd6-6a22-4314-8ad2-3d3b510a7b9a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:LetterAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_82509859-a65e-439a-a5e3-9a2599d1d6ef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:LetterAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4adec9d2-4308-425f-a580-f05b8bbce014"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6e1a4a6c-604a-4324-a4ca-eb6aff2132cb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialSupportToNonconsolidatedLegalEntityAxis">vir:SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-30</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_94806f35-4a90-434e-acce-cb420888cb77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_87f06556-ced9-44e3-ae60-d194dd7923ff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:HepatitisBVirusProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0640f8ac-c552-4f54-8a09-1b99e32573ac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:VaccinalAntibodyGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1364cd0a-2ace-4aed-b2bb-6a20b02ffe7e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_99fe8501-acd9-4f49-adf9-24150da9294f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vir:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2ecba0e0-1f16-471e-a9c9-563bd3c3a21a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:ContractRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_db0c1ec0-28ae-4df5-8ac3-748f417365f4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e170955d-d5d7-40a0-b36e-ac2e1046968a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:VaccinalAntibodyGrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_181582de-b0b6-4d34-a602-8545a05e16ac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:LetterAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e81fb921-41bb-4624-975a-443a7c7cdf16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f22a75a3-1d5c-4569-b00b-c460e4c440a5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">vir:ClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_363509bf-b0e5-4bc4-a76d-8682508915cc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:DevelopmentProgramsExercisedByBriiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d1b3ce8b-0ec8-4d9b-ab94-b0c5e209d62d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_402569c9-a676-4ead-a6ec-b7f313ab6266"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9390c172-8de0-44cd-beb2-d80a53d6291b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:EachInfectiousDiseaseSiRNAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_20115010-b125-459b-ab42-c3f84a9a5259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:RockefellerAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:InfectiousDiseaseProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:RockefellerUniversityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b8ad5282-2271-4d16-8946-c9bc284a5384"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_90313909-a6bc-4583-86a7-47d337dd4cb1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:InfluenzaAAndHBVResearchProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:XencorIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandNineteenXencorAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ecd49638-d3b0-4e7d-9c09-1defc1de59fc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:PreliminaryCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0c441e33-191d-47b1-a7d6-6ce061bb3ae1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandTwentyXencorAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:XencorIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5ee09e36-b7d5-4bd7-a7a8-de86d1ea831c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_76ae8c43-fd41-420f-aeae-ad3941b0fec6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_80319ba1-d62f-4b44-b5e2-f5e9eb0ceb54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7c11953b-e6ce-4d9b-8cf9-80604a06d01a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-01</xbrli:startDate><xbrli:endDate>2022-09-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3906357f-ca70-49f3-97fc-ebdecba43cf9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:GlaxoGroupLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-23</xbrli:startDate><xbrli:endDate>2021-03-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1a446893-56a8-4407-9044-e0e0fd59cfee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">vir:MeasurementInputExpectedVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cf8b6b9e-762d-454d-adc8-ca7fb3750e7b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c5248545-d73b-4cb5-a202-3d3703194709"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandAndTwentyOneGSKAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0e941a4e-4958-42af-89e7-b694adf192d4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBioParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b3553947-036a-44ba-af30-42a5788b9180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d81100b1-9c19-43b5-a076-b271e6dffdee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">vir:BriiBioParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cce2c08e-9755-4a1d-ac18-7f295a943893"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_053e3050-3042-4c21-b384-4dbc933b1860"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">vir:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_017385f6-1d68-484c-9c95-8c9c74dccda7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_70c61983-c30b-4442-b262-ed8ba12eed88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:GlaxoGroupLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandTwentyOneStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-14</xbrli:startDate><xbrli:endDate>2021-02-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e4ef837c-de22-4e63-b673-9b05c1a2fa71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:GlaxoGroupLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d7a958db-9d20-44ef-a677-68d2c31b101f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a34f69de-db65-4bed-a804-9fff69f8bba0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:AntibodyProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2d2b4307-0211-44cc-a6ea-58f34976c023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_81d21c4d-29ea-4221-9ced-d1956f3f0671"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_decb4aa5-5378-4f20-b098-06e2d05697eb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:PreliminaryCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f8f016eb-9b56-4d62-8dd6-7ea4594702e3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vir:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ffa6727e-7fad-43e1-84bd-2106591a8a4a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">vir:MeasurementInputProbabilityRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">vir:CommercialMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f1574fdc-3dbc-4686-99a7-37e3229c36eb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ca5589eb-ea15-4baa-83f9-5cfcb0672b1d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a4c83d47-f369-4173-b21b-90aff8652ace"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:LetterAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e4ea1ea2-14fb-4c40-b6b7-6c502c2c3167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_85d8bb4b-5225-414c-87d0-df7003801fcd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">vir:ContingentConsiderationLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7619716a-9e49-48b5-abed-ff43a16e8263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c81037e3-36e7-429d-8e76-acaab8a63eee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fa700c83-f248-4007-a04a-6e5b18f6eef8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">vir:ContingentConsiderationLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">vir:LetterAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8ca9f390-7fbb-41d3-a8cc-0dc299a46f0e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vir:ClinicalDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-09-01</xbrli:startDate><xbrli:endDate>2016-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0df2a759-92c0-474a-a802-8afc81cf6ad0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_268c2c6c-2e46-49ef-8b34-85c3eb6476c2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2cb7e32a-2474-4d3b-85d8-13557d0b4572"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ffc264f2-dd56-4ceb-b96e-fbf5c3db3606"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6ff10353-fa1d-4c3b-ac8e-ff5c4ae62117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandAndTwentyOneGSKAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:GlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0dde6c02-78fb-47ad-a243-45289278021b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vir:FollowOnOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0fd0f713-f953-4286-a81c-0606471c2227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:DevelopmentProgramsExercisedByBriiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_41c05a89-da87-4a31-a87a-9e37c464d328"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:PreliminaryCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-29</xbrli:startDate><xbrli:endDate>2020-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d76d05eb-1a75-4e9c-ae43-cb41d047d900"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7b6a9230-282e-4c93-9f43-93b0661820c0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_774f1d32-810d-4510-b5e3-aaafabf8e63c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a3f62ca6-5d34-48b4-8e19-7e9bd3f388e8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_89ca23f5-e12c-4dba-be08-03251a397eda"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">vir:MeasurementInputProbabilityRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">vir:ClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4e62b6c4-3cd3-449d-8c77-954fc619391a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBioParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">vir:Vir3434Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1c1249b0-5ad3-449c-a242-9282e54fdb6f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4be62c4c-687d-4539-b972-f167d33aa2d8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_12eb10d1-8cbc-4e43-9179-de76706ed182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b7110cbe-39a4-4c4a-904d-1a47b20ffc0f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:Vir2218Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBioParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2b3229e8-bd98-49b7-9746-e7ce783e8031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">vir:MeasurementInputExpectedRevenueVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">vir:CommercialMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c98c2bac-151f-4ae1-99e5-12401ef3eb67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:ContractRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c8ff574f-fed5-42aa-939d-486187b621e5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_43f8e518-6996-4956-b1a9-bf1a73666d0b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fa73886f-e92f-4966-af95-e6e76cd8ccc3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:XencorIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandNineteenAndTwoThousandTwentyXencorAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0ab585f4-7932-4fcf-9d20-a8bc39178ab4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b432db30-4d2c-4ea5-b2ca-fe2523b09386"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ea8871a7-9d90-4943-89b3-944727e32088"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">vir:ClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_39cb96e3-900d-40c8-b3e6-6c07096acd7e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_94daadad-3dc0-454a-8e31-99a471e99b3d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d45858f9-5f23-4ea3-a7e2-ddac9afb63ae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vir:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0d93da71-2399-418f-85e8-9b6b02f4b192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:PreliminaryCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:AntibodyProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-29</xbrli:startDate><xbrli:endDate>2020-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0ab96725-0d67-4b9b-8abe-9354e48096b0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eeb8aa97-5f2d-4952-8244-3a5e12f77095"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8919d223-48db-4e72-8f84-bb9a105b4296"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:Vir2218Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBioParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4e221e13-8b5d-42ea-833d-86521dba2dea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d39ab2c8-69ae-4434-87f5-e53d359487e4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:SwissFederalTaxAdministrationFTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_03609c47-c098-4a60-97bd-053e2bf319bf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:RockefellerAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:RockefellerUniversityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:FirstInfectiousDiseaseProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2a70a582-48c1-408b-b426-be7b95e3333e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c7b72547-d6ee-4bc9-986d-72368f004917"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ce64793d-668a-40e8-af07-6ebdbdd93828"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bd901335-c247-4a9a-ba1a-0d36065664ba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b553a367-b665-4001-8f33-c723ff21ad71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:HBVProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:XencorIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandNineteenXencorAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a88db863-7765-4796-a308-9513b1e29b15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:FirstSiRNAProductHBVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_62304650-1cd7-4013-b062-3aa4e9d5ad9f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0d8c8a20-2403-4408-9856-613c5c82c189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">vir:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_112ed8a7-7988-46af-99b9-84ca6fe5334e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2f1d51a5-d28e-426b-b4cb-bbde0b7f3943"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-09-01</xbrli:startDate><xbrli:endDate>2016-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_75214fe5-9907-465b-9eda-dcd555754a33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:PreliminaryCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:VaccineProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-29</xbrli:startDate><xbrli:endDate>2020-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bf980098-c647-4144-87a4-a5feba093982"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a17e8413-fa17-4363-9bcc-2c63c792146e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">vir:ContingentConsiderationLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_474023a2-9be4-4db1-9135-5888440e1408"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ab38e818-8e19-4d32-855b-4a5d8c7332dc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f315ae4d-c3f9-4374-877b-5e513e6b3e19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">vir:ClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7c77693b-4357-4bb2-a8c3-270864bc9cad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandTwentyStockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-29</xbrli:startDate><xbrli:endDate>2020-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_60880c52-6f5a-486b-a848-501a5bacdd60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:AnotherProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_df66ba80-8dcb-4c94-abeb-511320bb1f34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_11d4ba09-a5bc-40ed-9952-89cf471e26ef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e08e7ea4-933b-4008-9b16-a6e809956279"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBioParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_65402f98-6f66-411f-989c-de9e545eb48a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-10-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ad4141b8-b5e4-429b-9b52-dd67e708016e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_edd96045-6b9c-4a57-a99c-8b916e5ab8d8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_29901d1b-12a7-4289-b365-64d76b343767"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b5817a9b-c37f-413a-ab0c-c78fc5c64179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:DevelopmentProgramsExercisedByBriiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBiosciencesOffshoreLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">vir:Vir3434Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_aa13a910-3dc3-4d53-a119-271c45df3af6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c5b01808-0860-4e26-906c-c9aecfd158e9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_63454d26-78fb-4850-a047-cf04ffc3c617"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ce26a70b-eafc-47b8-8306-b96c9e3a25d4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0365acdf-5aea-4a92-8f52-bcf73ab2f285"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:NationalInstitutesOfHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_35e38548-67c8-4cef-8f37-1a11a25cc2ea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_61fecc05-bbcc-451c-ad8a-57bf80b34de9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBioParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8159e296-cbd0-46c5-bb89-4442f5253f01"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2da3af76-3a2c-4087-bd64-efb611a69cc8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:DevelopmentProgramsExercisedByBriiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">vir:Vir3434Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c8f5798c-ad39-4045-8160-7af430bcb734"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:RockefellerAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:RockefellerUniversityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_00a912ce-4cfe-416b-b075-dffc321d18b6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_48f14b99-b9bb-45aa-acd6-6b16710aedb4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_27c0e6df-cfdf-4bca-b0d3-1b934d52a189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandAndTwentyOneGSKCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-12</xbrli:startDate><xbrli:endDate>2021-02-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dd2fc99d-7a9d-45e3-995a-8f33afb52a81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:HepatitisBVirusProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6cddb4e4-b247-4253-a284-b9685fd836de"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_11e2fb59-6582-4888-956d-443f42d7adbb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_da5feba6-e631-4bec-b33d-106ac3401870"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e28b382b-9754-42d1-868b-c2ea43f958c4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBioParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_236e9ea2-3639-4c4a-84d1-b0cbf28005ee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fb57c6da-b1f8-44af-a1d9-109cfe493bad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:DevelopmentProgramsExercisedByVirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-31</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a1ff86c5-33e9-4326-b1f2-a4f7b5d2c716"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:RockefellerAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:RockefellerUniversityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_faecd853-fee9-460a-9e6f-a4fc83b058a2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">vir:BriiBioParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ca130bf4-8380-4419-9f23-7747d3b7b6f9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6ea95d1d-1302-408e-b108-02685b997985"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-31</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a7262ac3-ad3a-4279-afb3-5136951286cf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_742108ce-79d0-443e-97ab-ce1b47aab7fb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_724a4a6c-eb88-43e1-9385-7a1ee1d59450"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:DevelopmentProgramsExercisedByVirMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ae72cfe1-e779-40b7-9892-e8d69ca5e6f9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d43fd0d1-a39e-4f48-bbed-09680ca7f602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_77979cee-0206-4722-a78e-8d7e1abeb723"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vir:FollowOnOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_91be3be0-e317-45a0-837e-46e0bcedc91e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_48f1b79a-a22f-4fe8-acd8-aae6fb94bd78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandTwentyStockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ecf4fb53-9e9a-460b-b2c7-36c48bc67120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">vir:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e70b1c74-320f-4d6a-81ff-72022442374d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">vir:MeasurementInputProbabilityRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">vir:ClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_de66dc29-7c5c-4788-af3e-b26710f8cb06"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AmendmentNumberOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5ff17edc-f10a-4706-a1cd-672e160dd990"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:GlaxoGroupLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-29</xbrli:startDate><xbrli:endDate>2020-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8354e95f-a997-4559-8f00-06918b2494db"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBiosciencesOffshoreLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b70442f4-3b9a-4721-b156-3f58ba42d7b0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBiosciencesOffshoreLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-31</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bcee63ec-ae69-4678-8b04-d29b3bc1370e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_10a388d6-6193-4e20-a608-d5203976d818"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b69ec4f4-b531-408c-b82a-92c8c2b9bcd4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:PreliminaryCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8e5b8d02-9b16-4b28-a5ac-d7b44ab9cd92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:VaccinalAntibodyGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-13</xbrli:startDate><xbrli:endDate>2022-01-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7c1b6e30-61ef-41a5-af65-74e946d04165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f9212404-81f7-4d0b-9f10-42f60cf103ef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vir:TwoThousandSixteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-09-01</xbrli:startDate><xbrli:endDate>2016-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6276028a-2d2e-482b-9ea8-a6448755d571"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ba34aded-037c-492e-95bf-8e2aee84865a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vir:DevelopedTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7b5b92b7-ec6c-4504-ad39-91288ac75cc0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vir:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_15a1a88f-77e5-43b6-91c1-62f17e7d6662"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ed2fc9b2-d46f-45fd-a059-f990d15eff81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a1e68275-f02d-43b0-8ccb-7c3d41000c0e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandAndTwentyGskAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bc63cc0a-80f2-4f25-8b71-3402b70afd98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandAndTwentyOneGSKCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-14</xbrli:startDate><xbrli:endDate>2021-02-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d31deef3-bfd7-4c38-8080-cbcd2d6f202c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:VaccinalAntibodyGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_48a91d5d-ea5c-4037-9225-755e30bfc6c5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandAndTwentyOneGSKAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:GlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e43e7416-30c1-47c2-8d8f-9a8fa8761fb6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_679bc2b6-7333-4652-aa5e-56403fa75188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:MedImmuneAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:MedImmuneLimitedLiabilityCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_09ba265a-6add-41f5-ae26-e28684a4a700"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:HepatitisBVirusProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_70da0710-1b2a-4c11-a63e-24ea296a4134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9238efac-e9f0-40db-8b4d-0bd6b667bce1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:FirstSiRNAProductHBVMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-31</xbrli:startDate><xbrli:endDate>2017-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f3c34215-8edc-4dd4-865f-ab771871ad3a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8616915b-46bc-4304-92c6-102f09231afc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vir:DevelopedTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e3df795a-3a56-41f0-b360-db9fa10cdc01"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandAndTwentyOneGSKAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-14</xbrli:startDate><xbrli:endDate>2021-02-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d6d82c19-9cbe-4f4b-b35e-d5f66e5d7598"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:InfluenzaAResearchProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:XencorIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandNineteenXencorAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_72d128cd-9dc7-4ded-bfa1-21c90dee3725"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vir:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_000e7047-27c6-405d-911b-7387dc00e8cb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:DevelopmentProgramsExercisedByBriiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_60fd6477-1423-4941-969e-7c5f8ad2c846"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:PreliminaryCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:AntibodyProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d4f38c3d-eb5d-48e7-8694-cfdc645585c7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:RockefellerAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:RockefellerUniversityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dad50c1a-a985-4cd9-83d5-54c441a295ba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">vir:CommercialMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7ca9fa0c-6fce-40ab-ad6a-72ab66e31dc8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:DevelopmentProgramsExercisedByBriiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4c048e8b-01e1-4aa6-a204-9ba59db26a4f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9dc90b6a-ec9c-43c8-abc2-fcbab105e2d2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ff18ae7e-33f9-49e0-b7ad-17646042d12e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_713f0ffb-32b7-4557-8121-be8edd691f8d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">vir:ClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_423db569-199e-451c-b19e-22f96e558a53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandTwentyXencorAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:XencorIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_db717f4e-f800-427d-a092-ed5b2685c250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBioParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">vir:Vir3434Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8338caa5-3a09-4312-9d81-25f2cf6a95d0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:VaccinalAntibodyGrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7bfa1f77-0aad-47a7-9222-be7a47061336"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:VaccinalAntibodyGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_981e1dc9-76fd-4fe4-a6ef-def1bcdbc1e7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">vir:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1c2df6fc-28b4-42ab-92ca-e8e7604a433d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:DevelopmentProgramsExercisedByBriiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBiosciencesOffshoreLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">vir:Vir3434Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c23e0019-4bdf-4a39-9f66-f78f5b7cf6ba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fec42e81-f129-4752-ad8b-0294488d4ba3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vir:FollowOnOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_24ffc582-325f-493e-a4b4-111a43d7f9d9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_53c3499f-95d7-41ad-aa6a-553955ca0961"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:HumanImmunodeficiencyVirusGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1ff854d5-f188-44b8-94e4-70a3c2f65c1a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialSupportToNonconsolidatedLegalEntityAxis">vir:SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b6e56cad-2ca6-48f8-b21a-16161998bf9e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cbf68543-981c-4f0c-a438-703247341f08"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6046760e-44a7-4084-a7d2-ce57ecf671fd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">vir:ContingentConsiderationLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_226affc5-a26a-4685-b939-df0a4de23d15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_029580f2-ed42-4e2c-a78b-e3a8e585aaa6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c9e8dc36-972e-4533-bbcc-9f347a84b7dc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0b6e95b2-e943-40ea-ba4d-dbf4d337d81a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vir:FollowOnOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-10</xbrli:startDate><xbrli:endDate>2020-07-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b6ba7de2-aef8-4b9a-a988-45dae6fa27d5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:PreliminaryCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-12</xbrli:startDate><xbrli:endDate>2021-02-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_07f1d79c-70ab-4760-854b-ccf98c1deed1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:PreliminaryCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2a4a265d-bb0f-4164-81c2-3cfe9f2c5fed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">vir:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8472ca01-d418-45f2-8494-45e935bbbc83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBioParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dbd52408-3a79-4789-b6f2-0d8c54a59ebf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_03bf1b7d-b075-4a4b-80d2-af36c3cd0aac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d8fb65c9-343c-4c85-898f-95ed557e0d7f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U_Segment"><xbrli:measure>vir:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_Antibodies"><xbrli:measure>vir:Antibodies</xbrli:measure></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_Unit"><xbrli:measure>vir:Unit</xbrli:measure></xbrli:unit><xbrli:unit id="U_sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_Milestone"><xbrli:measure>vir:Milestone</xbrli:measure></xbrli:unit><xbrli:unit id="U_Program"><xbrli:measure>vir:Program</xbrli:measure></xbrli:unit><xbrli:unit id="U_Product"><xbrli:measure>vir:Product</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="U_USDollarShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_e1b04269-f99c-420d-9953-f9f240029909" fromRefs="F_f2ee8c17-9247-4204-9405-460cc56f15e9 F_36b8b5e2-054e-47cc-b86d-523e8cbc6e77 F_95c3d196-361b-4bb9-bbfc-19a0145e77ff F_e67a3f38-3954-40a0-a395-2d43a7a52199"></ix:relationship><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_0c55a751-de0a-4516-8374-b7d3de9b6dd1" fromRefs="F_549f2f58-0809-43a7-af9f-aa62d6cab632 F_e42ea656-1acd-403e-8417-882547909ce9 F_c5e69a23-b98a-4558-b375-80f9e0916679 F_69ac5583-03ad-40a0-a1ae-3d91bf3c9102"></ix:relationship><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_309d5bc3-a5ff-45a0-b9dd-16d51cf30514" fromRefs="F_94b5821e-c6b0-49b4-bd92-b25178e3d93a F_de81d354-d0b9-4919-aaaf-c3852c79312a F_6ed74193-b982-4779-9300-7e451bc0ef5b F_badce134-8528-4753-8a8b-28ca3cf397fa F_faed9603-c7e8-4971-b88c-45fb1a1abd5f F_24f706d2-1a5c-4606-a102-532a52e31e5b"></ix:relationship></ix:resources></ix:header></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:2.25pt double;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:15.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">UNITED STATES</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:15.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:15.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:15.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Washington, D.C. 20549</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:15.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FORM </span><span style="font-size:15.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a21f9a7c-ad25-4580-a62e-4e6440eab0ac" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="dei:DocumentType"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:15.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-K</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:15.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Mark One)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.0%;"></td>
    <td style="width:96.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_9282cd3d-90a5-4cb7-8737-7ed5a064fdb1" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the fiscal year ended </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ddb4a7cf-6a25-4712-ba3b-3ef8fb4da70b" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1da58fb7-dec0-4701-a083-521d80f3cc0d" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="dei:DocumentFiscalYearFocus"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></ix:nonNumeric></span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">OR</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.0%;"></td>
    <td style="width:96.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_244ebe93-1ccd-4de6-a1b8-8eabaf9ab0b8" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM                      TO</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">                     </span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commission File Number </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_139367c2-b8ea-4057-9b6c-4e9f24c2f926" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="dei:EntityFileNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1-39083</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:22.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f90ebe43-74a2-4869-8805-3e2f75c33efe" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="dei:EntityRegistrantName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:22.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vir Biotechnology, Inc.</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exact Name of Registrant as Specified in its Charter)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:50.0%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6aefd8cf-5a82-458d-9e76-fa492aba12a6" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_55efb6d6-5653-4d2b-98a9-75a58c6b105a" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="dei:EntityTaxIdentificationNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81-2730369</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(State or Other Jurisdiction of</span></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Incorporation or Organization)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(I.R.S. Employer</span></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Identification No.)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:50.0%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7148a00b-277b-4055-ad15-0c92597a03ac" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="dei:EntityAddressAddressLine1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">499 Illinois Street</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7a923ca4-bcbd-4751-8616-65189f530dfa" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="dei:EntityAddressAddressLine2"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Suite 500</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0113242a-1e86-47be-9c1b-d18348650608" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="dei:EntityAddressCityOrTown"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">San Francisco</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0b9d268e-96ce-4f37-becf-c3f34825bf28" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">California</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b4b107cb-7d09-46d7-bd20-f00cf14d6174" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="dei:EntityAddressPostalZipCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">94158</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Address of Principal Executive Offices)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Registrant&#x2019;s telephone number, including area code: (</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_bd3dcbce-dd56-47c9-8516-9fd83894c6fd" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="dei:CityAreaCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">415</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">) </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6c0e95de-d6df-42f9-b93f-d927f9c15cfd" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="dei:LocalPhoneNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">906-4324</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:38.0%;"></td>
    <td style="width:2.0%;"></td>
    <td style="width:20.0%;"></td>
    <td style="width:2.0%;"></td>
    <td style="width:38.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title of each class</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Trading</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Symbol(s)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8876844d-142d-4972-912a-66fda807ef4d" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="dei:Security12bTitle"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common Stock,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$0.0001 par value</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_538b224e-739f-4ddf-b8ee-06dcab846201" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="dei:TradingSymbol"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VIR</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e4936080-cedb-45a2-9eab-4e4a84ca6c06" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nasdaq Global Select Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securities registered pursuant to Section 12(g) of the Act: None</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_985cb338-78bd-4885-a47c-fb83f8419168" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="dei:EntityWellKnownSeasonedIssuer"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9746; No &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.  Yes &#9744; </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_889964e7-d926-4381-bcca-0f0b6a5b6e7c" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="dei:EntityVoluntaryFilers"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9746;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_380925e8-8840-4981-ac42-b4bfa76e03ee" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="dei:EntityCurrentReportingStatus"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9746; No &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).  </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4123865b-0439-4cfd-9421-090640af4ded" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="dei:EntityInteractiveDataCurrent"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#9746; No &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#x201c;large accelerated filer,&#x201d; &#x201c;accelerated filer,&#x201d; &#x201c;smaller reporting company,&#x201d; and &#x201c;emerging growth company&#x201d; in Rule 12b-2 of the Exchange Act.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:19.843%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:54.157%;"></td>
    <td style="width:1.12%;"></td>
    <td style="width:20.741%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:2.139%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c2bed82d-547e-4849-ad30-4b35ea5c2cf5" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Large accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Smaller reporting company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f05a8333-3a09-4c38-abc6-e765f29e5f93" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:3.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Emerging growth company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_195fe85f-76fa-4880-b515-4fe2ced288e4" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the Registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_24526c9a-2d80-4e61-9470-8d8b6959d738" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#x2019;s executive o&#xfb03;cers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0c073963-0090-4dc2-a51b-33effc055572" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> No &#9746;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The aggregate market value of the voting and non-voting common equity held by non-affiliates of the Registrant as of June 30, 2022 was approximately $</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b2864618-fbeb-4d72-80a0-6a565f38e2ae" contextRef="C_d76d05eb-1a75-4e9c-ae43-cb41d047d900" name="dei:EntityPublicFloat" unitRef="U_USD" scale="9" decimals="-8" format="ixt:numdotdecimal">2.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> billion based upon the closing price of its Common Stock on June 30, 2022 of $25.47 per share, as reported by The Nasdaq Global Select Market.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The number of shares of the Registrant&#x2019;s Common Stock outstanding as of February 21, 2023 was </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_11e222ae-e23f-425d-b35a-02450de139b2" contextRef="C_e4a53be8-c056-44f1-b563-47390cc21dad" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">133,531,379</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p>
  <div><ix:nonNumeric id="F_8f50f807-0df0-40c4-b4d3-f7b8bbb9019c" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Portions of the definitive proxy statement, or the Proxy Statement, for the Registrant&#x2019;s 2023 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K. The Proxy Statement will be filed with the Securities and Exchange Commission within 120 days of the Registrant&#x2019;s fiscal year ended December 31, 2022.</span></p></ix:nonNumeric></div>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:95.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:29.571%;"></td>
    <td style="width:35.215%;"></td>
    <td style="width:35.215%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Auditor PCAOB ID: </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3a4f8955-5e1e-4d86-9512-33e79684a6c1" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="dei:AuditorFirmId"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Auditor: </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_923f5d39-72be-4646-9654-01217fd1c50f" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="dei:AuditorName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Ernst &amp; Young LLP</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Address: </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ee30432e-3009-44e8-a182-c15fc70204bc" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="dei:AuditorLocation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">San Mateo, California</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:2.25pt double;text-align:center;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Table of Contents</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10.0%;"></td>
    <td style="width:84.398%;"></td>
    <td style="width:5.602%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART I</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1_business"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Business</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1a_risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">76</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1B.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1b_unresolved_staff_comments"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">120</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 2.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_2_properties"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Properties</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">121</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 3.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_3_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">121</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 4.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">121</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_ii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART II</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 5.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_5_market_for_registrants_common_equ"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Market for Registrant&#x2019;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">122</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 6.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#reserved"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[Reserved]</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">123</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7_managements_discussion_analysis_f"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">124</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7a_quantitative_qualitative_disclos"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">137</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 8.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_8_financial_statements"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">138</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9_changes_in_disagreements_with_acc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">181</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9a_controls_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">181</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9B.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9b_or_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other Information</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">183</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9C.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9c_disc_re_foreign_jurisdiction"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disclosure Regarding Foreign Jurisdiction that Prevent Inspections</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">183</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_iii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART III</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 10.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_10_directors_executive_ficers_corpo"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">184</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 11.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_11_executive_compensation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Executive Compensation</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">184</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 12.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_12_security_ownership_certain_benef"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">184</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 13.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_13_certain_relationships_related_tr"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">184</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 14.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_14_principal_accounting_fees_servic"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Principal Accounting Fees and Services</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">184</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_iv"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART IV</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 15.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_15_exhibits_financial_statement_sch"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibits, Financial Statement Schedules</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">185</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 16</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_16_form_10k_summary"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form 10-K Summary</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">191</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">i</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Annual Report on Form 10-K contains forward-looking statements about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this Annual Report on Form 10-K, including statements regarding our strategy, future financial condition, future operations, research and development, potential of, and expectations for, our pipeline, planned clinical trials and preclinical studies, technology platforms, the timing and likelihood of regulatory filings and approvals for our product candidates, our ability to commercialize our product candidates, the potential benefits of collaborations, projected costs, prospects, plans, objectives of management, expected market growth, the timing of availability of clinical data, program updates and data disclosures, the ability of sotrovimab to treat and/or prevent COVID-19, our plans for sotrovimab, and our plans for our hepatitis B virus, hepatitis D virus, influenza, COVID-19 and human immunodeficiency virus portfolios, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#x201c;aim,&#x201d; &#x201c;anticipate,&#x201d; &#x201c;assume,&#x201d; &#x201c;believe,&#x201d; &#x201c;contemplate,&#x201d; &#x201c;continue,&#x201d; &#x201c;could,&#x201d; &#x201c;design,&#x201d; &#x201c;due,&#x201d; &#x201c;estimate,&#x201d; &#x201c;expect,&#x201d; &#x201c;goal,&#x201d; &#x201c;intend,&#x201d; &#x201c;may,&#x201d; &#x201c;objective,&#x201d; &#x201c;plan,&#x201d; &#x201c;positioned,&#x201d; &#x201c;potential,&#x201d; &#x201c;predict,&#x201d; &#x201c;seek,&#x201d; &#x201c;should,&#x201d; &#x201c;target,&#x201d; &#x201c;will,&#x201d; &#x201c;would&#x201d; and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements are subject to a number of known and unknown risks, uncertainties and assumptions described in the sections titled &#x201c;Risk Factors&#x201d; and &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations&#x201d; and elsewhere in this report. Other sections of this report may include additional factors that could harm our business and financial performance. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements, or the scientific data presented. Moreover, we operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time, and it is not possible for our management to predict all risk factors nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in, or implied by, any forward-looking statements.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. Although we believe that we have a reasonable basis for each forward-looking statement contained in this report, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur at all. You should refer to the section titled &#x201c;Risk Factors&#x201d; for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Annual Report on Form 10-K includes statistical and other industry and market data that we obtained from industry publications and research, surveys, and studies conducted by third parties as well as our own estimates of potential market opportunities. All of the market data used in this Annual Report on Form 10-K involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such data. Industry publications and third-party research, surveys, and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. Our estimates of the potential market opportunities for our product candidates include several key assumptions based on our industry knowledge, industry publications, third-party research, and other surveys, which may be based on a small sample size and may fail to accurately reflect market opportunities. While we believe that our internal assumptions are reasonable, no independent source has verified such assumptions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RISK FACTOR SUMMARY</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Investing in our securities involves a high degree of risk. Below is a summary of material factors that make an investment in our securities speculative or risky. Importantly, this summary does not address all of the risks that we face. Additional discussion of the risks summarized in this risk factor summary, as well as other risks that we face, can be found under the heading &#x201c;Risk Factors&#x201d; in Part I, Item 1A of this Annual Report on Form 10-K.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our business is subject to a number of risks of which you should be aware before making a decision to invest in our common stock. These risks include, among others, the following:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have incurred net losses and anticipate that we will continue to incur net losses in the foreseeable future.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may require substantial additional funding to finance our operations. If we are unable to raise capital when needed, we could be forced to delay, reduce or terminate certain of our development programs or other operations.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Although we have an Emergency Use Authorization, or EUA, from the U.S. Food and Drug Administration, or FDA, for sotrovimab for the early treatment of COVID-19, the disease caused by the virus SARS-CoV-2, the FDA has excluded the use of sotrovimab in all U.S. regions, and sotrovimab has limitations on its use in some countries outside of the U.S. If the FDA does not reauthorize the use of sotrovimab in the U.S., the FDA revokes or terminates our EUA for sotrovimab, the federally-declared COVID-19 public health emergency ends, or countries outside of the U.S. continue to limit its use, we may be unable to sell sotrovimab in or outside of the U.S.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are committing substantial financial resources and personnel and making substantial capital commitments with third parties in connection with therapies for COVID-19. Market demand and utilization of any of our COVID-19 product candidates has been, and may continue to be, adversely impacted by factors such as the development of monoclonal antibodies, or mAbs, of other third parties, the rollout of oral antivirals and vaccines, the emergence of new variants or subvariants and the current challenges in the delivery and administration of mAbs to patients.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our near-term revenue is dependent on the continued sales and commercialization of sotrovimab for the early treatment of COVID-19, including our ability to enter into procurement contracts with government entities. If we are unable to continue to sell and/or commercialize sotrovimab in or outside of the U.S., our business, financial condition, results of operations and prospects may be adversely affected. In addition, sotrovimab may be rendered inferior or obsolete due to rapid changes in epidemiology and the emergence of new variants or subvariants.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our future success is substantially dependent on the successful clinical development, regulatory approval and commercialization of our product candidates in a timely manner. If we are not able to obtain required regulatory approvals, we will not be able to commercialize our product candidates and our ability to generate product revenue will be adversely affected.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials and we cannot assure you that any ongoing, planned or future clinical trials will lead to results sufficient for the necessary regulatory approvals and marketing authorizations.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be delayed, made more difficult or rendered impossible by multiple factors outside our control.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a party to strategic collaboration and license agreements pursuant to which we are obligated to make substantial payments upon achievement of milestone events and, in certain cases, have relinquished important rights over the development and commercialization of certain current and future product candidates. We also intend to explore additional strategic collaborations, which may never materialize or may require that we relinquish rights to and control over the development and commercialization of our product candidates.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We rely on third parties to produce clinical and commercial supplies of our product candidates.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we are unable to obtain and maintain patent protection for our product candidates and technology, or if the scope of the patent protection obtained is not sufficiently broad or robust, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to successfully commercialize our product candidates and technology may be adversely affected.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are highly dependent on our key personnel, and if we are not able to retain these members of our management team or recruit and retain additional management, clinical and scientific personnel, our business will be harmed.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If our information systems, or those maintained on our behalf, fail or suffer security breaches, such events could result in, without limitation, the following: a significant disruption of our product development programs; an inability to operate our business effectively; unauthorized access to or disclosure of the personal information we process; and other adverse effects on our business, financial condition, results of operations and prospects.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The market price of our common stock has been, and in the future, may be, volatile and fluctuate substantially, which could result in substantial losses for purchasers of our common stock.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1_business"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Overview</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our mission is to create a world without infectious disease.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Infectious diseases are among the leading causes of death worldwide and can cause trillions of dollars of direct and indirect economic burden each year &#x2013; as evidenced by the coronavirus disease 2019, or COVID-19, pandemic. We believe that now is the time to apply the recent and remarkable advances in immunology to combat current and prepare for future infectious diseases. Our approach begins with identifying the limitations of the immune system in combating a particular pathogen, the vulnerabilities of that pathogen and the reasons why previous approaches have failed. We then bring to bear powerful technologies that we believe, individually or in combination, will lead to effective therapies.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our current pipeline consists of sotrovimab (previously VIR-7831; and where marketing authorization has been granted, marketed under the brand name Xevudy&#174;) and other product candidates targeting hepatitis B virus, or HBV, hepatitis D virus, or HDV, influenza A virus, COVID-19, and human immunodeficiency virus, or HIV. We have assembled four technology platforms, focused on antibodies, T cells, innate immunity and small interfering ribonucleic acid, or siRNA, through internal development, collaborations and acquisitions. We have built an industry-leading team that has deep experience in immunology, infectious diseases, and product development and commercialization. Given the global impact of infectious diseases, we are committed to developing cost-effective treatments that can be delivered at scale.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Pipeline</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our current product and product candidates are summarized in the chart below:</span></p>
  <p style="margin-left:4.813%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img62602283_0.jpg" alt="img62602283_0.jpg" style="width:662px;height:333px;" />&#160;</p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">IFN-&#x3b1;: interferon alfa-2a; HBV: Hepatitis B Virus; HDV: Hepatitis D Virus; HIV: Human Immunodeficiency Virus</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">1: MARCH trial (Part B), PREVAIL platform trial (THRIVE/STRIVE sub-protocols); 2: GS-9688</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">*Vaccine designed to establish proof of concept in Phase 1 clinical trial to determine whether unique immune response observed in non-human primates can be replicated in humans; ultimately, any candidates we advance as a potential HIV vaccine will require modifications to VIR-1111 before further clinical development.</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">&#134;sotrovimab for early treatment by intravenous (IV) administration currently has marketing approval, temporary authorization or emergency authorization, supplying &gt;40 countries. In April 2022, the FDA (as defined below) deauthorized sotrovimab&#x2018;s use in all U.S. regions.</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sotrovimab and VIR-2482 incorporate Xencor&#x2019;s Xtend</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> technology. VIR-3434 incorporates Xencor&#x2019;s Xtend</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> and other Fc technologies.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">HBV</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: According to the Hepatitis B Foundation, approximately 300 million people globally are chronically infected with HBV and approximately</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">900,000 of them die from HBV-associated complications each year. There is a significant unmet medical need for more effective therapies that lead to life-long control of the virus after a finite duration of therapy, which is the definition of a functional cure. For a registrational trial to demonstrate a functional cure, the formal endpoint accepted by the U.S. Food and Drug Administration, or FDA, is undetectable hepatitis B virus surface antigen, or HBsAg, defined as less than 0.05 international units per milliliter, or IU/ml, as well as HBV deoxyribonucleic acid, or DNA, less than the lower limit of quantification, in the blood six months after the end of therapy. Currently, a year-long course of pegylated interferon-alpha, or IFN-&#x3b1;, is the best available curative therapy. It has a low functional cure rate of approximately 3% to 7%. Alternatively, suppressive therapy with nucleotide/nucleoside reverse transcriptase inhibitors, or NRTIs, is commonly used, but patients often require a lifetime of therapy.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are developing VIR-2218 and VIR-3434 for the functional cure of HBV. Each of these product candidates has the potential to stimulate an effective immune response and also has direct antiviral activity against HBV. We believe that a functional cure for HBV will require an effective immune response in addition to antiviral activity based on the observation that severe immunosuppression can reactivate HBV disease. While monotherapy with VIR-2218 and VIR-3434 may provide a functional cure in some patients, we believe combination therapy will be necessary for a functional cure in many patients.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">VIR-2218 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">is an investigational subcutaneously administered HBV-targeting siRNA. By targeting a conserved region of the HBV genome, it is</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">designed to inhibit the production of all HBV proteins: X, polymerase, S, and core. Suppression of HBV proteins, particularly HBsAg, is hypothesized to remove the inhibition of T cell and B cell activity directed against HBV, allowing VIR-2218 to potentially result in</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a functional cure. VIR-2218 was the first siRNA in the clinic to include Alnylam Pharmaceuticals, Inc.&#x2019;s, or Alnylam, Enhanced Stabilization Chemistry Plus, or ESC+, technology, which has the potential to enhance the therapeutic index.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Building on previously disclosed data, in November 2022, we announced initial end of treatment data from our ongoing Phase 2 clinical trial (NCT04412863) evaluating VIR-2218 in combination with IFN-&#x3b1; for 24 and up to 48 weeks. 30.8% (4/13) of the participants receiving up to 48 weeks of VIR-2218 plus IFN-&#x3b1; treatment achieved higher rates of HBsAg seroclearance with anti-HBs seroconversion by the end of treatment. Participants receiving longer duration of VIR-2218 plus IFN-&#x3b1; had the greatest mean declines from baseline HBsAg (log10 IU/mL) levels at week 48 (2.9 &#xb1; 1.36). Across all cohorts, 10 participants receiving VIR-2218 plus IFN-&#x3b1; for 24 or up to 48 weeks achieved HBsAg seroclearance by week 48, and nine achieved anti-HBs levels &gt;10 mIU/mL. All patients were virally suppressed on NRTIs. The treatment regimens were generally well tolerated and resulted in no new safety signals.  Additional data are expected in the first half of 2023.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VIR-2218 is also being evaluated in additional clinical trials with collaborators. Brii Biosciences Offshore Limited, or Brii Bio, continues to lead the Phase 2 trial (NCT04749368) of VIR-2218 in combination with BRII-179, an investigational T cell vaccine, for the treatment of chronic HBV infection. Treatment has completed in this trial. Interim safety and efficacy were presented at the Asian Pacific Association for the Study of the Liver (APASL) in February 2023. Treatment of VIR-2218 alone or in combination with BRII-179 with and without coadjuvant IFN-&#x3b1; was generally well tolerated. Although the combination of VIR-2218 and BRII-179 had greater anti-HBs responses and improved HBsAg-specific T-cell responses, comparable HBsAg reduction was observed in all cohorts at end of treatment (EOT) (-1.7-1.8 log10 IU/mL).  In December 2021, we and Gilead Sciences, Inc., or Gilead, initiated a Phase 2 clinical trial (NCT04891770) of VIR-2218 in combination with GS-9688 (selgantolimod), Gilead&#x2019;s investigational TLR-8 agonist, and nivolumab, an approved PD-1 inhibitor, in both NRTI-suppressed patients and viremic patients. Patients with HBV treatment experience also may receive tenofovir alafenamide fumarate, or TAF. In February 2023, due to immune-related adverse events associated with nivolumab, which are consistent with the safety profile of the class, in the cohorts evaluating nivolumab in combination with VIR-2218 and GS-9688, nivolumab was discontinued.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">VIR-3434 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">is an investigational subcutaneously administered HBV-neutralizing monoclonal antibody, or mAb. By targeting a conserved region of HBsAg, it is designed to</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">block entry of all 10 genotypes of HBV into liver cells called hepatocytes and reduce the level of virions and subviral particles in the blood. VIR-3434, which incorporates Xencor, Inc.'s, or Xencor, Xtend and other Fc technologies, has been engineered to potentially function as a T cell vaccine against HBV in infected patients, as well as to have an extended half-life. These modifications are intended to enhance its potential to result in an HBV functional cure.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page10"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Building on previously disclosed data, in November 2022 we announced that a single dose of 75 mg or 300 mg of VIR-3434 to trial participants with chronic HBV infection with viremia resulted in rapid reductions in HBsAg and HBV DNA in the majority of participants not on NRTI therapy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In July 2021, we initiated the Phase 2 Monoclonal Antibody siRNA Combination against Hepatitis B, or MARCH, trial (NCT04856085) to evaluate the combination of VIR-2218 and VIR-3434 as a functional cure regimen for chronic HBV infection. In April 2022, we announced initial results from MARCH Part A, demonstrating that the combination of VIR-3434 and VIR-2218 resulted in an approximate 3 log decline in HBsAg with no drug-related safety signals reported at that time. In November 2022, we announced end of treatment data for all MARCH Part A cohorts, including that the combination of VIR-3434 and VIR-2218 achieved</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">mean HBsAg reductions &#x2265;2.7 log10 IU/mL in all cohorts, absolute HBsAg levels &lt;10 IU/mL were achieved in most participants, and the combination was generally well tolerated with most adverse events being mild. All patients were virally suppressed on NRTIs. Additional MARCH Part A data are expected in the first half of 2023 and initial MARCH Part B data, evaluating VIR-2218 in combination with VIR-3434 for 24 and 48 weeks with and without interferon, are expected in the second half of 2023.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Initiation of the Phase 2 PREVAIL platform trial (NCT05612581) and its THRIVE/STRIVE sub-protocols of VIR-3434 and/or VIR-2218 and/or IFN-&#x3b1; in viremic patients with chronic HBV infection is expected in the first half of 2023. The THRIVE sub-protocol will evaluate inactive carriers defined as adults with chronic HBV that are hepatitis B virus e-antigen, or HBeAg, negative with HBV DNA &#x2264;2000 IU/mL and alanine transaminase, or ALT, less than the upper limits of normal, or ULN. The STRIVE sub-protocol will evaluate immune active, treatment-na&#xef;ve patients defined as adults with chronic HBV who have not received prior NRTI or IFN-&#x3b1; therapy and are HBeAg positive or negative with HBV DNA &gt;2000 IU/mL, ALT &gt; ULN and &#x2264; 5&#xd7; ULN. Initial data are expected in the first half of 2024.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">HDV: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">According to a 2020 article in the Journal of Hepatology, approximately 12 million people globally are infected with HDV, representing approximately 5% of the HBV population. HDV is considered the most severe and aggressive form of viral hepatitis leading to increased rates of cirrhosis, hepatocellular carcinoma, or HCC, hepatic decomposition, and liver failure. People with HDV are 3.9 times more likely to have hepatocellular carcinoma than people with HBV and have more rapid progression to liver-related death. There are no approved therapies for HDV in the U.S. and Hepcludex (bulevirtide), a once daily subcutaneous injection, has conditional approval in the European Union, or EU, and the U.K.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are developing VIR-2218 and VIR-3434 for the chronic treatment and suppression of HDV. HBsAg is a critical component necessary for the HDV lifecycle. Both VIR-2218 and VIR-3434 act independently to inhibit the replication of HDV by targeting HBsAg. VIR-2218 inhibits the production of HBsAg by targeting a conserved region of the HBV genome and inhibiting production of all HBV proteins including HBsAg. VIR-3434 binds to a conserved region of HBsAg, which reduces the levels of HDV virions and also prevents the infection of hepatocytes with HDV.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In September 2022, we initiated the Phase 2 SOLSTICE trial (NCT05461170) evaluating once monthly subcutaneous injections of VIR-2218 and VIR-3434 as monotherapy and in combination for the chronic treatment of people living with HDV. The trial is assessing the safety and ability of the combination to reduce HDV viremia and normalize ALT, surrogate endpoints used for regulatory approval and endpoints that may improve clinical outcomes. Initial data are expected in the second half of 2023.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Influenza</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: According to the World Health Organization, or WHO, on average, each year the influenza virus is estimated to infect 1 billion people</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and to result in 290,000 to 650,000 deaths globally. According to the Centers for Disease Control and Prevention, or CDC, in the 2018-2019 flu season, despite the availability of the flu vaccine, approximately 36 million people were diagnosed with influenza, 500,000 people were hospitalized, and 34,000 people died from influenza in the United States alone. Influenza vaccines have historically</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">had limited success, with an average efficacy of 40% overall, across all populations. This limited efficacy results from incomplete coverage against seasonal strains and the lack of an effective immune response in many individuals after receiving the vaccine.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are developing VIR-2482 as a universal prophylactic for influenza A and have designed it to address the limitations of flu vaccines, which we believe will lead to meaningfully higher levels of protection against seasonal and pandemic strains of influenza A. We anticipate that the initial registration population for VIR-2482 will include individuals at high risk of influenza A complications, such as the elderly with chronic lung disease or congestive heart failure.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In May 2021, we signed a definitive collaboration agreement, or the 2021 GSK Agreement, with Glaxo Wellcome UK Limited to expand our existing collaboration to include the research and development of new therapies for influenza and other respiratory viruses. See the section titled &#x201c;Our Collaboration, License and Grant Agreements&#x2014;Collaboration Agreements with GSK&#x201d; for a description of the 2021 GSK Agreement.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">VIR-2482 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">is an investigational intramuscularly, or IM, administered influenza A-neutralizing mAb. In vitro, VIR-2482 has been shown to neutralize all major strains of</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">influenza A that have arisen since the 1918 Spanish flu pandemic and is designed as a universal prophylactic for influenza A. We believe that VIR-2482 has the potential to address the limitation of current flu vaccines and be able to be used year after year because it has broad strain coverage as opposed to the limited strain coverage generated by current vaccines. We also believe that it provides passive immunity rather than relying on a person to generate active immunity via a functional immune response, an ability that is known to decline with age. VIR-2482, which incorporates Xencor&#x2019;s Xtend technology, has been engineered to extend its half-life so that a single IM dose has the potential to last the entire flu season, which is typically five to six months long. VIR-2482 is estimated to have a half-life of 58 days based on preliminary data.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In August 2019, we initiated a Phase 1 clinical trial (NCT04033406) for VIR-2482. VIR-2482 was well-tolerated in the approximately 100 healthy volunteers under age 65 dosed in Phase 1. In September 2022, we initiated a Phase 1b prophylaxis trial evaluating the safety of VIR-2482 in elderly participants (aged 65 and older) receiving a flu vaccine.  Initial data are expected in mid-2023. In October 2022, we initiated the Phase 2 PrevENtIoN of IllnesS DUe to InfLuenza A, or PENINSULA, trial (NCT05567783) in healthy volunteers aged 18 to 64 to evaluate the safety, tolerability and efficacy of two different IM administered doses of VIR-2482 in preventing illness due to influenza A. The primary efficacy endpoint is the proportion of trial participants with protocol-defined influenza illness, requiring one systemic symptom and one respiratory symptom, with PCR confirmed influenza A infection, compared to placebo. Other endpoints will evaluate the effect of VIR-2482 on the severity and duration of illness in trial participants with confirmed influenza A compared to placebo. Initial data are expected in mid-2023. The PENINSULA trial is being funded in part with federal funds from the U.S. Department of Health and Human Services, or HHS; the Administration for Strategic Preparedness and Response, or ASPR; and the Biomedical Advanced Research and Development Authority, or BARDA, under Other Transaction, or OT, number 75A50122C00081.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">COVID-19: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">According to the John Hopkins Coronavirus Resource Center, as of February 27, 2023, there have been almost 675.1 million recorded</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">infections and almost 6.9 million recorded deaths worldwide from COVID-1</span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9. The</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FDA has granted either</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Emergency Use Authorization, or EUA, or marketing approvals to multiple vaccines, drugs and/or antibodies to prevent or treat COVID-19. The ongoing efficacy of these medicines, however, particularly as the virus mutates while it infects more people and comes under increased immune pressure, is uncertain.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In response to the ongoing COVID-19 pandemic, we have moved rapidly to address this global health challenge. Our focus is on treating and preventing severe acute respiratory syndrome coronavirus 2, or SARS-CoV-2 (the virus that causes COVID-19 illness), as well as potential future coronavirus outbreaks. To do so, together with our collaborator Glaxo Wellcome UK Limited and GlaxoSmithKline Biologicals S.A. (individually and collectively referred to as GSK), we are developing sotrovimab, as well as small molecules. Vir is also developing additional differentiated mAbs as well as vaccines.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sotrovimab </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">is a SARS-CoV-2-neutralizing mAb, based on a parent antibody, S309, which was</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">derived from samples previously gathered for research on pan-coronavirus-neutralizing mAbs. Data suggest that sotrovimab has the potential for &#x2018;dual-action&#x2019;, or the ability to block viral entry into healthy cells and an enhanced ability to clear infected cells.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Early Treatment</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In August 2020, we initiated the lead-in phase of our Phase 2/3 trial (NCT04545060) COVID-19 Monoclonal antibody Efficacy Trial - Intent to Care Early, or COMET-ICE, for the treatment of adults at high risk of hospitalization or death from COVID-19 via intravenous, or IV, administration. In May 2021, the FDA granted an EUA to sotrovimab for the early treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and at high risk for progression to severe COVID-19, including hospitalization or death. In December 2021, the European Commission granted marketing authorization to Xevudy&#174; (sotrovimab) in the EU for the treatment of adults and adolescents at increased risk of progressing to severe COVID-19.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In March 2022, the FDA de-authorized sotrovimab&#x2019;s use in all U.S. regions due to increases in the proportion of COVID-19 cases caused by the Omicron BA.2 subvariant. Sotrovimab has obtained emergency authorization, temporary authorization or marketing approval (under the brand name Xevudy&#174;&#xfe0f;) for early treatment of COVID-19, supplying more than 40 countries. Sotrovimab is not authorized in the U.S. Over 2.1 million doses of sotrovimab have been delivered as of December 31, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We continue to conduct in vitro testing of sotrovimab against new variants and subvariants as they emerge, and to collect and evaluate real-world evidence, both of which are being shared with regulatory authorities.</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Prophylaxis</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In August 2022, sotrovimab entered the Phase 3 PROphylaxis for PaTiEnts at Risk of COVID-19 InfecTion, or PROTECT-V, platform trial (NCT04870333) sponsored by Cambridge University Hospitals National Health Service, or NHS, Foundation Trust assessing the use of a 2 g dose of sotrovimab administered IV in uninfected, high-risk immunocompromised individuals. Timing of initial data will depend on continued rate of enrollment.</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Hospitalized treatment</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2021, sotrovimab entered the Randomized Evaluation of COVID-19 Therapy, or RECOVERY, trial, a Phase 3 trial (NCT04381936) in the U.K.  evaluating standard of care alone versus usual standard of care plus a single 1 g dose of sotrovimab given IV. Timing of initial data will depend on continued rate of enrollment.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to sotrovimab, we are preparing for future pandemics with coronavirus mAbs that have the potential to be even broader and more potent than sotrovimab, pan-coronavirus vaccines designed with the aim to be variant-proof (initial pre-clinical proof of concept achieved), and small molecules that have the potential to treat multiple respiratory diseases like COVID-19 and influenza (initial pre-clinical proof of concept achieved).</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VIR-7832, which has similar properties to sotrovimab, but is also designed to potentially enhance virus-specific T cell function, was evaluated in the U.K.&#x2019;s NHS-supported AGILE initiative. The Phase 1b portion of the trial (NCT04746183) assessed safety of VIR-7832 at 50 mg, 150 mg and 500 mg IV doses. The Phase 2 portion of the trial was designed to assess safety and efficacy at 500 mg IV dose. The Phase 2a was stopped early due to concerns about the evolving COVID landscape, including circulating SARS-CoV-2 variants. No safety signals were reported in the Phase 1b or 2a portions of the trial.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">HIV</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: According to the Joint United Nations Programme on HIV/AIDS, or UNAIDS, each year there are approximately 1.5 million new cases of</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">HIV and approximately 700,000 HIV-related deaths globally. Current prevention approaches such as behavioral modification and pharmacological intervention have had only a modest effect on HIV transmission globally, leaving a high unmet medical need for a safe and effective vaccine for the billions of individuals who are or may become sexually active.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are developing VIR-1111 as a proof-of-concept HIV vaccine designed to elicit a type of immune response that is different from other vaccines. Learnings from VIR-1111 have informed the trial design for VIR-1388, which has additional modifications that have the potential to enhance immunogenicity compared to VIR-1111. We anticipate the initial registration population for our eventual HIV vaccine will be individuals at high risk of contracting HIV.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">VIR-1111 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">is an investigational subcutaneously administered HIV T cell vaccine based on human cytomegalovirus, or HCMV. VIR-1111 has been</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">designed to elicit T cells that recognize HIV epitopes that are different from those recognized by prior HIV vaccines and to stimulate a different and specific type of T cell immune response to HIV, known as an HLA-E restricted immune response. An HLA-E restricted immune response has been shown to be associated with protection of non-human primates, or NHPs, from simian immunodeficiency virus, or SIV, the NHP equivalent of HIV. VIR-1111 is a vaccine designed solely to establish proof of concept in a Phase 1 clinical trial to determine whether the unique immune response observed in NHPs can be replicated in humans.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2020, we initiated a Phase 1 trial (NCT04725877) of VIR-1111. In November 2022, we announced that safety and immunology data from the initial two cohorts of the trial showed no safety signals and no vector shedding or viremia reported to date. In addition, no sustained HIV insert-specific T cell responses were observed in the lower dose cohorts 1 and 2. Safety and immunology data from the highest dose cohort 3 are expected in the first half of 2023. This trial is being funded in part by the Bill &amp; Melinda Gates Foundation.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">VIR-1388 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">is a preclinical subcutaneously administered HIV T cell vaccine based on HCMV. Like VIR-1111, VIR-1388 has been</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">designed to elicit T cells that recognize HIV epitopes that are different from those recognized by prior HIV vaccines and to stimulate a different and specific type of T cell immune response to HIV, known as an HLA-E restricted immune response. VIR-1388 has additional modifications that have the potential to enhance immunogenicity compared to VIR-1111. We expect to initiate a Phase 1 trial of VIR-1388 in the second half of 2023. This trial will be funded in part by the Bill &amp; Melinda Gates Foundation and the National Institutes of Health&#x2019;s Division of AIDS, through the HIV Vaccine Trials Network.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, in January 2022, we expanded our collaboration with the Bill &amp; Melinda Gates Foundation to explore the development of broadly neutralizing antibodies designed to provide a &#x201c;vaccinal effect&#x201d; for the functional cure of HIV as well as the prevention of malaria.</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page11"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Technology Platforms</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our four current technology platforms are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. We are using our platforms to advance sotrovimab and other current product candidates and generate additional product candidates for multiple indications.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Antibody Platform</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: We have established a robust method for capitalizing on unusually successful immune responses naturally occurring in people</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">who are protected from, or have recovered from, infectious diseases. We identify rare antibodies from survivors that have the potential to treat and prevent rapidly evolving and/or previously untreatable pathogens via direct pathogen neutralization and immune system stimulation. The fully-human antibodies that we discover may also be modified to enhance their therapeutic potential. We have applied these methods to identify mAbs for a range of pathogens including SARS-CoV-2, HBV, HDV, influenza A and influenza B virus, Ebola, HIV, respiratory syncytial virus, or RSV, metapneumovirus, or MPV, malaria, rabies, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">clostridium difficile, Staphylococcus</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">aureus</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> Klebsiella pneumoniae</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, and</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> Acinetobacter spp</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Examples of the power of this platform are sotrovimab (previously VIR-7831; and where marketing authorization has been granted, marketed under the brand name Xevudy&#174;),</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our anti-SARS-CoV-2 mAb, and Ebanga (ansuvimab-zykl, formerly known as mAb114), the anti-Ebola virus mAb identified by our scientists in collaboration with the NIH and others and marketed by Ridgeback Biotherapeutics LP.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">T Cell Platform</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: We are exploiting the unique immunology of HCMV, a commonly occurring virus in humans, as a vaccine vector to potentially</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">treat and prevent infection by pathogens refractory to current vaccine technologies. This approach is based on fundamental observations made in NHPs, with rhesus cytomegalovirus, or RhCMV. HCMV is the most potent known inducer of T cell responses of any human virus and may induce potent and long-lasting T cell responses to a broader range of epitopes than observed for other viral vaccines. In addition, we can make proprietary modifications in the HCMV genome that we expect will elicit different types of pathogen-appropriate T cell responses. We term this approach &#x201c;immune programming.&#x201d; We believe that this platform may also have applicability beyond infectious diseases, to areas such as cancer.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Innate Immunity Platform</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: Moving beyond more traditional approaches that are used to evoke adaptive immunity or that directly target pathogens,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">where the development of resistance can occur, we plan to target host proteins as a means of creating host-directed therapies with high barriers to resistance. We believe that by leveraging the power of innate immunity, we can create medicines that break the &#x201c;one-drug-for-one-bug&#x201d; paradigm by producing &#x201c;one-drug-for-multiple-bugs.&#x201d; For example, we believe this platform can create a single product for respiratory viruses, such as SARS-CoV-2 and influenza. This is enabled using clustered regularly interspaced short palindromic repeats, or CRISPR, -based genomics, computational biology and machine learning to identify key host factors necessary for each pathogen&#x2019;s survival and the protective effects of the innate immune system. We then identify product candidates that may be able to safely target host proteins to block pathogen replication or induce innate immunity to control infection. We believe that this platform may also have applicability beyond infectious diseases.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">siRNA Platform</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: We are harnessing the power of siRNA to inhibit pathogen replication, eliminate key host factors necessary for pathogen survival</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and remove microbial immune countermeasures. Our collaboration with Alnylam includes VIR-2218 for HBV and up to four additional programs for infectious diseases. This platform can leverage Alnylam&#x2019;s proprietary N-acetylgalactosamine, or GalNAc, delivery technology, for product candidates targeting the liver, allowing for subcutaneous administration and extended tissue half-life, as well as ESC+ technology to enhance stability and minimize off-target activity, which potentially can result in an increased therapeutic index.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Team</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have an industry-leading management team and board of directors with significant experience in immunology and infectious diseases and progressing product candidates from early-stage research to clinical trials, regulatory approval and ultimately commercialization.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Chief Executive Officer, George Scangos, Ph.D., has spent over 30 years developing treatments in infectious disease, neuroscience and oncology, among other fields, and was previously the Chief Executive Officer of Biogen Inc., or Biogen, the Chief Executive Officer of Exelixis, Inc. and the President of Bayer Biotechnology.  Dr. Scangos notified us on January 19, 2023, that he will retire from his position as President and CEO, effective April 3, 2023. Upon his retirement as President and CEO, Dr. Scangos will transition to an advisory role through June 2, 2023 and will continue as a member of the Board of Directors.  His appointed successor is Marianne De Backer, MSc, Ph.D., MBA, currently Executive Vice President, Head of Pharmaceuticals Strategy, Business Development and Licensing/Open Innovation, and member of the Executive Committee for Bayer Pharmaceuticals. Dr. De Backer brings deep scientific expertise to her new role, as well as more than two decades of broad international leadership experience, including a strong track record in global expansion, innovation technology licensing and multiple billion-dollar mergers and acquisitions. She will be appointed as a member of the Board of Directors on April 3, 2023. Our Chief Medical Officer and Interim Head of Research, Phil Pang, M.D., Ph.D., was previously Chief Medical Officer of Riboscience LLC, and before that was the Harvoni&#174; project lead at Gilead, where he led the team responsible for worldwide regulatory approval. Our Senior Vice President and Senior Research Fellow, Antonio Lanzavecchia, M.D., is a Member of the National Academy of Sciences, was a co-founder of Humabs BioMed SA, or Humabs, which we acquired in 2017, and was the Director of the Institute for Research in Biomedicine in Bellinzona, Switzerland. Our Executive Vice President and Chief Operating Officer, Johanna Friedl-Naderer, was previously President of Europe, Canada &amp; Partner Markets for Biogen, where she served on the company's Global Leadership Team. Our Chief Technology Officer, Aine Hanly, Ph.D., was previously Vice President of Process Development for Amgen Inc., where she was accountable for clinical manufacturing and global supply of clinical trial materials. Our Senior Vice President of Regulatory Affairs and Program Leadership &amp; Management, Lynne Krummen, Ph.D., previously served in many roles at Genentech, Inc. and F. Hoffmann-La Roche AG, including Head of U.S. Technical Development, Global Head of Technical Regulatory for Biologics, Head of Process Development and Clinical Development Project Team Lead for Avastin&#174;. Our Chief Corporate Affairs Officer, Bolyn Hubby, Ph.D., was previously Chief Scientific Officer at Agenovir Corporation, which we acquired in 2018, and before that was the Vice President of Vaccines and Antimicrobials at Synthetic Genomics, Inc. Our Chief Administrative Officer, Steven Rice, was previously Chief Human Resources Officer at the Bill &amp; Melinda Gates Foundation, and before that was Executive Vice President of Global Human Resources at Juniper Networks, Inc. Our Chief Financial Officer, Howard Horn, was previously Vice President,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Business Planning at Biogen, and before that was a senior consultant at McKinsey &amp; Company and an equity analyst at UBS Group AG. On February 13, 2023, the Board of Directors appointed Sung Lee as Executive Vice President and Chief Financial Officer of the Company, effective as of March 27, 2023. Mr. Horn will step down as Chief Financial Officer of the Company effective upon Mr. Lee&#x2019;s appointment on March 27, 2023, and will remain with the Company as Executive Vice President until April 28, 2023, to assist with the transition. Mr. Lee is currently the Chief Financial Officer and Management Board member of MorphoSys AG, a biopharmaceutical company. Mr. Lee brings a strong track record of driving financial performance, scaling global operations, leading large teams and communicating with investors around the world. Our Chief Data Officer, Amalio Telenti, was previously Chief Scientific Officer at Human Longevity, Inc., and before that was Chief Data Scientist at the Scripps Research Translational Institute and professor of genomics at Scripps Research.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our board of directors is composed of leaders: from academia, Nobel laureate Phillip Sharp, Ph.D.; from the biopharmaceutical industry, Jeffrey Hatfield, Robert Perez, Saira Ramasastry, Elliott Sigal, M.D., Ph.D., and our Chairman Vicki Sato, Ph.D.; from the life science investment community, Robert More and Robert Nelsen (a co-founder); and from government, Janet Napolitano.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Strategy</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The core elements of our business strategy include:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Maximizing the impact of sotrovimab. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sotrovimab has been granted emergency authorization, temporary authorization or marketing approval, supplying more than 40</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">countries. We and GSK will continue to work actively with governments and payors around the world to make sotrovimab available to patients in need.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Rapidly advancing our pipeline</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Currently underway are two Phase 3 clinical trials, seven Phase 2 clinical trials, and two Phase 1 clinical</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">trials across five distinct therapeutic areas. We anticipate moving additional preclinical candidates into the clinic and initiating additional later-stage combination trials where applicable in the next 12-18 months.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expanding our pipeline using our current technology platforms</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. We are leveraging our four current technology platforms to discover and</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">develop novel product candidates for HBV, HDV, influenza A virus, COVID-19, and HIV, as well as additional viral, bacterial, fungal and parasitic infections, and potentially cancers.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Acquiring or accessing new technology platforms and assets</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. We continually evaluate external technology platforms and assets that may</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">help us develop therapies to treat and prevent serious infectious diseases.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Scaling our capabilities</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. We are investing in our people, processes and systems across all functions of our company to ensure that we are</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">able to take full advantage of our multiple product candidates and multiple technology platforms.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Enabling global access to our future medicines</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. We have established relationships with organizations seeking to make a global impact like</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the Bill &amp; Melinda Gates Foundation, BARDA, the NIH, and the NHS to further enable and facilitate access to our future medicines and to support our clinical development efforts. We will continue to pursue additional relationships like these moving forward.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page13"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pipeline</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our current pipeline consists of a product and product candidates that address unmet needs caused by HBV, HDV, influenza A virus, COVID-19, and HIV.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:4.813%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img62602283_1.jpg" alt="img62602283_1.jpg" style="width:662px;height:333px;" />&#160;</p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">IFN-&#x3b1;: interferon alfa-2a; HBV: Hepatitis B Virus; HDV: Hepatitis D Virus; HIV: Human Immunodeficiency Virus</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">1: MARCH trial (Part B), PREVAIL platform trial (THRIVE/STRIVE sub-protocols); 2: GS-9688</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">*Vaccine designed to establish proof of concept in Phase 1 clinical trial to determine whether unique immune response observed in non-human primates can be replicated in humans; ultimately, any candidates we advance as a potential HIV vaccine will require modifications to VIR-1111 before further clinical development.</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">&#134;sotrovimab for early treatment by intravenous (IV) administration currently has marketing approval, temporary authorization or emergency authorization, supplying &gt;40 countries. In April 2022, the FDA (as defined below) deauthorized sotrovimab&#x2018;s use in all U.S. regions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sotrovimab and VIR-2482 incorporate Xencor&#x2019;s Xtend</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> technology. VIR-3434 incorporates Xencor&#x2019;s Xtend</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> and other Fc technologies.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Functional Cure for HBV</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Summary</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are developing VIR-2218 and VIR-3434 for the functional cure of HBV. Each of these product candidates has the potential to stimulate an effective immune response and also has direct antiviral activity against HBV. We believe that a functional cure for HBV will require an effective immune response, in addition to antiviral activity, based on the observation that severe immunosuppression can reactivate HBV disease. While monotherapy with VIR-2218 and VIR-3434 may provide a functional cure in some patients, we believe combination therapy will be necessary for a functional cure in many patients.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VIR-2218, an HBV-targeting siRNA, is currently </span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">in several Phase 2 clinical trials.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Initial data with VIR-2218 in healthy volunteers demonstrated that it was generally well tolerated up to 900 mg. In addition, durable, dose-dependent reductions in HBsAg were observed in patients with chronic HBV suppressed on NRTI therapy at doses ranging from 20 mg to 200 mg with durability out to at least 48 weeks. In November 2022, we announced initial end of treatment data from our ongoing Phase 2 clinical trial evaluating VIR-2218 in combination with IFN-&#x3b1; for 24 and up to 48 weeks. 30.8% (4/13) of the participants receiving up to 48 weeks of VIR-2218 plus IFN-&#x3b1; treatment achieved higher rates of HBsAg seroclearance with anti-HBs seroconversion by the end of treatment. Participants receiving longer duration of VIR-2218 plus IFN-&#x3b1; had the greatest mean declines from baseline HBsAg (log10 IU/mL) levels at week 48 (2.9 &#xb1; 1.36). Across all cohorts, 10 participants receiving VIR-2218 plus IFN-&#x3b1; for 24 or up to 48 weeks achieved HBsAg seroclearance by week 48, and nine achieved anti-HBs levels &gt;10 mIU/mL. All patients were virally suppressed on NRTIs. The treatment regimens were generally well tolerated and resulted in no new safety signals. Additional data are expected in the first half of 2023.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VIR-2218 is also being evaluated in additional Phase 2 clinical trials with collaborators. Brii Bio continues to lead the Phase 2 trial of VIR-2218 in combination with BRII-179, an investigational T cell vaccine, for the treatment of chronic HBV infection. Treatment has completed in this trial. Interim safety and efficacy data was presented at the APASL in February 2023.  Treatment of VIR-2218 alone or in combination with BRII-179 with and without coadjuvant IFN-&#x3b1; was generally well tolerated. Although the combination of VIR-2218 and BRII-179 had greater anti-HBs responses and improved HBsAg-specific T-cell responses, comparable</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">HBsAg reduction was observed in all cohorts at EOT (-1.7-1.8 log10 IU/mL). In December 2021, we and Gilead initiated a Phase 2 clinical trial of VIR-2218 in combination with GS-9688 (selgantolimod), Gilead's investigational TLR-8 agonist, and nivolumab in both NRTI-suppressed patients and viremic patients. Patients with HBV treatment experience also may receive TAF. In February 2023, due to immune-related adverse events associated with nivolumab, which are consistent with the safety profile of the class, in the cohorts evaluating nivolumab in combination with VIR-2218 and GS-9688, nivolumab was discontinued.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VIR-3434, an HBV-neutralizing mAb, is currently in a Phase 2 clinical trial. Two analyses from our Phase 1 trial showed no safety signals in healthy volunteers dosed with up to 3,000 mg. Single doses of VIR-3434 up to 300 mg demonstrated dose-dependent, rapid reductions in HBsAg in chronic HBV patients suppressed on NRTI therapy. In November 2022, we announced that a single dose of 75 mg or 300 mg of VIR-3434 to trial participants with chronic HBV with viremia not on NRTI therapy resulted in rapid reductions in HBsAg and HBV DNA in the majority of participants. In July 2021, we initiated the Phase 2 MARCH trial to evaluate the combination of VIR-2218 and VIR-3434 as a functional cure regimen for chronic HBV infection in patients suppressed on NRTI therapy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In April 2022, we announced initial results from MARCH Part A that the combination of VIR-3434 and VIR-2218 resulted in an approximate 3 log decline in HBsAg with no safety signals reported to date. In November 2022, we announced end of treatment data for all MARCH Part A that the combination of VIR-3434 and VIR-2218 achieved mean HBsAg reductions &gt;2.7 log10 IU/mL in all cohorts, absolute HBsAg levels &lt;10 IU/mL were achieved in most participants, and no safety signals were reported to date. Additional MARCH Part A data are expected in the first half of 2023 and initial MARCH Part B data, evaluating VIR-2218 in combination with VIR-3434 for 24 and 48 weeks with and without interferon, are expected in the second half of 2023.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Initiation of the Phase 2 PREVAIL platform trial, which will evaluate the efficacy and safety of investigational therapies in participants with chronic HBV infection, is expected in the first half of 2023. The trial allows for a modular approach with a master protocol containing common elements shared across sub-protocol trials and interventions with an adaptive approach. Two sub-protocols are initially planned: the THRIVE sub-protocol in inactive carriers and the STRIVE sub-protocol in immune active, treatment na&#xef;ve patients. Initial data are expected in the first half of 2024.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Disease Overview and Limitations of Current Standard of Care</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">HBV is a significant global health threat, characterized by high morbidity, mortality, and economic burden. According to the Hepatitis B Foundation, approximately 300 million people globally are chronically infected with HBV. In the United States, up to two million people are chronically infected with HBV. Up to 40% of patients with chronic HBV will develop significant clinical consequences including cirrhosis, decompensated cirrhosis, liver failure, and HCC. Globally, approximately 900,000 people die each year from HBV-associated complications.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There is a significant unmet medical need for finite versus chronic therapies that achieve functional cure. The most commonly used therapy for chronic HBV is life-long suppressive therapy with NRTIs, like tenofovir or entecavir. However NRTIs rarely achieve functional cure , defined as the sustained loss (seroclearance) of detectable HBsAg and HBV DNA in serum, after a finite course of treatment NRTIs prevent HBV ribonucleic acid, or RNA, from being transcribed into HBV DNA, which is a process known as reverse transcription. NRTIs therefore have little to no direct impact on covalently closed circular DNA, or cccDNA, the reservoir for HBV. It has been reported that after a year of therapy with NRTIs, zero to 3% of patients experience a functional cure. Additionally, NRTIs reduce, but do not eliminate, the risk of HBV associated liver failure and liver cancer. Despite its low utilization rate, suppressive therapy with NRTIs for HBV represented over a billion-dollar market in 2021.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">An alternative treatment option for chronic HBV is a year-long course of IFN-&#x3b1; therapy, which has poor tolerability and low functional cure approximately 3% to 7% of the time. The mechanisms by which IFN-&#x3b1;, an immune cytokine, achieves a functional cure are not known, but there is additional evidence supporting the need for immune stimulation to achieve a functional cure.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Of the hundreds of millions of people with chronic HBV worldwide, only about 10% are diagnosed, and of those diagnosed, only about 22% are treated. New, functional cure therapies have potential to increase diagnosis and treatment rates. The projected size of the global HBV functional cure market is &gt;$10 billion annually.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">HBV Life Cycle and Undetectable  HBsAg as a Clinical Endpoint</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The viral life cycle of HBV is shown in the figure below. After infecting a cell, the virus forms cccDNA. This form of HBV DNA is located in the nucleus of hepatocytes and acts like a mini-chromosome. HBV DNA can also integrate into the patient&#x2019;s DNA. This form of HBV DNA is known as integrated DNA, or intDNA.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img62602283_2.jpg" alt="img62602283_2.jpg" style="width:291px;height:314px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="border-top:0.75pt solid;margin-left:4.533%;padding-top:1.0pt;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">HBV lifecycle with inhibition of processes by currently available therapies</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Arrows indicate viral life cycle process. Perpendicularly-ended lines indicate inhibition of viral process.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">HBV releases infectious virions and subviral particles, or SVPs, from infected cells. Both virions and SVPs include forms of an HBV protein called HBsAg, a blood biomarker that indicates that the HBV cccDNA and/or intDNA in that patient&#x2019;s hepatocytes are actively making HBV RNA and HBV proteins. For a registrational trial to demonstrate a functional cure, the formal endpoint accepted by the FDA, is undetectable HBsAg, defined as less than 0.05 IU/ml, as well as HBV DNA less than the lower limit of quantification, in the blood six months after the end of therapy. Achievement of this endpoint has been shown to predict improved clinical outcomes and the lack of need for further therapy.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page18"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">VIR-2218 for HBV</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Molecular Characteristics. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VIR-2218 is an investigational, single siRNA targeting a conserved sequence of HBV that allows for predicted activity</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">against 99.7% of the strains of HBV, including all 10 HBV genotypes. Because this conserved sequence falls within a specific region of the X gene of HBV that exists within all four HBV RNA transcripts, VIR-2218 is able to degrade each transcript, and consequently decrease the expression of all proteins produced by the virus: X, polymerase, S, and core. VIR-2218 is thus potentially a broad-spectrum, potent antiviral.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">HBV DNA can become integrated into human DNA as intDNA. Because VIR-2218 targets a region of HBV that is conserved in the large majority of HBV intDNA, this single siRNA is predicted to be able to prevent the production of HBV proteins derived from intDNA, as well as the production of all other HBV proteins from cccDNA.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe that the large amount of HBV protein that is transcribed in liver cells can suppress the immune system. There are at least two potential mechanisms by which suppression occurs. The first mechanism is T cell tolerance and exhaustion by the presentation of intracellular HBV antigens on hepatocytes. The second is the large quantities of HBV proteins that are released into the blood, especially HBsAg, which may also be immunosuppressive. By directly reducing the amount of HBV proteins made, VIR-2218 has the potential to decrease the ability of HBV to suppress the immune system&#x2014;in effect removing a brake on the immune system. In mice models, siRNAs that are able to reduce HBsAg expression can transform an otherwise ineffective therapeutic HBV vaccine into one that can functionally cure such mice of HBV, suggesting that HBsAg suppression has the ability to enhance the immune response against HBV.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe that VIR-2218 is the only HBV-targeting siRNA currently in development that includes ESC+ technology. We believe this technology may be able to enhance the potential safety of VIR-2218.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Phase 1/2 Trial of VIR-2218. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The trial</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">was an adaptive clinical trial designed to evaluate the safety, tolerability, pharmacokinetics and antiviral</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">activity of VIR-2218. It evaluated single ascending doses of VIR-2218 in healthy volunteers and multiple ascending doses in adults with chronic HBV suppressed on NRTI therapy. The study design is shown below.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img62602283_3.jpg" alt="img62602283_3.jpg" style="width:611px;height:287px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="border-top:0.75pt solid;margin-left:4.533%;padding-top:1.0pt;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">VIR-2218 trial in healthy volunteers and patients with chronic HBV infection</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">. Arrows indicate trial progression. HBeAg- = hepatitis B virus e-antigen negative;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">HBeAg+ = hepatitis B virus e-antigen positive; MAD = multiple ascending dose; SAD = single ascending dose; SC = subcutaneous.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Across healthy volunteers and chronic HBV patients, VIR-2218 has been generally well-tolerated. No clinically significant ALT abnormalities, which are a marker of liver inflammation, have been observed. In the Part A 900 mg cohort, asymptomatic Grade 1 ALT elevations with no associated changes in bilirubin, or other markers of liver function, have been observed. Three serious adverse events, or SAEs, have been reported, all in Part B. The first, a Grade 2 headache, resolved with intravenous fluids and non-opioid pain medications. This patient had additional symptoms of fever, nausea, vomiting and dehydration, assessed by us as consistent with a viral syndrome. The second SAE, a Grade 4 depression, occurred over 50 days after the last drug dose was administered, and was assessed by us as not related to VIR-2218. The third SAE, a patient suicide, occurred 241 days after the last dose of study drug and was assessed by us as not related to VIR-2218. Three Grade 3 adverse events of upper-respiratory tract infection, chest pain and low phosphate levels in the blood have also been reported. We did not consider any of these Grade 3 events as related to VIR-2218.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The biologic activity of VIR-2218 was assessed by declines in HBsAg. The activity of VIR-2218 through Week 48 for each dose level is shown in the graph below. For Parts B and C, the average baseline HBsAg levels were 3.3 log10 IU/mL and 3.9 log10 IU/mL, respectively. The average decline in HBsAg across HBeAg negative and HBeAg positive subjects at Week 16 was 1.5 log10, or an approximately 32-fold reduction. The declines observed in HBsAg at Week 16 ranged from 0.97 log10 to 2.2 log10, or an approximately nine to 160-fold reduction, after two 200 mg doses of VIR-2218 given four weeks apart. </span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The average HBsAg level at Week 16 was 314 IU/mL, with half of the patients achieving HBsAg values &lt; 100 IU/mL and 5/6 achieving</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">HBsAg values &lt; 1000 IU/mL. Five of the 12 patients that achieved HBsAg values of &lt;100 IU/mL maintained it through Week 48. Therefore, even though HBsAg levels gradually rebounded, overall, a durable effect was observed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page20"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The ability of VIR-2218 to result in substantial and durable declines in HBsAg after only two doses suggests that VIR-2218 has the potential to play an important role in the functional cure of chronic HBV. We have initiated and plan to initiate additional clinical trials evaluating VIR-2218 in combination with other immunomodulatory agents.</span></p>
  <p style="text-indent:4.724%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.37%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img62602283_4.jpg" alt="img62602283_4.jpg" style="width:615px;height:244px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="border-top:0.75pt solid;margin-left:4.533%;padding-top:1.0pt;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Change from Baseline in HBsAg following administration of VIR-2218</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">. Each line represents the average decline from baseline in HBsAg for VIR-2218 for each dosing level or pooled</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">placebo in Parts B and C.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">VIR-3434 for HBV</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Molecular Characteristics and Preclinical Data</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. VIR-3434 is an investigational mAb targeting a conserved region on HBsAg that allows it to</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">neutralize strains from all 10 HBV genotypes. VIR-3434 specifically targets the antigenic loop, or AGL, on HBsAg. The AGL helps the virus bind to hepatocytes and subsequently infect these liver cells. By binding to the AGL, VIR-3434 prevents viral entry, which prevents the spread of HBV to uninfected hepatocytes. VIR-3434, through a process called opsonization, also helps remove HBV virions and SVPs from the blood. Hepatitis B immunoglobulin, or HBIG, an approved therapy for preventing reinfection after transplantation and which consists of polyclonal antibodies against HBV, acts by similar mechanisms. In vitro, VIR-3434 demonstrates approximately 5000-fold greater potency than HBIG in neutralization assays. As shown in the figure below, VIR-3434 is better able to prevent the spread of HBV to uninfected cells in vivo compared to HBIG.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img62602283_5.jpg" alt="img62602283_5.jpg" style="width:476px;height:250px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="border-top:0.75pt solid;margin-left:4.533%;padding-top:1.0pt;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Progression of infection in primary human hepatocytes with hepatitis B immune globulin or VIR-3434 in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">. PHH = primary human hepatocytes.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VIR-3434 also has the potential to activate the immune system, via three different processes. First, due to specialized mutations in the Fc domain of VIR-3434, it has the potential to act as a T cell vaccine. VIR-3434, which incorporates Xencor&#x2019;s Xtend</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and other Fc technologies, has been engineered with mutations that enhance binding to the FcR IIa activating receptor and diminish binding to the FcR IIb inhibitory receptor. As such, VIR-3434 is designed to capture virions and SVPs, deliver such virions and SVPs to dendritic cells, or DCs, and instruct these DCs to mature and stimulate T cells that can eliminate HBV infected hepatocytes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Second, VIR-3434 has the potential to act via antibody-dependent cell cytotoxicity, or ADCC. In this process, by binding to HBsAg at the cell surface, VIR-3434 recruits natural killer cells to eliminate infected hepatocytes. The Fc domain of VIR-3434 has been engineered to promote ADCC. Third, by reducing the amount of HBsAg in the blood, VIR-3434 has the potential to remove a brake on the immune system by decreasing the ability of HBV to suppress it.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have also evaluated the antiviral activity of the combination of VIR-2218 and VIR-3434 in an adeno-associated virus-HBV mouse model. As shown in the figure below, VIR-2218 and VIR-3434 work together to reduce the level of HBsAg.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img62602283_6.jpg" alt="img62602283_6.jpg" style="width:564px;height:251px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="border-top:0.75pt solid;margin-left:4.533%;padding-top:1.0pt;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">VIR-2218 and VIR-3434, which was modified to have a mouse mAb backbone for this experiment, administered alone or together result in reduced HBsAg in a mouse model</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Phase 1 Trial of VIR-3434. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The trial is an adaptive clinical trial designed to evaluate the safety, tolerability, pharmacokinetics and antiviral</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">activity of VIR-3434. The current trial design of VIR-3434-1002 is shown below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page22"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Phase 1 clinical trial has four parts. Part A is a single ascending dose design in healthy volunteers with Parts B and C as single ascending dose designs in adults with chronic HBV on NRTIs. Patients in Part B had HBsAg levels less than 1,000 IU/ml for the 6 mg cohort and less than 3,000 IU/mL for the other cohorts. It is possible that patients with lower HBsAg levels will have a more profound response to VIR-3434 than patients with higher HBsAg levels. Patients with</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> HBsAg levels greater than or equal to 3,000 IU/ml were evaluated in an optional Part C. In Part D, patients with HBV DNA greater than or equal to 1,000 IU/mL who were not receiving NRTI therapy were evaluated.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img62602283_7.jpg" alt="img62602283_7.jpg" style="width:651px;height:224px;" />&#160;</p>
  <p style="margin-left:4.813%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">VIR-3434-1002 is an adaptive clinical trial design in healthy volunteers and patients with chronic hepatitis B virus infection</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">. Arrows indicate trial progression. SC = subcutaneous.</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">SAD = single ascending dose. IV = intravenous.</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:2.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:1.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;transform-origin:top left;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:1.396352513539277%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The six mg SC cohort in Part B enrolled participants with screening HBsAg less than 1,000 IU/ml.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:1.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;transform-origin:top left;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:1.396352513539277%;">(2)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The 18 mg SC cohort in Part C enrolled participants with any screening HBsAg.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The primary endpoints across all parts of the trial were safety and tolerability. The key secondary endpoint in Parts B and C is the maximum reduction of serum HBsAg from baseline. In Part D, an additional key secondary endpoint is the maximum change of HBV DNA from baseline.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All cohorts have completed dosing up to 3,000 mg administered intravenously. Data from Part A up to 3000 mg IV was generally well tolerated with no clinical safety concerns observed. In Part B, most participants achieved a &#x2265;1 log10 IU/mL reduction from baseline in HBsAg within 1-3 days. Mean HBsAg reductions in the 6 mg, 18 mg, 75 mg, and 300 mg groups were 1.30, 1.27, 1.96, and 2.21 log10 IU/mL, respectively, at nadir. All participants who received 75 mg or 300 mg of VIR-3434 achieved HBsAg &lt;100 IU/mL and 5/6 (83%) in the 300 mg group achieved HBsAg &lt;10 IU/mL. In Part D, single doses of 75 mg or 300 mg was associated with rapid reductions in HBsAg and HBV DNA in the majority of participants. Across both cohorts, 11/12 participants receiving VIR-3434 achieved a &gt;1 log10 IU/mL decline in HBsAg and 11/12 achieved a &gt;1 log10 IU/mL decline in HBV DNA with the changes in HBsAg and HBV DNA showing similar kinetics. Across all parts of the study, VIR-3434 was generally well tolerated with the majority of adverse events being mild to moderate in severity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">HBV Combinations and New Product Candidates</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page23"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Phase 2 Trial of VIR-2218 in combination with IFN-&#x3b1;. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The trial is a clinical trial evaluating the safety, tolerability,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">pharmacokinetics and antiviral activity of VIR-2218 alone and in combination with </span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IFN-&#x3b1; in adults with chronic HBV infection on NRTIs</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The trial is evaluating multiple doses of VIR-2218 200 mg, alone or in combination with IFN-&#x3b1; for 24 to 48 weeks. The trial cohorts are shown below.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img62602283_8.jpg" alt="img62602283_8.jpg" style="width:633px;height:532px;" />&#160;</p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">VIR-2218-1001 Parts D and F are evaluating multiple doses of VIR-2218 alone or in combination with IFN-&#x3b1; in patients with chronic hepatitis B virus infection</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="text-indent:4.533%;font-size:0;margin-top:2.0pt;justify-content:flex-start;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:4.984988947906702%;">1.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">HBsAg assay LLOQ and LLOD are 0.05 IU/mL. LLOD, lower limit of detection; LLOQ, lower limit of quantitation. All participants are virally suppressed on NRTIs.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VIR-2218 in combination with IFN-&#x3b1; for 24 weeks from Day 1 (Cohort 3) resulted in a more rapid and substantial decline in HBsAg compared to VIR-2218 alone (Cohort 1) and VIR-2218 lead-in followed by concomitant administration with IFN-&#x3b1; from Week 12-24 (Cohort 2). Through Week 24, mean HBsAg change from baseline were -1.9, -2.0, and -2.4 log10 IU/mL in Cohorts 1, 2, and 3, respectively, with greater than 1 log10 decline in HBsAg still at Week 48. Cohorts 4 and 5 evaluated treatment beyond 24 weeks. In both Cohorts 4 and 5, participants took VIR-2218 and IFN-&#x3b1; from Day 1 through Week 24. In Cohort 4, participants were eligible to continue IFN-&#x3b1; up to 48 weeks if they did not achieve HBsAg less than the lower limit of quantitation, or LLOQ, and participants in Cohort 5 were able to continue VIR-2218 and IFN-&#x3b1; up to Week 48 if they did not achieve HBsAg &lt;LLOQ. If a participant in Cohorts 4 or 5 achieved HBsAg &lt;LLOQ at 2 consecutive visits, they were eligible to stop therapy. Through Week 48, mean HBsAg change from baseline were -1.8 and -2.9 log10 IU/mL in Cohorts 4 and 5, respectively. Overall, 10 participants achieved HBsAg seroclearance by Week 48 across all cohorts with the majority occurring in Cohorts 4 and 5. Importantly, nine out of these 10 participants, including all four in Cohort 5, also achieved seroconversion defined as anti-HBsAb &gt; 10 mIU/mL, which suggests the potential for durability of response after stopping therapy. The treatment regimens were generally well tolerated and resulted in no new safety signals.</span></p>
  <p style="margin-left:0.08%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.037%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img62602283_9.jpg" alt="img62602283_9.jpg" style="width:672px;height:168px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Preliminary 48-week safety and efficacy data from novel investigative cohorts of VIR-2218 alone and in combination with IFN-&#x3b1; in participants with chronic HBV infection. All participants are virally suppressed on NRTIs.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Phase 2 Trial of VIR-2218 and VIR-3434 with and without IFN--&#x3b1;. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In July 2021, we initiated the Phase 2 MARCH trial to evaluate the combination of VIR-2218 and VIR-3434 as a functional cure regimen for chronic HBV infection. We believe VIR-2218 and VIR-3434 have the potential to act in concert by inhibiting virion production, removing potentially tolerogenic HBV proteins, and stimulating new HBV specific T cells. All patients were virally suppressed on NRTIs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img62602283_10.jpg" alt="img62602283_10.jpg" style="width:672px;height:234px;" />&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">MARCH: Monoclonal Antibody siRNA Combination against Hepatitis B; QW: weekly; Q4W, every 4 weeks</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">*Not exhaustive &#x2013; does not include mono therapy arms for VIR-3434. Additional cohorts may be added</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Part A of the MARCH trial evaluated the safety of the combination of VIR-2218 and VIR-3434. Cohort 1 was a lead-in with VIR-2218 followed by coadministration of VIR-3434 from Week 16-20. Cohort 2 and 3 evaluated the concomitant administration of VIR-2218 and VIR-3434 from Day 1 through Week 12, evaluating 18 mg and 75 mg VIR-3434 administered weekly. Cohort 1 demonstrated a mean 3.1 log10 decline in HBsAg at end of treatment while Cohorts 2 and 3 demonstrated a 2.7 log10 decline in</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">HBsAg. Although no participants achieved HBsAg &lt;LLOQ, most participants achieved HBsAg &lt;10 IU/mL. VIR-2218 in combination with VIR-3434 was generally well tolerated with most adverse events being mild.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img62602283_11.jpg" alt="img62602283_11.jpg" style="width:672px;height:255px;" />&#160;</p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Preliminary data from the ongoing open-label Phase 2 MARCH trial evaluating the safety, tolerability and antiviral activity of VIR-2218 in combination with VIR-3434 in virally suppressed participants with chronic HBV infection who received continuous NRTI therapy for two months or more. All participants are virally suppressed on NRTIs</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Part B of the MARCH trial is currently enrolling and is evaluating the combination of VIR-2218 and VIR-3434 with and without IFN-&#x3b1; for 24 and 48 weeks. Initial data from Part B is expected in the second half of 2023.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other Collaborators. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2021, we and Gilead initiated a multi-center, open-label Phase 2 clinical trial which is designed to evaluate the</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">safety, tolerability and efficacy of various combinations of VIR-2218, GS-9688 (selgantolimod), Gilead&#x2019;s investigational TLR-8 agonist, nivolumab, an approved PD-1 inhibitor, and TAF in adults with chronic HBV. The trial will enroll approximately 120 patients ages 18 to 65 who are either viremic or are NTRI-suppressed. Patients who are HBeAg-positive (an indicator of acute viral replication), as well as those who are HBeAg-negative, will be enrolled. The primary efficacy endpoint is the proportion of patients who achieve a functional cure (defined as HBsAg loss and HBV DNA &lt;20 IU/mL at follow-up week 24). In February 2023, due to immune-related adverse events associated with nivolumab, which are consistent with the safety profile of the class, in the cohorts evaluating nivolumab in combination with VIR-2218 and GS-9688, nivolumab was discontinued.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In April 2021, Brii Bio initiated a Phase 2 trial of VIR-2218 in combination with BRII-179, an investigational T cell vaccine, for the treatment of chronic HBV infection. Treatment has completed in this trial. Interim safety and efficacy data were presented at the APASL in February 2023. Treatment of VIR-2218 alone or in combination with BRII-179 with and without coadjuvant IFN-&#x3b1; was generally well tolerated. Although the combination of VIR-2218 and BRII-179 had greater anti-HBs responses and improved HBsAg-specific T-cell responses, comparable HBsAg reduction was observed in all cohorts at EOT (-1.7-1.8 log10 IU/mL).</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Initiation of the Phase 2 PREVAIL platform trial (NCT05612581) and its THRIVE/STRIVE sub-protocols of VIR-3434 and/or VIR-2218 and/or IFN-&#x3b1; in viremic patients with chronic HBV infection is expected in the first half of 2023. The PREVAIL platform approach allows for a modular approach with a master protocol containing common elements shared across sub-protocol trials and interventions with an adaptive approach. Two sub-protocols are initially planned. The THRIVE sub-protocol will initially evaluate the safety and efficacy of regimens containing combinations of an NRTI with VIR-3434 and/or VIR-2218 in inactive carriers defined as adults with chronic HBV that are HBeAg negative with HBV DNA &#x2264;2000 IU/mL and ALT &#x2264;ULN. The STRIVE sub-protocol will evaluate the safety and efficacy of regimens containing combinations of an NRTI with VIR-3434 and/or VIR-2218 and/or IFN-&#x3b1; in adults with chronic HBV infection who have not received prior NRTI or IFN-&#x3b1; treatment. Participants will be HBeAg positive or negative with HBV DNA &gt;2000 IU/mL, ALT&gt;ULN and &#x2264; 5&#xd7; ULN. Initial data from the PREVAIL platform trial are expected in the first half of 2024.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furthermore, in parallel with the above development programs, research efforts are underway to use our innate immunity platform to identify and disrupt the host proteins necessary for HBV cccDNA formation and stability, which we believe could result in a complete cure. We also have an HBV therapeutic vaccine that leverages our T cell platform in preclinical development. This is an example of the potential value of combining outputs from our four technology platforms to complex infectious diseases.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Chronic Treatment for HDV</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Summary</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are developing VIR-2218 and VIR-3434 for the chronic treatment and suppression of HDV. HBsAg is a critical component necessary for the HDV lifecycle and both VIR-2218 and VIR-3434 act independently to inhibit the replication of HDV by targeting HBsAg. VIR-2218 inhibits the production of HBsAg by targeting a conserved region of the HBV genome and inhibiting production of all HBV proteins including HBsAg. VIR-3434 binds to a conserved region of HBsAg, which reduces the levels of HDV virions and prevents the infection of hepatocytes with HDV. VIR-2218 and VIR-3434 as monotherapy have independently demonstrated reduction in HBsAg of greater than 1 log10 and initial data when VIR-2218 and VIR-3434 are given together have demonstrated an additive effect of almost 3 log10 decline in HBsAg through at least 20 weeks of treatment. As HBsAg is required for the lifecycle of HDV, both VIR-2218 and VIR-3434 are expected to suppress the replication of HDV and to potentially improve clinical outcomes.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Disease Overview and Limitations of Current Standard of Care</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">HDV is a replication-defective virus that uses HBsAg as its envelope protein and therefore only occurs with HBV co-infection.  Approximately 12 million people globally are infected with HDV, representing approximately 5% of the HBV population. HDV is considered the most severe and aggressive form of viral hepatitis leading to significantly more rapid progression towards cirrhosis, hepatocellular carcinoma, hepatic decomposition, and liver failure. People with HDV are 3.9 times more likely to have hepatocellular carcinoma than people with HBV and 2 times more likely to die from HDV vs. HBV mono-infection. Despite this high disease severity, there are no approved therapies for HDV in the U.S. although pegylated interferon alpha has been used off label with limited success due to its tolerability profile and low rates of sustained virologic response. Hepcludex (bulevirtide), a once daily subcutaneous injection, has conditional approval in the EU and the U.K. for the chronic treatment of HDV but has not yet been approved in the U.S. The projected size of the global HDV treatment market is &gt;$2 billion annually.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">VIR-2218 + VIR-3434 for HDV</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Phase 2 Trial of VIR-2218 in combination with VIR-3434. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In September 2022, we initiated the Phase 2 SOLSTICE trial evaluating once monthly subcutaneous injections of VIR-2218 and VIR-3434 as monotherapy and in combination for the chronic treatment of people living with HDV. The trial is assessing the safety and ability of the combination to reduce HDV viremia and normalize ALT, surrogate endpoints used for regulatory approval and endpoints that may improve clinical outcomes. Initial data are expected in the second half of 2023.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Universal Prophylaxis for Influenza A</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Summary</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are developing VIR-2482 as universal prophylaxis for influenza A. VIR-2482 is a mAb that targets a conserved region of the influenza A hemagglutinin protein and consequently has the potential to prevent illness from any strain of influenza A, including seasonal and pandemic strains. In vitro, VIR-2482 has been shown to cover all major strains of influenza A that have arisen since the 1918 Spanish flu pandemic. Since flu vaccines have incomplete strain coverage and limited efficacy, the broad coverage of VIR-2482 may allow it to achieve higher protection levels and for it to be used year after year. In addition, because VIR-2482 is an antibody that can directly confer protection, it does not rely on a person to create their own antibodies. Thus, we believe VIR-2482 has the potential to be effective even in a person with a compromised immune system. VIR-2482 has been half-life engineered so that a single dose has the potential to last the entire flu season, which is typically five to six months long. VIR-2482 is currently in a Phase 2 clinical trial. VIR-2482 was well-tolerated in the approximately 100 healthy volunteers dosed in Phase 1.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In May 2021, we signed the 2021 GSK Agreement to expand our existing collaboration to include the research and development of new therapies for influenza and other respiratory viruses. See the section titled &#x201c;Our Collaboration, License and Grant Agreements&#x2014;Collaboration Agreements with GSK&#x201d; for a description of the 2021 GSK Agreement.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Disease Overview and Limitations of Current Standard of Care</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Seasonal influenza is a significant medical and economic burden, even with vaccines. There are two major types of influenza virus: type A and type B. Influenza A has been associated with more severe illness and has been the source of all known influenza pandemics. According to the CDC, influenza A accounts for nearly 80% of infections and approximately 75-85% of influenza hospitalizations.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Seasonal influenza is a huge medical and economic burden, even with vaccines. According to the WHO, on average, each year the influenza virus is estimated to infect 1 billion people and results in approximately 6 million hospitalizations and 290,000 to 650,000 deaths globally. According to the CDC, there are approximately X infections, 500,000 hospitalizations and 34,000 deaths in</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the U.S. alone each year due to flu. The large majority of these influenza-related deaths occurred in the elderly, defined as those 65 and older, and/or those with comorbidities at high risk for severe disease. These patients comprise a population with a high unmet need for better preventive measures. There are approximately 140 million people in the U.S., U.K., Germany, France, Spain, Italy and Japan who are 65 and older with a risk-factor for severe disease and between 21 and 42% of them are hospitalized each year if they get the flu.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">According to the CDC, the efficacy of the seasonal flu vaccine has ranged from 10% to 60% over the past 16 years, with an average of 40%, overall, across all populations. The seasonal flu vaccine's efficacy in the elderly has been found to be notably lower, in some flu seasons as low as 10%. The limited success rate of current influenza vaccines has been attributed to two primary factors. First, flu vaccines have incomplete strain coverage and therefore often do not provide protection against all strains of influenza that circulate in a given season, despite being updated every year.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page25"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Second, flu vaccines are active immunizations that rely on a person's own immune system to create protective influenza virus antibodies, and many individuals do not generate an effective immune response. Clinical and technological advances in flu vaccines, such as cell-based manufacturing, mRNA-based vaccines and higher dose administration, do not address these fundamental limitations.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The projected size of the mAb flu prevention market is &gt;$5 billion annually.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">VIR-2482 for Influenza A</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Molecular Characteristics and Preclinical Data. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VIR-2482 is an investigational mAb targeting a functionally conserved epitope on the influenza A</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">hemagglutinin protein located within the stem region. We believe that all strains of influenza, past and future, have and likely will contain this conserved epitope within the stem region. In preclinical studies, we have demonstrated that, in vitro, VIR-2482 covers all the major strains of influenza A that have arisen since 1918. Thus, unlike flu vaccines, whose incomplete strain coverage results in limited efficacy despite being updated every year, the broad coverage of VIR-2482 may allow it to achieve higher protection levels and to be used year after year. In addition, because VIR-2482 is an antibody that can directly confer protection, it does not rely on a person to create their own antibodies. Thus, we believe VIR-2482 has the potential to be effective irrespective of the status of a person&#x2019;s immune system.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notably, in a 2019 clinical epidemiology study, it was observed that the presence of rare, stem-binding influenza antibodies correlated with protection from influenza infection.  While other stem-binding influenza A antibodies have been identified, we have demonstrated that VIR-2482 has the broadest coverage when compared to a large representative panel of stem-binding mAbs. In prophylactic lethal challenge studies of influenza A in mice, VIR-2482 was able to protect mice from death at VIR-2482 exposures we believe to be clinically relevant.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We engineered the parent form of VIR-2482 to extend its half-life to create VIR-2482, which incorporates Xencor&#x2019;s Xtend</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> technology. This half-life extension potentially allows for a single injection of VIR-2482 given at the start of the influenza season to maintain a protective concentration in the respiratory tract for the duration of the influenza season.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img62602283_12.jpg" alt="img62602283_12.jpg" style="width:516px;height:184px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="border-top:0.75pt solid;margin-left:4.8%;padding-top:1.0pt;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">VIR-2482 targets a highly conserved region of the influenza virus and exhibits potency against the last century of influenza viruses</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">. Following vaccination, most anti-influenza</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">antibodies target the variable head region. VIR-2482 binds to the stem region which is highly conserved over time. HA = hemagglutinin.</span></p>
  <p style="text-indent:4.733%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.556%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Phase 1 and 2 Trials of VIR-2482.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VIR-2482-3001 was a Phase 1 first-in-human, randomized, double-blinded, placebo-controlled single ascending dose trial in healthy adult volunteers with endpoints of safety, tolerability, and pharmacokinetics, or PK, when VIR-2482 is administered IM in four different doses: 60 mg, 300 mg, 1200 mg, and 1800 mg. This trial initiated in August 2019 and is now complete. The trial showed VIR-2482 was well-tolerated up to 1800 mg and is estimated to have a half-life of 58 days based on preliminary clinical data.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In September 2022, we initiated VIR-2482-4004, a Phase 1b prophylaxis trial evaluating the safety of VIR-2482 in elderly participants (aged 65 and older) receiving a flu vaccine. The trial is ongoing and initial data are expected in mid-2023.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2022, we initiated PENINSULA, a Phase 2 randomized, double-blind, placebo-controlled, dose-ranging trial in healthy adult volunteers aged 18 to 64 to evaluate the safety, tolerability and efficacy of two different intramuscularly administered doses of VIR-2482 in preventing illness due to influenza A. The primary efficacy endpoint is the proportion of trial participants with protocol-defined influenza illness, requiring one systemic symptom and one respiratory symptom, with PCR confirmed influenza A infection, compared to placebo. Other endpoints will evaluate the effect of VIR-2482 on the severity and duration of illness in trial participants with confirmed influenza A compared to placebo. Enrollment is complete and initial data are expected in mid-2023. The PENINSULA trial is being funded in part with federal funds from the HHS; the ASPR; and the BARDA, under OT number 75A50122C00081.</span></p>
  <p style="text-indent:4.814%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.222%;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.814%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.222%;text-align:center;"><img src="img62602283_13.jpg" alt="img62602283_13.jpg" style="width:552px;height:228px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.222%;text-align:center;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to VIR-2482, we are developing next generation antibodies that have the potential to be even broader, treating both influenza A and B, and more potent.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Treatment and Prophylaxis for COVID-19</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Summary</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In response to the ongoing COVID-19 pandemic, we have moved rapidly to address this global health challenge. Our focus is on treating and preventing COVID-19, as well as potential future coronavirus outbreaks. To do so, together with our collaborator GSK, we are developing the mAb sotrovimab, as well as small molecules. Vir is also developing additional differentiated mAbs as well as vaccines.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are developing sotrovimab for the treatment and prophylaxis of COVID-19. Sotrovimab is based on a parent antibody, S309, which was derived from samples previously gathered for research on pan-coronavirus-neutralizing mAbs. Data suggest that sotrovimab and VIR-7832 have the potential for &#x2018;dual-action&#x2019;, or the ability to block viral entry into healthy cells and an enhanced ability to clear infected cells.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In May 2021, the FDA granted an EUA to sotrovimab for the early treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and at high risk for progression to severe COVID-19, including hospitalization or death. In December 2021, the European Commission granted marketing authorization to Xevudy&#174; (sotrovimab) in the EU for the treatment of adults and adolescents at increased risk of progressing to severe COVID-19. In March 2022, the FDA de-authorized sotrovimab&#x2019;s use in all U.S. regions due to increases in the proportion of COVID-19 cases caused by the Omicron BA.2 subvariant.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sotrovimab has obtained emergency authorization, temporary authorization or marketing approval (under the brand name Xevudy&#174;&#xfe0f;) for early treatment of COVID-19, supplying more than 40 countries. Sotrovimab is not authorized in the U.S. Over 2.1 million doses of sotrovimab have been delivered as of December 31, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We continue to conduct in vitro testing of sotrovimab against new variants and subvariants as they emerge, and to collect and evaluate real-world evidence, both of which are being shared with regulatory authorities.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are also evaluating the use of sotrovimab in two additional indications: (1) to determine if sotrovimab can prevent symptomatic COVID-19 infection in uninfected immunocompromised adults, and (2) to evaluate if sotrovimab treatment can improve clinical outcomes in patients hospitalized with COVID-19.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to sotrovimab, we are preparing for future pandemics with coronavirus mAbs that have the potential to be even broader and more potent than sotrovimab, pan-coronavirus vaccines designed with the aim to be variant-proof (initial pre-clinical proof of concept achieved), and small molecules that have the potential to treat multiple respiratory diseases like COVID-19 and influenza (initial pre-clinical proof of concept achieved).</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VIR-7832, which has similar properties to sotrovimab, but is also designed to potentially enhance virus-specific T cell function, was evaluated in the U.K.&#x2019;s NHS-supported AGILE initiative. The Phase 1b portion of the trial assessed safety of VIR-7832 at 50 mg, 150 mg and 500 mg IV doses. The Phase 2 portion of the trial was designed to assess safety and efficacy at 500 mg IV dose. The Phase 2a was stopped early due to concerns about the evolving COVID landscape, including circulating SARS-CoV-2 variants. No safety signals were reported in the Phase 1b or 2a portions of the trial.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Disease Overview and Limitations of Current Standard of Care</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">According to the John Hopkins Coronavirus Resource Center, as of February 27, 2023, there were almost 675.1 million recorded infections and almost 6.9 million recorded deaths worldwide from COVID-19. The FDA has granted either EUAs or marketing approvals to multiple vaccines, drugs and/or antibodies to prevent or treat COVID-19 in the U.S.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For prophylaxis, despite the high efficacy of the COVID-19 vaccines, there are still populations in whom vaccine immunogenicity is suboptimal, such as the elderly with comorbidities, immunocompromised persons, or those who may not want or be able to tolerate vaccines.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For early treatment, both mAbs and small molecules have shown strong efficacy data and have pros and cons around convenience and compliance. For example, for some patients and their physicians, IM or IV mAbs may be preferred to small molecules due to administration in a single treatment visit (&#x201c;one and done&#x201d;), concerns about compliance with small molecules (multiple pills, multiple times per day, over multiple days), and concerns about oral treatment initiation requirements.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For hospitalized patients, there is still significant unmet need. Preliminary data suggest that COVID-19 mAbs may have a role in improving clinical outcomes such as decreasing intensive care unit stays and/or mortality in hospitalized patients who have severe or critical COVID-19.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Importantly, the ongoing durability of current vaccines, small molecules, and mAbs in the setting of the continued emergence of variants is uncertain.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The size of the COVID-19 prevention and treatment market is projected to continue to be double-digit billions of dollars annually.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sotrovimab for COVID-19</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Molecular Characteristics. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sotrovimab is an investigational engineered human IgG1 neutralizing anti-SARS-CoV-2 monoclonal antibody that has Fc</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">modifications that are designed to improve bioavailability in the respiratory mucosa and increase half-life, and incorporates Xencor&#x2019;s Xtend</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> technology. Sotrovimab binds with high affinity to the receptor binding domain of the SARS-CoV-2 spike protein. It is designed to have dual-actions of neutralizing the virus by blocking viral entry into healthy cells, while also enhancing the ability to clear infected cells. Sotrovimab potently neutralizes live SARS-CoV-2 in vitro and in vivo, and binds to a highly conserved epitope that is shared with SARS-CoV-1, thus potentially leading to a wide breadth of sarbecovirus coverage and a higher barrier to resistance.</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Phase 2/3 Trials of Sotrovimab.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">COMET-ICE: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sotrovimab was evaluated as a treatment in adults with mild to moderate COVID-19 at high risk of hospitalization or death. This trial</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">was a Phase 2/3, randomized, double-blind, multi-center, placebo-controlled trial investigating IV infusion of 500 mg of sotrovimab in adults with mild to moderate COVID-19 at high-risk of progression to severe disease, who were not hospitalized and did not require oxygen. The trial included a lead-in phase to evaluate the safety and tolerability of sotrovimab, followed by an expansion phase with 1:1 randomization of sotrovimab and placebo. The final COMET-ICE trial results in the full trial population of 1,057 participants demonstrated an adjusted relative risk reduction of 79% (p&lt;0.001) in all-cause hospitalization for more than 24 hours or death due to any cause by Day 29 compared to placebo, meeting the primary endpoint of the trial.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">PROTECT-V</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: Sotrovimab is being evaluated in a Phase 3 platform trial sponsored by Cambridge University Hospitals NHS Foundation Trust assessing the use of a 2 g IV dose of sotrovimab in uninfected, high-risk individuals. This is a randomized, double-blinded, placebo-controlled trial that is currently enrolling participants. The primary endpoint is PCR-confirmed symptomatic COVID-19 infection at three months. Key secondary endpoints include PCR-confirmed symptomatic COVID-19 infection at subsequent timepoints, time to confirmed SARS-CoV2 infection, safety, mortality and disease severity. Due to significant uncertainty in the anticipated infection rate, the sample size will be monitored and reviewed regularly by the independent Data Monitoring Committee (IDMC). Timing of initial data will depend on continued rate of enrollment.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">RECOVERY: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sotrovimab is being evaluated in a randomized, controlled, open-label, platform trial assessing several possible treatments in patients</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">hospitalized with COVID-19 in the U.K. Trial participants who are hospitalized with COVID-19 are eligible for random assignment in a 1:1 ratio to usual standard of care alone versus usual standard of care plus a single dose of sotrovimab given IV. Timing of initial data will depend on continued rate of enrollment.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Vaccine for HIV Prophylaxis</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Summary</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are developing a vaccine to prevent HIV. We have designed VIR-1111 and VIR-1388 to elicit T cells that recognize HIV epitopes that are different from those recognized by prior HIV vaccines and to stimulate a different and specific type of T cell immune response to HIV, known as an HLA-E restricted immune response. An HLA-E restricted immune response has been shown to be associated with protection of NHPs from SIV. In December 2020, we initiated a Phase 1 trial for VIR-1111. VIR-1111 is a proof of concept vaccine, because, at minimum, changes to the vaccine antigen from HIV will be required before starting subsequent phases of clinical development. VIR-1388 has incorporated modifications that have the potential to enhance immunogenicity compared to VIR-1111 and provide broader coverage against circulating strains of HIV. We expect to initiate a Phase 1 trial of VIR-1388 in the second half of 2023.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Disease Overview and Limitations of the Current Standard of Care</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">According to UNAIDS, each year there are approximately 1.5 million new cases of HIV and approximately 700,000 HIV-related deaths globally. Unless treated, infection with HIV results in an almost universally fatal disease, acquired immune deficiency syndrome, or AIDS. According to the WHO, almost 36 million people have died from HIV-related illnesses globally.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Highly effective HIV treatments are now available, but these medicines only suppress HIV and are not curative. They require life-long administration and carry the risk for viral breakthrough and resistance. Furthermore, while HIV prevention programs based on behavioral modification, pharmacological intervention, use of barrier devices and other methods continue to be developed, such approaches have had at most a modest effect on HIV transmission globally in high-risk populations. Therefore, we believe the most effective means of curbing the worldwide HIV epidemic would be a safe and effective vaccine for individuals who are or may become sexually active. We believe that the target population for an HIV vaccine is comprised of billions of individuals and is potentially larger than the target population for Gardasil</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, a vaccine to prevent human papillomavirus and the cancers human papillomavirus cause, due to the higher lethality associated with HIV. In 2022, Gardasil</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> revenue approximated $6.9 billion. Despite nearly 30 years of intensive efforts, no vaccine for HIV has been successfully developed.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The projected size of the HIV functional cure and prevention market is &gt;$40 billion annually.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">VIR-1111 and VIR-1388 for HIV</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Molecular Characteristics and Preclinical Data. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VIR-1111 is a proof-of-concept T cell vaccine based on HCMV that is designed to elicit T cells that</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">recognize parts of HIV epitopes that are different from those recognized by prior HIV vaccines, and to stimulate a different and specific type of T cell immune response to HIV, known as an HLA-E restricted immune response. VIR-1388 contains modifications to enhance its immunogenicity and provide broader coverage against circulating strains of HIV compared to VIR-1111. In NHP models, T cell vaccines based on an RhCMV elicited T cells that recognized 3-4 times the number of epitopes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">compared to other vaccine platforms; the specific epitopes recognized were also different, as shown in the figure below. SIV is the NHP equivalent of HIV.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img62602283_14.jpg" alt="img62602283_14.jpg" style="width:591px;height:326px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="border-top:0.75pt solid;margin-left:4.533%;padding-top:1.0pt;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Number of epitopes recognized by T cells using RhCMV compared to other vaccine vector technologies or NHPs naturally achieving SIV control</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Each line represents a different</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">NHP. Each box denotes the relative location of the epitope within the antigen that is recognized by the T cells elicited by that vaccine vector or SIV. The total number of epitopes recognized is shown on the right. RM = rhesus macaque; SIVmac239-controller = infected with a virulent strain of SIV; EP DNA/gag = electroporation of DNA expressing the SIV gag protein; Ad5/gag = Adenovirus type 5 expressing the SIV gag protein; MVA/gag = Modified vaccinia virus Ankara expressing the SIV gag protein.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further, in such NHP models, introducing different mutations to RhCMV allows the vector to be programmed to elicit an HLA-E restricted immune response. An HLA-E restricted immune response has been shown to be associated with protection of NHPs from SIV. In these series of experiments, large groups of NHPs were given an RhCMV-based vaccine, which protected more than 50% of the NHPs from repeated exposure to SIV.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Preliminary data suggest the ability to predict which NHPs will be protected from SIV after administration of the RhCMV-based vaccine. This is made possible using transcriptomic signatures, a blood test that evaluates how cells in the body respond to the vaccine. Transcriptomic signatures will be analyzed in human clinical trials. If protection effectiveness is found to be less than 100%, such data may allow us to predict who will be protected as well as to generate next-generation vaccines.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page29"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Phase 1 Trial of VIR-1111. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The trial is a multiple ascending dose clinical trial designed to evaluate the safety, tolerability, reactogenicity and</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">immunogenicity of VIR-1111 in CMV-positive healthy adult volunteers. The immunogenicity evaluation includes an assessment of the breadth and nature of the T cell response to the vaccine. The current trial design of VIR-1111-2001 is shown below. We initiated a Phase 1 clinical trial for VIR-1111 in December 2020. In November 2022, we announced that safety and immunology data from the initial two cohorts of the trial showed no safety signals and no vector shedding or viremia reported to date. In addition, no sustained HIV insert-specific T cell responses were observed in the first two cohorts. Safety and immunology data from the highest dose cohort is expected in the first half of 2023. The manufacture and early clinical development of VIR-1111 is funded by the Bill &amp; Melinda Gates Foundation. Modifications to VIR-1111 will be required before subsequent phases of clinical development, as VIR-1111 is a proof of concept vaccine and will not in its current format result in a commercial product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img62602283_15.jpg" alt="img62602283_15.jpg" style="width:394px;height:53px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="border-top:0.75pt solid;margin-left:4.8%;padding-top:1.0pt;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">VIR-1111-2001 is a multiple ascending dose escalation trial in CMV seropositive, HIV uninfected healthy adult volunteers. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Arrows indicate trial progression. CMV =</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">cytomegalovirus, HIV = human immunodeficiency virus, SC = subcutaneous, ffu = focus forming units</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Phase 1 Trial of VIR-1388. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Learnings from VIR-1111 have informed the trial design of VIR-1388. We expect to initiate a Phase 1 trial of VIR-1388 in the second half of 2023. This trial will be funded in part by the Bill &amp; Melinda Gates Foundation and the NIH&#x2019;s Division of AIDS, through the HIV Vaccine Trials Network.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Technology Platforms</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Platforms for the Creation of Transformative Medicines for Infectious Diseases</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have purposefully assembled a portfolio of technology platforms that we believe will, individually or in combination, allow us to stimulate and enhance the immune system in innovative ways and to exploit the vulnerabilities of pathogens. Our current platforms are focused on antibodies, T cells, the innate immune response and siRNAs. We have assembled these platforms through internal development, collaborations and acquisitions. We are using our platforms, and continue to evaluate others, to advance our current product candidates and generate additional product candidates for multiple indications.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We follow the science to select the modality, or combination of modalities, that gives us the highest chance of success for a specific infection in a given patient population. The diversity of our different platforms allows us to select the best modality or modalities for a given clinical need.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Antibody Platform</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Overview</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are using specialized mAbs to treat or prevent rapidly evolving and/or previously untreatable pathogens. These mAbs act in a variety of ways, including direct pathogen neutralization and immune system stimulation. We combine high-throughput, rapid isolation of rare, highly potent, broad-spectrum and fully human antibodies with targeted engineering to enhance their therapeutic potential. We expect that these specialized mAbs can be administered to transfer protective immunity to all at-risk individuals.</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect the following benefits from our antibody platform:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effective regardless of an individual&#x2019;s ability to generate their own immune response</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Diminished likelihood of self-reactivity because they are selected in humans</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Broad coverage of most or all strains of a pathogen, or even multiple pathogens</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">High affinity binding to conserved pathogen antigens, resulting in a high barrier to resistance</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Longer half-life than naturally occurring antibodies</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Potential to induce a vaccinal effect, i.e., to elicit continued protection even after the mAb is no longer present</span></div></div>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sotrovimab (previously VIR-7831), VIR-3434 and VIR-2482 were generated using our antibody platform.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our Approach</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img62602283_16.jpg" alt="img62602283_16.jpg" style="width:580px;height:160px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We use a proprietary antibody screening technology that allows us to characterize the antibodies produced from hundreds of millions of B cells derived from survivors of an infection to identify those rare antibodies that have the characteristics needed to create an effective medicine. Rare characteristics include, for example, the ability to bind to a highly conserved antigen within a pathogen and the ability to neutralize multiple different pathogens. We refer to this technology as High Throughput Isolation since we are able to screen hundreds of millions of B cells to find rare antibodies in just weeks.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Following isolation, we clone the antibody genes and express the resulting fully human antibody for further trials, engineering and development.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have applied these methods to identify mAbs for a range of pathogens including SARS-CoV-2, HBV, HDV, influenza A and influenza B virus, Ebola, HIV, RSV, MPV, malaria, rabies, clostridium difficile, Staphylococcus aureus, Klebsiella pneumoniae, and Acinetobacter spp. Examples of the power of this platform are sotrovimab (previously VIR-7831; and where marketing authorization has been granted, marketed under the brand name Xevudy&#174;),</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our anti-SARS-CoV-2 mAb, and Ebanga (ansuvimab-zykl, formerly known as mAb114), the anti-Ebola virus mAb identified by our scientists in collaboration with the NIH and others and marketed by Ridgeback Biotherapeutics LP.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Precision Antibody Engineering to Create the Best Medicines</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our strategy is to optimize both the Fab and Fc domains of a mAb to generate the best medicine to treat or prevent infection. Having isolated a rare, fully human antibody via High Throughput Isolation, we then engineer as desired both parts of the mAb, the Fab and Fc domains, to enhance efficacy, potency and manufacturability. The Fab portion binds to the protective antigen on the pathogen. The Fc portion binds to effector proteins and cells in the body to engage the immune system in killing and clearing the infection.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fab engineering is performed to further increase mAb potency and breadth of coverage. mAb potency and breadth are based on the epitope bound, affinity of binding and valency. In some cases, it may be valuable to create mAbs that bind to more than one epitope, so-called &#x201c;multi-specific&#x201d; mAbs, by engineering the Fab region. There are many approaches to creating multi-specific antibodies, and we are exploring a number of them, including some that naturally occur in people. We believe that naturally occurring multi-specific antibodies can be leveraged to create new and potent therapeutics and to enhance antibody prophylaxis of disease, and have the potential for higher manufacturing yields and better pharmacokinetics in patients, as compared to artificial multi-specific formats currently being developed.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fc engineering selects and optimizes the specific ways in which mAbs engage Fc receptors, or FcRs, which in turn govern &#x201c;effector functions&#x201d; such as the half-life of the antibody and the way that the immune system is recruited by the mAb to fight infection. Effector functions can be enhanced or reduced via Fc mutations that alter the binding affinity of the Fc domain of a mAb to the various FcRs, based on a detailed understanding of the role of individual FcRs in half-life and immunity. Examples of immunity that can be altered in this way include the recruitment of serum proteins to infected areas, phagocytosis and destruction of viruses and viral particles, the killing of virus-infected cells through a process known as ADCC and the presentation of antigens to elicit B and T cell immunity.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page31"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Antibodies as T Cell Vaccines</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are using Fc engineering to create antibodies that are designed to not only directly treat or prevent infection but also to immunize an infected individual against future infections. We refer to this property as a vaccinal effect, i.e., eliciting continued protection even after the mAb is no longer present. This technology benefits from the fact that FcRs on specialized antigen-presenting cells, which are called dendritic cells, or DCs, internalize complexes of antibody and antigen. Our strategy leverages the observation that different FcRs on antigen presenting cells can bind different parts of the Fc portion of the mAb. By engineering the Fc region, we can select which FcRs interact with the antibody-antigen complex to generate activated DCs that we believe can effectively induce T cell immunity.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img62602283_17.jpg" alt="img62602283_17.jpg" style="width:537px;height:237px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="border-top:0.75pt solid;margin-left:4.533%;padding-top:1.0pt;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Design and mechanism of vaccinal antibodies intended to induce enhanced immunity through induction of T cells</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The Fc portion of mAbs interacts with FcRs on DCs to trigger</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">uptake of antigen and induction of T cells. Engineering of the Fc portion of the mAb is predicted to increase the induction of T cells by these DCs.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Specific vaccinal mutations in the Fc domain can enhance immune responses to a pathogen in two ways. First, the mAb can deliver increased amounts of antigen to DCs. Second, FcRs deliver signals that activate DCs. In turn, activated DCs can stimulate T cells specific to the delivered antigen, resulting in T cell immunity. In this way, an antibody with vaccinal mutations can potentially actively immunize infected patients. The in vivo data supporting enhancement of the vaccinal effect through Fc mutants has been demonstrated by others in a CD20 positive tumor model, using mice with humanized Fc receptors. In this experiment, anti-CD20 mAbs and CD20 tumor cells were administered to mice months before being later rechallenged with a lethal dose of CD20 tumor cells. 80% of the mice who received a mAb with Fc mutants that enhanced binding to activating FcRs IIa and IIIa survived. Conversely, 70% or more mice who received a mAb without the enhancing Fc mutations died. This durable protection is believed to be the result of the induction of a T-cell response. We have also generated similarly compelling animal data in influenza. We are testing this technology in chronic HBV infection with VIR-3434, and if it performs as expected, we believe it may have applicability to multiple other infections including influenza and HIV.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">T Cell Platform</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Overview</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">T cells can prevent or control infection and cancer. T cells are diverse in how they sense pathogens and cancer cells, the tissues that they protect and the effector functions that they use to control infection or cancer. Our approach is to use HCMV as a vaccine vector to potentially treat and prevent infection by pathogens refractory to current vaccine technologies because HCMV may induce potent and long-lasting T cell responses to a broader range of epitopes than observed for other viral vaccines. In addition, we can make proprietary modifications in the HCMV genome that we expect will elicit different types of pathogen-appropriate T cell responses. Experiments in NHPs demonstrate the ability of vaccine vectors based on the closely related RhCMV to protect against SIV, a close relative of HIV, and TB, two of the most challenging infections for which to create effective vaccines.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page32"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">HCMV infects a large proportion of the human population and causes a life-long asymptomatic infection that typically causes no harm. This is due to millions of years of co-evolution between the virus and host in which the virus evades</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> sterilizing immunity using specialized viral genes, while at the same time allowing the generation of certain T cell responses that prevent HCMV infection from becoming lethal.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect the following benefits from our T cell platform:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Highly potent and long-lived T cell responses throughout the body</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Induction of high numbers of specialized T cells, known as effector memory cells, that allow control of disease in the first few days after infection</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Immune responses to three- to four-fold more antigenic epitopes in a target protein than other viral vectors</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Programmable T cell responses allowing selection of the type of T cells elicited</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Generation of universal T cells that may be active in most or all people despite high genetic variability between people in immune response genes</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Opportunity for repeated vaccination using the same backbone HCMV vector against different infections</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Opportunity to use the same vaccine to protect against multiple pathogens</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Potential to induce responses even to proteins that the host is tolerant of, such as self-proteins expressed in a tumor</span></div></div>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VIR-1111 and VIR-1388 were generated using our T cell platform.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our Approach</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe that the type of T cell response elicited by an HCMV-based vaccine vector can be selected by mutating certain genes in HCMV. We term this approach &#x201c;immune programming.&#x201d; We believe that immune programming is critical to combatting infections such as HIV and TB that have proven intractable, to date, for other vaccine technologies.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Immune programming is best understood in the context of the normal processes that elicit T cell immunity. T cells that fight infection and cancer are elicited by DCs, as well as other types of cells. The elicited T cells detect small peptide fragments from antigens on the surface of DCs and other antigen presenting cells, which have been captured in grooves found within specialized proteins encoded by major histocompatibility complex, or MHC, genes.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The unique immunology of HCMV depends on the virus&#x2019;s ability to regulate the normal immune processes of antigen presentation by MHC genes. HCMV contains multiple genes that regulate many of the steps in antigen presenting cells that elicit T cell immunity by altering antigen presenting cell biology, the types of antigen presenting cells infected by the viral vaccine and the mechanisms responsible for the ability of a T cell to recognize antigens together with MHC molecules. Through manipulation of the HCMV genome, we believe we can program different types of pathogen-appropriate T cell responses.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">MHC-E as a Near-Universal Target for Medicines that Leverage T Cell Receptors</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">T cells need to be able to recognize a highly diverse set of pathogen proteins to be effective. This diversity comes from the use of multiple different host immune response MHC genes to present foreign antigens to T cells. Some immune response MHC genes are highly variable between individuals, while others are less variable between individuals as illustrated below. The immune response MHC genes that are highly variable between individuals are responsible for most T cell responses. These MHC molecules enable T cells to recognize foreign proteins through the use of a highly specialized T cell receptor, or TCR, on the T cell surface.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">An important consequence of the inter-individual variation in some immune response MHC genes is that a TCR that recognizes an antigenic peptide associated with one person&#x2019;s MHC molecules could attack even normal tissues of a person with different MHC genes. As a result, identifying universal TCRs and universal T cell antigens that work in all people has been very challenging.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page33"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our T cell platform may enable us to create vaccines or other types of medicines that are near universal in their effects on human immunity. The programmed T cell responses elicited by engineered HCMV vectors are predicted to use immune response MHC genes that vary minimally between people, instead of the highly variable immune response MHC genes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> targeted by other types of vaccines. As demonstrated by the graphic below, TCRs recognizing antigenic peptides together with MHC-E may be functional in all individuals, potentially allowing for the generation of universal TCR-based medicines, such as off-the-shelf cancer cell therapy. The peptides presented by MHC-E may be immunogenic in all individuals, potentially allowing for the generation of universal infectious disease and cancer vaccines.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img62602283_18.jpg" alt="img62602283_18.jpg" style="width:478px;height:271px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="border-top:0.75pt solid;margin-left:4.533%;padding-top:1.0pt;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Comparison of standard T cell responses to MHC-E responses</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Peptides that are bound to MHC-I, -II or -E proteins are expressed on cell surfaces where they are recognized by T cell</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">receptors on T cells (TCRs). This interaction results in the expansion of T cells that can recognize diverse antigen peptides (top row) and that carry out functions that protect the host. Since MHC-I and MHC-II molecules are highly variable between people, peptide presentation to TCRs has a high degree of individual specificity, as illustrated by the different colors of each peptide in the top row. In contrast to MHC-I and MHC-II, MHC-E proteins (bottom row) are conserved in the human population.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Specifically programmed RhCMV vectors can elicit strong T cell responses that target MHC molecules which vary minimally between NHPs. One such protein is MHC-E. The fundamental discovery, by some of our founders, that enables this part of our T cell platform is that RhCMV responses can be programmed to generate abundant MHC-E-restricted T cells.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe that using our T cell programming approach will allow us to select vaccine antigens and to identify TCRs that work across the human population. An example of a use of such a TCR would be creating a biological product that specifically recognizes infected cells in all individuals.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page34"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Programming T Cell Responses to Create HIV and TB Vaccines</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Two of the most challenging infections for vaccine development are HIV and TB. Preclinical studies have demonstrated that programmed RhCMV vectors can be used to vaccinate against either SIV or TB in NHPs. For example, as shown in the figure below, in an NHP study, an MHC-E programmed RhCMV vaccine effectively protected more than half of NHPs from infection when challenged with a highly virulent form of SIV, under conditions in which all animals in the control group became infected. SIV vaccines programmed in other ways were not protective, demonstrating the potential value of having a programmable T cell vaccine platform.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img62602283_19.jpg" alt="img62602283_19.jpg" style="width:606px;height:172px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="border-top:0.75pt solid;margin-left:4.533%;padding-top:1.0pt;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Primary data for the protective effects of RhCMV-derived T cell vaccines on SIV infection</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Rhesus monkeys were vaccinated with an RhCMV vaccine that elicits CD8 T cells</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">recognizing SIV peptides presented by MHC-E and MHC-II or a control before challenge with SIV by rectal or vaginal routes. SIV genome copies were measured in peripheral blood (vertical axis) at intervals</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="border-top:0.75pt solid;margin-left:4.533%;padding-top:1.0pt;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">after challenge (horizontal axis). SIV infection was cleared in approximately 51% of intrarectal challenged animals and approximately 60% of intravaginal challenged animals while the infection was progressive in all unvaccinated controls.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Protection has also been observed against TB in preclinical studies of NHPs after immunization with either of two different RhCMV vaccines. One of the protective vaccines was programmed to elicit MHC-II and MHC-E responses, while the other was programmed to elicit a response depending on MHC-I genes. This shows the potential significance of being able to specifically program a T cell vaccine to target a given infection, as the programming of a vaccine to protect against SIV can be different from the programming of a vaccine to protect against TB. These preclinical data support our plans to use our T cell platform to vaccinate against HIV and TB.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Bill &amp; Melinda Gates Foundation is providing funds for the process development and manufacturing and early clinical development of our HIV and TB vaccine programs. If proof of concept for the potential efficacy of our T cell vaccine platform is obtained in currently planned clinical trials, we plan to apply this T cell platform for treating additional types of infections, as well as potentially even cancers.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Innate Immunity Platform</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Overview</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Innate immunity protects us during the early stages of infection until antibodies and T cells can be generated by the immune system. Importantly, innate immunity is not pathogen-specific. We believe that we can target innate immunity to create medicines that break the &#x201c;one-drug-for-one-bug&#x201d; paradigm by producing &#x201c;one-drug-for-multiple-bugs.&#x201d; We term this concept &#x201c;host-directed therapy&#x201d; because the medicine would target a host protein instead of pathogen proteins, which are the target of standard antibiotics and antivirals. We can also identify proteins that are critical for a high priority infection, such as HBV, for which host-directed therapy might be part of a functional cure or complete cure. This platform may also identify targets relevant to diseases outside of infection.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page35"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our scientists have developed and applied cutting-edge CRISPR-based genetic technologies to identify host genes that regulate innate immunity and/or pathogen replication. We have built internal capacity to systematically extend such trials to multiple pathogens and multiple aspects of innate immunity. We have joined the Broad Institute&#x2019;s Functional Genomics Consortium, which provides us access to cutting-edge CRISPR reagents and computational services for whole-genome and custom-designed genetic screens.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img62602283_20.jpg" alt="img62602283_20.jpg" style="width:495px;height:218px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="border-top:0.75pt solid;margin-left:4.8%;padding-top:1.0pt;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Design of steps in our innate immunity platform</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">. We are systematically mapping the genes that regulate pathogen control across a diverse set of pathogens. To accomplish this, advanced gene editing technology (CRISPR) is used to create cell libraries in which individual genes are either knocked out or activated. By exposing these cell libraries to pathogens of interest, under different screening conditions, we can systematically create genomic maps that identify genes that could lead to pathogen control. By computationally comparing these genomic maps, genes or pathways that are common to multiple pathogens can be identified and could lead to the development of products that could treat more than a single pathogen. Human rhinovirus = HRV.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect the following benefits from our innate immunity platform:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Enhancement of the potency of innate immunity, allowing for control of multiple unrelated pathogens</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">High barrier to resistance since the targeted host protein is not likely to mutate</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Identification of key host targets in areas outside of infectious disease</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our Approach</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our innate immunity platform envisions three steps leading to new medicines, as illustrated in the figure above.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Step 1: CRISPR Screens to Map the Genomic Landscape of Infection and Innate Immunity</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Multiple types of proteins participate in innate immunity and infection, as they may be required for entry, replication, gene expression, pathogenicity and/or innate immune control of an infectious agent.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page36"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To identify such proteins, we screen CRISPR-derived cell libraries after infection, treatment with cytokines that trigger innate immunity, or both, and then select cells with desired properties. Using next-generation sequencing, we identify genes responsible for the desired property. By combining these data across screens and across pathogens, our team has created, and is continuously expanding, a proprietary database of the genomic landscape of infection and innate immunity.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img62602283_21.jpg" alt="img62602283_21.jpg" style="width:485px;height:265px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="border-top:0.75pt solid;margin-left:4.8%;padding-top:1.0pt;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:4.813%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.741%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">CRISPR screen for genes involved in RSV replication</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">. A CRISPR cell library was prepared in cells in which RSV can replicate. After a period of infection with an RSV strain</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">expressing a fluorescent protein which serves as a surrogate for viral replication, cells were separated using flow cytometry into populations in which RSV replication was decreased or increased. Deep sequencing of the population exhibiting decreased replication compared to control revealed candidate genes required for efficient replication. Computational analysis represented on the right panel revealed that some of these genes fall into nodes that function in specific cellular processes. These nodes are represented as dots interconnected with a dense network of lines.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As an example, to identify genes required for RSV growth, we performed a screen in which a CRISPR-generated cell library was infected with RSV, as shown in the figure above. We then purified and sequenced populations exhibiting low or high RSV growth. Sequencing of the RSV low population revealed genes potentially required for RSV infection. When analyzed computationally, these genes fell into sets involved in specific cellular processes. These genes are potential targets for product candidates. We performed a similar screen with the influenza A virus and HRV and found that certain genes are shared between RSV, influenza A virus and HRV. Targeting such proteins might result in a pan-respiratory virus product candidate capable of treating RSV, influenza A virus and HRV.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The result from this step of the innate immune platform is a continuously updated database of the genomic landscape of pathogen replication and innate immunity. We have already performed multiple screens, and additional screens and target validation trials are in progress.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Step 2: Computational Analysis for Identification of Product Targets</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Results from CRISPR screens provide the critical data that helps identify host targets necessary for a given pathogen. When creating a single drug for multiple pathogens, host targets in common among multiple pathogens are identified. After having identified the critical set of host targets necessary for a pathogen or pathogens, the specific target for a new medicine is selected by computationally integrating diverse data sets that account for tissue gene expression, human genetic variation, redundancies in cellular pathways and protein-protein interaction networks, among other factors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Step 3: Product Discovery</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page37"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Once a specific target has been chosen, the modality used to disrupt the function of the target is then selected. Potential modalities may include small molecules, antibodies or siRNAs. Standard drug discovery efforts are then applied to identify a lead product candidate. Alternatively, machine learning and database mining can be used to identify pre-existing chemical matter that is already known to inhibit an identified host target. This chemical matter can then be verified as having</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> anti-pathogen activity, and serve as a lead compound. There are two potential outcomes from Step 3: one-drug-for-one-bug and one-drug-for-multiple-bugs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">siRNA Platform</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Overview</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gene expression can be altered by two main types of synthetic oligonucleotides: (i) antisense oligonucleotides; and (ii) siRNAs. We believe that our current approach leveraging siRNAs may have safety and potency advantages over antisense oligonucleotides. The first FDA-approved siRNA in the United States was ONPATTRO&#174; (patisiran), which was developed by our collaborator, Alnylam.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img62602283_22.jpg" alt="img62602283_22.jpg" style="width:455px;height:302px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="border-top:0.75pt solid;margin-left:4.533%;padding-top:1.0pt;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Mechanism of siRNA action to regulate gene expression</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Intracellular double stranded RNA, or dsRNA, is processed by the &#x201c;dicer&#x201d; complex to produce siRNAs that become integrated</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">into a multi-subunit protein complex, the RNA-induced silencing complex, or RISC, which guides the siRNAs to the target messenger RNA, or mRNA, sequence. The siRNA duplex unwinds, and the antisense strand remains bound to RISC and directs site-specific cleavage of the target complementary mRNA sequence, resulting in mRNA degradation and reduced expression of the target protein. (A)n = polyadenylation.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">siRNAs act via an RNA interference, or RNAi, mechanism involving sequence-specific knockdown of target RNAs. Our bodies create their own so-called endogenous siRNAs, which act via the RNAi mechanism. This RNAi mechanism can be exploited by chemically synthesizing synthetic siRNAs that are introduced as medicines to knock down target RNAs that express pathogen or host proteins of interest. Pursuant to our collaboration and license agreement with Alnylam, we have an option to license Alnylam&#x2019;s siRNA technology for use in up to four other infectious disease targets in addition to VIR-2218 for HBV. See the section titled &#x201c;Our Collaboration, License and Grant Agreements&#x201d; for a description of the collaboration and license agreement.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect the following benefits from our siRNA platform and siRNAs generally:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cutting-edge siRNA design, through collaboration with Alnylam</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Direct anti-pathogen activity and potential for immunomodulation</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Diminished off-target siRNA effects via use of next generation ESC+ technology as a differentiator compared to other siRNA approaches, which has the potential to increase the therapeutic index</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;" id="page38"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Efficient targeting of siRNAs to the liver using GalNAc technology</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">33</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Extended effects of siRNA may last for weeks to months in humans</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VIR-2218 was generated using our siRNA platform.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our Approach</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have elected to develop modified siRNAs initially for infectious diseases of the liver because these product candidates can be administered subcutaneously, are highly stable in the blood stream and are efficiently delivered into hepatocytes via GalNAc sugar modification. Once in a liver cell, the siRNA can act to reduce pathogen or host gene expression. Such siRNAs can be further modified to reduce off-target activity, and potentially increase the therapeutic index. Since October 2017, we have collaborated with Alnylam to leverage this validated technology, with the goal of eliminating key host factors necessary for pathogen survival and removing microbial immune countermeasures.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe that HBV persists in part due to the expression of viral proteins such as HBsAg, which potentially inhibit antibody, T cell, and innate immune responses. This prevents the immune response from clearing HBV. By inhibiting the expression of these viral proteins, we envision enhancing immune function in persistently infected individuals. Furthermore, we believe that combining siRNA therapy with products derived from our other platforms, including antibodies, T cells and innate immune modulators, may allow us to rapidly advance a functional cure for HBV and a chronic treatment for HDV as well.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">siRNA Delivery Mechanism</span></p>
  <p style="text-indent:4.707%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since unmodified synthetic siRNAs can be unstable in the blood stream, methods to stabilize synthetic siRNAs have been pioneered by Alnylam including using their ESC technology.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">An approach that has been used successfully to deliver siRNA to liver cells is to conjugate siRNAs to a specific sugar known as a GalNAc, whose receptor is exclusively expressed at high levels on hepatocytes, allowing for uptake of large quantities of siRNA into hepatocytes. Importantly, a GalNAc-conjugated siRNA can be delivered to the liver by subcutaneous injection, making administration relatively simple.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page39"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Potentially Enhancing the Therapeutic Index by Diminishing Off-Target Activity of siRNAs</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A distinguishing characteristic of VIR-2218 siRNA, and of future siRNAs that we may develop with Alnylam, is the application of a new approach to diminish off-target effects of RNAi. siRNAs may cause unwanted alterations to non-target host RNAs, a process known as off-target activity, which can result in short- or long-term toxicity. To reduce off-target activity, which is thought to be due in part to microRNA, or miRNA, activity, it is necessary to preserve the RNAi activity of an siRNA while simultaneously decreasing its miRNA activity, as shown in the figure below. Alnylam scientists have pioneered placement of a modified nucleotide called a glycol nucleic acid, or GNA, into the part of the siRNA that generates miRNA-like activity. GNA modification has been shown to reduce miRNA activity, while preserving the RNAi activity of siRNA. The combination of GNA modification and other chemical modifications that enhance siRNA stability is called ESC+ technology. In animal models, reducing off-target miRNA activity can result in an increased therapeutic index of approximately five-fold. A higher therapeutic index has the potential to allow for higher siRNA doses and/or a longer duration of therapy, while maintaining a favorable safety profile. VIR-2218 was the first siRNA to enter the clinic with ESC+ technology.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img62602283_23.jpg" alt="img62602283_23.jpg" style="width:401px;height:271px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="border-top:0.75pt solid;margin-left:4.8%;padding-top:1.0pt;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">On-Target and Off-Target Activity of siRNA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">siRNAs can have off-target activity when siRNA binds to mRNA with a partial sequence match, leading to translation repression or mRNA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">destabilization of unrelated messages (right side). This contrasts with the intended on-target activity of an siRNA, which binds to an mRNA through a match to the entire sequence, leading to mRNA cleavage (left side). mRNA = messenger ribonucleic acid; RISC = ribonucleic acid-induced silencing complex.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Collaboration, License and Grant Agreements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Collaboration Agreements with GSK</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2020 Collaboration Agreement with GSK</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2020, we entered into a definitive collaboration agreement with GSK, or the 2020 GSK Agreement, pursuant to which we agreed to collaborate to research, develop and commercialize products for the prevention, treatment and prophylaxis of diseases caused by SARS-CoV-2, the virus that causes COVID-19, and potentially other coronaviruses. The collaboration initially focused on the development and commercialization of three types of collaboration products under three programs: (1) antibodies targeting SARS-CoV-2, and potentially other coronaviruses, or the Antibody Program; (2) vaccines targeting SARS-CoV-2, and potentially other coronaviruses, or the Vaccine Program, and (3) products based on genome-wide CRISPR screening of host targets expressed in connection with exposure to SARS-CoV-2, and potentially other coronaviruses, or the Functional Genomics Program. The initial antibodies under the Antibody Program are sotrovimab (previously VIR-7831) and VIR-7832.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page40"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The original 2020 GSK Agreement contained the following key terms. For a period of four years beginning April 2020, the parties agreed to conduct certain research and development activities under mutually agreed development plans and associated budgets for each of the three programs, and under the oversight of a joint steering committee, or JSC. During such period, generally, subject to certain rights granted to WuXi Biologics (Hong Kong) Limited, or WuXi Biologics, under then existing agreements between us and WuXi Biologics, the parties would have an exclusive research collaboration with respect to antibody products directed to SARS-CoV-2 or to any other coronavirus, and in connection with</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> functional genomics CRISPR screens for drug discovery and development in connection with SARS-CoV-2 or other coronaviruses. We are primarily responsible for the development and clinical manufacturing activities for the Antibody Program, and for conducting the initial development activities directed to a vaccine in the Vaccine Program. GSK is primarily responsible for the commercialization activities for the Antibody Program (except in connection with sales of antibody products licensed to WuXi Biologics in mainland China, Hong Kong, Macau and Taiwan), the later-stage development, manufacturing and commercialization activities for the Vaccine Program and the development, manufacturing and commercialization activities for the Functional Genomics Program. We and GSK are required to use commercially reasonable efforts to conduct the activities assigned to each party under each development plan and to seek and obtain regulatory approval for collaboration products that arise from such activities in the United States and specified major markets. Subject to an opt-out mechanism, we and GSK share all development costs, manufacturing costs and costs and expenses for the commercialization of the collaboration products, with us bearing 72.5% of such costs for the antibody products, 27.5% of such costs for the vaccine products, and we and GSK sharing equally all such costs for the functional genomics products, and all profits will be shared in the same ratios. If we and GSK elect to conduct a technology transfer of manufacturing technology under our agreement with WuXi Biologics (as further described below), we will bear 72.5% of the costs related to such manufacturing technology transfer and for commercial manufacturing of the antibody products under such agreement with WuXi Biologics, and GSK will bear 27.5% of such costs. The parties will also share the committed costs for the reservation of manufacturing capacity for the drug substance for antibody products in the foregoing ratio under our agreement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">with Samsung as well as such costs relating to committed manufacturing capacity for antibody products as are approved by the JSC from time to time.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On a collaboration product-by-collaboration product basis, each party has the one-time right, at specified points in development, to opt out of its co-funding obligations, and the other party may, at its election, either pursue such program unilaterally, or also cease research and development activities and funding of such collaboration product. If the opt-out provisions are not exercised by either party subject to the terms of the 2020 GSK Agreement, the parties share all profits and losses arising from any collaboration product in the same ratios in which the parties bore development costs for such collaboration program. For each collaboration product as to which a party exercises its opt-out right, the commercializing party pays to the opt-out party royalties on net sales of the applicable collaboration product at rates based on factors such as the stage of development of such collaboration product at the time the opt-out party exercises such right, and whether the opt-out party is the lead party, or a portion of the sublicense revenue if the commercializing party chooses to sublicense or otherwise divest rights to such collaboration product. On an antibody product-by-antibody product basis, we have a co-promotion right for such antibody product in the United States, under which we have the right to perform up to 20% of details in connection with such antibody product. GSK will lead commercialization and book all sales and is required to use commercially reasonable efforts to commercialize each collaboration product following regulatory approval in the United States and specified major markets. This definitive agreement superseded and replaced the April 2020 preliminary agreement with GSK. In connection with the 2020 GSK Agreement, we also entered into a stock purchase agreement in April 2020, pursuant to which we issued 6,626,027 shares of our common stock to Glaxo Group Limited, or GGL, an affiliate of GSK, at a price per share of $37.73, for an aggregate purchase price of approximately $250.0 million.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2020 GSK Agreement as amended will remain in effect with respect to each collaboration program for as long as there is a collaboration product being developed or commercialized by the lead party, or the non-opt-out party, in such program. Either party has the right to terminate the 2020 GSK Agreement in the case of the insolvency of the other party, an uncured material breach of the other party with respect to a collaboration program or collaboration product, or as mutually agreed by the parties.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2021, Beecham S.A. assigned and transferred all its rights, title, interest, and benefit in the 2020 GSK Agreement to GlaxoSmithKline Biologicals S.A., including all its rights to bring claims under such agreement.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On May 27, 2022, we entered into Amendment No. 1 to the 2020 GSK Agreement, or Amendment No. 1. Pursuant to Amendment No. 1, we and GSK acknowledged that the antibody products that had been licensed to WuXi Biologics in mainland China, Hong Kong, Macau and Taiwan and had reverted to us pursuant to the Termination Agreement (described below) and agreed with GSK that they are now included in and governed by the 2020 GSK Agreement, subject to certain amendments relating to sotrovimab.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Under the terms of Amendment No. 1, GSK has the sole right to develop (including to seek, obtain or maintain regulatory approvals), manufacture and commercialize sotrovimab in and for mainland China, Hong Kong, Macau and Taiwan at GSK&#x2019;s sole cost and expense (other than certain payments for which we remain responsible under certain of our existing agreements with third parties). GSK paid us a one-time upfront payment of $7.0 million in consideration for the rights and licenses granted to GSK under Amendment No. 1. In addition, GSK will be obligated to pay us tiered royalties on net sales of sotrovimab in mainland China, Hong Kong, Macau and Taiwan in percentages ranging from the high teens to the low thirties. Such royalties are payable to us during the term of the 2020 GSK Agreement applicable to the Antibody Program.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On February 8, 2023, we and GSK entered into Amendment No. 2 and Amendment No. 3 to the 2020 GSK Agreement.  Pursuant to Amendment No. 2 to the 2020 GSK Agreement, effective as of March 31, 2022, or the Effective Date, we and GSK agreed to remove the Vaccine Program from the 2020 GSK Agreement, and to wind down and terminate the cost-sharing arrangements and all ongoing activities in relation to the Vaccine Program.  As of the Effective Date, the Vaccine Program had not yet advanced to its predefined development candidate stage. We retain the right to progress development of vaccine products directed to SARS-CoV-2 and other coronaviruses independently (including with or for third parties) outside the scope of the 2020 GSK Agreement, subject to the payment of tiered royalties to GSK on net sales of any vaccine products covered by certain GSK intellectual property rights in the low single digits, subject to certain deductions in certain circumstances. Pursuant to Amendment No. 3 to the 2020 GSK Agreement, we and GSK agreed to modify the Antibody Program to remove from the collaboration all coronavirus antibodies other than sotrovimab and VIR-7832, and certain variants thereof.  Sotrovimab and VIR-7832, and certain variants thereof, remain subject to the terms of the 2020 GSK Agreement, and we retain the sole right to progress the development and commercialization of the terminated antibody products independently (including with or for third parties), subject to the payment of tiered royalties to GSK on net sales of such terminated antibody products at percentages ranging from the very low single digits to the mid-single digits, depending on the nature of the antibody product being commercialized, and subject to certain deductions in certain circumstances.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2021 Expanded GSK Collaboration</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In May 2021, we entered into the 2021 GSK Agreement under which the parties agreed to expand the 2020 GSK Agreement, to include collaboration on three separate programs: (1) a program to research, develop and commercialize mAbs for the prevention, treatment or prophylaxis of the influenza virus, or the Influenza Program, excluding VIR-2482 unless GSK exercises its option as described below; (2) an expansion of the parties' current Functional Genomics Program to focus on functional genomics screens directed to targets associated with respiratory viruses, or the Expanded Functional Genomics Program; and (3) additional programs to develop neutralizing mAbs directed to up to three non-influenza target pathogens selected by GSK, or the Selected Pathogens, and such programs, or the Additional Programs. Under the Influenza Program, we will collaborate to research, develop and commercialize our next generation mAbs for the prevention, treatment or prophylaxis of influenza. In addition, after we complete and report the Phase 2 clinical trial outcomes for VIR-2482, GSK has the exclusive option to obtain exclusive rights to co-develop and commercialize VIR-2482, or the Option.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page41"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the 2021 GSK Agreement, we entered into a stock purchase agreement with GGL pursuant to which we issued 1,924,927 shares of our common stock to GGL for an aggregate purchase price of approximately $120.0 million. The 2021 GSK Agreement superseded and replaced the preliminary agreement entered into with GSK in February 2021, or the 2021 Preliminary Agreement.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For a period of three years following the effective date of the 2021 GSK Agreement, or the Research Term, the parties will conduct certain research and development activities under mutually agreed development plans and associated budgets for the programs within the expanded collaboration. Subject to certain exceptions, we will exclusively collaborate with respect to (a) all of our mAbs that the parties agree to develop for the prevention, treatment or prophylaxis of the influenza virus, until such time there are none of our mAbs being developed under the expanded collaboration, (b) functional genomic screens for targets associated with respiratory viruses during the Research Term, and compounds or products developed through the Expanded Functional Genomics Program directed to a collaboration target for five years following the target selection (unless either party elects to opt-out earlier), and (c) products directed to Selected Pathogens during the Research Term. We will be responsible for continuing the development and clinical manufacturing activities for VIR-2482 unless and until GSK exercises the Option. If GSK does not exercise the Option for VIR-2482, then, in general, we have the right to continue the development and/or commercialization of VIR-2482 by itself or with a third party. GSK will be the lead party for development, clinical and commercial manufacturing, and commercialization activities for products under the Influenza Program (other than VIR-2482 unless and until GSK exercises the Option, if applicable). We will mutually agree upon the allocation of responsibility for the development of products under the Expanded Functional Genomics Program, and for the development and early-stage manufacturing of products under the Additional Programs if and when GSK decides which Selected Pathogens to pursue. GSK will be primarily responsible for commercial manufacturing and commercialization activities for products under the Expanded Functional Genomics Program and Additional Programs, if and when selected by GSK. For each collaboration program, upon execution of the definitive agreement, we will grant GSK certain license rights related to the development, manufacturing and commercialization of products arising from the program.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The parties will share 50% of all development costs in accordance with the budget for each of the collaboration programs (other than for the Selected Pathogens and VIR-2482, unless GSK exercises the Option), with each party having the right (on a target-by-target, or collaboration product-by-collaboration product basis, as applicable) to opt-out of its co-funding obligations at specified points in development. In such case, the party continuing with the program will pay to the opt-out party a royalty on net sales of products arising from such program at specified rates based on the stage of development at which the opt-out is exercised. Following the exercise of an opt-out right by a party the other party may, at its election, either pursue development and commercialization of such product or program unilaterally, or also cease the conduct and funding of such collaboration product or program. In the absence of any opt-out, the parties will also share 50% of all profits and losses arising from any collaboration product. Each party is required to use commercially reasonable efforts to conduct the activities assigned to it under each development plan and, where applicable, to seek and obtain regulatory approval for collaboration products that arise from such activities in the United States and specified major markets. GSK will lead commercialization and book all sales, and is required to use commercially reasonable efforts to commercialize each collaboration product following regulatory approval in the United States and specified major markets.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">GSK made an upfront payment to us of $225.0 million, 50% became payable at the effective date of the 2021 Preliminary Agreement and 50% of became payable following the execution of the 2021 GSK Agreement. If GSK exercises the Option, GSK will pay us an Option exercise fee of $300.0 million unless certain agreed product criteria for VIR-2482 are not met, in which case the parties will negotiate an alternative option exercise fee. Upon achievement of a pre-defined regulatory milestone for the first product in the Influenza Program, which may be (i) VIR-2482 (if GSK exercised the Option), (ii) a next-generation mAb, or (iii) any other influenza mAb approved by the JSC to be included in the collaboration, arising from the Influenza Program, GSK will make a milestone payment to us of up to $200.0 million.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In September 2022, GSK exercised its first Selected Pathogen Right, selecting RSV as its first pathogen under the Additional Programs of the 2021 GSK Agreement. GSK agreed to retroactively share the research and development costs that we had incurred under its RSV program since April 2022 in accordance with the applicable provisions of the 2021 GSK Agreement.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">With respect to the Influenza Program and each Additional Program, unless earlier terminated, the 2021 GSK Agreement will remain in effect for as long as there is a product from such collaboration program being developed or commercialized by the lead party in the collaboration program or by the non-opt-out party, if applicable. With respect to the Expanded Functional Genomics Program, unless earlier terminated, the 2021 GSK Agreement will remain in effect (a) until the end of the Research Term, if no targets are selected for the Expanded Functional Genomics Program prior to the end of the Research Term, or (b) if at least one target is selected for the Expanded Functional Genomics Program prior to the end of the Research Term, for as long as there is a product from the Expanded Functional Genomics Program being developed or commercialized by the lead party in the Expanded Functional Genomics Program or by the non-opt-out party, if applicable. Either party has the right to terminate the 2021 GSK Agreement in the case of the insolvency of the other party, an uncured material breach of the other party with respect to a collaboration program or a collaboration product, or as mutually agreed by the parties.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page42"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Collaboration and License Agreement with Alnylam</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2017, we entered into a collaboration and license agreement with Alnylam, or the Alnylam Agreement, for the development of siRNA products for the treatment of HBV and following the exercise of certain program options, the development and commercialization of siRNA products directed to up to four other infectious disease targets selected by us. The technology licensed under the Alnylam Agreement forms the basis of our siRNA technology platform.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the Alnylam Agreement, we obtained a worldwide, exclusive license to develop, manufacture and commercialize the HBV siRNA product candidates, including VIR-2218, for all uses and purposes other than agricultural, horticultural, forestry, aquaculture and other residential applications, such excluded fields, the Excluded Fields. In addition, Alnylam granted us an exclusive option, for each of the infectious disease siRNA programs directed to our selected targets, to obtain a worldwide, exclusive license to develop, manufacture and commercialize siRNA products directed to the target of each such program for all uses and purposes other than the Excluded Fields. Our options are each exercisable during a specified period following selection of candidates for each program, or two years following the initiation of certain activities under an agreed-upon development plan, if earlier. On a product-by-product basis for each product arising from the HBV and, following our option exercise, the infectious disease programs, Alnylam has an exclusive option, exercisable during a specified period prior to the initiation of a Phase 3 clinical trial for each such product, to negotiate and enter into a profit-sharing agreement for such product.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We and Alnylam were jointly responsible for funding the initial research and development activities for VIR-2218 through completion of proof of concept trials. Prior to the exercise of our option for each siRNA program directed to one of our selected infectious disease targets, Alnylam is responsible for conducting all development activities, at our expense, in accordance with an agreed-upon development plan. Following our exercise of an option for a program and payment of the program option exercise fee and any outstanding program costs due to Alnylam, we are solely responsible, at our expense, for conducting all development, manufacture and commercialization activities for products arising from each such program unless Alnylam exercises its profit-sharing option. We are required to use commercially reasonable efforts to develop and commercialize one siRNA product directed to HBV and one siRNA product directed to the target of each other infectious disease program for which we exercise our option, in each of the major markets. If Alnylam exercises a profit-sharing option for a product, we will negotiate the terms of such profit-sharing agreement, which will include sharing equally with Alnylam all subsequent costs associated with the development of such product, as well as the profits and losses in connection with such product, subject to reimbursement by Alnylam of a portion of specified development costs in certain circumstances.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We retain final decision-making authority with respect to which infectious disease product candidates we advance and the development programs for the HBV and infectious disease product candidates, subject to certain limitations. During the term of the Alnylam Agreement, neither we nor Alnylam may develop or commercialize any gene-silencing, oligonucleotide-based product directed to the same target as any product candidate under the Alnylam Agreement, other than pursuant to the Alnylam Agreement, subject to certain exceptions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page43"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the Alnylam Agreement, we paid Alnylam an upfront fee of $10.0 million and issued to Alnylam 1,111,111 shares of our common stock. Upon the achievement of a certain development milestone, as further discussed below, we were obligated to issue shares of our common stock equal to the lesser of (i) 1,111,111 shares or (ii) a certain number of shares based on our stock price at the time such milestone was achieved. We will be required to pay Alnylam up to $190.0 million in the aggregate for the achievement of specified development and regulatory milestones by the first siRNA product directed to HBV, and up to $115.0 million for the achievement of specified development and regulatory milestones for the first product directed to the target of each infectious disease siRNA program for which we exercised our option. Following commercialization, we will be required to pay to Alnylam up to $250.0 million in the aggregate for the achievement of specified levels of net sales by siRNA products directed to HBV and up to $100.0 million for the achievement of specified levels of net sales by products directed to the target of each infectious disease siRNA program for which we exercised our option. We will also be required to pay Alnylam tiered royalties at percentages ranging from the low double-digits to mid-teens on annual net sales of HBV products, and tiered royalties at percentages ranging from</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the high single-digits to the sub-teen double-digits on annual net sales of licensed infectious disease products, in each case subject to specified reductions and offsets. The royalties are payable on a product-by-product and country-by-country basis until the later of the expiration of all valid claims of specified patents covering such product in such country and 10 years after the first commercial sale of such product in such country. Alnylam is also entitled to receive a portion of any consideration we receive as a result of granting a sublicense under the licenses granted to us by Alnylam under the Alnylam Agreement or an option to acquire such a sublicense, determined based on the timing of the grant of such sublicense. In November 2018, in connection with the inclusion of the HBV siRNA program as the subject of a potential grant of a sublicense to Brii Bio under the Brii Agreement, as defined under the section titled &#x201c;&#x2014;Collaboration, Option and License Agreement with Brii Bio,&#x201d; which triggered certain payment obligations under the Alnylam Agreement, we entered into a letter agreement with Alnylam, or the Alnylam Letter, making certain modifications to the payments due to Alnylam as a result of the grant of the option and potential payments that would result from Brii Bio&#x2019;s exercise of rights under such sublicense. As a result of the rights granted under the Brii Agreement and pursuant to the Alnylam Letter, in February 2020 we transferred to Alnylam a specified percentage of the equity consideration allocable to the HBV siRNA program that we received from Brii Bio and its affiliated companies in connection with the entry into the Brii Agreement.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The term of the Alnylam Agreement will continue, on a product-by-product and country-by-country basis, until expiration of all royalty payment obligations under the Alnylam Agreement. If we do not exercise our option for an infectious disease program directed to one of our selected targets, the Alnylam Agreement will expire upon the expiration of the applicable option period with respect to such program. However, if Alnylam exercises its profit-sharing option for any product, the term of the Alnylam Agreement will continue until the expiration of the profit-sharing arrangement for such product. We may terminate the Alnylam Agreement on a program-by-program basis or in its entirety for any reason on 90 days&#x2019; written notice. Either party may terminate the agreement for cause for the other party&#x2019;s uncured material breach on 60 days&#x2019; written notice (or 30 days&#x2019; notice for payment breach), or if the other party challenges the validity or enforceability of any patent licensed to it under the Alnylam Agreement on 30 days&#x2019; notice.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In March 2020, we achieved one of the specified development milestones relating to VIR-2218 pursuant to the Alnylam Agreement, as amended. As such, we paid Alnylam $15.0 million in April 2020, and issued Alnylam 1,111,111 shares of our common stock in May 2020.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In March and April 2020, we entered into two further amendments to the Alnylam Agreement, or the Amended Alnylam Agreement, to expand our existing collaboration to include the development and commercialization of siRNA products targeting SARS-CoV-2 and potentially other coronaviruses, and up to three targeting human host factors for SARS-CoV-2, or collectively, the COVID Collaboration Targets.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2020, we and Alnylam entered into a letter amendment, or the Letter Agreement, further amending the Amended Alnylam Agreement to modify certain funding and governance provisions in connection with the siRNA products directed to the COVID Collaboration Targets, including VIR-2703, or the COV Target, and to modify certain rights of each party with respect to products arising from such programs. Pursuant to the Letter Agreement, Alnylam was responsible for conducting pre-clinical research activities set forth in the existing workplan for the COV Target, or the COV Workplan, at its discretion and sole expense, and we were no longer obligated to reimburse Alnylam for any share of costs incurred by Alnylam in conducting activities under the COV Workplan after July 1, 2020. In July 2021, Alnylam elected to discontinue the development of the COV Target, and all other related research and development activities in accordance with their rights under the Letter Agreement. As a result, the COV Target and the siRNA program related thereto are no longer included within the Amended Alnylam Agreement and all rights to the siRNA program directed to the COV Target reverted to Alnylam.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page44"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">License Agreements with MedImmune</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2012 Sub-License and Collaboration Agreement with MedImmune</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In March 2012, our subsidiary Humabs entered into a sub-license and collaboration agreement with MedImmune, LLC, or MedImmune, as amended, or the 2012 MedImmune Agreement, pursuant to which Humabs conducted certain activities under a mutually agreed research plan for the development of therapeutic antibodies directed to influenza viruses (including influenza A and influenza B) and to Klebsiella bacteria. The 2012 MedImmune Agreement was amended in April 2013, April 2015, December 2015, August 2016, July 2017, and September 2018 to designate Klebsiella as an extra target, to extend the term of the research program and provide for related payments, and to incorporate certain research activities funded by MedImmune under a specified government grant. Under the 2012 MedImmune Agreement, as amended, MedImmune obtained a worldwide exclusive license from Humabs to develop and commercialize products directed to such targets for all uses in humans and animals except for active vaccination. MedImmune is obligated to use commercially reasonable efforts to develop at least one product directed to influenza viruses.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In consideration for the grant of the license, MedImmune made certain upfront payments to Humabs. MedImmune is obligated to pay Humabs development, regulatory and commercial milestone payments of up to $96.5 million in the aggregate for the first product directed to influenza viruses to achieve the applicable milestones, and up to $12.0 million for the first product directed to</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">39</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Klebsiella to achieve the applicable milestones. MedImmune will also be obligated to pay royalties based on net sales of products directed to influenza viruses or Klebsiella at certain fixed percentages in the low to mid-single-digits, with the rate determined based on the specific target to which the product is directed, in each case subject to specified reductions and a royalty floor. The royalties are payable, on a product-by-product and country-by-country basis, until the later of the last to expire valid claim that would, but for the licenses granted under the 2012 MedImmune Agreement, be infringed by the sale of such product in such country, and 10 years from the first commercial sale of the first product in such country. MedImmune also made certain payments to Humabs in consideration for Humabs&#x2019; conduct of the research program. We will be obligated to pass through the milestone payments and royalty payments that we receive under the 2012 MedImmune Agreement, following deduction of certain expenses incurred by us or Humabs thereunder, to Humabs&#x2019; securities holders pursuant to the Humabs SPA, as defined under the section titled &#x201c;&#x2014;Securities Purchase Agreement with Humabs.&#x201d;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2012 MedImmune Agreement will remain in force until MedImmune has fulfilled all of its obligations to make milestone and royalty payments. MedImmune may terminate the 2012 MedImmune Agreement in its entirety, or on a product-by-product, license-by-license or country-by-country basis, for convenience, upon 90 days&#x2019; notice. Either MedImmune or Humabs may terminate the 2012 MedImmune Agreement for the other party&#x2019;s uncured material breach or in the event of bankruptcy of the other party.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page45"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2018 License Agreement with MedImmune</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In September 2018, we entered into a license agreement with MedImmune, or the 2018 MedImmune Agreement, pursuant to which we obtained a worldwide, exclusive license to develop and commercialize half-life extended versions of two specified antibodies under development by MedImmune that target influenza A and influenza B, respectively, for all uses in humans and animals. The license from MedImmune includes the grant of a sublicense under MedImmune&#x2019;s license to certain intellectual property controlled by Humabs that was granted to MedImmune pursuant to the 2012 MedImmune Agreement. Under certain circumstances and during certain periods of time we have the right to nominate up to two variants of each of these antibodies for inclusion under the license. MedImmune retained the rights to continue to develop and to commercialize the two specified antibodies that target influenza A and influenza B, in each case that are not the half-life extended versions that are licensed to us. Additionally, we obtained a worldwide, exclusive license under MedImmune&#x2019;s antibody half-life extension technology to develop and commercialize half-life extended antibodies directed to up to two additional targets selected by us for all uses in humans or animals for the prevention, treatment or diagnosis of infectious diseases and had the right to nominate such additional targets during a specified period following the effective date of the 2018 MedImmune Agreement.We are solely responsible, at our sole cost, for the development of products containing half-life extended versions of antibodies directed to the influenza targets and any additional selected targets, and are obligated to use commercially reasonable efforts to develop and obtain regulatory approval for at least one product containing half-life extended versions of antibodies directed to each of influenza A, influenza B and any additional targets, if applicable, in the United States and specified markets in Europe and Asia. We are also obligated to use commercially reasonable efforts to commercialize products containing half-life extended versions of antibodies directed to such targets in such markets. We are developing VIR-2482 using technology licensed under the 2018 MedImmune Agreement.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In consideration for the grant of the licenses under the 2018 MedImmune Agreement, we made an upfront payment to MedImmune of $10.0 million. We will be obligated to make development and regulatory milestone payments to MedImmune of up to $92.0 million, of which $5.0 million was paid in the third quarter of 2019, in the aggregate for products containing half-life extended versions of antibodies directed to influenza A that we licensed, up to an additional $39.2 million in the aggregate for such products directed to influenza B that we licensed, and up to $250,000 in the aggregate for certain specified products directed to the additional selected targets, if applicable. We will also be required to make sales-related milestone payments to MedImmune following commercialization up to an aggregate of $200.0 million for the achievement of specified levels of aggregate annual net sales of products containing half-life extended versions of antibodies directed to influenza A and/or influenza B. MedImmune will also be entitled to receive tiered royalties based on net sales of products containing half-life extended versions of antibodies directed to influenza A and/or influenza B at percentages ranging from the mid-single-digits to sub-teen double-digits and a royalty based on net sales of products containing half-life extended versions of antibodies directed to any additional selected targets, if applicable, at a percentage in the low single-digits, in each case subject to specified reductions. These royalties are payable, on a product-by-product and country-by-country basis, until the latest to occur of expiration of the last to expire valid claim covering such product in such country, expiration of regulatory exclusivity for such product in such country, and 12 years after the first commercial sale of such product in such country. Additionally, we are responsible for paying any royalties due under the 2012 MedImmune Agreement as a result of our commercialization of products under the 2018 MedImmune Agreement.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2018 MedImmune Agreement will remain in force until the expiration on a country-by-country and product-by-product basis of all of our obligations to pay royalties to MedImmune. We may terminate the 2018 MedImmune Agreement in its entirety or on a product-by-product basis, for convenience, upon 120 days&#x2019; notice. Either party may terminate the 2018 MedImmune Agreement for cause for the other party&#x2019;s uncured material breach on 60 days&#x2019; notice or immediately in the event of bankruptcy of the other party.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, MedImmune may terminate the 2018 MedImmune Agreement for cause on 30 days&#x2019; written notice if we challenge the validity or enforceability of the patents to which we have obtained a license under the 2018 MedImmune Agreement.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Master Exclusive License Agreement with OHSU</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page46"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2012, our subsidiary TomegaVax, Inc., or TomegaVax, entered into a master exclusive license agreement, or the OHSU Agreement, with Oregon Health &amp; Science University, or OHSU. The OHSU Agreement was revised and restated in August 2014 and again in August 2019, at which time we assumed TomegaVax&#x2019;s rights and obligations as licensee under the OHSU Agreement. Under the OHSU Agreement, we obtained a worldwide exclusive license under certain patent rights</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and a non-exclusive license under certain know-how to make, have made, use, offer to sell, sell, have sold and import certain products relating to CMV vectors in all fields of use. The OHSU Agreement provides for us to include within the license grant additional patent or know-how rights covering certain inventions arising at OHSU and relating to the use of CMV vaccine vectors through the execution of technology addenda, each such addendum, a Technology Addendum. Each Technology Addendum relates to one or more invention disclosures and their corresponding patent family or know-how rights. During the term of the OHSU Agreement to date, we have entered into 17 such Technology Addenda. We must use reasonably diligent efforts to develop and commercialize the CMV vector products consistent with its reasonable business practices and judgment, including by achieving certain specified development and regulatory milestones within certain periods. We use technology licensed under the OHSU Agreement in our T cell platform and in our product candidate VIR-1111.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the initial entry into the OHSU Agreement and certain of the Technology Addenda, TomegaVax issued a specified percentage of its then outstanding common stock to OHSU, which was subsequently exchanged for shares of our common stock as a result of our acquisition of TomegaVax in September 2016. In connection with the second revision and restatement of the OHSU Agreement in August 2019, we issued an additional specified number of shares of our common stock to OHSU. We are obligated to pay OHSU up to $1.3 million upon the achievement of certain development and regulatory milestones for each CMV vector product, and up to $2.0 million upon the achievement of certain aggregate annual net sales milestones for all CMV vector products. We will also be required to pay OHSU a royalty in the low single-digits on net sales of licensed products on a product-by-product basis, subject to specified reductions and offsets, and specified minimum annual royalty payments. The royalties are payable, on a product-by-product and country-by-country basis, until the later of (a) the expiration of all valid claims in the licensed patents covering such product in the country of sale or country of manufacture, as applicable, and (b) 10 years after the first commercial sale of such product in the country of sale. OHSU is also entitled to receive a specified percentage of any consideration received by us as a result of the grant of a sublicense under the rights granted under the OHSU Agreement, with the applicable percentage based on the development stage of the applicable program at the time of the grant of the sublicense.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The OHSU Agreement will remain in force until the expiration of all licensed patent rights or 10 years after the effective date of the last Technology Addendum, whichever is the later. Each individual Technology Addendum remains in force until the expiration of the patent rights to which it applies, or 10 years after the effective date of such Technology Addendum, whichever is later. Either party may terminate the OHSU Agreement, or any individual Technology Addendum, for the other party&#x2019;s uncured material breach on 60 days&#x2019; written notice, which may be extended by an additional 120 days under certain conditions. The OHSU Agreement and each Technology Addendum also terminate in the event of bankruptcy of either party. We may also terminate the OHSU Agreement in its entirety, or any Technology Addendum individually, upon 60 days&#x2019; notice. OHSU may immediately terminate the OHSU Agreement if we or our sublicensees bring any action or proceeding against OHSU, subject to certain exceptions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Exclusive License Agreement with the Institute for Research in Biomedicine</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2011, Humabs Holdings GmbH, or Humabs Holdings, the former parent company of our subsidiary Humabs, entered into an exclusive license agreement, or the IRB Agreement, with the Institute for Research in Biomedicine, or IRB. The IRB Agreement amended and restated an original 2004 exclusive license agreement between the parties in connection with IRB&#x2019;s proprietary technologies relating to human monoclonal antibodies and the discovery of unique epitopes recognized by such antibodies. In May 2008, Humabs entered into an exclusive license agreement with IRB, or the Humabs IRB Agreement, and together with the IRB Agreement, the Current IRB License Agreements. Pursuant to the Humabs IRB Agreement, IRB granted to Humabs an exclusive license under certain intellectual property rights for the development of certain monoclonal antibodies. Following the entry into the Humabs IRB Agreement, in February 2012, Humabs and IRB entered into a research agreement, or the IRB Research Agreement, concurrently with the termination of an original research agreement dated July 2004 between Humabs Holdings and IRB, to provide for a continuing research collaboration between Humabs and IRB, and to coordinate the exploitation of intellectual property rights arising from the IRB Research Agreement with the rights granted under the Current IRB License Agreements. Under the terms of the IRB Research Agreement, IRB performs certain research activities for Humabs, and all intellectual property rights arising under the IRB Research Agreement are either owned by Humabs, or included in and licensed to Humabs pursuant to the terms of the Current IRB License Agreements. In August 2017, we acquired all of the share capital of Humabs as described further below. Prior to the closing of such acquisition, Humabs Holdings was consolidated into Humabs, such that Humabs Holdings ceased to exist as a separate</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">41</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">legal entity, and Humabs became the successor-in-interest to Humabs Holdings&#x2019; rights under the IRB Agreement. As a result, Humabs is the licensee under each of the Current IRB License Agreements.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We use technology licensed under the Current IRB License Agreements in our antibody platform and in our product candidates VIR-2482 and VIR-3434.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page47"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the Current IRB License Agreements, IRB granted to Humabs an exclusive, worldwide, royalty-bearing, sublicensable license under patent and know-how rights covering or associated with IRB&#x2019;s proprietary technology platform relating to antibody discovery, as well as rights in certain antibodies, including as a result of activities under the IRB Research Agreement, in each case for all purposes, including to practice the licensed technology platform, and to develop, manufacture and commercialize any drug, vaccine or diagnostic product containing such licensed antibodies. Humabs is required to use commercially reasonable efforts to develop and commercialize licensed products, and must maintain an active program to commercialize licensed products. Humabs is required to pay to IRB a flat royalty on net sales of licensed products approved for non-diagnostic use in the low single-digits, and a flat royalty on licensed products for diagnostic use at 50% of the non-diagnostic product rate, in each case subject to standard reductions and offsets. A single royalty stream is payable on products that include the licensed antibodies (including antibodies that are owned by Humabs, but developed using the licensed technology), irrespective of whether a given product is covered by patents under both of the Current IRB License Agreements. Humabs&#x2019; obligation to pay royalties to IRB, on a country-by-country basis, is reduced upon the expiration of the relevant patents in such country, and expires 10 years after the date of first commercialization of a licensed product in such country. Humabs is also required to pay to IRB a specified percentage in the sub-teen double-digits of consideration received in connection with the grant of a sublicense to a non-affiliate third party, subject to a specified maximum dollar amount for the first up front or milestone payment received under such sublicense for each licensed product, and a lower specified maximum dollar amount for subsequent up front or milestone payments for such licensed product.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Each of the Current IRB License Agreements remains in force until the expiration of all valid claims of the licensed patent rights and trade secrets included in the licensed IRB know-how. Humabs may terminate the IRB Agreement at will on 90 days&#x2019; written notice to IRB, and either party may terminate either of the Current IRB License Agreements on 60 days&#x2019; written notice for the uncured material breach of the other party.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Exclusive License Agreement with The Rockefeller University</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In July 2018, we entered into an exclusive license agreement with The Rockefeller University, or Rockefeller, which was amended in May 2019, in September 2020, and in March 2021, or the Rockefeller Agreement. Pursuant to the Rockefeller Agreement, Rockefeller granted us a worldwide exclusive license under certain patent rights, and a worldwide non-exclusive license under certain materials and know-how covering certain antibody variants relating to a specified mutation leading to enhanced antibody function and utility, to develop, manufacture and commercialize infectious disease products covered by the licensed patents, or that involve the use or incorporation of the licensed materials and know-how, in each case for all uses and purposes for infectious diseases. The licenses granted to us are freely sublicensable to third parties. Rockefeller retains the right to use the licensed patents outside the field of use, and within the field of use solely in connection with educational, research and non-commercial purposes, as well as for certain research being conducted in collaboration with us. We are obligated to grant sublicenses to third parties with respect to products that are not being pursued and are not of interest to us following a specified anniversary of the May 2019 amendment date. Pursuant to the Rockefeller Agreement, we are required to use commercially reasonable efforts to develop and commercialize infectious disease products as soon as reasonably practicable, including by achieving certain specified development milestone events within specified time periods for products arising from our HBV and influenza programs.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We use technology licensed under the Rockefeller Agreement in our antibody platform and in our product candidates VIR-3434 and VIR-7832.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We paid Rockefeller an upfront fee of $0.3 million for entry into the Rockefeller Agreement, and are required to pay annual license maintenance fees of $1.0 million, which will be creditable against royalties following commercialization. In addition, for the achievement of specified development, regulatory and commercial success milestone events, we will be required to pay up to $80.3 million, in the aggregate, for up to six infectious disease products. Any follow-on products beyond six products may result in additional milestone event payments. We will also be required to pay to Rockefeller a tiered royalty at a low single-digit percentage rate on net sales of licensed products, subject to certain adjustments. Our obligation to pay royalties to Rockefeller will terminate, on a product-by-product and jurisdiction-by-jurisdiction basis, upon the latest of the expiration of the last valid claim of a licensed patent in such jurisdiction, the expiration of all regulatory exclusivity in such jurisdiction or 12 years following the first commercial sale of the applicable licensed product in such jurisdiction. If we grant a sublicense to a non-affiliate third party under the Rockefeller technology, we will be required to pay to Rockefeller a specified percentage of the consideration received from such sublicensee for the grant of the sublicense, depending on the date of receipt of the applicable sublicense income from such sublicensee.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page48"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Rockefeller Agreement will remain in force, absent earlier termination, until the expiration of all of our obligations to pay royalties to Rockefeller in all jurisdictions. We have the right to terminate the Rockefeller Agreement in its entirety, or</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in part, for any reason on 60 days&#x2019; written notice to Rockefeller. Rockefeller may terminate the Rockefeller Agreement on 90 days&#x2019; written notice for our uncured material breach, or if we challenge the validity or enforceability of any of the licensed patents, or immediately in the event of our insolvency. Rockefeller may also terminate the Rockefeller Agreement if we cease to carry on business with respect to the rights granted to us under the agreement.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Collaboration, Option and License Agreement with Brii Bio</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In May 2018, we entered into a collaboration, option and license agreement with Brii Biosciences Limited (previously named BiiG Therapeutics Limited), or Brii Bio Parent, and Brii Bio, and such agreement, the Brii Agreement, pursuant to which we granted to Brii Bio, with respect to up to four of our programs (excluding mAbs in Vir&#x2019;s active research and development program against coronaviruses), an exclusive option to obtain exclusive rights to develop and commercialize compounds and products arising from such programs in China, Taiwan, Hong Kong and Macau, or collectively the China Territory, for the treatment, palliation, diagnosis, prevention or cure of acute and chronic diseases of infectious pathogen origin or hosted by pathogen infection, or the Field of Use. Our HBV siRNA program being developed under the Amended Alnylam Agreement (described above) is included within the Brii Agreement as a program for which Brii Bio may exercise one of its options. Brii Bio may exercise each of its options following the achievement by us of proof of concept for the first product in such program. In partial consideration for the options granted by us to Brii Bio, Brii Bio Parent and Brii Bio granted us, with respect to up to four of Brii Bio Parent&#x2019;s or Brii Bio&#x2019;s programs, an exclusive option to be granted exclusive rights to develop and commercialize compounds and products arising from such Brii Bio programs in the United States for the Field of Use. The number of options that we may exercise for a Brii Bio program is limited to the corresponding number of options that Brii Bio exercises for a Vir program. All options granted to Brii Bio under the Brii Agreement that are not exercised will expire no later than seven years following the effective date, or two years earlier than such date if Brii Bio has not undergone an initial public offering within such shorter period. All options granted to us under the Brii Agreement that are not exercised will expire no later than two years following the expiration of all options granted to Brii Bio.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are responsible, at our expense and discretion, for the conduct of all development activities under our programs prior to the exercise of Brii Bio&#x2019;s options, and Brii Bio is responsible, at its expense and discretion, for all activities under its programs prior to the exercise of our options. Following the exercise of an option for a specified program by either us or Brii Bio, the exercising party is granted an exclusive, royalty-bearing license to develop, manufacture and commercialize products arising from the applicable program in the United States (where we are exercising the option) or the China Territory (where Brii Bio is exercising the option), and such party is thereafter responsible for all development and commercialization activities, at its expense, in the optioned territory. If Brii Bio exercises its option with respect to our development program being conducted under the Amended Alnylam Agreement, Brii Bio&#x2019;s rights will be subject to the terms of such amended agreement.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the terms of the Brii Agreement, following our option exercise, we are obligated to use commercially reasonable efforts to develop at least one licensed product arising from each optioned Brii Bio program, and to commercialize each such product in the United States following regulatory approval, and following Brii Bio&#x2019;s option exercise, Brii Bio is obligated to use commercially reasonable efforts to develop at least one licensed product arising from each optioned Vir program and to commercialize each such product in the China Territory following regulatory approval.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">With respect to programs for which Brii Bio exercises its options, Brii Bio will be required to pay us an option exercise fee for each such Vir program ranging from the mid-single-digit millions up to $20.0 million, determined based on the commercial potential of the licensed program. Brii Bio will also be required to pay regulatory milestone payments on a licensed product-by-licensed product basis ranging from the mid-single-digit millions up to $30.0 million, also determined based on the commercial potential of such program. Following commercialization, Brii Bio will be required to make sales milestone payments based on certain specified levels of aggregate annual net sales of products arising from each licensed program in the China Territory, up to an aggregate of $175.0 million per licensed program. Brii Bio also will pay us royalties that range from the mid-teens to the high-twenties, as described below. On June 12, 2020, Brii Bio notified us of the exercise of its option to obtain exclusive rights to develop and commercialize compounds and products arising from VIR-2218 in the China Territory. Brii Bio paid us a $20.0 million option exercise fee in connection with the option exercise. We separately paid $10.0 million, half of the option proceeds, to Alnylam in connection with the Amended Alnylam Agreement. In July 2022, Brii Bio notified us of the exercise of its option to obtain exclusive rights to develop and commercialize compounds and products arising from VIR-3434 in the China Territory. Brii Bio paid us a $20.0 million option exercise fee in connection with the option exercise. We are also eligible to receive the following payments related to VIR-3434 in the China Territory: a $30.0 million regulatory milestone payment, up to $175.0 million in sales-based milestone payments, and royalties on net sales ranging from mid-teens to mid-twenties.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As partial consideration for our entry into the Brii Agreement, upon closing of Brii Bio Parent&#x2019;s Series A preferred stock financing, we received Class A ordinary shares equal to 9.9% of the outstanding shares in Brii Bio Parent. As a result of Brii Bio&#x2019;s</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page49"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">right to exercise one of its options for our HBV siRNA program, under the terms of the Amended Alnylam Agreement, in February 2020 we transferred to Alnylam a specified percentage of such equity consideration allocable to such program. In July 2021, Brii Bio Parent completed its initial public offering, or the Brii Bio Parent IPO, on the Stock</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Exchange of Hong Kong Limited. Upon completion of the Brii Bio Parent IPO, our Class A ordinary shares held at Brii Bio Parent converted into the same single class of ordinary shares issued in the Brii Bio Parent IPO.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Upon exercise of each option for a Brii Bio program, we will be required to pay to Brii Bio an option exercise fee ranging from the low tens of millions to up to $50.0 million, determined based on the commercial potential of the licensed program. We will be required to make regulatory milestone payments to Brii Bio on a licensed product-by-licensed product basis ranging from the low tens of millions up to $100.0 million, also determined based on the commercial potential of such program. We will also be required to make sales milestone payments based on certain specified levels of aggregate annual net sales of products in the United States arising from each licensed program, up to an aggregate of $175.0 million per licensed program.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, we are obligated under the Brii Agreement to pay Brii Bio tiered royalties based on net sales of products arising from the licensed programs in the United States, and Brii Bio is obligated to pay us tiered royalties based on net sales of products arising from the licensed programs in the China Territory. The rates of royalties payable by us to Brii Bio, and by Brii Bio to us on net sales range from mid-teens to high-twenties. Each party&#x2019;s obligations to pay royalties expires, on a product-by-product and territory-by-territory basis, on the latest of 10 years after the first commercial sale of such licensed product in the United States or China Territory, as applicable; the expiration or abandonment of licensed patent rights that cover such product in the United States or China Territory, as applicable; and the expiration of regulatory exclusivity in the United States or the China Territory, as applicable. Royalty rates are subject to specified reductions and offsets.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Brii Agreement will remain in force until the expiration of all options or, if any option is exercised, expiration of all royalty payment obligations for all licensed products within such licensed program, unless terminated in its entirety or on a program-by-program basis by either party. Each party may terminate for convenience all rights and obligations with respect to any program for which it has an option, with 30 days&#x2019; written notice (if the terminating party has not exercised an option for such program) or 180 days&#x2019; notice (following the exercise of an option for such program). The Brii Agreement may also be terminated by either party for insolvency of the other party, and either party may terminate the Brii Agreement in its entirety or on a program-by-program basis for the other party&#x2019;s uncured material breach on 60 days&#x2019; written notice (or 30 days&#x2019; notice following failure to make payment).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Patent License Agreements with Xencor</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In August 2019, we entered into a patent license agreement, which was amended in February 2021, or the 2019 Xencor Agreement, with Xencor, pursuant to which we obtained a non-exclusive, sublicensable (only to our affiliates and subcontractors) license to incorporate Xencor&#x2019;s licensed technologies into, and to evaluate, antibodies that target influenza A and HBV, and a worldwide, non-exclusive, sublicensable license to develop and commercialize products containing such antibodies incorporating such technologies for all uses, including the treatment, palliation, diagnosis and prevention of human or animal diseases, disorders or conditions. We are obligated to use commercially reasonable efforts to develop and commercialize an antibody product that incorporates Xencor&#x2019;s licensed technologies, for each of the influenza A and HBV research programs. These technologies are used in our VIR-2482, incorporating Xencor&#x2019;s Xtend technology, and VIR-3434, incorporating Xencor&#x2019;s Xtend and other Fc technologies.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In consideration for the grant of the license, we paid Xencor an upfront fee. For each of the influenza A and HBV research programs, we will be required to pay Xencor development and regulatory milestone payments of up to $17.8 million in the aggregate, and commercial sales milestone payments of up to $60.0 million in the aggregate, for a total of up to $77.8 million in aggregate milestones for each program and $155.5 million in aggregate milestones for both programs. On a product-by-product basis, we will also be obligated to pay tiered royalties based on net sales of licensed products ranging from low- to mid-single-digits. The royalties are payable, on a product-by-product and country-by-country basis, until the expiration of the last to expire valid claim in the licensed patents covering such product in such country.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In March 2020, we entered into a patent license agreement, which was amended in February 2021, or the 2020 Xencor Agreement, with Xencor pursuant to which we obtained a non-exclusive license to Xencor&#x2019;s licensed technologies into, and to evaluate, antibodies that target any component of a coronavirus, including SARS-CoV-2, SARS-CoV and MERS-CoV, and a worldwide, non-exclusive, sublicensable license to develop and commercialize products containing such antibodies incorporating such technologies for all uses, including the treatment, palliation, diagnosis and prevention of human or animal diseases, disorders or conditions. We are obligated to use commercially reasonable efforts to develop and commercialize an antibody product that incorporates Xencor&#x2019;s licensed technologies, for each of the coronavirus research programs. These technologies are used in sotrovimab, incorporating Xencor&#x2019;s Xtend technology, and VIR-7832, incorporating Xencor&#x2019;s Xtend and other Fc technologies.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">44</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page50"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In consideration for the grant of the license, we are obligated to pay royalties based on net sales of licensed products at the mid-single-digits. The royalties are payable, on a product-by-product and country-by-country basis, until the later of the expiration of the last to expire valid claim in the licensed patents covering such product in such country or 12 years.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2019 Xencor Agreement and 2020 Xencor Agreement will remain in force, on a product-by-product and country-by-country basis, until the expiration of all royalty payment obligations under each of the respective agreements. We may terminate each agreement in its entirety, or on a target-by-target basis, for convenience upon 60 days&#x2019; written notice. Either party may terminate each agreement for the other party&#x2019;s uncured material breach upon 60 days&#x2019; written notice (or 30 days in the case of non-payment) or in the event of bankruptcy of the other party immediately upon written notice. Xencor may terminate each agreement immediately upon written notice if we challenge, or upon 30 days&#x2019; written notice if any of our sublicensees challenge, the validity or enforceability of any patent licensed to us under each respective agreement.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Amended and Restated Letter Agreement with the Bill &amp; Melinda Gates Foundation</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In January 2022, we entered into an amended and restated letter agreement with the Bill &amp; Melinda Gates Foundation, or the Gates Agreement, which amended and restated the letter agreement with the Bill &amp; Melinda Gates Foundation that we entered into in December 2016. In connection with the Gates Agreement, the Bill &amp; Melinda Gates Foundation purchased $10.0 million of shares of our Series A-1 convertible preferred stock in December 2016, $10.0 million of shares of our Series B convertible preferred stock in January 2019 and $40.0 million of shares of our common stock in January 2022. We were obligated to use the proceeds of the Bill &amp; Melinda Gates Foundation&#x2019;s December 2016 and January 2019 investments in furtherance of its charitable purposes to (i) conduct our programs to develop products to treat or prevent infectious disease caused by HIV and TB, respectively, with at least 50% of the funds to be used for such programs and (ii) develop our HCMV-based vaccine technology platform in a manner reasonably expected to result in the generation of products for the treatment or prevention of other specified infectious diseases, and we are obligated to use the proceeds of the Bill &amp; Melinda Gates Foundation&#x2019;s January 2022 investment in furtherance of its charitable purposes to develop our vaccinal antibody program, in each case for use in specified developing countries. We agreed to use reasonable efforts to achieve specified research and development milestones with respect to our HIV program, TB program and vaccinal antibody program, and, if requested by the Bill &amp; Melinda Gates Foundation, to work with the Bill &amp; Melinda Gates Foundation on an additional mutually agreeable infectious disease program. Additionally, we are bound by specified global access commitments including a commitment to provide any products developed using the proceeds of the Bill &amp; Melinda Gates Foundation&#x2019;s investment at an affordable price to the people most in need within the specified developing countries, not to exceed a specified percentage over our fully burdened manufacturing and sales costs.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we fail to comply with (i) our obligations to use the proceeds of the Bill &amp; Melinda Gates Foundation&#x2019;s investment for the purposes described in the paragraph above and to not use such proceeds for specified prohibited uses, (ii) specified reporting requirements or (iii) specified applicable laws, or if we materially breach our specified global access commitments (any such failure or material breach, a Specified Default), we will be obligated to redeem or arrange for a third party to purchase all of our stock purchased by the Bill &amp; Melinda Gates Foundation under the Gates Agreement at the Bill &amp; Melinda Gates Foundation&#x2019;s request, at a price equal to the greater of (a) the original purchase price or (b) the fair market value, such redemption or sale, a Gates Foundation Redemption. Following a Gates Foundation Redemption, if a sale of the company or all of our material assets relating to the Gates Agreement occurs prior to the six month anniversary of the first redemption or sale of any stock in such Gates Foundation Redemption, then the Bill &amp; Melinda Gates Foundation will receive compensation equal to the excess of what it would have received in such transaction if it still held the stock redeemed or sold at the time of such sale transaction over what it actually received in the Gates Foundation Redemption. Additionally, if a specified default occurs, if we are unable or unwilling to continue the HIV program, TB program, vaccinal antibody program or, if applicable, the mutually agreed additional program (except for scientific or technical reasons), or if we institute bankruptcy or insolvency proceedings, then the Bill &amp; Melinda Gates Foundation will have the right to exercise a non-exclusive, fully-paid license (with the right to sublicense) under our intellectual property to the extent necessary to use, make and sell products arising from such programs, in each case solely to the extent necessary to benefit people in the developing countries in furtherance of the Bill &amp; Melinda Gates Foundation&#x2019;s charitable purpose.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page51"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the event that we sell, exclusively license or transfer to a third party all or substantially all of our assets, the technology platform, or products arising from programs that are funded using the proceeds of the Bill &amp; Melinda Gates Foundation&#x2019;s investment, such third party is required to assume our specified global access commitments on terms that are reasonably acceptable to the Bill &amp; Melinda Gates Foundation. Additionally, we will not grant to any third party any rights or enter into any agreement with any third party that would restrict the Bill &amp; Melinda Gates Foundation&#x2019;s rights with respect to our specified global access commitments unless such third party expressly assumes such commitments to the reasonable satisfaction of the Bill &amp; Melinda Gates Foundation. Consistent with the foregoing restriction, we also specifically will not</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> enter into any such agreement negotiated in connection with a decision by us not to pursue the technology platform controlled by us as a result of our acquisition of TomegaVax. The global access commitments will continue for as long as the Bill &amp; Melinda Gates Foundation continues to be a charitable entity.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the purchase of $40.0 million of shares of our common stock in January 2022, we entered into a stock purchase agreement, or the Gates Stock Purchase Agreement, with the Bill &amp; Melinda Gates Foundation. The Bill &amp; Melinda Gates Foundation purchased the shares of our common stock at $45.3841 price per share, which is the average of the volume weighted average price of a share of our common stock for the 30 trading day period prior to the date of the Gates Stock Purchase Agreement. We have agreed to register the shares for resale following expiration of the one-year lock-up period if Rule 144 under the Securities Act of 1933, as amended, is not available for such resale without any volume or manner of sale restrictions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Separately, in January 2018, March 2018 and January 2022, we entered into three grant agreements with the Bill &amp; Melinda Gates Foundation, pursuant to which the Bill &amp; Melinda Gates Foundation agreed to grant additional funding to us for our HIV, TB and vaccinal antibody programs, respectively, through the award of three research grants totaling in the aggregate up to $12.2 million with respect to the HIV program, up to $14.9 million with respect to the TB program, and up to $10.0 million with respect to the vaccinal antibody program if we achieve all the specified research and development milestones or reporting deliverables under the grants. In February 2020, we amended the HIV grant agreement pursuant to which we were awarded with a supplemental grant of $8.6 million. In addition, the term of the HIV grant agreement was extended through October 31, 2022, and we entered another amendment in September 2022 to further extend the term through September 2023. The TB grant agreement remained in effect until March 31, 2022 and was amended to extend the term through December 31, 2023. As of December 31, 2022, we had received $29.7 million with respect to the HIV program and $12.2 million with respect to the TB program.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In November 2021, we entered into a grant agreement with the Bill &amp; Melinda Gates Foundation under which we were awarded a grant totaling up to $10.0 million to support the manufacturing and clinical activities of our HIV and TB vaccine programs. This grant agreement will remain in effect until August 30, 2023. As of December 31, 2022, we had received $6.5 million under this grant agreement.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The grant agreements may be terminated early by the Bill &amp; Melinda Gates Foundation for our breach, failure to progress the applicable funded projects, in the event of our change of control, change in our tax status, or significant changes in our leadership that the Bill &amp; Melinda Gates Foundation reasonably believes may threaten the success of the applicable project.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Acquisition Agreements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Agreement and Plan of Merger with TomegaVax</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In September 2016, we entered into an agreement and plan of merger with TomegaVax, or the TomegaVax Merger Agreement, pursuant to which we purchased all equity interests of TomegaVax, a preclinical private biotechnology company. The primary asset purchased in the acquisition was a CMV vector-based vaccine platform for the development of products directed to HBV, HIV and TB.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page52"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the entry into the TomegaVax Merger Agreement, we also entered into a letter agreement with TomegaVax, or the TomegaVax Letter Agreement, which provides for certain payments to TomegaVax&#x2019;s former stockholders prior to September 2024, in each case so long as we are continuing to pursue the development of the TomegaVax technology. Under the terms of the TomegaVax Letter Agreement, we will be required to pay to the former stockholders of TomegaVax milestone payments of up to an aggregate of $30.0 million if the per-share price of our publicly traded common stock, or implied price per share of our Series A-1 convertible preferred stock (or common stock upon conversion) upon a certain asset sale, merger or stock sale, is at least $45 (as adjusted in the case of any stock dividend, stock split or other similar recapitalization), with the amount of such payments determined by the share price and/or the stage of our clinical development at the time of the relevant event triggering the payment. The share price of our publicly traded common stock will be determined using the average of the daily volume-weighted average trading price of our common stock for each trading day during a consecutive 90-day period. The foregoing payments are payable (i) during any date after the completion of an initial public offering by the company or any successor or affiliate controlling the TomegaVax technology, provided that no payment will be due before the first anniversary of the initial public offering, (ii) upon the sale of all assets related to the TomegaVax technology or (iii) upon a merger or stock sale of the company or any successor or affiliate controlling the TomegaVax technology, in each case subject to certain conditions with respect to the timing of the payments. The payments under the TomegaVax Letter Agreement can be made in cash or shares of our common stock, at the discretion of our board of directors.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The TomegaVax Letter Agreement may be amended, modified or terminated and the observance of any term may be waived only with the written consent of the stockholders&#x2019; representative (as such term is defined in the TomegaVax Merger Agreement) and us.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In February 2021, we achieved one of the milestones related to the specified per-share price of our common stock, which resulted in a $10.0 million payable to TomegaVax&#x2019;s former stockholders. In July 2021, we made the milestone payment to the former TomegaVax stockholders through a combination of $8.1 million in cash and the issuance of 42,737 shares of common stock with a total fair value of $1.9 million. The remaining milestone payments of up to $20.0 million in the aggregate will be triggered if (i) the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">46</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">per-share price of our publicly traded common stock is at least $45 (as adjusted in the case of any stock dividend, stock split or other similar recapitalization) and upon the achievement of a certain milestone related to the stage of our clinical development at the time of the relevant event triggering the payment and/or (ii) the per-share price of our publicly traded common stock is at least $90 (as adjusted in the case of any stock dividend, stock split or other similar recapitalization).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Securities Purchase Agreement with Humabs</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In August 2017, we entered into a securities purchase agreement with Humabs and its securities holders, or the Humabs SPA, pursuant to which we purchased all equity interests of Humabs. Pursuant to the Humabs SPA, we are required to pay up to $135.0 million upon the first achievement of certain clinical, regulatory and commercial milestones for an HBV product, or the HBV Milestones, and up to $105.0 million upon the first achievement of certain clinical, regulatory and commercial milestones for another product. Pursuant to the Humabs SPA, we are required to use commercially reasonable efforts to achieve such milestones during a specified period following the closing of the Humabs acquisition. In addition, Humabs&#x2019; securities holders are also entitled to receive certain pass-through payments that Humabs receives under certain license agreements, including the 2012 MedImmune Agreement, following deduction of certain expenses incurred by us or Humabs thereunder.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sales and Marketing</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Given our stage of development, we have not yet established a commercial organization or distribution capabilities. We intend to build a commercial infrastructure to support sales of our product candidates. We expect to manage sales, marketing and distribution through internal resources and third-party relationships. While we may commit significant financial and management resources to commercial activities, we will also consider collaborating with one or more pharmaceutical companies to enhance our commercial capabilities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page53"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Manufacturing</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are currently manufacturing product candidates from three of our platforms: antibodies, T cells and siRNAs. We have established our own internal process development, manufacturing and quality capabilities and are working with contract development and manufacturing organizations, or CDMOs, to supply our early- and late-stage product candidates in the near term. We continue to expand our internal capabilities and resources in process development, analytical development, quality, manufacturing and supply chain, which are supported by our San Francisco, California, and Portland, Oregon facilities that include laboratories for process development, production of HCMV research viral seed stock and selected quality control testing for our product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have established relationships with multiple CDMOs and have produced material to support preclinical studies and Phase 1, Phase 2 and Phase 3 clinical trials. Material for any Phase 3 clinical trials and commercial supply will generally require large-volume, low-cost-of-goods production. For example, for our COVID-19 program, we and our collaborator GSK have executed manufacturing agreements with CDMOs having large-scale capacity to support future scale-up and product supply, particularly for commercialization. However, there are no assurances that our manufacturing and supply chain infrastructure will remain uninterrupted and reliable, or that the third parties we rely on to manufacture our COVID-19 therapies will be able to satisfy demand in a timely manner or not have supply chain disruptions due to COVID-19 related shutdowns, stock-outs due to raw material shortages, extended lead times, and/or greater than anticipated demand or quality issues given the operational challenges and raw material shortages that have been experienced during the COVID-19 pandemic.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Production Modalities</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Antibody Platform</span></p>
  <p style="text-indent:4.667%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The technology and industrial processes for producing mAbs are well-established across the biopharmaceutical industry. Over the last 30 years, process optimization and standardization has enabled process portability and facilitated manufacturing with high success rates at most biologic CDMOs, as well as the partnered use of excess capacity with other biopharmaceutical companies. We rely on the mAb process platforms and manufacturing facilities of our CDMOs and strategic collaborators for all of our product candidate clinical supplies. For sotrovimab, we and our collaborator GSK have executed manufacturing agreements with large-scale CDMOs to support future scale-up and capacity, particularly for potential commercialization.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">T Cell Platform</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our T cell platform is based on genetically engineered HCMV. We have attenuated the HCMV for the purpose of patient safety, but this attenuation also reduces its yield in production. To improve manufacturing efficiency and scale-up, we have made significant internal investments in process development, largely funded by the Bill &amp; Melinda Gates Foundation. We have established a</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">47</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reproducible current Good Manufacturing Practices, or cGMP, manufacturing process in support of Phase 1 and Phase 2 clinical trials that has been successfully transferred to and executed at CDMOs specializing in live virus manufacturing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">siRNA Platform</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We assumed responsibility for all manufacturing of Phase 2 and 3 clinical supplies for VIR-2218 in the first half of 2022 as well as for all commercial manufacturing in advance of any Phase 3 clinical trial. In addition to the current CDMOs supplying our clinical trials, other CDMOs as well as Alnylam are capable of producing kilogram-scale batches of siRNA and we may contract for scale-up and Phase 3 manufacturing at one of these qualified facilities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page54"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Manufacturing Agreements</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the ongoing COVID-19 pandemic</span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, we have entered into the following agreements to date in support of our COVID-19 program:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Letter Agreement, Assignment and Master Services Agreement with Samsung</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In April 2020, we entered into a binding letter agreement with Samsung pursuant to which Samsung will perform process development and manufacturing services for our SARS-CoV-2 mAbs. Under the terms of the letter agreement, we had committed to purchase a firm and binding capacity reservation for a specified number of drug substance manufacturing slots in 2021 and 2022. Samsung will reserve such manufacturing slots on a non-cancellable, non-adjustable basis and will not offer such manufacturing slots under our capacity reservation to third parties. We were obligated to pay a total of approximately $362.0 million for such capacity reservation on a take-or-pay basis regardless of whether such manufacturing slots are utilized by us, subject to annual adjustment based on the Korean Consumer Price Index. The amounts were to be payable during 2021 and 2022 and invoiced on a per-batch basis, with shortfalls invoiced at the end of the year in which such shortfall occurs.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In August 2020, we entered into an Assignment and Novation Agreement with GlaxoSmithKline Trading Services Limited, or GSKTSL, and Samsung effective as of July 31, 2020 pursuant to which we assigned and transferred to GSKTSL all of our right, title, and interest in, to and under the letter agreement, and GSKTSL became our successor in interest in and to all of our rights, duties, and obligations in, to and under the letter agreement. On August 4, 2020, GSKTSL entered into a Master Services Agreement with Samsung effective as of July 31, 2020, or the Samsung MSA, thereby superseding the letter agreement, and pursuant to which, among other things, Samsung will perform technology transfer, development, and manufacturing services for clinical and commercial supply of antibody products under our SARS-CoV-2 antibody program.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Development and Manufacturing Collaboration Agreement with WuXi Biologics</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In February 2020, we entered into a development and manufacturing collaboration agreement with WuXi Biologics, or the WuXi Biologics Collaboration Agreement, for the clinical development, manufacturing, and commercialization of our proprietary antibodies developed for SARS-CoV-2. Under the WuXi Biologics Collaboration Agreement, WuXi Biologics conducted cell-line development, process and formulation development, and initial manufacturing for clinical development. WuXi Biologics had the right to commercialize products incorporating such SARS-CoV-2 antibodies in mainland China, Hong Kong, Macau and Taiwan pursuant to an exclusive license granted for the selected SARS-CoV-2 antibodies that were developed. We had the right to commercialize such products in all other markets worldwide.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On May 16, 2022, we and WuXi Biologics entered into a Termination Agreement, or the Termination Agreement, pursuant to which we and WuXi Biologics terminated the WuXi Biologics Collaboration Agreement. Other existing agreements between us and WuXi Biologics remain in effect. Under the terms of the Termination Agreement, all licenses granted under the WuXi Biologics Collaboration Agreement were terminated and all rights to the SARS-CoV-2 antibody products in mainland China, Hong Kong, Macau and Taiwan reverted to us. We made a one-time termination payment to WuXi Biologics of $7.0 million in consideration for WuXi Biologics&#x2019; development activities under the WuXi Biologics Collaboration Agreement. Under the terms of the Termination Agreement, we are obligated to pay WuXi Biologics tiered royalties on net sales of sotrovimab in mainland China, Hong Kong, Macau and Taiwan ranging from low single digits to low double digits. Royalties are payable to WuXi Biologics for a specified royalty term and are subject to reduction in certain circumstances.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Letter Agreement, Assignment and Master Services Agreement with WuXi Biologics</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2020, we entered into a binding letter of intent with WuXi Biologics, or WuXi Biologics Letter of Intent, pursuant to which WuXi Biologics performs certain development and manufacturing services for our SARS-CoV-2 antibody program. Under the terms of the WuXi Biologics Letter of Intent, we had committed to purchase a firm and binding capacity reservation for the manufacture of a specified number of batches of drug substance of our SARS-CoV-2 antibody in 2020 and 2021. In addition, we had the right to order an additional specified number of batches of drug substance, provided we make such election by a specified date in the fourth calendar quarter in 2020. WuXi Biologics is obligated to reserve such manufacturing slots on a non-cancellable basis, and will manufacture the agreed number of batches of drug substance in accordance with an agreed manufacturing schedule. We were obligated to pay a total of approximately $130.0 million for such capacity reservation, if all batches are manufactured, inclusive of estimated raw material costs, with between 70% and 80% of the batch production fees owed to WuXi Biologics on a take-or-pay basis regardless of whether we utilize such manufacturing slots. The amounts were to be payable during 2020 and 2021 and invoiced on a per-batch basis. The SARS-CoV-2 antibody drug substance contemplated to be manufactured in accordance with the terms of the WuXi Biologics Letter of Intent will be utilized in connection with progressing the development and commercialization of the SARS-CoV-2 antibody product under our collaboration with GSK.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In August 2020, we entered into an Assignment and Novation Agreement with GSKTSL and WuXi Biologics effective as of July 29, 2020 pursuant to which we assigned and transferred to GSKTSL all of our right, title, and interest in, to and under the  WuXi Biologics Letter of Intent, and GSKTSL became our successor in interest in and to all of our rights, duties, and obligations in, to and under the WuXi Biologics Letter of Intent. On August 4, 2020, GSKTSL entered into a non-exclusive Master Services Agreement for Commercial Manufacture of Drug Substance with WuXi Biologics effective as of July 29, 2020, or the WuXi Biologics MSA, thereby superseding the WuXi Biologics Letter of Intent, and pursuant to which, among other things, WuXi Biologics will perform development and manufacturing services for clinical and commercial supply of antibody products under our SARS-CoV-2 antibody program.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">GSKTSL entered into the WuXi Biologics MSA and Samsung MSA in connection with the performance of GSK and our obligations pursuant to the 2020 GSK Agreement. In accordance with the terms of the 2020 GSK Agreement, we will continue to be responsible for 72.5% of the costs under each of the WuXi Biologics MSA and Samsung MSA, and GSK will bear 27.5% of such costs under each of the Samsung MSA and the WuXi Biologics MSA, subject to certain conditions and exceptions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Competition</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The pharmaceutical industry is characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. While we believe that our technology, the expertise of our executive and scientific team, research, clinical capabilities, development experience and scientific knowledge provide us with competitive advantages, we face increasing competition from many different sources, including pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions. Product candidates that we successfully develop and commercialize may compete with existing therapies and new therapies that may become available in the future. For example, the industry and competitive landscape for COVID-19 treatments is rapidly changing, which could result in more competition from new and existing therapies in the future.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Many of our competitors, either alone or with their collaborators, have significantly greater financial resources, established presence in the market, expertise in research and development, manufacturing, preclinical and clinical testing, obtaining regulatory approvals and reimbursement and marketing approved products than we do. These competitors also compete with us in recruiting and retaining qualified scientific, sales, marketing and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or potentially necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. Additional mergers and acquisitions may result in even more resources being concentrated in our competitors.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page56"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our commercial potential could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market or make our development more complicated. The key competitive factors affecting the success of all of our programs are likely to be efficacy, safety, convenience, and cost/access.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">COVID-19</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">49</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There are limited FDA-approved treatments and prophylactic vaccines for COVID-19 and several treatments, and a prophylactic vaccine are available under EUA. An IV administered antiviral, remdesivir, marketed by Gilead, is FDA-approved for treatment in the hospitalized and early-treatment settings. Currently, there are no mAbs available in the U.S. for use as treatment or prophylaxis against COVID-19. For example, in February 2022, the FDA approved an EUA for Eli Lilly and Company&#x2019;s, or Eli Lilly, antibody, bebtelovimab, for the treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kilograms) with positive results of direct SARS-CoV-2 testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death and when alternative treatment options are not accessible or clinically appropriate; however, in November 2022 the FDA announced that bebtelovimab is no longer authorized in any U.S. region due to lack of activity against recent Omicron subvariants.  AstraZeneca  plc&#x2019;s, or AstraZeneca . EVUSHELD&#153;, a cocktail of two mAbs, was previously approved under an EUA for pre-exposure prophylaxis of COVID-19 in adults and pediatric individuals over the age of 12 at risk for severe disease progression of COVID-19, but was deauthorized by the FDA in January 2023.  EVUSHELD&#153; currently remains authorized in other countries where it is approved for COVID-19 pre-exposure prophylaxis and treatment, including the EU and Japan. Oral antiviral therapies from Merck &amp; Co, Inc., or Merck, and Pfizer Inc., or Pfizer (molnupiravir and nirmatrelvir/ritonavir, respectively), are available under EUA in the mild to moderate early treatment setting. Additionally, Pfizer&#x2019;s COVID-19 vaccine, Comirnaty&#174;, was approved by the FDA for individuals 12 years of age or older, Moderna, Inc.'s COVID-19 vaccine, Spikevax&#174;, was approved by the FDA for individuals 18 years of age or older and a COVID-19 vaccine is available in the United States under EUA from Janssen Biotech, Inc. Numerous large and small pharmaceutical and biotechnology companies are developing programs with various mechanisms of actions, including prophylactic vaccines, oral antivirals, immunomodulators, and antibodies, some of which are further along in the development process than we are. Companies with antibodies in clinical development include Invivyd, Inc., or Invivyd, AstraZeneca, Brii Bio, Celltrion Healthcare Co., Ltd., Eli Lilly and Regeneron Pharmaceuticals, Inc. Companies with oral antivirals in clinical development include Shionogi Inc., Gilead, Pardes Biosciences, Inc., Enanta Pharmaceuticals, Inc. and others. Companies with prophylactic vaccines in clinical development include AstraZeneca, GSK, Novavax, Inc. and Sanofi S.A. In addition, COVID-19 treatment standards are susceptible to rapid changes in epidemiology and the emergence of new variants, thus, sotrovimab may be rendered inferior or obsolete in the future.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">HBV</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current FDA-approved treatments for chronic HBV infection include IFN-&#x3b1;, marketed by Roche Holding AG, or Roche, and oral antiviral agents such as NRTIs, marketed by Gilead and Bristol-Myers Squibb Company. These treatments do not lead to either a functional or a complete cure in the vast majority of patients, and in the case of NRTIs, require life-long therapy. Several large and small pharmaceutical companies are developing programs with various mechanisms of action, to be used alone or in combination, with the goal of achieving an HBV functional or complete cure. Companies with RNAi agents in clinical development include Arbutus Biopharma Corporation, GSK, Janssen Pharmaceuticals, Inc., or Janssen (part of Johnson &amp; Johnson, in partnership with Arrowhead Pharmaceuticals, Inc.), and Roche (in partnership with Dicerna Pharmaceuticals, Inc.) In addition, several companies are developing antibodies against surface antigen including GC Pharma, Bluejay Therapeutics &amp; Huahui Health. Several companies, including Gilead, GSK, Janssen, and Vaccitech plc have therapeutic vaccines in late-preclinical or early-clinical development.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Influenza</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There are numerous approved seasonal flu vaccines, including trivalent, quadrivalent, high-dose, and adjuvanted products, marketed by GSK, Sanofi Pasteur, and Seqirus (owned by CSL Limited). In addition, there are approved antiviral agents to treat influenza, such as Xofluza and Tamiflu, marketed by Roche, as well as other neuraminidase inhibitors. Cidara Therapeutics, Inc. (in partnership with Janssen) is working to develop an antiviral conjugate which could be a novel method for long-acting prophylaxis.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">While several companies, including Janssen and SAB Biotherapeutics, Inc., have conducted clinical trials of antibodies for the treatment of influenza, to our knowledge, there are no other prophylactic antibodies currently in clinical development. Invivyd has stated that it intends to develop prophylactic antibodies for influenza.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Several vaccines are in clinical development from large and small pharmaceutical companies including GSK (in partnership with CureVac N.V.), Moderna, Inc., Novavax, Inc., Pfizer (in partnership with BioNTech SE) and Sanofi S.A. (in partnership with Translate Bio). Some aim to improve efficacy or convenience over existing seasonal vaccines, and others are pursuing a universal flu vaccine approach with broad strain coverage and at least one year of protection.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page57"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">HIV</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No FDA-approved vaccine is currently available for the prevention of HIV. Several pharmaceutical companies, including GSK, Moderna Inc., and Worcester HIV Vaccine are actively engaged in vaccine research and development in this area. These and other companies are developing vaccines using viral vectors, nanoparticles, DNA, RNA, or formulations, with the goal of stimulating T cell-mediated and/or neutralizing antibody responses against HIV. To our knowledge, none are using a CMV-based vector. Numerous clinical trials of these vaccines are ongoing with support from the NIH Vaccine Research Center, the Bill &amp; Melinda Gates Foundation, the U.S. military, the International AIDS Vaccine Initiative, the European Vaccine Initiative, the South African AIDS Initiative, and their academic and industry partners. In addition, many of these institutions, as well as pharmaceutical companies like Gilead and Viiv Healthcare Limited, or Viiv, are also studying the passive transfer of broadly neutralizing antibodies against HIV for prophylactic and therapeutic applications.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may also compete with oral or long-acting antiretroviral therapies for pre-exposure prophylaxis of HIV. Truvada, marketed by Gilead, is a once-daily therapy approved for this indication. Viiv recently received FDA approval for long-acting antiretroviral therapy, cabotegravir for pre-exposure prophylaxis of HIV. Gilead, Janssen, Merck and Viiv have additional long-acting formulations in development.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intellectual Property</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our intellectual property is critical to our business and we strive to protect it, including by obtaining and maintaining patent protection in the United States and internationally for our product candidates, new therapeutic approaches and potential indications, and other inventions that are important to our business. Our policy is to seek to protect our proprietary and intellectual property position by, among other methods, filing U.S. and foreign patent applications related to our proprietary technology, inventions and improvements that are important for the development and implementation of our business. We also rely on the skills, knowledge and experience of our scientific and technical personnel, as well as that of our advisors, consultants and other contractors. To help protect our proprietary know-how that is not patentable, we rely on confidentiality agreements to protect our interests. We require our employees, consultants and advisors to enter into confidentiality agreements prohibiting the disclosure of confidential information and requiring disclosure and assignment to us of the ideas, developments, discoveries and inventions important to our business.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our patent portfolio includes patents and patent applications that are licensed from a number of collaborators and other third parties, including Alnylam, OHSU, MedImmune, IRB, Rockefeller and Xencor, and patents and patent applications that are owned by us. Our patent portfolio includes patents and patent applications that cover our product candidates sotrovimab (previously VIR-7831), VIR-7832, VIR-2218, VIR-3434, VIR-2482, VIR-1111 and VIR-1388, and the use of these candidates for therapeutic purposes. Our proprietary technology has been developed primarily through acquisitions, relationships with academic research centers and contract research organizations.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For our product candidates, we will, in general, initially pursue patent protection covering compositions of matter and methods of use. Throughout the development of our product candidates, we seek to identify additional means of obtaining patent protection that would potentially enhance commercial success, including through additional methods of use, process of making, formulation and dosing regimen-related claims.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In total, our patent portfolio, including patents licensed from our collaborators and other third parties, comprises over 100 different patent families as of December 31, 2022, filed in various jurisdictions worldwide. Our patent portfolio includes issued patents and patent applications in the United States and in many international countries. Our patent portfolio for our product candidates and technology platforms is outlined below:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Patent Portfolio by Product Candidate</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sotrovimab</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Licensed Patents</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our sotrovimab intellectual property portfolio includes patents and patent applications that we have non- exclusively licensed from Xencor. As of December 31, 2022, these patents and applications include five issued patents in the United States directed to composition of matter claims, methods of extending antibody serum half-life claims, pharmaceutical composition claims and process (methods of producing) claims. The 20-year term of these patents is presently estimated to expire in 2025, absent any available patent</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">51</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page58"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">term adjustments or extensions. Additionally, as of December 31, 2022, these patents and applications include 90 issued patents in Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Croatia,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Cyprus, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, India, Ireland, Israel, Italy, Japan, South Korea, Latvia, Lithuania, Luxembourg, Malta, Monaco, Netherlands, Norway, Poland, Portugal, Romania, Russia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey and the U.K. directed to composition of matter claims, composition for use in treatment claims and process (methods of producing) claims. The 20-year term of these patents is presently estimated to expire between 2025 and 2028, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The patents and applications we have non-exclusively licensed from Xencor also include, as of December 31, 2022, one patent application pending in the United States directed to composition of matter claims. The 20-year term of any patents issuing from this application is estimated to expire in 2025, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Patents Owned by Us</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, we own four patent families relating to sotrovimab. These families collectively include, as of December 31, 2022, two issued patents in the United States directed to composition of matter claims and method of treatment claims. The 20-year term of these patents is presently estimated to expire in 2041, absent any available patent term adjustments or extensions. Additionally, as of December 31, 2022, these families collectively include two patent applications and three provisional patent applications in the United States, one pending international Patent Cooperation Treaty, or PCT, application and 50 patent applications in Algeria, Argentina, Australia, Bahrain, Brazil, Canada, Chile, China, Colombia, Egypt, Eurasia, Europe, Hong Kong, India, Indonesia, Israel, Japan, Kuwait, Malaysia, Mexico, New Zealand, Nigeria, Oman, Philippines, Qatar, Russia, Saudi Arabia, Singapore, South Korea, Taiwan, Ukraine, United Arab Emirates, and Vietnam. The applications in these families include composition of matter claims, pharmaceutical composition claims, method of treatment claims and composition for use in treatment claims. The 20-year term of any patents issuing from pending patent applications in these families is presently estimated to expire between 2041 and 2043, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also co-own two patent families that collectively include, as of December 31, 2022, two pending PCT applications. These applications include pharmaceutical composition claims, method of treatment claims and composition for use in treatment claims. The 20-year term of any patents issuing from patent applications in this family is presently estimated to expire in 2042, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also co-own one patent family that includes, as of December 31, 2022, one pending PCT application. This application includes method of treatment claims. The 20-year term of any patents issuing from patent applications in this family is presently estimated to expire in 2042, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also co-own one patent family that includes, as of December 31, 2022, one pending PCT application related to delivery of sotrovimab. This application includes composition of matter claims, pharmaceutical composition claims and method of treatment claims. The 20-year term of any patents issuing from patent applications in this family is presently estimated to expire in 2042, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">VIR-7832</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Licensed Patents</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our VIR-7832 intellectual property portfolio includes a patent family that we have exclusively licensed from Rockefeller, which includes, as of December 31, 2022, issued patents in Nigeria and Organisation Africaine de la Propri&#xe9;t&#xe9; Intellectuelle (OAPI) (Africa), one pending patent application in the United States and 31 pending patent applications in the African Regional Intellectual Property Organization (ARIPO) (Africa), Algeria, Australia, Brazil, Canada, Chile, China, Colombia, Costa Rica, the Dominican Republic, Ecuador, Eurasia, Europe, Guatemala, Hong Kong, Indonesia, Israel, India, Japan, Malaysia, Mexico, New Zealand, Panama, Peru, Philippines, Singapore, South Africa, South Korea, Thailand, the Ukraine and Vietnam. The applications in this family include composition of matter claims, pharmaceutical composition claims, method of treatment claims, composition for use in treatment claims and process (methods of producing) claims. The 20-year term of any patents issuing from the application in this family is presently estimated to expire in 2038, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our VIR-7832 intellectual property portfolio also includes patents and patent applications that we have non-exclusively licensed from Xencor. As of December 31, 2022, these patents and applications include 10 issued patents in the United States directed to</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">composition of matter claims, methods of extending antibody serum half-life claims, pharmaceutical composition claims, methods of treatment claims and process (methods of producing) claims. The 20-year term of these patents is presently estimated to expire between 2023 and 2026, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, as of December 31, 2022, these patents and applications include 119 issued patents in Australia, Austria, Belgium, Bulgaria, Brazil, Canada, China, Croatia, Cyprus, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, India, Ireland, Israel, Italy, Japan, South Korea, Latvia, Lithuania, Luxembourg, Malta, Monaco, Netherlands, Norway, Poland, Portugal, Romania, Russia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey and the U.K. directed to composition of matter claims, pharmaceutical composition claims, method of treatment claims, composition for use in treatment claims and process (methods of producing) claims. The 20-year term of these patents is presently estimated to expire between 2023 and 2028, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The patents and applications we have non-exclusively licensed from Xencor also include, as of December 31, 2022, one patent application pending in the United States directed to composition of matter claims, and one patent application pending in India. The 20-year term of any patents issuing from these patent applications is presently estimated to expire between 2023 and 2025, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Patents Owned by Us</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, we own three patent families relating to VIR-7832. These families collectively include, as of December 31, 2022, two issued patents in the United States directed to composition of matter claims and method of treatment claims. The 20-year term of these patents is presently estimated to expire in 2041, absent any available patent term adjustments or extensions. Additionally, as of December 31, 2022, these families collectively include two patent applications in the United States, one pending international PCT application and s50 patent applications in Algeria, Argentina, Australia, Bahrain, Brazil, Canada, Chile, China, Colombia, Egypt, Eurasia, Europe, Hong Kong, India, Indonesia, Israel, Japan, Kuwait, Malaysia, Mexico, New Zealand, Nigeria, Oman, Philippines, Qatar, Russia, Saudi Arabia, Singapore, South Korea, Taiwan, Ukraine, United Arab Emirates, and Vietnam. The applications in these families include composition of matter claims, pharmaceutical composition claims, method of treatment claims and composition for use in treatment claims. The 20-year term of any patents issuing from pending patent applications in these families is presently estimated to expire between 2041 and 2042, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also co-own two patent families that collectively include, as of December 31, 2022, two pending PCT patent applications. These applications include pharmaceutical composition claims, method of treatment claims and composition for use in treatment claims. The 20-year term of any patents issuing from patent applications in this family is presently estimated to expire in 2042, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also co-own one patent family that includes, as of December 31, 2022, one pending PCT application. This application includes method of treatment claims. The 20-year term of any patents issuing from patent applications in this family is presently estimated to expire in 2042, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also co-own one patent family that includes, as of December 31, 2022, one pending PCT application related to delivery of VIR-7832. This application includes composition of matter claims, pharmaceutical composition claims and method of treatment claims. The 20-year term of any patents issuing from patent applications in this family is presently estimated to expire in 2042, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">VIR-2218</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Licensed Patents</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our VIR-2218 intellectual property portfolio includes three different patent families that we have exclusively licensed from Alnylam.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">One of these families includes, as of December 31, 2022, two issued patents in the United States directed to composition of matter claims, pharmaceutical composition claims and method of treatment claims. This family also includes 52 issued patents in Albania, Australia, Austria, Belgium, Bosnia and Herzegovina, Bulgaria, China, Croatia, Cyprus, Czechia, Denmark, Estonia, Eurasia, Finland, France, Germany, Greece, Hong Kong, Hungary, Iceland, India, Ireland, Italy, Japan, Jordan, Latvia, Lebanon, Lithuania, Luxembourg, Macao, Monaco, North Macedonia, Malta, Mexico, Netherlands, Norway, Poland, Portugal, Romania, Singapore, Slovakia, Slovenia, Spain, Sweden, Switzerland, Taiwan, Turkey, the U.K. and Vietnam directed to composition of matter claims, pharmaceutical composition claims, method of treatment claims and composition for use in treatment claims. The 20-year term of these patents is presently estimated to expire in 2035, absent any available patent term adjustments or extensions. A third party filed a</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">53</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">request for invalidation of the patent issued in China with the China National Intellectual Property Administration on December 31, 2021 and this invalidation proceeding has now concluded in favor of Vir and the subject China patent was held valid as amended.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Another of these families includes, as of December 31, 2022, one issued patent in the United States directed to method of treatment claims. This family also includes three issued patents in ARIPO (Africa), Nigeria and OAPI (Africa) directed to method of treatment claims and composition for use in treatment claims. The 20-year term of these patents is presently estimated to expire in 2038, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Another of these families includes, as of December 31, 2022, one issued patent in the United States directed to composition of matter claims, pharmaceutical composition claims and method of treatment claims. This family also includes two issued patents in Nigeria and OAPI (Africa) directed to composition of matter claims, pharmaceutical composition claims, method of treatment claims and composition for use in treatment claims. The 20-year term of these patents is presently estimated to expire in 2039, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The three licensed families also collectively include, as of December 31, 2022, three patent applications in the United States and 82 patent applications in ARIPO (Africa), Algeria, Argentina, Australia, Brazil, Canada, China, Eurasia, Europe, Gulf Cooperation Council (GCC), Hong Kong, India, Indonesia, Israel, Japan, Jordan, Malaysia, Mexico, New Zealand, OAPI (Africa), Pakistan, Paraguay, Philippines, Singapore, South Africa, South Korea, Taiwan, Thailand, Ukraine, Venezuela and Vietnam directed to composition of matter claims, pharmaceutical composition claims, method of treatment claims and composition for use in treatment claims. The 20-year term of any patents issuing from pending patent applications in these families is presently estimated to expire between 2035 and 2039, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Patents Owned by Us</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, we own four different patent families that are directed to VIR-2218 in combination with one or more other therapeutics. One of these families includes, as of December 31, 2022, one issued patent in OAPI (Africa) directed to composition for use in treatment claims. The 20-year term of this patent is presently estimated to expire in 2040, absent any available patent term adjustments or extensions. The four families also collectively include, as of December 31, 2022, three pending provisional patent applications in the United States, two patent applications in the United States and 46 patent applications in ARIPO (Africa), Algeria, Australia, Brazil, Canada, China, Eurasia, Europe, Hong Kong, India, Indonesia, Israel, Japan, Malaysia, Mexico, New Zealand, Philippines, Singapore, South Africa, South Korea, Taiwan, Thailand, Ukraine and Vietnam. The applications in these families include method of treatment claims and composition for use in treatment claims for VIR-2218 in combination as a second therapeutic. The 20-year term of any patents issuing from pending patent applications in these families is presently estimated to expire between 2039 and 2043, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also co-own another patent family directed to VIR-2218 in combination with another therapeutic. This family includes a pending PCT application and patent applications in Argentina and Taiwan, directed to method of treatment claims. The 20-year term of any patents issuing from pending patent applications in these families is presently estimated to expire in 2042, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">VIR-3434</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Licensed Patents</span></p>
  <p style="text-indent:4.749%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our VIR-3434 intellectual property portfolio includes a patent family that we have exclusively licensed from Rockefeller, which includes, as of December 31, 2022, issued patents in Nigeria and OAPI (Africa), one pending patent application in the United States and 31 pending patent applications in ARIPO (Africa), Algeria, Australia, Brazil, Canada, Chile, China, Colombia, Costa Rica, the Dominican Republic, Ecuador, Eurasia, Europe, Guatemala, Hong Kong, Indonesia, Israel, India, Japan, Malaysia, Mexico, New Zealand, Panama, Peru, Philippines, Singapore, South Africa, South Korea, Thailand, the Ukraine and Vietnam. The applications in this family include composition of matter claims, pharmaceutical composition claims, method of treatment claims, composition for use in treatment claims and process (methods of producing) claims. The 20-year term of any patents issuing from the application in this family is presently estimated to expire in 2038, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our VIR-3434 intellectual property portfolio also includes patents and patent applications that we have non-exclusively licensed from Xencor. As of December 31, 2022, these patents and applications include 10 issued patents in the United States directed to composition of matter claims, methods of extending antibody serum half-life claims, pharmaceutical composition claims, method of treatment claims and process (methods of producing) claims. The 20-year term of these patents is presently estimated to expire between 2023 and 2026, absent any available patent term adjustments or extensions. Additionally, as of December 31, 2022, these</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">54</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">patents and applications include 119 issued patents in Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Croatia, Cyprus, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, India, Ireland, Israel, Italy, Japan, South Korea, Latvia, Lithuania, Luxembourg, Malta, Monaco, Netherlands, Norway, Poland, Portugal, Romania, Russia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey and the U.K. directed to composition of matter claims, pharmaceutical composition claims, method of treatment claims, composition for use in treatment claims and process (methods of producing) claims. The 20-year term of these patents is presently estimated to expire between 2023 and 2028, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The patents and applications we have non-exclusively licensed from Xencor also include, as of December 31, 2022, one patent application pending in the United States directed to composition of matter claims, and one patent application pending in India. The 20-year term of any patents issuing from these patent applications is presently estimated to expire between 2023 and 2025, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Patents Owned by Us</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also own two different patent families that include, as of December 31, 2022, one pending PCT patent application, one patent application in the United States and 19 patent applications in Australia, Brazil, Canada, China, Eurasia, Europe, Hong Kong, Indonesia, Israel, Japan, Mexico, New Zealand, Singapore, South Africa, South Korea, Taiwan, Thailand, and Ukraine. These applications include composition of matter claims, pharmaceutical composition claims and method of treatment claims. The 20-year term of any patents issuing from patent applications in this family is presently estimated to expire between 2040 and 2042, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page61"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, through our subsidiary Humabs, we own two different patent families related to VIR-3434. One of these families includes, as of December 31, 2022, two issued patents in the United States directed to composition of matter claims, pharmaceutical composition claims and method of treatment claims. This family also includes, as of December 31, 2022, 47 issued patents in Albania, ARIPO (Africa), Austria, Belgium, Bulgaria,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> China, Croatia, Cyprus, Czechia, Denmark, Estonia, Eurasia, Finland, France, Germany, Greece, Hong Kong, Hungry, Iceland, Indonesia, Ireland, Israel, Italy, Japan, Latvia, Lithuania, Luxembourg, Malaysia, Malta, Mexico, Monaco, Netherlands, North Macedonia, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, South Africa, Spain, Sri Lanka, Sweden, Switzerland, Turkey and the U.K. that include composition of matter claims, pharmaceutical composition claims and composition for use in treatment claims. The 20-year term of these patents is presently estimated to expire in 2036, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The other patent family owned through our subsidiary Humabs that relates to VIR-3434 includes, as of December 31, 2022, two issued patents in Nigeria and OAPI (Africa), directed to composition of matter claims, pharmaceutical composition claims, method of treatment claims, composition for use in treatment claims and process (methods of producing) claims. The 20-year term of these patents is presently estimated to expire in 2039, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These two families owned by Humabs also collectively include, as of December 31, 2022, two pending patent applications in the United States and 50 pending patent applications in ARIPO (Africa), Australia, Bahrain, Brazil, Canada, China, Eurasia, Europe, Hong Kong, India, Indonesia, Israel, Japan, Kuwait, Macao, Malaysia, Mexico, Nigeria, New Zealand, OAPI (Africa), Oman, the Philippines, Qatar, Saudi Arabia, Singapore, South Africa, South Korea, Taiwan, Thailand, Ukraine, United Arab Emirates and Vietnam. The applications in these families include composition of matter claims, pharmaceutical composition claims, method of treatment claims, composition for use in treatment claims and process (methods of producing) claims. The 20-year term of any patents issuing from patent applications in these families is presently estimated to expire between 2036 and 2039, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">VIR-2482</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Licensed Patents</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our VIR-2482 intellectual property patent portfolio includes two different patent families that we have exclusively licensed from MedImmune, which collectively include, as of December 31, 2022, two issued patents in the United States directed to composition of matter claims, pharmaceutical composition claims and method of treatment claims. These families also collectively include, as of December 31, 2022, 55 issued patents in Albania, Australia, Austria, Belgium, Bulgaria, China, Croatia, Cyprus, Czechia, Denmark, Estonia, Finland, France, Germany, Gibraltar, Greece, Guernsey, Hong Kong, Hungry, Iceland, Ireland, Italy, Japan, Jersey, Latvia, Lithuania, Luxembourg, Malta, Mexico, Monaco, Netherlands, North Macedonia, Norway, Poland, Portugal, Romania, Russia, San Marino, Serbia, Singapore, Slovakia, Slovenia, South Korea, Spain, Sweden, Switzerland, Taiwan, Turkey and the U.K. that include composition of matter claims, pharmaceutical composition claims, method of treatment claims, composition for use in treatment claims and process (methods of producing) claims. The 20-year term of these patents is presently estimated to expire between 2034 and 2037, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">55</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The two families licensed from MedImmune also collectively include, as of December 31, 2022, three patent applications in the United States and 25 patent applications in Australia, Brazil, Canada, China, Europe, Hong Kong, Israel, Japan, Mexico, Russia, Singapore, South Korea and Taiwan. The applications in these families include composition of matter claims, pharmaceutical composition claims, method of treatment claims, composition for use in treatment claims and process (methods of producing) claims. The 20-year term of any patents issuing from patent applications in these families is presently estimated to expire between 2034 and 2037, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our VIR-2482 intellectual property portfolio also includes patents and patent applications that we have non-exclusively licensed from Xencor. As of December 31, 2022, these patents and applications include five issued patents in the United States directed to composition of matter claims, methods of extending antibody serum half-life claims, pharmaceutical composition claims and process (methods of producing) claims. The 20-year term of these patents is presently estimated to expire in 2025, absent any available patent term adjustments or extensions. Additionally, as of December 31, 2022, these patents and applications include 90 issued patents in Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Croatia, Cyprus, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, India, Ireland, Israel, Italy, Japan, South Korea, Latvia, Lithuania, Luxembourg, Malta, Monaco, Netherlands, Norway, Poland, Portugal, Romania, Russia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey and the U.K. directed to composition of matter claims, composition for use in treatment claims and process (methods of producing) claims. The 20-year term of these patents is presently estimated to expire between 2025 and 2028, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The patents and applications we have non-exclusively licensed from Xencor also include, as of December 31, 2022, one patent application pending in the United States directed to composition of matter claims. The 20-year term of any patents issuing from this application is estimated to expire in 2025, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Patents Owned by Us</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also own one patent family that includes, as of December 31, 2022, one pending application in the United States and 18 patent applications in Australia, Brazil, Canada, China, Eurasia, Europe, Hong Kong, Indonesia, Israel, Japan, Mexico, New Zealand, Singapore, South Africa, South Korea, Thailand and Ukraine. These applications include composition of matter claims, pharmaceutical composition claims, method of treatment claims and composition for use in treatment claims. The 20-year term of any patents issuing from patent applications in this family is presently estimated to expire in 2040, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page62"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Through our subsidiary Humabs, we co-own a patent family (with MedImmune) that includes, as of December 31, 2022, two issued patents in the United States directed to composition of matter claims, pharmaceutical composition claims and method of treatment claims. This family also includes 54 issued patents in Albania, Australia, Austria, Belgium, Bulgaria, China, Croatia, Cyprus, Czechia, Denmark, Estonia, Finland, France, Germany, Gibraltar, Greece, Guernsey, Hong Kong, Hungry, Iceland, Ireland, Italy, Japan, Jersey, Latvia, Lithuania, Luxembourg, Malta, Mexico, Monaco, Netherlands, North Macedonia, Norway, Poland, Portugal, Romania, Russia, San Marino, Serbia, Singapore, Slovakia, Slovenia, South Korea, Spain, Sweden, Switzerland, Taiwan, Turkey and the U.K. that include composition of matter claims, pharmaceutical composition claims, method of treatment claims, composition for use in treatment claims and process (methods of producing) claims. The 20-year term of these patents is presently estimated to expire in 2034, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This co-owned family also includes, as of December 31, 2022, one patent application in the United States and 15 patent applications in Australia, Brazil, Canada, China, Europe, Hong Kong, Japan, South Korea, Mexico, Russia, Singapore and Taiwan. The applications in this family include composition of matter claims, pharmaceutical composition claims, method of treatment claims, composition for use in treatment claims and process (methods of producing) claims. The 20-year term of any patents issuing from patent applications in this family is presently estimated to expire in 2034, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, through our subsidiary Humabs, we own a patent family that includes, as of December 31, 2022, one pending application in the United States and 34 pending applications in Algeria, Australia, Bahrain, Brazil, Canada, Chile, China, Colombia, Egypt, Eurasia, Europe, Hong Kong, India, Indonesia, Israel, Japan, Kuwait, Malaysia, Mexico, New Zealand, Nigeria, Oman, Philippines, Qatar, Saudi Arabia, Singapore, South Africa, South Korea, Taiwan, Thailand, Ukraine, United Arab Emirates and Vietnam. The application in this family includes composition of matter claims, pharmaceutical composition claims, method of treatment claims and composition for use in treatment claims. The 20-year term of any patents issuing from the patent application in this family is presently estimated to expire in 2040, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, through our subsidiary Humabs, we own a patent family that includes, as of December 31, 2022, two pending provisional applications in the United States. These applications include pharmaceutical composition claims, method of treatment</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">56</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">claims and composition for use in treatment claims. The 20-year term of any patents issuing from the patent application in this family is presently estimated to expire in 2043, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">VIR-1111</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Licensed Patents</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our VIR-1111 intellectual property patent portfolio includes three different patent families that we have exclusively licensed from OHSU. These patent families are generally directed to composition of matter claims, pharmaceutical composition claims, method of treatment claims and composition for use in treatment claims.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The three families collectively include, as of December 31, 2022, five issued patents in the United States directed to composition of matter claims, pharmaceutical composition claims and method of treatment claims. The 20-year term of these patents is presently estimated to expire between 2031 and 2035, absent any available patent term adjustments or extensions. Additionally, the three patent families collectively include, as of December 31, 2022, 180 issued patents in Albania, ARIPO (Africa), Australia, Austria, Belgium, Bulgaria, Canada, China, Croatia, Cyprus, Czechia, Denmark, Estonia, Eurasia, Finland, France, Germany, Greece, Hong Kong, Hungary, Iceland, Ireland, Israel, Italy, Japan, Latvia, Lithuania, Luxembourg, Macao, Monaco, North Macedonia, Malta, Mexico, New Zealand, Netherlands, Norway, Poland, Portugal, Romania, San Marino, Serbia, Singapore, Slovakia, Slovenia, South Korea, Spain, Sweden, Switzerland, Turkey, Ukraine and the U.K. The 20-year term of these patents is presently estimated to expire between 2025 and 2035, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The three licensed families also collectively include, as of December 31, 2022, three patent applications in the United States and 20 patent applications in ARIPO (Africa), Australia, Brazil, Canada, China, Europe, Hong Kong, Indonesia, India, Japan, Mexico, New Zealand, Singapore, South Africa and Thailand. The 20-year term of any patents issuing from patent applications in these families is presently estimated to expire between 2025 and 2035, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">VIR-1388</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Licensed Patents</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our VIR-1388 intellectual property patent portfolio includes four different patent families that we have exclusively licensed from OHSU. These patent families are generally directed to composition of matter claims, pharmaceutical composition claims, method of treatment claims and composition for use in treatment claims.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Two of these four families collectively include, as of December 31, 2022, three issued patents in the United States directed to composition of matter claims, pharmaceutical composition claims and method of treatment claims. The 20-year term of these patents is presently estimated to expire in 2035, absent any available patent term adjustments or extensions. Additionally, three of the four patent families collectively include, as of December 31, 2022, 33 issued patents in ARIPO (Africa), Australia, Canada, China, Eurasia, France, Germany, Israel, Japan, Macao, Mexico, New Zealand, Netherlands, Singapore, South Korea, Switzerland, Ukraine and the U.K. The 20-year term of these patents is presently estimated to expire between 2025 and 2035, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The four licensed families also collectively include, as of December 31, 2022, five patent applications in the United States and 77 patent applications in ARIPO (Africa), Australia, Brazil, Canada, Chile, China, Colombia, Costa Rica, Dominican Republic, Ecuador, Eurasia, Europe, Guatemala, Hong Kong, Indonesia, India, Israel, Japan, Mexico, Malaysia, New Zealand, Nigeria, OAPI (Africa), Panama, Peru, Philippines, Singapore, South Africa, South Korea, Thailand, Ukraine and Vietnam. The 20-year term of any patents issuing from patent applications in these families is presently estimated to expire between 2025 and 2040, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Patents Owned by Us</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We co-own a patent family that includes, as of December 31, 2022, one issued patent in the United States directed to composition of matter claims and method of treatment claims. Additionally, this patent family includes, as of December 31, 2022, two issued patents in Eurasia and Mexico, directed to composition of matter claims, pharmaceutical composition claims, method of treatment claims and composition for use in treatment claims. The family also includes two patent applications in the United States and 28 patent applications in ARIPO (Africa), Australia, Brazil, Canada, China, Eurasia, Europe, Hong Kong, Indonesia, Israel, India, Japan, Mexico, New Zealand, Singapore, South Africa, South Korea, Thailand and the Ukraine directed to composition of matter claims, pharmaceutical composition claims, method of treatment claims and composition for use in treatment claims. The 20-year term of the issued patents and any patents issuing from patent applications in this family is presently estimated to expire in 2035, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">57</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Additionally, we own a family that includes, as of December 31, 2022, a pending PCT application and patent applications in Argentina and Taiwan, directed to composition of matter claims, pharmaceutical composition claims, method of treatment claims and composition for use in treatment claims. The 20-year term of any patents issuing from patent applications in this family is presently estimated to expire in 2042, absent any available patent term adjustments or extensions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Patent Portfolio by Technology Platform</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">siRNA Platform</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Licensed Patents</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our siRNA intellectual property portfolio includes three additional different patent families that we have exclusively licensed from Alnylam. Two of the three families collectively include, as of December 31, 2022, 10 issued patents in the United States directed to composition of matter claims, pharmaceutical composition claims and method of treatment claims. The 20-year term of these patents is presently estimated to expire between 2024 and 2031, absent any available patent term adjustments or extensions. Additionally, the three patent families collectively include, as of December 31, 2022, 79 issued patents in Albania, Australia, Belgium, Canada, China, Croatia, Denmark, Finland, France, Germany, Hungary, Iceland, India, Indonesia, Ireland, Japan, Latvia, Lithuania, Luxembourg, Macao, Monaco, Netherlands, North Macedonia, Norway, Russia, Singapore, Slovenia, South Korea, Sweden, Switzerland and the U.K. directed to composition of matter claims, pharmaceutical composition claims, method of treatment claims and composition for use in treatment claims. The 20-year term of these patents is presently estimated to expire between 2024 and 2031, absent any available patent term adjustments or extensions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The three licensed families also collectively include, as of December 31, 2022, two patent applications in the United States and seven patent applications in Canada, Europe, Hong Kong, India, Japan, and Thailand directed to composition of matter claims, pharmaceutical composition claims, method of treatment claims and composition for use in treatment claims. The 20-year term of the issued patent and any patents issuing from pending patent applications in these families is presently estimated to expire between 2024 and 2031, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have also exclusively licensed from Alnylam, as of December 31, 2022, three issued patents in the United States directed to composition of matter claims, pharmaceutical composition claims and method of treatment claims. The 20-year term of these patents is presently estimated to expire between 2022 and 2028, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also have an exclusive license to additional Alnylam platform technology for HBV licensed products.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Antibody Platform</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Licensed Patents</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have exclusively licensed from Rockefeller a patent family that includes, as of December 31, 2022, issued patents in Nigeria and OAPI (Africa), one pending patent application in the United States and 31 pending patent applications in ARIPO (Africa), Algeria, Australia, Brazil, Canada, Chile, China, Colombia, Costa Rica, the Dominican Republic, Ecuador, Eurasia, Europe, Guatemala, Hong Kong, Indonesia, Israel, India, Japan, Malaysia, Mexico, New Zealand, Panama, Peru, Philippines, Singapore, South Africa, South Korea, Thailand, the Ukraine and Vietnam. The applications in this family include composition of matter claims, pharmaceutical composition claims, method of treatment claims, composition for use in treatment claims and process (methods of producing) claims. The 20-year term of any patents issuing from the application in this family is presently estimated to expire in 2038, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have exclusively licensed from IRB two patent families that relate to our antibody platform technology. One of these families includes, as of December 31, 2022, two issued patents in the United States directed to process (methods of producing) claims, and 23 issued patents in Austria, Australia, Belgium, Czechia, Denmark, Finland, France, Germany, Hungary, Ireland, Israel, Italy, Netherlands, Portugal, Romania, Singapore, Spain, Sweden, Switzerland, Turkey and the U.K. directed to process (methods of producing) claims. The two families also collectively include, as of December 31, 2022, two pending patent applications in the United States directed to process (methods of producing) claims, as well as one patent application in the United States and 19 patent applications in Australia, Brazil, Canada, China, Eurasia, Europe, Hong Kong, India, Indonesia, Israel, Japan, Mexico, New Zealand, Singapore, South Africa, South Korea, Thailand and Ukraine directed to composition of matter claims, method of treatment claims, composition for use in treatment claims and process (methods of producing) claims. The 20-year term of the issued patents and any patent issuing from the pending patent applications in these families is presently estimated to expire between 2024 and 2038, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, we have non-exclusively licensed a group of patents and applications from Xencor. As of December 31, 2022, these patents and applications include 10 issued patents in the United States directed to composition of matter claims, methods of extending antibody serum half-life claims, pharmaceutical composition claims, method of treatment claims and process (methods of producing) claims. The 20-year term of these patents is presently estimated to expire between 2023 and 2026, absent any available patent term adjustments or extensions. Additionally, as of December 31, 2022, these patents and applications include 119 issued patents in Australia, Austria, Belgium, Bulgaria, Canada, China, Croatia, Cyprus, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, India, Ireland, Israel, Italy, Japan, South Korea, Latvia, Lithuania, Luxembourg, Malta, Monaco, Netherlands, Norway, Poland, Portugal, Romania, Russia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey and the U.K. directed to composition of matter claims, pharmaceutical composition claims, method of treatment claims, composition for use in treatment claims and process (methods of producing) claims. The 20-year term of these patents is presently estimated to expire between 2023 and 2028, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The patents and applications we have non-exclusively licensed from Xencor also include, as of December 31, 2022, two patent applications pending in the United States directed to composition of matter claims and process (methods of producing) claims, and one patent application pending in India. The 20-year term of any patents issuing from these patent applications is presently estimated to expire between 2023 and 2025, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Patents Owned by Us</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also own, with our subsidiary Humabs, one patent family that includes, as of December 31, 2022, one pending PCT application and one patent application in Taiwan. These applications include composition of matter claims, pharmaceutical composition claims, method of treatment claims and composition for use in treatment claims. The 20-year term of any patents issuing from patent applications in this family is presently estimated to expire in 2042, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">T Cell Platform</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Licensed Patents</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have exclusively licensed from OHSU 10 different patent families related to our T cell portfolio.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Eight of the 10 families collectively include, as of December 31, 2022, 15 issued patents in the United States, directed to composition of matter claims, pharmaceutical composition claims, method of treatment claims and process (methods of producing) claims. The 20-year term of the issued patents in these families is presently estimated to expire between 2031 and 2037, absent any available patent term adjustments or extensions. In addition, nine of the 10 families collectively include, as of December 31, 2022, 259 issued patents in Albania, ARIPO (Africa), Australia, Austria, Belgium, Bulgaria, Canada, China, Croatia, Cyprus, Czechia, Denmark, Germany, Estonia, Eurasia, Finland, France, Greece, Hong Kong, Hungary, Iceland, Ireland, Israel, Italy, Japan, Latvia, Lithuania, Luxembourg, North Macedonia, Malta, Macao, Mexico, Monaco, Netherlands, Norway, New Zealand, OAPI (Africa), Poland, Portugal, Romania, San Marino, Serbia, Singapore, Slovakia, Slovenia, South Korea, Spain, Sweden, Switzerland, Tunisia, Turkey, Ukraine and the U.K. directed to composition of matter claims, pharmaceutical composition claims, method of treatment claims, composition for use in treating claims and process (methods of producing) claims. The 20-year term of the issued patents in these families is presently estimated to expire between 2025 and 2037, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 10 patent families also collectively include, as of December 31, 2022, nine patent applications in the United States,  and 100 patent applications in Algeria, ARIPO (Africa), Australia, Brazil, Canada, Chile, China, Colombia, Costa Rica, the Dominican Republic, Ecuador, Eurasia, Europe, Guatemala, Hong Kong, Indonesia, Israel, India, Japan, Malaysia, Mexico, New Zealand, Nigeria, OAPI (Africa) Panama,  Peru, Philippines, Singapore, South Africa, South Korea, Thailand, the Ukraine and Vietnam directed to composition of matter claims, pharmaceutical composition claims, method of treatment claims, composition for use in treating claims and process (methods of producing) claims. The 20-year term of any patents issuing from pending patent applications in these families is presently estimated to expire between 2025 and 2040, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page65"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Patents Owned by Us</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, we own two patent families that include, as of December 31, 2022, two pending PCT applications and three patent applications in Argentina and Taiwan directed to composition of matter claims, pharmaceutical composition claims, method of treatment claims, composition for use in treating claims and process (method of producing) claims. The 20-year term of any patent issuing in these families is presently estimated to expire in 2042, absent any available patent term adjustments or extensions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Innate Immunity Platform</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">59</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have know-how relating to our innate immunity platform and are continually developing our intellectual property in this area, as well as evaluating external technologies and assets that may also help grow this platform.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We do not currently license or own any patents related to our innate immunity platform.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Patent Term and Term Extensions</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Individual patents have terms for varying periods depending on the date of filing of the patent application or the date of patent issuance and the legal term of patents in the countries in which they are obtained. Generally, utility patents issued for applications filed in the United States are granted a term of 20 years from the earliest effective filing date of a non-provisional patent application. In addition, in certain instances, the term of a U.S. patent can be extended to recapture a portion of the U.S. Patent and Trademark Office&#x2019;s, or the USPTO, delay in issuing the patent as well as a portion of the term effectively lost</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">as a result of the FDA regulatory review period. However, as to the FDA component, the restoration period cannot be longer than five years and the restoration period cannot extend the patent term beyond 14 years from FDA approval. In addition, only one patent applicable to an approved drug is eligible for the extension, and only those claims covering the approved drug, a method for using it, or a method of manufacturing may be extended. The duration of foreign patents varies in accordance with provisions of applicable local law, but typically is also 20 years from the earliest effective filing date. All taxes, annuities or maintenance fees for a patent, as required by the USPTO and various foreign jurisdictions, must be timely paid in order for the patent to remain in force during this period of time.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The actual protection afforded by a patent may vary on a product by product basis, from country to country, and can depend upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions and the availability of legal remedies in a particular country and the validity and enforceability of the patent.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our patents and patent applications may be subject to procedural or legal challenges by others. We may be unable to obtain, maintain and protect the intellectual property rights necessary to conduct our business, and we may be subject to claims that we infringe or otherwise violate the intellectual property rights of others, which could materially harm our business. For more information, see the section titled &#x201c;Risk Factors&#x2014;Risks Related to Our Intellectual Property.&#x201d;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Trademarks and Know-How</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the ongoing development and advancement of our products and services in the United States and various international jurisdictions, we seek to create protection for our marks and enhance their value by pursuing trademarks and service marks where available and when appropriate. In addition to patent and trademark protection, we rely upon know-how and continuing technological innovation to develop and maintain our competitive position. We seek to protect our proprietary information, in part, by using confidentiality agreements with our commercial partners, collaborators, employees and consultants, and invention assignment agreements with our employees and consultants. These agreements are designed to protect our proprietary information and, in the case of the invention assignment agreements, to grant us ownership of technologies that are developed by our employees and through relationships with third parties. These agreements may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our contractors, commercial partners, collaborators, employees, and consultants use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions. For more information, see the section titled &#x201c;Risk Factors&#x2014;Risks Related to Our Intellectual Property.&#x201d;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Government Regulation and Product Approval</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page66"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA and other regulatory authorities at federal, state and local levels, as well as in foreign countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> effectiveness, labeling, packaging, storage, distribution, record keeping, approval, advertising, promotion, marketing, post-approval monitoring and post-approval reporting of drugs and biologics such as those we are developing.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the United States, the FDA approves and regulates drugs under the Federal Food, Drug, and Cosmetic Act, or the FDCA. Biological products, or biologics, are licensed for marketing under the Public Health Service Act, or the PHSA, and regulated under the FDCA. A company, institution, or organization which takes responsibility for the initiation and management of a clinical development program for such products is typically referred to as a sponsor. We, along with third-party contractors, will be required to navigate the various preclinical, clinical and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or trials or seek approval or licensure of our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">U.S. Biopharmaceuticals Regulation</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The process required by the FDA before drug and biologic product candidates may be marketed in the United States generally involves the following:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">completion of extensive preclinical laboratory tests and animal trials performed in accordance with applicable regulations, including the FDA&#x2019;s Good Laboratory Practice, or GLP, regulations;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">design of a clinical protocol and submission to the FDA of an IND application which must become effective before clinical trials may begin;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">approval by an independent institutional review board or ethics committee at each clinical site before the trial is commenced;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">performance of adequate and well-controlled human clinical trials in accordance with FDA&#x2019;s Good Clinical Practice, or GCP, regulations to establish the safety and efficacy of a drug candidate, and compliance with cGMP to establish safety, purity and potency of a proposed biologic product candidate for its intended purpose;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">preparation of and submission to the FDA of a new drug application, or NDA, or biologics licensing application, or BLA, as applicable, after completion of all pivotal clinical trials;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">satisfactory completion of an FDA Advisory Committee review, if applicable;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">a determination by the FDA within 60 days of its receipt of an NDA or BLA to file the application for review;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities at which the proposed product is produced to assess compliance with cGMPs and of selected clinical investigation sites to assess compliance with GCPs;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FDA review and approval of an NDA or BLA to permit commercial marketing of the product for particular indications for use in the United States; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">completion of any post-approval requirements, including the potential requirement to implement a risk evaluation and mitigation strategy, or REMS, and any post-approval studies required by the FDA.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Preclinical and Clinical Development</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prior to beginning the first clinical trial with a product candidate, we must submit an IND to the FDA. An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol or protocols for preclinical studies and clinical trials. The IND also includes results of animal and in vitro studies assessing the toxicology, pharmacokinetics, pharmacology and pharmacodynamic characteristics of the product, chemistry, manufacturing and controls information, and any available human data or literature to support the use of the investigational product. These studies are typically referred to as IND-enabling studies. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day period, raises safety concerns or questions about the proposed clinical trial. In such a case, the IND may be placed on clinical hold and the IND sponsor, and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page67"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical study. Clinical trials are conducted under protocols detailing, among</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. Furthermore, an independent institutional review board for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins at that site, and must monitor the trial until completed.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Regulatory authorities, the institutional review board or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives. Some trials also include oversight by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board, which provides authorization for whether or not a trial may move forward at designated check points based on access to certain data from the trial and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For purposes of biopharmaceutical development, human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Phase 1. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The investigational product is initially introduced into patients with the target disease or condition. These trials are designed to test</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Phase 2. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The investigational product is administered to a limited patient population to evaluate the preliminary efficacy, optimal dosages and</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">dosing schedule and to identify possible adverse side effects and safety risks.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Phase 3. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The investigational product is administered to an expanded patient population to further evaluate dosage, to provide statistically</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product. These so-called Phase 4 trials may be made a condition to approval of the application. Concurrent with clinical trials, companies may complete additional animal trials and develop additional information about the characteristics of the product candidate, and must finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final product, or for biologics, the safety, purity and potency. Additionally, appropriate packaging must be selected and tested and stability trials must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2022, with the passage of the Food and Drug Omnibus Reform Act, or FDORA, Congress required sponsors to develop and submit a diversity action plan for each phase 3 clinical trial or any other &#x201c;pivotal study&#x201d; of a new drug or biological product.  These plans are meant to encourage the enrollment of more diverse patient populations in late-stage clinical trials of FDA-regulated products.  Specifically, action plans must include the sponsor&#x2019;s goals for enrollment, the underlying rationale for those goals, and an explanation of how the sponsor intends to meet them.  In addition to these requirements, the legislation directs the FDA to issue new guidance on diversity action plans.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical data, and clinical trial investigators. The FDA or the sponsor or its data safety monitoring board may suspend a clinical trial at any time on various grounds, including a finding that the research patients or patients are being exposed to an unacceptable health risk. Similarly, an institutional review board can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the institutional review board&#x2019;s requirements or if the product candidate has been associated with unexpected serious harm to patients.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A sponsor may choose, but is not required, to conduct a foreign clinical study under an IND. When a foreign clinical study is conducted under an IND, all IND requirements must be met unless waived by the FDA. When a foreign clinical study is not conducted under an IND, the sponsor must ensure that the study complies with certain regulatory requirements of the FDA in order to use the study as support for an IND or application for marketing approval. Specifically, the studies must be conducted in accordance with GCP, including undergoing review and receiving approval by an independent ethics committee and seeking and receiving informed consent from subjects.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the PHSA, sponsors of clinical trials are required to register and disclose certain clinical trial information on a public registry (clinicaltrials.gov) maintained by the NIH. In particular, information related to the product, patient population, phase of investigation, study sites and investigators and other aspects of the clinical trial is made public as part of the registration of the clinical trial. The failure to submit clinical trial information to clinicaltrials.gov, as required, is a prohibited act under the FDCA with violations subject to potential civil monetary penalties of up to $10,000 for each day the violation continues. Although the FDA has historically not enforced these reporting requirements due to HHS&#x2019;s long delay in issuing final implementing regulations, those regulations have now been issued and the FDA has issued several Notices of Noncompliance to manufacturers since April 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page68"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">NDA/BLA Submission and Review</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, nonclinical trials and clinical trials are submitted to the FDA as part of an NDA or BLA, as applicable, requesting approval to market the product for one or more indications. The application must include all relevant data available from pertinent preclinical studies and clinical trials, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#x2019;s chemistry, manufacturing, controls, and proposed labeling, among other things. The</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">62</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">submission of an application requires payment of a substantial application user fee to the FDA, unless a waiver or exemption applies. The FDA has sixty days from the applicant&#x2019;s submission to either issue a refusal to file letter, or RTF, or accept the application for filing, indicating that it is sufficiently complete to permit substantive review.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Once an NDA or BLA has been accepted for filing, the FDA&#x2019;s goal is to review standard applications within 10 months after it accepts the application for filing, or, if the application qualifies for priority review, six months after the FDA accepts the application for filing. In both standard and priority reviews, the review process is often significantly extended by FDA requests for additional information or clarification. The FDA reviews an NDA to determine whether a drug is safe and effective for its intended use and a BLA to determine whether a biologic is safe, pure and potent. The FDA also reviews whether the facility in which the product is manufactured, processed, packed or held meets standards designed to assure and preserve the product&#x2019;s identity, safety, strength, quality, potency and purity. The FDA may convene an advisory committee to provide clinical insight on application review questions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Before approving an NDA or BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. The PREVENT Pandemics Act, which was enacted in December 2022, clarifies that foreign drug manufacturing establishments are subject to registration and listing requirements even if a drug or biologic undergoes further manufacture, preparation, propagation, compounding, or processing at a separate establishment outside the United States prior to being imported or offered for import into the United States.   Additionally, before approving an application, the FDA will typically inspect one or more clinical sites to assure compliance with GCPs. With passage of FDORA, Congress clarified the FDA&#x2019;s authority to conduct inspections by expressly permitting inspection of facilities involved in the preparation, conduct or analysis of clinical and non-clinical studies submitted to the FDA as well as other persons holding study records or involved in the study process.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">After the FDA evaluates an application and conducts inspections of manufacturing facilities where the investigational product and/or its drug substance will be manufactured, the FDA may issue an approval letter or a Complete Response letter, or CRL. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A CRL will describe all of the deficiencies that the FDA has identified in the application, except that where the FDA determines that the data supporting the application are inadequate to support approval, the FDA may issue the CRL without first conducting required inspections, testing submitted product lots and/or reviewing proposed labeling. In issuing the CRL, the FDA may recommend actions that the applicant might take to place the application in condition for approval, including requests for additional information or clarification, which may include the potential requirement for additional clinical trials. The FDA may delay or refuse approval of an application if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post-marketing testing and surveillance to monitor safety or efficacy of a product.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations on the indicated uses for which such product may be marketed. For example, the FDA may approve the application with a REMS to ensure the benefits of the product outweigh its risks. A REMS is a safety strategy to manage a known or potential serious risk associated with a product and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing requirements is not maintained or if problems occur after the product reaches the marketplace. The FDA may require one or more Phase 4 post-market trials and surveillance to further assess and monitor the product&#x2019;s safety and effectiveness after commercialization, and may limit further marketing of the product based on the results of these post-marketing trials.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page69"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expedited Development and Review Programs</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA offers a number of expedited development and review programs for qualifying product candidates. The fast track program is intended to expedite or facilitate the process for reviewing new products that meet certain criteria. Specifically, new products are eligible for fast track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a fast track product has opportunities for frequent interactions with the review team during product development and, once an NDA or BLA is submitted, the product may be eligible for priority review. A fast track product may also be eligible for rolling review, where the FDA may consider for review sections of the NDA or BLA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the application, the FDA agrees to accept sections of the application and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the application.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">63</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A product intended to treat a serious or life-threatening disease or condition may also be eligible for breakthrough therapy designation to expedite its development and review. A product can receive breakthrough therapy designation if preliminary clinical evidence indicates that the product, alone or in combination with one or more other drugs or biologics, may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the fast track program features, as well as more intensive FDA interaction and guidance beginning as early as Phase 1 and an organizational commitment to expedite the development and review of the product, including involvement of senior managers.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any marketing application for a drug or biologic submitted to the FDA for approval, including a product with a fast track designation and/or breakthrough therapy designation, may be eligible for other types of FDA programs intended to expedite the FDA review and approval process, such as priority review and accelerated approval. A product is eligible for priority review if it has the potential to provide a significant improvement in the treatment, diagnosis or prevention of a serious disease or condition. Priority review designation means the FDA&#x2019;s goal is to take action on the marketing application within six months of the 60-day filing date.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, products studied for their safety and effectiveness in treating serious or life-threatening diseases or conditions may receive accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of accelerated approval, the FDA will generally require the sponsor to perform adequate and well-controlled post-marketing clinical trials to verify and describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">With the passage of FDORA in December 2022, Congress modified certain provisions governing accelerated approval of drug and biologic products. Specifically, the new legislation authorized the FDA to require a sponsor to have its confirmatory clinical trial underway before accelerated approval is awarded; require a sponsor of a product granted accelerated approval to submit progress reports on its post-approval studies to the FDA every six months until the study is completed; and use expedited procedures to withdraw accelerated approval of an NDA or BLA after the confirmatory trial fails to verify the product&#x2019;s clinical benefit. Further, FDORA requires the agency to publish on its website &#x201c;the rationale for why a post-approval study is not appropriate or necessary&#x201d; whenever it decides not to require such a study upon granting accelerated approval.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fast track designation, breakthrough therapy designation and priority review do not change the standards for approval but may expedite the development or approval process. Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Emergency Use Authorization</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In emergency situations, such as a pandemic, and with a declaration of a public health emergency by the Secretary of the U.S. Department of Health and Human Services, or HHS, the FDA has the authority to allow unapproved medical products or unapproved uses of cleared or approved medical products to be used to diagnose, treat or prevent serious or life-threatening diseases or conditions caused by chemical, biological, radiological or nuclear warfare threat agents when there are no adequate, approved, and available alternatives.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page70"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under this authority, the FDA may issue an EUA if the following four statutory criteria have been met: (1) a serious or life-threatening condition exists; (2) evidence of effectiveness exists; (3) a risk-benefit analysis shows that the benefits of the product outweigh the risks; and (4) no other alternatives exist for diagnosing, preventing or treating the disease or condition. The &#x201c;may be effective&#x201d; standard for EUAs requires a lower level of evidence than the &#x201c;effectiveness&#x201d; standard that FDA uses for product clearances or approvals in non-emergency situations. The FDA assesses the potential effectiveness of a possible EUA product on a case-by-case basis using a risk-benefit analysis. In determining whether the known and potential benefits of the product outweigh the known and potential risks, the FDA examines the totality of the scientific evidence to make an overall risk-benefit determination. Such evidence, which could arise from a variety of sources, may include (but is not limited to) results of domestic and foreign clinical trials, in vivo efficacy data from animal models, in vitro data, as well as the quality and quantity of the available evidence.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Once granted, an EUA will remain in effect and generally terminate on the earlier of (1) the determination by the Secretary of HHS that the public health emergency has ceased or (2) a change in the approval status of the product such that the authorized use(s) of the product are no longer unapproved. After the EUA is no longer valid, the product is no longer considered to be legally marketed</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">64</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and one of the FDA&#x2019;s non-emergency premarket pathways would be necessary to resume or continue distribution of the subject product.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA also may revise or revoke an EUA if the circumstances justifying its issuance no longer exist, the criteria for its issuance are no longer met, or other circumstances make a revision or revocation appropriate to protect public health or safety.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On January 31, 2020, the Secretary of HHS issued a declaration of a public health emergency related to COVID-19. On February 4, 2020, HHS determined that COVID-19 represents a public health emergency that has a significant potential to affect national security or the health and security of U.S. citizens living abroad and, subsequently, declared on March 24, 2020, that circumstances exist to justify the authorization of emergency use of certain medical products, during the COVID-19 pandemic, subject to the terms of any authorization as issued by the FDA. The declaration of the Secretary of HHS has been further updated and the FDA has issued numerous guidance to sponsors seeking to obtain EUAs to diagnose and treat COVID-19. The declaration of a public health emergency related to COVID-19 was most recently renewed on January 11, 2023.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Orphan Drug Designation</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, which is a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States for which there is no reasonable expectation that the cost of developing and making available in the United States a drug or biologic for this type of disease or condition will be recovered from sales in the United States for that drug or biologic. Orphan drug designation must be requested before submitting an NDA or BLA. After the FDA grants orphan drug designation, the generic identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. The orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review or approval process. Among the benefits of orphan drug designation are tax credits for certain research and a waiver of the NDA or BLA application fee.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug exclusive approval (or exclusivity), which means that the FDA may not approve any other applications, including a full NDA or BLA, to market the same drug or biologic for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or if the FDA finds that the holder of the orphan drug exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated. Orphan drug exclusivity does not prevent the FDA from approving a different drug or biologic for the same disease or condition, or the same drug or biologic for a different disease or condition.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. In addition, exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective. In September 2021, the Court of Appeals for the 11</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">th</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Circuit held that, for the purpose of determining the scope of market exclusivity, the term &#x201c;same disease or condition&#x201d; in the statute means the designated &#x201c;rare disease or condition&#x201d; and could not be interpreted by the FDA to mean the &#x201c;indication or use.&#x201d; Thus, the court concluded, orphan drug exclusivity applies to the entire designated disease or condition rather than the &#x201c;indication or use.&#x201d;  Although there have been legislative proposals to overrule this decision, they have not been enacted into law. On January 23, 2023, the FDA announced that, in matters beyond the scope of that court order, the FDA will continue to apply its existing regulations tying orphan-drug exclusivity to the uses or indications for which the orphan drug was approved.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page71"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Post-Approval Requirements</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any products manufactured or distributed by us pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing user fee requirements, under which the FDA assesses an annual program fee for each product identified in an approved NDA or BLA. Biopharmaceutical manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMPs, which impose certain procedural and documentation requirements upon us and our third-party manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMPs and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMPs and other aspects of regulatory compliance.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market trials or clinical trials to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">restrictions on the marketing or manufacturing of a product, complete withdrawal of the product from the market or product recalls;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">fines, warning or untitled letters or holds on post-approval clinical trials;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of existing product approvals;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">product seizure or detention, or refusal of the FDA to permit the import or export of products;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">mandated modification of promotional materials and labeling and the issuance of corrective information;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications containing warnings or other safety information about the product; or</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA closely regulates the marketing, labeling, advertising and promotion of biopharmaceutical products. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#x2019;s FDA approved labeling. Moreover, with passage of the Pre-Approval Information Exchange Act, or PIE Act, in December 2022, sponsors of products that have not been approved may proactively communicate to payors certain information about products in development to help expedite patients access upon product approval. Previously, such communications were permitted under FDA guidance, but the new legislation explicitly provides protection to sponsors who convey certain information about products in development to payors, including unapproved uses of approved products.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product&#x2019;s labeling and that differ from those tested by us and approved by the FDA. Such off-label uses are common across medical specialties. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#x2019;s communications on the subject of off-label use of their products. In September 2021, the FDA published final regulations which describe the types of evidence that the FDA will consider in determining the intended use of a drug or biologic.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page72"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Biosimilars and Regulatory Exclusivity</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively the ACA, signed into law in 2010, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. The FDA has approved a number of biosimilars and the first interchangeable biosimilar product was approved on July 30, 2021, and a second product previously approved as a biosimilar was designated as interchangeable in October 2021.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity and potency, can be shown through analytical trials, animal trials and a clinical trial or trials. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual, the biologic and the reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. In</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">66</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 2022, Congress clarified through FDORA that the FDA may approve multiple first interchangeable biosimilar biological products so long as the products are all approved on the first day on which such a product is approved as interchangeable with the reference product.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing that applicant&#x2019;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. Since passage of the BPCIA, many states have passed laws or amendments to laws that address pharmacy practices involving biosimilar products.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Generic Drugs and Regulatory Exclusivity</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 505 of the FDCA describes three types of marketing applications that may be submitted to the FDA to request marketing authorization for a new drug. A Section 505(b)(1) NDA is an application that contains full reports of investigations of safety and efficacy. A 505(b)(2) NDA is an application that contains full reports of investigations of safety and efficacy but where at least some of the information required for approval comes from investigations that were not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use from the person by or for whom the investigations were conducted. This regulatory pathway enables the applicant to rely, in part, on the FDA&#x2019;s prior findings of safety and efficacy for an existing product, or published literature, in support of its application. Section 505(j) establishes an abbreviated approval process for a generic version of approved drug products through the submission of an Abbreviated New Drug Application, or ANDA.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">An ANDA provides for marketing of a generic drug product that has the same active ingredients, dosage form, strength, route of administration, labeling, performance characteristics and intended use, among other things, to a previously approved product. ANDAs are termed &#x201c;abbreviated&#x201d; because they are generally not required to include preclinical (animal) and clinical (human) data to establish safety and efficacy. Instead, generic applicants must scientifically demonstrate that their product is bioequivalent to, or performs in the same manner as, the innovator drug through in vitro, in vivo or other testing. The generic version must deliver the same amount of active ingredient(s) in the same amount of time as the innovator drug and can often be substituted by pharmacists under prescriptions written for the reference listed drug. In seeking approval for a drug through an NDA, applicants are required to list with the FDA each patent with claims that cover the applicant&#x2019;s drug or a method of using the drug. Upon approval of a drug, each of the patents listed in the application for the drug is then published in the FDA&#x2019;s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. Drugs listed in the Orange Book can, in turn, be cited by potential competitors in support of approval of an ANDA or 505(b)(2) NDA.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page73"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Upon submission of an ANDA or a 505(b)(2) NDA, an applicant must certify to the FDA that (1) no patent information on the drug product that is the subject of the application has been submitted to the FDA; (2) such patent has expired; (3) the date on which such patent expires; or (4) such patent is invalid or will not be infringed upon by the manufacture, use or sale of the drug product for which the application is submitted. Generally, the ANDA or 505(b)(2) NDA cannot be approved until all listed patents have expired, except where the ANDA or 505(b)(2) NDA applicant challenges a listed patent through the last type of certification, also known as a paragraph IV certification. The filing of a patent infringement lawsuit within 45 days after the receipt of a Paragraph IV certification automatically prevents the FDA from approving the ANDA or 505(b)(2) NDA until the earliest of 30 months after the receipt of the Paragraph IV notice, expiration of the patent and a decision in the infringement case that is favorable to the ANDA or 505(b)(2) NDA applicant. If the applicant does not challenge the listed patents, or indicates that it is not seeking approval of a patented method of use, the ANDA or 505(b) (2) NDA application will not be approved until all of the listed patents claiming the referenced product have expired.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA also cannot approve an ANDA or 505(b)(2) application until all applicable non-patent exclusivities listed in the Orange Book for the branded reference drug have expired. For example, a pharmaceutical manufacturer may obtain five years of non-patent exclusivity upon NDA approval of a new chemical entity, or NCE, which is a drug containing an active moiety that has not been approved by FDA in any other NDA. This interpretation was confirmed with enactment of the Ensuring Innovation Act in April 2021. An &#x201c;active moiety&#x201d; is defined as the molecule responsible for the drug substance&#x2019;s physiological or pharmacologic action. During that five-year exclusivity period, the FDA cannot accept for filing (and therefore cannot approve) any ANDA seeking approval of a generic version of that drug or any 505(b)(2) NDA that relies on the FDA&#x2019;s approval of the drug, provided that the FDA may accept an ANDA four years into the NCE exclusivity period if the ANDA applicant also files a paragraph IV certification.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Pediatric Exclusivity</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">67</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pediatric exclusivity is a type of non&#x2011;patent marketing exclusivity in the United States and, if granted, provides for the attachment of an additional six months of exclusivity. For drug products, the six-month exclusivity may be attached to the term of any existing patent or regulatory exclusivity, including the orphan exclusivity and regulatory exclusivities available under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act. For biologic products, the six-month period may be attached to any existing regulatory exclusivities but not to any patent terms. The conditions for pediatric exclusivity include the FDA&#x2019;s determination that information relating to the use of a new product in the pediatric population may produce health benefits in that population, the FDA making a written request for pediatric clinical trials, and the sponsor agreeing to perform, and reporting on, the requested clinical trials within the statutory timeframe. This six&#x2011;month exclusivity may be granted if a sponsor submits pediatric data that fairly responds to a written request from the FDA for such data. The data do not need to show the product to be effective in the pediatric population studied; rather, if the clinical trial is deemed to fairly respond to the FDA&#x2019;s request, additional protection is granted.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Patent Term Restoration and Extension</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the United States, a patent claiming a new product, its method of use or its method of manufacture may be eligible for a limited patent term extension under the Hatch&#x2011;Waxman Act, which permits a patent extension of up to five years for patent term lost during product development and FDA regulatory review. Assuming grant of the patent for which the extension is sought, the restoration period for a patent covering a product is typically one&#x2011;half the time between the effective date of the IND involving human beings and the submission date of the NDA or BLA, plus the time between the submission date of the application and the ultimate approval date. Patent term restoration cannot be used to extend the remaining term of a patent past a total of 14 years from the product&#x2019;s approval date in the United States. Only one patent applicable to an approved product is eligible for the extension, and the application for the extension must be submitted prior to the expiration of the patent for which extension is sought. A patent that covers multiple products for which approval is sought can only be extended in connection with one of the approvals. The U.S. Patent and Trademark Office reviews and approves the application for any patent term extension in consultation with the FDA.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Federal and State Fraud and Abuse, and Transparency Laws and Regulations</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page74"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to strict FDA regulation of marketing of biopharmaceutical products, federal and state healthcare laws strictly regulate business practices in the biopharmaceutical industry. These laws may impact, among other things, our current and future business operations, including our clinical research activities, and proposed sales, marketing and education programs and constrain the business or financial arrangements and relationships with healthcare providers and other parties through which we market, sell and distribute our products for which we obtain marketing approval. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These laws include anti-kickback and false claims laws and regulations, and transparency laws and regulations, including, without limitation, those laws described below.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The U.S. federal Anti-Kickback Statute prohibits any person or entity from, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration to induce or in return for purchasing, leasing, ordering or arranging for or recommending the purchase, lease or order of any item or service reimbursable under Medicare, Medicaid or other federal healthcare programs. The term &#x201c;remuneration&#x201d; has been broadly interpreted to include anything of value. The U.S. federal Anti-Kickback Statute has been interpreted to apply to, among others, arrangements between biopharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers on the other. Although there are a number of statutory exceptions and regulatory safe harbors protecting some common arrangements and other activities from prosecution, the exceptions and safe harbors are drawn narrowly. Practices that involve remuneration that may be alleged to be intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor. Courts have interpreted the statute&#x2019;s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered business, the statute has been violated.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A person or entity does not need to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation. In addition, the government may assert that a claim including items or services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act or the civil monetary penalties laws.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal civil and criminal false claims laws, including the federal civil False Claims Act, which can be enforced by individuals through civil whistleblower and qui tam actions, and civil monetary penalties laws, prohibit any person or entity from, among other things, knowingly presenting, or causing to be presented, a false claim for payment to the federal government or knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government. A claim includes &#x201c;any request or demand&#x201d; for money or property presented to the U.S. government. A number of biopharmaceutical and other healthcare companies have been prosecuted under these laws for allegedly providing payments or other items of value to customers with the expectation that the customers would bill federal programs for their products or services. Other companies have</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">68</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">been prosecuted for causing false claims to be submitted because of the companies&#x2019; marketing of products for unapproved, and thus non-reimbursable, uses.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, created additional federal criminal statutes that prohibit, among other things, knowingly and willfully executing a scheme to defraud any healthcare benefit program, including private third-party payors and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Also, many states have similar fraud and abuse statutes or regulations that apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#x2019;s Health Insurance Program, with specific exceptions, to report annually to the Centers for Medicare &amp; Medicaid Services, or CMS, information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), and teaching hospitals, and applicable manufacturers and applicable group purchasing organizations to report annually to CMS ownership and investment interests held by physicians and their immediate family members. As of January 2022, applicable manufacturers are also required to report such information regarding its payments and other transfers of value to physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists and certified nurse midwives during the previous year.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may also be subject to state laws that require biopharmaceutical companies to comply with the biopharmaceutical industry&#x2019;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers, marketing expenditures or drug pricing, and state and local laws that require the registration of biopharmaceutical sales representatives.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page75"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Because of the breadth of these laws and the narrowness of available statutory exceptions and regulatory safe harbors, it is possible that some of our business activities could be subject to challenge under one or more of such laws. If our operations are found to be in violation of any of the federal and state laws described above or any other governmental regulations that apply to us, we may be subject to significant criminal, civil and administrative penalties including damages, fines, imprisonment, disgorgement, additional reporting requirements and oversight if we become subject to a corporate</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, contractual damages, reputational harm, diminished profits and future earnings, exclusion from participation in government healthcare programs and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. To the extent that any of our products are sold in a foreign country, we may be subject to similar foreign laws and regulations, which may include, for instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws, implementation of corporate compliance programs, and reporting of payments or transfers of value to healthcare professionals.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Coverage and Reimbursement</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The future commercial success of our product candidates, if approved, will depend in part on the extent to which third-party payors, such as governmental payor programs at the federal and state levels, including Medicare and Medicaid, private health insurers and other third-party payors, provide coverage of and establish adequate reimbursement levels for our product candidates. Third-party payors generally decide which products they will pay for and establish reimbursement levels for those products. In particular, in the United States, no uniform policy for coverage and reimbursement exists. Private health insurers and other third-party payors often provide coverage and reimbursement for products based on the level at which the government, through the Medicare program, provides coverage and reimbursement for such products, but also on their own methods and approval process apart from Medicare determinations. Therefore, coverage and reimbursement can differ significantly from payor to payor.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the United States, the EU and other potentially significant markets for our product candidates, government authorities and third-party payors are increasingly attempting to limit or regulate the price of products, particularly for new and innovative products, which often has resulted in average selling prices lower than they would otherwise be. Further, the increased emphasis on managed healthcare in the United States and on country and regional pricing and reimbursement controls in the EU will put additional pressure on product pricing, reimbursement and usage. These pressures can arise from rules and practices of managed care groups, judicial decisions and laws and regulations related to Medicare, Medicaid and healthcare reform, biopharmaceutical coverage and reimbursement policies and pricing in general.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Third-party payors are increasingly imposing additional requirements and restrictions on coverage and limiting reimbursement levels for products. For example, federal and state governments reimburse products at varying rates generally below average wholesale price. These restrictions and limitations influence the purchase of products. Third-party payors may limit coverage to</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">69</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">specific products on an approved list, or formulary, which might not include all of the FDA-approved products for a particular indication. Similarly, because certain of our product candidates are physician-administered, separate reimbursement for the product itself may or may not be available. Instead, the administering physician may only be reimbursed for providing the treatment or procedure in which our product is used. Third-party payors are increasingly challenging the price and examining the medical necessity and cost-effectiveness of products, in addition to their safety and efficacy. We may need to conduct expensive pharmacoeconomic trials in order to demonstrate the medical necessity and cost-effectiveness of our product candidates, in addition to the costs required to obtain the FDA approvals. Our product candidates may not be considered medically necessary or cost-effective. A payor&#x2019;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Adequate third-party payor reimbursement may not be available to enable us to realize an appropriate return on our investment in product development. Legislative proposals to reform healthcare or reduce costs under government insurance programs may result in lower reimbursement for our product candidates, if approved, or exclusion of our product candidates from coverage and reimbursement. The cost containment measures that third-party payors and providers are instituting and any healthcare reform could significantly reduce our revenue from the sale of any approved product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Healthcare Reform</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The United States and some foreign jurisdictions are considering enacting or have enacted a number of additional legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell our product candidates profitably, if approved. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and expanding access. In the United States, the biopharmaceutical industry has been a particular focus of these efforts, which include major legislative initiatives to reduce the cost of care through changes in the healthcare system, including limits on the pricing, coverage, and reimbursement of biopharmaceutical products, especially under government-funded healthcare programs, and increased governmental control of drug pricing.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page76"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There have been several U.S. government initiatives over the past few years to fund and incentivize certain comparative effectiveness research, including creation of the Patient-Centered Outcomes Research Institute under the ACA.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> It is also possible that comparative effectiveness research demonstrating benefits in a competitor&#x2019;s product could adversely affect the sales of our product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The ACA became law in March 2010 and substantially changed the way healthcare is financed by third-party payors, and significantly impacts the U.S. biopharmaceutical industry. Among other measures that may have an impact on our business, the ACA established an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents; a new Medicare Part D coverage gap discount program; and a new formula that increased the rebates a manufacturer must pay under the Medicaid Drug Rebate Program. Additionally, the ACA extended manufacturers&#x2019; Medicaid rebate liability, expands eligibility criteria for Medicaid programs, and expanded entities eligible for discounts under the PHSA. At this time, we are unsure of the full impact that the ACA will have on our business.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In March 2010, the United States Congress enacted the ACA, which, among other things, includes changes to the coverage and payment for pharmaceutical products under government healthcare programs. Other legislative changes have been proposed and adopted since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#x2019;s automatic reduction to several government programs. These changes included aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which went into effect in April 2013 and will remain in effect through 2031. Pursuant to the Coronavirus Aid, Relief and Economic Security Act, or CARES Act, and subsequent legislation, these Medicare sequester reductions were suspended and reduced through the end of June 2022, with the full 2% cut resuming thereafter.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since enactment of the ACA, there have been, and continue to be, numerous legal challenges and Congressional actions to repeal and replace provisions of the law. For example, with enactment of the Tax Cuts and Jobs Act of 2017, or the Tax Act, which was signed by President Trump on December 22, 2017, Congress repealed the &#x201c;individual mandate.&#x201d; The repeal of this provision, which requires most Americans to carry a minimal level of health insurance, became effective in 2019. On December 14, 2018, a U.S. District Court judge in the Northern District of Texas ruled that the individual mandate portion of the ACA is an essential and inseverable feature of the ACA, and therefore because the mandate was repealed as part of the Tax Act, the remaining provisions of the ACA are invalid as well. The U.S. Supreme Court heard this case on November 10, 2020 and, on June 17, 2021, dismissed this action after finding that the plaintiffs do not have standing to challenge the constitutionality of the ACA. Litigation and legislation over the ACA are likely to continue, with unpredictable and uncertain results.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">70</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Pharmaceutical Prices</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The prices of prescription pharmaceuticals have also been the subject of considerable discussion in the United States. There have been several recent U.S. Congressional inquiries, as well as proposed and enacted state and federal legislation designed to, among other things, bring more transparency to pharmaceutical pricing, review the relationship between pricing and manufacturer patient programs, and reduce the costs of pharmaceuticals under Medicare and Medicaid. In 2020 President Trump issued several executive orders intended to lower the costs of prescription products and certain provisions in these orders have been incorporated into regulations. These regulations include an interim final rule implementing a most favored nation model for prices that would tie Medicare Part B payments for certain physician-administered pharmaceuticals to the lowest price paid in other economically advanced countries, effective January 1, 2021. That rule, however, has been subject to a nationwide preliminary injunction and, on December 29, 2021, CMS issued a final rule to rescind it. With issuance of this rule, CMS stated that it will explore all options to incorporate value into payments for Medicare Part B pharmaceuticals and improve beneficiaries' access to evidence-based care.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, in October 2020, HHS and the FDA published a final rule allowing states and other entities to develop a Section 804 Importation Program, or SIP, to import certain prescription drugs from Canada into the United States. The final rule is currently the subject of ongoing litigation, but at least six states (Vermont, Colorado, Florida, Maine, New Mexico, and New Hampshire) have passed laws allowing for the importation of drugs from Canada with the intent of developing SIPs for review and approval by the FDA. Further, on November 20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The final rule would eliminate the current safe harbor for Medicare drug rebates and create new safe harbors for beneficiary point-of-sale discounts and pharmacy benefit manager, or PBM, service fees. It originally was set to go into effect on January 1, 2022, but with passage of the Inflation Reduction Act has been delayed by Congress to January 1, 2032.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">More recently, on August 16, 2022, the Inflation Reduction Act of 2022, or IRA, was signed into law by President Biden.  The new legislation has implications for Medicare Part D, which is a program available to individuals who are entitled to Medicare Part A or enrolled in Medicare Part B to give them the option of paying a monthly premium for outpatient prescription drug coverage. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025).  The IRA permits the Secretary of HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Specifically, with respect to price negotiations, Congress authorized Medicare to negotiate lower prices for certain costly single-source drug and biologic products that do not have competing generics or biosimilars and are reimbursed under Medicare Part B and Part D.  CMS may negotiate prices for ten high-cost drugs paid for by Medicare Part D starting in 2026, followed by 15 Part D drugs in 2027, 15 Part B or Part D drugs in 2028, and 20 Part B or Part D drugs in 2029 and beyond.  This provision applies to drug products that have been approved for at least nine years and biologics that have been licensed for 13 years, but it does not apply to drugs and biologics that have been approved for a single rare disease or condition.  Nonetheless, since CMS may establish a maximum price for these products in price negotiations, we would be fully at risk of government action if our products are the subject of Medicare price negotiations. Moreover, given the risk that could be the case, these provisions of the IRA may also further heighten the risk that we would not be able to achieve the expected return on our drug products or full value of our patents protecting our products if prices are set after such products have been on the market for nine years.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further, the legislation subjects drug manufacturers to civil monetary penalties and a potential excise tax for failing to comply with the legislation by offering a price that is not equal to or less than the negotiated &#x201c;maximum fair price&#x201d; under the law or for taking price increases that exceed inflation. The legislation also requires manufacturers to pay rebates for drugs in Medicare Part D whose price increases exceed inflation. The new law also caps Medicare out-of-pocket drug costs at an estimated $4,000 a year in 2024 and, thereafter, beginning in 2025, at $2,000 a year. In addition, the IRA potentially raises legal risks with respect to individuals participating in a Medicare Part D prescription drug plan who may experience a gap in coverage if they required coverage above their initial annual coverage limit before they reached the higher threshold, or &#x201c;catastrophic period&#x201d; of the plan. Individuals requiring services exceeding the initial annual coverage limit and below the catastrophic period, must pay 100% of the cost of their prescriptions until they reach the catastrophic period. Among other things, the IRA contains many provisions aimed at reducing this financial burden on individuals by reducing the co-insurance and co-payment costs, expanding eligibility for lower income subsidy plans, and price caps on annual out-of-pocket expenses, each of which could have potential pricing and reporting implications.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">71</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page77"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accordingly, while it is currently unclear how the IRA will be effectuated, we cannot predict with certainty what impact any federal or state health reforms will have on us, but such changes could impose new or more stringent regulatory requirements on our activities or result in reduced reimbursement for our products, any of which could adversely affect our business, results of operations and financial condition.<br /><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control biopharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine which drugs and suppliers will be included in their healthcare programs. A number of states, for example, require drug manufacturers and other entities in the drug supply chain, including health carriers, pharmacy benefit managers, and wholesale distributors, to disclose information about pricing of pharmaceuticals. Furthermore, there has been increased interest by third party payors and governmental authorities in reference pricing systems and publication of discounts and list prices. These measures could reduce future demand for our products or put pressure on our pricing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Foreign Regulation</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In order to market any product outside of the United States, we would need to comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of our product candidates. For example, in the EU, we must obtain authorization of a clinical trial application in each member state in which we intend to conduct a clinical trial. Whether or not we obtain FDA approval for a drug, we would need to obtain the necessary approvals by the comparable regulatory authorities of foreign countries before we can commence clinical trials or marketing of the drug in those countries. The approval process varies from country to country and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country may negatively impact the regulatory process in others.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further, some countries outside of the United States, including the EU member states, Switzerland and the U.K., have also adopted data protection laws and regulations, which impose significant compliance obligations. In the EU, the collection and use of personal health data is governed by the provisions of the General Data Protection Regulation, or GDPR. The GDPR, together with the national legislation of the EU member states governing the processing of personal data, impose strict obligations and restrictions on the ability to process personal data, including health data from clinical trials and adverse event reporting. For additional information regarding the GDPR, see the section titled &#x201c;Business&#x2014;Government Regulation and Product Approval &#x2014;Privacy Laws.&#x201d;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Privacy Laws</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We, and our service providers, receive, process, store and use personal information and other data about our clinical trial participants, employees, collaborators and others. We are subject to numerous domestic and foreign laws and regulations regarding privacy and data security, the scope of which is changing, subject to differing applications and interpretations, and may be inconsistent among countries, or conflict with other rules.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At the federal level, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their respective implementing regulations, impose specific requirements on certain types of individuals and entities relating to the privacy, security and transmission of individually identifiable health information. HITECH, among other things, also increased the civil and criminal penalties that may be imposed for non-compliance with the law, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorney&#x2019;s fees and costs associated with pursuing federal civil actions. Penalties for failure to comply with a requirement of HIPAA and HITECH vary significantly, and include significant civil monetary penalties and, in certain circumstances, criminal penalties and/or imprisonment.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Various states, such as California and Texas, have implemented privacy laws and regulations similar to HIPAA, such as the California Confidentiality of Medical Information Act, that impose restrictive requirements regulating the use and disclosure of health information. These laws and regulations are not necessarily preempted by HIPAA, particularly if a state affords greater protection to individuals than HIPAA. Where state laws are more protective, we have to comply with the stricter provisions. In addition to fines and penalties imposed upon violators, some of these state laws also afford private rights of action to individuals who believe their personal information has been misused.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, in 2018, California passed into law the California Consumer Privacy Act, or the CCPA, which took effect on January 1, 2020, and imposed many requirements on businesses that process the personal information of California residents. Many of the CCPA&#x2019;s requirements are similar to those found in the GDPR, including requiring businesses to provide notice to data subjects regarding the information collected about them and how such information is used and shared, and providing data subjects the right to request access to such personal information and, in certain cases, request the erasure of such personal information. The CCPA also affords California residents the right to opt-out of &#x201c;sales&#x201d; of their personal information. The CCPA contains significant penalties for companies that violate its requirements. In November 2020, California voters passed a ballot initiative for the California Privacy Rights Act, or the CPRA, which went into effect on January 1, 2023 and significantly expanded the CCPA to incorporate additional GDPR-like provisions including requiring that the use, retention, and sharing of personal information of California residents be reasonably necessary and proportionate to the purposes of collection or processing, granting additional protections for sensitive personal information, and requiring greater disclosures related to notice to residents regarding retention of information. The CPRA also created a new enforcement agency &#x2013; the California Privacy Protection Agency &#x2013; whose sole responsibility is to enforce the CPRA, which will further increase compliance risk. The provisions in the CPRA may apply to some of our business activities. In addition, other states, including Virginia, Colorado, Utah, and Connecticut already have passed state privacy laws. Virginia&#x2019;s privacy law also went into effect on January 1, 2023, and the laws in the other three states will go into effect later in the year. Other states will be considering these laws in the future, and Congress has also been debating passing a federal privacy law. These laws may impact our business activities, including our identification of research subjects, relationships with business partners and ultimately the marketing and distribution of our products.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Regulation of privacy, data protection and data security has also become more stringent in foreign jurisdictions. For example, the EU adopted the GDPR, which imposes onerous and comprehensive privacy, data protection, and data security obligations onto data controllers and processors, including, as applicable, contractual privacy, data protection, and data security commitments, expanded disclosures to data subjects about how their personal information is used, honoring individuals&#x2019; data protection rights, limitations on retention of personal information, additional requirements pertaining to sensitive information (such as health data) and pseudonymized (i.e., key-coded) data, data breach notification requirements, and higher standards for obtaining consent from data subjects. Penalties for non-compliance with the GDPR can be significant and include fines in the amount of the greater of &#x20ac;20 million or 4% of global turnover and restrictions or prohibitions on data processing, which could hinder our ability to do business in the EU, reduce demand for our services and adversely impact our business and results of operations. The GDPR also provides that EU member states may implement further laws and regulations limiting the processing of genetic, biometric, or health data, which could limit our ability to collect, use and share European data, or could cause our compliance costs to increase, require us to change our practices, adversely impact our business, and harm our financial condition. Assisting parties with whom we exchange personal data in complying with the GDPR, or complying with the GDPR ourselves, may cause us to incur substantial operational costs or require us to change our business practices.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furthermore, European privacy, data protection, and data security laws, including the GDPR, generally restrict the transfer of personal information from the U.K., European Economic Area, or EEA, and Switzerland to the United States and most other countries unless the parties to the transfer have implemented specific safeguards to protect the transferred personal information. There is uncertainty as to how to implement such safeguards and how to conduct such transfers in compliance with the GDPR, and certain safeguards may not be available or applicable with respect to some or all the personal information processing activities necessary to research, develop and market our products and services. One of the primary safeguards allowing U.S. companies to import personal information from Europe was certification to the EU-U.S. Privacy Shield and Swiss-U.S. Privacy Shield frameworks. However, the EU-U.S. Privacy Shield framework was invalidated in July 2020 in a decision by the Court of Justice of the European Union and the Swiss-U.S. Privacy Shield Framework was declared as inadequate by the Swiss Federal Data Protection and Information Commissioner. The decision by the Court of Justice and the announcement by the Swiss Commissioner both raised questions about whether one of the primary alternatives to the Privacy Shield frameworks, the European Commission&#x2019;s Standard Contractual Clauses, can lawfully be used for personal information transfers from Europe to the United States or most other countries. Since that time, EU regulators have adopted a new set of Standard Contractual Clauses, which impose additional obligations and requirements with respect to the transfer of EU personal data to other jurisdictions and may increase the legal risks and liabilities under the GDPR and local EU laws associated with cross-border data transfers, and result in material increased compliance and operational costs. If we are unable to implement a valid mechanism for personal information transfers to the United States and other countries, we may face increased exposure to regulatory actions, substantial fines, and injunctions against processing or transferring personal information from Europe, and we may be required to increase our data processing capabilities in Europe at significant expense. Inability to import personal information from Europe to the United States or other countries may limit our ability to conduct clinical trials in Europe and collaborate with other entities subject to European data protection laws. At present, there are few, if any, viable alternatives to the Standard Contractual Clauses. Other countries outside of Europe have enacted or are considering enacting similar cross-border data transfer restrictions and laws requiring local data residency, which could increase the cost and complexity of delivering our services and operating our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">73</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This data transfer issue is also continually evolving. In October 2022, President Biden signed an executive order to implement the EU-U.S. Data Privacy Framework, which would serve as a replacement to the EU-US Privacy Shield. The European Commission initiated the process to adopt an adequacy decision for the EU-U.S. Data Privacy Framework in December 2022. It is unclear if and when the framework will be finalized and whether it will be challenged in court (and whether such a court challenge will further affect the viability of the new Standard Contractual Clauses). The uncertainty around this issue may further impact our business operations in the EU.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There are also relevant data transfer issues in the U.K. that we must address as part of our business operations. The European Commission and U.K. regulators have both adopted adequacy decisions that permit data transfers between the EEA and the U.K. in light of Brexit. However, the U.K. has its own guidance for data transfers to other jurisdictions that are not covered by an &#x201c;adequacy&#x201d; decision (which includes the United States) and recently adopted the international data transfer agreement, which can serve as a basis for companies to lawfully transfer outside of the U.K. We must also account for these requirements as part of addressing our compliance obligations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Compliance with U.S. and foreign privacy, data protection, and data security laws and regulations could cause us to incur substantial costs or require us to change our business practices and compliance procedures in a manner adverse to our business. Moreover, complying with these various laws could require us to take on more onerous obligations in our contracts, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. We may rely on others, such as health care providers, to obtain valid and appropriate consents from data subjects whose data we process. The failure of third parties to obtain consents that are valid under applicable law could result in our own non-compliance with privacy laws. Such failure to comply with U.S. and foreign privacy, data protection, and data security laws and regulations could result in government enforcement actions (which could include civil or criminal penalties), private litigation and/or adverse publicity and could negatively affect our operating results and business. Claims that we have violated individuals&#x2019; privacy rights, failed to comply with privacy, data protection, and data security laws, or breached our contractual obligations, even if we are not found liable, could be expensive and time consuming to defend, could result in adverse publicity and could have a material adverse effect on our business, financial condition, and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Legal Proceedings</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. We are not currently a party to any material legal proceedings. Regardless of outcome, such proceedings or claims can have an adverse impact on us because of defense and settlement costs, diversion of resources and other factors, and there can be no assurances that favorable outcomes will be obtained.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Human Capital Management</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Employees</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, we had 576 full-time employees, 424 of whom were primarily engaged in research and development activities. Substantially all of our employees are located in San Francisco, California; St. Louis, Missouri; Portland, Oregon; and Bellinzona, Switzerland. None of our employees are represented by a labor union and we consider our employee relations to be good.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As the clinical development of our product candidates progresses, we expect to continue to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of research, development, regulatory affairs and, if any of our product candidates receives marketing approval, sales, marketing and distribution. In addition, we also expect to hire additional personnel in order to sustain operations as a public company.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and additional employees. The principal purpose of our equity incentive plan is to attract, retain, and motivate our employees, non-employee directors, and consultants through the granting of stock-based compensation and performance cash awards.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">74</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page80"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Response to COVID-19</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have implemented a number of plans and policies designed to address and mitigate the impact of the COVID-19 pandemic on our employees and our business. We continue to closely monitor the COVID-19 situation and will evolve our plans and policies as needed going forward. As a result of these developments, in March 2020, we implemented work-from-home policies for most of our employees. We  now offer all of our employees the choice of working full time in the office, a hybrid approach, or full-time remote. As a result, we expect to continue to be subject to the challenges and risks of having a remote workforce, as well as new challenges and risks from operating with a hybrid workforce. We are also working to provide our employees with the support they need to ensure continuity of business operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Corporate Information</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="page220"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We were incorporated under the laws of the State of Delaware on April 7, 2016. Our principal executive offices are located at 499 Illinois Street, Suite 500, San Francisco, California 94158, and our telephone number is (415) 906-4324. Our corporate website address is www.vir.bio. Information contained on, or accessible through, our website shall not be deemed incorporated into and is not a part of this Annual Report on Form 10-K, and the inclusion of our website address in this report is an inactive textual reference only. We make available free of charge through our website our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Sections 13(a) and 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act. We make these reports available through our website as soon as reasonably practicable after we electronically file such reports with, or furnish such reports to, the SEC. We may use our website as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation Fair Disclosure promulgated by the SEC. These disclosures will be included on our website under the &#x201c;Investors&#x201d; section.</span><span id="page109"></span><span id="page245"></span><span id="page371"></span><span id="page222"></span><span id="page294"></span><span id="page279"></span><span id="page118"></span><span id="page364"></span><span id="page215"></span><span id="page354"></span><span id="page122"></span><span id="page379"></span><span id="page169"></span><span id="page322"></span><span id="page297"></span><span id="page317"></span><span id="page158"></span><span id="page149"></span><span id="page278"></span><span id="page296"></span><span id="page95"></span><span id="page339"></span><span id="page106"></span><span id="page207"></span><span id="page320"></span><span id="page300"></span><span id="page340"></span><span id="page201"></span><span id="page358"></span><span id="page171"></span><span id="page200"></span><span id="page196"></span><span id="page115"></span><span id="page183"></span><span id="page202"></span><span id="page133"></span><span id="page194"></span><span id="page318"></span><span id="page382"></span><span id="page140"></span><span id="page180"></span><span id="page87"></span><span id="page153"></span><span id="page323"></span><span id="page217"></span><span id="page315"></span><span id="page330"></span><span id="page329"></span><span id="page161"></span><span id="page205"></span><span id="page394"></span><span id="page113"></span><span id="page116"></span><span id="page353"></span><span id="page145"></span><span id="page343"></span><span id="page228"></span><span id="page393"></span><span id="page301"></span><span id="page89"></span><span id="page344"></span><span id="page97"></span><span id="page178"></span><span id="page142"></span><span id="page137"></span><span id="page182"></span><span id="page316"></span><span id="page117"></span><span id="page184"></span><span id="page396"></span><span id="page88"></span><span id="page285"></span><span id="page157"></span><span id="page399"></span><span id="page213"></span><span id="page362"></span><span id="page107"></span><span id="page155"></span><span id="page186"></span><span id="page181"></span><span id="page206"></span><span id="page328"></span><span id="page310"></span><span id="page302"></span><span id="page401"></span><span id="page209"></span><span id="page395"></span><span id="page152"></span><span id="page119"></span><span id="page237"></span><span id="page251"></span><span id="page276"></span><span id="page135"></span><span id="page138"></span><span id="page189"></span><span id="page164"></span><span id="page126"></span><span id="page85"></span><span id="page381"></span><span id="page338"></span><span id="page303"></span><span id="page298"></span><span id="page324"></span><span id="page400"></span><span id="page176"></span><span id="page342"></span><span id="page384"></span><span id="page144"></span><span id="page141"></span><span id="page204"></span><span id="page103"></span><span id="page151"></span><span id="page235"></span><span id="page356"></span><span id="page123"></span><span id="page163"></span><span id="page175"></span><span id="page345"></span><span id="page314"></span><span id="page191"></span><span id="page124"></span><span id="page308"></span><span id="page319"></span><span id="page360"></span><span id="page82"></span><span id="page81"></span><span id="page347"></span><span id="page243"></span><span id="page125"></span><span id="page312"></span><span id="page369"></span><span id="page162"></span><span id="page249"></span><span id="page187"></span><span id="page335"></span><span id="page110"></span><span id="page134"></span><span id="page233"></span><span id="page291"></span><span id="page386"></span><span id="page210"></span><span id="page190"></span><span id="page368"></span><span id="page216"></span><span id="page91"></span><span id="page102"></span><span id="page389"></span><span id="page177"></span><span id="page160"></span><span id="page198"></span><span id="page334"></span><span id="page252"></span><span id="page273"></span><span id="page147"></span><span id="page244"></span><span id="page166"></span><span id="page387"></span><span id="page288"></span><span id="page275"></span><span id="page112"></span><span id="page127"></span><span id="page98"></span><span id="page293"></span><span id="page352"></span><span id="page84"></span><span id="page101"></span><span id="page372"></span><span id="page192"></span><span id="page108"></span><span id="page351"></span><span id="page139"></span><span id="page100"></span><span id="page247"></span><span id="page321"></span><span id="page197"></span><span id="page219"></span><span id="page203"></span><span id="page332"></span><span id="page373"></span><span id="page239"></span><span id="page227"></span><span id="page313"></span><span id="page376"></span><span id="page199"></span><span id="page349"></span><span id="page327"></span><span id="page309"></span><span id="page374"></span><span id="page355"></span><span id="page286"></span><span id="page377"></span><span id="page295"></span><span id="page388"></span><span id="page336"></span><span id="page391"></span><span id="page277"></span><span id="page346"></span><span id="page378"></span><span id="page242"></span><span id="page136"></span><span id="page281"></span><span id="page232"></span><span id="page390"></span><span id="page150"></span><span id="page92"></span><span id="page392"></span><span id="page348"></span><span id="page250"></span><span id="page143"></span><span id="page304"></span><span id="page359"></span><span id="page246"></span><span id="page238"></span><span id="page96"></span><span id="page173"></span><span id="page299"></span><span id="page367"></span><span id="page193"></span><span id="page385"></span><span id="page154"></span><span id="page361"></span><span id="page236"></span><span id="page337"></span><span id="page240"></span><span id="page185"></span><span id="page383"></span><span id="page241"></span><span id="page289"></span><span id="page226"></span><span id="page214"></span><span id="page114"></span><span id="page167"></span><span id="page211"></span><span id="page156"></span><span id="page380"></span><span id="page331"></span><span id="page280"></span><span id="page284"></span><span id="page305"></span><span id="page188"></span><span id="page363"></span><span id="page397"></span><span id="page231"></span><span id="page94"></span><span id="page148"></span><span id="page93"></span><span id="page398"></span><span id="page325"></span><span id="page253"></span><span id="page375"></span><span id="page292"></span><span id="page168"></span><span id="page195"></span><span id="page255"></span><span id="page86"></span><span id="page165"></span><span id="page159"></span><span id="page230"></span><span id="page111"></span><span id="page311"></span><span id="page366"></span><span id="page248"></span><span id="page234"></span><span id="page333"></span><span id="page370"></span><span id="page218"></span><span id="page104"></span><span id="page221"></span><span id="page365"></span><span id="page208"></span><span id="page350"></span><span id="page341"></span><span id="page307"></span><span id="page224"></span><span id="page146"></span><span id="page121"></span><span id="page179"></span><span id="page283"></span><span id="page274"></span><span id="page90"></span><span id="page225"></span><span id="page282"></span><span id="page306"></span><span id="page357"></span><span id="page287"></span><span id="page105"></span><span id="page170"></span><span id="page99"></span><span id="page174"></span><span id="page290"></span><span id="page120"></span><span id="page229"></span><span id="page172"></span><span id="page83"></span><span id="page254"></span><span id="page212"></span><span id="page223"></span><span id="page326"></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1a_risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1A. Risk</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Factors.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">An investment in shares of our common stock involves a high degree of risk. You should carefully consider the following risk factors,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">some of which have manifested and any of which may occur in the future, as well as the other information in this Annual Report on Form 10-K, including our audited consolidated financial statements and the related notes included elsewhere in this Annual Report on Form 10-K and &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations,&#x201d; before deciding whether to invest in our common stock. The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations and/or prospects or cause our actual results to differ materially from those contained in forward-looking statements we have made in this report and those we may make from time to time. In such an event, the market price of our common stock could decline, and you may lose all or part of your investment. You should consider all the risk factors described when evaluating our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Our Financial Position and Capital Needs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have incurred net losses and anticipate that we will continue to incur net losses in the foreseeable future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Although we recorded net income for the years ended December 31, 2022, and 2021, we have otherwise incurred net losses since inception in April 2016. We had net income of $515.8 million and $528.6 million for the years ended December 31, 2022, and 2021, respectively. As of December 31, 2022, we had retained earnings of $377.2 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect to continue to incur significant expenses and will continue to incur net losses in the foreseeable future. Since inception, we have devoted substantially all of our efforts to identifying, researching and conducting preclinical and clinical activities of our product candidates, acquiring and developing our technology platforms and product candidates, organizing and staffing our company, business planning, raising capital and establishing our intellectual property portfolio.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We received an Emergency Use Authorization, or EUA, from the U.S. Food and Drug Administration, or FDA, for sotrovimab (previously VIR-7831). In March and April 2022, the FDA amended the EUA fact sheet to exclude sotrovimab use in geographic regions where infection is likely to have been caused by a non-susceptible SARS-CoV-2 variant based on available information, including variant susceptibility to these drugs and regional variant frequency. With this EUA revision, sotrovimab is not currently authorized for use in any U.S. region. In light of these developments, we cannot predict whether (if at all) or to what extent sotrovimab may be reauthorized for use by the FDA in any U.S. region in the future. In addition, there can be no assurance with respect to how long the EUA will remain in effect or whether the EUA will be further revised or revoked by the FDA based on the determination by the Secretary of the U.S. Department of Health and Human Services, or HHS, that the underlying health emergency no longer exists or warrants such authorization or other reasons. Furthermore, due to the evolving COVID-19 landscape and based on discussions with the FDA, we and Glaxo Wellcome UK Limited and GlaxoSmithKline Biologicals S.A. (individually and collectively referred to as GSK) do not plan to file a Biologics License Application, or BLA, for sotrovimab at this time.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We received a positive scientific opinion from the Committee for Human Medicinal Products, or CHMP, in the European Union, or EU, for sotrovimab and to date, sotrovimab has obtained emergency authorization, temporary authorization or marketing approval (under the brand name Xevudy&#174;&#xfe0f;) for early treatment of COVID-19, supplying more than 40 countries. However, foreign regulatory authorities may impose similar limitations to the FDA on the use of sotrovimab in jurisdictions where sotrovimab has been granted EUA, temporary authorization or marketing approval.  For example, certain countries outside of the U.S., such as Canada and Japan, continue to maintain access to sotrovimab 500 mg intravenous, or IV, while noting that it is unlikely to maintain efficacy against certain Omicron subvariants. We cannot predict whether other countries will further limit the use of sotrovimab.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furthermore, based on the evolving COVID-19 landscape and the Company&#x2019;s expectations for future sales in light of these factors, there are no assurances that we will secure future supply commitments from governments. In addition, COVID-19 treatment standards are susceptible to rapid changes in epidemiology and the emergence of new variants or subvariants, which may render sotrovimab inferior or obsolete in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">It could be several years, if ever, before we are able to commercialize any of our other product candidates. Any net losses we incur may fluctuate significantly from quarter to quarter and year to year. To remain profitable, we must succeed in developing and eventually commercializing products that generate significant revenue. This will require us to be successful in a range of challenging activities, including completing preclinical studies and clinical trials of our current and future product candidates, obtaining regulatory approval, procuring commercial-scale manufacturing and marketing and selling any products for which we obtain regulatory approval (including through third parties), as well as discovering or acquiring and developing additional product candidates. We are only in the preliminary stages of most of these activities. We may never succeed in these activities and, even if we do, may not be able to continue to generate revenue that is sufficient to offset our expenses and maintain profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">76</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Because of the numerous risks and uncertainties associated with biopharmaceutical product development, we are unable to accurately predict the timing or amount of expenses, or if we will be able to maintain profitability. If we are required by regulatory authorities to perform studies and trials in addition to those currently expected, or if there are any delays in the initiation and completion of our clinical trials or the development of any of our product candidates, our expenses could increase.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We could be required to perform additional studies and trials on sotrovimab based on any additional feedback we may receive from the regulatory and health authorities. For example, we and GSK continue to conduct </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> testing of sotrovimab against new variants and subvariants as they emerge, and to collect and evaluate real-world evidence, both of which are being shared with regulatory authorities.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to remain profitable would decrease the value of our company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a commercial-stage company founded in April 2016 and our operations to date have been largely focused on identifying, researching and conducting preclinical and clinical activities of our product candidates, acquiring and developing our technology platforms and product candidates, organizing and staffing our company, business planning, raising capital and establishing our intellectual property portfolio. Sotrovimab has received marketing authorization in the EU and has been granted emergency authorization, temporary authorization or marketing approval (under the brand name Xevudy&#174;), supplying more than 40 countries. Although certain countries outside of the U.S., such as Canada and Japan, continue to maintain access to sotrovimab 500 mg IV while noting that it is unlikely to maintain efficacy against certain Omicron subvariants, we cannot predict whether other countries will further limit the use of sotrovimab.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furthermore, although we have an EUA from the FDA for sotrovimab, the FDA has excluded the use of sotrovimab in all U.S. regions due to the continued proportion of COVID-19 cases caused by certain Omicron subvariants. With this EUA revision, sotrovimab is not currently authorized for use in any U.S. region. In light of these developments, we cannot predict whether (if at all) or to what extent sotrovimab may be reauthorized for use by the FDA in any U.S. region in the future. In addition, due to the evolving COVID-19 landscape and based on discussions with the FDA, we and GSK do not plan to file a BLA for sotrovimab at this time. Moreover, even if we were to file a BLA or marketing applications in other jurisdictions, it is possible that the FDA and other regulatory authorities may not grant sotrovimab full marketing approval for the treatment of COVID-19, or that any such marketing approvals, if granted, may have similar or other significant limitations on its use. As an organization, we have not yet demonstrated an ability to successfully manufacture a BLA-approved, commercial-scale product or conduct sales and marketing activities necessary for successful commercialization. Consequently, any predictions about our future success or viability may not be as accurate as they could be if we had a longer operating history.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We currently have four technology platforms and eight product candidates in our development pipeline. We may encounter unforeseen expenses, difficulties, complications, delays and other known or unknown factors in achieving our business objectives, including with respect to our technology platforms and product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may require substantial additional funding to finance our operations. If we are unable to raise capital when needed, we could be forced to delay, reduce or terminate certain of our development programs or other operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, we had cash, cash equivalents and investments of $2.4 billion. Based upon our current operating plan, we believe that the $2.4 billion as of December 31, 2022, will fund our current operating plans for at least the next 12 months. However, our operating plan may change as a result of many factors currently unknown to us, and we may need to seek additional financing to fund our long-term operations sooner than planned. Moreover, it is particularly difficult to estimate with certainty our future revenue and expenses given the dynamic and rapidly evolving nature of our business and the COVID-19 pandemic environment generally. We may also need to raise additional capital to complete the development and commercialization of our product candidates and fund certain of our existing manufacturing and other commitments. We expect to finance our cash needs through public or private equity or debt financings, third-party (including government) funding and marketing and distribution arrangements, as well as other collaborations, strategic alliances and licensing arrangements, or any combination of these approaches. Our future capital requirements will depend on many factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing, progress and results of our ongoing preclinical studies and clinical trials of our product candidates; </span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the scope, progress, results and costs of preclinical development, laboratory testing and clinical trials of other product candidates that we may pursue; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">77</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to establish and maintain collaboration, license, grant and other similar arrangements, and the financial terms of any such arrangements, including timing and amount of any future milestones, royalty or other payments due thereunder; </span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs, timing and outcome of regulatory review of our product candidates; </span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs and timing of commercialization activities, including product manufacturing, marketing, sales and distribution, for our product candidates for which we receive marketing approval; </span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the amount of revenue received from commercial sales of any product candidates for which we receive marketing approval; </span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims; </span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any expenses needed to attract, hire and retain skilled personnel; </span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the costs of operating as a public company; and </span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the extent to which we acquire or in-license other companies&#x2019; product candidates and technologies. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General economic conditions, both inside and outside the U.S., including heightened inflation, capital market volatility, interest rate and currency rate fluctuations, and economic slowdown or recession as well as the COVID-19 pandemic, including the evolution of new and existing variants of COVID-19, and geopolitical events, including civil or political unrest (such as the ongoing war between Ukraine and Russia), have resulted in a significant disruption of global financial markets. If the disruption persists and deepens, we could experience an inability to access additional capital, which could in the future negatively affect our capacity for certain corporate development transactions or our ability to make other important, opportunistic investments. In addition, market volatility, high levels of inflation and interest rate fluctuations may increase our cost of financing or restrict our access to potential sources of future liquidity. Adequate additional financing may not be available to us on acceptable terms, or at all. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or altogether terminate our research and development programs or commercialization efforts, which may adversely affect our business, financial condition, results of operations and prospects. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through public or private equity or debt financings, third-party (including government) funding and marketing and distribution arrangements, as well as other collaborations, strategic alliances and licensing arrangements, or any combination of these approaches. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest in our company may be diluted and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a stockholder. Debt and equity financings, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as redeeming our shares, making investments, incurring additional debt, making capital expenditures, declaring dividends or placing limitations on our ability to acquire, sell or license intellectual property rights.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we raise additional capital through future collaborations, strategic alliances or licensing arrangements, we may have to relinquish valuable rights to our intellectual property, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional capital when needed, we may be required to delay, limit, reduce or terminate our product development or commercialization efforts or grant rights to develop and market product candidates that we would otherwise develop and market ourselves.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Although we have an EUA from the FDA for sotrovimab for the early treatment of COVID-19, the disease caused by the virus SARS-CoV-2, the FDA has excluded the use of sotrovimab in all U.S. regions, and sotrovimab has limitations on its use in some countries outside of the U.S. If the FDA does not reauthorize the use of sotrovimab in the U.S., the FDA revokes or terminates our EUA for sotrovimab, the federally-declared COVID-19 public health emergency ends, or countries outside of the U.S. continue to limit its use, we may be unable to sell sotrovimab in or outside of the U.S.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sotrovimab received an EUA from the FDA on May 26, 2021, for the early treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at risk for progression to severe COVID-19, including hospitalization or death. In March and April 2022, the FDA amended the EUA fact sheet to exclude sotrovimab use in geographic regions where infection is likely to have been caused by a non-susceptible</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">78</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SARS-CoV-2 variant based on available information, including variant susceptibility to these drugs and regional variant frequency. With these EUA revisions, sotrovimab is not currently authorized for use in any U.S. region. In light of these developments, we cannot predict whether (if at all) or to what extent sotrovimab may be reauthorized for use by the FDA in any U.S. region in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, there can be no assurance with respect to how long the EUA will remain in effect or whether the EUA will be further revised or revoked by the FDA based on the determination by the Secretary of HHS that the underlying health emergency no longer exists or warrants such authorization or other reasons. Any such revision or revocation of our EUA by the FDA could adversely impact our business in a variety of ways, including having to absorb related manufacturing and overhead costs as well as potential inventory write-offs. Furthermore, if we or our collaborators experience inventory revaluation adjustments, lower of cost or market inventory adjustments, and excess inventory, it may be necessary to write down or write-off inventory or incur an impairment charge with respect to the facility where such product is manufactured, which could adversely affect our operating results. For example, during the year ended December 31, 2022, we recorded a non-cash charge for potential write-offs related to excess supply and unused binding manufacturing capacity of $369.7 million related to sotrovimab against uncertain future pandemic demand, which has not been reported by GSK as cost-sharing amounts.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, due to the evolving COVID-19 landscape and based on discussions with the FDA, we and GSK do not plan to file a BLA for sotrovimab at this time. Furthermore, foreign regulatory authorities may impose similar limitations to the FDA on the use of sotrovimab in jurisdictions where sotrovimab has been granted EUA, temporary authorization or marketing approval.  Although certain countries outside of the U.S., such as Canada and Japan, continue to maintain access to sotrovimab 500 mg IV while noting that it is unlikely to maintain efficacy against certain Omicron subvariants, we cannot predict whether other countries will limit the use of sotrovimab.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if we were to file a BLA or marketing applications in other jurisdictions, itis possible that the FDA and other regulatory authorities may not grant sotrovimab full marketing approval for the treatment of COVID-19, or that any such marketing approvals, if granted, may have similar or other significant limitations on its use. If the FDA does not reauthorize the use of sotrovimab in the U.S., and/or countries outside of the U.S. continue to limit its use, we may be unable to sell sotrovimab in or outside of the U.S.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The FDA may revise or revoke an EUA if the circumstances justifying its issuance no longer exist, the criteria for its issuance are no longer met, or other circumstances make a revision or revocation appropriate to protect public health or safety. An EUA may also be terminated upon a declaration by the Secretary of HHS that the public health emergency has ended. We cannot predict how long our EUA will remain in effect, and we may not receive advance notice from the FDA regarding revocation of our EUA or withdrawal of the public health emergency declaration. If our EUA is terminated or revoked, sotrovimab will no longer be available in the United States unless and until we have obtained FDA approval of a BLA for the product. Changing policies and regulatory requirements could limit, delay or prevent further commercialization of sotrovimab and could adversely impact our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are committing substantial financial resources and personnel and making substantial capital commitments with third parties in connection with therapies for COVID-19. Market demand and utilization of any of our COVID-19 product candidates has been, and may continue to be, adversely impacted by factors such as the development of monoclonal antibodies, or mAbs, of other third parties, the rollout of oral antivirals and vaccines, the emergence of new variants or subvariants and the current challenges in the delivery and administration of mAbs to patients.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In response to the COVID-19 pandemic, we continue to pursue various potential therapies to address the disease, including through mAbs using our antibody platform (in collaboration with several partners), such as sotrovimab and VIR-7832.  To prepare for new waves of variants and future pandemics, we are also actively pursuing multiple next-generation mAbs as well as small molecules aimed at treating COVID-19.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are committing substantial financial resources, both internally and externally, and personnel to the development of therapies for COVID-19. There are no assurances that there will be sufficient market demand for our COVID-19 product candidates or that the FDA and other regulatory authorities will grant us full marketing approvals. For example, market demand and utilization for sotrovimab has been, and may continue to be adversely impacted by factors such as the development of mAbs of other third parties, the rollout of oral antivirals and vaccines, the emergence of new variants and subvariants, such as certain Omicron subvariants, and the current challenges in the delivery and administration of mAbs to patients. There are no assurances that these factors will not adversely impact our other COVID-19 product candidates. In addition, COVID-19 treatment standards are susceptible to rapid changes in epidemiology and the emergence of new variants or subvariants, which may render sotrovimab or any of our future COVID-19 product candidates inferior or obsolete in the future. For example,  although we have an EUA from the FDA for sotrovimab, the FDA has excluded the use of sotrovimab in all U.S. regions due to the continued proportion of COVID-19 cases caused by certain Omicron subvariants. In addition, certain countries outside of the U.S., such as Canada and Japan, continue to maintain access to sotrovimab 500 mg IV, while noting that it is unlikely to maintain efficacy against certain Omicron subvariants. We</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">79</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">cannot predict whether other countries will further limit the use of sotrovimab. Any of these developments may adversely affect our financial condition and business.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our ability to develop a successful therapy will also depend on the success of our manufacturing capabilities, for which we are dependent on third-party manufacturing organizations, and which will require significant additional funding. Although our current estimated aggregate commitment to GSK under a master services agreement with Samsung Biologics Co., Ltd. for sotrovimab drug substance, drug product and raw material has been substantially recognized on our balance sheet as part of the profit-sharing amount constrained as of December 31, 2022, under the definitive collaboration agreement dated June 9, 2020, between the Company and GSK, or the 2020 GSK Agreement, any future commitments for sotrovimab or any of our other future COVID-19 product candidates, may, in the future, exceed our available cash and cash equivalents and investments. We may also need to enter into additional manufacturing agreements in the future in order to create an effective supply chain for our other COVID-19 product candidates that will adequately support demand. In the event that there is not enough demand for the manufacturing capacity that we have already secured or regulatory approval of our product candidates is delayed or unsuccessful, we may remain obligated to pay for such excess manufacturing capacity and/or related costs under the agreements, which could adversely affect our business, financial condition, results of operations and prospects. For example, during the year ended December 31, 2022, we recorded a non-cash charge for potential write-offs related to excess supply and unused binding manufacturing capacity of $369.7 million related to sotrovimab against uncertain future pandemic demand, which has not been reported by GSK as cost-sharing amounts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may need to raise substantial additional capital to fund the development of our product candidates and meet our capital commitments to our manufacturing partners in connection therewith. There can be no assurance that sufficient funds will be available to us on attractive terms or at all and our ability to obtain additional capital could be adversely affected if there is a significant decline in the demand for our products or other significantly unfavorable changes in economic conditions. If we are unable to obtain additional funding from these or other sources, it may be necessary to significantly reduce our rate of spending through reductions in staff and delaying, scaling back, or stopping certain research and development programs. Insufficient liquidity may also require us to relinquish rights to product candidates at an earlier stage of development or on less favorable terms than we would otherwise choose. Furthermore, there are no assurances that we will secure additional supply commitments from governments, which may be material to the commercial success of our product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Product candidates that we successfully develop and commercialize may compete with existing therapies, including competing antibody therapies, oral antivirals, prophylactic vaccines, and new therapies that may become available in the future. In addition, one or more of our competitors may be successful in producing a more efficacious therapy for SARS-CoV-2 and current and future variants, such as certain Omicron subvariants, or in producing a therapy that is easier to deliver and administer to patients in a timelier manner. For example, in February 2022, the FDA approved an EUA for Eli Lilly Company&#x2019;s, or Eli Lilly, antibody, bebtelovimab, for the treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kilograms) with positive results of direct SARS-CoV-2 testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death and when alternative treatment options are not accessible or clinically appropriate; however, in November 2022 the FDA announced that bebtelovimab is no longer authorized in any U.S. region due to lack of activity against recent Omicron subvariants. Merck &amp; Co., Inc., or Merck, Pfizer Inc., or Pfizer, and Eli Lilly have all been successful in securing government support and funding. AstraZeneca plc&#x2019;s, or AstraZeneca, EVUSHELD&#153;, a cocktail of two mAbs, showed topline efficacy of 50% reduction in risk for hospitalization or death risk in early treatment clinical trials and currently has an EUA for use as pre-exposure prophylaxis of COVID-19 in adults and pediatric individuals over the age of 12. EVUSHELD has also been approved in Japan and the EU for use in treatment of adults and adolescents over the age of 12 at risk of severe disease progression of COVID-19. There are several other manufacturers exploring options for pre-exposure and post-exposure prophylaxis such as Invivyd, Inc.&#x2019;s, or Invivyd, adintrevimab.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There are FDA-approved treatments for COVID-19 including an intravenously administered antiviral, remdesivir, marketed by Gilead Sciences, Inc., or Gilead, which is FDA approved for the treatment of COVID-19 in both outpatient and hospitalized settings, and several treatments and a prophylactic vaccine are available under EUA. In December 2021 the FDA approved EUAs for the oral antiviral, molnupiravir, from Merck for the treatment of mild-to-moderate COVID-19 in adults with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options authorized by the FDA are not accessible or clinically appropriate, which has shown topline efficacy of 30% reduction in risk for hospitalization or death risk in early treatment clinical trials, and the oral antiviral, PAXLOVID&#153;, from Pfizer for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kilograms) with positive results of direct SARS-CoV-2 testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death, which has demonstrated an 89% reduction in risk of COVID-19-related hospitalization or death. Additionally, Pfizer&#x2019;s COVID-19 vaccine, Comirnaty&#174;, is approved by the FDA for individuals 5 years of age or older, Moderna, Inc.&#x2019;s, or Moderna, COVID-19 vaccine, Spikevax&#174;, is approved by the FDA for individuals 18 years of age or older and a COVID-19 vaccine is available in the United States under EUA from Janssen Biotech, Inc., or Janssen. These other entities may be more successful at developing, manufacturing or commercializing a therapy for COVID-19. Several of these other</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">80</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">organizations are much larger than we are and have access to larger pools of capital, including U.S. government funding, and broader manufacturing infrastructure. There are no assurances that there will be sufficient market demand for our COVID-19 therapies, that we will secure additional U.S. government funding, that our manufacturing and supply chain infrastructure will remain uninterrupted and reliable, or that the third parties we rely on to manufacture our COVID-19 therapies will be able to satisfy demand in a timely manner and not have supply chain disruptions, all of which could negatively impact or eliminate demand for our COVID-19 therapies.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our near-term revenue is dependent on the continued sales and commercialization of sotrovimab for the early treatment of COVID-19, including our ability to enter into procurement contracts with government entities. If we are unable to continue to sell and/or commercialize sotrovimab in or outside of the U.S., our business, financial condition, results of operations and prospects may be adversely affected. In addition, sotrovimab may be rendered inferior or obsolete due to rapid changes in epidemiology and the emergence of new variants or subvariants.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our near-term revenue is dependent on the continued sales and commercialization of sotrovimab, which is our only currently available commercial product. Our ability to sell and commercialize sotrovimab will depend on a number of factors, some of which are outside of our control, including the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the ability of sotrovimab to be effective in patients with COVID-19 and its variants;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to comply with all regulatory requirements applicable to sotrovimab;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the reauthorization of EUA in the U.S. and/or the receipt of additional marketing authorizations and approvals from the FDA and other similar regulatory authorities;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">whether we are required by the FDA or other similar regulatory authorities to conduct additional clinical trials or required to modify the design of our current trials to support the approval of sotrovimab;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our expectations for future sales of sotrovimab and our ability to secure supply commitments from governments;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">limitation on use or warnings required by the FDA and other similar regulatory authorities;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to achieve and maintain compliance with all regulatory requirements applicable to sotrovimab;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">perceptions by the public and members of the medical community, including physicians, as to the safety and efficacy of sotrovimab as well as the accuracy and sufficiency of clinical evidence supporting its performance;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">demand from the public and members of the medical community for sotrovimab;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the availability, perceived advantages, relative cost, relative convenience and relative efficacy of sotrovimab compared to other COVID-19 therapies as well as the accuracy and sufficiency of clinical evidence supporting its performance;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">positive or negative media coverage of sotrovimab;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to raise additional capital on acceptable terms, or at all, if needed to support the commercialization of sotrovimab;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the ability to enter into procurement contracts with government entities, and our ability to meet our obligations under any such contracts;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our reliance on GSK and other collaborators for development, commercialization and manufacturing of sotrovimab; </span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to obtain, maintain and enforce our intellectual property rights;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to maintain a continued supply of sotrovimab that meets our quality control requirements;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the ability of third-party manufacturing partners to meet demand in a timely manner, in accordance with our specifications, and in compliance with applicable regulatory requirements;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our current and future arrangements with healthcare providers, physicians and third-party payors; and </span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">availability of, or changes in, coverage or reimbursement rates for sotrovimab from government or other commercial or healthcare payors.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, COVID-19 treatment standards are susceptible to rapid changes in epidemiology and the emergence of new variants or subvariants, which may render sotrovimab inferior or obsolete. In March and April 2022, the FDA amended the EUA fact sheet to exclude sotrovimab use in geographic regions where infection is likely to have been caused by a non-susceptible SARS-CoV-2 variant based on available information, including variant susceptibility to these drugs and regional variant frequency. With this EUA revision, sotrovimab is not currently authorized for use in any U.S. region. In light of these developments, we cannot predict whether (if at all)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">or to what extent sotrovimab may be reauthorized for use by the FDA in any U.S. region in the future. Given the EUA revision by the FDA, it is possible that other regulatory authorities may not grant sotrovimab full marketing approval for the treatment of COVID-19, or that any such marketing approvals, if granted, may have similar or other significant limitations on its use. In addition, there can be no assurance with respect to how long the EUA will remain in effect or whether the EUA will be further revised or revoked by the FDA based on the determination by the Secretary of HHS that the underlying health emergency no longer exists or warrants such authorization or other reasons. Furthermore, due to the evolving COVID-19 landscape and based on discussions with the FDA, we and GSK do not plan to file a BLA for sotrovimab at this time.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Although certain countries outside of the U.S., such as Canada and Japan, continue to maintain access to sotrovimab 500 mg IV while noting that it is unlikely to maintain efficacy against certain Omicron subvariants, we cannot predict whether other countries will further limit the use of sotrovimab. If we are unable to sell or commercialize sotrovimab, our business, financial condition, results of operations and prospects may be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to the Development and Commercialization</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our future success is substantially dependent on the successful clinical development, regulatory approval and commercialization of our product candidates in a timely manner. If we are not able to obtain required regulatory approvals, we will not be able to commercialize our product candidates and our ability to generate product revenue will be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have invested a significant portion of our time and financial resources in the development of our product candidates and have initiated clinical trials for multiple product candidates. Our business is dependent on our ability to successfully complete development of, obtain regulatory approval for, and successfully commercialize our product candidates, if approved, in a timely manner. We may face unforeseen challenges in our product development strategy, and we can provide no assurances that our product candidates will be successful in clinical trials or will ultimately receive regulatory approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sotrovimab has received marketing authorization in the EU and has been granted emergency authorization, temporary authorization or marketing approval (under the brand name Xevudy&#174;), supplying more than 40 countries. Although certain countries outside of the U.S., such as Canada and Japan, have maintained access to sotrovimab 500 mg IV while noting that it is unlikely to maintain efficacy against certain Omicron subvariants, we cannot predict whether other countries will limit the use of sotrovimab. Furthermore, although we have an EUA from the FDA for sotrovimab, the FDA has excluded the use of sotrovimab in all U.S. regions due to the continued proportion of COVID-19 cases caused by certain Omicron subvariants. With this EUA revision, sotrovimab is not currently authorized for use in any U.S. region. In light of these developments, we cannot predict whether (if at all) or to what extent sotrovimab may be reauthorized for use by the FDA in any U.S. region in the future. In addition, there can be no assurance with respect to how long the EUA will remain in effect or whether the EUA will be further revised or revoked by the FDA based on the determination by the Secretary of HHS that the underlying health emergency no longer exists or warrants such authorization or other reasons. Furthermore, due to the evolving COVID-19 landscape and based on discussions with the FDA, we and GSK do not plan to file a BLA for sotrovimab at this time. We have not obtained BLA approval in the U.S. for any product candidate to date. We operate in a highly regulated field, and it is possible that none of our product candidates will obtain regulatory approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prior to obtaining approval to commercialize any product candidate in the United States or abroad, we must demonstrate with substantial evidence from well-controlled clinical trials, and to the satisfaction of the FDA or comparable foreign regulatory authorities, that such product candidate is safe and effective for its intended uses. Results from preclinical studies and clinical trials can be interpreted in different ways. Even if we believe that the preclinical or clinical data for our product candidates are promising, such data may not be sufficient to support approval for further development, manufacturing or commercialization of our product candidates by the FDA and other regulatory authorities. The FDA or other regulatory authorities may also require us to conduct additional preclinical studies or clinical trials for our product candidates either prior to or post-approval, or it may object to elements of our clinical development program, requiring their alteration.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if we eventually complete clinical testing and receive approval of a new drug application, or NDA, BLA, or foreign marketing application for our product candidates, the FDA or the comparable foreign regulatory authorities may grant approval or other marketing authorization contingent on the performance of costly additional clinical trials, including post-market clinical trials. The FDA or the comparable foreign regulatory authorities also may approve or authorize for marketing a product candidate for a more limited indication or patient population than we originally request, and the FDA or comparable foreign regulatory authorities may not approve or authorize the labeling that we believe is necessary or desirable for the successful commercialization of a product candidate. Any delay in obtaining, or inability to obtain, applicable regulatory approval or other marketing authorization would delay or prevent commercialization of that product candidate and would adversely impact our business and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the FDA or comparable foreign regulatory authorities may change their policies, adopt additional regulations or revise existing regulations or take other actions, which may prevent or delay approval of our future product candidates under</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">82</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">development on a timely basis. Such policy or regulatory changes could impose additional requirements upon us that could delay our ability to obtain applicable regulatory approvals, increase the costs of compliance or restrict our ability to maintain any marketing authorizations we may have obtained.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furthermore, even if we obtain regulatory approval for our product candidates, we may still need to develop a commercial organization, establish a commercially viable pricing structure and obtain approval for coverage and adequate reimbursement from third-party and government payors, including government health administration authorities. If we are unable to successfully commercialize our product candidates or if there is an insufficient demand for our product candidates, we may not be able to generate sufficient revenue to continue our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The development of additional product candidates is risky and uncertain, and we can provide no assurances that we will be able to replicate our approach for other diseases.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A core element of our business strategy is to expand our product candidate pipeline. Efforts to identify, acquire or in-license, and then develop product candidates require substantial technical, financial and human resources, whether or not any product candidates are ultimately identified. Our efforts may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development, approved products or commercial revenue for many reasons.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have limited financial and management resources and, as a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater market potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, strategic alliances, licensing or other royalty arrangements in circumstances under which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. In addition, we may not be successful in replicating our approach to development for other disease indications. If we are unsuccessful in identifying and developing additional product candidates or are unable to do so, our business may be harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furthermore, we intend to seek approval to market our product candidates outside of the United States, and may also do so for future product candidates. If we market approved products outside of the United States, we expect that we will be subject to additional risks in commercialization. We have no prior experience in these areas. In addition, there are complex regulatory, tax, labor and other legal requirements imposed by many of the individual countries in which we may operate, with which we will need to comply. Many biopharmaceutical companies have found the process of marketing their products in foreign countries to be challenging.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are developing, and in the future may develop, other product candidates in combination with other therapies, which exposes us to additional risks.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are developing VIR-2218 and VIR-3434 for the functional cure of hepatitis B virus, or HBV, and for the chronic treatment of hepatitis D virus, or HDV. Each of these product candidates has the potential to stimulate an effective immune response and has direct antiviral activity against HBV. We believe that a functional cure for HBV will require an effective immune response, in addition to antiviral activity, based on the observation that severe immunosuppression can reactivate HBV disease. Monotherapy with each of these agents may provide a functional cure in some patients, while combination therapy may be necessary for others. We have an ongoing Phase 2 clinical trial that combines VIR-2218 with pegylated interferon-alpha and a Phase 2 clinical trial that combines VIR-2218 with VIR-3434. We are also evaluating additional combinations with other immunotherapy agents and direct acting antiviral agents. We also have a Phase 2 clinical trial evaluating VIR-2218 and VIR-3434 as a monotherapy or in combination for the treatment of chronic HDV. Even if any product candidate we develop were to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to be subject to the risks that the FDA or comparable foreign regulatory authorities could revoke approval of the therapy used in combination with our product candidate. There is also a risk that safety, efficacy, manufacturing or supply issues could arise with these other existing therapies. This could result in our own products being removed from the market or being less successful commercially.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may also evaluate our future product candidates in combination with one or more other therapies that have not yet been approved for marketing by the FDA or comparable foreign regulatory authorities. We will not be able to market any product candidate we develop in combination with any such unapproved therapies that do not ultimately obtain marketing approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If the FDA or comparable foreign regulatory authorities do not approve these other drugs or revoke their approval of, or if safety, efficacy, manufacturing or supply issues arise with, the drugs we choose to evaluate in combination with any product candidate we develop, we may be unable to obtain approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">83</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials and we cannot assure you that any ongoing, planned or future clinical trials will lead to results sufficient for the necessary regulatory approvals and market authorizations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Success in preclinical testing and earlier clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate. Success in preclinical studies and earlier clinical trials does not ensure that later efficacy trials will be successful, nor does it predict final results. Our product candidates may fail to show the desired characteristics in clinical development sufficient to obtain regulatory approval, despite positive results in preclinical studies or having successfully advanced through earlier clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A trial design that is considered appropriate for regulatory approval includes a sufficiently large sample size with appropriate statistical power, as well as proper control of bias, to allow a meaningful interpretation of the results. If we do not conduct clinical trials with a large enough patient sample size, we may not achieve statistically significant results or the same level of statistical significance, if any, that would have been possible to achieve in a larger trial.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As an organization, we have limited experience designing clinical trials and may be unable to design and execute a clinical trial to support regulatory approval, which could mean we will suffer setbacks. Any such setbacks could negatively impact our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Interim, &#x201c;top-line&#x201d; and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, we may publish interim, &#x201c;top-line&#x201d; or preliminary data from our clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary or &#x201c;top-line&#x201d; data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data is available. Differences between preliminary or interim data and final data could significantly harm our business prospects and may cause the trading price of our common stock to fluctuate significantly.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Clinical product development involves a lengthy and expensive process. We may incur additional costs and encounter substantial delays or difficulties in our clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may not commercialize, market, promote or sell any product candidate without obtaining marketing approval from the FDA or comparable foreign regulatory authority, and we may never receive such approvals. It is impossible to predict when or if any of our product candidates will prove effective or safe in humans and will receive regulatory approval. Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must complete preclinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Clinical testing is expensive, is difficult to design and implement, can take many years to complete and is uncertain as to outcome. We do not know whether our planned clinical trials will begin or enroll on time, need to be redesigned or be completed on schedule, if at all. For example, the availability of superior or competitive therapies coupled with changing standards of care could limit our ability to perform placebo-controlled trials and/or require us to enroll a larger number of subjects to address competing treatments. A failure of one or more clinical trials can occur at any stage of testing. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products. We may experience numerous unforeseen events prior to, during, or as a result of clinical trials that could delay or prevent our ability to receive marketing approval or commercialize our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any inability to successfully complete preclinical and clinical development could result in additional costs to us or impair our ability to generate revenue from future product sales or other sources. In addition, if we make manufacturing or formulation changes to our product candidates, we may need to conduct additional testing to bridge our modified product candidate to earlier versions. Clinical trial delays could also shorten any periods during which we may have the exclusive right to commercialize our product candidates, if approved, or allow our competitors to bring competing products to market before we do, which could impair our ability to successfully commercialize our product candidates and may harm our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">84</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, if the results of our clinical trials are inconclusive or if there are safety concerns or serious adverse events associated with our product candidates, we may:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">be delayed in obtaining marketing approval, or not obtain marketing approval at all; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obtain approval for indications or patient populations that are not as broad as intended or desired; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">be subject to additional post-marketing testing requirements; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">be required to perform additional clinical trials to support approval or be subject to additional post-marketing testing requirements; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">have regulatory authorities withdraw, or suspend, their approval of the product or impose restrictions on its distribution in the form of a risk evaluation and mitigation strategy, or REMS; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">be subject to the addition of labeling statements, such as warnings or contraindications; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">be sued; or</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">experience damage to our reputation. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our product development costs will also increase if we experience delays in testing or obtaining marketing approvals. We do not know whether any of our preclinical studies or clinical trials will begin as planned, need to be restructured or be completed on schedule, if at all. For example, enrollment and retention of patients in clinical trials could be disrupted by geopolitical events, including civil or political unrest (such as the ongoing war between Ukraine and Russia), terrorism, insurrection or war, man-made or natural disasters, or public health pandemics or epidemics or other business interruptions, including the current COVID-19 pandemic and future outbreaks of the disease.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furthermore, our product candidates are based on certain innovative technology platforms, which makes it even more difficult to predict the time and cost of product candidate development and obtaining necessary regulatory approvals, particularly for our small interfering ribonucleic acid, or siRNA, and cytomegalovirus, or CMV, vector technologies. In addition, the compounds we are developing may not demonstrate in patients the chemical and pharmacological properties ascribed to them in preclinical studies, and they may interact with human biological systems in unforeseen, ineffective or harmful ways.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As part of our T cell platform, our approach is to use human CMV, or HCMV, as a vaccine vector to potentially treat and prevent pathogens refractory to current vaccine technologies because HCMV may induce potent and long-lasting T cell responses to a broader range of epitopes than observed for other viral vaccines. Safety and toxicity trials for this technology have so far only been conducted in animal species, in which HCMV has limited ability to replicate. If our first clinical trial for VIR-1111 causes unexpected side effects that are not tolerable in the treatment of the relevant patient group, the further development of the product candidates and any other potential products based on HCMV-vector technology may be significantly limited or become impossible. Also, because our HCMV-vector technology is novel, regulatory agencies may lack experience with product candidates such as VIR-1111, which may lengthen the regulatory review process, increase our development costs and delay or prevent commercialization of our product candidates. In addition, our HCMV-vector technology utilizes live-attenuated, genetically-modified organisms for which the FDA, the European Medicines Agency, or EMA, and other comparable foreign regulatory authorities and other public health authorities, such as the Centers for Disease Control and Prevention and hospitals involved in clinical trials, have established additional safety and contagion rules and procedures, which could establish additional hurdles for the development, manufacture or use of our vectors. These hurdles may lead to delays in the conduct of clinical trials or in obtaining regulatory approvals for further development, manufacturing or commercialization of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further, we, the FDA, a foreign regulatory authority or an institutional review board may place a full or partial hold on our clinical trials at any time if it appears that we or our collaborators are failing to conduct a trial in accordance with regulatory requirements, including the FDA&#x2019;s current Good Clinical Practice, or GCP, regulations, that we are exposing participants to unacceptable health risks, or if the FDA or foreign regulatory authority finds deficiencies in our investigational new drug, or IND, applications or clinical trial applications, respectively, or the conduct of these trials. Moreover, we may not be able to file INDs to commence additional clinical trials on the timelines we expect because our filing schedule is dependent on further preclinical and manufacturing progress. Therefore, we cannot predict with any certainty the schedule for commencement and completion of future clinical trials. If we experience delays in the commencement or completion of our clinical trials, or if we terminate a clinical trial prior to completion, the commercial prospects of our product candidates could be negatively impacted, and our ability to generate revenue from our product candidates may be delayed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">85</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be delayed, made more difficult or rendered impossible by multiple factors outside our control.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Identifying and qualifying patients to participate in our clinical trials is critical to our success.  In particular, clinical trials for prophylaxis are impacted by many factors including competing therapies that tend to require enrollment of a larger number of subjects than clinical trials for treatments. We may encounter difficulties in enrolling patients in our clinical trials, thereby delaying or preventing development and approval of our product candidates. Even once enrolled, we may be unable to retain a sufficient number of patients to complete any of our trials. Patient enrollment and retention in clinical trials depend on many factors, including the size of the patient population, the nature of the trial protocol, the existing body of safety and efficacy data, changing standards of care, the number and nature of competing treatments and ongoing clinical trials of competing therapies for the same indication, the proximity of patients to clinical sites and the eligibility criteria for the trial. The enrollment and retention of patients in the clinical trials for sotrovimab and VIR-7832 for the treatment of COVID-19 may be disrupted or delayed as a result of regulatory feedback, clinicians&#x2019; and patients&#x2019; perceptions as to the potential advantages of sotrovimab and VIR-7832 in relation to other available therapies, including products that have been recently authorized under EUAs or approved and licensed through NDAs and BLAs to treat COVID-19 as well as any other new products that may be approved in the future for the treatment of COVID-19.  In addition, enrollment and retention of patients in clinical trials could be disrupted by geopolitical events, including civil or political unrest (such as the ongoing war between Ukraine and Russia), terrorism, insurrection or war, man-made or natural disasters, or public health pandemics or epidemics or other business interruptions, including, the current COVID-19 pandemic and future outbreaks of the disease.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our efforts to build relationships with patient communities may not succeed, which could result in delays in patient enrollment in our clinical trials. Any negative results we may report in clinical trials of our product candidates may make it difficult or impossible to recruit and retain patients in other clinical trials of that same product candidate. Delays or failures in planned patient enrollment or retention may result in increased costs, program delays or both, which could have a harmful effect on our ability to develop our product candidates or could render further development impossible. In addition, we may rely on contract research organizations, or CROs, and clinical trial sites to ensure proper and timely conduct of our future clinical trials and, while we intend to enter into agreements governing their services, we will be limited in our ability to ensure their actual performance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The continued spread of COVID-19 globally, or the evolution of new variants or subvariants of COVID-19 that are more contagious, have more severe effects or are resistant to treatments or vaccinations, could adversely impact our preclinical or clinical trial operations in the United States, including our ability to enroll and retain patients as well as CROs and clinical trial site staff who, as healthcare providers, may have heightened exposure to COVID-19 if an outbreak occurs in their geography. In response to the COVID-19 pandemic, the FDA issued guidance on March 18, 2020, and subsequently updated it, to address the conduct of clinical trials during the pandemic. The guidance sets out a number of considerations for sponsors of clinical trials impacted by the pandemic, including the requirement to include in the clinical study report (or as a separate document) contingency measures implemented to manage the study, and any disruption of the study as a result of COVID-19; a list of all study participants affected by COVID-19-related study disruptions by a unique subject identifier and by investigational site, and a description of how the individual&#x2019;s participation was altered; and analyses and corresponding discussions that address the impact of implemented contingency measures (e.g., participant discontinuation from investigational product and/or study, alternative procedures used to collect critical safety and/or efficacy data) on the safety and efficacy results reported for the study. On January 30, 2023, the Biden administration announced that it will end the public health emergency declarations related to COVID-19 on May 11, 2023. On January 31, 2023, the FDA indicated that it would soon issue a Federal Register notice describing how the termination of the public health emergency will impact the FDA&#x2019;s COVID-19 related guidance, including the clinical trial guidance and updates thereto. An inability to enroll a sufficient number of patients for the clinical trials would result in significant delays or might require us to abandon one or more clinical trials altogether.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit their commercial potential or result in significant negative consequences following any potential marketing approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the conduct of clinical trials, patients report changes in their health, including illnesses, injuries and discomforts, to their doctor. Often, it is not possible to determine whether or not the product candidate being studied caused these conditions. Regulatory authorities may draw different conclusions and may require us to pause our clinical trials or require additional testing to confirm these determinations, if they occur.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">86</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, it is possible that as we test our product candidates in larger, longer and more extensive clinical trials, or as use of these product candidates becomes more widespread if they receive regulatory approval, illnesses, injuries, discomforts and other adverse events that were not observed in earlier trials, as well as conditions that did not occur or went undetected in previous trials, will be reported by subjects or patients. Many times, side effects are only detectable after investigational products are tested in large-scale pivotal trials or, in some cases, after they are made available to patients on a commercial scale after approval. If additional clinical experience indicates that any of our product candidates have side effects or cause serious or life-threatening side effects, the development of the product candidate may fail or be delayed, or, if the product candidate has received regulatory approval, such approval may be revoked, which would harm our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are a party to strategic collaboration and license agreements pursuant to which we are obligated to make substantial payments upon achievement of milestone events and, in certain cases, have relinquished important rights over the development and commercialization of certain current and future product candidates. We also intend to explore additional strategic collaborations, which may never materialize or may require that we relinquish rights to and control over the development and commercialization of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a party to various strategic collaboration and license agreements that are important to our business and to our current and future product candidates pursuant to which we license a number of technologies to form our technology platforms. These agreements contain obligations that require us to make substantial payments in the event certain milestone events are achieved. We may in the future be required to make these payments, which could adversely affect our financial condition. In addition, we cannot be certain that we will achieve the results or benefits that justify entering into these agreements. For additional information regarding these and other collaboration, license and grant agreements, see the section titled &#x201c;Business&#x2014;Our Collaboration, License and Grant Agreements&#x201d;.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A core element of our business strategy also includes continuing to acquire or in-license additional technologies or product candidates for the treatment and prevention of serious infectious diseases. As a result, we intend to periodically explore a variety of possible strategic collaborations or licenses in an effort to gain access to additional product candidates, technologies or resources.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At this time, we cannot predict what form such strategic collaborations or licenses might take in the future. We are likely to face significant competition in seeking appropriate strategic collaborators, and strategic collaborations and licenses can be complicated and time-consuming to negotiate and document. We may not be able to negotiate strategic collaborations on acceptable terms, or at all. We are unable to predict when, if ever, we will enter into any additional strategic collaborations or licenses because of the numerous risks and uncertainties associated with establishing them. Any delays in entering into new strategic collaborations or licenses related to our product candidates could delay the development and commercialization of our product candidates in certain geographies for certain indications, which would harm our business prospects, financial condition and results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our current and future strategic collaborations and licenses could subject us to a number of risks, including the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may be required to undertake the expenditure of substantial operational, financial and management resources; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may be required to assume substantial actual or contingent liabilities; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">we may not be able to control the amount and timing of resources that our strategic collaborators devote to the development or commercialization of our product candidates; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">strategic collaborators may select indications or design clinical trials in a way that may be less successful than if we were doing so; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">strategic collaborators may delay clinical trials, provide insufficient funding, terminate a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new version of a product candidate for clinical testing; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">strategic collaborators may not pursue further development and commercialization of products resulting from the strategic collaboration arrangement or may elect to discontinue research and development programs; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">disputes may arise between us and our strategic collaborators that result in costly litigation or arbitration that diverts management&#x2019;s attention and consumes resources; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">strategic collaborators may experience financial difficulties; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">strategic collaborators may not properly maintain, enforce or defend our intellectual property rights or may use our proprietary information in a manner that could jeopardize or invalidate our proprietary information or expose us to potential litigation; and</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">strategic collaborators could terminate the arrangement or allow it to expire, which would delay the development and may increase the cost of developing our product candidates. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">87</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furthermore, license agreements we enter into in the future may not provide exclusive rights to use intellectual property and technology in all relevant fields of use and in all territories in which we may wish to develop or commercialize our technology and products. As a result, we may not be able to prevent competitors from developing and commercializing competitive products in territories included in all of our licenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If the market opportunities for our product candidates are smaller than we believe they are or any approval we obtain is based on a narrower definition of the patient population, our business may suffer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We currently focus our product development on product candidates for the treatment and prevention of serious infectious diseases. Our eligible patient population, pricing estimates and available coverage and reimbursement may differ significantly from the actual market addressable by our product candidates. Our estimates of the number of people who have these diseases, the subset of people with these diseases who have the potential to benefit from treatment with our product candidates, and the market demand for our product candidates are based on our beliefs and analyses. These estimates have been derived from a variety of sources, including the scientific literature, patient foundations or market research, and may prove to be incorrect. Further, new trials may change the estimated incidence or prevalence of the diseases we are targeting. The number of patients may turn out to be lower than expected. Likewise, the potentially addressable patient population for each of our product candidates may be limited or may not be receptive to treatment with our product candidates, and new patients may become increasingly difficult to identify or access. Additionally, the availability of superior or competitive therapies from our competitors could negatively impact or eliminate market demand for our product candidates. If the market opportunities for our product candidates are smaller than we estimate, it could have an adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We face substantial competition, which may result in others developing or commercializing products before or more successfully than we do.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The biopharmaceutical industry is characterized by rapidly advancing technologies, intense competition and an emphasis on proprietary products. We face potential competition from many different sources, including pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our commercialization potential could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than products that we may develop. The key competitive factors affecting the success of all our programs are likely to be efficacy, safety, convenience and timing. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, regulatory incentives to develop products for treatment of infectious diseases have increased interest and activity in this area and may lead to increased competition for clinical investigators and clinical trial subjects, as well as for future prescriptions, if any of our product candidates are successfully developed and approved.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our competitors may have significantly greater financial resources, established presence in the market, and expertise in research and development, manufacturing, preclinical and clinical testing, obtaining regulatory approvals and reimbursement and marketing approved products than we do. These competitors also compete with us in acquiring third-party contract manufacturing capacity and raw materials, recruiting and retaining qualified scientific, sales, marketing and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. Additional mergers and acquisitions may result in even more resources being concentrated in our competitors.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since the beginning of the COVID-19 pandemic, and even before, there has been substantial research in the development of new drugs and biologics to address diseases caused by the coronavirus. Numerous large and small pharmaceutical and biotechnology companies are developing COVID-19 therapy programs with various mechanisms of actions, including prophylactic vaccines, oral antivirals, immunomodulators, and antibodies, some of which are further along in the development process than we are. Other parties may be successful in producing a more efficacious therapy for SARS-CoV-2 or in producing a therapy that is easier to deliver and administer to patients in a timelier manner, which may also lead to the diversion of funding away from us and toward other companies or lead to decreased demand for our potential therapies. Companies with antibodies in clinical development include Invivyd, AstraZeneca, Brii Biosciences Offshore Limited, Celltrion Healthcare Co., Ltd., Eli Lilly and Regeneron Pharmaceuticals, Inc. Companies with oral antivirals in clinical development include Shionogi Inc., Gilead, Pardes Biosciences, Enanta Pharmaceuticals and others. Companies with prophylactic vaccines in clinical development include AstraZeneca, GSK, Novavax, Inc. and Sanofi S.A. The industry and competitive landscape for COVID-19 treatments is rapidly changing, and we could have more competition in the future.  Although certain countries outside of the U.S., such as Canada and Japan, continue to maintain access to sotrovimab 500 mg IV while</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">noting that it is unlikely to maintain efficacy against certain Omicron subvariants, we cannot predict whether other countries will  further limit the use of sotrovimab.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The availability of superior or competitive therapies, or preventative measures such as vaccines, coupled with the unpredictable nature of pandemics and the prevalence of new variants or subvariants of COVID-19, such as certain Omicron subvariants, could negatively impact or eliminate demand for our COVID-19 therapies. For example, in March and April 2022, the FDA amended the EUA fact sheet to exclude sotrovimab use in geographic regions where infection is likely to have been caused by a non-susceptible SARS-CoV-2 variant based on available information, including variant susceptibility to these drugs and regional variant frequency. With these EUA revisions, sotrovimab is not currently authorized for use in any U.S. region. In light of these developments, we cannot predict whether (if at all) or to what extent sotrovimab may be reauthorized for use by the FDA in any U.S. region in the future. In addition, due to the evolving COVID-19 landscape and based on discussions with the FDA, we and GSK do not plan to file a BLA for sotrovimab at this time.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Product candidates that we successfully develop and commercialize may compete with existing therapies, including prophylactic vaccines, competing antibody therapies, oral antivirals, and new therapies that may become available in the future. In addition, one or more of our competitors may be successful in producing a more efficacious therapy for SARS-CoV-2 and current and future variants, such as certain Omicron subvariants, or in producing a therapy that is easier to deliver and administer to patients in a timelier manner. For example, there are FDA-approved treatments for COVID-19 including an intravenously administered antiviral, remdesivir, marketed by Gilead, which is FDA approved for the treatment of COVID-19 in both outpatient and hospitalized settings, and several treatments and a prophylactic vaccine are available under EUA. Additionally, Pfizer&#x2019;s COVID-19 vaccine, Comirnaty&#174;, is approved by the FDA for individuals 5 years of age or older, Moderna&#x2019;s COVID-19 vaccine, Spikevax&#174;, is approved by the FDA for individuals 18 years of age or older and a COVID-19 vaccine is available in the United States under EUA from Janssen. In December 2021 the FDA approved EUAs for the oral antiviral, molnupiravir, from Merck for the treatment of mild-to-moderate COVID-19 in adults with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options authorized by the FDA are not accessible or clinically appropriate, which has shown topline efficacy of 30% reduction in risk for hospitalization or death risk in early treatment clinical trials, and the oral antiviral, PAXLOVID&#153;, from Pfizer for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kilograms) with positive results of direct SARS-CoV-2 testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death, which has demonstrated an 89% reduction in risk of COVID-19-related hospitalization or death.  Currently, there are no mAbs available in the U.S. for use as treatment or prophylaxis against COVID-19. For example, in February 2022, the FDA approved an EUA for Eli Lilly&#x2019;s antibody, bebtelovimab, for the treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kilograms) with positive results of direct SARS-CoV-2 testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death and when alternative treatment options are not accessible or clinically appropriate; however, in November 2022 the FDA announced that bebtelovimab is no longer authorized in any U.S. region due to lack of activity against recent Omicron subvariants.  AstraZeneca&#x2019;s EVUSHELD&#153;, a cocktail of two mAbs, was previously approved under an EUA for pre-exposure prophylaxis of COVID-19 in adults and pediatric individuals over the age of 12 at risk for severe disease progression of COVID-19, but was deauthorized by the FDA in January 2023.  EVUSHELD currently remains authorized in other countries where it is approved for COVID-19 pre-exposure prophylaxis and treatment, including the EU and Japan. There are several other manufacturers exploring options for pre-exposure and post-exposure prophylaxis such as Invivyd&#x2019;s adintrevimab.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a result of these factors, our competitors may achieve patent protection or obtain regulatory approval or authorization of their products before we are able to, which may limit our ability to develop or commercialize our product candidates. Our competitors may also develop therapies that are safer, more effective, more widely accepted or less expensive than ours, and may also be more successful than we are in manufacturing and marketing their products. These advantages could render our product candidates obsolete or non-competitive before we can recover the costs of such product candidates&#x2019; development and commercialization. For additional information regarding our competitors, see the section titled &#x201c;Business&#x2014;Competition&#x201d;.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Even if any of our product candidates receive marketing approval, they may fail to achieve adoption by physicians, patients, third-party payors or others in the medical community necessary for commercial success.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To date, sotrovimab has been granted emergency authorization, temporary authorization or marketing approval (under the brand name Xevudy&#174;), supplying more than 40 countries. Although certain countries outside of the U.S., such as Canada and Japan, have maintained access to sotrovimab 500 mg IV while noting that it is unlikely to maintain efficacy against certain Omicron subvariants, we cannot predict whether other countries will further limit the use of sotrovimab. Furthermore, although we have an EUA from the FDA for sotrovimab, the FDA has excluded the use of sotrovimab in all U.S. regions due to the continued proportion of COVID-19 cases caused by certain Omicron subvariants. With this EUA revision, sotrovimab is not currently authorized for use in any U.S. region. In light of these developments, we cannot predict whether (if at all) or to what extent sotrovimab may be reauthorized for use by the FDA in any U.S. region in the future. In addition, there can be no assurance with respect to how long the EUA will remain in</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">89</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">effect or whether the EUA will be further revised or revoked by the FDA based on the determination by the Secretary of HHS that the underlying health emergency no longer exists or warrants such authorization or other reasons. In addition, due to the evolving COVID-19 landscape and based on discussions with the FDA, we and GSK do not plan to file a BLA for sotrovimab at this time. Moreover, even if we were to file a BLA or marketing applications in other jurisdictions, itis possible that the FDA and certain other regulatory authorities may not grant sotrovimab full marketing approval for the treatment of COVID-19, or that any such marketing approvals, if granted, may have similar or other significant limitations on its use.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if any of our product candidates receive marketing approval, they may fail to achieve adoption by physicians, patients, third-party payors and others in the medical community. If such product candidates do not achieve an adequate level of acceptance, we may not generate significant product revenue and may not become profitable. The degree of market acceptance of any product candidate, if approved for commercial sale, will depend on a number of factors, including but not limited to:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the convenience and ease of administration compared to alternative treatments and therapies; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the efficacy and potential advantages compared to alternative treatments and therapies; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the effectiveness of sales and marketing efforts; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> acceptance in the medical and patient communities of our product candidates as a safe and effective treatments; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the cost of treatment in relation to alternative treatments and therapies, including any similar generic treatments; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to offer such product for sale at competitive prices; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the strength of marketing and distribution support; </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the availability of third-party coverage and adequate reimbursement, and patients&#x2019; willingness to pay out-of-pocket in the absence of third-party coverage or adequate reimbursement;</span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the products&#x2019; safety profile; and </span></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any restrictions on the use of the product together with other medications. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If any of our product candidates are approved but fail to achieve market acceptance among physicians, patients, third-party payors and others in the medical community, we will not be able to generate significant revenue, which would compromise our ability to become profitable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Even if we obtain regulatory approvals for our product candidates, they will remain subject to ongoing regulatory oversight and potential enforcement actions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if we obtain regulatory approval in a jurisdiction, the regulatory authority may still impose significant restrictions on the indicated uses or marketing of our product candidates, or impose ongoing requirements for potentially costly post-approval trials, post-market surveillance or patient or drug restrictions. Additionally, the holder of an approved BLA is required to comply with FDA rules and is subject to FDA review and periodic inspections, in addition to other potentially applicable federal and state laws, to ensure compliance with current good manufacturing practices, or cGMP, and adherence to commitments made in the BLA.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we or a regulatory agency discovers previously unknown problems with a product such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions relative to that product or the manufacturing facility, including requiring recall or withdrawal of the product from the market or suspension of manufacturing. Moreover, product labeling, advertising and promotion for any approved product will be subject to regulatory requirements, continuing regulatory review and review by other government agencies and third parties. For example, a company may not promote &#x201c;off-label&#x201d; uses for its drug products. An off-label use is the use of a product for an indication that is not described in the product&#x2019;s FDA-approved or authorized label in the United States or for uses in other jurisdictions that differ from those approved by the applicable regulatory agencies. Physicians, on the other hand, may prescribe products for off-label uses. Although the FDA and comparable foreign regulatory agencies do not regulate a physician&#x2019;s choice of drug treatment made in the physician&#x2019;s independent medical judgment, they do restrict promotional communications from companies or their sales force with respect to off-label uses of products for which marketing clearance has not been issued.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Failure to comply with such requirements, when and if applicable, could subject us to a number of actions ranging from warning letters to product seizures or significant fines or monetary penalties, among other actions. The FDA and other agencies, including the Department of Justice, or the DOJ, closely regulate and monitor the marketing and promotion of products to ensure that they are</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">marketed and distributed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturers&#x2019; communications regarding off-label use and if we market our medicines for uses other than their respective approved indications, we may be subject to DOJ-led enforcement actions for off-label marketing. Violations of the Food, Drug, and Cosmetic Act and other statutes, including the False Claims Act, relating to the promotion and advertising of prescription drugs may lead to investigations and enforcement actions alleging violations of federal and state health care fraud and abuse laws, as well as state consumer protection laws, which violations may result in the imposition of significant administrative, civil and criminal penalties. Any government investigation of alleged violations of laws or regulations could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue. For additional information regarding regulatory approval and ongoing regulatory oversight, see the section titled &#x201c;Business&#x2014;Government Regulation and Product Approval&#x201d;.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our product candidates, we may not be successful in commercializing them, if and when they are approved.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To successfully commercialize any product candidate that may result from our development programs, we will need to build out our sales and marketing capabilities, either on our own or with others. The establishment and development of our own commercial team or the establishment of a contract sales force to market any product candidate we may develop will be expensive and time-consuming and could delay any product launch. Moreover, we cannot be certain that we will be able to successfully develop this capability, and we have no experience as a company in commercializing products. Establishing sales and marketing capabilities will be particularly important to the commercial success of our product candidates that target diseases with large patient populations throughout the world. We may seek to enter into collaboration agreements with other entities to utilize their established marketing and distribution capabilities, but we may be unable to enter into such agreements on favorable terms, if at all. For example, GSK is primarily responsible for the commercialization of sotrovimab. If any current or future collaborators, including GSK, do not commit sufficient time or resources to commercialize our product candidates, or we are unable to develop the necessary capabilities on our own, we may be unable to generate sufficient revenue to sustain our business. We compete with many companies that currently have extensive, experienced and well-funded marketing and sales operations to recruit, hire, train and retain marketing and sales personnel, and will have to compete with those companies to recruit, hire, train and retain any of our own marketing and sales personnel. We will likely also face competition if we seek third parties to assist us with the sales and marketing efforts of our product candidates. Without an internal team or the support of a third party to perform marketing and sales functions, we may be unable to compete successfully against these more established companies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Even if we obtain and maintain approval for our product candidates from the FDA, we may never obtain approval outside of the United States, which would limit our market opportunities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Approval of a product candidate in the United States by the FDA does not ensure approval of such product candidate by regulatory authorities in other countries or jurisdictions, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other foreign countries or by the FDA. Sales of our product candidates outside of the United States will be subject to foreign regulatory requirements governing clinical trials and marketing approval. Even if the FDA grants marketing approval for a product candidate, comparable foreign regulatory authorities also must approve the manufacturing and marketing of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and more onerous than, those in the United States, including additional preclinical studies or clinical trials. In many countries outside of the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that country. In some cases, the price that we intend to charge for any product candidates, if approved, is also subject to approval. Obtaining approval for our product candidates in the EU from the European Commission following the opinion of the EMA if we choose to submit a marketing authorization application there, would be a lengthy and expensive process. Even if a product candidate is approved, the EMA may limit the indications for which the product may be marketed, require extensive warnings on the product labeling or require expensive and time-consuming additional clinical trials or reporting as conditions of approval. Approval of certain product candidates outside of the United States, particularly those that target diseases that are more prevalent outside of the United States will be particularly important to the commercial success of such product candidates. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our product candidates in certain countries.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, following the result of a referendum in 2016, the U.K. left the EU on January 31, 2020, commonly referred to as Brexit. After lapse of a transition period, the U.K. is no longer part of the European Single Market and European Union Customs Union as of January 1, 2021. A trade and cooperation agreement that outlines the future trading relationship between the U.K. and the EU was agreed to in December 2020 and entered into force on May 1, 2021. As of January 1, 2021, the Medicines and Healthcare products Regulatory Agency, or the MHRA, became responsible for supervising medicines and medical devices in Great Britain, comprising England, Scotland and Wales under domestic law, whereas Northern Ireland will continue to be subject to EU rules under</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">91</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the Northern Ireland Protocol. The MHRA will rely on the Human Medicines Regulations 2012 (SI 2012/1916) (as amended), or the HMR, as the basis for regulating medicines. The HMR has incorporated into the domestic law of the body of EU law instruments governing medicinal products that pre-existed prior to the U.K.&#x2019;s withdrawal from the EU. Since a significant proportion of the regulatory framework for pharmaceutical products in the U.K. covering the quality, safety, and efficacy of pharmaceutical products, clinical trials, marketing authorization, commercial sales, and distribution of pharmaceutical products is derived from EU directives and regulations, Brexit may have a material impact upon the regulatory regime with respect to the development, manufacture, importation, approval and commercialization of our product candidates in the U.K. For example, the U.K. is no longer covered by the centralized procedures for obtaining EU-wide marketing authorization from the EMA, and a separate marketing authorization will be required to market our product candidates in the U.K. Until December 31, 2023, it is possible for the MHRA to rely on a decision taken by the European Commission on the approval of a new marketing authorization via the centralized procedure. However, it is unclear whether the MHRA in the U.K. is sufficiently prepared to handle the increased volume of marketing authorization applications that it is likely to receive after such time. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of Brexit or otherwise, may force us to restrict or delay efforts to seek regulatory approval in the U.K. for our product candidates, which could significantly and materially harm our business. Further, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries. Also, regulatory approval for our product candidates may be withdrawn. If we fail to comply with the applicable regulatory requirements, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed and our business, financial condition, results of operations and prospects could be harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Negative developments and negative public opinion of new technologies on which we rely may damage public perception of our product candidates or adversely affect our ability to conduct our business or obtain regulatory approvals for our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The clinical and commercial success of our product candidates will depend in part on public acceptance of the use of new technologies for the prevention or treatment of human diseases. For example, we use CMV, a commonly occurring virus in humans, as a vaccine vector to prevent and treat pathogens refractory to current vaccine technologies. We also use CRISPR gene-editing technology as a research tool to systematically identify human genes that control infection.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Public perception may be influenced by claims that CMV technology is unsafe and products incorporating this technology may not gain the acceptance of the public or the medical community, or that CRISPR gene-editing technology is unethical or immoral. Adverse public attitudes may adversely impact our ability to enroll clinical trials. Moreover, our success will depend upon physicians specializing in our targeted diseases prescribing, and their patients being willing to receive, our product candidates as treatments in lieu of, or in addition to, existing, more familiar, treatments for which greater clinical data may be available. Any increase in negative perceptions of the technologies that we rely on may result in fewer physicians prescribing our products or may reduce the willingness of patients to utilize our products or participate in clinical trials for our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Increased negative public opinion or more restrictive government regulations in response thereto, would have a negative effect on our business, financial condition, results of operations or prospects and may delay or impair the development and commercialization of our product candidates or demand for such product candidates. Adverse events in our preclinical studies or clinical trials or those of our competitors or of academic researchers utilizing similar technologies, even if not ultimately attributable to product candidates we may discover and develop, and the resulting publicity could result in increased governmental regulation, unfavorable public perception, potential regulatory delays in the testing or approval of potential product candidates we may identify and develop, stricter labeling requirements for those product candidates that are approved, a decrease in demand for any such product candidates and a suspension or withdrawal of approval by regulatory authorities of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any product candidate that we may develop. In addition, our insurance policies may be inadequate and potentially expose us to unrecoverable risks.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We face an inherent risk of product liability exposure related to the testing of our product candidates in clinical trials and may face an even greater risk if we commercialize any product candidate that we may develop. If we cannot successfully defend ourselves against claims that any such product candidates caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">decreased demand for any product candidate that we may develop; </span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">loss of revenue; </span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">substantial monetary awards to trial participants or patients; </span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">significant time and costs to defend the related litigation; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">92</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">withdrawal of clinical trial participants; </span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">increased insurance costs; </span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the inability to commercialize any product candidate that we may develop; and </span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">injury to our reputation and significant negative media attention. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any such outcomes could negatively impact our business, financial condition, results of operations and prospects. Furthermore, although we maintain product liability insurance coverage, such insurance may not be adequate to cover all liabilities that we may incur. We anticipate that we will need to increase our insurance coverage each time we commence a clinical trial and if we successfully commercialize any product candidate. Insurance availability, coverage terms and pricing continue to vary with market conditions. We endeavor to obtain appropriate insurance coverage for insurable risks that we identify such as cybersecurity-related issues; however, we may fail to correctly anticipate or quantify insurable risks, we may not be able to obtain appropriate insurance coverage and insurers may not respond as we intend to cover insurable events that may occur. Conditions in the insurance markets relating to nearly all areas of traditional corporate insurance change rapidly and may result in higher premium costs, higher policy deductibles and lower coverage limits. For some risks, we may not have or maintain insurance coverage because of cost or availability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Regulatory Compliance</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The regulatory pathways for our product candidates targeting SARS-CoV-2, the virus that causes COVID-19, are continually evolving, and may result in unexpected or unforeseen challenges.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our product candidates targeting SARS-CoV-2, the virus that causes COVID-19, are in various development and approval stages. To date, sotrovimab has been granted emergency authorization, temporary authorization or marketing approval (under the brand name Xevudy&#174;), supplying more than 40 countries. Although certain countries outside of the U.S., such as Canada and Japan, have maintained access to sotrovimab 500 mg IV while noting that it is unlikely to maintain efficacy against certain Omicron subvariants, we cannot predict whether other countries will further limit the use of sotrovimab. Furthermore, although we have an EUA from the FDA for sotrovimab, the FDA has excluded the use of sotrovimab in all U.S. regions due to the continued proportion of COVID-19 cases caused by certain Omicron subvariants. With this EUA revision, sotrovimab is not currently authorized for use in any U.S. region. In light of these developments, we cannot predict whether (if at all) or to what extent sotrovimab may be reauthorized for use by the FDA in any U.S. region in the future. In addition, there can be no assurance with respect to how long the EUA will remain in effect or whether the EUA will be further revised or revoked by the FDA based on the determination by the Secretary of HHS that the underlying health emergency no longer exists or warrants such authorization or other reasons. In addition, due to the evolving COVID-19 landscape and based on discussions with the FDA, we and GSK do not plan to file a BLA for sotrovimab at this time.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Evolving or changing plans or priorities within the FDA, including changes based on new knowledge of COVID-19, variants and subvariants of the disease, and how the disease affects the human body, may significantly affect the regulatory timelines for our COVID-19 product candidates. Results from our continued development and planned clinical trials may raise new questions and require us to redesign proposed clinical trials, including revising proposed endpoints or adding new clinical trial sites or cohorts of subjects. As part of these ongoing discussions, the FDA may require us to conduct additional preclinical studies and/or clinical trials than we originally anticipated, which could result in significant delay in our development program for these product candidates.  For example, we and GSK continue to conduct </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> testing of sotrovimab against new variants and subvariants as they emerge, and to collect and evaluate real-world evidence, both of which are being shared with regulatory authorities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">93</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If any of our future small molecule drug product candidates obtain regulatory approval, competitors could enter the market with generic or follow-on versions of such products, which may result in a material decline in sales of affected products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act, a pharmaceutical manufacturer may file an abbreviated new drug application, or ANDA, seeking approval of a generic version of an approved, small molecule innovator drug product. Under the Hatch-Waxman Act, a manufacturer may also submit an NDA under section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act that references the FDA&#x2019;s prior approval of the small molecule innovator product. A 505(b)(2) NDA product may be for a new or improved version of the original innovator product. The Hatch-Waxman Act also provides for certain periods of regulatory exclusivity, which preclude FDA approval (or in some circumstances, FDA filing and review) of an ANDA or 505(b)(2) NDA. In addition to the benefits of regulatory exclusivity, an innovator NDA holder may have patents claiming the active ingredient, product formulation or an approved use of the drug, which would be listed with the product in the FDA publication, &#x201c;Approved Drug Products with Therapeutic Equivalence Evaluations,&#x201d; known as the Orange Book, see the section titled &#x201c;&#x2014;Risks Related to Our Intellectual Property&#x2014; Patent terms may be inadequate to protect our competitive position on our product candidates or any products approved in the future for an adequate amount of time and additional competitors could enter the market with generic or biosimilar versions of such products.&#x201d;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accordingly, if any of our future small molecule drug product candidates are approved, competitors could file ANDAs following the expiration of regulatory exclusivity for generic versions of these products or 505(b)(2) NDAs that reference our products. If competitors are able to obtain marketing approval for generics referencing our small molecule drug product candidates, such competitive products may be able to immediately compete with us in each indication for which our product candidates may have received approval. They may also be prescribed by healthcare providers for off-label uses that are otherwise protected by regulatory exclusivity. For additional information regarding competition, see the section titled &#x201c;Business&#x2014;Competition&#x201d;.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Any biologic product candidates for which we intend to seek approval may face competition sooner than anticipated.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we are successful in achieving regulatory approval to commercialize any biologic product candidate faster than our competitors, such product candidates may face competition from biosimilar products. In the United States, biologic product candidates are subject to approval and licensure under the BLA pathway. The Biologics Price Competition and Innovation Act of 2009, or BPCIA, creates an abbreviated pathway for the approval of biosimilar and interchangeable biologic products following the approval of an original BLA. For additional information regarding biosimilars and exclusivity, see the section titled &#x201c;Business&#x2014;Government Regulation and Product Approval&#x2014;Biosimilars and Regulatory Exclusivity&#x201d;.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If competitors are able to obtain marketing approval for biosimilars referencing our biologic product candidates, if approved and after the expiration of regulatory exclusivity, such products may become subject to competition from such biosimilars, with the attendant competitive pressure and potential adverse consequences. Such competitive products may be able to immediately compete with us in each indication for which our product candidates may have received approval. In addition, the extent to which any regulatory exclusivity may apply to competing products authorized under an EUA is unclear and may not apply. For additional information regarding competition, see the section titled &#x201c;Business&#x2014;Competition&#x201d;.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, we may also face competition from product candidates that receive EUA approval, which could negatively impact sales of our product candidates. For example, numerous large and small pharmaceutical and biotechnology companies are developing COVID-19 therapy programs, including prophylactic vaccines, oral antivirals, immunomodulators, and antibodies, some of which have received full approval or EUAs from the FDA. For additional information regarding competition, see the section titled &#x201c;&#x2014;Risks Related to the Development and Commercialization &#x2014; We face substantial competition, which may result in others developing or commercializing products before or more successfully than we do.&#x201d;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our relationships with customers, physicians, and third-party payors are subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, and other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Healthcare providers, physicians and third-party payors in the United States and elsewhere play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our current and future arrangements with healthcare professionals, principal investigators, consultants, customers and third-party payors subject us to various federal and state fraud and abuse laws and other healthcare laws, such as the U.S. federal Anti-Kickback Statute, federal civil and criminal false claims laws, the healthcare fraud provisions of the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, and the Physician Payments Sunshine Act.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute any product candidates, if approved. For additional information regarding these</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">94</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">laws, see the section titled &#x201c;Business&#x2014;Government Regulation and Product Approval&#x201d;. Ensuring that our internal operations and business arrangements with third parties comply with applicable healthcare laws and regulations will likely be costly. It is possible that governmental authorities will conclude that our business practices, including our relationships with physicians and other healthcare providers may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participating in government-funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of noncompliance with these laws, contractual damages, reputational harm and the curtailment or restructuring of our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If the physicians or other providers or entities with whom we expect to do business are found not to be in compliance with applicable laws, they may be subject to significant civil, criminal or administrative sanctions, including exclusions from government-funded healthcare programs. Even if resolved in our favor, litigation or other legal proceedings relating to healthcare laws and regulations may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development, manufacturing, sales, marketing or distribution activities. Uncertainties resulting from the initiation and continuation of litigation or other proceedings relating to applicable healthcare laws and regulations could have an adverse effect on our ability to compete in the marketplace.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we obtain regulatory approval in the United States, coverage and adequate reimbursement may not be available for any product candidates that we commercialize, which could make it difficult for us to sell profitably.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Even if we obtain BLA approval in the United States, market acceptance and sales of any product candidates that we commercialize may depend in part on the extent to which reimbursement for these product and related treatments will be available from third-party payors, including government health administration authorities, managed care organizations and other private health insurers. Third-party payors decide which therapies they will pay for and establish reimbursement levels. While no uniform policy for coverage and reimbursement exists in the United States, third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own coverage and reimbursement policies. However, decisions regarding the extent of coverage and amount of reimbursement to be provided for any product candidates that we develop will be made on a payor-by-payor basis. Therefore, one payor&#x2019;s determination to provide coverage for a product does not assure that other payors will also provide coverage, and adequate reimbursement, for the product. Additionally, a third-party payor&#x2019;s decision to provide coverage for a therapy does not imply that an adequate reimbursement rate will be approved. Each payor determines whether or not it will provide coverage for a therapy, what amount it will pay the manufacturer for the therapy and on what tier of its formulary it will be placed. The position on a payor&#x2019;s list of covered drugs and biological products, or formulary, generally determines the co-payment that a patient will need to make to obtain the therapy and can strongly influence the adoption of such therapy by patients and physicians. Patients who are prescribed treatments for their conditions and providers prescribing such services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Patients are unlikely to use our products unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our products. In addition, because certain of our product candidates are physician-administered, separate reimbursement for the product itself may or may not be available. Instead, the administering physician may only be reimbursed for providing the treatment or procedure in which our product is used.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. We cannot be sure that coverage and reimbursement will be available for any product that we commercialize and, if reimbursement is available, what the level of reimbursement will be. Inadequate coverage and reimbursement may impact the demand for, or the price of, any product for which we obtain marketing approval. If coverage and adequate reimbursement are not available, or are available only at limited levels, we may not be able to successfully commercialize any product candidates that we develop.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Healthcare legislative reform measures may have a negative impact on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the United States and some foreign jurisdictions, there have been, and we expect there will continue to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any product candidates for which we obtain marketing approval. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">95</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect that additional U.S. federal healthcare reform measures will be adopted in the future,  any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for our current or any future product candidates or additional pricing pressures. It is possible that additional governmental action is taken in response to the COVID-19 pandemic. For example, on June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively the ACA, is unconstitutional in its entirety because the &#x201c;individual mandate&#x201d; was repealed by Congress. Thus, the ACA will remain in effect in its current form. Additionally, in August 2011, the President signed into law the Budget Control Act of 2011, as amended, which, among other things, included aggregate reductions to Medicare payments to providers of 2% per fiscal year, which began in 2013 and, following passage of subsequent legislation, including the Bipartisan Budget Act of 2018, will continue through 2031.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, as a result of litigation challenging the interim final rule implementing President Trump&#x2019;s Most Favored Nation executive order, which would tie Medicare Part B payments for certain physician-administered drugs to the lowest price paid in other economically advanced countries, on December 27, 2021, the Centers for Medicare &amp; Medicaid Services, or CMS, published a final rule that rescinds the Most Favored Nation Model interim final rule. In July 2021, the Biden administration released an executive order, &#x201c;Promoting Competition in the American Economy,&#x201d; with multiple provisions aimed at prescription drugs. In response to President Biden&#x2019;s executive order, on September 9, 2021,  HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue to advance these principles. Further, with passage of the Inflation Reduction Act in August 2022, Congress authorized Medicare, beginning in 2026, to negotiate lower prices for certain high Medicare expenditure single-source drug and biologic products that do not have competing generics or biosimilars. This provision is limited in terms of the number of pharmaceuticals whose prices can be negotiated in any given year, and it only applies to drug products that have been approved for at least 9 years and biologics that have been licensed for 13 years. Drugs and biologics that have been approved for a single rare disease or condition and for which the only approved indication is for such disease are categorically excluded from price negotiation. Nonetheless, since CMS may establish a maximum price for these products in price negotiations, we would be fully at risk of government action if our products are the subject of Medicare price negotiations. Moreover, given the risk that could be the case, these provisions of the IRA may also further heighten the risk that we would not be able to achieve the expected return on our drug products or full value of our patents protecting our products if prices are set after such products have been on the market for nine years. In addition, the new legislation provides that if pharmaceutical companies raise prices in Medicare faster than the rate of inflation, they must pay rebates back to the government for the difference.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The new law also caps Medicare out-of-pocket drug costs at an estimated $4,000 a year in 2024 and, thereafter beginning in 2025, at $2,000 a year. In addition, the IRA potentially raises legal risks with respect to individuals participating in a Medicare Part D prescription drug plan who may experience a gap in coverage if they required coverage above their initial annual coverage limit before they reached the higher threshold, or &#x201c;catastrophic period&#x201d; of the plan. Individuals requiring services exceeding the initial annual coverage limit and below the catastrophic period, must pay 100% of the cost of their prescriptions until they reach the catastrophic period. Among other things, the IRA contains many provisions aimed at reducing this financial burden on individuals by reducing the co-insurance and co-payment costs, expanding eligibility for lower income subsidy plans, and price caps on annual out-of-pocket expenses, each of which could have potential pricing and reporting implications.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accordingly, while it is currently unclear how the IRA will be effectuated, we cannot predict with certainty what impact any federal or state health reforms will have on us, but such changes could impose new or more stringent regulatory requirements on our activities or result in reduced reimbursement for our products, any of which could adversely affect our business, results of operations and financial condition.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For additional information regarding other healthcare legislative reform measures, see the section titled &#x201c;Business&#x2014;Government Regulation and Product Approval&#x2014;Healthcare Reform&#x201d;.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Should we seek and obtain BLA approval in the United States, we expect that these and other healthcare reform measures that may be adopted in the future may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product, which could have an adverse effect on demand for our product candidates. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">96</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are subject to anti-corruption, anti-bribery, anti-money laundering, and similar laws, and non-compliance with such laws can subject us to criminal and/or civil liability and harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are subject to the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act and other anti-bribery and anti-money laundering laws in the countries in which we conduct activities. Anti-corruption and anti-bribery laws have been enforced aggressively in recent years and are interpreted broadly to generally prohibit companies and their employees and third-party intermediaries from authorizing, offering or providing, directly or indirectly, improper payments or benefits to recipients in the public or private sector. We interact with officials and employees of government agencies and government-affiliated hospitals, universities and other organizations. In addition, we may engage third-party intermediaries to promote our clinical research activities abroad or to obtain necessary permits, licenses and other regulatory approvals. We can be held liable for the corrupt or other illegal activities of these third-party intermediaries, our employees, representatives, contractors, collaborators and agents, even if we do not explicitly authorize such activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">While we have policies and procedures to address compliance with such laws in the United States, we cannot assure you that all of our employees and agents will not take actions in violation of our policies and applicable law, for which we may be ultimately held responsible. Detecting, investigating and resolving actual or alleged violations can require a significant diversion of time, resources and attention from senior management. In addition, noncompliance with anti-corruption, anti-bribery or anti-money laundering laws could subject us to whistleblower complaints, investigations, sanctions, settlements, prosecution, other enforcement actions, disgorgement of profits, significant fines, damages, other civil and criminal penalties or injunctions, suspension and/or debarment from contracting with certain persons, the loss of export privileges, reputational harm, adverse media coverage and other collateral consequences. If any subpoenas or investigations are launched, or governmental or other sanctions are imposed, or if we do not prevail in any possible civil or criminal litigation, our business, financial condition, results of operations and prospects could be materially harmed. In addition, responding to any action will likely result in a materially significant diversion of management&#x2019;s attention and resources and significant defense costs and other professional fees. Enforcement actions and sanctions could further harm our business, reputation, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Our Dependence on Third Parties</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We rely on third parties to produce clinical and commercial supplies of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are currently conducting process development and manufacturing material for product candidates of three different modalities: mAbs, HCMV-based vaccines and siRNAs. Except for limited process development and quality control testing capabilities in certain of our facilities, we do not own or operate facilities for full process development or product manufacturing, storage and distribution, or testing. We are dependent on third parties to develop the manufacturing process and manufacture the clinical supplies of our current and any future product candidates. We have established relationships with multiple contract development and manufacturing organizations, or CDMOs, that have produced material to support our preclinical, Phase 1, 2, and 3 clinical trials. We have limited experience manufacturing our product candidates on a commercial scale, and we do not yet have sufficient information to reliably estimate the cost of the commercial manufacturing of our future product candidates. Certain of our product candidates may have to compete with existing and future products, such as the annual flu vaccine or any current or future COVID-19 vaccine, that may have a lower price point. The actual cost to manufacture our product candidates could materially and adversely affect the commercial viability of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The facilities used by third parties to develop and manufacture our product candidates must be approved by the FDA or other regulatory authorities pursuant to inspections that will be conducted after we submit our NDA or BLA to the FDA or foreign marketing application to the appropriate regulatory authority. We do not control the manufacturing process of, and are completely dependent on, third-party manufacturers for compliance with the cGMP requirements. If our third-party manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or others, we will not be able to secure and/or maintain regulatory approval for our product candidates. In addition, we have no control over the ability of our third-party manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved. Any significant delay in the supply of a product candidate, or the raw material components thereof, for an ongoing clinical trial due to the need to replace a third-party manufacturer could considerably delay completion of our clinical trials, product testing and potential regulatory approval of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also intend to rely on third-party manufacturers to supply us with sufficient quantities of our product candidates to be used, if approved, for commercialization. There is, however, no assurance that our third-party manufacturers will meet our working assumptions of manufacturing titer and yield per batch of our product candidates or consistently manufacture product meeting our quality requirements. Any reduction in anticipated manufacturing titer, yield per batch or batch success rates may adversely impact</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">97</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to meet market demand for any approved product. Furthermore, if we are not able to produce supply at low enough costs, it would negatively impact our ability to generate revenue, harm our reputation, and could have an adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, we currently rely on strategic collaborators and foreign CDMOs, including a CDMO in China, which we, in part, rely on for the clinical development, manufacturing, and commercialization of our proprietary antibodies developed for SARS-CoV-2, and will likely continue to rely on foreign CDMOs in the future. Foreign CDMOs may be subject to trade restrictions and other foreign regulatory requirements which could increase the cost or reduce the supply of material available to us, delay the procurement of such material or have an adverse effect on our ability to secure significant commitments from governments to purchase our potential therapies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, the biopharmaceutical industry in China is strictly regulated by the Chinese government. Changes to Chinese regulations or government policies affecting biopharmaceutical companies are unpredictable and may have a material adverse effect on our collaborators in China which could have an adverse effect on our business, financial condition, results of operations and prospects. Evolving changes in China&#x2019;s public health, economic, political, and social conditions and the uncertainty around China&#x2019;s relationship with other governments, such as the United States and the U.K., could also negatively impact our ability to manufacture our product candidates for our planned clinical trials or have an adverse effect on our ability to secure government funding, which could adversely affect our financial condition and cause us to delay our clinical development programs.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further, our reliance on third-party suppliers and manufacturers entails risks to which we would not be exposed to or that may be reduced if we conducted process development or manufactured product candidates ourselves, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delay or inability to procure or expand sufficient manufacturing capacity;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">delays in process development; </span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">issues related to scale-up of manufacturing; </span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">excess manufacturing capacity due to insufficient market demand for our product candidates and responsibility for the associated costs;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">costs and validation of new equipment and facilities required for scale-up; </span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">inability of our third-party manufacturers to execute process development, manufacturing, technology transfers, manufacturing procedures and other logistical support requirements appropriately or on a timely basis; </span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">inability to negotiate development and manufacturing agreements with third parties under commercially reasonable terms, if at all; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">breach, termination or nonrenewal of development and manufacturing agreements with third parties in a manner or at a time that is costly or damaging to us; </span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reliance on single sources for product raw materials or components; </span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">lack of qualified backup suppliers for those raw materials or components that are currently purchased from a sole or single-source supplier; </span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">lack of ownership to the intellectual property rights to any improvements made by our third parties in the manufacturing process for our product candidates; </span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">price increases or decreased availability of product raw materials or components;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">disruptions to operations of our third-party manufacturers or suppliers by conditions unrelated to our business or operations, including supply chain issues, capacity constraints, transportation and labor disruptions, global competition for resources, the bankruptcy of the manufacturer and/or general economic conditions, heightened inflation, interest rate and currency rate fluctuations, and economic slowdown or recession; </span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">disruptions caused by geopolitical events, including civil or political unrest (such as the ongoing war between Ukraine and Russia), terrorism, insurrection or war, man-made or natural disasters or public health pandemics or epidemics, including, for example, the COVID-19 pandemic; and</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">carrier disruptions or increased costs that are beyond our control, including increases in material, labor or other manufacturing-related costs or higher supply chain logistics costs. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">98</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may be unable to obtain product raw materials or components for an indeterminate period of time if any of third-party suppliers and manufacturers were to cease or interrupt production or otherwise fail to supply these materials or components to us for any reason, including due to regulatory requirements or actions (including recalls), adverse financial developments at or affecting the supplier or manufacturer, failure by the supplier or manufacturer to comply with cGMPs, contaminations, business interruptions, or labor shortages or disputes. Suppliers may extend lead times, limit supplies or increase prices due to capacity constraints or other factors beyond our control. We cannot be sure that single source suppliers for our product raw materials or components will remain in business or that they will not be purchased by one of our competitors or another company that is not interested in continuing to produce these raw materials or components for our intended purpose. In addition, the lead time needed to establish a relationship with a new supplier can be lengthy and we may experience delays in meeting demand in the event we must switch to a new supplier. The time and effort to qualify a new supplier could result in manufacturing delays, additional costs, diversion of resources or reduced manufacturing yields, any of which would negatively impact our operating results.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furthermore, there are a limited number of suppliers and manufacturers that supply synthetic siRNAs. We currently rely on a limited number of suppliers and CDMOs for our supply of synthetic siRNAs. There are risks inherent in pharmaceutical manufacturing that could affect the ability of our CDMOs to meet our delivery time requirements or provide adequate amounts of synthetic siRNAs to meet our needs. Included in these risks are potential extended lead times, delays or shortages of raw materials and component including as a result of the COVID-19 pandemic, synthesis and purification failures and/or contamination during the manufacturing process, as well as other issues with the CDMO&#x2019;s facility and ability to comply with the applicable manufacturing requirements, including cGMP requirements which could result in unusable product. This would cause delays in our manufacturing timelines and ultimately delay our clinical trials and potentially put at risk commercial supply, as well as result in additional expense to us. To fulfill our siRNA supply requirements, we may need to secure alternative suppliers of synthetic siRNAs and/or key raw materials and components, and such alternative suppliers are limited and may not be readily available, or we may be unable to enter into agreements with them on reasonable terms and in a timely manner.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, manufacturers may have little or no experience with viral vector products and therefore may require a significant amount of support from us in order to implement and maintain the infrastructure and processes required to manufacture our HCMV vector-based product candidates. The challenges to HCMV-based vaccine manufacturing include the large size of the virus, which precludes terminal sterile filtration, and that some vectors have a restricted growth phenotype in cells that reduces yields during manufacturing. To address these challenges, we have made significant internal investments in process development and scale-up, largely funded by grants from the Bill &amp; Melinda Gates Foundation. We have established a cGMP process in support of Phase 1 and Phase 2 clinical trials that has been successfully transferred and executed at a CDMO specializing in live vaccine manufacturing. However, the existing process will require additional process development and scale-up for later stages of clinical development and commercial supply. To fulfill our HCMV supply requirements, we may need to secure alternative suppliers of viral vector products and/or key raw materials and components, and such alternative suppliers may not have the manufacturing experience or capacity required for HCMV-based vaccine manufacturing, or we may be unable to enter into agreements with them on reasonable terms and in a timely manner.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any of these events could lead to clinical trial delays or failure to obtain regulatory approval or impact our ability to successfully commercialize our current or any future product candidates once approved. Some of these events could be the basis for FDA action, including injunction, request for recall, seizure or total or partial suspension of production. Any such recall, seizure or suspension could adversely impact our business in a variety of ways, including having to absorb related manufacturing and overhead costs as well as potential inventory write-offs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Changes in U.S. and international trade policies, particularly with respect to China, may adversely impact our business and operating results.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The U.S. government has made statements and taken actions that have led to certain changes and may lead to additional changes to U.S. and international trade policies, including imposing several rounds of tariffs affecting certain products manufactured in China. In addition, the Chinese government took certain actions, including tariffs, which affect certain products manufactured in the U.S. It is unknown whether and to what extent new tariffs (or other new laws or regulations) will be adopted, or the effect that any such actions would have on us or our industry. Any unfavorable government policies on international trade, such as export controls, capital controls or tariffs, may affect the demand for our product candidates, the competitive position of our product candidates, and import or export of raw materials and product used in our drug development activities and commercial manufacturing, particularly with respect to raw materials and product that we import from China, including pursuant to our development and manufacturing arrangements with WuXi Biologics. If any new tariffs, export controls, legislation and/or regulations are implemented, or if existing trade agreements are renegotiated or if the U.S. government takes retaliatory trade actions due to the recent U.S.-China trade tension, such changes could have an adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our business involves the use of hazardous materials and we and our third-party manufacturers and suppliers must comply with environmental, health and safety laws and regulations, which can be expensive and restrict how we do, or interrupt our, business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our research and development activities and the activities of our third-party manufacturers and suppliers involve the generation, storage, use and disposal of hazardous materials, including the components of our product candidates and other hazardous compounds and wastes. We and our manufacturers and suppliers are subject to environmental, health and safety laws and regulations governing, among other matters, the use, manufacture, generation, storage, handling, transportation, discharge and disposal of these hazardous materials and wastes and worker health and safety. In some cases, these hazardous materials and various wastes resulting from their use are stored at our and our manufacturers&#x2019; facilities pending their use and disposal. We cannot eliminate the risk of contamination or injury, which could result in an interruption of our commercialization efforts, research and development efforts and business operations, damages and significant cleanup costs and liabilities under applicable environmental, health and safety laws and regulations. We also cannot guarantee that the safety procedures utilized by our third-party manufacturers for handling and disposing of these materials and wastes generally comply with the standards prescribed by these laws and regulations. We may be held liable for any resulting damages costs or liabilities, which could exceed our resources, and state or federal or other applicable authorities may curtail our use of certain materials and/or interrupt our business operations. Furthermore, environmental, health and safety laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. Failure to comply with these environmental, health and safety laws and regulations may result in substantial fines, penalties or other sanctions. We do not currently carry hazardous waste insurance coverage.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We rely on third parties to conduct, supervise and monitor our preclinical studies and clinical trials, and if those third parties perform in an unsatisfactory manner, it may harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We rely on CROs and clinical trial sites to ensure the proper and timely conduct of our preclinical studies and clinical trials, and we expect to have limited influence over their actual performance. We rely on CROs to monitor and manage data for our clinical programs, as well as the execution of future preclinical studies. We expect to control only certain aspects of our CROs&#x2019; activities. Nevertheless, we will be responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on the CROs does not relieve us of our regulatory responsibilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We and our CROs are required to comply with the good laboratory practices, or GLPs, and GCPs, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities in the form of International Conference on Harmonization guidelines for any of our product candidates that are in preclinical and clinical development. The regulatory authorities enforce GCPs through periodic inspections of trial sponsors, principal investigators and clinical trial sites. Although we rely on CROs to conduct GCP-compliant clinical trials, we remain responsible for ensuring that each of our GLP preclinical studies and clinical trials is conducted in accordance with its investigational plan and protocol and applicable laws and regulations. If we or our CROs fail to comply with GCPs, the clinical data generated in our clinical trials may be deemed unreliable, and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. Accordingly, if our CROs fail to comply with these regulations or fail to recruit a sufficient number of subjects, we may be required to repeat clinical trials, which would delay the regulatory approval process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our reliance on third parties to conduct clinical trials will result in less direct control over the management of data developed through clinical trials than would be the case if we were relying entirely upon our own staff. Communicating with CROs and other third parties can be challenging, potentially leading to mistakes as well as difficulties in coordinating activities. If our CROs do not successfully carry out their contractual duties or obligations, fail to meet expected deadlines or fail to comply with regulatory requirements, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for any other reasons, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize, any product candidate that we develop. As a result, our financial results and the commercial prospects for any product candidate that we develop would be harmed, our costs could increase, and our ability to generate revenue could be delayed. While we will have agreements governing their activities, our CROs will not be our employees and we will not control whether or not they devote sufficient time and resources to our future clinical and preclinical programs. These CROs may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other product development activities which could harm our business. We face the risk of potential unauthorized disclosure or misappropriation of our intellectual property by CROs, which may reduce our trade secret protection and allow our potential competitors to access and exploit our proprietary technology.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If our relationship with any of these CROs terminates, we may not be able to enter into arrangements with alternative CROs or do so on commercially reasonable terms. Switching or adding additional CROs involves substantial cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can negatively impact our ability to meet our desired clinical development timelines. While we intend to carefully manage our relationships with our CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a negative impact on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA. The FDA may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the trial. The FDA may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval or rejection of our marketing applications by the FDA and may ultimately lead to the denial of marketing approval of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Our Intellectual Property</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we breach our license agreements or any of the other agreements under which we acquired, or will acquire, the intellectual property rights to our product candidates, we could lose the ability to continue the development and commercialization of the related product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We license a number of technologies to form our antibody platform and T cell platform, and the technology we use in our siRNA platform is licensed from Alnylam Pharmaceuticals, Inc. We have also developed certain product candidates using intellectual property licensed from third parties. A core element of our business strategy includes continuing to acquire or in-license additional technologies or product candidates for the treatment and prevention of serious infectious diseases.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we fail to meet our obligations under these agreements, our licensors may have the right to terminate our licenses. If any of our license agreements are terminated, and we lose our intellectual property rights under such agreements, this may result in a complete termination of our product development and any commercialization efforts for the product candidates which we are developing under such agreements. While we would expect to exercise all rights and remedies available to us, including seeking to cure any breach by us, and otherwise seek to preserve our rights under such agreements, we may not be able to do so in a timely manner, at an acceptable cost or at all. We may also be subject to risks related to disputes between us and our licensors regarding the intellectual property subject to a license agreement.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we are unable to obtain and maintain patent protection for our product candidates and technology, or if the scope of the patent protection obtained is not sufficiently broad or robust, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to successfully commercialize our product candidates and technology may be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our success depends, in large part, on our ability to obtain and maintain patent protection in the United States and other countries with respect to our product candidates and our technology. We and our licensors have sought, and intend to seek, to protect our proprietary position by filing patent applications in the United States and abroad related to our product candidates and our technology that are important to our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has, in recent years, been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our technology or product candidates or which effectively prevent others from commercializing competitive technologies and product candidates. Because patent applications in the United States and most other countries are confidential for a period of time after filing, and some remain so until issued, we cannot be certain that we or our licensors were the first to file a patent application relating to any particular aspect of a product candidate. Furthermore, if third parties have filed such patent applications with a priority date before March 16, 2013, an interference proceeding in the United States can be initiated by such third party, or by the U.S. Patent and Trademark Office, or USPTO, itself, to determine who was the first to invent any of the subject matter covered by the claims of our patent applications or issued patents.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The patent prosecution process is expensive, time-consuming and complex, and we may not be able to file, prosecute, maintain, enforce or license all necessary or desirable patent applications or patents at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. In addition, changes in either the patent laws or interpretation of the patent laws in the United States could increase the uncertainties and costs surrounding the prosecution of patent applications and the term, enforcement or defense of issued patents. Similarly, changes in patent law and regulations in other countries or jurisdictions, changes in the governmental bodies that enforce them or changes in how the relevant governmental authority enforces patent laws or regulations may weaken our ability to obtain new patents or to enforce patents that we own or have licensed or that we may obtain in the future.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We or our licensors have not pursued or maintained, and may not pursue or maintain in the future, patent protection for our product candidates in every country or territory in which we may sell our products, if approved. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from infringing our patents in all countries outside of the United States, or from selling or importing products that infringe our patents in and into the United States or other jurisdictions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Moreover, the coverage claimed in a patent application can be significantly reduced before the patent is issued and its scope can be reinterpreted after issuance. Even if the patent applications we license or own do issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us or otherwise provide us with any competitive advantage. Our competitors or other third parties may be able to circumvent our patents by developing similar or alternative products in a non-infringing manner.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and product candidates. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. In addition, if the breadth or strength of protection provided by the patents and patent applications we hold with respect to our product candidates is threatened, it could dissuade companies from collaborating with us to develop, and threaten our ability to commercialize, our product candidates, or could result in licensees seeking release from their license agreements.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furthermore, our owned and in-licensed patents may be subject to a reservation of rights by one or more third parties. For example, the research resulting in certain of our owned and in-licensed patent rights and technology was funded in part by the U.S. government. As a result, the government may have certain rights, or march-in rights, to such patent rights and technology. When new technologies are developed with government funding, the government generally obtains certain rights in any resulting patents, including a nonexclusive license authorizing the government to use the invention for noncommercial purposes. These rights may permit the government to disclose our confidential information to third parties and to exercise march-in rights to use or allow third</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">102</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">parties to use our licensed technology. The government can exercise its march-in rights if it determines that action is necessary because we fail to achieve practical application of the government-funded technology, because action is necessary to alleviate health or safety needs, to meet requirements of federal regulations, or to give preference to U.S. industry. In addition, our rights in such inventions may be subject to certain requirements to manufacture products embodying such inventions in the United States. Any exercise by the government of such rights could harm our competitive position, business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Obtaining and maintaining our patent rights depends on compliance with various procedural, document submission, fee payment and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. In addition, periodic maintenance fees, renewal fees, annuity fees and various other government fees on patents and/or patent applications will have to be paid to the USPTO and various government patent agencies outside of the United States over the lifetime of our owned and licensed patents and/or applications and any patent rights we may own or license in the future. We rely on our service providers or our licensors to pay these fees. The USPTO and various non-U.S. government patent agencies require compliance with several procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and we are also dependent on our licensors to take the necessary action to comply with these requirements with respect to our licensed intellectual property. Noncompliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, nonpayment of fees and failure to properly legalize and submit formal documents. If we or our licensors fail to maintain the patents and patent applications covering our product candidates or technologies, including as a result of geopolitical events such as civil or political unrest (including the ongoing war between Ukraine and Russia), we may not be able to use such patents and patent applications or stop a competitor from marketing products that are the same as or similar to our product candidates, which would have an adverse effect on our business. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market and this circumstance could harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, if we fail to apply for applicable patent term extensions or adjustments, we will have a more limited time during which we can enforce our granted patent rights. In addition, if we are responsible for patent prosecution and maintenance of patent rights in-licensed to us or out-licensed by us, any of the foregoing could expose us to liability to the applicable patent owner or licensee, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Patent terms may be inadequate to protect our competitive position on our product candidates or any products approved in the future for an adequate amount of time and additional competitors could enter the market with generic or biosimilar versions of such products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after its first effective filing date. Although various extensions may be available, the life of a patent and the protection it affords is limited. In addition, although upon issuance in the United States a patent&#x2019;s life can be increased based on certain delays caused by the USPTO, this increase can be reduced or eliminated based on certain delays caused by the patent applicant during patent prosecution. If we do not have sufficient patent life to protect our products, our business and results of operations could be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Given the amount of time required for the development, testing and regulatory review of our product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. We expect to seek extensions of patent terms in the United States and, if available, in other countries where we have or will obtain patent rights. In the United States, the Hatch-Waxman Act permits a patent term extension of up to five years beyond the normal expiration of the patent, provided that the patent is not enforceable for more than 14 years from the date of drug approval, which is limited to the approved indication (or any additional indications approved during the period of extension). Furthermore, only one patent per approved product can be extended and only those claims covering the approved product, a method for using it or a method for manufacturing it may be extended. However, the applicable authorities, including the FDA and the USPTO in the United States, and any equivalent regulatory authority in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more limited extensions than we request. If this occurs, our competitors may be able to take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">103</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Also, there are detailed rules and requirements regarding the patents that may be submitted to the FDA for listing in the FDA publication, &#x201c;Approved Drug Products with Therapeutic Equivalence Evaluations,&#x201d; known as the Orange Book. We may be unable to obtain patents covering our product candidates that contain one or more claims that satisfy the requirements for listing in the Orange Book. Even if we submit a patent for listing in the Orange Book, the FDA may decline to list the patent, or a manufacturer of generic drugs may challenge the listing. If one of our product candidates is approved and a patent covering that product candidate is not listed in the Orange Book, a manufacturer of generic drugs would not have to provide advance notice to us of any ANDA filed with the FDA to obtain permission to sell a generic version of such product candidate. We cannot predict which, if any, patents in our current portfolio or patents we may obtain in the future will be eligible for listing in the Orange Book, how any generic competitor would address such patents, whether we would sue on any such patents or the outcome of any such suit. For additional information regarding the Hatch-Waxman Act and exclusivity, see the section titled &#x201c;Business&#x2014;Government Regulation and Product Approval&#x2014;Hatch-Waxman Amendments and Exclusivity&#x201d;.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may not be successful in securing or maintaining proprietary patent protection for products and technologies we develop or license. Moreover, if any of our owned or in-licensed patents are successfully challenged by litigation, the affected product could immediately face competition and its sales would likely decline rapidly. Any of the foregoing could harm our competitive position, business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a negative impact on the success of our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our commercial success depends, in part, upon our ability and the ability of others with whom we may collaborate to develop, manufacture, market and sell our current and any future product candidates and use our proprietary technologies without infringing, misappropriating or otherwise violating the proprietary rights and intellectual property of third parties. The biotechnology and pharmaceutical industries are characterized by extensive and complex litigation regarding patents and other intellectual property rights. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing sotrovimab and other product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that sotrovimab and other product candidates may give rise to claims of infringement of the patent rights of others. We may in the future become party to, or be threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our current and any future product candidates and technology, including interference proceedings, derivation proceedings, post grant review and inter partes review before the USPTO. If we are found to infringe a third party&#x2019;s valid and enforceable intellectual property rights, we could be required to obtain a license from such third party to continue developing, manufacturing and marketing our product candidate(s) and technology. Under any such license, we would most likely be required to pay various types of fees, milestones, royalties or other amounts. Moreover, we may not be able to obtain any required license on commercially reasonable terms or at all, and if such an instance arises, our ability to commercialize our product candidates may be impaired or delayed, which could in turn significantly harm our business. Parties making claims against us may also seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The licensing or acquisition of third-party intellectual property rights is a competitive area, and more established companies may also pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of the relevant program or product candidate, which could have an adverse effect on our business, financial condition, results of operations and prospects. Furthermore, even if we were able to obtain a license, it could be nonexclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us, and it could require us to make substantial licensing and royalty payments. We could be forced, including by court order, to cease developing, manufacturing and commercializing the infringing technology or product candidate. We may also have to redesign our products, which may not be commercially or technically feasible or require substantial time and expense. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#x2019; fees, if we are found to have willfully infringed a patent or other intellectual property right. We may be required to indemnify collaborators or contractors against such claims. A finding of infringement could prevent us from manufacturing and commercializing our current or any future product candidates or force us to cease some or all of our business operations, which could harm our business. Even if we are successful in defending against such claims, litigation can be expensive and time-consuming and would divert management&#x2019;s attention from our core business. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">104</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have an adverse effect on the price of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may be subject to claims asserting that our employees, consultants or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain of our employees, consultants or advisors are currently, or were previously, employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these individuals or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#x2019;s current or former employer. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, we may in the future be subject to claims by our former employees or consultants asserting an ownership right in our patents or patent applications as a result of the work they performed on our behalf. For example, we may have inventorship disputes arise from conflicting obligations of consultants or others who are involved in developing our product candidates. Although it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own, and we cannot be certain that our agreements with such parties will be upheld in the face of a potential challenge or that they will not be breached, for which we may not have an adequate remedy. The assignment of intellectual property rights may not be self-executing or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may be involved in lawsuits to protect or enforce our patents, the patents of our licensors or our other intellectual property rights, which could be expensive, time-consuming and unsuccessful.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Competitors may infringe, misappropriate or otherwise violate our patents, the patents of our licensors or our other intellectual property rights. To counter infringement or unauthorized use, we may be required to file legal claims, which can be expensive and time-consuming and are likely to divert significant resources from our core business, including distracting our technical and management personnel from their normal responsibilities.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, in an infringement proceeding, a court may decide that a patent of ours or our licensors is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our owned or licensed patents at risk of being invalidated or interpreted narrowly and could put our owned or licensed patent applications at risk of not issuing. The initiation of a claim against a third party might also cause the third party to bring counterclaims against us, such as claims asserting that our patent rights are invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, non-enablement or lack of statutory subject matter. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant material information from the USPTO, or made a materially misleading statement, during prosecution. Third parties may also raise similar validity claims before the USPTO in post-grant proceedings such as ex parte reexaminations, inter partes review, post-grant review, or oppositions or similar proceedings outside of the United States, in parallel with litigation or even outside the context of litigation. Third parties may also challenge inventorship through a derivation proceeding or other litigation proceeding challenging inventorship, which can include claims of misappropriation of intellectual property, filing a patent application without authorization of the true inventor, not listing inventors, or listing non-inventors as inventors. The outcome following legal assertions of invalidity and unenforceability is unpredictable. We cannot be certain that there is or will be no invalidating prior art, of which we and the patent examiner were unaware during prosecution. For the patents and patent applications that we have licensed, we may have limited or no right to participate in the defense of any licensed patents against challenge by a third party. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of any future patent protection on our current or future product candidates. Such a loss of patent protection could harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">105</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States. Our business could be harmed if in litigation the prevailing party does not offer us a license, or if the license offered as a result is not on commercially reasonable terms. Any litigation or other proceedings to enforce our intellectual property rights may fail and, even if successful, may result in substantial costs and distract our management and other employees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have an adverse effect on the price of our common stock.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing upon or misappropriating or from successfully challenging our intellectual property rights. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have an adverse effect on our ability to compete in the marketplace.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We may not be able to protect our intellectual property rights throughout the world, which could negatively impact our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Filing, prosecuting and defending patents covering our current and any future product candidates and technology platforms in all countries throughout the world would be prohibitively expensive. Competitors may use our technologies in jurisdictions where we or our licensors have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we may obtain patent protection but where patent enforcement is not as strong as that in the United States. These products may compete with our products in jurisdictions where we do not have any issued or licensed patents, and any future patent claims or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issued patents may be challenged by third parties in the courts or patent offices in various countries throughout the world. Invalidation proceedings may result in patent claims being narrowed, invalidated or held unenforceable. Uncertainties regarding the outcome of such proceedings, as well as any resulting losses of patent protection, could harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our intellectual property and proprietary rights generally. Proceedings to enforce our intellectual property and proprietary rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. Some countries do not enforce patents related to medical treatments, or limit enforceability in the case of a public emergency. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The intellectual property systems in other countries can be destabilized or unpredictable as a result of geopolitical events such as civil or political unrest (including the ongoing war between Ukraine and Russia). Therefore, during such geopolitical events, the ability to obtain, retain and enforce intellectual property protection in the affected countries may be uncertain and evolve during the course of such geopolitical event. For example, as a result of the ongoing war between Ukraine and Russia, Russian officials have suggested that they may treat patents or patent applications owned by parties from certain countries, including the United States, as unenforceable and/or provide for zero compensation compulsory licenses to such patents or patent applications. Recent court decisions in Russia have raised questions about the strength of trademark protections in Russia. The U.S. government&#x2019;s response to geopolitical events may also negatively affect our ability to obtain, retain and enforce intellectual property protection in the affected countries. For example, the U.S. government has issued sanctions against Russia related to the ongoing war in Ukraine, and as a result of these sanctions, it may not be possible to pay fees necessary for prosecution and maintenance of Russian patent applications and patents,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">106</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">including Russian patent rights based on Eurasian patents, in the absence of licenses or exclusions set forth by the U.S. government authorizing transactions in connection with intellectual property. Payments for trademark protection may be similarly restricted. Failure to make such payments can result in the loss of intellectual property protection in Russia. The U.S. Department of the Treasury has issued General License No. 31, authorizing such transactions to allow filing, prosecution and maintenance of Russian patents and trademarks. Uncertainties regarding geopolitical events, including the ongoing war between Ukraine and Russia, as well as any resulting losses of intellectual property protection, could harm our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If the U.S. government, the World Trade Organization, or WTO, or other governmental body imposes an intellectual property rights waiver, our ability to successfully commercialize our COVID-19 product candidates and protect our related technology could be adversely affected.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On June 17, 2022, the WTO adopted a Ministerial Decision to waive certain intellectual property rights for COVID-19 vaccines. The waiver allows certain developing countries to permit the manufacture and use of COVID-19 vaccines without the consent of the patent holder(s) to the extent necessary to address the COVID-19 pandemic. The waiver is also expected to allow certain developing countries to permit compulsory licensing for the export of COVID-19 vaccines to certain other developing countries. The waiver is in effect initially for five years from the date of the Ministerial Decision and will be reviewed annually. The WTO is considering whether to extend the waiver to diagnostics and therapeutics. The WTO may consider additional waivers, the ultimate timing and scope of which, if approved, are unknown. The scope and timing of such extensions and/or additional waivers will likely be subject to extensive negotiations given the complexity of the matter, which may result in prolonged uncertainty, which could adversely affect our business. If a waiver covering COVID-19 treatments or prophylactics, such as sotrovimab and VIR-7832, is approved, our ability to successfully commercialize our COVID-19 product candidates and protect our related technology could be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The current waiver is the result of public health concerns from the COVID-19 pandemic and an effort to make vaccines more widely available worldwide. This waiver may also lead to similar waivers of intellectual property rights in the future in connection with other public health pandemics or epidemics or other situations of public health concern, or to waivers for treatments or prophylactics in addition to vaccines. Given that our business is focused on treating and preventing infectious diseases, there is a risk that our business and our ability to protect our technology could be adversely affected in situations beyond COVID-19.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to seeking intellectual property protection for our product candidates, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. Because we rely on third parties to help us discover, develop and manufacture our current and any future product candidates, or if we collaborate with third parties for the development, manufacturing or commercialization of our current or any future product candidates, we must, at times, share trade secrets with them. We may also conduct joint research and development programs that may require us to share trade secrets under the terms of our research and development collaborations or similar agreements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with our advisors, employees, third-party contractors and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of these parties to use or disclose our confidential information, including our trade secrets. We also enter into invention or patent assignment agreements with our employees, advisors and consultants. Despite our efforts to protect our trade secrets, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others or are disclosed or used in violation of these agreements. Moreover, we cannot guarantee that we have entered into such agreements with each party that may have or have had access to our confidential information or proprietary technology and processes. Monitoring unauthorized uses and disclosures is difficult, and we do not know whether the steps we have taken to protect our proprietary technologies will be effective. If any of the collaborators, scientific advisors, employees, contractors and consultants who are parties to these agreements breaches or violates the terms of any of these agreements, we may not have adequate remedies for any such breach or violation, and we could lose our trade secrets as a result. Moreover, if confidential information that is licensed or disclosed to us by our partners, collaborators or others is inadvertently disclosed or subject to a breach or violation, we may be exposed to liability to the owner of that confidential information. Enforcing a claim that a third-party illegally or unlawfully obtained and is using our trade secrets, like patent litigation, is expensive and time-consuming, and the outcome is unpredictable. In addition, courts outside of the United States are sometimes less willing to protect trade secrets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, our competitors may independently develop knowledge, methods and know-how equivalent to our trade secrets. Competitors could purchase our products and replicate some or all of the competitive advantages we derive from our development efforts for technologies on which we do not have patent protection. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">107</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">that technology or information to compete with us. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#x2019;s discovery of our trade secrets or other unauthorized use or disclosure could have an adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also seek to preserve the integrity and confidentiality of our data and other confidential information by maintaining physical security of our premises and physical and electronic security of our information technology systems. Additionally, the risk of cyber-attacks or other privacy or data security incidents may be heightened as a result of our work-from-home policies for most of our employees, which provides our employees the choice of working full time in the office, a hybrid approach, or full-time remote. A remote working environment may be less secure and more susceptible to hacking attacks. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and detecting the disclosure or misappropriation of confidential information and enforcing a claim that a party illegally disclosed or misappropriated confidential information is difficult, expensive and time-consuming, and the outcome is unpredictable. Further, we may not be able to obtain adequate remedies for any breach. In addition, our confidential information may otherwise become known or be independently discovered by competitors, in which case we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Any trademarks we may obtain may be infringed or successfully challenged, resulting in harm to our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We rely and expect to continue to rely on trademarks as one means to distinguish any of our products and product candidates that are approved for marketing from the products of our competitors. Additionally, the process of obtaining trademark protection is expensive and time-consuming, and we may not be able to prosecute all necessary or desirable trademark applications at a reasonable cost or in a timely manner or obtain trademark protection in all jurisdictions that we consider to be important to our business. Once we select trademarks and apply to register them, our trademark applications may not be approved. Third parties may oppose our trademark applications in certain jurisdictions, as in currently pending oppositions filed against EU-wide registration of our VIR Pharmaceuticals house mark and logo by Industria Quimica y Farmaceutica Vir. S.A., a Spanish company which claims exclusive rights in the term VIR in Spain and Portugal.  Third parties may also challenge our use of our trademarks. In the event that our trademarks are successfully challenged, we could be forced to rebrand our products, which could result in loss of brand recognition and could require us to devote resources to advertising and marketing new brands. Our competitors may infringe our trademarks, and we may not have adequate resources to enforce our trademarks.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, any proprietary product name we propose to use with our current or any other product candidate in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. The FDA typically conducts a review of proposed product names, including an evaluation of the potential for confusion with other product names. If the FDA objects to any of our proposed proprietary product names, we may be required to expend significant additional resources in an effort to identify a suitable proprietary product name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The exercise by the Bill &amp; Melinda Gates Foundation of its licenses to certain of our intellectual property and its development and commercialization of products that we are also developing and commercializing could have an adverse impact on our market position.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We entered into an amended and restated letter agreement with the Bill &amp; Melinda Gates Foundation, or the Gates Agreement, in January 2022, which amends and restates the letter agreement with the Bill &amp; Melinda Gates Foundation that we entered into in December 2016. In connection with the Gates Agreement, the Bill &amp; Melinda Gates Foundation purchased $20.0 million of shares of our convertible preferred stock which converted to shares of our common stock after our initial public offering and purchased $40.0 million of shares of our common stock. We are obligated to use the proceeds of the Bill &amp; Melinda Gates Foundation&#x2019;s investment in furtherance of its charitable purposes to perform certain activities set forth in the Gates Agreement. For additional information regarding our obligations under the Gates Agreement, see the section titled &#x201c;Business&#x2014;Our Collaboration, License and Grant Agreements&#x2014;Amended and Restated Letter Agreement with the Bill &amp; Melinda Gates Foundation&#x201d;.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we fail to comply with (i) our obligations to use the proceeds of the Bill &amp; Melinda Gates Foundation&#x2019;s investment for the purposes described in the paragraph above and to not use such proceeds for specified prohibited uses, (ii) specified reporting requirements or (iii) specified applicable laws, or if we materially breach our specified global access commitments (any such failure or material breach, a specified default), we will be obligated to redeem or arrange for a third party to purchase all of our stock purchased by the Bill &amp; Melinda Gates Foundation under the Gates Agreement, at the Bill &amp; Melinda Gates Foundation&#x2019;s request, at a price equal to the greater of (1) the original purchase price or (2) the fair market value, which amount may increase in the event of a sale of our company or all of our material assets relating to the Gates Agreement. Additionally, if a specified default occurs or if we are unable or unwilling to continue the HIV program, tuberculosis program, vaccinal antibody program or, if applicable, the mutually agreed additional program (except for scientific or technical reasons), or if we institute bankruptcy or insolvency proceedings, then the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">108</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Bill &amp; Melinda Gates Foundation will have the right to exercise a non-exclusive, fully-paid license (with the right to sublicense) under our intellectual property to the extent necessary to use, make and sell products arising from such programs, in each case solely to the extent necessary to benefit people in the developing countries in furtherance of the Bill &amp; Melinda Gates Foundation&#x2019;s charitable purpose.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The exercise by the Bill &amp; Melinda Gates Foundation of any of its non-exclusive licenses to certain of our intellectual property (or its right to obtain such licenses), and its development and commercialization of product candidates and products that we are also developing and commercializing, could have an adverse impact on our market position.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Our Business Operations, Employee Matters and Managing Growth</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are highly dependent on our key personnel, and if we are not able to retain these members of our management team or recruit and retain additional management, clinical and scientific personnel, our business will be harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are highly dependent on our management, scientific and medical personnel. Our key personnel may currently terminate their employment with us at any time. The loss of the services of any of these persons could impede the achievement of our research, development and commercialization objectives. Additionally, we do not currently maintain &#x201c;key person&#x201d; life insurance on the lives of our executives or any of our employees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We announced a Chief Executive Officer transition in January 2023 that will be effective April 3, 2023 and announced a Chief Financial Officer transition in February 2023 that will be effective March 27, 2023. Management transitions may create uncertainty and involve a diversion of resources and management attention, be disruptive to our daily operations or impact public or market perception, any of which could negatively impact our ability to operate effectively or execute our strategies.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Recruiting and retaining other senior executives, qualified scientific and clinical personnel and, if we progress the development of any of our product candidates, commercialization, manufacturing and sales and marketing personnel, will be critical to our success. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize our product candidates. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. Macroeconomic conditions, specifically labor shortages, increased competition for employees and wage inflation, could also have a material impact on our ability to attract and retain talent, our turnover rate and the cost of operating our business. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high-quality personnel, our ability to pursue our growth strategy will be limited.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our future performance will also depend, in part, on our ability to successfully integrate newly hired executive officers into our management team and our ability to develop an effective working relationship among senior management. Our failure to integrate these individuals and create effective working relationships among them and other members of management could result in inefficiencies in the development and commercialization of our product candidates, harming future regulatory approvals, sales of our product candidates and our results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have in the past and may in the future acquire or invest in other companies or technologies, which could divert our management&#x2019;s attention, result in dilution to our stockholders and otherwise disrupt our operations and adversely affect our operating results.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have in the past and may in the future seek to acquire or invest in additional businesses and/or technologies that we believe complement or expand our product candidates, enhance our technical capabilities or otherwise offer growth opportunities in the United States and internationally. The pursuit of potential acquisitions and investments may divert the attention of management and cause us to incur various expenses in identifying, investigating and pursuing suitable acquisitions, whether or not they are consummated. In addition, we are exposed to market risks related to our investments, including changes in fair value of equity securities we hold, which is discussed in greater detail under Item 7A. Quantitative and Qualitative Disclosures About Market Risk in this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For example, we acquired TomegaVax, Inc., or TomegaVax, in September 2016, Humabs BioMed SA, or Humabs, in August 2017, Agenovir Corporation, or Agenovir, in January 2018 and Statera Health, LLC, or Statera, in February 2018. Realizing the benefits of these acquisitions will depend upon the successful integration of the acquired technology into our existing and future</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">109</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">product candidates. We also may not realize the anticipated benefits from any acquired business. We face many risks in connection with acquisitions and investments, whether or not consummated. A significant portion of the purchase price of companies we acquire may be allocated to acquired goodwill and other intangible assets, which must be assessed for impairment at least annually. If our acquisitions do not yield expected returns, we may in the future be required to take charges to our operating results based on this impairment assessment process, which could adversely affect our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, in connection with our acquisitions of TomegaVax, Humabs and Agenovir, we are required to make future contingent payments upon the achievement of certain milestones. We may in the future be required to make these payments, which could adversely affect our financial condition. For additional information regarding our obligations under these agreements, see the section titled &#x201c;Business&#x2014;Our Acquisition Agreements&#x201d;.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furthermore, acquisitions could also result in dilutive issuances of equity securities or the incurrence of debt, which could adversely affect our operating results. In addition, if an acquired business fails to meet our expectations, our business, financial condition, results of operations and prospects may suffer. We cannot assure you that we will be successful in integrating the businesses or technologies we may acquire. The failure to successfully integrate these businesses could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have experienced significant growth in our organization in recent years and expect to continue to expand, and we may experience difficulties in managing this growth, which could disrupt our operations.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have experienced significant growth in the number of our employees and the scope of our operations in recent years at both our sites and remote locations, particularly in the areas of research, development and regulatory affairs, and we expect to continue to experience growth as the clinical development of our product candidates progresses. In addition, if any of our product candidates receives marketing approval, we will need to build out our sales and marketing capabilities, either on our own or with others. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities, and continue to recruit and train additional qualified personnel. As a result of the global pandemic, the majority of our workforce has been working from home since March 2020. Despite this, we must continue to effectively integrate, develop and motivate a growing number of new employees, and maintain the beneficial aspects of our corporate culture. In April 2022, we reopened our offices to allow employees to return to work and we now offer all our employees the choice of working full-time in the office, a hybrid approach, or full-time remote. Although the reopening of our offices is consistent with local government requirements, is focused on employee safety, and contemplates returning to remote work should the COVID-19 situation change, there is uncertainty regarding the long-term impact that the COVID-19 pandemic has had on the nature of the office environment and remote working, which could present operational and workplace culture challenges as we seek to expand our organization.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The expansion of our operations may lead to significant costs and may divert our management and business development resources. We may not be able to effectively manage the expansion of our operations, recruit and train additional qualified personnel, or succeed at effectively integrating employees that have joined during the global pandemic. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our operations, and those of our CDMOs, CROs and other contractors and consultants, could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, public health pandemics or epidemics (including, for example, the COVID-19 pandemic), geopolitical events, including civil or political unrest (such as the ongoing war between Ukraine and Russia), terrorism, insurrection or war, and other natural or man-made disasters or business interruptions, for which we are predominantly self-insured. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our ability to develop our product candidates could be disrupted if our operations or those of our suppliers are affected by geopolitical events, man-made or natural disasters or other business interruptions. Our corporate headquarters are located in California near major earthquake faults and fire zones. The ultimate impact on us, our significant suppliers and our general infrastructure of being located near major earthquake faults and fire zones and being consolidated in certain geographical areas is unknown, but our operations and financial condition could suffer in the event of a major earthquake, fire or other natural disaster.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our business could be materially adversely affected by the effects of health pandemics or epidemics, including the COVID-19 pandemic and future pandemics.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our business could be materially adversely affected by the effects of health pandemics or epidemics, including the COVID-19 pandemic, the evolution of new and existing variants or subvariants of COVID-19 that are resistant to existing treatments or vaccinations and any future pandemics.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">110</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The COVID-19 pandemic resulted in travel restrictions, quarantines orders and other restrictions by governments to reduce the spread of the disease. The effects of the restrictions related to the COVID-19 pandemic and our hybrid work policies, discussed below, may negatively impact productivity, disrupt our business and delay our clinical programs and timelines, the magnitude of which will depend, in part, on the length and severity of any future restrictions and other limitations on our ability to conduct our business in the ordinary course. Quarantines, shelter-in-place and similar government orders, or the perception that such orders or other restrictions on the conduct of business operations could occur, related to COVID-19 or other infectious diseases could impact personnel at third-party manufacturing facilities in the United States and other countries, or the availability or cost of materials, which would disrupt our supply chain. In particular, some of our CDMOs that we use to supply our early-stage product candidates are located in China, where there continue to government-imposed quarantines. While many of these materials may be obtained by more than one supplier, including suppliers outside of China, port closures and other restrictions resulting from the COVID-19 outbreak in the region or other regions may disrupt our supply chain or limit our ability to obtain sufficient materials for our product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, our clinical trials have been affected by the COVID-19 pandemic. Site initiation and patient enrollment has been and may be further delayed due to prioritization of hospital resources toward the COVID-19 pandemic, and some patients may not be able or willing to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services. Similarly, our ability to recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19, has been delayed or disrupted, which has adversely impacted our clinical trial operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since March 2020, due to the COVID-19 pandemic, the majority of our workforce has been working from home. We now offer all of our employees the choice of working full time in the office, a hybrid approach, or full-time remote. Coming into the office remains 100% voluntary, unless a person&#x2019;s role requires them to be on site to do their job. As a result, we expect to continue to be subject to the challenges and risks of having a remote workforce, as well as new challenges and risks from operating with a hybrid workforce. For example, our employees are accessing our servers remotely through home or other networks to perform their job responsibilities. Such security systems may be less secure than those used in our offices, which may subject us to increased security risks, including cybersecurity-related events, and expose us to risks of data or financial loss and associated disruptions to our business operations. Additionally, employees who access company data and systems remotely may not have access to technology that is as robust as that in our offices, which could place additional pressure on our user infrastructure and third parties that are not easily mitigated. We may also be exposed to risks associated with the locations of remote employees, including compliance with local laws and regulations or exposure to compromised internet infrastructure. Allowing our employees to work remotely may create intellectual property risk if employees create intellectual property on our behalf while residing in a jurisdiction with unenforced or uncertain intellectual property laws. Further, if employees fail to inform us of changes in their work location, we may be exposed to additional risks without our knowledge.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, operating our business with both remote and in-person workers could have a negative impact on our corporate culture, decrease the ability of our workforce to collaborate and communicate effectively, decrease innovation and productivity, or negatively affect workforce morale. If we are unable to manage cybersecurity and other risks of a flexible-first workforce model, and maintain our corporate culture and workforce morale, our business could be harmed or otherwise adversely impacted.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The continued spread of COVID-19, which has caused a broad impact globally, may materially affect us economically. While the potential economic impact brought by, and the duration of, the COVID-19 pandemic, may be difficult to assess or predict, it has already resulted in significant disruption of global financial markets. This disruption, if sustained or recurrent, could make it more difficult for us to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 could materially affect our business and the value of our common stock.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The global pandemic of COVID-19 and the evolution of new and existing variants or subvariants that are resistant to existing treatments or vaccinations continue to rapidly evolve. The ultimate impact of the COVID-19 pandemic or a similar health pandemic or epidemic is highly uncertain and subject to change. We do not yet know the full extent of potential delays or impacts on our business, our clinical trials, healthcare systems or the global economy as a whole. These effects could have a material impact on our operations, and we will continue to monitor the COVID-19 situation closely.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">111</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If our information systems, or those maintained on our behalf, fail or suffer security breaches, such events could result in, without limitation, the following: a significant disruption of our product development programs; an inability to operate our business effectively; unauthorized access to or disclosure of the personal information we process; and other adverse effects on our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our computer and information technology systems, cloud-based computing services and those of our current and any future collaborators, service providers and other parties upon whom we rely are potentially vulnerable to malware, computer viruses, denial-of-service attacks (such as credential stuffing), ransomware attacks, user error or malfeasance, data corruption, cyber-based attacks, natural disasters, public health pandemics or epidemics (including, for example, the COVID-19 pandemic), geopolitical events, including civil or political unrest (such as the ongoing war between Ukraine and Russia), terrorism, war and telecommunication and electrical failures that may result in damage to or the interruption or impairment of key business processes, or the loss or corruption of our information, including intellectual property, proprietary business information and personal information. We may also experience server malfunction, software or hardware failures, supply-chain cyber-attacks, loss of data or other computer assets and other similar issues. We have experienced security breaches of our information technology systems, such as through business email compromises. The techniques used to sabotage or to obtain unauthorized access to information systems, and networks in which cyber threat actors store data or through which they transmit data change frequently and we may be unable to implement adequate preventative measures. Any significant system failure, accident or security breach could have a material adverse effect on our business, financial condition and operations.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may be required to expend significant resources (including financial), fundamentally change our business activities and practices, or modify our operations, including our clinical trial activities, or information technology in an effort to protect against security breaches and to detect (including performing required forensics), mitigate and remediate actual and potential vulnerabilities. Relevant laws, regulations, industry standards and contractual obligations may require us to implement specific security measures or use industry-standard or reasonable measures to protect against security breaches. The costs to us to mitigate network security problems, bugs, viruses, worms, malicious software programs, security breaches and security vulnerabilities could be significant, and while we have implemented security measures to protect our data security and information technology systems, our efforts to address these problems may not be successful, and these problems could result in unexpected interruptions, data loss or corruption, delays, cessation of service and other harm to our business and our competitive position. If the information technology systems of our third-party vendors become subject to disruptions or security breaches, we may have insufficient recourse against such third parties and we may have to expend significant resources to mitigate the impact of such an event, and to develop and implement protections to prevent future events of this nature from occurring. Although we maintain cybersecurity insurance coverage, such insurance may not be adequate to cover all liabilities that we may incur. Furthermore, if a security breach were to occur and cause interruptions in our operations, it could result in a disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other proprietary information or other similar disruptions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For example, we, our third-party vendors, and our partners&#x2019; third-party vendors have experienced social engineering efforts (including phishing attacks) designed to gain unauthorized access to our systems and information, including recent business email and system compromises. Similarly, we and our partners&#x2019; third-party vendors may be a target of other phishing attacks, social engineering attacks and other cyber-attacks in the future. If a data security breach affects our or third parties&#x2019; systems upon which we rely, corrupts our data or results in the unauthorized disclosure or release of personally identifiable information, our reputation could be materially damaged or our operations disrupted. In addition, such a breach may require notification to governmental agencies, supervisory bodies, credit reporting agencies, the media, individuals, collaborators or others pursuant to various federal, state and foreign data protection, privacy and security laws, regulations and guidelines, industry standards, our policies and our contracts, if applicable. Such laws may include HIPAA and the Health Information Technology for Economic and Clinical Health Act, or HITECH, and General Data Protection Regulation. Under these laws specifically, notice of certain security breaches must be made to affected individuals, the Secretary of HHS, applicable Supervisory Authority, and for extensive breaches, to the media or state attorneys general. Such a notice could further harm our reputation and our ability to compete. Such disclosures are costly, and the disclosure or the failure to comply with such requirements could lead to a material adverse effect on our reputation, business, or financial condition. Furthermore, a data security breach could result in fines, increased costs or loss of revenue and we could incur liability (such as through regulatory fines and penalties as well as private claims), our competitive position could be harmed and the further development and commercialization of our product candidates could be delayed. Additionally, federal, state and foreign laws and regulations can expose us to enforcement actions and investigations by regulatory authorities, and potentially result in regulatory penalties and significant legal liability, if our information technology security efforts fail.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">112</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We are subject to stringent privacy laws, information security laws, regulations, policies and contractual obligations related to data privacy and security and changes in such laws, regulations, policies, contractual obligations and failure to comply with such requirements could subject us to significant fines and penalties, which may have a material adverse effect on our business, financial condition or results of operations.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are subject to data privacy and protection laws and regulations that apply to the collection, transmission, storage and use of personally identifying information, which among other things, impose certain requirements relating to the privacy, security and transmission of personal information, including comprehensive regulatory systems in the United States, EU and the U.K. The legislative and regulatory landscape for privacy and data protection continues to evolve in jurisdictions worldwide, and there has been an increasing focus on privacy and data protection issues with the potential to affect our business. Failure to comply with any of these laws and regulations could result in enforcement action against us, including fines, claims for damages by affected individuals, damage to our reputation and loss of goodwill, any of which could have a material adverse effect on our business, financial condition, results of operations or prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There are numerous U.S. federal and state laws and regulations related to the privacy and security of personal information. In particular, regulations promulgated pursuant to HIPAA establish privacy and security standards that limit the use and disclosure of individually identifiable health information, or protected health information, and require the implementation of administrative, physical and technological safeguards to protect the privacy of protected health information and ensure the confidentiality, integrity and availability of electronic protected health information. Determining whether protected health information has been handled in compliance with applicable privacy standards and our contractual obligations can be complex and may be subject to changing interpretation. These obligations may be applicable to some or all of our business activities now or in the future.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If we are unable to properly protect the privacy and security of protected health information, we could be found to have breached our contracts. Further, if we fail to comply with applicable privacy laws, including applicable HIPAA privacy and security standards, we could face civil and criminal penalties. HHS enforcement activity can result in financial liability and reputational harm, and responses to such enforcement activity can consume significant internal resources. In addition, state attorneys general are authorized to bring civil actions seeking either injunctions or damages in response to violations that threaten the privacy of state residents. We cannot be sure how these regulations will be interpreted, enforced or applied to our operations. In addition to the risks associated with enforcement activities and potential contractual liabilities, our ongoing efforts to comply with evolving laws and regulations at the federal and state level may be costly and require ongoing modifications to our policies, procedures and systems.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In 2018 California passed into law the California Consumer Privacy Act, or CCPA, which took effect on January 1, 2020, and imposed many requirements on businesses that process the personal information of California residents. Many of the CCPA&#x2019;s requirements are similar to those found in the General Data Protection Regulation, or GDPR, including requiring businesses to provide notice to data subjects regarding the information collected about them and how such information is used and shared, and providing data subjects the right to request access to such personal information and, in certain cases, request the erasure of such personal information. The CCPA also affords California residents the right to opt-out of &#x201c;sales&#x201d; of their personal information. The CCPA contains significant penalties for companies that violate its requirements. In November 2020 California voters passed a ballot initiative for the California Privacy Rights Act, or CPRA, which went into effect on January 1, 2023, and significantly expanded the CCPA to incorporate additional GDPR-like provisions including requiring that the use, retention and sharing of personal information of California residents be reasonably necessary and proportionate to the purposes of collection or processing, granting additional protections for sensitive personal information, and requiring greater disclosures related to notice to residents regarding retention of information. The CPRA also created a new enforcement agency &#x2013; the California Privacy Protection Agency &#x2013; whose sole responsibility is to enforce the CPRA, which will further increase compliance risk. The provisions in the CPRA may apply to some of our business activities. In addition, other states, including Virginia, Colorado, Utah and Connecticut, already have passed state privacy laws. Virginia&#x2019;s privacy law also went into effect on January 1, 2023, and the laws in the other three states will go into effect later in the year. Other states will be considering these laws in the future, and Congress has also been debating passing a federal privacy law. These laws may impact our business activities, including our identification of research subjects, relationships with business partners and ultimately the marketing and distribution of our products.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">113</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Similar to the laws in the United States, there are significant privacy and data security laws that apply in Europe and other countries. The collection, use, disclosure, transfer or other processing of personal data, including personal health data, regarding individuals who are located in the European Economic Area, or EEA, and the processing of personal data that takes place in the EEA, is regulated by the GDPR, which went into effect in May 2018 and which imposes obligations on companies that operate in our industry with respect to the processing of personal data and the cross-border transfer of such data. The GDPR imposes onerous accountability obligations requiring data controllers and processors to maintain a record of their data processing and policies. If our or our collaboration partners&#x2019; or service providers&#x2019; privacy or data security measures fail to comply with the GDPR requirements, we may be subject to litigation, regulatory investigations, enforcement notices requiring us to change the way we use personal data and/or fines of up to 20 million Euros or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, as well as compensation claims by affected individuals, negative publicity, reputational harm and a potential loss of business and goodwill.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The GDPR places restrictions on the cross-border transfer of personal data from the EU to countries that have not been found by the European Commission to offer adequate data protection legislation, such as the United States. There are ongoing concerns about the ability of companies to transfer personal data from the EU to other countries. In July 2020 the Court of Justice of the European Union, or CJEU, invalidated the EU-U.S. Privacy Shield, one of the mechanisms used to legitimize the transfer of personal data from the EEA to the United States. The CJEU decision also drew into question the long-term viability of an alternative means of data transfer, the standard contractual clauses, for transfers of personal data from the EEA to the United States. While we were not self-certified under the Privacy Shield, this CJEU decision may lead to increased scrutiny on data transfers from the EEA to the United States generally and increase our costs of compliance with data privacy legislation as well as our costs of negotiating appropriate privacy and security agreements with our vendors and business partners.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additionally, in October 2022 President Biden signed an executive order to implement the EU-U.S. Data Privacy Framework, which would serve as a replacement to the EU-U.S. Privacy Shield. The European Commission initiated the process to adopt an adequacy decision for the EU-U.S. Data Privacy Framework in December 2022. It is unclear if and when the framework will be finalized and whether it will be challenged in court. The uncertainty around this issue may further impact our business operations and activities in the EU.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Following the withdrawal of the U.K. from the EU, the U.K. Data Protection Act 2018 applies to the processing of personal data that takes place in the U.K. and includes parallel obligations to those set forth by GDPR. In relation to data transfers, both the U.K. and the EU have determined, through separate &#x201c;adequacy&#x201d; decisions, that data transfers between the two jurisdictions are in compliance with the U.K. Data Protection Act and the GDPR, respectively. Any changes or updates to these adequacy decisions have the potential to impact our business.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Beyond the GDPR, there are privacy and data security laws in a growing number of countries around the world. While many loosely follow the GDPR as a model, other laws contain different or conflicting provisions. These laws will impact our ability to conduct our business activities, including both our clinical trials and the sale and distribution of commercial products, if approved, through increased compliance costs, costs associated with contracting and potential enforcement actions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">While we continue to address the implications of the recent changes to data privacy regulations, data privacy remains an evolving landscape at both the domestic and international level, with new regulations coming into effect and continued legal challenges, and our efforts to comply with the evolving data protection rules may be unsuccessful. It is possible that these laws may be interpreted and applied in a manner that is inconsistent with our practices. We must devote significant resources to understanding and complying with this changing landscape. Failure to comply with laws regarding data protection would expose us to risk of enforcement actions taken by data protection authorities in the EEA and elsewhere and carries with it the potential for significant penalties if we are found to be non-compliant. Similarly, failure to comply with federal and state laws in the United States regarding privacy and security of personal information could expose us to penalties under such laws. Any such failure to comply with data protection and privacy laws could result in government-imposed fines or orders requiring that we change our practices, claims for damages or other liabilities, regulatory investigations and enforcement action, litigation and significant costs for remediation, any of which could adversely affect our business. Even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could harm our business, financial condition, results of operations or prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are exposed to the risk of fraud or other misconduct by our employees, principal investigators, consultants and commercial partners. Misconduct by these parties could include intentional failures, reckless and/or negligent conduct or unauthorized activities that violates (i) the laws and regulations of FDA and other regulatory authorities, including those laws requiring the reporting of true,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">114</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">complete and accurate information to such authorities, (ii) manufacturing standards, (iii) federal and state data privacy, security, fraud and abuse and other healthcare laws and regulations in the United States and abroad, (iii) laws that require the true, complete and accurate reporting of financial information or data and (iv) insider trading laws that restrict the buying and selling of shares of our common stock while in possession of material non-public information. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct also could involve the improper use of individually identifiable information, including, without limitation, information obtained in the course of clinical trials, creating fraudulent data in our preclinical studies or clinical trials or illegal misappropriation of drug product, which could result in regulatory sanctions and cause serious harm to our reputation. In addition, during the course of our operations, our directors, executives and employees may have access to material non-public information regarding our business, our results of operations or potential transactions we are considering. We may not be able to prevent a director, executive or employee from violating our insider trading policies and buying or selling, or &#x201c;tipping&#x201d; others who might buy or sell, shares of our common stock on the basis of, or while having access to, material non-public information. If a director, executive or employee was to be investigated, or an enforcement action was to be brought against a director, executive or employee for insider trading, it could have a negative impact on our reputation and our stock price.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from government investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could result in significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participating in government-funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of noncompliance with these laws, contractual damages, reputational harm and the curtailment or restructuring of our operations, any of which could have a negative impact on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our ability to use our</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">net operating losses, or NOLs, to offset future taxable income may be subject to certain limitations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, we had net operating loss carryforwards of $20.9 million for federal tax purposes and $111.4 million for state tax purposes. If not utilized, federal carryforwards will begin expiring in 2037 and state carryforwards will begin expiring in 2031. Our ability to use our federal and state NOLs to offset potential future taxable income is dependent upon our generation of future taxable income before any expiration dates of the NOLs, and we cannot predict with certainty when, or whether, we will generate sufficient taxable income to use all of our NOLs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Beginning in 2022, the Tax Cuts and Jobs Act of 2017 eliminates the option to deduct research and development expenditures currently and requires taxpayers to capitalize and amortize them over five or fifteen years pursuant to Section 174 of the Internal Revenue Code of 1986, as amended, or the Code. Although Congress is considering legislation that could repeal such requirement or defer the amortization requirement to later years, it is not certain that the provision will be repealed or otherwise modified. If the requirement is not modified, it is expected to reduce our NOLs beginning in 2022.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, under Sections 382 and 383 of the Code, a corporation that undergoes an &#x201c;ownership change&#x201d; (generally defined as a greater than 50 percentage point change (by value) in its equity ownership by certain stockholders over a rolling three-year period) is subject to limitations on its ability to utilize its pre-change NOLs to offset future taxable income. We may have experienced ownership changes in the past or as a result of our initial public offering and may experience ownership changes as a result of future offerings and/or subsequent changes in our stock ownership (some of which shifts are outside our control). In addition, Agenovir has experienced at least one ownership change in the past resulting in a limitation under Section 382 of the Code, which has been accounted for in calculating our available NOL carryforwards. As a result, if, and to the extent that we earn net taxable income, our ability to use our pre-change NOLs to offset such taxable income may be subject to limitations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Tax Cuts and Jobs Act of 2017 and the Coronavirus Aid, Relief and Economic Security Act, or the CARES Act, include, among other things, changes to U.S. federal tax rates and the rules governing NOL carryforwards. For example, NOLs arising in tax years ending after December 31, 2017, can be carried forward indefinitely, but the deductibility of such federal NOLs may be limited to 80% of current year taxable income for tax years beginning on or after January 1, 2021. Deferred tax assets for NOLs will need to be measured at the applicable tax rate in effect when the NOL is expected to be utilized. The changes in the carryforward periods, as well as the new limitation on use of NOLs may impact our ability to utilize our NOLs to offset taxable income in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">115</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risks Related to Ownership of Our Common Stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our financial condition and results of operations may fluctuate from quarter to quarter and year to year, which makes them difficult to predict.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect our financial condition and results of operations to fluctuate from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Accordingly, you should not rely upon the results of any quarterly or annual periods as indications of future operating performance. Factors that may cause fluctuations in our financial condition and results of operations include, without limitation, those listed elsewhere in this &#x201c;Risk Factors&#x201d; section and those listed below:</span></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing and cost of, and level of investment in, research and development activities relating to our product candidates, which will change from time to time;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the cost of manufacturing our product candidates and any future product candidates, which may vary depending on FDA, EMA or other comparable foreign regulatory authority guidelines and requirements, the quantity of production and the terms of our agreements with manufacturers;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">expenditures that we will or may incur to acquire or develop additional product candidates and technologies or other assets;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the timing and outcomes of preclinical studies and clinical trials for our product candidates;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the need to conduct unanticipated clinical trials that are larger or more complex than anticipated;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">competition from existing and potential future products that compete with our product candidates, and changes in the competitive landscape of our industry, including consolidation among our competitors or partners;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any delays in regulatory review or approval of our product candidates;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the level of demand for any of our product candidates, if approved, which may fluctuate significantly and be difficult to predict;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the risk/benefit profile, cost and reimbursement policies with respect to our product candidates, if approved, and existing and potential future products that compete with our product candidates;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to commercialize our product candidates, if approved, inside and outside of the U.S., either independently or working with third parties;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">our ability to adequately support future growth;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">potential unforeseen business disruptions that increase our costs or expenses;</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">future accounting pronouncements or changes in our accounting policies; and</span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the changing and volatile global economic and political environment both inside and outside the U.S., including heightened inflation, capital market volatility, interest rate and currency rate fluctuations, and economic slowdown or recession.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, our collaboration revenue and certain assets and liabilities are subject to foreign currency exchange rate fluctuations due to the global nature of our operations. As a result, currency fluctuations among our reporting currency, the U.S. dollar, and other currencies in which we do business will affect our operating results, often in unpredictable ways. Currency exchange rates have been especially volatile in the recent past, and these currency fluctuations have affected, and may continue to affect, our assets and liabilities denominated in foreign currency. We are also exposed to market risks related to our investments, including changes in fair value of equity securities we hold which may fluctuate from quarter to quarter and year to year. For additional information, see Item 7A. Quantitative and Qualitative Disclosures About Market Risk in this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The market price of our common stock has been, and in the future, may be, volatile and fluctuate substantially, which could result in substantial losses for purchasers of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our stock price has been, and in the future, may be, subject to substantial volatility. From October 11, 2019, our first day of trading on The Nasdaq Global Select Market, or Nasdaq, through February 21, 2023, the closing price of our stock ranged from $11.83 per share to $83.07 per share. As a result of the volatility in our stock price, our stockholders could incur substantial losses.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The stock market in general and the market for biopharmaceutical and pharmaceutical companies in particular, has experienced extreme volatility that has often been unrelated to the operating performance of particular companies. The COVID-19 pandemic, for example, has negatively affected some sectors of the stock market and investor sentiment and has resulted in significant volatility. In</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">116</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">addition, economic trends and other external factors including, but not limited to, heightened inflation, interest rate and currency rate fluctuations, economic slowdown or recession, capital markets volatility, foreign market trends, national crisis, and disasters, may impact the market price of our common stock and result in volatility. As a result of this volatility, you may not be able to sell your common stock at or above the price you paid for your shares. Market and industry factors may cause the market price and demand for our common stock to fluctuate substantially, regardless of our actual operating performance, which may limit or prevent investors from selling their shares at or above the price paid for the shares and may otherwise negatively affect the liquidity of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, public statements by us, government agencies, our competitors, the media or others relating to the COVID-19 pandemic (including regarding our and others&#x2019; efforts to develop COVID-19 therapies) and the impact of such statements on investors&#x2019; general perception of our company and our business have in the past resulted, and may in the future result, in significant fluctuations in our stock price. Given the global focus on the COVID-19 pandemic, information in the public arena on this topic, whether or not accurate, has had and will likely continue to have an outsized impact (positive or negative) on our stock price. Moreover, sales of a substantial number of shares of our common stock by our stockholders in the public market or the perception that these sales might occur, have in the past, and may in the future depress the market price of our common stock. Information related to our research, development, manufacturing, regulatory and commercialization efforts with respect to any of our product candidates or information regarding such efforts by competitors with respect to their potential therapies, may meaningfully impact our stock price.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Some companies that have experienced volatility in the trading price of their shares have been the subject of securities class action litigation. Any lawsuit to which we are a party, with or without merit, may result in an unfavorable judgment. We also may decide to settle lawsuits on unfavorable terms. Any such negative outcome could result in payments of substantial damages or fines, damage to our reputation or adverse changes to our business practices. Defending against litigation is costly and time-consuming and could divert our management&#x2019;s attention and our resources. Furthermore, during the course of litigation, there could be negative public announcements of the results of hearings, motions or other interim proceedings or developments, which could have a negative effect on the market price of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentration of ownership of our common stock among our existing executive officers, directors and principal stockholders may prevent new investors from influencing significant corporate decisions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our executive officers, directors and stockholders who own more than 5% of our outstanding common stock beneficially own a significant percentage of our outstanding common stock. If these persons acted together, they may be able to significantly influence all matters requiring stockholder approval, including the election and removal of directors and approval of any merger, consolidation or sale of all or substantially all of our assets. The concentration of voting power and transfer restrictions could delay or prevent an acquisition of our company on terms that other stockholders may desire or result in the management of our company in ways with which other stockholders disagree.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The trading market for our common stock will be influenced by the research and reports that industry or financial analysts publish about us or our business. If any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property or our stock performance, or if the clinical trials and operating results fail to meet the expectations of analysts, our stock could decline. If analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">You should not rely on an investment in our common stock to provide dividend income. We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. In addition, the terms of any future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain in the foreseeable future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">117</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">We have incurred and we will continue to incur significant increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a public company, we have incurred and we will continue to incur significant legal, accounting, investor relations and other expenses. In addition, the Sarbanes-Oxley Act and rules subsequently implemented by the Securities and Exchange Commission, or SEC, and Nasdaq have imposed various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Further, in July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act was enacted, pursuant to which the SEC adopted rules and regulations related to corporate governance and executive compensation, such as &#x201c;say on pay&#x201d; and proxy access.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stockholder activism, the current political environment and the current high level of U.S. government intervention and regulatory reform may also lead to substantial new regulations and disclosure obligations, which may in turn lead to additional compliance costs and impact the manner in which we operate our business in ways we do not currently anticipate. Our management and other personnel will need to devote a substantial amount of time to comply with these requirements. Moreover, these requirements will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. For example, we expect that these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a public company, we may also be subject to more stringent state law requirements, such as California Senate Bill 826, which generally requires public companies with principal executive offices in California to have a minimum number of females on the company&#x2019;s board of directors, and California Assembly Bill 979, which generally requires public companies with principal executive offices in California to include specified numbers of directors from &#x201c;underrepresented communities.&#x201d; We are currently compliant with the requirements, but there are no assurances that we will be compliant in the future. Both Senate Bill 826 and Assembly Bill 979 have been challenged in legal proceedings and there is uncertainty whether the courts will uphold Senate Bill 826 or Assembly Bill 979. If we fail to comply with either Senate Bill 826 or Assembly Bill 979, we could be fined by the California Secretary of State, with a $100,000 fine for the first violation and a $300,000 for each subsequent violation, and our reputation may be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">If we fail to develop or maintain proper and effective internal control over financial reporting, our ability to produce accurate and timely financial statements could be impaired, investors may lose confidence in us and the trading price of our common stock may decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effective internal control over financial reporting are necessary for us to provide reliable financial reports and effectively<br /><br />prevent fraud and operate successfully as a public company. Any failure to maintain internal control over financial reporting could<br /><br />severely inhibit our ability to accurately report our financial condition, results of operations or cash flows. If our internal control over<br /><br />financial reporting is not effective, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by Nasdaq, the SEC or other<br /><br />regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting could also restrict our<br /><br />future access to the capital markets.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A material weakness in internal control over financial reporting has in the past and could in the future lead to deficiencies in<br /><br />the preparation of financial statements. Deficiencies in the preparation of financial statements, could lead to litigation claims against<br /><br />us. The defense of any such claims may cause the diversion of management&#x2019;s attention and resources, and we may be required to pay<br /><br />damages if any such claims or proceedings are not resolved in our favor. Any litigation, even if resolved in our favor, could cause us to incur significant legal and other expenses. Such events could also affect our ability to raise capital to fund future business initiatives.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to Section 404 of the Sarbanes-Oxley Act, we are required to furnish a report by our management on our internal control over financial reporting, including an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation. To comply with the Sarbanes-Oxley Act, the requirements of being a reporting company under the Securities Exchange Act of 1934, as amended, or the Exchange Act, and any complex accounting rules in the future, we may need to upgrade our information technology systems;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">118</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">implement additional financial and management controls, reporting systems and procedures; and hire additional accounting and finance staff. We are currently in the process of hiring additional accounting and finance staff as we grow our business. If we are unable to hire the additional accounting and finance staff necessary to comply with these requirements, we may need to retain additional outside consultants.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our reported financial results may be adversely affected by changes in accounting principles generally accepted in the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Generally accepted accounting principles in the United States are subject to interpretation by the Financial Accounting Standards Board or the SEC, and various bodies formed to promulgate and interpret appropriate accounting principles. A change in these principles or interpretations could have a significant effect on our reported financial results, may retroactively affect previously reported results, could cause unexpected financial reporting fluctuations and may require us to make costly changes to our operational processes and accounting systems.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Provisions in our corporate charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Provisions in our corporate charter and our bylaws may discourage, delay or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions also could limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. For a summary of these provisions, see the section titled &#x201c;Anti-Takeover Provisions of Delaware Law and Our Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws&#x2014;Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws&#x201d; in Exhibit 4.3 Description of Capital Stock filed as part of this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#x2019; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state court located within the State of Delaware or, if and only if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware) will be the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any derivative action or proceeding brought on our behalf; </span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any action or proceeding asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, officers or other employees to us or our stockholders; </span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any action or proceeding asserting a claim against us or any of our current or former directors, officers or other employees, arising out of or pursuant to any provision of the Delaware General Corporation Law, our certificate of incorporation or our bylaws; </span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any action or proceeding to interpret, apply, enforce or determine the validity of our certificate of incorporation or our bylaws; and </span></div></div>
  <div style="margin-left:6.667%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">any action asserting a claim against us or any of our directors, officers or other employees governed by the internal affairs doctrine. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act or any other claim for which the U.S. federal courts have exclusive jurisdiction. Furthermore, Section 22 of the Securities Act of 1933, as amended, or the Securities Act, creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our amended and restated certificate of incorporation further provides that the federal district courts of the United States will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act, unless we consent in writing to the selection of an alternative forum. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our amended and restated</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">119</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">certificate of incorporation. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These exclusive-forum provisions may limit a stockholder&#x2019;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage these types of lawsuits. Furthermore, the enforceability of similar choice of forum provisions in other companies&#x2019; certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. If a court were to find the exclusive-forum provision contained in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with resolving such action in other jurisdictions, all of which could harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1b_unresolved_staff_comments"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 1B. Unresolved </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Staff Comments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:4.749%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">120</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_2_properties"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 2. Pr</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">operties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our corporate headquarters are located in San Francisco, California, where we lease approximately 179,566 square feet of office, research and development, engineering, and laboratory space pursuant to three lease agreements that expire at various dates through 2033, two of which are renewable for additional one and five years, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also have several other locations, including St. Louis, Missouri, where we lease approximately 60,649 square feet of office, research and development, and laboratory space pursuant to two lease agreements that expire at various dates through 2028; Portland, Oregon, where we lease approximately 7,536 square feet of office, research and development, engineering, and laboratory space pursuant to two lease agreements that expire at various dates through 2027, one of which is renewable for an additional five years; and Bellinzona, Switzerland, where we lease approximately 15,642 square feet of office, research and development, engineering, and laboratory space pursuant to a lease agreement which expires on December 31, 2028, with an option to extend for five years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We believe that our existing facilities are adequate for our near-term needs, but expect to need additional space as we grow, and we believe that suitable additional alternative spaces will be available in the future on commercially reasonable terms, if required.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_3_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 3. Legal </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceedings.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. We are not currently party to any material legal proceedings, and we are not aware of any pending or threatened legal proceeding against us that we believe could have an adverse effect on our business, operating results or financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_4_mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 4. Mine Safe</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ty Disclosures.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Not applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">121</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_ii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> II</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_5_market_for_registrants_common_equ"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 5. Market for Registrant&#x2019;s Common Equity, Related Stock</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">holder Matters and Issuer Purchases of Equity Securities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Market Information for Common Stock</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our common stock has been listed on The Nasdaq Global Select Market under the symbol &#x201c;VIR&#x201d; since October 11, 2019.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Holders of Record</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of February 21, 2023, there were approximately 133,531,379 stockholders of record of our common stock. The actual number of stockholders is greater than this number of record holders, and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dividend Policy</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We currently intend to retain future earnings, if any, for use in operation of our business and to fund future growth. We have never declared or paid any cash dividends on our capital stock and do not anticipate paying any cash dividends in the foreseeable future. Payment of cash dividends, if any, in the future will be at the discretion of our board of directors and will depend on then-existing conditions, including our financial condition, operating results, contractual restrictions, capital requirements, business prospects and other factors our board of directors may deem relevant.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock Performance Graph</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following graph shows the total stockholder&#x2019;s return on an investment of $100 in cash at market close on October 11, 2019 (the first day of trading of our common stock), through December 31, 2022 for (i) our common stock, (ii) the Nasdaq Composite Index and (iii) the Nasdaq Biotechnology Index. Pursuant to applicable Securities and Exchange Commission, rules, all values assume reinvestment of the full amount of all dividends; however, no dividends have been declared on our common stock to date. The stockholder return shown on the graph below is not necessarily indicative of future performance, and we do not make or endorse any predictions as to future stockholder return. This graph shall not be deemed &#x201c;soliciting material&#x201d; or be deemed &#x201c;filed&#x201d; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities under that Section, and shall not</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">122</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">be deemed to be incorporated by reference into any of our filings under the Securities Act of 1933, as amended, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img62602283_24.jpg" alt="img62602283_24.jpg" style="width:672px;height:265px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:56.435%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:11.423%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.992%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:11.423%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.992%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:11.736%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VIR</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nasdaq<br />Composite<br />Index</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nasdaq<br />Biotechnology<br />Index</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10/11/2019</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100.00</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100.00</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100.00</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10/31/2019</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100.57</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">102.92</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">106.95</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12/31/2019</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">89.69</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">111.36</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">120.19</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3/31/2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">244.44</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">95.57</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">107.67</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6/30/2020</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">292.23</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">124.84</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">136.40</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9/30/2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">244.86</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">138.61</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">135.11</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12/31/2020</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">191.01</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">159.96</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">151.06</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3/31/2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">365.69</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">164.41</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">149.97</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6/30/2021</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">337.23</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">180.02</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">163.40</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9/30/2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">310.41</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">179.33</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">161.40</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12/31/2021</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">298.64</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">194.18</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">150.10</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3/31/2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">183.45</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">176.50</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">132.24</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6/30/2022</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">181.67</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">136.88</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">118.99</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9/30/2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">137.52</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">131.26</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">119.59</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12/31/2022</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">180.53</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">129.90</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">133.73</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securities Authorized for Issuance Under Equity Compensation Plans</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by this Item regarding equity compensation plans is incorporated by reference to the information set forth in PART III Item 12 of this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Use of Proceeds from Registered Securities</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Recent Sales of Unregistered Equity Securities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuer Purchases of Equity Securities</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_6_selected_financial_data"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 6. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">[</span><span id="reserved"></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reserved]</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">123</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_7_managements_discussion_analysis_f"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7. Management&#x2019;s Discussion and Analysis of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial Condition and Results of Operations.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our audited consolidated financial statements and the related notes and other financial information included elsewhere in this Annual Report on Form 10-K. Unless the context requires otherwise, references in this Annual Report on Form 10-K to the &#x201c;Company&#x201d;, &#x201c;Vir,&#x201d; &#x201c;we,&#x201d; &#x201c;us&#x201d; and &#x201c;our&#x201d; refer to Vir Biotechnology, Inc. and its consolidated subsidiaries.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Our discussion and analysis below are focused on our financial results and liquidity and capital resources for the years ended December 31, 2022 and 2021, including year-over-year comparisons of our financial performance and condition for these years. Discussion and analysis of the year ended December 31, 2020 specifically, as well as the year-over-year comparison of our financial performance and condition for the years ended December 31, 2021 and 2020, are located in the section titled &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations&#x201d; included in the Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the SEC on February 28, 2022. For a detailed discussion on our business environment, please read Item 1. Business, included in this Annual Report on Form 10-K. For additional information on the risks that could negatively impact our business, please read Item 1A. Risk Factors, included in this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Infectious diseases are among the leading causes of death worldwide and can cause trillions of dollars of direct and indirect economic burden each year &#x2013; as evidenced by the coronavirus disease 2019, or COVID-19, pandemic. We believe that now is the time to apply the recent and remarkable advances in immunology to combat current and prepare for future infectious diseases. Our approach begins with identifying the limitations of the immune system in combating a particular pathogen, the vulnerabilities of that pathogen and the reasons why previous approaches have failed. We then bring to bear powerful technologies that we believe, individually or in combination, will lead to effective therapies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our current pipeline consists of sotrovimab (previously VIR-7831; and where marketing authorization has been granted, marketed under the brand name Xevudy&#174;) and other product candidates targeting hepatitis B virus, or HBV, hepatitis D virus, or HDV, influenza A virus, COVID-19, and human immunodeficiency virus, or HIV. We have assembled four technology platforms, focused on antibodies, T cells, innate immunity and small interfering ribonucleic acid, or siRNA, through internal development, collaborations and acquisitions. We have built an industry-leading team that has deep experience in immunology, infectious diseases, and product development and commercialization. Given the global impact of infectious diseases, we are committed to developing cost-effective treatments that can be delivered at scale.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">HBV</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VIR-2218 is an investigational HBV-targeting siRNA, and VIR-3434 is an investigational HBV-neutralizing mAb that incorporates Xencor&#x2019;s Xtend and other Fc technologies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In November 2022, at the American Association for the Study of Liver Diseases, or AASLD, The Liver Meeting&#174;, we presented new data from multiple ongoing trials evaluating the potential for VIR-2218 and VIR-3434 to achieve a functional cure for chronic HBV, as well as health outcomes research. Highlights included: </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Initial Phase 2 end-of-treatment data demonstrated that 30.8% of participants receiving 48 weeks of VIR-2218 plus IFN-&#x3b1; achieved hepatitis B surface antigen, or HBsAg seroclearance and each of those participants also achieved seroconversion, suggesting an improvement in those participants&#x2019; immune function (anti-HBs levels &gt;10mIU/mL). No safety signals have been reported to date. Additional data are expected in the first half of 2023.</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Initial end-of-treatment results from Part A of the Phase 2 Monoclonal Antibody siRNA Combination against Hepatitis B, or MARCH, trial demonstrated mean HBsAg reductions of &#x2265;2.7 log</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:sub;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> IU/mL across all three cohorts. These data show that VIR-2218 and VIR-3434 are additive in reducing HBsAg. No safety signals have been reported to date. Additional data from Part A are expected in the first half of 2023. Initial data from Part B, evaluating VIR-2218 in combination with VIR-3434 for 24 and 48 weeks, and in triple combination with VIR-3434 and IFN-&#x3b1; for 24 and 48 weeks, are expected in the second half of 2023.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Initiation of the Phase 2 PREVAIL platform trial and its THRIVE/STRIVE sub-protocols of VIR-3434 and/or VIR-2218 and/or IFN-&#x3b1; in viremic patients is expected in the first half of 2023. The THRIVE sub-protocol will evaluate inactive carriers defined as adults with chronic HBV that are HBeAg negative with HBV DNA &#x2264;2000 IU/mL and ALT &#x2264; ULN. The STRIVE sub-protocol will evaluate immune active, treatment-na&#xef;ve patients defined as adults with chronic HBV who have not received prior NRTIs, or IFN-&#x3b1; therapy and are HBeAg positive or negative with HBV DNA &gt;2000 IU/mL, ALT &gt; ULN and &#x2264; 5&#xd7; ULN. Initial data are expected in the first half of 2024. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">124</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In February 2022, initial data from the Phase 2 trial led by Brii Biosciences evaluating VIR-2218 in combination with BRII-179, an investigational T cell vaccine, for the potential treatment of chronic HBV infection were presented at the Asian Pacific Association for the Study of the Liver. Although the combination of VIR-2218 and BRII-179 had greater anti-HBs responses and improved HBsAg-specific T-cell responses, comparable HBsAg reduction was observed in all cohorts at end of treatment (-1.7-1.8 log10 IU/mL). The combination of VIR-2218 and BRII-179 was generally well tolerated.</span></div></div>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">HDV</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Initial data from the Phase 2 SOLSTICE trial, which began in September 2022, evaluating VIR-2218 and VIR-3434 as monotherapy and in combination for the treatment of people living with chronic HDV, the most aggressive form of viral hepatitis, are expected in the second half of 2023.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Influenza A virus</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VIR-2482 is an investigational influenza A-neutralizing mAb.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2022, we initiated the groundbreaking Phase 2 Prevention of Illness Due to Influenza A (PENINSULA) trial evaluating VIR-2482, and in December 2022, we achieved the target enrollment of approximately 3,000 participants. This is the first Phase 2 outpatient trial to evaluate the role of a mAb in the prevention of influenza A illness. The primary efficacy endpoint is the proportion of trial participants with protocol-defined influenza illness, requiring one systemic symptom and one respiratory symptom, with confirmed influenza A infection compared to placebo. Other endpoints will evaluate the effect of VIR-2482 on the severity and duration of illness in trial participants with confirmed influenza A compared to placebo. Initial data are expected in mid-2023. The PENINSULA trial is being supported in part with federal funds from the Department of Health and Human Services, or HHS; Administration for Strategic Preparedness and Response, or ASPR; and Biomedical Advanced Research and Development Authority, or BARDA, under Other Transaction Number: 75A50122C00081.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In August 2022, we initiated the Phase 1b prophylaxis trial evaluating the safety of VIR-2482 in adults aged 65 and older receiving a flu vaccine, and initial data are expected in mid-2023. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">COVID-19</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sotrovimab is an investigational severe acute respiratory syndrome coronavirus 2, or SARS-CoV-2, neutralizing monoclonal antibody, or mAb, that incorporates Xencor, Inc.'s, or Xencor, Xtend&#153; technology.</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In 2022, a total of approximately 1.5 million doses were delivered worldwide.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sotrovimab has obtained emergency authorization, temporary authorization or marketing approval (under the brand name Xevudy&#174;&#xfe0f;) for early treatment of COVID-19, supplying more than 40 countries. Sotrovimab is not authorized in the U.S.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In February 2023, the U.K.&#x2019;s National Institute for Health and Care Excellence (NICE) provided positive final draft guidance recommending the use of sotrovimab in adults who do not need supplemental oxygen for COVID-19 and who have an increased risk for progression to severe COVID-19 where nirmatrelvir/ritonavir (Paxlovid) is contraindicated or unsuitable.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In February of 2022, Vir and GSK amended their existing agreement to reflect that: </span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We will continue to discover, develop and advance next-generation solutions for COVID-19 and other potential coronavirus outbreaks, independently or with other partners.</span></div></div>
  <div style="margin-left:9.065%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.66525540221037%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We and GSK will continue working together to ensure ongoing access to sotrovimab for patients around the world, where authorized, and to develop new therapies for influenza and other respiratory diseases.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">125</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">HIV</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VIR-1111 is an investigational HIV T cell vaccine based on human cytomegalovirus, or HCMV, and VIR-1388 is a preclinical HIV T cell vaccine based on HCMV.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Safety and immunology data from the initial two cohorts of the proof-of-concept Phase 1 trial of VIR-1111 show no safety signals and no vector shedding or viremia reported to date. No sustained HIV insert-specific T cell responses have been observed in the lower dose cohorts 1 and 2. Safety and immunology data from the highest dose cohort 3 of the proof-of-concept Phase 1 trial of VIR-1111 are anticipated in the first half of 2023. This trial is being funded in part by the Bill &amp; Melinda Gates Foundation.</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Initiation of a Phase 1 trial of VIR-1388, a novel vector that has the potential to have enhanced immunogenicity, is expected in the second half of 2023. This trial is being funded in part by the Bill &amp; Melinda Gates Foundation and the National Institutes of Health&#x2019;s Division of AIDS through the HIV Vaccine Trials Network. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Financial Overview</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We were incorporated in April 2016 and commenced principal operations later that year. To date, we have focused primarily on organizing and staffing our company, business planning, raising capital, identifying, acquiring, developing and in-licensing our technology platforms and product candidates, and conducting preclinical studies and clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have financed our operations primarily through sales of our common stock from our initial public offering, subsequent follow-on offering and convertible preferred securities, and payments received under our grant and collaboration agreements. As of December 31, 2022, we had $2.4 billion in cash, cash equivalents, and investments. Based upon our current operating plan, we believe that the $2.4 billion will enable us to fund our operations for at least the next 12 months. However, our operating plan may change as a result of many factors currently unknown to us, and we may need to seek additional financing to fund our long-term operations sooner than planned. See the section titled &#x201c;Liquidity, Capital Resources and Capital Requirements&#x2014;Future Funding Requirements&#x201d; below for additional information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">    </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Although we recorded net income for the years ended December 31, 2022 and 2021, we have otherwise incurred net losses since inception and may continue to incur net losses in the foreseeable future. To date, sotrovimab has been granted emergency authorization, temporary authorization or marketing approval (under the brand name Xevudy&#174;), supplying more than 40 countries. Although we have an EUA from the FDA for sotrovimab, the FDA has excluded the use of sotrovimab in all U.S. regions due to the continued proportion of COVID-19 cases caused by certain Omicron subvariants. With this EUA revision, sotrovimab is not currently authorized for use in any U.S. region. In light of these developments, we cannot predict whether (if at all) or to what extent sotrovimab may be reauthorized for use by the FDA in any U.S. region in the future. Furthermore, due to the evolving COVID-19 landscape and based on discussions with the FDA, we and GSK do not plan to file a BLA for sotrovimab at this time. Although certain countries outside of the U.S., such as Canada and Japan, continue to maintain access to sotrovimab 500 mg IV while noting that it is unlikely to maintain efficacy against certain Omicron subvariants, we cannot predict whether other countries will further limit the use of sotrovimab. We have not obtained regulatory approval for any other product candidates, and we do not expect to generate significant revenue from the sale of our other product candidates until we complete clinical development, submit regulatory filings and receive approvals from the applicable regulatory bodies for such product candidates, if ever.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our net income was $515.8 million and $528.6 million for the years ended December 31, 2022 and 2021, respectively. Our net loss was $298.7 million for the year ended December 31, 2020. As of December 31, 2022, we had retained earnings of $377.2 million. Our primary use of our capital resources is to fund our operating expenses, which consist primarily of expenditures related to identifying, acquiring, developing, manufacturing and in-licensing our technology platforms and product candidates, and conducting preclinical studies and clinical trials, and to a lesser extent, selling, general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses. Although we began recognizing revenue for sotrovimab and have substantial deferred revenue under our definitive collaboration agreement with GSK executed in May 2021, or the 2021 GSK Agreement, we may continue to incur net operating losses for at least the next several years as the extent of future revenue remains uncertain. In particular, we expect our expenses and losses to increase as we continue our research and development efforts, advance our product candidates through preclinical and clinical development, seek regulatory approval, and prepare for commercialization, as well as hire additional personnel, protect our intellectual property and incur additional costs associated with being a public company. We also expect to increase the size of our administrative functions to support the growth of our business. Our net losses may fluctuate significantly from quarter-to-quarter and year-to-year, depending on the timing of our clinical trials and our expenditures on other research and development activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">126</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are currently manufacturing product candidates from three of our platforms: antibodies, T cells and siRNAs. We have established our own internal process development, manufacturing and quality capabilities and are working with contract development and manufacturing organizations, or CDMOs, to supply our early- and late-stage product candidates in the near term. We continue to expand our internal capabilities and resources in process development, analytical development, quality, manufacturing and supply chain, which are supported by our San Francisco, California, and Portland, Oregon facilities that include laboratories for process development, production of HCMV research viral seed stock and selected quality control testing for our product candidates. We have established relationships with multiple CDMOs and have produced material to support preclinical studies and Phase 1 through Phase 3 clinical trials. Material for Phase 3 clinical trials and commercial supply will generally require large-volume, low-cost-of-goods production. For example, for sotrovimab, we and our collaborator GSK have executed manufacturing agreements with CDMOs having large-scale capacity to support future scale-up and product supply, particularly for potential commercialization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">COVID-19 Business Update and Macroeconomic Uncertainties</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have implemented a number of plans and policies designed to address and mitigate the impact of the COVID-19 pandemic on our employees and our business. We continue to closely monitor the COVID-19 situation and will evolve our plans and policies as needed going forward. As a result of these developments, in March 2020, we implemented work-from-home policies for most of our employees. We now offer all our employees the choice of working full time in the office, a hybrid approach, or full-time remote. As a result, we expect to continue to be subject to the challenges and risks of having a remote workforce, as well as new challenges and risks from operating with a hybrid workforce. We are working closely with our CDMOs to manage our supply chain activities and mitigate any potential disruptions to our clinical trial supplies as a result of the COVID-19 pandemic. However, there are no assurances that our manufacturing and supply chain infrastructure will remain uninterrupted and reliable, or that the CDMOs will be able to satisfy demand in a timely manner and not have supply chain disruptions due to COVID-19 related shutdowns, stock-outs due to raw material shortages and/or greater than anticipated demand or quality issues given the operational challenges and raw material shortages that have been experienced during the COVID-19 pandemic. In addition, we rely on contract research organizations or other third parties to assist us with clinical trials, and we cannot guarantee that they will continue to perform their contractual duties in a timely and satisfactory manner as a result of the COVID-19 pandemic.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition to the impacts described above, the global economy, including the financial and credit markets, has recently experienced extreme volatility and disruptions, including increases to inflation rates, rising interest rates, declines in consumer confidence, declines in economic growth, and uncertainty about economic stability. The severity and duration of the impact of these conditions on our business cannot be predicted.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our Collaboration, License and Grant Agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have entered into collaboration, license and grant arrangements with various third parties. For details regarding these and other agreements, see the section titled &#x201c;Business&#x2014;Our Collaboration, License and Grant Agreements&#x201d; and Note</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6&#x2014;Grant Agreements and Note 7&#x2014;Collaboration and License Agreements to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Components of Operating Results</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenues</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To date, sotrovimab has been granted emergency authorization, temporary authorization or marketing approval (under the brand name Xevudy&#174;), supplying more than 40 countries. Although we have previously recognized revenue from our profit-share under our definitive collaboration agreement with GSK executed in June 2020, or the 2020 GSK Agreement, related to sotrovimab, we may continue to incur net operating losses for at least the next several years as the extent of future revenue from the sale of sotrovimab remains uncertain. Although we have an EUA from the FDA for sotrovimab, the FDA has excluded the use of sotrovimab in all U.S. regions due to the continued proportion of COVID-19 cases caused by certain Omicron subvariants. With this EUA revision, sotrovimab is not currently authorized for use in any U.S. region. Although certain countries outside of the U.S., such as Canada and Japan, continue to maintain access to sotrovimab 500 mg IV while noting that it is unlikely to maintain efficacy against certain Omicron subvariants, we cannot predict whether other countries will further limit the use of sotrovimab. In addition, due to the evolving COVID-19 landscape and based on discussions with the FDA, we and GSK do not plan to file a BLA for sotrovimab at this time. In light of these developments, we cannot predict whether (if at all) or to what extent sotrovimab may be reauthorized for use by the FDA in any U.S. region in the future. In addition, we have not obtained regulatory approval for any other product candidates, and we do not expect to generate any significant revenue from the sale of our other product candidates until we complete clinical development, submit regulatory filings and receive approvals from the applicable regulatory bodies for such product candidates, if ever.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">127</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our revenues consist of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Collaboration revenue</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> includes recognition of our profit-share from the sales of sotrovimab pursuant to the 2020 GSK Agreement. Our contractual share of 72.5% from the sales of sotrovimab is applied to the net sales reported in the period by GSK, net of cost of goods sold and allowable expenses from both GSK and us (e.g., manufacturing, distribution, medical affairs, selling, and marketing expenses). In order to record collaboration revenue, we utilize certain information from our collaboration partner, including actual net product sales and costs incurred for sales activities, and make key judgments based on business updates related to commercial and clinical activities such as expected commercial demand, commercial supply plan, manufacturing commitments, risks related to expired or obsolete inventories, and risks related to potential product returns or contract terminations.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Constraint on variable consideration</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In May 2021, the FDA granted an EUA in the U.S. for sotrovimab. In April 2022, the FDA excluded the use of sotrovimab in all U.S. regions due to the continued proportion of COVID-19 cases caused by certain Omicron subvariants. As the lead party for all manufacturing and commercialization activities, GSK incurs all of the manufacturing, sales and marketing expenses and is the principal on sales transactions with third parties. Our accounting policy related to the profit-share is to consider the agreed-upon share of the profit-sharing amounts each quarter and evaluate whether those amounts are subject to potential future adjustments based on the latest available facts and circumstances, subject to the terms of the 2020 GSK Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As we are the agent under the 2020 GSK Agreement, we recognize our contractual share of the profit-sharing amounts or royalties (in case of an opt-out) as revenue, based on sales net of estimated various deductions such as rebates, discounts, chargebacks, credits and returns, less cost of sales and allowable expenses (including manufacturing, distribution, medical affairs, selling, and marketing expenses) in the period the sale occurs. Manufacturing costs include inventory revaluation adjustments, lower of cost or market inventory adjustments, inventory write-downs and write-offs, and binding purchase commitments with a third-party manufacturer among other manufacturing costs. Our contractual share of the profit-sharing amounts is subject to potential future adjustments to allowable expenses, which we account for as a form of variable consideration.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, GSK held certain potentially excess binding supply manufacturing commitments of sotrovimab and reserved certain binding manufacturing capacity potentially not expected to be utilized, which have not yet been reported to us as allowable manufacturing expenses for the cumulative profit-sharing amounts to date. We expect GSK to adjust allowable manufacturing expenses for our share of the potential charge for excess supply write-offs and unused binding manufacturing capacity and report to us as cost-sharing amounts in future periods. We evaluated the latest available facts and circumstances to determine whether any portion of profit-sharing amounts should be constrained. In doing so, as of December 31, 2022, based on the current state of the COVID-19 pandemic, including the continued proportion of cases caused by certain Omicron subvariants, discussions with the FDA and other regulatory authorities, and our expectations for future sales in light of these factors, we revised our estimates and determined that $369.7 million should be constrained from profit-sharing revenues earned in relation to our anticipated contractual share of potential future adjustments to manufacturing expenses and recorded such amount as adjustments to profit-sharing amounts recognized in the year ended December 31, 2022 and accrued and other liabilities. We will re-assess these estimates each reporting period. Actual results could materially differ from this estimate.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Contract revenue</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> includes recognition of revenue generated from license rights issued to GSK, from research and development services under other third-party contracts, and from a clinical supply agreement with Brii Bio, a related party.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Grant revenue</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> is comprised of revenue derived from grant agreements with government-sponsored and private organizations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">License revenue</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">from a related party</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> is comprised of revenue related to Brii Bio&#x2019;s exercise of its option to obtain exclusive rights to develop and commercialize compounds arising from VIR-3434 in mainland China, Hong Kong, Macau and Taiwan recognized in the year ended December 31, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Operating Expenses</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cost of Revenue</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cost of revenue currently represents royalties earned by third-party licensors on net sales of sotrovimab by us or our collaborators. We recognize these royalties as cost of revenue when we recognize the corresponding revenue that gives rise to payments due to our licensors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">128</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To date, our research and development expenses have related primarily to discovery efforts and preclinical and clinical development of our product candidates. Research and development expenses are recognized as incurred and payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received. We do not track research and development expenses by product candidate.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expenses consist primarily of costs incurred for our product candidates in development and prior to regulatory approval, which include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">expenses related to license and collaboration agreements, and change in fair value of certain contingent consideration obligations arising from business acquisitions; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">personnel-related expenses, including salaries, benefits and stock-based compensation for personnel contributing to research and development activities; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">expenses incurred under agreements with third-party contract manufacturing organizations, contract research organizations, and consultants; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">clinical costs, including laboratory supplies and costs related to compliance with regulatory requirements; and </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">other allocated expenses, including expenses for rent and facilities maintenance, and depreciation and amortization. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect our research and development expenses to increase substantially in absolute dollars for the foreseeable future as we advance our product candidates into and through preclinical studies and clinical trials and pursue regulatory approval of our product candidates. The process of conducting the necessary clinical research to obtain regulatory approval is costly and time-consuming. The actual probability of success for our product candidates may be affected by a variety of factors including: the safety and efficacy of our product candidates, early clinical data, investment in our clinical programs, the ability of collaborators to successfully develop our licensed product candidates, competition, manufacturing capability and commercial viability. To date, sotrovimab has been granted emergency authorization, temporary authorization or marketing approval (under the brand name Xevudy&#174;), supplying more than 40 countries. Although we have an EUA from the FDA for sotrovimab, the FDA has excluded the use of sotrovimab in all U.S. regions due to the continued proportion of COVID-19 cases caused by certain Omicron subvariants. With this EUA revision, sotrovimab is not currently authorized for use in any U.S. region. In light of these developments, we cannot predict whether (if at all) or to what extent sotrovimab may be reauthorized for use by the FDA in any U.S. region in the future. In addition, due to the evolving COVID-19 landscape and based on discussions with the FDA, we and GSK do not plan to file a BLA for sotrovimab at this time. Although certain countries outside of the U.S., such as Canada and Japan, continue to maintain access to sotrovimab 500 mg IV while noting that it is unlikely to maintain efficacy against certain Omicron subvariants, we cannot predict whether other countries will further limit the use of sotrovimab. Furthermore, COVID-19 treatment standards are susceptible to rapid changes in epidemiology and the emergence of new variants or subvariants, which may render sotrovimab inferior or obsolete in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a result of the uncertainties discussed above, we are unable to determine the duration and completion costs of our research and development projects or when and to what extent we will generate significant revenue from the commercialization and sale of any of our product candidates. Clinical and preclinical development timelines, the probability of success and development costs can differ materially from expectations. We anticipate that we will make determinations as to which product candidates to pursue and how much funding to direct to each product candidate on an ongoing basis in response to the results of ongoing and future preclinical studies and clinical trials, regulatory developments, our ongoing assessments as to each product candidate&#x2019;s commercial potential and the impact of public health epidemics, such as the COVID-19 pandemic. In addition, we cannot forecast which product candidates may be subject to future collaborations, when such arrangements will be secured (if at all) and to what degree such arrangements would affect our development plans and capital requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our clinical development costs may vary significantly based on factors such as:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">whether a collaborator is paying for some or all of the costs; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">per patient trial costs; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the number of trials required for approval; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the number of sites included in the trials; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">enrollment and retention of patients in trials in countries disrupted by geopolitical events, including civil or political unrest;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the length of time required to enroll eligible patients; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">129</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the number of patients that participate in the trials; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the number of doses that patients receive; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the drop-out or discontinuation rates of patients; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">potential additional safety monitoring requested by regulatory agencies; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the duration of patient participation in the trials and follow-up; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the cost and timing of manufacturing our product candidates; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the phase of development of our product candidates; and </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the efficacy and safety profile of our product candidates. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Selling, General and Administrative</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our selling, general and administrative expenses consist primarily of personnel-related expenses for personnel in executive, finance and other administrative functions, facilities and other allocated expenses, other expenses for outside professional services, including legal, audit and accounting services, insurance costs and change in fair value of certain contingent consideration obligations arising from business acquisitions. Personnel-related expenses consist of salaries, benefits and stock-based compensation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We expect our selling, general and administrative expenses to increase substantially in absolute dollars in the foreseeable future as we continue to support our research and development activities, and commercialization activities for any of our product candidates, if approved, and to grow our business. We also anticipate incurring additional expenses associated with operating as a public company, including increased expenses related to audit, legal, regulatory, and tax-related services associated with maintaining compliance with the rules and regulations of the Securities and Exchange Commission, or SEC, and standards applicable to companies listed on a national securities exchange, additional insurance expenses, investor relations activities and other administrative and professional services.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Change in Fair Value of Equity Investments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in fair value of equity investments consists of the remeasurement of our investment in Brii Biosciences Limited&#x2019;s, or Brii Bio Parent, ordinary shares based on the quoted market price at each reporting date.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Interest Income</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest income consists of interest earned on our cash, cash equivalents and investments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other Income (Expense), Net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income (expense), net consists of gains and losses from foreign currency transactions and the remeasurement of contingent consideration related to our acquisition of TomegaVax, Inc., or TomegaVax.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Provision for Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Provision for income taxes consisted primarily of income tax on our domestic and foreign operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">130</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Results of Operations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Comparison of Years Ended December 31, 2022 and 2021</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes our results of operations for the periods presented:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.024%;"></td>
    <td style="width:1.496%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.700000000000001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.496%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.894%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.496%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.894%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenues:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaboration revenue</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,505,469</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">917,194</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">588,275</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contract revenue</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52,714</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">169,874</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(117,160</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">License revenue from a related party</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22,289</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22,289</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Grant revenue</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35,325</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,347</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26,978</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total revenues</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,615,797</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,095,415</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">520,382</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cost of revenue</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">146,319</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65,865</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">80,454</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">474,648</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">448,006</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26,642</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Selling, general and administrative</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">161,762</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">160,793</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">969</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">782,729</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">674,664</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">108,065</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income from operations</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">833,068</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">420,751</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">412,317</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income (expense):</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in fair value of equity investments</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(111,140</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">138,049</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(249,189</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest income</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28,092</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">439</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,653</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income (expense), net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,260</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(9,437</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,697</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total other income (expense)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(78,788</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">129,051</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(207,839</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income before provision for income taxes</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">754,280</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">549,802</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">204,478</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Provision for income taxes</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(238,443</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(21,218</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(217,225</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net income</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">515,837</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">528,584</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(12,747</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenues</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The increase in collaboration revenue for the year ended December 31, 2022 compared to the same period in 2021 was due to our profit-sharing arrangement with GSK for the sale of sotrovimab under the 2020 GSK Agreement. Our contractual share of 72.5% from the sales of sotrovimab is applied to the profit-sharing amounts, based on sales net of various estimated deductions such as rebates, discounts, chargebacks, credits and returns, less cost of sales and allowable expenses (including manufacturing, distribution, medical affairs, selling, and marketing expenses) in the period the sale occurs, and any amount constrained in relation to our anticipated contractual share of potential future adjustments to manufacturing expenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The decrease in contract revenue for the year ended December 31, 2022 compared to the same period in 2021 was primarily due to $168.3 million related to the license granted to GSK upon execution of the 2021 GSK Agreement, partially offset by $39.8 million recognized in 2022 related to GSK&#x2019;s selection of respiratory syncytial virus, or RSV, as its first pathogen under the additional programs to develop neutralizing mAbs under the 2021 GSK Agreement, or First Option Exercise, and $7.0 million related to the additional license granted to GSK in mainland China, Hong Kong, Macau and Taiwan upon execution of the Amendment No. 1 to the 2020 GSK Agreement in the second quarter of 2022.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The increase in license revenue from a related party for the year ended December 31, 2022 compared to the same period in 2021 was due to $22.3 million related to Brii Bio&#x2019;s exercise of its option to obtain exclusive rights to develop and commercialize compounds and products arising from VIR-3434 in China, Taiwan, Hong Kong and Macau. No comparable amount was incurred for the same period in 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The increase in grant revenue for the year ended December 31, 2022 compared to the same period in 2021 was primarily due to the grant revenue recognized in connection with the BARDA agreement and the timing of research activities under the grant agreements with the Bill &amp; Melinda Gates Foundation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">131</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cost of Revenue</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The increase in cost of revenue for the year ended December 31, 2022 compared to the same period in 2021 was due to third-party royalties owed based on the sales of sotrovimab under the 2020 GSK Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">   </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table shows the primary components of our research and development expenses for the periods presented:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.449%;"></td>
    <td style="width:1.388%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.504%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.407%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.922%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.407%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.922%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Personnel</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">157,167</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">121,779</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35,388</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Clinical costs</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">118,849</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">97,505</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21,344</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Licenses, collaborations and contingent consideration</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">54,087</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">132,355</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(78,268</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contract manufacturing</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">47,960</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31,613</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,347</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">96,585</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">64,754</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31,831</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total research and development expenses</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">474,648</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">448,006</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26,642</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The increase in research and development expenses for the year ended December 31, 2022 compared to the same period in 2021 was primarily due to the following factors:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">personnel-related expenses increased by $35.4 million, which was primarily attributable to an increase in our headcount; </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">clinical costs increased by $21.3 million, which was primarily attributable to activities related to VIR-2482, VIR-2218 and VIR-3434, partially offset by activities related to the clinical trials for sotrovimab in the same period of 2021;</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">contract manufacturing increased by $16.3 million, which was primarily related to an increase in manufacturing activities for our product candidates; and</span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">other research and development expenses increased by $31.8 million, which was primarily attributable to the allocation of facilities and other costs due to an increase in our headcount, and higher outsource research and lab-related expenses;</span></div></div>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">partially offset by</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">licenses, collaborations and contingent consideration expenses decreased by $78.3 million, which was primarily attributable to a decrease of $50.6 million in costs under our collaboration agreements with GSK, and $37.2 million related to the change in fair value of the contingent consideration from our acquisition of Humabs BioMed SA, or Humabs, partially offset by $7.0 million recognized in connection with the termination of our development and manufacturing collaboration agreement with WuXi Biologics (Hong Kong) Limited, or WuXi Biologics.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Selling, General and Administrative Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The increase in selling, general and administrative expenses for the year ended December 31, 2022 compared to the same period in 2021 was primarily due to higher personnel-related expenses related to additional headcount, external consulting services, business tax expenses related to increased profit-sharing amount and allocated facilities costs due to higher lease expenses. This was partially offset by $39.4 million in fair value of the contingent consideration related to sales-based milestones from our acquisition of Humabs that were achieved in 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Change in Fair Value of Equity Investments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In July 2021, Brii Bio Parent became a publicly traded company on the Stock Exchange of Hong Kong Limited. In connection with the initial public offering, our investment in shares of Brii Bio Parent became a marketable equity investment and subsequently remeasured to fair value at each reporting period. For the year ended December 31, 2022, we recognized an unrealized loss of $111.1 million due to the change in fair value of the equity investment, compared to an unrealized gain of $138.0 million for the same period in 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">132</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Interest Income</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The increase in interest income was primarily due to higher interest rates as well as higher balances of short-term and long-term investments, partially offset by higher amortization of premium on investment balances, for the year ended December 31, 2022 compared to the same period in 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Other Income (Expense), Net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The increase in other income (expense), net for the year ended December 31, 2022 compared to the same period in 2021 was primarily due to the change in fair value of the contingent consideration related to our acquisition of TomegaVax.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Provision for Income Taxes</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The increase in provision for income taxes for the year ended December 31, 2022 compared to the same period in 2021 was primarily due to taxable income for 2022 attributable to collaboration revenue under the 2020 GSK agreement and the requirement under the Tax Cuts and Jobs Act of 2017 for taxpayers to capitalize and amortize research and development expenditures over five or fifteen years pursuant to Section 174 of the Internal Revenue Code of 1986, as amended.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Liquidity, Capital Resources and Capital Requirements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sources of Liquidity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To date, we have financed our operations primarily through sales of our common stock from our initial public offering and subsequent follow-on offering, sales of our convertible preferred securities, and payments received under our grant and collaboration agreements. As of December 31, 2022, we had $2.4 billion in cash, cash equivalents, and investments. As of December 31, 2022, we had retained earnings of $377.2 million. We entered into a sales agreement, or the Sales Agreement, with Cowen and Company, LLC, or Cowen, in 2020 pursuant to which we may from time to time offer and sell shares of our common stock for an aggregate offering price of up to $300.0 million, through or to Cowen, acting as sales agent or principal. We will pay Cowen a commission of up to 3.0% of the aggregate gross proceeds from each sale of shares, reimburse legal fees and disbursements and provide Cowen with customary indemnification and contribution rights. As of December 31, 2022, no shares have been issued under the Sales Agreement.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our primary use of our capital resources is to fund our operating expenses, which consist primarily of expenditures related to identifying, acquiring, developing, manufacturing and in-licensing our technology platforms and product candidates, and conducting preclinical studies and clinical trials, and to a lesser extent, selling, general and administrative expenditures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Future Funding Requirements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based upon our current operating plan, we believe that our existing cash, cash equivalents and investments as of December 31, 2022 as noted above will enable us to fund our operations for at least the next 12 months. However, our operating plan may change as a result of many factors currently unknown to us, and we may need to seek additional financing to fund our long-term operations sooner than planned. Moreover, it is particularly difficult to estimate with certainty our future revenue and expenses given the dynamic and rapidly evolving nature of our business and the COVID-19 pandemic environment generally. For example, in March and April 2022, the FDA amended the EUA fact sheet to exclude sotrovimab use in geographic regions where infection is likely to have been caused by a non-susceptible SARS-CoV-2 variant based on available information, including variant susceptibility to these drugs and regional variant frequency. With these EUA revisions, sotrovimab is not currently authorized for use in any U.S. region. In light of these developments, we cannot predict whether (if at all) or to what extent sotrovimab may be reauthorized for use by the FDA in any U.S. region in the future. In addition, due to the evolving COVID-19 landscape and based on discussions with the FDA, we and GSK do not plan to file a BLA for sotrovimab at this time. It is possible that the FDA and other regulatory authorities may not grant sotrovimab full marketing approval for the treatment of COVID-19, or that any such marketing approvals, if granted, may have similar or other significant limitations on its use.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We may also need to raise additional capital to complete the development and commercialization of our product candidates and fund certain of our existing manufacturing and other commitments. We expect to finance our cash needs through public or private equity or debt financings, third-party (including government) funding and marketing and distribution arrangements, as well as other collaborations, strategic alliances and licensing arrangements, or any combination of these approaches. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be or could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise funds through collaborations, licenses and other similar arrangements with third parties, we may have to</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">133</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us and/or may reduce the value of our common stock. There can be no assurance that sufficient funds will be available to us on attractive terms or at all. If we are unable to obtain additional funding from these or other sources, it may be necessary to significantly reduce our rate of spending through reductions in staff and delaying, scaling back, or stopping certain research and development programs. Insufficient liquidity may also require us to relinquish rights to product candidates at an earlier stage of development or on less favorable terms than we would otherwise choose.  General economic conditions , both inside and outside the U.S., including heightened inflation, capital market volatility, interest rate and currency rate fluctuations, and economic slowdown or recession as well as the COVID-19 pandemic and geopolitical events, including civil or political unrest (such as the ongoing war between Ukraine and Russia) have resulted in a significant disruption of global financial markets. If the disruption persists and deepens, we could experience an inability to access additional capital. and geopolitical events, including civil or political unrest (such as the ongoing war between Ukraine and Russia) have resulted in a significant disruption of global financial markets, market volatility, high levels of inflation, and interest rate fluctuations may increase our cost of financing or restrict our access to potential sources of future liquidity.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have based our projections of operating capital requirements on assumptions that may prove to be incorrect and we may use all of our available capital resources sooner than we expect. Because of the numerous risks and uncertainties associated with research, development and commercialization of biotechnology products, we are unable to estimate the exact amount of our operating capital requirements. See the section titled &#x201c;Risk Factors&#x2014;Risks Related to Our Financial Position and Capital Needs&#x201d; for a description of certain risks that will affect our future capital requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have various operating lease arrangements for office and laboratory spaces located in California, Oregon, Missouri and Switzerland with contractual lease periods expiring between 2022 and 2033. As of December 31, 2022, we expect to make total lease payments of $175.0 million through 2033.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To date, we have entered into collaboration, license and acquisition agreements where the payment obligations are contingent upon future events such as our achievement of specified development, regulatory and commercial milestones, and we are required to make royalty payments in connection with the sale of products developed under those agreements. For additional information regarding these agreements, including our payment obligations thereunder, see the sections titled &#x201c;Business&#x2014;Our Collaboration, License and Grant Agreements&#x201d; and &#x201c;Business&#x2014;Our Acquisition Agreements,&#x201d; as well as Note 4&#x2014;Acquisitions and Note 7&#x2014;Collaboration and License Agreements to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K. For information related to our future commitments under our facilities and manufacturing agreements, see Note 9&#x2014;Commitments and Contingencies to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash Flows</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes our cash flows for the periods indicated:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.416%;"></td>
    <td style="width:1.56%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.208%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.56%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.254%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash provided by (used in):</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,663,253</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(47,589</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Investing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1,193,461</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(140,814</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financing activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34,761</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100,331</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net (decrease) increase in cash and cash equivalents and restricted <br />&#160;&#160;&#160;cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">504,553</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(88,072</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Operating Activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the year ended December 31, 2022, net cash provided by operating activities was $1.7 billion. This consisted primarily of net income of $515.8 million, non-cash charges of $575.9 million, and an increase in our net operating assets of $665.4 million, partially offset by $93.8 million for payment for contingent consideration in excess of acquisition date fair value. The change in our net operating assets of $665.4 million was primarily due to a decrease in collaboration receivable by $770.0 million resulting from our profit-share from the sale of sotrovimab, partially offset by a $33.3 million decrease in deferred revenue primarily driven by GSK's First Option Exercise and Brii Bio's exercise for VIR-3434 netted with the grants received from Bill &amp; Melinda Gates Foundation, an increase in prepaid expenses and other current assets by $39.4 million and an increase in other assets by $11.8 million, which are due to timing of payments. The non-cash charges of $575.9 million primarily consisted of $369.5 million for change in estimated</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">134</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">constraint on profit-sharing amount, an unrealized loss of $111.1 million on our equity investment, $102.1 million for stock-based compensation expense and $8.7 million for noncash lease expense, partially offset by $15.2 million for deferred income tax.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the year ended December 31, 2021, net cash used in operating activities was $47.6 million. This consisted primarily of net income of $528.6 million and non-cash charges of $203.3 million, offset by an unrealized gain of $138.0 million on our equity investment, payment of contingent consideration of $8.1 million for the achievement of a milestone related to our TomegaVax acquisition, a gain of $4.8 million from a sublease termination, and an increase in our net operating assets of $628.4 million. The change in our net operating assets of $628.4 million was primarily due to an increase in receivable from collaboration by $773.1 million resulting from our profit share from the sale of sotrovimab, and an increase in prepaid expenses and other current assets of $3.7 million, partially offset by an increase in deferred revenue of $92.0 million driven by the upfront fee received under the 2021 GSK Agreement, and an increase in accrued liabilities and other long-term liabilities of $58.5 million due to timing of payments. The non-cash charges of $203.3 million primarily consisted of $91.8 million for revaluation of contingent consideration, $83.8 million for stock-based compensation expense, $15.2 million for deferred income tax expense, $6.2 million for noncash lease expense, and $5.3 million for depreciation and amortization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Investing Activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the year ended December 31, 2022, net cash used in investing activities was $1.2 billion. This consisted primarily of purchases of investments of $1.5 billion and property and equipment of $68.0 million, partially offset by $351.5 million in proceeds received from investments that matured during the period.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the year ended December 31, 2021, net cash used in investing activities was $140.8 million. This consisted primarily of purchases of investments of $420.2 million and property and equipment of $21.8 million, partially offset by $301.2 million in proceeds received from investments that matured during the period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Financing Activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the year ended December 31, 2022, net cash provided by financing activities was $34.8 million. This consisted primarily of proceeds from the issuance of our common stock to the Bill &amp; Melinda Gates Foundation of $28.5 million under the stock purchase agreement, from exercises of stock options of $4.5 million, and from issuance of common stock under our employee stock purchase plan of $3.2 million, partially offset by $1.2 million for payment of contingent consideration.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the year ended December 31, 2021, net cash provided by financing activities was $100.3 million. This consisted primarily of proceeds received from the issuance of our common stock to Glaxo Group Limited (an affiliate of GSK) of $85.2 million in March 2021, from exercises of stock options of $13.1 million, and from issuance of common stock under our employee stock purchase plan of $2.3 million.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Critical Accounting Policies and Estimates</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States. The preparation of our consolidated financial statements requires us to make assumptions and estimates about future events and apply judgments that affect the reported amounts of assets, liabilities, revenue and expenses and the related disclosures. We base our estimates on historical experience and other assumptions that we believe to be reasonable under the circumstances. Actual results may differ from these estimates. The critical accounting policies, estimates and judgments that we believe to have the most significant impacts on our consolidated financial statements are described below. For more detail on our critical accounting policies, refer to Note 2&#x2014;Summary of Significant Accounting Policies to our consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue Recognition</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Collaboration, License and Contract Revenue</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under Accounting Standards Codification, or ASC, Topic 606, Revenue from Contracts with Customers, or ASC 606, we recognize revenue when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods and services. To determine revenue recognition for arrangements within the scope of ASC 606, we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when or as we satisfy a performance obligation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">135</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For collaborative arrangements that fall within the scope of ASC 808, Collaborative Arrangements, or ASC 808, we first determine which elements of the collaboration are deemed to be performance obligations with a customer within the scope of ASC 606. For elements of collaboration arrangements that are accounted for pursuant to ASC 808 and are not subject to the guidance in ASC 606, we apply the revenue recognition model under ASC 606, including the royalty exception guidance and variable consideration guidance under ASC 606 as described below, or other guidance, as deemed appropriate. When we are considered an agent in elements of collaboration arrangements within the scope of ASC 808, we record our share of collaboration revenue in the period in which such sales occur. We are considered an agent when the collaboration partner controls the product before transfer to the customers and has the ability to direct the use of and obtain substantially all of the remaining benefits from the product. In these instances, collaboration revenue is based upon the net sales reported by our collaboration partners, net of cost of goods sold and allowable expenses (e.g., manufacturing, distribution, medical affairs, selling, and marketing expenses) in the period. In order to record collaboration revenue, we utilize certain information from our collaboration partner, including actual net product sales, and costs incurred for sales activities, and make key judgments based on business updates related to commercial and clinical activities such as expected commercial demand, commercial supply plan, manufacturing commitments, risks related to expired or obsolete inventories, and risks related to potential product returns or contract terminations. We use these estimates to determine whether payments due to us under our collaboration arrangements, such as profit-share payments, should be recognized as revenues in the period that they become due or whether any portion of the payments due should be constrained from revenue recognition because it is not probable that recognizing such amounts would not result in a material reversal of revenues in future reporting periods. For the periods covered in the financial statements presented, there have been no material changes to prior period estimates of revenues and expenses, except the profit-share amount constrained in the year ended December 31, 2022, as discussed in Note 7&#x2014;Collaboration and License Agreements to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have entered into a number of license and collaboration agreements that fall within the scope of ASC 606. We evaluate the promised goods or services in these agreements to determine which ones represent distinct performance obligations. These agreements may include the following types of promised goods or services: (i) grants of licenses, (ii) performance of research and development services, and (iii) participation on joint research and/or development committees. They also may include options to obtain licenses to our intellectual property.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prior to recognizing revenue, we make estimates of the transaction price, including variable consideration that is subject to a constraint. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur and when the uncertainty associated with the variable consideration is subsequently resolved. These estimates are re-assessed each reporting period as required. These agreements may include the following types of consideration: non-refundable upfront payments, reimbursement for research services, research, development or regulatory milestone payments, profit-sharing arrangements, and royalty and commercial sales milestone payments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If there are multiple distinct performance obligations, we allocate the transaction price to each distinct performance obligation based on their estimated standalone selling prices, or SSP. We estimate the SSP for each distinct performance obligation by considering information such as market conditions, entity-specific factors, and information about our customer that is reasonably available to us. We consider estimation approaches that allow us to maximize the use of observable inputs. These estimation approaches may include the adjusted market assessment approach, the expected cost plus a margin approach or the residual approach. We also consider whether to use a different estimation approach or a combination of approaches to estimate the SSP for each distinct performance obligation. Developing certain assumptions (e.g., treatable patient population, expected market share, probability of success and product profitability, and discount rate based on weighted-average cost of capital) to estimate the SSP of a distinct performance obligation requires significant judgment. Accordingly, these assumptions are subject to uncertainty, and changing the methodology and/or assumptions could materially impact the estimated SSP for distinct performance obligations, and as a result, the amount and/or timing of revenue recognition.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For performance obligations satisfied over time, we estimate the efforts needed to complete the performance obligation and recognize revenue by measuring the progress towards complete satisfaction of the performance obligation using an input measure. For arrangements that include sales-based royalties, including commercial milestone payments based on pre-specified levels of sales, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Achievement of these royalties and commercial milestones may solely depend upon the performance of the licensee.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management may be required to exercise considerable judgment in estimating revenue to be recognized. Judgment is required in identifying performance obligations, estimating the transaction price, estimating the SSP of identified performance obligations, and estimating the progress towards satisfaction of performance obligations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">136</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Contingent Consideration and Embedded Derivatives</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contingent consideration related to business combinations and obligations required to be accounted for as embedded derivative financial instruments under Topic ASC 815, Derivatives and Hedging, are considered to be Level 3 instruments that are initially measured at their estimated fair values on the transaction date and subsequently remeasured with changes recorded in the consolidated statement of operations each subsequent reporting period.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The estimated fair value of the contingent consideration related to the Humabs acquisition was determined by calculating the probability-weighted clinical and regulatory milestone payments based on the assessment of the likelihood and estimated timing that certain milestones would be achieved, as well as use of a Monte Carlo simulation model that includes significant estimates and assumptions pertaining to commercialization events and sales targets. The most significant unobservable inputs are the probabilities of achieving clinical and regulatory approval of the development projects and the subsequent commercial success and discount rates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The estimated fair value of the contingent consideration related to our acquisition of TomegaVax was determined based on a Monte Carlo simulation model that includes significant estimates and assumptions pertaining to probability and timing to achieve the required share price of our common stock, expected volatility and discount rate. Although the TomegaVax acquisition was accounted for as an asset acquisition, such contingent consideration met the definition of an embedded derivative financial instrument.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Recent Accounting Pronouncements Not Yet Adopted</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">See Note 2&#x2014;Summary of Significant Accounting Policies to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K for information about recent accounting pronouncements, the timing of their adoption, and our assessment, to the extent we have made one yet, of their potential impact on our financial condition or results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_7a_quantitative_qualitative_disclos"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7A. Quantitative and Qualitati</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ve Disclosures About Market Risk.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We are exposed to market risks in the ordinary course of our business. These risks primarily relate to interest rate and market price sensitivities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Interest Rate Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We had cash, cash equivalents and restricted cash and cash equivalents of $868.0 million as of December 31, 2022, which primarily consisted of money market funds. We also had short-term and long-term investments of $1.5 billion as of December 31, 2022. The primary objective of our investment activities is to preserve capital to fund our operations. We also seek to maximize income from our investments without assuming significant risk. Because our investments are primarily short-term in duration and our holdings in U.S. government treasury bonds mature prior to our expected need for liquidity, we believe that our exposure to interest rate risk is not significant, and a 1% movement in market interest rates would not have a significant impact on the total value of our portfolio. We had no debt outstanding as of December 31, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Foreign Currency</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The functional currency of our foreign subsidiaries is the U.S. dollar. Monetary assets and liabilities of our foreign subsidiaries are translated into U.S. dollars at period-end exchange rates and non-monetary assets and liabilities are translated to U.S. dollars using historical exchange rates. Revenue and expenses are translated at average rates throughout the respective periods. As of the date of this Annual Report on Form 10-K, we are exposed to foreign currency risk primarily related to the operations of our Swiss and Australian subsidiaries and our collaboration with GSK and consequently the Swiss Franc, Australian dollar and British pound. Transaction gains and losses are included in other income (expenses), net on the condensed consolidated statements of operations and were not material for the years ended December 31, 2022, 2021 and 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Equity Investment Risk</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We hold ordinary shares of Brii Bio Parent, which we acquired in connection with our collaboration, option and license agreement. These equity securities are measured at fair value with any changes in fair value recognized in our consolidated statements of operations. The fair value of these equity securities was approximately $31.9 million as of December 31, 2022. Changes in the fair value of these equity securities are impacted by the volatility of the stock market and changes in general economic conditions, among other factors. A hypothetical 10% increase or decrease in the stock prices of these equity securities would increase or decrease their fair value as of December 31, 2022 by approximately $3.2 million.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">137</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_8_financial_statements"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 8. Financial St</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">atements and Supplementary Data.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:92.861%;"></td>
    <td style="width:7.139%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.069in;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Page</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Audited Consolidated Financial Statements</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.069in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#report_of_public_accounting_firm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Report of Independent Registered Public Accounting Firm (PCAOB ID: 42)</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.069in;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">139</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Balance Sheets as of December 31, 2022 and 2021</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.069in;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">141</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_operations"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements of Operations for the years ended December 31, 2022, 2021 and 2020</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.069in;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">142</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_comprehensive_lo"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements of Comprehensive Income (Loss) for the years ended December 31, 2022, 2021 and 2020</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.069in;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">143</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_convertible_pref"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements of Stockholders&#x2019; Equity for the years ended December 31, 2022, 2021 and 2020</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.069in;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">144</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements of Cash Flows for the years ended December 31, 2022, 2021 and 2020</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.069in;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">145</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#notes_to_consolidated_financial_statemen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.069in;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">146</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">138</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="report_of_public_accounting_firm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To the Shareholders and the Board of Directors of Vir Biotechnology, Inc.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Opinion on the Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of Vir Biotechnology, Inc. (the Company) as of December 31, 2022 and 2021, the related consolidated statements of operations, consolidated statements of comprehensive income (loss),  consolidated statements of stockholders&#x2019; equity and cash flows for each of the three years in the period ended December 31, 2022, and the related notes (collectively referred to as the &#x201c;consolidated financial statements&#x201d;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2022, in conformity with U.S. generally accepted accounting principles.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated February 28, 2023 expressed an unqualified opinion thereon.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basis for Opinion</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#x2019;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Critical Audit Matter</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:15.519%;"></td>
    <td style="width:2.898%;"></td>
    <td style="width:81.583%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Collaboration revenue constraint</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Description of the Matter</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company constrained collaboration revenue by $369.7 million for the year ended December 31, 2022 under its June 9, 2020 Definitive Collaboration Agreement with Glaxo Wellcome UK Limited and GlaxoSmithKline Biologicals S.A (individually and collectively referred to as &#x201c;GSK&#x201d;)  (collectively referred to as the &#x201c;2020 GSK Collaboration&#x201d;). As discussed in Note 7 to the consolidated financial statements, the Company recognized collaboration revenue under the 2020 GSK Collaboration in connection with its contractual share of sotrovimab profit-sharing amounts, net of amounts constrained in relation to anticipated future adjustments to manufacturing costs not yet charged by GSK.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Auditing the Company&#x2019;s determination of collaboration revenue constrained was especially challenging because the calculation required a number of judgmental inputs, such as projected sales of sotrovimab, estimates made for future costs related to excess binding supply manufacturing commitments of sotrovimab and certain binding manufacturing capacity potentially not expected to be utilized, which have not yet been charged by GSK to the Company as allowable manufacturing expenses for the cumulative profit-sharing amounts earned to date.</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">139</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:15.519%;"></td>
    <td style="width:2.898%;"></td>
    <td style="width:81.583%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;margin-top:0.0pt;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;margin-top:0.0pt;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">How We Addressed the Matter in Our Audit</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.08in;vertical-align:top;padding-right:0.08in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To test the collaboration revenue constraint, our audit procedures included, among others, testing the completeness and accuracy of the underlying data by obtaining direct confirmation from GSK regarding the terms and conditions of the collaboration, the amount of excess supply manufacturing commitments of sotrovimab and binding manufacturing capacity not expected to be utilized. To assess the reasonableness of the estimates made, we inquired of personnel outside of the accounting and finance function to verify the appropriateness of assumptions based on their understanding of the agreements in place between GSK and its counterparties.  We inspected Joint Steering Committee minutes between GSK and the Company and the collaboration agreement between GSK and the Company. We also evaluated the Company&#x2019;s accounting analysis, which documents the judgments made to determine the amount of collaboration revenue to recognize during the year.</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Ernst &amp; Young LLP</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have served as the Company&#x2019;s auditor since 2017.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">San Mateo, California</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 28, 2023</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">140</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VIR BIOTECHNOLOGY, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Ba</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">lance Sheets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(in thousands, except share and per share data)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:62.789%;"></td>
    <td style="width:1.9%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:14.483%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.9%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:14.928%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ASSETS</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CURRENT ASSETS:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0c0372fe-e0e1-4011-a3b3-1d3f0add0892" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">848,631</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cc8d3e34-bad8-4afc-8a39-c397695fd051" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">347,815</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term investments</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7d5ee069-082a-44e1-af98-508aee134033" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,521,517</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9f909d58-36d9-473d-8962-ed869e905612" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">217,182</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted cash and cash equivalents, current</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4d60c376-d21a-4a11-8b4c-b5e6a3c674a0" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,681</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b3cda6af-1aac-498d-b98c-d91be18ffac7" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,594</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Receivable from collaboration</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ecab5e4d-4d02-431d-af31-26a84799387c" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d1958196-f68c-4533-9db2-17f502a56a26" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">773,079</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity investments</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_34360fb7-e882-4526-b756-0e95c4d3f8d8" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="vir:EquityInvestmentCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">31,892</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0fa9ed09-13fe-4c88-a2f4-d6d3ca1f42e1" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="vir:EquityInvestmentCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">143,148</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_698576d7-8d45-415b-90d3-39a23c3ecb21" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">104,356</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_09e578df-75d8-4e10-a0d5-50626d3dcea2" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">73,003</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total current assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5737418e-ab7e-4560-8d5d-85ad8d758638" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,519,077</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d8bf0bbe-1b03-40fe-aecc-e8cc1db2a1c3" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,562,821</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intangible assets, net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3e74716a-9c67-4b72-9670-1f607e1fc9c3" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">32,755</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_675b2a8f-a8c4-4c24-a5b7-298ce5cfd762" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">33,287</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Goodwill</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b776654b-02ae-4433-9823-be030fe98cce" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:Goodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,937</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f76d884e-d2e6-412f-8e99-2841afd63ea6" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:Goodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,937</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_61333742-ac47-4090-aaf3-97eaeee486af" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">105,609</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_17dd2498-3a32-4824-aaf7-be1a9c5b00da" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">42,834</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating right-of-use assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_95b554fd-06ac-4771-9bef-dab36dff8c0e" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">82,557</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_55da1375-bf9e-48f0-89e2-d5331e52fbd6" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">87,220</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted cash and cash equivalents, noncurrent</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fbdb5938-9505-44d4-8cf9-2eed0c53d0ca" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,656</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fee6c95b-9547-419a-b2f3-f4bae46cc81f" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,006</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Long-term investments</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_240292a7-9e08-456e-87b0-847ddae8dc52" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:LongTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">23,927</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4491bfe4-3dcd-4ac3-b475-296a4437b490" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:LongTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">201,388</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2a3a6f17-257a-45f1-a87a-a02447a2593a" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:OtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,570</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_035577b4-efc7-4eb4-9834-a8878a77c2f9" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:OtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,775</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TOTAL ASSETS</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_87fe50f0-7e09-4a92-bfae-1e532092773e" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,802,088</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f9292b64-e6cd-42ab-8543-abee57af2143" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,954,268</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LIABILITIES AND STOCKHOLDERS&#x2019; EQUITY</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CURRENT LIABILITIES:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ed85cb6b-63a1-4edc-810f-fa98a8339d78" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,422</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_02edaea8-063c-40bd-9b31-a00295367431" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,521</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued and other liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_59e2a8b8-cac3-4944-ad92-b23020af1380" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">489,090</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1674f22b-8b55-467b-b676-1bd8d7f0d92b" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">236,512</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred revenue, current portion</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e512eacb-c332-45a0-8b50-1d760ea5c013" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:DeferredRevenueCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,517</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f4c129da-d275-49bd-8aa1-681d9ef7a7ff" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:DeferredRevenueCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">98,209</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7247cd79-f35d-4f15-bc9d-b248e6d08553" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">511,029</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6dc4d817-0378-45ca-a333-4d327a7b0343" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">341,242</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred revenue, noncurrent</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_16dbbe9c-c16f-4d8a-863d-840a72296acc" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:DeferredRevenueNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">53,207</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_047fab38-bbdc-40be-89c5-5233ebe0919f" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:DeferredRevenueNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,815</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities, noncurrent</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_58c1daa1-bc60-48f1-9209-1adb42f95004" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">123,837</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c7978db1-548a-4f13-ab47-786c702312a1" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">133,561</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contingent consideration, noncurrent</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8509d840-3a3a-4a6e-8c15-3b8e5c423796" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">24,937</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b88bf1a8-b61e-42df-93f4-d686b71e5ced" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">22,822</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax liability</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eac83158-2631-41e8-adcf-2edb1a822fed" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,253</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_361dcc03-61c3-4c0e-9c6c-872560a1d855" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,439</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other long-term liabilities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cdb6393a-809f-4cfe-aaf9-d0410324f250" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,862</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_89063183-2ca0-47ab-ab59-545bb2e99e68" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,540</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TOTAL LIABILITIES</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ef38042c-53e1-4be1-9d03-65978125046d" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">724,125</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a54e8690-7114-42f7-bb9c-f231f52d759c" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">522,419</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_f8694a50-65fb-4c52-8533-1d35751b0dcd;"><span style="-sec-ix-hidden:F_51add2ca-9313-4a69-901e-884acd814211;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commitments and contingencies (Note 9)</span></span></span></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">STOCKHOLDERS&#x2019; EQUITY:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Preferred stock, $</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d8a233b8-7028-4ee6-bfe3-8a94d1a84626" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_USDollarShare" decimals="INF"><ix:nonFraction id="F_de428578-70d4-4e40-aab2-3563080cca8c" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_USDollarShare" decimals="INF">0.0001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;par value; </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d2282a3d-a3a6-49fe-8c81-e3598bbbbb20" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_ecc9e8c2-4c77-4416-921e-261d303209ff" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,000,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares authorized as of<br />&#160;&#160;&#160;December 31, 2022 and 2021, respectively; </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_50dc5163-65f7-4292-9ead-401b15e68c10" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_2dd59076-c38f-470c-9cd5-be03c02ecad8" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_704c1acc-8bc5-4142-b6c6-ac15745cbdb8" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_9bfc636d-d5ef-467f-9556-386899dd8666" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares issued and outstanding <br />&#160;&#160;&#160;as of December 31, 2022 and 2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_366ac0cc-12ef-4c69-af8b-9587847291c4" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f93df005-babf-428f-985e-0d226f7bb2ed" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stock, $</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e87c98de-bce5-44d5-b4bd-627a49e7cced" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_USDollarShare" scale="0" decimals="4"><ix:nonFraction id="F_4b990e6c-3bc0-4791-a1c2-d6e8f3b7471b" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_USDollarShare" scale="0" decimals="4">0.0001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;par value; </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_595263de-a873-4cde-b934-a78e0de0766b" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_cba8792f-e65b-4c70-be2c-55b4f153464f" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">300,000,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares authorized as of <br />&#160;&#160;&#160;December 31, 2022 and 2021, respectively; </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_def8766c-677c-4523-a9c1-fed94f23d7ed" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_2b042b3c-8939-4b9f-9c21-139e8bee712e" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">133,236,687</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;and </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fda68d90-39bb-42e9-957d-5c62c86d86eb" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_9f72fc3a-ef83-437b-bace-ac409bc3a023" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">131,161,404</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;shares <br />&#160;&#160;&#160;issued and outstanding as of December 31, 2022 and 2021, respectively</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5090a4fa-0317-4732-95a8-03ab3aad065a" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cf7f7a29-6b62-4fae-9825-06ea66ab8659" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_efaa3630-9ddf-463b-9a24-01f7fa112a83" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,709,835</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_065040b0-1132-41f9-8205-e9c146aa8e8b" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,571,535</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated other comprehensive loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8fe13a9c-2f07-4d92-9660-1fd2b6f04b57" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">9,122</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6f0ec6fb-8cdc-44cd-b17b-ec592c5053a2" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,099</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Retained earnings (Accumulated deficit)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_09ad07f4-761d-4924-850d-8f2fd6aa32d6" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">377,237</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fca94cbc-6f17-4eb8-af57-6eef8847cc3c" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">138,600</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TOTAL STOCKHOLDERS&#x2019; EQUITY</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b7ff6b25-c997-4735-a908-627a356fc9af" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,077,963</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7cc74789-5df0-4035-b3ed-1987b2e0827e" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,431,849</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TOTAL LIABILITIES AND STOCKHOLDERS&#x2019; EQUITY</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_936ef299-c3a2-4aef-b88d-6e05b1bd3f24" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,802,088</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a32324eb-88b7-4574-8e53-a061c9a9fdfa" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,954,268</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">141</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VIR BIOTECHNOLOGY, INC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_statements_operations"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Stateme</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">nts of Operations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(in thousands, except share and per share data)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.131%;"></td>
    <td style="width:1.499%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.725000000000001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.499%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.725000000000001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.499%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.92%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Revenues:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaboration revenue</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1b5231e3-d6e6-4b6b-8e9c-14fc948bb306" contextRef="C_ab50ccb4-8ce1-479d-85a9-8614fa9f9f31" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,505,469</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c5930e15-aba6-4fe3-a356-06fe2fe08144" contextRef="C_81d21c4d-29ea-4221-9ced-d1956f3f0671" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">917,194</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f7855fbb-062a-4476-9c8d-929ee3ee2e2c" contextRef="C_7b6a9230-282e-4c93-9f43-93b0661820c0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contract revenue</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3c1a3819-f4e2-40a3-98ab-ab44f585691f" contextRef="C_2ecba0e0-1f16-471e-a9c9-563bd3c3a21a" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">52,714</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cdc8885a-17cd-42d9-beba-1ed38b67c427" contextRef="C_c98c2bac-151f-4ae1-99e5-12401ef3eb67" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">169,874</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_61dd2de3-c41e-471e-bee6-456147dbb50a" contextRef="C_57d6ead3-d03e-4250-b98c-0c50109e7cfe" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">44,498</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">License revenue from a related party</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d27ebb54-55e4-4afe-8dba-60cb7da877bd" contextRef="C_b3553947-036a-44ba-af30-42a5788b9180" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">22,289</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c2a12076-021d-4673-9231-c5d3dc9c8806" contextRef="C_bcee63ec-ae69-4678-8b04-d29b3bc1370e" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1f650dca-fe98-41bc-8baa-a18a8f581706" contextRef="C_0df2a759-92c0-474a-a802-8afc81cf6ad0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">22,747</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Grant revenue</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_24ad1a7d-73fb-4146-8526-03cdbacc0682" contextRef="C_4c048e8b-01e1-4aa6-a204-9ba59db26a4f" name="us-gaap:RevenueNotFromContractWithCustomer" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">35,325</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f3fb9de7-733c-4f30-b847-bfeb7b4df014" contextRef="C_4e221e13-8b5d-42ea-833d-86521dba2dea" name="us-gaap:RevenueNotFromContractWithCustomer" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,347</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_696fa435-e3ca-4ee3-8d69-dd2a84b3c448" contextRef="C_d43fd0d1-a39e-4f48-bbed-09680ca7f602" name="us-gaap:RevenueNotFromContractWithCustomer" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,123</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total revenues</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b3025694-b833-4d27-aae4-43979a98d609" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,615,797</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c1017267-13a4-497e-a479-90ed844de680" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,095,415</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_07689af5-55ce-410b-878b-a5cd4680ea1c" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">76,368</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cost of revenue</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f21df124-66d1-46e7-9040-09768aa743c8" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:CostOfRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">146,319</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c8b02826-0280-4c14-97c7-2d5bd6acb55f" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:CostOfRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">65,865</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b8e3ea5d-5df5-44f3-9a58-de92ab3a09f7" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:CostOfRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_727dd20f-44be-4d6c-973e-b7be1d842a9f" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">474,648</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_331bb189-4b46-469c-a67b-86326178f9bd" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">448,006</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b3741e71-c2f1-440f-bef6-7bd2dea908cd" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">302,411</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Selling, general and administrative</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d77dffb6-8fa5-43a0-a746-e014ad390d68" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:SellingGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">161,762</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_103a9f60-2e5e-4a88-b823-06de263dba8d" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:SellingGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">160,793</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4f21a8d6-84a4-4f32-85ea-4025ba067740" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:SellingGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">70,937</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6376d491-7f2e-47ef-8538-b54da20c36ef" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:CostsAndExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">782,729</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a07fc4b6-8cc0-48cc-8a9b-d6dde10dbacb" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:CostsAndExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">674,664</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8a3a7ba8-63a0-45ed-a0fa-8635389e50b2" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:CostsAndExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">373,348</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income (loss) from operations</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9d514a94-d2ca-4921-9b82-077656184e5e" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">833,068</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c2204b34-29f8-4f00-8685-118d06cd65b2" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">420,751</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bfc46062-6c1d-492d-876e-025652fff2cb" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">296,980</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income (expense):</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in fair value of equity investments</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f20b14bc-3ef2-4cbb-8389-b2341f7698e3" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">111,140</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e47ccdf6-5b85-4d21-8b56-e91f2a1522e3" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">138,049</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cee00324-2e30-429f-a047-90b3e8338353" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Interest income</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4959e0b8-6d7e-4e34-92e6-475fc455fd0b" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">28,092</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_242ab647-b131-4d06-82b2-6888756d0185" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">439</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d90c36a6-68d7-4009-bec3-308113092448" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,836</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other income (expense), net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ea6a07ff-6b5b-40e0-9bd3-368f51b57670" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,260</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7f3a8181-d08b-4403-99f7-a6fa3f7bb684" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">9,437</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_29b7ae0f-2040-4e89-b2fd-9dff71b02d68" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">4,467</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total other income (expense)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_20751e25-9aa7-412f-870f-39115d09f627" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">78,788</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_df628013-14cf-4b78-aebb-7689026fc97a" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">129,051</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dbf0fc69-c7a1-4adc-bb0b-206fefd9142d" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,631</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income (loss) before provision for income taxes</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_12799b60-fb49-4169-84f4-e34298e1cdd8" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">754,280</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b46f63e8-07cf-4ecf-9868-639da0ce005b" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">549,802</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_16db759d-d929-49d3-b767-60d13252a768" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">298,611</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Provision for income taxes</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_926a81e1-a8db-4437-8d99-82c9873fbe96" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">238,443</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3ae53690-acfb-478c-8240-9106462d5dd1" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21,218</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8f46c547-cfb1-4f40-b5d6-156a2db0fd34" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">54</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net income (loss)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ae79d814-0b88-4cea-8be0-52d6e1cbe620" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">515,837</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d3a43965-27ee-40e1-a0b9-b0e18c4399ff" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">528,584</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2f79cd56-4607-4f66-999e-19cc32984747" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">298,665</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net income (loss) per share, basic</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c3699c1c-3df7-467e-8edf-56023ca812fa" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">3.89</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0ca7b7cc-033c-4b7c-89a2-6e95ff44bc1f" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">4.07</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c2f9bf05-9d67-4418-8d17-16ce821944a4" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">2.51</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net income (loss) per share, diluted</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f1b68431-50cb-4f62-9bce-ab160c2dd11d" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">3.83</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ab0ded15-d6e2-4d79-bdb4-240a03a10c74" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">3.96</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2a697693-4502-4ade-bb40-c728b54a4c65" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">2.51</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average shares outstanding, basic</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b462da0f-19e0-46e7-b53f-a5a30ceb3588" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">132,606,767</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6212f4a3-e0bd-43a1-bea8-d1d00d53f04b" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">129,884,967</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8d90179d-0ab8-4e0a-99dc-e729a8d4e35b" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">119,159,424</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average shares outstanding, diluted</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cefe93ee-0d7b-482f-8243-1dbd14108b19" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">134,810,908</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_59869817-9958-4e83-8ceb-05e0691ebcba" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">133,437,126</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b886b04b-9855-49aa-a777-8b7d7656273a" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">119,159,424</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">142</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VIR BIOTECHNOLOGY, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_statements_comprehensive_lo"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of Comprehensive Income (Loss)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(in thousands)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.241%;"></td>
    <td style="width:1.419%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.738%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.447%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.738%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.447%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.97%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net income (loss)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dce59fd7-939b-46b8-89a8-1be97e616cea" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">515,837</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dac284c0-c9b8-4e1a-868f-7e5ff89f7595" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">528,584</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7eacb998-c678-4087-a933-ef1bbc77678f" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">298,665</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other comprehensive income (loss):</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized losses on investments</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b292aa09-9ec5-4f6c-8f51-99377ea92951" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">7,524</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f0c8b4a3-42c0-4c5b-b029-4c64422c4567" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">957</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0ed186a1-eb86-435b-a026-ff9a7d5524e3" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">50</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortization of actuarial loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6e7f4c04-bfb4-49f1-a3f4-ade86321b30d" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">499</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7677af4f-3627-4502-bf21-1d0f7c003406" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">55</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d4487cfa-2958-4e5e-935a-2019940490a4" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">23</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Adjustment to projected benefit obligations, net of tax</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c78d26cf-61ca-4315-8acd-688837acbe1f" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="vir:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentToProjectedBenefitObligationsNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0ca534b8-c485-4dfc-8c80-dc326e39390b" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="vir:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentToProjectedBenefitObligationsNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,081</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_56ac3a3d-ddb6-404f-82c8-170fab01553c" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="vir:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentToProjectedBenefitObligationsNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">650</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other comprehensive income (loss)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_291f88e3-b328-41f4-afbe-263aad247eca" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">8,023</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b3a8ef8f-bcb9-4483-b0ae-c556f1735eed" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">179</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1cf00d62-8f7f-4e68-9bb1-6dc214ad95ca" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">677</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Comprehensive income (loss)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3c68da68-804a-4fb3-bd22-d17bfde6908b" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">507,814</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_df1de6c7-fef0-48cd-ad6f-1cadf02b3687" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">528,763</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2fd67437-54e6-46a3-b9c7-fdfa8be562f4" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">299,342</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">143</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VIR BIOTECHNOLOGY, INC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_statements_convertible_pref"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Statements of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stockholders&#x2019; Equity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(in thousands, except share data)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:32.736%;"></td>
    <td style="width:1.198%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.593%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.031%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:8.229999999999999%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.031%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:8.229999999999999%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.031%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:8.247%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.039%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:8.247%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.039%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:8.347%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common Stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Additional<br />Paid-In<br />Capital</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated <br />Other<br />Comprehensive<br />Loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accumulated<br />Deficit</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total<br />Stockholders&#x2019;<br />Equity</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2019</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_03900b95-99e4-42ef-8b3c-46714c27381e" contextRef="C_12eb10d1-8cbc-4e43-9179-de76706ed182" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">107,648,925</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9def42cf-431f-4f6a-ae16-582ca3b7f557" contextRef="C_12eb10d1-8cbc-4e43-9179-de76706ed182" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_63b99d70-0cee-43e3-8b62-a0ad415c2d6f" contextRef="C_1364cd0a-2ace-4aed-b2bb-6a20b02ffe7e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">793,051</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9e2a484f-9452-4dd0-8083-54e33797c2e9" contextRef="C_95d1c581-2af9-4924-b965-78baf570226f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">601</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cc838735-7e4a-495b-b821-05ec2fa6c771" contextRef="C_d3f945e7-1296-4c70-9ecd-08b3a017a4df" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">368,519</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f96226a6-ddf6-4d15-9dd2-012d667c689c" contextRef="C_ce64793d-668a-40e8-af07-6ebdbdd93828" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">423,942</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reclassification of derivative liability to addition paid-in-capital</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ee534d95-739b-4a63-9218-defb98ffbbae" contextRef="C_39cb96e3-900d-40c8-b3e6-6c07096acd7e" name="vir:ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">29,245</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b19979c7-3a5c-4ad9-b7ac-6f8e95a7d840" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="vir:ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">29,245</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common stock in connection with the achievement of a milestone</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_30023f63-d884-4c36-899d-5b8b98b4996c" contextRef="C_ad4974d2-db54-4104-9b56-2ebf05ffda38" name="vir:StockIssuedDuringPeriodSharesAchievementOfMilestone" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,111,111</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common stock in connection with a collaboration agreement</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7bbde8fe-091e-47eb-8c74-4a2047c63390" contextRef="C_ad4974d2-db54-4104-9b56-2ebf05ffda38" name="vir:StockIssuedDuringPeriodSharesCollaborationAgreement" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">6,626,027</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_18ee2aab-b4ac-43ea-9c6c-8a6810f5df94" contextRef="C_ad4974d2-db54-4104-9b56-2ebf05ffda38" name="vir:StockIssuedDuringPeriodValueCollaborationAgreement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_465594d9-7737-4aaf-a3a4-9db796c756b3" contextRef="C_39cb96e3-900d-40c8-b3e6-6c07096acd7e" name="vir:StockIssuedDuringPeriodValueCollaborationAgreement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">206,698</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4eb735da-4f19-48c1-9417-82354a57e9da" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="vir:StockIssuedDuringPeriodValueCollaborationAgreement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">206,699</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common stock for cashless exercise of warrants</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5744d8df-04b1-44b6-9527-97f8963addb6" contextRef="C_ad4974d2-db54-4104-9b56-2ebf05ffda38" name="vir:StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">211,774</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common stock in connection with a follow-on offering, net of issuance costs of $</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8d0a08c0-4543-4677-ac40-eb128b880365" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="vir:CommonStockIssuanceCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21,786</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a1c14c34-91e6-4b38-a5d2-fdd0fd5bbd0b" contextRef="C_fec42e81-f129-4752-ad8b-0294488d4ba3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">8,214,285</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a895774e-2893-41d5-86a3-4e78e12928c8" contextRef="C_fec42e81-f129-4752-ad8b-0294488d4ba3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5cf35633-5301-48f5-990f-d25bfd2ebe55" contextRef="C_0dde6c02-78fb-47ad-a243-45289278021b" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">323,213</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_11547210-5792-4373-8331-09ec3e1bee3d" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">323,214</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vesting of restricted common stock</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8e7acab2-7534-42de-a171-ef57f0a14966" contextRef="C_ad4974d2-db54-4104-9b56-2ebf05ffda38" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,986,250</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dec48ed9-5072-4d2f-be1b-8c8cca3ceea9" contextRef="C_39cb96e3-900d-40c8-b3e6-6c07096acd7e" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,435</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_718edb14-33ab-4206-9f50-bba03148e3b8" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,435</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercise of stock options</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ec880663-6089-4b0c-9b2c-eaf3b30a3fae" contextRef="C_ad4974d2-db54-4104-9b56-2ebf05ffda38" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,618,368</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b012decb-5d8b-4f38-bf71-f8e2633dea8e" contextRef="C_39cb96e3-900d-40c8-b3e6-6c07096acd7e" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,059</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_24b1145f-9607-4335-9451-4c9e4b7ff7dc" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,059</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_788314e6-119b-4375-bf1b-1a5429ca0e99" contextRef="C_39cb96e3-900d-40c8-b3e6-6c07096acd7e" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27,600</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e4bddd58-9875-4b8e-84ec-a322a743db6c" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27,600</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other comprehensive loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3f3ec6db-4893-462e-bbf2-ca099215516c" contextRef="C_ab38e818-8e19-4d32-855b-4a5d8c7332dc" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">677</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5770dfcd-2352-49d9-b386-0a28a346a157" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">677</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_868b9186-0651-4ccc-88d8-f6ccb1f4e9d3" contextRef="C_a3f62ca6-5d34-48b4-8e19-7e9bd3f388e8" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">298,665</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b9514ec1-9d43-4315-a919-764206040ea9" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">298,665</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_51b68fd5-7ade-461a-846c-99f2a12353df" contextRef="C_ad4141b8-b5e4-429b-9b52-dd67e708016e" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">127,416,740</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_568463dc-76c0-4560-a75d-6bca8fd85f3c" contextRef="C_ad4141b8-b5e4-429b-9b52-dd67e708016e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e02bde4a-e980-4b92-8a5b-efb2a8d505ea" contextRef="C_017385f6-1d68-484c-9c95-8c9c74dccda7" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,385,301</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e361dd88-30d3-4f73-a2d2-beabf9af46a6" contextRef="C_00a912ce-4cfe-416b-b075-dffc321d18b6" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,278</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_748ddab3-c36d-44ce-a8a3-62b2733940cd" contextRef="C_c23e0019-4bdf-4a39-9f66-f78f5b7cf6ba" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">667,184</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1f3346f8-6d1e-4284-b66b-ad8e2c79a567" contextRef="C_da5feba6-e631-4bec-b33d-106ac3401870" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">716,852</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common stock in connection with a collaboration agreement</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5e2e903f-f537-49ce-b818-989c440e6c86" contextRef="C_e43e7416-30c1-47c2-8d8f-9a8fa8761fb6" name="vir:StockIssuedDuringPeriodSharesCollaborationAgreement" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,924,927</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_43883ffc-20f6-40a4-a5b2-5a4bb54bb8ff" contextRef="C_48f14b99-b9bb-45aa-acd6-6b16710aedb4" name="vir:StockIssuedDuringPeriodValueCollaborationAgreement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">85,213</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aca1c45a-dee7-4d4b-ae58-44f692e29140" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="vir:StockIssuedDuringPeriodValueCollaborationAgreement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">85,213</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common stock to settle a contingent consideration</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b3346c6e-f63f-42a1-be18-305f57a552fc" contextRef="C_e43e7416-30c1-47c2-8d8f-9a8fa8761fb6" name="vir:StockIssuedDuringPeriodSharesIssuedForSettlementOfContingentConsideration" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">42,737</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f2a811de-43ea-4aa5-a60d-c81e3db58ec6" contextRef="C_48f14b99-b9bb-45aa-acd6-6b16710aedb4" name="vir:StockIssuedDuringPeriodValueIssuedForSettlementOfContingentConsideration" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,860</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fae955da-84ba-4d14-b6f0-5c9c626b5846" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="vir:StockIssuedDuringPeriodValueIssuedForSettlementOfContingentConsideration" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,860</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vesting of restricted common stock</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1118b52f-d1a4-4fd2-ac54-eb8a5a28172a" contextRef="C_e43e7416-30c1-47c2-8d8f-9a8fa8761fb6" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">89,261</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercise of stock options</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a6198736-c974-4e07-8590-72c3107c4ec2" contextRef="C_e43e7416-30c1-47c2-8d8f-9a8fa8761fb6" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,622,718</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a7635e0f-8870-400b-af5a-bf1ba30a2f7f" contextRef="C_48f14b99-b9bb-45aa-acd6-6b16710aedb4" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,077</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7d526f2c-72b8-4cc7-8f60-25db7845278d" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,077</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common stock under employee stock purchase plan</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1efb2d50-39f4-4742-bde1-3175ed41f708" contextRef="C_e43e7416-30c1-47c2-8d8f-9a8fa8761fb6" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">65,021</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_82e9a676-6837-4698-92dd-6482270a90de" contextRef="C_48f14b99-b9bb-45aa-acd6-6b16710aedb4" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,300</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dca9b266-23b4-4951-a3f5-5b62cb3543fa" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,300</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ec37f9ad-c376-45ab-a0bc-cf8a32a0b8ad" contextRef="C_48f14b99-b9bb-45aa-acd6-6b16710aedb4" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">83,784</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5cfe309f-98ad-4b5a-9108-3be6d9abfc4d" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">83,784</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other comprehensive income</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b1914697-1ed5-45c6-aa38-66559fac87c4" contextRef="C_cbf68543-981c-4f0c-a438-703247341f08" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">179</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_714db82d-cb22-49ba-a3fa-a20dd82c3c61" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">179</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net income</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4809cd26-daab-448b-ba9c-b64786aafba6" contextRef="C_94daadad-3dc0-454a-8e31-99a471e99b3d" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">528,584</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ce6614dd-46e2-443c-8ff3-d4c158317f7e" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">528,584</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_adbe163b-c4ec-4a70-b54b-679ce5318e6e" contextRef="C_43f8e518-6996-4956-b1a9-bf1a73666d0b" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">131,161,404</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_63b2ff58-026d-450d-8f70-0816833d3ffa" contextRef="C_43f8e518-6996-4956-b1a9-bf1a73666d0b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b8c4fe70-3eab-450c-8b15-f90fdd208fc3" contextRef="C_80319ba1-d62f-4b44-b5e2-f5e9eb0ceb54" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,571,535</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_56c8034b-9c3c-4020-920e-a4a15d6eb49c" contextRef="C_76ae8c43-fd41-420f-aeae-ad3941b0fec6" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,099</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d977fd77-3b50-4602-9c5c-c5841110fe54" contextRef="C_c7b72547-d6ee-4bc9-986d-72368f004917" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">138,600</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_064a58c1-702a-4a24-bda7-4a3ed5e022be" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,431,849</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common stock in connection with a grant agreement</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3665c726-613e-4195-a1b2-bec874526fbb" contextRef="C_aa13a910-3dc3-4d53-a119-271c45df3af6" name="vir:IssuanceOfCommonStockInConnectionWithAGrantAgreementShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">881,365</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_12eb5651-ca85-445f-aad3-7d02b3c8693d" contextRef="C_d7a958db-9d20-44ef-a677-68d2c31b101f" name="vir:ProceedsFromIssuanceOfCommonStockInConnectionWithAGrantAgreement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">28,462</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5ac69f8f-e9d6-4b76-ae1c-5407e86b5e2e" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="vir:ProceedsFromIssuanceOfCommonStockInConnectionWithAGrantAgreement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">28,462</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vesting of restricted common stock</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d344499c-4f11-4866-b756-fa314128e43c" contextRef="C_aa13a910-3dc3-4d53-a119-271c45df3af6" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">349,496</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercise of stock options</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_99dd1ffd-26d1-4e39-ae66-3a6afd4a436c" contextRef="C_aa13a910-3dc3-4d53-a119-271c45df3af6" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">696,963</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cb4b4a55-0926-4183-914a-9ce6ecc920e5" contextRef="C_d7a958db-9d20-44ef-a677-68d2c31b101f" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,534</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c9d75942-038c-47ec-a121-c26441dd5989" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,534</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Issuance of common stock under employee stock purchase plan</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4aca7d91-70a5-4fb4-8694-dee929beff36" contextRef="C_aa13a910-3dc3-4d53-a119-271c45df3af6" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">147,459</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0532266d-b113-46b3-9b6c-a5bf50cd8e71" contextRef="C_d7a958db-9d20-44ef-a677-68d2c31b101f" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,222</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3f4f54f5-ae00-4e3c-a955-9ec11246e665" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,222</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6892b171-ee1f-4626-bb7f-7b2b6fa558bd" contextRef="C_d7a958db-9d20-44ef-a677-68d2c31b101f" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">102,082</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_874f0563-3e11-4cc3-bcff-aa57cd50cc89" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">102,082</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other comprehensive loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_da22b4a9-3eaf-43b7-9a43-09e34063215b" contextRef="C_29901d1b-12a7-4289-b365-64d76b343767" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">8,023</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aa0a2be0-d4e0-492e-9491-a1d9485b071d" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">8,023</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net income</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_30f798d6-aa6f-44b3-8347-f5495b2f5356" contextRef="C_64b0a6fe-b0bf-4dcf-a49e-f88368c52dbd" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">515,837</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bf757149-d3ac-45b9-8b71-7abee319d332" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">515,837</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0c0c0eac-5b64-47bf-9bc6-6f8064201742" contextRef="C_04175337-eb05-48c1-8aac-bc7c29d50097" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">133,236,687</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cdcd8624-5565-4f1f-828e-a6f4f7335ed0" contextRef="C_04175337-eb05-48c1-8aac-bc7c29d50097" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_067368af-ea5f-4a09-b375-9edc6d687c0a" contextRef="C_b6e56cad-2ca6-48f8-b21a-16161998bf9e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,709,835</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f08153b0-d48d-4ddb-8e5a-a31b6cee1281" contextRef="C_bd901335-c247-4a9a-ba1a-0d36065664ba" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">9,122</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_378066c6-3fa9-4d76-b5d8-e57733e0dc20" contextRef="C_c5b01808-0860-4e26-906c-c9aecfd158e9" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">377,237</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_28ea7534-7113-4ee4-a17e-01c1ad15f6fc" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,077,963</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">144</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VIR BIOTECHNOLOGY, INC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_statements_cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consolidated Stateme</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">nts of Cash Flows</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(in thousands)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:58.092%;"></td>
    <td style="width:1.204%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.609%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.195%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.609%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.195%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:11.098%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CASH FLOWS FROM OPERATING ACTIVITIES:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net income (loss)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2c97b812-85d7-4127-917a-bc53c69ad40d" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">515,837</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_529773e6-2356-45c0-bcde-275e71a67d49" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">528,584</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a98b5b13-ce0d-4280-a5a6-d97f311d3a62" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">298,665</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Adjustments to reconcile net income (loss) to net cash used in operating activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in estimated constraint on profit-sharing amount</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1208a242-e4e9-4ea6-8628-650c5497ad91" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="vir:ChangesInEstimatedConstraintOnProfitSharingAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">369,535</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_70ecdba2-a986-4393-b39c-d493fc38ec58" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="vir:ChangesInEstimatedConstraintOnProfitSharingAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c3025564-2935-40b8-b599-bdd0ddfaaba9" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="vir:ChangesInEstimatedConstraintOnProfitSharingAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation and amortization</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8dd6885a-04e0-4e64-86c4-2a203efdf811" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,251</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_72e7de13-562c-4cc8-bdb2-bc0ac2cd73ab" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,278</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ae6b3333-f784-4c2d-a048-288a062d68a7" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,400</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortization of intangible assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_615c2083-8c60-47ca-901b-ac51c6708845" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">532</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dcaf3125-f963-4029-bea0-a80b2215ed7f" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">533</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_78710f9a-0611-42c4-a325-e788ac3c8dd9" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,042</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Impairment of intangible assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_664add06-d0f8-4b87-aa46-14535dbcf787" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5f6157aa-1e5b-416d-a011-6ef54c3b893d" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d46b32f0-96f0-40ef-a165-5ed44289a872" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">832</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Accretion of discounts) amortization of premiums on investments, net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e9771179-6c35-4902-bb8b-8bd15f60624e" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,943</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0fb4de7d-bb7e-42dd-99e0-9c603a73859f" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">244</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_066486dd-4580-42d2-9199-cf92dc31d36d" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,548</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Noncash lease expense</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_39dba800-e09b-4219-9d5f-f62a8a279fa1" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="vir:NoncashLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,709</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b06b0499-264d-4090-856f-a25fb9481a49" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="vir:NoncashLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,172</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dbb12aa4-3697-435e-86a1-7541f7ae6938" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="vir:NoncashLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,371</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in fair value of equity investments</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3f31b1a2-ad15-44cc-8094-5738ae0f6c8f" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:AssetsFairValueAdjustment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">111,140</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9ba55365-d12e-43a0-b317-aa1b7974531a" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:AssetsFairValueAdjustment" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">138,049</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_035d8f44-50eb-4be3-83dc-bac1da1c218f" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:AssetsFairValueAdjustment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in estimated fair value of contingent consideration</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_acb73974-66c2-4fdd-ab1e-41998eee56f6" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,115</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6d70c240-c9ab-4a2c-8362-82c54babce0d" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">91,848</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ed636deb-b5af-4de9-972f-36dbb850be50" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">38,394</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Payment of contingent consideration in excess of acquisition date fair value</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9666e325-bb65-48ca-9eb8-fb2323ada9f4" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="vir:IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">93,803</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_df8606a1-62d1-441c-9135-bdd7e3058235" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="vir:IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">8,140</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_73b8fc0d-3381-46b5-b335-126a412e2276" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="vir:IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">15,752</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in estimated fair value of derivative liability</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0740b238-a2aa-4290-b9a3-e2b68fd5d1a1" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:DerivativeGainLossOnDerivativeNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_77f83c7b-a7aa-40d5-9b4f-8c86267b7b88" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:DerivativeGainLossOnDerivativeNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5f45185e-287e-4943-b932-5dbe57236146" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:DerivativeGainLossOnDerivativeNet" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">16,796</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8805848b-ef84-45cb-b3ee-a1836c391d14" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">102,082</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9be9307e-cf50-4d77-b4f9-073fa8024a5d" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">83,784</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_33ac9efb-86cc-4558-9ca4-86b86ea68aef" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27,600</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change in deferred income taxes</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1f6d35fa-545e-4c9e-9655-d012741f9c79" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,186</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_41313cb5-db3b-4349-b566-b474edc16ec5" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">15,186</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_564d27d1-bbd7-4965-b203-9143123e257f" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">52</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gain from a sublease termination</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2a541dc2-99a0-47ef-87bf-d7997cde8497" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:GainLossOnTerminationOfLease" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2aee0d35-2a22-41a1-a7dd-4aa60f36eefd" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:GainLossOnTerminationOfLease" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,844</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_103dc34d-4d87-4e3b-874f-2c2501bdf1af" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:GainLossOnTerminationOfLease" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e0ed491b-8321-450e-8c5d-e2907e1f5199" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">383</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ab4cc893-d653-45c9-9ebd-108e07a909a2" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">697</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f28b6ffa-2f61-4b8f-bd80-11a0ae548062" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">23</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:16.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:16.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Receivable from collaboration</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_93155f8c-d08c-49c2-b18d-0f639c86d17e" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">770,038</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_876855bb-6cb0-4d46-a455-d58b9fc9c73c" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">773,079</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d9c7b5e4-0855-49c8-8348-cc88bd7dfcff" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:16.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:16.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2c8259c6-8ec1-4a8d-b1df-cdbb936d90db" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">39,358</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_533221cd-6982-48c2-b5ea-eccc28976886" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,665</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_550a8592-8df1-4be5-ade2-26b5ee3d983e" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,475</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:16.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:16.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8b51ee57-48c5-42ea-9b50-b14b91e0e313" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,795</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aeb50ac7-0738-4b48-87d3-d5fb5aae1b44" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,483</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c334989b-75ff-4895-b8d9-8fe59a383ddb" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,100</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:16.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:16.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3e70791a-d8fb-4752-a1a0-67359d743948" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">797</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6dfe4112-19db-498c-b2da-841d9c62ac1f" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">171</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0b66bf15-28c8-406d-be7a-045f38fca1ee" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">790</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:16.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:16.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued liabilities and other long-term liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bc78ce89-2b41-4c14-9f17-ad05fd7eb98c" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">15,513</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_555f6fca-983f-4078-b60c-305b2e048f25" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">58,498</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ea2ede0c-15e9-485b-a231-9e905e7ecad1" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">46,614</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:16.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:16.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_acb8ad5e-6987-41fc-9df3-aa0d6f42ace7" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">5,502</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_63751004-2d74-47df-973f-728fec884978" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">535</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_28c02ab7-9561-46a2-943a-7e19366e2f84" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">3,684</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:16.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:16.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred revenue</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1e48a6e1-61bb-4233-90d7-151849f6981d" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:IncreaseDecreaseInDeferredRevenue" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">33,300</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_570e3471-53bf-4459-be98-df10492fad11" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:IncreaseDecreaseInDeferredRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">92,041</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_576387bd-a212-4165-82f6-0555f14789c3" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:IncreaseDecreaseInDeferredRevenue" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">7,043</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:24.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:24.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash provided by (used in) operating activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_94bbe078-02b8-4a22-8d68-6b0680f23527" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,663,253</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e2dcb264-2eea-492b-aac3-4163a626d523" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">47,589</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b52148cb-7617-4473-9115-4be0446f5c9b" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">190,941</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CASH FLOWS FROM INVESTING ACTIVITIES:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from sale of equipment</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_24c2fda2-d1a1-450a-9c0d-33ce91aa8ea8" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:ProceedsFromSaleOfMachineryAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">22</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f740ad23-7db8-474d-a985-5354ffaf4ca0" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:ProceedsFromSaleOfMachineryAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_807acb5f-1e3e-4f07-a7b5-3a7d2af44ffa" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:ProceedsFromSaleOfMachineryAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Purchases of property and equipment</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e1840f1b-69d3-481e-80ab-0cd797db262c" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">68,028</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a96acb63-c352-4530-8e90-d4c0b18f27da" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21,817</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_11aa0767-ff8b-4090-8a5b-3aaca04a921e" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,549</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Purchases of investments</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d924c94c-aeb3-4e6e-8925-2142a40827bb" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:PaymentsToAcquireInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,476,965</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8d18ad03-1aed-4363-8936-84e8e9a01716" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:PaymentsToAcquireInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">420,240</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7218d04e-84fe-4bcc-8792-a12f7f64e887" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:PaymentsToAcquireInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">403,841</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Maturities of investments</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ab382ea0-9d38-42c6-8ee4-24f8947d9bac" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">351,510</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8972c615-e0d6-4491-a020-25d379263061" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">301,243</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e2f80cbf-a7d5-442d-b6f2-899617c09a03" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">400,348</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from disposal of an asset held for sale</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_12766284-115c-4518-bd5f-6ae85d3047a6" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="vir:ProceedsFromDisposalOfAnEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f94f135c-2820-4454-9a21-039686cc15dd" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="vir:ProceedsFromDisposalOfAnEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d7c3a46d-8820-4306-986b-25f1bc80666d" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="vir:ProceedsFromDisposalOfAnEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">180</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:24.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:24.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash used in investing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6a9bbd02-cec3-4aa6-ae57-acbdb8f44fef" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,193,461</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_11130b86-470d-4aaa-83a9-ecf3e91c06ef" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">140,814</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e5b68fb7-41c6-4f42-bfb2-c964868ae9b9" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">9,862</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CASH FLOWS FROM FINANCING ACTIVITIES:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from issuance of common stock, net of issuance costs</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6b1886cc-b64d-4542-882b-62320146f75b" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c06e2c14-8237-48bf-b2d9-f486ab004c44" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0d6c2f09-79d2-4e13-8b18-4a42558231dd" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">323,214</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from issuance of common stock in connection with a collaboration agreement</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8ef15133-16f7-4221-87ca-32441008b367" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="vir:ProceedsFromIssuanceOfCommonStockInConnectionWithCollaboration" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_06850c5b-30b1-4230-8225-a65c1b6b8d16" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="vir:ProceedsFromIssuanceOfCommonStockInConnectionWithCollaboration" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">85,213</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3d04067c-9157-41d0-9fed-6edd546fb586" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="vir:ProceedsFromIssuanceOfCommonStockInConnectionWithCollaboration" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">206,699</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from issuance of common stock in connection with a grant agreement</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d5c259e9-2bae-4c8d-9008-d222f659d0d2" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="vir:ProceedsFromIssuanceOfCommonStockInConnectionWithAGrantAgreement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">28,462</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_32c2a5f4-c588-40e5-a633-e334d9636062" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="vir:ProceedsFromIssuanceOfCommonStockInConnectionWithAGrantAgreement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e915ad9f-6b92-4a1c-8987-61e6e76457d0" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="vir:ProceedsFromIssuanceOfCommonStockInConnectionWithAGrantAgreement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Payment of contingent consideration</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ef53cad0-23ba-4b5c-b1c1-9b2a6beed4e8" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="vir:PaymentOfContingentConsideration" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,197</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e2df721b-c419-4d8e-8a56-f4d59809e95b" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="vir:PaymentOfContingentConsideration" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7f39799e-114c-4575-ba3a-bbf31db20f47" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="vir:PaymentOfContingentConsideration" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,248</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Payment of principal on financing lease obligations</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b18e5023-ec90-4d13-9829-0633b653246e" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:FinanceLeasePrincipalPayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">260</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_77a307e2-e0e5-4559-9e06-96339ab00a95" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:FinanceLeasePrincipalPayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">259</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d1fff42b-b9e6-49b4-ba4b-b624f55959b2" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:FinanceLeasePrincipalPayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">250</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from exercise of stock options</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_27c2bb25-ad92-41de-a261-31c9ee98cebb" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,534</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b86e7ea5-3b2b-4183-9c60-8e979dc981c3" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,077</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3a091073-9326-4c86-b375-183c2c7e39d4" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,059</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:8.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:8.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Proceeds from issuance of common stock under the employee stock purchase plan</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b0c7444e-b2a1-4cdc-acf2-cdad0d25f814" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:ProceedsFromStockPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,222</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_27aa0e3f-680f-44ba-a7a6-4f72b1aaaa20" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:ProceedsFromStockPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,300</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bdaabb5e-31f9-46a8-a68b-464e11ad8865" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:ProceedsFromStockPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:24.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:24.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3d21cb71-6308-423a-80fc-f5265d9e92a2" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">34,761</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_81161ad6-0ee3-4db0-bac0-462f05b3e7bf" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">100,331</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0d405aaf-c816-49fd-ba4f-cb3120571bfe" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">529,474</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net increase (decrease) in cash, cash equivalents and restricted cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2f2451dd-c22e-46df-8bca-fba4e83d966f" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">504,553</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4db56b11-ffb5-46ab-b4d7-c9b31d838f8c" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">88,072</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7944d5de-0db0-4021-8370-19145b627304" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">328,671</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash, cash equivalents and restricted cash and cash equivalents at beginning of period</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7095a7a3-47e4-4793-85ab-2658950aff35" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">363,415</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a6afacf2-108d-469c-9547-082dd538c7d6" contextRef="C_da5feba6-e631-4bec-b33d-106ac3401870" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">451,487</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_76051d69-b2a7-4489-a4ce-e602242a64aa" contextRef="C_ce64793d-668a-40e8-af07-6ebdbdd93828" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">122,816</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash, cash equivalents and restricted cash and cash equivalents at end of period</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6053208c-8505-4d15-84b4-a870dedccd6f" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">867,968</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c9bc5c83-4b07-467d-bc8b-19e0d11e2969" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">363,415</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a5ee7aa5-420f-479e-b359-eb80db145ef5" contextRef="C_da5feba6-e631-4bec-b33d-106ac3401870" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">451,487</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NONCASH INVESTING AND FINANCING ACTIVITIES:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment purchases included in accounts payable and accrued liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eacbf29d-9fc5-459e-b466-d1d457c4997b" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,020</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_df263720-b90a-40d4-b6e6-b9de8309f102" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,731</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c87f3352-9029-4549-a685-f68a69bf3b66" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">382</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common stock issued for payment of contingent consideration</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4dd5b9a6-7f3d-4521-8be5-6b97084c9814" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="vir:NonCashCommonStockIssuedForContingentConsideration" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e05dc186-1a6a-4888-b947-e760a81d7b5a" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="vir:NonCashCommonStockIssuedForContingentConsideration" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,860</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bf9eb96c-1a60-499e-a53e-95681298a558" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="vir:NonCashCommonStockIssuedForContingentConsideration" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities obtained in exchange of right-of-use asset</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a54069cc-304b-4437-b675-1c460485228a" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,046</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2f3102a9-d38f-4fdd-ab96-ef0cb50fcc4e" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">77,187</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_014e1c57-740d-47ea-b5b3-2ebbf9fd89a3" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">48,495</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reclassification of derivative liability to additional paid-in capital</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9591e2e8-39fe-4bd8-beb6-a09bb1bc0cd3" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="vir:ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3537ea58-956f-46e6-8064-487683e21d9d" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="vir:ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_25f85e56-c9d3-48b6-98b1-d18e6c465136" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="vir:ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">29,245</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SUPPLEMENTAL DISCLOSURE OF CASHFLOW INFORMATION:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash paid during the period for income tax</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1b550c30-e700-44f5-9882-24df3b183784" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:IncomeTaxesPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">252,030</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_01a6a8ea-2e36-4330-b041-f39325dec21a" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:IncomeTaxesPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_38c339df-de52-4e2d-9ba8-ab284e296ff7" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:IncomeTaxesPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RECONCILIATION OF CASH, CASH EQUIVALENTS AND<br />&#160;&#160;&#160;RESTRICTED CASH TO THE CONSOLIDATED BALANCE SHEETS:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c337e470-2a60-4157-a863-c5202bfd5f81" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">848,631</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_15194233-17f4-4696-96eb-c3de3edd33cf" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">347,815</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2013809e-7530-4a09-97d7-367b80de8e4d" contextRef="C_da5feba6-e631-4bec-b33d-106ac3401870" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">436,575</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted cash and cash equivalents, current</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e3f9ad77-c02d-4e50-b4b9-ffcc45a55c82" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,681</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9beae488-b661-44c0-b826-b2a377375f91" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,594</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5611cb52-7c67-4797-9a6e-93b66b11a63e" contextRef="C_da5feba6-e631-4bec-b33d-106ac3401870" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,993</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted cash and cash equivalents, noncurrent</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_da65f71b-7988-43ce-a73d-be01170b147a" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,656</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d47f86d0-e81f-457b-84ad-65315be7d2f6" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,006</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e7c7c86c-42f4-42e6-8863-8c06e5be5276" contextRef="C_da5feba6-e631-4bec-b33d-106ac3401870" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,919</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:16.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:16.0pt;text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total cash, cash equivalents and restricted cash</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_175c52f6-78ba-47fd-a69f-3ae20b85688c" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">867,968</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_92eb1f7c-cdaa-4a37-a9b7-c5807c158bea" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">363,415</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e0d8fa97-e7db-44f5-9f40-51a395c66757" contextRef="C_da5feba6-e631-4bec-b33d-106ac3401870" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">451,487</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:6.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">145</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VIR BIOTECHNOLOGY, INC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="notes_to_consolidated_financial_statemen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Financial Statements</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_302291a1-f1dc-4e7f-a6e0-3f2bda5e83c5" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" escape="true" continuedAt="F_302291a1-f1dc-4e7f-a6e0-3f2bda5e83c5_1"><div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">1.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Organization </span></div></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vir Biotechnology, Inc. (&#x201c;Vir&#x201d; or the &#x201c;Company&#x201d;) is a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Its current pipeline consists of sotrovimab (previously VIR-7831; and where marketing authorization has been granted, marketed under the brand name Xevudy&#174;) and other product candidates targeting hepatitis B virus (&#x201c;HBV&#x201d;), hepatitis D virus (&#x201c;HDV&#x201d;), influenza A virus, coronavirus disease 2019 (&#x201c;COVID-19&#x201d;), and human immunodeficiency virus (&#x201c;HIV&#x201d;). Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In September 2022, the Company formed a new wholly-owned subsidiary in Switzerland, Vir Biotechnology International GmbH (&#x201c;VBI&#x201d;), a Swiss limited liability company. The primary purpose of VBI is to support Vir's research and development and international commercial activities outside of the United States.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Follow-On Offering</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On July 10, 2020, the Company issued and sold </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_78cba3f7-b5d4-4e4d-b502-ca609b80b11c" contextRef="C_0b6e95b2-e943-40ea-ba4d-dbf4d337d81a" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">8,214,285</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company&#x2019;s common stock pursuant to a registration statement on Form S-1 (File No. 333-239689) and a registration statement on Form S-1 filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;) (File No. 333-239747) (collectively, the &#x201c;Registration Statements&#x201d;). The Registration Statements became effective on July 7, 2020. The price of the shares sold in the follow-on offering was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_37667d3e-6a23-48c9-8ebb-a0d97e739b75" contextRef="C_77979cee-0206-4722-a78e-8d7e1abeb723" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_USDollarShare" decimals="INF" format="ixt:numdotdecimal">42.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share and the Company received total gross proceeds from the offering of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a4b8ebb9-fb44-47ee-86d8-53cfdc3964b6" contextRef="C_0b6e95b2-e943-40ea-ba4d-dbf4d337d81a" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">345.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. After deducting underwriting discounts and commissions of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c62ea782-a202-4b37-b537-f3201afedc95" contextRef="C_0b6e95b2-e943-40ea-ba4d-dbf4d337d81a" name="vir:PaymentsOfUnderwritingDiscountsAndCommissions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">20.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and offering expenses of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fe7fd97a-d51f-4a6e-becd-83d1963be95f" contextRef="C_0b6e95b2-e943-40ea-ba4d-dbf4d337d81a" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, the net proceeds were approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_40b5063b-719b-4a86-8894-5f3cab131d09" contextRef="C_0b6e95b2-e943-40ea-ba4d-dbf4d337d81a" name="vir:NetProceedsFromIssuanceSecondaryPublicOffering" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">323.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sales Agreement</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In November 2020, the Company entered into a sales agreement (the &#x201c;Sales Agreement&#x201d;) with Cowen and Company, LLC (&#x201c;Cowen&#x201d;), under which the Company may from time to time offer and sell shares of its common stock for an aggregate offering price of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_96934ff6-7d09-487f-bebe-957d9c041d5d" contextRef="C_ca5589eb-ea15-4baa-83f9-5cfcb0672b1d" name="vir:SaleOfStockConsiderationAggregateOfferingPrice" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">300.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, through or to Cowen, acting as sales agent or principal. The shares will be offered and sold under the Company&#x2019;s shelf registration statement on Form S-3 and a related prospectus filed with the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) on November 10, 2020. The Company will pay Cowen a commission of up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2199e1d7-8fbe-4ae4-add9-c7fa759c18f5" contextRef="C_6e1a4a6c-604a-4324-a4ca-eb6aff2132cb" name="vir:PercentageOfCommissionRateFromSaleOfShares" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">3.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the aggregate gross proceeds from each sale of shares, reimburse legal fees and disbursements and provide Cowen with customary indemnification and contribution rights. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3a8725d3-0877-480d-bf7e-8226a149618c" contextRef="C_1ff854d5-f188-44b8-94e4-70a3c2f65c1a" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares have been issued under the Sales Agreement.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Need for Additional Capital</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:continuation id="F_302291a1-f1dc-4e7f-a6e0-3f2bda5e83c5_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Although the Company recorded net income for the years ended December 31, 2022 and 2021, respectively, it has otherwise incurred net losses since inception. The Company expects its earnings to be volatile and may continue to incur net losses over the next several years and may need to raise additional capital to fully implement its business plan. As of December 31, 2022, the Company had retained earnings of  </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a57e5916-66a4-4b2a-a77c-c7b5a784a04e" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">377.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Company had </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_408ecd3a-48c9-479c-b779-2ab66bbbcf74" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" unitRef="U_USD" scale="9" decimals="-8" format="ixt:numdotdecimal">2.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> billion</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in cash, cash equivalents, and investments as of December 31, 2022. Based on the Company&#x2019;s current operating plan, management believes that the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_46caf930-a3e6-4571-87be-0291effb12e2" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="vir:CashCashEquivalentsAndShortTermInvestmentsExcludingEquityInvestment" unitRef="U_USD" scale="9" decimals="-8" format="ixt:numdotdecimal">2.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> billion</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> as of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> will be sufficient to fund its operations through at least the next 12 months from the issuance date of these consolidated financial statements.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">146</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VIR BIOTECHNOLOGY, INC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a2cc2dcd-0e7b-4255-917f-040818c71bf0" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">2.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Summary of Significant Accounting Policies </span></div></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_23ab19d6-5a56-49bc-862e-2377d4ed386c" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Basis of Presentation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) and include all adjustments necessary for the fair presentation of the Company&#x2019;s financial position for the periods presented. The consolidated financial statements include the accounts of Vir and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated upon consolidation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a0a168ce-cadd-4cd5-badb-408e9ca99865" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Foreign Currency</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The functional currency of the Company&#x2019;s foreign subsidiaries is the U.S. dollar. Monetary assets and liabilities of foreign subsidiaries are translated into U.S. dollars at period-end exchange rates and non-monetary assets and liabilities are translated to U.S. dollars using historical exchange rates. Revenue and expenses are translated at average rates throughout the respective periods. Transaction gains and losses are included in other income (expense), net on the consolidated statements of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c3e17c86-479b-4f60-aef7-7169965e7771" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:UseOfEstimates" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting periods. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b649fea9-b638-4aef-b0f6-9927f2a356e3" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Segments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company operates as </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ad3c06a8-6b9e-490d-9a7e-756b7c856e8f" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:NumberOfOperatingSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> reportable segment. The Company&#x2019;s chief operating decision maker, its Chief Executive Officer, manages the Company&#x2019;s operations on a consolidated basis for purposes of allocating resources.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_277f5497-d034-44d8-8d7e-52ccf383482e" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="vir:ConcentrationOfCreditRiskCreditLossAndOtherRisksAndUncertaintiesPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentration of Credit Risk, Credit Loss and Other Risks and Uncertainties</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Although the Company received Emergency Use Authorization (&#x201c;EUA&#x201d;), temporary authorization or marketing approval for sotrovimab (under the brand name Xevudy&#174;), sotrovimab is currently de-authorized in the U.S. and has limitations in use outside of the U.S. In addition, the Company is still subject to a number of other challenges and risks similar to other biopharmaceutical companies in the early stage, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its other product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of sotrovimab and other product candidates and protection of proprietary technology. If the Company does not successfully obtain regulatory approval, commercialize or partner any of its product candidates, it will be unable to generate revenue from product sales or maintain profitability. In addition, to the extent the COVID-19 pandemic, including the emergence of new variants or subvariants, adversely affects the Company&#x2019;s business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties discussed above.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has implemented a number of plans and policies designed to address and mitigate the impact of the COVID-19 pandemic on its business. The extent to which the changing COVID-19 landscape impacts the Company&#x2019;s business, clinical development and regulatory efforts, corporate development objectives and the value of and market for its common stock, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and investments. Cash and cash equivalents are deposited in checking and sweep accounts at a financial institution. Such deposits may, at times, exceed federally insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">147</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s investment policy limits investments to certain types of securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and investments, and issuers of the investments to the extent recorded on the consolidated balance sheets. As of December 31, 2022 and 2021, the Company has no off-balance sheet concentrations of credit risk.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is exposed to credit losses primarily through receivables from customers and collaborators and through its available-for-sale debt securities. The Company&#x2019;s expected loss allowance methodology for the receivables is developed using historical collection experience, current and future economic market conditions, a review of the current aging status and financial condition of the entities. Specific allowance amounts are established to record the appropriate allowance for customers that have a higher probability of default. Balances are written off when determined to be uncollectible. The Company&#x2019;s expected loss allowance methodology for the debt securities is developed by reviewing the extent of the unrealized loss, the size, term, geographical location, and industry of the issuer, the issuers&#x2019; credit ratings and any changes in those ratings, as well as reviewing current and future economic market conditions and the issuers&#x2019; current status and financial condition. The Company considered the current and expected future economic and market conditions surrounding the COVID-19 pandemic and interest rate policies and determined that the estimate of credit losses was not significantly impacted. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_690089cc-ed61-43ec-80fb-786104c7c250" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_16aef68a-58fa-4254-88a3-f14c570dabac" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> allowance for losses on available-for-sale debt securities attributable to credit risk for the years ended December 31, 2022 and 2021.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a1ca5dc1-8662-4b09-88cc-32acc611d16a" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash Equivalents</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents, which consist of amounts invested in money market funds, and are stated at fair value.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a62e240e-82a7-4d1d-b0a4-747ea65e6fed" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:InvestmentPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Investments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Investments include available-for-sale debt securities and equity investments, which are carried at estimated fair value.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Available-for-Sale Debt Securities</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s valuations of marketable securities are generally derived from independent pricing services based on quoted prices in active markets for similar securities at period end. Generally, investments with original maturities beyond three months at the date of purchase and which mature at, or less than 12 months from, the consolidated balance sheet date are considered short-term investments, with all others considered to be long-term investments. Unrealized gains and losses deemed temporary in nature are reported as a component of accumulated comprehensive income (loss). The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income on the consolidated statements of operations. The cost of securities sold is based on the specific identification method.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Equity Investments</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company measures its investment in equity securities at fair value at each reporting date based on the market price at period end if it has a readily determinable fair value. Otherwise, the investments in equity securities are measured at cost less impairment, adjusted for observable price changes for identical or similar investments of the same issuer unless the Company has significant influence or control over the investee. Changes in fair value resulting from observable price changes are presented as change in fair value of equity investments and changes in fair value resulting from foreign currency translation are included in other income (expense), net </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">on the consolidated statements of operations.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_26c73da0-cd8d-472a-818a-3f8656bfe25c" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Restricted Cash and Cash Equivalents</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted cash and cash equivalents represent money market funds to secure standby letters of credit and security deposits with financial institutions, both under office and laboratory space lease agreements. Additionally, funds received from certain grants are restricted as to their use and are therefore classified as restricted cash and cash equivalents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_9737d065-8b93-4381-921e-aaaea04baee6" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Property and Equipment, Net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment are stated at cost, net of accumulated depreciation and amortization. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2e6192fe-62ae-4599-8f96-d2741f981f92" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the respective assets, generally </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_8818a887-324c-4500-a98b-191605dee51d;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_77c0b448-2e82-4303-884c-cea6999409f8" contextRef="C_9a41c817-24ee-4d06-ab61-6c839a61c843" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Leasehold </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">improvements are amortized over the lesser of their useful lives or the remaining life of the lease. When assets are retired or</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">148</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">otherwise </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">disposed of, the cost and related accumulated depreciation and amortization are removed from the balance sheet and the resulting gain or loss is reflected in operations in the period realized. Maintenance and repairs are charged to operations as incurred.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparing the carrying amount to the future net undiscounted cash flows which the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows arising from the asset. No material impairment losses have been incurred to date.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_cf593d72-caeb-4d0a-91cf-15256a70b402" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acquired Intangible Assets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s intangible assets were acquired via business combinations or asset acquisitions. Indefinite-lived intangible assets represent the estimated fair value assigned to in-process research and development (&#x201c;IPR&amp;D&#x201d;) acquired in a business combination. The Company reviews indefinite-lived intangible assets for impairment at least annually or more frequently if events or changes in circumstances indicate that the carrying value of the assets might not be recoverable. If the carrying value of an indefinite-lived intangible asset exceeds its fair value, then it is written down to its adjusted fair value. As of December 31, 2022, there have been </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_00c50b82-ca10-4420-8ea4-403bcf9eb4d6" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> such impairments. For IPR&amp;D, if a product candidate derived from the indefinite-lived intangible asset is developed and commercialized, the useful life will be determined, and the carrying value will be amortized prospectively over that estimated useful life. Alternatively, if a product candidate is abandoned, the carrying value of the intangible asset will be charged to research and development expenses. IPR&amp;D assets acquired as part of an asset acquisition are recorded at cost and expensed immediately if they have no alternative future uses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Finite-lived intangible assets acquired are initially recognized at their fair value at the acquisition date. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_aec8171c-d9ae-4d0a-955f-f69693ced462" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationMethod"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortization is computed using the straight-line method over the estimated useful lives of the respective finite-lived intangible assets, generally </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_e5972bc8-c341-44f2-a1e7-401190923bbf;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">seven</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_64757c04-4dc4-4747-9802-bd55552aebcb" contextRef="C_9a41c817-24ee-4d06-ab61-6c839a61c843" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15 years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Finite-lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6a079995-fe9d-4232-a80d-07f367b39eb5" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Goodwill</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Goodwill represents the excess of the purchase price over the estimated fair value of the net tangible and intangible assets acquired in a business combination. The Company tests goodwill for impairment at least annually or more frequently if events or changes in circumstances indicate that this asset may be impaired.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6dd20547-eac6-4dd3-ab0f-7c1402f306a8" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:RevenueRecognitionPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue Recognition</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Collaboration, License and Contract Revenue</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;), the Company recognizes revenue when the Company&#x2019;s customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods and services. To determine revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when or as the Company satisfies a performance obligation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">149</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For collaborative arrangements that fall within the scope of ASC 808, Collaborative Arrangements (&#x201c;ASC 808&#x201d;), the Company first determines which elements of the collaboration are deemed to be a performance obligation with a customer within the scope of ASC 606. For elements of collaboration arrangements that are accounted for pursuant to ASC 808 and are not subject to the guidance in ASC 606, the Company applies the revenue recognition model under ASC 606, including the royalty exception guidance and variable consideration guidance under ASC 606 as described below, or other guidance, as deemed appropriate. When the Company is considered an agent in elements of collaboration arrangements within the scope of ASC 808, it records its share of collaboration revenue in the period in which such sales occur. The Company is considered an agent when the collaboration partner controls the product before transfer to the customers and has the ability to direct the use of and obtain substantially all of the remaining benefits from the product. In these instances, collaboration revenue is based upon the net sales reported by the Company's collaboration partners, net of cost of goods sold and allowable expenses (e.g., manufacturing, distribution, medical affairs, selling, and marketing expenses) in the period. In order to record collaboration revenue, the Company utilizes certain information from its collaboration partner, including actual net product sales, and costs incurred for sales activities, and makes key judgments based on business updates related to commercial and clinical activities such as expected commercial demand, commercial supply plan, manufacturing commitments, risks related to expired or obsolete inventories, and risks related to potential product returns or contract terminations. The Company uses these estimates to determine whether payments due to us under our collaboration arrangements, such as profit-share payments, should be recognized as revenues in the period that they become due or whether any portion of the payments due should be constrained from revenue recognition because it is not probable that recognizing such amounts would not result in a material reversal of revenues in future reporting periods.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has entered into a number of license and collaboration agreements that fall within the scope of ASC 606. The Company evaluates the promised goods or services in these agreements to determine which ones represent distinct performance obligations. These agreements may include the following types of promised goods or services: (i) grants of licenses, (ii) performance of research and development services, and (iii) participation on joint research and/or development committees. They also may include options to obtain licenses to the Company&#x2019;s intellectual property.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prior to recognizing revenue, the Company makes estimates of the transaction price, including variable consideration that is subject to a constraint. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur and when the uncertainty associated with the variable consideration is subsequently resolved. These estimates are re-assessed each reporting period as required. These agreements may include the following types of consideration: non-refundable upfront payments, reimbursement for research services, research, development or regulatory milestone payments, profit-sharing arrangements, and royalty and commercial sales milestone payments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">150</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If there are multiple distinct performance obligations, the Company allocates the transaction price to each distinct performance obligation based on their estimated standalone selling prices (&#x201c;SSP&#x201d;). The Company estimates the SSP for each distinct performance obligation by considering information such as market conditions, entity-specific factors, and information about its customer that is reasonably available. The Company considers estimation approaches that allow it to maximize the use of observable inputs. These estimation approaches may include the adjusted market assessment approach, the expected cost plus a margin approach or the residual approach. The Company also considers whether to use a different estimation approach or a combination of approaches to estimate the SSP for each distinct performance obligation. Developing certain assumptions (e.g., treatable patient population, expected market share, probability of success and product profitability, discount rate based on weighted-average cost of capital) to estimate the SSP of a distinct performance obligation requires significant judgment.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For performance obligations satisfied over time, the Company estimates the efforts needed to complete the performance obligation and recognizes revenue by measuring the progress towards complete satisfaction of the performance obligation using an input measure.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For arrangements that include sales-based royalties, including commercial milestone payments based on pre-specified level of sales, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Achievement of these royalties and commercial milestones may solely depend upon the performance of the licensee.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Grant Revenue</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Grants received, including cost reimbursement agreements, are assessed to determine if the agreement should be accounted for as an exchange transaction or a contribution. An agreement is accounted for as a contribution if the resource provider does not receive commensurate value in return for the assets transferred. Contributions are recognized as grant revenue when all donor-imposed conditions have been met.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_26be7e5a-d7da-4520-8f8e-2f94f08a3b82" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To date, research and development expenses have related primarily to discovery efforts and preclinical and clinical development of product candidates. Research and development expenses are recognized as incurred and payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received. Research and development expenses include expenses related to license and collaboration agreements; contingent consideration from business acquisitions; personnel-related expenses, including salaries, benefits, and stock-based compensation for personnel contributing to research and development activities; expenses incurred under agreements with third-party contract manufacturing organizations, contract research organizations, and consultants; clinical costs, including laboratory supplies and costs related to compliance with regulatory requirements; and other allocated expenses, including expenses for rent, facilities maintenance, and depreciation and amortization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has acquired and may continue to acquire the rights to develop and commercialize new product candidates from third parties. Upfront payments and research and development milestone payments made in connection with acquired license or product rights are expensed as incurred, provided that they do not relate to a regulatory approval milestone or assets acquired in a business combination.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s expense accruals for clinical trials and manufacturing are based on estimates of contracted services provided by third-party vendors not yet billed. When billing terms under these contracts do not coincide with the timing of when the work is performed, the Company is required to make estimates of its outstanding obligations to those third parties as of the period end. The accrual estimates are based on a number of factors, including the Company&#x2019;s knowledge of the research and development programs and clinical manufacturing activities, the status of the programs and activities, invoicing to date, and the provisions in the contracts. The Company obtains information regarding unbilled services directly from these service providers and performs procedures to support its estimates based on its internal understanding of the services provided to date. However, the Company may also be required to estimate these services based on information available to its internal clinical and manufacturing administrative staff if such information is not able to be obtained timely from its service providers.</span></p></ix:nonNumeric></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">151</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_fe0977a1-d6c2-4043-b108-3758ddd09ca4" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock-based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes stock-based compensation to employees over the requisite service period based on the grant-date fair value of the awards. The Company calculates the estimated fair value of stock options and employees' purchase rights under the Company's 2019 employee stock purchase plan (&#34;ESPP&#34;) using the Black-Scholes valuation model, which requires the use of subjective assumptions including volatility and expected term, among others. The fair value of restricted stock awards (&#34;RSAs&#34;) and restricted stock units (&#34;RSUs&#34;) is based on the market value of the Company's common stock on the date of grant. Stock-based compensation is recognized using the straight-line method for awards that vest only upon the employee&#x2019;s or non-employee&#x2019;s continued service to the Company. Stock-based compensation expense of the employees' purchase rights under the ESPP is recognized over the offering period. Forfeitures are recognized as they occur.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6047c522-677f-45c7-b16b-d6878586cf41" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:BusinessCombinationsPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acquisitions</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Business combinations are accounted for using the acquisition method of accounting. Under the acquisition method, assets acquired, including IPR&amp;D projects, and liabilities assumed are recorded at their respective fair values as of the acquisition date. Any excess fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill. Contingent consideration obligations incurred in connection with the business combination are recorded at their fair values on the acquisition date, are remeasured each subsequent reporting period until the related contingencies are resolved and are classified as contingent consideration on the consolidated balance sheets. The changes in fair values of contingent consideration related to the achievement of various milestones are recorded within research and development expenses or selling, general and administrative expenses based on the nature of the relevant underlying activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">    </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">When the Company determines that an entity acquired does not meet the definition of a business, the transaction is accounted for as an acquisition of assets. Therefore, the consideration paid to acquire IPR&amp;D is expensed, and no goodwill is recorded. Any contingent consideration is generally recognized only when it becomes payable or is paid.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a3d93290-69d7-4fcc-8603-e768a1858798" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:DerivativesEmbeddedDerivatives" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Embedded Derivatives</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company evaluates its acquisitions, collaborative arrangements and other business development transactions to determine if embedded components of these contracts meet the definition of a derivative under ASC 815, Derivatives and Hedging. In general, embedded derivatives are required to be bifurcated from the host instrument if (i) the embedded feature is not clearly and closely related to the host contract and (ii) the embedded feature, if considered a freestanding instrument, meets the definition of a derivative. Embedded derivatives are reported on the consolidated balance sheets at their estimated fair values. Contingent consideration related to asset acquisitions that meet the definition of an embedded derivative is classified as contingent consideration on the consolidated balance sheets. Any change in estimated fair values, as determined at each measurement period, are recorded in the consolidated statements of operations based on the nature of the related contingencies.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in fair values of embedded derivatives related to the achievement of various milestones for product candidates are recorded within research and development expenses or selling, general and administrative expenses based on the nature of the relevant underlying activities</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Otherwise, changes in fair values are recorded within other income (expense), net.</span></p></ix:nonNumeric></div><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_02ff588e-0acf-4c62-b2a2-0fa5cf812a03" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In accordance with ASC 842, Leases, the Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use (&#34;ROU&#34;) assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. ROU assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable. On the lease commencement date, the Company estimates and includes in its lease payments any lease incentive amounts based on future events when (1) the events are within the Company&#x2019;s control and (2) the event triggering the right to receive the incentive is deemed reasonably certain to occur. If the lease incentive received is greater or less than the amount recognized at lease commencement, the Company recognizes the difference as an adjustment to right-of-use asset and/or lease liability, as applicable.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">152</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As the implicit rate in the Company's leases is generally unknown, the Company uses an incremental borrowing rate estimated based on the information available at the lease commencement date in determining the present value of future lease payments. When calculating its estimated incremental borrowing rates, the Company considers its credit risk, the lease term, the total lease payments and the impact of collateral, as necessary. The lease terms may include options to extend or terminate the lease when the Company is reasonably certain it will exercise such options. ROU assets and lease liabilities are remeasured upon certain modifications to leases using the present value of remaining lease payments and estimated incremental borrowing rate upon lease modification. Rent expense for the Company's operating leases is recognized on a straight-line basis within operating expenses over the reasonably assured lease term.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company elected to not separate lease and non-lease components for any leases within its existing classes of assets and, as a result, accounts for the lease and non-lease components as a single lease component. The Company also elected to not apply the recognition requirement to any leases within its existing classes of assets with a term of 12 months or less.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_292877a3-4cd7-4908-9fa7-ad79aaf0a9b4" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true" continuedAt="F_292877a3-4cd7-4908-9fa7-ad79aaf0a9b4_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company uses the asset and liability method of accounting for income taxes. Current income tax expense or benefit represents the amount of income taxes expected to be payable or refundable for the current year. Deferred income tax assets and liabilities are determined based on differences between the financial statement reporting and tax bases of assets and liabilities and net operating losses and credit carryforwards and are measured using the enacted tax rates and laws that will be in effect when such items are expected to reverse. Deferred income tax assets are reduced, as necessary, by a valuation allowance when management determines it is more likely than not that some or all of the tax benefits will not be realized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s tax positions are subject to income tax audits. The Company recognizes the tax benefit of an uncertain tax position only if it is more likely than not that the position is sustainable upon examination by the taxing authority, based on the technical merits. The tax benefit recognized is measured as the largest amount of benefit which is more likely than not to be realized upon settlement with the taxing authority. The Company evaluates uncertain tax positions on a regular basis. The evaluations are based on several factors, including changes in facts and circumstances, changes in tax law, correspondence with tax authorities during the course of the audit, and effective settlement of audit issues. The provision for income taxes includes the effects of any accruals that the Company believes are appropriate, as well as any related net interest and penalties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f80b8605-0c4e-4115-b39c-0506698aeeee" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Net Income (Loss) Per Share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic net income (loss) per common share is computed by dividing the net income (loss) by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net income per common share is computed by dividing the net income by the sum of the weighted average number of common shares outstanding during the period plus any potential dilutive effects of common stock equivalents outstanding during the period calculated in accordance with the treasury stock method.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e46bbdbe-e7b6-44f1-95f4-cf2a48131826" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">New Accounting Pronouncement Recently Adopted</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In November 2021, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standard Update (&#x201c;ASU&#x201d;) No. 2021-10, Government Assistance (Topic 832) (&#x201c;ASU 2021-10&#x201d;), which adds certain disclosure requirements with respect to government assistance, including (1) the types of assistance, (2) an entity&#x2019;s accounting for the assistance, and (3) the effect of the assistance on financial statements. ASU 2021-10 is effective for annual periods beginning after December 15, 2021. The Company's adoption of ASU 2021-10 on January 1, 2022 did not result in any material impact on its consolidated financial statements and related disclosures.</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">153</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VIR BIOTECHNOLOGY, INC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_d6dc3078-cc74-49b4-ba53-7ad4df10eb51" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:FairValueDisclosuresTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">3.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value Measurements </span></div></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company determines the fair value of financial assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value, as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1: Inputs which include quoted prices in active markets for identical assets and liabilities. </span></div></div><div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </span></div></div><div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. </span></div></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The carrying amounts of the Company&#x2019;s financial instruments, including receivable from collaboration, accounts payable and accrued liabilities approximate fair value due to their relatively short maturities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash Equivalents and Available-for-Sale Debt Securities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ee044b5d-2ff3-40e7-a9a2-062e0242f938" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following tables summarize the Company&#x2019;s Level 1 and Level 2 financial assets measured at fair value on a recurring basis by level within the fair value hierarchy:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:43.006%;"></td>
        <td style="width:1.024%;"></td>
        <td style="width:10.242%;"></td>
        <td style="width:1.024%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.067%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.024%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:7.9%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.043%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:7.226999999999999%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.024%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.418%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Valuation<br />Hierarchy</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized<br />Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross<br />Unrealized<br />Holding<br />Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross<br />Unrealized<br />Holding<br />Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate<br />Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_95c3d196-361b-4bb9-bbfc-19a0145e77ff" contextRef="C_f1574fdc-3dbc-4686-99a7-37e3229c36eb" name="vir:FinancialAssetsAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">909,342</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_36b8b5e2-054e-47cc-b86d-523e8cbc6e77" contextRef="C_f1574fdc-3dbc-4686-99a7-37e3229c36eb" name="vir:FinancialAssetsGrossUnrealizedHoldingGains" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f2ee8c17-9247-4204-9405-460cc56f15e9" contextRef="C_f1574fdc-3dbc-4686-99a7-37e3229c36eb" name="vir:FinancialAssetsGrossUnrealizedHoldingLosses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e67a3f38-3954-40a0-a395-2d43a7a52199" contextRef="C_f1574fdc-3dbc-4686-99a7-37e3229c36eb" name="vir:FinancialAssetsFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">909,342</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government treasuries</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cbfb5b0e-8009-4674-9c4d-63931bf62d93" contextRef="C_cf8b6b9e-762d-454d-adc8-ca7fb3750e7b" name="vir:FinancialAssetsAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,493,841</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d4ab685d-3d1f-4d74-b54e-07d428fc0d97" contextRef="C_cf8b6b9e-762d-454d-adc8-ca7fb3750e7b" name="vir:FinancialAssetsGrossUnrealizedHoldingGains" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cc52a59f-ab97-489f-a2dc-bb47c1f5e526" contextRef="C_cf8b6b9e-762d-454d-adc8-ca7fb3750e7b" name="vir:FinancialAssetsGrossUnrealizedHoldingLosses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,396</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5cb4ee98-5a46-4de3-83fe-5ae5ed996ff3" contextRef="C_cf8b6b9e-762d-454d-adc8-ca7fb3750e7b" name="vir:FinancialAssetsFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,485,445</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_758f8a97-c01d-4d17-98fb-3f30dd973dc5" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="vir:FinancialAssetsAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,403,183</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_25e84f0b-b2cd-4b95-bb11-8731c4e86f57" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="vir:FinancialAssetsGrossUnrealizedHoldingGains" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b4b9186d-a648-455a-bb38-08c802a4fe03" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="vir:FinancialAssetsGrossUnrealizedHoldingLosses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,396</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8942699e-96ab-45d3-b201-247b6fbc516d" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="vir:FinancialAssetsFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,394,787</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:80.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1) </span><ix:footnote id="FNT_e1b04269-f99c-420d-9953-f9f240029909" xml:lang="en-US"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Includes </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4d5c1eef-f0e1-4c47-b9a6-a8840e88c1ea" contextRef="C_f1574fdc-3dbc-4686-99a7-37e3229c36eb" name="us-gaap:RestrictedCashEquivalents" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">19.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of restricted cash equivalents.</span></ix:footnote><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:42.871%;"></td>
        <td style="width:1.03%;"></td>
        <td style="width:10.205%;"></td>
        <td style="width:1.021%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.414%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.058%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:7.883%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.058%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:8.110000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.058%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:8.290000000000001%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Valuation<br />Hierarchy</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized<br />Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross<br />Unrealized<br />Holding<br />Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross<br />Unrealized<br />Holding<br />Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate<br />Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_69ac5583-03ad-40a0-a1ae-3d91bf3c9102" contextRef="C_742108ce-79d0-443e-97ab-ce1b47aab7fb" name="vir:FinancialAssetsAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">345,098</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_549f2f58-0809-43a7-af9f-aa62d6cab632" contextRef="C_742108ce-79d0-443e-97ab-ce1b47aab7fb" name="vir:FinancialAssetsGrossUnrealizedHoldingGains" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c5e69a23-b98a-4558-b375-80f9e0916679" contextRef="C_742108ce-79d0-443e-97ab-ce1b47aab7fb" name="vir:FinancialAssetsGrossUnrealizedHoldingLosses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e42ea656-1acd-403e-8417-882547909ce9" contextRef="C_742108ce-79d0-443e-97ab-ce1b47aab7fb" name="vir:FinancialAssetsFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">345,098</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government treasuries</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5c3e9140-ffb1-4e87-9bce-31dce2d0ab2e" contextRef="C_e4ea1ea2-14fb-4c40-b6b7-6c502c2c3167" name="vir:FinancialAssetsAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">419,442</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c257ff65-0870-4938-9a64-3f6f029c42da" contextRef="C_e4ea1ea2-14fb-4c40-b6b7-6c502c2c3167" name="vir:FinancialAssetsGrossUnrealizedHoldingGains" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d0a77136-f8f1-4d4c-ba05-8fa83aea7bba" contextRef="C_e4ea1ea2-14fb-4c40-b6b7-6c502c2c3167" name="vir:FinancialAssetsGrossUnrealizedHoldingLosses" unitRef="U_USD" scale="3" decimals="-3">872</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_083dd05f-fc86-45b5-9866-d91455172172" contextRef="C_e4ea1ea2-14fb-4c40-b6b7-6c502c2c3167" name="vir:FinancialAssetsFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">418,570</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_435eb469-dd55-4186-9832-144dab9cdd98" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="vir:FinancialAssetsAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">764,540</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2ebf7aea-c6ae-4216-a4b9-1a9acda8b9dc" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="vir:FinancialAssetsGrossUnrealizedHoldingGains" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8ad8202c-e7f8-443a-9082-c2b0ba02d601" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="vir:FinancialAssetsGrossUnrealizedHoldingLosses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">872</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c5e7aebe-6316-4680-9723-9b831fd79f44" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="vir:FinancialAssetsFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">763,668</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:80.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1) </span><ix:footnote id="FNT_0c55a751-de0a-4516-8374-b7d3de9b6dd1" xml:lang="en-US"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Includes $</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_11104768-92b5-4b62-af36-56bb4791b2e6" contextRef="C_742108ce-79d0-443e-97ab-ce1b47aab7fb" name="us-gaap:RestrictedCashEquivalents" unitRef="U_USD" scale="6" decimals="-5">15.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of restricted cash equivalents.</span></ix:footnote><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued interest receivable excluded from both the fair value and amortized cost basis of the available-for-sale debt securities are presented within prepaid expenses and other current assets, and other assets in the consolidated balance sheets. Accrued interest receivable amounted to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3f1623ea-2114-479f-be2e-4cc7c00528cf" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:InterestReceivable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5110fc10-2548-444c-a97f-bdbec8473ab3" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:InterestReceivable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as of December 31, 2022 and 2021, respectively. The Company did </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_85db6fdf-d63d-45fc-9e68-1c2e614476f4" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:FinancingReceivableAccruedInterestWriteoff" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_9ba477cc-5577-4dc9-b881-90eac78ae240" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:FinancingReceivableAccruedInterestWriteoff" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t write off any accrued interest receivable during the years ended December 30, 2022 and 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognized total net unrealized loss of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ac6d1894-77c8-4128-9eaf-23610c306fc5" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">8.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_107ccf56-5459-4c64-b7b2-b806d9d638ba" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in accumulated other comprehensive income (loss) as of December 31, 2022 and 2021, respectively. The gross unrealized losses related to U.S. government treasuries as of December 31, 2022 and 2021 were due to changes in interest rates. As of December 31, 2022 and 2021, there were no investments that have been in a continuous unrealized loss position for longer than 12 months. The Company determined that the gross unrealized losses on our investments as of December 31, 2022 were temporary in nature. The Company currently does not intend, and it is highly unlikely that it will be required, to sell these securities before recovery of their amortized cost basis. As of December 31, 2022, no securities have contractual maturities of longer than</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_cf6ec027-605a-4379-b133-52e9f6ef338a" contextRef="C_268c2c6c-2e46-49ef-8b34-85c3eb6476c2" name="us-gaap:DebtSecuritiesAvailableForSaleTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> two years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">154</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Equity Investments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, the Company's equity investment consisted solely of ordinary shares of Brii Biosciences Limited (&#x201c;Brii Bio Parent&#x201d;). The Company acquired the securities as partial consideration for entering into the collaboration, option and license agreement (the &#x201c;Brii Agreement&#x201d;) with Brii Bio Parent and Brii Biosciences Offshore Limited (&#x201c;Brii Bio&#x201d;) in May 2018. The Company concluded it does not have a controlling interest or significant influence over Brii Bio based on its ownership percentage and other factors. See further discussion in Note 7&#x2014;Collaboration and License Agreements. In July 2021, Brii Bio Parent completed its initial public offering (&#x201c;Brii Bio Parent IPO&#x201d;) on the Stock Exchange of Hong Kong Limited, prior to which the securities were accounted for as equity securities without a readily determinable fair value. Upon the completion of the Brii Bio Parent IPO, the securities were considered to be marketable equity securities and subsequently remeasured at fair value at each reporting date. As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company remeasured the equity investment at a fair value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b39c7dc7-e05c-4752-9489-fedb548fa84c" contextRef="C_d81100b1-9c19-43b5-a076-b271e6dffdee" name="us-gaap:InvestmentOwnedAtFairValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">31.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. For the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company recognized an unrealized loss of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_919c0ba5-c7cf-4203-8ffc-7218ef94a126" contextRef="C_faecd853-fee9-460a-9e6f-a4fc83b058a2" name="us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">111.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as other income in the consolidated statement of operations, net of an unrealized loss of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cd765c4e-aee7-46e4-bac5-ac53a993754a" contextRef="C_faecd853-fee9-460a-9e6f-a4fc83b058a2" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million related to foreign currency translation for the period. The Company classifies its equity investment in Brii Bio Parent as a Level 1 asset within the fair value hierarchy, as the value is based on a quoted market price in an active market.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Contingent Consideration</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contingent consideration includes potential milestone payments in connection with the acquisitions of Humabs BioMed SA (&#x201c;Humabs&#x201d;) and TomegaVax, Inc. (&#x201c;TomegaVax&#x201d;). See further discussion in Note 4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Acquisitions. The Company classifies the contingent consideration as Level 3 financial liabilities within the fair value hierarchy as of December 31, 2022 and 2021.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The estimated fair value of the contingent consideration related to the Humabs acquisition was determined by calculating the probability-weighted clinical, regulatory and commercial milestone payments based on the assessment of the likelihood and estimated timing that certain milestones would be achieved. </span><span><ix:nonNumeric id="F_c232c74c-b075-42af-afdd-4f17cae26309" contextRef="C_ea8871a7-9d90-4943-89b3-944727e32088" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" escape="true" continuedAt="F_c232c74c-b075-42af-afdd-4f17cae26309_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of Decemb</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">er 31, 2022, the Company calculated the estimated fair value of the remaining clinical and regulatory milestones related to VIR-3434 using the following significant unobservable inputs: </span></ix:nonNumeric></span><span style=""></span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:continuation id="F_c232c74c-b075-42af-afdd-4f17cae26309_1" continuedAt="F_c232c74c-b075-42af-afdd-4f17cae26309_2"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.176%;"></td>
        <td style="width:2.444%;"></td>
        <td style="width:32.38%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unobservable input</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Range<br />(Weighted-Average)1</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Discount rates</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_badce134-8528-4753-8a8b-28ca3cf397fa" contextRef="C_f22a75a3-1d5c-4569-b00b-c460e4c440a5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">13.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_faed9603-c7e8-4971-b88c-45fb1a1abd5f" contextRef="C_713f0ffb-32b7-4557-8121-be8edd691f8d" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">15.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% (</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_94b5821e-c6b0-49b4-bd92-b25178e3d93a" contextRef="C_f315ae4d-c3f9-4374-877b-5e513e6b3e19" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">14.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Probability of achievement</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_de81d354-d0b9-4919-aaaf-c3852c79312a" contextRef="C_ef41dda9-45c7-47f2-94ae-8f41c2af548c" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">14.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6ed74193-b982-4779-9300-7e451bc0ef5b" contextRef="C_e70b1c74-320f-4d6a-81ff-72022442374d" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">60.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% (</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_24f706d2-1a5c-4606-a102-532a52e31e5b" contextRef="C_89ca23f5-e12c-4dba-be08-03251a397eda" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">43.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%)</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:80.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:continuation></div><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_c232c74c-b075-42af-afdd-4f17cae26309_2"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1) </span><ix:footnote id="FNT_309d5bc3-a5ff-45a0-b9dd-16d51cf30514" xml:lang="en-US"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unobservable inputs were weighted based on the relative fair value of the clinical and regulatory milestone payments.</span></ix:footnote><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></ix:continuation></span><span style=""></span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the commercial milestones, the Company used a Monte Carlo simulation because of the availability of discrete revenue forecasts. A</span><span><ix:nonNumeric id="F_fdbcda46-22d8-4510-8430-20bd74b1fb46" contextRef="C_c00e1b15-1ac9-46ef-8ed8-c2ca882b705b" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" escape="true" continuedAt="F_fdbcda46-22d8-4510-8430-20bd74b1fb46_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">s of December 31, 2022, the Monte Carlo simulation assumed a commercial product launch and associated discrete revenue forecasts, as well as the following significant unobservable inputs f</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">or the remaining commercial milestones related to VIR-3434: </span></ix:nonNumeric></span><span style=""></span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:continuation id="F_fdbcda46-22d8-4510-8430-20bd74b1fb46_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.176%;"></td>
        <td style="width:2.444%;"></td>
        <td style="width:32.38%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unobservable input</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Value</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d61311fe-620c-4cf4-a5fe-4802f9b8a5f8" contextRef="C_2b3229e8-bd98-49b7-9746-e7ce783e8031" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">80.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Discount rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_44cc508b-6b42-4adf-9ee1-5750021b76fb" contextRef="C_dad50c1a-a985-4cd9-83d5-54c441a295ba" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">12.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Probability of achievement</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_84b2de71-2371-4b50-ba3a-1bd2c0e20ca4" contextRef="C_ffa6727e-7fad-43e1-84bd-2106591a8a4a" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">25.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The discount rate captures the credit risk associated with the payment of the contingent consideration when earned and due. As of December 31, 2022 and 2021, the estimated fair value of the contingent consideration related to the Humabs acquisition was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e7369fd8-7846-4f5a-8966-43ab9618438f" contextRef="C_e422f02f-6b34-4d0a-8361-270372955b88" name="us-gaap:BusinessCombinationContingentConsiderationLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">23.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fc9e1cf3-1d7e-461b-8187-7b3c7444e215" contextRef="C_ef53fffe-7284-4da2-ade0-6081e04aa2dd" name="us-gaap:BusinessCombinationContingentConsiderationLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">17.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, with changes in the estimated fair value recorded in research and development expenses, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and selling, general and administrative expenses in the consolidated statements of operations based on the nature of the relevant underlying activities.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The estimated fair value of the contingent consideration related to the TomegaVax acquisition was determined by using a Monte Carlo simulation model which included estimates of both the probability and timing to achieve the required per-share price of the Company&#x2019;s common stock, and incorporates assumptions as to expected volatility and discount rate. The discount rate captures the credit risk associated with the payment of the contingent consideration when earned and due. Although the TomegaVax acquisition was accounted for as an asset acquisition, such contingent consideration met the definition of an embedded derivative financial instrument. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 2021, the Company achieved one of the milestones related to a specified per-share price of its common stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">155</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">resulting </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">in a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b820c778-819b-4ca0-8520-31ac539346f9" contextRef="C_fa700c83-f248-4007-a04a-6e5b18f6eef8" name="vir:AssetAcquisitionMilestoneAchieved" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million payable to the former TomegaVax&#x2019;s stockholders which was paid in July 2021. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_9c8c9048-6dcb-4904-bfa3-3c6f44e4ef5c" contextRef="C_236e9ea2-3639-4c4a-84d1-b0cbf28005ee" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" escape="true" continuedAt="F_9c8c9048-6dcb-4904-bfa3-3c6f44e4ef5c_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, the fair value of the remaining contingent consideration was estimated using the following significant unobservable inputs:</span></ix:nonNumeric></span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:continuation id="F_9c8c9048-6dcb-4904-bfa3-3c6f44e4ef5c_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.176%;"></td>
        <td style="width:2.444%;"></td>
        <td style="width:32.38%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unobservable input</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Value</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f26d98e9-5316-4421-b846-54cc894c1188" contextRef="C_1a446893-56a8-4407-9044-e0e0fd59cfee" name="us-gaap:EmbeddedDerivativeLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">90.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Discount rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3281bdeb-c214-46f3-9c5b-cd7c4e6c4fea" contextRef="C_15a1a88f-77e5-43b6-91c1-62f17e7d6662" name="us-gaap:EmbeddedDerivativeLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">4.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022 and 2021, the estimated fair value of the contingent consideration related to the TomegaVax acquisition was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3f4b7ac9-aade-41d0-823b-381922fd68fe" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_415345cf-682b-4089-9ec6-a9208ab2e6a1" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:BusinessCombinationContingentConsiderationLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, with changes in the estimated fair value recorded in other income (expense), net in the consolidated statements of operations.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The estimated fair value of the contingent consideration related to the Humabs and TomegaVax acquisitions involves significant estimates and assumptions which give rise to measurement uncertainty.</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8957bd33-fdec-4746-b2d4-54dd8ff581aa" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table sets forth the changes in the estimated fair value of the Company&#x2019;s contingent consideration (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.81%;"></td>
        <td style="width:2.096%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:16.094%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contingent<br />Consideration</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_59bb4c1d-b9d3-442c-9678-16a9fd89ef5e" contextRef="C_a17e8413-fa17-4363-9bcc-2c63c792146e" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">22,822</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in fair value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b4ca3507-da4f-4227-91af-e4b0b2383067" contextRef="C_85d8bb4b-5225-414c-87d0-df7003801fcd" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,115</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_23e14ad3-3dc4-4922-befa-05f3cef3f28e" contextRef="C_6046760e-44a7-4084-a7d2-ce57ecf671fd" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">24,937</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1eeae131-6917-4c01-9ca1-0cfe0910ca23" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:BusinessCombinationDisclosureTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">4.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Acquisitions </span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acquisition of TomegaVax</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In September 2016, the Company entered into an agreement and plan of merger (&#x201c;TomegaVax Merger Agreement&#x201d;) to acquire all of the equity interests of TomegaVax. The primary asset purchased in the acquisition was an in-process cytomegalovirus (&#x201c;CMV&#x201d;) vector-based vaccine platform for use in HBV, HIV, and tuberculosis. The acquisition was accounted for as an asset purchase.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the entry into the TomegaVax Merger Agreement, the Company also entered into a letter agreement with TomegaVax (the &#x201c;TomegaVax Letter Agreement&#x201d;), which provides for certain payments to TomegaVax&#x2019;s former stockholders before September 2024, in each case so long as the Company is continuing to pursue the development of the TomegaVax technology. Under the terms of the TomegaVax Letter Agreement, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d04284ff-1f37-4d10-910e-39b77453730a" contextRef="C_ef2dbdd6-6a22-4314-8ad2-3d3b510a7b9a" name="vir:MilestonePaymentsRelatedTermsDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the Company will be required to pay to the former stockholders of TomegaVax milestone payments of up to an aggregate of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cf69195a-9e07-4b4e-a28f-9df5bf3a3708" contextRef="C_82509859-a65e-439a-a5e3-9a2599d1d6ef" name="vir:AssetAcquisitionMilestonePaymentAggregate" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">30.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million if the per-share price of the Company&#x2019;s publicly traded common stock, or implied price per share of the Company&#x2019;s Series A-1 convertible preferred stock (or common stock upon conversion) upon a certain asset sale, merger or stock sale, is at least $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3c55385b-3151-4c50-a2a4-5b590a2730cf" contextRef="C_904cd630-0ecd-4275-ad9e-ee81b3b5999d" name="vir:MinimumCommonStockPriceForMilestonePaymentsConsideration" unitRef="U_USDollarShare" decimals="INF">45</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (as adjusted in the case of any stock dividend, stock split or other similar recapitalization), with the amount of such payments determined by the share price and/or the stage of the Company&#x2019;s clinical development at the time of the relevant event triggering the payment.</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The share price of the Company&#x2019;s publicly traded common stock will be determined using the average of the daily volume-weighted average trading price of the Company&#x2019;s common stock for each trading day during a consecutive 90-day period. The foregoing payments are payable (i) during any date after the completion of an initial public offering by the Company or any successor or affiliate controlling the TomegaVax technology, provided that no payment will be due before the first anniversary of the initial public offering, (ii) upon the sale of all assets related to the TomegaVax technology or (iii) upon a merger or stock sale of the Company or any successor or affiliate controlling the TomegaVax technology, in each case subject to certain conditions with respect to the timing of the payments. The payments under the TomegaVax Letter Agreement can be made in cash or shares of the Company&#x2019;s common stock, at the discretion of the Company&#x2019;s board of directors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In February 2021, the Company achieved </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e5b4d738-5ad4-4549-be6e-5767e00bbccb" contextRef="C_181582de-b0b6-4d34-a602-8545a05e16ac" name="vir:AssetAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration" unitRef="U_Milestone" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of the milestones related to the specified per-share price of its common stock, which resulted in a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a69a5ae7-daa9-4920-b544-17b8cb244cf7" contextRef="C_a4c83d47-f369-4173-b21b-90aff8652ace" name="us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million payable to TomegaVax&#x2019;s former stockholders. In July 2021, the Company made the milestone payment to the former TomegaVax stockholders through a combination of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3c868f9c-e112-4745-a75f-b6349a55a2fc" contextRef="C_11d4ba09-a5bc-40ed-9952-89cf471e26ef" name="vir:PaymentMadeForAssetAcquisitionMilestone" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">8.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in cash and the issuance of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6d9f72f7-c392-467f-8cff-605c98694492" contextRef="C_0ab96725-0d67-4b9b-8abe-9354e48096b0" name="vir:CommonStockSharesIssuedForMilestonePaymentShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">42,737</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock with a total fair value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0a7c8ee3-af4b-4d7e-8fe5-b58fbaed9152" contextRef="C_ab10cbf0-1e01-4fdf-9b82-e97488c8af01" name="us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The remaining milestone payments of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_827daedf-cb9d-457c-8753-ec2704e52454" contextRef="C_c81037e3-36e7-429d-8e76-acaab8a63eee" name="vir:RemainingPaymentForAssetAcquisitionMilestoneAggregate" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">20.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in the aggregate will be triggered if (i) the per-share price of the Company&#x2019;s publicly traded common stock is at least $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9d105262-4298-4688-b41f-e794b7c34ebe" contextRef="C_8ca9f390-7fbb-41d3-a8cc-0dc299a46f0e" name="vir:MinimumCommonStockPriceForMilestonePaymentsConsideration" unitRef="U_USDollarShare" decimals="0">45</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (as adjusted in the case of any stock dividend, stock split or other similar recapitalization) and upon the achievement of a certain milestone related to the stage of the Company&#x2019;s clinical development at the time of the relevant event triggering the payment and/or (ii) the per-share price of the Company&#x2019;s publicly traded common stock is at least $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eb7b7013-693c-4d6f-86f1-81272c2fce24" contextRef="C_2f1d51a5-d28e-426b-b4cb-bbde0b7f3943" name="vir:MinimumCommonStockPriceForMilestonePaymentsConsideration" unitRef="U_USDollarShare" decimals="0">90</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (as adjusted in the case of any stock dividend, stock split or other similar recapitalization).</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">156</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company determined that the future milestone payments contain net settlement provisions and, therefore, they were required to be accounted for as embedded derivatives under the relevant accounting guidance. As of December 31, 2022, the estimated fair value of the embedded derivative was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_42f8d0a2-af56-466b-a0b4-4ee1d3e77ecb" contextRef="C_e5b7cf6a-c235-492c-a434-ae21534824b2" name="us-gaap:AssetAcquisitionContingentConsiderationLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and was included in the contingent consideration liability on the consolidated balance sheet.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acquisition of Humabs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In August 2017, the Company acquired all of the outstanding equity of Humabs, a private Swiss company, which discovers and develops monoclonal antibodies (&#x201c;mAbs&#x201d;) derived from individuals whose immune systems have successfully responded to major diseases. The Company acquired all of Humabs&#x2019; rights, title and interest in and to substantially all of the assets of Humabs except for rights under certain license agreements with third parties. The Company is obligated to pass through to the former Humabs shareholders any amounts received by Humabs under such license agreements, net of any program expenses. The transaction was accounted for as an acquisition of a business. In addition to the cash payment and issuance of common stock to the former Humabs shareholders at the acquisition date, the Company also agreed to pay additional amounts in cash upon the achievement of specified milestone events: (i) up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_194b39c6-6614-43a7-8958-6ffc383fa05b" contextRef="C_dd2fc99d-7a9d-45e3-995a-8f33afb52a81" name="vir:BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">135.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million upon the achievement of clinical, regulatory and commercial milestones for VIR-3434; and (ii) up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_146ea849-546e-42ca-b75e-703d87ff3221" contextRef="C_60880c52-6f5a-486b-a848-501a5bacdd60" name="vir:BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">105.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million upon the achievement of clinical, regulatory and commercial milestones for another product, which the Company elected as sotrovimab, a severe acute respiratory syndrome coronavirus 2 (&#x201c;SARS-CoV-2&#x201d;) product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the year ended December 31, 2020, the Company achieved </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_33934fc1-6a8f-4be8-a8db-e60971a0ffe0" contextRef="C_59d1854c-78da-4bb2-8d89-3e539c321e00" name="vir:BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved" unitRef="U_Milestone" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of the specified clinical milestones for the HBV product and sotrovimab totaling $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_af3557cc-76ef-4662-991f-31ba1791f1a3" contextRef="C_87f06556-ced9-44e3-ae60-d194dd7923ff" name="vir:SpecifiedClinicalDevelopmentMilestonesPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_31034b29-c6c6-4b2f-b5a9-94beb8272eb2" contextRef="C_59d1854c-78da-4bb2-8d89-3e539c321e00" name="vir:SpecifiedClinicalDevelopmentMilestonesPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">20.0</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the year ended December 31, 2021, the Company achieved the specified regulatory milestone of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f65f4f4f-6518-429b-bf00-2d117dcccab6" contextRef="C_a055c3a3-3329-46bd-a235-0271e1908c6b" name="vir:RegulatoryMilestonesAchieved" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">35.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and sales milestones totaling $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_682defeb-749c-4381-ac4b-df4713f15129" contextRef="C_a055c3a3-3329-46bd-a235-0271e1908c6b" name="vir:SalesMilestonesAchieved" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">60.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million related to sotrovimab, which were paid</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in January and February 2022, respectively. The estimated fair value of the remaining contingent consideration was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_df110bfd-2f3a-4d38-9479-b887d6568a5e" contextRef="C_09ba265a-6add-41f5-ae26-e28684a4a700" name="us-gaap:BusinessCombinationContingentConsiderationLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">23.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as of December 31, 2022.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The acquired developed technologies that have associated patents issued are classified as finite-lived intangible assets and are amortized on a straight-lined basis over their estimated remaining useful lives, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">generally between </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_42ecc27d-dd4e-4bd9-a1b3-ab9d1b0e44c1;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">seven</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_48c3df9b-4d9a-4bc8-a43d-ef518ca1bb6c" contextRef="C_b67fb883-45a1-44e2-8338-3440f618fc44" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12 years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Company also acquired indefinite-lived intangible assets consisting of IPR&amp;D. These assets will not be amortized until regulatory approval is obtained in a major market. At that time, the Company will determine the useful life of the asset and begin amortization. If the associated research and development effort is abandoned or otherwise impaired, the related IPR&amp;D assets will be written-off and an impairment charge will be recorded. As of December 31, 2022, there have been </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_14df5f90-3700-4477-a538-633bb700cecf" contextRef="C_edd96045-6b9c-4a57-a99c-8b916e5ab8d8" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> such impairments related to the IPR&amp;D assets. The estimated fair value of the intangible assets was determined using the replacement cost method. The excess of the purchase price over the estimated fair value of the net assets acquired was recorded as goodwill. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bd9eb6b8-750a-4384-ad94-0dc8ea45616c" contextRef="C_e422f02f-6b34-4d0a-8361-270372955b88" name="us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">None</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of the goodwill is expected to be deductible for income tax purposes.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5587061b-fe82-4913-a3b2-c665e6a7a2bb" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">5.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Goodwill and Intangible Assets </span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Goodwill</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Goodwill of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a1d65373-5ab1-4671-bad1-2484c753ae80" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:Goodwill" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">16.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> represents the excess of the purchase price over the estimated fair value of the net assets acquired from Humabs. The Company tests goodwill for impairment on an annual basis or sooner, if deemed necessary. There was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_18632fa5-475d-4c45-b74d-ce6d1401fa5f" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:GoodwillImpairmentLoss" unitRef="U_USD" scale="6" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> impairment for the year ended December 31, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Intangible Assets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a6ed9b65-85ec-4aaf-a505-dab6aa50367c" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the carrying amount of the Company&#x2019;s finite-lived intangible assets (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.244%;"></td>
        <td style="width:0.375%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.274%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.116%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.591999999999999%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.078%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:14.318999999999999%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-<br />Average<br />Remaining Useful</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Life (Years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Developed technology</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cfafa59a-e89a-4432-bad6-987d67be8d61" contextRef="C_4afe2d0e-b9a0-4c40-9bbf-4330eabe88fe" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,260</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bd84bcf1-18de-4411-9756-921f13a50f9b" contextRef="C_ba34aded-037c-492e-95bf-8e2aee84865a" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2c3dd3ec-1c52-4652-96db-add0622306e8" contextRef="C_8616915b-46bc-4304-92c6-102f09231afc" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.5</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contract-based intangible asset</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d876f6e2-d0c8-4388-89be-ad1ebddff77f" contextRef="C_8ea58521-d0a7-4461-a025-c44f108acb5b" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">502</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_29ee1ecd-1bbe-4fe2-a864-e73eed8288d3" contextRef="C_7619716a-9e49-48b5-abed-ff43a16e8263" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">502</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_88a1804f-cba5-463a-af56-aa74f8b2e46e" contextRef="C_1c1249b0-5ad3-449c-a242-9282e54fdb6f" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.9</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Finite-lived intangible assets, gross</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3b8e5d7b-45e3-4298-a341-783a76a35de0" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,762</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c896a3a9-7283-4fc8-acbf-0db7dc659552" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,502</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less accumulated amortization</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_39b7a26f-6f01-4887-baea-ba4937eca201" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,738</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8e895c34-a6f7-4728-a33d-cd656846204f" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,114</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less impairment of intangible assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c6a4d043-993b-4270-b212-fc05a3c950fd" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="vir:FiniteLivedIntangibleAssetsAccumulatedImpairment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_47bd085c-939d-43be-81e0-31239424f978" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="vir:FiniteLivedIntangibleAssetsAccumulatedImpairment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">832</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Finite-lived intangible assets, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b65e6495-33cf-4a8a-968f-971574daacf2" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,024</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e40fc6fc-5eb4-466c-8130-7cba01e1cc62" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,556</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">157</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Finite-lived intangible assets are carried at cost less accumulated amortization. The contract-based intangible asset resulted from the product approval of a sublicensed intellectual property right in December 2020. The intellectual property right was previously accounted for as IPR&amp;D. Amortization expense related to finite-lived intangible assets, included in research and development expenses on the consolidated statements of operations, totaled $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3547a1ce-87e8-43bf-9c0f-9e48dca1d811" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_92c6344b-5d3f-4652-8905-d0f1d85b00cf" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cba85717-1400-4c99-a058-285eb75328e6" contextRef="C_ff18ae7e-33f9-49e0-b7ad-17646042d12e" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the years ended December 31, 2022, 2021 and 2020, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management reviews finite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable, like that of property and equipment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2ad5980f-0798-410c-bf25-cec6e928639a" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on the finite-lived intangible assets recorded as of December 31, 2022, the estimated future amortization expense for the next five years is as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.682%;"></td>
        <td style="width:1.865%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:16.451999999999998%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ending December 31:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4eb22015-318f-4599-ae30-95e79e680878" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">532</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e09585cd-2745-4caa-9857-b291ad777845" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">260</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_173d329d-cc74-41db-88d8-02ffde4f88d8" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">213</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_394f2fc9-6a62-4aed-98f0-a71ba2181d2b" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">213</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2027</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_82b949e9-306e-44f2-b47f-3235719d9b9d" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">213</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8f815239-08a1-471d-bceb-e9c2eb4106d1" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="vir:FiniteLivedIntangibleAssetsAmortizationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,431</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Indefinite-Lived Intangible Assets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022 and 2021, the Company had indefinite-lived intangible assets of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0e39f03d-79f1-4b90-87d6-196dbadf3851" contextRef="C_edd96045-6b9c-4a57-a99c-8b916e5ab8d8" name="us-gaap:IndefinitelivedIntangibleAssetsAcquired" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_da347572-843c-4984-a23d-888a51dd1639" contextRef="C_8d7f14bb-4690-4c57-9bee-e30534233b77" name="us-gaap:IndefinitelivedIntangibleAssetsAcquired" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">30.7</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, related to the purchased IPR&amp;D from the Humabs acquisition. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f69be224-2822-4a02-a924-b3ed972cf0ca" contextRef="C_edd96045-6b9c-4a57-a99c-8b916e5ab8d8" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" unitRef="U_USD" scale="6" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_3bcbd321-287d-4cd0-80d0-67f22329e6e1" contextRef="C_8d7f14bb-4690-4c57-9bee-e30534233b77" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" unitRef="U_USD" scale="6" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> impairment losses have been recorded for the years ended December 31, 2022 and 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b38c32f7-d19f-41a5-934d-021f75fc3108" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="vir:GrantAgreementsDisclosureTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">6.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Grant Agreements </span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Bill &amp; Melinda Gates Foundation Grants</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has entered into various grant agreements with the Bill &amp; Melinda Gates Foundation, under which it was awarded grants totaling up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9753a1c5-c4fe-4344-8761-8896c8bf482e" contextRef="C_53c3499f-95d7-41ad-aa6a-553955ca0961" name="vir:GrantAwardedAmountMaximum" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">55.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to support its HIV vaccine program, tuberculosis vaccine program, HIV vaccinal antibody program and malaria vaccinal antibody program. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The term of the grant agreements will expire at various dates through December 2023, unless earlier terminated by the Bill &amp; Melinda Gates Foundation for the Company&#x2019;s breach, failure to progress the funded project, in the event of the Company&#x2019;s change of control, change in the Company&#x2019;s tax status, or significant changes in the Company&#x2019;s leadership that the Bill &amp; Melinda Gates Foundation reasonably believes may threaten the success of the project.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Concurrently with the execution of the grant agreement for the vaccinal antibody program, the Company entered into a stock purchase agreement with the Bill &amp; Melinda Gates Foundation, under which the Bill &amp; Melinda Gates Foundation purchased </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ab1b6962-a5cc-4a80-9c90-74a51d60c6be" contextRef="C_0640f8ac-c552-4f54-8a09-1b99e32573ac" name="vir:CommonStockSharesPurchased" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">881,365</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company&#x2019;s common stock on January 13, 2022, at a price per share of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_05bffe40-8fb1-45a7-b3b5-95e7edaf1e1f" contextRef="C_0640f8ac-c552-4f54-8a09-1b99e32573ac" name="vir:CommonStockSharesPurchasedSharePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">45.38</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, for an aggregate purchase price of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d2f2aee3-e758-4502-87f3-2bc5671c96b3" contextRef="C_0640f8ac-c552-4f54-8a09-1b99e32573ac" name="vir:CommonStockSharesPurchasedAggregatePurchasePrice" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">40.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The fair market value of the common stock issued to the Bill &amp; Melinda Gates Foundation was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_127d9eac-4582-41f6-89ad-63e12171893c" contextRef="C_8e5b8d02-9b16-4b28-a5ac-d7b44ab9cd92" name="vir:CommonStockSharesIssuedFairMarketValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">28.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, based on the closing stock price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c609a161-0d4c-4214-8c36-8fdd24eded04" contextRef="C_0640f8ac-c552-4f54-8a09-1b99e32573ac" name="vir:ClosingStockPrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">37.65</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share on the closing date and taking into account a discount for the lack of marketability due to the restrictions in place on the underlying shares, resulting in a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b7f973dd-339e-4db6-9383-40d011c1cbf4" contextRef="C_8e5b8d02-9b16-4b28-a5ac-d7b44ab9cd92" name="vir:UnderlyingSharesPremiumReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">11.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million premium received by the Company. The Company accounted for the common stock issued to the Bill &amp; Melinda Gates Foundation based on its fair market value on the closing date and determined that the premium paid by the Bill &amp; Melinda Gates Foundation should be included in the deferred revenue from the vaccinal antibody grant.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Payments received in advance that are related to future research activities along with the aforementioned premium received are deferred and recognized as revenue when the donor-imposed conditions are met, which is as the research and development activities are performed. The premium received by the Company is deferred and recognized over the same period as the grant proportionally. The Company recognized grant revenue of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_17e997ad-c494-4302-9640-d9591409880c" contextRef="C_e170955d-d5d7-40a0-b36e-ac2e1046968a" name="us-gaap:RevenueNotFromContractWithCustomer" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">8.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8ec6b920-de04-4a4b-96a1-0a7a4d316454" contextRef="C_8338caa5-3a09-4312-9d81-25f2cf6a95d0" name="us-gaap:RevenueNotFromContractWithCustomer" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">8.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0c966236-a255-4992-ba3e-95407415e8b4" contextRef="C_34578bdd-5e64-44f6-8af5-ed7833cd36ba" name="us-gaap:RevenueNotFromContractWithCustomer" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">8.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the years ended December 31, 2022, 2021 and 2020, respectively. As of December 31, 2022 and 2021, the Company had deferred revenue of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5657c115-0b73-4ac1-a31c-7ea0dc60b944" contextRef="C_7bfa1f77-0aad-47a7-9222-be7a47061336" name="us-gaap:DeferredIncome" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">15.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9601f062-74dd-4403-b275-cabf40e5f40d" contextRef="C_d31deef3-bfd7-4c38-8080-cbcd2d6f202c" name="us-gaap:DeferredIncome" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">6.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively. As of December 31, 2022 and 2021, the Company had $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_44087b06-0762-4693-bed9-c24a9bb89aeb" contextRef="C_7bfa1f77-0aad-47a7-9222-be7a47061336" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">7.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_967f6338-ec66-4230-b1ca-2b4f2ea95486" contextRef="C_d31deef3-bfd7-4c38-8080-cbcd2d6f202c" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, within accrued and other liabilities, which may need to be refunded to the Bill &amp; Melinda Gates Foundation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">158</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Biomedical Advanced Research and Development Authority</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In September 2022, the Company entered into an other transaction for advanced research agreement (the &#x201c;BARDA Agreement&#x201d;) with the Biomedical Advanced Research and Development Authority (&#x201c;BARDA&#x201d;), part of the U.S. Department of Health and Human Services&#x2019; Administration for Strategic Preparedness and Response. Under the BARDA Agreement, the Company may receive up to an estimated $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_55be3588-23a4-4d18-812e-95645548641f" contextRef="C_7c11953b-e6ce-4d9b-8cf9-80604a06d01a" name="vir:MaximumAmountGrantAggregate" unitRef="U_USD" scale="9" decimals="-8" format="ixt:numdotdecimal">1.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> billion to advance the development of a full portfolio of innovative solutions to address influenza and potentially other infectious disease threats. The Base Period (as defined below) for the BARDA Agreement includes government funding of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c4a019eb-ea02-4cf5-843c-6f36cfebf215" contextRef="C_7c11953b-e6ce-4d9b-8cf9-80604a06d01a" name="vir:MaximumAmountGrantBasePeriod" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">55.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to reimburse a portion of expenses incurred by the Company to support the development of VIR-2482, an investigational prophylactic monoclonal antibody designed with the aim to protect against seasonal and pandemic influenza, including expenses related to the Phase 2 pre-exposure prophylaxis trial of VIR-2482. The BARDA Agreement also provides for additional BARDA funding after the exercise by BARDA of up to twelve options to further support the development of pre-exposure prophylactic antibodies including and beyond VIR-2482 for the prevention of influenza illness or possibly supporting medical countermeasures for other pathogens of pandemic potential. The BARDA Agreement has an initial term that commenced on September 30, 2022 and extends through January 2026 (&#x201c;Base Period&#x201d;), which may be extended by mutual written agreement of the Company and BARDA if certain conditions are met or if BARDA exercises any of its options, as described above, and is terminable by the Company and BARDA at any time under specified circumstances, including for convenience.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognized grant revenue under the BARDA Agreement of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c52ee024-4e78-4dcc-96e8-8c57684129ca" contextRef="C_0365acdf-5aea-4a92-8f52-bcf73ab2f285" name="us-gaap:RevenueNotFromContractWithCustomer" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">26.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the year ended December 31, 2022 and a corresponding other receivable in prepaid expenses and other current assets of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_09bb0ba6-8991-40c0-ad9e-bdb14b833bad" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">26.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as of December 31, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c311b295-db17-4f18-9c84-90fc104afc05" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">7.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaboration and License Agreements </span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Collaboration Agreements with GSK</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2020 GSK Agreement</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On June 9, 2020, the Company, Glaxo Wellcome UK Limited and Beecham S.A. entered into a definitive collaboration agreement under the terms set forth in the preliminary collaboration agreement entered into by the Company and certain GSK entities in April 2020 (the &#x201c;2020 Preliminary Agreement&#x201d;) (such definitive collaboration agreement, the &#x201c;2020 GSK Agreement&#x201d;). In December 2021, Beecham S.A. assigned and transferred all its rights, title, interest, and benefit in the 2020 GSK Agreement to GlaxoSmithKline Biologicals S.A. (Glaxo Wellcome UK Limited and GlaxoSmithKline Biologicals S.A., referred to, individually and together, as &#x201c;GSK&#x201d;), including all its rights to bring claims under such agreement. Concurrently with the execution of the 2020 Preliminary Agreement, the Company entered into a stock purchase agreement (the &#x201c;2020 Stock Purchase Agreement&#x201d;) with Glaxo Group Limited (&#x201c;GGL&#x201d;), an affiliate of GSK, under which GGL purchased </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6f5bdc29-ad55-4ccb-8df2-b64197a7b70b" contextRef="C_7c77693b-4357-4bb2-a8c3-270864bc9cad" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">6,626,027</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company&#x2019;s common stock on April 29, 2020, at a price per share of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8fd75026-1ab3-4785-8b14-60333c3ebb82" contextRef="C_48f1b79a-a22f-4fe8-acd8-aae6fb94bd78" name="us-gaap:SharePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">37.73</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, for an aggregate purchase price of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c94ef604-9663-45c6-8fe6-f29e8868dd9b" contextRef="C_7c77693b-4357-4bb2-a8c3-270864bc9cad" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">250.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The 2020 Preliminary Agreement became effective as of April 29, 2020, which was also the closing date for the 2020 Stock Purchase Agreement (&#x201c;Effective Date&#x201d;). The 2020 GSK Agreement superseded and replaced the 2020 Preliminary Agreement between the parties. Under the terms of the 2020 GSK Agreement, the Company and GSK agreed to collaborate to research, develop and commercialize products for the prevention, treatment and prophylaxis of diseases caused by SARS-CoV-2, the virus that causes COVID-19, and potentially other coronaviruses. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6e748486-9449-43ec-888d-736cff54e081" contextRef="C_bc722d93-c8c5-4bb5-99b0-064fd7628401" name="vir:CollaborationTypeAndPrograms"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The collaboration initially focused on the development and commercialization of three types of collaboration products under three programs: (1) antibodies targeting SARS-CoV-2 and potentially other coronaviruses (the &#x201c;Antibody Program&#x201d;); (2) vaccines targeting SARS-CoV-2 and potentially other coronaviruses (the &#x201c;Vaccine Program&#x201d;), and (3) products based on genome-wide CRISPR screening of host targets expressed in connection with exposure to SARS-CoV-2 and potentially other coronaviruses (the &#x201c;Functional Genomics Program&#x201d;)</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_34f36cd1-b27e-494c-af7c-6d7af0fc32c1" contextRef="C_41c05a89-da87-4a31-a87a-9e37c464d328" name="vir:NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> four years </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">following the Effective Date, the parties agreed to conduct certain research and development activities under mutually agreed development plans and associated budgets for each of the three programs, and under the oversight of a joint steering committee (&#x201c;JSC&#x201d;). The Company is primarily responsible for the development and clinical manufacturing activities for the Antibody Program, and for conducting the initial development activities directed to a vaccine in the Vaccine Program. GSK is primarily responsible for the commercialization activities for the Antibody Program (including in mainland China, Hong Kong, Macau and Taiwan following the purchase of these rights in May 2022, as described below), the later-stage development, manufacturing and commercialization activities for the Vaccine Program and the development, manufacturing and commercialization activities for the Functional Genomics Program. Subject to an opt-out mechanism and Amendment No. 1 to the 2020 GSK Agreement (described below), the parties share all development costs, manufacturing costs and costs and expenses for the commercialization of the collaboration products, with the Company bearing </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0256a6d1-f70b-405b-8b6d-ba086a78174f" contextRef="C_0d93da71-2399-418f-85e8-9b6b02f4b192" name="vir:PercentageOfDevelopmentCosts" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">72.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of such costs for the antibody products, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bea10a80-648f-4967-a10d-a52cfe711abf" contextRef="C_75214fe5-9907-465b-9eda-dcd555754a33" name="vir:PercentageOfDevelopmentCosts" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">27.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of such costs for the vaccine products, and equal sharing of such costs for the functional genomics products.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">159</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On a collaboration product-by-collaboration product basis, each party has the one-time right, at specified points in development, to opt-out of its co-funding obligations, and the other party may, at its election, either pursue such program unilaterally, or also cease research and development activities and funding of such collaboration product. If the opt-out provisions are not exercised by either party subject to the terms of the 2020 GSK Agreement, the parties share all profits and losses arising from any collaboration product in the same ratios in which the parties bore development costs for such collaboration program. For each collaboration product as to which a party exercises its opt-out right, the commercializing party pays to the opt-out party royalties on net sales of the applicable collaboration product at rates based on factors such as the stage of development of such collaboration product at the time the opt-out party exercises such right, and whether the opt-out party is the lead party, or a portion of the sublicense revenue if the commercializing party chooses to sublicense or otherwise divest rights to such collaboration product. On an antibody product-by-antibody product basis, the Company has a co-promotion right for such antibody product in the United States, under which the Company has the right to perform up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dc05e0d6-3a02-45f0-a3db-bfc7085ad8dd" contextRef="C_41c05a89-da87-4a31-a87a-9e37c464d328" name="vir:MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">20</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of details in connection with such antibody product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2020 GSK Agreement will remain in effect with respect to each collaboration program for as long as there is a collaboration product being developed or commercialized by the lead party, or the non-opt-out party, in such program. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_920d3009-4170-4f46-b9a1-99a68eb5ed62" contextRef="C_decb4aa5-5378-4f20-b098-06e2d05697eb" name="vir:CollaborationAgreementTerminationDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Either party has the right to terminate the 2020 GSK Agreement in the case of the insolvency of the other party, an uncured material breach of the other party with respect to a collaboration program or collaboration product, or as mutually agreed by the parties.</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company considered the ASC 606 criteria for combining contracts and determined that the 2020 GSK Agreement and 2020 Stock Purchase Agreement should be combined into a single contract because they were negotiated and entered into in contemplation of one another. The fair market value of the common stock issued to GGL was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_604473af-7edd-4a7c-b135-4ba88ec940f4" contextRef="C_5ff17edc-f10a-4706-a1cd-672e160dd990" name="vir:FairMarketValueOfCommonStockIssued" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">206.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, based on the closing stock price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ce27e422-68df-4088-b022-856dd5c2f03d" contextRef="C_e4ef837c-de22-4e63-b673-9b05c1a2fa71" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">36.70</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> on the date of execution of the 2020 Preliminary Agreement and 2020 Stock Purchase Agreement and taking into account a discount for the lack of marketability due to the restrictions in place on the underlying shares, resulting in a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b5986792-1933-4a86-8d70-a3f51f940361" contextRef="C_5ff17edc-f10a-4706-a1cd-672e160dd990" name="vir:PremiumReceivedOnSalePriceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">43.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million premium received by the Company. The Company accounted for the common stock issued to GGL based on its fair market value on the transaction date and determined that the premium paid by GSK should be attributed to the transaction price of the 2020 GSK Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company concluded that the 2020 GSK Agreement contained </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d47e4031-4016-476d-ae20-1f6bde759f99" contextRef="C_41c05a89-da87-4a31-a87a-9e37c464d328" name="vir:CollaborationAgreementNumberOfUnitsOfAccount" unitRef="U_Unit" decimals="INF" format="ixt-sec:numwordsen">four</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> units of account: (i) the license granted to GSK under the Antibody Program (the &#x201c;Antibody License&#x201d;); (ii) the research and development activities (including clinical manufacturing) under the Antibody Program; (iii) the research and development activities under the Vaccine Program; and (iv) the research and development activities under the Functional Genomics Program. The Company considered the guidance in ASC 606 to determine which of these elements of the 2020 GSK Agreement are performance obligations with a customer. The Company determined that the Antibody License is within the scope of ASC 606, and accordingly, accounted for the Antibody License as a distinct performance obligation under ASC 606. The Antibody License is a functional intellectual property and is distinct from the associated research and development activities to be performed under the program due to its significant standalone functionality. All other elements of the 2020 GSK Agreement, including the research and development activities and participation in the JSC and subcommittees for each collaboration program, were not determined to be distinct performance obligations with a customer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The transaction price for the Antibody License at inception was determined to be $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_93982ba0-dfb1-4e39-9ef8-22ae160159b2" contextRef="C_0d93da71-2399-418f-85e8-9b6b02f4b192" name="vir:AntibodyLicenseTransactionPrice" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">43.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, representing the premium on the sale of common stock to GSK. The Company determined that GSK can benefit from the Antibody License at the time of grant and, therefore, the related performance obligation is satisfied at a point in time. As such, the Company recognized the $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f378db18-43e2-4b8c-ae61-cdec3c4b56fc" contextRef="C_60fd6477-1423-4941-969e-7c5f8ad2c846" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">43.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as contract revenue during the second quarter of 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The remaining units of account of the 2020 GSK Agreement were determined to be within the scope of ASC 808 as the Company and GSK are both active participants in the development, manufacturing and commercialization activities and are exposed to significant risks and rewards that are dependent on the commercial success of the activities of the arrangement. Furthermore, the Company and GSK participate in the commercial profit and loss sharing arrangement for each program commensurate with each party&#x2019;s cost-sharing responsibilities during research and development. Because ASC 808 does not provide recognition and measurement guidance, the Company determined that the guidance in ASC 730, Research and Development, was appropriate to analogize to, based on the nature of the cost-sharing provisions of the 2020 GSK Agreement. The Company has concluded that payments to or reimbursements from GSK related to these services will be accounted for as an increase to or reduction of research and development expenses, respectively. Additionally, the Company is entitled to consideration from GSK related to profit and loss sharing arrangements (including royalties) contingent upon future sales of collaboration products. The Company concluded that any payments from GSK related to the profit and loss sharing arrangement (including royalties) contingent upon the commercialization of the products will be analogized to ASC 606 and, therefore, will be recognized when the related sales occur.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">160</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In May 2021, the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) granted an EUA in the United States for sotrovimab, the first collaboration product under the Antibody Program. In April 2022, the FDA excluded the use of sotrovimab in all U.S. regions due to the continued proportion of COVID-19 cases caused by certain Omicron subvariants. As the lead party for all manufacturing and commercialization activities, GSK incurs all of the manufacturing, sales and marketing expenses and is the principal on sales transactions with third parties. As described in Note 2&#x2014;Summary of Significant Accounting Policies, the Company&#x2019;s accounting policy related to the profit-share is to consider the agreed-upon share of the profit-sharing amounts each quarter and evaluate whether those amounts are subject to potential future adjustments based on the latest available facts and circumstances, subject to the terms of the 2020 GSK Agreement. As the Company is the agent, the Company recognizes its contractual share of the profit-sharing amounts or royalties (in case of an opt-out) as revenue, based on sales net of various estimated deductions such as rebates, discounts, chargebacks, credits and returns, less cost of sales and allowable expenses (including manufacturing, distribution, medical affairs, selling, and marketing expenses) in the period the sale occurs. Manufacturing costs include inventory revaluation adjustments, lower of cost or market inventory adjustments, inventory write-downs and write-offs, and binding purchase commitments with a third-party manufacturer among other manufacturing costs. The Company&#x2019;s contractual share of the profit-sharing amounts is subject to potential future adjustments to allowable expenses, which represents a form of variable consideration. At each reporting period, the Company evaluates the latest available facts and circumstances to determine whether any portion of profit-sharing amounts should be constrained.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, GSK held certain potentially excess binding supply manufacturing commitments of sotrovimab and reserved certain binding manufacturing capacity potentially not expected to be utilized, which have not yet been reported to us as allowable manufacturing expenses for the cumulative profit-sharing amounts to date. We expect GSK to adjust allowable manufacturing expenses for our share of the potential charge for excess supply write-offs and unused binding manufacturing capacity and report to us as cost-sharing amounts in future periods. We evaluated the latest available facts and circumstances to update our evaluation of whether any portion of profit-sharing amounts should be constrained. In doing so, as of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, based on the current state of the COVID-19 pandemic, including the continued proportion of cases caused by certain Omicron subvariants, discussions with the FDA and other regulatory authorities, and the Company&#x2019;s expectations for future sales in light of these factors, the Company revised its estimate and determined that $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_17c162db-b415-4d6c-812b-13e23ac96075" contextRef="C_6cddb4e4-b247-4253-a284-b9685fd836de" name="vir:ProfitSharingAmountConstrained" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">369.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million should be constrained from profit-sharing revenues earned during the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 in relation to the Company&#x2019;s anticipated contractual share of potential future adjustments to manufacturing expenses and recorded such amount as adjustments to profit-sharing amounts. The Company re-assesses these estimates each reporting period. Actual results could materially differ from this estimate.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3edfaf01-e001-4f22-8ad6-5dac353135c3" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="vir:CollaborationRevenueTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the years ended December 31, 2022 and 2021, the Company recorded profit-sharing amounts and profit-sharing amounts constrained as components of collaboration revenue in the consolidated statements of operations, as follows:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.078%;"></td>
        <td style="width:2.396%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:19.968%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:2.396%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:20.162%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaboration revenue, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Profit-sharing amount</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_59d5c16f-1ffa-4d0f-be73-e5c19859dd97" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="vir:ProfitSharingAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,875,147</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a4163713-6001-4521-ba68-42a3bb0b99cb" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="vir:ProfitSharingAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">917,194</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Profit-sharing amount constrained</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e16e18f4-ed7f-43ba-8fec-8dd8bb434459" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="vir:ProfitSharingAmountConstrained" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">369,678</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_990e05c4-6d75-4e0c-a1fb-56663b321cfd" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="vir:ProfitSharingAmountConstrained" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total collaboration revenue, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_576e69e2-839a-4cc3-8249-7f31cd9c550b" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="vir:TotalcollaborationRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,505,469</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7834807b-e1bd-41b1-a04e-afc70e13aa29" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="vir:TotalcollaborationRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">917,194</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Costs associated with co-development activities performed under the 2020 GSK Agreement are included in research and development expenses on the consolidated statements of operations, with any reimbursement of costs by GSK reflected as a reduction of such expenses. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the 2020 GSK Agreement, the Company recognized additional net research and development expenses of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_73834e39-9383-41ed-9b12-0eca0f0ad4f7" contextRef="C_decb4aa5-5378-4f20-b098-06e2d05697eb" name="vir:IncreaseDecreaseInResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">31.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_06533b46-7d3b-46b1-9f0b-8481297ad403" contextRef="C_07f1d79c-70ab-4760-854b-ccf98c1deed1" name="vir:IncreaseDecreaseInResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">77.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d59064ce-5c00-430d-96dc-724993264a15" contextRef="C_ecd49638-d3b0-4e7d-9c09-1defc1de59fc" name="vir:IncreaseDecreaseInResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">25.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million during the years ended December 31, 2022, 2021 and 2020, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Amendment No. 1 to the 2020 GSK Agreement</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On May 27, 2022, the Company and GSK entered into Amendment No. 1 to the 2020 GSK Agreement (&#x201c;Amendment No. 1&#x201d;). Pursuant to Amendment No. 1, the parties acknowledged that the antibody products that had been licensed to WuXi Biologics (Hong Kong) Limited (&#x201c;WuXi Biologics&#x201d;) in mainland China, Hong Kong, Macau and Taiwan and had reverted to the Company pursuant to the Termination Agreement (described below) are now included in and governed by the 2020 GSK Agreement, subject to certain amendments relating to sotrovimab.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the terms of Amendment No. 1, GSK has the sole right to develop (including to seek, obtain or maintain regulatory approvals), manufacture and commercialize sotrovimab in and for mainland China, Hong Kong, Macau and Taiwan at GSK's sole cost</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">161</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">expense (other than certain payments for which the Company remains responsible under certain of the Company&#x2019;s existing agreements with third parties). GSK paid the Company a one-time upfront payment of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f72c4257-d351-4799-b0bb-f20139092c61" contextRef="C_5d48d11c-c737-4016-a687-853508a51066" name="vir:UpfrontPaymentReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">7.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in consideration for the rights and licenses granted to GSK under Amendment No. 1. The Company recognized contract revenue of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dbb732a1-4a63-4c6a-8827-cd98bc87c527" contextRef="C_de66dc29-7c5c-4788-af3e-b26710f8cb06" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">7.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million during the year ended December 31, 2022. In addition, GSK will be obligated to pay the Company tiered royalties on net sales of sotrovimab in mainland China, Hong Kong, Macau and Taiwan in percentages ranging from the high teens to the low thirties. Such royalties are payable to the Company during the term of the 2020 GSK Agreement applicable to the Antibody Program.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2021 Expanded GSK Collaboration</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On February 14, 2021, the Company and GSK entered into a binding preliminary collaboration agreement (the &#x201c;2021 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Preliminary Agreement&#x201d;) under which the parties agreed to expand the 2020 GSK Agreement to collaborate on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0f4e51d6-8afe-49b8-9b9f-c632dd8f0332" contextRef="C_b6ba7de2-aef8-4b9a-a988-45dae6fa27d5" name="vir:CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate" unitRef="U_Program" decimals="INF" format="ixt-sec:numwordsen">three</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> separate programs: (1) a program to research, develop and commercialize mAbs for the prevention, treatment or prophylaxis of the influenza virus (the &#x201c;Influenza Program&#x201d;), excluding VIR-2482 unless GSK exercises its option as described below; (2) an expansion of the parties&#x2019; current Functional Genomics Program to focus on functional genomics screens directed to targets associated with respiratory viruses (the &#x201c;Expanded Functional Genomics Program&#x201d;); and (3) additional programs to develop neutralizing mAbs directed to up to three non-influenza target pathogens selected by GSK (the &#x201c;Selected Pathogens&#x201d; and such programs, the &#x201c;Additional Programs&#x201d;).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Concurrently with the execution of the 2021 Preliminary Agreement, the Company entered into a stock purchase agreement (the &#x201c;2021 Stock Purchase Agreement&#x201d;) with GGL under which GGL agreed to purchase shares of the Company&#x2019;s common stock for an aggregate purchase price of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_89552881-250f-459b-bbb3-cf4aadb15caa" contextRef="C_70c61983-c30b-4442-b262-ed8ba12eed88" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">120.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The consummation of the transactions under each of the 2021 Preliminary Agreement and the 2021 Stock Purchase Agreement were subject to the satisfaction of customary closing conditions, including the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, which expiration was effective on March 24, 2021. The 2021 Preliminary Agreement and 2021 Stock Purchase Agreement consummated on March 25, 2021, which the Company used as the measurement date for accounting purposes. On March 31, 2021, the Company closed the sale of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ffd0e430-1426-4954-9659-7026208312be" contextRef="C_ae08f4b9-a601-42cb-8ece-21e5e2b7b3f0" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,924,927</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of its common stock to GGL.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2021 Preliminary Agreement was superseded on May 18, 2021 upon execution of the definitive collaboration agreement (the &#x201c;2021 GSK Agreement&#x201d;, and collectively with the 2021 Preliminary Agreement, the &#x201c;2021 GSK Collaboration&#x201d;). The material terms of the 2021 GSK Agreement, including the promised goods and services, are discussed below and are consistent with those of the 2021 Preliminary Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the 2021 GSK Collaboration, the parties agreed to conduct certain research and development activities under mutually agreed development plans and associated budgets for the programs within the expanded collaboration for a period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_13199045-d16a-4efe-8115-98ba42f35128" contextRef="C_bc63cc0a-80f2-4f25-8b71-3402b70afd98" name="vir:NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> following the effective date. Under the Influenza Program, the parties collaborate to research, develop and commercialize mAbs for the prevention, treatment or prophylaxis of influenza, including the Company&#x2019;s influenza mAbs (with respect to VIR-2482, only if GSK exercises its option). The Company conducts the development and clinical manufacturing activities for VIR-2482 up to the completion of a Phase 2 clinical trial. Provided that the Company conducts and completes a Phase 2 clinical trial for VIR-2482, GSK has the exclusive option to obtain exclusive rights to co-develop and commercialize VIR-2482 under the Influenza Program (the &#x201c;VIR-2482 Option&#x201d;). GSK is the lead party for development, clinical and commercial manufacturing and commercialization activities for products under the Influenza Program (other than VIR-2482 unless and until GSK exercises the VIR-2482 Option, if applicable). The parties mutually agree upon the allocation of responsibility for the development of products under the Expanded Functional Genomics Program, and for the development and early-stage manufacturing of products under the Additional Programs if and when GSK decides which Selected Pathogens to pursue. GSK is primarily responsible for commercial manufacturing and commercialization activities for products under the Expanded Functional Genomics Program and Additional Programs, if and when selected by GSK. For each collaboration program, the Company granted or will grant GSK certain license rights related to the development, manufacturing and commercialization of products arising from the program.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The parties share </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_93c4edb6-3841-4ad4-acb1-187a393ff42c" contextRef="C_27c0e6df-cfdf-4bca-b0d3-1b934d52a189" name="vir:PercentageOfShareDevelopmentCosts" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">50</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of all development costs in accordance with the budget for each of the collaboration programs (other than for the Selected Pathogens and VIR-2482, unless GSK exercises the VIR-2482 Option), with each party having the right to opt-out of its co-funding obligations at specified points in development. In such case, the party continuing with the program pays to the opt-out party a royalty on net sales of products arising from such program at specified rates based on the stage of development at which the opt-out is exercised. Following the exercise of an opt-out right by a party, the other party may, at its election, either pursue development and commercialization of such product or program unilaterally, or also cease the conduct and funding of such collaboration product or program. In the absence of any opt-out, the parties also share </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a6f4eacf-5e6b-49a8-b017-eacd9fc68f7b" contextRef="C_27c0e6df-cfdf-4bca-b0d3-1b934d52a189" name="vir:ProfitsAndLossesSharingPercentage" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">50</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of all profits and losses arising from any collaboration product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">162</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">GSK made an upfront payment to the Company of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1075e80c-8c22-4d3d-9e74-c237bed212df" contextRef="C_f3bae72e-0345-4ef5-af24-752bbadb5f0b" name="vir:UpfrontPaymentReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">225.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. If GSK exercises the VIR-2482 Option, GSK will pay the Company an option exercise fee of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7cb75ec1-3678-44c2-a88e-5d17d927e92a" contextRef="C_f3bae72e-0345-4ef5-af24-752bbadb5f0b" name="vir:OptionExerciseFeeConsiderationToBeReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">300.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million unless certain agreed product criteria for VIR-2482 are not met, in which case the parties will negotiate an alternative option exercise fee. Upon achievement of a pre-defined regulatory milestone for the first product in the Influenza Program, which may be (i) VIR-2482 (if GSK exercised the VIR-2482 Option), (ii) a next-generation mAb, or (iii) any other influenza mAb approved by the JSC to be included in the collaboration, arising from the Influenza Program, GSK will make a milestone payment to the Company of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_290d7b1a-5d5f-4e14-8778-6adc49b4d132" contextRef="C_b69ec4f4-b531-408c-b82a-92c8c2b9bcd4" name="vir:PreDefinedRegulatoryMilestoneConsiderationToBeReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">200.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company concluded that the 2021 GSK Agreement is a collaboration arrangement as defined in ASC 808, Collaborative Agreements, under which certain elements are required to be accounted for under ASC 606 where the counterparty is a customer for a good or service that is a distinct unit of account. In addition, the 2021 GSK Agreement is considered a contract modification to the 2021 Preliminary Agreement and will be accounted for prospectively as a termination of the 2021 Preliminary Agreement and commencement of a new contract. There was no impact to the accounting assessment of the original contract as no goods or services had been delivered to GSK, no performance obligations were satisfied, and accordingly, no contract revenue was recognized under ASC 606 prior to the execution of the 2021 GSK Agreement.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company considered the ASC 606 criteria for combining contracts and determined that the 2021 GSK Collaboration and 2021 Stock Purchase Agreement should be combined into a single contract because they were negotiated and entered into in contemplation of one another. The fair market value of the common stock issued to GGL was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_37e00a99-6e7d-4a27-97a2-470469d660f0" contextRef="C_3906357f-ca70-49f3-97fc-ebdecba43cf9" name="vir:FairMarketValueOfCommonStockIssued" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">85.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, based on the closing stock price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c49a9f93-f31c-4a00-a4c6-70fd97a8b5e8" contextRef="C_1b0ce50f-5b97-4517-8931-808c3219617e" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_USDollarShare" decimals="INF" format="ixt:numdotdecimal">52.70</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> on March 25, 2021, and taking into account a discount for the lack of marketability due to the restrictions in place on the underlying shares, resulting in a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_23cc00cc-4244-4b65-b80c-c01737473872" contextRef="C_3906357f-ca70-49f3-97fc-ebdecba43cf9" name="vir:PremiumReceivedOnSalePriceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">34.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million premium received by the Company. The Company accounted for the common stock issued to GGL based on its fair market value on the transaction date and determined that the premium paid by GSK should be attributed to the transaction price of the 2021 GSK Agreement.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company concluded that the 2021 GSK Agreement contained the following units of account: (i) the VIR-2482 Option; (ii) three distinct rights granted to GSK related to the Selected Pathogens (each, a &#x201c;Selected Pathogen Right&#x201d;); (iii) the license and know-how to the next-generation mAbs under the Influenza Program (the &#x201c;Next Gen License&#x201d;); (iv) the research and development activities for next-generation mAbs under the Influenza Program; and (v) the research and development activities, including license rights and know-how, under the Expanded Functional Genomics Program. The Company considered the guidance in ASC 606 to determine which of these elements of the 2021 GSK Agreement are performance obligations with a customer. The Company determined that the distinct performance obligations under ASC 606 consisted of (i) the Next Gen License and (ii) the three Selected Pathogen Rights, each representing a material right. All other elements of the 2021 GSK Agreement including the VIR-2482 Option, research and development activities, and participation in the JSC and subcommittees for each collaboration program were not determined to be distinct performance obligations with a customer. As of December 31, 2022, GSK had not exercised the VIR-2482 Option or the remaining two Selected Pathogen Rights (see below for GSK's selection of first pathogen).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The transaction price for the 2021 GSK Agreement included fixed consideration consisting of the $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cfde0f22-7df7-48b1-9958-84633b85dce6" contextRef="C_e3df795a-3a56-41f0-b360-db9fa10cdc01" name="vir:CollaborationAgreementTransactionPriceUpfrontFee" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">225.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million upfront fee paid by GSK and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_03faa7af-03c2-4b4d-a840-37dfdcc895c6" contextRef="C_083fe6a6-b404-46c5-8780-c18507a330b4" name="vir:PremiumReceivedOnSalePriceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">34.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, representing the premium on the sale of common stock to GSK for a total of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_36a36936-bd40-4a90-bc5c-64b6d578ed54" contextRef="C_e3df795a-3a56-41f0-b360-db9fa10cdc01" name="vir:CollaborationAgreementTransactionPriceConsideration" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">259.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. All potential future milestones and other payments under the 2021 GSK Agreement are constrained since the Company could not conclude it was probable that a significant reversal in the amount recognized would not occur.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The respective estimated SSP for each of the performance obligations was determined to allocate the transaction price. The estimated SSP of each performance obligation was determined using methods that considered relevant market conditions, entity-specific factors and information about GSK, while maximizing the use of available observable inputs and using certain management assumptions (e.g., treatable patient population, expected market share, probability of success and product profitability, discount rate based on weighted-average cost of capital). For the Next Gen License, the Company determined that GSK can benefit from the license at the time the license is granted and, therefore, the related performance obligation is satisfied at a point in time. If any of the Selected Pathogen Rights are exercised, the Company will evaluate the related promises to identify the performance obligations to be transferred and the timing of revenue recognition. If any of the Selected Pathogen Rights expire prior to being exercised, the Company will recognize any deferred revenue allocated to that right as revenue at the time of expiration.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The research and development activities for the next-generation mAbs under the Influenza Program and the Expanded Functional Genomics Program were determined to be within the scope of ASC 808 as the Company and GSK are both active participants in the development, manufacturing and commercialization activities and are exposed to significant risks and rewards that are dependent on the commercial success of the activities of the arrangement. Furthermore, the Company and GSK participate in the commercial profit and loss sharing arrangement for each program commensurate with each party&#x2019;s cost-sharing responsibilities during research and development. Because ASC 808 does not provide recognition and measurement guidance, the Company determined that</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">163</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the guidance in ASC 730, Research and Development, was appropriate to analogize to based on the nature of the cost-sharing provisions of the agreement. The Company has concluded that payments to or reimbursements from GSK related to these services will be accounted for as an increase to or reduction of research and development expenses, respectively. The Company also concluded that any payments from GSK related to the profit and loss sharing arrangement (including royalties) contingent upon the commercialization of the related products will be analogized to ASC 606 and, therefore, will be recognized when the related sales occur.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Upon execution of the 2021 GSK Agreement, the Company granted the Next Gen License to GSK and therefore, recognized $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_71c8c0c6-fbbc-4df7-99b9-c88d3c7e235b" contextRef="C_46218237-5c98-4a62-bcee-3c18140a4029" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">168.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as contract revenue in the second quarter of 2021. As of December 31, 2022, the total unrecognized transaction price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_62447cb1-5068-4c87-8b5e-77debef4f719" contextRef="C_5cf7a8d0-261c-43e4-b66c-26e9b9c2e5b8" name="us-gaap:DeferredRevenueNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">51.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million is classified as noncurrent deferred revenue on the Company's consolidated balance sheet related to the remaining performance obligations, being the remaining two material rights resulting from the Selected Pathogen Rights. The Company reclassified the deferred revenue of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1464563b-4008-4c6f-8aed-71d848f1e679" contextRef="C_5cf7a8d0-261c-43e4-b66c-26e9b9c2e5b8" name="vir:ReclassifiedDeferredRevenue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">51.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million from current to noncurrent as of December 31, 2022 based on the Company's revised expectations for future option exercises by GSK.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Costs associated with co-development activities performed under the 2021 GSK Agreement are included in research and development expenses in the consolidated statements of operations, with any reimbursement of costs by GSK reflected as a reduction of such expenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Option Exercise by GSK</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In September 2022, GSK exercised its first Selected Pathogen Right, selecting respiratory syncytial virus (&#x201c;RSV&#x201d;) as its first pathogen under the Additional Programs of the 2021 GSK Agreement (&#x201c;First Option Exercise&#x201d;). GSK agreed to retroactively share the research and development costs that the Company had incurred under its RSV program since April 2022 in accordance with the applicable provisions of the 2021 GSK Agreement.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company evaluated the First Option Exercise under ASC 606 and identified one performance obligation consisting of the license for a Selected Pathogen Right granted to GSK. The transaction price was determined to be $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a37c6b50-83bd-4ed1-ab37-8d94a274e229" contextRef="C_6ff10353-fa1d-4c3b-ac8e-ff5c4ae62117" name="us-gaap:DeferredIncome" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">39.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million which equals the deferred revenue allocated to the first Selected Pathogen Right at the inception of the 2021 GSK Agreement. The Company determined that the license is considered a functional intellectual property that is a distinct performance obligation. Specifically, the Company believes the license is capable of being distinct, as GSK has the capabilities to develop the license either on its own or by contracting with other third-parties. GSK can benefit from the license at the time of grant and, therefore, the related performance obligation is satisfied at a point in time. During the year ended December 31, 2022, the Company recognized the $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b91d7e89-e06e-4456-b0ee-89e98663c1a8" contextRef="C_48a91d5d-ea5c-4037-9225-755e30bfc6c5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="3" decimals="-2" format="ixt:numdotdecimal">39.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as contract revenue.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the year ended December 31, 2022 and 2021, the Company recognized additional net research and development expenses of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c2c74b30-134d-43b0-b77a-62c179014bf6" contextRef="C_c5248545-d73b-4cb5-a202-3d3703194709" name="vir:IncreaseDecreaseInResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e74d833d-c99d-44c8-8a2f-3d0b6eb52b44" contextRef="C_ef38c128-b6f9-4268-8e29-dbff882abc57" name="vir:IncreaseDecreaseInResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, under the 2021 GSK Agreement.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under both the 2020 GSK Agreement and the 2021 GSK Agreement, the Company has a receivable from collaboration of zero and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e9420278-55ab-4e1b-8aa5-50d5a8fc26ef" contextRef="C_a1e68275-f02d-43b0-8ccb-7c3d41000c0e" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">773.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as of December 31, 2022 and 2021, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">164</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Brii Biosciences</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In May 2018, the Company entered into the Brii Agreement with Brii Bio Parent and Brii Bio, pursuant to which the Company granted to Brii Bio, with respect to up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_89c75d27-f7e4-4a9a-be05-11b216396523" contextRef="C_61fecc05-bbcc-451c-ad8a-57bf80b34de9" name="vir:MaximumNumberOfDevelopmentProgramGrantedToCounterparty" unitRef="U_Program" decimals="INF" format="ixt-sec:numwordsen">four</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of the Company&#x2019;s programs, an exclusive option to obtain exclusive rights to develop and commercialize compounds and products arising from such programs in China, Taiwan, Hong Kong and Macau (collectively, the &#x201c;China Territory&#x201d;) for the treatment, palliation, diagnosis, prevention or cure of acute and chronic diseases of infectious pathogen origin or hosted by pathogen infection (the &#x201c;Field of Use&#x201d;). The Company&#x2019;s HBV </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">small interfering ribonucleic acid (</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;siRNA&#x201d;) program being developed under the Amended Alnylam Agreement (described below) is included within the Brii Agreement as a program for which Brii Bio may exercise one of its options. In partial consideration for the options granted by the Company to Brii Bio, Brii Bio Parent and Brii Bio granted the Company, with respect to up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a5613e25-21cd-4bcd-8522-7f4c558ec007" contextRef="C_61fecc05-bbcc-451c-ad8a-57bf80b34de9" name="vir:MaximumNumberOfDevelopmentProgramGrantedFromCounterparty" unitRef="U_Program" decimals="INF" format="ixt-sec:numwordsen">four</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of Brii Bio Parent&#x2019;s or Brii Bio&#x2019;s programs, an exclusive option to be granted exclusive rights to develop and commercialize compounds and products arising from such Brii Bio programs in the United States for the Field of Use. The number of options that the Company may exercise for a Brii Bio program is limited to the corresponding number of options that Brii Bio exercises for a Vir program.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As partial consideration for the Company&#x2019;s entry into the Brii Agreement, upon closing of Brii Bio Parent&#x2019;s Series A preferred stock financing, the Company received ordinary shares equal to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3bafdd3f-7baa-45f6-b88c-3a10132bcf77" contextRef="C_61fecc05-bbcc-451c-ad8a-57bf80b34de9" name="vir:PercentageOfOrdinaryShareEqualToOutstandingShare" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">9.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the outstanding shares in Brii Bio Parent. As a result of Brii Bio&#x2019;s right to exercise one of its options for the Company&#x2019;s HBV siRNA program, under the terms of the Amended Alnylam Agreement, the Company transferred to Alnylam Pharmaceuticals, Inc. (&#x201c;Alnylam&#x201d;) a specified percentage of such equity consideration allocable to such program </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">under a share transfer agreement in February 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">With respect to programs for which Brii Bio exercises its options, Brii Bio is required to pay the Company an option exercise fee for each such Vir program ranging from the</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_11c9e293-eecf-43a1-baa0-f2bbdda1131a" contextRef="C_363509bf-b0e5-4bc4-a76d-8682508915cc" name="vir:OptionExerciseFeeLowEndOfTheRange"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> mid-single-digit millions</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b5e3eaa2-9014-4a1f-9a14-ba7005bb9bdd" contextRef="C_0fd0f713-f953-4286-a81c-0606471c2227" name="vir:OptionExerciseFeeHighEndOfTheRange" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">20.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, determined based on the commercial potential of the licensed program. Brii Bio will also be required to pay regulatory milestone payments on a licensed product-by-licensed product basis ranging from the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0b5237ab-2788-464b-b8d3-6e6d0cde4c97" contextRef="C_363509bf-b0e5-4bc4-a76d-8682508915cc" name="vir:RegulatoryMilestonePaymentOnLicensedProductLowEndOfTheRange"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">mid-single-digit millions</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8c95640f-7ec3-4ad0-8a88-b8c726eb03da" contextRef="C_0fd0f713-f953-4286-a81c-0606471c2227" name="vir:RegulatoryMilestonePaymentOnLicensedProductHighEndOfRange" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">30.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, also determined based on the commercial potential of such program. Following commercialization, Brii Bio will be required to make sales milestone payments based on certain specified levels of aggregate annual net sales of products arising from each licensed program in the China Territory, up to an aggregate of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4393765d-f1a2-48de-be48-13b8254180bb" contextRef="C_724a4a6c-eb88-43e1-9385-7a1ee1d59450" name="vir:MaximumAggregateSalesMilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">175.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million per licensed program.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Upon exercise of each option for a Brii Bio program, the Company will be required to pay to Brii Bio an option exercise fee ranging from the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_94490d90-223f-4206-b1cf-ff176ac18326" contextRef="C_fb57c6da-b1f8-44af-a1d9-109cfe493bad" name="vir:OptionExerciseFeeLowEndOfTheRange"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">low tens of millions</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cc85e8a0-3b0b-4229-ac59-c98c9f343bf7" contextRef="C_2ec7ad16-c1b2-49f2-9adb-7d795c32364a" name="vir:OptionExerciseFeeHighEndOfTheRange" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">50.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, determined based on the commercial potential of the licensed program. The Company will be required to make regulatory milestone payments to Brii Bio on a licensed product-by-licensed product basis ranging from the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_84be40b7-d9ca-400b-8adb-874d75701282" contextRef="C_724a4a6c-eb88-43e1-9385-7a1ee1d59450" name="vir:RegulatoryMilestonePaymentOnLicensedProductLowEndOfTheRange"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">low tens of millions</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_77af593f-c523-4269-a133-1371c8ccbbf4" contextRef="C_2ec7ad16-c1b2-49f2-9adb-7d795c32364a" name="vir:RegulatoryMilestonePaymentOnLicensedProductHighEndOfRange" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">100.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, also determined based on the commercial potential of such program. The Company will also be required to make sales milestone payments based on certain specified levels of aggregate annual net sales of products in the United States arising from each licensed program, up to an aggregate of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_565054ff-1540-4dba-87d7-1887da3c1a19" contextRef="C_363509bf-b0e5-4bc4-a76d-8682508915cc" name="vir:MaximumAggregateSalesMilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">175.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million per licensed program. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, the Company has not exercised any of its options.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the Company is obligated under the Brii Agreement to pay Brii Bio tiered royalties based on net sales of products arising from the licensed programs in the United States, and Brii Bio is obligated to pay the Company tiered royalties based on net sales of products arising from the licensed programs in the China Territory. The rates of royalties payable by the Company to Brii Bio, and by Brii Bio to the Company, on net sales range from </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c5f9fa6b-8b0f-4167-a647-391056634098" contextRef="C_b70442f4-3b9a-4721-b156-3f58ba42d7b0" name="vir:RangeOfRoyaltyPaymentToBePaid"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">mid-teens to high-twenties</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Each party&#x2019;s obligations to pay royalties expires, on a product-by-product and territory-by-territory basis, on the latest of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d0478d0c-1437-42e7-a14a-16f89ad2cadb" contextRef="C_b70442f4-3b9a-4721-b156-3f58ba42d7b0" name="vir:RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years after the first commercial sale of such licensed product in the United States or China Territory, as applicable; the expiration or abandonment of licensed patent rights that cover such product in the United States or China Territory, as applicable; and the expiration of regulatory exclusivity in the United States or the China Territory, as applicable. Royalty rates are subject to specified reductions and offsets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Brii Agreement will remain in force until the expiration of all options or, if any option is exercised, expiration of all royalty payment obligations for all licensed products within such licensed program, unless terminated in its entirety or on a program-by-program basis by either party. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_19046b68-c519-48c6-a2e5-0c940cd268d6" contextRef="C_6ea95d1d-1302-408e-b108-02685b997985" name="vir:CollaborationAgreementTerminationDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Each party may terminate for convenience all rights and obligations with respect to any program for which it has an option, with </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8031d8ce-ef9f-45fe-84d6-c887bf740e5c" contextRef="C_1e2fb995-8c8f-44b9-a52f-67b970d66f9a" name="vir:WrittenNoticeToTerminateLicensedProgramIfNotExercise" format="ixt-sec:durday"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> days&#x2019; written notice (if the terminating party has not exercised an option for such program) or </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_9a977ed3-68d0-4d09-89d0-8fed4535c5b5" contextRef="C_1e2fb995-8c8f-44b9-a52f-67b970d66f9a" name="vir:WrittenNoticeToTerminateLicensedProgramIfExercise" format="ixt-sec:durday"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">180</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> days&#x2019; notice (following the exercise of an option for such program). The Brii Agreement may also be terminated by either party for insolvency of the other party, and either party may terminate the Brii Agreement in its entirety or on a program-by-program basis for the other party&#x2019;s uncured material breach on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6aa6ea07-04b2-4466-a099-d913b464ce0f" contextRef="C_1e2fb995-8c8f-44b9-a52f-67b970d66f9a" name="vir:WrittenNoticePeriodToTerminateLicensedProgramForUncuredMaterialBreach" format="ixt-sec:durday"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> days&#x2019; written notice (or </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_fc1c3445-5a51-462b-bfaa-48b3c7032944" contextRef="C_1e2fb995-8c8f-44b9-a52f-67b970d66f9a" name="vir:WrittenNoticePeriodToTerminateLicensedProgramForFailureToMakePayment" format="ixt-sec:durday"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> days&#x2019; notice following failure to make payment).</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From May 2018 until the closing of the Brii Bio Parent IPO in July 2021, Brii Bio Parent and its wholly-owned subsidiary Brii Bio were determined to be variable interest entities (&#x201c;VIE&#x201d;) due to their reliance on future financing and having insufficient equity at risk. However, the Company did not have the power to direct activities that most significantly impact the economic success of these</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">165</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">entities and was not considered the primary beneficiary of these entities. Therefore, the Company did not consolidate Brii Bio Par</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ent or Brii Bio. Subsequent to the Brii Bio Parent IPO, the Company determined that these entities are no longer VIEs. In addition, as Brii Bio Parent is a publicly-traded company, the Company's investment in its ordinary shares became a marketable equity investment with readily determinable fair value and is then subsequently remeasured to fair value at each reporting date (see Note 3&#x2014;Fair Value Measurements). Prior to the Brii Bio Parent IPO, the Company accounted for its investment in Brii Bio Parent, which had a carrying value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6ee781a4-599b-43da-836b-139f119a2096" contextRef="C_3e754139-9f86-457e-a6d3-61f2f6892dbf" name="us-gaap:Investments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment from the same issuer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Option Exercises by Brii Bio</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2020, Brii Bio exercised its option to obtain exclusive rights to develop and commercialize compounds and products arising from VIR-2218 in the China Territory. In consideration of the Company&#x2019;s grant to Brii Bio of an exclusive license related to VIR-2218 in the China Territory, the Company received a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9a996b72-4dbf-4d06-9798-28fc75f81113" contextRef="C_0e941a4e-4958-42af-89e7-b694adf192d4" name="vir:OptionExerciseFeeReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">20.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million option exercise fee in connection with the option exercise. Also, the Company is eligible to receive the following payments related to VIR-2218 in the China Territory: a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bd5097d0-a5b0-4b08-89db-67092ee3688b" contextRef="C_7ca9fa0c-6fce-40ab-ad6a-72ab66e31dc8" name="vir:RegulatoryMilestonePaymentToBeReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">30.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million regulatory milestone payment, up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f71c095d-3b83-40d3-81e2-cea2e0b8d2ec" contextRef="C_000e7047-27c6-405d-911b-7387dc00e8cb" name="vir:MaximumSalesMilestonePaymentsToBeReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">175.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in sales-based milestone payments, and royalties on net sales ranging from </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_78918a20-0f1a-4c35-87f7-2a649a34b0b0" contextRef="C_7ca9fa0c-6fce-40ab-ad6a-72ab66e31dc8" name="vir:RangeOfRoyaltyPaymentToBeReceived"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">high-teens to high-twenties</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company evaluated the VIR-2218 transaction under ASC 606 and identified one performance obligation consisting of the license granted to Brii Bio. Under the Brii Agreement, Brii Bio is responsible for performing all research and development activities and the Company does not have any other performance obligations within the context of ASC 606 under the arrangement after the option exercise. The transaction price is determined to be $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_af60d5f6-cc12-49a4-a8cd-012b9d766f5e" contextRef="C_8919d223-48db-4e72-8f84-bb9a105b4296" name="vir:OptionsTransactionPrice" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">22.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million which consists of the $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e6181125-f15d-4560-899f-d3fd5d92a753" contextRef="C_8919d223-48db-4e72-8f84-bb9a105b4296" name="vir:OptionExerciseFeeReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">20.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million option exercise fee and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_851dd675-cda4-4751-9765-cf6778608776" contextRef="C_b7110cbe-39a4-4c4a-904d-1a47b20ffc0f" name="us-gaap:DeferredRevenue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of the deferred revenue allocated to the VIR-2218 option at the inception of the Brii Agreement. The Company determined that the license is considered a functional intellectual property that is a distinct performance obligation under ASC 606. Specifically, the Company believes the license is capable of being distinct, as Brii Bio has the capabilities to develop the license either on its own or by contracting other third parties. Brii Bio can benefit from the license at the time of grant and therefore, the related performance obligation is satisfied at a point in time. Additionally, all potential future milestones and other payments are constrained because the Company cannot conclude it is probable that a significant reversal in the amount recognized would not occur. The Company will re-evaluate the transaction price in each reporting period.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In July 2022, Brii Bio exercised its option to obtain exclusive rights to develop and commercialize compounds and products arising from VIR-3434 in the China Territory. In consideration of the Company&#x2019;s grant to Brii Bio of an exclusive license related to VIR-3434 in the China Territory, the Company received a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_38daef88-47d3-480f-94a6-13a43d538ec7" contextRef="C_2da3af76-3a2c-4087-bd64-efb611a69cc8" name="vir:OptionExerciseFeeReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">20.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million option exercise fee in connection with the option exercise. Also, the Company is eligible to receive the following payments related to VIR-3434 in the China Territory: a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_73aa511c-6df0-4789-9b6b-18b552fd16af" contextRef="C_b5817a9b-c37f-413a-ab0c-c78fc5c64179" name="vir:RegulatoryMilestonePaymentToBeReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">30.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million regulatory milestone payment, up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5c87ba8c-45be-4185-b390-fd4d1d16c5cc" contextRef="C_b5817a9b-c37f-413a-ab0c-c78fc5c64179" name="vir:MaximumSalesMilestoneToBeReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">175.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in sales-based milestone payments, and royalties on net sales ranging from </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_cb056eef-e8ee-42d9-bf80-12734fc21ab8" contextRef="C_1c2df6fc-28b4-42ab-92ca-e8e7604a433d" name="vir:RangeOfRoyaltyPaymentToBeReceived"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">mid-teens to mid-twenties</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company evaluated the VIR-3434 transaction under ASC 606 and identified one performance obligation consisting of the license granted to Brii Bio. Under the Brii Agreement, Brii Bio is responsible for performing all research and development activities and the Company does not have any other performance obligations within the context of ASC 606 under the arrangement after the option exercise. The transaction price was determined to be $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e23ce458-cd2f-4d79-8ee3-f24ebebfd7af" contextRef="C_4e62b6c4-3cd3-449d-8c77-954fc619391a" name="vir:OptionsTransactionPrice" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">22.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, which consists of the $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8cef9004-1c7f-4d20-995d-b02fd6aaffa9" contextRef="C_cafcd678-0319-424b-834a-70769b2cb74b" name="vir:OptionExerciseFeeReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">20.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million option exercise fee and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9b34e3c1-402a-4d32-95b1-af1b571b8281" contextRef="C_db717f4e-f800-427d-a092-ed5b2685c250" name="us-gaap:DeferredRevenue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of the deferred revenue allocated to the VIR-3434 option at the inception of the Brii Agreement. The Company determined that the license is considered a functional intellectual property that is a distinct performance obligation. Specifically, the Company believes the license is capable of being distinct, as Brii Bio has the capabilities to develop the license either on its own or by contracting with other third parties. Brii Bio can benefit from the license at the time of grant and, therefore, the related performance obligation is satisfied at a point in time. Additionally, all potential future milestones and other payments are constrained because the Company cannot conclude it is probable that a significant reversal in the amount recognized would not occur. The Company will re-evaluate the transaction price in each reporting period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the years ended December 31, 2022, 2021 and 2020, the Company recognized $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8e6d4455-f52b-4ea0-92d8-4037193e45b8" contextRef="C_e08e7ea4-933b-4008-9b16-a6e809956279" name="us-gaap:RevenueFromRelatedParties" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">22.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_49bdeaa1-9073-4b87-9b33-c53e9f098b13" contextRef="C_6b24e017-0f8a-429b-817a-9ef0927b8433" name="us-gaap:RevenueFromRelatedParties" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">zero</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0da01478-a1f2-4d3d-afcc-6f8029687b76" contextRef="C_e28b382b-9754-42d1-868b-c2ea43f958c4" name="us-gaap:RevenueFromRelatedParties" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">22.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, as license revenue from a related party. During the year ended December 31, 2020, the Company separately paid $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1e4aa25e-9c4b-41f9-b90c-8215b7a787dc" contextRef="C_e28b382b-9754-42d1-868b-c2ea43f958c4" name="vir:PaymentToCollaboratorResultingFromProgramOptionExercise" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, half of the option exercise proceeds, to Alnylam in connection with the Amended Alnylam Agreement (as defined below) that was recognized as research and development expense.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, the Company also has a contract liability of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_514ad89d-d3f7-4e67-ab05-239ca5f1f58d" contextRef="C_8354e95f-a997-4559-8f00-06918b2494db" name="us-gaap:DeferredRevenueNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million within noncurrent deferred revenues, which represents deferred consideration for the remaining two options that the Company granted to Brii Bio. The deferred consideration will be recognized when Brii Bio exercises its remaining options or the remaining options expire.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">166</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Alnylam</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2017, the Company entered into the collaboration and license agreement with Alnylam, as amended in December 2019 and March, April and December 2020 (the &#x201c;Amended Alnylam Agreement&#x201d;) for the development of siRNA products for the treatment of HBV, and following the exercise of certain program options, the development and commercialization of siRNA therapeutic products directed to up to four other infectious disease targets selected by the Company. The technology licensed under the Amended Alnylam Agreement forms the basis of the Company&#x2019;s siRNA technology platform.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the Amended Alnylam Agreement, the Company obtained a worldwide, exclusive license to develop, manufacture and commercialize the HBV siRNA product candidates, including VIR-2218, for all uses and purposes other than agricultural, horticultural, forestry, aquaculture and other residential applications (such excluded fields, the &#x201c;Excluded Fields&#x201d;). In addition, Alnylam granted the Company an exclusive option, for each of the infectious disease siRNA programs directed to the Company&#x2019;s selected targets, to obtain a worldwide, exclusive license to develop, manufacture and commercialize siRNA products directed to the target of each such program for all uses and purposes other than the Excluded Fields. On a product-by-product basis for each product arising from the HBV program and, following the Company&#x2019;s option exercise, the infectious disease program, Alnylam has an exclusive option, exercisable during a specified period prior to the initiation of a Phase 3 clinical trial for each such product, to negotiate and enter into a profit-sharing agreement for such product.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company and Alnylam were jointly responsible for funding the initial research and development activities for VIR-2218 through the completion of proof-of-concept trials. Prior to the exercise of the Company&#x2019;s option for each siRNA program directed to one of the Company&#x2019;s selected infectious disease targets, Alnylam is responsible for conducting all development activities, at the Company&#x2019;s expense, in accordance with an agreed-upon development plan. Following the Company&#x2019;s exercise of an option for a program and payment of the program option exercise fee and any outstanding program costs due to Alnylam, the Company is solely responsible, at the Company&#x2019;s expense (subject to Alnylam&#x2019;s exercise of a profit-sharing option), for conducting all development, manufacture and commercialization activities for products arising from each such program. If Alnylam exercises a profit-sharing option for a product, the Company will negotiate the terms of such profit-sharing agreement, which will include sharing equally with Alnylam all subsequent costs associated with the development of such product, as well as the profits and losses in connection with such product, subject to reimbursement by Alnylam of a portion of specified development costs in certain circumstances.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Upon the achievement of a certain development milestone, as further discussed below, the Company was obligated to issue shares of the Company&#x2019;s common stock equal to the lesser of (i) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_45ded1c3-e4f2-4ca6-93d8-815bf28046f0" contextRef="C_ffc264f2-dd56-4ceb-b96e-fbf5c3db3606" name="vir:MaximumSharesToBeIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,111,111</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares or (ii) a certain number of shares based on the Company&#x2019;s stock price at the time such milestone is achieved (the &#x201c;Milestone Shares&#x201d;). The Company will be required to pay Alnylam up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cc8eed54-b9b7-42db-ae6f-03a39300495e" contextRef="C_a88db863-7765-4796-a308-9513b1e29b15" name="vir:MaximumMilestonePaymentForAchievementOfSpecifiedMilestones" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">190.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in the aggregate for the achievement of specified development and regulatory milestones by the first siRNA product directed to HBV, and up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_80bb12c2-b0f3-4df7-b16e-7d0f9d3643e4" contextRef="C_9390c172-8de0-44cd-beb2-d80a53d6291b" name="vir:MaximumMilestonePaymentForAchievementOfSpecifiedMilestones" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">115.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the achievement of specified development and regulatory milestones by the first product directed to the target of each infectious disease siRNA program for which the Company exercised its option. Following commercialization, the Company will be required to pay to Alnylam up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5389a799-2c93-4465-8117-94a0b82779aa" contextRef="C_a88db863-7765-4796-a308-9513b1e29b15" name="vir:MaximumAggregateSalesMilestonePayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">250.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in the aggregate for the achievement of specified levels of net sales by siRNA products directed to HBV and up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eb910feb-b28f-43e7-9991-f0a3fa7b68e4" contextRef="C_9390c172-8de0-44cd-beb2-d80a53d6291b" name="vir:MaximumSalesMilestonePayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">100.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the achievement of specified levels of net sales by products directed to the target of each infectious disease siRNA program for which the Company exercised its option. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1b31f2dd-e2ed-4028-b07a-5d9bb058aa4d" contextRef="C_9238efac-e9f0-40db-8b4d-0bd6b667bce1" name="vir:RangeOfTieredRoyaltiesToPayToNetSalesOfProducts"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company may also be required to pay Alnylam tiered royalties at percentages ranging from the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d5f1742d-808e-4fd6-aac2-f0e469fb58d7" contextRef="C_a88db863-7765-4796-a308-9513b1e29b15" name="vir:RangeOfTieredRoyaltiesToPayToNetSalesOfProducts"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">low double-digits to mid-teens</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> on annual net sales of HBV products, and tiered royalties at percentages ranging from the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_08777d55-9fbe-48f9-bed3-71fb07edcaab" contextRef="C_9390c172-8de0-44cd-beb2-d80a53d6291b" name="vir:RangeOfTieredRoyaltiesToPayToNetSalesOfProducts"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">high single-digits to the sub-teen double-digits</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> on annual net sales of licensed infectious disease products, in each case subject to specified reductions and offsets. </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The royalties are payable on a product-by-product and country-by-country basis until the later of the expiration of all valid claims of specified patents covering such product in such country and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_56397382-a1bb-43ff-9bb9-f98d7f97f2e0" contextRef="C_7c1b6e30-61ef-41a5-af65-74e946d04165" name="vir:RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years after the first commercial sale of such product in such country.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In March 2020, the Company achieved the specified development milestone relating to the Milestone Shares, which was accounted for as an embedded derivative. Consequently, the Company remeasured and reclassified the derivative liability to additional paid-in capital based on the estimated fair value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0fd6b1fc-f4b8-4f10-98da-7d3a7ee0d87a" contextRef="C_a0ca781f-26e8-4b49-94e4-3f01a982fe52" name="us-gaap:DerivativeFairValueOfDerivativeLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">29.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The Company issued Alnylam </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7470fe0f-b97e-4ea0-9d4e-8dcf62fb41ac" contextRef="C_70da0710-1b2a-4c11-a63e-24ea296a4134" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,111,111</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of its common stock and paid Alnylam $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_87cd25fc-809f-4066-a519-643cf5d669ae" contextRef="C_402569c9-a676-4ead-a6ec-b7f313ab6266" name="vir:MilestonePaymentsPaid" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">15.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in the second quarter of 2020.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">167</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The term of the Amended Alnylam Agreement will continue, on a product-by-product and country-by-country basis, until the expiration of all royalty payment obligations under the Amended Alnylam Agreement. If the Company does not exercise its option for an infectious disease program directed to one of its selected targets, the Amended Alnylam Agreement will expire upon the expiration of the applicable option period with respect to such program. However, if Alnylam exercises its profit-sharing option for any product, the term of the Amended Alnylam Agreement will continue until the expiration of the profit-sharing arrangement for such product. The Company may terminate the Amended Alnylam Agreement on a program-by-program basis or in its entirety for any reason on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_deeca964-b2d6-40fd-89d5-474bc205ae52" contextRef="C_e81fb921-41bb-4624-975a-443a7c7cdf16" name="vir:WrittenNoticePeriodForTerminationOfLicensedProgram" format="ixt-sec:durday"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> days&#x2019; written notice. Either party may terminate the agreement for cause for the other party&#x2019;s uncured material breach on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ba6f01aa-2318-4acc-82e5-9f0db4a612c4" contextRef="C_e81fb921-41bb-4624-975a-443a7c7cdf16" name="vir:WrittenNoticePeriodToTerminateLicensedProgramForUncuredMaterialBreach" format="ixt-sec:durday"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> days&#x2019; written notice (or </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_667c1865-e5ee-41f6-b033-04a4073bd576" contextRef="C_e81fb921-41bb-4624-975a-443a7c7cdf16" name="vir:WrittenNoticePeriodToTerminateLicensedProgramForPaymentBreach" format="ixt-sec:durday"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> days&#x2019; notice for payment breach), or if the other party challenges the validity or enforceability of any patent licensed to it under the Amended Alnylam Agreement on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_370b2e48-c4a6-4a7c-ae6a-018023621f02" contextRef="C_e81fb921-41bb-4624-975a-443a7c7cdf16" name="vir:WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenge" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30 days</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2019; notice.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company incurred expenses under the Amended Alnylam Agreement of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a712cefa-44a5-4f69-81ee-c6a5670ed213" contextRef="C_6276028a-2d2e-482b-9ea8-a6448755d571" name="vir:CollaborationAgreementRelatedCostsAndExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7fd836e5-237c-443d-931d-4b540d30f12a" contextRef="C_7c1b6e30-61ef-41a5-af65-74e946d04165" name="vir:CollaborationAgreementRelatedCostsAndExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">11.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million during the years ended December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022 and 2021, respectively. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the year ended December 31, 2020, in addition to the Milestone Shares, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c361d388-7bf4-4064-aed9-96831e2a953b" contextRef="C_474023a2-9be4-4db1-9135-5888440e1408" name="vir:MilestonePaymentsPaid" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">15.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million milestone payment to Alnylam, and the $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_480feaf6-0f05-4c78-bef7-f4c9f81a7174" contextRef="C_8472ca01-d418-45f2-8494-45e935bbbc83" name="vir:PaymentToCollaboratorResultingFromProgramOptionExercise" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million payment resulting from Brii Bio&#x2019;s option exercise in the first half of 2020, the Company incurred expenses of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ef7ad6e8-1bfe-4555-8a84-f1b496d80e1c" contextRef="C_946bca5b-a819-49fc-a9eb-3deae58d8824" name="vir:CollaborationAgreementRelatedCostsAndExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">11.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million under the Amended Alnylam Agreement.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">WuXi Biologics</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In February 2020, the Company entered into a development and manufacturing collaboration agreement with WuXi Biologics (the &#x201c;WuXi Biologics Collaboration Agreement&#x201d;) for the clinical development, manufacturing, and commercialization of the Company&#x2019;s proprietary antibodies developed for SARS-CoV-2. Under the WuXi Biologics Collaboration Agreement, WuXi Biologics conducted cell-line development, process and formulation development, and initial manufacturing for clinical development and had the right to commercialize products incorporating such SARS-CoV-2 antibodies in mainland China, Hong Kong, Macau and Taiwan under an exclusive license granted for the selected SARS-CoV-2 antibodies that were developed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Termination of the WuXi Biologics Collaboration Agreement</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On May 16, 2022, the Company and WuXi Biologics entered into a Termination Agreement (the &#x201c;Termination Agreement&#x201d;) pursuant to which the Company and WuXi Biologics terminated the WuXi Biologics Collaboration Agreement. Other existing agreements between the Company and WuXi Biologics remain in effect.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the terms of the Termination Agreement, all licenses granted under the WuXi Biologics Collaboration Agreement were terminated and all rights to the SARS-CoV-2 antibody products in mainland China, Hong Kong, Macau and Taiwan reverted to the Company. The Company made a one-time termination payment to WuXi Biologics of $7.0 million and accounted for the payment as an acquisition of an IPR&amp;D asset and, therefore, recognized research and development expense of $7.0 million during the second quarter of 2022. Under the terms of the Termination Agreement, the Company will be obligated to pay WuXi Biologics tiered royalties on net sales of sotrovimab in mainland China, Hong Kong, Macau and Taiwan ranging from low single digits to low double digits. Royalties are payable to WuXi Biologics for a specified royalty term and are subject to reduction in certain circumstances.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Rockefeller University</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In July 2018, the Company entered into an exclusive license agreement with The Rockefeller University (&#x201c;Rockefeller&#x201d;), which was amended in May 2019, in September 2020, and in March 2021 (as amended, the &#x201c;Rockefeller Agreement&#x201d;). Under the Rockefeller Agreement, Rockefeller granted the Company a worldwide exclusive license under certain patent rights, and a worldwide non-exclusive license under certain materials and know-how covering certain antibody variants relating to a specified mutation leading to enhanced antibody function and utility, to develop, manufacture and commercialize infectious disease products covered by the licensed patents, or that involve the use or incorporation of the licensed materials and know-how, in each case for all uses and purposes for infectious diseases. The Company uses technology licensed under the Rockefeller Agreement in the Company&#x2019;s antibody platform and in the Company&#x2019;s product candidate VIR-3434.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is required to pay annual license maintenance fees of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_66ab7763-7b17-4c8a-ad95-07eb24e25182" contextRef="C_c8f5798c-ad39-4045-8160-7af430bcb734" name="vir:AnnualLicenseMaintenanceFees" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which can be creditable against royalties following commercialization. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, upon achievement of specified development, regulatory and commercial success milestone events, the Company is required to pay up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_246b87c5-7017-42cb-8142-822237debeb7" contextRef="C_03609c47-c098-4a60-97bd-053e2bf319bf" name="vir:MaximumAggregateMilestonePaymentForAchievementOfSpecifiedMilestones" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">80.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, in the aggregate, for up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3564190f-6f09-4260-b106-af3de719a980" contextRef="C_20115010-b125-459b-ab42-c3f84a9a5259" name="vir:MaximumNumberOfProductsCoveredAgainstMilestonePayment" unitRef="U_Product" decimals="INF" format="ixt-sec:numwordsen">six</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> infectious </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">disease products. Any follow-on products beyond six products may result in additional milestone event payments. The Company will also be required to pay to Rockefeller a royalty at a low single-digit percentage rate on net sales of licensed products, subject to certain adjustments. The Company&#x2019;s obligation to pay royalties to Rockefeller will terminate, on a product-by-product and jurisdiction-by-jurisdiction basis,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">168</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">upon </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the latest of the expiration of the last valid claim of a licensed patent in such jurisdiction, the expiration of all regulatory exclusivity in such jurisdiction or </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_50e7d6db-7352-40f0-8930-866290579317" contextRef="C_c8f5798c-ad39-4045-8160-7af430bcb734" name="vir:RoyaltyObligationPeriodFromDateOfFirstCommercialSale" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years following the first commercial sale of the applicable licensed product in such jurisdiction.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the Rockefeller Agreement, the Company recognized a total of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b5d5463a-fd87-46a3-971d-587fa8a21b05" contextRef="C_a1ff86c5-33e9-4326-b1f2-a4f7b5d2c716" name="vir:ResearchAndDevelopmentExpenseUnderLicenseAgreement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_52e5821e-0567-49e1-903f-1b6c90bdb434" contextRef="C_44ac39fd-62b7-430a-9b57-c2cfeb3f1006" name="vir:ResearchAndDevelopmentExpenseUnderLicenseAgreement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a90bf6ac-4f70-457e-8f24-e499910d7669" contextRef="C_d4f38c3d-eb5d-48e7-8694-cfdc645585c7" name="vir:ResearchAndDevelopmentExpenseUnderLicenseAgreement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million during the years ended December 31, 2022, 2021 and 2020, respectively, as research and development expenses related to certain development milestone payments, annual license maintenance fees, and estimated sublicense fees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Rockefeller Agreement will remain in force, absent earlier termination, until the expiration of all of the Company&#x2019;s obligations to pay royalties to Rockefeller in all jurisdictions. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_fb38425e-c6d3-4d43-94d8-4e8ab067bb1d" contextRef="C_c8f5798c-ad39-4045-8160-7af430bcb734" name="vir:CollaborationAgreementTerminationDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has the right to terminate the Rockefeller Agreement in its entirety, or in part, for any reason on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e2aa4b00-84fd-4ff9-bfbb-634961682c43" contextRef="C_c8f5798c-ad39-4045-8160-7af430bcb734" name="vir:WrittenNoticePeriodToTerminateAgreementByCompany" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60 days</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2019; written notice to Rockefeller. Rockefeller may terminate the Rockefeller Agreement on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_92b8924c-7be0-41b5-9d55-6ecc5a829e67" contextRef="C_c8f5798c-ad39-4045-8160-7af430bcb734" name="vir:WrittenNoticePeriodToTerminateAgreementByCounterparty" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90 days</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2019; written notice for the Company&#x2019;s uncured material breach, or if the Company challenges the validity or enforceability of any of the licensed patents, or immediately in the event of the Company&#x2019;s insolvency. Rockefeller may also terminate the Rockefeller Agreement if the Company ceases to carry on business with respect to the rights granted to the Company under the Rockefeller Agreement.</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">MedImmune</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In September 2018, the Company entered into a license agreement, which was amended in September 2020 (as amended, the &#x201c;MedImmune Agreement&#x201d;), with MedImmune, LLC (&#x201c;MedImmune&#x201d;), under which the Company obtained a worldwide, exclusive license to develop and commercialize half-life extended versions of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4f7ba760-7c5b-4e52-b7c4-23e6d303792e" contextRef="C_679bc2b6-7333-4652-aa5e-56403fa75188" name="vir:NumberOfAntibodiesToDevelop" unitRef="U_Antibodies" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> specified antibodies under development by MedImmune that target influenza A and influenza B, respectively, for all uses in humans and animals. The Company is developing VIR-2482 using technology licensed under the MedImmune Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is obligated to make development, regulatory, and commercial milestone payments of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8873f83c-37d5-4feb-8ba3-9acd7184af7a" contextRef="C_440e7984-bced-4ce9-9125-e4710cb5f43b" name="vir:MaximumAggregateMilestonePaymentForAchievementOfSpecifiedMilestones" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">331.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in the aggregate relating to influenza A and influenza B products. MedImmune is also entitled to receive tiered royalties based on net sales of products containing half-life extended versions of antibodies directed to influenza A and/or influenza B at percentages ranging from the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_5dac47e7-0c9b-40b2-b070-76af35962042;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">mid-single-digits</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to sub-teen double-digits.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The MedImmune Agreement will remain in force until the expiration on a country-by-country and product-by-product basis of all of the Company&#x2019;s obligations to pay royalties to MedImmune. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1c423622-d9bd-4e2e-97ba-b9b2e62f44a9" contextRef="C_440e7984-bced-4ce9-9125-e4710cb5f43b" name="vir:CollaborationAgreementTerminationDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company may terminate the MedImmune Agreement in its entirety or on a product-by-product basis, for convenience, upon </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e6b07f3c-9301-4580-a2f2-dd0303988a92" contextRef="C_440e7984-bced-4ce9-9125-e4710cb5f43b" name="vir:WrittenNoticePeriodForTerminationOfLicensedProgram" format="ixt-sec:durday"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">120</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> days&#x2019; notice. Either party may terminate the MedImmune Agreement for cause for the other party&#x2019;s uncured material breach on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e9383e3c-d679-4de4-b4ed-94be6350c343" contextRef="C_440e7984-bced-4ce9-9125-e4710cb5f43b" name="vir:WrittenNoticePeriodToTerminateLicensedProgramForUncuredMaterialBreach" format="ixt-sec:durday"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> days&#x2019; notice or immediately in the event of bankruptcy of the other party. Additionally, MedImmune may terminate the MedImmune Agreement for cause on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_e7330068-f2a3-46b8-ad57-1eb9bc922c3d" contextRef="C_440e7984-bced-4ce9-9125-e4710cb5f43b" name="vir:WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenges" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30 days</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2019; written notice if the Company challenges the validity or enforceability of the patents to which the Company has obtained a license under the MedImmune Agreement.</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Xencor</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">August 2019 License Agreement</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In August 2019, the Company entered into a patent license agreement, which was amended in February 2021 (as amended, the &#x201c;2019 Xencor Agreement&#x201d;) with Xencor, Inc. (&#x201c;Xencor&#x201d;). Under the 2019 Xencor Agreement, the Company obtained a non-exclusive, sublicensable (only to its affiliates and subcontractors) license to incorporate Xencor&#x2019;s licensed technologies into, and to evaluate, antibodies that target influenza A and HBV, and a worldwide, non-exclusive, sublicensable license to develop and commercialize products containing such antibodies incorporating such technologies for all uses, including the treatment, palliation, diagnosis and prevention of human or animal diseases, disorders or conditions. The Company is obligated to use commercially reasonable efforts to develop and commercialize an antibody product that incorporates Xencor&#x2019;s licensed technologies, for each of the influenza A and HBV research programs. These technologies are used in the Company&#x2019;s product candidates VIR-2482, incorporating Xencor&#x2019;s Xtend technology, and VIR-3434, incorporating Xencor&#x2019;s Xtend and other Fc technologies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">169</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For each of the influenza A and HBV research programs, the Company is required to pay Xencor development and regulatory milestone payments of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_66eca115-2085-410a-a39e-855552947b35" contextRef="C_90313909-a6bc-4583-86a7-47d337dd4cb1" name="vir:MaximumAggregateDevelopmentAndRegulatoryMilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">17.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in the aggregate, and commercial sales milestone payments of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b8ad7442-7c4d-4784-a269-7adc0bea3945" contextRef="C_90313909-a6bc-4583-86a7-47d337dd4cb1" name="vir:MaximumAggregateCommercialSalesMilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">60.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in the aggregate, for a total of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_30908db4-0bf8-451a-95ae-dd26e7029239" contextRef="C_d6d82c19-9cbe-4f4b-b35e-d5f66e5d7598" name="vir:MaximumAggregateMilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_48b4eff5-d180-4c65-80a0-f8a2c9940574" contextRef="C_b553a367-b665-4001-8f33-c723ff21ad71" name="vir:MaximumAggregateMilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">77.8</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in aggregate milestones for each program and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9643122f-624d-4b85-9046-dcea4e671816" contextRef="C_90313909-a6bc-4583-86a7-47d337dd4cb1" name="vir:MaximumAggregateMilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">155.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in aggregate milestones for both programs. On a product-by-product basis, the Company is also obligated to pay tiered royalties based on net sales of licensed products ranging from </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0baab0f2-cbaa-40d9-a612-42b2917b3409" contextRef="C_90313909-a6bc-4583-86a7-47d337dd4cb1" name="vir:RoyaltiesPaymentRangeOnNetSalesOfLicensedProduct"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">low- to mid-single-digits</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The royalties are payable, on a product-by-product and country-by-country basis, until the expiration of the last to expire valid claim in the licensed patents covering such product in such country.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the 2019 Xencor Agreement, the Company recognized an immaterial amount during each of the years ended December 31, 2022, 2021 and 2020, as research and development expenses related to certain development milestone payments.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">March 2020 License Agreement</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In March 2020, the Company entered into a patent license agreement, which was amended in February 2021 (as amended, the &#x201c;2020 Xencor Agreement&#x201d;), with Xencor under which the Company obtained a non-exclusive, sublicensable (only to its affiliates and subcontractors) license to incorporate Xencor&#x2019;s licensed technologies into, and to evaluate, antibodies that target any component of a coronavirus, including SARS-CoV-2, SARS-CoV and MERS-CoV, and a worldwide, non-exclusive, sublicensable license to develop and commercialize products containing such antibodies incorporating such technologies for all uses, including the treatment, palliation, diagnosis and prevention of human or animal diseases, disorders or conditions. The Company is obligated to use commercially reasonable efforts to develop and commercialize an antibody product that incorporates Xencor&#x2019;s licensed technologies, for each of the coronavirus research programs. These technologies are used in sotrovimab, incorporating Xencor&#x2019;s Xtend technology.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In consideration for the grant of the license, the Company is obligated to pay royalties based on net sales of licensed products at the</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8c48b4bb-6f2f-49b1-aa9a-b0bd7ae767ff" contextRef="C_423db569-199e-451c-b19e-22f96e558a53" name="vir:RoyaltiesBasedOnNetSalesOfLicensedProducts"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> mid-single-digits</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The royalties are payable, on a product-by-product and country-by-country basis, until the later of the expiration of the last to expire valid claim in the licensed patents covering such product in such country or </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_263959c4-b0f2-4bb4-8b49-a3554c9075cf" contextRef="C_423db569-199e-451c-b19e-22f96e558a53" name="vir:RoyaltiesPaymentExpirationPeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12 years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. During the years ended December 31, 2022 and 2021, the Company recognized $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1513ee37-e20a-49a1-a5ed-071d58cf0886" contextRef="C_423db569-199e-451c-b19e-22f96e558a53" name="us-gaap:CostOfRevenue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">114.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a6ef6ca0-2272-4f0a-a86c-e20f7727d9cc" contextRef="C_0c441e33-191d-47b1-a7d6-6ce061bb3ae1" name="us-gaap:CostOfRevenue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">52.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, as cost of revenue for royalties due to Xencor from the sale of sotrovimab.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2020 Xencor Agreement and 2019 Xencor Agreement will remain in force, on a product-by-product and country-by-country basis, until the expiration of all royalty payment obligations under each of the respective agreements. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_960ab404-9960-4a9f-ad7a-f9cc260aef49" contextRef="C_fa73886f-e92f-4966-af95-e6e76cd8ccc3" name="vir:CollaborationAgreementTerminationDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company may terminate each agreement in its entirety, or on a target-by-target basis, for convenience upon </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6b923547-5232-4f39-91f5-0dc813898c49" contextRef="C_fa73886f-e92f-4966-af95-e6e76cd8ccc3" name="vir:WrittenNoticePeriodForTerminationOfLicensedProgram" format="ixt-sec:durday"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> days&#x2019; written notice. Either party may terminate each agreement for the other party&#x2019;s uncured material breach upon </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5847707d-c41e-49b2-bb10-ebdedb258394" contextRef="C_fa73886f-e92f-4966-af95-e6e76cd8ccc3" name="vir:WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach" format="ixt-sec:durday"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> days&#x2019; written notice (or </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_762e8959-2b3c-4e60-95a3-40841b7364fe" contextRef="C_fa73886f-e92f-4966-af95-e6e76cd8ccc3" name="vir:WrittenNoticePeriodToTerminateLicensedProgramForFailureToMakePayment" format="ixt-sec:durday"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> days in the case of non-payment) or in the event of bankruptcy of the other party immediately upon written notice. Xencor may terminate each agreement immediately upon written notice if the Company challenges, or upon </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d4ed40f6-139e-41ff-9b94-9b988f115b69" contextRef="C_fa73886f-e92f-4966-af95-e6e76cd8ccc3" name="vir:WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenges" format="ixt-sec:durday"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> days&#x2019; written notice if any of the Company&#x2019;s sublicensees challenge, the validity or enforceability of any patent licensed to the Company under each respective agreement.</span></ix:nonNumeric></span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_319bfc2d-c806-47e5-b0d8-2865b74a0ea8" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:8.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">8.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance Sheet Components </span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Property and Equipment, net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_9d7157c4-39ad-4d29-aedf-a4df66bdbcdb" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net consists of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.747%;"></td>
        <td style="width:1.427%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.186%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.427%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.213000000000001%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d2f82680-9745-44e2-9d3e-0b860574457e" contextRef="C_ecf4fb53-9e9a-460b-b2c7-36c48bc67120" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">36,533</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_33d4a906-010e-4d5d-b867-e4782a0a36f2" contextRef="C_0d8c8a20-2403-4408-9856-613c5c82c189" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20,012</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6fcc6903-fba5-4673-af7a-2efc4b0e3172" contextRef="C_0ab585f4-7932-4fcf-9d20-a8bc39178ab4" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,545</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3f50e93a-85d5-43df-8466-ab8cafb8dae1" contextRef="C_c8ff574f-fed5-42aa-939d-486187b621e5" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,112</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_95db74de-78b6-4ea3-88be-2ba735999861" contextRef="C_cce2c08e-9755-4a1d-ac18-7f295a943893" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,852</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9522cbd2-bfe7-4306-87a4-fb30f0c1ca93" contextRef="C_5ee09e36-b7d5-4bd7-a7a8-de86d1ea831c" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,443</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a82318e1-56d8-4767-a2ae-abfc6ab1b5f7" contextRef="C_1e3fe30c-1972-4e8c-8649-eeb82a737029" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">84,422</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d7f60c2d-527c-4c9f-826f-a19037c06149" contextRef="C_f3c34215-8edc-4dd4-865f-ab771871ad3a" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,834</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Construction in progress</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bf98837c-f44e-429e-a021-0884d0eff21e" contextRef="C_029580f2-ed42-4e2c-a78b-e3a8e585aaa6" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3fe90f18-8827-405a-8148-e1b043d0756d" contextRef="C_db0c1ec0-28ae-4df5-8ac3-748f417365f4" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">26,925</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, gross</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f3a4a558-e709-402a-8177-4b6fe1e2aa32" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">126,352</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4399fdd7-231d-4b0c-93ac-71b02912922d" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">57,326</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less accumulated depreciation and amortization</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cd5b0c9d-a166-471f-b33b-84f22fcdd159" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20,743</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_926549e1-1f53-47a9-a28f-9f8ddc9d4df2" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,492</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total property and equipment, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9d40118f-ff31-41a0-8b58-1e26968e413d" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">105,609</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6e938ded-b2d9-4669-92fe-28d9c4c5e338" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">42,834</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation and amortization expenses were </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3617ef64-f200-4ddb-840e-75598ad98eff" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">6.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d5d91b25-fe90-4e45-b5d6-591a74be8d4b" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_02aa91a9-7feb-451f-a007-a8d4ef50e84e" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the years ended December 31, 2022, 2021 and 2020, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">170</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Accrued and Other Liabilities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_426f4a2e-d01b-440e-98f1-3cbca2321889" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="vir:ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued and other liabilities consist of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.12%;"></td>
        <td style="width:1.655%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.246%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.655%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.324%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Milestone payable</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f546a1b3-79f0-4794-ab29-8fd3f4fc3a83" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="vir:MilestonePayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_44a421b5-bdf0-4c31-a699-f3068045a561" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="vir:MilestonePayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">95,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net profit-sharing constrained</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9f07e145-b5a9-43dd-85fd-665b23d752d2" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="vir:ProfitShareAmountConstraint" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">357,762</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued royalties</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fad3005a-d7cc-4ea7-8d4a-cbdb20eabe9b" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:AccruedRoyaltiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,447</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7148476d-180f-4345-893f-b12424e1151a" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:AccruedRoyaltiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">58,672</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expenses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4e0bb352-8c3c-4ed2-b589-289a8c74fa0d" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="vir:ResearchAndDevelopmentExpensesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">48,880</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_01817f39-7992-494d-a1a3-3deb29fca0b3" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="vir:ResearchAndDevelopmentExpensesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">28,073</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Payroll and related expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ddc2181f-a323-42ce-94ef-7dec04a0eed2" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="vir:PayrollAndRelatedExpensesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">28,286</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_78181a44-4529-4ddf-977f-7db51353a277" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="vir:PayrollAndRelatedExpensesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">29,753</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued income taxes</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2eac896e-cccb-4e84-a19c-86f16c0c2157" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:AccruedIncomeTaxesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,228</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ae88ac76-84a0-4172-90f0-eb670175d792" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:AccruedIncomeTaxesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,217</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Excess funds payable under grant agreements</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7db89fe8-1779-4b1f-bcf5-040e137f8c5b" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="vir:ExcessFundsPayableUnderGrantAgreementsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,652</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_35abb471-c9bb-41c6-82ab-a8d419f7cf4d" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="vir:ExcessFundsPayableUnderGrantAgreementsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,825</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities, current</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1eb0a340-eb06-43e2-9732-07dc33963caa" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,137</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b269aaf8-8f41-4432-be4f-1518ba3c2e90" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,927</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other professional and consulting expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_839b67b4-3f1c-4512-aec6-aaaeae86b276" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,987</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3087d04b-07e9-48ef-a526-b647af9a47a8" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,791</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other accrued expenses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b35358ae-d2f3-4c34-b445-c09e70145fb8" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,711</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ee6812e2-9b7e-4610-9ed5-d0b7fe63b7d1" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,254</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total accrued and other liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_59104e4c-1fbe-4187-a89d-b16c0aafd25c" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">489,090</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bc201673-b25f-46c4-8d95-51f43dc6c77d" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">236,512</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0ef18571-9e5b-4967-8a3b-9cddc8f39999" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true" continuedAt="F_0ef18571-9e5b-4967-8a3b-9cddc8f39999_1"><div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">9.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commitments and Contingencies </span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Lease Agreements</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has various operating lease arrangements for office and laboratory spaces located in California, Oregon, Missouri, and Switzerland with contractual lease periods expiring at various dates through </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_029176bb-9e8d-45a3-ac45-fa0f144995a6" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="vir:LeaseArrangementContractualExpirationEndingYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2033</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4d7aa5dc-eaeb-486d-acd9-b113bc62e691" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:LesseeOperatingLeaseOptionToExtend"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These leases require monthly lease payments that may be subject to annual increases throughout the lease term. Certain lease agreements also provide the Company with the option to renew for additional periods ranging from </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_6e3bf6bc-7e1c-4d4c-81d7-17386f7ad6b8;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7f587a49-50ff-4e81-9b95-bb7ed7401f17" contextRef="C_268c2c6c-2e46-49ef-8b34-85c3eb6476c2" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> These renewal options are not considered in the remaining lease term unless it is reasonably certain that the Company will exercise such options.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2021, the Company entered into a new sublease agreement for office and laboratory spaces in Missouri that will expire in December 2028, with no option to renew. Under this sublease arrangement, the Company is entitled to tenant improvement allowance of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7cca40f0-cc39-4f53-8411-0f0c9c2e2ccb" contextRef="C_65402f98-6f66-411f-989c-de9e545eb48a" name="vir:TenantImprovementAllowanceAggregate" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">14.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">related to the design and construction of certain Company improvements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2021, the Company entered into a lease agreement with the new owner of the building at 1800 Owens Street in San Francisco for the lease of approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b5086857-7b80-4d6f-9784-a3e365f5982d" contextRef="C_8159e296-cbd0-46c5-bb89-4442f5253f01" name="us-gaap:NetRentableArea" unitRef="U_sqft" decimals="INF" format="ixt:numdotdecimal">133,896</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> rentable square feet of office and laboratory space of such building. The Company previously occupied the same premises under a sublease agreement with a sublessor, which sublease was terminated concurrently with the execution of the new lease agreement. Accordingly, the related ROU asset and lease liability under the sublease arrangement were extinguished and the Company recognized a gain of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6dd66fa7-ab7e-4dea-9074-1ee2d2b690e4" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:GainLossOnTerminationOfLease" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in the consolidated statement of operations for the year ended December 31, 2021. The new lease will expire in December 2033, with no option to renew. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under this lease arrangement, the Company is entitled to tenant improvement allowance of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fd008bdd-d466-4ce5-9715-848a6446419b" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="vir:TenantImprovementAllowanceAggregate" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">37.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">related to the design and construction of certain Company improvements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">    </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under two of the operating lease arrangements in California and Missouri discussed above, the Company expected to fully utilize the tenant improvement allowance and, therefore, such amount was treated as a lease incentive that is payable to the Company at the lease commencement date.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Throughout the term of the lease agreements, the Company is responsible for paying certain operating costs, in addition to rent, such as common area maintenance, taxes, utilities and insurance. These additional charges are considered variable lease costs and are recognized in the period in which the costs are incurred.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">171</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ec7ef530-a69c-499a-b126-91bc93cc4850" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="vir:SummaryOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table contains a summary of the lease costs recognized under ASC 842 and additional information related to operating leases (in thousands, except weighted average amounts):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.778%;"></td>
        <td style="width:1.336%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:14.484%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.107%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.598%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.107%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.589%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aa02b69b-d121-4b1b-9fb2-43811a752313" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,910</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_97e6fa93-2f0b-4263-88ab-6ebccc41673a" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,921</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_41314f8d-af2d-4be4-9bbd-73ca79d58275" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,591</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term lease cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d3df0d17-e755-4540-9c39-b21588ea9838" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:ShortTermLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">239</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ae8df2eb-bfd9-4487-83f8-044c0c7ff251" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:ShortTermLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">261</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9ced196c-d7a0-47b0-9744-5a6901cd0dea" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:ShortTermLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">459</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Variable lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f6a3e4a1-6c63-4d53-979a-6cf5ad9f1ec8" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,937</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_eb311e59-0184-4594-bd8c-808369de8bf1" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,256</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fccc5b13-382b-4921-9160-85fc573f0172" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,299</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_965a8a07-39ce-4aa0-abf0-f92c9603cfdb" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">26,086</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_477e3f8a-507e-42a2-9909-bfa686cfed6d" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,438</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_155ec79c-8e2c-420f-8bde-a018562de707" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,349</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other Information</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted average remaining lease term (in years)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ba934251-e34e-47fb-830a-e30a737da0de" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.0</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_cb4059a6-314d-4328-80ce-df619568e554" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.4</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c895d9e8-6078-430d-be64-79fc394c2bdd" contextRef="C_da5feba6-e631-4bec-b33d-106ac3401870" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.6</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted average incremental borrowing rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8e46fb6e-48d3-4475-8474-1c0a67efd147" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">5.2</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c045dd71-b975-4c04-9c53-91c510dba86e" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">5.2</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c509d3f1-c94c-47b3-af74-bf767a9b3944" contextRef="C_da5feba6-e631-4bec-b33d-106ac3401870" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">7.7</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash paid for amounts included in the measurement of operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_797d062f-86bf-4e2d-bcab-b0a3d07a0cce" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,716</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fffbbba3-c819-463c-8c55-d7b42836eb57" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,250</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fb1925f6-ad92-4479-bf4e-787976ba5e9b" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,081</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ROU assets obtained in exchange for new operating lease liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2804fb41-1520-40ad-8903-3fdd3941fe55" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,046</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8f0427e9-f841-4598-b4ab-4b9a6a8a6665" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">77,187</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d0c6d5c7-01c1-48ce-822d-4042982f8e00" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">48,495</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The discount rate used to determine the present value of the lease payments is our estimated collateralized incremental borrowing rate, based on the yield curve for the respective lease terms, as we generally cannot determine the interest rate implicit in the leases.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5aef16c1-97a8-40ba-a1a6-30b5d39c0c16" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The maturity of the Company&#x2019;s operating lease liabilities as of December 31, 2022 was as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.944%;"></td>
        <td style="width:2.036%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:16.02%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amounts</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b04c4151-b1b8-454f-91c1-8ade81a13242" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19,450</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e433d06a-6040-48fa-882f-60a0353b52d1" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,610</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6084a98a-fe93-45e0-a5e2-4814c70a341b" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,303</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_14a958ee-5272-4f1b-8b08-bb1748b4486d" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,747</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2027</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3afde10b-04a9-44c4-8b91-6639da098ca9" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,927</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Thereafter</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_853da714-ed17-47cc-8879-bfbde39c7c2c" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">86,994</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_618e4d10-6938-4a42-8e0f-98404edab1e8" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">175,031</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f5ccc718-b2ee-4dd0-8bd2-c25f84b239de" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">38,379</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: net tenant improvement allowance yet to be received</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c2c4bb3d-545f-4717-a7ec-f1694cd8b5c4" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="vir:LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">26,294</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Present value of operating lease liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_feedc662-a588-48b3-92df-85c4fdce2791" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="vir:PresentValueOfOperatingLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">110,358</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_79bcaa83-eac9-4688-a834-5909c4ada0b6" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="vir:ScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following amounts were recorded in the consolidated balance sheets as of December 31, 2022 and 2021 (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.225%;"></td>
        <td style="width:1.604%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:16.382%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.465%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:15.325%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating Leases</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses and other current assets</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">&#160;(1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6678866e-bd13-4f40-999a-3c8f24de0f4e" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="vir:OperatingLeaseIncentiveOverLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17,616</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b923aa6f-c464-41ea-83e3-a20e9f874644" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="vir:OperatingLeaseIncentiveOverLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">49,536</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating ROU assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3a11278d-f849-41ce-88fd-a82fde479d1c" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">82,557</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6afcf1e5-0f59-4fbc-a47a-cedf3a25d5fa" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">87,220</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_b8b36721-3cb4-433a-80d0-34cd8d9386fc;"><span style="-sec-ix-hidden:F_0ef0daab-8a05-4fa7-ae0c-27cd8627c533;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued and other liabilities</span></span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_86afe23e-6bd9-4fad-8296-b1a4d7c3f0d1" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,137</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cbc97407-858c-4b13-8205-6b6a98ef0149" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,927</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities, noncurrent</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b348eff3-a7cf-4cbf-8674-1f3c76c7afa9" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">123,837</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a6831ba4-c9eb-41b5-aab9-5599586038d9" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">133,561</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8b553819-52d1-4dd8-a2b0-99b51c569855" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">127,974</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2b8e5063-1fc9-4a5c-97a3-8aaf09158ba7" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">137,488</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:80.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="text-indent:0.0%;display:flex;margin-top:2.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:8.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For certain operating leases, lease incentives expected to be received exceeds the minimum lease payments expected to be paid over the next 12 months, therefore the net amount is recorded in prepaid expenses and other current assets.</span></div></div></ix:nonNumeric></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">172</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Manufacturing and Supply Letter Agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In April 2020, the Company and Samsung Biologics Co., Ltd. (&#x201c;Samsung&#x201d;) entered into a binding letter agreement (the &#x201c;Samsung Letter Agreement&#x201d;), under which Samsung performs development and manufacturing services for the Company&#x2019;s SARS-CoV-2 antibody program. In August 2020, the Company, GlaxoSmithKline Trading Services Limited (&#x201c;GSKTSL&#x201d;) and Samsung entered into an Assignment and Novation Agreement effective as of July 31, 2020, under which the Company assigned and transferred to GSKTSL all of the Company&#x2019;s right, title, and interest in, to and under the Samsung Letter Agreement, and GSKTSL became the Company&#x2019;s successor in interest in and to all of the Company&#x2019;s rights, duties, and obligations in, to and under the Samsung Letter Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In August 2020, GSKTSL entered into a Master Services Agreement with Samsung (the &#x201c;Samsung MSA&#x201d;) in connection with the performance of the obligations of the Company and GSK under the 2020 GSK Agreement. In accordance with the terms of the 2020 GSK Agreement, the Company continues to be responsible for </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f534e361-d7ef-490a-9798-1e42f59a118e" contextRef="C_5996e992-06fd-457c-9ae0-b6c5639ae79b" name="vir:PercentageOfDevelopmentCostsResponsibleByCompany" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">72.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the costs under the Samsung MSA, and GSK bears </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5cb69e78-18dc-46e4-bc3e-7dd5832ed120" contextRef="C_a34f69de-db65-4bed-a804-9fff69f8bba0" name="vir:PercentageOfDevelopmentCostsResponsibleByGsk" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">27.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of such costs under the Samsung MSA, subject to certain conditions and exceptions. The Company&#x2019;s commitment has been substantially recognized on its consolidated balance sheet as part of the profit-sharing amount constrained as of December 31, 2022, which is part of accrued and other liabilities, as discussed in Note 7&#x2014;Collaboration and License Agreements.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Indemnification</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_0ef18571-9e5b-4967-8a3b-9cddc8f39999_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Under such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. In addition, the Company has entered into indemnification agreements with its directors and certain officers that may require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. To date, no demands have been made upon the Company to provide indemnification under these agreements, and thus, there are no indemnification claims that the Company is aware of that could have a material effect on the Company&#x2019;s consolidated balance sheets, consolidated statements of operations, or consolidated statements of cash flows.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_08d5c270-811e-4f1d-b914-f19bb2cc137f" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">10.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Related Party Transactions </span></div></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a result of the Brii Agreement, the Company holds a minority equity interest in Brii Bio through its parent company, Brii Bio Parent. At the time when the Company entered into the Brii Agreement, the Company's Chief Executive Officer (the  &#x201c;CEO&#x201d;), and another member of the Company's board of directors served on Brii Bio Parent&#x2019;s board of directors. The Company's CEO, who is also a member of the Company's board of directors, resigned from Brii Bio Parent&#x2019;s board of directors in June 2021. As of December 31, 2022, one member of the Company&#x2019;s board of directors serves on Brii Bio Parent&#x2019;s board of directors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_f34aa3b0-b617-45d4-96e2-e6b3d9711897" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:8.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">11.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-Based Awards </span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2019 Equity Incentive Plan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In September 2019, the Company&#x2019;s board of directors adopted, with the approval of its stockholders, the 2019 Equity Incentive Plan (the &#x201c;2019 Plan&#x201d;) for the issuance of incentive stock options (&#x201c;ISO&#x201d;), non-qualified stock options (&#x201c;NSO&#x201d;), stock appreciation rights (&#x201c;SARs&#x201d;), restricted stock, other stock awards and performance cash awards, to employees, non-employee directors, and consultants. The 2019 Plan became effective concurrent with the Company&#x2019;s initial public offering (&#x201c;IPO&#x201d;).</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Awards granted under the 2019 Plan expire no later than </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c644b00e-9c73-4afd-bb25-f4c5384e71cc" contextRef="C_d876049e-5055-4f47-995e-2fbfc3f91f50" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years from the date of grant. For ISO and NSO, the option price shall not be less than </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e6fc3396-b849-4cfd-b848-c89a7f315f7c" contextRef="C_896e4988-6bb1-4c02-8cd3-19e59ff58b81" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" unitRef="U_pure" scale="-2" decimals="INF">100</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the estimated fair value on the date of grant. Options granted typically vest over a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3419ff46-4afd-4cb9-a91c-b2ee12d9ecd9" contextRef="C_896e4988-6bb1-4c02-8cd3-19e59ff58b81" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">four-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> period but may be granted with different vesting terms. As of December 31, 2022, there are </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_da637071-7fad-4ab7-8013-08af42f42c6f" contextRef="C_99fe8501-acd9-4f49-adf9-24150da9294f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">12,911,263</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares available for the Company to grant under the 2019 Plan.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2016 Equity Incentive Plan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In September 2016, the Company adopted the 2016 Equity Incentive Plan (the &#x201c;2016 Plan&#x201d;) for the issuance of ISO, NSO, SARs, restricted stock and other stock awards, to employees, non-employee directors, and consultants under terms and provisions established by the Company&#x2019;s board of directors and approved by the stockholders.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">173</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Awards granted under the 2016 Plan expire no later than </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_306c0518-21ca-4407-9a08-779e00833fe0" contextRef="C_720cbd98-e278-45a4-979c-db878614348b" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years from the date of grant. For ISO and NSO, the option price shall not be less than </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e23d9cc7-33e1-45c6-86c4-9b495c73c46e" contextRef="C_f9212404-81f7-4d0b-9f10-42f60cf103ef" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">100</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the estimated fair value on the date of grant. Options granted typically vest over a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f2501ede-ec5a-4eb4-bd00-ee71c6c91ec5" contextRef="C_f9212404-81f7-4d0b-9f10-42f60cf103ef" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">four-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> period but may be granted with different vesting terms.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In conjunction with adopting the 2019 Plan, the Company discontinued the 2016 Plan with respect to the new equity awards.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2019 Employee Stock Purchase Plan</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In September 2019, the Company&#x2019;s board of directors adopted, with the approval of its stockholders, the ESPP. The ESPP became effective on the completion of the Company&#x2019;s IPO.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The ESPP initially authorized the issuance of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_11e565ab-a99d-481b-866e-460ef1a31ef3" contextRef="C_c80ea697-a368-4975-9736-adb7c05cefbd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,280,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company&#x2019;s common stock under purchase rights granted to its employees or employees of any of the Company&#x2019;s designated affiliates. The number of shares of the Company&#x2019;s common stock reserved for issuance is subject to an automatic increase at each calendar year. Under the ESPP, the Company may specify offerings with durations of not more than </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_79cafdd2-4a10-4938-955e-80f35076da3f" contextRef="C_7b5b92b7-ec6c-4504-ad39-91288ac75cc0" name="vir:OfferingPeriodEmployeeStockPurchasePlan" format="ixt-sec:durmonth"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> months and may specify shorter purchase periods within each offering. The ESPP allows eligible employees to purchase shares of the Company&#x2019;s common stock at a discount through payroll deductions of up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3e708dda-cc32-45fd-a5d9-c3e6664a743f" contextRef="C_c80ea697-a368-4975-9736-adb7c05cefbd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">15</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of their earnings, subject to any plan limitations. Unless otherwise determined by the Company&#x2019;s board of directors, employees can purchase shares at </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_472f0049-c2ca-4fbe-a058-c303a185f0e8" contextRef="C_72d128cd-9dc7-4ded-bfa1-21c90dee3725" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">85</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the lower of the fair market value of the Company&#x2019;s common stock on the first date of an offering or the purchase date. During the year ended December 31, 2022, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1a3dc7f1-9f0c-41b1-baca-5cf4d766c819" contextRef="C_87139d89-e3fd-445f-b6c1-4593f57a1d30" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">118,288</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares were issued under the ESPP.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock Option Activity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b56f3ece-547f-4554-8e8c-b944db40766b" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Activity under the Company&#x2019;s stock option plans is set forth below:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:55.387%;"></td>
        <td style="width:0.173%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.722000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.074%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:7.6899999999999995%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.148%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:7.911%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.247%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.65%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of<br />Options</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted<br />Average<br />Exercise<br />Price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted<br />Average<br />Remaining<br />Contractual<br />Term</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate<br />Intrinsic<br />Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ab97b53d-5893-48de-9a75-5882c4dff15c" contextRef="C_63454d26-78fb-4850-a047-cf04ffc3c617" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,308,928</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5cf485f9-b2f1-4c4c-b184-a752ccba6d8c" contextRef="C_63454d26-78fb-4850-a047-cf04ffc3c617" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2">31.75</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_52351454-3590-4d33-acfa-bad0bd92963b" contextRef="C_35e38548-67c8-4cef-8f37-1a11a25cc2ea" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.2</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0cc2d5b1-6876-4d9e-a86b-62b979d78e88" contextRef="C_2af6ea14-ac98-4568-81e0-3bef718e3542" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,051,535</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aad4446f-6acc-474e-95fc-5a73faf3b99d" contextRef="C_2af6ea14-ac98-4568-81e0-3bef718e3542" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">28.07</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_01c7a404-8e75-4dd2-af6b-99215af156fd" contextRef="C_2af6ea14-ac98-4568-81e0-3bef718e3542" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">696,963</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a2794900-ebb6-4466-bcf4-6b60fa85cd0d" contextRef="C_2af6ea14-ac98-4568-81e0-3bef718e3542" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">6.51</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8ec9899c-bde3-408b-9828-da5db238956a" contextRef="C_2af6ea14-ac98-4568-81e0-3bef718e3542" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,059,133</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c144327d-5d7b-4105-ab3f-772653d0ae3f" contextRef="C_2af6ea14-ac98-4568-81e0-3bef718e3542" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">41.67</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d0ab913c-07ff-4185-a8b3-153f4ba3f7e6" contextRef="C_eeb8aa97-5f2d-4952-8244-3a5e12f77095" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,604,367</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_574afc4b-a446-4f9c-9324-36fb23a7c020" contextRef="C_eeb8aa97-5f2d-4952-8244-3a5e12f77095" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">31.70</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a3269ef6-b013-41e7-8c9e-66d5b6c1c083" contextRef="C_2af6ea14-ac98-4568-81e0-3bef718e3542" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.6</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9cbf2020-4a83-4680-a286-d8daa3216f55" contextRef="C_eeb8aa97-5f2d-4952-8244-3a5e12f77095" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">52,307</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested and expected to vest at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_177c8d8c-6f13-4e87-ab1f-c447491b7767" contextRef="C_eeb8aa97-5f2d-4952-8244-3a5e12f77095" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,604,367</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_50997fce-6f92-4066-8737-193db4b6c7c0" contextRef="C_eeb8aa97-5f2d-4952-8244-3a5e12f77095" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">31.70</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_495d221c-1e54-47de-adcc-e0170dc9fa47" contextRef="C_2af6ea14-ac98-4568-81e0-3bef718e3542" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.6</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5cd05d8f-83cb-4955-a18f-efc0580b5363" contextRef="C_eeb8aa97-5f2d-4952-8244-3a5e12f77095" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">52,307</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested and exercisable at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2ad3cbdd-00be-4172-93e0-9ecdb20dc0d1" contextRef="C_eeb8aa97-5f2d-4952-8244-3a5e12f77095" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">6,069,564</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cdef5fdf-50b7-431e-82a4-b8efededb8ef" contextRef="C_eeb8aa97-5f2d-4952-8244-3a5e12f77095" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">27.06</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_eaf9612d-8a8a-4df7-8f85-febbaed2dac5" contextRef="C_2af6ea14-ac98-4568-81e0-3bef718e3542" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.0</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_16adc57b-ffda-474d-9744-70e632f2a07d" contextRef="C_eeb8aa97-5f2d-4952-8244-3a5e12f77095" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">48,178</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The aggregate intrinsic value of options exercised during the years ended December 31, 2022, 2021 and 2020 was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_def99e06-1b8e-424c-aa23-636bea25fc0d" contextRef="C_2af6ea14-ac98-4568-81e0-3bef718e3542" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="3" decimals="-2" format="ixt:numdotdecimal">12.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9cd5ffbe-5061-43af-85fd-2f8b83196621" contextRef="C_35e38548-67c8-4cef-8f37-1a11a25cc2ea" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">65.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bc18defc-6dd7-4977-9d6a-dfee2f1d5631" contextRef="C_9dc90b6a-ec9c-43c8-abc2-fcbab105e2d2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">53.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the years ended December 31, 2022, 2021, and 2020, the estimated weighted-average grant date fair value of the options granted was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c9dd0296-4ce1-4b3d-b16e-fab65a5d2b56" contextRef="C_2af6ea14-ac98-4568-81e0-3bef718e3542" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">22.69</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d475068c-de5a-46be-bb9c-832e9c6768d6" contextRef="C_35e38548-67c8-4cef-8f37-1a11a25cc2ea" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">47.62</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_28576313-f6c1-41a9-b37d-1d3bfca10e9b" contextRef="C_9dc90b6a-ec9c-43c8-abc2-fcbab105e2d2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">25.49</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">174</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, the Company expects to recognize the remaining unamortized stock-based compensation expense of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_87e2c049-69c3-4ef0-b83e-b8de1e11833a" contextRef="C_eeb8aa97-5f2d-4952-8244-3a5e12f77095" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">127.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million related to stock options, over an estimated weighted average period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a2386009-f418-4237-b9af-b7561b1ad8ac" contextRef="C_2af6ea14-ac98-4568-81e0-3bef718e3542" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.2</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock Options Granted to Employees</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6d7f739f-1b17-4651-8822-90d09ea14db2" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair value of stock options granted to employees was estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.472%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:15.343%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:15.343%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:15.343%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="5" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected term of options (in years)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0d3a955f-5201-48ad-ace7-961022615bf8" contextRef="C_62304650-1cd7-4013-b062-3aa4e9d5ad9f" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.3</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#x2013; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c6913a00-5b15-4387-8451-cb258ec40ef1" contextRef="C_9a41c817-24ee-4d06-ab61-6c839a61c843" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.1</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_71d1c322-cc37-4024-8eda-d68f0dc0ceff" contextRef="C_dbd52408-3a79-4789-b6f2-0d8c54a59ebf" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.3</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#x2013; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_66dc0b57-10fb-4f54-bc8c-5f61f405af26" contextRef="C_b1fed0e5-7cc7-463c-bdd6-e6e1458d55b5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.1</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c326bfa3-cb2c-4a6c-8ec6-a242b1b1e110" contextRef="C_4adec9d2-4308-425f-a580-f05b8bbce014" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.0</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#x2013; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6fbc700c-89b1-4639-bff5-d36caa087511" contextRef="C_bbef5af8-652f-4bae-a181-e9df48dc51ea" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.1</span></ix:nonNumeric></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected stock price volatility</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4d137b0f-cbc0-4312-9c84-36098e7aeb42" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">101.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% &#x2013; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f5bd62c2-1e51-46a9-878c-2e80968c2ce3" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">111.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6eca9f03-c192-4a2d-b1bb-b37e75963731" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">103.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% &#x2013; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8b1f18ad-38b2-4553-bb06-769ff05a9b9a" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">112.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9e91f04d-276d-44e7-a655-847a85dd083c" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">88.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% &#x2013; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e424e792-99a1-4d93-9a17-16a5b566865c" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">108.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_29895985-b837-4977-8976-a1c9aa735218" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">1.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% &#x2013; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6ec6e83d-409c-4e4a-9dd7-4c51d8bca1a5" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">4.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_07ce599d-89b1-4b0f-99c5-f9ee47dbf2bc" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% &#x2013; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_98404f9f-d16f-4afb-88af-fb5298eac22e" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">1.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_01659a47-be04-48c6-b507-737d52587044" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% &#x2013; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8f40e647-eaa6-4e4c-abba-2470f4991d09" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">1.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c9d78394-23b5-49b2-bfbb-2e8beb41a8ad" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_242697d8-14d6-42f6-ad7c-851e7e707a58" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c73778a8-1129-4fc7-a023-f1566b287f09" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The valuation assumptions for stock options were determined as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expected Term&#x2014;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The expected term represents the period that the stock options granted are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term) as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expected Volatility&#x2014;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since inception the expected volatility was determined by examining the historical volatilities for industry peers and using an average of historical volatilities of the Company&#x2019;s industry peers. Beginning the first quarter of 2022, the expected volatility is determined by using a blended approach of the Company and its industry peers&#x2019; historical volatilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Risk-Free Interest Rate&#x2014;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company based the risk-free interest rate over the expected term of the stock options based on the constant maturity rate of U.S. Treasury securities with similar maturities as of the date of the grant.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expected Dividend Rate&#x2014;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The expected dividend is zero as the Company has not paid nor does it anticipate paying any dividends on its profit interest units in the foreseeable future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Employees Stock Purchase Plan</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2021, the Company initiated its first offering period under the ESPP. Each offering period is </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_58836567-1eb6-4992-b57a-e2b518b62045" contextRef="C_f8f016eb-9b56-4d62-8dd6-7ea4594702e3" name="vir:OfferingPeriodEmployeeStockPurchasePlan" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">six months</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which commences on the grant date on or after June 1 and December 1 of each year and ends on the purchase date on or before November 30 and May 31 of each year.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_cadfc506-1bf9-44c3-9356-3641e60e94f7" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair value of employees' purchase rights under the ESPP was estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:59.491%;"></td>
        <td style="width:1.824%;"></td>
        <td style="width:18.444%;"></td>
        <td style="width:1.824%;"></td>
        <td style="width:18.417%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected term of ESPP (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_11c9923c-8e19-4a4d-9adc-c5efe9e4cc42" contextRef="C_87139d89-e3fd-445f-b6c1-4593f57a1d30" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.5</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_83054c0c-0bb8-4b99-b46f-54f7e2d5b046" contextRef="C_d45858f9-5f23-4ea3-a7e2-ddac9afb63ae" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.5</span></ix:nonNumeric></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected stock price volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_abeb1249-e523-41dc-a568-88a69cfa090b" contextRef="C_87139d89-e3fd-445f-b6c1-4593f57a1d30" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">59.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% &#x2013; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3a740cdd-3081-4f7c-85a8-445eecbbd2ff" contextRef="C_87139d89-e3fd-445f-b6c1-4593f57a1d30" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">86.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_80a1fe1d-0b96-41a8-9c01-cc0a60ad1232" contextRef="C_d45858f9-5f23-4ea3-a7e2-ddac9afb63ae" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">76.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% &#x2013; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4dcc81de-8b34-4b2d-b187-70347c7c821a" contextRef="C_d45858f9-5f23-4ea3-a7e2-ddac9afb63ae" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">144.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1e5c81d0-c667-4d4a-b863-433c13c9ffdf" contextRef="C_87139d89-e3fd-445f-b6c1-4593f57a1d30" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% &#x2013; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_226d79bc-d9a4-40b2-8aa7-83f60456c8e0" contextRef="C_87139d89-e3fd-445f-b6c1-4593f57a1d30" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">4.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f73e96f2-1b82-48e2-af78-7e3b9b0f3f73" contextRef="C_d45858f9-5f23-4ea3-a7e2-ddac9afb63ae" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">0.04</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% &#x2013; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_285afe71-0a3d-4363-92ab-b0c46ba178aa" contextRef="C_d45858f9-5f23-4ea3-a7e2-ddac9afb63ae" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3cdf9171-bdf7-4127-9e1d-5da614215f13" contextRef="C_87139d89-e3fd-445f-b6c1-4593f57a1d30" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_954de329-8ed5-4cce-b9de-27c55c1d3b0f" contextRef="C_d45858f9-5f23-4ea3-a7e2-ddac9afb63ae" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The expected term of employees&#x2019; purchase rights is equal to the purchase period. The expected volatility was determined based on the Company's historical volatility. The risk-free interest rate is based on the constant maturity rate of U.S. Treasury securities with similar maturities as of the date of the grant over the expected term of the employees&#x2019; purchase rights. The expected dividend is zero as the Company has not paid nor does it anticipate paying any dividends on its profit interest units in the foreseeable future. Based on the Black-Scholes option-pricing model, the estimated weighted-average grant date fair value of the employees' purchase rights granted for the years ended December 31, 2022 and 2021 was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_26497bdb-a73e-42a2-abd6-1d88e5b5dd81" contextRef="C_87139d89-e3fd-445f-b6c1-4593f57a1d30" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">9.09</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_91024402-40ed-4fd8-982f-37b685df5c91" contextRef="C_d45858f9-5f23-4ea3-a7e2-ddac9afb63ae" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2">19.85</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share, respectively.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">175</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Restricted Stock Activity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4942759d-5603-4c11-8b85-e84d5218caae" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s RSAs and RSUs were summarized as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:69.706%;"></td>
        <td style="width:1.36%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.302%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.552%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:14.081%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="4" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted Average Grant Date Fair Value Per Share</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RSU</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RSU</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6704d525-c588-4689-a7c0-3714cabd20aa" contextRef="C_c9e8dc36-972e-4533-bbcc-9f347a84b7dc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,271,334</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_16ccd51f-af75-4394-a8b0-141c91a2da08" contextRef="C_c9e8dc36-972e-4533-bbcc-9f347a84b7dc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">59.93</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_53aa4a65-fb91-4982-b68a-3b3202517ade" contextRef="C_ce26a70b-eafc-47b8-8306-b96c9e3a25d4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,097,128</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e029ea6c-ce1f-4ad1-a6a2-453624054d22" contextRef="C_ce26a70b-eafc-47b8-8306-b96c9e3a25d4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">27.87</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5e3e7b4b-aea4-405d-aedb-98141bcbe77d" contextRef="C_ce26a70b-eafc-47b8-8306-b96c9e3a25d4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">349,496</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5638643c-2a1d-4b16-8dc7-ab1fc4853c09" contextRef="C_ce26a70b-eafc-47b8-8306-b96c9e3a25d4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">58.26</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_40c0134d-0f6c-42f6-81f4-cd44bbfc4e39" contextRef="C_ce26a70b-eafc-47b8-8306-b96c9e3a25d4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">349,788</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_010cc1f1-81ff-4cdd-9d06-186362b20b3b" contextRef="C_ce26a70b-eafc-47b8-8306-b96c9e3a25d4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">40.86</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested as of December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_28b16e95-353d-42a5-9855-3519196661b9" contextRef="C_2aa5b5ab-23ab-4d0b-881f-3bccc42774eb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">2,669,178</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_66070611-8ea8-4a06-a223-8fac37c3d5c7" contextRef="C_2aa5b5ab-23ab-4d0b-881f-3bccc42774eb" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">37.46</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The unvested shares of RSUs have not been included in the shares issued and outstanding.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, there was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_66ef8f50-18a4-4924-a8c5-f1ee137eeb05" contextRef="C_b432db30-4d2c-4ea5-b2ca-fe2523b09386" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">77.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of total unrecognized compensation cost related to unvested restricted stock units, all of which is expected to be recognized over a remaining weighted-average period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8dfc9017-0160-4700-af33-57eadfb13a6b" contextRef="C_ae72cfe1-e779-40b7-9892-e8d69ca5e6f9" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.8</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock-Based Compensation Expense</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation is recognized on a straight-line basis over the requisite service period, which is generally the vesting period. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_be7a83fd-5080-4d1c-9760-f12226eb8a62" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" escape="true" continuedAt="F_be7a83fd-5080-4d1c-9760-f12226eb8a62_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table sets forth the total stock-based compensation expense for all awards granted to employees and the ESPP in the consolidated statements of operations: </span></ix:nonNumeric></span><span style=""></span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:continuation id="F_be7a83fd-5080-4d1c-9760-f12226eb8a62_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.136%;"></td>
        <td style="width:1.358%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.821%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.369%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.833%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.369%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.112%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7ea02975-69cf-4149-a039-e7eebdf90dba" contextRef="C_ca130bf4-8380-4419-9f23-7747d3b7b6f9" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">53,153</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b6ac1b88-1393-479b-8595-2f6ee04d5801" contextRef="C_ed2fc9b2-d46f-45fd-a059-f990d15eff81" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">42,554</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7b4f6790-50d0-45fb-8780-2ecd5f1dcbda" contextRef="C_ff18ae7e-33f9-49e0-b7ad-17646042d12e" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,663</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Selling, general and administrative</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_138f8900-5a12-4586-99e8-26a2f80b1bf3" contextRef="C_226affc5-a26a-4685-b939-df0a4de23d15" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">48,929</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_88d83408-1a76-4e12-b4e4-f54a36835773" contextRef="C_2a70a582-48c1-408b-b426-be7b95e3333e" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">41,230</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_07aa31a0-61ad-40d1-93e9-60cee186e84c" contextRef="C_bf980098-c647-4144-87a4-a5feba093982" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,937</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total stock-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_387229d3-b5d1-4d68-9c42-50311346c78f" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">102,082</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_20b1a8e3-f474-46e2-9890-109e5327fc34" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">83,784</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e3d5a913-63c9-4fde-b4c2-fa2d906a1c56" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27,600</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_aca4afa5-2d31-4ad9-b27b-0c7e69c7afc6" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:EarningsPerShareTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">12.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net Income (Loss) Per Share</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></div></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic net income (loss) per common share is computed by dividing the net income (loss) by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net income (loss) per common share is computed by dividing the net income (loss) by the sum of the weighted-average number of common shares outstanding during the period plus any potential dilutive effects of common stock equivalents outstanding during the period calculated in accordance with the treasury stock method. For periods that the Company was in a net loss position, basic net loss per share is the same as diluted net loss per share as the inclusion of all potential common securities outstanding would have been anti-dilutive. The following is a calculation of the basic and diluted net income per share (in thousands, except share and per share data):</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_3bde2ec7-b0df-4014-b8bf-5e31fec84104" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;">&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.361%;"></td>
        <td style="width:1.506%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.574%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.506%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.574%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.506%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.974%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net income (loss), basic and diluted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_122029e7-13a6-4728-9e5d-01abbe20ee65" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">515,837</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c41bd841-28e5-4a88-8051-9dc1161e8e0b" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">528,584</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_359aaffc-58b8-496f-bfd0-399ede2e9234" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">298,665</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average shares outstanding, basic</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a4ba9a5a-ffb2-43d7-aeb2-0756252355a0" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">132,606,767</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6a56330e-a9e6-43b7-bd24-4a158f502519" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">129,884,967</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_caf9c47f-c53c-4c75-85ad-03d34b388411" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">119,159,424</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average effect of dilutive securities:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options to purchase common stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f36d87aa-2fad-4c70-8662-253bbac15b1c" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">2,130,212</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_55d064dc-623f-4477-8048-484a38283744" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">3,513,438</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5a02ec2e-d045-444c-b2d2-7eae86f790f4" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" unitRef="U_shares" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted shares subject to future vesting</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e99aa4ad-43a2-4fdb-98a5-599ec0019f0c" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="vir:IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">73,851</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_21b1cf19-919d-4c22-b3fd-4c5329e5f269" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="vir:IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">35,488</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cb0e78d3-ea1a-4d61-bfa0-2abdcd3b5ac8" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="vir:IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting" unitRef="U_shares" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares to purchase under Employee Stock Purchase Plan</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7e1edb57-b6a8-427e-b192-3ece3f15e6ea" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="vir:IncrementalCommonSharesAttributabletoShareBasedPaymentArrangementsEmployeeStockPurchasePlan" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">78</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e38a967f-d8f0-48ee-a48e-edf85cc7b50e" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="vir:IncrementalCommonSharesAttributabletoShareBasedPaymentArrangementsEmployeeStockPurchasePlan" unitRef="U_shares" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b5047153-8ec2-4f3b-a05c-3977013a07a0" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="vir:IncrementalCommonSharesAttributabletoShareBasedPaymentArrangementsEmployeeStockPurchasePlan" unitRef="U_shares" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contingently issuable shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e79aeba9-713a-4564-b62a-4aa91c4671bd" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:IncrementalCommonSharesAttributableToContingentlyIssuableShares" unitRef="U_shares" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_680406a6-f1bb-40af-80d2-2068732dd20d" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:IncrementalCommonSharesAttributableToContingentlyIssuableShares" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">3,233</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dcd565b6-ff27-4d54-b440-ce2f03bbb33f" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:IncrementalCommonSharesAttributableToContingentlyIssuableShares" unitRef="U_shares" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average shares outstanding, diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_81f1da48-f9c8-4bef-88b2-1c733b4a55d8" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">134,810,908</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_11d82071-0c42-483c-8d65-6467c5e4d6c2" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">133,437,126</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_662c6730-3b9a-4952-88da-314f9f5263d5" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">119,159,424</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net income (loss) per share, basic</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_591ca7a2-204e-422d-86c4-81940acc1f07" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">3.89</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f84898cf-aede-41a3-a2d9-688a3b21716c" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">4.07</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cdd630dd-6193-4778-860e-c28cf09cc1a5" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">2.51</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net income (loss) per share, diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0d630472-5ff4-4067-9ff0-1e8ba867894f" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">3.83</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3c033b04-491e-40ec-8784-a916893b9190" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" format="ixt:numdotdecimal">3.96</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f4c66a4b-245d-4a2b-af1e-9b1f0ef55b48" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">2.51</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">176</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude></ix:nonNumeric></div><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5b7af926-408c-4472-90c2-b09c2b2f9a66" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:58.205%;"></td>
        <td style="width:1.068%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.735%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.058%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.735%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.058%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.141%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options issued and outstanding</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2c34e898-16bb-4220-ad40-b4dd79157384" contextRef="C_91be3be0-e317-45a0-837e-46e0bcedc91e" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">8,853,734</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c9bbca75-414b-4c39-bae0-adc4c0f6d434" contextRef="C_bdb11187-f9e0-4206-b870-fc0fe6a80046" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">5,764,308</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_46f76340-0004-4058-a27f-ed841eb85581" contextRef="C_df66ba80-8dcb-4c94-abeb-511320bb1f34" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">9,798,282</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted shares subject to future vesting</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9b7419fc-1461-438e-ad73-d787edc63851" contextRef="C_112ed8a7-7988-46af-99b9-84ca6fe5334e" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">2,646,748</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a4f72946-c2d9-4963-baee-9b63fe0475ad" contextRef="C_03bf1b7d-b075-4a4b-80d2-af36c3cd0aac" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">1,088,304</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ded91f09-a12f-41b9-9ed1-181305293e7e" contextRef="C_11e2fb59-6582-4888-956d-443f42d7adbb" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">89,261</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Warrants to purchase common stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_62407461-bffd-4222-8c16-a36154398388" contextRef="C_2a4a265d-bb0f-4164-81c2-3cfe9f2c5fed" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0bcf38ed-f3d7-4f43-934a-8575289f9181" contextRef="C_981e1dc9-76fd-4fe4-a6ef-def1bcdbc1e7" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_11d232f1-9104-4187-98b3-d11ca09e9c35" contextRef="C_053e3050-3042-4c21-b384-4dbc933b1860" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c538f673-1ac9-4344-a29a-5105fcc5faa0" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">11,500,482</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7a8af2f4-387a-4fe1-880c-c79055139419" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">6,852,612</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0606f13f-b4f8-4a10-928a-4eae5bb33715" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">9,887,543</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8854076d-885b-4b36-aa8d-7e43ae86e1b6" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">13.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Defined Contribution Plan </span></div></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company sponsors a 401(k) retirement savings plan for the benefit of its employees. Eligible employees may contribute a percentage of their compensation to this plan, subject to statutory limitations. The Company made contributions to the plan for eligible participants, and recorded contribution expenses of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4ed6551e-821b-4837-bbd3-d5e62a34907e" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:DefinedContributionPlanCostRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0039c32b-1143-4ee8-9dd6-ac678dc8da7a" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:DefinedContributionPlanCostRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_245a4b54-7e70-4e3a-86da-e3220174e4de" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:DefinedContributionPlanCostRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the years ended December 31, 2022, 2021 and 2020, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">177</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VIR BIOTECHNOLOGY, INC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_152db799-0a6e-4e8c-b9e1-b2957411a180" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true"><div style="text-indent:0.0%;display:flex;margin-top:8.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">14.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income Taxes </span></div></div><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_88e31b66-fc59-48f8-a423-55c776809395" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income (loss) before provision for income taxes consists of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.739%;"></td>
        <td style="width:1.281%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.587%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.281%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.752%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.281%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.081%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Domestic</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_22ddb718-ba83-4677-97d0-1163fd16bb9c" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">692,445</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_355c6671-0224-418d-9c34-8bbe4c73fd00" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">535,989</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_236c6ce0-ffd5-43fb-a9b4-7fa64005feed" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">309,697</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Foreign</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3c17e166-1f89-4f01-b72e-d7cd95722f98" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">61,835</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_622d4173-9b74-49ff-affa-dfb3f80ee19f" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,813</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ea9bc6d0-96f4-4639-acbe-420c1cf7f5ae" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,086</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total income (loss) before provision for income taxes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_39a6860d-2e5d-49ae-bde5-7021c9b88c9c" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">754,280</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8b816b34-7664-4dad-86ce-f469bcb7dac9" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">549,802</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_20937271-399a-41eb-86b4-d95358138178" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">298,611</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_1da36aff-a27d-4ca5-9eb0-85e0776b4168" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The components of income tax expense consist of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:37.715%;"></td>
        <td style="width:2.141%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:16.708%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:2.141%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:16.456%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:2.141%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:16.697%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2d5774ba-bca4-408a-89ea-bff1bec4a569" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">238,550</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d4fb6ad7-71e7-4dff-9b7c-4f915b3ed48c" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,526</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c704e193-ee6d-4f51-8e32-b6fa6d488653" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ef57ffb8-e707-49ff-b61a-17c5f80900ab" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,432</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c52845d4-514f-4380-bff3-c6a13880d6d4" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">105</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b8bf2123-cd42-4ae2-8433-0c28c78a9c60" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Foreign</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8bd1e07c-dd8f-4263-8041-20339343ad41" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:CurrentForeignTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,647</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_04690a59-b611-441f-a74a-3588db8f6fd3" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:CurrentForeignTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,401</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3c6aba07-0bf9-4cc4-9be6-3dc37f647367" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:CurrentForeignTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">106</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_78fcf687-7104-4748-8c29-d586aaa46040" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">253,629</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_356da162-7b4a-4e31-9730-6dfb1ff81775" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,032</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0cf58def-602b-401c-a0c8-ec79a8d832e5" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">106</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ae749f7a-7828-45c5-82a5-2b9272e38ea8" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">15,186</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_955d7dec-3516-48e3-ba46-0157eeeb6176" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,186</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_66db909c-cd6e-4f28-8208-950901361b98" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">21</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_91d27e81-9b74-4046-af9d-3404fbce9c87" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2e2c18b2-8b14-4c6c-82c0-911ff623242e" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e523422a-9b87-4ddf-8f61-c903f5d2bfec" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">31</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0bed4393-ffa1-435d-a2a2-2245f7773703" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">15,186</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7936ac71-714c-4ad5-9ddf-3f6d2cdcbc69" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,186</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_856a7da9-7532-41b5-8b2d-3a4cd39e16df" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">52</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Provision for income taxes</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5a3cd632-b4c4-4af7-aeec-4416b305e2e9" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">238,443</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ef31a209-d82a-4a12-a46f-79a158f7cbed" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21,218</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_74a7f82f-d9cd-46b0-8ba5-34ae917ac65b" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">54</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8d7b8886-4852-476c-9b1e-1ad811c771d2" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A reconciliation between the expected income tax provision at the federal statutory rate and the reported income tax expense is as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.221%;"></td>
        <td style="width:1.39%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:14.771%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.39%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:14.771%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.39%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:14.07%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. federal statutory income tax rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_206da469-5288-49c2-8018-f06ffd7c2e23" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_c9537cf4-d25c-46a2-96da-d86088d2d49b" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2731fe3d-7797-4fea-bc86-6ad5359484c1" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Foreign tax at less than federal statutory rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6656e810-81f4-445a-956d-e0b4cb1ba1bf" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b0e566fa-51df-4ede-8a06-a7e87fe4f4e4" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bcc24e01-c6f5-4f1f-83f4-a53feeae0e27" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.9</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prior year tax rate adjustment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3dba834c-a191-44bb-98e2-01f6991f2850" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e0c0063e-ba83-4139-a04d-1859db941301" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7b118604-3d1a-400f-a1d2-908c92203b01" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">1.9</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State taxes, net of federal benefit</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a04795c6-fe41-4ecd-bdbe-84f920cdacba" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_905fa70b-c5bd-4207-a018-56cfe5ad263e" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_68040c28-4533-40ac-b23e-d0a1fe203a96" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">2.7</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development tax credit</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_22cf7147-460a-46b8-8bac-bb97b28f6e28" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">2.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e6160158-e81b-434b-8caa-dc3a4d76c1c8" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">1.6</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ac7388f4-6cec-48e1-8a31-ced9909762cb" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">1.8</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Permanent items</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fc418fa2-267a-4280-a280-cfa25ebc0958" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="vir:EffectiveIncomeTaxRateReconciliationPermanentItemsPercent" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">7.4</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_30cf30d3-8cef-4007-b94b-eca589906d32" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="vir:EffectiveIncomeTaxRateReconciliationPermanentItemsPercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">1.8</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4cf089a6-4745-4437-9aba-5ebc232dc1e8" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="vir:EffectiveIncomeTaxRateReconciliationPermanentItemsPercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">1.3</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cd515e16-c63a-4ed2-9973-337edb601fc2" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">21.1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dc0480b6-ecba-4081-a6d1-7da82501d62c" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">17.9</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_645d4f48-00e3-4c1b-9143-a15992739c92" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">25.3</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_25b2127a-0f46-456f-9d87-6a03fa403051" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">0.9</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3f7510a5-b6c1-4ad3-b7b4-81ae641115a9" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_d322d900-bf3d-46bb-83a0-4d5a40261266" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">0.5</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effective income tax rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_94b50a57-c499-4139-af57-afc459de5986" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">31.6</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aca2cc4f-00ec-4156-a4c6-e4e721820bb7" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">3.9</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_752a51d6-1ffc-4055-8bb7-d5eee17cd6fb" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">178</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0926d2a6-5432-4c57-a1a2-f49866a5d5f3" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The tax effects of temporary differences that give rise to significant portions of the Company&#x2019;s deferred tax assets and liabilities as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021, are related to the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:58.692%;"></td>
        <td style="width:2.103%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:16.569%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:2.103%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:16.534%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_60e0644e-302a-4138-a463-f6b0626e591d" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,793</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_aea45f96-4e66-4651-abba-2e2787455aec" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,030</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development tax credit carryforward</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_90143095-a498-4b27-8c6a-e1c8e82a5793" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,123</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_919124f5-b6a8-4d21-92e5-035cb46bf5d1" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,375</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity compensations</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b2e4150f-971d-4314-9547-a64bf5d185ca" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">24,250</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_a24f6e5e-2bc7-416b-a5d0-30f620c62029" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,065</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reserves and accruals</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ef9e0491-1ffd-4616-8647-b6d5e467bc16" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">85,977</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ef91281e-6cad-4180-898a-2c061e2db72e" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,115</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Capitalized research and development</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_24efea2c-9b9c-497c-a43f-d33890e18322" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:ResearchAndDevelopmentInProcess" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">75,680</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_834d23e5-1219-459d-b581-b4396e976b21" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:ResearchAndDevelopmentInProcess" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_de559909-ef26-41fc-a121-536c54f2a3f9" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="vir:DeferredTaxAssetsLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,553</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_785ff286-ca76-457f-a662-357ab8e5323d" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="vir:DeferredTaxAssetsLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">28,612</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intangible assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_97dd83b0-0024-4c34-a47f-95a0e67cf33b" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,348</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_92a296c5-9ec8-4eb9-a02d-1dd3d1bddb83" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19,657</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_50d50eb0-bb85-46a1-90fd-60d53bc636a1" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">249,724</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_63b9d7c7-f5e2-43de-a3a0-e46a47fb9b23" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">96,854</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized gain on investments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_085fb317-fa19-4ceb-a478-6d6864adc43e" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,880</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_62806d81-dc2a-41b1-8e49-61c99922d7d4" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">30,170</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ROU assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_50a1fff7-a141-4c93-ae9e-849205ea60aa" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="vir:DeferredTaxLiabilitiesRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20,834</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3265c199-2f91-4390-aacb-a946b2cc49de" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="vir:DeferredTaxLiabilitiesRightOfUseAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">28,483</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6cbdda36-8f77-4a71-9302-93f16c98cb7c" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,151</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_de1f0c8b-3691-4e42-9ac6-20990ae53179" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,422</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IPR&amp;D</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fb312d93-68b3-44b5-bacb-684ed4b69db0" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="vir:DeferredTaxLiabilitiesInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,511</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_0e698373-eaf9-47ec-b7a4-e677290b9e11" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="vir:DeferredTaxLiabilitiesInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,511</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_81284f41-f083-43dd-899a-4dba292c996f" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">48,376</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_466bb986-5249-4154-8b69-ba8946c29d23" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">69,586</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_434716dc-3d55-4a8e-8a08-9d8a80c4d9f6" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">204,601</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7eaa396b-6baf-4d5c-9895-5c98a76ea77f" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">45,707</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6e85bd67-1837-479e-812f-7c4d84e7d254" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:DeferredTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,253</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b861197f-7e8a-4d0d-a279-93451155e666" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:DeferredTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,439</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Although the Company has taxable income for the year ended December 31, 2022 and 2021, it has otherwise incurred accumulated tax losses since inception. Based on the available objective evidence, the Company cannot conclude it is more likely than not that the net deferred tax assets will be fully realizable.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Accordingly, the Company has provided a valuation allowance against its net deferred tax assets. For the year ended December 31, 2022, the Company recorded a valuation allowance increase of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_8a51da04-2306-4a16-9cf6-14bc74d4014f" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">158.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, primarily based on the estimated 2022 taxable income. The valuation allowance is decreased by $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_34ff2fbd-bece-4446-a261-796b19181412" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">114.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the year ended December 31, 2021 and increased by $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_dd93f65e-495b-4c4b-aa84-1d27623b8c37" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">74.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the year ended December 31, 2020.  As of December 31, 2022, the Company has net operating loss carryforwards of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_32f9f56c-c926-4f71-affa-c2142a4620dc" contextRef="C_b8ad5282-2271-4d16-8946-c9bc284a5384" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">20.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for federal purposes and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_41172bab-5140-40d5-9964-af70614c3db7" contextRef="C_2d2b4307-0211-44cc-a6ea-58f34976c023" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">111.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for state tax purposes. If not utilized, these carryforwards will begin to expire in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ba14da5d-bd42-4777-9a23-ed57fa0620fd" contextRef="C_10a388d6-6193-4e20-a608-d5203976d818" name="vir:OperatingLossCarryforwardsExpirationBeginningYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2037</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for federal and in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_a5df8296-dc11-418e-9f92-c7ba4f345749" contextRef="C_24ffc582-325f-493e-a4b4-111a43d7f9d9" name="vir:OperatingLossCarryforwardsExpirationBeginningYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2031</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for state tax purposes. As of December 31, 2022, the Company also has net operating loss carryforwards of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_5fc02f42-5a2b-4386-9fc6-db16bf4b7627" contextRef="C_774f1d32-810d-4510-b5e3-aaafabf8e63c" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for Australian tax purposes, which have an indefinite carryforward period, and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_f65fd33c-c486-4890-a27a-14ff08477316" contextRef="C_d39ab2c8-69ae-4434-87f5-e53d359487e4" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> net operating loss carryforward for Swiss tax purposes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the Tax Reform Act of 1986, the amounts of and benefits from net operating loss carryforwards may be impaired or limited in certain circumstances. Events which cause limitations in the amount of net operating losses that the Company may utilize in any one year include, but are not limited to, a cumulative ownership change of more than 50% over a three-year period. The Company completed its Section 382 analysis as of December 31, 2022 and based on this analysis, it does not expect that the annual limitations will significantly impact its ability to utilize its net operating loss or tax credit carryforwards prior to expiration.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, the Company has research tax credit carryforwards of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6a2bd6f1-489e-4fae-b946-3371bef94363" contextRef="C_b8ad5282-2271-4d16-8946-c9bc284a5384" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_e1c3159f-86ca-4850-8051-9d66e0f2ec18" contextRef="C_2d2b4307-0211-44cc-a6ea-58f34976c023" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">15.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for federal and state tax purposes, respectively. If not utilized, the federal carryforward will expire in various amounts beginning in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f1bb6347-8486-4738-8c51-49db52826db1" contextRef="C_d8fb65c9-343c-4c85-898f-95ed557e0d7f" name="vir:OperatingLossCarryforwardsExpirationBeginningYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2036</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The California credits can be carried forward indefinitely.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:continuation id="F_292877a3-4cd7-4908-9fa7-ad79aaf0a9b4_1"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax Cuts and Jobs Act of 2017 subjects a U.S. shareholder to current tax on global intangible low-taxed income (&#34;GILTI&#34;) earned by certain foreign subsidiaries. The FASB </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Staff Q&amp;A, Topic 740 No. 5, Accounting for Global Intangible Low-Taxed Income, states that an entity can make an accounting policy election to either recognize deferred taxes for temporary differences expected to reverse as GILTI in future years or provide for the tax expense related to GILTI in the year the tax is incurred. The Company has elected to recognize the tax on GILTI as a period expense in the period the tax is incurred.</span></p></ix:continuation></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Uncertain Tax Positions</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022 and 2021, the Company had an unrecognized tax benefit balance of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_fffd2f93-ccdb-4c6c-9a54-a81eb199ca96" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_bb7bde7c-bb8f-47c0-a781-33ff5830d0a5" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">7.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, related to transfer pricing and research and development tax credits. A portion of the unrecognized tax benefits as of December 31, 2022, if recognized, would reduce the Company&#x2019;s effective tax rate by </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ebc1391d-da9f-46b9-a482-40fde1c866ae" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="vir:UnrecognizedTaxBenefitsIfRecognizedWouldReduceEffectiveTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other unrecognized tax benefits as of</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">179</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notes to Consolidated Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31, 2022, if recognized, would be in the form of net operating loss and tax credit carryforwards, which attract a full valuation allowance offset, and would not reduce the Company&#x2019;s effective tax rate. There are no provisions for which it is reasonably possible that the total amounts of unrecognized tax benefits will significantly increase or decrease within 12 months of the reporting date. Because the statute of limitations does not expire until after the net operating loss and credit carryforwards are actually used, the statutes are still open on calendar years ending December 31, 2017 forward for federal and state purposes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company did </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_7d1001c0-1478-4d58-8bb9-9d13fba68970" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_d912ae25-e52e-4aa6-a8fe-ab2312f7b92d" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_93ec68af-898e-4d11-b782-2dd819477ebb" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t recognize any expense for interest and penalties related to uncertain tax positions during 2022, 2021 and 2020, and the Company does </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_cc5cfa11-afa3-46fc-946d-2de08dec1215" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t have any amounts related to interest and penalties accrued at December 31, 2022. The Company files U.S. federal, state, Switzerland and Australia tax returns. The Company&#x2019;s tax years remain open for all years. As of December 31, 2022, the Company was not under examination by the Internal Revenue Service or any state or foreign tax jurisdiction.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_2daab237-bb19-4f0b-8dda-3d42af2b9bf4" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" escape="true"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A reconciliation of the beginning and ending amounts of the liability for uncertain tax positions is as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.843%;"></td>
        <td style="width:1.27%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.085%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.282%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.085%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.282%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.152999999999999%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross unrecognized tax benefits at January 1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_3e90cfd8-326b-4e24-8c5c-d0fab380e0fb" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,422</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_6dffdadb-eea0-410c-adca-b7bc6d0041d7" contextRef="C_da5feba6-e631-4bec-b33d-106ac3401870" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,877</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ef487356-c0f9-4ac1-a7be-a25e36672367" contextRef="C_ce64793d-668a-40e8-af07-6ebdbdd93828" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,725</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Addition for tax positions taken in the prior years</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_1d0ec088-a8f1-45e3-a546-63f0cbcf4426" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_4d7a1162-0d5a-4202-9da0-70ceeba57cbb" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_871e8816-4703-4ae5-bacf-7bd07a5bc600" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reduction for tax positions taken in the prior years</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_ac69dddf-3895-4e5c-8506-5c59fc542da2" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_78632a09-8157-4ddd-805f-de603f61e13d" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">62</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_55d83caa-402f-468e-b552-7e639bedab6d" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">588</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Addition for tax positions taken in current year</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2a55186e-49ea-483d-a90b-745e0df44d54" contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,228</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_401c92fd-10c9-48e1-900d-0853323d9dda" contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,607</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_2943f177-1279-4f00-8cb8-a88533364586" contextRef="C_94806f35-4a90-434e-acce-cb420888cb77" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,740</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross unrecognized tax benefits at December 31</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_b7615371-f18a-434f-b74f-c1b9ce558ffa" contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,638</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_617e2317-404e-48f4-834f-22d737c46526" contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,422</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><ix:nonFraction id="F_9c678344-7f0a-48af-a742-16e423af8296" contextRef="C_da5feba6-e631-4bec-b33d-106ac3401870" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,877</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">180</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9_changes_in_disagreements_with_acc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9. Changes in and Disagreements With Accou</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ntants on Accounting and Financial Disclosure.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9a_controls_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9A. Controls </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and Procedures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Evaluation of Disclosure Controls and Procedures.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our management, with the participation and supervision of our Chief Executive Officer and our Chief Financial Officer, have evaluated our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e)) under the Exchange Act as of the end of the period covered by this Annual Report on Form 10-K. Based on that evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that, as of the end of the period covered by this Annual Report on Form 10-K, our disclosure controls and procedures were effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Management&#x2019;s Report on Internal Control Over Financial Reporting</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f) under the Exchange Act). Our internal control over financial reporting is designed under the supervision of our Chief Executive Officer and Chief Financial Officer to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with generally accepted accounting principles. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management assessed the effectiveness of our internal control over financial reporting based on the framework set forth by the Committee of Sponsoring Organizations of the Treadway Commission (&#x201c;COSO&#x201d;) in Internal Control&#x2014;Integrated Framework (2013 Framework). Based on our assessment, we concluded that our internal control over financial reporting was effective as of December 31, 2022.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The effectiveness of our internal control over financial reporting has been audited by Ernst &amp; Young LLP, an independent registered public accounting firm, as stated in their attestation report herein, which expresses an unqualified opinion on the effectiveness of our internal control over financial reporting as of December 31, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Changes in Internal Control Over Financial Reporting</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Remediation of Previously Reported Material Weakness</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A material weakness, as defined in Rule 12b-2 under the Exchange Act, is a deficiency, or combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of annual or interim financial statements will not be prevented or detected on a timely basis.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with our preparation of our financial statements as of and for the quarter ended June 30, 2022, we identified a material weakness in our internal control over financial reporting. With respect to the determination of the estimated profit-sharing amount to be constrained under the definitive collaboration agreement dated June 9, 2020, or the 2020 GSK Agreement, between the Company and Glaxo Wellcome UK Limited and GlaxoSmithKline Biologicals S.A. (individually and collectively referred to as GSK), our management review control procedures were not designed in a manner that would ensure relevant information and key judgments are obtained and analyzed at the appropriate level of precision, on a timely basis, between non-financial personnel and those</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">181</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">responsible for financial reporting as of June 30, 2022. Management concluded that the control deficiency represented a material weakness as of June 30, 2022.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Following the identification of the material weakness in our internal controls over financial reporting as of June 30, 2022, we prepared a remediation action plan and implemented that plan to improve the controls related to the determination of the estimated profit-sharing amount to be constrained under the 2020 GSK Agreement, which included the following actions:</span></p>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We enhanced communication procedures and the timeliness of those procedures between non-financial personnel and those responsible for financial reporting related to relevant business information. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></div></div>
  <div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We designed specific procedures, at the appropriate level of precision, to review and ensure the completeness of the Company&#x2019;s analysis, including the analysis of material assumptions, resulting in comprehensive documentation supporting management&#x2019;s judgments and ensuring the completeness and the accuracy of the underlying information. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the fourth quarter of 2022, we successfully completed the testing necessary to conclude that the material weakness has been remediated. The material weakness had no impact on any amounts reported in the financial statements for the fiscal year ended December 31, 2022 or for any previous period.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There have been no changes in our internal control over financial reporting that occurred during our fourth fiscal quarter ended December 31, 2022 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Report of Independent Registered Public Accounting Firm</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To the Shareholders and the Board of Directors of Vir Biotechnology, Inc.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Opinion on Internal Control Over Financial Reporting</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We have audited Vir Biotechnology, Inc.&#x2019;s internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control&#x2014;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Vir Biotechnology, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2022, based on the COSO criteria.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2022 and 2021, the related consolidated statements of operations, consolidated statements of comprehensive income (loss),  consolidated statements of stockholders&#x2019; equity and cash flows for each of the three years in the period ended December 31, 2022, and the related notes and our report dated February 28, 2023 expressed an unqualified opinion thereon.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basis for Opinion</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#x2019;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#x2019;s Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company&#x2019;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">182</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Definition and Limitations of Internal Control Over Financial Reporting</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A company&#x2019;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#x2019;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#x2019;s assets that could have a material effect on the financial statements.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Ernst &amp; Young LLP</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">San Mateo, California</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 28, 2023</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9b_or_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9B. Other</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9c_disc_re_foreign_jurisdiction"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9C. Disclosu</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">re Regarding Foreign Jurisdictions that Prevent Inspections.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Not applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">183</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_iii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> III</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_10_directors_executive_ficers_corpo"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 10. Directors, Executive Off</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">icers and Corporate Governance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by this item is incorporated by reference to the information set forth in the sections titled &#x201c;Proposal 1&#x2014;Election of Directors,&#x201d; &#x201c;Information Regarding the Board of Directors and Corporate Governance&#x2014;Code of Business Conduct and Ethics,&#x201d; &#x201c;Delinquent Section 16(a) Reports,&#x201d; &#x201c;Information Regarding the Board of Directors and Corporate Governance&#x2014;Nominating and Corporate Governance Committee&#x201d; and &#x201c;Information Regarding the Board of Directors and Corporate Governance&#x2014;Audit Committee&#x201d; in our definitive proxy statement for our 2023 Annual Meeting of Stockholders, or the Proxy Statement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_11_executive_compensation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 11. Executiv</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">e Compensation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by this item is incorporated by reference to the information set forth in the sections titled &#x201c;Executive Compensation&#x201d; (except for the section titled &#x201c;Executive Compensation&#x2014;Pay Versus Performance&#x201d;) in our Proxy Statement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_12_security_ownership_certain_benef"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 12. Security Ownership of Certain Beneficial Own</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ers and Management and Related Stockholder Matters.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by this item is incorporated by reference to the information set forth in the sections titled &#x201c;Security Ownership of Certain Beneficial Owners and Management&#x201d; and &#x201c;Executive Compensation&#x2014;Equity Compensation Plan Information&#x201d; in our Proxy Statement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_13_certain_relationships_related_tr"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 13. Certain Relationships and Related </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Transactions, and Director Independence.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by this item is incorporated by reference to the information set forth in the sections titled &#x201c;Information Regarding the Board of Directors and Corporate Governance&#x2014;Independence of the Board of Directors&#x201d; and &#x201c;Transactions with Related Persons&#x201d; in our Proxy Statement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_14_principal_accounting_fees_servic"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 14. Principal Accoun</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ting Fees and Services.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information required by this item is incorporated by reference to the information set forth in the section titled &#x201c;Proposal 3&#x2014;Ratification of Selection of Independent Registered Public Accounting Firm&#x201d; in our Proxy Statement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">184</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_iv"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PART</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> IV</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_15_exhibits_financial_statement_sch"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 15. Exhibits, Financ</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ial Statement Schedules.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The financial statements, financial statement schedules and exhibits filed as part of this Annual Report on Form 10-K are as follows:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(a)(1) Financial Statements</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reference is made to the financial statements included in Item 8 of Part II hereof.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(a)(2) Financial Statement Schedules</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All financial statements schedules are omitted because the required information is included in the consolidated financial statements or the notes thereto included in Item 8 of Part II hereof.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(a)(3) Exhibits</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:21.278%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:77.722%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519268465/d820601dex31.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Certificate of Incorporation of the Company (incorporated herein by reference to Exhibit 3.1 to the Company&#x2019;s Current Report on Form 8-K (File No. 001-39083), filed with the SEC on October 16, 2019).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519268465/d820601dex32.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Bylaws of the Company (incorporated herein by reference to Exhibit 3.2 to the Company&#x2019;s Current Report on Form 8-K (File No. 001-39083), filed with the SEC on October 16, 2019).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519257981/d755217dex41.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Common Stock Certificate of the Company (incorporated herein by reference to Exhibit 4.1 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 30, 2019).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000119312519236592/d755217dex42.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Investors&#x2019; Rights Agreement, by and among the Company and certain of its stockholders, dated November 29, 2017 (incorporated herein by reference to Exhibit 4.2 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000156459020013194/vir-ex44_1069.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description of Capital Stock (incorporated herein by reference to Exhibit 4.4 to the Company&#x2019;s Form 10-K (File No. 001-39083), filed with the SEC on March 26, 2020).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.1+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519267739/d809856dex48.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vir Biotechnology, Inc. 2019 Equity Incentive Plan, (incorporated herein by reference to Exhibit 4.8 to the Company&#x2019;s Form S-8 (File No. 333-234212), filed with the SEC on October 15, 2019).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.2+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519267739/d809856dex411.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2019 Employee Stock Purchase Plan (incorporated herein by reference to Exhibit 4.11 to the Company&#x2019;s Form S-8 (File No. 33-234212), filed with the SEC on October 15, 2019).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.3+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex101.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Indemnity Agreement by and between the Company and its directors and executive officers (incorporated herein by reference to Exhibit 10.1 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.4+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex103.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forms of Option Grant Notice and Option Agreement under Vir Biotechnology, Inc. 2019 Equity Incentive Plan, (incorporated herein by reference to Exhibit 10.3 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.5+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000156459021008915/vir-ex105_2690.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form of Restricted Stock Unit Grant Notice and Unit Award Agreement under Vir Biotechnology, Inc. 2019 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.5 to the Company's Form 10-K (File No. 001-39083), filed with the SEC on February 25, 2021).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.6+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex105.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vir Biotechnology, Inc. 2016 Equity Incentive Plan, as amended (incorporated herein by reference to Exhibit 10.5 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">185</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:21.278%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:77.722%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.7+</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex106.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forms of Incentive Stock Option Notice and Agreement, Non-Qualified Stock Option Notice and Agreement, Restricted Stock Agreement, Restricted Stock Agreement and Restricted Stock Purchase Agreement under the Vir Biotechnology, Inc. 2016 Equity Incentive Plan, as amended (incorporated herein by reference to Exhibit 10.6 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.8+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="vir-ex10_8.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-Employee Director Compensation Policy.</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.9+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex109.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Employment Letter Agreement between the Company and George Scangos, dated August 27, 2019 (incorporated herein by reference to Exhibit 10.9 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.10+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex1010.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Employment Letter Agreement between the Company and Howard Horn, dated August 27, 2019 (incorporated herein by reference to Exhibit 10.10 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.11+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex1012.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Employment Letter Agreement between the Company and Phil Pang, dated August 27, 2019 (incorporated herein by reference to Exhibit 10.12 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.12+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex1014.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Employment Letter Agreement between the Company and Herbert Virgin, dated September 3, 2019 (incorporated herein by reference to Exhibit 10.14 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.13+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000156459020052966/vir-ex103_150.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employment Letter Agreement between the Company and Steven Rice, dated August 22, 2019 (incorporated herein by reference to Exhibit 10.3 to the Company&#x2019;s Form 10-Q (File No. 001-39083), filed with the SEC on November 10, 2020).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.14+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000156459020052966/vir-ex104_149.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Promotion Letter Agreement between the Company and Steven Rice, dated July 30, 2020 (incorporated herein by reference to Exhibit 10.4 to the Company&#x2019;s Form 10-Q (File No. 001-39083), filed with the SEC on November 10, 2020).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.15+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000156459021024948/vir-ex106_307.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Employment Letter Agreement between the Company and Ann (Aine) M. Hanly, dated May 4, 2021 (incorporated herein by reference to Exhibit 10.6 to the Company&#x2019;s Form 10-Q (File No. 001-39083), filed with the SEC on May 6, 2021).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.16+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000095017022007811/vir-ex10_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Employment Agreement between Humabs BioMed SA (f/k/a Humabs Holding GmbH) and Johanna Friedl-Naderer, dated December 16, 2021 (incorporated herein by reference to Exhibit 10.1 to the Company's Form 10-Q (File No. 001-39803), filed with the SEC on May 5, 2022).</span></a><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.17+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="vir-ex10_17.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Agreement on Transfer of Employment and Amendment of Employment Agreement between Humabs BioMed SA, Vir Biotechnology International GmbH and Johanna Friedl-Naderer, dated December 19, 2022.</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.18+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex1015.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vir Biotechnology, Inc. Change in Control and Severance Benefit Plan (incorporated herein by reference to Exhibit 10.15 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.19&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex1016.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaboration, Option, and License Agreement between the Company and Brii Biosciences Limited (previously named BiiG Therapeutics Limited), dated May 23, 2018 (incorporated herein by reference to Exhibit 10.16 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.20&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex1017.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaboration and License Agreement between the Company and Alnylam Pharmaceuticals, Inc., dated October 16, 2017 (incorporated herein by reference to Exhibit 10.17 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:41.05pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.21&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000156459020013194/vir-ex1019_1067.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment No.1 to the Collaboration and License Agreement between the Company and Alnylam Pharmaceuticals, Inc., dated December 17, 2019 (incorporated herein by reference to Exhibit 10.19 to the Company&#x2019;s Form 10-K (File No. 001-39083), filed with the SEC on March 26, 2020).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.22&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000156459020013194/vir-ex1020_1312.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment No.2 to the Collaboration and License Agreement between the Company and Alnylam Pharmaceuticals, Inc., dated March 3, 2020 (incorporated herein by reference to Exhibit 10.20 to the Company&#x2019;s Form 10-K (File No. 001-39083), filed with the SEC on March 26, 2020).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">186</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:21.278%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:77.722%;"></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.23&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000119312520187304/d945110dex1021.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment No.3 to the Collaboration and License Agreement between the Company and Alnylam Pharmaceuticals, Inc., dated April 1, 2020 (incorporated herein by reference to Exhibit 10.21 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-239689), filed with the SEC on July 6, 2020).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:15.1pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.24&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000156459021008915/vir-ex1024_828.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Letter Agreement between the Company and Alnylam Pharmaceuticals, Inc., dated December 23, 2020 (incorporated herein by reference to Exhibit 10.24 to the Company's Form 10-K (File No. 001-39083), filed with the SEC on February 25, 2021).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.25&#134;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex1018.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common Stock Issuance Agreement between the Company and Alnylam Pharmaceuticals, Inc., dated October 16, 2017 (incorporated herein by reference to Exhibit 10.18 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.26&#134;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000156459020013194/vir-ex1022_1066.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment No. 1 to the Common Stock Issuance Agreement between the Company and Alnylam Pharmaceuticals, Inc., dated December 17, 2019 (incorporated herein by reference to Exhibit 10.22 to the Company&#x2019;s Form 10-K (File No. 001-39083), filed with the SEC on March, 26, 2020).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.27&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex1019.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Letter Agreement between the Company and Alnylam Pharmaceuticals, Inc., dated November 13, 2018 (incorporated herein by reference to Exhibit 10.19 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.28&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex1020.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">License Agreement between the Company and MedImmune, LLC, dated September 7, 2018 (incorporated herein by reference to Exhibit 10.20 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.29&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000156459021008915/vir-ex1029_829.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment No. 1 to License Agreement between the Company and MedImmune, LLC, dated September 1, 2020 (incorporated herein by reference to Exhibit 10.29 to the Company's Form 10-K (File No. 001-39083), filed with the SEC on February 25, 2021).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.30&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex1021.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Second Revised and Restated Master License Agreement between the Company and Oregon Health &amp; Science University, dated August 27, 2019 (incorporated herein by reference to Exhibit 10.21 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.31&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex1022.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Letter Agreement between the Company and the stockholders of TomegaVax, Inc. set forth therein, dated September 12, 2016 (incorporated herein by reference to Exhibit 10.22 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.32&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex1023.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Agreement and Plan of Merger between the Company, Vir Merger Sub, Inc., Agenovir Corporation, and Dr. Stephen R. Quake, dated January 2, 2018 (incorporated herein by reference to Exhibit 10.23 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.33&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex1024.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securities Purchase Agreement between the Company, Humabs BioMed SA, the shareholders of Humabs set forth therein, the option-holders of Humabs set forth therein and Fortis Advisors LLC and certain Securityholders, dated August 22, 2017 (incorporated herein by reference to Exhibit 10.24 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.34&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex1026.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Grant Agreement between the Company and the Bill &amp; Melinda Gates Foundation, dated January 26, 2018 (incorporated herein by reference to Exhibit 10.26 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.35&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000156459020013194/vir-ex1031_1064.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment No. 1 to the Grant Agreement between the Company and the Bill &amp; Melinda Gates Foundation, dated April 18, 2019 (incorporated herein by reference to Exhibit 10.31 to the Company&#x2019;s Form 10-K (File No. 001-39083), filed with the SEC on March 26, 2020).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.36&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000156459020013194/vir-ex1032_1065.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment No. 2 to the Grant Agreement between the Company and the Bill &amp; Melinda Gates Foundation, dated February 24, 2020 (incorporated herein by reference to Exhibit 10.32 to the Company&#x2019;s Form 10-K (File No. 001-39083), filed with the SEC on March 26, 2020).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.37&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000156459021008915/vir-ex1038_490.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment No. 3 to the Grant Agreement between the Company and the Bill &amp; Melinda Gates Foundation, dated May 22, 2020 (incorporated herein by reference to Exhibit 10.38 to the Company's Form 10-K (File No. 001-39083), filed with the SEC on February 25, 2021).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">187</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:21.278%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:77.722%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.38&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000156459021008915/vir-ex1039_491.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment No. 4 to the Grant Agreement between the Company and the Bill &amp; Melinda Gates Foundation, dated December 8, 2020 (incorporated herein by reference to Exhibit 10.39 to the Company's Form 10-K (File No. 001-39083), filed with the SEC on February 25, 2021).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.39&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000095017021000935/vir-20210630ex10_3.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment No. 5 to the Grant Agreement between the Company and the Bill &amp; Melinda Gates Foundation, dated June 2, 2021 (incorporated herein by reference to Exhibit 10.3 to the Company's Form 10-Q (File No. 001-39083), filed with the SEC on August 5, 2021).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.40&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex1027.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Grant Agreement between the Company and the Bill &amp; Melinda Gates Foundation, dated March 16, 2018 (incorporated herein by reference to Exhibit 10.27 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.41&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000156459020013194/vir-ex1034_1063.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment No. 1 to the Grant Agreement between the Company and the Bill &amp; Melinda Gates Foundation, dated April 22, 2019 (incorporated herein by reference to Exhibit 10.34 to the Company&#x2019;s Form 10-K (File No. 001-39083), filed with the SEC on March 26, 2020).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.42&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000156459020013194/vir-ex1035_1062.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment No. 2 to the Grant Agreement between the Company and the Bill &amp; Melinda Gates Foundation, dated October 28, 2019 (incorporated herein by reference to Exhibit 10.35 to the Company&#x2019;s Form 10-K (File No. 001-39083), filed with the SEC on March 26, 2020).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.43&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000156459020039295/vir-ex1012_223.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment No. 3 to the Grant Agreement between the Company and the Bill &amp; Melinda Gates Foundation, dated May 29, 2020 (incorporated herein by reference to Exhibit 10.12 to the Company&#x2019;s Form 10-Q (File No. 001-39083), filed with the SEC on August 11, 2020).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.44&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000095017021000935/vir-20210630ex10_4.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment No. 4 to the Grant Agreement between the Company and the Bill &amp; Melinda Gates Foundation, dated June 16, 2021 (incorporated herein by reference to Exhibit 10.4 to the Company's Form 10-Q (File No. 001-39083), filed with the SEC on August 5, 2021).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.45&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000095017022002295/vir-ex10_43.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment No. 5 to Grant Agreement between the Company and the Bill &amp; Melinda Gates Foundation, dated December 8, 2021 (incorporated herein by reference to Exhibit 10.43 to the Company&#x2019;s Form 10-K (File No. 001-39083), filed with the SEC on February 28, 2022).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.46&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000095017022002295/vir-ex10_44.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Grant Agreement between the Company and the Bill &amp; Melinda Gates Foundation, dated November 5, 2021 (incorporated herein by reference to Exhibit 10.44 to the Company&#x2019;s Form 10-K (File No. 001-39083), filed with the SEC on February 28, 2022).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.47&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000095017022002295/vir-ex10_45.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Letter Agreement between the Company and the Bill &amp; Melinda Gates Foundation, dated January 12, 2022 (incorporated by reference to Exhibit 10.45 to the Company&#x2019;s Form 10-K (File No. 001-39083), filed with the SEC on February 28, 2022).</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.48</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000095017022002295/vir-ex10_46.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock Purchase Agreement between the Company and the Bill &amp; Melinda Gates Foundation, dated January 12, 2022 (incorporated herein by reference to Exhibit 10.46 to the Company&#x2019;s Form 10-K (File No. 001-39083), filed with the SEC on February 28, 2022).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.49&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000095017022002295/vir-ex10_47.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Grant Agreement between the Company and the Bill &amp; Melinda Gates Foundation, dated January 12, 2022 (incorporated herein by reference to Exhibit 10.47 to the Company&#x2019;s Form 10-K (File No. 001-39083), filed with the SEC on February 28, 2022).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.50&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex1028.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amended and Restated Exclusive License Agreement between the Company (as successor in interest to Humabs BioMed SA (f/k/a Humabs Holding GmbH)) and the Institute for Research in Biomedicine, dated December 16, 2011 (incorporated herein by reference to Exhibit 10.28 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.51&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex1029.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment to Amended and Restated Exclusive License Agreement between the Company (as successor in interest to Humabs BioMed SA (f/k/a Humabs Holding GmbH)) and the Institute for Research in Biomedicine, dated February 10, 2012 (incorporated herein by reference to Exhibit 10.29 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.52&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex1030.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exclusive License Agreement between the Company (as successor in interest to Humabs BioMed SA) and the Institute for Research in Biomedicine, dated December 16, 2011 (incorporated herein by reference to Exhibit 10.30 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">188</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:21.278%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:77.722%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.53</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex1031.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment to License Agreement between the Company (as successor in interest to Humabs BioMed SA) and the Institute for Research in Biomedicine, dated February 10, 2012 (incorporated herein by reference to Exhibit 10.31 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.54&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex1032.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment Agreement between the Company (as successor in interest to Humabs BioMed SA) and the Institute for Research in Biomedicine, dated January 29, 2018 (incorporated herein by reference to Exhibit 10.32 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.55&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex1033.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exclusive License Agreement between the Company and The Rockefeller University, dated July 31, 2018 (incorporated herein by reference to Exhibit 10.33 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.56&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex1034.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment to Exclusive License Agreement between the Company and The Rockefeller University, dated May 17, 2019 (incorporated herein by reference to Exhibit 10.34 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span></a></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.57&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000156459021008915/vir-ex1051_886.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Second Amendment to Exclusive License Agreement between the Company and The Rockefeller University, dated September 28, 2020 (incorporated herein by reference to Exhibit 10.51 to the Company's Form 10-K (File No. 001-39083), filed with the SEC on February 25, 2021).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.58&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000156459021024948/vir-ex105_306.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Third Amendment to Exclusive License Agreement between the Company and The Rockefeller University, dated March 1, 2021 (incorporated herein by reference to Exhibit 10.5 to the Company's Form 10-Q (File No. 001-39083), filed with the SEC on May 6, 2021).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.59&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex1035.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sub-License and Collaboration Agreement between the Company (as successor in interest to Humabs BioMed SA) and MedImmune, LLC, dated March 20, 2012 (incorporated herein by reference to Exhibit 10.35 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.60&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex1036.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment 1 to Sub-License and Collaboration Agreement between the Company (as successor in interest to Humabs BioMed SA) and MedImmune, LLC, dated April 19, 2013 (incorporated herein by reference to Exhibit 10.36 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.61&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex1037.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment 2 to Sub-License and Collaboration Agreement between the Company (as successor in interest to Humabs BioMed SA) and MedImmune, LLC, dated April 27, 2015 (incorporated herein by reference to Exhibit 10.37 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.62&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex1038.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment 3 to Sub-License and Collaboration Agreement between the Company (as successor in interest to Humabs BioMed SA) and MedImmune, LLC, dated December 31, 2015 (incorporated herein by reference to Exhibit 10.38 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.63&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex1039.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment 4 to Sub-License and Collaboration Agreement between the Company (as successor in interest to Humabs BioMed SA) and MedImmune, LLC, dated August 29, 2016 (incorporated herein by reference to Exhibit 10.39 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.64&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex1040.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment 5 to Sub-License and Collaboration Agreement between the Company (as successor in interest to Humabs BioMed SA) and MedImmune, LLC, dated July 15, 2017 (incorporated herein by reference to Exhibit 10.40 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.65&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex1041.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment 6 to Sub-License and Collaboration Agreement between the Company (as successor in interest to Humabs BioMed SA) and MedImmune, LLC, dated September 7, 2018 (incorporated herein by reference to Exhibit 10.41 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.66</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000119312519236592/d755217dex1042.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease Agreement between the Company and ARE-SAN FRANCISCO NO. 43, LLC, dated March  30, 2017 (incorporated herein by reference to Exhibit 10.42 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span></a></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">189</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:21.278%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:77.722%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.67</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex1043.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">First Amendment to Lease Agreement between the Company and ARE-SAN FRANCISCO NO. 43, LLC, dated April 10, 2019 (incorporated herein by reference to Exhibit 10.43 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.68&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000095017022002295/vir-ex10_66.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease Agreement between the Company and KRE Exchange Owner LLC, dated December 16, 2021 (incorporated herein by reference to Exhibit 10.66 to the Company&#x2019;s Form 10-K (File No. 001-39083), filed with the SEC on February 28, 2022).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.69&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519236592/d755217dex1044.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Patent License Agreement between the Company and Xencor, Inc., dated August 15, 2019 (incorporated herein by reference to Exhibit 10.44 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-233604), filed with the SEC on September 3, 2019).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.70&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000156459021024948/vir-ex103_304.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment 1 to Patent License Agreement between the Company and Xencor, Inc., dated February 23, 2021 (incorporated herein by reference to Exhibit 10.3 to the Company's Form 10-Q (File No. 001-39083), filed with the SEC on May 6, 2021).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.71&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000119312520174259/d946838dex991.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Patent License Agreement between the Company and Xencor, Inc., dated March 25, 2020 (incorporated herein by reference to Exhibit 99.1 to the Company&#x2019;s Form 8-K (File No. 001-39083), filed with the SEC on June 19, 2020).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.72&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000156459021024948/vir-ex104_305.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment 1 to Patent License Agreement between the Company and Xencor, Inc., dated February 23, 2021 (incorporated herein by reference to Exhibit 10.4 to the Company's Form 10-Q (File No. 001-39083), filed with the SEC on May 6, 2021).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.73&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000119312520187304/d945110dex1054.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Definitive Collaboration Agreement between the Company, Glaxo Wellcome UK Limited and Beecham S.A., dated June 9, 2020 (incorporated herein by reference to Exhibit 10.54 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-239689), filed with the SEC on July 6, 2020).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.74</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000119312520187304/d945110dex1055.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock Purchase Agreement between the Company and Glaxo Group Limited, dated April 5, 2020 (incorporated herein by reference to Exhibit 10.55 to the Company's Registration Statement on Form S-1 (File No. 333-239689), filed with the SEC on July 6, 2020).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.75&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000156459021024948/vir-ex101_302.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Preliminary Collaboration Agreement between the Company and Glaxo Wellcome UK Limited, dated February 14, 2021 (incorporated herein by reference to Exhibit 10.1 to the Company's Form 10-Q (File No. 001-39083), filed with the SEC on May 6, 2021).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.76&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000095017021000935/vir-20210630ex10_2.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Definitive Collaboration Agreement between the Company and Glaxo Wellcome UK Limited, dated May 18, 2021 (incorporated herein by reference to Exhibit 10.2 to the Company's Form 10-Q (File No. 001-39083), filed with the SEC on August 5, 2021).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.77&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000095017022016060/vir-ex10_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendment No. 1 to the Definitive Collaboration Agreement between the Company and Glaxo Wellcome UK Limited dated May 27, 2022 (incorporated herein by reference to Exhibit 10.2 to the Company&#x2019;s Form 10-Q (File No. 001-39083), filed with the SEC on August 9, 2022).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.78&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000156459021024948/vir-ex102_303.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock Purchase Agreement between the Company and Glaxo Group Limited, dated February 14, 2021 (incorporated herein by reference to Exhibit 10.2 to the Company's Form 10-Q (File No. 001-39083), filed with the SEC on May 6, 2021).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.79&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000119312520187304/d945110dex1057.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Binding Letter Agreement between the Company and Samsung Biologics Co., Ltd., dated April 9, 2020 (incorporated herein by reference to Exhibit 10.57 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-239689), filed with the SEC on July 6, 2020).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.80</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000119312520213032/d941033dex992.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assignment and Novation Agreement among the Company, GlaxoSmithKline Trading Services Limited and Samsung Biologics Co., Ltd., dated July 31, 2020 (incorporated herein by reference to Exhibit 99.2 to the Company&#x2019;s Form 8-K (File No. 001-39083), filed with the SEC on August 7, 2020).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.81&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312520187304/d945110dex1059.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Letter of Intent between the Company and WuXi Biologics (Hong Kong) Limited, dated June 15, 2020 (incorporated herein by reference to Exhibit 10.59 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-239689), filed with the SEC on July 6, 2020).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.82&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000095017022016060/vir-ex10_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Termination Agreement between the Company and WuXi Biologics (Hong Kong) Limited dated May 16, 2022 (incorporated herein by reference to Exhibit 10.1 to the Company&#x2019;s Form 10-Q (File No. 001-39083), filed with the SEC on August 9, 2022).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">190</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:21.278%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:77.722%;"></td>
   </tr>
   <tr style="height:13.7pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.83</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000119312520290303/d862544dex12.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Sales Agreement, dated as of November 10, 2020, by and between the Company and Cowen and Company, LLC. (incorporated by reference to Exhibit 1.2 to the Company&#x2019;s registration statement on Form S-3 (Filed No. 333-250013), filed with the SEC on November 10, 2020).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="vir-ex21_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">List of subsidiaries of the Company.</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="vir-ex23_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm.</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#power_of_attorney"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Power of Attorney (included on the signature page to this report).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="vir-ex31_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="vir-ex31_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32.1*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="vir-ex32_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.INS</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Instance Document the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.SCH</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema Document.</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.CAL</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.DEF</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.LAB</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.PRE</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">104</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;margin-right:80.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">+ Indicates a management contract or compensatory plan or arrangement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#134; Certain portions of this exhibit (indicated by &#x201c;[***]&#x201d;) have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">* The certification attached as Exhibit 32.1 that accompany this Annual Report on Form 10-K is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Annual Report on Form 10-K, irrespective of any general incorporation language contained in such filing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_16_form_10k_summary"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 16. Form </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10-K Summary</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">191</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="signatures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SIGNAT</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">URES</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.463%;"></td>
    <td style="width:5.037%;"></td>
    <td style="width:4.0%;"></td>
    <td style="width:45.5%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VIR BIOTECHNOLOGY, INC.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: February 28, 2023</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;George Scangos</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">George Scangos, Ph.D.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">President, Chief Executive Officer and Director</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Principal Executive Officer)</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: February 28, 2023</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Howard Horn</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Howard Horn</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Financial Officer and Secretary</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Principal Financial and Accounting Officer)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">192</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="power_of_attorney"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">POWER OF</span><span id="power_attorney"></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> ATTORNEY</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints George Scangos, Ph.D., Johanna Friedl-Naderer, Howard Horn and Vanina de Verneuil, and each of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution for him or her and in his or her name, place, and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the SEC, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, and any of them or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:34.657%;"></td>
    <td style="width:1.361%;"></td>
    <td style="width:28.676%;"></td>
    <td style="width:17.204%;"></td>
    <td style="width:1.139%;"></td>
    <td style="width:16.963%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Signature</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date</span></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.25pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ George Scangos</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.25pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">President, Chief Executive Officer and</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 28, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">George Scangos, Ph.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Principal Executive Officer)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Howard Horn</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.25pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Financial Officer and Secretary </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Principal Financial and Accounting Officer)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 28, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Howard Horn</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Vicki Sato</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.25pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chairman of the Board of Directors</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 28, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vicki Sato, Ph.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Jeffrey S. Hatfield</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 28, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Jeffrey S. Hatfield</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.25pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Robert More</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.25pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 28, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Robert More</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Janet Napolitano</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 28, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Janet Napolitano</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.25pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Robert Nelsen</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.25pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 28, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Robert Nelsen</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.25pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Robert Perez</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.25pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 28, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Robert Perez</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:11.5pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.25pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Saira Ramasastry</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.25pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 28, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Saira Ramasastry</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.25pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Phillip Sharp</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.25pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 28, 2023</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Phillip Sharp, Ph.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.25pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Elliott Sigal</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.25pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;border-bottom:0.25pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 28, 2023</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Elliott Sigal, M.D., Ph.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="margin-left:9.173%;text-indent:2.76%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">193</span></p>
  <hr style="page-break-after:always;" />
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>2
<FILENAME>vir-ex10_8.htm
<DESCRIPTION>EX-10.8
<TEXT>
<html>
 <head>
  <title>EX-10</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.95pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.759%;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 10.8</font></p>
  <p style="margin-left:20.467%;text-indent:0.0%;font-size:10.0pt;margin-top:3.95pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:20.463%;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.467%;text-indent:0.0%;font-size:10.0pt;margin-top:3.95pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:20.463%;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VIR BIOTECHNOLOGY, I</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NC</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:20.467%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:20.472%;text-align:center;"><font style="background-color:rgba(0,0,0,0);font-variant:small-caps;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-Employee Director Compensation Policy</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.45pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.293%;text-indent:0.0%;font-size:10.0pt;margin-top:4.55pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.241%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Each member of the Board of Directors (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Board</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) of Vir Biotechnology, Inc. (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) who is not also serving as an employee of the Company or any of its subsidiaries (each such member, an &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Eligible Director</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) will receive the compensation described in this Non-Employee Director Compensation Policy (this &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Policy</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;). An Eligible Director may decline all or any portion of his or her compensation by giving notice to the Company prior to the date cash is to be paid or equity awards are to be granted, as the case may be. This Policy may be amended at any time in the sole discretion of the Board, or by the Compensation Committee of the Board at the recommendation of the Board.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.293%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Annual Cash Compensation</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.293%;text-indent:6.827%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.25%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The annual cash compensation amount set forth below is payable to Eligible Directors in equal quarterly installments, payable in arrears on the last day of each fiscal quarter in which the service occurred. If an Eligible Director joins the Board or a committee of the Board at a time other than effective as of the first day of a fiscal quarter, each annual retainer set forth below will be pro-rated based on days served in the applicable fiscal year, with the pro-rated amount paid for the first fiscal quarter in which the Eligible Director provides the service, and regular full quarterly payments to be paid thereafter. All annual cash fees are vested upon payment.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:8.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:7.246739130434782%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Annual Board Service Retainer</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">:</font></div></div>
  <div style="margin-left:14.667%;text-indent:0.0%;display:flex;margin-top:0.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:7.812921144223219%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All Eligible Directors: $50,000</font></div></div>
  <div style="margin-left:14.667%;text-indent:0.0%;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.204%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:8.474964089135215%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Non-executive chairperson of the Board: $75,000 (inclusive of Annual Board Service Retainer)</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.1pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:8.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:7.246739130434782%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Annual Committee Member Service Retainer</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">:</font></div></div>
  <div style="margin-left:14.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:7.812921144223219%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Member of the Audit Committee: $10,000</font></div></div>
  <div style="margin-left:14.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:7.812921144223219%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Member of the Compensation Committee: $7,500</font></div></div>
  <div style="margin-left:14.667%;text-indent:0.0%;display:flex;margin-top:0.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:7.812921144223219%;">c.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Member of the Nominating and Corporate Governance Committee: $5,000</font></div></div>
  <div style="margin-left:14.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:7.812921144223219%;">d.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Member of the Science and Technology Committee: $7,500</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:8.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.204%;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:7.246739130434782%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Annual Committee Chair Service Retainer (inclusive of Committee Member Service</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Retainer)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">:</font></div></div>
  <div style="margin-left:14.667%;text-indent:0.0%;display:flex;margin-top:0.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:7.812921144223219%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chairperson of the Audit Committee: $20,000</font></div></div>
  <div style="margin-left:14.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:7.812921144223219%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chairperson of the Compensation Committee: $15,000</font></div></div>
  <div style="margin-left:14.667%;text-indent:0.0%;display:flex;margin-top:0.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:7.812921144223219%;">c.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chairperson of the Nominating and Corporate Governance Committee: $10,000</font></div></div>
  <div style="margin-left:14.667%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:7.812921144223219%;">d.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chairperson of the Science and Technology Committee: $15,000</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.293%;text-indent:6.827%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.25%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company will also reimburse each of the Eligible Directors for his or her travel expenses incurred in connection with his or her attendance at Board and committee meetings. Such reimbursements shall be paid on the same date as the annual cash fees are paid.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.293%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity Compensation</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.293%;text-indent:6.828%;font-size:10.0pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.259%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The equity compensation set forth below will be granted under the Company&#x2019;s 2019 Equity Incentive Plan (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Plan</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;). All stock options granted under this Policy will be nonstatutory stock options, with an exercise price per share equal to 100% of the Fair Market Value (as defined in the Plan) of the</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:1.293%;text-indent:0.0%;font-size:10.0pt;margin-top:3.95pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">underlying common stock on the date of grant, and a term of 10 years from the date of grant (subject to earlier termination in connection with a termination of service as provided in the Plan).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:8.0%;text-indent:0.0%;display:flex;margin-top:0.05pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.204%;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:7.246739130434782%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Initial Grant</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: For each Eligible Director who is first elected or appointed to the Board following the effective date of this Policy, on the date of such Eligible Director&#x2019;s initial election or appointment to the Board (or, if such date is not a market trading day, the first market trading day thereafter), the Eligible Director will be automatically, and without further action by the Board or Compensation Committee of the Board, granted two equity awards (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Initial Grants</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) with a value of $400,000 in the aggregate comprised of (i) a stock option to purchase shares of the Company&#x2019;s common stock (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Initial Option Grant</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) and (ii) a restricted stock unit award covering shares of the Company&#x2019;s common stock (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Initial RSU Grant</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;). The total number of shares subject to the Initial Option Grant will be initially calculated in accordance with the Black-Scholes valuation methodology and the total number of shares subject to the Initial RSU Grant will be initially calculated in accordance with the Fair Market Value as of the grant date, and such resulting number of shares shall be divided between the Initial Grants based on a fixed ratio of two shares subject to the Initial Option Grant for every one share subject to the Initial RSU Grant, with the number of shares subject to the Initial Option Grant rounded down to the nearest whole share and in no event exceeding 16,000 shares and the number of shares subject to the Initial RSU Grant rounded down to the nearest whole share and in no event exceeding 8,000 shares.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:14.627%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.231%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">One-third of the shares subject to each Initial Option Grant will vest on the one-year anniversary of the Eligible Director&#x2019;s initial election or appointment to the Board and thereafter the remainder of the shares subject to each such Initial Grant will vest monthly over a two-year period, subject to the Eligible Director&#x2019;s Continuous Service (as defined in the Plan) on each vesting date, and will vest in full upon a Change in Control (as defined in the Plan), subject to the Eligible Director&#x2019;s Continuous Service (as defined in the Plan) on such date. The Initial RSU Grant will vest in three equal installments on the first, second and third anniversaries of the Eligible Director&#x2019;s initial election or appointment to the Board, subject to the Eligible Director&#x2019;s Continuous Service (as defined in the Plan) on each vesting date, and will vest in full upon a Change in Control (as defined in the Plan), subject to the Eligible Director&#x2019;s Continuous Service (as defined in the Plan) on such date.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:14.627%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.222%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, on the date of such Eligible Director&#x2019;s initial election or appointment to the Board (or, if such date is not a market trading day, the first market trading day thereafter), the Eligible Director will be automatically, and without further action by the Board or Compensation Committee of the Board, granted the additional awards on the same terms as the Annual Grants (as defined below), except (i) the $400,000 aggregate value of the additional awards shall first be multiplied by a fraction, the numerator of which equals 12 minus the number of calendar months that have occurred since the last annual meeting of stockholders and the denominator of which equals 12, and (ii) such additional awards will vest in full upon the earlier of (i) the one-year anniversary of the date the Annual Grants to the Eligible Directors were last made and (ii) the next annual meeting of stockholders, subject to the Eligible Director&#x2019;s Continuous Service (as defined in the Plan) on the vesting date, and will vest in full upon a Change in Control (as defined in the Plan), subject to the Eligible Director&#x2019;s Continuous Service (as defined in the Plan) on such date.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:8.0%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.333%;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:7.246739130434782%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Annual Grant</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">: On the first market trading day after each annual stockholders meeting of the Company, each Eligible Director who continues to serve as a member of the Board following such stockholders meeting will be automatically, and without further action by</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:14.627%;text-indent:0.0%;font-size:10.0pt;margin-top:3.95pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.231%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the Board or Compensation Committee of the Board, granted two equity awards (collectively, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Annual Grants</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) with a value of $400,000 in the aggregate comprised of (i) a stock option to purchase shares of the Company&#x2019;s common stock (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Annual Option Grant</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;); and (ii) a restricted stock unit award covering shares of the Company&#x2019;s common stock (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Annual RSU Grant</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;). The shares subject to each Annual Grant will vest in full on the one-year anniversary of the grant date, subject to the Eligible Director&#x2019;s Continuous Service (as defined in the Plan) on the vesting date, and will vest in full upon a Change in Control (as defined in the Plan), subject to the Eligible Director&#x2019;s Continuous Service (as defined in the Plan) on such date. The total number of shares subject to the Annual Option Grant will be initially calculated in accordance with the Black-Scholes valuation methodology as of the grant date and the total number of shares subject to the Annual RSU Grant will be initially calculated in accordance with the Fair Market Value as of the grant date, and such resulting number of shares shall be divided between the Annual Grants based on a fixed ratio of two shares subject to the Annual Option Grant for every one share subject to the Annual RSU Grant, with the number of shares subject to the Annual Option Grant rounded down to the nearest whole share and in no event exceeding 16,000 shares and the number of shares subject to the Annual RSU Grant rounded down to the nearest whole share and in no event exceeding 8,000 shares.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.293%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Eligible Director Compensation Limit</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.293%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.287%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notwithstanding anything herein to the contrary, the cash compensation and equity compensation that each Eligible Director is entitled to receive under this Policy shall be subject to the limits set forth in Section 3(d) of the Plan.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.55pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:1.293%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:32.148%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Approved by the Board of Directors: December 14, 2022 Effective: January 1, 2023</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.56%;text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>3
<FILENAME>vir-ex10_17.htm
<DESCRIPTION>EX-10.17
<TEXT>
<html>
 <head>
  <title>EX-10</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><img src="img64083768_0.jpg" alt="img64083768_0.jpg" style="width:179px;height:54px;">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Exhibit 10.17</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:14.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:14.0pt;margin-top:36.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">AGREEMENT ON TRANSFER<br>OF EMPLOYMENT AND AMENDMENT OF EMPLOYMENT AGREEMENT</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(&#34;Agreement&#34;)</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Dated: December 19, 2022</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Between</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Humabs BioMed SA	(&#x201c;Humabs&#x201d;)</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Via dei Gaggini 3</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6500 Bellinzona, Switzerland</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">A subsidiary of</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Vir Biotechnology, Inc.	(&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">VIR</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201d;)</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">499 Illinois Street, Suite 500</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">San Francisco, CA 94158</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">USA</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">And</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Vir Biotechnology International GmbH	(&#x201c;VBI&#x201d;)</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Grafenauweg 8</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6300 Zug, Switzerland</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">And</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Johanna Friedl-Naderer	(&#x201c;Employee&#x201d;)</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">[Address]</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">[Address]</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(Humabs, VBI and the Employee together the &#34;Parties&#34;, each a &#34;Party&#34;)</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(Humabs, VBI and their direct and indirect affiliates (i.e. any entity which, directly or indirectly, controls, or is controlled by, or is under common control with such entity) from time to time the &#34;Group&#34;, each a &#34;Group Company&#34;)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Recitals</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Humabs BioMed SA and the Employee concluded an employment contract dated 16 December 2021 (the &#34;Employment Agreement&#34;).  Humabs BioMed SA appreciates and values the Employee's commitment and engagement and wishes the Employee to assume the role of Group Chief Operations Officer (COO) retroactively as of March 2, 2022, and to amend the Employment Agreement accordingly;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In addition, the Employee shall receive a monthly housing allowance retroactively as of 1 September 2022;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As of January 1, 2023, the employment relationship shall be transferred and continued between VBI and the Employee; and,</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Based on the above premises, which form an integral part hereof, the Parties agree as follows:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Amendment of Section 3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Section 3 of the Employment Agreement is amended as follows:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201c;As of March 2, 2022, the Employee shall hold the position of Group Chief Operations Officer (COO) of the Group.&#x201d;  The Employee&#x2019;s duties and responsibilities shall encompass the usual and customary duties, responsibilities and authority of the Group COO and such other duties and responsibilities as are assigned to the Employee hereunder by the Board of her then-current direct Employer (whether Humabs or VBI), the Group&#x2019;s CEO and/or the Group&#x2019;s Board, from time to time. Furthermore, the Employee&#x2019;s duties and responsibilities are additionally governed by the organizational regulations of her then-current Employer and/or the Group.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Employee reports to the Group CEO as well as the Board of her then-current direct Employer and/or the Group&#x2019;s Board.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Amendment of Section 7</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The following addition is made to section 7 of the Employment Agreement:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#34;As of 1 September 2022, the Employee is entitled to a monthly housing allowance of USD 10'000 gross to be paid in CHF for a gross total of monthly CHF 9&#x2019;861, minus applicable withholding and deductions if any.&#34;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Change of Employer</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Parties hereby agree to transfer the Employment Agreement with all rights and obligations as of January 1, 2023. As of said date, the Employee will have an employment relationship with VBI only, and her employment relationship will then become subject to the jurisdiction and any unique statutory requirements of the Canton of Zug, including without limitation, the public holidays recognized from time to time within Zug.  For calculation of years of service, March 2, 2022 will be considered the start date of the employment.  The Parties agree that the transfer does not trigger any severance payment obligation.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Miscellaneous</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">All other provisions of the Employment Agreement and of the Letter Agreement (dated February 18</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:7.37pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, 2022) remain in force unchanged and related rights and obligations set forth therein extend to VBI on and after January 1, 2023.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">		</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Governing Law and Jurisdiction</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">This Agreement shall be governed by the substantive laws of Switzerland (excluding its rules on conflict of laws). Venue for any dispute arising from this Agreement shall be the courts according to article 34 of the Swiss Civil Procedural Code.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">This Addendum is made on the date set forth on the cover page of this Agreement.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:93.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:49.994%;"></td>
    <td style="width:50.006%;"></td>
   </tr>
   <tr style="height:11.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.049in;vertical-align:top;padding-right:0.049in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Humabs BioMed SA:</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.049in;vertical-align:top;padding-right:0.049in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.049in;vertical-align:top;padding-right:0.049in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.049in;vertical-align:top;padding-right:0.049in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">_______________________________</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.049in;vertical-align:top;padding-right:0.049in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.049in;vertical-align:top;padding-right:0.049in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Filippo Riva</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Managing Director</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.049in;vertical-align:top;padding-right:0.049in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.049in;vertical-align:top;padding-right:0.049in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Vir Biotechnology International GmbH:</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.049in;vertical-align:top;padding-right:0.049in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.049in;vertical-align:top;padding-right:0.049in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.049in;vertical-align:top;padding-right:0.049in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">_______________________________</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.049in;vertical-align:top;padding-right:0.049in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.049in;vertical-align:top;padding-right:0.049in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">George Scangos</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Group CEO and VBI Managing Director</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.049in;vertical-align:top;padding-right:0.049in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.049in;vertical-align:top;padding-right:0.049in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Employee:</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.049in;vertical-align:top;padding-right:0.049in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.049in;vertical-align:top;padding-right:0.049in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.049in;vertical-align:top;padding-right:0.049in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">________________________________</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.049in;vertical-align:top;padding-right:0.049in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.049in;vertical-align:top;padding-right:0.049in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Johanna Friedl-Naderer</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.049in;vertical-align:top;padding-right:0.049in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">		</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21
<SEQUENCE>4
<FILENAME>vir-ex21_1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<html>
 <head>
  <title>EX-21</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 21.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(15,15,15,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Subsidiaries of Vir Biotechnology, Inc.</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:40.385%;"></td>
    <td style="width:59.615%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;border-bottom:0.5pt solid;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name of Subsidiary</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State or Other Jurisdiction of Incorporation or Organization</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Agenovir Corporation</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Encentrio Therapeutics, Inc.</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Encentrio Therapeutics International GmbH</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Humabs BioMed SA</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Statera Health, LLC</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">TomegaVax, Inc.</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vir AU Biotechnology Pty Ltd.</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vir Biotechnology International GmbH</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vir Predictive Medicine, Inc.</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VirAb, Inc.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Switzerland</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Switzerland</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Australia</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Switzerland</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>5
<FILENAME>vir-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 23.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">We consent to the incorporation by reference in the following Registration Statements:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(1)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Registration Statements (Forms S-8 Nos. 333-234212, 333-237410, 333-253547 and 333-263088) pertaining to the 2016 Equity Incentive Plan, 2019 Equity Incentive Plan and 2019 Employee Stock Purchase Plan of Vir Biotechnology, Inc.; and </font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(2)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Registration Statement (Form S-3 No. 333-250013) of Vir Biotechnology, Inc.;</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of our reports dated February 28, 2023, with respect to the consolidated financial statements of Vir Biotechnology, Inc. and the effectiveness of internal control over financial reporting of Vir Biotechnology, Inc. included in this Annual Report (Form 10-K) of Vir Biotechnology, Inc. for the year ended December 31, 2022.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Ernst &amp; Young LLP</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">San Mateo, California</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 28, 2023</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>6
<FILENAME>vir-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 31.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I, George Scangos, Ph.D., certify that:</font></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of Vir Biotechnology, Inc.;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.406%;"></td>
    <td style="width:3.996%;"></td>
    <td style="width:4.177%;"></td>
    <td style="width:46.421%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: February 28, 2023</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;George Scangos</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">George Scangos, Ph.D.</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">President, Chief Executive Officer and Director</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>7
<FILENAME>vir-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 31.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I, Howard Horn, certify that:</font></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of Vir Biotechnology, Inc.;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.406%;"></td>
    <td style="width:3.996%;"></td>
    <td style="width:4.177%;"></td>
    <td style="width:46.421%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: February 28, 2023</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Howard Horn</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Howard Horn</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Financial Officer and Secretary</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Principal Financial and Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>8
<FILENAME>vir-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 32.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the Annual Report of Vir Biotechnology, Inc. (the &#x201c;Company&#x201d;) on Form 10-K for the period ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), George Scangos, Ph.D., President, Chief Executive Officer and Director of the Company and Howard Horn, Chief Financial Officer and Secretary of the Company, each hereby certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that, to such officer's knowledge:</font></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(1)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">(2)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IN WITNESS WHEREOF, the undersigned have set their hands hereto as of the 28</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of February 2023.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:46.656%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:3.237%;"></td>
    <td style="width:49.103%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;George Scangos</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;Howard Horn</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">George Scangos, Ph.D.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Howard Horn</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">President, Chief Executive Officer and Director</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chief Financial Officer and Secretary</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">(Principal Financial and Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Vir Biotechnology, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.&#x201d;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>img62602283_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img62602283_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" .N!U0# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)Z2#ISU^M5B*'VHK^OZ_S7DJ53HSN*X/QEXRG@@N[31!(PM2JZAJ$:AEM%)
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MZ*4>6S[I.UM+:V:5]+V?<FU.492UN:]%'6BO8.8**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5/4;&2^A6..]GM
M2K9W0G!/L:N44T[.Z)E%27*SB]2LM2@O(["QU/4[BZ<;B6?;&BYZD_Y_I74:
M78+IFF06:,6$2X+>I)R3^9-7**N51R5C"CA8TIN:>_X(****S.D**** "BBB
M@ HHHH **** "O*;_1=6_P"$L>PCTNZ>.;7H=46[5/W(B"D,"W9@3T[_ )9]
M6HK6E5=-NRW(G!3/++;2-4/B]+%],NT2/Q!/JANS'^X,+ ;0'[L?2O4Z***M
M5U+76P0ARW"BBBLBPHHHH **** "BBB@"O:VHMHY%+;_ #'+MD>M95U9-+<M
M)!8H(H2<J<CS?H*W:*\_$9=2K4HTMDO1_G?KKY]3:%:49.74@MXXA;CRX?*#
MKRNW:1]:2RMOLEJL&_=MS@XQWJQ175&A"+C*VJ5NV]KZ?(S<V[H****V)"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MKNPD.$N[.7S(B?3/4?E3T%J7_P#A9_C'_H,?^2T/_P 11_PL_P 8_P#08_\
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M11_PL_QC_P!!C_R6A_\ B*Y&BBR"[.N_X6?XQ_Z#'_DM#_\ $4?\+/\ &/\
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M_&/_ $&/_):'_P"(KD:*+(+LZ[_A9_C'_H,?^2T/_P 11_PL_P 8_P#08_\
M):'_ .(KD:N7NEWNG16LEW#Y:7<0FA.X'<AZ'@\?C19!=G1?\+/\8_\ 08_\
MEH?_ (BC_A9_C'_H,?\ DM#_ /$5R-:-KHUQ=:->ZJ'BCMK1D1BY.79CPJ@
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M9"QWECCD#&,<^M95%D%V==_PL_QC_P!!C_R6A_\ B*/^%G^,?^@Q_P"2T/\
M\17(T46079UW_"S_ !C_ -!C_P EH?\ XBC_ (6?XQ_Z#'_DM#_\16-<>'[N
MW\-VFNO) ;6YE:%$5\R C.<C'3CUK*HL@NSKO^%G^,?^@Q_Y+0__ !%'_"S_
M !C_ -!C_P EH?\ XBN1HHL@NSKO^%G^,?\ H,?^2T/_ ,11_P +/\8_]!C_
M ,EH?_B*Y&BBR"[.N_X6?XQ_Z#'_ )+0_P#Q%'_"S_&/_08_\EH?_B*Y&BBR
M"[/4_'WCKQ)HOC&]L-/U'R;6,1E$\B-L912>2I/4FN:_X6?XQ_Z#'_DM#_\
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M,?\ H,?^2T/_ ,13_ O_ !X>*O\ L#3?TKCJ5D%V==_PL_QC_P!!C_R6A_\
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M_P"(H_X6?XQ_Z#'_ )+0_P#Q%<C119!=G7?\+/\ &/\ T&/_ "6A_P#B*/\
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M^,?^@Q_Y+0__ !%<C119!=G7?\+/\8_]!C_R6A_^(H_X6?XQ_P"@Q_Y+0_\
MQ%<C4UG:O>WL%I$5$D\BQJ7. "3@9/8<T6079U'_  L_QC_T&/\ R6A_^(H_
MX6?XQ_Z#'_DM#_\ $5@:UI-QH6KW&F73Q/- P5FB;<IX!X.!ZU0HL@NSKO\
MA9_C'_H,?^2T/_Q%'_"S_&/_ $&/_):'_P"(KD:*+(+LZ[_A9_C'_H,?^2T/
M_P 11_PL_P 8_P#08_\ ):'_ .(K&M] NKGPW>:XDD(M;658G0L=Y+8Q@8QC
MGUK*HL@NSKO^%G^,?^@Q_P"2T/\ \11_PL_QC_T&/_):'_XBN1HHL@NSKO\
MA9_C'_H,?^2T/_Q%=A\-O&GB#7_%#6>IZAY]N+9WV>3&OS K@Y50>YKR&O0/
M@]_R.K_]><G\UI-*P)NY[S11161J%%%% '@?Q>_Y'@_]>L?]:X*N]^+W_(\'
M_KUC_K7!5M'8R>YZ!+_R0^#_ +"1_K1X/\S_ (5SXN^U9_L_RU\K?]WSN>GO
MG9^E8^D^.+S2="71SIFE7MHLAE"WMN9/F/MN _2JVN>+]3UVTCLI%MK2PC.4
MM+.+RX@?7'4_G2LPN:NIV-I'\)]%O$M8%NI+V17G$8#L!OX+=2.!^5;5M'IM
M]X7@M_#NE:'J$J6>;R&Y4K>B7'S,A.,J.O!]A7#W'B&[N?#-IH+QP"UM9FF1
MPIWDG/4YQCYCVK5@\?ZG:Z>+>"RTN.=8/LXO4M0)PF,8W XZ>U%F%T;O@K1;
M!/"%QK4JZ*]Z]S]GB.LOBWC  )X[L>?R_//\6:5ILGB/21HL6GW<]VJ_:+/3
MKC?#YH/(4C!52/IBL30?%=_H%O<6L4-I=V=P09+6\B\R)B.^,CG_ .M27/BF
M^GURTU:*&SM)K3;Y$=K $C0 YQCN.3U/>BSN%U8]#U'0K6Z\+ZXM[IWAVUNK
M&#S84TM\W$)7)VRGOG&/SKG?!+Z.=&GA2#1I=>DN $36$)B:+' 0] Q/TJA=
M_$/5+J"_@6QTNVBOHFCN%M[;9O+=7)SDMUY)(Y/%4=#\776A6GV9-.TN[C$O
MG(;RV#M&_'S*00<\"BSL.ZN=%X7\/6U]XXU==8TZVLUL(GG-B\FV%6XP&;GY
M!G.>GX<5)XPL](E\+_:S+X:CU:&<!4T2<;9(CURG7(/>N4M_%FKVWB237DN!
M]NE),A*C:X/&TCTP!^0I^M^*KC6K06ITW2K&'S/,865J(R[=,DY)[FBSN*ZL
M8->WZ5HFOZ#H'AB'2=/:8B?[9J.)$C/S#&T[B,G:Q'_ 17BEO-]GN8IMB2>6
MX?8XRK8.<'':K^OZ[>>)-6DU*^\L2N H6,$*H P  23^O>FU<$['2^(M 32?
MBG#:/$K6EU>13(K+E61W&5QW&<C\*;X[N;-=?N= L='TZR@AN@?/BBQ*Q(Y!
M;LOS?= XP*R+OQ=?WO\ 8S3PVS2Z2%$$NUMSA2" _P W/0=,5G:QJL^MZO<Z
ME<I&DUPVYEB!"@XQQDD]O6A(&SV"XT'P[IEZNC7"^%H]-6$).]U<[;_<1G>&
M/3L<9_PKAO".ER_;M4FM]-TF^MK9MGVS5)/]'BY.">S9'^>>8%^(FJFUA2XL
M=*N[F%/+BO;FT#SH.V&)Q^E9^A^++W0K:[M8[6QN[6[(:6WO(-\>X=" "/\
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M1VZ5R@\078\,'0/+A^R&X^T[]IW[L8QG.,?A3]8\2WVM7]G>S"*&>TA2*)H
M5P$.0>2>>:+!<].U32/#I&IZ;<'PG:6<4;+;-!<A;V.11QO)Z\YR/YUR_ALZ
M?I_PXU'6)]'L;^Z@OE2(W4>X#*J.>Y')^7.*S;[X@:EJ%M*D^G:0;J:,Q27H
MLQY[J1@Y8G'3VK(AU^Z@\-7.@K'";6XG$[.5.\,,< YQCCTH28[HZ+QK#8PQ
M>'-<M--M;9[ZW$TUM&F(2RE?X?0YZ5J?$C6 VE:+:#3-.07.GQ3>:D&)(><[
M(SGY5]JXG5-?NM7T_3+*XCA6/3HC%$8U(+ X^]DG)X[8JWJ'B^]U30+?2;JT
ML'$")&EUY'[\(O1=V>GT%%A7.?KKO$W_ !)O#>C^'5^64I]OO!G_ ):.,*I]
MPH_6N9L)XK74+>XG@,\44BN\6[;O .<9P<9^E3ZUJLVN:S=ZE<#$EQ(6V@\*
M.@7\!@?A3$4*]3U33]&OO GA+^V-;.F*D,FS%J\QDR5S]W[N..OK7EE:VI^(
M;O5=(TS3)XX%ATY66%D4AF#8SNR2#T[ 4-#3.CUK7-/\1>,M!M;*-I--LV@M
M$,ZY,JAADL/0],&F>.[FS77[G0+'1].LH(;H'SXHL2L2.06[+\WW0.,"N0LK
MJ2QOK>\B"F2"195##@E3D9]N*GUC59];U>YU*Y2-)KAMS+$"%!QCC))[>M%@
MN>EW/]BZ/XSLO!Z^&K"XLW$<4MS-%F=V<#YU?L.?T.,5F>%]!TVV^(>N:7<V
MT5[9VMO/L28 \ C'/8XXR.:RK?XE:U!##NMM-GO((_+BOYK;=<(N,<-G^GUS
M2>!?$5OI/B2]U+5+LHTUK*!*R,Y:1B",X!ZG/7BE9V'=&G(VG>)_A]J^H?V)
MI^G76FRIY4EI'Y896(&UC_$<>OMTJS'JT.C_  JT*XDTNSU!S=RJB7BET7YF
MR=O<X]>E<MK'C34=8TI=,^S6-E9[_,>*R@\H2-ZMR<^M4;G7[JZ\.6>AO'"+
M6TE:6-U4[R6SG)SC'/I18+G2^+X--\.^/;*ZM]/@^QO%%<R6C(&C(;.Y0IXQ
M@5M7_AW3?#]YK_B)[2WFTQ[9'TR.2-6C:2;IA2,84YXQT-<!K^OW7B.^BN[R
M.%)(X5@ A4@;5SCJ3SS6QXIU^WN?#^AZ%87K75O90;II"K*&E/8 @'"C(''>
MBS"Y;T__ )(YJ_\ V$H_Y+6KX+TQTTFQEN]&\.QVUU-C[3JS_O;A<XQ$#G![
M#CGCZUP\.OW4'AJYT%8X3:W$XG9RIWAAC@'.,<>E:=EX\U2RTFUL%MM/E-GG
M[-<S6P>:')S\I)P/RH:8KHL:E%9^%_B9<00Z=%>6<5P%^R2QB4,K@': 0>1G
MCOP*W/'.@Z=X0T69+*Q29]3N6(N)8U;[(B\^4IYVMR>?0'TXY,>+KS_A+7\2
M/:64EZQW!'1C&C;0H8#=G(QW)YI@\6:BVCZCIER(;J"^F\]VF!+))G)9"",$
M_B*+,+HU]3L;2/X3Z+>):P+=27LBO.(P'8#?P6ZD<#\JVK:/3;[PO!;^'=*T
M/4)4L\WD-RI6]$N/F9"<94=>#["N'N/$-W<^&;307C@%K:S-,CA3O).>ISC'
MS'M6K!X_U.UT\6\%EI<<ZP?9Q>I:@3A,8QN!QT]J+,+HY2BBBJ$%%%% !111
M0!V/Q2_Y*%J/^[%_Z+6N.KL?BE_R4+4?]V+_ -%K7'4EL-[A1113$%>IZII^
MC7W@3PE_;&MG3%2&39BU>8R9*Y^[]W''7UKRRM;4_$-WJND:9ID\<"PZ<K+"
MR*0S!L9W9)!Z=@*30TSH]:US3_$7C+0;6RC:33;-H+1#.N3*H89+#T/3!IGC
MNYLUU^YT"QT?3K*"&Z!\^*+$K$CD%NR_-]T#C KD+*ZDL;ZWO(@ID@D650PX
M)4Y&?;BI]8U6?6]7N=2N4C2:X;<RQ A0<8XR2>WK18+GL%QH/AW3+U=&N%\+
M1Z:L(2=[JYVW^XC.\,>G8XS_ (5Q?A;3=-LM/\1ZW/:PZI_99$=O#(-\;%F(
MWL.A'0_G5-?B)JIM84N+'2KNYA3RXKVYM \Z#MAB<?I63H'B;4/#MW-/9B%T
MN$*3V\T>Z*5?0J,>O:E9CNC0AUB'6?%NB31Z38Z>ZW,2R"S0HCG>.=N<#C_/
MIT36MO>?'22WNH(IX'N&W1RH&5OW7<'@UR5_XJO+_4["]-K8VXL6#6]O;0>7
M$N&W= <\D>M*GBR_3Q>?$HAMOMI<OLVMY>2NWIG/3WHL*YTGA'3M.N/B!KUO
M=V$$]K%'=%8'0;1A^-O]WC@$=*;?/I_B'X=7^K#1;#3[JQNTCC:SCV;D; PW
MJ>>I_2N;TSQ3?:5K5]JL$5NT]XLBR*ZL5 <Y. "#].:@M]?NK;PW>:&D<)M;
MJ597<J=X*XQ@YQCCTHL%S?U.QM(_A/HMXEK MU)>R*\XC =@-_!;J1P/RK3U
M2XTSP9I>BVD?A_3M1:\M%N;FXO(M[/N_A1OX<?X5QUQXAN[GPS::"\< M;69
MID<*=Y)SU.<8^8]JU-/\?ZK8:9;6+VNG7BVO_'K+=V_F20?[ASQBBS"Y8\%V
M4]W<:A?0Z-I,T$>,S:FY%M;9/0@GYOU(QUYYL_$C2;&Q?1KVTALHGO;<M,+
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M.1GSU17T+_PJKPE_SXR_^!#_ .-'_"JO"7_/C+_X$/\ XT<Z#D9\]45]"_\
M"JO"7_/C+_X$/_C1_P *J\)?\^,O_@0_^-'.@Y&?/5%?0O\ PJKPE_SXR_\
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M\9?_  (?_&C_ (55X2_Y\9?_  (?_&CG0<C/GJBOH7_A57A+_GQE_P# A_\
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M_P"!#_XT<Z#D9\]45]"_\*J\)?\ /C+_ .!#_P"-'_"JO"7_ #XR_P#@0_\
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MCG0<C/GJBOH7_A57A+_GQE_\"'_QH_X55X2_Y\9?_ A_\:.=!R,^>J*^A?\
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M?\*J\)?\^,O_ ($/_C1SH.1GSU17T+_PJKPE_P ^,O\ X$/_ (T?\*J\)?\
M/C+_ .!#_P"-'.@Y&?/5%?0O_"JO"7_/C+_X$/\ XT?\*J\)?\^,O_@0_P#C
M1SH.1GSU17T+_P *J\)?\^,O_@0_^-'_  JKPE_SXR_^!#_XT<Z#D9\]45]"
M_P#"JO"7_/C+_P"!#_XT?\*J\)?\^,O_ ($/_C1SH.1GSU17T+_PJKPE_P ^
M,O\ X$/_ (T?\*J\)?\ /C+_ .!#_P"-'.@Y&?/5%?0O_"JO"7_/C+_X$/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'_"?ZK_S[V7_ 'PW_P 51]4J!_;.%[O[CT>BO./^$_U7_GWLO^^&_P#BJ/\
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MIWD8I"O+-U$:]@/?_P#77<+!I/ABP\Q(@@R%! W22,>@SW/Z5#X/LEL_#T#
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M:93X^C_[M,H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !BN7N_C!XDN+Y9H6AMH57'V>.-2K'GDE@3GD="!Q55OBEXON+O$>K) CL
M;>+:@]R4S7;'"U(ZQBE\_P#@'!4H.I[M6K)KT5OS.G_L75?^@9>_]^&_PH_L
M75?^@9>_]^&_PK,U/XF>(;"TCMXM56:]P/,<V\9 R,Y&% [C''UHT?QSXPN8
MFO;W62MFJEN+>'+8//\ !TX/O3]G6M?3\?\ (X_JN%4.=RE;T6OXFG_8NJ_]
M R]_[\-_A1_8NJ_] R]_[\-_A6!-\3?%]_J'EZ9J#*A'RH;:')XY)RIKI+3Q
M9XICM MSJRR7&<EO(CVCV "CM2E"M%:V_'_(53#82FDY2EKTLK_F1?V+JO\
MT#+W_OPW^%']BZK_ - R]_[\-_A3AXE\3Y&?$$Y]<6T _P#9*K:OXO\ &H*-
MIVHH$ ^9?(BW$_BN,4DJK=M/Q_R(C2P4I**G+[E_F3_V+JO_ $#+W_OPW^%'
M]BZK_P! R]_[\-_A5(_$#Q/I6FM)J6K"2ZD!,48MX\#@<'"CN>>?I6?IGQ \
M;ZK=D)JP2%6!DQ;P_*">@RA]\52IUK7TM\_\C583"M.7-*RZV7^9N_V+JO\
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MI!8RVQ#]GCRY.!SE3WZ=.M/V5>]M/Q_R!8+#.;BI2T\E;\S?_L75?^@9>_\
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MCR7_ +OZU:HH J^2_P#=_6CR7_N_K5JB@"KY+_W?UH\E_P"[^M6J* *ODO\
MW?UH\E_[OZU:HH J^2_]W]:/)?\ N_K5JB@"!XW.W Z+BF>2_P#=_6K5% %7
MR7_N_K1Y+_W?UJU10!5\E_[OZT>2_P#=_6K5% %7R7_N_K1Y+_W?UJU10!5\
ME_[OZT>2_P#=_6K5% %7R7_N_K1Y+_W?UJU10!5\E_[OZT>2_P#=_6K5% %7
MR7_N_K1Y+_W?UJU10!5\E_[OZT>2_P#=_6K5% %7R7_N_K1Y+_W?UJU10!5\
ME_[OZT>2_P#=_6K5% %7R7_N_K4D4;*^2,#%344 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !534M3L](M#
M=WTWDP!@I?:6 ).!G -6ZHZQIL>KZ/=Z?+C;/&5!(S@]C^!P: +W6J UFP-Q
M?0"?,EBH>Y 1L1@C/7&#QV&36/X=UT+X-:ZOR5FTU7AN@QR0T?\ 4C'YU3T2
MRE@\"ZE?72XO-1BFNYO;<IVC\L?G3L*YO7/B/2;31X=6GN]EC-CRY?+<YSTX
M SV]*KZ=XR\/:M="VL]3C>9N%1U:,L?0;@,GV%<IJ,T=O\-?#DTK;8XY[9V.
M,X R35G7=8T_QC%:Z?H227ETMQ'(;E865;90<EBS 8X_.GRBN=_574-2L]*M
M&NKZX2"!3@LY[^@]3["H[K6=+L9O)O-2L[>7&=DTZHV/7!-1WNCVFH:A9:A<
M%Y39[FBBR#&6(^\1CDCMS2&-TCQ'I&N[QIMZD[)RRX*L!ZX8 X]ZNWEY;V%G
M+=W4JQ01+N=VZ 5R&G7T.N>/(KK[/+ILUK:NOD72&.>X#=#CIM'/<_2G:SN\
M437T0/\ Q)],5RY!XN+A5)V^ZKW]33MJ*^AUD%];7-@E]%,IM7C\U9&^4;<9
MR<]./6LNR\8^']0OQ96NIQ/<$X52K*&/H"0 ?P-5=*TN'6? &FV-Q)*D,EM%
MO\I@"P !QG!X..:R_%5U:W%Q9^'_ +')81I<Q>7?31;(4Q@XC8?Q8X[#KS0D
M@NSNJI:=JUCJPG:QN%G6"4Q2,H. PZ@$]?J.*R_$%W<7=S%X?TZ39<W2EKB8
M?\N\'0M_O'H*J^"K.'3WURSMDV0PWY1%]@BTK:#OJ=715:_N_L%C+=?9[BX\
ML9\JW3?(W/8=ZXR/QE-_PE$[G1?$!A-H@%K]E.Y6W'Y]F[ !Z9]J$K@W8[RJ
MFGZI9ZK%+)93>:L4K0R?*5*N.H((!J6TN/M=I#<>3+#YB!O+F7:ZY[,.QKF;
M0?V)X_N;7[MKK$?VB(=A,GWQ]2.:+!<Z&^U.TTWR/M<NPW$HAB 0L6<]!@ T
M1:E:3:C<:?'+FZMU5Y4VGY0W3G&#^%<\P_MOX@J/O6FBPY/7F=_\%_6G:7_R
M437_ /KV@_D:+!<D/Q!\++*8CJ@#!MIS!( #]=M=#;W$-W;I/;RI+"XRKHP(
M8>Q%>>>%?%NAZ9X?;3[V9GNO/E_T98'<OEC@#C!S]:WO"47]@^&6EU0QZ?%+
M</*D4[A!"K'Y5.>GT]Z;5A)W.JK 3QMX;>_^Q+JT)FW;1PVPG_?QM_6K[R6.
MOZ9<P6M^DL,JF)Y;656*Y'//(!P:P_%-I86'@TZ-!:J[S*+>S@51N:3LWU'4
MFDD-LZ'4M4LM(M#=7]RD$(.-S=SZ =2?856TCQ%I.NA_[-O4G*?>7!5@/7#
M''O4:^'X)WTJ>]9IIM/BVHA(*%\ %B",D\<'-992._\ B-%<6:#%A;/'>3+T
M9F^[&3W(Z^U%D%V;VI:QI^D+"U_<K#YSB.,$$EF/H!S^-6Y98X(7FFD6.)%+
M,[' 4#J2:X7QKH=M;PC57>2XO)KZ!5>4Y\I-WW$'8?J:W?&L*S^$KY&N(X%
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M4+RO+8/'X<#WHUG6([E/L5DJI9J0?E4KN//;TY].HJ_:VL'AVU%Y>#?<OPB
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4 7-R_WA^=&Y?[P_.J=% %S<O]X?G1N7^\/SJG10!<W+_>'YT;E_O#\ZIT4
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M.NW)X'7/.:DTSP=JFG69O[C1+^>X #1PBU?*GMVZ].W&*[/_ (3#7O\ G_\
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MHUB_S>:7J<?R\R26;@ #L!@#\/K7HG_"8:]_S_\ _D%/_B:/^$PU[_G_ /\
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M:C$:I]ED53SP3\HP.G';%=[_ ,)AKW_/_P#^04_^)H_X3#7O^?\ _P#(*?\
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MR/F(I+#=KWB--:0%=/M(VAM6(P9F;[SC_9XP/6M'4+ZST"RS%;J)97(AMH4
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M2%.78<A%[*/?_P#7793'2O">GAHH%#,=JCC?(WNQ[?H*/"-DMGX=MV &^?\
M>N?7/3],57\6I+']BO464QPEU=HG"E=VW!)((QP:Z)3YZG)T1YM&C[##/$/6
MH];[VO\ Y(U-,U:"]CCC:ZM7NRNYXX'R!]*KZSX:L-7B8F-8;G^&9!SGW]:H
M:7I^H27"2227D$)4,LBW,3AO0<+T-=16,GR2O!G=27UBERUHZ>:/%[^QGTV]
MEM+A<21G!QT([$>U5J[OX@V2^5:7R@!@QB8^O&1_(_G7"5Z=*?/!2/DL;A_J
M]>5-;= HHHK0Y HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** -SP?_P C59?\#_\ 0&KTBO-_!_\
MR-5E_P #_P#0&KTBO.QGQKT/J\C_ -WE_B_1!1117(>R%%%% !1110 4444
M%%%% #X^C_[M,I\?1_\ =IE !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 22=$_W14=22=$_P!T5'0 4444 %%%% !1110
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MT6>QGN]0U"2.;4KM\R/'DJB#[J+GG _STK;HI#"BBB@ HHHH **** "BBB@
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MKT*,.2"3/F,?B%B*\IQVZ!1116IQA1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ;G@__ )&JR_X'
M_P"@-7I%>;^#_P#D:K+_ ('_ .@-7I%>=C/C7H?5Y'_N\O\ %^B"BBBN0]D*
M*** "BBB@ HHHH **** 'Q]'_P!VF4^/H_\ NTR@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** )).B?[HJ.I).B?[HJ.@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *E@_UGX5
M%4L'^L_"@"Q1110 4444 121%VSG%-^SG^\*GHH @^SG^\*/LY_O"IZ* (/L
MY_O"C[.?[PJ>B@"#[.?[PH^SG^\*GHH @^SG^\*/LY_O"IZ* (/LY_O"C[.?
M[PJ>B@"#[.?[PH^SG^\*GHH @^SG^\*/LY_O"IZ* (/LY_O"C[.?[PJ>B@"#
M[.?[PH^SG^\*GHH @^SG^\*<D)4DYZC%2T4 0?9S_>%'V<_WA4]% $'V<_WA
M1]G/]X5/10!!]G/]X4?9S_>%3T4 0?9S_>%'V<_WA4]% $'V<_WA1]G/]X5/
M10!!]G/]X4?9S_>%3T4 0?9S_>%'V<_WA4]% $'V<_WA1]G/]X5/10!!]G/]
MX4?9S_>%3T4 0?9S_>%'V<_WA4]% $'V<_WA1]G/]X5/10!!]G/]X4?9S_>%
M3T4 0?9S_>%'V<_WA4]% $'V<_WA1]G/]X5/10!!]G/]X4?9S_>%3T4 0?9S
M_>%'V<_WA4]% $'V<_WA1]G/]X5/10!!]G/]X4?9S_>%3T4 0?9S_>%'V<_W
MA4]% $'V<_WA1]G/]X5/10!!]G/]X4?9S_>%3T4 0?9S_>%'V<_WA4]% $'V
M<_WA1]G/]X5/10!!]G/]X4?9S_>%3T4 0?9S_>%'V<_WA4]% $'V<_WA1]G/
M]X5/10!$D)7//48IOV<_WA4]% $'V<_WA1]G/]X5/10!!]G/]X4?9S_>%3T4
M 0?9S_>%'V<_WA4]% $'V<_WA1]G/]X5/10!!]G/]X4?9S_>%3T4 0?9S_>%
M'V<_WA4]% $'V<_WA1]G/]X5/10!!]G/]X4?9S_>%3T4 0?9S_>%'V<_WA4]
M% $'V<_WA1]G/]X5/10!!]G/]X4?9S_>%3T4 0?9S_>%'V<_WA4]% $'V<_W
MA1]G/]X5/10!!]G/]X4?9S_>%3T4 0?9S_>%'V<_WA4]% $'V<_WA1]G/]X5
M/10!!]G/]X4?9S_>%3T4 0?9S_>%'V<_WA4]% &'K/AJVUB,%V\N=1A95'/T
M/J*Y(Z%XET*5FLC*R9ZV[9#?5?\ ZU=[J6J6FDVWGW<H1>BJ.68^@%<7>>/;
MR:0I86J1J3A2X+L?P''\ZZZ#JM62NO,\7,(X.,^:<G&?]W<@_M7QE)F/R[S/
M?%H ?SV\55F\->)+U_/GMI978?>DF7/ZMQ4TOB/Q2!YA,T:>OV48_,K57_A,
M->_Y_P#_ ,@I_P#$UTJ-1? HH\J=3#RTK2J/[OU;#_A#]>_Y\/\ R,G_ ,51
M_P (?KW_ #X?^1D_^*H_X3#7O^?_ /\ (*?_ !-'_"8:]_S_ /\ Y!3_ .)I
M_O\ R_$S_P"$[^__ .2A_P (?KW_ #X?^1D_^*H_X0_7O^?#_P C)_\ %4?\
M)AKW_/\ _P#D%/\ XFC_ (3#7O\ G_\ _(*?_$T?O_+\0_X3O[__ )*'_"'Z
M]_SX?^1D_P#BJ/\ A#]>_P"?#_R,G_Q5'_"8:]_S_P#_ )!3_P")H_X3#7O^
M?_\ \@I_\31^_P#+\0_X3O[_ /Y*'_"'Z]_SX?\ D9/_ (JC_A#]>_Y\/_(R
M?_%4?\)AKW_/_P#^04_^)H_X3#7O^?\ _P#(*?\ Q-'[_P OQ#_A._O_ /DH
M?\(?KW_/A_Y&3_XJC_A#]>_Y\/\ R,G_ ,51_P )AKW_ #__ /D%/_B:/^$P
MU[_G_P#_ ""G_P 31^_\OQ#_ (3O[_\ Y*'_  A^O?\ /A_Y&3_XJC_A#]>_
MY\/_ ",G_P 51_PF&O?\_P#_ .04_P#B:/\ A,->_P"?_P#\@I_\31^_\OQ#
M_A._O_\ DH?\(?KW_/A_Y&3_ .*H_P"$/U[_ )\/_(R?_%4?\)AKW_/_ /\
MD%/_ (FC_A,->_Y__P#R"G_Q-'[_ ,OQ#_A._O\ _DH?\(?KW_/A_P"1D_\
MBJ/^$/U[_GP_\C)_\51_PF&O?\__ /Y!3_XFC_A,->_Y_P#_ ,@I_P#$T?O_
M "_$/^$[^_\ ^2A_PA^O?\^'_D9/_BJ/^$/U[_GP_P#(R?\ Q5'_  F&O?\
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M .2A_P (?KW_ #X?^1D_^*H_X0_7O^?#_P C)_\ %4?\)AKW_/\ _P#D%/\
MXFC_ (3#7O\ G_\ _(*?_$T?O_+\0_X3O[__ )*'_"'Z]_SX?^1D_P#BJ/\
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MH_X0_7O^?#_R,G_Q5'_"8:]_S_\ _D%/_B:/^$PU[_G_ /\ R"G_ ,31^_\
M+\0_X3O[_P#Y*'_"'Z]_SX?^1D_^*H_X0_7O^?#_ ,C)_P#%4?\ "8:]_P _
M_P#Y!3_XFC_A,->_Y_\ _P @I_\ $T?O_+\0_P"$[^__ .2A_P (?KW_ #X?
M^1D_^*H_X0_7O^?#_P C)_\ %4?\)AKW_/\ _P#D%/\ XFC_ (3#7O\ G_\
M_(*?_$T?O_+\0_X3O[__ )*'_"'Z]_SX?^1D_P#BJ/\ A#]>_P"?#_R,G_Q5
M'_"8:]_S_P#_ )!3_P")H_X3#7O^?_\ \@I_\31^_P#+\0_X3O[_ /Y*'_"'
MZ]_SX?\ D9/_ (JC_A#]>_Y\/_(R?_%4?\)AKW_/_P#^04_^)H_X3#7O^?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MB:-9?,;A0Q7&,XZ>U%D%V=U1114E!1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!N>#_\ D:K+_@?_ * U>JUY5X/_ .1JLO\ @?\ Z U>JUYV,^->A]7D
M?^[R_P 7Z(****Y#V0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(?KW_/A_Y&3_ .*KU6BCZY/L@_L/#_S2_#_(\J_X0_7O^?#_ ,C)_P#%4?\
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M?^1D_P#BJ]5HH^N3[(/[#P_\TOP_R/*O^$/U[_GP_P#(R?\ Q5'_  A^O?\
M/A_Y&3_XJO5:*/KD^R#^P\/_ #2_#_(\J_X0_7O^?#_R,G_Q5'_"'Z]_SX?^
M1D_^*KU6BCZY/L@_L/#_ ,TOP_R/*O\ A#]>_P"?#_R,G_Q5'_"'Z]_SX?\
MD9/_ (JO5:*/KD^R#^P\/_-+\/\ (\J_X0_7O^?#_P C)_\ %4?\(?KW_/A_
MY&3_ .*KU6BCZY/L@_L/#_S2_#_(\_\ #?AO5K#7[6ZNK3RX4W[F\Q#C*D#@
M'/4UZ!116%2HZCNSOPF$AA8.$&[7OJ%%%%9G4%%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !15"YTBVNYS-)+
M>JQQD17LT:_]\JX'Z5%_PC]E_P ]M2_\&=Q_\<H U**R_P#A'[+_ )[:E_X,
M[C_XY1_PC]E_SVU+_P &=Q_\<IZ"-2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_S
MVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\
M'*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'
M[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[
MC_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_S
MVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\
M'*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'
M[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[
MC_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_S
MVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\
M'*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'
M[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[
MC_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_S
MVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\
M'*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'
M[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[
MC_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_S
MVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\
M'*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'
M[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[
MC_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_S
MVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\
M'*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'
M[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[
MC_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_S
MVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\
M'*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'
M[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[
MC_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_S
MVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\
M'*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'
M[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[
MC_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_S
MVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\
M'*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'
M[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[
MC_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_S
MVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\
M'*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'
M[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[
MC_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_S
MVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\
M'*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'
M[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[
MC_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_S
MVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\
M'*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'
M[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[
MC_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_S
MVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\
M'*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'
M[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[
MC_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_S
MVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\
M'*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'
M[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[
MC_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_S
MVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\
M'*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'
M[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[
MC_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_S
MVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\
M'*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'
M[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[
MC_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_S
MVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\
M'*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'
M[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[
MC_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_S
MVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\
M'*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'
M[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[
MC_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_S
MVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\
M'*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'
M[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[
MC_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_S
MVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\
M'*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'
M[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[
MC_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_S
MVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\
M'*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'
M[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[
MC_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_S
MVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\
M'*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'
M[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[
MC_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_S
MVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\
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M\]?0T>>OH:KT4 6//7T-'GKZ&J]% %CSU]#1YZ^AJO10!8\]?0T>>OH:KT4
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M"5_:5Y\BCMOKM^!]2[C_ '#^E&X_W#^E?-445OX9M#-,5EOI 5 1NQZ<'''
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MXYXX'?-4[NZNM?U!8XU)0-B-=OW < DX[=,T?V;=Z3T]/^""S-.32CHMW?\
MX!]4[C_</Z4;C_</Z5\U75U!X=M39V9WW+\NY.=O7!(['D<8JAHVCQW*?;;U
ME2S4D?,Q7<>._ISZ]12_L[2[EIZ?\$2S5<KFXV737?\  ^I-Q_N']*-Q_N']
M*^6=5U6?6;@06Z2&$$%(PF6) //'U-:7^C^&+3(Q->R@9&[@#Z>G7!Q0\M:2
M][7T_P""#S-Q2O#WGTO_ , ^E-Q_N']*-Q_N']*^6-+TY]5N9+JX<"!7W3.W
M&XG)..WUZ8S4VKZK]H"Z;8@_9EQ'@ -O((Q@\G' QZT_[-ULI?A_P2GF7O\
M)&-^^NWX'U#N/]P_I1N/]P_I7S1:V\&@6*WUQEKN1/DCS@J3VQQZC/I6;;6U
MQX@U265B%!(9VQPJ\  <=<=/I0LM3N^?3T_X(HYHG=\ONKK?_@'U3N/]P_I1
MN/\ </Z5\Q:KJL5K;?V9II B4%7<$,&!'(!Y]33],T^'3;4:IJ 974G9$?E8
M'MP<<\'CTI?V=I=R_#_@D_VI:'-*&^ROJ_P/IK<?[A_2C<?[A_2OE5VNO$6J
M@*%5BN .=J*/4@>O\ZT[V_AT.U^P:<W[\D,\F0P!Z'KGGCICO3>6O1<VOI_P
M2I9FTU%0]Y]+[?.Q]+[C_</Z4;C_ '#^E?+^CZ3'Y+:A?YCAC(*JWR[N.#GC
MCD8]:KW][-KVHPPQ)M7<5C4CU/4X]@,_2C^S;NRG^'_!&LS3FXJ.BW=_^ ?5
M&X_W#^E&X_W#^E?-,DL'ARP,$)#W\J_.RG(4CN0>GWN..:HZ5IC:G/+>7K%8
M ?,9V&T.<\\],<'..E)9=I?FT]/^"2LU7*YN-H]-=_E8^I-Q_N']*-Q_N']*
M^6M8U4ZBZ6=M&?(C8! !DN<8']<?6M"**W\,VAFF*RWT@*@(W8].#CC@<XH>
M6V7Q:^G_  0>:.,5>'O/97_X!]*[C_</Z4I)'\)-?*UC97.O7[2W#-M(^>7;
M@9   &!C/3\*L:SJL7D?V99*!;)@%@=V[!S@'GCIS3_LW6RE^'_!*>9/G4%"
M[ZZ[?@?4&X_W#^E&X_W#^E?,]A90:';#4;[!G(!BC!PP!&#P<9///I6<BW?B
M'5%,F=N<%@O$:\G&0/KC/6A9;>_OZ>G_  1+-$VVH^ZNM_\ @'U3N/\ </Z4
M;C_</Z5\R:G?PZ;9MI5C@_*5EDSGD]?7D\Y]*;I.FQ6MN-5OR BC?"F<,2,D
M=<<\<#OFE_9VEW+\/^"+^U+0YW#TUU?X'T[N/]P_I1N/]P_I7RM=W5UK^H+'
M&I*!L1KM^X#@9..W3-:EU=0>';4V=F=]R_+N3G;UP2.QY'&*;RUJRYM?3_@A
M+,VK1Y/>?2_ZV/I7<?[A_2C<?[A_2OEO1M'CN4^VWK*EFI(^9BNX\=_3GUZB
MFZKJL^LW @MTD,((*1A,L2 >>/J:/[-N[*7X?\$K^TKSY8QVW=]OP/J;<?[A
M_2C<?[A_2OFO_1_#%ID8FO90,C=P!]/3K@XK,TO37U:YDNKAP(%?=,[<;B<D
MX[?7IC-)9<K-\^GI_P $F.:IQ<W'W5UOO^!]3[C_ '#^E,\]?0UX?X&U=9?B
M)I-A9_+:1B9#T._$3XP>>.!SWKVBN/$4'1DHM^9VX6O*O#GE&Q8\]?0T>>OH
M:KT5@=)8\]?0T>>OH:KT4 6//7T-'GKZ&J]% %CSU]#1YZ^AJO10!8\]?0T>
M>OH:KT4 65E5LX!X&:3SU]#44?1_]VF4 6//7T-'GKZ&J]% %CSU]#1YZ^AJ
MO10!8\]?0T>>OH:KT4 6//7T-'GKZ&J]% %CSU]#1YZ^AJO10!8\]?0T>>OH
M:KT4 6//7T-'GKZ&J]% %CSU]#1YZ^AJO10!8\]?0T>>OH:KT4 6//7T-'GK
MZ&J]% %CSU]#1YZ^AJO10!9:55QD'D9I//7T-1R=$_W14= %CSU]#1YZ^AJO
M10!8\]?0T>>OH:KT4 6//7T-'GKZ&J]% %CSU]#1YZ^AJO10!8\]?0T>>OH:
MKT4 6//7T-'GKZ&J]% %CSU]#1YZ^AJO10!8\]?0T>>OH:KT4 6//7T-'GKZ
M&J]% %CSU]#1YZ^AJO10!8\]?0TY)5<X /XU5J6#_6?A0!8HHHH **** *T_
M^L_"HZDG_P!9^%1T <9J-[=I\4-+M$NIEMGMRSPB0A&.).2O0]!^5:/CBYGM
M/"-Y-;320RJ4VO&Y5A\X[BN>\1V?V_XG:9;?:;BVWVO^MMWV.N!(>#VZ4OC#
MPW_9_ABZN?[:UFYV%/W5S=;T;+ <C%79:$7=F/\ %VHWUMX%T>X@O+B*>0Q;
MY8Y65FS&2<D')YK4F\+7]O;-/IOB/5S=JN46ZG$L;'T*D?K6%XU_Y)[H?UA_
M]%FN]O+^VTS3WN[N58X8UR23UXZ#U/M0]@6YP=_KVHZSX.&K6LT]KJ&FS@74
M4+LJN.,Y /(Z'GI@UV@UJW/AP:R2!#]G\[!/MG'USQ7-> M-:XT'4I[N(K!J
M4K%4/="",_J?RKES/>)IS>!QN\_^T/+#;3_JL[L_G\WT-.R>@7:U.W\"&_N=
M&DU+4+F>62\E+HLCDA$!P-H/09ST[8KJ:BM;:.SM(;:%0L<2!%'H ,5+4-W9
M2T04444AA1110 4444 %%%% !1110 5)%]X_[IJ.I(OO'_=- $=9'B:WN[CP
M_=?8)YH;J-?-C:)B"2O...N1D5KT4 4=(U)-4T:UU!<*LL8=AG[I[C\#FN>T
MJ\N]0TG7M;-S-Y,WF"S42, B(I 91V)(_2LB[NYM"CUCPU;\2W<Z_8!T^6;A
ML>R\UV%S91Z=X3GLX1B.&S=![X0\U5K$[G-7]W>2> M#<7UU'-<2P))/'*1(
M0V0?FZU+J]G>^%8(=1L];U&Z'GI&]O>RB42ACC"\#!JEJ$?G?#OP]'O=-\UN
MNY#AESGD'UJQ)ID6@^*;*35;B[U"PEPMM<7DS2?9Y^V>W/8X_EFF([NL;7+;
M5;^>ULK&=[2T?<UU=1$;U Z*O.03Z@<8HU/3=:NKSS+#7_L,&T#R?L:2\]SD
MG-6=4U:'1[-9)MTTSD)#"@^>9_0#_.*E%&'9)>:'XKMM+_M*YOK.[@>3%V^^
M2)E[[O0]*D;1-7UBYNKF_P!5O].42%;6WLY0H"#HS$9W$]<5?T;2IXKB75=2
M*OJ5PH4A?NP)U$:_U/<U!J6H7&HWCZ+I#[9 ,7=V.1;J>P]7/8=J=Q6(M U;
M49_#5Q-)']NO+:62!?+(3SRIP#D\#_ZU5O#TVK?\)=J,&JW?FO\ 9HY/*C)\
MJ(D]%'MZ]ZZ73["WTRQAL[5-D,2X4?S)]R>:PK'_ )*)JW_7G#1W#L,UAKG4
MO%$.C?VC<:?:_9C/NMV"23-NQM#>PYXI^@37-KK^H:,]_+J%O;QI(DLS!I(R
M<@HS=SWJGJ%K;:_XVDTO5VW6MM;K);6^[9YC-]YLCDX] ?ZT_0X[?1O%]UHF
MF$&Q-M]HDCSN\F7=C&[KR,<$FGT#J=?5!-2W:[+IGE8\NW6?S-W7+$8QCVZY
MJ>^M/MUG);?:)[?>,>;;OL=>>Q[5QD?AC/BR>U_MS6QMLTD\X7?[PY=AM)QT
MXZ5*2&VSNZYOP_<W-MKNKZ-=SRS&.07-N\KEB8G[#/8'BMZU@^RVL4'FRS>6
MH7S)6W.V.Y/<USOB<?V9JFEZ^N L$GV>Y./^63\9/L#_ #H78'W)-9NI[OQ/
MI>CVL\D07-W=&-RI\M>%4D=B>WTIVGW,[^-]9MWGD:&."$I&7)521R0.@J+P
MD#J$VHZ_(.;V8I!D](4X'YG-&F_\C_KG_7O!_*GY",KP[HUUK6DF^E\0ZU%.
M9I% 2Z.P88@?*1_6M[PCJ-UJ6C,UY(LLT,[P><HP)0IX;%<;I^@7EYX1FO;&
M_OVE6>0M8K.5AE4,=RA1@Y(]Z['3O*U+PK;CP[=+IJ$#81")#&0?F4J>^<Y/
MXTY"1L7LEQ%93R6L/G7"H3'&6 W-V&37':GI^J:5HCZS<>(KQ=31 YA,@\@M
M_<"8P?2M^-[S0='NKK5K^34_*S)NCMEC8+CH%!P>YS67XGM='N](?Q''<^5=
M0P[K6[CE(Y&2JXS@Y)QC&>:2&S=N-4CL-$&HWX\D+$KNG<,0/E'ODXK"\+7.
MJS:_J@U65P[112K;[B5@#;L*!TS@#/O5:[;Q#?76DW;:)]MMH8$G\O[2D0,Y
M7EF#?W><#'6FZ1J&L2>-;XRZ%Y32QP+./M:-Y"\X;I\V>>!Z4[:!?4T)-(U7
M59[JZU+5+W3(4D*VT-I.J (.C.1G.>N.U6_"E_=7VA>;>RB5HY9(UN,8$R*<
M!_3_ /539/[%\8:;)'=1LT=M,PDCD<H\3KD9.#QW/-<Y!+K>H^%9;+3D?4+8
M7KV_G><L;R6RXZ,>.>1GFEN&Q;.L7VI^+-+N8)GCT=YI(855B!<80EG([C(
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M%% !1110!))T3_=%1U))T3_=%1T %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !4L'^L_"HJE@_UGX4 6**** "BBB@"M/_K/PJ.I
M)_\ 6?A4= %"71K";5X=5D@S>PKLCEWMP.>V<=SVJ74-/M=5LGL[V+S;>3&Y
M-Q7.#D<@@]15JBBX&;>Z!IFHZ=!87=MYEK!CRT\QAMP,#D')XJA!X&\-6TPE
M32XRPZ"1W<?DQ(KH:*=V*R$50JA5   P .U9YT+3#K0U<VJ_;P,>=N;TQTSC
MIQTK1HI#"BBB@ HHHH **** "BBB@ HHHH **** "I(OO'_=-1U)%]X_[IH
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M:E%*X[!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MSL>1GU/.1G%9]I8W&M7KW5R62 DM)+V YX&3TXQWQ2T:_N_F3:+C9:4U^/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 22=$_W14=22=$_P!T5'0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %2P?ZS\
M*BJ6#_6?A0!8HHHH **** &M&K')'--\E/3]:DHH C\E/3]:/)3T_6I** (_
M)3T_6CR4]/UJ2B@"/R4]/UH\E/3]:DHH C\E/3]:/)3T_6I** (_)3T_6CR4
M]/UJ2B@"/R4]/UH\E/3]:DHH C\E/3]:/)3T_6I** (_)3T_6CR4]/UJ2B@"
M/R4]/UH\E/3]:DHH C\E/3]:41JO04^B@"/R4]/UH\E/3]:DHH C\E/3]:/)
M3T_6I** (_)3T_6CR4]/UJ2B@"/R4]/UH\E/3]:DHH C\E/3]:/)3T_6I**
M(_)3T_6CR4]/UJ2B@"/R4]/UH\E/3]:DHH C\E/3]:/)3T_6I** (_)3T_6C
MR4]/UJ2B@"/R4]/UH\E/3]:DHH C\E/3]:/)3T_6I** (_)3T_6CR4]/UJ2B
M@"/R4]/UH\E/3]:DHH C\E/3]:/)3T_6I** (_)3T_6CR4]/UJ2B@"/R4]/U
MH\E/3]:DHH C\E/3]:/)3T_6I** (_)3T_6CR4]/UJ2B@"/R4]/UH\E/3]:D
MHH C\E/3]:/)3T_6I** (_)3T_6CR4]/UJ2B@"/R4]/UH\E/3]:DHH C\E/3
M]:/)3T_6I** (_)3T_6CR4]/UJ2B@"/R4]/UH\E/3]:DHH C\E/3]:/)3T_6
MI** &"-5S@=1BD\E/3]:DHH C\E/3]:/)3T_6I** (_)3T_6CR4]/UJ2B@"/
MR4]/UH\E/3]:DHH C\E/3]:/)3T_6I** (_)3T_6CR4]/UJ2B@"/R4]/UH\E
M/3]:DHH C\E/3]:/)3T_6I** (_)3T_6CR4]/UJ2B@"/R4]/UH\E/3]:DHH
MC\E/3]:/)3T_6I** (_)3T_6CR4]/UJ2B@"/R4]/UH\E/3]:DHH C\E/3]:/
M)3T_6I** (_)3T_6CR4]/UJ2B@"/R4]/UH\E/3]:DHH C\E/3]:/)3T_6I**
M (_)3T_6CR4]/UJ2B@"/R4]/UH\E/3]:DHH H:EHNG:Q9/9ZA:I<0-U1^Q]0
M>H/N*\RUCX)1O*TFCZIY:D\0W29 _P"!#_#\:]<HK:EB*E+X&9SI0G\2/"$^
M"OB-GVO?:8J#N))#^0V5NV?P1BB3?<ZR))<<*+;Y ?\ OL$_I7K5%;RQ]=];
M&7U2DU9K\3R1_@CYMQYLOB+<"V2JV6./0?O...!6C?\ PH>ZMEMK;7!:0C.5
MCL^O7CAQQSTKTJBH>-KO[7X(3P5"33<=O-GF&D_!V+3)6E.M&64@J#]EP ..
MV\\\5H?\*[NDA_Y"L,LG_7N8Q_Z$U=_12>+K-W;_ ",ZF6X:H[RCKZO_ #/.
M5\ ZH6PUQ:!1WWL?_9:MK\.G."VJ@>PM\_KNKNZ*3Q57N91RC"+>-_FSRS4O
M@[-J=QYDGB+:JY"(++A1_P!_.OO[5:A^$PM---K:ZRL4K+M>?[)\QZ\\./7C
MGBO2:*KZY7M;F_!'0\!AW%1Y=%YL\GM_@E&EUY]SKS7'.X@VF-QSGG+G-6=5
M^$<NJ,H/B 1PIRL8L\\X[_O.>_;O7I]%'UVO>_-^"&\%0<E)QU7FSS33OA(F
MFVK)#JZ&X;/[YK/],;\XX'&:SQ\$?,N/-NO$<DV?O?Z+ACQQR7->MT4+&UUK
MS?@@6"H)MJ.K\V>::E\)I+^!;>/75M[=<?(MGUQ_P,<=.,=J9I?P?BTP.W]L
M++,WW9&L\;..WS^Y[UZ=12^N5K6YOP1/U##\G)RZ>K_S/)I_@M)=W7GW/B1I
M,MDC['T&<X&9#@5H7/PG9].6QMM;%O$%VL1:9+#\''7G/KFO2:*;QM=_:_!#
M>!P[M>.WJ>6Z9\&8=/G::361<-@;-UF %.<Y^^>>E1W_ ,&I]0N#+-XE./X4
M^QG"_3]Y[5ZM11]=KWOS?@A_4J'-S\NOJSS=?A1]GTXVEEK7D9SF0VN6.?HX
MY]_:J%C\$X;6Z$TVMBX4 XC:R !/OESFO5Z*%C*Z^U^0E@<.DTH[[ZO_ #/+
MM3^$$^IS;G\1E(A]V(69('7G_6=>>M6++X3+IUF\5MK $SX+2O:9YX[;QQUX
MSQFO2:*7URM:W-^"$\!AW%0Y=/5_YGDL'P25+Q)Y_$!G ;<RM9_?/N2Y[U=U
M/X22Z@B1)X@\BW08$26?!Z=?W@'&...*]-HI_7:[=^;\$4\%0<E)QU7J>9Z;
M\(8],BD,>L;[AUQYC6G ZXP-_P!,\\XJC+\$VN+MI[CQ&7+-E@+/!(] ?,./
M2O6J*%C:Z=^;\$"P5!2<E'5^;/-;_P"%#W5LMM;:X+2$9RL=GUZ\<...>E0Z
M7\'(=-E,S:R9I>0I-J %''0;SS[^]>H44OKE>UN;\B5@,.H\BCIZO_,\GO?@
MO-?W+3S^),L1C LN /0?O*T)?A05L!:66M_91QN=;3YCC'.0XYXY->D44WC*
M[^U^"&\#AW9..WJ>5:=\%H;*Y$\NM&=E.4!M  #[_.<__6IVI?!V;4[CS)/$
M6U5R$067"C_OYU]_:O4Z*/KM>]^;\$/ZE0YN?EU]6>;0_"86FFFUM=96*5EV
MO/\ 9/F/7GAQZ\<\50M_@E&EUY]SKS7'.X@VF-QSGG+G->L44+&UU]K\A+ T
M%>T=_-_YGF&J_".75&4'Q (X4Y6,6>><=_WG/?MWJ33OA(FFVK)#JZ&X;/[Y
MK/\ 3&_..!QFO2Z*7URM:W-^"%]0P_)R<NGJ_P#,\D'P1\RX\VZ\1R39^]_H
MN&/'')<UH:E\)I+^!;>/75M[=<?(MGUQ_P #''3C':O2Z*;QM=N_-^"*>"H-
MIN.WJ>8Z7\'XM,#M_;"RS-]V1K/&SCM\_N>]5)_@M)=W7GW/B1I,MDC['T&<
MX&9#@5ZS11]=KWOS?@@6"H*3ERZOS9YM<_"=GTY;&VUL6\07:Q%IDL/P<=><
M^N:K:9\&8=/G::361<-@;-UF %.<Y^^>>E>I44?7*]K<WY$K 8=1<5'1^;_S
M/*;_ .#4^H7!EF\2G'\*?8SA?I^\]JO+\*/L^G&TLM:\C.<R&URQS]''/O[5
MZ110\97:MS?@AO X=I1<=%ZGE%C\$X;6Z$TVMBX4 XC:R !/OESFIM3^$$^I
MS;G\1E(A]V(69('7G_6=>>M>HT4?7:][\WX(;P5!RYW'7U9YM9?"9=.LWBMM
M8 F?!:5[3//';>..O&>,UG0?!)4O$GG\0&<!MS*UG]\^Y+GO7K5%"QM=?:_!
M"6!H*[4=_-_YGF6I_"274$2)/$'D6Z# B2SX/3K^\ XQQQQ2Z;\(8],BD,>L
M;[AUQYC6G ZXP-_TSSSBO3**7URO:W-^"%]0P_)R<NGJ_P#,\EE^";7%VT]Q
MXC+EFRP%G@D>@/F''I6C?_"A[JV6VMM<%I",Y6.SZ]>.'''/2O2:*;QM=_:_
M!%/!4&TW';U/+]+^#D.FRF9M9,TO(4FU "CCH-YY]_>J][\%YK^Y:>?Q)EB,
M8%EP!Z#]Y7K%%'UVO>_-^"!8*@I<_+KZL\WE^%!6P%I9:W]E'&YUM/F.,<Y#
MCGCDU2T[X+0V5R)Y=:\]E.4!M  #[_.<_P#UJ]5HH6,KI6YOR$L#AU%Q4=_-
M_P"9PFD?#J;3?%EIK<FM>>MKO"6XMMHPRLO7>>?FZXYQ7;^2GI^M245C4JRJ
M.\F;TJ4*4>2"LB/R4]/UH\E/3]:DHK,T(_)3T_6CR4]/UJ2B@"/R4]/UH\E/
M3]:DHH C\E/3]:/)3T_6I** (_)3T_6CR4]/UJ2B@!@C49P.O%)Y*>GZU)10
M!'Y*>GZT>2GI^M244 1^2GI^M'DIZ?K4E% $?DIZ?K1Y*>GZU)10!'Y*>GZT
M>2GI^M244 1^2GI^M'DIZ?K4E% $?DIZ?K1Y*>GZU)10!'Y*>GZT>2GI^M24
M4 1^2GI^M'DIZ?K4E% $?DIZ?K1Y*>GZU)10!'Y*>GZT>2GI^M244 1^2GI^
MM'DIZ?K4E% ##&IQD=!BD\E/3]:DHH C\E/3]:/)3T_6I** (_)3T_6CR4]/
MUJ2B@"/R4]/UH\E/3]:DHH C\E/3]:/)3T_6I** (_)3T_6CR4]/UJ2B@"/R
M4]/UH\E/3]:DHH C\E/3]:/)3T_6I** (_)3T_6CR4]/UJ2B@"/R4]/UH\E/
M3]:DHH C\E/3]:/)3T_6I** (_)3T_6G+&JG('-.HH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]M2_\&=Q_P#'*/\ A'[+_GMJ7_@SN/\ XY1H!J45E_\ "/V7_/;4O_!G<?\
MQRC_ (1^R_Y[:E_X,[C_ ..4: :E%9?_  C]E_SVU+_P9W'_ ,<H_P"$?LO^
M>VI?^#.X_P#CE&@&I167_P (_9?\]M2_\&=Q_P#'*/\ A'[+_GMJ7_@SN/\
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ME&@&I167_P (_9?\]M2_\&=Q_P#'*/\ A'[+_GMJ7_@SN/\ XY1H!J45E_\
M"/V7_/;4O_!G<?\ QRC_ (1^R_Y[:E_X,[C_ ..4: :E%9?_  C]E_SVU+_P
M9W'_ ,<H_P"$?LO^>VI?^#.X_P#CE&@&I167_P (_9?\]M2_\&=Q_P#'*/\
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M]M2_\&=Q_P#'*/\ A'[+_GMJ7_@SN/\ XY1H!J45E_\ "/V7_/;4O_!G<?\
MQRC_ (1^R_Y[:E_X,[C_ ..4: :E%9?_  C]E_SVU+_P9W'_ ,<H_P"$?LO^
M>VI?^#.X_P#CE&@&I167_P (_9?\]M2_\&=Q_P#'*/\ A'[+_GMJ7_@SN/\
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ME&@&I167_P (_9?\]M2_\&=Q_P#'*/\ A'[+_GMJ7_@SN/\ XY1H!J45E_\
M"/V7_/;4O_!G<?\ QRC_ (1^R_Y[:E_X,[C_ ..4: :E%9?_  C]E_SVU+_P
M9W'_ ,<H_P"$?LO^>VI?^#.X_P#CE&@&I167_P (_9?\]M2_\&=Q_P#'*/\
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M]M2_\&=Q_P#'*/\ A'[+_GMJ7_@SN/\ XY1H!J45E_\ "/V7_/;4O_!G<?\
MQRC_ (1^R_Y[:E_X,[C_ ..4: :E%9?_  C]E_SVU+_P9W'_ ,<H_P"$?LO^
M>VI?^#.X_P#CE&@&I167_P (_9?\]M2_\&=Q_P#'*/\ A'[+_GMJ7_@SN/\
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M34= $WV@_P!T4?:#_=%0T4 3?:#_ '11]H/]T5#10!-]H/\ =%'V@_W14-%
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M#44_[+P_9_>'URJ>\_\ "[/#?_/EJO\ WZC_ /CE'_"[/#?_ #Y:K_WZC_\
MCE>#44?V7A^S^\/KE4]Y_P"%V>&_^?+5?^_4?_QRC_A=GAO_ )\M5_[]1_\
MQRO!J*/[+P_9_>'URJ>\_P#"[/#?_/EJO_?J/_XY1_PNSPW_ ,^6J_\ ?J/_
M ..5X-11_9>'[/[P^N53WG_A=GAO_GRU7_OU'_\ '*/^%V>&_P#GRU7_ +]1
M_P#QRO!J*/[+P_9_>'URJ>\_\+L\-_\ /EJO_?J/_P".4?\ "[/#?_/EJO\
MWZC_ /CE>#44?V7A^S^\/KE4]Y_X79X;_P"?+5?^_4?_ ,<H_P"%V>&_^?+5
M?^_4?_QRO!J*/[+P_9_>'URJ>\_\+L\-_P#/EJO_ 'ZC_P#CE'_"[/#?_/EJ
MO_?J/_XY7@U%']EX?L_O#ZY5/>?^%V>&_P#GRU7_ +]1_P#QRC_A=GAO_GRU
M7_OU'_\ '*\&HH_LO#]G]X?7*I[S_P +L\-_\^6J_P#?J/\ ^.4?\+L\-_\
M/EJO_?J/_P".5X-11_9>'[/[P^N53WG_ (79X;_Y\M5_[]1__'*/^%V>&_\
MGRU7_OU'_P#'*\&HH_LO#]G]X?7*I[S_ ,+L\-_\^6J_]^H__CE'_"[/#?\
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M2"- (D4(J]@ ,8J2B@"J^F6$EFMF]E;-:KRL)B4H/HN,4ITZQ90K6=N5$9A
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M#T%&!Z"EHH 3 ]!1@>@I:* $P/048'H*6B@!,#T%&!Z"EHH 3 ]!1@>@I:*
M$P/048'H*6B@!,#T%&!Z"EHH 3 ]!1@>@I:* $P/2C ]!2T4 )@>@HP/04M%
M "8'H*,#T%+10 F!Z"C ]!2T4 )@>@HP/04M% "8'H*,#T%+10 F!Z"C ]!2
MT4 )@>@HP/04M% "8'H*,#T%+10 F!Z"C ]!2T4 )@>@HP/04M% "8'H*,#T
M%+10 F!Z"C ]!2T4 )@>@HP/04M% "8'H*,#T%+10 F!Z"C ]!2T4 )@>@HP
M/04M% "8'H*,#T%+10 F!Z"C ]!2T4 )@>@K)U3PMH6M$MJ.E6T[GK(4VO\
M]]#!_6M>BG&3B[IV$TGHSCT^%W@Y)-XTC/H&N)2!_P"/5K1^#_#4<:HOA_2R
M%&!NM$8_F1DUM45HZU1[R?WDJG!;(Q_^$2\-_P#0OZ5_X!1_X4?\(EX;_P"A
M?TK_ , H_P#"MBBI]K/NQ\D>QC_\(EX;_P"A?TK_ , H_P#"C_A$O#?_ $+^
ME?\ @%'_ (5L44>UGW8<D>QC_P#")>&_^A?TK_P"C_PH_P"$2\-_]"_I7_@%
M'_A6Q11[6?=AR1[&/_PB7AO_ *%_2O\ P"C_ ,*/^$2\-_\ 0OZ5_P" 4?\
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M_ */_"C_ (1+PW_T+^E?^ 4?^%;%%'M9]V')'L8__")>&_\ H7]*_P# */\
MPH_X1+PW_P!"_I7_ (!1_P"%;%%'M9]V')'L8_\ PB7AO_H7]*_\ H_\*/\
MA$O#?_0OZ5_X!1_X5L44>UGW8<D>QC_\(EX;_P"A?TK_ , H_P#"C_A$O#?_
M $+^E?\ @%'_ (5L44>UGW8<D>QC_P#")>&_^A?TK_P"C_PH_P"$2\-_]"_I
M7_@%'_A6Q11[6?=AR1[&/_PB7AO_ *%_2O\ P"C_ ,*/^$2\-_\ 0OZ5_P"
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M%_2O_ */_"C_ (1+PW_T+^E?^ 4?^%;%%'M9]V')'L8__")>&_\ H7]*_P#
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M4M% "8'H*,#T%+10 F!Z"C ]!2T4 )@>@HP/04M% "8'H*,#T%+10 F!Z"C
M]!2T4 )@>@HP/04M% "8'H*,#T%+10 F!Z"C ]!2T4 )@>@HP/04M% "8'H*
M,#T%+10 F!Z"C ]!2T4 )@>@HP/04M% "8'H*,#T%+10 F!Z48'H*6B@!,#T
M%&!Z"EHH 3 ]!1@>@I:* $P/048'H*6B@!,#T%&!Z"EHH 3 ]!1@>@I:* $P
M/048'H*6B@!,#T%&!Z"EHH 3 ]!1@>@I:* $P/048'H*6B@!,#T%&!Z"EHH
M3 ]!1@>E+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MHK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\
MGMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE
M'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_
M  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4
MHK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\
MGMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE
M'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_
M  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4
MHK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\
MGMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE
M'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_
M  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4
MHK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\
MGMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE
M'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_
M  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4
MHK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\
MGMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE
M'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_
M  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4
MHK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\
MGMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE
M'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_
M  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4
MHK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\
MGMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE
M'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_
M  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4
MHK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\
MGMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE
M'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_
M  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4
MHK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\
MGMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE
M'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_
M  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4
MHK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\
MGMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE
M'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_
M  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4
MHK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\
MGMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE
M'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_
M  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4
MHK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\
MGMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE
M'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_
M  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4
MHK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\
MGMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE
M'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_
M  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4
MHK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\
MGMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE
M'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_
M  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4
MHK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\
MGMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE
M'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_
M  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4
MHK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\
MGMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE
M'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_
M  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4
MHK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\
MGMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE
M'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_
M  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4
MHK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\
MGMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE
M'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_
M  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4
MHK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\
MGMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE
M'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_
M  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4
MHK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\
MGMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE
M'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_
M  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4
MHK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\
MGMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE
M'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_
M  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4
MHK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\
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MZ4><_P#>_2N?LO&7A[4+@06^IQ&1N )%:/)] 6 R:W:5K#N/\Y_[WZ4><_\
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M_P#$UR%%'U:A_(ON0>VJ?S/[SK_^%H>,O^@R?_ >+_XFC_A:'C+_ *#)_P#
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M (FC_A:'C+_H,G_P'B_^)KD**/JU#^1?<@]M4_F?WG7_ /"T/&7_ $&3_P"
M\7_Q-'_"T/&7_09/_@/%_P#$UR%%'U:A_(ON0>VJ?S/[SK_^%H>,O^@R?_ >
M+_XFC_A:'C+_ *#)_P# >+_XFN0HH^K4/Y%]R#VU3^9_>=?_ ,+0\9?]!D_^
M \7_ ,31_P +0\9?]!D_^ \7_P 37(44?5J'\B^Y![:I_,_O.O\ ^%H>,O\
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M_P#$UR%%'U:A_(ON0>VJ?S/[SK_^%H>,O^@R?_ >+_XFC_A:'C+_ *#)_P#
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M (FC_A:'C+_H,G_P'B_^)KD**/JU#^1?<@]M4_F?WG7_ /"T/&7_ $&3_P"
M\7_Q-'_"T/&7_09/_@/%_P#$UR%%'U:A_(ON0>VJ?S/[SK_^%H>,O^@R?_ >
M+_XFC_A:'C+_ *#)_P# >+_XFN0HH^K4/Y%]R#VU3^9_>=?_ ,+0\9?]!D_^
M \7_ ,31_P +0\9?]!D_^ \7_P 37(44?5J'\B^Y![:I_,_O.O\ ^%H>,O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0Z(<>JQJI_4&N3KW<-)RIIOLCSJJ2FT@HHHK<S"BBB@ HHHH **** "BBB@
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M3^5 #:*=L;^Z?RHV-_=/Y4 -HIVQO[I_*C8W]T_E0 VBG;&_NG\J-C?W3^5
M#:*=L;^Z?RHV-_=/Y4 -HIVQO[I_*C8W]T_E0 VI(OO'_=--V-_=/Y4^-6!.
M01P>U $5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% #9(TFB>.10R."K*>A!ZBH[2UBLK2*U@4K#$@1%+$X Z<FIJ* "BB
MB@ HHHH HII<":S+JI:1[AX1" Q&U$!SA1CN>3G-32V-O/>6]W)'NFM]WE,2
M?EW#!XZ9Q5BB@ HHHH **** "BBB@ HHHH **** "BBB@ KFO'NA/X@\)W5M
M"NZYBQ/",=67L/<@D?C72T54)N$E)=!2BI)IGE7P?\610J_AN]D",SF2T9N
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MS;MHX8(3_OXV_K6_18+A114<4\4ZEH94D56*DHP(# X(X[@T 24444 %%%%
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M^%/_  6__95RUY9W%A>36EU$T5Q"Q21&'((J"O7C0I25TCB=2:ZG8?\ "?\
M_4H^%/\ P6__ &5'_"?_ /4H^%/_  6__95Q]%/ZM2["]K/N=A_PG_\ U*/A
M3_P6_P#V5'_"?_\ 4H^%/_!;_P#95Q]%'U:EV#VL^YV'_"?_ /4H^%/_  6_
M_94?\)__ -2CX4_\%O\ ]E7'T4?5J78/:S[G8?\ "?\ _4H^%/\ P6__ &5'
M_"?_ /4H^%/_  6__95Q]%'U:EV#VL^YV'_"?_\ 4H^%/_!;_P#94?\ "?\
M_4H^%/\ P6__ &5<?11]6I=@]K/N=A_PG_\ U*/A3_P6_P#V5'_"?_\ 4H^%
M/_!;_P#95Q]%'U:EV#VL^YV'_"?_ /4H^%/_  6__94?\)__ -2CX4_\%O\
M]E7'T4?5J78/:S[G8?\ "?\ _4H^%/\ P6__ &5'_"?_ /4H^%/_  6__95Q
M]%'U:EV#VL^YV'_"?_\ 4H^%/_!;_P#94?\ "?\ _4H^%/\ P6__ &5<?11]
M6I=@]K/N=A_PG_\ U*/A3_P6_P#V5'_"?_\ 4H^%/_!;_P#95Q]%'U:EV#VL
M^YV'_"?_ /4H^%/_  6__94?\)__ -2CX4_\%O\ ]E7'T4?5J78/:S[G8?\
M"?\ _4H^%/\ P6__ &5'_"?_ /4H^%/_  6__95Q]%'U:EV#VL^YV'_"?_\
M4H^%/_!;_P#94?\ "?\ _4H^%/\ P6__ &5<?11]6I=@]K/N=A_PG_\ U*/A
M3_P6_P#V5'_"?_\ 4H^%/_!;_P#95Q]%'U:EV#VL^YV'_"?_ /4H^%/_  6_
M_94?\)__ -2CX4_\%O\ ]E7'T4?5J78/:S[G8?\ "?\ _4H^%/\ P6__ &5'
M_"?_ /4H^%/_  6__95Q]%'U:EV#VL^YV'_"?_\ 4H^%/_!;_P#94?\ "?\
M_4H^%/\ P6__ &5<?11]6I=@]K/N=A_PG_\ U*/A3_P6_P#V5'_"?_\ 4H^%
M/_!;_P#95Q]%'U:EV#VL^YV'_"?_ /4H^%/_  6__94?\)__ -2CX4_\%O\
M]E7'T4?5J78/:S[G8?\ "?\ _4H^%/\ P6__ &5'_"?_ /4H^%/_  6__95Q
M]%'U:EV#VL^YV'_"?_\ 4H^%/_!;_P#94?\ "?\ _4H^%/\ P6__ &5<?11]
M6I=@]K/N=A_PG_\ U*/A3_P6_P#V5'_"?_\ 4H^%/_!;_P#95Q]%'U:EV#VL
M^YV'_"?_ /4H^%/_  6__94?\)__ -2CX4_\%O\ ]E7'T4?5J78/:S[G8?\
M"?\ _4H^%/\ P6__ &5'_"?_ /4H^%/_  6__95Q]%'U:EV#VL^YV'_"?_\
M4H^%/_!;_P#94?\ "?\ _4H^%/\ P6__ &5<?11]6I=@]K/N=A_PG_\ U*/A
M3_P6_P#V5'_"?_\ 4H^%/_!;_P#95Q]%'U:EV#VL^YV'_"?_ /4H^%/_  6_
M_94?\)__ -2CX4_\%O\ ]E7'T4?5J78/:S[G8?\ "?\ _4H^%/\ P6__ &5'
M_"?_ /4H^%/_  6__95Q]%'U:EV#VL^YV'_"?_\ 4H^%/_!;_P#94?\ "?\
M_4H^%/\ P6__ &5<?11]6I=@]K/N=A_PG_\ U*/A3_P6_P#V5'_"?_\ 4H^%
M/_!;_P#95Q]%'U:EV#VL^YV'_"?_ /4H^%/_  6__94?\)__ -2CX4_\%O\
M]E7'T4?5J78/:S[G8?\ "?\ _4H^%/\ P6__ &5'_"?_ /4H^%/_  6__95Q
M]%'U:EV#VL^YV'_"?_\ 4H^%/_!;_P#94?\ "?\ _4H^%/\ P6__ &5<?11]
M6I=@]K/N=A_PG_\ U*/A3_P6_P#V5'_"?_\ 4H^%/_!;_P#95Q]%'U:EV#VL
M^YV'_"?_ /4H^%/_  6__94?\)__ -2CX4_\%O\ ]E7'T4?5J78/:S[G8?\
M"?\ _4H^%/\ P6__ &5'_"?_ /4H^%/_  6__95Q]%'U:EV#VL^YV'_"?_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ K/UVRFU'0;ZRMW"33PLB$G R1WK0
MJKJ,MY!I\TMA;)<W*C*1.^P-[9^E" Y33==TRTT^TT37M*?360+&%NH ;=W'
M=7Y!YYR?SK1U36]4DUHZ/H-M;27,48EN)[LL(HP>BX7DD_Y]LO6-3U#Q/I,N
MBV_AS4;>>XVK)+>1!(8@""6#9^;&.,"IIHKSPOXCGU&+3;K4+&\MXHY/LJ[Y
M8W08'RYY!'?_ ";L27+#7-7GN+W1[NVLX=:@B$L1#,8)E)QN'\0 /!K)\$S>
M(#8R3R?V8=/\^X>3'F>;OW,3C^'&[]*T]%BOM4\3W'B"ZLIK&W%J+6VAG $C
M#=N+,/X>>U5/"\U[8P7>AW&D7R.LL[_:?+_<LI)(PV>2<]!F@";0?$&NZO96
M^JSVUC:Z4(V:=FW^:^T'+(.@7([DGBHX=<\5W]D=7L=,T\:<07CMYG?[1*@[
M@CY03VS^M7/#6FRR?#ZWTVZCD@DDMI(G612K+N+#D'GO6;IVM:OHVC1:-)X<
MU"74+>/R8I(8PUN^.%8OG@>O]* -'_A*C+_8-]"D0TS4G,,I<'?%*0=HSG'W
M@0>*OW>K3KXFL-)M4C8/&\]TS DQQCA<<]2W'>LN+PM,GP^717<?;%C,BL#P
MLVXN,'T#<5)X0M[V?[9K>J6\D%[>,J".12I2-!@#!Y&3D_E2T#4@L-<EC\,Z
M_J$-G9PRV=S<!5BB*JY7^)@#R3W-,G\4:Y96]KJUUIEM_95P%411R$W"LP^4
MG^'!...<9ZU6L]/O5\&>*(&M+@337-TT49C.Z0'H5&,G/;%7==L[J;P3IMO%
M;3/,C6NZ-4)9<%<Y'48[T]+AJ20ZYKUEKMC9ZW9V*6]^66%K5V+1,!G:^[@G
MMQ5K4KCQ4;N8:79::MK%T:[D8O/QGY0OW?3FHO$EK<3ZYX<DA@ED2&[9I&1"
M0@V]21T%<_<Z?+J&MWUMKFB:MJ4KSM]D992EHL7\.6! 7WZG\:2 L:QK1U;2
M_"VJP6K-))J"D6X89W@,"N3QU'6M-=<UW3=:L[;7+2Q%I?2>5#+9NQ,;]E?=
MUS[ 5@VNFZG:>%_#,::;/)<6FHO(\.TJ0 TAY)' /&">.16M-/?>*M9TQ$TF
M^L+*QN!<S2WL0C9F4':JC)R/4_Y+$=E1114%A1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !7*P_P#)4KG_ +!2_P#HRNJKFHK6X'Q'N+HP2BW.FJ@EV'86
MWYQGIGVIH3)_$VN76B#3S:6JW+W5R(/*/!.5.,'MR!R<\9JC?^(M5T/3XAJJ
MZ7_:-W,4MECF,<** "6=G]/;KQBK7B>VGN+[0&A@DD6+44>0HA(1<'DXZ#WJ
M'QAI,UXVG:C#81ZA]@D9I+.10?-C88; /!(P"*:L)W(-&\574NL0:;J-QHUR
M;D-Y4NEW!<*RC.UU)SR,X/MBI=3U3Q79I=7\>G::NGVVYC#)*QGD1>K K\HR
M.<'I3-&:QN]2C:R\&/IXC!)NKFSC@9&QQM'4YZ<=*YE](GU2RNX-5T+5[O7%
M60_:9Y2MNIYVE"#@]L*%-.RN*[L:WB*^UB]U/PW/IHL!!<.)K7S]^=YC)._'
M;![=ZT[K6]>L;[2]->UL;B^O(I2_E,RQJRD8.3SM .3P3Z5GWD%]9:+X2O5T
MZZN#8!/M$$,9,JYCV_=Z\&M"3[5J'BSP_J'V"Z@B%O<>8)4YBR!@,1D GTS0
M,AAUWQ--=SZ,+'3AJ\($C3%W%MY1Z''WB2<C'MFK%AXL==#U.[U>!(+K3)&B
MN$B;*NW&-N?4G'-36MM.OC[4+EH9! ]E$JRE#M)#'(!Z9K'&@W>IV_B^R:)X
M3=W(:!Y4*J^ ""#W&1U%+0-2,>.-0M@M]=S>'WLR07M;:]W7,:D_7:Q'H.M:
MNH:[K)\22:/I%I:2DVJ3K-.S*L>202V.2.F *R;5[5TBM)/AX?[0&%D+642P
M9[D2$8QWK<M[2:/X@W-P+>1;;^S4C6380F0Y^4'IG':F[ KC-+UG6KI]3TNZ
MM[*/6+159&4MY$@;H?[PZ5F^!'U^2W,DO]F_V<US.9-N_P [>6.<?PXW?I6M
M86TZ>.M7N&AD6"2V@5)"A"L1G(!Z'%4?!\]Y8--HMSI-]&R7$S_:C&!"5+$@
MAB><YZ"ET N^,SYFDVUCDA;Z]AMVQ_=+9/Z*:S_&=[:Z7K?AJ[NI/*MH9Y"[
M;2=HV =!S6CXS5DT6*^52WV"ZBNF &?E5OF_0FH]=AFN_$/AFYMXI)8$FD=Y
M$0E54IP2>P/O0@92U3Q_X8N=(O8(M3W220.B+Y$HR2I _AI=(UA=#^'&F7?D
MM/*T:Q0PJ<&1V) &>U=+K"/+HM_'&K.[6\@55&225/ %<F-%U"Y^'FD10VY&
MH6+1W"6\PV%F4GY3G&.">M&E@UN6IM=\2:((;S7K/3CI[NJ2-9N^^WW'@MNX
M('3BK%_K.MW'B"?2M$@T\&VB2262]=OFW= H7G\:S=6O]1\6V T6WT+4;+SW
M3[5/>1!$C0,"=IS\QR*O>(;J)+SR+OPO?WVU1]FN[- [ XY^8$-'S[^] $VL
MZ]JFE66DL-/B>\N[@026XDR,E3@*W '(')'3-0IKFO:9K%E;:]:V'V6^D\J&
M6S9SY;]E;=US[5DZG_:MKHWA1KZ-[C44OU8Q&0;FX8A2W3.,#/K5^:>^\5:S
MIB)I-]865C<"YFEO8Q&S,H.U5&3D<]?\EV"Y<L;ZZN-:\26UE:V$=S;-$(Y&
M0KYI*Y_>$<G%9G@:3Q ]JTD@TUM/:XG:0+O$Q?<<X_AQN_2M30;6XA\5^))I
M8)4BFEA,3LA"N G.#W_"LK09M7L=-U'1(M*O8KU'N'ANV0" DDE"&/7DCL?Y
MT 6KW7?$^DP#5-2T_38]-#J)8(Y6:>)6(&2WW3C/:I0V/B)J# !L:2IP>A^<
MUQ]]HAU/0)G'AW6GUF)%,MU>N_+9&[RQGY\\]%QBNS%I<_\ ";7MQ]GE\EM*
M6-9-AVEMQ^4'IGVH8D,T6]U;4/!=A=:/;:5;7,C$M$Z.D*KN8':%Y!SC]:9I
M>M^(#J]Y%JO]D_8;&(O<SV@D^5L9V@L>H')XX%4;&ZU70?AM8Q6^FWK:@^Z(
M(ENS/#EF.\KCL.F>IQ5S1[FWO-,DT"'1M:M$F@D5[F]M=@9F!W,S9Y8DYH&9
M_P#PG.I31'4(9?#Z68!<6<U]BZ91]#M#'T/3I6SJ'B>YF.F6NA6T4]YJ$/VA
M#<$A(H\?>;'/M@5@6$4.FV<>F7_@1KO4(1Y8GALHWAFQT8R'IGOFM34K>ZT;
M7-,URVT>66W6S-K/:6:AF@YW#:HQGG(XXXHLA:D-F^J-\1K-=6AMDN%TYQNM
MG+1N-PY&[D=Q@UJZ$/LWBCQ#9+Q&9(KI![R+\WZK5*U:^U'QS9:I)I=U:6AL
M713.OS#Y@?G R%)SP"<\5;\/'[9XA\0:DH/E-,EK&3W\I<,1[9)_*DQHZ6BB
MBI*"O.OC)JCV?A*&RC)!O9PKX/\  HW$?GMKT6O)_CC"S:=H\PSL261#Z9(4
MC_T$UTX-)UXIF-=M4W8SO#VJ0^"? UNT:F+5-91YQ=.F4A0':I/][&0=JY(#
M$X(&#T7@_P ;W"$V&NL?+#A(;N20.R[L;1(P&"&S\L@X;ZUJ^'=-T_Q1\,])
MM;I T7V9%5T.&BD3Y=RGLP(/_P"JN,OO!6K:0VI7<H0VEC932),&'E2_Q;1%
MV#8.Y"-H/*GD5UMTJKE&>DK_ -6,;3@DX['K]W=V]C:2W5U,D,$2[GD<X"BO
M+-=\>:J^L1W%K(;#3+4JY5P"TF>@D7U9<[8P0>=S%0,CGTUK4-1GBTB5W6SM
M9FCLR[[]N;B.-6(/WBBL0N[O@]JZ?2/AQ>2:I<1:KF/3HY78$3EVG5CG:IZJ
M&&-['YF^Z,#K,*-.AK5=QRJ2J:0.6^)1M=;L]/\ %-I;/ T[O9W2M@CS$Z$,
M.'& PW#C@5YS7N'QG:VM/"6EZ?#''&/M0,4:C 5$1A@#T^85X?7JY=+FI>1Q
MXI6F%%%%=YS!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 ?2/PM_Y)QI/_;;_P!'/785Q_PM
M_P"2<:3_ -MO_1SUV%?(8G^//U?YGN4?X<?1!1116!H%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#Z1^%O_ "3C2?\ MM_Z.>NPKC_A;_R3C2?^VW_HYZ["OD,3_'GZ
MO\SW*/\ #CZ(****P- HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"M-_K/
MPJ/)]:DG_P!9^%1T &3ZT9/K110 9/K1D^M%% !D^M&3ZT44 &3ZT9/K110
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M=GB3_GRTK_OU)_\ '*/^%V>)/^?+2O\ OU)_\<KS>BCZEA_Y$'UBK_,>D?\
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MPJ*I8/\ 6?A0!8HHHH **** *T_^L_"HZDG_ -9^%1T %%%% !1110 4444
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M+4%UJ^^T:%8Z@+F=I(]0NI0PC0]%*$$\>@Q]:2 AOM5N=8T;POJ$<<7VJ2_
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M>(M+O+MK&_TTQ&^L)#)&DO"R*1AESVS1<5B@;K6_#^HV*ZGJ,>I65Y,+<O\
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M6VL_"VE:9"B1 W.Z.-%P%1$(X'8?.*\1KU<NES4O+4X\4K3"BBBN\Y@HHHH
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M^A?U7_P"D_PH]K#N@Y)=C'HK8_X1+Q)_T+^J_P#@%)_A1_PB7B3_ *%_5?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@! JABP !/4XZTM%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110!0N=7MK2<PR17K,,9,5E-(O_ 'TJ$?K47_"067_/'4O_
M  67'_QNM,LH."0*3S$_O#\Z ,W_ (2"R_YXZE_X++C_ .-T?\)!9?\ /'4O
M_!9<?_&ZTO,3^\/SH\Q/[P_.GH(S?^$@LO\ GCJ7_@LN/_C='_"067_/'4O_
M  67'_QNM+S$_O#\Z/,3^\/SHT S?^$@LO\ GCJ7_@LN/_C='_"067_/'4O_
M  67'_QNM+S$_O#\Z/,3^\/SHT S?^$@LO\ GCJ7_@LN/_C='_"067_/'4O_
M  67'_QNM+S$_O#\Z/,3^\/SHT S?^$@LO\ GCJ7_@LN/_C='_"067_/'4O_
M  67'_QNM+S$_O#\Z/,3^\/SHT S?^$@LO\ GCJ7_@LN/_C='_"067_/'4O_
M  67'_QNM+S$_O#\Z/,3^\/SHT S?^$@LO\ GCJ7_@LN/_C='_"067_/'4O_
M  67'_QNM+S$_O#\Z/,3^\/SHT S?^$@LO\ GCJ7_@LN/_C='_"067_/'4O_
M  67'_QNM+S$_O#\Z/,3^\/SHT S?^$@LO\ GCJ7_@LN/_C='_"067_/'4O_
M  67'_QNM+S$_O#\Z/,3^\/SHT S?^$@LO\ GCJ7_@LN/_C='_"067_/'4O_
M  67'_QNM+S$_O#\Z4.IZ,*- ,S_ (2"R_YXZE_X++C_ .-T?\)!9?\ /'4O
M_!9<?_&ZTO,3^\/SH\Q/[P_.C0#-_P"$@LO^>.I?^"RX_P#C='_"067_ #QU
M+_P67'_QNM+S$_O#\Z/,3^\/SHT S?\ A(++_GCJ7_@LN/\ XW1_PD%E_P \
M=2_\%EQ_\;K2\Q/[P_.CS$_O#\Z- ,W_ (2"R_YXZE_X++C_ .-T?\)!9?\
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M='_"067_ #QU+_P67'_QNM+S$_O#\Z/,3^\/SHT S?\ A(++_GCJ7_@LN/\
MXW1_PD%E_P \=2_\%EQ_\;K2\Q/[P_.CS$_O#\Z- ,W_ (2"R_YXZE_X++C_
M .-T?\)!9?\ /'4O_!9<?_&ZTO,3^\/SH\Q/[P_.C0#-_P"$@LO^>.I?^"RX
M_P#C='_"067_ #QU+_P67'_QNM+S$_O#\Z/,3^\/SHT S?\ A(++_GCJ7_@L
MN/\ XW1_PD%E_P \=2_\%EQ_\;K2\Q/[P_.CS$_O#\Z- ,W_ (2"R_YXZE_X
M++C_ .-T?\)!9?\ /'4O_!9<?_&ZTO,3^\/SH\Q/[P_.C0#-_P"$@LO^>.I?
M^"RX_P#C='_"067_ #QU+_P67'_QNM+S$_O#\Z/,3^\/SHT S?\ A(++_GCJ
M7_@LN/\ XW1_PD%E_P \=2_\%EQ_\;K2\Q/[P_.CS$_O#\Z- ,W_ (2"R_YX
MZE_X++C_ .-T?\)!9?\ /'4O_!9<?_&ZTO,3^\/SH\Q/[P_.C0#-_P"$@LO^
M>.I?^"RX_P#C='_"067_ #QU+_P67'_QNM+S$_O#\Z/,3^\/SHT S?\ A(++
M_GCJ7_@LN/\ XW1_PD%E_P \=2_\%EQ_\;K2\Q/[P_.CS$_O#\Z- ,W_ (2"
MR_YXZE_X++C_ .-T?\)!9?\ /'4O_!9<?_&ZTO,3^\/SH\Q/[P_.C0#-_P"$
M@LO^>.I?^"RX_P#C='_"067_ #QU+_P67'_QNM+S$_O#\Z/,3^\/SHT S?\
MA(++_GCJ7_@LN/\ XW1_PD%E_P \=2_\%EQ_\;K2\Q/[P_.CS$_O#\Z- ,W_
M (2"R_YXZE_X++C_ .-T?\)!9?\ /'4O_!9<?_&ZTO,3^\/SH\Q/[P_.C0#-
M_P"$@LO^>.I?^"RX_P#C='_"067_ #QU+_P67'_QNM+S$_O#\Z/,3^\/SHT
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MZTO,3^\/SH\Q/[P_.C0#-_X2"R_YXZE_X++C_P"-T?\ "067_/'4O_!9<?\
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MI^I?8)0^3)Y"RY&#Q@_AS[5(S'\"_P#(!F_Z_)O_ $*D\<@#1+?  S?0D_\
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M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %=+IW_(*MO^!?\
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M_2@""BI_L_\ M?I1]G_VOTH @HJ?[/\ [7Z4?9_]K]* (**G^S_[7Z4?9_\
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M**G^S_[7Z4?9_P#:_2@""BI_L_\ M?I1]G_VOTH @HJ?[/\ [7Z4?9_]K]*
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MH_X1^[_YZ0_]]'_"MO['Q_\ SZ9/UFC_ #&316M_PC]W_P ](?\ OH_X4?\
M"/W?_/2'_OH_X4?V/C_^?3#ZS1_F,FBM;_A'[O\ YZ0_]]'_  H_X1^[_P">
MD/\ WT?\*/['Q_\ SZ8?6:/\QDT5K?\ "/W?_/2'_OH_X4?\(_=_\](?^^C_
M (4?V/C_ /GTP^LT?YC)HK6_X1^[_P">D/\ WT?\*/\ A'[O_GI#_P!]'_"C
M^Q\?_P ^F'UFC_,9-%:W_"/W?_/2'_OH_P"%'_"/W?\ STA_[Z/^%']CX_\
MY],/K-'^8R:*UO\ A'[O_GI#_P!]'_"C_A'[O_GI#_WT?\*/['Q__/IA]9H_
MS&316M_PC]W_ ,](?^^C_A1_PC]W_P ](?\ OH_X4?V/C_\ GTP^LT?YC)HK
M6_X1^[_YZ0_]]'_"C_A'[O\ YZ0_]]'_  H_L?'_ //IA]9H_P QDT5K?\(_
M=_\ /2'_ +Z/^%'_  C]W_STA_[Z/^%']CX__GTP^LT?YC)HK6_X1^[_ .>D
M/_?1_P */^$?N_\ GI#_ -]'_"C^Q\?_ ,^F'UFC_,9-=+IW_(*MO^!?^A&J
M'_"/W?\ STA_[Z/^%;%G9O!910NR[DSDKR.3FO>X=P&)P^*E.M!I<K7XHY,;
M6A.FE%WU$HJ?[/\ [7Z4?9_]K]*^R/,(**G^S_[7Z4?9_P#:_2@""BI_L_\
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M?I1]G_VOTH @HJ?[/_M?I1]G_P!K]* (**G^S_[7Z4?9_P#:_2@""BI_L_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*0@,"",@\$&EHH \X_M.7PUI&N>'X]QN8IQ'IX!Y*3?= SZ<UU1TR/1_!$VG
MQ ;8+)U)'=MI)/XG)J:^\-:?J&O66L3J_P!IM!A "-K=<;ACL3D8Q6E=6Z7=
MI-;2%@DR-&Q7J 1CBJ;)2//-161_AKX<2*3RY&GM@K[<[3S@X[XJQ)9WB>+;
M'3_%.J2WUH^);%Q&L,3S+_"ZJ.3Z<_SQ732>&+*71K#2VEN/(LGCDC8,-Q*=
M,\8_05:UG1[77-/:SN]X7<'1XSAXV'1E/8T7"Q4U3_A*?MO_ !*/['^R[1_Q
M]^;OW=_N\8K:7=M&[&['..F:;#&8H4C:1Y2J@%WQN;W. !GZ"J6KZ7_:ULD'
MV^^L]K[O,LYO+<\$8)P>.:0S%\ ?\B_/_P!?L_\ Z%5^\@M/%FDXM-3NX81(
MP,EHYC8E<J5;(Z9[?2H-$\(6^@W2S6VJ:K(@+$P37 ,3$]25"CGOFFWG@JPN
M;V>Y@O=2L#<'=/'9W/EI*>Y88-/2XM;'.?VK-!X$NM/\JS<Q7YTP2^4!$5S_
M *PJ.._YU)K7AQ?"^EV^L'4[S4/[/=&%M?2>9$<D+\B\;2,Y'7&*Z\>'=*&A
M_P!C?8T^P8QY63ZYSGKG/.>M9D'@;3DFA>ZO=3OXH&#16]W<[XD(Z87 Z4[H
M+,S]1M6\3>-39&XEL$T^V6436QV7#E^P;LH]/7ZU+H%NN@^,;S1A*UV;FV%X
M;J8[I^#MVNW<=QP.M;&L>&++6+F.[:6ZM+V-=JW5G+Y<FW^[GN*?HWARQT22
M::%I[BZFP);FYD\R1P.@)I7T"VIKT445)04444 %%%% !1110 4444 %%%%
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MUITGAY-$".EJ@&QD(#JP.=X./O9YS[FI8-$@AUG^U3-/)<FV6V8N5PR@YR0
M.<_A[4FPL<M_8MEX<M99-9TBVOK;SS*VHH TR[FR"X;D8)'W2?IUKO <C(KF
M?^$&TTS@O=ZD]HKB1;%[HF $'/W>O7WKIJ3=QI!1112&%%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ ILD:RQM&XRK#!%.HI-*2LP
M6ARY%QHM]D?,AZ9Z./\ &MNWU&TO(R!(%9A@HQP:LS0QW$9CE0,I[&L>?P\"
M28)L#^ZX_K7SBPF-RZ3^J)3IO[+W7I_7RZG=[2E67[S27<UHK>WMLM&BQ@@
MX. 0/\]:IWFL6]LA6$B63L%Z#ZFLT>'[K.#)#CZG_"IAX<..;K!]H_\ Z]3/
M%9G.G[/#8;D^:_#9?F-4Z"E><[F-+*\TK22,69CDFF5N_P#".?\ 3W_Y#_\
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M'_H":;_X"1_X4?\ "-:#_P! 33?_  $C_P *U**+L+&7_P (UH/_ $!--_\
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M?^@)IO\ X"1_X4?\(UH/_0$TW_P$C_PK4HHNPL9?_"-:#_T!--_\!(_\*/\
MA&M!_P"@)IO_ ("1_P"%:E%%V%C+_P"$:T'_ * FF_\ @)'_ (4?\(UH/_0$
MTW_P$C_PK4HHNPL9?_"-:#_T!--_\!(_\*/^$:T'_H":;_X"1_X5J44786,O
M_A&M!_Z FF_^ D?^%'_"-:#_ - 33?\ P$C_ ,*U**+L+&7_ ,(UH/\ T!--
M_P# 2/\ PH_X1K0?^@)IO_@)'_A6I11=A8R_^$:T'_H":;_X"1_X4?\ "-:#
M_P! 33?_  $C_P *U**+L+&7_P (UH/_ $!--_\  2/_  H_X1K0?^@)IO\
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M'_H":;_X"1_X4?\ "-:#_P! 33?_  $C_P *U**+L+&7_P (UH/_ $!--_\
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M?^@)IO\ X"1_X4?\(UH/_0$TW_P$C_PK4HHNPL9?_"-:#_T!--_\!(_\*/\
MA&M!_P"@)IO_ ("1_P"%:E%%V%C+_P"$:T'_ * FF_\ @)'_ (4?\(UH/_0$
MTW_P$C_PK4HHNPL9?_"-:#_T!--_\!(_\*/^$:T'_H":;_X"1_X5J44786,O
M_A&M!_Z FF_^ D?^%'_"-:#_ - 33?\ P$C_ ,*U**+L+&7_ ,(UH/\ T!--
M_P# 2/\ PH_X1K0?^@)IO_@)'_A6I11=A8R_^$:T'_H":;_X"1_X4?\ "-:#
M_P! 33?_  $C_P *U**+L+&7_P (UH/_ $!--_\  2/_  H_X1K0?^@)IO\
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M'_H":;_X"1_X4?\ "-:#_P! 33?_  $C_P *U**+L+&7_P (UH/_ $!--_\
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M?^@)IO\ X"1_X4?\(UH/_0$TW_P$C_PK4HHNPL9?_"-:#_T!--_\!(_\*/\
MA&M!_P"@)IO_ ("1_P"%:E%%V%C+_P"$:T'_ * FF_\ @)'_ (4?\(UH/_0$
MTW_P$C_PK4HHNPL9?_"-:#_T!--_\!(_\*/^$:T'_H":;_X"1_X5J44786,O
M_A&M!_Z FF_^ D?^%'_"-:#_ - 33?\ P$C_ ,*U**+L+&7_ ,(UH/\ T!--
M_P# 2/\ PH_X1K0?^@)IO_@)'_A6I11=A8R_^$:T'_H":;_X"1_X4?\ "-:#
M_P! 33?_  $C_P *U**+L+&7_P (UH/_ $!--_\  2/_  H_X1K0?^@)IO\
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M'_H":;_X"1_X4?\ "-:#_P! 33?_  $C_P *U**+L+&7_P (UH/_ $!--_\
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M?^@)IO\ X"1_X4?\(UH/_0$TW_P$C_PK4HHNPL9?_"-:#_T!--_\!(_\*/\
MA&M!_P"@)IO_ ("1_P"%:E%%V%C+_P"$:T'_ * FF_\ @)'_ (4?\(UH/_0$
MTW_P$C_PK4HHNPL9?_"-:#_T!--_\!(_\*/^$:T'_H":;_X"1_X5J44786,O
M_A&M!_Z FF_^ D?^%'_"-:#_ - 33?\ P$C_ ,*U**+L+&7_ ,(UH/\ T!--
M_P# 2/\ PH_X1K0?^@)IO_@)'_A6I11=A8R_^$:T'_H":;_X"1_X4?\ "-:#
M_P! 33?_  $C_P *U**+L+&7_P (UH/_ $!--_\  2/_  H_X1K0?^@)IO\
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M'_H":;_X"1_X4?\ "-:#_P! 33?_  $C_P *U**+L+&7_P (UH/_ $!--_\
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M?^@)IO\ X"1_X4?\(UH/_0$TW_P$C_PK4HHNPL9?_"-:#_T!--_\!(_\*/\
MA&M!_P"@)IO_ ("1_P"%:E%%V%C+_P"$:T'_ * FF_\ @)'_ (4?\(UH/_0$
MTW_P$C_PK4HHNPL9?_"-:#_T!--_\!(_\*/^$:T'_H":;_X"1_X5J44786,O
M_A&M!_Z FF_^ D?^%'_"-:#_ - 33?\ P$C_ ,*U**+L+&7_ ,(UH/\ T!--
M_P# 2/\ PH_X1K0?^@)IO_@)'_A6I11=A8KV=A9Z?&T=E:06R,=S+#&$!/K@
M"K%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
B444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>img62602283_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img62602283_1.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" .N!U0# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)Z2#ISU^M5B*'VHK^OZ_S7DJ53HSN*X/QEXRG@@N[31!(PM2JZAJ$:AEM%)
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MZ*4>6S[I.UM+:V:5]+V?<FU.492UN:]%'6BO8.8**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *R=3T;[7<+>VDQM;^
M,864#(8>C#N*UJYO7=819#:1W%];2QL"TD-OO##'3GZUI34G+W3GQ4J<:?[S
M_+7R+-EKK)<K8:O%]EO#PK?\LYO=3_2MNO.KR2._A\JYU/4I5!R ]B#@_G77
M^&KF6[\.V<TS;I-I4D]]K%1^@JZM-17,CEP>*=2;IO72Z>E_G8UJ***P/2"B
MBB@ HHHH **** "JU_86NJ6,UE>P)-;S+M=&'!']#[]JLT4TVG= <'8^!]2M
M_$&GR3ZE')IVEL6M)0#]J9#TA=NA0<_4''&>.2U6.;?>V]G(L#_\)?&(6VY6
M-RC8.WIUP:]IKQR]_P"0I<_]CE!_Z U=^'JRG)N73_,Y:L%%*Q'I\,OF65I>
MRBY?_A,)A.VW"RNJKEMON<G'O76WW@2\N?$-_/%J8CT[4R#>';_I.T=8D?M&
M>,_0#D5S4'_(8M_^QSN?Y"O7Z,15E!IQZ_YCI04D[E>RLK;3K.*SLX$AMXEV
MI&@P *L445Y[=]6=(4444 %%%% !6'<03O/>26R-#'L82;A_K#SG'^-;E5[J
M[CM57S%=M_ 55SFN#,,/3JTTZLN5+K^&_P ^F^QM1G*,O=5[A8%3I]OMZ>6O
M\JL5B6-^EMY@V2?8M_R2%?N>Q]JUDN(9%W),C#U#"IR_&4JM&,4U=*S7II==
MT^C"M3E&3=M"6L.Z6Y>\OS:]-J"0#[QX[>]7[G48T!2W'GSXX5.<?6J^F7EJ
M$6/>QFE.YF*GECVKFQU:AB:D,/[2VK=T^MFK)]]?\]S2E&<(N=OZW_0NV7D_
M8X_(5ECYPK=1SSG\:L445Z].')!0[*VFGX=#FD[ML****L04444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MKNPD.$N[.7S(B?3/4?E3T%J7_P#A9_C'_H,?^2T/_P 11_PL_P 8_P#08_\
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M11_PL_QC_P!!C_R6A_\ B*Y&BBR"[.N_X6?XQ_Z#'_DM#_\ $4?\+/\ &/\
MT&/_ "6A_P#B*Y&BBR"[.N_X6?XQ_P"@Q_Y+0_\ Q%'_  L_QC_T&/\ R6A_
M^(KD:*+(+LZ[_A9_C'_H,?\ DM#_ /$4?\+/\8_]!C_R6A_^(KD:*+(+LZ[_
M (6?XQ_Z#'_DM#_\11_PL_QC_P!!C_R6A_\ B*Y&BBR"[.N_X6?XQ_Z#'_DM
M#_\ $4?\+/\ &/\ T&/_ "6A_P#B*Y&BBR"[.N_X6?XQ_P"@Q_Y+0_\ Q%'_
M  L_QC_T&/\ R6A_^(KD:*+(+LZ[_A9_C'_H,?\ DM#_ /$4?\+/\8_]!C_R
M6A_^(KD:*+(+LZ[_ (6?XQ_Z#'_DM#_\11_PL_QC_P!!C_R6A_\ B*Y&BBR"
M[.N_X6?XQ_Z#'_DM#_\ $4?\+/\ &/\ T&/_ "6A_P#B*Y&BBR"[.N_X6?XQ
M_P"@Q_Y+0_\ Q%'_  L_QC_T&/\ R6A_^(KD:*+(+LZ[_A9_C'_H,?\ DM#_
M /$4?\+/\8_]!C_R6A_^(KD:*+(+LZ[_ (6?XQ_Z#'_DM#_\11_PL_QC_P!!
MC_R6A_\ B*Y&BBR"[/4_!WCKQ)JLNM"]U'S1;:3/<Q?N(UVR+MPW"C/4\'BN
M:_X6?XQ_Z#'_ )+0_P#Q%/\ A[_KO$?_ & KG_V2N.I65PNSKO\ A9_C'_H,
M?^2T/_Q%'_"S_&/_ $&/_):'_P"(K T?2_[7OOLOV^QLOD+>;>S>7'QVS@\U
MT\WPUN[:WAN)_$7AV*&<$PR/>E5D Z[25P?PIZ!J5_\ A9_C'_H,?^2T/_Q%
M'_"S_&/_ $&/_):'_P"(KDW79(R;E;:2,J<@_2FT6079UW_"S_&/_08_\EH?
M_B*/^%G^,?\ H,?^2T/_ ,17(T46079UW_"S_&/_ $&/_):'_P"(H_X6?XQ_
MZ#'_ )+0_P#Q%<[IVEWNJRRQV4/FO#$TSC<%VHO4\D53HL@NSKO^%G^,?^@Q
M_P"2T/\ \11_PL_QC_T&/_):'_XBN1HHL@NSKO\ A9_C'_H,?^2T/_Q%'_"S
M_&/_ $&/_):'_P"(KD:*+(+LZ[_A9_C'_H,?^2T/_P 11_PL_P 8_P#08_\
M):'_ .(KD:N7NEWNG16LEW#Y:7<0FA.X'<AZ'@\?C19!=G1?\+/\8_\ 08_\
MEH?_ (BC_A9_C'_H,?\ DM#_ /$5R-:-KHUQ=:->ZJ'BCMK1D1BY.79CPJ@
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M9"QWECCD#&,<^M95%D%V==_PL_QC_P!!C_R6A_\ B*/^%G^,?^@Q_P"2T/\
M\17(T46079UW_"S_ !C_ -!C_P EH?\ XBC_ (6?XQ_Z#'_DM#_\16-<>'[N
MW\-VFNO) ;6YE:%$5\R C.<C'3CUK*HL@NSKO^%G^,?^@Q_Y+0__ !%'_"S_
M !C_ -!C_P EH?\ XBN1HHL@NSKO^%G^,?\ H,?^2T/_ ,11_P +/\8_]!C_
M ,EH?_B*Y&BBR"[.N_X6?XQ_Z#'_ )+0_P#Q%'_"S_&/_08_\EH?_B*Y&BBR
M"[/4_'WCKQ)HOC&]L-/U'R;6,1E$\B-L912>2I/4FN:_X6?XQ_Z#'_DM#_\
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M,?\ H,?^2T/_ ,13_ O_ !X>*O\ L#3?TKCJ5D%V==_PL_QC_P!!C_R6A_\
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M_P"(H_X6?XQ_Z#'_ )+0_P#Q%<C119!=G7?\+/\ &/\ T&/_ "6A_P#B*/\
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M^,?^@Q_Y+0__ !%<C119!=G7?\+/\8_]!C_R6A_^(H_X6?XQ_P"@Q_Y+0_\
MQ%<C4UG:O>WL%I$5$D\BQJ7. "3@9/8<T6079U'_  L_QC_T&/\ R6A_^(H_
MX6?XQ_Z#'_DM#_\ $5@:UI-QH6KW&F73Q/- P5FB;<IX!X.!ZU0HL@NSKO\
MA9_C'_H,?^2T/_Q%'_"S_&/_ $&/_):'_P"(KD:*+(+LZ[_A9_C'_H,?^2T/
M_P 11_PL_P 8_P#08_\ ):'_ .(K&M] NKGPW>:XDD(M;658G0L=Y+8Q@8QC
MGUK*HL@NSKO^%G^,?^@Q_P"2T/\ \11_PL_QC_T&/_):'_XBN1HHL@NSKO\
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M=*N[F%/+BO;FT#SH.V&)Q^E9^A^++W0K:[M8[6QN[6[(:6WO(-\>X=" "/\
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M1VZ5R@\078\,'0/+A^R&X^T[]IW[L8QG.,?A3]8\2WVM7]G>S"*&>TA2*)H
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M4]W<:A?0Z-I,T$>,S:FY%M;9/0@GYOU(QUYYL_$C2;&Q?1KVTALHGO;<M,+
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M.1GSU17T+_PJKPE_SXR_^!#_ .-'_"JO"7_/C+_X$/\ XT<Z#D9\]45]"_\
M"JO"7_/C+_X$/_C1_P *J\)?\^,O_@0_^-'.@Y&?/5%?0O\ PJKPE_SXR_\
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M\9?_  (?_&C_ (55X2_Y\9?_  (?_&CG0<C/GJBOH7_A57A+_GQE_P# A_\
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M_P"!#_XT<Z#D9\]45]"_\*J\)?\ /C+_ .!#_P"-'_"JO"7_ #XR_P#@0_\
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MCG0<C/GJBOH7_A57A+_GQE_\"'_QH_X55X2_Y\9?_ A_\:.=!R,^>J*^A?\
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M?\*J\)?\^,O_ ($/_C1SH.1GSU17T+_PJKPE_P ^,O\ X$/_ (T?\*J\)?\
M/C+_ .!#_P"-'.@Y&?/5%?0O_"JO"7_/C+_X$/\ XT?\*J\)?\^,O_@0_P#C
M1SH.1GSU17T+_P *J\)?\^,O_@0_^-'_  JKPE_SXR_^!#_XT<Z#D9\]45]"
M_P#"JO"7_/C+_P"!#_XT?\*J\)?\^,O_ ($/_C1SH.1GSU17T+_PJKPE_P ^
M,O\ X$/_ (T?\*J\)?\ /C+_ .!#_P"-'.@Y&?/5%?0O_"JO"7_/C+_X$/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'_"?ZK_S[V7_ 'PW_P 51]4J!_;.%[O[CT>BO./^$_U7_GWLO^^&_P#BJ/\
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MIWD8I"O+-U$:]@/?_P#77<+!I/ABP\Q(@@R%! W22,>@SW/Z5#X/LEL_#T#
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M:93X^C_[M,H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !BN7N_C!XDN+Y9H6AMH57'V>.-2K'GDE@3GD="!Q55OBEXON+O$>K) CL
M;>+:@]R4S7;'"U(ZQBE\_P#@'!4H.I[M6K)KT5OS.G_L75?^@9>_]^&_PH_L
M75?^@9>_]^&_PK,U/XF>(;"TCMXM56:]P/,<V\9 R,Y&% [C''UHT?QSXPN8
MFO;W62MFJEN+>'+8//\ !TX/O3]G6M?3\?\ (X_JN%4.=RE;T6OXFG_8NJ_]
M R]_[\-_A1_8NJ_] R]_[\-_A6!-\3?%]_J'EZ9J#*A'RH;:')XY)RIKI+3Q
M9XICM MSJRR7&<EO(CVCV "CM2E"M%:V_'_(53#82FDY2EKTLK_F1?V+JO\
MT#+W_OPW^%']BZK_ - R]_[\-_A3AXE\3Y&?$$Y]<6T _P#9*K:OXO\ &H*-
MIVHH$ ^9?(BW$_BN,4DJK=M/Q_R(C2P4I**G+[E_F3_V+JO_ $#+W_OPW^%'
M]BZK_P! R]_[\-_A5(_$#Q/I6FM)J6K"2ZD!,48MX\#@<'"CN>>?I6?IGQ \
M;ZK=D)JP2%6!DQ;P_*">@RA]\52IUK7TM\_\C583"M.7-*RZV7^9N_V+JO\
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MI!8RVQ#]GCRY.!SE3WZ=.M/V5>]M/Q_R!8+#.;BI2T\E;\S?_L75?^@9>_\
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MCR7_ +OZU:HH J^2_P#=_6CR7_N_K5JB@"KY+_W?UH\E_P"[^M6J* *ODO\
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MFDD-LZ'4M4LM(M#=7]RD$(.-S=SZ =2?856TCQ%I.NA_[-O4G*?>7!5@/7#
M''O4:^'X)WTJ>]9IIM/BVHA(*%\ %B",D\<'-992._\ B-%<6:#%A;/'>3+T
M9F^[&3W(Z^U%D%V;VI:QI^D+"U_<K#YSB.,$$EF/H!S^-6Y98X(7FFD6.)%+
M,[' 4#J2:X7QKH=M;PC57>2XO)KZ!5>4Y\I-WW$'8?J:W?&L*S^$KY&N(X%
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M4+RO+8/'X<#WHUG6([E/L5DJI9J0?E4KN//;TY].HJ_:VL'AVU%Y>#?<OPB
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4 7-R_WA^=&Y?[P_.J=% %S<O]X?G1N7^\/SJG10!<W+_>'YT;E_O#\ZIT4
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M.NW)X'7/.:DTSP=JFG69O[C1+^>X #1PBU?*GMVZ].W&*[/_ (3#7O\ G_\
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MHUB_S>:7J<?R\R26;@ #L!@#\/K7HG_"8:]_S_\ _D%/_B:/^$PU[_G_ /\
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M:C$:I]ED53SP3\HP.G';%=[_ ,)AKW_/_P#^04_^)H_X3#7O^?\ _P#(*?\
MQ-'MJU[M+\1_6\(Y\[YGVT6GXG'Q^%]5T73MT6AW\^H.IVNEF[;#TZX.,9/U
MQ6?8>#?$.IZ@TU_I6HHH(9S+:N"_L.!V';IQ7H'_  F&O?\ /_\ ^04_^)H_
MX3#7O^?_ /\ (*?_ !-"JUE?17^8EBL*DW>5WULO\SAM7TGQ$RBQL/#VK16L
M65)2TDQ)_P".].O?G.:LV/A#4](M#=7&AWUS=9^1$M7;:>H['T'..,UV'_"8
M:]_S_P#_ )!3_P")H_X3#7O^?_\ \@I_\32]K6M:R^]B>(PG(H+F2ZZ+7\3S
MN/PIXHUB_P WFEZG'\O,DEFX  [ 8 _#ZUI:IH^NVD/]GZ5X?U6.,$,TL5M)
MS[9VY].<]L5V7_"8:]_S_P#_ )!3_P")H_X3#7O^?_\ \@I_\33=6LWLOQ*E
MBL)*2;YK+I96_,XK2O!6IVL!O+_1+Z4X&V$6CL1G')&.O/3'&*HS^'?%6LZ@
M@GT;5(XRQ"[[1PL:]?[H_P#K\5Z'_P )AKW_ #__ /D%/_B:/^$PU[_G_P#_
M ""G_P 31[:M>]E^(+%X7F<WS-^BT_$J^"=%O-#\6:;;C1KQ(F5S/=O ZH"(
MVQDD8Y/;/&?>O7MR_P!X?G7 >&_$FK7^OVMK=7?F0OOW+Y:#.%)'(&>HKLZ\
MW%N3FG+>Q[.5RIRHMT[[ZWWO9%S<O]X?G1N7^\/SJG17*>D7-R_WA^=&Y?[P
M_.J=% %S<O\ >'YT;E_O#\ZIT4 7-R_WA^=&Y?[P_.J=% %S<O\ >'YT;E_O
M#\ZIT4 7-P/<4;E_O#\ZK1]'_P!VF4 7-R_WA^=&Y?[P_.J=% %S<O\ >'YT
M;E_O#\ZIT4 7-R_WA^=&Y?[P_.J=% %S<O\ >'YT;E_O#\ZIT4 7-R_WA^=&
MY?[P_.J=% %S<O\ >'YT;E_O#\ZIT4 7-R_WA^=&Y?[P_.J=% %S<O\ >'YT
M;E_O#\ZIT4 7-R_WA^=&Y?[P_.J=% %S<O\ >'YT;E_O#\ZIT4 7-R_WA^=&
MY?[P_.J=% %S<!W%&Y?[P_.J\G1/]T5'0!<W+_>'YT;E_O#\ZIT4 7-R_P!X
M?G1N7^\/SJG10!<W+_>'YT;E_O#\ZIT4 7-R_P!X?G1N7^\/SJG10!<W+_>'
MYT;E_O#\ZIT4 7-R_P!X?G1N7^\/SJG10!<W+_>'YT;E_O#\ZIT4 7-R_P!X
M?G1N7^\/SJG10!<W+_>'YT;E_O#\ZIT4 7-R_P!X?G1N7^\/SJG10!<W+_>'
MYT!@>A!JG4L'^L_"@"Q1110 4444 5I_]9^%1U)/_K/PJ.@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ J2+[Q_W34=21?>/^Z: (ZS=>
MU1]%TB6_2U-R(B"Z!]I"DX)Z'I6E45S;QW=K+;S+NBE0HX]01@T .AE2>%)H
MF#1NH96'0@]*QX?$/VB363%:[H--ROF^9_K7"Y9<8XQTSS6-I6M-HGA/4K>Z
M8&ZT=F@4'C>#_JS^.1^57[#3&TGP)/!*2;A[:269B<DNRDG/\OPJK$W'7?BE
M[?PU8ZO'8>;)>-&BV_G;<%NGS8_I4?\ PE-]930C6]!EL+>5Q&LZW"3*K'IN
MV]!6'J#.GP[\/-''YDBS6Y5,XW'G SVJU=76I^*-330+ZRBTI8RES,CS>:\R
M YPA  Z]?_K4[(5V=S65K6MC21!%%:RWE[<L5@MX^"V.I)/0#UJ/4_$/]F7?
MV?\ L?5KKY0WF6MMO3GMG/6M)H[8NMY+%&LD:'$KJ R*>HSV'K4E&1IGB*:Y
MU3^S-3TR33KUD,D:-()%D4=<,.,^U0W'B:\DO+B'2-$FU&.V8I--YRQ*&'55
MR/F(I+#=KWB--:0%=/M(VAM6(P9F;[SC_9XP/6M'4+ZST"RS%;J)97(AMH4
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M2%.78<A%[*/?_P#7793'2O">GAHH%#,=JCC?(WNQ[?H*/"-DMGX=MV &^?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** -SP?_P C59?\#_\ 0&KTBO-_!_\
MR-5E_P #_P#0&KTBO.QGQKT/J\C_ -WE_B_1!1117(>R%%%% !1110 4444
M%%%% #X^C_[M,I\?1_\ =IE !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 22=$_W14=22=$_P!T5'0 4444 %%%% !1110
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MT6>QGN]0U"2.;4KM\R/'DJB#[J+GG _STK;HI#"BBB@ HHHH **** "BBB@
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MKT*,.2"3/F,?B%B*\IQVZ!1116IQA1110 4444 %%%% !1110 4444 %%%%
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M_A._O_\ DH?\(?KW_/A_Y&3_ .*H_P"$/U[_ )\/_(R?_%4?\)AKW_/_ /\
MD%/_ (FC_A,->_Y__P#R"G_Q-'[_ ,OQ#_A._O\ _DH?\(?KW_/A_P"1D_\
MBJ/^$/U[_GP_\C)_\51_PF&O?\__ /Y!3_XFC_A,->_Y_P#_ ,@I_P#$T?O_
M "_$/^$[^_\ ^2A_PA^O?\^'_D9/_BJ/^$/U[_GP_P#(R?\ Q5'_  F&O?\
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M .2A_P (?KW_ #X?^1D_^*H_X0_7O^?#_P C)_\ %4?\)AKW_/\ _P#D%/\
MXFC_ (3#7O\ G_\ _(*?_$T?O_+\0_X3O[__ )*'_"'Z]_SX?^1D_P#BJ/\
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MH_X0_7O^?#_R,G_Q5'_"8:]_S_\ _D%/_B:/^$PU[_G_ /\ R"G_ ,31^_\
M+\0_X3O[_P#Y*'_"'Z]_SX?^1D_^*H_X0_7O^?#_ ,C)_P#%4?\ "8:]_P _
M_P#Y!3_XFC_A,->_Y_\ _P @I_\ $T?O_+\0_P"$[^__ .2A_P (?KW_ #X?
M^1D_^*H_X0_7O^?#_P C)_\ %4?\)AKW_/\ _P#D%/\ XFC_ (3#7O\ G_\
M_(*?_$T?O_+\0_X3O[__ )*'_"'Z]_SX?^1D_P#BJ/\ A#]>_P"?#_R,G_Q5
M'_"8:]_S_P#_ )!3_P")H_X3#7O^?_\ \@I_\31^_P#+\0_X3O[_ /Y*'_"'
MZ]_SX?\ D9/_ (JC_A#]>_Y\/_(R?_%4?\)AKW_/_P#^04_^)H_X3#7O^?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MB:-9?,;A0Q7&,XZ>U%D%V=U1114E!1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!N>#_\ D:K+_@?_ * U>JUY5X/_ .1JLO\ @?\ Z U>JUYV,^->A]7D
M?^[R_P 7Z(****Y#V0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@#G=3\)6VI^)K+67F*?9\&2 +D3%<E"3G@@GT-;=[;?;+"XM=^SSHFCW8SC(
MQG%3T4[BL<Y-X5\WP[I>D_;<?898I/-\K[^SMC/&?J:NZ_H4>NV<:><;>Z@D
M$MO<JN6B<=_<>U:U%%V%D,A618469U>4* [JNT,>Y R<?3)KG_$WAN^\036Q
MAU@6EO 0_DFU$JNX/#') /T(KHZ*$[#L8&G:3X@MKZ.6]\3?;+=<[X/L$<>_
M@X^8'(YP?PK,C\(:]!J5SJ$/BH)<W/WW.G(QP.BC<QP!Z"NRHHNQ6,JRL-6@
MTNXM[K6OM-X^[RKK[*B>5D8'R#@X//-8<'A+7H=6DU(>*\W,JJDK?V<GS*.@
MQNP/J!78T47"Q@:MX;EN]475=,U.73=0V>4\BQB19$]&0\$^].T;PX=.OYM2
MO;^74-2F01M.Z! J YVJHX K=HHNPL%5Q8VZZ@]^(_\ 27C$3/N/*@D@8Z=2
M:L44AA65XBT;^WM'>P^T>1O=&W[-V-K ],CTK5HH 3'&*X^Q\):]I<!M[#Q7
MY%OO9Q'_ &=&V"3D\EB:[&BFG85C"ET"XNKC1;F[U'SI].=G=_("^>2,= <+
M^M2:UH/]IW=E?VUS]DU"T?,<_E[]RGJC#(R#]:V:*+A8YJ\\+W0U2?4=%UF7
M3)KG!N%\A9DD(Z,%;H:NZ%H$>BBYE:YEN[VZ8/<7,O5R.@ '0#G K8HHNPL%
M%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !64FB[/%,FM?:,[[46WD[.F&SNW9_3%:M% &7JVC_
M -J7&FR^?Y7V*Z6XQLW;\ C'48Z]>:-=T.'7+6-&EDM[B!Q+;W$1^:)QW'J/
M45J44[BL86FZ)JD%X+C5/$-Q?A%*I$L*P1\C!W!?O>WI6?;^#;J"SFTW^W[D
MZ2RNL=J(E4J&SP9!\S#GIQFNMHHNPLCF[WPK)<:/I-K;:DUM=Z8$\FZ6(-DA
M=IRA/?ZU8CT";^U-*O[C47N)K&*1'9X@#*7[\8"X],&MRBB["R,R'2/*\1W.
MK^?GS[=(?*V?=VDG.<\]?2JUOX:@1M:6YD%Q!JDN]X]FW8,8QG//UXK<HHN%
MCE;;PMJT CM3XJO#IT> D*PHLH4= 9>OZ5K1Z/L\33:SY^?,M5M_*V=,-G.<
M_IBM2BB["QF6^D?9_$-[JWG[OM,4<?E;,;=N><YYSGTJCHWANZT:_E:+6)7T
MYI'E2R,*@*S>K\DC\JZ&BBX6"BBBD,**** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *X[X@P,UA9S@9$<A4GTR/_ *U=C5+5M/35-,GLWXWK
M\K?W6'(/YUI2GR34CFQE%UJ$J:W:*GA>Y6Z\.6;*>43RV'H5X_PK1N[B.VMG
MDEVD8.%9@NXXZ<D"O/?#^L2^&=2FL-01E@9L2#&2C?WAZC']*[RXAMM7L,HT
M$JL,Q2M&L@4^H!XJZM/EG=[,YL%B?:X?EC\<59KT.875O[*G$]G;M%9%LS6Q
MFC90.[( Q(/L.#[5VE<;<^'+Q[R.S1H'A=<RS"PCC"KZ CG=]*Z?4=3M-*MC
M/=RA%'1?XF/H!WHJI2MRZL>$E.FINKI%=[?.UNFQS/Q!N56PM+7/S/*9,>P&
M/_9J\_K0UG59=9U%[J0;1]U$_NJ.@K/KT*,.2"3/F,?B%B*\IQVZ!1116IQA
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 ;G@_\ Y&JR_P"!_P#H#5ZK7E7@_P#Y&JR_X'_Z U>J
MUYV,^->A]7D?^[R_Q?H@HHHKD/9"BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH R-<\.VFMQ R?NKA1A)E'(]CZBN-.A>)="E8V32M'GK;MD-]5_^M7I-
M%;0KR@K;HX<1E]*M+GUC+NCSC^U?&4F8_+O,]\6@!_/;Q56;PUXDO7\^>VEE
M=A]Z29<_JW%>HT5HL2X_#%(YI92JFE6I*7S_ ,[GE7_"'Z]_SX?^1D_^*H_X
M0_7O^?#_ ,C)_P#%5ZK13^N3[(G^P\/_ #2_#_(\J_X0_7O^?#_R,G_Q5'_"
M'Z]_SX?^1D_^*KU6BCZY/L@_L/#_ ,TOP_R/*O\ A#]>_P"?#_R,G_Q5'_"'
MZ]_SX?\ D9/_ (JO5:*/KD^R#^P\/_-+\/\ (\J_X0_7O^?#_P C)_\ %4?\
M(?KW_/A_Y&3_ .*KU6BCZY/L@_L/#_S2_#_(\J_X0_7O^?#_ ,C)_P#%4?\
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M?^1D_P#BJ]5HH^N3[(/[#P_\TOP_R/*O^$/U[_GP_P#(R?\ Q5'_  A^O?\
M/A_Y&3_XJO5:*/KD^R#^P\/_ #2_#_(\J_X0_7O^?#_R,G_Q5'_"'Z]_SX?^
M1D_^*KU6BCZY/L@_L/#_ ,TOP_R/*O\ A#]>_P"?#_R,G_Q5'_"'Z]_SX?\
MD9/_ (JO5:*/KD^R#^P\/_-+\/\ (\J_X0_7O^?#_P C)_\ %4?\(?KW_/A_
MY&3_ .*KU6BCZY/L@_L/#_S2_#_(\_\ #?AO5K#7[6ZNK3RX4W[F\Q#C*D#@
M'/4UZ!116%2HZCNSOPF$AA8.$&[7OJ%%%%9G4%%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !15"YTBVNYS-)+
M>JQQD17LT:_]\JX'Z5%_PC]E_P ]M2_\&=Q_\<H U**R_P#A'[+_ )[:E_X,
M[C_XY1_PC]E_SVU+_P &=Q_\<IZ"-2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_S
MVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\
M'*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'
M[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[
MC_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_S
MVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\
M'*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'
M[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[
MC_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_S
MVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\
M'*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'
M[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[
MC_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_S
MVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\
M'*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'
M[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[
MC_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_S
MVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\
M'*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'
M[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[
MC_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_S
MVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\
M'*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'
M[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[
MC_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_S
MVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\
M'*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'
M[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[
MC_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_S
MVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\
M'*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'
M[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[
MC_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_S
MVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\
M'*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'
M[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[
MC_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_S
MVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\
M'*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'
M[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[
MC_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_S
MVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\
M'*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'
M[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[
MC_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_S
MVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\
M'*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'
M[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[
MC_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_S
MVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\
M'*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'
M[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[
MC_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_S
MVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\
M'*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'
M[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[
MC_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_S
MVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\
M'*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'
M[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[
MC_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_S
MVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\
M'*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'
M[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[
MC_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_S
MVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\
M'*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'
M[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[
MC_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_S
MVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\
M'*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'
M[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[
MC_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_S
MVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\
M'*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'
M[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[
MC_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_S
MVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\
M'*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'
M[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[
MC_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_S
MVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\
M'*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'
M[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[
MC_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_S
MVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\
M'*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'
M[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[
MC_XY1_PC]E_SVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_S
MVU+_ ,&=Q_\ '*- -2BLO_A'[+_GMJ7_ (,[C_XY1_PC]E_SVU+_ ,&=Q_\
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M\]?0T>>OH:KT4 6//7T-'GKZ&J]% %CSU]#1YZ^AJO10!8\]?0T>>OH:KT4
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M"5_:5Y\BCMOKM^!]2[C_ '#^E&X_W#^E?-445OX9M#-,5EOI 5 1NQZ<'''
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MXYXX'?-4[NZNM?U!8XU)0-B-=OW < DX[=,T?V;=Z3T]/^""S-.32CHMW?\
MX!]4[C_</Z4;C_</Z5\U75U!X=M39V9WW+\NY.=O7!(['D<8JAHVCQW*?;;U
ME2S4D?,Q7<>._ISZ]12_L[2[EIZ?\$2S5<KFXV737?\  ^I-Q_N']*-Q_N']
M*^6=5U6?6;@06Z2&$$%(PF6) //'U-:7^C^&+3(Q->R@9&[@#Z>G7!Q0\M:2
M][7T_P""#S-Q2O#WGTO_ , ^E-Q_N']*-Q_N']*^6-+TY]5N9+JX<"!7W3.W
M&XG)..WUZ8S4VKZK]H"Z;8@_9EQ'@ -O((Q@\G' QZT_[-ULI?A_P2GF7O\
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M7KV_G><L;R6RXZ,>.>1GFEN&Q;.L7VI^+-+N8)GCT=YI(855B!<80EG([C(
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M%% !1110!))T3_=%1U))T3_=%1T %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !4L'^L_"HJE@_UGX4 6**** "BBB@"M/_K/PJ.I
M)_\ 6?A4= %"71K";5X=5D@S>PKLCEWMP.>V<=SVJ74-/M=5LGL[V+S;>3&Y
M-Q7.#D<@@]15JBBX&;>Z!IFHZ=!87=MYEK!CRT\QAMP,#D')XJA!X&\-6TPE
M32XRPZ"1W<?DQ(KH:*=V*R$50JA5   P .U9YT+3#K0U<VJ_;P,>=N;TQTSC
MIQTK1HI#"BBB@ HHHH **** "BBB@ HHHH **** "I(OO'_=-1U)%]X_[IH
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M:E%*X[!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5YY\7]->Z\+P7J DVDX+^RL,9_/;7H=07MG!J%E/9W*!X)D*.I[@BM:-3V=1
M3[$5(\\7$YOX5:S'JG@J"V+@SV),$B]]N25/TQQ^!J/Q'X,TG3M'UW5+=)%;
M^SYQ';[OW41898J.V2,XS@') %>:'^V_A5XK,D0,UI)P"P(CN8_0^C#]#Z@\
M^GGQAHOC3PKJ%C8WL-O?W-K)$MM=.(V#LI '/!&>XS7;5IRA4]K3?NR.>$U*
M/)+='F&GKNU^5GEDD$UT1(CME?\ C\AXQ[]37M.E>#])TC5)]1@21YY'9D\U
M]PA+'+[/3)ZDY/;..*\XLO ^OVMY:WUU;0PQ2W)EGW7"?Z.OGQR98YP<A#]W
M/;I74^*OBEHVB6\D6G31ZC?XPBQ-NC0^K,./P'/TZU6(<JK4:3OZ"I6@FYZ'
M,?&W68Y)=/T6-@6CS<3#T)&%'Y;OS%<MHUO!I:PP2/\ Z9<KN*D= ,G&<5S=
MQJ-Q>:E)JU^_VFXDD+G>?O-V./[HXXX]!5K2+"YO[O[=--)'''AS.QR6P1QD
MGTSSR.*[X453I*%]OS/(Q\O;7;=E_5CZ%\&WZWF@1Q;AYMN?+8>W4'\OY5IZ
MK<3V]D[00LY((9UE2/RQC[V6XKR/PWXG%I=FZT^995'RRQG(W#W'7Z&O4M/\
M0Z5K$&SS8U9QAH)\ GVP>#^%>/7HRA/FMH=>!QD:M'V,WRS2M_5SE+ZZN71;
MDW$C3VYWQ,;RW<@_1>3GT%>AUCSZ!IS7T5W)'!'!",B)8U52V?O,>_TJIK/C
M"PT^)DM9$NKG'RA#E ?<_P!!42_>V4$:T;83GG7EH[=>QC_$"_5GM;!3DKF6
M3V[#^M>4&W@MKB?6[PAE8Y@0#/\ NGOR< CTK=UC5]@GOKR4/,^6PQP7/H/T
M'M7$L;SQ#J? 81[AP#E8EZ9Y]AGWKUL-2Y(6Z'B.<L35G6>D7^78':[\0ZHP
MCSMSD*6XC7@9P3],XZUHW][!H=L=.L<&<@B60C# $9'(QD\\>E-O+Z#1;3^S
M[!D>X(*SS8PP/U'?DXY.,5!I>D(J?;M3)AA0AE5\?.1R<@\]NF.:Z=&KO;H6
MW%I2EI!;+N+HVE1>1_:=ZP%LF2%(W;L'&2.>.O%5[Z]N=>OUBMU;:1\D6[ R
M 22<G&>OX4EY>WFO7BI#$P7 VPJV0,=SVSSUK3DEMO#5L88&CGOV;+,R8PI^
MG;@<9[YIZIW>XVY*7-+6;V78666W\,V@AA"RWT@#$NO8]>1CC@\9K/T?2CJ+
MO>7,A\B-B7).2YQD_P!,_6DTW2'OF:ZOG>*VZF5B 6)]S]>M+J>IRZI,EG9Q
ME8%RB)&3^\&>"1QQ@#CM0ET6_5@DU>$'J]WV%U74VU.>*SLE*P ^6J*=H<YX
MXZ8X&,]*O1Q0>'+ 3S /?RK\BL,A2.P(Z?>YYYIL<=OX<LS+*4EU"10T<;+]
MSL>1GU/.1G%9]I8W&M7KW5R62 DM)+V YX&3TXQWQ2T:_N_F3:+C9:4U^/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 22=$_W14=22=$_P!T5'0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %2P?ZS\
M*BJ6#_6?A0!8HHHH **** &M&K')'--\E/3]:DHH C\E/3]:/)3T_6I** (_
M)3T_6CR4]/UJ2B@"/R4]/UH\E/3]:DHH C\E/3]:/)3T_6I** (_)3T_6CR4
M]/UJ2B@"/R4]/UH\E/3]:DHH C\E/3]:/)3T_6I** (_)3T_6CR4]/UJ2B@"
M/R4]/UH\E/3]:DHH C\E/3]:41JO04^B@"/R4]/UH\E/3]:DHH C\E/3]:/)
M3T_6I** (_)3T_6CR4]/UJ2B@"/R4]/UH\E/3]:DHH C\E/3]:/)3T_6I**
M(_)3T_6CR4]/UJ2B@"/R4]/UH\E/3]:DHH C\E/3]:/)3T_6I** (_)3T_6C
MR4]/UJ2B@"/R4]/UH\E/3]:DHH C\E/3]:/)3T_6I** (_)3T_6CR4]/UJ2B
M@"/R4]/UH\E/3]:DHH C\E/3]:/)3T_6I** (_)3T_6CR4]/UJ2B@"/R4]/U
MH\E/3]:DHH C\E/3]:/)3T_6I** (_)3T_6CR4]/UJ2B@"/R4]/UH\E/3]:D
MHH C\E/3]:/)3T_6I** (_)3T_6CR4]/UJ2B@"/R4]/UH\E/3]:DHH C\E/3
M]:/)3T_6I** (_)3T_6CR4]/UJ2B@"/R4]/UH\E/3]:DHH C\E/3]:/)3T_6
MI** &"-5S@=1BD\E/3]:DHH C\E/3]:/)3T_6I** (_)3T_6CR4]/UJ2B@"/
MR4]/UH\E/3]:DHH C\E/3]:/)3T_6I** (_)3T_6CR4]/UJ2B@"/R4]/UH\E
M/3]:DHH C\E/3]:/)3T_6I** (_)3T_6CR4]/UJ2B@"/R4]/UH\E/3]:DHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]M2_\&=Q_P#'*/\ A'[+_GMJ7_@SN/\ XY1H!J45E_\ "/V7_/;4O_!G<?\
MQRC_ (1^R_Y[:E_X,[C_ ..4: :E%9?_  C]E_SVU+_P9W'_ ,<H_P"$?LO^
M>VI?^#.X_P#CE&@&I167_P (_9?\]M2_\&=Q_P#'*/\ A'[+_GMJ7_@SN/\
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ME&@&I167_P (_9?\]M2_\&=Q_P#'*/\ A'[+_GMJ7_@SN/\ XY1H!J45E_\
M"/V7_/;4O_!G<?\ QRC_ (1^R_Y[:E_X,[C_ ..4: :E%9?_  C]E_SVU+_P
M9W'_ ,<H_P"$?LO^>VI?^#.X_P#CE&@&I167_P (_9?\]M2_\&=Q_P#'*/\
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M]M2_\&=Q_P#'*/\ A'[+_GMJ7_@SN/\ XY1H!J45E_\ "/V7_/;4O_!G<?\
MQRC_ (1^R_Y[:E_X,[C_ ..4: :E%9?_  C]E_SVU+_P9W'_ ,<H_P"$?LO^
M>VI?^#.X_P#CE&@&I167_P (_9?\]M2_\&=Q_P#'*/\ A'[+_GMJ7_@SN/\
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ME&@&I167_P (_9?\]M2_\&=Q_P#'*/\ A'[+_GMJ7_@SN/\ XY1H!J45E_\
M"/V7_/;4O_!G<?\ QRC_ (1^R_Y[:E_X,[C_ ..4: :E%9?_  C]E_SVU+_P
M9W'_ ,<H_P"$?LO^>VI?^#.X_P#CE&@&I167_P (_9?\]M2_\&=Q_P#'*/\
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M]M2_\&=Q_P#'*/\ A'[+_GMJ7_@SN/\ XY1H!J45E_\ "/V7_/;4O_!G<?\
MQRC_ (1^R_Y[:E_X,[C_ ..4: :E%9?_  C]E_SVU+_P9W'_ ,<H_P"$?LO^
M>VI?^#.X_P#CE&@&I167_P (_9?\]M2_\&=Q_P#'*/\ A'[+_GMJ7_@SN/\
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M34= $WV@_P!T4?:#_=%0T4 3?:#_ '11]H/]T5#10!-]H/\ =%'V@_W14-%
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M#44_[+P_9_>'URJ>\_\ "[/#?_/EJO\ WZC_ /CE'_"[/#?_ #Y:K_WZC_\
MCE>#44?V7A^S^\/KE4]Y_P"%V>&_^?+5?^_4?_QRC_A=GAO_ )\M5_[]1_\
MQRO!J*/[+P_9_>'URJ>\_P#"[/#?_/EJO_?J/_XY1_PNSPW_ ,^6J_\ ?J/_
M ..5X-11_9>'[/[P^N53WG_A=GAO_GRU7_OU'_\ '*/^%V>&_P#GRU7_ +]1
M_P#QRO!J*/[+P_9_>'URJ>\_\+L\-_\ /EJO_?J/_P".4?\ "[/#?_/EJO\
MWZC_ /CE>#44?V7A^S^\/KE4]Y_X79X;_P"?+5?^_4?_ ,<H_P"%V>&_^?+5
M?^_4?_QRO!J*/[+P_9_>'URJ>\_\+L\-_P#/EJO_ 'ZC_P#CE'_"[/#?_/EJ
MO_?J/_XY7@U%']EX?L_O#ZY5/>?^%V>&_P#GRU7_ +]1_P#QRC_A=GAO_GRU
M7_OU'_\ '*\&HH_LO#]G]X?7*I[S_P +L\-_\^6J_P#?J/\ ^.4?\+L\-_\
M/EJO_?J/_P".5X-11_9>'[/[P^N53WG_ (79X;_Y\M5_[]1__'*/^%V>&_\
MGRU7_OU'_P#'*\&HH_LO#]G]X?7*I[S_ ,+L\-_\^6J_]^H__CE'_"[/#?\
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M2"- (D4(J]@ ,8J2B@"J^F6$EFMF]E;-:KRL)B4H/HN,4ITZQ90K6=N5$9A
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M#T%&!Z"EHH 3 ]!1@>@I:* $P/048'H*6B@!,#T%&!Z"EHH 3 ]!1@>@I:*
M$P/048'H*6B@!,#T%&!Z"EHH 3 ]!1@>@I:* $P/2C ]!2T4 )@>@HP/04M%
M "8'H*,#T%+10 F!Z"C ]!2T4 )@>@HP/04M% "8'H*,#T%+10 F!Z"C ]!2
MT4 )@>@HP/04M% "8'H*,#T%+10 F!Z"C ]!2T4 )@>@HP/04M% "8'H*,#T
M%+10 F!Z"C ]!2T4 )@>@HP/04M% "8'H*,#T%+10 F!Z"C ]!2T4 )@>@HP
M/04M% "8'H*,#T%+10 F!Z"C ]!2T4 )@>@K)U3PMH6M$MJ.E6T[GK(4VO\
M]]#!_6M>BG&3B[IV$TGHSCT^%W@Y)-XTC/H&N)2!_P"/5K1^#_#4<:HOA_2R
M%&!NM$8_F1DUM45HZU1[R?WDJG!;(Q_^$2\-_P#0OZ5_X!1_X4?\(EX;_P"A
M?TK_ , H_P#"MBBI]K/NQ\D>QC_\(EX;_P"A?TK_ , H_P#"C_A$O#?_ $+^
ME?\ @%'_ (5L44>UGW8<D>QC_P#")>&_^A?TK_P"C_PH_P"$2\-_]"_I7_@%
M'_A6Q11[6?=AR1[&/_PB7AO_ *%_2O\ P"C_ ,*/^$2\-_\ 0OZ5_P" 4?\
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M_ */_"C_ (1+PW_T+^E?^ 4?^%;%%'M9]V')'L8__")>&_\ H7]*_P# */\
MPH_X1+PW_P!"_I7_ (!1_P"%;%%'M9]V')'L8_\ PB7AO_H7]*_\ H_\*/\
MA$O#?_0OZ5_X!1_X5L44>UGW8<D>QC_\(EX;_P"A?TK_ , H_P#"C_A$O#?_
M $+^E?\ @%'_ (5L44>UGW8<D>QC_P#")>&_^A?TK_P"C_PH_P"$2\-_]"_I
M7_@%'_A6Q11[6?=AR1[&/_PB7AO_ *%_2O\ P"C_ ,*/^$2\-_\ 0OZ5_P"
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M%_2O_ */_"C_ (1+PW_T+^E?^ 4?^%;%%'M9]V')'L8__")>&_\ H7]*_P#
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M4M% "8'H*,#T%+10 F!Z"C ]!2T4 )@>@HP/04M% "8'H*,#T%+10 F!Z"C
M]!2T4 )@>@HP/04M% "8'H*,#T%+10 F!Z"C ]!2T4 )@>@HP/04M% "8'H*
M,#T%+10 F!Z"C ]!2T4 )@>@HP/04M% "8'H*,#T%+10 F!Z48'H*6B@!,#T
M%&!Z"EHH 3 ]!1@>@I:* $P/048'H*6B@!,#T%&!Z"EHH 3 ]!1@>@I:* $P
M/048'H*6B@!,#T%&!Z"EHH 3 ]!1@>@I:* $P/048'H*6B@!,#T%&!Z"EHH
M3 ]!1@>E+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MHK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\
MGMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE
M'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_
M  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4
MHK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\
MGMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE
M'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_
M  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4
MHK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\
MGMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE
M'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_
M  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4
MHK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\
MGMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE
M'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_
M  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4
MHK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\
MGMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE
M'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_
M  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4
MHK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\
MGMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE
M'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_
M  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4
MHK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\
MGMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE
M'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_
M  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4
MHK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\
MGMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE
M'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_
M  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4
MHK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\
MGMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE
M'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_
M  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4
MHK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\
MGMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE
M'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_
M  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4
MHK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\
MGMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE
M'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_
M  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4
MHK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\
MGMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE
M'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_
M  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4
MHK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\
MGMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE
M'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_
M  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4
MHK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\
MGMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE
M'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_
M  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4
MHK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\
MGMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE
M'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_
M  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4
MHK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\
MGMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE
M'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_
M  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4
MHK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\
MGMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE
M'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_
M  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4
MHK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\
MGMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE
M'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_
M  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4
MHK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\
MGMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE
M'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_
M  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4
MHK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\
MGMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE
M'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_
M  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4
MHK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\
MGMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE
M'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_
M  9W'_QRC0#4HK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4
MHK+_ .$?LO\ GMJ7_@SN/_CE'_"/V7_/;4O_  9W'_QRC0#4HK+_ .$?LO\
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MZ4><_P#>_2N?LO&7A[4+@06^IQ&1N )%:/)] 6 R:W:5K#N/\Y_[WZ4><_\
M>_2F50M]:TZ[U.;3K>Z26Z@7=(B@G:,XZXQG)Z9H TO.?^]^E'G/_>_2LS5-
M<TW18U?4;M( _P!T$$L?H!DT_3-7T_6+<SZ?=).@.&VY!4^X/(_&BP7-#SG_
M +WZ4><_][]*910 _P Y_P"]^E'G/_>_2F44 /\ .?\ O?I3XY&8D$]JAJ2+
M[Q_W30 W>W]X_G1O;^\?SIM(2 "20 .I- #][?WC^=&]O[Q_.L!/&7AZ2]^R
M)JD)EW;1PP4G_>QM_6MVBP7';V_O'\Z-[?WC^=-ID4T4ZEHI$D"L5)1@<$'!
M'U% $N]O[Q_.C>W]X_G3:* ';V_O'\Z-[?WC^=-HH =O;^\?SHWM_>/YU2L-
M3LM425[*<3+%(8G(!&&'4<U;H =O;^\?SHWM_>/YTVB@!V]O[Q_.C>W]X_G5
M2ZO[6RDMTN)=C7$HBB&TG<Q[<#CIWJS0 [>W]X_G1O;^\?SIM% #M[?WC^=&
M]O[Q_.FT4 .WM_>/YT;V_O'\Z;10 [>W]X_G1O;^\?SIM% #M[?WC^=&]O[Q
M_.FT4 .WM_>/YT;V_O'\Z;10 [>W]X_G1O;^\?SIM% #M[?WC^=&]O[Q_.FT
M4 .WM_>/YT;V_O'\Z;10 [>W]X_G1O;^\?SIM% #M[?WC^=&]O[Q_.FT4 .W
MM_>/YT;V_O'\Z;10 [>W]X_G1O;^\?SIM% #M[?WC^=&]O[Q_.FT4 .WM_>/
MYT;V_O'\Z;10 [>W]X_G1O;^\?SIM% #M[?WC^=&]O[Q_.FT4 .WM_>/YT;V
M_O'\Z;10 [>W]X_G1O;^\?SIM% #M[?WC^=&]O[Q_.J.IZI9:/9F[OYO)@#!
M=VTMR>G !-8W_"P/#'_03_\ ($O_ ,33LV*Z.GWM_>/YT;V_O'\ZI:;J=GJ]
MFMW8S>; Q(#[2O(Z\$ U;I#';V_O'\Z-[?WC^=-HH =O;^\?SHWM_>/YU%)-
M%$R+)(B&1MJ!F W'&<#U/!I] #M[?WC^=&]O[Q_.FT4 .WM_>/YT;V_O'\Z;
M10 [>W]X_G1O;^\?SIM,BFBG4M%(D@5BI*,#@@X(^HH EWM_>/YT;V_O'\ZA
MGGCM;>2>9@D4:EW8]@!DUEW7B?2K"PM+R^G>VBNUW1!XF+'@'D*#CJ*+!<VM
M[?WC^=&]O[Q_.N?LO&>@:C>16EI?^9/*<(GDR#)^I7%;U%K!<=O;^\?SHWM_
M>/YTVJTM_:PW\%C)+BYG5FC3:?F"]><8'XT 6][?WC^=&]O[Q_.FU4N-1@M;
MZTM)=P>Z+"-L?+E1G!/J1T^AH N[V_O'\Z-[?WC^=-HH =O;^\?SHWM_>/YT
MVB@!V]O[Q_.C>W]X_G3:* ';V_O'\Z-[?WC^=-HH =O;^\?SHWM_>/YTVB@!
MV]O[Q_.C>W]X_G3:* ';V_O'\Z-[?WC^=-JO?7L&G6$][<OL@@0R.WL!32OH
M@&:IK-GHUDUWJ-XMO O&YCU/H!U)]A7FVJ?&E4E*:5IKR(#_ *VYDVY_X"/\
M:YI5UCXJ^+F17,-I'DC=REM%G]6/ZGV''L6A>!/#V@0*MOI\4TP'S7%PH>1C
M]3T^@Q7H.E1PZ7M?>EV['+SU*K]S1'BL_P 4_%\D\DD>J>2C,2L:P1D("> "
M5)X]SFH_^%H>,O\ H,G_ ,!XO_B:^@[S1-*U"$Q7FG6LZ'M)$I_IQ7C_ ,0?
MAA'I%K)K&AAS:)S/;,2QB']Y3U*^H/(Z].G3A\3AIR494TODC&K2K15U)LYS
M_A:'C+_H,G_P'B_^)H_X6AXR_P"@R?\ P'B_^)KD**]58:@_L+[D<?M:G\S^
M\Z__ (6AXR_Z#)_\!XO_ (FC_A:'C+_H,G_P'B_^)KD**/JU#^1?<@]M4_F?
MWG7_ /"T/&7_ $&3_P" \7_Q-'_"T/&7_09/_@/%_P#$UR%%'U:A_(ON0>VJ
M?S/[SK_^%H>,O^@R?_ >+_XFC_A:'C+_ *#)_P# >+_XFN0HH^K4/Y%]R#VU
M3^9_>=?_ ,+0\9?]!D_^ \7_ ,31_P +0\9?]!D_^ \7_P 37(44?5J'\B^Y
M![:I_,_O.O\ ^%H>,O\ H,G_ ,!XO_B:/^%H>,O^@R?_  'B_P#B:Y"BCZM0
M_D7W(/;5/YG]YU__  M#QE_T&3_X#Q?_ !-'_"T/&7_09/\ X#Q?_$UR%%'U
M:A_(ON0>VJ?S/[SK_P#A:'C+_H,G_P !XO\ XFC_ (6AXR_Z#)_\!XO_ (FN
M0HH^K4/Y%]R#VU3^9_>=?_PM#QE_T&3_ . \7_Q-'_"T/&7_ $&3_P" \7_Q
M-<A11]6H?R+[D'MJG\S^\Z__ (6AXR_Z#)_\!XO_ (FC_A:'C+_H,G_P'B_^
M)KD**/JU#^1?<@]M4_F?WG7_ /"T/&7_ $&3_P" \7_Q-'_"T/&7_09/_@/%
M_P#$UR%%'U:A_(ON0>VJ?S/[SK_^%H>,O^@R?_ >+_XFC_A:'C+_ *#)_P#
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M (FC_A:'C+_H,G_P'B_^)KD**/JU#^1?<@]M4_F?WG7_ /"T/&7_ $&3_P"
M\7_Q-'_"T/&7_09/_@/%_P#$UR%%'U:A_(ON0>VJ?S/[SK_^%H>,O^@R?_ >
M+_XFC_A:'C+_ *#)_P# >+_XFN0HH^K4/Y%]R#VU3^9_>=?_ ,+0\9?]!D_^
M \7_ ,31_P +0\9?]!D_^ \7_P 37(44?5J'\B^Y![:I_,_O.O\ ^%H>,O\
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M_P#$UR%%'U:A_(ON0>VJ?S/[SK_^%H>,O^@R?_ >+_XFC_A:'C+_ *#)_P#
M>+_XFN0HH^K4/Y%]R#VU3^9_>=?_ ,+0\9?]!D_^ \7_ ,31_P +0\9?]!D_
M^ \7_P 37(44?5J'\B^Y![:I_,_O.O\ ^%H>,O\ H,G_ ,!XO_B:/^%H>,O^
M@R?_  'B_P#B:Y"BCZM0_D7W(/;5/YG]YU__  M#QE_T&3_X#Q?_ !-'_"T/
M&7_09/\ X#Q?_$UR%%'U:A_(ON0>VJ?S/[SK_P#A:'C+_H,G_P !XO\ XFC_
M (6AXR_Z#)_\!XO_ (FN0HH^K4/Y%]R#VU3^9_>=?_PM#QE_T&3_ . \7_Q-
M'_"T/&7_ $&3_P" \7_Q-<A11]6H?R+[D'MJG\S^\Z__ (6AXR_Z#)_\!XO_
M (FC_A:'C+_H,G_P'B_^)KD**/JU#^1?<@]M4_F?WG7_ /"T/&7_ $&3_P"
M\7_Q-'_"T/&7_09/_@/%_P#$UR%%'U:A_(ON0>VJ?S/[SK_^%H>,O^@R?_ >
M+_XFC_A:'C+_ *#)_P# >+_XFN0HH^K4/Y%]R#VU3^9_>=?_ ,+0\9?]!D_^
M \7_ ,31_P +0\9?]!D_^ \7_P 37(44?5J'\B^Y![:I_,_O.O\ ^%H>,O\
MH,G_ ,!XO_B:/^%H>,O^@R?_  'B_P#B:Y"BCZM0_D7W(/;5/YG]YU__  M#
MQE_T&3_X#Q?_ !-'_"T/&7_09/\ X#Q?_$UR%%'U:A_(ON0>VJ?S/[SK_P#A
M:'C+_H,G_P !XO\ XFC_ (6AXR_Z#)_\!XO_ (FN0HH^K4/Y%]R#VU3^9_>=
M?_PM#QE_T&3_ . \7_Q-'_"T/&7_ $&3_P" \7_Q-<A11]6H?R+[D'MJG\S^
M\Z__ (6AXR_Z#)_\!XO_ (FC_A:'C+_H,G_P'B_^)KD**/JU#^1?<@]M4_F?
MWG7_ /"T/&7_ $&3_P" \7_Q-'_"T/&7_09/_@/%_P#$UR%%'U:A_(ON0>VJ
M?S/[SK_^%H>,O^@R?_ >+_XFM#0/B-XLO?$>EVEQJQ>">[BCD7R(AN5G (R%
MST-<!6MX5_Y&_1?^O^#_ -&+4U,-14&U!;=D5&K4YE[S^\^H-[?WC^=&]O[Q
M_.FT5\D>T.WM_>/YT;V_O'\Z;10 [>W]X_G1O;^\?SIM% #M[?WC^=&]O[Q_
M.FT4 .WM_>/YT;V_O'\Z;10 [>W]X_G3HF8R %B?QJ.GP_ZT4 6J*** "BBB
M@"M/_K/PJ.I)_P#6?A4= '!W2+KWQ/\ L-Z/,M-/@\Q(6Y5F(4Y([_>'Y"NT
MN+&TNC$;BVAE,+!HRZ [".A'I7+Z]I.HV'B2'Q)I$'VEMGEW5L#AG7ID>O&/
MR'6K2^)]0NYH8;'PWJ09G'F->1B%%7N023DU3UV)6FYDZ%&NO^.]8OKX"4:>
MPAMXWY5.2,@>ORD_4UK>.M-M[SPU<W3(!<VB^;#*.&4@\X-4[G3=1\.^)KC6
M=-M'O;*]'^E6T1'F*W]Y1WYR?Q/UIFKWNK>*K(Z7IVD7ME#,0+BXOXQ%M7.?
ME&<G_/U#ZW%TL4M<%QK/@'3-=3/VZRVS;P.3@X8_F WX5>\5>(!<>"+>2T!,
MVJA8HU'4;OO#^8_&NHM=,M[71X],"[[=(?)(8?>&,'/UKSWPYX<U-?%,-I?P
M3?V=I3RR6\DD9".2W&">#SAN/2A6!W)?&NF+H_@/2K!<9BG4.0.K;6+'\\U=
M\:_\C'X4_P"OD?\ H:5;^)%E=WVA6T=I:S7#BY#%88RY VMS@57\;V]V=6\/
MW<%C=W4=K*9)1;PER &0]N_!ZTT]@?4Z+Q+I5MJVA7<-Q&I*Q,\;D<HP&00>
MW2LGP=X@B?PE:S:K?0Q.K-"))Y0F_;TY/4X(IFI:[JNLV$NGZ3H.I033J4::
M]B$*QJ>"0<\G&?\ Z]:NE>&-/L="M=.N;:WN_)RQ::(."YZD9''^%3LK,?70
MLWBC6]&ECTS5%B\T;5NK<B3'/.,'\.#FN0\*Z7!HWQ U+3[<L8X;-1N8Y+$[
M"2?Q-=LR6^DZ=(;6RQ%$I<06L0RW?"J,9)KA;+4[J'QO?ZP^@:W]FN85B1?L
M9W @*,GG&/E/>A;,'NBSJ5W%H?Q$?4]91Q8RVP2UGV%UC/&1P.#][\_>CPY?
M1:G\1-4N].1A9&W"R$H4#/D8)'KUZ\]:W_%&I:A8Z:(M*LKBXO;@[(VCC++%
M_M,>@Z\9_I4GAK0DT#25M]PDN'/F7$O7>YZ\^@IWT"VILT445!04444 %21?
M>/\ NFHZDB^\?]TT 1U0UNSFU#0[VSMW"2S0LB$G R15^JVH2W<-C+)8VZ7%
MRHRD3/M#>V:$!R^G:WIUK86NC:YI;Z>R!8PMS#F!V'=6Y'7G)_.M#4M9U.36
M#I.AVUM)<11B6>:Z+".,'H,+R2?\^V9JVHW_ (DTN31X/#]_!//A7ENXPL40
M!!+!OXL8XP*FFCN_#?B";4(M/N;^RNX(XY/LJ[Y8W08'RYY!'?\ R;L26['6
M=5FGO-)NK:TAUB&(2Q$,Q@F4G&X?Q  \5E^#I=>-E)-)_9WV#SIW?&_S=^XD
MX[8W?I6CH\5[J?B2?7;FSFLH!;"VMXIP!(PW;BS#MSVJKX:EO+*&ZT:?2KU'
M66=_M/E_N2"21AN^<]!0!-H>NZWJMG;ZI/;V5MI@C9IV;?YCX!RR#H%R.Y)X
MJ.+6O%%]9G5;+3; :>07C@F=_/D0=P1\H)[?UJWX=TZ63P)!IUS')!));O$Z
MR*59=Q8<@\]ZSM/UC5M(TB/2)/#U_+?P)Y,4D2!H'QPK%\\#UH T/^$G,G]B
M7D2QC3=0<Q2%\[XY"#M&<XZ@@\5>NM4G7Q'9:5:I&P>-YKEF!)2,<+CGJ6XK
M,B\,RIX#71W<?:UC,BL#]V7<7&#['BI/"=O>3_:]9U."2&\NV5!'(I4I&@P.
M#TR<G\J6@:D%CK4L?AS7;^&TM(9+2XG"K'&55RO\3 'DGN:;/XEUJSM[;5+G
M3;?^S)PJB.-R9P6'RD_PX)QQSC-5[2QO%\(>)8&M9Q+-<7+11F,[G!Z%1WS[
M5<UNTN9?!VG01V\KS(UMNC5"67!7.1[4]+AJ/AUK6[/6[.TUFTLE@OBRPM;.
MQ,; 9VMGKZ<59U&X\3FZF&FV>GK;1=&NI&+3<9^4+]WTYJ/Q#;3SZUX?DBAD
MD2*Z9I&1"0@V]2>PK"N;"2_UF]M]:T;5-0E:=OLK+(4M5B_A^8$!??J?QI("
M?5M8.J:;X9U."V9I)+]2( PSN 8%<GCJ.M:*ZUK>G:Q:6^M6MD+6]D\J&6T9
MB8W[*V[KGV K$M=.U*U\->'(TT^9Y[6_>1X=I! !<\DC@'C!/'(K4EGO?$VK
MZ<B:7>V-G93BXFEO(PA9@#M51DY^O^2Q'74445!84444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0Z(<>JQJI_4&N3KW<-)RIIOLCSJJ2FT@HHHK<S"BBB@ HHHH **** "BBB@
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M3^5 #:*=L;^Z?RHV-_=/Y4 -HIVQO[I_*C8W]T_E0 VBG;&_NG\J-C?W3^5
M#:*=L;^Z?RHV-_=/Y4 -HIVQO[I_*C8W]T_E0 VI(OO'_=--V-_=/Y4^-6!.
M01P>U $5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% #9(TFB>.10R."K*>A!ZBH[2UBLK2*U@4K#$@1%+$X Z<FIJ* "BB
MB@ HHHH HII<":S+JI:1[AX1" Q&U$!SA1CN>3G-32V-O/>6]W)'NFM]WE,2
M?EW#!XZ9Q5BB@ HHHH **** "BBB@ HHHH **** "BBB@ KFO'NA/X@\)W5M
M"NZYBQ/",=67L/<@D?C72T54)N$E)=!2BI)IGE7P?\610J_AN]D",SF2T9N
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MS;MHX8(3_OXV_K6_18+A114<4\4ZEH94D56*DHP(# X(X[@T 24444 %%%%
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M^%/_  6__95RUY9W%A>36EU$T5Q"Q21&'((J"O7C0I25TCB=2:ZG8?\ "?\
M_4H^%/\ P6__ &5'_"?_ /4H^%/_  6__95Q]%/ZM2["]K/N=A_PG_\ U*/A
M3_P6_P#V5'_"?_\ 4H^%/_!;_P#95Q]%'U:EV#VL^YV'_"?_ /4H^%/_  6_
M_94?\)__ -2CX4_\%O\ ]E7'T4?5J78/:S[G8?\ "?\ _4H^%/\ P6__ &5'
M_"?_ /4H^%/_  6__95Q]%'U:EV#VL^YV'_"?_\ 4H^%/_!;_P#94?\ "?\
M_4H^%/\ P6__ &5<?11]6I=@]K/N=A_PG_\ U*/A3_P6_P#V5'_"?_\ 4H^%
M/_!;_P#95Q]%'U:EV#VL^YV'_"?_ /4H^%/_  6__94?\)__ -2CX4_\%O\
M]E7'T4?5J78/:S[G8?\ "?\ _4H^%/\ P6__ &5'_"?_ /4H^%/_  6__95Q
M]%'U:EV#VL^YV'_"?_\ 4H^%/_!;_P#94?\ "?\ _4H^%/\ P6__ &5<?11]
M6I=@]K/N=A_PG_\ U*/A3_P6_P#V5'_"?_\ 4H^%/_!;_P#95Q]%'U:EV#VL
M^YV'_"?_ /4H^%/_  6__94?\)__ -2CX4_\%O\ ]E7'T4?5J78/:S[G8?\
M"?\ _4H^%/\ P6__ &5'_"?_ /4H^%/_  6__95Q]%'U:EV#VL^YV'_"?_\
M4H^%/_!;_P#94?\ "?\ _4H^%/\ P6__ &5<?11]6I=@]K/N=A_PG_\ U*/A
M3_P6_P#V5'_"?_\ 4H^%/_!;_P#95Q]%'U:EV#VL^YV'_"?_ /4H^%/_  6_
M_94?\)__ -2CX4_\%O\ ]E7'T4?5J78/:S[G8?\ "?\ _4H^%/\ P6__ &5'
M_"?_ /4H^%/_  6__95Q]%'U:EV#VL^YV'_"?_\ 4H^%/_!;_P#94?\ "?\
M_4H^%/\ P6__ &5<?11]6I=@]K/N=A_PG_\ U*/A3_P6_P#V5'_"?_\ 4H^%
M/_!;_P#95Q]%'U:EV#VL^YV'_"?_ /4H^%/_  6__94?\)__ -2CX4_\%O\
M]E7'T4?5J78/:S[G8?\ "?\ _4H^%/\ P6__ &5'_"?_ /4H^%/_  6__95Q
M]%'U:EV#VL^YV'_"?_\ 4H^%/_!;_P#94?\ "?\ _4H^%/\ P6__ &5<?11]
M6I=@]K/N=A_PG_\ U*/A3_P6_P#V5'_"?_\ 4H^%/_!;_P#95Q]%'U:EV#VL
M^YV'_"?_ /4H^%/_  6__94?\)__ -2CX4_\%O\ ]E7'T4?5J78/:S[G8?\
M"?\ _4H^%/\ P6__ &5'_"?_ /4H^%/_  6__95Q]%'U:EV#VL^YV'_"?_\
M4H^%/_!;_P#94?\ "?\ _4H^%/\ P6__ &5<?11]6I=@]K/N=A_PG_\ U*/A
M3_P6_P#V5'_"?_\ 4H^%/_!;_P#95Q]%'U:EV#VL^YV'_"?_ /4H^%/_  6_
M_94?\)__ -2CX4_\%O\ ]E7'T4?5J78/:S[G8?\ "?\ _4H^%/\ P6__ &5'
M_"?_ /4H^%/_  6__95Q]%'U:EV#VL^YV'_"?_\ 4H^%/_!;_P#94?\ "?\
M_4H^%/\ P6__ &5<?11]6I=@]K/N=A_PG_\ U*/A3_P6_P#V5'_"?_\ 4H^%
M/_!;_P#95Q]%'U:EV#VL^YV'_"?_ /4H^%/_  6__94?\)__ -2CX4_\%O\
M]E7'T4?5J78/:S[G8?\ "?\ _4H^%/\ P6__ &5'_"?_ /4H^%/_  6__95Q
M]%'U:EV#VL^YV'_"?_\ 4H^%/_!;_P#94?\ "?\ _4H^%/\ P6__ &5<?11]
M6I=@]K/N=A_PG_\ U*/A3_P6_P#V5'_"?_\ 4H^%/_!;_P#95Q]%'U:EV#VL
M^YV'_"?_ /4H^%/_  6__94?\)__ -2CX4_\%O\ ]E7'T4?5J78/:S[G8?\
M"?\ _4H^%/\ P6__ &5'_"?_ /4H^%/_  6__95Q]%'U:EV#VL^YV'_"?_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 -EC2:)XI%#1NI5E/0@]14=I:0V-G#:6ZE884"(I8G
M '09/-344 %%%% !1110!0U'28-3FLI9GD5K.<7$>P@ L 1@Y'3FK]%% !11
M10 4444 %%%% !1110 $9&*KV-C;:;9QVEI'Y<,>=JY)ZG)Y/)Y-6** "BBB
M@ KFO'GA]O$GA*ZLH0#<IB: >KKV_$9'XUTM%5";A)26Z%**DK,\7^$GC"+3
MWD\.:E((EDD+6K2<!7/WD/IGJ/?/J*]-\8\^"M;_ .O&;_T UQOC_P"&']M3
MR:MH@1+]^9K=B%68^H/9OKP?;OQUA\0O%?A,G2]8M3<Q(-IAOD(<+TP&[CZY
MKTI4HXB2K4=^J.13=)<D]NY6TMPVMH0V5>\(C.?O?Z7">/6OH266."%Y9I%C
MC12S.YP% ZDGM7B7_"VM.CAMQ;>#;&)[8DVY\Q=L)/4J!&,9]L5RWB7Q[KOB
MA3#>7"Q6F<_9H 50_7G)_$UK4PM7$25URI?/\B(5H4D[.Y8^(OBQ?%7B'?;%
MOL%JIBM\\;N?F?'N<?@!7'T45[%&DJ4%%'#4FYRNPHHHK4@**** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#Z1^%O_ "3C2?\ MM_Z.>NPKC_A;_R3C2?^VW_HYZ["OD,3_'GZ
MO\SW*/\ #CZ(****P- HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"M-_K/
MPJ/)]:DG_P!9^%1T &3ZT9/K110 9/K1D^M%% !D^M&3ZT44 &3ZT9/K110
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M=GB3_GRTK_OU)_\ '*/^%V>)/^?+2O\ OU)_\<KS>BCZEA_Y$'UBK_,>D?\
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MPJ*I8/\ 6?A0!8HHHH **** *T_^L_"HZDG_ -9^%1T %%%% !1110 4444
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M+4%UJ^^T:%8Z@+F=I(]0NI0PC0]%*$$\>@Q]:2 AOM5N=8T;POJ$<<7VJ2_
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M>(M+O+MK&_TTQ&^L)#)&DO"R*1AESVS1<5B@;K6_#^HV*ZGJ,>I65Y,+<O\
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M6VL_"VE:9"B1 W.Z.-%P%1$(X'8?.*\1KU<NES4O+4X\4K3"BBBN\Y@HHHH
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M^A?U7_P"D_PH]K#N@Y)=C'HK8_X1+Q)_T+^J_P#@%)_A1_PB7B3_ *%_5?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@! JABP !/4XZTM%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110!0N=7MK2<PR17K,,9,5E-(O_ 'TJ$?K47_"067_/'4O_
M  67'_QNM,LH."0*3S$_O#\Z ,W_ (2"R_YXZE_X++C_ .-T?\)!9?\ /'4O
M_!9<?_&ZTO,3^\/SH\Q/[P_.GH(S?^$@LO\ GCJ7_@LN/_C='_"067_/'4O_
M  67'_QNM+S$_O#\Z/,3^\/SHT S?^$@LO\ GCJ7_@LN/_C='_"067_/'4O_
M  67'_QNM+S$_O#\Z/,3^\/SHT S?^$@LO\ GCJ7_@LN/_C='_"067_/'4O_
M  67'_QNM+S$_O#\Z/,3^\/SHT S?^$@LO\ GCJ7_@LN/_C='_"067_/'4O_
M  67'_QNM+S$_O#\Z/,3^\/SHT S?^$@LO\ GCJ7_@LN/_C='_"067_/'4O_
M  67'_QNM+S$_O#\Z/,3^\/SHT S?^$@LO\ GCJ7_@LN/_C='_"067_/'4O_
M  67'_QNM+S$_O#\Z/,3^\/SHT S?^$@LO\ GCJ7_@LN/_C='_"067_/'4O_
M  67'_QNM+S$_O#\Z/,3^\/SHT S?^$@LO\ GCJ7_@LN/_C='_"067_/'4O_
M  67'_QNM+S$_O#\Z/,3^\/SHT S?^$@LO\ GCJ7_@LN/_C='_"067_/'4O_
M  67'_QNM+S$_O#\Z4.IZ,*- ,S_ (2"R_YXZE_X++C_ .-T?\)!9?\ /'4O
M_!9<?_&ZTO,3^\/SH\Q/[P_.C0#-_P"$@LO^>.I?^"RX_P#C='_"067_ #QU
M+_P67'_QNM+S$_O#\Z/,3^\/SHT S?\ A(++_GCJ7_@LN/\ XW1_PD%E_P \
M=2_\%EQ_\;K2\Q/[P_.CS$_O#\Z- ,W_ (2"R_YXZE_X++C_ .-T?\)!9?\
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M='_"067_ #QU+_P67'_QNM+S$_O#\Z/,3^\/SHT S?\ A(++_GCJ7_@LN/\
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M@LO^>.I?^"RX_P#C='_"067_ #QU+_P67'_QNM+S$_O#\Z/,3^\/SHT S?\
MA(++_GCJ7_@LN/\ XW1_PD%E_P \=2_\%EQ_\;K2\Q/[P_.CS$_O#\Z- ,W_
M (2"R_YXZE_X++C_ .-T?\)!9?\ /'4O_!9<?_&ZTO,3^\/SH\Q/[P_.C0#-
M_P"$@LO^>.I?^"RX_P#C='_"067_ #QU+_P67'_QNM+S$_O#\Z/,3^\/SHT
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MZTO,3^\/SH\Q/[P_.C0#-_X2"R_YXZE_X++C_P"-T?\ "067_/'4O_!9<?\
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MI^I?8)0^3)Y"RY&#Q@_AS[5(S'\"_P#(!F_Z_)O_ $*D\<@#1+?  S?0D_\
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M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %=+IW_(*MO^!?\
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M_2@""BI_L_\ M?I1]G_VOTH @HJ?[/\ [7Z4?9_]K]* (**G^S_[7Z4?9_\
M:_2@""BI_L_^U^E'V?\ VOTH 9%U;_=-1U86';GYLY&.E)]G_P!K]* (**G^
MS_[7Z4?9_P#:_2@""BI_L_\ M?I1]G_VOTH @HJ?[/\ [7Z4?9_]K]* (**G
M^S_[7Z4?9_\ :_2@""BI_L_^U^E'V?\ VOTH @HJ?[/_ +7Z4?9_]K]* (**
MG^S_ .U^E'V?_:_2@""BI_L_^U^E'V?_ &OTH @HJ?[/_M?I1]G_ -K]* (*
M*G^S_P"U^E'V?_:_2@""BI_L_P#M?I1]G_VOTH @HJ?[/_M?I1]G_P!K]* (
M**G^S_[7Z4?9_P#:_2@""BI_L_\ M?I1]G_VOTH @HJ?[/\ [7Z4?9_]K]*
M(**G^S_[7Z4?9_\ :_2@""BI_L_^U^E'V?\ VOTH @ILB+)&R,,JPP:L_9_]
MK]*/L_\ M?I2E%25GL"=M3FT>?1[S(&Y#^3#_&MZWU"UO(R%D"LPP48X/^?I
M3Y;))D*2893V(K*N/#X7+17 4>D@Z?C7SGU7&Y:W]52G2>O*WJO1_P!>G4[O
M:4JZ_>:2[FQ%;06V6C18Q@ X.!QZ_P"-4[S6+>V0K$RRR]@O0?4UC'3""5-[
M9C'K+_\ 6I/[,_Z?K+_O[_\ 6KDK9MC/9^SP]%0^:=O1:&D</2O><KE265YY
M6DD;<[')-,J__9G_ $_67_?W_P"M1_9G_3]9?]_?_K5\S+ XJ3<I1NWYK_,[
ME5IK1,H45?\ [,_Z?K+_ +^__6H_LS_I^LO^_O\ ]:E_9^)_E_%?YC]M#N4*
M*O\ ]F?]/UE_W]_^M1_9G_3]9?\ ?W_ZU']GXG^7\5_F'MH=RA15_P#LS_I^
MLO\ O[_]:C^S/^GZR_[^_P#UJ/[/Q/\ +^*_S#VT.Y0HJ_\ V9_T_67_ ']_
M^M2II+R.$2[M&8] LF2?TH678ENRC^*_S%[:GW,^BM;_ (1^[_YZ0_\ ?1_P
MH_X1^[_YZ0_]]'_"MO['Q_\ SZ9/UFC_ #&316M_PC]W_P ](?\ OH_X4?\
M"/W?_/2'_OH_X4?V/C_^?3#ZS1_F,FBM;_A'[O\ YZ0_]]'_  H_X1^[_P">
MD/\ WT?\*/['Q_\ SZ8?6:/\QDT5K?\ "/W?_/2'_OH_X4?\(_=_\](?^^C_
M (4?V/C_ /GTP^LT?YC)HK6_X1^[_P">D/\ WT?\*/\ A'[O_GI#_P!]'_"C
M^Q\?_P ^F'UFC_,9-%:W_"/W?_/2'_OH_P"%'_"/W?\ STA_[Z/^%']CX_\
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M6A.FE%WU$HJ?[/\ [7Z4?9_]K]*^R/,(**G^S_[7Z4?9_P#:_2@""BI_L_\
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M?I1]G_VOTH @HJ?[/_M?I1]G_P!K]* (**G^S_[7Z4?9_P#:_2@""BI_L_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M::%I[BZFP);FYD\R1P.@)I7T"VIKT445)04444 %%%% !1110 4444 %%%%
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MUITGAY-$".EJ@&QD(#JP.=X./O9YS[FI8-$@AUG^U3-/)<FV6V8N5PR@YR0
M.<_A[4FPL<M_8MEX<M99-9TBVOK;SS*VHH TR[FR"X;D8)'W2?IUKO <C(KF
M?^$&TTS@O=ZD]HKB1;%[HF $'/W>O7WKIJ3=QI!1112&%%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ ILD:RQM&XRK#!%.HI-*2LP
M6ARY%QHM]D?,AZ9Z./\ &MNWU&TO(R!(%9A@HQP:LS0QW$9CE0,I[&L>?P\"
M28)L#^ZX_K7SBPF-RZ3^J)3IO[+W7I_7RZG=[2E67[S27<UHK>WMLM&BQ@@
MX. 0/\]:IWFL6]LA6$B63L%Z#ZFLT>'[K.#)#CZG_"IAX<..;K!]H_\ Z]3/
M%9G.G[/#8;D^:_#9?F-4Z"E><[F-+*\TK22,69CDFF5N_P#".?\ 3W_Y#_\
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M'_H":;_X"1_X4?\ "-:#_P! 33?_  $C_P *U**+L+&7_P (UH/_ $!--_\
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M?^@)IO\ X"1_X4?\(UH/_0$TW_P$C_PK4HHNPL9?_"-:#_T!--_\!(_\*/\
MA&M!_P"@)IO_ ("1_P"%:E%%V%C+_P"$:T'_ * FF_\ @)'_ (4?\(UH/_0$
MTW_P$C_PK4HHNPL9?_"-:#_T!--_\!(_\*/^$:T'_H":;_X"1_X5J44786,O
M_A&M!_Z FF_^ D?^%'_"-:#_ - 33?\ P$C_ ,*U**+L+&7_ ,(UH/\ T!--
M_P# 2/\ PH_X1K0?^@)IO_@)'_A6I11=A8R_^$:T'_H":;_X"1_X4?\ "-:#
M_P! 33?_  $C_P *U**+L+&7_P (UH/_ $!--_\  2/_  H_X1K0?^@)IO\
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M'_H":;_X"1_X4?\ "-:#_P! 33?_  $C_P *U**+L+&7_P (UH/_ $!--_\
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M?^@)IO\ X"1_X4?\(UH/_0$TW_P$C_PK4HHNPL9?_"-:#_T!--_\!(_\*/\
MA&M!_P"@)IO_ ("1_P"%:E%%V%C+_P"$:T'_ * FF_\ @)'_ (4?\(UH/_0$
MTW_P$C_PK4HHNPL9?_"-:#_T!--_\!(_\*/^$:T'_H":;_X"1_X5J44786,O
M_A&M!_Z FF_^ D?^%'_"-:#_ - 33?\ P$C_ ,*U**+L+&7_ ,(UH/\ T!--
M_P# 2/\ PH_X1K0?^@)IO_@)'_A6I11=A8R_^$:T'_H":;_X"1_X4?\ "-:#
M_P! 33?_  $C_P *U**+L+&7_P (UH/_ $!--_\  2/_  H_X1K0?^@)IO\
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M'_H":;_X"1_X4?\ "-:#_P! 33?_  $C_P *U**+L+&7_P (UH/_ $!--_\
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M?^@)IO\ X"1_X4?\(UH/_0$TW_P$C_PK4HHNPL9?_"-:#_T!--_\!(_\*/\
MA&M!_P"@)IO_ ("1_P"%:E%%V%C+_P"$:T'_ * FF_\ @)'_ (4?\(UH/_0$
MTW_P$C_PK4HHNPL9?_"-:#_T!--_\!(_\*/^$:T'_H":;_X"1_X5J44786,O
M_A&M!_Z FF_^ D?^%'_"-:#_ - 33?\ P$C_ ,*U**+L+&7_ ,(UH/\ T!--
M_P# 2/\ PH_X1K0?^@)IO_@)'_A6I11=A8R_^$:T'_H":;_X"1_X4?\ "-:#
M_P! 33?_  $C_P *U**+L+&7_P (UH/_ $!--_\  2/_  H_X1K0?^@)IO\
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M'_H":;_X"1_X4?\ "-:#_P! 33?_  $C_P *U**+L+&7_P (UH/_ $!--_\
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M?^@)IO\ X"1_X4?\(UH/_0$TW_P$C_PK4HHNPL9?_"-:#_T!--_\!(_\*/\
MA&M!_P"@)IO_ ("1_P"%:E%%V%C+_P"$:T'_ * FF_\ @)'_ (4?\(UH/_0$
MTW_P$C_PK4HHNPL9?_"-:#_T!--_\!(_\*/^$:T'_H":;_X"1_X5J44786,O
M_A&M!_Z FF_^ D?^%'_"-:#_ - 33?\ P$C_ ,*U**+L+&7_ ,(UH/\ T!--
M_P# 2/\ PH_X1K0?^@)IO_@)'_A6I11=A8R_^$:T'_H":;_X"1_X4?\ "-:#
M_P! 33?_  $C_P *U**+L+&7_P (UH/_ $!--_\  2/_  H_X1K0?^@)IO\
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M'_H":;_X"1_X4?\ "-:#_P! 33?_  $C_P *U**+L+&7_P (UH/_ $!--_\
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M?^@)IO\ X"1_X4?\(UH/_0$TW_P$C_PK4HHNPL9?_"-:#_T!--_\!(_\*/\
MA&M!_P"@)IO_ ("1_P"%:E%%V%C+_P"$:T'_ * FF_\ @)'_ (4?\(UH/_0$
MTW_P$C_PK4HHNPL9?_"-:#_T!--_\!(_\*/^$:T'_H":;_X"1_X5J44786,O
M_A&M!_Z FF_^ D?^%'_"-:#_ - 33?\ P$C_ ,*U**+L+&7_ ,(UH/\ T!--
M_P# 2/\ PH_X1K0?^@)IO_@)'_A6I11=A8KV=A9Z?&T=E:06R,=S+#&$!/K@
M"K%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
B444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img62602283_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img62602283_2.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M_A,M'_Z"NF_^!*?XT :5%9O_  F6C_\ 05TW_P "4_QH_P"$RT?_ *"NF_\
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MF0LP&!].*S_V<?VD+?XLZ?KDM]-I=BVFZK<V48$Z+YBQOM#=>]>E?\)EH_\
MT%=-_P# E/\ &O.RG)*6!HQI+WG&^KWU=Q>QI\RJ6U74T@-HHK-_X3+1_P#H
M*Z;_ .!*?XT?\)EH_P#T%=-_\"4_QKV;&QI45F_\)EH__05TW_P)3_&C_A,M
M'_Z"NF_^!*?XT :1&301FLW_ (3+1_\ H*Z;_P"!*?XT?\)EH_\ T%=-_P#
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MB0HHHH **** "BBB@ HHHH **"<4$XH *.]&<49YQ0 $9HJU8Z'=:FP$,,C
MG&=O KI-*^%<DJJUS-Y:GLHS2<D@.1SS2HCR?=1F^@KTG3OAWI]B=QC:1O5C
MG-:\&F6]J/W<$,?^Z@%3[1%<IY=9>&+[4#^[@;\>*TK?X9ZA*/F\N/ZG->B!
M?:G"I]HPY3A8?A+<$#S+J+\ :LQ_":/^*Z;\!78T4N9CL<G%\*+4?>N)OR%2
MK\+;-?\ EK(?P%=/11S,=CF1\+;$=&<<YX IC_"JS;_EO,OT KJ:*.9A8Y&3
MX36_\-U+^(%5YOA,P^Y=+^*UVU%',Q6//Y_A7>1?=FAD]@#5"Z\!ZE:\F'<O
MJ#7I](1D^U'.Q<IX]/I\]LVUXI%_"H>E>RO DHPR*P]"*HW_ (4L-07#V\:^
MZ*%-5[0.4\HHKO-0^%5N_-O-)'['YJYW5O E]I98^69E]4&:I23)L8M%+)$T
M388%2.N1250!1110 4444 %%%% !1110 4444 %&:*",B@"MJ]A'JVF7-K*
MT=Q$T; CJ&!!_G5K]A[5IF^%%UH]TS-<:#J$UL23R5)\Q?T<#\*0KFLW]FB[
M^P?'GQMIJ_+')##>A1TR0B=/PJ9[#CN>]4445B6%%%% !1110 5\P:/_ ,G,
M_$;_ *_8_P#T1#7T_7S!HW_)S'Q&_P"OV/\ ])X:NGN3([>B@# HK4D****
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M^3L?%O\ V K?_P!&U,MAQW/H6BBBL2PHHHH **** "OF#1O^3F/B-_U^Q_\
MI/#7T_7S!HW_ "<Q\1O^OV/_ -)X:NGN3([>BBBM20HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *AU+_ )!UQ_US;^535#J7_(.N
M/^N;?R- 'C/[%_\ R!_%'_8>O?\ T97ME>)_L7_\@?Q1_P!AZ]_]&5[90 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6%^
MS]_R=CXM_P"P%;_^C:W:POV?O^3L?%O_ & K?_T;4RV''<^A:***Q+"BBB@
MHHHH *^8-&_Y.8^(W_7['_Z3PU]/U\P:-_R<Q\1O^OV/_P!)X:NGN3([>BBB
MM20HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *IZ]
M?0Z=HUU-<31P0I$Q9Y&"JO'<GBKE8OQ$\'Q>/O!&J:/.6$>H6[0G;P1D<?K0
M!Y'^Q3KUC<V/B:".\M9)I-<O'6-9E+,OF9R!G./>O=J^8?V%OV1[_P""?BC7
M=8UB28W!FEM+9&/!0-CS.O\ $#7T]0 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !6%^S]_R=CXM_[ 5O\ ^C:W:POV?O\
MD['Q;_V K?\ ]&U,MAQW/H6BBBL2PHHHH **** "OF#1O^3F/B-_U^Q_^D\-
M?3]?,&C?\G,?$;_K]C_])X:NGN3([>BBBM20HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH \;_ &L?C/K?PE72?['>!?MF_P SS8]V<8QCD5XU_P -F^-O
M^>]A_P!^#_\ %5W/[?G)\/\ _;3^E?/6@:'-XCUJWL;?9]HNG$488X!8D #/
MUKT:%.#A=H\VO4FJC29Z9_PV;XV_Y[V'_?@__%4?\-F^-O\ GO8?]^#_ /%5
MS'Q5^!?B+X,/:IX@M4M)+Y#)"H<-O4<9XJE;?"S5KOPO:ZQ%'"]G>3?9XCY@
M#,_IBM>2FU>QGSU+V.T_X;-\;?\ />P_[\'_ .*H_P"&S?&W_/>P_P"_!_\
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MY@T;_DYCXC?]?L?_ *3PU=/<F1V]%%%:DA1110 4444 %%%% !1110 4444
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M?B?T<_\ "2:=_P _]E_W_7_&GP:Y9W4@2*[M9)&Z*DJL3^ -?SA_\+S\8_\
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MOJ7^E5QA%+'))W7+'\B<B;>&;?=_F>Y4445\J>T%%%% !1110 4444 %>"_
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M ?5OS3_&OE6BNSZK3./ZU,^JO^&]/#__ $!]6_-/\:/^&]/#_P#T!]6_-/\
M&OE7/-6(M(NYX]\=K<.G]Y8R1^=+ZK30?6JG0^HO^&]/#_\ T!]6_-/\:/\
MAO3P]_T!]6_-/\:^6;BSFM/];#)'GIO4KFGKIETT/F"VN#'_ 'Q&=OYT_JM,
M?UJH?4?_  WIX?\ ^@/JWYI_C1_PWIX?_P"@/JWYI_C7RS;VDMV6\J*23;R=
MJEL5&1M-'U6G<7UJH?57_#>GA_\ Z ^K?FG^-<CXR_:,\!^._&FBZYJ'A[4I
MK[0W+V['9P3Z\]J\%F@>W?;(K(V,X88IM/ZK3%]:J'U4O[>?AU!M&CZJ,#
M*?XT']O3P^1_R!]6_-/\:^5-OS9I:/JM,/K50^KK/]NSP_=W,<2Z3JF9&"@D
MIQG\:]JTN_75-.@NDW*EQ&LB@]@1FOSQT3_D,6O_ %U7^=?H)X/_ .14TW_K
MUC_]!%<N(I1A;E.K#U93OS&E7!_&3X_:=\%GLUOK.[NOM@)7R2O&/7)KO*^:
M_P!OD8N-!_W7K.C%2G9FM:3C#F1O?\-Z>'_^@/JWYI_C1_PWIX?_ .@/JWYI
M_C7RK03BN[ZK3.#ZU,^JC^WGX>(_Y ^K?FG^-<AX4_:(\!^#?B/K7B>R\.ZE
M'J6N*HN'&SJ,\CGOFO#(](NYHO,2UN&C_O+&2/SQ4<]I+:MB2*2,^CJ5_G2^
MJTQ_6JA]3?\ #>?A_/\ R"-6^F4_QH_X;T\/_P#0'U;\T_QKY33FG9I_5:8O
MK4SZJ_X;T\/_ /0'U;\T_P :/^&]/#__ $!]6_-/\:^5"V!2XYH^JP']:F?5
M7_#>GA__ * ^K?FG^-'_  WIX?\ ^@/JWYI_C7RO'&TTJHBLSL<!0,DTZZM9
M+*;RYHWAD'577:?RI?5:8OK50^IO^&]/#_\ T!]6_-/\:/\ AO3P_P#] ?5O
MS3_&OE6BCZK3#ZU4/JK_ (;T\/\ _0'U;\T_QH_X;T\/_P#0'U;\T_QKY5HI
M_58!]:F?:GPD_:=TKXO^)FTRRL+ZVF6)I=\I7;@?0UZ97R+^P]_R5J3_ *\Y
M/Z5]=5PUX*$K([L/4<H784445B;!1110 4444 %87[/W_)V/BW_L!6__ *-K
M=W<XK$_9[C+_ +5'BZ3^%=&MX_Q\S/\ 6IEL..Y]!T445B6%%%% !1110 5\
MP^+[=O#7[9FJQOQ%K6F"X0D=6&T8_):^GJ\)_;.TE_#%MHGC2TA9KC2+Q(;A
M@,_N9 8SD>Q?-5'<4MB]15?3-3AUBPANK=UEM[A \;KT8'H:L5L0%%%% !11
M10 4444 %?%?[6G_ "634O\ >_H*^U*^*_VM/^2R:E_O?T%=6$^,Y<9\)YG1
M117I'F@>>E?8G[->OW@_8E\97/VB3[18@B"3/S1?*O2OCOI7UC^SSK%CIW['
MOBS1[B]LX=3U0$VUN\JAY/E7IS[=ZY\3\*]4=&'^)^@GP(T.']JC]G;Q+:ZY
M&EQKFAC_ $74&^:;D%E!)[<5-^RC\7M/T+P$/"OBIDGTO4;^?3DFE;_4D*=H
M].H_6L/X-_$[2?V9OV??$4,VH6\OBK7 1%9H=YBX*J6QQWSUKR77K>=O@K:W
M3-&L\FK/<E5D&]0PX;&<]:Q]GS-KI?0TY^5*76VIZC\0OA+JG[-7BSQ=)I%S
M<1Z+J&FR2V-Q']TC>AQD<<9Q[UX;\/\ 0?\ A,?&EO'=.WV</]HNY#U$2G=(
M?KM!KW3P%^TQ#XT_9>\4>$_$$UO_ &AINEE=-E<?/,-P&W/<X(_*O+O#B_\
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M2$)!SG<3T!ZBCVE2WS)]G"Y\F,NUB/0XI*GU185U*X^SY-OYK>43_=R<?I4
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M $ ;+_Q[_&C_ (4)X/\ ^@#9?^/?XUU?7(]CE^IR[GP=1T/%?>/_  H3P?\
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M0G@__H V7_CW^-'UR/8/J<NY\'-DFBOO'_A0G@__ * -E_X]_C1_PH3P?_T
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M7@'[%^F_$:?]GS1VT?P_IMWIY>7RY9)<,WSG/\8[^U>J_P!C_%K_ *%;2?\
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MTBVMH;6,+#''&J\!57 %<S_8_P 6O^A6TG_O_P#_ &RD_L?XM#_F5=(_[_\
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MOZ1]IOHIY"\6ISKG E!^_CW]:_2W7/@9X0\2?#B3P?J&@Z?=^&98Q$VFR(3
MR#!"XST&!^590_99^']OX,TOP_!X3TB#2=#<2:=;I#A;)AT*<Y%.-56LR73=
M[H_-W_A:GBV7X)_M,>'Q>WS>&/"NJ^7H[>8=NG'S(3Y<1_A'S.<#BGV6IZA\
M./B!^R#JNEZQJT.H>-HU@UFXDNWD:]C\JT(5R3RH+' [9K])#^S-X"?X?7GA
M63PKI+^'[]_,N;(Q?NKA]V[<W<G=SS5%OV._AB\V@R'P5H9;PNV[23Y1_P!
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M(LQ9+J"1I H&[!+@1.2!VKY3_:K\*:MXP_X(=> X]'AFGDLK+2;NX$8SM@2
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img62602283_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img62602283_3.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M^-4?\+X^('_1)=0_\'"?_&J /7J*\@/QY^(/_1)=0_\ !PG_ ,:H'QY^(/\
MT274/_!PG_QJ@#U^BO'Q\>OB!_T26_\ _!PG_P :I?\ A?7Q _Z)+?\ _@X3
M_P"-4 >OT5Y#_P +X^('_1)=0_\ !PG_ ,:H_P"%\?$#_HDNH?\ @X3_ .-4
M >O49KR'_A?'Q _Z)+J'_@X3_P"-4?\ "^/B!_T274/_  <)_P#&J /7J*\D
M\(_M"^*-6^*.E^'=:^'MUH%OJ4$TPOI-468(8P#MV",9SGKD8KUN@ HH)YKS
M3XJ?&_7O!/Q#L] T3P7/XF:YL6O7FCU 6_DX?9MVE&SZYS^% 'I=%>/_ /"^
M?B"/^:2ZA_X.$_\ C5._X7S\0,?\DEU#_P '"?\ QJ@#UZBO(?\ A?/Q /\
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M\?$#_HDNH?\ @X3_ .-4 >O45Y#_ ,+X^('_ $274/\ P<)_\:H_X7Q\0/\
MHDNH?^#A/_C5 'KU%>0_\+X^('_1)=0_\'"?_&J/^%\?$#_HDNH?^#A/_C5
M'KU%>0_\+X^('_1)=0_\'"?_ !JC_A?'Q _Z)+J'_@X3_P"-4 >O45Y#_P +
MX^('_1)=0_\ !PG_ ,:K-\6?M->/O"GAV\U&3X1WSQV<1E8'6D7('OY1_E0!
M[A15'PSK#>(- L[UX?L[742R-%NW>62,XS@9Q]*O4 %%<M\9OB)<?"OX>WVM
MVNEMK5Q:E EFL_D&8LZKC?M;'7/0]*XK_A?'Q _Z)+J'_@X3_P"-4 >O45Y
M?CS\0!_S26__ /!PG_QJ@?'GX@_]$EU#_P '"?\ QJ@#U^BO(?\ A?'Q _Z)
M+J'_ (.$_P#C5'_"^/B!_P!$EU#_ ,'"?_&J /7J*\A_X7S\0/\ HDNH?^#A
M/_C5(?CS\0<?\DEU#_P<)_\ &J /7Z*\@'QY^(./^22ZA_X.$_\ C5 ^//Q!
M/_-)=0_\'"?_ !J@#U^BO(?^%\?$#_HDNH?^#A/_ (U1_P +X^('_1)=0_\
M!PG_ ,:H ]>HKR'_ (7Q\0/^B2ZA_P"#A/\ XU1_POGX@?\ 1)=0_P#!PG_Q
MJ@#UZBO(=+_:(\5#QCH>F:Q\.[K1;?6KL6HNY-4601':6SM$8STZ9%>O Y%
M!117 ?&CXPZM\--6T&RT?PM-XGN=:DF0I'>BW, C0-GE&W9S[8Q0!W]%>0_\
M+Y^(/_1)=0_\'"?_ !JD_P"%\_$#_HDM_P#^#A/_ (U0!Z_17D'_  OGX@_]
M$EU#_P '"?\ QJD'QZ^(/_1)=0_\'"?_ !J@#V"BO(?^%\?$#_HDNH?^#A/_
M (U1_P +X^('_1)=0_\ !PG_ ,:H ]>HKR#_ (7U\0,_\DEU#_P<)_\ &J/^
M%\_$#/\ R274/_!PG_QJ@#U^BO(?^%\_$ _\TEU#_P '"?\ QJC_ (7Q\0/^
MB2ZA_P"#A/\ XU0!Z]17D/\ POCX@?\ 1)=0_P#!PG_QJC_A?/Q _P"B2ZA_
MX.$_^-4 >O45Y!_POGX@'_FDNH?^#A/_ (U6S\*/C3K?CGQM?:)K7A";PS-:
M6:WB-)?"X,H+[<8"+CZY_"@#T:BBB@!LLH@C9F^ZHR:\%UC_ (*<_!'0?&?B
M'P_=>-K:+5O"CJFK6_V.X)LBS[%W$)C!;C.<5[U+PA^E?CI\./@!X@_:C_X*
M>?M>>"]"UK1]%AUBSM8KZ6\@>8M%]LER(]I&&Z\G/44 ?KWX0\7Z;X^\,V>L
M:/>0ZAINH1+-;W$1RLJ,,@C\*T>@K\M/VIO%?B+_ ()Z>#-%^%_@KXA7$,?A
M7PI)/!IEG,;>]DEAMF;SGE;Y#'E =N,D CJ:K_$#]L7XL?$&X_98LM$\<7FC
M7'Q-T>5=;DAF.V1UCMAY@P?]8#(QR<\T ?J-?>(['3M1M[.:ZACNKK)BA9QO
MD ZD#KW%7/NK^%?F%XS\'>*/!?\ P6!^$/A?Q!\1O%&J0KX=U&X^T37NWS&$
MEJ0H+#H<\CO7Z!_M _$B3X7?"Z[NK%EN-8FC^SZ; [#=>7!!V(/<X- &SX)^
M*OA_XDZCJ]KHNIVVH7&@W M+Y8FS]GE*A@I]]I!I/B?\6/#_ ,&O"\FL>)-1
MATW3XR%,D@)R20   "2>1T%?F#^PKXUU3]@__@J7XB\ >(WU"S\,_&A1JVD_
M;I@S&\Q'&06Z<;9 .G&*^R/^"H'P+T_]HSX,:?X9/BK_ (1#Q%?7N= U$OMC
MBNPI8;CZ;58=1UH ]D^'7[07A?XI>)KO1=)OFFU33[9;NXMW@DC:.-FVALLH
M!Y]#6DGQ9\.R?$63PG_:EK_PD,5NMVUEN_>B)MV&QZ?*?RKX5_X)Y_M(_%?X
M=?M$^*OAK\=-/T_4/$6@Z$EU:>)[3 _M&S$C!?,8LQSE6ZXZBO#_ -L;XC>(
MOV>?VT?AY^TO!#J4FAZYJ7]C7YDD!@BTZ3"0$_1IF- S])OC;^V]\,_V=O&F
MD^'O&'B:'1M8UTE;"V>WED:Y(QD*44CN/SK>^$/[27@OXZSWT/A?7;?4KC37
M,=S!M:*6$Y(Y1P&['G&*_/G_ (*V^+=-\3_MN?LJZI9W<$VGWFJ3SQ3!QM9&
M%N0<U:^%]M?7G_!Q/XBOO".Y_"9\*(NM36WS6KW'V?Y 2."X;?WX- C]-A12
M,,BE' H **** "BBB@ J&_'^BR'VJ:H;_P#X\Y/I0!P_[-XS\-C_ -A"[_\
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M$>$5MO#]QK4WBN=K=(TE6,P-\@!.[ME_TH ^C*0\U\'?"[_@LRWC#7M#COO
M^I6]GJPUR)62XC=FFTQUCD4 9/S,>*]*_97_ ."@^I?M$_&>U\--X6O+*SOK
M.YO5O" 4MQ$ZJ(W/]X[OT- 'U*SJAQN53]>M#3K$N695]R:_/']M7]JGQU^S
M3^TAXBD\6_\ "41_"_4A''8ZYH=T-OAT[%W&9 &?DAFR .*W?V:_V@O$7[9/
M[>/Q"\+W7B36M)\*?#VUAAT^VM)C"=2+PP2_:) 0=W^M(S@=* /O0-NHKE?A
M;X+O/ FG7EK=Z[?:\LEP7AENY?,FB3 ^4GCZUU0.: "@C-%% #6P*X?X:_\
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M:_$7_!3'XL>+?">J:DNLZEI4W@_P9K.HP)&S(M_<6SQK%(X_B.,],?>-??\
M\:OVW;[]G[]C;PG\0[O1Y]8O-4M;3S[576-W=X=S'+<<D?K0!]+T5\"^&?\
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M !7,_&*[6P^&^L3R;O+AM)';:I8X"DG '6NFKG?BH?\ BA-4_P"O=_\ T$T
M>:_#K]KOPC;^ M'C:/Q)N2SB!QHER?X1_L5L3?MA^$8XF;R_$G _Z ES_P#$
M5W'PT_Y)YHG_ %Y1?^@"MHQ[AANAZT ?FW^RI_P6CTO]MOXG?\(+>>$]>TG6
M-(\4-;17PM9'L[A(Y9$7+!-L;8QPS9ZU^CEU9KJ.E&"1G59H]I*'# $=C7CF
MM?L_^#O@7IFFQ^%?#^FZ+_:.OQW5T]M L;W$CL[,S$ 9.6/7UKT/XL_$F/X2
M?"_5/$4MLUY'I-MY[1*VTN!@8SSZT >:^&/^">'PY\+_  N\1^$([?5+K1?%
M-U]MO5NKD22"7Y?F0[?E^Z.QJ2[_ .">GPUO-"FLI--NC-/J4FK/?>:OVLW3
MQ")Y?,V_>,8"DXZ5!X$_;/D\;:C=6/\ PCL=C?1VPOK>.YU%(UGMR0N_<P 4
M[B1M//&:QOVCOVB_$VC_  <UC5-/TZQ@DTX1RO%::O%<7%PAD4,J;.0P!)X!
MSC% 'I_AW]FGPKX1^!TGP]TVUFM?#LUF]E(L;@32(Z;&);'+$=\5Y%9_\$D_
MA+86$%M#'XB6&VTB/0XU^WCY;:-&15^YUPQYKOOV*OBE+\8_A1<:X;J:>SN-
M0E^PQW(*W=I!A2D4ZM\RRKDY# 'GD5[!0!\'_%'_ ()P>.(_CRFL>#-<U2PT
M?2=-T[3])62^!AMQ;)L!>/(+=!G&,XKZRUKX'Q>.;7P_=ZSJ>J0ZYH]HL4EU
MIUQ]G\URJ^9V)VLRYQFN^HH \/US_@GK\-?$/A)=+N-.NA-'J U6/4TE5=0A
MNEW;95EV\,N\X..*]&^'_P *+;X>G=%JFNZHXC$0?4;O[0RKQP#@>E=510 4
M444 %%%% 'E/QG\8V?@CXN^%;V^6Z:$07*_N(&F;)"?PJ":U?^&F/#6/]7KO
M_@IN/_B:/''_ "7+PI_U[77\DKT'[PH ^0_^"AG_  57TG]BOX-6?BZQT'6M
M?']IQ6L]F;22V:2-E<G:[I@-\H[&M[]C#]LK1/VVO&6F^+-%TG7-%5M!99K7
M4K.6W>-C,#A2ZKO'NHQ7NWQ3^#'A?XU:-;Z?XJT6PUW3[6X6Z2VO(5EC\Q<@
M$JP([FL'3-%L_#OQ[T^RL+:&SL[?P^Z10Q(%2-1.. !TH S/VH?V//#/[6EC
MI=KXDU/Q-8QZ1.;B :3J'V4ERI7)^5L\$U@:M_P3F^&^MZ%HUE=6^K3-HMI%
M8K=-= W%Y#&^]4F?;\XW'/:M_P#:/_:='P!USPQI_P#8LNK77BJ[DL[0)/Y8
M$B0O,<G!Q\D;<GOQ5#P3^UG+\1OA[H'B/2M%L38Z]9+>(MUJ\5M)'DD8*M@]
MNM $&M_\$^OACKGCA==ET5XI@MNK6L3*MI(8',D3-'MY*L<@YZ@5T/[07[)7
MA/\ :8O-#N/$O]I>9X=F-Q9FTN!%AB5)W?*<_=%>!_M,_M5^(_ 'Q/TN.Z1X
M=(U>.UCLO[,O!<#3KAI,.]R8\_NF!4*6V@D'!-?77AB::[\.6,EQ<0W4SPJS
MS0X\N1L<E<9&#0!\VW7_  2R\ ^$=%AN?"[^(+76]%_M.YTJ5KX$0W%\PDF8
M_*.K@'J,5RO[#_[%/Q'_ &<OC(=1O->N&\,W<-PU_:75Q]H:XN'<%'4@X7'S
M]0>M?9@&!10!Y1X__8[\+?$R;Q,NK76NS6/B_:-4L!>8M;@*@0#9MQC JG<?
ML->"(?B2GBS25U;PSK?V1;*>?1[H6IO(UQ@2X4[ONKW["O8Z* ,WPMX9A\)Z
M3':0S75QL^]-<2>9+(?5F[FM*BB@ HHHH ,UXWI'QAT?P+\9?'%K?+J32M+:
M,/(L99EQY)[J"*]BVY:N'^&I_P"+J>.O^NUI_P"B30!!_P -,>&O^>>N_P#@
MIN/_ (FODC]MS_@MQH?[(O[2'A;P9-X1\1^(-)\4:4UP\UM:21SVLGFLF?+*
M%G7"]%'>OOBN'\>? +P;XV\9V_BS5_#NEZEX@TJT:VL[VXMUDEMD)+81B,CD
MD\>M &/^R%XXM?B1\"M'URQCNH[35(O/C2XA:&502>&1@"I]B*H_%;]ACX9_
M&?QYH_B36_#MLVL:)>/?13Q*J&:5UVDR<'=Q]*Z;X!?N_AY"%'1CQ7F_BO\
M;K@\)^.-4TV;P[,UCHVHG3KJ]^T@!&)"J0NWG+,!UXZT ;.E?L$_#G2?%<VK
MKI<TLTUQ?72P2NK6\,E['Y=RR)M^7>F >>@%:/P3_8W\$? /Q3=:QX?L;A+Z
MY@2V5YY!(+:) 0L<? VJ <8],5-+\==5?43:KI.CJ"_EB0Z[ 2N>,[>OX5XG
M^S#^TIX@\=_M2WGA75;B:UGL+K4OM,<TA:WO85)^SFW;[K%0"7"Y*Y&<<4 >
M@?$[_@F_\.?BUXS\1:]JRZX=0\436<]^T-X$5VM598<#:<8#&O.?CW_P3-M;
M?X7WVE_#F[URQO->URQU'5&:_"O+';Q/&%5L# VL,CG-?85% 'S_ /LB?LW^
M*?AW\&];\)^-]6DU+3[J4+I\8?,]K 5^96DR0Q+9.0!746O[&_@^76-/OM3&
MJ:]-I,316?\ :ER+A;<-NR5!48.&(SZ&O6** /'_ (4_L3>$_@I:/9>&K[Q)
MIFCF;SH]*BO]MC!_LI&%PJ]\5Z\>F*=10  8%%%% !7)?'-O^+2>(/:S?^5=
M;7)_'/\ Y)+K_P#UYO0!R_@_]H_PY9^&;.)X];W1Q!3C2IR,CWVU:UC]J3PY
M8:1=7"1ZX6AB9QG2I\$@9_NUVG@49\(:?_UQ7^5:5U;)=VTD,B[HY%*L#W!Z
MT ?FU\)O^"VVB?M9>(?$7PYO?!_B32]6L=1BM8=02UDEL[C;*ARQ6/$7?[[5
M^BGC7P7I_P 0O">H:+JUNMUI^I0/;SQ-T9&!4_H:\I^(?P%\'_!SX6:Q)X:\
M/:5H\^H7$$EU-;6ZQR7#>='RY &X\#KZ5ZC\1/%__" ^"=4UHV[72:7;273Q
MAMI944L<'Z T >+>'?\ @F1\*/#NFW5J-*N[Y;BRM-/1KR996M8;4DP+$=OR
M["3CTJ_!_P $[_AI!X#70?[/O#&FHIJHO3,OVSST?>K>9M[-[5F_"+]NU/BX
MUY%:>'5L[J#2K'68DNM02))K>[W>6=[ !6PI^4\TWX_?M">*+'X37NH:98Z9
M9RV-Q"TZP:O%<37$&29(X@O/F,HPH&22> : /1?"'[,?A+P-\'-0\"Z39R6>
M@ZFUP]PL;@22/.Q>5]V/O,S$DXZFO))?^"27PDEL%MVC\1&./1KO0A_IXR+6
MZE$LR_<ZEU!S77?L)_%^X^-/PJGUB2XN#;M=/'#:W9/VRTVLP99=V&SD<9 Z
M5[AU% 'P5\9_^";'C;_A9^GWW@;7-5LK'0+,6FD-+?@K;KN#$.O!;G/3'6OK
M/Q-\"X_B1H/A=?$&I:G'JGAR07*7.FS_ &??-Y90D\'C#'BO0C10!XCXD_X)
M\?#3Q=X6U+3-1TNXNGU34SK,M\\BF\6[.T&59-O#?(O.*]"^'_PCM_A_+YBZ
MQXAUB0($5M4O?M)7W' Y/<UUE% !1110 4444 >6?M)>*[7P=K?@6]O!<&&/
M6USY,+2M_JI/X5!-:1_:8\-#_EGKO_@IN/\ XFD^-)QXP\!_]AM?_13UZ 7H
M ^7_ -NO_@I/H_[*/[-&O>.M-TO6-5NM&,)%K)82PK*&E1&&YEP#ACUK!_8Y
M_P""A>@_\% M3\"^(-)\/^(?#MQ"UVT]IJ5I(@7,(^Y*R*LG_ <U]/\ Q/\
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M]L#%??5-*<4 ?&OAK]G^*^\2_&BS\96<.E^&_&WD-:S3.(UEV6L*=\88,A_
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MW0!P?QT/^BZ!_P!A>#_V:M7XH_#N'XK?#34O#UQ,T$&K6WD.ZCE0<?X5B_M
MWD6F:/HUS<21PV\&JPR22.<+&HW9)-:</QN\("&/_BI=&^Z./M2_XT <G\/O
MV5-+\&^,_P"U[J6/5&_LT:8(IH 5""0/G!R,Y%;GQ'_9[T#QSH'V.&SM=,G5
MU=);>$)R"#\P&-PXZ&M1OC=X/;_F9M%_\"D_QH_X7;X/S_R,VC?^!2?XT ,^
M$7PEL_A+INJ1VNUI]:U"75+UT38LD\@&]@O\(.T<5UM<K_PO#P?_ -#+HO\
MX%)_C1_PO#P?_P!#+HO_ (%)_C0!U5%<J?CAX/\ ^AET7_P*3_&FM\=O!JD9
M\3Z*-W3_ $I>?UH ZRBN5_X7AX/_ .AFT7_P*3_&C_A>'@__ *&71?\ P*3_
M !H ZJBN5_X7AX/_ .AET7_P*3_&C_A>'@__ *&71?\ P*3_ !H ZJBN5_X7
MAX/_ .AET7_P*3_&C_A>'@__ *&71?\ P*3_ !H R/''_)<O"G_7M=?R2O00
M,5Y-JWQ!T/Q=\>/"\>EZK8W\B6MT66"8.1POI7K(.: "N#N/^3D+7_L R?\
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M!U=%<K_PO#P?_P!#+HO_ (%)_C1_PO#P?_T,NB_^!2?XT =517*_\+P\'_\
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MGJ3Q3O\ A!=#_P"@-I7_ ("1_P"%:M% &5_P@NA_] ;2O_ 2/_"C_A!=#_Z
MVE?^ D?^%:M% &5_P@NA_P#0&TK_ ,!(_P#"C_A!=#_Z VE?^ D?^%:M% &5
M_P (+H?_ $!M*_\  2/_  H_X070_P#H#:5_X"1_X5JT4 97_""Z'_T!M*_\
M!(_\*/\ A!=#_P"@-I7_ ("1_P"%:M% &5_P@NA_] ;2O_ 2/_"C_A!=#_Z
MVE?^ D?^%:M% &5_P@NB?] ;2O\ P$C_ ,*1? VBAO\ D#Z4,<@BTCX_2M:D
M"X- "1QK#&JJJJJC  & !3J** (-0TRWU6#RKJ"&XB/5)4#J?P-4?^$%T/\
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M_H#:5_X"1_X4?\(+H?\ T!M*_P# 2/\ PK5HH RO^$%T/_H#:5_X"1_X4?\
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MT/\ Z VE?^ D?^%:M% &5_P@NA_] ;2O_ 2/_"C_ (070_\ H#:5_P" D?\
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MCYH^ORGC]* -[-%<_P#\++TG[-YWVCY <$[3_A1)\2-+C:/=<8\W[ORGG]*
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M_*D\A,?<3\J?10 WR$_N+^5-6!0?NK^5244 1F!<<*G_ 'S2^0F/N+^5/HH
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M,_=7\J! @_@7\J=10 WR(\?<7\J/(3^XOY4ZB@!OD)G[B_E1Y$8_@7\J=10
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M% !1110 4444 %&:** "BBB@ HHHH *\_P#BO_R.'AO_ *^U_P#0A7H%>?\
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M3Q>;&A:15.5R,\$]ZRT\,?$A@/\ BK- Z?\ 0(/_ ,70!Z)FBO/?^$5^)/\
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M66\FCL+F10[@Y;#(IY)H _4DL :3&ROQ$\)?MO\ Q0^*7A'16U;5M6MCX?\
M ^A:S:2PSR0_;KF6:02,^TC>&"+P<BOT0_:+_;C\1_LX_L0>!/B(FBV^LZSX
M@N=&T^XM)I?LZB2]ECB+9VG&TOG&* /JT'(I">.*_/+P;_P6'\9WOC#3]/U?
MP3I<%O+XGB\/3O#?^8P,TYB1@-@Z8->@? G_ (*.^-_C)\>-!\-_\(']ETW5
MKO4H+J1I6\W34M+H0*[+LZ2+\XR1QZT ?9AD4=3B@R*HSFO@7_@I%\0/B)\'
M_CM9^,+/2=4\8?#33].DL]:L]&U&6WO=+=V5A+Y<0R^%!Y)'WJYGX)_'.?\
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M><Y]J@T'_@LCI&I>%M:O+O3;"SU#3?$2^&TL&G;SX9Y'E6(SC^!6$98$9XH
M^F?'7[+/A'XBZY?:AJEOJ$DVIQ>3<K%?2QQRKP.45@.PYQ6;XK_8H^'?BO4=
M"O)-'>QO/#L7DV,]A</:2)'DG86C(++DDX/&>:\'U[_@JW<>#=:\%:?X@\)C
MP[)XL615N]0=HK,3"4I'&C]2SJ-P!'05]>7FNO%X5DU&-8I&6V^T!=WRM\N[
MKZ4 1>"? FG_  _TMK/3_M/DLV\F>=IF)Z?>8DULU\P_"W]O35O'EEIEQ>Z'
MI.EP:]I7]H6$LERX7<)VC*R''RC"$Y&><5T&N_MFQ>"O#]YJGB&^\(VFFVJ
M-+:W[R,C,=JD@@<;B,^U 'OU%?+G_!-S]HF+XY-X]CD\56'B2^L==N7V6L@=
M+:!F 0*<#*<-@GK7U'0 5P_[2=U]B^!7BF8QR2>7ITK;8UW,W'85W%<9^T-_
MR13Q-_UX2_RH P_#/Q_AB\,Z>O\ PBGC9MMK&,C2B0?E'^U5*X_:PT^]TS76
ML?#GC![K1%=9D?3,".0)O /S>A%>F>%/^14TW_KTB_\ 0!7 ?!B!+KX@?$B.
M10T<FKJK ]P;>.@#X;_8W_X+!Z_^W5X*\1>'_$'PYUS2YM/N4@35[.W>:Q?$
MZ<RR$*(SVP >WK7Z,>._ MA\2/!MYHNJ?:&T_4(3#,L,S0N5(P0&4@C\*X;X
MM?#O0?AU\$]2M-#TG3]+AW0Y6V@6/=^^0\X S^-=M\1M?U#PKX!U/4M+LXM0
MOK&U>>*WD8JLI52=N1SSC% 'COPN_P""9_PD^$?A75-%TK1M2FT[6/)-Q%?Z
MI/>8,3[XRGF,=A5N05Q6[)^PA\,KCX?GPRV@?\2[[:VH%_/?[09F;<S>;G?R
M>V:R/V%?VP;[]L;P'>:[)HUMHL6GS-I]U;^8QGM[R/'G1LIZ!<K@YSUKR[Q?
MX \>Z'_P48\,7?AOQMJ6I:/-;W4GB2QFB1;6PC95-LO&>6^< \$XH ^EE_9\
M\*)\(+SP+'IJP^&K^WDMI[:)RAD608?+#G<<DD]2>:\IO?\ @E9\%]1T^ZM9
MO#MX\-YI4VBRJ=2F^:UEV[T^]WVCGVKCO^"AW[:^H?#?6-0^&?A>SAF\2:EX
M4U+6_M4LK1K9QVT:$D%<Y;]X" 1CBO)/A9_P5AN/A#\"-/AU+3VU_4-!\+WW
MB;6[B5B&6&W=,JF/O,0XQG'2@#K_ (Q_\$N/$7B'XLS:UX3UMM$M;.**#2G:
MZ:5K-$50 %;C^&OJSQG\!-'^*&D>'8?$3WEU=>'76X@FM[E[9C,(RA8[",C!
M/!XKYF'_  6-\/6OQ&U72=0T^'3+/3[&'4H&N9"EQJ-N\4;M)"N<,%9]IY'(
MI-1_X*QWV@_!J^\97O@B8:7"?-AOHMS6:P;@N^5\Y4[O0&@#WK7/V'/AKXA\
M$WF@W7A])+.^O?[1ED\UA<?:,*/-$OWPV% R#G%=;\./@OHOPME=M,.I.TB"
M,FZOI;G@<C&\G!]Z9\ _BS!\;O@UX?\ %EK+830ZY:"Z5[.4R0$$D?*QY(XK
MQOQ?^W-JWA+QUK%K+H%B=$T75FTNXNC.XDR2JHP'3[S#/H* /I:BO#[O]J&^
MTO4)/M5QX,CLX')E8:C)YBH.IQMQG&>*\H^$G[9>F_%K]NVQTRS\9:;=:?<6
M5TD.E02AMAC48<\9W-UQVH ^QZ*:!Q]ZG+T]: (-3_Y!T_\ N'^5<A^SK_R1
M?0_^N<G_ *->NOU/_D'3_P"X?Y5R'[.O_)%]"_ZYR?\ HUZ .VHHHH ****
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MH \?_:-_89\'_M*>+;/7M6$]IK%II]QI7VJ#[TEK/M$L1YQA@H&>O%<M??\
M!+?X8W_AVSTQ[&3[/#I<^BW&"<WEG.RM)"_/1MJ\CGCK7T3_ &Q:?\_5O_W\
M'^-']L6G_/U;_P#?P?XT >':]_P3M^'GBKQ:NI:IIZWT$,"006C)M2%40(N&
M!#'@="<4SP=_P3[\*^"/ADOA2SNKPZ7#(YMED17$$;9S'@Y#+EB?FR>:]S.L
M68_Y>K?_ +^#_&D.LVF/^/JW/_;04 >(_ W]AO1_V?\ XE6.I>';JYLM'TS1
M$TB"R$S,C!96DY4D@?>ZCFMKQ%^QQX?\2ZIJ=Q<75UMU741J<T84;3*'5_YJ
M*]5_M>T(_P"/JW_[^"E_MBT_Y^K?_OX/\: (CX;T]U^:QLWW=28%Y_2N8A^
M7ABU^)]KXM@TNRM]6M('@22*!4PK#!Z5UG]L6G_/U;_]_!_C1_;%I_S]6_\
MW\'^- $^RE Q5?\ MBT_Y^K?_OX/\:/[8M/^?JW_ ._@_P : %U/_D'3_P"X
M?Y5R'[.O_)%]"_ZYR?\ HUZZ;4M7M#I\W^E6_P!P_P#+0>E<S^SF=WP6T+'_
M #RD_P#1KT =M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MA%6$YX^5T/(/(- 'L \&:;G_ )(_??\ ?^/_ ..4?\(5IO\ T1^^_P"_\?\
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ME55&22> !WKQ;PA^U%J7QF\7^)++P3H0U+2_"M])IMUJ,MRL<<]U']^)%8=
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M.O<USN@_\$H?"OA_XD>./$UKXF\66EY\0E\O5Q;W^P.OSC"?+\O#MUS1H/\
MP4=UG4O@QK7CRX^'TD.A^']<N-&O#_:\6]! X5Y0-N6X)(4#)QBNEU[]NAM%
M^-'PWT$^&9O^$;^).G?;[+7'NUC2$E8V6)HRN=S>8  2#QTH ]._9V_9Q\*?
MLM_#BW\+>#]/73]+@=I6'&^:1R6=W( RS,22<<DFN[S7GW_"WM4N?CPOA.TT
M,W6F0VC3WFJ"Y4"T?Y2D9CQDE@20<_PUS/QP_:FOOA#\<O!'@Z+PZVI1^,KD
M6ZW@NUC%J2V,E2"6_ B@#V>C->%ZW^UKJFE_M8R_#!/"[2,GAN3Q&NH?;4"M
M$DPB*;,9SN/7/X5P.A?\%)M8OO@1J7Q$NOA[);^']'NA;WC?VO$9(E+JF\#;
MEN6' % 'UE17-Z/\6_#^J>&-/U:35;&QM=3B6:#[9.L#,&Z<,0:Q/VC/C_IO
M[.GP@U+QAJ$4MY9Z>F_R[<%WES_=P#G\!0!WY.* <UQ_P6^,&G?&GX.Z%XPL
MV2&PUJPCOL.X_P!'#(&*N>Q&><XQ6UIWCO0]4O\ [':ZUI-U=;=WDQ7<;R8]
M=H.<4 :U%%-#'- #J*** "BBB@ HHHH **** "BBB@ HHHH **** /.];Y_:
M9T'_ + MW_Z,CKR__@IY^TGXG_9H^ *ZIX162/5[ZZ%JMT-+FU%+(%6/F-%%
M\S 8[8ZUZAK8S^TSH/\ V!;O_P!&1U/\<O /BKQQIVG1^%?$-GH%Q:W0EG:Z
MM6N8[B/!!0J&7KD=?2@#X0D_X*9>,X_!?@+3[#Q5H_B35=9TQ]8U#4[?39K-
M&17D0Q>3(V^-LJ/O?UKZJ^'W[<VGW7[!7A_XU:]:2QV.HZ='>W$40^9-\OE#
M P>^*Y'QW_P2M\,^(CIE]I=Q;Z1KMN2+RXC@_<W"-NW*J#&W).>IKO\ Q]^Q
M5I.O_L<1_!S1[IM+T>WM8K2WE9=YC5)5E[8[C]: /,_^'R7PYB:Z\ZPU:%;&
M:U2X9E;]U'<S""&0_)T:0XQU'>NOU;_@IAX)LOB2OAVUM;Z]=M4_L<SKE56X
M#A&7:5S@$CGH:\EU_P#X(UIX@@UY9O%T>W7$TU7VVK#;]BNA<K_%W88KS^R_
M9X^+WA/]K*XUBSTWPOJ.EC7]ZZ=-HG)MVF&^Z%P6VB3;EL8SE10'H>]?\%%/
MVSM6_9)\8^"9;FSU&/P+JWVA=9U2QMWGET^4;/))" ML)+;N.@ZBO.]9_P""
MAWB+Q7\1?A5\.?">N:+JNJ?$(W.HR:[% ?)BL(98UV!=V1-LE7G/# Y':OJ/
MXY?!'5OBQJUC):ZI80Z;#;3VUYI]]:&ZM[T2* -R;@#CGKZUX;I'_!(OPO\
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MR3&KHV#SR>!BOJ']M[]N+1_V9-!OM'L[B23QQ<Z)>:MIELMHUP@2W4%G<+T
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M \]B3OX/MT%>D5B_#GQY8_$[P/IFOZ:9&L-5A$\!D0HQ4Y'(/(Z5M4 %%%%
M!1110!!J?_(.G_W#_*N0_9U_Y(OH7_7.3_T:]=?J?_(.G_W#_*N0_9U_Y(OH
M7_7.3_T:] ';4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M5O+(W?<5D7CH02,4 >T67_!13X6W_A*]UR/6+IM-L;V+3VF^S'$L\C%%2/\
MOG<,''3BDTO_ (*,?"K7-6T&QL=<FO+SQ&UREE##;F1V:WD$<H8 Y7:Q .:^
M;=<_X(O7%U:^(+C1_$UQHT]]KFG:]9V+'[19P7%K*TKE8RP15E8C*@87&.:[
M_P"+7_!,Z3XGS^![K[5INBZIX9O/MS7FCVJ:>P=G#RC$6W<&898$X;'.: /K
MC5/$$&DZ#)J4HD^SQQ><VU"S[<9Z=<^U>5^#_P!N?P%X[N9H;";6&DCM)+X+
M)I\B>;"DGELR9^\ _'%1?L_>&_B/%X'\2Z7XVU>WUN19O)TBY%DEFQA (PZK
MW' R3DXSWKD_@M^Q5>?#SQQX?U#4+R.[M-)T"[T26)<*9/.O#<[\CTSMQ0!Z
M;I/[3OAG7(+HVYU*,VL?F$W%HT*]< 9/J36'^R+\>]9^.R^.VUBRCL&\.^(Y
MM*MX5ZK$L<;#<<#)RQK<\<?LO>%?B#X9NM)O(]2AM;Q=LAM;V2"3 (/#*01R
M!7+_ +(?[&FG?LG:IXTGL=5UK4E\4ZL]^@OKZ2Y,*%4 4EV.YOE^\>2.* /;
MJ*** .(_: LX=0^'LT$\:30S2HKHXW*X)Y!%+H'P,\&G1;/_ (I70>8$)/V&
M/^Z/:G_'7_D1V_Z[Q_SKJ- _Y 5E_P!<$_\ 010!\Y>,/V)_A[^TG9_$[P7K
MV@VL6BZI/!!,+-%@E"&#D*RC*]>U:7P9_9+^'_[)WQ"\/Z+X%\-Z=HELEB4>
M2&%5FGP_61P 6/N:](^%7_)3O'W_ %^6W_H@4GBHX^-^B_\ 7HW_ *'0!'^T
MY\#G_:*^$FJ>$7OH+&PUJ(PW9DM_.WIP1CD8(8*<^U<Y^RO^S5XB_9P_9?L?
MA[-XN76KK1[1K/3M3>T*M"FW";E+$L023G/-;G[2_P"T78_L\>#[6[FC6YU+
M5KE;/3K4MM^TRGDC/LNX].U9=[^VAX%\+>-['PKJVNPIKEQ,UH^ ODQSJNYD
M9LX5@.WTH X[]CS]D3XA_ +QAK>H>,/B18^,;75',Z06VC_8629B=[NV]M^>
M.#TQ7EWQ_P#^"0]]\6O&_BJ\TKQS#HVC^*M8TO6KFSET[SY%FLKDW'$F\<.Q
MQC''O77?&W_@I9IOA'XW^"?#?AI1JNGZWK%YI.IWCH%M[:2WC5V"2<AB-W(X
MP,53^+7_  4XM-&^/OA'PSX4A_M;2]<_M6*ZO)$V0Q2V42L0C\A^6YZ8H QY
MO^"/U@_BM9SXF)T5=8M=>^QFV)<WD#F0-OW?=+DG;CIQ63XK_P"",=OKEEXG
M:Q\71Z7>:UK%OKMG'!8;;&SNH1)M=H P5R3(2>F3GUKL/ W_  5#TUX/">FZ
MU837GB#QAJ5];6:Z9']HA6*VF5&+.HP& 89&.M=!\$?^"B?A_5OAG+J_C#4-
M/M[Y]5OK2WMK"1;B1XH+AXMQ48(VA5#>A.#0!S?Q3_X)<_\ "W-.\'B\UW1M
M-U+PJ@8W^DZ.ME<23 Y#HR-E!R<J#R>:^MM&L#I6DVMJSM(UO$D1=NK[0!D_
M7%>+_$7_ (*)?"WX8"S.I:W(RWVG2:K";>(2A[>-@COP?X6(!]#6AXK_ &[_
M (9^#Y]-CN_$$/\ Q-+<743IADBC)VAI#GY1GCGN: /8J*^.[;_@HYJ]AX[^
M+4=YI=O-H7PQU..W>2-OWES _D*& QUW3 ]>@KZUT3Q':^(O#UOJ=G(L]G=1
M":-UY#+CM0!?)Q06Q7F&B_M;>#?$/C Z':WES)?"XN+0+Y/RO- NZ6,'/+*,
M9'7D5NV?QOTB^F*FWU:W55+-)/:-'&@'))/:@#LBV*XS]H;_ )(IXF_Z\)?Y
M5Q_P"_:0OOC)\;?B%X?FTW['IOA1;$V<Q/SW0G1V+8P/E^4$')R#77_M"-GX
M*>)O^O"7^5 '2>%/^14TW_KTB_\ 0!7E?@3X<:)X]\=?$>/5M,LK[S-2$&^:
M%695:WCR 2..M>J>%/\ D5--_P"O2+_T 5PWP3_Y*'\0_P#L,)_Z3QT >.:-
M_P $Y?A)^QY\)-4F\&^%;&WU*2:*1M0N(UFN\F9,XD(W >V:^E_%6CS^(O#%
MY8V\T=O)=P-%ODC\Q0&&#E>_!KFOVCO^22:E_O0_^CDK7^*7Q&LOA/\ #O4O
M$&H,JVVFVS3')QN('"_B<"@#QK]B#]B;5?V.KOQ1;)XLCUCP_P"(+U]2AT];
M+R19W$C9D93N/RG"@* ,8K*TW]C/XF)^U?=>/KWXH:?<:'<.H72$T3RY8HE)
MVHLWF<<'#''S5MZ/_P % ?"7AWX7>&?$'BZZ;3[CQ9;QWUM:0QB1[>&0 KO&
M00!DY)]#7)?ME?\ !2_0O@MX(E;PC<'6M>A^PW,D44(EBAM[DY1G;G;N4'&1
MS@T 7?VQ/^"=]Y^T=\8K/QMH?BJ/PWJD?A^_\.W FLOM230W2QJQ W+@@)U]
MZ\QU7_@BS'J7@TZ7_P )H%DU#PQ>^&-5E%D?]*AN60ED&_Y" @'?K77?M-?\
M%.+/X7?#+29M!5M2\3LVDG4X$A\RWLUO(O, =^0K$9P"!G!J*_\ ^"H=K\/?
M#_CS5_$%JU]!X>N-,M+*TLHM\WG75J9ML@494$J<$]J *NN?\$?=&USXF1ZY
M_;QL;6'3XM-:"RM_L\EU$L:*1,ZMF0DH#\PX&!4WAC_@EC<0?L^_\(#KFN^&
M=8MD5[=+T>'HX[GR"Q<*7W$E@QSNSVKJO!/_  4,TEO''C ^(KR#2]#\/VT-
MRD4BA;I=\4;[2AP2?G./:NLU_P#X*+?"WP]X>_M*XUBZ\M=0&ERPI!NG@N3%
MYPC=,Y4F/#8/8B@#M?V7/@HW[.GP$\,^"7U:ZUQO#UF+4WUPQ:2XP2<G))[X
MZ]J] KPVV_X*'_"^Y\#:?KZ:M<?9=4N9+." P_Z2TJ1F5T,><@A 6/L*\VUK
M_@HC<>)_CQX5TKP:]GJGA7Q5X?;7+2ZPNZ55BED Z'[WE@=>,T ?7=&>:X+]
MFSXZ6?[0_P )K'Q):QB"20F"[@#;OLTZ@;X\]\$]:S/&G[7/@WP#XXN_#^H3
M:@NI6+VR7 CMBR0_:"1&6.> <'GM0!ZA17#R?'K35NO+72?$LRDX66/37:-A
MV(;H0?6N%\1?M37P_:8\-^#]+L4FT;4H&:[O)#M99-RA548YX)R<\$8H ]KU
M/_D'3?[A_E7(?LZ_\D7T+_KG)_Z->NNU-O\ B7S?[A_E7(_LZ_\ )%]"_P"N
M<G_HUZ .VHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH ****  4$9HS10  8HHHH 0+BE/
M2B@]* "C%%% "%<TM%% "%<TM%% #=E. Q110 4!<&BCK0 4@7%+10 4444
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M>@#A_P#@H/\ L_:G\9?#GA'6-(CDN+[P/K"ZLEJG6YRAB*X]@Y/X5X/\=_\
M@FKX[_:!_:$A\:?VGIL.DPZD][:1+MMY/*=-A5U4?,X&3N.2>!7T4/$NO ?\
MC-XO/_<%M_\ &E'B774&%\2^+P/;1;?_ !H&CYN?_@E/XS77](TM=2T]O#FB
M^)M5UR*[:;_2I4OH8XBA7'!0)G.XDDTWPY_P2R\=>'/%'AB,7VES:3X1O=<N
M+69IL372ZA&B*'&."NP'.3G-?29\3Z]_T,WC#_P2P?XTG_"3:^!_R,WC _\
M<%M_\: / _A7_P $O/%?PVU'X=ZI'J-C-?>#-4U>YDA,@"2QWTZ2$[L=5"],
M<UR_A;_@C?XF\*6%OJ$>LVMQK5C=ZQY4#2;8)(=0NS<,Q/\ >3"@#'.3R*^I
M!XGUX#_D9?%__@EM_P#&E_X2;7F'_(R^,/\ P2V_^- 'S/\ $[_@CQKVLVNB
MVNDZO;3V^E^#M0\.EKE\,9;NZ6X+\YX4@J/:J7QO_P""3OQ%^*GAS0]+75M'
M6UT71ELHPA6)S*)Q)\S@9==N?O=\5]3?\)/KP_YF7QA_X);?_&C_ (2?7O\
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M5&OZ]I7Q$7^V;>.X\87NE:A !@K&]E:-;A#[-NSGM7U>?ACXL/\ S/\ J/\
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M.=[I;%"@E=0K/EBQ) ^M &PIXI:11@4M !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M48HH **** "@]**#TH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MST]J .B^R1?\\H_^^11]DB_YY1_]\BI** (_LD7_ #RC_P"^11]DB_YY1_\
M?(J2B@"/[)%_SSC_ .^17&_M"6T:_!7Q+B-!_H$O11Z5VU<9^T-_R13Q-_UX
M2_RH Z/PI_R*FF_]>D7_ * *X;X)_P#)0_B'_P!AA/\ TGCKN?"G_(J:;_UZ
M1?\ H KAO@G_ ,E#^(?_ &&$_P#2>.@#TFBBB@ HHHH **** "BBB@ HHHH
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M\BIIO_7I%_Z *X;X)_\ )0_B'_V&$_\ 2>.NY\*?\BIIO_7I%_Z *X;X)_\
M)0_B'_V&$_\ 2>.@#TFBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **,T4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !10>110 4444 %!HHH ***,T %%%
M% !1110 4444 %%%% !111F@ HHHH **** "BBB@ HHS10 4444 %%%% !11
M10 449XHH **** "BBB@ HHHH **** "BBB@ HHH)Q0 44 YHH **,T4 %%%
M% !7"_$?PUK3>+]-UK1[6&^DM8S$\,DPBX))SDUW'S"G8R* //;_ %;QKJMF
M]O<>$].G@D&&1]0C96'N,4ZTUGQM86Z0P^$]/CCC&%5=1C 4>PQ7?$8'%.%
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M]>:Z.B@#G5^'EK]L:;[1?;F&"/M#X_+--3X:VL<4B_:K[$AR<W#\?3FNDHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^;?_ .(H ]$HKSO_ (4OXA_Z*-XF_P"_-O\ _$4?\*8\1?\ 11O$W_?FW_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4^8%;[Q]@0>*_9N:(31LASAAC@X->._"7]A/X?\ P3^/7B;XDZ#;ZM#XJ\7
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M1^,/$&DK&5?07@5V_O\ FH7'Y8KH*\1^&W['&B^#_BCXDUEUU+R+R:UEL?\
MB:SL?W<95MX+<\^N:]LC41JJ#HHP.: ' YHH"[:* "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ /2O.?@Q_R/_C_ /["Z?\
MHB.O1CTKSGX,?\C_ ./_ /L+I_Z(CH T?VA+^;3OA/JDEO\ 9?._=JOVBW6X
MC&9$'*-D-U[U@)\!=6=?^0]H_P#X3=K_ (5M?M'?\DDU+_>A_P#1R59^.MOK
MM[\(-<M_#:V<FM75G)#:BZG,$6YE*C+J"5Z]0* .>;X":LHR=>T;_P )RU_P
MI$^ NK.N5U[12/7_ (1RUK\ICXF^(G[)WPP\7>&-8T'6O#_CZ36O#T>IZG!K
MUYJEC>6=SJ*Q$Q-,<(67S,[%'!%?;7_!+SXG>(=1T?XJ:5>7%U>:;X<UJ[_L
MV6XD:1O]9)E-S9) V@=: /H#_A0>K$?\A[1__";M?\*#\ ]6'_,>T;_PG+7_
M  KX6\/?\%E?BAXCDL)(?"/AM;;4K[Q!IT1-^^Y3IUW]G5R-G5NN.E=GK7_!
M5WXA:A\/- U+2/!-K)-J7A[5=5+^<YCFO+.X6%+13MZRY8^OR\4#/K5O@+JR
M#G7M&_\ ";M:1/@1JDB[E\0:*P/3'ARU_P *\W_:;F^(?QH_883^QY+;PSX_
M\06:FWLY;AH5DF89$/F8W+D=P,U\-_%O]N[QMX(_9J\8:?\ \(SX@\!?$2RG
M@T_78Y9I;BWMX2T0-U"\AS@Y5?N@98T"/TJC^!>IRDA?$&BDJ<'_ (IRUX-2
M?\*"U;_H/:-_X3EK_A6-\*?V7_"_AJR\#ZIINK:PTNDJ)XFDU&:9;XM$00X9
MR&^\3SGI7M= 'EO_  H+5O\ H/:-_P"$Y:_X4?\ "@M6_P"@]HW_ (3EK_A7
MJ5% 'EO_  H+5O\ H/:-_P"$Y:_X4?\ "@M6_P"@]HW_ (3EK_A7J5% 'E-U
M\"-6M[:23^W=&;8I./\ A'+7G]*ZCX$ZI-K/PET6YG6W662)MPAA6&/(=APB
M@ =.@KI]3_Y!T_\ N'^5<A^SK_R1?0O^N<G_ *->@#MJ*** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@!",TN***  \TFWG-+10 F.>E+UHHH #1C%%%  1FD"XI:*
M#%!&:** #&*.M%% !1110 8HHH)Q0!S_ ,3_ (8:-\7_  ?<Z'KUNUUIMUCS
M(UD:,G'0AE((_ US/PC_ &7O"OP9N8Y])M[EIX4,44EQ<R3&-.FT;F/8 9]J
M]&(S2*N* !1BEHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1110 4444 0:G_R#I_\ </\ *N0_9U_Y(OH7_7.3_P!&O77ZG_R#I_\ </\
M*N0_9T_Y(OH?_7.3_P!&O0!VU%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 &CO1W
MHH **** "@]**#TH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "F7,"75O)'(H>.12K*>X-/H- 'E?Q9^'FA_#OX(ZA9Z)I=GI=JK0X2",+_
M ,MD/7K7HGB'1O\ A(-"FLS-);K<1[&>/&X CGK7*_M'?\DDU+_>A_\ 1R4W
M]H_XN+\#O@IK?B5D\QM/MB8E_P"FA&U,^VXB@#!_9]_8]\,?LV^(M<U+PY)=
M1-X@(>[B8CRWDR27Q_>)//TKF],_X)W>";+X_3?$:2XU*ZUZ:;SF\R3Y,YRH
MP.PSQ7ENO?\ !26X_9Y^ O@G7/$^DZCKE]XHL8=2NYHI4\NW,BJ61%)W;5YQ
MUK@_VS?^"HM_XE\"ZMIOPWAUK2]0T:VT;5;S4X)HU\F*^RR1X//12#@4 ?4W
M[1/[$/@_]I+Q59ZYK"SVNL6=A<:8+NWQYDEK/M$L)SQM8*H/?BN:O/\ @F'\
M,-0\/V>FR:>S6UOID^C3C_G\LYF5I(9/]EMJ],'CK7S=^T__ ,%(_$FI_"R+
M2_!<FM6>K>%I?#RZSK4,R*)VO8#(RX/S<[6W<<TFM_\ !1[Q-\,O#_Q4O-/_
M .$AUS5]'O\ 0]/CAU&>-K6T:ZL&E+PA<$ E<MDDY/% 'U=J7[ 7P_U_QI'J
M^H6 OH[:)(;:SD4>3;A$"+MQAN .Y-5O!?\ P3^\(^ _AZ?#.GW>H1Z7'([6
ML95&%I&V28UR/NDLQYR<FOGW3O\ @I:OPE^)GQ!NO$R^++J;2;>U:'29+F(V
MIEDMXGVP#&5SN)^8^M=%XK_X+*:+X8TJ^5/!^L:AJVD^(D\-WMG#-$K),]H+
ML,"QQMV,HZYS0!]8?!SX1Z/\"OAKI/A/P_;BUT?181!;1C^%<D_U-=..#TKX
MXM/^"M^GWOP=L_$W_"'ZM#)+J4^F7,+3Q9M'B@,Y)&?F!7@;<D$YZ5YSH7[>
M'B3]H_X\?#G6/"NLZUH/A;QOX/;6TTIY5*Q2>1-(N[ P3E5S@]J /T.HKQW]
MB']H23]H?X&VNK7S(-5L;J72[SG_ %L\(7>RCK@DUSWQ6_;L_P"%:?%;7?#*
M^#=8U!/#K:>;N^BGB6)4NRV&P3N^4*2: /H.FJ?FZUXBW[;EC_:"PQ^%M>D1
MR-LJJ-K ]#7F]_\ M>7/C3]L;P9I>EZX]GX=OD:![(97[9+O4'<,?PG<O:@#
MZQU/_D'3_P"X?Y5R'[.O_)%]"_ZYR?\ HUZZ[4CG3IO]P_RKD?V=?^2+Z%_U
MSD_]&O0!VU%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 =Z*** "BBB@ H/2BB@ H
MHHH **** "BC-% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !11FB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHS10 4444 %%%% !1110!P?[2MQ':
M_!_4Y))$CC5H268[0/WR=Z;\9M!\-_&;X7:MX;OM4TOR=2MFC!:X0A'Q\K=>
MS8/X5UWBCPKIOC70Y]-U:QM]0T^Y $MO.F^.0 @C(/N ?PKG_P#AG_P3C_D5
M]%_\!EH ^8M0_P"";_@?XN^!_"=CXS\7:E%J'@_3?['B;3]4BBAND$?E^:5(
M8Y(R>M7?%'_!+/X0>)C)M\5ZUIZW6GV&FWBVFK0H+Z.S4K 9/E.YAD\^YKZ0
M_P"% >"?^A7T7_P&6C_A0'@G_H5]%_\  9: /G?QI_P3(^$?BZ_O)%\4ZSID
M.I#3OMEO9:M#'%=-8Q^7 [C:<L%)R?4FK^I_\$XOA'J^G>++>;Q%J)_X3":R
MN+R3^TX=\<EK 8(F0XX(0GKGFO>?^% >"?\ H5]%_P# 9:/^% >"?^A7T7_P
M&6@#P77?^"<'PA\3ZIXDO-0UZ_O;KQ-!%!/)-J<+& QQI&KQ\?*P5!SSU-0Z
MK_P3/^#>L:?+%)K=Y'<76M+K]S=QZE")[JZ6W%L"[8Y'E@#\!7T!_P * \$_
M]"OHO_@,M'_"@/!/_0KZ+_X#+0!\VZG_ ,$LOA'J.AV&GKXQ\06\.GZK/JZ&
M+6(59IIK<V[@_+]W8>GK5CP1_P $Z_AO\#-(\.3>%_$6I76H>#=#;0M(6ZU6
M%HUB,;Q@N,#. Y/!'2OHK_A0'@G_ *%?1?\ P&6C_A0'@G_H5]%_\!EH \)^
M /[)%A\$/$W@R_M?'$L:Z.EU/J]I#J"+8ZC<SQ!6?R^O##/)KMO'_P"S-X#^
M(/C'Q#KEYXENH;KQ*EHEVL&HQ*@%MN\O:,<?>.:] _X4!X)_Z%?1?_ 9:/\
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<* "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img62602283_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img62602283_4.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]<6OB?2((9-0TZ&Z>)#X?TUMH9U) RQ.,]2:]@C_ &7_ (:A!_Q;WP/P,?\
M(!M?_C= ':?VG;_\]X?^_@_QH_M.W_Y[P_\ ?P?XUQ3?LQ_#55_Y)[X%S_V
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M ,]X?^_@_P :XS_AF#X:_P#1/? __@AM?_C='_#,'PU_Z)[X'_\ !#:__&Z
M.S_M.W_Y[P_]_!_C1_:=O_SWA_[^#_&N,_X9@^&O_1/? _\ X(;7_P"-T?\
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M'_\ !#:__&Z .S_M.W_Y[P_]_!_C1_:=O_SWA_[^#_&N,_X9@^&O_1/? _\
MX(;7_P"-T?\ #,'PU_Z)[X'_ /!#:_\ QN@#L_[3M_\ GO#_ -_!_C1_:=O_
M ,]X?^_@_P :XS_AF#X:_P#1/? __@AM?_C='_#,'PU_Z)[X'_\ !#:__&Z
M.S_M.W_Y[P_]_!_C1_:=O_SWA_[^#_&N,_X9@^&O_1/? _\ X(;7_P"-T?\
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M'_\ !#:__&Z .S_M.W_Y[P_]_!_C1_:=O_SWA_[^#_&N,_X9@^&O_1/? _\
MX(;7_P"-T?\ #,'PU_Z)[X'_ /!#:_\ QN@#L_[3M_\ GO#_ -_!_C1_:=O_
M ,]X?^_@_P :XS_AF#X:_P#1/? __@AM?_C='_#,'PU_Z)[X'_\ !#:__&Z
M.S_M.W_Y[P_]_!_C1_:=O_SWA_[^#_&N,_X9@^&O_1/? _\ X(;7_P"-T?\
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M'_\ !#:__&Z .S_M.W_Y[P_]_!_C1_:=O_SWA_[^#_&N,_X9@^&O_1/? _\
MX(;7_P"-T?\ #,'PU_Z)[X'_ /!#:_\ QN@#L_[3M_\ GO#_ -_!_C1_:=O_
M ,]X?^_@_P :XS_AF#X:_P#1/? __@AM?_C='_#,'PU_Z)[X'_\ !#:__&Z
M.S_M.W_Y[P_]_!_C1_:=O_SWA_[^#_&N,_X9@^&O_1/? _\ X(;7_P"-T?\
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M=Q'!:1--(YZ*JC)/Y"K59/CKP[_PF'@K6-)\SRO[4LIK/?\ W/,0IG\,T ?
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M9ZXR,]LT ?I]X%_;9^&WQ"U%[.S\306]QSM6\B>U$F,D[2X&>/?Z5X3\7?\
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M\M_\$X?@;XAO;#5O%EMJUUX=L[Y196LD4,<C795@7)5P?E!SST))QTKZ>N?
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M\:H_X5)JG_0]>*_SMO\ XU7;T4 <1_PJ35/^AZ\5_G;?_&J\H_;0^!NMZI\
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M^9J6@Z7>2CI+);KY@^C#YOUK#G^ MC91XT/4O$'AU@#L%G?NT8/NDA9?PXH
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M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 48HHH -M%%% !1110
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M5Q?[-O\ R;MX!_[%S3__ $FCKM* "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** (;W<+9]OWN@^OY'C\*_-G3?AWXZ_
M;D_X*M_M$:#;?M"?&+X;^"/A(-!L8_#7AC6K>&6YN[RP\]KD+);2"VM2N% ^
M=Y)!,^Y%VJ?TFOCMMF/S?+@G'H#_ )Z<^G-?EO\ \%!]3\!_MB_MB>+/ ?A'
M]F3XI?%CXA_">WL[?Q'XR\&^+(/!K6)NK=;B"Q>]:YA>\'E%6,<FX(2<8Y-
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MF - 'WI'()%W+]*=571;.73M'M;>>YDO9K>%(Y+AU56G8  N0H"@D\X4 #/
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M'@#IR!6'I/[2_P 0M&UP:E!XV\4)=[ED=I-2DD5R#D@JS%77/R\CH*[W1_\
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MB1CLUI4*?LER0OJXO4^G?V(/^"A7B;1?'\.@^-=2U;Q)INL$16LF//NK:;G
M&/FD5OE7 R03FOL>_P#BOXV\56B_\(KX0G@5AQ<Z[(MOM_[8J3(?QP:_/O\
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MJJ.#T4#H* /GO]BWXQ>&_P!LG_@I/\5OBI\.[M]0^'_AOP;I?@5M<@B9=/\
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M_/OX8\%ZQXQ>Y.EZ??7)L89+JY>*+<EK%&I>21F'"JJJ6).*]=T7_@HA\4/
M'PN\/^#_  EXA?PGH?AZ%HH8;2&-I)W:1Y'DDDD0Y^9R J_*!U!/-:X?%2IZ
M5-F?A_#O%57 <RQKE.+6GK\S]UQ$)&'/3KVQ3EM(0Q,:IN[D<9KX%_X)5_\
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M/V7+\IHT*,*4E=Q23;*6G>';'2D\NSL[6W3CY8XE0#\L59,83TQ["GL^WO\
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M'\17S/\ \%<?#5]X1_9/N+G4_%EUK6K7%]:QFWE>*&,PE\.T5NH^9AD#)W$
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M_P""JNM?L?>(K[X<^ ;GP]X^TK09=EKK5\TDBJK -Y(\IU60(6(W[P!D#
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M%!L1R0ER/FZ>U-DM=QX8+Q4U% E%+4A:W/S8;'&!QTJ8444#V"BBB@!N,?\
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MNI01]?\ 48R_BMR.3^'_ ,&?#7PITT6_A_0]/TM<;6:&$+))_O-RS?B36?\
M'/\ 9Z\)_M)^!W\.^,M$M]8TUG$R(Y*M#(,@.C*0RL,Y!!KO-I/84@1L=NM5
MRJQO+#4I0]DXJQ\M_#;_ ()"_!3X9>,+76H-!U#4KJQF6>WCU&_>>")E.5_=
M\*V" 1O!Y'6OJ&"/RUQ_2G"'#9[TY014PC&*M%&6%P-##)JA!1OV!1Q3J!TH
MJCL"BBB@ HHHH **** "@C-% H 3&*#UI:* "BBB@ HHI&;:N: %HK.\1>*]
M.\(Z3/?ZI>6UC8VL9EFN)Y5CBA0=69F( 'N:X3X:?MB?#3XP:\NE^'?%^DZG
MJ$C,L<"2;7FV]=@8#<!ZC(XK*5:G%\LI*YT4\+6J0=2$&TMVD['IE%1M<80L
M%+8],4W[;&%W;AQUR1Q6NYS];$U%<7\1/VAO!OPIA+Z_X@T_3MJERDD@,@7U
MV#+?I7DVK?\ !2CP1?3"'PQI_B+Q5>R?+"EG9[8Y&[#<W/X $^W-5RO<]"CE
M.,JQYJ=-V[VLOO9W7[5/[0EE^S+\'-6\67T<<SVI\BTM\X^TW#G$:9[ D9)[
M $U^;6L?\%9?C%J.O2WEMK-CIULTA9+*/389(47/"_.K.V!U.]<UZY_P46\?
M_$SXO_ "34=3\%S>'?"=CJ,%Q+YV?M"DYC0L,AL9DYR@ XSCG'P8;C:FX\)G
M!8] ?3_]7%>#FV>?46HPJ17?W>9OR[6/VKP]X.P57!3K8RFJD[VM?1?/N?K]
M^P1^W%:?M4_#Z[;51;:;XFT/8NI0@E8G#;@DJ%B0 Q5CMW';QZBO6==^./@?
MPT_F:EXN\+V)QG_2-2@C/'U.:_.7_@E1^S'I?QVU[Q5?^(K.^ET?38H(HO)N
M)+=99F=\J60@G 7D9XR*^\- _83^%.DA'3P3HLS YS=(]RP_&1C7IX7&0Q--
M5J4;7^7W(_.^+,HRO 9G5PJG+W7M%)I>5V1:W^W5\*=%E8-XQTNZE3^&T5[H
MG_OVIKB/$W_!2?P_YCP^']%UK6I,XC9HO(BD^A;YOS45[9HW[/7@;PWM_L_P
M=X7LMGW3!ID,97Z86NBMO#MKIZ!;>UM88U& L<87'Y5TQIQWDW\CPJ>(RVGM
M2E+_ !27Z(^4KG]I_P")'Q LYF@T6+1;"1#D1:+>WT^W'W=P 0'KS7Y93VKQ
M3,LGF"7<5(=2&+#J".N<]:_?XZ>Q5EVIM/J?_K5\#_M4_P#!'C4O%GQ#N-;^
M'E]HUC8Z@S336&H3R1BVD+$GRF5&^0Y^X<8P,9I2R'+LQ_=UGRS6L7)OD^:1
M^@\#\:8+ 5*E*I!4HR6Z_(^.?V2O#:^-?VD/!NF"YU"V2\U*-&GL)?+GA7G+
M(_.TCU[?6OU*\(_L*>&?!KR2:9K_ (YL[N89FGBUIDFES_>;&3W/U)]:\_\
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M_P!B/K7_ *0S5ZU7DO[?7_)B_P 9O^Q'UK_TAFH Z;]FW_DW;P#_ -BYI_\
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M'4/@O\3?!?@OP[X!UKX@^+/&UCJ&IVVGV%_9V!MK6R:U2::22ZEC3 DO+9,
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MXA<21W$3*&1U8<,K*001P0<U;J'3]/ATJPAM;>*."WMT$<4<:!4C4#   X
M["IJ "CK110 4U_NTZFR?=H \'_9D_Y.H_:2_P"QLT?_ -1[3*]Y3[M>#?LR
M?\G4?M)?]C9H_P#ZCVF5[RGW: %J.<9 ^;'4?7_/7\*DJ*Y7>!D9'/3J..WY
MT 9FFP2-K&J,VH17B^8HCA$:J^GCRU^3*_,=Q!?+<_-Z8K77[H^E8&@6ME%X
MCUZ2STZXM+V6YC^V7$D+(EZXA4*5;^(*N%R!C(-;Z_='7IWH 6BBB@ HHHH
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M^KR[PWGC\/\ 77544U=>94O!FAG'_"E.IRWULNOKYL_:_P#9Z^$.G_ /X/\
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M6!&\N=EB>54,@;RQ-,5P7)KSK]K[QIHOPH_:@_:WA^(^J:?877Q+^$^B:/\
M#5+^0+)K>V/5(9+"Q!_UMS_:%S"WEH"^Z>%B" I4 ^[?'G[6GPO^%OQ/T?P5
MXE^('@_0?%WB#RO[,T>_U6&WO;_S7:.(1Q,P9C(ZLJ #+LI"Y(KNS<QRKN4Y
M7'#8.W!]Z_,+XL^-]#^'O_#6W@GXF:II?_"T_B%XPTF;P#I\DBM?:T)-+TRW
MT:6RC^^ZPZE#=;F0$0O'*6(&<_5/[?/B3Q!:>+?@#H.@>)]<\)V_CCXC#0=7
MN-*:-;B:R_L35IVC5G1Q'F2W@(=5!4CY6&[) /=]$^&?AO0?%M[KVFZ#H=CK
M6I@?;=0MK"..ZNAV#R!=SCY1U/8>E=$LRNVT,"WI_GZBOAWP5KWQ*\':%X)U
MZS\>>+_&6NZCXU\8^"XM*UEK4V.H6VG1^(C8I(L<$;><9-+M=TY?>Q:0%MKA
M!A_\$Y/VLI/C)\8OA3IUU\8M1\8>,O$'PXU+7?'_ (2E:U"^&-9BN-(A:%[>
M*-7LGAFEO8!!(V=JDE2P9V /T HIJ'/Z"G4 %%%% !1110 R==\+ \AA@\=:
M_)S]L+_@F]X@^-OQ;_;?T6?X:G5O&?Q4T72?$_PT\930P21N=,MK.-=+2Y8Y
MM)A>6X(C.T2)([[L*2/UDFR8FQ][M7XM_P#!97XG?$3X_P![^UI?6'QA\:_"
M_2_V6])TD^'O#'A;6I-+N/$=Q?103R:EJ#(1)+;?O7@CC&%!B)+ Y! /J#_@
ME7\5/"?QK_:?\=>(/A1\.-2^''@?_A&-,M/&%I=^%SX=2X\4I-,V! R+YDJ6
M[L))44 _N 2V%Q^@JG*#Z5\:?L:77B3X4?M[?%SP#>?$'Q!\1?#?B;1+/X@V
ML6JW0NI/ ]S=7-Q!)ID; GRX)0B2Q1D+L$4O!W;C]E1($B55^ZH % #J***
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M-_V(^M?^D,U '3?LV_\ )NW@'_L7-/\ _2:.NTKB_P!FW_DW;P#_ -BYI_\
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MXZ4DHKR_SW/FWC))<M)**\O\]S/T7PU9^'K&*WL[>"UM[==D<4,81(U'0 #
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M6Z@\]^G->N6NH0:E:I-;RQS0RHLB.AW*ZL,JP/0@CN* /#?V9/\ DZG]I/\
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MTJ&SL;6"UM;==D442!41?0#M5]3DT1'*TZOMXI)61^(2;E+F;"BBBF 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !7DG[?0_P",&/C-_P!B/K7_ *035ZW7DO[?
M7_)B_P 9O^Q'UK_TAFH Z;]FWC]G7P#_ -BYIW_I-'7:5Q?[-O\ R;MX!_[%
MS3__ $FCKM* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "O/]'_:A^&OB[Q8OAO3_ (A>";[7
M[B5[5=,MM?MI+YI5SN01+)OW+M8D#D8S7H%<[9?"3PKI.M#5+7PSH%MJ22-,
M+N+3XEG5SG+!PN[)R<G/.: /F3XH?LUV_@G_ (* _!OQ_J/B+7O$GB'Q%XNU
M6UMQ?3!;31K'_A'M39;2VA3"JN40LYRSE<GDG/UAJEQ-9Z;-);P&ZG2-GCB!
MP78+E5!/')&,D@<]:X+XQ?"?4O'GQ@^%.OV=Q8QV?@77KO4[Z.9G$D\4VDWU
MF!$%4@N)+F-L-M&U7.<@ ZGB&P\4:_XTO]/;^QK/P7=:*T(NX;B6/6(+]G*E
MEP#&L:PG<K9WAL=!T /SU_9\^%OQW_9,_99U;Q1XF^!_PM\1?8M0O_$?B./6
M+\7'B+4 \K3331>7$\"JL8^5-[9V9 !.VOM_XA_M(7>@_LGP?$KX>^"-6^(S
M7VGV5]I7A_372VNKV&X:+D$A@NR.0N0 >$P.N:\.T_\ 9N_:<T3X3W/PG?QE
M\/\ Q#X3O;.;23XQU0WLGB*.QE4QOF%LQO<+&S!6:3;TR">:^J_A-\.]/^$?
MPP\.^%=)61=)\-Z7;:99AP-WE01+&N<<9PHR1Z\4 ?-W_!,GXM:_\</B#\?O
M$OBCP-J_PXUR_P#%^G+<>']3F6:YL@FB:>B%F4*"'15D' P' ]Z^MT^[7@W[
M,G'[5'[27_8V:1_ZCVF5[RGW: %J.X"G:&Z<]._!_IFI*CN!NPN!\V1SWH Q
M?#T6GQ^)->>UO)+B^>>(WL+S,ZVKB%=@53PF4P<#J3FMX=*Q=&U34+O6-4CN
MM/6SL[695M+O[2LGVU3&"S[%'R;6)7#$DXS6ROW1]/2@!:*** "BBB@#G?%]
MOI4OBKPW)?7TMMJ$-S*=.@6Y,:W<AA8.&3($F$W'!Z$9K>MQB/@EAZUD^)M4
MU*SUK1[>STG[?9WDSI>77VH0_P!GJ$)5]OWI,D;<*1C-:\ PG QWZ8H ?111
M0 4444 %%%% !1110 4G>EHH _,'_@MGXXUBZ^/>A>'IIK@:#9:*M_';KGRY
M9Y))D+[>C,!& #C*Y_VJ^+'CRQ^ZW; &5;\.]?LW^VO^Q7H_[87AVSMKF\DT
M;6-)D\VQU..$2M%GK&R\90\'&1R!7R[X)_X(?W,WB*3_ (2+QO"VCJ^%73[(
MI/.G?)9B(SU'\7Z5^=YWD6+JXWFIKF3UOV/Z$X)X^R; Y)'#8E\LX7O&S?-_
MPY[=^P9^U9I$_P"S1X4M?%VL+8:Q:VQMB]]NC6>-#MC?S'^5LH%).XY))KZ,
MT+XC:'XBPUCJVE7BMT,-VCY_ &H_#'@32_"GA>ST6ULX8]-L+9+6* H"HC0!
M1^@KD_&G[*G@'QS(9+SPS9PS,.)[1#;2@^NZ/'/US7VF%HXBE1C!V;2/Q7'X
MC!8K%5*R4H*4F]+/?R/0VU+J5"%>Q+5,L^17B]A^R/)X0FW>&?'OC+1XQREO
M+<)=0)]$=?ZUJKHWQ2\-VFZSU?PMX@*=%OM/DM)6^KQN5_\ ':Z/;S7QQ^XX
MY86E)VI55\[I_P"1Z@+EB?NC_OK^>:YO6OC;X3\-ZJ+'4?$WA^QOFX%O<:A%
M'(Q],$YS7SA^UW^V)\3/@7\&-2O;[P39Z5=7#"QMM5AU)+BVMI9,@.4P'XQP
M,=<9K\L-1U*XU2_N+FZFDFN;IVDGD=MS2.QR6;/.XDYYYY[=!X&<<20P<E",
M6WYZ(^]X3\.*F;TYUJM50A'1-6E=OT/W_L=6CU&V66%HY8Y%W(R-N5AVY'%6
M(I"ZC*XK\_O^",O[0VI:U;:U\/\ 4)))K/2XOM^GSR.SM$K/B2$EB<C)##N
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M%5L1+FKS<FM-6V &VBBBM# **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M\E_;Z_Y,7^,W_8CZU_Z0S5ZU7DO[?7_)B_QF_P"Q'UK_ -(9J .F_9M_Y-V\
M _\ 8N:?_P"DT==I7%_LV_\ )NW@'_L7-/\ _2:.NTH **** "BBB@ HHHH
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MVS,ZY'W2,=J]@'_!.2PQ_P EC_:+_P##AWG^- 'T9YG^S^HH\S_9_45\Y_\
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M%D_:*_\ #AWG^- 'T9YG^S^HH\S_ &?U%?.?_#N.P_Z+)^T5_P"'#O/\:/\
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M_AP[S_&C_AW'8?\ 19/VBO\ PX=Y_C0!]&>9_L_J*/,_V?U%?.?_  [CL/\
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MGAGPG)#?_"/POXF6W\'ZC"XFCN#)%YE[$D_+7"QSY D9F)S]Y@,T ?7]%%%
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M'/'?BB^U#2?A7?6_CNRN-3N-TMEH5]I,=P8$!QB*&YM;Y5QT! H ^NI8!*K
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M!O;'6M*B@#+\3>"M)\9VMO#JVG6>I0VMS%>P)<PK*L,\3AXI5# X=' 93U!
M(Y%:4,*P+M487T]*=10 4444 (R[A_GBLSQ#X+TKQ;;VL.JV%KJ45E=0WMNM
MU&)1#/$P:.5=P.'5@&#=01D8-:E% '(_%?X!^"_CMH\&G^-/"^A^*K&UD,L4
M&JV4=TD3XQN7>#M."1D8ZUJ^!/AWH/PN\*V.A>&]'TW0=%TU/+M+#3[=+>VM
ME]$C0!5')Z"MFB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!'Y4XZU^67_!9;]C[
MXC>.?VU=#NO ?AWQ)K'A?]I'P6GP?\<7NE6,EQ%X7M5U>VN/[3N"@(1/LDUX
MFY\ ;,9R<']3JBN;5;DJ6^\N=IQTS_GI0!^:G_!<;]E[QUH?P]^'OBSX%^#=
M8USQ=#HFJ_")M/T:S>9K#2=:LUA%T_EC*1VDEK$0QPJ^;G(&37,?\%.O^">F
ML?#SX7_L?Z/X8_X7E-X)^"-I<^%M?U/X37;6WBK3+:73[6WCOXE1)'=-ULXE
MCC1F99B ,U^J(M #]YL#TZ_GUIPME 7_ &>!QB@#\@?@A_P3^3QX_P"T0W@'
M6OVLO'4FO?!O5?!&D^*_C1J<L,=Y=WQ=_L5E97MC;7>U'2-FF9EB#2[=I)W#
MROX;?L0VOQ#^'GPW\.ZEKG_!3+5/'%YJND6^M^"?$FL7EIX9T1X+F!Y;JXU"
M;3?L4EI;[#+&8Y&D<0HJK&QR/W0%HN[//7//./IGIWZ>M'V10^X'G@=.H'0?
MAD_G0!^4?[3G[!7Q7U'_ (*$?'K]I;X<6WB6X^(/PQU70]1\"^'=1S'X;\8P
M-H,%MJD:!T"R320F2!9D<[)$52!7Z4?LX_%JX^.OP0\)^,+WPSK_ (-O_$&F
MQ7=YH6MV4EIJ&CSLO[RVF2158-&^]"<8;:",@@GLA8JLV]=@;^]LYY.3S[_S
M]:=;6@ML*I&U0 H"XP/3\* )J*** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
<B@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img62602283_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img62602283_5.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR72>7&P8'>N#UX/!KVWX<?L\RZ1^RE9_#_7+B34)/[+^Q3M(0Y8[0,D],C%
M&/HO_!17X4ZOJ_A^RM_$$<DWBB-I=*(((O% ))'/.,&M[QU^V-X'\ V%G<:E
MJL<8U"1HX82PWR!20S8ST!'6OSQM?^"/WQ%T7X>Z)<:?J3KK'A?Q*K:;O8?Z
M/8-)%O4?\!W_ )UZA^V=^QUX\TO]HWX=>+M$\/WOC/P]96 L]9T^TNXK>569
M1N;]X<'D9X'>@#ZRU_\ ;D^&7AW2[2\7Q#;W45]$)E,+"1O+ R7// 4<GTKP
MGQ1_P4!\0_\ #>_A_P &Z/J>FWG@?6M(;4<K;*TTJ#<,JV>N5_2O!_''[!WB
M+X6?M">'M>TOX=ZKK/@/6+)[&ZTB+4(O-M P  <D]]Q!QCIVJK^U?_P3L^)'
MC']HSP[=?#_2=6\&Z/HNBE+5[:[B;RV)9_+<G)(RQZ8H ^^O$'[;GP^\+:=8
MR7FJ7,<FH,8[>W9 +AMN >,^XIO[3_QXOO!/[(NO>//!]U;P7EK8M=V#7, =
M>,\,A.#T-?"_Q=_9Q^)7[1O[/'ANP\2>&]<\._$KP2ACT_7-)EC\NY*  %E(
M;*MM!]:^J/%GPG\<^+/^":UQX4UN-=2\:WFB/;LD6(_,D^; .>!VH ;^S'^W
M[I^I?LJ^$_%7Q"U*W3Q%KD#3R0V5NJ-(0>JQ9]Z/CE_P59\ ?"KX>^'-<TEI
MM>C\37R6-L( "%=F5><9_OBOD7Q)^S3\7-,_9G^&'A&S^&\LVIZ?#(E[>Q7<
M:WEL3T".6\L#Z@]!6'X+_8%^+EI^RA\/]+_X0V:/4O"/BU+V\@EO(6D> 20$
MD<^BM0!^C&K?MN_#_0I+*SU#5&M[R:&.:90@9;,N 1YAR-OWL?C6%XP_X*5_
M!OP-XWNO#NI>++.TUZT56^R$JSNC9PR+D9!P:^1(?V/_ !IHW[7&M:EXG^'.
MJ>)O"?C*TA94AU*%?LC)Y0V2<],INXQVKT#]FW]C?7/!W_!37Q5XDUGP?$G@
M^YTE+73IIY8YE@QOQ&.3TR/>@#[J\+>([?Q=H=IJ=C+]HL[Z,212#Y?E/M6M
M:2"2'AMVT[<TV/3X8(E2-%C6,815& H]A4D:;!CK[T .HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "CH*** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** #%%%% !BC%%% !BC%% Z4 &**** "BBB@
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M5\8^ A=ZE#J\-]]H+[6AD!9>3Z&OZ1?VY>?V7_%:[9&W6;C"#D_*:_G.\/\
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MKJJ\I'Q[U@'_ )$36?;]\G'Z4_\ X:!UK_H1=9_[_)_A0!ZG17EG_#06M?\
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MR.]6,8:JEJ7AMXTD_P!8P_(U<49-?IB_AQ1T2=W<(Z=38Z=6Q(4444 %%%%
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M1OV%?A#X?\(7_ARS^'7AFUT/5G:6[L([-?L\[$Y)8=,D\T ?DK\7_#NN0?\
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M<'[WM7\_'[57P]DT/5I+N/PUX?TWSI&\IEB41C)//"U_0%^V;HDWB/\ 9O\
M$UG!<QVDTUHRI,YPL9P>2:_$7XX_#'5F\"6VCW4UKXBGL9&FN6C.[?'G) .3
MZ&OC>(:S6*I(\W$8ET:G-+X3YS\=?&+QQX7^$D5GX9L[6&'($[01K(DN.O##
MO]*UOAI\:/'WQ ^'C:;H6A6.FRV:"2ZNE0!I?H",#H>GK73:=X;_ +;M5BT&
MW6WO(5.RV)_?\=@.OZ5Y!J>J?%0^*Y+&W@N[5HYMDBS*R,RDX[_C7'S4982,
M9?S'H8-4L6TX['K?P4\#ZAXS\7+=:WJ3:5;S'9<3*%3<P['IZ5Z]^T1^QM9^
M-?AG;_V5XDN-/97!E.WY)%]L9KY\\27OAS3&TW3?B!#JVDZ;#MDFEA8JSOUS
MT]37J_QO^*OB+P[\+_#MW\-;^WU30X\!([LY,@P.O-?/8ZA65>/+\)P5J<U7
M]G3/"?VB[+P_X$\,6FBZ3J6L7LMG\T]U%,RI"Z\XP&]AV[U-\)[.#XM:#8Z[
MJNL%K6%#9?9KJ1AO(X#<9/\ #U]ZTO%7A/[7J]K?:GINCV?]J+]JOHDN%&^3
MH<#Z 5QFJZA#;:Y]FTP/8Z9'*-P2 E4]]PX'UKZ;"X?#R@]=3WXX*:II2CJ4
M+WX"ZAX/\=?VM9ZU:RV4\F8_)8MM&>F6&:^D/@W;Z'XMCDM+S4(8V,>V5@20
MIKS?QSXT\+Z3\,X;&WMVO-47_EJ#T)Q[4_X'PW7@7P'?WSSM;W%]DQR),!)S
MTXZT8R7+A8QY=.9%1C4J+V<%:VID_$?X9VB_$*[TGPQY>M,Y.95)VI[<\UWO
M[.MCJ7AW3[_29K>>2)>+@0\^5TZYK@? 6H:U8_%:-@&NY+QLO-))NDV]P!7T
M!??"F;X>> K[Q1I.L:AI[7#AKFSN =DO3ITKS\RQ52348G#C:S@N6H<+XQ^+
M$'P2\W2].\-Z??0Z@3))=2,=Q!Z@\<'FLNRU?3O%OC/0];M_#]Q9Z6LH28F0
M21Q-U+89NG(Z5A_'[2)?$G@:RO++4K/4#=R>8T (W0L>=O7MTK.\&?#AXM*=
M=<U"W@C6+<L"2 9/:O1IX5_4_;<WQ:''3P].K&R9]6_&;7_"-IX:M[^WU2QO
M[J")2+5X@P P.,8->=^(/AIX1\<?#%_'=N/[!UA<[;=<I"3[#IW]*\1^$OQ!
MM/A[XYWS1Q26L;E7\T[AMSQ7>?M"^.KCXM^%[?1O#J:E=6WF@L;%3Y>,CK@&
MN6A@YX>HL-?W'JWV//\ [-J4,3%P>CW.4L/CQJ7A27[)8:@EZU\")5&?W;]!
MCCT%=+\)+FV\<&ZL_%=]<Q,K$Q3PL?W;=L\BF?#WPGH>@7%GH>NV:VJZ@ZQO
M,_#HV.IKHT\#^'_@5\=FW0W.NZ8J;;>"#YFN&[8P#[5Z69JA*"HI>ZNI]%&I
M33:CO8W-4^ GAO3?!=[?2:M;6=]>82"YE8[B..370_#?X':M%\-5%YK6C:QH
ML",WEQ*3N_$J*2P^&$OQIM;J:ZT74K'3U;= DQ(V'L#D"NLM=*U3X1?!#6+B
M^CN;>UM!M@C4$QLN#S^.!7QF*QMJGNGRSQ$J=6\7<\]^"/COQ1:?$3^QX/"<
M,WAEG9?M"H'$>!P<-^%<U^T$FO:'XJN'U*2QAL9I_P#1E5?+RO./NK7I/[.7
MQ>AL-0W;)6M=44X9UVPQGOGL*/CEK\'C+6O[.MK2'5+5!ND_?"8I]& ^6BIB
M)SDKGHK&5)XJ,ZJLK'F&B?%Q[.&UM=2M)H80 J2VK%6<>N1BO1?V?_VK[C5/
MVCO!_A_P[KA6W_M)%N5G3,FW!XW8)ZX[UYWX]^)_AOPU;:?I-O;QPW5NH!CE
M</L]MV!GZUJ? ;_A&=#_ &I/A_<6L-BU]J&IQF7R,;L;3UQVKV,NP\O:1FSU
ML4J4VITS^BC3?EL8VW%L#DMU-7$^]^%5K':;6/;PK+P#5E?O?A7Z+]B)B$=.
MIL=.K4 HHHH **** "BBB@#D_C7X]N/AM\,M=UJSCMYKK2[&6ZCBF#;)"H)P
M2*_'OP__ ,',WQ6UGX;KKW_"O/ L<D;[6MFFN=S*>C<25^MW[5,/VC]GKQDG
M][29^G7[IZ5_)WINMR>"O!UU#'+,WF2.K>9']U.V.:QK5'!7/:RG +$7N?J!
MJ'_!T[\3K3;_ ,6V\$=.0);KC_R)1X?_ .#ICXA>(;E8E\!^"8[@-AD,MR,#
M_OY7Y8QZFMW$KVMQ"\C#YA(N*R_%'P\U+0#;ZQ)<V=K%(P<-&WS-]>*Q^N.4
M;)'N1RFC2IN<DF?K%XG_ .#I[QIX;U2:VG\#^$G,:@GRVN<_GOK3M/\ @Y\\
M::KX975+7P;X)A1.-EQ)<Y/Y/7Y-6OB:/Q;JZQSZ9;31LNWSD R?J<5:\2>'
MX)8ULD,%M;]<$ BK]ZA'VC=S2&7X>=%RY5<_2[3_ /@[$^)5SXAFT]?AKX&D
M4'"21S76&/J/WE=I:?\ !RY\4-5$93X?^"H?EW.6EN3C\I*_)/0O"=GIE[#)
MI\,-Q<QG=*V[ 'TK7M;R1=.U"Z34_)NE/,&_&$__ %XJ)5G1:>]RLMRG".+J
M5-C]1_$?_!T#\1M(1EL? '@74+A>&5FN_P#XL5FZY_P=-?%#P_);M)\*?">U
MQG<LUP<?E+7Y4^#]<UK71=0VT+?:I"1&X8\_4UU?@^WN?#JM'X@DV,H."[F0
M?K7H3I^[&IW,:>4X6I4E);'ZB1_\'.GQ(O?"R:E:?#GP;)(Q(:-I+E=N?^VE
M41_P=(_$*UE1;KX<^$H=W_36XZ_]_*_-AY)/$.E20Z>\ES-"2\*PQ[5*]\X/
MTH\0>'=-U'3;>SNM07^UHP))88_FVKGD'WX-8U:RY?=%+ X.$DFC]+-1_P"#
MH/XBV7DI'\.O!DGG'@^=<'K_ -M*LZC_ ,',WQ2L;2'[/\.?!K2, !F:X_+_
M %E?FSX?\,:;<Z-,T<4S/:CY68<"N1N-4OKG7(I(V'V&%\-\_<=:SP,*U:5Z
MFB._$97ET8_N;-GZNZ;_ ,'*OQ4NM*GFN/A_X M# ,X>>YYS@=I/>JES_P '
M+WQ3AC62'P+\.Y O99+S_P"+K\O?$VA7&LW"S1LK"88C"3'K[\5L^"_#J^$M
M'N/[6@DDD890QREUKJS:5.G:G1W,\MR/#U+NLK'Z,7?_  <[_&3^SYY(?A?\
M/[@1G(Q-=@OC_MK7)W__  =D?&"W?%Q\(?!<;L=C#S+O\_\ 6U\+^#/%&G3/
M)]L5K5(6.UL9!^M=]8)HOB>+S'T^.>-4PK^2-I_&L:D:M.DI)79M2X;P=:4H
MQD?4]O\ \';/Q7,_ES?"GP+'&GW7,UWEO_(M=O!_P='?$;4=-@N;;X?^!9%D
M'[T>9=AD_.2OS5^(.G:+;>-K.62Q&R!@5ABC#(W/>K&N/I^J7D**UKI\D@.Z
MWCC"Y7MT[]*Y?K$^6]56%'A7#4Y6E*Y^FVE?\',WQ"U"Q-U<> ?!J6^?D?SK
M@[L?22I])_X.5O'NM"9M/\"^#99"WS R7/7_ +[K\M?#FA-:17=O8W N;,-Q
M&YW,A^G:I_#^K?V'++!:M;PW'7:Z[=QK..,7*E$].CPQ@Y.Y^J%W_P '(_Q*
MA58T\ ^#_M&/FW27&W_T.L*X_P"#FGXJ(\FSX>>"U$9P1(UUR?;#U^=7A;QQ
M#/J&W6H]GEG#1)R/P--^)_B:-$5='CD\EE\TEQL ]OTKT,,W55CGS+(<'0I.
M<(JY^@&F_P#!U3\3)M?CL;KX<^!8]S[25:\W$>W[S%?>G_!+W_@IOX@_;W_M
M5M4T/2M$^P#*BV\T[NO]XGTK^>/X<VJ:SK?]I:BHC^SG*8.[GIR*_8[_ (-V
MKZ2_N_$?,/DKC9L.">O6NNM14(GR\<KIK"3K/<_6&WD\V)6Z^^*?3("3$,T^
MN0^7"BBB@ HHHH **** "BBB@ HHHH **** "BBBL_M 4=>_Y .H?]<)/_03
M7!?LM_\ (@7'_7Y-_P"C&KO=>_Y .H?]<)/_ $$UP7[+?_(@7'_7Y-_Z,:ME
MLP/2Z***D HHHH **** "BBB@ HHHH **** "@C(HHH ;LHV4ZB@#RG]MCPT
M_BS]F#Q?IT=U]CDNK"1!-_<X//'-?BM\#/B))X>\!ZQ#>7<6J7.CR26_VEXR
M X]#D GK7[<_M8W-Q9_L_>)I+6-9;A;-S&K#()QZ5^".H^$?$?C+Q;>:?/>6
MN@#S6GD6*((K]3RHP#TKXOB*+=9/R//Q>&]N_9LY^"#6;OXN?VUX=\/277#,
M)HY, .>V"PXZ]JYZ+X7^-O'GQ-;5O'BWMC80S^9'#:2QAEP<Y;!R>U4/&\OC
MC2/$7]E^ _$.V^W%9(5E*[SGJH'KZ>]7/AO\'/B[)J.J0^+KC5)Y)("\;6TC
M37$;D'&5.,#/?/K7CQIJ&'<I[(TP='ZJ_9WT+7Q=@\*_'KQ"+&ZDO NCJ(\[
M=LDH''<8-<_XVU?4="T[3/#GA^RDCT.R4!C)(N]^GO7F'BCX;_&;X+^,HKIM
M/U&YCN9&/VFX0S+MYQG=T/2K<O[1EUX>V2>)+6%-6B3 66((A/M713P_-#VD
M'<]N%/#6YW+4^@M1^$%P/AC!K$$UQ+=*/-*W+Q>7&.F/[U<=X;\$ZSXLC:2Y
MLT"W#;4:&/"-]<]JW/@?K7B;XA?!G7/$%_;0ZEI-B-Z6X3RVQQPK 'BM?P;X
MO;QCX9M]4T2T\36\97R);'#.L3>JG/MZ"O/IU*U*M*;0\+BU!SO*ZZ'F.B?L
MX:AXR^*LNF6:?:-2 WM;-E4P,GV]*]8TWX3ZYI^A7=MJ.@JRZ?P"K]<?CVK:
M^#'PVUC3=?U#5M:_MS1;@1&2.^$C E<'@G(]_P ZXSXP_%#5?"OB0IIWB.>[
MAN.6\V8[6^IR:WIUJV85/J]^5+4\>EF$ZM?E@[:E31?&LG@RUN=>C\.7SW&G
M9!2!5>0^X#'&!7HZV'B[XL_8[Z.UU"X\.7T(DGMKI0HB/?[N#7A$'Q9UR#5H
M3')=6ZW3A2ZY,<H/49]Z]:T/]O?XC:1(OAZQ\'QMI3E(&NB,[EXR?N_UJ\=A
M,;2A:DXR%G"]]79-\=/A3H-]I^GV_AVXM+/4EQ&UJFXEVXSZCK6;XG_8\U?P
M=HEIJ6O(J6#8>9(I"TBCUZUZ;XQ\%Z1JME'J_ANZL[CQ!'&MS/IBX:X:0C)
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M%5[(+';(/F^5>"W6K2CYJ^_EJDT9R:;N@B.<TZFQTZK)"BBB@ HHHH ****
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MXKU,MG2FG19[.55/9SN9'COP?)X@>&\6Z-I9V>%9%.6;ZUJ:5I>EW$MK<-Y
MMECVK*SB/!&,]:P[G0;B#XAWUXM\LFEV^=UMO')^E<;?:[K/CCQ!)::?;W M
M/,V>2H555<]<G_&N-JA0Q#P\.USZ>OBFXIV.N^(.N:78PVZV<RW$LLGS>5,'
MVX^E6)_&EUHNBP26LJS0/@/GY?+IOPW\/:;X>\0W.DA6-V8R^9\,H.#G!'TK
M/;XD/IGB";0Y+"WN(V8C[AKR<74E.5D>CA9)1YF3>(_'MG>6ENEYJ6Z- '.T
M9S^M7K[XH:7KNFV]CHNK7%K,5&1M* _CGGZ5S?B#X<KK%W-(D*VL;K\A/3\*
MUO#W[/D:6<-]=ZJL,5NN_:J'+=L<"JAA::5QO$9BZZYG[O3T-[Q)X5^U^!XF
MNKZQN+B,99C*&/Y5YKX9\2375W<:?<7$>]<[!T4^G-=1IGARPTW5+B\6:::U
M8GAMQQ^%0>./AWI=I:+<6;>3>S?=B8[=V?<TJR48WA\R<7AZM2]2&Z+/A#QM
MKG@B=IKBU6YM8T;:J#C'UKI+/2;SXE3V<>FJD,NH'<0YX3V-<QX=\.^,/#_A
MB222&&XLVQO1B&,8YK<M9+BYT;S]/F^SWD*$"-&^8G%3B*BK8=<O0WP].NJ/
MM);EWXE:(/!VF_8KU8[>^MSM+1#S!)^(Z5A6NJVD/AXP-)YGG#<4<;@,]:A\
M(OXBD>XGUQ08U. LQ^9OIGK4NNM&VG_Z'9E>=[<<UWX.?M8V1R2IM1U.BL_%
MFEMX,2QL]-ACO(QD3NPX/7CCBN<L"/$+W3S>3YG=FX]>GK64E[YEF9?+95A^
M^N<;NW]:JK'/<7RR6N)H^K MMV?RKNIX24(WD>9&M[-\K+UY81QR'"R^7)]T
M^654?CWJW9WR^']$FDLYI/M3#8PZJ5/4?H*LZSXD73M!A62:.ZW)A(@OW/QQ
M5[P7';7?A29IT$<KMD*PQQSWKT,)3NU+FL.MBO=M$FTBTL6\.K=1V;1:C&-Y
MEQOW?ABKUE<7&N:-Y:SJ[3G#@KG9^&:X_4-5DT37S]EO)-A3A-A([^U:OAI+
MNQ+74#@"0$LLGR\GV-2Y+FES>]Z:'1E]24I<LCJ;>YT?1]-V6EHNH7B*1/Y2
M;#Q^?O5#POH^F^,7GDCM95>(Y9'7&TBM'P7X9NIM%DO/(A6\W$C>2%<'Z5)>
M:C:Z5<_Z1':6>\8=HW;EO7K]*RP/U>"E.E'EJ=;GHX^C5?*J>PZS\3[GFL_[
M%A0QIM\T'@_ABL/0M/OM9OIK58Y(5Y^1!][WK,EO9O[:F6WOM_/WAT/XUHZ7
M+/:7*S37$RE3AFC]*\NO*A4O?^)?\#TJ-6M3:C/:QC_$?X:W@L?)DLF9AS'@
M8YK]0/\ @U-L?[/\0>-89%*2JHRN/]ZOSS^(T46IZ-::AI.I2-<6OS%)7 #'
MIWK]._\ @V2MHQ>^+YF6,7DB@L5.<_>KOE",:%T?"<2X>%.M^[ZG[%Q_<%.J
M.V.814E>:?*A1110 4&BB@ HHHH **** "BBB@ HHHH ****S^T!1U[_ ) .
MH?\ 7"3_ -!-<%^RW_R(%Q_U^3?^C&KO=>_Y .H?]<)/_037!?LM_P#(@7'_
M %^3?^C&K9;,#TNBBBI **** "BBB@ HHHH **** "BBB@ HHHH **** /'?
MV^'9/V3?&3*%XL7))&=HVGD>]?SK_$;]HKQ#J?@)-%T_5KR-;>X8+(Q+LG/:
MOZ(O^"A0E/[(/C;R6VM_9\G/MM-?R]:#XNN/"GB::6Z:.XMOM;Y4G/>O/S##
MX>M#EFO>.RA0YXW.M\,>''^(WB?2X%L#K6M>9N>XD?R_+([G(-=YX^T#Q-=>
M-TGOO%&G^%8[';$(GNUVN,]3R,_2LMOCE>:*;BZT?2;6WNKF%5A<)M/0<UX5
M\1_$FOVGBV'6]=T^74B&RRR%Q"/K@C-?+5,+B*KY8O1!7PON-GV>/V&+CQ!;
M6WC:;QII5Y9^5EII5$D.<?[^*XGX-7&A3^,=>\+P>)K=K[)=#:X'G=>$.36/
M;7EY\??@$EKX?GO=&N !NB$A6UQW SS7*_#?P[X8_96\866K:UJ]OJ&N2*!'
M#'D_9CQU..?S/2O.P?UF<)J70\>I1<ERGHWQ7^+GB3X,7^C:#8ZQJ5C'KD^W
M%]F1F/3 Z8&!6!^TC::QXL\)PV^FS?:-2MF'G36DNZ0''?'(KVJR^)%CX[UC
M3]2USP[#J\UK%]HL[QX\K$.>, _7G'>O)O'GQ,,WBO7-7\,V]K;2R*PF0 [0
MX/7:W/KTJ,'.,U:HM3##T(J?++H>:_ CXNZI+</X7O-'@=S\HN;F+YD/N3UK
MW+1?!VE^*;)-*2UC_MJ-LVK6LPCY/7(P<UQOA:VUGQUX*766MK.U^ROFXD6(
MJS 8SVIW@+QOI^C?$.'Q1H<DM]+IX*/$V54L.#UQWKT*D;Q?)T5SW)8ZU)TJ
M6]C:^+7P#\2_#:UDU"]"V<LT9_>1R?/)[$=37*V_Q(\4'P+91ZU;WLVC>;Y:
M;5*AN3]:^IK7XJ']H#X82:OJ'A&.[U#3)%(C>;9&R?Q'.\=,>M>+_&:V\(^.
M?%.CZ3'--I@5O/N;2#>Z+C/0C/\ .O(P=;VUY5>AX6!Q5:2<9H9\-_V4_A7\
M4/&UG-J6L74=Q?)NDTT08P_&06SSU]*]C\(_LU_#W]E_Q9:W.AVFHV^K:@&6
M"0QYCB.#@]/QKYQU7X+:U\1_C?9ZEX+U"XTW1='*I)+*?+R!Z[A[5],>*_B[
MJUEX173[6ZL;JXM\0_:) LFXX'0CIUKFQ<JT:ZI2UB^QY&:1DX6B<+\8OB[J
MO@?Q2MOKEYINK:A,Y=+JXBW%5/W5&6[9'Y52O/BGXDUSP[9R^(YO#]K:PR"2
M5H,;I>A^YG*]*S?'WA_4%OK&:6/3O$NL7(#"P$@,G/H 0:ZCXS^&O#FD_!*W
ML[K2H[7Q%?$+<VWFGS(LXZ?-CUK?%5Z4)0ITUZGLY7AW&A'FZG _&F;_ (65
M/I]U8^9>V+ *ZP'<H ]0.AXKC]2_:*\5?";XA:3X8T?2(X=&GE2,^=&2\F3C
M Z=:ZS5/A=X^T+PWH=OX4U+3]+TU1Y\S3/&'(R>N_D_A70>'?VA++QGXS;PW
MJ$FEZM>V$.TRK;@L''&05'MVKKFTX6BMSVI48I674]1^*'BZ?PA8:?9:+#+:
MWU]:"::* ;_.)SD/BODGXG: GB#7I+/4([RSUBZ?<()("+=R>F#T'6NZTWXJ
MZ;)XQU+38QXD@U4,=LQ"F%0.WS?,!5_Q#\5M4U/X:ZA<6^CZ9:ZA9YB_M)B&
MDPN0& 8GG\*G"4ZU%<FYT9?A70DV/L;*3P9\'9K/6M'LIO(C^22.'<T1[?/]
M:Z+]F[X:KH'AVU\26>H0M>:A-M> , P7)[9]A7 ^%9=>^*7P[6:ZU!;E8D8R
MW+87.!G&T8!].E5_V>M6F\,?$&X$;376V!C!$7^7S..@_.N^IAI*@U4J6D^A
MY^,IU\11E&&US[%^)G@WPWJ]C:R:M;W$LEJH6+$@D;CUXX^E<I\-_C+KMS^U
M%X%T>&22STV&_C2-8P2C+@\'WKY?^#GQ_P#B=>?&+5X-;_M'^S9"_FVUQ;;4
MC// .W./QKTK]DSQ1-9?M5>%[B-K6XFN=;6,Q&0LT:X)[G';M7FX' XI55/E
M3C??J>/EN5TZ#YJC]X_HPM5Q"O7IDY[U8[BJUE/Y]LCM\K8S@59QRM?I*_AQ
M/8'4445LM@"BBBF 4444 %%%% '!?M-6D%[\"_%D=P_EQ2:5.K'=M_@-?RM:
MK\$M/\%Z"=4TFX7S)(-QD\XGRSCK^%?U5?M'E4^!_BII-S1KI<^0.I^4U_+#
M\0?B-#HNGPVE]*UO:LA153[S#WKUL'3H+!5I3WN>IE<92J:'E>@^$KX:Y-?1
MZM$V3F0R#K77^$-4N+?5)'1M/:S3JT8 =F[]JBEU.P\03P6MR7M;%AEY+="'
MQ]>?Y57T.#PMX:\0F*VENKC<QVLYY(/3/%>++DC4C."UL?:4JCOR,TO#GCZ/
M4?%<BVNEVZLK8-P\89A^&/ZTWQIJ]OX/\0?;)_)EO+E<1C[*O%8D_@NXUCQB
MT\-Y'8PYR/X0?K5CX@) +".SNI+6ZN%XBEC^]GW.:JK*45S&E3$)KE0[7O$6
MH0:##J%]Y?EJ-VT+C'X5K^$_B+J&O6:S6'EM"%Q(C1"3Y?H:YO3- OK/P^/[
M5VW$;?=5>>/>L_4_%5YX;OX(=/L/L\!^^RJ?G'I54:E6,;G/"K/F29Z0JVVH
M:I'&RW4<,W^M\F(*/T-6/&WA?3]56W:>ROF:#'E.\?3T[UR>BS?\)/\ *R-"
MK]6;((^E:FM>&+[6+>WAAU*T'DG.V6[3)_45QR<W&?/U/<5:*BKDT0NK>22*
M34)E6=,)"PQD#\:Y?P9K5_)XYFC33UMX[,$-,PP,<^U:^D&^L/$7[Z'2%6WQ
M^\63?GZX:JWC_7(?%\4MI8:A;6-U,P$A'RJ_L#[U,<,XTE(XL5BFOA-KQ1XV
ML?$)C6X>-[BVX0I571M/N=2N(@TTBV\[D,^>@XJG8:#;_#32()M0@MYMPX=&
MW?R-26/C]SJ'VFVA::U?Y511PI]<=:]K!UH1.:M*=169KZ[X2TO09)F69KKR
MUW;6Z$UQ=AJ6G:GJ#+)#)')NVG9Z5T?B.YDO(;.Y*JT,S[9O+_@'/;\JTO!W
MP_T>]U2]N8;_ ,N6!-R(Y&,^]>I4Q-":M(\FIAY*7L^ADOX BL+:XF\Q7MW7
M-NK_ '@/_P!>:MZ4UY=1PVU[:K':QPET=>Y&,#]:PM8-_-<W'VU9KB% =AM>
M OUZU6O/%^I1:?8JB2>7'_$>H^M:X65"G)..YRXKFI+DALSH=%M9/#UY-?7U
MHUQ"3^X7KBEOKN1+TO)9R,MUA@';=C\*?H>NS)8M=/-]HR/N$@HE275S_:FK
M6E_'):Q_9^65!Q^/-1B*/M*G,ST,'B)TJ6A-XA^(5Q)ID,,%TT4<>$:.-,8'
MO63XIO[&X-K^\\Q6P9<IU]:K:YXA:'Q#--:W"K;N?G!7.?I5D^*##Y,<BK)#
M(P(<I\P-<N(IQ?N'90K3J>^P@T5(M5CN[5[:'3>HC=_F_E6]%XBTVQMF98VW
M2/Y;?/\ +CBM:76;&\T>1[V:0B'[ACP"?KQ7':Y>:/XLBB2:XN)(V;RP,@,/
MIQ7D8J,:$.:&^Q[&'J2CJR#QKH,>MWD"V:7$BJ=^V-B8R?>OUH_X-C')UKQ<
MOV/R&A0 DCK]ZORI\*V-OX4(6QCU"3:V")"""/RK]?O^#<:[6>?Q.%MS;O,H
M+$]?XJY,'.I2BX3ZGFYYE]*.#E63U/ULA.8EIU1VPVPJ.OO4E=1^91=U<***
M*!A1110 4444 %%%% !1110 4444 %%%%9_: HZ]_P @'4/^N$G_ *":X+]E
MO_D0+C_K\F_]&-7>Z]_R =0_ZX2?^@FN"_9;_P"1 N/^OR;_ -&-6W0#TNBB
MBI **** "BBB@ HHHH **** "BBB@ HHHH **** .7^,WPOL?C+\.-2\-ZDT
MR6>J1&&0QL58 C%?GR__  ;)?!.?59+B35/$C222F8KYK;<D_P"_7Z62QB5?
MF['- CP#_M5,HJ6C-(U)15D?G_\ \0]?PG*QJ^J:UMB 5!N/ ' _BK5N/^"!
M_P )=0TH6-Y<:I>VXZ)(25'_ (]7W6, ?2EX88KBGE].7Q!*K)JS/B*?_@AQ
M\+8_#"Z3;3ZCIUG'T^SL5S^3"O+_ !C_ ,&ROP5\8:U]NN-:\0&=G\U5$C<D
M<_WZ_2IX<1,%.WCBN6^)CW@^'.JM97<UM>+;/Y<T:_/&^."!Z55+ 8>.R,SX
MX\._\$'_ (=>&C&+?Q)XH5%A\I4\]]H'/&-]5_"W_!O]\'_#_C)-4FO-8O)6
M#%X96(23D=1N-='\/OVT?%0_9R\0:;JDRCXA:3+)#$Y4KE.HE(/;!Q]17;_
M[]K:6Q^$>G_VXTWB?Q)%:/>WV9U@9(@5W,H;[P&X<#-1/+L,Y7L+E.-U7_@B
M3\,KZUFMX;W5K6UF!!BCD(7'TW5CZ'_P0-^#_AWP_-8PR:E^^+,9,G=DG/\
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M4'_%OX_QU=?_ (W3_P#A;7CK_HG\/_@W7_XW6C/@%L>G[A1N%>8?\+:\=?\
M1/X?_!NO_P ;H_X6UXZ_Z)_#_P"#=?\ XW0!Z?N%&X5YA_PMKQU_T3^'_P &
MZ_\ QNC_ (6UXZ_Z)_#_ .#=?_C= 'I^X4;A7F'_  MKQU_T3^'_ ,&Z_P#Q
MNC_A;7CK_HG\/_@W7_XW0!Z?N%&X5YA_PMKQU_T3^'_P;K_\;H_X6UXZ_P"B
M?P_^#=?_ (W0!Z?N%&X5YA_PMKQU_P!$_A_\&Z__ !NC_A;7CK_HG\/_ (-U
M_P#C= 'I^X4;A7F'_"VO'7_1/X?_  ;K_P#&Z/\ A;7CK_HG\/\ X-U_^-T
M>G[A1N%>8?\ "VO'7_1/X?\ P;K_ /&Z/^%M>.L?\D_B_P#!NO\ \;I<NMQ7
M/0?$!QH&H?\ 7"3_ -!-<)^RW_R($WO>3?\ HQJR=9^*7CF/0[Q9/ +;&A?+
M?VJ),?*>WEU<_9"O)K_X6M-<0&VF>[F+Q%L[#YC<5KRVB),]4HHHK,H****
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MZ&1J/B%K-)(K9&5FCS@KW^IJBT\GB+P]#YTDEO(DG+@#)K7LH[S6[\VKV]O
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M?M?EP>#? <:[@-SM<[<?]_*I^+O^#H#XX>'_ "VA\'> +K</F"-=''_D2OS
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M_P"OR;_T8U;+8#TNBBBI **** "BBB@ HHHH *!THHH **** "BBB@ HHHH
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M3D%3_L&OY.?#EA"FLM+))<?:O+ C+$JI;MS7]8O[39D'P)\5^6?F_LN? _X
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M=O-2C[]0Z=\]F@S_  U.D?S5YD])'R.JD[CT.2U.IL?>G4B([!1110,****
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MD NQ'>O4)(4>!E*!HY 5=,9!SP:X:[_9B^'^N7DL]YX-T">5FR7>V5V;/X4
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MC1YM/^T:/#/YA&[RSD#\JZR\\1Z3X7\(WC-*EJUQ$ MN(U;:<#\:\Y\%G7M
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MWL-M):D\8.1TJ[X6N(XS^[^\YZ5>URP6?0X998%DFQ@N*I^'X+?1KY2;,R9
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M_K2LR'MH^O(_.IQPU069/V:'_=YJ?^/\:\26LV>&*O4TZFKU-.HI[ %%%%4
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M;FK]LYDDW?-T((-&I4HM;EBBBB@D**** "BBB@ HHHH **** "BBB@ HHHH
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M/VC_ !@R-)$SZBZLK-C/3G-=U_P3&D5OVWO!,?VGYO/((,W*_.G:OV(\;?\
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M#Q'_ (*+?\F;^.OD,G_$MEX!Q_":_E"U3Q@L6H:@L+- RW#KL/.>?6OZO_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHILK[$)H
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M4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 &BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *1R%0[NE+4=X%-LV[
M;M[[NE &+XT\>Z1\.O#TFJZO>1VEG&0ID<'&3T%4? GQ@T/X@7=Q;Z=>+-/:
M())H_+=?+4XP<D 'J.A[UR?[5_A72?''P<U32]8AU6:SG(+M8Y-Q;'G#KCG
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MRQBMYK*.2.WBDA< Q$(O0C.?:G-IMLKH!:VIVL"A2,#;_GVKY;\>_M8ZQ;?
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MU"Q?,P&2<D#V-?#O@O\ :"URZL8M+M_$5WINOZ79)_9EK//)-+J;A?[K<')
MZGO6O\)OB-8_$O\ :*\$:I=:U<7FN7.CW4>JVS%E6U<"<=.@. /SH ^\-(U"
M'4X/-MY%DB;&"HXJW7C?[%5]?77PYU.*Z\YH;;5KJ.V>5RS/'YKXZ^P%>R4
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:MCI]O':VL9)6->Q/4GZFM:BB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img62602283_6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img62602283_6.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
M  $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $" Q$$!2$Q!A)!
M40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF)R@I*C4V-S@Y
M.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$A8:'B(F*DI.4
ME9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:XN/D
MY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]_**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MCI7P)^RM^R;\0/V+?VO_ !=I>FZ7<:E\-?B%;M-%K,4H2ZTJ:17.T9^;Y6D
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M[R@4+C/+*1G&!0!Z]17B6C?MT>%O%5CI[:3;WEY<7T[6[0,#"UL4;:Q?>!@
M_GVKV?3[K[=9QS#&)%##!SUYZT 34444 %%%% !1110 4444 %%%% !1110
M'D4U5VBG44 -"\\4=>M. Q01DT -"4!?FZTZDQB@!&X-.%%&: $;-&<"EHH
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MG<+>UNED<@9.!6/JMW+JVI7%U(C>9<2-(V!W)S71_ VP6]^+OAZ*:+S(Y+U
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M*L<)%5>Q]3@5+V?O;=!>]%%%>L=@4444 %%%% !1110 4444 %%%% !1110
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M 4444 %%%% !1110 449HH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.ROM#DAFTJ>(-;O$,*R]L5_-+^T[^S#\2-2^.VN736.O^(/M%WD:E=$-+<G
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MI8_>F!2$_#/-?'G[>^GZ&OQF^W7=[9Z;JD>FRPQ1ZW9SW>GWT3;-^%@4L",
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M)*-N.GX"OW4^*?PHT/XR> =3\,^(-/@OM'UB+R+J!U^65,@X/X@5\Q?LL_\
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M $:E>D5YO^UI_P D%UO_ +8_^C4H \\T[FRC_P!T5/4.G_\ 'E%_NBIJ[#G
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M6(XS$@4?PC&37Y3_ ++'Q\^*OPU_;#A@\07'B;Q-H,EU_9@NK^) R09!,GR
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M^8=>#7TA^QK:K:? ?2XX[/7+ !I/W&KHL=VG[QOOA21^M 'JJX%+2+Q]:6@
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MOQA^R?JWBCXF6_B)?$%U"UJ)$CB!& KD$]O:O;M'LWT_2[>"1C(\,:H6/\1
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MXSV_BO6O[<O-,AUS4"X$,2/O0;".6]Q7T)X,\/7GAK2_L]YJEQJS@\2S1JC
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M/']FL9V>&2)(MR@N@(^\,'!S77_MB>#M)MOA)/>-%:+)90^3 +B_DM8U!&,
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MBC_A$?A%K-X&VL(?+'U8A?ZUVIY%>)?MF:BVHZ1X?\/1G]YKFH")E'<+\_\
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MO_MC_P"C4KTBO-_VM/\ D@NM_P#;'_T:E 'GNGG_ $*/_=%3'FH=/_X\HO\
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M_H$/_HM:Z>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/_HM:ZBN8^#*;?A9X?\ ^O"'_P!%K73T %%%% !1110 4444 %%%!H ****
M"BBB@ HHHH **** "BBB@ HHHH *\A_;/TPR?"B/4$7]YH][%>!AU 3)->O5
MRWQK\/#Q3\*M>L=NYKBSD1>.Y4@5P9I1]KA*D/)GH936]EC*<WW7XZ&C\/\
M5?[:\%Z7=;MWGVT;_FH-;%>7?LC^(V\0?!ZSW-NDLWDM3GMY;%/Z5ZC5Y?6]
MKAH5.Z1.94/8XJI2[-A11178<(4444 %%%% !11FB@ HHHH POB7KL?AKP)J
MEY(=JQ6[_F1@5Y]^Q;HDEC\&;.^F'[_5_P#2Y,]26 _PIW[9?B%M-^$[6$)_
M?ZM/' F.I^=2?TS7H'PX\/1^%?!>GZ?&-JVT*H,5XEO:YI?I3C^+_P" >]?V
M.4VZU)_A%?YFY1117MG@A1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 5YO^UI_P D%UO_ +8_^C4KTBO-_P!K
M3_D@NM_]L?\ T:E 'GNG_P#'E'_NBIJAT[_CRC_W14U=ASA112%L4 +10#D4
M4 %%%% !7$_M(_\ )!_%?_8.E_E7;=J\O_;"U;4M)^ >O-I]HMX9;=HYE)QL
MC(.6'TXI2V Z;X.?\DXTG_KW7^5=57G'[+>N:IKOP@TNXU2S%C,8\+&#D[1D
M ]!7HXYI@%%%(&S0 M>1_M*?\C'X4_Z_8_\ T-:]<QQ7SG^V3XJU_0?'GA.'
M3]+%Y;S72>7)NZ-O7@\<<TF5$^B83^Y7Z4\'(JGHLEQ/I-L]P@CF:-3(H.0K
M8YJTIQ3)'48S2;N* <T +1110 4444 %96B_\EW\,_[[_P#H#5JUE:+_ ,EW
M\,_[[_\ H#5-3X1QW/ID=**!THKE-PHHHH **** "BBB@ KA_P!I'3+K6/@5
MXJM;,VWVJXT^1(OM#!8@W;<3P!]:[BN._:"M]&N_@IXFC\133V^AO8N+V2%R
MDB1]RI!!!^AH ^2+3P]\?!XSTKQ! OP[6XTVP:Q@;[9!N\MB&Z[,]AQ7TE^Q
MOI>L:)\#K"'7FT]]4,LSS&Q=7AR97/!4 =Z^(;_X>_LQ#XH:;"OC3QB-+DL9
M'GQXMNU EWC'_+7CC/%?<7['>G>$M+^!>EP^"+R\OO#J-)]FFNKAIY'^=LY=
MB2><]30!ZBO'6EI -@JMI.MV>O6WG65U!=0ABA>)PRY!P1D>A&* +5%([A%+
M,< =365<^.M%L]#FU*;5;"/3[=BLERTRB)",@@MG Q@_E0!K5Q'[0^FWVH?"
M'718:A_9\BVDCN_DB7>@4[EP>F1QGM6K'\6_"\VGVUTOB#2&MKPD02BZ39,1
MUVG.#^%0?%VYCNOA)X@DC8.CZ=,RL.01Y9H 7X,JP^%GA_)S_H$&?^_:UU%<
MS\&S_P 6NT#_ *\(?_1:UTU !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 5'<P+<V[QL-RL""/6I*">*F2NK,$[:H^;_ -F;X@6O
MP[\;^)O"EQ%?/-'?27$210E\*[,W]17T;;SBXA5P&4,,X88(KXR\2_M$>&?A
MQ^VQ>:CYDK6EQ&MK,R+PCX"_H0:^QM(U2+7-,@O+=MT-PBR(?52,C^=?+\,X
MV$XU,-&:?LY-67:^A]=Q9@*E*=+%2@XJK%.[[VU+5%(&R:4'-?5'R(9JO?7\
M.FQ&6XFCAC&,L[8%3%<FH-3@AN+207"QO%C)#C*U,I65T5&S:3(K'Q#8:L^R
MWO+>=AR0CAB*N+]VN1^%<=C-9WDENMNS"[D7<@' W<#(KKE %9X>HZD%-]>Q
MMBJ2IU'!7T[C9;A+>-F=@JJ,DGM6=9>-=)U&Z\BWO[6:;IL60$_E6E,J-$WF
M!63'.X<8KAO =WHMUXPU2.U;3FN(I#\L>W>G)].16=:LX3C&ZU[EX>@ITYS:
M?N]OU.Z/S8H"8H7'O1NW"NDY#PO]H>3_ (3'X[>"?#W6*WG:\G _NE& S^(K
MW.W3RHE7LHQ7A7@%?^$X_:U\2:A)\\.CVZV49[*ZNV?T:O=@AKQ,G_>3K8A_
M:E9>BT/>SK]W3H89?9BF_66K'4445[AX(4444 %%%% !1110 4444 %%%% !
M1110 449HH **** "BBB@ HHHH **** "BBB@ HHHH *\W_:S_Y(+K?_ &Q_
M]&I7I%<C\=O#S>*/A5J]FJ[F>(/C_=(;^E"W \BT_P#X\X_]T5/6'\/M:_X2
M'PE8W2G_ %T8)'I6X%P:[#G"N7^,?B"Z\+?#G5+^S81W%O%N1BN<'([5U%<7
M^T+_ ,DAUK_KA_[,*J/Q(F?PL^<O^&IO&':]M^/^G=:7_AJ3QA_S^V__ (#K
M7G9.!2%CVKTO9Q['F>TEW/1?^&I/&'_/[;_^ ZT']J7Q@/\ E^M__ =:[[1?
MA]H+^!_A[)<:>)F\2 I>%3M9OG<?*<<<*.E1Z#\*/"=KXGU_PEJS"*9KA8=.
MOM^%A9D! ;VY/)-8\U/L:VGW.#_X:F\8 _\ '];X_P"O=:CU#]I7Q9JME+;W
M%S9S6\RE71K92K#T(J3QQ\,)O#_BO3]'OH?+:,'[0\29RF[AN/;%._:+^$\/
MPQ\2V[6(=M+OX%EMW/\ %@ -_P"/9JER.RL3^\6MR.V_:<\66,"Q175K'&@P
MJK;* !5_0?VF_%U[K-K%)>0%)) K 0+TKR[&1P*T?"W_ ",-E_UU6M'3BEL2
MJDK[GW3HURUUI-M*_,DD:L?J17C/[37QAUSX=Z_:0Z7<1PQRH68-&&R>/6O9
M/#BYT&S_ .N*_P A7SI^VB/^*JT__KFW]*X:*3G9G97DU"Z.7/[4OC CB^M_
M_ =:K7_[1?B?53&;F:RF:%@R%K5"5(].*X>!O+E4@#@YP1FOI/XE?#+P7X:T
M%%OHX[7[3I=O/;F-QYAF>$,>.N"QKKGR1M='+&4Y+<\M/[4OC!1_Q^V__@.M
M!_:D\9?\_P!;_P#@.M:NH?LORVNMQ:;'JD<E[)9)J/E[!Q"4#D]>RGI5S1_V
M7XX4OKG4+Y_L<-F9X61.9&V$\\\8XI<U(K][L<\_[4OC$?\ +];_ /@.M*/V
MI?&!_P"7VW_\!UK0L_V=IM)O]-EN[R#,TUHXMV(5I4F8;<<\\'GTK3N?V8SK
MNLZE,MXMC''>30)$$W<JQ &<T<U,251['.?\-2>,/^?ZW_\  =:/^&I/&'_/
M[;_^ ZU'X@^ 5]X=\$W&L23K*MO<M;LD2[PI4@98C[OXUY_GFKC&#V)E*<=S
MZ_\ V;/'6I>/_ 7V[4I4EN/M#QY5 O QCC\:]%KR+]CC_DEA_P"ON7_V6O7:
MX*FDF=])MP38'-9.AG/QX\,COO?./]QJUB<53^$%BWB;]H69A\T.D6:2;NV\
MEE(^M8RV-H[GT=NQ2ALT@'&:56S7*;"T444 %%%% !1110 54UW1+3Q)H]Q8
M7T$=U9W2&.:*10RR*>Q!X-6Z",T <9'^SMX!5<?\(3X1;'<Z/;DG_P <KH/"
M_A33?!&D1Z?I-C:Z?9Q9*06\8CC7)R<*H '6M,#%!7)H P?B/X-/C[P;>:/]
MMN+!;Z,Q/-;N8Y5!&#M8$%3[@U\;?LT:KX@^$O\ P3KO)/#%YJMYK^GZ]?QV
M!>)]0ENI!=3A4?))"D@98YQ7W.5S6'X'^'.D?#K0SIVDVJVUHTTEQL']]V+,
M?Q8DT ?-_P"S7J_C[]I?]GWQ!:_$:YU30]?N&\NYB@M&LC!%A@!'(NTDLN#N
M&,&O%?AO;26G[.W@O0;Z\NY?#_\ PFL\%Q)<7#.9BE\ZQQR.Q^8,,@@]:_1*
M2TCD1E91^\&&]ZXC4_V;_".K> )O#,FF[=*FN6O-J-M>.9F+&16'*MN8D$<B
M@#Y4^&OP[UKQ3\5_$WA_PGI^FZEX-TV^BE#S3*/(+%FE2)B#CYLC"XQ@5]$?
MM">)-9\!?"2XM;'2]-DT]M/:WFENM1$)A_=[<+D?.>N/7%=M\*O@_H7P8\-K
MI>@VK06V]G9I'\R21B<DLQY8Y/>N7_:]9%^"FJ;PY&S VV/VOG!_A_A_WNW6
M@#J/@TQ;X5>'VX&;"#I_US6NHSD5R_P6 /PH\/C_ *A\';'_ "S6NH Q0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 !I",J:4G%
M-)H ^2?BY_P3WT_QA\;8[J'5I;2UU0/<2Q[-Q!!&<'/?)KMK;P5\3?V?K6--
M%NH?%6AVRX%M/B.:-1V#?,3@5ZUKW_)2M)_Z]IOYK749S7R^'X;PD*E2KA[P
MFWNF?78GBK'5*-*CBK5(*/PR7].YY+X _:YT'Q%=K8:S'<>'=4Z/%?1F%,_[
M+-C=71>/_'5QH,-O=V5]8_9KF6.*,,R_-N.,@]^M:7COX0>'OB-9-#JFFV\S
M-QYH0"5?HW4?A7PO^V)\"O%7PS\<PVNAS>(KW0'V&UQ<2S>5(<<=3CG&*Y,Z
MS+,,MPSG./M5M>.C^:.S(,JRS-<6J4)^R=FVI:Q?H_\ ,^ZM1^(>F^#-%6XU
MS5;&W^7=EY%3=]!7SW^TQ^TCJ7Q4\!WVD^ =.UNX?@RWL=O(B!1UVL!SD9Z&
MMC]FW]DR&_\ ".GZMXTDU+5-59 P@N[EY(HUP, HQ(S^%?0&F^'+'0=/-O9V
MEO:P!<;(HPJ_D*Z?98_,<+:;]E&2]9:_D<GM<NRK&<T%[:<'Z0T[+=GPC^Q=
MHOQ:_M'4FTF:ZM;?@2'4E9E+<YVA^_KBOHP>'/C=(/\ D.:*G_;I&:]*^&=M
M'#8WH1%4?:Y>@Q_%73@;16>3\-K#X6-)UIOYV-,]XH>*QDJRH4UMO&_XGS_X
MJ\$?&R_\.WD?_"2:62T+C8EG&K-P> 0<@U\K_ N#QA\&_CE;ZIX@CUJVL;><
MQWL[+(T1)X&XG@C)ZFOTH/(KC+7PY9^*KK6K&_MX[BVF9D9'4,,$FN?->%?;
M5J5:G6ES1=U=W1UY+QA]7H5J%6A#DFK.R29TVA:Y:^(M+AN[.:*X@F4,KHP9
M2#[T[Q#J"Z7H5Y<,VWR87?/T4FOG^:SUS]D'Q!YEO]HU3P-=2_<YDET_/YG;
MT] *M_M-^.K2\^%,>N:/J4TMOJA$/[J8[2&P,8!]Z].IG7)AY^UCRU(+5?JN
MZ/'IY#SXFFJ,N:E-Z2_-/LS5_8UM?[8\/ZQXBD7,FO7[W2N>ZL%Q7MG05PW[
M.7A'_A"?@YH6GE=KV]JBMZD@5W->CD]%T\'"+WM=^KU/-SJNJN.J26U[+T6@
M444'I7I'EA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 5'<P+=6\D3\K(I0CU!XJ2B@#Y<UO0F^#_ ,3;W19U
M,>FZE(9].?\ A4'_ )9YZ9 !-;RG*UZW\6_A18_%CPTUG=+Y=Q'\]O.O#POZ
M@]?:OGZ]U#5OA/JHTGQ1!)MSMAU"-"89E]6(X3Z$UO3G?1F4HG3UQ?[0G_)(
M=:_ZX?\ LPKK;/4(=1A62WFCF1OXD8,#^5,UC1K?7]-EM+J,203#:ZGN*VB[
M.YE)75CX%I.<U]J_\*'\+_\ 0-A_[Y'^%'_"A_"__0-A_(?X5V_6H]CC^JR/
MFO3_ -HK6-*T'1;&&*UV^'U(LV>(,4Y)YSUY8US.J>.+S6([AKAF:XN)_M#S
M;OFW8QQW%?77_"A_"_\ T#8?R'^%<!^TI\*=#\*_"R^O+&QCAN(URK #C]*A
M5H+9#^KS>[/$M3^+NJ:X[R7DAFN7@^SB;HP7CO\ A4GBCXO:CXM\%:?HEZ(Y
MH=-R(97&9 "22-W7J:^E_"WP/\-7?AVQEDTV%GD@1F.!R<#VJ^OP(\+L?^09
M#_WR/\*?MX=A_5Y]SXKV"M'PMQXALO\ KJM?8O\ PH?PO_T#8?\ OD?X4L/P
M.\,V\ZR1Z="KH<@X'!_*J^M+L2L+).YT/AL_\2*S_P"N*_R%?.O[:)_XJRP_
MZYM_2OI2*W2WA6-1A5& /2L7Q-\.-'\8W"3:A:I<21C"E@.*Y:53EES'34IN
M4;(^&4?9*IQD YKJOB%\5K[XD7FGSWR1^9I\,<";%"Y1%"K^@%?4&I?![P9H
ML!EN[6RM8QU>5E1?S-><>*O&'P\TR^^PZ1H=UKU^QPJVEL9(2?>15*BNCZS'
M=HY_JT]DSS+4_CSK%_XPM]:W11WD-DNGG:F T(0)C'^Z,9JY)^TEKQGFY@^S
MS6YM_*,8VA=NW\Z[ _L\>)?B> 9;'3/"6GR?-Y85+B9E_P!X8*U/\4OV<M#^
M$_PG\ZU^T7%XUW CS2R%LY?!QGIFE[:G;8?U>IW.#U3]H36-9CTLW,=K)-I+
MQM#((@&Q&04!^F!5V#]I[7())F$=ONFN'N6S&/OL<FO>/"GP1\-7?AJRFDTZ
M)GDB5F) Y)'TK1'P'\+D?\@V'\A_A2]M3[![&IW/F#4/CEJU[HNIV7RQQ:M)
MYDZ@#:3G/ KB<Y/ K[6_X4/X7_Z!L/Y#_"C_ (4/X7_Z!L/Y#_"KCB(+9"EA
MYO=G(_L;G_BUA_Z^Y?\ V6O7@<UF^'/"MAX0L/LMA"MO#N+[5]357Q)X]L/#
MD>WS#=73':EO;CS92>WRKD_CBN2<KNYUTXVBD6/%7B.+PSH\EQ,WS8VQJ.KL
M>  /J17H_P"R]\/+CPMX0DU/48_+U36G-U,IZQ;L'9^%<G\(O@;J/C76[?Q'
MXJB\FWA_>66GDYV_[3^IYZ$<$5[VL84<=!TKEJ3OHC:,>HI7)I0,445F:!11
M10 4444 %%%% !1110 4444 %%%% !1110 5YK^U@U@/@QJW]H?VL(_*.S[!
MOW[\';NV<[,]<\8ZUZ57$?M#7NH6'PBUQM.L4OY&M)%D1IQ%L0J=S9/7 YQW
MH O?!@@?"KP_U_X\(,?]^UKJ>@KE_@TW_%J_#^[@_8(,C_MFM=,#N/M0 X'-
M% &** "@T4TDB@!=U*#FF@ TJG(H 6BFN<4Z@ H)Q2#.:4C- !FBD"X-#9H
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MW-N36>&C*--*:U-,5*,JCE#8<:YGPFO_ !46I_\ 74_S-=%=Q/-;NL;^6S#
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M)=9\'6HATOQ%HUC&!C$.E;,_DU?1N<T4N9ARH\'_ .&6_%__ $.5C_X+C_\
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M -!S1_\ P-C_ /BJ -BBL?\ X6)X?_Z#FC_^!L?_ ,51_P +$\/_ /0<T?\
M\#8__BJ -@#%%8__  L3P_\ ]!S1_P#P-C_^*H_X6)X?_P"@YH__ (&Q_P#Q
M5 &QMYHK'_X6)X?_ .@YH_\ X&Q_XT@^(OA\_P#,<T?_ ,#8_P#XJ@#9HK%C
M^)/AV9<KK^BL.F1?1'_V:G?\+$\/_P#0<T?_ ,#8_P#XJ@#8HK'_ .%B>'_^
M@YH__@;'_P#%4?\ "Q/#_P#T'-'_ / V/_XJ@#8HK'_X6)X?_P"@YH__ (&Q
M_P#Q5'_"Q/#_ /T'-'_\#8__ (J@#8HK'_X6)X?_ .@YH_\ X&Q__%4?\+$\
M/_\ 0<T?_P #8_\ XJ@#8H(S6/\ \+$\/_\ 0<T?_P #8_\ XJC_ (6)X?\
M^@YH_P#X&Q__ !5 &P!BBL?_ (6)X?\ ^@YH_P#X&Q_XTU?B3X=<D+KVBL5Z
M@7T7'_CU &U16,/B+X?/_,<T?_P-C_\ BJ7_ (6)X?\ ^@YH_P#X&Q__ !5
M&Q16/_PL3P__ -!S1_\ P-C_ /BJ/^%B>'_^@YH__@;'_P#%4 ;%%8__  L3
MP_\ ]!S1_P#P-C_^*H_X6)X?_P"@YH__ (&Q_P#Q5 &Q16/_ ,+$\/\ _0<T
M?_P-C_\ BJ/^%B>'_P#H.:/_ .!L?_Q5 &Q16/\ \+$\/_\ 0<T?_P #8_\
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M_D0^7%&L9;R@ 2>54XSGDBNX^+_P<\/?%?PS=6>L:?IMQ+/ ]O#-=1!_)+C
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M=L#FB@#B?^&</ ?_ $*.@_\ @(M'_#.'@/\ Z%'0?_ 1:[:B@#B?^&</ ?\
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M=!_\!%H_X9P\!?\ 0HZ#_P" BUVU% '$_P##.'@/_H4=!_\  1:/^&</ ?\
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M735U[Q%KZJ>)]8N_M,P]MV!7644 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]I*]F<C^T/\ 'K1?V;OA9J7BK7#,;/3XRPCBC9WF?!(08!Y.,9/%?E!\#?\
M@X:\2:O^UW<1^(M/D_X075+C[-#;1(QEL@&VJ^,GMRV!FOUP^,MG#>?"W7EF
MC2118RG##(^Z:_G?_8=M(YO^"H5G&\:M'_;TXVD<?\?%5PW@\-6PU:5:%W%?
MU8G.,37I5J4:<K)L_HS\&^+;+QSX;L]6T^0R6E]"L\3%2I*L 1P0#WIWB_Q5
M9>"/#=YJVH2>59V,332L%+$*H)/ !/:KFGVZ6]G$L:A%5!@#H*?/ EU$8Y%5
MU;J#T-?(^[S>1]!K;S/QL^/G_!PUXDT7]KNUC\-Z;(O@;2[@VL]K*A66]!8*
MTF,CT)7(SS7ZM?L[?'[1_P!I'X6:;XIT-IA:W\89HY8V1XGP"RG('0G''%?S
MZ?MVVT4/_!3ZXC2-%C_X2. ;0./^/FOZ'?@K90V?PLT-8HUC7[%$<*,?P"OK
M>(L'AJ.&H2HPLY+^KGS^3XBO4K5%4E=)G37%REK;232';'&I=CCH!R:_)_\
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M HHHH **** "BBB@ HHHH *!110 44"B@ HHHH **** "BBB@ HHHH ****
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M3_$5IJ$,9NHXR)A<SL2G.[&685Z]J?P&U6V_:'DU:SDA'AO6@ES?QX.^*>
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MTUIHTO&$AM<?ND? &X=\X&.N*]"' HHI.3>YI"G&"M%!1112*"BBB@ HHHH
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JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img62602283_7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img62602283_7.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )J!P<# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M==_L./PHECINJW&GK]N6X$C>61@G82#P1SQSGBO4*\_^%G_,Z_\ 8UWW_LE
M!_Q=_P#ZD;_R;H_XN_\ ]2-_Y-UZ!10!Y_\ \7?_ .I&_P#)NC_B[_\ U(W_
M )-UZ!10!Y__ ,7?_P"I&_\ )NC_ (N__P!2-_Y-UZ!10!Y__P 7?_ZD;_R;
MH_XN_P#]2-_Y-UZ!10!Y_P#\7?\ ^I&_\FZ/^+O_ /4C?^3=>@44 >?_ /%W
M_P#J1O\ R;H_XN__ -2-_P"3=>@44 >?_P#%W_\ J1O_ ";H_P"+O_\ 4C?^
M3=>@44 >?_\ %W_^I&_\FZ/^+O\ _4C?^3=>@44 >?\ _%W_ /J1O_)NC_B[
M_P#U(W_DW7H%% 'G_P#Q=_\ ZD;_ ,FZ/^+O_P#4C?\ DW7H%% 'G_\ Q=__
M *D;_P FZ/\ B[__ %(W_DW7H%% 'G__ !=__J1O_)NC_B[_ /U(W_DW7H%%
M 'G_ /Q=_P#ZD;_R;H_XN_\ ]2-_Y-UZ!10!Y_\ \7?_ .I&_P#)NC_B[_\
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M 'G_ /Q=_P#ZD;_R;H_XN_\ ]2-_Y-UZ!10!Y_\ \7?_ .I&_P#)NC_B[_\
MU(W_ )-UZ!10!Y__ ,7?_P"I&_\ )NC_ (N__P!2-_Y-UZ!10!Y__P 7?_ZD
M;_R;H_XN_P#]2-_Y-UZ!10!Y_P#\7?\ ^I&_\FZ/^+O_ /4C?^3=>@44 >?_
M /%W_P#J1O\ R;H_XN__ -2-_P"3=>@44 >?_P#%W_\ J1O_ ";H_P"+O_\
M4C?^3=>@44 >?_\ %W_^I&_\FZ/^+O\ _4C?^3=>@44 >?\ _%W_ /J1O_)N
MC_B[_P#U(W_DW7H%% 'G_P#Q=_\ ZD;_ ,FZ/^+O_P#4C?\ DW7H%% 'E^H^
M)/B/X<U'0O[<C\*/8ZEJMOI[?85N#(OF$Y(WD < \\\XXKU"O/\ XI_\R5_V
M-=C_ .SUZ!0 4444 %%%% !7G_B3Q)XP_P"%AQ^%_"\>A_\ (*&H/)J:S?\
M/4QD QG_ '>,>O->@5Y__P W"_\ <J?^W= !_P 7?_ZD;_R;H_XN_P#]2-_Y
M-UZ!10!Y_P#\7?\ ^I&_\FZ/^+O_ /4C?^3=>@44 >?_ /%W_P#J1O\ R;H_
MXN__ -2-_P"3=>@44 >?_P#%W_\ J1O_ ";H_P"+O_\ 4C?^3=>@44 >?_\
M%W_^I&_\FZ/^+O\ _4C?^3=>@44 >?\ _%W_ /J1O_)NC_B[_P#U(W_DW7H%
M% 'G_P#Q=_\ ZD;_ ,FZ/^+O_P#4C?\ DW7H%% 'G_\ Q=__ *D;_P FZ/\
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M2?\ U=K"TA']X@<#\3@?C7@GPX\(/XY@\4:IJ.'EN(GAAD8<?:'.\M^!"_\
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M110 4444 %>?_!+_ ))#H7_;Q_Z425Z!7G_P2_Y)#H7_ &\?^E$E 'H%%%%
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MPWVLK&);F:X/[JW4@'GD<X(.2>X&"3BO2J\=\5Z%XL\(?$>Z\<>%M.&KV]_
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MEU5D$=S*59)E7  #*>V% STXZUQ/AM#K?[2GB*\NL.-,M3';AOX#A$X_ O\
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M =A3J "BBB@ HHHH \__ .;A?^Y4_P#;NO0*\_\ ^;A?^Y4_]NZ] H ****
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M5YS/\ / TUQYJ17\"9SY4=T2O_CP)_6@#F=!BTK_ (:/!\'"(::EE)_:/V7
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MG()_6NW\.>%=$\)V!L]$L([6-L%V&2\A'=F/)[]>F>* -FBBB@ HHHH \_\
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M97\1?;U>$1<R1(<<G'(&[:1_ND]JL>+)(O"OQ\\/^(+UQ#INHVC6DD[G"I(
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M+ILX@DDD& [\YP/08ZFMZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M110!YC\1;J_LOB5X N-,T[^T;Q/[1\NU\]8?,S"@/SMP, D_ABM;_A)_'?\
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M HHHH **** "D(#*58 @C!![TM% '/-X"\(M=_:CX9TGSMV[=]C3KZXQC-=
MJJBA54*H&  , "N#\=>/KS0=:T[PWX?TQ=2\0ZBN^**1BL<29/S-TS]UNXP%
M))]<2Y^(/C/P7J%B?'>CZ8-(O)1%]NTQWQ QY^8,3G SZ< X)(Q0!ZQ11U&1
M10 4444 %%%% !1110 4444 ><?&"6>"P\)36MM]IN$\36;10;PGFN!(0NX\
M#)P,GIFK_P#PD_CO_HG7_E;@_P *K_%/_F2O^QKL?_9Z] H X?\ X2?QW_T3
MK_RMP?X4?\)/X[_Z)U_Y6X/\*[BB@#A_^$G\=_\ 1.O_ "MP?X4?\)/X[_Z)
MU_Y6X/\ "NXHH ^>O'/CCQEI/CFTN_L,NB736<:?8?M2W23KYCX8A1CDDC'4
M8Z\UU'A#5M6UKXRQ7FM:2VF7;>%L>26^\OVH?/@\KG)^4\\5Z>^BZ;+K*ZO)
M90OJ"1"%+AURR("3A<].6/(YYKC?^;A?^Y4_]NZ /0**** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ K!U#P5X7U6[:ZO_  ]IEQ<.<M+);(68^YQS
M^-8_Q \>OX1&GZ?INGG4=;U.3R[.UW;5[#<Q],D<<=^1BN:U'QW\0/!:6^I>
M+]"TJ;1I)%2:33'?S+<GIG<QS_+/&>10!ZM:VMO96R6UI!%!!&,)%$@55'H
M.!4M16UQ%>6L-S X>&9%DC<?Q*1D'\JEH **** "BBB@ HHHH **** /'_VC
MO^2>:?\ ]A6/_P!%2T4?M'?\D\T__L*Q_P#HJ6B@#V"BBB@#G/'_ /R3_7_^
MO&7_ -!->9^!/BUX<\.>"].TF^2^-S;JX<Q0@KR[,,'<.Q%>F>/_ /DG^O\
M_7C+_P"@FL[X2_\ ),-%_P!V7_T:] '">._BUX<\1^"]1TFQ2^%S<*@0RP@+
MPZL<G<>P-=OHFNVWAGX/:9J]T-T=MIT3! <%V( 51]20*D^+7_),-:_W8O\
MT:E<AXHMI[G]G;3#"&(AM[620 9RHP#^60?PH&:>F0?$OQ/I\>MKK]GH\=P/
M-MK$6BR#81\NYB">1SW_  Z5J>$?&]]>P:SINNV6-<T529HK52WVA0,AD7U.
M.@ZY&.N!E^'_  (=6\/:??V?COQ.+>:!&18[\[4XY4>F#QCVJCI@\/\ @[5_
M$^LV>NZGK6LZ?9LEW'=DL&.5VYDV\D%0O7@9XXH OZ8GQ'\7V9U3^V(?#EO*
MY\FR^Q"20*#C+%QGM^/7 &*M>"?$_B'_ (3+5/"'B:2"ZO+2$3Q7<*!0Z_+P
M0 !T<'H,<BLWP_HOC#QOHUOK>I>,[FP@NP7CM=.C$>U<D#YP1C]?K6;X&L+7
M2_CEK%A:7US>I!8%&GN9?,=GS$6R?8Y'X4 +\-;74KSX>>(8M)U%;"Z_M20^
M>T(E^4(F1M/'(XJ?X(6.M'0X[Q=84:.)I5;3_LZY+X'S>9U]./:K?P:!;P=X
M@ Y)U&8#_OVE7/@:0?AY@'I>2@_DM '%_#1O%M_9ZKI7ARXMM.MTO6GN-0FC
M\QLL H15((SA2?RZ=^PT+Q'XHT+XA6WA'Q/=V^HQWL!DM;R.,(W 8C(  _A8
M8QG.#FF? X#_ (1S63W.J2#_ ,<2F>*_^2\>$?\ KV;_ -JT :EWXDU?1?B]
M:Z/?W?F:)JEO_HB&-!Y4H'3<!D\J>I/WQ5WXF>)[SPWX93^RGVZK>W"6]IA0
MQ#$Y)P00>!CZL*S_ (P:3-<>%H-;LN+_ $6X6ZB<#D+D;OR(5O\ @-8]I?Q_
M$/XJ:1<Q#=INC6"7C+U GD 8#Z@E?^^#0(]2T^.YATVVBO9_/NDB432[0N]\
M?,<  #)STJS110!Y/X+7_A$/BOKOA9ODL]17[;9#MW.!^!8?]LZV/B_K$MAX
M._LRTRU[J\RV<2+U*G[WYC"_\"JE\6K673)-$\9V:$SZ1=*LV/XH6/0^V>/^
M!FH8Y$\;_&:&:)A-I7A^U65&'*M-(,@_7D?]^Z!EW6=6D^'/A30?#6BVT=UK
M-UMMK9&!V%^-\AZ?Q-^OL:KW>G_%'2-/DU9?$5EJ,T2>;+IWV10K <E58 $G
MKZ$U#X_D73OBKX+U.[;;8[GA+M]U')QDGM]X?E7IMY>6^GV4]Y=2K%;P(9)'
M;HJ@9)H$>-_$3Q1;^+_@U9ZM GELU]&DT6<^7(%;(SW[$>Q%=7X[\1:KH>J>
M#[?3KKR(K^]6&Y7RU;S$W1C'S X^\>F*\C\F5/@3<3LA2&?7@\2]MOEX)'X@
MC\*]&^*TB6^J>!;F5@D,6HJSNQP%&Z,Y/X T#/1/$5U-8^&=6O+9]D\%G-+&
M^ =K*A(.#P>17 6GB[79?@5+XD>^SJRJY%QY2=I]H^7;M^[QTKL_&UU!9^!M
M<EGD6-#8S("QQEF0JH^I) _&O,;#_DV.?_=D_P#2F@#8TB;XB^,]!M=4L]8M
M-&@:%1$K0+))<,O#2-\N%#,"0 .G;N;W@KQ-XA\3:7KVAW\\=EXATQ_)^UI$
MK+DE@&*_=)!4^Q&*Z;P(H7P#X?"C _L^$_F@-<?\./\ DI'Q _Z_$_\ 0I:!
M&#\*M.\0/XCUV2'74CM[?4B+^+[*A^UMELD'^#//3UKJ_$OBK7=0\8#PAX1,
M$-W%$)KV_F7<MNO!P%(()P5]?O8XY-4OA)QK/C5#]Y=5;(]/F>N>AT%M1^-/
MB/3Y]<U/2;F=1-;O93^4TR8!VY[@#_T$^E S>U35?&_P]^SZEK6IP:]HC2B.
MY*VZQ2P[C]X;1S^.?3C(-=!XX\;/H&FZ='H\*7NJ:NXCL8R?E(./G/J/F7CC
MK[&N8\5^!]+TG0WF\2>.O$K:<[JC1S7)E5VSD#9@YQC/3MFLGQ_ID-OK7@(?
MVE>V^E"W6UCOT)BECQMPY.!M;!4G('0T ='=:=\4=*T]]5'B.QU":)/,ET\V
MBA& Y*JP )/Y9JOXG^(]W/\ "RQ\3:%-]CN9;M(9EVK)L.&W)\P([ @XZ8K1
MN?AW+:VLMQ<>/_%201(7D=M0.%4#))_"N!\2V.AV/P4 \/:A=7MA+JZOYES&
M4(?800,J,C@?CF@#O?#A^(-_JMKKVJ7]G;Z'.K3-IJ(&D2,J2@^YG/3/S9_D
M,K0=2\<?$*UN-9TOQ%::-9I.T<%FELLK#'3>Q&>X]CUP*]162*RTP2/E88(=
MQVJ6PJKV Y/ [5Y9;?#_ $'Q*DGB+P+XBO=),LC _9]PC# \C;\K+ZXSC!&!
M0(ZOP1J?BJ>?4M-\4V6)K.0"&^CBV1W*\\CMZ'C'!Z BNQKS+P-K_B.T\;ZA
MX,\17D6H26UOY\5V@^;'R\,<#LW?G/<Y%>FT %%%% !1110 4444 %%%% !1
M110 4444 %>?_!+_ ))#H7_;Q_Z425Z!7G_P2_Y)#H7_ &\?^E$E 'H%%%%
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M/^9U_P"QKOO_ &2O0*\_^%G_ #.O_8UWW_LE 'H%%%% !1110 4444 %%%%
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MR#^%</\ \(7\5O\ HH<'_@(O_P 37<^+_#U[XET=+&QUV]T659EE-S9L0[
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M!5U.M^"?#OB+4X-1U;34NKF!!&C/(X&T$D J#@\D]1WK=1%C1410J*,*JC
M]!0 ZBBB@"EK&E6VMZ-=Z7=@F"ZB:)\=1D=1[CJ/I61X,\%:?X)T^>TL99IS
M/+YDDL^-QP  . .!S^9KI** ,KQ#X<TSQ3I3Z=JL'FP$[E(.&1NS*>QY-<8?
MA%#<116=_P"*==N]+C(VV4EQ\N!T'I@?3Z8KTBB@#E_$/@72M?\ "UOX>!DL
MK&W=7C6VQE=H( Y!]3[U=\2>%=,\5Z)_9>IH[1 AHW1L/&P& P/K@GKQS6W1
M0!YY9_"2P38FIZWJ^JP0@BWMKJ?=%%Q@';T)&>.WM6O#X!L(? #^#UN[DV;
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M'0# I:* "BBB@ HHHH Q?$WA/1?%^F_8=:LDN(U.8WSM>,^JL.1_7O7+:?\
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M#_Z)A_Y7[?\ PH_X2WXA_P#1,/\ ROV_^%>@44 >?_\ "6_$/_HF'_E?M_\
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M_A7H%% 'G_\ PEOQ#_Z)A_Y7[?\ PH_X2WXA_P#1,/\ ROV_^%>@44 >?_\
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M^5^W_P */^$M^(?_ $3#_P K]O\ X5Z!10!Y_P#\);\0_P#HF'_E?M_\*/\
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M^5^W_P */^$M^(?_ $3#_P K]O\ X5Z!10!Y_P#\);\0_P#HF'_E?M_\*/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5P_Q)_YE'_L9;/\ ]GKN*X?XD_\ ,H_]C+9_^ST
M=Q1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
MP_Q)_P"91_[&6S_]GKN*X?XD_P#,H_\ 8RV?_L] '<4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/_\ A=OP\_Z&'_R2N/\ XW1_PNWX>?\ 0P_^25Q_\;KT"B@#S_\ X7;\//\
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M^-UZ!10!Y_\ \+M^'G_0P_\ DE<?_&Z/^%V_#S_H8?\ R2N/_C=>@44 >?\
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MUZ!10!Y__P +M^'G_0P_^25Q_P#&Z/\ A=OP\_Z&'_R2N/\ XW7H%% 'G_\
MPNWX>?\ 0P_^25Q_\;H_X7;\//\ H8?_ "2N/_C=>@44 >?_ /"[?AY_T,/_
M ))7'_QNC_A=OP\_Z&'_ ,DKC_XW7H%% '+^&_B)X5\7:C)8:'JOVNZCB,S)
M]GECP@(!.74#JP_.NHKS_P#YN%_[E3_V[KT"@ HHHH **** "N'O_B_X$TS4
M;FPO-=\NZM97AF3[).=KJ2&&0F#@@]*[BO/_ (6?\SK_ -C7??\ LE !_P +
MM^'G_0P_^25Q_P#&Z/\ A=OP\_Z&'_R2N/\ XW7H%% 'G_\ PNWX>?\ 0P_^
M25Q_\;H_X7;\//\ H8?_ "2N/_C=>@44 >?_ /"[?AY_T,/_ ))7'_QNC_A=
MOP\_Z&'_ ,DKC_XW7H%% 'G_ /PNWX>?]##_ .25Q_\ &Z/^%V_#S_H8?_)*
MX_\ C=>@44 >?_\ "[?AY_T,/_DE<?\ QNC_ (7;\//^AA_\DKC_ .-UZ!10
M!Y__ ,+M^'G_ $,/_DE<?_&Z/^%V_#S_ *&'_P DKC_XW7H%% 'G_P#PNWX>
M?]##_P"25Q_\;H_X7;\//^AA_P#)*X_^-UZ!10!Y_P#\+M^'G_0P_P#DE<?_
M !NC_A=OP\_Z&'_R2N/_ (W7H%% 'G__  NWX>?]##_Y)7'_ ,;H_P"%V_#S
M_H8?_)*X_P#C=>@44 >?_P#"[?AY_P!##_Y)7'_QNC_A=OP\_P"AA_\ )*X_
M^-UZ!10!Y_\ \+M^'G_0P_\ DE<?_&Z/^%V_#S_H8?\ R2N/_C=>@44 >?\
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MZ/\ A=OP\_Z&'_R2N/\ XW7H%% 'G_\ PNWX>?\ 0P_^25Q_\;H_X7;\//\
MH8?_ "2N/_C=>@44 >?_ /"[?AY_T,/_ ))7'_QNC_A=OP\_Z&'_ ,DKC_XW
M7H%% 'G_ /PNWX>?]##_ .25Q_\ &Z/^%V_#S_H8?_)*X_\ C=>@44 >?_\
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M+L_&6F7PT^6-"MW;QPY%UG())R,$@\\'D ]: .YHHHH **** "BBB@ HHHH
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M;4 %%%% !1110!Y_XM_Y*]\.O^XG_P"DZUZ!7G_BW_DKWPZ_[B?_ *3K7H%
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M;>,.MUG(R6#>A(S@]!Z5R'Q:FE\2_$/PKX#\R1+&Y875XL9QYB[F&/P5'/\
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M_:(\,ZU=$)97]L;8R'@!\.F"?JT?YUM^%/ACJ,'B:/Q3XRUPZSK$(Q;HHQ#
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M96LKW-S._FW5U(,-,_K[ =A]>I- '!?L_P!Q_9^G^(/"]T0FH6&H-(\9X."
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MDT'F#SHD:"9=N[:,MDG /5?X375UPWC_ .&]OXS>UU&UOI=,URR_X]KV+.0
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MK:UX@<$+*PQ'!V^4'OC@<  $X% 'HU%%% !1110!Y_\ %/\ YDK_ +&NQ_\
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M?&VB^%=+T32KN74M3N)VCN=5E7=Y$9;AL$YZ$<\]#[50^'"C_A9/C]L<B[0
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M_P!T60N!@)_<STQ[8Q[5WOASPYIGA71H=*TBW\FUCR>3EG8]68]R?\\5JT4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5B^)O"NE>+M.CLM6B=XHY!*A1]K!L$=?H36U10!6T[3[;2M-M
MM/M$V6]M&L4:]<*!@?4UGP^&--@\5W'B1%D_M&> 0.Q?Y=OR]O\ @(K9HH Q
MM)\,:;HNK:IJ=FL@N=3D$EP6?()!)X';[QIOB7PEH_BVR2VU>V\T1G=%(K%7
MC)ZX(]?3I6W10!QFF_"WPQ872W4MO<:A.@PCW\QEVCV'3].*D/PV\/MX67PX
MRW3:<MQ]H53,=RMC'!].2<>]=?10!BZSX6TS7KG2[B^64R:9,)K?8^W# @\^
MOW15'QAXTT#PW975OJES&;E[9G2S():8'( X[$@BNHK-OO#^CZG>Q7E_I=G=
M7,(VQRS0J[*,Y &1ZDF@#D_A#X:?P]X)BEN(C'>:@_VF16&"JD813^'/U8UW
MU%% !7/^)?!6@>+$3^UK%994&$G1BDBCTW#J/8Y%=!10!YS:_!'P=;7"RR17
MMRJ_\LYKCY3]=H!_6O0;:V@L[:.VMH4A@B4*D<:A54#H !TJ6B@#@[[X/^$+
M[47O/LD\!D),D-O,4C;/MV'L,5MZ7X*T/1=975-.M3;S+:BT5$;Y!&"#T]<C
MKU-=#10!XMX;\+:1XJ\>>/+;5;;S!%?(\4B,5>-MTG*L.1_+@>E=_P"&_AYX
M>\+WK7UG;RS7S C[5=2&1P#UQV'U S706VF6%G<W%S:V5M!/<G=/+%$JM*>>
M6(&6/)Z^M6J /)O&NGVFJ_&SPQ8W]NEQ:SV,JR1N.&&)?\Y[5OV/PC\)V6H1
MW9MKBY\H@Q0W,YDCCQZ+W'L<BNPETRPFOX;^6RMI+V$%8KAXE,D8.<A6QD#D
M]/4U:H Q_$GAG3O%>EC3M461K<2"4"-]IW $#G\36NJA5"CH!@4M% ')Z_\
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M"X,]G>W(Q'+"68X5SP.J\>V.U26MQ;>+/V@K'6O"Z^=I]A:-'J-_$I$4CE7
M&>C'YD'X9Z+4/PMT&Q^(\.I>+_%JC5;Q[QH(;>=BT5L@56PJ=/X@/H/4FI/$
MFF0?#+XD^%KOPSOM;+6KG[)>::CDQ/\ ,B[E4]_G'T('J: /;**** "BBB@
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M^9*_[&NQ_P#9Z] KS_XI_P#,E?\ 8UV/_L]>@4 %%%% !1110 4444 %%%%
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MM& 3T^]DGCMR.:I7OA7QKHD5OJ?A?Q5?:VXD4R6=],K)*IZD,S8 ]A@\\'-
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M ."7_)(="_[>/_2B2O0*\_\ @E_R2'0O^WC_ -*)* /0**** "BBB@ HHHH
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M3<6 Q^OTST]9HH CM[>*UMHK>WC6.&) D:*,!5 P /8"I*** "BBB@ HHHH
M**** "BBB@#S_P"*?_,E?]C78_\ L]>@5Y_\4_\ F2O^QKL?_9Z] H ****
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M2"*)$A10BQJH"JH&  .PQVKA;_X/^$[Z\EN%@NK59FW206TY2-_^ XX'L,4
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MGU.1;:RU>T AFD.U V$ZGH/FC8?B*]2N]8TVQL6OKJ_MHK55W&5I!MQ['O\
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M6N0JR>9*7X7.,?F: .EHHHH **** "BBB@ HHHH *\G^$'BSPWIGPMT:SO\
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M#_\ %4?\()X/_P"A4T/_ ,%T/_Q-'_"">#_^A4T/_P %T/\ \30 ?\)WX/\
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MJ:'_ ."Z'_XFC_A!/!__ $*FA_\ @NA_^)H /^$[\'_]#7H?_@QA_P#BJ/\
MA._!_P#T->A_^#&'_P"*H_X03P?_ -"IH?\ X+H?_B:/^$$\'_\ 0J:'_P""
MZ'_XF@ _X3OP?_T->A_^#&'_ .*H_P"$[\'_ /0UZ'_X,8?_ (JC_A!/!_\
MT*FA_P#@NA_^)H_X03P?_P!"IH?_ (+H?_B: #_A._!__0UZ'_X,8?\ XJC_
M (3OP?\ ]#7H?_@QA_\ BJ/^$$\'_P#0J:'_ ."Z'_XFC_A!/!__ $*FA_\
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M#_\ H:]#_P#!C#_\51_PG?@__H:]#_\ !C#_ /%4?\()X/\ ^A4T/_P70_\
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M#_\ H:]#_P#!C#_\51_PG?@__H:]#_\ !C#_ /%4?\()X/\ ^A4T/_P70_\
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MOP?_ -#7H?\ X,8?_BJ/^$$\'_\ 0J:'_P""Z'_XFC_A!/!__0J:'_X+H?\
MXF@ _P"$[\'_ /0UZ'_X,8?_ (JC_A._!_\ T->A_P#@QA_^*H_X03P?_P!"
MIH?_ (+H?_B:/^$$\'_]"IH?_@NA_P#B: #_ (3OP?\ ]#7H?_@QA_\ BJ/^
M$[\'_P#0UZ'_ .#&'_XJC_A!/!__ $*FA_\ @NA_^)H_X03P?_T*FA_^"Z'_
M .)H /\ A._!_P#T->A_^#&'_P"*H_X3OP?_ -#7H?\ X,8?_BJ/^$$\'_\
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M_P!"IH?_ (+H?_B:/^$$\'_]"IH?_@NA_P#B: #_ (3OP?\ ]#7H?_@QA_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KA_B3_ ,RC_P!C
M+9_^SUW%</\ $G_F4?\ L9;/_P!GH [BBBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ KA_B3_S*/\ V,MG_P"SUW%</\2?^91_
M[&6S_P#9Z .XHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *X?XD_\RC_V,MG_ .SUW%>;_$C7M&:X\-6XU:P,]IXBM9+B,7*;
MH57?N9QG*@=R>E 'I%%5;#4K#5;<W&G7MM>0ABIDMY5D7([94D9Y%6J "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH R/%.L2>'_  OJ&K11++):Q&18W. W/>O(
M(/COKDR&5?#,4L*G#-&[X!],X(%>F?$G_DG.N_\ 7L?YBO,?@YXR\/\ AOP[
M?VVKZE':S27?F(K(QRNQ1G@'N#0,VO#_ ,=;2_U:.QUG2CIR2.$%PLV]4/\
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M_P *2^'G_0O?^3MQ_P#'*/\ A27P\_Z%[_R=N/\ XY0!Z!17G_\ PI+X>?\
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M)?#S_H7O_)VX_P#CE'_"DOAY_P!"]_Y.W'_QR@#T"BO/_P#A27P\_P"A>_\
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M?]"]_P"3MQ_\<H ] HKS_P#X4E\//^A>_P#)VX_^.4?\*2^'G_0O?^3MQ_\
M'* /0**\_P#^%)?#S_H7O_)VX_\ CE'_  I+X>?]"]_Y.W'_ ,<H ] HKQ^?
MP3X=\'?%[P)_8&G_ &/[5_:'G?OI)-VVW^7[['&-S=/6O8* "BBB@ HHHH *
M**\?@\$^'?&/Q>\=_P!OZ?\ ;/LO]G^3^^DCV[K?YON,,YVKU]* /8**\_\
M^%)?#S_H7O\ R=N/_CE'_"DOAY_T+W_D[<?_ !R@#T"BO/\ _A27P\_Z%[_R
M=N/_ (Y1_P *2^'G_0O?^3MQ_P#'* /0**\__P"%)?#S_H7O_)VX_P#CE'_"
MDOAY_P!"]_Y.W'_QR@#T"BO/_P#A27P\_P"A>_\ )VX_^.4?\*2^'G_0O?\
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M27P\_P"A>_\ )VX_^.4?\*2^'G_0O?\ D[<?_'* /0**\_\ ^%)?#S_H7O\
MR=N/_CE'_"DOAY_T+W_D[<?_ !R@#T"BO/\ _A27P\_Z%[_R=N/_ (Y1_P *
M2^'G_0O?^3MQ_P#'* /0**\7\8?#OPKX1U'P=?Z'I7V2ZD\2V4+/]HEDRA+$
MC#L1U4?E7M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[^=KE5/4)@*OY[<_0BO1J155$"JH55&  , "EH$%%%% !1110 4444 %%%%
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M_P#S<+_W*G_MW7H% !1110 4444 %>?_  L_YG7_ +&N^_\ 9*] KS_X6?\
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M_P#BG_S)7_8UV/\ [/7H% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2K61@%N)8CCGH2"!^F?QKT:RO;;4;*&\LYDFMID#QR(<A@: )Z*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHJIJE\NEZ3>Z@Z%TM8'G9%."P52
MV!^5 %NBL?PKX@B\5>&[36H('@CN=^(W()&UV7M_NUL4 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>?_"S_
M )G7_L:[[_V2O0*\_P#A9_S.O_8UWW_LE 'H%%%% !7D?Q>_Y'KX:?\ 88'_
M *-@KURO-?B9H.JZOXO\!76GV,MQ!8:F);IT'$2>9"<GVPI_*@#L/%WB!/"O
MA/4M;>/S?LD6Y8\XW.2%4'V+$5Y)X4^$S^+](/BC6=8NM/NM87[0+;252WB5
M6^[N !W9!SVZ\DG)KU[Q1H,/BCPQJ&BSR&-+N(IO SL;JIQWP0#7F7AOQ!XZ
M\!Z1%X<U7P5>:NMF#%:WFG/N1T_A!X.![G!QCCB@"3X9W%UX+\9W_P .+]+:
M1$C^UV=Y#"(VF7C[^.IQW/(VD9(Q7L%>8>!/#'B"^\:W_COQ5;I97=Q#]GL[
M!6#&&/CECZX _-LXX%>GT >*^*=*M=8_:6\/6]["DUNFFB9HW&02GG,N1W^8
M _A5C]HRVBE\$:5*47SAJB1JY'(5HY"1]"57\JV-1T'59?V@-)UR.QE;3(M,
M:*2Y ^17_>\?7YA^='QNT'5?$/A#3[72+&6\GCU..5TB&2$$<@)^F2/SH Z#
MQ/H]A8?"W6-*@M8EL[?2IECBVC VQD@_7(!SUSS7BNK7]U%^S!X:MXY"J7M^
MUO,_;8)9F /XHOY5[[XJMIKWPAK=K;1M)/-83QQHO5F,;  ?4FO/-%^'EUKG
MP$LO"VJ1-8:E&998_-',4GG2,I('8JV/HU 'I=EHNG:?HD6C6]I$-/CB\D0%
M 59<8.1WSWSUS7E/P1T^#2?$WC_3K;_CWM=12&/G.%5Y@!^0J[I_B#XK6>G1
MZ)/X-@N-1C3REU5[Y1"0.!(R]2<<GD$^G:LWX"6MS::KXVBO)Q<7$=\D4LP.
M?,=6E#-^)Y_&@#VJN5\3:;X2\93'PQK$MK<7R+YRVZR@3Q#'WEQR.,>QXS75
M5Y=\0_!.OOXIL/&_@UHFUJS3RY;64@"=,$=R!G!(()'&,$$4 93_  2UC06:
M7P7XVO[#!R+>X)V-_O%, _BAK:^&7C;7-3UG5O"7BN./^W-+&\S1@ 3)D D@
M<9^92",9##@8YS5^)OQ!V_9F^&%Z;P\"42.(L]/[F/\ QZM7X:^#-;T[6=6\
M6^*GB_MW50%,$1!$$?!VDC(S\JC )P%')S0!@_ Y19^(O'.G3C;>17X+[NK
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M+X)TJ8HOG+JB1*Y'(5HY"1],JOY5L:CH.JR_M :3KD=C*VF1:8T4ER!\BO\
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M!'D';D'&>%&!G 4<G- '/_ L"TU_QQI\XVWL5^/,!ZD!I!^AS^=>T5Y3XO\
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M6G:;XJL(,^1:^)+N"+<<G8BQJ,GOP!0!Z/1110 4444 %%%% !1110 4444
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MD7=@L3CYMW))^F*W?AQH]GH'Q'\>Z78(R6MNNFJ@=RQY@8G)/N30!Z?1110
M4444 %%%% !1110 4444 %%%% !1110 A 8$$ @\$&O(]-\'_$/P#+=V?A*[
MTG4M&FE,D,&IE]\&<# P1V '7!QT%>NT4 ><^$? 6LQ>,)_&7B_4+>[UEXO)
M@@M0?)MTQC@GGID8QW)R2:]&K*OO$V@:9="UO]<TVTN#C$,]W'&_/L3GO6G'
M(DT2R1.KQN RLIR&!Z$&@!U%%% !1110 4444 %%%% !1110!Y_\4_\ F2O^
MQKL?_9Z] KS_ .*?_,E?]C78_P#L]>@4 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !7(>/_  1_PF=E9+!>_8;VTE+Q7&S=A2,,O!'7"_E77T4
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M:03L>R;3G\?3WK3KD/%7PYT?QAJUO?ZE<7RF*,1-##*%CD4,6&X8)SDGD$4
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ME>?N9E02(RNS[E=3U!VK^70UV>E_#[4;CQ);Z]XNUS^U[JT.;2!(A'%$>H;
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MK%&<Q6D6<B-/4]"6[G]>HH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *\_\ A9_S.O\ V-=]_P"R5Z!7G_PL_P"9U_[&N^_]DH ]
M HHHH **** "BBB@ HHHH *\U^"V@ZKX?\.ZO!JUC+:2S:G)+&L@P60H@!'M
MP:]*HH \U\1Z#JMW\<O"NLP6,LFG6MI(D]P!\L;%9< _]]#\Z]*HHH ****
M"BBB@#QN+2_%'PN\7:O>Z/H<NO>'=6E\]H;8_OK=\DX"XR1R1T.1CD&DU*Q\
M4?%G6M*AU#0+C0?#5A.MS,+PXFG<#@!<9'&1TXR3G.!7LM% !1110 4444 %
M%%% !1110 4444 >?_\ -PO_ '*G_MW7H%>?_P#-PO\ W*G_ +=UZ!0 4444
M %%%% !7G_PL_P"9U_[&N^_]DKT"O/\ X6?\SK_V-=]_[)0!Z!1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .<\?\
M_)/]?_Z\9?\ T$US'PP\,>']0^'6D75[H6F7-Q(LF^6:TC=VQ*X&21D\ 5V_
MB'2FUSP[J&EK*(6NX'A$A7(7(QG'>JW@_0&\+^%;'1GN!<-;!P957:&R[-TR
M?6@#D?B?X8\/Z?\ #K5[JRT+3+:XC6/9+#:1HZYE0'! R.":9=_\F\+_ -@B
M/^0KL?&&@-XH\*WVC)<"W:Y" 2LNX+AU;ID>E4IO"4DOPW'A3[8H<6:VOVCR
M^,C'.W/MZT <_P##WP;X:U'P#H]W>:'83W$L)+RR0J68[CU-<Y\3O#^F^ UT
MSQ'X8SIFHBZ$7E0L=DJ[23E?P (Z$'FM>P^&OC/3+&*RLO'LD%M"-L<:6W"C
MK_>J]IWPJ:36[?5O%'B&[UZ:V(:&*5-D:GKR"S9&><#&<<YH&7O&_A_2O%;:
M5:7&L+I.OQYEL2D@\T$C+?+D$CY>H(P1UKF=0O?B9X M&O[Z[LM>TB CS688
MD520.3@'//7YL9KM/&G@B+Q8EG<0WLNGZI8OOM;R(9*'K@C(R,@'V_.L&Y\!
M>+?$$"6'B7Q@)],#*98+6U6-I@#G!88Q^1^E BWXX\9PVWPJ;6;1BDFJ6Z1V
MP)^93(O/XJNX_45SOA3PM\2]!\.VUGIE[H%O;L/.\N=7,@+<D-\G4=/PKJ?$
M?P^37;_P]&EU';Z-HY4BQ$9/F8QQG/3"@=^I]:[>@#PW1AK?@/XN0/XADLV7
MQ"&662S)\HR%N#R!AMV,^SUO B#]HP_:B!Y^F8M=W^[SC_OEZZ;Q_P""%\;:
M7:P)=BSN[6;S8I]F[ Q@CJ.O!_ 5D^+-,T37M4T?0M2UB2Q\610K-:7EO&RE
MCSN([8)1C@D$=O<&:?Q4D@C^&NM?:"H5HE50>[[UVX_&KW@#_DG^@?\ 7C%_
MZ"*\U^(GA6]T[P;=7_B;Q=<ZK+$52QMS$(4,A8#) )W';N/MSUKU'P7;26?@
MC0[>52LB6,(93U!V#(H$:M[-);V%Q-#'YLL<3.D><;F R!^->7C1_&GC'Y_$
M?B*WT/3WZV&G2#S&'HS _P RWT%>I75M'>6DUK*"8YHVC?!P<$8/\Z\^_P"%
M(^#?^>%Y_P"!)H V_#?@[PGX9*?V9;6QNNGVB5Q)*Q]B>GT&*ZNN"T_X/^$]
M,U*UO[:&[$]K,DT9:X)&Y2",CZBN]H R)O$^DP>)H/#LMP5U.>(RQQ&-L,O)
MX;&/X6[]JY/XD>#O#S>"M2OH].M+*[LXC/#<6\2Q.'!R!E1SD\8/KZUK^,_
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M_84 >@45Y_\ \*L_ZGWQS_X./_L*/^%6?]3[XY_\''_V% 'H%%>?_P#"K/\
MJ??'/_@X_P#L*/\ A5G_ %/OCG_P<?\ V% 'H%%>?_\ "K/^I]\<_P#@X_\
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M -A0!Z!17G__  JS_J??'/\ X./_ +"C_A5G_4^^.?\ P<?_ &% 'H%%>?\
M_"K/^I]\<_\ @X_^PH_X59_U/OCG_P ''_V% 'H%%>?_ /"K/^I]\<_^#C_[
M"C_A5G_4^^.?_!Q_]A0!Z!17G_\ PJS_ *GWQS_X./\ ["C_ (59_P!3[XY_
M\''_ -A0!Z!17G__  JS_J??'/\ X./_ +"C_A5G_4^^.?\ P<?_ &% 'H%%
M>?\ _"K/^I]\<_\ @X_^PH_X59_U/OCG_P ''_V% 'H%%>?_ /"K/^I]\<_^
M#C_["C_A5G_4^^.?_!Q_]A0!Z!17G_\ PJS_ *GWQS_X./\ ["C_ (59_P!3
M[XY_\''_ -A0!Z!17G__  JS_J??'/\ X./_ +"C_A5G_4^^.?\ P<?_ &%
M'H%%>?\ _"K/^I]\<_\ @X_^PH_X59_U/OCG_P ''_V% 'H%%>?_ /"K/^I]
M\<_^#C_["C_A5G_4^^.?_!Q_]A0 ?%/_ )DK_L:['_V>O0*\_C^$]G_:.GWE
MYXJ\5ZA]@NX[R&&^U 2Q^8ARI*E/J.,'!/->@4 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<[XI\%:/XOBA
M_M&.5+B YAN;=]DL?T/([=P:Z*B@#@[/X3Z'%J$-YJ-]JNL/ VZ)-1N?,1>>
M. !GMUX/I7>444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M9C\K[F5BOJH90&_,5W'BSQY;^'/!]KXCM;3^T+>Z:,1KYOE95U+ YVGTZ8H
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH ***\?\->&KSQCJ/BN\O/&/BNS^R^(+NSAAL=3,<:QJ05
M4@XQN(XXP!Q0![!17G__  JS_J??'/\ X./_ +"C_A5G_4^^.?\ P<?_ &%
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M (59_P!3[XY_\''_ -A0!Z!17G__  JS_J??'/\ X./_ +"C_A5G_4^^.?\
MP<?_ &% 'H%%>?\ _"K/^I]\<_\ @X_^PH_X59_U/OCG_P ''_V% 'H%%>?_
M /"K/^I]\<_^#C_["C_A5G_4^^.?_!Q_]A0!Z!17G_\ PJS_ *GWQS_X./\
M["C_ (59_P!3[XY_\''_ -A0!Z!17G__  JS_J??'/\ X./_ +"C_A5G_4^^
M.?\ P<?_ &% 'H%%>?\ _"K/^I]\<_\ @X_^PH_X59_U/OCG_P ''_V% 'H%
M%>3G1+SPC\4O!MG#XI\1ZC:ZE]M^T0ZEJ!F0^7!E?E  ZMGG/05ZQ0 4444
M%%%% !117DXT2\\7?%+QE9S>*?$>G6NF_8OL\.FZ@84'F09;Y2".JYXQU- '
MK%%>?_\ "K/^I]\<_P#@X_\ L*/^%6?]3[XY_P#!Q_\ 84 >@45Y_P#\*L_Z
MGWQS_P"#C_["C_A5G_4^^.?_  <?_84 >@45Y_\ \*L_ZGWQS_X./_L*/^%6
M?]3[XY_\''_V% 'H%%>?_P#"K/\ J??'/_@X_P#L*/\ A5G_ %/OCG_P<?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M75["Q:3[BW-RD9;Z!B,T :5%4DUC3))+:./4;1WN@6@59U)E ZE1GYNG:KM
M!17)_$GQ3/X.\#7^K6J!KM=L4&X9"NQP&/TY/X5PND?"*\\2:3::QXD\9:U/
M?W<:W %M. D6X9 &<],]L#TH ]FHKQWP^?%7P^^(MEX9OM0O-;\/:DA\BYF1
MF:W;G +<XY !&<8((QTKH_BAXZN_"=E8Z=HL*SZ]JTODV:,-P3D MCN<L  >
M,_0B@#OZ*\DM_@U?:I;K=>*/&FN7&IN-S?9;C;'&WHH(/ YZ;?H*KZ)>>*OA
MWX_L/#&KW]SKF@ZF"+2ZD5FD@;..3R< D @G&"",<B@#V.BBB@ HHHH \_\
MBG_S)7_8UV/_ +/7H%>?_%/_ )DK_L:['_V>O0* "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!)15/3-5L=9L4O=.N8[FV<D++&>"0<']:74]4L=&L'OM1NH[:V0@-)(< $G
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MW6I:19W<XO)$\R:(,VT*N!D_4UZUJ?\ R";S_K@__H)KSSX%?\D_D_Z_I/\
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MC'YY4T"#X9:/9^,I-7\8:]:0WMS=7;10)<H)$BC !P%/'<#_ (#[FI)K.W\
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M_,E?]C78_P#L]>@4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MC@'@#IWN^&_#FOZSXU_X3'Q5;Q64EO$8;"PC</Y0.1N8CC.&;ZD]L 5Z-10
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M\,(CJ_B3Q7XLY,%[=FWM6_O1H>OY;/R-=KXIL=4U/P[=V&CSP6]U<KY1FF)
MC0\,1@'+8SCIR>M6-"T:T\/:)::58J5M[9-JYZL>I8^Y))/UH T:*** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^&4"W4K2FUN9+>-F.2$&& S[;B![ 5Z90! ;ZT!(-U ".H,@I/M]G_S]P?\
M?P5X]>^ /@[-?W$MSXALEG>5FD4ZS&I#$\C&>.:@_P"%>?!;_H8['_P=Q_XT
M >X5S_CCQ$WA3P7JFMQQK)+:Q QJW0NS!5S[989K>0*(U"G*@#'TKF?B'J>B
MZ7X&U.;Q!$TVGR1^2T*?>E9N%5?0YYSVQGM0!P6@^ /$?BGPQ:^(=0\?:Y!J
MU_"+F$6TY2"$.,J-@([$9QM[CWKI/A)XMU/Q-H5]:ZTR2:GI5TUK-.@P)0.C
M<#&>"/PSWKA/#.A?%R/P4$T._M;+3)(RUE:7T@:[CB;E0'\O )!XR1CT6NL^
M"EWHJZ!?:196-Q8ZM93XU.&ZDWRM*>-^[ R/E(Q@8Q[Y(!ZA1110 4444 %%
M%% !1110 4444 >?^+?^2O?#K_N)_P#I.M>@5Y_XM_Y*]\.O^XG_ .DZUZ!0
M 4444 %%%% !7G_A+_DKWQ%_[AG_ *3M7H%>?^$O^2O?$7_N&?\ I.U 'H%%
M%% !1110 4444 %%%% $%Y?6FGVYGO;J"VA! ,DT@1<GMD\55O?$&BZ;.D%_
MJ]A:RO\ =CGN41F^@)YK@/C]_P DOG_Z^X?YFI=%^$GAG4/#,,VNV<FH:M?P
M+-=WTTK>;YC*"=ISA<9P![<YH ])1UD171@R, 593D$>HIU>3_ 6YNAX;UC2
MIKAIH=-U%X("_55P./IG)Q[FO6* (&O;5&*M<PJP."#( 12?;[/_ )^X/^_@
MKR?7? WPEO=?U"ZU37K.+4)KAWN8VU>-"LA8E@5)XYSQ6?\ \*\^"W_0QV/_
M (.X_P#&@#V\$,H92"",@CO6=XAU8:#X;U/5C'YGV*UDG"9QN*J2!^)&*L:9
M#:VVDV<%BXDM(X$2!U;<&0* ISWXQS5'Q7J.E:5X5U.\UM=VF) RW"8R75OE
MV@>K9 'UH \L\)^$O$7Q \.IXHUCQOK-I<WI=[6#3YS'%  Q4?*/IT&#ZG-=
M!\*/$^LZA<Z_X9U^X%Y?Z%<"$7@ZS)EEY]P4ZGDYYY!KBO!&D?$P^&Y9O"%W
M;Z7X?G9I+"VU602S*AYW(1&0 3DC.!SGG.3TGP6FT^QFUO0[JTNK7Q7'+YVJ
M&ZE$C3\_?5@!\N6S_P #!R<T >N4444 %%%% !1110 4444 %%%% 'G_ ,4_
M^9*_[&NQ_P#9Z] KS_XI_P#,E?\ 8UV/_L]>@4 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\_\ A9_S.O\
MV-=]_P"R5Z!7G_PL_P"9U_[&N^_]DH ] HHHH **** "BBB@ HHHH \C_:!_
MY%70_P#L,1?^@/7K$_\ Q[R_[A_E3;BTMKM%2YMXIE5MRB1 P!]1GO4W48-
M'D_[//\ R363_L(2_P#H*5ZQ45O:V]G%Y5M!%!'G.V) HSZX%2T <7-\)? M
MQ/)/+X>@:21B[L99.23DG[U1_P#"G_ /_0N0?]_9/_BJ[BB@!%4*H4#  P*X
M#XR^&K[Q/\/;BWTZ-IKJVF2Z6%?O2!000!W.&) [XKT"B@#S+1/C9X0ET"*7
M5+YK#4(8PMQ9O ^]7 P0N!@\CC]<53^$EE>ZIXD\3^-[BSEL[35Y0ME%*,,\
M8).\C_OGGN<UZ7/HFDW-T+J?3+*6X'_+62W1G_,C-7N@P* "BBB@ HHHH **
M** "BBB@ HHHH \_\6_\E>^'7_<3_P#2=:] KS_Q;_R5[X=?]Q/_ -)UKT"@
M HHHH **** "O/\ PE_R5[XB_P#<,_\ 2=J] KS_ ,)?\E>^(O\ W#/_ $G:
M@#T"BBB@ HHHH **** "BBB@#R_X_?\ )+Y_^ON'^9KT32?^0-8_]>\?_H(J
M>XMH+N+RKF".:/.=DB!AGZ&I  JA5   P .U 'DGP*_X]_%G_88?^5>N5#!:
M6UJ'%O;Q0[VW-Y:!=Q]3CJ:FH X^^^%G@G4[^XOKS089;FXD:660RR LS')/
M#>M5_P#A3_@'_H7(/^_LG_Q5=Q10!%:VT-E:0VMN@C@A18XT!^ZH& /R%<M\
M3?#UUXH^'NJZ78C==NBR1+G&]D</M_$ @>Y%==10!Y/X,^+OABS\*V>G:]=/
MI.J:; EM<6T\#@Y0!<C"]\=.H].]0?#I;CQ7\4=>\?1V<UKI$]N+2S,R[6GQ
ML&_W&(_U [&O4KK1M+OIQ/=Z;9W$R]))8%=A^)%7%544*JA5 P !@ 4 +111
M0 4444 %%%% !1110 4444 >?_%/_F2O^QKL?_9Z] KS_P"*?_,E?]C78_\
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M>@'P]X$L()%VW-POVJ?/7>_.#[A=H_"O.-?\+/=?&<Z! X.EZG-%JMY"O0;
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7Q#_ .BG_P#E M_\: /0**\__P"$2^(?_13_ /R@6_\ C1_PB7Q#_P"BG_\
ME M_\: /0**\_P#^$2^(?_13_P#R@6_^-'_")?$/_HI__E M_P#&@#T"BO/_
M /A$OB'_ -%/_P#*!;_XT?\ ")?$/_HI_P#Y0+?_ !H ] HKS_\ X1+XA_\
M13__ "@6_P#C1_PB7Q#_ .BG_P#E M_\: /0**\__P"$2^(?_13_ /R@6_\
MC1_PB7Q#_P"BG_\ E M_\: /0**\_P#^$2^(?_13_P#R@6_^-'_")?$/_HI_
M_E M_P#&@ \6_P#)7OAU_P!Q/_TG6O0*\_T_P%XB_P"$OT?7]?\ &?\ :_\
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M@#T"BO/_ /A$OB'_ -%/_P#*!;_XT?\ ")?$/_HI_P#Y0+?_ !H ] HKS_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ K,\00:M<Z'<Q:%>16FI':89I5#(N
M&!(((/49'3O6G10!QG@OP9>Z)J%_K>O:BNHZ[? )).BX5$&/E48'H.P' XKL
MZ** "BBB@ HHHH **** "BBB@ HHHH *R_$>A6WB;P_>:/=EEAN4P67JI!!5
MA]" :U** /,[3PQ\2]+L8]*L?$VE/8Q)Y44\T+><B#@<;2.!ZDUTO@CP;;^#
M-)EMDN'N[NYD\VYN7&#(WTYP!]3U-=/10 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
=44 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>img62602283_8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img62602283_8.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (4 GD# 2(  A$! Q$!_\0
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M#ZUS7AZS-EXAUV)KB2>4K;L\LIR68JV3CL/0#H*Z:LFTT-K349[X:I>RR7
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M/6O8JBCAV3RR;L^9CC'3 HYO(?+YGC__  D'Q)_YXZE_X+!_\;H_X2#XD_\
M/'4O_!8/_C=>RT4<R["Y?,\:_P"$@^)/_/'4O_!8/_C=/_MOXD^1YNV]^]MV
M?8$W],YV[,X]\8KV*HO)_P!*\[=_!LQCWS1S>0^7S/'_ /A(/B3_ ,\=2_\
M!8/_ (W1_P )!\2?^>.I?^"P?_&Z]EHHYEV%R^9XU_PD'Q)_YXZE_P""P?\
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MP![FO9*;*GF1.F<;E(S1S+L/E\SQU]=^)*2,GEW[;21N33E93[@A,$>XI/\
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M>*+;GS,\YZ8% $M%%% !5>Z+CR=A;_6KG'I5BHIIO)\OY<[W"=>F: ):***
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MB@"6BBB@ HHHH **** "H+RW-W93VXEDA,L;()(V*LA(QD$<@BIZ*$[ </\
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M5HV5OND$'Z41JJQJJ_=  'TI)E+P2*O5E('Y40J4@C5NJJ ?RH ?1110 5'
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ML_XT /HIGE+ZO_WV?\:/*7U?_OL_XT /HIGE+ZO_ -]G_&CRE]7_ .^S_C0
M^HDAV3RR[L^9CC'3 IWE+ZO_ -]G_&H(D8W,ZL7V#;M^8^G- %JBF>4OJ_\
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M.=J@9IU0PQY@C+%]Q4$_,>N*?Y2^K_\ ?9_QH ?13/*7U?\ [[/^-'E+ZO\
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ME_ZX'_T):P*W_"/_ "%I?^N!_P#0EK3!_P >/J"W.THHHKZ<L**** "BBB@
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MHVC7)T&VN;V]? C2YO&EVG^]F5^@ZX!&:FHH.:Y?ZUZ]AQ<N74JPZUK&[5K
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M_P 31R1[ASR_E/2HRK1JR?=(!'TIU>9_\*[U?_GXL?\ OM__ (FC_A7>K_\
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M>%4 +SG.1@<YS6C1119(+MF+%X3T6&6*2*U='A?S(2MQ(/*/.0GS?*IR<J,
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M6IJ@N8FE\K;CY9 Q^@H D\I?5_\ OL_XT>4OJ_\ WV?\:?10 SRE]7_[[/\
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M9<]:?Y2^K_\ ?9_QJ.YB:7RMN/ED#'Z"IZ &>4OJ_P#WV?\ &CRE]7_[[/\
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MT@C/]J67_@0O^-+_ &YI'_05L?\ P(3_ !KD?^%:_P#46_\ );_[*C_A6O\
MU%O_ "6_^RHM#N'-4['7?VYI'_05L?\ P(3_ !J/_A(-*^T>7_:-EMV[M_VA
M<9STZURO_"M?^HM_Y+?_ &5)_P *W7=M_M@;L9Q]GYQ_WW1:'<.:IV.O_MS2
M/^@K8_\ @0G^-']N:1_T%;'_ ,"$_P :Y'_A6O\ U%O_ "6_^RH_X5K_ -1;
M_P EO_LJ+0[AS5.QUW]N:1_T%;'_ ,"$_P :C?Q!I2S1H-1LBK9RWVA?EQ^-
M<K_PK7_J+?\ DM_]E2'X;J&"G6 ">@^S]?\ Q^BT.X<U3L=?_;FD?]!6Q_\
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MJH?$&E20J[ZC9(QZJ;A>/UJ3^W-(_P"@K8_^!"?XUR"_#=74,NL!@>XM\_\
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M%%% !1110 445#=75O96SW%U/'!"F-TDC!5&3@9)]S0E<&[$U%9'_"5^'_\
MH-6'_@0O^-'_  E?A_\ Z#5A_P"!"_XU?LY]F1[2'=&O161_PE?A_P#Z#5A_
MX$+_ (T?\)7X?_Z#5A_X$+_C1[.?9A[2'=&O161_PE?A_P#Z#5A_X$+_ (T?
M\)7X?_Z#5A_X$+_C1[.?9A[2'=&O161_PE?A_P#Z#5A_X$+_ (T?\)7X?_Z#
M5A_X$+_C1[.?9A[2'=&O161_PE?A_P#Z#5A_X$+_ (U/::YI6H2F*RU"VN9
MNXI#('('3.!VY'YT.$EJT-3B]$S0HIGFKZ/_ -\'_"CS5]'_ .^#_A4%#Z*9
MYJ^C_P#?!_PH\U?1_P#O@_X4 /HIGFKZ/_WP?\*/-7T?_O@_X4 /HIGFKZ/_
M -\'_"CS5]'_ .^#_A0 ^BF>:OH__?!_PH\U?1_^^#_A0 ^H8HF2ZGD.-K[<
M?@*?YJ^C_P#?!_PJ&.<FXF5L[5V[0%.1QS0!9HIGFKZ/_P!\'_"CS5]'_P"^
M#_A0 ^H?*;[=YO&WR]OXYS3_ #5]'_[X/^%0^>?MFSG9Y><;3G.?SH LT4SS
M5]'_ .^#_A1YJ^C_ /?!_P * 'U#+$SW4$@QM3=G\13_ #5]'_[X/^%0R3D7
M$*KG:V[<"IR>.* +-%,\U?1_^^#_ (4>:OH__?!_PH ?4-Q$TOE;<?+(&/T%
M/\U?1_\ O@_X5#/.5\K9D9D .5/3\: +-%,\U?1_^^#_ (4>:OH__?!_PH ?
M3)E+P2(.K*0/RH\U?1_^^#_A3)9ML+E=P8*2,H>M #X5*01H>JJ ?RI]0Q3;
MH4+;BQ4$X0]:?YJ^C_\ ?!_PH ?13/-7T?\ [X/^%'FKZ/\ ]\'_  H 9:1-
M#:I&^-PSG'UJ:JUK.7MT:3)8YR0I(Z^U3>:OH_\ WP?\* 'T4SS5]'_[X/\
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MR* ):*** "HY71-F\9W.%7CO4E130^=Y?S8V.'Z=<4 2T444 %-D95C9F^Z
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MC\: ):*** "J]J''G;PP_>MC/I5BHH)O.\SC&QRGUQ0!+1110 4444 %%%%
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MXF-[?M.)%'!Q<C]U_P!\E814>T:+]E%Z?+Y_UH=]I>IP:OIR7UNLBP.SA3(
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MDALWC1#CC<IE8MSZ,O\ 6BPAUI(9QJ-]I\\I'[EK>S>)4//W@TK;NW0KW_
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M .WOI6OM>YW?:#;S&3.,9W8STI2DY=.I=*$*?VD]$M^NOYW-#Q#;VNI>$?\
MA)9-,73M2FU62"1$>3;,"I=FPY)!#<'''7BN,KI+[1/&VJ2+)J&E^(+MT&%:
MXMYI"![$@U4_X1#Q-_T+NK_^ 4G_ ,3423;O8VI2C"-G)?>8U>S? 3_F8/\
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M ,51_P (7X?_ .@?_P"1I/\ XJCW/,/WGD,C\8>'(D")?84=!Y,G_P 33_\
MA-/#_P#T$/\ R#)_\34</@K0Q"HFL0TG<B:3_&I/^$+\/_\ 0/\ _(TG_P 5
M1[GF'[SR#_A-/#__ $$/_(,G_P 35>\\<Z-#:O);3FXF ^6(1NN3]2.*L?\
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M<36LUM#!()&:52A..< 'KFM(QBXW9E*4E*R1ZE11169J%1Q",;_+QRY+8/\
M%WJ2H;>)HO-W8^>0L,>AH FHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P )K_U+/B3_ , /_LJZBBBZ"S.7_P"$U_ZEGQ)_X ?_ &5'_":_]2SXD_\
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M]2SXD_\  #_[*NHHHN@LSDHO%XBWX\->)3O<O_QX>O\ P*I?^$U_ZEGQ)_X
M?_95T$!/VFY4G^,$?3:/\#5BBZ"S.7_X37_J6?$G_@!_]E1_PFO_ %+/B3_P
M _\ LJZBBBZ"S.4_X3!?.\W_ (1CQ+NV[?\ CP[9S_>I_P#PFO\ U+/B3_P
M_P#LJZBBBZ"S.7_X37_J6?$G_@!_]E1_PFO_ %+/B3_P _\ LJZBBBZ"S.2?
MQ>'FBD_X1KQ*#'G ^P=<_P# JE_X37_J6?$G_@!_]E74447069R__":_]2SX
MD_\  #_[*C_A-?\ J6?$G_@!_P#95U%%%T%F<E+XO$NS/AKQ*-CA_P#CP]/^
M!5+_ ,)K_P!2SXD_\ /_ +*NHHHN@LSE_P#A-?\ J6?$G_@!_P#94?\ ":_]
M2SXD_P# #_[*NHHHN@LSE)/&7F1LA\,^)!N!&?L'_P!E1'XR\N-4'AGQ(=H
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P#&C[%%_?G_ ._[_P"-2PR>=#')L=-ZAMKC#+D=".QI] %?[%%_?G_[_O\
MXT?8HO[\_P#W_?\ QJQ63XA\06WAO35OKJ&>9&F2%4@"EBS' ^\0/UH O?8H
MO[\__?\ ?_&C[%%_?G_[_O\ XU@3^.+"SAU(WUE?6MSI\ N);654,C1DX#*5
M<JPSQ]ZK]EKYN+5KNZTN]T^R6 SFYNGAV;< _P $C$<<\CL: -#[%%_?G_[_
M +_XT?8HO[\__?\ ?_&N7T_XCZ5J5[;PPZ?K"VUS((H+Y[)A!(Q.  W7D^U=
M#K6K0:%HUUJETDCP6R;W6( L1[9('ZT 3_8HO[\__?\ ?_&C[%%_?G_[_O\
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M0#\H*@#CBNNNKA+2TFN9 Q2)&D8+U( SQ6#I_C33M2N-%AA@NE;5X))X"Z*
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M=K&QBM[^#7K>">YDN2;EP6",!'@XA(./O 'L,U6TVQMHM.M=4CB"WX\6"(7
M^^(VGVLF?[I!.1T.:]4O=4MM/N+*"=F$E[-Y$( SEMI;GT&%-%GJ'VNZO(/L
MEW#]ED$?F31[4ER,Y0Y^8=L^M%PL>1:E]C?[0]^(V\1#Q)&&W\RK!YHV;>XC
MQC';/O7M-%%#8!1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !5/5[F.ST:]N9HII8HH'=XX<[V 4DA<8.:N5'<7$%I;R
M7%S-'##&-SR2,%51ZDG@4 >+/=6DUGX@.F6MI9V,WATR&&TN3,K.'QN<[0/,
MP<'ECZG-;;:/:0W3V=I9IMO/"LLLL07<)I0R;78?Q/ECR>:] U/6+>PL))XY
M;:6<V[SP0O<I%YP5=Q(9N ,8RW0 Y-)'KVG".R6[OK*VNKN)9$MVND);(SA>
M?F'N.M.XK'G6F?V:;3X>#2Q:*PEQ<^0H_P!?]F&XN!C+9QG//%:OQ$AU)?",
M2ZA>VTLC:C;;'M;8P[/F]&=\G_.*V9_'%GI\*OJ8M;5GU)K%%%]&_P JG!D8
MC[N,C<IY7(SUK<76]*:[BM%U.R-S*H>.$7"[W4C((7.2"* .)\06%S9^._!I
MGU:\O@US/@7"0C9^[[>7&OZYKC;62%_!MW#'JYN+Y=6=XM"W1LMP1*"-RJ!)
MCOG=MXKUC0=7U'4-4UBUU"UAMOL<J+$D;;FV,NX;CT)^G3ISUK>HN%CR^V+6
M7Q2;8=-U?[9>/N.#]LL,)R#_ -,AT'8GI@UTWC/1[W6?L$&G6:"\4NT>I-.T
M9LONY(V_,Q;^[T.WFNJHHN%BK9VLL6F16M]<?;91'LEF>,+YO')*CCGTKSS2
MYM-U+6?'FFZ1>V)-Y;0Q626\J8;%MM^0 X(!X..E>FT4AGF&FW,>L)X#TVR)
M:[TL*]\F/FMA'#L8/_=RW !ZU;\4:?::CX_N([RWCGC3PW-(JR#(#"48./49
M./3K7HE4+O3#=S[_ +;=0QD?-'$^T;AT8'J,>G0X&1UR-M;%0C%NTG8\LTB-
M+1= E@79)J'A^Z>\<'F=@H(9S_$02>3]*33+@:)IO@+Q%=QRG3+:TGAN)8HR
M_E%Q\I8#G'7\J]-_L21OOZK?'=\TFV3;N?LPQ]T#^Z.#@9!YR?V)(WW]5OCN
M^:3;)MW/V88^Z!_='!P,@\Y7-+L:>RI?S_@_Z_I?+BM*UJ,W_B_QK;Q3?V<\
M$,5FTD94W#HI'R@\X+%0/7-+K&A1V-AX(TF\19B=1!N@>DDC([29]06)KL_[
M"61XS=7D]T@=99(IL%'D4Y5L8^7!QP,#@?CKTTV^AG.,4_==SQRSLK:P\FZM
M85BGA\9&RBD7JEOYA7RAZ)@GY>E=%X#UC2[.^\36-UJ5G!=S>([KRH)9U61\
ME0-JDY.2,#'>O0:*=R+'G_Q!O=,-X-.NM.@N+MK"62&:[N3%&F>/W8PVZ7(R
M,+D>HS679QZ?)XD\%ZAK$-LWVK0X_P!_<HI\RXQ&5Y(Y?GCOS7JE%%PL<?X]
M\:V_A:TAM5N(XK^]RL4DBLR0KWD8*"3CL!U-/\+G3Q\/VC\+7C7@2*58[AT9
M6DGP26(8 \L:ZVB@9Y1:-IQ^'=Q_PC^W_A*CIF;KRP?M._*^;O[[LYQGGTJG
MK']F_9]7_P"$7V?V1_PC\GVOR/N>;D;-W;S,9SW]:]CHHN*QY>NFVMC?_9[2
M?^S([SPO))//&#_K-Z 2-CEF&X\]>:PH'O/^$8FLXH-+2RMM1M$O-1TZ-GMK
MJ##;F<*06VG9OP1G)SWKVVBBX6/);B"VMM+B,.K6E[H#ZS$;]+&W,5M!'LY4
M#>P\LMM+8..?K6E+<Z!IWB_P_J.GR6MOHJQ7D/GQ?+")3M.T'ISVQP>U>D44
M7"QXK86VG-X9\#WNJ6ULUDE_>)<2W,0*!2\I"MN'3(Z'O5Z^MS'?^*-:M%4R
MZ-JMO>IM'6(1 2*,=BA/Y5ZY11<+'D%Q;74FDZ/J]Z\,%EK&I2WM^UW 9(45
MEQ;B5=RY0 +U(&2,Y[]YX)@@M]!9+74XM0MC<2-$\$)CBC4G.Q 6;Y0<XY(P
M>*Z.BBX6"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "H;JVBO;.>UG7=#-&T;KZJ1@C\C4U% 'DVEZ%K4NA^(/[2L[@
MS:;I$^CZ>#&<SC#G>@QD[AY:@CK@BI/[-U>PU32;O2%OQ>R6]C#>V=Q8,UO(
MJ*,GS2,1E.<C@YZ>E>JT4[BL>6OINH06AN&T^\*6_C*2]=4MW9S!EAYBJ!EE
MY'0&KD=KJ5MX^%WH_P!O:TOKM9+ZUO;!EC0>7_K4E(P"!QMSG)]*]&HHN%C)
MT[0QIVJWVH?VC>7#WI!DCF$6P$#"XVH#P..2??)YK6HHI#"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
<* "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>img62602283_9.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img62602283_9.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $%!!8# 2(  A$! Q$!_\0
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M4 /_ +0@_P"FW_?A_P#"C^T(/^FW_?A_\*910 _^T(/^FW_?A_\ "C^T(/\
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MK?E<]O"95"O1C4<FK_YGJ_\ PDFC_P#00A_,T?\ "2:/_P!!"'\S7E%%<O\
MK!5_D1T_V)3_ )V>K_\ "2:/_P!!"'\S1_PDFC_]!"'\S7":;X4U+4[87$8B
MBC;[IE8C=]  :H:GI5WI%P(;I "PRK*<JP]JWGFV+IP52=*R?J81RS#2G[.-
M77MH>E?\))H__00A_,T?\))H_P#T$(?S->45?_LBX_L;^U-\7D;]FW)W9_+'
MZUG#/*\[\M-:*[]#26348VYIO70](_X231_^@A#^9H_X231_^@A#^9KRBBH_
MU@J_R(O^Q*?\[/5_^$DT?_H(0_F:/^$DT?\ Z"$/YFO**MC3KG^S3J!3%N'"
M!B?O'VJHY[6E?EIK3U)EDU*.\V>F?\))H_\ T$(?S-'_  DFC_\ 00A_,UY1
M6A=:-=V>EP:A.%6.9MJH2=W0G)&.G%..>5Y)RC35EN*63T8M)S>IZ/\ \))H
M_P#T$(?S-'_"2:/_ -!"'\S7E%%1_K!5_D1?]B4_YV>K_P#"2:/_ -!"'\S4
MIUO3A$DIN5$<F=C[3AL=<''->1UTTO\ R*^C?]M__0ZZ<-G-2MS7BM%?\4OU
M.',,NCA:2G&5];?F=I_;VE_\_B?D?\*/[>TO_G\3\C_A7GE%:_VK/^5'C\QZ
M'_;VE_\ /XGY'_"C^WM+_P"?Q/R/^%>>44?VK/\ E0<QZ'_;VE_\_B?D?\*/
M[>TO_G\3\C_A7GE%']JS_E0<QZ'_ &]I?_/XGY'_  H_M[2_^?Q/R/\ A7GE
M%']JS_E0<QZ'_;VE_P#/XGY'_"C^WM+_ .?Q/R/^%>>44?VK/^5!S'H?]O:7
M_P _B?D?\*/[>TO_ )_$_(_X5YY11_:L_P"5!S'H?]O:7_S^)^1_PH_M[2_^
M?Q/R/^%>>44?VK/^5!S'H?\ ;VE_\_B?D?\ "C^WM+_Y_$_(_P"%>>44?VK/
M^5!S'H?]O:7_ ,_B?D?\*/[>TO\ Y_$_(_X5YY11_:L_Y4',>A_V]I?_ #^)
M^1_PH_M[2_\ G\3\C_A7GE%']JS_ )4',>A_V]I?_/XGY'_"FS^(M(MK87$]
M]%% 7V"63*KNQG&3QG'.*\^JCXT_Y)W#_P!A9?\ T4U=>"QDL165-JUQQ=W8
M]%_X33PU_P!!RQ_[^BC_ (33PU_T'+'_ +^BOFJBO=^JKN:\A]*_\)IX:_Z#
MEC_W]%'_  FGAK_H.6/_ ']%?-5%'U5=PY#Z5_X33PU_T'+'_OZ*/^$T\-?]
M!RQ_[^BOFJBCZJNX<A]*_P#":>&O^@Y8_P#?T4?\)IX:_P"@Y8_]_17S511]
M57<.0^E?^$T\-?\ 0<L?^_HH_P"$T\-?]!RQ_P"_HKYJHH^JKN'(?2O_  FG
MAK_H.6/_ ']%'_":>&O^@Y8_]_17S511]57<.0^E?^$T\-?]!RQ_[^BC_A-/
M#7_0<L?^_HKYJHH^JKN'(?2O_":>&O\ H.6/_?T4?\)IX:_Z#EC_ -_17S51
M1]57<.0^E?\ A-/#7_0<L?\ OZ*G?Q1HD=O#</J=NL$V[RI"V%DP<':>AP>#
MBOF.NVU7_DGOA+_M\_\ 1HJH8.,IJ-]_\CGQ,_8TG-=#V'_A,/#O_09L_P#O
MX*/^$P\._P#09L_^_@KYZHKJ_LN'\QY?]IS_ )3Z%_X3#P[_ -!FS_[^"C_A
M,/#O_09L_P#OX*^>J*/[+A_,']IS_E/H7_A,/#O_ $&;/_OX*/\ A,/#O_09
ML_\ OX*^>J*/[+A_,']IS_E/H7_A,/#O_09L_P#OX*/^$P\._P#09L_^_@KY
MZHH_LN'\P?VG/^4^A?\ A,/#O_09L_\ OX*/^$P\._\ 09L_^_@KYZHH_LN'
M\P?VG/\ E/H7_A,/#O\ T&;/_OX*/^$P\._]!FS_ ._@KYZHH_LN'\P?VG/^
M4^A?^$P\._\ 09L_^_@H_P"$P\._]!FS_P"_@KYZHH_LN'\P?VG/^4^A?^$P
M\._]!FS_ ._@H_X3#P[_ -!FS_[^"OGJBC^RX?S!_:<_Y3Z%_P"$P\._]!FS
M_P"_@I\7BO09I4BBU6VDD=@J(CY+$\  =S7SO6IX:_Y&K1_^OV'_ -#%*661
M46^8<<RDY)<I[?-XS\-6\\D$^MV44L;%'C>4*RL#@@@]"#3/^$Y\*_\ 0P:?
M_P!_Q7S?XN_Y'77O^PC<?^C&K&KYAXN2=K'VT,GA**?,]3ZI_P"$Y\*_]#!I
M_P#W_%'_  G/A7_H8-/_ ._XKY6HI?7)=B_[%I_S,^J?^$Y\*_\ 0P:?_P!_
MQ1_PG/A7_H8-/_[_ (KY6HH^N2[!_8M/^9GU3_PG/A7_ *&#3_\ O^*/^$Y\
M*_\ 0P:?_P!_Q7RM11]<EV#^Q:?\S/JG_A.?"O\ T,&G_P#?\4?\)SX5_P"A
M@T__ +_BOE:BCZY+L']BT_YF?5/_  G/A7_H8-/_ ._XH_X3GPK_ -#!I_\
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M'KFH-<1!JDLL<\,R2G>#$^['L?>L:K@Z/NI+WF-]436&JSP6\5GI]NJ7+/\
M-+PQ?VP1Q3O$\446J+Y:JKM&&D"]-U7]#6TL].:X6ZLQ?2 [?.E "#W[UA:E
M%)'=%I;J"Y>3YB\+[A5U^94$I.[T^7E_F);%.BBBN 04444 %4?&G_).X?\
ML++_ .BFJ]5'QI_R3N'_ +"R_P#HIJ]/*/\ >HEPW/+Z***^T-PKN_AYIM@M
MMJWB'4;<7,>EQ;XX6&0SX)S^G'USVKA*[/P%KVG6 U'1]9<QZ?J4?EM(/X&Y
M&3Z=>O; J*E^1\NY,OP-1_BA!J]C=V7B#1()H'0B 6_!0]LEB<'_ &AZ=*P=
M'\')>Z$VN:KJD6EZ;O\ +CD:(RM(V<<*,>_Y'BMYO#'@?1;.[NK[Q%'JF4(@
M@M9%#@]ONL<GMDX'7BH[.YTWQ-\/;707U2UTZ_L9RZ?;)-D<BDM_%]&_,=.:
MQ323]FNP=NP[1/"L_AWQYH$RW,=Y87;%[>ZB& XV'J.QYJSK7@:#7?$VM_9=
M=MSJBL\YL1"W"GH"^<9Y&< XS5Q-?T>RU7PIH<&HP3PZ:Q:XO=X$0;8PP&/&
M.3W]*K^'-6TZ#XHZ_>3:A:QVTL<HCF>90CY9<88G!Z5#<[\W9/\ ,6N_I^IR
MVC^#5O-#?6]6U2+2].W^7'(T1E:1LXX4$>_Y'BK;_#R=?$&EV*ZA'+8:D"UO
M?11[@0%+<KG@_CWK0M;G3?$_P_MM!DU6TTZ_L9RZ&[DV1R*2W\7T;]/>MF#Q
M!H]CJ_A70X=2@FATTNUQ>EPL6XQL,!CQC)/?TK1SGS.W]*VX-O7Y_P# ,W0_
M!F@6/C*VL+O78;ZYBE97L39MM8A20"V<=.3U'&*Y;QS;6=MXMOUL[L7 :5VD
M B,8B?<<ISUQQR.*U+#5;.V^+CZC-=1_9/MTI\\-E-K;@#D=N1S65XUMXHO%
M-[/!?V=Y%=2-.CVLHD"AF/RL1T;VHAS<T6WT+M9M?UU.C\":[J<OV'0M!T^"
M&59O.O;IBI,L61D$$<=<<'/3%87Q 6Q3QI?II\/DQJ0'785&_'S$#TS5S2?#
M^@ZCI-C=VGB.+3]3CD!NDOIEC"@'K'P"3T(Y_*HOB-K=AKGBCS]/82110K$9
M@,>8P))/TYQ^%.R]K=>=_P"OR)AU.1HHHK<H*[;5?^2>^$O^WS_T:*XFNVU7
M_DGOA+_M\_\ 1HJJ?\6/K^C.+,?]WE\OS.;HHHKTSYH*V_".D1:WXFL[&?/D
M,2T@!QE5!./QQBL2M;PUK']@^(+34"I9(V(D4=2I&#_.IJ<W(^7>Q<+<RYMK
MG;7/Q'33=8ETR+2+7^QX',+1JN'(!P2/X?PQ^-<Y9Z%%XKUG4+K3PFF:5#^]
MD>7D1 CH /H3CL.]=#/X>\':AJK:P?$ENEG*_G26A8*Y)Y(ZA@/;&:K:)JOA
M_P#XG^A0W#65A?#%K/.> 0,')[#N,]J\Z#C"#=)/FMKO\_5GHS4IS2JR7+?3
M;^DC$U/PFEMHXUC2M3CU.P5]DKK$8VC/NI)XY'YBNU\9>';/6_$=A'<:S%93
M36ZQP1&(R-(P)/." HYXR>:P9[FP\,^![O1DU.UU"^OI=Q^R2;XXUX_B^@_7
MVJ[XBU2PG^(N@W45];26\2Q;Y4F4HF&.<G.!3;J2FFGMS6=O)"2IPIRTU:5U
M?S.=L?!%Y<ZSJ%E/<PVT&G\W-TW*J,9! [\<]J34O"*0Z0NK:5J<>I6 D\N6
M18C&T9SCE2>G(_,5U7]N:3<ZSXHTF>_AA@U''D788-'G8!RPX_\ U&LU[G3_
M  SX+N='74[6_O;Z8,WV23?'&O');Z#]?:JC6K-J_P#=TMO?<F5&BE*VWO:W
MVMM_74@U/P-I6B74<.H^)DB=PK(GV-B67.#T;C^O-/\ B9INFV%_:+9RI%(L
M"H+-(2H5,L=^[H<GMU[U7^(^H6M[XGMYK2ZAN8DMD&Z&0.H.YLC([U+\1I+/
M4KVUU:RU&SN(GA6+RHY<RJ1N.2O8<]Z*;J-TY3;UO_6P35.*J1@EI;_@]3"\
M,:,FKZH3<MLL+53/=2'@!!VSZGI73?%-XY)]&>)=D;6I*+Z#C K#T3Q-8:9H
M5SI5YHOVV.XE$DC"Z:$L!C"G:,X!!/7O6W\0]6TB^LM+CLT@EF$((EBN=_DK
MC_5D#OTY//%5/G>)BVM-;?=N13Y%AYI/5[_?M_7<\_HHHKN.$*U/#7_(U:/_
M -?L/_H8K+K4\-?\C5H__7[#_P"ABIJ? _0NG\:]3F_%W_(ZZ]_V$;C_ -&-
M6-6SXN_Y'77O^PC<?^C&K&K\ZE\3/V&E_#CZ(****DT+NCV']J:U8V&XK]IG
M2+<.VY@,UZUX@\?1^ -83PYH6CVGV.T5!<&0$-(2 >".^#U.>37D6FWTFF:G
M:WT0S);S+*H/<J<_TKUC6-*\%^/+^+7QXIM]+DE1?M5M.R*Y(&.-S#!P,9^8
M=*ZZ3?L_<>M]?0\W&*#JQ=9-PL^^_P O+8Y34+>U^(GC>./PSIWV 3Q[IO-P
MJ@C.YR%Z=OJ?K5BX^&L$UKJ!T+Q%;ZK>Z>";FU6W,;#'7:22&[]/3UK5T?7_
M  ?X6^)*OH[2KI3VQMIKAF9E#D@[AGG;P!G\1Q5K0SH7@"76M9/B*PU(W$;1
MV=M:3;Y&!.1O ^Z>GZ_2CD@XW?G=^?0RE6JPLJ=UHK)K?O=^7J3ZCI5CJGPG
M\++J6L1:7;1D$S/$9"6(8 !1U_H!7)7WPRU.W\86V@6MS#<BYB\^.YP541]R
MPYQCTYZBKWBG4[&Y^%?A>SAOK:2ZADS+ DJETX;[R@Y'7O77WWC/1--^(&C7
M9O[>>T?3#;2S02"00L6!&[;G'0?G6DHTYS;EW_0RA.O2A[FM^;2W9G$W'PU@
MFM=0.A>(K?5;W3P3<VJVYC88Z[220W?IZ>M+'\.=.A\-:;K>I^*([""^485[
M,N58]%&&Y[\\8K>T,Z%X EUK63XBL-2-Q&T=G;6DV^1@3D;P/NGI^OTK'\9:
MI8W7PS\+6EO?6\MQ"/WT,<JL\?R_Q*#D?C6<HPC!RMKII\S6-6O*HH*3Y;[V
M7:_;OY&GXQT+0+'X7Z.]I?QQM_K8I%M&!O7(YSW7CGGTQ7.?">Q%[X_LW;&V
MV1YSGV&!^I%:^OW.GZW\*-#2WU;3TNM-4^=:RS[96XVX5>I/?T]ZX_PG9:#J
M&L?9?$-Y/9VSH=D\3* K]MQ(/'6G)VQ%TO3[BJ49/"3C)N^M]+O<[OQ\_C2X
MT6_N9=7L-0\/R7!5H[(QOY(#Y568(#P< X)YZUY/7J+S:5X,^'NLZ0NMV&K7
MFIR;8DLI?,5%Z;F(Z' SCUQUZUY=6%;XM^B.C!? U:R3TTM?SL%%%%9':%>A
M_!?_ )'L_P#7I)_-:\\KT/X+_P#(]G_KTD_FM;4/XB./'_[M/T/H:BBBO6/C
MPK-@^[)_UUD_]#-:59L'W9/^NLG_ *&: ):*** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .
M+\;_ /'W:?\ 7-OYURM=5XW_ ./NT_ZYM_.N5KXC-_\ ?9_+\D?7Y7_ND/G^
M;"BBBO-/0"BBMO1-.MIK'4-0O(_,AMH\*FXC+GIT_P \UK1HRK2Y8^;^XSJU
M53CS,Q**TK;P_JEW;Q3P6A>*7.Q@Z\X_'CIWIIT/4AJ L#:D7++N"%E&1Z@Y
MQ5?5J^CY'KY,7MZ5VN9:>:,^BMH^$M< )-EP/^FJ?XUI>&_#$5VB7>H[6AE4
M^5"'(+^IX]*VI9?B*D^3E:];HRJ8VA"#GS)V[:G)T5O^&M+MM0U*Y%U"9((8
MV8H"1DYXZ<U'>O8QSV\;Z#+98D#2"29R73N,'&/K4K!R=.-1R24MM^]NUOQ*
M>)7M'32;:]/\S$HK6\1:8FEZL\4/^H=1)%SG"GM^8-9-85:<J4W"6Z-:=2-2
M"G'9A1116985TTO_ "*^C?\ ;?\ ]#KF:Z:7_D5]&_[;_P#H=>A@-ZG^'_VZ
M)X^>?[NO5?DRA11174?*!1110 4444 %/:&5(TD:-U1_NL5(#?0]Z2-#)*B#
MJQ KH]2MH[G7K/3"66".,(-IY'&?\*WIT7.-UO=)?,#FJ*Z--#TV>YNK.&YN
M#<P@D%@-OT]_TJK9VVA/:HUW>SQSG.]5!P.?]TT_JTENU]X[&-3VAE2-)'C=
M4?[K%2 WT/>M62+0HKR QW$\UOAC*""#[ <#K5OQ#,D^E:=+'&(XVW;4'8<8
MI_5TJ<I.2NNP):F)'87DT8DBM)W0]&6,D'\:8UM.BNS0R*J-M8E2 I]#Z&NH
M_=3V6GV5KJXMY1']V(D[F/8D'BJNE0S-/J>FW9+.Z$L2<_,.AS^-:RPB4N5/
MOKI:Z5P2V.<HHHKA$%%%% !1110 51\:?\D[A_["R_\ HIJO51\:?\D[A_["
MR_\ HIJ]/*/]ZB7#<\OHHHK[0W"BBB@ J>:SNK>&&:>VFBBG!:)WC*K(!W4G
MK^%.TZU-]J=K: X,\R1Y_P!X@?UKTGQ%IMKKWQ0L/#<K216%M;"%1"0"N(R_
M&01Z#IVJ)2LTO7\!7W\CRVBO2(? WAO4)]9T[3]2U!M1TX,VZ14\HXSQP,G!
MX)X]A6=I.F?#V;2K:34]=U""^9,S1QH2JMZ#]T?YFI56+V"YQ%3RV5W!;17,
MMK-';S9\J5XR%?'7:>A_"NKN+3P)::]8FWU&^O-,V.USO4AMP'RJ/D7J?_UB
MMSXCWD%_X0\-W5K;"WMY"YBA'\"X  X]J'4U5EN"=Y6//XM%U6>S-Y%IEY):
M@$^<D#%,#_:QBH!9W1LS>"VF-J'V&?RSL#>F[IGVKWJV-Y<:UHE[!?"RL18$
MMH[MME?@XQ'WQQSVQ[UQ7A?9K47C+1FMVAAF#W,,,@P8G#' ([$';^51[9ZZ
M;?YBC*Z3]/Q/,Z***Z"@HHHH *[;5?\ DGOA+_M\_P#1HKB:[;5?^2>^$O\
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M ($=$UUH>TX\3:N3CH9'_P#B*H^"Y'?70'=F"P,%!.<#C@5C?V-JG_0-O/\
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M-_T+NK?^ 4G_ ,31_P (CXF_Z%W5O_ *3_XFH=2J[KH.&&PD;;-JVM]=#?\
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M)K'EEV.SVM/^9?>8U%;/_"(^)O\ H7=6_P# *3_XFC_A$?$W_0NZM_X!2?\
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M,1W-1?:9_P#GM)_WT:=>_P#'W_VS'\S4% $OVF?_ )[2?]]&C[3/_P ]I/\
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M8[F"-9U(;</,!."/4U6U';]NU!3)LG:ZA:.QXQ<@;/FZ;CWZ$ ;>>]/K\_\
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MECCYA['UI:V CM?%$5WH;:BEN5D1T22!GP5W, #G'(P<]*WZX^?P_?C1]/\
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M\4+;[@ZG4RS10J&ED2-20H+,!DGH/K0DT4I<1RHYC.UPK [3Z'T-9M_;23Z
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MRO\ W[_^O6K10!E?V.__ #\K_P!^_P#Z]']CO_S\K_W[_P#KUJT4 97]CO\
M\_*_]^__ *]']CO_ ,_*_P#?O_Z]:M% &5_8[_\ /RO_ '[_ /KTAL99'%J9
MT A0,&\L\[B??_9K6JNG_(1F_P"N4?\ -Z *7]CO_P _*_\ ?O\ ^O1_8[_\
M_*_]^_\ Z]:M% &5_8[_ //RO_?O_P"O1_8[_P#/RO\ W[_^O6K10!E?V.__
M #\K_P!^_P#Z]']CO_S\K_W[_P#KUJT4 97]CO\ \_*_]^__ *]']CO_ ,_*
M_P#?O_Z]:M% &5_8[_\ /RO_ '[_ /KT?V.__/RO_?O_ .O6K10!E?V._P#S
M\K_W[_\ KT?V._\ S\K_ -^__KUJT4 97]CO_P _*_\ ?O\ ^O1_8[_\_*_]
M^_\ Z]:M% &5_8[_ //RO_?O_P"O1_8[_P#/RO\ W[_^O6K10!E?V.__ #\K
M_P!^_P#Z]']CO_S\K_W[_P#KUJT4 97]CO\ \_*_]^__ *]']CO_ ,_*_P#?
MO_Z]:M% &5_8[_\ /RO_ '[_ /KTAL904M//3:VZ7=Y9R",#'7WK6JN__(1A
M_P"N4G\TH I?V.__ #\K_P!^_P#Z]']CO_S\K_W[_P#KUJT4 97]CO\ \_*_
M]^__ *]']CO_ ,_*_P#?O_Z]:M% &5_8[_\ /RO_ '[_ /KT?V.__/RO_?O_
M .O6K10!E?V._P#S\K_W[_\ KT?V._\ S\K_ -^__KUJT4 97]CO_P _*_\
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MYNP =-W&<>]69?#8E\8)KS7/"VIMS;F/KUYW9]^F*J6[MY_EI^)"V5_+\_\
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MS_#L3]FWE^/<Z>BBBD,**** "BBB@ HHHH **** "BBB@"NG_(1F_P"N4?\
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M*NS._!C\G&1QW_&CK8.ESTVBN,UZ[NCJ6K[[J>V%AIRW%J(IB@9SNRQ X;D
M8.1[<UIVUY=:KJ-C#N>);6%+B\"$KF1E^6/Z=6(_W:%K_7]=@>G]>G^9T%%8
MWB.YETZRCU6.1PMG(&FC!.)(R<,"/4 Y'T]ZV%8.H93D$9!H 6BBB@ JO<?Z
M^T_ZZG_T!JL57N/]?:?]=3_Z U %BBBB@ JM:MMM9&P3B24X'4_.U6:KV?\
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M** "BBB@ HHHH **** *Z?\ (1F_ZY1_S>K%5T_Y",W_ %RC_F]6* "BBB@
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MA!_TV_[\/_A0!:HJK_:$'_3;_OP_^%']H0?]-O\ OP_^% %JBJO]H0?]-O\
MOP_^%']H0?\ 3;_OP_\ A0!:HJK_ &A!_P!-O^_#_P"%']H0?]-O^_#_ .%
M%JBJO]H0?]-O^_#_ .%']H0?]-O^_#_X4 6J*J_VA!_TV_[\/_A1_:$'_3;_
M +\/_A0!:HJK_:$'_3;_ +\/_A1_:$'_ $V_[\/_ (4 .3_D(S?]<H_YO5BL
M]+Z$7TK?O<&)!_J7]6]O>IO[0@_Z;?\ ?A_\* +5%5?[0@_Z;?\ ?A_\*/[0
M@_Z;?]^'_P * +5%5?[0@_Z;?]^'_P */[0@_P"FW_?A_P#"@"U157^T(/\
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MV_[\/_A1_:$'_3;_ +\/_A0!:HJK_:$'_3;_ +\/_A1_:$'_ $V_[\/_ (4
M6J*J_P!H0?\ 3;_OP_\ A1_:$'_3;_OP_P#A0!:HJK_:$'_3;_OP_P#A1_:$
M'_3;_OP_^% %JBJO]H0?]-O^_#_X4?VA!_TV_P"_#_X4 6J*J_VA!_TV_P"_
M#_X4?VA!_P!-O^_#_P"% %JBJO\ :$'_ $V_[\/_ (4?VA!_TV_[\/\ X4 6
MJ*J_VA!_TV_[\/\ X4?VA!_TV_[\/_A0!:JN_P#R$8?^N4G\TIO]H0?]-O\
MOP_^%0O?0F^B;][@1./]2_JOM[4 :%%5?[0@_P"FW_?A_P#"C^T(/^FW_?A_
M\* +5%5?[0@_Z;?]^'_PH_M"#_IM_P!^'_PH M455_M"#_IM_P!^'_PH_M"#
M_IM_WX?_  H M455_M"#_IM_WX?_  H_M"#_ *;?]^'_ ,* +5%5?[0@_P"F
MW_?A_P#"C^T(/^FW_?A_\* +5%5?[0@_Z;?]^'_PH_M"#_IM_P!^'_PH M45
M5_M"#_IM_P!^'_PH_M"#_IM_WX?_  H M455_M"#_IM_WX?_  H_M"#_ *;?
M]^'_ ,* +55[?_7W?_74?^@+3?[0@_Z;?]^'_P *A@OH5FN2?-^:4$?N7_N*
M/2@#0HJK_:$'_3;_ +\/_A1_:$'_ $V_[\/_ (4 6J*J_P!H0?\ 3;_OP_\
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MNT1ECN-.F+Q\#)4Y)(. 368?B%>- ^I1II0L%?;]D>YQ=LN<;@,X]\8_QIW
M[UKRU2[2T:YA6Y==RPEP'8>H7J1P:GKSG7=;L[+QWI.L2N?LO]G&1<#ELA\
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M9NM<C^SSW#:A;11VCI$656&006 PF"=V3BK46I6PU07=],QCM5:WM@B-(9'
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M;KTFJ:581W\=S"L4T!G$3!E)PP)XQ@XJUX<TZ[LX+NYU!8UO+V<SR)&<JG
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M#A5 R,D#K74I:PI=272IB:10KL"?F SC(Z=SS4U'6X/L58I[I]0N(9+/R[9
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M(\,S?^._J*ZBH3:PF\6[*9G5#&K$GA2<D =!G _*C^OU#^OT)J*** "BBB@
MJ&#_ %US_P!=!_Z M35#!_KKG_KH/_0%H FHHHH *R-8?6K:XANM+B2\B52L
MMFSK&6)Z,KD<$>E:]% &#HUC?R:K=:SJ=O':SSQ)"ENDGF;$4D_,W0G)[>E)
MXCC\J]T?4S]RTNMLA_NK(-F?S(K?J.>"*ZMY()T#Q2*5=3T(-'8"+4(GGTVZ
MAC&YWA=5&<9)! K ;0+NX\%6%@0D.H6B121ASE5D3G!([=1QZUTT:".-47.U
M0 ,DDX^IZTZC^ON YB.WUG6M5L9M4TV+3[>QD,HQ<"4S/C Q@<#DGFMVTGNY
MGN1<V7V=8Y"L1\T/YJ]FX^[]#5JB@#%\+V%S8Z4_VV(1W<]Q+/*N0>68XY''
M3%3ZS:W%_%#8QI_HTSXNGW 8C')7U^;@?0FM.B@#D]4T:_:?6(+:V\V+5(XT
M67>H6#:-IW G.,<C /X5;U^ W!T;2E)=GNDD<GG]W$-Q)_':/QKH:A%K"+PW
M>S]^4\O>23A<YP!T'/Y\>E"_KY 34444 %0WG_'E<?\ 7-OY5-4-Y_QY7'_7
M-OY4 34444 %%%% &3K6@1:V;9I+R]M7MV+(]I*$.2,=<'M_,UC:3X5N=/\
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M=PZ/]FT\%I]BQ([$?(. 7.>N!S67-I$^F7]E<Z?:M<PP6;VGDJZJP)((;YB
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M36+_ $DZ/]AG\K[1?)%+\BMN0]1R#C\*.WG;\0[G1?8+/_GT@_[]BC[!9_\
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M^_8JQ10!7^P6?_/I!_W[%'V"S_Y](/\ OV*L44 5_L%G_P ^D'_?L4?8+/\
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M%%4W=W$E9!1112&%%%% !1110 4444 %%%% !1110 4444 5T_Y",W_7*/\
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MPUXK\KPDFK^)-21/M$S^460 [0< !5&3T/8USGCZW?PW+8SV:XCGTY].?'H
M,?S_ $INKZ?<:3JWA.-M07388[/RUNY(5D2*7!+9#<<Y')^O:B_;T_/_ "7W
MATU]?R_6YZ5IVMZ9JUDUY8WD4UNGWWSC9_O X(_&J=AXOT#4[\V-GJ<4EQG
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MW_7*/^;U8H **** "L'7=)U&XOK34]'GMHK^V5H]MRI,<B-C(..1R,\5O44
M8>@Z1?6ES>:CJUQ!-J%WM#"W!$<:*.%7//<\FH_$\1B;3=6 ^73[D/+[1,"K
M'\,@_0&N@I&571D=0RL,$$9!% '.ZKI6L)K/]K:!<62RRPB&>*\5MC@$E6!7
MG/-7/#VD3:5:3F\G6XO;J9I[B1!A2QP, >@  K51$C1410J*,*JC  ]!3J%I
ML&YA2Z"]_!K O95$U^I@1H^?*B (4<XYR2Q]S2:7I%Y'JJ:AJ!MQ)!:"TB6!
MV8$9R6.0,$X''./4UO4C*&4JP!4C!!'!HVV#<P/#<9GO-6U<@[;VXVPGUCC&
MP'Z$AC704V.-(HUCC14C0!551@ #H *=0 4444 %5T_Y",W_ %RC_F]6*KI_
MR$9O^N4?\WH L4444 %%%% !1110!C:CI,]WXCT?48WC$-EYWF*Q.X[U &./
M\*V2,@@]Z**.E@.5T;2XI_#NH^&;K(\AY(3Z^6Y+(PS['\P:8F@^(+W[-8ZQ
M>Z?+IEM(C[H8V$T^SE0^?E'(&<5U0AB$QF$:>:5"E]HW$#H,^G)I]'F#*D/]
MH?VC<>=]F^P[5\C9N\S/\6[/&/3%4M TJXTS^T9+IXWFN[R2XRA) 4X"CD#H
M!6Q10!0UBTN+_3VM+>18Q,P25R2"(R?FVX[D<?C6=?Z)=)J(O=*%L"UF;)HY
MF*JBYRK+@'./3C/J*Z"BE8+G)ZMI:P>'M*\,P,7,TD43'OY:$,[?I_X\*ZSH
M*888C,)C&GFA2H?:-P'7&?3BGU5PL%%%%( HHHH *KO_ ,A&'_KE)_-*L57?
M_D(P_P#7*3^:4 6**** "BBB@!LD:RQO&XRK J1Z@UQ0\,>(VT]=!DU"P.B*
M0GF*C?:&B!SL_N].,UV]%'4!H150(!A0, >U<MHVF)-X<U'PS<$J8'D@SW\M
MR61A^!_,&NKI@AB$QF$:>:5"E]HW$#H,^G)HWW!:;')PZ#XCO9;*WUJ^T]]/
MLY5E'V9&$DY3[N_/ YP>*W]8LI]1LQ9Q.B0RN!<$D@F+^)5XZGI]":T** .=
MU/0[QK^YN=--L!=V8LY%F)7R@,X9< YX8_*<=!S4.KZ>@L=$\.P99?-C+Y/(
MABP23^(4?C744SR8O.\[RT\W;MW[1NV]<9]*%_7Y@/HHHH **** "J]O_K[O
M_KJ/_0%JQ5>W_P!?=_\ 74?^@+0!8HHHH *QM:L=8DN8+W1KV*.>)2C6]T6,
M$H/<A>0P[&MFB@##T72+V"^N=4U:>WEU"X18R+9"L<:+D[1GD\DG)J/Q/$8F
MTW5@/ET^Y#R^T3 JQ_#(/T!KH*1E5T9'4,K#!!&010!!?0M=Z=<P1E=TL3(I
M)XR1@5B_\(U)/X-M-&FG6*ZMXX]D\8W!)$P0PSC(R*Z!$2-%1%"HHPJJ, #T
M%.H YFUTC7+[5+2ZU^XT]HK)R\$=FCC>Y& SENF 3P*V[/\ M#?<_;?LNWS3
M]G\C=GR^V_/\7TXJW10!C^&M*N-(TC[/=O&]R\TDTK1DE2S,3U(!Z8J?5K"7
M4OLUON068E#W*DG+A>0H&.A;&?8>]:-% ',:GX<O+FYU5;62 6^JHB7#2,0\
M6T;25 !#9'J1@^M2ZY;B[O-%TB(':LZW,O/W8XAQGZL5%=%3!#$)FF$:"5E"
MLX4;B!G )].3^="_K] 'T444 %5[_P#Y!US_ -<G_D:L57O_ /D'7/\ UR?^
M1H L4444 %%%% &7K/AW2O$"PKJEKYXA)*?O&7&>OW2/2L72? FGZ1XHDU*V
MMHTMDB46RB61F1^0Q.3R"#ZFNNHH6CN@>JL8WBFPEU'P]<Q6XW7";9HAZLC!
M@/QQC\:CODOM7L;#4]#OEAF4>8D<V[R90P^ZX'IZ]16[3(H8H$V11I&N2VU%
M &2<D_B>: .;M_#M_J$UU=^(9[5[B:U:T2.S5A'&C=3EN23Q]*J1^'?$=U':
M:;JE_I[Z5;.C;H4833!""H;/ Z#./2NRHHV#<H2P7EU=75O<"V.F2P;%"[O-
MW'AL]L8Z5S9\.^)'T[^P7U#3O['\L0^<(F^T&,<;<9VYQQFNSHHL!GZA93R:
M0;&PD6$LJQ;R3E$Z$CCKMSCWJA=Z)/;W]I>Z0ML&@M6M/)F8HH0X(((!Y!'3
M'/J*WZ*'J&QRFI::=+\$PZ!;OYD]P%M$/3<6.7;Z ;C^%=1#$L$$<*?=C4*/
MH!BAH8GE25HT:1,['*@E<]<'M3Z+@%%%% !5>X_U]I_UU/\ Z U6*KW'^OM/
M^NI_] :@"Q1110 57LO]0W_763_T-JL5C2Z;J!FD:*Z"1L[,JB1AC)SZ4 1:
M=H<VF^*=2OX7C^Q7Z*[IN.Y91U(&,8(/KUK>K$_LW5?^?W_R*W^%']FZK_S^
M_P#D5O\ "ETL'6YKS017,+PSQ)+$XPR.H96'H0>M$=O#%;K;QPQI"J[!&J@*
M%],=,5D?V;JO_/[_ .16_P */[-U7_G]_P#(K?X4 :5GI]EIZLME9V]LK'+"
M&)4!/J<"I+FUM[R!H+J"*>%OO1RH&4]^0>*R?[-U7_G]_P#(K?X4?V;JO_/[
M_P"16_PH TI-/LIO(\VSMW^SD&'=$I\HCIMXXZ#I2_8;3[6UW]E@^TLFQIO+
M&\KZ%NN/:LS^S=5_Y_?_ "*W^%']FZK_ ,_O_D5O\*8&G;6-I90&"TM8((22
M3'%&%7)Z\#BH;?1=*M+C[1;:99PS\_O(X%5N?<#-4O[-U7_G]_\ (K?X4?V;
MJO\ S^_^16_PH UDM;>.XDN$@B6>4 22J@#.!TR>IQ44>FV$4,\,=E;)%.29
MD6)0)">NX8YS[UG?V;JO_/[_ .16_P */[-U7_G]_P#(K?X4@-!]*TZ2TCM'
ML+5K:,YCA:%2B'U"XP.IIEWHNE7\WG7FF65Q+C;OF@5VQZ9(JE_9NJ_\_O\
MY%;_  H_LW5?^?W_ ,BM_A0 FH>'X$T>^@T.QL+.\N83$)%B$0P>#DJ,]/UJ
M]HVF1:/H]KI\/*01A<_WCW/XG)JE_9NJ_P#/[_Y%;_"C^S=5_P"?W_R*W^%,
M#1N--L;N>.>YLK:::+_5R21*S)]"1D4)IEA'#/"EE;+%.2TR")0)">I88Y_&
ML[^S=5_Y_?\ R*W^%']FZK_S^_\ D5O\*0&K;6MO90+!:V\4$*YQ'$@51^ I
MMQI]E=S0S7-I!-+"<Q/)&&:,^JDCCH.E9G]FZK_S^_\ D5O\*/[-U7_G]_\
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MW^% &W16)_9NJ_\ /[_Y%;_"C^S=5_Y_?_(K?X4 ;=%8G]FZK_S^_P#D5O\
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M\_O_ )%;_"@#;HK$_LW5?^?W_P BM_A1_9NJ_P#/[_Y%;_"@#;HK$_LW5?\
MG]_\BM_A1_9NJ_\ /[_Y%;_"@#;HK$_LW5?^?W_R*W^%']FZK_S^_P#D5O\
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MKV],T ;-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
&%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>img62602283_10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img62602283_10.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )L!O<# 2(  A$! Q$!_\0
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MU@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&RWU=O+MT_ ZW4=>LM+N(X;KS 9$+A@,CCMUZUCZQXF\S0UGL([J,S-@2E
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MD>3-QP5'<"M"Z\16=BT NHYXC-$9 '3!7V(SD&L_5I8[?QEIDTSK'$(FR[G
M'#=_Q%-U;RKGQ9HK#;)$ZE@>H/4@UUQPN'JJBI0:7LVVT]VN9_?H9.I.//9Z
MW2_(U$\0V+Z4NHL9$B9BBJR_.S>@ )IUGKEO=W0MG@N;6=@2B7,6PN!UQ65X
MOB/FZ;<.\L=M'*1+)$<,F<8(_(T06^D?VE:NNM7=[<IEX8VN!(.G(Z<?F*QC
M@L+/#>V2E>7,U:[Y;;)NWS;=M'T+=6HJG)=:6^9>F\3V4+O^XO'AC;8\ZPGR
MU.<<DU7\3:T]KI2&S\[,X5DN$7Y .O7U(K(NM8N=4T>ZFEU.VME8,JV:1AG8
M>ASR/J*EU8$^ K XX'EY_(UVT<LHT:U%SCKS\K5VUM?JDGKVNC&6(E*$DGTO
M_6INOX@A@TUKVXM+R%%<1[98@K'/< GI3/\ A*-/67;*ES"C*6CEEB*K(!_=
M[G\JH^*KJ"Z\,E[>:.51*@)1@P!].*3Q".="/_3=/Z5RX? X:HH<\&G)S6^W
M*D^J-9UJD6[/9+\6:MCKUM?7AM/*N+>?;N"7$>PL/44R?Q%:Q7$D44%W<^4<
M2O;Q;E0^YJCJ(_XK?3,<$PN,_@U9&C6]K''<V]]J]Y87$4IW1K<>6I]QD<FJ
MIY=A90]LT[.,7RZO=M/97MI^(I5ZB?)YM7^2?ZG3W/B'3[:VM;EG9X+EMJR(
MN0/7/>DM?$%K<WJ6C075O+(,Q_:(M@?Z5SNH0V4%AHJV$[S6YNR5=^N<C/8?
MRK4\0?\ (PZ%_P!=3_-:7]GX7W8).\O::O1KEO:ZMOI9A[>IJ[K3E_'S(3XB
MF'B66/[)?O D.T0)#EMV1\V,]/>NI##;N/ QGGM7+BY@M/'5U)<S)"C6P :1
M@H)^7U^AK?U&*2?3+J*'F1XF5<'N17)F%*GS45&/*G&.OK_EU-:$I6FV[V;,
MX^*+(NWEP7<L"-M:XCA+1C\?_K59OM;M;&2.$I--/(-RPPQ[GQZX[5E^'M8T
MVS\/Q1SW,<$D.X21L<-G)[=34:7$-CXSN+B[=8XKF &"5SA<<=STZ5T2R^DJ
MTX>SE:"E;7X[6\O.[MT^\S5>7(GS+6WR_K8V;/6K6\BG9!*DD )DAD7:Z_A1
M!K-O<:,^J(DH@568J0-W'7OCMZUAQXU'Q1J%Q98D@6U,;2)RKL1P >__ -:J
MUCJ%G%X'GMI+B-;C9(GE$_-DDXXZU4LJI-)P3NW"ZW:4D[I_=N)8F75]'\['
M02^(K*"SL[J42K%='"DJ/E]VY_EFF0^)].FL)KW]ZD43^7\RC+MVV@&N=O55
M]!\.HP!5I "#W&:Z3Q#!83Z<D-]<?9E,@\J0?PM@X_"E4P6$IN$)1DW*4EH]
ME&5MK:NPXU:LKM-:)?BB:QUB*^E:+[-=V[JN_%Q$5R/7/2JS>*+(,S)!=R6Z
M'#7*0DQ#\?\ ZU9=M=W\\M]I2WT>HQFU8I<1@#:V, $C_$U2TN+37T;;=ZW>
MVK(&66V^T;0.3D!,<_K6T<KP\7*4TVO=LHW>C3UVOZ76_?0EXB;LEY[^7SL=
M1>:[:69@51+<R3KOCCMTWLR^N/2K-A?1ZA 98XYH\-M9)4*L#Z5SES::6K6)
MM-9^QW,4 ,,LA&&CYQG.!W/^%:GAO4+K4+&5KHJ[1RF-9E&!(!WKBQ.!I0PO
MM::=UO>Z>K=M+6:]'<UIUI.IRR_ GU#6[;3YX[=DFGN'&1# FYL>N*Q]%NDN
MO%VI3J'16A7(D7:5QMR".U*L\-AXXNY+V1(EF@'E/(<#MQD_0U6MW74=>UTV
M;[_-M2L;+W. ./QKMH82G3H323]ZFFY=-91T^7KT9C.I*4TV]I/3T3-AO%%D
M&9D@NY+=#AKE(28A^/\ ]:I[S7;2S,"J);F2==\<=NF]F7UQZ5R^EQ::^C;;
MO6[VU9 RRVWVC:!R<@)CG]:O7-II:M8FTUG['<Q0 PRR$8:/G&<X'<_X45<M
MP<*W):6C:V=G9:-M+OO;H.->JXWNOP_K[RQKE[:ZCX<DE<W=NBRJ&'E8<'/0
M@D _G6C<:M;:7!:Q.)YY9$ CCC7?(X ZXKF[[4+K4/!]RUT5=H[@1K,HP) #
MUJSKL_\ 9^H:5?12+%-Y)0O,C&,KCH=O.>>U4LO4E##R7VJEDGU48M:VOKZ7
M^9+KM7FNRU^;-2U\36UW<R0+:7J/$I:3S(P-N!GGGCI48\6V+VXGCMKUXA]]
MUAR(^?XCG%4])FMKA-4NC?PW%[<1$ND2LJJH! P& )^M)H__ "(-Q_USF_K4
M5,#A(-WIO24(VNU\2=]U??;[RHUJCMKT;^[8WKG5K*UL$O7ES#(!Y>T9+D]
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MGJY?\+*.L_\ ($OO^N#_ ,C7/Z38:;)X.$]W;P E)-TQ0!A\QQ\W7-=!K/\
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MK?W7:S^STVWZZ L1)RC9]K[=5]Y=\)=-3_Z^VJ]?ZT;>^6PL[1[R[*[C&KA
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MV$I$P  '<<9)]L4Z3Q2PMA>PZ9-)8 @/.7"D'OA>_/%5/#?_ ""M9_ZZR?\
MH-0V_P#R3B7Z-_Z'73/!X.-5P]DK*<8[RVDKM[[KIT[IF:JU7&_-T;Z=#0U!
M[.?Q%HTIA=WE4M&XDV@#J,C'/YBICX@N)-0N[*UTQ[B:!L<2A5(]22./ISFL
ML?\ (2\+_P#7N/\ T&K>A_\ (U:W_O#^9K.KAZ4:/-./-R0NKM_\_&NC73L.
M,Y.=D[7?_MMS0LM?M[G3[BZG1K=K8E9XV.2I'\ZK?\)%<1PK=W&DS1:>V,3^
M8I(!Z$IU K'M[.6_L_$EO",R&XRH]<,3C]*CM5\,FUBCGT^X:_ "R6ZB0ON[
M\9Q6BR["1E/W'+5:+5I.*=_BC;5M7=UIJA>WJM+5+3KU=[=G]RL=RTB+$9"P
M" ;BW;'K7,7FO3ZAI-X]OI<S6)C=/M&\ ],9V]<5O7EL9M*GM8?EWPE$SVXP
M*Y:TU:"/PM+I;QS"^2*1&A$1R.O)[ <\UY^68>$HNK&'/)2BK:Z+7WM'^>BZ
MFV(FT^5NRL_F^Q?T[58=*\*Z>[HTDD@*11)U=LFK<.NRI>PVNI:>]D\_$3>:
M'5CZ9'0UA""9-%T'44B:6.T8M*JC)"[NOZ5:U&[B\1WVGP:;OE2*7S)9=A41
MCCU'6N^K@J-2I*4HW3=3FE=^ZTW9;V[;IWOH8QJSC%)/9*R[[&B^OSR7EQ!I
M^F/=I;MME<2A,'V!Z]ZL7NL_91;11VDLM[<+N2VR 1Z[CT%<[JSZ;'>74MG/
M?6>J;B!&B,!,WKC'0_4?2EU:T<W6FZCK%J\MN8 ESLR-C<\G'3K4PR[#2=-N
M-DT]'?FDU&_5V:;VY7'MHQNO42E9W^ZRU]-/G<Z&PU=[B\:RN[-[2[">8$+A
MPR],AA6I7,Z2?#\=U+<:9:SDPQ%C.%D*X[K\QZ_A6WIVH0ZI9)=0!PC$C#C!
M&#BO)S##*$W*G!QBK7NK6;\KR:VZMLZ:-2ZM)IO^O)&-K'_(VZ-_P.KEQK<Q
MO9;33K![V2'_ %I\P1JI],GJ:IZQ_P C;HW_  .LF2RTRQUN^&NV[^5-(9()
M_GVD$DD?+WYKUJ.'HUJ5+VB<FJ=TDKM^^^B<6[+HFCFG.4)2Y=+O?Y+R?Y&[
M/XFCBTA[T6SEXIO)E@=MI1N_.#2-XBE@F@:[TR6WLYW"QSM(">>F5[?G6-JL
M>GKX4F?3;6:")KA?]8&^?'\0R3Q5_P 5?\@;3O\ KO'_ .@FB&"PCE"'LW[\
MI+5M-62>R=KIOK?S!UJJ3?-LD_ZT-&]UJ2+4386-BUY<*F^0"0($'U/?I^=4
M8O$=_=VEX\6D%3;@JQ-P/E8=>H'3K536'GA\3O)8?:4E\@"5K6$3D^FY21CC
MU]JMZ0UJ^E:A9VPN3>%6:9;A-LC,PZXJ5A,/2PT:KIJ3:B]Y75WJY6:5NW7N
M/VDY5''FMOV^5NMR+0+J]E\/-'+:'R/)E(N3,"6.3QMZ^OY55T'5KJP\/*T6
MF2SP1,QDE\P* ,]AU-6O#U];GP[)I^YA=0Q2F1"A&WD]\8[TW1_^1!N/^N<W
M]:Z:Z@I5HU*2LZL=/>5T^;7?JNVGD9P;:@XR^R^WEH=-:745[:17,))CD7<,
M]:S+C79#?R66G6#WLL/^M/F"-5]LGJ:?X9_Y%RR_W#_,UDV=U'X=UC4EU$-%
M%<R>9%,$)5N2<<=^:\FC@Z?MZ\%'G<+\L==?>MTLW9:V1TRJRY(-NR>[[:%\
MZZUWI%Y):VSB[MP5E@=PIC//.>^.?RJEX.1_LB2'34565C]MWJ6<[NF.H_\
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MT.><U8KY:JHJ;4=K]=ST8W:5PHHHK,9/9?\ '_;?]=5_F*[.N,LO^/\ MO\
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MC@AG\L98'KD]ZSKG5KBS\1V]C,D7V2X7]VX!W!O0G..OMW%6=;U+^RM+EN@
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M4SG;(H89_&I:*Y%)Q=T]35I/1D<,$-O'Y<$21)_=10H_(4);P1S/,D,:RO\
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M>VFQKAZ4J=T]OZZA1117DG2%%%% !1110 4444 %%%% !1110 4444 %%%%
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M*/\ 52C_ ,_']R#^T)?RG&?8KO\ Y]9O^_9H^Q7?_/K-_P!^S79T4?ZJ4?\
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MIQE%=G]BM/\ GUA_[]BC[%:?\^L/_?L4?ZJ5O^?B^YA_:$?Y3C**[/[%:?\
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M5Y]H?_"-?;=>_MG^R?M']J3;?MGE[]O'3=SC.?UJ[XQATR#1M$2**TCTXZI
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M*Y&>3P..G:G;2XKZV.BHKA9-9U#5?$FDWEM,\.C&[:WB56(^U?(Q9S_L@K@
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MJ32WC6=Q;F5!([$@D!U.5!_ UV]%.XK')6$6ICQY>>==VCD6<)DV6K+N7<^
M,R'!]^?I76T44-W!(****0SG-?C:TUS2-9*L;>V,D5P5!.Q' PQ [ @9^M17
M=Q#X@\0:0NG2I<VME(US//$=R*=I5%W#@DDG@>E=113N*QQ>A7NFZ1HUU9ZY
M+#%?F:4W23CY[@EC@J#S("N,8SZ5M>$Q?#PU:#41()\-@2_?";CM#>^W'7FM
MJBAL$@HHHI#"N.U;6M*'C;17.IV82!+E96,ZXC8@##<\'([UV-%-,3.5\5^,
M+71(8+:&YC6ZNU#1S%2Z1(?^6AP#GV Z_2CPCJOAV0/I^DW[W=V09[B62-P\
MK9 +L6 [D<5U5%%U8+:A1112&%5=0O[.PMB]Y=P6R-E5::0("<=!GO5JB@#C
M_"%U!>^!8K"TO(#>BVD!C60%XR2V"1U'456M;G1;7P,-'ECC%Z;8Q26&S,S3
M8P?DZD[N=W3OFNYHIW%8H:)!<VVA6,%ZVZYC@193G/S <\]ZOT44AA4<\\=M
M;R3S.$BC4N['L ,DU)10!YL/&7A_6=5%WJVH&&RM7S:V1AD;<P_Y:R84@GT'
M:M^2Z@M?$UMKYD_XE=_8B+[000J,&W*6S]T$$\G%=5157%8YJW==9\81:A:D
M2V%E:M&MPO*22.1D*?X@ .HR.:Z6BBI&%%%% '&>+/&%I8WJZ*E_]CE< W%U
ML9C AYPH .7(Z=AUI;1=&\1^&I]$\-ZF88HMHF?R')(8G(;=M)W8.2#7944[
MBL<7J]EJ=I=^'K=;O3U1+O9"L=BZJF(VZCS3D8[<?6NS7<$4.06QR0, GZ4M
M%#8)!1112&5=2U&VTG3I[Z[?9!"NYB!D^@ ]R>*X+3O&'A^]U,:QK.I!9TR+
M2T$,C+;+TR2%P7/<]N@KT>BFFA-'*^?!IOC6^O-6ECAAFMXA97$QVHH&=ZAC
MPI)P<<9J;PY,]SK&L7%KG^R'>/[,=N$9\?.R>Q..1P3^-=)11<+!1112&%8\
M^O16&KRVFI".SMBBM;W4LF$E/.Y22 %8>F>16Q10!Q^EWMOIDWB+6F#0:*TB
M/%A,+(P7#N@[AC@9[FLC3O&'A^]U,:QK.I!9TR+2T$,C+;+TR2%P7/<]N@KT
M>BJN*P Y (Z&BBBI&%4-7OY]-LA=0VC7*+(HF5"=R1D_,P !W8ZXJ_10!R.K
M7=IK>IZ+_8TT=S=0W:RO/;D-Y,(!WAF'W<CC!ZTNFRV&AZWKDFKRPVUQ<W'F
M13SD*)8=HPJL>#@Y! YKK:*=Q6.=\(V[PV^H2K$T-E<7CRVD3*5*QG'(4_=!
M.2![^]=%1128T%%%% '+P:!J>FG4KF+4[266[9I))9[)FD(QPN1*!@#IQ6/9
MVE\?!7A^_&VX%C+#<K%#$0XB (8?>.XX.> .G2O0**=Q6.4UN]MO$4=EINES
MI=F2ZCDG:([A#&AW$L?X3D  '!YKJZ** "BBBD,QO$6B2Z[;06Z7:0Q1RB22
M*2'S$F Y"L RG&?>LBX@U9?&NE*][8E_LLVTI9NJA<ID8\T\],'/'H:["BG<
M5CEX- U/33J5S%J=I++=LTDDL]DS2$8X7(E P!TXJ?P2MPOA+3C-+$Z&!?+"
M1E2JXZ$ECD^_'TKH:*+A8****0QLJL\3JC['*D*^,[3ZXKB-1T'4-$\%ZK"N
MH6<T;0RRSNUFPEF8@DDMYN,^^/PKN:*:=A-7..U.&YC3P[<ZD\<]A!*6N?+A
M8(N4_=LR[FX![^^>*L2:A%J/B[36T6=+B-$D^W30'='LQ\BLPX)W=!U'/:NI
MHHN%@HHHI#"BBB@ KEO&]K>_8K+4],MWGOK"?>B1J68JPVL !]1^5=3133L)
MJYS$WALGP =%7FX6WW CJ9A\^?\ ONCP5:WOV"ZU/4X7BO[^8R2)(I5E51M4
M$'GL3^-=/11<+'(>'KK^R;C6X[RTU!#-J<TL92QFD#(<8(*J1C@U)XJ=[^PT
M>ZM;:\DCBU.&611:R;U1=V24V[L?A75T47ZA;2QGV^LVMS.L,<5\&;H9+">-
M?Q9D 'XFN>TG01J%GX@M=0MYH1-JLLL$A4HR_=VR(3[C@BNQHHN%C&T&\U%E
MFL-5@D%W:X7[2$(CN5[.#T!]5[']-FBBD,**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ KEXIHM \5:I)?R+;V>H".6*>5ML>]5VLI8\ ]#SC-=1
M13 X+4M-N?$/]NZE9QLR&.&.R/3SO+;>2,]B> >]:.N:U;:UX>FT_39!-J%Z
M@A^S#[\6X@,77J@ SR<5UE%%Q6([>(6]M%"O(C0(/P&*DHHI#"L7Q9I\^I>&
M[J"U4O<+MEC4'&YD8-C\<8K:HH Y/7-:MM:\/3:?IL@FU"]00_9A]^+<0&+K
MU0 9Y.*GM_#=_9:M-J%OJ5J\CQI#']ILVD,,:C[JD2+QGGI72T4[BL<OX)2[
M73[LS3P/']LN %2$J=WF')R6/'H,<>IKJ***&[C04444@.4TB[MO#MSJEAJ<
MZ6JO=O<V\DS;5E1^<*3P2#D8Z^U9-W8W=SI5]J;V\WV:[U6.>:#8=SVB87E>
MO(&[&.E>@T4[BL<EJNIVNH7ND1:#<13WB7*%S;$,(X.=X<CA1CL>^,#(KK:*
M* "BBBD,9--%;PO--(D<2#<SNP"J/4D]*Y+0-7TQ_%FOA-1M&^T30"#$ZGS<
M1X^7GGGTKL**8C@?$GC#3+C59-#EU)K*SC.+R9$<O)ZQ)M!Q[G\!75:!J6DZ
MEIBG19%:S@/D@+&R!2 .,, >A%:E%%T%@HHHI#"N3\?:A91>'YK22\MTN2\+
M"%I5#E?,7G;G..#^5=9130F<QXG,&MZ!%)9R1WUG%=Q/<K;L) \:L"X^7K@<
MX]JKZS<V.LSZ1;Z)+#<7D%U'*'M\$6\0^]N(^Z".-IZ^E=?11<+!1112&%8/
MBGQ/;>&=/667#7$Q*P1G.">Y..PR,]ZWJ*$!Q/A?6/#LUR]NFK&^UB_SY\Q@
MD7?@$[5RH"J!G JSX>U2UT#1%TK5)U@N[(O&(G^],NXE3&.KY!'3/I76T4[B
ML8?A.RN++0D-W&8KBXEDN)(SU0NQ;!_#%;E%%)C"BBB@#SC4O&6A:UJC6E]J
M)@TBW;YHQ&Y-XP]=JG"#T[UT$]E'XI_LO5=,U&$V5N6:*&:U9HV<$J&V[D.1
M@XKIZ*=^PK=SDK"+4QX\O/.N[1R+.$R;+5EW+N? &9#@^_/TKK:**&[@D%%%
M%(9@^*?$]MX9T]99<-<3$K!&<X)[DX[#(SWK)\*:WX?>\,46K&^UJ].Z:9H)
M%WD G:N5 50 <"NTHIW5A6U.+T*]TW2-&NK/7)88K\S2FZ2<?/<$L<%0>9 5
MQC&?2MKPF+X>&K0:B)!/AL"7[X3<=H;WVXZ\UM44-@D%%%%(9'.TB02-"@DE
M"DHC-M#'' SVKE-4UW3M7\+7-M/&IU&6$I_9I&Z=)L< (1G@\[L8[UU]%-"9
MQFM^*#X:T?3M.N;E5U::!%>:12ZQ<8:1L D\@X'<U9\(ZKX=D#Z?I-^]W=D&
M>XEDC</*V0"[%@.Y'%=511?0+:A1112&%96H:T-+U*".\B6*PE0_Z8SX5) >
M%;C"@CH2?:M6B@#CXHSJ?B35+O1V M)=.\EKB/B.:?)VD$<,5'&1ZXJM:W.B
MVO@8:/+'&+TVQBDL-F9FFQ@_)U)W<[NG?-=S13N*Q0T2"YMM"L8+UMUS' BR
MG.?F YY[U?HHI#"JNHVTUYIUQ;6]TUK+*A59E7<4)[XJU10!PFLZ1?Z/X6M;
M*.[L/LT5S;JJI9.K%O,7YB?-.>>3QS[5I3^9HWBJ'5-0D3[-<6?V::X5"D:2
M*VY202=H()&2>W7FNIHIW%8YJW==9\81:A:D2V%E:M&MPO*22.1D*?X@ .HR
M.:Z6BBD,**** .>&@:A%K]WJT.HVK2SJ$07%FTAA0?PJ1(O&>>E8VD:1J.L>
M%]0L3J<5O'+>3JQCMCD_O3N!^?[I]!@CU-=U13N*QQ>KV6IVEWX>MUN]/5$N
M]D*QV+JJ8C;J/-.1CMQ]:[-=P10Y!;') P"?I2T4-@D%%%%(9F:_I<VLZ1+8
M0WAM/-P'<)NRO=2,C@]."*Y[5[+4[2[\/6ZW>GJB7>R%8[%U5,1MU'FG(QVX
M^M=I133L)HY02Q:9XSO;O69HHDEMHEM+F7Y8UQGS%#$X4DX.,\^]3^')GN=8
MUBXM<_V0[Q_9CMPC/CYV3V)QR."?QKHED1F95=2R<, >1]:=1<+!1112&%%%
M% !4%S?6EEM^U74$&[.WS9 N<>F:GKA_B+X<OO$":<MD8AY)D+>8Q'7;C''L
M::5V)NR.I_MS2/\ H*67_@0G^-']N:1_T%++_P "$_QKQO\ X5OKG]^T_P"_
MI_PH_P"%;ZY_?M/^_I_PJ^1=R.9]CV3^W-(_Z"EE_P"!"?XT?VYI'_04LO\
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M K_R8B_^*HY5W#F?8]YHKP;_ (5UXK_Z!7_DQ%_\51_PKKQ7_P! K_R8B_\
MBJ.5=PYGV/>:*\&_X5UXK_Z!7_DQ%_\ %4S_ (5]XH\WRO[+^?;NQ]HBZ?\
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M +YD_P */[2\<?\ /76_^^9/\*.0.<]YHKP7_A(/&D?R&ZU,$<8:-L_J*/\
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MXG_Q%7%1MJ0V^A?_ .%M:#_SZ:E_W[C_ /BZ/^%M:#_SZ:E_W[C_ /BZH?\
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M_P#BZH?\*ST7_GZO_P#OXG_Q%'_"L]%_Y^K_ /[^)_\ $46B%Y%__A;6@_\
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M_OW'_P#%U(_Q3T>.&.9]/U58I<^6[0H%?'!P=_.*C_X5+H/_ #]ZE_W\C_\
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M[W4[4;J1A1@\=3Q4'_"I=!_Y^]2_[^1__$4>Z'O!_P +:T'_ )]-2_[]Q_\
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M%M:#_P ^FI?]^X__ (NC_A;6@_\ /IJ7_?N/_P"+H_X5+H/_ #]ZE_W\C_\
MB*/^%2Z#_P _>I?]_(__ (BCW ]X/^%M:#_SZ:E_W[C_ /BZ?'\4=%N=WEZ;
MJDOE*9&VP(VP#JQ^?@#UIG_"I=!_Y^]2_P"_D?\ \14]M\.=*TOSOLT]^_VJ
M)K:7>ZG:C=2,*,'CJ>*/=#WB#_A;6@_\^FI?]^X__BZ/^%M:#_SZ:E_W[C_^
M+H_X5+H/_/WJ7_?R/_XBC_A4N@_\_>I?]_(__B*/<#W@_P"%M:#_ ,^FI?\
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MEP=N!D^N:@_X5+H/_/WJ7_?R/_XBCW0]X/\ A;6@_P#/IJ7_ '[C_P#BZ/\
MA;6@_P#/IJ7_ '[C_P#BZ/\ A4N@_P#/WJ7_ '\C_P#B*/\ A4N@_P#/WJ7_
M '\C_P#B*/<#W@_X6UH/_/IJ7_?N/_XNC_A;6@_\^FI?]^X__BZ/^%2Z#_S]
MZE_W\C_^(H_X5+H/_/WJ7_?R/_XBCW ]X/\ A;6@_P#/IJ7_ '[C_P#BZDG^
M*>CVTS0SZ?JL4J_>22%%8=^07J/_ (5+H/\ S]ZE_P!_(_\ XBI[SX<Z5K5T
M^H7D]_'<38W)&ZA1@;1P5)Z 4>Z'O$'_  MK0?\ GTU+_OW'_P#%T?\ "VM!
M_P"?34O^_<?_ ,71_P *ET'_ )^]2_[^1_\ Q%'_  J70?\ G[U+_OY'_P#$
M4>X'O!_PMK0?^?34O^_<?_Q='_"VM!_Y]-2_[]Q__%T?\*ET'_G[U+_OY'_\
M11_PJ70?^?O4O^_D?_Q%'N![P?\ "VM!_P"?34O^_<?_ ,73U^*NBO&\B6&J
MLB8WL(4(7/3)W\4S_A4N@_\ /WJ7_?R/_P"(J>+X=:59VT]A%/?-#>A1*S.I
M*[3D8.W Y]<T>Z'O$'_"VM!_Y]-2_P"_<?\ \71_PMK0?^?34O\ OW'_ /%T
M?\*ET'_G[U+_ +^1_P#Q%'_"I=!_Y^]2_P"_D?\ \11[@>\'_"VM!_Y]-2_[
M]Q__ !='_"VM!_Y]-2_[]Q__ !='_"I=!_Y^]2_[^1__ !%'_"I=!_Y^]2_[
M^1__ !%'N![P?\+:T'_GTU+_ +]Q_P#Q=.C^*^B2R+''8ZH[N0JJL2$DGH -
M]-_X5+H/_/WJ7_?R/_XBI(?A?HMC/'=PW.H-+ PE16D0@LIR <)ZBCW ]X\_
M\1^*)YO&%QJNE27=B^%0K(-C@J "& )'4=#74:!\5_NP:[;^WVF ?^A+_A^5
M<MXIT*8>,[FRT^"XN)9=LQ0+N8,X#-T' !/>NDT#X42R;9]<G\I>OV: Y;_@
M3=!^&?K5OEMJ2N:^AZ98:E9:I;"XL;F*XB/\2-G'L?0^QJU5+3=(T_1[86^G
MVL=O'WV#EOJ>I_&KM8FH4444 %4[_P#Y9_C_ $JY5.__ .6?X_TIH3,^66.&
M-I)9%CC49+.< ?C4-KJ%E?;OLEY;W&WKY4JOC\C7*7$8\0>/I=/O<O8Z?"'$
M!/RNY Y([_>_3W-=%'H&D07L5[#I]O#/"#L:)=@&1SP.#^-78DTJJW>I6EC+
M;17,NQ[E_+B&TG<WIP./QKFX?$&NZI!<:AI-E9&PA9E59V;S9=O7;C@?C5#6
M]8_M>W\-:C9P;I'N^(6;'SC VY^O>BPKG>T5S5AK>J1>(QH^L0V@>6$S126I
M;&!G@[OH?3I5:'Q!KNJ07&H:3961L(6956=F\V7;UVXX'XT6'<ZZFO(D:[I'
M55]6.!7*7'C"5[#1[O3[5)/MTQB:%SR&Z8!Z#GOCI5'Q;)X@72K-;S^S0'NT
M&(2_WLY7KVXYHL*YW=0SW=M;&,7%Q%$9&VH)'"[CZ#/4U%IW]H?9!_:?V7[3
MDY^S;MF.WWN<UQ/B;2);76]-U"YOI+F6;4$5%(VK%'G(4#^M"0-GH-%%%(84
M444 /A_U\?\ O#^=:U9,/^OC_P!X?SK6J64@HHHI#"BBB@ HHHH **** "BB
MB@!AC4RB7'S 8S[4^JSG_B8Q>Z&K- !1110 4444 (2 I)Z <TB,KH&0Y4CB
MB09C8#J0:CM49+:-6&& Y% $U%%% !1110 4SRU\[S<?/MVY]J?5;/\ Q,\=
MO)_]FH LT444 %%%% !2,H=&5NC#!I:BN?\ CUE_W#_*@"15"(JKT48%+45M
M_P >L7^X/Y5+0 4444 %%%% #/+7S?-Q\^W;GVI]5B?^)F!_TR_K5F@ HHHH
M **** $90Z,K=&&#0JA$55Z*,"H[G_CUE_W#_*BV_P"/6+_<'\J ):*** "B
MBB@ IGEKYWFX^?;MS[4^JV?^)GCMY/\ [-0!9HHHH **** "D90Z,K=&&#2U
M%<_\>LO^X?Y4 2*H1%5>BC I:BMO^/6+_<'\JEH **** "BBB@!GEKYWFX^?
M;MS[4^JV?^)GCMY/_LU6: "BBB@ HHHH 9+&LT91QE3UI]5M0.+&3'M_,59H
M **** "BBB@ IBQJLCN!\SXS^%/JM"?].NO^ ?RH LT444 %%%% !3)8UFC*
M.,J>M/JMJ!Q8R8]OYB@"S1110 4444 %%%% '->,?#4OB/3([2VECA=KE)))
M'R0%"L.!W/(IF@> =%T+;+Y/VNZ'/G3@'!_V5Z#^?O6_"?\ 3KK_ (!_*K-.
M[M85E>X4444AA1110 R;_42?[I_E7.:MJEOHVFRWMR3Y:=%7JQ/0"NCF_P!1
M)_NG^5>>_$*VEG\.I+&F];>=99%_V<$?UJHDR)8K_P 67-NM[#IVG) X#K;2
M2/YQ'IG[H/UK>%XL%C'<7YBM"5!D#RC:A]-W --MM2L[G35OXKB/[*4W&0L
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M .* 'T444 %%%% !4:2J\LD8!RF,_C4E0QQ,ES-(2,/MQ^ H FHHHH ****
M"HYI5@B:1@2!Z5)4-U$T]L\:D G'7ZT 34444 %%%% !1110!&DJO+)& <IC
M/XU)4,<3)<S2$C#[<?@*FH **** "BBB@".658MFX$[V"C'J:DJ&XB:7RMI
MV2!CGT%34 %%%% !1110 5'%*LN_:"-C%3GU%25#;Q-%YNX@[Y"PQZ&@":BB
MB@ HHHH *CEE6+9N!.]@HQZFI*AN(FE\K:0-D@8Y]!0!-1110 4444 %%%%
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MX5K?8/\ IK_X[_\ 7H^P?]-?_'?_ *]%PL4J*N_8/^FO_CO_ ->C[!_TU_\
M'?\ Z]%PL4J*N_8/^FO_ ([_ /7H^P?]-?\ QW_Z]%PL36G_ ![)^/\ .IJ9
M%'Y403.<=Z?4E!1110 4444 %%%% !1110 4444 0^:WVSR<#;Y>[/?.<5-4
M?E+Y_G9.[;MQVQG-24 %%%% !1110 R9S'#(XQE5)&:(7,D,;G&64$XI7021
MLASA@0<4(@CC5!G"@ 9H =1110 4444 %0QRL]S-&0,)MQ^(J:HTB5)9) 3E
M\9_"@"2BBB@ HHHH *ANI6@MGD4 D8Z_6IJCFB6>)HV) /I0!)1110 4444
M%%%% $,<K/<S1D#";<?B*FJ-(E2620$Y?&?PJ2@ HHHH **** (;B5HO*V@'
M?(%.?0U-4<L2R[-Q(V,&&/45)0 4444 %%%% !4-O*TOF[@!LD*C'H*FJ.*)
M8M^TD[V+'/J: )**** "BBB@ J&XE:+RMH!WR!3GT-35'+$LNS<2-C!ACU%
M$E%%% !1110 4444 0V\K2^;N &R0J,>@J:HXHEBW[23O8L<^IJ2@ HHHH *
M*** (9)62YAC &'W9_ 5-4;Q*\L<A)RF<?C4E !1110 4444 %0VLK3VR2,
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M.*DJ+R?]+\[/&S9C\<T 2T444 %%%% !39'\N)WQG:"<4ZF2IYD3IG&Y2,T
M+&_F1(^,;@#BG4R)/+B1,YVJ!FGT %%%% !1110!'YW^D^3CG9OS^.*DJ+R?
M]+\[/&S9C\<U+0 4444 %%%% $=Q-Y$#2$9VXX_&I*BN8?/@:,'&['/XU+0
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M-WXUNU&DJO+)& <IC/XUPXC+<+B9JI6@FU_7S^9K"O4@K18Z.-8HUC0;548
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MOG(Q]:Y33OBH\^JI%>6$<5I(X7>CDM&">I]?TH46',CT:Y_X]9?]P_RHMO\
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M=01N7&X4 .HHHH **** "JVH'%C)CV_F*LTV1TCC+2$!1U)H =1110 4444
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M8S/?7=J^+RXMO(428,8QG'&/4^]9-MIEU&EG%:6NH630LF]YK[?%M&-RA [
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M1!'&J#.%  S3JCMR6MHB222@))^E24 %%%% !1110 4V1Q&A=LX'I3JAN_\
MCV?\/YT 0_;_ /IG_P"/4?;_ /IE_P"/?_6JE156)N7?M_\ TR_\>_\ K4?;
M_P#IE_X]_P#6JE3)IHK>%I9Y$BC499W8* /<FBP7-#[?_P!,O_'O_K4?;_\
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M!<T?M_\ TR_\>_\ K4?;_P#IE_X]_P#6JE118+EW[?\ ],O_ ![_ .M1]O\
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M10!%D^;]R+S-O][G'Y=*=F7^XG_?1_PJ+:W]H[MIV^3C..,YJQ0 S,O]Q/\
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MFGU6OCBW!']]?YU9H **** "BBB@ IJNC.RJ1N7[U.J"&-EN;AB,*Q!!]>*
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M^/6+_<'\JEH **** "BBB@!GEKYWFX^?;MS[4^JV?^)GCMY/_LU6: "BBB@
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M4AA1110!IVG_ ![)^/\ .IJAM/\ CV3\?YU-4%A1110 4444 %%%% !1110
M4444 1^:OG^3@[MN[/;&<5)4/E-]L\[(V^7MQWSG-34 %%%% !1110 UW$<;
M.<X4$G%".)(U<9PP!&:29#)#(@QEE(&:(4,<,:'&54 XH ?1110 4444 %1I
M*KRR1@'*8S^-25#'$R7,TA(P^W'X"@":BBB@ HHHH *CFE6")I&!('I4E0W4
M33VSQJ0"<=?K0!-1110 4444 %%%% $:2J\LD8!RF,_C4E0QQ,ES-(2,/MQ^
M J:@ HHHH **** (Y95BV;@3O8*,>IJ2H;B)I?*VD#9(&.?05-0 4444 %%%
M% !4<4JR[]H(V,5.?45)4-O$T7F[B#OD+#'H: )J*** "BBB@ J.658MFX$[
MV"C'J:DJ&XB:7RMI V2!CGT% $U%%% !1110 4444 1Q2K+OV@C8Q4Y]14E0
MV\31>;N(.^0L,>AJ:@ HHHH **** (WE5)8XR#E\X_"I*ADB9[F&0$83=G\1
M4U !1110 4444 %1PRK/$LB@@'UJ2H;6)H+9(V()&>GUH FHHHH **** "F/
M*L;(ISES@8I]0S1-)+"PQA&R: )J*** "BBB@ IKN(XV<YPH).*=3)D,D,B#
M&64@9H 5'$D:N,X8 C-.ID*&.&-#C*J <4^@ HHHH **** "H;O_ (]G_#^=
M344 8U%;-%.XK&-16S11<+&-16S11<+&-16S11<+&-16S11<+&-16S11<+&-
M16S11<+%.P_Y:?A_6KE%%(84444 %%%% !1110 4444 %%%% #9'2--SD!?>
MG55OF5H#&'7S"1A2P!ZU:I*2>B86"BBBF 4444 %1I-OGEBQC9CGUS3V=47<
M[!1ZDXJ&%%,TLRR*ROCISC%+F5[7U"W4GHHHI@%%%% !3=Z>;LR-^W./:G55
MW+_:>=Z_ZK;C<,YSZ4G)+=A:Y:HHHI@%%%% !2,P52S?= R:6HYU+6\BJ,DJ
M0!^% #U8,H9?ND9%+4<"E;>-6&"% (_"I* "BBB@ HHHH :702!"1O(R!3J@
M>-C>QN!\H4@FIZ "BBB@ HHHH 1F"J6;[H&30K!E#+]TC(IDZEK>15&25( _
M"B!2MO&K#!"@$?A0!)1110 4444 %-WIYNS(W[<X]J=4'EM_:'F8^3RMN??-
M $]%%% !1110 4C,%4LWW0,FEJ.=2UO(JC)*D ?A0 ]6#*&7[I&12U' I6WC
M5A@A0"/PJ2@ HHHH **** &[T\W9D;]N<>U.J#RV_M#S,?)Y6W/OFIZ "BBB
M@ HHHH ;(Z1QEI" HZDTZH+V-I;1T098XP/QJ>@ HHHH **** "FJZ-(Z@C<
MN-PIU011LMW<.1A6VX/K@4 3T444 %%%% !39'2.,M(0%'4FG5!>QM+:.B#+
M'&!^- $]%%% !1110 4444 -5T:1U!&Y<;A3J@BC9;NX<C"MMP?7 J>@ HHH
MH **** &3?ZB3_=/\JR:V:JW>I6EC<6D%S+Y<EW(8H 5)#-@G&0,#@'K35]D
M)E"BM&_OK;3+":]O)1%;0J7D<@G ^@Y-01:S837;VB3'STMUN60QL"(VS@\C
MV/'7VJDFU=(6FURK144/C+0YX(KA;BX2VEQLN9K.:.$Y.!^\9 OZUO424H_$
MK K/9F-15F_UNPTV9(+B21IW4N(H('F?:/XBJ D#W(Q3QJ^GG2CJ?VR+[$%W
M&;=\H'3\\\8ZYXZT6E:]@T[E.BK-AK=AJ,[6\$DJSJN_RIX)(7*_W@KJ"1[C
MBG7&L:?:ZK:Z9-=(M[=!C##@EF !)/'0<'DXZ46E>U@TWN5**N:AJUEI?E"Z
ME823$B**.-I)),==J*"QQWP.*?8:C::G;F:TE\Q58HP*E61AU5E(!4^Q -%G
M:]M TO:Y0HJ[J&JV6EI&UW/L,K;8XU4N\A]%1068_05'8ZU8:A.UO!,ZW"KO
M,$\3PR;>F[8X#8]\8HM*U[:!I>URM15[4M3LM'T^6^U"X6"VB&7=LG'X#DGV
M%,_MFP%Y9VAN,3WL9EMU*-^\4 $X.,=".#S0E)JZ0:=RQ:?\>R?C_.IJI7.K
M6-IJ5GI\]PJ7=YN\B,@Y?:,GGH/QIUSJ=G9WUG93S!+B\9E@CVDERHRW0<8'
MK2Y7V'=%NBJM_J-KIEMY]Y,(XRP1>"S,QZ*JC)8GT S3-/U:RU/S1:RMOB($
MD4L312)GIE' 89[''-+E=KVT"ZO8NT5D1>)M(FN4@CNF/F2>5'*87$3O_=64
MKL8^P-3W^M6&FS)!<22-.ZEQ%! \S[1_$50$@>Y&*?)*]K!S+>YH45!9WEOJ
M%I'=6DR302#*NIX/^?2IZEJVC&%%%% !115:]OH[&'>^23PJCJ:SJU848.I4
M=DAQBY.RW'^:WVSR<#;Y>[/?.<5-7-C7'^U><8%^[MP&[9S6]:W4=Y )8CP>
M"#U!KCP>:X7&2<*,KM=-C6IAZE-7DB:BBBO0,0HHHH 9,YCAD<8RJDC-$+F2
M&-SC+*"<5C7VN+EX8(PRX*ER>OTJQI>J1W.VW9=CJN%YR&Q_6O,IYQ@JE;V$
M9^]MY7]3=X:JH\[6AJ4445Z9@%%%% !4,<K/<S1D#";<?B*COKZ.QAWN-S'A
M5'>L:+7&2YDD: $28R >F*\W%9MA,+4]E5E9_-V]3>GAZE1<T5H='14<$R7$
M*RQG*L,BI*]",E**E%W3,6FG9A1115""H;J5H+9Y% )&.OUJ5F"J68@ #))[
M5S][K8F5HHHOW9_B8\FN+&9AA\&DZTK7V-:=&=3X4=#16;I^KI>OY3KY<O4#
M/!K2K7#8JEB:?M*+NB9TY0?+)!111700%%%4M0U*.P4 C?(W10?U-8UZ]/#T
MW4JNR14(2F^6.Y/'*SW,T9 PFW'XBIJYR'7&2Y>1X01)C=M/3'I700S)/"LL
M9RK#(KFP>98;&-JC*[738NK0G3^)#Z***[S(**** (;B5HO*V@'?(%.?0U-6
M7J6HVT$B1L&>1&#X4XP?<T^RUB"[D$>#'(>@/0_C7#_:6$]M[#VBYMK>?;M<
MU]A4Y>>VAHT445W&04444 %0V\K2^;N &R0J,>@J:HXHEBW[23O8L<^IH DH
MHHH **** "H;B5HO*V@'?(%.?0U-4<L2R[-Q(V,&&/44 24444 %%%% !111
M0!#;RM+YNX ;)"HQZ"IJCBB6+?M).]BQSZFI* "BBB@ HHHH ADE9+F&, 8?
M=G\!4U1O$KRQR$G*9Q^-24 %%%% !1110 5#:RM/;)(P )ST^M35'#$L$2QJ
M20/6@"2BBB@ HHHH *AFE,<D2@ AVP<U-4<D0D>-B2"AR* )**** "BBB@ I
MDSF.&1QC*J2,T^FN@DC9#G# @XH 2%S)#&YQEE!.*?3401QJ@SA0 ,TZ@ HH
MHH **** "L?Q/J5YHVA3ZC9PI,;8K)+&X)S$"-^.1R%R1]*V*9+%'/"\,J!X
MY%*LIZ$'@BJBTFFQ-76A0U36;?3?#UQK!8/!'!YR8_CR/E ^N1^=95IKFJC5
MM T^_AMEEOK.6>Y"(P*.H4A5RQQ][!SGIVKEK$37MW8>!9U9ETR]:6X9AG?;
M1X:'/;YBRC_@-=-J?_)2= _Z\[K_ -DKI]G&/NO7=_*VG^9ESMZ^G_!(M,U?
MQ%JUC?WT$VEJMM=3PI;O;29<1L0,R>9@$XZ[:W]#U1-;T2SU..,QK<Q"383G
M:>XSWYKSZSL=5D\+:O<V%]=O$FIW)N-/C"*)HA(=ZJX7>K$?[7MCFNWLV-YH
M>GR^&[JRM[(Q#R_-MFE&S'  $BX(Z'.:5:$5MW^[U"G)DNHW6IG4(+'38(TW
MHTDMY<1L\48!P% !7<QSTR, 9JC:^(;L0:S!/9_:M0TME4I9J<3[E#)M!R5Z
MX().,=33]?\ $,FC6]M9P1+?:W=#9;VT8VAVQRY&3M0=3D_CWHT;3H?"NBW-
MWJ=ZKW,K&YO[R0X#.1SCT4= /\:A)*%VO3S_ *V*;?-HR.35M7TF[TP:L;&6
M&_G%MMMHV1H9&!(Y9CO'&"<+Z^U5M>\6W5AK%K8:?8-*GVR""[N9E(CC\PC"
MIR-S8.<C@<9SFH]'ANO%6L0^(K^&2WTZVS_9=H_#-D8,[CU(^Z.PY]S;\;?\
M>6D?]A>T_P#1E6E'VBBUKU);?*VF7=<U:XL)].LK..(W>H3&*-YL^7& I8L0
M.3P.!D9]:;INJ7G]NW&BZCY$EQ' MRD]NC(C(S%<%2S%2"/4Y'I6?XN(N-4T
M'3;F3R=/NKAS+,/E8.BYC17_ ("3GD8/& >:CTF&'3/'U[I]D[3Q2V2SW#RN
M998I VU5,C$L002=K$XQD8S4J"]GYVO^/]:#<GS&MJ^LS6VH6FE:?"DVHW2L
MZ^:2(XHUZNV.3R0 !U/<=:K7NJ:KH"Q7.JFTN[!I%CFFM86A:WW' 8JSON7.
M,D$$9Z&JVHD:5\0+/5+HA+*ZL39><W"QRA]ZACVW D#W%+X_NX_^$9FTN/$E
M]J16VMH!RSLQZX] ,G/;%.,5>,;:/^OP!MV;[&KK^M#1K /%$;B\G816ELO6
M60]![ =2>P!K!/BW4(O"N@ZW-#;!+NXCCO<*P6-')7<OS<8..N>M2IH^NV_B
M"74WM].OA'$(+(RWCQF"/'S':(F^9CU.>F!5#0].NM;^$XTZ:&&/S;4BW9)2
MY)!)4D%1M.X#H3]:J,(**;UU5_G<3E)O0U/&/BN3PTVG""!)C-+NN-P)\NW4
M@.XP>H++5W7M:N+"YT>UL$BEGU"[6+]YD@1 %G88(Y 'ZUS/A4?\)M'J.I7\
M;"-K%-+ 88.[;NF/_?3 ?\!J+P1-=:SKT37H(DT"R-B^>\Y<JS?]\H/SINE&
M*U6L=_GL+G;>G78[C5[RZLK'?96C75S(ZQQH,[06.-S$=%'4_2LZ+5=0L->M
M-+U5[2?[;%))#-;1-%L* %E969LC!X.1TZ5I:OJ]GH>FRW]]+LAC';EF/95'
M<GTK T72;_5;FX\0ZRC6]W<0M!9VA/\ QZ0GU_VVZD]NGL,8)<C<EI^O_ +D
MW>R'0Z[K6H:1+KNGQ6?V!=[PVLL;^;/&I(W;]P"$X) VGMDU.?$4NJ7EC9Z&
M80]S:"]>XN(V98HCPHV@@EB<\9&,&J/AW4K?3_ANOVIA%)IT#V]Q&Q^9)$RN
MW'J>,>N15#P?93:!K>GVU^'C>[T:%$WG@21L2T?U <''UK9PC[VFVW]>6Y',
M]/,ZG1]5N+F^OM+OTB6^LBA9H00DL;@E7 ))'0@C)P1UYJ]=:E86)87=[;6Y
M5/,/FRJF%SC=R>F2!FL+2@+SQYK5_"=UO#;PV9<'Y6D!9F'U&X _6FW,4<GQ
M0L6DC1S'I4K(67.T^:HR/0X)'XUDX)R^5_P+4G;YFVVM:4C6RMJ=DK70#0 S
MJ#*#T*\_-^%27VI6&F1K)?WMM:(QPK3RK&"?0$FN 6V@3P'XUVQ(-M[>;>.F
MTY7'T/(]*O:IJ(TOQ+I-ZT]D)9=+9/\ B93^1$/F4DK)M;YSGD8Y ZCO7L%>
MR\_\R?:.VIV%CJ>GZFCOI]];7:(<,UO,L@4^AP3BFZI=-:6+.G#D[5/IFL[P
MA9VEEH*I:7EK=J\TDKRVC Q[V8L57!/ SC\*T]1M3>63Q+]_[R_45Y^81J>P
MJ1H?%9V[G10:YHN>QR+,68LQ))Y)/>M[0;MY-]L[%@HW+GL/2L-X98I/+>-E
M?T(K?T.QD@5YY5*LXPJGKBO@<AAB/K\>5/2_-Z>?];GL8MP]D[_(V****_13
MQ0HHHH X^_NWN[IV9CL!PBYX I+&[>SN5=6.TG#+V(J74;"6UN'.TF)CE6 X
M^E)I]A+=W"?(1$#EF(XQ7Y@Z>,^OVU]I?^OE^%CW;TO9?W;'6T445^GGA!11
M10!F:W=O;6JI&=KR'&1U '6N8[UU6KV3W=J/+&9(SD#U]:YCRI/,V;&W_P!W
M'-? <2PKO&7E?ELN7MY_.YZ^!<?9Z;]3H]$NWN+9TD8LT9 R>I!K4K.T>R>T
MMF,HQ)(<D>@[5HU]?E2K+!TU6^*W7\/PL>=B.5U7R[!1117H&(4V1_+B=\9V
M@G%.IDJ>9$Z9QN4C- "QOYD2/C&X XIU,B3RXD3.=J@9I] !1110 4444 1M
M-MN$BQ]X$Y^E25$T.ZY27/W01CZU+0 4444 %%%% #9'\N)WQG:"<41OYD2/
MC&X XI)4\R)TSC<I&:(D\N)$SG:H&: 'T444 %%%% !4?G?Z3Y..=F_/XXJ2
MHO)_TOSL\;-F/QS0!+1110 4444 %-D?RXG?&=H)Q3J9*GF1.F<;E(S0 L;^
M9$CXQN .*=3(D\N)$SG:H&:?0 4444 %%%% $?G?Z3Y..=F_/XXJ2HO)_P!+
M\[/&S9C\<U+0 4444 %%%% $=Q-Y$#2$9VXX_&I*BN8?/@:,'&['/XU+0 44
M44 %%%% !4:3;YY8\8\O'/KD5)44<.RXFDSGS,<>F!0!+1110 4444 %1W$W
MD0-(1G;CC\:DJ*YA\^!HP<;L<_C0!+1110 4444 %%%% $:3;YY8\8\O'/KD
M5)44<.RXFDSGS,<>F!4M !1110 4444 %8/C#2Y=4\.3BU ^VVS+=6IQR)8S
MN7'UP1^-;U%5&3C)20FKJQPVIZC%XO7PYIMN0UO?XOKM1_#%'@[3Z9?"_@:L
M_P#-1-8_[ \?_H;U=\/>$;?P_JFHWL=PTOVIB(8RF!;QEBY1>>FYB>U6_P"P
MO^*BO-6^T_\ 'S9K:^5L^[@D[LYYZ],5T.I!7C':WZ_U]QDHR>KW.$TW4IKK
MX>:1X<&GRP2:I ;:&\N6C\@YSD@ABV[&<*0"2*]!DO[;2([>SE6]E*QJH:&R
MFF! XY**0#QWK.C\(P?\(7!X=GN&D\F,+'<HNQD<'*NHR<$'WK<LX[B&SACN
MIUN)T0!YECV!SZ[<G'YTJM2$MN[_ .''",EOV,[5;K2O#D-YKMRNR6151V!)
M>4KG8B@GKR>!ZY-9WAK07;00=:M@)[B]?43;[CB%V;<J\=<<'TS2ZGX7U#4/
M$T.L?VI:LELN+6UN;)I$A;C+C$JY;CJ>GX9JQJ^BZUK&@RZ<^M6]M+*^'GM[
M-E!CQRF#(2,]R#TXQWI)Q44E+?=ZZ!9W;L9]I<GQ)XXBO[+G3-(CE@-R.D\S
MXRJ^JJ!U]?SJ#4-%LM,\;^'[F!&:YN[RXDFFD8L[?N6PN3T4#@#H*W='TK4=
M)BM[1;K3!80KM$%O8/&V,=F,S<YY)(.>?7-5]4T+5M0UFROX]4LHA8R.\$;6
M+O\ >4J0Q\T9X/8"J52*E9.RLUU\_P!1<KMJM;E76))E\<Z<=+B6XU%+.3S8
MIFV1+ 6'S%P"5;<,#"MGGIUIWA4R'6O$!O0(M3>>-Y[=,E$39B,JW\0(!YP#
MGC Q6A>Z)<3:E;ZK:7R6VI1P?9Y': O%,F<X*;@1@\C#9&>]2:/HK:==7M]<
MW9NK^]*F:4)L0!1A55<G  )ZDGGK4N<>2WE^OY#47S7,O2O])^(NOR3\R6D%
MO#;@_P ,;*68CZMU/M[4>-B+=-&OX@!>0ZE#'"PZD2':Z?0CK]!6GJ&B-/J4
M>J6%U]CU!(_*:0Q^8DJ9SM=<C(!Y!!!'K6'J.GZM'XETK4=8?^T[&!R$CL;5
MD%O*>!(R;G+CKSGY<YQ3@XN:E?9;?+]12346C"\0:UI7B2/6)KO4[*.SL()X
MK&SDN%62>?8092F<\'(48[D^E:.M7-M_PC?A[Q'9SQSC2IH3+)"X<"-@$D7(
M^HS]*[35++^TM(O+#S/+^TP/#OVYV[E(SCOUJ&YTB.[\.R:/,^Z-[;[.7V_[
M.,X_6FJT?=TV?X=0=-ZG"Z_%+JE]K/B6WRS:#+$EI@]?*.^?\PQ'_ :W-.GB
MU_Q]-J$1$EKIMBD<+#IYDWSDY]=H4?C6OH'A^'0_#L.D&3[2JJPED9<&4L26
M)&3USZU#X2\,1^%-)>QCN6N2\S2&5EVG&  .IZ  4Y58\K2Z:+T_K\P4'=-_
M/^OZV-.[M+*26"]NU3=9[I(Y'; CRN"W7'3/)Z5P5Y>76JVGB?Q39H\=D--:
MSLGZ-,%+%I1Z#)./Z5U'BKP]=^([6"TBU)+6U5]\\+0&07 !!"L0ZD+Z@'FK
M5IIM\('L]0GTZ>P:$P_9[>R:' QC',K#&,C&*BG*,(WO=_I_P1R3D[6,?Q!:
MV\'PMN(H@%C@T]6BP?NE5!4@^N0*/"+R76N^(;NY4BZ,D$9!.=J"%2 /;+,?
MQJP/"MS)I\.D7.J";1HBH$'V?$KHIRL;R;L%> #A02!UJY<Z)<1ZM-J>DWD5
MI<7$:QW"S6YECDV_=; 92& .,YZ=N*?/'E<;[W_3_(7*[IV_K4I>%28]8\36
MZ#%O'J.Y,'@,T:LP'X\_C3#/JVH^*M9TV'57L[>U@@>+RH8V8,X;/+ C''(Q
MGT([[6CZ3'I%H\2R----*TT\[@!I9&ZL<=.P [  5':Z/]FU_4M4\_=]MCA3
MRMF-FP,,YSSG=Z#I4N<>:3\M/P*Y79(Y:#7M9?PQIGB66^&9[B**6Q2)!"5:
M3RR02-X;^+.[';%6M:UN:+6]0M+G7#HL<%NCV8"1$W3$')^=6W8.!M7!_,5=
M3PCL\(V6@_;L_9IHY?/\K[VV7S,;=W&>G6J-TEQ!XHU2ZFGUFP$JQ)"VGVGV
ME)T53RV8Y-K!BPQ\O&.O6M4X2;LN_P":MT_0AJ22N;WAG^TCX=LI-7FDEOY8
MQ)-YB*A4D9VX4 #'TS57Q$C^="_\&TC\:N^'VU)M&B.K9^U[FR650Q3<=I8+
MP&VXSCC-7YH8[B,QRH&4]C7C9M@WC*$Z*=F]NVC_ ".O#5/924CB:Z'P\CB"
M9SG8S #\.M2#0[$2X+.3C.PN.G\ZTXXTB0)&H51T KY_)LBKX7$JO6:TO9+K
M?0[<3BX5(<D1U%%%?6GG!4<ZL]O(J?>*D#ZXJ2BIE'FBXOJ-.SN<,002",$=
M15K349]1@"=0X)^@ZUT%WI-I<N97!C;JS*<9]S4MG8VUHN8%R6'WR<DBOBL/
MPUB(8E.4ER)WOU=O(].>.@X-):EJBBBOMSRPHHHH Y_Q"C^?"_\ !MP/KFL6
MNVG@BN8C'*@93V-9\>B6(E/S.Y7JA8<5\?FF08C$8IUJ35I=^AZ6'QD(4^67
M0=H2,NG MT9R5^E:5(JA5"J  !@ =J6OJ,)0^KT(4;WY58X*D^>;EW"BBBN@
M@JZDCR:=.J?>*]JX^NZK-N='LI&,K9B]2K #]:^;SW)ZN-G&K1:NE:S.W"8F
M-).,C"TQ'?48 F<A@3]!UKKZK6MC;V8/E)\QZL>2:LUV9+ET\#0<:CO)N^FQ
MGBJRJSNM@HHHKV#F"N8UU'742S?=91MKIZAN;6&[CV3(&'8]Q]*\S-\!+'89
MTHNSO=&^'JJE/F9Q==1H:.FG MG#,2OTIL6B6*RGEW*]59AQ^5:8 50J@ #@
M =J\G),DK82LZU9K:R2.C%8J-2/+$6BBBOJ3@"BBB@#B9]WGR;_O[CN^N:2+
M<)DV??W#;]:Z2_TFWN9/-\SR9&.">S'Z>M+9:-#:2"5G,KCH2, ?A7P+X<QG
MUFWV;_%?IZ;W/7^NT^3S[&E1117WQY 4444 %5[1F;S]S$XF8#)Z"K%-3R_F
MV;?O'=M]??WH =1110 4444 %5[MF7R-K$9F4'!ZBK%-?R_EW[?O#;N]?;WH
M =1110 4444 %%%% %>T9F\_<Q.)F R>@JQ34\OYMFW[QW;?7W]Z=0 4444
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M&*G/J* )**** "BBB@ JO=JS>1M4G$RDX'058J.658MFX$[V"C'J: )****
M"BBB@ HHHH KVBLOG[E(S,Q&1U%6*CBE67?M!&QBISZBI* "BBB@ HHHH KS
M*QO+9@I(&[)QTXJQ4;RJDL<9!R^<?A4E !1110 4444 %5[%62SC5E*D9X(Q
MW-6*CAE6>)9%! /K0!)1110 4444 %5KE29;<@$X?G':K-,DE6-D5LY<X&*
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MC?MSCVIU !1110 4444 5M0.+&3'M_,59ILCI'&6D("CJ33J "BBB@ HHHH
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M/HQ4@?K5FB@#YH=&C=D=2KJ2&4C!!]*GTZ">ZU*V@M@3.\JA,#.#GK7M&O\
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MU8^<:]H^&<$T/A%6F!"RSN\8(_AX'\P:@L_AOH,>I3%Q<RI&5*QR2#;R,\X
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MB?\ ?0H\Z+_GHG_?0H (88K>)8H8TCC485$4  >P%/IGG1?\]$_[Z%'G1?\
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M5$!!# Y;/ I_G1?\]$_[Z% #Z*9YT7_/1/\ OH4>=%_ST3_OH4 /HIGG1?\
M/1/^^A1YT7_/1/\ OH4 ).I:WD51DE2 /PH@4K;QJPP0H!'X4CW$:HS!U8@$
MX#=:$N(V16+JI(!P6Z4 2T4SSHO^>B?]]"CSHO\ GHG_ 'T* 'T4SSHO^>B?
M]]"CSHO^>B?]]"@!]0>6W]H>9CY/*VY]\U)YT7_/1/\ OH4S[2GG^7D;=N[?
MGCKTH FHIGG1?\]$_P"^A1YT7_/1/^^A0 ^BF>=%_P ]$_[Z%'G1?\]$_P"^
MA0 ^HYU+6\BJ,DJ0!^%+YT7_ #T3_OH4U[B-49@ZL0"<!NM "P*5MXU88(4
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M11+%OVDG>Q8Y]34E5+2-&\_<BG$S 9'058\F+_GFG_?(H ?13/)B_P">:?\
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MV3CIQ5B@ HHHH **** "FQ^7Y8\K;L[;>E.JO8JR6<:LI4C/!&.YH L4444
M%%%% !37"$KOVY!^7/K3JK72DO;X!.) 3CM0!9HHHH **** "D;;M.[&W'.>
MF*6H[@%K:4 $DH0 /I0 ]=NT;<;<<8Z8I:CMP5MH@000@!!^E24 %%%% !11
M10 56OO]0O\ O?T-6:K7W^H7_>_H:$)GGFO.NF^/=)U.[PMF\1A\UNB-\W7T
M^\/U]*ZV:\MK<1&:XBC$K!8R[@;R>@'K27=G;7]NUO=0I-"W5'&169:>$M!L
M;@7$&G1B4'(+LSX/J Q(%:$&)H-E9ZEKGB!]6@AGN4N"H6=0VR/G&,]!CO\
M2N?<EO!%["K,]E'J82W).?DSV/IS^M>@:CX;T?5IQ/>V*2RCC>&92?K@C/XU
M-/HFG7&G)I\EJGV1"&6)"5 (^A%.X6.7UG3[/2O$WAHV%M%;%YF1C$NW</E'
M/KP3U]:=H-E9ZEKGB!]6@AGN4N"H6=0VR/G&,]!CO]*ZJZTRSO;FUN+B'?+:
MMNA;<1M/'H>>@ZU5U'PWH^K3B>]L4EE'&\,RD_7!&?QI7"QY^[,?!%[%'(S6
M<>J!+9LYPF>Q_P ]:Z?Q;I&G6?@V[-M8V\;($*LL8W9W 9SUSCO6_/HFG7&G
M)I\EJGV1"&6)"5 (^A%6;FU@O+62VN(EDAD7:R-T(HN%BKHUI:6NF0&UMX8O
M,C1G\I NX[1R<=:J74MCXABO-.AU"YMI;9\3&%C&XZ]<CE:O:9I%AH\#0V%N
M(8V;<PW%LGZDFJVH^&=&U6Y^T7MBDDV,%PS*3]=I&?QH&9O@.=I-"D@Q&8K:
MX>&.6-=HE48.[Z\]:ZBHK:V@L[=+>VB2*%!A408 J6DP04444 7;#_EI^']:
MN53L/^6GX?UJY4LI!1112&%%%% !1110 4444 %%%% "$!@0>AXI(T6- BC"
MC@4/]QOH:ALCFSB/M0!8HHHH **** "FLZ*Z*Q&YL[:=4$T;-=6[ 952V3Z<
M4 3T444 %%%% !3/+7SO-Q\^W;GVI]5L_P#$SQV\G_V:@"S1110 4444 %(R
MAT96Z,,&EJ*Y_P"/67_</\J )%4(BJO11@4M16W_ !ZQ?[@_E4M !1110 44
M44 ,:-6D20CYESC\:?5:8_Z=;?1OY59H **** "BBB@!&4.C*W1A@T*H1%5>
MBC J.Y_X]9?]P_RHMO\ CUB_W!_*@"6BBB@ HHHH *9Y:^=YN/GV[<^U/JMG
M_B9X[>3_ .S4 6:*** "BBB@ I&4.C*W1A@TM17/_'K+_N'^5 $BJ$157HHP
M*6HK;_CUB_W!_*I: "BBB@ HHHH 9Y:^=YN/GV[<^U/JMG_B9X[>3_[-5F@
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M %%%% #=Z>;LR-^W./:G5!Y;?VAYF/D\K;GWS4] !1110 4444 -D=(XRTA
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MUQYP444R9_+ADD SM4G'T%*4E%-L$KZ#)[NWMB!-*J$]CUIEG=I=B0JRG:Y
MQZ=C7(22/+(TCL69CDDU):SO;7*2H3D'H.X]*^-CQ5)UK."Y+_/_ "^1Z;P"
MY='J=I1117V9Y@4444 (S!5+,0 .I-49=5M@\:QS1L2X#9Z >N:H>(9W#10
MD(1N/O6'7RN9\0SPN(=&E!/EWO\ H>A0P:J0YI/<[KK161H$[R6TD3$D1D;2
M?0]JUZ^@P6*CBL/&O%6N<=6FZ<W%] HHHKJ,PJ&>[M[8@32JA/8]:?,_EPR2
M 9VJ3CZ"N*DD>61I'8LS'))KP\YS=X!1C"-Y2[['5AL/[9MMZ(Z^SNTNQ(59
M3M<@8].QJS7%VL[VURDJ$Y!Z#N/2NTK3)\U_M"G)RC:4=^VHL3A_8M6>C"BB
MBO8.8*1F5%+,0%'))[4M8/B&=P\4 )"$;C[FN+,,8L'AY5FKVZ&M&E[6:B:'
M]IV[7444<T9#9#$]O2KU<+75:+.\VGC>22C% 3W%>1D^>3QM5T:L4G:ZL=&)
MPBI1YHLT****^D.(***9,YC@DD R54G'T%*4E%-OH-*^A'/>6]L0)IE4GMWI
M+*Y%U;+)N4MSD+VKCY)&ED:1V+,QR2:MZ5.\.H1;2<.P1AZ@U\A0XGE4Q*A*
M"4&[>9Z,\"E"Z>IUM%%%?8'FA1110 UY$B0O(P51U).*IMJENTD:0S(Q9PIS
MGI61KT[O>^22=B 8'J3WK*KY+'\23H8F5*G!-1=G?KW]/Q/1I8)3@I2>YW5%
M9^C3O/IX+DDHQ7)[BM"OIL-7CB*,:T=I*YPS@X2<7T"BBBMR JK=7]O;*P:5
M!(!PO7FG7\S6]C-*GWE7CV[5QQ)8DDDD]2:\#.<YE@)1ITXWD]==K'9AL,JJ
M;;T.SMITN8%D5E8D#=M/0U-7):5.\&H1!2<.P5AZ@UUM=64YE]?HN;5FG9F>
M(H>QE:^@4445ZISA1110 5C^*-);6O#MW9Q-MN-OF6[_ -V53N0_F!6Q13C)
MQ::$U=69P/\ :B^-+GPU9*/W13^T;],?=,9VJA^LF>/]FKW_ #476/\ L#Q_
M^AO6OH_AG3]#U#4;VT$GG7\GF2;R"%Y)PO' R2<>]3_V);?VU<ZIOE\^XMEM
MG7(VA02<CC.>3WKHE4A=J.UOUN9J$MWN>>:=>:B_P_T/2+B&WL]-U.,6IU%9
MFD*!L\,FT!2W(!W$#O7HDUQ-IJP6MKI-[=Q*@4/"\("@<8.^13GZ U7C\,Z>
MGA9?#L@DFL1#Y/[P@OCJ#D #(/(..U:5G;FTLX;<SS7!B0+YLQ!=L=V( !/X
M4JM6,G=+J_\ APA!K<R]?UFQ\.6SW9MUDO[HB.""-1YMS)T5>.3C/7L*A\/:
M-_96A%M8,$ET\[W]R[ ;(I6.XE2>FT<9]LT7?A..Z\0G6UU74(;L1^7&$\EU
MB7N$#QMMSW/7DT_4_#']L:,^F7VLZE)$\@=Y 84=@/X#MC *YYQC\:2<>51O
MON.SNW;T,W2)I/%7BA-?C4II%@DD%DQ!!N7; >3V48P/7K[4:IIUGI_BWPT+
M2WCA\^]NII2@Y=VA8ECZFMNPT>>P>$#6;Z:")=JV[Q6ZQXQ@#Y(E( ]B.E5]
M0\--J&IV]^^M:C%);.SVZQK!MB++M.,Q$G@G[Q-5SKFWTM;KYBY7;;4H:O\
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M'XC\87FM1?-:VMG%;6Y[;I )'_'!45T6C:-::'HMOI5H&-M"I4>9@ELDDDX
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M(_EQ.^,[03BB-_,B1\8W '%)*GF1.F<;E(S1$GEQ(F<[5 S0 ^BBB@ HHHH
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MST/I2:'I-U:VUYH.J6RWFE1-_H<TQ60/$>1&ZDYRO3)&",>E=)12=635O3\
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M=2UO(JC)*D ?A4E-D?RXG?&=H)Q0 V!2MO&K#!"@$?A4E-C?S(D?&-P!Q3J
M"BBB@ HHHH @\MO[0\S'R>5MS[YJ>H_._P!)\G'.S?G\<5)0 4444 %%%% $
M%[&TMHZ(,L<8'XU/4=Q-Y$#2$9VXX_&I* "BBB@ HHHH *@BC9;NX<C"MMP?
M7 J>HTFWSRQXQY>.?7(H DHHHH **** "H+V-I;1T098XP/QJ>H[B;R(&D(S
MMQQ^- $E%%% !1110 4444 011LMW<.1A6VX/K@5/4:3;YY8\8\O'/KD5)0
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MV$DC%G0<L$W'DX9" 3S@^U;VF'6- TZ/3)-+GU)+9?+@N;:6(;T'W=XD=2&
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MHHHN%CE_^*\_ZEO_ ,CT?\5Y_P!2W_Y'KJ**+A8Y?_BO/^I;_P#(]'_%>?\
M4M_^1ZZBBBX6.7_XKS_J6_\ R/1_Q7G_ %+?_D>NHHHN%CE_^*\_ZEO_ ,CT
M?\5Y_P!2W_Y'KJ**+A8Y?_BO/^I;_P#(]'_%>?\ 4M_^1ZZBBBX6.7_XKS_J
M6_\ R/1_Q7G_ %+?_D>NHHHN%CE_^*\_ZEO_ ,CT?\5Y_P!2W_Y'KJ**+A8Y
M?_BO/^I;_P#(]'_%>?\ 4M_^1ZZBBBX6.7_XKS_J6_\ R/1_Q7G_ %+?_D>N
MHHHN%CE_^*\_ZEO_ ,CT?\5Y_P!2W_Y'KJ**+A8Y?_BO/^I;_P#(]'_%>?\
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MR_\ Q7G_ %+?_D>C_BO/^I;_ /(]=111<+'+_P#%>?\ 4M_^1Z/^*\_ZEO\
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M@_X4 /HIGFKZ/_WP?\*/-7T?_O@_X4 /HIGFKZ/_ -\'_"CS5]'_ .^#_A0
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M^E7?-7T?_O@_X5!>$RVCHBN6.,#:?6B["R(O[#TC_H%6/_@.G^%']AZ1_P!
MJQ_\!T_PJYYJ^C_]\'_"CS5]'_[X/^%%V%D4_P"P](_Z!5C_ . Z?X4?V'I'
M_0*L?_ =/\*N>:OH_P#WP?\ "CS5]'_[X/\ A1=A9%/^P](_Z!5C_P" Z?X4
M?V'I'_0*L?\ P'3_  JYYJ^C_P#?!_PH\U?1_P#O@_X478612&BZ,6*C3+ D
M=1Y"<?I2_P!AZ1_T"K'_ ,!T_P *EB)6[N'*N%?;M.T\X%3^:OH__?!_PHNP
MLBG_ &'I'_0*L?\ P'3_  H_L/2/^@58_P#@.G^%7/-7T?\ [X/^%'FKZ/\
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M,L#@X.($X/Y5=\U?1_\ O@_X5!;$Q^=N5QNE9A\IZ47861%_8>D?] JQ_P#
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>5&, =,]:+!<Z>BF23111&621$C R79@ !]:CM;VTO5+6EU#<*."8I X'Y4
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M&I )QU^M $U%%% !1110 4444 1I*KRR1@'*8S^-25#'$R7,TA(P^W'X"IJ
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MB#&64@9H 5'$D:N,X8 C-.ID*&.&-#C*J <4^@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.,XS^%%PL7+V[BL+*:[G;;%"A=C]*Y[P=:2S17.NWB_Z5J+[E!_AC'W0/\]
M*WM0TZUU2T:UO(S) Q!*!V7..G0BK$:)%&L:*%10%51T %+H,=1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MPL4_L'_37_QW_P"O1]@_Z:_^._\ UZN447"Q3^P?]-?_ !W_ .O1]@_Z:_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBWJK!E()4JPZ$$<@^XIMII]K8F1H(R'D(+R.[.[8Z99B2<?6KJ4Y5';I_P
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MCY$'<D_TK=6L8.]SWZRNEO;"WNT&%GB60#V8 _UJ>HK6W2TM(;:/[D,:QK]
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M_A1_8>D?] JQ_P# =/\ "CVJ[![!]SQ2BO:_[#TC_H%6/_@.G^%']AZ1_P!
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MWRBO!O\ A8OBO_H*_P#DO%_\31_PL7Q7_P!!7_R7B_\ B:/9L.='O-%>#?\
M"Q?%?_05_P#)>+_XFC_A8OBO_H*_^2\7_P 31[-ASH]YJ&ZE:"V>10"1CK]:
M\,_X6+XK_P"@K_Y+Q?\ Q-,D^(/BB6,H^J94]1]GB_\ B:/9L.='OE%>#?\
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M?_PL7Q7_ -!7_P EXO\ XFCV;#G1[S17@W_"Q?%?_05_\EXO_B:/^%B^*_\
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6B,94N 1D+GH:]JJ7&Q2=PHHHI#/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>img62602283_11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img62602283_11.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $V S(# 2(  A$! Q$!_\0
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M:';&Q/W<\Y /8D"J)-VBC(SBJMMJ$-U=7=O'N#VL@CDW# )*AN/P(H M449
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MS ;,\L1@[?QQBA_%NDSVL$=GMO+J9E1;)?\ 6*<C.Y3]W;U)/I71TT(H8L%
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M*[H)XY1ZHP/\JTA6IU/@DF9SHU*?QQ:):***U,@HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MK5M)LVLEVVIA0PKZ)@8_2N4\9V8EUW3;B;1+O5K9(9%>&%250DC#<=^O'^%
M%OP;:7"RZC?W1M$FNC$#!:RB0)L7&6(XW'K75USGA)+1(KK[+H%SI W+N6=2
M/,Z\CZ?UKHZ8%&_FU*)HQ864%PISO,MP8]OICY3GO7-:GJFF:I=W.B)=V5E8
MK+_I\KRHC2MG+(@)Y)_B;\!DUV=5FT^R=BS6=NS$Y),2DD_E0 R^N+JVA1K.
MQ-XQ."BRJF!CKDUD:%/<7'B367NK0VLGEVX\LR!^,/SD<5T=8NG_ /(V:U_U
MQMOY24 ;5%%% !1110 4444 %96N6+W%NMS!D7-N=Z$=2.XK5HJ*E-5(N+ J
M:;?)J%DDZX#='7T;O5NN=F<:!JYE.1977+ ?PM]/\]:UK+5;/4"1;R[F7JI&
M#6-&LG[DW[R_JXDRY11172,*P_$?A+2O%$4:ZA$XDC^Y-$VUU'IGN/K6Y2;E
M+;0PR.V::DXNZ P/#?@W2/"_F/8QNT\@VM-,VYL>@X  ^E=!110Y.3NP"F30
MQW$$D$R*\4BE71AD,#P0:?02 ,G@4@//6^$&AF_\X7-VMONSY 8?ENQG'Z^]
M=NNF6*VD5H+. V\2A$C9 0H'0<U:!##(((]12U<JDI;L=VS"N?!GAN[SYNBV
M>3U,<>P_^.XK(N/A9X9F.Z*&YMCV,4YX_P"^LUVE%"J36S"[/F?Q/H-WX?UR
MXM+E)"F\F*5_^6B9X.>_'7WKK/ B>*] L9M3L-$-Y97) :-FVN=N<,HZ]SS@
MU[3)%'* )(T< Y 89I];2Q+E'E:'S:'$V?Q.TAIOL^JVUWI5QW6XB) _$<_F
M!766.IV.IQ>;8WD%RGK%(&Q]<=*=>:?9ZA"8KVUAN(_[LJ!A^M<E??#'1)I?
M/TZ2ZTRX'*O;2' /T/\ 0BL_W;\OQ%H=HS*BEG8*H&22< 5'!<V]TA>WGBF4
M'!,;AA^E>(>/X_$>B1VVDZCK<E_92@R1L5VDXXPQZG''4GK7/^$M?F\.^(;:
M\$KK;[PMPJ\[HSUX[^H]ZU6&O'F3'RZ'TI16%IOC+P]JN!:ZK;[STCD;RV_)
ML9K=!!&0<BN9IK<D****0!1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 57OK9;RQGMFZ2(5^A[&K%%*24DTQQ;BTT8_AFY:?1HXW_ -;;L87'ICI^
MF*V*Y^Q_T#Q7>VIXCNT$Z?[W?^OY5T%<^%;]GRO>.GW&^*2]IS+:6OWA1117
M2<X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!@^,=/N-4\
M-SVMJ8A,7C9?-;:ORN#R?PKDI;3Q7+=:M<&+1@VIP+!*!<'"@*5R.>O/>NW\
M0QZ3)HTRZV5%@2OF%F(&<C'(YZXKS2RM? 9\2:HEP\7]G*D7V4F23&[!WX.<
M]<=:3 ]0T.U>RT'3[64J9(;>.-BIR,A0.#7!:A?V3N;<ZAXLC:*60EH5/S9;
MIGN!CCVKT/3EM5TVU6QP;01*(<$D;,<=>>E<AX_U6[L6A@34)=/MVMII%FB7
MF690-L>[^'- %[P5)#)#>>3=ZS<89<G4^HX/W?Z_A755RWA#5I]4N=4_TIKN
MRC>,P3%<8)7+H#W ..?>NII@%%%% !6+I_\ R-FM?]<;;^4E;58NG_\ (V:U
M_P!<;;^4E &U1110 4444 %%%% !1110!Q_B^.7[9!(<F+9@>@.3G^E9FBQ7
MDFHH;+ E4$Y;H!CO7H$L4<\9CEC5T/56&138+:"V4K!"D8/4(N,UYM3 .=?V
MG-I^)-M3(W>(D_@M7_S]11]KU]/O:?"W^ZP_^*K<HKJ^KOI-_P!?(=CFM1U;
M5HK&0O8&#(QYH;[M<I'/+%,)DD82 Y# \YKTV:&.>%HI5#(PP0:Q8_"EA'<"
M0M*Z@Y"$C%<.)P=:<DXROZ]!-,2+7;UH48Z3.Y*@[AG!]^E/_MR]_P"@-<?K
M_P#$UM@   # '045VJE5_P"?C^Y#,3^W+W_H#7'Z_P#Q-86OZK=W3)#)!);1
MXR8VS\WOT%=Q5'4M*MM3C59@0R_==>HK*OAZTZ;BIW^X&F<;HFJ/IUX"Q=H&
M^^B\_C751^(]-DZS,G^\A_I3]-T.UTQS)'N>0C&Y^P]JNR6EM-_K;>)_]Y :
MG#4,12A;F7IO^H),CCU.QE^Y=PD^F\ TR_U2VTZW$LK;MW"JG):HY-!TV7K:
MJO\ N$K_ "KGM>T$6<:36B.T7.\$YV^]76JXBG3<K+Y?Y [FWIWB&UU"?R K
M1R'[H;HU:]>>:1I]S>WJ"$O&%.3*!]VNG_L;41]W69OQ4_\ Q59X7$UIPO*-
M_/1"39N4=*Q/[*U8=-78_5/_ *]0W6G:U]EE U'S!L.4"\L/3I70Z\TK^S?X
M?YCN0>(!X;\10?V?J3;PK921 04;U#?Y%-\/> -!T"<W=LDES,RD+)<,&V@^
M@  Z=ZY8@AB"#FNNT^]U6QL(4DTUYH@N593\V#STYKFPN9U)WC/;RN"DQ^I>
M!O#>J9,^EPHY_C@_=G_QW&?QK#/P]O\ 2SN\.^);VT Z0S'>GZ<?H:Z1/$UJ
M&VW$,\#?[2_Y/Z5=AU?3Y\;+N/)[,=I_6N^&,@]%/^OF/F.&O=;\>^&K*:?4
M;&QU"VB7)N(FVE?0D<?^@UYD_C3Q')J'VTZQ=B7=D!9"$'MMZ8]L5[MKFK:<
M+>;3[F,W"31E)$4\;2/6O-[#X66VJ7326NL%;56^:-X?WJCTZX/U_2NFAC,.
MY.#:YBHR1Z3X2UX>(O#EI?.T?VAEQ,B'HP)!X[9QG\:W*X:X^%^EQ[)=(O;W
M3+I% $L4A.3ZD=?R(J#=\0/#W5;;7K5?3Y9<?H<_]]4G",G>+%9=#T"BN*L?
MB9I$DWV;58+K2KH<,EQ&=H/U S^8%:>K^.- T>SBN9;Y)UF_U:VQ$A;\C@?B
M:ETYIVL%F=%16#X=\7Z1XG$@T^9Q-&,O#*NUP/7T(^E;U2TT[,04444@"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@# \2 VLMAJBC_CVF"O_ +C=?\^];P((!!R#T-5=
M3M!?:9<6W=T(7Z]1^N*J^';LW>B0,V=\8\I\]<KQ_+%<L?<Q#722O\UH_P!#
MJE[^'3_E=OD]5^IJT445U'*%%%% !1110 4444 %%%% !1110 4444 %%%%
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M=5E=0RD,I&00<@BK6J4ELP%HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@C=7D(PK$C 7W/?\*THTX2PZJ<U_/;Y6'96N>X4445D2%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !5#6K/[=H]S !EBF5_WAR/Y
M5?HJ9P4XN+V94)N$E);HSM"O/MVC6TQ.7V[7^HX-:-<_H?\ H.KZEIAX4/Y\
M0_V3U_I705EAIN5)<VZT?JM#7$P4:KY=GJO1ZA1116Y@%%%% !1110 4444
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M7.!('&W'K7G8YXV#BH.Z\E^9Z.!6"FI.:L_-_D=O;>(-,GM8YFNX8BZY*/(
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MHWA73K72XX;W2K"2<,Y9C K<%R1SCT(J]_PCNB?] ?3_ /P&3_"@"Y]NM/\
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M$_Z ^G_^ R?X4?\ ".Z)_P! ?3__  &3_"@"Y]NM/^?J#_OX*/MUI_S]0?\
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M?_X#)_A0!<^W6G_/U!_W\%'VZT_Y^H/^_@JG_P ([HG_ $!]/_\  9/\*/\
MA'=$_P"@/I__ (#)_A0!<^W6G_/U!_W\%'VZT_Y^H/\ OX*I_P#".Z)_T!]/
M_P# 9/\ "C_A'=$_Z ^G_P#@,G^% %S[=:?\_4'_ '\%'VZT_P"?J#_OX*I_
M\([HG_0'T_\ \!D_PH_X1W1/^@/I_P#X#)_A0!<^W6G_ #]0?]_!1]NM/^?J
M#_OX*I_\([HG_0'T_P#\!D_PH_X1W1/^@/I__@,G^% %S[=:?\_4'_?P4?;K
M3_GZ@_[^"J?_  CNB?\ 0'T__P !D_PH_P"$=T3_ * ^G_\ @,G^% %S[=:?
M\_4'_?P4?;K3_GZ@_P"_@JG_ ,([HG_0'T__ ,!D_P */^$=T3_H#Z?_ . R
M?X4 7/MUI_S]0?\ ?P4?;K3_ )^H/^_@JG_PCNB?] ?3_P#P&3_"C_A'=$_Z
M ^G_ /@,G^% %S[=:?\ /U!_W\%'VZT_Y^H/^_@K%A\*Z<NN75P^EV!M7@B2
M-/(7A@7W'&.."O/M5[_A'=$_Z ^G_P#@,G^% %S[=:?\_4'_ '\%'VZT_P"?
MJ#_OX*I_\([HG_0'T_\ \!D_PH_X1W1/^@/I_P#X#)_A0!<^W6G_ #]0?]_!
M1]NM/^?J#_OX*I_\([HG_0'T_P#\!D_PH_X1W1/^@/I__@,G^% %S[=:?\_4
M'_?P4?;K3_GZ@_[^"J?_  CNB?\ 0'T__P !D_PH_P"$=T3_ * ^G_\ @,G^
M% %S[=:?\_4'_?P4?;K3_GZ@_P"_@JG_ ,([HG_0'T__ ,!D_P */^$=T3_H
M#Z?_ . R?X4 7/MUI_S]0?\ ?P4?;K3_ )^H/^_@JG_PCNB?] ?3_P#P&3_"
MC_A'=$_Z ^G_ /@,G^% %S[=:?\ /U!_W\%'VZT_Y^H/^_@JG_PCNB?] ?3_
M /P&3_"C_A'=$_Z ^G_^ R?X4 7/MUI_S]0?]_!1]NM/^?J#_OX*I_\ ".Z)
M_P! ?3__  &3_"C_ (1W1/\ H#Z?_P" R?X4 7/MUI_S]0?]_!0+VT) %S"2
M>WF"J?\ PCNB?] ?3_\ P&3_  JCJ_A?3Y],DCL-,L8KK<A1UA52,.">0..
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M^@JT\D1#;%W$NZX.#TXQZT7 ]:HJAHK0/HMH]M<RW,+1!EFF<L[Y[DGO5^F
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M@2&%<E8T& ,\GBIZ** $+8IOF#THHH <#FEHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *.E%% ##(!VI0X-%% #J*** "BBB@ HHHH **** "BBB@ HHH
;H **** "FE@*** $$@/:G@YHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>img62602283_12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img62602283_12.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M_;'\"_$+X+7'Q TO6+>7PO:H99+MB H08YZX[T >JT5Q/P7^.VA_M > ]/\
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 &>:.]'>C/- !11WHH
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M(S[30 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MD\"G>3*QDC63:G!1_P"(>WTKE;_XX^%;/1YKZ36[#[/",LRR=*O?#_XF:/\
M$3P['JFC7L=]:/P&0Y'^>:TA4C;XD_0SJ86M&*;BUZHZ**-5965>K%C@U8$F
M:A VR\?=Q4E:QU.6[YK#HWWBG4V(;13J&4PHHHH !33)@_=-.KRW]I#Q/K'A
M?289-/F:-6;#'TZ4 >E-J5NT_DB5/,7DKGFN5\:_&S1_!LWDW$K--W1.J_6O
M"? 'Q!OK+Q]9W-Q=O,TKA6!/'/']:U_VE=!CTKQM]O$9DCNXAM/;=S_C0!ZS
M\-_BQ9_$2\N$M5F7[.,MO'7Z5VGF!]O'WJ^:?V==?/AWQRL+<+>(%Q[\U]+%
M<.#V% $E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MFS]EGX*:':Z/:WH^(7BB\LKR2[):2W#74:9!#?[9]>E 'ZU&QCG+1M$K1@Y
M=05'TIDEG%YJQQQM;[QDR(HZ#UKXX^)__!42;X2?M=?$SP'JFFV/]@^ O#<>
MN12HK>?>R-;-,8@<[>2N!G'7K7+_ +-O[>G[27Q=N_#_ (HO/A7ID_P\\27&
M(UM"%OM.@+#;+*S2["-IW?*">* /O"#3(;=S)#&L;#D[$4%_<GWHGL+>?][)
M%''(W&[8-P_&OS!^(/\ P78\8S?$3Q5=>$M T&;P9X,U%M.O+>[5WU&Z:-V2
M8QE6V8!1L9]1UKT;XC_\%4?&WQ2^,/A7P'\$O#&DZMJFNZ$-:U2XU1'\JQ4Q
M1R&/:&5MV'(R 1\M 'W197^FZI?2F"6SN[JU^65H&5G0>C?7%:4%I&MKLV1[
M6.X*RC:._2OS;_X(*^(M>\8?%G]H:[\2QO9ZPNM6\;VY;<L+ SABG)^4D9 S
MG&*_2NUC5W+'.[&&_P!J@"O>:+!J!C\Z&WN%7IYB9V_2M!$$:!5&U5& !VIA
MMP?7/8^E2#@4 %%%% #77(KDOC1\.(/BU\.]3T&YD:*UU&!H)BO7:PP<5UCM
MD]:H>*=8B\.Z'=7TT@BAM8C*['H .>:J.XI;'"_$7X$6WCGX>:+HL-Q]AN=
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M<]*KZQ2[F?\ 96-OI3.J\6_LI^#_ (C?"W0_"?B#1K?4M+\.K&+02+\RRHN
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M-GZ=:^B? ?QKUJ70YX[72]2UB_\ #^8XG9"T,('&<=3U/2NQ^%/P?\(?M >
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MKBSD\6> YKAIH9 A>2-O<Y/\J^:?'NNQ_M,^/9]3TVQL]-:8!W@E4,&<G&W
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M59QYC':.>K'CK7A^C?'/Q5X6^)WA];G5]<G_ +9S<S)>7BS636I8?/'"/F7
M*]:^IO'WPKTGXA^ KKP[J5K')I%Q$()(F&2(PNWY?0X[UQ^F?LA>%;#4H;Z5
M;JZOHK5M/@N[AP\\<#8R@;' ^4?D*/:1'[-GBVG>+_&B^!_"?B35/%&KQS:]
MXA^P0V<4QV;#)(%W#GC"BL+P4NI:1%KFN0ZI>WLWCKQ#!I,"2S;XP"C(W'^\
ME?5T7P=T.YCT>W-FL<&@S"XMX6P<2 DANGN?SK%\+?LR^%_"[PF!+AH;>^_M
M"UC9N()@6.1QQRQH]I$?LY'S#INH:QX;\'_$#XE:1XGN8;JXN4>WTVWFVI<2
M0Q^7L*]\E#7=6_CSQ-\6-#\5>()O%5UX;_X1=(?LULDI2-7:%7+2K_%SGIC@
MUZIH7[(7@CPYJ=K,EG,ZQW#7$=ID?9S(6)+%<=<D\Y[U-KO[+GA/Q-KUU?74
M.H+#>8:^M4F'V:[*@*OF)CYL*,=>E'M$+V<CQWP9\8_$7[0%W=-?:]=>%+#P
M]:,9FMY3%)+,,;7/7(*DGIWKS;P/\:M4^%_@J/5KJ1M3>TTR[\3:B74^:TD%
MP84(/J4(KZG\3_LH^%?$MY#<7$-Y:R7"?99H;*410NG8LN#G  %:&G_LS^%;
M.UN+:;3X;R*\M6LIHI5#0M$2"4VX[X!/O1[2(>SD>!_#CXJ_$#3?$GAF^OFO
MX_[6E$^K&[U".2U2U;/[Q8P=P(&P=^]:?PW^(7B>[^,MK:>(->U+3[G5+[Y(
MYYO.TS4K?IB"->8VX RY['UKU_PY^ROX5\/ZG</):3ZIYT1@B6]<2I%"<$H!
MCA<CI4WA/]F+P[X/U:'47EU#4&LV+V\-U)YD%F<Y_=)CY?S[FCVD0]G(]0M&
M+6Z[EV\8Q3W&Y:9;#$"CV[5)6)NMBNMHZ-N63J>0>E2PHR#YCEC3Z* "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (9X]SBG;,)3G^]377
MY<47LKAOH>(?M@?&/Q3\*_"MN_A6+1VNKJ<1M/?W4<*VR8.6VNRESD#A>:^9
MM!_X*A^+(/A9\2+C4+6RO_$'@=-V^"#RK>7Y%;C)(/WAWKW+]NO]CG6OVEM0
M\-ZCH>J:;;7_ (9NENDM=0M_M-I=8S\KQ[@#U[FO'[#_ ()7^++_ ,-?$2SU
M+Q/HYD\?6WER+:6!@AM7"(H*+O.  O0>M>7B*DW+W3[/*?[+CAV\4U?\2K=?
MM_?&#1_'WA'3+K0=+_XKBT']F[57-M(3@&3YN1P?3K57QO\ MAZ[\1/V>OBA
MI7C70K/^W/!L@@>.,+Y,H**^<9(_B'>O:-;_ &%]4UCXG?#/7VUJVV^ X$@N
MXQ"?]/ )/'/RGH.<]*Y'QC_P38U[Q#H?Q;MT\26OF>/[A9H"UN<VX$2)MSN_
MV:S:GT;+AB,G;]Z)CW7[9OCC2O''A7P'X+T6QD-]H7VU9+@*R1,'"],CCFHO
M"W_!4?6+#X(>([[Q!HJ7'BWP[JHTAK>!?*AN)6C\P%<Y&,$#J:]+\$?L,ZMX
M3^./ASQ1)K-K);:3H1TN2,0']XQ<-_>]NM<>W_!+6ZU7P9XZT_4/$.;[7]97
M5M(N8T*K8$1!!N7.6YST(ZUI2YT@E4R6=35:%CX:?ME_$3PK\9O#/A;XEZ1I
MT2>,@#I4UDR)Y)8G"R %MW /I7K_ .U=\8_$7PQ^'4EYX7@TS^TV;9%+J-Q&
MD$/&=VUBN[Z YKRCX0_L+>/-9^+OASQ1\4O$VCZRO@D :+!86+6S*PSAI&+M
MO."?2NU_;H_9#UC]IGP?H\6A:I9Z?>:/?"\"7EN9X)L*R[73(W+\V<9[5MS2
MMI<\J2R[ZPNW4\<^$/\ P4^UFTLO']KXQM[.ZO/!UB;_ .UV0"0SIF->!EMO
MS/Z]JZKX(_M(_&+Q@FGZCK?A73;[PMXA1F2>WFCA:SC^;#."Q+=.P'6N>^&W
M_!*S6[;6O&L_BK7-#NK+QQI1L;FUTW3C:QVYW(0%&YN/W8/XUK_"#]AWXQ>&
MM2TG2=?^(>GR^$O#;D65O86;V\MS%AL),WF'>/F/4#H*Y^:?6YZ<IY39^S5O
M>3^1YG\+OVW!\)?@UXTN=$\/QR:I<>*/[)M5RJHTAA5]Q'\0ZBLW6?B7X_3]
MNSP#-XZ@M?M7]G&XM7L5VI(<R':4!8],UZA=?\$KM4NOA9KVE_\ "1VL.MSZ
MW_;6F7<=N52W<1A &7=EN_<=:F\/?L$_$G6OCAH/C;QIXRTB]NM#M3;6T-C8
M-;^4OS8W'>0QYZU*IU)[7.J.(RMU92C:S[_H<I\#?^"E'CCXJ?$:#8NBPZ;-
MJ)MYM)NU6SOK.( _.6D8;^0.%7/-?>T-Q)>V4,N[RMRAG7[W'X5\%:O_ ,$M
M/&?CWQQ8MKFO>%VM;.[^TOJMGI)@U2<<_+Y^\L.O7':OO#P]I']AZ7;V>Z21
M;:,1!Y&W,X [FNC#TZD9>\>!GWU1R7U>R7D7(8EG#,=S*W][O3A9QQ1[5C4*
M>V*(_D/UYQZ5(3@5Z4FTCY[E4=%LSP/]O>VMW_9O\3M-HO\ ;B_9RJPQQY,;
M9'S8P2?PK^?SPMX?L?\ A=5U=:@UYHMG;W9#+!:26X5AS\P(].]?MS^VK_P4
M>T_]G;QW<>%_^$?NM5DDL_.>59@L<>6*_,I4YZ"OS+UOQ+%^TU\;]6:YAL[7
M[6QFEBMXO+55/'/O[UQT\=!UHT;)MGLOA?&QRZKF>$FZ;BMTVK^MFA_Q&_:9
M\0>-=/M_#G@JWO-6M;U/(^W;3^Y'7J?I^M<+\1/#_AOP+\%3H=YJ%K<>)KAR
M]Z)!N>-\= ?PK"^,OQPA_8\\53:'IBZI:Z?-D0R#< Y]CCVK0^"MAX;_ &H?
M .M75GX=NM2\3QDRI--* S=.22O7K714QU1IT5!?<?/8G@MX#!8;/95E?F3=
MF<C\,?AA8Q_#-;_3?.77GN"%N)#R1@<9]/QH\2_"'Q41::YXHM[.ZLT;Y%A4
M;F^O)K(U_P 3^+/A9-)IUSI5Y%80YRXA;;$1_M8Q^-=3X%^+5]\6_!MO)#<7
M$-O"<$3*0#],XKX/&4Y4E+F;3;V1_5?#>*I9Y*A"G--+5Q:3O9;ZWU-2:*XU
M'1M/\N.2&.&Z$B#=M6->.,5]?Z5XOT5]#L9+N2SDCM;7&Q67@X(-?(6O7BV.
MB,UQ<.T#88A?ESR.E<;\3_C/:^#TCM;5KI/M$8 /G9 ^O'%5D>?XC#2Y5&_J
M<GB)X>9?Q)AH8W%8B5&%.5G?]/(]8^+ZR64>I:AX=U[5H6NISY5M%=8C@''W
M0.G%><ZUXYTNTT)=)NM-^WZ_-(IN[R^'F&5<CA21P<CU/%=-^QQX?_X32WUN
M^O/M&H0VX9XX@^5!^O2O+X_$=QXJ^+%Y#<:7/-]GO62WM O+'_>QBOK,/FF,
M2TB?B?\ JGP=5S%Y71G)2IK6I=V?J>Z>!O!6N?#V;_A)8=8L=,T59!*EI"N7
M5&( 7*MQU]*9^UI\0=-\1>(M)U.&SF9XXU6\NXY0CL.?O'&3@G-9GQ)^'OC_
M $GX87TNGZ>MLUXB&.S9A=21)N!R=OW?RK@_AQ\*+KQ_+>1^,-:U*QA,!.P0
M2(N0">_7\*X\?B,=BH\BIZ+5Z';PUEV1<,X>OFRK>TE&5E[V]W;N=5\*O!-Y
M\:_BM'X7\'WDFI7.J?.CS3#;#G/KCIBOVT_X)W?LG2_LG_LZ66A7LS7FL7C?
M;+^21M[>:P7(S[%:_!?]G[Q+I?[-?BS_ (2RQUYIIM)OP!'#/Y4CQJPR,=3P
M3VK]O?V.O^"IG@/]K74-*L=+-U:ZG?0>8(I%8%FP203@=,5AE^'PZJ7O[Y]3
MQX\3C:%&I0A>"CS/7OWU/K&#]Y#N/ SFN%^-OQ$O/AO8I=6-I',TGRERO2N\
MTX>=:!NH<9QZ5S?Q:^'\GC_PV+6%_+D!R"?PKZ,_'8ZZM6/GW7?C5XD\0R%7
MU!X(VZK&2H/ZUS=U--?7:M(S,Q/5OWA?\NE>VZ%^R7;QE6U"\%P1U"*5KN/#
MOP9T'PZW[NP5VQPTN'_I04?(&O\ PHUSQ=J _L_3+IO]IAM4_G74>$/V)?$F
MN,O]I26NG6\B\DC<<?@:^O(=.2VCVJJ*HZ!!MH%J51L;FW?WSNQ0!P7P"^!D
M?P4TJ2SCNFNED.2P.%'X5Z-MYSWJ&*W\IEX^N.!4] $-U;1SP&.1%9&ZJ>]>
M=_$/]GK3?%4;26BK9S8)S&-NZO2#'N-"'F@#Y'\:?#C4O!$OEW5NTEHO1E%0
M^%?B%J?@VZ6;3YIO)'6/=U'N*^LM5T.VUFW:.Z@CG5AC##->1_$?]F?S9)+_
M $>3RY!DB#.!0!:\(?$W1/B_"MAJEBKWC#!8KDK^.*]2\/>'K3PWI<=K9PK%
M#&NW '7W->:_ #X22>$H9KW4(4^V2=N&Q7JT1S&O&..E !L4$<=.GM3J** &
M/ DCJS*I9>A/:EV ]NE.HH 3;2"-1VIU% $;6D;R*Q1=RY /IGK2_9T!^Z.W
MZ4^B@!@MXQ_"O)R:?CBBB@! H4T@B42%@HW-U/K3J* &M$KL&9067H?2C8N<
MXYIU% #2@9LTZBB@ HHHH 0KFD\M3_"*=10 U4"DG'WNM"QJB;57 ]*=0* &
M^2N/NB@1J#G ]*=10 FT%MV.>F:3RU(''0Y%.HH :T*M(&*C<!@&AXED'S#(
M]Z=10 U855MP49 P#20V\<";4554= *?10 S[-'YA;:NYNIQUI1$H ^7[IR/
M:G44 -$:@8QQ3@,444  &T4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% #7^]32,K3GCWTUAA*'KH3=]3D_'_ ,0]-^&N@_VE
MJDS+&S;08XRS,>>,#GM7(>#_ -J31]?\20:?=6NI:;-=?Z@W-L\:2CV+ "L7
M]J8-!K_AEKCY=)-VHNF89C R>W0'WKH_$?COPG]OT>"Z:QOKJ0JMFL:+.RG'
M' SBNZG1I\EFM3P\1BO9U5)7TZ'HWVA45OF15?D$$ FI/,PK<YV],GK7S3#<
M-\3/%OB:75M=OM+FTJ4+8VD=RUJ NP')&1NY/I6;-XRU[Q1X+\)13:A>0376
MI"U:6*5D,T67[@]>!S4_4XC_ +<?\A]3Q3JXR67<.JALXILD\<C;5D5F]-W(
M_"OG#1[?4/"GQ0\0:'::Y>+;S:<9$DO+@R?9WRGS;F/ Z_G6'X$\3W'@/QKI
MEUK#ZN;G4'*"5-2:\@GY/(C7A>E5'!)ZHC^WG&2;@SZM::-<))(JMV&[FF&[
M5E^9EBV],MUKY+NM=USQEK'B*^-S=0W>FW86U8:IY,:C:#AH^_6NH\66NK>-
M_B=X-TNZU2[M8KK3C-<1VUR8S))YC+U!]*7U1+<JGG4ISNH'T6+C,VY6#1XY
MPW2D%TD95EDRC=26Z5\X^.?%M]^SUXBU2TDO+^ZMKZUS9B1VD*R;@.OX&J7C
MNZUO0;3PGHMQ=WTG]KGSKO;=&!I'.["J_P#",8XI?58E5<ZG3:YH=/Q/IUYU
MG:-U.Y1W!XKF?%'Q5L/#'B72=/N,22:M/]GB*\[3@GG\J\&G\8>)/ G@/Q%:
MQW<RI'(([=#<?:Y(%(7DRCZFH;SPC8^%_B%X#FL]6N-6>:Y$TIGO//PQ5P<9
M/'TK2&%BMSF6;5:_)&"LUN?5:*NT,OX>]*J$M4=IN(C!QMVY&>N:LD;A7#))
M2/=7OI.0@&XT2_+&V.N*2-?+!QZTZ0;A]14R=CHT=C\9?^"N6JS_  _^.?C!
M_$"WD$6LV -A=*C%5/G+P#] >]>*_LJ>+/"7PZU";4'D;5O[>C DNF4R>0,@
M^^/N_K7ZI?\ !4/]C+_AJ?X1,FGV4-QKUBA\@.PYZ\'/7J:_"_QC^SO\8OV5
M/B'=:/\ V#<-',Y+0NQ:.09Z*<87IGBOG*W[K%1KK9,_5LGQ>#QN4U,LQDG&
M$XM-K=>GS/L?XX_#[PG^VCH+:+;VUO'(%Q87QM<$M]<>F>]+^Q#^R)JO[)Z:
MK#JDT-V+D%_,1?X>.V3Z5F_L^^+K&/X?:7#-:W&CZUH*><UN\O4X((S@;NO2
MN\U?]MSPM9^!9IYC>?VQ) 8C;/ V[/MQ7Z#A?848J5>UY;'\L9M@LPA@*F%P
M4YU80GHM;VN>6_M0_&/2[JZBT>32+B33+Z7R99A"=I[]<5Y7\2/A5K$FN:/I
M/PYT_P"SO-%O>"[&(SUYYP.U>@/\7O#GC3X/137MG--J$%P6CA\S:Z?*.JXR
M:\[;]H37/AG-_:\.J6_V.Y3RHA<VOFS*#T523E<9KRZF6X/%U6ZS5UL?H-'C
M/B'(\NP\L'3E"=KWMK;8XOQ/^RGXLTJVO[SQ7XJM;2>SB$PM(KI54<XV@;JR
M?@AX?\%^+DU2U\53----&?*=KD?)W[UMQ_#/7/VJO$BZ1IU]<?VHQW74\[$1
M;NNS)./PSWKR7XX_LY^*/@YXPO-%O(4CF4X^U*XCC(![-T[>M>;B,IITVU0B
M?3</^(F;YI.F\\K7@I7<+;_(];U+XS-\!/A9<:=X-FCMW)*LV<EQQ77?L.:1
M_P -"^"KJ\@FAA\56-RMQ([ 9*EE!_K7B/@R/P/?_#6.UOO[6DUZQG9;N42M
M- PV@#! V]?>O;OV%A;? SQNFNP7EM-I6I@1W0+@*%/3'/7)!K@RO'U:<^3$
M)'U7%>1T\PH5\7E-+EJR5^7;0^\K30[+0PS3-;QW#0GS9),%9@,G@5X[\3?C
M+X6T1,7&DV.H!H62,(JYA7:>O!YJQ\7?B98W^LM:Z)>2:K/% 7@BAS((DYX;
M&<]Z^-K_ ,2^(OB=\3F\,:3IC-<75P1<O(_DB%3UY(XX!KV<XS>I"G"&%C9R
M=FWHK>1^8^&?".%S#VN*SV3^K4_B@GKS)[I:',>)?V=[?XV>/_\ BC[3RGNC
M]IF.[Y(LY^GI7OG[(%UK'_!.WXTZ3XBU"XMM66Y"I#:$!W16R.!D^OI74'2_
M!O[)VDP:=I5Q)?:[):BWO6AE^T+!C/4KGGK7U)_P2F_9\\._M#>*;KQ)XFT?
M^V(-)MT2SDOH/E0@GLXY//6N;_5V,*?UM/WCV,-Q_A\1FT\-AZ<OJ\4XJ^]E
MMH?I%\$O'$?Q)^&>E:]'%-"NJ0+<&.12I0L,XP>U=95'P]IEOHNE0VUK&D-M
M$H6-$&%4=@!V%7JTI\SBN?<YY\O,^1670****LD**** "BBB@ HHHH *9+\W
MRG[IZT^@\B@"%56W&U5XJ53\M)Y2XIP&T4 %%%% !1110 4444 %%%% !111
M0 44"B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MV=E'%0J:1-('-*Q^44R$9SQWYJ3/%9G5+LBG):+,&7;_ ,"SR:^)_P#@K_\
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M VMNX4<9_"OH?X137U]X,M&U*W6"94&=J>7G_@(Z5O\ V>.:+]X(_,QG. P
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M/M1YJXSNKA?C3\7=%^ OPXU#Q-X@NOLNEZ;$]U-G_6-@%@@[9.,5\[?LX?\
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M;5)+&]N+>"\F 5;LK*X!.T?PXQQ6QK_[*O@_77L8[C27_P!!@\F*2.9U81C
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MCO1CFCO0 4&@T=Z #'-'>BCO0 9H-&>:* "CO1WH'6@ H-%% !1110 4444
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M.$#4)KN/H!D\$?05U8BLFE)'S\?;SCR1Z$'P8^,UYX2\/?V9>Z.+K1KD;S/
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MV*:WWQ3JX8G8&.*3;Q2T50!BDVCT_2EHH ,4;>>E%% !BC;CM110 8HQ110
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M0<BHV-2*<J*PCM8OJ%%%%4,**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
F*** "BBB@ HHHH **** "BBB@ H-%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>img62602283_13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img62602283_13.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %D U\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBH[BXAM;=Y[B58HHQEG<X %&X$E%<)??%'3H)F2SLI
MKE1_&S",'Z<$X^H%4O\ A;'_ %!?_)K_ .PKJ6"KM7Y?R,7B*:ZGI%%>;_\
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MF_\ PMC_ *@O_DU_]A1_PMC_ *@O_DU_]A1]1Q'\OXK_ ##ZS2[GI%%>;_\
M"V/^H+_Y-?\ V%'_  MC_J"_^37_ -A1]1Q'\OXK_,/K-+N>D45YO_PMC_J"
M_P#DU_\ 84?\+8_Z@O\ Y-?_ &%'U'$?R_BO\P^LTNYZ117F_P#PMC_J"_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M75K%J4$].IT7@/3KE/$<>H31/%:V:2/+*ZD*/E(QD_7]#3_".IQ2>-+J-_\
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M/^_:C^E>AEO\5^GZHY<7\"]3F:***]P\X**** "BBB@ HHHH **** "BBB@
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M  JS_J??'/\ X./_ +"@#T"BO/\ _A5G_4^^.?\ P<?_ &%'_"K/^I]\<_\
M@X_^PH ] HKS_P#X59_U/OCG_P ''_V%'_"K/^I]\<_^#C_["@#T"BO/_P#A
M5G_4^^.?_!Q_]A1_PJS_ *GWQS_X./\ ["@#T"BO/_\ A5G_ %/OCG_P<?\
MV%'_  JS_J??'/\ X./_ +"@#T"BO/\ _A5G_4^^.?\ P<?_ &%'_"K/^I]\
M<_\ @X_^PH ] HKS_P#X59_U/OCG_P ''_V%'_"K/^I]\<_^#C_["@#T"BO/
M_P#A5G_4^^.?_!Q_]A1_PJS_ *GWQS_X./\ ["@#T"BO/_\ A5G_ %/OCG_P
M<?\ V%'_  JS_J??'/\ X./_ +"@#T"BO/\ _A5G_4^^.?\ P<?_ &%'_"K/
M^I]\<_\ @X_^PH ] HKS_P#X59_U/OCG_P ''_V%'_"K/^I]\<_^#C_["@#T
M"BO/_P#A5G_4^^.?_!Q_]A1_PJS_ *GWQS_X./\ ["@#T"BO/_\ A5G_ %/O
MCG_P<?\ V%'_  JS_J??'/\ X./_ +"@#T"BO/\ _A5G_4^^.?\ P<?_ &%'
M_"K/^I]\<_\ @X_^PH ] HKS_P#X59_U/OCG_P ''_V%'_"K/^I]\<_^#C_[
M"@#T"BO/_P#A5G_4^^.?_!Q_]A2'P'XHT\"31OB%JQD7I'J<:72-['(!'UH
M]!HKS_3?'>I:/JUOH?CNPATZZN&V6NI6[%K2Z;TR>4;V/Z<5Z!0 4444 %%%
M% 'S=X^_Y*?J'_7Q'_Z"M?2-?-WC[_DI^H?]?$?_ *"M?2->IF'\*CZ?HCCP
MOQS]?\PHHHKRSL"BBB@ HHHH **** "BBB@ HHHH *\^^(WAJ:\":Q9QF1XD
MV3HHR2HZ,![9.?;'I7H-%:T:LJ4U.)%2"G'E9\W45[M>^$- U"<S7&FQ&0G)
M9&:/)]]I&:K?\(#X9_Z!G_D>3_XJO6694K:IG$\)/NCQ*BO;?^$!\,_] S_R
M/)_\51_P@/AG_H&?^1Y/_BJ/[2I=G^'^8OJD^Z/$J*]M_P"$!\,_] S_ ,CR
M?_%4?\(#X9_Z!G_D>3_XJC^TJ79_A_F'U2?='B5%>V_\(#X9_P"@9_Y'D_\
MBJ/^$!\,_P#0,_\ (\G_ ,51_:5+L_P_S#ZI/NCQ*BO;?^$!\,_] S_R/)_\
M51_P@/AG_H&?^1Y/_BJ/[2I=G^'^8?5)]T>)45[;_P (#X9_Z!G_ )'D_P#B
MJ/\ A ?#/_0,_P#(\G_Q5']I4NS_  _S#ZI/NCQ*BO;?^$!\,_\ 0,_\CR?_
M !5'_" ^&?\ H&?^1Y/_ (JC^TJ79_A_F'U2?='B5%>V_P#" ^&?^@9_Y'D_
M^*H_X0'PS_T#/_(\G_Q5']I4NS_#_,/JD^Z/$J*]M_X0'PS_ - S_P CR?\
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MT7^8/#56K-GDNF>(=6T9"EA>R0HQR4P&7/K@@BH-2U6^U>Y^T7]R\\@& 6X
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M_%4?\(#X9_Z!G_D>3_XJC^TJ79_A_F'U2?='B5%>V_\ " ^&?^@9_P"1Y/\
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MZ"?_ ) C_P#B:/[-J]U^/^0?6X=F>VT5XE_PGWB;_H)_^0(__B:/^$^\3?\
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M-'_"?>)O^@G_ .0(_P#XFC^S:O=?C_D'UN'9GMM%>)?\)]XF_P"@G_Y C_\
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M/_XFC_A/O$W_ $$__($?_P 31_9M7NOQ_P @^MP[,]MHKQ+_ (3[Q-_T$_\
MR!'_ /$T?\)]XF_Z"?\ Y C_ /B:/[-J]U^/^0?6X=F>VT5XW:_$;Q!!(IFF
MAN5'59(@,_\ ?.*](\->*+/Q):LT(,5Q'_K8&.2ON#W'O6-;"5:2YI;&E.O"
M;LCF_@E_R2'0O^WC_P!*)*] KS_X)?\ )(="_P"WC_THDKT"N4V"N?\ '?\
MR3SQ+_V"KK_T4U=!10!Y_P#!+_DD.A?]O'_I1)7 _&_PC=Z)/<^+M#S';ZA$
M;35HD'!W8PY'H2%S_M!3W->_44 <+\.-.LM1^%OA<7MM%<+!"LT:R+N"N-P#
M8]1DUT^M>'=&\16WV?6-,MKV,?=\Z,$K_NGJ/P-:=% '/^'_  -X9\+2R3:+
MH]O:32##2C+/CT#,20/85YWHGQ!OO 6MZGH/Q%N;QD:<RV&IM"722/ICY1TZ
M'@'!)!QQ7LE,EABN(S'-$DB'JKJ"#^!H \3O+]OB_P#$/P]+HEK<#P]H4_VB
M?4)HRBRON5MBY_W%'KR3C@5H^-5NO ?Q0MO'R64USHUW:_8]3, RT/0!R/3Y
M4_[Y(R,BO75544*JA5 P !@"EH \0\<>-[7XGZ?!X-\%K/>R7\L;7ERT#)';
MQ*P;YMP!Z@<].,#)(KH/B=X.O7\)Z#=>'H#/?>&9HI;>%1\SQH%!  ZGY$./
M8XYQ7I<-O#;J5@ACB!.2$4+D_A4E 'DE[\=M!N?#K#2(;V7Q#.ACATX6[%TF
M(P,G&" ?3DXZ"K7AKX:S6_P3N?"UYMBU#4(GFESTCF;!0'']W:@/T->FBWA$
MYG$,8F(P9-HW$?6I* /&/"'Q7TOPEX:A\.>,8KO3=7TF,6YB:!G\Y%X0J0,?
M=QUX.,@\UI_"[3M0U?Q/X@\?ZG9R6?\ :Q6&RAE&'$"X )^H5![X)Z8KU"6W
MAG9&EACD*'*%U!VGV]*DH *\C^.O_'OX3_[#"?RKURB@"GJW_(&OO^O>3_T$
MUXOX!\-R>+?V=K[18659YYI6A+=/,5U=03VR5 S[U[I10!XMX4^*'AS0?#]O
MH?C&SETO6=-B6WDCELV?S0HPK @'D@#K@9[XJWHVM^*_&MAXJO\ 2=,CT[2'
MLI8M'9H!'<2R%< AL].IST!88)P:]:E@AG $L228Z;U!Q4E 'SY\-?%WP^\)
M>%TM=<LOLOB2&1Q<B:P:2:1MQQAMIQ@8&"1R#]3/X?UN\U3]H:SU;4=,GTN'
M4K%UL(KD;7>(*0K$=B=C''TZ\$^\^3$91+Y2>8.-^T9_.GT >/\ P(_YF_\
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M44 %%%% !7C_ ,2;Z2Y\3FU+?N[6-55<\98!B?U'Y5[!7B7C[_D=M0_[9_\
MHM:[\N2=9^AS8M_NSFZ***]T\T**** "BBB@ HHHH *WAH,)\%MKGG/YPN/*
M\O VX_QK!KT'2+.WOOADT-U?1V49O"?.D7(!XXKGKS<%%KNC6E'F;7D<1IEJ
MM_JUG9NQ59YTB+#J S 9_6KNKZ7;:3XGETYYI#:Q2JK28&X*0"3]<&M_1_#N
MD0:W82Q>)K2:1+F-EB6(@N0P( Y[]*I^)463XC3(ZAE:ZB!4C((PO%2JW-4L
MMK#]G:%WW,/6(M.AU.6/2;B6>S &R2488\#/8=\]A5&NM\0Z9;S_ !);3HT2
M""6>&,B-0H4,J9P.F>3^-:4NL6UEXL70X= TUK)+A;<J]N&D;) W;CU/?FA5
MK1C97TN#IZN[MK8XC3XDGU*UBD&Y'F16&>H) -:GC"QMM-\57MI9Q"*"/9M0
M$G&44GK[DUH^(&C3QW#:0VMG;QVUS&B_98O+W D'YO4C./PK8\6:]8:/XFNE
M@TBUNKQMAN);M=X'R+A4';C'/J:GVLG.+2W3T^X?(E%IO9GG5%=3XTL+*(Z9
MJ=A;K;0ZA;^:85Z*W!./3[PZ>E8.F63:EJEK9*=IGE6/=Z9/6NB%12ASF<H-
M2Y2I72>)=*L]/TC09[6'RY+JU\R8[B=S87GD\=3TK5UG6]+T/4WT>TT"PGL[
M?$<SS)F20XYPW8^_-)XZ6":R\-K8HZP/;8A5^H4[< ^]<_M92G#2R=_R-.1*
M,M;LX>BNZU>ZL/!DL.EV>EV-Y=K&KW-Q=Q[\L>RCC _QJKK-KI^L>%$\0V-E
M'93Q3>1<PQ#"'IR!VZK^?M6D:][.VCV9+I6NKZHX^BN_O%/A_0=+N=*T:RO+
M::W$EQ=30>:2YZ@_W1_GM7/Z391>)_%L<*P):03-O>.+[J*!D@>F<?AFB-=-
M.5M%^@.G9I=3 HKO)-1D@U%K:'P= VE(^S#6+-(RCC=N]>_^<U@^,-'AT/Q#
M+:VV1;LJR1J3G:#VS]0:<*W-+E:M<4J=E=,J^'=/M=5URVL;N9XHYB5#IC.[
M!P.?4\56U2Q?3-4NK&3EH)"F?4 \'\1S4$$TEM<13Q-MDB<.I]"#D5UOCZ%+
MJ;3]=@7$6H6X+8[. .OX$#\#1*3C52>S7X@DG!OJC,TK0H;OP[JFKW4TD4=J
M D(4#YY#V.>W*_G0-!A/@MM<\Y_.%QY7EX&W'^-:?B,_V1X0T?1%^668?;+@
M=\G[H/YD?\!IZ?\ ))7_ .O[_"L?:3:4KZ.7X&G)';LOQ*^C>'-(G\--K.K7
MUQ!&)C$!"H..GL:2X\*V-WI%SJ.@ZH;Q;4;IH9(BCJ.3D?@#V['GM6MI%@NI
M?#)K=KRVM ;PGS;E]J<8XS2FSC\$>&KR7[1]MGU./R8WA7]R@P>=W?J?R^M9
MNK+F=I:WLET*4%976EMSSVK6FV:7^H0VTES%;(Y.Z:4X5 !DD_E2VNEZA?1F
M2SL+JX13M+0PLX!],@5%=6=S92^5=V\UO)C=LE0H<>N#7<VGHGJ<]K:M'6VG
MA[PKJ%R+"TUZX:\?Y4=H<1LWH./ZURVHV$VF:C/97&/-A<JV.A]Q]:V?!>F/
M>Z]#=N?+M+%A<3RMP%V\@9]R/RS5/5[E_$7B>XFM8V9KJ;;$O<CA5_0"L8.4
M:CCS75NO1FDDG!.UF6_"OAM-=GEDNIVM[*(JAD7JTC$!5&?<_P O6L_7]-31
M]<NK".1I$A8 ,PY.0#_6NIGN(M.US0?#5FX:*TO(7NG7_EI.7&?RZ?\ ZJQ/
M&_\ R.6I?[Z_^@BIIU)RJZ[-:(<XQ4/-,NS>'-&T6"V&NZA<K=SQB3R+6,'R
MU/J3^-4/$/AZ/28+.]L[O[787BDQ2%=K CL1_GO75W&FVOB_2K#4M5E.DWF%
MA$LI7;<+ZJ"0>_Z]ZQ/'#SVCV6CK9R6UA9H1 SD,9O5\CC\/?WK.E5E*:5]=
M;]OE_7J5."46[:="O::/X<AL8)M5UMQ/,@?R;6/<8P>S'!Y]N*B\1^&X](@M
M;ZQN_M>G78_=R8P0?0_Y[&L&**2>9(8D9Y'8*JJ,DD] *Z_Q;(FEZ#I/AL.'
MGM@9KC!R%=LG;_X\WX8K67-&I%*5[]/(A6<7IL<;111748A1110 4444 %%%
M% !6GH.L2Z'JT=[">55E9>S CH?QP?PK,HJ914DTQIM.Z/4?@E_R2'0O^WC_
M -*)*] KS_X)?\DAT+_MX_\ 2B2O0*^5/:"BBB@ HHHH ***9--%;PO--(D4
M2#+.[!54>I)Z4 /HKF1\1?!AN?LX\4:29/7[4FW_ +ZSC]:Z1'22-9$=61AN
M# Y!'KF@!U%8$'C?PM<ZG_9L/B'3)+PG:(EN5)9LXVCGD^PYK@_@E=$67BV6
MYF/EQ:K(2TC<*H&3UZ"@#UNBJ>EZMI^M60O-,O8+RV+%1+"X9<CJ,BFC6M,.
MLG1Q?V_]I"/S3:[QYFS^]MZXH O45X[X*OEM?C)\09KNY\NUMT\QVD?"1J#D
MGGH *G\!?$B'5O'GBJVU37[9K9KR&WT>(R*JR+OE4>6/XB?DR>IR/:@#UNBL
MC6?%.@^'=HUC5[.R9QE4FE 9AZA>IJQI6N:5KL#3Z3J5I?1(=K-;S*X4^AP>
M#]: +]%%% !17/7_ (\\)Z9<FVO/$>F13JVUHS<J64^C 'C\:U]/U*QU:T6[
MTZ\M[NV8X$MO('4GZCB@"U16'JOC+PUHEX+/4]=L+2Y./W4LZAAGH2.P]S5J
M+Q#HUQJ$%A#JEI+=W$/GPQ1S*S21\_.N.J\'D>E &E15'5-9TS1+87.JZA:V
M4).T/<2K&"?09/)]J@T;Q-H?B%6.CZM9WI0 NL$P9D!]5ZC\: -6BJ>IZMIV
MC6AN]3OK>SMP<>;/($7/ID]Z\K^,/B?2M;^%=S<:'J]O=!+J'>;:8%DR3]X#
MD?C0![!15/223H]B2<G[/'_Z"*N4 %%%% !1110 5Y__ ,W"_P#<J?\ MW7H
M%>?_ /-PO_<J?^W= 'H%%%% !1110!\W>/O^2GZA_P!?$?\ Z"M?2-?-WC[_
M )*?J'_7Q'_Z"M?2->IF'\*CZ?HCCPOQS]?\PHHHKRSL"BBB@ HHHH ****
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M>%O^O1OY)7/Z'>IIVNV-Y)GRXIE9\?W<\_I5 LS  L2!T!/2DJX4N6'(_/\
M$F4[RYD=SXB\':EJ.OS7^GK%-879\Y;CS5"*",DGGIU/':CQFT=E:^&3;S+<
M);P825> ^W;R/;BN)$L@B,0D?RR<E-QP?PII9B "20.@)Z5G&A*\>:5TO+RL
M6ZBL[+<[[Q1X?NO$M['KFAJMW;W,:[PLBAD8#&""?3'ZU4U9%\.>"AH4\B-J
M-W.)YHD8'RE&, X_W1^M<='-+"28I'0G@E6(S3"2223DFB-"22BWHOZ0.HG=
MI:L[K1=(\8Z+=P"P&^TD*L=LJM"RGJ2">./8&G-J>EZ1\4&N+=HTLR?+E9/N
M*S+@GZ;NOXUQ"W,Z1&)9I%C/5 Y /X5%2^KN3;F]U;16#VMDE$[R_P!&\:K?
MRBQOK^YM68M#+'>G:RGIU;CBN3UJ+4+?5)(-3N&GNXPH=FE\PCC.-WMFJB75
MQ%&8XYY40]55R!4573IRB];?<3.2>WYA7H?A&WA\3^&/['N&&ZPNTF7/_/,G
MD?\ H?YBO/*<KNA)1F4GT.*=:G[2-D[,5.?*[LV/%FI_VMXEO+A3F)7\N+'3
M:O Q]>OXUM)_R29_^O[_  KBZ7<VS9N.W.<9XH=%<L8KI;\!JIJV^IV:?\DF
M?_K^_P *7P;(-8TC4_#4[#]]&9K;=_"X_P#K[3^!KB]S;-FX[<YQGBA69&W*
MQ4^H.*AT+QDK[N_H-5-4[=+%ZUU;5-*62WM;VXMAO)=$<J-W0Y'KQ5FQ@U#Q
M9KMO:S7;R3R#;YLS%MJC)/\ 7BL<G)R:56*L&4D$=P:V<-VM'W(4NCV/3=<\
M-:R-/31-#LECTU,-+(TRA[A_5N>GM_@*X^ 7_@KQ%#+=6D;7$:%EC9P00P(S
MD?C6+]HG_P">TG_?1IC.SG+,6/J3FL:=&44XR::?E_P32=1-W2LSM]*\4V=Y
MK]DG_".Z>DLUU&/. ^96+#YL^O>H_&NI6K^*6MI-.@06]PC2S(/GE7 R#^%<
M6"000<$="*5F+$EB23W-"PT5/F783JMQLSO_ !AH&K:]JR:AIB"]L)(E$)BD
M7"#'(P3Z\_C5?Q*'T[P3IND:C*DFII,7V;PS11X/!/XC_(KC(KF> $1321@]
M0C$9J,DL26))/4FE&A)<J;TCY#E43NTM6>E>'_"][I&AKJEG;1W6KW* P;V
M2W5AUYZM@_T]<\IK/A77K""74M2A!4OF20RJQ))ZGG/6L,3S* !*X Z ,:1I
MI7&&D=AZ%B:<*52,W)R3OY?AN$IQ<;6&4445TF(4444 %%%% !1110 4444
M>H_!+_DD.A?]O'_I1)7H%>?_  2_Y)#H7_;Q_P"E$E>@5\F>V%%%% !1110
M5Q/Q.\.6_B3P[#!J.OIH^DP7"SWC.HQ,HZ)N+#;U]^<<<5VU>.?':VG,_A>_
MO+:>Z\-VEV6U*&'/3*8+8]5#@'CJ1D9H S/$FN?!A]!N=+L+"RGNS"R0-8:>
MWFJX4[3YFT9YY^\>G-<Z/$NI0?L[:5IMM<.LU_J+Z>'W8(AR6*Y^N!]"17<W
M?Q%\*W&BW&B_#[2CJ&J7D!@BM[*P,"1[AC<Y*J !U]/<=:XKP_X9NO%OP$-O
MI:E]6TC57N$A'WF( RN/7#9'J5Q0!ZU#\(O!L?AE-'?1[9W$05KWRP+@OC[^
M_J#GG&<=L8KB/@[:RV/@GQQ:3N7E@N9XG8_Q,L9!/YBMVT^.>@3:0BR6M_\
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MUO3B_P!G?EXD?&WZD!U/U'('. #I_A3X T*_\%P:[KNGV^JZGJV^>::]02D
ML0 -V<'')/7)]A6)HGABU\)_M'V^GV&];%["2>WB9BWDJRME03VW!C^-6O!W
MCYOASHR>$O&.E:A!=6+LEM/!!YD=PA)8;2.IYX]NN#5#PWK&H^(/VB8-3OM.
MGL(Y=/<VMO.,2+!L(4L.Q)R<>_XT 9<WBOPGJOQ9U[4?'4YFL].E-IIEFT+2
MQ85BI8J 1_#G!ZEO88K>,_%_@6SO-,\0^ "MEK5I<+YD,%J\$4T.#D,N O7
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M .3%'_%R/^IK_P#)BOI&BC^T_P#IV@^J?WF?-W_%R/\ J:__ "8H_P"+D?\
M4U_^3%?2-%']I_\ 3M!]4_O,^;O^+D?]37_Y,5SVL?VM]O/]M_;?MFT9^V[_
M #-O;[W.*^LJ^?OBQ!+=?$0P01/+-)#$J(@R6)'  KLP6-]M4Y>5+0PQ&'Y(
M7NV>?U]'?#:3Q+)X=4^(%^3C[*TN?.*?[?MZ9Y]>U8O@+X70Z3Y6J:ZB37_W
MH[<\I"?4_P!YOT'OUKTVN;,<9"K^[@KVZ_Y&V%H2A[TON"O$O'W_ ".VH?\
M;/\ ]%K7MM>)>/O^1VU#_MG_ .BUK#+?XK]/U1>+^!>IS=%%%>X><%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 45TEUI]KIO@>UGF@5K_49BT;
MMUCB7T^O'X&KWAWP5#KN@/>F]:*Y:1HX4P-I(&<'O6#Q$(QYI;7L:*E)NRW.
M-HJ9;9Q>BUF5HY!)Y;@CE3G!K4\4Z+%H&MO8PRO*@16#.!GD>U:<ZYE'N3RN
MUS%HHI0"Q  R3P *LD2BNVT[P$KV]Q_:=ZL-XD#3+:1$,Z@=W]/I7$UG"K";
M:B]BY0E&UPHKK/\ A&=)TJTMG\0ZE-!<W">8MM;Q[F5>Q)_S^E4?$/AY=)CM
M;RSNA=Z==C,,V,'Z$>O_ ->IC7A)V0W3DE<P:*Z>S\-V%OH\&IZ]J#VL=R?]
M'AA3<[KZ^W_ZO6H]:\.6UMI,.L:3>-=Z=(WEL77:\;>A'^>WK0J\'*W_  WW
MA[.5KG.45T6D>'+:?27UC5[TV=@'\N,JFYY6] /\]#Z5-?\ AO3YM$EU;0KZ
M2YAMSBXBF3:Z>_N/\]J'7@I6^7E?U#V<K7.7HKIM TVUUCP[J]MY*_VC;*+F
M"3^)E'WE^G'YM7,U<9J3:[$N-DGW"BBBK)"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH ]1^"7_)(="_[>/_ $HDKT"O/_@E_P DAT+_ +>/_2B2
MO0*^3/;"BBB@ HHHH *" 001D'J#110 R.*.%=L4:(N<X50!3Z** &"&,2F4
M1H)&&"X49(^M/HHH :T<;LK,BLR\J2,D?2G444 %-9%8J64$J<J2.GTIU% #
M9(HY4V2(KKZ,,BA(TB0)&BHHZ*HP!3J* "BBB@!BPQ)(TBQ()&ZL%&3^-1WD
M,EQ8W$$,[02R1LB2KUC)& P^G6IZ* /)=)\8>/O"]LVE>(_"&IZY=12$1ZA8
M8=9D).,[1@8_ XQD ];'@3PWXBU'QWJ/CSQ1:+833P_9[*PW!FBCXY8CO@8Y
MY)9C@<5ZE10 A 92K $$8(/>FQPQPKMBC2-2<X50!FGT4 (RJZE6 *D8((X(
MI$C2) D:*BCHJC %.HH **** "BBB@ HHHH *\__ .;A?^Y4_P#;NO0*\_\
M^;A?^Y4_]NZ /0**** "BBB@#YN\??\ )3]0_P"OB/\ ]!6OI&OF[Q]_R4_4
M/^OB/_T%:^D:]3,/X5'T_1''A?CGZ_YA1117EG8%%%% !1110 4444 %9J:%
MIZ:[-K7D!K^1%C\UN2B@8POI[UI44U)K832>X4444AA7B7C[_D=M0_[9_P#H
MM:]MKQ?XAPM%XRNG8$"5(W7W&P+_ #4UZ&6_Q7Z?Y'+B_@^9RU%%%>X><%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110!V?Q#5;:ZTFP3[MO8J /3
MDC_V6K%A=RV'PSCO(#B6'40Z'W!%0?$$BZ;1M14?+<V2X/TYQ_X]0G_))G_Z
M_O\ "O.2O1II]_\ ,ZG_ !)6[#O%%G#>76F>);%<6U^R"4#^"4'D'\C^(/K2
M>.Q:GQVHO6D6UV1^:8@"P7OC--\$7T-W'<^'+UPL-U^\MV/\$HP1CZX'Y>].
M\=70L_':W)ABG$21L8I1E6XZ$4X*4:JIOHG;TTM_D$K.'-W:*V_P9J6Z 0W>
MDL/N7!8RJW^\N3C\/SK'UJ#2+66&+2;N:Z*J?-G==JLV>-HZBMC_ (3JXN]T
M6L:=9ZA:G[L17RS'_NL,XK'UG5(-4E@6TTV"Q@A4JD<7+')ZLW>MJ<9J6M[>
MMU_F9S<6M/R_I'0> '>6]UEY&9W:Q<EF.23D5RVE1+-K%E$X!5[B-3GI@L!7
M?^#?"VLZ5/J+7MGY0FM&CC_>HV6)''!-<7>Z1JGAJ\M9;^U\ERWF1@NK!MI!
M_A)]JFG4A*I-1:UM;[BI1DH1;1H_$&1G\9WBL<B-8U7V&Q3_ #)JY(?-^$\6
M_!\F^PF>W7_XHU<\3^'[KQ->Q:YH:+=P74:APKJ"C 8P<D=L?D:H^)&CT7PO
M8>&Q*DEXLAN+K8<A&.<+G\?T]ZSA)2A3@MU:_E;<J2:E*3V8OQ%_=:EIEJN/
M*BL$V@=!RP_]E%+H!\WX>>(HFQL1D< ^O'^ JYK6FW'C'2-,U320L]Q#"+>Y
MA#@,I'/?W)_,55OH?^$6\%3:5=,@U/495=X58,8XQC&2..WZ^U*,DZ4:?VKK
M3T8--3<^EOT&>*OW'@WPO F!&\+R$#UPI_\ 9C2^ CO@UZW;'ER6+%@?;(_J
M:L+:/XN\$V$%@4?4=,)1X"P4LAZ$9]@OY&FVEE+X.\-:G/J6R*_OXOL]O;[@
MS;3U8X^N?P]Z.9>R=+[5]OG<+/G4^EOT*/PZF\OQ?#'VFBD3'KQN_P#9:YR_
M@%MJ-U OW8I70?@2*Z7X<P[_ !6LQX6""21F/0#&W^M<S>S_ &J^N+C_ )ZR
ML_YG-=,?X\K=E^ID_P"&O5D%%%%=!D%%%% !1110 4444 %%%% !1110 444
M4 %%%% !114UI:RWMREO A>1\X4=\#/]*3=M6,]+^"7_ "2'0O\ MX_]*)*]
M KS_ ."Y\KX;VU@3\]A=7-LX[AA,S<_]]"O0*^4/:"BBB@ HHHH **** "BB
MB@ HHHH *^>_B1\3M4\5>&M2C\*V-S'X>MRJ7FJN-GFY8*$3/0$D9[XZ@#.?
MH2O-_C3;P6GP<U2WMH8X88S;JD<:A54><G  X% '8^%"6\'Z(S$DFP@))[_N
MUKRJRM;[XL^/?$MOJ6LW]EHFB3_98K&RE\LR'++N;COL)Y'? QBO5/"?_(FZ
M'_V#[?\ ]%K7C&GVNL^-?B%K'B#X=S?V#:)(8+N_F??'>2<'(B*D9[_B#P3B
M@#<TE]3^'GQ:TWPHNL7FIZ'J\#211WC^9);L V,'TRF.PPW3(S7L=>%Z&E]X
M-^+5JWCY1J6IZJ/)TW6EE_=Q_P /EB/ "Y+8XZ;AC@DUZ!JOQ9\$:)JEQINH
MZWY-Y;OLEC^RS-M/IE4(/X&@"W\1/%H\%>#+S5T17N1B*V1^C2MP,^PY8CT%
M<7I_PGU'7]'CU/Q-XLUP:[<IYV(+C;':LPR%"8[9P0"!UQCK61\:_%&F>(/A
MWHFJ:/<"\L&U8'<4= Y1'R,, ?7M6U'\/?&'B/3$U;5?'6J6&KSKYT=M9.4M
M[8D9";01G' )^O7J0#I?AJ?%L&C76G>+HW>YLYS';WCL&-S%V8D')(QU.#@C
M/.:7XB>+I_#VFV^G:0GG^(=5?[/I\ Y*D\&0^RY[]_;-<[X"^(]Q%X>\10>,
M9E6^\,R>5=7 Q^^7+*N/5MRD>^5[FI/AW:MK>JW/Q!\12PI?WZ^7IUL\@_T2
MU[8ST+#OZ$G^(B@"O^SW-<3^!=3>YFDFE_M>7<[L6)/E1=S7K5>0?L\S1+X)
MU.(RH)&U>4A2PR?W47:O7Z "BBB@ HHHH **** "BBB@ HHHH *\_P#^;A?^
MY4_]NZ] K@(2L_Q_N9(SD6WAI89,=F:XW ?ES0!W]%%% !1110!\W>/O^2GZ
MA_U\1_\ H*U](U\W>/O^2GZA_P!?$?\ Z"M?2->IF'\*CZ?HCCPOQS]?\PHH
MHKRSL"BBB@ HHHH **** "BBB@ HHHH *Y;QGX4_X2*S26V*K?0 ["W =?[I
M/\O_ *]=315TZDJ<E*.Y,HJ2LSYWO=/O-.G,-Y;2P2 XPZXS]/6JU?2-%>DL
MT=M8_C_P#D>#\SYNHKZ1HI_VI_<_'_@!]3_O?@?-U%?2-%']J?W/Q_X ?4_[
MWX'S=17TC11_:G]S\?\ @!]3_O?@?-U%?2-%']J?W/Q_X ?4_P"]^!\W45](
MT4?VI_<_'_@!]3_O?@?-U%?2-%']J?W/Q_X ?4_[WX'S=17TC11_:G]S\?\
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MCHG_ #ZZA_W[3_XNC_A:.B?\^NH?]^T_^+H^J5OY0]O3[G;45Q/_  M'1/\
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M_A:.B?\ /KJ'_?M/_BZ/JE;^4/;T^YVU%<3_ ,+1T3_GUU#_ +]I_P#%T?\
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MI5BRP!&#M]*YNM:,+-NUK^=R)RO97.S\-QRR^ _$:0JS.?+X09.._P"F:H^
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M?^O.;_T UX!7T!X@!;PUJH R39S ?]\&OG^O9RSX)'!C/B04445Z9QA1110
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M)>*$'T,?^!_*N+K6A]I>;(J]'Y!111709!1110 4444 %%%% !1110 4444
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M'.#@YR172^$KV>__ &;GGN9&DD&D7L6YCD[4\U%'X*H%9^CZGXP3P)%X/L_
M=Q:7R6ILWNIV5+51MVM)D<L3R<#.2>IK8\'Z'JEG\ 'T:YL9XM2-A?1BV=</
MN=I2HQZG</SH QOA9\.?#^L^ ]/U;7;<ZK<W4+(GVEB5MXE9E"1C/R]"<]<D
MU+\*;V3P_HOCC3!(TMKH&H7 MUD.<*N[CZ?)G\3ZUV7POTZ\TKX;:+8W]M);
M7443"2*089<NQ&1]"*POA]X=OK;5_'Z:I8S06NIZK,T+.,>;$S/\R^V&'- &
M%\+? NB>+/"$GB;Q-9IJNI:O-*\DMPQ)10Y3"\_+RIY'/3TI?AAHD?AWXO\
MC'28;B:>&VMX%B>=MSA"%*J3WV@A1[ 4>$KCQI\-K&?PM)X1NM;MXIG>PO+2
M4+&RL<X8G[O))YQC)X/6M'X>:%XHLOB5XEU;Q):JDM];0MYL(_<[N/W:GOM
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MMU% ',?$WPEHW@=?"^O^&[)-.N[?58K<F%C^\1@S?-D\_<QD]0Q!S6W\4?\
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M:T?AYH7BBR^)7B75O$EJJ2WUM"WFPC]SNX_=J>^T *?IWZD ]6HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
**** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>img62602283_14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img62602283_14.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M.W%?F#H7_!2'XA3_ !<L]!L_$$FI:U<>(9+(Z;.H2$6@B+!]V ,[AC&[MTH
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MG.WMZ]Z[_P"*7QL\3?%C]CB^\;^!8-2\.ZU#;B[M[6Y"F1E5QO5L9'W0QXH
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M@#])**^0M8_X+"^"?#VBWEW>Z#KT+6<MO&T8V,66:/S%?() 7&.OK7%>,_\
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MLF_CMM!KU\? KXM?]%,_\<_^PK/&8>-&JZ<9*275;%X>HZD%-JWD>\45X/\
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M'U4TR1G#,J^Q-*)U<_*RM]#7PI^U%^S1^T'J^OVK:'XHOM9A5,,\+J@4_P#
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MJGA:R5W!V]&2JU-NRDOO/F+Q_P#\%>-)\._$2WT[3?#?B*?3)&4/+<Z9-;7
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MOCJ6.36=$TK57A&$:[M4F*#T!8'%=>#G2HU[XF',ENMC"O&<Z=J4K/N?!?\
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MO&\6K1>)]>M8XG5C"7\XG!SC>Q+?K7I%M_P3V\&PPHAOO$3;5 S_ &K<#/\
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M'PKI,<ODML:-CN4XX(^?K7FPQ-7V7U9/W6[V\SKE2AS^VMJD: _X)]># /\
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MLP'\7Y/\C#$?!\U^9[-'_JU^E.IL?^K7Z4ZN,W"BBB@ HHHH *,T44 %%%%
M!1110 4444 %%%!_SS0!E^)?&6C^#H8YM8U;3=)CD;:CWETD"N?0%B,FDO\
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MD:ZT6QMY)#N4/(%W5T8:67*4_;4Y--^[;L9UHXIJ/LYJ_4R/B-_P4V\!^ _
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MH/A>WXPOFV,(S_X[5RW^$'@R[A5X_#/AQT89#+I\.#_X[7DM=>AWI]#PF_\
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MLY-_GP3--)'P1E4==I//>O=?#W[6_P 3KS1+::3X!^,9Y)(PS21ZK8JKDCJ
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M^I:7,WQ:U76?L*!=U[%':M#@DX40J W_  *O5?\ AJWXE$?\F_>-?_!OI_\
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M"S<;4M?O\^IG2K4>95HIWGH>P?\ #*_Q,+?\G ^,L?\ 8&T__P"-UY#\?/\
M@FG\1OBMXDCO&^*VI:YL0+YMZB6CCCIMA4"O7A^U;\2L?\F^>-O_  ;Z?_\
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MUC7/LQSF]@BM#'TZ>2@ST[U7^&/[=7Q?U_X4WFH77PAUK4;R%6V7MM+%# F
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M (1316$:A06M(R3CWVU+_P ,H?#O_H4]#_\  .+_ .)KQ96OH>BO,XKXF_\
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M9/\ AY_T*6A_^ <7_P 37FGQ+_X);?"WXF>(6U&XTV:SD90OEVDK01C'^RI
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MD;=)&@5CZD"O'?C-^TQ??#'Q'JEA%:07'V2W6>,X/&2V0W/M7H/PD\=O\1?
M6GZM)#Y,EW$KLOH2 : ,3XQ:-\0-4N[<^#M0TFSC53YHO"PW'VPIKP/]I3X(
M_M ?$'PC;VMGKVDK(DVX_8I'5^G?Y1Q7OGQD_:6\-_ ZX@AUK^T?,N4+1_9K
M&:X!QZ^6IQ^-?(?B7_@L7K%AKMU#9^#+R>UCD*QR- ZEQZX.#7K9/A,35K>T
MPR3<===CAQU:E"GRU79/L>J_ OX1_'WP9X!M;&YU[0VDC&#]J=S)VZ_(:[+_
M (1'XZ9_Y#WA?_OI_P#XBO / _\ P6&U+6?%%K:ZGX/O+.RD;$LJ6SNR#U &
M3^E>^1?\%$OA\\:DMKZMCG_B2W?_ ,;K/-<'B*%;FQ"2<M="L'B*52%J3ND.
M?P?\=MI_XGOA?I_>D_\ B*^8/B)^R'^T=KWBZ\NH?$!\N9R5\F=PGX<5]/M_
MP42^'H4_-X@Z?] 6[_\ C=>1:/\ \%:([OXI_P!F7'AO4HM#\TK]K%E*7VXZ
M[0-WZ5T9-4Q--SJ8>*=EK?L9X^G2FHQJMJ[TL:?PC^!O[0/A7X576FW&O:3Y
M\D;J/M$CF7E<<';5']G+X ?M!^ ;C4FO/$&FM]H?*_:Y7;UZ?*?6O3M>_P""
MCG@2QT6ZFM5UZ:XCB9HT;1KM0[ ' R8\<FN#^!W_  51TSQG-?+XET75-(6%
ML0F'3YYO,'/7:K8[=:(UL16HU:BBN5M7\O0'3I0J0@V[K8Y_X7?LZ?M"^&OC
M%?:M-K]C]GF+D>?*YAY;/ VUS_QW_98_:*\:^/KJ^M?$$/E2'@6LSK'^'RBN
MU^'_ /P5;M-=^)MYINK:#J=EHL181726$TCO@\94*6Y'J*]3_P"'B/P\_O>(
M/_!+=_\ QNMJV.Q.$Q"J5(1YN5:6NK?YF=/#T:U)QC)VN?)>D_L9?M(6NJVL
MK>()ML<R,=UP^W@CKQ7U1HG@;X[6>EP1-KWAG=&@!W,^>G?Y*M?\/#OA[C[_
M (@_\$MW_P#&Z/\ AXC\/ ?O>(/_  2W?_QNN+,,TJ8RWM(I6[*QT87!QH7Y
M6W?NQW_"(?';_H/>%_\ OI__ (BO _VA_P!F/]HCQ[XP-U:^(+81XQBSF=4_
M]!%>^?\ #Q'X>?WO$'_@EN__ (W2?\/$?AY_>U__ ,$MW_\ &ZPP..GA:GM(
M)-^:N:8C#QK0Y)-KT/'/V9OV>/VA/AW<W;7FOV!$H 'VV5V_+Y37L?\ PB'Q
MU _Y#WA?_OI__B*7_AXC\//[WB#_ ,$MW_\ &Z/^'B/P]_O>(/\ P2W?_P ;
MJ<9BY8FJZLTDWVT16'HJE#D7XF#\2_AK\>O$/@?4K.'7O#_F7$)1?)=Q)^'R
M5\Q/^Q9^TDTC'_A()NO_ #\/_A7UW_P\2^'G][Q!_P""6[_^-UY9\;_^"K-G
MX+\16$'AG0=3U:SF \^6:PFA,?)!P'"D\>@->IDN-Q,&Z&'C&3>NJ70X\PP]
M*252JVDNQSW[-7[-?[0WP\\3WEQ>:]:&.6(*/MLKLN03T^4UZ/\ &GX4_'SQ
MC\/[JQM]>T$32$8^S.XD[]/D%='I'_!1CP'=:=#)<#7HYG4%E&C71 /_ '[J
MU_P\1^'8'WO$'_@EN_\ XW7#B,PJ5,3[>:2:Z)::'11PL8T?91;M^)\I^%OV
M./VD--\1V=Q)X@DVPRASYD[[?QXKU#]H'X _M!^.]*TN*UU_30;7&[[)(ZG\
M?E%6OB?_ ,%6[/PW\0+.PT70=4U#2I6 EN)+":-D'?Y64$_E7IEC_P %%OA_
M+9QM)_;Z2,H+ :+=G!_[]UZF,S#%)TL34A%=K):^J./#X6BU.C"3\S*^'OPY
M^/&@^$+.UEU[P[YD,84^<[E_Q^2O*?'G[-O[0VM?&6VUB+Q!9_9XY$8^5,XA
MX/<;:]P/_!0_X>8^]X@_\$MW_P#&ZR_&7_!2+P5H_AB\N-/AURZO(8RT43Z1
M=*KMC@9,8 _$UY>%QE2%9R@DW+35::G96H1E32DW9'E7[27[.7[0WQ!N]/:S
MU^Q'D1[6^Q2NHS[_ "BJ/[-W[-'[1'P^\73W5YX@M6CDBVC[;*Y3.>WRGFNT
M^!7_  5/TKQK!>-XHT;5M':%\0B'3IYMX]]BMBO0S_P40^'A_B\0?^"6[_\
MC==V(Q^(P])X&I&/K;7ON<]/"TJLUB8-_H \'_'7'_(>\+_]]/\ _$4?\(?\
M=3_S'?"__?3_ /Q%(?\ @HA\/<?>\0#_ +@MW_\ &Z4?\%$?AZ!][Q!_X);O
M_P"-UX)Z0O\ PA_QU_Z#WA?_ +Z?_P"(KC?CC\)/CYXP\#S6=MKVAB23I]F=
MUD_] %=D?^"B7P\'\7B#_P $MW_\:II_X*(?#TM][Q!_X);O_P"-UI1K.E-5
M(]"*E-3BX/J?,/PX_9#_ &CM \96=W-X@_=POD^=,Y3\>*[O]I/]G?\ :$^(
M+V/V/7[!?)7!^Q2NOIU^45Z;X[_X*3^#-#\*W5UI=OKEY?1+F*%](ND5S]3&
M!^M>!R_\%F?$"N=O@>XVYX)B;_&OJ<+5Q^.JK$T:<?=TZ)?<>-6AAL/#V,Y/
M4Y?_ (8J_:2_Z&"?_P "'_PK>^&'[(W[1WAOQ]IM]-X@_=6\NYA/,YCZ'K\M
M6?\ A\SXBS_R(]Q_WZ;_ !KW7X:_\%+?"/B/PC:W6LVNM6.H2KF2&/2;F14/
ML50C]:Z<RQN8X>E>O3@E+31(RP>'PM6?[J<FUKNS>3PA\==O_(>\+_\ ?3__
M !%._P"$/^.O_0>\+?\ ?3__ !%>3_%__@K!;^$_&UK9^'_#VI:GILI3S9Y;
M&:)DR<'Y6 )P/:KGQI_X*K6'@_0]-F\-Z'JFJW5P,W$<VGS0B(\="RJ#U/3/
M2OFXY3B9.'*E[^VIZTL=27-=_#N>6_$W]DC]H[Q#XRO+N'Q!^[F<D>1.X3\/
MEKUS]G?X,?'_ ,">#_LMUK^CF3/_ "]R.S_^@&N5^$'_  5SE\6>,([/Q!X7
MO],T]E):>*TEE8'([*"?7M7M0_X*(_#P?Q>(/_!+=_\ QNO0S;$XJ%-8/$0B
MMMDK_><F!HT92=>E)OU >$/CL!_R'O"__?3_ /Q%>?\ [1'P6^/_ (]\(K:V
MNO:.) ^?]#D=7_\ 0!5?XW?\%4]-\&ZC91^&]%U75H9F F:73YX3&,\XW*N?
MPJQ\2?\ @J9I/AWP!:WVC:/JU_JT@'F6\FG3QJN>OS,H'ZUQX/!XFG.G6@D^
M9Z7_ %.JM7I2C.G)[;G@I_8J_:2)_P"1AN/_  (?_"IM+_8R_:1M=3@D;Q!)
MMCD5OFG?'![\5[Q8?\%2M&F^$LFJRZ3JR:\J%ELQILYC)]-^W;^M+\#/^"H^
MB>-])N)O%&DZMH]Q&^V-(=-N)@PXYRBM7N5,VQRI2G*G"T79Z+<\R&!PW/&*
MG*[U6IV-AX'^.\6CQQ-KWAK<L>WYF?/3_<KQ7P/^S/\ M$:/\;Y-9D\069MF
M:0XEE<V_)]-O]*[7X]_\%2M'\$:1:R^%=(U;6)Y7(D2;3IX @XP<NJBN0^$7
M_!76X\5>-;>SU_PK?:;IKJ2\\5I)*RD=.%R?TKS<#A<9'#3Q%.*<9)WO;\#K
MQ%:@ZL:4VTUV/6O&_P //CQK'@_4+6/7O#F^>$H/*9P^?;Y.M?+MW^Q;^TE)
M=2-_PD$VUF)XN'_PKZW_ .'B/P]Q][Q!_P""6[_^-TRX_P""BGP_CMW93K[,
MJD@?V+=\G''_ "SKDR[-JN$3C3BG?NKFV*P4*]G)M6[,\+_9O_9G_:'\ ^++
MBZNM?M3&\84?;)79._3Y37NQ\(?'5!_R'O"__?3_ /Q%?//B7_@L9K&FZ[<0
M67@NZN+6-R(Y&@=2P]P<&O0;3_@JEI<WPC?59-%U5=?7I9#3IS&?^![=OZUW
M9I@,=5G&O6BES62M8PP>)P\(NG3DW;74]%'@_P".Q'_(>\+_ /?3_P#Q%+_P
MA_QU'_,=\+_]]/\ _$5\U/\ \%FO$()QX'N<9_YXM_C7=? G_@K'#XUUR>'Q
M1X=U+1[5$W)+#8RS%CGIA QKFQ'#^-HTW5J15EYHUIYIAZDU"+U?D>MCPC\=
MC_S'O"__ 'T__P 10?"/QV'_ #'?"_\ WT__ ,10/^"B/P\'\7B#_P $MW_\
M;KR3XB?\%9(M ^)5MIVD>'=2OM'D=!)=/92QNH.,G:P#<?2O.PN#JXF3A26J
M5SJK8B%)<TSUH^#_ (ZY_P"0]X7_ .^G_P#B*!X.^.P/_(>\+_\ ?4G_ ,13
M+3_@HI\/Y;:-I/[?5V4%A_8MWP?^_=/'_!1#X>@_>\08_P"P+=__ !NN9WV-
MAW_"(?'7_H/>%_\ OI__ (BJ>N^!_CO?:-=0KKWAG=)$RC:S[N1V^2O,=0_X
M*QPP?&-M(A\/:D_AT2%1>FQF$FWL=F-WZ5Z?J?\ P49\!VVDW$L"Z])<)&61
M#HUV S8X&?+Q796P=:A*#FOBLT<\,1"JI*/31GRQK'[&G[2-UJT\@\02;9)"
MPVSOMZ_2O7?$7P'_ &@K_P""4&CIX@TO[2JX)21_/_/;_6H_A+_P5?M_%7C.
MYL]?\/ZEINFQ[O+GCL9I&;!X^503^E.T7_@J]:WGQ6ETNX\/ZE%H:MA;L6,S
M.1_N8W?I7T.*JXZ<E&4(IT[2T2V_4\NC##15XR?O:'C1_8L_:2Q_R,%Q_P"!
M#_X4Z#]BS]I)95/_  D$WRG_ )[OC^5?7'_#Q#X>=VU__P $MW_\;KS;X^?\
M%5-.\""T_P"$5T/5-9\[/F^=I\\.SI_?5:>%S[&8BHJ-*G"[\D%;+:%*/M)R
ME;U9V_@WX?\ QXTGPQ96\FO>&]\,2J?,9]V0._R=:J_$OX:_'KQ#X&U*SAU[
MP[YEQ%M7R7<2=1T^2O-O@O\ \%;V\8>,EL_$GAC4-*T\QEC/%:2S-G(XVJ&/
M<]J]/\=_\%)?!FB>$;ZZTN'7+S4((]T,+Z1=(LC9'!)C 'XFO%Q&#Q&'Q2C4
M2YFT[=-ST*>(I5:+E%^Z?,.G_L8?M)0:I;R-X@F*QRJQW7#[< CVKZH\/> _
MCO8Z+;0OKWAK=&@!WL^[IW^2N'^#/_!5'2_%_AJ_N/$6C:KI5Y!O\F*+3IYE
MDP.,E5(&3ZUYSK/_  61URTU.:.W\%74L*.0CF!@6';@FO6Q6'Q^85'1<(IP
MWM9;G#1JX7"Q]IS.TN]V4OBI^R5^T9XD\:7EY#X@41S-D>1,X3\/EKU+]G+X
M)?M > O"TEO=Z]I)=FR/MDCLW_H)KD_A;_P5YNO$WB^WM-<\*7VGZ?)]^:*U
MDD9?P7)_2O8_$7_!1WP-I^@W$UG'KTUU'&6CC;1[I0S>F3&!66:5L9"$<%7A
M%;6M:_WFF#A0E)XBE)OU+ESX.^.DD$B_V]X7RRD<,^>G^Y7R]XZ_8^_:.UGQ
M9?74?B!A'-*S#RIW"8R>G%>K_!#_ (*KZ?XTUB\B\3:%JFDP0_ZEX;":8OU[
M*K8_&NB^,G_!3CPUX2\'R7GAZQUG5-05@%@ETNXB4CO\S(!^M88.6*P.)]A&
M*<I66MF:8B-'$TO:-NR[:'@W@']C_P#:.T3QIIMW+X@_=V\X=O.G<I@>O'2O
MJ&W\'?'5(57^WO"_R@#[S_\ Q%<'X4_X*DZ-JWPCNM6OM(U:UU^.-FCLUTV=
MD<@\ N%*\_6HO@)_P5-TOQQ9WS>*-'U71I(9-L(ATZ>;S%P.3L5L=^M5F;Q6
M)3JU8Q2IZ.UD3@_8TFH0;?-JKC/VE?@C^T!\0?"MK:VFO:2LD<I8_8Y'5NW7
MY1Z5YC\(?V3/VC/"_CNTO)_$"^7%G/VB9S'VZ_+7KGQV_P""HNA>"?#MO<>&
M-+U?6+R20J\<VF3PJJ\<Y=5'KWK@_AG_ ,%?;WQ'XOMK76O"=[8:?)GS)H[6
M21E_!<G]*Z<O^N_49>RA%PUU=KF.*^K_ %E<\FI::=#V3Q'X#^/%]X<NK==>
M\-[I(BHV,^[\/DKS?]G?X _M!> M1U22[U_36%U)N3[9([#MT^4UZ9KG_!1O
MP+9Z)<36RZ]-=1QEHT;1KI0S>F3'BN%^"?\ P51TOQE>Z@GB31=4TF.W?; T
M6G3S>8..3L5L=^N*\K#>W^JU.2*Y=+OK\CNJ>S]M#F;OT/7_  )X9^+EIXHM
MY->UCP_<:6I/G) S^8>.,905ZZ <5Y#X%_;8\%?$;Q3;Z1IK:S]LNB=GFZ5<
MQ)P,\LT8 _$UZ\HW+UKRSL.?^*>DRZYX!U.SA^WK)=0F,-9A3,N>Z[N,UYG\
M'_AEXB\(^,=#DO5U":UM=,,,LLLF?G\UF&X9QNP17J7C_P :6_@#PM=:E<++
M(D"DA8XR[,?3 !KR3X1_M.:Q\4KK1[BW&DM9ZD6$EM@QW4(!8;CN/3@#&,\T
M >[CI7BW[0(_XOW\._I<_P XZ]G3I7C/[0!_XOU\._I<_P XZ[<O_B_)_D<^
M(^#YK\SJ_$_[,W@7QOJC7^J>';&\O)1\TK@Y/ZUG?\,;?#3_ *%/3?R/^->F
M1_ZI?I3JA8S$15E-_>ROJ])ZN*^X\Q_X8V^&G_0IZ;^1_P :/^&-OAI_T*>F
M_D?\:].HH^O8G_GX_O8?5J7\J^X\Q_X8W^&@_P"93TW\C_C3G_8]^&\BX;PK
MI[#MG<<?K7IE%'U[$_\ /Q_>P^KTOY5]QYC_ ,,;?#3_ *%/3?R/^-'_  QM
M\-/^A3TW\C_C7IU%'U[$_P#/Q_>P^K4OY5]QYC_PQM\-/^A3TW\C_C1_PQM\
M-/\ H4]-_(_XUZ=11]>Q/_/Q_>P^K4OY5]QYC_PQM\-/^A3TW\C_ (T?\,;?
M#3_H4]-_(_XUZ=11]>Q/_/Q_>P^K4OY5]QYC_P ,;?#3_H4]-_(_XT?\,;?#
M3_H4]-_(_P"->G44?7L3_P _'][#ZM2_E7W'"^#_ -FGP/X U^'5-'\/6-C?
MVX(CFC!W+D8/?TKNB,T45C4JSJ/FFVWYFD:<8JT58****S*"B@T4 %%%% !1
M110 5\7_ +27_*0[P%_NG^4E?:%?%_[27_*0[P%_NG^4E>UD?\:7^&7Y'!F'
MP+U7YGV@.E% Z45XIWA1110 4444 %%%!H XCQ4/!=QJVH+JEGI\MWL1;HRP
MAF==QVY]1G-=/X:M;&VT6WCTZ.*&R5!Y21KM51CC ^E<#XV^"5UXH\6:IJ*S
M1QK?0Q1*OIL8G)_.N\\)Z2VA>'[6TD8,T"!21[#% &@V&X_"O.?B;IWPY^'-
MB-2\26&@V4-Q(5\ZXB1=[8SU-'QK_9<\-_'N\MI]:O/%%J]JI5!I>N7.GJ0?
M[PB=<_C7CGQ1_P""37@GQ_H\=K9^(_&UE)&^XO?:W=:HAXQPDTA4'W%=6#E!
M54JLG&/5HQQ"?(W%7?2Y[?\ #OPYX"\6:=;ZSX?TW19H6^:*X@A7]"*[2_OH
M-)L)9YV6."W0N['HJCJ:^9_ '_!*KP+X/\/0V5UX@\>74L8P7M/$5Y81GZ11
MR;5_"M75?^"8_@#4--FA36OB,C2H5#/XOU"103ZJ9<,/8]:5>4'5LI-QOHWV
M"DFJ>JLSMY_VSOAK:7#PR>*M+613M93.F0>GK76>%O#?A7Q$8M=TW3]-EDG^
M=+J.)=S>^:^/[K_@A_X:ENGD'C;5PK,3AK-6/XDOD_6O5/"__!+OP'H.BPVL
MVN?$*:2-<%X/%-]:HWTC27:OT%=^.A@J=-/!U&WUTL<V&EB)R:KP273J>M^,
MOCYX+\*>(1H.L:Q8V]]<$1?9I9%!?<<8P3WZ56\0_$+X?_ 18WO)M)T'[>-Z
MD;8O-]^WK7S[XU_X(Y>#_$_B^+4H/%GBJW@C=6,5S=RWDQ .>)I)-X^HZ=:L
M?$[_ () ^#?'BVJVGBCQ=9FW7#&]U"?4@WT$TAV_044Z>!]R,JDDFO>TV?ZA
M*>)]YJ"NMCZ:\)>'O#=XR:WI-CI^^\7>+J&-=T@/.<CUKHJ^;_#W_!+_ , Z
M-H]O:R:W\0Y7A0*6A\5W]NC8]$67:OT%7?\ AVG\/O\ H+_$K_PM-1_^.UY=
M62<G9W72YVP5EM8]]N[F.PM99Y&"QPJ7=CT50,DUR/@G]H'PC\0M<DTW1]:L
M[Z\AR'BCD5F7'L#7E=]_P3,^']W931+K'Q(5I$9 6\8:@Z@D8Y4RX(]CUKAO
MA]_P1V\'^#O$,U[<^*O%5U'(3B.TO9M/D'UEBDW-^-=&'IX:5.;K2:DME;<Q
MJRJJ<5!:=3[!HKY\_P"':?P^_P"@O\2O_"TU'_X[2?\ #M+X?9_Y"_Q*_P#"
MSU'_ ..UQG0?0A.*3.17SX?^":GP_P _\ACXE8_['/4?_CM'_#M/X?D_\ACX
ME?\ A9ZC_P#': /4-2^/_A#2/&L?AZXUJSBUB9PB6QD7>Q/08SFLSXN^//AW
MX9UFQC\72:.E[, ;;[6$W'DXQN]Z\$U;_@CKX/U'Q_#K$?BKQ5';QN&,,EY+
M-<''I<M)Y@/N.E3?$K_@CYX/\<:K:7%KXI\66:6X 9;W4)M29L'/RO-(2GX5
M[%.G@5.'[QI6U=MGV.&4L0XR]U7OIZ'TAXR^+WAGX7^'K6^U;4K73=/NOE@=
MW"JWTR?>MCPIXKT[QMHL.H:7=1W=G<+N21&#*P^M?+_Q$_X)&>"_&OAZUL;;
MQ-XRM)+<DL]YJMQJ$;=/NQ2R;4Z=JVO!7_!+/P+X9T"&SN-=\?W$D0P7MO$U
M[9QGZ1QR[5^@KDJ0PRH*4)-SN[JW3N;1E5]K9KW;;^9[UXJ\+^'WWZMJVGV$
MC6:^8;B:,%HP.^36?\/?C=X6^)-S-::#JUG?R6?#I"X;9^1KR/6?^"8O@'4]
M*GMX]:^(L;S(5#2>+;^95^J-+AOH:Y'X:_\ !(+P;X%U"YFNO%'BZ\68_*ME
MJ,^FLOU:*0%OQITO82H2=6;YE\*Z!/VBJ)02L]V?70Z5YW\1/VC/ /@[4)M'
M\0ZUIMO,5Q)!/(O(/J":\_'_  33^'XZ:M\2O_"TU'_X[7FOQ#_X(Q^%/&6O
M27EKXN\1VL;#&R[D?4)!]9)9-QHR^GA95+8J;BNZ5]18J590_<J[\SZ3^#/C
M+P+XOMKI_!LFER1HW[XV>W&??;7=CFODOX4_\$B_!?P^@G2\\3>,KYICD&PU
M6XTH+]1#( WXUV"_\$T_A_\ ]!;XE?\ A::C_P#':SQOLO;/V$G*/=[EX?G]
MFO:*S[(^A**^?/\ AVG\/O\ H+_$K_PM-1_^.TG_  [6^'O_ $%_B5_X6>H_
M_':Y38^@V;:,UYKX@_:Z^'GAC5I;&^\3:;;W5NVUXWF4%3^=<,W_  32^'P7
M_D+_ !*_\+/4?_CM>3>)?^")WA?7=8GNH_&>N0QS-D)/%]I=?K([[F^IKT<N
MIX.<FL9-Q72RN<N*G7BE["*;\SZZ\*^-/#_QB\-M<:;<6NK:;-P2I#QO7'>/
MXOA7\,[RW@UZQ\/6,UX<1++$BES[9^HKR_X;_P#!*+P/X*T%;2Z\1>.+R0'[
M]GKUWIT?_?N*3:*S?B7_ ,$B/!?CB]M9;7Q-XPM%MSEA>:I<:DS=/NM+)E?P
MITOJZQ#A[1JGW6_W$U/:.DI<J<NQ[1XNTOX7^ _#<.L:KIWA^STZ;&R:2%%4
MY&1S4?@?]I[X:ZG?6>BZ'KVD^=,WEP6\$B<GDX !^M>0^-_^"2'@OQ5X4AT^
MW\2^-+::/&9;K6+F^A.!CB&238OX=*Y7PG_P10\+^'O$=K>S>,M=FC@?<R0(
M;61N,<2H^Y3[BNJC' U*+=>K+FULK-KR,:DL1&HE2@N7JSZ.^)_C_P"&OA[Q
M=:VOBB715U>0KY(N@GF$D_+C)SUKLM1\)Z'XVTZW^V:?97]NJYA$L8=5!]*^
M6/B%_P $=_!_C+Q+;WUMXJ\56L,)4M'=WDVH2'!SQ++)N7\.E=OI_P#P3,^'
M]K:1QMK'Q(9D4 E?&&H(#] )<#Z"N/$2HQI0=&;<NJ[>AT4_:.<E4BK=/,]L
MT3X7>'?#=\+FPT73K2X P)(H0K#\:W#@&OG[_AVG\/O^@O\ $K_PL]1_^.TC
M?\$T_A]_T%OB5_X6>H__ !VN&4I2=Y.YT1BEHCT+XR>._A_X/NK<^,)=)CE;
MF$WFW/X;JJ^%OC!\-_C5(FBZ?>Z/K'EC*VP*2!0/;->(_%/_ ()!^#?B#)"U
MGXH\76/ECG[=J,^J$_0S2''X51^&O_!&OPCX'UO[5=>+?$]Y'C&RRN)--?\
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M6[6J748<1,0Q3(!QD<4 <9\:F^*B7#'P/'X0>T\L[CJ<LZS;O]D("/SKYQ^
M.J_M6W?CK5$UBWTO[*I/E?VUF.VZC_5F$;C_ ,"KZ0^,W[6'@_X%WPM=?FU9
M+ATWJMMI=Q<J1_O1HP'XFOG6_P#^"UO@FRO)85\,ZY*L;%0QE5-WO@C(_&O7
MRVCB*U.=.A24[]>J]#AQE2E3E&=2?+^IUGQYN_VFK3X?7#Z3!X+^V C;_8TD
M\EUU'02KM_.LC]F74?VH[[P=(VN6_AK[5YK8_P"$@:2*XQGC @4KBNR\%?\
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MM777Q*U*/5+?3/L*NWE_VOF.SQGC88AO^F:]IS^T1_SQ^%?_ ($WO_Q-1?\
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MMR58<LGLO4>'Q%.=/F@[I=3R7]IW5?VKK#6=/&AV^F^6R_O/^$>_>Q]?X_/
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M[_4=0&O6^G[%"^7_ ,)&/*3OG9]G!/Y^U>S_ /#QWX6D_P#'YXC_ /"<O_\
MXU7)?%/_ (*R_#OX>V]O)9V6OZNTQ.5:PFL=F/>9%S^%>Y1QDZ]!8&E1BY/K
M;WOO/-J8>-*I]9G-I=NA7_:%O?VG;'X>2/H]OX/^V>8 /[#DFDNL8/03+LQ7
MA7@'Q'^V1-XTT];RWUG[*9?WGVZ&W6WQ@_?*#=CZ5[]K7_!6;X=:9X$CU=+/
MQ!-<OC-H=/FC49_Z;,@C/X&K7PY_X*I?#?QQH_VJ[A\0:6^?]4NE7%W_ ./1
M1E:TPM>MAL++FH1E&[7,UJF36IPK5ERU&GO9&]<M^T6-(E98/ACYGE,1MN+S
MS,X[?+C->'_"#6OVM+CXM7$>I6]K_9V7V_VHH2QZ\;6C'F?3->Y7'_!2'X76
M]M(RW?B-BBDA?^$=OAG';)BKA?!__!7KX?\ B7Q=)IMQI>O6<,9(%P+5[@MC
M_IFB%Q^(KDP/M?95>2FI*VK?3T-\1&'/#FDT^GF>@?\ &1'_ #P^%?\ X$WO
M_P 32Y_:(_YX?"O_ ,";W_XFF?\ #Q[X6_\ /[XD_P#"<O\ _P"-4A_X*/?"
MW_G]\2?^$Y?_ /QJO*.T\N_:CU+]J>PT*Q.@V^@&8R'?_P (ZSRRXX^\)U Q
M]*KZ[JG[5"_L^1S1V^B?VQA,^26.J=.<J1Y7UKUC_AXY\+6'_']XD_\ "<O_
M /XU1_P\;^%N/^/[Q)_X3E__ /&J]&GF"A3A3]G%\KO>VK\GY'++"N4Y2YGJ
MK>AY'\)-4_:JG^$.J2:A;Z/_ &DJ-Y7]I[DO\\XV+&OED^F:@_9FU3]JZ]U;
M41KEOI?E@_N_^$@S%'V^YY R?QKV,_\ !1SX6X_X_?$?_A.7W_QJC_AX[\+1
M_P OGB/_ ,)R_P#_ (U55,RYHU(^SBN9]MO0F.#<7%\S]W\?4ES^T1_SP^%?
M_@3>_P#Q-)N_:(S_ ,>_PK_\";W_ .)IO_#Q[X6_\_OB3_PG+_\ ^-5E^+?^
M"G?PS\.:%-=POXBO)(AD1'1+N -_P-X@H_$UYU.G*<E".[.N4E%<TMC6W?M$
M#_EA\*__  )O?_B:25OVB!&W[CX5].US>_\ Q-<=X _X*S_#OQCH]U=75GX@
MT^2W^[&MA-=;_P#@4:%5_&J_P_\ ^"N/P]\::[<6=UI^OZ;'!]V5;.6ZW\_W
M(D++^(KLEEV)CS.4/AWVT,(XJD^6S^+;S/%_BKX@_;#@\>:@NGV^I_8UE(C_
M +-BA>UQG^ R#=CZUZ]^S3?_ +4-_P"!2^N6_A?[7YK?\C \L5UC/'$"[<>G
M>O0!_P %'?A;_P _GB3_ ,)N_P#_ (U1_P /'OA;_P _GB3_ ,)R_P#_ (U7
M1BLU5:@J'LHQVU2U,:."=.K[3G;\GL2Y_:(_YX?"O_P)O?\ XFC/[1'_ #P^
M%?\ X$WO_P 33/\ AX]\+?\ G]\2?^$Y?_\ QJC_ (>/?"W_ )_?$G_A.7__
M ,:KR3N,'XI3?M)P>![Y[&#X?_:E3Y/[.FN6N<_[ D7;GZU\QZ=XD_;,;6(5
MDM_$7E^:-WF6]MY>,]R!G%?7/_#QWX6G_E]\2?\ A.7_ /\ &JBO?^"DGPOM
M;:21;KQ'(44L%_X1V^7/MDQ8'XUZV7YE]7@Z?LHROW6IPXK!NK)2YW&W8A\-
M2_M&R:%:M-;_  S\SRUW?:+B[63./XMJXS]*Q?C+<?M+6_P_OWTVW\"&\"?N
M_P"RI;A[K.1]P2+LS]:XG4?^"UO@BRO985\,ZY(L;%0_F*F[WP1D?0UZ-X/_
M ."G7PS\3:!!>7#>(K*249,(T2[N O\ P-(RI_ U-; XK"M8BM3LK]=GY%4\
M11K)TJ<M;'S-X+\1_MD2^*+);JWUS[.91O\ M<-NL.,_Q%1NQ].:^K;5_P!H
MK[)'NM_A;NVC.ZXO-WX_+0/^"CGPM'_+YXD_\)N__P#C5+_P\>^%O_/YXD_\
M)R__ /C51F&8+%--4XPM_*K7*PN%=!-.3EZC\_M$?\\?A7_X$WO_ ,37A_Q#
MU;]K"'XXVL5G;V7]E>;A_L(W:;C'\3./,Q]*[3P__P %>/A]K7CB729--U^V
MMXR0+H6DDI.#C_5*AD'XBNX7_@HY\+?^?WQ)_P"$Y?\ _P :IT_:X&?[ZFG=
M;/SZBER8F/N2>CZ'B?[1&J_M8V?B_3%T:WL?L[*GF?V$/,M\YYWF8;A[X[5Z
M_P"$YOVCIO#UJ;BW^&OG>6-_VF>[$N<?Q!5QGZ5;N?\ @I%\+8+=W6Z\1L44
MD#_A';X9XZ9\K^=>4:I_P6K\#Z=J$T,?AG7)EC8J'\Q8]WX,,CZ&NBG3Q&.I
M*CAZ2?)NUN_4RE.GAIN=6;][H_T/70?VB!_RP^%?_@3>_P#Q-9WC";]HZ'PS
M>M;P?#;[0L1V?99[MIL_[(9<9^M5_!7_  5!^&?BG0HKRX/B*QDDZQ+HUW<!
M?^!QQE3^!K!\<?\ !6_X>^%?$MK8V^GZ_?PW!PT[64ML8_\ @$B!F_ 5PT<+
M7=;V<8WDMUZ'34K4U3YF[)]?4^>)?$G[9O\ :./L_B,Q^8.EO;>7C\LXKVKX
MC:E^U-#\$+66SM_#_P#:A5-WV!G;4>G.Y77R_KBNA^(?_!6;X=^"+:UDM;+7
M]3-P<,K6$UIY?XRH WX5T>@?\%+_ (8ZUH]O<RS>(K:290QC&@WDNSVW+$0?
MJ*];&8ZI*-.O*A&,4]++1VZ,X,/AHIRI*HV[?<>>>!-3_:FF^ E[->6_A_\
MM98GV?;"ZZGG)QM5%\K/IGBH?V7-3_:HU#3]2_MZWT/S%F_=_P#"1%HFQ@?<
M\A2"/KSUKT?Q%_P4Q^&.AZ)=7D4WB*ZDMXRZPG0KR$2'TWM$%'U)Q6#\+?\
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M,J%56RU&:WC_ !5' -?/OP9_X)8WGA3Q?J-UKGBK7)+&<GR1::G-%(.?XBK
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MZ.YA4"4WFJ3S*3[!F('X5VG@+_@G'I.B^%K6WU'Q-XO:\C0"0P:W<I&3[ 2
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MZ@K0![]17S_X,_X*8?"?QXEXVGZS=/\ 8;8W4@:QF5O+& 2 4R<$@<5-9?\
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M_P )X?\ QRC_ (;/N/\ HD/QF_\ ">'_ ,<H ]NHKQ'_ (;/N/\ HD/QF_\
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M_P"&S[C_ *)#\9O_  GA_P#'*/\ AL^X_P"B0_&;_P )X?\ QR@#VZBO$?\
MAL^X_P"B0_&;_P )X?\ QRC_ (;/N/\ HD/QF_\ ">'_ ,<H ]NHKQ'_ (;/
MN/\ HD/QF_\ ">'_ ,<H_P"&T+C_ *)%\9O_  GA_P#'* /;N]%>(/\ MHW
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MU"#7R?\ MK_-^VC\#?\ =O\ _P!"@H ^L5.Y0:*;#_JE^@IU !1110 4444
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M/^%C>'_^@WI/_@4G^->9?\.[_@C_ -$U\,?^ Y_QH_X=W_!'_HFOAC_P'/\
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M=2.X5F;\ :U!P*\N\%_L3?"?X<^([?5]#\!Z!IFIVI)BN((2LB9&#@YKU D
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M.XYW(KL'_2NY^*'_  7#^#OPX\63:7')K&N+%_R]:? LL+\=FWC^5=1\$/\
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MQ3X)_P#11O#7_@3_ /6H HGX2_'\?\U?\+?^$@G_ ,>KA_VA?A/^TDOPMO\
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M>*?!/_HHWAK_ ,"?_K4 4?\ A4GQ^_Z*_P"%O_"/3_X]1_PJ3X_?]%?\+?\
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M **_X6_\(]/_ (]1_P *D^/W_17_  M_X1Z?_'JO#_@HI\$\?\E&\-?^!/\
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MA;AFMP53RG"]?P-<?_PP)X"_YYZC_P!_A_\ $T >D'1_!Y_Y=?#?_?J'_"N
M^)G[)OP>^+OB:SU?7M!\-WE]8,K02>8(]A&,<*P!Z=Q5;_A@3P%_SSU'_O\
M#_XFC_A@3P%_SSU'_O\ #_XFA-IW02BGN>AV'AGP7IMG';PV?AM8H5"J-D/
M'2LCXA_"/X<_%'PQ<:/K6F^&[K3[H;9(\1IN[]5(/;UKD_\ A@3P%_SSU'_O
M\/\ XFD/[ G@+'^KU+_O\/\ XFB[W"RM8V_AM\$OA7\!?"#6.AZ7X;TW2[<&
M1E.R7: .3EBQ[5R/BOX1_ ']K2]BDO+/PMKTNE-\I1C#Y1_X"5STJ3Q-_P $
M[O NO>'[RSC_ +0A>ZA:)7,P.TD$9^[7FW[.7_!(#PG\$;C47OM5O=5^VON4
M(VW9U]1[UI%JSDWJ9R6T;:'M7C[]F3X3?$SP-;^'-8T3PW=:3:[?+AWJFW:,
M#YE(;I[UM?#CX/\ PY^%'A2VT70]+\-V>G6HVQQ8CDVCZL2?UKDQ^P)X"(_U
M6I?]_A_\32_\,"> O^>>H_\ ?X?_ !-1S.UBN57N/^*O['OP9^,_BJTUKQ#X
M?\-WVH6.SR9!*(]NTY'", >?45WVF^%_!>E645O#9^&TAA4(B^7"< <5Y]_P
MP)X"_P">>H_]_A_\31_PP)X"_P">>H_]_A_\31S-JS&HI'I/]C^#_P#GU\-_
M]^X:/[(\'_\ /KX;_P"_4/\ A7FW_# G@+_GGJ/_ '^'_P 31_PP)X"_YYZC
M_P!_A_\ $TAGI/\ 9'@__GU\-_\ ?J'_  H_L?P?_P ^OAO_ +]P_P"%>;?\
M,"> O^>>H_\ ?X?_ !-'_# G@+_GGJ/_ '^'_P 30!E_$K]@7X#_ !;\42ZQ
MKOA?PY>:A-]^3[08\]NBN!^E=+\%_P!F+X2_L_Z==6OA;1/#>GP7C^9*I=9=
MS8 _C9CV'2L[_A@3P%_SSU'_ +_#_P")H_X8$\!?\\]1_P"_P_\ B:ISDU:Y
M*A%.Z1J_&7]F_P"%/Q]T:VT_Q1HOAO4+6U<R1IN6+:3C/*%3V%1W/[,/PEN_
MAB/!\FB>&V\/J HMMZ] ,#YL[OUK./[ G@+'^JU'_O\ C_XFC_A@3P%_SSU'
M_O\ #_XFCF>P<L;W.6T3_@FG^SOX=UBWO[3PCX<BNK5_,C?[4YVMZX,F*]LM
M?#O@VPM8X8K3PVL<:[5'EP\"O//^&!/ 7_//4?\ O\/_ (FC_A@3P%_SSU'_
M +_#_P")HE)R^)A&*6QZ2-(\'X_X]?#?_?J#_"C^R/!__/KX;_[]0_X5YM_P
MP)X"_P">>H_]_A_\31_PP)X"_P">>H_]_A_\34E'I/\ 9'@__GU\-_\ ?J'_
M  I&TGP>HYM?#?\ WZA_PKS?_A@3P%_SSU'_ +_#_P")I)/V O 3HR^7J/(Q
M_KA_\30!7^+OC7X"^)M+O_"_BB^\(M#(0ES;-'M.0?5 #^1KQK2?V>/V,]%U
M6"\M[?P@EQ;2"6-O.G.UAR."V*Y/XJ?\$&M!^('CS4-6M_%%Q9PWDA=86!)0
M$].!7/?\0]&D?]#E-_WRU=D?9I:29RRYV_A1]/\ B'X0?L\_M:6EK!<6OA77
MH]%7RXA&QA\D=>Q7/XYK7TOXE_ GX2V$>@P:EX1L(]/'EB!H0Y3';)4_SKR+
M]F;_ ((X>%?@3_:']H:Q>:M]L(*[&V;.,=Q7 _$/_@@EH7C3Q;>:E!XJN+6*
MZD+K$P)*_I6:Y&[.3L5[Z5U'4^T_"'B#X=^.M+6\TEO"][;-_P M$AB /Y@5
MS/Q7_95^$/QLU"SNO$>A^'+Z:Q;="V\1[#QV1AZ#K7F_[/\ _P $JO!_P=\$
MQZ7>WM]J<R'/FK)M!Z=B/:NZ7]@7P'WBU+_O\/\ XFL6^67NLV6J]XU?B'^S
M1\)_BGX+M_#^MZ+X<N]*M=OEP[E3;@8'*D'I[U0\":M\$OAA):^#=(F\)VLU
MN?)BL_+#L#UQN8']34)_8#\!$?ZO4?\ O\/_ (FO"+K_ ((F^&KCXZP^+1KU
MTMG'<><;3)W$;2,9QBJC9Z29,DT[Q1]@#1O!_P#SZ^&_^_<-+_9'@_\ Y]?#
M?_?J'_"O-5_8#\! ?ZO4?^_P_P#B:7_A@3P%_P \]1_[_#_XFLS0])_LCP?_
M ,^OAO\ []P?X56U<>!]"TV:\O(O#,-M;KNDD,4.%'X"O/\ _A@3P%_SSU'_
M +_#_P")K&^('_!-[P/XQ\&ZAID+:A;2WD7EK*900G(.>E"WU#T/1/"/C;X8
M^.[":YTFX\*WT%N2)'2&,!<=>JBH_#7Q"^%OC#5YK#3;KPI=WEN<21+!&"GY
MJ!VKP7]G[_@D+X3^#OA?4=/O=4O-3DO2Y616V[,C'<51^"W_  1P\*_"[Q_J
M>L76L7E_#?,66%6VE.OJ/>M.6&NOH9\T]-#Z:\2ZAX \'Z5)?:D/#%I:Q_>D
M:&(@?D,U3\%^+?AK\0[22?19O"M_#&=K,D,0P?\ @0%>2_&?_@F%X+^*/@.Z
MTFTN+_3YI^DK2!@O![ 5@?LU_P#!)/PC\$- NK._U&^U62>3>'5]NWIZCVJ;
M1Y;]1WES6Z'TF^E>#T4LUKX;  R?W4/^%<OIGQ2^$^L^*&T6UOO"<VJ*2#;B
M!-PQU_AQ^M<[<?L > YH'41ZB"RD9\X<?^.UX;X)_P""*OAGPI\;Y/%4VN7=
MQ:2-(PM 2&&XY'.,<4XJ+OS,<G)-<I]??V1X/_Y]?#?_ 'ZA_P */[(\'_\
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MD>#_ /GU\-_]^H?\*/[(\'_\^OAO_OU#_A7FW_# G@+_ )YZC_W^'_Q-'_#
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MV8+']K6'XKVK?%"?P6_A/RW\\6'E^=OXVXV\^M>=_P##K'XK?]%J\0_]]?\
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MYG^4M;4/B?H8UMEZGWT.E% Z45B;!1110 4444 -FB6XB9&&Y6&"/6N%T_\
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MBE&]P4GS6L?3@&!17S__ ,*J_: _Z*3X*_\ !)/_ /'J3_A5G[0'_12/!?\
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MY#_PU]X@_P"B;^*/_ 63_P")H_X:^\0?]$W\4?\ @))_\37N']K6O_/U;_\
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M^)JU\+/VLO@3\3O&JVOA/Q)X-U#7I06'V1$$[=>=VT'U[U[*=5M6'_'U;_\
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M9FNK<*HR3Y@K$V/$?^&OO$'_ $3?Q1_X"2?_ !-'_#7WB#_HF_BC_P !)/\
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MXT?VM:_\_5O_ -_!4E'A_P#PU]X@_P"B;^*/_ 23_P")H_X:^\0?]$W\4?\
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M+$[ATW..AZ4 ?IYH&O0>)-&M;ZU8/;W2"1&'<&KH7;7YQ?\ !*+XZS_MX_\
M!-&\\(WVH7EMXN\/V4FG3213-'<+<1QC:<J0?O$5Y3_P31^+NN^.AX@^ /BS
M4]:F\:>'O$+S37<E[+O-M',WREMV>5% ['ZZ45^._P 9-;\;:?\ %[XS:3\0
M-8U[3]0TW2MG@V"VO9HA,0B;=H0C<Q_VL]Z]N^ W['_C/XN_\$W_  ]IOBGQ
MEXD^'?B>ZN1>7=Y)>.\T@#D!27;Y05"]*!'Z-5\S_M]?\%+?#_["%KI*ZMH.
MN:G=:U<I;6[16K"URQ YE&0.HKV_X-^$)/ /PVTG29M4FUJ2S@6-KV7[T^/X
MC]:^ /\ @XYP?A#\/_\ L.P_^C4H''5GUY\6/VMY/AY^SY8^,M/\,:KXCU75
M;=)K/1]/C:::5F7< =H)"]BV.]>(?\$]/^"Q=K^V9\8]>^'OB+P1J7@#QEH:
M^:VGW3,Q9,J,DLJD'YNF*^@?A!XNT?X>?LJ^']>UJ2WMK/3-'AEDGE _=J(U
M[FOF;]A_]G_29?VM/&GQX\27%CI.K^.)?*TJQW@,MNH3DCU)C8_0T"/KSX[_
M !:F^$/@2;4K/1;_ ,0:A@BVL;2-G:=_0X!('/7%?,W[#G_!6>;]J'X]:]\.
M/%/@'4/ ?BC13E8)I&E$R?-SED7'3]:^M)M>LO%6C3'2M2LWGVLD,RLK"-\<
M=?3BOR]_9F7XF?LX?\%G-=\.^-+6P\00^-K9[VWU:.(!K:,9*)D*.</S]* 1
M^KU%(N:6@ HHHH ***!UH **** "BBB@ HHHH *^!?VL?^4HWPW_ .N9_E+7
MWU7P+^U@?^-HWPW_ .N9_E+6U#XGZ&-;9>I]]#I10.E%8FP4444 %%%% !11
M10!Q_P 2?AM)\0-0L/,:SAM[&431RX;[0C9&=O\ #@X YKJ[9/(MUCR6V@#)
M[UY5^T'J/C:#Q-H4?AW3[F;3!.INIH+I8C@D9#*>2!7JE@[-:1;U(;:-V?6@
M#B_BM^S7X'^.5S!-XJ\/P:O):C;$TDTL>P?\ 9:X_P#X=W?!G_H1;'_P+N?_
M (Y71?&WPW\4M;O;9O /BCPKH,"J?/75M(DO6<]MI61,?K7!_P#"N_VF/^BE
M?"__ ,)2X_\ DB@#:/\ P3M^#/\ T(UC_P"!=S_\<H'_  3M^#(_YD>R_P#
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MK?2(L3?C&%;]:]N'_!.SX,]_ ]E_X&7/_P <K&'P[_:8'_-2OA?_ .$I<?\
MR11_PKS]I@?\U*^%_P#X2EQ_\D4I5)2=Y#C",5:)M?\ #NWX,_\ 0C6/_@9<
M_P#QRC_AW=\&?^A&L?\ P,N?_CE8H^'?[3 '_)2OA?\ ^$I<?_)%'_"N_P!I
MC_HI7PO_ /"4N/\ Y(J2C:_X=W?!G_H1;'_P+N?_ (Y7D?Q7_P""*'PG^)?Q
M'M=?@DU;08;<H3I]G-N@DVXZF3<_/?!KT+_A7?[3'_12OA?_ .$I<?\ R10W
MPZ_:8_Z*5\+_ /PE+C_Y(JHR<7=$RBI*S.'^-W_!&#X3_%^QTV&V75/#9T]-
MC/83%VN?=O,W#/TQ7<^ _P#@F)\'?!OABUT^;PM'JCVZ;3<7%U.LDGN0K@?D
M*0?#W]I@_P#-2OAA_P"$I/\ _)%'_"N_VF/^BE?"_P#\)2X_^2*'.35GL"@D
M[HX?Q;_P1?\ A/XF^*\/B:,:I86\+;O[+AFS;/UX);+_ /CU>H0_\$ZO@RD2
MK_P@]FVT8R;RYY_\B5C_ /"N_P!IC_HI7PO_ /"4N/\ Y(H_X5W^TQ_T4KX7
M_P#A*7'_ ,D42DWN$8I;&U_P[M^#/_0C6/\ X%W/_P <H_X=W?!G_H1;'_P+
MN?\ XY6+_P *[_:8_P"BE?"__P )2X_^2*/^%=_M,?\ 12OA?_X2EQ_\D5)1
MJ:I_P3A^#6HZ;<6Z^"[6%KB)HQ(EW<;H\@C(S)C(Z\UYO\$O^"-/PG^#^NZE
M>7,6I>)EU!LK!?3%$M^OW?+VGOW)Z5VG_"N_VF/^BE?"_P#\)2X_^2*\)_;7
M\'?M=Z?IFE?\(_XUT?4Y&9O,'AVQDTMDZ8WEI6W?A[UI3N_=3M<SJ67O6V/I
M#_AW?\&?^A%LO_ NY_\ CE _X)W_  9/_,BV/_@9<_\ QRO-_@CX!_:DN/AY
MI[:A\0O MM=^6-\>H^'YKJX4_P"U()P&/OBNN_X5W^TQ_P!%*^%__A*7'_R1
M6;5G8T6JN:U[_P $Y?@S>6<T(\$V<9E0H'6[N<ID8R,R=J\I^&G_  15^%'P
M[^(=SKDSZMK4-P6(L+J7;#'GT*;6X]S7H'_"O?VF,_\ )2OA?_X2EQ_\D5Y-
M^UUX(_:RL? *-H?CKPSJ%UO'[O0M)ETZX _WVF88_"M*;E?E3M<BHE\3UL>Y
MM_P3N^#/_0BV7_@7<_\ QR@?\$[O@R!_R(UC_P"!=S_\<KRG]G/P+^U5=?#*
MS?5OB!X+LKS'SQ:MH<U[<CK]Z19P#^5=-X[^'W[3T7@_4&MOB-\.99Q"?+2V
M\,SQ3,?]ES<84^^*EQM+E&I75SL/^'=_P8/_ #(]C_X&7/\ \<I/^'=GP9_Z
M$>R_\#+G_P".5\L?L?>$/VPK[QUJZ:[XPL]-ME0&*37K=]2@<Y/W$612I_$U
M]''X=_M,#_FI7PO_ /"4N/\ Y(IU(\KL$)<RN;0_X)W?!G_H1K'_ ,"[G_XY
M1_P[N^#/_0BV/_@7<_\ QRL4?#S]I@_\U*^%_P#X2EQ_\D4?\*[_ &F/^BE?
M"_\ \)2X_P#DBH*-K_AW=\&?^A%L?_ NY_\ CE'_  [M^#/_ $(MC_X%W/\
M\<K%_P"%=_M,?]%*^%__ (2EQ_\ )%'_  KO]IC_ **5\+__  E+C_Y(H VA
M_P $[_@Q_P!"/8_^!=S_ /'*;-_P3L^#,D;+_P (/9+N& ?M=SQ_Y$KYE_:>
M\'?M?VGQ,T5='\9:;?6C,/.ET:TDL;9.GWXVE8M^8KW;0OAY^TT^BVIE^)'P
MU63RP667PO.[@^Y^T<FJ<+)2N3&5VT<+H7_!$?X4Z/\ %]O%3SZQ=6Y=G&E/
M*/LHSGC(P_&?[U>P?\.[O@SG_D1K'_P+N?\ XY6+_P *[_:8_P"BE?"__P )
M2X_^2*/^%=_M,?\ 12OA?_X2EQ_\D42FY;A&*CL;7_#N[X,_]"+8_P#@7<__
M !RC_AW=\&?^A%L?_ NY_P#CE8O_  KO]IC_ **5\+__  E+C_Y(H_X5W^TQ
M_P!%*^%__A*7'_R14E&U_P .[O@S_P!"+8_^!=S_ /'*/^'=WP9_Z$6Q_P#
MNY_^.5B_\*[_ &F/^BE?"_\ \)2X_P#DBC_A7?[3'_12OA?_ .$I<?\ R10!
MM?\ #N[X,_\ 0BV/_@7<_P#QR@_\$[?@S_T(]C_X%W/_ ,<K%_X5W^TQ_P!%
M*^%__A*7'_R10?AY^TP/^:E?##_PE+C_ .2* -K_ (=V_!D#_D1K+_P,N?\
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MA%6SN)"3A5;.><$CCM7;^.OVC/"?@#0[Z^NM4MYO[/MA>2PPN&D$9(&['U-
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M?C=A)'(_A%?4'6CI0 *-JX]**** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P!HW]A/QQ\0_B?X8^(WA[4+FU\76-U(E]%,R^3);-'(H4;>>&8-U[5]P44
M?G3X;_X)T?$73OBAIVIZK:Z7K-OIDETTSSE_].62+:%.&!Y_#K7HGPC_ ."?
MTG@SQK/?Z7H\?@_P_JTT-U>Z1#(SQ1SPDDNF68X<LQZ_E7UMXH\>Z?X3U?2[
M&\:03ZQ(\=N%0L"5 )R1TX/>MO;0!^37@+X::]XC^*'B+P];?#SQ?-<)#?V>
ME:C?SQ_V5-YESO/F*K"7KTQC@5'\2?V3/B/^SCX9?5-<TK6/%5UJ'B-[RSL=
M&D 9(VL_**_.< #YL9/7%?J!X]^,'AGX8W$<>M:E;V$EP,IYC ;JYU_VMOAZ
MR8/B*Q/_  ,?XT </_P3^\.VE]^R+I>AS>'=?T&VDLVM9K+6GCDN@K(%8,4^
M7H3TKD_@C^P=K/P*^%_Q)TFWO[;5_P#A(6O3H]E<;O)MDD+[(SC!QAE!P>U>
MRI^UQ\/@/^1BL?\ OL?XTO\ PUS\/\_\C%8_]]C_ !H ^'/#?_!-?XPZ2VKW
MLVHV+,VL6FIPV&]_(FCB@:-H>N>2>Y[5Z;9?L'>)M+^*BZE)H>BWF@WU@XBL
MO,E_XE%PRLNY<OT_/[U?2W_#7/P^_P"ABL?^^Q_C1_PUS\/O^ABL?^^Q_C0/
M4^&-1_X);_$:]\(Z#I[26[2:3;O&Q\QMNXI@$<^OK6I>_P#!.CXL7_Q"\*W@
MFTVULM%2TCN'B>3S+@(%#[LL1V[>M?:?_#7/P^_Z&*Q_[['^-'_#7/P^_P"A
MBL?^^Q_C0+4^+-*_X)A_$CP]X?TVR_M"UFLH[^Z-]:PEE^UPS3O+DY/500.M
M3^)?^"9WQ 7XMB]MYK34-+D\0IK,4DS,6M8A;K$8NO7*D\<<U]F?\-<_#[_H
M8K'_ +['^-'_  US\/O^ABL?^_@_QH'J>"_MU?L->(OVG_B+X-N+.4VFGZ+:
MW,-Q,C8D5I82BE?H>3[5C^ OV$?$[?L[R?#/Q-I]A=6RPW=M%J%OQNW\1RMD
MYWCJ2!UKT'X\_P#!5_X5_ ._M[>^OY[]KA=P-K&T@'UV@U2^"'_!7KX4?'#Q
M#)IUE>75C)&NXM=1-&OYLHK3V<K<UM#/VD>;EOJ>?^ /^"='BKX8?M#?#+7%
MO_[8T_P=ITUC<W$Q_>R;Y5=<=.%48Y]*^YHQA%^E>;_\-<_#[_H8K'_OL?XT
M?\-<_#[_ *&*Q_[['^-9EGI5%>:_\-<_#[_H8K'_ +['^-<?\:?^"C/PS^"_
MA-M6O-76\B5@OEVP\Q^?9<FFDV[(&[:L]ZHKPWX0_P#!0GX:_%WP?#K%IK4=
MK#,3B.X^1QR1T.#VKJ/^&N?A]_T,5C_WV/\ &AIIV8+571Z517FO_#7/P^_Z
M&*Q_[['^-'_#7/P^_P"ABL?^^Q_C2 ]*'6@5YK_PUS\/O^ABL?\ OL?XUYW\
M>_\ @J-\+?@%:VLU_J4E^MUT%JID*]>NT'TJHQ<G9$RDHJ[/HZC.:^2?A!_P
M65^$OQB\6QZ/9W%]9S2 D27$+H@Z]RH%>V#]KGX?_P#0QV/_ 'V/\:)1E%V8
M1DI*\3TJBO-?^&N?A]_T,5C_ -]C_&C_ (:Y^'__ $,5C_WV/\:DH]*HS7R'
M\4_^"TGPC^%7C:]T.ZFU"ZFLG*-)! [1MCT(4BN\^!__  4F^&7QT\*?VM8Z
MM]AA\QH_+NAY;Y!QT8 U<J<DKM$1J1;Y4SZ HKS4?M<_#X?\S%8_]]C_ !H_
MX:Y^'W_0Q6/_ 'V/\:@L]*HKS7_AKGX??]#%8_\ ?8_QH_X:Y^'W_0Q6/_?8
M_P : /2J*\U_X:Y^'W_0Q6/_ 'V/\:/^&NOA\/\ F8['_OX/\: /2J*^5_CG
M_P %>OA1\"_$J:7>WEU?2N@D#VL32* <]U!]*M_ /_@J]\*_V@+^\@L;^XT]
MK,*6-W&8PV<]-P'I5^SE;FMH9^TCS<M]3Z=HKS0?M<_#]1_R,=C_ -_!_C7E
MWCK_ (*O?"OP+\3K/PO-J$\]S>/L6:*-FB7J>6 ([>M*,6]BI22W/IS.**\S
MA_:\^'L\2M_PD5E\PS]\?XT[_AKGX??]#%8_]]C_ !J2CTJBO-?^&N?A]_T,
M5C_WV/\ &C_AKGX??]#%8_\ ?8_QH ]*HKS7_AKGX??]#%8_]]C_ !H_X:Y^
M'W_0Q6/_ 'V/\: /2J*\U_X:Y^'W_0Q6/_?8_P :\Q^.W_!5GX5_ ?6=/L[[
M4)[Y]04,C6J&14R2.=H/I51BY.R%*2BKL^F**\E\+?MM?#OQ5H5O?1:_:QQW
M"!U5V 89]16A_P -<_#[_H8K'_OL?XU(STJBO-?^&N?A]_T,5C_WV/\ &FS?
MM>_#V*)F_P"$BLOE!/WQ_C0!Z9FC-?+&A_\ !73X4:W\6V\(I>72W@=D^T-$
MPA.W/\6,?K7KH_:Y^'^/^1BL?^^Q_C52BX[DQDGL>E49Q7FO_#7/P^_Z&*Q_
M[['^-!_:X^'S?\S%8_\ ?P?XU)1Z5FC-?+>I?\%;/A3I_P 86\&M>W37B2F+
M[0(V\G([[L8_6IOBW_P5B^%7P@\86>C7=]<7<UYLVR6\;.B[L=2 1WJ_9R[$
M>TCO<^GJ*\MTC]LOX>:OIL-TOB&S59T#@,X!&>>>:L?\-<_#[_H8K'_OL?XU
M!9Z517FO_#7/P^_Z&*Q_[['^-'_#7/P^_P"ABL?^^Q_C0!Z517FO_#7/P^_Z
M&*Q_[['^-'_#7/P^_P"ABL?^^Q_C0!Z517FO_#7/P^_Z&*Q_[['^-'_#7/P^
M_P"ABL?^^Q_C0!Z517FO_#7/P^_Z&*Q_[['^-'_#7/P^_P"ABL?^^Q_C0!Z5
M17FO_#7/P^_Z&*Q_[['^-'_#7/P^_P"ABL?^^Q_C0!Z517FO_#7/P^_Z&*Q_
M[['^-'_#7/P^_P"ABL?^^Q_C0!Z517FO_#7/P^_Z&*Q_[['^-'_#7/P^_P"A
MBL?^^Q_C0!Z517FO_#7/P^_Z&*Q_[['^-'_#7/P^_P"ABL?^^Q_C0!Z517!^
M'/VDO!?C'68=/T_7+6XNYL[(T<;F_6N\!R* "BL_Q5XEMO!_AV\U2\+BUL8S
M+*44LVT>@')KGT^-^ARZQIMBLTK7&K)YD($38 YZGL>.AH Z+5O%.F: ZK?:
MC8V3-T$]PD>?^^B*AT_QQHNKW(AM-8TNZF;I'#=1NQ_ '-<#\>?V// _[2=]
M;W/BJQFNY;9=J&.0+@?B#7RO\2?V5?"?[*_[:GP@;P9#>::-72]6Z0S K,%,
M.,@ ?WC^= 'WUFC.:CCXB7Z4Y!MH =1110 4444 %%&:1FVT +11FFEJ '44
MBFAC@4 +12*<BEH **** "BBB@ HH-% &7XS\*6?CCPQ?:3J%O'<V5_"T,L;
MC*NI]17YQ_L*^$]>^$GQD\?? 74]+:;P[H^I-?6\\L'^C-:$*P4,1C(DY^@K
M],*S8_"6G0ZO-?K9VZWEP-LDWEC>X]">M 'YN>-/^"E_C#X?_M6V7A?1=8TC
M4-"74K^P>SAMH\!((@T:!AWR<9ZFMGP5_P %!?B/XN^&WCCQU9^)-%DD\-KJ
M"/X=:TC^T0M"6$;?WB!M.>.:^W'_ &6O $GB#^U3X7TO^T!<-=";RAN\QL;F
M_'%6])_9V\%Z'J^H7UKX=TV&XU12MT5B&V8'.<KTYR<\<T ?GU\8?VI?&GBC
M]EZQ\8OXP\)^)K'5-5M1%82Z9;SFQ8Q-YBL#GG<#@GD5S/Q._P""C'QB\$?$
M[Q'8Z;XETJWT7PSJ%M;P60TB+YT=8<C?U_Y:&OT=@_96\ V^B2::GAK3UL))
MOM!A"_)OYYQVZFLS6_@+\*_^$A^RWVDZ/_:5^P?RY/\ 63%>A]\;1^5 7/D&
MU_;P^,'Q+_:!\3:!X=OO">G+X7DE1K34YDMVN8P"$D!*D]03^%>B_P#!.[]L
M'QY\7?B_XL\*?$2-K/6-+V2PPPVH^RRQ-N*R1S<;@P /3BOIEOV=O!;>*/[:
M_P"$?L1J?E>29PF&=.>#Z]3UK0\(?"#P[X"U.XO=*TNWMKNZP))1\S$#H,GL
M/2@#I@<T4#I10 4444 %%%% '.^,_ $?B_7-%OI)VB;1Y7E10N=^Y0#G\JZ%
M3E:\M^.6@R^(?%NBQPZ/KMPT,H=KVSD(CA&1P1N /3G(KTZS7R[6-?FRJ@?-
MU_&@#+\2> M#\7RHVK:/I>IM'PANK5)BOTW UG#X&>"\?\BCX;_\%L/_ ,36
M-\9?A!XD^)%W;R:'\0=9\&K"I#QV5E!.)CZGS%./PKB/^&4?B)_T7CQ=_P""
MBQ_^(H ]0_X49X+_ .A2\-_^"V'_ .)JO=?"+P#8RB.;PSX7C9N@;3X03_X[
M7FQ_90^(A_YKQXN_\%%C_P#$5\_?M/\ _!-#XR?$_P")^BZII?Q;OM2M;&2-
MI)KW%K+'@C.U(5V-T_BJX13=F[$SDTKK4^T4^!_@F1<KX3\-D?\ 8-A_^)I?
M^%&>"_\ H4O#?_@MA_\ B:\CT#]D7XC6&BVL,GQV\61O'&JLJ:59,H('8E,G
M\:N?\,H_$3_HO'B[_P %%C_\14%79ZA_PHSP7_T*7AO_ ,%L/_Q-'_"C/!?_
M $*7AO\ \%L/_P 37E__  RC\1/^B\>+O_!18_\ Q%'_  RC\1/^B\>+O_!1
M8_\ Q% 7/4/^%&>"_P#H4O#?_@MA_P#B:/\ A1G@O_H4O#?_ (+8?_B:\O\
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M]M470XST#@XZUG?\,H_$3_HO'B[_ ,%%C_\ $4?\,H_$3_HO'B[_ ,%%C_\
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MY6;L3*32NCV;0?V"?@K9_$W_ (2:ST'3Y-79F<(7#PDGK^[QMKU3_A1G@O\
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M\JD'["OP;(_Y)GX-_P#!;'_A0!V1^,WA _\ ,T>'_P#P8P__ !5'_"YO"/\
MT-'A_P#\&,/_ ,57$R?L-?!J'[_PW\%K]=.C']*$_8?^"LIPOPY\%,WMIT7^
M% ';'XR^$#_S-'A__P &,7_Q5(/C+X1!_P"1H\/?^#&+_P"*KCA^PI\&\?\
M)-/!O_@MC_PH_P"&%/@W_P!$S\&_^"V/_"@#LO\ A<WA'_H:/#__ (,8?_BJ
M\UUS_@H=\)?#_P 5H?!MSXLL/[:GD\I%4EHMV,_ZP#9T'K6Q_P ,*?!O_HFG
M@W_P6Q_X5YCXA_X)"?!?6?BQ#XL;0?LK0R>9_9T+*E@W&,-%MP1_6KAR_:)E
MS?9/H!/C-X1V_P#(T>'_ /P80_\ Q5!^,OA$C_D:/#__ (,(?_BJX<?L1?!;
M  ^'/@DG_L'Q?X5,/V%?@V1_R33P;_X+8_\ "H*.R'QE\(@?\C1X>_\ !C%_
M\55?5_CUX,T73)KJ;Q1H/DVZ%WVW\3' ]@V:Y7_AA7X-_P#1,_!O_@MC_P *
MIZW^P;\%]3TZ>T;X>>$;?[0A3?'81I(F>X..#0@&_"#]OOX4_&_4;RUT+Q9I
MLDMD?WOGO]G ^A?:#^%>@?\ "Y_"/_0T>'__  8P_P#Q5>$_!K_@DG\%_A#J
M%W<KX;AUW[9SLU8+=)'_ +H*\5Z(?V%?@W_T3/P;_P""V/\ PJJG+?W=B8\U
MO>W.R_X7/X1_Z&CP_P#^#&'_ .*H_P"%S^$?^AH\/_\ @QA_^*KC?^&%/@W_
M -$S\&_^"V/_  H_X84^#?\ T3/P;_X+8_\ "I*.R_X7/X1_Z&CP_P#^#&'_
M .*H_P"%S^$?^AH\/_\ @QA_^*KC?^&%/@W_ -$S\&_^"V/_  H_X84^#?\
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M1P_\*W\(R^6H7?)IT;,V.Y..M3?\,*?!O_HF?@W_ ,%L?^%8FQV7_"Y_"/\
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MH P](_X*1_"#6_BB?"$'BVR_MA79-K!ECRN<_O"-G;UKU#_A<_A'_H:/#_\
MX,(?_BJ^>-'_ .".7P8TGXJ'Q1_8DTS%V?\ L^60-8\]O*VXP*]5_P"&%/@W
M_P!$S\&_^"V/_"JER_9)AS?:.R_X7/X1_P"AH\/_ /@QA_\ BJ/^%S^$?^AH
M\/\ _@QA_P#BJXT?L*_!O_HF?@W_ ,%L?^%'_#"GP;_Z)GX-_P#!;'_A4E'9
M?\+G\(_]#1X?_P#!C#_\51_PN?PC_P!#1X?_ /!C#_\ %5QO_#"GP;_Z)GX-
M_P#!;'_A1_PPI\&_^B9^#?\ P6Q_X4 =E_PN?PC_ -#1X?\ _!C#_P#%4?\
M"Y_"/_0T>'__  8P_P#Q5<;_ ,,*?!O_ *)GX-_\%L?^%!_84^#G_1-/!O\
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M3P;_ ."V/_"FO^PW\&47+?#7P8H]]-C_ ,* .T_X7/X1_P"AH\/_ /@QA_\
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MG_ML_!^3P+I(T-M62]6[$4KD3!3#C()/3)_.OT '2OD_]MC_ )/1^!O^[?\
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M/_!+%_\ %U5_X;,\6?\ 1!?BM_WZL_\ X]2?\-F>+/\ H@OQ6_[]6?\ \>H
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MD5K&A*4>9&4JT8RY6?:G_#,?C[_HKFH?^"6+_P"+H_X9C\??]%<U#_P2Q?\
MQ=4T_;,\6;!_Q87XK?\ ?JS_ /CU._X;,\6?]$%^*W_?JS_^/5D:EH_LQ^/L
M?\E<U#_P2P__ !=?-WQF_P"">OQ\\3_M&:7K>D_$JXGT&WE#33->O:LHP?\
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M@OQ6_P"_5G_\>H_X;,\6?]$%^*W_ 'ZL_P#X]4E%K_AF/Q]_T5S4/_!+%_\
M%T']F/Q]_P!%<U#_ ,$L7_Q=5?\ ALSQ9_T07XK?]^K/_P"/4T?ME^*R<_\
M"A?BO_WZL_\ X]0!<_X9B\? _P#)7=0_\$L7_P 71_PS'X^_Z*YJ'_@EB_\
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MW&T $<=?+ST[U]%_&+]@+PG\>/@?8_#_ ,276I7GAZP542)93$6500H)4@G
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M9])NE4?CY=>L'PEI8'_'A:_]^Q7._%;X16/Q!^'NIZ/!:VEO->QA%D,0.W#
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MH **** "BBB@ HHHH **** "BBB@ HHHH *#S110  8H Q110 4444 %%%%
C!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>img62602283_15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img62602283_15.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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MK% !1110!#>GY5Q][M[UXK\0OV]OA'\*/%LNA^)/'&C:7JEN0LMO*3F,]1G
M.*]EU9V2)2I*X.20F[%?GW^R7^R7\,_VC?VJ_P!HS4O''@'PKXLOK3Q!IZP3
MZGIL<A5?LI'5@: /I3_AYS\ _P#HIWAG_OJ3_P"(H_X><_ /_HIWAG_OJ3_X
MBJW_  [ _9X_Z(O\.?\ P3P__$T?\.P/V>/^B+_#G_P3P_\ Q- %G_AYS\ _
M^BG>&?\ OJ3_ .(H_P"'G/P#_P"BG>&?^^I/_B*K?\.P/V>/^B+_  Y_\$\/
M_P 31_P[ _9X_P"B+_#G_P $\/\ \30!9_X><_ /_HIWAG_OJ3_XBC_AYS\
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M";'CGX[_ +.WA;]G..U\<0W'@WXL17>DVVC1)@VC@Q;).4 Z9[]Z^@OV0_\
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MVSR^=K;2-A!Q@CJ?K7X+_L__ /!3OX\?%#]K'2/&&ESZSK.B3>)IM+U#1(4
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MP!PJ@?A5+2_^"GFGZC^UM??!U/"NIMXVLM32U>T!&1IS.5%Y][;LP&/KQTH
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M[MN,'D9YZ5\U_ 3XC?$+X,?'_P#:.NO%7BQM>;P[X:N->LK'G[/;&*.1PJ#
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MO?N6_,5QG[1/_!/WX\^(?&?BO2_!.H>')O!'C2:PO;]]2F/GQM"8"PC^4_\
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MM_$:^-8#$TYP$/ER].10!]_#I17PW'\)/VO[V-6E\8Z7;,1C".IQ_P"/T/\
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M]@_2+;_@GO-\&? ]F]KI_A^P#:';2?Q2QR>='D^\O.>: -6+X]:IX1\;^'?
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M5X*_[ 5E_P"B$HH_9]_Y(5X*_P"P%9?^B$HH [$C-&T>E%% !M'I1M![444
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M?_?-.PW]Y?\ OFOC+ROV\/[_ .SI_P!^]6_^*H\K]O#_ )Z?LZ?]^]6_^*H
M^S?F_O+_ -\T?-_>7_OFOC+ROV\/[_[.G_?O5O\ XJCROV\/[_[.G_?O5O\
MXJ@#[-^;^\O_ 'S1\W]Y?^^:^,O*_;P_O_LZ?]^]6_\ BJ/*_;P_O_LZ?]^]
M6_\ BJ /LWYO[R_]\T?-_>7_ +YKXR\K]O#^_P#LZ?\ ?O5O_BJ/*_;P_O\
M[.G_ '[U;_XJ@#Z_\3AO^$:U'[K?Z++QC'\)KYI_X(Q2?\:OO@F NUO[ ;_T
M=+7'ZE:_MTW-C+#=']G9H)E,;[5U52 01P2U>R?\$[_@+K/[+/[$?P[^'_B2
MZL[K7/">E?9+N2V#>4[;V8[<\_Q4 >[I]P?2EIL1W1K]!BG4 %%!Z44 <O\
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MM_\ %4>5^WA_?_9T_P"_>K?_ !5 'V;\W]Y?^^:/F_O+_P!\U\9>5^WA_?\
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D[0W][]*9+&LVZ1E!=5.&[BBB@!ND#]W&=S-\IZL31110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>img62602283_16.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img62602283_16.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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MA_KA_%U^E24;"WJO&6PWRG%$MXL,;,0V%ZXJN=T<Q$>W]XNX9Z UX_\ $/\
M:TTGP+XVNM'DT[5;M;4A;J>%HQ%%D \Y.>E 'M@E#)NYZ9H5]RYK/T+4/[6L
MK>XC93;W$2R1^N",\U:,BNK-G:J]Z "74XXI_+(;KC/:GP7:SLRKN^7U[UQ$
M7Q>\*ZKX@;1X]3MY+K?L$1)P'SCTZYKK-/V_:8U5O.V @L?X/84 :%%'2B@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO+F7[%'*?E$0<KQ^(-?2O_!%OX]ZAX"_:#>QU+6KFV\+C39"\5RW[F'YU_\
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M?_M"_'_2OV>_ %UX@U:Y\J&%2$0X^9L<#]*NG%SGR+<BK45-79'^T7\<="^
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MPT_Q"+IKW[.,,Q10?ZFOD?XW$_#+Q7J/A_2[R2WM+66RNK-@?WFYI,R*?]X
M"OK+QIXPU+XL>.WO]0N4AM=*N+B&Q"@?,,[2?Q %>,_'SX.VM_XDM/%?VG=(
M+JUM[B$J.@D 4_J:Z#G.^OM>N[KX737UO-)'??V87",H#!A&21^%>1_ K5['
M6/#^J_;%AN]2_L=+RY60_=+ALL/<XKT[XH_$+3=+L)=$L[Z%-1<QHJ$#[KG:
M1^6:H_"O]GO3?AK=:K)'(]W<:Y$8[G/1$Y.%]ADT ><_L\>(I[G5_#\.GMNL
MM\D\\+']ZJ.F%9A_=)Z'U%>L?&2;'A'^R6CGFN[IF$9B&2&4;L?I7,VGPXT[
MX*^+['5-)F_T>Z0VTZ2=8HT!(/?N:Z#Q=XM@\4?\(_!I-U'<?VW<R0B? _<N
M(]Q_2@#S2P^'=NOPUD\13S2?VY!-YT+2\+"6PI!]\$]N]7_V9O%(D\?:]I<D
MDS3:8WDI ?NQ09&#C_>->G?\*KM_^$+;P[-<?:%<;))5'.X<Y_2N&_9X^'MO
M\)-4\774TZMY=\RSW4QY:+"XZ_[5:1U5AQET,3]L;5-1FT^XT&&5H;35[(VD
M,H.&:0-OX]\+7QM^QE<ZG=_&B73_ +9)LU -;W$DS<Q*#GG\0*]+_P""AO[3
MMU?^*=/TK2VC^RZ6INH[E3R^=R?UKY9\/>*M4\*ZRUY8WGV.^D^;>3]ZOON'
M\B=?+ZDEV/E,7F7LL4HON?K-^S]<7E_\(=+:3)O)(FC;=U;YV_PKA_%EI%XI
M^*37-TE\MG%KL.@;D'R!I(O-R.?O<5C_ +#?[1MGXI^!6GVNO7BVMPLXM8)0
M!EF(+>WO7::=K-CXS\1:A-=:S9V^GV&KQWUK;$JKRRK'M#'OW(KX6MA9X;$N
M#/H</65:-XG _%G0=.^$?BV/26OFM]-U2RDED=FQY+!@ P_"O9OA3KTFK_#>
MQOO,N)+NX@:*V#+R<'"G]*\Y_:F\&Z)\1-.GU)-9MX;C3;1HVMRP/FJ>2/6N
MOU[XR:!X&\&?V?;ZMIK7;:>IM8@X#3,$'3TYXXK&:UN:TTUN>>? K4H=;\:*
M-8E%UK5ZMVTD4OW=B2[<GZ#':L_X6^)6N?%$T.BMY;W>L*[V^?OQQ.RNRCT'
M]:[3X8_#?PKX1\4R^*1K$-]=:A;$%/,XB+ ;E'/J*KZ_X&\(>!O$VGZ]I6IP
MBZM9LM;^;U5VW/W]14FAZ9\0[Q;;PW-:^7(T=]*EN@0?,=^0V/?/2O'?!_P^
MM?$6@>)-5UC[6NHZ>Y^S1O\ \LC!N$1//7@&NZ\9?%W1=5\/P?V=J5G+YUY%
M&&WC]U(3_0U;\-MH>FZ#-9RZS:>;J!D$TFX'YLG_ !- 'K/[$GABU\7>+-:N
M]0L[6\^SV.GRQ23+EDE,9+?FU?66G+LM0O3GD#H*^,_V$_%UKX*^*'C*UOM<
MM'LU@M$B.X?W6Q^7%?5%K\6_#-K%M;7]-9LDG=, :SF5#<ZRBN8_X7)X7_Z#
MVE_]_P 4?\+C\+_]![2_^_XK,V-W4E#^6N&SG@CH/K7&^)?AQI&HQW^J3:39
M2WWER+O9<EAM/^-6]7^,GAE+&23^V].D\E2Y59QEL<UQ?PQ_:W\#?&GQ%>:7
MH^MPKJ5JWEO:3,JSMCT3)X]ZSJ=#*5-3?O['S1H_P]T;3KR\9M*M4E>=]\3$
MA8SCL*XKPOXYUCX<>/=4M?#.GWGB:2=W"Z02S+*>RKCGCKQZ5]*_M"_LN:?J
MFHWGB"SU)/#L<IW7+R3'9YA/)P>.XKR_X2>%?#?@/XZ6T<'BK3]8:VMC-+.D
MJY#$,O;WQ58['0IPC#J<E50IR7L]CX9_; T'X[_&#QUX#UCQA\&;NR\/>'-<
M,FU8Y1LC\MA\W ^7+=?6OOG]D.W'B#XTW$EQI#PZ9?6BF*&:/<(SD<\].F*S
M/B+\6[>+P)'I-QJJWEU#J[RRJ6W8A\O _P#'J[/]DKQ79>)_C'+;VLRR?9[
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MC!?*?]9&2/,C'=6 SR.F*^8_^"F7[ ]Q\6O ]_XI\#:>L?BBPB:4V3)Y<=X
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MTBXP)C+U&4.,M@'@YXKQ#]H3X]>(?VE?'S7VJ23-NF\NTM(^5A4]$4<9/?\
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M-;9>1PW_  4[_9T\;_LV?$:&VD$DGA2X)FT:]@SY,Z<%27P/F *G'/-?0_\
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M)M=L&H>*KJVUB*^<<I#;*5D0'T/F#\J5BCB[OX>R>&?AA;ZE'>*OVZYC9XS
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M['_OPO\ A0OA32V_YAUC_P!^%_PK2%&,5S1V-.IG_P#")Z6/^8?8_P#?A?\
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M;_M6Z+. Q4;3_P#7JY9LLMN[OSN]MN[Z_P!W\*(9?M99F;"J, [><>FWI^-
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MP:7_ (1+2\_\@^Q_\!U_PK1HJMBC/_X1+2_^@?8_]^%_PIK>$]+8[?[-L?\
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MG:,_[*G %32T6HJFI]$?\$ZO"<7BG1]3\97=NTDD-S+I]D\HVN(XF9"V>IW
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M:>USZ&AA86O!W/; V13XZ@MY?.3*YZ5+ >6HIR3C=&,])V)*KK(L;E?E9CV
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M5W"G\)XS:^)KOQOX3U:2%1:-XDN?,\M#SY( 4MV_B7%;UEXF/@SQ\MG:J?\
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ME=7#7$@'R1R&-$([;0<?CWJ#0]2#,)<%/E]<U8JO%'Y<:_,67MS5B@ HHHH
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M5,)D6&ITY\KGJWYLY\IPM&>,]G)::GF?QR^!UMX-_:N\6:%=,;/3;B]%FN.
M$\I'S^=?//B?0FT+Q%-I>?\ 2K*X\L-V8'I_.OTD_;I\#^'!^U5=2Z\KQZ?>
M6@NF*OL8N!@$'KV%?F[XJU1M5\47=\VYO,N20X'W0. 3^0K'PWS;$UY5:U1\
MS47%7%G&#P\*RLCZF_9E_9V:Y_:'M[.\MQ>VO@&W6>88W+*I"OSZ_P"LKQ?X
MC>$XKSPW<7 ^5K-YP1TVMYK$#\J^[O\ @E?>6>NIK/B"^D6:[UW0GNK@,N2
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M?AO\#]5\&V8FNH=:,\DUQ.2TTC.O\1/.,CO7PU^PK\"M/\)_MD_%+3UE#?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=4;2;EI(7C>68%!A05RP)=>0"*[SX._&'2/B[X:76+%I;58U'FQW3?-&?4C
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M'KCK7SA_P4>^&WA#XW_"6S\(^+)-5MX=:NS]DU'3@?.TV:/;(CY"MCY@N>*
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MIL\.HW=E=7Z2?:H-X=A$ RJVV/(5!C@#O0![H==AED62-ED>'.8EF7YU[O\
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MW1NN.HQTQTYK\V=4_P""LWQ=\):IX]@NK#PC=V?@3Q+9Z9.+>WE0303627#
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M(HT)R>?O;_4'BOI;]L.34?V)_P#@G;?:A\.DTCP[JEJ]IY[P1.()3--'&Y4
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MPQQ7HO["/[6'Q'_:+O[6\U[PO OAG5+*>]M=5MI$!21)=BQN"Y;>1DY Q@4
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M'!(*K]TGI7T5^SW^W?X+^/OCM-*T=M0^RZK9"_TZ_<J;75XRY4/'CYA]T_>
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MUJSM;C5"$MXV?EG. OYY[T:Y\</".C7LEC>Z]I\=U:RPP/$S_,LDGW.,=^U
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MY&&!T- 'QIXW_P""/]UXZT_Q3;MXHLUU2_\ %;^+;"1=VVW:6X69HY?E^[A
M!C)ZUW?[0O\ P3QO/C_\.="TG5H_#\FH:3?QW]O.JR+]EN-R&62 C!^8*/O9
MX%>J?#G]JJP\0>(O%46I0+H^BZ1<K'!J4K#9=NTA7 Y)QP,<#K5WQO\ ME_#
M_P #_$+1?#M]KMG-K7B(2_8[:,G;F--Y[9R1Q0!M?$3]GC3_ (J?L^3> =<D
M_M"&ZL19232\[W3E7/N&P?PKPKX%?\$O-#^ _CWP[XFM]2635M#\.Q:#+.P.
MZ[>,/\S<<YWU[)\$OVG[+Q]X'U[6M>A7PW;Z;J]SIT7VEQ\\<>W$G!/7=^E=
M0/C=X5L]/TV[F\2:;]CU:)6M7WY\_=T8<=Z /D9?^"4VIS>$K^.;6+./4+OQ
MO/XOAC4-L#RQQH8^G0!,_P!:L_'#_@E=KGQ:U[XL7TWB#38?^%D64%D(U#YM
M_+NHKC=]WOY>/QK[9MH2R-&DYD\OY"PZC']:LA7G.T*=NW<']30!B?#K0(_"
MGAC3=)>9)I].B6%V7/S.!C^5=/WJA:6,PFC9Y)%*?>&!B0^M7Z "BBB@ HHH
MH **** "BBB@ H[444 %%%% !1110 CG"GZ5\K?MS_L.W/[4'CCP'XLTG5;?
M3_$7@/4GO;*)]WV>Z1XFB*RX!/W68\8YQ7U2_*'Z5C7=M<&58X5GW2 %F8#R
M\]\]_P J /D/XS?\$T]2^+/Q6T;Q/;ZWI-A]@T :.]K$KB(29=B4^7[N'[U@
M>'_^"46JZ=I_PDC7Q-IY;X:Z0VE(<-_I+-YQS]WTE]NE?<,UA(]I)';IY$D>
M%0GIU[?K4@AD295$3+&ORKC^$_WJ /@B]_X)'>*IO@'\/?A^GC.S71?!<3QS
MP -MN79Y6W'Y<]),=NE6])_X)-:UIGASX3)_;FDQS?#72)=+Y$F)P]Q--D_+
M_P!-?TK[P^S^0@CV,ZR-R1_#[FF_OC/AHY-N=@(Z?[W]* /A7PC_ ,$L-;^$
MMO\ "G4_"OB>U7Q'\,[*?346\!-KJ-M+=2W+1L%7.-\GMTKJ[K_@GKJ/_#60
M^)6FZUI-XVO61M]<L[Q7VJ^4'FP!5QE0@ W>O2OK5]%=H+B-FD62X7YI4ZJ?
M:IHX9Y+>,F&,%.5#?>R/7% 'SU^W/^QXW[67@#PI9Z?J4>BZYX3UFVU*SFES
MM,L0;:C;0?E.[/'/%<QX[_8+UCQMXL^%NL?;](M)/A_?QW=]!$K[;IEDW[NG
MU].M?5D5C(2^1Y>Y@P91\WXTZ2T;#YC+-(A#,._I0!\0Z[_P2SU[Q!X(^+FD
MQ^(=+<_$S5[34EED#X@6&.5-IPO3]Y[]*ZSX-?L%^(/@/^T%<^+/#/B;3VT7
M7K#3K/6M-N%8AI;2W6!'B^7V<\GO7UA/:R+ ?+C.V-"-G]\FH;K3[B2+]TI5
MF &6ZQ>X^GO0!\"ZG_P2,\3:]\:;?Q=X@\:6>N7%OJ=S/B=3NDLY9MYC^5 -
MT:85?US7I_[+?[+FL_L'^ ?%&G:GJUKXH\"27>H:K:6X4F\5;EWE>%OE"[1N
M"C';K7U;'8R2PQ;4>.504+M^I^IZU'%I+222+)$S0L K;A\TOU'3% 'SI_P3
M5_9;T[X#^!O$6K6+7ZV_C+5KG5H+*YQBS265I%5<=,!\=>U?3MA<><6W?+(O
M5:KS6;6L*K;JRJ-H54  058L?,;<TB;6SC/J* +%%%% !1110 4444 %%%%
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MBB@ HHHH **** "BBB@ HHHH .M%%%  **** #O1110 4444 %%%% !1110
&4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>img62602283_17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img62602283_17.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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MT!S'8_VE;_\ /Q#_ -]BC^TK?_GXA_[[%<@C;A_(>E+0',==_:5O_P _$/\
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M[2M_^?B'_OL4?VE;_P#/Q#_WV*Y&B@.8Z[^TK?\ Y^(?^^Q1_:5O_P _$/\
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M #\0_P#?8H_M*W_Y^(?^^Q7(T54I6E8.8Z[^TK?_ )^(?^^Q1_:5O_S\0_\
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M%%%%  .M=9I?_'JM<F.M=9I?_'JM!42Q1103Q04%%%% !1110 4444 %%%%
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M,4=)XXKB/ CD'EJF?]7MYS^.:\NU3]CKP/K'Q)U/Q=>Z;OOM2V"Z&.,J^Y7
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M/@S5C%=QF--WV<&3]YC'W<*I_&KC#F1,JG*?>H=7D8[MNT;BC<'%> ?M._\
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MHTR_.655Z*@YJ914E:6IMEN.G@ZW/2;B^Z/DG]F7_@G9_P ,;^ ;R'1;Z_\
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M2S^+MY^UC^R3;6/C+1Y5ETO;:DW,>UIUYPP].,=*^N;"PCTRU6&%=L:KL ]
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M6DDAD=(Y#Y2[W*CU&?PJQ;_\$V;BRL[/4K77=/C\46.I3ZI-/.DC0NLTIE9
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M_P \11_9-O\ \\10'*CE,M_LT9;_ &:ZO^R;?_GB*/[)M_\ GB* Y4<IEO\
M9HRW^S75_P!DV_\ SQ%']DV__/$4!RHY3+?[-&6_V:ZO^R;?_GB*/[)M_P#G
MB* Y4<IEO]FC+?[-=7_9-O\ \\11_9-O_P \10'*CE,M_LT9;_9KJ_[)M_\
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M\'?#-[:6=K#=7&FP,[QI@DM&I.:]+7I0 M%%% !1110 4444 %%%% !1110
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M/Y4SQ?\ LV^-M.US4+2#PUJ%UX<O+'21HMO+>2WK6DMO(S3&4N,HQ4IZY(H
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M ."A#>'O!MQKT/AI[W0[>\O=+,GV\&5;B!_+12-N?G8')_A]ZZ;X#?M8ZO\
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M0?%.F33>7%J5C/(3AD\]=Q[X&#UITVJ:?F&;[=:,H/F0YE&,=/RZT ?#NI?
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MWS'%G_97CJ:]:L(Q#'L].?H#0!8HHHZ4 %%%% 'SCXD_:ZUZ;Q+X@72?"/\
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M0A/S=0@Q]*WO"_[(WBWP]KFD:EH/AV32M/G\4_VT+?[0C1V41T\P94!L_?\
MYU]R>*O 6F^-=/6SU;3[+4K3?YCQW$7F*2/8]ZM66DBQM46&%8A$NP1IPN.W
M% 'Q=\._V>O$<]SK5KXD\#ZS<:U;VWV-M2EOH#;ZJA;AT7.Y2I;=\W]VJ5M\
M _B5X#^&::"OAVZUZST?4YQ*EO<QQS:Q;R!$4LS-C>N"Q)P#7W$UA(T:AFW2
MK_&>0/7 HAM)(Y7;9MW,0,'Y0/7'J: /C'4_V<?%]GK/A>[\-:#JEO\ 9;NS
M:YL-0O(I;6*W5U+C"D?O47.#G&>QK[4TOBS7Y=OMZ5"VGM';LL8V_-OXZD_7
MWJU:HR0+NX/7'I0!)1TH)HH **** &M$K,K%>5Z>U"P*K9"\T[-&<T ,%N@&
M-O&<_C7$?&3XGP? GX8ZYXJO(9[RQT.V:ZFC0_O9L=@>@KNJ\I_;-\#ZM\2_
MV6O&WA_0[=KK5M8TN6VMHA*(2[G&!O/"_4T 0_"KQSI7B#5KS6X_";:+<ZA;
MK=SWTLT9\XG: &8' .,=?2F?&[]J;3?A!J7A^S737\0W'B*9[>S%E<1[3(D;
M2-R3CA%)_"O/]9_9_P#$GA;]G:QA\/?VIJ6I*\4^I:3?7X:.\54V&'<0%VYP
M>XXK@OCI^S%XB^+\7PYAT?P[=>"[;3]7N+N^:PU!$DL ]I)&"I4?,I8A2H[,
M: /I;X/?M :'\9O"<6MZ?<0K;LQAE#N$\IP 2,GAL9'(KLCKEK%8_:&N+?[.
MS!1*T@522>.2<'/;'6OCEOV<O&6A_ /PYX531[;1]:\,WDL*WUM(IL=17RU
MDEMU.6#\@ M\IY.:],^,'PK\9>(?@;X)M;6QMVO--GL_[5TP2*(945X]Y7G'
MR ,0.?:@#VZ3QII5L$DFUC257+JI-TB@X//4]N]8?QI^+>G_  ;^%.J>*YXV
MO]-T>$W4P@8;BH!;<K=*^0[W]CGQ9J7BR.XO-"BOM'C@USR[.6=&\F2=@;?!
MZ<X]/E[UZ]X_^$GBS7?V!M?\(1:?]I\0:IH\UG#;23+Y<;;2J)GH.,#/3B@#
MK]'_ &O-(E\0:3INO6%UX9FUVT%U9M>.KQ72'& &7@,<]S4^F_M$V/Q)\)R:
MA;Z!=:AX7N08FFR,2#=MW;>N,C'2O&OBK^RQXP_:@\,^ _#^H:>_AW3_  LD
M-S-??;$DD>6./9Y( P=IR3GIQ7HO[*FB>+/AG\+M,\(ZMH"QW%C(T#.LZM$J
M99A+QVY VYSDYH ]>^'/PQ\/_#W3Y(]#TFUTN.8Y=(E(R?>NB%M&K[MHW9SF
MBUB\F/;S]3U-2 Y% $8MHPFW:-I.2/>GJ@0<#%+10 4444 >6_M1?&K5O@WI
M&AG1[6WN[W6KXV:+,/E!V,V>H]*\33]O+QE-?'1FT&UAUJQU>XTB\.,QEK>(
M3/(@W9VE3@#GD5[1^U/\#]2^-^F^';;3[E;7^S=1^U3N>NS8R\<CG)J>Q_9>
M\-V6M6>HK9R27EH[R-+(X8SNZ;6D;CEB#@GN* /*H?VSO%EQICZU#X9M]0T.
MX02B:"=%>UCZDNA;<S ?PJ,\=*BL/VYM2\8Z7;Q^&;"VUK5)O-D9"XMM\:8.
MQ5D*D2$<9/ /7%>HZ7^R-X5\.7]]<6-K,GVZ87/E[QY<$F=Q,8Q\N>/R%5[S
M]BCP+>W5G='3)(KRVN9;L7*N/M!>4AI07QR'(Y'>@#S1OVT_%$/B9(;W0[72
M[.2^L-+>*4^9-'+<J3O+*VTJA4@@<GM7,Z9^WMXF\.? 74O%6O1Z7>26*WUV
M1:QLF8[>X:()M9MV2 #GI7T'=?LJ>%;JY4M;W#1M>6]^0T@/ES0 B,KQQC)K
M!UW]A#P%K]A]EN+*_P#(821NJ7 4-'(Y>2,_+RC-R1W- 'E-[^U3XDU3PO\
M%6_U;^QK[0_#,=N\%I%&RR[9$@?DEL'!D/2MS4/V[IM,M+K4+'2UNM&T*_.D
MWV/]<7$(D#J,Y ^91C&>M>FR_L?^#Y=)U6S^PM%#K$*P7RJPVW:KMP6&.HVJ
M,GTIZ?LG>#[75)KB'3VC6ZF,]RF\>7=RE-GFN,<OM &3V H \Y^"O[8'B#XD
M^-=%M=0T^WM]-\0*?LWE';-&54N2Q)QR.,8S5'Q[^V)KGPK^+OB>WUJ72YM*
MM[FPL-.M8HG$V^YG,2NS$[2 2I.,=#7L/AK]F3POX8U2QO+6UE^T::6,1=PR
M@LNTG&/2E\6?LM>$/&NO7NHZII<%Y->+#N#J#M:)BR,,C@@G(/K0!D?!WXN2
M?';3_$FAZM9O8WVFS/:S2PG"LI+*K(>>< FO,/@5X!DNOVO_ (F:7-JFH_8?
M#%QI,EA&L@Q#OM2[J>.CMR?>OH/P/\,-/^'VFRV^GV\B^;)YS2,X+N<Y 8]\
M9JOH'P<TOPOX[USQ+9PS+J_B$1->R&0%)6B39'QCJJ\#F@#A_$7[0=UJ?Q/O
MM#\/PVDS^'9474%N3MDD0H&_=9(YY'7->:>+OVG]?^)WP]U:XM-#\OPYJ%J7
MBO;>ZB$L$BRA2)!NS_">PZBO<O%G[-7AGQA\0;7Q1<VLT&K0 !Y+=Q']H_ZZ
M<?-TQ67I7[&_@O0SK M+"6U@UTYNK:W<1P=NBXX^Z* / ?"OQJU;X:?$6[U0
MO<7K1^";2\:U4%U>1KQE9L#J0O/X5](? CXRQ_&?X=0ZY#=1SQR2E"T$+PD$
M8PI1_F5N>014*?LM^'8);B: WUM=3V<>GK-%-M>*!'\Q54XX^;/YUTG@[X9:
M?X TNXM](A-O)=3&:>:0[I+J1L;I7/&7;'6@#IHG:2-6*[21R/2G4RWC\F!5
MRQVC&6.2:?0 4444 -FSY;;>N,US_B6]O+7PGJUQ:?\ 'TUG*]O&3\PE"':,
M_7%=!,GF1E<L,]QUJK<6.]5^168]^RGUQ0!\$Z9KOB#XJ?"/6+S5M4\2MJT=
MK;6FJZ;Y$B6]K.KG>R KEF.<$J2.!5F+PQKO@#Q[K.K:%#??:+7POISV[/ Q
M65!"YE/ ^\HQQUSVK[IL[*>/:LC>8NX[BYW$^X/8>U31V3(S<]<_,/TH ^%[
M+XD:W;VVFZE>:_XIF\ WP5+Z2*UE6XM;M\<(A3=MW;\G:1P.:F\7IXH\">+_
M !?K6AW'B:ZEN].22PGG^:9H1&@;;A1A\XP"/PK[@ELY),?,I4$=1SCO^=)-
M9S.GR^7YJY"MMZ>E 'PIKNI_$+4?'.D16/B#Q58^#;SQ) DQ12)((C:9=?N_
M<,F2>.M?1'[3_A[ROV5->L[7[1JU^EI%&))(RTTW[Y#Z5["]O<9S@'RST[./
MZ5+&K,OS!CCWX- 'E/PZ2ZT;]F&SN-*MI(]9M=%8Q1%-LGF!&('UST]Z^;?^
M%N>)(O@W#KUGJ'BR.]F-K#XBL[B!V6QDW@2LBA,LW+;RN0P Q7W0P= RJNYN
MHYZ5"+29HV7!7YSG>=V1ZCTH ^'_ !/8:A?:UX0OI+K6M>MYM"\0;;F>!_,@
M25(_*505!7C[H(SQ5SPCK/C#P[KO@E=->XN]$2Y@MY[ 6TD=U$KXW-O8!-O&
M6'4DBOME[-E;</F?&,]_SI8[,H<L6=F[D\K]* %MCYD$9967<H(#'IQTJ>%]
M\8-5XX6A95VO(H.=[-DBK$>Y4&XAF[D#% #LXHHHH **** "BBB@ HHHH *,
MT44 %%%% !1103B@ HQBBB@ HHHH **** "BBB@ HHHH CE'S XS3)'*#+!5
M7W-.N S,H7UR?<5QWQIT?6/$'PUUJ/0[S[)JRPEK.0*& 88/([]Z .-^ B*G
MQ?\ B$\C1*'U>39AO9*]D@^4L"<\U^8'[#?B_P"*WC_]J?4M)N-2D6"RG-WK
M>Z$#>QXZXXZ#I7Z=V3[F;YMZL-RMCMZ4 6**** "BBC- !0:** "BBB@ HZ4
M44 %!HH/2@ K!^)^NS>&/AYK6I6_,VGV4UP,_P"PA;^E;(D)8+W]:\8_;'_:
M3\-?!?X=:I9Z]<2VTNL6-Q:VFU<^8S1E2.2/[PH ]&^$?BF3QU\.-%U:9=LE
M]9QS,/\ >0'^M=,!@5X/^Q/^TGX8^,?PUTW3-!NYI[C0[*"VN08P K! /7MM
M->\+]WU]Z "BBB@ HHHH **** "BBB@ HHHH **** "H1N!PS!E/M4U(%P*
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M%>/_ ++NH6T.M>+4,A$DVK,8T90"_P"[7D4 >T6SLV/3:#FIJKVD^\A=H7"
M]:L4 '>BBC- !10:* "BC-% !1110 4449H ***": "B@&B@ HHHH *,XHHH
M *.]%% !1110 W<*!*N>HJ.=]L#$=0*X^Z\170NV"R;=I[UI3AS(QJU>1G;9
MIOF+ZUQ7_"1WG_/84?\ "1WG_/857L60\0NAVOF+ZT>8O]ZN)_X2*\_Y[4?\
M)'>?\]J/8LEXH[.0!VZ]L5&Z*5^Z?E_\>KD/^$ENS_RV_6@>);H?\MOUH]C(
M/K2'>#O@UHG@/Q+K6L:79QVVH:Y)YMS*%P6Z?+^E=?:D*.%V+@8!ZBN/_P"$
MCO/^>PH_X2.\_P">XJ?9L/K43M=ZX^]1YB^M<5_PD=Y_SV%)_P )%>?\]JI4
M9"^M+H=MYB^M'F+ZUQ/_  DEX/\ EM1_PDMU_P ]OUI^P8?6EU.V\Q?6CS%]
M:XG_ (2.\/\ RVH_X2.\_P">]3[)C^M([;S%]:/,7UKB?^$CO/\ GO1_PD=Y
M_P ]Z7LV+ZTCMMZ^M'F+ZUQ/_"1WG_/>C_A([S_GO1[-A]:1VWF+ZT,X*]:X
MG_A([S_GO1_PD=Y_SWI^R8?6D=EGY%_O5X?^WU^S2O[2/P2O+&SB#:U8G[19
MN!\Q8<E1]< 5WW_"1WG_ #WI3XCO/*;]YNH]FP^M(\T_X)\?LQ)^S=\%X8+R
MW:'6M0/G7I=?F#'G'X9-?0"R+M^]7$P^);Q(BNX4#Q%> ?ZZCV8_K2.V\Q?6
MCS%]:XG_ (2.\_Y[T?\ "1WG_/>CV3%]:1VV]?6CS%]:XG_A([S_ )[T?\)'
M>?\ />CV3#ZTCMO,7UH\Q?6N)_X2.\_Y[T?\)'>?\]Z/9,/K2.V\Q?6CS%]:
MXG_A([S_ )[T?\)'>?\ />CV3#ZTCMO,7UH\Q?6N)_X2.\_Y[T?\)'>?\]Z/
M9,/K2.V\Q?6CS%]:XG_A([S_ )[T?\)'>?\ />CV3#ZTCMMZ^M&]?6N)_P"$
MCO/^>]'_  D=Y_SWH]DP^M([;S%]:-Z^M<3_ ,)'>?\ />C_ (2.\_Y[T>R8
M?6D=9<VZWZ3Q3*K6\J&-E8?>!X-?#OAS_@FZ;']N.[UR2Q!\'QL=1B./E>9M
MS!1_NL%_.OK;_A*+XC&\8]?6@>(+L<^8%/K1[,?UI'66L/D1*N%6-5"A%_A
MJQ$X"8STKB_^$BO/^>]'_"1WG_/>E[-A]:1VWF+ZT;U]:XG_ (2.\_Y[T?\
M"1WG_/>G[)B^M([;S%]:/,7UKB?^$CO/^>]'_"1WG_/>CV3#ZTCMMZ^M'F+Z
MUQ/_  D=Y_SWH_X2.\_Y[T>R8?6D=MYB^M&]?6N)_P"$CO/^>]'_  D=Y_SW
MH]DP^M([;>OK1YB^M<3_ ,)'>?\ />C_ (2.\_Y[T>R8?6D=MYB^M'F+ZUQ/
M_"17G_/>C_A(KS_GO2]FP^M([;S%]:-Z^M<3_P )'>?\]Z/^$GNU_P"6U'LV
M/ZTCLKIE>WD5L;6&#FOS5_:O_8;UC6?VT=)&E?:UT/Q%<"YFD4?)9+R2A^NW
M]:^^/^$GNF.#-M7U]*KMJ4EU*'E9&N(_]7(5Y6G[,/K2.H\#>%[;P1X5LM*L
MP5M;&(11*>H4=*U]XKAU\4WRKM6;S-O!/O2_\)3?_P!X4O9L/K2.V\Q?6CS%
M]:XG_A([S_GM1_PD=Y_SWH]FP^M([;S%]:/,7UKB?^$CO/\ GO1_PD=Y_P ]
MZ?LF+ZTCMO,7UH\Q?6N)_P"$CO/^>]'_  D=Y_SWH]DP^M([;>OK1YB^M<3_
M ,)'>?\ />C_ (2.\_Y[T>R8?6D=MYB^M'F+ZUQ/_"1WG_/>C_A([S_GO1[)
MA]:1VWF+ZT>8OK7$_P#"1WG_ #WH_P"$CO/^>]'LF'UI';"1?6CS%'\5<3_P
MD=YG_74'Q%=?\]J/9A+&+H=L)%/\50W 5I%;DX..*X\>([L?\MJ/^$CO ?\
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MI?+!%0Z?J<&JVHGADCDCD&<JP(%6%S\OHW2G[1'#4A.+&A5I&V@>_:I "?\
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M66+R&!_#_"L>4WPM6-*7,U<\=U;]I_4K#0[6[T^SL;B&;2!?S><S!HY!-Y1
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M;&7/D7)!;<_7(8<DDD#@52C\+Z=XB^+]B/BAXN\/Z/!HTRK+IL,<SM,5(YW
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M6/R[.&\&I64P'W"Q"LO_ 'R#^=?46EQRO8P^?(L<ZQA)<'[Y%>IC*-&%N4^
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M63KX?CT_P)H[:?J,:W#-(7(G&Z/Y/F_UB]2.]5&-*&L0]MCIZ21=_9V_;_\
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M!M9/]'TNUBB,A_B*#']*W ^\;NN[G/K42DGL>DOA0?,!C=N'IBBBBI ****
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MBBB@ HHHH **** "@GFBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH !1110 4444 %%%% !1110 4444 %'>BB@ HHHH ****
G"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>img62602283_18.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img62602283_18.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_X0 B17AI9@  34T *@    @  0$2  ,
M   !  $       #_VP!#  (! 0(! 0(" @(" @(" P4# P,# P8$! ,%!P8'
M!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_VP!# 0(" @,#
M P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# S_P  1" &G NL# 2(  A$! Q$!_\0 'P   04! 0$!
M 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%! 0   %] 0(#
M  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*%A<8&1HE)B<H
M*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY#*/EXKZ _8RUR2>;4;$R,T4."JGH.M?/^<*VTC=TZU[A^Q=)&-<U%1N\R0
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MU&*DBL+%GIE%%%<)W!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *!110 4444 %%%% !1110
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MH **,T9Q0 49Q03BHSS][K0 [963XU&/"VH?]<'_ /036D)3BLKQK-GPM?\
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M^]4UAS?0_P"^/YU4=T$OA/2[0?Z/']!4F[:345N^(T]@*DW!B:]Z,HGS4HL
MW/6I*C.TG^E25IIT(BFMPSBD+8%,D(=]M-SC^$\4/1:E#RQ)KG/BE_R*\U=
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M@-]/I7P-\8_^"NNJW'POT>\\(>'8UU^;Q?%X7U*UNIRJVMQYPB;:=IRN[/)
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M[O<5](?PUYU\/?@SI?P_UN2ZM9)BS+L(+GCI[^U>BJ<K7+4DN;E/"QDE.J[
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M>'?$&J7EOJ=BWES(FFS2*#C/#*I!X/:O8O!/PVL_ $TGV=FVS*?O?PU^,?\
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MIZ'Z-DV(K5\%2K5_BDDPHHHKSSTPHHHH **** "BBB@ HHHH **** "BBB@
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MYK>4&&6%BKQYW*"/<5TWP/\ F^+WAK_L(Q]*JH^;4Z*E.,:3G&UGKLCK/VX
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M <9&3T]Z %HI-XSU%()5.WYE^;ISUH =11N!.,\CJ** "BBB@ HHHH ****
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M'MU]*[Y4P:X']H9L_#^ZKS,VY889M(SK6Y3Y=4Y_[YKJ?A7_ ,ARX_Z])?\
MT6U<M_\ $UU'PK_Y#EQ_UYS?^BVK\=HUG*O*<M$F>9)ZG,-UK>^&O_(Y:?\
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MN_OHXED9I856/AT<XYSGK6HW2N+^-FA6WB;X5:]9S.JK)92KNR5VMM.#D<T
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M?X%^!U]JT>O7[6_]B0Q3:@5_Y=UD+"/OW*L/PJEXD_;V^'GAB+PJU]J$EO\
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M-6NHX]0(4W$^!(PP.GRC\JZCQO\ &33_  7\1=-T^Z\1:?IL5PC/-:7)Q,X
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M..Q2UB!EAB8&-'(&X+CHN1P.PKT"B@"$##*WX?A4U%% !1110 4444 %%%%
M!1110 4444 %%%% $<H8LN.F>:HZU)';:3<O,ZB':<Y[5H2';ZU!=V,=_;-%
M)&LD;]0: /R6\1?#_P 1?LQ?MP>#?'_@&S74M'^)=Q=Z)K@MV#K;N9V*MA3\
MORQ=\]:J_L9Z?IO@;]LC]K#2Q<11PQ^&W+-+(N)'_>$Y/K7ZJ67PMT#15MTL
MM!TNWA@E-PJI;HFV4DY<8'4Y//O6+:?LV^ [;5]4U&+P;X=AU#7E*ZA<?V?$
M7O >JR';EA['-!?M)(_%W0'\2#_@B9XL\O5O#8T*37[YF38WVP?O9<8;=MQU
M[5Z_XSN;ZU_:R_9+U;7I)+KX8?V2K7#R#%HMSMN%&X]!Q@\]Z_3V+]ECX<V_
MA*3PZGP_\'KX?F?>]BNE0BW=CG<QCV[>Y_.M/6_@1X1\1>%K/0[[PQH=UHFF
M'-I9R6D9AMNOW$Q@=3T]:%H0]=SFOBAX]TS1[==9\*Z)9>.O$^G1.UE::?>P
M1RE&&& D8[1D#'-? /\ P6&^*NO_ !!_9@\!WWBKP+>?#O4%\76YBL;S4(+N
M0C$V6W1$J,]>?6OTJ\)_"G0? 19M%T73--=E&)+>T1&P/X< "H_B)\$O"?QA
MBM4\4^'-)\00VL@FB34+5)UC<="%8$#J:KF8=+'R_P",)X_BKJOC37"T-YI'
MA/PDUK:2;PODW)A;S.2<8\M\<>M?#_@#5-/7_@@7XIACN;3;+K^HXC$@R@9C
M@CFOV$LO@[X=T?2M0T^VT/3H]/U/)N(/(4Q39 4ADQ@C: .:Q[/]E3X;V/@I
MO#<?@+PA%H,AWR:>FDP"V=CU)CV[?TJ1W9S?[!]Q#=?LB^ GADCF4:7"NY"/
MEPM>U#I6+X;\(:;X1T6'3])T^UTJQM1LAM[6(1Q(!Z(, 5M+TH$1NW[P?3K7
M-_%*6*+X>:L+F2/RVM9 =_3&TUTDR[UQZCK5/4M(M]8LWM;JWCGAD4JRNNY6
M![$4 ?E'\+/A9XH_9Q_;4M;'PG"S>!?C)X=$U[- 0T<$T:,TG(X7/F]_2N/_
M &1TM_#G[.?[6EA!<):JNH%(P"!NPF"1GU/-?KOIGPZT;2$@CM](TV&"QC,=
MLD=LJ")2,,% '0@#BL*T_9O\!V-CJ4-OX-\.P6^KL7O8ETR+;>$]3(NW#'W.
M:5@/QN^(J>)H/^"4/P/6\U;P_)IJZI9%88(76Y7_ $F/+.2Q!(]@.E>_^&;N
MZ\%_\%B_ ^M>-F_XH[4O!MO!HMW<<6B7(A@&=Q^4'/J17Z'3_LR^ [KP[#HL
MW@7PJVBV&UK2V-A$T49!R,)MPO..16OX@^#7A7Q;I=C9ZMX9T74[730/L\5U
M9QS+;#^Z@88&,#IZ57,PLCB/BI\1KSPW9R:UX!\(VOC[Q*L7ERP:=J%O TL.
M<[?,=MN,X.,YKX0_X*3^/=;\6?&S]F.[\5^'7\&ZHWBI))M.FO89VM$$EL>9
M$)7'7OVK]+_"WP[TGP0KQZ-I6GZ3&6!_T>W5?,7'L!BL_P =_ KPE\3-1M[S
M7O#.B:Q>:>QEM9[^RCN6@8XY7<#@\#I1=@?&?[6/D_$OX!_'KQI<3)-;6]BV
ME:?+V> #$JY[_/&,8]*^7?C%-9W?_!(GX"0K-;R;=2M&\L'YH\7:GFOUXG^%
M'A^?PK/H+^']'?1[CE[(VB?9IL_>W1XV\DFLNY_9F^']]X;M]'F\%>&6TNQD
M$EO:'38C# P((*+MP.1U%(#6^$]U'=^ = D5MP:QC(../NCI755GZ?I<>G01
MPVUO';V\(")&ORJBCH O05H4 1LWS,.G'6O-?VL&LV^ WB"/4&A-O):.'#="
M,5Z5.OF+MZ5F^(O#5CXKTR2SU&QMKRVD7:T<\0D1QZ%3P1[4 ?E7\)/@]XJ_
M9R_:*^*WPOLXI6^&_C33&\16MS#S;VZ[%0KGH/FB/YUY3X#NH=-_X(X?%BTM
MKV"-K?Q#?HD0^](I8A=N>OX5^T$G@'2S;&!=+TXP20FWD7[,H'D_W,8Z9[5S
M7_#,7PYL_"LVC+X#\,?V-<-O>T73(C'(YZLR;<9]Z%H!^37[3K^)1\/OV67U
M34] 6S^WVC0)9PNLMN/)D&9,L<GZ =:]S_8LOIOA]_P5O^,4OQ$9;-]8MHG\
M,WE^XC@,6Y\A"W'3/?O7WW??LY>!M8BL5O/!GAN>/2RILEEL(G^RX&!L!7Y<
M>U6/$_P1\*>.+RUGUSPQH>L36<6R*XO+..6:(<X"[@2/P-5S,#S[XN_$_6?
MMG<:E\,_AY_PL74+QUCU*+3]2MK,,!D*Q>5@K8&>A[U\4?'[QQ>7?_!7_P"
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MCLO7@X]*^M_$/[#_ ,)?%$>CIJ'P_P#"MTOAU_-TY9K)7^R'U3T-:NK?LO\
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M=Z *S6D9?*[,=< #D>E1"U4*A"C=D$(^"$'?'I5_R5R/E QZ4U[=7&&&><T
M48K0'[T<<C2DEVX.1V_I4B)'=V\4BKY;*,[5(_6K7V=<#C&/2A;=5/"XH IO
M"MN-L<*JK?,",;2WTIL5C;H8U\E-MO\ /&0OW&/I^9J\ELJ$\=\\]J$MEB "
MY^7WH 6 8CZ[O<T^FQQB,<>N:=0 4444 %%%% !1110 4444 %(74'J*6N5U
M?XD:!HVJ2VEUK&G0WGF;!&TZK)G/W2,YH ZD/DTM4]+E6Y59,;=PR C;HR/4
M&KE #3.HW<_=ZT"52.O2JSMY5RP50N!U)QN)[52TOQ#8ZNUW';W5O<M:OY=S
MY;AC$^,@''3B@#42Y20M@_=.#Q2(<BLNT\3Z?J6IR6L-_;W%S8X\Z&-PS1YX
M&X=N:U1P*3V &&4_&O"_VCA_Q4$3=MF*]RD?:1^M>)_M&:3=:EK4+6\#R*.Z
MBNW _$>'Q!AYU,*^4\XT#0F\0ZU#:0_N?.. 3W-=O=?LNZK?VDT<>J0!9(RH
MW*>"1CTK'^&GA^^A\;Z?)):2K&'Y)6O6OB_XWO\ P1IUJ]B\,;2.58R1[LX%
M=6-Q3AHCQ\CRKG5Y'RG\$O\ @D?-\*/#/C72;[7++5;#QM=S7-Q$8V_=^:SL
MW8?WZVOV>_\ @FYXL_9\T&T\,V/BRSNO"]C*SVRE&^T0 L7V@XVXR3VKU2/X
M^>(FB,C7%EM]?L__ ->H4_:&\2.W^LM/_ ?_ .O7#]8E:Y]!'*Z/-9GSE\4?
M^"(K?%OXC_$/Q'JFO64EQXVDBGA?8WGV,T3O)'(IQMX9@3UZ5ZG)^P9XU@^#
MEGX:@\90-?6=O'%]OEB+-)M7;R-N/TKO7^/_ (D"[O.LUQ_T[]?UI!^T/XDE
MX$]FO_;O_P#7H^M2+J9/0J:,XWX._P#!/Z\^%D^IZA_:&E'4-4<-<-;PLJ-P
M.Q'M47BOP])X9UFZLWDCD:/CY<BO=_A#X]OO'<%XUYY:B/IM%>4?%C1[J3X@
M74BVTTR'H0IYKNP&)<EJ?/<099RTURFO^SCSXNG=?NF+;GWXKWZO!_V=M*O+
M;Q-(TUO)#&>F17O%<>,=YGK9'3E3PUI!)_JZ^=?CWSXYW?P@'-?0TDFQ_;'-
M?/\ \=-%N[[QDTD-O(\8[J*UP/Q$\086=3#^Z<GX/\,OXSUO['"_V<L,C/I7
M7:M^R3=>)=)N+&\OK>YLKE"CPNK?,#[BH?@?HMY#X^ADEM9(HRG4J17H'Q>^
M(NI>"+ZWCL)(%6:,LPDBWY(.*UQN+<'8\W*<G4U>1X_\/_\ @F]HOPO\!3>&
M]'MM+M]'O"YN+=E=DDW#!!SGK[5-\)/^"=VD_";5;>73XK6&&RG$\,*M)Y8&
M<[ ,YP.E=,G[0OB(1_--9^W^C_\ UZ;_ ,-"^)/[UG_X#BN/ZQ):GO?V/2>A
MYS??\$F/!$MAKEG_ &+I;V/B2\^VWT"!]K3#&),DYS\H'!KH_$/_  3QT[Q7
MX.MO#^I0Z3=:39[##&RR[HV3!1@<]5(!KH_^&A/$G_/:S7_MW_\ KTJ_M"^(
MU89FLV&>1]GQG]:/K4B?[%HF%X"_8<A^%_A_['HXT^QM6D9YEC5]\IR?F)_'
M]:Y[4]-;1+V:S;:QMG*9'>OH?X6>+[SQQX;N+B\5596(  ^M>'>,=$O/^$MU
M!OL4S!IC@A3@UZ&!Q+E%IGS?$&4\J7(=U^S,I^UW#=J]K7[M>-_LW:9=6=]<
M?:(6A5AD9%>R5Y^,E>1]%DM&5/#)2&W)_<GZ5\Q_%,8\>73,NY>>/6OIF63
M8=B*^;OBEH=[+XXN)$M9I$R2,*>:Z<OT9Y_$V%G4I1<3.\!^")O'E[)#%,MO
MMZ;AFMKQC^Q>/B'X=N-(UN6SU32[Q&BE@G5@I5A@YVX-;'[.VCW5IXAE:XMY
M(58<;ABM_P"*_P 4]6\%^(_LEBUNL056P\6X\^]/&8QQE8PRG)5*/-(\ST?_
M ()UZ/X>^'I\)VMGH\/ATH5:T59&1LG./F)/Y&KGPO\ ^"?VA_#)KF*SM;/[
M+<V4MDJ!Y"L8=&7."?\ :[5MG]H/Q$&8-)9]./\ 1^OZU%_PT-XFW?>L]O\
MU[__ %ZYWB))'L_V32YKL\]A_P""4O@>/PS;Z&V@Z-_9EM<&^$/[S:;G)8R9
MSNY8D\'O7::U^Q@?$OAJ/2+Z?3Y+&,*/+ ?]V%.5V]^PZY[UH/\ M!>(B?\
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MC&17V%IG_!,#X:Z)!X%73X-4TVZ^'FYM,N[6=4E=WV;V<[3DGRUSC%8^H?\
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M@A91YH@#ALKTS(V,9Z"OJ@_LP>!8_!^H:"_AO3WTG4HO*NX77<)8U!"J1UP
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M>^\&:3/>:ACSV9,B8KPK'_:&3@^]/A_8G^%J>/&\3)X)T-?$ 01M>"(AF 4
M$\\_* * /-OV>OVDO%'B/]I"\\(^*+C5+659+J2P_P!'A_L_5($7(DC<?O.
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M+2%?WB [ESM9N^/:O.!^R'\.3\7(_'2^#](?Q1$HV7YB(G4K@+@YQQCTKTN
MY9 O"J>=P_04 6J*** "BBB@!LAP.N*CBVL-S8W>N*F*[J0H".E  IR*6@#
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MPC%_.@TB=?\ \%$64_MU_%1CT7Q%=#\=YKR7P[:QZGXAMH9/NSN% _&O5O\
M@HE_R?+\5O\ L9+S_P!#KRSP;_R-VE_]=5_F*"C^C7]ES_@WU_9L^)O[.W@_
M7=2\,:JU]JFFI+<$7R_,QS_L5WX_X-O/V7@$_P"*7UCY5"X%^H! ]?DKZ?\
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MV-@,+CO]:^F/V'$S^S[\?AW_ .$2=OP%Q;BOF=/^/B/\*^FOV&_^2 _M ?\
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M[N(96:=Y#&=\P;.Y0",X4_A7Q[IWQ&37O 7Q,LX]4NK]=0@LI[.#S9IXRP6
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M)&*@_,>1R<]:^<?&_AS0]*\+_$_1':XAU"X\0PS"*>XG\V1&60MR,X&2.AH
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MJ /F#PI^WW\7;W_@FC\1OB3J'C!H_%'A?59[2.=84*J(6E7IL[[1VK0^/?\
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M9V12>'!Z8&?O5^IGP9^(]I\5_ =OK=C:W%G:W,LJI'-&8V(5RN[! .#C(^M
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MJMU:965(HY)HT;T9E4@8^M=MI?B+3]5T6/4K>YMYK"9#*9H]Q4@=Q^=?%/\
MP1%T_0-;_8-6ZU1;.XUC5)Y#X@>Y==\DA"[O-ST/L>:]B/[1MG\.?BA;?#?1
M_ ?B230\Q@:O:VLC6,:RC/!";< =]V!0!V5E^VG\,=8N[M+'Q=:W$EC+Y-Q'
M#!*WE/QPYV<=?6O5-#U:WUW2+>\M9(YK>YC$D<D?W74]"*_)7_@EU-XIG_:;
M^*T,36,G@=?%<L>L&5<M]F^RH0"V<?ZS;U'6OU:^'<>EQ>!M*71/+_LA;9!:
M;/N^7CY<8]J -JBBB@ HHHH **** "BBB@ HHHH &Z5Y=^U!8:U=_ 77[7P[
MI]QJ&I20".&WMF432[G .PN0N<$GYCCBO4::\*R,I9<E3D'TH ^$?V;_ -D7
MQ9XBTZ70?&5Y\1+?PK=6+VDNF^((=-18VVD1F-[0;^"?XFXXKUZ#]@6QN_A7
M-X7UKQMXFU:T<A!)<B(O% I^6%=J@;0 O/WOE'/6OI PJ2/E'R]*(X%B&%4*
M!SQ0!\W_ ! _X)\>&OB/)KUQJ6O:PTVO>2()(]@.GF%P\93C/# 'YLU<M_V'
ME33?#,.H^,/$FM7'A[4H=56[NA#NGEA.4SM4=,G&!]:^@U@12V% W_>]Z# C
M*JE1M4@CVH ^9_&__!/30_''B/7M0N/%'B*VAUF]CO);<"$Q><@0;Q\N[[JX
MQG'.<=ZU]=_8,T76WUQ(->UJSL]>O%O[B&)8RGFJV[^($\G%>_?8(?.\SREW
M[M^['.[&,_E4GD+@_*/F.X_6@#P2Y_86T"\O-2EM=5U*QL=<MX8-4LT">5J#
M0H(U9\C.0H(^4@<U!J/[".DWM[X@:WUO6+.W\000VTELJ1>5"L<BR J=N[JO
M<U]!-$LBX901Z&CREW9V\D8_"@#R[QY^SGHOQ"^$5EX1U::ZDCL0BVMV<":)
MD&$8;>,_A6!)^QCI6I>&=0M[W5M5O=0U*!;1K]EC\^*%=OR#C&,J#R,U[@D2
MQG*J!GCBG;1NSWH \_M/@I:V/P27P2UY>W%C]C:Q>8JGF^6RE3GC'0GM7CMI
M_P $V-+@UJUU"7QEXBN-0L=+FT2T<K#_ *+:2%/E7Y>PC0?A7U $ )..3UI/
M(7>&VC(Z'TH ^?K3]A/28/[+,'B37@-+L)-/B^2'$B.7+9^7K\YK8G_8R\+R
M?!C0_!.H-<:EIWA^:&XLI6P)4DB(*],#D@=:]H^S1Y7Y%^4Y''0TY(%C'RJ!
MSF@#PGXN_L9:;\5O%N@^(M/\0:[X-\0:%#]CAO\ 3O+:66'@F)@X92I(!Z9X
MZU<T?]DRS\+?$:^\26NM:I'>:II"Z-+"-K*8E+L#DC.07+=>M>T):1QHJK&J
MJI+  =#0UK&W5%Y&#Q0!\TZ[_P $[/#_ (OBFFN->UQ]65?+AU%8X(YHPO P
MJJ%<CCEP:BTO_@G'HEMH_B+2Y/&'B&ZB\2:A!J6H;X8!YLL21JI.$ Z1IT]*
M^FQ;1JX;:NX# /H*<T*O'L*@J>HH YWQ#X)M?%7A.XTG4X_MUO<6SPS>8?EN
M-RE3G']*\GUG]B70]:^%>D^%=-UK5]#BT>\-_:W=J$>1),L<8D!4JNX@!@>
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M&/E' /R[>17L;1J_4=\T+"J+A5 'M0!$5*0JJ\^]2A1CK2J@7I1L% "T444
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..%% !FBBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>img62602283_19.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img62602283_19.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
M  $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $" Q$$!2$Q!A)!
M40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF)R@I*C4V-S@Y
M.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$A8:'B(F*DI.4
ME9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:XN/D
MY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]_**.]% !10>E'6@ HH)Q
M1G- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (YVJ?I7!6/[1'
MA>Z^*=UX*76+9_$5G"+J6VZ,L1&1VQTKO6^Z?I7Y3?MS6WB/3?VO_B1J&BKK
M%C>7&BPP0WEI$Q+#RF!"D C/2@#].]?^(>E>&-%OM0OM2M+6SLT\R29I 5B7
MU.,U!X3^*^@^.]#AU+1]6L[^QN1NBGCD 5_IG%?DKX@^$GB;PU!<6::QXUO-
M+\2>&'N[^.Y)D5Y@T:\83@XSP>:I_"/X=WWBQ_A#X7TW7/&UCH*6CW&HQ0AH
MF5E,IVMN3@G:O7UH _8S_A(+9Y#&+F!967Y4,B[L_2BWUZW,C*]U!N7 *EQE
M37XH_&3XF>*],_:/M[WPYJWCBRATG7!8QQ7<;RR&/S%7(*H %QZ]JZU_"_Q,
MU+]FGXH^/;7Q/XTF\36FJ&&WMVW&*"V/G;Y$CV[B1M3H3G- '[ 6OB*VOPQ@
MN89DA.)'1P50^AK%\9?%W0?A_P"'6U;6-8L;'3;>01RSR2 JQ) 7IGN17XU?
M"GQU\4O#'PY\83>'_&7B/4+61(_[3MH;"X1H5(CW.I9<%NV!D\GBNE^('A;P
MGXZ_9?UZ/P[XE^(VN6]D+6>^MKVWE^SHYF7=M7R@21CL30!^O^F^-['5K"UN
MK>]M9K:^3S8)1*H5U/*D9^M<[IW[07AG6?BI<^"[76K:3Q'IRK-<VH!W",@'
MTQ_$*_&[]H/X@WDOAC1;'PG=>,K.?0=&MY[6:6"4HS^6#MC4("""!D'VKZE_
MX)ZS^(/$O[9G]L:PFIW4]QX>MQ<7ES$RJS>5",9('/M[4 ?6'[1'_!1OX5_L
MO^)H]'\6>)8;/5)3E;5(WDD"^IVJ<=^M:W@W]NWX8^/I-!&F>+-/F7Q#&7LF
MR0)B%R5Y'!&1U]:^*=,^*_A7]DK]NWXJW_Q<TV]>U\0*?[+N7TV:[BDCVH/+
M0HK8)(;\ZX3XG?#OP[^TM\0O ]UX-\&Z]\._#=U#=31?98C#/(1$&#Y*_+GC
M@@'B@#]8SX@A2T$K3PK$QXF,BA/SKB?B?^TUX1^#NI6%CX@\06>GW&L M9,V
M65P,YZ ^AK\E_'GQ*\567PBA\%ZGJ7CR:UAU6X@AGE#/:[5E*KYJA-S<?W2,
M\U5^'GB/QIXU^%/@";6YM6U>;2;BXB!N;27<D>^8+P1D#&,9[8H _8#X7_'_
M ,+_ !B\)MX@T#6K.\T??Y(G#;5+C&>N/45TDOB:WCE7?=0PB3E0S#E1U.>E
M?A_XEN_'?A?X0^$]%AFUK0/",EQ,]TZ6DK!I=A()51G@A3TKT+X>Z1\0OBA_
MP@?AG5/''BV]\.W2W'^EVUO+;[HPJ;8V$B9Y''3O0!^PTNOVWV9I?/A6'^&8
MN-A^AJ*'784A622\MY(LY,@==H'N:_&N?QSXVT;P+H^A>*?$WCFV\ V'B2>V
MNKF"&1[@0K-*J\!"<!1UVUY>OQG\?:[X1U+3_#/B_P 77G@-M8\O[7/#(\J1
M;!PRA0P&[GH* /WI&J+*WF12++#@[=A#;R/0U;@E\Z!'*LA8 E3U6OBS_@CU
M+X@G^%NOV^J>)KCQ%H]O>NFGFXLYH/* VXQY@&1TZ5]IP#$"[MN<<X'% #Z*
M** "BBB@ HHHH **** "B@<44 %%%% !110* "BBB@ HHSBC.: "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH ****  G KS/]HG]J#0?V:;+1[O
MQ 9UM]:NQ90B,#_6'US]17IC?=KXK_X+$^"]8\5^ O 2:787^J&/76>YBM8B
MX5?+&"0 <#- 'UA%\3M%(A:36=-C:3!$37"!_F^Z,9ZUS/@;]JGP;\0/&&L:
M'IFM65W>Z(X2[42JODD]CG'I7Y277[(%WJ/@GQ-XLN/#&HR>+;/Q9 UC.;6;
MSH8?M SM]L=^E5_'?[/$&C77Q(MX_!^KV_B;6H+2:.]CT^=FF)@).'48ZD4
M?L;)\2=&&';5M.MX=^T2/<Q[9>/X3FK \5V-S)&T6I66P LP$RL67L?I7X[_
M +9?[.UG\-O /P]\-V/@=8[&XTLR/=7^DW>I$W):0Y M^8S_ +]4X?AG\2OA
M-^ROX!\<>']'U:;7-4QX=U"R2TF#K%(%C\S8>54>:QY_NT ?L3>?$+3;#:UU
MJ^FV<9+*#+<1CS#V(YJ>[\=Z3IJ0M<:MI\(F7='YEPB^8/8DU^+_ .V]\!-2
M\(V^B^%;CPNUU<V7A_[3#<W.DW=_))</$I/EO#\J,&'&_O6#\2M&6QTO29/B
MUH.K>(-$C\/[-%@5'#6DXV<LF-RX.[E@* /V4UK]H?3=$^)5GX=:*:X?4(OM
M$5U%)$8 G(Y.[/8UU5GX^TG4[K[/:ZQIMQ,I^=([A&8#Z9K\7?@MX2\0>)=!
M\+W.FV'B>2PCT*5%V!I&B<M+A0P&!P1P>:ZGP1^S+?\ P5T7P#XFT7P;KD?B
M"_TVZ_MCR8W$EW(8!M\TD8Y8GTZF@#]9_%'QDT/PQX;U34?[1L[[^R8)+B6"
MWG1I65.H SU^M<W\,_VI?#OQ.^$E_P"-+>Z:RT6UW%GN  8@N0<XSW!]:_&O
MX.>"?$$O[2*ZI9^&I-/_ +0L=0AU*WL]!OK<NQD08E>0%'/7E>#SBOOGX#?!
MOQ1XJ_X)D>*/"L=GJ%CK=Y!,MI'*/+D4><6^3.-N1GKZT =3X3_X+-?#_P 3
M>.(;%]"\4V.BWDA@L];F@3[#=N/[I5BWIU ZU[-\%/VRO!_QQOM5M=+U*&&;
M2[QK5_/E1-[!B,*,Y[>E?$'[.G[8,.C?!WPW\)8?A+XDU3QAHY-M/%=Z<\=M
M" .9C,R!&XST;M7C^I_L9^;HWB[QVW@N[C\8VGC. 6MS':RB18C<MD(/[H '
M/2@#]@)O'VEV=RUO/J-C'<*,A6N$#'Z#->$>(?\ @I=X)T76-6T_-\TVFZBN
MFM(JIM$A"MZ^C5^7/[2/AWQ)XW^,EO='PK=V6O:;=VRI(^BWDUS,GE\L)D_=
MA<XR#ST]#7::I\)O&.JZ-KK?V#KCSW6OQS0>9:2$Y^SQC<..!D=30!^P=I\2
M-)NS"G]J6*27&&C1IT#8/;&<YJ0_$+2TE,+:E8?:M[ 1?:(P[8., 9ZU^(D?
MP+\:R_M,26NNPK8^-/[26YM[TZ%?33M"7'RBX3,*\!NOK7=M^Q]=W'P[\4>-
MM0\*ZU>>/-,\70)87DD4AN/+$LV67CE/E4_E0!^O\OC_ $NUU@P3:QIUO(J;
MC;R3HL@/'O3Y?B!I-E=1PW&J:?'-<MB%&G0,WX9K\*OVG;"Q\/OXL?Q]H^N:
ME\1)TA?1]5A+-':C;'\I(! (]">U2:Q\'_&'B#XJV;:ZC1ZEJ'V9M O+G1KV
M^DV^8,F.:']W&,!OO^] '[T6L_F+]Y9.3R.E35Q_P/TS4-$^&.A6>I3R75[:
M6B0W$K @LZJ <Y]Z["@ HHHH **** "BBB@ HHHH **** "BBC% !1110 44
M49H **,YHQ0 448HH .M%%%  >E&*#TH/2@!LO*]A[FH7DS\J_-]&Q4^,]?U
MK-U'PI;:G)ND:9?]R1E_D: +T18)Z?CFG;C6)_PKK3S_ !7W_@5)_C1_PKG3
MO[U]_P"!<G^- &WN-&XUB?\ "N=._O7W_@7)_C1_PKG3O[U]_P"!<G^- &WN
M-&XUB?\ "N=._O7W_@7)_C1_PKG3O[U]_P"!<G^- &WN-&XUB?\ "N=._O7W
M_@7)_C39?AW8+&Q5KTL!QF[D_P : -W<:3<:YR/P7I<D:MNOOF'"_:I-Q_6G
M1^ ["9EV_;E!&6#7<@9?3C- '1;B*-QKG/\ A"=+,Y17O&*C+*+N3</PS2?\
M(+8CC-T"#R#>2<#\Z .DW&C<:YX>!=-9&8-?;<9W&ZDP?UJ.7P5IT,2LS7?S
M=#]LDP?IS0!TNXT;C7-1>!K/Y1(E]N<G!6[D*@=L\TH\$Z8(5<RW05AP?MDG
M^- '2;C61>^$]+N)7N+G3[6:9OXS$"35.+P/IK@?-?8;^(7<FW\\U:_X5_8;
M=NZ\Q_U\O_C0!(_A'2YXEW:?:/M7 4QC@5#8_#W0]-N&GMM*L8;ANK+"H-'_
M  KK3P<AKT'_ *^G_P :4_#S3V^\U]_X%/\ XT 5+GX5>'6U>34)=%L9;R?A
MW,*L3^./>M"W\*Z;IUO);0V5O##<#]XJQ@*P]#44?P]L8RQ\R]Y];E_\:1?A
MY8A&7S+PJW4?:7_QH AT'X?:'X=TZYM['2;*SMK@DS1QP@>=GN<#FFZ/\,]!
MT?3+BQM=)L;>SO&WO"L2JK'W&/:K$?P[T^&3<K7F[MFZD/\ 6FO\-]/=MQDO
MMWK]J?\ QH JM\(/#5S+%,^@Z:TD VQYA7Y?IQ6I8^%=-TE]UK8VMO+VV1@8
MJO\ \*YT_.=U]G_KZD_QI1\/-/!SNO<^]T_^- $7BGX=:#XX\DZWI.FZH+<[
MH1=6ZR&(^HS5A_">E^9#FSM\6Z[8P(QM4'C J.+X=:?"S%6O,MUW7+M_,TB?
M#C3XONO??C=.?ZT 07WPQ\/ZK$L-SHMA-'"_FKOA4@'KZ5+;_#?P_;0^7%H^
MGK&>N(5X_2GM\.M/<?,]\?\ MZD']:!\.M."[=U[C_KZ?_&@!-6^'VB:EIGV
M6?2+&YM5.1&\2E<_3%/A\%Z3:PVRQZ?:1K;?ZD+"/W7TJ-?AOIZMGS+[_P "
MI/\ &GK\/-/4-\UY\W7-R_\ C0!YC^TQ^QYH_P"T3X<333JVL>'O+8NYTF[:
MT\S/)SMZYS4'[-'[#'@G]F3P1=Z'807.K1:@WFW,NH/]H:4\=2P]A7JT?@"Q
MA/R-=#US.[9'YU&/AIIHE+[K[<W_ $]R8_+- %KP_H-GX9T]+.PMK>QLX^(X
MHT"C\JTPS8K%D^'FGRNK,UYN7I_I+\?K2'X=:>[9+7V3_P!/4G^- &WN-&XU
MB?\ "N=._O7W_@7)_C1_PKG3O[U]_P"!<G^- &WN-&XUSI\":>F[<UYP>OVN
M3 'YTB^!].,VTF^^;!3%W)DCN>M '1[C1N-<U!X,TRX9MLEXR]MMW(3^/-.B
M\"6+CG[=Z@K=R8(_.@#H]QHW&N>7P)II)7?>!AU!NY,@?G2CP#I^!DWPYQS=
MR?XT =!N-&XUSO\ P@=CCI?]<#_2I/UYIZ^ -/\ ,"G[=D]2+J3 _6@#?W&C
M<:Q/^%<Z=_>OO_ N3_&C_A7.G?WK[_P+D_QH V]QHW&L3_A7.G?WK[_P+D_Q
MH_X5SIW]Z^_\"Y/\: -O<:;*6:,[>3V&<5C?\*YT[^]??^!<G^-'_"N=/_O7
MW_@5)_C0!K)$P'S9'U;-30_<ZAOI5/3M @TQ<1F;_@<C-_,U=5=HH 27B-NO
MX5&J'&1N/L34Q&15>YTZ.[7:WF?@Q% $B/E:7<:QIO %C<2;G:\W?[-RZC^=
M-_X5SIW]Z^_\"Y/\: -O<:-QK$_X5SIW]Z^_\"Y/\:/^%<Z=_>OO_ N3_&@#
M;W&C<:Q/^%<Z=_>OO_ N3_&C_A7.G?WK[_P+D_QH V]QHW&L3_A7.G?WK[_P
M+D_QH_X5SIW]Z^_\"Y/\: -O<:-QK$_X5SIW]Z^_\"Y/\:9+\/=/3'S7OS=,
MW<G^- &]N-&XUSDG@73U/R_;V4=<74GZ<T#P-IKS*JM>9QEE-W)N'X9H Z/<
M:-QKGU\ :>3_ ,OX&?\ GZD_QI(_ NES\QR7C+C.1=R?XT =#N-&XUST?@/3
MW"_\?Q#<@B[DQC\Z:? ^G["P_M!@#C_CZDZ_G0!T>XT;JYX> =/8_*;SKD_Z
M7)T_.F_\(-IS!67[>R-W%W)Q]>: .CW&C=7/VO@/2[N/<DEXR]"5NY.OYU+_
M ,*YT[^]??\ @7)_C0!M49Q6-_PKO3_[U]_X%2?XTA^'>GG^*^_\"I/\: -O
M<:\2_:%_8=\%_M.ZU]N\03>(+:54\MAI=^UFTHXX<J#N''>O4O\ A7.G?WK[
M_P "Y/\ &BX^'6GW,'ELUX%W;OEN7#?GG- %'X1?"S1?@OX,LO#N@68L=/L8
MMBH/F+<]6;'S-[UU.XUB#X<Z?N;+WQW'/_'T_'ZT?\*YT[^]??\ @7)_C0!M
M;S0WS#FL7_A7.G?WK[_P+D_QH_X5SIW]Z^_\"Y/\: -94&>_Y5+NQ6)_PKC3
ML_>OO_ N3_&C_A7.G?WK[_P+D_QH V]U&XUB?\*YT[^]??\ @7)_C1_PKG3O
M[U]_X%R?XT ;5,G.$XV[CP,^M9(^'>GC^*^_\"I/\:7_ (5[8+G:UYNQP3<N
MV/UH \1^)O\ P3=^'?Q8\=KKNJCQ(9!*)Y;>#5&BLY7']Z'&&KWCPUH]KX?T
M"ULK.&.WM;6,1Q1(FQ44=@.U4_\ A7.GE2&>^.[K_I4G^-+_ ,*\T_\ O7W_
M (%2?XT ;(XI=QK%/P[T\_Q7W_@5)_C2?\*YT[^]??\ @7)_C0!M[C1N-8!^
M'VGG=M-]\I[W<@_K39? NF1JWSWI*]OM<G^- '0[C1N-<P?!FGI%N8W85>6?
M[9)M [\YJ9/ >GNN?].QZ_:Y,$?G0!T.XT;C7//X!L%A9E^W;E[&[DY_6H?^
M$+L?*#[;[;(!L_TN3.3Z\\4 =,&.:7<:YX> [#:N[[<#D _Z7)_C1%X"TZ4[
M=U[NZ\7<G^- '0[C1N-8G_"N=._O7W_@7)_C1_PKG3O[U]_X%R?XT ;>XT;C
M6)_PKG3O[U]_X%R?XT?\*YT[^]??^!<G^- &WN-&XUB?\*YT[^]??^!<G^-'
M_"N=._O7W_@7)_C0!M[C3'DQ)]Y?H:Q_^%<Z?_>OO_ N3_&K%CX,M=.?,;7&
M,YP\S-_,T :FX*._/I3J:L6Q<*2*=0 4444 ':C-%!H **** "BCO10 4448
MH *,T44 %%%% !39XQ+"RL-P88Q3NM-F&8V^;;[],4 ?!O[0G[=_C+X ?%'Q
MUX5U*>V-Y=-&/# 488@O&"!GKQYE%I_P5]L_AMXOT_PGXT\&Z_#<&)Q<:DLD
M+6YDC4D]'W;N.XQR*]V_:,_8%\$_M._%KPOXP\007(U;PLY>W\J10&X<9/!_
MO&O-?%__  1X^'_C'XGWOB*\U;Q,RWMU+<RV7VQ1;[I>#@%.OX^E $&@_P#!
M773]1TJ^UBZ^&_B_3_#-NLIM-5D>V*:@R<!$ D+9/;< *R/%7_!3/6-6\'V%
M_=^!_%7@4W6H+% ]V]LXU"(HS#&UWQG'?'2NL\._\$HO"ND:5J&B3>*/&MYH
M,FY;?39-07R;(OD[D&S ([58T_\ X)<^'Y_"Z:=K'B[QMX@M[2[$]J+K4%;[
M)A2H RGH: ..T#_@LE87WB.PM;KX;^+K72[R9[)-2DDMO)FF5-Y0 29'&.H[
MUS/C_P#X+8F%?$VDZ-\.?$D>N:'")+=9I;=H[D?-]TK(?[OMUKUW6_\ @E;X
M#UGPA9Z&U[KZVMG=27GG?:E+EW38>=GH*Y?P=_P1?\ ^%[N\9=>\3S+-&\*@
MW0RFX$'G90!QT/\ P6ULO"[>']-U;P#XEU#6+JT2[U":V:+R=.5@K'<"^3C<
M.@/2J'Q4_P""P6J>/=0\/Q> ?!OB"'1;S54LY]=<PBW7*$F,J7W9[\+7ID__
M  2$\'Q>)=-U>S\2^,-/U"S403E;]=MW",#8?D[@"GQ_\$@?"-OXDL[R'Q1X
MVM=(L;T:BNEQZ@@MWF"[<E=G)H ^K/#LC7^CVMQ(^]IHE9E[ ^M;-9^EVPT^
MRAC4_NT0(N[YF_$UH4 %%%% !1110 4444 %%%!YH **** "BBC% !110* "
MBBB@ HH[T4 %%%% 'R!^V!\=/B)K_P"TII/PE\ ZY8^%+B\M#J$VK3*6D "[
MM@&&&/E(^[WK.U']MWQE^S1X=T_PGXMT63X@>-M0>1;(:%+'YEU"K;6E?S&4
M C*<#'WNE>K?M._L.:/^T;XHL_$*>(/$7A/Q+8(8(=3T:Z%O-Y;#!0DJ<C&1
M^-><ZG_P2E\,6ND6+:;XJ\6:;XBTTN[:XEUF_E=SN)+A.03R1CTH Y76?^"S
M^CSZ5:KH_P -?&&N:A-$9)[.WDMEDL0KE&W[I ."/X2>M<U>?\%D]0'Q$U:>
M3X=ZQ>>"]-TZ*\#021BY$KNRJC9D ZA>G'->S>"_^"6O@/P%)'/!/K%Y>1V;
M02--<KON69]QD8[>O)K,O/\ @DAX'FED\O7?$T0DM8H)$2[7;,J.7&[Y.>30
M!S-__P %?)K>QM3'\(?&TVH7-@-2FM1+:[HK4H'\S_6] ISP<US,W_!7J'1O
MB3X@U:32+_5/"UG912)I]N!]JAD,:$J<D+G.[O7L_P 5?^"9WAWXB-I=S9^(
MO%/AV^L=/33))=/O%C,T 4(4;Y#P0,&LZ/\ X)0^ ;6WU2/3]4\3:;/JD<<%
MQ<VEZBO+M0*2WR>U '>_L6?M=6G[7?@BXUJT\/ZMX>V'+)?21/(>G4(S8/Y5
M[A"W*M_>'45X5^QO^PYX;_8PTK4HM%OM6U"XUB7?<3W4OF-(>.20HYX%>Z1E
MO-V]54=^M $U%%% !11UHH **** "BBB@ HHHH ***,4 %%&*#0 4444 %%%
M H *@NU+2)_=!SFIZCN%#1\T > _MY_&+Q)^SW\.]$\2:')_Q+=-OE&KY&<P
M,54?D37SK%_P5AUWPFVN>*;CPYJOB;PK',R6*:=)"K.H)_YZ.N>,=*^V/C5\
M)-)^.WPRU+POK4;'3]8C,<FW[P'J.O/%?./B/_@CU\/==^%'A_PI;ZCKUA:^
M'Y)&MYX[E1.=^T'+;/\ 9':@#"T[_@L;I/C.QTM?"_PW\5^)-6O(S<7EC:R0
M+)IRJ<?O-\B@]?X2:V)?^"IT.M^,_P"R=#^&_B[5K6V4Q:AJ4#VRQZ;)L+8<
M-("<9'0'K4>G_P#!'[PGX<N+>ZT/QAXTT745C\F>XM+Y8Y+E>.&.SGH*WXO^
M"7'AW1O'2ZUI?C+QMIL-P_F7]I#J"B&];9LRXV<GI^5 'F>B?\%:)/"NDM"?
M"/BSQGJ5R\KPQVS6ZB..-=Q^\R]LU<\:_P#!:;1?"/A;1]9_X5[XJF:^Q]J@
M\VVSIXXW9 D_QZ5ZCX5_X)?^!_"FK_;+:_U[S_+E0_Z2O_+1"I_AK@/%'_!%
M3X?^(=3:\;7/$UJ\BNLHCNAAQ_WQ0!P]O_P6AN/#?CSQ+-J_@O5Y/#=ND3:6
M(VC$DCO&CX.7]VK<L_\ @MQHWBCP9*NE_#OQC<^,&+*NAJ8%N+7Y?O,6<(1W
MX8UV6O\ _!'SP#XG2Z\[7/%3->P)&6-VN0R*JJ?N>BTU/^"1OA=/#$-M_P )
M=XR;6+=\Q:D=07[2$QC&[9Z9H [G_@G#^T;XB_:0^&6I:IXDL[G3[Z"]DB^R
MW&WS8 #]T[21Q[&OHVO*_P!E;]F#2_V7/"5SH^EZEK6KK<3&>6ZU*Y$TLCGK
MR%%>J4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 1R?>/
M]W%?./[:7[6'B7X(:QX:\+>"=+T>\\4>*IO*M'U8R?9(\8+%_+(?@9/%?1SC
M+^VWK7S_ /MD?L?W_P"T@=#UCPWX@C\.>*?#LIDLK^:)I$B)P#E5()R/>@#D
M]._;:\8?!'PI>?\ "[?#>EZ3JRS_ &;37T$N\&L9) ,(D8M_=^^!]X47'_!6
M7X8VOA^QO-VI3W%^6C^Q^7^^@*D@A@/<=JYG7/\ @G)X^\9>%M-U3Q'\5)]4
M^(FD7_VK3[]H9#IL2[MVWR,[\\+SN[57^&W_  2=N/#/C+2_$VK>*[>^\0VL
MSSW$T-NT<4K,2> 22.OK0!-JG_!9/PR/''AJQTW1;R\T?6;9KBYNR/\ CT5=
M^>_^SZ'K731?\%9_AE=>&FUBRCU*XBF=HH (CFX*8)VCTY'-<#-_P2+U*S;3
MFL/%UB@MA(C*UNV2'W9[_P"U71^+O^"96K6_PX\,VOA#Q99Z'XF\-QFU2]GM
MGDM9(R%5@L:D,#@'G..10 EY_P %6?#Y\?6<=I%:OX5DL7N;NZ&_[78R#8=C
M _+W;L>E>P_LK_MH^%_VK;F\_L%;N&XT\;9892C?+D?/E21W'&<^U> :9_P2
M 73G>7_A)1=7FH0R'4/M$;2+>2M@L3C^ L6PIYP1S7<?\$ZO^"?%Y^QMX@\2
M7TVM://#K4VY++1[-[.SB'R]49FR_'4'')H ^M**** "BBB@ HHHQ0 4444
M%%%% !1110 4UWV+GG\*7O4=YQ;D_+A>22<8% "K+N4Y!'UIRN66O*/'7[:7
MPK^&>NKINN>-]%T^^8[?(ED;(/Y5W/@KQ_HOQ*T:'4-#U"#4+*<;HYH6RD@Z
M9'XT ;B2Y;#=:DJ.)MYYZK4F>: "@GB@'-&: &[O:FM*V\!5SZ\]*<TBH.65
M?J:CE;Y_E_BZD4),5QRS[GQM:G>:,XYKG[WXC:+8/=1R:G;Q-9#,V6^Z..OY
MU?T7Q%9^(+-;BSN8;F%NCH>*KD9/.D:2DD<C%)(GF1E<9SZU"DZA?O#'UIWG
M+G[R_G4\C%[05K;<?[N1@XZTTVH*[/O* ,;N>E.:4+U8#ZFD\]<_?'YT<K'[
M1#9(5F&TGZXZFFHA57Z;>PJ.\U:WL #)(B[CC.14BW$<BAED79]:'"0_:1"&
M/:/F&?E[# H171U;<%7)R,=<]*S;[QUI>G:BMK-?0Q7#<JA;DUI1W,<R@AU9
M>N<TO9R6X_:1V''3U,>S)*Y)(/)R?>G?9R"WS9!X /85()58_>7\Z=U%,9"+
M9B!EONGC'&*FHHH **** #M1110 4444 %%%% !1031NH **-WO1F@ H-!;
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MX8/&\\C1M*,J@ ST!['K4G[/OP.C^+G@O7+;3;2\T;3X9PEK_:5E)$Z'+;F
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MXY /M"QJLF.Q K3J&.+R]O5MO<\FI-WM69I<=10#FB@ HHS10 4444 %%%%
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MC@] ,4 ?5/A'XHZ/XWU"XM=/N/,FLU)D'W?TKDO@+;R2C7]I6:2XG89+_=X
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M[:OAW0D^-EY;ZAHWA/35TBU%QI[2^&_[2DN)-JGEU(XS_#_A7U9^R)\4]/\
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M8X.5.'O(X)XI*7NGU]^Q_?:MJ_@AKB_N/,MV8B*-OO(??]:]B"Y'\/Y5\X_
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MJWQ O]-GTB'5%2,(4C7=$C-QG)!Y_&L_Q3^T7XR\0ZKIMG?2_8W8J@2WN&7
M]6P!7E>K?%C4=5\-VNDM<M';VO*;$4,3[G&<<5S]]?37+++)NAD QO5B2WYT
M>Q70KVS/KS1/C[X \)^---TJ:SM;ZXO(\7=]( ZQ-@YR3GT%;G@[3/AIJ7Q>
MDFTZ5II!^]0QQ*+;?ST<'V'&/YU\4V-[&FJ17"VZR[/O)EOG^O>MR#6+F_\
M$:?9]*$S,.+5)738/[V00>?KVK-T+E1K/J?HUI?Q,T'5_$,FF6=[:R7UN/WL
M:N!M7N>/2J?B?XZ>'?#?AG4-2;4X9AIH.Y589!';%?GCH^LR>$O$M]J.KS7^
MEZ?"I:8VTFYHU[\L2>*Y/P)^UQX+^*[:WINGWU[)>6LACBA=ABX]VYJ?J$YZ
MQ3:-)8R-/1L^ZM'_ ."@7A_4?#=U>3V\UO<*2+=/^>PQPWT_PK#O/^"@UK<^
M!V^SQ^3J^[LH947UQWKY2T6.SL_#-U<->1O?#(:W?_E@OMVQ5?5_'GASP;\*
M9-1OIECVY=KG>NTXYQUS^E=%/+9/[(I9E!+5GU/>?MT:U%\/8+FWTV[,S2$-
M>O /+89/;H*YWQG^WAKVL:)8_9X[>Q9.7=7SYIR?;CZ5\Y>%?B7I/C_X<VLN
MGVMI<1N^8;E)I29CSP!G;GZCM6[XXA1= TQ)-1M;IU&_RE4JT9R?E/ I5,*J
M;M)69E&LVKH] ^(/Q>N/B?J=GJ5\)M/N8]N2['9,,_PCID]L5T-W^VSX@T9=
M/TW18UMK.$B"5IE\QL< GY@:\7\3?$C[9%IUK/\ 9HGC95B61MHSD8Z5%JMQ
M'=^(XY(YF\Y?OK'C:[]P,^].I14+*:WV"->_4^B+#0_A_P")/%J33>*GN/$%
M[";C[, (E#\?Q!L_ABN)D_:3\;2>*+C24U!9+6Z8V<"P -(H]EQ^M>.W&J>;
MJOG232_*<':-K+CWXKB;C]L;POH?Q"O-%\+IJ=YXCC0QQ7"!&:&0\9(8X[^E
M=%'+:E36,=#.>-@MV?3GPP^#?B;2/B-(MYJEUI)NMRB<$L3)VC<'&"20._6M
M[6=$\:_"[0+]M?O+RTLKJ5X@5!(=B3L(/&<C)]J^$?A5HOQJ^%GCCQ%XPN_$
M$.J7$TCW!L+N5R';).<*.#]*[SX'_P#!2WQ9^T'J]]X5^(NDK%)9S?Z"L18)
MD9 Y)SZ5OB,IIMIT6F98?'2A'W]#ZJ^&G[4EA^S=X=U3Q!XLU"186B,@54 0
M $ 9Y [?K7OW[('[8GAS]KSP)_;7A^0L%/[Q"<[>E?F3\;]6M?B1X8E\!+8R
M7EYK$_[Z5&8I:Q^A.>.@_.OMO_@E+^SIHW[-WP]NM)L9IS<-]^-^_3I7)C<#
M&E3O+1FN'Q%2I4\C[!5RTC?W,<4XGBH[<LR_=V>QZBI'7"U\[%OFL>[+X=!J
M?.P(^[_.O(_V@_BYXL^&OC3PK;:/8:?<:7JUT\5]-/+L>%1MV[1M.[))!Y&*
M]<*;X%'/X5SOCOX>Z?XUN]+FO%;S-+E:6%P?NYQD'Z@8JAG@>C_M.>+M8^)K
M?O+1=!:_:QDMHX5=HPKE2X;&2>"<5WWA7XAZQX=T35M4\6:I,NER,Z6Z3V*6
MS 8..AYZ4ZV_9*\-Z=\1U\0(UQ,OG?:%LM^(HI"=QDZYZ\\^M>D7EG!=Z;=(
MRP3Q[&_=X5U7@BI8'S&?$TVJ_L=S7VEW]K#:SSDRDD%I5R,;3ZYKY\\<ZU?:
MEX(L3=:J+F%4Q% S[G[>O->[^.]*:X_94"VJQI]FO' C(V[B=HX KY;U72[C
M1YHENHV5G SN/W<^E>MA=CS<=KL51B1%RO;IZ58CU.>VC54N9XEC;=&%<A5;
MUJ.XMI+:'S-I>#IY@Z U-I5U%!>)]HC\V&3B1!]\K_L]NM=TGH>?&/F;>K^-
MM4UVYTT320M<6Y'EO@9?ZG'-6M;\4:E:>,K&^6]F6[M</M$APIX.![54\4>&
MHTEMKO3[>XM[7@H9RNX?D367J5Q-)JB*Z[IMO!'<5C%7W.CFLM#T+Q)^U-XS
M\0:D&CO/)A,7V=UWX#=.<>O'6N'\.^(+[0/$TMY:M(MU(<F8L>#6.+D/<L65
MEP>4;K]:L:;??V?=M(6W1M_"U5R(7M&>L_L\ZCXP\1_$+4H])UI[;4+B)I&6
M5=RRY!.1FO2_ O@+5-*M]4U;Q]-?2:79EV>&6=UBFDR=N!G'8U\ZZ#X[_P"$
M:NIY+6 "XN$^6:-R'C_7%:7AKXSWB1S6NO37&J6KJV(2_P N[L3R.E8RILOV
MB/>_$]G\,?%/POO!IMW_ &+>6?[[:\F7E[8R3G'->,67@&^^)Y8:#:ZKJD<(
MVO$JLPSZKR>*!\1_#E_\-[BSNM+F76)'.R>,_NPO;J<_I6EX!_:-3X7?#6;3
M]#MWBU:X&Z2[?[H/' Y]O2A0:V#F4MRSXC^"_C+X=>$;=;IKRST^8;C$T?"-
MV7ZGUZUO:G?^)_!OAK1[>70[.,0XGBGNX@99>_WBI..?6L#QG^VCX@\=^#=-
MTV2U@6XM&4R3'K(PQ@_I5'QU\1;KQ?:Z3<:[JJW$W"-$AP(T_ #T%'O]4'+$
M/CW?W6I^(+&XU2ZT^ZOKA \]IN$*6G.,!E&3QSR!UJ&2Y\"K-##$UW))Y:M,
MD4?F1"7^']YG/WO;FLGQ?/HUEXJTL-'#>6L( GFA=FEEY)YW''H.*] \1_'W
MP59>)=-N-/T.1K2SBV-'L7]XX'!;GUJN:2Z!RQ. \)W^J6'CF.\M=+BO6CG^
MZ8@RLF?3&,UV-UX]TNXUC5)M0\-RV+W$>;9DD:-H2, \#&WD$\5S_A3XVZE_
MPN236-(L+>6:0_)8XQ'C/OWK=7X[Z[X1\5:I>WVAP37E\,36\ZJ4@Z8VX]L'
M\:'>6@72ZCO@K!KGC;Q?';V#+=8Y$1U66W\P?[;*"?SS7TA8?"WQ1-930S:!
MX5ACD7!E>X^U2K_P)X\_K7QGHWQ7U+PYXYEUC26>PNI 3MC VJ?;-=N/VV_&
MUQX=NK6:XB<2@@2=&'Y"N>I1D]C:G62W/9/B[^SOJ4/PMNHAJ&GQVEN_FRHM
MM&&P<D@28W=ZXW1?V=KOPSX*BU[1]7FAT^4_OH(IV'F=N<'UQ7CVJ_&?Q-KO
MA^.UNM=N)K0,6^S<8?GG)QG]:S(_B=JQT)+%KZ\M;>.3>R1L#'C''7GKBCV;
M:#VBN?H5\ M+U'2/A[:1:E(TV\!D9G+-CCJ37H%N&"?-Z\5XE^P]?:E>_"2&
M749;B:-O]6\I!XP.F*]OA&$_6N&IH['93N]1+@J(6WXVXYS7,?$76]4T;P=J
M5YI$-I<:I:VSR1QRR[4^4$^A_E742KNC851OK1;W3KBWD5G6XB9'&!N 88/\
MZS-CY9\/?M5^/?B)X*L#:VMCINLPV+ZA=.BB:)U5-VP%E&.AZ#O7H'PT^(?B
M[XH:SH&H6^H"'3VC U"U^R)M/W=Q#]?7\ZO>(/V0/"]_H5C:6]Q<Z?':[DD>
M!OFN%8 ;#[=N/6O0O!GAC2_ 6AV>DV*QVL=NFV.//S$#OZ__ *Z /*=<^)>F
M>*/VK/#]C;_:%NK6T96+1_*?G;WKU?XCZY_PCO@C4KK[S)$X&>Q(Q7!>.K*.
M#]IGPPT<44):S8LX4;F^=JYO]L;]H+2?#OA.[T*UO4FU2Z78T:]4%:4Z<I/1
M&=2<4M3Y>TV^O/%[:YH]M&#>3S/=,\OW0N2>#VZ]J]__ &>/VP=$TGX>RZ3K
M$SQWVCCRQ&O63'OG->8S^$H-7_9UCOM-N(%U:W?]]L/[QU[BO./AU;:MH.N?
MVY#I\-W;VW^O$G,9^N.:]+V=X^\>;S/F]T^R_A9^V+IGB[4KJ'4UM]-P"\!\
MW(,?OG&#G/%>F>#/B)H_CZV:32[R.XV-A@KY-?&'@[XD>'?%FBZU;W?A8Q3S
M,9HY;)B<-@#^)L@<4SX'?'>Y^"AU&3^SA=9RL10MM3.1ELGMU.*Y)8=7.N-9
M['W9<W20PLUPRQQKT;=BO./CA^T5I_PDL[7;)%-=7(W(N_@IG!/YU\Q?%O\
M;)UGXJZ&MC96OV;RN)9(BV'^G-8)\(>)O$7@R.]NK%I;?>%22Z<A@/;GI2A0
MC?4<JDTKV/MSP'\6-+\=^&+?4(;B%8Y\;@9.0Q[5%XO^->@^!]8M[/4;Y8Y)
MCC@C]W]>:^&_$_@;Q1;0VB:3)-)R"(K20A5/K\V!65XPTCQ#=:O;_P!L7GEW
MEJ SK*QW/]<?3M6OU>'<R]O,^QO$_P"VEX5\.>*H['[8MU"R$F6(@@'CCK[U
MYW=?M\75I\26@6U6313]PX^8_P"?K7S*^C+>>.[6-[JW@AN&5))CN,43'IVS
M^E:%_P"'(=.\=?9;?4H;ANBNH8HQQVXS3]A 7MZA]0>'/V\$U/QY<6EWIL\-
MC A(>(;V;KVXK>\&?MN:'XAUNXMM0']EPY/D2R-@R*/O$@],<=,]:^0] T#Q
MAX<\57E]8V-VLD:$3R>6&XY['\>U+\.M6_MSQ)>6NK7D.FV^I,5N+IU^93R.
M.#CJ>E/ZO!A]8F?6/B;]M[2-2\,Z@?#^Z\U2T8H$'1E_O#K5?X(_M=)>:=(?
M$]VMLH_U<[*%64^@KYML=+A\+^%]5OK'Q7'-J$4A@MXX(E/F)[Y7VKG[.[\2
M7/@.>)[!KS1XWVK,XV[#QR,8-/ZK /K,C[I\2_M7^$?#_A];YM0CF9B0L$;!
MF/OUZ5SWB;]MSPSI&@VEU:2M?W%R>(E_Y9^QP:^*1XIFMO!;6+6$.Q6PUUN8
MR8_$]*[;5+.XUKX6::%;1TB4];<OY[=>N[C\J7U6)4<1*Q]-:Y^VEI]S!8KH
MMK#J-Q,0TZRSF)8A[$9S^E>R>"_%4/B[28;RWV[)D#8SR#7QKXO\.ZA#HOAV
M35#ITEO<0A+=;/AHVW'ENGI[U];?!FQFTOP'IMO=3)-<);J691BL*U.$8Z&U
M.I*3LT=911FC-<IT!1110 9J&[?&P?+\S8Y-35'<H77KCT([4 >3_M(?%KQ-
M\++;2)M TNPU2SO+H0WDDUP8VB4D D *?7VKSF/]K;Q5>^.I6L]-TV/PW:WB
M:?,&FS*6W;2RC;S^=>[^/?AG8?$/3K>WOFD86<GFAQP01BO.I_V/M'N/'O\
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MM/P[X%\4VNJWUUJ.EZI<:;%_Q^1&5D:3.<9XY[_G2YH]!QC)O4SO@5\(-/\
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M)9<X.!GJ*\5B\'ZI=_&2;3'TO5$U:;4IW^WF/_EU\S@]>FTBOJSXC?&3P_\
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MN?THYD'LV<MI_AZ.[T^2X\Q@T?4=JM:5X,&L>'IKFWF\V13N=&;I]!6AX=\
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MY#$#DG_Z]8LG['6KZ#9W7B"^NK62U8&1;.(N)-O8'MT]ZYW4ON5&GV.+\*?
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MOA[^PIX?MO!4,.N6JW%[G=(T;$>O3I7T*W+K3?F\[C[M7[>25D3[&-[GS_\
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MUK),WV<'UW8)_2O&OB7\*O$'PIUB/3?&%K8S--B:'[!.T@C3/3D+CH:_2;:
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MHQ76H>#KUYXB"K>6><?\!K9A^*U_IUFJP^$[]/*.Q%2-MH'Y54JM@]@:>O\
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M9WEY-9QW7V<^; ,"/ISD>M5O#/[$^@^+['3]4:XNMTGSNDLAD+\GJ2:=K_[
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MJC +E5^4>O%>C)\9_AKX.U#Q-<6^KZ*UUIOF76J0QMN=6&3D>Y(->9_L7?\
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M%%% !1110 8HHHH ****  4'I110 4444 %&:** "BBB@ HHHH !UZ49HHH
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MOJDJ,QNHN?E(VDALYY)[5^M]WX%T:]T?^S;C2-,DTU,>7;O;H\2_1",4V_\
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M_P")/P_^(GAFTT7[!XNOKAY+O9-M[*5//2JY8$>^GN>]%<TZ-,#[N?K7EO\
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M/RW;$(W;@#^==E\5_P!H+Q1X&^*,VEC2["/1;?37NH[E[A6=V"9X]/IWK?\
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M10!#L97^\S9]>E.*LQ[ =QZU)10!7\MHY#]YE;L,86E6-HPJKGY?7O4] XH
MA,>\["O'7(IK)(/S_AZ_C5BB@"&0^3%DC\<5FKXLTVXU2:S74+5;JVP98@X#
M+GIG/TK4N<"%LY'TKY"^.O[/7B#Q#^T<=5TG1V^PWD:"5XY JR'GKS[T ?5Z
M:W9R/)_I5JPC&2!*I*_6G?VU91Q+*UY;M'(<!C(NT'ZU^?VJ_ CXL3>/WM+3
MP_\ 8="GWK=_8)UCDNU#8'F,6((QQ@ 5O?$K]FSXA>%-1N+72-&O+O0]R-9V
MRW2?8XWPI.8\[L_>YS0!]MV_C'2;JXN(EU"WWVK^7(I8+L;TYKE?CM>PW7@7
M;'<0NR7,<A'F+PHSDU\@^-/@=\;-3EDN9=+L9K&Z<-'!-(K[#G/ #\5K:/\
MLF_$/5?A;J3:A;7$WB2>0"))+I/*AAYP!SZ8[]J /M+PSKEG?>'[>YANK>2W
M\M1Y@<;<@ 'FKIUVQ5%8W=L%?A29!S7R]=_![Q)I/[,&FZ+IOA^YT^^M[L/?
MVD5RFZ\3#Y(;IR2*\ZM/@M\06N+:;5O"^J7FFSP$65HFH1!K&3G#-S0!]SQZ
MW9S2,J75NS)]Y1(,C\*Q_$?Q3\.^%KR*UU#6+.SN+@?NUD;[U?'NF_#;Q[X?
M\-/<1^#]:7Q-9O 9+]=3AV7<1;E-O7( /?\ BK#UG]G;XB?%BQ@O=:\--+Y=
MYYHM[FY1G* GC.?I0!][6US%J$$<L;+*K#<CJ<J1[5(H<$LV"OH*P_A]I?\
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D@!:,4'K1WH ***,4 %%%% !0>:#TH- !THHHH **,44 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>img62602283_20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img62602283_20.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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MY5&4<_,<"OB/7?VPOBMK_BKQ4OA^RTRQT_PS:K<SV]XP$A^5"0,H3_%7TG\
M_BC>?'3X+6.M.HT_4;RV.[:N[RWR1D XSTI.FUN/F1WC>*[ 7[V@N8FO(QN:
M ./, Z9VYS5LWT8DV\_=W ]F^E?%W[-_AK7O!W[;_BZUUKQ+?:[=M9>9;^?
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M\CA'S';SCFDDO8X=Q;(5%W%OX0/K7Q'\<OB!\;M,^!>N'4[WPY;E1#(EW!=
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M%U)*\C&0R#;\V<_[(K.U?_@FEX7UJXDFFU+4?,NHA'=-GF<#D#KQSZ59MO\
M@H#X?_X3--%BTG5M6:U=8)M1A,8A1B.X+!NXZ#O7T!97C7UDL\32,LH#@''
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M+=*DIKHLB%6&5;J* /'_ -J+X>>-_'/ARRD\&:]#I%]8R>9-;SH6M[Q.?E8
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M=QV %NS'%6("WE?,06]12"!5QCY5'&T=*>B"-=JC J#06BBB@ HHHH ****
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MBBB@ HHHH **** "BBB@ I"V#2T=* &[Z-].HH#4;OHWTZB@-1N^E5MU+10
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MV]BMY)@CRV'0>M>*^&M,TR]OKN34M672\@_NO-965N>,=*M; +HS:&FK7_\
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M_P!_J\WZK7['T7]L9=?^*OO/3# =P.Y1UIRJP'WEKS'_ (:_^&W_ $-FC?\
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M $-6N?E'_P#$U'\24/\ PF>A?OIO]>W (Q]VN^\G_::@#S_4?@?<7VGW%O\
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M_P .HOB!_P!!C2__ ")_A1_PZB^('_08TO\ \B?X5^D6[VHW>U'^L^*[(/\
MB$^1]G]Y^;O_  ZB^('_ $&-+_\ (G^%'_#J+X@?]!C2_P#R)_A7Z1;O:C=[
M4?ZT8KL@_P"(3Y'V?WGYKWW_  2N\?6=MYS:QI+) V]@#)N('X5YW^RQ:W?@
M_P#:GT/3);Y)'AO/*D$9;!(S7ZL:_"RV=U(/E!C.:_+7X*3R1?MHV:B1L-JS
M9'8C!KZ#)\TEB*-=3M?E/@^,.$\#D^9Y=/#2?Q;7/U5 WVJX]!5JW.2WLU4K
M-O\ 0E^@J[;#[Q]Z_/I=#^BJ,G*G%DM%%%,T"BBB@ HHHH **** "CI45Q)L
MY.-H[DXK-U3Q19Z>FZ6^MXXUZC<,_P Z ->O//B?I=U>>("ZZTFGP^4 (RV.
M<'W[UT[>-;>ZLY)+62.3:I(.X<UY'>>+-,\2^)+R;7%EDF5?+B2,$KQG%7'1
MD\Q4\.:C#I+:@EUICZT<D+,HW;3SSWKHOA)<BTU*2YDN[>QA8_ZJ1MK']:PO
M PU17U!='D1(V5O,C<X"ISD@>N*J13Z2;&Z_MV.1G3.R6-<MW[U<G<.8^@=/
MN(KN,R1/YBM_%V-6*\2\!Z]KMU%&='DA-G""J+<S!2PSZ-UK<L/C_'H\DUOK
M$<IND./]'A,B_I6,J=PYCU&BN;\*?$6Q\63[(RT<F/NOP370H_SE>>*"A^:*
M** "BBB@ HHHJ=0"JNH*KJ59=RL,'FK5-:-7/*TIP4E:2NAQ=G<\UUSX(Z:]
MO?7%C"6O;CD><<J&X^E<FO[.VJ64"W2_V6^H3?ZX&#*@=^]>[-$KCE0:/*4'
M[HKX#-/#/),=5G6JTDI2\D>G1SC%4X\L9:'C]I^SA8_:;.;>MM>6["28P#:K
M].U>HVJ+8PK"O\"XR>]7O(3)^4<]>*7R%S]T5[F1\)9=E4I3PD$FTE?T1QXW
M&5\0DI2V*SW'EA?>I(Y<W 7U%2&%&_A7CVI1&H;.!7T?*^5+J<\M4DAV:KZA
M_J)/]PU8JOJ'^HD_W#5@>0?LC?\ (,UC_K\;^E>SUXQ^R-_R#-8_Z_&_I7L]
M !1110 4444 %%%5P\F_[X*^@6@"QFBJDIW%5W.K9R/2N&^-O[06A_ 31+2\
MUR2^8WTQ@@M[2V>YGF<*6(55!/0'H*+H<HM*YV\ETHD=OFQ&S!LCG@9X]?PK
MF)/C'H%EI4UU=:E%I\-O*8V-\?)RW' W8[FOFGQW_P %);/4=/O+O2]/U*+P
M_P"68EU"YMWM[G3+H<F.:!AO48*C+8R6Q7AOB[1O%GQBMK6\N(]2\36>L16>
MJQJ\+S11RM+F4 <C8%48[5,I)=14[RZ'W%K'[5/A33O!UWK,-Y'/!:74=G<M
M%\V&9PG;W->7Z5_P4)B\7_%B/P_9^%PNG1S^4+Z_U&&SSAL91),,WMBN/\9_
MLF^-IDE@\)Z;I,.@^)H(9+H2LD":;(I+&01'&Y@3G(P<K3=;_81TVXN=';Q7
MXV\-S'2W@N/,NK9/M!:(AFVR,^0&QTJHWDOW:;?H36;A;;7S1]FV<JS)#(!N
M61=P<L&Z\\'^M7\USFB7UK8:!:/'<0_9(856*4,"K( ,8/IC%0'Q_IOG?+J=
MJWMYH_QKCQ.88?#?[S.,/5I&DJ=7_EW!R]%<ZJBL/3/$=OJA;R[J&3'&%D!S
M5U69Y?X@O^]2PV88?$+FHS4EW33_ ")E&:=I)KUT+^:;),L(^8[<U19FC?<T
MC.N>-IKY:_X*&_M%ZMX<?2?!OA3^U+C5+R9;C4VTU7:ZM;52&R@0%LDJ5P/6
MNN4XJ7*M05CZO+))T-2H-JXKYG^"7[;^E?%GXBZ;X/\ "NE:M?-8VBSZC-J1
M:TN+$,& 61)%W%\J1@X.:^D8V\Q?E;<OKGI5:]0+!-%1HW[S'I4E !1110 5
M'=_Z@U)4=W_J#0!P?Q)_Y'30?^NS?^@UZ!7G_P 2?^1TT'_KLW_H->@4 %%%
M% %=2<MN]?6@G/2IFC5NHH$2CL*S47?8)7>Q7,)[XH#$+QMQ]:LE%/:F^0F?
MNBJ=[$QC;4@+-Z#\Z8SG/W:M^2H_AH"TN1/=%W75%6,J%RP&?>E+Y7^%JL/$
MK?> _*A8%0<**GV;]HI+;L3KV179?F[?A21R'<P&*M>4N>E!@0G[HK*-.<'*
M47=OOL-6ZHAW-GGI0VW'_P!>IMBXX6@PIC[J_E6DX<Z7.D&J?NE"=1O7D=>.
M:E27"[6&3TJQ]GC<_='!XXIQ@4G[H_*CEG9I65]K"BES<TMRCN$+\+PQKFM:
M^&FEZIJ$]X(%6\D0JKX^Z3G!_6NS\I?[HI#;KG[H_*O/S3)Z&88?V&+2EK=7
M6QKAZDJ4G*+/&;;]G.\BL)YFU".XOY'.R1E/RKZ=:T4_9OT[4M$CCU A[H-N
M>:/Y2<5ZL(54?=H\A?[J_E7RU/PWR2%I1HI-*VV_FST)9UC&N7GT,G0-(AT/
M3HK>%F=85" N<G%:$VWR^>E2BW0#[J_E2F%3U (],5]OA<-3P]-4J2LDMD>;
M4E*3YNI4C@4M\K4^X@\S^+%6!"J]%'X4>6I[5T7UU,Y7FK3(P&Q1AJEV@4N*
M+LNY#AJ,-4V*,47'S$.&HPU38I,<_P#UJ+L7,9GB'_D"70/_ #S-?E=\%^?V
MTK/_ +"K?UK]3_$IQIEU_N'^5?EC\%1G]M.R_P"PJW]:^MX;M&G7;_E/Q;Q.
MC3_M++936\['ZJ118LHU]A5JV/##T-0H?W4?^Z*FM?XOK7R$G=I^I^R4?@45
MT)LYHHHJC0**** "BBB@ )Q36E"OM[XS1*<(:@NB5A=A][9Q0!POQ(UZWU>*
MXM_[2FL&@Y^48W_3D5P>F^(;JTTBXAATF/7(L M,TGSJ,]<8-3:EJNFI<ZA_
M:%L9KH#]VR2L<<]QTHT#2-7U#1;B;0KP6L?E S1RQ+AQGUY-'4"KHMM;W=Q)
M)=:C)IK;<B",Y09[$Y%.\&ZC=Z?JM]':Z/;ZDI!'G/\ =4<\YP:9I&I:;933
M)?VLMPP!9F0?Q-P?RJUX(T[69YK[^R9H8M/4$D.?F*\\=*T,RKHT5KJ%Y>?:
M-1?3)%W,1&<*_7Y>H^E2^']4NM+TN\-OI<.L0,3R_+#KVP:K:+=:?:75XNI6
MDDR\A&0?Q\X_6KWA2QOK_3KYM%N(K?KN64_7ZT 1:-;1:U"TE]?+HK*K%8HE
M!(&>?3%,\.ZE/HTUQ'::6NN*,GS2^UL?D:;I\FFZ5%-'JL<EW>21L2T?W5Y^
MM2>$K+4M0FN3H=Q%:KL/$OX>QH L>%+BUE\6/<7MT--DC&[:#A?H.F:]J\/Z
ME'JFF1312&2-AE6(QD5X3:76FZ/KUQ_;-K)> I^[\KG#9'T]Z]F^'4JS^&+5
MDB,49C^0'L,UF:&]1110 4444 %%%% !110>E !32_-*QRM1++O'RL&_&@";
M/-%1P]:DH **",BB@ JOJ'^HD_W#5BJ^H?ZB3_<- 'D'[(W_ "#-8_Z_&_I7
ML]>,?LC?\@S6/^OQOZ5[/0 4444 %1S7*P,H.2S'  &34E5[X,P4*%RQQN/8
M4 227<<(8NP15XRW K(U?Q58Z)I]W=7&H6MK;VXS))(P"P\=6/8?6O-OVB_C
M_P#\*E:RTC1[>/6?&&LR#[#IKMC[0HX);&2H!*\@'K7QM\1-8\3_ +2]]?Z[
M<0_V/XH\&W ;7O#^E7\MS9:K !G +;3OV[1M"CG/-1.5M"HQNSVK]IC]KG4]
M$\(:MHNA:M'-K2KYQ>*,%)+;(!\IQU?)' YZUY5:_ 7QGK_B#P]<^%]<U7Q%
MIK3#6K"\OIGN!;3%3&;61F+>6N-S;B>X&*[CX:_L5Z9X[OM-US2[^XA\+S 7
MRV4[E[BQN1\AC9B2QCQN."<9(XK6^*O[8.F_!RZA^'OPMTB3Q%XHN7,<J6Z[
MH+8X/S$C..GI731P3J['-BL=&DM3:\+?#C3OA]9^)?%/Q<DT&UE\1.9KC3!Y
M9@ X/)X#MD=2,]*X'_AO^.5(_#_P8\!WVO\ V5?)2YV,MO!VP&"L"H[=A6/:
M?LGMXFG3Q9\;O$NH:I?Y\X:5:3,L,;?W2%*\?A7HF@_$*[AMETGP1X>L-%TY
MU*0M#"HE<8ZD[<Y_&N7&9]D^6JU2E*M4\MDRL'D.<YC[U.JJ4-]>QQFJ?"[X
M]_&(QW'COQMI_@?2Y ZQ1Z>R^;!D< A2A;MUK*L_V*/AOI^9?%7Q%\6^)KA!
MY<C)>S(&;ID*)#@>U=]J'@:\GU.VC\0:A>2-)'SO<A0^/KZUWWPF^#OA_4='
MO%N;;S[B$YW9)SUQ6<<\XBQ,/:82$:5%[7^(V_LKA_"S='$U93K6W7PG:Z1/
MH?@?X'!K?[1<Z'IMCM596+S-&J8ZG)S@5\X>%/VM/@UX[\72:<EOXDM;I"<@
MI(J\'!YS7U!XNTVUL/@[?6\<*B'[*Z[3W&*^5_V:_A5X9\0_'"2*33(_E@D=
M\#W6O"S3AG&9E3<\53I5._,>YDN89;@(RI5%4=]N65OS/5K&'P??3XT7Q)?:
M?)C=B60]?Q:NDTFZ\7>'K<3:=J-IKD/4!Y!N(_6K&L_LV>&==EO)(XYK957[
MRD@+Q]:XS3_@'XFTVT-YX=U639;L0D;L2&'ZU\+BN#Z^#C>E%TTO^?5[+Y'I
M^VP571MQ;Z3U?WH]*\._'VW69;?6[2729GX+-'^[!_WCBM>U\#>'Y_$=WXHT
MV."XURXMC#%=*0Q/7:/IDUXS+\4M0T4?V=XZT42PO\HN$7[OOT%;WANSGM+=
MKWP=JBW-NX!DM7;<8U'/'7KTKJRSB+-<(^2I:=);MZ22]'N<>(R2#CSK3M?5
M?+L?*7[1OP5\7?"SQ[>R7VMV^APZ].=4U"_CE%BVH2R'+6PNEPRA,9&">7Z"
MO4?V4/VX;?X5^'[7P[XS75I)[JZ9=/6V+ZD\%J"-DL\IP=I7G>W7!->]S^,[
M7XO^%;W39-/TUM<C1HX+6]@2?R),</AP>AQV[5\O>*_V?/B5^RQX$\277F:#
MXAL_$#L^J:I+&BWEHDA.^&"((5V@,P7!7VQ7Z'E^<0QD+Q/#K865+XC[T\/^
M)[+Q#:I>6<OG6]PBO&Z\AP1G(K2%VA[]\9]:^#_V=?VW?^%;^*_"O@R6VDL=
M'NK<+%!J_P"XU1% 4>:(N<QD'.=W2OM#PSXZTOQC;3-I-U;W_DMGY&R,UZ*3
M6YRQE<Z2BH[1@\ *G.>O/0]ZDIE!4=W_ *@U)4=W_J#0!P?Q)_Y'30?^NS?^
M@UZ!7G_Q)_Y'30?^NS?^@UZ!0 4444 %&:*,\T %&**,T &:*,T9H **,T4
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M!Z44-PM #5!S4,]MYEPLA'S*"!^-21OFF3#?Q^M3&7,%N8\(_:__ &0#\?=
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M]-7[.VVS6/:X_O&O!HTY1A9GK>T:=XA/X6L?B/J$RWEJL]BHPH8?UKROXA_
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M%[+:7#1A?,3!*@C@ '(Y[\5\G#B3$JI=[']%X[P*R+$48K"M7:Z6/Z&/@?\
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M2)I<<=RQ/^MQBO$Q5&TW&)]'2Q$6N?H>A:C:3)ILD^H3"TA1<K!G]V:XN_\
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MJQM[UY/.M_M$F\L)G_Y9X'0#I_\ KJ;7[B^\1:A?-8ZA#8+''F2,XVRC//\
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M*0_\%D?A7Y_EBXNF;:&XC;D?E5?6J+^TBI<;9)'XL0OQ_P CZX)HSQ7R4?\
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M>?\ 7L<8_P!FN]Q7G_Q)_P"1TT'_ *[-_P"@UZ!0 UD);C\J:T;?_6J2@C-
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M_!)?X/,X;_A';S<,<C4I5Z?C5SPQ_P $KOA+X3\06^JV>@W2WUK*LT9?4)7
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MO9$M2/FER_/W3Q\HKFX?VL_B+IW[/FFZ;-XIN3JM]X@DTC^W&/[[RU\K!SC
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[L?A3[(;RTG/S=1FBBA-@6****H HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
=BB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>img62602283_21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img62602283_21.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
M  $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $" Q$$!2$Q!A)!
M40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF)R@I*C4V-S@Y
M.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$A8:'B(F*DI.4
ME9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:XN/D
MY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]_#TH)I*6@ [T=Z#UH[T
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M_P#?0K@_^&3OA[_T+D/_ (%3_P#Q='_#)WP]_P"A<A_\"I__ (N@#O/M4/\
MSTC_ .^A1]JA_P">D?\ WT*X/_AD[X>_]"Y#_P"!4_\ \71_PR=\/?\ H7(?
M_ J?_P"+H [S[5#_ ,](_P#OH4?:H?\ GI'_ -]"N#_X9.^'O_0N0_\ @5/_
M /%T?\,G?#W_ *%R'_P*G_\ BZ .\^U0_P#/2/\ [Z%'VJ'_ )Z1_P#?0K@_
M^&3OA[_T+D/_ (%3_P#Q='_#)WP]_P"A<A_\"I__ (N@#O/M47:6/_OH4T7T
M>_;YR_F*X3_AE/X?QNNWP[#SU_TF?_XNL+XC?LT>!]'\)W=U:Z#'#<1KE7%S
M-D?^/T >PI]WKD4M9G@N)8/!^E1J,*EI$H&<X 05IT %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%9>H>*-/L+U;
M6;4;.WNI#\D3SJKM^!.:L+?"=CLD4J#MXXP10!<HJC)>-/&RJS=U8IU3WYH:
M6:/Y0WS<'<WW: +U%9<WB.SMK];:2]MH[J0?+"TRAB?9<YJP]Q*JL5^\I"G=
M]WKS[T 7**HB\D-QM568;B/I_P#6H:[\S=(DF/+4@C'RD^OKQ0!>HJK#.2AW
M/D,,[Q]U?:G&=E0-M8^N"* +%%5/M,ABRORNQR _IWZ54U+Q58Z)!YE]?6MH
MLAVH9IEC#'VW8H UJ*R+[QAIVGV*W$]_:00,/EDDN$5'^C$XIEUXZTFU\C?J
MVG1K<_ZO=<H&;Z GG\* -JBJZS&>#Y&ZG"M_>'K3)'8?=D.?NX[9[T 6Z*IK
M=LZ[E;<J_+P/F)H%\V]5;$>Y2QSV .* +E%48[MQN:3S(UW\;NXQVQ2W-U);
M!I)&C6%>,YY_'M0!=HK!E\=Z7%^[_M;3D?)'SW"]OH:O?VFTL*O&RLH4'(.?
M,^A'K0!H455,TGF*JLN,;CGK3C*RM\W'<#/6@"Q15&'4,;O,W*5&3GH">U31
MR32'YFCVGIC.: +%%1P'='U)Y[U)0 4444 %%%% !1110 =J.U':B@ [T?Q4
M=Z.] !0*.E&: "BBB@ HHHH *CF^\OUJ3-1R]12E*RN!"X8[L>E> ?&V+6K?
MQC;SQQWGE+D-&E_%#D9'/S5] D_(U>#_ !CTF;Q[XSB>T:XMXK<,CBZTII%)
M! .&.!CBL<1*R1[G#M6-+$.#ZH]9^%>Y?"5JTAG&Y,XEE$A7_@0XKI?-4#K_
M /7KC]&UFV\%^ 89[AO.M[6 F3R(N#SV0=*Q_$W[1FA^%_!%KKDR7GV6Z0-$
MHMVR,MCFKIQY8Z'DXF2=:5N[/0OM,<KK@G.3QCTKRF?6K.X_:IM;.-?]*AT^
M5G/ED8!5>_2H/!/[7_A'QSXS&EV=Q>-J<\<@>(P'$8B4L3^//Y5SW@;XV>'?
MBA^U3';Z0;P75E9313^=:M&'*@#@GTP:T,3Z$3_5T)TH3_5T)TH =1110 44
M44 %%%% !1110 4444 %%%% !1110 U_OK7,_%C_ )$2^_W:Z9_OK7,_%C_D
M1+[_ ': -?PA_P BIIO_ %ZQ_P#H(K1K.\(?\BIIO_7K'_Z"*T: "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /S+_
M &]=)M9/^"KGPMW1_+<.2X)^^P60YK[+_:]^-U]\%_AE=7VAZ?9ZIJ5J0!%-
M=1Q^0&X\S#$9V]<#DXQ6!\>_^"?WAOXW_';1_B!>:EJ5MKF@Y-J8YRJ)D$=/
M^!&LOXH_\$X/#?QOT34K/Q+XE\4WDE]+'-YEKJ4D#1E&W!<@G@G@CTH ^?\
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M:+7KY+Z=!,Q9BH3'/U05]&>*O@GX=^(_PO;PKK-DNH:4UL(?+G&XA>QY'!H
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MHOCSPQJ6HWDACM[>VO%>60@'/ [\&OD3]K'X&^-O%G_!0"/Q#9^%-4N?#O\
MPCTUJUW:X\IIC(I"G+#D@5X)^SQ^R%\4/#7C?X2W4_@'7K)],UR:XU6:1(U:
MUA,4@7=M;[N2/?F@?*S[W_X*3?MFZU^PS\%-/\4Z3H.FZZSWT=B8KZ\:W \Q
MT0$,%8G[WZ5YUH/_  5$\2Z!\=/!OA'QIX1T?3X_&.D)J=M<:;J#W7V=3&C_
M #!D7KO'Y58_X+6_"CQ1\<OV5[/1/"/A_4/$%[)J=N\EI:JIE2,2QEF^8@<
M$]>U?/OP3_9D^(_['_[3WA7Q5;^#=8\<>&]:T*&QNH&"RS:',L2J<[F  R3T
M)^[0'*SZ0^#7_!1/4/V@M?U^U\&6OA[4KC0;Y[6739=19;HQJS!I-H4GJ!C_
M 'J=IO\ P4:\3:%^W-I?PC\6^%-+T>SUF#S=.U&.^>1[E^Z[2@ QANA/2OGO
M]HS]@[_A<7B&S^(G@?PMXL^&OQ4CU#,L=J56'480QY9=[+SA.PZUZY_P4@_8
MH\9?&WPI\._$OA-F@\<>%Y83<7%L/](==I#=1C^*@7*SZ@^'_P 2O$/C;Q[K
MD,^EZ?:^']-?RH;M;@M),PQDE=N.A]:^>?B)_P %$_'.B_MO7?PCT+P7X?U"
MWATB35H=0NM4D@\P)'(Y! C('">O>OJ/X6>$Y/!'@'3[*Y?SKZ.%3<S$?ZU\
M<DU^<G[3_P"Q5XU^/G_!2C7-4M])\1:;H5UX?N+.VUZ JMN)3#,$7(;/5E'3
MO0%FSZG_ &'?^"B5C^U7X!\5:MK5CI_A>\\(ZE+IU]']H,EON1W7>KL <?(3
MTKT_4?VN/AMH^@W&H7WCKPU;V<+!)))+Q52$D9P3[]:_-[P_^S]\:M(_8F\2
M?#N#P'K6FZKX?U(R17-NB!O$<>Z0[L[LG.!UQ]^L/]L+X9_\(A^S/H>O-X=\
M5:+JFI7MK%J%EJB1*_F)$4(4(Q!!V]Z!\LGLC] ?CO\ M\>'?"/P2USQ?X!U
M3PWXXO\ 04'G6<.H;40%EZLH)Z,#TKFO@3^WWJ_QG\<>!X?L?A&QTWQ-HXU"
M^C;5F_M"U.USA8=F"N5ZEAW]*^1-6_9@^(WCNT^+&LZ+X/UVST?7]&M[:RTT
M1QK_ &A*'MV+I@_W5/<?=-1^%OV5OBQ=?$SP3-;>&_$&BKIW@N33)[HI&%MY
MQ#.%C;!/)9E&1ZT72W#E9^E_A_\ :7\ >)];OM&T[Q=HMYJFFJ\UU EROF0(
M@)<L!V4 D_2LU_VO?AQ!HFIW]OXNT*^CT>%Y[@07*R% .3D]OI7Q#^S3\*]<
MTW]F'5K#Q%\$?%%W\1M)M[FU%Y*XC74EV%<(4E!.['&X#K7E?[./[+?Q7N/B
M]XDN=5^&OBG1--USPQ=6,,%TL?DVTK+&$4X<D]#R<GB@.5GV;JW_  4YTSQ]
MX=\/:M\/[CPMJ%OJVH?89DU+4C:R'!<$QA5;<?E]J]ZF_:.\$1^*QX?N/%6A
MP:^%&^Q^TK]H5L9V[>M?F'K'[+/Q/U/X _"OP[;_  ]\06.M>'M=DDU 111+
M"D)><B0D-NQAE_.IM=_8U^*]U=^)M'_X1_6[K4M2\11ZA8:@2!'% %B!!<'?
M_"W'2@.5GZ0:_P#MG?"GPAXDGTG4O'_A>TU*U(BEM9;Q5D@<G&#WR3Q7HGA[
M7(?$>GV]W:SVUQ:S*)()87WK(AY!!]Q7X]_'/]CWXJ:K\1OB;<1^"=<U1KV2
MS6RFA1#YYCN&8LA+ XP03GM7ZN?LXV%YH?P#\(6NI0R6^I6NC6L=S;N 'BE$
M2AE..X.10+E9W5N<Q?Q=3UZU)4,,JB,<_P#UJD\Y?[U AU%-\Y?[U E4_P 5
M #J*3>,4GFJ?XJ!70ZB@-NHH&'449H%% !WH[T&CO0 @ZTM-/0TX4 %%%% !
M0:*,T %,F&13Z;(,XH!D" -$P;I7A7[0*SZ9XPLY]-%S(DBE7%O=6\4:G(^^
M'^9O^ U[E<LHC*MGGTKY]^)GC;X>W^M-'?>'M1NKRW=E68:#.ZHX/4-MQ^/?
MK6-2&I[.25G#%W78[[]E^/Q!'X2E_M[_ %AD)@^8-E/;%>H Y%<I\)IDF\&6
M#1+Y:M&2%\HPX&3CY3R.*Z<LWJ!Z9HPZM X,9/FKS?FP\W<<8(]Z\EO[ZS3]
MJ33UC96NOL,W '.,+FO6 6Z,*\ENSIL?[4VG^6T/VO[!,"H7YL87-;'*>JW-
MT4*;5X;K5F)MR<5#))'$@+$;:?%*IC!4_+ZT 2T4T/O^[02PH =12*>*6@ H
MHHH ***,4 %%%% !1110 4444 -?[ZUS/Q8_Y$2^_P!VNF?[ZUS/Q8_Y$2^_
MW: -?PA_R*FF_P#7K'_Z"*T:SO"'_(J:;_UZQ_\ H(K1H **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@"&ZF\HKTY]:B^TLPX53^-,UA0ZI\NZO&
M_P!J;XR>(/A1H6G1^'+>U;5-4O([:#SX_,3YL]1D>U$Y*,;FF&P]>M5Y(<MO
M-V/9C)(P^ZOYTL60>5Q]#7SC;ZC^T/<Q)(K^$1N4-@V0X_\ (E2-+^T4W_+7
MPBON+0#_ -J5,:DG'8]*62RO[TZ:_P"WCZ-S[&C/L:^<?,_:)_Y^/"7_ ("C
M_P".4>9^T3_S\>$O_ 4?_'*GFD/^P_\ I[3_ / CZ,<\<9IV>.]?./F?M$_\
M_'A+_P !1_\ '*-_[1 _Y>/"/_@*/_CE/FD']A_]/:?_ ($?1111_"/Q%"HI
M_A_(5\Z^9^T3_P _'A+_ ,!1_P#'*;)+^T8NW;<>$?O#.;4=,\_\M*7,^H?V
M*[?QJ?\ X$?1O ^8 U'Y$9E\QHQO7H>]?.]Q+^T,3,PN_"*1K]S-H"3^/F4C
M2_M$+%N\[PBQ&"#]E'_QRB5>2^%.PO[%?_/VG_X$?17E+&^Y5&YOO&I&Y3 '
M'?-?.1;]HG?_ ,?7@]E(X'V0<?\ D2EW_M$?\_'A'_P%'_QRIC6YU>(?V*_^
M?M/_ ,"/HE;:.*+8D>%SG [TL*")?N[?I7SKO_:(_P"?CPC_ . H_P#CE!?]
MH@_\O'A'_P !1_\ '*KFD5_8C_Y^T_\ P(^BC$OWF7<WK0D0!+;?F]:^==_[
M1'_/QX1_\!1_\<HW_M$?\_'A'_P%'_QRGS2#^P_^GM/_ ,"/HIHQ*O[Q0U!A
M1E"[5^7MZ5\ZE_VB#_R\>$?_  %'_P <IH/[1"DG[1X2^;_IU'_QRCFF+^PW
M_P _J?\ X$?1+VD9G63RUW*,!L<BGGGYAR:^==W[1'_/QX2_\!1_\<H#?M$#
M_EX\(_\ @*/_ (Y2YI"_L-_\_:?_ ($?1>6;[M)Y"F57VC<.IKYUW?M$?\_'
MA'_P%'_QRA7_ &B-W-QX2V_]>H_^.4^:0_[#?_/ZG_X$?131C#?+U_6O-?VA
M?V8/#'[2VBZ?IOB&W:2RL;@7**F!\ZYQ_,UP#2_M#1PLQN?"(QT_T4?_ !RO
M+-2_:P^-.D^-%TEI/"3&1]F\6Z[0W3_GI657$QIM>T(EE+AI[6GK_>/M'0M'
MAT;2+>SMXQ';VR"-%] !@5;^R1@Y5=K?A7S?9W7[0UU:K-'>>$9%FPXQ:C@?
M]_*F\W]H@C_7^$?_  %'_P <K1UX25[%?V&WK[:G_P"!'T5' L(^5=K-U([T
M%<-POS5\Z;OVB#_R\>$O_ 4?_'*7?^T0?^7CPC_X"C_XY0I2Z#_L-_\ /ZG_
M .!'T9Y2]=OS>M1F!&??Y?[Q>,U\[[_VB/\ GX\(_P#@*/\ XY1O_:(S_P ?
M'A+_ ,!1_P#'*?-(/[$?_/ZG_P"!'T0MO'G=Y8W-U/K3MK+TX%?.N_\ :(S_
M ,?'A+_P%'_QR@O^T0?^7CPE_P" H_\ CE'-(/[#?_/VG_X$?1P/'<T9]C7S
MB'_:('_+QX2_\!1_\<H\S]HG_GX\)?\ @*/_ (Y1S2%_8?\ T]I_^!'T=GV-
M1R,RO\JY^IKYU\W]HD?\O'A+_P !1_\ '*$N?VB0V/,\(M[FS'_QRGSR0?V*
MTK^TIO\ [>/HKS)&XV+^=-'R<[?UKYZ\[]H@-\TG@\#N?L8./_(E7/@-\7_B
M!JOQ!U#PWXRM])EO+:(RQM9P^4"O'^T?6G&H]K$/)ZLH.K%P?+_>/H&V?S4/
MW>O:BH=(+>2VY0G/8T4SS+-:/\"W2-*J#D@>OM3;F/S+9EQ]X=,XKSOXL_M(
M^"_@9=Z;:^*M>L])FU.00P1RO_K'[#)H ]&,RC^(4*X8\5R^G?%#0]4\21Z9
M%?P27=U%YJ1*>=F"<_CBI?''Q!T?X:^&;K7-;O8]-T^P4^?,Y^6-?[Q]L"@#
MHRZH=I89ZXH,BH.3@5A^%O&>G^._#=KJNDWT6H6%XH>"Y@^99%]>:Y/XI?M.
M>!_@OJ]M9^)?$.GZ7>Z@X2VAED^>?/' ^H/Y4 >D&15*@GENGO3@V[I63I]R
MEW$LD;-Y+<KW##KN!ZTW7M;LM(ME:]FCBAGE2*,[]I9F. /S(H UO-7S-NX;
MO2A9E<?*P/.*IB=8TV\+-RL>[^+TKD-;^/'A?PO\1].\*ZAK-G;:]J2XM[8G
MYI#GL* .]IDO\-/4Y44R;I1>VHF02L-GW2?I7F7QA^)$/P^UR"WFM[);6[0M
MOFG$>6&.!QSUKT\=&_"O!_V@/'$,'BRR2TN/#N,D23:@Y.P@@$*-I&?\*RQ%
M1PLT>MDU)3Q;4NQZKX=\96TOA*#4[K9I\#0EF#G 4 XSGTI-3^+&@Z?H=KJ'
MVZ&:UNLF*5'!60#.2#^!J+1-,A\7>#X(_M$;V]S;[&\I T;<]1FN2\;_  "/
MB'PE:Z9;:A-;PZ6QCC40KT/!_F:JG\)YU:*C4DEW9TOAG]H/P?XMO4MM/URQ
MN+B16<(LRDD*,L>O0#DUY]X?\=>"_&_[5MN='U?3=2O[>QG646]PLACX&0<5
MD_!O]AS3OA!\66\3_P!K7EY'# ULENT2A-TBLCG\B*V]'^'GASPE^T[;KI6F
MPV-TUC*\[J@4R%@#G^=69GM,C6]S$5W?K573-0\F62%F18X^%)/6ITTU<9W5
M4U6QBB0, 69NX[T 65NYVF^55:/L5YJS#,W\2G\JJ:/)Y6U-K8:M.@ !S111
M0 4444 %&:** "BBB@ HHHH **** &O]]:YGXL?\B)??[M=,_P!]:YGXL?\
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M/\2\@UJ:=%#<1"1%VT 75;<*6FQ\+3J "BBB@ HHHH **** "BBB@ HHQ10
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MH !Q7.^)O%YT3Q/I=AY>[[>Q7/IP?\*Z'/6N%^(B&3XF>%,-M"7!8C'7Y7H
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M$?\ 87@_G7OMWT6O OVU?^0GX(_["\'_ *%6-0]C(?\ ?8_/\CV^R_Y!\/\
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M !1110 4444 %%%% !1110 U_OK7,_%C_D1+[_=KIG^^M<S\6/\ D1+[_=H
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M(Q(?4]NU 'N/P6_8%3P++:W=[=-!='EP!G!_&OICPKX:A\,Z;';HA9HAC?\
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MM#_Z%6-0]C(?]]C\_P CVZR_X\(?]Q/_ $&M""L^R_X\(?\ <3_T&M""MH?
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M?\(CX=@#<[#JL;%?QVTG4:UL9RR>K'XYQ_\  DSZ0EY'6HBO'S,17SLWBO\
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M@?IS7@/C_P#;GT'3M3;3?"MC?^.-65]AMM*7)@;.,N7*C'T)Z5BS>'?C=\?
MOVS5;/X<Z7-]UM._>Z@!Z,)%://TK.-2Z/6AD]1P]K.2A'S>OW;L]V\:_$?0
M_AUI\EWK>K6FF6\8R[W+B, 5XSK/_!0_P7>RM%X7AU?QM<*=K#0H!=!3[X88
MJYX._8+\':+?1WVO-J?BW6$^9KV_G8;S[HK!/_':]=TCP5I?A^W5=-TVPLU4
M8Q! JG\>*/9SEJ9QK9=3?+.+K/R]U'@K_&?XY>/[G/AOX>Z-I-B_'G:SJ$MK
M<(/7R_+8?K5^/]GGXN>/(MWB#XGMI=O-R]G8:="P4'J!)\K?C7T!;K(C;?\
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MN^EA\1&BJ]56N=6"<:5/DEN>HY;SANQ]/>O.OC&LFL>)O#NE+M_?7!FE7_=
M/]*]%E(E9N/F4\&O.?#R-XE^/.HW#MNM]+C"H3T!)(K+E2V-(Q:U9U'Q)N?L
MVB00H2OVAQ$$ Z@\?UKF_CO\(KGXN_ W5/#%M,MG-=6AB0[<J"5P#FM[4V_M
MWX@VD'WH;%69Q[GI_*NG3(A8?Q*?R':JIU'"2G'=:E^1^='[%7_!-7Q-X2^.
MCZOX@.F_V9HL^-J/YAE;J,J0!TK]$+"R%C'LAC55C^4+G"@>PKG?AP,7FN?-
M_P O0/ _V1761C'X]:[,5F%;%RYJBL1+W-!JVY7)W?+Z8JGJN@1:U9207$:2
M0R JR$<'/?ZUH-\PI$X%<<8\HTSR;0+JX^"'B_[!>2-)H6H$M#(3GR#GH<]!
MR>]>C2W"R7UNRG]W(-RN.C5'XW\'V?C'0Y;.ZCSYXV!AU0GO7G?@S7[KP5=S
M>&=<DVQVI_T&[8_>'I^IK*8]SU*WVHO#?E3F0.!O;GTQUJ.PNH;F%7BDCD3'
M534DURD:^9N^5>M7*G#E]G5U)@HIVI T:E=H_2G#Y0O5AG&?2O,_%?[4_A+P
M;XC_ +-NM4A6X?JO]VMC_A9LGBK8OA^UDNHY$YN^D:9_SZ5G"O'^%1Z'1B<#
M6IPC4KJR>QE_''X^VOPIBA5K>2>9V^48^7\ZU/@Y\0H?B5H:ZCY+0SR#!0]1
M7#_%[]G2X\8>'+K4;S4IYM0A7?MB VN/[O(_E6!\'O@!I/BCP+'J6GWM[H=\
MK&*22"0LP88[,2._I7C4*>,^N7EL>A6E@E@_=^(^A8[L0LWF-\H.,U'>O]NB
M>)A^[F7'/<5\=?M+6/BKP)<V^FW/B&\OK$D"(R85Y#QS\@'M7O/[)FI:Q=?#
MR-M8,S;#MB+C^'G\?3K7V=3"\D.<^*PN<2JXZ6$E2TMN5Y_V.-#O/&7]JSW%
MQ+&6WM 1\I/YUVUI\$_#,<04:'I;)LP2UNA9C[G&374!6\S=_#4R !:\ZI-V
MY5UW._!8.C0<G3ARML\]\1_L^:-K,$,=O#'IOEG.8$ _EBNJ\(>$H?!^D+:0
MDR1KW;O6J\>3]ZG(/EKQJ.482A5=>E\1ZDJC:M<@:^2U7]XP7;[\4\:C&8MQ
M^5?[QZ5\\?MG:SJMC=VJV<]PELG^L2#[[5H?LY^%=6\8>%O.U?4KR2Q;B."3
MY6'U.,_K7T3P;]DJDNJ/G</F\:F)E1[.QZEK'Q:TK3[C[/;2-J5YG BM1YC*
M??TK.V^)?%5VR2O'HMNPRK*H>8CT*D<?G72Z1X6L= B5;6UAAS_$1EC^-7MB
MEVXVMSU[UP1A[_++8][W;-M7T/(?B!^R!H/C]EN+NZNOM0^_,6+;_P ,X'X5
MQGP3^%VG_#+]J+4M+T^,+!_9I+,1\Q/R5](Q?ZM5(SGK7B?AUL_M@:Q_V#2/
M_1=80P-!5.9'O9=FV.J8*MAZD[T^1Z?,]LTG;'$T8XV''UHI^G#"-_>SS179
M+1Z'SL4E%**LBQVI3S0*0]*"A"@8]*-@/&.*=1WH R_$W@S2_&.F36>J6-O?
M6LR%'BE7<K*>Q%>5_%#X!^#-8U[P;H5UX<TN;2+&X+P6C1?NXCA^0/Q->T"N
M&\?\_$OPO_UV/_H+T^9F;I0>K2.GTGPSI^A6$-K:6<$%O'PD:K\J_2KRVT:'
MY5 [\4#_ )9U)2N5&*6PU8U5L@=>M.- HH*"FR'BG4V4XH A9VV]:Y_Q+XZM
M?#\D7VF\6WWY 5NK8K?D=8XR3T'M7@W[06J-?>-[%7T>SO+6,'_2GU>&%HSQ
M_ PS6?,[Z'HY7A8UL3R3VL>Y:/J/]I1QS1ONBD3*^]:%<S\-75?#-F<M\T>!
M^\\Q>O8CBNB^T+ACG[IP:=-W1Q5:?LZDH^;(YY'A#,S+M. !TQ7'7GQ<M+C6
MM0TVWW&ZTV(RL1*IWX&<8Z]JZR=4=G616>.0<!AD9KQ4^'])TWXMZXUC#8BZ
M:S9YGCC&\?*3C-.?PLFFKR2M?5:?-'CF@_MW?&/X@>)-<A\)_#4ZUI^CW#0F
M4W,2[R"?[SCT-:TW[5'[1NS_ )(XVWU%[!_\=K2_X)I9_L3QQ&S^9G6G+C;T
M^9^*^H"8XX_N?)V4#I6=.BY1N[GUF<5J&&Q\Z4<,DE;2_DO,^31^U-^T>$7_
M (LVV/7[;!S_ .1:/^&J?VCO^B-M_P"!L'_QVOK01Y^;+;3T7THV?[U3'#ON
MSR5FE+_H&C^/^9\E_P##5/[1W_1&V_\  V#_ ..T']J/]HZ8;?\ A3K1[N-W
MVV#C_P BU]:;/]Z@Q;^.N:M8=WO=E?VG2_Z!H_U\SXE^(O[:_P ?/AMH']H:
MU\+Y-.M<!#/]M@9$)8#) D)[UW7A+X >*?VFM*L=;^)'B22XTJ\598M%LB4M
M O4;@<DMZX..!6]_P4GM?^,=;ORS'%^^C4EDW9&]:]5^!5IM^#WA_P"5=HLT
MV\>U<].,G7M)Z'J8C$4'EU.I3@E)MW:6I9\$?";P[\-M)BT_0M)L]/M8B (H
MDXQW.3S760:?!;H?+C51Z"H8QM)9L;@PYJZ'RN:[>7EV/CU-U$ISU>NI =.A
M/_+-:D6W5%VA1BG>8 >],EO(X3\S4[LN[%^RQD8VBA;=8_NJ*=OI0V:5V*[&
M26L<ARRBG>0O]VG44^9D\D=[#?*7^[1Y:^E.HI7'RH *,444##%-\M<_=%.H
MH"PWRE_NBCRE_NBG447%RH:JJ!P*=BBB@88I"BGM2T4!9#?+'I1Y:^E.HHN+
ME0T1J.U(UNC?PBGT47&,:!77!6FI9QJVX*M2FBG=D\D;WL0OI\,GWHU-$=A#
M&?EC45-12+YG:QX+^WO^SUKWQ_\ @W=:#X9FTNRO+Q'CDFN8F9MK#'!!^M?F
M=X+_ ."5WQ&_8T^+?A77)-6TW4D;4XOW:1N!R<GJ:_:*]R)$[\'\:\"_;/9H
MM8\$?ZSY]7A#;'VX&XUY^.PBG::/M^$N*,1AIK QBG#WNG='MF@&0>'+'S.)
M?*3?]=M:EN-K-6?IO-E$/]A?Y"M*+YG+>V*]#X8I'Q-22G)R\W^9)111020W
M:LR+M;;S5>?>S?+(?<"K%W$9$7'KFJ\5JR7&[^&J5DN;J1*G[1.,M.QP_P :
MOVAO"_[/7AQM4\4:A'IMF&Y=@7)^@7)JK\"?VH/!O[2ND&^\)ZQ'J4*G!VY4
MC_@) ->#?\%4_P!CSQ9^T[X,ME\)R0O?6KY^RRD*DP]R2!7*?\$I/V%?&W[)
M\VJ:AXGCM8;B^'R6T4JLJ]>X)'>O*EC,7[51C#3N?HM/(<C_ -7?KTL1_M*^
MP:/_  5!_8QUGXS7UOXFTFZ56L8PCQ'OP.?TKI/V(_ NH?L?>!;?3?$$<LD.
MK%9EFC&8X<COU]:]Y^->IHWP]OO.CD61\(5'*@X/>MKPWIEOXA\"V=K=+#/9
MR6X62-OFW5[_ /:<JE+V$NA^9T:<E6=1[&A)KMO/HSWD4D<MNL1<2(V17&_
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M@?W9]C16RE?4\B"M%(G'2CM2'I2F@H,4=Z#1WH  :X;Q_P#\E+\+_P#78_\
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M8<5.%<N17/7XHC'^U:BUW7Y(8(F9LAOE;H*=]G;^]^E2PKE5]A4N*WYF?/\
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M^K2,&;\P*]FC[)4['CUL)B/K2FG[IU$D8@@5$CVQA< #HOM7C6@'/[8FI?\
M8-_^-U[7<-N4K[9KQ3P^,?MBZI_V#O\ XW7%.RDK'V64Q:]O?_GVSW*R^Z?K
M12V7^KHJCS([(F%)Z4F\9Z^] E4C[W0X- QW>CO49G3<?F''!YIWFJ!G<,9Q
M^- $:V*)%MRVW.>O>O&_C=^R#H/Q:^*WA[Q-<*J76FO^\&!EU^8]?J17L_G*
M5^]]XX%07++(3MVLV.* &P6_D?*JJNW"(,<!15RJI;9,NX?='&/6K(<$=: %
MHILDRQ(69@JKU)[4"52N[=QUS0 ZHY_X:4W"*"=PP.#3)F#;<<T$RV(9" C;
ML[?:O+OB7X#T?Q$5N)M:U!9+4LXC@OVC+'.<'!KU%H?M 93ZUY'X_P#AWX+T
M[QA''=M?+?7"M*$6[D (R,G&['4U-2*D[,];+*DXXCW&]NAZ!\+K.W@\-6K6
M\;*K(<ESN9L$]3WKJ*YWP)]@M/#MNUC(K6*1D!_,+8Y-:EQXDL+2&"22ZA2.
MZ.(F+<2'VJ::2C9'#B)2E5DY=R:1,;L-\S<?A7BL?A^WTKXNZ_)!-<2&2T<N
M))RX!VGH.U>Q?VG;W:,(YDD;&?E/(7UKQ\^&8]&^+6M7"2W$OVFR=@2<I]T^
M_O14^!BH?Q(^J_-' ?\ !,D[M+\>?]AQOYO7U/)_%]*^5_\ @F1_R"O'O_8<
M;^;U]42'.[Z48;X4>MQ1_P C:IZK\D20=%J2HX.BU)6G4\0;GYJAO)F2-MO6
MIA]^HKB,L>G% (^>/^"DKD_LXW+-][SX_P#T-:]3^!T"R_![PZS=?L<8X^E>
M6_\ !2TX_9TNA_TWB_\ 0UKU7X&LJ?!KPZS=K-/Y5QP_W@]ZI_R+*7^)G4HJ
MH6'N*3496^Q.$/S]JAGNTM]S[MJY&#V)K+U":>358SY@5&]^M=W5GS5/2'S9
M9TN>2QA92A,TAW D5:LK^0SE9E#$^@JOJE])!;[U7+1C .*IV>O+:1^=+(F3
M_"35%\QMS7\:3>7'RWI4AN7$+;5VLOMUKGT\2QRZCN5=LF?NGK6O!J6_=YC*
M-PZ9Z5F%R>"\E>95.,=^*M0R>8A-9]D[*6W*1D_+[U/:S>7\K_+ST-!42ZIR
M**:AR*=04%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 0W)
MSMKP+]M+G4_ _P#V%X?_ $*O?;G[R_0UX%^VE_R%/ __ &%X?_0JQJ'L\/J^
M-C\_R/<+,8T^'_<7_P!!JY!(<U4L_P#D'P_[B_\ H-3^9Y0S[UT05X'C54W-
M)=W^9.9.*C\V0[L%>._O22?>7G[W2N9\??%#3?AY:NU[,&F8?NK9.9'/L*E3
M5[$Q<M58S/BC\?\ 0?A;/%;ZM=.LLPRJ1IN;'K6?KO[4/@FP\-QZA=:Q;K#(
MO^K#!G/U7.:^1_VP_CM8/KD-_?7$$ESTBLHL-<A?=?3IS7R5=_&A_$/BZ:2:
MVN+.S4_*LA/'OMZ56=1>&R_ZSA]:AXN#QE;Z\Z6*TI=^I^@/BG]N_P"'NB:N
MVFZ':M;W6H';]ICL_*S[Y%6-!^)%M;ZO:SR;=:&?,\M7WL.^<<].M?GCK_QF
M\-PVD\<T<UQ=,VR&5#MQZ$8-:/P'OX_"?CVPN]5UK4!;7X8")+MVDVD= ,CU
MKX/!Y?F>/:QF(;7)K;O;H=V*S"G"O[+ OGB]&WT\S]6M$^.>E^(FC,EGJT%O
M$/G;[(S0_P# FZ?G5+XM_$WPSXR\.M9Z?J-G=:A&-\"1S+PPXP2.GTKYSNOV
M<]4\>Q1-X1MO%.CV,D(EEEOK^=8)P0#GEB,'GI7A?QA\,Z%\!M:*W^I:LGB.
M,[UL].G>XA([LS%@0.F>.]?7862DOWJL<V,QU7#QO#WF?;/PW^*.F>-(([7Q
M%J#-K%O\C1!O)A51SR<X:F>+?'.D_&7Q,_A_1]0@L60XEO(& 8^V01Z>O>O%
M?V:O!TW[0VG3/"MS:F&'+EQL+>F&ZGJ*\Z\0?#OQ5\#_ (H&[NH[S2[>"X!-
MPV?)=<]R:]C!Y70JR=3FZ'%EN;UW!SK0LKV/6/VT?A%>>$O#>BWEC9^<VDR@
MBYB_=O.,KDO@?-T[^M>M^ [:'XI?#72-<MHK>:YM[=8I[-8AERH (]B<=<5R
M7Q8U;5?V@_!FE_\ "/VNI75O9Q(S3I%F*X; W!3GGI^M<EX&\0>-/V;-;MYK
MJS:WT>ZD'FQ3#:Q_W1CKUKY.O4JQQ3H5EST[Z)[+S/NJF7X6A@OKE::NULSO
M/B_\,[5K-?%WA91;WEF09;;&=[CC:%[5RFO:C)JN@:?XRT519Z]X?PNIVP&)
M"H.3QU/WJ]+C^(FG_$;0YM4\.F.'6+?YIK%SQ*/]E>>>G:O+/'=A<>/]?MI/
M#C&'4)XBFIV\?5%&2=R]-QX_"G*4\/4]K!61Y>$QE.I3]G!:'IEIXIL?VF-(
MC\12872U58EMB_/F]#^'(Y[U['\,/!5KX2\)0V]K#Y"M\S =Z^-?@/XSB\#_
M !<AT:>.6/3;>0));9^Z_0'_ '0<'/>ONB'4('L(YUD1;? (8'Y2*[\.J=1^
MU44I=^IU5I5E!4W)\O8+R-;>SD;D87G'6H;:&.?2(]^2N"?F/3K6)K?Q(M9)
M9K?3DDU&ZC4C$(W+'_O54T[2-8\26,,VI74=O;==D9P0,]#TKJ<KOE?Q''&G
MR[''?&SXJWG@>""VTV>&Z:X^\CX<Q_4TSX.?$G7O'VCS027EM:-:_?D,0;CV
MY]NO:M;QQX0T>\F.EQVZ[&'F7-P[DM"!SU[=/UKF=)TJ3Q_*VC^'86TO0+5C
M'<:@H^>XQT"GN#ZY[U\O4RO&RQZE3J.,>U]!2YG6YH_"6/$3R>/=6FT/0VGO
M;EAB[O)G,EM%V. >">O&:\DUKX>67@N]U#25LXYY[.X2Z>39\Q&.<'L,MTKZ
M?\.:/:_#CP\MJL*010\F4=']RW4D]<&O(/'OE:S\2KZ\M=IM;RQ:*63^%3E?
M\*[\PS#">UCA\3:ZV;.M1A5;YE>VQ[_X;AC31K=H\*K1*0!VX%7I>(^*Y_X8
M:C_:?@/2YMVYI(>H/7!(_I6]<2K'#\S;>.]>O&,*5/FAL<_*KZ%/3(_->27^
M(,1Q5QR%P*KZ."L;\<,Q(]Q5ID&>E1&4Y03I:.XD[[E'6]831-.DN)3\JC/%
M<WX1^*UKXJU,VRJ5.?E8_P 5=!XBTN/7=-DM9.!(,5S/@SX4+X9U7[1YFY4^
MX!7S>;2S%8V$J;_=]4N_F:<KMJ=<;"*>X_B)'4@]*D_LV/?NV_-TW#K4D2A/
M;/K3I)U0<GZU]9K*"UL8U6G9SUML>7?'/]HG3_@#:QQM;RWEQ)\R0J/F;UYK
M4^"/QRLOC7X?6]M8Y('SAXF'*&L#]H#]GJU^.K031WK6UQ:Y5&49K6_9[^ ]
MG\$=%>SMYYKF:4[I9'Z$^W->Q*G@WA5).\CRJ<JTZS<GI<]&,(E7YJ1(%CZ?
MK3^M*W)KR*<NAZVMK,KW<(5F;YLXKQ'0>/VPM4_[!W_QNO<;WH:\.T+_ )/"
MU3_L'?\ QNB45HSULJU^L?\ 7M_FCW.RYMU/K118_P#'LM%$=CQZ?PH\Y_:>
M_:,T7]EWX9W7BC7+>XFL+7"R+%C<03T&2!7G_@;_ (*/>"/%_B<Z/>1W7AO5
M);'[?!#J( ^T0<_,NPG^ZW7TKF_^"OO@O5OB+^QMK6CZ7:W-YJ%T5*"W7<V=
MPZ"OEG]F_P"#?BSX-?'.UN/B'H.K>-]$U_0?(T^[>/+:</GS&XQGU[?Q511]
MQ>%OVS-%\<:4U_I7A_6;K3=KE+M#&R2*HR&'S9P?<57^"_[=7AWX[>!/$6L:
M)9ZI(WAFZ>RN[7"><'5F7(!..JFOE7]GO]FCQ-\#OVA-(OOAKKGB >#O$$C?
MVMX<U$9L]/;JYB&U2H.<<D_=%=]\.OV1/&7PM_X*":Y<:3%]F^''BB+[;J"9
M&R29<D@ '^(NV<B@#ZB\=_&Z#X>_"MO%-YI>IK;PQ"4VR^7Y[9&>YQ^M;V@^
M/=/\0:1;737$=I]IC5S!-*BR0YY&[G^7K7A7_!4GP?J7B3]CGQ!I_AVSEN]8
M\K9:+$I+)\IQC]*^$O'_ ,$_'6N>(?$%U_9>N?:+?1+9+24JV[S!-"6Z>VZ@
M#]&O'O[;?AOP3\9(/!,-G?:YXBFV;X+$H1 A8C>VYA\HP?RKUJ?5K5ANCN+=
ME3(?$J[>>N3FOS!\:?!;QH?V@_%'B;P[H=Q#J%SX2@ACN?)82-,))"P!Z9(.
M/QJA??#OXBP?LVZ3K6C6_BB2\>ZL$\4:43MQ%'(IGV@CYMREP<$]* /TNUSX
ML>&O#.LV-KJ'B"Q@N=3E%O:0B0,)&)P /7-;L>N6\G[A;J-Y5/SCS%W1CU(]
M*_-GQ]^S9]L^*GPI\0>%?#^MW&AQ3O+'#= ^;83O)&Q8<#: V>H[5F^#?A7\
M3/$I\<23R>(=.\;::\CPR)D17T&>%)Q@\%1P>U 'WF?VM?#9^/\ '\.56X;6
M;J#[1',K(T3#)'8^Q[5Z>H42JW'F,OS5^9/[!WPMU*P_:K\%:S+H.HV#6^F/
M#>W$\#@M)YDIY)^HK].K6-A''O.Y@O)[F@F6J'*-K5XQ^T,=/DUZRMY=/34K
MC.$@A+B<@]<'('YFO9V3S%;G'TKY\^/FJZQI/CJS@MI/$ A4,3)!J-M AR0>
M5?DX]JSJS46KGM9+%O%:=CTV3PG:Z_\ # Z?;V;V;>3^YA=R"A^H->/_ !N_
M9O\ %GC;PCX9TW26BM9-*8M*_FR9(PW^->[?#.,3>$K/<TNYH\L&8,2<]21P
M3]*Z,6BB5FZ[A@U4=CS\5I6DO,^7_@;^RAXH\+ZMJ2>(M8^T:?J2.BJDK[H\
M@]/SJW\*_@/8_!#X@^(+:WU"XOS-9LZF:5G9 5)QS]:^D)K?RH]J*?0'^[GT
MKQ<Z!-I?Q@U^22\N;L3638,K [ %/ J:GP,BA_$CZK\T<%_P3(_Y!/CW_L.'
M^;U]3-]UOI7RU_P3*&W2O'G_ &'#_.2OJ9Q@-]*,+\"/6XH_Y&U3U7Y(=$VU
M?PIWG5&A^7FG;,CBM.IXA*C;A3+J18K=F8X4#DTTL\47;\:BEG\VU?=M/'3U
MIK<:W/GG_@I++'<?LY73*V[]_'_Z&M>I? ^59/@_X=A93G[%'_*O,/\ @I)'
M'!^SA=_* //C'';YUKTCX.2/#\%O#LB'[MHG7Z5Q4U?$'OU(VRJE)_S-'5^1
M'%+Y4BEL,,9[56NY)'U/=N3RX_TK#USQE)!<[5C9F(YP*SEU^2XL9,LL>[U!
MS7H*F[L^3E*T;/HV=3=W\5XY61L]@%K'D-GIESODW/D_*I]:IZ1<*(5\J3S+
MACW^[BF:W:2?;U:-EG;^(!Q@57(S.-2[T-?^TY-0F^:*.*3NV*T[>V'V*3;)
MYDBXSCM7,6VOK:RQP7,+%6.-Z]:Z:S862LT31M&XX_O?C6?*T=7.C6L)U?3@
MQ^]&*CLKY9)"S#=SQ5'3ED-M,S\*QZ"KF@1JD)PK$9_BJ32+-2/YCN]13J;$
MV[_=IU!04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!#<_>
M7Z&O OVTO^0IX'_["\/_ *%7OMU_#7@7[:?&I^"/^PO#_P"A5C4/8R!VQL?G
M^1[?:'_B7P_[J_\ H-<Y\3_BUI_PML(YM05G60X4+ZUT=GSI\/\ NI_Z#7#_
M !X^"K?%;2H4ANFM[B%]R[ON'ZBNS#RA&SJ;'S>:2K*FY8?XKNWWGBG[17_!
M273/AUH$-KI%A-<:E??+#_LDX]Z\@\#ZHOQ,OVUSQ]X[CLH&/FC3K5':3GG:
M24QGMP:M?M)?L(^*-9U&"XM+N.233QOVPC#/CTS]*\N@^*7CSX4Z3-;V]W,L
M<#&.6.=1&X(X(^;&?PKS,=I4YJ>QV9;4KQPS==+F/1_&$7A?Q!J,CZ#9E[38
M8C)=+\P_V^?I7QK\2O#O]I>-=5M+&-KZ*VR7EAZ)T^E>N2_&VX\9-)_:UUJT
M,#*6D6,A?,/H#CO7C_BNXDT+4[J;3[Z;2[.\R!"%/F2_[QQBNZC*J[.W-Y'R
M%2CBG7E4KVY>R=V9/@_2[5O#Q7$<KN-WS_>2NI\)>.]-T5[>.\6WF:!@!))G
M]V>V,=Z\^\,6<ESXC6W\XPR-Q@?=D/M747_PRU#PX[7E]:R1VKRHAV#E@S8-
M=..SRFN6E)<K[;7,J?+!N5/W?(^Y_"_[:D^I?LXQ23:A:JFGEK4PQ9^U2A<J
MO;;C ]<UPG@K]G6ZU[PQ?>./&49>/57/]F6KD_(F>Y//)&>M9G@W0?#^CZ+I
M<;6L+6,RQN8H?F<D <X&>>:]'UO7=6_:D^).B^$-)U*2UT#3(Q)+]J.R8E<
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MA"3N(5L#)YYKQE--N]/^+FO&XOHIDDM',<80!@-I[U%3X&9T?XD?5?FC@?\
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M?Y5Z>:T<%24)4I<NC\SCP=:IR3IUG=W5C:^.G@Z'Q5XWT>>[O='TN*]5U/\
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M\QXHPV8U%AZ:UAOH>_P?PZ\6JS]IS<J3UTMJ^Y[?_P $Y_V7=0\5^(I=>/\
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M1110 4444 %%%% !1110!#>'$>>]> _MI+F_\%Y_BU:$_K7OUT,_D<5\Q_\
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M=M\V#3YL'R#Z!L;O3^*ONER./*>/&E)5.:IJ<[\;/A+8?!?6[>&S8V^E7#*
M[MG9ST!/UKZB^$]K'8>!]-CBF:ZC:$,)>H((!QFO@WX@?%K6- \26'AGX@6]
MU!#"#Y#@95>G?VXKZ=_9._:4\/>-M(@T&/5%DU"#<D4;?>9%.!CCTQ7FX'(Y
M\DL326B;-J=2,'8]ZSBJE_:PWD3+,J/"QPP:GA?."[L[E;CFIH8R%PU:J=TG
M+N=FC5S\Z_\ @J-\1_&'PB\5V=GH>IWFBZ1<_,# QW,1R /J<5] _P#!-'XE
M>*/B5\#UNO$GVB1D.V.:8?-(/6O>/%_PXT?QO%MU2PM[Q00P$D8;D'WK0T31
M;70+!;:QMHK6WC& B*% KVZ^/HO#JG&/O")]OF)MDVJ#Q@<AJIVWA^UM)FDC
MM(8F)R65 ":\P_:C_;'\*_LJ:-'=Z\99FN/NPPX,A_.MS]G']I7P_P#M+^$Q
MK&A/((3P8I<;T^N*\NI@?:15=QV%"LT['H"1YZ5,#D48H P*5.IS!*[E<CO>
MAKP[0O\ D\+5/^P=_P#&Z]QO>AKP[0O^3PM4_P"P=_\ &Z)=#U,I_P"8C_KV
M_P T>YV/_'LM%%C_ ,>RT4H['D4_@7H2XP*7M1VH/%46&?FHSS0>M'>@ HI.
MQI10 4444 %%%% !1110!&\.]<51E\/1S2EVCA9NQ9,FM(T'K4\JW*C-QV*\
M%GY+)@*-HQQ3[B!IH9%! W=*EHJEH2W?4\DT/X2^(/#GBS7-4MKS2C-<*YMD
M$+XR0<%^>??%>$_&[XO_ ! _9HO_ .UO%7AFU\87&N8L;0:"/LPBW_*-_FL<
MGD=/>OLO!WLV?E(Q6?KOA73?$QA74+6&\%JXDC69-RJPY!&>X]:"H2<9*2Z'
MY&Q>+_C#\)]1\0WV@Z'\1_#MK-,=2N;>WNX0C+R< X(_B]:X?]G[_@H=\:/V
MC6N8]$D^*SR6LK1R(]W#Q@XS]ROVMNM$M=3L9+6XC::UF4QM$_*LOH1Z5Q7@
MOP9X!^$GB/\ L_0=-T'1=4O 3Y-E&B/(,Y)VKSUKG^KTV?13XJQDZGM9Q@WI
MO"/0_-J/XN_M$'QK8:+<77Q*M6U%@D$TE_ J$_\ ?->M^(?A3^TUHT=L8_$G
MC:Y6XD6/*:E;C9D@9/'O7WKJ'A;3]=>VDO+2&\>W?=%)(H+1'VS6B;82J-P7
M:#N V]*GZK%;7^\F7$V+D[\E/_P"/^1^=FN?#[]IC0]46U7Q!XXGRN[S$U"#
M;].E8.KP?M*:;(8WU3XA2?(7RE]#^72OTQ)3>#R&4XXXZTYU4.S97=]T$GI4
MK"Q3OK]X/B;%6LX0_P# (GY(Z@_QH^+/Q/TWP-XJA\=3)J;JZ"YO83'E3NVL
M<>BU^@&D_%7Q9\,/"6F::?AEKEY';QI:H4U"WY/3/7WKTCQ'%X:T_7;2ZU*3
M38-1=S);F>1%E+;2#MSST!KSKXR?$]]3N]$;PO=WUY,MRGGI9,98S'N'#;<@
M=^M:*$%+G6YPYAG6*QE&%"M;EAJDDE^0_6/VD/&6B:G]E;X4>(&_=M+N74+;
M:,#..O4U@7?[;7BRW.H+'\&?%4TMA&LFT7]L/-R,X'/;I7O<<DD\,#21_/)\
MS1L_W/?\*L"%8W\QL-)T^7J1VK;F1XZ5NA\W_"'_ (* :W\8/'.J>'[7X1^*
M=/O=+B\V0SW]N%?[O Y_VJ[>3]H?Q8-8:U;X8>(%94W[OM]OM/MUKK[O4O"_
MA3Q#=7DD^DVVI^47F83(LP7(ZC.?2N$O?'WBS6?V@M%CTU?M'@TQEYIX3NW$
MA@,D>^*GF3"2YMT5;G]K7Q98VTDG_"H_$S^6Y3 O[?G'?K7,>-O^"@?BCP/:
MS7%Q\$_%\UO;Q"5WCO[;Y01GUKZ5NH3)"4[D@GGWJMK-I;M82&80M;D;)A*P
M\LIT.<\=*:DD5'1:(\=^$O[7^O?&#X=6OB.P^&'B"&VNF91')?V^]-K$'//M
M5H?M/>,'TMKI?A3XB95?85.HVP;ZXS722^,_"WA/PE)9Z1J&F6*?.;=+6X1E
M+[CGA3ZYXK#_ &5K_7-8T#4&UO[?>2BZ)CENPR,%[8#<XI\U]A==$<_XI_;,
M\5>&)/WGPC\4S*HR#'?6YW>W6N,\0?\ !27Q)I^N:#I]Q\)_$FCC7[U+**XN
M;F%TB+,J[CM/3YLU]'^(/B'H^DZHUC-J%K%? $^6T@Z#KN&>!P:\5UC4KSXB
M?'?23)"VL>%XCOMWME\R"*9>>6&5X.VA2M\14[Q5['TAIYD-C#YVWSM@WXZ;
ML<XJ:FPC;&HQMXZ>E.JAH**** "BBB@ HHHH **** #%%%% !1110 4444 %
M%%% $-X/E]^:^?\ ]M2-O[4\$G/S'5H/YU] 7)Y%> _MI\ZIX'_["\/\S652
M*DN5GM</RMC8V\_R'?M9006_P_L]05GCOK$H\>/XOE[UY9J?[4%U\1/#L6DW
MFGV\<\JB-[E(6D(7V"Y.:^G?&_PVT_XD^$_L-\HVRQJ%D'\)VBN?^#_[-&A?
M"F:::&-KB=A@R.<X'7BO.G2Q2K*4'[J/D\1&NL3"UN6\KZ'SKX:\!>&_!G^E
M>%O^$CF\2MS+.UNZ*#WVED'O4?C#XC^*/%\4=CJEQ</MD$>P#YV8' R?7UKZ
MI\0^+)M>U+^R=(\P;3MGE5"!&/8UC7/PYTD^.=+M9+=9+B-&G>0C.\C!R:]2
MA4?4Y\RP\^=.F0_!WP#:Z=\/8[Z>%VOIDRSRXWKC@<U0\3BSUF^AUK0=0MEU
MW2^)X8W&)%]"/7I7>?$[1KJ]\!7UGI;>3<&(B+8.^*^+?@5\+_&^G_%Z:273
M]4ME6X)FED#".9?RQ7J8;!TITFV[:F=24J-11MK;<^V_ ?CRW\:Z)'=1KME4
M;9HR?FC?NN*WH;G?)MQA@,D5X[XB+?#7Q%'KFFHR6]P^+VT[!N[X_+\J]"\,
M?$[1O%+QK9ZC:RS2+D@."3[=>U>;5I.$O=>AZ5'%1E92>IT^<CTJ&3D_WL57
MGU2&R3]Y)NW^E0#56QMMX7)[,PZUCS1O<[":]/E6DC2;=BC)!KQOQO\ M,QZ
M=;7&D:?!))J$C^4)-PVKGC_&O5M1TZ\U>VDAN)ECAF7:P0<D?6O(M0_9=:Q\
M7?V@ETHME?S&!^]_.O%S:MBHRC/#Z+KH$ZC2YGL=?\#/AA'X.T=K^ZVW&KWQ
M,TDW=0W('X9-=S>7XTV/S),;<=/[Q]JX32?C[X9LM3_LE;Y6NH0(MO=B.,5U
M5C8-X@F6ZN&9;=N8XC^AKUL+65:DI.US&G6A/^&+#8R>([GS+DD6Z\JE+XXS
MIOA#4&15_=PG'IBMR*%8(]N %'2L#XHS^3X!U3T\DX_2NR4NQT*31F?!"V_X
MMG92*V3,GFD?4"OSU_;_ /$4=M\:-4M[*3R[C8#.<[0Z\Y7GOU%?<"_$N'X0
M?LT6>K/@R+8[XL]VV9 _.ORU^+OC+4_CMXYN]0OH7DN+^4LD< ^; /M]:VP>
M7U<1&4J*VZ]CP\\J<M*Z5V<)XM235?$]K/:M]GT^SMF9T/\ "V1GGOGDUA7E
MN7D@DME5;RY&^/RF 8$'')Z=LUT%YJ.H^)M4704T>X2:2)K:-50[FY R>*^D
M? 7["6AP> _M%U+<+JWE>>K$_P"I[?SKY_BO,L/EN'5/$2;;:V/#P.6SQ5/F
MI)PEYGSAXUU/6%TRU'B*2:WNM@?<"&-S_LMC/]*IZ+X7M]6N;34(3)H]T^W;
MY:GRX,_Q8ZY/]*[Y+&.?Q-?:3>6LVN-8S^3YQ!;R1D>QKZ.^'GPCT.^T.SMS
MID<\;8223:/E[#MZUSYIFD,-RT5!\CZ/4^FRG**E>%Z[U^X\#\)V0AEM[Z^E
MEU*YM92(GD1BK@'J/RK]0/V7/C+;_%;X<VK;8[:^@C6*6'NP48! ^@%<I\//
MV8/".J;+:32X5^Q6ZK]T?>=0<]/:O(O&T&N?L:_&"UUB"%WT"ZDVNH'RJ/\
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MRHQ:T8!1115 %%%% "-]VDW8%*_W:91RK<5];#+@!D.[[IZBN4\)C^QM?O\
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MAGC_ )#T?Z?XUW?_  JCPS_T+OA__P %\7_Q-+_PJCPS_P!"[X?_ /!?#_\
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MX9A?^0]'^G^-=Y_PJCPS_P!"[X?_ /!?%_\ $T?\*H\,_P#0N^'_ /P7Q?\
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MUQ_P9^*>C_%G]J+5M4T29[JS6R\LR;<9/R=/RKV]_A!X3*$_\(WH7T%A%_\
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*Y4_6BIW#7J?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>img62602283_22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img62602283_22.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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MHHN@"BBBF 4444 %%%!;% !13=]&^BQ/,AU%(&R:7-!04444 %%%% !1110
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M_P#A(#YSW4EQNAM,_P &T-NW#.,\CBKT/[._CJ*>WU1='OO.T7-FMF;M/.O
MPQYJMNVA1NS@D'Y3WI\TA/+\KZ8G\#X:E_X)>?M37OP7\3V+?$[0[>:\UJ1[
M=5UGS&DA\R3"O/D;>"!MQQ^%>EV/_!-O]H<_'W^U&^(F@)H*Z#+:K:F[#JUP
M8I%'R;N#N*_/VZ]J^C)OV0/'"6-UI9BF:2^<WJWL-R!:VQ))\IE9MY<;L9'R
M\'VK2_X9[\>2:I%X@&CZAYT,)LA8+>1^8VX%?,SNV[1NS@G/%3S2$L'EG_02
M_N/A6[_X)7?M4+\&K33?^%E^'[?4CKCRS1OJF[$!E=A^^S\QVX^7''3M7H>I
M?\$WOV@Y?C_XPO(/B#HL.AWVA^59PF[PT<^V7_EGNX'*_-7TG_PQ_P"./L(T
MMH;B259#>&Z^U#[.,G=Y6-V_=SUZ<&M(_L[>.DU";7IM*O?,O$^Q?8H[M/-C
M)X\TL6V[1G. <\4<\@E@\M_Z"7]Q\,S_ /!+C]J2;X<>"K%?B=HJWNF:HTNH
M_P#$XY:'S'89;/S\%1M_PKTK4/\ @E?^TQK'C3XCZE9^.-*%GJUFD>AL;KS=
MK@/]T;AY/)7GG]*^G/#?[&_BS4]1T_2M6^U6EKIDWVT:A#< I<<D^6 26SSU
M(QQ7UUX3T_[#H4,;;L@=&/(^N./RK2%WN>7C*&$@E]7JN;]+'@/_  3'^!OQ
M2^ ?[.MCH?Q6\0?\)!XB@D;?+]I,_EKV&X]?I7TE0% [45H>>%%%% !2;!2U
M&LC?W6_.DU<!^P4%1BF/-CI3?/X^8_D*7(',/X]Z./>H)+^*W'[R1$_WF JE
M>>,]*L%+2:E8Q[>2&F7/Y9S1RS#FB:HQGO3JX?4OV@_"FE.5FU:'Y>NV-F_4
M"L/4_P!K;PO9+^XDFO#_ + Q_,5I&G-D^TB>J45X?>_MLZ7%N6'2;YF'1F*[
M36/>?MMW# ^3I=NOIYA/^-5[*78GVD;'T1FC.:^8[G]M'7+MML&FZ?'[Y;_X
MJLJ\_:U\42[MK0P\_P  Z57U=D^V1]8DXIN^OCVY_:<\7W/W=3N(?]U%Y_2J
MLO[1/C23[NOW:_\ ;-/_ (FCZNQ>V1]E%SCYL#\:;\LG?\J^+Y/CIXLF^]KE
MXWX)_A5>3XO^)I&^;6+O/U'^%4L-?<3Q%MC[8\I?]JCRQ_M5\3'XM>)#_P Q
MJ[_,?X4G_"U?$G_08O/S%'U5"^M,^VMF/6@J!US7Q.GQ=\21#;_;-U^8_P *
M<GQF\31'<NM70;\#_2CZJA?66?:^Q0.*D3[M?%:?M >,(?NZ]=#_ ( O^%6;
M?]H[QE'_ ,QZZ;V,:8_]!I/#6V*CB+[GV91FOD&W_:D\70?>OO.]BH_PK1M?
MVO/$\"_-':R_[_\ ^NE]797MD?5M%?,MM^VSKT?^OTO3=O\ LLW_ ,56II_[
M;SON\_2%;G_EDVW'_?1J?92[%>TCW/H:BO#[3]MG26PLVEWRL3@D.IQ6UIO[
M6WAB[/[V2>W_ -\9_D*/92[#]I'N>K45P^G?M ^%=6*^3JT?/'((Y_$5O6/C
MK2]0*^3J%FZGMY@R:ETY![2/<VL45535([@?NV23_=<&I-[;<]/8U%I%<R)L
M8HJ%9LG!84XN6Z!OJ#3UZC]"2B@=** "BBB@ HHHH **** "BBB@ -%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $9G"KEACGO7 ZM
M^U9\.]!UHZ=>^+M'MKU9A 8GFPV\X^7I[BNRU&);JT>-GVK(I1W!^Y7Y[ZY>
M^./V'-7OK/Q9HUCX]^$NN:J)5U2Q ^V:9O90GF'+9Q)CHHX- 'Z(1:C%/;+,
MC!H74.K@\$'H:D>?:!P6SZ=J^/=;_:KU[X;?%";0]0NK1=%UW28[KPILA=)9
MI"J$1,2<$G=T '2L/Q5^T#\98_B1XDT>WU;PG9KI.A/K9WV$WFD1I(_EY\S&
M2(\=.] 'VQJ.L6^DVDL]Q(L,,*&1W8\*HZFN>^'7QC\,_&'1VU#PWJUKJ]M$
MVQWMVW!#[U\9:;\:/&GQ>^-'PKNIM9^RVFN>'[JXOK6)#Y,Q5@I]?YUR_P"S
M[\5_&OP+\*Z+JECJ.CKX<O\ Q#)9S61M'9]K&-<@AN.IZB@#]%X[A;F'*A6W
M9_&L#QAXSTKP!H37VK7D.G64;;'=GX4^@]*^6_#/[1?QA^-TO]N>!]+TAM(L
M-1>VO!=WL2[80&4L%+J<[L<5QOA/XN?$'PE\-_B]KPUK3[R?2=7EBB2]C,R
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MHX1W'W:DJ@"J'B"U6ZTVX6104:%QWXX-7ZI:Q;M<VLT<<DD<DJ% P7<%S[4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ )P*9N-//2HZ (KB3YQ_L\_6O'?VT/#6F>*_A7"NJ:DNE
M6=G>QW'VAHG8H5#<87DCGTKV*55BD\SG<PVUP'[3/@FU\<_"+5K/4+JXM[94
M\TO!"LDBX_N@D GGUHY6]@YDEJ=7X+DAG\':8T<BW$)@4K(%*AP!U /(_&N
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&8Y5VD+&J\@]2:GH **** "@444 %%%% !1110 4444 %%%% !1110 4444
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M5K/""N5>-5"L< ]5/6M#X)_L'R?#SP/XNT+6=>_M:S\7;S(B6R0B%F;=E0H
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M?"S7]/MK59#'<7"M&L[ <8^7O2^"OVB/'^N_VDVH?#'6M-2QB+1"3=NNCNP
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M+,D$>W<QZD^M=!:LK0C:<[>#QWJ2@"H;-O+5%^7N=IX'X5+Y#';ENG7%344
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MOC/I0!1\/VT6F6T=G:K&(+==F ^XICI6E4:V^Q]W3V Z_6I* "BBB@ HHHH
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M?,OS$XR.:]._9B_9=\3?!/QKXEU[7O%%AXANO$TGVB5;;339A'RQ.,NV/O4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MSXC\+:EIL?AW5(_MEO)%O\L\%E(_+FM)+#U$Y)HPI_7L'BDJ<'RMVV/S5_9
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M#8_0^ ^$Y9-AG[:5YO[B6W8-%\M25';0K!'M7I4E>2?>Q;:NPHHHH*"BBB@
MJ&[42CRSM;</NL,JP]ZFI"NZ@"C8Z;;:2/\ 1X+>UC8\B*,+N/O@5?IH0"G=
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ S1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3#@@("1CC'05[SI'[$O@/1-?T+5+;2I([KP\GEZ<P<?N V"PZ>JBM6Y_9/\
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MWYZ#=N]^OM7RCX>\;^!?C%X;O+79=:A');,&ADG42038/.W;GT[5ZC_P3?\
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MX8E\'>&K.QEU":^-N@7SYAF1_K6\MM&O10,G)^M.\OY<5K*O)PY0"%]Z<?\
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MZ!LUS&O? /PMXE)-YHUNY;KC*?\ H)%=O16D*DX[,Y:V#H55:I%,\EN/V-?
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH ****  ]*\;_ &J?]=X5_P"O]?\
MT)*]BF+",[<;NV>E>._M3MB[\)Y^\;]>><#YDH ]4BC1M.C#?,C1KE?4\5XA
M\6_VG-1M_C_9_##PC#;S>))(1>W%S=+YD-G&V"N1D9ZGC(Z5[?:G9:6O&XE
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MI<;BQKJ^KPJ*TSYG^V<3@ZWM:"L>]?#']L+1_#G[3UOK4W_$IMO%4*KJ$?\
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M=ZBFO$LMSNV@'&"2O4?6@#SW_AL3X;_]#-#_ . EQ_\ &Z/^&Q/AO_T,T/\
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*444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>img62602283_23.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img62602283_23.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M2[L5W"0H/)N?7RVSEL8/4"N\!S3 **** "BBB@ HHHH **** "BBB@ HHHH
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M(:<MGIMI#9VZXPL0Q_\ K_&M%1@=OPIH.5%:&(^<S&/&[&34BVB*A7:NTG)
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M*_>'KUJ'7?V1_A_XCUZ;4;KP[8O-<>694$2"*1D ".R8P6  &X\X ]!7I5%
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MC]O$UNQ>"479=5ZK'G)4D'!^E:4:M1RUB98K*,#&G*4<2FTG;1_YGYV^%/\
M@F]\<-*\'_$^"X\?I!<>)[N2:W'F,YO@S2$'/_+/((X[5B^)_P#@G1\9+CX'
M>!=&7Q<DE[HEZ)[J,2L-B^9GA^K<'H>*^I-1\=W_ (=NI;.[T_7(9M4;_1T2
M%VSG_GIUVGU!Z53NO']U.&T_^S-6^U6($DVZ-C$%Z_*V.3[5[T8U>5/V3^\^
M!Q5#+5.RS&*]Y;P6UK]==]#YU\8_L,_%B\_:DB\30^-(X]+%AY'GC=A7RXVA
M.G?J:R/A9^P/\7D\(_%316\5!9_$D9:Q^<GS&,@PV?X>">!ZU]'7_P 9EDT]
MM473-;-DK>6Q>W/V@O\ [GISUK=^'_C"[UL7$<6BZTLM_;E;5HX6"L<C&\C[
MM=%3VMW^Z=O4\K"X? 5*L(K,87=KI4UU>JWZ'S;\2/\ @F7\;-7^!/P^T6'Q
M="VH:+>"XN092! ,9SNZOT[UHZE_P3U^+D'[4FC^(YO&,=UI-E8107,A)&\J
MI!79T//>OIW4-<U2[MAI,>FZU]MT<E[KS$<1;0IYB;/S>@Q6;=_$"::8:P-/
MUX:?!LA8M;MY^X_[/L3SZ5SQG5O94W]YWULMRY0?_"A&]IK^&M[^Z?(.@_\
M!/+XNZ-\/_B-I]SXFB%QX@\T62EV;.7# [NJ\#I4O@;_ ()0?&KXV?#?PGX1
ML_&FGVNH:5J#SW37-P8OL\+@* K$_/CGCKS7U)=^/[K3U6WFTG5!-JB;K<")
MO+)+8 <XX..U4I/B1,+F6QBTS5UO+%G:4!&54"KG*'C.>,>N*Z7]8:]VF[^I
MPT,#E$*\95LQAR\RT<$M.77\3L_@O_P1M^+?PO\ V]M#\8Z3\2M-C\&Z?:6O
MVF+>6:XD1%211%NQRQ)#>F*Y7X3?\$<?VC?#/PD^.VDW7Q2L8KCQ=A-)07!D
MSB8ON+;OW8P0,#ICBG^%_P!L+7/ U_;^(K>W\4/'"XA^9I&?# YRN< #'//:
MO4OV9_BAJ/Q8\/>)]/5O$T.M^((XS;0(CR)EI"-S$-\I&0<8Z"O&Q&$QD/WM
M6#MJ?79/C^':_P#L]#&Q3LFEYMV:^X\A\7?\$3?VE/%G[,_PE\/:9\3K!=:\
M-7=X^J7*3%EV3S1M&0V?GV $D'KSG->]:+_P32^/&@?\%1O"_P 38_'_ )?P
M_P!.TBSM+ZVBD9?.>"R2!T,8.#ND&_)]?:ON#]E[X4ZG\'?A59Z/K&H?VC?1
MN\C."6"ACD*#[5Z0J =JPB[I,Z,7&$*TJ=)WBNO<(59(E#'<P !/J:=1THIG
M.%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M'':NDD\-:;H7QV\41>(OAKK'CCP-XZBM[KP]?VN5C0*J1>0R@AAMVX.5 Y-
M'U=8_MKZ#K_[25O\/=-AGO9)-.CU!KV)28BD@)CVGN"!G/O7&_MF_M&:K\!?
MVD/@[;OK%K8>%M:O9X=6CE@!:15AD8$2;LCD#@"N?^'O@G5/A9^V]H<UMX+U
M"V\/W7A"PTRV:/:T>F^3&%,1;DG9NQDFMK]N3PA?R_M&?!'Q5+H\]_X9\+ZO
M+-K-VL/G)9HT$BAF0 L1N(Z T =IXD_:D\$_%#X-2:YH_CS3M!MDU".TFO2T
M4LEO,"N8&1F&&.\#!(/-:&J?MF> OA^D.EW_ (BL;K6(=-6\:WCD3[1*@13N
M*!C@G<..:^4?CQ^SUJU_X:^*GB[1]'NOL/B[Q!9/I=A'%S=0QRJ[7:IC*A_<
M X6NF^$/A"YT_P#;:T/7M0T6XCT6U\%FUENIK8L@G\JUPAX^]PPH ^KM1_:'
M\,#P%I6O0ZE!<V/B!2=+,#K*U^<,P\H _.?ER0.F:^8_V;?VLKSXK^!/BO?>
M*/'%KHUMHVN"PL=0>T2-K5/WF(V0MMW#:.O>O,?A3X;\9?![P'^S3KEWX:U;
M4=*\&PRV/B"R6/=)H[N9-LK+C./G'*YJ'2/ 7B.\^ GQPAD\%:I:?V]K\=SI
M2RP+NO%(F(=1C/.0?7F@#[2\0_MA> ?AKJ*:'JOB:QFUFUTM-2EB$J>=)#A?
MWFP'N#DXX&*WD_:2\*W/@30_$5KJ$6H6/B1/,TP6C"62^7;N;RE'WRHY..@!
MKY#O/ 5_=_MPG79-#O)-(7X4'2/M,MJ63[:8^(^1]X$@?C7%Z!<:M\$_V<?V
M>;BWT/46\;>$+C4(_LNW*6(>T:-_-B +E2K?*5& >M 'Z ?"_P"./AGXPVUR
MV@ZM97]Q8/Y5[;0RAYK*4$AHY%_A8$$$'N*ZZOFO_@GSJWA.^L?%W]C1W4/B
M:XU.34=<M[BU>!H)+B1Y5 W(,CYFQC/&.]?2@Z4 %%%% !1110 445'/.MO&
MTDC+'&@RS$X 'N: )&.%..::DJN6"L&VG!QVKS?Q;\7K[Q+JS:'X*2.^U $K
M<7SH3:V0]3_>/;C/-=3\/O!Q\(:<T<EY<7UU-\\\L[ L7/7&. /0=: .AHHH
MH **** "BBB@ HHHH **** "C/-%!'- $<LRI][:!ZFA'5_X@?H:SO%OA>'Q
M=HLUC-)+&DP^_&=K*:\DT[XD>(O@/K/]G^+M^I^'I"/LFM11DFW7IMG"C[QX
M.0,8-3*5M#JP^%=9/D?O=N_H>WCK2UGZ)XCL_$=C'=6-U;W4$HRKQ.'4_B*N
M*['/S"J.62<7:1)10.E% !1110 4&BB@#B/C_P#%FW^"/PSU?Q%<A76QM7D1
M&;:'<#Y5S[G _&O/]!O?B%XE^"@\6'5[*/5KFR%_!8"P&R-64.(2V[)X.-W6
MNO\ VJ/A$?CE\&-=\.QMMN+JV+0=OWJY9/\ QX#-<#X5^*>K>&_V>AX?N=#O
M8_&EGI_V*'3&C)-W(JA X<?+M."<DUSU.9SY?(^@P$:#PT73LY\]I7[?UN<7
M<_M\'QQ^S=X=\0V%N+'4=<U)M.N%5#(+<QR2)(>W)\LC!Z;L\XYAMOBAKEW\
M;1\-%UZ\2WN(GO;:[%B/.MPREHHS\V'5".I^]T..V#I7[-VK? []G/P+X?N+
M2:_U-M??5-15$W^296D8\CC W@5Z''H-W-^W-%J<=G=0Z:VBB$7JQ?(C[&!&
M2,9''6N-NL_B/HU'+Z<)JE%/2;3\TU;];'K'CGXAI\ ?@Y>:YK4TNJ?V/:!I
MY(H0GG,.,[03MR>V3C-5K+]I715\*:;J5]YEO-?0F;[.HW.J@9)QZ#UKA?B[
M\ _$EO\ !CQQ$OB;Q%XJFU2PD2WL;T6_EH^[<"H1$YX Y8\>]<#XS\2Z[K"Z
M';+X5U>PLKK0I($N$B5IC.1(I@;@[1@+S@=:Z:N(G"5DCQ,'E.'Q$;.:DV]7
MMI9=';J>^Z_^U+X)\.Z;IMS<:Y8*NK1>=9CSEW3KZ@9_"DO?VGO"%AIRWDFJ
M6_V98_-FD$JE;53T,A!^4'IS7RO\+_ >KSZA\'1?^&;ZS70Y)HKSS8MWV;,B
M+R0/;KTYJQ\6EM],^.'C[3K72]5DT7666/4IHX_/'F;(SF,*K8^51P?<XK*6
M,FM;'=_J[A/:>R3;:3;U6U['UAK'QUT#1M$MK];Q+V"\3SHS:N),QXR7X_A
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M=49*2NCY[%8>>'JNC/=#J***HP"BBB@ HHHH **** "BBB@ ILT?G0LNYEW
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M$N+6^M]46097[+(L@_,'BOS<\!?"?2_!$$E[J=G#K&JZDN;Y[H;M^1AEZ].
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M?;-<S*.))@?F &>A 'RCUKX>\*_M<:EX3*^(M.G\0+:Z-(@=F+8C;/SC9_$
M,=!SGM7HGP&_:"U+XIZCK5B+_P 0QZUXFM)/[/A8N3<OYD9!)'"?(&ZUXN,K
M8RTJ[H^\^I^P93F?#U6<<'3Q<(3Y5I;K>UE\M3]1]+>U%A%':&-H(5"($Y4
M< 5)?6D>H6,UO-'YD<R%&4C[P/:O+OV3OA?KOPK^&_V#7+IKB\=S)M,A?R@Q
MSMR?2O5OO-UKQJ;;7.]S;&4H4:\J=*7,EM+N?)[_  W\>?L7_$>9_ /A^;Q1
M\/\ 79OM%U8*3)<Z7*?E/E!025(VG!XX^N/J#P;JLVN^&;.\N+2>QGN(P[V\
MRE9(CZ$'I6DR;N_:E5=M=%;$>U2YEKW,9U.;<6BBBL#,**** "BBB@ HHHH
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MD6J*@$[&3[RX^E#W7EL%9DW,>!G!- *SV)Z*C\PFG!LT"NAU%'>B@84449H
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 &D)R*20;ABOGO7?VD=>T[]O'3?AU&+4:'=:6;Q\QYD+
M?WOJ:YL1B8TDG+JTOO,:U:-.W-U=CMOVO/\ DB%__P!?-M_Z.2NT\ #/@O2_
M^O5/Y5Q?[7AS\$=0_P"OFV_]'I7;?#S_ )$O2_\ KV3^55'^-\CUIJ^!C?\
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MDEUI*6^F:AJ<FF8#YDC92H#].AR:Z;P_^R39Z3/!:RWBW&A:9>RW^FV+1?\
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M976GZ'9PWLBW%Y'$JS2*,!F Y/XUK1YE\1X^9+#.:EAGIV-*BBBMSS0HHHH
M**** "F[.>WY4ZB@!-N6S^%&*6B@!ABSGW]:41[1UIU% $8@4.S<?,<]*=Y?
M_P"OO3J* $ P*0Q[C_2G44 -*9H6/8FT&G44 9?BSPA8^-_#MWI.I0K<Z??1
M-#-$W1U88-</\&_V2O!/P$O6N/#.GS6LQ3RU,MP\PC'^R&.!VZ5Z910 V./9
M^=$W^J;Z&G4V;_5-]#0!Y?\ L?\ _)%[?_K]O/\ TIEKU*O+?V/_ /DB]O\
M]?MY_P"E,M>I4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !111G% !32_7VIU-+]: &-<[1R.?3/--^V_[-
M>;?M(?#+QI\2_"L%IX*\7'PC?1S!WN0FXNO=>AZUXG_PR#^T%_T72;_P'/\
MA7#6Q56$N6-)R]+?J<=7$U(2LJ;?I;]3ZS:]7/S?+Z<]37R!XL_Y2W:#Z?\
M"/$?RJU)^Q]^T S_ #?'*1F'/-MT_P#':\W^$'P]\7?#?_@IQHEEXS\4'Q9J
M?]BNRWNS:0AVX7&!_*O)QN(J3<%.FX^\MSSL5B*LW#FIN*YEN?6W[7AS\$+_
M /Z^;;_T>E=M\/3CP9I?_7LG\JXC]KO_ )(??_\ 7S;?^CTKMOA\/^*,TO\
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M]F+Q'<?#"Q\/W%G:S21_$!?$\Q\PF)K-;LR[>5SYFT<+@+_M"NO^!_P3\0?
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M$10O"@#@#VJT%Y'(_*JIQ<8VEJSES#%0Q%;GIP48[)+MYCL4445H<848HHH
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MMUL&_FE+8KS7]H']J/PW^SWHZR:E*]YJ5PXCM].LU\Z[F)](U^8CWKR#1_\
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M)INFS1H8\+)(1RI]*\ \6^)+B\EE>6ZF>21MQ^<XJOJ_CK[>\C23*TC'<_\
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M%QQ4?_!7C]C/Q)^T_P# GP/J_@6WNH_'W@W5+:YL6C CD2-_+6;<#U"JIXH
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M2^,$Y&<#I5;X9_MCR?&2;7V\/V^C^?X?U2?3)-.ED/VT>6Y4N!N PV,@8S7
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M#2E*FI3W/&S[#X?#XV=#"N\$]'ZZ_AL*GW:6A1@45N>,%%%% !1110 4444
M&*:8P?[WYT44 !BS_$W'/6@QY'?UXHHH 3R/]IN1CM[_ ./Z4JQ;<_,WY]**
M* $>'>>K?Y_S^E+L'^3110 &/([C\:&B5AS110 +'M[GICF@PYQRW'ZT44
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;>X1P+&ZXXQVJ:BB@84444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>img62602283_24.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img62602283_24.jpg
M_]C_X  02D9)1@ ! 0$!2@%*  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 3C#&(# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]%O#?ANWU
M^REN;F6<2^:5^1ASP#DY!YYK7_X5_I__ #VNO^^E_P#B:/A__P @:;_KX;_T
M%:Z:@#F?^%?Z?_SVNO\ OI?_ (FC_A7^G_\ /:Z_[Z7_ .)KIJ* .9_X5_I_
M_/:Z_P"^E_\ B:/^%?Z?_P ]KK_OI?\ XFNFHH YG_A7^G_\]KK_ +Z7_P")
MH_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\ OI?_ (FC_A7^G_\ /:Z_
M[Z7_ .)KIJ* .9_X5_I__/:Z_P"^E_\ B:/^%?Z?_P ]KK_OI?\ XFNFHH Y
MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
MOI?_ (FC_A7^G_\ /:Z_[Z7_ .)KIJ* .9_X5_I__/:Z_P"^E_\ B:/^%?Z?
M_P ]KK_OI?\ XFNFHH YG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B
M:Z:B@#F?^%?Z?_SVNO\ OI?_ (FC_A7^G_\ /:Z_[Z7_ .)KIJ* .9_X5_I_
M_/:Z_P"^E_\ B:/^%?Z?_P ]KK_OI?\ XFNFHH YG_A7^G_\]KK_ +Z7_P")
MH_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\ OI?_ (FC_A7^G_\ /:Z_
M[Z7_ .)KIJ* .9_X5_I__/:Z_P"^E_\ B:/^%?Z?_P ]KK_OI?\ XFNFHH Y
MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
MOI?_ (FC_A7^G_\ /:Z_[Z7_ .)KIJ* .9_X5_I__/:Z_P"^E_\ B:/^%?Z?
M_P ]KK_OI?\ XFNFHH YG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B
M:Z:B@#F?^%?Z?_SVNO\ OI?_ (FC_A7^G_\ /:Z_[Z7_ .)KIJ* .9_X5_I_
M_/:Z_P"^E_\ B:/^%?Z?_P ]KK_OI?\ XFNFHH YG_A7^G_\]KK_ +Z7_P")
MH_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\ OI?_ (FC_A7^G_\ /:Z_
M[Z7_ .)KIJ* .9_X5_I__/:Z_P"^E_\ B:/^%?Z?_P ]KK_OI?\ XFNFHH Y
MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
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MG_A7^G_\]KK_ +Z7_P")H_X5_I__ #VNO^^E_P#B:Z:B@#F?^%?Z?_SVNO\
MOI?_ (FC_A7^G_\ /:Z_[Z7_ .)KIJ* .9_X5_I__/:Z_P"^E_\ B:KZAX'L
M;33[F=);@O%$S@,RXR 3S\M==5+6O^0-?_\ 7O)_Z": /+EO[E5 %Q* .  Y
MHJO10!Z!\/\ _D#3?]?#?^@K735S/P__ .0--_U\-_Z"M=-0 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %4M:_Y U__ ->\G_H)J[5+6O\ D#7_ /U[R?\ H)H \FHH
MHH ] ^'_ /R!IO\ KX;_ -!6NFKF?A__ ,@:;_KX;_T%:Z:@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *I:U_R!K__ *]Y/_035VJ6M?\ (&O_ /KWD_\ 030!Y-11
M10!Z!\/_ /D#3?\ 7PW_ *"M=-7,_#__ ) TW_7PW_H*UTU !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%9WB+Q!IOA/0=0UK6;V'3=)T^![J[O+AML<,2*6
M9V/8  F@"U>WMOIMG-=W<\5K:P(9)9YG")&H&2S,>  .YKY2^*G_  5$_9_^
M%NI2:=_PDUQXNO8LB1/"]L+N-2.WG%EB;_@+GWQ7Y@_MQ?M_>*_VHO$FH:%I
M%Y/HOPPMK@K9:5#F-[Y5/RSW7.7)(W"/[J?+P6!8_:'_  3I_P""<?AC0? N
MC_$OXH:)#K_B75X4O--T74H0]MIT#?-&[Q-P\S##?,,("!C<": .UT'_ (+!
M_"C6EFN7\$_$*UTM'V_VE_94$L*#!Y<I<':>#P,]#7T-\)OVR?@Q\;8T'A/X
M@Z1<WC+N.GWDIL[L>O[F8*S8[E01[U[+'&D,:QQJJ(H"JJC  '0 5\<?MP?\
M$\?"/[1'@_4M:\(Z/I_AWXFVR-/:WMK&L$>I,.3#<A<*Q;H)#\RG&3MR* /H
M;X3_ !S\,?&C4O&<'A:Y&HVGAC51I$^HPNDEO<S>1'*YB92=RJ9-A/'S(V,C
M!/H=?GE_P1<T^YTGX)?$2QO(7MKRV\5O#-#(,-&ZVT(92.Q!!%?H;0 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[=7_ ">!\6_^Q@N/YU^OW_!*O_DQSP#_ -=M2_\ 2^XK\@?VZO\ D\#XM_\
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MI:=XST*WL;B.P4/!<RQ296Y\P-P^Q5C9"N04Y(.17N- !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %4M:_Y U__P!>\G_H)J[5+6O^0-?_ /7O)_Z": /)J***
M /0/A_\ \@:;_KX;_P!!6NFKF?A__P @:;_KX;_T%:Z:@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=PJK:#^;?I7BO_!&7P]<:G^U-K&II&WV73/#5RTDO\(>2:!%4^Y!<_\  37
M?M_?M0Q?MG?'#14\$:9J5UH.E6O]G:3;-;LUU>S.^Z201+DC<=BA>N(P3@G
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M/L]LS!?[1M6^9[?)_C##<F3C)<?Q9 !P?_!$Z=&_9U\:P@_O$\52.5] ;.V
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M3DYK^D_]E/P[=^$OV9OA7I%^C1WMIX9T])XV&"C_ &="RGZ$D?A7X]?\$_\
M]@?Q%^T1XXTGQ5XHTF?3?A?I\Z74]Q=QF/\ M?:<BW@!Y=&(P[C@+N .[%?M
MYXU\=^&_AKX>FUWQ5KFG^'-%@*I)?:E<)!"K,<*NYB!DG@#J: /P4_X*:?\
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MJ2>#YKH:A:6R%Y!:3K&6G"CDB-H%SCH)"QX4D?GO^P?^U]#^Q_\ $K6-;O\
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MBC%3R,K@X/3- '[;?\$N/^3$_AE_W$__ $Z7=?F7_P %;/\ D]+Q!_V#-/\
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M? OS8_''CG1]"OT@^TC3);E7O7C.<,MNN9""5(!VX)!H _GE_:$_Y+[\2_\
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M.Y02!YL9)9"<=UR QK]Q7\0?#+]M[X$>)M'\/>(;/Q%X;UNR>PN)K;F6RE=
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M"H^>_P#@L)^S?XI^*7@[PEX\\*Z;/K+>%Q<P:G8VD9DG%M*8V695'+*C1G<
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M 9VF^&])T>YN+FPTNRL;BX.9IK:W2-Y/]X@ G\:T:** "BBB@ HHHH ****
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MBBB@ JEK7_(&O_\ KWD_]!-7:I:U_P @:_\ ^O>3_P!!- 'DU%%% 'H'P_\
M^0--_P!?#?\ H*UTU<S\/_\ D#3?]?#?^@K734 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !5+6O^0-?_\ 7O)_Z":NU2UK_D#7_P#U[R?^@F@#R:BBB@#T#X?_ /(&
MF_Z^&_\ 05KIJYGX?_\ (&F_Z^&_]!6NFH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7=O('BEC8;E=6!P5((((XQ7R/XU_9_\ !?[1/BC]I;P_XQLK=DCU+3IK/57
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M;K_OE?\ XJC_ (6!I_\ SQNO^^5_^*KIJ* .9_X6!I__ #QNO^^5_P#BJ/\
MA8&G_P#/&Z_[Y7_XJNFHH YG_A8&G_\ /&Z_[Y7_ .*H_P"%@:?_ ,\;K_OE
M?_BJZ:B@#F?^%@:?_P \;K_OE?\ XJC_ (6!I_\ SQNO^^5_^*KIJ* .9_X6
M!I__ #QNO^^5_P#BJ/\ A8&G_P#/&Z_[Y7_XJNFHH YG_A8&G_\ /&Z_[Y7_
M .*H_P"%@:?_ ,\;K_OE?_BJZ:B@#F?^%@:?_P \;K_OE?\ XJC_ (6!I_\
MSQNO^^5_^*KIJ* .9_X6!I__ #QNO^^5_P#BJ/\ A8&G_P#/&Z_[Y7_XJNFH
MH YG_A8&G_\ /&Z_[Y7_ .*H_P"%@:?_ ,\;K_OE?_BJZ:B@#F?^%@:?_P \
M;K_OE?\ XJC_ (6!I_\ SQNO^^5_^*KIJ* .9_X6!I__ #QNO^^5_P#BJ/\
MA8&G_P#/&Z_[Y7_XJNFHH YG_A8&G_\ /&Z_[Y7_ .*H_P"%@:?_ ,\;K_OE
M?_BJZ:B@#F?^%@:?_P \;K_OE?\ XJC_ (6!I_\ SQNO^^5_^*KIJ* .9_X6
M!I__ #QNO^^5_P#BJ/\ A8&G_P#/&Z_[Y7_XJNFHH YG_A8&G_\ /&Z_[Y7_
M .*H_P"%@:?_ ,\;K_OE?_BJZ:B@#F?^%@:?_P \;K_OE?\ XJC_ (6!I_\
MSQNO^^5_^*KIJ* .9_X6!I__ #QNO^^5_P#BJ/\ A8&G_P#/&Z_[Y7_XJNFH
MH YG_A8&G_\ /&Z_[Y7_ .*H_P"%@:?_ ,\;K_OE?_BJZ:B@#F?^%@:?_P \
M;K_OE?\ XJC_ (6!I_\ SQNO^^5_^*KIJ* .9_X6!I__ #QNO^^5_P#BJ/\
MA8&G_P#/&Z_[Y7_XJNFHH YG_A8&G_\ /&Z_[Y7_ .*H_P"%@:?_ ,\;K_OE
M?_BJZ:B@#F?^%@:?_P \;K_OE?\ XJC_ (6!I_\ SQNO^^5_^*KIJ* .9_X6
M!I__ #QNO^^5_P#BJ/\ A8&G_P#/&Z_[Y7_XJNFHH YG_A8&G_\ /&Z_[Y7_
M .*H_P"%@:?_ ,\;K_OE?_BJZ:B@#F?^%@:?_P \;K_OE?\ XJC_ (6!I_\
MSQNO^^5_^*KIJ* .9_X6!I__ #QNO^^5_P#BJ/\ A8&G_P#/&Z_[Y7_XJNFH
MH YG_A8&G_\ /&Z_[Y7_ .*H_P"%@:?_ ,\;K_OE?_BJZ:B@#F?^%@:?_P \
M;K_OE?\ XJC_ (6!I_\ SQNO^^5_^*KIJ* .9_X6!I__ #QNO^^5_P#BJ/\
MA8&G_P#/&Z_[Y7_XJNFHH YG_A8&G_\ /&Z_[Y7_ .*H_P"%@:?_ ,\;K_OE
M?_BJZ:B@#F?^%@:?_P \;K_OE?\ XJC_ (6!I_\ SQNO^^5_^*KIJ* .9_X6
M!I__ #QNO^^5_P#BJ/\ A8&G_P#/&Z_[Y7_XJNFHH YG_A8&G_\ /&Z_[Y7_
M .*H_P"%@:?_ ,\;K_OE?_BJZ:B@#F?^%@:?_P \;K_OE?\ XJC_ (6!I_\
MSQNO^^5_^*KIJ* .9_X6!I__ #QNO^^5_P#BJ/\ A8&G_P#/&Z_[Y7_XJNFH
MH YG_A8&G_\ /&Z_[Y7_ .*H_P"%@:?_ ,\;K_OE?_BJZ:B@#F?^%@:?_P \
M;K_OE?\ XJC_ (6!I_\ SQNO^^5_^*KIJ* .9_X6!I__ #QNO^^5_P#BJ/\
MA8&G_P#/&Z_[Y7_XJNFHH YG_A8&G_\ /&Z_[Y7_ .*H_P"%@:?_ ,\;K_OE
M?_BJZ:B@#F?^%@:?_P \;K_OE?\ XJC_ (6!I_\ SQNO^^5_^*KIJ* .9_X6
M!I__ #QNO^^5_P#BJ/\ A8&G_P#/&Z_[Y7_XJNFHH YG_A8&G_\ /&Z_[Y7_
M .*H_P"%@:?_ ,\;K_OE?_BJZ:B@#F?^%@:?_P \;K_OE?\ XJC_ (6!I_\
MSQNO^^5_^*KIJ* .9_X6!I__ #QNO^^5_P#BJ/\ A8&G_P#/&Z_[Y7_XJNFH
MH YG_A8&G_\ /&Z_[Y7_ .*H_P"%@:?_ ,\;K_OE?_BJZ:B@#F?^%@:?_P \
M;K_OE?\ XJC_ (6!I_\ SQNO^^5_^*KIJ* .9_X6!I__ #QNO^^5_P#BJ/\
MA8&G_P#/&Z_[Y7_XJNFHH YG_A8&G_\ /&Z_[Y7_ .*H_P"%@:?_ ,\;K_OE
M?_BJZ:B@#F?^%@:?_P \;K_OE?\ XJC_ (6!I_\ SQNO^^5_^*KIJ* .9_X6
M!I__ #QNO^^5_P#BJ/\ A8&G_P#/&Z_[Y7_XJNFHH YG_A8&G_\ /&Z_[Y7_
M .*H_P"%@:?_ ,\;K_OE?_BJZ:B@#F?^%@:?_P \;K_OE?\ XJC_ (6!I_\
MSQNO^^5_^*KIJ* .9_X6!I__ #QNO^^5_P#BJ/\ A8&G_P#/&Z_[Y7_XJNFH
MH YG_A8&G_\ /&Z_[Y7_ .*H_P"%@:?_ ,\;K_OE?_BJZ:B@#F?^%@:?_P \
M;K_OE?\ XJC_ (6!I_\ SQNO^^5_^*KIJ* .9_X6!I__ #QNO^^5_P#BJ/\
MA8&G_P#/&Z_[Y7_XJNFHH YG_A8&G_\ /&Z_[Y7_ .*H_P"%@:?_ ,\;K_OE
M?_BJZ:B@#F?^%@:?_P \;K_OE?\ XJC_ (6!I_\ SQNO^^5_^*KIJ* .9_X6
M!I__ #QNO^^5_P#BJ/\ A8&G_P#/&Z_[Y7_XJNFHH YG_A8&G_\ /&Z_[Y7_
M .*H_P"%@:?_ ,\;K_OE?_BJZ:B@#F?^%@:?_P \;K_OE?\ XJC_ (6!I_\
MSQNO^^5_^*KIJ* .9_X6!I__ #QNO^^5_P#BJ/\ A8&G_P#/&Z_[Y7_XJNFH
MH YG_A8&G_\ /&Z_[Y7_ .*H_P"%@:?_ ,\;K_OE?_BJZ:B@#F?^%@:?_P \
M;K_OE?\ XJC_ (6!I_\ SQNO^^5_^*KIJ* .9_X6!I__ #QNO^^5_P#BJ/\
MA8&G_P#/&Z_[Y7_XJNFHH YG_A8&G_\ /&Z_[Y7_ .*H_P"%@:?_ ,\;K_OE
M?_BJZ:B@#F?^%@:?_P \;K_OE?\ XJC_ (6!I_\ SQNO^^5_^*KIJ* .9_X6
M!I__ #QNO^^5_P#BJ/\ A8&G_P#/&Z_[Y7_XJNFHH YG_A8&G_\ /&Z_[Y7_
M .*H_P"%@:?_ ,\;K_OE?_BJZ:B@#F?^%@:?_P \;K_OE?\ XJC_ (6!I_\
MSQNO^^5_^*KIJ* .9_X6!I__ #QNO^^5_P#BJ/\ A8&G_P#/&Z_[Y7_XJNFH
MH YG_A8&G_\ /&Z_[Y7_ .*H_P"%@:?_ ,\;K_OE?_BJZ:B@#F?^%@:?_P \
M;K_OE?\ XJC_ (6!I_\ SQNO^^5_^*KIJ* .9_X6!I__ #QNO^^5_P#BJ/\
MA8&G_P#/&Z_[Y7_XJNFHH YG_A8&G_\ /&Z_[Y7_ .*H_P"%@:?_ ,\;K_OE
M?_BJZ:B@#F?^%@:?_P \;K_OE?\ XJC_ (6!I_\ SQNO^^5_^*KIJ* .9_X6
M!I__ #QNO^^5_P#BJ/\ A8&G_P#/&Z_[Y7_XJNFHH YG_A8&G_\ /&Z_[Y7_
M .*H_P"%@:?_ ,\;K_OE?_BJZ:B@#F?^%@:?_P \;K_OE?\ XJC_ (6!I_\
MSQNO^^5_^*KIJ* .9_X6!I__ #QNO^^5_P#BJ/\ A8&G_P#/&Z_[Y7_XJNFH
MH YG_A8&G_\ /&Z_[Y7_ .*H_P"%@:?_ ,\;K_OE?_BJZ:B@#F?^%@:?_P \
M;K_OE?\ XJC_ (6!I_\ SQNO^^5_^*KIJ* .9_X6!I__ #QNO^^5_P#BJ/\
MA8&G_P#/&Z_[Y7_XJNFHH YG_A8&G_\ /&Z_[Y7_ .*H_P"%@:?_ ,\;K_OE
M?_BJZ:B@#F?^%@:?_P \;K_OE?\ XJC_ (6!I_\ SQNO^^5_^*KIJ* .9_X6
M!I__ #QNO^^5_P#BJ/\ A8&G_P#/&Z_[Y7_XJNFHH YG_A8&G_\ /&Z_[Y7_
M .*H_P"%@:?_ ,\;K_OE?_BJZ:B@#F?^%@:?_P \;K_OE?\ XJC_ (6!I_\
MSQNO^^5_^*KIJ* .9_X6!I__ #QNO^^5_P#BJ/\ A8&G_P#/&Z_[Y7_XJNFH
MH YG_A8&G_\ /&Z_[Y7_ .*H_P"%@:?_ ,\;K_OE?_BJZ:B@#F?^%@:?_P \
M;K_OE?\ XJC_ (6!I_\ SQNO^^5_^*KIJ* .9_X6!I__ #QNO^^5_P#BJ/\
MA8&G_P#/&Z_[Y7_XJNFHH YG_A8&G_\ /&Z_[Y7_ .*H_P"%@:?_ ,\;K_OE
M?_BJZ:B@#F?^%@:?_P \;K_OE?\ XJC_ (6!I_\ SQNO^^5_^*KIJ* .9_X6
M!I__ #QNO^^5_P#BJ/\ A8&G_P#/&Z_[Y7_XJNFHH YG_A8&G_\ /&Z_[Y7_
M .*H_P"%@:?_ ,\;K_OE?_BJZ:B@#F?^%@:?_P \;K_OE?\ XJC_ (6!I_\
MSQNO^^5_^*KIJ* .9_X6!I__ #QNO^^5_P#BJ/\ A8&G_P#/&Z_[Y7_XJNFH
MH YG_A8&G_\ /&Z_[Y7_ .*H_P"%@:?_ ,\;K_OE?_BJZ:B@#F?^%@:?_P \
M;K_OE?\ XJC_ (6!I_\ SQNO^^5_^*KIJ* .9_X6!I__ #QNO^^5_P#BJ/\
MA8&G_P#/&Z_[Y7_XJNFHH YG_A8&G_\ /&Z_[Y7_ .*H_P"%@:?_ ,\;K_OE
M?_BJZ:B@#F?^%@:?_P \;K_OE?\ XJC_ (6!I_\ SQNO^^5_^*KIJ* .9_X6
M!I__ #QNO^^5_P#BJ/\ A8&G_P#/&Z_[Y7_XJNFHH YG_A8&G_\ /&Z_[Y7_
M .*H_P"%@:?_ ,\;K_OE?_BJZ:B@#F?^%@:?_P \;K_OE?\ XJC_ (6!I_\
MSQNO^^5_^*KIJ* .9_X6!I__ #QNO^^5_P#BJ/\ A8&G_P#/&Z_[Y7_XJNFH
MH YG_A8&G_\ /&Z_[Y7_ .*H_P"%@:?_ ,\;K_OE?_BJZ:B@#F?^%@:?_P \
M;K_OE?\ XJC_ (6!I_\ SQNO^^5_^*KIJ* .9_X6!I__ #QNO^^5_P#BJ/\
MA8&G_P#/&Z_[Y7_XJNFHH YG_A8&G_\ /&Z_[Y7_ .*H_P"%@:?_ ,\;K_OE
M?_BJZ:B@#F?^%@:?_P \;K_OE?\ XJC_ (6!I_\ SQNO^^5_^*KIJ* .9_X6
M!I__ #QNO^^5_P#BJ/\ A8&G_P#/&Z_[Y7_XJNFHH YG_A8&G_\ /&Z_[Y7_
M .*H_P"%@:?_ ,\;K_OE?_BJZ:B@#F?^%@:?_P \;K_OE?\ XJC_ (6!I_\
MSQNO^^5_^*KIJ* .9_X6!I__ #QNO^^5_P#BJ/\ A8&G_P#/&Z_[Y7_XJNFH
MH YG_A8&G_\ /&Z_[Y7_ .*H_P"%@:?_ ,\;K_OE?_BJZ:B@#F?^%@:?_P \
M;K_OE?\ XJC_ (6!I_\ SQNO^^5_^*KIJ* .9_X6!I__ #QNO^^5_P#BJ/\
MA8&G_P#/&Z_[Y7_XJNFHH YG_A8&G_\ /&Z_[Y7_ .*H_P"%@:?_ ,\;K_OE
M?_BJZ:B@#F?^%@:?_P \;K_OE?\ XJC_ (6!I_\ SQNO^^5_^*KIJ* .9_X6
M!I__ #QNO^^5_P#BJ/\ A8&G_P#/&Z_[Y7_XJNFHH YG_A8&G_\ /&Z_[Y7_
M .*H_P"%@:?_ ,\;K_OE?_BJZ:B@#F?^%@:?_P \;K_OE?\ XJC_ (6!I_\
MSQNO^^5_^*KIJ* .9_X6!I__ #QNO^^5_P#BJ/\ A8&G_P#/&Z_[Y7_XJNFH
MH YG_A8&G_\ /&Z_[Y7_ .*H_P"%@:?_ ,\;K_OE?_BJZ:B@#F?^%@:?_P \
M;K_OE?\ XJC_ (6!I_\ SQNO^^5_^*KIJ* .9_X6!I__ #QNO^^5_P#BJ/\
MA8&G_P#/&Z_[Y7_XJNFHH YG_A8&G_\ /&Z_[Y7_ .*H_P"%@:?_ ,\;K_OE
M?_BJZ:B@#F?^%@:?_P \;K_OE?\ XJC_ (6!I_\ SQNO^^5_^*KIJ* .9_X6
M!I__ #QNO^^5_P#BJ/\ A8&G_P#/&Z_[Y7_XJNFHH YG_A8&G_\ /&Z_[Y7_
M .*H_P"%@:?_ ,\;K_OE?_BJZ:B@#F?^%@:?_P \;K_OE?\ XJC_ (6!I_\
MSQNO^^5_^*KIJ* .9_X6!I__ #QNO^^5_P#BJ/\ A8&G_P#/&Z_[Y7_XJNFH
MH YG_A8&G_\ /&Z_[Y7_ .*H_P"%@:?_ ,\;K_OE?_BJZ:B@#F?^%@:?_P \
M;K_OE?\ XJC_ (6!I_\ SQNO^^5_^*KIJ* .9_X6!I__ #QNO^^5_P#BJ/\
MA8&G_P#/&Z_[Y7_XJNFHH YG_A8&G_\ /&Z_[Y7_ .*H_P"%@:?_ ,\;K_OE
M?_BJZ:B@#F?^%@:?_P \;K_OE?\ XJC_ (6!I_\ SQNO^^5_^*KIJ* .9_X6
M!I__ #QNO^^5_P#BJ/\ A8&G_P#/&Z_[Y7_XJNFHH YG_A8&G_\ /&Z_[Y7_
M .*H_P"%@:?_ ,\;K_OE?_BJZ:B@#F?^%@:?_P \;K_OE?\ XJC_ (6!I_\
MSQNO^^5_^*KIJ* .9_X6!I__ #QNO^^5_P#BJ/\ A8&G_P#/&Z_[Y7_XJNFH
MH YG_A8&G_\ /&Z_[Y7_ .*H_P"%@:?_ ,\;K_OE?_BJZ:B@#F?^%@:?_P \
M;K_OE?\ XJC_ (6!I_\ SQNO^^5_^*KIJ* .9_X6!I__ #QNO^^5_P#BJ/\
MA8&G_P#/&Z_[Y7_XJNFHH YG_A8&G_\ /&Z_[Y7_ .*H_P"%@:?_ ,\;K_OE
M?_BJZ:B@#F?^%@:?_P \;K_OE?\ XJC_ (6!I_\ SQNO^^5_^*KIJ* .9_X6
M!I__ #QNO^^5_P#BJ/\ A8&G_P#/&Z_[Y7_XJNFHH YG_A8&G_\ /&Z_[Y7_
M .*H_P"%@:?_ ,\;K_OE?_BJZ:B@#F?^%@:?_P \;K_OE?\ XJC_ (6!I_\
MSQNO^^5_^*KIJ* .9_X6!I__ #QNO^^5_P#BJ/\ A8&G_P#/&Z_[Y7_XJNFH
MH YG_A8&G_\ /&Z_[Y7_ .*H_P"%@:?_ ,\;K_OE?_BJZ:B@#F?^%@:?_P \
M;K_OE?\ XJC_ (6!I_\ SQNO^^5_^*KIJ* .9_X6!I__ #QNO^^5_P#BJ/\
MA8&G_P#/&Z_[Y7_XJNFHH YG_A8&G_\ /&Z_[Y7_ .*H_P"%@:?_ ,\;K_OE
M?_BJZ:B@#F?^%@:?_P \;K_OE?\ XJC_ (6!I_\ SQNO^^5_^*KIJ* .9_X6
M!I__ #QNO^^5_P#BJ/\ A8&G_P#/&Z_[Y7_XJNFHH YG_A8&G_\ /&Z_[Y7_
M .*H_P"%@:?_ ,\;K_OE?_BJZ:B@#F?^%@:?_P \;K_OE?\ XJC_ (6!I_\
MSQNO^^5_^*KIJ* .9_X6!I__ #QNO^^5_P#BJ/\ A8&G_P#/&Z_[Y7_XJNFH
MH YG_A8&G_\ /&Z_[Y7_ .*H_P"%@:?_ ,\;K_OE?_BJZ:B@#F?^%@:?_P \
M;K_OE?\ XJC_ (6!I_\ SQNO^^5_^*KIJ* .9_X6!I__ #QNO^^5_P#BJ/\
MA8&G_P#/&Z_[Y7_XJNFHH YG_A8&G_\ /&Z_[Y7_ .*H_P"%@:?_ ,\;K_OE
M?_BJZ:B@#F?^%@:?_P \;K_OE?\ XJC_ (6!I_\ SQNO^^5_^*KIJ* .9_X6
M!I__ #QNO^^5_P#BJ/\ A8&G_P#/&Z_[Y7_XJNFHH YG_A8&G_\ /&Z_[Y7_
M .*H_P"%@:?_ ,\;K_OE?_BJZ:B@#F?^%@:?_P \;K_OE?\ XJC_ (6!I_\
MSQNO^^5_^*KIJ* .9_X6!I__ #QNO^^5_P#BJ/\ A8&G_P#/&Z_[Y7_XJNFH
MH YG_A8&G_\ /&Z_[Y7_ .*H_P"%@:?_ ,\;K_OE?_BJZ:B@#F?^%@:?_P \
M;K_OE?\ XJC_ (6!I_\ SQNO^^5_^*KIJ* .9_X6!I__ #QNO^^5_P#BJ/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 52UK_D
M#7__ %[R?^@FKM4M:_Y U_\ ]>\G_H)H \FHHHH ] ^'_P#R!IO^OAO_ $%:
MZ:N9^'__ "!IO^OAO_05KIJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JEK7_(&O\
M_KWD_P#035VJ6M?\@:__ .O>3_T$T >34444 >@?#_\ Y TW_7PW_H*UTU<S
M\/\ _D#3?]?#?^@K734 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ JEK7_(&O_P#KWD_]!-7:I:U_R!K_ /Z]Y/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJMEJ\/G6-Y;WL7_/2WE61?S!JU7M*2DKIZ'B2BXNTE9A1113)"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MW8#'W3\4/M ^&?BTVB[KO^R+OR5]7\E]H_/%?G__ ,$0[>)?A-\2)P1Y[ZW
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MHKF?[6\1?] J/_OK_P"RH_M;Q%_T"H_^^O\ [*@#IJ*YG^UO$7_0*C_[Z_\
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M +*C^UO$7_0*C_[Z_P#LJ .FHKF?[6\1?] J/_OK_P"RH_M;Q%_T"H_^^O\
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MHKF?[6\1?] J/_OK_P"RH_M;Q%_T"H_^^O\ [*@#IJ*YG^UO$7_0*C_[Z_\
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M +*C^UO$7_0*C_[Z_P#LJ .FHKF?[6\1?] J/_OK_P"RH_M;Q%_T"H_^^O\
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M_?7_ -E1_:WB+_H%1_\ ?7_V5=)RG345S/\ :WB+_H%1_P#?7_V5']K>(O\
MH%1_]]?_ &5 '345S/\ :WB+_H%1_P#?7_V5']K>(O\ H%1_]]?_ &5 '345
MS/\ :WB+_H%1_P#?7_V5']K>(O\ H%1_]]?_ &5 '345S/\ :WB+_H%1_P#?
M7_V5']K>(O\ H%1_]]?_ &5 '345S/\ :WB+_H%1_P#?7_V5']K>(O\ H%1_
M]]?_ &5 '345S/\ :WB+_H%1_P#?7_V5']K>(O\ H%1_]]?_ &5 '345S/\
M:WB+_H%1_P#?7_V5']K>(O\ H%1_]]?_ &5 '345S/\ :WB+_H%1_P#?7_V5
M']K>(O\ H%1_]]?_ &5 '345S/\ :WB+_H%1_P#?7_V5']K>(O\ H%1_]]?_
M &5 '345S/\ :WB+_H%1_P#?7_V5']K>(O\ H%1_]]?_ &5 '345S/\ :WB+
M_H%1_P#?7_V5']K>(O\ H%1_]]?_ &5 '345S/\ :WB+_H%1_P#?7_V5']K>
M(O\ H%1_]]?_ &5 '345S/\ :WB+_H%1_P#?7_V5']K>(O\ H%1_]]?_ &5
M'345S/\ :WB+_H%1_P#?7_V5']K>(O\ H%1_]]?_ &5 '345S/\ :WB+_H%1
M_P#?7_V5']K>(O\ H%1_]]?_ &5 '345S/\ :WB+_H%1_P#?7_V5']K>(O\
MH%1_]]?_ &5 '345S/\ :WB+_H%1_P#?7_V5']K>(O\ H%1_]]?_ &5 '345
MS/\ :WB+_H%1_P#?7_V5']K>(O\ H%1_]]?_ &5 '345S/\ :WB+_H%1_P#?
M7_V5']K>(O\ H%1_]]?_ &5 '345S/\ :WB+_H%1_P#?7_V5']K>(O\ H%1_
M]]?_ &5 '345S/\ :WB+_H%1_P#?7_V5']K>(O\ H%1_]]?_ &5 '345S/\
M:WB+_H%1_P#?7_V5']K>(O\ H%1_]]?_ &5 '345S/\ :WB+_H%1_P#?7_V5
M']K>(O\ H%1_]]?_ &5 '345S/\ :WB+_H%1_P#?7_V5']K>(O\ H%1_]]?_
M &5 '345S/\ :WB+_H%1_P#?7_V5']K>(O\ H%1_]]?_ &5 '345S/\ :WB+
M_H%1_P#?7_V5']K>(O\ H%1_]]?_ &5 '345S/\ :WB+_H%1_P#?7_V5']K>
M(O\ H%1_]]?_ &5 '345S/\ :WB+_H%1_P#?7_V5']K>(O\ H%1_]]?_ &5
M'345S/\ :WB+_H%1_P#?7_V5']K>(O\ H%1_]]?_ &5 '345S/\ :WB+_H%1
M_P#?7_V5']K>(O\ H%1_]]?_ &5 '345S/\ :WB+_H%1_P#?7_V5']K>(O\
MH%1_]]?_ &5 '345S/\ :WB+_H%1_P#?7_V5']K>(O\ H%1_]]?_ &5 '345
MS/\ :WB+_H%1_P#?7_V5']K>(O\ H%1_]]?_ &5 '345S/\ :WB+_H%1_P#?
M7_V5']K>(O\ H%1_]]?_ &5 '345S/\ :WB+_H%1_P#?7_V5']K>(O\ H%1_
M]]?_ &5 '345S/\ :WB+_H%1_P#?7_V5']K>(O\ H%1_]]?_ &5 '345S/\
M:WB+_H%1_P#?7_V5']K>(O\ H%1_]]?_ &5 '345S/\ :WB+_H%1_P#?7_V5
M']K>(O\ H%1_]]?_ &5 '345S/\ :WB+_H%1_P#?7_V5']K>(O\ H%1_]]?_
M &5 '345S/\ :WB+_H%1_P#?7_V5']K>(O\ H%1_]]?_ &5 '345S/\ :WB+
M_H%1_P#?7_V5']K>(O\ H%1_]]?_ &5 '345S/\ :WB+_H%1_P#?7_V5']K>
M(O\ H%1_]]?_ &5 '345S/\ :WB+_H%1_P#?7_V5']K>(O\ H%1_]]?_ &5
M'345S/\ :WB+_H%1_P#?7_V5']K>(O\ H%1_]]?_ &5 '345S/\ :WB+_H%1
M_P#?7_V5']K>(O\ H%1_]]?_ &5 '345S/\ :WB+_H%1_P#?7_V5']K>(O\
MH%1_]]?_ &5 '345S/\ :WB+_H%1_P#?7_V5']K>(O\ H%1_]]?_ &5 '345
MS/\ :WB+_H%1_P#?7_V5']K>(O\ H%1_]]?_ &5 '345S/\ :WB+_H%1_P#?
M7_V5']K>(O\ H%1_]]?_ &5 '345S/\ :WB+_H%1_P#?7_V5']K>(O\ H%1_
M]]?_ &5 '345S/\ :WB+_H%1_P#?7_V5']K>(O\ H%1_]]?_ &5 '345S/\
M:WB+_H%1_P#?7_V5']K>(O\ H%1_]]?_ &5 '345S/\ :WB+_H%1_P#?7_V5
M']K>(O\ H%1_]]?_ &5 '345S/\ :WB+_H%1_P#?7_V5']K>(O\ H%1_]]?_
M &5 '345S/\ :WB+_H%1_P#?7_V5']K>(O\ H%1_]]?_ &5 '345S/\ :WB+
M_H%1_P#?7_V5']K>(O\ H%1_]]?_ &5 '345S/\ :WB+_H%1_P#?7_V5']K>
M(O\ H%1_]]?_ &5 '345S/\ :WB+_H%1_P#?7_V5']K>(O\ H%1_]]?_ &5
M'345S/\ :WB+_H%1_P#?7_V5']K>(O\ H%1_]]?_ &5 '345S/\ :WB+_H%1
M_P#?7_V5']K>(O\ H%1_]]?_ &5 '345S/\ :WB+_H%1_P#?7_V5']K>(O\
MH%1_]]?_ &5 '345S/\ :WB+_H%1_P#?7_V5']K>(O\ H%1_]]?_ &5 '345
MS/\ :WB+_H%1_P#?7_V5']K>(O\ H%1_]]?_ &5 '345S/\ :WB+_H%1_P#?
M7_V5']K>(O\ H%1_]]?_ &5 '345S/\ :WB+_H%1_P#?7_V5']K>(O\ H%1_
M]]?_ &5 '345S/\ :WB+_H%1_P#?7_V5']K>(O\ H%1_]]?_ &5 '345S/\
M:WB+_H%1_P#?7_V5']K>(O\ H%1_]]?_ &5 '345S/\ :WB+_H%1_P#?7_V5
M']K>(O\ H%1_]]?_ &5 '345S/\ :WB+_H%1_P#?7_V5']K>(O\ H%1_]]?_
M &5 '345S/\ :WB+_H%1_P#?7_V5']K>(O\ H%1_]]?_ &5 '345S/\ :WB+
M_H%1_P#?7_V5']K>(O\ H%1_]]?_ &5 '345S/\ :WB+_H%1_P#?7_V5']K>
M(O\ H%1_]]?_ &5 '345S/\ :WB+_H%1_P#?7_V5']K>(O\ H%1_]]?_ &5
M'345S/\ :WB+_H%1_P#?7_V5']K>(O\ H%1_]]?_ &5 '345S/\ :WB+_H%1
M_P#?7_V5']K>(O\ H%1_]]?_ &5 '345S/\ :WB+_H%1_P#?7_V5']K>(O\
MH%1_]]?_ &5 '345S/\ :WB+_H%1_P#?7_V5']K>(O\ H%1_]]?_ &5 '345
MS/\ :WB+_H%1_P#?7_V5']K>(O\ H%1_]]?_ &5 '345S/\ :WB+_H%1_P#?
M7_V5']K>(O\ H%1_]]?_ &5 '345S/\ :WB+_H%1_P#?7_V5']K>(O\ H%1_
M]]?_ &5 '345S/\ :WB+_H%1_P#?7_V5']K>(O\ H%1_]]?_ &5 '345S/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4M:_Y U__P!>
M\G_H)J[5+6O^0-?_ /7O)_Z": /)J*** /0/A_\ \@:;_KX;_P!!6NFKF?A_
M_P @:;_KX;_T%:Z:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ML16>LOP\EZ!11178<(4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8_9'^\VE>(?]V*\M_P";J?\ V6O)>0YS@=</*_\ AE;\['L+B'),>K8F-O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "DI:* .<UCX<^%_$&XW^@:?.[=9/(59/\ OH8/ZUPFL_LO^#=1
MW&T^W:4_;R)]Z_B'#''XUZ]17G5\MP>)_BTHOY*_W[GIT,SQN%_@UI+YNWW;
M'S/K/[)%_&6;2=?M[@=DO(6BQ_P)=V?RKA=8_9]\<Z/N;^R/MT:_QV<JR9^B
MY#?I7VE17S]?A7+JOP)P]'_G<^BP_%V94?C:GZK_ "L?GKJF@ZGH<FS4=.NK
M!\XVW4#1G_QX"J-?HK+$D\;1R(LB-P589!_"N3UGX1^#=>W&\\.V.]NKP1^2
MQ^I3!KY^OP;46M"LGZJWXJ_Y'T=#C:F],11:]'?\';\SXPT?QMX@\/;1INM7
MUDB](XKA@G_?.<'\J[O1OVEO&VE[1/<VNJ(.-MW;@'\TVFO6M8_95\+7NYK"
M\U#37/1=ZRH/P89_\>KA=9_9-URVW-IFLV-\H_AN$:!C^6X?K7G_ -E9[@/X
M+=E_++3[O^ >E_:_#^8_QTKO^:.OWV_4VM&_:XC.%U;P\R^LMG.#_P".,!_Z
M%7=:/^T=X'U;:)-0FTV1NB7ENP_-EW*/SKYQUCX&^.-$W&70+BX0=&LRL^?P
M0D_F*XN\T^ZTV8PW=M-:RCK'-&4;\C37$&<8%VQ$;_XHV_*PGPYDF.5\-*W^
M&5_SN??FC^*]%\0 ?V9JUE?G^[;W".?Q .16K7YSJQ5@0<$<@BNFT;XF>*_#
M^T6/B"_A1>D;3%T'_ 6R/TKUJ'&4=J]'[G^C_P SQJ_!,M\/6^37ZK_(^\J*
M^1]'_:B\8:?M6\2QU1/XFFA\MS]"A 'Y5W6C?M;:;-A=5T&ZM?5[299A^3;<
M?F:^@H<39;6WFXOS3_2Z_$^=K\*YI0V@I+R:_6S_  /?J*\[T;X_>!M9V@:R
MME(?^6=Y$T6/^!$;?UKM]-UK3]9C\S3[^VOH\9WVTRR#\U)KWZ.+P^(_@U%+
MT:9\[7P>)PW\>FX^J:+M%%%=9QA1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 52UK_D#7_P#U[R?^@FKM4M:_Y U__P!>\G_H)H \FHHHH ]
M^'__ "!IO^OAO_05KIJYGX?_ /(&F_Z^&_\ 05KIJ "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M59O'#4_[-PVC:]ZW1=(_/\O4?1117ZD?DP4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5+6O\
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M^;7)_"'@[QM\1M T.9K?4?$?A32XKC3XI%_UBH\DT;SE!R3 D@P003D5P/\
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M^;Y+GNA$,RD'M*_J:[C_ (*8?M$OX)_8U2]\-WC07/CTV^G6LR??%I/"TTS
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M?FW5R^U?11U+'T &2?I6?<7$MY<23S2--/*Y=Y'.69B<DD]R37UU^S_\*?\
MA!]"_M748=NN:@@+*PY@B/(3ZG@G\!VK\@HTZ_$V8N<](+?RCT7J_P [L_:*
M]2APMEBA3UF]O[TNK?DORLCN_ _@VQ\!^&[31[!<QPC,DI&&ED/WG/N?T  [
M5OT45^R4Z<*,%3IJR6B/Q*I4G6FZE1WD]6PHHHK0S"BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M (FCR/%'_/Q:_D/_ (FNFHH XGQ!JVM^&=&N]4U"^M8+.U0O(^!GV &.23@
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M_P")KIJ* .9\CQ1_S\6OY#_XFCR/%'_/Q:_D/_B:Z:B@#F?(\4?\_%K^0_\
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M_P")KIJ* .9\CQ1_S\6OY#_XFCR/%'_/Q:_D/_B:Z:B@#F?(\4?\_%K^0_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MK-3ZC0?N1^+S?;T7Y^@4445]\?G84444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 C*&4JPR#P0:^;/C=^S^;/[1X@\+V^8.9
M+K38QRG<O&/3U7MVXX'TI17EYCEU#,J/LJR]'U3/6RW,\1E=;VU!^JZ->?\
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MH **** "BBB@ HHHH **** "BBB@ HHHH *I:U_R!K__ *]Y/_035VJ6M?\
M(&O_ /KWD_\ 030!Y-1110!Z!\/_ /D#3?\ 7PW_ *"M=-7,_#__ ) TW_7P
MW_H*UTU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7BOQL^
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MCV?1K^MUT'4445ZQXX4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %4M:_Y U__P!>\G_H)J[5+6O^0-?_ /7O)_Z": /)J*** /0/
MA_\ \@:;_KX;_P!!6NFKF?A__P @:;_KX;_T%:Z:@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBBBNTX0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MRFKRSU@]I=_\F6Z***]T^?"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'\->#_C?X5T?PQ%XIF:UT3Q3X<U22\TN6ZXQ:S^=%%)"YW !B"K$]@"1]*4
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MY9V\80'W..I]S71A>%,9B9>TQD^6_P#V]+_+\6<V*XNP>%C[+ T^:W_;L?\
M/\$?+OA']EWQ'K&R;69X=#MSR8S^^FQ_N@[1^+9'I7M?A'X!^#_">R3^S_[5
MNUY^T:AB3GV3&T?EGWKT:BOM\'D. P5G&'-+O+7_ ('W(^#QO$.8XZZE4Y8]
MHZ+_ #?S8U56-0JJ%51@*!@ 4ZBBOH3YL**** "BBB@ HHHH **** "BBB@
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M'YJB_>2W\O+_ #\SYKB+.'FF(Y*;_=PV\_/_ "\OF%%%%?4GR04444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MKF?^$;U?_H-R?D?\:/\ A&]7_P"@W)^1_P : .FHKF?^$;U?_H-R?D?\:/\
MA&]7_P"@W)^1_P : .FHKF?^$;U?_H-R?D?\:/\ A&]7_P"@W)^1_P : .FH
MKF?^$;U?_H-R?D?\:/\ A&]7_P"@W)^1_P : .FHKF?^$;U?_H-R?D?\:/\
MA&]7_P"@W)^1_P : .FHKF?^$;U?_H-R?D?\:/\ A&]7_P"@W)^1_P : .FH
MKF?^$;U?_H-R?D?\:/\ A&]7_P"@W)^1_P : .FHKF?^$;U?_H-R?D?\:/\
MA&]7_P"@W)^1_P : .FHKF?^$;U?_H-R?D?\:/\ A&]7_P"@W)^1_P : .FH
MKF?^$;U?_H-R?D?\:/\ A&]7_P"@W)^1_P : .FHKF?^$;U?_H-R?D?\:/\
MA&]7_P"@W)^1_P : .FHKF?^$;U?_H-R?D?\:/\ A&]7_P"@W)^1_P : .FH
MKF?^$;U?_H-R?D?\:/\ A&]7_P"@W)^1_P : .FHKF?^$;U?_H-R?D?\:/\
MA&]7_P"@W)^1_P : .FHKF?^$;U?_H-R?D?\:/\ A&]7_P"@W)^1_P : .FH
MKF?^$;U?_H-R?D?\:/\ A&]7_P"@W)^1_P : .FHKF?^$;U?_H-R?D?\:/\
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M_0;D_(_XT =-17,_\(WJ_P#T&Y/R/^-'_"-ZO_T&Y/R/^- '345S/_"-ZO\
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MNOSZT'Q-JOA>\%UI.H7&GS]V@<J&]F'0CV->U>#?VK+ZT\N#Q+IZWT?0WEF
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4-Y9P:A:S
M6MU"EQ;S*4DBD4,K*>H(/6IJ*32:LQIM.Z/DCXU? F?P1)+K&BH]SH#'+Q\L
M]H2>A]4]&[=#ZGR_P]XBU#PKJUOJ>EW+VMY"<JZ]QW!'<'N#7Z"21I-&\<B+
M)&X*LK#((/4$>E?+_P ;O@$_A_S]>\-PM)IG+W-B@RUOZLGJGM_#].GY;GG#
M\L+)XW ;+5I;KS7E^7IM^LY#Q'#%16!S!ZO1-[2\GY_GZ[^P?"7XP:?\2]/\
MMMEGK<*YGL\\-_MQYZK[=1W[$^AU^>.EZI=Z)J$%]87$EI=P-OCFC.&4_P">
MW>OKOX-_&VT^(=LFGZ@8[/Q!&OS1=$N !RR>_JO;J..GM9%Q#'&I8;%.U3H^
MDO\ @_GT/#X@X;E@6\5A%>GU76/_  /RZ]SU.BBBON3X$**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *I:U_R!K_\ Z]Y/_035VJ6M?\@:_P#^O>3_ -!- 'DU
M%%% 'H'P_P#^0--_U\-_Z"M=-7,_#_\ Y TW_7PW_H*UTU !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %9OB+Q!8^%=%NM4U*806=LF]V/4^@ [DG@#U-7YIH[:&2:9UBB
MC4N\CG"JH&22>PKXY^.'Q<D^(FL_8[&1DT"S<^2O3SWZ&5A_(=A]37@YQFL,
MKP_.]9OX5^OHCZ')<HJ9MB.1:07Q/R[>K_X)S7Q)^(5]\1_$DNI768K=?DM;
M7.5ACSP/<GJ3W/M@5U?P*^$3_$#5_P"T=1C9= LW'F9X^T..?+!].FX^G'?(
MYCX8_#F]^)/B2/3[?=%:1X>[NL<11_\ Q1Z ?T!K[;T'0[+PUI%KIFG0+;V=
MLFR.-?YGU).23W)KX'(\KJ9KB'CL9K&]]?M/_)?\ _1,_P VIY1AU@,%I.UM
M/LK_ #?_  >Q=CC2&-8XU5(U 5548  Z "G445^N'XT%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %5=2TNRUFS>UO[2&]MG^]#<1AT/X&K5%*45)6:NAQDXN\79GB?C+]
MEO0=8WSZ%<R:)<GGR6S+ 3]"=R_@2!Z5X3XR^#?BKP/ODOM-:XLU_P"7RSS+
M%CU.!E1_O 5]Q45\GCN&<#B[RIKV<O+;[MONL?88#BK'X.T:C]I'SW^_?[[G
MYTQR/#(KQLR.IRK*<$'U!KT_P;^T5XL\+;(;J==<LEX\J^),@'M)][/^]N^E
M?0_C+X&^$O&>^6;3QI]ZW/VJPQ$Q/JRXVM]2,^]>$^,OV8_$F@[Y](>/7K0<
M[8_W<X'NA.#_ ,!))]*^*JY-FV3R=7"MM=X_K'_AT?=4L\R?.H*EBXI/M+])
M?\,SV7P;^T5X3\5;(;JX;0[UN/*OB!&3[2?=_/'TKT^.19HU=&5T895E.01Z
M@U^=]Y8W.FW+V]W;RVMQ&</#,A1U/H0>170^$?B5XD\#R+_9.J30P Y-K(=\
M+>OR'C\1@UZ."XNJ4WR8V%_-:/YK;\CS,=P;2J+VF J6\GJOD]_S/O&BO ?!
MO[5EA=[(/$NGM8R=#=V8,D7U*?>7\-U>UZ#XFTKQ19BZTG4+?4(.[0.&V^Q'
M4'V-?>X/,\)CU?#U$WVV?W;GYYC<KQF7NV(IM+ONOO6AIT445ZAY04444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9OB+Q!9>%=$N]5
MU&7R;2U3>[=SZ*!W). !ZFOAKQ[XVO?'_B:ZU>].TR';##G*PQC[J#Z?J23W
MKOOVA/BM_P )EK?]BZ;-G1=/<@LIXN)AP6]U'('XGN*XWX8_#ZZ^(_BB#38=
MT5JO[RZN .(HP>?Q/0#U/H#7Y%GV8SS7%1P.%UBG;3[4O\E_FS]EX>RRGE&$
MEC\7I)J^OV8_YO\ R1Z+^S?\*?[>U)?$^IPYTZS?%I&XXFF'\7^ZO_H7T-?4
MU5-)TNUT/3;:PL85M[2WC$<4:]%45;K]%RK+H99AE1CJ]V^[_K8_-,WS.IFN
M*=>6D=DNR_S[A1117L'BA1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !5+6O\ D#7_ /U[R?\ H)J[5+6O^0-?_P#7O)_Z": /)J*** /0/A__ ,@:
M;_KX;_T%:Z:N9^'_ /R!IO\ KX;_ -!6NFH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBO&?V
M@/C#_P (?I[:#I$W_$[ND_>RH>;6,CK[.1T]!SZ5PXW&4L!0E7K/1?B^R._
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MF(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ JEK7_ "!K_P#Z]Y/_ $$U=JEK7_(&O_\ KWD_]!- 'DU%
M%% 'H'P__P"0--_U\-_Z"M=-7,_#_P#Y TW_ %\-_P"@K734 %%%% !1110
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M***]$\T**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *X[QE\)/"_CD.^HZ9&EVW_+Y;?NIL^I8?>_X$#78T5A6H4L1#V=:*DNS5
MS>CB*N&G[2C)Q?=.Q\L>,OV6-9TO?/X>NX]7@'(MYL13CV!/RM^8^E>-:MHM
M_H-X]IJ5E/8W*]8KB,HWUYZCWK]#*SM<\.Z9XFLS:ZK86]_;G^">,-CW'H?<
M5\3CN$L/6O+"RY'V>J_S7X^A]Y@.,<31M#%QYUW6C_R?X>I\)^&/&VN^#;CS
MM&U.XL23ED1LQO\ [R'*G\17N'@W]J[_ %<'B?3/8WFG_P VC)_4'\*T_&7[
M*FFWWF3^&[]M.EZBUNR9(?H&^\OX[J\*\8?##Q+X&=CJNERQVX.!=1?O(3_P
M,<#Z'!]J^6]GG.0.ZOR+_MZ/_ _!GUGM,CXB5I6YWW]V7_!_%'VGX7\<:%XR
MM_.T;4X+X 9:-&Q(G^\APP_$5N5^=EI>3Z?<1W%K/);7$9RDL+E64^H(Y%>M
M>#?VF?$WA[9!JHCUZT7C]\=DX'M(!S_P($^]?28'BZC4M'&0Y7W6J^[=?B?,
M8_@VM3O/!3YEV>C^_9_@?7-%>>>#?CQX2\9;(DOO[,O6X^RZAB,D^BMG:?SS
M[5Z%7W.'Q-'%0YZ$U)>1\#B,+7PD_9UX.+\T+11172<H4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?I&M>'G@T^_=M,MY D;)<%[488+U?)7<<9-?0O[,?Q>U/X[?!'P_XTUK0/\
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M#[VT+0[#PSHFGZ/I5I'8:7I]O':6MK",)#$BA411V 4 #Z5\"_M+>!!\8/\
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M\Y_^"+:W'B#2_C/XPU$_:-5UC5[47%TP^9WVS2OS[M,3^- 'T!;_ +07B_\
M9[^/GA?X8?&#6;#Q+H?C17'AKQK;V*Z>XNE8*UG=PJQCR2\861,<R)D?,2OT
M3\2/B%HGPG\!Z[XP\1W7V/1-&M'O+J4#+;5'W5'=F.%4=R0.]?"?_!:C3S;_
M  /^'OB*W+0ZAIOBE8(+F,X>/S+::3(/8YMT/_ :P/\ @J9\8K_7OV)?A0Z,
M(CXVEL-1O I(W1BS\_9C'3S'C;_@ H ]V^$?BWX]_M/_  ]'Q,T7Q9H_POTG
M4GDE\.>&YM#74?/MD<A)+Z=W# R%3_J0N%(8;LXKO_V2_P!J&+]HGP_K^GZO
MIT?AWXB>$KY])\2:%')N6"X1F3S8B>3$[(X&>058$G 9N]^ 6AQ^&?@7\.])
MBB6&.Q\.Z?;B-1C&VVC!_45\!_"+6I?AS_P66^(_ART)BL?$UM*)X0?E9VL8
M;[?CGG<K<_[9]<4 ?IS1110 4444 %%%1S7$5N 994B!Z;V S^= $E%5?[4L
M_P#G[@_[^+_C1_:EG_S]P?\ ?Q?\: +5%5?[4L_^?N#_ +^+_C1_:EG_ ,_<
M'_?Q?\: +5%5?[4L_P#G[@_[^+_C1_:EG_S]P?\ ?Q?\: +5%5?[4L_^?N#_
M +^+_C1_:EG_ ,_<'_?Q?\: +5%5?[4L_P#G[@_[^+_C1_:EG_S]P?\ ?Q?\
M: +5%5?[4L_^?N#_ +^+_C1_:EG_ ,_<'_?Q?\: +5%5?[4L_P#G[@_[^+_C
M1_:EG_S]P?\ ?Q?\: +5%5?[4L_^?N#_ +^+_C1_:EG_ ,_<'_?Q?\: +5%5
M?[4L_P#G[@_[^+_C1_:EG_S]P?\ ?Q?\: +5%5?[4L_^?N#_ +^+_C1_:EG_
M ,_<'_?Q?\: +5%5?[4L_P#G[@_[^+_C1_:EG_S]P?\ ?Q?\: +5%5?[4L_^
M?N#_ +^+_C1_:EG_ ,_<'_?Q?\: +5%5?[4L_P#G[@_[^+_C1_:EG_S]P?\
M?Q?\: +5%5?[4L_^?N#_ +^+_C1_:EG_ ,_<'_?Q?\: +5%5?[4L_P#G[@_[
M^+_C1_:EG_S]P?\ ?Q?\: +5%5?[4L_^?N#_ +^+_C1_:EG_ ,_<'_?Q?\:
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M$OQ $D#PZ/:D-=W"\<=HU_VC^@R?0'[1T^PM]+L8+.TA2WM8$$<448PJJ!@
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M@_[^+_C0!:HJK_:EG_S]P?\ ?Q?\:/[4L_\ G[@_[^+_ (T 6J*J_P!J6?\
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MXO\ C0!:HJK_ &I9_P#/W!_W\7_&C^U+/_G[@_[^+_C0!:HJK_:EG_S]P?\
M?Q?\:/[4L_\ G[@_[^+_ (T 6J*J_P!J6?\ S]P?]_%_QH_M2S_Y^X/^_B_X
MT 6J*J_VI9_\_<'_ '\7_&C^U+/_ )^X/^_B_P"- %JBJO\ :EG_ ,_<'_?Q
M?\:/[4L_^?N#_OXO^- %JBJO]J6?_/W!_P!_%_QH_M2S_P"?N#_OXO\ C0!:
MHJK_ &I9_P#/W!_W\7_&C^U+/_G[@_[^+_C0!:IKHLB,CJ'1A@JPR"/2J_\
M:EG_ ,_<'_?Q?\:/[4L_^?N#_OXO^- 'G?C+]GGPGXLWS06QT6];GSK$!4)_
MVH_N_E@^]>$^,OV<?%?A?S)K.)==LEY\RS!\T#WC/.?]W=7UU_:EG_S]P?\
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M\_<'_?Q?\: +5%5?[4L_^?N#_OXO^-']J6?_ #]P?]_%_P : +5%5?[4L_\
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M\_<'_?Q?\: +5%5?[4L_^?N#_OXO^-']J6?_ #]P?]_%_P : +5%5?[4L_\
MG[@_[^+_ (T?VI9_\_<'_?Q?\: +5%5?[4L_^?N#_OXO^-']J6?_ #]P?]_%
M_P : +5%5?[4L_\ G[@_[^+_ (T?VI9_\_<'_?Q?\: +5%5?[4L_^?N#_OXO
M^-']J6?_ #]P?]_%_P : +5%5?[4L_\ G[@_[^+_ (T?VI9_\_<'_?Q?\: +
M5%5?[4L_^?N#_OXO^-']J6?_ #]P?]_%_P : +5%5?[4L_\ G[@_[^+_ (T?
MVI9_\_<'_?Q?\: +5%5?[4L_^?N#_OXO^-']J6?_ #]P?]_%_P : +5%5?[4
ML_\ G[@_[^+_ (T?VI9_\_<'_?Q?\: +5%5?[4L_^?N#_OXO^-']J6?_ #]P
M?]_%_P : +5%5?[4L_\ G[@_[^+_ (T?VI9_\_<'_?Q?\: +5%5?[4L_^?N#
M_OXO^-']J6?_ #]P?]_%_P : +5%5?[4L_\ G[@_[^+_ (T?VI9_\_<'_?Q?
M\: +5%5?[4L_^?N#_OXO^-']J6?_ #]P?]_%_P : +5%5?[4L_\ G[@_[^+_
M (T?VI9_\_<'_?Q?\: +5%5?[4L_^?N#_OXO^-']J6?_ #]P?]_%_P : +5%
M5?[4L_\ G[@_[^+_ (T?VI9_\_<'_?Q?\: +5%5?[4L_^?N#_OXO^-']J6?_
M #]P?]_%_P : +5%5?[4L_\ G[@_[^+_ (T?VI9_\_<'_?Q?\: +5%5?[4L_
M^?N#_OXO^-']J6?_ #]P?]_%_P : +5%5?[4L_\ G[@_[^+_ (T?VI9_\_<'
M_?Q?\: +5%5?[4L_^?N#_OXO^-']J6?_ #]P?]_%_P : ,3QYX!TKXB:(^GZ
MG%\PRT%R@_>0/_>4_P QT-?&?Q ^'NJ_#G6FL-2CW1MEK>Z0?NYU]1Z'ID=1
M^1/W/_:EG_S]P?\ ?Q?\:QO%VA^'_&^BS:7JSV\]O)RK"50\;=G0]B/_ ->1
M7RV=9'3S2'M(>[56S[^3_P ^A];D>?U<JG[.?O4GNNWFO\NI\C?"GXMZE\,]
M3^3==Z1,P^TV1/!_VT]&'Y'H>Q'V/X9\3Z;XOT>#4]*N5N;28<$=5/=6'8CT
MKXK^)'PWO?AWK!@DE2]T^0DVU["05<>C8^ZP]/RR*3X;_$S5?AKK NK)O.M)
M"!<V3MA)E_HP[-V]QD5\3E6<5\FJO!XU/D7WQ\UW7_#KS^ZS?)</GE%8W M<
M[6_27D^S_P"&?E]U45S?A'XA:'XTT6+4=/O8PC##PRN%DB;NK#/!_0]JVO[4
ML_\ G[@_[^+_ (U^MTZD*T%4INZ>S/QVI3G1FZ=16DMTRU157^U+/_G[@_[^
M+_C1_:EG_P _<'_?Q?\ &M#(M455_M2S_P"?N#_OXO\ C1_:EG_S]P?]_%_Q
MH M455_M2S_Y^X/^_B_XT?VI9_\ /W!_W\7_ !H M455_M2S_P"?N#_OXO\
MC1_:EG_S]P?]_%_QH M455_M2S_Y^X/^_B_XT?VI9_\ /W!_W\7_ !H M455
M_M2S_P"?N#_OXO\ C1_:EG_S]P?]_%_QH M455_M2S_Y^X/^_B_XT?VI9_\
M/W!_W\7_ !H M455_M2S_P"?N#_OXO\ C1_:EG_S]P?]_%_QH M455_M2S_Y
M^X/^_B_XT?VI9_\ /W!_W\7_ !H M455_M2S_P"?N#_OXO\ C1_:EG_S]P?]
M_%_QH M455_M2S_Y^X/^_B_XT?VI9_\ /W!_W\7_ !H M455_M2S_P"?N#_O
MXO\ C1_:EG_S]P?]_%_QH M455_M2S_Y^X/^_B_XT?VI9_\ /W!_W\7_ !H
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MH M455_M2S_Y^X/^_B_XT?VI9_\ /W!_W\7_ !H M455_M2S_P"?N#_OXO\
MC1_:EG_S]P?]_%_QH M455_M2S_Y^X/^_B_XT?VI9_\ /W!_W\7_ !H M455
M_M2S_P"?N#_OXO\ C1_:EG_S]P?]_%_QH M455_M2S_Y^X/^_B_XT?VI9_\
M/W!_W\7_ !H M455_M2S_P"?N#_OXO\ C1_:EG_S]P?]_%_QH M455_M2S_Y
M^X/^_B_XT?VI9_\ /W!_W\7_ !H M455_M2S_P"?N#_OXO\ C1_:EG_S]P?]
M_%_QH M455_M2S_Y^X/^_B_XT?VI9_\ /W!_W\7_ !H M455_M2S_P"?N#_O
MXO\ C1_:EG_S]P?]_%_QH M44BL& (.0>012T %%%% !1110 4444 %%%% !
M5+6O^0-?_P#7O)_Z":NU2UK_ ) U_P#]>\G_ *": /)J*** /0/A_P#\@:;_
M *^&_P#05KIJYGX?_P#(&F_Z^&_]!6NFH **** "JR:E:2:A-8)=0M?0Q)/+
M:K(#*D;EU1V7.0K&.0 G@E&QT-6:^7_C'X>^-/@?]IZQ^*'P\\,Z?XZ\(7?A
MFW\/ZUX<_M..ROF>&ZN9EGB:4"/*"XP 7^;,@('RM0!\P?M"?L'Q?&+XM?''
MQA\-[U_"/CSPGJMA=Z;:Z<OD073-IEM<.%\L!HYVE9G61>K,=PYW+])_\$V_
MVEM>_:8_9[_M/Q45G\2Z%J#Z/>7RJ%^VA8XY$F(' 8K(%;'!*$\;L#S[0OBM
M\7/$WCSX\6'PZ^$FL:;XMUJ_TZ-KSQ1>V=K::$W]EVT7F3&.=VE8 &15B#94
MH3@Y4>W_ ++W[.B_L>_L\-X7T.%O%OB-?.U2\\J1;<:E?NBC8C2';&F(XXP6
M[+N/)- 'H'QF^+EE\(_#,5U]BFUSQ#J4WV'0O#]F1]IU2\8$K$G]U0 6>0_*
MB*S'ISRO[-_P&F^%5IK_ (G\47%OK'Q/\877]H^)-6@!\L/_ ,L[2WSR+>%3
ML0'DX)/4 ?'K>'_VZ5^+FL?$)/A]X+N=8NHC9Z>NHZA!<+I-GG)M[;_2%"!B
M 7?&YR!DX"J.FF;]OOQ]);>'=9TOPGX-T34IX[74=<T6>W^UVEJ[!9I(LSN0
MP0L057=D#&#0!#_P6G\&W.L?L]^%/$%O;M,FBZ^J7#J/]5%/"Z[C[;UC7ZL*
M^VO@WK$/B'X0^!]4MW62"^T.QN8W3H5>W1@1^!JM\4/@[X>^+/PBUKX<ZS"_
M]@:E8"P(5B7A"@&*12<Y9&5'!.>5&<U\]_!6^^-G[-WPNMOA;>?"N]^(E[H"
M/9>'O$VCZI9P:??6VXF'[4)IEEMRBD*0J2<*,9ZD ^?/@YI4GQ _X+,?$;7K
M1?,M/#MO<//+V5DLX+';]=SGCT!]*F_X)MZ*_P ./VXOVC?!=Y%]ENHWGFAA
M;AF@2^.QQ_LE)XV^C"OK']CW]EN?X :7XH\1>*+^WUOXF>-K]]6\1:E:@^0D
MC.[BW@R,^6K2.<G!8MG  4#FOC=^SUXG\*?M):%^T+\+M*BU_P 01VATOQ-X
M7>Y2V;5[,IL62&5R$$R!8_E<A6$2<@@[@#(_X*S:U%I?[%/BBVD;:^I:AI]I
M&/[S"Y2;'Y0L?PKTK]@SPA<^!OV/?A5I5Y'Y-PVCK>M&>J_:7>X /H<2C(['
M->:?%WX0^-?VXO$W@_2/&/@_4/AQ\(O#]\NKZA9ZS=VTFIZW=*I5(5CMY9%A
MA4-("[/N(?A0<$?4?CI==T_X>Z^O@RUM7\20:7.-&M;C"0&Z6)O(1N@";PH[
M#'I0!=\7:&OB;PIK6CO@IJ%E-:-GIB2-D_K7YX_\$5VET?P7\6_#%]&;;5M)
MUV W5J_$D3-&\9##V:!Q^!KZN_8VU+XV:I\(Y)OCQ8V]CXP&HS+ (1 LCV@5
M-C2+ 3&K;_, QCY0I([GSC4O@7XM_9S_ &G/$GQ>^&OAJ3QIX7\;0;/%'A6R
MNH;>]M[H.'%Y;&9TCDW,7+1LRG,CD9R-H!Y-_P %K]4#?!/X>Z%&&DO+[Q+]
MHBA0$L_EVTJ' [G,ZC\:P?\ @JC\);[P_P#L4_"-!;^;)X-FL=,O&C^80H;(
MPEL_W?,CC7/JPKWF^^!/BO\ :E_:$\(?$;XE^&Y/!G@7P+NF\.^%+^YAN+^^
MO&=6-S=B%WBB0&.+$8=B3&,D D'Z*^,'PLT3XV_#'Q'X&\11L^D:W:-;2M']
M^-LADD7_ &D=5<9XRHS0 OP;UB'Q#\(? ^J6[K)!?:'8W,;IT*O;HP(_ U^=
M_P '-*D^('_!9CXC:]:+YEIX=M[AYY>RLEG!8[?KN<\>@/I7T'\%;[XV?LW?
M"ZV^%MY\*[WXB7N@(]EX>\3:/JEG!I]];;B8?M0FF66W**0I"I)PHQGJ>T_8
M]_9;G^ &E^*/$7BB_M];^)GC:_?5O$6I6H/D)(SNXMX,C/EJTCG)P6+9P %
M /HFBBB@ HHHH *I:EI%MJ\:)<H75#D88C^57:* ,+_A"])_YX-_W\;_ !H_
MX0O2?^>#?]_&_P :W:* ,+_A"])_YX-_W\;_ !H_X0O2?^>#?]_&_P :W:*
M,+_A"])_YX-_W\;_ !H_X0O2?^>#?]_&_P :W:* ,+_A"])_YX-_W\;_ !H_
MX0O2?^>#?]_&_P :W:* ,+_A"])_YX-_W\;_ !H_X0O2?^>#?]_&_P :W:*
M,+_A"])_YX-_W\;_ !H_X0O2?^>#?]_&_P :W:* ,+_A"])_YX-_W\;_ !H_
MX0O2?^>#?]_&_P :W:* ,+_A"])_YX-_W\;_ !H_X0O2?^>#?]_&_P :W:*
M,+_A"])_YX-_W\;_ !H_X0O2?^>#?]_&_P :W:* ,+_A"])_YX-_W\;_ !H_
MX0O2?^>#?]_&_P :W:* ,+_A"])_YX-_W\;_ !H_X0O2?^>#?]_&_P :W:*
M,+_A"])_YX-_W\;_ !H_X0O2?^>#?]_&_P :W:* ,+_A"])_YX-_W\;_ !H_
MX0O2?^>#?]_&_P :W:* ,+_A"])_YX-_W\;_ !H_X0O2?^>#?]_&_P :W:*
M,+_A"])_YX-_W\;_ !H_X0O2?^>#?]_&_P :W:* ,+_A"])_YX-_W\;_ !H_
MX0O2?^>#?]_&_P :W:* ,+_A"])_YX-_W\;_ !H_X0O2?^>#?]_&_P :W:*
M,+_A"])_YX-_W\;_ !H_X0O2?^>#?]_&_P :W:* ,+_A"])_YX-_W\;_ !H_
MX0O2?^>#?]_&_P :W:* ,+_A"])_YX-_W\;_ !H_X0O2?^>#?]_&_P :W:*
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M?XT?\(7I/_/!O^_C?XUNT4 87_"%Z3_SP;_OXW^-'_"%Z3_SP;_OXW^-;M%
M&%_PA>D_\\&_[^-_C1_PA>D_\\&_[^-_C6[10!A?\(7I/_/!O^_C?XT?\(7I
M/_/!O^_C?XUNT4 87_"%Z3_SP;_OXW^-'_"%Z3_SP;_OXW^-;M% &%_PA>D_
M\\&_[^-_C1_PA>D_\\&_[^-_C6[10!A?\(7I/_/!O^_C?XT?\(7I/_/!O^_C
M?XUNT4 87_"%Z3_SP;_OXW^-'_"%Z3_SP;_OXW^-;M% &%_PA>D_\\&_[^-_
MC1_PA>D_\\&_[^-_C6[10!A?\(7I/_/!O^_C?XT?\(7I/_/!O^_C?XUNT4 8
M7_"%Z3_SP;_OXW^-'_"%Z3_SP;_OXW^-;M% &%_PA>D_\\&_[^-_C1_PA>D_
M\\&_[^-_C6[10!A?\(7I/_/!O^_C?XT?\(7I/_/!O^_C?XUNT4 87_"%Z3_S
MP;_OXW^-'_"%Z3_SP;_OXW^-;M% &%_PA>D_\\&_[^-_C1_PA>D_\\&_[^-_
MC6[10!A?\(7I/_/!O^_C?XT?\(7I/_/!O^_C?XUNT4 87_"%Z3_SP;_OXW^-
M'_"%Z3_SP;_OXW^-;M% &%_PA>D_\\&_[^-_C1_PA>D_\\&_[^-_C6[10!A?
M\(7I/_/!O^_C?XT?\(7I/_/!O^_C?XUNT4 87_"%Z3_SP;_OXW^-'_"%Z3_S
MP;_OXW^-;M% &%_PA>D_\\&_[^-_C1_PA>D_\\&_[^-_C6[10!A?\(7I/_/!
MO^_C?XT?\(7I/_/!O^_C?XUNT4 87_"%Z3_SP;_OXW^-'_"%Z3_SP;_OXW^-
M;M% &%_PA>D_\\&_[^-_C1_PA>D_\\&_[^-_C6[10!A?\(7I/_/!O^_C?XT?
M\(7I/_/!O^_C?XUNT4 87_"%Z3_SP;_OXW^-'_"%Z3_SP;_OXW^-;M% &%_P
MA>D_\\&_[^-_C1_PA>D_\\&_[^-_C6[10!A?\(7I/_/!O^_C?XT?\(7I/_/!
MO^_C?XUNT4 87_"%Z3_SP;_OXW^-'_"%Z3_SP;_OXW^-;M% &%_PA>D_\\&_
M[^-_C1_PA>D_\\&_[^-_C6[10!A?\(7I/_/!O^_C?XT?\(7I/_/!O^_C?XUN
MT4 87_"%Z3_SP;_OXW^-'_"%Z3_SP;_OXW^-;M-9EC4LQ"J.I)P*-M6!B?\
M"%Z3_P \&_[^-_C1_P (7I/_ #P;_OXW^-6[CQ)I-GGS]3LXL=GG4'^=9EQ\
M2/#5KG?JT3?]<U9__00:\FOF^787^/B81]9Q7YLZH87$5/@IM^B98_X0O2?^
M>#?]_&_QH_X0O2?^>#?]_&_QK"N/C)X>ASL-U<?]<X<?^A$5F7'QSL5SY&F7
M$GIYCJG\LU\_7XVX=P_QXR#]+R_])3.Z&3X^IM2?ST_,[#_A"])_YX-_W\;_
M !H_X0O2?^>#?]_&_P :\[N/CI>-GR-*@C_ZZ2L_\@*R[CXS>(9L[!:6_P#U
MSB)_]")KYZOXG<.4?@J2GZ0?_MW*=T.'<?+>*7J_\KGK'_"%Z3_SP;_OXW^-
M'_"%Z3_SP;_OXW^->)W'Q,\2W6=VJ2(/2-$3^0K+N/%&L7G^NU6\D'HT[8_+
M-?/U_%S+8_P,-.7KRQ_)R.Z'"^(?QU$O2[_R/?9?".C0+ND3RU_O-*0/YUFW
M%KX0M,^=?VJ$?PF[&?RS7@<DCRMN=F=O5CDTVOGZ_B_7E_ P:7K-O\HH[X<*
MP7QU6_16_5GM_P#:7@7S-GV^//\ OOC\\8K2M=/\)WV/L]Y;3'^ZEV"?RS7S
M]17%1\7,QC+]]AH->3DOS<OR-9<+X=KW*C7W/_(^DE\&:0R@B%B#R")&_P :
M7_A"])_YX-_W\;_&OG.VOKFS.;>XE@/_ $S<K_*MBU\?>(K/'EZO=-C_ )ZO
MYG_H6:^EP_B]@Y?[SA)1_P ,E+\U$\^IPM57\.JGZIK_ #/=/^$+TG_G@W_?
MQO\ &C_A"])_YX-_W\;_ !KR.U^,7B*WQYDEO=?]=80/_02*V;7XZ7:X^TZ5
M#+Z^5*4_F#7T^'\3N':_\2<J?^*+_P#;>8\ZIP[CX?"E+T?^=CT/_A"])_YX
M-_W\;_&C_A"])_YX-_W\;_&N4M?CAI4F!<6%W"?^F>UQ_,5LVOQ8\-76 U\T
M#>DL+C]0"*^HP_&'#^*_AXV'S?+_ .E6/-J95CJ?Q4G\E?\ (TO^$+TG_G@W
M_?QO\:/^$+TG_G@W_?QO\:FM?%VB7V!#JUF['^'SE#?D3FM6.1)E#(RNIZ,I
MR*^FH8K#XI7H5%)>33_(\Z=.I3TG%KU1B?\ "%Z3_P \&_[^-_C1_P (7I/_
M #P;_OXW^-;M%=1F87_"%Z3_ ,\&_P"_C?XT?\(7I/\ SP;_ +^-_C6[10!A
M?\(7I/\ SP;_ +^-_C1_PA>D_P#/!O\ OXW^-;M% &%_PA>D_P#/!O\ OXW^
M-'_"%Z3_ ,\&_P"_C?XUNT4 87_"%Z3_ ,\&_P"_C?XT?\(7I/\ SP;_ +^-
M_C6[10!A?\(7I/\ SP;_ +^-_C1_PA>D_P#/!O\ OXW^-;M% '+ZI\-?#^M6
M,MG>69F@D&"K2-^8YX/O7RE\6O@[J'PTU#S4WWFAS-B"\QRI_N28Z-[]#V[@
M?:M5=3TRTUK3Y[&^MX[JTG4I)#(,JPKY_-\GHYK3UTFMG^C\OR/H\FSNME-3
M36F]X_JNS_/J?!/A;Q1>>$]5CO;0A@"!+ Y.R5?[K8_GU%?7/P\U+PI\2-%%
M[I\;).F!<6CRGS(&]#SR#S@]_KD#P+XR?!&[^'MP^HZ<)+OP_(W$G5[8GHK^
MWHWX'GKP7A7Q9J?@O6H=4TJX-O<Q\'NLB]U8=U/I_6OSO 9CBN'L0\+BHODZ
MK]8_UKZGZ5F&6X3B3#+%862Y^C_27]:>A]R?\(7I/_/!O^_C?XT?\(7I/_/!
MO^_C?XUB?"WXK:9\3-*\R BUU2%1]IL6;+)_M+_>4^O;H:[BOURAB*6*IJM1
ME>+/QK$8>KA:LJ-:-I+=&%_PA>D_\\&_[^-_C1_PA>D_\\&_[^-_C6[170<Y
MA?\ "%Z3_P \&_[^-_C1_P (7I/_ #P;_OXW^-;M% &%_P (7I/_ #P;_OXW
M^-'_  A>D_\ /!O^_C?XUNT4 87_  A>D_\ /!O^_C?XT?\ "%Z3_P \&_[^
M-_C6[10!A?\ "%Z3_P \&_[^-_C1_P (7I/_ #P;_OXW^-;M% &%_P (7I/_
M #P;_OXW^-'_  A>D_\ /!O^_C?XUNT4 87_  A>D_\ /!O^_C?XT?\ "%Z3
M_P \&_[^-_C6[10!A?\ "%Z3_P \&_[^-_C1_P (7I/_ #P;_OXW^-;M% &%
M_P (7I/_ #P;_OXW^-'_  A>D_\ /!O^_C?XUNT4 87_  A>D_\ /!O^_C?X
MT?\ "%Z3_P \&_[^-_C6[10!A?\ "%Z3_P \&_[^-_C1_P (7I/_ #P;_OXW
M^-;M% &%_P (7I/_ #P;_OXW^-'_  A>D_\ /!O^_C?XUNT4 87_  A>D_\
M/!O^_C?XT?\ "%Z3_P \&_[^-_C6[10!A?\ "%Z3_P \&_[^-_C1_P (7I/_
M #P;_OXW^-;M% &%_P (7I/_ #P;_OXW^-'_  A>D_\ /!O^_C?XUNT4 87_
M  A>D_\ /!O^_C?XT?\ "%Z3_P \&_[^-_C6[10!A?\ "%Z3_P \&_[^-_C1
M_P (7I/_ #P;_OXW^-;M% &%_P (7I/_ #P;_OXW^-'_  A>D_\ /!O^_C?X
MUNT4 87_  A>D_\ /!O^_C?XT?\ "%Z3_P \&_[^-_C6[10!A?\ "%Z3_P \
M&_[^-_C1_P (7I/_ #P;_OXW^-;M% &%_P (7I/_ #P;_OXW^-'_  A>D_\
M/!O^_C?XUNT4 87_  A>D_\ /!O^_C?XT?\ "%Z3_P \&_[^-_C6[10!A?\
M"%Z3_P \&_[^-_C1_P (7I/_ #P;_OXW^-;M% &%_P (7I/_ #P;_OXW^-'_
M  A>D_\ /!O^_C?XUNT4 87_  A>D_\ /!O^_C?XT?\ "%Z3_P \&_[^-_C6
M[10!A?\ "%Z3_P \&_[^-_C1_P (7I/_ #P;_OXW^-;M% &%_P (7I/_ #P;
M_OXW^-'_  A>D_\ /!O^_C?XUNT4 87_  A>D_\ /!O^_C?XT?\ "%Z3_P \
M&_[^-_C6[10!A?\ "%Z3_P \&_[^-_C1_P (7I/_ #P;_OXW^-;M% &%_P (
M7I/_ #P;_OXW^-'_  A>D_\ /!O^_C?XUNT4 87_  A>D_\ /!O^_C?XT?\
M"%Z3_P \&_[^-_C6[10!A?\ "%Z3_P \&_[^-_C1_P (7I/_ #P;_OXW^-;M
M% &%_P (7I/_ #P;_OXW^-'_  A>D_\ /!O^_C?XUNT4 87_  A>D_\ /!O^
M_C?XT?\ "%Z3_P \&_[^-_C6[10!A?\ "%Z3_P \&_[^-_C1_P (7I/_ #P;
M_OXW^-;M% &%_P (7I/_ #P;_OXW^-'_  A>D_\ /!O^_C?XUNT4 87_  A>
MD_\ /!O^_C?XT?\ "%Z3_P \&_[^-_C6[10!A?\ "%Z3_P \&_[^-_C1_P (
M7I/_ #P;_OXW^-;M% &%_P (7I/_ #P;_OXW^-'_  A>D_\ /!O^_C?XUNT4
M 87_  A>D_\ /!O^_C?XT?\ "%Z3_P \&_[^-_C6[10!A?\ "%Z3_P \&_[^
M-_C1_P (7I/_ #P;_OXW^-;M% #8T$<:HO"J,"G444 %%%% !1110 4444 %
M%%% !5+6O^0-?_\ 7O)_Z":NU2UK_D#7_P#U[R?^@F@#R:BBB@#T#X?_ /(&
MF_Z^&_\ 05KIJYGX?_\ (&F_Z^&_]!6NFH **** "BBB@"C9Z'IVFZAJ%]::
M?:VM[J+I)>W,,*I)<NB"-&D8#+E455!;. H'05>HHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "N5^(_Q L/ASX;FU*[(DG/R6UJ#AII.P
M]@.I/8>^ =GQ!KUCX8T>ZU349UM[.V3>[G] !W). !W)KXD^)GQ$OOB1XDEU
M&YW16J92UM<Y$,>>G^\>I/?Z 5\OGN<1RRCRP_B2V\O-_IW?S/J^'\EEFM?F
MJ:4H[OOY+]>R^1B^)/$5_P"+-:NM5U*8SW=P^YF[#T4#L . /:O</V<_@[]L
MDA\6:U!^X0[M/MY!]]A_RU(]!_#ZGGL,\?\  SX1O\0M8^WZA&RZ!9N/-/3[
M0_41@^G=CZ<=\U]APPI;Q)%$BQQHH5448"@<  >E?*<.9/+%3_M#%ZJ]U?J^
M[_K5GU_$V=1PM/\ LW!Z.UG;HOY5Y_DOP?1117ZF?DH4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M445'-<Q6R[II4B7U=@!^M3*2BKR=D-)O1$E%8USXRT*S_P!;J]F#_=696/Y
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MDH?&X_.7_!+UQ\:M>FR(X;. =ML;$_JU9=Q\4?$USD'4C&OI'$B_KC-;5O\
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MCS[^SB'_ $SW/_,"O:**^AH>%W#U'XU.?K+_ .143AGQ)CI;67HO\[GE5O\
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M/_/E_>B?]2:W_/\ 7W/_ #/ORBO@K_A9/B[_ *&G6O\ P83?_%4?\+)\7?\
M0TZU_P"#";_XJK_URH?\^7]Z(_U)Q'_/Z/W,^]:*^$E^+'C)5 'B?5./6Z8_
MUI?^%L>,_P#H9]4_\"6_QJO]<<-_SZE^!/\ J3BO^?L?Q/NRBOAB+XQ>-H5V
MKXEU C.?FEW'\S3_ /A='C?_ *&2]_[Z'^%5_KCA/^?<OP_S)_U*QG_/V/X_
MY'W)17P]#\;?',+;E\279.,?.%8?D14W_"]O'G_0Q3_]^HO_ (FJ7&&#ZTY?
MA_F0^"\=TJ0_'_(^VZ*^)%^/'CQ6!'B*;CUAB/\ [+5G_AH;X@_]#!_Y)6__
M ,;JEQA@>L)_<O\ Y(E\%X_I4A]\O_D3[2HKXM_X:&^(/_0P?^25O_\ &ZGC
M_:/\>H@!U:)R/XFM(LG\EJEQ?@/Y)_<O_DB7P9F/\\/O?_R)]ET5\;?\-(^/
M/^@G!_X"1?\ Q-20_M+>.8\[KVUES_?M4X_("J7%V7_RR^Y?YDO@W,?YH?>_
M\C[%HKX^_P"&F_&__/>R_P# 4?XTZ/\ :>\;(X8RV,@_NM;#!_(U7^MN7=I?
M<O\ ,G_4[,N\?O?^1]?T5\C_ /#4OC/_ )Y:7_X#M_\ %T?\-2^,_P#GEI?_
M (#M_P#%U7^MF7?WON_X)'^I^9_W?O\ ^ ?7%%?)X_:O\78_Y!^BG_MA-_\
M':7_ (:P\7?] [1?^_$W_P =JO\ 6K+>[^XG_5'-.T?O/J^BOE:+]K+Q,J_O
M-)TEV]5251^6\UV'A7]J[2KS9%KVF3::YX-Q:GSH_J5X8#Z;JZ:/$F65I<OM
M+>J:_'8YJW"^:48\WL^;T:;^[<]YHK%\.>--"\70^9H^JVU^,9*1O\Z_[R'Y
MA^(K:KZ.%2%6*G3::?5:GS%2G.E)PJ1::Z/0****T,PHHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI&8*I).
M.237"^)OC?X-\*EDN-8CN[A?^6%C^_;Z$K\H/U(KGK8BCAH\]::BO-V.FAAJ
M^*ER4(.3\E<[NBN>\#^.M*^(6C-J>D/(UNLI@=9HRC*X )!'T8=,CFNAK2G4
MA6@JE-W3V:,ZM*=&;IU%:2W3"BBBM#(**** "BBB@ HHHH *I:U_R!K_ /Z]
MY/\ T$U=JEK7_(&O_P#KWD_]!- 'DU%%% 'H'P__ .0--_U\-_Z"M=-7,_#_
M /Y TW_7PW_H*UTU !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !3)IDMXGEE=8XT4LSL<!0.22?2GU\T_M&?&+[9)-X3T6?\
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M O\ S'_K32_Y]/[SY@HKZ?\ ^$=TK_H&6?\ X#I_A1_PCNE?] RS_P# =/\
M"C_B$.*_Z#(_^ O_ ##_ %II?\^G]Y\P45]/-X;TB12K:59,IZ@VZ$?RJ/\
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MPSX<K_!3E#_#-_\ MW,>C3XBQ\-Y)^J7Z6/G&Z^'?B2SSYFDSMC_ )Y8D_\
M02:Q[K2;ZQS]IL[BWQU\V)E_F*^IJ*^8Q'A%@9?[MBIQ_P 24ORY3TJ?%-9?
MQ*2?HVO\SY/H!*D$'!KZBNM"TV^S]IT^UG_ZZ0JW\Q6-=?#7PU>9W:7&A]8F
M9/Y&OE\1X1YC#_=L5"7JI1_+F/1I\44'_$IM>EG_ )'@]KXDU:QQ]GU.[A [
M).P'Y9K9M?BAXEM, :DTJ_W98T;]2,_K7H]U\%="FR8I;RW/8+(&'ZC^M8UU
M\"AR;;5_HLL']0W]*\__ %-XVRS_ '2I)I?R5;?@W'\C?^ULGQ'\6*^<?^ S
M)M?C9K4.!/;6=P/78RM^AQ^E<S=P^ =>U![K4_"#6LLAW2/I]VZJQ/?R^%'X
M5TEU\%-<AR89[.X7MAV4_JN/UK!U/X>^(=)0O/IDK1_WH<2C\=I./QKEQ&,X
MXP,?]LISG"/\]-5%]_*[>MT=6'_LOF;PM10D_P"63B_NNC<T?X7_  DUK:L*
M/%*>/*N+N6-L^G+8/X9K<?\ 9G\#2,66VO$4]%6Z;'ZUY*P*D@C!'!!K5TGQ
M5J^A$?8=0F@4?\L]VY/^^3Q^E>IEOB+@U:&:9?!_WH))_P#@+_\ DD&(R_,-
M\-C)^DFW^/\ P#T/_AF/P1_SPO?_  */^%1S?LO^"I,;1J$6/[ER.?S4U7T?
MXWWL.U-2L8[I>\D)\MOKCD']*[?1_BAX>U?:OVS[%*?^6=T-G_CWW?UK]7RS
M/N$,VM&DX1D^DURO\='\FSYK$2S_  NLJDVNZ=_Z^9QG_#+7@S_GKJG_ ($+
M_P#$4V3]E?P<Z%1/JL9/\2W"9'YI7K\4R3QK)&ZR(W(93D'\:?7W"R;+9*ZH
MQMZ'D?VYF:?\>7WGBW_#)_A'_H(ZU_W_ (?_ (U1_P ,G^$?^@CK7_?^'_XU
M7M-%+^P\M_Y\(K^WLT_Y_P CPT_LF>',G&L:H!VYC_\ B*/^&2_#O_08U3_R
M'_\ $U[E14?V#EG_ #Y7X_YE_P"L.:?\_P!_A_D>#R_LDZ(S?N]=OT7T:-&/
M\A3/^&2-(_Z#][_WY2O>Z*G_ %?RS_GROO?^97^L>:_\_P!_<O\ (\!E_9'T
MQE'E>(;M&SU:W5A_,5%_PR+9_P#0RS_^ :__ !=?0=%2^'<K?_+G\9?YE+B7
M-E_R_P#PC_D?/;?LB6FT[?$TP..";,'_ -GJO_PR#_U-O_E-_P#MM?1E%2^&
M\J?_ "Y_&7^92XGS=?\ +[_R6/\ D?.?_#(/_4V_^4W_ .VU7D_9$N@Q">)X
M67L6LB#^6^OI2BI?#65?\^O_ ":7^92XHS=?\OO_ "6/^1\U?\,BWG_0RP?^
M ;?_ !=13?LCZDN/*\16K^N^W9?ZFOIJBI_U9RO_ )]_^32_S+7%6;?\_?\
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M>&'B[J*L?E&-Q4L;B9XF2LY.]@HHHKL.(**** "BBB@ HHHH *I:U_R!K_\
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MD"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/^Z&/\A4,GQ0\,1G!U13_NPR'^2URRX@R>'Q8RDO^XD/\S58'%RVI2_\!?\
MD=517'-\6O#*L0+YW'J('Q^HJ%OC%X<7.);AL>D)YKDEQ5D,=\;3_P# XO\
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MA04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_)@*\<\5?LV^+_#^^6SABUNV7G=9M^\Q[HV#GV7-?-/+L[R=\U!MQ_NNZ_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%9MYXETG3\_:=2M82/X6F4'
M\LYK"O/BOX:L\@7K7+#^&&)C^I 'ZUXN*SO*\#_O.)A#UE%/[KW.RG@\36_A
MTV_DSKZ*\RO/CE81Y^R:9<3^GG.L?\MU8-Y\;M7FR+:SM+<>K!G8?J!^E?'X
MKQ%X;PNBQ'.^T8R?XV2_$]6GD.85/L6]6O\ ASVNBOG>\^)OB2]R&U)XE_NP
MHJ8_$#/ZUA7FL7^H9^U7MQ<Y_P">TK-_,U\?BO%S+X?[KAIS_P 34?RYCU:?
M"]>7\2HEZ7?^1])7GB;2=/S]IU.TA(_A:9=WY9S6%>?%CPW9Y"WCW+#M#$Q_
M4@#]:^?ZD@MY;I]D,3RO_=C4L?TKY'$>+.:UGRX3#PC?OS2?YQ_(]2GPQAH*
M]6HW]R_S/7KSXYV*9^R:9<3>GG.L?\MU85Y\;M7FR+:SM+<>K!G8?J!^E<Q9
M^ _$-_CRM(N0#T,J>6/S;%;MG\&?$%Q@S&UM!W$DNX_^.@UQ?VYQ[F_\&-11
M?\M/E7_@7*OS-?J>287XW&_G*_X7_0S+SXF>)+[.[4WB7^["BIC\0,_K6>_C
M'7I&R=9OP?\ 9N7'\C7H-G\"QP;O5B?588?ZD_TK47X(Z'@9N]0)[_O$_P#B
M*I<(<<8[]Y7J23_O5?\ *3#^U,GH^["*^4?^ CR-O$FKNQ9M4O6)ZDW#_P"-
M0-JU\P(-Y<$'J#*W^->U+\&?#ZL"6O&'H91_A4Z?!_PVK9,$[CT:9OZ57_$-
M^**OQUH_.<O\F+_6#+8[1?W+_,\(>XED7:\KL/1F)J.OH&/X3^&$SG3VD_WI
MY/Z-4T?PQ\,1K@:4A'^U+(?YM37A/GD]9UJ7_@4W_P"V!_K-@X[0E]R_S/GB
MBOHY?AYX<50!I%OCWR?ZU,O@?P^N,:/9\>L*FNB/A'FGVL337_@7^2,WQ1AN
ME.7X?YGS717TVOA71(V#+H^GJP[BU0'^53QZ#IL9RFG6J'_9@4?TKKCX0XM_
M%BXK_MUO]49/BFETI/[SY=HKZHCT^UBR$MH4'^S&!_2IDC6-=J*%7T48%=4?
M!^;^+')?]P[_ /MZ,GQ4NE'_ ,F_X!\K+:SLH*PR$'H0IJ=='U!F %C<DGH!
M"W^%?4E%=<?!^E]K&M_]N+_Y)F;XJETH_C_P#YA3PSK$C;4TJ^8^BVSG^E31
M^#=>DSC1KX8_O6[K_,5],45UQ\(L"OBQ<W\DO\S)\4UNE)?>SYNC\ ^(I%R-
M(NA_O)C^=3+\-_$KJ"-)EQ[LH/\ .OHNBNJ/A)E/VL14?_@/_P BS-\48KI"
M/X_YGSVOPK\4-C_B68!];B+_ .*J=?A%XE9@#:Q*/4SKC^=>^T5UQ\)\BCO4
MJO\ [>C_ /(&3XFQK^S'[G_F>$1_!OQ$S8*VJ>[3?X"IH_@GKSYS/8I_O2O_
M $2O<:*ZH^%O#\=^=_\ ;W^21D^),<^WW?\ !/%4^!^L%?GOK%3Z*SG_ -EJ
M9?@;J&T9U.V![X1C7LE%=<?#/AN.]*3_ .WY?HS-\0Y@_M+[D>1+\"9]PW:Q
M&!WQ;D_^S5,GP(4-\^MEE]%M<'_T.O5Z*ZH^'7#$?^86_P#V_4_^2,GGV8O_
M )>?A'_(\OC^!=J,[]6F8?[,(']34T?P-TT#Y]1NV/\ LA1_2O2J*ZX\!<-0
MVP:^^3_.1D\[S!_\O7]R_P C@[7X,:!!CS&N[@]_,E '_CH%:MK\-?#5KC9I
M4;GUE=G_ )DUT]%>MA^%\CPO\+!T_G%-_>TV<T\RQE3XJLOO9G6OAW2K''V?
M3;2$CO' H/YXK050J@ 8 X %-DE2%"\CK&@ZLQP!6+?>._#>FY^U^(-+MO::
M]C4_JU>]"GA\+&T(J"\K(\^I5<M:DOO9NT5P=]\=? 6GY\WQ-:-C_G@'E_\
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M,?;/$\\WJ(+-8_YNU'U7.:V[E_X%;]0]CC9[W^\\ OOB%XIU+/VKQ'JTX/\
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M^"+^RU_/^'_!/S4HK]*Z9-#'<+MEC61>NUP"*G_5K_I]_P"2_P#!%_9?]_\
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MGY^T^&M6@ S\SV,H''4YVXH_M3-*?QQ^^/\ PP?6\7'XE^!];6O[37P_N/\
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M5_:RN8=D7B+2$N%Z&YT]MC?BC'!/_ A6SXJ_9/TVZW2^']5FL9.HM[P>;']
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M#/V//VJM%_:V^$T/BFPMETK6+64V>KZ1YOF&TG R"K8!9'4AE./4=5-?%?\
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M"^(VI^(/V)?@*UQ</YGB06.JWO\ TU==/#<GTW3DX]0#VKM_^"SEQ<:[\/\
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M3_S^+_WRW^%3?\(_IO\ SXP?]\"C_A']-_Y\8/\ O@4 0_\ "5Z3_P _B_\
M?+?X4?\ "5Z3_P _B_\ ?+?X5-_PC^F_\^,'_? H_P"$?TW_ )\8/^^!0!#_
M ,)7I/\ S^+_ -\M_A1_PE>D_P#/XO\ WRW^%3?\(_IO_/C!_P!\"C_A']-_
MY\8/^^!0!#_PE>D_\_B_]\M_A1_PE>D_\_B_]\M_A4W_  C^F_\ /C!_WP*/
M^$?TW_GQ@_[X% $/_"5Z3_S^+_WRW^%'_"5Z3_S^+_WRW^%3?\(_IO\ SXP?
M]\"C_A']-_Y\8/\ O@4 0_\ "5Z3_P _B_\ ?+?X4?\ "5Z3_P _B_\ ?+?X
M5-_PC^F_\^,'_? H_P"$?TW_ )\8/^^!0!#_ ,)7I/\ S^+_ -\M_A1_PE>D
M_P#/XO\ WRW^%3?\(_IO_/C!_P!\"C_A']-_Y\8/^^!0!#_PE>D_\_B_]\M_
MA1_PE>D_\_B_]\M_A4W_  C^F_\ /C!_WP*/^$?TW_GQ@_[X% $/_"5Z3_S^
M+_WRW^%'_"5Z3_S^+_WRW^%3?\(_IO\ SXP?]\"C_A']-_Y\8/\ O@4 0_\
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M3_S^+_WRW^%3?\(_IO\ SXP?]\"C_A']-_Y\8/\ O@4 0_\ "5Z3_P _B_\
M?+?X4?\ "5Z3_P _B_\ ?+?X5-_PC^F_\^,'_? H_P"$?TW_ )\8/^^!0!#_
M ,)7I/\ S^+_ -\M_A1_PE>D_P#/XO\ WRW^%3?\(_IO_/C!_P!\"C_A']-_
MY\8/^^!0!#_PE>D_\_B_]\M_A1_PE>D_\_B_]\M_A4W_  C^F_\ /C!_WP*/
M^$?TW_GQ@_[X% $/_"5Z3_S^+_WRW^%'_"5Z3_S^+_WRW^%3?\(_IO\ SXP?
M]\"C_A']-_Y\8/\ O@4 0_\ "5Z3_P _B_\ ?+?X4?\ "5Z3_P _B_\ ?+?X
M5-_PC^F_\^,'_? H_P"$?TW_ )\8/^^!0!#_ ,)7I/\ S^+_ -\M_A1_PE>D
M_P#/XO\ WRW^%3?\(_IO_/C!_P!\"C_A']-_Y\8/^^!0!#_PE>D_\_B_]\M_
MA1_PE>D_\_B_]\M_A4W_  C^F_\ /C!_WP*/^$?TW_GQ@_[X% $/_"5Z3_S^
M+_WRW^%'_"5Z3_S^+_WRW^%3?\(_IO\ SXP?]\"C_A']-_Y\8/\ O@4 0_\
M"5Z3_P _B_\ ?+?X4?\ "5Z3_P _B_\ ?+?X54O&\,:?G[2^G0$?PR.@/Y9K
M"O/&O@BSR!Y-PP_AAMR?U( _6O&Q6=99@?\ >L3"'K**?W7N==/!XBM_#IM^
MB9U'_"5Z3_S^+_WRW^%'_"5Z3_S^+_WRW^%>=7GQ2\.1Y^R^'VG_ .NH2,?I
MNK!O/B>\N1;:'IUN/5T+D?J!^E?'XKQ$X;PNGUCG?:,9/\;)?B>K3R',*G_+
MNWJU_P .>Q_\)7I/_/XO_?+?X4?\)7I/_/XO_?+?X5\_WGC#4[S.7AA7^[#
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MJ_\ @;+_ /%5]8_\,L^!/^?>^_\  H_X4R;]E7P-(H"IJ,1SG<EUS].5-/\
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M._Z"6N?]_P"'_P"-4?\ #(?@[_H):Y_W_A_^-4?V3F:VE_Y,'U/%=_Q/G/\
MX6]XV_Z&G5?_  *;_&C_ (6]XV_Z&G5?_ IO\:^A&_9 \,[CMUC5@N> 6B)_
M/93?^&/_  U_T&M5_.+_ .(H_LO-/YO_ "87U3%]_P 3P"'XR>.(6W+XHU,G
MI\\Y8?D:F_X7=X[_ .AGOO\ OH?X5[S_ ,,?^&O^@UJOYQ?_ !%13?L>Z$S#
MRM>U%!CD.D;?R H_LS-5M)_^!?\ !']5Q??\3PO_ (7=X[_Z&>^_[Z'^%'_"
M[O'?_0SWW_?0_P *]P_X8[T?_H8;[_ORE'_#'>C_ /0PWW_?E*/[-S;^9_\
M@7_!%]5QG=_>>+I\?/'\:A1XEN" ,?-'&3^96E_X7_\ $#_H9)_^_,7_ ,17
MLDW['>ELO[KQ'>(WJ]NC#\LBH?\ ACBS_P"AHG_\ U_^+H^H9Q_,_P#P/_@C
M^KXWN_O_ .">0_\ "_\ X@?]#)/_ -^8O_B*DA_:$^(4+;E\1R$XQ\]O"P_(
MI7K7_#'%G_T-$_\ X!K_ /%TA_8WM,''BF8'M_H0_P#BZ/J.<=Y?^!_\$7U?
M&]W]_P#P3RS_ (:0^(O_ $,7_DE;?_&Z/^&D/B+_ -#%_P"25M_\;KTK_AC3
M_J</_*9_]NH_X8T_ZG#_ ,IG_P!NH^IYUWE_X'_]L'L<=W?_ (%_P3S7_AI#
MXB_]#%_Y)6W_ ,;JPG[3/Q!50#J\+D#[S6<.3^2UZ%_PQI_U.'_E,_\ MU02
M?L;W0<A/%4++V+6)!_+S#1]4SI=9?^!_\$/8X[N_O_X)YI??M _$"_)W^(YH
MQZ00Q1X_[Y45S]]\2/%FI9%SXEU:93P5:]DV],=,XKWJR_8XM5 -WXHFE/<0
MV83]2YKH+']DGP?;D&>]U:[/=6FC5?T3/ZT?V9FM;^))_.7_  6'U7%S^)_B
M?)%U>7%[)ON)Y)W_ +TKEC^M0U]N67[-OP^L\;M%>Y8?Q37<Q_0,!^E;UG\'
M?!%C_JO"^F'_ *ZP"3_T+-7'AW$RUG-?B_T*66U7\4D? M6[;2;Z\Q]GLKB?
M/3RXF;^0K]!K;P5H%GC[/HMC!CIY=NJ_R%6O^$?TW_GQ@_[X%=<>&_YZOX?\
M$V65]Y_@? MK\/?$MYCR]$O%_P"NL1C_ /0L5LV7P5\5WF-]E#:K_>FN8_Y
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MM_A1_P )7I/_ #^+_P!\M_A4W_"/Z;_SXP?]\"C_ (1_3?\ GQ@_[X% $/\
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M7I/_ #^+_P!\M_A1_P )7I/_ #^+_P!\M_A4W_"/Z;_SXP?]\"C_ (1_3?\
MGQ@_[X% $/\ PE>D_P#/XO\ WRW^%'_"5Z3_ ,_B_P#?+?X5-_PC^F_\^,'_
M 'P*/^$?TW_GQ@_[X% $/_"5Z3_S^+_WRW^%'_"5Z3_S^+_WRW^%3?\ "/Z;
M_P ^,'_? H_X1_3?^?&#_O@4 0_\)7I/_/XO_?+?X4?\)7I/_/XO_?+?X5-_
MPC^F_P#/C!_WP*/^$?TW_GQ@_P"^!0!#_P )7I/_ #^+_P!\M_A1_P )7I/_
M #^+_P!\M_A4W_"/Z;_SXP?]\"C_ (1_3?\ GQ@_[X% $/\ PE>D_P#/XO\
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MM_A1_P )7I/_ #^+_P!\M_A4W_"/Z;_SXP?]\"C_ (1_3?\ GQ@_[X% $/\
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M?&#_ +X%'_"/Z;_SXP?]\"@"'_A*])_Y_%_[Y;_"C_A*])_Y_%_[Y;_"IO\
MA']-_P"?&#_O@4?\(_IO_/C!_P!\"@"'_A*])_Y_%_[Y;_"C_A*])_Y_%_[Y
M;_"IO^$?TW_GQ@_[X%'_  C^F_\ /C!_WP* (?\ A*])_P"?Q?\ OEO\*/\
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M68^MT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5YI\;?
MBU%\.=$^SVCK)KUXI%O'P?*7H96'H.P[GV!KH_B)X^L/AWX;FU.](>3[EO;
MX::3'"CV[D]A7Q%XF\27_B[7+K5=2F,UW<-N8]E'95'8 < 5\9Q#G7U"G]7H
M/]Y+_P E7?U[?>?;\-Y'_:-7ZQ77[J/_ ),^WIW^XH7%Q->W,D\TCS3RN7>1
MR2SL3DDGN2:^KOV?_@]_PA^GKKVKP_\ $[ND_=1..;6,CI[.1U]!QZUQO[.G
MP=_M":'Q7K4'^C1MNL+>0?ZQA_RU(] >GJ>>PS],5Y7#.2\ML?B5J_A3_P#2
MO\OO['K\4YYS7R["O1?$U_Z2OU^[N%%%%?I!^8A1110 4444 %%%% !1110
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M.C_:H\=*X)EL' _A:U&#^1I_ZP8/L_N_X(?VC1\S[,HKX[_X:P\;?\\M*_\
M 9O_ (NC_AK#QM_SRTK_ ,!F_P#BZ?\ ;^#\_N'_ &C0\S[$HKX[_P"&L/&W
M_/+2O_ 9O_BZGC_:X\91H%:PT60_WFMY<_I**?\ ;^"\_N#^T*'F?7M%?(G_
M  UYXQ_Z!NA_]^)O_CM'_#7GC'_H&Z'_ -^)O_CM/^WL%W?W#_M"AW9]=T5\
MCQ?M>>+5<&32]%=.X6*93^?FFIO^&P/$O_0&TK\I?_BZ?]O8+N_N#^T*'?\
M ^LJ*^3?^&P/$O\ T!M*_*7_ .+H_P"&P/$O_0&TK\I?_BZ?]NX+^9_<Q_VA
M0[_@?65%?*J?MA:V%&_P_8,W<K*X'Y4[_AL36/\ H7K'_O\ /3_MS _S/[F'
MU_#]_P #ZHHKY7_X;$UC_H7K'_O\]/A_;$U16/F^&[1UQT2X=3G\C3_MS _S
M_@Q_7\/W_ ^I:*^7V_;&O=IQX8MP?>\8_P#LE5)OVPM<;/E:#I\?^]([?U%9
MU,^P4%>+<O1?YV+CC<,]YV^3_P CZKHKY"N/VL/%,V=EO;6__7-0?_0@:S[C
M]I7Q'=?ZQ[@'_IG<!/\ T%!7AXCBV-/2EA*D_G32_&=_P.VG6P,OCQ,5_P!N
MS_\ D3[-J&>\@M1F::.$?]-'"_SKXEN/CCJ5YGSTNIO^NE\S?S6J1^*A8DG3
M,G_KX_\ L:^>K<:YJM*&5M^M6"_!7_,[X2R?[>-^Z$_\C[4N/&6A6N?,U>R!
M_NK.K'\@:RKSXJ^&K3.+XW#?W88F/ZD ?K7R"OQ24YW::P^DV?\ V6DE^*0V
M_N].Y]6F_P#K5\]7XQXMJ/EH8&G'U=__ &]+\#OA4X=BN:>*;_[=:_\ ;3ZB
MO/CEIT>?LNG7,_\ UU98P?RW5A7GQPU23(M;"U@'_30M(1^H_E7S7/\ $S47
MXB@MXA[AF/\ .J$_CO6IN/M?ECTCC4?KC->)6QW&^.TGB8TUV5E^*BW^)7]L
M\-X?X*<IOT_S:_(^A;SXH>);S(.HF%?[L,:K^N,_K6!J&O7UZK->ZA<3+W\^
M9B/U->$S^(-3N/\ 67]PP]/,('Y"J,DCRMN=V=O5CFO%K<.9MC_]_P PE+U<
MI?G)?D3_ *YX.A_NN$M\TOR3/:I]?TVVSYE_;J?3S03^6:SY_'6BP9_TSS#Z
M1QL?UQBO(ZEM[6>\D$=O#)/(?X8U+'\A3I<#X-?Q*LGZ67Z,X:O'6-E_"I17
MK=_JCT>?XF:;'D1P7$I_W0!_.J$_Q2/2'3_QDE_H!_6LC3_ACXNU;!M?#6JR
M*W1_LCJG_?1 '>NFT_\ 9Q^(&H8)T06J'^*XN8E_3=G]*^@P_ ^!Z8>4_7F_
M2QYM3BK.ZWP2MZ17ZIF!-\2]3DXCAMXA_NDG]35"?QQK4_\ R^%!Z1HH_IFO
M5-/_ &1?%EQ@W>HZ5:+W DDD8?@$Q^M=-I_['"#!OO%#'U2WL\?^/%_Z5])A
M^#:4?@P<?FE^IY]3,,[Q'Q5I_P#@5ORL?.TVO:E<',E_<-[>:P'Y9JE)(\S%
MI&9V/5F.37UWI_[)/@^UP;F\U6];N&F1%_()G]:Z;3_V=_A_I^"N@+._]ZXN
M)9,_@6Q^E?24.&<1!6BHP7]=D<$L'BJSO5G?U;9\.5/:V-S?2;+:WEN'_NQ(
M6/Z5^@6G_#GPKI>/LGAO2H&'\2V<>[\\9K?BA2",)&BQH.BJ,"O3APW+[=7[
ME_P2HY6_M3_ ^ =/^%7C'5,&W\,:JRGHSVCHIZ]V ':NFT_]FOX@7V"VCQVB
MG^*XNHA^@8G]*^VZ*[8<.X=?'-O[E^AT1RVFMVSY*T_]D/Q1-@WFJZ7:KZ1M
M)(P_#8!^M=+I_P"QQ;K@WWBB23U6WLPGZES_ "KZ0HKNAD>!AO"_JV;QP%"/
M2YXKI_[)O@RUP;BXU2];N))T5?\ QU ?UKIM/_9]\ :;@IX=BE;^]<32RY_!
MF(_2O1**[H9?A*?PTE]QT1P]&.T$8.G^ ?#.DX^Q^'M+MB/XHK.-6_/&:W$C
M6-0J*$4<!5& *=17;&$8:15C914=D%%%%64%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^?1 Q]5NL?\ LE64^.EJ6^?29E'^S,#_ $KMAXA<,SVQ?WPFO_;3%Y%F,?\
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M-\6BV=QK,PX$C?N(?KDC<?\ OD?6OE2M;P_X3UGQ5/Y.D:9=:@^<$PQDJO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;3^BW-LT7ZJS?RKZAHKSYY/@:F].WHVCFE@J$OLGQGJ7[+'CJQSY,-AJ./\
MGVN@,_\ ?P+7*:E\&/'&DY\_PQJ# =3;Q>>/_',U][T5P3X=PLO@DU]W^1SR
MRVD]FT?F_?Z3?:6^R]L[BS?IMN(F0_J*J5^E,D:RH4=0ZGJK#(-<_J7PY\*Z
MQG[9X<TNX8_QM:)O_P"^L9KSY\-R^Q5^]?\ !.:65O[,_P #\^[:ZGLY1);S
M202#H\;%3^8KI-/^*?C#2@!;>)M411T1KIW4?@Q(KZUU+]G#P!J66&BFT<_Q
M6US(OZ;B/TKEK[]D/PO,Q-IJNJ6V?X7:.0#_ ,<!_6N3^P\?1_AR7R;7^1C]
M0Q$/A?W,\4L?VC?B#8X']O>>G]V>UA;]=F?UKH+']K3QG;8$UMI5V.YDMW4_
M^.N!^E=5??L;GDV?BH'T2>Q_J)/Z5@7W[(?BF')M=5TFY [2/)&Q_P#'"/UH
M]AG-'K+[[_JP]GCH=_ON:EC^V-J$>/MGAFVG]?(NFB_FK5T%E^V'HTF/M?A^
M^@]?)E23^>VO++W]F+Q_:D^5IMO>?]<;R,9_[[*US][\%/'6G@F7PQJ#8_YX
MQB7_ - )I?7<XH_$G\X_\ /;XV&Z?W'TE8_M6>![K'F_VE99_P">]L#C_OAF
MK?L?V@OA_? ;/$449[B>"6/''^TH%?%]]X/U[3<_;-$U*TQU\^TD3^8K)92K
M%6!# X(/44UG^-IZ3BOFFOU'_:%>/Q)'Z#67Q*\)ZC@6WB;296/\(O8]WY9S
M6[:WUM?+NMKB*X7^]$X8?I7YMTZ.1HG#HQ1AT93@BNJ/$D_MTD_G_P !FJS2
M76'XGZ4T5^=UEXV\1:: +37M4M0.GDWDB>W9JZ"R^.7CS3R#%XFO&Q_SVVR_
M^A@UUQXDHOXZ;7W/_(V69PZQ9]XT5\6V/[4'CVTQYM]:7O\ UWM$&?\ OC;6
M_9?M?>)HP!=Z/I5Q[Q"2,G\W-=<<_P '+>Z^7^5S99C0>]T?6=%?-EC^V0AP
M+SPLRCNT%]GOZ&,?SK?L?VO/"LV!=:7JULQ[JD<BC\=X/Z5V1S? SVJ?FOT-
MEC*$OM'NE%>567[3?@"Z_P!9JD]F?2:SE/\ Z"K5T%C\:O VH8\KQ1IZY_Y[
MR^5_Z'BNN.-PT_AJ1?S1LJ]*6TE]YVM%9-CXNT+4L?8]:T^[ST\BZC?/?L:U
M00P!'(KKC*,M8NYLFGL+1115#"BBB@ HHHH *ANK."^A,5S!'<1'JDJ!E/X&
MIJ*F48SBXR5TQIN+NCB]6^$?A_4F+1PR6#GO;/@?D<C\L5D2? W3BWR:E=*/
M]I5/]*]+HKX[$<&</XJ;J5,'"[[7C_Z2T>M3S;'4URQJO\_S/*Y/@3"5.S6)
M%/;=;@_^S5!)\"9!C9K2L.^ZV(_]F->MT5Y<_#OAB?\ S"V])S_^2.A9]F*_
MY>_A'_(\;D^!E^,[-3MV]-R,*@D^!^LC&R]L6]=S./\ V4U[717%/PSX;EM2
MDO2<OU;-EQ#F"WDG\D>%R?!?Q N[#V;X_NRMS^:U7D^$'B1,8MX7_P!V=?ZU
M[Y17%/PKR"6SJ+TDOUBS9<2XY;\K^7_!/GR3X4^*$8@::' [K/'_ /%56D^'
M'B6-<G29C_NLI_D:^C**XI^$N2OX*U5?.#_]L-5Q1B^L(_C_ )GS8_@3Q#&V
M#H]V3_LQD_RJL_A76XUW/H]^H]6M7']*^G**XI^$67OX,5->JB_\C9<4U^M-
M?B?+DFB:C&V'L+I#UPT+#^E5I+6:-27BD0#J64C%?5E%<<_!^B_@QK7K!/\
M]N1LN*I=:/X_\ ^3Z*^K9(8Y<%XU<CIN4&JTFCV$F=]E;ONZ[HE.?TKBGX/U
M5\&.3]86_P#;V:KBJ/6C_P"3?\ ^6Z*^G9/"^C38WZ18OCINMD/]*K2>"/#\
MF[.CV8S_ '85'\JXI^$6/7P8J#]5)?YFRXIH]:;^]'S717T9)\.?#<F =)A'
M^Z6'\C4$GPM\+R,2=+ )_NSR#]-U<4_"7.5\%>D_G-?^V,V7%&$ZPE^'^9X"
MFH74;92YF4^JN14\>O:G&N$U&[0=<+.P_K7MTGPA\-,N!;3)[K.W]34#_!GP
M\S9!NT'HLP_J*R_XAIQ-1_AU8?*<E_[:BO\ 6'+I?%%_<O\ ,\AC\8:[&P*Z
MS?\ '0&Y<C\LU/'X]\0QYQJ]T?\ >?/\Z].?X'Z*5^2\OU/JSH?_ &2H)/@;
MIQ;Y-2NE'^TJG^E'^I/&E'^'4?RJV_5!_;&42^**_P# ?^ <!'\3/$T>W&JR
M'']Z-#_-:LQ_%CQ.F<Z@LG^]!'Q^2UULGP)A*G9K$BGMNMP?_9J@D^!,@QLU
MI6'?=;$?^S&C_5_Q!H_#.K\JZ_+G#Z]D4]U'_P  _P#M3 C^,/B-<9EMWQ_>
MA'/Y4S4/BIJ.L6KVVHZ;I.HV[=8;JV+K^6ZMF3X&7XSLU.W;TW(PJ"3X'ZR,
M;+VQ;UW,X_\ 932E@_$*FK2]JU_B4OU8XULCO>/*GZ-'"6<?ARSOOM8\(:5)
M-G.V1IGBZ_\ /-I"OZ5W-M\:+^S@2&WTO3X(4&%CC5E51[ 'BH6^"VOJQ DL
MF'J)6_\ B:3_ (4OX@_OV?\ W]/_ ,36%&/'N&NJ-.I'TA%?DCHK5\IQ-O;5
M%*W>3?YLM_\ "\=5_P"?"S_\?_QJ;_A>=_\ ] RW_P"^VK._X4OX@_OV?_?T
M_P#Q-1?\*=\1_P#/.W_[_"NGZYXAT^E7_P  3_\ ;3E]ED,NL?O_ .":W_"\
M[[_H&6__ 'VU'_"\[[_H&6__ 'VU9/\ PIWQ'_SSM_\ O\*/^%.^(_\ GG;_
M /?X4?VAXB?RU?\ P6O_ )$?L,A[Q_\  O\ @FS'\=+L9WZ3"WIME(_H:=_P
MO:?_ * \?_?\_P#Q-8,GPA\2*<"VA?W6=?ZTS_A4?B;_ )\X_P#O^G^-']K>
M(<=.6K_X*3_]L%]5R%ZWC_X%_P $Z'_A>T__ $!X_P#O^?\ XFE'QVGR,Z/&
M1_U\'_XFN6N_AGKE@NZY2UMU]9KN-1^IKG=0M[73%8SZUHH8#.Q-3@9OR#9K
M*6>>(%/6:JK_ +A1_P#D"7A\@CO*"_[?_P"">H?\+X_Z@?\ Y-__ &%'_"^/
M^H'_ .3?_P!A7A=WXUT:S<HUZLC#_GB"X_,#'ZUG3?$K2X_N17,I]D 'ZFHA
MQ1QW4=E*?SI07YP1RU(\-4OBJ0^4V_R;/H7_ (7Q_P!0/_R;_P#L*?'\=HBO
MSZ,ZG_9N0?\ V45\TS?%*,?ZK3V;W>4#^0-4IOB??-_JK2W3_?W-_45ZE'.N
M/IN[JI>L:7Z1N>55Q_"U/9W].?\ 70^I?^%[0?\ 0'D_[_C_ .)H_P"%[0?]
M >3_ +_C_P")KY,F^(6LR?=FCB_W(A_7-49O%NL3_>U"8?[AV_RKUZ>8<;2^
M/&07_;L7_P"V?J>14SKAZ/P4)OYV_P#;OT/L)?CK;;ANTB4#OB8'^E)-\?M*
MM_\ 6V4D7^_,@KXPFU*\N/\ 6W4\O^_(3_6JU>O1QW$R_BX]?*E#_@?D>35S
M[+O^76#?SF_\OU/LN;]IKPW;_?3_ +YG1OY51F_:P\+1=+6ZD/\ L#_$5\A5
M-:V-Q?/LMK>6X?\ NQ(6/Z5ZU+,LW7QXMOTA!?\ MK/*J9TI:4Z$5\Y/_P!N
M1]57'[7_ (=2/]UHVI2R>C&-5_/=G]*Q;[]L@<BS\+?1Y[[_ -E$?]:\-L_A
MKXMOU#6_AC5Y4/1UL9=OY[<5J6_P1\=7'(\,WR#UD0+^A->G+-\QC'WIO_P%
M?Y'(J^-KO]W%_)?\.=[??M>>*9LBUTK2;9?5TDD8?^/@?I7.WW[3'C^\R(]5
MALP>"(+2+^;*35.']GWQK)]_2I(A_M(Q/Z+5Q/V>?$BKF:VNE'I'9N]>+B,_
MKPNZE2?RC/\ ]MB=<,NS:O\ "G\Y17YM'.WWQB\;ZCGS?%&IKG_GA<&+_P!
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MH \FHHHH ] ^'_\ R!IO^OAO_05KIJYGX?\ _(&F_P"OAO\ T%:Z:@ HHHH
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M.,OA=S924MF/HHHJQA1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MM2.&?$F.EMRKT7^;9Y+;_ EN#/K '^S';Y_4M_2M.W^!^DI@S7UY+[*44?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !5:\TVTU 8NK6&Y'_3:,/_,59HI-)Z,#E[[X7>#]0SY_
MAC26)X++9QJW3'4 &L"^_9W^'U]DMX?2%O[T%Q*F/P#X_2O1Z*YI87#S^*FG
M\D9.C3EO%?<>,7W[)_@FZSY4NJ6?_7&Y4C_QY#6!>_L=Z7)G['XCO(/3SK=)
M.WL5[U]#45QRRK!3WI+\OR,'@Z$MXGRU??L=ZI'G['XCLY_3S[=XOY%JY^^_
M9/\ &UKGRI=+O/\ KC<L#_X\@K[%HKDED."ELFOG_G<Q>7T'LK?,^&[[]G?X
M@V.2WA]YE_O07$3Y_ /G]*P+[X7>,-/SY_AC5E X++9R,O7'4 BOT#HKDEPY
MAW\,VON?Z(Q>64^DF?F[>:;>:?Q=6L]L>G[Z,I_,56K]*F4,I!&0>"#63?>#
M]!U//VS1-.N\]?/M(W_F*XY<-O[%7\/^"8O*WTG^!^==6K/5;W33FTO+BU/_
M $QE9/Y&ONN]^"G@74"3+X8T]<_\\8S%_P"@$5S][^S%X N@?*TVXL_^N-Y(
M<?\ ?9:N67#V*CK":_%?H8O+:R^%H^4['XJ>,=/QY'BC5E Z*UY(ZC\"2*W[
M']HGX@V. /$#3*/X9[:%\_B4S^M>W7W[(?A:;)M=5U:V)[2/'(H_\<!_6L"]
M_8W7DVGBHC_9FL<_J)/Z5']G9M2^!OY2_P""A?5L9#X6_O.0L?VL?&MKCSH=
M+O!W\VW8'_QUQ6_8_MBZG'C[9X;M)_7R+EHOYJU9]]^R#XGB!-KJ^E7 ':1I
M(R>/]P_SK OOV8/'UKGRK"UO?^N%V@S_ -]E:.;.J/\ -]U_\PYL=#O^9Z=9
M?MB:5)C[7X<O(/7R9TD_F%K?L?VKO!-UCS4U2S_Z[6RG_P! =J^<K[X(>.]/
MSYOAB^;_ *X*)?\ T FL"^\&>(-,S]LT+4K3'7S[.1,=^XH_M;,Z7\2/WQ_X
M8/KF*A\2^]'V98_M#?#^_P !?$,<3?W9[>6/'XE,?K6_8_%#PAJ./L_B?27)
M_A-Y&K?D3FOS\96C8JRE64X*D8(I*UCQ'B%\<$_O7^92S.IUBC](K34K34!F
MUNH;D>L,@;^1JS7YJJQ1@RDJP.01U%6/[4O/^?N?_OXW^-=2XE[TOQ_X!LLT
M[P_'_@'Z145^;4U[<7"[99Y9%Z[7<D5#1_K+_P!.?_)O^ ']J?W/Q_X!^E=%
M?FI12_UE_P"G/_DW_ #^U/[GX_\  /TKHK\U**/]9?\ IS_Y-_P _M3^Y^/_
M  #]*ZBFN8;?!EE2+/3>P&?SK\V:*/\ 67_IS_Y-_P  /[4_N?C_ , _2'^U
M+/\ Y^X/^_B_XT?VI9_\_<'_ '\7_&OS>HI?ZRO_ )]?C_P!?VH_Y/Q_X!^D
M/]J6?_/W!_W\7_&C^U+/_G[@_P"_B_XU^;U%'^LK_P"?7X_\ /[4?\GX_P#
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MYVI:A:Z?#_STNIEC'YL12<E%78F[:LO45Y;KW[2G@30V9$U&75)%ZI80%_\
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MJ^;K\64G\>-C\I+]#NAE>=XC:C/[N7\['/ZI\3/%NLY%YXDU293UC^U.J?\
M?(('Z5S<DCRN7=F=SU9CDFO8;+X<^$;3!N$U;46';[3' A_ (Q_6MVRTSPEI
M>#;>#[*60?QWUQ-/GZJ6"_I7A5>*LHWJ8KF?I-_^VV_$[H<(YQ6UG!+UDO\
M@GS_ %L:7X-U_7-O]G:)J%\&Z-;VKN/KD#I7T+9^-)-)Q_9>CZ+I1'0V=@B$
M?CS4MQ\3/$UQ][59%_ZYHB?R%<$N,LCI]:DO2$4OO<_T/4I<"XR7\2I%??\
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M/<WYMG^5<MJ/B+5-7S]LU"XN5/\ #)(2OY=*^0QOBOE.'7+@J$ZEO2"_5_\
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MQ136E&FWZNWY7/ --^%?B/4,$V:VB'^*Y<+^@R?TKJ=-^!9X:_U0#UCMH_\
MV8_X5ZS17Z%@?#'A_"6=:,JK_O2T^Z/+^-SPJW$6.J_"U'T7^=SC]-^%'AS3
M\%K1[QQ_%<R%OT&!^E=/9:;::;'LM+6&U3^[#&%'Z59HK]"P649=EJM@\/"G
MZ12?W[L\*MBJ^(_BS<O5A1117KG*%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% %>ZT^UOUVW-M#<+Z2QAA^M8-]\,O".HY^T>&=)D8_Q?8HPWY@9K
MIJ*SE3A/XHIDN,9;H\[NOV?/A]>-ND\-Q*?^F4\T8_)7%0?\,W_#K_H7?_)V
MY_\ CE>ET5S/ X5ZNE'_ ,!7^1E["E_(ON1YI_PS?\.O^A=_\G;G_P".4?\
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M<'_?Z7_XNO0J*/J>&_Y]1^Y#]A2_D7W(\]_X4!\/_P#H6X/^_P!+_P#%T?\
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M5?;N!DSG*BOMKP-XPT[XA>"]!\4:1+YVE:U8PZA:N>ICE0.N?0X89'K7S/\
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M5\^7]4>FVOQOTB3 GLKR$_[(5Q_,5KVOQ8\,W'!OF@/I+"X_4 BO$)O#.KP
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MV>X^M]OE7EI_P?Q+NF^#M$TG!M=+MHV'1V3>W_?39-;-<S_PF%Q_T![K]?\
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MK]?_ (FC_A,+C_H#W7Z__$T =-17,_\ "87'_0'NOU_^)H_X3"X_Z ]U^O\
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M] >Z_7_XFC_A,+C_ * ]U^O_ ,30!TU%<S_PF%Q_T![K]?\ XFC_ (3"X_Z
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M =-17,_\)A<?] >Z_7_XFC_A,+C_ * ]U^O_ ,30!TU%<S_PF%Q_T![K]?\
MXFC_ (3"X_Z ]U^O_P 30!TU%<S_ ,)A<?\ 0'NOU_\ B:/^$PN/^@/=?K_\
M30!TU%<S_P )A<?] >Z_7_XFC_A,+C_H#W7Z_P#Q- '345S/_"87'_0'NOU_
M^)H_X3"X_P"@/=?K_P#$T =-17,_\)A<?] >Z_7_ .)H_P"$PN/^@/=?K_\
M$T =-17,_P#"87'_ $![K]?_ (FC_A,+C_H#W7Z__$T =-17,_\ "87'_0'N
MOU_^)H_X3"X_Z ]U^O\ \30!TU%<S_PF%Q_T![K]?_B:/^$PN/\ H#W7Z_\
MQ- '345S/_"87'_0'NOU_P#B:/\ A,+C_H#W7Z__ !- '345S/\ PF%Q_P!
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M@/=?K_\ $T =-17,_P#"87'_ $![K]?_ (FC_A,+C_H#W7Z__$T =-17,_\
M"87'_0'NOU_^)H_X3"X_Z ]U^O\ \30!TU%<S_PF%Q_T![K]?_B:/^$PN/\
MH#W7Z_\ Q- '345S/_"87'_0'NOU_P#B:/\ A,+C_H#W7Z__ !- '345S/\
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M<S_PF%Q_T![K]?\ XFC_ (3"X_Z ]U^O_P 30!TU%<S_ ,)A<?\ 0'NOU_\
MB:/^$PN/^@/=?K_\30!TU%<S_P )A<?] >Z_7_XFC_A,+C_H#W7Z_P#Q- '3
M45S/_"87'_0'NOU_^)H_X3"X_P"@/=?K_P#$T =-17,_\)A<?] >Z_7_ .)H
M_P"$PN/^@/=?K_\ $T =-17,_P#"87'_ $![K]?_ (FC_A,+C_H#W7Z__$T
M=-17,_\ "87'_0'NOU_^)H_X3"X_Z ]U^O\ \30!TU%<S_PF%Q_T![K]?_B:
M/^$PN/\ H#W7Z_\ Q- '345S/_"87'_0'NOU_P#B:/\ A,+C_H#W7Z__ !-
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M ,30!TU%<S_PF%Q_T![K]?\ XFC_ (3"X_Z ]U^O_P 30!TU%<S_ ,)A<?\
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M5>K45VQR;+HJRH1^Y%?VUF7_ $$2^]GF'_#-W@/_ *!D_P#X%R__ !595_\
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MOJ^HYK>*Y7;-$DJ^CJ"/UKYK$>$%)ZX?&-?XH)_BI+\CT*?%4O\ EY2^Y_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M444 >@?#_P#Y TW_ %\-_P"@K735S/P__P"0--_U\-_Z"M=-0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>0>Q (KXI_:2_P""37P]\7:#=:S\(X)/ /CBT!N;.&&[D-C<RJ=P5@Y8PG(
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MO^@5'_WU_P#95TU% ',_VMXB_P"@5'_WU_\ 94?VMXB_Z!4?_?7_ -E7344
M<S_:WB+_ *!4?_?7_P!E1_:WB+_H%1_]]?\ V5=-10!S/]K>(O\ H%1_]]?_
M &5']K>(O^@5'_WU_P#95TU% ',_VMXB_P"@5'_WU_\ 94?VMXB_Z!4?_?7_
M -E7344 <S_:WB+_ *!4?_?7_P!E1_:WB+_H%1_]]?\ V5=-10!S/]K>(O\
MH%1_]]?_ &5']K>(O^@5'_WU_P#95TU% ',_VMXB_P"@5'_WU_\ 94?VMXB_
MZ!4?_?7_ -E7344 <S_:WB+_ *!4?_?7_P!E1_:WB+_H%1_]]?\ V5=-10!S
M/]K>(O\ H%1_]]?_ &5']K>(O^@5'_WU_P#95TU% ',_VMXB_P"@5'_WU_\
M94?VMXB_Z!4?_?7_ -E7344 <S_:WB+_ *!4?_?7_P!E1_:WB+_H%1_]]?\
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MO^@5'_WU_P#95TU% ',_VMXB_P"@5'_WU_\ 94?VMXB_Z!4?_?7_ -E7344
M<S_:WB+_ *!4?_?7_P!E1_:WB+_H%1_]]?\ V5=-10!S/]K>(O\ H%1_]]?_
M &5']K>(O^@5'_WU_P#95TU% ',_VMXB_P"@5'_WU_\ 94?VMXB_Z!4?_?7_
M -E7344 <S_:WB+_ *!4?_?7_P!E1_:WB+_H%1_]]?\ V5=-10!S/]K>(O\
MH%1_]]?_ &5']K>(O^@5'_WU_P#95TU% ',_VMXB_P"@5'_WU_\ 94?VMXB_
MZ!4?_?7_ -E7344 <S_:WB+_ *!4?_?7_P!E1_:WB+_H%1_]]?\ V5=-10!S
M/]K>(O\ H%1_]]?_ &5']K>(O^@5'_WU_P#95TU% ',_VMXB_P"@5'_WU_\
M94?VMXB_Z!4?_?7_ -E7344 <S_:WB+_ *!4?_?7_P!E1_:WB+_H%1_]]?\
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MO^@5'_WU_P#95TU% ',_VMXB_P"@5'_WU_\ 94?VMXB_Z!4?_?7_ -E7344
M<S_:WB+_ *!4?_?7_P!E1_:WB+_H%1_]]?\ V5=-10!S/]K>(O\ H%1_]]?_
M &5']K>(O^@5'_WU_P#95TU% ',_VMXB_P"@5'_WU_\ 94?VMXB_Z!4?_?7_
M -E7344 <S_:WB+_ *!4?_?7_P!E1_:WB+_H%1_]]?\ V5=-10!S/]K>(O\
MH%1_]]?_ &5']K>(O^@5'_WU_P#95TU% ',_VMXB_P"@5'_WU_\ 94?VMXB_
MZ!4?_?7_ -E7344 <S_:WB+_ *!4?_?7_P!E1_:WB+_H%1_]]?\ V5=-10!S
M/]K>(O\ H%1_]]?_ &5']K>(O^@5'_WU_P#95TU% ',_VMXB_P"@5'_WU_\
M94?VMXB_Z!4?_?7_ -E7344 <S_:WB+_ *!4?_?7_P!E1_:WB+_H%1_]]?\
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MO^@5'_WU_P#95TU% ',_VMXB_P"@5'_WU_\ 94?VMXB_Z!4?_?7_ -E7344
M<S_:WB+_ *!4?_?7_P!E1_:WB+_H%1_]]?\ V5=-10!S/]K>(O\ H%1_]]?_
M &5']K>(O^@5'_WU_P#95TU% ',_VMXB_P"@5'_WU_\ 94?VMXB_Z!4?_?7_
M -E7344 <S_:WB+_ *!4?_?7_P!E1_:WB+_H%1_]]?\ V5=-10!S/]K>(O\
MH%1_]]?_ &5']K>(O^@5'_WU_P#95TU% ',_VMXB_P"@5'_WU_\ 94?VMXB_
MZ!4?_?7_ -E7344 <S_:WB+_ *!4?_?7_P!E1_:WB+_H%1_]]?\ V5=-10!S
M/]K>(O\ H%1_]]?_ &5']K>(O^@5'_WU_P#95TU% ',_VMXB_P"@5'_WU_\
M94?VMXB_Z!4?_?7_ -E7344 <S_:WB+_ *!4?_?7_P!E1_:WB+_H%1_]]?\
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M:U_R!K__ *]Y/_035VJ6M?\ (&O_ /KWD_\ 030!Y-1110!Z!\/_ /D#3?\
M7PW_ *"M=-7,_#__ ) TW_7PW_H*UTU !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 52
MUK_D#7__ %[R?^@FKM4M:_Y U_\ ]>\G_H)H \FHHHH ] ^'_P#R!IO^OAO_
M $%:Z:N9^'__ "!IO^OAO_05KIJ "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ML'BC_H)6O_?(_P#B* .FHKF?L'BC_H)6O_?(_P#B*/L'BC_H)6O_ 'R/_B*
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ML'BC_H)6O_?(_P#B* .FHKF?L'BC_H)6O_?(_P#B*/L'BC_H)6O_ 'R/_B*
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M[!XH_P"@E:_]\C_XBC[!XH_Z"5K_ -\C_P"(H Z:BN9^P>*/^@E:_P#?(_\
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MJ]QXBT6U$\]_"Z%@F(T4G)!/=!Z5=6Q\4, ?[1MO^^1_\10!T]%<S]@\4?\
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MTU%<S]@\4?\ 02M?^^1_\11]@\4?]!*U_P"^1_\ $4 =-17,_8/%'_02M?\
MOD?_ !%'V#Q1_P!!*U_[Y'_Q% '345S/V#Q1_P!!*U_[Y'_Q%'V#Q1_T$K7_
M +Y'_P 10!TU%<S]@\4?]!*U_P"^1_\ $4?8/%'_ $$K7_OD?_$4 =-17,_8
M/%'_ $$K7_OD?_$4?8/%'_02M?\ OD?_ !% '345S/V#Q1_T$K7_ +Y'_P 1
M1]@\4?\ 02M?^^1_\10!TU%<S]@\4?\ 02M?^^1_\11]@\4?]!*U_P"^1_\
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M-$\6G7(=&0F<GYACL*Z2B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH YNUB<>.+QRC!#  &QQT3O72444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %<[XZC>;1XU1&<^<IPHSV:NBHH :GW%^E.HHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YNUB<>.+QRC!#
M &QQT3O7244 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% &1XK1I/#]VJJ68A<!1D_>%6=#4KH]BK @B% 0?H
M*O44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %5-64MI=X ,DPN !_NFK=% &+X/C:/P_;*ZE&RW##!^\:VJ** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "N;\-Q/'KFMLR,JM+P2, _,U=)10 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 9'BM&D\/W:JI9B%P%&3
M]X59T-2NCV*L""(4!!^@J]10 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 <WJ43MXTTUPC%!$<MC@??KI***
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "N;U*)V\:::X1B@B.6QP/OUTE% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!SOCJ-YM'C5$9SYRG"C
M/9JZ!/N+]*=10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 <W:Q./'%XY1@A@ #8XZ)WKI*** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J>L*6
MT>^ &28)  /]TU<HH Q_"*-'X>M%=2K#?D,,'[[5L444 %%%% !1110 4444
M %%%% !5+6O^0-?_ /7O)_Z":NU2UK_D#7__ %[R?^@F@#R:BBB@#T#X?_\
M(&F_Z^&_]!6NFKF?A_\ \@:;_KX;_P!!6NFH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ME%&6W%%EC5]I/J-V#[@T =+1110 4444 %%%% !1110 4444 %%%% !1110
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M K],=+U.TUK3;34+"XCO+&[A2XM[B%@R2QNH974CJ"""#[T >4?!O]D/X/\
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M?@I\)?[#NK)+76;C5]2O]1G&W==RR7DI2<E3_%$(L=PH4'D&OA']NKX-Z_\
ML3_&+1_VCO@RG]D:3>78@\0:3 "+59G;)#QCCR)\$$=$D *D%EV_HU\%/BUH
MWQT^%?AOQWH#'^S=:M%N%B9@7@DR5DA8CC<CJR'W4T ?+7_!3;X:6FJ:9\(O
M'UE"(O%.@^-=,M(+J*/]Z\,TW^KR.>)4C9<\ [L?>KZI^,?PHT+XX_#+Q#X&
M\20M-I&LVQ@D9/OQ,"&CE0]G1U5QGC*C.17G?[3EG'XK\4?!+P@!OFU#QO;:
MK(I' @TZ":\=C[;XH5_[: =ZK?MA?M=^%_V5?A[/?WFHV4_BRY"+I>A,V^>X
MRX5I#&""(U7<2QP,J!R2 0#XP_9&^+'B/_@GO\8-2^ _QH>2Q\$:M=O/X<\1
MS*19K(7V^8KDX6&4;2PS^Z?[P&YF'TA_P5$\&V7Q(_96_LFW2.^\27FO:7'X
M;MT(9[F]EG6+9'CJ3!+.>.P)KZ.^(WPK\$_'#PF-'\8^']-\5:),!+''>1!P
MI(XDB<?,C8/WD(.#UKC/A5^R+\+O@SJMIJ/AK0;@7=@KQZ<VJ:G=:@NFHXPR
MVRSR.L.1D$H Q!()(H ]3\.Z6VA^']+TUI/.:SM8K<R 8W%$"Y_'%:-%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%175U#8VTMQ<S1V]O$
MI>265@J(HY))/  ]:R_#?C3P]XSMY)_#^NZ9KL,>-\FFWD=PJYSC)1CCH?R-
M %7X@?$+P_\ "WPG?>)?$^HQZ7H]F%\R=U9BS,P5$1%!9W9B%5%!+$@ $UX7
M??\ !0#X;^%_$NGZ/XYTCQE\,QJ.19:AXQ\/S6-I.<XP)/FV]L[@H7(W8KS;
M_@HQ\4$^''Q._9C?56">%!XS_M'4V?A$,!@6.1B>,()Y7Y_NY[5]4?&;X-^%
MOCY\.]5\&>+]/6_TC4(\!A@2V\@^Y-$W\+J>0?J#D$@@'&?M%?"VV_: \*_#
M^"W2WU[P];>*M+UR[ABD22"]LD+$\D[7C.]7.,[E4XSD5[5TX' K\M/V)?BY
MXM_8[_:8U+]F'XE7TEUX>O+LQ^';Z8G9%-)\T!B)/$5P,#8"=LI X)<U^IE
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M%?Q8GBK6?":VGBM7$@UW1+R?3;PO_?:2W=-[8XW-DX[UZ-\/?AKX9^%7A_\
ML7PKI,6DZ>97N)%1FDDGE8Y>665RSRR'C+NQ8X'/% '34444 %%%% !1110
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M\">'+/P_IPP9/(7,UPP&-\TK9>1O=B?0<<5W5 !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%)G')X%86@^/O#'BF\GL]%\1Z3J]W;EA-;V%]%
M/)&5(#!E5B1@D9SZB@"_KNNZ=X7T6^U?5[V#3=+L8'N;J\NI!'%#$@+,[,>
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M3+$.Y#Q;QM[L$/85=_X)Q^/+OXA_L9_#F_OF>2[LK672G>0[BRVTSPQG/?\
M=HGZUSGA/]K[QEXN\ W?A[7/@?XXTWXM-:-:_P!CMHLHTJYG92@F6]?]U';;
MB"S.WR@D OC)]C_9;^",?[.OP%\(> %GCN[G2K4F\N8@0LMS([2S,N>=N]V
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M=&*Z77#H?_"0+*R*('MQ<>055LY+JQ4D8P Z\\X'6PS)<1)+$ZR1.H970Y#
M\@@]Q7@'QL_XI/\ :=^ OBL?N;;49M5\(WDO][[3:BYMU/\ VULL#_>- '@O
MQD^"GBK]OG]H[QIX1UOQ3?\ A7X+?#V:VT][/2F7S=5U%X$GD8[@5!02J,N&
M"@+M7+N1X)^TM^P_KG_!/V+2_C?\$_&.LW%EH=U"FI6NK-&TT22.J!G:-426
M%V81LA0$;U.3R5_5OP_X.TWPSJWB34;!'CN/$%^NI7V6RK3K;06P91V_=VT6
M?<$]Z\K_ &X(X)OV0_BXMPB.G_".W942 $;PA*'ZA@N/?% 'C?\ P4 ^%LO[
M6?[$^G>*O#MH[ZO86MKXOT^U0;Y)86MRTL(XR3Y4I8 #+-$H[UN_\$T_VG(/
MVA/V?--T[4;U9O&?A../2]4C=OWDL:C%O<>X=% )_OH_J*^B/@_X9E\%_"3P
M1X>FR)M)T.QL'W==T5NB']5KX5^*_P"R)X]_9U^- ^/W[,D=OKMCJ1,VL>"H
M701W-O*0\@M\$*\3X#!%^9&VE-PPJ@$W_!8?X'OJWPY\._&/0UDMO$7A"[BM
MKNZM_E?['))^Z?<.<Q3E-OIYSGL*^U?#GQ4M;KX"Z7\2=40V]E)X:B\172J.
M4C-J+AP/H,U\Z?$GXI:O^V/\&;_X9:!\-/&GA37_ !)Y-CK$WBS1);*TT*$2
M(\TS2R +,P56$:1Y9F*DA!G'UKX7\.V7@_PSI&@Z;'Y6G:79PV-M&?X8HD"(
M/P510!^6WP:_9X_:7_:T\#VNC^-=:G^$?PDNKN[U*ZLX86AU'6I+JXDN97DC
M)WN&:5L&4J@&PK&^,U^@?[/_ .RS\-OV9M!.G>!?#T5E<R($NM6N<37UW_UT
MF(SC(SL7" ]%%>M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 44V21(8VDD941069F.  .I)I(9H[B&.6)UEBD4,DB$%64C(((ZB@!]?.GQ.
M_:J^Q_L@^*/BWX0TNY.HP>?IVGZ??(IFCOOMYT]!(BD@XF(8J"<CC/-?1=?+
MOP7\#Z9X@U#X_?"C65D%GI_CI==@6$@&.&\%OJ4)3((&+@2GIQMQVH ^=(O^
M"1>J?%K0I?$_Q;^+6N7_ ,3=4B\^XEBC2XM;25AD1'><R*I.,(8UXPH  -=!
M_P $YO&'Q%^$OQL^(/[-'Q'U&36'\-V8U71KN61I0MN'B4K&['/E.D\+JA^X
M0XX.0/T-KYAC\*Q3?\%*KC78(T3[-\+(XKID'+R2ZHXC+?\  (7'_ 1Z4 ?(
MO[?&C:W^R'^VSX)_:-T.VFN-!UF:*/5(XAA3-'$(9X">@\VV 9<]75S_  U^
MGW@OQCH_Q"\)Z1XE\/WT>I:+JMM'=VEU$?EDC<9!]CV(/(((/(KG_C3\)/"W
MQX^'>K>!/%UN+G2]6A(PC*L\+J05FB)!PZ,5(.".Q!!(/Q)\#O#_ ,=/^">G
MB*Z\&:AX5UKXQ_!&YG>73=0\*VOVG4-,9FR3]E!W@'.7CY7)W(V=RL <]\-?
MAK/^RS_P5J'A_1(6MO"7Q&TN^O+:%.(HT:&2Y= !Q\D]JX4?PHZ^O/T%_P %
M%O%'C6W^'O@SPE\.O#<WBSQ=KWB.TN8M,6W:6%H+*1;EFFP0!&)EM@Q9E7#'
M)%;/A#P;J7QV_::T'XRZIX9U7PEX=\(Z+/IN@VFOVWV74;VZN<B>X> DM#$D
M;&-5?#EF<X  S]-T ? /PR_X)PZ]\5/%$'Q"_:C\877C[Q(W[R'PS;7!73[,
M$[O+9DV@J#C,<01,CDN#7W=H'A_2_"NBV>D:+IUKI.E6<8BMK&QA6&&%!T5$
M4 */H*T** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **JZ7JM
MEKFG6VH:=>6^H6%S&)8+JUE66*5",AE920P([BK5 'A_B3]IS3V_9-\0?&GP
M[8S-;6ND7E]9V.I@1R>=$SQ".4*S $2IA@">AP:^3/"/_!*$?&O05\<?'7XB
M>*M0^).NPK>72:?+ D=BSKE8&\R)]VS(&U-BK@JHP :^AOV??!VF^(?!_P >
M/@[K:.=+L?%NKV/V6-MKQV&HHM[&4./E/^ER;3V*YKZ=H _-3]A^R\=_L?\
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MC?\ !+5X?#_Q9TMXYS$'1+?5'B^56WGY5EVC8=^4=0%;')/4^$_VJ/B;XO\
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M-I_V8?\ @K5X5U#0H6M_"WQ+@NY7AB.U!)+'(;B+Z+<1Q38Q@"10.E;?PA\
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MXT#PEI^IG4]4@L8@US>LL92*-';Y8P/,D))5N=OR]QWGP8^ ?@+]GWPRNA>
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M@W?V4+U^T)&9(2/I(B'\*^(_V&O%>J_L=_M.>+OV8/&=W(^B:G<MJ/A/4+C
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M/@1I>F>"_AQ%/(FBRZDEJ=0UN)&*^:!=(ZJ&(R.$ Z;FP37M'_!/O]J;Q?\
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MX?N'9+E$^T1S1R",C<>DNYY-A;>NU=H&/MNBB@ HHHH **** "BBB@ HHHH
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MBBB@#T#X?_\ (&F_Z^&_]!6NFKF?A_\ \@:;_KX;_P!!6NFH **** "BBB@
MHHHH ***^?O'_P 0/&?Q(^-FH?";X=Z];>$%T+28=4\1^*&LX[VYMVN&<6UI
M;PR'RQ(RQO(SR!@%V@+DT ?0-5]0L8-4L;FSNHUFMKB-H98VZ,C A@?J":_/
MKX[?$/\ :5_8.NK7QC?^*X_CE\)Y)E@OH=4T^*SOM/=C@;I85R Q 42'<F3M
M* E2WVI\%?C)X:^/GPUT;QOX4N_M6DZE%NV/@2V\HX>&50?E=&R".G<$@@D
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MTR\$K?V;-$#[>?:1?B?>O%_V#/VQOB#X\^(WB/X*?&[3/[.^).A0-<17;0)
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MT.=DP4@,%D#*& ;&0" #S#]EC]IJ7]I3P#H6O)X*\0:&+BR$E[?7ULL%B+@
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M'WPKTSXA>(/ ^LWMQ=6E[X2U<ZO9R6I4&1C;S0-$Y(/[MEFR0,$[1R*7X?\
MP7\ _">2[?P7X+T'PK)>?\?$FD:=%;-*,YPQ102 >@Z#M79T %%%% !1110
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MDUM-<6T,\ML_F0221AFB8@@LI(^4X)&1V)H _*G]FW_@J,WP3T3P/\.?B/\
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MO'&KZ=<7+-XLU9=8NK64KY4,XMH8&,8 R-P@5CDGDGH*[.BB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "LGQ#XJT?PG!:2ZQJ5OIR7=S'9VW
MGN%,\\AVI$@ZLY/11D\'TK3FFCMX9)976**-2SR.0%50,DDGH*^5OV0_$0_:
M8\3>*_CMJN;JR&IW.@^#+.3)CT[38MJR3HI^[-</DNW) 15!VC% 'U97S)X1
MT-+7]J3]H#P+/(UI:^,]!TSQ%;&,#Y=\,NGW+@>NZ"(_4^]?3=?.WQ5_XH_]
MLCX*>(U/EP^(],UGPE=R'H2$CO;=?Q:WE ]R* /;/"/AO3OAWX'T70+-U@TG
M0M.AL87E(4)#!$J*2>@PJBOROU/_ (*)2?!;]HCXQ>-?!'PS/C#P'XEU6T:7
M7EDFM8YUM;9+;?'*(WC"M*)7#$<[QWYK]9[RS@U"TGM;J".YM9T:*6&9 Z2(
MPPRLIX(()!!IDVFVEUI[V$UK#+8R1&![5XPT31D8*%2,%<<8Z8H ^=]+UKX9
M_P#!23]ER_BA$PT;5@UM/%,J_;-(OX\,IX) ="58$'#*PSPQ%?)W[)_QF\4_
M\$^?'4OP)^/"-I_@R^N'G\-^+-Q:PB+-\P$A'$+DACG!B=CO #EE]]_8U^$V
MG_!3]IK]I'PMX4#V_@B*XT6[M+$-F*SN9K>:6:%/]T/'QV4Q@] :^K/%?@WP
M_P"/-'?2?$NA:;XBTN0AGL=6M([J!B.A*2 J3^% 'R=^V-H?A[]HSX@? /PE
MX7U&SUOQ#:>*X/$5Q-ILR3BRT:%&:YF=E)"*[BW5"3AVP!G%?3'B7X7:;XH^
M)/@OQK<7%S!JGA6.^BM8X2HCF2ZC1)%DR"2H\M& !'S*IZ#!E^'OPD\$_"6Q
MGL_!?A/1O"UM<,'G32;&.W\YAG!<J 6(R<9SBNMH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **^:]2\5>/?VBOB)X]\+^!/&:_#OPAX
M.NET6]UVQL(KW4=0U(Q++-'%YN8X8XED12=I<N6P5 KY]^(W[1/Q_P#V!/'6
MF'XJ:C%\8_A%K%RMO!XBAL8[*_LSU:-A& OF!=S!'W"0+\KIA@H!]L?'[P+_
M ,+.^!_C[PH(_-EUC0[RSA7&2)6A81D>X?:1[BN/^"EO8?'#P#\$?BG=SO-J
M-AX?^T1IP1]IN;:*.=B>N5*RK_P(UZMX/\7Z/X^\+:7XC\/ZA#JNB:I;I=6E
MY;ME)8V&0?8]B#R""#@BO%?V*_\ B1_#OQ;X()X\%>,=9T2('K]G-R;JWS_V
MQNH\>PQVH S_ /@H5\0M!\$_LJ>.-/U8I<ZEXDL)=%TC3%7S)KN[E7:GEH,D
ME,^83VV>N,_,/[/?_!5VTTCQ%X:^'OQ.^',OP\TSR8+"SU19Y/+MD $<1FBE
M16$?RX,@8XQ]W&2/TGETZTGOK>]DM89+RW1XX;AHP9(U?;O56QD!MJY Z[1G
MI7SU_P % /@WX3^+7[+_ (YF\26T"WGAW2;O6=+U)L+):W$,+.H5O[K[=C+T
M(;ID*0 >.?\ !1+]BG7_ (FZII'QE^$:M;?%'P^T<TT-JXCFU".'YHI(CT,\
M9  !^^OR\E54^F_LA_MU^$_VA/"?V#Q'=VO@[XDZ2IAUG0-2E%NQD08>:$/@
ME"025^]&<AN,,WL?[._]J_\ #/\ \,O[=,QUO_A&-,^WFX_UGVC[)%YF[_:W
M;L^]/\:?L_\ PR^(^L1:MXJ^'WAGQ#JL;*RWVI:3!/,=O0%V4L5_V22/:@#P
M']C/P#:7'QV_:%^+&B!3X1\7:W!;:-<1 >5?>0K_ &JZC(^_&]Q(X5QPVUCD
M]:^A_A7\*M,^$NFZ]8Z3<W4]OJ^N7VO/'<LI6"6ZF,KQQ  8C#$X!R>3ST Z
M^SL[?3K."UM(([6U@18XH(4")&@& JJ.  . !4U !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%>=?M"?&O2?V>/@]XD\?ZS"UU:Z3 &CLXVV
MO<SNP2*('!QN=E&<' ).#B@#T6BOS'U0?\%"OBIHDGCS2+W3?!=E/%]JL?",
M M8KKRC\RKMFC<[B".)I >.0.E>^?\$^?VQ=<_:3T/Q-X8\>Z:NC_$CPC,L.
MI1+"8!<(S.H?RCS'(C(R.O0$J1C=M !W6O\ _%'_ +<WA*^;Y+;QIX+O=).W
M@-<V%S'<QD^_E74_X#VKUGP+\/--\ 3>)9=/:223Q!K$VMW;2XSY\B1H0, <
M!8D SSQ7DW[67_%-ZM\&/'*'RF\/^.;*VN9NR6E^DMA+GVW7$1_X#7T%0!^>
M'[:_[4%]X%_:B\$WGPV\!3?$WQ-X%TO4H-5-G;3S16,EZ( L;O"IPZQPN2#T
M$XZ'(KU[]B7]O[0OVMI-4\/WVC-X1\=Z7&9Y])>;S8[B$,%:2)B%;*L5#(PR
MNY<%N<?5EO:PVJLL$,<*L[2,(U"@LQRS''<DDD]\U\;_ !F^$6E>'O\ @H1\
M!O&WA2!=/\1ZZFL1^(8[7"K=VL-G\L\J],@R!"Q'S$Q\Y44 ?6_BSPMI?CCP
MQJWA[7+./4-'U2UDLKRUD^[+%(I5U/ID$\CD5^97[(OQ4U#]A/\ :,\=?LY^
M,8M8USPW<W9OO#<VF64M]<%G4-'MAB5FQ+%MW;1A)(SG@LP_4NN-\%?"/PSX
M$UK5]<L+'[1XEUA]^I:]?-YU]=XP%5I3R(U  6-=J* -JB@"K\0/ .G?'KX6
M3>'O$%KJ>AV>J?9KB2#?$EY;/%/'/'RID17#QJ>"V*[RBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ JEK7_(&O_P#KWD_]!-7:I:U_
MR!K_ /Z]Y/\ T$T >34444 >@?#_ /Y TW_7PW_H*UTU<S\/_P#D#3?]?#?^
M@K734 %%%% !1110 4444 %?FI\0?C0_[&O_  4[\1ZWXM5H/A]\3=,L%DON
M2EJ8XHX%G8]_+EAD#*.B3;L' !_2NO*OVB?V9_ G[4/@M/#GCC3I+B.WD,UE
MJ%I)Y5U92D8+Q/@]1U5@5.!D$@8 .E\?3>#/%/PIUR3Q->Z;=>!-0TN4WUY-
M.AM'LWC.Y_,SMV[3D,#Z$5^</_!(/Q9J'@KXO_%?X0S&\CTE(1KMC;ZE$8;A
M-DD<6]H_X&DBFMRP[;%KZ"^#?_!+_P !?"_4K5M7\7>*O'.A6-R+JR\,ZQ>
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MC  '0 4ZBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MA5FC+!6).-M?6-%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4?W?]*49'4@CM7TQXC^&&JW?[2'@KXA:9+;16%EH.IZ)K*2N1)-'++;36PC
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M@/8J* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$X&> !Q7I%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !7S-^T?KW[48^)6CZ+\%_#7A/_A$9[-6O/$GB"<,8+@L
MP(,8E#A54(1MC?))^E?3-% 'D_P.^"-W\-YM5\2>+/$4OC?XCZ\D2:MXAFA6
M!!%'GRK6VA7Y88$+,0HY9F9F))X]8HHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH \-_::_8W^''[5NEVL?C"PGM
MM8LE*66O:7((;VW7.=FXJ5=,\[74@9)&"<US/@3]C[Q#I_A]/"WC_P"-7BKX
MD>"8MJKX>O;>WMH[F->D5U<*K7$\?3,9E56 PP925KZ8HH 9#"EO$D42+'$B
MA51!@*!P !V%/HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<LQ)/<FNDHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH Q?&EYK>G^#]<NO#6GP:MXBALII--L+J;R8KBY"$Q1N_\
M*LV 3VSVKY+^'_PS_:;_ &@K*6Q^/NJZ+X"\$3'9?>%?"87[;JL>?F@FN4DD
M\J!APWER%G7*G:#FOLZB@"O86%MI=C;65G!':VEM&L,,$*A4C10 JJ!T
M]JL444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ7#L,\QS+<RL2\LTA[N[LS'W;CC%=K110 4444 %%%% !1110 4444 %%%%
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MD_\ 030!Y-1110!Z!\/_ /D#3?\ 7PW_ *"M=-7,_#__ ) TW_7PW_H*UTU
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 52UK_D#7__ %[R?^@FKM4M:_Y U_\ ]>\G
M_H)H \FHHHH ] ^'_P#R!IO^OAO_ $%:Z:N9^'__ "!IO^OAO_05KIJ "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ JEK7_(&O\ _KWD_P#035VJ6M?\@:__ .O>3_T$
MT >34444 >@?#_\ Y TW_7PW_H*UTU<S\/\ _D#3?]?#?^@K734 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !5+6O\ D#7_ /U[R?\ H)J[5+6O^0-?_P#7O)_Z": /
M)J*** /0/A__ ,@:;_KX;_T%:Z:N9^'_ /R!IO\ KX;_ -!6NFH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "J6M?\ (&O_ /KWD_\ 035VJ6M?\@:__P"O>3_T$T >
M34444 >@?#__ ) TW_7PW_H*UTU<S\/_ /D#3?\ 7PW_ *"M=-0 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M89''0T :E%?$_P"R[\)[Z\_:#^.%GK_Q%^(7B/2?".N6EIHFGW_C/4S# DD
MN#YBK,/.QO5,2;@0IR"3FOMB@ HHHH **** "F+,C2M&'4R* S(#R <X)'O@
M_D:Q_&7AEO&'AVZTD:QJFA+<#:UYHTX@NE7N$D*DIGU7!]"*_/?_ ()!M??\
M)A^T3%J6J7NMWD&KV%O)J&HS--<3[&O5#N[$DL0* /TCHHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %4M:_Y U__P!>\G_H)J[5+6O^0-?_ /7O)_Z": /)J***
M /0/A_\ \@:;_KX;_P!!6NFKF?A__P @:;_KX;_T%:Z:@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH P
M?'7BE/!7A+4]:DB\\6D6Y8\XW,2%4$]AN(KY2OOVC_'MU<O)%JT5FC'B&&TB
M*K]"ZL?S-?7>O:':>)=&O-+OX_-M+J,Q2*#@X/<'L0>1[BO![C]D.)IW,'BE
MXX2?D22P#L!Z$B09/X"OB\_PV;5ZD'@)/EMK:7*[_>C[GA[%9/AZ<UF,5S7T
M;CS*WW.VIYK_ ,-#?$'_ *&#_P DK?\ ^-T?\-#?$'_H8/\ R2M__C=>C?\
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MO%_\376?\*'_ .HY_P"2G_V='_"A_P#J.?\ DI_]G7PO^K_B)_/5_P#!Z_\
MEA[/U[(>T?\ P!__ ")R?_"U/%/_ $%/_)>+_P")H_X6IXI_Z"G_ )+Q?_$U
MUG_"A_\ J.?^2G_V='_"A_\ J.?^2G_V='^K_B)_/5_\'K_Y8'U[(>T?_ '_
M /(G)_\ "U/%/_04_P#)>+_XFC_A:GBG_H*?^2\7_P 376?\*'_ZCG_DI_\
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MUGXI>.-073M$LKTDP6R$@27<X7DQID<9&>3T5A7.?%#X-?&+PG\-=3\8:/\
M'WQ'?^.]%L)+][:\T[3TT6],2;WA^RQP!D5@I4-YC,-V237@'[4WBB/PC_P5
MH^!&H:[)'#HW]CV]K;R2G$:O/+?0J2>@/F2)^&W-??OQ9_Y)7XR_[ M[_P"B
M'H ^</\ @F/\;O&?[0'P%\0>*_'6L-K.LMXHNK=)/*2)(81;VS+$B(  H+MC
MOR<DFOKJO@K_ ((P_P#)J&M_]C;>?^DMI7WK0 4444 %%%% !1110 4444 %
M%%% !6!X^\6)X'\'ZIKDD1G%G%N6+.-S$A5!/8;B*WZS_$&@V?B?1;W2M0C\
MVSNXS%(H.#@]P>Q!Y!]16=13<)*F[2MIZDROROEW/C:^_:8^(-W=/+%J\5E&
MQR(8;.$JOL"ZL?S-0?\ #2'Q%_Z&+_R2MO\ XW7I]Q^QM"UQ(;?Q8\4)/R))
MIX=@/0L)1D^^!47_  QI_P!3A_Y3/_MU? /!YU?>7_@:_P SYWV..[O[_P#@
MGFO_  TA\1?^AB_\DK;_ .-T?\-(?$7_ *&+_P DK;_XW7I7_#&G_4X?^4S_
M .W4?\,:?]3A_P"4S_[=2^IYUWE_X'_]L+V..[O_ ,"_X)YK_P -(?$7_H8O
M_)*V_P#C='_#2'Q%_P"AB_\ )*V_^-UZ5_PQI_U.'_E,_P#MU'_#&G_4X?\
ME,_^W4?4\Z[R_P# _P#[8/8X[N__  +_ ()YK_PTA\1?^AB_\DK;_P"-T?\
M#2'Q%_Z&+_R2MO\ XW7I7_#&G_4X?^4S_P"W4?\ #&G_ %.'_E,_^W4?4\Z[
MR_\  _\ [8/8X[N__ O^">:_\-(?$7_H8O\ R2MO_C='_#2'Q%_Z&+_R2MO_
M (W7I7_#&G_4X?\ E,_^W4?\,:?]3A_Y3/\ [=1]3SKO+_P/_P"V#V..[O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %4M:_P"0-?\ _7O)_P"@FKM4M:_Y U__
M ->\G_H)H \FHHHH ] ^'_\ R!IO^OAO_05KIJYGX?\ _(&F_P"OAO\ T%:Z
M:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OFKX:?
ML8:-\._VP/B!\:8'MFB\064:V-BH.^UNI3F]E(QCYS'&P().99@0!C/TK10
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M:M-\9:[\/=9T?P38:'>:KJ=E/9>9KVHS6<%OYD902?NK>9I,;L[?ESC&X9R
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M_P#B_J$/P^U"S\9"X2YTFVUV^22T629)4*2&PPY7RPIRJ[LD_+TH ^Z:***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JEK7_(&O\ _KWD
M_P#035VJ6M?\@:__ .O>3_T$T >34444 >@?#_\ Y TW_7PW_H*UTU<S\/\
M_D#3?]?#?^@K734 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-_C[I'A7XZ_#GX602P77B/Q2;NYGM]Q+VEE!:SR"4@="\L:(N>H$F/NUZM0
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MI^-GQ]TCX0ZYX \/RRP3^(_&6OVFD6%@['?Y3RJ+B? YVHA(!Z;G0<]*]6H
M**** "BBB@"AJFOZ9H;6::EJ-II[7DZVMLMU.L1GF8X6--Q&YR>BCDU?K\N/
MVROAUI?@C_@HQ^SA?Z=<:K-+K.L6,]TNI:I<7P$BZ@@W1^<[F,$$#8A" *N%
M'.?U'H **** "BBB@ HHJ.XA%Q!)$S.JR*5+1L589&,@CD'W% %6YUW3;/5+
M/3+C4+6#4KP.UM9R3JLTX49<HA.6P.3@<5>K\P_#'P^T[X;_ /!9#3M.TJ?4
M)[2XT26\SJFHSW\P=]/DWYFG=Y&RREOF8XW$# P!^GE !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 52UK_D#7__ %[R?^@FKM4M:_Y U_\ ]>\G_H)H \FHHHH
M] ^'_P#R!IO^OAO_ $%:Z:N9^'__ "!IO^OAO_05KIJ "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@+X*_%7]I+]FGX<7&K?&'7OAW93>%---I;>%I2;NZ8VD6+N]O"1)*9.7,*%
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MXR^(/VD/VMM8^!_@_P 0W_A+P7X/L&O/%6N:+*(M0O;DE56S@FP3"JM(-SJ
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MM)&.&SD]*_8*ORU_X)E_\GR?M&_]=K__ -.9H ](_;._;X\7>"_A5J6FZ/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *I:U_P @:_\ ^O>3_P!!-7:I:U_R!K__ *]Y/_030!Y-
M1110!Z!\/_\ D#3?]?#?^@K735S/P_\ ^0--_P!?#?\ H*UTU !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M**<X.5^4@'IG[,/Q&UOXM_L_^!?&'B.UBM-;U?3([BZ2W&(W?)'F(,G"N '
MST<5XC\6/AGX:^.7[?WPU/\ 9Z7%Y\-]%DUW6KWJ"\LH&F6K>C+(L]P/8>]:
MW[8'[(GC3X^W7@RX^'_Q4O\ X8IX>1H18:?YT4#*2NV1/)D0JZ*NT#!&#@%>
M<^H_LZ?L]Z7^SSX/N].@U;4/$_B#5;DW^N>)=8D,EYJET5"^8Y))"A0%5<G
M'4DDD ]7HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *I:U_R!K_\ Z]Y/_035VJ6M?\@:_P#^O>3_ -!-
M 'DU%%% 'H'P_P#^0--_U\-_Z"M=-7,_#_\ Y TW_7PW_H*UTU !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117A_P"U
M]\(/!?Q+^!/CVZ\2^&-+U?4-/\.W\UCJ%S:(]U9R)!(Z-#*1N0AAG@X/.<@D
M4 >X45^9?_!&?X.^#==^#_B7QSJOAG2M5\2V_B=K.TU*^M$FFM%AM[:9#"S
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MR&V)*P&X'& >H!H _8FBH+&QMM+L;>RLK>*TL[>-88;>! D<2* %15' 4
M#@ 5/0 4444 <YXV^)'A3X;6,-YXK\2:5X<M9I!%#)JEY';B5R0 J;B-S<C@
M9-='7Y<_\%?OAKX:T'7OA/XLL-+CMO$.J:W+!>WRNQ>X1?)*JV21A3G&.F3Z
MU^HU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !5+6O\ D#7_ /U[R?\ H)J[5+6O^0-?_P#7O)_Z": /
M)J*** /0/A__ ,@:;_KX;_T%:Z:N9^'_ /R!IO\ KX;_ -!6NFH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 52UK_ ) U_P#]>\G_
M *":NU2UK_D#7_\ U[R?^@F@#R:BBB@#T#X?_P#(&F_Z^&_]!6NFKF?A_P#\
M@:;_ *^&_P#05KIJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JEK7_ "!K_P#Z]Y/_
M $$U=JEK7_(&O_\ KWD_]!- 'DU%%% 'H'P__P"0--_U\-_Z"M=-7,_#_P#Y
M TW_ %\-_P"@K734 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5+6O^0-?_ /7O)_Z"
M:NU2UK_D#7__ %[R?^@F@#R:BBB@"6Z01W4R*,*KL /;-1444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
E1110 4444 %%%% !1110!N6^FVTEO$S1Y9E!/S'T^M%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>img64083768_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img64083768_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $S _D# 2(  A$! Q$!_\0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M */-7[!V75]/4?QWE_G_ +^-5TM[>3_,C%JZE_B_]L.TI::/NBG5J>8%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %+24M !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 E%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQ]%%% @HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *6DI: "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!****
M "H9YDBC9G.%'>IB0 237)ZMJ!N6:*,X1&M74^H>X"_R4_G2;L:4Z;G))>7X
MNQ7UO49+RWN@,K']CO@!G^*/:F?U-"_\AI?^PJG_ *1U1N_^/2[_ .O;5O\
MT:*O+SK8]/[53_TBK%.]F_[IW\BC3:7:?YHS[7_D'VO_ %YZ7_Z/-+=_\>EW
M_P!>VK?^C13;7_D'VO\ UYZ7_P"CS3KO_CTN_P#KVU;_ -&BH?P_)_F='_+W
M_M[_ -L+X_Y#8_["J?\ I%6?:_\ (/M?^O/2_P#T>:T!_P AL?\ 853_ -(J
MS[7_ )!]K_UYZ7_Z/-6_B^;_ ",H?"O2G^8MW_QZ7?\ U[:M_P"C15\?\AL?
M]A5/_2*J%W_QZ7?_ %[:M_Z-%7Q_R&Q_V%4_](J2Z?\ ;H3^!^D__2C/M?\
MD'VO_7GI?_H\TMW_ ,>EW_U[:M_Z-%):_P#(/M?^O/2__1YI;O\ X]+O_KVU
M;_T:*E[?)_F:_P#+W_M[_P!L+X_Y#8_["J?^D59]K_R#[7_KSTO_ -'FM ?\
MAL?]A5/_ $BK/M?^0?:_]>>E_P#H\U;^+YO\C*'PKTI_F/N&*0SR+]Y(=59?
M8B48K>T[5/L]S+93M^[A>.".0]V*!L?K7/W?_'I=_P#7MJW_ *-%7702ZOL8
M9!U5,CZ6>?Z4X2M_Y*95J:E%OJE-_=([3(*\THZGUKGO#FJM<V5K%<M_I$D
MG&?[I/%=$"#6QP2BXR<7T"BBB@D**** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *6DI10 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 )37.,4ZH+VX2UM)9Y/NQJ6/X#-)NRN-*[LBAJ-[Y=Q:6ZGF:8
M1L?^ LW_ ++7'QOC3(9#SBQTYV'KB=B?ZUJ&5GUF/?R5U10/_ 0G^IK-L94M
M;:WNY%#1Q:59AE/?<[@?K6:UEKW?Y'H4X^SIW6_N/_R8FU&!X+:Z#J0&L]2?
M)]'96'\ZM*/^)V,=/[53_P!(ZVM9LQ?:1<F+!=K>2-<>C+C'\JQ%(.M*?^HH
MG_I%2<;.WH33J\])WWY9?BTRA:_\@^U_Z\]+_P#1YI;O_CTN_P#KVU;_ -&B
MDM?^0?:_]>>E_P#H\TMW_P >EW_U[:M_Z-%9O;Y/\SL_Y>_]O?\ MA?'_(;'
M_853_P!(JS[7_D'VO_7GI?\ Z/-: _Y#8_["J?\ I%6?:_\ (/M?^O/2_P#T
M>:M_%\W^1E#X5Z4_S%N_^/2[_P"O;5O_ $:*OC_D-C_L*I_Z150N_P#CTN_^
MO;5O_1HJ^/\ D-C_ +"J?^D5)=/^W0G\#])_^E&?:_\ (/M?^O/2_P#T>:6[
M_P"/2[_Z]M6_]&BDM?\ D'VO_7GI?_H\TMW_ ,>EW_U[:M_Z-%2]OD_S-?\
ME[_V]_[87Q_R&Q_V%4_](JS[7_D'VO\ UYZ7_P"CS6@/^0V/^PJG_I%6?:_\
M@^U_Z\]+_P#1YJW\7S?Y&4/A7I3_ #'77_'I=_\ 7OJW_HT5HI&S:G#.JGRI
M+])0W;'V8I_,?K56*-I[R" )N6>348&]@TP/]#73ND-E:V]J,88K'&#Z@?X
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M7.:G_P A^#ZK_6NC[USFI_\ (?@^J_UJ9= >S-ZX_P"/=_\ =/\ *N<\-_\
M(7N_^N2_S-='<?\ 'N_^Z?Y5SGAO_D+W?_7)?YM5QW8/9'4#O2T@ZFEI -/7
M\*YO5_\ D-P_6/\ ]"-=(>OX&N;U?_D-P?6/_P!"-)E(Z7M6)X@8?9(@#_'S
M^5;?:N:\3RX6.,'D\#ZDX%.UVD3>P[P[.B/-;\@N0X'X '^5=%@;1^=<J\:V
M>OP2= >/P8?X@5U2XVCFG>^HEV'4ULTZD>D,Q]<N1';"(_>D_E6?X=E9=1N;
M8C@HKCZY(/\ 2C5YEN=6MX!SEU3'XY/Z"I+-1!XF<?[++^9!HC;=^8F^QT@.
M<TM(#D4M QOM6-XBN$CL]C'&3D_05L,,@BN8U-%O=92W;E6(0CV&2:6^@;*Y
M7TZ>2RU&V+J0)\*?H>0?\^M=@"<X-<WKD8AD@D1>%&1^!!%;EG<I=6D<Z=&4
M$56C$6@,5F:Y_P @YOJ*TQ69KG_(.;ZBI>Q2&>'?^03'_P!=)/\ T,UIR#/^
M%9GAW_D$Q_\ 723_ -#-:C=:TJ?&R(['.ZY9[=L\6%'?'8]JT]&N7NM-AED_
MUA7:WU'6DU<9TZ7(["H/#Y_XEH'H[_\ H1J%U0WNC1NY1#;O(?X0<5SFB0)>
M7\TSKGR&&,_WCR3^6*VM9!.FRX]C^M9WAET,5XH^\)>?R&*:74;V.B[54U"T
M2[@,;<'J#[U;I&[ T@,;1+&6R28RGB1@57TK:I@&#GJ.PI]%P"BBB@#E;W_D
M8E_ZZK_*NH6N7O?^1B7_ *ZK_*NG !%,ID,\$<\;1R+D'BN<M%6QU\IC ;,9
M/MU'^?>NJ'(P>U<EKQ\O5(V7KYL?_H0H2U)Z:G5>A'7K7/W6M3+>X3"Q(^&!
M[X.#BN@&".M94VB)+>"8,53<&*XZ\YI=0Z&RIW*#ZC-+0!@ #M10 4444 %%
M%% %2^?R[64]@AKE=,?9JUO(&^5LQL/7/_UQ6_K<OE:?L[NVW^O]*YUK&2VT
MJ&YC/[QBS#ZDEA_.A:.X/8[5<;0!TI]5;&83V,$W]] :M4VK.P("<"J5]*T-
ME+)G#!25^N*N$XK"\07)CA2%<_/D_E_^NI8T9>E3;-5B;^\2O^?RKL%ZGTKB
MKNVETVWLG/\ K059S[[LG]#7:1G*#/I5-=42A]%%%(84444 %%%% !1110!'
M<?\ 'O)_NFJNB_\ ()A^K?\ H1JU<?\ 'O)_NFJNB_\ ()A^K?\ H1I=0+]%
M%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@#-U>X^SV61P7D1/\ OIU7^M<;=_\ 'I=_]>VK
M?^C170^(I\Q+#_$DML_YSH/Z5SUW_P >EW_U[:M_Z-%85'OZ/]#T<)&RB_/_
M -M?^9?'_(;'_853_P!(JSK7_D'VO_7GI?\ Z/-:(_Y#8_["J?\ I%6?:_\
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M*I_Z150N_P#CTN_^O;5O_1HJ^/\ D-C_ +"J?^D5)=/^W0G\#])_^E&?:_\
M(/M?^O/2_P#T>:6[_P"/2Z_Z]]6_]&BDM?\ D'VO_7GI?_H\TMW_ ,>EV/6W
MU;_T:*3V^3_,U_Y>?]O?^V%R200ZMYC'Y1JL8_.TQ_45M:)9#2M%BBF^^B8S
MZ =!5*PLQ=ZU>B9,PI<13H?5A$J_TJSKMYA/LZ'E);<MCT:95_H:W^&]^_Z'
MFR;J.,%VC_7XF+JURUU%=2-U^Q:BF/\ <9%_I4X_Y#8_["J?^D54+O\ X]+O
M_KVU;_T:*OC_ )#8_P"PJG_I%6*Z?]NG6THTVEVG^9GVO_(/M?\ KSTO_P!'
MFEN_^/2[_P"O?5O_ $:*2U_Y!]K_ ->>E_\ H\TZZ_X]+O\ Z]M6_P#1HJ7M
M\G^9O_R]_P"WO_;"Q=2O!J#&/[S:M"I^GV92?Y5VRMYBANQYKCBH;6=IYSJB
M?^D5;WAN]^WZ';W!/+ C\CBNF+=FO/\ R/,KQMRR_NQ_7_(UP,"BD%+3.<*.
M]%'>@#F_$W6'_<;^E;T3#R4Z?='>L+Q+C?!GIM;^8JD(]2P,"?;VY/2DBGL=
M;N'M^=&X>WYUR?EZGZ7'YFCRM3QTN.GK3).J! Z8QCUKG]2_Y#UO_P  _K57
MR]3':?&?4U'&)AJ-N)]V_<OWNM)@]F=;<?\ 'N_^Z?Y5SGAO_D+W?_7)?YM7
M1W'_ ![O_NG^5<YX;_Y"]W_UR7^;54=V#V1U ZFEI!U-+2 :>OX&N;U?_D-P
M?6/_ -"-=(?Z&N;U?_D-P_6/_P!"-)E(Z7M7+7\7VW7D@;[JR+C\/F_G74?P
MUSEHWF^)G]0'/Y8%-7OH3>R'>([3?$LT9VM@)GT]#6OITPGT^WD;JR+GZTW4
M[<W%@Z#KP?RYK-\.SLZSVTG2)@4^A_\ KYIJ]F@?<Z"HYV"1ECT )J2LW7)3
M'I[!3@L0,U+&C)T9$N=6FF;G9R/JQ/\ A27K_9?$*RM]UI /S&/YU>\/VBPV
M?G_Q3D.?Z?I53Q1$ (Y0.5^;\CD522ND*[U9TJ=*6F1'=&I]A3Z0EL13.(XG
M;LH-<WHMNUUJ37;GF,$?4GK6EK=T8;,(G5S@^PIOAVWD@T\O+]Z5R_X=OT%"
MZC9-K$2OI\AQRHW56\.RI]C,7>)CQ[$Y_K6O*B2QL&&0PP:YK3(_LGB"2,GA
MT*?D<C^9H6]K@^AU*Y)/I6;KG_(.;ZBM('/TK-US_D'-]12>PT1^'L_V3&<\
M>9)_Z&:U3Z ]*Y&RU66RM_(15*[F.3[DG^M3/KUTXP JY]*N;O)M$Q5D7=>N
MQ'!Y .689/MBK&@QM'I,.\;6;+D>F237.I(LMW&]U*VS=DY[\]#Z"NQA:-XP
M\9!7'&*2V!ZL2X020%",@C!KEH)I=*OFW( C'#CO@'J*ZXCCCK5"^TZ*]4[A
MMD X;TI;#+%K<QW$8DC8,I[CO4P)W5R#Q7>ES%D8H6X#=0PK;T_6(KDB-U"2
MG^$GJ/:CT UNW%+30>F.AIU !1110!RU[_R,2_\ 75?Y5TJ#(/&*Y75&,>L/
M(.J,"/RJ8:_<=1&G;UH&SI'=57<3@"N5=!J.N@#[F_?^"X_KBH[K4[BZ0JY
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M_P"CS4S)YTJVN.;G^TX1]6F'_P!>H;<@:;;9X_T+3/\ T>:W]#LC)///.O\
MJ+N<PD^CN3G]:J$>;1]G^9.)J>S;:WYG_P"D&I;0_P!GZ?%&[!I-JJ3ZMBN3
M>=KI5N&.3-!ITA^K7+&MN_O3/JEE&OW8[P1M[_N7;_"N=M/^0?:_]>>F?^E!
MJIRYI7]?R,<-3Y8W?]W_ -*_X Z[_P"/2[_Z]M6_]&BKX_Y#8_["J?\ I%5"
M[_X]+O\ Z]M6_P#1HJ^/^0V/^PJG_I%6:Z?]NG1/X'Z3_P#2C/M?^0?:_P#7
MGI?_ */-+=_\>EW_ ->VK?\ HT4EK_R#[7_KSTO_ -'FEN_^/2[_ .O;5O\
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M (]+O_KVU;_T:*OC_D-C_L*I_P"D5)=/^W0G\#])_P#I1GVO_(/M?^O/2_\
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M7[+K;6C?\M$/_CI_^O4_B*1GEAA0]1C'J20!3=WOU!6B3>'H%%M)<_Q2,1^
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M$C%@&'0?Y_G5/7+:1)ENXFV],'T:G>S%NCHU^Z/K3N3[5G:=J$=Y;*0P\Q0
MX]#5]B-G)P*3T&5]0F%O9RR$]L#ZTS1>=)@_X%_Z$:RM8O1,1:1#/S#)'<^E
M:NBC&D0#_>_]"-)#+]%%%,04444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!YU;<:?;?]>>E_^CS2
MW7_'I=_]>^K?^C13@NR"-?[MMIH_\F6IMW_QZ7?_ %[:M_Z-%<S^'Y/\SVT[
MU+_WO_;"^/\ D-C_ +"J?^D59]K_ ,@^U_Z\]+_]'FM ?\AL?]A5/_2*L^U_
MY!]K_P!>>E_^CS5/XOF_R,H?"O2G^8MW_P >EW_U[:M_Z-%7Q_R&Q_V%4_\
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M?^D59]K_ ,@^U_Z\]+_]'FA_%\W^1</A7I3_ #%N_P#CTN_^O;5O_1HJ^/\
MD-C_ +"J?^D54+O_ (]+O_KVU;_T:*OC_D-C_L*I_P"D5)=/^W0G\#])_P#I
M1GVO_(/M?^O/2_\ T>:6[_X]+O\ Z]M6_P#1HI+7_D'VO_7GI?\ Z/-+=_\
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M^!&K. 33ATH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MVI)=U#]6=*@QGW-.I%Y_#BEJSB"BBB@ HHHH **** "BBB@ HHHH ***,B@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **"0.I
MHH **** "BBB@ HHHH **** "BC-% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !11FB@ HHHH **** "BBB@ I:2EH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** .=\1P (L_=Y;9?RG0_UKG;O_ (]+O_KWU;_T:*[+6+?S[$#J
M4D1_^^75OZ5QUW_QZ7?_ %[:M_Z-%85%OZ,]'"2NHKS_ /;7_D7A_P AL?\
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MD_\ THS[7_D'VO\ UYZ7_P"CS3KK_CTN_P#KVU;_ -&BFVO_ "#[7_KSTO\
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MG/IC_&M%>] "T444 %%%% &)X@NI[2TC>!RA:0 X[BMB(Y0?2L+Q5@V$6/\
MGJ*WHR-B_2J^S_7D#W0ZBBBI **** "D8\8%+2$X&: ,;4+F:WU?3XHWPDI(
M<>O%;58&K\ZYI)]7;_T$UOT+;[P"BBB@ HHHH **** "EI*6@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH C<!E*G^($5PVJP-;Q749Z_8M2;_OID;^M=PPYXKGO$]J3
M9W5TJ\"QN(S_ ,"0?_$UG47NMG3A9\M57_K1K]2@O_(;'_853_TBK/M?^0?:
M_P#7GI?_ */-7U_Y#8_["J?^D54+;_D'VO\ UYZ7_P"CS4/XOF_R.V'PKTI_
MF+=_\>EW_P!>VK?^C15\?\AL?]A5/_2*J%W_ ,>EW_U[:M_Z-%7Q_P AL?\
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M "#[7_KSTO\ ]'FF_B^;_(</A7I3_,6[_P"/2[_Z]M6_]&BKX_Y#8_["J?\
MI%5"[_X]+O\ Z]M6_P#1HJ^/^0V/^PJG_I%273_MT)_ _2?_ *49]K_R#[7_
M *\]+_\ 1YI;O_CTNQ_T[ZM_Z-%):_\ (/M?^O/2_P#T>:DE3SDEA'WI8M5C
M'U,RBET^3_,TDTJC;_F_]L-K1[>0^(-3=QF+=$Z'U/E*I_E735G:3 \%A")!
M^]**7/OCFM&NJ2LVCQ7)RU?9?E8****0!2,,X/I2TC'% $,LJ11M(YVJHR<U
MD/X@7S"L<+,!QFDUR=FEM+,' N'"G\_\,UJ1V<,$"Q)&H4#&*/,"I#J]O/+
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MQ7!ZY%17NKQ6C[,%Y.I451\.,$T:=_[LTAJ71K3*M>28=YFR 1]T9[4Y*SL
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ML+;[+KCQD@KL)'TSFG11_9/$;LQQ'<+@#W'^30@-MB I)P0.M)9W N;595!
M)(_(D?TJGJ]R+/3)I0>@Q_C4VD1F+2;96&&V D>YY/\ .BW4"[1110 4444
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M^9]GV[??%-; OC7]=A?#G&A6^>GS?S-&OPNU@9(CB1""IQT]Z=H<,D&DPPR
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M42&'Q5([=)(F /K]W_ UMD^_'I69JUB]V$EA?;-'R,=350ZEJ)3ROLC>8>I
M_.AML.MRQ#(DWB!@IR%C(_6F^(;=VM4FA)#1/NX]O_KU#IEN]OJH63F1HB7]
MB36W<(LL+H>ZD5*TU&8U_<)?7-G9CD2X<X],$_TKH(QM0 =A7,Z!;![EKE^3
M /+3VSR?Z5TZ_=IB%HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 2BBB@ (!!!'6N2U?3C
M:LTD8_=NUI&N.P2XW?R;]*ZVH)HDF1D=<@]J35S2G4<)7]/P=SA+O_CTN_\
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MHHHH)"BBB@ HHHH *0JIY('Y4M% !@>E%%% !2;1G.!FEHH *3:"<X&:6B@
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M8_["J?\ I%5OP8RKX0ME) .QNI]S5-2#K2D'@ZHA'T^QUGV!,6F6J(Q"_9+
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M 4M)2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I:** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
**** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>35
<FILENAME>vir-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-02-28T15:30:33.8714+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:href="vir-20221231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails2" xlink:href="vir-20221231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails2" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows2" xlink:href="vir-20221231.xsd#StatementConsolidatedStatementsOfCashFlows2" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3" xlink:href="vir-20221231.xsd#StatementConsolidatedStatementsOfCashFlows3" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" xlink:href="vir-20221231.xsd#Role_StatementConsolidatedStatementsOfOperations" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:href="vir-20221231.xsd#StatementConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:href="vir-20221231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails" xlink:href="vir-20221231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails" xlink:href="vir-20221231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsCollaborationCollaborationRevenueDetails" xlink:href="vir-20221231.xsd#DisclosureCollaborationAndLicenseAgreementsCollaborationCollaborationRevenueDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" xlink:href="vir-20221231.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails" xlink:href="vir-20221231.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:href="vir-20221231.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetDetails" xlink:href="vir-20221231.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails" xlink:href="vir-20221231.xsd#DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeLossBeforeProvisionForBenefitFromIncomeTaxesDetails" xlink:href="vir-20221231.xsd#DisclosureIncomeTaxesScheduleOfIncomeLossBeforeProvisionForBenefitFromIncomeTaxesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" xlink:href="vir-20221231.xsd#Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails" xlink:href="vir-20221231.xsd#Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="vir-20221231.xsd#Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple"/>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Goodwill" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="vir_EquityInvestmentCurrent" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_LongTermInvestments" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssets" order="6" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="7" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_EquityInvestmentCurrent" xlink:label="vir_EquityInvestmentCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vir.bio/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails2">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="vir_LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="vir_PresentValueOfOperatingLeaseLiabilities" order="2" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived" xlink:label="vir_LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PresentValueOfOperatingLeaseLiabilities" xlink:label="vir_PresentValueOfOperatingLeaseLiabilities"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vir.bio/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows2">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="2" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vir.bio/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="2" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostOfRevenue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_Revenues" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_RevenueNotFromContractWithCustomer" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_CostsAndExpenses" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="2" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vir.bio/20221231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="vir_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentToProjectedBenefitObligationsNetOfTax" order="2" weight="-1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentToProjectedBenefitObligationsNetOfTax" xlink:label="vir_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentToProjectedBenefitObligationsNetOfTax"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="vir_ProceedsFromIssuanceOfCommonStockInConnectionWithCollaboration" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockPlans" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireInvestments" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="vir_ProceedsFromIssuanceOfCommonStockInConnectionWithAGrantAgreement" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnTerminationOfLease" order="2" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="3" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" order="3" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfMachineryAndEquipment" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="4" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="vir_ProceedsFromDisposalOfAnEquipment" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="vir_PaymentOfContingentConsideration" order="6" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="6" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" order="7" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="8" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" order="9" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_LaborAndRelatedExpense" order="11" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="12" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="vir_ChangesInEstimatedConstraintOnProfitSharingAmount" order="13" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" order="14" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="15" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AssetsFairValueAdjustment" order="16" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="17" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OtherOperatingActivitiesCashFlowStatement" order="18" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="19" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="vir_NoncashLeaseExpense" order="20" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="21" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="vir_IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue" order="22" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ProceedsFromIssuanceOfCommonStockInConnectionWithCollaboration" xlink:label="vir_ProceedsFromIssuanceOfCommonStockInConnectionWithCollaboration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ProceedsFromIssuanceOfCommonStockInConnectionWithAGrantAgreement" xlink:label="vir_ProceedsFromIssuanceOfCommonStockInConnectionWithAGrantAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="us-gaap_GainLossOnTerminationOfLease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfMachineryAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ProceedsFromDisposalOfAnEquipment" xlink:label="vir_ProceedsFromDisposalOfAnEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PaymentOfContingentConsideration" xlink:label="vir_PaymentOfContingentConsideration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ChangesInEstimatedConstraintOnProfitSharingAmount" xlink:label="vir_ChangesInEstimatedConstraintOnProfitSharingAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueAdjustment" xlink:label="us-gaap_AssetsFairValueAdjustment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:label="us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_NoncashLeaseExpense" xlink:label="vir_NoncashLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue" xlink:label="vir_IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="vir_FiniteLivedIntangibleAssetsAccumulatedImpairment" order="2" weight="-1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_FiniteLivedIntangibleAssetsAccumulatedImpairment" xlink:label="vir_FiniteLivedIntangibleAssetsAccumulatedImpairment"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="vir_FiniteLivedIntangibleAssetsAmortizationExpense" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="vir_FiniteLivedIntangibleAssetsAmortizationExpense" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="vir_FiniteLivedIntangibleAssetsAmortizationExpense" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="vir_FiniteLivedIntangibleAssetsAmortizationExpense" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="vir_FiniteLivedIntangibleAssetsAmortizationExpense" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="4" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_FiniteLivedIntangibleAssetsAmortizationExpense" xlink:label="vir_FiniteLivedIntangibleAssetsAmortizationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vir.bio/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsCollaborationCollaborationRevenueDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="vir_TotalcollaborationRevenue" xlink:to="vir_ProfitSharingAmount" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="vir_TotalcollaborationRevenue" xlink:to="vir_ProfitSharingAmountConstrained" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="vir_TotalcollaborationRevenue" xlink:to="vir_ProfitSharingAmountPreviouslyConstrainedReleased" order="2" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TotalcollaborationRevenue" xlink:label="vir_TotalcollaborationRevenue"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ProfitSharingAmount" xlink:label="vir_ProfitSharingAmount"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ProfitSharingAmountConstrained" xlink:label="vir_ProfitSharingAmountConstrained"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ProfitSharingAmountPreviouslyConstrainedReleased" xlink:label="vir_ProfitSharingAmountPreviouslyConstrainedReleased"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="vir_ResearchAndDevelopmentExpensesCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="vir_ProfitShareAmountConstraint" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedRoyaltiesCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="vir_MilestonePayable" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="vir_PayrollAndRelatedExpensesCurrent" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="vir_ExcessFundsPayableUnderGrantAgreementsCurrent" order="7" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="8" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="11" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="12" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ResearchAndDevelopmentExpensesCurrent" xlink:label="vir_ResearchAndDevelopmentExpensesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ProfitShareAmountConstraint" xlink:label="vir_ProfitShareAmountConstraint"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MilestonePayable" xlink:label="vir_MilestonePayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PayrollAndRelatedExpensesCurrent" xlink:label="vir_PayrollAndRelatedExpensesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ExcessFundsPayableUnderGrantAgreementsCurrent" xlink:label="vir_ExcessFundsPayableUnderGrantAgreementsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="5" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="3" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vir.bio/20221231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="vir_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares" order="3" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting" xlink:label="vir_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares" xlink:label="us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vir.bio/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeLossBeforeProvisionForBenefitFromIncomeTaxesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="2" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="vir_EffectiveIncomeTaxRateReconciliationPermanentItemsPercent" order="6" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="7" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="8" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_EffectiveIncomeTaxRateReconciliationPermanentItemsPercent" xlink:label="vir_EffectiveIncomeTaxRateReconciliationPermanentItemsPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="vir_DeferredTaxLiabilitiesRightOfUseAssets" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="vir_DeferredTaxLiabilitiesInProcessResearchAndDevelopment" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="vir_DeferredTaxAssetsLeaseLiabilities" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="5" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities" xlink:label="us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="vir_DeferredTaxLiabilitiesRightOfUseAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_DeferredTaxLiabilitiesInProcessResearchAndDevelopment" xlink:label="vir_DeferredTaxLiabilitiesInProcessResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_DeferredTaxAssetsLeaseLiabilities" xlink:label="vir_DeferredTaxAssetsLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>36
<FILENAME>vir-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-02-28T15:30:31.9863+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="vir-20221231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:href="vir-20221231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:href="vir-20221231.xsd#Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" xlink:href="vir-20221231.xsd#Role_StatementConsolidatedStatementsOfOperations" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:href="vir-20221231.xsd#StatementConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:href="vir-20221231.xsd#Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:href="vir-20221231.xsd#Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:href="vir-20221231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureOrganization" xlink:href="vir-20221231.xsd#Role_DisclosureOrganization" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="vir-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:href="vir-20221231.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitions" xlink:href="vir-20221231.xsd#Role_DisclosureAcquisitions" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssets" xlink:href="vir-20221231.xsd#Role_DisclosureGoodwillAndIntangibleAssets" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGrantAgreements" xlink:href="vir-20221231.xsd#Role_DisclosureGrantAgreements" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreements" xlink:href="vir-20221231.xsd#Role_DisclosureCollaborationAndLicenseAgreements" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponents" xlink:href="vir-20221231.xsd#Role_DisclosureBalanceSheetComponents" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:href="vir-20221231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" xlink:href="vir-20221231.xsd#Role_DisclosureRelatedPartyTransactions" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStock" xlink:href="vir-20221231.xsd#Role_DisclosureConvertiblePreferredStock" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantLiability" xlink:href="vir-20221231.xsd#Role_DisclosureConvertiblePreferredStockWarrantLiability" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwards" xlink:href="vir-20221231.xsd#Role_DisclosureStockBasedAwards" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/DisclosureNetIncomeLossPerShare1" xlink:href="vir-20221231.xsd#DisclosureNetIncomeLossPerShare1" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/DisclosureDefinedContributionPlan" xlink:href="vir-20221231.xsd#DisclosureDefinedContributionPlan" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:href="vir-20221231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/DisclosureSubsequentEvent1" xlink:href="vir-20221231.xsd#DisclosureSubsequentEvent1" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="vir-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:href="vir-20221231.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsTables" xlink:href="vir-20221231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTables" xlink:href="vir-20221231.xsd#DisclosureCollaborationAndLicenseAgreementsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables" xlink:href="vir-20221231.xsd#Role_DisclosureBalanceSheetComponentsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" xlink:href="vir-20221231.xsd#Role_DisclosureCommitmentsAndContingenciesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsTables" xlink:href="vir-20221231.xsd#Role_DisclosureStockBasedAwardsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/DisclosureNetIncomeLossPerShareTables" xlink:href="vir-20221231.xsd#DisclosureNetIncomeLossPerShareTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:href="vir-20221231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureSelectedQuarterlyFinancialDataUnauditedTables" xlink:href="vir-20221231.xsd#Role_DisclosureSelectedQuarterlyFinancialDataUnauditedTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails" xlink:href="vir-20221231.xsd#Role_DisclosureOrganizationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="vir-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails" xlink:href="vir-20221231.xsd#Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyParentheticalDetails" xlink:href="vir-20221231.xsd#Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyParentheticalDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:href="vir-20221231.xsd#Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails" xlink:href="vir-20221231.xsd#Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails" xlink:href="vir-20221231.xsd#Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails" xlink:href="vir-20221231.xsd#Role_DisclosureAcquisitionsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails" xlink:href="vir-20221231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails" xlink:href="vir-20221231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails" xlink:href="vir-20221231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails" xlink:href="vir-20221231.xsd#Role_DisclosureGrantAgreementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" xlink:href="vir-20221231.xsd#Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsCollaborationCollaborationRevenueDetails" xlink:href="vir-20221231.xsd#DisclosureCollaborationAndLicenseAgreementsCollaborationCollaborationRevenueDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" xlink:href="vir-20221231.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails" xlink:href="vir-20221231.xsd#Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails" xlink:href="vir-20221231.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="vir-20221231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsAndAdditionalInformationRelatedToOperatingLeasesDetails" xlink:href="vir-20221231.xsd#Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsAndAdditionalInformationRelatedToOperatingLeasesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:href="vir-20221231.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetDetails" xlink:href="vir-20221231.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/DisclosureManufacturingAndSupplyLetterAgreementsAdditionalInformationDetails" xlink:href="vir-20221231.xsd#DisclosureManufacturingAndSupplyLetterAgreementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="vir-20221231.xsd#Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:href="vir-20221231.xsd#Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantLiabilityAdditionalInformationDetails" xlink:href="vir-20221231.xsd#Role_DisclosureConvertiblePreferredStockWarrantLiabilityAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails" xlink:href="vir-20221231.xsd#Role_DisclosureStockBasedAwardsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails" xlink:href="vir-20221231.xsd#Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails" xlink:href="vir-20221231.xsd#Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/DisclosureStockbasedAwardsSummaryOfEmployeesStockPurchasePlanDetails" xlink:href="vir-20221231.xsd#DisclosureStockbasedAwardsSummaryOfEmployeesStockPurchasePlanDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityDetails" xlink:href="vir-20221231.xsd#Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockBasedCompensationExpenseDetails" xlink:href="vir-20221231.xsd#Role_DisclosureStockBasedAwardsSummaryOfStockBasedCompensationExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails" xlink:href="vir-20221231.xsd#DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails" xlink:href="vir-20221231.xsd#DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/DisclosureNetIncomeLossPerShareAdditionalInformationDetails" xlink:href="vir-20221231.xsd#DisclosureNetIncomeLossPerShareAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails" xlink:href="vir-20221231.xsd#DisclosureDefinedContributionPlanAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeLossBeforeProvisionForBenefitFromIncomeTaxesDetails" xlink:href="vir-20221231.xsd#DisclosureIncomeTaxesScheduleOfIncomeLossBeforeProvisionForBenefitFromIncomeTaxesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" xlink:href="vir-20221231.xsd#Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails" xlink:href="vir-20221231.xsd#Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="vir-20221231.xsd#Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="vir-20221231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfLiabilityForUncertainTaxPositionsDetails" xlink:href="vir-20221231.xsd#Role_DisclosureIncomeTaxesReconciliationOfLiabilityForUncertainTaxPositionsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" xlink:href="vir-20221231.xsd#DisclosureSubsequentEventAdditionalInformationDetails" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="80.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="81.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="82.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="83.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="84.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="85.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="86.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_EquityInvestmentCurrent" xlink:label="vir_EquityInvestmentCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Goodwill" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="vir_EquityInvestmentCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_LongTermInvestments" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssets" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_CollaborationRevenueMember" xlink:label="vir_CollaborationRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ContractRevenueMember" xlink:label="vir_ContractRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostOfRevenue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_CollaborationRevenueMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueNotFromContractWithCustomer" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_ContractRevenueMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_Revenues" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_GrantMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentToProjectedBenefitObligationsNetOfTax" xlink:label="vir_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentToProjectedBenefitObligationsNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="vir_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentToProjectedBenefitObligationsNetOfTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_FollowOnOfferingMember" xlink:label="vir_FollowOnOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_SeriesAOneConvertiblePreferredStockMember" xlink:label="vir_SeriesAOneConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_SeriesATwoConvertiblePreferredStockMember" xlink:label="vir_SeriesATwoConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_SeriesBConvertiblePreferredStockMember" xlink:label="vir_SeriesBConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital" xlink:label="vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_StockIssuedDuringPeriodSharesAchievementOfMilestone" xlink:label="vir_StockIssuedDuringPeriodSharesAchievementOfMilestone"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_StockIssuedDuringPeriodValueCollaborationAgreement" xlink:label="vir_StockIssuedDuringPeriodValueCollaborationAgreement"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_StockIssuedDuringPeriodSharesCollaborationAgreement" xlink:label="vir_StockIssuedDuringPeriodSharesCollaborationAgreement"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_StockIssuedDuringPeriodValueIssuedForSettlementOfContingentConsideration" xlink:label="vir_StockIssuedDuringPeriodValueIssuedForSettlementOfContingentConsideration"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_StockIssuedDuringPeriodSharesIssuedForSettlementOfContingentConsideration" xlink:label="vir_StockIssuedDuringPeriodSharesIssuedForSettlementOfContingentConsideration"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant" xlink:label="vir_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_StockIssuedDuringPeriodValueLicenseAgreement" xlink:label="vir_StockIssuedDuringPeriodValueLicenseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ProceedsFromIssuanceOfCommonStockInConnectionWithAGrantAgreement" xlink:label="vir_ProceedsFromIssuanceOfCommonStockInConnectionWithAGrantAgreement"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_StockIssuedDuringPeriodSharesLicenseAgreement" xlink:label="vir_StockIssuedDuringPeriodSharesLicenseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_IssuanceOfCommonStockInConnectionWithAGrantAgreementShares" xlink:label="vir_IssuanceOfCommonStockInConnectionWithAGrantAgreementShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_26"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_27"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_28"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_29"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="vir_FollowOnOfferingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="vir_SeriesAOneConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="vir_SeriesATwoConvertiblePreferredStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="vir_SeriesBConvertiblePreferredStockMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_StockIssuedDuringPeriodSharesAchievementOfMilestone" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_StockIssuedDuringPeriodValueCollaborationAgreement" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_StockIssuedDuringPeriodSharesCollaborationAgreement" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_StockIssuedDuringPeriodValueIssuedForSettlementOfContingentConsideration" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_StockIssuedDuringPeriodSharesIssuedForSettlementOfContingentConsideration" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_StockIssuedDuringPeriodValueLicenseAgreement" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_ProceedsFromIssuanceOfCommonStockInConnectionWithAGrantAgreement" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_StockIssuedDuringPeriodSharesLicenseAgreement" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_IssuanceOfCommonStockInConnectionWithAGrantAgreementShares" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_26" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_27" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_28" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding_29" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_SeriesAOneConvertiblePreferredStockMember" xlink:label="vir_SeriesAOneConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ConvertiblePreferredStockIssuanceCost" xlink:label="vir_ConvertiblePreferredStockIssuanceCost"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_SeriesBConvertiblePreferredStockMember" xlink:label="vir_SeriesBConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_InitialPublicOfferingCosts" xlink:label="vir_InitialPublicOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_CommonStockIssuanceCost" xlink:label="vir_CommonStockIssuanceCost"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="vir_SeriesAOneConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_ConvertiblePreferredStockIssuanceCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="vir_SeriesBConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_InitialPublicOfferingCosts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_CommonStockIssuanceCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_CollaborationAgreementMember" xlink:label="vir_CollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfMachineryAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ProceedsFromIssuanceOfCommonStockInConnectionWithCollaboration" xlink:label="vir_ProceedsFromIssuanceOfCommonStockInConnectionWithCollaboration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ChangesInEstimatedConstraintOnProfitSharingAmount" xlink:label="vir_ChangesInEstimatedConstraintOnProfitSharingAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ProceedsFromIssuanceOfCommonStockInConnectionWithAGrantAgreement" xlink:label="vir_ProceedsFromIssuanceOfCommonStockInConnectionWithAGrantAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_NonCashCommonStockIssuedForContingentConsideration" xlink:label="vir_NonCashCommonStockIssuedForContingentConsideration"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PaymentOfContingentConsideration" xlink:label="vir_PaymentOfContingentConsideration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ConversionOfPreferredStockIntoCommonStockUponCompletionOfInitialPublicOffering" xlink:label="vir_ConversionOfPreferredStockIntoCommonStockUponCompletionOfInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ProceedsFromDisposalOfAnEquipment" xlink:label="vir_ProceedsFromDisposalOfAnEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_AdvancedProceedsAppliedToConvertiblePreferredStockIssuance" xlink:label="vir_AdvancedProceedsAppliedToConvertiblePreferredStockIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_NoncashLeaseExpense" xlink:label="vir_NoncashLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone" xlink:label="vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueAdjustment" xlink:label="us-gaap_AssetsFairValueAdjustment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ReclassificationOfPreferredStockWarrantLiabilityToAdditionalPaidInCapital" xlink:label="vir_ReclassificationOfPreferredStockWarrantLiabilityToAdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue" xlink:label="vir_IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="us-gaap_GainLossOnTerminationOfLease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:label="us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_CollaborationAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfMachineryAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_LaborAndRelatedExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="vir_ProceedsFromIssuanceOfCommonStockInConnectionWithCollaboration" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="vir_ChangesInEstimatedConstraintOnProfitSharingAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="vir_ProceedsFromIssuanceOfCommonStockInConnectionWithAGrantAgreement" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireInvestments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="vir_NonCashCommonStockIssuedForContingentConsideration" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="vir_PaymentOfContingentConsideration" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="vir_ConversionOfPreferredStockIntoCommonStockUponCompletionOfInitialPublicOffering" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="vir_ProceedsFromDisposalOfAnEquipment" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="vir_AdvancedProceedsAppliedToConvertiblePreferredStockIssuance" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="vir_NoncashLeaseExpense" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AssetsFairValueAdjustment" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="vir_ReclassificationOfPreferredStockWarrantLiabilityToAdditionalPaidInCapital" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="vir_IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnTerminationOfLease" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherOperatingActivitiesCashFlowStatement" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureOrganization" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitions" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssets" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGrantAgreements" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_GrantAgreementsDisclosureTextBlock" xlink:label="vir_GrantAgreementsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="vir_GrantAgreementsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreements" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponents" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStock" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TemporaryEquityTextBlock" xlink:label="vir_TemporaryEquityTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="vir_TemporaryEquityTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantLiability" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ConvertiblePreferredStockWarrantLiabilityAbstract" xlink:label="vir_ConvertiblePreferredStockWarrantLiabilityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ConvertiblePreferredStockWarrantLiabilityTextBlock" xlink:label="vir_ConvertiblePreferredStockWarrantLiabilityTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_ConvertiblePreferredStockWarrantLiabilityAbstract" xlink:to="vir_ConvertiblePreferredStockWarrantLiabilityTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwards" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/DisclosureNetIncomeLossPerShare1" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/DisclosureDefinedContributionPlan" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xlink:label="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/DisclosureSubsequentEvent1" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ConcentrationOfCreditRiskCreditLossAndOtherRisksAndUncertaintiesPolicyTextBlock" xlink:label="vir_ConcentrationOfCreditRiskCreditLossAndOtherRisksAndUncertaintiesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="us-gaap_BusinessCombinationsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesEmbeddedDerivatives" xlink:label="us-gaap_DerivativesEmbeddedDerivatives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy" xlink:label="us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="vir_ConcentrationOfCreditRiskCreditLossAndOtherRisksAndUncertaintiesPolicyTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BusinessCombinationsPolicy" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DerivativesEmbeddedDerivatives" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_HumabsBiomedSAMember" xlink:label="vir_HumabsBiomedSAMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ClinicalAndRegulatoryMilestonesMember" xlink:label="vir_ClinicalAndRegulatoryMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TomegaVaxIncMember" xlink:label="vir_TomegaVaxIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_CommercialMilestonesMember" xlink:label="vir_CommercialMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="vir_HumabsBiomedSAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="vir_ClinicalAndRegulatoryMilestonesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="vir_TomegaVaxIncMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="vir_CommercialMilestonesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionAbstract" xlink:label="us-gaap_RevenueRecognitionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_CollaborationRevenueTableTextBlock" xlink:label="vir_CollaborationRevenueTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAbstract" xlink:to="vir_CollaborationRevenueTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock" xlink:label="vir_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="vir_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_SummaryOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock" xlink:label="vir_SummaryOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetTableTextBlock" xlink:label="vir_ScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="vir_SummaryOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="vir_ScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/DisclosureNetIncomeLossPerShareTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureSelectedQuarterlyFinancialDataUnauditedTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:label="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" xlink:label="us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_SalesAgreementMember" xlink:label="vir_SalesAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:label="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" xlink:label="us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_FollowOnOfferingMember" xlink:label="vir_FollowOnOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_SeriesAOneConvertiblePreferredStockMember" xlink:label="vir_SeriesAOneConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ConvertiblePreferredStockWarrantLiabilityMember" xlink:label="vir_ConvertiblePreferredStockWarrantLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PaymentsOfUnderwritingDiscountsAndCommissions" xlink:label="vir_PaymentsOfUnderwritingDiscountsAndCommissions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_NetProceedsFromIssuanceSecondaryPublicOffering" xlink:label="vir_NetProceedsFromIssuanceSecondaryPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ProceedsFromIssuanceSecondaryPublicOffering" xlink:label="vir_ProceedsFromIssuanceSecondaryPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PercentageOfAggregateGrossProceedsFromSaleOfShares" xlink:label="vir_PercentageOfAggregateGrossProceedsFromSaleOfShares"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PercentageOfCommissionRateFromSaleOfShares" xlink:label="vir_PercentageOfCommissionRateFromSaleOfShares"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_SaleOfStockConsiderationAggregateOfferingPrice" xlink:label="vir_SaleOfStockConsiderationAggregateOfferingPrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_CashCashEquivalentsAndShortTermInvestmentsExcludingEquityInvestment" xlink:label="vir_CashCashEquivalentsAndShortTermInvestmentsExcludingEquityInvestment"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" xlink:to="vir_SalesAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" xlink:to="us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="vir_FollowOnOfferingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="vir_SeriesAOneConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="vir_ConvertiblePreferredStockWarrantLiabilityMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="srt_RangeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="vir_PaymentsOfUnderwritingDiscountsAndCommissions" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="vir_NetProceedsFromIssuanceSecondaryPublicOffering" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="vir_ProceedsFromIssuanceSecondaryPublicOffering" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="vir_PercentageOfAggregateGrossProceedsFromSaleOfShares" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="vir_PercentageOfCommissionRateFromSaleOfShares" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="vir_SaleOfStockConsiderationAggregateOfferingPrice" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="vir_CashCashEquivalentsAndShortTermInvestmentsExcludingEquityInvestment" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="vir_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_SummaryOfSignificantAccountingPoliciesTable" xlink:label="vir_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201613Member" xlink:label="us-gaap_AccountingStandardsUpdate201613Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201704Member" xlink:label="us-gaap_AccountingStandardsUpdate201704Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201814Member" xlink:label="us-gaap_AccountingStandardsUpdate201814Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201818Member" xlink:label="us-gaap_AccountingStandardsUpdate201818Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201613Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="vir_SummaryOfSignificantAccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_SummaryOfSignificantAccountingPoliciesTable" xlink:to="vir_SummaryOfSignificantAccountingPoliciesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201704Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201814Member" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201818Member" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_FinancialAssetsAmortizedCostBasis" xlink:label="vir_FinancialAssetsAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_FinancialAssetsGrossUnrealizedHoldingGains" xlink:label="vir_FinancialAssetsGrossUnrealizedHoldingGains"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BankTimeDepositsMember" xlink:label="us-gaap_BankTimeDepositsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_FinancialAssetsGrossUnrealizedHoldingLosses" xlink:label="vir_FinancialAssetsGrossUnrealizedHoldingLosses"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_FinancialAssetsFairValue" xlink:label="vir_FinancialAssetsFairValue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="vir_FinancialAssetsAmortizedCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="vir_FinancialAssetsGrossUnrealizedHoldingGains" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_BankTimeDepositsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="vir_FinancialAssetsGrossUnrealizedHoldingLosses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="vir_FinancialAssetsFairValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyParentheticalDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashEquivalents" xlink:label="us-gaap_RestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_RestrictedCashEquivalents" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_HumabsBiomedSAMember" xlink:label="vir_HumabsBiomedSAMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ContingentConsiderationLiabilityMember" xlink:label="vir_ContingentConsiderationLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_BriiBioParentMember" xlink:label="vir_BriiBioParentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_LetterAgreementMember" xlink:label="vir_LetterAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TomegaVaxIncMember" xlink:label="vir_TomegaVaxIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivable" xlink:label="us-gaap_InterestReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivableAccruedInterestWriteoff" xlink:label="us-gaap_FinancingReceivableAccruedInterestWriteoff"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedAtFairValue" xlink:label="us-gaap_InvestmentOwnedAtFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:label="us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_RegulatoryMilestoneAchieved" xlink:label="vir_RegulatoryMilestoneAchieved"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_SpecifiedSalesDevelopmentMilestonesPayment" xlink:label="vir_SpecifiedSalesDevelopmentMilestonesPayment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_SalesMilestonesAchieved" xlink:label="vir_SalesMilestonesAchieved"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_FormerBusinessCombinationContingentConsiderationLiability" xlink:label="vir_FormerBusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_AssetAcquisitionMilestoneAchieved" xlink:label="vir_AssetAcquisitionMilestoneAchieved"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiability" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiability"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="vir_HumabsBiomedSAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="vir_ContingentConsiderationLiabilityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain" xlink:to="vir_BriiBioParentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="vir_LetterAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="vir_TomegaVaxIncMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_InterestReceivable" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FinancingReceivableAccruedInterestWriteoff" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_InvestmentOwnedAtFairValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_RangeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_OwnershipAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="vir_RegulatoryMilestoneAchieved" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="vir_SpecifiedSalesDevelopmentMilestonesPayment" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="vir_SalesMilestonesAchieved" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTerm" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="vir_FormerBusinessCombinationContingentConsiderationLiability" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="vir_AssetAcquisitionMilestoneAchieved" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationLiability" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_HumabsBiomedSAMember" xlink:label="vir_HumabsBiomedSAMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ClinicalAndRegulatoryMilestonesMember" xlink:label="vir_ClinicalAndRegulatoryMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TomegaVaxIncMember" xlink:label="vir_TomegaVaxIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_CommercialMilestonesMember" xlink:label="vir_CommercialMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmbeddedDerivativeLiabilityMeasurementInput" xlink:label="us-gaap_EmbeddedDerivativeLiabilityMeasurementInput"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MeasurementInputProbabilityRateMember" xlink:label="vir_MeasurementInputProbabilityRateMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_WeightedAverageMember" xlink:label="srt_WeightedAverageMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MeasurementInputExpectedVolatilityMember" xlink:label="vir_MeasurementInputExpectedVolatilityMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MeasurementInputExpectedRevenueVolatilityMember" xlink:label="vir_MeasurementInputExpectedRevenueVolatilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="vir_HumabsBiomedSAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="vir_ClinicalAndRegulatoryMilestonesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountRateMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="vir_TomegaVaxIncMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="vir_CommercialMilestonesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_EmbeddedDerivativeLiabilityMeasurementInput" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="vir_MeasurementInputProbabilityRateMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_WeightedAverageMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="vir_MeasurementInputExpectedVolatilityMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="vir_MeasurementInputExpectedRevenueVolatilityMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ContingentConsiderationLiabilityMember" xlink:label="vir_ContingentConsiderationLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:label="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_FairValueReclassificationOfDerivativeLiabilityToAccruedLiabilitiesUponAchievementOfDevelopmentMilestone" xlink:label="vir_FairValueReclassificationOfDerivativeLiabilityToAccruedLiabilitiesUponAchievementOfDevelopmentMilestone"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherExpenseMember" xlink:label="us-gaap_OtherExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_FairValueReclassificationOfContingentConsiderationToAccruedLiabilitiesUponAchievementOfMilestone" xlink:label="vir_FairValueReclassificationOfContingentConsiderationToAccruedLiabilitiesUponAchievementOfMilestone"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="vir_ContingentConsiderationLiabilityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="vir_FairValueReclassificationOfDerivativeLiabilityToAccruedLiabilitiesUponAchievementOfDevelopmentMilestone" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_OtherExpenseMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="vir_FairValueReclassificationOfContingentConsiderationToAccruedLiabilitiesUponAchievementOfMilestone" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_HumabsBiomedSAMember" xlink:label="vir_HumabsBiomedSAMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="us-gaap_DevelopedTechnologyRightsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_LetterAgreementMember" xlink:label="vir_LetterAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TomegaVaxIncMember" xlink:label="vir_TomegaVaxIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_HepatitisBVirusProductMember" xlink:label="vir_HepatitisBVirusProductMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_AnotherProductMember" xlink:label="vir_AnotherProductMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ClinicalDevelopmentMember" xlink:label="vir_ClinicalDevelopmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_SARSCoV2ProductMember" xlink:label="vir_SARSCoV2ProductMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_AssetAcquisitionMilestonePaymentAggregate" xlink:label="vir_AssetAcquisitionMilestonePaymentAggregate"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MilestonePaymentsRelatedTermsDescription" xlink:label="vir_MilestonePaymentsRelatedTermsDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiability" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents" xlink:label="vir_BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved" xlink:label="vir_BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_SpecifiedClinicalDevelopmentMilestonesPayment" xlink:label="vir_SpecifiedClinicalDevelopmentMilestonesPayment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_RegulatoryMilestonesAchieved" xlink:label="vir_RegulatoryMilestonesAchieved"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_SalesMilestonesAchieved" xlink:label="vir_SalesMilestonesAchieved"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:label="us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_BusinessAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration" xlink:label="vir_BusinessAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_AssetAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration" xlink:label="vir_AssetAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PaymentMadeForBusinessCombinationMilestone" xlink:label="vir_PaymentMadeForBusinessCombinationMilestone"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PaymentMadeForAssetAcquisitionMilestone" xlink:label="vir_PaymentMadeForAssetAcquisitionMilestone"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_CommonStockSharesIssuedForMilestonePaymentShares" xlink:label="vir_CommonStockSharesIssuedForMilestonePaymentShares"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ValueOfCommonStockSharesIssuedForMilestonePayment" xlink:label="vir_ValueOfCommonStockSharesIssuedForMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_RemainingPaymentMadeForBusinessCombinationMilestone" xlink:label="vir_RemainingPaymentMadeForBusinessCombinationMilestone"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_RemainingPaymentMadeForAssetAcquisitionMilestone" xlink:label="vir_RemainingPaymentMadeForAssetAcquisitionMilestone"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_RemainingPaymentForAssetAcquisitionMilestoneAggregate" xlink:label="vir_RemainingPaymentForAssetAcquisitionMilestoneAggregate"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MinimumCommonStockConversionPriceForMilestonePaymentsConsideration" xlink:label="vir_MinimumCommonStockConversionPriceForMilestonePaymentsConsideration"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MinimumCommonStockPriceForMilestonePaymentsConsideration" xlink:label="vir_MinimumCommonStockPriceForMilestonePaymentsConsideration"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="vir_HumabsBiomedSAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_DevelopedTechnologyRightsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_LetterAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="vir_TomegaVaxIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_HepatitisBVirusProductMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_AnotherProductMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="vir_ClinicalDevelopmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_SARSCoV2ProductMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_ProductOrServiceAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_RangeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_AssetAcquisitionMilestonePaymentAggregate" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_MilestonePaymentsRelatedTermsDescription" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationLiability" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_SpecifiedClinicalDevelopmentMilestonesPayment" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_RegulatoryMilestonesAchieved" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_SalesMilestonesAchieved" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_BusinessAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_AssetAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_PaymentMadeForBusinessCombinationMilestone" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_PaymentMadeForAssetAcquisitionMilestone" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_CommonStockSharesIssuedForMilestonePaymentShares" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_ValueOfCommonStockSharesIssuedForMilestonePayment" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_RemainingPaymentMadeForBusinessCombinationMilestone" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_RemainingPaymentMadeForAssetAcquisitionMilestone" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_RemainingPaymentForAssetAcquisitionMilestoneAggregate" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_MinimumCommonStockConversionPriceForMilestonePaymentsConsideration" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_MinimumCommonStockPriceForMilestonePaymentsConsideration" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_HumabsBiomedSAMember" xlink:label="vir_HumabsBiomedSAMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ScheduleOfGoodwillAndIntangibleAssetsTable" xlink:label="vir_ScheduleOfGoodwillAndIntangibleAssetsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ScheduleOfGoodwillAndIntangibleAssetsLineItems" xlink:label="vir_ScheduleOfGoodwillAndIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:label="us-gaap_IndefinitelivedIntangibleAssetsAcquired"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_FiniteLivedIntangibleAssetsReclassifiedFromIndefiniteLived" xlink:label="vir_FiniteLivedIntangibleAssetsReclassifiedFromIndefiniteLived"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="vir_HumabsBiomedSAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="vir_ScheduleOfGoodwillAndIntangibleAssetsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_ScheduleOfGoodwillAndIntangibleAssetsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_ScheduleOfGoodwillAndIntangibleAssetsLineItems" xlink:to="us-gaap_Goodwill" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_ScheduleOfGoodwillAndIntangibleAssetsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_ScheduleOfGoodwillAndIntangibleAssetsLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_ScheduleOfGoodwillAndIntangibleAssetsTable" xlink:to="vir_ScheduleOfGoodwillAndIntangibleAssetsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_ScheduleOfGoodwillAndIntangibleAssetsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_ScheduleOfGoodwillAndIntangibleAssetsLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_ScheduleOfGoodwillAndIntangibleAssetsLineItems" xlink:to="us-gaap_IndefinitelivedIntangibleAssetsAcquired" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_ScheduleOfGoodwillAndIntangibleAssetsLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_ScheduleOfGoodwillAndIntangibleAssetsLineItems" xlink:to="vir_FiniteLivedIntangibleAssetsReclassifiedFromIndefiniteLived" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:label="us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_DevelopedTechnologyMember" xlink:label="vir_DevelopedTechnologyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractBasedIntangibleAssetsMember" xlink:label="us-gaap_ContractBasedIntangibleAssetsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_FiniteLivedIntangibleAssetsAccumulatedImpairment" xlink:label="vir_FiniteLivedIntangibleAssetsAccumulatedImpairment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="vir_DevelopedTechnologyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_ContractBasedIntangibleAssetsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="vir_FiniteLivedIntangibleAssetsAccumulatedImpairment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_FiniteLivedIntangibleAssetsAmortizationExpense" xlink:label="vir_FiniteLivedIntangibleAssetsAmortizationExpense"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="vir_FiniteLivedIntangibleAssetsAmortizationExpense" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_BillAndMelindaGatesFoundationMember" xlink:label="vir_BillAndMelindaGatesFoundationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_GrantAwardedAmount" xlink:label="vir_GrantAwardedAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TwoThousandSeventeenGrantMember" xlink:label="vir_TwoThousandSeventeenGrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_NationalInstitutesOfHealthMember" xlink:label="vir_NationalInstitutesOfHealthMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_GrantAwardedAmountMaximum" xlink:label="vir_GrantAwardedAmountMaximum"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_HumanImmunodeficiencyVirusGrantMember" xlink:label="vir_HumanImmunodeficiencyVirusGrantMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_CommonStockSharesPurchased" xlink:label="vir_CommonStockSharesPurchased"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TuberculosisTBGrantMember" xlink:label="vir_TuberculosisTBGrantMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_CommonStockSharesPurchasedSharePrice" xlink:label="vir_CommonStockSharesPurchasedSharePrice"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_HcmvVaccinePlatformGrantMember" xlink:label="vir_HcmvVaccinePlatformGrantMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_CommonStockSharesPurchasedAggregatePurchasePrice" xlink:label="vir_CommonStockSharesPurchasedAggregatePurchasePrice"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_VaccinalAntibodyGrantMember" xlink:label="vir_VaccinalAntibodyGrantMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_CommonStockSharesIssuedFairMarketValue" xlink:label="vir_CommonStockSharesIssuedFairMarketValue"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:label="vir_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ClosingStockPrice" xlink:label="vir_ClosingStockPrice"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_UnderlyingSharesPremiumReceived" xlink:label="vir_UnderlyingSharesPremiumReceived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_GrantAgreementExpirationDate" xlink:label="vir_GrantAgreementExpirationDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MaximumAmountGrantAggregate" xlink:label="vir_MaximumAmountGrantAggregate"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MaximumAmountGrantBasePeriod" xlink:label="vir_MaximumAmountGrantBasePeriod"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_GrantAgreementExpirationDateBeforeAmendment" xlink:label="vir_GrantAgreementExpirationDateBeforeAmendment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_GrantAgreementAmendedExpirationDate" xlink:label="vir_GrantAgreementAmendedExpirationDate"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_GrantAgreementAmendedDate" xlink:label="vir_GrantAgreementAmendedDate"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_GrantsAgreementAmendedDate" xlink:label="vir_GrantsAgreementAmendedDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncome" xlink:label="us-gaap_DeferredIncome"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MilestonePaymentDueToCompany" xlink:label="vir_MilestonePaymentDueToCompany"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MilestonePaymentReceived" xlink:label="vir_MilestonePaymentReceived"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_UnusedFundsReceivedInAdvance" xlink:label="vir_UnusedFundsReceivedInAdvance"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_FundsReceivedInAdvance" xlink:label="vir_FundsReceivedInAdvance"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_GrantAgreementEffectiveEndDate" xlink:label="vir_GrantAgreementEffectiveEndDate"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_BillAndMelindaGatesFoundationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_GrantAwardedAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_TwoThousandSeventeenGrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_GrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_NationalInstitutesOfHealthMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_GrantAwardedAmountMaximum" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_HumanImmunodeficiencyVirusGrantMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_CommonStockSharesPurchased" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_TuberculosisTBGrantMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_CommonStockSharesPurchasedSharePrice" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_HcmvVaccinePlatformGrantMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_CommonStockSharesPurchasedAggregatePurchasePrice" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_VaccinalAntibodyGrantMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_CommonStockSharesIssuedFairMarketValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_ClosingStockPrice" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_UnderlyingSharesPremiumReceived" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_GrantAgreementExpirationDate" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueNotFromContractWithCustomer" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumAmountGrantAggregate" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumAmountGrantBasePeriod" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_GrantAgreementExpirationDateBeforeAmendment" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_GrantAgreementAmendedExpirationDate" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_GrantAgreementAmendedDate" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_GrantsAgreementAmendedDate" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredIncome" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_OtherAssetsCurrent" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenue" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MilestonePaymentDueToCompany" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MilestonePaymentReceived" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_UnusedFundsReceivedInAdvance" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_FundsReceivedInAdvance" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_GrantAgreementEffectiveEndDate" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_GlaxoGroupLimitedMember" xlink:label="vir_GlaxoGroupLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember" xlink:label="vir_TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CN" xlink:label="country_CN"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_AccruedLiabilitiesAndOtherLiabilitiesMember" xlink:label="vir_AccruedLiabilitiesAndOtherLiabilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="us-gaap_AccountingStandardsUpdate201409Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_Vir3434Member" xlink:label="vir_Vir3434Member"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TwoThousandTwentyStockPurchaseAgreementMember" xlink:label="vir_TwoThousandTwentyStockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ContractRevenueMember" xlink:label="vir_ContractRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_GlaxoWellcomeUKLimitedAndBeechamSAMember" xlink:label="vir_GlaxoWellcomeUKLimitedAndBeechamSAMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="country_US"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PreliminaryCollaborationAgreementMember" xlink:label="vir_PreliminaryCollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember" xlink:label="vir_TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember" xlink:label="vir_TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_CollaborationRevenueMember" xlink:label="vir_CollaborationRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_BriiBioParentMember" xlink:label="vir_BriiBioParentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_AmendmentNumberOneMember" xlink:label="vir_AmendmentNumberOneMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_AntibodyProgramMember" xlink:label="vir_AntibodyProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_BriiBiosciencesOffshoreLimitedMember" xlink:label="vir_BriiBiosciencesOffshoreLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans" xlink:label="vir_NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_DefinitiveCollaborationAgreementMember" xlink:label="vir_DefinitiveCollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_VaccineProgramMember" xlink:label="vir_VaccineProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_AlnylamPharmaceuticalsIncMember" xlink:label="vir_AlnylamPharmaceuticalsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PercentageOfShareDevelopmentCosts" xlink:label="vir_PercentageOfShareDevelopmentCosts"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TwoThousandTwentyOneStockPurchaseAgreementMember" xlink:label="vir_TwoThousandTwentyOneStockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_DevelopmentProgramsExercisedByVirMember" xlink:label="vir_DevelopmentProgramsExercisedByVirMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_WuXiBiologicsLimitedMember" xlink:label="vir_WuXiBiologicsLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PercentageOfDevelopmentCosts" xlink:label="vir_PercentageOfDevelopmentCosts"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember" xlink:label="vir_TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_DevelopmentProgramsExercisedByBriiMember" xlink:label="vir_DevelopmentProgramsExercisedByBriiMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_RockefellerUniversityMember" xlink:label="vir_RockefellerUniversityMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct" xlink:label="vir_MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TwoThousandAndTwentyOneGSKCollaborationMember" xlink:label="vir_TwoThousandAndTwentyOneGSKCollaborationMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_BiologicalMaterialsMember" xlink:label="vir_BiologicalMaterialsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MedImmuneLimitedLiabilityCompanyMember" xlink:label="vir_MedImmuneLimitedLiabilityCompanyMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_CollaborationAgreementTerminationDescription" xlink:label="vir_CollaborationAgreementTerminationDescription"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TwoThousandAndTwentyGskAgreementMember" xlink:label="vir_TwoThousandAndTwentyGskAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_Vir2218Member" xlink:label="vir_Vir2218Member"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_XencorIncorporationMember" xlink:label="vir_XencorIncorporationMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_FairMarketValueOfCommonStockIssued" xlink:label="vir_FairMarketValueOfCommonStockIssued"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TwoThousandAndTwentyOneGSKAgreementMember" xlink:label="vir_TwoThousandAndTwentyOneGSKAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_Vir2248Member" xlink:label="vir_Vir2248Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_BriiAgreementMember" xlink:label="vir_BriiAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_FirstSiRNAProductMember" xlink:label="vir_FirstSiRNAProductMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PremiumReceivedOnSalePriceOfCommonStock" xlink:label="vir_PremiumReceivedOnSalePriceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_AlnylamAgreementMember" xlink:label="vir_AlnylamAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_FirstSiRNAProductHBVMember" xlink:label="vir_FirstSiRNAProductHBVMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_AntibodyLicenseTransactionPrice" xlink:label="vir_AntibodyLicenseTransactionPrice"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_DevelopmentAndManufacturingCollaborationAgreementMember" xlink:label="vir_DevelopmentAndManufacturingCollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_EachInfectiousDiseaseSiRNAMember" xlink:label="vir_EachInfectiousDiseaseSiRNAMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_RockefellerAgreementMember" xlink:label="vir_RockefellerAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_FirstInfectiousDiseaseProductMember" xlink:label="vir_FirstInfectiousDiseaseProductMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_SpecifiedResearchAndDevelopmentExpensesMilestonePayments" xlink:label="vir_SpecifiedResearchAndDevelopmentExpensesMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MedImmuneAgreementMember" xlink:label="vir_MedImmuneAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_InfectiousDiseaseProductMember" xlink:label="vir_InfectiousDiseaseProductMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_WrittenNoticePeriodToTerminateAgreementByCompany" xlink:label="vir_WrittenNoticePeriodToTerminateAgreementByCompany"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TwoThousandNineteenXencorAgreementMember" xlink:label="vir_TwoThousandNineteenXencorAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_HBVProgramMember" xlink:label="vir_HBVProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_RangeOfRoyaltyPaymentToBeReceived" xlink:label="vir_RangeOfRoyaltyPaymentToBeReceived"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TwoThousandTwentyXencorAgreementMember" xlink:label="vir_TwoThousandTwentyXencorAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_InfluenzaAAndInfluenzaBMember" xlink:label="vir_InfluenzaAAndInfluenzaBMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MaximumNumberOfProductsCoveredAgainstMilestonePayment" xlink:label="vir_MaximumNumberOfProductsCoveredAgainstMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_XencorAgreementsMember" xlink:label="vir_XencorAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_InfluenzaAResearchProgramsMember" xlink:label="vir_InfluenzaAResearchProgramsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="us-gaap_RevenueFromRelatedParties"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TwoThousandNineteenAndTwoThousandTwentyXencorAgreementMember" xlink:label="vir_TwoThousandNineteenAndTwoThousandTwentyXencorAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_InfluenzaAAndHBVResearchProgramsMember" xlink:label="vir_InfluenzaAAndHBVResearchProgramsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_WrittenNoticePeriodToTerminateLicensedProgramForUncuredMaterialBreach" xlink:label="vir_WrittenNoticePeriodToTerminateLicensedProgramForUncuredMaterialBreach"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_RegulatoryMilestonePaymentToBeReceived" xlink:label="vir_RegulatoryMilestonePaymentToBeReceived"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_AnnualLicenseMaintenanceFees" xlink:label="vir_AnnualLicenseMaintenanceFees"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_WrittenNoticeToTerminateLicensedProgramIfExercise" xlink:label="vir_WrittenNoticeToTerminateLicensedProgramIfExercise"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_WrittenNoticePeriodToTerminateAgreementByCounterparty" xlink:label="vir_WrittenNoticePeriodToTerminateAgreementByCounterparty"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenge" xlink:label="vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenge"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MaximumSalesMilestonePaymentsToBeReceived" xlink:label="vir_MaximumSalesMilestonePaymentsToBeReceived"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PaymentToCollaboratorResultingFromProgramOptionExercise" xlink:label="vir_PaymentToCollaboratorResultingFromProgramOptionExercise"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_RoyaltiesPaymentExpirationPeriod" xlink:label="vir_RoyaltiesPaymentExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_CollaborationAgreementNumberOfUnitsOfAccount" xlink:label="vir_CollaborationAgreementNumberOfUnitsOfAccount"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_IncreaseDecreaseInResearchAndDevelopmentExpense" xlink:label="vir_IncreaseDecreaseInResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate" xlink:label="vir_CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ProfitsAndLossesSharingPercentage" xlink:label="vir_ProfitsAndLossesSharingPercentage"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_OptionExerciseFeeLowEndOfTheRange" xlink:label="vir_OptionExerciseFeeLowEndOfTheRange"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_RegulatoryMilestonePaymentOnLicensedProductLowEndOfTheRange" xlink:label="vir_RegulatoryMilestonePaymentOnLicensedProductLowEndOfTheRange"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_RegulatoryMilestonePaymentOnLicensedProductHighEndOfRange" xlink:label="vir_RegulatoryMilestonePaymentOnLicensedProductHighEndOfRange"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_AdjustmentsToProfitSharingAmounts" xlink:label="vir_AdjustmentsToProfitSharingAmounts"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ProfitSharingAmountConstrained" xlink:label="vir_ProfitSharingAmountConstrained"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_RangeOfRoyaltyPaymentToBePaid" xlink:label="vir_RangeOfRoyaltyPaymentToBePaid"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_OptionsTransactionPrice" xlink:label="vir_OptionsTransactionPrice"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_OptionExerciseFeeHighEndOfTheRange" xlink:label="vir_OptionExerciseFeeHighEndOfTheRange"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MaximumAggregateSalesMilestonePayments" xlink:label="vir_MaximumAggregateSalesMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MaximumNumberOfDevelopmentProgramGrantedToCounterparty" xlink:label="vir_MaximumNumberOfDevelopmentProgramGrantedToCounterparty"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_WrittenNoticeToTerminateLicensedProgramIfNotExercise" xlink:label="vir_WrittenNoticeToTerminateLicensedProgramIfNotExercise"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MaximumNumberOfDevelopmentProgramGrantedFromCounterparty" xlink:label="vir_MaximumNumberOfDevelopmentProgramGrantedFromCounterparty"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_UpfrontPaymentReceivable" xlink:label="vir_UpfrontPaymentReceivable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_UpfrontPaymentReceived" xlink:label="vir_UpfrontPaymentReceived"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PercentageOfUpfrontPaymentReceivableAtEffectiveDateOfAgreement" xlink:label="vir_PercentageOfUpfrontPaymentReceivableAtEffectiveDateOfAgreement"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PercentageOfUpfrontPaymentReceivableAtExecutionDateOfAgreement" xlink:label="vir_PercentageOfUpfrontPaymentReceivableAtExecutionDateOfAgreement"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_OptionExerciseFeeConsiderationToBeReceived" xlink:label="vir_OptionExerciseFeeConsiderationToBeReceived"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PreDefinedRegulatoryMilestoneConsiderationToBeReceived" xlink:label="vir_PreDefinedRegulatoryMilestoneConsiderationToBeReceived"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_CollaborationAgreementTransactionPriceUpfrontFee" xlink:label="vir_CollaborationAgreementTransactionPriceUpfrontFee"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_CollaborationAgreementTransactionPriceConsideration" xlink:label="vir_CollaborationAgreementTransactionPriceConsideration"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_RoyaltiesPaymentRangeOnNetSalesOfLicensedProduct" xlink:label="vir_RoyaltiesPaymentRangeOnNetSalesOfLicensedProduct"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PercentageOfOrdinaryShareEqualToOutstandingShare" xlink:label="vir_PercentageOfOrdinaryShareEqualToOutstandingShare"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_RangeOfTieredRoyaltiesToPayToNetSalesOfProducts" xlink:label="vir_RangeOfTieredRoyaltiesToPayToNetSalesOfProducts"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales" xlink:label="vir_RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach" xlink:label="vir_WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ValueOfSharesTransferredToCollaborator" xlink:label="vir_ValueOfSharesTransferredToCollaborator"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncome" xlink:label="us-gaap_DeferredIncome"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ReclassifiedDeferredRevenue" xlink:label="vir_ReclassifiedDeferredRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Investments" xlink:label="us-gaap_Investments"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_CollaborationTypeAndPrograms" xlink:label="vir_CollaborationTypeAndPrograms"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_OptionExerciseFeeReceived" xlink:label="vir_OptionExerciseFeeReceived"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_DeterminedTransactionPrice" xlink:label="vir_DeterminedTransactionPrice"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_UpfrontFeePaid" xlink:label="vir_UpfrontFeePaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MaximumSharesToBeIssued" xlink:label="vir_MaximumSharesToBeIssued"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory" xlink:label="vir_MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MaximumMilestonePaymentForAchievementOfSpecifiedMilestones" xlink:label="vir_MaximumMilestonePaymentForAchievementOfSpecifiedMilestones"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MaximumAggregateSalesMilestonePayment" xlink:label="vir_MaximumAggregateSalesMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MaximumSalesMilestonePayment" xlink:label="vir_MaximumSalesMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MaximumAggregateMilestonePayments" xlink:label="vir_MaximumAggregateMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_RoyaltiesBasedOnNetSalesOfLicensedProducts" xlink:label="vir_RoyaltiesBasedOnNetSalesOfLicensedProducts"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_RangeOfRoyaltyPaymentsToBeReceived" xlink:label="vir_RangeOfRoyaltyPaymentsToBeReceived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MaximumSalesMilestoneToBeReceived" xlink:label="vir_MaximumSalesMilestoneToBeReceived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MilestonePaymentsPaid" xlink:label="vir_MilestonePaymentsPaid"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_CollaborationAgreementRelatedCostsAndExpenses" xlink:label="vir_CollaborationAgreementRelatedCostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_NumberOfAntibodiesToDevelop" xlink:label="vir_NumberOfAntibodiesToDevelop"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MaximumAggregateMilestonePaymentForAchievementOfSpecifiedMilestones" xlink:label="vir_MaximumAggregateMilestonePaymentForAchievementOfSpecifiedMilestones"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_RoyaltyObligationPeriodFromDateOfFirstCommercialSale" xlink:label="vir_RoyaltyObligationPeriodFromDateOfFirstCommercialSale"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ResearchAndDevelopmentExpenseUnderLicenseAgreement" xlink:label="vir_ResearchAndDevelopmentExpenseUnderLicenseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_LicenseAgreementUpfrontPayment" xlink:label="vir_LicenseAgreementUpfrontPayment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MaximumAggregateDevelopmentAndRegulatoryMilestonePayments" xlink:label="vir_MaximumAggregateDevelopmentAndRegulatoryMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MaximumAggregateCommercialSalesMilestonePayments" xlink:label="vir_MaximumAggregateCommercialSalesMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_WrittenNoticePeriodForTerminationOfLicensedProgram" xlink:label="vir_WrittenNoticePeriodForTerminationOfLicensedProgram"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenges" xlink:label="vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenges"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_WrittenNoticePeriodToTerminateLicensedProgramForFailureToMakePayment" xlink:label="vir_WrittenNoticePeriodToTerminateLicensedProgramForFailureToMakePayment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_WrittenNoticePeriodToTerminateLicensedProgramForPaymentBreach" xlink:label="vir_WrittenNoticePeriodToTerminateLicensedProgramForPaymentBreach"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="vir_GlaxoGroupLimitedMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CN" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="vir_AccruedLiabilitiesAndOtherLiabilitiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201409Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="vir_Vir3434Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_TwoThousandTwentyStockPurchaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_ContractRevenueMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_GlaxoWellcomeUKLimitedAndBeechamSAMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_PreliminaryCollaborationAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SharePrice" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_CollaborationRevenueMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_BriiBioParentMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_AmendmentNumberOneMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_AntibodyProgramMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_BriiBiosciencesOffshoreLimitedMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_DefinitiveCollaborationAgreementMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_VaccineProgramMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_AlnylamPharmaceuticalsIncMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_PercentageOfShareDevelopmentCosts" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_TwoThousandTwentyOneStockPurchaseAgreementMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_DevelopmentProgramsExercisedByVirMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_WuXiBiologicsLimitedMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_PercentageOfDevelopmentCosts" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_DevelopmentProgramsExercisedByBriiMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_RockefellerUniversityMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementGeographicalAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_TwoThousandAndTwentyOneGSKCollaborationMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_BiologicalMaterialsMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_MedImmuneLimitedLiabilityCompanyMember" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_CollaborationAgreementTerminationDescription" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_TwoThousandAndTwentyGskAgreementMember" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_Vir2218Member" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_XencorIncorporationMember" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_FairMarketValueOfCommonStockIssued" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_TwoThousandAndTwentyOneGSKAgreementMember" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_Vir2248Member" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_BriiAgreementMember" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_FirstSiRNAProductMember" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_PremiumReceivedOnSalePriceOfCommonStock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_AlnylamAgreementMember" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_FirstSiRNAProductHBVMember" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_AntibodyLicenseTransactionPrice" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_DevelopmentAndManufacturingCollaborationAgreementMember" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_EachInfectiousDiseaseSiRNAMember" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_RockefellerAgreementMember" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_FirstInfectiousDiseaseProductMember" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_SpecifiedResearchAndDevelopmentExpensesMilestonePayments" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_MedImmuneAgreementMember" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_InfectiousDiseaseProductMember" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_WrittenNoticePeriodToTerminateAgreementByCompany" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_TwoThousandNineteenXencorAgreementMember" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_HBVProgramMember" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_RangeOfRoyaltyPaymentToBeReceived" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_TwoThousandTwentyXencorAgreementMember" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_InfluenzaAAndInfluenzaBMember" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumNumberOfProductsCoveredAgainstMilestonePayment" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_XencorAgreementsMember" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_InfluenzaAResearchProgramsMember" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromRelatedParties" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_TwoThousandNineteenAndTwoThousandTwentyXencorAgreementMember" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_InfluenzaAAndHBVResearchProgramsMember" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_WrittenNoticePeriodToTerminateLicensedProgramForUncuredMaterialBreach" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_RegulatoryMilestonePaymentToBeReceived" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_AnnualLicenseMaintenanceFees" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_WrittenNoticeToTerminateLicensedProgramIfExercise" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_WrittenNoticePeriodToTerminateAgreementByCounterparty" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenge" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumSalesMilestonePaymentsToBeReceived" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_PaymentToCollaboratorResultingFromProgramOptionExercise" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_RoyaltiesPaymentExpirationPeriod" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_CollaborationAgreementNumberOfUnitsOfAccount" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_IncreaseDecreaseInResearchAndDevelopmentExpense" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_ProfitsAndLossesSharingPercentage" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_OptionExerciseFeeLowEndOfTheRange" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_RegulatoryMilestonePaymentOnLicensedProductLowEndOfTheRange" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_RegulatoryMilestonePaymentOnLicensedProductHighEndOfRange" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_AdjustmentsToProfitSharingAmounts" order="35" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_ProfitSharingAmountConstrained" order="36" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_RangeOfRoyaltyPaymentToBePaid" order="37" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_OptionsTransactionPrice" order="38" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_OptionExerciseFeeHighEndOfTheRange" order="39" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumAggregateSalesMilestonePayments" order="40" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumNumberOfDevelopmentProgramGrantedToCounterparty" order="41" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_WrittenNoticeToTerminateLicensedProgramIfNotExercise" order="42" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumNumberOfDevelopmentProgramGrantedFromCounterparty" order="43" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_UpfrontPaymentReceivable" order="44" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_UpfrontPaymentReceived" order="45" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_PercentageOfUpfrontPaymentReceivableAtEffectiveDateOfAgreement" order="46" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_PercentageOfUpfrontPaymentReceivableAtExecutionDateOfAgreement" order="47" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_OptionExerciseFeeConsiderationToBeReceived" order="48" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_PreDefinedRegulatoryMilestoneConsiderationToBeReceived" order="49" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_CollaborationAgreementTransactionPriceUpfrontFee" order="50" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_CollaborationAgreementTransactionPriceConsideration" order="51" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_RoyaltiesPaymentRangeOnNetSalesOfLicensedProduct" order="52" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_PercentageOfOrdinaryShareEqualToOutstandingShare" order="53" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_RangeOfTieredRoyaltiesToPayToNetSalesOfProducts" order="54" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales" order="55" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach" order="56" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_ValueOfSharesTransferredToCollaborator" order="57" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredIncome" order="58" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="59" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="60" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_ReclassifiedDeferredRevenue" order="61" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_Investments" order="62" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_CollaborationTypeAndPrograms" order="63" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_OptionExerciseFeeReceived" order="64" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_DeterminedTransactionPrice" order="65" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_UpfrontFeePaid" order="66" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" order="67" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumSharesToBeIssued" order="68" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory" order="69" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumMilestonePaymentForAchievementOfSpecifiedMilestones" order="70" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumAggregateSalesMilestonePayment" order="71" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumSalesMilestonePayment" order="72" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumAggregateMilestonePayments" order="73" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_RoyaltiesBasedOnNetSalesOfLicensedProducts" order="74" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_RangeOfRoyaltyPaymentsToBeReceived" order="75" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability" order="76" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumSalesMilestoneToBeReceived" order="77" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="78" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MilestonePaymentsPaid" order="79" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_CollaborationAgreementRelatedCostsAndExpenses" order="80" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_NumberOfAntibodiesToDevelop" order="81" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumAggregateMilestonePaymentForAchievementOfSpecifiedMilestones" order="82" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_RoyaltyObligationPeriodFromDateOfFirstCommercialSale" order="83" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_ResearchAndDevelopmentExpenseUnderLicenseAgreement" order="84" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_LicenseAgreementUpfrontPayment" order="85" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumAggregateDevelopmentAndRegulatoryMilestonePayments" order="86" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumAggregateCommercialSalesMilestonePayments" order="87" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CostOfRevenue" order="88" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="89" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_WrittenNoticePeriodForTerminationOfLicensedProgram" order="90" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenges" order="91" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_WrittenNoticePeriodToTerminateLicensedProgramForFailureToMakePayment" order="92" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_WrittenNoticePeriodToTerminateLicensedProgramForPaymentBreach" order="93" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsCollaborationCollaborationRevenueDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_CollaborationAndLicenseAgreements" xlink:label="vir_CollaborationAndLicenseAgreements"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ProfitSharingAmount" xlink:label="vir_ProfitSharingAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionAbstract" xlink:label="us-gaap_RevenueRecognitionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ProfitSharingAmountConstrained" xlink:label="vir_ProfitSharingAmountConstrained"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ProfitSharingAmountPreviouslyConstrainedReleased" xlink:label="vir_ProfitSharingAmountPreviouslyConstrainedReleased"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TotalcollaborationRevenue" xlink:label="vir_TotalcollaborationRevenue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_CollaborationAndLicenseAgreements" xlink:to="vir_ProfitSharingAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAbstract" xlink:to="vir_CollaborationAndLicenseAgreements" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_CollaborationAndLicenseAgreements" xlink:to="vir_ProfitSharingAmountConstrained" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_CollaborationAndLicenseAgreements" xlink:to="vir_ProfitSharingAmountPreviouslyConstrainedReleased" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_CollaborationAndLicenseAgreements" xlink:to="vir_TotalcollaborationRevenue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_LaboratoryEquipmentMember" xlink:label="vir_LaboratoryEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="vir_LaboratoryEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_SaleLeasebackTransactionProceedsFromFinancingObligations" xlink:label="vir_SaleLeasebackTransactionProceedsFromFinancingObligations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:label="us-gaap_LesseeFinanceLeaseTermOfContract1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="vir_SaleLeasebackTransactionProceedsFromFinancingObligations" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_LesseeFinanceLeaseTermOfContract1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MilestonePayable" xlink:label="vir_MilestonePayable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ProfitShareAmountConstraint" xlink:label="vir_ProfitShareAmountConstraint"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ResearchAndDevelopmentExpensesCurrent" xlink:label="vir_ResearchAndDevelopmentExpensesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PayrollAndRelatedExpensesCurrent" xlink:label="vir_PayrollAndRelatedExpensesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ExcessFundsPayableUnderGrantAgreementsCurrent" xlink:label="vir_ExcessFundsPayableUnderGrantAgreementsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="vir_MilestonePayable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="vir_ProfitShareAmountConstraint" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_AccruedRoyaltiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="vir_ResearchAndDevelopmentExpensesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="vir_PayrollAndRelatedExpensesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="vir_ExcessFundsPayableUnderGrantAgreementsCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_SamsungBiologicsCompanyLimitedMember" xlink:label="vir_SamsungBiologicsCompanyLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseAgreementsMember" xlink:label="us-gaap_LeaseAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember" xlink:label="vir_WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_LeaseArrangementContractualExpirationBeginningYear" xlink:label="vir_LeaseArrangementContractualExpirationBeginningYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_AntibodyProgramMember" xlink:label="vir_AntibodyProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_WuXiBiologicsLimitedMember" xlink:label="vir_WuXiBiologicsLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_LeaseArrangementContractualExpirationEndingYear" xlink:label="vir_LeaseArrangementContractualExpirationEndingYear"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_GlaxoSmithKlineTradingServiceLimitedMember" xlink:label="vir_GlaxoSmithKlineTradingServiceLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember" xlink:label="vir_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="us-gaap_GainLossOnTerminationOfLease"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember" xlink:label="vir_TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ClinicalDevelopmentAndManufacturingOrganizationMember" xlink:label="vir_ClinicalDevelopmentAndManufacturingOrganizationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetRentableArea" xlink:label="us-gaap_NetRentableArea"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TenantImprovementAllowanceAggregate" xlink:label="vir_TenantImprovementAllowanceAggregate"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PercentageOfDevelopmentCostsResponsibleByCompany" xlink:label="vir_PercentageOfDevelopmentCostsResponsibleByCompany"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PercentageOfDevelopmentCostsResponsibleByGsk" xlink:label="vir_PercentageOfDevelopmentCostsResponsibleByGsk"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PaymentCommitmentManufacturingCapacity" xlink:label="vir_PaymentCommitmentManufacturingCapacity"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PaymentCommitmentRawMaterials" xlink:label="vir_PaymentCommitmentRawMaterials"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PrepaymentRawMaterials" xlink:label="vir_PrepaymentRawMaterials"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_OperatingAndFinanceRentExpense" xlink:label="vir_OperatingAndFinanceRentExpense"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ObligationToPayCapacityReservation" xlink:label="vir_ObligationToPayCapacityReservation"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PercentageOfEstimatedBatchProductionFees" xlink:label="vir_PercentageOfEstimatedBatchProductionFees"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PercentageOfDevelopmentCosts" xlink:label="vir_PercentageOfDevelopmentCosts"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_SamsungBiologicsCompanyLimitedMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LeaseAgreementsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="vir_LeaseArrangementContractualExpirationBeginningYear" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LossContingenciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_AntibodyProgramMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_WuXiBiologicsLimitedMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="vir_LeaseArrangementContractualExpirationEndingYear" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_CounterpartyNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_GlaxoSmithKlineTradingServiceLimitedMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_GainLossOnTerminationOfLease" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_ProductOrServiceAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_ClinicalDevelopmentAndManufacturingOrganizationMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_NetRentableArea" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_TenantImprovements" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="vir_TenantImprovementAllowanceAggregate" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="vir_PercentageOfDevelopmentCostsResponsibleByCompany" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="vir_PercentageOfDevelopmentCostsResponsibleByGsk" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="vir_PaymentCommitmentManufacturingCapacity" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="vir_PaymentCommitmentRawMaterials" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="vir_PrepaymentRawMaterials" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="vir_OperatingAndFinanceRentExpense" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="vir_ObligationToPayCapacityReservation" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="vir_PercentageOfEstimatedBatchProductionFees" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="vir_PercentageOfDevelopmentCosts" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsAndAdditionalInformationRelatedToOperatingLeasesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_OperatingLeaseOtherInformationAbstract" xlink:label="vir_OperatingLeaseOtherInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OperatingLeaseOtherInformationAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OperatingLeaseOtherInformationAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ShortTermLeaseCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OperatingLeaseOtherInformationAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_VariableLeaseCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OperatingLeaseOtherInformationAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeaseCost" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="vir_OperatingLeaseOtherInformationAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived" xlink:label="vir_LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PresentValueOfOperatingLeaseLiabilities" xlink:label="vir_PresentValueOfOperatingLeaseLiabilities"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="vir_LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="vir_PresentValueOfOperatingLeaseLiabilities" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_OperatingLeaseAbstract" xlink:label="vir_OperatingLeaseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_OperatingLeaseIncentiveOverLeaseLiabilities" xlink:label="vir_OperatingLeaseIncentiveOverLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="vir_OperatingLeaseAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OperatingLeaseAbstract" xlink:to="vir_OperatingLeaseIncentiveOverLeaseLiabilities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OperatingLeaseAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OperatingLeaseAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OperatingLeaseAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OperatingLeaseAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OperatingLeaseAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/DisclosureManufacturingAndSupplyLetterAgreementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingenciesLineItems" xlink:label="us-gaap_GainContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PercentageOfDevelopmentCostsResponsibleByGsk" xlink:label="vir_PercentageOfDevelopmentCostsResponsibleByGsk"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_GlaxoSmithKlineTradingServiceLimitedMember" xlink:label="vir_GlaxoSmithKlineTradingServiceLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingenciesTable" xlink:label="us-gaap_GainContingenciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_WuxiBiologicsLetterAgreementAssignmentAndMasterServiceAgreementsMember" xlink:label="vir_WuxiBiologicsLetterAgreementAssignmentAndMasterServiceAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_AntibodyProgramMember" xlink:label="vir_AntibodyProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PaymentCommitmentManufacturingCapacity" xlink:label="vir_PaymentCommitmentManufacturingCapacity"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember" xlink:label="vir_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PaymentCommitmentRawMaterials" xlink:label="vir_PaymentCommitmentRawMaterials"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ClinicalDevelopmentAndManufacturingOrganizationMember" xlink:label="vir_ClinicalDevelopmentAndManufacturingOrganizationMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PrepaymentRawMaterials" xlink:label="vir_PrepaymentRawMaterials"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GainContingenciesLineItems" xlink:to="vir_PercentageOfDevelopmentCostsResponsibleByGsk" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_GlaxoSmithKlineTradingServiceLimitedMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GainContingenciesTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_GainContingenciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="vir_WuxiBiologicsLetterAgreementAssignmentAndMasterServiceAgreementsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_AntibodyProgramMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GainContingenciesLineItems" xlink:to="vir_PaymentCommitmentManufacturingCapacity" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GainContingenciesTable" xlink:to="srt_CounterpartyNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GainContingenciesLineItems" xlink:to="vir_PaymentCommitmentRawMaterials" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_ClinicalDevelopmentAndManufacturingOrganizationMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GainContingenciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GainContingenciesLineItems" xlink:to="vir_PrepaymentRawMaterials" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GainContingenciesTable" xlink:to="us-gaap_GainContingenciesLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_SeriesBConvertiblePreferredStockMember" xlink:label="vir_SeriesBConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="vir_SeriesBConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_FirstAndSecondClosingsMember" xlink:label="vir_FirstAndSecondClosingsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_SeriesAOneConvertiblePreferredStockMember" xlink:label="vir_SeriesAOneConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="vir_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ThirdClosingMember" xlink:label="vir_ThirdClosingMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_SeriesBConvertiblePreferredStockMember" xlink:label="vir_SeriesBConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TemporaryEquityAdditionalSharesAuthorized" xlink:label="vir_TemporaryEquityAdditionalSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_NumberOfClassOfStock" xlink:label="vir_NumberOfClassOfStock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="vir_FirstAndSecondClosingsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="vir_SeriesAOneConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="vir_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="vir_ThirdClosingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="vir_SeriesBConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="vir_TemporaryEquityAdditionalSharesAuthorized" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="vir_NumberOfClassOfStock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantLiabilityAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_SeriesAOneConvertiblePreferredStockMember" xlink:label="vir_SeriesAOneConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ConvertiblePreferredStockWarrantLiabilityAbstract" xlink:label="vir_ConvertiblePreferredStockWarrantLiabilityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_StockIssuedDuringPeriodWarrantExercised" xlink:label="vir_StockIssuedDuringPeriodWarrantExercised"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="vir_SeriesAOneConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_ConvertiblePreferredStockWarrantLiabilityAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="vir_StockIssuedDuringPeriodWarrantExercised" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TwoThousandSixteenEquityIncentivePlanMember" xlink:label="vir_TwoThousandSixteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_RestrictedStockPurchaseAgreementMember" xlink:label="vir_RestrictedStockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ExecutiveOfficerAndDirectorMember" xlink:label="vir_ExecutiveOfficerAndDirectorMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TwoThousandNineteenEquityIncentivePlanMember" xlink:label="vir_TwoThousandNineteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TwoThousandNineteenEmployeeStockPurchasePlanMember" xlink:label="vir_TwoThousandNineteenEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_OfferingPeriodEmployeeStockPurchasePlan" xlink:label="vir_OfferingPeriodEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MaximumTermOfOfferingPeriodSpecifiedUnderPlan" xlink:label="vir_MaximumTermOfOfferingPeriodSpecifiedUnderPlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_RepaymentOfOutstandingPromissoryNotesAndAccruedInterestReceived" xlink:label="vir_RepaymentOfOutstandingPromissoryNotesAndAccruedInterestReceived"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_RestrictedStockLiabilityRecognizedForPortionOfPromissoryNoteRepayment" xlink:label="vir_RestrictedStockLiabilityRecognizedForPortionOfPromissoryNoteRepayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="vir_TwoThousandSixteenEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_RestrictedStockPurchaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="vir_ExecutiveOfficerAndDirectorMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="vir_TwoThousandNineteenEquityIncentivePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="vir_TwoThousandNineteenEmployeeStockPurchasePlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="vir_OfferingPeriodEmployeeStockPurchasePlan" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="vir_MaximumTermOfOfferingPeriodSpecifiedUnderPlan" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="vir_RepaymentOfOutstandingPromissoryNotesAndAccruedInterestReceived" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="vir_RestrictedStockLiabilityRecognizedForPortionOfPromissoryNoteRepayment" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/DisclosureStockbasedAwardsSummaryOfEmployeesStockPurchasePlanDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TwoThousandNineteenEmployeeStockPurchasePlanMember" xlink:label="vir_TwoThousandNineteenEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="vir_TwoThousandNineteenEmployeeStockPurchasePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_RestrictedStockAwardsRSAMember" xlink:label="vir_RestrictedStockAwardsRSAMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="vir_RestrictedStockAwardsRSAMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockBasedCompensationExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalariesWagesAndOfficersCompensationAbstract" xlink:label="us-gaap_SalariesWagesAndOfficersCompensationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SalariesWagesAndOfficersCompensationAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting" xlink:label="vir_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_IncrementalCommonSharesAttributabletoShareBasedPaymentArrangementsEmployeeStockPurchasePlan" xlink:label="vir_IncrementalCommonSharesAttributabletoShareBasedPaymentArrangementsEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares" xlink:label="us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="vir_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="vir_IncrementalCommonSharesAttributabletoShareBasedPaymentArrangementsEmployeeStockPurchasePlan" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_EstimatedSharesIssuableUnderTheESPPMember" xlink:label="vir_EstimatedSharesIssuableUnderTheESPPMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_WarrantsToPurchaseCommonStockMember" xlink:label="vir_WarrantsToPurchaseCommonStockMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="vir_EstimatedSharesIssuableUnderTheESPPMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="vir_WarrantsToPurchaseCommonStockMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/DisclosureNetIncomeLossPerShareAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_EstimatedSharesEmployeeStockPurchasePlans" xlink:label="vir_EstimatedSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_EsppDiscountedPurchasePricePercentage" xlink:label="vir_EsppDiscountedPurchasePricePercentage"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="vir_EstimatedSharesEmployeeStockPurchasePlans" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="vir_EsppDiscountedPurchasePricePercentage" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_HumabsBiomedSAMember" xlink:label="vir_HumabsBiomedSAMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xlink:label="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="us-gaap_RetirementPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_FirstPlanMember" xlink:label="vir_FirstPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanNameAxis" xlink:label="us-gaap_RetirementPlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_SecondPlanMember" xlink:label="vir_SecondPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities" xlink:label="us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="vir_HumabsBiomedSAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanTypeDomain" xlink:to="us-gaap_PensionPlansDefinedBenefitMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_RetirementPlanTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanNameDomain" xlink:to="vir_FirstPlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_RetirementPlanNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanNameDomain" xlink:to="vir_SecondPlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeLossBeforeProvisionForBenefitFromIncomeTaxesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_HumabsBiomedSAMember" xlink:label="vir_HumabsBiomedSAMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ReconciliationOfEffectiveIncomeTaxRateLineItems" xlink:label="vir_ReconciliationOfEffectiveIncomeTaxRateLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ReconciliationOfEffectiveIncomeTaxRateTable" xlink:label="vir_ReconciliationOfEffectiveIncomeTaxRateTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_EffectiveIncomeTaxRateReconciliationPermanentItemsPercent" xlink:label="vir_EffectiveIncomeTaxRateReconciliationPermanentItemsPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="vir_HumabsBiomedSAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_ReconciliationOfEffectiveIncomeTaxRateLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="vir_ReconciliationOfEffectiveIncomeTaxRateTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_ReconciliationOfEffectiveIncomeTaxRateTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_ReconciliationOfEffectiveIncomeTaxRateLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_ReconciliationOfEffectiveIncomeTaxRateTable" xlink:to="vir_ReconciliationOfEffectiveIncomeTaxRateLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_ReconciliationOfEffectiveIncomeTaxRateLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_ReconciliationOfEffectiveIncomeTaxRateLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_ReconciliationOfEffectiveIncomeTaxRateLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_ReconciliationOfEffectiveIncomeTaxRateLineItems" xlink:to="vir_EffectiveIncomeTaxRateReconciliationPermanentItemsPercent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_ReconciliationOfEffectiveIncomeTaxRateLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_ReconciliationOfEffectiveIncomeTaxRateLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_ReconciliationOfEffectiveIncomeTaxRateLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities" xlink:label="us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="vir_DeferredTaxLiabilitiesRightOfUseAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_DeferredTaxLiabilitiesInProcessResearchAndDevelopment" xlink:label="vir_DeferredTaxLiabilitiesInProcessResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_DeferredTaxAssetsLeaseLiabilities" xlink:label="vir_DeferredTaxAssetsLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="vir_DeferredTaxLiabilitiesRightOfUseAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="vir_DeferredTaxLiabilitiesInProcessResearchAndDevelopment" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_ResearchAndDevelopmentInProcess" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="vir_DeferredTaxAssetsLeaseLiabilities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_OR" xlink:label="stpr_OR"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_IncomeTaxesTable" xlink:label="vir_IncomeTaxesTable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_IncomeTaxesLineItems" xlink:label="vir_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SwissFederalTaxAdministrationFTAMember" xlink:label="us-gaap_SwissFederalTaxAdministrationFTAMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ReleaseOfValuationAllowanceDeferredTaxInAmount" xlink:label="vir_ReleaseOfValuationAllowanceDeferredTaxInAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AustralianTaxationOfficeMember" xlink:label="us-gaap_AustralianTaxationOfficeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_OperatingLossCarryforwardsExpirationBeginningYear" xlink:label="vir_OperatingLossCarryforwardsExpirationBeginningYear"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_OperatingLossCarryforwardsLimitationOnUsePercentage" xlink:label="vir_OperatingLossCarryforwardsLimitationOnUsePercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TaxCreditCarryforwardsExpirationBeginningYear" xlink:label="vir_TaxCreditCarryforwardsExpirationBeginningYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_UnrecognizedTaxBenefitsIfRecognizedWouldReduceEffectiveTaxRate" xlink:label="vir_UnrecognizedTaxBenefitsIfRecognizedWouldReduceEffectiveTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_OR" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="vir_IncomeTaxesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_IncomeTaxesLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_SwissFederalTaxAdministrationFTAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_IncomeTaxesLineItems" xlink:to="vir_ReleaseOfValuationAllowanceDeferredTaxInAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_AustralianTaxationOfficeMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_IncomeTaxesLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_IncomeTaxesTable" xlink:to="srt_StatementGeographicalAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_IncomeTaxesLineItems" xlink:to="vir_OperatingLossCarryforwardsExpirationBeginningYear" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_IncomeTaxesTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_IncomeTaxesLineItems" xlink:to="vir_OperatingLossCarryforwardsLimitationOnUsePercentage" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_IncomeTaxesTable" xlink:to="vir_IncomeTaxesLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_IncomeTaxesLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_IncomeTaxesLineItems" xlink:to="vir_TaxCreditCarryforwardsExpirationBeginningYear" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_IncomeTaxesLineItems" xlink:to="vir_UnrecognizedTaxBenefitsIfRecognizedWouldReduceEffectiveTaxRate" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfLiabilityForUncertainTaxPositionsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_4"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20221231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_BusinessAgreementGrantAmount" xlink:label="vir_BusinessAgreementGrantAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PreliminaryCollaborationAgreementMember" xlink:label="vir_PreliminaryCollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_CashGrantAwarded" xlink:label="vir_CashGrantAwarded"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_DefinitiveCollaborationAgreementMember" xlink:label="vir_DefinitiveCollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ValueStockIssuedGrantAgreement" xlink:label="vir_ValueStockIssuedGrantAgreement"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TwoThousandTwentyOneStockPurchaseAgreementMember" xlink:label="vir_TwoThousandTwentyOneStockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_StockIssuedGrantAgreement" xlink:label="vir_StockIssuedGrantAgreement"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_LetterAgreementMember" xlink:label="vir_LetterAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_BusinessAgreementEquityInvestmentCommitment" xlink:label="vir_BusinessAgreementEquityInvestmentCommitment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_BillMelindaGatesFoundationMember" xlink:label="vir_BillMelindaGatesFoundationMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="vir_BusinessAgreementGrantAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_PreliminaryCollaborationAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="vir_CashGrantAwarded" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_DefinitiveCollaborationAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="vir_ValueStockIssuedGrantAgreement" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_TwoThousandTwentyOneStockPurchaseAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="vir_StockIssuedGrantAgreement" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_LetterAgreementMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="vir_BusinessAgreementEquityInvestmentCommitment" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_BillMelindaGatesFoundationMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>37
<FILENAME>vir-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-02-28T15:30:32.0603+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" xlink:href="vir-20221231.xsd#Role_StatementConsolidatedStatementsOfOperations" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:href="vir-20221231.xsd#Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:href="vir-20221231.xsd#Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:href="vir-20221231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:href="vir-20221231.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsTables" xlink:href="vir-20221231.xsd#Role_DisclosureStockBasedAwardsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails" xlink:href="vir-20221231.xsd#Role_DisclosureOrganizationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="vir-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails" xlink:href="vir-20221231.xsd#Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyParentheticalDetails" xlink:href="vir-20221231.xsd#Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyParentheticalDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:href="vir-20221231.xsd#Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails" xlink:href="vir-20221231.xsd#Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails" xlink:href="vir-20221231.xsd#Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails" xlink:href="vir-20221231.xsd#Role_DisclosureAcquisitionsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails" xlink:href="vir-20221231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails" xlink:href="vir-20221231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails" xlink:href="vir-20221231.xsd#Role_DisclosureGrantAgreementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" xlink:href="vir-20221231.xsd#Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" xlink:href="vir-20221231.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="vir-20221231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/DisclosureManufacturingAndSupplyLetterAgreementsAdditionalInformationDetails" xlink:href="vir-20221231.xsd#DisclosureManufacturingAndSupplyLetterAgreementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="vir-20221231.xsd#Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:href="vir-20221231.xsd#Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantLiabilityAdditionalInformationDetails" xlink:href="vir-20221231.xsd#Role_DisclosureConvertiblePreferredStockWarrantLiabilityAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails" xlink:href="vir-20221231.xsd#Role_DisclosureStockBasedAwardsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails" xlink:href="vir-20221231.xsd#Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails" xlink:href="vir-20221231.xsd#Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/DisclosureStockbasedAwardsSummaryOfEmployeesStockPurchasePlanDetails" xlink:href="vir-20221231.xsd#DisclosureStockbasedAwardsSummaryOfEmployeesStockPurchasePlanDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityDetails" xlink:href="vir-20221231.xsd#Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockBasedCompensationExpenseDetails" xlink:href="vir-20221231.xsd#Role_DisclosureStockBasedAwardsSummaryOfStockBasedCompensationExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails" xlink:href="vir-20221231.xsd#DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails" xlink:href="vir-20221231.xsd#DisclosureDefinedContributionPlanAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails" xlink:href="vir-20221231.xsd#Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="vir-20221231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20221231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" xlink:href="vir-20221231.xsd#DisclosureSubsequentEventAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm" xlink:type="simple"/>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_CollaborationRevenueMember" xlink:label="vir_CollaborationRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ContractRevenueMember" xlink:label="vir_ContractRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostOfRevenue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_CollaborationRevenueMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueNotFromContractWithCustomer" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_ContractRevenueMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_Revenues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_GrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_FollowOnOfferingMember" xlink:label="vir_FollowOnOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_SeriesAOneConvertiblePreferredStockMember" xlink:label="vir_SeriesAOneConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_SeriesATwoConvertiblePreferredStockMember" xlink:label="vir_SeriesATwoConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_SeriesBConvertiblePreferredStockMember" xlink:label="vir_SeriesBConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital" xlink:label="vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_StockIssuedDuringPeriodSharesAchievementOfMilestone" xlink:label="vir_StockIssuedDuringPeriodSharesAchievementOfMilestone"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_StockIssuedDuringPeriodValueCollaborationAgreement" xlink:label="vir_StockIssuedDuringPeriodValueCollaborationAgreement"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_StockIssuedDuringPeriodSharesCollaborationAgreement" xlink:label="vir_StockIssuedDuringPeriodSharesCollaborationAgreement"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_StockIssuedDuringPeriodValueIssuedForSettlementOfContingentConsideration" xlink:label="vir_StockIssuedDuringPeriodValueIssuedForSettlementOfContingentConsideration"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_StockIssuedDuringPeriodSharesIssuedForSettlementOfContingentConsideration" xlink:label="vir_StockIssuedDuringPeriodSharesIssuedForSettlementOfContingentConsideration"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant" xlink:label="vir_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_StockIssuedDuringPeriodValueLicenseAgreement" xlink:label="vir_StockIssuedDuringPeriodValueLicenseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ProceedsFromIssuanceOfCommonStockInConnectionWithAGrantAgreement" xlink:label="vir_ProceedsFromIssuanceOfCommonStockInConnectionWithAGrantAgreement"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_StockIssuedDuringPeriodSharesLicenseAgreement" xlink:label="vir_StockIssuedDuringPeriodSharesLicenseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_IssuanceOfCommonStockInConnectionWithAGrantAgreementShares" xlink:label="vir_IssuanceOfCommonStockInConnectionWithAGrantAgreementShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="vir_FollowOnOfferingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="vir_SeriesAOneConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="vir_SeriesATwoConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="vir_SeriesBConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_StockIssuedDuringPeriodSharesAchievementOfMilestone" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_StockIssuedDuringPeriodValueCollaborationAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_StockIssuedDuringPeriodSharesCollaborationAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_StockIssuedDuringPeriodValueIssuedForSettlementOfContingentConsideration" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_StockIssuedDuringPeriodSharesIssuedForSettlementOfContingentConsideration" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_StockIssuedDuringPeriodValueLicenseAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_ProceedsFromIssuanceOfCommonStockInConnectionWithAGrantAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_StockIssuedDuringPeriodSharesLicenseAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_IssuanceOfCommonStockInConnectionWithAGrantAgreementShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_SeriesAOneConvertiblePreferredStockMember" xlink:label="vir_SeriesAOneConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ConvertiblePreferredStockIssuanceCost" xlink:label="vir_ConvertiblePreferredStockIssuanceCost"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_SeriesBConvertiblePreferredStockMember" xlink:label="vir_SeriesBConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_InitialPublicOfferingCosts" xlink:label="vir_InitialPublicOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_CommonStockIssuanceCost" xlink:label="vir_CommonStockIssuanceCost"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="vir_SeriesAOneConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_ConvertiblePreferredStockIssuanceCost" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="vir_SeriesBConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_InitialPublicOfferingCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_CommonStockIssuanceCost" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_CollaborationAgreementMember" xlink:label="vir_CollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfMachineryAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ProceedsFromIssuanceOfCommonStockInConnectionWithCollaboration" xlink:label="vir_ProceedsFromIssuanceOfCommonStockInConnectionWithCollaboration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ChangesInEstimatedConstraintOnProfitSharingAmount" xlink:label="vir_ChangesInEstimatedConstraintOnProfitSharingAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ProceedsFromIssuanceOfCommonStockInConnectionWithAGrantAgreement" xlink:label="vir_ProceedsFromIssuanceOfCommonStockInConnectionWithAGrantAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_NonCashCommonStockIssuedForContingentConsideration" xlink:label="vir_NonCashCommonStockIssuedForContingentConsideration"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PaymentOfContingentConsideration" xlink:label="vir_PaymentOfContingentConsideration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ConversionOfPreferredStockIntoCommonStockUponCompletionOfInitialPublicOffering" xlink:label="vir_ConversionOfPreferredStockIntoCommonStockUponCompletionOfInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ProceedsFromDisposalOfAnEquipment" xlink:label="vir_ProceedsFromDisposalOfAnEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_AdvancedProceedsAppliedToConvertiblePreferredStockIssuance" xlink:label="vir_AdvancedProceedsAppliedToConvertiblePreferredStockIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_NoncashLeaseExpense" xlink:label="vir_NoncashLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone" xlink:label="vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueAdjustment" xlink:label="us-gaap_AssetsFairValueAdjustment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ReclassificationOfPreferredStockWarrantLiabilityToAdditionalPaidInCapital" xlink:label="vir_ReclassificationOfPreferredStockWarrantLiabilityToAdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue" xlink:label="vir_IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="us-gaap_GainLossOnTerminationOfLease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:label="us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_CollaborationAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfMachineryAndEquipment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_LaborAndRelatedExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="vir_ProceedsFromIssuanceOfCommonStockInConnectionWithCollaboration" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="vir_ChangesInEstimatedConstraintOnProfitSharingAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="vir_ProceedsFromIssuanceOfCommonStockInConnectionWithAGrantAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireInvestments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="vir_NonCashCommonStockIssuedForContingentConsideration" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="vir_PaymentOfContingentConsideration" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="vir_ConversionOfPreferredStockIntoCommonStockUponCompletionOfInitialPublicOffering" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="vir_ProceedsFromDisposalOfAnEquipment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="vir_AdvancedProceedsAppliedToConvertiblePreferredStockIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="vir_NoncashLeaseExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AssetsFairValueAdjustment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="vir_ReclassificationOfPreferredStockWarrantLiabilityToAdditionalPaidInCapital" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="vir_IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnTerminationOfLease" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherOperatingActivitiesCashFlowStatement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_HumabsBiomedSAMember" xlink:label="vir_HumabsBiomedSAMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ClinicalAndRegulatoryMilestonesMember" xlink:label="vir_ClinicalAndRegulatoryMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TomegaVaxIncMember" xlink:label="vir_TomegaVaxIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_CommercialMilestonesMember" xlink:label="vir_CommercialMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="vir_HumabsBiomedSAMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="vir_ClinicalAndRegulatoryMilestonesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="vir_TomegaVaxIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="vir_CommercialMilestonesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:label="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:label="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" xlink:label="us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_SalesAgreementMember" xlink:label="vir_SalesAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" xlink:label="us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" xlink:label="us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_FollowOnOfferingMember" xlink:label="vir_FollowOnOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_SeriesAOneConvertiblePreferredStockMember" xlink:label="vir_SeriesAOneConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ConvertiblePreferredStockWarrantLiabilityMember" xlink:label="vir_ConvertiblePreferredStockWarrantLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PaymentsOfUnderwritingDiscountsAndCommissions" xlink:label="vir_PaymentsOfUnderwritingDiscountsAndCommissions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_NetProceedsFromIssuanceSecondaryPublicOffering" xlink:label="vir_NetProceedsFromIssuanceSecondaryPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ProceedsFromIssuanceSecondaryPublicOffering" xlink:label="vir_ProceedsFromIssuanceSecondaryPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PercentageOfAggregateGrossProceedsFromSaleOfShares" xlink:label="vir_PercentageOfAggregateGrossProceedsFromSaleOfShares"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PercentageOfCommissionRateFromSaleOfShares" xlink:label="vir_PercentageOfCommissionRateFromSaleOfShares"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_SaleOfStockConsiderationAggregateOfferingPrice" xlink:label="vir_SaleOfStockConsiderationAggregateOfferingPrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_CashCashEquivalentsAndShortTermInvestmentsExcludingEquityInvestment" xlink:label="vir_CashCashEquivalentsAndShortTermInvestmentsExcludingEquityInvestment"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" xlink:to="vir_SalesAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" xlink:to="us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" xlink:to="us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="vir_FollowOnOfferingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="vir_SeriesAOneConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="vir_ConvertiblePreferredStockWarrantLiabilityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="vir_PaymentsOfUnderwritingDiscountsAndCommissions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="vir_NetProceedsFromIssuanceSecondaryPublicOffering" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="vir_ProceedsFromIssuanceSecondaryPublicOffering" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="vir_PercentageOfAggregateGrossProceedsFromSaleOfShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="vir_PercentageOfCommissionRateFromSaleOfShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="vir_SaleOfStockConsiderationAggregateOfferingPrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="vir_CashCashEquivalentsAndShortTermInvestmentsExcludingEquityInvestment" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="vir_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_SummaryOfSignificantAccountingPoliciesTable" xlink:label="vir_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201613Member" xlink:label="us-gaap_AccountingStandardsUpdate201613Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201704Member" xlink:label="us-gaap_AccountingStandardsUpdate201704Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201814Member" xlink:label="us-gaap_AccountingStandardsUpdate201814Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201818Member" xlink:label="us-gaap_AccountingStandardsUpdate201818Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="vir_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="vir_SummaryOfSignificantAccountingPoliciesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="vir_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201613Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="vir_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201704Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201814Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201818Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_FinancialAssetsAmortizedCostBasis" xlink:label="vir_FinancialAssetsAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_FinancialAssetsGrossUnrealizedHoldingGains" xlink:label="vir_FinancialAssetsGrossUnrealizedHoldingGains"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BankTimeDepositsMember" xlink:label="us-gaap_BankTimeDepositsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_FinancialAssetsGrossUnrealizedHoldingLosses" xlink:label="vir_FinancialAssetsGrossUnrealizedHoldingLosses"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_FinancialAssetsFairValue" xlink:label="vir_FinancialAssetsFairValue"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="vir_FinancialAssetsAmortizedCostBasis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="vir_FinancialAssetsGrossUnrealizedHoldingGains" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_BankTimeDepositsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="vir_FinancialAssetsGrossUnrealizedHoldingLosses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="vir_FinancialAssetsFairValue" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyParentheticalDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashEquivalents" xlink:label="us-gaap_RestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_RestrictedCashEquivalents" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_HumabsBiomedSAMember" xlink:label="vir_HumabsBiomedSAMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ContingentConsiderationLiabilityMember" xlink:label="vir_ContingentConsiderationLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_BriiBioParentMember" xlink:label="vir_BriiBioParentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_LetterAgreementMember" xlink:label="vir_LetterAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TomegaVaxIncMember" xlink:label="vir_TomegaVaxIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivable" xlink:label="us-gaap_InterestReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivableAccruedInterestWriteoff" xlink:label="us-gaap_FinancingReceivableAccruedInterestWriteoff"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedAtFairValue" xlink:label="us-gaap_InvestmentOwnedAtFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:label="us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_RegulatoryMilestoneAchieved" xlink:label="vir_RegulatoryMilestoneAchieved"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_SpecifiedSalesDevelopmentMilestonesPayment" xlink:label="vir_SpecifiedSalesDevelopmentMilestonesPayment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_SalesMilestonesAchieved" xlink:label="vir_SalesMilestonesAchieved"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_FormerBusinessCombinationContingentConsiderationLiability" xlink:label="vir_FormerBusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_AssetAcquisitionMilestoneAchieved" xlink:label="vir_AssetAcquisitionMilestoneAchieved"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiability" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiability"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="vir_HumabsBiomedSAMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="vir_ContingentConsiderationLiabilityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="vir_BriiBioParentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="vir_LetterAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="vir_TomegaVaxIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_InterestReceivable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FinancingReceivableAccruedInterestWriteoff" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_InvestmentOwnedAtFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_MeasurementInputTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_OwnershipAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="vir_RegulatoryMilestoneAchieved" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="vir_SpecifiedSalesDevelopmentMilestonesPayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="vir_SalesMilestonesAchieved" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="vir_FormerBusinessCombinationContingentConsiderationLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="vir_AssetAcquisitionMilestoneAchieved" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationLiability" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_HumabsBiomedSAMember" xlink:label="vir_HumabsBiomedSAMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ClinicalAndRegulatoryMilestonesMember" xlink:label="vir_ClinicalAndRegulatoryMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TomegaVaxIncMember" xlink:label="vir_TomegaVaxIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_CommercialMilestonesMember" xlink:label="vir_CommercialMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmbeddedDerivativeLiabilityMeasurementInput" xlink:label="us-gaap_EmbeddedDerivativeLiabilityMeasurementInput"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MeasurementInputProbabilityRateMember" xlink:label="vir_MeasurementInputProbabilityRateMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_WeightedAverageMember" xlink:label="srt_WeightedAverageMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MeasurementInputExpectedVolatilityMember" xlink:label="vir_MeasurementInputExpectedVolatilityMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MeasurementInputExpectedRevenueVolatilityMember" xlink:label="vir_MeasurementInputExpectedRevenueVolatilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="vir_HumabsBiomedSAMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="vir_ClinicalAndRegulatoryMilestonesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountRateMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="vir_TomegaVaxIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="vir_CommercialMilestonesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_EmbeddedDerivativeLiabilityMeasurementInput" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="vir_MeasurementInputProbabilityRateMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_WeightedAverageMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="vir_MeasurementInputExpectedVolatilityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="vir_MeasurementInputExpectedRevenueVolatilityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ContingentConsiderationLiabilityMember" xlink:label="vir_ContingentConsiderationLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:label="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_FairValueReclassificationOfDerivativeLiabilityToAccruedLiabilitiesUponAchievementOfDevelopmentMilestone" xlink:label="vir_FairValueReclassificationOfDerivativeLiabilityToAccruedLiabilitiesUponAchievementOfDevelopmentMilestone"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherExpenseMember" xlink:label="us-gaap_OtherExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_FairValueReclassificationOfContingentConsiderationToAccruedLiabilitiesUponAchievementOfMilestone" xlink:label="vir_FairValueReclassificationOfContingentConsiderationToAccruedLiabilitiesUponAchievementOfMilestone"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="vir_ContingentConsiderationLiabilityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="vir_FairValueReclassificationOfDerivativeLiabilityToAccruedLiabilitiesUponAchievementOfDevelopmentMilestone" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_OtherExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="vir_FairValueReclassificationOfContingentConsiderationToAccruedLiabilitiesUponAchievementOfMilestone" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_HumabsBiomedSAMember" xlink:label="vir_HumabsBiomedSAMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="us-gaap_DevelopedTechnologyRightsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_LetterAgreementMember" xlink:label="vir_LetterAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TomegaVaxIncMember" xlink:label="vir_TomegaVaxIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_HepatitisBVirusProductMember" xlink:label="vir_HepatitisBVirusProductMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_AnotherProductMember" xlink:label="vir_AnotherProductMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ClinicalDevelopmentMember" xlink:label="vir_ClinicalDevelopmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_SARSCoV2ProductMember" xlink:label="vir_SARSCoV2ProductMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_AssetAcquisitionMilestonePaymentAggregate" xlink:label="vir_AssetAcquisitionMilestonePaymentAggregate"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MilestonePaymentsRelatedTermsDescription" xlink:label="vir_MilestonePaymentsRelatedTermsDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiability" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents" xlink:label="vir_BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved" xlink:label="vir_BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_SpecifiedClinicalDevelopmentMilestonesPayment" xlink:label="vir_SpecifiedClinicalDevelopmentMilestonesPayment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_RegulatoryMilestonesAchieved" xlink:label="vir_RegulatoryMilestonesAchieved"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_SalesMilestonesAchieved" xlink:label="vir_SalesMilestonesAchieved"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:label="us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_BusinessAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration" xlink:label="vir_BusinessAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_AssetAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration" xlink:label="vir_AssetAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PaymentMadeForBusinessCombinationMilestone" xlink:label="vir_PaymentMadeForBusinessCombinationMilestone"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PaymentMadeForAssetAcquisitionMilestone" xlink:label="vir_PaymentMadeForAssetAcquisitionMilestone"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_CommonStockSharesIssuedForMilestonePaymentShares" xlink:label="vir_CommonStockSharesIssuedForMilestonePaymentShares"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ValueOfCommonStockSharesIssuedForMilestonePayment" xlink:label="vir_ValueOfCommonStockSharesIssuedForMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_RemainingPaymentMadeForBusinessCombinationMilestone" xlink:label="vir_RemainingPaymentMadeForBusinessCombinationMilestone"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_RemainingPaymentMadeForAssetAcquisitionMilestone" xlink:label="vir_RemainingPaymentMadeForAssetAcquisitionMilestone"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_RemainingPaymentForAssetAcquisitionMilestoneAggregate" xlink:label="vir_RemainingPaymentForAssetAcquisitionMilestoneAggregate"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MinimumCommonStockConversionPriceForMilestonePaymentsConsideration" xlink:label="vir_MinimumCommonStockConversionPriceForMilestonePaymentsConsideration"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MinimumCommonStockPriceForMilestonePaymentsConsideration" xlink:label="vir_MinimumCommonStockPriceForMilestonePaymentsConsideration"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="vir_HumabsBiomedSAMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_DevelopedTechnologyRightsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_LetterAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="vir_TomegaVaxIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_HepatitisBVirusProductMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_AnotherProductMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="vir_ClinicalDevelopmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_SARSCoV2ProductMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_AssetAcquisitionMilestonePaymentAggregate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_MilestonePaymentsRelatedTermsDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_SpecifiedClinicalDevelopmentMilestonesPayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_RegulatoryMilestonesAchieved" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_SalesMilestonesAchieved" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_BusinessAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_AssetAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_PaymentMadeForBusinessCombinationMilestone" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_PaymentMadeForAssetAcquisitionMilestone" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_CommonStockSharesIssuedForMilestonePaymentShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_ValueOfCommonStockSharesIssuedForMilestonePayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_RemainingPaymentMadeForBusinessCombinationMilestone" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_RemainingPaymentMadeForAssetAcquisitionMilestone" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="31" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_RemainingPaymentForAssetAcquisitionMilestoneAggregate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="32" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_MinimumCommonStockConversionPriceForMilestonePaymentsConsideration" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="33" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_MinimumCommonStockPriceForMilestonePaymentsConsideration" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ScheduleOfGoodwillAndIntangibleAssetsLineItems" xlink:label="vir_ScheduleOfGoodwillAndIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ScheduleOfGoodwillAndIntangibleAssetsTable" xlink:label="vir_ScheduleOfGoodwillAndIntangibleAssetsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_HumabsBiomedSAMember" xlink:label="vir_HumabsBiomedSAMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:label="us-gaap_IndefinitelivedIntangibleAssetsAcquired"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_FiniteLivedIntangibleAssetsReclassifiedFromIndefiniteLived" xlink:label="vir_FiniteLivedIntangibleAssetsReclassifiedFromIndefiniteLived"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="vir_ScheduleOfGoodwillAndIntangibleAssetsLineItems" xlink:to="vir_ScheduleOfGoodwillAndIntangibleAssetsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="vir_HumabsBiomedSAMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="vir_ScheduleOfGoodwillAndIntangibleAssetsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_ScheduleOfGoodwillAndIntangibleAssetsLineItems" xlink:to="us-gaap_Goodwill" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="vir_ScheduleOfGoodwillAndIntangibleAssetsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_ScheduleOfGoodwillAndIntangibleAssetsLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_ScheduleOfGoodwillAndIntangibleAssetsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_ScheduleOfGoodwillAndIntangibleAssetsLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_ScheduleOfGoodwillAndIntangibleAssetsLineItems" xlink:to="us-gaap_IndefinitelivedIntangibleAssetsAcquired" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_ScheduleOfGoodwillAndIntangibleAssetsLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_ScheduleOfGoodwillAndIntangibleAssetsLineItems" xlink:to="vir_FiniteLivedIntangibleAssetsReclassifiedFromIndefiniteLived" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:label="us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_DevelopedTechnologyMember" xlink:label="vir_DevelopedTechnologyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractBasedIntangibleAssetsMember" xlink:label="us-gaap_ContractBasedIntangibleAssetsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_FiniteLivedIntangibleAssetsAccumulatedImpairment" xlink:label="vir_FiniteLivedIntangibleAssetsAccumulatedImpairment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="vir_DevelopedTechnologyMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_ContractBasedIntangibleAssetsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="vir_FiniteLivedIntangibleAssetsAccumulatedImpairment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_BillAndMelindaGatesFoundationMember" xlink:label="vir_BillAndMelindaGatesFoundationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_GrantAwardedAmount" xlink:label="vir_GrantAwardedAmount"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TwoThousandSeventeenGrantMember" xlink:label="vir_TwoThousandSeventeenGrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_NationalInstitutesOfHealthMember" xlink:label="vir_NationalInstitutesOfHealthMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_GrantAwardedAmountMaximum" xlink:label="vir_GrantAwardedAmountMaximum"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_HumanImmunodeficiencyVirusGrantMember" xlink:label="vir_HumanImmunodeficiencyVirusGrantMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_CommonStockSharesPurchased" xlink:label="vir_CommonStockSharesPurchased"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TuberculosisTBGrantMember" xlink:label="vir_TuberculosisTBGrantMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_CommonStockSharesPurchasedSharePrice" xlink:label="vir_CommonStockSharesPurchasedSharePrice"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_HcmvVaccinePlatformGrantMember" xlink:label="vir_HcmvVaccinePlatformGrantMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_CommonStockSharesPurchasedAggregatePurchasePrice" xlink:label="vir_CommonStockSharesPurchasedAggregatePurchasePrice"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_VaccinalAntibodyGrantMember" xlink:label="vir_VaccinalAntibodyGrantMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_CommonStockSharesIssuedFairMarketValue" xlink:label="vir_CommonStockSharesIssuedFairMarketValue"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:label="vir_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ClosingStockPrice" xlink:label="vir_ClosingStockPrice"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_UnderlyingSharesPremiumReceived" xlink:label="vir_UnderlyingSharesPremiumReceived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_GrantAgreementExpirationDate" xlink:label="vir_GrantAgreementExpirationDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MaximumAmountGrantAggregate" xlink:label="vir_MaximumAmountGrantAggregate"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MaximumAmountGrantBasePeriod" xlink:label="vir_MaximumAmountGrantBasePeriod"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_GrantAgreementExpirationDateBeforeAmendment" xlink:label="vir_GrantAgreementExpirationDateBeforeAmendment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_GrantAgreementAmendedExpirationDate" xlink:label="vir_GrantAgreementAmendedExpirationDate"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_GrantAgreementAmendedDate" xlink:label="vir_GrantAgreementAmendedDate"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_GrantsAgreementAmendedDate" xlink:label="vir_GrantsAgreementAmendedDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncome" xlink:label="us-gaap_DeferredIncome"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MilestonePaymentDueToCompany" xlink:label="vir_MilestonePaymentDueToCompany"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MilestonePaymentReceived" xlink:label="vir_MilestonePaymentReceived"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_UnusedFundsReceivedInAdvance" xlink:label="vir_UnusedFundsReceivedInAdvance"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_FundsReceivedInAdvance" xlink:label="vir_FundsReceivedInAdvance"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_GrantAgreementEffectiveEndDate" xlink:label="vir_GrantAgreementEffectiveEndDate"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_BillAndMelindaGatesFoundationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_GrantAwardedAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_TwoThousandSeventeenGrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_GrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_NationalInstitutesOfHealthMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_GrantAwardedAmountMaximum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_HumanImmunodeficiencyVirusGrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_CommonStockSharesPurchased" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_TuberculosisTBGrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_CommonStockSharesPurchasedSharePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_HcmvVaccinePlatformGrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_CommonStockSharesPurchasedAggregatePurchasePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_VaccinalAntibodyGrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_CommonStockSharesIssuedFairMarketValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_ClosingStockPrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_UnderlyingSharesPremiumReceived" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_GrantAgreementExpirationDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueNotFromContractWithCustomer" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumAmountGrantAggregate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumAmountGrantBasePeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_GrantAgreementExpirationDateBeforeAmendment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_GrantAgreementAmendedExpirationDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_GrantAgreementAmendedDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_GrantsAgreementAmendedDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredIncome" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_OtherAssetsCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MilestonePaymentDueToCompany" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MilestonePaymentReceived" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_UnusedFundsReceivedInAdvance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_FundsReceivedInAdvance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_GrantAgreementEffectiveEndDate" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_GlaxoGroupLimitedMember" xlink:label="vir_GlaxoGroupLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember" xlink:label="vir_TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CN" xlink:label="country_CN"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_AccruedLiabilitiesAndOtherLiabilitiesMember" xlink:label="vir_AccruedLiabilitiesAndOtherLiabilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="us-gaap_AccountingStandardsUpdate201409Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_Vir3434Member" xlink:label="vir_Vir3434Member"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TwoThousandTwentyStockPurchaseAgreementMember" xlink:label="vir_TwoThousandTwentyStockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ContractRevenueMember" xlink:label="vir_ContractRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_GlaxoWellcomeUKLimitedAndBeechamSAMember" xlink:label="vir_GlaxoWellcomeUKLimitedAndBeechamSAMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="country_US"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PreliminaryCollaborationAgreementMember" xlink:label="vir_PreliminaryCollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember" xlink:label="vir_TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember" xlink:label="vir_TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_CollaborationRevenueMember" xlink:label="vir_CollaborationRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_BriiBioParentMember" xlink:label="vir_BriiBioParentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_AmendmentNumberOneMember" xlink:label="vir_AmendmentNumberOneMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_AntibodyProgramMember" xlink:label="vir_AntibodyProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_BriiBiosciencesOffshoreLimitedMember" xlink:label="vir_BriiBiosciencesOffshoreLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans" xlink:label="vir_NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_DefinitiveCollaborationAgreementMember" xlink:label="vir_DefinitiveCollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_VaccineProgramMember" xlink:label="vir_VaccineProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_AlnylamPharmaceuticalsIncMember" xlink:label="vir_AlnylamPharmaceuticalsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PercentageOfShareDevelopmentCosts" xlink:label="vir_PercentageOfShareDevelopmentCosts"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TwoThousandTwentyOneStockPurchaseAgreementMember" xlink:label="vir_TwoThousandTwentyOneStockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_DevelopmentProgramsExercisedByVirMember" xlink:label="vir_DevelopmentProgramsExercisedByVirMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_WuXiBiologicsLimitedMember" xlink:label="vir_WuXiBiologicsLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PercentageOfDevelopmentCosts" xlink:label="vir_PercentageOfDevelopmentCosts"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember" xlink:label="vir_TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_DevelopmentProgramsExercisedByBriiMember" xlink:label="vir_DevelopmentProgramsExercisedByBriiMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_RockefellerUniversityMember" xlink:label="vir_RockefellerUniversityMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct" xlink:label="vir_MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TwoThousandAndTwentyOneGSKCollaborationMember" xlink:label="vir_TwoThousandAndTwentyOneGSKCollaborationMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_BiologicalMaterialsMember" xlink:label="vir_BiologicalMaterialsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MedImmuneLimitedLiabilityCompanyMember" xlink:label="vir_MedImmuneLimitedLiabilityCompanyMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_CollaborationAgreementTerminationDescription" xlink:label="vir_CollaborationAgreementTerminationDescription"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TwoThousandAndTwentyGskAgreementMember" xlink:label="vir_TwoThousandAndTwentyGskAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_Vir2218Member" xlink:label="vir_Vir2218Member"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_XencorIncorporationMember" xlink:label="vir_XencorIncorporationMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_FairMarketValueOfCommonStockIssued" xlink:label="vir_FairMarketValueOfCommonStockIssued"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TwoThousandAndTwentyOneGSKAgreementMember" xlink:label="vir_TwoThousandAndTwentyOneGSKAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_Vir2248Member" xlink:label="vir_Vir2248Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_BriiAgreementMember" xlink:label="vir_BriiAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_FirstSiRNAProductMember" xlink:label="vir_FirstSiRNAProductMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PremiumReceivedOnSalePriceOfCommonStock" xlink:label="vir_PremiumReceivedOnSalePriceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_AlnylamAgreementMember" xlink:label="vir_AlnylamAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_FirstSiRNAProductHBVMember" xlink:label="vir_FirstSiRNAProductHBVMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_AntibodyLicenseTransactionPrice" xlink:label="vir_AntibodyLicenseTransactionPrice"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_DevelopmentAndManufacturingCollaborationAgreementMember" xlink:label="vir_DevelopmentAndManufacturingCollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_EachInfectiousDiseaseSiRNAMember" xlink:label="vir_EachInfectiousDiseaseSiRNAMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_RockefellerAgreementMember" xlink:label="vir_RockefellerAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_FirstInfectiousDiseaseProductMember" xlink:label="vir_FirstInfectiousDiseaseProductMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_SpecifiedResearchAndDevelopmentExpensesMilestonePayments" xlink:label="vir_SpecifiedResearchAndDevelopmentExpensesMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MedImmuneAgreementMember" xlink:label="vir_MedImmuneAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_InfectiousDiseaseProductMember" xlink:label="vir_InfectiousDiseaseProductMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_WrittenNoticePeriodToTerminateAgreementByCompany" xlink:label="vir_WrittenNoticePeriodToTerminateAgreementByCompany"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TwoThousandNineteenXencorAgreementMember" xlink:label="vir_TwoThousandNineteenXencorAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_HBVProgramMember" xlink:label="vir_HBVProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_RangeOfRoyaltyPaymentToBeReceived" xlink:label="vir_RangeOfRoyaltyPaymentToBeReceived"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TwoThousandTwentyXencorAgreementMember" xlink:label="vir_TwoThousandTwentyXencorAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_InfluenzaAAndInfluenzaBMember" xlink:label="vir_InfluenzaAAndInfluenzaBMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MaximumNumberOfProductsCoveredAgainstMilestonePayment" xlink:label="vir_MaximumNumberOfProductsCoveredAgainstMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_XencorAgreementsMember" xlink:label="vir_XencorAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_InfluenzaAResearchProgramsMember" xlink:label="vir_InfluenzaAResearchProgramsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="us-gaap_RevenueFromRelatedParties"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TwoThousandNineteenAndTwoThousandTwentyXencorAgreementMember" xlink:label="vir_TwoThousandNineteenAndTwoThousandTwentyXencorAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_InfluenzaAAndHBVResearchProgramsMember" xlink:label="vir_InfluenzaAAndHBVResearchProgramsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_WrittenNoticePeriodToTerminateLicensedProgramForUncuredMaterialBreach" xlink:label="vir_WrittenNoticePeriodToTerminateLicensedProgramForUncuredMaterialBreach"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_RegulatoryMilestonePaymentToBeReceived" xlink:label="vir_RegulatoryMilestonePaymentToBeReceived"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_AnnualLicenseMaintenanceFees" xlink:label="vir_AnnualLicenseMaintenanceFees"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_WrittenNoticeToTerminateLicensedProgramIfExercise" xlink:label="vir_WrittenNoticeToTerminateLicensedProgramIfExercise"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_WrittenNoticePeriodToTerminateAgreementByCounterparty" xlink:label="vir_WrittenNoticePeriodToTerminateAgreementByCounterparty"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenge" xlink:label="vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenge"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MaximumSalesMilestonePaymentsToBeReceived" xlink:label="vir_MaximumSalesMilestonePaymentsToBeReceived"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PaymentToCollaboratorResultingFromProgramOptionExercise" xlink:label="vir_PaymentToCollaboratorResultingFromProgramOptionExercise"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_RoyaltiesPaymentExpirationPeriod" xlink:label="vir_RoyaltiesPaymentExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_CollaborationAgreementNumberOfUnitsOfAccount" xlink:label="vir_CollaborationAgreementNumberOfUnitsOfAccount"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_IncreaseDecreaseInResearchAndDevelopmentExpense" xlink:label="vir_IncreaseDecreaseInResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate" xlink:label="vir_CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ProfitsAndLossesSharingPercentage" xlink:label="vir_ProfitsAndLossesSharingPercentage"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_OptionExerciseFeeLowEndOfTheRange" xlink:label="vir_OptionExerciseFeeLowEndOfTheRange"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_RegulatoryMilestonePaymentOnLicensedProductLowEndOfTheRange" xlink:label="vir_RegulatoryMilestonePaymentOnLicensedProductLowEndOfTheRange"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_RegulatoryMilestonePaymentOnLicensedProductHighEndOfRange" xlink:label="vir_RegulatoryMilestonePaymentOnLicensedProductHighEndOfRange"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_AdjustmentsToProfitSharingAmounts" xlink:label="vir_AdjustmentsToProfitSharingAmounts"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ProfitSharingAmountConstrained" xlink:label="vir_ProfitSharingAmountConstrained"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_RangeOfRoyaltyPaymentToBePaid" xlink:label="vir_RangeOfRoyaltyPaymentToBePaid"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_OptionsTransactionPrice" xlink:label="vir_OptionsTransactionPrice"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_OptionExerciseFeeHighEndOfTheRange" xlink:label="vir_OptionExerciseFeeHighEndOfTheRange"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MaximumAggregateSalesMilestonePayments" xlink:label="vir_MaximumAggregateSalesMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MaximumNumberOfDevelopmentProgramGrantedToCounterparty" xlink:label="vir_MaximumNumberOfDevelopmentProgramGrantedToCounterparty"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_WrittenNoticeToTerminateLicensedProgramIfNotExercise" xlink:label="vir_WrittenNoticeToTerminateLicensedProgramIfNotExercise"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MaximumNumberOfDevelopmentProgramGrantedFromCounterparty" xlink:label="vir_MaximumNumberOfDevelopmentProgramGrantedFromCounterparty"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_UpfrontPaymentReceivable" xlink:label="vir_UpfrontPaymentReceivable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_UpfrontPaymentReceived" xlink:label="vir_UpfrontPaymentReceived"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PercentageOfUpfrontPaymentReceivableAtEffectiveDateOfAgreement" xlink:label="vir_PercentageOfUpfrontPaymentReceivableAtEffectiveDateOfAgreement"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PercentageOfUpfrontPaymentReceivableAtExecutionDateOfAgreement" xlink:label="vir_PercentageOfUpfrontPaymentReceivableAtExecutionDateOfAgreement"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_OptionExerciseFeeConsiderationToBeReceived" xlink:label="vir_OptionExerciseFeeConsiderationToBeReceived"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PreDefinedRegulatoryMilestoneConsiderationToBeReceived" xlink:label="vir_PreDefinedRegulatoryMilestoneConsiderationToBeReceived"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_CollaborationAgreementTransactionPriceUpfrontFee" xlink:label="vir_CollaborationAgreementTransactionPriceUpfrontFee"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_CollaborationAgreementTransactionPriceConsideration" xlink:label="vir_CollaborationAgreementTransactionPriceConsideration"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_RoyaltiesPaymentRangeOnNetSalesOfLicensedProduct" xlink:label="vir_RoyaltiesPaymentRangeOnNetSalesOfLicensedProduct"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PercentageOfOrdinaryShareEqualToOutstandingShare" xlink:label="vir_PercentageOfOrdinaryShareEqualToOutstandingShare"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_RangeOfTieredRoyaltiesToPayToNetSalesOfProducts" xlink:label="vir_RangeOfTieredRoyaltiesToPayToNetSalesOfProducts"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales" xlink:label="vir_RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach" xlink:label="vir_WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ValueOfSharesTransferredToCollaborator" xlink:label="vir_ValueOfSharesTransferredToCollaborator"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncome" xlink:label="us-gaap_DeferredIncome"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ReclassifiedDeferredRevenue" xlink:label="vir_ReclassifiedDeferredRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Investments" xlink:label="us-gaap_Investments"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_CollaborationTypeAndPrograms" xlink:label="vir_CollaborationTypeAndPrograms"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_OptionExerciseFeeReceived" xlink:label="vir_OptionExerciseFeeReceived"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_DeterminedTransactionPrice" xlink:label="vir_DeterminedTransactionPrice"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_UpfrontFeePaid" xlink:label="vir_UpfrontFeePaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MaximumSharesToBeIssued" xlink:label="vir_MaximumSharesToBeIssued"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory" xlink:label="vir_MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MaximumMilestonePaymentForAchievementOfSpecifiedMilestones" xlink:label="vir_MaximumMilestonePaymentForAchievementOfSpecifiedMilestones"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MaximumAggregateSalesMilestonePayment" xlink:label="vir_MaximumAggregateSalesMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MaximumSalesMilestonePayment" xlink:label="vir_MaximumSalesMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MaximumAggregateMilestonePayments" xlink:label="vir_MaximumAggregateMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_RoyaltiesBasedOnNetSalesOfLicensedProducts" xlink:label="vir_RoyaltiesBasedOnNetSalesOfLicensedProducts"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_RangeOfRoyaltyPaymentsToBeReceived" xlink:label="vir_RangeOfRoyaltyPaymentsToBeReceived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MaximumSalesMilestoneToBeReceived" xlink:label="vir_MaximumSalesMilestoneToBeReceived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MilestonePaymentsPaid" xlink:label="vir_MilestonePaymentsPaid"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_CollaborationAgreementRelatedCostsAndExpenses" xlink:label="vir_CollaborationAgreementRelatedCostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_NumberOfAntibodiesToDevelop" xlink:label="vir_NumberOfAntibodiesToDevelop"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MaximumAggregateMilestonePaymentForAchievementOfSpecifiedMilestones" xlink:label="vir_MaximumAggregateMilestonePaymentForAchievementOfSpecifiedMilestones"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_RoyaltyObligationPeriodFromDateOfFirstCommercialSale" xlink:label="vir_RoyaltyObligationPeriodFromDateOfFirstCommercialSale"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ResearchAndDevelopmentExpenseUnderLicenseAgreement" xlink:label="vir_ResearchAndDevelopmentExpenseUnderLicenseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_LicenseAgreementUpfrontPayment" xlink:label="vir_LicenseAgreementUpfrontPayment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MaximumAggregateDevelopmentAndRegulatoryMilestonePayments" xlink:label="vir_MaximumAggregateDevelopmentAndRegulatoryMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MaximumAggregateCommercialSalesMilestonePayments" xlink:label="vir_MaximumAggregateCommercialSalesMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_WrittenNoticePeriodForTerminationOfLicensedProgram" xlink:label="vir_WrittenNoticePeriodForTerminationOfLicensedProgram"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenges" xlink:label="vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenges"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_WrittenNoticePeriodToTerminateLicensedProgramForFailureToMakePayment" xlink:label="vir_WrittenNoticePeriodToTerminateLicensedProgramForFailureToMakePayment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_WrittenNoticePeriodToTerminateLicensedProgramForPaymentBreach" xlink:label="vir_WrittenNoticePeriodToTerminateLicensedProgramForPaymentBreach"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="vir_GlaxoGroupLimitedMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CN" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="vir_AccruedLiabilitiesAndOtherLiabilitiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201409Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="vir_Vir3434Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_TwoThousandTwentyStockPurchaseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_ContractRevenueMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_GlaxoWellcomeUKLimitedAndBeechamSAMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_PreliminaryCollaborationAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SharePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_CollaborationRevenueMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_BriiBioParentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_AmendmentNumberOneMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_AntibodyProgramMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_BriiBiosciencesOffshoreLimitedMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_DefinitiveCollaborationAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_VaccineProgramMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_AlnylamPharmaceuticalsIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_PercentageOfShareDevelopmentCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_TwoThousandTwentyOneStockPurchaseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_DevelopmentProgramsExercisedByVirMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_WuXiBiologicsLimitedMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_PercentageOfDevelopmentCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_DevelopmentProgramsExercisedByBriiMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_RockefellerUniversityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_TwoThousandAndTwentyOneGSKCollaborationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_BiologicalMaterialsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_MedImmuneLimitedLiabilityCompanyMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_CollaborationAgreementTerminationDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_TwoThousandAndTwentyGskAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_Vir2218Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_XencorIncorporationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_FairMarketValueOfCommonStockIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_TwoThousandAndTwentyOneGSKAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_Vir2248Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_BriiAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_FirstSiRNAProductMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_PremiumReceivedOnSalePriceOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_AlnylamAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_FirstSiRNAProductHBVMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_AntibodyLicenseTransactionPrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_DevelopmentAndManufacturingCollaborationAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_EachInfectiousDiseaseSiRNAMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_RockefellerAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_FirstInfectiousDiseaseProductMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_SpecifiedResearchAndDevelopmentExpensesMilestonePayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_MedImmuneAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_InfectiousDiseaseProductMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_WrittenNoticePeriodToTerminateAgreementByCompany" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_TwoThousandNineteenXencorAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_HBVProgramMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_RangeOfRoyaltyPaymentToBeReceived" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_TwoThousandTwentyXencorAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_InfluenzaAAndInfluenzaBMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumNumberOfProductsCoveredAgainstMilestonePayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_XencorAgreementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_InfluenzaAResearchProgramsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromRelatedParties" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_TwoThousandNineteenAndTwoThousandTwentyXencorAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_InfluenzaAAndHBVResearchProgramsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_WrittenNoticePeriodToTerminateLicensedProgramForUncuredMaterialBreach" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_RegulatoryMilestonePaymentToBeReceived" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_AnnualLicenseMaintenanceFees" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_WrittenNoticeToTerminateLicensedProgramIfExercise" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_WrittenNoticePeriodToTerminateAgreementByCounterparty" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenge" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumSalesMilestonePaymentsToBeReceived" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_PaymentToCollaboratorResultingFromProgramOptionExercise" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_RoyaltiesPaymentExpirationPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_CollaborationAgreementNumberOfUnitsOfAccount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_IncreaseDecreaseInResearchAndDevelopmentExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="31" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_ProfitsAndLossesSharingPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="32" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_OptionExerciseFeeLowEndOfTheRange" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="33" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_RegulatoryMilestonePaymentOnLicensedProductLowEndOfTheRange" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="34" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_RegulatoryMilestonePaymentOnLicensedProductHighEndOfRange" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="35" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_AdjustmentsToProfitSharingAmounts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="36" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_ProfitSharingAmountConstrained" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="37" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_RangeOfRoyaltyPaymentToBePaid" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="38" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_OptionsTransactionPrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="39" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_OptionExerciseFeeHighEndOfTheRange" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="40" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumAggregateSalesMilestonePayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="41" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumNumberOfDevelopmentProgramGrantedToCounterparty" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="42" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_WrittenNoticeToTerminateLicensedProgramIfNotExercise" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="43" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumNumberOfDevelopmentProgramGrantedFromCounterparty" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="44" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_UpfrontPaymentReceivable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="45" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_UpfrontPaymentReceived" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="46" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_PercentageOfUpfrontPaymentReceivableAtEffectiveDateOfAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="47" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_PercentageOfUpfrontPaymentReceivableAtExecutionDateOfAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="48" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_OptionExerciseFeeConsiderationToBeReceived" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="49" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_PreDefinedRegulatoryMilestoneConsiderationToBeReceived" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="50" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_CollaborationAgreementTransactionPriceUpfrontFee" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="51" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_CollaborationAgreementTransactionPriceConsideration" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="52" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_RoyaltiesPaymentRangeOnNetSalesOfLicensedProduct" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="53" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_PercentageOfOrdinaryShareEqualToOutstandingShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="54" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_RangeOfTieredRoyaltiesToPayToNetSalesOfProducts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="55" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="56" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="57" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_ValueOfSharesTransferredToCollaborator" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="58" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredIncome" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="59" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="60" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="61" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_ReclassifiedDeferredRevenue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="62" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_Investments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="63" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_CollaborationTypeAndPrograms" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="64" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_OptionExerciseFeeReceived" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="65" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_DeterminedTransactionPrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="66" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_UpfrontFeePaid" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="67" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="68" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumSharesToBeIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="69" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="70" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumMilestonePaymentForAchievementOfSpecifiedMilestones" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="71" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumAggregateSalesMilestonePayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="72" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumSalesMilestonePayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="73" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumAggregateMilestonePayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="74" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_RoyaltiesBasedOnNetSalesOfLicensedProducts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="75" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_RangeOfRoyaltyPaymentsToBeReceived" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="76" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="77" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumSalesMilestoneToBeReceived" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="78" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenueNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="79" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MilestonePaymentsPaid" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="80" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_CollaborationAgreementRelatedCostsAndExpenses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="81" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_NumberOfAntibodiesToDevelop" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="82" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumAggregateMilestonePaymentForAchievementOfSpecifiedMilestones" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="83" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_RoyaltyObligationPeriodFromDateOfFirstCommercialSale" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="84" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_ResearchAndDevelopmentExpenseUnderLicenseAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="85" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_LicenseAgreementUpfrontPayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="86" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumAggregateDevelopmentAndRegulatoryMilestonePayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="87" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumAggregateCommercialSalesMilestonePayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="88" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CostOfRevenue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="89" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccountsReceivableNetCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="90" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_WrittenNoticePeriodForTerminationOfLicensedProgram" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="91" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenges" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="92" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_WrittenNoticePeriodToTerminateLicensedProgramForFailureToMakePayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="93" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_WrittenNoticePeriodToTerminateLicensedProgramForPaymentBreach" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_LaboratoryEquipmentMember" xlink:label="vir_LaboratoryEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="vir_LaboratoryEquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_SamsungBiologicsCompanyLimitedMember" xlink:label="vir_SamsungBiologicsCompanyLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseAgreementsMember" xlink:label="us-gaap_LeaseAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember" xlink:label="vir_WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_LeaseArrangementContractualExpirationBeginningYear" xlink:label="vir_LeaseArrangementContractualExpirationBeginningYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_AntibodyProgramMember" xlink:label="vir_AntibodyProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_WuXiBiologicsLimitedMember" xlink:label="vir_WuXiBiologicsLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_LeaseArrangementContractualExpirationEndingYear" xlink:label="vir_LeaseArrangementContractualExpirationEndingYear"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_GlaxoSmithKlineTradingServiceLimitedMember" xlink:label="vir_GlaxoSmithKlineTradingServiceLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember" xlink:label="vir_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="us-gaap_GainLossOnTerminationOfLease"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember" xlink:label="vir_TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ClinicalDevelopmentAndManufacturingOrganizationMember" xlink:label="vir_ClinicalDevelopmentAndManufacturingOrganizationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetRentableArea" xlink:label="us-gaap_NetRentableArea"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TenantImprovementAllowanceAggregate" xlink:label="vir_TenantImprovementAllowanceAggregate"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PercentageOfDevelopmentCostsResponsibleByCompany" xlink:label="vir_PercentageOfDevelopmentCostsResponsibleByCompany"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PercentageOfDevelopmentCostsResponsibleByGsk" xlink:label="vir_PercentageOfDevelopmentCostsResponsibleByGsk"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PaymentCommitmentManufacturingCapacity" xlink:label="vir_PaymentCommitmentManufacturingCapacity"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PaymentCommitmentRawMaterials" xlink:label="vir_PaymentCommitmentRawMaterials"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PrepaymentRawMaterials" xlink:label="vir_PrepaymentRawMaterials"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_OperatingAndFinanceRentExpense" xlink:label="vir_OperatingAndFinanceRentExpense"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ObligationToPayCapacityReservation" xlink:label="vir_ObligationToPayCapacityReservation"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PercentageOfEstimatedBatchProductionFees" xlink:label="vir_PercentageOfEstimatedBatchProductionFees"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PercentageOfDevelopmentCosts" xlink:label="vir_PercentageOfDevelopmentCosts"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_SamsungBiologicsCompanyLimitedMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LeaseAgreementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="vir_LeaseArrangementContractualExpirationBeginningYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_AntibodyProgramMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_WuXiBiologicsLimitedMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="vir_LeaseArrangementContractualExpirationEndingYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_GlaxoSmithKlineTradingServiceLimitedMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_GainLossOnTerminationOfLease" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_ClinicalDevelopmentAndManufacturingOrganizationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_NetRentableArea" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_TenantImprovements" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="vir_TenantImprovementAllowanceAggregate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="vir_PercentageOfDevelopmentCostsResponsibleByCompany" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="vir_PercentageOfDevelopmentCostsResponsibleByGsk" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="vir_PaymentCommitmentManufacturingCapacity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="vir_PaymentCommitmentRawMaterials" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="vir_PrepaymentRawMaterials" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OperatingLeasePayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="vir_OperatingAndFinanceRentExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="vir_ObligationToPayCapacityReservation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="vir_PercentageOfEstimatedBatchProductionFees" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="vir_PercentageOfDevelopmentCosts" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20221231/taxonomy/role/DisclosureManufacturingAndSupplyLetterAgreementsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingenciesLineItems" xlink:label="us-gaap_GainContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingenciesTable" xlink:label="us-gaap_GainContingenciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PercentageOfDevelopmentCostsResponsibleByGsk" xlink:label="vir_PercentageOfDevelopmentCostsResponsibleByGsk"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_GlaxoSmithKlineTradingServiceLimitedMember" xlink:label="vir_GlaxoSmithKlineTradingServiceLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_WuxiBiologicsLetterAgreementAssignmentAndMasterServiceAgreementsMember" xlink:label="vir_WuxiBiologicsLetterAgreementAssignmentAndMasterServiceAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_AntibodyProgramMember" xlink:label="vir_AntibodyProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PaymentCommitmentManufacturingCapacity" xlink:label="vir_PaymentCommitmentManufacturingCapacity"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember" xlink:label="vir_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PaymentCommitmentRawMaterials" xlink:label="vir_PaymentCommitmentRawMaterials"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ClinicalDevelopmentAndManufacturingOrganizationMember" xlink:label="vir_ClinicalDevelopmentAndManufacturingOrganizationMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PrepaymentRawMaterials" xlink:label="vir_PrepaymentRawMaterials"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_GainContingenciesLineItems" xlink:to="us-gaap_GainContingenciesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GainContingenciesLineItems" xlink:to="vir_PercentageOfDevelopmentCostsResponsibleByGsk" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_GlaxoSmithKlineTradingServiceLimitedMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_GainContingenciesTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="vir_WuxiBiologicsLetterAgreementAssignmentAndMasterServiceAgreementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_AntibodyProgramMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GainContingenciesLineItems" xlink:to="vir_PaymentCommitmentManufacturingCapacity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_GainContingenciesTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GainContingenciesLineItems" xlink:to="vir_PaymentCommitmentRawMaterials" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_ClinicalDevelopmentAndManufacturingOrganizationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_GainContingenciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GainContingenciesLineItems" xlink:to="vir_PrepaymentRawMaterials" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_SeriesBConvertiblePreferredStockMember" xlink:label="vir_SeriesBConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="vir_SeriesBConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_FirstAndSecondClosingsMember" xlink:label="vir_FirstAndSecondClosingsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_SeriesAOneConvertiblePreferredStockMember" xlink:label="vir_SeriesAOneConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="vir_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ThirdClosingMember" xlink:label="vir_ThirdClosingMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_SeriesBConvertiblePreferredStockMember" xlink:label="vir_SeriesBConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TemporaryEquityAdditionalSharesAuthorized" xlink:label="vir_TemporaryEquityAdditionalSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_NumberOfClassOfStock" xlink:label="vir_NumberOfClassOfStock"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="vir_FirstAndSecondClosingsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="vir_SeriesAOneConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="vir_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="vir_ThirdClosingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="vir_SeriesBConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="vir_TemporaryEquityAdditionalSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="vir_NumberOfClassOfStock" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantLiabilityAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_SeriesAOneConvertiblePreferredStockMember" xlink:label="vir_SeriesAOneConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_StockIssuedDuringPeriodWarrantExercised" xlink:label="vir_StockIssuedDuringPeriodWarrantExercised"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="vir_SeriesAOneConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="vir_StockIssuedDuringPeriodWarrantExercised" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TwoThousandSixteenEquityIncentivePlanMember" xlink:label="vir_TwoThousandSixteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_RestrictedStockPurchaseAgreementMember" xlink:label="vir_RestrictedStockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ExecutiveOfficerAndDirectorMember" xlink:label="vir_ExecutiveOfficerAndDirectorMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TwoThousandNineteenEquityIncentivePlanMember" xlink:label="vir_TwoThousandNineteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TwoThousandNineteenEmployeeStockPurchasePlanMember" xlink:label="vir_TwoThousandNineteenEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_OfferingPeriodEmployeeStockPurchasePlan" xlink:label="vir_OfferingPeriodEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MaximumTermOfOfferingPeriodSpecifiedUnderPlan" xlink:label="vir_MaximumTermOfOfferingPeriodSpecifiedUnderPlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_RepaymentOfOutstandingPromissoryNotesAndAccruedInterestReceived" xlink:label="vir_RepaymentOfOutstandingPromissoryNotesAndAccruedInterestReceived"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_RestrictedStockLiabilityRecognizedForPortionOfPromissoryNoteRepayment" xlink:label="vir_RestrictedStockLiabilityRecognizedForPortionOfPromissoryNoteRepayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="vir_TwoThousandSixteenEquityIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_RestrictedStockPurchaseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="vir_ExecutiveOfficerAndDirectorMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="vir_TwoThousandNineteenEquityIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="vir_TwoThousandNineteenEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="vir_OfferingPeriodEmployeeStockPurchasePlan" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="vir_MaximumTermOfOfferingPeriodSpecifiedUnderPlan" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="vir_RepaymentOfOutstandingPromissoryNotesAndAccruedInterestReceived" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="vir_RestrictedStockLiabilityRecognizedForPortionOfPromissoryNoteRepayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20221231/taxonomy/role/DisclosureStockbasedAwardsSummaryOfEmployeesStockPurchasePlanDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TwoThousandNineteenEmployeeStockPurchasePlanMember" xlink:label="vir_TwoThousandNineteenEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="vir_TwoThousandNineteenEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_RestrictedStockAwardsRSAMember" xlink:label="vir_RestrictedStockAwardsRSAMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="vir_RestrictedStockAwardsRSAMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20221231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_EstimatedSharesIssuableUnderTheESPPMember" xlink:label="vir_EstimatedSharesIssuableUnderTheESPPMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_WarrantsToPurchaseCommonStockMember" xlink:label="vir_WarrantsToPurchaseCommonStockMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="vir_EstimatedSharesIssuableUnderTheESPPMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="vir_WarrantsToPurchaseCommonStockMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20221231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_HumabsBiomedSAMember" xlink:label="vir_HumabsBiomedSAMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="us-gaap_RetirementPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_FirstPlanMember" xlink:label="vir_FirstPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanNameAxis" xlink:label="us-gaap_RetirementPlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="us-gaap_RetirementPlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_SecondPlanMember" xlink:label="vir_SecondPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities" xlink:label="us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="vir_HumabsBiomedSAMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RetirementPlanTypeDomain" xlink:to="us-gaap_PensionPlansDefinedBenefitMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_RetirementPlanTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RetirementPlanNameDomain" xlink:to="vir_FirstPlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_RetirementPlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RetirementPlanNameDomain" xlink:to="vir_SecondPlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails">
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ReconciliationOfEffectiveIncomeTaxRateLineItems" xlink:label="vir_ReconciliationOfEffectiveIncomeTaxRateLineItems"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ReconciliationOfEffectiveIncomeTaxRateTable" xlink:label="vir_ReconciliationOfEffectiveIncomeTaxRateTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_HumabsBiomedSAMember" xlink:label="vir_HumabsBiomedSAMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_EffectiveIncomeTaxRateReconciliationPermanentItemsPercent" xlink:label="vir_EffectiveIncomeTaxRateReconciliationPermanentItemsPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="vir_ReconciliationOfEffectiveIncomeTaxRateLineItems" xlink:to="vir_ReconciliationOfEffectiveIncomeTaxRateTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="vir_HumabsBiomedSAMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_ReconciliationOfEffectiveIncomeTaxRateLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="vir_ReconciliationOfEffectiveIncomeTaxRateTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_ReconciliationOfEffectiveIncomeTaxRateLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_ReconciliationOfEffectiveIncomeTaxRateLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_ReconciliationOfEffectiveIncomeTaxRateLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_ReconciliationOfEffectiveIncomeTaxRateLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_ReconciliationOfEffectiveIncomeTaxRateLineItems" xlink:to="vir_EffectiveIncomeTaxRateReconciliationPermanentItemsPercent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_ReconciliationOfEffectiveIncomeTaxRateLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_ReconciliationOfEffectiveIncomeTaxRateLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_ReconciliationOfEffectiveIncomeTaxRateLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_IncomeTaxesLineItems" xlink:label="vir_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_IncomeTaxesTable" xlink:label="vir_IncomeTaxesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_OR" xlink:label="stpr_OR"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SwissFederalTaxAdministrationFTAMember" xlink:label="us-gaap_SwissFederalTaxAdministrationFTAMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ReleaseOfValuationAllowanceDeferredTaxInAmount" xlink:label="vir_ReleaseOfValuationAllowanceDeferredTaxInAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AustralianTaxationOfficeMember" xlink:label="us-gaap_AustralianTaxationOfficeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_OperatingLossCarryforwardsExpirationBeginningYear" xlink:label="vir_OperatingLossCarryforwardsExpirationBeginningYear"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_OperatingLossCarryforwardsLimitationOnUsePercentage" xlink:label="vir_OperatingLossCarryforwardsLimitationOnUsePercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TaxCreditCarryforwardsExpirationBeginningYear" xlink:label="vir_TaxCreditCarryforwardsExpirationBeginningYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_UnrecognizedTaxBenefitsIfRecognizedWouldReduceEffectiveTaxRate" xlink:label="vir_UnrecognizedTaxBenefitsIfRecognizedWouldReduceEffectiveTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="vir_IncomeTaxesLineItems" xlink:to="vir_IncomeTaxesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_OR" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_IncomeTaxesLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_SwissFederalTaxAdministrationFTAMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="vir_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_IncomeTaxesLineItems" xlink:to="vir_ReleaseOfValuationAllowanceDeferredTaxInAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_AustralianTaxationOfficeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="vir_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_IncomeTaxesLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="vir_IncomeTaxesTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_IncomeTaxesLineItems" xlink:to="vir_OperatingLossCarryforwardsExpirationBeginningYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="vir_IncomeTaxesTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_IncomeTaxesLineItems" xlink:to="vir_OperatingLossCarryforwardsLimitationOnUsePercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_IncomeTaxesLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_IncomeTaxesLineItems" xlink:to="vir_TaxCreditCarryforwardsExpirationBeginningYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_IncomeTaxesLineItems" xlink:to="vir_UnrecognizedTaxBenefitsIfRecognizedWouldReduceEffectiveTaxRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20221231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_BusinessAgreementGrantAmount" xlink:label="vir_BusinessAgreementGrantAmount"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PreliminaryCollaborationAgreementMember" xlink:label="vir_PreliminaryCollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_CashGrantAwarded" xlink:label="vir_CashGrantAwarded"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_DefinitiveCollaborationAgreementMember" xlink:label="vir_DefinitiveCollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ValueStockIssuedGrantAgreement" xlink:label="vir_ValueStockIssuedGrantAgreement"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TwoThousandTwentyOneStockPurchaseAgreementMember" xlink:label="vir_TwoThousandTwentyOneStockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_StockIssuedGrantAgreement" xlink:label="vir_StockIssuedGrantAgreement"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_LetterAgreementMember" xlink:label="vir_LetterAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_BusinessAgreementEquityInvestmentCommitment" xlink:label="vir_BusinessAgreementEquityInvestmentCommitment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_BillMelindaGatesFoundationMember" xlink:label="vir_BillMelindaGatesFoundationMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="vir_BusinessAgreementGrantAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_PreliminaryCollaborationAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="vir_CashGrantAwarded" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_DefinitiveCollaborationAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="vir_ValueStockIssuedGrantAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_TwoThousandTwentyOneStockPurchaseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="vir_StockIssuedGrantAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_LetterAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="vir_BusinessAgreementEquityInvestmentCommitment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_BillMelindaGatesFoundationMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" priority="2" use="optional"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>38
<FILENAME>vir-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-02-28T15:30:33.7599+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.vir.bio/20221231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:vir="http://www.vir.bio/20221231" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" namespace="http://xbrl.sec.gov/stpr/2022"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" namespace="http://fasb.org/us-gaap/2022"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" namespace="http://xbrl.sec.gov/country/2022"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" namespace="http://www.xbrl.org/dtr/type/2020-01-21"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" namespace="http://fasb.org/srt/2022"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vir-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Labels link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vir-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vir-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vir-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation link" xlink:type="simple"/>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" id="Role_StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails2" id="DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails2">
        <link:definition>100020 - Disclosure - Commitments and Contingencies - Schedule of Maturities of Operating Lease Liabilities (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" id="Role_StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100030 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows2" id="StatementConsolidatedStatementsOfCashFlows2">
        <link:definition>100040 - Statement - Consolidated Statements of Cash Flows 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3" id="StatementConsolidatedStatementsOfCashFlows3">
        <link:definition>100050 - Statement - Consolidated Statements of Cash Flows 3</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations" id="Role_StatementConsolidatedStatementsOfOperations">
        <link:definition>100060 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss" id="StatementConsolidatedStatementsOfComprehensiveIncomeLoss">
        <link:definition>100070 - Statement - Consolidated Statements of Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" id="Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit">
        <link:definition>100080 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" id="Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical">
        <link:definition>100090 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" id="Role_StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100100 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureOrganization" id="Role_DisclosureOrganization">
        <link:definition>100110 - Disclosure - Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>100120 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>100130 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitions" id="Role_DisclosureAcquisitions">
        <link:definition>100140 - Disclosure - Acquisitions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssets" id="Role_DisclosureGoodwillAndIntangibleAssets">
        <link:definition>100150 - Disclosure - Goodwill and Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGrantAgreements" id="Role_DisclosureGrantAgreements">
        <link:definition>100160 - Disclosure - Grant Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreements" id="Role_DisclosureCollaborationAndLicenseAgreements">
        <link:definition>100170 - Disclosure - Collaboration and License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponents" id="Role_DisclosureBalanceSheetComponents">
        <link:definition>100180 - Disclosure - Balance Sheet Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100190 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" id="Role_DisclosureRelatedPartyTransactions">
        <link:definition>100200 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStock" id="Role_DisclosureConvertiblePreferredStock">
        <link:definition>100210 - Disclosure - Convertible Preferred Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantLiability" id="Role_DisclosureConvertiblePreferredStockWarrantLiability">
        <link:definition>100220 - Disclosure - Convertible Preferred Stock Warrant Liability</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwards" id="Role_DisclosureStockBasedAwards">
        <link:definition>100230 - Disclosure - Stock-Based Awards</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/DisclosureNetIncomeLossPerShare1" id="DisclosureNetIncomeLossPerShare1">
        <link:definition>100240 - Disclosure - Net Income (Loss) Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/DisclosureDefinedContributionPlan" id="DisclosureDefinedContributionPlan">
        <link:definition>100250 - Disclosure - Defined Contribution Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100260 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/DisclosureSubsequentEvent1" id="DisclosureSubsequentEvent1">
        <link:definition>100270 - Disclosure - Subsequent Event</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100280 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" id="Role_DisclosureFairValueMeasurementsTables">
        <link:definition>100290 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsTables" id="Role_DisclosureGoodwillAndIntangibleAssetsTables">
        <link:definition>100300 - Disclosure - Goodwill and Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTables" id="DisclosureCollaborationAndLicenseAgreementsTables">
        <link:definition>100310 - Disclosure - Collaboration and License Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables" id="Role_DisclosureBalanceSheetComponentsTables">
        <link:definition>100320 - Disclosure - Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" id="Role_DisclosureCommitmentsAndContingenciesTables">
        <link:definition>100330 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsTables" id="Role_DisclosureStockBasedAwardsTables">
        <link:definition>100340 - Disclosure - Stock-Based Awards (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/DisclosureNetIncomeLossPerShareTables" id="DisclosureNetIncomeLossPerShareTables">
        <link:definition>100350 - Disclosure - Net Income (Loss) Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100360 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureSelectedQuarterlyFinancialDataUnauditedTables" id="Role_DisclosureSelectedQuarterlyFinancialDataUnauditedTables">
        <link:definition>100370 - Disclosure - Selected Quarterly Financial Data (Unaudited) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails" id="Role_DisclosureOrganizationAdditionalInformationDetails">
        <link:definition>100380 - Disclosure - Organization - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100390 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails" id="Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails">
        <link:definition>100400 - Disclosure - Fair Value Measurements - Financial Assets Measured at Fair Value on a Recurring Basis by Level Within Fair Value Hierarchy (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyParentheticalDetails" id="Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyParentheticalDetails">
        <link:definition>100410 - Disclosure - Fair Value Measurements - Financial Assets Measured at Fair Value on a Recurring Basis by Level Within Fair Value Hierarchy (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" id="Role_DisclosureFairValueMeasurementsAdditionalInformationDetails">
        <link:definition>100420 - Disclosure - Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails" id="Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails">
        <link:definition>100430 - Disclosure - Fair Value Measurements - Estimated Fair Value of Significant Unobservable Inputs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails" id="Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails">
        <link:definition>100440 - Disclosure - Fair Value Measurements - Summary of Changes in Estimated Fair Value of Financial Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails" id="Role_DisclosureAcquisitionsAdditionalInformationDetails">
        <link:definition>100450 - Disclosure - Acquisitions - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails" id="Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails">
        <link:definition>100460 - Disclosure - Goodwill and Intangible Assets - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails" id="Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails">
        <link:definition>100470 - Disclosure - Goodwill and Intangible Assets - Schedule of Finite Lived Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails" id="Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails">
        <link:definition>100480 - Disclosure - Goodwill and Intangible Assets - Schedule of Estimated Future Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails" id="Role_DisclosureGrantAgreementsAdditionalInformationDetails">
        <link:definition>100490 - Disclosure - Grant Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" id="Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails">
        <link:definition>100500 - Disclosure - Collaboration and License Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsCollaborationCollaborationRevenueDetails" id="DisclosureCollaborationAndLicenseAgreementsCollaborationCollaborationRevenueDetails">
        <link:definition>100510 - Disclosure - Collaboration and License Agreements - Collaboration Collaboration revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" id="Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails">
        <link:definition>100520 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails" id="Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails">
        <link:definition>100530 - Disclosure - Balance Sheet Components - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails" id="Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails">
        <link:definition>100540 - Disclosure - Balance Sheet Components - Schedule of Accrued and Other Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>100550 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsAndAdditionalInformationRelatedToOperatingLeasesDetails" id="Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsAndAdditionalInformationRelatedToOperatingLeasesDetails">
        <link:definition>100560 - Disclosure - Commitments and Contingencies - Summary of Lease Costs and Additional Information Related to Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" id="Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails">
        <link:definition>100570 - Disclosure - Commitments and Contingencies - Schedule of Maturities of Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetDetails" id="Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetDetails">
        <link:definition>100580 - Disclosure - Commitments and Contingencies - Schedule of Operating Lease Amounts Recorded in Condensed Consolidated Balance Sheet (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/DisclosureManufacturingAndSupplyLetterAgreementsAdditionalInformationDetails" id="DisclosureManufacturingAndSupplyLetterAgreementsAdditionalInformationDetails">
        <link:definition>100590 - Disclosure - Manufacturing and Supply Letter Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" id="Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>100600 - Disclosure - Related Party Transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" id="Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails">
        <link:definition>100610 - Disclosure - Convertible Preferred Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantLiabilityAdditionalInformationDetails" id="Role_DisclosureConvertiblePreferredStockWarrantLiabilityAdditionalInformationDetails">
        <link:definition>100620 - Disclosure - Convertible Preferred Stock Warrant Liability - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails" id="Role_DisclosureStockBasedAwardsAdditionalInformationDetails">
        <link:definition>100630 - Disclosure - Stock-Based Awards - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails" id="Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails">
        <link:definition>100640 - Disclosure - Stock-Based Awards - Summary of Stock Option Plans Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails" id="Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails">
        <link:definition>100650 - Disclosure - Stock-Based Awards - Summary of Assumptions Used for Estimating the Fair Value of Stock Options Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/DisclosureStockbasedAwardsSummaryOfEmployeesStockPurchasePlanDetails" id="DisclosureStockbasedAwardsSummaryOfEmployeesStockPurchasePlanDetails">
        <link:definition>100660 - Disclosure - Stock-Based Awards -Summary of Employees Stock Purchase Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityDetails" id="Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityDetails">
        <link:definition>100670 - Disclosure - Stock-Based Awards - Summary of Restricted Stock Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockBasedCompensationExpenseDetails" id="Role_DisclosureStockBasedAwardsSummaryOfStockBasedCompensationExpenseDetails">
        <link:definition>100680 - Disclosure - Stock-Based Awards - Summary of Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails" id="DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails">
        <link:definition>100690 - Disclosure - Net Income (Loss) Per Share - Schedule of Basic and Diluted Net Income (loss) Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails" id="DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails">
        <link:definition>100700 - Disclosure - Net Income (Loss) Per Share - Schedule of Potentially Dilutive Securities Not Included in Diluted Per Share Calculations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/DisclosureNetIncomeLossPerShareAdditionalInformationDetails" id="DisclosureNetIncomeLossPerShareAdditionalInformationDetails">
        <link:definition>100710 - Disclosure - Net Income (Loss) Per Share (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails" id="DisclosureDefinedContributionPlanAdditionalInformationDetails">
        <link:definition>100720 - Disclosure - Defined Contribution Plan - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeLossBeforeProvisionForBenefitFromIncomeTaxesDetails" id="DisclosureIncomeTaxesScheduleOfIncomeLossBeforeProvisionForBenefitFromIncomeTaxesDetails">
        <link:definition>100730 - Disclosure - Income Taxes - Schedule of Income (Loss) Before Provision for (Benefit from) Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails" id="Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails">
        <link:definition>100740 - Disclosure - Income Taxes - Components of Income Tax Expense (Benefit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails" id="Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails">
        <link:definition>100750 - Disclosure - Income Taxes - Reconciliation Between Expected Income Tax Provision at Federal Statutory Rate and Reported Income Tax Benefit (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" id="Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
        <link:definition>100760 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" id="Role_DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>100770 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfLiabilityForUncertainTaxPositionsDetails" id="Role_DisclosureIncomeTaxesReconciliationOfLiabilityForUncertainTaxPositionsDetails">
        <link:definition>100780 - Disclosure - Income Taxes - Reconciliation of Liability for Uncertain Tax Positions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20221231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" id="DisclosureSubsequentEventAdditionalInformationDetails">
        <link:definition>100790 - Disclosure - Subsequent Event - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="vir_CollaborationAndLicenseAgreements" name="CollaborationAndLicenseAgreements" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_ConvertiblePreferredStockWarrantLiabilityAbstract" name="ConvertiblePreferredStockWarrantLiabilityAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_OperatingLeaseAbstract" name="OperatingLeaseAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_OperatingLeaseOtherInformationAbstract" name="OperatingLeaseOtherInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_AdjustmentsToProfitSharingAmounts" name="AdjustmentsToProfitSharingAmounts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_AdvancedProceedsAppliedToConvertiblePreferredStockIssuance" name="AdvancedProceedsAppliedToConvertiblePreferredStockIssuance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_AnnualLicenseMaintenanceFees" name="AnnualLicenseMaintenanceFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_AntibodyLicenseTransactionPrice" name="AntibodyLicenseTransactionPrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_AssetAcquisitionMilestoneAchieved" name="AssetAcquisitionMilestoneAchieved" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_AssetAcquisitionMilestonePaymentAggregate" name="AssetAcquisitionMilestonePaymentAggregate" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_AssetAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration" name="AssetAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_BusinessAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration" name="BusinessAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved" name="BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_BusinessAgreementEquityInvestmentCommitment" name="BusinessAgreementEquityInvestmentCommitment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_BusinessAgreementGrantAmount" name="BusinessAgreementGrantAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents" name="BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_CashCashEquivalentsAndShortTermInvestmentsExcludingEquityInvestment" name="CashCashEquivalentsAndShortTermInvestmentsExcludingEquityInvestment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_CashGrantAwarded" name="CashGrantAwarded" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_ChangesInEstimatedConstraintOnProfitSharingAmount" name="ChangesInEstimatedConstraintOnProfitSharingAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_ClosingStockPrice" name="ClosingStockPrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="vir_CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate" name="CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_CollaborationAgreementNumberOfUnitsOfAccount" name="CollaborationAgreementNumberOfUnitsOfAccount" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_CollaborationAgreementRelatedCostsAndExpenses" name="CollaborationAgreementRelatedCostsAndExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_CollaborationAgreementTerminationDescription" name="CollaborationAgreementTerminationDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_CollaborationAgreementTransactionPriceConsideration" name="CollaborationAgreementTransactionPriceConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_CollaborationAgreementTransactionPriceUpfrontFee" name="CollaborationAgreementTransactionPriceUpfrontFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_CollaborationTypeAndPrograms" name="CollaborationTypeAndPrograms" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_CommonStockIssuanceCost" name="CommonStockIssuanceCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_CommonStockSharesIssuedFairMarketValue" name="CommonStockSharesIssuedFairMarketValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_CommonStockSharesIssuedForMilestonePaymentShares" name="CommonStockSharesIssuedForMilestonePaymentShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="vir_CommonStockSharesPurchased" name="CommonStockSharesPurchased" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="vir_CommonStockSharesPurchasedAggregatePurchasePrice" name="CommonStockSharesPurchasedAggregatePurchasePrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_CommonStockSharesPurchasedSharePrice" name="CommonStockSharesPurchasedSharePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="vir_ConversionOfPreferredStockIntoCommonStockUponCompletionOfInitialPublicOffering" name="ConversionOfPreferredStockIntoCommonStockUponCompletionOfInitialPublicOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_ConvertiblePreferredStockIssuanceCost" name="ConvertiblePreferredStockIssuanceCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_DeferredTaxAssetsLeaseLiabilities" name="DeferredTaxAssetsLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_DeferredTaxLiabilitiesInProcessResearchAndDevelopment" name="DeferredTaxLiabilitiesInProcessResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_DeferredTaxLiabilitiesRightOfUseAssets" name="DeferredTaxLiabilitiesRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_DeterminedTransactionPrice" name="DeterminedTransactionPrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_EffectiveIncomeTaxRateReconciliationPermanentItemsPercent" name="EffectiveIncomeTaxRateReconciliationPermanentItemsPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_EquityInvestmentCurrent" name="EquityInvestmentCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_EsppDiscountedPurchasePricePercentage" name="EsppDiscountedPurchasePricePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_EstimatedSharesEmployeeStockPurchasePlans" name="EstimatedSharesEmployeeStockPurchasePlans" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_ExcessFundsPayableUnderGrantAgreementsCurrent" name="ExcessFundsPayableUnderGrantAgreementsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_FairMarketValueOfCommonStockIssued" name="FairMarketValueOfCommonStockIssued" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_FairValueReclassificationOfContingentConsiderationToAccruedLiabilitiesUponAchievementOfMilestone" name="FairValueReclassificationOfContingentConsiderationToAccruedLiabilitiesUponAchievementOfMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_FairValueReclassificationOfDerivativeLiabilityToAccruedLiabilitiesUponAchievementOfDevelopmentMilestone" name="FairValueReclassificationOfDerivativeLiabilityToAccruedLiabilitiesUponAchievementOfDevelopmentMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_FinancialAssetsAmortizedCostBasis" name="FinancialAssetsAmortizedCostBasis" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_FinancialAssetsFairValue" name="FinancialAssetsFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_FinancialAssetsGrossUnrealizedHoldingGains" name="FinancialAssetsGrossUnrealizedHoldingGains" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_FinancialAssetsGrossUnrealizedHoldingLosses" name="FinancialAssetsGrossUnrealizedHoldingLosses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_FiniteLivedIntangibleAssetsAccumulatedImpairment" name="FiniteLivedIntangibleAssetsAccumulatedImpairment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_FiniteLivedIntangibleAssetsAmortizationExpense" name="FiniteLivedIntangibleAssetsAmortizationExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_FiniteLivedIntangibleAssetsReclassifiedFromIndefiniteLived" name="FiniteLivedIntangibleAssetsReclassifiedFromIndefiniteLived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_FormerBusinessCombinationContingentConsiderationLiability" name="FormerBusinessCombinationContingentConsiderationLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_FundsReceivedInAdvance" name="FundsReceivedInAdvance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_GrantAgreementAmendedDate" name="GrantAgreementAmendedDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_GrantAgreementAmendedExpirationDate" name="GrantAgreementAmendedExpirationDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_GrantAgreementEffectiveEndDate" name="GrantAgreementEffectiveEndDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_GrantAgreementExpirationDate" name="GrantAgreementExpirationDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_GrantAgreementExpirationDateBeforeAmendment" name="GrantAgreementExpirationDateBeforeAmendment" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_GrantAwardedAmount" name="GrantAwardedAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_GrantAwardedAmountMaximum" name="GrantAwardedAmountMaximum" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_GrantsAgreementAmendedDate" name="GrantsAgreementAmendedDate" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue" name="IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_IncreaseDecreaseInResearchAndDevelopmentExpense" name="IncreaseDecreaseInResearchAndDevelopmentExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting" name="IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_IncrementalCommonSharesAttributabletoShareBasedPaymentArrangementsEmployeeStockPurchasePlan" name="IncrementalCommonSharesAttributabletoShareBasedPaymentArrangementsEmployeeStockPurchasePlan" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_InitialPublicOfferingCosts" name="InitialPublicOfferingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_IssuanceOfCommonStockInConnectionWithAGrantAgreementShares" name="IssuanceOfCommonStockInConnectionWithAGrantAgreementShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_LeaseArrangementContractualExpirationBeginningYear" name="LeaseArrangementContractualExpirationBeginningYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_LeaseArrangementContractualExpirationEndingYear" name="LeaseArrangementContractualExpirationEndingYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived" name="LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_LicenseAgreementUpfrontPayment" name="LicenseAgreementUpfrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_MaximumAggregateCommercialSalesMilestonePayments" name="MaximumAggregateCommercialSalesMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_MaximumAggregateDevelopmentAndRegulatoryMilestonePayments" name="MaximumAggregateDevelopmentAndRegulatoryMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_MaximumAggregateMilestonePaymentForAchievementOfSpecifiedMilestones" name="MaximumAggregateMilestonePaymentForAchievementOfSpecifiedMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_MaximumAggregateMilestonePayments" name="MaximumAggregateMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_MaximumAggregateSalesMilestonePayment" name="MaximumAggregateSalesMilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_MaximumAggregateSalesMilestonePayments" name="MaximumAggregateSalesMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_MaximumAmountGrantAggregate" name="MaximumAmountGrantAggregate" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_MaximumAmountGrantBasePeriod" name="MaximumAmountGrantBasePeriod" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory" name="MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_MaximumMilestonePaymentForAchievementOfSpecifiedMilestones" name="MaximumMilestonePaymentForAchievementOfSpecifiedMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_MaximumNumberOfDevelopmentProgramGrantedFromCounterparty" name="MaximumNumberOfDevelopmentProgramGrantedFromCounterparty" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_MaximumNumberOfDevelopmentProgramGrantedToCounterparty" name="MaximumNumberOfDevelopmentProgramGrantedToCounterparty" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_MaximumNumberOfProductsCoveredAgainstMilestonePayment" name="MaximumNumberOfProductsCoveredAgainstMilestonePayment" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct" name="MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_MaximumSalesMilestonePayment" name="MaximumSalesMilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_MaximumSalesMilestonePaymentsToBeReceived" name="MaximumSalesMilestonePaymentsToBeReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_MaximumSalesMilestoneToBeReceived" name="MaximumSalesMilestoneToBeReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_MaximumSharesToBeIssued" name="MaximumSharesToBeIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="vir_MaximumTermOfOfferingPeriodSpecifiedUnderPlan" name="MaximumTermOfOfferingPeriodSpecifiedUnderPlan" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_MilestonePayable" name="MilestonePayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_MilestonePaymentDueToCompany" name="MilestonePaymentDueToCompany" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_MilestonePaymentReceived" name="MilestonePaymentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_MilestonePaymentsPaid" name="MilestonePaymentsPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_MilestonePaymentsRelatedTermsDescription" name="MilestonePaymentsRelatedTermsDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_MinimumCommonStockConversionPriceForMilestonePaymentsConsideration" name="MinimumCommonStockConversionPriceForMilestonePaymentsConsideration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_MinimumCommonStockPriceForMilestonePaymentsConsideration" name="MinimumCommonStockPriceForMilestonePaymentsConsideration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_NetProceedsFromIssuanceSecondaryPublicOffering" name="NetProceedsFromIssuanceSecondaryPublicOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_NonCashCommonStockIssuedForContingentConsideration" name="NonCashCommonStockIssuedForContingentConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_NoncashLeaseExpense" name="NoncashLeaseExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_NumberOfAntibodiesToDevelop" name="NumberOfAntibodiesToDevelop" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_NumberOfClassOfStock" name="NumberOfClassOfStock" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="vir_NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans" name="NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_ObligationToPayCapacityReservation" name="ObligationToPayCapacityReservation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_OfferingPeriodEmployeeStockPurchasePlan" name="OfferingPeriodEmployeeStockPurchasePlan" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_OperatingAndFinanceRentExpense" name="OperatingAndFinanceRentExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_OperatingLeaseIncentiveOverLeaseLiabilities" name="OperatingLeaseIncentiveOverLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_OperatingLossCarryforwardsExpirationBeginningYear" name="OperatingLossCarryforwardsExpirationBeginningYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_OperatingLossCarryforwardsLimitationOnUsePercentage" name="OperatingLossCarryforwardsLimitationOnUsePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_OptionExerciseFeeConsiderationToBeReceived" name="OptionExerciseFeeConsiderationToBeReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_OptionExerciseFeeHighEndOfTheRange" name="OptionExerciseFeeHighEndOfTheRange" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_OptionExerciseFeeLowEndOfTheRange" name="OptionExerciseFeeLowEndOfTheRange" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_OptionExerciseFeeReceived" name="OptionExerciseFeeReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_OptionsTransactionPrice" name="OptionsTransactionPrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentToProjectedBenefitObligationsNetOfTax" name="OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentToProjectedBenefitObligationsNetOfTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_PaymentCommitmentManufacturingCapacity" name="PaymentCommitmentManufacturingCapacity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_PaymentCommitmentRawMaterials" name="PaymentCommitmentRawMaterials" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_PaymentMadeForAssetAcquisitionMilestone" name="PaymentMadeForAssetAcquisitionMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_PaymentMadeForBusinessCombinationMilestone" name="PaymentMadeForBusinessCombinationMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_PaymentOfContingentConsideration" name="PaymentOfContingentConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_PaymentsOfUnderwritingDiscountsAndCommissions" name="PaymentsOfUnderwritingDiscountsAndCommissions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_PaymentToCollaboratorResultingFromProgramOptionExercise" name="PaymentToCollaboratorResultingFromProgramOptionExercise" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_PayrollAndRelatedExpensesCurrent" name="PayrollAndRelatedExpensesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_PercentageOfAggregateGrossProceedsFromSaleOfShares" name="PercentageOfAggregateGrossProceedsFromSaleOfShares" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_PercentageOfCommissionRateFromSaleOfShares" name="PercentageOfCommissionRateFromSaleOfShares" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_PercentageOfDevelopmentCosts" name="PercentageOfDevelopmentCosts" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_PercentageOfDevelopmentCostsResponsibleByCompany" name="PercentageOfDevelopmentCostsResponsibleByCompany" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_PercentageOfDevelopmentCostsResponsibleByGsk" name="PercentageOfDevelopmentCostsResponsibleByGsk" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_PercentageOfEstimatedBatchProductionFees" name="PercentageOfEstimatedBatchProductionFees" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_PercentageOfOrdinaryShareEqualToOutstandingShare" name="PercentageOfOrdinaryShareEqualToOutstandingShare" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_PercentageOfShareDevelopmentCosts" name="PercentageOfShareDevelopmentCosts" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_PercentageOfUpfrontPaymentReceivableAtEffectiveDateOfAgreement" name="PercentageOfUpfrontPaymentReceivableAtEffectiveDateOfAgreement" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="vir_PercentageOfUpfrontPaymentReceivableAtExecutionDateOfAgreement" name="PercentageOfUpfrontPaymentReceivableAtExecutionDateOfAgreement" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="vir_PreDefinedRegulatoryMilestoneConsiderationToBeReceived" name="PreDefinedRegulatoryMilestoneConsiderationToBeReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_PremiumReceivedOnSalePriceOfCommonStock" name="PremiumReceivedOnSalePriceOfCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_PrepaymentRawMaterials" name="PrepaymentRawMaterials" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_PresentValueOfOperatingLeaseLiabilities" name="PresentValueOfOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_ProceedsFromDisposalOfAnEquipment" name="ProceedsFromDisposalOfAnEquipment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_ProceedsFromIssuanceOfCommonStockInConnectionWithAGrantAgreement" name="ProceedsFromIssuanceOfCommonStockInConnectionWithAGrantAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_ProceedsFromIssuanceOfCommonStockInConnectionWithCollaboration" name="ProceedsFromIssuanceOfCommonStockInConnectionWithCollaboration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_ProceedsFromIssuanceSecondaryPublicOffering" name="ProceedsFromIssuanceSecondaryPublicOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_ProfitsAndLossesSharingPercentage" name="ProfitsAndLossesSharingPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_ProfitShareAmountConstraint" name="ProfitShareAmountConstraint" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_ProfitSharingAmount" name="ProfitSharingAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_ProfitSharingAmountConstrained" name="ProfitSharingAmountConstrained" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_ProfitSharingAmountPreviouslyConstrainedReleased" name="ProfitSharingAmountPreviouslyConstrainedReleased" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_RangeOfRoyaltyPaymentsToBeReceived" name="RangeOfRoyaltyPaymentsToBeReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_RangeOfRoyaltyPaymentToBePaid" name="RangeOfRoyaltyPaymentToBePaid" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_RangeOfRoyaltyPaymentToBeReceived" name="RangeOfRoyaltyPaymentToBeReceived" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_RangeOfTieredRoyaltiesToPayToNetSalesOfProducts" name="RangeOfTieredRoyaltiesToPayToNetSalesOfProducts" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital" name="ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone" name="ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_ReclassificationOfPreferredStockWarrantLiabilityToAdditionalPaidInCapital" name="ReclassificationOfPreferredStockWarrantLiabilityToAdditionalPaidInCapital" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_ReclassifiedDeferredRevenue" name="ReclassifiedDeferredRevenue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_RegulatoryMilestoneAchieved" name="RegulatoryMilestoneAchieved" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_RegulatoryMilestonePaymentOnLicensedProductHighEndOfRange" name="RegulatoryMilestonePaymentOnLicensedProductHighEndOfRange" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_RegulatoryMilestonePaymentOnLicensedProductLowEndOfTheRange" name="RegulatoryMilestonePaymentOnLicensedProductLowEndOfTheRange" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_RegulatoryMilestonePaymentToBeReceived" name="RegulatoryMilestonePaymentToBeReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_RegulatoryMilestonesAchieved" name="RegulatoryMilestonesAchieved" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_ReleaseOfValuationAllowanceDeferredTaxInAmount" name="ReleaseOfValuationAllowanceDeferredTaxInAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_RemainingPaymentForAssetAcquisitionMilestoneAggregate" name="RemainingPaymentForAssetAcquisitionMilestoneAggregate" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_RemainingPaymentMadeForAssetAcquisitionMilestone" name="RemainingPaymentMadeForAssetAcquisitionMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_RemainingPaymentMadeForBusinessCombinationMilestone" name="RemainingPaymentMadeForBusinessCombinationMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_RepaymentOfOutstandingPromissoryNotesAndAccruedInterestReceived" name="RepaymentOfOutstandingPromissoryNotesAndAccruedInterestReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_ResearchAndDevelopmentExpensesCurrent" name="ResearchAndDevelopmentExpensesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_ResearchAndDevelopmentExpenseUnderLicenseAgreement" name="ResearchAndDevelopmentExpenseUnderLicenseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_RestrictedStockLiabilityRecognizedForPortionOfPromissoryNoteRepayment" name="RestrictedStockLiabilityRecognizedForPortionOfPromissoryNoteRepayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_RoyaltiesBasedOnNetSalesOfLicensedProducts" name="RoyaltiesBasedOnNetSalesOfLicensedProducts" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_RoyaltiesPaymentExpirationPeriod" name="RoyaltiesPaymentExpirationPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_RoyaltiesPaymentRangeOnNetSalesOfLicensedProduct" name="RoyaltiesPaymentRangeOnNetSalesOfLicensedProduct" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_RoyaltyObligationPeriodFromDateOfFirstCommercialSale" name="RoyaltyObligationPeriodFromDateOfFirstCommercialSale" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales" name="RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_SaleLeasebackTransactionProceedsFromFinancingObligations" name="SaleLeasebackTransactionProceedsFromFinancingObligations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_SaleOfStockConsiderationAggregateOfferingPrice" name="SaleOfStockConsiderationAggregateOfferingPrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_SalesMilestonesAchieved" name="SalesMilestonesAchieved" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_SpecifiedClinicalDevelopmentMilestonesPayment" name="SpecifiedClinicalDevelopmentMilestonesPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_SpecifiedResearchAndDevelopmentExpensesMilestonePayments" name="SpecifiedResearchAndDevelopmentExpensesMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_SpecifiedSalesDevelopmentMilestonesPayment" name="SpecifiedSalesDevelopmentMilestonesPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_StockIssuedDuringPeriodSharesAchievementOfMilestone" name="StockIssuedDuringPeriodSharesAchievementOfMilestone" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant" name="StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_StockIssuedDuringPeriodSharesCollaborationAgreement" name="StockIssuedDuringPeriodSharesCollaborationAgreement" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_StockIssuedDuringPeriodSharesIssuedForSettlementOfContingentConsideration" name="StockIssuedDuringPeriodSharesIssuedForSettlementOfContingentConsideration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_StockIssuedDuringPeriodSharesLicenseAgreement" name="StockIssuedDuringPeriodSharesLicenseAgreement" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_StockIssuedDuringPeriodValueCollaborationAgreement" name="StockIssuedDuringPeriodValueCollaborationAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_StockIssuedDuringPeriodValueIssuedForSettlementOfContingentConsideration" name="StockIssuedDuringPeriodValueIssuedForSettlementOfContingentConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_StockIssuedDuringPeriodValueLicenseAgreement" name="StockIssuedDuringPeriodValueLicenseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_StockIssuedDuringPeriodWarrantExercised" name="StockIssuedDuringPeriodWarrantExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_StockIssuedGrantAgreement" name="StockIssuedGrantAgreement" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="vir_TaxCreditCarryforwardsExpirationBeginningYear" name="TaxCreditCarryforwardsExpirationBeginningYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_TemporaryEquityAdditionalSharesAuthorized" name="TemporaryEquityAdditionalSharesAuthorized" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="vir_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_TenantImprovementAllowanceAggregate" name="TenantImprovementAllowanceAggregate" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_TotalcollaborationRevenue" name="TotalcollaborationRevenue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_UnderlyingSharesPremiumReceived" name="UnderlyingSharesPremiumReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_UnrecognizedTaxBenefitsIfRecognizedWouldReduceEffectiveTaxRate" name="UnrecognizedTaxBenefitsIfRecognizedWouldReduceEffectiveTaxRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="vir_UnusedFundsReceivedInAdvance" name="UnusedFundsReceivedInAdvance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_UpfrontFeePaid" name="UpfrontFeePaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_UpfrontPaymentReceivable" name="UpfrontPaymentReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_UpfrontPaymentReceived" name="UpfrontPaymentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_ValueOfCommonStockSharesIssuedForMilestonePayment" name="ValueOfCommonStockSharesIssuedForMilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_ValueOfSharesTransferredToCollaborator" name="ValueOfSharesTransferredToCollaborator" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_ValueStockIssuedGrantAgreement" name="ValueStockIssuedGrantAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach" name="WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_WrittenNoticePeriodForTerminationOfLicensedProgram" name="WrittenNoticePeriodForTerminationOfLicensedProgram" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_WrittenNoticePeriodToTerminateAgreementByCompany" name="WrittenNoticePeriodToTerminateAgreementByCompany" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_WrittenNoticePeriodToTerminateAgreementByCounterparty" name="WrittenNoticePeriodToTerminateAgreementByCounterparty" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_WrittenNoticePeriodToTerminateLicensedProgramForFailureToMakePayment" name="WrittenNoticePeriodToTerminateLicensedProgramForFailureToMakePayment" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_WrittenNoticePeriodToTerminateLicensedProgramForPaymentBreach" name="WrittenNoticePeriodToTerminateLicensedProgramForPaymentBreach" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_WrittenNoticePeriodToTerminateLicensedProgramForUncuredMaterialBreach" name="WrittenNoticePeriodToTerminateLicensedProgramForUncuredMaterialBreach" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenge" name="WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenge" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenges" name="WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenges" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_WrittenNoticeToTerminateLicensedProgramIfExercise" name="WrittenNoticeToTerminateLicensedProgramIfExercise" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_WrittenNoticeToTerminateLicensedProgramIfNotExercise" name="WrittenNoticeToTerminateLicensedProgramIfNotExercise" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_IncomeTaxesLineItems" name="IncomeTaxesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" name="OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_ReconciliationOfEffectiveIncomeTaxRateLineItems" name="ReconciliationOfEffectiveIncomeTaxRateLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_ScheduleOfGoodwillAndIntangibleAssetsLineItems" name="ScheduleOfGoodwillAndIntangibleAssetsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_SummaryOfSignificantAccountingPoliciesLineItems" name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_AccruedLiabilitiesAndOtherLiabilitiesMember" name="AccruedLiabilitiesAndOtherLiabilitiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_AlnylamAgreementMember" name="AlnylamAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_AlnylamPharmaceuticalsIncMember" name="AlnylamPharmaceuticalsIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_AmendmentNumberOneMember" name="AmendmentNumberOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_AnotherProductMember" name="AnotherProductMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_AntibodyProgramMember" name="AntibodyProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_BillAndMelindaGatesFoundationMember" name="BillAndMelindaGatesFoundationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_BillMelindaGatesFoundationMember" name="BillMelindaGatesFoundationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_BiologicalMaterialsMember" name="BiologicalMaterialsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" name="BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_BriiAgreementMember" name="BriiAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_BriiBioParentMember" name="BriiBioParentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_BriiBiosciencesOffshoreLimitedMember" name="BriiBiosciencesOffshoreLimitedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_ClinicalAndRegulatoryMilestonesMember" name="ClinicalAndRegulatoryMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_ClinicalDevelopmentAndManufacturingOrganizationMember" name="ClinicalDevelopmentAndManufacturingOrganizationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_ClinicalDevelopmentMember" name="ClinicalDevelopmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_CollaborationAgreementMember" name="CollaborationAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_CollaborationRevenueMember" name="CollaborationRevenueMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_CommercialMilestonesMember" name="CommercialMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_ContingentConsiderationLiabilityMember" name="ContingentConsiderationLiabilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_ContractRevenueMember" name="ContractRevenueMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_ConvertiblePreferredStockWarrantLiabilityMember" name="ConvertiblePreferredStockWarrantLiabilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_DefinitiveCollaborationAgreementMember" name="DefinitiveCollaborationAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_DevelopedTechnologyMember" name="DevelopedTechnologyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_DevelopmentAndManufacturingCollaborationAgreementMember" name="DevelopmentAndManufacturingCollaborationAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_DevelopmentProgramsExercisedByBriiMember" name="DevelopmentProgramsExercisedByBriiMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_DevelopmentProgramsExercisedByVirMember" name="DevelopmentProgramsExercisedByVirMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_EachInfectiousDiseaseSiRNAMember" name="EachInfectiousDiseaseSiRNAMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_EstimatedSharesIssuableUnderTheESPPMember" name="EstimatedSharesIssuableUnderTheESPPMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_ExecutiveOfficerAndDirectorMember" name="ExecutiveOfficerAndDirectorMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_FirstAndSecondClosingsMember" name="FirstAndSecondClosingsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_FirstInfectiousDiseaseProductMember" name="FirstInfectiousDiseaseProductMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_FirstPlanMember" name="FirstPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_FirstSiRNAProductHBVMember" name="FirstSiRNAProductHBVMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_FirstSiRNAProductMember" name="FirstSiRNAProductMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_FollowOnOfferingMember" name="FollowOnOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_GlaxoGroupLimitedMember" name="GlaxoGroupLimitedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember" name="GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_GlaxoSmithKlineTradingServiceLimitedMember" name="GlaxoSmithKlineTradingServiceLimitedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_GlaxoWellcomeUKLimitedAndBeechamSAMember" name="GlaxoWellcomeUKLimitedAndBeechamSAMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_HBVProgramMember" name="HBVProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_HcmvVaccinePlatformGrantMember" name="HcmvVaccinePlatformGrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_HepatitisBVirusProductMember" name="HepatitisBVirusProductMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_HumabsBiomedSAMember" name="HumabsBiomedSAMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_HumanImmunodeficiencyVirusGrantMember" name="HumanImmunodeficiencyVirusGrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_InfectiousDiseaseProductMember" name="InfectiousDiseaseProductMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_InfluenzaAAndHBVResearchProgramsMember" name="InfluenzaAAndHBVResearchProgramsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_InfluenzaAAndInfluenzaBMember" name="InfluenzaAAndInfluenzaBMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_InfluenzaAResearchProgramsMember" name="InfluenzaAResearchProgramsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_LetterAgreementMember" name="LetterAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_MeasurementInputExpectedRevenueVolatilityMember" name="MeasurementInputExpectedRevenueVolatilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_MeasurementInputExpectedVolatilityMember" name="MeasurementInputExpectedVolatilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_MeasurementInputProbabilityRateMember" name="MeasurementInputProbabilityRateMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_MedImmuneAgreementMember" name="MedImmuneAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_MedImmuneLimitedLiabilityCompanyMember" name="MedImmuneLimitedLiabilityCompanyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_NationalInstitutesOfHealthMember" name="NationalInstitutesOfHealthMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_PreliminaryCollaborationAgreementMember" name="PreliminaryCollaborationAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_RestrictedStockAwardsRSAMember" name="RestrictedStockAwardsRSAMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_RestrictedStockPurchaseAgreementMember" name="RestrictedStockPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_RockefellerAgreementMember" name="RockefellerAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_RockefellerUniversityMember" name="RockefellerUniversityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_SalesAgreementMember" name="SalesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_SamsungBiologicsCompanyLimitedMember" name="SamsungBiologicsCompanyLimitedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_SARSCoV2ProductMember" name="SARSCoV2ProductMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_SecondPlanMember" name="SecondPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_SeriesAOneConvertiblePreferredStockMember" name="SeriesAOneConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_SeriesATwoConvertiblePreferredStockMember" name="SeriesATwoConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_SeriesBConvertiblePreferredStockMember" name="SeriesBConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_ThirdClosingMember" name="ThirdClosingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_TomegaVaxIncMember" name="TomegaVaxIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_TuberculosisTBGrantMember" name="TuberculosisTBGrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_TwoThousandAndTwentyGskAgreementMember" name="TwoThousandAndTwentyGskAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_TwoThousandAndTwentyOneGSKAgreementMember" name="TwoThousandAndTwentyOneGSKAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_TwoThousandAndTwentyOneGSKCollaborationMember" name="TwoThousandAndTwentyOneGSKCollaborationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember" name="TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember" name="TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_TwoThousandNineteenAndTwoThousandTwentyXencorAgreementMember" name="TwoThousandNineteenAndTwoThousandTwentyXencorAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_TwoThousandNineteenEmployeeStockPurchasePlanMember" name="TwoThousandNineteenEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_TwoThousandNineteenEquityIncentivePlanMember" name="TwoThousandNineteenEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_TwoThousandNineteenXencorAgreementMember" name="TwoThousandNineteenXencorAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_TwoThousandSeventeenGrantMember" name="TwoThousandSeventeenGrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_TwoThousandSixteenEquityIncentivePlanMember" name="TwoThousandSixteenEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember" name="TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember" name="TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_TwoThousandTwentyOneStockPurchaseAgreementMember" name="TwoThousandTwentyOneStockPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_TwoThousandTwentyStockPurchaseAgreementMember" name="TwoThousandTwentyStockPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_TwoThousandTwentyXencorAgreementMember" name="TwoThousandTwentyXencorAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_VaccinalAntibodyGrantMember" name="VaccinalAntibodyGrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_VaccineProgramMember" name="VaccineProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_Vir2218Member" name="Vir2218Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_Vir2248Member" name="Vir2248Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_Vir3434Member" name="Vir3434Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_WarrantsToPurchaseCommonStockMember" name="WarrantsToPurchaseCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember" name="WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_WuxiBiologicsLetterAgreementAssignmentAndMasterServiceAgreementsMember" name="WuxiBiologicsLetterAgreementAssignmentAndMasterServiceAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_WuXiBiologicsLimitedMember" name="WuXiBiologicsLimitedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_XencorAgreementsMember" name="XencorAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_XencorIncorporationMember" name="XencorIncorporationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_ConcentrationOfCreditRiskCreditLossAndOtherRisksAndUncertaintiesPolicyTextBlock" name="ConcentrationOfCreditRiskCreditLossAndOtherRisksAndUncertaintiesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_IncomeTaxesTable" name="IncomeTaxesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" name="OrganizationConsolidationAndPresentationOfFinancialStatementsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_ReconciliationOfEffectiveIncomeTaxRateTable" name="ReconciliationOfEffectiveIncomeTaxRateTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_ScheduleOfGoodwillAndIntangibleAssetsTable" name="ScheduleOfGoodwillAndIntangibleAssetsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_SummaryOfSignificantAccountingPoliciesTable" name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock" name="ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_ScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetTableTextBlock" name="ScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_SummaryOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock" name="SummaryOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_CollaborationRevenueTableTextBlock" name="CollaborationRevenueTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_ConvertiblePreferredStockWarrantLiabilityTextBlock" name="ConvertiblePreferredStockWarrantLiabilityTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_GrantAgreementsDisclosureTextBlock" name="GrantAgreementsDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_TemporaryEquityTextBlock" name="TemporaryEquityTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>39
<FILENAME>vir-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-02-28T15:30:35.6180+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_IncrementalCommonSharesAttributabletoShareBasedPaymentArrangementsEmployeeStockPurchasePlan" xlink:label="vir_IncrementalCommonSharesAttributabletoShareBasedPaymentArrangementsEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_LeaseArrangementContractualExpirationEndingYear" xlink:label="vir_LeaseArrangementContractualExpirationEndingYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MaximumAggregateDevelopmentAndRegulatoryMilestonePayments" xlink:label="vir_MaximumAggregateDevelopmentAndRegulatoryMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PremiumReceivedOnSalePriceOfCommonStock" xlink:label="vir_PremiumReceivedOnSalePriceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue" xlink:label="vir_IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_UpfrontPaymentReceived" xlink:label="vir_UpfrontPaymentReceived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities" xlink:label="us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenges" xlink:label="vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenges"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_GrantAgreementExpirationDateBeforeAmendment" xlink:label="vir_GrantAgreementExpirationDateBeforeAmendment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TwoThousandNineteenEquityIncentivePlanMember" xlink:label="vir_TwoThousandNineteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_RegulatoryMilestonePaymentToBeReceived" xlink:label="vir_RegulatoryMilestonePaymentToBeReceived"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MaximumSalesMilestonePaymentsToBeReceived" xlink:label="vir_MaximumSalesMilestonePaymentsToBeReceived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_AlnylamPharmaceuticalsIncMember" xlink:label="vir_AlnylamPharmaceuticalsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_DeferredTaxLiabilitiesInProcessResearchAndDevelopment" xlink:label="vir_DeferredTaxLiabilitiesInProcessResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:label="us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_GlaxoGroupLimitedMember" xlink:label="vir_GlaxoGroupLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MeasurementInputExpectedVolatilityMember" xlink:label="vir_MeasurementInputExpectedVolatilityMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_CommonStockSharesIssuedForMilestonePaymentShares" xlink:label="vir_CommonStockSharesIssuedForMilestonePaymentShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares" xlink:label="us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_NoncashLeaseExpense" xlink:label="vir_NoncashLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_OptionExerciseFeeConsiderationToBeReceived" xlink:label="vir_OptionExerciseFeeConsiderationToBeReceived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_CollaborationAgreementRelatedCostsAndExpenses" xlink:label="vir_CollaborationAgreementRelatedCostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MaximumAggregateCommercialSalesMilestonePayments" xlink:label="vir_MaximumAggregateCommercialSalesMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant" xlink:label="vir_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_LaboratoryEquipmentMember" xlink:label="vir_LaboratoryEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_SeriesBConvertiblePreferredStockMember" xlink:label="vir_SeriesBConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_FinancialAssetsFairValue" xlink:label="vir_FinancialAssetsFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans" xlink:label="vir_NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_AlnylamAgreementMember" xlink:label="vir_AlnylamAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_SeriesATwoConvertiblePreferredStockMember" xlink:label="vir_SeriesATwoConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PaymentCommitmentManufacturingCapacity" xlink:label="vir_PaymentCommitmentManufacturingCapacity"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenge" xlink:label="vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenge"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:label="us-gaap_IndefinitelivedIntangibleAssetsAcquired"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_AssetAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration" xlink:label="vir_AssetAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MilestonePaymentsPaid" xlink:label="vir_MilestonePaymentsPaid"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="vir_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TomegaVaxIncMember" xlink:label="vir_TomegaVaxIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_HumanImmunodeficiencyVirusGrantMember" xlink:label="vir_HumanImmunodeficiencyVirusGrantMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ClinicalDevelopmentMember" xlink:label="vir_ClinicalDevelopmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TwoThousandAndTwentyGskAgreementMember" xlink:label="vir_TwoThousandAndTwentyGskAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="us-gaap_BusinessCombinationsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_DevelopmentAndManufacturingCollaborationAgreementMember" xlink:label="vir_DevelopmentAndManufacturingCollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_DevelopmentProgramsExercisedByVirMember" xlink:label="vir_DevelopmentProgramsExercisedByVirMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:label="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_NationalInstitutesOfHealthMember" xlink:label="vir_NationalInstitutesOfHealthMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_SaleOfStockConsiderationAggregateOfferingPrice" xlink:label="vir_SaleOfStockConsiderationAggregateOfferingPrice"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_StockIssuedDuringPeriodWarrantExercised" xlink:label="vir_StockIssuedDuringPeriodWarrantExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_OR" xlink:label="stpr_OR"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember" xlink:label="vir_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:label="us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember" xlink:label="vir_TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ProceedsFromIssuanceSecondaryPublicOffering" xlink:label="vir_ProceedsFromIssuanceSecondaryPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_UpfrontPaymentReceivable" xlink:label="vir_UpfrontPaymentReceivable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_GrantAgreementExpirationDate" xlink:label="vir_GrantAgreementExpirationDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_GlaxoSmithKlineTradingServiceLimitedMember" xlink:label="vir_GlaxoSmithKlineTradingServiceLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_BillMelindaGatesFoundationMember" xlink:label="vir_BillMelindaGatesFoundationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone" xlink:label="vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_OperatingLeaseIncentiveOverLeaseLiabilities" xlink:label="vir_OperatingLeaseIncentiveOverLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingenciesLineItems" xlink:label="us-gaap_GainContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_RangeOfRoyaltyPaymentsToBeReceived" xlink:label="vir_RangeOfRoyaltyPaymentsToBeReceived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PaymentCommitmentRawMaterials" xlink:label="vir_PaymentCommitmentRawMaterials"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_OptionExerciseFeeLowEndOfTheRange" xlink:label="vir_OptionExerciseFeeLowEndOfTheRange"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_InitialPublicOfferingCosts" xlink:label="vir_InitialPublicOfferingCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ClinicalDevelopmentAndManufacturingOrganizationMember" xlink:label="vir_ClinicalDevelopmentAndManufacturingOrganizationMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ChangesInEstimatedConstraintOnProfitSharingAmount" xlink:label="vir_ChangesInEstimatedConstraintOnProfitSharingAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_FirstPlanMember" xlink:label="vir_FirstPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_WrittenNoticeToTerminateLicensedProgramIfNotExercise" xlink:label="vir_WrittenNoticeToTerminateLicensedProgramIfNotExercise"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_Vir3434Member" xlink:label="vir_Vir3434Member"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ProceedsFromIssuanceOfCommonStockInConnectionWithAGrantAgreement" xlink:label="vir_ProceedsFromIssuanceOfCommonStockInConnectionWithAGrantAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_WrittenNoticePeriodForTerminationOfLicensedProgram" xlink:label="vir_WrittenNoticePeriodForTerminationOfLicensedProgram"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" xlink:label="us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_SpecifiedResearchAndDevelopmentExpensesMilestonePayments" xlink:label="vir_SpecifiedResearchAndDevelopmentExpensesMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ProfitShareAmountConstraint" xlink:label="vir_ProfitShareAmountConstraint"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived" xlink:label="vir_LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_LeaseArrangementContractualExpirationBeginningYear" xlink:label="vir_LeaseArrangementContractualExpirationBeginningYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesEmbeddedDerivatives" xlink:label="us-gaap_DerivativesEmbeddedDerivatives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TemporaryEquityTextBlock" xlink:label="vir_TemporaryEquityTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_WuXiBiologicsLimitedMember" xlink:label="vir_WuXiBiologicsLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved" xlink:label="vir_BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedAtFairValue" xlink:label="us-gaap_InvestmentOwnedAtFairValue"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_WuxiBiologicsLetterAgreementAssignmentAndMasterServiceAgreementsMember" xlink:label="vir_WuxiBiologicsLetterAgreementAssignmentAndMasterServiceAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_WarrantsToPurchaseCommonStockMember" xlink:label="vir_WarrantsToPurchaseCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_FairValueReclassificationOfDerivativeLiabilityToAccruedLiabilitiesUponAchievementOfDevelopmentMilestone" xlink:label="vir_FairValueReclassificationOfDerivativeLiabilityToAccruedLiabilitiesUponAchievementOfDevelopmentMilestone"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_VaccineProgramMember" xlink:label="vir_VaccineProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_AnotherProductMember" xlink:label="vir_AnotherProductMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_DevelopmentProgramsExercisedByBriiMember" xlink:label="vir_DevelopmentProgramsExercisedByBriiMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivableAccruedInterestWriteoff" xlink:label="us-gaap_FinancingReceivableAccruedInterestWriteoff"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MaximumNumberOfProductsCoveredAgainstMilestonePayment" xlink:label="vir_MaximumNumberOfProductsCoveredAgainstMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ReconciliationOfEffectiveIncomeTaxRateLineItems" xlink:label="vir_ReconciliationOfEffectiveIncomeTaxRateLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="us-gaap_AccountingStandardsUpdate201409Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TuberculosisTBGrantMember" xlink:label="vir_TuberculosisTBGrantMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_LetterAgreementMember" xlink:label="vir_LetterAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseAgreementsMember" xlink:label="us-gaap_LeaseAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_WrittenNoticePeriodToTerminateAgreementByCompany" xlink:label="vir_WrittenNoticePeriodToTerminateAgreementByCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_CashCashEquivalentsAndShortTermInvestmentsExcludingEquityInvestment" xlink:label="vir_CashCashEquivalentsAndShortTermInvestmentsExcludingEquityInvestment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy" xlink:label="us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_GlaxoWellcomeUKLimitedAndBeechamSAMember" xlink:label="vir_GlaxoWellcomeUKLimitedAndBeechamSAMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_RestrictedStockAwardsRSAMember" xlink:label="vir_RestrictedStockAwardsRSAMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PaymentsOfUnderwritingDiscountsAndCommissions" xlink:label="vir_PaymentsOfUnderwritingDiscountsAndCommissions"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PercentageOfDevelopmentCostsResponsibleByCompany" xlink:label="vir_PercentageOfDevelopmentCostsResponsibleByCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainContingenciesTable" xlink:label="us-gaap_GainContingenciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="vir_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_AssetAcquisitionMilestoneAchieved" xlink:label="vir_AssetAcquisitionMilestoneAchieved"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ExcessFundsPayableUnderGrantAgreementsCurrent" xlink:label="vir_ExcessFundsPayableUnderGrantAgreementsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_SARSCoV2ProductMember" xlink:label="vir_SARSCoV2ProductMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TwoThousandNineteenXencorAgreementMember" xlink:label="vir_TwoThousandNineteenXencorAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ClinicalAndRegulatoryMilestonesMember" xlink:label="vir_ClinicalAndRegulatoryMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_CollaborationAgreementTransactionPriceConsideration" xlink:label="vir_CollaborationAgreementTransactionPriceConsideration"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_SalesMilestonesAchieved" xlink:label="vir_SalesMilestonesAchieved"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_BusinessAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration" xlink:label="vir_BusinessAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_SummaryOfSignificantAccountingPoliciesTable" xlink:label="vir_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PercentageOfAggregateGrossProceedsFromSaleOfShares" xlink:label="vir_PercentageOfAggregateGrossProceedsFromSaleOfShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PaymentOfContingentConsideration" xlink:label="vir_PaymentOfContingentConsideration"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_GrantAgreementAmendedDate" xlink:label="vir_GrantAgreementAmendedDate"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_WrittenNoticeToTerminateLicensedProgramIfExercise" xlink:label="vir_WrittenNoticeToTerminateLicensedProgramIfExercise"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MedImmuneLimitedLiabilityCompanyMember" xlink:label="vir_MedImmuneLimitedLiabilityCompanyMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MeasurementInputExpectedRevenueVolatilityMember" xlink:label="vir_MeasurementInputExpectedRevenueVolatilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_RoyaltyObligationPeriodFromDateOfFirstCommercialSale" xlink:label="vir_RoyaltyObligationPeriodFromDateOfFirstCommercialSale"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_UnusedFundsReceivedInAdvance" xlink:label="vir_UnusedFundsReceivedInAdvance"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_StockIssuedGrantAgreement" xlink:label="vir_StockIssuedGrantAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_OperatingLeaseOtherInformationAbstract" xlink:label="vir_OperatingLeaseOtherInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:label="us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MaximumAggregateMilestonePayments" xlink:label="vir_MaximumAggregateMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_EquityInvestmentCurrent" xlink:label="vir_EquityInvestmentCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_CollaborationRevenueTableTextBlock" xlink:label="vir_CollaborationRevenueTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_OfferingPeriodEmployeeStockPurchasePlan" xlink:label="vir_OfferingPeriodEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_GrantAwardedAmountMaximum" xlink:label="vir_GrantAwardedAmountMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_SpecifiedClinicalDevelopmentMilestonesPayment" xlink:label="vir_SpecifiedClinicalDevelopmentMilestonesPayment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_FirstInfectiousDiseaseProductMember" xlink:label="vir_FirstInfectiousDiseaseProductMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ReclassificationOfPreferredStockWarrantLiabilityToAdditionalPaidInCapital" xlink:label="vir_ReclassificationOfPreferredStockWarrantLiabilityToAdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_IncomeTaxesLineItems" xlink:label="vir_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_OperatingLossCarryforwardsLimitationOnUsePercentage" xlink:label="vir_OperatingLossCarryforwardsLimitationOnUsePercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_GrantAwardedAmount" xlink:label="vir_GrantAwardedAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ConvertiblePreferredStockWarrantLiabilityMember" xlink:label="vir_ConvertiblePreferredStockWarrantLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ConversionOfPreferredStockIntoCommonStockUponCompletionOfInitialPublicOffering" xlink:label="vir_ConversionOfPreferredStockIntoCommonStockUponCompletionOfInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate" xlink:label="vir_CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_CommonStockSharesIssuedFairMarketValue" xlink:label="vir_CommonStockSharesIssuedFairMarketValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_FollowOnOfferingMember" xlink:label="vir_FollowOnOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting" xlink:label="vir_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_EstimatedSharesIssuableUnderTheESPPMember" xlink:label="vir_EstimatedSharesIssuableUnderTheESPPMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_GrantAgreementAmendedExpirationDate" xlink:label="vir_GrantAgreementAmendedExpirationDate"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_CollaborationAndLicenseAgreements" xlink:label="vir_CollaborationAndLicenseAgreements"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales" xlink:label="vir_RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_BriiBiosciencesOffshoreLimitedMember" xlink:label="vir_BriiBiosciencesOffshoreLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ReconciliationOfEffectiveIncomeTaxRateTable" xlink:label="vir_ReconciliationOfEffectiveIncomeTaxRateTable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ScheduleOfGoodwillAndIntangibleAssetsTable" xlink:label="vir_ScheduleOfGoodwillAndIntangibleAssetsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xlink:label="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="vir_DeferredTaxLiabilitiesRightOfUseAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201613Member" xlink:label="us-gaap_AccountingStandardsUpdate201613Member"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_RemainingPaymentForAssetAcquisitionMilestoneAggregate" xlink:label="vir_RemainingPaymentForAssetAcquisitionMilestoneAggregate"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_AmendmentNumberOneMember" xlink:label="vir_AmendmentNumberOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_NumberOfAntibodiesToDevelop" xlink:label="vir_NumberOfAntibodiesToDevelop"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_CommonStockSharesPurchasedSharePrice" xlink:label="vir_CommonStockSharesPurchasedSharePrice"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MilestonePaymentDueToCompany" xlink:label="vir_MilestonePaymentDueToCompany"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MaximumAggregateMilestonePaymentForAchievementOfSpecifiedMilestones" xlink:label="vir_MaximumAggregateMilestonePaymentForAchievementOfSpecifiedMilestones"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ResearchAndDevelopmentExpenseUnderLicenseAgreement" xlink:label="vir_ResearchAndDevelopmentExpenseUnderLicenseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfMachineryAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_RegulatoryMilestonesAchieved" xlink:label="vir_RegulatoryMilestonesAchieved"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncome" xlink:label="us-gaap_DeferredIncome"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_EffectiveIncomeTaxRateReconciliationPermanentItemsPercent" xlink:label="vir_EffectiveIncomeTaxRateReconciliationPermanentItemsPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TemporaryEquityAdditionalSharesAuthorized" xlink:label="vir_TemporaryEquityAdditionalSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_DefinitiveCollaborationAgreementMember" xlink:label="vir_DefinitiveCollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_RockefellerUniversityMember" xlink:label="vir_RockefellerUniversityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_BillAndMelindaGatesFoundationMember" xlink:label="vir_BillAndMelindaGatesFoundationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:label="vir_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_BriiAgreementMember" xlink:label="vir_BriiAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentToProjectedBenefitObligationsNetOfTax" xlink:label="vir_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentToProjectedBenefitObligationsNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PrepaymentRawMaterials" xlink:label="vir_PrepaymentRawMaterials"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PayrollAndRelatedExpensesCurrent" xlink:label="vir_PayrollAndRelatedExpensesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ProceedsFromDisposalOfAnEquipment" xlink:label="vir_ProceedsFromDisposalOfAnEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ValueOfCommonStockSharesIssuedForMilestonePayment" xlink:label="vir_ValueOfCommonStockSharesIssuedForMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetRentableArea" xlink:label="us-gaap_NetRentableArea"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueAdjustment" xlink:label="us-gaap_AssetsFairValueAdjustment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_FirstSiRNAProductHBVMember" xlink:label="vir_FirstSiRNAProductHBVMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_WeightedAverageMember" xlink:label="srt_WeightedAverageMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TenantImprovementAllowanceAggregate" xlink:label="vir_TenantImprovementAllowanceAggregate"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_CashGrantAwarded" xlink:label="vir_CashGrantAwarded"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ProfitsAndLossesSharingPercentage" xlink:label="vir_ProfitsAndLossesSharingPercentage"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_InfluenzaAAndHBVResearchProgramsMember" xlink:label="vir_InfluenzaAAndHBVResearchProgramsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_StockIssuedDuringPeriodSharesIssuedForSettlementOfContingentConsideration" xlink:label="vir_StockIssuedDuringPeriodSharesIssuedForSettlementOfContingentConsideration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_CollaborationRevenueMember" xlink:label="vir_CollaborationRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_BriiBioParentMember" xlink:label="vir_BriiBioParentMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_AntibodyProgramMember" xlink:label="vir_AntibodyProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiability" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_UnrecognizedTaxBenefitsIfRecognizedWouldReduceEffectiveTaxRate" xlink:label="vir_UnrecognizedTaxBenefitsIfRecognizedWouldReduceEffectiveTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_AdjustmentsToProfitSharingAmounts" xlink:label="vir_AdjustmentsToProfitSharingAmounts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MaximumAggregateSalesMilestonePayments" xlink:label="vir_MaximumAggregateSalesMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_GrantAgreementsDisclosureTextBlock" xlink:label="vir_GrantAgreementsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_RockefellerAgreementMember" xlink:label="vir_RockefellerAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_OptionsTransactionPrice" xlink:label="vir_OptionsTransactionPrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_RemainingPaymentMadeForAssetAcquisitionMilestone" xlink:label="vir_RemainingPaymentMadeForAssetAcquisitionMilestone"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember" xlink:label="vir_TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_AnnualLicenseMaintenanceFees" xlink:label="vir_AnnualLicenseMaintenanceFees"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ScheduleOfGoodwillAndIntangibleAssetsLineItems" xlink:label="vir_ScheduleOfGoodwillAndIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_FairValueReclassificationOfContingentConsiderationToAccruedLiabilitiesUponAchievementOfMilestone" xlink:label="vir_FairValueReclassificationOfContingentConsiderationToAccruedLiabilitiesUponAchievementOfMilestone"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MaximumSalesMilestoneToBeReceived" xlink:label="vir_MaximumSalesMilestoneToBeReceived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:label="us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PercentageOfUpfrontPaymentReceivableAtExecutionDateOfAgreement" xlink:label="vir_PercentageOfUpfrontPaymentReceivableAtExecutionDateOfAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_RangeOfTieredRoyaltiesToPayToNetSalesOfProducts" xlink:label="vir_RangeOfTieredRoyaltiesToPayToNetSalesOfProducts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_RoyaltiesPaymentRangeOnNetSalesOfLicensedProduct" xlink:label="vir_RoyaltiesPaymentRangeOnNetSalesOfLicensedProduct"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_HcmvVaccinePlatformGrantMember" xlink:label="vir_HcmvVaccinePlatformGrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_DeferredTaxAssetsLeaseLiabilities" xlink:label="vir_DeferredTaxAssetsLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TwoThousandNineteenAndTwoThousandTwentyXencorAgreementMember" xlink:label="vir_TwoThousandNineteenAndTwoThousandTwentyXencorAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_CommonStockSharesPurchasedAggregatePurchasePrice" xlink:label="vir_CommonStockSharesPurchasedAggregatePurchasePrice"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_StockIssuedDuringPeriodSharesCollaborationAgreement" xlink:label="vir_StockIssuedDuringPeriodSharesCollaborationAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory" xlink:label="vir_MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ReleaseOfValuationAllowanceDeferredTaxInAmount" xlink:label="vir_ReleaseOfValuationAllowanceDeferredTaxInAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="country_US"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities" xlink:label="us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_InfluenzaAResearchProgramsMember" xlink:label="vir_InfluenzaAResearchProgramsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PercentageOfShareDevelopmentCosts" xlink:label="vir_PercentageOfShareDevelopmentCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MaximumNumberOfDevelopmentProgramGrantedFromCounterparty" xlink:label="vir_MaximumNumberOfDevelopmentProgramGrantedFromCounterparty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_StockIssuedDuringPeriodValueIssuedForSettlementOfContingentConsideration" xlink:label="vir_StockIssuedDuringPeriodValueIssuedForSettlementOfContingentConsideration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetTableTextBlock" xlink:label="vir_ScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_SaleLeasebackTransactionProceedsFromFinancingObligations" xlink:label="vir_SaleLeasebackTransactionProceedsFromFinancingObligations"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_SeriesAOneConvertiblePreferredStockMember" xlink:label="vir_SeriesAOneConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractBasedIntangibleAssetsMember" xlink:label="us-gaap_ContractBasedIntangibleAssetsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_UnderlyingSharesPremiumReceived" xlink:label="vir_UnderlyingSharesPremiumReceived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionAbstract" xlink:label="us-gaap_RevenueRecognitionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_RoyaltiesBasedOnNetSalesOfLicensedProducts" xlink:label="vir_RoyaltiesBasedOnNetSalesOfLicensedProducts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_StockIssuedDuringPeriodValueCollaborationAgreement" xlink:label="vir_StockIssuedDuringPeriodValueCollaborationAgreement"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_Vir2248Member" xlink:label="vir_Vir2248Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_Vir2218Member" xlink:label="vir_Vir2218Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_CollaborationAgreementTransactionPriceUpfrontFee" xlink:label="vir_CollaborationAgreementTransactionPriceUpfrontFee"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_WrittenNoticePeriodToTerminateLicensedProgramForPaymentBreach" xlink:label="vir_WrittenNoticePeriodToTerminateLicensedProgramForPaymentBreach"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_SalesAgreementMember" xlink:label="vir_SalesAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PercentageOfEstimatedBatchProductionFees" xlink:label="vir_PercentageOfEstimatedBatchProductionFees"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Investments" xlink:label="us-gaap_Investments"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ExecutiveOfficerAndDirectorMember" xlink:label="vir_ExecutiveOfficerAndDirectorMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MaximumSharesToBeIssued" xlink:label="vir_MaximumSharesToBeIssued"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_StockIssuedDuringPeriodSharesLicenseAgreement" xlink:label="vir_StockIssuedDuringPeriodSharesLicenseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_FirstAndSecondClosingsMember" xlink:label="vir_FirstAndSecondClosingsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MilestonePayable" xlink:label="vir_MilestonePayable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_VaccinalAntibodyGrantMember" xlink:label="vir_VaccinalAntibodyGrantMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_FundsReceivedInAdvance" xlink:label="vir_FundsReceivedInAdvance"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_WrittenNoticePeriodToTerminateLicensedProgramForUncuredMaterialBreach" xlink:label="vir_WrittenNoticePeriodToTerminateLicensedProgramForUncuredMaterialBreach"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_AccruedLiabilitiesAndOtherLiabilitiesMember" xlink:label="vir_AccruedLiabilitiesAndOtherLiabilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CN" xlink:label="country_CN"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_HBVProgramMember" xlink:label="vir_HBVProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_FinancialAssetsGrossUnrealizedHoldingGains" xlink:label="vir_FinancialAssetsGrossUnrealizedHoldingGains"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ProfitSharingAmountPreviouslyConstrainedReleased" xlink:label="vir_ProfitSharingAmountPreviouslyConstrainedReleased"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_AdvancedProceedsAppliedToConvertiblePreferredStockIssuance" xlink:label="vir_AdvancedProceedsAppliedToConvertiblePreferredStockIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_EachInfectiousDiseaseSiRNAMember" xlink:label="vir_EachInfectiousDiseaseSiRNAMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PercentageOfDevelopmentCosts" xlink:label="vir_PercentageOfDevelopmentCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_FiniteLivedIntangibleAssetsReclassifiedFromIndefiniteLived" xlink:label="vir_FiniteLivedIntangibleAssetsReclassifiedFromIndefiniteLived"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_SummaryOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock" xlink:label="vir_SummaryOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_FiniteLivedIntangibleAssetsAccumulatedImpairment" xlink:label="vir_FiniteLivedIntangibleAssetsAccumulatedImpairment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="us-gaap_RetirementPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember" xlink:label="vir_TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MaximumTermOfOfferingPeriodSpecifiedUnderPlan" xlink:label="vir_MaximumTermOfOfferingPeriodSpecifiedUnderPlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents" xlink:label="vir_BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ResearchAndDevelopmentExpensesCurrent" xlink:label="vir_ResearchAndDevelopmentExpensesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_FormerBusinessCombinationContingentConsiderationLiability" xlink:label="vir_FormerBusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ConvertiblePreferredStockWarrantLiabilityAbstract" xlink:label="vir_ConvertiblePreferredStockWarrantLiabilityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:label="us-gaap_LesseeFinanceLeaseTermOfContract1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MilestonePaymentReceived" xlink:label="vir_MilestonePaymentReceived"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MinimumCommonStockPriceForMilestonePaymentsConsideration" xlink:label="vir_MinimumCommonStockPriceForMilestonePaymentsConsideration"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_FirstSiRNAProductMember" xlink:label="vir_FirstSiRNAProductMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_CommonStockIssuanceCost" xlink:label="vir_CommonStockIssuanceCost"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ObligationToPayCapacityReservation" xlink:label="vir_ObligationToPayCapacityReservation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PreliminaryCollaborationAgreementMember" xlink:label="vir_PreliminaryCollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_RestrictedStockPurchaseAgreementMember" xlink:label="vir_RestrictedStockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MaximumSalesMilestonePayment" xlink:label="vir_MaximumSalesMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashEquivalents" xlink:label="us-gaap_RestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_NetProceedsFromIssuanceSecondaryPublicOffering" xlink:label="vir_NetProceedsFromIssuanceSecondaryPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MaximumNumberOfDevelopmentProgramGrantedToCounterparty" xlink:label="vir_MaximumNumberOfDevelopmentProgramGrantedToCounterparty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivable" xlink:label="us-gaap_InterestReceivable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_CollaborationAgreementMember" xlink:label="vir_CollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TwoThousandSixteenEquityIncentivePlanMember" xlink:label="vir_TwoThousandSixteenEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PaymentMadeForBusinessCombinationMilestone" xlink:label="vir_PaymentMadeForBusinessCombinationMilestone"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_OperatingLeaseAbstract" xlink:label="vir_OperatingLeaseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct" xlink:label="vir_MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_SecondPlanMember" xlink:label="vir_SecondPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_GrantsAgreementAmendedDate" xlink:label="vir_GrantsAgreementAmendedDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_InfluenzaAAndInfluenzaBMember" xlink:label="vir_InfluenzaAAndInfluenzaBMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital" xlink:label="vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_StockIssuedDuringPeriodValueLicenseAgreement" xlink:label="vir_StockIssuedDuringPeriodValueLicenseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_HumabsBiomedSAMember" xlink:label="vir_HumabsBiomedSAMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_RemainingPaymentMadeForBusinessCombinationMilestone" xlink:label="vir_RemainingPaymentMadeForBusinessCombinationMilestone"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MaximumAggregateSalesMilestonePayment" xlink:label="vir_MaximumAggregateSalesMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_FiniteLivedIntangibleAssetsAmortizationExpense" xlink:label="vir_FiniteLivedIntangibleAssetsAmortizationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach" xlink:label="vir_WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PreDefinedRegulatoryMilestoneConsiderationToBeReceived" xlink:label="vir_PreDefinedRegulatoryMilestoneConsiderationToBeReceived"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_CommercialMilestonesMember" xlink:label="vir_CommercialMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_FinancialAssetsGrossUnrealizedHoldingLosses" xlink:label="vir_FinancialAssetsGrossUnrealizedHoldingLosses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" xlink:label="us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_UpfrontFeePaid" xlink:label="vir_UpfrontFeePaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_XencorAgreementsMember" xlink:label="vir_XencorAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PercentageOfCommissionRateFromSaleOfShares" xlink:label="vir_PercentageOfCommissionRateFromSaleOfShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_WrittenNoticePeriodToTerminateLicensedProgramForFailureToMakePayment" xlink:label="vir_WrittenNoticePeriodToTerminateLicensedProgramForFailureToMakePayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MinimumCommonStockConversionPriceForMilestonePaymentsConsideration" xlink:label="vir_MinimumCommonStockConversionPriceForMilestonePaymentsConsideration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TwoThousandTwentyStockPurchaseAgreementMember" xlink:label="vir_TwoThousandTwentyStockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_OperatingLossCarryforwardsExpirationBeginningYear" xlink:label="vir_OperatingLossCarryforwardsExpirationBeginningYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalariesWagesAndOfficersCompensationAbstract" xlink:label="us-gaap_SalariesWagesAndOfficersCompensationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ClosingStockPrice" xlink:label="vir_ClosingStockPrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmbeddedDerivativeLiabilityMeasurementInput" xlink:label="us-gaap_EmbeddedDerivativeLiabilityMeasurementInput"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_CollaborationAgreementTerminationDescription" xlink:label="vir_CollaborationAgreementTerminationDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_FairMarketValueOfCommonStockIssued" xlink:label="vir_FairMarketValueOfCommonStockIssued"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_RegulatoryMilestonePaymentOnLicensedProductLowEndOfTheRange" xlink:label="vir_RegulatoryMilestonePaymentOnLicensedProductLowEndOfTheRange"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_RegulatoryMilestonePaymentOnLicensedProductHighEndOfRange" xlink:label="vir_RegulatoryMilestonePaymentOnLicensedProductHighEndOfRange"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_BiologicalMaterialsMember" xlink:label="vir_BiologicalMaterialsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ReclassifiedDeferredRevenue" xlink:label="vir_ReclassifiedDeferredRevenue"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_OptionExerciseFeeHighEndOfTheRange" xlink:label="vir_OptionExerciseFeeHighEndOfTheRange"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PercentageOfUpfrontPaymentReceivableAtEffectiveDateOfAgreement" xlink:label="vir_PercentageOfUpfrontPaymentReceivableAtEffectiveDateOfAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:label="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TwoThousandTwentyXencorAgreementMember" xlink:label="vir_TwoThousandTwentyXencorAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_AntibodyLicenseTransactionPrice" xlink:label="vir_AntibodyLicenseTransactionPrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ValueOfSharesTransferredToCollaborator" xlink:label="vir_ValueOfSharesTransferredToCollaborator"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_CollaborationTypeAndPrograms" xlink:label="vir_CollaborationTypeAndPrograms"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_HepatitisBVirusProductMember" xlink:label="vir_HepatitisBVirusProductMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201814Member" xlink:label="us-gaap_AccountingStandardsUpdate201814Member"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_IncreaseDecreaseInResearchAndDevelopmentExpense" xlink:label="vir_IncreaseDecreaseInResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_SamsungBiologicsCompanyLimitedMember" xlink:label="vir_SamsungBiologicsCompanyLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TaxCreditCarryforwardsExpirationBeginningYear" xlink:label="vir_TaxCreditCarryforwardsExpirationBeginningYear"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_NonCashCommonStockIssuedForContingentConsideration" xlink:label="vir_NonCashCommonStockIssuedForContingentConsideration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MilestonePaymentsRelatedTermsDescription" xlink:label="vir_MilestonePaymentsRelatedTermsDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_RegulatoryMilestoneAchieved" xlink:label="vir_RegulatoryMilestoneAchieved"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_DeterminedTransactionPrice" xlink:label="vir_DeterminedTransactionPrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TotalcollaborationRevenue" xlink:label="vir_TotalcollaborationRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_AssetAcquisitionMilestonePaymentAggregate" xlink:label="vir_AssetAcquisitionMilestonePaymentAggregate"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_CommonStockSharesPurchased" xlink:label="vir_CommonStockSharesPurchased"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SwissFederalTaxAdministrationFTAMember" xlink:label="us-gaap_SwissFederalTaxAdministrationFTAMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_RangeOfRoyaltyPaymentToBeReceived" xlink:label="vir_RangeOfRoyaltyPaymentToBeReceived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_CollaborationAgreementNumberOfUnitsOfAccount" xlink:label="vir_CollaborationAgreementNumberOfUnitsOfAccount"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ConvertiblePreferredStockIssuanceCost" xlink:label="vir_ConvertiblePreferredStockIssuanceCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ValueStockIssuedGrantAgreement" xlink:label="vir_ValueStockIssuedGrantAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_IssuanceOfCommonStockInConnectionWithAGrantAgreementShares" xlink:label="vir_IssuanceOfCommonStockInConnectionWithAGrantAgreementShares"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TwoThousandNineteenEmployeeStockPurchasePlanMember" xlink:label="vir_TwoThousandNineteenEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_NumberOfClassOfStock" xlink:label="vir_NumberOfClassOfStock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MaximumAmountGrantAggregate" xlink:label="vir_MaximumAmountGrantAggregate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_LicenseAgreementUpfrontPayment" xlink:label="vir_LicenseAgreementUpfrontPayment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_RestrictedStockLiabilityRecognizedForPortionOfPromissoryNoteRepayment" xlink:label="vir_RestrictedStockLiabilityRecognizedForPortionOfPromissoryNoteRepayment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_StockIssuedDuringPeriodSharesAchievementOfMilestone" xlink:label="vir_StockIssuedDuringPeriodSharesAchievementOfMilestone"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_RepaymentOfOutstandingPromissoryNotesAndAccruedInterestReceived" xlink:label="vir_RepaymentOfOutstandingPromissoryNotesAndAccruedInterestReceived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="us-gaap_DevelopedTechnologyRightsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_InfectiousDiseaseProductMember" xlink:label="vir_InfectiousDiseaseProductMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ProfitSharingAmount" xlink:label="vir_ProfitSharingAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ProceedsFromIssuanceOfCommonStockInConnectionWithCollaboration" xlink:label="vir_ProceedsFromIssuanceOfCommonStockInConnectionWithCollaboration"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_RoyaltiesPaymentExpirationPeriod" xlink:label="vir_RoyaltiesPaymentExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MaximumMilestonePaymentForAchievementOfSpecifiedMilestones" xlink:label="vir_MaximumMilestonePaymentForAchievementOfSpecifiedMilestones"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="us-gaap_RevenueFromRelatedParties"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TwoThousandAndTwentyOneGSKCollaborationMember" xlink:label="vir_TwoThousandAndTwentyOneGSKCollaborationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BankTimeDepositsMember" xlink:label="us-gaap_BankTimeDepositsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_EsppDiscountedPurchasePricePercentage" xlink:label="vir_EsppDiscountedPurchasePricePercentage"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_DevelopedTechnologyMember" xlink:label="vir_DevelopedTechnologyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ContractRevenueMember" xlink:label="vir_ContractRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock" xlink:label="vir_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember" xlink:label="vir_TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ContingentConsiderationLiabilityMember" xlink:label="vir_ContingentConsiderationLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PercentageOfDevelopmentCostsResponsibleByGsk" xlink:label="vir_PercentageOfDevelopmentCostsResponsibleByGsk"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_BusinessAgreementGrantAmount" xlink:label="vir_BusinessAgreementGrantAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_IncomeTaxesTable" xlink:label="vir_IncomeTaxesTable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PresentValueOfOperatingLeaseLiabilities" xlink:label="vir_PresentValueOfOperatingLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MeasurementInputProbabilityRateMember" xlink:label="vir_MeasurementInputProbabilityRateMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PaymentToCollaboratorResultingFromProgramOptionExercise" xlink:label="vir_PaymentToCollaboratorResultingFromProgramOptionExercise"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TwoThousandTwentyOneStockPurchaseAgreementMember" xlink:label="vir_TwoThousandTwentyOneStockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanNameAxis" xlink:label="us-gaap_RetirementPlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ThirdClosingMember" xlink:label="vir_ThirdClosingMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_WrittenNoticePeriodToTerminateAgreementByCounterparty" xlink:label="vir_WrittenNoticePeriodToTerminateAgreementByCounterparty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="us-gaap_GainLossOnTerminationOfLease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MedImmuneAgreementMember" xlink:label="vir_MedImmuneAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PaymentMadeForAssetAcquisitionMilestone" xlink:label="vir_PaymentMadeForAssetAcquisitionMilestone"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_EstimatedSharesEmployeeStockPurchasePlans" xlink:label="vir_EstimatedSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_RangeOfRoyaltyPaymentToBePaid" xlink:label="vir_RangeOfRoyaltyPaymentToBePaid"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_XencorIncorporationMember" xlink:label="vir_XencorIncorporationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember" xlink:label="vir_WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ConvertiblePreferredStockWarrantLiabilityTextBlock" xlink:label="vir_ConvertiblePreferredStockWarrantLiabilityTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_OptionExerciseFeeReceived" xlink:label="vir_OptionExerciseFeeReceived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:label="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201818Member" xlink:label="us-gaap_AccountingStandardsUpdate201818Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TwoThousandSeventeenGrantMember" xlink:label="vir_TwoThousandSeventeenGrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherExpenseMember" xlink:label="us-gaap_OtherExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_BusinessAgreementEquityInvestmentCommitment" xlink:label="vir_BusinessAgreementEquityInvestmentCommitment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201704Member" xlink:label="us-gaap_AccountingStandardsUpdate201704Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_OperatingAndFinanceRentExpense" xlink:label="vir_OperatingAndFinanceRentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AustralianTaxationOfficeMember" xlink:label="us-gaap_AustralianTaxationOfficeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_PercentageOfOrdinaryShareEqualToOutstandingShare" xlink:label="vir_PercentageOfOrdinaryShareEqualToOutstandingShare"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ProfitSharingAmountConstrained" xlink:label="vir_ProfitSharingAmountConstrained"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_MaximumAmountGrantBasePeriod" xlink:label="vir_MaximumAmountGrantBasePeriod"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_FinancialAssetsAmortizedCostBasis" xlink:label="vir_FinancialAssetsAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_GrantAgreementEffectiveEndDate" xlink:label="vir_GrantAgreementEffectiveEndDate"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_ConcentrationOfCreditRiskCreditLossAndOtherRisksAndUncertaintiesPolicyTextBlock" xlink:label="vir_ConcentrationOfCreditRiskCreditLossAndOtherRisksAndUncertaintiesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_SpecifiedSalesDevelopmentMilestonesPayment" xlink:label="vir_SpecifiedSalesDevelopmentMilestonesPayment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20221231.xsd#vir_TwoThousandAndTwentyOneGSKAgreementMember" xlink:label="vir_TwoThousandAndTwentyOneGSKAgreementMember"/>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_IncrementalCommonSharesAttributabletoShareBasedPaymentArrangementsEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares to purchase under Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_IncrementalCommonSharesAttributabletoShareBasedPaymentArrangementsEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incremental Common Shares AttributableTo Share Based Payment Arrangements Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_IncrementalCommonSharesAttributabletoShareBasedPaymentArrangementsEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Incremental common shares attributable to share based payment arrangements employee stock purchase plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_LeaseArrangementContractualExpirationEndingYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease arrangement, contractual expiration period, ending year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_LeaseArrangementContractualExpirationEndingYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Arrangement Contractual Expiration Ending Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_LeaseArrangementContractualExpirationEndingYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease arrangement, contractual expiration ending year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumAggregateDevelopmentAndRegulatoryMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum aggregate development and regulatory milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumAggregateDevelopmentAndRegulatoryMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Aggregate Development And Regulatory Milestone Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumAggregateDevelopmentAndRegulatoryMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum aggregate development and regulatory milestone payments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation Between Expected Income Tax Provision at Federal Statutory Rate and Reported Income Tax Benefit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PremiumReceivedOnSalePriceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Premium received on sale price of common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PremiumReceivedOnSalePriceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Premium Received On Sale Price Of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PremiumReceivedOnSalePriceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Premium received on sale price of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment of contingent consideration in excess of acquisition date fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Payment Of Contingent Consideration In Excess Of Acquisition Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in payment of contingent consideration in excess of acquisition date fair value.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_UpfrontPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payment received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_UpfrontPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Payment Received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_UpfrontPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront Payment Received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Unrealized Gains on Trading Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized gain on investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Authority [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Value of shares agreed to purchase</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from IPO</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenges_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Notice period to terminate licensed program if under challenges</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenges_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Written notice period to terminate licensed program if the party challenges the validity or enforceability of the patent licensed.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GrantAgreementExpirationDateBeforeAmendment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Grant agreement expiration date before amendment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GrantAgreementExpirationDateBeforeAmendment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grant Agreement Expiration Date Before Amendment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GrantAgreementExpirationDateBeforeAmendment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant agreement expiration date before amendment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Expected dividend yield</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandNineteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Equity Incentive Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandNineteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen Equity Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandNineteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand nineteen equity incentive plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RegulatoryMilestonePaymentToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Regulatory milestone payment to be received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RegulatoryMilestonePaymentToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Regulatory milestone payment to be received by the company upon exercised of the development programs by counterparty.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RegulatoryMilestonePaymentToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Regulatory Milestone Payment to be Received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumSalesMilestonePaymentsToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum amount of payment to be received by the company upon achievement of sales milestone by the counterparty</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumSalesMilestonePaymentsToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum Sales Milestone Payment To Be Received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumSalesMilestonePaymentsToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Sales Milestone Payments To Be Received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Value of common stock shares Issued for milestone payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment purchases included in accounts payable and accrued liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares authorized to issue under purchase rights granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Debt Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AlnylamPharmaceuticalsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Alnylam Pharmaceuticals Inc</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AlnylamPharmaceuticalsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Alnylam Pharmaceuticals Inc [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AlnylamPharmaceuticalsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Alnylam Pharmaceuticals, Inc.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less accumulated amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DeferredTaxLiabilitiesInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">IPR&amp;D</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DeferredTaxLiabilitiesInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities In Process Research And Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DeferredTaxLiabilitiesInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities in process research and development.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Goodwill, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Goodwill, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Goodwill, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Goodwill</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating ROU assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Acquired Finite Lived Intangible Asset By Major Class [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GlaxoGroupLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">GGL</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GlaxoGroupLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Glaxo Group Limited [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GlaxoGroupLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Glaxo Group Limited.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Finite-Lived Intangible Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MeasurementInputExpectedVolatilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Measurement input expected volatility.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MeasurementInputExpectedVolatilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Expected Volatility [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MeasurementInputExpectedVolatilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Input Expected Volatility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CommonStockSharesIssuedForMilestonePaymentShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock shares Issued for milestone payment| shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CommonStockSharesIssuedForMilestonePaymentShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Total number of common shares issued for milestone payment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CommonStockSharesIssuedForMilestonePaymentShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common stock shares Issued for milestone payment| shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingently issuable shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_NoncashLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncash lease expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_NoncashLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Lease Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_NoncashLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Noncash lease expense.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: imputed interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Income (Loss) Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OptionExerciseFeeConsiderationToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Option exercise fee consideration to be received.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OptionExerciseFeeConsiderationToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option Exercise Fee Consideration To Be Received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OptionExerciseFeeConsiderationToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option exercise fee to be received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAgreementRelatedCostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expenses incurred under agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAgreementRelatedCostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement Related Costs And Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAgreementRelatedCostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Costs and expenses for the period incurred under the collaboration agreements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits, if recognized, would reduce effective tax rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumAggregateCommercialSalesMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum aggregate commercial sales milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumAggregateCommercialSalesMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Aggregate Commercial Sales Milestone Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumAggregateCommercialSalesMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum aggregate commercial sales milestone payments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cash paid for amounts included in the measurement of operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share issued under plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock under employee stock purchase plan (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Operating Segments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock for cashless exercise of warrant (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Cashless Exercise Of Warrant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares cashless exercise of warrant.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Firm ID</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Grant Date Fair Value, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Grant Date Fair Value, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Laboratory Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Laboratory equipment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value, Vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SeriesBConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SeriesBConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SeriesBConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B convertible preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FinancialAssetsFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Assets, Aggregate Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FinancialAssetsFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Assets Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FinancialAssetsFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Financial assets fair value.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Deferred Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of years conduct certain research and development activities under mutually agreed development plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Years Conduct Certain Research And Development Activities Under Mutually Agreed Development Plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of years conduct certain research and development activities under mutually agreed development plans.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquisitions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AlnylamAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Alnylam agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AlnylamAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Alnylam Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AlnylamAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Alnylam Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Business Combination, Contingent Consideration, Liability, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Estimated fair value of contingent consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Contingent Consideration, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SeriesATwoConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A-2 Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SeriesATwoConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A Two Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SeriesATwoConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A -2 convertible preferred stock member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PaymentCommitmentManufacturingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment committed for manufacturing capacity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PaymentCommitmentManufacturingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment Commitment Manufacturing Capacity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PaymentCommitmentManufacturingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment Commitment Manufacturing Capacity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenge_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Notice period to terminate licensed program if under challenge</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenge_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Written notice period to terminate licensed program if the party challenges the validity or enforceability of the patent licensed.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-Average Remaining Useful Life (Years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-lived intangible asset, estimated useful life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefinitelivedIntangibleAssetsAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Indefinite-lived intangible assets IPR&amp;D</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefinitelivedIntangibleAssetsAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Indefinite-Lived Intangible Assets Acquired</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AssetAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset acquisition number of milestones achieved related to contingent consideration.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AssetAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition Number Of Milestones Achieved Related To Contingent Consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AssetAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of milestones achieved</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Options Issued and Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining lease term (in years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MilestonePaymentsPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MilestonePaymentsPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments paid.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MilestonePaymentsPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TomegaVaxIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">TomegaVax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TomegaVaxIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tomega Vax Inc [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TomegaVaxIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">TomegaVax, Inc.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputDiscountRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Input, Discount Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputDiscountRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Discount Rate [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price,Vested and exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split, description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity, Reverse Stock Split</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock under the employee stock purchase plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_HumanImmunodeficiencyVirusGrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Human Immunodeficiency Virus ("HIV") Grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_HumanImmunodeficiencyVirusGrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Human Immunodeficiency Virus Grant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_HumanImmunodeficiencyVirusGrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Human immunodeficiency virus grant.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ClinicalDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ClinicalDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical Development [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ClinicalDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Clinical Development [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Revenue, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Financing lease obligation, current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of finance lease obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LaborAndRelatedExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in estimated constraint on profit-sharing amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LaborAndRelatedExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Labor and Related Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandAndTwentyGskAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand And Twenty GSK Agreement Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandAndTwentyGskAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty GSK Agreement Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandAndTwentyGskAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 GSK Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquisitions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combinations Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under employee stock purchase plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Loss Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DevelopmentAndManufacturingCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development and manufacturing collaboration agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DevelopmentAndManufacturingCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development And Manufacturing Collaboration Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DevelopmentAndManufacturingCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development and Manufacturing Collaboration Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition, Acquiree</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term lease cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DevelopmentProgramsExercisedByVirMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development Programs Exercised by Vir</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DevelopmentProgramsExercisedByVirMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development Programs Exercised by Vir [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DevelopmentProgramsExercisedByVirMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development Programs Exercised by Vir [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization Consolidation And Presentation Of Financial Statements [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization consolidation and presentation of financial statements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of employee payroll deduction on earnings</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Percentage of employee payroll deduction on earnings, maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Liabilities, Net, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Net deferred tax liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_NationalInstitutesOfHealthMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">National Institutes of Health</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_NationalInstitutesOfHealthMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">National Institutes Of Health [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_NationalInstitutesOfHealthMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">National institutes of health.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SaleOfStockConsiderationAggregateOfferingPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Consideration Aggregate Offering Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SaleOfStockConsiderationAggregateOfferingPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate offering price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SaleOfStockConsiderationAggregateOfferingPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the aggregate offering price for which the entity may sell shares of its common stock under the sales agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodWarrantExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The number of new shares issued in the exercise of warrant during the period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodWarrantExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Warrant Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodWarrantExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock shares issued for conversion of warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average incremental borrowing rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_OR_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Oregon</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="stpr_OR_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OREGON</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total cash, cash equivalents and restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash and cash equivalents at beginning of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash and cash equivalents at end of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total cash, cash equivalents and restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Compensation Related Costs, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquired Intangible Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">GSK</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Glaxo Smith Kline Intellectual Property Development Limited And Glaxo Smith Kline Biologicals S A [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">GlaxoSmithKline Intellectual Property Development Limited and GlaxoSmithKline Biologicals SA.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase price as percentage of lower of fair market value on purchase date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Equity Securities, FV-NI</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase Decrease In Equity Securities Fv Ni</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and twenty one preliminary collaboration agreement and stock purchase agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty One Preliminary Collaboration Agreement And Stock Purchase Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Preliminary Collaboration Agreement and Stock Purchase Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ProceedsFromIssuanceSecondaryPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds after deducting underwriting discounts, commissions and offering expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ProceedsFromIssuanceSecondaryPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Secondary Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ProceedsFromIssuanceSecondaryPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The cash inflow associated with the amount received from entity's follow on offering of stock to the public.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_UpfrontPaymentReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront Payment Received.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_UpfrontPaymentReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payment received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_UpfrontPaymentReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Payment Receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GrantAgreementExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant agreement expiration date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GrantAgreementExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grant Agreement Expiration Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GrantAgreementExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The date the grant agreement expires.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares outstanding, basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GlaxoSmithKlineTradingServiceLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">GSKTSL</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GlaxoSmithKlineTradingServiceLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Glaxo Smith Kline Trading Service Limited [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GlaxoSmithKlineTradingServiceLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Glaxo SmithKline Trading Service Limited.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BillMelindaGatesFoundationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Bill &amp; Melinda Gates Foundation.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BillMelindaGatesFoundationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Bill &amp; Melinda Gates Foundation [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BillMelindaGatesFoundationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Bill &amp; Melinda Gates Foundation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options,Forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassification of derivative liability to additional paid-in capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reclassification Of Derivative Liability To Additional Paid In Capital Upon Achievement Of Development Milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reclassification&#8203; of derivative liability&#8203; to additional paid-&#8203;in capital upon achievement of development milestone.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OperatingLeaseIncentiveOverLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating Lease Incentive Over Lease Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OperatingLeaseIncentiveOverLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Incentive Over Lease Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OperatingLeaseIncentiveOverLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">TOTAL LIABILITIES</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain Contingencies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Assets, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Stock Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted Shares Subject to Future Vesting</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RangeOfRoyaltyPaymentsToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Regulatory Milestone Payment To Be Received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RangeOfRoyaltyPaymentsToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Regulatory Milestone Payment To Be Received.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RangeOfRoyaltyPaymentsToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Range of Royalty Payments to be Received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction in Progress</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Construction in Progress [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PaymentCommitmentRawMaterials_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre pay for raw materials</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PaymentCommitmentRawMaterials_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment Commitment Raw Materials</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PaymentCommitmentRawMaterials_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment Commitment Raw Materials</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity compensations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value of options granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, operating lease, renewal term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Renewal Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueNotFromContractWithCustomer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenues not from contract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueNotFromContractWithCustomer_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Revenue from grants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueNotFromContractWithCustomer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Not from Contract with Customer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OptionExerciseFeeLowEndOfTheRange_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option exercise fee, low end of the range</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OptionExerciseFeeLowEndOfTheRange_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option exercise fee, low end of the range</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OptionExerciseFeeLowEndOfTheRange_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the low end of the range of option exercise fee upon exercise of a program.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Current Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_InitialPublicOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial public offering costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_InitialPublicOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Initial Public Offering Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_InitialPublicOfferingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial public offering costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ClinicalDevelopmentAndManufacturingOrganizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical Development And Manufacturing Organization [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ClinicalDevelopmentAndManufacturingOrganizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">CLINICAL DEVELOPMENT AND MANUFACTURING ORGANIZATION [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ClinicalDevelopmentAndManufacturingOrganizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">CLINICAL DEVELOPMENT AND MANUFACTURING ORGANIZATION [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ChangesInEstimatedConstraintOnProfitSharingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Changes in estimated constraint on profit-sharing amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ChangesInEstimatedConstraintOnProfitSharingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Changes in estimated constraint on profit-sharing amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">TOTAL ASSETS</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2016-02</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FirstPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FirstPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">First Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FirstPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">First plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of convertible preferred stock converted to shares of common stock (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock into common stock (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined contribution plan, employee contribution</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net income (loss) per share, diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetirementPlanTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Retirement Plan Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetirementPlanTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Plan Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticeToTerminateLicensedProgramIfNotExercise_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written notice to terminate licensed program if not exercise</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticeToTerminateLicensedProgramIfNotExercise_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Written notice to terminate licensed program if not exercise.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticeToTerminateLicensedProgramIfNotExercise_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written notice to terminate licensed program if not exercise</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_Vir3434Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">VIR-3434</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_Vir3434Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">VIR-3434 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_Vir3434Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">VIR-3434 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ProceedsFromIssuanceOfCommonStockInConnectionWithAGrantAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock in connection with a grant agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ProceedsFromIssuanceOfCommonStockInConnectionWithAGrantAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock in connection with a grant agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ProceedsFromIssuanceOfCommonStockInConnectionWithAGrantAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance of Common Stock in Connection With a Grant Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ProceedsFromIssuanceOfCommonStockInConnectionWithAGrantAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of common stock in connection with a grant agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Potentially Dilutive Securities Not Included in the Diluted Per Share Calculations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at December 31, 2020</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at December 31, 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticePeriodForTerminationOfLicensedProgram_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written notice period for termination of licensed program</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticePeriodForTerminationOfLicensedProgram_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Notice Period For Termination Of Licensed Program</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticePeriodForTerminationOfLicensedProgram_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Written notice period for termination of licensed program.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer, Including Assessed Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Support to Nonconsolidated Legal Entity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Support to Nonconsolidated Legal Entity [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SpecifiedResearchAndDevelopmentExpensesMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Specified research and development expenses milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SpecifiedResearchAndDevelopmentExpensesMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Specified Research And Development Expenses Milestone Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SpecifiedResearchAndDevelopmentExpensesMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development expenses related to certain development milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Warrant Or Right [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Current income tax expense (benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Receivable from collaboration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PensionPlansDefinedBenefitMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pension Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PensionPlansDefinedBenefitMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pension Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Valuation Allowance, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of December 31, 2022 and 2021, respectively; no shares issued and outstanding as of December 31, 2022 and 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Value, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Value, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Value, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ProfitShareAmountConstraint_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net profit-sharing constrained</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ProfitShareAmountConstraint_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Profit share amount constraint</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ProfitShareAmountConstraint_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Profit share amount constraint</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options to purchase common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Incremental Common Shares Attributable to Share-based Payment Arrangements, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: net tenant improvement allowance yet to be received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Net Tenant Improvement Allowance Yet To Be Received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease liability net tenant improvement allowance yet to be received.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_LeaseArrangementContractualExpirationBeginningYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease arrangement, contractual expiration period, beginning year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_LeaseArrangementContractualExpirationBeginningYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Arrangement Contractual Expiration Beginning Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_LeaseArrangementContractualExpirationBeginningYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease arrangement, contractual expiration beginning year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Present value of operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativesEmbeddedDerivatives_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Embedded Derivatives</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativesEmbeddedDerivatives_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivatives, Embedded Derivatives [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TemporaryEquityTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TemporaryEquityTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TemporaryEquityTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of key terms, rights and preferences of convertible preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WuXiBiologicsLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">WuXi Biologics</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WuXiBiologicsLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Wu Xi Biologics Limited [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WuXiBiologicsLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">WuXi Biologics Limited.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of specified clinical milestones achieved</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition Number Of Specified Clinical Milestones Achieved</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business acquisition number of specified clinical milestones achieved.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentOwnedAtFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Investment Owned, at Fair Value, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentOwnedAtFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Investment Owned, at Fair Value, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentOwnedAtFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Owned, at Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentOwnedAtFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Owned At Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WuxiBiologicsLetterAgreementAssignmentAndMasterServiceAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Wuxi Biologics Letter Agreement Assignment And Master Service Agreements Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WuxiBiologicsLetterAgreementAssignmentAndMasterServiceAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Wuxi Biologics Letter Agreement Assignment And master Service Agreements Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WuxiBiologicsLetterAgreementAssignmentAndMasterServiceAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Wuxi Biologics Letter Agreement Assignment And master Service Agreements Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of convertible preferred stock, net of issuance cost (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Indefinite-lived impairment of intangible assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Impairment of indefinite-lived intangible assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Embedded derivative liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Embedded Derivative, Fair Value of Embedded Derivative Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Estimated fair value of embedded derivative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WarrantsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants to Purchase Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WarrantsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants To Purchase Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WarrantsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants to purchase common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FairValueReclassificationOfDerivativeLiabilityToAccruedLiabilitiesUponAchievementOfDevelopmentMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value reclassification of derivative liability to accrued liabilities upon achievement of development milestone.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FairValueReclassificationOfDerivativeLiabilityToAccruedLiabilitiesUponAchievementOfDevelopmentMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Reclassification Of Derivative Liability To Accrued Liabilities Upon Achievement Of Development Milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FairValueReclassificationOfDerivativeLiabilityToAccruedLiabilitiesUponAchievementOfDevelopmentMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassification of derivative liability to accrued liabilities upon achievement of development milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue Arrangement Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Sale, Maturity and Collection of Investments, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturities of investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale, Maturity and Collection of Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_VaccineProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vaccine Program</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_VaccineProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vaccine Program [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_VaccineProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Vaccine Program.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant to purchase of convertible preferred stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Benefits [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined Contribution Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Warrant Or Right [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AnotherProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Another Product</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AnotherProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Another Product [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AnotherProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Another product.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Option price as a percentage of estimated fair value on the date of grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase price as percentage of lower of fair market value on offering date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DevelopmentProgramsExercisedByBriiMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development Programs Exercised by Brii</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DevelopmentProgramsExercisedByBriiMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development Programs Exercised by Brii [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DevelopmentProgramsExercisedByBriiMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development Programs Exercised by Brii [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancingReceivableAccruedInterestWriteoff_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Write off of accrued interest receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancingReceivableAccruedInterestWriteoff_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financing Receivable, Accrued Interest, Writeoff</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumNumberOfProductsCoveredAgainstMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum number of products covered against milestone payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumNumberOfProductsCoveredAgainstMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum number of products covered against milestone payment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumNumberOfProductsCoveredAgainstMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Number of Products Covered Against Milestone Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ReconciliationOfEffectiveIncomeTaxRateLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation Of Effective Income Tax Rate [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ReconciliationOfEffectiveIncomeTaxRateLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reconciliation Of Effective Income Tax Rate [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ReconciliationOfEffectiveIncomeTaxRateLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reconciliation of effective income tax rate.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201409Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASC 606</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201409Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2014-09 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term,Vested and exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TuberculosisTBGrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tuberculosis ("TB") Grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TuberculosisTBGrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tuberculosis T B Grant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TuberculosisTBGrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tuberculosis (&#8220;TB&#8221;) grant.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_LetterAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Letter Agreement Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_LetterAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">TomegaVax Letter Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_LetterAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Letter Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_LetterAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Letter agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from issuance of common stock in connection with a collaboration agreements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Agreements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Agreements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred income tax expense (benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development tax credit carryforward</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticePeriodToTerminateAgreementByCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written notice period to terminate agreement by company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticePeriodToTerminateAgreementByCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Written notice period to terminate agreement by company.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticePeriodToTerminateAgreementByCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Notice Period to Terminate Agreement by Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Income Tax Liabilities, Net, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Liabilities, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property and Equipment Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value contingent consideration measurement input</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant Revenue [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Grant Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CashCashEquivalentsAndShortTermInvestmentsExcludingEquityInvestment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, cash equivalents and short-term investments, excluding equity investment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CashCashEquivalentsAndShortTermInvestmentsExcludingEquityInvestment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash, cash equivalents and short-term investments, excluding equity investment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CashCashEquivalentsAndShortTermInvestmentsExcludingEquityInvestment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents And Short Term Investments Excluding Equity Investment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pension Benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pension and Other Postretirement Plans, Pensions, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, cash equivalents and investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, and Short-term Investments, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, and Short-Term Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business acquisition, transaction costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Transaction Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Components</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares outstanding, diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GlaxoWellcomeUKLimitedAndBeechamSAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">GSK</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GlaxoWellcomeUKLimitedAndBeechamSAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Glaxo Wellcome U K Limited And Beecham S A [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GlaxoWellcomeUKLimitedAndBeechamSAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Glaxo Wellcome U K Limited And Beecham S A.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets, Major Class Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RestrictedStockAwardsRSAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted stock awards (RSA).</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RestrictedStockAwardsRSAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Awards R S A [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RestrictedStockAwardsRSAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Awards (RSAs)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation cost related to unvested restricted stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PaymentsOfUnderwritingDiscountsAndCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments of underwriting discounts and commissions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PaymentsOfUnderwritingDiscountsAndCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Underwriting Discounts And Commissions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PaymentsOfUnderwritingDiscountsAndCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments of underwriting discounts and commissions.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PercentageOfDevelopmentCostsResponsibleByCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of development costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PercentageOfDevelopmentCostsResponsibleByCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Development Costs Responsible By Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PercentageOfDevelopmentCostsResponsibleByCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of development costs that the Company is responsible for.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain Contingencies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unamortized stock-based compensation expense related to stock option</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Convertible preferred stock, shares sold</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of convertible preferred stock, net of issuance cost (in Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Shares New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of new stock classified as temporary equity issued during the period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AssetAcquisitionMilestoneAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition Milestone Achieved</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AssetAcquisitionMilestoneAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset acquisition milestone achieved</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AssetAcquisitionMilestoneAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset acquisition milestone achieved during the reporting period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ExcessFundsPayableUnderGrantAgreementsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Excess funds payable under grant agreements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ExcessFundsPayableUnderGrantAgreementsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Excess Funds Payable Under Grant Agreements Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ExcessFundsPayableUnderGrantAgreementsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Excess funds payable under grant agreements current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SARSCoV2ProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SARS-CoV-2 Product</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SARSCoV2ProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">S A R S Co V2 Product [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SARSCoV2ProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">SARS-CoV-2 product.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liability Class</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liability Class [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandNineteenXencorAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand nineteen xencor agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandNineteenXencorAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen Xencor Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandNineteenXencorAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Xencor Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Noncash or Part Noncash Acquisition, Value of Assets Acquired, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of preferred stock in connection with asset acquisition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncash or Part Noncash Acquisition, Value of Assets Acquired</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ClinicalAndRegulatoryMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical and Regulatory Milestones</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ClinicalAndRegulatoryMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Clinical And Regulatory Milestones [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ClinicalAndRegulatoryMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical and regulatory milestones [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign tax at less than federal statutory rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAgreementTransactionPriceConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration Agreement Transaction Price Consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAgreementTransactionPriceConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration agreement transaction price consideration.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAgreementTransactionPriceConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement Transaction Price Consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SalesMilestonesAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sales Milestones Achieved</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SalesMilestonesAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales milestone achieved</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SalesMilestonesAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sales milestones achieved during the reporting period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BusinessAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of milestones achieved</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BusinessAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition Number Of Milestones Achieved Related To Contingent Consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BusinessAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business acquisition number of milestones achieved related to contingent consideration.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Investment Income, Net, Amortization of Discount and Premium, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income, Net, Amortization of Discount and Premium</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Revenue, Noncurrent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Employees Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets by Major Class</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SUPPLEMENTAL DISCLOSURE OF CASHFLOW INFORMATION:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PercentageOfAggregateGrossProceedsFromSaleOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of aggregate gross proceeds from sale of shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PercentageOfAggregateGrossProceedsFromSaleOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Aggregate Gross Proceeds From Sale Of Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PercentageOfAggregateGrossProceedsFromSaleOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of aggregate gross proceeds from sale of shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContingentConsiderationTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Consideration Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContingentConsiderationTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Provision for income taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Provision for income taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Provision for income taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Provision for income taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PaymentOfContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of contingent consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PaymentOfContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment Of Contingent Consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PaymentOfContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment of contingent consideration.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GrantAgreementAmendedDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Grant agreement amended date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GrantAgreementAmendedDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grant Agreement Amended Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GrantAgreementAmendedDate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Grant agreement amended date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticeToTerminateLicensedProgramIfExercise_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Written notice to terminate licensed program following the exercise of an option for such program.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticeToTerminateLicensedProgramIfExercise_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written notice to terminate licensed program if exercise</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MedImmuneLimitedLiabilityCompanyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">MedImmune</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MedImmuneLimitedLiabilityCompanyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Med Immune Limited Liability Company [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MedImmuneLimitedLiabilityCompanyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">MedImmune, limited liability company.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MeasurementInputExpectedRevenueVolatilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Input Expected Revenue Volatility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MeasurementInputExpectedRevenueVolatilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Expected Revenue Volatility [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MeasurementInputExpectedRevenueVolatilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Measurement input expected revenue volatility.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Shares Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RoyaltyObligationPeriodFromDateOfFirstCommercialSale_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty obligation period from date of first commercial sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RoyaltyObligationPeriodFromDateOfFirstCommercialSale_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Obligation Period From Date Of First Commercial Sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RoyaltyObligationPeriodFromDateOfFirstCommercialSale_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty obligation period from date of first commercial sale.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_UnusedFundsReceivedInAdvance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unused funds received in advance.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_UnusedFundsReceivedInAdvance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unused Funds Received In Advance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_UnusedFundsReceivedInAdvance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unused funds received in advance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedGrantAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Total common stock issued in connection with the grant agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedGrantAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued Grant Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedGrantAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock issued in connection with the grant agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OperatingLeaseOtherInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Information</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OperatingLeaseOtherInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Other Information [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OperatingLeaseOtherInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease other information.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill expected to be deductible for income tax purposes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Goodwill, Expected Tax Deductible Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reserves and accruals</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumAggregateMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum aggregate milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumAggregateMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Aggregate Milestone Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumAggregateMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum aggregate milestone payments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_EquityInvestmentCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Investment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_EquityInvestmentCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity Investment Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_EquityInvestmentCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Investment Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Costs and Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationRevenueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Collaboration revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationRevenueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration revenue table text block</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationRevenueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration revenue table text block</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OfferingPeriodEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Duration of offering period under the Plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OfferingPeriodEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Offering Period Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OfferingPeriodEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GrantAwardedAmountMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum grant awarded amount.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GrantAwardedAmountMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grant Awarded Amount Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GrantAwardedAmountMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant awarded amount. maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SpecifiedClinicalDevelopmentMilestonesPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Specified clinical development milestones payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SpecifiedClinicalDevelopmentMilestonesPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Specified Clinical Development Milestones Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SpecifiedClinicalDevelopmentMilestonesPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Specified clinical development milestones payment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FirstInfectiousDiseaseProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">First Infectious Disease Product [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FirstInfectiousDiseaseProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">First infectious disease product.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FirstInfectiousDiseaseProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Infectious Disease Product</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ReclassificationOfPreferredStockWarrantLiabilityToAdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassification of preferred stock warrant liability to additional paid-in capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ReclassificationOfPreferredStockWarrantLiabilityToAdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reclassification Of Preferred Stock Warrant Liability To Additional Paid In Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ReclassificationOfPreferredStockWarrantLiabilityToAdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reclassification of preferred stock warrant liability to additional paid-in capital.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_IncomeTaxesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_IncomeTaxesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_IncomeTaxesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income taxes line items.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income (loss) from operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prior year tax rate adjustment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, operating lease, option to extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Option to Extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OperatingLossCarryforwardsLimitationOnUsePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss deduction limitation as percentage of taxable income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OperatingLossCarryforwardsLimitationOnUsePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Limitation On Use Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OperatingLossCarryforwardsLimitationOnUsePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards limitation on use percentage.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GrantAwardedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant awarded amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GrantAwardedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grant Awarded Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GrantAwardedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Grant awarded amount.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition, Consideration Transferred, Transaction Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset acquisition, transaction costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ConvertiblePreferredStockWarrantLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrant to Purchase Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ConvertiblePreferredStockWarrantLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock Warrant Liability [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ConvertiblePreferredStockWarrantLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible preferred stock warrant liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ConversionOfPreferredStockIntoCommonStockUponCompletionOfInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of preferred stock into common stock upon completion of initial public offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ConversionOfPreferredStockIntoCommonStockUponCompletionOfInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Of Preferred Stock Into Common Stock Upon Completion Of Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ConversionOfPreferredStockIntoCommonStockUponCompletionOfInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Conversion of preferred stock into common stock upon completion of initial public offering.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration agreement, number of separate programs agreed to collaborate.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement Number Of Separate Programs Agreed To Collaborate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of separate programs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentInProcess_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized research and development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentInProcess_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development in Process</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other professional and consulting expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued and other liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued and other liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities and Other Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TenantImprovements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tenant improvement allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TenantImprovements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tenant Improvements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other comprehensive income (loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value by Liability Class</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value by Liability Class [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of restricted common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Restricted Stock Award, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CommonStockSharesIssuedFairMarketValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued, fair market value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CommonStockSharesIssuedFairMarketValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common stock, shares issued, fair market value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CommonStockSharesIssuedFairMarketValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock, shares issued, fair market value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current State and Local Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FollowOnOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Follow-on Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FollowOnOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Follow On Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FollowOnOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Follow-on offering.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted shares subject to future vesting</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of restricted shares subject to future vesting using the treasury stock method.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incremental Common Shares Attributable To Dilutive Effect Of Restricted Share Subject To Future Vesting</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_EstimatedSharesIssuableUnderTheESPPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Shares Issuable Under The E S P P [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_EstimatedSharesIssuableUnderTheESPPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Estimated Shares Issuable Under the E S P P [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_EstimatedSharesIssuableUnderTheESPPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Estimated Shares Issuable Under the E S P P [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GrantAgreementAmendedExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant agreement amended expiration date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GrantAgreementAmendedExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Grant agreement amended expiration date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GrantAgreementAmendedExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grant Agreement Amended Expiration Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAndLicenseAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration revenue, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAndLicenseAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration and License Agreements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAndLicenseAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration and License Agreements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combinations [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Finite-Lived Intangible Assets, Net, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Finite-Lived Intangible Assets, Net, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Finite-lived intangible assets, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">TOTAL STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty payment obligation expiration period after first commercial sales</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Payment Obligation Expiration Period After First Commercial Sales</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty payment obligation expiration period after first commercial sales.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BriiBiosciencesOffshoreLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Brii Bio</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BriiBiosciencesOffshoreLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Brii Biosciences Offshore Limited [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BriiBiosciencesOffshoreLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Brii Biosciences Offshore Limited.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">In-Process Research and Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">In Process Research and Development [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ReconciliationOfEffectiveIncomeTaxRateTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation Of Effective Income Tax Rate [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ReconciliationOfEffectiveIncomeTaxRateTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reconciliation Of Effective Income Tax Rate [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ReconciliationOfEffectiveIncomeTaxRateTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reconciliation of effective income tax rate.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ScheduleOfGoodwillAndIntangibleAssetsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Goodwill And Intangible Assets [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ScheduleOfGoodwillAndIntangibleAssetsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Goodwill And Intangible Assets [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ScheduleOfGoodwillAndIntangibleAssetsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of goodwill and intangible assets.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Securities contractual term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares, Forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of shares, Forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.0001 par value; 300,000,000 shares authorized as of December 31, 2022 and 2021, respectively; 131,161,404 and 131,161,404 shares issued and outstanding as of December 31, 2022 and 2021, respectively</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Retained earnings (Accumulated deficit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Derivative, Gain (Loss) on Derivative, Net, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in estimated fair value of derivative liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative, Gain (Loss) on Derivative, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DeferredTaxLiabilitiesRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">ROU assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DeferredTaxLiabilitiesRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Right Of Use Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DeferredTaxLiabilitiesRightOfUseAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities right of use assets.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201613Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2016-13</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201613Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2016-13 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RemainingPaymentForAssetAcquisitionMilestoneAggregate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">For contingent consideration arrangements recognized in connection with an asset acquisition, this element represents an estimate of the high-end of the potential range (undiscounted) of the remaining consideration which may be paid.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RemainingPaymentForAssetAcquisitionMilestoneAggregate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Remaining Payment For Asset Acquisition Milestone Aggregate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RemainingPaymentForAssetAcquisitionMilestoneAggregate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining payment for asset acquisition milestone, maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AmendmentNumberOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Number One Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AmendmentNumberOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Number One [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AmendmentNumberOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amendment number one.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_NumberOfAntibodiesToDevelop_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of antibodies to develop.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_NumberOfAntibodiesToDevelop_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Antibodies to Develop</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_NumberOfAntibodiesToDevelop_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of antibodies to develop</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CommonStockSharesPurchasedSharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock, Shares Purchased, Share Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CommonStockSharesPurchasedSharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Purchased, Share Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CommonStockSharesPurchasedSharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common Stock, Shares Purchased, Share Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MilestonePaymentDueToCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payment due to Vir</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MilestonePaymentDueToCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payment Due To Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MilestonePaymentDueToCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payment due to company under grant agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumAggregateMilestonePaymentForAchievementOfSpecifiedMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum aggregate milestone payment for achievement of specified milestones</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumAggregateMilestonePaymentForAchievementOfSpecifiedMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum aggregate milestone payment for achievement of specified milestones, including development, regulatory and commercial.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Contract with Customer, Liability, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ResearchAndDevelopmentExpenseUnderLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development expense under license agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ResearchAndDevelopmentExpenseUnderLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and development expense under license agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrant, expiration date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Date from which Warrants or Rights Exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfMachineryAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sale of an equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfMachineryAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale of Machinery and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected Stock Price Volatility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Price Volatility [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RegulatoryMilestonesAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Regulatory milestones achieved during the reporting period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RegulatoryMilestonesAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Regulatory Milestones Achieved</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RegulatoryMilestonesAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Regulatory milestones achieved</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction Price Upon Option Exercise</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_EffectiveIncomeTaxRateReconciliationPermanentItemsPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Permanent items</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_EffectiveIncomeTaxRateReconciliationPermanentItemsPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Permanent Items Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_EffectiveIncomeTaxRateReconciliationPermanentItemsPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation permanent items percent.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options,Vested and exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Federal Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetirementPlanTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Retirement Plan Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetirementPlanTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Plan Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TemporaryEquityAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, additional shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TemporaryEquityAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Additional Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TemporaryEquityAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity additional shares authorized.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DefinitiveCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Definitive Collaboration Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DefinitiveCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Definitive Collaboration Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DefinitiveCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Definitive collaboration agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RockefellerUniversityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rockefeller</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RockefellerUniversityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Rockefeller University [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RockefellerUniversityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Rockefeller University.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BillAndMelindaGatesFoundationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Bill &amp; Melinda Gates Foundation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BillAndMelindaGatesFoundationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Bill And Melinda Gates Foundation [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BillAndMelindaGatesFoundationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Bill &amp; Melinda Gates Foundation.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cost of Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cost of Revenue, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Expected term of ESPP (in years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term of options (in years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Investments, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">BARDA [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Biomedical Advanced Research and Development Authority [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Biomedical advanced research and development authority member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Voluntary Filers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected stock price volatility,maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BriiAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Brii Agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BriiAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Brii Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BriiAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Brii Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research Tax Credit Carryforward</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Tax Credit Carryforward [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentToProjectedBenefitObligationsNetOfTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Adjustment to projected benefit obligations, net of tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentToProjectedBenefitObligationsNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment To Projected Benefit Obligations Net Of Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentToProjectedBenefitObligationsNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other comprehensive income loss pension and other postretirement benefit plans adjustment to projected benefit obligations net of tax.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PrepaymentRawMaterials_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-refundable prepayment for raw materials</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PrepaymentRawMaterials_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepayment Raw Materials</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PrepaymentRawMaterials_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepayment Raw Materials</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Income (Loss) Before Provision for (Benefit from) Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other income (expense)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Depreciation and amortization expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PayrollAndRelatedExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payroll and related expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PayrollAndRelatedExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payroll And Related Expenses Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PayrollAndRelatedExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payroll and related expenses current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Separately Recognized Transactions [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration and License Agreements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Deferred Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in deferred income taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Receivable from collaboration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Receivable, after Allowance for Credit Loss, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ProceedsFromDisposalOfAnEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from disposal of an asset held for sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ProceedsFromDisposalOfAnEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Disposal of an Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ProceedsFromDisposalOfAnEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from disposal of an equipment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-sale, Unrealized Gain (Loss), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total unrealized gains recorded in accumulated other comprehensive income (loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Unrealized Gain (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ValueOfCommonStockSharesIssuedForMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Value of common stock shares Issued for milestone payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ValueOfCommonStockSharesIssuedForMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Value of common shares issued for milestone payment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ValueOfCommonStockSharesIssuedForMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Value of common stock shares Issued for milestone payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetRentableArea_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Rentable Area</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of equity investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Adjustment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net income (loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net income (loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FirstSiRNAProductHBVMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">First SiRNA product HBV.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FirstSiRNAProductHBVMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">First Si R N A Product H B V [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FirstSiRNAProductHBVMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First siRNA Product HBV</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_WeightedAverageMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_WeightedAverageMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TenantImprovementAllowanceAggregate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum amount of tenant improvement allowance available.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TenantImprovementAllowanceAggregate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tenant Improvement Allowance Aggregate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TenantImprovementAllowanceAggregate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tenant improvement allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CashGrantAwarded_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of cash grant awarded.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CashGrantAwarded_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Grant Awarded</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CashGrantAwarded_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business agreement grant amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ProfitsAndLossesSharingPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Profits and losses sharing percentage.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ProfitsAndLossesSharingPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Profits And Losses Sharing Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ProfitsAndLossesSharingPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of share Profit and loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_InfluenzaAAndHBVResearchProgramsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Influenza A and HBV Research Programs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_InfluenzaAAndHBVResearchProgramsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Influenza A And H B V Research Programs [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_InfluenzaAAndHBVResearchProgramsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Influenza A and HBV research programs member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodSharesIssuedForSettlementOfContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of shares issued for settlement of contingent consideration.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodSharesIssuedForSettlementOfContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Issued For Settlement Of Contingent Consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodSharesIssuedForSettlementOfContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock to settle a contingent consideration (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration revenue.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Revenue [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration Revenue [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Restricted Stock Activity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BriiBioParentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Brii Bio Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BriiBioParentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Brii Bio Parent [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BriiBioParentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Brii Bio Parent.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AntibodyProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antibody Program</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AntibodyProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antibody Program [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AntibodyProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Antibody Program.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated fair value of contingent consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition, Contingent Consideration, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Asset Acquisition, Contingent Consideration, Liability, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_UnrecognizedTaxBenefitsIfRecognizedWouldReduceEffectiveTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized tax benefits, if recognized, would reduce effective tax rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_UnrecognizedTaxBenefitsIfRecognizedWouldReduceEffectiveTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unrecognized tax benefits, if recognized, would reduce effective tax rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AdjustmentsToProfitSharingAmounts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Profit sharing amount constrained</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AdjustmentsToProfitSharingAmounts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Profit sharing amount constrained.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AdjustmentsToProfitSharingAmounts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Profit Sharing Amounts</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Fair Value of Significant Unobservable Inputs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumAggregateSalesMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum aggregate sales milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumAggregateSalesMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum aggregate sales milestone payments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumAggregateSalesMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Aggregate Sales Milestone Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and Cash Equivalents, at Carrying Value, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and Cash Equivalents, at Carrying Value, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Income (Loss) Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Assumptions Used for Estimating the Fair Value of Stock Options Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total revenues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Noncash Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GrantAgreementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant Agreements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GrantAgreementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grant Agreements Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GrantAgreementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Grant agreements disclosure.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RockefellerAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Rockefeller agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RockefellerAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Rockefeller Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RockefellerAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rockefeller Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Net, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Net, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OptionsTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Transaction Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OptionsTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options Transaction Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OptionsTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options transaction price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term,Vested and expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RemainingPaymentMadeForAssetAcquisitionMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Remaining payment made for asset acquisition milestone.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RemainingPaymentMadeForAssetAcquisitionMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Remaining Payment Made For Asset Acquisition Milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RemainingPaymentMadeForAssetAcquisitionMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining payment made for asset acquisition milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty one Glaxo Wellcome UK Limited and Beecham S.A.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty One Glaxo Wellcome U K Limited And Beecham S A [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 GSK</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AnnualLicenseMaintenanceFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License maintenance fees required to pay annually.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AnnualLicenseMaintenanceFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Annual License Maintenance Fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase price as percentage of lower of fair market value on offering date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Offering Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ScheduleOfGoodwillAndIntangibleAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Goodwill and Intangible Assets [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ScheduleOfGoodwillAndIntangibleAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Goodwill And Intangible Assets [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ScheduleOfGoodwillAndIntangibleAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of goodwill and intangible assets.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FairValueReclassificationOfContingentConsiderationToAccruedLiabilitiesUponAchievementOfMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value, reclassification of contingent consideration to accrued liabilities upon achievement of milestone.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FairValueReclassificationOfContingentConsiderationToAccruedLiabilitiesUponAchievementOfMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Reclassification Of Contingent Consideration To Accrued Liabilities Upon Achievement Of Milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FairValueReclassificationOfContingentConsiderationToAccruedLiabilitiesUponAchievementOfMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment of contingent consideration upon achievement of the TomegaVax milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary Equity By Class Of Stock [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, by Class of Stock [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumSalesMilestoneToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum sales milestone to be received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumSalesMilestoneToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Sales Milestone To Be Received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumSalesMilestoneToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum sales milestone to be received.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price,Vested and expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Finite-Lived Intangible Assets, Gross, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-lived intangible assets, gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherOperatingActivitiesCashFlowStatement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherOperatingActivitiesCashFlowStatement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Operating Activities, Cash Flow Statement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_OwnershipDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ownership [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PercentageOfUpfrontPaymentReceivableAtExecutionDateOfAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of upfront payment receivable at execution date of agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PercentageOfUpfrontPaymentReceivableAtExecutionDateOfAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of upfront payment receivable at execution date of agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RangeOfTieredRoyaltiesToPayToNetSalesOfProducts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Range of tiered royalties to pay on annual net sales of products.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RangeOfTieredRoyaltiesToPayToNetSalesOfProducts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Range of Tiered Royalties to Pay to Net Sales of Products</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RangeOfTieredRoyaltiesToPayToNetSalesOfProducts_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Range of tiered royalties to pay on net sales of products</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expiration period of awards from issuance date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash and Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RoyaltiesPaymentRangeOnNetSalesOfLicensedProduct_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalties payment range on net sales of licensed product</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RoyaltiesPaymentRangeOnNetSalesOfLicensedProduct_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalties payment range on net sales of licensed product.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RoyaltiesPaymentRangeOnNetSalesOfLicensedProduct_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalties Payment Range on Net Sales of Licensed Product</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenues from contract with customers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Revenue from Contract with Customer, Excluding Assessed Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income (loss) before provision for income taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income (loss) before provision for income taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_HcmvVaccinePlatformGrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">HCMV-Vaccine Platform Grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_HcmvVaccinePlatformGrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Hcmv Vaccine Platform Grant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_HcmvVaccinePlatformGrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Hcmv Vaccine Platform Grant [Member].</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DeferredTaxAssetsLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DeferredTaxAssetsLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Lease Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DeferredTaxAssetsLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandNineteenAndTwoThousandTwentyXencorAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Nineteen And Two Thousand Twenty Xencor Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandNineteenAndTwoThousandTwentyXencorAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen And Two Thousand Twenty Xencor Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandNineteenAndTwoThousandTwentyXencorAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 and 2020 Xencor Agreement member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CommonStockSharesPurchasedAggregatePurchasePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock, Shares Purchased , Aggregate Purchase Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CommonStockSharesPurchasedAggregatePurchasePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Purchased , Aggregate Purchase Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CommonStockSharesPurchasedAggregatePurchasePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common Stock, Shares Purchased , Aggregate Purchase Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodSharesCollaborationAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in connection with a collaboration agreement (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodSharesCollaborationAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Collaboration Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodSharesCollaborationAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of shares issued in connection with a collaboration agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term,Vested and exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum milestone payment for achievement of specified development and regulatory</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Milestone Payment For Achievement Of Specified Development And Regulatory</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum milestone payment for achievement of specified development and regulatory.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net (decrease) increase in cash, cash equivalents and restricted cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ReleaseOfValuationAllowanceDeferredTaxInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Release of valuation allowance deferred tax in amount.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ReleaseOfValuationAllowanceDeferredTaxInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Release of Valuation Allowance Deferred Tax In Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ReleaseOfValuationAllowanceDeferredTaxInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Release of valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_US_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">United States</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_US_lbl" xlink:role="http://www.xbrl.org/2003/role/label">UNITED STATES</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net liability recognized under pension plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liability, Defined Benefit Pension Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_InfluenzaAResearchProgramsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Influenza A Research Programs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_InfluenzaAResearchProgramsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Influenza A Research Programs [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_InfluenzaAResearchProgramsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Influenza A research programs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PercentageOfShareDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of share development costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PercentageOfShareDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Share Development Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PercentageOfShareDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of share development costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumNumberOfDevelopmentProgramGrantedFromCounterparty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum number of development program granted from Brii to Vir | Program</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumNumberOfDevelopmentProgramGrantedFromCounterparty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum Number of Development Program Granted from Counterparty</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumNumberOfDevelopmentProgramGrantedFromCounterparty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Number of Development Program Granted from Counterparty</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodValueIssuedForSettlementOfContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Issued For Settlement Of Contingent Consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodValueIssuedForSettlementOfContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Value of stock issued for settlement of contingent considerations.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodValueIssuedForSettlementOfContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock to settle a contingent consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition, Contingent Consideration, Liability, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss Contingencies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingencies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Operating Lease Amounts Recorded in Condensed Consolidated Balance Sheet</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Operating Lease Amounts Recorded In Condensed Consolidated Balance Sheet Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of operating lease amounts recorded in condensed consolidated balance sheet.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SaleLeasebackTransactionProceedsFromFinancingObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sale leaseback of financing obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SaleLeasebackTransactionProceedsFromFinancingObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale Leaseback Transaction Proceeds From Financing Obligations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SaleLeasebackTransactionProceedsFromFinancingObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">sale leaseback transaction proceeds from financing obligations.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SeriesAOneConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A-1 Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SeriesAOneConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A One Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SeriesAOneConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A-1 convertible preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractBasedIntangibleAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract-Based Intangible Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractBasedIntangibleAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract-Based Intangible Assets [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_UnderlyingSharesPremiumReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underlying shares, Premium received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_UnderlyingSharesPremiumReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Underlying shares, Premium received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_UnderlyingSharesPremiumReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Underlying shares, Premium received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term portion of finance lease obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognition [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RoyaltiesBasedOnNetSalesOfLicensedProducts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalties payment based on net sales of licensed products.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RoyaltiesBasedOnNetSalesOfLicensedProducts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalties Based on Net Sales of Licensed Products</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RoyaltiesBasedOnNetSalesOfLicensedProducts_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Royalties based on net sales of licensed products</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated weighted average period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodValueCollaborationAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in connection with a collaboration agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodValueCollaborationAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Collaboration Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodValueCollaborationAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Value of stock issued in connection with a collaboration agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_Vir2248Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vir 2248</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_Vir2248Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vir 2248 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_Vir2248Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Vir 2248 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive income (loss):</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business acquisition, cash consideration paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Businesses, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Income Taxes, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued income taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-lived intangible assets, amortization method description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Amortization Method</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_Vir2218Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vir 2218</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_Vir2218Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">VIR-2218 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_Vir2218Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">VIR-2218.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Maturities of Operating Lease Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of Liability for Uncertain Tax Positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrants to Purchase Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Plans Activity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Adopted Accounting Pronouncements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAgreementTransactionPriceUpfrontFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront payment received under the Collaboration agreement, which represents part of the transaction price.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAgreementTransactionPriceUpfrontFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement Transaction Price Upfront Fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAgreementTransactionPriceUpfrontFee_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Upfront fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">(Accretion of discounts) amortization of premiums on investments, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedRoyaltiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued royalties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedRoyaltiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Royalties, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development tax credit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Research and development tax credit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Revenue, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticePeriodToTerminateLicensedProgramForPaymentBreach_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written notice period to terminate licensed program for payment breach</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticePeriodToTerminateLicensedProgramForPaymentBreach_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Notice Period To Terminate Licensed Program For Payment Breach</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticePeriodToTerminateLicensedProgramForPaymentBreach_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Written Notice Period To Terminate Licensed Program For Payment Breach</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sales Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sales agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash and Cash Equivalents, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash and cash equivalents, current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash and Cash Equivalents, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PercentageOfEstimatedBatchProductionFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Estimated Batch Production Fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PercentageOfEstimatedBatchProductionFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of estimated batch production fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PercentageOfEstimatedBatchProductionFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of estimated batch production fees owed.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Addition for tax positions taken in current year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Investments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Investments, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Investments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Investments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Carrying value of investment at cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ExecutiveOfficerAndDirectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Executive Officer and Director</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ExecutiveOfficerAndDirectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Executive Officer And Director [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ExecutiveOfficerAndDirectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Executive officer and director.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 9)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumSharesToBeIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum shares to be issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumSharesToBeIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Shares To Be Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumSharesToBeIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum shares to be issued.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodSharesLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in connection with a grant agreement (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodSharesLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodSharesLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of common stock issued in connection with a license agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Government Treasuries</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Treasury Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FirstAndSecondClosingsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Two Closings</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FirstAndSecondClosingsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">First And Second Closings [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FirstAndSecondClosingsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">First and second closings.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MilestonePayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MilestonePayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MilestonePayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_VaccinalAntibodyGrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vaccinal Antibody Grant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_VaccinalAntibodyGrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vaccinal Antibody Grant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_VaccinalAntibodyGrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Vaccinal Antibody Grant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FundsReceivedInAdvance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Funds received in advance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FundsReceivedInAdvance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Funds Received In Advance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FundsReceivedInAdvance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Funds received in advance.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticePeriodToTerminateLicensedProgramForUncuredMaterialBreach_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Written notice period to terminate licensed program for uncured material breach.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticePeriodToTerminateLicensedProgramForUncuredMaterialBreach_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written notice period to terminate licensed program for uncured material breach</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AccruedLiabilitiesAndOtherLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Liabilities And Other Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AccruedLiabilitiesAndOtherLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities And Other Liabilities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AccruedLiabilitiesAndOtherLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued Liabilities And Other Liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority, Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_CN_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">China Territory</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_CN_lbl" xlink:role="http://www.xbrl.org/2003/role/label">CHINA</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_HBVProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">HBV Program</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_HBVProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">H B V Program [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_HBVProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">HBV program.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FinancialAssetsGrossUnrealizedHoldingGains_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Assets, Gross Unrealized Holding Gains</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FinancialAssetsGrossUnrealizedHoldingGains_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Assets Gross Unrealized Holding Gains</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FinancialAssetsGrossUnrealizedHoldingGains_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Financial assets gross unrealized holding gains.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ProfitSharingAmountPreviouslyConstrainedReleased_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Profit-sharing amount previously constrained, released</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ProfitSharingAmountPreviouslyConstrainedReleased_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Profit-Sharing Amount Previously Constrained, Released</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ProfitSharingAmountPreviouslyConstrainedReleased_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Profit-Sharing Amount Previously Constrained, Released</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AdvancedProceedsAppliedToConvertiblePreferredStockIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Advanced proceeds applied to convertible preferred stock issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AdvancedProceedsAppliedToConvertiblePreferredStockIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Advanced Proceeds Applied To Convertible Preferred Stock Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AdvancedProceedsAppliedToConvertiblePreferredStockIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Advanced proceeds applied to convertible preferred stock issuance.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_EachInfectiousDiseaseSiRNAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Each Infectious Disease siRNA</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_EachInfectiousDiseaseSiRNAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Each Infectious Disease Si R N A [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_EachInfectiousDiseaseSiRNAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Each infectious disease siRNA.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">STOCKHOLDERS&#8217; EQUITY:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State taxes, net of federal benefit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PercentageOfDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of development costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PercentageOfDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Development Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PercentageOfDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of development costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Foreign Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash and Cash Equivalents, Noncurrent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash and cash equivalents, noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign Currency</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenuesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenues [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenuesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenues:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value, Forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortization of Intangible Assets, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Amortization expense of intangible assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of intangible assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of Intangible Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FiniteLivedIntangibleAssetsReclassifiedFromIndefiniteLived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-lived intangible asset, reclassified from indefinite-lived asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FiniteLivedIntangibleAssetsReclassifiedFromIndefiniteLived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Reclassified From Indefinite Lived</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FiniteLivedIntangibleAssetsReclassifiedFromIndefiniteLived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Finite-lived Intangible assets, reclassified from Indefinite-lived.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SummaryOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Lease Costs and Additional Information Related to Operating Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SummaryOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Lease Cost And Other Information Related To Operating Leases Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SummaryOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of lease cost and other information related to operating leases.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Subsequent Event [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FiniteLivedIntangibleAssetsAccumulatedImpairment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less impairment of intangible assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FiniteLivedIntangibleAssetsAccumulatedImpairment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Accumulated Impairment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FiniteLivedIntangibleAssetsAccumulatedImpairment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Finite lived intangible assets accumulated impairment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetirementPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Retirement Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetirementPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Business Combination, Consideration Transferred, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business acquisition purchase price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Consideration Transferred</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and twenty preliminary collaboration agreement and stock purchase agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty Preliminary Collaboration Agreement And Stock Purchase Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Preliminary Collaboration Agreement and Stock Purchase Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumTermOfOfferingPeriodSpecifiedUnderPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum term of offering period specified under plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumTermOfOfferingPeriodSpecifiedUnderPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Term Of Offering Period Specified Under Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumTermOfOfferingPeriodSpecifiedUnderPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum term of offering period specified under plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional consideration payable upon achievement of specified milestone events</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combinations Additional Consideration Payable Upon Achievement Of Specified Events</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combinations additional consideration payable upon achievement of specified events.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss Contingencies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingencies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Aggregate intrinsic value of options exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Nonoperating Income (Expense), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other expense, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ResearchAndDevelopmentExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ResearchAndDevelopmentExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expenses Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ResearchAndDevelopmentExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Carrying value as of the balance sheet date of current obligations incurred and payable to vendors for goods and services attributable to the entity's research and development activities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FormerBusinessCombinationContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of former liability recognized arising from contingent consideration in a business combination.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FormerBusinessCombinationContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Former Business Combination, Contingent Consideration, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FormerBusinessCombinationContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated fair value of former contingent consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense):</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ConvertiblePreferredStockWarrantLiabilityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock Warrant Liability [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ConvertiblePreferredStockWarrantLiabilityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible preferred stock warrant liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeFinanceLeaseTermOfContract1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease, term of contract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeFinanceLeaseTermOfContract1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Finance Lease, Term of Contract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Reduction for tax positions taken in the prior years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MilestonePaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payment received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MilestonePaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payment Received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MilestonePaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payment received.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MinimumCommonStockPriceForMilestonePaymentsConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum common stock price that triggers milestone payment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MinimumCommonStockPriceForMilestonePaymentsConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Common Stock Price For Milestone Payments Consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MinimumCommonStockPriceForMilestonePaymentsConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum common stock price for milestone payments consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FirstSiRNAProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">First Si R N A Product [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FirstSiRNAProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">First siRNA product member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FirstSiRNAProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First siRNA Product HBV</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CommonStockIssuanceCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock issuance cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CommonStockIssuanceCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Issuance Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CommonStockIssuanceCost_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock issuance cost.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ObligationToPayCapacityReservation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Obligation To Pay Capacity Reservation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ObligationToPayCapacityReservation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Obligation to pay capacity reservation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ObligationToPayCapacityReservation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount obligated to pay for capacity reservation under the agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PreliminaryCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preliminary Collaboration Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PreliminaryCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preliminary Collaboration Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PreliminaryCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Preliminary Collaboration Agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase/decrease in valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RestrictedStockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Purchase Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RestrictedStockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Purchase Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RestrictedStockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted stock purchase agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Outstanding, Maturity Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant, expiration date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration, noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite Lived Intangible Assets [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumSalesMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum sales milestone payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumSalesMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Sales Milestone Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumSalesMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum milestone payment for achievement of specified annual net sales.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued liabilities and other long-term liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash Equivalents, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_NetProceedsFromIssuanceSecondaryPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The cash inflow associated with the amount received from entity's follow on offering of stock to the public, net of commissions and expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_NetProceedsFromIssuanceSecondaryPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net proceeds From Issuance Secondary Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_NetProceedsFromIssuanceSecondaryPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from issuance secondary public offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumNumberOfDevelopmentProgramGrantedToCounterparty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum number of development program granted from Vir to Brii | Program</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumNumberOfDevelopmentProgramGrantedToCounterparty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum Number of Development Program Granted to Counterparty</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumNumberOfDevelopmentProgramGrantedToCounterparty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Number of Development Program Granted to Counterparty</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest receivable excluded from fair value and amortized cost basis of available for sale securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less accumulated depreciation and amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Expected stock price volatility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected stock price volatility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandSixteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2016 Equity Incentive Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandSixteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Sixteen Equity Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandSixteenEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand sixteen equity incentive plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PaymentMadeForBusinessCombinationMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment made for business combination milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PaymentMadeForBusinessCombinationMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment made for business combination milestone.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PaymentMadeForBusinessCombinationMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment made for business combination milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OperatingLeaseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OperatingLeaseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OperatingLeaseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares available for grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Awards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum percentage of right to perform details in connection with antibody product</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Percentage Of Right To Perform Details In Connection With Antibody Product</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum percentage of right to perform details in connection with antibody product.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SecondPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Second Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SecondPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Second Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SecondPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Second plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Vested and expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration, current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in estimated fair value of contingent consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GrantsAgreementAmendedDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Grants Agreement Amended Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GrantsAgreementAmendedDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grants Agreement Amended Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Input Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Exercise Price, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Exercise Price, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments aggregate amount payable, maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of principal on financing lease obligations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Principal Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_InfluenzaAAndInfluenzaBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Influenza A and Influenza B</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_InfluenzaAAndInfluenzaBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Influenza A And Influenza B [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_InfluenzaAAndInfluenzaBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Influenza A and Influenza B member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassification of derivative liability to addition paid-in-capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reclassification Of Derivative Liability To Additional Paid In Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reclassification of derivative liability to additional paid In capital.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid Expenses And Other Current Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expenses and Other Current Assets [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodValueLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in connection with a grant agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodValueLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodValueLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Value of common stock issued in connection with a license agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total lease cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Lease, Cost, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_HumabsBiomedSAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Humabs IP Transfer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_HumabsBiomedSAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Humabs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_HumabsBiomedSAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Humabs Biomed S A [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_HumabsBiomedSAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Humabs Biomed SA.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ROU assets in exchange for operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease liabilities obtained in exchange of right-of-use asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RemainingPaymentMadeForBusinessCombinationMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Remaining Payment Made For Business Combination Milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RemainingPaymentMadeForBusinessCombinationMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Remaining Payment Made For Business Combination Milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RemainingPaymentMadeForBusinessCombinationMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining payment made for business combination milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumAggregateSalesMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum aggregate sales milestone payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumAggregateSalesMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Aggregate Sales Milestone Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumAggregateSalesMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum aggregate milestone payment for achievement of specified annual net sales</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FiniteLivedIntangibleAssetsAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FiniteLivedIntangibleAssetsAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Amortization Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FiniteLivedIntangibleAssetsAmortizationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of total amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in the next five years following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business acquisition, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Input Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective income tax rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written notice period for uncured material breach</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Notice Period For Licensed Program Uncured Material Breach</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Written notice period for licensed program, uncured material breach.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PreDefinedRegulatoryMilestoneConsiderationToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Consideration to be received upon achievement of a pre-defined regulatory milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PreDefinedRegulatoryMilestoneConsiderationToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Defined Regulatory Milestone Consideration To Be Received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PreDefinedRegulatoryMilestoneConsiderationToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre Defined Regulatory Milestone Consideration To Be Received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CommercialMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Milestones</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CommercialMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Milestones [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CommercialMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commercial milestones.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business acquisition, shares issued value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FinancialAssetsGrossUnrealizedHoldingLosses_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Financial Assets, Gross Unrealized Holding Losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FinancialAssetsGrossUnrealizedHoldingLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Assets Gross Unrealized Holding Losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FinancialAssetsGrossUnrealizedHoldingLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Financial assets gross unrealized holding losses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Support to Nonconsolidated Legal Entity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Support to Nonconsolidated Legal Entity [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_UpfrontFeePaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront fee paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_UpfrontFeePaid_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront fee paid.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_UpfrontFeePaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Fee Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Additional Paid in Capital, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_XencorAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Xencor Agreements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_XencorAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Xencor Agreements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_XencorAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Xencor Agreements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options,Vested and expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PercentageOfCommissionRateFromSaleOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the percentage of maximum commission rate, based on aggregate gross proceeds from sale of shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PercentageOfCommissionRateFromSaleOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of commission rate from sale of shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PercentageOfCommissionRateFromSaleOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of commission rate from sale of shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transactions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Temporary Equity [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticePeriodToTerminateLicensedProgramForFailureToMakePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written notice period to terminate licensed program for failure to make payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticePeriodToTerminateLicensedProgramForFailureToMakePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Written notice period to terminate licensed program for failure to make payment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticePeriodToTerminateLicensedProgramForFailureToMakePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written notice period to terminate licensed program for failure to make payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Debt Securities, Available-for-sale, Allowance for Credit Loss, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Debt Securities, Available-for-sale, Allowance for Credit Loss, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-sale, Allowance for Credit Loss, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Allowance for losses on available-for-sale debt securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Allowance for Credit Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MinimumCommonStockConversionPriceForMilestonePaymentsConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum common stock conversion price for milestone payments consideration.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MinimumCommonStockConversionPriceForMilestonePaymentsConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Common Stock Conversion Price For Milestone Payments Consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MinimumCommonStockConversionPriceForMilestonePaymentsConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum common stock conversion price for milestone payments consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Amortization of actuarial loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, after Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Outstanding convertible preferred stock (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandTwentyStockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty stock purchase agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandTwentyStockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Stock Purchase Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandTwentyStockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Stock Purchase Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds after deducting underwriting discounts, commissions and offering expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. federal statutory income tax rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OperatingLossCarryforwardsExpirationBeginningYear_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net operating loss carryforwards expiration beginning year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OperatingLossCarryforwardsExpirationBeginningYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Expiration Beginning Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OperatingLossCarryforwardsExpirationBeginningYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards expiration beginning year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Asset Acquisition, Consideration Transferred, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition, Consideration Transferred</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset acquisition purchase price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Gross unrecognized tax benefits at January 1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Gross unrecognized tax benefits at December 31</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SalariesWagesAndOfficersCompensationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Salary and Wage, Excluding Cost of Good and Service Sold [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ClosingStockPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Closing stock price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ClosingStockPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Closing stock price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ClosingStockPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Closing stock price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Financial Assets Measured at Fair Value on a Recurring Basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Impairment of Intangible Assets (Excluding Goodwill), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of intangible assets, excluding goodwill</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmbeddedDerivativeLiabilityMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Embedded Derivative Liability, Measurement Input</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmbeddedDerivativeLiabilityMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value contingent consideration measurement input</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAgreementTerminationDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Termination description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAgreementTerminationDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement Termination Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAgreementTerminationDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration agreement termination description.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Basic and Diluted Net Income (loss) Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FairMarketValueOfCommonStockIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair market value of the common stock issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FairMarketValueOfCommonStockIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Market Value Of Common Stock Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FairMarketValueOfCommonStockIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair market value of common stock issued.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RegulatoryMilestonePaymentOnLicensedProductLowEndOfTheRange_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Regulatory milestone payment on licensed product, low end of the range</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RegulatoryMilestonePaymentOnLicensedProductLowEndOfTheRange_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Regulatory milestone payment on licensed product, low end of the range.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RegulatoryMilestonePaymentOnLicensedProductLowEndOfTheRange_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Regulatory Milestone Payment On Licensed Product Low End Of The Range</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options vesting period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RegulatoryMilestonePaymentOnLicensedProductHighEndOfRange_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Regulatory milestone payment on licensed product, high end of the range.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RegulatoryMilestonePaymentOnLicensedProductHighEndOfRange_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Regulatory Milestone Payment On Licensed Product High End Of Range</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RegulatoryMilestonePaymentOnLicensedProductHighEndOfRange_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Regulatory milestone payment on licensed product, high end of the range</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BiologicalMaterialsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Biological materials.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BiologicalMaterialsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Biological Materials [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BiologicalMaterialsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Biological Materials</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Selected Quarterly Financial Data</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Quarterly Financial Information [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ReclassifiedDeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassified deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ReclassifiedDeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reclassified Deferred Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ReclassifiedDeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reclassified deferred revenue.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OptionExerciseFeeHighEndOfTheRange_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option exercise fee, high end of the range</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OptionExerciseFeeHighEndOfTheRange_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the high end of the range of option exercise fee upon exercise of a program.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OptionExerciseFeeHighEndOfTheRange_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option exercise fee, high end of the range</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PercentageOfUpfrontPaymentReceivableAtEffectiveDateOfAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of upfront payment receivable at effective date of agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PercentageOfUpfrontPaymentReceivableAtEffectiveDateOfAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Upfront Payment Receivable At Effective Date Of Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PercentageOfUpfrontPaymentReceivableAtEffectiveDateOfAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of upfront payment receivable at effective date of agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IPO</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">IPO [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net proceeds from sale of convertible preferred stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of convertible preferred stock, net of issuance cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization Consolidation And Presentation Of Financial Statements [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization consolidation and presentation of financial statements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of equity investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Equity Securities, FV-NI, Unrealized Gain (Loss), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, operating lease, existence of option to extend [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Existence of Option to Extend [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandTwentyXencorAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty xencor agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandTwentyXencorAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Xencor Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandTwentyXencorAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Xencor Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options,Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AntibodyLicenseTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Transaction price for the Antibody License under the collaboration agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AntibodyLicenseTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antibody License Transaction Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AntibodyLicenseTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antibody license transaction price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Liabilities, Noncurrent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long-term liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Changes in Estimated Fair Value of Financial Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split, conversion ratio</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Input Risk Free Interest Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ValueOfSharesTransferredToCollaborator_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Value of shares transferred to collaborator</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ValueOfSharesTransferredToCollaborator_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Value of shares transferred to collaborator under the terms of the collaboration agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selling, General and Administrative Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Selling, General and Administrative Expenses [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationTypeAndPrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration Type and Programs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationTypeAndPrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Type and Programs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationTypeAndPrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration type and program</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_HepatitisBVirusProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">HBV product</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_HepatitisBVirusProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Hepatitis B Virus Product [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_HepatitisBVirusProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Hepatitis B Virus Product Member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Shares, Unvested, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Shares, Unvested, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201814Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2018-14</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201814Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2018-14 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_IncreaseDecreaseInResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_IncreaseDecreaseInResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Research And Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_IncreaseDecreaseInResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in research And development expense.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_IncreaseDecreaseInResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Increase (decrease) in research and development expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Prepaid Expense and Other Assets, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContingentConsiderationByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Consideration by Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContingentConsiderationByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration by Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SamsungBiologicsCompanyLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Samsung Biologics Co., Ltd</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SamsungBiologicsCompanyLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Samsung Biologics Company Limited [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SamsungBiologicsCompanyLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Samsung Biologics Co., Ltd.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Options,Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Options,Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share purchase price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TaxCreditCarryforwardsExpirationBeginningYear_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Tax credit carryforwards expiration beginning year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TaxCreditCarryforwardsExpirationBeginningYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforwards Expiration Beginning Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TaxCreditCarryforwardsExpirationBeginningYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax credit carryforwards expiration beginning year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_NonCashCommonStockIssuedForContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock issued for payment of contingent consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_NonCashCommonStockIssuedForContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non cash common stock issued for contingent consideration.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_NonCashCommonStockIssuedForContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Cash Common Stock Issued For Contingent Consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Marketable Securities, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Intangible Assets, Net (Excluding Goodwill), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MilestonePaymentsRelatedTermsDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments related terms</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MilestonePaymentsRelatedTermsDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments Related Terms Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MilestonePaymentsRelatedTermsDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments related terms description.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest and penalties accrued related to uncertain tax positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RegulatoryMilestoneAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Regulatory milestones achieved during the reporting period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RegulatoryMilestoneAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Regulatory Milestone Achieved</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RegulatoryMilestoneAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Regulatory milestone achieved</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DeterminedTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Determined transaction price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DeterminedTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Determined Transaction Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DeterminedTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Determined transaction price.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net income (loss) per share, basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TotalcollaborationRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total collaboration revenue, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TotalcollaborationRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total collaboration revenue, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TotalcollaborationRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Totalcollaboration revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TotalcollaborationRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Totalcollaboration revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASSETS</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AssetAcquisitionMilestonePaymentAggregate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">For contingent consideration arrangements recognized in connection with an asset acquisition, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AssetAcquisitionMilestonePaymentAggregate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition Milestone Payment Aggregate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AssetAcquisitionMilestonePaymentAggregate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments aggregate amount payable, maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CommonStockSharesPurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock, Shares Purchased</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CommonStockSharesPurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Purchased</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CommonStockSharesPurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common Stock, Shares Purchased</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SwissFederalTaxAdministrationFTAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Swiss Federal Tax Administration (FTA)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SwissFederalTaxAdministrationFTAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Swiss Federal Tax Administration (FTA) [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RangeOfRoyaltyPaymentToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Range of royalty payment to be received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RangeOfRoyaltyPaymentToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Range of royalty payment to be received by the company upon exercised of the development programs by counterparty.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RangeOfRoyaltyPaymentToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Range of Royalty Payment to be Received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH TO THE CONSOLIDATED BALANCE SHEETS:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected stock price volatility,minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAgreementNumberOfUnitsOfAccount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration agreement, number of units of account.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAgreementNumberOfUnitsOfAccount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement Number Of Units Of Account</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAgreementNumberOfUnitsOfAccount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of units of account</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ConvertiblePreferredStockIssuanceCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, net of issuance cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ConvertiblePreferredStockIssuanceCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock Issuance Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ConvertiblePreferredStockIssuanceCost_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible preferred stock issuance cost.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ValueStockIssuedGrantAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Total value of common stock issued in connection with the grant agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ValueStockIssuedGrantAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Value Stock Issued Grant Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ValueStockIssuedGrantAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Value of common stock issued in connection with the grant agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, shares sold, price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_IssuanceOfCommonStockInConnectionWithAGrantAgreementShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in connection with a grant agreement (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_IssuanceOfCommonStockInConnectionWithAGrantAgreementShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of common stock in connection with a grant agreement, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_IssuanceOfCommonStockInConnectionWithAGrantAgreementShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock in connection with a grant agreement, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandNineteenEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandNineteenEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen Employee Stock Purchase Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandNineteenEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand nineteen employee stock purchase plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_NumberOfClassOfStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of class of stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_NumberOfClassOfStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Class of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_NumberOfClassOfStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of class of stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumAmountGrantAggregate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potential maximum amount of grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumAmountGrantAggregate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Amount Grant Aggregate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumAmountGrantAggregate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum Amount Grant Aggregate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_LicenseAgreementUpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License agreement upfront payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_LicenseAgreementUpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Upfront Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_LicenseAgreementUpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement upfront payment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RestrictedStockLiabilityRecognizedForPortionOfPromissoryNoteRepayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted stock liability recognized for portion of promissory note repayment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RestrictedStockLiabilityRecognizedForPortionOfPromissoryNoteRepayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Liability Recognized For Portion Of Promissory Note Repayment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RestrictedStockLiabilityRecognizedForPortionOfPromissoryNoteRepayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted stock liability recognized for portion of promissory note repayment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodSharesAchievementOfMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in connection with the achievement of a milestone (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodSharesAchievementOfMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Achievement Of Milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodSharesAchievementOfMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares achievement of milestone.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment of Intangible Assets, Finite-Lived</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less impairment of intangible assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Impairment of intangible assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of intangible assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid during the period for income tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes Paid, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Taxes Paid, Net, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RepaymentOfOutstandingPromissoryNotesAndAccruedInterestReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repayment of outstanding promissory notes and accrued interest received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RepaymentOfOutstandingPromissoryNotesAndAccruedInterestReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayment Of Outstanding Promissory Notes And Accrued Interest Received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RepaymentOfOutstandingPromissoryNotesAndAccruedInterestReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Repayment of outstanding promissory notes and accrued interest received.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DevelopedTechnologyRightsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Developed Technologies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DevelopedTechnologyRightsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Developed Technology Rights [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_InfectiousDiseaseProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Infectious Disease Product [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_InfectiousDiseaseProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Infectious Disease Product [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net income (loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ProfitSharingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Profit-sharing amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ProfitSharingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Profit sharing amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ProfitSharingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Profit sharing amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Transaction Gain (Loss), Unrealized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign Currency Transaction Gain Loss Unrealized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CURRENT ASSETS:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ProceedsFromIssuanceOfCommonStockInConnectionWithCollaboration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds From Issuance of Common Stock in Connection With Collaboration.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ProceedsFromIssuanceOfCommonStockInConnectionWithCollaboration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance of Common Stock in Connection With Collaboration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ProceedsFromIssuanceOfCommonStockInConnectionWithCollaboration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock in connection with a collaboration agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RoyaltiesPaymentExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of years that royalties payment expired.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RoyaltiesPaymentExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalties Payment Expiration Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RoyaltiesPaymentExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Royalties payment expiration period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants issued, exercise price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumMilestonePaymentForAchievementOfSpecifiedMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum milestone payment for achievement of specified milestones</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumMilestonePaymentForAchievementOfSpecifiedMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Milestone Payment For Achievement Of Specified Milestones</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumMilestonePaymentForAchievementOfSpecifiedMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum Milestone Payment For Achievement Of Specified Milestones</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue from Related Parties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Related Parties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandAndTwentyOneGSKCollaborationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 GSK Collaboration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandAndTwentyOneGSKCollaborationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2021 GSK Collaboration [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandAndTwentyOneGSKCollaborationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty One G S K Collaboration [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BankTimeDepositsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Bank Time Deposits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BankTimeDepositsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Bank Time Deposits [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Addition for tax positions taken in the prior years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_EsppDiscountedPurchasePricePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">ESPP Discounted Purchase Price Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_EsppDiscountedPurchasePricePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ESPP Discounted Purchase Price Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_EsppDiscountedPurchasePricePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ESPP discounted purchase price percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DevelopedTechnologyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Developed Technology</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DevelopedTechnologyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Developed Technology [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DevelopedTechnologyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Developed technology.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ContractRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ContractRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract Revenue [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ContractRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract revenue.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued and Other Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accrued Liabilities And Other Liabilities Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of accrued liabilities and other liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand wenty Glaxo Wellcome UK Limited and Beecham S.A.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Glaxo Wellcome U K Limited And Beecham S A [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 GSK</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Domestic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest and penalties expense related to uncertain tax positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated remaining useful lives</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ContingentConsiderationLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Contingent Consideration Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ContingentConsiderationLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ContingentConsiderationLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration Liability [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ContingentConsiderationLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent consideration liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares, Vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill impairment loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill, Impairment Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PercentageOfDevelopmentCostsResponsibleByGsk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of development costs responsible by GSK</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PercentageOfDevelopmentCostsResponsibleByGsk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Development Costs Responsible By GSK</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PercentageOfDevelopmentCostsResponsibleByGsk_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of development costs that GSK is responsible for.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BusinessAgreementGrantAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business agreement grant amount.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BusinessAgreementGrantAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Agreement Grant Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BusinessAgreementGrantAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business agreement grant amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CURRENT LIABILITIES:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income taxes table.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PresentValueOfOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Present value of operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PresentValueOfOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Present Value Of Operating Lease Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PresentValueOfOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Present value of lessee's discounted obligation for lease payments from operating lease, net of tenant improvement allowance yet to be received.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PresentValueOfOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Present value of operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MeasurementInputProbabilityRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Probability of Achievement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MeasurementInputProbabilityRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Probability Rate [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MeasurementInputProbabilityRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Measurement input, probability rate.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined contribution plan, company contribution</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PaymentToCollaboratorResultingFromProgramOptionExercise_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment to collaborator resulting from program option exercise</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PaymentToCollaboratorResultingFromProgramOptionExercise_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of payment to a collaborator due to a program option exercise under a separate agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PaymentToCollaboratorResultingFromProgramOptionExercise_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment to collaborator resulting from program option exercise</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandTwentyOneStockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Stock Purchase Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandTwentyOneStockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty One Stock Purchase Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandTwentyOneStockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty one stock purchase agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized losses on investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetirementPlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Retirement Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetirementPlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Plan Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ThirdClosingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Third Closing</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ThirdClosingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Third Closing [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ThirdClosingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Third closing.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticePeriodToTerminateAgreementByCounterparty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written notice period to terminate agreement by counterparty</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticePeriodToTerminateAgreementByCounterparty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Written notice period to terminate agreement by counterparty.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticePeriodToTerminateAgreementByCounterparty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Notice Period to Terminate Agreement by Counterparty</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Fixtures</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnTerminationOfLease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Termination of Lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnTerminationOfLease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gain from a sublease termination</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnTerminationOfLease_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gain from a sublease termination</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MedImmuneAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">MedImmune agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MedImmuneAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Med Immune Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MedImmuneAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">MedImmune Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options,Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock option (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill and Intangible Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock-based Compensation Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PaymentMadeForAssetAcquisitionMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment made for asset acquisition milestone.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PaymentMadeForAssetAcquisitionMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment Made For Asset Acquisition Milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PaymentMadeForAssetAcquisitionMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment made for asset acquisition milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of restricted common stock (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Vesting of restricted common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Derivative Liability, Fair Value, Gross Liability, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated fair value of the derivative liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Liability, Subject to Master Netting Arrangement, before Offset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Liabilities, Gross, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Deferred tax liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_EstimatedSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Estimated Shares Employee Stock Purchase Plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_EstimatedSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Estimated Shares Employee Stock Purchase Plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_EstimatedSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated shares to be issued under plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RangeOfRoyaltyPaymentToBePaid_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Range of royalty payment to be paid by counterparty.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RangeOfRoyaltyPaymentToBePaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Range of Royalty Payment to be Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RangeOfRoyaltyPaymentToBePaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Range of royalty payment to be paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_XencorIncorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Xencor</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_XencorIncorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Xencor Incorporation [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_XencorIncorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Xencor, incorporation member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">WuXi Biologics MSA and Samsung MSA</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Wuxi Biologics And Samsung Letter Agreement Assignments And Master Services Agreements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">WuXi biologics and Samsung letter agreement assignments and master services agreements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-term Investments, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Vested and exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ConvertiblePreferredStockWarrantLiabilityTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock Warrant Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ConvertiblePreferredStockWarrantLiabilityTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock Warrant Liability [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ConvertiblePreferredStockWarrantLiabilityTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of key terms of the warrant agreement and valuation assumptions.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, estimated useful life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OptionExerciseFeeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option exercise fee received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OptionExerciseFeeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option Exercise Fee Received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OptionExerciseFeeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Option exercise fee received.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined contribution plan, contribution expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Tax Authority [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Financial Instruments, Liabilities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201818Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2018-18</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201818Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2018-18 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandSeventeenGrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2017 Grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandSeventeenGrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Seventeen Grant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandSeventeenGrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand seventeen grant.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_OwnershipAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ownership [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BusinessAgreementEquityInvestmentCommitment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business agreement equity investment commitment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BusinessAgreementEquityInvestmentCommitment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Agreement Equity Investment Commitment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BusinessAgreementEquityInvestmentCommitment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business agreement equity investment commitment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201704Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2017-04</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201704Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2017-04 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selling, general and administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Selling, General and Administrative Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Selling, General and Administrative Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OperatingAndFinanceRentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OperatingAndFinanceRentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating And Finance Rent Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OperatingAndFinanceRentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating and finance rent expense.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive income (loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Risk-free interest rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Other Operating Assets, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Operating Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AustralianTaxationOfficeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Australian Taxation Office</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AustralianTaxationOfficeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Australian Taxation Office [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Well-known Seasoned Issuer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PercentageOfOrdinaryShareEqualToOutstandingShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of ordinary share equal to outstanding share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PercentageOfOrdinaryShareEqualToOutstandingShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Ordinary Share Equal To Outstanding Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PercentageOfOrdinaryShareEqualToOutstandingShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of ordinary share equal to outstanding share.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ProfitSharingAmountConstrained_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Profit-sharing amount constrained</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ProfitSharingAmountConstrained_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Profit sharing amount constrained</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ProfitSharingAmountConstrained_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Profit sharing amount constrained</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable lease cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Separately Recognized Transactions [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumAmountGrantBasePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum amount of grant during the base period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumAmountGrantBasePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Amount Grant Base Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumAmountGrantBasePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum Amount Grant Base Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FinancialAssetsAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Assets, Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FinancialAssetsAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Financial Assets, Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FinancialAssetsAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Assets Amortized Cost Basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FinancialAssetsAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Financial assets amortized cost basis.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GrantAgreementEffectiveEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Grant agreement effective end date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GrantAgreementEffectiveEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grant Agreement Effective End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GrantAgreementEffectiveEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant agreement effective end date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ConcentrationOfCreditRiskCreditLossAndOtherRisksAndUncertaintiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk, Credit Loss and Other Risks and Uncertainties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ConcentrationOfCreditRiskCreditLossAndOtherRisksAndUncertaintiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Of Credit Risk Credit Loss And Other Risks And Uncertainties Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ConcentrationOfCreditRiskCreditLossAndOtherRisksAndUncertaintiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Concentration of credit risk credit loss and other risks and uncertainties.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, estimated useful lives description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Estimated Useful Lives</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive shares excluded from calculation of diluted net loss per share (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NONCASH INVESTING AND FINANCING ACTIVITIES:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SpecifiedSalesDevelopmentMilestonesPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Specified sales development milestones payment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SpecifiedSalesDevelopmentMilestonesPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Specified Sales Development Milestones Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SpecifiedSalesDevelopmentMilestonesPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Specified sales development milestones payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandAndTwentyOneGSKAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 GSK Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandAndTwentyOneGSKAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2021 GSK Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandAndTwentyOneGSKAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty One G S K Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_IncrementalCommonSharesAttributabletoShareBasedPaymentArrangementsEmployeeStockPurchasePlan" xlink:to="vir_IncrementalCommonSharesAttributabletoShareBasedPaymentArrangementsEmployeeStockPurchasePlan_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_LeaseArrangementContractualExpirationEndingYear" xlink:to="vir_LeaseArrangementContractualExpirationEndingYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MaximumAggregateDevelopmentAndRegulatoryMilestonePayments" xlink:to="vir_MaximumAggregateDevelopmentAndRegulatoryMilestonePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_PremiumReceivedOnSalePriceOfCommonStock" xlink:to="vir_PremiumReceivedOnSalePriceOfCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue" xlink:to="vir_IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_UpfrontPaymentReceived" xlink:to="vir_UpfrontPaymentReceived_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities" xlink:to="us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenges" xlink:to="vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenges_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_GrantAgreementExpirationDateBeforeAmendment" xlink:to="vir_GrantAgreementExpirationDateBeforeAmendment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_TwoThousandNineteenEquityIncentivePlanMember" xlink:to="vir_TwoThousandNineteenEquityIncentivePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_RegulatoryMilestonePaymentToBeReceived" xlink:to="vir_RegulatoryMilestonePaymentToBeReceived_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MaximumSalesMilestonePaymentsToBeReceived" xlink:to="vir_MaximumSalesMilestonePaymentsToBeReceived_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_AlnylamPharmaceuticalsIncMember" xlink:to="vir_AlnylamPharmaceuticalsIncMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_DeferredTaxLiabilitiesInProcessResearchAndDevelopment" xlink:to="vir_DeferredTaxLiabilitiesInProcessResearchAndDevelopment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:to="us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_GlaxoGroupLimitedMember" xlink:to="vir_GlaxoGroupLimitedMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MeasurementInputExpectedVolatilityMember" xlink:to="vir_MeasurementInputExpectedVolatilityMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_CommonStockSharesIssuedForMilestonePaymentShares" xlink:to="vir_CommonStockSharesIssuedForMilestonePaymentShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares" xlink:to="us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_NoncashLeaseExpense" xlink:to="vir_NoncashLeaseExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_OptionExerciseFeeConsiderationToBeReceived" xlink:to="vir_OptionExerciseFeeConsiderationToBeReceived_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_CollaborationAgreementRelatedCostsAndExpenses" xlink:to="vir_CollaborationAgreementRelatedCostsAndExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MaximumAggregateCommercialSalesMilestonePayments" xlink:to="vir_MaximumAggregateCommercialSalesMilestonePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant" xlink:to="vir_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_LaboratoryEquipmentMember" xlink:to="vir_LaboratoryEquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_SeriesBConvertiblePreferredStockMember" xlink:to="vir_SeriesBConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_FinancialAssetsFairValue" xlink:to="vir_FinancialAssetsFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans" xlink:to="vir_NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_AlnylamAgreementMember" xlink:to="vir_AlnylamAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_SeriesATwoConvertiblePreferredStockMember" xlink:to="vir_SeriesATwoConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_PaymentCommitmentManufacturingCapacity" xlink:to="vir_PaymentCommitmentManufacturingCapacity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenge" xlink:to="vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenge_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:to="us-gaap_IndefinitelivedIntangibleAssetsAcquired_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_AssetAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration" xlink:to="vir_AssetAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MilestonePaymentsPaid" xlink:to="vir_MilestonePaymentsPaid_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="vir_SummaryOfSignificantAccountingPoliciesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_TomegaVaxIncMember" xlink:to="vir_TomegaVaxIncMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputDiscountRateMember" xlink:to="us-gaap_MeasurementInputDiscountRateMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockPlans" xlink:to="us-gaap_ProceedsFromStockPlans_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_HumanImmunodeficiencyVirusGrantMember" xlink:to="vir_HumanImmunodeficiencyVirusGrantMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ClinicalDevelopmentMember" xlink:to="vir_ClinicalDevelopmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LaborAndRelatedExpense" xlink:to="us-gaap_LaborAndRelatedExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_TwoThousandAndTwentyGskAgreementMember" xlink:to="vir_TwoThousandAndTwentyGskAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsPolicy" xlink:to="us-gaap_BusinessCombinationsPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_DevelopmentAndManufacturingCollaborationAgreementMember" xlink:to="vir_DevelopmentAndManufacturingCollaborationAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_DevelopmentProgramsExercisedByVirMember" xlink:to="vir_DevelopmentProgramsExercisedByVirMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_NationalInstitutesOfHealthMember" xlink:to="vir_NationalInstitutesOfHealthMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_SaleOfStockConsiderationAggregateOfferingPrice" xlink:to="vir_SaleOfStockConsiderationAggregateOfferingPrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_StockIssuedDuringPeriodWarrantExercised" xlink:to="vir_StockIssuedDuringPeriodWarrantExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_OR" xlink:to="stpr_OR_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember" xlink:to="vir_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:to="us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember" xlink:to="vir_TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ProceedsFromIssuanceSecondaryPublicOffering" xlink:to="vir_ProceedsFromIssuanceSecondaryPublicOffering_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_UpfrontPaymentReceivable" xlink:to="vir_UpfrontPaymentReceivable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_GrantAgreementExpirationDate" xlink:to="vir_GrantAgreementExpirationDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_GlaxoSmithKlineTradingServiceLimitedMember" xlink:to="vir_GlaxoSmithKlineTradingServiceLimitedMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_BillMelindaGatesFoundationMember" xlink:to="vir_BillMelindaGatesFoundationMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone" xlink:to="vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_OperatingLeaseIncentiveOverLeaseLiabilities" xlink:to="vir_OperatingLeaseIncentiveOverLeaseLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainContingenciesLineItems" xlink:to="us-gaap_GainContingenciesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssets" xlink:to="us-gaap_OtherAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_RangeOfRoyaltyPaymentsToBeReceived" xlink:to="vir_RangeOfRoyaltyPaymentsToBeReceived_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_PaymentCommitmentRawMaterials" xlink:to="vir_PaymentCommitmentRawMaterials_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueNotFromContractWithCustomer" xlink:to="us-gaap_RevenueNotFromContractWithCustomer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_OptionExerciseFeeLowEndOfTheRange" xlink:to="vir_OptionExerciseFeeLowEndOfTheRange_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_InitialPublicOfferingCosts" xlink:to="vir_InitialPublicOfferingCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ClinicalDevelopmentAndManufacturingOrganizationMember" xlink:to="vir_ClinicalDevelopmentAndManufacturingOrganizationMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ChangesInEstimatedConstraintOnProfitSharingAmount" xlink:to="vir_ChangesInEstimatedConstraintOnProfitSharingAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201602Member" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_FirstPlanMember" xlink:to="vir_FirstPlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_WrittenNoticeToTerminateLicensedProgramIfNotExercise" xlink:to="vir_WrittenNoticeToTerminateLicensedProgramIfNotExercise_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_Vir3434Member" xlink:to="vir_Vir3434Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ProceedsFromIssuanceOfCommonStockInConnectionWithAGrantAgreement" xlink:to="vir_ProceedsFromIssuanceOfCommonStockInConnectionWithAGrantAgreement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_WrittenNoticePeriodForTerminationOfLicensedProgram" xlink:to="vir_WrittenNoticePeriodForTerminationOfLicensedProgram_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" xlink:to="us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_SpecifiedResearchAndDevelopmentExpensesMilestonePayments" xlink:to="vir_SpecifiedResearchAndDevelopmentExpensesMilestonePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionPlansDefinedBenefitMember" xlink:to="us-gaap_PensionPlansDefinedBenefitMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ProfitShareAmountConstraint" xlink:to="vir_ProfitShareAmountConstraint_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived" xlink:to="vir_LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_LeaseArrangementContractualExpirationBeginningYear" xlink:to="vir_LeaseArrangementContractualExpirationBeginningYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesEmbeddedDerivatives" xlink:to="us-gaap_DerivativesEmbeddedDerivatives_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_TemporaryEquityTextBlock" xlink:to="vir_TemporaryEquityTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_WuXiBiologicsLimitedMember" xlink:to="vir_WuXiBiologicsLimitedMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved" xlink:to="vir_BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedAtFairValue" xlink:to="us-gaap_InvestmentOwnedAtFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_WuxiBiologicsLetterAgreementAssignmentAndMasterServiceAgreementsMember" xlink:to="vir_WuxiBiologicsLetterAgreementAssignmentAndMasterServiceAgreementsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:to="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_WarrantsToPurchaseCommonStockMember" xlink:to="vir_WarrantsToPurchaseCommonStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_FairValueReclassificationOfDerivativeLiabilityToAccruedLiabilitiesUponAchievementOfDevelopmentMilestone" xlink:to="vir_FairValueReclassificationOfDerivativeLiabilityToAccruedLiabilitiesUponAchievementOfDevelopmentMilestone_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_VaccineProgramMember" xlink:to="vir_VaccineProgramMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_AnotherProductMember" xlink:to="vir_AnotherProductMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_DevelopmentProgramsExercisedByBriiMember" xlink:to="vir_DevelopmentProgramsExercisedByBriiMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancingReceivableAccruedInterestWriteoff" xlink:to="us-gaap_FinancingReceivableAccruedInterestWriteoff_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MaximumNumberOfProductsCoveredAgainstMilestonePayment" xlink:to="vir_MaximumNumberOfProductsCoveredAgainstMilestonePayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ReconciliationOfEffectiveIncomeTaxRateLineItems" xlink:to="vir_ReconciliationOfEffectiveIncomeTaxRateLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201409Member" xlink:to="us-gaap_AccountingStandardsUpdate201409Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_TuberculosisTBGrantMember" xlink:to="vir_TuberculosisTBGrantMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_LetterAgreementMember" xlink:to="vir_LetterAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAgreementsMember" xlink:to="us-gaap_LeaseAgreementsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_WrittenNoticePeriodToTerminateAgreementByCompany" xlink:to="vir_WrittenNoticePeriodToTerminateAgreementByCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantMember" xlink:to="us-gaap_GrantMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_CashCashEquivalentsAndShortTermInvestmentsExcludingEquityInvestment" xlink:to="vir_CashCashEquivalentsAndShortTermInvestmentsExcludingEquityInvestment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy" xlink:to="us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:to="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_GlaxoWellcomeUKLimitedAndBeechamSAMember" xlink:to="vir_GlaxoWellcomeUKLimitedAndBeechamSAMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_RestrictedStockAwardsRSAMember" xlink:to="vir_RestrictedStockAwardsRSAMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_PaymentsOfUnderwritingDiscountsAndCommissions" xlink:to="vir_PaymentsOfUnderwritingDiscountsAndCommissions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_PercentageOfDevelopmentCostsResponsibleByCompany" xlink:to="vir_PercentageOfDevelopmentCostsResponsibleByCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainContingenciesTable" xlink:to="us-gaap_GainContingenciesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="vir_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_AssetAcquisitionMilestoneAchieved" xlink:to="vir_AssetAcquisitionMilestoneAchieved_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ExcessFundsPayableUnderGrantAgreementsCurrent" xlink:to="vir_ExcessFundsPayableUnderGrantAgreementsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_SARSCoV2ProductMember" xlink:to="vir_SARSCoV2ProductMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueByLiabilityClassAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_TwoThousandNineteenXencorAgreementMember" xlink:to="vir_TwoThousandNineteenXencorAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ClinicalAndRegulatoryMilestonesMember" xlink:to="vir_ClinicalAndRegulatoryMilestonesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_CollaborationAgreementTransactionPriceConsideration" xlink:to="vir_CollaborationAgreementTransactionPriceConsideration_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_SalesMilestonesAchieved" xlink:to="vir_SalesMilestonesAchieved_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_BusinessAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration" xlink:to="vir_BusinessAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_SummaryOfSignificantAccountingPoliciesTable" xlink:to="vir_SummaryOfSignificantAccountingPoliciesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_PercentageOfAggregateGrossProceedsFromSaleOfShares" xlink:to="vir_PercentageOfAggregateGrossProceedsFromSaleOfShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="us-gaap_ContingentConsiderationTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_PaymentOfContingentConsideration" xlink:to="vir_PaymentOfContingentConsideration_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_GrantAgreementAmendedDate" xlink:to="vir_GrantAgreementAmendedDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_WrittenNoticeToTerminateLicensedProgramIfExercise" xlink:to="vir_WrittenNoticeToTerminateLicensedProgramIfExercise_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MedImmuneLimitedLiabilityCompanyMember" xlink:to="vir_MedImmuneLimitedLiabilityCompanyMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MeasurementInputExpectedRevenueVolatilityMember" xlink:to="vir_MeasurementInputExpectedRevenueVolatilityMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_RoyaltyObligationPeriodFromDateOfFirstCommercialSale" xlink:to="vir_RoyaltyObligationPeriodFromDateOfFirstCommercialSale_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_UnusedFundsReceivedInAdvance" xlink:to="vir_UnusedFundsReceivedInAdvance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_StockIssuedGrantAgreement" xlink:to="vir_StockIssuedGrantAgreement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_OperatingLeaseOtherInformationAbstract" xlink:to="vir_OperatingLeaseOtherInformationAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:to="us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MaximumAggregateMilestonePayments" xlink:to="vir_MaximumAggregateMilestonePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_EquityInvestmentCurrent" xlink:to="vir_EquityInvestmentCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_CollaborationRevenueTableTextBlock" xlink:to="vir_CollaborationRevenueTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_OfferingPeriodEmployeeStockPurchasePlan" xlink:to="vir_OfferingPeriodEmployeeStockPurchasePlan_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_GrantAwardedAmountMaximum" xlink:to="vir_GrantAwardedAmountMaximum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_SpecifiedClinicalDevelopmentMilestonesPayment" xlink:to="vir_SpecifiedClinicalDevelopmentMilestonesPayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_FirstInfectiousDiseaseProductMember" xlink:to="vir_FirstInfectiousDiseaseProductMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ReclassificationOfPreferredStockWarrantLiabilityToAdditionalPaidInCapital" xlink:to="vir_ReclassificationOfPreferredStockWarrantLiabilityToAdditionalPaidInCapital_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_IncomeTaxesLineItems" xlink:to="vir_IncomeTaxesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_OperatingLossCarryforwardsLimitationOnUsePercentage" xlink:to="vir_OperatingLossCarryforwardsLimitationOnUsePercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_GrantAwardedAmount" xlink:to="vir_GrantAwardedAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ConvertiblePreferredStockWarrantLiabilityMember" xlink:to="vir_ConvertiblePreferredStockWarrantLiabilityMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ConversionOfPreferredStockIntoCommonStockUponCompletionOfInitialPublicOffering" xlink:to="vir_ConversionOfPreferredStockIntoCommonStockUponCompletionOfInitialPublicOffering_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate" xlink:to="vir_CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentInProcess" xlink:to="us-gaap_ResearchAndDevelopmentInProcess_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TenantImprovements" xlink:to="us-gaap_TenantImprovements_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_CommonStockSharesIssuedFairMarketValue" xlink:to="vir_CommonStockSharesIssuedFairMarketValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_FollowOnOfferingMember" xlink:to="vir_FollowOnOfferingMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting" xlink:to="vir_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_EstimatedSharesIssuableUnderTheESPPMember" xlink:to="vir_EstimatedSharesIssuableUnderTheESPPMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_GrantAgreementAmendedExpirationDate" xlink:to="vir_GrantAgreementAmendedExpirationDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_CollaborationAndLicenseAgreements" xlink:to="vir_CollaborationAndLicenseAgreements_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales" xlink:to="vir_RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_BriiBiosciencesOffshoreLimitedMember" xlink:to="vir_BriiBiosciencesOffshoreLimitedMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ReconciliationOfEffectiveIncomeTaxRateTable" xlink:to="vir_ReconciliationOfEffectiveIncomeTaxRateTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ScheduleOfGoodwillAndIntangibleAssetsTable" xlink:to="vir_ScheduleOfGoodwillAndIntangibleAssetsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract" xlink:to="us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_DeferredTaxLiabilitiesRightOfUseAssets" xlink:to="vir_DeferredTaxLiabilitiesRightOfUseAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201613Member" xlink:to="us-gaap_AccountingStandardsUpdate201613Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_RemainingPaymentForAssetAcquisitionMilestoneAggregate" xlink:to="vir_RemainingPaymentForAssetAcquisitionMilestoneAggregate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_AmendmentNumberOneMember" xlink:to="vir_AmendmentNumberOneMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_NumberOfAntibodiesToDevelop" xlink:to="vir_NumberOfAntibodiesToDevelop_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_CommonStockSharesPurchasedSharePrice" xlink:to="vir_CommonStockSharesPurchasedSharePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MilestonePaymentDueToCompany" xlink:to="vir_MilestonePaymentDueToCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MaximumAggregateMilestonePaymentForAchievementOfSpecifiedMilestones" xlink:to="vir_MaximumAggregateMilestonePaymentForAchievementOfSpecifiedMilestones_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ResearchAndDevelopmentExpenseUnderLicenseAgreement" xlink:to="vir_ResearchAndDevelopmentExpenseUnderLicenseAgreement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfMachineryAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfMachineryAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_RegulatoryMilestonesAchieved" xlink:to="vir_RegulatoryMilestonesAchieved_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncome" xlink:to="us-gaap_DeferredIncome_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_EffectiveIncomeTaxRateReconciliationPermanentItemsPercent" xlink:to="vir_EffectiveIncomeTaxRateReconciliationPermanentItemsPercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanTypeDomain" xlink:to="us-gaap_RetirementPlanTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_TemporaryEquityAdditionalSharesAuthorized" xlink:to="vir_TemporaryEquityAdditionalSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_DefinitiveCollaborationAgreementMember" xlink:to="vir_DefinitiveCollaborationAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_RockefellerUniversityMember" xlink:to="vir_RockefellerUniversityMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_BillAndMelindaGatesFoundationMember" xlink:to="vir_BillAndMelindaGatesFoundationMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInvestments" xlink:to="us-gaap_PaymentsToAcquireInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:to="vir_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_BriiAgreementMember" xlink:to="vir_BriiAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentToProjectedBenefitObligationsNetOfTax" xlink:to="vir_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentToProjectedBenefitObligationsNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_PrepaymentRawMaterials" xlink:to="vir_PrepaymentRawMaterials_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_PayrollAndRelatedExpensesCurrent" xlink:to="vir_PayrollAndRelatedExpensesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ProceedsFromDisposalOfAnEquipment" xlink:to="vir_ProceedsFromDisposalOfAnEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ValueOfCommonStockSharesIssuedForMilestonePayment" xlink:to="vir_ValueOfCommonStockSharesIssuedForMilestonePayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetRentableArea" xlink:to="us-gaap_NetRentableArea_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueAdjustment" xlink:to="us-gaap_AssetsFairValueAdjustment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_FirstSiRNAProductHBVMember" xlink:to="vir_FirstSiRNAProductHBVMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_WeightedAverageMember" xlink:to="srt_WeightedAverageMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_TenantImprovementAllowanceAggregate" xlink:to="vir_TenantImprovementAllowanceAggregate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_CashGrantAwarded" xlink:to="vir_CashGrantAwarded_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ProfitsAndLossesSharingPercentage" xlink:to="vir_ProfitsAndLossesSharingPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_InfluenzaAAndHBVResearchProgramsMember" xlink:to="vir_InfluenzaAAndHBVResearchProgramsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_StockIssuedDuringPeriodSharesIssuedForSettlementOfContingentConsideration" xlink:to="vir_StockIssuedDuringPeriodSharesIssuedForSettlementOfContingentConsideration_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_CollaborationRevenueMember" xlink:to="vir_CollaborationRevenueMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_BriiBioParentMember" xlink:to="vir_BriiBioParentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_AntibodyProgramMember" xlink:to="vir_AntibodyProgramMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionContingentConsiderationLiability" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_UnrecognizedTaxBenefitsIfRecognizedWouldReduceEffectiveTaxRate" xlink:to="vir_UnrecognizedTaxBenefitsIfRecognizedWouldReduceEffectiveTaxRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_AdjustmentsToProfitSharingAmounts" xlink:to="vir_AdjustmentsToProfitSharingAmounts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MaximumAggregateSalesMilestonePayments" xlink:to="vir_MaximumAggregateSalesMilestonePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="us-gaap_AssetAcquisitionDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_GrantAgreementsDisclosureTextBlock" xlink:to="vir_GrantAgreementsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_RockefellerAgreementMember" xlink:to="vir_RockefellerAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_OptionsTransactionPrice" xlink:to="vir_OptionsTransactionPrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_RemainingPaymentMadeForAssetAcquisitionMilestone" xlink:to="vir_RemainingPaymentMadeForAssetAcquisitionMilestone_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember" xlink:to="vir_TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_AnnualLicenseMaintenanceFees" xlink:to="vir_AnnualLicenseMaintenanceFees_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ScheduleOfGoodwillAndIntangibleAssetsLineItems" xlink:to="vir_ScheduleOfGoodwillAndIntangibleAssetsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_FairValueReclassificationOfContingentConsiderationToAccruedLiabilitiesUponAchievementOfMilestone" xlink:to="vir_FairValueReclassificationOfContingentConsiderationToAccruedLiabilitiesUponAchievementOfMilestone_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MaximumSalesMilestoneToBeReceived" xlink:to="vir_MaximumSalesMilestoneToBeReceived_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="us-gaap_OtherOperatingActivitiesCashFlowStatement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipDomain" xlink:to="srt_OwnershipDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_PercentageOfUpfrontPaymentReceivableAtExecutionDateOfAgreement" xlink:to="vir_PercentageOfUpfrontPaymentReceivableAtExecutionDateOfAgreement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_RangeOfTieredRoyaltiesToPayToNetSalesOfProducts" xlink:to="vir_RangeOfTieredRoyaltiesToPayToNetSalesOfProducts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_RoyaltiesPaymentRangeOnNetSalesOfLicensedProduct" xlink:to="vir_RoyaltiesPaymentRangeOnNetSalesOfLicensedProduct_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_HcmvVaccinePlatformGrantMember" xlink:to="vir_HcmvVaccinePlatformGrantMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_DeferredTaxAssetsLeaseLiabilities" xlink:to="vir_DeferredTaxAssetsLeaseLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_TwoThousandNineteenAndTwoThousandTwentyXencorAgreementMember" xlink:to="vir_TwoThousandNineteenAndTwoThousandTwentyXencorAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_CommonStockSharesPurchasedAggregatePurchasePrice" xlink:to="vir_CommonStockSharesPurchasedAggregatePurchasePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_StockIssuedDuringPeriodSharesCollaborationAgreement" xlink:to="vir_StockIssuedDuringPeriodSharesCollaborationAgreement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory" xlink:to="vir_MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ReleaseOfValuationAllowanceDeferredTaxInAmount" xlink:to="vir_ReleaseOfValuationAllowanceDeferredTaxInAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities" xlink:to="us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_InfluenzaAResearchProgramsMember" xlink:to="vir_InfluenzaAResearchProgramsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_PercentageOfShareDevelopmentCosts" xlink:to="vir_PercentageOfShareDevelopmentCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MaximumNumberOfDevelopmentProgramGrantedFromCounterparty" xlink:to="vir_MaximumNumberOfDevelopmentProgramGrantedFromCounterparty_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_StockIssuedDuringPeriodValueIssuedForSettlementOfContingentConsideration" xlink:to="vir_StockIssuedDuringPeriodValueIssuedForSettlementOfContingentConsideration_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetTableTextBlock" xlink:to="vir_ScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_SaleLeasebackTransactionProceedsFromFinancingObligations" xlink:to="vir_SaleLeasebackTransactionProceedsFromFinancingObligations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_SeriesAOneConvertiblePreferredStockMember" xlink:to="vir_SeriesAOneConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractBasedIntangibleAssetsMember" xlink:to="us-gaap_ContractBasedIntangibleAssetsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_UnderlyingSharesPremiumReceived" xlink:to="vir_UnderlyingSharesPremiumReceived_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionAbstract" xlink:to="us-gaap_RevenueRecognitionAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_RoyaltiesBasedOnNetSalesOfLicensedProducts" xlink:to="vir_RoyaltiesBasedOnNetSalesOfLicensedProducts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_StockIssuedDuringPeriodValueCollaborationAgreement" xlink:to="vir_StockIssuedDuringPeriodValueCollaborationAgreement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_Vir2248Member" xlink:to="vir_Vir2248Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeTaxesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_Vir2218Member" xlink:to="vir_Vir2218Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_CollaborationAgreementTransactionPriceUpfrontFee" xlink:to="vir_CollaborationAgreementTransactionPriceUpfrontFee_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRoyaltiesCurrent" xlink:to="us-gaap_AccruedRoyaltiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_WrittenNoticePeriodToTerminateLicensedProgramForPaymentBreach" xlink:to="vir_WrittenNoticePeriodToTerminateLicensedProgramForPaymentBreach_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_SalesAgreementMember" xlink:to="vir_SalesAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_PercentageOfEstimatedBatchProductionFees" xlink:to="vir_PercentageOfEstimatedBatchProductionFees_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Investments" xlink:to="us-gaap_Investments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ExecutiveOfficerAndDirectorMember" xlink:to="vir_ExecutiveOfficerAndDirectorMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MaximumSharesToBeIssued" xlink:to="vir_MaximumSharesToBeIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_StockIssuedDuringPeriodSharesLicenseAgreement" xlink:to="vir_StockIssuedDuringPeriodSharesLicenseAgreement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_FirstAndSecondClosingsMember" xlink:to="vir_FirstAndSecondClosingsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MilestonePayable" xlink:to="vir_MilestonePayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_VaccinalAntibodyGrantMember" xlink:to="vir_VaccinalAntibodyGrantMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_FundsReceivedInAdvance" xlink:to="vir_FundsReceivedInAdvance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_WrittenNoticePeriodToTerminateLicensedProgramForUncuredMaterialBreach" xlink:to="vir_WrittenNoticePeriodToTerminateLicensedProgramForUncuredMaterialBreach_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_AccruedLiabilitiesAndOtherLiabilitiesMember" xlink:to="vir_AccruedLiabilitiesAndOtherLiabilitiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_CN" xlink:to="country_CN_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_HBVProgramMember" xlink:to="vir_HBVProgramMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_FinancialAssetsGrossUnrealizedHoldingGains" xlink:to="vir_FinancialAssetsGrossUnrealizedHoldingGains_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ProfitSharingAmountPreviouslyConstrainedReleased" xlink:to="vir_ProfitSharingAmountPreviouslyConstrainedReleased_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_AdvancedProceedsAppliedToConvertiblePreferredStockIssuance" xlink:to="vir_AdvancedProceedsAppliedToConvertiblePreferredStockIssuance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_EachInfectiousDiseaseSiRNAMember" xlink:to="vir_EachInfectiousDiseaseSiRNAMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_PercentageOfDevelopmentCosts" xlink:to="vir_PercentageOfDevelopmentCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_FiniteLivedIntangibleAssetsReclassifiedFromIndefiniteLived" xlink:to="vir_FiniteLivedIntangibleAssetsReclassifiedFromIndefiniteLived_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_SummaryOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock" xlink:to="vir_SummaryOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_FiniteLivedIntangibleAssetsAccumulatedImpairment" xlink:to="vir_FiniteLivedIntangibleAssetsAccumulatedImpairment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanNameDomain" xlink:to="us-gaap_RetirementPlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember" xlink:to="vir_TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MaximumTermOfOfferingPeriodSpecifiedUnderPlan" xlink:to="vir_MaximumTermOfOfferingPeriodSpecifiedUnderPlan_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents" xlink:to="vir_BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ResearchAndDevelopmentExpensesCurrent" xlink:to="vir_ResearchAndDevelopmentExpensesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_FormerBusinessCombinationContingentConsiderationLiability" xlink:to="vir_FormerBusinessCombinationContingentConsiderationLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ConvertiblePreferredStockWarrantLiabilityAbstract" xlink:to="vir_ConvertiblePreferredStockWarrantLiabilityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:to="us-gaap_LesseeFinanceLeaseTermOfContract1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MilestonePaymentReceived" xlink:to="vir_MilestonePaymentReceived_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MinimumCommonStockPriceForMilestonePaymentsConsideration" xlink:to="vir_MinimumCommonStockPriceForMilestonePaymentsConsideration_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_FirstSiRNAProductMember" xlink:to="vir_FirstSiRNAProductMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_CommonStockIssuanceCost" xlink:to="vir_CommonStockIssuanceCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ObligationToPayCapacityReservation" xlink:to="vir_ObligationToPayCapacityReservation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_PreliminaryCollaborationAgreementMember" xlink:to="vir_PreliminaryCollaborationAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_RestrictedStockPurchaseAgreementMember" xlink:to="vir_RestrictedStockPurchaseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MaximumSalesMilestonePayment" xlink:to="vir_MaximumSalesMilestonePayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCashEquivalents_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_NetProceedsFromIssuanceSecondaryPublicOffering" xlink:to="vir_NetProceedsFromIssuanceSecondaryPublicOffering_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MaximumNumberOfDevelopmentProgramGrantedToCounterparty" xlink:to="vir_MaximumNumberOfDevelopmentProgramGrantedToCounterparty_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivable" xlink:to="us-gaap_InterestReceivable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_CollaborationAgreementMember" xlink:to="vir_CollaborationAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_TwoThousandSixteenEquityIncentivePlanMember" xlink:to="vir_TwoThousandSixteenEquityIncentivePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_PaymentMadeForBusinessCombinationMilestone" xlink:to="vir_PaymentMadeForBusinessCombinationMilestone_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_OperatingLeaseAbstract" xlink:to="vir_OperatingLeaseAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct" xlink:to="vir_MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_SecondPlanMember" xlink:to="vir_SecondPlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_GrantsAgreementAmendedDate" xlink:to="vir_GrantsAgreementAmendedDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_InfluenzaAAndInfluenzaBMember" xlink:to="vir_InfluenzaAAndInfluenzaBMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital" xlink:to="vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_StockIssuedDuringPeriodValueLicenseAgreement" xlink:to="vir_StockIssuedDuringPeriodValueLicenseAgreement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_HumabsBiomedSAMember" xlink:to="vir_HumabsBiomedSAMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_RemainingPaymentMadeForBusinessCombinationMilestone" xlink:to="vir_RemainingPaymentMadeForBusinessCombinationMilestone_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MaximumAggregateSalesMilestonePayment" xlink:to="vir_MaximumAggregateSalesMilestonePayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_FiniteLivedIntangibleAssetsAmortizationExpense" xlink:to="vir_FiniteLivedIntangibleAssetsAmortizationExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach" xlink:to="vir_WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_PreDefinedRegulatoryMilestoneConsiderationToBeReceived" xlink:to="vir_PreDefinedRegulatoryMilestoneConsiderationToBeReceived_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_CommercialMilestonesMember" xlink:to="vir_CommercialMilestonesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_FinancialAssetsGrossUnrealizedHoldingLosses" xlink:to="vir_FinancialAssetsGrossUnrealizedHoldingLosses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" xlink:to="us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_UpfrontFeePaid" xlink:to="vir_UpfrontFeePaid_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_XencorAgreementsMember" xlink:to="vir_XencorAgreementsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_PercentageOfCommissionRateFromSaleOfShares" xlink:to="vir_PercentageOfCommissionRateFromSaleOfShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_WrittenNoticePeriodToTerminateLicensedProgramForFailureToMakePayment" xlink:to="vir_WrittenNoticePeriodToTerminateLicensedProgramForFailureToMakePayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MinimumCommonStockConversionPriceForMilestonePaymentsConsideration" xlink:to="vir_MinimumCommonStockConversionPriceForMilestonePaymentsConsideration_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseMember" xlink:to="us-gaap_LicenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_TwoThousandTwentyStockPurchaseAgreementMember" xlink:to="vir_TwoThousandTwentyStockPurchaseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_OperatingLossCarryforwardsExpirationBeginningYear" xlink:to="vir_OperatingLossCarryforwardsExpirationBeginningYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalariesWagesAndOfficersCompensationAbstract" xlink:to="us-gaap_SalariesWagesAndOfficersCompensationAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ClosingStockPrice" xlink:to="vir_ClosingStockPrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmbeddedDerivativeLiabilityMeasurementInput" xlink:to="us-gaap_EmbeddedDerivativeLiabilityMeasurementInput_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_CollaborationAgreementTerminationDescription" xlink:to="vir_CollaborationAgreementTerminationDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_FairMarketValueOfCommonStockIssued" xlink:to="vir_FairMarketValueOfCommonStockIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_RegulatoryMilestonePaymentOnLicensedProductLowEndOfTheRange" xlink:to="vir_RegulatoryMilestonePaymentOnLicensedProductLowEndOfTheRange_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_RegulatoryMilestonePaymentOnLicensedProductHighEndOfRange" xlink:to="vir_RegulatoryMilestonePaymentOnLicensedProductHighEndOfRange_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_BiologicalMaterialsMember" xlink:to="vir_BiologicalMaterialsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ReclassifiedDeferredRevenue" xlink:to="vir_ReclassifiedDeferredRevenue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_OptionExerciseFeeHighEndOfTheRange" xlink:to="vir_OptionExerciseFeeHighEndOfTheRange_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_PercentageOfUpfrontPaymentReceivableAtEffectiveDateOfAgreement" xlink:to="vir_PercentageOfUpfrontPaymentReceivableAtEffectiveDateOfAgreement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_TwoThousandTwentyXencorAgreementMember" xlink:to="vir_TwoThousandTwentyXencorAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_AntibodyLicenseTransactionPrice" xlink:to="vir_AntibodyLicenseTransactionPrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ValueOfSharesTransferredToCollaborator" xlink:to="vir_ValueOfSharesTransferredToCollaborator_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_CollaborationTypeAndPrograms" xlink:to="vir_CollaborationTypeAndPrograms_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_HepatitisBVirusProductMember" xlink:to="vir_HepatitisBVirusProductMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201814Member" xlink:to="us-gaap_AccountingStandardsUpdate201814Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_IncreaseDecreaseInResearchAndDevelopmentExpense" xlink:to="vir_IncreaseDecreaseInResearchAndDevelopmentExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationByTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_SamsungBiologicsCompanyLimitedMember" xlink:to="vir_SamsungBiologicsCompanyLimitedMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_TaxCreditCarryforwardsExpirationBeginningYear" xlink:to="vir_TaxCreditCarryforwardsExpirationBeginningYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_NonCashCommonStockIssuedForContingentConsideration" xlink:to="vir_NonCashCommonStockIssuedForContingentConsideration_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MilestonePaymentsRelatedTermsDescription" xlink:to="vir_MilestonePaymentsRelatedTermsDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_RegulatoryMilestoneAchieved" xlink:to="vir_RegulatoryMilestoneAchieved_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_DeterminedTransactionPrice" xlink:to="vir_DeterminedTransactionPrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_TotalcollaborationRevenue" xlink:to="vir_TotalcollaborationRevenue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_AssetAcquisitionMilestonePaymentAggregate" xlink:to="vir_AssetAcquisitionMilestonePaymentAggregate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_CommonStockSharesPurchased" xlink:to="vir_CommonStockSharesPurchased_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SwissFederalTaxAdministrationFTAMember" xlink:to="us-gaap_SwissFederalTaxAdministrationFTAMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_RangeOfRoyaltyPaymentToBeReceived" xlink:to="vir_RangeOfRoyaltyPaymentToBeReceived_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_CollaborationAgreementNumberOfUnitsOfAccount" xlink:to="vir_CollaborationAgreementNumberOfUnitsOfAccount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ConvertiblePreferredStockIssuanceCost" xlink:to="vir_ConvertiblePreferredStockIssuanceCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ValueStockIssuedGrantAgreement" xlink:to="vir_ValueStockIssuedGrantAgreement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_IssuanceOfCommonStockInConnectionWithAGrantAgreementShares" xlink:to="vir_IssuanceOfCommonStockInConnectionWithAGrantAgreementShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_TwoThousandNineteenEmployeeStockPurchasePlanMember" xlink:to="vir_TwoThousandNineteenEmployeeStockPurchasePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_NumberOfClassOfStock" xlink:to="vir_NumberOfClassOfStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MaximumAmountGrantAggregate" xlink:to="vir_MaximumAmountGrantAggregate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_LicenseAgreementUpfrontPayment" xlink:to="vir_LicenseAgreementUpfrontPayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_RestrictedStockLiabilityRecognizedForPortionOfPromissoryNoteRepayment" xlink:to="vir_RestrictedStockLiabilityRecognizedForPortionOfPromissoryNoteRepayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_StockIssuedDuringPeriodSharesAchievementOfMilestone" xlink:to="vir_StockIssuedDuringPeriodSharesAchievementOfMilestone_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_RepaymentOfOutstandingPromissoryNotesAndAccruedInterestReceived" xlink:to="vir_RepaymentOfOutstandingPromissoryNotesAndAccruedInterestReceived_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DevelopedTechnologyRightsMember" xlink:to="us-gaap_DevelopedTechnologyRightsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_InfectiousDiseaseProductMember" xlink:to="vir_InfectiousDiseaseProductMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ProfitSharingAmount" xlink:to="vir_ProfitSharingAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="us-gaap_TemporaryEquityDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ProceedsFromIssuanceOfCommonStockInConnectionWithCollaboration" xlink:to="vir_ProceedsFromIssuanceOfCommonStockInConnectionWithCollaboration_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_RoyaltiesPaymentExpirationPeriod" xlink:to="vir_RoyaltiesPaymentExpirationPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MaximumMilestonePaymentForAchievementOfSpecifiedMilestones" xlink:to="vir_MaximumMilestonePaymentForAchievementOfSpecifiedMilestones_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromRelatedParties" xlink:to="us-gaap_RevenueFromRelatedParties_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_TwoThousandAndTwentyOneGSKCollaborationMember" xlink:to="vir_TwoThousandAndTwentyOneGSKCollaborationMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BankTimeDepositsMember" xlink:to="us-gaap_BankTimeDepositsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_EsppDiscountedPurchasePricePercentage" xlink:to="vir_EsppDiscountedPurchasePricePercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_DevelopedTechnologyMember" xlink:to="vir_DevelopedTechnologyMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ContractRevenueMember" xlink:to="vir_ContractRevenueMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock" xlink:to="vir_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember" xlink:to="vir_TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ContingentConsiderationLiabilityMember" xlink:to="vir_ContingentConsiderationLiabilityMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_PercentageOfDevelopmentCostsResponsibleByGsk" xlink:to="vir_PercentageOfDevelopmentCostsResponsibleByGsk_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_BusinessAgreementGrantAmount" xlink:to="vir_BusinessAgreementGrantAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_IncomeTaxesTable" xlink:to="vir_IncomeTaxesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_PresentValueOfOperatingLeaseLiabilities" xlink:to="vir_PresentValueOfOperatingLeaseLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MeasurementInputProbabilityRateMember" xlink:to="vir_MeasurementInputProbabilityRateMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_PaymentToCollaboratorResultingFromProgramOptionExercise" xlink:to="vir_PaymentToCollaboratorResultingFromProgramOptionExercise_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_TwoThousandTwentyOneStockPurchaseAgreementMember" xlink:to="vir_TwoThousandTwentyOneStockPurchaseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ThirdClosingMember" xlink:to="vir_ThirdClosingMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_WrittenNoticePeriodToTerminateAgreementByCounterparty" xlink:to="vir_WrittenNoticePeriodToTerminateAgreementByCounterparty_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnTerminationOfLease" xlink:to="us-gaap_GainLossOnTerminationOfLease_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MedImmuneAgreementMember" xlink:to="vir_MedImmuneAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_PaymentMadeForAssetAcquisitionMilestone" xlink:to="vir_PaymentMadeForAssetAcquisitionMilestone_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_EstimatedSharesEmployeeStockPurchasePlans" xlink:to="vir_EstimatedSharesEmployeeStockPurchasePlans_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_RangeOfRoyaltyPaymentToBePaid" xlink:to="vir_RangeOfRoyaltyPaymentToBePaid_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_XencorIncorporationMember" xlink:to="vir_XencorIncorporationMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember" xlink:to="vir_WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermInvestments" xlink:to="us-gaap_LongTermInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ConvertiblePreferredStockWarrantLiabilityTextBlock" xlink:to="vir_ConvertiblePreferredStockWarrantLiabilityTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_OptionExerciseFeeReceived" xlink:to="vir_OptionExerciseFeeReceived_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:to="us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201818Member" xlink:to="us-gaap_AccountingStandardsUpdate201818Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_TwoThousandSeventeenGrantMember" xlink:to="vir_TwoThousandSeventeenGrantMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenseMember" xlink:to="us-gaap_OtherExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_BusinessAgreementEquityInvestmentCommitment" xlink:to="vir_BusinessAgreementEquityInvestmentCommitment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201704Member" xlink:to="us-gaap_AccountingStandardsUpdate201704Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_OperatingAndFinanceRentExpense" xlink:to="vir_OperatingAndFinanceRentExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AustralianTaxationOfficeMember" xlink:to="us-gaap_AustralianTaxationOfficeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_PercentageOfOrdinaryShareEqualToOutstandingShare" xlink:to="vir_PercentageOfOrdinaryShareEqualToOutstandingShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ProfitSharingAmountConstrained" xlink:to="vir_ProfitSharingAmountConstrained_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MaximumAmountGrantBasePeriod" xlink:to="vir_MaximumAmountGrantBasePeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_FinancialAssetsAmortizedCostBasis" xlink:to="vir_FinancialAssetsAmortizedCostBasis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_GrantAgreementEffectiveEndDate" xlink:to="vir_GrantAgreementEffectiveEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ConcentrationOfCreditRiskCreditLossAndOtherRisksAndUncertaintiesPolicyTextBlock" xlink:to="vir_ConcentrationOfCreditRiskCreditLossAndOtherRisksAndUncertaintiesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_SpecifiedSalesDevelopmentMilestonesPayment" xlink:to="vir_SpecifiedSalesDevelopmentMilestonesPayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_TwoThousandAndTwentyOneGSKAgreementMember" xlink:to="vir_TwoThousandAndTwentyOneGSKAgreementMember_lbl"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139790637088176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Feb. 21, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">VIR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Vir Biotechnology, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001706431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133,531,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-39083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-2730369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">499 Illinois Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Francisco<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">906-4324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Portions of the definitive proxy statement, or the Proxy Statement, for the Registrant&#8217;s 2023 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K. The Proxy Statement will be filed with the Securities and Exchange Commission within 120 days of the Registrant&#8217;s fiscal year ended December 31, 2022.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Mateo, California<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139790630581808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 848,631<span></span>
</td>
<td class="nump">$ 347,815<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">1,521,517<span></span>
</td>
<td class="nump">217,182<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash and cash equivalents, current</a></td>
<td class="nump">12,681<span></span>
</td>
<td class="nump">8,594<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivable from collaboration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">773,079<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_EquityInvestmentCurrent', window );">Equity Investment</a></td>
<td class="nump">31,892<span></span>
</td>
<td class="nump">143,148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">104,356<span></span>
</td>
<td class="nump">73,003<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">2,519,077<span></span>
</td>
<td class="nump">1,562,821<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">32,755<span></span>
</td>
<td class="nump">33,287<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">16,937<span></span>
</td>
<td class="nump">16,937<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">105,609<span></span>
</td>
<td class="nump">42,834<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating right-of-use assets</a></td>
<td class="nump">82,557<span></span>
</td>
<td class="nump">87,220<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash and cash equivalents, noncurrent</a></td>
<td class="nump">6,656<span></span>
</td>
<td class="nump">7,006<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">23,927<span></span>
</td>
<td class="nump">201,388<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Other assets</a></td>
<td class="nump">14,570<span></span>
</td>
<td class="nump">2,775<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">2,802,088<span></span>
</td>
<td class="nump">1,954,268<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">6,422<span></span>
</td>
<td class="nump">6,521<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued and other liabilities</a></td>
<td class="nump">489,090<span></span>
</td>
<td class="nump">236,512<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue, current portion</a></td>
<td class="nump">15,517<span></span>
</td>
<td class="nump">98,209<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">511,029<span></span>
</td>
<td class="nump">341,242<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, noncurrent</a></td>
<td class="nump">53,207<span></span>
</td>
<td class="nump">3,815<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, noncurrent</a></td>
<td class="nump">123,837<span></span>
</td>
<td class="nump">133,561<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration, noncurrent</a></td>
<td class="nump">24,937<span></span>
</td>
<td class="nump">22,822<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="nump">3,253<span></span>
</td>
<td class="nump">18,439<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">7,862<span></span>
</td>
<td class="nump">2,540<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">724,125<span></span>
</td>
<td class="nump">522,419<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS&#8217; EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of December 31, 2022 and 2021, respectively; no shares issued and outstanding as of December 31, 2022 and 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 300,000,000 shares authorized as of December 31, 2022 and 2021, respectively; 131,161,404 and 131,161,404 shares issued and outstanding as of December 31, 2022 and 2021, respectively</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,709,835<span></span>
</td>
<td class="nump">1,571,535<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(9,122)<span></span>
</td>
<td class="num">(1,099)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings (Accumulated deficit)</a></td>
<td class="nump">377,237<span></span>
</td>
<td class="num">(138,600)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="nump">2,077,963<span></span>
</td>
<td class="nump">1,431,849<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="nump">$ 2,802,088<span></span>
</td>
<td class="nump">$ 1,954,268<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_EquityInvestmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Investment Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_EquityInvestmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139790636946576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">133,236,687<span></span>
</td>
<td class="nump">131,161,404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">133,236,687<span></span>
</td>
<td class="nump">131,161,404<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139790630985104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 1,615,797<span></span>
</td>
<td class="nump">$ 1,095,415<span></span>
</td>
<td class="nump">$ 76,368<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue</a></td>
<td class="nump">146,319<span></span>
</td>
<td class="nump">65,865<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">474,648<span></span>
</td>
<td class="nump">448,006<span></span>
</td>
<td class="nump">302,411<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">161,762<span></span>
</td>
<td class="nump">160,793<span></span>
</td>
<td class="nump">70,937<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">782,729<span></span>
</td>
<td class="nump">674,664<span></span>
</td>
<td class="nump">373,348<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="nump">833,068<span></span>
</td>
<td class="nump">420,751<span></span>
</td>
<td class="num">(296,980)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Change in fair value of equity investments</a></td>
<td class="num">(111,140)<span></span>
</td>
<td class="nump">138,049<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium', window );">Interest income</a></td>
<td class="nump">28,092<span></span>
</td>
<td class="nump">439<span></span>
</td>
<td class="nump">2,836<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="nump">4,260<span></span>
</td>
<td class="num">(9,437)<span></span>
</td>
<td class="num">(4,467)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="num">(78,788)<span></span>
</td>
<td class="nump">129,051<span></span>
</td>
<td class="num">(1,631)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before provision for income taxes</a></td>
<td class="nump">754,280<span></span>
</td>
<td class="nump">549,802<span></span>
</td>
<td class="num">(298,611)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="num">(238,443)<span></span>
</td>
<td class="num">(21,218)<span></span>
</td>
<td class="num">(54)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 515,837<span></span>
</td>
<td class="nump">$ 528,584<span></span>
</td>
<td class="num">$ (298,665)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per share, basic</a></td>
<td class="nump">$ 3.89<span></span>
</td>
<td class="nump">$ 4.07<span></span>
</td>
<td class="num">$ (2.51)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (loss) per share, diluted</a></td>
<td class="nump">$ 3.83<span></span>
</td>
<td class="nump">$ 3.96<span></span>
</td>
<td class="num">$ (2.51)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding, basic</a></td>
<td class="nump">132,606,767<span></span>
</td>
<td class="nump">129,884,967<span></span>
</td>
<td class="nump">119,159,424<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding, diluted</a></td>
<td class="nump">134,810,908<span></span>
</td>
<td class="nump">133,437,126<span></span>
</td>
<td class="nump">119,159,424<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=vir_CollaborationRevenueMember', window );">Collaboration Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues from contract with customers</a></td>
<td class="nump">$ 1,505,469<span></span>
</td>
<td class="nump">$ 917,194<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=vir_ContractRevenueMember', window );">Contract Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues from contract with customers</a></td>
<td class="nump">52,714<span></span>
</td>
<td class="nump">169,874<span></span>
</td>
<td class="nump">44,498<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Revenues not from contract</a></td>
<td class="nump">35,325<span></span>
</td>
<td class="nump">8,347<span></span>
</td>
<td class="nump">9,123<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues from contract with customers</a></td>
<td class="nump">$ 22,289<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 22,747<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueNotFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue that is not accounted for under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueNotFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vir_CollaborationRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vir_CollaborationRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vir_ContractRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vir_ContractRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139790636946128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income (Loss) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 515,837<span></span>
</td>
<td class="nump">$ 528,584<span></span>
</td>
<td class="num">$ (298,665)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized losses on investments</a></td>
<td class="num">(7,524)<span></span>
</td>
<td class="num">(957)<span></span>
</td>
<td class="num">(50)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax', window );">Amortization of actuarial loss</a></td>
<td class="num">(499)<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentToProjectedBenefitObligationsNetOfTax', window );">Adjustment to projected benefit obligations, net of tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,081<span></span>
</td>
<td class="num">(650)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="num">(8,023)<span></span>
</td>
<td class="nump">179<span></span>
</td>
<td class="num">(677)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss)</a></td>
<td class="nump">$ 507,814<span></span>
</td>
<td class="nump">$ 528,763<span></span>
</td>
<td class="num">$ (299,342)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL34724391-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e689-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentToProjectedBenefitObligationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other comprehensive income loss pension and other postretirement benefit plans adjustment to projected benefit obligations net of tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentToProjectedBenefitObligationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139790632886992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>Follow-on Offering</div>
</th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Follow-on Offering</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 423,942<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 793,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (601)<span></span>
</td>
<td class="num">$ (368,519)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,648,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital', window );">Reclassification of derivative liability to addition paid-in-capital</a></td>
<td class="nump">29,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_StockIssuedDuringPeriodSharesAchievementOfMilestone', window );">Issuance of common stock in connection with the achievement of a milestone (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,111,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_StockIssuedDuringPeriodValueCollaborationAgreement', window );">Issuance of common stock in connection with a collaboration agreement</a></td>
<td class="nump">206,699<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">206,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_StockIssuedDuringPeriodSharesCollaborationAgreement', window );">Issuance of common stock in connection with a collaboration agreement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,626,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant', window );">Issuance of common stock for cashless exercise of warrant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">211,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Value of shares agreed to purchase</a></td>
<td class="nump">323,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 323,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,214,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_ProceedsFromIssuanceOfCommonStockInConnectionWithAGrantAgreement', window );">Issuance of common stock in connection with a grant agreement</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Vesting of restricted common stock</a></td>
<td class="nump">1,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,986,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">4,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock option (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,618,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">27,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss</a></td>
<td class="num">(677)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(677)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(298,665)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(298,665)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="nump">716,852<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,385,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,278)<span></span>
</td>
<td class="num">(667,184)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,416,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_StockIssuedDuringPeriodValueCollaborationAgreement', window );">Issuance of common stock in connection with a collaboration agreement</a></td>
<td class="nump">85,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_StockIssuedDuringPeriodSharesCollaborationAgreement', window );">Issuance of common stock in connection with a collaboration agreement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,924,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_StockIssuedDuringPeriodValueIssuedForSettlementOfContingentConsideration', window );">Issuance of common stock to settle a contingent consideration</a></td>
<td class="nump">1,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_StockIssuedDuringPeriodSharesIssuedForSettlementOfContingentConsideration', window );">Issuance of common stock to settle a contingent consideration (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_ProceedsFromIssuanceOfCommonStockInConnectionWithAGrantAgreement', window );">Issuance of common stock in connection with a grant agreement</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">13,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock option (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,622,718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">83,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss</a></td>
<td class="nump">179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">528,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">528,584<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">$ 1,431,849<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,571,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,099)<span></span>
</td>
<td class="num">(138,600)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">131,161,404<span></span>
</td>
<td class="nump">131,161,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_ProceedsFromIssuanceOfCommonStockInConnectionWithAGrantAgreement', window );">Issuance of common stock in connection with a grant agreement</a></td>
<td class="nump">$ 28,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_IssuanceOfCommonStockInConnectionWithAGrantAgreementShares', window );">Issuance of common stock in connection with a grant agreement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">881,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">349,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">4,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock option (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">696,963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">3,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">147,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">102,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive loss</a></td>
<td class="num">(8,023)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,023)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">515,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">515,837<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="nump">$ 2,077,963<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,709,835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (9,122)<span></span>
</td>
<td class="nump">$ 377,237<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">133,236,687<span></span>
</td>
<td class="nump">133,236,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_IssuanceOfCommonStockInConnectionWithAGrantAgreementShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock in connection with a grant agreement, shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_IssuanceOfCommonStockInConnectionWithAGrantAgreementShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_ProceedsFromIssuanceOfCommonStockInConnectionWithAGrantAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock in connection with a grant agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_ProceedsFromIssuanceOfCommonStockInConnectionWithAGrantAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reclassification of derivative liability to additional paid In capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_StockIssuedDuringPeriodSharesAchievementOfMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares achievement of milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_StockIssuedDuringPeriodSharesAchievementOfMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares cashless exercise of warrant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_StockIssuedDuringPeriodSharesCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in connection with a collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_StockIssuedDuringPeriodSharesCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_StockIssuedDuringPeriodSharesIssuedForSettlementOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for settlement of contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_StockIssuedDuringPeriodSharesIssuedForSettlementOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_StockIssuedDuringPeriodValueCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in connection with a collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_StockIssuedDuringPeriodValueCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_StockIssuedDuringPeriodValueIssuedForSettlementOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued for settlement of contingent considerations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_StockIssuedDuringPeriodValueIssuedForSettlementOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139790634520624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_CommonStockIssuanceCost', window );">Common stock issuance cost</a></td>
<td class="nump">$ 21,786<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_CommonStockIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock issuance cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_CommonStockIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139790631368000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 515,837<span></span>
</td>
<td class="nump">$ 528,584<span></span>
</td>
<td class="num">$ (298,665)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_ChangesInEstimatedConstraintOnProfitSharingAmount', window );">Changes in estimated constraint on profit-sharing amount</a></td>
<td class="nump">369,535<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">6,251<span></span>
</td>
<td class="nump">5,278<span></span>
</td>
<td class="nump">4,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">532<span></span>
</td>
<td class="nump">533<span></span>
</td>
<td class="nump">1,042<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">832<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">(Accretion of discounts) amortization of premiums on investments, net</a></td>
<td class="num">(8,943)<span></span>
</td>
<td class="num">(244)<span></span>
</td>
<td class="nump">1,548<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_NoncashLeaseExpense', window );">Noncash lease expense</a></td>
<td class="nump">8,709<span></span>
</td>
<td class="nump">6,172<span></span>
</td>
<td class="nump">3,371<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueAdjustment', window );">Change in fair value of equity investments</a></td>
<td class="nump">111,140<span></span>
</td>
<td class="num">(138,049)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in estimated fair value of contingent consideration</a></td>
<td class="nump">2,115<span></span>
</td>
<td class="nump">91,848<span></span>
</td>
<td class="nump">38,394<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue', window );">Payment of contingent consideration in excess of acquisition date fair value</a></td>
<td class="num">(93,803)<span></span>
</td>
<td class="num">(8,140)<span></span>
</td>
<td class="num">(15,752)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in estimated fair value of derivative liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,796<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">102,082<span></span>
</td>
<td class="nump">83,784<span></span>
</td>
<td class="nump">27,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Change in deferred income taxes</a></td>
<td class="num">(15,186)<span></span>
</td>
<td class="nump">15,186<span></span>
</td>
<td class="num">(52)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnTerminationOfLease', window );">Gain from a sublease termination</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,844)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other</a></td>
<td class="num">(383)<span></span>
</td>
<td class="nump">697<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Receivable from collaboration</a></td>
<td class="nump">770,038<span></span>
</td>
<td class="num">(773,079)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(39,358)<span></span>
</td>
<td class="num">(3,665)<span></span>
</td>
<td class="num">(4,475)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(11,795)<span></span>
</td>
<td class="num">(1,483)<span></span>
</td>
<td class="num">(1,100)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">797<span></span>
</td>
<td class="num">(171)<span></span>
</td>
<td class="num">(790)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued liabilities and other long-term liabilities</a></td>
<td class="num">(15,513)<span></span>
</td>
<td class="nump">58,498<span></span>
</td>
<td class="nump">46,614<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(5,502)<span></span>
</td>
<td class="num">(535)<span></span>
</td>
<td class="num">(3,684)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="num">(33,300)<span></span>
</td>
<td class="nump">92,041<span></span>
</td>
<td class="num">(7,043)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="nump">1,663,253<span></span>
</td>
<td class="num">(47,589)<span></span>
</td>
<td class="num">(190,941)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfMachineryAndEquipment', window );">Proceeds from sale of an equipment</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(68,028)<span></span>
</td>
<td class="num">(21,817)<span></span>
</td>
<td class="num">(6,549)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(1,476,965)<span></span>
</td>
<td class="num">(420,240)<span></span>
</td>
<td class="num">(403,841)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Maturities of investments</a></td>
<td class="nump">351,510<span></span>
</td>
<td class="nump">301,243<span></span>
</td>
<td class="nump">400,348<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_ProceedsFromDisposalOfAnEquipment', window );">Proceeds from disposal of an asset held for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">180<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(1,193,461)<span></span>
</td>
<td class="num">(140,814)<span></span>
</td>
<td class="num">(9,862)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">323,214<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_ProceedsFromIssuanceOfCommonStockInConnectionWithCollaboration', window );">Proceeds from issuance of common stock in connection with a collaboration agreement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">85,213<span></span>
</td>
<td class="nump">206,699<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_ProceedsFromIssuanceOfCommonStockInConnectionWithAGrantAgreement', window );">Proceeds from issuance of common stock in connection with a grant agreement</a></td>
<td class="nump">28,462<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_PaymentOfContingentConsideration', window );">Payment of contingent consideration</a></td>
<td class="num">(1,197)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,248)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payment of principal on financing lease obligations</a></td>
<td class="num">(260)<span></span>
</td>
<td class="num">(259)<span></span>
</td>
<td class="num">(250)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">4,534<span></span>
</td>
<td class="nump">13,077<span></span>
</td>
<td class="nump">4,059<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from issuance of common stock under the employee stock purchase plan</a></td>
<td class="nump">3,222<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">34,761<span></span>
</td>
<td class="nump">100,331<span></span>
</td>
<td class="nump">529,474<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash, cash equivalents and restricted cash and cash equivalents</a></td>
<td class="nump">504,553<span></span>
</td>
<td class="num">(88,072)<span></span>
</td>
<td class="nump">328,671<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash and cash equivalents at beginning of period</a></td>
<td class="nump">363,415<span></span>
</td>
<td class="nump">451,487<span></span>
</td>
<td class="nump">122,816<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash and cash equivalents at end of period</a></td>
<td class="nump">867,968<span></span>
</td>
<td class="nump">363,415<span></span>
</td>
<td class="nump">451,487<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>NONCASH INVESTING AND FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment purchases included in accounts payable and accrued liabilities</a></td>
<td class="nump">1,020<span></span>
</td>
<td class="nump">8,731<span></span>
</td>
<td class="nump">382<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_NonCashCommonStockIssuedForContingentConsideration', window );">Common stock issued for payment of contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,860<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease liabilities obtained in exchange of right-of-use asset</a></td>
<td class="nump">4,046<span></span>
</td>
<td class="nump">77,187<span></span>
</td>
<td class="nump">48,495<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone', window );">Reclassification of derivative liability to additional paid-in capital</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">29,245<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURE OF CASHFLOW INFORMATION:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid during the period for income tax</a></td>
<td class="nump">252,030<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH TO THE CONSOLIDATED BALANCE SHEETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">848,631<span></span>
</td>
<td class="nump">347,815<span></span>
</td>
<td class="nump">436,575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash and cash equivalents, current</a></td>
<td class="nump">12,681<span></span>
</td>
<td class="nump">8,594<span></span>
</td>
<td class="nump">7,993<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash and cash equivalents, noncurrent</a></td>
<td class="nump">6,656<span></span>
</td>
<td class="nump">7,006<span></span>
</td>
<td class="nump">6,919<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 867,968<span></span>
</td>
<td class="nump">$ 363,415<span></span>
</td>
<td class="nump">$ 451,487<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which an asset could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnTerminationOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on termination of lease before expiration of lease term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 40<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123386189&amp;loc=SL77918607-209975<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnTerminationOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfMachineryAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sale of machinery and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfMachineryAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_ChangesInEstimatedConstraintOnProfitSharingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Changes in estimated constraint on profit-sharing amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_ChangesInEstimatedConstraintOnProfitSharingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in payment of contingent consideration in excess of acquisition date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_NonCashCommonStockIssuedForContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non cash common stock issued for contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_NonCashCommonStockIssuedForContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_NoncashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_NoncashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_PaymentOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_PaymentOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_ProceedsFromDisposalOfAnEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from disposal of an equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_ProceedsFromDisposalOfAnEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_ProceedsFromIssuanceOfCommonStockInConnectionWithAGrantAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock in connection with a grant agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_ProceedsFromIssuanceOfCommonStockInConnectionWithAGrantAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_ProceedsFromIssuanceOfCommonStockInConnectionWithCollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Issuance of Common Stock in Connection With Collaboration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_ProceedsFromIssuanceOfCommonStockInConnectionWithCollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reclassification&#8203; of derivative liability&#8203; to additional paid-&#8203;in capital upon achievement of development milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139790639699104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">1.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Organization </span></div></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vir Biotechnology, Inc. (&#8220;Vir&#8221; or the &#8220;Company&#8221;) is a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Its current pipeline consists of sotrovimab (previously VIR-7831; and where marketing authorization has been granted, marketed under the brand name Xevudy&#174;) and other product candidates targeting hepatitis B virus (&#8220;HBV&#8221;), hepatitis D virus (&#8220;HDV&#8221;), influenza A virus, coronavirus disease 2019 (&#8220;COVID-19&#8221;), and human immunodeficiency virus (&#8220;HIV&#8221;). Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In September 2022, the Company formed a new wholly-owned subsidiary in Switzerland, Vir Biotechnology International GmbH (&#8220;VBI&#8221;), a Swiss limited liability company. The primary purpose of VBI is to support Vir's research and development and international commercial activities outside of the United States.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Follow-On Offering</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On July 10, 2020, the Company issued and sold </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,214,285</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company&#8217;s common stock pursuant to a registration statement on Form S-1 (File No. 333-239689) and a registration statement on Form S-1 filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) (File No. 333-239747) (collectively, the &#8220;Registration Statements&#8221;). The Registration Statements became effective on July 7, 2020. The price of the shares sold in the follow-on offering was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share and the Company received total gross proceeds from the offering of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">345.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. After deducting underwriting discounts and commissions of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and offering expenses of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, the net proceeds were approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">323.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Sales Agreement</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In November 2020, the Company entered into a sales agreement (the &#8220;Sales Agreement&#8221;) with Cowen and Company, LLC (&#8220;Cowen&#8221;), under which the Company may from time to time offer and sell shares of its common stock for an aggregate offering price of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">300.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, through or to Cowen, acting as sales agent or principal. The shares will be offered and sold under the Company&#8217;s shelf registration statement on Form S-3 and a related prospectus filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on November 10, 2020. The Company will pay Cowen a commission of up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the aggregate gross proceeds from each sale of shares, reimburse legal fees and disbursements and provide Cowen with customary indemnification and contribution rights. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares have been issued under the Sales Agreement.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Need for Additional Capital</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Although the Company recorded net income for the years ended December 31, 2022 and 2021, respectively, it has otherwise incurred net losses since inception. The Company expects its earnings to be volatile and may continue to incur net losses over the next several years and may need to raise additional capital to fully implement its business plan. As of December 31, 2022, the Company had retained earnings of  </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">377.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Company had </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> billion</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in cash, cash equivalents, and investments as of December 31, 2022. Based on the Company&#8217;s current operating plan, management believes that the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> billion</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> as of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> will be sufficient to fund its operations through at least the next 12 months from the issuance date of these consolidated financial statements.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139790634559808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">2.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Summary of Significant Accounting Policies </span></div></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Basis of Presentation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and include all adjustments necessary for the fair presentation of the Company&#8217;s financial position for the periods presented. The consolidated financial statements include the accounts of Vir and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated upon consolidation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Foreign Currency</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The functional currency of the Company&#8217;s foreign subsidiaries is the U.S. dollar. Monetary assets and liabilities of foreign subsidiaries are translated into U.S. dollars at period-end exchange rates and non-monetary assets and liabilities are translated to U.S. dollars using historical exchange rates. Revenue and expenses are translated at average rates throughout the respective periods. Transaction gains and losses are included in other income (expense), net on the consolidated statements of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting periods. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Segments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company operates as </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> reportable segment. The Company&#8217;s chief operating decision maker, its Chief Executive Officer, manages the Company&#8217;s operations on a consolidated basis for purposes of allocating resources.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentration of Credit Risk, Credit Loss and Other Risks and Uncertainties</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Although the Company received Emergency Use Authorization (&#8220;EUA&#8221;), temporary authorization or marketing approval for sotrovimab (under the brand name Xevudy&#174;), sotrovimab is currently de-authorized in the U.S. and has limitations in use outside of the U.S. In addition, the Company is still subject to a number of other challenges and risks similar to other biopharmaceutical companies in the early stage, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its other product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of sotrovimab and other product candidates and protection of proprietary technology. If the Company does not successfully obtain regulatory approval, commercialize or partner any of its product candidates, it will be unable to generate revenue from product sales or maintain profitability. In addition, to the extent the COVID-19 pandemic, including the emergence of new variants or subvariants, adversely affects the Company&#8217;s business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties discussed above.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has implemented a number of plans and policies designed to address and mitigate the impact of the COVID-19 pandemic on its business. The extent to which the changing COVID-19 landscape impacts the Company&#8217;s business, clinical development and regulatory efforts, corporate development objectives and the value of and market for its common stock, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and investments. Cash and cash equivalents are deposited in checking and sweep accounts at a financial institution. Such deposits may, at times, exceed federally insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s investment policy limits investments to certain types of securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and investments, and issuers of the investments to the extent recorded on the consolidated balance sheets. As of December 31, 2022 and 2021, the Company has no off-balance sheet concentrations of credit risk.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is exposed to credit losses primarily through receivables from customers and collaborators and through its available-for-sale debt securities. The Company&#8217;s expected loss allowance methodology for the receivables is developed using historical collection experience, current and future economic market conditions, a review of the current aging status and financial condition of the entities. Specific allowance amounts are established to record the appropriate allowance for customers that have a higher probability of default. Balances are written off when determined to be uncollectible. The Company&#8217;s expected loss allowance methodology for the debt securities is developed by reviewing the extent of the unrealized loss, the size, term, geographical location, and industry of the issuer, the issuers&#8217; credit ratings and any changes in those ratings, as well as reviewing current and future economic market conditions and the issuers&#8217; current status and financial condition. The Company considered the current and expected future economic and market conditions surrounding the COVID-19 pandemic and interest rate policies and determined that the estimate of credit losses was not significantly impacted. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> allowance for losses on available-for-sale debt securities attributable to credit risk for the years ended December 31, 2022 and 2021.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash Equivalents</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents, which consist of amounts invested in money market funds, and are stated at fair value.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Investments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Investments include available-for-sale debt securities and equity investments, which are carried at estimated fair value.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Available-for-Sale Debt Securities</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s valuations of marketable securities are generally derived from independent pricing services based on quoted prices in active markets for similar securities at period end. Generally, investments with original maturities beyond three months at the date of purchase and which mature at, or less than 12 months from, the consolidated balance sheet date are considered short-term investments, with all others considered to be long-term investments. Unrealized gains and losses deemed temporary in nature are reported as a component of accumulated comprehensive income (loss). The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income on the consolidated statements of operations. The cost of securities sold is based on the specific identification method.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Equity Investments</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company measures its investment in equity securities at fair value at each reporting date based on the market price at period end if it has a readily determinable fair value. Otherwise, the investments in equity securities are measured at cost less impairment, adjusted for observable price changes for identical or similar investments of the same issuer unless the Company has significant influence or control over the investee. Changes in fair value resulting from observable price changes are presented as change in fair value of equity investments and changes in fair value resulting from foreign currency translation are included in other income (expense), net </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">on the consolidated statements of operations.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Restricted Cash and Cash Equivalents</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted cash and cash equivalents represent money market funds to secure standby letters of credit and security deposits with financial institutions, both under office and laboratory space lease agreements. Additionally, funds received from certain grants are restricted as to their use and are therefore classified as restricted cash and cash equivalents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Property and Equipment, Net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment are stated at cost, net of accumulated depreciation and amortization. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the respective assets, generally </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_8818a887-324c-4500-a98b-191605dee51d;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Leasehold </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">improvements are amortized over the lesser of their useful lives or the remaining life of the lease. When assets are retired or</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">otherwise </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">disposed of, the cost and related accumulated depreciation and amortization are removed from the balance sheet and the resulting gain or loss is reflected in operations in the period realized. Maintenance and repairs are charged to operations as incurred.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparing the carrying amount to the future net undiscounted cash flows which the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows arising from the asset. No material impairment losses have been incurred to date.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acquired Intangible Assets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s intangible assets were acquired via business combinations or asset acquisitions. Indefinite-lived intangible assets represent the estimated fair value assigned to in-process research and development (&#8220;IPR&amp;D&#8221;) acquired in a business combination. The Company reviews indefinite-lived intangible assets for impairment at least annually or more frequently if events or changes in circumstances indicate that the carrying value of the assets might not be recoverable. If the carrying value of an indefinite-lived intangible asset exceeds its fair value, then it is written down to its adjusted fair value. As of December 31, 2022, there have been </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> such impairments. For IPR&amp;D, if a product candidate derived from the indefinite-lived intangible asset is developed and commercialized, the useful life will be determined, and the carrying value will be amortized prospectively over that estimated useful life. Alternatively, if a product candidate is abandoned, the carrying value of the intangible asset will be charged to research and development expenses. IPR&amp;D assets acquired as part of an asset acquisition are recorded at cost and expensed immediately if they have no alternative future uses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Finite-lived intangible assets acquired are initially recognized at their fair value at the acquisition date. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortization is computed using the straight-line method over the estimated useful lives of the respective finite-lived intangible assets, generally </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_e5972bc8-c341-44f2-a1e7-401190923bbf;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">seven</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15 years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Finite-lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Goodwill</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Goodwill represents the excess of the purchase price over the estimated fair value of the net tangible and intangible assets acquired in a business combination. The Company tests goodwill for impairment at least annually or more frequently if events or changes in circumstances indicate that this asset may be impaired.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue Recognition</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Collaboration, License and Contract Revenue</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;), the Company recognizes revenue when the Company&#8217;s customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods and services. To determine revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when or as the Company satisfies a performance obligation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For collaborative arrangements that fall within the scope of ASC 808, Collaborative Arrangements (&#8220;ASC 808&#8221;), the Company first determines which elements of the collaboration are deemed to be a performance obligation with a customer within the scope of ASC 606. For elements of collaboration arrangements that are accounted for pursuant to ASC 808 and are not subject to the guidance in ASC 606, the Company applies the revenue recognition model under ASC 606, including the royalty exception guidance and variable consideration guidance under ASC 606 as described below, or other guidance, as deemed appropriate. When the Company is considered an agent in elements of collaboration arrangements within the scope of ASC 808, it records its share of collaboration revenue in the period in which such sales occur. The Company is considered an agent when the collaboration partner controls the product before transfer to the customers and has the ability to direct the use of and obtain substantially all of the remaining benefits from the product. In these instances, collaboration revenue is based upon the net sales reported by the Company's collaboration partners, net of cost of goods sold and allowable expenses (e.g., manufacturing, distribution, medical affairs, selling, and marketing expenses) in the period. In order to record collaboration revenue, the Company utilizes certain information from its collaboration partner, including actual net product sales, and costs incurred for sales activities, and makes key judgments based on business updates related to commercial and clinical activities such as expected commercial demand, commercial supply plan, manufacturing commitments, risks related to expired or obsolete inventories, and risks related to potential product returns or contract terminations. The Company uses these estimates to determine whether payments due to us under our collaboration arrangements, such as profit-share payments, should be recognized as revenues in the period that they become due or whether any portion of the payments due should be constrained from revenue recognition because it is not probable that recognizing such amounts would not result in a material reversal of revenues in future reporting periods.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has entered into a number of license and collaboration agreements that fall within the scope of ASC 606. The Company evaluates the promised goods or services in these agreements to determine which ones represent distinct performance obligations. These agreements may include the following types of promised goods or services: (i) grants of licenses, (ii) performance of research and development services, and (iii) participation on joint research and/or development committees. They also may include options to obtain licenses to the Company&#8217;s intellectual property.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prior to recognizing revenue, the Company makes estimates of the transaction price, including variable consideration that is subject to a constraint. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur and when the uncertainty associated with the variable consideration is subsequently resolved. These estimates are re-assessed each reporting period as required. These agreements may include the following types of consideration: non-refundable upfront payments, reimbursement for research services, research, development or regulatory milestone payments, profit-sharing arrangements, and royalty and commercial sales milestone payments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If there are multiple distinct performance obligations, the Company allocates the transaction price to each distinct performance obligation based on their estimated standalone selling prices (&#8220;SSP&#8221;). The Company estimates the SSP for each distinct performance obligation by considering information such as market conditions, entity-specific factors, and information about its customer that is reasonably available. The Company considers estimation approaches that allow it to maximize the use of observable inputs. These estimation approaches may include the adjusted market assessment approach, the expected cost plus a margin approach or the residual approach. The Company also considers whether to use a different estimation approach or a combination of approaches to estimate the SSP for each distinct performance obligation. Developing certain assumptions (e.g., treatable patient population, expected market share, probability of success and product profitability, discount rate based on weighted-average cost of capital) to estimate the SSP of a distinct performance obligation requires significant judgment.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For performance obligations satisfied over time, the Company estimates the efforts needed to complete the performance obligation and recognizes revenue by measuring the progress towards complete satisfaction of the performance obligation using an input measure.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For arrangements that include sales-based royalties, including commercial milestone payments based on pre-specified level of sales, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Achievement of these royalties and commercial milestones may solely depend upon the performance of the licensee.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Grant Revenue</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Grants received, including cost reimbursement agreements, are assessed to determine if the agreement should be accounted for as an exchange transaction or a contribution. An agreement is accounted for as a contribution if the resource provider does not receive commensurate value in return for the assets transferred. Contributions are recognized as grant revenue when all donor-imposed conditions have been met.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To date, research and development expenses have related primarily to discovery efforts and preclinical and clinical development of product candidates. Research and development expenses are recognized as incurred and payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received. Research and development expenses include expenses related to license and collaboration agreements; contingent consideration from business acquisitions; personnel-related expenses, including salaries, benefits, and stock-based compensation for personnel contributing to research and development activities; expenses incurred under agreements with third-party contract manufacturing organizations, contract research organizations, and consultants; clinical costs, including laboratory supplies and costs related to compliance with regulatory requirements; and other allocated expenses, including expenses for rent, facilities maintenance, and depreciation and amortization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has acquired and may continue to acquire the rights to develop and commercialize new product candidates from third parties. Upfront payments and research and development milestone payments made in connection with acquired license or product rights are expensed as incurred, provided that they do not relate to a regulatory approval milestone or assets acquired in a business combination.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s expense accruals for clinical trials and manufacturing are based on estimates of contracted services provided by third-party vendors not yet billed. When billing terms under these contracts do not coincide with the timing of when the work is performed, the Company is required to make estimates of its outstanding obligations to those third parties as of the period end. The accrual estimates are based on a number of factors, including the Company&#8217;s knowledge of the research and development programs and clinical manufacturing activities, the status of the programs and activities, invoicing to date, and the provisions in the contracts. The Company obtains information regarding unbilled services directly from these service providers and performs procedures to support its estimates based on its internal understanding of the services provided to date. However, the Company may also be required to estimate these services based on information available to its internal clinical and manufacturing administrative staff if such information is not able to be obtained timely from its service providers.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock-based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes stock-based compensation to employees over the requisite service period based on the grant-date fair value of the awards. The Company calculates the estimated fair value of stock options and employees' purchase rights under the Company's 2019 employee stock purchase plan ("ESPP") using the Black-Scholes valuation model, which requires the use of subjective assumptions including volatility and expected term, among others. The fair value of restricted stock awards ("RSAs") and restricted stock units ("RSUs") is based on the market value of the Company's common stock on the date of grant. Stock-based compensation is recognized using the straight-line method for awards that vest only upon the employee&#8217;s or non-employee&#8217;s continued service to the Company. Stock-based compensation expense of the employees' purchase rights under the ESPP is recognized over the offering period. Forfeitures are recognized as they occur.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acquisitions</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Business combinations are accounted for using the acquisition method of accounting. Under the acquisition method, assets acquired, including IPR&amp;D projects, and liabilities assumed are recorded at their respective fair values as of the acquisition date. Any excess fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill. Contingent consideration obligations incurred in connection with the business combination are recorded at their fair values on the acquisition date, are remeasured each subsequent reporting period until the related contingencies are resolved and are classified as contingent consideration on the consolidated balance sheets. The changes in fair values of contingent consideration related to the achievement of various milestones are recorded within research and development expenses or selling, general and administrative expenses based on the nature of the relevant underlying activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">    </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">When the Company determines that an entity acquired does not meet the definition of a business, the transaction is accounted for as an acquisition of assets. Therefore, the consideration paid to acquire IPR&amp;D is expensed, and no goodwill is recorded. Any contingent consideration is generally recognized only when it becomes payable or is paid.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Embedded Derivatives</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company evaluates its acquisitions, collaborative arrangements and other business development transactions to determine if embedded components of these contracts meet the definition of a derivative under ASC 815, Derivatives and Hedging. In general, embedded derivatives are required to be bifurcated from the host instrument if (i) the embedded feature is not clearly and closely related to the host contract and (ii) the embedded feature, if considered a freestanding instrument, meets the definition of a derivative. Embedded derivatives are reported on the consolidated balance sheets at their estimated fair values. Contingent consideration related to asset acquisitions that meet the definition of an embedded derivative is classified as contingent consideration on the consolidated balance sheets. Any change in estimated fair values, as determined at each measurement period, are recorded in the consolidated statements of operations based on the nature of the related contingencies.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in fair values of embedded derivatives related to the achievement of various milestones for product candidates are recorded within research and development expenses or selling, general and administrative expenses based on the nature of the relevant underlying activities</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Otherwise, changes in fair values are recorded within other income (expense), net.</span></p></div><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In accordance with ASC 842, Leases, the Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use ("ROU") assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. ROU assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable. On the lease commencement date, the Company estimates and includes in its lease payments any lease incentive amounts based on future events when (1) the events are within the Company&#8217;s control and (2) the event triggering the right to receive the incentive is deemed reasonably certain to occur. If the lease incentive received is greater or less than the amount recognized at lease commencement, the Company recognizes the difference as an adjustment to right-of-use asset and/or lease liability, as applicable.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As the implicit rate in the Company's leases is generally unknown, the Company uses an incremental borrowing rate estimated based on the information available at the lease commencement date in determining the present value of future lease payments. When calculating its estimated incremental borrowing rates, the Company considers its credit risk, the lease term, the total lease payments and the impact of collateral, as necessary. The lease terms may include options to extend or terminate the lease when the Company is reasonably certain it will exercise such options. ROU assets and lease liabilities are remeasured upon certain modifications to leases using the present value of remaining lease payments and estimated incremental borrowing rate upon lease modification. Rent expense for the Company's operating leases is recognized on a straight-line basis within operating expenses over the reasonably assured lease term.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company elected to not separate lease and non-lease components for any leases within its existing classes of assets and, as a result, accounts for the lease and non-lease components as a single lease component. The Company also elected to not apply the recognition requirement to any leases within its existing classes of assets with a term of 12 months or less.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company uses the asset and liability method of accounting for income taxes. Current income tax expense or benefit represents the amount of income taxes expected to be payable or refundable for the current year. Deferred income tax assets and liabilities are determined based on differences between the financial statement reporting and tax bases of assets and liabilities and net operating losses and credit carryforwards and are measured using the enacted tax rates and laws that will be in effect when such items are expected to reverse. Deferred income tax assets are reduced, as necessary, by a valuation allowance when management determines it is more likely than not that some or all of the tax benefits will not be realized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s tax positions are subject to income tax audits. The Company recognizes the tax benefit of an uncertain tax position only if it is more likely than not that the position is sustainable upon examination by the taxing authority, based on the technical merits. The tax benefit recognized is measured as the largest amount of benefit which is more likely than not to be realized upon settlement with the taxing authority. The Company evaluates uncertain tax positions on a regular basis. The evaluations are based on several factors, including changes in facts and circumstances, changes in tax law, correspondence with tax authorities during the course of the audit, and effective settlement of audit issues. The provision for income taxes includes the effects of any accruals that the Company believes are appropriate, as well as any related net interest and penalties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Net Income (Loss) Per Share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic net income (loss) per common share is computed by dividing the net income (loss) by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net income per common share is computed by dividing the net income by the sum of the weighted average number of common shares outstanding during the period plus any potential dilutive effects of common stock equivalents outstanding during the period calculated in accordance with the treasury stock method.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">New Accounting Pronouncement Recently Adopted</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In November 2021, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standard Update (&#8220;ASU&#8221;) No. 2021-10, Government Assistance (Topic 832) (&#8220;ASU 2021-10&#8221;), which adds certain disclosure requirements with respect to government assistance, including (1) the types of assistance, (2) an entity&#8217;s accounting for the assistance, and (3) the effect of the assistance on financial statements. ASU 2021-10 is effective for annual periods beginning after December 15, 2021. The Company's adoption of ASU 2021-10 on January 1, 2022 did not result in any material impact on its consolidated financial statements and related disclosures.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139790634541744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">3.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Fair Value Measurements </span></div></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company determines the fair value of financial assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value, as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1: Inputs which include quoted prices in active markets for identical assets and liabilities. </span></div></div><div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. </span></div></div><div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. </span></div></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The carrying amounts of the Company&#8217;s financial instruments, including receivable from collaboration, accounts payable and accrued liabilities approximate fair value due to their relatively short maturities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash Equivalents and Available-for-Sale Debt Securities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following tables summarize the Company&#8217;s Level 1 and Level 2 financial assets measured at fair value on a recurring basis by level within the fair value hierarchy:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:43.006%;"/>
        <td style="width:1.024%;"/>
        <td style="width:10.242%;"/>
        <td style="width:1.024%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.067%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.024%;"/>
        <td style="width:1.0%;"/>
        <td style="width:7.9%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.043%;"/>
        <td style="width:1.0%;"/>
        <td style="width:7.226999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.024%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.418%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Valuation<br/>Hierarchy</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross<br/>Unrealized<br/>Holding<br/>Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross<br/>Unrealized<br/>Holding<br/>Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate<br/>Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">909,342</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">909,342</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government treasuries</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,493,841</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,396</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,485,445</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,403,183</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,396</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,394,787</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:80.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1) </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Includes </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of restricted cash equivalents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:42.871%;"/>
        <td style="width:1.03%;"/>
        <td style="width:10.205%;"/>
        <td style="width:1.021%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.414%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.058%;"/>
        <td style="width:1.0%;"/>
        <td style="width:7.883%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.058%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.110000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.058%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.290000000000001%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Valuation<br/>Hierarchy</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross<br/>Unrealized<br/>Holding<br/>Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross<br/>Unrealized<br/>Holding<br/>Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate<br/>Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">345,098</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">345,098</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government treasuries</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">419,442</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">872</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">418,570</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">764,540</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">872</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">763,668</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:80.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1) </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Includes $</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of restricted cash equivalents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued interest receivable excluded from both the fair value and amortized cost basis of the available-for-sale debt securities are presented within prepaid expenses and other current assets, and other assets in the consolidated balance sheets. Accrued interest receivable amounted to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as of December 31, 2022 and 2021, respectively. The Company did </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t write off any accrued interest receivable during the years ended December 30, 2022 and 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognized total net unrealized loss of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in accumulated other comprehensive income (loss) as of December 31, 2022 and 2021, respectively. The gross unrealized losses related to U.S. government treasuries as of December 31, 2022 and 2021 were due to changes in interest rates. As of December 31, 2022 and 2021, there were no investments that have been in a continuous unrealized loss position for longer than 12 months. The Company determined that the gross unrealized losses on our investments as of December 31, 2022 were temporary in nature. The Company currently does not intend, and it is highly unlikely that it will be required, to sell these securities before recovery of their amortized cost basis. As of December 31, 2022, no securities have contractual maturities of longer than</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> two years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Equity Investments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, the Company's equity investment consisted solely of ordinary shares of Brii Biosciences Limited (&#8220;Brii Bio Parent&#8221;). The Company acquired the securities as partial consideration for entering into the collaboration, option and license agreement (the &#8220;Brii Agreement&#8221;) with Brii Bio Parent and Brii Biosciences Offshore Limited (&#8220;Brii Bio&#8221;) in May 2018. The Company concluded it does not have a controlling interest or significant influence over Brii Bio based on its ownership percentage and other factors. See further discussion in Note 7&#8212;Collaboration and License Agreements. In July 2021, Brii Bio Parent completed its initial public offering (&#8220;Brii Bio Parent IPO&#8221;) on the Stock Exchange of Hong Kong Limited, prior to which the securities were accounted for as equity securities without a readily determinable fair value. Upon the completion of the Brii Bio Parent IPO, the securities were considered to be marketable equity securities and subsequently remeasured at fair value at each reporting date. As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company remeasured the equity investment at a fair value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. For the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the Company recognized an unrealized loss of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">111.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as other income in the consolidated statement of operations, net of an unrealized loss of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million related to foreign currency translation for the period. The Company classifies its equity investment in Brii Bio Parent as a Level 1 asset within the fair value hierarchy, as the value is based on a quoted market price in an active market.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Contingent Consideration</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contingent consideration includes potential milestone payments in connection with the acquisitions of Humabs BioMed SA (&#8220;Humabs&#8221;) and TomegaVax, Inc. (&#8220;TomegaVax&#8221;). See further discussion in Note 4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Acquisitions. The Company classifies the contingent consideration as Level 3 financial liabilities within the fair value hierarchy as of December 31, 2022 and 2021.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The estimated fair value of the contingent consideration related to the Humabs acquisition was determined by calculating the probability-weighted clinical, regulatory and commercial milestone payments based on the assessment of the likelihood and estimated timing that certain milestones would be achieved. </span><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of Decemb</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">er 31, 2022, the Company calculated the estimated fair value of the remaining clinical and regulatory milestones related to VIR-3434 using the following significant unobservable inputs: </span></span><span style=""/></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.176%;"/>
        <td style="width:2.444%;"/>
        <td style="width:32.38%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unobservable input</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Range<br/>(Weighted-Average)1</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Discount rates</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% (</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Probability of achievement</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% (</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%)</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:80.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1) </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unobservable inputs were weighted based on the relative fair value of the clinical and regulatory milestone payments.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></span><span style=""/></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the commercial milestones, the Company used a Monte Carlo simulation because of the availability of discrete revenue forecasts. A</span><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">s of December 31, 2022, the Monte Carlo simulation assumed a commercial product launch and associated discrete revenue forecasts, as well as the following significant unobservable inputs f</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">or the remaining commercial milestones related to VIR-3434: </span></span><span style=""/></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.176%;"/>
        <td style="width:2.444%;"/>
        <td style="width:32.38%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unobservable input</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Value</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">80.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Discount rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Probability of achievement</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The discount rate captures the credit risk associated with the payment of the contingent consideration when earned and due. As of December 31, 2022 and 2021, the estimated fair value of the contingent consideration related to the Humabs acquisition was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, with changes in the estimated fair value recorded in research and development expenses, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and selling, general and administrative expenses in the consolidated statements of operations based on the nature of the relevant underlying activities.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The estimated fair value of the contingent consideration related to the TomegaVax acquisition was determined by using a Monte Carlo simulation model which included estimates of both the probability and timing to achieve the required per-share price of the Company&#8217;s common stock, and incorporates assumptions as to expected volatility and discount rate. The discount rate captures the credit risk associated with the payment of the contingent consideration when earned and due. Although the TomegaVax acquisition was accounted for as an asset acquisition, such contingent consideration met the definition of an embedded derivative financial instrument. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">February 2021, the Company achieved one of the milestones related to a specified per-share price of its common stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">resulting </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">in a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million payable to the former TomegaVax&#8217;s stockholders which was paid in July 2021. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, the fair value of the remaining contingent consideration was estimated using the following significant unobservable inputs:</span></span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.176%;"/>
        <td style="width:2.444%;"/>
        <td style="width:32.38%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unobservable input</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Value</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Discount rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022 and 2021, the estimated fair value of the contingent consideration related to the TomegaVax acquisition was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, with changes in the estimated fair value recorded in other income (expense), net in the consolidated statements of operations.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The estimated fair value of the contingent consideration related to the Humabs and TomegaVax acquisitions involves significant estimates and assumptions which give rise to measurement uncertainty.</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table sets forth the changes in the estimated fair value of the Company&#8217;s contingent consideration (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.81%;"/>
        <td style="width:2.096%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.094%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contingent<br/>Consideration</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22,822</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in fair value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,115</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24,937</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139790634227088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisitions</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">4.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Acquisitions </span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acquisition of TomegaVax</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In September 2016, the Company entered into an agreement and plan of merger (&#8220;TomegaVax Merger Agreement&#8221;) to acquire all of the equity interests of TomegaVax. The primary asset purchased in the acquisition was an in-process cytomegalovirus (&#8220;CMV&#8221;) vector-based vaccine platform for use in HBV, HIV, and tuberculosis. The acquisition was accounted for as an asset purchase.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with the entry into the TomegaVax Merger Agreement, the Company also entered into a letter agreement with TomegaVax (the &#8220;TomegaVax Letter Agreement&#8221;), which provides for certain payments to TomegaVax&#8217;s former stockholders before September 2024, in each case so long as the Company is continuing to pursue the development of the TomegaVax technology. Under the terms of the TomegaVax Letter Agreement, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the Company will be required to pay to the former stockholders of TomegaVax milestone payments of up to an aggregate of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million if the per-share price of the Company&#8217;s publicly traded common stock, or implied price per share of the Company&#8217;s Series A-1 convertible preferred stock (or common stock upon conversion) upon a certain asset sale, merger or stock sale, is at least $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (as adjusted in the case of any stock dividend, stock split or other similar recapitalization), with the amount of such payments determined by the share price and/or the stage of the Company&#8217;s clinical development at the time of the relevant event triggering the payment.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> The share price of the Company&#8217;s publicly traded common stock will be determined using the average of the daily volume-weighted average trading price of the Company&#8217;s common stock for each trading day during a consecutive 90-day period. The foregoing payments are payable (i) during any date after the completion of an initial public offering by the Company or any successor or affiliate controlling the TomegaVax technology, provided that no payment will be due before the first anniversary of the initial public offering, (ii) upon the sale of all assets related to the TomegaVax technology or (iii) upon a merger or stock sale of the Company or any successor or affiliate controlling the TomegaVax technology, in each case subject to certain conditions with respect to the timing of the payments. The payments under the TomegaVax Letter Agreement can be made in cash or shares of the Company&#8217;s common stock, at the discretion of the Company&#8217;s board of directors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In February 2021, the Company achieved </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of the milestones related to the specified per-share price of its common stock, which resulted in a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million payable to TomegaVax&#8217;s former stockholders. In July 2021, the Company made the milestone payment to the former TomegaVax stockholders through a combination of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in cash and the issuance of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42,737</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of common stock with a total fair value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The remaining milestone payments of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in the aggregate will be triggered if (i) the per-share price of the Company&#8217;s publicly traded common stock is at least $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (as adjusted in the case of any stock dividend, stock split or other similar recapitalization) and upon the achievement of a certain milestone related to the stage of the Company&#8217;s clinical development at the time of the relevant event triggering the payment and/or (ii) the per-share price of the Company&#8217;s publicly traded common stock is at least $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (as adjusted in the case of any stock dividend, stock split or other similar recapitalization).</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company determined that the future milestone payments contain net settlement provisions and, therefore, they were required to be accounted for as embedded derivatives under the relevant accounting guidance. As of December 31, 2022, the estimated fair value of the embedded derivative was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and was included in the contingent consideration liability on the consolidated balance sheet.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acquisition of Humabs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In August 2017, the Company acquired all of the outstanding equity of Humabs, a private Swiss company, which discovers and develops monoclonal antibodies (&#8220;mAbs&#8221;) derived from individuals whose immune systems have successfully responded to major diseases. The Company acquired all of Humabs&#8217; rights, title and interest in and to substantially all of the assets of Humabs except for rights under certain license agreements with third parties. The Company is obligated to pass through to the former Humabs shareholders any amounts received by Humabs under such license agreements, net of any program expenses. The transaction was accounted for as an acquisition of a business. In addition to the cash payment and issuance of common stock to the former Humabs shareholders at the acquisition date, the Company also agreed to pay additional amounts in cash upon the achievement of specified milestone events: (i) up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">135.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million upon the achievement of clinical, regulatory and commercial milestones for VIR-3434; and (ii) up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">105.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million upon the achievement of clinical, regulatory and commercial milestones for another product, which the Company elected as sotrovimab, a severe acute respiratory syndrome coronavirus 2 (&#8220;SARS-CoV-2&#8221;) product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the year ended December 31, 2020, the Company achieved </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">two</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of the specified clinical milestones for the HBV product and sotrovimab totaling $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the year ended December 31, 2021, the Company achieved the specified regulatory milestone of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and sales milestones totaling $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million related to sotrovimab, which were paid</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> in January and February 2022, respectively. The estimated fair value of the remaining contingent consideration was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">23.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as of December 31, 2022.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The acquired developed technologies that have associated patents issued are classified as finite-lived intangible assets and are amortized on a straight-lined basis over their estimated remaining useful lives, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">generally between </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_42ecc27d-dd4e-4bd9-a1b3-ab9d1b0e44c1;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">seven</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12 years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Company also acquired indefinite-lived intangible assets consisting of IPR&amp;D. These assets will not be amortized until regulatory approval is obtained in a major market. At that time, the Company will determine the useful life of the asset and begin amortization. If the associated research and development effort is abandoned or otherwise impaired, the related IPR&amp;D assets will be written-off and an impairment charge will be recorded. As of December 31, 2022, there have been </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> such impairments related to the IPR&amp;D assets. The estimated fair value of the intangible assets was determined using the replacement cost method. The excess of the purchase price over the estimated fair value of the net assets acquired was recorded as goodwill. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">None</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of the goodwill is expected to be deductible for income tax purposes.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI https://asc.fasb.org/topic&amp;trid=2303972<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4946-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139790634355056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">5.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Goodwill and Intangible Assets </span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Goodwill</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Goodwill of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> represents the excess of the purchase price over the estimated fair value of the net assets acquired from Humabs. The Company tests goodwill for impairment on an annual basis or sooner, if deemed necessary. There was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> impairment for the year ended December 31, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Intangible Assets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the carrying amount of the Company&#8217;s finite-lived intangible assets (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.244%;"/>
        <td style="width:0.375%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.274%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.116%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.591999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.078%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.318999999999999%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-<br/>Average<br/>Remaining Useful</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Life (Years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Developed technology</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,260</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.5</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contract-based intangible asset</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">502</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">502</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.9</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Finite-lived intangible assets, gross</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,762</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,502</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less accumulated amortization</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,738</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,114</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less impairment of intangible assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">832</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Finite-lived intangible assets, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,556</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Finite-lived intangible assets are carried at cost less accumulated amortization. The contract-based intangible asset resulted from the product approval of a sublicensed intellectual property right in December 2020. The intellectual property right was previously accounted for as IPR&amp;D. Amortization expense related to finite-lived intangible assets, included in research and development expenses on the consolidated statements of operations, totaled $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the years ended December 31, 2022, 2021 and 2020, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management reviews finite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable, like that of property and equipment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on the finite-lived intangible assets recorded as of December 31, 2022, the estimated future amortization expense for the next five years is as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.682%;"/>
        <td style="width:1.865%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.451999999999998%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ending December 31:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">532</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">260</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">213</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">213</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2027</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">213</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,431</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Indefinite-Lived Intangible Assets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022 and 2021, the Company had indefinite-lived intangible assets of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, related to the purchased IPR&amp;D from the Humabs acquisition. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> impairment losses have been recorded for the years ended December 31, 2022 and 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI https://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139790634561520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Grant Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_GrantAgreementsDisclosureTextBlock', window );">Grant Agreements</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">6.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Grant Agreements </span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Bill &amp; Melinda Gates Foundation Grants</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has entered into various grant agreements with the Bill &amp; Melinda Gates Foundation, under which it was awarded grants totaling up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">55.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to support its HIV vaccine program, tuberculosis vaccine program, HIV vaccinal antibody program and malaria vaccinal antibody program. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The term of the grant agreements will expire at various dates through December 2023, unless earlier terminated by the Bill &amp; Melinda Gates Foundation for the Company&#8217;s breach, failure to progress the funded project, in the event of the Company&#8217;s change of control, change in the Company&#8217;s tax status, or significant changes in the Company&#8217;s leadership that the Bill &amp; Melinda Gates Foundation reasonably believes may threaten the success of the project.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Concurrently with the execution of the grant agreement for the vaccinal antibody program, the Company entered into a stock purchase agreement with the Bill &amp; Melinda Gates Foundation, under which the Bill &amp; Melinda Gates Foundation purchased </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">881,365</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company&#8217;s common stock on January 13, 2022, at a price per share of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45.38</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, for an aggregate purchase price of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The fair market value of the common stock issued to the Bill &amp; Melinda Gates Foundation was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, based on the closing stock price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37.65</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share on the closing date and taking into account a discount for the lack of marketability due to the restrictions in place on the underlying shares, resulting in a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million premium received by the Company. The Company accounted for the common stock issued to the Bill &amp; Melinda Gates Foundation based on its fair market value on the closing date and determined that the premium paid by the Bill &amp; Melinda Gates Foundation should be included in the deferred revenue from the vaccinal antibody grant.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Payments received in advance that are related to future research activities along with the aforementioned premium received are deferred and recognized as revenue when the donor-imposed conditions are met, which is as the research and development activities are performed. The premium received by the Company is deferred and recognized over the same period as the grant proportionally. The Company recognized grant revenue of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the years ended December 31, 2022, 2021 and 2020, respectively. As of December 31, 2022 and 2021, the Company had deferred revenue of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively. As of December 31, 2022 and 2021, the Company had $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, within accrued and other liabilities, which may need to be refunded to the Bill &amp; Melinda Gates Foundation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Biomedical Advanced Research and Development Authority</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In September 2022, the Company entered into an other transaction for advanced research agreement (the &#8220;BARDA Agreement&#8221;) with the Biomedical Advanced Research and Development Authority (&#8220;BARDA&#8221;), part of the U.S. Department of Health and Human Services&#8217; Administration for Strategic Preparedness and Response. Under the BARDA Agreement, the Company may receive up to an estimated $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> billion to advance the development of a full portfolio of innovative solutions to address influenza and potentially other infectious disease threats. The Base Period (as defined below) for the BARDA Agreement includes government funding of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">55.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million to reimburse a portion of expenses incurred by the Company to support the development of VIR-2482, an investigational prophylactic monoclonal antibody designed with the aim to protect against seasonal and pandemic influenza, including expenses related to the Phase 2 pre-exposure prophylaxis trial of VIR-2482. The BARDA Agreement also provides for additional BARDA funding after the exercise by BARDA of up to twelve options to further support the development of pre-exposure prophylactic antibodies including and beyond VIR-2482 for the prevention of influenza illness or possibly supporting medical countermeasures for other pathogens of pandemic potential. The BARDA Agreement has an initial term that commenced on September 30, 2022 and extends through January 2026 (&#8220;Base Period&#8221;), which may be extended by mutual written agreement of the Company and BARDA if certain conditions are met or if BARDA exercises any of its options, as described above, and is terminable by the Company and BARDA at any time under specified circumstances, including for convenience.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognized grant revenue under the BARDA Agreement of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the year ended December 31, 2022 and a corresponding other receivable in prepaid expenses and other current assets of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as of December 31, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_GrantAgreementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grant agreements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_GrantAgreementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139790634285488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration and License Agreements</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">7.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaboration and License Agreements </span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Collaboration Agreements with GSK</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2020 GSK Agreement</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On June 9, 2020, the Company, Glaxo Wellcome UK Limited and Beecham S.A. entered into a definitive collaboration agreement under the terms set forth in the preliminary collaboration agreement entered into by the Company and certain GSK entities in April 2020 (the &#8220;2020 Preliminary Agreement&#8221;) (such definitive collaboration agreement, the &#8220;2020 GSK Agreement&#8221;). In December 2021, Beecham S.A. assigned and transferred all its rights, title, interest, and benefit in the 2020 GSK Agreement to GlaxoSmithKline Biologicals S.A. (Glaxo Wellcome UK Limited and GlaxoSmithKline Biologicals S.A., referred to, individually and together, as &#8220;GSK&#8221;), including all its rights to bring claims under such agreement. Concurrently with the execution of the 2020 Preliminary Agreement, the Company entered into a stock purchase agreement (the &#8220;2020 Stock Purchase Agreement&#8221;) with Glaxo Group Limited (&#8220;GGL&#8221;), an affiliate of GSK, under which GGL purchased </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,626,027</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company&#8217;s common stock on April 29, 2020, at a price per share of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37.73</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, for an aggregate purchase price of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">250.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The 2020 Preliminary Agreement became effective as of April 29, 2020, which was also the closing date for the 2020 Stock Purchase Agreement (&#8220;Effective Date&#8221;). The 2020 GSK Agreement superseded and replaced the 2020 Preliminary Agreement between the parties. Under the terms of the 2020 GSK Agreement, the Company and GSK agreed to collaborate to research, develop and commercialize products for the prevention, treatment and prophylaxis of diseases caused by SARS-CoV-2, the virus that causes COVID-19, and potentially other coronaviruses. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The collaboration initially focused on the development and commercialization of three types of collaboration products under three programs: (1) antibodies targeting SARS-CoV-2 and potentially other coronaviruses (the &#8220;Antibody Program&#8221;); (2) vaccines targeting SARS-CoV-2 and potentially other coronaviruses (the &#8220;Vaccine Program&#8221;), and (3) products based on genome-wide CRISPR screening of host targets expressed in connection with exposure to SARS-CoV-2 and potentially other coronaviruses (the &#8220;Functional Genomics Program&#8221;)</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> four years </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">following the Effective Date, the parties agreed to conduct certain research and development activities under mutually agreed development plans and associated budgets for each of the three programs, and under the oversight of a joint steering committee (&#8220;JSC&#8221;). The Company is primarily responsible for the development and clinical manufacturing activities for the Antibody Program, and for conducting the initial development activities directed to a vaccine in the Vaccine Program. GSK is primarily responsible for the commercialization activities for the Antibody Program (including in mainland China, Hong Kong, Macau and Taiwan following the purchase of these rights in May 2022, as described below), the later-stage development, manufacturing and commercialization activities for the Vaccine Program and the development, manufacturing and commercialization activities for the Functional Genomics Program. Subject to an opt-out mechanism and Amendment No. 1 to the 2020 GSK Agreement (described below), the parties share all development costs, manufacturing costs and costs and expenses for the commercialization of the collaboration products, with the Company bearing </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of such costs for the antibody products, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of such costs for the vaccine products, and equal sharing of such costs for the functional genomics products.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On a collaboration product-by-collaboration product basis, each party has the one-time right, at specified points in development, to opt-out of its co-funding obligations, and the other party may, at its election, either pursue such program unilaterally, or also cease research and development activities and funding of such collaboration product. If the opt-out provisions are not exercised by either party subject to the terms of the 2020 GSK Agreement, the parties share all profits and losses arising from any collaboration product in the same ratios in which the parties bore development costs for such collaboration program. For each collaboration product as to which a party exercises its opt-out right, the commercializing party pays to the opt-out party royalties on net sales of the applicable collaboration product at rates based on factors such as the stage of development of such collaboration product at the time the opt-out party exercises such right, and whether the opt-out party is the lead party, or a portion of the sublicense revenue if the commercializing party chooses to sublicense or otherwise divest rights to such collaboration product. On an antibody product-by-antibody product basis, the Company has a co-promotion right for such antibody product in the United States, under which the Company has the right to perform up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of details in connection with such antibody product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2020 GSK Agreement will remain in effect with respect to each collaboration program for as long as there is a collaboration product being developed or commercialized by the lead party, or the non-opt-out party, in such program. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Either party has the right to terminate the 2020 GSK Agreement in the case of the insolvency of the other party, an uncured material breach of the other party with respect to a collaboration program or collaboration product, or as mutually agreed by the parties.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company considered the ASC 606 criteria for combining contracts and determined that the 2020 GSK Agreement and 2020 Stock Purchase Agreement should be combined into a single contract because they were negotiated and entered into in contemplation of one another. The fair market value of the common stock issued to GGL was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">206.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, based on the closing stock price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36.70</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> on the date of execution of the 2020 Preliminary Agreement and 2020 Stock Purchase Agreement and taking into account a discount for the lack of marketability due to the restrictions in place on the underlying shares, resulting in a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million premium received by the Company. The Company accounted for the common stock issued to GGL based on its fair market value on the transaction date and determined that the premium paid by GSK should be attributed to the transaction price of the 2020 GSK Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company concluded that the 2020 GSK Agreement contained </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">four</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> units of account: (i) the license granted to GSK under the Antibody Program (the &#8220;Antibody License&#8221;); (ii) the research and development activities (including clinical manufacturing) under the Antibody Program; (iii) the research and development activities under the Vaccine Program; and (iv) the research and development activities under the Functional Genomics Program. The Company considered the guidance in ASC 606 to determine which of these elements of the 2020 GSK Agreement are performance obligations with a customer. The Company determined that the Antibody License is within the scope of ASC 606, and accordingly, accounted for the Antibody License as a distinct performance obligation under ASC 606. The Antibody License is a functional intellectual property and is distinct from the associated research and development activities to be performed under the program due to its significant standalone functionality. All other elements of the 2020 GSK Agreement, including the research and development activities and participation in the JSC and subcommittees for each collaboration program, were not determined to be distinct performance obligations with a customer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The transaction price for the Antibody License at inception was determined to be $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, representing the premium on the sale of common stock to GSK. The Company determined that GSK can benefit from the Antibody License at the time of grant and, therefore, the related performance obligation is satisfied at a point in time. As such, the Company recognized the $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as contract revenue during the second quarter of 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The remaining units of account of the 2020 GSK Agreement were determined to be within the scope of ASC 808 as the Company and GSK are both active participants in the development, manufacturing and commercialization activities and are exposed to significant risks and rewards that are dependent on the commercial success of the activities of the arrangement. Furthermore, the Company and GSK participate in the commercial profit and loss sharing arrangement for each program commensurate with each party&#8217;s cost-sharing responsibilities during research and development. Because ASC 808 does not provide recognition and measurement guidance, the Company determined that the guidance in ASC 730, Research and Development, was appropriate to analogize to, based on the nature of the cost-sharing provisions of the 2020 GSK Agreement. The Company has concluded that payments to or reimbursements from GSK related to these services will be accounted for as an increase to or reduction of research and development expenses, respectively. Additionally, the Company is entitled to consideration from GSK related to profit and loss sharing arrangements (including royalties) contingent upon future sales of collaboration products. The Company concluded that any payments from GSK related to the profit and loss sharing arrangement (including royalties) contingent upon the commercialization of the products will be analogized to ASC 606 and, therefore, will be recognized when the related sales occur.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In May 2021, the U.S. Food and Drug Administration (&#8220;FDA&#8221;) granted an EUA in the United States for sotrovimab, the first collaboration product under the Antibody Program. In April 2022, the FDA excluded the use of sotrovimab in all U.S. regions due to the continued proportion of COVID-19 cases caused by certain Omicron subvariants. As the lead party for all manufacturing and commercialization activities, GSK incurs all of the manufacturing, sales and marketing expenses and is the principal on sales transactions with third parties. As described in Note 2&#8212;Summary of Significant Accounting Policies, the Company&#8217;s accounting policy related to the profit-share is to consider the agreed-upon share of the profit-sharing amounts each quarter and evaluate whether those amounts are subject to potential future adjustments based on the latest available facts and circumstances, subject to the terms of the 2020 GSK Agreement. As the Company is the agent, the Company recognizes its contractual share of the profit-sharing amounts or royalties (in case of an opt-out) as revenue, based on sales net of various estimated deductions such as rebates, discounts, chargebacks, credits and returns, less cost of sales and allowable expenses (including manufacturing, distribution, medical affairs, selling, and marketing expenses) in the period the sale occurs. Manufacturing costs include inventory revaluation adjustments, lower of cost or market inventory adjustments, inventory write-downs and write-offs, and binding purchase commitments with a third-party manufacturer among other manufacturing costs. The Company&#8217;s contractual share of the profit-sharing amounts is subject to potential future adjustments to allowable expenses, which represents a form of variable consideration. At each reporting period, the Company evaluates the latest available facts and circumstances to determine whether any portion of profit-sharing amounts should be constrained.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, GSK held certain potentially excess binding supply manufacturing commitments of sotrovimab and reserved certain binding manufacturing capacity potentially not expected to be utilized, which have not yet been reported to us as allowable manufacturing expenses for the cumulative profit-sharing amounts to date. We expect GSK to adjust allowable manufacturing expenses for our share of the potential charge for excess supply write-offs and unused binding manufacturing capacity and report to us as cost-sharing amounts in future periods. We evaluated the latest available facts and circumstances to update our evaluation of whether any portion of profit-sharing amounts should be constrained. In doing so, as of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, based on the current state of the COVID-19 pandemic, including the continued proportion of cases caused by certain Omicron subvariants, discussions with the FDA and other regulatory authorities, and the Company&#8217;s expectations for future sales in light of these factors, the Company revised its estimate and determined that $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">369.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million should be constrained from profit-sharing revenues earned during the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 in relation to the Company&#8217;s anticipated contractual share of potential future adjustments to manufacturing expenses and recorded such amount as adjustments to profit-sharing amounts. The Company re-assesses these estimates each reporting period. Actual results could materially differ from this estimate.</span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the years ended December 31, 2022 and 2021, the Company recorded profit-sharing amounts and profit-sharing amounts constrained as components of collaboration revenue in the consolidated statements of operations, as follows:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.078%;"/>
        <td style="width:2.396%;"/>
        <td style="width:1.0%;"/>
        <td style="width:19.968%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.396%;"/>
        <td style="width:1.0%;"/>
        <td style="width:20.162%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaboration revenue, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Profit-sharing amount</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,875,147</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">917,194</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Profit-sharing amount constrained</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">369,678</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total collaboration revenue, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,505,469</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">917,194</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Costs associated with co-development activities performed under the 2020 GSK Agreement are included in research and development expenses on the consolidated statements of operations, with any reimbursement of costs by GSK reflected as a reduction of such expenses. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the 2020 GSK Agreement, the Company recognized additional net research and development expenses of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">77.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million during the years ended December 31, 2022, 2021 and 2020, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Amendment No. 1 to the 2020 GSK Agreement</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On May 27, 2022, the Company and GSK entered into Amendment No. 1 to the 2020 GSK Agreement (&#8220;Amendment No. 1&#8221;). Pursuant to Amendment No. 1, the parties acknowledged that the antibody products that had been licensed to WuXi Biologics (Hong Kong) Limited (&#8220;WuXi Biologics&#8221;) in mainland China, Hong Kong, Macau and Taiwan and had reverted to the Company pursuant to the Termination Agreement (described below) are now included in and governed by the 2020 GSK Agreement, subject to certain amendments relating to sotrovimab.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the terms of Amendment No. 1, GSK has the sole right to develop (including to seek, obtain or maintain regulatory approvals), manufacture and commercialize sotrovimab in and for mainland China, Hong Kong, Macau and Taiwan at GSK's sole cost</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">expense (other than certain payments for which the Company remains responsible under certain of the Company&#8217;s existing agreements with third parties). GSK paid the Company a one-time upfront payment of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in consideration for the rights and licenses granted to GSK under Amendment No. 1. The Company recognized contract revenue of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million during the year ended December 31, 2022. In addition, GSK will be obligated to pay the Company tiered royalties on net sales of sotrovimab in mainland China, Hong Kong, Macau and Taiwan in percentages ranging from the high teens to the low thirties. Such royalties are payable to the Company during the term of the 2020 GSK Agreement applicable to the Antibody Program.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2021 Expanded GSK Collaboration</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On February 14, 2021, the Company and GSK entered into a binding preliminary collaboration agreement (the &#8220;2021 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Preliminary Agreement&#8221;) under which the parties agreed to expand the 2020 GSK Agreement to collaborate on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> separate programs: (1) a program to research, develop and commercialize mAbs for the prevention, treatment or prophylaxis of the influenza virus (the &#8220;Influenza Program&#8221;), excluding VIR-2482 unless GSK exercises its option as described below; (2) an expansion of the parties&#8217; current Functional Genomics Program to focus on functional genomics screens directed to targets associated with respiratory viruses (the &#8220;Expanded Functional Genomics Program&#8221;); and (3) additional programs to develop neutralizing mAbs directed to up to three non-influenza target pathogens selected by GSK (the &#8220;Selected Pathogens&#8221; and such programs, the &#8220;Additional Programs&#8221;).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Concurrently with the execution of the 2021 Preliminary Agreement, the Company entered into a stock purchase agreement (the &#8220;2021 Stock Purchase Agreement&#8221;) with GGL under which GGL agreed to purchase shares of the Company&#8217;s common stock for an aggregate purchase price of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">120.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The consummation of the transactions under each of the 2021 Preliminary Agreement and the 2021 Stock Purchase Agreement were subject to the satisfaction of customary closing conditions, including the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, which expiration was effective on March 24, 2021. The 2021 Preliminary Agreement and 2021 Stock Purchase Agreement consummated on March 25, 2021, which the Company used as the measurement date for accounting purposes. On March 31, 2021, the Company closed the sale of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,924,927</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of its common stock to GGL.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2021 Preliminary Agreement was superseded on May 18, 2021 upon execution of the definitive collaboration agreement (the &#8220;2021 GSK Agreement&#8221;, and collectively with the 2021 Preliminary Agreement, the &#8220;2021 GSK Collaboration&#8221;). The material terms of the 2021 GSK Agreement, including the promised goods and services, are discussed below and are consistent with those of the 2021 Preliminary Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the 2021 GSK Collaboration, the parties agreed to conduct certain research and development activities under mutually agreed development plans and associated budgets for the programs within the expanded collaboration for a period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> following the effective date. Under the Influenza Program, the parties collaborate to research, develop and commercialize mAbs for the prevention, treatment or prophylaxis of influenza, including the Company&#8217;s influenza mAbs (with respect to VIR-2482, only if GSK exercises its option). The Company conducts the development and clinical manufacturing activities for VIR-2482 up to the completion of a Phase 2 clinical trial. Provided that the Company conducts and completes a Phase 2 clinical trial for VIR-2482, GSK has the exclusive option to obtain exclusive rights to co-develop and commercialize VIR-2482 under the Influenza Program (the &#8220;VIR-2482 Option&#8221;). GSK is the lead party for development, clinical and commercial manufacturing and commercialization activities for products under the Influenza Program (other than VIR-2482 unless and until GSK exercises the VIR-2482 Option, if applicable). The parties mutually agree upon the allocation of responsibility for the development of products under the Expanded Functional Genomics Program, and for the development and early-stage manufacturing of products under the Additional Programs if and when GSK decides which Selected Pathogens to pursue. GSK is primarily responsible for commercial manufacturing and commercialization activities for products under the Expanded Functional Genomics Program and Additional Programs, if and when selected by GSK. For each collaboration program, the Company granted or will grant GSK certain license rights related to the development, manufacturing and commercialization of products arising from the program.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The parties share </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of all development costs in accordance with the budget for each of the collaboration programs (other than for the Selected Pathogens and VIR-2482, unless GSK exercises the VIR-2482 Option), with each party having the right to opt-out of its co-funding obligations at specified points in development. In such case, the party continuing with the program pays to the opt-out party a royalty on net sales of products arising from such program at specified rates based on the stage of development at which the opt-out is exercised. Following the exercise of an opt-out right by a party, the other party may, at its election, either pursue development and commercialization of such product or program unilaterally, or also cease the conduct and funding of such collaboration product or program. In the absence of any opt-out, the parties also share </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of all profits and losses arising from any collaboration product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">GSK made an upfront payment to the Company of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">225.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. If GSK exercises the VIR-2482 Option, GSK will pay the Company an option exercise fee of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">300.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million unless certain agreed product criteria for VIR-2482 are not met, in which case the parties will negotiate an alternative option exercise fee. Upon achievement of a pre-defined regulatory milestone for the first product in the Influenza Program, which may be (i) VIR-2482 (if GSK exercised the VIR-2482 Option), (ii) a next-generation mAb, or (iii) any other influenza mAb approved by the JSC to be included in the collaboration, arising from the Influenza Program, GSK will make a milestone payment to the Company of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">200.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company concluded that the 2021 GSK Agreement is a collaboration arrangement as defined in ASC 808, Collaborative Agreements, under which certain elements are required to be accounted for under ASC 606 where the counterparty is a customer for a good or service that is a distinct unit of account. In addition, the 2021 GSK Agreement is considered a contract modification to the 2021 Preliminary Agreement and will be accounted for prospectively as a termination of the 2021 Preliminary Agreement and commencement of a new contract. There was no impact to the accounting assessment of the original contract as no goods or services had been delivered to GSK, no performance obligations were satisfied, and accordingly, no contract revenue was recognized under ASC 606 prior to the execution of the 2021 GSK Agreement.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company considered the ASC 606 criteria for combining contracts and determined that the 2021 GSK Collaboration and 2021 Stock Purchase Agreement should be combined into a single contract because they were negotiated and entered into in contemplation of one another. The fair market value of the common stock issued to GGL was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">85.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, based on the closing stock price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52.70</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> on March 25, 2021, and taking into account a discount for the lack of marketability due to the restrictions in place on the underlying shares, resulting in a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million premium received by the Company. The Company accounted for the common stock issued to GGL based on its fair market value on the transaction date and determined that the premium paid by GSK should be attributed to the transaction price of the 2021 GSK Agreement.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company concluded that the 2021 GSK Agreement contained the following units of account: (i) the VIR-2482 Option; (ii) three distinct rights granted to GSK related to the Selected Pathogens (each, a &#8220;Selected Pathogen Right&#8221;); (iii) the license and know-how to the next-generation mAbs under the Influenza Program (the &#8220;Next Gen License&#8221;); (iv) the research and development activities for next-generation mAbs under the Influenza Program; and (v) the research and development activities, including license rights and know-how, under the Expanded Functional Genomics Program. The Company considered the guidance in ASC 606 to determine which of these elements of the 2021 GSK Agreement are performance obligations with a customer. The Company determined that the distinct performance obligations under ASC 606 consisted of (i) the Next Gen License and (ii) the three Selected Pathogen Rights, each representing a material right. All other elements of the 2021 GSK Agreement including the VIR-2482 Option, research and development activities, and participation in the JSC and subcommittees for each collaboration program were not determined to be distinct performance obligations with a customer. As of December 31, 2022, GSK had not exercised the VIR-2482 Option or the remaining two Selected Pathogen Rights (see below for GSK's selection of first pathogen).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The transaction price for the 2021 GSK Agreement included fixed consideration consisting of the $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">225.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million upfront fee paid by GSK and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">34.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, representing the premium on the sale of common stock to GSK for a total of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">259.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. All potential future milestones and other payments under the 2021 GSK Agreement are constrained since the Company could not conclude it was probable that a significant reversal in the amount recognized would not occur.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The respective estimated SSP for each of the performance obligations was determined to allocate the transaction price. The estimated SSP of each performance obligation was determined using methods that considered relevant market conditions, entity-specific factors and information about GSK, while maximizing the use of available observable inputs and using certain management assumptions (e.g., treatable patient population, expected market share, probability of success and product profitability, discount rate based on weighted-average cost of capital). For the Next Gen License, the Company determined that GSK can benefit from the license at the time the license is granted and, therefore, the related performance obligation is satisfied at a point in time. If any of the Selected Pathogen Rights are exercised, the Company will evaluate the related promises to identify the performance obligations to be transferred and the timing of revenue recognition. If any of the Selected Pathogen Rights expire prior to being exercised, the Company will recognize any deferred revenue allocated to that right as revenue at the time of expiration.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The research and development activities for the next-generation mAbs under the Influenza Program and the Expanded Functional Genomics Program were determined to be within the scope of ASC 808 as the Company and GSK are both active participants in the development, manufacturing and commercialization activities and are exposed to significant risks and rewards that are dependent on the commercial success of the activities of the arrangement. Furthermore, the Company and GSK participate in the commercial profit and loss sharing arrangement for each program commensurate with each party&#8217;s cost-sharing responsibilities during research and development. Because ASC 808 does not provide recognition and measurement guidance, the Company determined that</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the guidance in ASC 730, Research and Development, was appropriate to analogize to based on the nature of the cost-sharing provisions of the agreement. The Company has concluded that payments to or reimbursements from GSK related to these services will be accounted for as an increase to or reduction of research and development expenses, respectively. The Company also concluded that any payments from GSK related to the profit and loss sharing arrangement (including royalties) contingent upon the commercialization of the related products will be analogized to ASC 606 and, therefore, will be recognized when the related sales occur.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Upon execution of the 2021 GSK Agreement, the Company granted the Next Gen License to GSK and therefore, recognized $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">168.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as contract revenue in the second quarter of 2021. As of December 31, 2022, the total unrecognized transaction price of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">51.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million is classified as noncurrent deferred revenue on the Company's consolidated balance sheet related to the remaining performance obligations, being the remaining two material rights resulting from the Selected Pathogen Rights. The Company reclassified the deferred revenue of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">51.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million from current to noncurrent as of December 31, 2022 based on the Company's revised expectations for future option exercises by GSK.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Costs associated with co-development activities performed under the 2021 GSK Agreement are included in research and development expenses in the consolidated statements of operations, with any reimbursement of costs by GSK reflected as a reduction of such expenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Option Exercise by GSK</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In September 2022, GSK exercised its first Selected Pathogen Right, selecting respiratory syncytial virus (&#8220;RSV&#8221;) as its first pathogen under the Additional Programs of the 2021 GSK Agreement (&#8220;First Option Exercise&#8221;). GSK agreed to retroactively share the research and development costs that the Company had incurred under its RSV program since April 2022 in accordance with the applicable provisions of the 2021 GSK Agreement.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company evaluated the First Option Exercise under ASC 606 and identified one performance obligation consisting of the license for a Selected Pathogen Right granted to GSK. The transaction price was determined to be $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">39.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million which equals the deferred revenue allocated to the first Selected Pathogen Right at the inception of the 2021 GSK Agreement. The Company determined that the license is considered a functional intellectual property that is a distinct performance obligation. Specifically, the Company believes the license is capable of being distinct, as GSK has the capabilities to develop the license either on its own or by contracting with other third-parties. GSK can benefit from the license at the time of grant and, therefore, the related performance obligation is satisfied at a point in time. During the year ended December 31, 2022, the Company recognized the $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">39.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as contract revenue.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the year ended December 31, 2022 and 2021, the Company recognized additional net research and development expenses of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, under the 2021 GSK Agreement.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under both the 2020 GSK Agreement and the 2021 GSK Agreement, the Company has a receivable from collaboration of zero and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">773.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million as of December 31, 2022 and 2021, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Brii Biosciences</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In May 2018, the Company entered into the Brii Agreement with Brii Bio Parent and Brii Bio, pursuant to which the Company granted to Brii Bio, with respect to up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">four</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of the Company&#8217;s programs, an exclusive option to obtain exclusive rights to develop and commercialize compounds and products arising from such programs in China, Taiwan, Hong Kong and Macau (collectively, the &#8220;China Territory&#8221;) for the treatment, palliation, diagnosis, prevention or cure of acute and chronic diseases of infectious pathogen origin or hosted by pathogen infection (the &#8220;Field of Use&#8221;). The Company&#8217;s HBV </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">small interfering ribonucleic acid (</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8220;siRNA&#8221;) program being developed under the Amended Alnylam Agreement (described below) is included within the Brii Agreement as a program for which Brii Bio may exercise one of its options. In partial consideration for the options granted by the Company to Brii Bio, Brii Bio Parent and Brii Bio granted the Company, with respect to up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">four</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of Brii Bio Parent&#8217;s or Brii Bio&#8217;s programs, an exclusive option to be granted exclusive rights to develop and commercialize compounds and products arising from such Brii Bio programs in the United States for the Field of Use. The number of options that the Company may exercise for a Brii Bio program is limited to the corresponding number of options that Brii Bio exercises for a Vir program.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As partial consideration for the Company&#8217;s entry into the Brii Agreement, upon closing of Brii Bio Parent&#8217;s Series A preferred stock financing, the Company received ordinary shares equal to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the outstanding shares in Brii Bio Parent. As a result of Brii Bio&#8217;s right to exercise one of its options for the Company&#8217;s HBV siRNA program, under the terms of the Amended Alnylam Agreement, the Company transferred to Alnylam Pharmaceuticals, Inc. (&#8220;Alnylam&#8221;) a specified percentage of such equity consideration allocable to such program </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">under a share transfer agreement in February 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">With respect to programs for which Brii Bio exercises its options, Brii Bio is required to pay the Company an option exercise fee for each such Vir program ranging from the</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> mid-single-digit millions</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, determined based on the commercial potential of the licensed program. Brii Bio will also be required to pay regulatory milestone payments on a licensed product-by-licensed product basis ranging from the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">mid-single-digit millions</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, also determined based on the commercial potential of such program. Following commercialization, Brii Bio will be required to make sales milestone payments based on certain specified levels of aggregate annual net sales of products arising from each licensed program in the China Territory, up to an aggregate of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">175.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million per licensed program.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Upon exercise of each option for a Brii Bio program, the Company will be required to pay to Brii Bio an option exercise fee ranging from the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">low tens of millions</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, determined based on the commercial potential of the licensed program. The Company will be required to make regulatory milestone payments to Brii Bio on a licensed product-by-licensed product basis ranging from the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">low tens of millions</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, also determined based on the commercial potential of such program. The Company will also be required to make sales milestone payments based on certain specified levels of aggregate annual net sales of products in the United States arising from each licensed program, up to an aggregate of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">175.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million per licensed program. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022, the Company has not exercised any of its options.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, the Company is obligated under the Brii Agreement to pay Brii Bio tiered royalties based on net sales of products arising from the licensed programs in the United States, and Brii Bio is obligated to pay the Company tiered royalties based on net sales of products arising from the licensed programs in the China Territory. The rates of royalties payable by the Company to Brii Bio, and by Brii Bio to the Company, on net sales range from </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">mid-teens to high-twenties</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Each party&#8217;s obligations to pay royalties expires, on a product-by-product and territory-by-territory basis, on the latest of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years after the first commercial sale of such licensed product in the United States or China Territory, as applicable; the expiration or abandonment of licensed patent rights that cover such product in the United States or China Territory, as applicable; and the expiration of regulatory exclusivity in the United States or the China Territory, as applicable. Royalty rates are subject to specified reductions and offsets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Brii Agreement will remain in force until the expiration of all options or, if any option is exercised, expiration of all royalty payment obligations for all licensed products within such licensed program, unless terminated in its entirety or on a program-by-program basis by either party. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Each party may terminate for convenience all rights and obligations with respect to any program for which it has an option, with </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> days&#8217; written notice (if the terminating party has not exercised an option for such program) or </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">180</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> days&#8217; notice (following the exercise of an option for such program). The Brii Agreement may also be terminated by either party for insolvency of the other party, and either party may terminate the Brii Agreement in its entirety or on a program-by-program basis for the other party&#8217;s uncured material breach on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> days&#8217; written notice (or </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> days&#8217; notice following failure to make payment).</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">From May 2018 until the closing of the Brii Bio Parent IPO in July 2021, Brii Bio Parent and its wholly-owned subsidiary Brii Bio were determined to be variable interest entities (&#8220;VIE&#8221;) due to their reliance on future financing and having insufficient equity at risk. However, the Company did not have the power to direct activities that most significantly impact the economic success of these</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">entities and was not considered the primary beneficiary of these entities. Therefore, the Company did not consolidate Brii Bio Par</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ent or Brii Bio. Subsequent to the Brii Bio Parent IPO, the Company determined that these entities are no longer VIEs. In addition, as Brii Bio Parent is a publicly-traded company, the Company's investment in its ordinary shares became a marketable equity investment with readily determinable fair value and is then subsequently remeasured to fair value at each reporting date (see Note 3&#8212;Fair Value Measurements). Prior to the Brii Bio Parent IPO, the Company accounted for its investment in Brii Bio Parent, which had a carrying value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment from the same issuer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Option Exercises by Brii Bio</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2020, Brii Bio exercised its option to obtain exclusive rights to develop and commercialize compounds and products arising from VIR-2218 in the China Territory. In consideration of the Company&#8217;s grant to Brii Bio of an exclusive license related to VIR-2218 in the China Territory, the Company received a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million option exercise fee in connection with the option exercise. Also, the Company is eligible to receive the following payments related to VIR-2218 in the China Territory: a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million regulatory milestone payment, up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">175.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in sales-based milestone payments, and royalties on net sales ranging from </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">high-teens to high-twenties</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company evaluated the VIR-2218 transaction under ASC 606 and identified one performance obligation consisting of the license granted to Brii Bio. Under the Brii Agreement, Brii Bio is responsible for performing all research and development activities and the Company does not have any other performance obligations within the context of ASC 606 under the arrangement after the option exercise. The transaction price is determined to be $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million which consists of the $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million option exercise fee and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of the deferred revenue allocated to the VIR-2218 option at the inception of the Brii Agreement. The Company determined that the license is considered a functional intellectual property that is a distinct performance obligation under ASC 606. Specifically, the Company believes the license is capable of being distinct, as Brii Bio has the capabilities to develop the license either on its own or by contracting other third parties. Brii Bio can benefit from the license at the time of grant and therefore, the related performance obligation is satisfied at a point in time. Additionally, all potential future milestones and other payments are constrained because the Company cannot conclude it is probable that a significant reversal in the amount recognized would not occur. The Company will re-evaluate the transaction price in each reporting period.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In July 2022, Brii Bio exercised its option to obtain exclusive rights to develop and commercialize compounds and products arising from VIR-3434 in the China Territory. In consideration of the Company&#8217;s grant to Brii Bio of an exclusive license related to VIR-3434 in the China Territory, the Company received a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million option exercise fee in connection with the option exercise. Also, the Company is eligible to receive the following payments related to VIR-3434 in the China Territory: a $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million regulatory milestone payment, up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">175.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in sales-based milestone payments, and royalties on net sales ranging from </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">mid-teens to mid-twenties</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company evaluated the VIR-3434 transaction under ASC 606 and identified one performance obligation consisting of the license granted to Brii Bio. Under the Brii Agreement, Brii Bio is responsible for performing all research and development activities and the Company does not have any other performance obligations within the context of ASC 606 under the arrangement after the option exercise. The transaction price was determined to be $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, which consists of the $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million option exercise fee and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of the deferred revenue allocated to the VIR-3434 option at the inception of the Brii Agreement. The Company determined that the license is considered a functional intellectual property that is a distinct performance obligation. Specifically, the Company believes the license is capable of being distinct, as Brii Bio has the capabilities to develop the license either on its own or by contracting with other third parties. Brii Bio can benefit from the license at the time of grant and, therefore, the related performance obligation is satisfied at a point in time. Additionally, all potential future milestones and other payments are constrained because the Company cannot conclude it is probable that a significant reversal in the amount recognized would not occur. The Company will re-evaluate the transaction price in each reporting period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the years ended December 31, 2022, 2021 and 2020, the Company recognized $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">zero</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, as license revenue from a related party. During the year ended December 31, 2020, the Company separately paid $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, half of the option exercise proceeds, to Alnylam in connection with the Amended Alnylam Agreement (as defined below) that was recognized as research and development expense.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, the Company also has a contract liability of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million within noncurrent deferred revenues, which represents deferred consideration for the remaining two options that the Company granted to Brii Bio. The deferred consideration will be recognized when Brii Bio exercises its remaining options or the remaining options expire.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Alnylam</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2017, the Company entered into the collaboration and license agreement with Alnylam, as amended in December 2019 and March, April and December 2020 (the &#8220;Amended Alnylam Agreement&#8221;) for the development of siRNA products for the treatment of HBV, and following the exercise of certain program options, the development and commercialization of siRNA therapeutic products directed to up to four other infectious disease targets selected by the Company. The technology licensed under the Amended Alnylam Agreement forms the basis of the Company&#8217;s siRNA technology platform.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the Amended Alnylam Agreement, the Company obtained a worldwide, exclusive license to develop, manufacture and commercialize the HBV siRNA product candidates, including VIR-2218, for all uses and purposes other than agricultural, horticultural, forestry, aquaculture and other residential applications (such excluded fields, the &#8220;Excluded Fields&#8221;). In addition, Alnylam granted the Company an exclusive option, for each of the infectious disease siRNA programs directed to the Company&#8217;s selected targets, to obtain a worldwide, exclusive license to develop, manufacture and commercialize siRNA products directed to the target of each such program for all uses and purposes other than the Excluded Fields. On a product-by-product basis for each product arising from the HBV program and, following the Company&#8217;s option exercise, the infectious disease program, Alnylam has an exclusive option, exercisable during a specified period prior to the initiation of a Phase 3 clinical trial for each such product, to negotiate and enter into a profit-sharing agreement for such product.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company and Alnylam were jointly responsible for funding the initial research and development activities for VIR-2218 through the completion of proof-of-concept trials. Prior to the exercise of the Company&#8217;s option for each siRNA program directed to one of the Company&#8217;s selected infectious disease targets, Alnylam is responsible for conducting all development activities, at the Company&#8217;s expense, in accordance with an agreed-upon development plan. Following the Company&#8217;s exercise of an option for a program and payment of the program option exercise fee and any outstanding program costs due to Alnylam, the Company is solely responsible, at the Company&#8217;s expense (subject to Alnylam&#8217;s exercise of a profit-sharing option), for conducting all development, manufacture and commercialization activities for products arising from each such program. If Alnylam exercises a profit-sharing option for a product, the Company will negotiate the terms of such profit-sharing agreement, which will include sharing equally with Alnylam all subsequent costs associated with the development of such product, as well as the profits and losses in connection with such product, subject to reimbursement by Alnylam of a portion of specified development costs in certain circumstances.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Upon the achievement of a certain development milestone, as further discussed below, the Company was obligated to issue shares of the Company&#8217;s common stock equal to the lesser of (i) </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,111,111</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares or (ii) a certain number of shares based on the Company&#8217;s stock price at the time such milestone is achieved (the &#8220;Milestone Shares&#8221;). The Company will be required to pay Alnylam up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">190.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in the aggregate for the achievement of specified development and regulatory milestones by the first siRNA product directed to HBV, and up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">115.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the achievement of specified development and regulatory milestones by the first product directed to the target of each infectious disease siRNA program for which the Company exercised its option. Following commercialization, the Company will be required to pay to Alnylam up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">250.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in the aggregate for the achievement of specified levels of net sales by siRNA products directed to HBV and up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the achievement of specified levels of net sales by products directed to the target of each infectious disease siRNA program for which the Company exercised its option. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company may also be required to pay Alnylam tiered royalties at percentages ranging from the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">low double-digits to mid-teens</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> on annual net sales of HBV products, and tiered royalties at percentages ranging from the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">high single-digits to the sub-teen double-digits</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> on annual net sales of licensed infectious disease products, in each case subject to specified reductions and offsets. </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The royalties are payable on a product-by-product and country-by-country basis until the later of the expiration of all valid claims of specified patents covering such product in such country and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years after the first commercial sale of such product in such country.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In March 2020, the Company achieved the specified development milestone relating to the Milestone Shares, which was accounted for as an embedded derivative. Consequently, the Company remeasured and reclassified the derivative liability to additional paid-in capital based on the estimated fair value of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million. The Company issued Alnylam </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,111,111</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of its common stock and paid Alnylam $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in the second quarter of 2020.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The term of the Amended Alnylam Agreement will continue, on a product-by-product and country-by-country basis, until the expiration of all royalty payment obligations under the Amended Alnylam Agreement. If the Company does not exercise its option for an infectious disease program directed to one of its selected targets, the Amended Alnylam Agreement will expire upon the expiration of the applicable option period with respect to such program. However, if Alnylam exercises its profit-sharing option for any product, the term of the Amended Alnylam Agreement will continue until the expiration of the profit-sharing arrangement for such product. The Company may terminate the Amended Alnylam Agreement on a program-by-program basis or in its entirety for any reason on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> days&#8217; written notice. Either party may terminate the agreement for cause for the other party&#8217;s uncured material breach on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> days&#8217; written notice (or </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> days&#8217; notice for payment breach), or if the other party challenges the validity or enforceability of any patent licensed to it under the Amended Alnylam Agreement on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30 days</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8217; notice.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company incurred expenses under the Amended Alnylam Agreement of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million during the years ended December 31, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022 and 2021, respectively. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the year ended December 31, 2020, in addition to the Milestone Shares, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million milestone payment to Alnylam, and the $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million payment resulting from Brii Bio&#8217;s option exercise in the first half of 2020, the Company incurred expenses of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million under the Amended Alnylam Agreement.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">WuXi Biologics</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In February 2020, the Company entered into a development and manufacturing collaboration agreement with WuXi Biologics (the &#8220;WuXi Biologics Collaboration Agreement&#8221;) for the clinical development, manufacturing, and commercialization of the Company&#8217;s proprietary antibodies developed for SARS-CoV-2. Under the WuXi Biologics Collaboration Agreement, WuXi Biologics conducted cell-line development, process and formulation development, and initial manufacturing for clinical development and had the right to commercialize products incorporating such SARS-CoV-2 antibodies in mainland China, Hong Kong, Macau and Taiwan under an exclusive license granted for the selected SARS-CoV-2 antibodies that were developed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Termination of the WuXi Biologics Collaboration Agreement</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On May 16, 2022, the Company and WuXi Biologics entered into a Termination Agreement (the &#8220;Termination Agreement&#8221;) pursuant to which the Company and WuXi Biologics terminated the WuXi Biologics Collaboration Agreement. Other existing agreements between the Company and WuXi Biologics remain in effect.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the terms of the Termination Agreement, all licenses granted under the WuXi Biologics Collaboration Agreement were terminated and all rights to the SARS-CoV-2 antibody products in mainland China, Hong Kong, Macau and Taiwan reverted to the Company. The Company made a one-time termination payment to WuXi Biologics of $7.0 million and accounted for the payment as an acquisition of an IPR&amp;D asset and, therefore, recognized research and development expense of $7.0 million during the second quarter of 2022. Under the terms of the Termination Agreement, the Company will be obligated to pay WuXi Biologics tiered royalties on net sales of sotrovimab in mainland China, Hong Kong, Macau and Taiwan ranging from low single digits to low double digits. Royalties are payable to WuXi Biologics for a specified royalty term and are subject to reduction in certain circumstances.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Rockefeller University</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In July 2018, the Company entered into an exclusive license agreement with The Rockefeller University (&#8220;Rockefeller&#8221;), which was amended in May 2019, in September 2020, and in March 2021 (as amended, the &#8220;Rockefeller Agreement&#8221;). Under the Rockefeller Agreement, Rockefeller granted the Company a worldwide exclusive license under certain patent rights, and a worldwide non-exclusive license under certain materials and know-how covering certain antibody variants relating to a specified mutation leading to enhanced antibody function and utility, to develop, manufacture and commercialize infectious disease products covered by the licensed patents, or that involve the use or incorporation of the licensed materials and know-how, in each case for all uses and purposes for infectious diseases. The Company uses technology licensed under the Rockefeller Agreement in the Company&#8217;s antibody platform and in the Company&#8217;s product candidate VIR-3434.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is required to pay annual license maintenance fees of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which can be creditable against royalties following commercialization. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In addition, upon achievement of specified development, regulatory and commercial success milestone events, the Company is required to pay up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">80.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, in the aggregate, for up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">six</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> infectious </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">disease products. Any follow-on products beyond six products may result in additional milestone event payments. The Company will also be required to pay to Rockefeller a royalty at a low single-digit percentage rate on net sales of licensed products, subject to certain adjustments. The Company&#8217;s obligation to pay royalties to Rockefeller will terminate, on a product-by-product and jurisdiction-by-jurisdiction basis,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">upon </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the latest of the expiration of the last valid claim of a licensed patent in such jurisdiction, the expiration of all regulatory exclusivity in such jurisdiction or </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years following the first commercial sale of the applicable licensed product in such jurisdiction.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the Rockefeller Agreement, the Company recognized a total of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million during the years ended December 31, 2022, 2021 and 2020, respectively, as research and development expenses related to certain development milestone payments, annual license maintenance fees, and estimated sublicense fees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Rockefeller Agreement will remain in force, absent earlier termination, until the expiration of all of the Company&#8217;s obligations to pay royalties to Rockefeller in all jurisdictions. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has the right to terminate the Rockefeller Agreement in its entirety, or in part, for any reason on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60 days</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8217; written notice to Rockefeller. Rockefeller may terminate the Rockefeller Agreement on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90 days</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8217; written notice for the Company&#8217;s uncured material breach, or if the Company challenges the validity or enforceability of any of the licensed patents, or immediately in the event of the Company&#8217;s insolvency. Rockefeller may also terminate the Rockefeller Agreement if the Company ceases to carry on business with respect to the rights granted to the Company under the Rockefeller Agreement.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">MedImmune</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In September 2018, the Company entered into a license agreement, which was amended in September 2020 (as amended, the &#8220;MedImmune Agreement&#8221;), with MedImmune, LLC (&#8220;MedImmune&#8221;), under which the Company obtained a worldwide, exclusive license to develop and commercialize half-life extended versions of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">two</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> specified antibodies under development by MedImmune that target influenza A and influenza B, respectively, for all uses in humans and animals. The Company is developing VIR-2482 using technology licensed under the MedImmune Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is obligated to make development, regulatory, and commercial milestone payments of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">331.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in the aggregate relating to influenza A and influenza B products. MedImmune is also entitled to receive tiered royalties based on net sales of products containing half-life extended versions of antibodies directed to influenza A and/or influenza B at percentages ranging from the </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_5dac47e7-0c9b-40b2-b070-76af35962042;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">mid-single-digits</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to sub-teen double-digits.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The MedImmune Agreement will remain in force until the expiration on a country-by-country and product-by-product basis of all of the Company&#8217;s obligations to pay royalties to MedImmune. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company may terminate the MedImmune Agreement in its entirety or on a product-by-product basis, for convenience, upon </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">120</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> days&#8217; notice. Either party may terminate the MedImmune Agreement for cause for the other party&#8217;s uncured material breach on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> days&#8217; notice or immediately in the event of bankruptcy of the other party. Additionally, MedImmune may terminate the MedImmune Agreement for cause on </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30 days</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8217; written notice if the Company challenges the validity or enforceability of the patents to which the Company has obtained a license under the MedImmune Agreement.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Xencor</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">August 2019 License Agreement</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In August 2019, the Company entered into a patent license agreement, which was amended in February 2021 (as amended, the &#8220;2019 Xencor Agreement&#8221;) with Xencor, Inc. (&#8220;Xencor&#8221;). Under the 2019 Xencor Agreement, the Company obtained a non-exclusive, sublicensable (only to its affiliates and subcontractors) license to incorporate Xencor&#8217;s licensed technologies into, and to evaluate, antibodies that target influenza A and HBV, and a worldwide, non-exclusive, sublicensable license to develop and commercialize products containing such antibodies incorporating such technologies for all uses, including the treatment, palliation, diagnosis and prevention of human or animal diseases, disorders or conditions. The Company is obligated to use commercially reasonable efforts to develop and commercialize an antibody product that incorporates Xencor&#8217;s licensed technologies, for each of the influenza A and HBV research programs. These technologies are used in the Company&#8217;s product candidates VIR-2482, incorporating Xencor&#8217;s Xtend technology, and VIR-3434, incorporating Xencor&#8217;s Xtend and other Fc technologies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For each of the influenza A and HBV research programs, the Company is required to pay Xencor development and regulatory milestone payments of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in the aggregate, and commercial sales milestone payments of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in the aggregate, for a total of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">77.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in aggregate milestones for each program and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">155.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in aggregate milestones for both programs. On a product-by-product basis, the Company is also obligated to pay tiered royalties based on net sales of licensed products ranging from </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">low- to mid-single-digits</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The royalties are payable, on a product-by-product and country-by-country basis, until the expiration of the last to expire valid claim in the licensed patents covering such product in such country.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the 2019 Xencor Agreement, the Company recognized an immaterial amount during each of the years ended December 31, 2022, 2021 and 2020, as research and development expenses related to certain development milestone payments.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">March 2020 License Agreement</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In March 2020, the Company entered into a patent license agreement, which was amended in February 2021 (as amended, the &#8220;2020 Xencor Agreement&#8221;), with Xencor under which the Company obtained a non-exclusive, sublicensable (only to its affiliates and subcontractors) license to incorporate Xencor&#8217;s licensed technologies into, and to evaluate, antibodies that target any component of a coronavirus, including SARS-CoV-2, SARS-CoV and MERS-CoV, and a worldwide, non-exclusive, sublicensable license to develop and commercialize products containing such antibodies incorporating such technologies for all uses, including the treatment, palliation, diagnosis and prevention of human or animal diseases, disorders or conditions. The Company is obligated to use commercially reasonable efforts to develop and commercialize an antibody product that incorporates Xencor&#8217;s licensed technologies, for each of the coronavirus research programs. These technologies are used in sotrovimab, incorporating Xencor&#8217;s Xtend technology.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In consideration for the grant of the license, the Company is obligated to pay royalties based on net sales of licensed products at the</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> mid-single-digits</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The royalties are payable, on a product-by-product and country-by-country basis, until the later of the expiration of the last to expire valid claim in the licensed patents covering such product in such country or </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12 years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. During the years ended December 31, 2022 and 2021, the Company recognized $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">114.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, as cost of revenue for royalties due to Xencor from the sale of sotrovimab.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The 2020 Xencor Agreement and 2019 Xencor Agreement will remain in force, on a product-by-product and country-by-country basis, until the expiration of all royalty payment obligations under each of the respective agreements. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company may terminate each agreement in its entirety, or on a target-by-target basis, for convenience upon </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> days&#8217; written notice. Either party may terminate each agreement for the other party&#8217;s uncured material breach upon </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> days&#8217; written notice (or </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> days in the case of non-payment) or in the event of bankruptcy of the other party immediately upon written notice. Xencor may terminate each agreement immediately upon written notice if the Company challenges, or upon </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> days&#8217; written notice if any of the Company&#8217;s sublicensees challenge, the validity or enforceability of any patent licensed to the Company under each respective agreement.</span></span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139790634301856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Components</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:8.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">8.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance Sheet Components </span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Property and Equipment, net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net consists of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.747%;"/>
        <td style="width:1.427%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.186%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.427%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.213000000000001%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36,533</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,012</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,545</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,112</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,852</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,443</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">84,422</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,834</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Construction in progress</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26,925</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, gross</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">126,352</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">57,326</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less accumulated depreciation and amortization</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,743</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,492</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total property and equipment, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">105,609</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42,834</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation and amortization expenses were </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the years ended December 31, 2022, 2021 and 2020, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Accrued and Other Liabilities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued and other liabilities consist of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.12%;"/>
        <td style="width:1.655%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.246%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.655%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.324%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Milestone payable</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">95,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net profit-sharing constrained</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">357,762</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued royalties</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,447</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58,672</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expenses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48,880</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28,073</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Payroll and related expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28,286</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29,753</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued income taxes</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,228</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,217</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Excess funds payable under grant agreements</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,652</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,825</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities, current</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,137</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,927</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other professional and consulting expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,987</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,791</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other accrued expenses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,711</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,254</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total accrued and other liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">489,090</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">236,512</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI https://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139790634559808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">9.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commitments and Contingencies </span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Lease Agreements</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has various operating lease arrangements for office and laboratory spaces located in California, Oregon, Missouri, and Switzerland with contractual lease periods expiring at various dates through </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2033</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These leases require monthly lease payments that may be subject to annual increases throughout the lease term. Certain lease agreements also provide the Company with the option to renew for additional periods ranging from </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_6e3bf6bc-7e1c-4d4c-81d7-17386f7ad6b8;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> These renewal options are not considered in the remaining lease term unless it is reasonably certain that the Company will exercise such options.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In October 2021, the Company entered into a new sublease agreement for office and laboratory spaces in Missouri that will expire in December 2028, with no option to renew. Under this sublease arrangement, the Company is entitled to tenant improvement allowance of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">related to the design and construction of certain Company improvements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2021, the Company entered into a lease agreement with the new owner of the building at 1800 Owens Street in San Francisco for the lease of approximately </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">133,896</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> rentable square feet of office and laboratory space of such building. The Company previously occupied the same premises under a sublease agreement with a sublessor, which sublease was terminated concurrently with the execution of the new lease agreement. Accordingly, the related ROU asset and lease liability under the sublease arrangement were extinguished and the Company recognized a gain of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million in the consolidated statement of operations for the year ended December 31, 2021. The new lease will expire in December 2033, with no option to renew. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under this lease arrangement, the Company is entitled to tenant improvement allowance of up to $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">related to the design and construction of certain Company improvements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">    </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under two of the operating lease arrangements in California and Missouri discussed above, the Company expected to fully utilize the tenant improvement allowance and, therefore, such amount was treated as a lease incentive that is payable to the Company at the lease commencement date.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Throughout the term of the lease agreements, the Company is responsible for paying certain operating costs, in addition to rent, such as common area maintenance, taxes, utilities and insurance. These additional charges are considered variable lease costs and are recognized in the period in which the costs are incurred.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table contains a summary of the lease costs recognized under ASC 842 and additional information related to operating leases (in thousands, except weighted average amounts):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.778%;"/>
        <td style="width:1.336%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.484%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.107%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.598%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.107%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.589%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,910</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,921</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,591</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term lease cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">239</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">261</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">459</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Variable lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,937</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,256</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,299</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26,086</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,438</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,349</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other Information</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted average remaining lease term (in years)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.0</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.4</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.6</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted average incremental borrowing rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.7</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash paid for amounts included in the measurement of operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,716</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,250</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,081</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ROU assets obtained in exchange for new operating lease liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,046</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">77,187</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48,495</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The discount rate used to determine the present value of the lease payments is our estimated collateralized incremental borrowing rate, based on the yield curve for the respective lease terms, as we generally cannot determine the interest rate implicit in the leases.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The maturity of the Company&#8217;s operating lease liabilities as of December 31, 2022 was as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.944%;"/>
        <td style="width:2.036%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.02%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amounts</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19,450</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,610</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,303</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,747</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2027</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,927</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Thereafter</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">86,994</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">175,031</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38,379</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: net tenant improvement allowance yet to be received</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26,294</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Present value of operating lease liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">110,358</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following amounts were recorded in the consolidated balance sheets as of December 31, 2022 and 2021 (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.225%;"/>
        <td style="width:1.604%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.382%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.465%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.325%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating Leases</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses and other current assets</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">&#160;(1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,616</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">49,536</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating ROU assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">82,557</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">87,220</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_b8b36721-3cb4-433a-80d0-34cd8d9386fc;"><span style="-sec-ix-hidden:F_0ef0daab-8a05-4fa7-ae0c-27cd8627c533;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued and other liabilities</span></span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,137</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,927</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities, noncurrent</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">123,837</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">133,561</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">127,974</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">137,488</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:80.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="text-indent:0.0%;display:flex;margin-top:2.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:8.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For certain operating leases, lease incentives expected to be received exceeds the minimum lease payments expected to be paid over the next 12 months, therefore the net amount is recorded in prepaid expenses and other current assets.</span></div></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Manufacturing and Supply Letter Agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In April 2020, the Company and Samsung Biologics Co., Ltd. (&#8220;Samsung&#8221;) entered into a binding letter agreement (the &#8220;Samsung Letter Agreement&#8221;), under which Samsung performs development and manufacturing services for the Company&#8217;s SARS-CoV-2 antibody program. In August 2020, the Company, GlaxoSmithKline Trading Services Limited (&#8220;GSKTSL&#8221;) and Samsung entered into an Assignment and Novation Agreement effective as of July 31, 2020, under which the Company assigned and transferred to GSKTSL all of the Company&#8217;s right, title, and interest in, to and under the Samsung Letter Agreement, and GSKTSL became the Company&#8217;s successor in interest in and to all of the Company&#8217;s rights, duties, and obligations in, to and under the Samsung Letter Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In August 2020, GSKTSL entered into a Master Services Agreement with Samsung (the &#8220;Samsung MSA&#8221;) in connection with the performance of the obligations of the Company and GSK under the 2020 GSK Agreement. In accordance with the terms of the 2020 GSK Agreement, the Company continues to be responsible for </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the costs under the Samsung MSA, and GSK bears </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of such costs under the Samsung MSA, subject to certain conditions and exceptions. The Company&#8217;s commitment has been substantially recognized on its consolidated balance sheet as part of the profit-sharing amount constrained as of December 31, 2022, which is part of accrued and other liabilities, as discussed in Note 7&#8212;Collaboration and License Agreements.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Indemnification</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Under such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. In addition, the Company has entered into indemnification agreements with its directors and certain officers that may require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. To date, no demands have been made upon the Company to provide indemnification under these agreements, and thus, there are no indemnification claims that the Company is aware of that could have a material effect on the Company&#8217;s consolidated balance sheets, consolidated statements of operations, or consolidated statements of cash flows.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139790634341648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">10.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Related Party Transactions </span></div></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As a result of the Brii Agreement, the Company holds a minority equity interest in Brii Bio through its parent company, Brii Bio Parent. At the time when the Company entered into the Brii Agreement, the Company's Chief Executive Officer (the  &#8220;CEO&#8221;), and another member of the Company's board of directors served on Brii Bio Parent&#8217;s board of directors. The Company's CEO, who is also a member of the Company's board of directors, resigned from Brii Bio Parent&#8217;s board of directors in June 2021. As of December 31, 2022, one member of the Company&#8217;s board of directors serves on Brii Bio Parent&#8217;s board of directors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139790634341648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Awards<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Awards</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:8.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">11.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-Based Awards </span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2019 Equity Incentive Plan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In September 2019, the Company&#8217;s board of directors adopted, with the approval of its stockholders, the 2019 Equity Incentive Plan (the &#8220;2019 Plan&#8221;) for the issuance of incentive stock options (&#8220;ISO&#8221;), non-qualified stock options (&#8220;NSO&#8221;), stock appreciation rights (&#8220;SARs&#8221;), restricted stock, other stock awards and performance cash awards, to employees, non-employee directors, and consultants. The 2019 Plan became effective concurrent with the Company&#8217;s initial public offering (&#8220;IPO&#8221;).</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Awards granted under the 2019 Plan expire no later than </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years from the date of grant. For ISO and NSO, the option price shall not be less than </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the estimated fair value on the date of grant. Options granted typically vest over a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">four-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> period but may be granted with different vesting terms. As of December 31, 2022, there are </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,911,263</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares available for the Company to grant under the 2019 Plan.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2016 Equity Incentive Plan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In September 2016, the Company adopted the 2016 Equity Incentive Plan (the &#8220;2016 Plan&#8221;) for the issuance of ISO, NSO, SARs, restricted stock and other stock awards, to employees, non-employee directors, and consultants under terms and provisions established by the Company&#8217;s board of directors and approved by the stockholders.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Awards granted under the 2016 Plan expire no later than </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years from the date of grant. For ISO and NSO, the option price shall not be less than </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">100</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the estimated fair value on the date of grant. Options granted typically vest over a </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">four-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> period but may be granted with different vesting terms.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In conjunction with adopting the 2019 Plan, the Company discontinued the 2016 Plan with respect to the new equity awards.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">2019 Employee Stock Purchase Plan</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In September 2019, the Company&#8217;s board of directors adopted, with the approval of its stockholders, the ESPP. The ESPP became effective on the completion of the Company&#8217;s IPO.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The ESPP initially authorized the issuance of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,280,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares of the Company&#8217;s common stock under purchase rights granted to its employees or employees of any of the Company&#8217;s designated affiliates. The number of shares of the Company&#8217;s common stock reserved for issuance is subject to an automatic increase at each calendar year. Under the ESPP, the Company may specify offerings with durations of not more than </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> months and may specify shorter purchase periods within each offering. The ESPP allows eligible employees to purchase shares of the Company&#8217;s common stock at a discount through payroll deductions of up to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of their earnings, subject to any plan limitations. Unless otherwise determined by the Company&#8217;s board of directors, employees can purchase shares at </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">85</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the lower of the fair market value of the Company&#8217;s common stock on the first date of an offering or the purchase date. During the year ended December 31, 2022, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">118,288</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> shares were issued under the ESPP.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock Option Activity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Activity under the Company&#8217;s stock option plans is set forth below:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:55.387%;"/>
        <td style="width:0.173%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.722000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.074%;"/>
        <td style="width:1.0%;"/>
        <td style="width:7.6899999999999995%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.148%;"/>
        <td style="width:1.0%;"/>
        <td style="width:7.911%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.247%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.65%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of<br/>Options</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,308,928</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31.75</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.2</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,051,535</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28.07</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">696,963</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.51</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,059,133</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">41.67</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,604,367</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31.70</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.6</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52,307</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested and expected to vest at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,604,367</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31.70</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.6</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52,307</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested and exercisable at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,069,564</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27.06</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.0</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48,178</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The aggregate intrinsic value of options exercised during the years ended December 31, 2022, 2021 and 2020 was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">65.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">53.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the years ended December 31, 2022, 2021, and 2020, the estimated weighted-average grant date fair value of the options granted was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22.69</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">47.62</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25.49</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, the Company expects to recognize the remaining unamortized stock-based compensation expense of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">127.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million related to stock options, over an estimated weighted average period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.2</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock Options Granted to Employees</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair value of stock options granted to employees was estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.472%;"/>
        <td style="width:1.5%;"/>
        <td style="width:15.343%;"/>
        <td style="width:1.5%;"/>
        <td style="width:15.343%;"/>
        <td style="width:1.5%;"/>
        <td style="width:15.343%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="5" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected term of options (in years)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.3</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#8211; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.1</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.3</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#8211; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.1</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.0</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#8211; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.1</span></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected stock price volatility</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% &#8211; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">111.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">103.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% &#8211; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">112.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% &#8211; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">108.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% &#8211; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% &#8211; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% &#8211; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The valuation assumptions for stock options were determined as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expected Term&#8212;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The expected term represents the period that the stock options granted are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term) as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expected Volatility&#8212;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Since inception the expected volatility was determined by examining the historical volatilities for industry peers and using an average of historical volatilities of the Company&#8217;s industry peers. Beginning the first quarter of 2022, the expected volatility is determined by using a blended approach of the Company and its industry peers&#8217; historical volatilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Risk-Free Interest Rate&#8212;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company based the risk-free interest rate over the expected term of the stock options based on the constant maturity rate of U.S. Treasury securities with similar maturities as of the date of the grant.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expected Dividend Rate&#8212;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The expected dividend is zero as the Company has not paid nor does it anticipate paying any dividends on its profit interest units in the foreseeable future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Employees Stock Purchase Plan</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In June 2021, the Company initiated its first offering period under the ESPP. Each offering period is </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">six months</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, which commences on the grant date on or after June 1 and December 1 of each year and ends on the purchase date on or before November 30 and May 31 of each year.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair value of employees' purchase rights under the ESPP was estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:59.491%;"/>
        <td style="width:1.824%;"/>
        <td style="width:18.444%;"/>
        <td style="width:1.824%;"/>
        <td style="width:18.417%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected term of ESPP (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.5</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.5</span></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected stock price volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">59.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% &#8211; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">86.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">76.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% &#8211; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">144.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% &#8211; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.04</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% &#8211; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The expected term of employees&#8217; purchase rights is equal to the purchase period. The expected volatility was determined based on the Company's historical volatility. The risk-free interest rate is based on the constant maturity rate of U.S. Treasury securities with similar maturities as of the date of the grant over the expected term of the employees&#8217; purchase rights. The expected dividend is zero as the Company has not paid nor does it anticipate paying any dividends on its profit interest units in the foreseeable future. Based on the Black-Scholes option-pricing model, the estimated weighted-average grant date fair value of the employees' purchase rights granted for the years ended December 31, 2022 and 2021 was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9.09</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19.85</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> per share, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Restricted Stock Activity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s RSAs and RSUs were summarized as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:69.706%;"/>
        <td style="width:1.36%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.302%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.552%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.081%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="4" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted Average Grant Date Fair Value Per Share</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RSU</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RSU</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,271,334</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">59.93</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,097,128</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27.87</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">349,496</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58.26</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">349,788</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40.86</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested as of December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,669,178</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37.46</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The unvested shares of RSUs have not been included in the shares issued and outstanding.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, there was $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">77.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of total unrecognized compensation cost related to unvested restricted stock units, all of which is expected to be recognized over a remaining weighted-average period of </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.8</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> years.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock-Based Compensation Expense</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Stock-based compensation is recognized on a straight-line basis over the requisite service period, which is generally the vesting period. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table sets forth the total stock-based compensation expense for all awards granted to employees and the ESPP in the consolidated statements of operations: </span></span><span style=""/></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.136%;"/>
        <td style="width:1.358%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.821%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.369%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.833%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.369%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.112%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">53,153</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42,554</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,663</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Selling, general and administrative</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48,929</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">41,230</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,937</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total stock-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">102,082</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">83,784</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,600</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139790634412016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Income (Loss) Per Share</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">12.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net Income (Loss) Per Share</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></div></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic net income (loss) per common share is computed by dividing the net income (loss) by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net income (loss) per common share is computed by dividing the net income (loss) by the sum of the weighted-average number of common shares outstanding during the period plus any potential dilutive effects of common stock equivalents outstanding during the period calculated in accordance with the treasury stock method. For periods that the Company was in a net loss position, basic net loss per share is the same as diluted net loss per share as the inclusion of all potential common securities outstanding would have been anti-dilutive. The following is a calculation of the basic and diluted net income per share (in thousands, except share and per share data):</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;">&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.361%;"/>
        <td style="width:1.506%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.574%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.506%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.574%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.506%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.974%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net income (loss), basic and diluted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">515,837</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">528,584</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">298,665</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average shares outstanding, basic</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">132,606,767</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">129,884,967</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">119,159,424</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average effect of dilutive securities:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options to purchase common stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,130,212</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,513,438</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted shares subject to future vesting</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">73,851</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35,488</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares to purchase under Employee Stock Purchase Plan</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">78</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contingently issuable shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,233</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average shares outstanding, diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">134,810,908</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">133,437,126</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">119,159,424</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net income (loss) per share, basic</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.89</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.07</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.51</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net income (loss) per share, diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.83</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.96</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.51</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:58.205%;"/>
        <td style="width:1.068%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.735%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.058%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.735%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.058%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.141%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options issued and outstanding</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,853,734</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,764,308</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,798,282</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted shares subject to future vesting</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,646,748</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,088,304</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">89,261</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Warrants to purchase common stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,500,482</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,852,612</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,887,543</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139790634321232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined Contribution Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Defined Contribution Plan</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">13.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Defined Contribution Plan </span></div></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company sponsors a 401(k) retirement savings plan for the benefit of its employees. Eligible employees may contribute a percentage of their compensation to this plan, subject to statutory limitations. The Company made contributions to the plan for eligible participants, and recorded contribution expenses of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the years ended December 31, 2022, 2021 and 2020, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139790634341648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="text-indent:0.0%;display:flex;margin-top:8.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">14.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income Taxes </span></div></div><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income (loss) before provision for income taxes consists of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.739%;"/>
        <td style="width:1.281%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.587%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.281%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.752%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.281%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.081%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Domestic</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">692,445</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">535,989</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">309,697</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Foreign</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61,835</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,813</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,086</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total income (loss) before provision for income taxes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">754,280</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">549,802</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">298,611</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The components of income tax expense consist of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:37.715%;"/>
        <td style="width:2.141%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.708%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.141%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.456%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.141%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.697%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">238,550</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,526</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,432</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">105</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Foreign</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,647</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,401</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">106</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">253,629</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,032</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">106</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,186</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,186</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,186</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,186</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Provision for income taxes</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">238,443</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21,218</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">54</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A reconciliation between the expected income tax provision at the federal statutory rate and the reported income tax expense is as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.221%;"/>
        <td style="width:1.39%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.771%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.39%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.771%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.39%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.07%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. federal statutory income tax rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Foreign tax at less than federal statutory rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.9</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prior year tax rate adjustment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.9</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State taxes, net of federal benefit</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.7</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.7</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development tax credit</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.6</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.8</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Permanent items</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.4</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.8</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17.9</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25.3</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.9</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.5</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effective income tax rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31.6</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.9</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The tax effects of temporary differences that give rise to significant portions of the Company&#8217;s deferred tax assets and liabilities as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021, are related to the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:58.692%;"/>
        <td style="width:2.103%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.569%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.103%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.534%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,793</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,030</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development tax credit carryforward</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,123</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,375</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity compensations</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24,250</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,065</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reserves and accruals</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">85,977</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,115</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Capitalized research and development</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75,680</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,553</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28,612</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intangible assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,348</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19,657</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">249,724</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">96,854</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized gain on investments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,880</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30,170</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ROU assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,834</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28,483</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,151</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,422</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IPR&amp;D</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,511</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,511</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48,376</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">69,586</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">204,601</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45,707</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,253</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,439</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></div><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Although the Company has taxable income for the year ended December 31, 2022 and 2021, it has otherwise incurred accumulated tax losses since inception. Based on the available objective evidence, the Company cannot conclude it is more likely than not that the net deferred tax assets will be fully realizable.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Accordingly, the Company has provided a valuation allowance against its net deferred tax assets. For the year ended December 31, 2022, the Company recorded a valuation allowance increase of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">158.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, primarily based on the estimated 2022 taxable income. The valuation allowance is decreased by $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">114.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the year ended December 31, 2021 and increased by $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">74.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for the year ended December 31, 2020.  As of December 31, 2022, the Company has net operating loss carryforwards of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for federal purposes and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">111.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for state tax purposes. If not utilized, these carryforwards will begin to expire in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2037</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for federal and in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2031</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> for state tax purposes. As of December 31, 2022, the Company also has net operating loss carryforwards of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for Australian tax purposes, which have an indefinite carryforward period, and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> net operating loss carryforward for Swiss tax purposes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under the Tax Reform Act of 1986, the amounts of and benefits from net operating loss carryforwards may be impaired or limited in certain circumstances. Events which cause limitations in the amount of net operating losses that the Company may utilize in any one year include, but are not limited to, a cumulative ownership change of more than 50% over a three-year period. The Company completed its Section 382 analysis as of December 31, 2022 and based on this analysis, it does not expect that the annual limitations will significantly impact its ability to utilize its net operating loss or tax credit carryforwards prior to expiration.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, the Company has research tax credit carryforwards of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million for federal and state tax purposes, respectively. If not utilized, the federal carryforward will expire in various amounts beginning in </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2036</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The California credits can be carried forward indefinitely.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p><div style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax Cuts and Jobs Act of 2017 subjects a U.S. shareholder to current tax on global intangible low-taxed income ("GILTI") earned by certain foreign subsidiaries. The FASB </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Staff Q&amp;A, Topic 740 No. 5, Accounting for Global Intangible Low-Taxed Income, states that an entity can make an accounting policy election to either recognize deferred taxes for temporary differences expected to reverse as GILTI in future years or provide for the tax expense related to GILTI in the year the tax is incurred. The Company has elected to recognize the tax on GILTI as a period expense in the period the tax is incurred.</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Uncertain Tax Positions</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022 and 2021, the Company had an unrecognized tax benefit balance of $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million, respectively, related to transfer pricing and research and development tax credits. A portion of the unrecognized tax benefits as of December 31, 2022, if recognized, would reduce the Company&#8217;s effective tax rate by </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other unrecognized tax benefits as of</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31, 2022, if recognized, would be in the form of net operating loss and tax credit carryforwards, which attract a full valuation allowance offset, and would not reduce the Company&#8217;s effective tax rate. There are no provisions for which it is reasonably possible that the total amounts of unrecognized tax benefits will significantly increase or decrease within 12 months of the reporting date. Because the statute of limitations does not expire until after the net operating loss and credit carryforwards are actually used, the statutes are still open on calendar years ending December 31, 2017 forward for federal and state purposes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company did </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t recognize any expense for interest and penalties related to uncertain tax positions during 2022, 2021 and 2020, and the Company does </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">t have any amounts related to interest and penalties accrued at December 31, 2022. The Company files U.S. federal, state, Switzerland and Australia tax returns. The Company&#8217;s tax years remain open for all years. As of December 31, 2022, the Company was not under examination by the Internal Revenue Service or any state or foreign tax jurisdiction.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><div style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A reconciliation of the beginning and ending amounts of the liability for uncertain tax positions is as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.843%;"/>
        <td style="width:1.27%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.085%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.282%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.085%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.282%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.152999999999999%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross unrecognized tax benefits at January 1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,422</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,877</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,725</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Addition for tax positions taken in the prior years</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reduction for tax positions taken in the prior years</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">62</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">588</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Addition for tax positions taken in current year</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,228</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,607</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,740</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross unrecognized tax benefits at December 31</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,638</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,422</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,877</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139790638054352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Basis of Presentation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and include all adjustments necessary for the fair presentation of the Company&#8217;s financial position for the periods presented. The consolidated financial statements include the accounts of Vir and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated upon consolidation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Foreign Currency</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The functional currency of the Company&#8217;s foreign subsidiaries is the U.S. dollar. Monetary assets and liabilities of foreign subsidiaries are translated into U.S. dollars at period-end exchange rates and non-monetary assets and liabilities are translated to U.S. dollars using historical exchange rates. Revenue and expenses are translated at average rates throughout the respective periods. Transaction gains and losses are included in other income (expense), net on the consolidated statements of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting periods. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Segments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company operates as </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> reportable segment. The Company&#8217;s chief operating decision maker, its Chief Executive Officer, manages the Company&#8217;s operations on a consolidated basis for purposes of allocating resources.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_ConcentrationOfCreditRiskCreditLossAndOtherRisksAndUncertaintiesPolicyTextBlock', window );">Concentration of Credit Risk, Credit Loss and Other Risks and Uncertainties</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentration of Credit Risk, Credit Loss and Other Risks and Uncertainties</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Although the Company received Emergency Use Authorization (&#8220;EUA&#8221;), temporary authorization or marketing approval for sotrovimab (under the brand name Xevudy&#174;), sotrovimab is currently de-authorized in the U.S. and has limitations in use outside of the U.S. In addition, the Company is still subject to a number of other challenges and risks similar to other biopharmaceutical companies in the early stage, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its other product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of sotrovimab and other product candidates and protection of proprietary technology. If the Company does not successfully obtain regulatory approval, commercialize or partner any of its product candidates, it will be unable to generate revenue from product sales or maintain profitability. In addition, to the extent the COVID-19 pandemic, including the emergence of new variants or subvariants, adversely affects the Company&#8217;s business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties discussed above.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has implemented a number of plans and policies designed to address and mitigate the impact of the COVID-19 pandemic on its business. The extent to which the changing COVID-19 landscape impacts the Company&#8217;s business, clinical development and regulatory efforts, corporate development objectives and the value of and market for its common stock, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and investments. Cash and cash equivalents are deposited in checking and sweep accounts at a financial institution. Such deposits may, at times, exceed federally insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s investment policy limits investments to certain types of securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and investments, and issuers of the investments to the extent recorded on the consolidated balance sheets. As of December 31, 2022 and 2021, the Company has no off-balance sheet concentrations of credit risk.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is exposed to credit losses primarily through receivables from customers and collaborators and through its available-for-sale debt securities. The Company&#8217;s expected loss allowance methodology for the receivables is developed using historical collection experience, current and future economic market conditions, a review of the current aging status and financial condition of the entities. Specific allowance amounts are established to record the appropriate allowance for customers that have a higher probability of default. Balances are written off when determined to be uncollectible. The Company&#8217;s expected loss allowance methodology for the debt securities is developed by reviewing the extent of the unrealized loss, the size, term, geographical location, and industry of the issuer, the issuers&#8217; credit ratings and any changes in those ratings, as well as reviewing current and future economic market conditions and the issuers&#8217; current status and financial condition. The Company considered the current and expected future economic and market conditions surrounding the COVID-19 pandemic and interest rate policies and determined that the estimate of credit losses was not significantly impacted. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There was </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> allowance for losses on available-for-sale debt securities attributable to credit risk for the years ended December 31, 2022 and 2021.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash Equivalents</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents, which consist of amounts invested in money market funds, and are stated at fair value.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Investments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Investments include available-for-sale debt securities and equity investments, which are carried at estimated fair value.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Available-for-Sale Debt Securities</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s valuations of marketable securities are generally derived from independent pricing services based on quoted prices in active markets for similar securities at period end. Generally, investments with original maturities beyond three months at the date of purchase and which mature at, or less than 12 months from, the consolidated balance sheet date are considered short-term investments, with all others considered to be long-term investments. Unrealized gains and losses deemed temporary in nature are reported as a component of accumulated comprehensive income (loss). The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income on the consolidated statements of operations. The cost of securities sold is based on the specific identification method.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Equity Investments</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company measures its investment in equity securities at fair value at each reporting date based on the market price at period end if it has a readily determinable fair value. Otherwise, the investments in equity securities are measured at cost less impairment, adjusted for observable price changes for identical or similar investments of the same issuer unless the Company has significant influence or control over the investee. Changes in fair value resulting from observable price changes are presented as change in fair value of equity investments and changes in fair value resulting from foreign currency translation are included in other income (expense), net </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">on the consolidated statements of operations.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash and Cash Equivalents</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Restricted Cash and Cash Equivalents</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted cash and cash equivalents represent money market funds to secure standby letters of credit and security deposits with financial institutions, both under office and laboratory space lease agreements. Additionally, funds received from certain grants are restricted as to their use and are therefore classified as restricted cash and cash equivalents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Property and Equipment, Net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment are stated at cost, net of accumulated depreciation and amortization. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the respective assets, generally </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_8818a887-324c-4500-a98b-191605dee51d;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">five years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Leasehold </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">improvements are amortized over the lesser of their useful lives or the remaining life of the lease. When assets are retired or</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">otherwise </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">disposed of, the cost and related accumulated depreciation and amortization are removed from the balance sheet and the resulting gain or loss is reflected in operations in the period realized. Maintenance and repairs are charged to operations as incurred.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparing the carrying amount to the future net undiscounted cash flows which the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows arising from the asset. No material impairment losses have been incurred to date.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Acquired Intangible Assets</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acquired Intangible Assets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s intangible assets were acquired via business combinations or asset acquisitions. Indefinite-lived intangible assets represent the estimated fair value assigned to in-process research and development (&#8220;IPR&amp;D&#8221;) acquired in a business combination. The Company reviews indefinite-lived intangible assets for impairment at least annually or more frequently if events or changes in circumstances indicate that the carrying value of the assets might not be recoverable. If the carrying value of an indefinite-lived intangible asset exceeds its fair value, then it is written down to its adjusted fair value. As of December 31, 2022, there have been </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> such impairments. For IPR&amp;D, if a product candidate derived from the indefinite-lived intangible asset is developed and commercialized, the useful life will be determined, and the carrying value will be amortized prospectively over that estimated useful life. Alternatively, if a product candidate is abandoned, the carrying value of the intangible asset will be charged to research and development expenses. IPR&amp;D assets acquired as part of an asset acquisition are recorded at cost and expensed immediately if they have no alternative future uses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Finite-lived intangible assets acquired are initially recognized at their fair value at the acquisition date. </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortization is computed using the straight-line method over the estimated useful lives of the respective finite-lived intangible assets, generally </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_e5972bc8-c341-44f2-a1e7-401190923bbf;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">seven</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15 years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> Finite-lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Goodwill</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Goodwill represents the excess of the purchase price over the estimated fair value of the net tangible and intangible assets acquired in a business combination. The Company tests goodwill for impairment at least annually or more frequently if events or changes in circumstances indicate that this asset may be impaired.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Revenue Recognition</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Collaboration, License and Contract Revenue</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Under Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;), the Company recognizes revenue when the Company&#8217;s customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods and services. To determine revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when or as the Company satisfies a performance obligation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For collaborative arrangements that fall within the scope of ASC 808, Collaborative Arrangements (&#8220;ASC 808&#8221;), the Company first determines which elements of the collaboration are deemed to be a performance obligation with a customer within the scope of ASC 606. For elements of collaboration arrangements that are accounted for pursuant to ASC 808 and are not subject to the guidance in ASC 606, the Company applies the revenue recognition model under ASC 606, including the royalty exception guidance and variable consideration guidance under ASC 606 as described below, or other guidance, as deemed appropriate. When the Company is considered an agent in elements of collaboration arrangements within the scope of ASC 808, it records its share of collaboration revenue in the period in which such sales occur. The Company is considered an agent when the collaboration partner controls the product before transfer to the customers and has the ability to direct the use of and obtain substantially all of the remaining benefits from the product. In these instances, collaboration revenue is based upon the net sales reported by the Company's collaboration partners, net of cost of goods sold and allowable expenses (e.g., manufacturing, distribution, medical affairs, selling, and marketing expenses) in the period. In order to record collaboration revenue, the Company utilizes certain information from its collaboration partner, including actual net product sales, and costs incurred for sales activities, and makes key judgments based on business updates related to commercial and clinical activities such as expected commercial demand, commercial supply plan, manufacturing commitments, risks related to expired or obsolete inventories, and risks related to potential product returns or contract terminations. The Company uses these estimates to determine whether payments due to us under our collaboration arrangements, such as profit-share payments, should be recognized as revenues in the period that they become due or whether any portion of the payments due should be constrained from revenue recognition because it is not probable that recognizing such amounts would not result in a material reversal of revenues in future reporting periods.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has entered into a number of license and collaboration agreements that fall within the scope of ASC 606. The Company evaluates the promised goods or services in these agreements to determine which ones represent distinct performance obligations. These agreements may include the following types of promised goods or services: (i) grants of licenses, (ii) performance of research and development services, and (iii) participation on joint research and/or development committees. They also may include options to obtain licenses to the Company&#8217;s intellectual property.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prior to recognizing revenue, the Company makes estimates of the transaction price, including variable consideration that is subject to a constraint. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur and when the uncertainty associated with the variable consideration is subsequently resolved. These estimates are re-assessed each reporting period as required. These agreements may include the following types of consideration: non-refundable upfront payments, reimbursement for research services, research, development or regulatory milestone payments, profit-sharing arrangements, and royalty and commercial sales milestone payments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If there are multiple distinct performance obligations, the Company allocates the transaction price to each distinct performance obligation based on their estimated standalone selling prices (&#8220;SSP&#8221;). The Company estimates the SSP for each distinct performance obligation by considering information such as market conditions, entity-specific factors, and information about its customer that is reasonably available. The Company considers estimation approaches that allow it to maximize the use of observable inputs. These estimation approaches may include the adjusted market assessment approach, the expected cost plus a margin approach or the residual approach. The Company also considers whether to use a different estimation approach or a combination of approaches to estimate the SSP for each distinct performance obligation. Developing certain assumptions (e.g., treatable patient population, expected market share, probability of success and product profitability, discount rate based on weighted-average cost of capital) to estimate the SSP of a distinct performance obligation requires significant judgment.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For performance obligations satisfied over time, the Company estimates the efforts needed to complete the performance obligation and recognizes revenue by measuring the progress towards complete satisfaction of the performance obligation using an input measure.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For arrangements that include sales-based royalties, including commercial milestone payments based on pre-specified level of sales, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Achievement of these royalties and commercial milestones may solely depend upon the performance of the licensee.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Grant Revenue</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Grants received, including cost reimbursement agreements, are assessed to determine if the agreement should be accounted for as an exchange transaction or a contribution. An agreement is accounted for as a contribution if the resource provider does not receive commensurate value in return for the assets transferred. Contributions are recognized as grant revenue when all donor-imposed conditions have been met.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Research and Development Expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To date, research and development expenses have related primarily to discovery efforts and preclinical and clinical development of product candidates. Research and development expenses are recognized as incurred and payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received. Research and development expenses include expenses related to license and collaboration agreements; contingent consideration from business acquisitions; personnel-related expenses, including salaries, benefits, and stock-based compensation for personnel contributing to research and development activities; expenses incurred under agreements with third-party contract manufacturing organizations, contract research organizations, and consultants; clinical costs, including laboratory supplies and costs related to compliance with regulatory requirements; and other allocated expenses, including expenses for rent, facilities maintenance, and depreciation and amortization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company has acquired and may continue to acquire the rights to develop and commercialize new product candidates from third parties. Upfront payments and research and development milestone payments made in connection with acquired license or product rights are expensed as incurred, provided that they do not relate to a regulatory approval milestone or assets acquired in a business combination.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s expense accruals for clinical trials and manufacturing are based on estimates of contracted services provided by third-party vendors not yet billed. When billing terms under these contracts do not coincide with the timing of when the work is performed, the Company is required to make estimates of its outstanding obligations to those third parties as of the period end. The accrual estimates are based on a number of factors, including the Company&#8217;s knowledge of the research and development programs and clinical manufacturing activities, the status of the programs and activities, invoicing to date, and the provisions in the contracts. The Company obtains information regarding unbilled services directly from these service providers and performs procedures to support its estimates based on its internal understanding of the services provided to date. However, the Company may also be required to estimate these services based on information available to its internal clinical and manufacturing administrative staff if such information is not able to be obtained timely from its service providers.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-based Compensation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Stock-based Compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company recognizes stock-based compensation to employees over the requisite service period based on the grant-date fair value of the awards. The Company calculates the estimated fair value of stock options and employees' purchase rights under the Company's 2019 employee stock purchase plan ("ESPP") using the Black-Scholes valuation model, which requires the use of subjective assumptions including volatility and expected term, among others. The fair value of restricted stock awards ("RSAs") and restricted stock units ("RSUs") is based on the market value of the Company's common stock on the date of grant. Stock-based compensation is recognized using the straight-line method for awards that vest only upon the employee&#8217;s or non-employee&#8217;s continued service to the Company. Stock-based compensation expense of the employees' purchase rights under the ESPP is recognized over the offering period. Forfeitures are recognized as they occur.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Acquisitions</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Acquisitions</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Business combinations are accounted for using the acquisition method of accounting. Under the acquisition method, assets acquired, including IPR&amp;D projects, and liabilities assumed are recorded at their respective fair values as of the acquisition date. Any excess fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill. Contingent consideration obligations incurred in connection with the business combination are recorded at their fair values on the acquisition date, are remeasured each subsequent reporting period until the related contingencies are resolved and are classified as contingent consideration on the consolidated balance sheets. The changes in fair values of contingent consideration related to the achievement of various milestones are recorded within research and development expenses or selling, general and administrative expenses based on the nature of the relevant underlying activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">    </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">When the Company determines that an entity acquired does not meet the definition of a business, the transaction is accounted for as an acquisition of assets. Therefore, the consideration paid to acquire IPR&amp;D is expensed, and no goodwill is recorded. Any contingent consideration is generally recognized only when it becomes payable or is paid.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesEmbeddedDerivatives', window );">Embedded Derivatives</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Embedded Derivatives</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company evaluates its acquisitions, collaborative arrangements and other business development transactions to determine if embedded components of these contracts meet the definition of a derivative under ASC 815, Derivatives and Hedging. In general, embedded derivatives are required to be bifurcated from the host instrument if (i) the embedded feature is not clearly and closely related to the host contract and (ii) the embedded feature, if considered a freestanding instrument, meets the definition of a derivative. Embedded derivatives are reported on the consolidated balance sheets at their estimated fair values. Contingent consideration related to asset acquisitions that meet the definition of an embedded derivative is classified as contingent consideration on the consolidated balance sheets. Any change in estimated fair values, as determined at each measurement period, are recorded in the consolidated statements of operations based on the nature of the related contingencies.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in fair values of embedded derivatives related to the achievement of various milestones for product candidates are recorded within research and development expenses or selling, general and administrative expenses based on the nature of the relevant underlying activities</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Otherwise, changes in fair values are recorded within other income (expense), net.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In accordance with ASC 842, Leases, the Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use ("ROU") assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. ROU assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable. On the lease commencement date, the Company estimates and includes in its lease payments any lease incentive amounts based on future events when (1) the events are within the Company&#8217;s control and (2) the event triggering the right to receive the incentive is deemed reasonably certain to occur. If the lease incentive received is greater or less than the amount recognized at lease commencement, the Company recognizes the difference as an adjustment to right-of-use asset and/or lease liability, as applicable.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As the implicit rate in the Company's leases is generally unknown, the Company uses an incremental borrowing rate estimated based on the information available at the lease commencement date in determining the present value of future lease payments. When calculating its estimated incremental borrowing rates, the Company considers its credit risk, the lease term, the total lease payments and the impact of collateral, as necessary. The lease terms may include options to extend or terminate the lease when the Company is reasonably certain it will exercise such options. ROU assets and lease liabilities are remeasured upon certain modifications to leases using the present value of remaining lease payments and estimated incremental borrowing rate upon lease modification. Rent expense for the Company's operating leases is recognized on a straight-line basis within operating expenses over the reasonably assured lease term.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company elected to not separate lease and non-lease components for any leases within its existing classes of assets and, as a result, accounts for the lease and non-lease components as a single lease component. The Company also elected to not apply the recognition requirement to any leases within its existing classes of assets with a term of 12 months or less.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Income Taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company uses the asset and liability method of accounting for income taxes. Current income tax expense or benefit represents the amount of income taxes expected to be payable or refundable for the current year. Deferred income tax assets and liabilities are determined based on differences between the financial statement reporting and tax bases of assets and liabilities and net operating losses and credit carryforwards and are measured using the enacted tax rates and laws that will be in effect when such items are expected to reverse. Deferred income tax assets are reduced, as necessary, by a valuation allowance when management determines it is more likely than not that some or all of the tax benefits will not be realized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s tax positions are subject to income tax audits. The Company recognizes the tax benefit of an uncertain tax position only if it is more likely than not that the position is sustainable upon examination by the taxing authority, based on the technical merits. The tax benefit recognized is measured as the largest amount of benefit which is more likely than not to be realized upon settlement with the taxing authority. The Company evaluates uncertain tax positions on a regular basis. The evaluations are based on several factors, including changes in facts and circumstances, changes in tax law, correspondence with tax authorities during the course of the audit, and effective settlement of audit issues. The provision for income taxes includes the effects of any accruals that the Company believes are appropriate, as well as any related net interest and penalties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax Cuts and Jobs Act of 2017 subjects a U.S. shareholder to current tax on global intangible low-taxed income ("GILTI") earned by certain foreign subsidiaries. The FASB </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Staff Q&amp;A, Topic 740 No. 5, Accounting for Global Intangible Low-Taxed Income, states that an entity can make an accounting policy election to either recognize deferred taxes for temporary differences expected to reverse as GILTI in future years or provide for the tax expense related to GILTI in the year the tax is incurred. The Company has elected to recognize the tax on GILTI as a period expense in the period the tax is incurred.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Income (Loss) Per Share</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Net Income (Loss) Per Share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Basic net income (loss) per common share is computed by dividing the net income (loss) by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net income per common share is computed by dividing the net income by the sum of the weighted average number of common shares outstanding during the period plus any potential dilutive effects of common stock equivalents outstanding during the period calculated in accordance with the treasury stock method.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">New Accounting Pronouncement Recently Adopted</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In November 2021, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standard Update (&#8220;ASU&#8221;) No. 2021-10, Government Assistance (Topic 832) (&#8220;ASU 2021-10&#8221;), which adds certain disclosure requirements with respect to government assistance, including (1) the types of assistance, (2) an entity&#8217;s accounting for the assistance, and (3) the effect of the assistance on financial statements. ASU 2021-10 is effective for annual periods beginning after December 15, 2021. The Company's adoption of ASU 2021-10 on January 1, 2022 did not result in any material impact on its consolidated financial statements and related disclosures.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesEmbeddedDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for embedded derivatives, including how such derivatives are identified and analyzed for possible separation from their host contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 25<br> -Paragraph 5B<br> -URI https://asc.fasb.org/extlink&amp;oid=107671284&amp;loc=SL5844817-113951<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 35<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125515679&amp;loc=d3e40733-113955<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 15<br> -Section 35<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=56949186&amp;loc=d3e50579-113967<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 15<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123589689&amp;loc=d3e48542-113965<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesEmbeddedDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144439<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_ConcentrationOfCreditRiskCreditLossAndOtherRisksAndUncertaintiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Concentration of credit risk credit loss and other risks and uncertainties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_ConcentrationOfCreditRiskCreditLossAndOtherRisksAndUncertaintiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139790630467248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Summary of Financial Assets Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following tables summarize the Company&#8217;s Level 1 and Level 2 financial assets measured at fair value on a recurring basis by level within the fair value hierarchy:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:43.006%;"/>
        <td style="width:1.024%;"/>
        <td style="width:10.242%;"/>
        <td style="width:1.024%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.067%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.024%;"/>
        <td style="width:1.0%;"/>
        <td style="width:7.9%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.043%;"/>
        <td style="width:1.0%;"/>
        <td style="width:7.226999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.024%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.418%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Valuation<br/>Hierarchy</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross<br/>Unrealized<br/>Holding<br/>Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross<br/>Unrealized<br/>Holding<br/>Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate<br/>Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">909,342</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">909,342</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government treasuries</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,493,841</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,396</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,485,445</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,403,183</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,396</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,394,787</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:80.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1) </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Includes </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of restricted cash equivalents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:42.871%;"/>
        <td style="width:1.03%;"/>
        <td style="width:10.205%;"/>
        <td style="width:1.021%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.414%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.058%;"/>
        <td style="width:1.0%;"/>
        <td style="width:7.883%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.058%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.110000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.058%;"/>
        <td style="width:1.0%;"/>
        <td style="width:8.290000000000001%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Valuation<br/>Hierarchy</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amortized<br/>Cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross<br/>Unrealized<br/>Holding<br/>Gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross<br/>Unrealized<br/>Holding<br/>Losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate<br/>Fair Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Money market funds</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">345,098</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">345,098</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. government treasuries</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">419,442</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">872</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">418,570</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">764,540</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">872</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">763,668</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:80.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1) </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Includes $</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of restricted cash equivalents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Summary of Changes in Estimated Fair Value of Financial Liabilities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table sets forth the changes in the estimated fair value of the Company&#8217;s contingent consideration (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.81%;"/>
        <td style="width:2.096%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.094%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contingent<br/>Consideration</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22,822</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in fair value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,115</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24,937</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember', window );">Humabs | Clinical and Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Estimated Fair Value of Significant Unobservable Inputs</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of Decemb</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">er 31, 2022, the Company calculated the estimated fair value of the remaining clinical and regulatory milestones related to VIR-3434 using the following significant unobservable inputs: </span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.176%;"/>
        <td style="width:2.444%;"/>
        <td style="width:32.38%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unobservable input</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Range<br/>(Weighted-Average)1</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Discount rates</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% (</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Probability of achievement</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% - </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">60.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% (</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">43.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%)</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:80.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(1) </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unobservable inputs were weighted based on the relative fair value of the clinical and regulatory milestone payments.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember', window );">Humabs | Commercial Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Estimated Fair Value of Significant Unobservable Inputs</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">s of December 31, 2022, the Monte Carlo simulation assumed a commercial product launch and associated discrete revenue forecasts, as well as the following significant unobservable inputs f</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">or the remaining commercial milestones related to VIR-3434: </span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.176%;"/>
        <td style="width:2.444%;"/>
        <td style="width:32.38%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unobservable input</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Value</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">80.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Discount rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Probability of achievement</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_TomegaVaxIncMember', window );">TomegaVax</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Estimated Fair Value of Significant Unobservable Inputs</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31, 2022, the fair value of the remaining contingent consideration was estimated using the following significant unobservable inputs:</span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.176%;"/>
        <td style="width:2.444%;"/>
        <td style="width:32.38%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unobservable input</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Value</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">90.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Discount rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=vir_ClinicalAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=vir_ClinicalAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=vir_CommercialMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=vir_CommercialMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=vir_TomegaVaxIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=vir_TomegaVaxIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139790634312240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table summarizes the carrying amount of the Company&#8217;s finite-lived intangible assets (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.244%;"/>
        <td style="width:0.375%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.274%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.116%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.591999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.078%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.318999999999999%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-<br/>Average<br/>Remaining Useful</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Life (Years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Developed technology</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,260</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.5</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contract-based intangible asset</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">502</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">502</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12.9</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Finite-lived intangible assets, gross</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,762</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,502</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less accumulated amortization</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,738</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,114</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less impairment of intangible assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">832</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Finite-lived intangible assets, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,556</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Based on the finite-lived intangible assets recorded as of December 31, 2022, the estimated future amortization expense for the next five years is as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.682%;"/>
        <td style="width:1.865%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.451999999999998%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ending December 31:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">532</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">260</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">213</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">213</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2027</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">213</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,431</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139790634285488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAbstract', window );"><strong>Revenue Recognition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_CollaborationRevenueTableTextBlock', window );">Schedule of Collaboration revenue</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">During the years ended December 31, 2022 and 2021, the Company recorded profit-sharing amounts and profit-sharing amounts constrained as components of collaboration revenue in the consolidated statements of operations, as follows:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:51.078%;"/>
        <td style="width:2.396%;"/>
        <td style="width:1.0%;"/>
        <td style="width:19.968%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.396%;"/>
        <td style="width:1.0%;"/>
        <td style="width:20.162%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Collaboration revenue, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Profit-sharing amount</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,875,147</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">917,194</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Profit-sharing amount constrained</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">369,678</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total collaboration revenue, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,505,469</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">917,194</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_CollaborationRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration revenue table text block</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_CollaborationRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139790636958768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment Net</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, net consists of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.747%;"/>
        <td style="width:1.427%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.186%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.427%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.213000000000001%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Laboratory equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">36,533</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,012</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,545</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,112</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,852</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,443</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">84,422</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,834</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Construction in progress</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26,925</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment, gross</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">126,352</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">57,326</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less accumulated depreciation and amortization</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,743</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,492</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total property and equipment, net</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">105,609</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42,834</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock', window );">Schedule of Accrued and Other Liabilities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued and other liabilities consist of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.12%;"/>
        <td style="width:1.655%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.246%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.655%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.324%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Milestone payable</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">95,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net profit-sharing constrained</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">357,762</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued royalties</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,447</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58,672</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development expenses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48,880</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28,073</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Payroll and related expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28,286</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">29,753</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued income taxes</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,228</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,217</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Excess funds payable under grant agreements</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,652</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,825</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities, current</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,137</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,927</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other professional and consulting expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,987</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,791</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other accrued expenses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,711</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,254</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total accrued and other liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">489,090</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">236,512</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of accrued liabilities and other liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139790636959728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_SummaryOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock', window );">Summary of Lease Costs and Additional Information Related to Operating Leases</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table contains a summary of the lease costs recognized under ASC 842 and additional information related to operating leases (in thousands, except weighted average amounts):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.778%;"/>
        <td style="width:1.336%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.484%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.107%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.598%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.107%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.589%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,910</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,921</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,591</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Short-term lease cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">239</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">261</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">459</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Variable lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,937</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,256</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,299</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26,086</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,438</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,349</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other Information</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted average remaining lease term (in years)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.0</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.4</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10.6</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted average incremental borrowing rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.7</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cash paid for amounts included in the measurement of operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,716</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,250</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,081</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ROU assets obtained in exchange for new operating lease liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,046</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">77,187</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48,495</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturities of Operating Lease Liabilities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The maturity of the Company&#8217;s operating lease liabilities as of December 31, 2022 was as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.944%;"/>
        <td style="width:2.036%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.02%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amounts</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19,450</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,610</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,303</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,747</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2027</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16,927</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Thereafter</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">86,994</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">175,031</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: imputed interest</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">38,379</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Less: net tenant improvement allowance yet to be received</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">26,294</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Present value of operating lease liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">110,358</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_ScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetTableTextBlock', window );">Schedule of Operating Lease Amounts Recorded in Condensed Consolidated Balance Sheet</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following amounts were recorded in the consolidated balance sheets as of December 31, 2022 and 2021 (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:61.225%;"/>
        <td style="width:1.604%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.382%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.465%;"/>
        <td style="width:1.0%;"/>
        <td style="width:15.325%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating Leases</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prepaid expenses and other current assets</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Times New Roman&quot;, serif;position:relative;min-width:fit-content;">&#160;(1)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17,616</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">49,536</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating ROU assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">82,557</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">87,220</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="-sec-ix-hidden:F_b8b36721-3cb4-433a-80d0-34cd8d9386fc;"><span style="-sec-ix-hidden:F_0ef0daab-8a05-4fa7-ae0c-27cd8627c533;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accrued and other liabilities</span></span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,137</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,927</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Operating lease liabilities, noncurrent</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">123,837</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">133,561</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">127,974</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">137,488</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:80.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="text-indent:0.0%;display:flex;margin-top:2.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:8.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For certain operating leases, lease incentives expected to be received exceeds the minimum lease payments expected to be paid over the next 12 months, therefore the net amount is recorded in prepaid expenses and other current assets.</span></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_ScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of operating lease amounts recorded in condensed consolidated balance sheet.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_ScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_SummaryOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of lease cost and other information related to operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_SummaryOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139790637011600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Awards (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Plans Activity</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Activity under the Company&#8217;s stock option plans is set forth below:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:55.387%;"/>
        <td style="width:0.173%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.722000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.074%;"/>
        <td style="width:1.0%;"/>
        <td style="width:7.6899999999999995%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.148%;"/>
        <td style="width:1.0%;"/>
        <td style="width:7.911%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.247%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.65%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of<br/>Options</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate<br/>Intrinsic<br/>Value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,308,928</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31.75</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8.2</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,051,535</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28.07</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">696,963</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.51</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,059,133</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">41.67</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Outstanding at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,604,367</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31.70</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.6</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52,307</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested and expected to vest at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,604,367</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31.70</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.6</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52,307</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested and exercisable at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,069,564</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27.06</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.0</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48,178</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Assumptions Used for Estimating the Fair Value of Stock Options Granted</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair value of stock options granted to employees was estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.472%;"/>
        <td style="width:1.5%;"/>
        <td style="width:15.343%;"/>
        <td style="width:1.5%;"/>
        <td style="width:15.343%;"/>
        <td style="width:1.5%;"/>
        <td style="width:15.343%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="5" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected term of options (in years)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.3</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#8211; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.1</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.3</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#8211; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.1</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5.0</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;&#8211; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6.1</span></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected stock price volatility</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">101.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% &#8211; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">111.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">103.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% &#8211; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">112.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% &#8211; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">108.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% &#8211; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% &#8211; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% &#8211; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Summary of Restricted Stock Activity</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company&#8217;s RSAs and RSUs were summarized as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:69.706%;"/>
        <td style="width:1.36%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.302%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.552%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.081%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="4" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted Average Grant Date Fair Value Per Share</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RSU</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RSU</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,271,334</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">59.93</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,097,128</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27.87</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vested</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">349,496</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">58.26</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">349,788</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40.86</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unvested as of December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,669,178</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">37.46</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Summary of Employees Stock Purchase Plan</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fair value of employees' purchase rights under the ESPP was estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:59.491%;"/>
        <td style="width:1.824%;"/>
        <td style="width:18.444%;"/>
        <td style="width:1.824%;"/>
        <td style="width:18.417%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected term of ESPP (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.5</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.5</span></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected stock price volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">59.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% &#8211; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">86.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">76.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% &#8211; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">144.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% &#8211; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.04</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% &#8211; </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Summary of Stock-based Compensation Expense</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following table sets forth the total stock-based compensation expense for all awards granted to employees and the ESPP in the consolidated statements of operations: </span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.136%;"/>
        <td style="width:1.358%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.821%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.369%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.833%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.369%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.112%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">53,153</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">42,554</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,663</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Selling, general and administrative</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48,929</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">41,230</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,937</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total stock-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">102,082</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">83,784</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">27,600</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139790634540144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Basic and Diluted Net Income (loss) Per Share</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;">&#160;</p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.361%;"/>
        <td style="width:1.506%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.574%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.506%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.574%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.506%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.974%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net income (loss), basic and diluted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">515,837</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">528,584</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">298,665</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average shares outstanding, basic</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">132,606,767</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">129,884,967</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">119,159,424</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average effect of dilutive securities:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options to purchase common stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,130,212</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,513,438</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted shares subject to future vesting</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">73,851</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">35,488</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares to purchase under Employee Stock Purchase Plan</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">78</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Contingently issuable shares</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,233</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Weighted-average shares outstanding, diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">134,810,908</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">133,437,126</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">119,159,424</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net income (loss) per share, basic</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.89</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4.07</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.51</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net income (loss) per share, diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.83</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.96</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.51</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potentially Dilutive Securities Not Included in the Diluted Per Share Calculations</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:58.205%;"/>
        <td style="width:1.068%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.735%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.058%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.735%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.058%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.141%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">As of December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Options issued and outstanding</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,853,734</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,764,308</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,798,282</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted shares subject to future vesting</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,646,748</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1,088,304</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">89,261</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Warrants to purchase common stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,500,482</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,852,612</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9,887,543</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139790638054640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Income (Loss) Before Provision for (Benefit from) Income Taxes</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Income (loss) before provision for income taxes consists of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.739%;"/>
        <td style="width:1.281%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.587%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.281%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.752%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.281%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.081%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Domestic</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">692,445</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">535,989</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">309,697</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Foreign</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">61,835</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,813</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,086</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Total income (loss) before provision for income taxes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">754,280</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">549,802</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">298,611</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Components of Income Tax Expense (Benefit)</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The components of income tax expense consist of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:37.715%;"/>
        <td style="width:2.141%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.708%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.141%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.456%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.141%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.697%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Current:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">238,550</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,526</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,432</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">105</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Foreign</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,647</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,401</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">106</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">253,629</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,032</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">106</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Federal</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,186</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,186</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,186</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,186</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">52</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Provision for income taxes</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">238,443</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21,218</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">54</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation Between Expected Income Tax Provision at Federal Statutory Rate and Reported Income Tax Benefit</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A reconciliation between the expected income tax provision at the federal statutory rate and the reported income tax expense is as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.221%;"/>
        <td style="width:1.39%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.771%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.39%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.771%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.39%;"/>
        <td style="width:1.0%;"/>
        <td style="width:14.07%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">U.S. federal statutory income tax rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Foreign tax at less than federal statutory rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.9</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prior year tax rate adjustment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.9</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State taxes, net of federal benefit</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.7</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.7</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development tax credit</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.6</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.8</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Permanent items</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7.4</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.8</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1.3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21.1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17.9</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25.3</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.9</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.5</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effective income tax rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">31.6</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3.9</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The tax effects of temporary differences that give rise to significant portions of the Company&#8217;s deferred tax assets and liabilities as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31, 2022 and 2021, are related to the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:58.692%;"/>
        <td style="width:2.103%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.569%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.103%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.534%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14,793</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,030</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Research and development tax credit carryforward</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12,123</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11,375</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Equity compensations</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24,250</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15,065</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reserves and accruals</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">85,977</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,115</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Capitalized research and development</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">75,680</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,553</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28,612</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intangible assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,348</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19,657</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">249,724</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">96,854</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unrealized gain on investments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,880</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30,170</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ROU assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20,834</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">28,483</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Property and equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13,151</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,422</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IPR&amp;D</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,511</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8,511</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">48,376</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">69,586</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">204,601</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">45,707</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Net deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,253</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18,439</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Reconciliation of Liability for Uncertain Tax Positions</a></td>
<td class="text"><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A reconciliation of the beginning and ending amounts of the liability for uncertain tax positions is as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.843%;"/>
        <td style="width:1.27%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.085%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.282%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.085%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.282%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.152999999999999%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross unrecognized tax benefits at January 1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,422</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,877</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,725</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Addition for tax positions taken in the prior years</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Reduction for tax positions taken in the prior years</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">62</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">588</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Addition for tax positions taken in current year</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3,228</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,607</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2,740</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Gross unrecognized tax benefits at December 31</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10,638</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,422</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4,877</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI https://asc.fasb.org/extlink&amp;oid=126976462&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139790632557904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization - Additional Information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th">
<div>Jul. 10, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Sep. 16, 2019</div></th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.222222222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Net proceeds from IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 323,214<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 323,214<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_SaleOfStockConsiderationAggregateOfferingPrice', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (377,237)<span></span>
</td>
<td class="nump">$ 138,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_CashCashEquivalentsAndShortTermInvestmentsExcludingEquityInvestment', window );">Cash, cash equivalents and short-term investments, excluding equity investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Sales Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_PercentageOfCommissionRateFromSaleOfShares', window );">Percentage of commission rate from sale of shares</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vir_FollowOnOfferingMember', window );">Follow-on Offering | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,214,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,214,285<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Common stock price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Net proceeds from IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 345,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_PaymentsOfUnderwritingDiscountsAndCommissions', window );">Payments of underwriting discounts and commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_NetProceedsFromIssuanceSecondaryPublicOffering', window );">Net proceeds from issuance secondary public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 323,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_CashCashEquivalentsAndShortTermInvestmentsExcludingEquityInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, cash equivalents and short-term investments, excluding equity investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_CashCashEquivalentsAndShortTermInvestmentsExcludingEquityInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_NetProceedsFromIssuanceSecondaryPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's follow on offering of stock to the public, net of commissions and expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_NetProceedsFromIssuanceSecondaryPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Organization consolidation and presentation of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_PaymentsOfUnderwritingDiscountsAndCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments of underwriting discounts and commissions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_PaymentsOfUnderwritingDiscountsAndCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_PercentageOfCommissionRateFromSaleOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of maximum commission rate, based on aggregate gross proceeds from sale of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_PercentageOfCommissionRateFromSaleOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_SaleOfStockConsiderationAggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the aggregate offering price for which the entity may sell shares of its common stock under the sales agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_SaleOfStockConsiderationAggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis=vir_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis=vir_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=vir_FollowOnOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=vir_FollowOnOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139790638048224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for losses on available-for-sale debt securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property and equipment, estimated useful lives description</a></td>
<td class="text">Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the respective assets, generally three to five years.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of indefinite-lived intangible assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod', window );">Finite-lived intangible assets, amortization method description</a></td>
<td class="text">Amortization is computed using the straight-line method over the estimated useful lives of the respective finite-lived intangible assets, generally seven to 15 years.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, estimated useful life</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, estimated useful life</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amortization method of a major finite-lived intangible asset class. A major class is composed of intangible assets that can be grouped together because they are similar either by their nature or by their use in the operations of a company. The straight-line method is the preferred amortization method, unless another method better reflects the pattern in which the asset is consumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 35<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121554622&amp;loc=d3e15372-109273<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905813&amp;loc=d3e1205-110223<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139790637904752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Financial Assets Measured at Fair Value on a Recurring Basis by Level Within Fair Value Hierarchy (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_FinancialAssetsAmortizedCostBasis', window );">Financial Assets, Amortized Cost</a></td>
<td class="nump">$ 2,403,183<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 764,540<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_FinancialAssetsGrossUnrealizedHoldingGains', window );">Financial Assets, Gross Unrealized Holding Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_FinancialAssetsGrossUnrealizedHoldingLosses', window );">Financial Assets, Gross Unrealized Holding Losses</a></td>
<td class="num">(8,396)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(872)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_FinancialAssetsFairValue', window );">Financial Assets, Aggregate Fair Value</a></td>
<td class="nump">2,394,787<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">763,668<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_FinancialAssetsAmortizedCostBasis', window );">Financial Assets, Amortized Cost</a></td>
<td class="nump">909,342<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">345,098<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_FinancialAssetsGrossUnrealizedHoldingGains', window );">Financial Assets, Gross Unrealized Holding Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_FinancialAssetsGrossUnrealizedHoldingLosses', window );">Financial Assets, Gross Unrealized Holding Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_FinancialAssetsFairValue', window );">Financial Assets, Aggregate Fair Value</a></td>
<td class="nump">909,342<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">345,098<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. Government Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_FinancialAssetsAmortizedCostBasis', window );">Financial Assets, Amortized Cost</a></td>
<td class="nump">1,493,841<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">419,442<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_FinancialAssetsGrossUnrealizedHoldingGains', window );">Financial Assets, Gross Unrealized Holding Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_FinancialAssetsGrossUnrealizedHoldingLosses', window );">Financial Assets, Gross Unrealized Holding Losses</a></td>
<td class="num">(8,396)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(872)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_FinancialAssetsFairValue', window );">Financial Assets, Aggregate Fair Value</a></td>
<td class="nump">$ 1,485,445<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 418,570<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Includes </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of restricted cash equivalents.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Includes $</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of restricted cash equivalents.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_FinancialAssetsAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial assets amortized cost basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_FinancialAssetsAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_FinancialAssetsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial assets fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_FinancialAssetsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_FinancialAssetsGrossUnrealizedHoldingGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial assets gross unrealized holding gains.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_FinancialAssetsGrossUnrealizedHoldingGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_FinancialAssetsGrossUnrealizedHoldingLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial assets gross unrealized holding losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_FinancialAssetsGrossUnrealizedHoldingLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139790638059280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Financial Assets Measured at Fair Value on a Recurring Basis by Level Within Fair Value Hierarchy (Parenthetical) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashEquivalents', window );">Restricted cash equivalents</a></td>
<td class="nump">$ 19.3<span></span>
</td>
<td class="nump">$ 15.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash equivalents restricted as to withdrawal or usage. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=127002003&amp;loc=SL6242269-115581<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139790632687312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss', window );">Total unrealized gains recorded in accumulated other comprehensive income (loss)</a></td>
<td class="nump">$ 8,400,000<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivable', window );">Accrued interest receivable excluded from fair value and amortized cost basis of available for sale securities</a></td>
<td class="nump">2,500,000<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableAccruedInterestWriteoff', window );">Write off of accrued interest receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Estimated fair value of contingent consideration</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="nump">5,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=vir_BriiBioParentMember', window );">Brii Bio Parent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtFairValue', window );">Investment Owned At Fair Value</a></td>
<td class="nump">31,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi', window );">Increase Decrease In Equity Securities Fv Ni</a></td>
<td class="nump">111,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Foreign Currency Transaction Gain Loss Unrealized</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTerm', window );">Securities contractual term</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember', window );">Humabs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Estimated fair value of contingent consideration</a></td>
<td class="nump">$ 23,400,000<span></span>
</td>
<td class="nump">$ 17,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=vir_ContingentConsiderationLiabilityMember', window );">Contingent Consideration Liability | TomegaVax Letter Agreement | TomegaVax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_AssetAcquisitionMilestoneAchieved', window );">Asset acquisition milestone achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableAccruedInterestWriteoff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of writeoff of accrued interest on financing receivable recognized by reversing interest income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3D<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL120267969-210447<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableAccruedInterestWriteoff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123583714&amp;loc=SL75117360-209713<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3444-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of the investment at close of period. For schedules of investments that are categorized, the value would be aggregated by category. For investment in and advances to affiliates, if operations of any controlled companies are different in character from those of the company, group such affiliates within divisions and by type of activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 5D<br> -Subparagraph (SX 210.12-13D(Column C))<br> -URI https://asc.fasb.org/extlink&amp;oid=122147990&amp;loc=SL120429264-123010<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C))<br> -URI https://asc.fasb.org/extlink&amp;oid=122147990&amp;loc=d3e611197-123010<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_AssetAcquisitionMilestoneAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition milestone achieved during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_AssetAcquisitionMilestoneAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=vir_BriiBioParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=vir_BriiBioParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=vir_ContingentConsiderationLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=vir_ContingentConsiderationLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=vir_LetterAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=vir_LetterAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=vir_TomegaVaxIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=vir_TomegaVaxIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139790632850608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Estimated Fair Value of Significant Unobservable Inputs (Details)<br></strong></div></th>
<th class="th" colspan="2"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember', window );">Humabs | Clinical and Regulatory Milestones | Measurement Input, Discount Rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Fair value contingent consideration measurement input</a></td>
<td class="nump">0.138<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember', window );">Humabs | Clinical and Regulatory Milestones | Measurement Input, Discount Rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Fair value contingent consideration measurement input</a></td>
<td class="nump">0.151<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember', window );">Humabs | Clinical and Regulatory Milestones | Measurement Input, Discount Rate | Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Fair value contingent consideration measurement input</a></td>
<td class="num">(0.145)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember', window );">Humabs | Clinical and Regulatory Milestones | Probability of Achievement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Fair value contingent consideration measurement input</a></td>
<td class="nump">0.144<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember', window );">Humabs | Clinical and Regulatory Milestones | Probability of Achievement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Fair value contingent consideration measurement input</a></td>
<td class="nump">0.600<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember', window );">Humabs | Clinical and Regulatory Milestones | Probability of Achievement | Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Fair value contingent consideration measurement input</a></td>
<td class="num">(0.436)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember', window );">Humabs | Commercial Milestones | Measurement Input, Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Fair value contingent consideration measurement input</a></td>
<td class="nump">0.120<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember', window );">Humabs | Commercial Milestones | Probability of Achievement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Fair value contingent consideration measurement input</a></td>
<td class="nump">0.259<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember', window );">Humabs | Commercial Milestones | Measurement Input Expected Revenue Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Fair value contingent consideration measurement input</a></td>
<td class="nump">0.800<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_TomegaVaxIncMember', window );">TomegaVax | Measurement Input Expected Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeLiabilityMeasurementInput', window );">Fair value contingent consideration measurement input</a></td>
<td class="nump">0.900<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_TomegaVaxIncMember', window );">TomegaVax | Measurement Input Risk Free Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeLiabilityMeasurementInput', window );">Fair value contingent consideration measurement input</a></td>
<td class="nump">0.044<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unobservable inputs were weighted based on the relative fair value of the clinical and regulatory milestone payments.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure embedded derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=vir_ClinicalAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=vir_ClinicalAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=vir_MeasurementInputProbabilityRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=vir_MeasurementInputProbabilityRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=vir_CommercialMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=vir_CommercialMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=vir_MeasurementInputExpectedRevenueVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=vir_MeasurementInputExpectedRevenueVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=vir_TomegaVaxIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=vir_TomegaVaxIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=vir_MeasurementInputExpectedVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=vir_MeasurementInputExpectedVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139790634730240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Changes in Estimated Fair Value of Financial Liabilities (Details) - Level 3 - Contingent Consideration Liability<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at December 31, 2020</a></td>
<td class="nump">$ 22,822<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Changes in fair value</a></td>
<td class="nump">2,115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at December 31, 2021</a></td>
<td class="nump">$ 24,937<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=vir_ContingentConsiderationLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=vir_ContingentConsiderationLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139790632222864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2021 </div>
<div>USD ($) </div>
<div>Milestone</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>Milestone</div>
</th>
<th class="th">
<div>Jul. 31, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="nump">$ 5,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=vir_TomegaVaxIncMember', window );">TomegaVax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_PaymentMadeForAssetAcquisitionMilestone', window );">Payment made for asset acquisition milestone</a></td>
<td class="nump">$ 8,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_CommonStockSharesIssuedForMilestonePaymentShares', window );">Common stock shares Issued for milestone payment| shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable', window );">Value of common stock shares Issued for milestone payment</a></td>
<td class="nump">1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_MinimumCommonStockPriceForMilestonePaymentsConsideration', window );">Minimum common stock price for milestone payments consideration | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=vir_TomegaVaxIncMember', window );">TomegaVax | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_RemainingPaymentForAssetAcquisitionMilestoneAggregate', window );">Remaining payment for asset acquisition milestone, maximum</a></td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=vir_TomegaVaxIncMember', window );">TomegaVax | Clinical Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_MinimumCommonStockPriceForMilestonePaymentsConsideration', window );">Minimum common stock price for milestone payments consideration | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=vir_TomegaVaxIncMember', window );">TomegaVax | TomegaVax Letter Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_AssetAcquisitionMilestonePaymentAggregate', window );">Milestone payments aggregate amount payable, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_MilestonePaymentsRelatedTermsDescription', window );">Milestone payments related terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company will be required to pay to the former stockholders of TomegaVax milestone payments of up to an aggregate of $30.0 million if the per-share price of the Company&#8217;s publicly traded common stock, or implied price per share of the Company&#8217;s Series A-1 convertible preferred stock (or common stock upon conversion) upon a certain asset sale, merger or stock sale, is at least $45 (as adjusted in the case of any stock dividend, stock split or other similar recapitalization), with the amount of such payments determined by the share price and/or the stage of the Company&#8217;s clinical development at the time of the relevant event triggering the payment.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent', window );">Contingent consideration recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiability', window );">Estimated fair value of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_AssetAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration', window );">Number of milestones achieved | Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_MinimumCommonStockPriceForMilestonePaymentsConsideration', window );">Minimum common stock price for milestone payments consideration | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember', window );">Humabs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,400,000<span></span>
</td>
<td class="nump">17,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets, excluding goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount', window );">Goodwill expected to be deductible for income tax purposes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember', window );">Humabs | Developed Technologies | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Estimated remaining useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember', window );">Humabs | Developed Technologies | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Estimated remaining useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember', window );">Humabs | HBV product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents', window );">Additional consideration payable upon achievement of specified milestone events</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 135,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_SpecifiedClinicalDevelopmentMilestonesPayment', window );">Specified clinical development milestones payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember', window );">Humabs | Another Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents', window );">Additional consideration payable upon achievement of specified milestone events</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember', window );">Humabs | SARS-CoV-2 Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved', window );">Number of specified clinical milestones achieved | Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_SpecifiedClinicalDevelopmentMilestonesPayment', window );">Specified clinical development milestones payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_RegulatoryMilestonesAchieved', window );">Regulatory milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_SalesMilestonesAchieved', window );">Sales milestone achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of acquirer's equity interest issued and issuable as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9215-128498<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=127000608&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized from contingent consideration in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 15<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6911878&amp;loc=d3e8732-128492<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized from contingent consideration in asset acquisition, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 15<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6911878&amp;loc=d3e8732-128492<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_AssetAcquisitionMilestonePaymentAggregate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with an asset acquisition, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_AssetAcquisitionMilestonePaymentAggregate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_AssetAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset acquisition number of milestones achieved related to contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_AssetAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business acquisition number of specified clinical milestones achieved.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combinations additional consideration payable upon achievement of specified events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_CommonStockSharesIssuedForMilestonePaymentShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares issued for milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_CommonStockSharesIssuedForMilestonePaymentShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_MilestonePaymentsRelatedTermsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payments related terms description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_MilestonePaymentsRelatedTermsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_MinimumCommonStockPriceForMilestonePaymentsConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum common stock price that triggers milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_MinimumCommonStockPriceForMilestonePaymentsConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_PaymentMadeForAssetAcquisitionMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment made for asset acquisition milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_PaymentMadeForAssetAcquisitionMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_RegulatoryMilestonesAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Regulatory milestones achieved during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_RegulatoryMilestonesAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_RemainingPaymentForAssetAcquisitionMilestoneAggregate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with an asset acquisition, this element represents an estimate of the high-end of the potential range (undiscounted) of the remaining consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_RemainingPaymentForAssetAcquisitionMilestoneAggregate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_SalesMilestonesAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales milestones achieved during the reporting period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_SalesMilestonesAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_SpecifiedClinicalDevelopmentMilestonesPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specified clinical development milestones payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_SpecifiedClinicalDevelopmentMilestonesPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=vir_TomegaVaxIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=vir_TomegaVaxIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vir_ClinicalDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vir_ClinicalDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vir_LetterAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vir_LetterAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vir_HepatitisBVirusProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vir_HepatitisBVirusProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vir_AnotherProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vir_AnotherProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vir_SARSCoV2ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vir_SARSCoV2ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139790636846224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_ScheduleOfGoodwillAndIntangibleAssetsLineItems', window );"><strong>Schedule of Goodwill and Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 16,937,000<span></span>
</td>
<td class="nump">$ 16,937,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense of intangible assets</a></td>
<td class="nump">532,000<span></span>
</td>
<td class="nump">533,000<span></span>
</td>
<td class="nump">$ 1,042,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">832,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of indefinite-lived intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember', window );">Humabs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_ScheduleOfGoodwillAndIntangibleAssetsLineItems', window );"><strong>Schedule of Goodwill and Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefinitelivedIntangibleAssetsAcquired', window );">Indefinite-lived intangible assets IPR&amp;D</a></td>
<td class="nump">30,700,000<span></span>
</td>
<td class="nump">30,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of indefinite-lived intangible assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_ScheduleOfGoodwillAndIntangibleAssetsLineItems', window );"><strong>Schedule of Goodwill and Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefinitelivedIntangibleAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets and goodwill, lacking physical substance with an indefinite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefinitelivedIntangibleAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_ScheduleOfGoodwillAndIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_ScheduleOfGoodwillAndIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139790637095568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Schedule of Finite Lived Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible assets, gross</a></td>
<td class="nump">$ 4,762<span></span>
</td>
<td class="nump">$ 7,502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less accumulated amortization</a></td>
<td class="num">(2,738)<span></span>
</td>
<td class="num">(4,114)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_FiniteLivedIntangibleAssetsAccumulatedImpairment', window );">Less impairment of intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(832)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets, net</a></td>
<td class="nump">2,024<span></span>
</td>
<td class="nump">2,556<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vir_DevelopedTechnologyMember', window );">Developed Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible assets, gross</a></td>
<td class="nump">$ 4,260<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted-Average Remaining Useful Life (Years)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember', window );">Contract-Based Intangible Asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible assets, gross</a></td>
<td class="nump">$ 502<span></span>
</td>
<td class="nump">$ 502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted-Average Remaining Useful Life (Years)</a></td>
<td class="text">12 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_FiniteLivedIntangibleAssetsAccumulatedImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite lived intangible assets accumulated impairment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_FiniteLivedIntangibleAssetsAccumulatedImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vir_DevelopedTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vir_DevelopedTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139790635720848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Schedule of Estimated Future Amortization Expense (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2024</a></td>
<td class="nump">260<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2025</a></td>
<td class="nump">213<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2026</a></td>
<td class="nump">213<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2027</a></td>
<td class="nump">213<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_FiniteLivedIntangibleAssetsAmortizationExpense', window );">Total</a></td>
<td class="nump">$ 1,431<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_FiniteLivedIntangibleAssetsAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of total amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in the next five years following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_FiniteLivedIntangibleAssetsAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139790633456336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Grant Agreements - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 01, 2022</div></th>
<th class="th"><div>Jan. 13, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued and other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 489,090<span></span>
</td>
<td class="nump">$ 236,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other Current Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Revenue from grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,325<span></span>
</td>
<td class="nump">8,347<span></span>
</td>
<td class="nump">$ 9,123<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=vir_NationalInstitutesOfHealthMember', window );">National Institutes of Health | Grant Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Revenue from grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_HumanImmunodeficiencyVirusGrantMember', window );">Human Immunodeficiency Virus ("HIV") Grant | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_GrantAwardedAmountMaximum', window );">Grant awarded amount. maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_VaccinalAntibodyGrantMember', window );">Vaccinal Antibody Grant [Member] | Grant Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Revenue from grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,600<span></span>
</td>
<td class="nump">8,200<span></span>
</td>
<td class="nump">$ 8,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_VaccinalAntibodyGrantMember', window );">Vaccinal Antibody Grant [Member] | Bill &amp; Melinda Gates Foundation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_CommonStockSharesPurchased', window );">Common Stock, Shares Purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">881,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_CommonStockSharesPurchasedSharePrice', window );">Common Stock, Shares Purchased, Share Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_CommonStockSharesPurchasedAggregatePurchasePrice', window );">Common Stock, Shares Purchased , Aggregate Purchase Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_CommonStockSharesIssuedFairMarketValue', window );">Common stock, shares issued, fair market value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_ClosingStockPrice', window );">Closing stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_UnderlyingSharesPremiumReceived', window );">Underlying shares, Premium received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued and other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,700<span></span>
</td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncome', window );">Transaction Price Upon Option Exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,500<span></span>
</td>
<td class="nump">$ 6,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember', window );">BARDA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_MaximumAmountGrantAggregate', window );">Potential maximum amount of grant</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_MaximumAmountGrantBasePeriod', window );">Maximum amount of grant during the base period</a></td>
<td class="nump">$ 55,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 25<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=28183603&amp;loc=d3e692-112598<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueNotFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue that is not accounted for under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueNotFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_ClosingStockPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Closing stock price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_ClosingStockPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_CommonStockSharesIssuedFairMarketValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock, shares issued, fair market value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_CommonStockSharesIssuedFairMarketValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_CommonStockSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Shares Purchased</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_CommonStockSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_CommonStockSharesPurchasedAggregatePurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Shares Purchased , Aggregate Purchase Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_CommonStockSharesPurchasedAggregatePurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_CommonStockSharesPurchasedSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Shares Purchased, Share Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_CommonStockSharesPurchasedSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_GrantAwardedAmountMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum grant awarded amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_GrantAwardedAmountMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_MaximumAmountGrantAggregate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum Amount Grant Aggregate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_MaximumAmountGrantAggregate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_MaximumAmountGrantBasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum Amount Grant Base Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_MaximumAmountGrantBasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_UnderlyingSharesPremiumReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Underlying shares, Premium received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_UnderlyingSharesPremiumReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vir_NationalInstitutesOfHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vir_NationalInstitutesOfHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vir_HumanImmunodeficiencyVirusGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vir_HumanImmunodeficiencyVirusGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vir_VaccinalAntibodyGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vir_VaccinalAntibodyGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vir_BillAndMelindaGatesFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vir_BillAndMelindaGatesFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vir_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vir_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139790540117168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="8">1 Months Ended</th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 25, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Feb. 14, 2021 </div>
<div>USD ($) </div>
<div>Program</div>
</th>
<th class="th">
<div>Feb. 14, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 29, 2020 </div>
<div>USD ($) </div>
<div>Unit </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2017 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($) </div>
<div>Antibodies</div>
</th>
<th class="th">
<div>Jul. 31, 2018 </div>
<div>USD ($) </div>
<div>Product</div>
</th>
<th class="th">
<div>May 31, 2018 </div>
<div>USD ($) </div>
<div>Program</div>
</th>
<th class="th">
<div>Oct. 31, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 27, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Value of shares agreed to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 323,214,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_ProfitSharingAmountConstrained', window );">Profit sharing amount constrained</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (369,678,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,207,000<span></span>
</td>
<td class="nump">3,815,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146,319,000<span></span>
</td>
<td class="nump">65,865,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivable from collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">773,079,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=vir_ContractRevenueMember', window );">Contract Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues from contract with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,714,000<span></span>
</td>
<td class="nump">169,874,000<span></span>
</td>
<td class="nump">44,498,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues from contract with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,289,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">22,747,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=vir_CollaborationRevenueMember', window );">Collaboration Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues from contract with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,505,469,000<span></span>
</td>
<td class="nump">917,194,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=vir_TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember', window );">2020 GSK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_ProfitSharingAmountConstrained', window );">Profit sharing amount constrained</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(369,700,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=vir_TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember', window );">2021 GSK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_ReclassifiedDeferredRevenue', window );">Reclassified deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=vir_BriiBiosciencesOffshoreLimitedMember', window );">Brii Bio | Development Programs Exercised by Brii | VIR-3434</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_RangeOfRoyaltyPaymentToBeReceived', window );">Range of royalty payment to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">mid-teens to mid-twenties<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_TwoThousandTwentyStockPurchaseAgreementMember', window );">2020 Stock Purchase Agreement | 2020 GSK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,626,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share purchase price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Value of shares agreed to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_PreliminaryCollaborationAgreementMember', window );">Preliminary Collaboration Agreement | 2020 GSK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans', window );">Number of years conduct certain research and development activities under mutually agreed development plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct', window );">Maximum percentage of right to perform details in connection with antibody product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_CollaborationAgreementTerminationDescription', window );">Termination description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Either party has the right to terminate the 2020 GSK Agreement in the case of the insolvency of the other party, an uncured material breach of the other party with respect to a collaboration program or collaboration product, or as mutually agreed by the parties.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_CollaborationAgreementNumberOfUnitsOfAccount', window );">Number of units of account | Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_IncreaseDecreaseInResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,400,000<span></span>
</td>
<td class="nump">77,300,000<span></span>
</td>
<td class="nump">25,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_CollaborationTypeAndPrograms', window );">Collaboration type and program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The collaboration initially focused on the development and commercialization of three types of collaboration products under three programs: (1) antibodies targeting SARS-CoV-2 and potentially other coronaviruses (the &#8220;Antibody Program&#8221;); (2) vaccines targeting SARS-CoV-2 and potentially other coronaviruses (the &#8220;Vaccine Program&#8221;), and (3) products based on genome-wide CRISPR screening of host targets expressed in connection with exposure to SARS-CoV-2 and potentially other coronaviruses (the &#8220;Functional Genomics Program&#8221;)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_PreliminaryCollaborationAgreementMember', window );">Preliminary Collaboration Agreement | 2020 GSK | Antibody Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_PercentageOfDevelopmentCosts', window );">Percentage of development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_AntibodyLicenseTransactionPrice', window );">Antibody license transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues from contract with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_PreliminaryCollaborationAgreementMember', window );">Preliminary Collaboration Agreement | 2020 GSK | Vaccine Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_PercentageOfDevelopmentCosts', window );">Percentage of development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_PreliminaryCollaborationAgreementMember', window );">Preliminary Collaboration Agreement | 2021 GSK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate', window );">Number of separate programs | Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_UpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225,000,000.0<span></span>
</td>
<td class="nump">$ 225,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_OptionExerciseFeeConsiderationToBeReceived', window );">Option exercise fee to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000.0<span></span>
</td>
<td class="nump">300,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_PreliminaryCollaborationAgreementMember', window );">Preliminary Collaboration Agreement | 2021 GSK | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_PreDefinedRegulatoryMilestoneConsiderationToBeReceived', window );">Pre Defined Regulatory Milestone Consideration To Be Received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000.0<span></span>
</td>
<td class="nump">200,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember', window );">2020 Preliminary Collaboration Agreement and Stock Purchase Agreement | GGL | ASC 606</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_FairMarketValueOfCommonStockIssued', window );">Fair market value of the common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 206,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Common stock price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_PremiumReceivedOnSalePriceOfCommonStock', window );">Premium received on sale price of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_AmendmentNumberOneMember', window );">Amendment Number One Member | 2020 GSK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_UpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Contract revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_TwoThousandTwentyOneStockPurchaseAgreementMember', window );">2021 Stock Purchase Agreement | GGL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,924,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Value of shares agreed to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember', window );">2021 Preliminary Collaboration Agreement and Stock Purchase Agreement | GGL | ASC 606</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_FairMarketValueOfCommonStockIssued', window );">Fair market value of the common stock issued</a></td>
<td class="nump">$ 85,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Common stock price per share | $ / shares</a></td>
<td class="nump">$ 52.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_PremiumReceivedOnSalePriceOfCommonStock', window );">Premium received on sale price of common stock</a></td>
<td class="nump">$ 34,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_TwoThousandAndTwentyOneGSKCollaborationMember', window );">2021 GSK Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans', window );">Number of years conduct certain research and development activities under mutually agreed development plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_PercentageOfShareDevelopmentCosts', window );">Percentage of share development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_ProfitsAndLossesSharingPercentage', window );">Percentage of share Profit and loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_TwoThousandAndTwentyGskAgreementMember', window );">2020 GSK Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivable from collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">773,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_TwoThousandAndTwentyOneGSKAgreementMember', window );">2021 GSK Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_PremiumReceivedOnSalePriceOfCommonStock', window );">Premium received on sale price of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_IncreaseDecreaseInResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_CollaborationAgreementTransactionPriceUpfrontFee', window );">Upfront fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_CollaborationAgreementTransactionPriceConsideration', window );">Collaboration Agreement Transaction Price Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 259,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_TwoThousandAndTwentyOneGSKAgreementMember', window );">2021 GSK Agreement | Contract Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues from contract with customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 168,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_TwoThousandAndTwentyOneGSKAgreementMember', window );">2021 GSK Agreement | GSK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncome', window );">Transaction Price Upon Option Exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Contract with Customer, Liability, Revenue Recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_BriiAgreementMember', window );">Brii Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_CollaborationAgreementTerminationDescription', window );">Termination description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Each party may terminate for convenience all rights and obligations with respect to any program for which it has an option, with 30 days&#8217; written notice (if the terminating party has not exercised an option for such program) or 180 days&#8217; notice (following the exercise of an option for such program). The Brii Agreement may also be terminated by either party for insolvency of the other party, and either party may terminate the Brii Agreement in its entirety or on a program-by-program basis for the other party&#8217;s uncured material breach on 60 days&#8217; written notice (or 30 days&#8217; notice following failure to make payment).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_WrittenNoticePeriodToTerminateLicensedProgramForUncuredMaterialBreach', window );">Written notice period to terminate licensed program for uncured material breach</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_WrittenNoticeToTerminateLicensedProgramIfExercise', window );">Written notice to terminate licensed program if exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_WrittenNoticeToTerminateLicensedProgramIfNotExercise', window );">Written notice to terminate licensed program if not exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_WrittenNoticePeriodToTerminateLicensedProgramForFailureToMakePayment', window );">Written notice period to terminate licensed program for failure to make payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_BriiAgreementMember', window );">Brii Agreement | Development Programs Exercised by Vir</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_OptionExerciseFeeLowEndOfTheRange', window );">Option exercise fee, low end of the range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">low tens of millions<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_RegulatoryMilestonePaymentOnLicensedProductLowEndOfTheRange', window );">Regulatory milestone payment on licensed product, low end of the range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">low tens of millions<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_RegulatoryMilestonePaymentOnLicensedProductHighEndOfRange', window );">Regulatory milestone payment on licensed product, high end of the range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_OptionExerciseFeeHighEndOfTheRange', window );">Option exercise fee, high end of the range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_MaximumAggregateSalesMilestonePayments', window );">Maximum Aggregate Sales Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_BriiAgreementMember', window );">Brii Agreement | Development Programs Exercised by Brii</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_RangeOfRoyaltyPaymentToBeReceived', window );">Range of royalty payment to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">high-teens to high-twenties<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_RegulatoryMilestonePaymentToBeReceived', window );">Regulatory milestone payment to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_MaximumSalesMilestonePaymentsToBeReceived', window );">Maximum Sales Milestone Payment To Be Received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_OptionExerciseFeeLowEndOfTheRange', window );">Option exercise fee, low end of the range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> mid-single-digit millions<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_RegulatoryMilestonePaymentOnLicensedProductLowEndOfTheRange', window );">Regulatory milestone payment on licensed product, low end of the range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">mid-single-digit millions<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_RegulatoryMilestonePaymentOnLicensedProductHighEndOfRange', window );">Regulatory milestone payment on licensed product, high end of the range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_OptionExerciseFeeHighEndOfTheRange', window );">Option exercise fee, high end of the range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_MaximumAggregateSalesMilestonePayments', window );">Maximum Aggregate Sales Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_BriiAgreementMember', window );">Brii Agreement | Development Programs Exercised by Brii | VIR-3434</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_OptionExerciseFeeReceived', window );">Option exercise fee received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_BriiAgreementMember', window );">Brii Agreement | Brii Bio Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_PaymentToCollaboratorResultingFromProgramOptionExercise', window );">Payment to collaborator resulting from program option exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_MaximumNumberOfDevelopmentProgramGrantedToCounterparty', window );">Maximum number of development program granted from Vir to Brii | Program | Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_MaximumNumberOfDevelopmentProgramGrantedFromCounterparty', window );">Maximum number of development program granted from Brii to Vir | Program | Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_PercentageOfOrdinaryShareEqualToOutstandingShare', window );">Percentage of ordinary share equal to outstanding share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Carrying value of investment at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_OptionExerciseFeeReceived', window );">Option exercise fee received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_BriiAgreementMember', window );">Brii Agreement | Brii Bio Parent | VIR-3434</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_OptionsTransactionPrice', window );">Options Transaction Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_BriiAgreementMember', window );">Brii Agreement | Brii Bio Parent | License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Revenue from Related Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,300,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">22,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_PaymentToCollaboratorResultingFromProgramOptionExercise', window );">Payment to collaborator resulting from program option exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_BriiAgreementMember', window );">Brii Agreement | Brii Bio Parent | Vir 2218</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_OptionsTransactionPrice', window );">Options Transaction Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_OptionExerciseFeeReceived', window );">Option exercise fee received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_BriiAgreementMember', window );">Brii Agreement | Brii Bio Parent | Vir 2218 | VIR-3434</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_OptionExerciseFeeReceived', window );">Option exercise fee received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_BriiAgreementMember', window );">Brii Agreement | Brii Bio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_RangeOfRoyaltyPaymentToBePaid', window );">Range of royalty payment to be paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">mid-teens to high-twenties<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales', window );">Royalty payment obligation expiration period after first commercial sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_BriiAgreementMember', window );">Brii Agreement | Brii Bio | Development Programs Exercised by Brii | VIR-3434</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_RegulatoryMilestonePaymentToBeReceived', window );">Regulatory milestone payment to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_MaximumSalesMilestoneToBeReceived', window );">Maximum sales milestone to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_AlnylamAgreementMember', window );">Alnylam Agreement | Alnylam Pharmaceuticals Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,111,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_WrittenNoticePeriodToTerminateLicensedProgramForUncuredMaterialBreach', window );">Written notice period to terminate licensed program for uncured material breach</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenge', window );">Written Notice period to terminate licensed program if under challenge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales', window );">Royalty payment obligation expiration period after first commercial sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_MaximumSharesToBeIssued', window );">Maximum shares to be issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,111,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,111,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Estimated fair value of the derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_MilestonePaymentsPaid', window );">Milestone payments paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_CollaborationAgreementRelatedCostsAndExpenses', window );">Expenses incurred under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="nump">$ 11,200,000<span></span>
</td>
<td class="nump">11,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_WrittenNoticePeriodForTerminationOfLicensedProgram', window );">Written notice period for termination of licensed program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_WrittenNoticePeriodToTerminateLicensedProgramForPaymentBreach', window );">Written notice period to terminate licensed program for payment breach</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_AlnylamAgreementMember', window );">Alnylam Agreement | Alnylam Pharmaceuticals Inc | First siRNA Product HBV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_RangeOfTieredRoyaltiesToPayToNetSalesOfProducts', window );">Range of tiered royalties to pay on net sales of products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company may also be required to pay Alnylam tiered royalties at percentages ranging from the low double-digits to mid-teens on annual net sales of HBV products, and tiered royalties at percentages ranging from the high single-digits to the sub-teen double-digits on annual net sales of licensed infectious disease products, in each case subject to specified reductions and offsets. <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">low double-digits to mid-teens<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_MaximumMilestonePaymentForAchievementOfSpecifiedMilestones', window );">Maximum milestone payment for achievement of specified milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 190,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_MaximumAggregateSalesMilestonePayment', window );">Maximum aggregate sales milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_AlnylamAgreementMember', window );">Alnylam Agreement | Alnylam Pharmaceuticals Inc | Each Infectious Disease siRNA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_RangeOfTieredRoyaltiesToPayToNetSalesOfProducts', window );">Range of tiered royalties to pay on net sales of products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">high single-digits to the sub-teen double-digits<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_MaximumMilestonePaymentForAchievementOfSpecifiedMilestones', window );">Maximum milestone payment for achievement of specified milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_MaximumSalesMilestonePayment', window );">Maximum sales milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_RockefellerAgreementMember', window );">Rockefeller Agreement | Rockefeller</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_CollaborationAgreementTerminationDescription', window );">Termination description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company has the right to terminate the Rockefeller Agreement in its entirety, or in part, for any reason on 60 days&#8217; written notice to Rockefeller. Rockefeller may terminate the Rockefeller Agreement on 90 days&#8217; written notice for the Company&#8217;s uncured material breach, or if the Company challenges the validity or enforceability of any of the licensed patents, or immediately in the event of the Company&#8217;s insolvency. Rockefeller may also terminate the Rockefeller Agreement if the Company ceases to carry on business with respect to the rights granted to the Company under the Rockefeller Agreement.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_WrittenNoticePeriodToTerminateAgreementByCompany', window );">Written notice period to terminate agreement by company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_AnnualLicenseMaintenanceFees', window );">Annual License Maintenance Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_WrittenNoticePeriodToTerminateAgreementByCounterparty', window );">Written notice period to terminate agreement by counterparty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_RoyaltyObligationPeriodFromDateOfFirstCommercialSale', window );">Royalty obligation period from date of first commercial sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_ResearchAndDevelopmentExpenseUnderLicenseAgreement', window );">Research and development expense under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="nump">4,700,000<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_RockefellerAgreementMember', window );">Rockefeller Agreement | Rockefeller | Infectious Disease Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_MaximumAggregateMilestonePaymentForAchievementOfSpecifiedMilestones', window );">Maximum aggregate milestone payment for achievement of specified milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_RockefellerAgreementMember', window );">Rockefeller Agreement | Rockefeller | Infectious Disease Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_MaximumNumberOfProductsCoveredAgainstMilestonePayment', window );">Maximum number of products covered against milestone payment | Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_MedImmuneAgreementMember', window );">MedImmune Agreement | Influenza A and Influenza B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_RoyaltiesPaymentRangeOnNetSalesOfLicensedProduct', window );">Royalties payment range on net sales of licensed product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">mid-single-digits to sub-teen double-digits<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_MedImmuneAgreementMember', window );">MedImmune Agreement | MedImmune</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_NumberOfAntibodiesToDevelop', window );">Number of antibodies to develop | Antibodies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_MedImmuneAgreementMember', window );">MedImmune Agreement | MedImmune | Influenza A and Influenza B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_CollaborationAgreementTerminationDescription', window );">Termination description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company may terminate the MedImmune Agreement in its entirety or on a product-by-product basis, for convenience, upon 120 days&#8217; notice. Either party may terminate the MedImmune Agreement for cause for the other party&#8217;s uncured material breach on 60 days&#8217; notice or immediately in the event of bankruptcy of the other party. Additionally, MedImmune may terminate the MedImmune Agreement for cause on 30 days&#8217; written notice if the Company challenges the validity or enforceability of the patents to which the Company has obtained a license under the MedImmune Agreement.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_WrittenNoticePeriodToTerminateLicensedProgramForUncuredMaterialBreach', window );">Written notice period to terminate licensed program for uncured material breach</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_MaximumAggregateMilestonePaymentForAchievementOfSpecifiedMilestones', window );">Maximum aggregate milestone payment for achievement of specified milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 331,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_WrittenNoticePeriodForTerminationOfLicensedProgram', window );">Written notice period for termination of licensed program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">120 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenges', window );">Written Notice period to terminate licensed program if under challenges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_TwoThousandNineteenXencorAgreementMember', window );">2019 Xencor Agreement | Xencor | HBV Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_MaximumAggregateMilestonePayments', window );">Maximum aggregate milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_TwoThousandNineteenXencorAgreementMember', window );">2019 Xencor Agreement | Xencor | Influenza A Research Programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_MaximumAggregateMilestonePayments', window );">Maximum aggregate milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_TwoThousandNineteenXencorAgreementMember', window );">2019 Xencor Agreement | Xencor | Influenza A and HBV Research Programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_RoyaltiesPaymentRangeOnNetSalesOfLicensedProduct', window );">Royalties payment range on net sales of licensed product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">low- to mid-single-digits<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_MaximumAggregateMilestonePayments', window );">Maximum aggregate milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 155,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_MaximumAggregateDevelopmentAndRegulatoryMilestonePayments', window );">Maximum aggregate development and regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_MaximumAggregateCommercialSalesMilestonePayments', window );">Maximum aggregate commercial sales milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_TwoThousandTwentyXencorAgreementMember', window );">2020 Xencor Agreement | Xencor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_RoyaltiesPaymentExpirationPeriod', window );">Royalties payment expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_RoyaltiesBasedOnNetSalesOfLicensedProducts', window );">Royalties based on net sales of licensed products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> mid-single-digits<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 114,500,000<span></span>
</td>
<td class="nump">$ 52,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_TwoThousandNineteenAndTwoThousandTwentyXencorAgreementMember', window );">2019 and 2020 Xencor Agreement member | Xencor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_CollaborationAgreementTerminationDescription', window );">Termination description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company may terminate each agreement in its entirety, or on a target-by-target basis, for convenience upon 60 days&#8217; written notice. Either party may terminate each agreement for the other party&#8217;s uncured material breach upon 60 days&#8217; written notice (or 30 days in the case of non-payment) or in the event of bankruptcy of the other party immediately upon written notice. Xencor may terminate each agreement immediately upon written notice if the Company challenges, or upon 30 days&#8217; written notice if any of the Company&#8217;s sublicensees challenge, the validity or enforceability of any patent licensed to the Company under each respective agreement.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach', window );">Written notice period for uncured material breach</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_WrittenNoticePeriodForTerminationOfLicensedProgram', window );">Written notice period for termination of licensed program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenges', window );">Written Notice period to terminate licensed program if under challenges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_WrittenNoticePeriodToTerminateLicensedProgramForFailureToMakePayment', window );">Written notice period to terminate licensed program for failure to make payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 25<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=28183603&amp;loc=d3e692-112598<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.1(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_AnnualLicenseMaintenanceFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License maintenance fees required to pay annually.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_AnnualLicenseMaintenanceFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_AntibodyLicenseTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction price for the Antibody License under the collaboration agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_AntibodyLicenseTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration agreement, number of separate programs agreed to collaborate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_CollaborationAgreementNumberOfUnitsOfAccount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration agreement, number of units of account.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_CollaborationAgreementNumberOfUnitsOfAccount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_CollaborationAgreementRelatedCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Costs and expenses for the period incurred under the collaboration agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_CollaborationAgreementRelatedCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_CollaborationAgreementTerminationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration agreement termination description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_CollaborationAgreementTerminationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_CollaborationAgreementTransactionPriceConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration agreement transaction price consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_CollaborationAgreementTransactionPriceConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_CollaborationAgreementTransactionPriceUpfrontFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront payment received under the Collaboration agreement, which represents part of the transaction price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_CollaborationAgreementTransactionPriceUpfrontFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_CollaborationTypeAndPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Type and Programs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_CollaborationTypeAndPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_FairMarketValueOfCommonStockIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair market value of common stock issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_FairMarketValueOfCommonStockIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_IncreaseDecreaseInResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in research And development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_IncreaseDecreaseInResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_MaximumAggregateCommercialSalesMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum aggregate commercial sales milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_MaximumAggregateCommercialSalesMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_MaximumAggregateDevelopmentAndRegulatoryMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum aggregate development and regulatory milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_MaximumAggregateDevelopmentAndRegulatoryMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_MaximumAggregateMilestonePaymentForAchievementOfSpecifiedMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum aggregate milestone payment for achievement of specified milestones, including development, regulatory and commercial.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_MaximumAggregateMilestonePaymentForAchievementOfSpecifiedMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_MaximumAggregateMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum aggregate milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_MaximumAggregateMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_MaximumAggregateSalesMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum aggregate milestone payment for achievement of specified annual net sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_MaximumAggregateSalesMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_MaximumAggregateSalesMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum aggregate sales milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_MaximumAggregateSalesMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_MaximumMilestonePaymentForAchievementOfSpecifiedMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum Milestone Payment For Achievement Of Specified Milestones</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_MaximumMilestonePaymentForAchievementOfSpecifiedMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_MaximumNumberOfDevelopmentProgramGrantedFromCounterparty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum Number of Development Program Granted from Counterparty</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_MaximumNumberOfDevelopmentProgramGrantedFromCounterparty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_MaximumNumberOfDevelopmentProgramGrantedToCounterparty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum Number of Development Program Granted to Counterparty</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_MaximumNumberOfDevelopmentProgramGrantedToCounterparty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_MaximumNumberOfProductsCoveredAgainstMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of products covered against milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_MaximumNumberOfProductsCoveredAgainstMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of right to perform details in connection with antibody product.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_MaximumSalesMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum milestone payment for achievement of specified annual net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_MaximumSalesMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_MaximumSalesMilestonePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of payment to be received by the company upon achievement of sales milestone by the counterparty</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_MaximumSalesMilestonePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_MaximumSalesMilestoneToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum sales milestone to be received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_MaximumSalesMilestoneToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_MaximumSharesToBeIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum shares to be issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_MaximumSharesToBeIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_MilestonePaymentsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payments paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_MilestonePaymentsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_NumberOfAntibodiesToDevelop">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of antibodies to develop.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_NumberOfAntibodiesToDevelop</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of years conduct certain research and development activities under mutually agreed development plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_OptionExerciseFeeConsiderationToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Option exercise fee consideration to be received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_OptionExerciseFeeConsiderationToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_OptionExerciseFeeHighEndOfTheRange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the high end of the range of option exercise fee upon exercise of a program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_OptionExerciseFeeHighEndOfTheRange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_OptionExerciseFeeLowEndOfTheRange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the low end of the range of option exercise fee upon exercise of a program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_OptionExerciseFeeLowEndOfTheRange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_OptionExerciseFeeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Option exercise fee received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_OptionExerciseFeeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_OptionsTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Options transaction price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_OptionsTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_PaymentToCollaboratorResultingFromProgramOptionExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payment to a collaborator due to a program option exercise under a separate agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_PaymentToCollaboratorResultingFromProgramOptionExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_PercentageOfDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_PercentageOfDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_PercentageOfOrdinaryShareEqualToOutstandingShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of ordinary share equal to outstanding share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_PercentageOfOrdinaryShareEqualToOutstandingShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_PercentageOfShareDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of share development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_PercentageOfShareDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_PreDefinedRegulatoryMilestoneConsiderationToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consideration to be received upon achievement of a pre-defined regulatory milestone</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_PreDefinedRegulatoryMilestoneConsiderationToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_PremiumReceivedOnSalePriceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Premium received on sale price of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_PremiumReceivedOnSalePriceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_ProfitSharingAmountConstrained">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Profit sharing amount constrained</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_ProfitSharingAmountConstrained</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_ProfitsAndLossesSharingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Profits and losses sharing percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_ProfitsAndLossesSharingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_RangeOfRoyaltyPaymentToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Range of royalty payment to be paid by counterparty.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_RangeOfRoyaltyPaymentToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_RangeOfRoyaltyPaymentToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Range of royalty payment to be received by the company upon exercised of the development programs by counterparty.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_RangeOfRoyaltyPaymentToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_RangeOfTieredRoyaltiesToPayToNetSalesOfProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Range of tiered royalties to pay on annual net sales of products.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_RangeOfTieredRoyaltiesToPayToNetSalesOfProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_ReclassifiedDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reclassified deferred revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_ReclassifiedDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_RegulatoryMilestonePaymentOnLicensedProductHighEndOfRange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Regulatory milestone payment on licensed product, high end of the range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_RegulatoryMilestonePaymentOnLicensedProductHighEndOfRange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_RegulatoryMilestonePaymentOnLicensedProductLowEndOfTheRange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Regulatory milestone payment on licensed product, low end of the range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_RegulatoryMilestonePaymentOnLicensedProductLowEndOfTheRange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_RegulatoryMilestonePaymentToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Regulatory milestone payment to be received by the company upon exercised of the development programs by counterparty.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_RegulatoryMilestonePaymentToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_ResearchAndDevelopmentExpenseUnderLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development expense under license agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_ResearchAndDevelopmentExpenseUnderLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_RoyaltiesBasedOnNetSalesOfLicensedProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalties payment based on net sales of licensed products.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_RoyaltiesBasedOnNetSalesOfLicensedProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_RoyaltiesPaymentExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of years that royalties payment expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_RoyaltiesPaymentExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_RoyaltiesPaymentRangeOnNetSalesOfLicensedProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalties payment range on net sales of licensed product.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_RoyaltiesPaymentRangeOnNetSalesOfLicensedProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_RoyaltyObligationPeriodFromDateOfFirstCommercialSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty obligation period from date of first commercial sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_RoyaltyObligationPeriodFromDateOfFirstCommercialSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty payment obligation expiration period after first commercial sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_UpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront Payment Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_UpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Written notice period for licensed program, uncured material breach.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_WrittenNoticePeriodForTerminationOfLicensedProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Written notice period for termination of licensed program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_WrittenNoticePeriodForTerminationOfLicensedProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_WrittenNoticePeriodToTerminateAgreementByCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Written notice period to terminate agreement by company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_WrittenNoticePeriodToTerminateAgreementByCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_WrittenNoticePeriodToTerminateAgreementByCounterparty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Written notice period to terminate agreement by counterparty.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_WrittenNoticePeriodToTerminateAgreementByCounterparty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_WrittenNoticePeriodToTerminateLicensedProgramForFailureToMakePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Written notice period to terminate licensed program for failure to make payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_WrittenNoticePeriodToTerminateLicensedProgramForFailureToMakePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_WrittenNoticePeriodToTerminateLicensedProgramForPaymentBreach">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Written Notice Period To Terminate Licensed Program For Payment Breach</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_WrittenNoticePeriodToTerminateLicensedProgramForPaymentBreach</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_WrittenNoticePeriodToTerminateLicensedProgramForUncuredMaterialBreach">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Written notice period to terminate licensed program for uncured material breach.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_WrittenNoticePeriodToTerminateLicensedProgramForUncuredMaterialBreach</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Written notice period to terminate licensed program if the party challenges the validity or enforceability of the patent licensed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Written notice period to terminate licensed program if the party challenges the validity or enforceability of the patent licensed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_WrittenNoticeToTerminateLicensedProgramIfExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Written notice to terminate licensed program following the exercise of an option for such program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_WrittenNoticeToTerminateLicensedProgramIfExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_WrittenNoticeToTerminateLicensedProgramIfNotExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Written notice to terminate licensed program if not exercise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_WrittenNoticeToTerminateLicensedProgramIfNotExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vir_ContractRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vir_ContractRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vir_CollaborationRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vir_CollaborationRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vir_TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vir_TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vir_TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vir_TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vir_BriiBiosciencesOffshoreLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vir_BriiBiosciencesOffshoreLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vir_DevelopmentProgramsExercisedByBriiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vir_DevelopmentProgramsExercisedByBriiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=vir_Vir3434Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=vir_Vir3434Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vir_TwoThousandTwentyStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vir_TwoThousandTwentyStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vir_PreliminaryCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vir_PreliminaryCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vir_AntibodyProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vir_AntibodyProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vir_VaccineProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vir_VaccineProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vir_TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vir_TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=vir_GlaxoGroupLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=vir_GlaxoGroupLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vir_AmendmentNumberOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vir_AmendmentNumberOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vir_TwoThousandTwentyOneStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vir_TwoThousandTwentyOneStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vir_TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vir_TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vir_TwoThousandAndTwentyOneGSKCollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vir_TwoThousandAndTwentyOneGSKCollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vir_TwoThousandAndTwentyGskAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vir_TwoThousandAndTwentyGskAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vir_TwoThousandAndTwentyOneGSKAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vir_TwoThousandAndTwentyOneGSKAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vir_GlaxoWellcomeUKLimitedAndBeechamSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vir_GlaxoWellcomeUKLimitedAndBeechamSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vir_BriiAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vir_BriiAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vir_DevelopmentProgramsExercisedByVirMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vir_DevelopmentProgramsExercisedByVirMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vir_BriiBioParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vir_BriiBioParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vir_Vir2218Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vir_Vir2218Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vir_AlnylamAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vir_AlnylamAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vir_AlnylamPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vir_AlnylamPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vir_FirstSiRNAProductHBVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vir_FirstSiRNAProductHBVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vir_EachInfectiousDiseaseSiRNAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vir_EachInfectiousDiseaseSiRNAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vir_RockefellerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vir_RockefellerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vir_RockefellerUniversityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vir_RockefellerUniversityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vir_FirstInfectiousDiseaseProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vir_FirstInfectiousDiseaseProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vir_InfectiousDiseaseProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vir_InfectiousDiseaseProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vir_MedImmuneAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vir_MedImmuneAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vir_InfluenzaAAndInfluenzaBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vir_InfluenzaAAndInfluenzaBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vir_MedImmuneLimitedLiabilityCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vir_MedImmuneLimitedLiabilityCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vir_TwoThousandNineteenXencorAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vir_TwoThousandNineteenXencorAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vir_XencorIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vir_XencorIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vir_HBVProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vir_HBVProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vir_InfluenzaAResearchProgramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vir_InfluenzaAResearchProgramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vir_InfluenzaAAndHBVResearchProgramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vir_InfluenzaAAndHBVResearchProgramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vir_TwoThousandTwentyXencorAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vir_TwoThousandTwentyXencorAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vir_TwoThousandNineteenAndTwoThousandTwentyXencorAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vir_TwoThousandNineteenAndTwoThousandTwentyXencorAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139790633640000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Collaboration Collaboration revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_CollaborationAndLicenseAgreements', window );"><strong>Collaboration revenue, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_ProfitSharingAmount', window );">Profit-sharing amount</a></td>
<td class="nump">$ 1,875,147<span></span>
</td>
<td class="nump">$ 917,194<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_ProfitSharingAmountConstrained', window );">Profit-sharing amount constrained</a></td>
<td class="num">(369,678)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_TotalcollaborationRevenue', window );">Total collaboration revenue, net</a></td>
<td class="nump">$ 1,505,469<span></span>
</td>
<td class="nump">$ 917,194<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_CollaborationAndLicenseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration and License Agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_CollaborationAndLicenseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_ProfitSharingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Profit sharing amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_ProfitSharingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_ProfitSharingAmountConstrained">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Profit sharing amount constrained</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_ProfitSharingAmountConstrained</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_TotalcollaborationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Totalcollaboration revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_TotalcollaborationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139790630592720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Property and Equipment Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 126,352<span></span>
</td>
<td class="nump">$ 57,326<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
<td class="num">(20,743)<span></span>
</td>
<td class="num">(14,492)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">105,609<span></span>
</td>
<td class="nump">42,834<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=vir_LaboratoryEquipmentMember', window );">Laboratory Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">36,533<span></span>
</td>
<td class="nump">20,012<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">2,545<span></span>
</td>
<td class="nump">1,112<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">2,852<span></span>
</td>
<td class="nump">1,443<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">84,422<span></span>
</td>
<td class="nump">7,834<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 26,925<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=vir_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=vir_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139790634284944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expenses</a></td>
<td class="nump">$ 6,251<span></span>
</td>
<td class="nump">$ 5,278<span></span>
</td>
<td class="nump">$ 4,400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139790630553920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Accrued and Other Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_MilestonePayable', window );">Milestone payable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 95,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_ProfitShareAmountConstraint', window );">Net profit-sharing constrained</a></td>
<td class="nump">357,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Accrued royalties</a></td>
<td class="nump">10,447<span></span>
</td>
<td class="nump">58,672<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_ResearchAndDevelopmentExpensesCurrent', window );">Research and development expenses</a></td>
<td class="nump">48,880<span></span>
</td>
<td class="nump">28,073<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_PayrollAndRelatedExpensesCurrent', window );">Payroll and related expenses</a></td>
<td class="nump">28,286<span></span>
</td>
<td class="nump">29,753<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Accrued income taxes</a></td>
<td class="nump">15,228<span></span>
</td>
<td class="nump">6,217<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_ExcessFundsPayableUnderGrantAgreementsCurrent', window );">Excess funds payable under grant agreements</a></td>
<td class="nump">7,652<span></span>
</td>
<td class="nump">1,825<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">4,137<span></span>
</td>
<td class="nump">3,927<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Other professional and consulting expenses</a></td>
<td class="nump">3,987<span></span>
</td>
<td class="nump">2,791<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">12,711<span></span>
</td>
<td class="nump">10,254<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Total accrued and other liabilities</a></td>
<td class="nump">$ 489,090<span></span>
</td>
<td class="nump">$ 236,512<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_ExcessFundsPayableUnderGrantAgreementsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Excess funds payable under grant agreements current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_ExcessFundsPayableUnderGrantAgreementsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_MilestonePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_MilestonePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_PayrollAndRelatedExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payroll and related expenses current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_PayrollAndRelatedExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_ProfitShareAmountConstraint">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Profit share amount constraint</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_ProfitShareAmountConstraint</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_ResearchAndDevelopmentExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of current obligations incurred and payable to vendors for goods and services attributable to the entity's research and development activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_ResearchAndDevelopmentExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139790632383696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_LeaseArrangementContractualExpirationEndingYear', window );">Lease arrangement, contractual expiration period, ending year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Lessee, Operating Lease, Existence of Option to Extend [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnTerminationOfLease', window );">Gain from a sublease termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,844<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Lessee, operating lease, option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">These leases require monthly lease payments that may be subject to annual increases throughout the lease term. Certain lease agreements also provide the Company with the option to renew for additional periods ranging from one to five years.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,260<span></span>
</td>
<td class="num">(9,437)<span></span>
</td>
<td class="num">(4,467)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_TenantImprovementAllowanceAggregate', window );">Tenant improvement allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,716<span></span>
</td>
<td class="nump">6,250<span></span>
</td>
<td class="nump">5,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">ROU assets in exchange for operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,046<span></span>
</td>
<td class="nump">$ 77,187<span></span>
</td>
<td class="nump">$ 48,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeaseAgreementsMember', window );">Lease Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetRentableArea', window );">Net Rentable Area | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=vir_GlaxoSmithKlineTradingServiceLimitedMember', window );">GSKTSL | WuXi Biologics MSA and Samsung MSA | Antibody Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_PercentageOfDevelopmentCostsResponsibleByCompany', window );">Percentage of development costs</a></td>
<td class="nump">72.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=vir_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember', window );">GSK | WuXi Biologics MSA and Samsung MSA | Antibody Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_PercentageOfDevelopmentCostsResponsibleByGsk', window );">Percentage of development costs responsible by GSK</a></td>
<td class="nump">27.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, operating lease, renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, operating lease, renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnTerminationOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on termination of lease before expiration of lease term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 40<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123386189&amp;loc=SL77918607-209975<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnTerminationOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetRentableArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net rentable area for properties owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetRentableArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_LeaseArrangementContractualExpirationEndingYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease arrangement, contractual expiration ending year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_LeaseArrangementContractualExpirationEndingYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_PercentageOfDevelopmentCostsResponsibleByCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of development costs that the Company is responsible for.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_PercentageOfDevelopmentCostsResponsibleByCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_PercentageOfDevelopmentCostsResponsibleByGsk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of development costs that GSK is responsible for.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_PercentageOfDevelopmentCostsResponsibleByGsk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_TenantImprovementAllowanceAggregate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of tenant improvement allowance available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_TenantImprovementAllowanceAggregate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vir_GlaxoSmithKlineTradingServiceLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vir_GlaxoSmithKlineTradingServiceLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vir_WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vir_WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vir_AntibodyProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vir_AntibodyProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vir_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vir_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139790632837104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Summary of Lease Costs and Additional Information Related to Operating Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 15,910<span></span>
</td>
<td class="nump">$ 11,921<span></span>
</td>
<td class="nump">$ 4,591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">239<span></span>
</td>
<td class="nump">261<span></span>
</td>
<td class="nump">459<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">9,937<span></span>
</td>
<td class="nump">4,256<span></span>
</td>
<td class="nump">2,299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 26,086<span></span>
</td>
<td class="nump">$ 16,438<span></span>
</td>
<td class="nump">$ 7,349<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_OperatingLeaseOtherInformationAbstract', window );"><strong>Other Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years 4 months 24 days<span></span>
</td>
<td class="text">10 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average incremental borrowing rate</a></td>
<td class="nump">5.20%<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="nump">7.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of operating lease liabilities</a></td>
<td class="nump">$ 12,716<span></span>
</td>
<td class="nump">$ 6,250<span></span>
</td>
<td class="nump">$ 5,081<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">ROU assets in exchange for operating lease liabilities</a></td>
<td class="nump">$ 4,046<span></span>
</td>
<td class="nump">$ 77,187<span></span>
</td>
<td class="nump">$ 48,495<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_OperatingLeaseOtherInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease other information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_OperatingLeaseOtherInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139790637107792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Maturities of Operating Lease Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 19,450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">18,610<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">16,303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">16,747<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">16,927<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">86,994<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">175,031<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(38,379)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived', window );">Less: net tenant improvement allowance yet to be received</a></td>
<td class="num">(26,294)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_PresentValueOfOperatingLeaseLiabilities', window );">Present value of operating lease liabilities</a></td>
<td class="nump">$ 110,358<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease liability net tenant improvement allowance yet to be received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_PresentValueOfOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, net of tenant improvement allowance yet to be received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_PresentValueOfOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139790635569280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Operating Lease Amounts Recorded in Condensed Consolidated Balance Sheet (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_OperatingLeaseAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_OperatingLeaseIncentiveOverLeaseLiabilities', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">$ 17,616<span></span>
</td>
<td class="nump">$ 49,536<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating ROU assets</a></td>
<td class="nump">$ 82,557<span></span>
</td>
<td class="nump">$ 87,220<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Accrued Liabilities and Other Liabilities<span></span>
</td>
<td class="text">Accrued Liabilities and Other Liabilities<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">$ 4,137<span></span>
</td>
<td class="nump">$ 3,927<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, noncurrent</a></td>
<td class="nump">123,837<span></span>
</td>
<td class="nump">133,561<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 127,974<span></span>
</td>
<td class="nump">$ 137,488<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_OperatingLeaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_OperatingLeaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_OperatingLeaseIncentiveOverLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Incentive Over Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_OperatingLeaseIncentiveOverLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139790632573056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Awards - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,100<span></span>
</td>
<td class="nump">$ 65,100,000<span></span>
</td>
<td class="nump">$ 53,100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.69<span></span>
</td>
<td class="nump">$ 47.62<span></span>
</td>
<td class="nump">$ 25.49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unamortized stock-based compensation expense related to stock option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 127,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Estimated weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Estimated weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost related to unvested restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Share issued under plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">147,459<span></span>
</td>
<td class="nump">65,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">349,496<span></span>
</td>
<td class="nump">89,261<span></span>
</td>
<td class="nump">1,986,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vir_TwoThousandSixteenEquityIncentivePlanMember', window );">2016 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Option price as a percentage of estimated fair value on the date of grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Options vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vir_TwoThousandSixteenEquityIncentivePlanMember', window );">2016 Equity Incentive Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period of awards from issuance date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vir_TwoThousandNineteenEquityIncentivePlanMember', window );">2019 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Option price as a percentage of estimated fair value on the date of grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Options vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,911,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vir_TwoThousandNineteenEquityIncentivePlanMember', window );">2019 Equity Incentive Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period of awards from issuance date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vir_TwoThousandNineteenEmployeeStockPurchasePlanMember', window );">2019 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_OfferingPeriodEmployeeStockPurchasePlan', window );">Offering period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">27 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Share issued under plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.09<span></span>
</td>
<td class="nump">$ 19.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vir_TwoThousandNineteenEmployeeStockPurchasePlanMember', window );">2019 Employee Stock Purchase Plan | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Option price as a percentage of estimated fair value on the date of grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized to issue under purchase rights granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,280,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Percentage of employee payroll deduction on earnings, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_OfferingPeriodEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Duration of offering period under the Plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_OfferingPeriodEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vir_TwoThousandSixteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vir_TwoThousandSixteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vir_TwoThousandNineteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vir_TwoThousandNineteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vir_TwoThousandNineteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vir_TwoThousandNineteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139790630958000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Awards - Summary of Stock Option Plans Activity (Details) - Employee Stock Option [Member] - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options,Outstanding, Beginning Balance</a></td>
<td class="nump">10,308,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options,Granted</a></td>
<td class="nump">2,051,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options,Exercised</a></td>
<td class="num">(696,963)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options,Forfeited</a></td>
<td class="num">(1,059,133)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options,Outstanding, Ending Balance</a></td>
<td class="nump">10,604,367<span></span>
</td>
<td class="nump">10,308,928<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Options,Vested and expected to vest</a></td>
<td class="nump">10,604,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Number of Options,Vested and exercisable</a></td>
<td class="nump">6,069,564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Beginning Balance</a></td>
<td class="nump">$ 31.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">28.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="nump">6.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited</a></td>
<td class="nump">41.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Ending Balance</a></td>
<td class="nump">31.70<span></span>
</td>
<td class="nump">$ 31.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price,Vested and expected to vest</a></td>
<td class="nump">31.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price,Vested and exercisable</a></td>
<td class="nump">$ 27.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term</a></td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term,Vested and expected to vest</a></td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term,Vested and exercisable</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Balance</a></td>
<td class="nump">$ 52,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and expected to vest</a></td>
<td class="nump">52,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and exercisable</a></td>
<td class="nump">$ 48,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139790630528112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Awards - Summary of Assumptions Used for Estimating the Fair Value of Stock Options Granted (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected stock price volatility,minimum</a></td>
<td class="nump">101.40%<span></span>
</td>
<td class="nump">103.10%<span></span>
</td>
<td class="nump">88.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected stock price volatility,maximum</a></td>
<td class="nump">111.20%<span></span>
</td>
<td class="nump">112.10%<span></span>
</td>
<td class="nump">108.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">1.60%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">4.30%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term of options (in years)</a></td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term of options (in years)</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139790631314784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Awards -Summary of Employees Stock Purchase Plan (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected stock price volatility,minimum</a></td>
<td class="nump">101.40%<span></span>
</td>
<td class="nump">103.10%<span></span>
</td>
<td class="nump">88.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected stock price volatility,maximum</a></td>
<td class="nump">111.20%<span></span>
</td>
<td class="nump">112.10%<span></span>
</td>
<td class="nump">108.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">1.60%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">4.30%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vir_TwoThousandNineteenEmployeeStockPurchasePlanMember', window );">2019 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term of ESPP (in years)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected stock price volatility,minimum</a></td>
<td class="nump">59.00%<span></span>
</td>
<td class="nump">76.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected stock price volatility,maximum</a></td>
<td class="nump">86.00%<span></span>
</td>
<td class="nump">144.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">0.04%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vir_TwoThousandNineteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vir_TwoThousandNineteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139790633443120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Awards - Summary of Restricted Stock Activity (Details) - Restricted Stock Units (RSUs) [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, Unvested, Beginning Balance | shares</a></td>
<td class="nump">1,271,334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of Shares, Granted | shares</a></td>
<td class="nump">2,097,128<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of Shares, Vested | shares</a></td>
<td class="num">(349,496)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of shares, Forfeited | shares</a></td>
<td class="num">(349,788)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, Unvested, Ending Balance | shares</a></td>
<td class="nump">2,669,178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Beginning Balance | $ / shares</a></td>
<td class="nump">$ 59.93<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Granted | $ / shares</a></td>
<td class="nump">27.87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Vested | $ / shares</a></td>
<td class="nump">58.26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Forfeited | $ / shares</a></td>
<td class="nump">40.86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Ending Balance | $ / shares</a></td>
<td class="nump">$ 37.46<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139790635404384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Awards - Summary of Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 102,082<span></span>
</td>
<td class="nump">$ 83,784<span></span>
</td>
<td class="nump">$ 27,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">53,153<span></span>
</td>
<td class="nump">42,554<span></span>
</td>
<td class="nump">13,663<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 48,929<span></span>
</td>
<td class="nump">$ 41,230<span></span>
</td>
<td class="nump">$ 13,937<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139790539863728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Share - Schedule of Basic and Diluted Net Income (loss) Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 515,837<span></span>
</td>
<td class="nump">$ 528,584<span></span>
</td>
<td class="num">$ (298,665)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding, basic</a></td>
<td class="nump">132,606,767<span></span>
</td>
<td class="nump">129,884,967<span></span>
</td>
<td class="nump">119,159,424<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Options to purchase common stock</a></td>
<td class="nump">2,130,212<span></span>
</td>
<td class="nump">3,513,438<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting', window );">Restricted shares subject to future vesting</a></td>
<td class="nump">73,851<span></span>
</td>
<td class="nump">35,488<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_IncrementalCommonSharesAttributabletoShareBasedPaymentArrangementsEmployeeStockPurchasePlan', window );">Shares to purchase under Employee Stock Purchase Plan</a></td>
<td class="nump">78<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares', window );">Contingently issuable shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,233<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted Average Number of Shares Outstanding, Diluted</a></td>
<td class="nump">134,810,908<span></span>
</td>
<td class="nump">133,437,126<span></span>
</td>
<td class="nump">119,159,424<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per share, basic</a></td>
<td class="nump">$ 3.89<span></span>
</td>
<td class="nump">$ 4.07<span></span>
</td>
<td class="num">$ (2.51)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (loss) per share, diluted</a></td>
<td class="nump">$ 3.83<span></span>
</td>
<td class="nump">$ 3.96<span></span>
</td>
<td class="num">$ (2.51)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of contingently issuable shares. Contingently issuable shares are those shares that are issuable for little or no cash contingent on certain conditions being met.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 54<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e2603-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 44<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e2062-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1828-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e2600-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e2597-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 48<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e2538-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 48<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e2538-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1757-109256<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 51<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e2574-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126962052&amp;loc=d3e4991-113900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1707-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1500-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of restricted shares subject to future vesting using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_IncrementalCommonSharesAttributabletoShareBasedPaymentArrangementsEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Incremental common shares attributable to share based payment arrangements employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_IncrementalCommonSharesAttributabletoShareBasedPaymentArrangementsEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139790637959184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Share - Schedule of Potentially Dilutive Securities Not Included in Diluted Per Share Calculations (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">11,500,482<span></span>
</td>
<td class="nump">6,852,612<span></span>
</td>
<td class="nump">9,887,543<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options Issued and Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">8,853,734<span></span>
</td>
<td class="nump">5,764,308<span></span>
</td>
<td class="nump">9,798,282<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted Shares Subject to Future Vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">2,646,748<span></span>
</td>
<td class="nump">1,088,304<span></span>
</td>
<td class="nump">89,261<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=vir_WarrantsToPurchaseCommonStockMember', window );">Warrants to Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=vir_WarrantsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=vir_WarrantsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139790634334688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined Contribution Plan - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Defined contribution plan, contribution expenses</a></td>
<td class="nump">$ 4.0<span></span>
</td>
<td class="nump">$ 2.7<span></span>
</td>
<td class="nump">$ 1.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139790635778672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Income (Loss) Before Provision for (Benefit from) Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="nump">$ 692,445<span></span>
</td>
<td class="nump">$ 535,989<span></span>
</td>
<td class="num">$ (309,697)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="nump">61,835<span></span>
</td>
<td class="nump">13,813<span></span>
</td>
<td class="nump">11,086<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before provision for income taxes</a></td>
<td class="nump">$ 754,280<span></span>
</td>
<td class="nump">$ 549,802<span></span>
</td>
<td class="num">$ (298,611)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139790630608064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of Income Tax Expense (Benefit) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 238,550<span></span>
</td>
<td class="nump">$ 3,526<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">2,432<span></span>
</td>
<td class="nump">105<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">12,647<span></span>
</td>
<td class="nump">2,401<span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current income tax expense (benefit)</a></td>
<td class="nump">253,629<span></span>
</td>
<td class="nump">6,032<span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(15,186)<span></span>
</td>
<td class="nump">15,186<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income tax expense (benefit)</a></td>
<td class="num">(15,186)<span></span>
</td>
<td class="nump">15,186<span></span>
</td>
<td class="num">(52)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 238,443<span></span>
</td>
<td class="nump">$ 21,218<span></span>
</td>
<td class="nump">$ 54<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139790540104400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation Between Expected Income Tax Provision at Federal Statutory Rate and Reported Income Tax Benefit (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_ReconciliationOfEffectiveIncomeTaxRateLineItems', window );"><strong>Reconciliation Of Effective Income Tax Rate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. federal statutory income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign tax at less than federal statutory rate</a></td>
<td class="num">(0.30%)<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes', window );">Prior year tax rate adjustment</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(1.90%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development tax credit</a></td>
<td class="num">(2.00%)<span></span>
</td>
<td class="num">(1.60%)<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_EffectiveIncomeTaxRateReconciliationPermanentItemsPercent', window );">Permanent items</a></td>
<td class="num">(7.40%)<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Changes in valuation allowance</a></td>
<td class="nump">21.10%<span></span>
</td>
<td class="num">(17.90%)<span></span>
</td>
<td class="num">(25.30%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(0.90%)<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">31.60%<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_EffectiveIncomeTaxRateReconciliationPermanentItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation permanent items percent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_EffectiveIncomeTaxRateReconciliationPermanentItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_ReconciliationOfEffectiveIncomeTaxRateLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reconciliation of effective income tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_ReconciliationOfEffectiveIncomeTaxRateLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139790636238720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 14,793<span></span>
</td>
<td class="nump">$ 15,030<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credit carryforward</a></td>
<td class="nump">12,123<span></span>
</td>
<td class="nump">11,375<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Equity compensations</a></td>
<td class="nump">24,250<span></span>
</td>
<td class="nump">15,065<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Reserves and accruals</a></td>
<td class="nump">85,977<span></span>
</td>
<td class="nump">7,115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Capitalized research and development</a></td>
<td class="nump">75,680<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_DeferredTaxAssetsLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">18,553<span></span>
</td>
<td class="nump">28,612<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">18,348<span></span>
</td>
<td class="nump">19,657<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax assets</a></td>
<td class="nump">249,724<span></span>
</td>
<td class="nump">96,854<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities', window );">Unrealized gain on investments</a></td>
<td class="num">(5,880)<span></span>
</td>
<td class="num">(30,170)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_DeferredTaxLiabilitiesRightOfUseAssets', window );">ROU assets</a></td>
<td class="num">(20,834)<span></span>
</td>
<td class="num">(28,483)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="num">(13,151)<span></span>
</td>
<td class="num">(2,422)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_DeferredTaxLiabilitiesInProcessResearchAndDevelopment', window );">IPR&amp;D</a></td>
<td class="num">(8,511)<span></span>
</td>
<td class="num">(8,511)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="num">(48,376)<span></span>
</td>
<td class="num">(69,586)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(204,601)<span></span>
</td>
<td class="num">(45,707)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax liabilities</a></td>
<td class="num">$ (3,253)<span></span>
</td>
<td class="num">$ (18,439)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from unrealized gains on trading securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_DeferredTaxAssetsLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_DeferredTaxAssetsLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_DeferredTaxLiabilitiesInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities in process research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_DeferredTaxLiabilitiesInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_DeferredTaxLiabilitiesRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities right of use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_DeferredTaxLiabilitiesRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139790536006080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase/decrease in valuation allowance</a></td>
<td class="nump">$ 158,900,000<span></span>
</td>
<td class="num">$ (114,200,000)<span></span>
</td>
<td class="nump">$ 74,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefit</a></td>
<td class="nump">$ 10,638,000<span></span>
</td>
<td class="nump">7,422,000<span></span>
</td>
<td class="nump">4,877,000<span></span>
</td>
<td class="nump">$ 2,725,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_UnrecognizedTaxBenefitsIfRecognizedWouldReduceEffectiveTaxRate', window );">Unrecognized tax benefits, if recognized, would reduce effective tax rate</a></td>
<td class="nump">0.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Interest and penalties expense related to uncertain tax positions</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Interest and penalties accrued related to uncertain tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 20,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_OperatingLossCarryforwardsExpirationBeginningYear', window );">Net operating loss carryforwards expiration beginning year</a></td>
<td class="text">2037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_OperatingLossCarryforwardsExpirationBeginningYear', window );">Net operating loss carryforwards expiration beginning year</a></td>
<td class="text">2036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 111,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_OperatingLossCarryforwardsExpirationBeginningYear', window );">Net operating loss carryforwards expiration beginning year</a></td>
<td class="text">2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 15,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign | Swiss Federal Tax Administration (FTA)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign | Australian Taxation Office</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vir_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 10,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income taxes line items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_OperatingLossCarryforwardsExpirationBeginningYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards expiration beginning year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_OperatingLossCarryforwardsExpirationBeginningYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_UnrecognizedTaxBenefitsIfRecognizedWouldReduceEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrecognized tax benefits, if recognized, would reduce effective tax rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_UnrecognizedTaxBenefitsIfRecognizedWouldReduceEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_SwissFederalTaxAdministrationFTAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_SwissFederalTaxAdministrationFTAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_AustralianTaxationOfficeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_AustralianTaxationOfficeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139790636899312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Liability for Uncertain Tax Positions (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Gross unrecognized tax benefits at January 1</a></td>
<td class="nump">$ 7,422<span></span>
</td>
<td class="nump">$ 4,877<span></span>
</td>
<td class="nump">$ 2,725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Addition for tax positions taken in the prior years</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Reduction for tax positions taken in the prior years</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(62)<span></span>
</td>
<td class="num">(588)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Addition for tax positions taken in current year</a></td>
<td class="nump">3,228<span></span>
</td>
<td class="nump">2,607<span></span>
</td>
<td class="nump">2,740<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Gross unrecognized tax benefits at December 31</a></td>
<td class="nump">$ 10,638<span></span>
</td>
<td class="nump">$ 7,422<span></span>
</td>
<td class="nump">$ 4,877<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>vir-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:vir="http://www.vir.bio/20221231"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="vir-20221231.xsd" xlink:type="simple"/>
    <context id="C_2af6ea14-ac98-4568-81e0-3bef718e3542">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_9a41c817-24ee-4d06-ab61-6c839a61c843">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_d3f945e7-1296-4c70-9ecd-08b3a017a4df">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_1e2fb995-8c8f-44b9-a52f-67b970d66f9a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="C_440e7984-bced-4ce9-9125-e4710cb5f43b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:MedImmuneLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:InfluenzaAAndInfluenzaBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:MedImmuneAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="C_720cbd98-e278-45a4-979c-db878614348b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vir:TwoThousandSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="C_ad4974d2-db54-4104-9b56-2ebf05ffda38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_cafcd678-0319-424b-834a-70769b2cb74b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBioParentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:Vir2218Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">vir:Vir3434Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="C_57d6ead3-d03e-4250-b98c-0c50109e7cfe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:ContractRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_6b24e017-0f8a-429b-817a-9ef0927b8433">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBioParentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_896e4988-6bb1-4c02-8cd3-19e59ff58b81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vir:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_d876049e-5055-4f47-995e-2fbfc3f91f50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vir:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_8ea58521-d0a7-4461-a025-c44f108acb5b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_5cf7a8d0-261c-43e4-b66c-26e9b9c2e5b8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_5996e992-06fd-457c-9ae0-b6c5639ae79b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:GlaxoSmithKlineTradingServiceLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:AntibodyProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="C_46218237-5c98-4a62-bcee-3c18140a4029">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:ContractRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandAndTwentyOneGSKAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_cff30d28-1ec5-4dba-ae19-25ca903d9e22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
        </entity>
        <period>
            <startDate>2019-09-16</startDate>
            <endDate>2019-09-16</endDate>
        </period>
    </context>
    <context id="C_f3bae72e-0345-4ef5-af24-752bbadb5f0b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:PreliminaryCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-14</instant>
        </period>
    </context>
    <context id="C_c80ea697-a368-4975-9736-adb7c05cefbd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vir:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="C_083fe6a6-b404-46c5-8780-c18507a330b4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandAndTwentyOneGSKAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-12</startDate>
            <endDate>2021-02-14</endDate>
        </period>
    </context>
    <context id="C_59d1854c-78da-4bb2-8d89-3e539c321e00">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:SARSCoV2ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_ab10cbf0-1e01-4fdf-9b82-e97488c8af01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-01</endDate>
        </period>
    </context>
    <context id="C_8d7f14bb-4690-4c57-9bee-e30534233b77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_a0ca781f-26e8-4b49-94e4-3f01a982fe52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_3e754139-9f86-457e-a6d3-61f2f6892dbf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBioParentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_1e3fe30c-1972-4e8c-8649-eeb82a737029">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_2ec7ad16-c1b2-49f2-9adb-7d795c32364a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:DevelopmentProgramsExercisedByVirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="C_ef53fffe-7284-4da2-ade0-6081e04aa2dd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_e4a53be8-c056-44f1-b563-47390cc21dad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
        </entity>
        <period>
            <instant>2023-02-21</instant>
        </period>
    </context>
    <context id="C_bdb11187-f9e0-4206-b870-fc0fe6a80046">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_a055c3a3-3329-46bd-a235-0271e1908c6b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:SARSCoV2ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_bbef5af8-652f-4bae-a181-e9df48dc51ea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_1b0ce50f-5b97-4517-8931-808c3219617e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:GlaxoGroupLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-25</instant>
        </period>
    </context>
    <context id="C_b1fed0e5-7cc7-463c-bdd6-e6e1458d55b5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_ae08f4b9-a601-42cb-8ece-21e5e2b7b3f0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:GlaxoGroupLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandTwentyOneStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_34578bdd-5e64-44f6-8af5-ed7833cd36ba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:VaccinalAntibodyGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_e5b7cf6a-c235-492c-a434-ae21534824b2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:LetterAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_4afe2d0e-b9a0-4c40-9bbf-4330eabe88fe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vir:DevelopedTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ef41dda9-45c7-47f2-94ae-8f41c2af548c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">vir:ClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">vir:MeasurementInputProbabilityRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_5d48d11c-c737-4016-a687-853508a51066">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AmendmentNumberOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-27</instant>
        </period>
    </context>
    <context id="C_bc722d93-c8c5-4bb5-99b0-064fd7628401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:PreliminaryCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_87139d89-e3fd-445f-b6c1-4593f57a1d30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vir:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e422f02f-6b34-4d0a-8361-270372955b88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_04175337-eb05-48c1-8aac-bc7c29d50097">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_44ac39fd-62b7-430a-9b57-c2cfeb3f1006">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:RockefellerUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:RockefellerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_904cd630-0ecd-4275-ad9e-ee81b3b5999d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:LetterAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="C_946bca5b-a819-49fc-a9eb-3deae58d8824">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_ab50ccb4-8ce1-479d-85a9-8614fa9f9f31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_c00e1b15-1ac9-46ef-8ed8-c2ca882b705b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">vir:CommercialMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b67fb883-45a1-44e2-8338-3440f618fc44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_2aa5b5ab-23ab-4d0b-881f-3bccc42774eb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ef38c128-b6f9-4268-8e29-dbff882abc57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandAndTwentyOneGSKAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_64b0a6fe-b0bf-4dcf-a49e-f88368c52dbd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_8accf173-e6d5-4267-8c30-3f78db2b46fa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:InfluenzaAAndInfluenzaBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:MedImmuneAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="C_95d1c581-2af9-4924-b965-78baf570226f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_ef2dbdd6-6a22-4314-8ad2-3d3b510a7b9a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:LetterAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_82509859-a65e-439a-a5e3-9a2599d1d6ef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:LetterAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-09-30</instant>
        </period>
    </context>
    <context id="C_4adec9d2-4308-425f-a580-f05b8bbce014">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_6e1a4a6c-604a-4324-a4ca-eb6aff2132cb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialSupportToNonconsolidatedLegalEntityAxis">vir:SalesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-30</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="C_94806f35-4a90-434e-acce-cb420888cb77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_87f06556-ced9-44e3-ae60-d194dd7923ff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:HepatitisBVirusProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0640f8ac-c552-4f54-8a09-1b99e32573ac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:VaccinalAntibodyGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-13</instant>
        </period>
    </context>
    <context id="C_1364cd0a-2ace-4aed-b2bb-6a20b02ffe7e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_99fe8501-acd9-4f49-adf9-24150da9294f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vir:TwoThousandNineteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_2ecba0e0-1f16-471e-a9c9-563bd3c3a21a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:ContractRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_db0c1ec0-28ae-4df5-8ac3-748f417365f4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_e170955d-d5d7-40a0-b36e-ac2e1046968a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:VaccinalAntibodyGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_181582de-b0b6-4d34-a602-8545a05e16ac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:LetterAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="C_e81fb921-41bb-4624-975a-443a7c7cdf16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="C_f22a75a3-1d5c-4569-b00b-c460e4c440a5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">vir:ClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_363509bf-b0e5-4bc4-a76d-8682508915cc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:DevelopmentProgramsExercisedByBriiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="C_d1b3ce8b-0ec8-4d9b-ab94-b0c5e209d62d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_402569c9-a676-4ead-a6ec-b7f313ab6266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_9390c172-8de0-44cd-beb2-d80a53d6291b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:EachInfectiousDiseaseSiRNAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="C_20115010-b125-459b-ab42-c3f84a9a5259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:RockefellerUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:InfectiousDiseaseProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:RockefellerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="C_b8ad5282-2271-4d16-8946-c9bc284a5384">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_90313909-a6bc-4583-86a7-47d337dd4cb1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:XencorIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:InfluenzaAAndHBVResearchProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandNineteenXencorAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="C_ecd49638-d3b0-4e7d-9c09-1defc1de59fc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:PreliminaryCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0c441e33-191d-47b1-a7d6-6ce061bb3ae1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:XencorIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandTwentyXencorAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_5ee09e36-b7d5-4bd7-a7a8-de86d1ea831c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_76ae8c43-fd41-420f-aeae-ad3941b0fec6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_80319ba1-d62f-4b44-b5e2-f5e9eb0ceb54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_7c11953b-e6ce-4d9b-8cf9-80604a06d01a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-01</endDate>
        </period>
    </context>
    <context id="C_3906357f-ca70-49f3-97fc-ebdecba43cf9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:GlaxoGroupLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-23</startDate>
            <endDate>2021-03-25</endDate>
        </period>
    </context>
    <context id="C_1a446893-56a8-4407-9044-e0e0fd59cfee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">vir:MeasurementInputExpectedVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_cf8b6b9e-762d-454d-adc8-ca7fb3750e7b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c5248545-d73b-4cb5-a202-3d3703194709">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandAndTwentyOneGSKAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0e941a4e-4958-42af-89e7-b694adf192d4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBioParentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_b3553947-036a-44ba-af30-42a5788b9180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_d81100b1-9c19-43b5-a076-b271e6dffdee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">vir:BriiBioParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_cce2c08e-9755-4a1d-ac18-7f295a943893">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_053e3050-3042-4c21-b384-4dbc933b1860">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">vir:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_017385f6-1d68-484c-9c95-8c9c74dccda7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_70c61983-c30b-4442-b262-ed8ba12eed88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:GlaxoGroupLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandTwentyOneStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-14</startDate>
            <endDate>2021-02-14</endDate>
        </period>
    </context>
    <context id="C_e4ef837c-de22-4e63-b673-9b05c1a2fa71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:GlaxoGroupLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-29</instant>
        </period>
    </context>
    <context id="C_d7a958db-9d20-44ef-a677-68d2c31b101f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_a34f69de-db65-4bed-a804-9fff69f8bba0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:AntibodyProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="C_2d2b4307-0211-44cc-a6ea-58f34976c023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_81d21c4d-29ea-4221-9ced-d1956f3f0671">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_decb4aa5-5378-4f20-b098-06e2d05697eb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:PreliminaryCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_f8f016eb-9b56-4d62-8dd6-7ea4594702e3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vir:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_ffa6727e-7fad-43e1-84bd-2106591a8a4a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">vir:CommercialMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">vir:MeasurementInputProbabilityRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f1574fdc-3dbc-4686-99a7-37e3229c36eb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ca5589eb-ea15-4baa-83f9-5cfcb0672b1d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="C_a4c83d47-f369-4173-b21b-90aff8652ace">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:LetterAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="C_e4ea1ea2-14fb-4c40-b6b7-6c502c2c3167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_85d8bb4b-5225-414c-87d0-df7003801fcd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">vir:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_7619716a-9e49-48b5-abed-ff43a16e8263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_c81037e3-36e7-429d-8e76-acaab8a63eee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-01</instant>
        </period>
    </context>
    <context id="C_fa700c83-f248-4007-a04a-6e5b18f6eef8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">vir:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">vir:LetterAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="C_8ca9f390-7fbb-41d3-a8cc-0dc299a46f0e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vir:ClinicalDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="C_0df2a759-92c0-474a-a802-8afc81cf6ad0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_268c2c6c-2e46-49ef-8b34-85c3eb6476c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_2cb7e32a-2474-4d3b-85d8-13557d0b4572">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ffc264f2-dd56-4ceb-b96e-fbf5c3db3606">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-31</instant>
        </period>
    </context>
    <context id="C_6ff10353-fa1d-4c3b-ac8e-ff5c4ae62117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:GlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandAndTwentyOneGSKAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0dde6c02-78fb-47ad-a243-45289278021b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vir:FollowOnOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0fd0f713-f953-4286-a81c-0606471c2227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:DevelopmentProgramsExercisedByBriiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="C_41c05a89-da87-4a31-a87a-9e37c464d328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:PreliminaryCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-29</startDate>
            <endDate>2020-04-29</endDate>
        </period>
    </context>
    <context id="C_d76d05eb-1a75-4e9c-ae43-cb41d047d900">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_7b6a9230-282e-4c93-9f43-93b0661820c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_774f1d32-810d-4510-b5e3-aaafabf8e63c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a3f62ca6-5d34-48b4-8e19-7e9bd3f388e8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_89ca23f5-e12c-4dba-be08-03251a397eda">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">vir:ClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">vir:MeasurementInputProbabilityRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_4e62b6c4-3cd3-449d-8c77-954fc619391a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBioParentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">vir:Vir3434Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_1c1249b0-5ad3-449c-a242-9282e54fdb6f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_4be62c4c-687d-4539-b972-f167d33aa2d8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_12eb10d1-8cbc-4e43-9179-de76706ed182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_b7110cbe-39a4-4c4a-904d-1a47b20ffc0f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBioParentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:Vir2218Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="C_2b3229e8-bd98-49b7-9746-e7ce783e8031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">vir:CommercialMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">vir:MeasurementInputExpectedRevenueVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c98c2bac-151f-4ae1-99e5-12401ef3eb67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:ContractRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_c8ff574f-fed5-42aa-939d-486187b621e5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_43f8e518-6996-4956-b1a9-bf1a73666d0b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_fa73886f-e92f-4966-af95-e6e76cd8ccc3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:XencorIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandNineteenAndTwoThousandTwentyXencorAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0ab585f4-7932-4fcf-9d20-a8bc39178ab4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b432db30-4d2c-4ea5-b2ca-fe2523b09386">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ea8871a7-9d90-4943-89b3-944727e32088">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">vir:ClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_39cb96e3-900d-40c8-b3e6-6c07096acd7e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_94daadad-3dc0-454a-8e31-99a471e99b3d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_d45858f9-5f23-4ea3-a7e2-ddac9afb63ae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vir:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0d93da71-2399-418f-85e8-9b6b02f4b192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:AntibodyProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:PreliminaryCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-29</startDate>
            <endDate>2020-04-29</endDate>
        </period>
    </context>
    <context id="C_0ab96725-0d67-4b9b-8abe-9354e48096b0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="C_eeb8aa97-5f2d-4952-8244-3a5e12f77095">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_8919d223-48db-4e72-8f84-bb9a105b4296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBioParentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:Vir2218Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="C_4e221e13-8b5d-42ea-833d-86521dba2dea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_d39ab2c8-69ae-4434-87f5-e53d359487e4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:SwissFederalTaxAdministrationFTAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_03609c47-c098-4a60-97bd-053e2bf319bf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:RockefellerUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:FirstInfectiousDiseaseProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:RockefellerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="C_2a70a582-48c1-408b-b426-be7b95e3333e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_c7b72547-d6ee-4bc9-986d-72368f004917">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_ce64793d-668a-40e8-af07-6ebdbdd93828">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_bd901335-c247-4a9a-ba1a-0d36065664ba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b553a367-b665-4001-8f33-c723ff21ad71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:XencorIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:HBVProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandNineteenXencorAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="C_a88db863-7765-4796-a308-9513b1e29b15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:FirstSiRNAProductHBVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="C_62304650-1cd7-4013-b062-3aa4e9d5ad9f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0d8c8a20-2403-4408-9856-613c5c82c189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">vir:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_112ed8a7-7988-46af-99b9-84ca6fe5334e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_2f1d51a5-d28e-426b-b4cb-bbde0b7f3943">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="C_75214fe5-9907-465b-9eda-dcd555754a33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:VaccineProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:PreliminaryCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-29</startDate>
            <endDate>2020-04-29</endDate>
        </period>
    </context>
    <context id="C_bf980098-c647-4144-87a4-a5feba093982">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_a17e8413-fa17-4363-9bcc-2c63c792146e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">vir:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_474023a2-9be4-4db1-9135-5888440e1408">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_ab38e818-8e19-4d32-855b-4a5d8c7332dc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_f315ae4d-c3f9-4374-877b-5e513e6b3e19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">vir:ClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_7c77693b-4357-4bb2-a8c3-270864bc9cad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandTwentyStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-29</startDate>
            <endDate>2020-04-29</endDate>
        </period>
    </context>
    <context id="C_60880c52-6f5a-486b-a848-501a5bacdd60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:AnotherProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-31</instant>
        </period>
    </context>
    <context id="C_df66ba80-8dcb-4c94-abeb-511320bb1f34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_11d4ba09-a5bc-40ed-9952-89cf471e26ef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-01</instant>
        </period>
    </context>
    <context id="C_e08e7ea4-933b-4008-9b16-a6e809956279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBioParentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_65402f98-6f66-411f-989c-de9e545eb48a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
        </entity>
        <period>
            <instant>2021-10-30</instant>
        </period>
    </context>
    <context id="C_ad4141b8-b5e4-429b-9b52-dd67e708016e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_edd96045-6b9c-4a57-a99c-8b916e5ab8d8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_29901d1b-12a7-4289-b365-64d76b343767">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b5817a9b-c37f-413a-ab0c-c78fc5c64179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBiosciencesOffshoreLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:DevelopmentProgramsExercisedByBriiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">vir:Vir3434Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="C_aa13a910-3dc3-4d53-a119-271c45df3af6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_c5b01808-0860-4e26-906c-c9aecfd158e9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_63454d26-78fb-4850-a047-cf04ffc3c617">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_ce26a70b-eafc-47b8-8306-b96c9e3a25d4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0365acdf-5aea-4a92-8f52-bcf73ab2f285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:NationalInstitutesOfHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_35e38548-67c8-4cef-8f37-1a11a25cc2ea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_61fecc05-bbcc-451c-ad8a-57bf80b34de9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBioParentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="C_8159e296-cbd0-46c5-bb89-4442f5253f01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_2da3af76-3a2c-4087-bd64-efb611a69cc8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:DevelopmentProgramsExercisedByBriiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">vir:Vir3434Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="C_c8f5798c-ad39-4045-8160-7af430bcb734">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:RockefellerUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:RockefellerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="C_00a912ce-4cfe-416b-b075-dffc321d18b6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_48f14b99-b9bb-45aa-acd6-6b16710aedb4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_27c0e6df-cfdf-4bca-b0d3-1b934d52a189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandAndTwentyOneGSKCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-12</startDate>
            <endDate>2021-02-14</endDate>
        </period>
    </context>
    <context id="C_dd2fc99d-7a9d-45e3-995a-8f33afb52a81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:HepatitisBVirusProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-31</instant>
        </period>
    </context>
    <context id="C_6cddb4e4-b247-4253-a284-b9685fd836de">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_11e2fb59-6582-4888-956d-443f42d7adbb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_da5feba6-e631-4bec-b33d-106ac3401870">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_e28b382b-9754-42d1-868b-c2ea43f958c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBioParentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_236e9ea2-3639-4c4a-84d1-b0cbf28005ee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_fb57c6da-b1f8-44af-a1d9-109cfe493bad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:DevelopmentProgramsExercisedByVirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-31</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="C_a1ff86c5-33e9-4326-b1f2-a4f7b5d2c716">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:RockefellerUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:RockefellerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_faecd853-fee9-460a-9e6f-a4fc83b058a2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">vir:BriiBioParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_ca130bf4-8380-4419-9f23-7747d3b7b6f9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_6ea95d1d-1302-408e-b108-02685b997985">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-31</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="C_a7262ac3-ad3a-4279-afb3-5136951286cf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_742108ce-79d0-443e-97ab-ce1b47aab7fb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_724a4a6c-eb88-43e1-9385-7a1ee1d59450">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:DevelopmentProgramsExercisedByVirMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="C_ae72cfe1-e779-40b7-9892-e8d69ca5e6f9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_d43fd0d1-a39e-4f48-bbed-09680ca7f602">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_77979cee-0206-4722-a78e-8d7e1abeb723">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vir:FollowOnOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-10</instant>
        </period>
    </context>
    <context id="C_91be3be0-e317-45a0-837e-46e0bcedc91e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_48f1b79a-a22f-4fe8-acd8-aae6fb94bd78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandTwentyStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-29</instant>
        </period>
    </context>
    <context id="C_ecf4fb53-9e9a-460b-b2c7-36c48bc67120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">vir:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e70b1c74-320f-4d6a-81ff-72022442374d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">vir:ClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">vir:MeasurementInputProbabilityRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_de66dc29-7c5c-4788-af3e-b26710f8cb06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AmendmentNumberOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_5ff17edc-f10a-4706-a1cd-672e160dd990">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:GlaxoGroupLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-29</startDate>
            <endDate>2020-04-29</endDate>
        </period>
    </context>
    <context id="C_8354e95f-a997-4559-8f00-06918b2494db">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBiosciencesOffshoreLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b70442f4-3b9a-4721-b156-3f58ba42d7b0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBiosciencesOffshoreLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-31</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="C_bcee63ec-ae69-4678-8b04-d29b3bc1370e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_10a388d6-6193-4e20-a608-d5203976d818">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b69ec4f4-b531-408c-b82a-92c8c2b9bcd4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:PreliminaryCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-14</instant>
        </period>
    </context>
    <context id="C_8e5b8d02-9b16-4b28-a5ac-d7b44ab9cd92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:VaccinalAntibodyGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-13</startDate>
            <endDate>2022-01-13</endDate>
        </period>
    </context>
    <context id="C_7c1b6e30-61ef-41a5-af65-74e946d04165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_f9212404-81f7-4d0b-9f10-42f60cf103ef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vir:TwoThousandSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="C_6276028a-2d2e-482b-9ea8-a6448755d571">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_ba34aded-037c-492e-95bf-8e2aee84865a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vir:DevelopedTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_7b5b92b7-ec6c-4504-ad39-91288ac75cc0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vir:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_15a1a88f-77e5-43b6-91c1-62f17e7d6662">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ed2fc9b2-d46f-45fd-a059-f990d15eff81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_a1e68275-f02d-43b0-8ccb-7c3d41000c0e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandAndTwentyGskAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_bc63cc0a-80f2-4f25-8b71-3402b70afd98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandAndTwentyOneGSKCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-14</startDate>
            <endDate>2021-02-14</endDate>
        </period>
    </context>
    <context id="C_d31deef3-bfd7-4c38-8080-cbcd2d6f202c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:VaccinalAntibodyGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_48a91d5d-ea5c-4037-9225-755e30bfc6c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:GlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandAndTwentyOneGSKAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e43e7416-30c1-47c2-8d8f-9a8fa8761fb6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_679bc2b6-7333-4652-aa5e-56403fa75188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:MedImmuneLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:MedImmuneAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="C_09ba265a-6add-41f5-ae26-e28684a4a700">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:HepatitisBVirusProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_70da0710-1b2a-4c11-a63e-24ea296a4134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_9238efac-e9f0-40db-8b4d-0bd6b667bce1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:FirstSiRNAProductHBVMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-31</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="C_f3c34215-8edc-4dd4-865f-ab771871ad3a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_8616915b-46bc-4304-92c6-102f09231afc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vir:DevelopedTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_e3df795a-3a56-41f0-b360-db9fa10cdc01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandAndTwentyOneGSKAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-14</startDate>
            <endDate>2021-02-14</endDate>
        </period>
    </context>
    <context id="C_d6d82c19-9cbe-4f4b-b35e-d5f66e5d7598">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:XencorIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:InfluenzaAResearchProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandNineteenXencorAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="C_72d128cd-9dc7-4ded-bfa1-21c90dee3725">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vir:TwoThousandNineteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_000e7047-27c6-405d-911b-7387dc00e8cb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:DevelopmentProgramsExercisedByBriiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="C_60fd6477-1423-4941-969e-7c5f8ad2c846">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:AntibodyProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:PreliminaryCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_d4f38c3d-eb5d-48e7-8694-cfdc645585c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:RockefellerUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:RockefellerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_dad50c1a-a985-4cd9-83d5-54c441a295ba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">vir:CommercialMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_7ca9fa0c-6fce-40ab-ad6a-72ab66e31dc8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:DevelopmentProgramsExercisedByBriiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_4c048e8b-01e1-4aa6-a204-9ba59db26a4f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_9dc90b6a-ec9c-43c8-abc2-fcbab105e2d2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_ff18ae7e-33f9-49e0-b7ad-17646042d12e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_713f0ffb-32b7-4557-8121-be8edd691f8d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">vir:ClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_423db569-199e-451c-b19e-22f96e558a53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:XencorIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandTwentyXencorAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_db717f4e-f800-427d-a092-ed5b2685c250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBioParentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">vir:Vir3434Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="C_8338caa5-3a09-4312-9d81-25f2cf6a95d0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:VaccinalAntibodyGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_7bfa1f77-0aad-47a7-9222-be7a47061336">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:VaccinalAntibodyGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_981e1dc9-76fd-4fe4-a6ef-def1bcdbc1e7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">vir:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_1c2df6fc-28b4-42ab-92ca-e8e7604a433d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBiosciencesOffshoreLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:DevelopmentProgramsExercisedByBriiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">vir:Vir3434Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="C_c23e0019-4bdf-4a39-9f66-f78f5b7cf6ba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_fec42e81-f129-4752-ad8b-0294488d4ba3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vir:FollowOnOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_24ffc582-325f-493e-a4b4-111a43d7f9d9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_53c3499f-95d7-41ad-aa6a-553955ca0961">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:HumanImmunodeficiencyVirusGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_1ff854d5-f188-44b8-94e4-70a3c2f65c1a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialSupportToNonconsolidatedLegalEntityAxis">vir:SalesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b6e56cad-2ca6-48f8-b21a-16161998bf9e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_cbf68543-981c-4f0c-a438-703247341f08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_6046760e-44a7-4084-a7d2-ce57ecf671fd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">vir:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_226affc5-a26a-4685-b939-df0a4de23d15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_029580f2-ed42-4e2c-a78b-e3a8e585aaa6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c9e8dc36-972e-4533-bbcc-9f347a84b7dc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0b6e95b2-e943-40ea-ba4d-dbf4d337d81a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vir:FollowOnOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-10</startDate>
            <endDate>2020-07-10</endDate>
        </period>
    </context>
    <context id="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b6ba7de2-aef8-4b9a-a988-45dae6fa27d5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:PreliminaryCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-12</startDate>
            <endDate>2021-02-14</endDate>
        </period>
    </context>
    <context id="C_07f1d79c-70ab-4760-854b-ccf98c1deed1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:PreliminaryCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_2a4a265d-bb0f-4164-81c2-3cfe9f2c5fed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">vir:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_8472ca01-d418-45f2-8494-45e935bbbc83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBioParentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_dbd52408-3a79-4789-b6f2-0d8c54a59ebf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_03bf1b7d-b075-4a4b-80d2-af36c3cd0aac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_d8fb65c9-343c-4c85-898f-95ed557e0d7f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <unit id="U_Segment">
        <measure>vir:Segment</measure>
    </unit>
    <unit id="U_Antibodies">
        <measure>vir:Antibodies</measure>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_Unit">
        <measure>vir:Unit</measure>
    </unit>
    <unit id="U_sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_Milestone">
        <measure>vir:Milestone</measure>
    </unit>
    <unit id="U_Program">
        <measure>vir:Program</measure>
    </unit>
    <unit id="U_Product">
        <measure>vir:Product</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_USDollarShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_62304650-1cd7-4013-b062-3aa4e9d5ad9f"
      id="F_8818a887-324c-4500-a98b-191605dee51d">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_eea247aa-b454-4118-bb33-6d0a7452daf1">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      id="F_0ef0daab-8a05-4fa7-ae0c-27cd8627c533">http://fasb.org/us-gaap/2022#AccruedLiabilitiesAndOtherLiabilities</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="C_cff30d28-1ec5-4dba-ae19-25ca903d9e22"
      decimals="9"
      id="F_c96f0ebc-77ee-4fcb-8f17-f5159dfe676a"
      unitRef="U_pure">0.222222222</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      id="F_f8694a50-65fb-4c52-8533-1d35751b0dcd"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_63d71f7a-f5e8-43cd-b54e-054d6fece2b0">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      id="F_b8b36721-3cb4-433a-80d0-34cd8d9386fc">http://fasb.org/us-gaap/2022#AccruedLiabilitiesAndOtherLiabilities</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_5e71ec6a-22b0-4059-a89c-67344cbf8a96">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      id="F_51add2ca-9313-4a69-901e-884acd814211"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="C_d1b3ce8b-0ec8-4d9b-ab94-b0c5e209d62d"
      id="F_42ecc27d-dd4e-4bd9-a1b3-ab9d1b0e44c1">P7Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_62304650-1cd7-4013-b062-3aa4e9d5ad9f"
      id="F_e5972bc8-c341-44f2-a1e7-401190923bbf">P7Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_2cb7e32a-2474-4d3b-85d8-13557d0b4572"
      id="F_6e3bf6bc-7e1c-4d4c-81d7-17386f7ad6b8">P1Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <dei:AmendmentFlag
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_04e7e692-80a4-4a41-b1fc-41a7859e5462">false</dei:AmendmentFlag>
    <vir:RoyaltiesPaymentRangeOnNetSalesOfLicensedProduct
      contextRef="C_8accf173-e6d5-4267-8c30-3f78db2b46fa"
      id="F_5dac47e7-0c9b-40b2-b070-76af35962042">mid-single-digits to sub-teen double-digits</vir:RoyaltiesPaymentRangeOnNetSalesOfLicensedProduct>
    <dei:EntityCentralIndexKey
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_9eaad379-f48b-4dc1-9088-41247d137fea">0001706431</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_a21f9a7c-ad25-4580-a62e-4e6440eab0ac">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_9282cd3d-90a5-4cb7-8737-7ed5a064fdb1">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_ddb4a7cf-6a25-4712-ba3b-3ef8fb4da70b">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_1da58fb7-dec0-4701-a083-521d80f3cc0d">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_244ebe93-1ccd-4de6-a1b8-8eabaf9ab0b8">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_139367c2-b8ea-4057-9b6c-4e9f24c2f926">1-39083</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_f90ebe43-74a2-4869-8805-3e2f75c33efe">Vir Biotechnology, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_6aefd8cf-5a82-458d-9e76-fa492aba12a6">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_55efb6d6-5653-4d2b-98a9-75a58c6b105a">81-2730369</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_7148a00b-277b-4055-ad15-0c92597a03ac">499 Illinois Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_7a923ca4-bcbd-4751-8616-65189f530dfa">Suite 500</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_0113242a-1e86-47be-9c1b-d18348650608">San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_0b9d268e-96ce-4f37-becf-c3f34825bf28">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_b4b107cb-7d09-46d7-bd20-f00cf14d6174">94158</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_bd3dcbce-dd56-47c9-8516-9fd83894c6fd">415</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_6c0e95de-d6df-42f9-b93f-d927f9c15cfd">906-4324</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_8876844d-142d-4972-912a-66fda807ef4d">Common Stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_538b224e-739f-4ddf-b8ee-06dcab846201">VIR</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_e4936080-cedb-45a2-9eab-4e4a84ca6c06">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_985cb338-78bd-4885-a47c-fb83f8419168">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_889964e7-d926-4381-bcca-0f0b6a5b6e7c">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_380925e8-8840-4981-ac42-b4bfa76e03ee">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_4123865b-0439-4cfd-9421-090640af4ded">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_c2bed82d-547e-4849-ad30-4b35ea5c2cf5">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_f05a8333-3a09-4c38-abc6-e765f29e5f93">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_195fe85f-76fa-4880-b515-4fe2ced288e4">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_24526c9a-2d80-4e61-9470-8d8b6959d738">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_0c073963-0090-4dc2-a51b-33effc055572">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_d76d05eb-1a75-4e9c-ae43-cb41d047d900"
      decimals="-8"
      id="F_b2864618-fbeb-4d72-80a0-6a565f38e2ae"
      unitRef="U_USD">2000000000.0</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_e4a53be8-c056-44f1-b563-47390cc21dad"
      decimals="0"
      id="F_11e222ae-e23f-425d-b35a-02450de139b2"
      unitRef="U_shares">133531379</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_8f50f807-0df0-40c4-b4d3-f7b8bbb9019c">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Portions of the definitive proxy statement, or the Proxy Statement, for the Registrant&#x2019;s 2023 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K. The Proxy Statement will be filed with the Securities and Exchange Commission within 120 days of the Registrant&#x2019;s fiscal year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_3a4f8955-5e1e-4d86-9512-33e79684a6c1">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_923f5d39-72be-4646-9654-01217fd1c50f">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_ee30432e-3009-44e8-a182-c15fc70204bc">San Mateo, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_0c0372fe-e0e1-4011-a3b3-1d3f0add0892"
      unitRef="U_USD">848631000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_cc8d3e34-bad8-4afc-8a39-c397695fd051"
      unitRef="U_USD">347815000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_7d5ee069-082a-44e1-af98-508aee134033"
      unitRef="U_USD">1521517000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_9f909d58-36d9-473d-8962-ed869e905612"
      unitRef="U_USD">217182000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_4d60c376-d21a-4a11-8b4c-b5e6a3c674a0"
      unitRef="U_USD">12681000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_b3cda6af-1aac-498d-b98c-d91be18ffac7"
      unitRef="U_USD">8594000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_ecab5e4d-4d02-431d-af31-26a84799387c"
      unitRef="U_USD">0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_d1958196-f68c-4533-9db2-17f502a56a26"
      unitRef="U_USD">773079000</us-gaap:AccountsReceivableNetCurrent>
    <vir:EquityInvestmentCurrent
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_34360fb7-e882-4526-b756-0e95c4d3f8d8"
      unitRef="U_USD">31892000</vir:EquityInvestmentCurrent>
    <vir:EquityInvestmentCurrent
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_0fa9ed09-13fe-4c88-a2f4-d6d3ca1f42e1"
      unitRef="U_USD">143148000</vir:EquityInvestmentCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_698576d7-8d45-415b-90d3-39a23c3ecb21"
      unitRef="U_USD">104356000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_09e578df-75d8-4e10-a0d5-50626d3dcea2"
      unitRef="U_USD">73003000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_5737418e-ab7e-4560-8d5d-85ad8d758638"
      unitRef="U_USD">2519077000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_d8bf0bbe-1b03-40fe-aecc-e8cc1db2a1c3"
      unitRef="U_USD">1562821000</us-gaap:AssetsCurrent>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_3e74716a-9c67-4b72-9670-1f607e1fc9c3"
      unitRef="U_USD">32755000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_675b2a8f-a8c4-4c24-a5b7-298ce5cfd762"
      unitRef="U_USD">33287000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_b776654b-02ae-4433-9823-be030fe98cce"
      unitRef="U_USD">16937000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_f76d884e-d2e6-412f-8e99-2841afd63ea6"
      unitRef="U_USD">16937000</us-gaap:Goodwill>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_61333742-ac47-4090-aaf3-97eaeee486af"
      unitRef="U_USD">105609000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_17dd2498-3a32-4824-aaf7-be1a9c5b00da"
      unitRef="U_USD">42834000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_95b554fd-06ac-4771-9bef-dab36dff8c0e"
      unitRef="U_USD">82557000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_55da1375-bf9e-48f0-89e2-d5331e52fbd6"
      unitRef="U_USD">87220000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_fbdb5938-9505-44d4-8cf9-2eed0c53d0ca"
      unitRef="U_USD">6656000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_fee6c95b-9547-419a-b2f3-f4bae46cc81f"
      unitRef="U_USD">7006000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:LongTermInvestments
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_240292a7-9e08-456e-87b0-847ddae8dc52"
      unitRef="U_USD">23927000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_4491bfe4-3dcd-4ac3-b475-296a4437b490"
      unitRef="U_USD">201388000</us-gaap:LongTermInvestments>
    <us-gaap:OtherAssets
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_2a3a6f17-257a-45f1-a87a-a02447a2593a"
      unitRef="U_USD">14570000</us-gaap:OtherAssets>
    <us-gaap:OtherAssets
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_035577b4-efc7-4eb4-9834-a8878a77c2f9"
      unitRef="U_USD">2775000</us-gaap:OtherAssets>
    <us-gaap:Assets
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_87fe50f0-7e09-4a92-bfae-1e532092773e"
      unitRef="U_USD">2802088000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_f9292b64-e6cd-42ab-8543-abee57af2143"
      unitRef="U_USD">1954268000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_ed85cb6b-63a1-4edc-810f-fa98a8339d78"
      unitRef="U_USD">6422000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_02edaea8-063c-40bd-9b31-a00295367431"
      unitRef="U_USD">6521000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_59e2a8b8-cac3-4944-ad92-b23020af1380"
      unitRef="U_USD">489090000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_1674f22b-8b55-467b-b676-1bd8d7f0d92b"
      unitRef="U_USD">236512000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:DeferredRevenueCurrent
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_e512eacb-c332-45a0-8b50-1d760ea5c013"
      unitRef="U_USD">15517000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_f4c129da-d275-49bd-8aa1-681d9ef7a7ff"
      unitRef="U_USD">98209000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_7247cd79-f35d-4f15-bc9d-b248e6d08553"
      unitRef="U_USD">511029000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_6dc4d817-0378-45ca-a333-4d327a7b0343"
      unitRef="U_USD">341242000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_16dbbe9c-c16f-4d8a-863d-840a72296acc"
      unitRef="U_USD">53207000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_047fab38-bbdc-40be-89c5-5233ebe0919f"
      unitRef="U_USD">3815000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_58c1daa1-bc60-48f1-9209-1adb42f95004"
      unitRef="U_USD">123837000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_c7978db1-548a-4f13-ab47-786c702312a1"
      unitRef="U_USD">133561000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_8509d840-3a3a-4a6e-8c15-3b8e5c423796"
      unitRef="U_USD">24937000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_b88bf1a8-b61e-42df-93f4-d686b71e5ced"
      unitRef="U_USD">22822000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_eac83158-2631-41e8-adcf-2edb1a822fed"
      unitRef="U_USD">3253000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_361dcc03-61c3-4c0e-9c6c-872560a1d855"
      unitRef="U_USD">18439000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_cdb6393a-809f-4cfe-aaf9-d0410324f250"
      unitRef="U_USD">7862000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_89063183-2ca0-47ab-ab59-545bb2e99e68"
      unitRef="U_USD">2540000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_ef38042c-53e1-4be1-9d03-65978125046d"
      unitRef="U_USD">724125000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_a54e8690-7114-42f7-bb9c-f231f52d759c"
      unitRef="U_USD">522419000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="INF"
      id="F_d8a233b8-7028-4ee6-bfe3-8a94d1a84626"
      unitRef="U_USDollarShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="INF"
      id="F_de428578-70d4-4e40-aab2-3563080cca8c"
      unitRef="U_USDollarShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="INF"
      id="F_d2282a3d-a3a6-49fe-8c81-e3598bbbbb20"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="INF"
      id="F_ecc9e8c2-4c77-4416-921e-261d303209ff"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="INF"
      id="F_50dc5163-65f7-4292-9ead-401b15e68c10"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="INF"
      id="F_2dd59076-c38f-470c-9cd5-be03c02ecad8"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="INF"
      id="F_704c1acc-8bc5-4142-b6c6-ac15745cbdb8"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="INF"
      id="F_9bfc636d-d5ef-467f-9556-386899dd8666"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_366ac0cc-12ef-4c69-af8b-9587847291c4"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_f93df005-babf-428f-985e-0d226f7bb2ed"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="4"
      id="F_e87c98de-bce5-44d5-b4bd-627a49e7cced"
      unitRef="U_USDollarShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="4"
      id="F_4b990e6c-3bc0-4791-a1c2-d6e8f3b7471b"
      unitRef="U_USDollarShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="INF"
      id="F_595263de-a873-4cde-b934-a78e0de0766b"
      unitRef="U_shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="INF"
      id="F_cba8792f-e65b-4c70-be2c-55b4f153464f"
      unitRef="U_shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="INF"
      id="F_def8766c-677c-4523-a9c1-fed94f23d7ed"
      unitRef="U_shares">133236687</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="INF"
      id="F_2b042b3c-8939-4b9f-9c21-139e8bee712e"
      unitRef="U_shares">133236687</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="INF"
      id="F_fda68d90-39bb-42e9-957d-5c62c86d86eb"
      unitRef="U_shares">131161404</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="INF"
      id="F_9f72fc3a-ef83-437b-bace-ac409bc3a023"
      unitRef="U_shares">131161404</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_5090a4fa-0317-4732-95a8-03ab3aad065a"
      unitRef="U_USD">13000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_cf7f7a29-6b62-4fae-9825-06ea66ab8659"
      unitRef="U_USD">13000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_efaa3630-9ddf-463b-9a24-01f7fa112a83"
      unitRef="U_USD">1709835000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_065040b0-1132-41f9-8205-e9c146aa8e8b"
      unitRef="U_USD">1571535000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_8fe13a9c-2f07-4d92-9660-1fd2b6f04b57"
      unitRef="U_USD">-9122000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_6f0ec6fb-8cdc-44cd-b17b-ec592c5053a2"
      unitRef="U_USD">-1099000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_09ad07f4-761d-4924-850d-8f2fd6aa32d6"
      unitRef="U_USD">377237000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_fca94cbc-6f17-4eb8-af57-6eef8847cc3c"
      unitRef="U_USD">-138600000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_b7ff6b25-c997-4735-a908-627a356fc9af"
      unitRef="U_USD">2077963000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_7cc74789-5df0-4035-b3ed-1987b2e0827e"
      unitRef="U_USD">1431849000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_936ef299-c3a2-4aef-b88d-6e05b1bd3f24"
      unitRef="U_USD">2802088000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_a32324eb-88b7-4574-8e53-a061c9a9fdfa"
      unitRef="U_USD">1954268000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_ab50ccb4-8ce1-479d-85a9-8614fa9f9f31"
      decimals="-3"
      id="F_1b5231e3-d6e6-4b6b-8e9c-14fc948bb306"
      unitRef="U_USD">1505469000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_81d21c4d-29ea-4221-9ced-d1956f3f0671"
      decimals="-3"
      id="F_c5930e15-aba6-4fe3-a356-06fe2fe08144"
      unitRef="U_USD">917194000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_7b6a9230-282e-4c93-9f43-93b0661820c0"
      decimals="-3"
      id="F_f7855fbb-062a-4476-9c8d-929ee3ee2e2c"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_2ecba0e0-1f16-471e-a9c9-563bd3c3a21a"
      decimals="-3"
      id="F_3c1a3819-f4e2-40a3-98ab-ab44f585691f"
      unitRef="U_USD">52714000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_c98c2bac-151f-4ae1-99e5-12401ef3eb67"
      decimals="-3"
      id="F_cdc8885a-17cd-42d9-beba-1ed38b67c427"
      unitRef="U_USD">169874000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_57d6ead3-d03e-4250-b98c-0c50109e7cfe"
      decimals="-3"
      id="F_61dd2de3-c41e-471e-bee6-456147dbb50a"
      unitRef="U_USD">44498000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_b3553947-036a-44ba-af30-42a5788b9180"
      decimals="-3"
      id="F_d27ebb54-55e4-4afe-8dba-60cb7da877bd"
      unitRef="U_USD">22289000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_bcee63ec-ae69-4678-8b04-d29b3bc1370e"
      decimals="-3"
      id="F_c2a12076-021d-4673-9231-c5d3dc9c8806"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0df2a759-92c0-474a-a802-8afc81cf6ad0"
      decimals="-3"
      id="F_1f650dca-fe98-41bc-8baa-a18a8f581706"
      unitRef="U_USD">22747000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="C_4c048e8b-01e1-4aa6-a204-9ba59db26a4f"
      decimals="-3"
      id="F_24ad1a7d-73fb-4146-8526-03cdbacc0682"
      unitRef="U_USD">35325000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="C_4e221e13-8b5d-42ea-833d-86521dba2dea"
      decimals="-3"
      id="F_f3fb9de7-733c-4f30-b847-bfeb7b4df014"
      unitRef="U_USD">8347000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="C_d43fd0d1-a39e-4f48-bbed-09680ca7f602"
      decimals="-3"
      id="F_696fa435-e3ca-4ee3-8d69-dd2a84b3c448"
      unitRef="U_USD">9123000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:Revenues
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_b3025694-b833-4d27-aae4-43979a98d609"
      unitRef="U_USD">1615797000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_c1017267-13a4-497e-a479-90ed844de680"
      unitRef="U_USD">1095415000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_07689af5-55ce-410b-878b-a5cd4680ea1c"
      unitRef="U_USD">76368000</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_f21df124-66d1-46e7-9040-09768aa743c8"
      unitRef="U_USD">146319000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_c8b02826-0280-4c14-97c7-2d5bd6acb55f"
      unitRef="U_USD">65865000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_b8e3ea5d-5df5-44f3-9a58-de92ab3a09f7"
      unitRef="U_USD">0</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_727dd20f-44be-4d6c-973e-b7be1d842a9f"
      unitRef="U_USD">474648000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_331bb189-4b46-469c-a67b-86326178f9bd"
      unitRef="U_USD">448006000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_b3741e71-c2f1-440f-bef6-7bd2dea908cd"
      unitRef="U_USD">302411000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_d77dffb6-8fa5-43a0-a746-e014ad390d68"
      unitRef="U_USD">161762000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_103a9f60-2e5e-4a88-b823-06de263dba8d"
      unitRef="U_USD">160793000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_4f21a8d6-84a4-4f32-85ea-4025ba067740"
      unitRef="U_USD">70937000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_6376d491-7f2e-47ef-8538-b54da20c36ef"
      unitRef="U_USD">782729000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_a07fc4b6-8cc0-48cc-8a9b-d6dde10dbacb"
      unitRef="U_USD">674664000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_8a3a7ba8-63a0-45ed-a0fa-8635389e50b2"
      unitRef="U_USD">373348000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_9d514a94-d2ca-4921-9b82-077656184e5e"
      unitRef="U_USD">833068000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_c2204b34-29f8-4f00-8685-118d06cd65b2"
      unitRef="U_USD">420751000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_bfc46062-6c1d-492d-876e-025652fff2cb"
      unitRef="U_USD">-296980000</us-gaap:OperatingIncomeLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_f20b14bc-3ef2-4cbb-8389-b2341f7698e3"
      unitRef="U_USD">-111140000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_e47ccdf6-5b85-4d21-8b56-e91f2a1522e3"
      unitRef="U_USD">138049000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_cee00324-2e30-429f-a047-90b3e8338353"
      unitRef="U_USD">0</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_4959e0b8-6d7e-4e34-92e6-475fc455fd0b"
      unitRef="U_USD">28092000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_242ab647-b131-4d06-82b2-6888756d0185"
      unitRef="U_USD">439000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_d90c36a6-68d7-4009-bec3-308113092448"
      unitRef="U_USD">2836000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_ea6a07ff-6b5b-40e0-9bd3-368f51b57670"
      unitRef="U_USD">4260000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_7f3a8181-d08b-4403-99f7-a6fa3f7bb684"
      unitRef="U_USD">-9437000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_29b7ae0f-2040-4e89-b2fd-9dff71b02d68"
      unitRef="U_USD">-4467000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_20751e25-9aa7-412f-870f-39115d09f627"
      unitRef="U_USD">-78788000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_df628013-14cf-4b78-aebb-7689026fc97a"
      unitRef="U_USD">129051000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_dbf0fc69-c7a1-4adc-bb0b-206fefd9142d"
      unitRef="U_USD">-1631000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_12799b60-fb49-4169-84f4-e34298e1cdd8"
      unitRef="U_USD">754280000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_b46f63e8-07cf-4ecf-9868-639da0ce005b"
      unitRef="U_USD">549802000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_16db759d-d929-49d3-b767-60d13252a768"
      unitRef="U_USD">-298611000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_926a81e1-a8db-4437-8d99-82c9873fbe96"
      unitRef="U_USD">238443000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_3ae53690-acfb-478c-8240-9106462d5dd1"
      unitRef="U_USD">21218000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_8f46c547-cfb1-4f40-b5d6-156a2db0fd34"
      unitRef="U_USD">54000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_ae79d814-0b88-4cea-8be0-52d6e1cbe620"
      unitRef="U_USD">515837000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_d3a43965-27ee-40e1-a0b9-b0e18c4399ff"
      unitRef="U_USD">528584000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_2f79cd56-4607-4f66-999e-19cc32984747"
      unitRef="U_USD">-298665000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="2"
      id="F_c3699c1c-3df7-467e-8edf-56023ca812fa"
      unitRef="U_USDollarShare">3.89</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="2"
      id="F_0ca7b7cc-033c-4b7c-89a2-6e95ff44bc1f"
      unitRef="U_USDollarShare">4.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="2"
      id="F_c2f9bf05-9d67-4418-8d17-16ce821944a4"
      unitRef="U_USDollarShare">-2.51</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="2"
      id="F_f1b68431-50cb-4f62-9bce-ab160c2dd11d"
      unitRef="U_USDollarShare">3.83</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="2"
      id="F_ab0ded15-d6e2-4d79-bdb4-240a03a10c74"
      unitRef="U_USDollarShare">3.96</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="2"
      id="F_2a697693-4502-4ade-bb40-c728b54a4c65"
      unitRef="U_USDollarShare">-2.51</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="0"
      id="F_b462da0f-19e0-46e7-b53f-a5a30ceb3588"
      unitRef="U_shares">132606767</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="0"
      id="F_6212f4a3-e0bd-43a1-bea8-d1d00d53f04b"
      unitRef="U_shares">129884967</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="0"
      id="F_8d90179d-0ab8-4e0a-99dc-e729a8d4e35b"
      unitRef="U_shares">119159424</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="INF"
      id="F_cefe93ee-0d7b-482f-8243-1dbd14108b19"
      unitRef="U_shares">134810908</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="INF"
      id="F_59869817-9958-4e83-8ceb-05e0691ebcba"
      unitRef="U_shares">133437126</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="INF"
      id="F_b886b04b-9855-49aa-a777-8b7d7656273a"
      unitRef="U_shares">119159424</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_dce59fd7-939b-46b8-89a8-1be97e616cea"
      unitRef="U_USD">515837000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_dac284c0-c9b8-4e1a-868f-7e5ff89f7595"
      unitRef="U_USD">528584000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_7eacb998-c678-4087-a933-ef1bbc77678f"
      unitRef="U_USD">-298665000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_b292aa09-9ec5-4f6c-8f51-99377ea92951"
      unitRef="U_USD">-7524000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_f0c8b4a3-42c0-4c5b-b029-4c64422c4567"
      unitRef="U_USD">-957000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_0ed186a1-eb86-435b-a026-ff9a7d5524e3"
      unitRef="U_USD">-50000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_6e7f4c04-bfb4-49f1-a3f4-ade86321b30d"
      unitRef="U_USD">499000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_7677af4f-3627-4502-bf21-1d0f7c003406"
      unitRef="U_USD">-55000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_d4487cfa-2958-4e5e-935a-2019940490a4"
      unitRef="U_USD">-23000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax>
    <vir:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentToProjectedBenefitObligationsNetOfTax
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_c78d26cf-61ca-4315-8acd-688837acbe1f"
      unitRef="U_USD">-0</vir:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentToProjectedBenefitObligationsNetOfTax>
    <vir:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentToProjectedBenefitObligationsNetOfTax
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_0ca534b8-c485-4dfc-8c80-dc326e39390b"
      unitRef="U_USD">-1081000</vir:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentToProjectedBenefitObligationsNetOfTax>
    <vir:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentToProjectedBenefitObligationsNetOfTax
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_56ac3a3d-ddb6-404f-82c8-170fab01553c"
      unitRef="U_USD">650000</vir:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentToProjectedBenefitObligationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_291f88e3-b328-41f4-afbe-263aad247eca"
      unitRef="U_USD">-8023000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_b3a8ef8f-bcb9-4483-b0ae-c556f1735eed"
      unitRef="U_USD">179000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_1cf00d62-8f7f-4e68-9bb1-6dc214ad95ca"
      unitRef="U_USD">-677000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_3c68da68-804a-4fb3-bd22-d17bfde6908b"
      unitRef="U_USD">507814000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_df1de6c7-fef0-48cd-ad6f-1cadf02b3687"
      unitRef="U_USD">528763000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_2fd67437-54e6-46a3-b9c7-fdfa8be562f4"
      unitRef="U_USD">-299342000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_12eb10d1-8cbc-4e43-9179-de76706ed182"
      decimals="INF"
      id="F_03900b95-99e4-42ef-8b3c-46714c27381e"
      unitRef="U_shares">107648925</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_12eb10d1-8cbc-4e43-9179-de76706ed182"
      decimals="-3"
      id="F_9def42cf-431f-4f6a-ae16-582ca3b7f557"
      unitRef="U_USD">11000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_1364cd0a-2ace-4aed-b2bb-6a20b02ffe7e"
      decimals="-3"
      id="F_63b99d70-0cee-43e3-8b62-a0ad415c2d6f"
      unitRef="U_USD">793051000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_95d1c581-2af9-4924-b965-78baf570226f"
      decimals="-3"
      id="F_9e2a484f-9452-4dd0-8083-54e33797c2e9"
      unitRef="U_USD">-601000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_d3f945e7-1296-4c70-9ecd-08b3a017a4df"
      decimals="-3"
      id="F_cc838735-7e4a-495b-b821-05ec2fa6c771"
      unitRef="U_USD">-368519000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_ce64793d-668a-40e8-af07-6ebdbdd93828"
      decimals="-3"
      id="F_f96226a6-ddf6-4d15-9dd2-012d667c689c"
      unitRef="U_USD">423942000</us-gaap:StockholdersEquity>
    <vir:ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital
      contextRef="C_39cb96e3-900d-40c8-b3e6-6c07096acd7e"
      decimals="-3"
      id="F_ee534d95-739b-4a63-9218-defb98ffbbae"
      unitRef="U_USD">29245000</vir:ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital>
    <vir:ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_b19979c7-3a5c-4ad9-b7ac-6f8e95a7d840"
      unitRef="U_USD">29245000</vir:ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital>
    <vir:StockIssuedDuringPeriodSharesAchievementOfMilestone
      contextRef="C_ad4974d2-db54-4104-9b56-2ebf05ffda38"
      decimals="INF"
      id="F_30023f63-d884-4c36-899d-5b8b98b4996c"
      unitRef="U_shares">1111111</vir:StockIssuedDuringPeriodSharesAchievementOfMilestone>
    <vir:StockIssuedDuringPeriodSharesCollaborationAgreement
      contextRef="C_ad4974d2-db54-4104-9b56-2ebf05ffda38"
      decimals="INF"
      id="F_7bbde8fe-091e-47eb-8c74-4a2047c63390"
      unitRef="U_shares">6626027</vir:StockIssuedDuringPeriodSharesCollaborationAgreement>
    <vir:StockIssuedDuringPeriodValueCollaborationAgreement
      contextRef="C_ad4974d2-db54-4104-9b56-2ebf05ffda38"
      decimals="-3"
      id="F_18ee2aab-b4ac-43ea-9c6c-8a6810f5df94"
      unitRef="U_USD">1000</vir:StockIssuedDuringPeriodValueCollaborationAgreement>
    <vir:StockIssuedDuringPeriodValueCollaborationAgreement
      contextRef="C_39cb96e3-900d-40c8-b3e6-6c07096acd7e"
      decimals="-3"
      id="F_465594d9-7737-4aaf-a3a4-9db796c756b3"
      unitRef="U_USD">206698000</vir:StockIssuedDuringPeriodValueCollaborationAgreement>
    <vir:StockIssuedDuringPeriodValueCollaborationAgreement
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_4eb735da-4f19-48c1-9417-82354a57e9da"
      unitRef="U_USD">206699000</vir:StockIssuedDuringPeriodValueCollaborationAgreement>
    <vir:StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant
      contextRef="C_ad4974d2-db54-4104-9b56-2ebf05ffda38"
      decimals="INF"
      id="F_5744d8df-04b1-44b6-9527-97f8963addb6"
      unitRef="U_shares">211774</vir:StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant>
    <vir:CommonStockIssuanceCost
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_8d0a08c0-4543-4677-ac40-eb128b880365"
      unitRef="U_USD">21786000</vir:CommonStockIssuanceCost>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_fec42e81-f129-4752-ad8b-0294488d4ba3"
      decimals="INF"
      id="F_a1c14c34-91e6-4b38-a5d2-fdd0fd5bbd0b"
      unitRef="U_shares">8214285</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_fec42e81-f129-4752-ad8b-0294488d4ba3"
      decimals="-3"
      id="F_a895774e-2893-41d5-86a3-4e78e12928c8"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0dde6c02-78fb-47ad-a243-45289278021b"
      decimals="-3"
      id="F_5cf35633-5301-48f5-990f-d25bfd2ebe55"
      unitRef="U_USD">323213000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_11547210-5792-4373-8331-09ec3e1bee3d"
      unitRef="U_USD">323214000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_ad4974d2-db54-4104-9b56-2ebf05ffda38"
      decimals="INF"
      id="F_8e7acab2-7534-42de-a171-ef57f0a14966"
      unitRef="U_shares">1986250</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_39cb96e3-900d-40c8-b3e6-6c07096acd7e"
      decimals="-3"
      id="F_dec48ed9-5072-4d2f-be1b-8c8cca3ceea9"
      unitRef="U_USD">1435000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_718edb14-33ab-4206-9f50-bba03148e3b8"
      unitRef="U_USD">1435000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_ad4974d2-db54-4104-9b56-2ebf05ffda38"
      decimals="INF"
      id="F_ec880663-6089-4b0c-9b2c-eaf3b30a3fae"
      unitRef="U_shares">1618368</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_39cb96e3-900d-40c8-b3e6-6c07096acd7e"
      decimals="-3"
      id="F_b012decb-5d8b-4f38-bf71-f8e2633dea8e"
      unitRef="U_USD">4059000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_24b1145f-9607-4335-9451-4c9e4b7ff7dc"
      unitRef="U_USD">4059000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_39cb96e3-900d-40c8-b3e6-6c07096acd7e"
      decimals="-3"
      id="F_788314e6-119b-4375-bf1b-1a5429ca0e99"
      unitRef="U_USD">27600000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_e4bddd58-9875-4b8e-84ec-a322a743db6c"
      unitRef="U_USD">27600000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_ab38e818-8e19-4d32-855b-4a5d8c7332dc"
      decimals="-3"
      id="F_3f3ec6db-4893-462e-bbf2-ca099215516c"
      unitRef="U_USD">-677000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_5770dfcd-2352-49d9-b386-0a28a346a157"
      unitRef="U_USD">-677000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="C_a3f62ca6-5d34-48b4-8e19-7e9bd3f388e8"
      decimals="-3"
      id="F_868b9186-0651-4ccc-88d8-f6ccb1f4e9d3"
      unitRef="U_USD">-298665000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_b9514ec1-9d43-4315-a919-764206040ea9"
      unitRef="U_USD">-298665000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_ad4141b8-b5e4-429b-9b52-dd67e708016e"
      decimals="INF"
      id="F_51b68fd5-7ade-461a-846c-99f2a12353df"
      unitRef="U_shares">127416740</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_ad4141b8-b5e4-429b-9b52-dd67e708016e"
      decimals="-3"
      id="F_568463dc-76c0-4560-a75d-6bca8fd85f3c"
      unitRef="U_USD">13000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_017385f6-1d68-484c-9c95-8c9c74dccda7"
      decimals="-3"
      id="F_e02bde4a-e980-4b92-8a5b-efb2a8d505ea"
      unitRef="U_USD">1385301000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_00a912ce-4cfe-416b-b075-dffc321d18b6"
      decimals="-3"
      id="F_e361dd88-30d3-4f73-a2d2-beabf9af46a6"
      unitRef="U_USD">-1278000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_c23e0019-4bdf-4a39-9f66-f78f5b7cf6ba"
      decimals="-3"
      id="F_748ddab3-c36d-44ce-a8a3-62b2733940cd"
      unitRef="U_USD">-667184000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_da5feba6-e631-4bec-b33d-106ac3401870"
      decimals="-3"
      id="F_1f3346f8-6d1e-4284-b66b-ad8e2c79a567"
      unitRef="U_USD">716852000</us-gaap:StockholdersEquity>
    <vir:StockIssuedDuringPeriodSharesCollaborationAgreement
      contextRef="C_e43e7416-30c1-47c2-8d8f-9a8fa8761fb6"
      decimals="INF"
      id="F_5e2e903f-f537-49ce-b818-989c440e6c86"
      unitRef="U_shares">1924927</vir:StockIssuedDuringPeriodSharesCollaborationAgreement>
    <vir:StockIssuedDuringPeriodValueCollaborationAgreement
      contextRef="C_48f14b99-b9bb-45aa-acd6-6b16710aedb4"
      decimals="-3"
      id="F_43883ffc-20f6-40a4-a5b2-5a4bb54bb8ff"
      unitRef="U_USD">85213000</vir:StockIssuedDuringPeriodValueCollaborationAgreement>
    <vir:StockIssuedDuringPeriodValueCollaborationAgreement
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_aca1c45a-dee7-4d4b-ae58-44f692e29140"
      unitRef="U_USD">85213000</vir:StockIssuedDuringPeriodValueCollaborationAgreement>
    <vir:StockIssuedDuringPeriodSharesIssuedForSettlementOfContingentConsideration
      contextRef="C_e43e7416-30c1-47c2-8d8f-9a8fa8761fb6"
      decimals="INF"
      id="F_b3346c6e-f63f-42a1-be18-305f57a552fc"
      unitRef="U_shares">42737</vir:StockIssuedDuringPeriodSharesIssuedForSettlementOfContingentConsideration>
    <vir:StockIssuedDuringPeriodValueIssuedForSettlementOfContingentConsideration
      contextRef="C_48f14b99-b9bb-45aa-acd6-6b16710aedb4"
      decimals="-3"
      id="F_f2a811de-43ea-4aa5-a60d-c81e3db58ec6"
      unitRef="U_USD">1860000</vir:StockIssuedDuringPeriodValueIssuedForSettlementOfContingentConsideration>
    <vir:StockIssuedDuringPeriodValueIssuedForSettlementOfContingentConsideration
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_fae955da-84ba-4d14-b6f0-5c9c626b5846"
      unitRef="U_USD">1860000</vir:StockIssuedDuringPeriodValueIssuedForSettlementOfContingentConsideration>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_e43e7416-30c1-47c2-8d8f-9a8fa8761fb6"
      decimals="INF"
      id="F_1118b52f-d1a4-4fd2-ac54-eb8a5a28172a"
      unitRef="U_shares">89261</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_e43e7416-30c1-47c2-8d8f-9a8fa8761fb6"
      decimals="INF"
      id="F_a6198736-c974-4e07-8590-72c3107c4ec2"
      unitRef="U_shares">1622718</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_48f14b99-b9bb-45aa-acd6-6b16710aedb4"
      decimals="-3"
      id="F_a7635e0f-8870-400b-af5a-bf1ba30a2f7f"
      unitRef="U_USD">13077000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_7d526f2c-72b8-4cc7-8f60-25db7845278d"
      unitRef="U_USD">13077000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_e43e7416-30c1-47c2-8d8f-9a8fa8761fb6"
      decimals="INF"
      id="F_1efb2d50-39f4-4742-bde1-3175ed41f708"
      unitRef="U_shares">65021</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_48f14b99-b9bb-45aa-acd6-6b16710aedb4"
      decimals="-3"
      id="F_82e9a676-6837-4698-92dd-6482270a90de"
      unitRef="U_USD">2300000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_dca9b266-23b4-4951-a3f5-5b62cb3543fa"
      unitRef="U_USD">2300000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_48f14b99-b9bb-45aa-acd6-6b16710aedb4"
      decimals="-3"
      id="F_ec37f9ad-c376-45ab-a0bc-cf8a32a0b8ad"
      unitRef="U_USD">83784000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_5cfe309f-98ad-4b5a-9108-3be6d9abfc4d"
      unitRef="U_USD">83784000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_cbf68543-981c-4f0c-a438-703247341f08"
      decimals="-3"
      id="F_b1914697-1ed5-45c6-aa38-66559fac87c4"
      unitRef="U_USD">179000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_714db82d-cb22-49ba-a3fa-a20dd82c3c61"
      unitRef="U_USD">179000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="C_94daadad-3dc0-454a-8e31-99a471e99b3d"
      decimals="-3"
      id="F_4809cd26-daab-448b-ba9c-b64786aafba6"
      unitRef="U_USD">528584000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_ce6614dd-46e2-443c-8ff3-d4c158317f7e"
      unitRef="U_USD">528584000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_43f8e518-6996-4956-b1a9-bf1a73666d0b"
      decimals="INF"
      id="F_adbe163b-c4ec-4a70-b54b-679ce5318e6e"
      unitRef="U_shares">131161404</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_43f8e518-6996-4956-b1a9-bf1a73666d0b"
      decimals="-3"
      id="F_63b2ff58-026d-450d-8f70-0816833d3ffa"
      unitRef="U_USD">13000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_80319ba1-d62f-4b44-b5e2-f5e9eb0ceb54"
      decimals="-3"
      id="F_b8c4fe70-3eab-450c-8b15-f90fdd208fc3"
      unitRef="U_USD">1571535000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_76ae8c43-fd41-420f-aeae-ad3941b0fec6"
      decimals="-3"
      id="F_56c8034b-9c3c-4020-920e-a4a15d6eb49c"
      unitRef="U_USD">-1099000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_c7b72547-d6ee-4bc9-986d-72368f004917"
      decimals="-3"
      id="F_d977fd77-3b50-4602-9c5c-c5841110fe54"
      unitRef="U_USD">-138600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_064a58c1-702a-4a24-bda7-4a3ed5e022be"
      unitRef="U_USD">1431849000</us-gaap:StockholdersEquity>
    <vir:IssuanceOfCommonStockInConnectionWithAGrantAgreementShares
      contextRef="C_aa13a910-3dc3-4d53-a119-271c45df3af6"
      decimals="INF"
      id="F_3665c726-613e-4195-a1b2-bec874526fbb"
      unitRef="U_shares">881365</vir:IssuanceOfCommonStockInConnectionWithAGrantAgreementShares>
    <vir:ProceedsFromIssuanceOfCommonStockInConnectionWithAGrantAgreement
      contextRef="C_d7a958db-9d20-44ef-a677-68d2c31b101f"
      decimals="-3"
      id="F_12eb5651-ca85-445f-aad3-7d02b3c8693d"
      unitRef="U_USD">28462000</vir:ProceedsFromIssuanceOfCommonStockInConnectionWithAGrantAgreement>
    <vir:ProceedsFromIssuanceOfCommonStockInConnectionWithAGrantAgreement
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_5ac69f8f-e9d6-4b76-ae1c-5407e86b5e2e"
      unitRef="U_USD">28462000</vir:ProceedsFromIssuanceOfCommonStockInConnectionWithAGrantAgreement>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_aa13a910-3dc3-4d53-a119-271c45df3af6"
      decimals="INF"
      id="F_d344499c-4f11-4866-b756-fa314128e43c"
      unitRef="U_shares">349496</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_aa13a910-3dc3-4d53-a119-271c45df3af6"
      decimals="INF"
      id="F_99dd1ffd-26d1-4e39-ae66-3a6afd4a436c"
      unitRef="U_shares">696963</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_d7a958db-9d20-44ef-a677-68d2c31b101f"
      decimals="-3"
      id="F_cb4b4a55-0926-4183-914a-9ce6ecc920e5"
      unitRef="U_USD">4534000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_c9d75942-038c-47ec-a121-c26441dd5989"
      unitRef="U_USD">4534000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_aa13a910-3dc3-4d53-a119-271c45df3af6"
      decimals="0"
      id="F_4aca7d91-70a5-4fb4-8694-dee929beff36"
      unitRef="U_shares">147459</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_d7a958db-9d20-44ef-a677-68d2c31b101f"
      decimals="-3"
      id="F_0532266d-b113-46b3-9b6c-a5bf50cd8e71"
      unitRef="U_USD">3222000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_3f4f54f5-ae00-4e3c-a955-9ec11246e665"
      unitRef="U_USD">3222000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_d7a958db-9d20-44ef-a677-68d2c31b101f"
      decimals="-3"
      id="F_6892b171-ee1f-4626-bb7f-7b2b6fa558bd"
      unitRef="U_USD">102082000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_874f0563-3e11-4cc3-bcff-aa57cd50cc89"
      unitRef="U_USD">102082000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_29901d1b-12a7-4289-b365-64d76b343767"
      decimals="-3"
      id="F_da22b4a9-3eaf-43b7-9a43-09e34063215b"
      unitRef="U_USD">-8023000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_aa0a2be0-d4e0-492e-9491-a1d9485b071d"
      unitRef="U_USD">-8023000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="C_64b0a6fe-b0bf-4dcf-a49e-f88368c52dbd"
      decimals="-3"
      id="F_30f798d6-aa6f-44b3-8347-f5495b2f5356"
      unitRef="U_USD">515837000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_bf757149-d3ac-45b9-8b71-7abee319d332"
      unitRef="U_USD">515837000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_04175337-eb05-48c1-8aac-bc7c29d50097"
      decimals="INF"
      id="F_0c0c0eac-5b64-47bf-9bc6-6f8064201742"
      unitRef="U_shares">133236687</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_04175337-eb05-48c1-8aac-bc7c29d50097"
      decimals="-3"
      id="F_cdcd8624-5565-4f1f-828e-a6f4f7335ed0"
      unitRef="U_USD">13000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_b6e56cad-2ca6-48f8-b21a-16161998bf9e"
      decimals="-3"
      id="F_067368af-ea5f-4a09-b375-9edc6d687c0a"
      unitRef="U_USD">1709835000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_bd901335-c247-4a9a-ba1a-0d36065664ba"
      decimals="-3"
      id="F_f08153b0-d48d-4ddb-8e5a-a31b6cee1281"
      unitRef="U_USD">-9122000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_c5b01808-0860-4e26-906c-c9aecfd158e9"
      decimals="-3"
      id="F_378066c6-3fa9-4d76-b5d8-e57733e0dc20"
      unitRef="U_USD">377237000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_28ea7534-7113-4ee4-a17e-01c1ad15f6fc"
      unitRef="U_USD">2077963000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_2c97b812-85d7-4127-917a-bc53c69ad40d"
      unitRef="U_USD">515837000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_529773e6-2356-45c0-bcde-275e71a67d49"
      unitRef="U_USD">528584000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_a98b5b13-ce0d-4280-a5a6-d97f311d3a62"
      unitRef="U_USD">-298665000</us-gaap:ProfitLoss>
    <vir:ChangesInEstimatedConstraintOnProfitSharingAmount
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_1208a242-e4e9-4ea6-8628-650c5497ad91"
      unitRef="U_USD">369535000</vir:ChangesInEstimatedConstraintOnProfitSharingAmount>
    <vir:ChangesInEstimatedConstraintOnProfitSharingAmount
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_70ecdba2-a986-4393-b39c-d493fc38ec58"
      unitRef="U_USD">0</vir:ChangesInEstimatedConstraintOnProfitSharingAmount>
    <vir:ChangesInEstimatedConstraintOnProfitSharingAmount
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_c3025564-2935-40b8-b599-bdd0ddfaaba9"
      unitRef="U_USD">0</vir:ChangesInEstimatedConstraintOnProfitSharingAmount>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_8dd6885a-04e0-4e64-86c4-2a203efdf811"
      unitRef="U_USD">6251000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_72e7de13-562c-4cc8-bdb2-bc0ac2cd73ab"
      unitRef="U_USD">5278000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_ae6b3333-f784-4c2d-a048-288a062d68a7"
      unitRef="U_USD">4400000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_615c2083-8c60-47ca-901b-ac51c6708845"
      unitRef="U_USD">532000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_dcaf3125-f963-4029-bea0-a80b2215ed7f"
      unitRef="U_USD">533000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_78710f9a-0611-42c4-a325-e788ac3c8dd9"
      unitRef="U_USD">1042000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_664add06-d0f8-4b87-aa46-14535dbcf787"
      unitRef="U_USD">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_5f6157aa-1e5b-416d-a011-6ef54c3b893d"
      unitRef="U_USD">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_d46b32f0-96f0-40ef-a165-5ed44289a872"
      unitRef="U_USD">832000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_e9771179-6c35-4902-bb8b-8bd15f60624e"
      unitRef="U_USD">8943000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_0fb4de7d-bb7e-42dd-99e0-9c603a73859f"
      unitRef="U_USD">244000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_066486dd-4580-42d2-9199-cf92dc31d36d"
      unitRef="U_USD">-1548000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <vir:NoncashLeaseExpense
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_39dba800-e09b-4219-9d5f-f62a8a279fa1"
      unitRef="U_USD">8709000</vir:NoncashLeaseExpense>
    <vir:NoncashLeaseExpense
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_b06b0499-264d-4090-856f-a25fb9481a49"
      unitRef="U_USD">6172000</vir:NoncashLeaseExpense>
    <vir:NoncashLeaseExpense
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_dbb12aa4-3697-435e-86a1-7541f7ae6938"
      unitRef="U_USD">3371000</vir:NoncashLeaseExpense>
    <us-gaap:AssetsFairValueAdjustment
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_3f31b1a2-ad15-44cc-8094-5738ae0f6c8f"
      unitRef="U_USD">111140000</us-gaap:AssetsFairValueAdjustment>
    <us-gaap:AssetsFairValueAdjustment
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_9ba55365-d12e-43a0-b317-aa1b7974531a"
      unitRef="U_USD">-138049000</us-gaap:AssetsFairValueAdjustment>
    <us-gaap:AssetsFairValueAdjustment
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_035d8f44-50eb-4be3-83dc-bac1da1c218f"
      unitRef="U_USD">0</us-gaap:AssetsFairValueAdjustment>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_acb73974-66c2-4fdd-ab1e-41998eee56f6"
      unitRef="U_USD">2115000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_6d70c240-c9ab-4a2c-8362-82c54babce0d"
      unitRef="U_USD">91848000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_ed636deb-b5af-4de9-972f-36dbb850be50"
      unitRef="U_USD">38394000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <vir:IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_9666e325-bb65-48ca-9eb8-fb2323ada9f4"
      unitRef="U_USD">-93803000</vir:IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue>
    <vir:IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_df8606a1-62d1-441c-9135-bdd7e3058235"
      unitRef="U_USD">-8140000</vir:IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue>
    <vir:IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_73b8fc0d-3381-46b5-b335-126a412e2276"
      unitRef="U_USD">-15752000</vir:IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_0740b238-a2aa-4290-b9a3-e2b68fd5d1a1"
      unitRef="U_USD">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_77f83c7b-a7aa-40d5-9b4f-8c86267b7b88"
      unitRef="U_USD">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_5f45185e-287e-4943-b932-5dbe57236146"
      unitRef="U_USD">-16796000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:ShareBasedCompensation
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_8805848b-ef84-45cb-b3ee-a1836c391d14"
      unitRef="U_USD">102082000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_9be9307e-cf50-4d77-b4f9-073fa8024a5d"
      unitRef="U_USD">83784000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_33ac9efb-86cc-4558-9ca4-86b86ea68aef"
      unitRef="U_USD">27600000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_1f6d35fa-545e-4c9e-9655-d012741f9c79"
      unitRef="U_USD">15186000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_41313cb5-db3b-4349-b566-b474edc16ec5"
      unitRef="U_USD">-15186000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_564d27d1-bbd7-4965-b203-9143123e257f"
      unitRef="U_USD">52000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:GainLossOnTerminationOfLease
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_2a541dc2-99a0-47ef-87bf-d7997cde8497"
      unitRef="U_USD">0</us-gaap:GainLossOnTerminationOfLease>
    <us-gaap:GainLossOnTerminationOfLease
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_2aee0d35-2a22-41a1-a7dd-4aa60f36eefd"
      unitRef="U_USD">4844000</us-gaap:GainLossOnTerminationOfLease>
    <us-gaap:GainLossOnTerminationOfLease
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_103dc34d-4d87-4e3b-874f-2c2501bdf1af"
      unitRef="U_USD">0</us-gaap:GainLossOnTerminationOfLease>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_e0ed491b-8321-450e-8c5d-e2907e1f5199"
      unitRef="U_USD">-383000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_ab4cc893-d653-45c9-9ebd-108e07a909a2"
      unitRef="U_USD">697000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_f28b6ffa-2f61-4b8f-bd80-11a0ae548062"
      unitRef="U_USD">23000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_93155f8c-d08c-49c2-b18d-0f639c86d17e"
      unitRef="U_USD">-770038000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_876855bb-6cb0-4d46-a455-d58b9fc9c73c"
      unitRef="U_USD">773079000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_d9c7b5e4-0855-49c8-8348-cc88bd7dfcff"
      unitRef="U_USD">0</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_2c8259c6-8ec1-4a8d-b1df-cdbb936d90db"
      unitRef="U_USD">39358000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_533221cd-6982-48c2-b5ea-eccc28976886"
      unitRef="U_USD">3665000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_550a8592-8df1-4be5-ade2-26b5ee3d983e"
      unitRef="U_USD">4475000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_8b51ee57-48c5-42ea-9b50-b14b91e0e313"
      unitRef="U_USD">11795000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_aeb50ac7-0738-4b48-87d3-d5fb5aae1b44"
      unitRef="U_USD">1483000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_c334989b-75ff-4895-b8d9-8fe59a383ddb"
      unitRef="U_USD">1100000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_3e70791a-d8fb-4752-a1a0-67359d743948"
      unitRef="U_USD">797000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_6dfe4112-19db-498c-b2da-841d9c62ac1f"
      unitRef="U_USD">-171000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_0b66bf15-28c8-406d-be7a-045f38fca1ee"
      unitRef="U_USD">-790000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_bc78ce89-2b41-4c14-9f17-ad05fd7eb98c"
      unitRef="U_USD">-15513000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_555f6fca-983f-4078-b60c-305b2e048f25"
      unitRef="U_USD">58498000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_ea2ede0c-15e9-485b-a231-9e905e7ecad1"
      unitRef="U_USD">46614000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_acb8ad5e-6987-41fc-9df3-aa0d6f42ace7"
      unitRef="U_USD">-5502000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_63751004-2d74-47df-973f-728fec884978"
      unitRef="U_USD">-535000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_28c02ab7-9561-46a2-943a-7e19366e2f84"
      unitRef="U_USD">-3684000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_1e48a6e1-61bb-4233-90d7-151849f6981d"
      unitRef="U_USD">-33300000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_570e3471-53bf-4459-be98-df10492fad11"
      unitRef="U_USD">92041000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_576387bd-a212-4165-82f6-0555f14789c3"
      unitRef="U_USD">-7043000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_94bbe078-02b8-4a22-8d68-6b0680f23527"
      unitRef="U_USD">1663253000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_e2dcb264-2eea-492b-aac3-4163a626d523"
      unitRef="U_USD">-47589000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_b52148cb-7617-4473-9115-4be0446f5c9b"
      unitRef="U_USD">-190941000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleOfMachineryAndEquipment
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_24c2fda2-d1a1-450a-9c0d-33ce91aa8ea8"
      unitRef="U_USD">22000</us-gaap:ProceedsFromSaleOfMachineryAndEquipment>
    <us-gaap:ProceedsFromSaleOfMachineryAndEquipment
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_f740ad23-7db8-474d-a985-5354ffaf4ca0"
      unitRef="U_USD">0</us-gaap:ProceedsFromSaleOfMachineryAndEquipment>
    <us-gaap:ProceedsFromSaleOfMachineryAndEquipment
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_807acb5f-1e3e-4f07-a7b5-3a7d2af44ffa"
      unitRef="U_USD">0</us-gaap:ProceedsFromSaleOfMachineryAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_e1840f1b-69d3-481e-80ab-0cd797db262c"
      unitRef="U_USD">68028000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_a96acb63-c352-4530-8e90-d4c0b18f27da"
      unitRef="U_USD">21817000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_11aa0767-ff8b-4090-8a5b-3aaca04a921e"
      unitRef="U_USD">6549000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_d924c94c-aeb3-4e6e-8925-2142a40827bb"
      unitRef="U_USD">1476965000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_8d18ad03-1aed-4363-8936-84e8e9a01716"
      unitRef="U_USD">420240000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_7218d04e-84fe-4bcc-8792-a12f7f64e887"
      unitRef="U_USD">403841000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_ab382ea0-9d38-42c6-8ee4-24f8947d9bac"
      unitRef="U_USD">351510000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_8972c615-e0d6-4491-a020-25d379263061"
      unitRef="U_USD">301243000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_e2f80cbf-a7d5-442d-b6f2-899617c09a03"
      unitRef="U_USD">400348000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <vir:ProceedsFromDisposalOfAnEquipment
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_12766284-115c-4518-bd5f-6ae85d3047a6"
      unitRef="U_USD">0</vir:ProceedsFromDisposalOfAnEquipment>
    <vir:ProceedsFromDisposalOfAnEquipment
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_f94f135c-2820-4454-9a21-039686cc15dd"
      unitRef="U_USD">0</vir:ProceedsFromDisposalOfAnEquipment>
    <vir:ProceedsFromDisposalOfAnEquipment
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_d7c3a46d-8820-4306-986b-25f1bc80666d"
      unitRef="U_USD">180000</vir:ProceedsFromDisposalOfAnEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_6a9bbd02-cec3-4aa6-ae57-acbdb8f44fef"
      unitRef="U_USD">-1193461000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_11130b86-470d-4aaa-83a9-ecf3e91c06ef"
      unitRef="U_USD">-140814000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_e5b68fb7-41c6-4f42-bfb2-c964868ae9b9"
      unitRef="U_USD">-9862000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_6b1886cc-b64d-4542-882b-62320146f75b"
      unitRef="U_USD">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_c06e2c14-8237-48bf-b2d9-f486ab004c44"
      unitRef="U_USD">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_0d6c2f09-79d2-4e13-8b18-4a42558231dd"
      unitRef="U_USD">323214000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <vir:ProceedsFromIssuanceOfCommonStockInConnectionWithCollaboration
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_8ef15133-16f7-4221-87ca-32441008b367"
      unitRef="U_USD">0</vir:ProceedsFromIssuanceOfCommonStockInConnectionWithCollaboration>
    <vir:ProceedsFromIssuanceOfCommonStockInConnectionWithCollaboration
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_06850c5b-30b1-4230-8225-a65c1b6b8d16"
      unitRef="U_USD">85213000</vir:ProceedsFromIssuanceOfCommonStockInConnectionWithCollaboration>
    <vir:ProceedsFromIssuanceOfCommonStockInConnectionWithCollaboration
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_3d04067c-9157-41d0-9fed-6edd546fb586"
      unitRef="U_USD">206699000</vir:ProceedsFromIssuanceOfCommonStockInConnectionWithCollaboration>
    <vir:ProceedsFromIssuanceOfCommonStockInConnectionWithAGrantAgreement
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_d5c259e9-2bae-4c8d-9008-d222f659d0d2"
      unitRef="U_USD">28462000</vir:ProceedsFromIssuanceOfCommonStockInConnectionWithAGrantAgreement>
    <vir:ProceedsFromIssuanceOfCommonStockInConnectionWithAGrantAgreement
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_32c2a5f4-c588-40e5-a633-e334d9636062"
      unitRef="U_USD">0</vir:ProceedsFromIssuanceOfCommonStockInConnectionWithAGrantAgreement>
    <vir:ProceedsFromIssuanceOfCommonStockInConnectionWithAGrantAgreement
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_e915ad9f-6b92-4a1c-8987-61e6e76457d0"
      unitRef="U_USD">0</vir:ProceedsFromIssuanceOfCommonStockInConnectionWithAGrantAgreement>
    <vir:PaymentOfContingentConsideration
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_ef53cad0-23ba-4b5c-b1c1-9b2a6beed4e8"
      unitRef="U_USD">1197000</vir:PaymentOfContingentConsideration>
    <vir:PaymentOfContingentConsideration
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_e2df721b-c419-4d8e-8a56-f4d59809e95b"
      unitRef="U_USD">0</vir:PaymentOfContingentConsideration>
    <vir:PaymentOfContingentConsideration
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_7f39799e-114c-4575-ba3a-bbf31db20f47"
      unitRef="U_USD">4248000</vir:PaymentOfContingentConsideration>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_b18e5023-ec90-4d13-9829-0633b653246e"
      unitRef="U_USD">260000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_77a307e2-e0e5-4559-9e06-96339ab00a95"
      unitRef="U_USD">259000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_d1fff42b-b9e6-49b4-ba4b-b624f55959b2"
      unitRef="U_USD">250000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_27c2bb25-ad92-41de-a261-31c9ee98cebb"
      unitRef="U_USD">4534000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_b86e7ea5-3b2b-4183-9c60-8e979dc981c3"
      unitRef="U_USD">13077000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_3a091073-9326-4c86-b375-183c2c7e39d4"
      unitRef="U_USD">4059000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_b0c7444e-b2a1-4cdc-acf2-cdad0d25f814"
      unitRef="U_USD">3222000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_27aa0e3f-680f-44ba-a7a6-4f72b1aaaa20"
      unitRef="U_USD">2300000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_bdaabb5e-31f9-46a8-a68b-464e11ad8865"
      unitRef="U_USD">0</us-gaap:ProceedsFromStockPlans>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_3d21cb71-6308-423a-80fc-f5265d9e92a2"
      unitRef="U_USD">34761000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_81161ad6-0ee3-4db0-bac0-462f05b3e7bf"
      unitRef="U_USD">100331000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_0d405aaf-c816-49fd-ba4f-cb3120571bfe"
      unitRef="U_USD">529474000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_2f2451dd-c22e-46df-8bca-fba4e83d966f"
      unitRef="U_USD">504553000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_4db56b11-ffb5-46ab-b4d7-c9b31d838f8c"
      unitRef="U_USD">-88072000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_7944d5de-0db0-4021-8370-19145b627304"
      unitRef="U_USD">328671000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_7095a7a3-47e4-4793-85ab-2658950aff35"
      unitRef="U_USD">363415000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_da5feba6-e631-4bec-b33d-106ac3401870"
      decimals="-3"
      id="F_a6afacf2-108d-469c-9547-082dd538c7d6"
      unitRef="U_USD">451487000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_ce64793d-668a-40e8-af07-6ebdbdd93828"
      decimals="-3"
      id="F_76051d69-b2a7-4489-a4ce-e602242a64aa"
      unitRef="U_USD">122816000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_6053208c-8505-4d15-84b4-a870dedccd6f"
      unitRef="U_USD">867968000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_c9bc5c83-4b07-467d-bc8b-19e0d11e2969"
      unitRef="U_USD">363415000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_da5feba6-e631-4bec-b33d-106ac3401870"
      decimals="-3"
      id="F_a5ee7aa5-420f-479e-b359-eb80db145ef5"
      unitRef="U_USD">451487000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_eacbf29d-9fc5-459e-b466-d1d457c4997b"
      unitRef="U_USD">1020000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_df263720-b90a-40d4-b6e6-b9de8309f102"
      unitRef="U_USD">8731000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_c87f3352-9029-4549-a685-f68a69bf3b66"
      unitRef="U_USD">382000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <vir:NonCashCommonStockIssuedForContingentConsideration
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_4dd5b9a6-7f3d-4521-8be5-6b97084c9814"
      unitRef="U_USD">0</vir:NonCashCommonStockIssuedForContingentConsideration>
    <vir:NonCashCommonStockIssuedForContingentConsideration
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_e05dc186-1a6a-4888-b947-e760a81d7b5a"
      unitRef="U_USD">1860000</vir:NonCashCommonStockIssuedForContingentConsideration>
    <vir:NonCashCommonStockIssuedForContingentConsideration
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_bf9eb96c-1a60-499e-a53e-95681298a558"
      unitRef="U_USD">0</vir:NonCashCommonStockIssuedForContingentConsideration>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_a54069cc-304b-4437-b675-1c460485228a"
      unitRef="U_USD">4046000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_2f3102a9-d38f-4fdd-ab96-ef0cb50fcc4e"
      unitRef="U_USD">77187000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_014e1c57-740d-47ea-b5b3-2ebbf9fd89a3"
      unitRef="U_USD">48495000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <vir:ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_9591e2e8-39fe-4bd8-beb6-a09bb1bc0cd3"
      unitRef="U_USD">0</vir:ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone>
    <vir:ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_3537ea58-956f-46e6-8064-487683e21d9d"
      unitRef="U_USD">0</vir:ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone>
    <vir:ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_25f85e56-c9d3-48b6-98b1-d18e6c465136"
      unitRef="U_USD">29245000</vir:ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_1b550c30-e700-44f5-9882-24df3b183784"
      unitRef="U_USD">252030000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_01a6a8ea-2e36-4330-b041-f39325dec21a"
      unitRef="U_USD">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_38c339df-de52-4e2d-9ba8-ab284e296ff7"
      unitRef="U_USD">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_c337e470-2a60-4157-a863-c5202bfd5f81"
      unitRef="U_USD">848631000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_15194233-17f4-4696-96eb-c3de3edd33cf"
      unitRef="U_USD">347815000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_da5feba6-e631-4bec-b33d-106ac3401870"
      decimals="-3"
      id="F_2013809e-7530-4a09-97d7-367b80de8e4d"
      unitRef="U_USD">436575000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_e3f9ad77-c02d-4e50-b4b9-ffcc45a55c82"
      unitRef="U_USD">12681000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_9beae488-b661-44c0-b826-b2a377375f91"
      unitRef="U_USD">8594000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="C_da5feba6-e631-4bec-b33d-106ac3401870"
      decimals="-3"
      id="F_5611cb52-7c67-4797-9a6e-93b66b11a63e"
      unitRef="U_USD">7993000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_da65f71b-7988-43ce-a73d-be01170b147a"
      unitRef="U_USD">6656000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_d47f86d0-e81f-457b-84ad-65315be7d2f6"
      unitRef="U_USD">7006000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="C_da5feba6-e631-4bec-b33d-106ac3401870"
      decimals="-3"
      id="F_e7c7c86c-42f4-42e6-8863-8c06e5be5276"
      unitRef="U_USD">6919000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_175c52f6-78ba-47fd-a69f-3ae20b85688c"
      unitRef="U_USD">867968000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_92eb1f7c-cdaa-4a37-a9b7-c5807c158bea"
      unitRef="U_USD">363415000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_da5feba6-e631-4bec-b33d-106ac3401870"
      decimals="-3"
      id="F_e0d8fa97-e7db-44f5-9f40-51a395c66757"
      unitRef="U_USD">451487000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_302291a1-f1dc-4e7f-a6e0-3f2bda5e83c5">&lt;div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;1.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Organization &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Vir Biotechnology, Inc. (&#x201c;Vir&#x201d; or the &#x201c;Company&#x201d;) is a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Its current pipeline consists of sotrovimab (previously VIR-7831; and where marketing authorization has been granted, marketed under the brand name Xevudy&#xae;) and other product candidates targeting hepatitis B virus (&#x201c;HBV&#x201d;), hepatitis D virus (&#x201c;HDV&#x201d;), influenza A virus, coronavirus disease 2019 (&#x201c;COVID-19&#x201d;), and human immunodeficiency virus (&#x201c;HIV&#x201d;). Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In September 2022, the Company formed a new wholly-owned subsidiary in Switzerland, Vir Biotechnology International GmbH (&#x201c;VBI&#x201d;), a Swiss limited liability company. The primary purpose of VBI is to support Vir's research and development and international commercial activities outside of the United States.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Follow-On Offering&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On July 10, 2020, the Company issued and sold &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,214,285&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock pursuant to a registration statement on Form S-1 (File No. 333-239689) and a registration statement on Form S-1 filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;) (File No. 333-239747) (collectively, the &#x201c;Registration Statements&#x201d;). The Registration Statements became effective on July 7, 2020. The price of the shares sold in the follow-on offering was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;42.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share and the Company received total gross proceeds from the offering of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;345.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. After deducting underwriting discounts and commissions of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and offering expenses of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, the net proceeds were approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;323.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Sales Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In November 2020, the Company entered into a sales agreement (the &#x201c;Sales Agreement&#x201d;) with Cowen and Company, LLC (&#x201c;Cowen&#x201d;), under which the Company may from time to time offer and sell shares of its common stock for an aggregate offering price of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;300.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, through or to Cowen, acting as sales agent or principal. The shares will be offered and sold under the Company&#x2019;s shelf registration statement on Form S-3 and a related prospectus filed with the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) on November 10, 2020. The Company will pay Cowen a commission of up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the aggregate gross proceeds from each sale of shares, reimburse legal fees and disbursements and provide Cowen with customary indemnification and contribution rights. As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares have been issued under the Sales Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Need for Additional Capital&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Although the Company recorded net income for the years ended December 31, 2022 and 2021, respectively, it has otherwise incurred net losses since inception. The Company expects its earnings to be volatile and may continue to incur net losses over the next several years and may need to raise additional capital to fully implement its business plan. As of December 31, 2022, the Company had retained earnings of  &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;377.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The Company had &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; billion&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; in cash, cash equivalents, and investments as of December 31, 2022. Based on the Company&#x2019;s current operating plan, management believes that the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; billion&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; as of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; will be sufficient to fund its operations through at least the next 12 months from the issuance date of these consolidated financial statements.&lt;/span&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0b6e95b2-e943-40ea-ba4d-dbf4d337d81a"
      decimals="INF"
      id="F_78cba3f7-b5d4-4e4d-b502-ca609b80b11c"
      unitRef="U_shares">8214285</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_77979cee-0206-4722-a78e-8d7e1abeb723"
      decimals="INF"
      id="F_37667d3e-6a23-48c9-8ebb-a0d97e739b75"
      unitRef="U_USDollarShare">42.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0b6e95b2-e943-40ea-ba4d-dbf4d337d81a"
      decimals="-5"
      id="F_a4b8ebb9-fb44-47ee-86d8-53cfdc3964b6"
      unitRef="U_USD">345000000.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <vir:PaymentsOfUnderwritingDiscountsAndCommissions
      contextRef="C_0b6e95b2-e943-40ea-ba4d-dbf4d337d81a"
      decimals="-5"
      id="F_c62ea782-a202-4b37-b537-f3201afedc95"
      unitRef="U_USD">20700000</vir:PaymentsOfUnderwritingDiscountsAndCommissions>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_0b6e95b2-e943-40ea-ba4d-dbf4d337d81a"
      decimals="-5"
      id="F_fe7fd97a-d51f-4a6e-becd-83d1963be95f"
      unitRef="U_USD">1100000</us-gaap:PaymentsOfStockIssuanceCosts>
    <vir:NetProceedsFromIssuanceSecondaryPublicOffering
      contextRef="C_0b6e95b2-e943-40ea-ba4d-dbf4d337d81a"
      decimals="-5"
      id="F_40b5063b-719b-4a86-8894-5f3cab131d09"
      unitRef="U_USD">323200000</vir:NetProceedsFromIssuanceSecondaryPublicOffering>
    <vir:SaleOfStockConsiderationAggregateOfferingPrice
      contextRef="C_ca5589eb-ea15-4baa-83f9-5cfcb0672b1d"
      decimals="-5"
      id="F_96934ff6-7d09-487f-bebe-957d9c041d5d"
      unitRef="U_USD">300000000.0</vir:SaleOfStockConsiderationAggregateOfferingPrice>
    <vir:PercentageOfCommissionRateFromSaleOfShares
      contextRef="C_6e1a4a6c-604a-4324-a4ca-eb6aff2132cb"
      decimals="3"
      id="F_2199e1d7-8fbe-4ae4-add9-c7fa759c18f5"
      unitRef="U_pure">0.030</vir:PercentageOfCommissionRateFromSaleOfShares>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_1ff854d5-f188-44b8-94e4-70a3c2f65c1a"
      decimals="INF"
      id="F_3a8725d3-0877-480d-bf7e-8226a149618c"
      unitRef="U_shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-5"
      id="F_a57e5916-66a4-4b2a-a77c-c7b5a784a04e"
      unitRef="U_USD">377200000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-8"
      id="F_408ecd3a-48c9-479c-b779-2ab66bbbcf74"
      unitRef="U_USD">2400000000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <vir:CashCashEquivalentsAndShortTermInvestmentsExcludingEquityInvestment
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-8"
      id="F_46caf930-a3e6-4571-87be-0291effb12e2"
      unitRef="U_USD">2400000000</vir:CashCashEquivalentsAndShortTermInvestmentsExcludingEquityInvestment>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_a2cc2dcd-0e7b-4255-917f-040818c71bf0">&lt;div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;2.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Summary of Significant Accounting Policies &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) and include all adjustments necessary for the fair presentation of the Company&#x2019;s financial position for the periods presented. The consolidated financial statements include the accounts of Vir and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated upon consolidation.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Foreign Currency&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The functional currency of the Company&#x2019;s foreign subsidiaries is the U.S. dollar. Monetary assets and liabilities of foreign subsidiaries are translated into U.S. dollars at period-end exchange rates and non-monetary assets and liabilities are translated to U.S. dollars using historical exchange rates. Revenue and expenses are translated at average rates throughout the respective periods. Transaction gains and losses are included in other income (expense), net on the consolidated statements of operations.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting periods. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Segments&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company operates as &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; reportable segment. The Company&#x2019;s chief operating decision maker, its Chief Executive Officer, manages the Company&#x2019;s operations on a consolidated basis for purposes of allocating resources.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Concentration of Credit Risk, Credit Loss and Other Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Although the Company received Emergency Use Authorization (&#x201c;EUA&#x201d;), temporary authorization or marketing approval for sotrovimab (under the brand name Xevudy&#xae;), sotrovimab is currently de-authorized in the U.S. and has limitations in use outside of the U.S. In addition, the Company is still subject to a number of other challenges and risks similar to other biopharmaceutical companies in the early stage, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its other product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of sotrovimab and other product candidates and protection of proprietary technology. If the Company does not successfully obtain regulatory approval, commercialize or partner any of its product candidates, it will be unable to generate revenue from product sales or maintain profitability. In addition, to the extent the COVID-19 pandemic, including the emergence of new variants or subvariants, adversely affects the Company&#x2019;s business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties discussed above.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has implemented a number of plans and policies designed to address and mitigate the impact of the COVID-19 pandemic on its business. The extent to which the changing COVID-19 landscape impacts the Company&#x2019;s business, clinical development and regulatory efforts, corporate development objectives and the value of and market for its common stock, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and investments. Cash and cash equivalents are deposited in checking and sweep accounts at a financial institution. Such deposits may, at times, exceed federally insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s investment policy limits investments to certain types of securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and investments, and issuers of the investments to the extent recorded on the consolidated balance sheets. As of December 31, 2022 and 2021, the Company has no off-balance sheet concentrations of credit risk.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company is exposed to credit losses primarily through receivables from customers and collaborators and through its available-for-sale debt securities. The Company&#x2019;s expected loss allowance methodology for the receivables is developed using historical collection experience, current and future economic market conditions, a review of the current aging status and financial condition of the entities. Specific allowance amounts are established to record the appropriate allowance for customers that have a higher probability of default. Balances are written off when determined to be uncollectible. The Company&#x2019;s expected loss allowance methodology for the debt securities is developed by reviewing the extent of the unrealized loss, the size, term, geographical location, and industry of the issuer, the issuers&#x2019; credit ratings and any changes in those ratings, as well as reviewing current and future economic market conditions and the issuers&#x2019; current status and financial condition. The Company considered the current and expected future economic and market conditions surrounding the COVID-19 pandemic and interest rate policies and determined that the estimate of credit losses was not significantly impacted. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;There was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; allowance for losses on available-for-sale debt securities attributable to credit risk for the years ended December 31, 2022 and 2021.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Cash Equivalents&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents, which consist of amounts invested in money market funds, and are stated at fair value.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Investments&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Investments include available-for-sale debt securities and equity investments, which are carried at estimated fair value.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Available-for-Sale Debt Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s valuations of marketable securities are generally derived from independent pricing services based on quoted prices in active markets for similar securities at period end. Generally, investments with original maturities beyond three months at the date of purchase and which mature at, or less than 12 months from, the consolidated balance sheet date are considered short-term investments, with all others considered to be long-term investments. Unrealized gains and losses deemed temporary in nature are reported as a component of accumulated comprehensive income (loss). The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income on the consolidated statements of operations. The cost of securities sold is based on the specific identification method.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Equity Investments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company measures its investment in equity securities at fair value at each reporting date based on the market price at period end if it has a readily determinable fair value. Otherwise, the investments in equity securities are measured at cost less impairment, adjusted for observable price changes for identical or similar investments of the same issuer unless the Company has significant influence or control over the investee. Changes in fair value resulting from observable price changes are presented as change in fair value of equity investments and changes in fair value resulting from foreign currency translation are included in other income (expense), net &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;on the consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Restricted Cash and Cash Equivalents&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted cash and cash equivalents represent money market funds to secure standby letters of credit and security deposits with financial institutions, both under office and laboratory space lease agreements. Additionally, funds received from certain grants are restricted as to their use and are therefore classified as restricted cash and cash equivalents.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment are stated at cost, net of accumulated depreciation and amortization. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the respective assets, generally &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_8818a887-324c-4500-a98b-191605dee51d;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; Leasehold &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;improvements are amortized over the lesser of their useful lives or the remaining life of the lease. When assets are retired or&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;otherwise &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;disposed of, the cost and related accumulated depreciation and amortization are removed from the balance sheet and the resulting gain or loss is reflected in operations in the period realized. Maintenance and repairs are charged to operations as incurred.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparing the carrying amount to the future net undiscounted cash flows which the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows arising from the asset. No material impairment losses have been incurred to date.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Acquired Intangible Assets&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s intangible assets were acquired via business combinations or asset acquisitions. Indefinite-lived intangible assets represent the estimated fair value assigned to in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;) acquired in a business combination. The Company reviews indefinite-lived intangible assets for impairment at least annually or more frequently if events or changes in circumstances indicate that the carrying value of the assets might not be recoverable. If the carrying value of an indefinite-lived intangible asset exceeds its fair value, then it is written down to its adjusted fair value. As of December 31, 2022, there have been &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; such impairments. For IPR&amp;amp;D, if a product candidate derived from the indefinite-lived intangible asset is developed and commercialized, the useful life will be determined, and the carrying value will be amortized prospectively over that estimated useful life. Alternatively, if a product candidate is abandoned, the carrying value of the intangible asset will be charged to research and development expenses. IPR&amp;amp;D assets acquired as part of an asset acquisition are recorded at cost and expensed immediately if they have no alternative future uses.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Finite-lived intangible assets acquired are initially recognized at their fair value at the acquisition date. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortization is computed using the straight-line method over the estimated useful lives of the respective finite-lived intangible assets, generally &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_e5972bc8-c341-44f2-a1e7-401190923bbf;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;seven&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15 years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; Finite-lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Goodwill&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Goodwill represents the excess of the purchase price over the estimated fair value of the net tangible and intangible assets acquired in a business combination. The Company tests goodwill for impairment at least annually or more frequently if events or changes in circumstances indicate that this asset may be impaired.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Revenue Recognition&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Collaboration, License and Contract Revenue&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Under Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;), the Company recognizes revenue when the Company&#x2019;s customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods and services. To determine revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when or as the Company satisfies a performance obligation.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For collaborative arrangements that fall within the scope of ASC 808, Collaborative Arrangements (&#x201c;ASC 808&#x201d;), the Company first determines which elements of the collaboration are deemed to be a performance obligation with a customer within the scope of ASC 606. For elements of collaboration arrangements that are accounted for pursuant to ASC 808 and are not subject to the guidance in ASC 606, the Company applies the revenue recognition model under ASC 606, including the royalty exception guidance and variable consideration guidance under ASC 606 as described below, or other guidance, as deemed appropriate. When the Company is considered an agent in elements of collaboration arrangements within the scope of ASC 808, it records its share of collaboration revenue in the period in which such sales occur. The Company is considered an agent when the collaboration partner controls the product before transfer to the customers and has the ability to direct the use of and obtain substantially all of the remaining benefits from the product. In these instances, collaboration revenue is based upon the net sales reported by the Company's collaboration partners, net of cost of goods sold and allowable expenses (e.g., manufacturing, distribution, medical affairs, selling, and marketing expenses) in the period. In order to record collaboration revenue, the Company utilizes certain information from its collaboration partner, including actual net product sales, and costs incurred for sales activities, and makes key judgments based on business updates related to commercial and clinical activities such as expected commercial demand, commercial supply plan, manufacturing commitments, risks related to expired or obsolete inventories, and risks related to potential product returns or contract terminations. The Company uses these estimates to determine whether payments due to us under our collaboration arrangements, such as profit-share payments, should be recognized as revenues in the period that they become due or whether any portion of the payments due should be constrained from revenue recognition because it is not probable that recognizing such amounts would not result in a material reversal of revenues in future reporting periods.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has entered into a number of license and collaboration agreements that fall within the scope of ASC 606. The Company evaluates the promised goods or services in these agreements to determine which ones represent distinct performance obligations. These agreements may include the following types of promised goods or services: (i) grants of licenses, (ii) performance of research and development services, and (iii) participation on joint research and/or development committees. They also may include options to obtain licenses to the Company&#x2019;s intellectual property.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Prior to recognizing revenue, the Company makes estimates of the transaction price, including variable consideration that is subject to a constraint. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur and when the uncertainty associated with the variable consideration is subsequently resolved. These estimates are re-assessed each reporting period as required. These agreements may include the following types of consideration: non-refundable upfront payments, reimbursement for research services, research, development or regulatory milestone payments, profit-sharing arrangements, and royalty and commercial sales milestone payments.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;If there are multiple distinct performance obligations, the Company allocates the transaction price to each distinct performance obligation based on their estimated standalone selling prices (&#x201c;SSP&#x201d;). The Company estimates the SSP for each distinct performance obligation by considering information such as market conditions, entity-specific factors, and information about its customer that is reasonably available. The Company considers estimation approaches that allow it to maximize the use of observable inputs. These estimation approaches may include the adjusted market assessment approach, the expected cost plus a margin approach or the residual approach. The Company also considers whether to use a different estimation approach or a combination of approaches to estimate the SSP for each distinct performance obligation. Developing certain assumptions (e.g., treatable patient population, expected market share, probability of success and product profitability, discount rate based on weighted-average cost of capital) to estimate the SSP of a distinct performance obligation requires significant judgment.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For performance obligations satisfied over time, the Company estimates the efforts needed to complete the performance obligation and recognizes revenue by measuring the progress towards complete satisfaction of the performance obligation using an input measure.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For arrangements that include sales-based royalties, including commercial milestone payments based on pre-specified level of sales, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Achievement of these royalties and commercial milestones may solely depend upon the performance of the licensee.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Grant Revenue&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Grants received, including cost reimbursement agreements, are assessed to determine if the agreement should be accounted for as an exchange transaction or a contribution. An agreement is accounted for as a contribution if the resource provider does not receive commensurate value in return for the assets transferred. Contributions are recognized as grant revenue when all donor-imposed conditions have been met.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Research and Development Expenses&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;To date, research and development expenses have related primarily to discovery efforts and preclinical and clinical development of product candidates. Research and development expenses are recognized as incurred and payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received. Research and development expenses include expenses related to license and collaboration agreements; contingent consideration from business acquisitions; personnel-related expenses, including salaries, benefits, and stock-based compensation for personnel contributing to research and development activities; expenses incurred under agreements with third-party contract manufacturing organizations, contract research organizations, and consultants; clinical costs, including laboratory supplies and costs related to compliance with regulatory requirements; and other allocated expenses, including expenses for rent, facilities maintenance, and depreciation and amortization.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has acquired and may continue to acquire the rights to develop and commercialize new product candidates from third parties. Upfront payments and research and development milestone payments made in connection with acquired license or product rights are expensed as incurred, provided that they do not relate to a regulatory approval milestone or assets acquired in a business combination.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s expense accruals for clinical trials and manufacturing are based on estimates of contracted services provided by third-party vendors not yet billed. When billing terms under these contracts do not coincide with the timing of when the work is performed, the Company is required to make estimates of its outstanding obligations to those third parties as of the period end. The accrual estimates are based on a number of factors, including the Company&#x2019;s knowledge of the research and development programs and clinical manufacturing activities, the status of the programs and activities, invoicing to date, and the provisions in the contracts. The Company obtains information regarding unbilled services directly from these service providers and performs procedures to support its estimates based on its internal understanding of the services provided to date. However, the Company may also be required to estimate these services based on information available to its internal clinical and manufacturing administrative staff if such information is not able to be obtained timely from its service providers.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Stock-based Compensation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recognizes stock-based compensation to employees over the requisite service period based on the grant-date fair value of the awards. The Company calculates the estimated fair value of stock options and employees' purchase rights under the Company's 2019 employee stock purchase plan ("ESPP") using the Black-Scholes valuation model, which requires the use of subjective assumptions including volatility and expected term, among others. The fair value of restricted stock awards ("RSAs") and restricted stock units ("RSUs") is based on the market value of the Company's common stock on the date of grant. Stock-based compensation is recognized using the straight-line method for awards that vest only upon the employee&#x2019;s or non-employee&#x2019;s continued service to the Company. Stock-based compensation expense of the employees' purchase rights under the ESPP is recognized over the offering period. Forfeitures are recognized as they occur.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Acquisitions&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Business combinations are accounted for using the acquisition method of accounting. Under the acquisition method, assets acquired, including IPR&amp;amp;D projects, and liabilities assumed are recorded at their respective fair values as of the acquisition date. Any excess fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill. Contingent consideration obligations incurred in connection with the business combination are recorded at their fair values on the acquisition date, are remeasured each subsequent reporting period until the related contingencies are resolved and are classified as contingent consideration on the consolidated balance sheets. The changes in fair values of contingent consideration related to the achievement of various milestones are recorded within research and development expenses or selling, general and administrative expenses based on the nature of the relevant underlying activities.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;    &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;When the Company determines that an entity acquired does not meet the definition of a business, the transaction is accounted for as an acquisition of assets. Therefore, the consideration paid to acquire IPR&amp;amp;D is expensed, and no goodwill is recorded. Any contingent consideration is generally recognized only when it becomes payable or is paid.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Embedded Derivatives&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company evaluates its acquisitions, collaborative arrangements and other business development transactions to determine if embedded components of these contracts meet the definition of a derivative under ASC 815, Derivatives and Hedging. In general, embedded derivatives are required to be bifurcated from the host instrument if (i) the embedded feature is not clearly and closely related to the host contract and (ii) the embedded feature, if considered a freestanding instrument, meets the definition of a derivative. Embedded derivatives are reported on the consolidated balance sheets at their estimated fair values. Contingent consideration related to asset acquisitions that meet the definition of an embedded derivative is classified as contingent consideration on the consolidated balance sheets. Any change in estimated fair values, as determined at each measurement period, are recorded in the consolidated statements of operations based on the nature of the related contingencies.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Changes in fair values of embedded derivatives related to the achievement of various milestones for product candidates are recorded within research and development expenses or selling, general and administrative expenses based on the nature of the relevant underlying activities&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Otherwise, changes in fair values are recorded within other income (expense), net.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In accordance with ASC 842, Leases, the Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use ("ROU") assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. ROU assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable. On the lease commencement date, the Company estimates and includes in its lease payments any lease incentive amounts based on future events when (1) the events are within the Company&#x2019;s control and (2) the event triggering the right to receive the incentive is deemed reasonably certain to occur. If the lease incentive received is greater or less than the amount recognized at lease commencement, the Company recognizes the difference as an adjustment to right-of-use asset and/or lease liability, as applicable.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As the implicit rate in the Company's leases is generally unknown, the Company uses an incremental borrowing rate estimated based on the information available at the lease commencement date in determining the present value of future lease payments. When calculating its estimated incremental borrowing rates, the Company considers its credit risk, the lease term, the total lease payments and the impact of collateral, as necessary. The lease terms may include options to extend or terminate the lease when the Company is reasonably certain it will exercise such options. ROU assets and lease liabilities are remeasured upon certain modifications to leases using the present value of remaining lease payments and estimated incremental borrowing rate upon lease modification. Rent expense for the Company's operating leases is recognized on a straight-line basis within operating expenses over the reasonably assured lease term.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company elected to not separate lease and non-lease components for any leases within its existing classes of assets and, as a result, accounts for the lease and non-lease components as a single lease component. The Company also elected to not apply the recognition requirement to any leases within its existing classes of assets with a term of 12 months or less.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company uses the asset and liability method of accounting for income taxes. Current income tax expense or benefit represents the amount of income taxes expected to be payable or refundable for the current year. Deferred income tax assets and liabilities are determined based on differences between the financial statement reporting and tax bases of assets and liabilities and net operating losses and credit carryforwards and are measured using the enacted tax rates and laws that will be in effect when such items are expected to reverse. Deferred income tax assets are reduced, as necessary, by a valuation allowance when management determines it is more likely than not that some or all of the tax benefits will not be realized.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s tax positions are subject to income tax audits. The Company recognizes the tax benefit of an uncertain tax position only if it is more likely than not that the position is sustainable upon examination by the taxing authority, based on the technical merits. The tax benefit recognized is measured as the largest amount of benefit which is more likely than not to be realized upon settlement with the taxing authority. The Company evaluates uncertain tax positions on a regular basis. The evaluations are based on several factors, including changes in facts and circumstances, changes in tax law, correspondence with tax authorities during the course of the audit, and effective settlement of audit issues. The provision for income taxes includes the effects of any accruals that the Company believes are appropriate, as well as any related net interest and penalties.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Net Income (Loss) Per Share&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Basic net income (loss) per common share is computed by dividing the net income (loss) by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net income per common share is computed by dividing the net income by the sum of the weighted average number of common shares outstanding during the period plus any potential dilutive effects of common stock equivalents outstanding during the period calculated in accordance with the treasury stock method.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;New Accounting Pronouncement Recently Adopted&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In November 2021, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standard Update (&#x201c;ASU&#x201d;) No. 2021-10, Government Assistance (Topic 832) (&#x201c;ASU 2021-10&#x201d;), which adds certain disclosure requirements with respect to government assistance, including (1) the types of assistance, (2) an entity&#x2019;s accounting for the assistance, and (3) the effect of the assistance on financial statements. ASU 2021-10 is effective for annual periods beginning after December 15, 2021. The Company's adoption of ASU 2021-10 on January 1, 2022 did not result in any material impact on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_23ab19d6-5a56-49bc-862e-2377d4ed386c">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) and include all adjustments necessary for the fair presentation of the Company&#x2019;s financial position for the periods presented. The consolidated financial statements include the accounts of Vir and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated upon consolidation.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_a0a168ce-cadd-4cd5-badb-408e9ca99865">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Foreign Currency&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The functional currency of the Company&#x2019;s foreign subsidiaries is the U.S. dollar. Monetary assets and liabilities of foreign subsidiaries are translated into U.S. dollars at period-end exchange rates and non-monetary assets and liabilities are translated to U.S. dollars using historical exchange rates. Revenue and expenses are translated at average rates throughout the respective periods. Transaction gains and losses are included in other income (expense), net on the consolidated statements of operations.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_c3e17c86-479b-4f60-aef7-7169965e7771">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting periods. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_b649fea9-b638-4aef-b0f6-9927f2a356e3">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Segments&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company operates as &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; reportable segment. The Company&#x2019;s chief operating decision maker, its Chief Executive Officer, manages the Company&#x2019;s operations on a consolidated basis for purposes of allocating resources.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="INF"
      id="F_ad3c06a8-6b9e-490d-9a7e-756b7c856e8f"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <vir:ConcentrationOfCreditRiskCreditLossAndOtherRisksAndUncertaintiesPolicyTextBlock
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_277f5497-d034-44d8-8d7e-52ccf383482e">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Concentration of Credit Risk, Credit Loss and Other Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Although the Company received Emergency Use Authorization (&#x201c;EUA&#x201d;), temporary authorization or marketing approval for sotrovimab (under the brand name Xevudy&#xae;), sotrovimab is currently de-authorized in the U.S. and has limitations in use outside of the U.S. In addition, the Company is still subject to a number of other challenges and risks similar to other biopharmaceutical companies in the early stage, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its other product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of sotrovimab and other product candidates and protection of proprietary technology. If the Company does not successfully obtain regulatory approval, commercialize or partner any of its product candidates, it will be unable to generate revenue from product sales or maintain profitability. In addition, to the extent the COVID-19 pandemic, including the emergence of new variants or subvariants, adversely affects the Company&#x2019;s business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties discussed above.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has implemented a number of plans and policies designed to address and mitigate the impact of the COVID-19 pandemic on its business. The extent to which the changing COVID-19 landscape impacts the Company&#x2019;s business, clinical development and regulatory efforts, corporate development objectives and the value of and market for its common stock, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and investments. Cash and cash equivalents are deposited in checking and sweep accounts at a financial institution. Such deposits may, at times, exceed federally insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s investment policy limits investments to certain types of securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and investments, and issuers of the investments to the extent recorded on the consolidated balance sheets. As of December 31, 2022 and 2021, the Company has no off-balance sheet concentrations of credit risk.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company is exposed to credit losses primarily through receivables from customers and collaborators and through its available-for-sale debt securities. The Company&#x2019;s expected loss allowance methodology for the receivables is developed using historical collection experience, current and future economic market conditions, a review of the current aging status and financial condition of the entities. Specific allowance amounts are established to record the appropriate allowance for customers that have a higher probability of default. Balances are written off when determined to be uncollectible. The Company&#x2019;s expected loss allowance methodology for the debt securities is developed by reviewing the extent of the unrealized loss, the size, term, geographical location, and industry of the issuer, the issuers&#x2019; credit ratings and any changes in those ratings, as well as reviewing current and future economic market conditions and the issuers&#x2019; current status and financial condition. The Company considered the current and expected future economic and market conditions surrounding the COVID-19 pandemic and interest rate policies and determined that the estimate of credit losses was not significantly impacted. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;There was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; allowance for losses on available-for-sale debt securities attributable to credit risk for the years ended December 31, 2022 and 2021.&lt;/span&gt;&lt;/p&gt;</vir:ConcentrationOfCreditRiskCreditLossAndOtherRisksAndUncertaintiesPolicyTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_690089cc-ed61-43ec-80fb-786104c7c250"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_16aef68a-58fa-4254-88a3-f14c570dabac"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_a1ca5dc1-8662-4b09-88cc-32acc611d16a">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Cash Equivalents&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase to be cash equivalents, which consist of amounts invested in money market funds, and are stated at fair value.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_a62e240e-82a7-4d1d-b0a4-747ea65e6fed">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Investments&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Investments include available-for-sale debt securities and equity investments, which are carried at estimated fair value.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Available-for-Sale Debt Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s valuations of marketable securities are generally derived from independent pricing services based on quoted prices in active markets for similar securities at period end. Generally, investments with original maturities beyond three months at the date of purchase and which mature at, or less than 12 months from, the consolidated balance sheet date are considered short-term investments, with all others considered to be long-term investments. Unrealized gains and losses deemed temporary in nature are reported as a component of accumulated comprehensive income (loss). The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income on the consolidated statements of operations. The cost of securities sold is based on the specific identification method.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Equity Investments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company measures its investment in equity securities at fair value at each reporting date based on the market price at period end if it has a readily determinable fair value. Otherwise, the investments in equity securities are measured at cost less impairment, adjusted for observable price changes for identical or similar investments of the same issuer unless the Company has significant influence or control over the investee. Changes in fair value resulting from observable price changes are presented as change in fair value of equity investments and changes in fair value resulting from foreign currency translation are included in other income (expense), net &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;on the consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_26c73da0-cd8d-472a-818a-3f8656bfe25c">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Restricted Cash and Cash Equivalents&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted cash and cash equivalents represent money market funds to secure standby letters of credit and security deposits with financial institutions, both under office and laboratory space lease agreements. Additionally, funds received from certain grants are restricted as to their use and are therefore classified as restricted cash and cash equivalents.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_9737d065-8b93-4381-921e-aaaea04baee6">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment are stated at cost, net of accumulated depreciation and amortization. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the respective assets, generally &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_8818a887-324c-4500-a98b-191605dee51d;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; Leasehold &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;improvements are amortized over the lesser of their useful lives or the remaining life of the lease. When assets are retired or&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;otherwise &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;disposed of, the cost and related accumulated depreciation and amortization are removed from the balance sheet and the resulting gain or loss is reflected in operations in the period realized. Maintenance and repairs are charged to operations as incurred.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparing the carrying amount to the future net undiscounted cash flows which the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the projected discounted future net cash flows arising from the asset. No material impairment losses have been incurred to date.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_2e6192fe-62ae-4599-8f96-d2741f981f92">Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the respective assets, generally three to five years.</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_9a41c817-24ee-4d06-ab61-6c839a61c843"
      id="F_77c0b448-2e82-4303-884c-cea6999409f8">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_cf593d72-caeb-4d0a-91cf-15256a70b402">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Acquired Intangible Assets&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s intangible assets were acquired via business combinations or asset acquisitions. Indefinite-lived intangible assets represent the estimated fair value assigned to in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;) acquired in a business combination. The Company reviews indefinite-lived intangible assets for impairment at least annually or more frequently if events or changes in circumstances indicate that the carrying value of the assets might not be recoverable. If the carrying value of an indefinite-lived intangible asset exceeds its fair value, then it is written down to its adjusted fair value. As of December 31, 2022, there have been &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; such impairments. For IPR&amp;amp;D, if a product candidate derived from the indefinite-lived intangible asset is developed and commercialized, the useful life will be determined, and the carrying value will be amortized prospectively over that estimated useful life. Alternatively, if a product candidate is abandoned, the carrying value of the intangible asset will be charged to research and development expenses. IPR&amp;amp;D assets acquired as part of an asset acquisition are recorded at cost and expensed immediately if they have no alternative future uses.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Finite-lived intangible assets acquired are initially recognized at their fair value at the acquisition date. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortization is computed using the straight-line method over the estimated useful lives of the respective finite-lived intangible assets, generally &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_e5972bc8-c341-44f2-a1e7-401190923bbf;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;seven&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15 years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; Finite-lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="INF"
      id="F_00c50b82-ca10-4420-8ea4-403bcf9eb4d6"
      unitRef="U_USD">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationMethod
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_aec8171c-d9ae-4d0a-955f-f69693ced462">Amortization is computed using the straight-line method over the estimated useful lives of the respective finite-lived intangible assets, generally seven to 15 years.</us-gaap:FiniteLivedIntangibleAssetsAmortizationMethod>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_9a41c817-24ee-4d06-ab61-6c839a61c843"
      id="F_64757c04-4dc4-4747-9802-bd55552aebcb">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_6a079995-fe9d-4232-a80d-07f367b39eb5">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Goodwill&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Goodwill represents the excess of the purchase price over the estimated fair value of the net tangible and intangible assets acquired in a business combination. The Company tests goodwill for impairment at least annually or more frequently if events or changes in circumstances indicate that this asset may be impaired.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_6dd20547-eac6-4dd3-ab0f-7c1402f306a8">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Revenue Recognition&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Collaboration, License and Contract Revenue&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Under Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;), the Company recognizes revenue when the Company&#x2019;s customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods and services. To determine revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when or as the Company satisfies a performance obligation.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For collaborative arrangements that fall within the scope of ASC 808, Collaborative Arrangements (&#x201c;ASC 808&#x201d;), the Company first determines which elements of the collaboration are deemed to be a performance obligation with a customer within the scope of ASC 606. For elements of collaboration arrangements that are accounted for pursuant to ASC 808 and are not subject to the guidance in ASC 606, the Company applies the revenue recognition model under ASC 606, including the royalty exception guidance and variable consideration guidance under ASC 606 as described below, or other guidance, as deemed appropriate. When the Company is considered an agent in elements of collaboration arrangements within the scope of ASC 808, it records its share of collaboration revenue in the period in which such sales occur. The Company is considered an agent when the collaboration partner controls the product before transfer to the customers and has the ability to direct the use of and obtain substantially all of the remaining benefits from the product. In these instances, collaboration revenue is based upon the net sales reported by the Company's collaboration partners, net of cost of goods sold and allowable expenses (e.g., manufacturing, distribution, medical affairs, selling, and marketing expenses) in the period. In order to record collaboration revenue, the Company utilizes certain information from its collaboration partner, including actual net product sales, and costs incurred for sales activities, and makes key judgments based on business updates related to commercial and clinical activities such as expected commercial demand, commercial supply plan, manufacturing commitments, risks related to expired or obsolete inventories, and risks related to potential product returns or contract terminations. The Company uses these estimates to determine whether payments due to us under our collaboration arrangements, such as profit-share payments, should be recognized as revenues in the period that they become due or whether any portion of the payments due should be constrained from revenue recognition because it is not probable that recognizing such amounts would not result in a material reversal of revenues in future reporting periods.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has entered into a number of license and collaboration agreements that fall within the scope of ASC 606. The Company evaluates the promised goods or services in these agreements to determine which ones represent distinct performance obligations. These agreements may include the following types of promised goods or services: (i) grants of licenses, (ii) performance of research and development services, and (iii) participation on joint research and/or development committees. They also may include options to obtain licenses to the Company&#x2019;s intellectual property.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Prior to recognizing revenue, the Company makes estimates of the transaction price, including variable consideration that is subject to a constraint. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur and when the uncertainty associated with the variable consideration is subsequently resolved. These estimates are re-assessed each reporting period as required. These agreements may include the following types of consideration: non-refundable upfront payments, reimbursement for research services, research, development or regulatory milestone payments, profit-sharing arrangements, and royalty and commercial sales milestone payments.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;If there are multiple distinct performance obligations, the Company allocates the transaction price to each distinct performance obligation based on their estimated standalone selling prices (&#x201c;SSP&#x201d;). The Company estimates the SSP for each distinct performance obligation by considering information such as market conditions, entity-specific factors, and information about its customer that is reasonably available. The Company considers estimation approaches that allow it to maximize the use of observable inputs. These estimation approaches may include the adjusted market assessment approach, the expected cost plus a margin approach or the residual approach. The Company also considers whether to use a different estimation approach or a combination of approaches to estimate the SSP for each distinct performance obligation. Developing certain assumptions (e.g., treatable patient population, expected market share, probability of success and product profitability, discount rate based on weighted-average cost of capital) to estimate the SSP of a distinct performance obligation requires significant judgment.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For performance obligations satisfied over time, the Company estimates the efforts needed to complete the performance obligation and recognizes revenue by measuring the progress towards complete satisfaction of the performance obligation using an input measure.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For arrangements that include sales-based royalties, including commercial milestone payments based on pre-specified level of sales, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Achievement of these royalties and commercial milestones may solely depend upon the performance of the licensee.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Grant Revenue&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Grants received, including cost reimbursement agreements, are assessed to determine if the agreement should be accounted for as an exchange transaction or a contribution. An agreement is accounted for as a contribution if the resource provider does not receive commensurate value in return for the assets transferred. Contributions are recognized as grant revenue when all donor-imposed conditions have been met.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_26be7e5a-d7da-4520-8f8e-2f94f08a3b82">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Research and Development Expenses&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;To date, research and development expenses have related primarily to discovery efforts and preclinical and clinical development of product candidates. Research and development expenses are recognized as incurred and payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received. Research and development expenses include expenses related to license and collaboration agreements; contingent consideration from business acquisitions; personnel-related expenses, including salaries, benefits, and stock-based compensation for personnel contributing to research and development activities; expenses incurred under agreements with third-party contract manufacturing organizations, contract research organizations, and consultants; clinical costs, including laboratory supplies and costs related to compliance with regulatory requirements; and other allocated expenses, including expenses for rent, facilities maintenance, and depreciation and amortization.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has acquired and may continue to acquire the rights to develop and commercialize new product candidates from third parties. Upfront payments and research and development milestone payments made in connection with acquired license or product rights are expensed as incurred, provided that they do not relate to a regulatory approval milestone or assets acquired in a business combination.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s expense accruals for clinical trials and manufacturing are based on estimates of contracted services provided by third-party vendors not yet billed. When billing terms under these contracts do not coincide with the timing of when the work is performed, the Company is required to make estimates of its outstanding obligations to those third parties as of the period end. The accrual estimates are based on a number of factors, including the Company&#x2019;s knowledge of the research and development programs and clinical manufacturing activities, the status of the programs and activities, invoicing to date, and the provisions in the contracts. The Company obtains information regarding unbilled services directly from these service providers and performs procedures to support its estimates based on its internal understanding of the services provided to date. However, the Company may also be required to estimate these services based on information available to its internal clinical and manufacturing administrative staff if such information is not able to be obtained timely from its service providers.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_fe0977a1-d6c2-4043-b108-3758ddd09ca4">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Stock-based Compensation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recognizes stock-based compensation to employees over the requisite service period based on the grant-date fair value of the awards. The Company calculates the estimated fair value of stock options and employees' purchase rights under the Company's 2019 employee stock purchase plan ("ESPP") using the Black-Scholes valuation model, which requires the use of subjective assumptions including volatility and expected term, among others. The fair value of restricted stock awards ("RSAs") and restricted stock units ("RSUs") is based on the market value of the Company's common stock on the date of grant. Stock-based compensation is recognized using the straight-line method for awards that vest only upon the employee&#x2019;s or non-employee&#x2019;s continued service to the Company. Stock-based compensation expense of the employees' purchase rights under the ESPP is recognized over the offering period. Forfeitures are recognized as they occur.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_6047c522-677f-45c7-b16b-d6878586cf41">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Acquisitions&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Business combinations are accounted for using the acquisition method of accounting. Under the acquisition method, assets acquired, including IPR&amp;amp;D projects, and liabilities assumed are recorded at their respective fair values as of the acquisition date. Any excess fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill. Contingent consideration obligations incurred in connection with the business combination are recorded at their fair values on the acquisition date, are remeasured each subsequent reporting period until the related contingencies are resolved and are classified as contingent consideration on the consolidated balance sheets. The changes in fair values of contingent consideration related to the achievement of various milestones are recorded within research and development expenses or selling, general and administrative expenses based on the nature of the relevant underlying activities.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;    &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;When the Company determines that an entity acquired does not meet the definition of a business, the transaction is accounted for as an acquisition of assets. Therefore, the consideration paid to acquire IPR&amp;amp;D is expensed, and no goodwill is recorded. Any contingent consideration is generally recognized only when it becomes payable or is paid.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:DerivativesEmbeddedDerivatives
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_a3d93290-69d7-4fcc-8603-e768a1858798">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Embedded Derivatives&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company evaluates its acquisitions, collaborative arrangements and other business development transactions to determine if embedded components of these contracts meet the definition of a derivative under ASC 815, Derivatives and Hedging. In general, embedded derivatives are required to be bifurcated from the host instrument if (i) the embedded feature is not clearly and closely related to the host contract and (ii) the embedded feature, if considered a freestanding instrument, meets the definition of a derivative. Embedded derivatives are reported on the consolidated balance sheets at their estimated fair values. Contingent consideration related to asset acquisitions that meet the definition of an embedded derivative is classified as contingent consideration on the consolidated balance sheets. Any change in estimated fair values, as determined at each measurement period, are recorded in the consolidated statements of operations based on the nature of the related contingencies.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Changes in fair values of embedded derivatives related to the achievement of various milestones for product candidates are recorded within research and development expenses or selling, general and administrative expenses based on the nature of the relevant underlying activities&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Otherwise, changes in fair values are recorded within other income (expense), net.&lt;/span&gt;&lt;/p&gt;</us-gaap:DerivativesEmbeddedDerivatives>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_02ff588e-0acf-4c62-b2a2-0fa5cf812a03">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In accordance with ASC 842, Leases, the Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use ("ROU") assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. ROU assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable. On the lease commencement date, the Company estimates and includes in its lease payments any lease incentive amounts based on future events when (1) the events are within the Company&#x2019;s control and (2) the event triggering the right to receive the incentive is deemed reasonably certain to occur. If the lease incentive received is greater or less than the amount recognized at lease commencement, the Company recognizes the difference as an adjustment to right-of-use asset and/or lease liability, as applicable.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As the implicit rate in the Company's leases is generally unknown, the Company uses an incremental borrowing rate estimated based on the information available at the lease commencement date in determining the present value of future lease payments. When calculating its estimated incremental borrowing rates, the Company considers its credit risk, the lease term, the total lease payments and the impact of collateral, as necessary. The lease terms may include options to extend or terminate the lease when the Company is reasonably certain it will exercise such options. ROU assets and lease liabilities are remeasured upon certain modifications to leases using the present value of remaining lease payments and estimated incremental borrowing rate upon lease modification. Rent expense for the Company's operating leases is recognized on a straight-line basis within operating expenses over the reasonably assured lease term.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company elected to not separate lease and non-lease components for any leases within its existing classes of assets and, as a result, accounts for the lease and non-lease components as a single lease component. The Company also elected to not apply the recognition requirement to any leases within its existing classes of assets with a term of 12 months or less.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_292877a3-4cd7-4908-9fa7-ad79aaf0a9b4">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company uses the asset and liability method of accounting for income taxes. Current income tax expense or benefit represents the amount of income taxes expected to be payable or refundable for the current year. Deferred income tax assets and liabilities are determined based on differences between the financial statement reporting and tax bases of assets and liabilities and net operating losses and credit carryforwards and are measured using the enacted tax rates and laws that will be in effect when such items are expected to reverse. Deferred income tax assets are reduced, as necessary, by a valuation allowance when management determines it is more likely than not that some or all of the tax benefits will not be realized.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s tax positions are subject to income tax audits. The Company recognizes the tax benefit of an uncertain tax position only if it is more likely than not that the position is sustainable upon examination by the taxing authority, based on the technical merits. The tax benefit recognized is measured as the largest amount of benefit which is more likely than not to be realized upon settlement with the taxing authority. The Company evaluates uncertain tax positions on a regular basis. The evaluations are based on several factors, including changes in facts and circumstances, changes in tax law, correspondence with tax authorities during the course of the audit, and effective settlement of audit issues. The provision for income taxes includes the effects of any accruals that the Company believes are appropriate, as well as any related net interest and penalties.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Tax Cuts and Jobs Act of 2017 subjects a U.S. shareholder to current tax on global intangible low-taxed income ("GILTI") earned by certain foreign subsidiaries. The FASB &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Staff Q&amp;amp;A, Topic 740 No. 5, Accounting for Global Intangible Low-Taxed Income, states that an entity can make an accounting policy election to either recognize deferred taxes for temporary differences expected to reverse as GILTI in future years or provide for the tax expense related to GILTI in the year the tax is incurred. The Company has elected to recognize the tax on GILTI as a period expense in the period the tax is incurred.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_f80b8605-0c4e-4115-b39c-0506698aeeee">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Net Income (Loss) Per Share&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Basic net income (loss) per common share is computed by dividing the net income (loss) by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net income per common share is computed by dividing the net income by the sum of the weighted average number of common shares outstanding during the period plus any potential dilutive effects of common stock equivalents outstanding during the period calculated in accordance with the treasury stock method.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_e46bbdbe-e7b6-44f1-95f4-cf2a48131826">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;New Accounting Pronouncement Recently Adopted&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In November 2021, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standard Update (&#x201c;ASU&#x201d;) No. 2021-10, Government Assistance (Topic 832) (&#x201c;ASU 2021-10&#x201d;), which adds certain disclosure requirements with respect to government assistance, including (1) the types of assistance, (2) an entity&#x2019;s accounting for the assistance, and (3) the effect of the assistance on financial statements. ASU 2021-10 is effective for annual periods beginning after December 15, 2021. The Company's adoption of ASU 2021-10 on January 1, 2022 did not result in any material impact on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_d6dc3078-cc74-49b4-ba53-7ad4df10eb51">&lt;div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;3.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Fair Value Measurements &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company determines the fair value of financial assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value, as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 1: Inputs which include quoted prices in active markets for identical assets and liabilities. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.537%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The carrying amounts of the Company&#x2019;s financial instruments, including receivable from collaboration, accounts payable and accrued liabilities approximate fair value due to their relatively short maturities.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Cash Equivalents and Available-for-Sale Debt Securities&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following tables summarize the Company&#x2019;s Level 1 and Level 2 financial assets measured at fair value on a recurring basis by level within the fair value hierarchy:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:43.006%;"/&gt;
        &lt;td style="width:1.024%;"/&gt;
        &lt;td style="width:10.242%;"/&gt;
        &lt;td style="width:1.024%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.067%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.024%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:7.9%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.043%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:7.226999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.024%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.418%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Valuation&lt;br/&gt;Hierarchy&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Holding&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Holding&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;position:relative;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;909,342&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;909,342&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. government treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,493,841&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,396&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,485,445&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,403,183&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,396&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,394,787&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:80.0%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(1) &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Includes &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; of restricted cash equivalents.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:42.871%;"/&gt;
        &lt;td style="width:1.03%;"/&gt;
        &lt;td style="width:10.205%;"/&gt;
        &lt;td style="width:1.021%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.414%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.058%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:7.883%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.058%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.110000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.058%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.290000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Valuation&lt;br/&gt;Hierarchy&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Holding&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Holding&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;position:relative;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;345,098&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;345,098&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. government treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;419,442&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;872&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;418,570&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;764,540&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;872&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;763,668&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:80.0%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(1) &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Includes $&lt;/span&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of restricted cash equivalents.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued interest receivable excluded from both the fair value and amortized cost basis of the available-for-sale debt securities are presented within prepaid expenses and other current assets, and other assets in the consolidated balance sheets. Accrued interest receivable amounted to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million as of December 31, 2022 and 2021, respectively. The Company did &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;t write off any accrued interest receivable during the years ended December 30, 2022 and 2021.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recognized total net unrealized loss of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in accumulated other comprehensive income (loss) as of December 31, 2022 and 2021, respectively. The gross unrealized losses related to U.S. government treasuries as of December 31, 2022 and 2021 were due to changes in interest rates. As of December 31, 2022 and 2021, there were no investments that have been in a continuous unrealized loss position for longer than 12 months. The Company determined that the gross unrealized losses on our investments as of December 31, 2022 were temporary in nature. The Company currently does not intend, and it is highly unlikely that it will be required, to sell these securities before recovery of their amortized cost basis. As of December 31, 2022, no securities have contractual maturities of longer than&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; two years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Equity Investments&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022, the Company's equity investment consisted solely of ordinary shares of Brii Biosciences Limited (&#x201c;Brii Bio Parent&#x201d;). The Company acquired the securities as partial consideration for entering into the collaboration, option and license agreement (the &#x201c;Brii Agreement&#x201d;) with Brii Bio Parent and Brii Biosciences Offshore Limited (&#x201c;Brii Bio&#x201d;) in May 2018. The Company concluded it does not have a controlling interest or significant influence over Brii Bio based on its ownership percentage and other factors. See further discussion in Note 7&#x2014;Collaboration and License Agreements. In July 2021, Brii Bio Parent completed its initial public offering (&#x201c;Brii Bio Parent IPO&#x201d;) on the Stock Exchange of Hong Kong Limited, prior to which the securities were accounted for as equity securities without a readily determinable fair value. Upon the completion of the Brii Bio Parent IPO, the securities were considered to be marketable equity securities and subsequently remeasured at fair value at each reporting date. As of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company remeasured the equity investment at a fair value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;31.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. For the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, the Company recognized an unrealized loss of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;111.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million as other income in the consolidated statement of operations, net of an unrealized loss of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million related to foreign currency translation for the period. The Company classifies its equity investment in Brii Bio Parent as a Level 1 asset within the fair value hierarchy, as the value is based on a quoted market price in an active market.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Contingent Consideration&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Contingent consideration includes potential milestone payments in connection with the acquisitions of Humabs BioMed SA (&#x201c;Humabs&#x201d;) and TomegaVax, Inc. (&#x201c;TomegaVax&#x201d;). See further discussion in Note 4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Acquisitions. The Company classifies the contingent consideration as Level 3 financial liabilities within the fair value hierarchy as of December 31, 2022 and 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The estimated fair value of the contingent consideration related to the Humabs acquisition was determined by calculating the probability-weighted clinical, regulatory and commercial milestone payments based on the assessment of the likelihood and estimated timing that certain milestones would be achieved. &lt;/span&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of Decemb&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;er 31, 2022, the Company calculated the estimated fair value of the remaining clinical and regulatory milestones related to VIR-3434 using the following significant unobservable inputs: &lt;/span&gt;&lt;/span&gt;&lt;span style=""/&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.176%;"/&gt;
        &lt;td style="width:2.444%;"/&gt;
        &lt;td style="width:32.38%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unobservable input&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Range&lt;br/&gt;(Weighted-Average)1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Discount rates&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% (&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Probability of achievement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;60.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% (&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;43.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:80.0%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(1) &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unobservable inputs were weighted based on the relative fair value of the clinical and regulatory milestone payments.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;span style=""/&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For the commercial milestones, the Company used a Monte Carlo simulation because of the availability of discrete revenue forecasts. A&lt;/span&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;s of December 31, 2022, the Monte Carlo simulation assumed a commercial product launch and associated discrete revenue forecasts, as well as the following significant unobservable inputs f&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;or the remaining commercial milestones related to VIR-3434: &lt;/span&gt;&lt;/span&gt;&lt;span style=""/&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.176%;"/&gt;
        &lt;td style="width:2.444%;"/&gt;
        &lt;td style="width:32.38%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unobservable input&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;80.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Probability of achievement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The discount rate captures the credit risk associated with the payment of the contingent consideration when earned and due. As of December 31, 2022 and 2021, the estimated fair value of the contingent consideration related to the Humabs acquisition was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;23.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively, with changes in the estimated fair value recorded in research and development expenses, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;and selling, general and administrative expenses in the consolidated statements of operations based on the nature of the relevant underlying activities.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The estimated fair value of the contingent consideration related to the TomegaVax acquisition was determined by using a Monte Carlo simulation model which included estimates of both the probability and timing to achieve the required per-share price of the Company&#x2019;s common stock, and incorporates assumptions as to expected volatility and discount rate. The discount rate captures the credit risk associated with the payment of the contingent consideration when earned and due. Although the TomegaVax acquisition was accounted for as an asset acquisition, such contingent consideration met the definition of an embedded derivative financial instrument. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;February 2021, the Company achieved one of the milestones related to a specified per-share price of its common stock&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;resulting &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;in a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million payable to the former TomegaVax&#x2019;s stockholders which was paid in July 2021. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022, the fair value of the remaining contingent consideration was estimated using the following significant unobservable inputs:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.176%;"/&gt;
        &lt;td style="width:2.444%;"/&gt;
        &lt;td style="width:32.38%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unobservable input&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;90.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022 and 2021, the estimated fair value of the contingent consideration related to the TomegaVax acquisition was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively, with changes in the estimated fair value recorded in other income (expense), net in the consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The estimated fair value of the contingent consideration related to the Humabs and TomegaVax acquisitions involves significant estimates and assumptions which give rise to measurement uncertainty.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table sets forth the changes in the estimated fair value of the Company&#x2019;s contingent consideration (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.81%;"/&gt;
        &lt;td style="width:2.096%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.094%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Contingent&lt;br/&gt;Consideration&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22,822&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Changes in fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,115&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;24,937&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_ee044b5d-2ff3-40e7-a9a2-062e0242f938">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following tables summarize the Company&#x2019;s Level 1 and Level 2 financial assets measured at fair value on a recurring basis by level within the fair value hierarchy:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:43.006%;"/&gt;
        &lt;td style="width:1.024%;"/&gt;
        &lt;td style="width:10.242%;"/&gt;
        &lt;td style="width:1.024%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.067%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.024%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:7.9%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.043%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:7.226999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.024%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.418%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Valuation&lt;br/&gt;Hierarchy&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Holding&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Holding&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;position:relative;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;909,342&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;909,342&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. government treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,493,841&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,396&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,485,445&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,403,183&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,396&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,394,787&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:80.0%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(1) &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Includes &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; of restricted cash equivalents.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:42.871%;"/&gt;
        &lt;td style="width:1.03%;"/&gt;
        &lt;td style="width:10.205%;"/&gt;
        &lt;td style="width:1.021%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.414%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.058%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:7.883%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.058%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.110000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.058%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:8.290000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Valuation&lt;br/&gt;Hierarchy&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Holding&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Holding&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;position:relative;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;345,098&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;345,098&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. government treasuries&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;419,442&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;872&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;418,570&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;764,540&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;872&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;763,668&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:80.0%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(1) &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Includes $&lt;/span&gt;&lt;span style="font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of restricted cash equivalents.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <vir:FinancialAssetsAmortizedCostBasis
      contextRef="C_f1574fdc-3dbc-4686-99a7-37e3229c36eb"
      decimals="-3"
      id="F_95c3d196-361b-4bb9-bbfc-19a0145e77ff"
      unitRef="U_USD">909342000</vir:FinancialAssetsAmortizedCostBasis>
    <vir:FinancialAssetsGrossUnrealizedHoldingGains
      contextRef="C_f1574fdc-3dbc-4686-99a7-37e3229c36eb"
      decimals="-3"
      id="F_36b8b5e2-054e-47cc-b86d-523e8cbc6e77"
      unitRef="U_USD">0</vir:FinancialAssetsGrossUnrealizedHoldingGains>
    <vir:FinancialAssetsGrossUnrealizedHoldingLosses
      contextRef="C_f1574fdc-3dbc-4686-99a7-37e3229c36eb"
      decimals="-3"
      id="F_f2ee8c17-9247-4204-9405-460cc56f15e9"
      unitRef="U_USD">0</vir:FinancialAssetsGrossUnrealizedHoldingLosses>
    <vir:FinancialAssetsFairValue
      contextRef="C_f1574fdc-3dbc-4686-99a7-37e3229c36eb"
      decimals="-3"
      id="F_e67a3f38-3954-40a0-a395-2d43a7a52199"
      unitRef="U_USD">909342000</vir:FinancialAssetsFairValue>
    <vir:FinancialAssetsAmortizedCostBasis
      contextRef="C_cf8b6b9e-762d-454d-adc8-ca7fb3750e7b"
      decimals="-3"
      id="F_cbfb5b0e-8009-4674-9c4d-63931bf62d93"
      unitRef="U_USD">1493841000</vir:FinancialAssetsAmortizedCostBasis>
    <vir:FinancialAssetsGrossUnrealizedHoldingGains
      contextRef="C_cf8b6b9e-762d-454d-adc8-ca7fb3750e7b"
      decimals="-3"
      id="F_d4ab685d-3d1f-4d74-b54e-07d428fc0d97"
      unitRef="U_USD">0</vir:FinancialAssetsGrossUnrealizedHoldingGains>
    <vir:FinancialAssetsGrossUnrealizedHoldingLosses
      contextRef="C_cf8b6b9e-762d-454d-adc8-ca7fb3750e7b"
      decimals="-3"
      id="F_cc52a59f-ab97-489f-a2dc-bb47c1f5e526"
      unitRef="U_USD">8396000</vir:FinancialAssetsGrossUnrealizedHoldingLosses>
    <vir:FinancialAssetsFairValue
      contextRef="C_cf8b6b9e-762d-454d-adc8-ca7fb3750e7b"
      decimals="-3"
      id="F_5cb4ee98-5a46-4de3-83fe-5ae5ed996ff3"
      unitRef="U_USD">1485445000</vir:FinancialAssetsFairValue>
    <vir:FinancialAssetsAmortizedCostBasis
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_758f8a97-c01d-4d17-98fb-3f30dd973dc5"
      unitRef="U_USD">2403183000</vir:FinancialAssetsAmortizedCostBasis>
    <vir:FinancialAssetsGrossUnrealizedHoldingGains
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_25e84f0b-b2cd-4b95-bb11-8731c4e86f57"
      unitRef="U_USD">0</vir:FinancialAssetsGrossUnrealizedHoldingGains>
    <vir:FinancialAssetsGrossUnrealizedHoldingLosses
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_b4b9186d-a648-455a-bb38-08c802a4fe03"
      unitRef="U_USD">8396000</vir:FinancialAssetsGrossUnrealizedHoldingLosses>
    <vir:FinancialAssetsFairValue
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_8942699e-96ab-45d3-b201-247b6fbc516d"
      unitRef="U_USD">2394787000</vir:FinancialAssetsFairValue>
    <us-gaap:RestrictedCashEquivalents
      contextRef="C_f1574fdc-3dbc-4686-99a7-37e3229c36eb"
      decimals="-5"
      id="F_4d5c1eef-f0e1-4c47-b9a6-a8840e88c1ea"
      unitRef="U_USD">19300000</us-gaap:RestrictedCashEquivalents>
    <vir:FinancialAssetsAmortizedCostBasis
      contextRef="C_742108ce-79d0-443e-97ab-ce1b47aab7fb"
      decimals="-3"
      id="F_69ac5583-03ad-40a0-a1ae-3d91bf3c9102"
      unitRef="U_USD">345098000</vir:FinancialAssetsAmortizedCostBasis>
    <vir:FinancialAssetsGrossUnrealizedHoldingGains
      contextRef="C_742108ce-79d0-443e-97ab-ce1b47aab7fb"
      decimals="-3"
      id="F_549f2f58-0809-43a7-af9f-aa62d6cab632"
      unitRef="U_USD">0</vir:FinancialAssetsGrossUnrealizedHoldingGains>
    <vir:FinancialAssetsGrossUnrealizedHoldingLosses
      contextRef="C_742108ce-79d0-443e-97ab-ce1b47aab7fb"
      decimals="-3"
      id="F_c5e69a23-b98a-4558-b375-80f9e0916679"
      unitRef="U_USD">0</vir:FinancialAssetsGrossUnrealizedHoldingLosses>
    <vir:FinancialAssetsFairValue
      contextRef="C_742108ce-79d0-443e-97ab-ce1b47aab7fb"
      decimals="-3"
      id="F_e42ea656-1acd-403e-8417-882547909ce9"
      unitRef="U_USD">345098000</vir:FinancialAssetsFairValue>
    <vir:FinancialAssetsAmortizedCostBasis
      contextRef="C_e4ea1ea2-14fb-4c40-b6b7-6c502c2c3167"
      decimals="-3"
      id="F_5c3e9140-ffb1-4e87-9bce-31dce2d0ab2e"
      unitRef="U_USD">419442000</vir:FinancialAssetsAmortizedCostBasis>
    <vir:FinancialAssetsGrossUnrealizedHoldingGains
      contextRef="C_e4ea1ea2-14fb-4c40-b6b7-6c502c2c3167"
      decimals="-3"
      id="F_c257ff65-0870-4938-9a64-3f6f029c42da"
      unitRef="U_USD">0</vir:FinancialAssetsGrossUnrealizedHoldingGains>
    <vir:FinancialAssetsGrossUnrealizedHoldingLosses
      contextRef="C_e4ea1ea2-14fb-4c40-b6b7-6c502c2c3167"
      decimals="-3"
      id="F_d0a77136-f8f1-4d4c-ba05-8fa83aea7bba"
      unitRef="U_USD">872000</vir:FinancialAssetsGrossUnrealizedHoldingLosses>
    <vir:FinancialAssetsFairValue
      contextRef="C_e4ea1ea2-14fb-4c40-b6b7-6c502c2c3167"
      decimals="-3"
      id="F_083dd05f-fc86-45b5-9866-d91455172172"
      unitRef="U_USD">418570000</vir:FinancialAssetsFairValue>
    <vir:FinancialAssetsAmortizedCostBasis
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_435eb469-dd55-4186-9832-144dab9cdd98"
      unitRef="U_USD">764540000</vir:FinancialAssetsAmortizedCostBasis>
    <vir:FinancialAssetsGrossUnrealizedHoldingGains
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_2ebf7aea-c6ae-4216-a4b9-1a9acda8b9dc"
      unitRef="U_USD">0</vir:FinancialAssetsGrossUnrealizedHoldingGains>
    <vir:FinancialAssetsGrossUnrealizedHoldingLosses
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_8ad8202c-e7f8-443a-9082-c2b0ba02d601"
      unitRef="U_USD">872000</vir:FinancialAssetsGrossUnrealizedHoldingLosses>
    <vir:FinancialAssetsFairValue
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_c5e7aebe-6316-4680-9723-9b831fd79f44"
      unitRef="U_USD">763668000</vir:FinancialAssetsFairValue>
    <us-gaap:RestrictedCashEquivalents
      contextRef="C_742108ce-79d0-443e-97ab-ce1b47aab7fb"
      decimals="-5"
      id="F_11104768-92b5-4b62-af36-56bb4791b2e6"
      unitRef="U_USD">15600000</us-gaap:RestrictedCashEquivalents>
    <us-gaap:InterestReceivable
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-5"
      id="F_3f1623ea-2114-479f-be2e-4cc7c00528cf"
      unitRef="U_USD">2500000</us-gaap:InterestReceivable>
    <us-gaap:InterestReceivable
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-5"
      id="F_5110fc10-2548-444c-a97f-bdbec8473ab3"
      unitRef="U_USD">1100000</us-gaap:InterestReceivable>
    <us-gaap:FinancingReceivableAccruedInterestWriteoff
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="0"
      id="F_85db6fdf-d63d-45fc-9e68-1c2e614476f4"
      unitRef="U_USD">0</us-gaap:FinancingReceivableAccruedInterestWriteoff>
    <us-gaap:FinancingReceivableAccruedInterestWriteoff
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="0"
      id="F_9ba477cc-5577-4dc9-b881-90eac78ae240"
      unitRef="U_USD">0</us-gaap:FinancingReceivableAccruedInterestWriteoff>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-5"
      id="F_ac6d1894-77c8-4128-9eaf-23610c306fc5"
      unitRef="U_USD">8400000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-5"
      id="F_107ccf56-5459-4c64-b7b2-b806d9d638ba"
      unitRef="U_USD">900000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleTerm
      contextRef="C_268c2c6c-2e46-49ef-8b34-85c3eb6476c2"
      id="F_cf6ec027-605a-4379-b133-52e9f6ef338a">P2Y</us-gaap:DebtSecuritiesAvailableForSaleTerm>
    <us-gaap:InvestmentOwnedAtFairValue
      contextRef="C_d81100b1-9c19-43b5-a076-b271e6dffdee"
      decimals="-5"
      id="F_b39c7dc7-e05c-4752-9489-fedb548fa84c"
      unitRef="U_USD">31900000</us-gaap:InvestmentOwnedAtFairValue>
    <us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi
      contextRef="C_faecd853-fee9-460a-9e6f-a4fc83b058a2"
      decimals="-5"
      id="F_919c0ba5-c7cf-4203-8ffc-7218ef94a126"
      unitRef="U_USD">111100000</us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="C_faecd853-fee9-460a-9e6f-a4fc83b058a2"
      decimals="-5"
      id="F_cd765c4e-aee7-46e4-bac5-ac53a993754a"
      unitRef="U_USD">100000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="C_ea8871a7-9d90-4943-89b3-944727e32088"
      id="F_c232c74c-b075-42af-afdd-4f17cae26309">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of Decemb&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;er 31, 2022, the Company calculated the estimated fair value of the remaining clinical and regulatory milestones related to VIR-3434 using the following significant unobservable inputs: &lt;/span&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.176%;"/&gt;
        &lt;td style="width:2.444%;"/&gt;
        &lt;td style="width:32.38%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unobservable input&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Range&lt;br/&gt;(Weighted-Average)1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Discount rates&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% (&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Probability of achievement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;60.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% (&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;43.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:80.0%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(1) &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unobservable inputs were weighted based on the relative fair value of the clinical and regulatory milestone payments.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="C_f22a75a3-1d5c-4569-b00b-c460e4c440a5"
      decimals="3"
      id="F_badce134-8528-4753-8a8b-28ca3cf397fa"
      unitRef="U_pure">0.138</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="C_713f0ffb-32b7-4557-8121-be8edd691f8d"
      decimals="3"
      id="F_faed9603-c7e8-4971-b88c-45fb1a1abd5f"
      unitRef="U_pure">0.151</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="C_f315ae4d-c3f9-4374-877b-5e513e6b3e19"
      decimals="3"
      id="F_94b5821e-c6b0-49b4-bd92-b25178e3d93a"
      unitRef="U_pure">-0.145</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="C_ef41dda9-45c7-47f2-94ae-8f41c2af548c"
      decimals="3"
      id="F_de81d354-d0b9-4919-aaaf-c3852c79312a"
      unitRef="U_pure">0.144</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="C_e70b1c74-320f-4d6a-81ff-72022442374d"
      decimals="3"
      id="F_6ed74193-b982-4779-9300-7e451bc0ef5b"
      unitRef="U_pure">0.600</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="C_89ca23f5-e12c-4dba-be08-03251a397eda"
      decimals="3"
      id="F_24f706d2-1a5c-4606-a102-532a52e31e5b"
      unitRef="U_pure">-0.436</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="C_c00e1b15-1ac9-46ef-8ed8-c2ca882b705b"
      id="F_fdbcda46-22d8-4510-8430-20bd74b1fb46">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;s of December 31, 2022, the Monte Carlo simulation assumed a commercial product launch and associated discrete revenue forecasts, as well as the following significant unobservable inputs f&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;or the remaining commercial milestones related to VIR-3434: &lt;/span&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.176%;"/&gt;
        &lt;td style="width:2.444%;"/&gt;
        &lt;td style="width:32.38%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unobservable input&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;80.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Probability of achievement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="C_2b3229e8-bd98-49b7-9746-e7ce783e8031"
      decimals="3"
      id="F_d61311fe-620c-4cf4-a5fe-4802f9b8a5f8"
      unitRef="U_pure">0.800</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="C_dad50c1a-a985-4cd9-83d5-54c441a295ba"
      decimals="3"
      id="F_44cc508b-6b42-4adf-9ee1-5750021b76fb"
      unitRef="U_pure">0.120</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="C_ffa6727e-7fad-43e1-84bd-2106591a8a4a"
      decimals="3"
      id="F_84b2de71-2371-4b50-ba3a-1bd2c0e20ca4"
      unitRef="U_pure">0.259</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="C_e422f02f-6b34-4d0a-8361-270372955b88"
      decimals="-5"
      id="F_e7369fd8-7846-4f5a-8966-43ab9618438f"
      unitRef="U_USD">23400000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="C_ef53fffe-7284-4da2-ade0-6081e04aa2dd"
      decimals="-5"
      id="F_fc9e1cf3-1d7e-461b-8187-7b3c7444e215"
      unitRef="U_USD">17100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <vir:AssetAcquisitionMilestoneAchieved
      contextRef="C_fa700c83-f248-4007-a04a-6e5b18f6eef8"
      decimals="-5"
      id="F_b820c778-819b-4ca0-8520-31ac539346f9"
      unitRef="U_USD">10000000.0</vir:AssetAcquisitionMilestoneAchieved>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="C_236e9ea2-3639-4c4a-84d1-b0cbf28005ee"
      id="F_9c8c9048-6dcb-4904-bfa3-3c6f44e4ef5c">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022, the fair value of the remaining contingent consideration was estimated using the following significant unobservable inputs:&lt;/span&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.176%;"/&gt;
        &lt;td style="width:2.444%;"/&gt;
        &lt;td style="width:32.38%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unobservable input&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;90.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:EmbeddedDerivativeLiabilityMeasurementInput
      contextRef="C_1a446893-56a8-4407-9044-e0e0fd59cfee"
      decimals="3"
      id="F_f26d98e9-5316-4421-b846-54cc894c1188"
      unitRef="U_pure">0.900</us-gaap:EmbeddedDerivativeLiabilityMeasurementInput>
    <us-gaap:EmbeddedDerivativeLiabilityMeasurementInput
      contextRef="C_15a1a88f-77e5-43b6-91c1-62f17e7d6662"
      decimals="3"
      id="F_3281bdeb-c214-46f3-9c5b-cd7c4e6c4fea"
      unitRef="U_pure">0.044</us-gaap:EmbeddedDerivativeLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-5"
      id="F_3f4b7ac9-aade-41d0-823b-381922fd68fe"
      unitRef="U_USD">1500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-5"
      id="F_415345cf-682b-4089-9ec6-a9208ab2e6a1"
      unitRef="U_USD">5700000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_8957bd33-fdec-4746-b2d4-54dd8ff581aa">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table sets forth the changes in the estimated fair value of the Company&#x2019;s contingent consideration (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.81%;"/&gt;
        &lt;td style="width:2.096%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.094%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Contingent&lt;br/&gt;Consideration&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22,822&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Changes in fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,115&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;24,937&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_a17e8413-fa17-4363-9bcc-2c63c792146e"
      decimals="-3"
      id="F_59bb4c1d-b9d3-442c-9678-16a9fd89ef5e"
      unitRef="U_USD">22822000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="C_85d8bb4b-5225-414c-87d0-df7003801fcd"
      decimals="-3"
      id="F_b4ca3507-da4f-4227-91af-e4b0b2383067"
      unitRef="U_USD">2115000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_6046760e-44a7-4084-a7d2-ce57ecf671fd"
      decimals="-3"
      id="F_23e14ad3-3dc4-4922-befa-05f3cef3f28e"
      unitRef="U_USD">24937000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_1eeae131-6917-4c01-9ca1-0cfe0910ca23">&lt;div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;4.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Acquisitions &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Acquisition of TomegaVax&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In September 2016, the Company entered into an agreement and plan of merger (&#x201c;TomegaVax Merger Agreement&#x201d;) to acquire all of the equity interests of TomegaVax. The primary asset purchased in the acquisition was an in-process cytomegalovirus (&#x201c;CMV&#x201d;) vector-based vaccine platform for use in HBV, HIV, and tuberculosis. The acquisition was accounted for as an asset purchase.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In connection with the entry into the TomegaVax Merger Agreement, the Company also entered into a letter agreement with TomegaVax (the &#x201c;TomegaVax Letter Agreement&#x201d;), which provides for certain payments to TomegaVax&#x2019;s former stockholders before September 2024, in each case so long as the Company is continuing to pursue the development of the TomegaVax technology. Under the terms of the TomegaVax Letter Agreement, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;the Company will be required to pay to the former stockholders of TomegaVax milestone payments of up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million if the per-share price of the Company&#x2019;s publicly traded common stock, or implied price per share of the Company&#x2019;s Series A-1 convertible preferred stock (or common stock upon conversion) upon a certain asset sale, merger or stock sale, is at least $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;45&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; (as adjusted in the case of any stock dividend, stock split or other similar recapitalization), with the amount of such payments determined by the share price and/or the stage of the Company&#x2019;s clinical development at the time of the relevant event triggering the payment.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; The share price of the Company&#x2019;s publicly traded common stock will be determined using the average of the daily volume-weighted average trading price of the Company&#x2019;s common stock for each trading day during a consecutive 90-day period. The foregoing payments are payable (i) during any date after the completion of an initial public offering by the Company or any successor or affiliate controlling the TomegaVax technology, provided that no payment will be due before the first anniversary of the initial public offering, (ii) upon the sale of all assets related to the TomegaVax technology or (iii) upon a merger or stock sale of the Company or any successor or affiliate controlling the TomegaVax technology, in each case subject to certain conditions with respect to the timing of the payments. The payments under the TomegaVax Letter Agreement can be made in cash or shares of the Company&#x2019;s common stock, at the discretion of the Company&#x2019;s board of directors.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In February 2021, the Company achieved &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; of the milestones related to the specified per-share price of its common stock, which resulted in a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million payable to TomegaVax&#x2019;s former stockholders. In July 2021, the Company made the milestone payment to the former TomegaVax stockholders through a combination of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in cash and the issuance of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;42,737&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of common stock with a total fair value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. The remaining milestone payments of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in the aggregate will be triggered if (i) the per-share price of the Company&#x2019;s publicly traded common stock is at least $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;45&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; (as adjusted in the case of any stock dividend, stock split or other similar recapitalization) and upon the achievement of a certain milestone related to the stage of the Company&#x2019;s clinical development at the time of the relevant event triggering the payment and/or (ii) the per-share price of the Company&#x2019;s publicly traded common stock is at least $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;90&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; (as adjusted in the case of any stock dividend, stock split or other similar recapitalization).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company determined that the future milestone payments contain net settlement provisions and, therefore, they were required to be accounted for as embedded derivatives under the relevant accounting guidance. As of December 31, 2022, the estimated fair value of the embedded derivative was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and was included in the contingent consideration liability on the consolidated balance sheet.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Acquisition of Humabs&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In August 2017, the Company acquired all of the outstanding equity of Humabs, a private Swiss company, which discovers and develops monoclonal antibodies (&#x201c;mAbs&#x201d;) derived from individuals whose immune systems have successfully responded to major diseases. The Company acquired all of Humabs&#x2019; rights, title and interest in and to substantially all of the assets of Humabs except for rights under certain license agreements with third parties. The Company is obligated to pass through to the former Humabs shareholders any amounts received by Humabs under such license agreements, net of any program expenses. The transaction was accounted for as an acquisition of a business. In addition to the cash payment and issuance of common stock to the former Humabs shareholders at the acquisition date, the Company also agreed to pay additional amounts in cash upon the achievement of specified milestone events: (i) up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;135.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million upon the achievement of clinical, regulatory and commercial milestones for VIR-3434; and (ii) up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;105.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million upon the achievement of clinical, regulatory and commercial milestones for another product, which the Company elected as sotrovimab, a severe acute respiratory syndrome coronavirus 2 (&#x201c;SARS-CoV-2&#x201d;) product.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;During the year ended December 31, 2020, the Company achieved &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; of the specified clinical milestones for the HBV product and sotrovimab totaling $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;During the year ended December 31, 2021, the Company achieved the specified regulatory milestone of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;35.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and sales milestones totaling $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;60.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million related to sotrovimab, which were paid&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; in January and February 2022, respectively. The estimated fair value of the remaining contingent consideration was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;23.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million as of December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The acquired developed technologies that have associated patents issued are classified as finite-lived intangible assets and are amortized on a straight-lined basis over their estimated remaining useful lives, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;generally between &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_42ecc27d-dd4e-4bd9-a1b3-ab9d1b0e44c1;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;seven&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12 years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The Company also acquired indefinite-lived intangible assets consisting of IPR&amp;amp;D. These assets will not be amortized until regulatory approval is obtained in a major market. At that time, the Company will determine the useful life of the asset and begin amortization. If the associated research and development effort is abandoned or otherwise impaired, the related IPR&amp;amp;D assets will be written-off and an impairment charge will be recorded. As of December 31, 2022, there have been &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; such impairments related to the IPR&amp;amp;D assets. The estimated fair value of the intangible assets was determined using the replacement cost method. The excess of the purchase price over the estimated fair value of the net assets acquired was recorded as goodwill. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;None&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; of the goodwill is expected to be deductible for income tax purposes.&lt;/span&gt;&lt;/p&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <vir:MilestonePaymentsRelatedTermsDescription
      contextRef="C_ef2dbdd6-6a22-4314-8ad2-3d3b510a7b9a"
      id="F_d04284ff-1f37-4d10-910e-39b77453730a">the Company will be required to pay to the former stockholders of TomegaVax milestone payments of up to an aggregate of $30.0 million if the per-share price of the Company&#x2019;s publicly traded common stock, or implied price per share of the Company&#x2019;s Series A-1 convertible preferred stock (or common stock upon conversion) upon a certain asset sale, merger or stock sale, is at least $45 (as adjusted in the case of any stock dividend, stock split or other similar recapitalization), with the amount of such payments determined by the share price and/or the stage of the Company&#x2019;s clinical development at the time of the relevant event triggering the payment.</vir:MilestonePaymentsRelatedTermsDescription>
    <vir:AssetAcquisitionMilestonePaymentAggregate
      contextRef="C_82509859-a65e-439a-a5e3-9a2599d1d6ef"
      decimals="-5"
      id="F_cf69195a-9e07-4b4e-a28f-9df5bf3a3708"
      unitRef="U_USD">30000000.0</vir:AssetAcquisitionMilestonePaymentAggregate>
    <vir:MinimumCommonStockPriceForMilestonePaymentsConsideration
      contextRef="C_904cd630-0ecd-4275-ad9e-ee81b3b5999d"
      decimals="INF"
      id="F_3c55385b-3151-4c50-a2a4-5b590a2730cf"
      unitRef="U_USDollarShare">45</vir:MinimumCommonStockPriceForMilestonePaymentsConsideration>
    <vir:AssetAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration
      contextRef="C_181582de-b0b6-4d34-a602-8545a05e16ac"
      decimals="INF"
      id="F_e5b4d738-5ad4-4549-be6e-5767e00bbccb"
      unitRef="U_Milestone">1</vir:AssetAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration>
    <us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent
      contextRef="C_a4c83d47-f369-4173-b21b-90aff8652ace"
      decimals="-5"
      id="F_a69a5ae7-daa9-4920-b544-17b8cb244cf7"
      unitRef="U_USD">10000000.0</us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent>
    <vir:PaymentMadeForAssetAcquisitionMilestone
      contextRef="C_11d4ba09-a5bc-40ed-9952-89cf471e26ef"
      decimals="-5"
      id="F_3c868f9c-e112-4745-a75f-b6349a55a2fc"
      unitRef="U_USD">8100000</vir:PaymentMadeForAssetAcquisitionMilestone>
    <vir:CommonStockSharesIssuedForMilestonePaymentShares
      contextRef="C_0ab96725-0d67-4b9b-8abe-9354e48096b0"
      decimals="INF"
      id="F_6d9f72f7-c392-467f-8cff-605c98694492"
      unitRef="U_shares">42737</vir:CommonStockSharesIssuedForMilestonePaymentShares>
    <us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable
      contextRef="C_ab10cbf0-1e01-4fdf-9b82-e97488c8af01"
      decimals="-5"
      id="F_0a7c8ee3-af4b-4d7e-8fe5-b58fbaed9152"
      unitRef="U_USD">1900000</us-gaap:AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable>
    <vir:RemainingPaymentForAssetAcquisitionMilestoneAggregate
      contextRef="C_c81037e3-36e7-429d-8e76-acaab8a63eee"
      decimals="-5"
      id="F_827daedf-cb9d-457c-8753-ec2704e52454"
      unitRef="U_USD">20000000.0</vir:RemainingPaymentForAssetAcquisitionMilestoneAggregate>
    <vir:MinimumCommonStockPriceForMilestonePaymentsConsideration
      contextRef="C_8ca9f390-7fbb-41d3-a8cc-0dc299a46f0e"
      decimals="0"
      id="F_9d105262-4298-4688-b41f-e794b7c34ebe"
      unitRef="U_USDollarShare">45</vir:MinimumCommonStockPriceForMilestonePaymentsConsideration>
    <vir:MinimumCommonStockPriceForMilestonePaymentsConsideration
      contextRef="C_2f1d51a5-d28e-426b-b4cb-bbde0b7f3943"
      decimals="0"
      id="F_eb7b7013-693c-4d6f-86f1-81272c2fce24"
      unitRef="U_USDollarShare">90</vir:MinimumCommonStockPriceForMilestonePaymentsConsideration>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="C_e5b7cf6a-c235-492c-a434-ae21534824b2"
      decimals="-5"
      id="F_42f8d0a2-af56-466b-a0b4-4ee1d3e77ecb"
      unitRef="U_USD">1500000</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <vir:BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents
      contextRef="C_dd2fc99d-7a9d-45e3-995a-8f33afb52a81"
      decimals="-5"
      id="F_194b39c6-6614-43a7-8958-6ffc383fa05b"
      unitRef="U_USD">135000000.0</vir:BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents>
    <vir:BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents
      contextRef="C_60880c52-6f5a-486b-a848-501a5bacdd60"
      decimals="-5"
      id="F_146ea849-546e-42ca-b75e-703d87ff3221"
      unitRef="U_USD">105000000.0</vir:BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents>
    <vir:BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved
      contextRef="C_59d1854c-78da-4bb2-8d89-3e539c321e00"
      decimals="INF"
      id="F_33934fc1-6a8f-4be8-a8db-e60971a0ffe0"
      unitRef="U_Milestone">2</vir:BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved>
    <vir:SpecifiedClinicalDevelopmentMilestonesPayment
      contextRef="C_87f06556-ced9-44e3-ae60-d194dd7923ff"
      decimals="-5"
      id="F_af3557cc-76ef-4662-991f-31ba1791f1a3"
      unitRef="U_USD">20000000.0</vir:SpecifiedClinicalDevelopmentMilestonesPayment>
    <vir:SpecifiedClinicalDevelopmentMilestonesPayment
      contextRef="C_59d1854c-78da-4bb2-8d89-3e539c321e00"
      decimals="-5"
      id="F_31034b29-c6c6-4b2f-b5a9-94beb8272eb2"
      unitRef="U_USD">20000000.0</vir:SpecifiedClinicalDevelopmentMilestonesPayment>
    <vir:RegulatoryMilestonesAchieved
      contextRef="C_a055c3a3-3329-46bd-a235-0271e1908c6b"
      decimals="-5"
      id="F_f65f4f4f-6518-429b-bf00-2d117dcccab6"
      unitRef="U_USD">35000000.0</vir:RegulatoryMilestonesAchieved>
    <vir:SalesMilestonesAchieved
      contextRef="C_a055c3a3-3329-46bd-a235-0271e1908c6b"
      decimals="-5"
      id="F_682defeb-749c-4381-ac4b-df4713f15129"
      unitRef="U_USD">60000000.0</vir:SalesMilestonesAchieved>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="C_09ba265a-6add-41f5-ae26-e28684a4a700"
      decimals="-5"
      id="F_df110bfd-2f3a-4d38-9479-b887d6568a5e"
      unitRef="U_USD">23400000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="C_b67fb883-45a1-44e2-8338-3440f618fc44"
      id="F_48c3df9b-4d9a-4bc8-a43d-ef518ca1bb6c">P12Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="C_edd96045-6b9c-4a57-a99c-8b916e5ab8d8"
      decimals="INF"
      id="F_14df5f90-3700-4477-a538-633bb700cecf"
      unitRef="U_USD">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
      contextRef="C_e422f02f-6b34-4d0a-8361-270372955b88"
      decimals="INF"
      id="F_bd9eb6b8-750a-4384-ad94-0dc8ea45616c"
      unitRef="U_USD">0</us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_5587061b-fe82-4913-a3b2-c665e6a7a2bb">&lt;div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;5.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Goodwill and Intangible Assets &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Goodwill&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Goodwill of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; represents the excess of the purchase price over the estimated fair value of the net assets acquired from Humabs. The Company tests goodwill for impairment on an annual basis or sooner, if deemed necessary. There was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; impairment for the year ended December 31, 2022.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Intangible Assets&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes the carrying amount of the Company&#x2019;s finite-lived intangible assets (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.244%;"/&gt;
        &lt;td style="width:0.375%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.274%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.116%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.591999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.078%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.318999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining Useful&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Life (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Developed technology&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,260&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Contract-based intangible asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12.9&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Finite-lived intangible assets, gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,762&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less accumulated amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,738&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,114&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less impairment of intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;832&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Finite-lived intangible assets, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,556&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Finite-lived intangible assets are carried at cost less accumulated amortization. The contract-based intangible asset resulted from the product approval of a sublicensed intellectual property right in December 2020. The intellectual property right was previously accounted for as IPR&amp;amp;D. Amortization expense related to finite-lived intangible assets, included in research and development expenses on the consolidated statements of operations, totaled $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the years ended December 31, 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Management reviews finite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable, like that of property and equipment.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Based on the finite-lived intangible assets recorded as of December 31, 2022, the estimated future amortization expense for the next five years is as follows (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.682%;"/&gt;
        &lt;td style="width:1.865%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.451999999999998%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ending December 31:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;532&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;260&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;213&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;213&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;213&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,431&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Indefinite-Lived Intangible Assets&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022 and 2021, the Company had indefinite-lived intangible assets of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively, related to the purchased IPR&amp;amp;D from the Humabs acquisition. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; impairment losses have been recorded for the years ended December 31, 2022 and 2021.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:Goodwill
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-5"
      id="F_a1d65373-5ab1-4671-bad1-2484c753ae80"
      unitRef="U_USD">16900000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="INF"
      id="F_18632fa5-475d-4c45-b74d-ce6d1401fa5f"
      unitRef="U_USD">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_a6ed9b65-85ec-4aaf-a505-dab6aa50367c">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table summarizes the carrying amount of the Company&#x2019;s finite-lived intangible assets (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.244%;"/&gt;
        &lt;td style="width:0.375%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.274%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.116%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.591999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.078%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.318999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining Useful&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Life (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Developed technology&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,260&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Contract-based intangible asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12.9&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Finite-lived intangible assets, gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,762&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less accumulated amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,738&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,114&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less impairment of intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;832&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Finite-lived intangible assets, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,556&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_4afe2d0e-b9a0-4c40-9bbf-4330eabe88fe"
      decimals="-3"
      id="F_cfafa59a-e89a-4432-bad6-987d67be8d61"
      unitRef="U_USD">4260000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_ba34aded-037c-492e-95bf-8e2aee84865a"
      decimals="-3"
      id="F_bd84bcf1-18de-4411-9756-921f13a50f9b"
      unitRef="U_USD">7000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_8616915b-46bc-4304-92c6-102f09231afc"
      id="F_2c3dd3ec-1c52-4652-96db-add0622306e8">P5Y6M</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_8ea58521-d0a7-4461-a025-c44f108acb5b"
      decimals="-3"
      id="F_d876f6e2-d0c8-4388-89be-ad1ebddff77f"
      unitRef="U_USD">502000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_7619716a-9e49-48b5-abed-ff43a16e8263"
      decimals="-3"
      id="F_29ee1ecd-1bbe-4fe2-a864-e73eed8288d3"
      unitRef="U_USD">502000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_1c1249b0-5ad3-449c-a242-9282e54fdb6f"
      id="F_88a1804f-cba5-463a-af56-aa74f8b2e46e">P12Y10M24D</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_3b8e5d7b-45e3-4298-a341-783a76a35de0"
      unitRef="U_USD">4762000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_c896a3a9-7283-4fc8-acbf-0db7dc659552"
      unitRef="U_USD">7502000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_39b7a26f-6f01-4887-baea-ba4937eca201"
      unitRef="U_USD">2738000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_8e895c34-a6f7-4728-a33d-cd656846204f"
      unitRef="U_USD">4114000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <vir:FiniteLivedIntangibleAssetsAccumulatedImpairment
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_c6a4d043-993b-4270-b212-fc05a3c950fd"
      unitRef="U_USD">0</vir:FiniteLivedIntangibleAssetsAccumulatedImpairment>
    <vir:FiniteLivedIntangibleAssetsAccumulatedImpairment
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_47bd085c-939d-43be-81e0-31239424f978"
      unitRef="U_USD">832000</vir:FiniteLivedIntangibleAssetsAccumulatedImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_b65e6495-33cf-4a8a-968f-971574daacf2"
      unitRef="U_USD">2024000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_e40fc6fc-5eb4-466c-8130-7cba01e1cc62"
      unitRef="U_USD">2556000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-5"
      id="F_3547a1ce-87e8-43bf-9c0f-9e48dca1d811"
      unitRef="U_USD">500000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-5"
      id="F_92c6344b-5d3f-4652-8905-d0f1d85b00cf"
      unitRef="U_USD">500000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_ff18ae7e-33f9-49e0-b7ad-17646042d12e"
      decimals="-5"
      id="F_cba85717-1400-4c99-a058-285eb75328e6"
      unitRef="U_USD">1000000.0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_2ad5980f-0798-410c-bf25-cec6e928639a">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Based on the finite-lived intangible assets recorded as of December 31, 2022, the estimated future amortization expense for the next five years is as follows (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.682%;"/&gt;
        &lt;td style="width:1.865%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.451999999999998%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ending December 31:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;532&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;260&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;213&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;213&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;213&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,431&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_4eb22015-318f-4599-ae30-95e79e680878"
      unitRef="U_USD">532000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_e09585cd-2745-4caa-9857-b291ad777845"
      unitRef="U_USD">260000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_173d329d-cc74-41db-88d8-02ffde4f88d8"
      unitRef="U_USD">213000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_394f2fc9-6a62-4aed-98f0-a71ba2181d2b"
      unitRef="U_USD">213000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_82b949e9-306e-44f2-b47f-3235719d9b9d"
      unitRef="U_USD">213000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <vir:FiniteLivedIntangibleAssetsAmortizationExpense
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_8f815239-08a1-471d-bceb-e9c2eb4106d1"
      unitRef="U_USD">1431000</vir:FiniteLivedIntangibleAssetsAmortizationExpense>
    <us-gaap:IndefinitelivedIntangibleAssetsAcquired
      contextRef="C_edd96045-6b9c-4a57-a99c-8b916e5ab8d8"
      decimals="-5"
      id="F_0e39f03d-79f1-4b90-87d6-196dbadf3851"
      unitRef="U_USD">30700000</us-gaap:IndefinitelivedIntangibleAssetsAcquired>
    <us-gaap:IndefinitelivedIntangibleAssetsAcquired
      contextRef="C_8d7f14bb-4690-4c57-9bee-e30534233b77"
      decimals="-5"
      id="F_da347572-843c-4984-a23d-888a51dd1639"
      unitRef="U_USD">30700000</us-gaap:IndefinitelivedIntangibleAssetsAcquired>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="C_edd96045-6b9c-4a57-a99c-8b916e5ab8d8"
      decimals="INF"
      id="F_f69be224-2822-4a02-a924-b3ed972cf0ca"
      unitRef="U_USD">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="C_8d7f14bb-4690-4c57-9bee-e30534233b77"
      decimals="INF"
      id="F_3bcbd321-287d-4cd0-80d0-67f22329e6e1"
      unitRef="U_USD">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <vir:GrantAgreementsDisclosureTextBlock
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_b38c32f7-d19f-41a5-934d-021f75fc3108">&lt;div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;6.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Grant Agreements &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Bill &amp;amp; Melinda Gates Foundation Grants&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has entered into various grant agreements with the Bill &amp;amp; Melinda Gates Foundation, under which it was awarded grants totaling up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;55.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million to support its HIV vaccine program, tuberculosis vaccine program, HIV vaccinal antibody program and malaria vaccinal antibody program. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The term of the grant agreements will expire at various dates through December 2023, unless earlier terminated by the Bill &amp;amp; Melinda Gates Foundation for the Company&#x2019;s breach, failure to progress the funded project, in the event of the Company&#x2019;s change of control, change in the Company&#x2019;s tax status, or significant changes in the Company&#x2019;s leadership that the Bill &amp;amp; Melinda Gates Foundation reasonably believes may threaten the success of the project.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Concurrently with the execution of the grant agreement for the vaccinal antibody program, the Company entered into a stock purchase agreement with the Bill &amp;amp; Melinda Gates Foundation, under which the Bill &amp;amp; Melinda Gates Foundation purchased &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;881,365&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock on January 13, 2022, at a price per share of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;45.38&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, for an aggregate purchase price of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. The fair market value of the common stock issued to the Bill &amp;amp; Melinda Gates Foundation was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, based on the closing stock price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;37.65&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share on the closing date and taking into account a discount for the lack of marketability due to the restrictions in place on the underlying shares, resulting in a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million premium received by the Company. The Company accounted for the common stock issued to the Bill &amp;amp; Melinda Gates Foundation based on its fair market value on the closing date and determined that the premium paid by the Bill &amp;amp; Melinda Gates Foundation should be included in the deferred revenue from the vaccinal antibody grant.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Payments received in advance that are related to future research activities along with the aforementioned premium received are deferred and recognized as revenue when the donor-imposed conditions are met, which is as the research and development activities are performed. The premium received by the Company is deferred and recognized over the same period as the grant proportionally. The Company recognized grant revenue of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the years ended December 31, 2022, 2021 and 2020, respectively. As of December 31, 2022 and 2021, the Company had deferred revenue of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively. As of December 31, 2022 and 2021, the Company had $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively, within accrued and other liabilities, which may need to be refunded to the Bill &amp;amp; Melinda Gates Foundation.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Biomedical Advanced Research and Development Authority&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In September 2022, the Company entered into an other transaction for advanced research agreement (the &#x201c;BARDA Agreement&#x201d;) with the Biomedical Advanced Research and Development Authority (&#x201c;BARDA&#x201d;), part of the U.S. Department of Health and Human Services&#x2019; Administration for Strategic Preparedness and Response. Under the BARDA Agreement, the Company may receive up to an estimated $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; billion to advance the development of a full portfolio of innovative solutions to address influenza and potentially other infectious disease threats. The Base Period (as defined below) for the BARDA Agreement includes government funding of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;55.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million to reimburse a portion of expenses incurred by the Company to support the development of VIR-2482, an investigational prophylactic monoclonal antibody designed with the aim to protect against seasonal and pandemic influenza, including expenses related to the Phase 2 pre-exposure prophylaxis trial of VIR-2482. The BARDA Agreement also provides for additional BARDA funding after the exercise by BARDA of up to twelve options to further support the development of pre-exposure prophylactic antibodies including and beyond VIR-2482 for the prevention of influenza illness or possibly supporting medical countermeasures for other pathogens of pandemic potential. The BARDA Agreement has an initial term that commenced on September 30, 2022 and extends through January 2026 (&#x201c;Base Period&#x201d;), which may be extended by mutual written agreement of the Company and BARDA if certain conditions are met or if BARDA exercises any of its options, as described above, and is terminable by the Company and BARDA at any time under specified circumstances, including for convenience.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company recognized grant revenue under the BARDA Agreement of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;26.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the year ended December 31, 2022 and a corresponding other receivable in prepaid expenses and other current assets of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;26.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million as of December 31, 2022.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</vir:GrantAgreementsDisclosureTextBlock>
    <vir:GrantAwardedAmountMaximum
      contextRef="C_53c3499f-95d7-41ad-aa6a-553955ca0961"
      decimals="-5"
      id="F_9753a1c5-c4fe-4344-8761-8896c8bf482e"
      unitRef="U_USD">55700000</vir:GrantAwardedAmountMaximum>
    <vir:CommonStockSharesPurchased
      contextRef="C_0640f8ac-c552-4f54-8a09-1b99e32573ac"
      decimals="0"
      id="F_ab1b6962-a5cc-4a80-9c90-74a51d60c6be"
      unitRef="U_shares">881365</vir:CommonStockSharesPurchased>
    <vir:CommonStockSharesPurchasedSharePrice
      contextRef="C_0640f8ac-c552-4f54-8a09-1b99e32573ac"
      decimals="2"
      id="F_05bffe40-8fb1-45a7-b3b5-95e7edaf1e1f"
      unitRef="U_USDollarShare">45.38</vir:CommonStockSharesPurchasedSharePrice>
    <vir:CommonStockSharesPurchasedAggregatePurchasePrice
      contextRef="C_0640f8ac-c552-4f54-8a09-1b99e32573ac"
      decimals="-5"
      id="F_d2f2aee3-e758-4502-87f3-2bc5671c96b3"
      unitRef="U_USD">40000000.0</vir:CommonStockSharesPurchasedAggregatePurchasePrice>
    <vir:CommonStockSharesIssuedFairMarketValue
      contextRef="C_8e5b8d02-9b16-4b28-a5ac-d7b44ab9cd92"
      decimals="-5"
      id="F_127d9eac-4582-41f6-89ad-63e12171893c"
      unitRef="U_USD">28500000</vir:CommonStockSharesIssuedFairMarketValue>
    <vir:ClosingStockPrice
      contextRef="C_0640f8ac-c552-4f54-8a09-1b99e32573ac"
      decimals="2"
      id="F_c609a161-0d4c-4214-8c36-8fdd24eded04"
      unitRef="U_USDollarShare">37.65</vir:ClosingStockPrice>
    <vir:UnderlyingSharesPremiumReceived
      contextRef="C_8e5b8d02-9b16-4b28-a5ac-d7b44ab9cd92"
      decimals="-5"
      id="F_b7f973dd-339e-4db6-9383-40d011c1cbf4"
      unitRef="U_USD">11300000</vir:UnderlyingSharesPremiumReceived>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="C_e170955d-d5d7-40a0-b36e-ac2e1046968a"
      decimals="-5"
      id="F_17e997ad-c494-4302-9640-d9591409880c"
      unitRef="U_USD">8600000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="C_8338caa5-3a09-4312-9d81-25f2cf6a95d0"
      decimals="-5"
      id="F_8ec6b920-de04-4a4b-96a1-0a7a4d316454"
      unitRef="U_USD">8200000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="C_34578bdd-5e64-44f6-8af5-ed7833cd36ba"
      decimals="-5"
      id="F_0c966236-a255-4992-ba3e-95407415e8b4"
      unitRef="U_USD">8600000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:DeferredIncome
      contextRef="C_7bfa1f77-0aad-47a7-9222-be7a47061336"
      decimals="-5"
      id="F_5657c115-0b73-4ac1-a31c-7ea0dc60b944"
      unitRef="U_USD">15500000</us-gaap:DeferredIncome>
    <us-gaap:DeferredIncome
      contextRef="C_d31deef3-bfd7-4c38-8080-cbcd2d6f202c"
      decimals="-5"
      id="F_9601f062-74dd-4403-b275-cabf40e5f40d"
      unitRef="U_USD">6800000</us-gaap:DeferredIncome>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_7bfa1f77-0aad-47a7-9222-be7a47061336"
      decimals="-5"
      id="F_44087b06-0762-4693-bed9-c24a9bb89aeb"
      unitRef="U_USD">7700000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_d31deef3-bfd7-4c38-8080-cbcd2d6f202c"
      decimals="-5"
      id="F_967f6338-ec66-4230-b1ca-2b4f2ea95486"
      unitRef="U_USD">1800000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <vir:MaximumAmountGrantAggregate
      contextRef="C_7c11953b-e6ce-4d9b-8cf9-80604a06d01a"
      decimals="-8"
      id="F_55be3588-23a4-4d18-812e-95645548641f"
      unitRef="U_USD">1000000000.0</vir:MaximumAmountGrantAggregate>
    <vir:MaximumAmountGrantBasePeriod
      contextRef="C_7c11953b-e6ce-4d9b-8cf9-80604a06d01a"
      decimals="-5"
      id="F_c4a019eb-ea02-4cf5-843c-6f36cfebf215"
      unitRef="U_USD">55000000.0</vir:MaximumAmountGrantBasePeriod>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="C_0365acdf-5aea-4a92-8f52-bcf73ab2f285"
      decimals="-5"
      id="F_c52ee024-4e78-4dcc-96e8-8c57684129ca"
      unitRef="U_USD">26400000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-5"
      id="F_09bb0ba6-8991-40c0-ad9e-bdb14b833bad"
      unitRef="U_USD">26400000</us-gaap:OtherAssetsCurrent>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_c311b295-db17-4f18-9c84-90fc104afc05">&lt;div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;7.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Collaboration and License Agreements &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Collaboration Agreements with GSK&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;2020 GSK Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On June 9, 2020, the Company, Glaxo Wellcome UK Limited and Beecham S.A. entered into a definitive collaboration agreement under the terms set forth in the preliminary collaboration agreement entered into by the Company and certain GSK entities in April 2020 (the &#x201c;2020 Preliminary Agreement&#x201d;) (such definitive collaboration agreement, the &#x201c;2020 GSK Agreement&#x201d;). In December 2021, Beecham S.A. assigned and transferred all its rights, title, interest, and benefit in the 2020 GSK Agreement to GlaxoSmithKline Biologicals S.A. (Glaxo Wellcome UK Limited and GlaxoSmithKline Biologicals S.A., referred to, individually and together, as &#x201c;GSK&#x201d;), including all its rights to bring claims under such agreement. Concurrently with the execution of the 2020 Preliminary Agreement, the Company entered into a stock purchase agreement (the &#x201c;2020 Stock Purchase Agreement&#x201d;) with Glaxo Group Limited (&#x201c;GGL&#x201d;), an affiliate of GSK, under which GGL purchased &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,626,027&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock on April 29, 2020, at a price per share of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;37.73&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, for an aggregate purchase price of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;250.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. The 2020 Preliminary Agreement became effective as of April 29, 2020, which was also the closing date for the 2020 Stock Purchase Agreement (&#x201c;Effective Date&#x201d;). The 2020 GSK Agreement superseded and replaced the 2020 Preliminary Agreement between the parties. Under the terms of the 2020 GSK Agreement, the Company and GSK agreed to collaborate to research, develop and commercialize products for the prevention, treatment and prophylaxis of diseases caused by SARS-CoV-2, the virus that causes COVID-19, and potentially other coronaviruses. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The collaboration initially focused on the development and commercialization of three types of collaboration products under three programs: (1) antibodies targeting SARS-CoV-2 and potentially other coronaviruses (the &#x201c;Antibody Program&#x201d;); (2) vaccines targeting SARS-CoV-2 and potentially other coronaviruses (the &#x201c;Vaccine Program&#x201d;), and (3) products based on genome-wide CRISPR screening of host targets expressed in connection with exposure to SARS-CoV-2 and potentially other coronaviruses (the &#x201c;Functional Genomics Program&#x201d;)&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; four years &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;following the Effective Date, the parties agreed to conduct certain research and development activities under mutually agreed development plans and associated budgets for each of the three programs, and under the oversight of a joint steering committee (&#x201c;JSC&#x201d;). The Company is primarily responsible for the development and clinical manufacturing activities for the Antibody Program, and for conducting the initial development activities directed to a vaccine in the Vaccine Program. GSK is primarily responsible for the commercialization activities for the Antibody Program (including in mainland China, Hong Kong, Macau and Taiwan following the purchase of these rights in May 2022, as described below), the later-stage development, manufacturing and commercialization activities for the Vaccine Program and the development, manufacturing and commercialization activities for the Functional Genomics Program. Subject to an opt-out mechanism and Amendment No. 1 to the 2020 GSK Agreement (described below), the parties share all development costs, manufacturing costs and costs and expenses for the commercialization of the collaboration products, with the Company bearing &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;72.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of such costs for the antibody products, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of such costs for the vaccine products, and equal sharing of such costs for the functional genomics products.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On a collaboration product-by-collaboration product basis, each party has the one-time right, at specified points in development, to opt-out of its co-funding obligations, and the other party may, at its election, either pursue such program unilaterally, or also cease research and development activities and funding of such collaboration product. If the opt-out provisions are not exercised by either party subject to the terms of the 2020 GSK Agreement, the parties share all profits and losses arising from any collaboration product in the same ratios in which the parties bore development costs for such collaboration program. For each collaboration product as to which a party exercises its opt-out right, the commercializing party pays to the opt-out party royalties on net sales of the applicable collaboration product at rates based on factors such as the stage of development of such collaboration product at the time the opt-out party exercises such right, and whether the opt-out party is the lead party, or a portion of the sublicense revenue if the commercializing party chooses to sublicense or otherwise divest rights to such collaboration product. On an antibody product-by-antibody product basis, the Company has a co-promotion right for such antibody product in the United States, under which the Company has the right to perform up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of details in connection with such antibody product.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The 2020 GSK Agreement will remain in effect with respect to each collaboration program for as long as there is a collaboration product being developed or commercialized by the lead party, or the non-opt-out party, in such program. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Either party has the right to terminate the 2020 GSK Agreement in the case of the insolvency of the other party, an uncured material breach of the other party with respect to a collaboration program or collaboration product, or as mutually agreed by the parties.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company considered the ASC 606 criteria for combining contracts and determined that the 2020 GSK Agreement and 2020 Stock Purchase Agreement should be combined into a single contract because they were negotiated and entered into in contemplation of one another. The fair market value of the common stock issued to GGL was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;206.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, based on the closing stock price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;36.70&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; on the date of execution of the 2020 Preliminary Agreement and 2020 Stock Purchase Agreement and taking into account a discount for the lack of marketability due to the restrictions in place on the underlying shares, resulting in a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;43.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million premium received by the Company. The Company accounted for the common stock issued to GGL based on its fair market value on the transaction date and determined that the premium paid by GSK should be attributed to the transaction price of the 2020 GSK Agreement.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company concluded that the 2020 GSK Agreement contained &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;four&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; units of account: (i) the license granted to GSK under the Antibody Program (the &#x201c;Antibody License&#x201d;); (ii) the research and development activities (including clinical manufacturing) under the Antibody Program; (iii) the research and development activities under the Vaccine Program; and (iv) the research and development activities under the Functional Genomics Program. The Company considered the guidance in ASC 606 to determine which of these elements of the 2020 GSK Agreement are performance obligations with a customer. The Company determined that the Antibody License is within the scope of ASC 606, and accordingly, accounted for the Antibody License as a distinct performance obligation under ASC 606. The Antibody License is a functional intellectual property and is distinct from the associated research and development activities to be performed under the program due to its significant standalone functionality. All other elements of the 2020 GSK Agreement, including the research and development activities and participation in the JSC and subcommittees for each collaboration program, were not determined to be distinct performance obligations with a customer.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The transaction price for the Antibody License at inception was determined to be $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;43.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, representing the premium on the sale of common stock to GSK. The Company determined that GSK can benefit from the Antibody License at the time of grant and, therefore, the related performance obligation is satisfied at a point in time. As such, the Company recognized the $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;43.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million as contract revenue during the second quarter of 2020.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The remaining units of account of the 2020 GSK Agreement were determined to be within the scope of ASC 808 as the Company and GSK are both active participants in the development, manufacturing and commercialization activities and are exposed to significant risks and rewards that are dependent on the commercial success of the activities of the arrangement. Furthermore, the Company and GSK participate in the commercial profit and loss sharing arrangement for each program commensurate with each party&#x2019;s cost-sharing responsibilities during research and development. Because ASC 808 does not provide recognition and measurement guidance, the Company determined that the guidance in ASC 730, Research and Development, was appropriate to analogize to, based on the nature of the cost-sharing provisions of the 2020 GSK Agreement. The Company has concluded that payments to or reimbursements from GSK related to these services will be accounted for as an increase to or reduction of research and development expenses, respectively. Additionally, the Company is entitled to consideration from GSK related to profit and loss sharing arrangements (including royalties) contingent upon future sales of collaboration products. The Company concluded that any payments from GSK related to the profit and loss sharing arrangement (including royalties) contingent upon the commercialization of the products will be analogized to ASC 606 and, therefore, will be recognized when the related sales occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In May 2021, the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) granted an EUA in the United States for sotrovimab, the first collaboration product under the Antibody Program. In April 2022, the FDA excluded the use of sotrovimab in all U.S. regions due to the continued proportion of COVID-19 cases caused by certain Omicron subvariants. As the lead party for all manufacturing and commercialization activities, GSK incurs all of the manufacturing, sales and marketing expenses and is the principal on sales transactions with third parties. As described in Note 2&#x2014;Summary of Significant Accounting Policies, the Company&#x2019;s accounting policy related to the profit-share is to consider the agreed-upon share of the profit-sharing amounts each quarter and evaluate whether those amounts are subject to potential future adjustments based on the latest available facts and circumstances, subject to the terms of the 2020 GSK Agreement. As the Company is the agent, the Company recognizes its contractual share of the profit-sharing amounts or royalties (in case of an opt-out) as revenue, based on sales net of various estimated deductions such as rebates, discounts, chargebacks, credits and returns, less cost of sales and allowable expenses (including manufacturing, distribution, medical affairs, selling, and marketing expenses) in the period the sale occurs. Manufacturing costs include inventory revaluation adjustments, lower of cost or market inventory adjustments, inventory write-downs and write-offs, and binding purchase commitments with a third-party manufacturer among other manufacturing costs. The Company&#x2019;s contractual share of the profit-sharing amounts is subject to potential future adjustments to allowable expenses, which represents a form of variable consideration. At each reporting period, the Company evaluates the latest available facts and circumstances to determine whether any portion of profit-sharing amounts should be constrained.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022, GSK held certain potentially excess binding supply manufacturing commitments of sotrovimab and reserved certain binding manufacturing capacity potentially not expected to be utilized, which have not yet been reported to us as allowable manufacturing expenses for the cumulative profit-sharing amounts to date. We expect GSK to adjust allowable manufacturing expenses for our share of the potential charge for excess supply write-offs and unused binding manufacturing capacity and report to us as cost-sharing amounts in future periods. We evaluated the latest available facts and circumstances to update our evaluation of whether any portion of profit-sharing amounts should be constrained. In doing so, as of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, based on the current state of the COVID-19 pandemic, including the continued proportion of cases caused by certain Omicron subvariants, discussions with the FDA and other regulatory authorities, and the Company&#x2019;s expectations for future sales in light of these factors, the Company revised its estimate and determined that $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;369.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million should be constrained from profit-sharing revenues earned during the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 in relation to the Company&#x2019;s anticipated contractual share of potential future adjustments to manufacturing expenses and recorded such amount as adjustments to profit-sharing amounts. The Company re-assesses these estimates each reporting period. Actual results could materially differ from this estimate.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;During the years ended December 31, 2022 and 2021, the Company recorded profit-sharing amounts and profit-sharing amounts constrained as components of collaboration revenue in the consolidated statements of operations, as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.078%;"/&gt;
        &lt;td style="width:2.396%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:19.968%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.396%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:20.162%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Collaboration revenue, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Profit-sharing amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,875,147&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;917,194&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Profit-sharing amount constrained&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;369,678&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total collaboration revenue, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,505,469&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;917,194&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Costs associated with co-development activities performed under the 2020 GSK Agreement are included in research and development expenses on the consolidated statements of operations, with any reimbursement of costs by GSK reflected as a reduction of such expenses. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Under the 2020 GSK Agreement, the Company recognized additional net research and development expenses of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;31.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;77.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million during the years ended December 31, 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Amendment No. 1 to the 2020 GSK Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On May 27, 2022, the Company and GSK entered into Amendment No. 1 to the 2020 GSK Agreement (&#x201c;Amendment No. 1&#x201d;). Pursuant to Amendment No. 1, the parties acknowledged that the antibody products that had been licensed to WuXi Biologics (Hong Kong) Limited (&#x201c;WuXi Biologics&#x201d;) in mainland China, Hong Kong, Macau and Taiwan and had reverted to the Company pursuant to the Termination Agreement (described below) are now included in and governed by the 2020 GSK Agreement, subject to certain amendments relating to sotrovimab.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Under &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;the terms of Amendment No. 1, GSK has the sole right to develop (including to seek, obtain or maintain regulatory approvals), manufacture and commercialize sotrovimab in and for mainland China, Hong Kong, Macau and Taiwan at GSK's sole cost&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;and &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;expense (other than certain payments for which the Company remains responsible under certain of the Company&#x2019;s existing agreements with third parties). GSK paid the Company a one-time upfront payment of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in consideration for the rights and licenses granted to GSK under Amendment No. 1. The Company recognized contract revenue of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million during the year ended December 31, 2022. In addition, GSK will be obligated to pay the Company tiered royalties on net sales of sotrovimab in mainland China, Hong Kong, Macau and Taiwan in percentages ranging from the high teens to the low thirties. Such royalties are payable to the Company during the term of the 2020 GSK Agreement applicable to the Antibody Program.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;2021 Expanded GSK Collaboration&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On February 14, 2021, the Company and GSK entered into a binding preliminary collaboration agreement (the &#x201c;2021 &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Preliminary Agreement&#x201d;) under which the parties agreed to expand the 2020 GSK Agreement to collaborate on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; separate programs: (1) a program to research, develop and commercialize mAbs for the prevention, treatment or prophylaxis of the influenza virus (the &#x201c;Influenza Program&#x201d;), excluding VIR-2482 unless GSK exercises its option as described below; (2) an expansion of the parties&#x2019; current Functional Genomics Program to focus on functional genomics screens directed to targets associated with respiratory viruses (the &#x201c;Expanded Functional Genomics Program&#x201d;); and (3) additional programs to develop neutralizing mAbs directed to up to three non-influenza target pathogens selected by GSK (the &#x201c;Selected Pathogens&#x201d; and such programs, the &#x201c;Additional Programs&#x201d;).&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Concurrently with the execution of the 2021 Preliminary Agreement, the Company entered into a stock purchase agreement (the &#x201c;2021 Stock Purchase Agreement&#x201d;) with GGL under which GGL agreed to purchase shares of the Company&#x2019;s common stock for an aggregate purchase price of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;120.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. The consummation of the transactions under each of the 2021 Preliminary Agreement and the 2021 Stock Purchase Agreement were subject to the satisfaction of customary closing conditions, including the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, which expiration was effective on March 24, 2021. The 2021 Preliminary Agreement and 2021 Stock Purchase Agreement consummated on March 25, 2021, which the Company used as the measurement date for accounting purposes. On March 31, 2021, the Company closed the sale of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,924,927&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of its common stock to GGL.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The 2021 Preliminary Agreement was superseded on May 18, 2021 upon execution of the definitive collaboration agreement (the &#x201c;2021 GSK Agreement&#x201d;, and collectively with the 2021 Preliminary Agreement, the &#x201c;2021 GSK Collaboration&#x201d;). The material terms of the 2021 GSK Agreement, including the promised goods and services, are discussed below and are consistent with those of the 2021 Preliminary Agreement.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Under the 2021 GSK Collaboration, the parties agreed to conduct certain research and development activities under mutually agreed development plans and associated budgets for the programs within the expanded collaboration for a period of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;three years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; following the effective date. Under the Influenza Program, the parties collaborate to research, develop and commercialize mAbs for the prevention, treatment or prophylaxis of influenza, including the Company&#x2019;s influenza mAbs (with respect to VIR-2482, only if GSK exercises its option). The Company conducts the development and clinical manufacturing activities for VIR-2482 up to the completion of a Phase 2 clinical trial. Provided that the Company conducts and completes a Phase 2 clinical trial for VIR-2482, GSK has the exclusive option to obtain exclusive rights to co-develop and commercialize VIR-2482 under the Influenza Program (the &#x201c;VIR-2482 Option&#x201d;). GSK is the lead party for development, clinical and commercial manufacturing and commercialization activities for products under the Influenza Program (other than VIR-2482 unless and until GSK exercises the VIR-2482 Option, if applicable). The parties mutually agree upon the allocation of responsibility for the development of products under the Expanded Functional Genomics Program, and for the development and early-stage manufacturing of products under the Additional Programs if and when GSK decides which Selected Pathogens to pursue. GSK is primarily responsible for commercial manufacturing and commercialization activities for products under the Expanded Functional Genomics Program and Additional Programs, if and when selected by GSK. For each collaboration program, the Company granted or will grant GSK certain license rights related to the development, manufacturing and commercialization of products arising from the program.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The parties share &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of all development costs in accordance with the budget for each of the collaboration programs (other than for the Selected Pathogens and VIR-2482, unless GSK exercises the VIR-2482 Option), with each party having the right to opt-out of its co-funding obligations at specified points in development. In such case, the party continuing with the program pays to the opt-out party a royalty on net sales of products arising from such program at specified rates based on the stage of development at which the opt-out is exercised. Following the exercise of an opt-out right by a party, the other party may, at its election, either pursue development and commercialization of such product or program unilaterally, or also cease the conduct and funding of such collaboration product or program. In the absence of any opt-out, the parties also share &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of all profits and losses arising from any collaboration product.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;GSK made an upfront payment to the Company of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;225.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. If GSK exercises the VIR-2482 Option, GSK will pay the Company an option exercise fee of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;300.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million unless certain agreed product criteria for VIR-2482 are not met, in which case the parties will negotiate an alternative option exercise fee. Upon achievement of a pre-defined regulatory milestone for the first product in the Influenza Program, which may be (i) VIR-2482 (if GSK exercised the VIR-2482 Option), (ii) a next-generation mAb, or (iii) any other influenza mAb approved by the JSC to be included in the collaboration, arising from the Influenza Program, GSK will make a milestone payment to the Company of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;200.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company concluded that the 2021 GSK Agreement is a collaboration arrangement as defined in ASC 808, Collaborative Agreements, under which certain elements are required to be accounted for under ASC 606 where the counterparty is a customer for a good or service that is a distinct unit of account. In addition, the 2021 GSK Agreement is considered a contract modification to the 2021 Preliminary Agreement and will be accounted for prospectively as a termination of the 2021 Preliminary Agreement and commencement of a new contract. There was no impact to the accounting assessment of the original contract as no goods or services had been delivered to GSK, no performance obligations were satisfied, and accordingly, no contract revenue was recognized under ASC 606 prior to the execution of the 2021 GSK Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company considered the ASC 606 criteria for combining contracts and determined that the 2021 GSK Collaboration and 2021 Stock Purchase Agreement should be combined into a single contract because they were negotiated and entered into in contemplation of one another. The fair market value of the common stock issued to GGL was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;85.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, based on the closing stock price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;52.70&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; on March 25, 2021, and taking into account a discount for the lack of marketability due to the restrictions in place on the underlying shares, resulting in a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;34.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million premium received by the Company. The Company accounted for the common stock issued to GGL based on its fair market value on the transaction date and determined that the premium paid by GSK should be attributed to the transaction price of the 2021 GSK Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company concluded that the 2021 GSK Agreement contained the following units of account: (i) the VIR-2482 Option; (ii) three distinct rights granted to GSK related to the Selected Pathogens (each, a &#x201c;Selected Pathogen Right&#x201d;); (iii) the license and know-how to the next-generation mAbs under the Influenza Program (the &#x201c;Next Gen License&#x201d;); (iv) the research and development activities for next-generation mAbs under the Influenza Program; and (v) the research and development activities, including license rights and know-how, under the Expanded Functional Genomics Program. The Company considered the guidance in ASC 606 to determine which of these elements of the 2021 GSK Agreement are performance obligations with a customer. The Company determined that the distinct performance obligations under ASC 606 consisted of (i) the Next Gen License and (ii) the three Selected Pathogen Rights, each representing a material right. All other elements of the 2021 GSK Agreement including the VIR-2482 Option, research and development activities, and participation in the JSC and subcommittees for each collaboration program were not determined to be distinct performance obligations with a customer. As of December 31, 2022, GSK had not exercised the VIR-2482 Option or the remaining two Selected Pathogen Rights (see below for GSK's selection of first pathogen).&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The transaction price for the 2021 GSK Agreement included fixed consideration consisting of the $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;225.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million upfront fee paid by GSK and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;34.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, representing the premium on the sale of common stock to GSK for a total of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;259.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. All potential future milestones and other payments under the 2021 GSK Agreement are constrained since the Company could not conclude it was probable that a significant reversal in the amount recognized would not occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The respective estimated SSP for each of the performance obligations was determined to allocate the transaction price. The estimated SSP of each performance obligation was determined using methods that considered relevant market conditions, entity-specific factors and information about GSK, while maximizing the use of available observable inputs and using certain management assumptions (e.g., treatable patient population, expected market share, probability of success and product profitability, discount rate based on weighted-average cost of capital). For the Next Gen License, the Company determined that GSK can benefit from the license at the time the license is granted and, therefore, the related performance obligation is satisfied at a point in time. If any of the Selected Pathogen Rights are exercised, the Company will evaluate the related promises to identify the performance obligations to be transferred and the timing of revenue recognition. If any of the Selected Pathogen Rights expire prior to being exercised, the Company will recognize any deferred revenue allocated to that right as revenue at the time of expiration.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The research and development activities for the next-generation mAbs under the Influenza Program and the Expanded Functional Genomics Program were determined to be within the scope of ASC 808 as the Company and GSK are both active participants in the development, manufacturing and commercialization activities and are exposed to significant risks and rewards that are dependent on the commercial success of the activities of the arrangement. Furthermore, the Company and GSK participate in the commercial profit and loss sharing arrangement for each program commensurate with each party&#x2019;s cost-sharing responsibilities during research and development. Because ASC 808 does not provide recognition and measurement guidance, the Company determined that&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;the guidance in ASC 730, Research and Development, was appropriate to analogize to based on the nature of the cost-sharing provisions of the agreement. The Company has concluded that payments to or reimbursements from GSK related to these services will be accounted for as an increase to or reduction of research and development expenses, respectively. The Company also concluded that any payments from GSK related to the profit and loss sharing arrangement (including royalties) contingent upon the commercialization of the related products will be analogized to ASC 606 and, therefore, will be recognized when the related sales occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Upon execution of the 2021 GSK Agreement, the Company granted the Next Gen License to GSK and therefore, recognized $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;168.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million as contract revenue in the second quarter of 2021. As of December 31, 2022, the total unrecognized transaction price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;51.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million is classified as noncurrent deferred revenue on the Company's consolidated balance sheet related to the remaining performance obligations, being the remaining two material rights resulting from the Selected Pathogen Rights. The Company reclassified the deferred revenue of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;51.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million from current to noncurrent as of December 31, 2022 based on the Company's revised expectations for future option exercises by GSK.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Costs associated with co-development activities performed under the 2021 GSK Agreement are included in research and development expenses in the consolidated statements of operations, with any reimbursement of costs by GSK reflected as a reduction of such expenses.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Option Exercise by GSK&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In September 2022, GSK exercised its first Selected Pathogen Right, selecting respiratory syncytial virus (&#x201c;RSV&#x201d;) as its first pathogen under the Additional Programs of the 2021 GSK Agreement (&#x201c;First Option Exercise&#x201d;). GSK agreed to retroactively share the research and development costs that the Company had incurred under its RSV program since April 2022 in accordance with the applicable provisions of the 2021 GSK Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company evaluated the First Option Exercise under ASC 606 and identified one performance obligation consisting of the license for a Selected Pathogen Right granted to GSK. The transaction price was determined to be $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;39.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million which equals the deferred revenue allocated to the first Selected Pathogen Right at the inception of the 2021 GSK Agreement. The Company determined that the license is considered a functional intellectual property that is a distinct performance obligation. Specifically, the Company believes the license is capable of being distinct, as GSK has the capabilities to develop the license either on its own or by contracting with other third-parties. GSK can benefit from the license at the time of grant and, therefore, the related performance obligation is satisfied at a point in time. During the year ended December 31, 2022, the Company recognized the $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;39.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million as contract revenue.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;During the year ended December 31, 2022 and 2021, the Company recognized additional net research and development expenses of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively, under the 2021 GSK Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Under both the 2020 GSK Agreement and the 2021 GSK Agreement, the Company has a receivable from collaboration of zero and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;773.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million as of December 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Brii Biosciences&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In May 2018, the Company entered into the Brii Agreement with Brii Bio Parent and Brii Bio, pursuant to which the Company granted to Brii Bio, with respect to up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;four&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; of the Company&#x2019;s programs, an exclusive option to obtain exclusive rights to develop and commercialize compounds and products arising from such programs in China, Taiwan, Hong Kong and Macau (collectively, the &#x201c;China Territory&#x201d;) for the treatment, palliation, diagnosis, prevention or cure of acute and chronic diseases of infectious pathogen origin or hosted by pathogen infection (the &#x201c;Field of Use&#x201d;). The Company&#x2019;s HBV &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;small interfering ribonucleic acid (&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x201c;siRNA&#x201d;) program being developed under the Amended Alnylam Agreement (described below) is included within the Brii Agreement as a program for which Brii Bio may exercise one of its options. In partial consideration for the options granted by the Company to Brii Bio, Brii Bio Parent and Brii Bio granted the Company, with respect to up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;four&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; of Brii Bio Parent&#x2019;s or Brii Bio&#x2019;s programs, an exclusive option to be granted exclusive rights to develop and commercialize compounds and products arising from such Brii Bio programs in the United States for the Field of Use. The number of options that the Company may exercise for a Brii Bio program is limited to the corresponding number of options that Brii Bio exercises for a Vir program.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As partial consideration for the Company&#x2019;s entry into the Brii Agreement, upon closing of Brii Bio Parent&#x2019;s Series A preferred stock financing, the Company received ordinary shares equal to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the outstanding shares in Brii Bio Parent. As a result of Brii Bio&#x2019;s right to exercise one of its options for the Company&#x2019;s HBV siRNA program, under the terms of the Amended Alnylam Agreement, the Company transferred to Alnylam Pharmaceuticals, Inc. (&#x201c;Alnylam&#x201d;) a specified percentage of such equity consideration allocable to such program &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;under a share transfer agreement in February 2020.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;With respect to programs for which Brii Bio exercises its options, Brii Bio is required to pay the Company an option exercise fee for each such Vir program ranging from the&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; mid-single-digit millions&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, determined based on the commercial potential of the licensed program. Brii Bio will also be required to pay regulatory milestone payments on a licensed product-by-licensed product basis ranging from the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;mid-single-digit millions&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, also determined based on the commercial potential of such program. Following commercialization, Brii Bio will be required to make sales milestone payments based on certain specified levels of aggregate annual net sales of products arising from each licensed program in the China Territory, up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;175.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million per licensed program.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Upon exercise of each option for a Brii Bio program, the Company will be required to pay to Brii Bio an option exercise fee ranging from the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;low tens of millions&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; to up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;50.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, determined based on the commercial potential of the licensed program. The Company will be required to make regulatory milestone payments to Brii Bio on a licensed product-by-licensed product basis ranging from the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;low tens of millions&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;100.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, also determined based on the commercial potential of such program. The Company will also be required to make sales milestone payments based on certain specified levels of aggregate annual net sales of products in the United States arising from each licensed program, up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;175.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million per licensed program. As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022, the Company has not exercised any of its options.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In addition, the Company is obligated under the Brii Agreement to pay Brii Bio tiered royalties based on net sales of products arising from the licensed programs in the United States, and Brii Bio is obligated to pay the Company tiered royalties based on net sales of products arising from the licensed programs in the China Territory. The rates of royalties payable by the Company to Brii Bio, and by Brii Bio to the Company, on net sales range from &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;mid-teens to high-twenties&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. Each party&#x2019;s obligations to pay royalties expires, on a product-by-product and territory-by-territory basis, on the latest of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; years after the first commercial sale of such licensed product in the United States or China Territory, as applicable; the expiration or abandonment of licensed patent rights that cover such product in the United States or China Territory, as applicable; and the expiration of regulatory exclusivity in the United States or the China Territory, as applicable. Royalty rates are subject to specified reductions and offsets.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Brii Agreement will remain in force until the expiration of all options or, if any option is exercised, expiration of all royalty payment obligations for all licensed products within such licensed program, unless terminated in its entirety or on a program-by-program basis by either party. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Each party may terminate for convenience all rights and obligations with respect to any program for which it has an option, with &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; days&#x2019; written notice (if the terminating party has not exercised an option for such program) or &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;180&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; days&#x2019; notice (following the exercise of an option for such program). The Brii Agreement may also be terminated by either party for insolvency of the other party, and either party may terminate the Brii Agreement in its entirety or on a program-by-program basis for the other party&#x2019;s uncured material breach on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;60&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; days&#x2019; written notice (or &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; days&#x2019; notice following failure to make payment).&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;From May 2018 until the closing of the Brii Bio Parent IPO in July 2021, Brii Bio Parent and its wholly-owned subsidiary Brii Bio were determined to be variable interest entities (&#x201c;VIE&#x201d;) due to their reliance on future financing and having insufficient equity at risk. However, the Company did not have the power to direct activities that most significantly impact the economic success of these&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;entities and was not considered the primary beneficiary of these entities. Therefore, the Company did not consolidate Brii Bio Par&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ent or Brii Bio. Subsequent to the Brii Bio Parent IPO, the Company determined that these entities are no longer VIEs. In addition, as Brii Bio Parent is a publicly-traded company, the Company's investment in its ordinary shares became a marketable equity investment with readily determinable fair value and is then subsequently remeasured to fair value at each reporting date (see Note 3&#x2014;Fair Value Measurements). Prior to the Brii Bio Parent IPO, the Company accounted for its investment in Brii Bio Parent, which had a carrying value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment from the same issuer.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Option Exercises by Brii Bio&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In June 2020, Brii Bio exercised its option to obtain exclusive rights to develop and commercialize compounds and products arising from VIR-2218 in the China Territory. In consideration of the Company&#x2019;s grant to Brii Bio of an exclusive license related to VIR-2218 in the China Territory, the Company received a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million option exercise fee in connection with the option exercise. Also, the Company is eligible to receive the following payments related to VIR-2218 in the China Territory: a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million regulatory milestone payment, up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;175.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in sales-based milestone payments, and royalties on net sales ranging from &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;high-teens to high-twenties&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company evaluated the VIR-2218 transaction under ASC 606 and identified one performance obligation consisting of the license granted to Brii Bio. Under the Brii Agreement, Brii Bio is responsible for performing all research and development activities and the Company does not have any other performance obligations within the context of ASC 606 under the arrangement after the option exercise. The transaction price is determined to be $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million which consists of the $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million option exercise fee and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of the deferred revenue allocated to the VIR-2218 option at the inception of the Brii Agreement. The Company determined that the license is considered a functional intellectual property that is a distinct performance obligation under ASC 606. Specifically, the Company believes the license is capable of being distinct, as Brii Bio has the capabilities to develop the license either on its own or by contracting other third parties. Brii Bio can benefit from the license at the time of grant and therefore, the related performance obligation is satisfied at a point in time. Additionally, all potential future milestones and other payments are constrained because the Company cannot conclude it is probable that a significant reversal in the amount recognized would not occur. The Company will re-evaluate the transaction price in each reporting period.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In July 2022, Brii Bio exercised its option to obtain exclusive rights to develop and commercialize compounds and products arising from VIR-3434 in the China Territory. In consideration of the Company&#x2019;s grant to Brii Bio of an exclusive license related to VIR-3434 in the China Territory, the Company received a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million option exercise fee in connection with the option exercise. Also, the Company is eligible to receive the following payments related to VIR-3434 in the China Territory: a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million regulatory milestone payment, up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;175.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in sales-based milestone payments, and royalties on net sales ranging from &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;mid-teens to mid-twenties&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company evaluated the VIR-3434 transaction under ASC 606 and identified one performance obligation consisting of the license granted to Brii Bio. Under the Brii Agreement, Brii Bio is responsible for performing all research and development activities and the Company does not have any other performance obligations within the context of ASC 606 under the arrangement after the option exercise. The transaction price was determined to be $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, which consists of the $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million option exercise fee and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of the deferred revenue allocated to the VIR-3434 option at the inception of the Brii Agreement. The Company determined that the license is considered a functional intellectual property that is a distinct performance obligation. Specifically, the Company believes the license is capable of being distinct, as Brii Bio has the capabilities to develop the license either on its own or by contracting with other third parties. Brii Bio can benefit from the license at the time of grant and, therefore, the related performance obligation is satisfied at a point in time. Additionally, all potential future milestones and other payments are constrained because the Company cannot conclude it is probable that a significant reversal in the amount recognized would not occur. The Company will re-evaluate the transaction price in each reporting period.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;During the years ended December 31, 2022, 2021 and 2020, the Company recognized $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;zero&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively, as license revenue from a related party. During the year ended December 31, 2020, the Company separately paid $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, half of the option exercise proceeds, to Alnylam in connection with the Amended Alnylam Agreement (as defined below) that was recognized as research and development expense.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022, the Company also has a contract liability of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million within noncurrent deferred revenues, which represents deferred consideration for the remaining two options that the Company granted to Brii Bio. The deferred consideration will be recognized when Brii Bio exercises its remaining options or the remaining options expire.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Alnylam&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In October 2017, the Company entered into the collaboration and license agreement with Alnylam, as amended in December 2019 and March, April and December 2020 (the &#x201c;Amended Alnylam Agreement&#x201d;) for the development of siRNA products for the treatment of HBV, and following the exercise of certain program options, the development and commercialization of siRNA therapeutic products directed to up to four other infectious disease targets selected by the Company. The technology licensed under the Amended Alnylam Agreement forms the basis of the Company&#x2019;s siRNA technology platform.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Under the Amended Alnylam Agreement, the Company obtained a worldwide, exclusive license to develop, manufacture and commercialize the HBV siRNA product candidates, including VIR-2218, for all uses and purposes other than agricultural, horticultural, forestry, aquaculture and other residential applications (such excluded fields, the &#x201c;Excluded Fields&#x201d;). In addition, Alnylam granted the Company an exclusive option, for each of the infectious disease siRNA programs directed to the Company&#x2019;s selected targets, to obtain a worldwide, exclusive license to develop, manufacture and commercialize siRNA products directed to the target of each such program for all uses and purposes other than the Excluded Fields. On a product-by-product basis for each product arising from the HBV program and, following the Company&#x2019;s option exercise, the infectious disease program, Alnylam has an exclusive option, exercisable during a specified period prior to the initiation of a Phase 3 clinical trial for each such product, to negotiate and enter into a profit-sharing agreement for such product.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company and Alnylam were jointly responsible for funding the initial research and development activities for VIR-2218 through the completion of proof-of-concept trials. Prior to the exercise of the Company&#x2019;s option for each siRNA program directed to one of the Company&#x2019;s selected infectious disease targets, Alnylam is responsible for conducting all development activities, at the Company&#x2019;s expense, in accordance with an agreed-upon development plan. Following the Company&#x2019;s exercise of an option for a program and payment of the program option exercise fee and any outstanding program costs due to Alnylam, the Company is solely responsible, at the Company&#x2019;s expense (subject to Alnylam&#x2019;s exercise of a profit-sharing option), for conducting all development, manufacture and commercialization activities for products arising from each such program. If Alnylam exercises a profit-sharing option for a product, the Company will negotiate the terms of such profit-sharing agreement, which will include sharing equally with Alnylam all subsequent costs associated with the development of such product, as well as the profits and losses in connection with such product, subject to reimbursement by Alnylam of a portion of specified development costs in certain circumstances.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Upon the achievement of a certain development milestone, as further discussed below, the Company was obligated to issue shares of the Company&#x2019;s common stock equal to the lesser of (i) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,111,111&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares or (ii) a certain number of shares based on the Company&#x2019;s stock price at the time such milestone is achieved (the &#x201c;Milestone Shares&#x201d;). The Company will be required to pay Alnylam up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;190.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in the aggregate for the achievement of specified development and regulatory milestones by the first siRNA product directed to HBV, and up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;115.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the achievement of specified development and regulatory milestones by the first product directed to the target of each infectious disease siRNA program for which the Company exercised its option. Following commercialization, the Company will be required to pay to Alnylam up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;250.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in the aggregate for the achievement of specified levels of net sales by siRNA products directed to HBV and up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;100.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the achievement of specified levels of net sales by products directed to the target of each infectious disease siRNA program for which the Company exercised its option. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company may also be required to pay Alnylam tiered royalties at percentages ranging from the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;low double-digits to mid-teens&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; on annual net sales of HBV products, and tiered royalties at percentages ranging from the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;high single-digits to the sub-teen double-digits&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; on annual net sales of licensed infectious disease products, in each case subject to specified reductions and offsets. &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The royalties are payable on a product-by-product and country-by-country basis until the later of the expiration of all valid claims of specified patents covering such product in such country and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; years after the first commercial sale of such product in such country.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In March 2020, the Company achieved the specified development milestone relating to the Milestone Shares, which was accounted for as an embedded derivative. Consequently, the Company remeasured and reclassified the derivative liability to additional paid-in capital based on the estimated fair value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;29.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million. The Company issued Alnylam &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,111,111&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of its common stock and paid Alnylam $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in the second quarter of 2020.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The term of the Amended Alnylam Agreement will continue, on a product-by-product and country-by-country basis, until the expiration of all royalty payment obligations under the Amended Alnylam Agreement. If the Company does not exercise its option for an infectious disease program directed to one of its selected targets, the Amended Alnylam Agreement will expire upon the expiration of the applicable option period with respect to such program. However, if Alnylam exercises its profit-sharing option for any product, the term of the Amended Alnylam Agreement will continue until the expiration of the profit-sharing arrangement for such product. The Company may terminate the Amended Alnylam Agreement on a program-by-program basis or in its entirety for any reason on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;90&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; days&#x2019; written notice. Either party may terminate the agreement for cause for the other party&#x2019;s uncured material breach on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;60&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; days&#x2019; written notice (or &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; days&#x2019; notice for payment breach), or if the other party challenges the validity or enforceability of any patent licensed to it under the Amended Alnylam Agreement on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30 days&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2019; notice.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company incurred expenses under the Amended Alnylam Agreement of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million during the years ended December 31, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022 and 2021, respectively. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For the year ended December 31, 2020, in addition to the Milestone Shares, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million milestone payment to Alnylam, and the $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million payment resulting from Brii Bio&#x2019;s option exercise in the first half of 2020, the Company incurred expenses of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million under the Amended Alnylam Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;WuXi Biologics&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In February 2020, the Company entered into a development and manufacturing collaboration agreement with WuXi Biologics (the &#x201c;WuXi Biologics Collaboration Agreement&#x201d;) for the clinical development, manufacturing, and commercialization of the Company&#x2019;s proprietary antibodies developed for SARS-CoV-2. Under the WuXi Biologics Collaboration Agreement, WuXi Biologics conducted cell-line development, process and formulation development, and initial manufacturing for clinical development and had the right to commercialize products incorporating such SARS-CoV-2 antibodies in mainland China, Hong Kong, Macau and Taiwan under an exclusive license granted for the selected SARS-CoV-2 antibodies that were developed.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Termination of the WuXi Biologics Collaboration Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;On May 16, 2022, the Company and WuXi Biologics entered into a Termination Agreement (the &#x201c;Termination Agreement&#x201d;) pursuant to which the Company and WuXi Biologics terminated the WuXi Biologics Collaboration Agreement. Other existing agreements between the Company and WuXi Biologics remain in effect.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Under the terms of the Termination Agreement, all licenses granted under the WuXi Biologics Collaboration Agreement were terminated and all rights to the SARS-CoV-2 antibody products in mainland China, Hong Kong, Macau and Taiwan reverted to the Company. The Company made a one-time termination payment to WuXi Biologics of $7.0 million and accounted for the payment as an acquisition of an IPR&amp;amp;D asset and, therefore, recognized research and development expense of $7.0 million during the second quarter of 2022. Under the terms of the Termination Agreement, the Company will be obligated to pay WuXi Biologics tiered royalties on net sales of sotrovimab in mainland China, Hong Kong, Macau and Taiwan ranging from low single digits to low double digits. Royalties are payable to WuXi Biologics for a specified royalty term and are subject to reduction in certain circumstances.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Rockefeller University&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In July 2018, the Company entered into an exclusive license agreement with The Rockefeller University (&#x201c;Rockefeller&#x201d;), which was amended in May 2019, in September 2020, and in March 2021 (as amended, the &#x201c;Rockefeller Agreement&#x201d;). Under the Rockefeller Agreement, Rockefeller granted the Company a worldwide exclusive license under certain patent rights, and a worldwide non-exclusive license under certain materials and know-how covering certain antibody variants relating to a specified mutation leading to enhanced antibody function and utility, to develop, manufacture and commercialize infectious disease products covered by the licensed patents, or that involve the use or incorporation of the licensed materials and know-how, in each case for all uses and purposes for infectious diseases. The Company uses technology licensed under the Rockefeller Agreement in the Company&#x2019;s antibody platform and in the Company&#x2019;s product candidate VIR-3434.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company is required to pay annual license maintenance fees of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, which can be creditable against royalties following commercialization. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In addition, upon achievement of specified development, regulatory and commercial success milestone events, the Company is required to pay up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;80.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, in the aggregate, for up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;six&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; infectious &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;disease products. Any follow-on products beyond six products may result in additional milestone event payments. The Company will also be required to pay to Rockefeller a royalty at a low single-digit percentage rate on net sales of licensed products, subject to certain adjustments. The Company&#x2019;s obligation to pay royalties to Rockefeller will terminate, on a product-by-product and jurisdiction-by-jurisdiction basis,&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;upon &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;the latest of the expiration of the last valid claim of a licensed patent in such jurisdiction, the expiration of all regulatory exclusivity in such jurisdiction or &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; years following the first commercial sale of the applicable licensed product in such jurisdiction.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Under the Rockefeller Agreement, the Company recognized a total of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million during the years ended December 31, 2022, 2021 and 2020, respectively, as research and development expenses related to certain development milestone payments, annual license maintenance fees, and estimated sublicense fees.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Rockefeller Agreement will remain in force, absent earlier termination, until the expiration of all of the Company&#x2019;s obligations to pay royalties to Rockefeller in all jurisdictions. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has the right to terminate the Rockefeller Agreement in its entirety, or in part, for any reason on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;60 days&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2019; written notice to Rockefeller. Rockefeller may terminate the Rockefeller Agreement on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;90 days&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2019; written notice for the Company&#x2019;s uncured material breach, or if the Company challenges the validity or enforceability of any of the licensed patents, or immediately in the event of the Company&#x2019;s insolvency. Rockefeller may also terminate the Rockefeller Agreement if the Company ceases to carry on business with respect to the rights granted to the Company under the Rockefeller Agreement.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;MedImmune&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In September 2018, the Company entered into a license agreement, which was amended in September 2020 (as amended, the &#x201c;MedImmune Agreement&#x201d;), with MedImmune, LLC (&#x201c;MedImmune&#x201d;), under which the Company obtained a worldwide, exclusive license to develop and commercialize half-life extended versions of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; specified antibodies under development by MedImmune that target influenza A and influenza B, respectively, for all uses in humans and animals. The Company is developing VIR-2482 using technology licensed under the MedImmune Agreement.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company is obligated to make development, regulatory, and commercial milestone payments of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;331.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in the aggregate relating to influenza A and influenza B products. MedImmune is also entitled to receive tiered royalties based on net sales of products containing half-life extended versions of antibodies directed to influenza A and/or influenza B at percentages ranging from the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_5dac47e7-0c9b-40b2-b070-76af35962042;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;mid-single-digits&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; to sub-teen double-digits.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The MedImmune Agreement will remain in force until the expiration on a country-by-country and product-by-product basis of all of the Company&#x2019;s obligations to pay royalties to MedImmune. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company may terminate the MedImmune Agreement in its entirety or on a product-by-product basis, for convenience, upon &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;120&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; days&#x2019; notice. Either party may terminate the MedImmune Agreement for cause for the other party&#x2019;s uncured material breach on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;60&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; days&#x2019; notice or immediately in the event of bankruptcy of the other party. Additionally, MedImmune may terminate the MedImmune Agreement for cause on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30 days&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2019; written notice if the Company challenges the validity or enforceability of the patents to which the Company has obtained a license under the MedImmune Agreement.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Xencor&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;August 2019 License Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In August 2019, the Company entered into a patent license agreement, which was amended in February 2021 (as amended, the &#x201c;2019 Xencor Agreement&#x201d;) with Xencor, Inc. (&#x201c;Xencor&#x201d;). Under the 2019 Xencor Agreement, the Company obtained a non-exclusive, sublicensable (only to its affiliates and subcontractors) license to incorporate Xencor&#x2019;s licensed technologies into, and to evaluate, antibodies that target influenza A and HBV, and a worldwide, non-exclusive, sublicensable license to develop and commercialize products containing such antibodies incorporating such technologies for all uses, including the treatment, palliation, diagnosis and prevention of human or animal diseases, disorders or conditions. The Company is obligated to use commercially reasonable efforts to develop and commercialize an antibody product that incorporates Xencor&#x2019;s licensed technologies, for each of the influenza A and HBV research programs. These technologies are used in the Company&#x2019;s product candidates VIR-2482, incorporating Xencor&#x2019;s Xtend technology, and VIR-3434, incorporating Xencor&#x2019;s Xtend and other Fc technologies.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For each of the influenza A and HBV research programs, the Company is required to pay Xencor development and regulatory milestone payments of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in the aggregate, and commercial sales milestone payments of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;60.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in the aggregate, for a total of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;77.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in aggregate milestones for each program and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;155.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in aggregate milestones for both programs. On a product-by-product basis, the Company is also obligated to pay tiered royalties based on net sales of licensed products ranging from &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;low- to mid-single-digits&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The royalties are payable, on a product-by-product and country-by-country basis, until the expiration of the last to expire valid claim in the licensed patents covering such product in such country.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Under the 2019 Xencor Agreement, the Company recognized an immaterial amount during each of the years ended December 31, 2022, 2021 and 2020, as research and development expenses related to certain development milestone payments.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;March 2020 License Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In March 2020, the Company entered into a patent license agreement, which was amended in February 2021 (as amended, the &#x201c;2020 Xencor Agreement&#x201d;), with Xencor under which the Company obtained a non-exclusive, sublicensable (only to its affiliates and subcontractors) license to incorporate Xencor&#x2019;s licensed technologies into, and to evaluate, antibodies that target any component of a coronavirus, including SARS-CoV-2, SARS-CoV and MERS-CoV, and a worldwide, non-exclusive, sublicensable license to develop and commercialize products containing such antibodies incorporating such technologies for all uses, including the treatment, palliation, diagnosis and prevention of human or animal diseases, disorders or conditions. The Company is obligated to use commercially reasonable efforts to develop and commercialize an antibody product that incorporates Xencor&#x2019;s licensed technologies, for each of the coronavirus research programs. These technologies are used in sotrovimab, incorporating Xencor&#x2019;s Xtend technology.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In consideration for the grant of the license, the Company is obligated to pay royalties based on net sales of licensed products at the&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; mid-single-digits&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The royalties are payable, on a product-by-product and country-by-country basis, until the later of the expiration of the last to expire valid claim in the licensed patents covering such product in such country or &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12 years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. During the years ended December 31, 2022 and 2021, the Company recognized $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;114.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;52.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively, as cost of revenue for royalties due to Xencor from the sale of sotrovimab.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The 2020 Xencor Agreement and 2019 Xencor Agreement will remain in force, on a product-by-product and country-by-country basis, until the expiration of all royalty payment obligations under each of the respective agreements. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company may terminate each agreement in its entirety, or on a target-by-target basis, for convenience upon &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;60&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; days&#x2019; written notice. Either party may terminate each agreement for the other party&#x2019;s uncured material breach upon &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;60&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; days&#x2019; written notice (or &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; days in the case of non-payment) or in the event of bankruptcy of the other party immediately upon written notice. Xencor may terminate each agreement immediately upon written notice if the Company challenges, or upon &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; days&#x2019; written notice if any of the Company&#x2019;s sublicensees challenge, the validity or enforceability of any patent licensed to the Company under each respective agreement.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_7c77693b-4357-4bb2-a8c3-270864bc9cad"
      decimals="INF"
      id="F_6f5bdc29-ad55-4ccb-8df2-b64197a7b70b"
      unitRef="U_shares">6626027</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="C_48f1b79a-a22f-4fe8-acd8-aae6fb94bd78"
      decimals="2"
      id="F_8fd75026-1ab3-4785-8b14-60333c3ebb82"
      unitRef="U_USDollarShare">37.73</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_7c77693b-4357-4bb2-a8c3-270864bc9cad"
      decimals="-5"
      id="F_c94ef604-9663-45c6-8fe6-f29e8868dd9b"
      unitRef="U_USD">250000000.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <vir:CollaborationTypeAndPrograms
      contextRef="C_bc722d93-c8c5-4bb5-99b0-064fd7628401"
      id="F_6e748486-9449-43ec-888d-736cff54e081">The collaboration initially focused on the development and commercialization of three types of collaboration products under three programs: (1) antibodies targeting SARS-CoV-2 and potentially other coronaviruses (the &#x201c;Antibody Program&#x201d;); (2) vaccines targeting SARS-CoV-2 and potentially other coronaviruses (the &#x201c;Vaccine Program&#x201d;), and (3) products based on genome-wide CRISPR screening of host targets expressed in connection with exposure to SARS-CoV-2 and potentially other coronaviruses (the &#x201c;Functional Genomics Program&#x201d;)</vir:CollaborationTypeAndPrograms>
    <vir:NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans
      contextRef="C_41c05a89-da87-4a31-a87a-9e37c464d328"
      id="F_34f36cd1-b27e-494c-af7c-6d7af0fc32c1">P4Y</vir:NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans>
    <vir:PercentageOfDevelopmentCosts
      contextRef="C_0d93da71-2399-418f-85e8-9b6b02f4b192"
      decimals="3"
      id="F_0256a6d1-f70b-405b-8b6d-ba086a78174f"
      unitRef="U_pure">0.725</vir:PercentageOfDevelopmentCosts>
    <vir:PercentageOfDevelopmentCosts
      contextRef="C_75214fe5-9907-465b-9eda-dcd555754a33"
      decimals="3"
      id="F_bea10a80-648f-4967-a10d-a52cfe711abf"
      unitRef="U_pure">0.275</vir:PercentageOfDevelopmentCosts>
    <vir:MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct
      contextRef="C_41c05a89-da87-4a31-a87a-9e37c464d328"
      decimals="2"
      id="F_dc05e0d6-3a02-45f0-a3db-bfc7085ad8dd"
      unitRef="U_pure">0.20</vir:MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct>
    <vir:CollaborationAgreementTerminationDescription
      contextRef="C_decb4aa5-5378-4f20-b098-06e2d05697eb"
      id="F_920d3009-4170-4f46-b9a1-99a68eb5ed62">Either party has the right to terminate the 2020 GSK Agreement in the case of the insolvency of the other party, an uncured material breach of the other party with respect to a collaboration program or collaboration product, or as mutually agreed by the parties.</vir:CollaborationAgreementTerminationDescription>
    <vir:FairMarketValueOfCommonStockIssued
      contextRef="C_5ff17edc-f10a-4706-a1cd-672e160dd990"
      decimals="-5"
      id="F_604473af-7edd-4a7c-b135-4ba88ec940f4"
      unitRef="U_USD">206700000</vir:FairMarketValueOfCommonStockIssued>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_e4ef837c-de22-4e63-b673-9b05c1a2fa71"
      decimals="2"
      id="F_ce27e422-68df-4088-b022-856dd5c2f03d"
      unitRef="U_USDollarShare">36.70</us-gaap:SaleOfStockPricePerShare>
    <vir:PremiumReceivedOnSalePriceOfCommonStock
      contextRef="C_5ff17edc-f10a-4706-a1cd-672e160dd990"
      decimals="-5"
      id="F_b5986792-1933-4a86-8d70-a3f51f940361"
      unitRef="U_USD">43300000</vir:PremiumReceivedOnSalePriceOfCommonStock>
    <vir:CollaborationAgreementNumberOfUnitsOfAccount
      contextRef="C_41c05a89-da87-4a31-a87a-9e37c464d328"
      decimals="INF"
      id="F_d47e4031-4016-476d-ae20-1f6bde759f99"
      unitRef="U_Unit">4</vir:CollaborationAgreementNumberOfUnitsOfAccount>
    <vir:AntibodyLicenseTransactionPrice
      contextRef="C_0d93da71-2399-418f-85e8-9b6b02f4b192"
      decimals="-5"
      id="F_93982ba0-dfb1-4e39-9ef8-22ae160159b2"
      unitRef="U_USD">43300000</vir:AntibodyLicenseTransactionPrice>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_60fd6477-1423-4941-969e-7c5f8ad2c846"
      decimals="-5"
      id="F_f378db18-43e2-4b8c-ae61-cdec3c4b56fc"
      unitRef="U_USD">43300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <vir:ProfitSharingAmountConstrained
      contextRef="C_6cddb4e4-b247-4253-a284-b9685fd836de"
      decimals="-5"
      id="F_17c162db-b415-4d6c-812b-13e23ac96075"
      unitRef="U_USD">-369700000</vir:ProfitSharingAmountConstrained>
    <vir:CollaborationRevenueTableTextBlock
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_3edfaf01-e001-4f22-8ad6-5dac353135c3">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;During the years ended December 31, 2022 and 2021, the Company recorded profit-sharing amounts and profit-sharing amounts constrained as components of collaboration revenue in the consolidated statements of operations, as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.078%;"/&gt;
        &lt;td style="width:2.396%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:19.968%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.396%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:20.162%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Collaboration revenue, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Profit-sharing amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,875,147&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;917,194&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Profit-sharing amount constrained&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;369,678&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total collaboration revenue, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,505,469&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;917,194&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</vir:CollaborationRevenueTableTextBlock>
    <vir:ProfitSharingAmount
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_59d5c16f-1ffa-4d0f-be73-e5c19859dd97"
      unitRef="U_USD">1875147000</vir:ProfitSharingAmount>
    <vir:ProfitSharingAmount
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_a4163713-6001-4521-ba68-42a3bb0b99cb"
      unitRef="U_USD">917194000</vir:ProfitSharingAmount>
    <vir:ProfitSharingAmountConstrained
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_e16e18f4-ed7f-43ba-8fec-8dd8bb434459"
      unitRef="U_USD">-369678000</vir:ProfitSharingAmountConstrained>
    <vir:ProfitSharingAmountConstrained
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_990e05c4-6d75-4e0c-a1fb-56663b321cfd"
      unitRef="U_USD">0</vir:ProfitSharingAmountConstrained>
    <vir:TotalcollaborationRevenue
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_576e69e2-839a-4cc3-8249-7f31cd9c550b"
      unitRef="U_USD">1505469000</vir:TotalcollaborationRevenue>
    <vir:TotalcollaborationRevenue
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_7834807b-e1bd-41b1-a04e-afc70e13aa29"
      unitRef="U_USD">917194000</vir:TotalcollaborationRevenue>
    <vir:IncreaseDecreaseInResearchAndDevelopmentExpense
      contextRef="C_decb4aa5-5378-4f20-b098-06e2d05697eb"
      decimals="-5"
      id="F_73834e39-9383-41ed-9b12-0eca0f0ad4f7"
      unitRef="U_USD">31400000</vir:IncreaseDecreaseInResearchAndDevelopmentExpense>
    <vir:IncreaseDecreaseInResearchAndDevelopmentExpense
      contextRef="C_07f1d79c-70ab-4760-854b-ccf98c1deed1"
      decimals="-5"
      id="F_06533b46-7d3b-46b1-9f0b-8481297ad403"
      unitRef="U_USD">77300000</vir:IncreaseDecreaseInResearchAndDevelopmentExpense>
    <vir:IncreaseDecreaseInResearchAndDevelopmentExpense
      contextRef="C_ecd49638-d3b0-4e7d-9c09-1defc1de59fc"
      decimals="-5"
      id="F_d59064ce-5c00-430d-96dc-724993264a15"
      unitRef="U_USD">25400000</vir:IncreaseDecreaseInResearchAndDevelopmentExpense>
    <vir:UpfrontPaymentReceived
      contextRef="C_5d48d11c-c737-4016-a687-853508a51066"
      decimals="-5"
      id="F_f72c4257-d351-4799-b0bb-f20139092c61"
      unitRef="U_USD">7000000.0</vir:UpfrontPaymentReceived>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="C_de66dc29-7c5c-4788-af3e-b26710f8cb06"
      decimals="-5"
      id="F_dbb732a1-4a63-4c6a-8827-cd98bc87c527"
      unitRef="U_USD">7000000.0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <vir:CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate
      contextRef="C_b6ba7de2-aef8-4b9a-a988-45dae6fa27d5"
      decimals="INF"
      id="F_0f4e51d6-8afe-49b8-9b9f-c632dd8f0332"
      unitRef="U_Program">3</vir:CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_70c61983-c30b-4442-b262-ed8ba12eed88"
      decimals="-5"
      id="F_89552881-250f-459b-bbb3-cf4aadb15caa"
      unitRef="U_USD">120000000.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_ae08f4b9-a601-42cb-8ece-21e5e2b7b3f0"
      decimals="INF"
      id="F_ffd0e430-1426-4954-9659-7026208312be"
      unitRef="U_shares">1924927</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <vir:NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans
      contextRef="C_bc63cc0a-80f2-4f25-8b71-3402b70afd98"
      id="F_13199045-d16a-4efe-8115-98ba42f35128">P3Y</vir:NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans>
    <vir:PercentageOfShareDevelopmentCosts
      contextRef="C_27c0e6df-cfdf-4bca-b0d3-1b934d52a189"
      decimals="INF"
      id="F_93c4edb6-3841-4ad4-acb1-187a393ff42c"
      unitRef="U_pure">0.50</vir:PercentageOfShareDevelopmentCosts>
    <vir:ProfitsAndLossesSharingPercentage
      contextRef="C_27c0e6df-cfdf-4bca-b0d3-1b934d52a189"
      decimals="INF"
      id="F_a6f4eacf-5e6b-49a8-b017-eacd9fc68f7b"
      unitRef="U_pure">0.50</vir:ProfitsAndLossesSharingPercentage>
    <vir:UpfrontPaymentReceived
      contextRef="C_f3bae72e-0345-4ef5-af24-752bbadb5f0b"
      decimals="-5"
      id="F_1075e80c-8c22-4d3d-9e74-c237bed212df"
      unitRef="U_USD">225000000.0</vir:UpfrontPaymentReceived>
    <vir:OptionExerciseFeeConsiderationToBeReceived
      contextRef="C_f3bae72e-0345-4ef5-af24-752bbadb5f0b"
      decimals="-5"
      id="F_7cb75ec1-3678-44c2-a88e-5d17d927e92a"
      unitRef="U_USD">300000000.0</vir:OptionExerciseFeeConsiderationToBeReceived>
    <vir:PreDefinedRegulatoryMilestoneConsiderationToBeReceived
      contextRef="C_b69ec4f4-b531-408c-b82a-92c8c2b9bcd4"
      decimals="-5"
      id="F_290d7b1a-5d5f-4e14-8778-6adc49b4d132"
      unitRef="U_USD">200000000.0</vir:PreDefinedRegulatoryMilestoneConsiderationToBeReceived>
    <vir:FairMarketValueOfCommonStockIssued
      contextRef="C_3906357f-ca70-49f3-97fc-ebdecba43cf9"
      decimals="-5"
      id="F_37e00a99-6e7d-4a27-97a2-470469d660f0"
      unitRef="U_USD">85200000</vir:FairMarketValueOfCommonStockIssued>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_1b0ce50f-5b97-4517-8931-808c3219617e"
      decimals="INF"
      id="F_c49a9f93-f31c-4a00-a4c6-70fd97a8b5e8"
      unitRef="U_USDollarShare">52.70</us-gaap:SaleOfStockPricePerShare>
    <vir:PremiumReceivedOnSalePriceOfCommonStock
      contextRef="C_3906357f-ca70-49f3-97fc-ebdecba43cf9"
      decimals="-5"
      id="F_23cc00cc-4244-4b65-b80c-c01737473872"
      unitRef="U_USD">34800000</vir:PremiumReceivedOnSalePriceOfCommonStock>
    <vir:CollaborationAgreementTransactionPriceUpfrontFee
      contextRef="C_e3df795a-3a56-41f0-b360-db9fa10cdc01"
      decimals="-5"
      id="F_cfde0f22-7df7-48b1-9958-84633b85dce6"
      unitRef="U_USD">225000000.0</vir:CollaborationAgreementTransactionPriceUpfrontFee>
    <vir:PremiumReceivedOnSalePriceOfCommonStock
      contextRef="C_083fe6a6-b404-46c5-8780-c18507a330b4"
      decimals="-5"
      id="F_03faa7af-03c2-4b4d-a840-37dfdcc895c6"
      unitRef="U_USD">34800000</vir:PremiumReceivedOnSalePriceOfCommonStock>
    <vir:CollaborationAgreementTransactionPriceConsideration
      contextRef="C_e3df795a-3a56-41f0-b360-db9fa10cdc01"
      decimals="-5"
      id="F_36a36936-bd40-4a90-bc5c-64b6d578ed54"
      unitRef="U_USD">259800000</vir:CollaborationAgreementTransactionPriceConsideration>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_46218237-5c98-4a62-bcee-3c18140a4029"
      decimals="-5"
      id="F_71c8c0c6-fbbc-4df7-99b9-c88d3c7e235b"
      unitRef="U_USD">168300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="C_5cf7a8d0-261c-43e4-b66c-26e9b9c2e5b8"
      decimals="-5"
      id="F_62447cb1-5068-4c87-8b5e-77debef4f719"
      unitRef="U_USD">51700000</us-gaap:DeferredRevenueNoncurrent>
    <vir:ReclassifiedDeferredRevenue
      contextRef="C_5cf7a8d0-261c-43e4-b66c-26e9b9c2e5b8"
      decimals="-5"
      id="F_1464563b-4008-4c6f-8aed-71d848f1e679"
      unitRef="U_USD">51700000</vir:ReclassifiedDeferredRevenue>
    <us-gaap:DeferredIncome
      contextRef="C_6ff10353-fa1d-4c3b-ac8e-ff5c4ae62117"
      decimals="-5"
      id="F_a37c6b50-83bd-4ed1-ab37-8d94a274e229"
      unitRef="U_USD">39800000</us-gaap:DeferredIncome>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_48a91d5d-ea5c-4037-9225-755e30bfc6c5"
      decimals="-2"
      id="F_b91d7e89-e06e-4456-b0ee-89e98663c1a8"
      unitRef="U_USD">39800</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <vir:IncreaseDecreaseInResearchAndDevelopmentExpense
      contextRef="C_c5248545-d73b-4cb5-a202-3d3703194709"
      decimals="-5"
      id="F_c2c74b30-134d-43b0-b77a-62c179014bf6"
      unitRef="U_USD">2300000</vir:IncreaseDecreaseInResearchAndDevelopmentExpense>
    <vir:IncreaseDecreaseInResearchAndDevelopmentExpense
      contextRef="C_ef38c128-b6f9-4268-8e29-dbff882abc57"
      decimals="-5"
      id="F_e74d833d-c99d-44c8-8a2f-3d0b6eb52b44"
      unitRef="U_USD">500000</vir:IncreaseDecreaseInResearchAndDevelopmentExpense>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_a1e68275-f02d-43b0-8ccb-7c3d41000c0e"
      decimals="-5"
      id="F_e9420278-55ab-4e1b-8aa5-50d5a8fc26ef"
      unitRef="U_USD">773100000</us-gaap:AccountsReceivableNetCurrent>
    <vir:MaximumNumberOfDevelopmentProgramGrantedToCounterparty
      contextRef="C_61fecc05-bbcc-451c-ad8a-57bf80b34de9"
      decimals="INF"
      id="F_89c75d27-f7e4-4a9a-be05-11b216396523"
      unitRef="U_Program">4</vir:MaximumNumberOfDevelopmentProgramGrantedToCounterparty>
    <vir:MaximumNumberOfDevelopmentProgramGrantedFromCounterparty
      contextRef="C_61fecc05-bbcc-451c-ad8a-57bf80b34de9"
      decimals="INF"
      id="F_a5613e25-21cd-4bcd-8522-7f4c558ec007"
      unitRef="U_Program">4</vir:MaximumNumberOfDevelopmentProgramGrantedFromCounterparty>
    <vir:PercentageOfOrdinaryShareEqualToOutstandingShare
      contextRef="C_61fecc05-bbcc-451c-ad8a-57bf80b34de9"
      decimals="INF"
      id="F_3bafdd3f-7baa-45f6-b88c-3a10132bcf77"
      unitRef="U_pure">0.099</vir:PercentageOfOrdinaryShareEqualToOutstandingShare>
    <vir:OptionExerciseFeeLowEndOfTheRange
      contextRef="C_363509bf-b0e5-4bc4-a76d-8682508915cc"
      id="F_11c9e293-eecf-43a1-baa0-f2bbdda1131a"> mid-single-digit millions</vir:OptionExerciseFeeLowEndOfTheRange>
    <vir:OptionExerciseFeeHighEndOfTheRange
      contextRef="C_0fd0f713-f953-4286-a81c-0606471c2227"
      decimals="INF"
      id="F_b5e3eaa2-9014-4a1f-9a14-ba7005bb9bdd"
      unitRef="U_USD">20000000.0</vir:OptionExerciseFeeHighEndOfTheRange>
    <vir:RegulatoryMilestonePaymentOnLicensedProductLowEndOfTheRange
      contextRef="C_363509bf-b0e5-4bc4-a76d-8682508915cc"
      id="F_0b5237ab-2788-464b-b8d3-6e6d0cde4c97">mid-single-digit millions</vir:RegulatoryMilestonePaymentOnLicensedProductLowEndOfTheRange>
    <vir:RegulatoryMilestonePaymentOnLicensedProductHighEndOfRange
      contextRef="C_0fd0f713-f953-4286-a81c-0606471c2227"
      decimals="-5"
      id="F_8c95640f-7ec3-4ad0-8a88-b8c726eb03da"
      unitRef="U_USD">30000000.0</vir:RegulatoryMilestonePaymentOnLicensedProductHighEndOfRange>
    <vir:MaximumAggregateSalesMilestonePayments
      contextRef="C_724a4a6c-eb88-43e1-9385-7a1ee1d59450"
      decimals="-5"
      id="F_4393765d-f1a2-48de-be48-13b8254180bb"
      unitRef="U_USD">175000000.0</vir:MaximumAggregateSalesMilestonePayments>
    <vir:OptionExerciseFeeLowEndOfTheRange
      contextRef="C_fb57c6da-b1f8-44af-a1d9-109cfe493bad"
      id="F_94490d90-223f-4206-b1cf-ff176ac18326">low tens of millions</vir:OptionExerciseFeeLowEndOfTheRange>
    <vir:OptionExerciseFeeHighEndOfTheRange
      contextRef="C_2ec7ad16-c1b2-49f2-9adb-7d795c32364a"
      decimals="-5"
      id="F_cc85e8a0-3b0b-4229-ac59-c98c9f343bf7"
      unitRef="U_USD">50000000.0</vir:OptionExerciseFeeHighEndOfTheRange>
    <vir:RegulatoryMilestonePaymentOnLicensedProductLowEndOfTheRange
      contextRef="C_724a4a6c-eb88-43e1-9385-7a1ee1d59450"
      id="F_84be40b7-d9ca-400b-8adb-874d75701282">low tens of millions</vir:RegulatoryMilestonePaymentOnLicensedProductLowEndOfTheRange>
    <vir:RegulatoryMilestonePaymentOnLicensedProductHighEndOfRange
      contextRef="C_2ec7ad16-c1b2-49f2-9adb-7d795c32364a"
      decimals="-5"
      id="F_77af593f-c523-4269-a133-1371c8ccbbf4"
      unitRef="U_USD">100000000.0</vir:RegulatoryMilestonePaymentOnLicensedProductHighEndOfRange>
    <vir:MaximumAggregateSalesMilestonePayments
      contextRef="C_363509bf-b0e5-4bc4-a76d-8682508915cc"
      decimals="-5"
      id="F_565054ff-1540-4dba-87d7-1887da3c1a19"
      unitRef="U_USD">175000000.0</vir:MaximumAggregateSalesMilestonePayments>
    <vir:RangeOfRoyaltyPaymentToBePaid
      contextRef="C_b70442f4-3b9a-4721-b156-3f58ba42d7b0"
      id="F_c5f9fa6b-8b0f-4167-a647-391056634098">mid-teens to high-twenties</vir:RangeOfRoyaltyPaymentToBePaid>
    <vir:RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales
      contextRef="C_b70442f4-3b9a-4721-b156-3f58ba42d7b0"
      id="F_d0478d0c-1437-42e7-a14a-16f89ad2cadb">P10Y</vir:RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales>
    <vir:CollaborationAgreementTerminationDescription
      contextRef="C_6ea95d1d-1302-408e-b108-02685b997985"
      id="F_19046b68-c519-48c6-a2e5-0c940cd268d6">Each party may terminate for convenience all rights and obligations with respect to any program for which it has an option, with 30 days&#x2019; written notice (if the terminating party has not exercised an option for such program) or 180 days&#x2019; notice (following the exercise of an option for such program). The Brii Agreement may also be terminated by either party for insolvency of the other party, and either party may terminate the Brii Agreement in its entirety or on a program-by-program basis for the other party&#x2019;s uncured material breach on 60 days&#x2019; written notice (or 30 days&#x2019; notice following failure to make payment).</vir:CollaborationAgreementTerminationDescription>
    <vir:WrittenNoticeToTerminateLicensedProgramIfNotExercise
      contextRef="C_1e2fb995-8c8f-44b9-a52f-67b970d66f9a"
      id="F_8031d8ce-ef9f-45fe-84d6-c887bf740e5c">P30D</vir:WrittenNoticeToTerminateLicensedProgramIfNotExercise>
    <vir:WrittenNoticeToTerminateLicensedProgramIfExercise
      contextRef="C_1e2fb995-8c8f-44b9-a52f-67b970d66f9a"
      id="F_9a977ed3-68d0-4d09-89d0-8fed4535c5b5">P180D</vir:WrittenNoticeToTerminateLicensedProgramIfExercise>
    <vir:WrittenNoticePeriodToTerminateLicensedProgramForUncuredMaterialBreach
      contextRef="C_1e2fb995-8c8f-44b9-a52f-67b970d66f9a"
      id="F_6aa6ea07-04b2-4466-a099-d913b464ce0f">P60D</vir:WrittenNoticePeriodToTerminateLicensedProgramForUncuredMaterialBreach>
    <vir:WrittenNoticePeriodToTerminateLicensedProgramForFailureToMakePayment
      contextRef="C_1e2fb995-8c8f-44b9-a52f-67b970d66f9a"
      id="F_fc1c3445-5a51-462b-bfaa-48b3c7032944">P30D</vir:WrittenNoticePeriodToTerminateLicensedProgramForFailureToMakePayment>
    <us-gaap:Investments
      contextRef="C_3e754139-9f86-457e-a6d3-61f2f6892dbf"
      decimals="-5"
      id="F_6ee781a4-599b-43da-836b-139f119a2096"
      unitRef="U_USD">5700000</us-gaap:Investments>
    <vir:OptionExerciseFeeReceived
      contextRef="C_0e941a4e-4958-42af-89e7-b694adf192d4"
      decimals="-5"
      id="F_9a996b72-4dbf-4d06-9798-28fc75f81113"
      unitRef="U_USD">20000000.0</vir:OptionExerciseFeeReceived>
    <vir:RegulatoryMilestonePaymentToBeReceived
      contextRef="C_7ca9fa0c-6fce-40ab-ad6a-72ab66e31dc8"
      decimals="-5"
      id="F_bd5097d0-a5b0-4b08-89db-67092ee3688b"
      unitRef="U_USD">30000000.0</vir:RegulatoryMilestonePaymentToBeReceived>
    <vir:MaximumSalesMilestonePaymentsToBeReceived
      contextRef="C_000e7047-27c6-405d-911b-7387dc00e8cb"
      decimals="-5"
      id="F_f71c095d-3b83-40d3-81e2-cea2e0b8d2ec"
      unitRef="U_USD">175000000.0</vir:MaximumSalesMilestonePaymentsToBeReceived>
    <vir:RangeOfRoyaltyPaymentToBeReceived
      contextRef="C_7ca9fa0c-6fce-40ab-ad6a-72ab66e31dc8"
      id="F_78918a20-0f1a-4c35-87f7-2a649a34b0b0">high-teens to high-twenties</vir:RangeOfRoyaltyPaymentToBeReceived>
    <vir:OptionsTransactionPrice
      contextRef="C_8919d223-48db-4e72-8f84-bb9a105b4296"
      decimals="-5"
      id="F_af60d5f6-cc12-49a4-a8cd-012b9d766f5e"
      unitRef="U_USD">22700000</vir:OptionsTransactionPrice>
    <vir:OptionExerciseFeeReceived
      contextRef="C_8919d223-48db-4e72-8f84-bb9a105b4296"
      decimals="-5"
      id="F_e6181125-f15d-4560-899f-d3fd5d92a753"
      unitRef="U_USD">20000000.0</vir:OptionExerciseFeeReceived>
    <us-gaap:DeferredRevenue
      contextRef="C_b7110cbe-39a4-4c4a-904d-1a47b20ffc0f"
      decimals="-5"
      id="F_851dd675-cda4-4751-9765-cf6778608776"
      unitRef="U_USD">2700000</us-gaap:DeferredRevenue>
    <vir:OptionExerciseFeeReceived
      contextRef="C_2da3af76-3a2c-4087-bd64-efb611a69cc8"
      decimals="-5"
      id="F_38daef88-47d3-480f-94a6-13a43d538ec7"
      unitRef="U_USD">20000000.0</vir:OptionExerciseFeeReceived>
    <vir:RegulatoryMilestonePaymentToBeReceived
      contextRef="C_b5817a9b-c37f-413a-ab0c-c78fc5c64179"
      decimals="-5"
      id="F_73aa511c-6df0-4789-9b6b-18b552fd16af"
      unitRef="U_USD">30000000.0</vir:RegulatoryMilestonePaymentToBeReceived>
    <vir:MaximumSalesMilestoneToBeReceived
      contextRef="C_b5817a9b-c37f-413a-ab0c-c78fc5c64179"
      decimals="-5"
      id="F_5c87ba8c-45be-4185-b390-fd4d1d16c5cc"
      unitRef="U_USD">175000000.0</vir:MaximumSalesMilestoneToBeReceived>
    <vir:RangeOfRoyaltyPaymentToBeReceived
      contextRef="C_1c2df6fc-28b4-42ab-92ca-e8e7604a433d"
      id="F_cb056eef-e8ee-42d9-bf80-12734fc21ab8">mid-teens to mid-twenties</vir:RangeOfRoyaltyPaymentToBeReceived>
    <vir:OptionsTransactionPrice
      contextRef="C_4e62b6c4-3cd3-449d-8c77-954fc619391a"
      decimals="-5"
      id="F_e23ce458-cd2f-4d79-8ee3-f24ebebfd7af"
      unitRef="U_USD">22300000</vir:OptionsTransactionPrice>
    <vir:OptionExerciseFeeReceived
      contextRef="C_cafcd678-0319-424b-834a-70769b2cb74b"
      decimals="-5"
      id="F_8cef9004-1c7f-4d20-995d-b02fd6aaffa9"
      unitRef="U_USD">20000000.0</vir:OptionExerciseFeeReceived>
    <us-gaap:DeferredRevenue
      contextRef="C_db717f4e-f800-427d-a092-ed5b2685c250"
      decimals="-5"
      id="F_9b34e3c1-402a-4d32-95b1-af1b571b8281"
      unitRef="U_USD">2300000</us-gaap:DeferredRevenue>
    <us-gaap:RevenueFromRelatedParties
      contextRef="C_e08e7ea4-933b-4008-9b16-a6e809956279"
      decimals="-5"
      id="F_8e6d4455-f52b-4ea0-92d8-4037193e45b8"
      unitRef="U_USD">22300000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="C_6b24e017-0f8a-429b-817a-9ef0927b8433"
      decimals="INF"
      id="F_49bdeaa1-9073-4b87-9b33-c53e9f098b13"
      unitRef="U_USD">0</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="C_e28b382b-9754-42d1-868b-c2ea43f958c4"
      decimals="-5"
      id="F_0da01478-a1f2-4d3d-afcc-6f8029687b76"
      unitRef="U_USD">22700000</us-gaap:RevenueFromRelatedParties>
    <vir:PaymentToCollaboratorResultingFromProgramOptionExercise
      contextRef="C_e28b382b-9754-42d1-868b-c2ea43f958c4"
      decimals="-5"
      id="F_1e4aa25e-9c4b-41f9-b90c-8215b7a787dc"
      unitRef="U_USD">10000000.0</vir:PaymentToCollaboratorResultingFromProgramOptionExercise>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="C_8354e95f-a997-4559-8f00-06918b2494db"
      decimals="-5"
      id="F_514ad89d-d3f7-4e67-ab05-239ca5f1f58d"
      unitRef="U_USD">1500000</us-gaap:DeferredRevenueNoncurrent>
    <vir:MaximumSharesToBeIssued
      contextRef="C_ffc264f2-dd56-4ceb-b96e-fbf5c3db3606"
      decimals="INF"
      id="F_45ded1c3-e4f2-4ca6-93d8-815bf28046f0"
      unitRef="U_shares">1111111</vir:MaximumSharesToBeIssued>
    <vir:MaximumMilestonePaymentForAchievementOfSpecifiedMilestones
      contextRef="C_a88db863-7765-4796-a308-9513b1e29b15"
      decimals="-5"
      id="F_cc8eed54-b9b7-42db-ae6f-03a39300495e"
      unitRef="U_USD">190000000.0</vir:MaximumMilestonePaymentForAchievementOfSpecifiedMilestones>
    <vir:MaximumMilestonePaymentForAchievementOfSpecifiedMilestones
      contextRef="C_9390c172-8de0-44cd-beb2-d80a53d6291b"
      decimals="-5"
      id="F_80bb12c2-b0f3-4df7-b16e-7d0f9d3643e4"
      unitRef="U_USD">115000000.0</vir:MaximumMilestonePaymentForAchievementOfSpecifiedMilestones>
    <vir:MaximumAggregateSalesMilestonePayment
      contextRef="C_a88db863-7765-4796-a308-9513b1e29b15"
      decimals="-5"
      id="F_5389a799-2c93-4465-8117-94a0b82779aa"
      unitRef="U_USD">250000000.0</vir:MaximumAggregateSalesMilestonePayment>
    <vir:MaximumSalesMilestonePayment
      contextRef="C_9390c172-8de0-44cd-beb2-d80a53d6291b"
      decimals="-5"
      id="F_eb910feb-b28f-43e7-9991-f0a3fa7b68e4"
      unitRef="U_USD">100000000.0</vir:MaximumSalesMilestonePayment>
    <vir:RangeOfTieredRoyaltiesToPayToNetSalesOfProducts
      contextRef="C_9238efac-e9f0-40db-8b4d-0bd6b667bce1"
      id="F_1b31f2dd-e2ed-4028-b07a-5d9bb058aa4d">The Company may also be required to pay Alnylam tiered royalties at percentages ranging from the low double-digits to mid-teens on annual net sales of HBV products, and tiered royalties at percentages ranging from the high single-digits to the sub-teen double-digits on annual net sales of licensed infectious disease products, in each case subject to specified reductions and offsets. </vir:RangeOfTieredRoyaltiesToPayToNetSalesOfProducts>
    <vir:RangeOfTieredRoyaltiesToPayToNetSalesOfProducts
      contextRef="C_a88db863-7765-4796-a308-9513b1e29b15"
      id="F_d5f1742d-808e-4fd6-aac2-f0e469fb58d7">low double-digits to mid-teens</vir:RangeOfTieredRoyaltiesToPayToNetSalesOfProducts>
    <vir:RangeOfTieredRoyaltiesToPayToNetSalesOfProducts
      contextRef="C_9390c172-8de0-44cd-beb2-d80a53d6291b"
      id="F_08777d55-9fbe-48f9-bed3-71fb07edcaab">high single-digits to the sub-teen double-digits</vir:RangeOfTieredRoyaltiesToPayToNetSalesOfProducts>
    <vir:RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales
      contextRef="C_7c1b6e30-61ef-41a5-af65-74e946d04165"
      id="F_56397382-a1bb-43ff-9bb9-f98d7f97f2e0">P10Y</vir:RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="C_a0ca781f-26e8-4b49-94e4-3f01a982fe52"
      decimals="-5"
      id="F_0fd6b1fc-f4b8-4f10-98da-7d3a7ee0d87a"
      unitRef="U_USD">29200000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_70da0710-1b2a-4c11-a63e-24ea296a4134"
      decimals="INF"
      id="F_7470fe0f-b97e-4ea0-9d4e-8dcf62fb41ac"
      unitRef="U_shares">1111111</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <vir:MilestonePaymentsPaid
      contextRef="C_402569c9-a676-4ead-a6ec-b7f313ab6266"
      decimals="-5"
      id="F_87cd25fc-809f-4066-a519-643cf5d669ae"
      unitRef="U_USD">15000000.0</vir:MilestonePaymentsPaid>
    <vir:WrittenNoticePeriodForTerminationOfLicensedProgram
      contextRef="C_e81fb921-41bb-4624-975a-443a7c7cdf16"
      id="F_deeca964-b2d6-40fd-89d5-474bc205ae52">P90D</vir:WrittenNoticePeriodForTerminationOfLicensedProgram>
    <vir:WrittenNoticePeriodToTerminateLicensedProgramForUncuredMaterialBreach
      contextRef="C_e81fb921-41bb-4624-975a-443a7c7cdf16"
      id="F_ba6f01aa-2318-4acc-82e5-9f0db4a612c4">P60D</vir:WrittenNoticePeriodToTerminateLicensedProgramForUncuredMaterialBreach>
    <vir:WrittenNoticePeriodToTerminateLicensedProgramForPaymentBreach
      contextRef="C_e81fb921-41bb-4624-975a-443a7c7cdf16"
      id="F_667c1865-e5ee-41f6-b033-04a4073bd576">P30D</vir:WrittenNoticePeriodToTerminateLicensedProgramForPaymentBreach>
    <vir:WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenge
      contextRef="C_e81fb921-41bb-4624-975a-443a7c7cdf16"
      id="F_370b2e48-c4a6-4a7c-ae6a-018023621f02">P30D</vir:WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenge>
    <vir:CollaborationAgreementRelatedCostsAndExpenses
      contextRef="C_6276028a-2d2e-482b-9ea8-a6448755d571"
      decimals="-5"
      id="F_a712cefa-44a5-4f69-81ee-c6a5670ed213"
      unitRef="U_USD">1400000</vir:CollaborationAgreementRelatedCostsAndExpenses>
    <vir:CollaborationAgreementRelatedCostsAndExpenses
      contextRef="C_7c1b6e30-61ef-41a5-af65-74e946d04165"
      decimals="-5"
      id="F_7fd836e5-237c-443d-931d-4b540d30f12a"
      unitRef="U_USD">11200000</vir:CollaborationAgreementRelatedCostsAndExpenses>
    <vir:MilestonePaymentsPaid
      contextRef="C_474023a2-9be4-4db1-9135-5888440e1408"
      decimals="-5"
      id="F_c361d388-7bf4-4064-aed9-96831e2a953b"
      unitRef="U_USD">15000000.0</vir:MilestonePaymentsPaid>
    <vir:PaymentToCollaboratorResultingFromProgramOptionExercise
      contextRef="C_8472ca01-d418-45f2-8494-45e935bbbc83"
      decimals="-5"
      id="F_480feaf6-0f05-4c78-bef7-f4c9f81a7174"
      unitRef="U_USD">10000000.0</vir:PaymentToCollaboratorResultingFromProgramOptionExercise>
    <vir:CollaborationAgreementRelatedCostsAndExpenses
      contextRef="C_946bca5b-a819-49fc-a9eb-3deae58d8824"
      decimals="-5"
      id="F_ef7ad6e8-1bfe-4555-8a84-f1b496d80e1c"
      unitRef="U_USD">11500000</vir:CollaborationAgreementRelatedCostsAndExpenses>
    <vir:AnnualLicenseMaintenanceFees
      contextRef="C_c8f5798c-ad39-4045-8160-7af430bcb734"
      decimals="-5"
      id="F_66ab7763-7b17-4c8a-ad95-07eb24e25182"
      unitRef="U_USD">1000000.0</vir:AnnualLicenseMaintenanceFees>
    <vir:MaximumAggregateMilestonePaymentForAchievementOfSpecifiedMilestones
      contextRef="C_03609c47-c098-4a60-97bd-053e2bf319bf"
      decimals="-5"
      id="F_246b87c5-7017-42cb-8142-822237debeb7"
      unitRef="U_USD">80300000</vir:MaximumAggregateMilestonePaymentForAchievementOfSpecifiedMilestones>
    <vir:MaximumNumberOfProductsCoveredAgainstMilestonePayment
      contextRef="C_20115010-b125-459b-ab42-c3f84a9a5259"
      decimals="INF"
      id="F_3564190f-6f09-4260-b106-af3de719a980"
      unitRef="U_Product">6</vir:MaximumNumberOfProductsCoveredAgainstMilestonePayment>
    <vir:RoyaltyObligationPeriodFromDateOfFirstCommercialSale
      contextRef="C_c8f5798c-ad39-4045-8160-7af430bcb734"
      id="F_50e7d6db-7352-40f0-8930-866290579317">P12Y</vir:RoyaltyObligationPeriodFromDateOfFirstCommercialSale>
    <vir:ResearchAndDevelopmentExpenseUnderLicenseAgreement
      contextRef="C_a1ff86c5-33e9-4326-b1f2-a4f7b5d2c716"
      decimals="-5"
      id="F_b5d5463a-fd87-46a3-971d-587fa8a21b05"
      unitRef="U_USD">1300000</vir:ResearchAndDevelopmentExpenseUnderLicenseAgreement>
    <vir:ResearchAndDevelopmentExpenseUnderLicenseAgreement
      contextRef="C_44ac39fd-62b7-430a-9b57-c2cfeb3f1006"
      decimals="-5"
      id="F_52e5821e-0567-49e1-903f-1b6c90bdb434"
      unitRef="U_USD">4700000</vir:ResearchAndDevelopmentExpenseUnderLicenseAgreement>
    <vir:ResearchAndDevelopmentExpenseUnderLicenseAgreement
      contextRef="C_d4f38c3d-eb5d-48e7-8694-cfdc645585c7"
      decimals="-5"
      id="F_a90bf6ac-4f70-457e-8f24-e499910d7669"
      unitRef="U_USD">1300000</vir:ResearchAndDevelopmentExpenseUnderLicenseAgreement>
    <vir:CollaborationAgreementTerminationDescription
      contextRef="C_c8f5798c-ad39-4045-8160-7af430bcb734"
      id="F_fb38425e-c6d3-4d43-94d8-4e8ab067bb1d">The Company has the right to terminate the Rockefeller Agreement in its entirety, or in part, for any reason on 60 days&#x2019; written notice to Rockefeller. Rockefeller may terminate the Rockefeller Agreement on 90 days&#x2019; written notice for the Company&#x2019;s uncured material breach, or if the Company challenges the validity or enforceability of any of the licensed patents, or immediately in the event of the Company&#x2019;s insolvency. Rockefeller may also terminate the Rockefeller Agreement if the Company ceases to carry on business with respect to the rights granted to the Company under the Rockefeller Agreement.</vir:CollaborationAgreementTerminationDescription>
    <vir:WrittenNoticePeriodToTerminateAgreementByCompany
      contextRef="C_c8f5798c-ad39-4045-8160-7af430bcb734"
      id="F_e2aa4b00-84fd-4ff9-bfbb-634961682c43">P60D</vir:WrittenNoticePeriodToTerminateAgreementByCompany>
    <vir:WrittenNoticePeriodToTerminateAgreementByCounterparty
      contextRef="C_c8f5798c-ad39-4045-8160-7af430bcb734"
      id="F_92b8924c-7be0-41b5-9d55-6ecc5a829e67">P90D</vir:WrittenNoticePeriodToTerminateAgreementByCounterparty>
    <vir:NumberOfAntibodiesToDevelop
      contextRef="C_679bc2b6-7333-4652-aa5e-56403fa75188"
      decimals="INF"
      id="F_4f7ba760-7c5b-4e52-b7c4-23e6d303792e"
      unitRef="U_Antibodies">2</vir:NumberOfAntibodiesToDevelop>
    <vir:MaximumAggregateMilestonePaymentForAchievementOfSpecifiedMilestones
      contextRef="C_440e7984-bced-4ce9-9125-e4710cb5f43b"
      decimals="INF"
      id="F_8873f83c-37d5-4feb-8ba3-9acd7184af7a"
      unitRef="U_USD">331500000</vir:MaximumAggregateMilestonePaymentForAchievementOfSpecifiedMilestones>
    <vir:CollaborationAgreementTerminationDescription
      contextRef="C_440e7984-bced-4ce9-9125-e4710cb5f43b"
      id="F_1c423622-d9bd-4e2e-97ba-b9b2e62f44a9">The Company may terminate the MedImmune Agreement in its entirety or on a product-by-product basis, for convenience, upon 120 days&#x2019; notice. Either party may terminate the MedImmune Agreement for cause for the other party&#x2019;s uncured material breach on 60 days&#x2019; notice or immediately in the event of bankruptcy of the other party. Additionally, MedImmune may terminate the MedImmune Agreement for cause on 30 days&#x2019; written notice if the Company challenges the validity or enforceability of the patents to which the Company has obtained a license under the MedImmune Agreement.</vir:CollaborationAgreementTerminationDescription>
    <vir:WrittenNoticePeriodForTerminationOfLicensedProgram
      contextRef="C_440e7984-bced-4ce9-9125-e4710cb5f43b"
      id="F_e6b07f3c-9301-4580-a2f2-dd0303988a92">P120D</vir:WrittenNoticePeriodForTerminationOfLicensedProgram>
    <vir:WrittenNoticePeriodToTerminateLicensedProgramForUncuredMaterialBreach
      contextRef="C_440e7984-bced-4ce9-9125-e4710cb5f43b"
      id="F_e9383e3c-d679-4de4-b4ed-94be6350c343">P60D</vir:WrittenNoticePeriodToTerminateLicensedProgramForUncuredMaterialBreach>
    <vir:WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenges
      contextRef="C_440e7984-bced-4ce9-9125-e4710cb5f43b"
      id="F_e7330068-f2a3-46b8-ad57-1eb9bc922c3d">P30D</vir:WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenges>
    <vir:MaximumAggregateDevelopmentAndRegulatoryMilestonePayments
      contextRef="C_90313909-a6bc-4583-86a7-47d337dd4cb1"
      decimals="-5"
      id="F_66eca115-2085-410a-a39e-855552947b35"
      unitRef="U_USD">17800000</vir:MaximumAggregateDevelopmentAndRegulatoryMilestonePayments>
    <vir:MaximumAggregateCommercialSalesMilestonePayments
      contextRef="C_90313909-a6bc-4583-86a7-47d337dd4cb1"
      decimals="-5"
      id="F_b8ad7442-7c4d-4784-a269-7adc0bea3945"
      unitRef="U_USD">60000000.0</vir:MaximumAggregateCommercialSalesMilestonePayments>
    <vir:MaximumAggregateMilestonePayments
      contextRef="C_d6d82c19-9cbe-4f4b-b35e-d5f66e5d7598"
      decimals="-5"
      id="F_30908db4-0bf8-451a-95ae-dd26e7029239"
      unitRef="U_USD">77800000</vir:MaximumAggregateMilestonePayments>
    <vir:MaximumAggregateMilestonePayments
      contextRef="C_b553a367-b665-4001-8f33-c723ff21ad71"
      decimals="-5"
      id="F_48b4eff5-d180-4c65-80a0-f8a2c9940574"
      unitRef="U_USD">77800000</vir:MaximumAggregateMilestonePayments>
    <vir:MaximumAggregateMilestonePayments
      contextRef="C_90313909-a6bc-4583-86a7-47d337dd4cb1"
      decimals="-5"
      id="F_9643122f-624d-4b85-9046-dcea4e671816"
      unitRef="U_USD">155500000</vir:MaximumAggregateMilestonePayments>
    <vir:RoyaltiesPaymentRangeOnNetSalesOfLicensedProduct
      contextRef="C_90313909-a6bc-4583-86a7-47d337dd4cb1"
      id="F_0baab0f2-cbaa-40d9-a612-42b2917b3409">low- to mid-single-digits</vir:RoyaltiesPaymentRangeOnNetSalesOfLicensedProduct>
    <vir:RoyaltiesBasedOnNetSalesOfLicensedProducts
      contextRef="C_423db569-199e-451c-b19e-22f96e558a53"
      id="F_8c48b4bb-6f2f-49b1-aa9a-b0bd7ae767ff"> mid-single-digits</vir:RoyaltiesBasedOnNetSalesOfLicensedProducts>
    <vir:RoyaltiesPaymentExpirationPeriod
      contextRef="C_423db569-199e-451c-b19e-22f96e558a53"
      id="F_263959c4-b0f2-4bb4-8b49-a3554c9075cf">P12Y</vir:RoyaltiesPaymentExpirationPeriod>
    <us-gaap:CostOfRevenue
      contextRef="C_423db569-199e-451c-b19e-22f96e558a53"
      decimals="-5"
      id="F_1513ee37-e20a-49a1-a5ed-071d58cf0886"
      unitRef="U_USD">114500000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="C_0c441e33-191d-47b1-a7d6-6ce061bb3ae1"
      decimals="-5"
      id="F_a6ef6ca0-2272-4f0a-a86c-e20f7727d9cc"
      unitRef="U_USD">52700000</us-gaap:CostOfRevenue>
    <vir:CollaborationAgreementTerminationDescription
      contextRef="C_fa73886f-e92f-4966-af95-e6e76cd8ccc3"
      id="F_960ab404-9960-4a9f-ad7a-f9cc260aef49">The Company may terminate each agreement in its entirety, or on a target-by-target basis, for convenience upon 60 days&#x2019; written notice. Either party may terminate each agreement for the other party&#x2019;s uncured material breach upon 60 days&#x2019; written notice (or 30 days in the case of non-payment) or in the event of bankruptcy of the other party immediately upon written notice. Xencor may terminate each agreement immediately upon written notice if the Company challenges, or upon 30 days&#x2019; written notice if any of the Company&#x2019;s sublicensees challenge, the validity or enforceability of any patent licensed to the Company under each respective agreement.</vir:CollaborationAgreementTerminationDescription>
    <vir:WrittenNoticePeriodForTerminationOfLicensedProgram
      contextRef="C_fa73886f-e92f-4966-af95-e6e76cd8ccc3"
      id="F_6b923547-5232-4f39-91f5-0dc813898c49">P60D</vir:WrittenNoticePeriodForTerminationOfLicensedProgram>
    <vir:WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach
      contextRef="C_fa73886f-e92f-4966-af95-e6e76cd8ccc3"
      id="F_5847707d-c41e-49b2-bb10-ebdedb258394">P60D</vir:WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach>
    <vir:WrittenNoticePeriodToTerminateLicensedProgramForFailureToMakePayment
      contextRef="C_fa73886f-e92f-4966-af95-e6e76cd8ccc3"
      id="F_762e8959-2b3c-4e60-95a3-40841b7364fe">P30D</vir:WrittenNoticePeriodToTerminateLicensedProgramForFailureToMakePayment>
    <vir:WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenges
      contextRef="C_fa73886f-e92f-4966-af95-e6e76cd8ccc3"
      id="F_d4ed40f6-139e-41ff-9b94-9b988f115b69">P30D</vir:WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenges>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_319bfc2d-c806-47e5-b0d8-2865b74a0ea8">&lt;div style="text-indent:0.0%;display:flex;margin-top:8.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;8.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Balance Sheet Components &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Property and Equipment, net&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment, net consists of the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.747%;"/&gt;
        &lt;td style="width:1.427%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.186%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.427%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.213000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;36,533&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20,012&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,545&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,112&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,852&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,443&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;84,422&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,834&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Construction in progress&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;26,925&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment, gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;126,352&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;57,326&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20,743&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;105,609&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;42,834&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Depreciation and amortization expenses were &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the years ended December 31, 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Accrued and Other Liabilities&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued and other liabilities consist of the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.12%;"/&gt;
        &lt;td style="width:1.655%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.246%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.655%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.324%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Milestone payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;95,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net profit-sharing constrained&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;357,762&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued royalties&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,447&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;58,672&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;48,880&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28,073&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Payroll and related expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28,286&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;29,753&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,228&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,217&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Excess funds payable under grant agreements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,652&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,825&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease liabilities, current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,137&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,927&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other professional and consulting expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,987&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,791&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,711&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,254&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total accrued and other liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;489,090&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;236,512&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_9d7157c4-39ad-4d29-aedf-a4df66bdbcdb">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment, net consists of the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.747%;"/&gt;
        &lt;td style="width:1.427%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.186%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.427%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.213000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;36,533&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20,012&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,545&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,112&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,852&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,443&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;84,422&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,834&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Construction in progress&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;26,925&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment, gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;126,352&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;57,326&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20,743&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;105,609&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;42,834&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_ecf4fb53-9e9a-460b-b2c7-36c48bc67120"
      decimals="-3"
      id="F_d2f82680-9745-44e2-9d3e-0b860574457e"
      unitRef="U_USD">36533000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0d8c8a20-2403-4408-9856-613c5c82c189"
      decimals="-3"
      id="F_33d4a906-010e-4d5d-b867-e4782a0a36f2"
      unitRef="U_USD">20012000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0ab585f4-7932-4fcf-9d20-a8bc39178ab4"
      decimals="-3"
      id="F_6fcc6903-fba5-4673-af7a-2efc4b0e3172"
      unitRef="U_USD">2545000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_c8ff574f-fed5-42aa-939d-486187b621e5"
      decimals="-3"
      id="F_3f50e93a-85d5-43df-8466-ab8cafb8dae1"
      unitRef="U_USD">1112000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_cce2c08e-9755-4a1d-ac18-7f295a943893"
      decimals="-3"
      id="F_95db74de-78b6-4ea3-88be-2ba735999861"
      unitRef="U_USD">2852000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_5ee09e36-b7d5-4bd7-a7a8-de86d1ea831c"
      decimals="-3"
      id="F_9522cbd2-bfe7-4306-87a4-fb30f0c1ca93"
      unitRef="U_USD">1443000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_1e3fe30c-1972-4e8c-8649-eeb82a737029"
      decimals="-3"
      id="F_a82318e1-56d8-4767-a2ae-abfc6ab1b5f7"
      unitRef="U_USD">84422000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_f3c34215-8edc-4dd4-865f-ab771871ad3a"
      decimals="-3"
      id="F_d7f60c2d-527c-4c9f-826f-a19037c06149"
      unitRef="U_USD">7834000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_029580f2-ed42-4e2c-a78b-e3a8e585aaa6"
      decimals="-3"
      id="F_bf98837c-f44e-429e-a021-0884d0eff21e"
      unitRef="U_USD">0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_db0c1ec0-28ae-4df5-8ac3-748f417365f4"
      decimals="-3"
      id="F_3fe90f18-8827-405a-8148-e1b043d0756d"
      unitRef="U_USD">26925000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_f3a4a558-e709-402a-8177-4b6fe1e2aa32"
      unitRef="U_USD">126352000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_4399fdd7-231d-4b0c-93ac-71b02912922d"
      unitRef="U_USD">57326000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_cd5b0c9d-a166-471f-b33b-84f22fcdd159"
      unitRef="U_USD">20743000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_926549e1-1f53-47a9-a28f-9f8ddc9d4df2"
      unitRef="U_USD">14492000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_9d40118f-ff31-41a0-8b58-1e26968e413d"
      unitRef="U_USD">105609000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_6e938ded-b2d9-4669-92fe-28d9c4c5e338"
      unitRef="U_USD">42834000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-5"
      id="F_3617ef64-f200-4ddb-840e-75598ad98eff"
      unitRef="U_USD">6300000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-5"
      id="F_d5d91b25-fe90-4e45-b5d6-591a74be8d4b"
      unitRef="U_USD">5300000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-5"
      id="F_02aa91a9-7feb-451f-a007-a8d4ef50e84e"
      unitRef="U_USD">4400000</us-gaap:DepreciationDepletionAndAmortization>
    <vir:ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_426f4a2e-d01b-440e-98f1-3cbca2321889">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued and other liabilities consist of the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.12%;"/&gt;
        &lt;td style="width:1.655%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.246%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.655%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.324%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Milestone payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;95,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net profit-sharing constrained&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;357,762&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued royalties&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,447&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;58,672&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;48,880&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28,073&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Payroll and related expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28,286&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;29,753&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,228&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,217&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Excess funds payable under grant agreements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,652&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,825&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease liabilities, current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,137&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,927&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other professional and consulting expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,987&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,791&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,711&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,254&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total accrued and other liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;489,090&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;236,512&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</vir:ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock>
    <vir:MilestonePayable
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_f546a1b3-79f0-4794-ab29-8fd3f4fc3a83"
      unitRef="U_USD">0</vir:MilestonePayable>
    <vir:MilestonePayable
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_44a421b5-bdf0-4c31-a699-f3068045a561"
      unitRef="U_USD">95000000</vir:MilestonePayable>
    <vir:ProfitShareAmountConstraint
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_9f07e145-b5a9-43dd-85fd-665b23d752d2"
      unitRef="U_USD">357762000</vir:ProfitShareAmountConstraint>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_fad3005a-d7cc-4ea7-8d4a-cbdb20eabe9b"
      unitRef="U_USD">10447000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_7148476d-180f-4345-893f-b12424e1151a"
      unitRef="U_USD">58672000</us-gaap:AccruedRoyaltiesCurrent>
    <vir:ResearchAndDevelopmentExpensesCurrent
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_4e0bb352-8c3c-4ed2-b589-289a8c74fa0d"
      unitRef="U_USD">48880000</vir:ResearchAndDevelopmentExpensesCurrent>
    <vir:ResearchAndDevelopmentExpensesCurrent
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_01817f39-7992-494d-a1a3-3deb29fca0b3"
      unitRef="U_USD">28073000</vir:ResearchAndDevelopmentExpensesCurrent>
    <vir:PayrollAndRelatedExpensesCurrent
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_ddc2181f-a323-42ce-94ef-7dec04a0eed2"
      unitRef="U_USD">28286000</vir:PayrollAndRelatedExpensesCurrent>
    <vir:PayrollAndRelatedExpensesCurrent
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_78181a44-4529-4ddf-977f-7db51353a277"
      unitRef="U_USD">29753000</vir:PayrollAndRelatedExpensesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_2eac896e-cccb-4e84-a19c-86f16c0c2157"
      unitRef="U_USD">15228000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_ae88ac76-84a0-4172-90f0-eb670175d792"
      unitRef="U_USD">6217000</us-gaap:AccruedIncomeTaxesCurrent>
    <vir:ExcessFundsPayableUnderGrantAgreementsCurrent
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_7db89fe8-1779-4b1f-bcf5-040e137f8c5b"
      unitRef="U_USD">7652000</vir:ExcessFundsPayableUnderGrantAgreementsCurrent>
    <vir:ExcessFundsPayableUnderGrantAgreementsCurrent
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_35abb471-c9bb-41c6-82ab-a8d419f7cf4d"
      unitRef="U_USD">1825000</vir:ExcessFundsPayableUnderGrantAgreementsCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_1eb0a340-eb06-43e2-9732-07dc33963caa"
      unitRef="U_USD">4137000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_b269aaf8-8f41-4432-be4f-1518ba3c2e90"
      unitRef="U_USD">3927000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_839b67b4-3f1c-4512-aec6-aaaeae86b276"
      unitRef="U_USD">3987000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_3087d04b-07e9-48ef-a526-b647af9a47a8"
      unitRef="U_USD">2791000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_b35358ae-d2f3-4c34-b445-c09e70145fb8"
      unitRef="U_USD">12711000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_ee6812e2-9b7e-4610-9ed5-d0b7fe63b7d1"
      unitRef="U_USD">10254000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_59104e4c-1fbe-4187-a89d-b16c0aafd25c"
      unitRef="U_USD">489090000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_bc201673-b25f-46c4-8d95-51f43dc6c77d"
      unitRef="U_USD">236512000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_0ef18571-9e5b-4967-8a3b-9cddc8f39999">&lt;div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;9.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Commitments and Contingencies &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Lease Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company has various operating lease arrangements for office and laboratory spaces located in California, Oregon, Missouri, and Switzerland with contractual lease periods expiring at various dates through &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2033&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;These leases require monthly lease payments that may be subject to annual increases throughout the lease term. Certain lease agreements also provide the Company with the option to renew for additional periods ranging from &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_6e3bf6bc-7e1c-4d4c-81d7-17386f7ad6b8;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; These renewal options are not considered in the remaining lease term unless it is reasonably certain that the Company will exercise such options.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In October 2021, the Company entered into a new sublease agreement for office and laboratory spaces in Missouri that will expire in December 2028, with no option to renew. Under this sublease arrangement, the Company is entitled to tenant improvement allowance of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;related to the design and construction of certain Company improvements.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In December 2021, the Company entered into a lease agreement with the new owner of the building at 1800 Owens Street in San Francisco for the lease of approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;133,896&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; rentable square feet of office and laboratory space of such building. The Company previously occupied the same premises under a sublease agreement with a sublessor, which sublease was terminated concurrently with the execution of the new lease agreement. Accordingly, the related ROU asset and lease liability under the sublease arrangement were extinguished and the Company recognized a gain of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million in the consolidated statement of operations for the year ended December 31, 2021. The new lease will expire in December 2033, with no option to renew. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Under this lease arrangement, the Company is entitled to tenant improvement allowance of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;37.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;related to the design and construction of certain Company improvements.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;    &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Under two of the operating lease arrangements in California and Missouri discussed above, the Company expected to fully utilize the tenant improvement allowance and, therefore, such amount was treated as a lease incentive that is payable to the Company at the lease commencement date.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Throughout the term of the lease agreements, the Company is responsible for paying certain operating costs, in addition to rent, such as common area maintenance, taxes, utilities and insurance. These additional charges are considered variable lease costs and are recognized in the period in which the costs are incurred.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table contains a summary of the lease costs recognized under ASC 842 and additional information related to operating leases (in thousands, except weighted average amounts):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.778%;"/&gt;
        &lt;td style="width:1.336%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.484%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.107%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.598%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.107%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.589%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,910&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,921&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,591&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Short-term lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;261&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;459&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Variable lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,937&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,256&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,299&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;26,086&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,438&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,349&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other Information&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted average remaining lease term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted average incremental borrowing rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash paid for amounts included in the measurement of operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,716&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,081&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ROU assets obtained in exchange for new operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,046&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;77,187&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;48,495&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The discount rate used to determine the present value of the lease payments is our estimated collateralized incremental borrowing rate, based on the yield curve for the respective lease terms, as we generally cannot determine the interest rate implicit in the leases.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The maturity of the Company&#x2019;s operating lease liabilities as of December 31, 2022 was as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.944%;"/&gt;
        &lt;td style="width:2.036%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.02%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amounts&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19,450&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,610&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,303&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,747&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,927&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;86,994&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;175,031&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;38,379&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: net tenant improvement allowance yet to be received&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;26,294&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Present value of operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;110,358&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following amounts were recorded in the consolidated balance sheets as of December 31, 2022 and 2021 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:61.225%;"/&gt;
        &lt;td style="width:1.604%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.382%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.465%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.325%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;position:relative;min-width:fit-content;"&gt;&#160;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17,616&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;49,536&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating ROU assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;82,557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;87,220&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_b8b36721-3cb4-433a-80d0-34cd8d9386fc;"&gt;&lt;span style="-sec-ix-hidden:F_0ef0daab-8a05-4fa7-ae0c-27cd8627c533;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued and other liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,137&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,927&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease liabilities, noncurrent&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;123,837&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;133,561&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;127,974&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;137,488&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:80.0%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="text-indent:0.0%;display:flex;margin-top:2.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:8.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;"&gt;(1)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For certain operating leases, lease incentives expected to be received exceeds the minimum lease payments expected to be paid over the next 12 months, therefore the net amount is recorded in prepaid expenses and other current assets.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Manufacturing and Supply Letter Agreements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In April 2020, the Company and Samsung Biologics Co., Ltd. (&#x201c;Samsung&#x201d;) entered into a binding letter agreement (the &#x201c;Samsung Letter Agreement&#x201d;), under which Samsung performs development and manufacturing services for the Company&#x2019;s SARS-CoV-2 antibody program. In August 2020, the Company, GlaxoSmithKline Trading Services Limited (&#x201c;GSKTSL&#x201d;) and Samsung entered into an Assignment and Novation Agreement effective as of July 31, 2020, under which the Company assigned and transferred to GSKTSL all of the Company&#x2019;s right, title, and interest in, to and under the Samsung Letter Agreement, and GSKTSL became the Company&#x2019;s successor in interest in and to all of the Company&#x2019;s rights, duties, and obligations in, to and under the Samsung Letter Agreement.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In August 2020, GSKTSL entered into a Master Services Agreement with Samsung (the &#x201c;Samsung MSA&#x201d;) in connection with the performance of the obligations of the Company and GSK under the 2020 GSK Agreement. In accordance with the terms of the 2020 GSK Agreement, the Company continues to be responsible for &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;72.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the costs under the Samsung MSA, and GSK bears &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of such costs under the Samsung MSA, subject to certain conditions and exceptions. The Company&#x2019;s commitment has been substantially recognized on its consolidated balance sheet as part of the profit-sharing amount constrained as of December 31, 2022, which is part of accrued and other liabilities, as discussed in Note 7&#x2014;Collaboration and License Agreements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Indemnification&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Under such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. In addition, the Company has entered into indemnification agreements with its directors and certain officers that may require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. To date, no demands have been made upon the Company to provide indemnification under these agreements, and thus, there are no indemnification claims that the Company is aware of that could have a material effect on the Company&#x2019;s consolidated balance sheets, consolidated statements of operations, or consolidated statements of cash flows.&lt;/span&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <vir:LeaseArrangementContractualExpirationEndingYear
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_029176bb-9e8d-45a3-ac45-fa0f144995a6">2033</vir:LeaseArrangementContractualExpirationEndingYear>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_4d7aa5dc-eaeb-486d-acd9-b113bc62e691">These leases require monthly lease payments that may be subject to annual increases throughout the lease term. Certain lease agreements also provide the Company with the option to renew for additional periods ranging from one to five years.</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_268c2c6c-2e46-49ef-8b34-85c3eb6476c2"
      id="F_7f587a49-50ff-4e81-9b95-bb7ed7401f17">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <vir:TenantImprovementAllowanceAggregate
      contextRef="C_65402f98-6f66-411f-989c-de9e545eb48a"
      decimals="-5"
      id="F_7cca40f0-cc39-4f53-8411-0f0c9c2e2ccb"
      unitRef="U_USD">14700000</vir:TenantImprovementAllowanceAggregate>
    <us-gaap:NetRentableArea
      contextRef="C_8159e296-cbd0-46c5-bb89-4442f5253f01"
      decimals="INF"
      id="F_b5086857-7b80-4d6f-9784-a3e365f5982d"
      unitRef="U_sqft">133896</us-gaap:NetRentableArea>
    <us-gaap:GainLossOnTerminationOfLease
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-5"
      id="F_6dd66fa7-ab7e-4dea-9074-1ee2d2b690e4"
      unitRef="U_USD">4800000</us-gaap:GainLossOnTerminationOfLease>
    <vir:TenantImprovementAllowanceAggregate
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-5"
      id="F_fd008bdd-d466-4ce5-9715-848a6446419b"
      unitRef="U_USD">37500000</vir:TenantImprovementAllowanceAggregate>
    <vir:SummaryOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_ec7ef530-a69c-499a-b126-91bc93cc4850">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table contains a summary of the lease costs recognized under ASC 842 and additional information related to operating leases (in thousands, except weighted average amounts):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.778%;"/&gt;
        &lt;td style="width:1.336%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.484%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.107%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.598%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.107%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.589%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,910&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,921&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,591&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Short-term lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;261&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;459&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Variable lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,937&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,256&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,299&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;26,086&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,438&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,349&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other Information&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted average remaining lease term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted average incremental borrowing rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Cash paid for amounts included in the measurement of operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,716&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,081&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ROU assets obtained in exchange for new operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,046&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;77,187&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;48,495&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</vir:SummaryOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_aa02b69b-d121-4b1b-9fb2-43811a752313"
      unitRef="U_USD">15910000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_97e6fa93-2f0b-4263-88ab-6ebccc41673a"
      unitRef="U_USD">11921000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_41314f8d-af2d-4be4-9bbd-73ca79d58275"
      unitRef="U_USD">4591000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_d3df0d17-e755-4540-9c39-b21588ea9838"
      unitRef="U_USD">239000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_ae8df2eb-bfd9-4487-83f8-044c0c7ff251"
      unitRef="U_USD">261000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_9ced196c-d7a0-47b0-9744-5a6901cd0dea"
      unitRef="U_USD">459000</us-gaap:ShortTermLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_f6a3e4a1-6c63-4d53-979a-6cf5ad9f1ec8"
      unitRef="U_USD">9937000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_eb311e59-0184-4594-bd8c-808369de8bf1"
      unitRef="U_USD">4256000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_fccc5b13-382b-4921-9160-85fc573f0172"
      unitRef="U_USD">2299000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_965a8a07-39ce-4aa0-abf0-f92c9603cfdb"
      unitRef="U_USD">26086000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_477e3f8a-507e-42a2-9909-bfa686cfed6d"
      unitRef="U_USD">16438000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_155ec79c-8e2c-420f-8bde-a018562de707"
      unitRef="U_USD">7349000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      id="F_ba934251-e34e-47fb-830a-e30a737da0de">P10Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      id="F_cb4059a6-314d-4328-80ce-df619568e554">P10Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_da5feba6-e631-4bec-b33d-106ac3401870"
      id="F_c895d9e8-6078-430d-be64-79fc394c2bdd">P10Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="3"
      id="F_8e46fb6e-48d3-4475-8474-1c0a67efd147"
      unitRef="U_pure">0.052</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="3"
      id="F_c045dd71-b975-4c04-9c53-91c510dba86e"
      unitRef="U_pure">0.052</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_da5feba6-e631-4bec-b33d-106ac3401870"
      decimals="3"
      id="F_c509d3f1-c94c-47b3-af74-bf767a9b3944"
      unitRef="U_pure">0.077</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeasePayments
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_797d062f-86bf-4e2d-bcab-b0a3d07a0cce"
      unitRef="U_USD">12716000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_fffbbba3-c819-463c-8c55-d7b42836eb57"
      unitRef="U_USD">6250000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_fb1925f6-ad92-4479-bf4e-787976ba5e9b"
      unitRef="U_USD">5081000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_2804fb41-1520-40ad-8903-3fdd3941fe55"
      unitRef="U_USD">4046000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_8f0427e9-f841-4598-b4ab-4b9a6a8a6665"
      unitRef="U_USD">77187000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_d0c6d5c7-01c1-48ce-822d-4042982f8e00"
      unitRef="U_USD">48495000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_5aef16c1-97a8-40ba-a1a6-30b5d39c0c16">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The maturity of the Company&#x2019;s operating lease liabilities as of December 31, 2022 was as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.944%;"/&gt;
        &lt;td style="width:2.036%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.02%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Amounts&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19,450&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,610&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,303&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,747&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;16,927&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;86,994&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;175,031&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;38,379&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Less: net tenant improvement allowance yet to be received&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;26,294&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Present value of operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;110,358&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_b04c4151-b1b8-454f-91c1-8ade81a13242"
      unitRef="U_USD">19450000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_e433d06a-6040-48fa-882f-60a0353b52d1"
      unitRef="U_USD">18610000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_6084a98a-fe93-45e0-a5e2-4814c70a341b"
      unitRef="U_USD">16303000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_14a958ee-5272-4f1b-8b08-bb1748b4486d"
      unitRef="U_USD">16747000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_3afde10b-04a9-44c4-8b91-6639da098ca9"
      unitRef="U_USD">16927000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_853da714-ed17-47cc-8879-bfbde39c7c2c"
      unitRef="U_USD">86994000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_618e4d10-6938-4a42-8e0f-98404edab1e8"
      unitRef="U_USD">175031000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_f5ccc718-b2ee-4dd0-8bd2-c25f84b239de"
      unitRef="U_USD">38379000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <vir:LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_c2c4bb3d-545f-4717-a7ec-f1694cd8b5c4"
      unitRef="U_USD">26294000</vir:LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived>
    <vir:PresentValueOfOperatingLeaseLiabilities
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_feedc662-a588-48b3-92df-85c4fdce2791"
      unitRef="U_USD">110358000</vir:PresentValueOfOperatingLeaseLiabilities>
    <vir:ScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetTableTextBlock
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_79bcaa83-eac9-4688-a834-5909c4ada0b6">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following amounts were recorded in the consolidated balance sheets as of December 31, 2022 and 2021 (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:61.225%;"/&gt;
        &lt;td style="width:1.604%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.382%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.465%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:15.325%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;position:relative;min-width:fit-content;"&gt;&#160;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17,616&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;49,536&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating ROU assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;82,557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;87,220&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="-sec-ix-hidden:F_b8b36721-3cb4-433a-80d0-34cd8d9386fc;"&gt;&lt;span style="-sec-ix-hidden:F_0ef0daab-8a05-4fa7-ae0c-27cd8627c533;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Accrued and other liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,137&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,927&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Operating lease liabilities, noncurrent&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;123,837&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;133,561&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;127,974&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;137,488&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;margin-right:80.0%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="text-indent:0.0%;display:flex;margin-top:2.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:8.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;"&gt;(1)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;For certain operating leases, lease incentives expected to be received exceeds the minimum lease payments expected to be paid over the next 12 months, therefore the net amount is recorded in prepaid expenses and other current assets.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</vir:ScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetTableTextBlock>
    <vir:OperatingLeaseIncentiveOverLeaseLiabilities
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_6678866e-bd13-4f40-999a-3c8f24de0f4e"
      unitRef="U_USD">17616000</vir:OperatingLeaseIncentiveOverLeaseLiabilities>
    <vir:OperatingLeaseIncentiveOverLeaseLiabilities
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_b923aa6f-c464-41ea-83e3-a20e9f874644"
      unitRef="U_USD">49536000</vir:OperatingLeaseIncentiveOverLeaseLiabilities>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_3a11278d-f849-41ce-88fd-a82fde479d1c"
      unitRef="U_USD">82557000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_6afcf1e5-0f59-4fbc-a47a-cedf3a25d5fa"
      unitRef="U_USD">87220000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_86afe23e-6bd9-4fad-8296-b1a4d7c3f0d1"
      unitRef="U_USD">4137000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_cbc97407-858c-4b13-8205-6b6a98ef0149"
      unitRef="U_USD">3927000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_b348eff3-a7cf-4cbf-8674-1f3c76c7afa9"
      unitRef="U_USD">123837000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_a6831ba4-c9eb-41b5-aab9-5599586038d9"
      unitRef="U_USD">133561000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_8b553819-52d1-4dd8-a2b0-99b51c569855"
      unitRef="U_USD">127974000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_2b8e5063-1fc9-4a5c-97a3-8aaf09158ba7"
      unitRef="U_USD">137488000</us-gaap:OperatingLeaseLiability>
    <vir:PercentageOfDevelopmentCostsResponsibleByCompany
      contextRef="C_5996e992-06fd-457c-9ae0-b6c5639ae79b"
      decimals="3"
      id="F_f534e361-d7ef-490a-9798-1e42f59a118e"
      unitRef="U_pure">0.725</vir:PercentageOfDevelopmentCostsResponsibleByCompany>
    <vir:PercentageOfDevelopmentCostsResponsibleByGsk
      contextRef="C_a34f69de-db65-4bed-a804-9fff69f8bba0"
      decimals="3"
      id="F_5cb69e78-18dc-46e4-bc3e-7dd5832ed120"
      unitRef="U_pure">0.275</vir:PercentageOfDevelopmentCostsResponsibleByGsk>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_08d5c270-811e-4f1d-b914-f19bb2cc137f">&lt;div style="text-indent:0.0%;display:flex;margin-top:18.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;10.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Related Party Transactions &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As a result of the Brii Agreement, the Company holds a minority equity interest in Brii Bio through its parent company, Brii Bio Parent. At the time when the Company entered into the Brii Agreement, the Company's Chief Executive Officer (the  &#x201c;CEO&#x201d;), and another member of the Company's board of directors served on Brii Bio Parent&#x2019;s board of directors. The Company's CEO, who is also a member of the Company's board of directors, resigned from Brii Bio Parent&#x2019;s board of directors in June 2021. As of December 31, 2022, one member of the Company&#x2019;s board of directors serves on Brii Bio Parent&#x2019;s board of directors.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_f34aa3b0-b617-45d4-96e2-e6b3d9711897">&lt;div style="text-indent:0.0%;display:flex;margin-top:8.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;11.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock-Based Awards &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;2019 Equity Incentive Plan&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In September 2019, the Company&#x2019;s board of directors adopted, with the approval of its stockholders, the 2019 Equity Incentive Plan (the &#x201c;2019 Plan&#x201d;) for the issuance of incentive stock options (&#x201c;ISO&#x201d;), non-qualified stock options (&#x201c;NSO&#x201d;), stock appreciation rights (&#x201c;SARs&#x201d;), restricted stock, other stock awards and performance cash awards, to employees, non-employee directors, and consultants. The 2019 Plan became effective concurrent with the Company&#x2019;s initial public offering (&#x201c;IPO&#x201d;).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Awards granted under the 2019 Plan expire no later than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; years from the date of grant. For ISO and NSO, the option price shall not be less than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the estimated fair value on the date of grant. Options granted typically vest over a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;four-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; period but may be granted with different vesting terms. As of December 31, 2022, there are &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,911,263&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares available for the Company to grant under the 2019 Plan.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;2016 Equity Incentive Plan&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In September 2016, the Company adopted the 2016 Equity Incentive Plan (the &#x201c;2016 Plan&#x201d;) for the issuance of ISO, NSO, SARs, restricted stock and other stock awards, to employees, non-employee directors, and consultants under terms and provisions established by the Company&#x2019;s board of directors and approved by the stockholders.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Awards granted under the 2016 Plan expire no later than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; years from the date of grant. For ISO and NSO, the option price shall not be less than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the estimated fair value on the date of grant. Options granted typically vest over a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;four-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; period but may be granted with different vesting terms.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In conjunction with adopting the 2019 Plan, the Company discontinued the 2016 Plan with respect to the new equity awards.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;2019 Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In September 2019, the Company&#x2019;s board of directors adopted, with the approval of its stockholders, the ESPP. The ESPP became effective on the completion of the Company&#x2019;s IPO.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The ESPP initially authorized the issuance of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,280,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock under purchase rights granted to its employees or employees of any of the Company&#x2019;s designated affiliates. The number of shares of the Company&#x2019;s common stock reserved for issuance is subject to an automatic increase at each calendar year. Under the ESPP, the Company may specify offerings with durations of not more than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; months and may specify shorter purchase periods within each offering. The ESPP allows eligible employees to purchase shares of the Company&#x2019;s common stock at a discount through payroll deductions of up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of their earnings, subject to any plan limitations. Unless otherwise determined by the Company&#x2019;s board of directors, employees can purchase shares at &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;85&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% of the lower of the fair market value of the Company&#x2019;s common stock on the first date of an offering or the purchase date. During the year ended December 31, 2022, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;118,288&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; shares were issued under the ESPP.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Stock Option Activity&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Activity under the Company&#x2019;s stock option plans is set forth below:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:55.387%;"/&gt;
        &lt;td style="width:0.173%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.722000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.074%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:7.6899999999999995%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.148%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:7.911%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.247%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.65%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Number of&lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,308,928&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;31.75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,051,535&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;696,963&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,059,133&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;41.67&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,604,367&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;31.70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;52,307&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Vested and expected to vest at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,604,367&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;31.70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;52,307&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Vested and exercisable at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,069,564&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27.06&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;48,178&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The aggregate intrinsic value of options exercised during the years ended December 31, 2022, 2021 and 2020 was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;65.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;53.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;During the years ended December 31, 2022, 2021, and 2020, the estimated weighted-average grant date fair value of the options granted was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;22.69&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;47.62&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25.49&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022, the Company expects to recognize the remaining unamortized stock-based compensation expense of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;127.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million related to stock options, over an estimated weighted average period of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.2&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Stock Options Granted to Employees&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The fair value of stock options granted to employees was estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.472%;"/&gt;
        &lt;td style="width:1.5%;"/&gt;
        &lt;td style="width:15.343%;"/&gt;
        &lt;td style="width:1.5%;"/&gt;
        &lt;td style="width:15.343%;"/&gt;
        &lt;td style="width:1.5%;"/&gt;
        &lt;td style="width:15.343%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="5" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected term of options (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.3&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.3&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected stock price volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;101.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;111.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;103.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;112.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;88.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;108.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The valuation assumptions for stock options were determined as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Expected Term&#x2014;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The expected term represents the period that the stock options granted are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term) as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Expected Volatility&#x2014;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Since inception the expected volatility was determined by examining the historical volatilities for industry peers and using an average of historical volatilities of the Company&#x2019;s industry peers. Beginning the first quarter of 2022, the expected volatility is determined by using a blended approach of the Company and its industry peers&#x2019; historical volatilities.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Risk-Free Interest Rate&#x2014;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company based the risk-free interest rate over the expected term of the stock options based on the constant maturity rate of U.S. Treasury securities with similar maturities as of the date of the grant.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Expected Dividend Rate&#x2014;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The expected dividend is zero as the Company has not paid nor does it anticipate paying any dividends on its profit interest units in the foreseeable future.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Employees Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;In June 2021, the Company initiated its first offering period under the ESPP. Each offering period is &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;six months&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;, which commences on the grant date on or after June 1 and December 1 of each year and ends on the purchase date on or before November 30 and May 31 of each year.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The fair value of employees' purchase rights under the ESPP was estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:59.491%;"/&gt;
        &lt;td style="width:1.824%;"/&gt;
        &lt;td style="width:18.444%;"/&gt;
        &lt;td style="width:1.824%;"/&gt;
        &lt;td style="width:18.417%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected term of ESPP (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected stock price volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;59.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;86.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;76.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;144.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.04&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The expected term of employees&#x2019; purchase rights is equal to the purchase period. The expected volatility was determined based on the Company's historical volatility. The risk-free interest rate is based on the constant maturity rate of U.S. Treasury securities with similar maturities as of the date of the grant over the expected term of the employees&#x2019; purchase rights. The expected dividend is zero as the Company has not paid nor does it anticipate paying any dividends on its profit interest units in the foreseeable future. Based on the Black-Scholes option-pricing model, the estimated weighted-average grant date fair value of the employees' purchase rights granted for the years ended December 31, 2022 and 2021 was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9.09&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19.85&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; per share, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Restricted Stock Activity&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s RSAs and RSUs were summarized as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:69.706%;"/&gt;
        &lt;td style="width:1.36%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.302%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.552%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.081%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="4" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted Average Grant Date Fair Value Per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;RSU&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;RSU&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unvested as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,271,334&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;59.93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,097,128&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27.87&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;349,496&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;58.26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;349,788&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40.86&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unvested as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,669,178&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;37.46&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The unvested shares of RSUs have not been included in the shares issued and outstanding.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022, there was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;77.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million of total unrecognized compensation cost related to unvested restricted stock units, all of which is expected to be recognized over a remaining weighted-average period of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Stock-based compensation is recognized on a straight-line basis over the requisite service period, which is generally the vesting period. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table sets forth the total stock-based compensation expense for all awards granted to employees and the ESPP in the consolidated statements of operations: &lt;/span&gt;&lt;/span&gt;&lt;span style=""/&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.136%;"/&gt;
        &lt;td style="width:1.358%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.821%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.369%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.833%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.369%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.112%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;53,153&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;42,554&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,663&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Selling, general and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;48,929&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;41,230&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,937&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;102,082&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;83,784&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_d876049e-5055-4f47-995e-2fbfc3f91f50"
      id="F_c644b00e-9c73-4afd-bb25-f4c5384e71cc">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="C_896e4988-6bb1-4c02-8cd3-19e59ff58b81"
      decimals="INF"
      id="F_e6fc3396-b849-4cfd-b848-c89a7f315f7c"
      unitRef="U_pure">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_896e4988-6bb1-4c02-8cd3-19e59ff58b81"
      id="F_3419ff46-4afd-4cb9-a91c-b2ee12d9ecd9">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_99fe8501-acd9-4f49-adf9-24150da9294f"
      decimals="INF"
      id="F_da637071-7fad-4ab7-8013-08af42f42c6f"
      unitRef="U_shares">12911263</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_720cbd98-e278-45a4-979c-db878614348b"
      id="F_306c0518-21ca-4407-9a08-779e00833fe0">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="C_f9212404-81f7-4d0b-9f10-42f60cf103ef"
      decimals="2"
      id="F_e23d9cc7-33e1-45c6-86c4-9b495c73c46e"
      unitRef="U_pure">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_f9212404-81f7-4d0b-9f10-42f60cf103ef"
      id="F_f2501ede-ec5a-4eb4-bd00-ee71c6c91ec5">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_c80ea697-a368-4975-9736-adb7c05cefbd"
      decimals="INF"
      id="F_11e565ab-a99d-481b-866e-460ef1a31ef3"
      unitRef="U_shares">1280000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <vir:OfferingPeriodEmployeeStockPurchasePlan
      contextRef="C_7b5b92b7-ec6c-4504-ad39-91288ac75cc0"
      id="F_79cafdd2-4a10-4938-955e-80f35076da3f">P27M</vir:OfferingPeriodEmployeeStockPurchasePlan>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="C_c80ea697-a368-4975-9736-adb7c05cefbd"
      decimals="INF"
      id="F_3e708dda-cc32-45fd-a5d9-c3e6664a743f"
      unitRef="U_pure">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="C_72d128cd-9dc7-4ded-bfa1-21c90dee3725"
      decimals="2"
      id="F_472f0049-c2ca-4fbe-a058-c303a185f0e8"
      unitRef="U_pure">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_87139d89-e3fd-445f-b6c1-4593f57a1d30"
      decimals="INF"
      id="F_1a3dc7f1-9f0c-41b1-baca-5cf4d766c819"
      unitRef="U_shares">118288</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_b56f3ece-547f-4554-8e8c-b944db40766b">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Activity under the Company&#x2019;s stock option plans is set forth below:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:55.387%;"/&gt;
        &lt;td style="width:0.173%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.722000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.074%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:7.6899999999999995%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.148%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:7.911%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.247%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.65%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Number of&lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,308,928&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;31.75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,051,535&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;696,963&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,059,133&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;41.67&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,604,367&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;31.70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;52,307&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Vested and expected to vest at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,604,367&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;31.70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;52,307&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Vested and exercisable at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,069,564&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27.06&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;48,178&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_63454d26-78fb-4850-a047-cf04ffc3c617"
      decimals="INF"
      id="F_ab97b53d-5893-48de-9a75-5882c4dff15c"
      unitRef="U_shares">10308928</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_63454d26-78fb-4850-a047-cf04ffc3c617"
      decimals="2"
      id="F_5cf485f9-b2f1-4c4c-b184-a752ccba6d8c"
      unitRef="U_USDollarShare">31.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_35e38548-67c8-4cef-8f37-1a11a25cc2ea"
      id="F_52351454-3590-4d33-acfa-bad0bd92963b">P8Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_2af6ea14-ac98-4568-81e0-3bef718e3542"
      decimals="INF"
      id="F_0cc2d5b1-6876-4d9e-a86b-62b979d78e88"
      unitRef="U_shares">2051535</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_2af6ea14-ac98-4568-81e0-3bef718e3542"
      decimals="2"
      id="F_aad4446f-6acc-474e-95fc-5a73faf3b99d"
      unitRef="U_USDollarShare">28.07</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_2af6ea14-ac98-4568-81e0-3bef718e3542"
      decimals="INF"
      id="F_01c7a404-8e75-4dd2-af6b-99215af156fd"
      unitRef="U_shares">696963</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_2af6ea14-ac98-4568-81e0-3bef718e3542"
      decimals="2"
      id="F_a2794900-ebb6-4466-bcf4-6b60fa85cd0d"
      unitRef="U_USDollarShare">6.51</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_2af6ea14-ac98-4568-81e0-3bef718e3542"
      decimals="INF"
      id="F_8ec9899c-bde3-408b-9828-da5db238956a"
      unitRef="U_shares">1059133</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_2af6ea14-ac98-4568-81e0-3bef718e3542"
      decimals="2"
      id="F_c144327d-5d7b-4105-ab3f-772653d0ae3f"
      unitRef="U_USDollarShare">41.67</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_eeb8aa97-5f2d-4952-8244-3a5e12f77095"
      decimals="INF"
      id="F_d0ab913c-07ff-4185-a8b3-153f4ba3f7e6"
      unitRef="U_shares">10604367</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_eeb8aa97-5f2d-4952-8244-3a5e12f77095"
      decimals="2"
      id="F_574afc4b-a446-4f9c-9324-36fb23a7c020"
      unitRef="U_USDollarShare">31.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_2af6ea14-ac98-4568-81e0-3bef718e3542"
      id="F_a3269ef6-b013-41e7-8c9e-66d5b6c1c083">P7Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_eeb8aa97-5f2d-4952-8244-3a5e12f77095"
      decimals="-3"
      id="F_9cbf2020-4a83-4680-a286-d8daa3216f55"
      unitRef="U_USD">52307000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_eeb8aa97-5f2d-4952-8244-3a5e12f77095"
      decimals="INF"
      id="F_177c8d8c-6f13-4e87-ab1f-c447491b7767"
      unitRef="U_shares">10604367</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_eeb8aa97-5f2d-4952-8244-3a5e12f77095"
      decimals="2"
      id="F_50997fce-6f92-4066-8737-193db4b6c7c0"
      unitRef="U_USDollarShare">31.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_2af6ea14-ac98-4568-81e0-3bef718e3542"
      id="F_495d221c-1e54-47de-adcc-e0170dc9fa47">P7Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="C_eeb8aa97-5f2d-4952-8244-3a5e12f77095"
      decimals="-3"
      id="F_5cd05d8f-83cb-4955-a18f-efc0580b5363"
      unitRef="U_USD">52307000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="C_eeb8aa97-5f2d-4952-8244-3a5e12f77095"
      decimals="INF"
      id="F_2ad3cbdd-00be-4172-93e0-9ecdb20dc0d1"
      unitRef="U_shares">6069564</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="C_eeb8aa97-5f2d-4952-8244-3a5e12f77095"
      decimals="2"
      id="F_cdef5fdf-50b7-431e-82a4-b8efededb8ef"
      unitRef="U_USDollarShare">27.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_2af6ea14-ac98-4568-81e0-3bef718e3542"
      id="F_eaf9612d-8a8a-4df7-8f85-febbaed2dac5">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="C_eeb8aa97-5f2d-4952-8244-3a5e12f77095"
      decimals="-3"
      id="F_16adc57b-ffda-474d-9744-70e632f2a07d"
      unitRef="U_USD">48178000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_2af6ea14-ac98-4568-81e0-3bef718e3542"
      decimals="-2"
      id="F_def99e06-1b8e-424c-aa23-636bea25fc0d"
      unitRef="U_USD">12100</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_35e38548-67c8-4cef-8f37-1a11a25cc2ea"
      decimals="-5"
      id="F_9cd5ffbe-5061-43af-85fd-2f8b83196621"
      unitRef="U_USD">65100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_9dc90b6a-ec9c-43c8-abc2-fcbab105e2d2"
      decimals="-5"
      id="F_bc18defc-6dd7-4977-9d6a-dfee2f1d5631"
      unitRef="U_USD">53100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_2af6ea14-ac98-4568-81e0-3bef718e3542"
      decimals="2"
      id="F_c9dd0296-4ce1-4b3d-b16e-fab65a5d2b56"
      unitRef="U_USDollarShare">22.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_35e38548-67c8-4cef-8f37-1a11a25cc2ea"
      decimals="2"
      id="F_d475068c-de5a-46be-bb9c-832e9c6768d6"
      unitRef="U_USDollarShare">47.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_9dc90b6a-ec9c-43c8-abc2-fcbab105e2d2"
      decimals="2"
      id="F_28576313-f6c1-41a9-b37d-1d3bfca10e9b"
      unitRef="U_USDollarShare">25.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_eeb8aa97-5f2d-4952-8244-3a5e12f77095"
      decimals="-5"
      id="F_87e2c049-69c3-4ef0-b83e-b8de1e11833a"
      unitRef="U_USD">127400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_2af6ea14-ac98-4568-81e0-3bef718e3542"
      id="F_a2386009-f418-4237-b9af-b7561b1ad8ac">P2Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_6d7f739f-1b17-4651-8822-90d09ea14db2">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The fair value of stock options granted to employees was estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.472%;"/&gt;
        &lt;td style="width:1.5%;"/&gt;
        &lt;td style="width:15.343%;"/&gt;
        &lt;td style="width:1.5%;"/&gt;
        &lt;td style="width:15.343%;"/&gt;
        &lt;td style="width:1.5%;"/&gt;
        &lt;td style="width:15.343%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="5" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected term of options (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.3&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.3&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected stock price volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;101.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;111.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;103.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;112.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;88.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;108.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_62304650-1cd7-4013-b062-3aa4e9d5ad9f"
      id="F_0d3a955f-5201-48ad-ace7-961022615bf8">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_9a41c817-24ee-4d06-ab61-6c839a61c843"
      id="F_c6913a00-5b15-4387-8451-cb258ec40ef1">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_dbd52408-3a79-4789-b6f2-0d8c54a59ebf"
      id="F_71d1c322-cc37-4024-8eda-d68f0dc0ceff">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_b1fed0e5-7cc7-463c-bdd6-e6e1458d55b5"
      id="F_66dc0b57-10fb-4f54-bc8c-5f61f405af26">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_4adec9d2-4308-425f-a580-f05b8bbce014"
      id="F_c326bfa3-cb2c-4a6c-8ec6-a242b1b1e110">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_bbef5af8-652f-4bae-a181-e9df48dc51ea"
      id="F_6fbc700c-89b1-4639-bff5-d36caa087511">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="3"
      id="F_4d137b0f-cbc0-4312-9c84-36098e7aeb42"
      unitRef="U_pure">1.014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="3"
      id="F_f5bd62c2-1e51-46a9-878c-2e80968c2ce3"
      unitRef="U_pure">1.112</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="3"
      id="F_6eca9f03-c192-4a2d-b1bb-b37e75963731"
      unitRef="U_pure">1.031</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="3"
      id="F_8b1f18ad-38b2-4553-bb06-769ff05a9b9a"
      unitRef="U_pure">1.121</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="3"
      id="F_9e91f04d-276d-44e7-a655-847a85dd083c"
      unitRef="U_pure">0.888</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="3"
      id="F_e424e792-99a1-4d93-9a17-16a5b566865c"
      unitRef="U_pure">1.086</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="3"
      id="F_29895985-b837-4977-8976-a1c9aa735218"
      unitRef="U_pure">0.016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="3"
      id="F_6ec6e83d-409c-4e4a-9dd7-4c51d8bca1a5"
      unitRef="U_pure">0.043</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="3"
      id="F_07ce599d-89b1-4b0f-99c5-f9ee47dbf2bc"
      unitRef="U_pure">0.006</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="3"
      id="F_98404f9f-d16f-4afb-88af-fb5298eac22e"
      unitRef="U_pure">0.013</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="3"
      id="F_01659a47-be04-48c6-b507-737d52587044"
      unitRef="U_pure">0.003</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="3"
      id="F_8f40e647-eaa6-4e4c-abba-2470f4991d09"
      unitRef="U_pure">0.012</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="2"
      id="F_c9d78394-23b5-49b2-bfbb-2e8beb41a8ad"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="2"
      id="F_242697d8-14d6-42f6-ad7c-851e7e707a58"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="2"
      id="F_c73778a8-1129-4fc7-a023-f1566b287f09"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <vir:OfferingPeriodEmployeeStockPurchasePlan
      contextRef="C_f8f016eb-9b56-4d62-8dd6-7ea4594702e3"
      id="F_58836567-1eb6-4992-b57a-e2b518b62045">P6M</vir:OfferingPeriodEmployeeStockPurchasePlan>
    <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_cadfc506-1bf9-44c3-9356-3641e60e94f7">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The fair value of employees' purchase rights under the ESPP was estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:59.491%;"/&gt;
        &lt;td style="width:1.824%;"/&gt;
        &lt;td style="width:18.444%;"/&gt;
        &lt;td style="width:1.824%;"/&gt;
        &lt;td style="width:18.417%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected term of ESPP (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected stock price volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;59.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;86.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;76.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;144.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.04&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;% &#x2013; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_87139d89-e3fd-445f-b6c1-4593f57a1d30"
      id="F_11c9923c-8e19-4a4d-9adc-c5efe9e4cc42">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_d45858f9-5f23-4ea3-a7e2-ddac9afb63ae"
      id="F_83054c0c-0bb8-4b99-b46f-54f7e2d5b046">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_87139d89-e3fd-445f-b6c1-4593f57a1d30"
      decimals="3"
      id="F_abeb1249-e523-41dc-a568-88a69cfa090b"
      unitRef="U_pure">0.590</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_87139d89-e3fd-445f-b6c1-4593f57a1d30"
      decimals="3"
      id="F_3a740cdd-3081-4f7c-85a8-445eecbbd2ff"
      unitRef="U_pure">0.860</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_d45858f9-5f23-4ea3-a7e2-ddac9afb63ae"
      decimals="3"
      id="F_80a1fe1d-0b96-41a8-9c01-cc0a60ad1232"
      unitRef="U_pure">0.761</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_d45858f9-5f23-4ea3-a7e2-ddac9afb63ae"
      decimals="3"
      id="F_4dcc81de-8b34-4b2d-b187-70347c7c821a"
      unitRef="U_pure">1.441</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_87139d89-e3fd-445f-b6c1-4593f57a1d30"
      decimals="3"
      id="F_1e5c81d0-c667-4d4a-b863-433c13c9ffdf"
      unitRef="U_pure">0.001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_87139d89-e3fd-445f-b6c1-4593f57a1d30"
      decimals="3"
      id="F_226d79bc-d9a4-40b2-8aa7-83f60456c8e0"
      unitRef="U_pure">0.045</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_d45858f9-5f23-4ea3-a7e2-ddac9afb63ae"
      decimals="4"
      id="F_f73e96f2-1b82-48e2-af78-7e3b9b0f3f73"
      unitRef="U_pure">0.0004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_d45858f9-5f23-4ea3-a7e2-ddac9afb63ae"
      decimals="3"
      id="F_285afe71-0a3d-4363-92ab-b0c46ba178aa"
      unitRef="U_pure">0.001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_87139d89-e3fd-445f-b6c1-4593f57a1d30"
      decimals="2"
      id="F_3cdf9171-bdf7-4127-9e1d-5da614215f13"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_d45858f9-5f23-4ea3-a7e2-ddac9afb63ae"
      decimals="2"
      id="F_954de329-8ed5-4cce-b9de-27c55c1d3b0f"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_87139d89-e3fd-445f-b6c1-4593f57a1d30"
      decimals="2"
      id="F_26497bdb-a73e-42a2-abd6-1d88e5b5dd81"
      unitRef="U_USDollarShare">9.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_d45858f9-5f23-4ea3-a7e2-ddac9afb63ae"
      decimals="2"
      id="F_91024402-40ed-4fd8-982f-37b685df5c91"
      unitRef="U_USDollarShare">19.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_4942759d-5603-4c11-8b85-e84d5218caae">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company&#x2019;s RSAs and RSUs were summarized as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:69.706%;"/&gt;
        &lt;td style="width:1.36%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.302%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.552%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.081%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="4" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted Average Grant Date Fair Value Per Share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;RSU&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;RSU&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unvested as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,271,334&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;59.93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,097,128&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27.87&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;349,496&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;58.26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;349,788&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;40.86&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unvested as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,669,178&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;37.46&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_c9e8dc36-972e-4533-bbcc-9f347a84b7dc"
      decimals="INF"
      id="F_6704d525-c588-4689-a7c0-3714cabd20aa"
      unitRef="U_shares">1271334</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_c9e8dc36-972e-4533-bbcc-9f347a84b7dc"
      decimals="2"
      id="F_16ccd51f-af75-4394-a8b0-141c91a2da08"
      unitRef="U_USDollarShare">59.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_ce26a70b-eafc-47b8-8306-b96c9e3a25d4"
      decimals="INF"
      id="F_53aa4a65-fb91-4982-b68a-3b3202517ade"
      unitRef="U_shares">2097128</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_ce26a70b-eafc-47b8-8306-b96c9e3a25d4"
      decimals="2"
      id="F_e029ea6c-ce1f-4ad1-a6a2-453624054d22"
      unitRef="U_USDollarShare">27.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_ce26a70b-eafc-47b8-8306-b96c9e3a25d4"
      decimals="INF"
      id="F_5e3e7b4b-aea4-405d-aedb-98141bcbe77d"
      unitRef="U_shares">349496</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_ce26a70b-eafc-47b8-8306-b96c9e3a25d4"
      decimals="2"
      id="F_5638643c-2a1d-4b16-8dc7-ab1fc4853c09"
      unitRef="U_USDollarShare">58.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_ce26a70b-eafc-47b8-8306-b96c9e3a25d4"
      decimals="INF"
      id="F_40c0134d-0f6c-42f6-81f4-cd44bbfc4e39"
      unitRef="U_shares">349788</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_ce26a70b-eafc-47b8-8306-b96c9e3a25d4"
      decimals="2"
      id="F_010cc1f1-81ff-4cdd-9d06-186362b20b3b"
      unitRef="U_USDollarShare">40.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_2aa5b5ab-23ab-4d0b-881f-3bccc42774eb"
      decimals="0"
      id="F_28b16e95-353d-42a5-9855-3519196661b9"
      unitRef="U_shares">2669178</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_2aa5b5ab-23ab-4d0b-881f-3bccc42774eb"
      decimals="2"
      id="F_66070611-8ea8-4a06-a223-8fac37c3d5c7"
      unitRef="U_USDollarShare">37.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="C_b432db30-4d2c-4ea5-b2ca-fe2523b09386"
      decimals="-5"
      id="F_66ef8f50-18a4-4924-a8c5-f1ee137eeb05"
      unitRef="U_USD">77000000.0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_ae72cfe1-e779-40b7-9892-e8d69ca5e6f9"
      id="F_8dfc9017-0160-4700-af33-57eadfb13a6b">P2Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_be7a83fd-5080-4d1c-9760-f12226eb8a62">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The following table sets forth the total stock-based compensation expense for all awards granted to employees and the ESPP in the consolidated statements of operations: &lt;/span&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.136%;"/&gt;
        &lt;td style="width:1.358%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.821%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.369%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.833%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.369%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.112%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;53,153&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;42,554&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,663&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Selling, general and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;48,929&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;41,230&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,937&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;102,082&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;83,784&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;27,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_ca130bf4-8380-4419-9f23-7747d3b7b6f9"
      decimals="-3"
      id="F_7ea02975-69cf-4149-a039-e7eebdf90dba"
      unitRef="U_USD">53153000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_ed2fc9b2-d46f-45fd-a059-f990d15eff81"
      decimals="-3"
      id="F_b6ac1b88-1393-479b-8595-2f6ee04d5801"
      unitRef="U_USD">42554000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_ff18ae7e-33f9-49e0-b7ad-17646042d12e"
      decimals="-3"
      id="F_7b4f6790-50d0-45fb-8780-2ecd5f1dcbda"
      unitRef="U_USD">13663000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_226affc5-a26a-4685-b939-df0a4de23d15"
      decimals="-3"
      id="F_138f8900-5a12-4586-99e8-26a2f80b1bf3"
      unitRef="U_USD">48929000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_2a70a582-48c1-408b-b426-be7b95e3333e"
      decimals="-3"
      id="F_88d83408-1a76-4e12-b4e4-f54a36835773"
      unitRef="U_USD">41230000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_bf980098-c647-4144-87a4-a5feba093982"
      decimals="-3"
      id="F_07aa31a0-61ad-40d1-93e9-60cee186e84c"
      unitRef="U_USD">13937000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_387229d3-b5d1-4d68-9c42-50311346c78f"
      unitRef="U_USD">102082000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_20b1a8e3-f474-46e2-9890-109e5327fc34"
      unitRef="U_USD">83784000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_e3d5a913-63c9-4fde-b4c2-fa2d906a1c56"
      unitRef="U_USD">27600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_aca4afa5-2d31-4ad9-b27b-0c7e69c7afc6">&lt;div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;12.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net Income (Loss) Per Share&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Basic net income (loss) per common share is computed by dividing the net income (loss) by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net income (loss) per common share is computed by dividing the net income (loss) by the sum of the weighted-average number of common shares outstanding during the period plus any potential dilutive effects of common stock equivalents outstanding during the period calculated in accordance with the treasury stock method. For periods that the Company was in a net loss position, basic net loss per share is the same as diluted net loss per share as the inclusion of all potential common securities outstanding would have been anti-dilutive. The following is a calculation of the basic and diluted net income per share (in thousands, except share and per share data):&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.361%;"/&gt;
        &lt;td style="width:1.506%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.574%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.506%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.574%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.506%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.974%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net income (loss), basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;515,837&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;528,584&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;298,665&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-average shares outstanding, basic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;132,606,767&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;129,884,967&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;119,159,424&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-average effect of dilutive securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,130,212&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,513,438&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted shares subject to future vesting&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;73,851&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;35,488&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Shares to purchase under Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;78&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Contingently issuable shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,233&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-average shares outstanding, diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;134,810,908&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;133,437,126&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;119,159,424&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net income (loss) per share, basic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.89&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net income (loss) per share, diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.83&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.96&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:58.205%;"/&gt;
        &lt;td style="width:1.068%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.735%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.058%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.735%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.058%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.141%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options issued and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,853,734&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,764,308&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,798,282&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted shares subject to future vesting&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,646,748&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,088,304&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;89,261&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,500,482&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,852,612&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,887,543&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_3bde2ec7-b0df-4014-b8bf-5e31fec84104">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.361%;"/&gt;
        &lt;td style="width:1.506%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.574%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.506%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.574%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.506%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.974%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:&amp;quot;Calibri&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net income (loss), basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;515,837&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;528,584&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;298,665&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-average shares outstanding, basic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;132,606,767&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;129,884,967&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;119,159,424&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-average effect of dilutive securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,130,212&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,513,438&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted shares subject to future vesting&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;73,851&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;35,488&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Shares to purchase under Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;78&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Contingently issuable shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,233&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Weighted-average shares outstanding, diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;134,810,908&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;133,437,126&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;119,159,424&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net income (loss) per share, basic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.89&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net income (loss) per share, diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.83&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.96&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_122029e7-13a6-4728-9e5d-01abbe20ee65"
      unitRef="U_USD">515837000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_c41bd841-28e5-4a88-8051-9dc1161e8e0b"
      unitRef="U_USD">528584000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_359aaffc-58b8-496f-bfd0-399ede2e9234"
      unitRef="U_USD">-298665000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="0"
      id="F_a4ba9a5a-ffb2-43d7-aeb2-0756252355a0"
      unitRef="U_shares">132606767</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="0"
      id="F_6a56330e-a9e6-43b7-bd24-4a158f502519"
      unitRef="U_shares">129884967</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="0"
      id="F_caf9c47f-c53c-4c75-85ad-03d34b388411"
      unitRef="U_shares">119159424</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="0"
      id="F_f36d87aa-2fad-4c70-8662-253bbac15b1c"
      unitRef="U_shares">2130212</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="0"
      id="F_55d064dc-623f-4477-8048-484a38283744"
      unitRef="U_shares">3513438</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="0"
      id="F_5a02ec2e-d045-444c-b2d2-7eae86f790f4"
      unitRef="U_shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <vir:IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="0"
      id="F_e99aa4ad-43a2-4fdb-98a5-599ec0019f0c"
      unitRef="U_shares">73851</vir:IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting>
    <vir:IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="0"
      id="F_21b1cf19-919d-4c22-b3fd-4c5329e5f269"
      unitRef="U_shares">35488</vir:IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting>
    <vir:IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="0"
      id="F_cb0e78d3-ea1a-4d61-bfa0-2abdcd3b5ac8"
      unitRef="U_shares">0</vir:IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting>
    <vir:IncrementalCommonSharesAttributabletoShareBasedPaymentArrangementsEmployeeStockPurchasePlan
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="0"
      id="F_7e1edb57-b6a8-427e-b192-3ece3f15e6ea"
      unitRef="U_shares">78</vir:IncrementalCommonSharesAttributabletoShareBasedPaymentArrangementsEmployeeStockPurchasePlan>
    <vir:IncrementalCommonSharesAttributabletoShareBasedPaymentArrangementsEmployeeStockPurchasePlan
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="0"
      id="F_e38a967f-d8f0-48ee-a48e-edf85cc7b50e"
      unitRef="U_shares">0</vir:IncrementalCommonSharesAttributabletoShareBasedPaymentArrangementsEmployeeStockPurchasePlan>
    <vir:IncrementalCommonSharesAttributabletoShareBasedPaymentArrangementsEmployeeStockPurchasePlan
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="0"
      id="F_b5047153-8ec2-4f3b-a05c-3977013a07a0"
      unitRef="U_shares">0</vir:IncrementalCommonSharesAttributabletoShareBasedPaymentArrangementsEmployeeStockPurchasePlan>
    <us-gaap:IncrementalCommonSharesAttributableToContingentlyIssuableShares
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="0"
      id="F_e79aeba9-713a-4564-b62a-4aa91c4671bd"
      unitRef="U_shares">0</us-gaap:IncrementalCommonSharesAttributableToContingentlyIssuableShares>
    <us-gaap:IncrementalCommonSharesAttributableToContingentlyIssuableShares
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="0"
      id="F_680406a6-f1bb-40af-80d2-2068732dd20d"
      unitRef="U_shares">3233</us-gaap:IncrementalCommonSharesAttributableToContingentlyIssuableShares>
    <us-gaap:IncrementalCommonSharesAttributableToContingentlyIssuableShares
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="0"
      id="F_dcd565b6-ff27-4d54-b440-ce2f03bbb33f"
      unitRef="U_shares">0</us-gaap:IncrementalCommonSharesAttributableToContingentlyIssuableShares>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="INF"
      id="F_81f1da48-f9c8-4bef-88b2-1c733b4a55d8"
      unitRef="U_shares">134810908</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="INF"
      id="F_11d82071-0c42-483c-8d65-6467c5e4d6c2"
      unitRef="U_shares">133437126</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="INF"
      id="F_662c6730-3b9a-4952-88da-314f9f5263d5"
      unitRef="U_shares">119159424</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="2"
      id="F_591ca7a2-204e-422d-86c4-81940acc1f07"
      unitRef="U_USDollarShare">3.89</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="2"
      id="F_f84898cf-aede-41a3-a2d9-688a3b21716c"
      unitRef="U_USDollarShare">4.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="2"
      id="F_cdd630dd-6193-4778-860e-c28cf09cc1a5"
      unitRef="U_USDollarShare">-2.51</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="2"
      id="F_0d630472-5ff4-4067-9ff0-1e8ba867894f"
      unitRef="U_USDollarShare">3.83</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="2"
      id="F_3c033b04-491e-40ec-8784-a916893b9190"
      unitRef="U_USDollarShare">3.96</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="2"
      id="F_f4c66a4b-245d-4a2b-af1e-9b1f0ef55b48"
      unitRef="U_USDollarShare">-2.51</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_5b7af926-408c-4472-90c2-b09c2b2f9a66">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:58.205%;"/&gt;
        &lt;td style="width:1.068%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.735%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.058%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.735%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.058%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.141%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Options issued and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,853,734&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,764,308&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,798,282&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Restricted shares subject to future vesting&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,646,748&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1,088,304&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;89,261&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Warrants to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,500,482&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,852,612&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;9,887,543&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_91be3be0-e317-45a0-837e-46e0bcedc91e"
      decimals="0"
      id="F_2c34e898-16bb-4220-ad40-b4dd79157384"
      unitRef="U_shares">8853734</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_bdb11187-f9e0-4206-b870-fc0fe6a80046"
      decimals="0"
      id="F_c9bbca75-414b-4c39-bae0-adc4c0f6d434"
      unitRef="U_shares">5764308</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_df66ba80-8dcb-4c94-abeb-511320bb1f34"
      decimals="INF"
      id="F_46f76340-0004-4058-a27f-ed841eb85581"
      unitRef="U_shares">9798282</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_112ed8a7-7988-46af-99b9-84ca6fe5334e"
      decimals="0"
      id="F_9b7419fc-1461-438e-ad73-d787edc63851"
      unitRef="U_shares">2646748</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_03bf1b7d-b075-4a4b-80d2-af36c3cd0aac"
      decimals="0"
      id="F_a4f72946-c2d9-4963-baee-9b63fe0475ad"
      unitRef="U_shares">1088304</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_11e2fb59-6582-4888-956d-443f42d7adbb"
      decimals="INF"
      id="F_ded91f09-a12f-41b9-9ed1-181305293e7e"
      unitRef="U_shares">89261</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_2a4a265d-bb0f-4164-81c2-3cfe9f2c5fed"
      decimals="0"
      id="F_62407461-bffd-4222-8c16-a36154398388"
      unitRef="U_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_981e1dc9-76fd-4fe4-a6ef-def1bcdbc1e7"
      decimals="0"
      id="F_0bcf38ed-f3d7-4f43-934a-8575289f9181"
      unitRef="U_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_053e3050-3042-4c21-b384-4dbc933b1860"
      decimals="0"
      id="F_11d232f1-9104-4187-98b3-d11ca09e9c35"
      unitRef="U_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="0"
      id="F_c538f673-1ac9-4344-a29a-5105fcc5faa0"
      unitRef="U_shares">11500482</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="0"
      id="F_7a8af2f4-387a-4fe1-880c-c79055139419"
      unitRef="U_shares">6852612</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="INF"
      id="F_0606f13f-b4f8-4a10-928a-4eae5bb33715"
      unitRef="U_shares">9887543</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_8854076d-885b-4b36-aa8d-7e43ae86e1b6">&lt;div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;13.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Defined Contribution Plan &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company sponsors a 401(k) retirement savings plan for the benefit of its employees. Eligible employees may contribute a percentage of their compensation to this plan, subject to statutory limitations. The Company made contributions to the plan for eligible participants, and recorded contribution expenses of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the years ended December 31, 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-5"
      id="F_4ed6551e-821b-4837-bbd3-d5e62a34907e"
      unitRef="U_USD">4000000.0</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-5"
      id="F_0039c32b-1143-4ee8-9dd6-ac678dc8da7a"
      unitRef="U_USD">2700000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-5"
      id="F_245a4b54-7e70-4e3a-86da-e3220174e4de"
      unitRef="U_USD">1800000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_152db799-0a6e-4e8c-b9e1-b2957411a180">&lt;div style="text-indent:0.0%;display:flex;margin-top:8.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;"&gt;14.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Income Taxes &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Income (loss) before provision for income taxes consists of the following (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.739%;"/&gt;
        &lt;td style="width:1.281%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.587%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.281%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.752%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.281%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.081%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Domestic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;692,445&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;535,989&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;309,697&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;61,835&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,813&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,086&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total income (loss) before provision for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;754,280&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;549,802&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;298,611&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The components of income tax expense consist of the following (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:37.715%;"/&gt;
        &lt;td style="width:2.141%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.708%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.141%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.456%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.141%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.697%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Current:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;238,550&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,526&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,432&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;105&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,647&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,401&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;106&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;253,629&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,032&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;106&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,186&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,186&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,186&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,186&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;52&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Provision for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;238,443&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21,218&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;54&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;A reconciliation between the expected income tax provision at the federal statutory rate and the reported income tax expense is as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:46.221%;"/&gt;
        &lt;td style="width:1.39%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.771%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.39%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.771%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.39%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.07%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. federal statutory income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Foreign tax at less than federal statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Prior year tax rate adjustment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;State taxes, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development tax credit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Permanent items&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Changes in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Effective income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;31.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The tax effects of temporary differences that give rise to significant portions of the Company&#x2019;s deferred tax assets and liabilities as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021, are related to the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:58.692%;"/&gt;
        &lt;td style="width:2.103%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.569%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.103%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.534%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14,793&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,030&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development tax credit carryforward&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,123&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,375&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Equity compensations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;24,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,065&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Reserves and accruals&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;85,977&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,115&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Capitalized research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;75,680&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,553&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28,612&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,348&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19,657&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;249,724&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;96,854&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized gain on investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,880&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30,170&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ROU assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20,834&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28,483&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,151&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,422&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,511&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,511&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;48,376&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;69,586&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;204,601&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;45,707&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,253&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,439&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Although the Company has taxable income for the year ended December 31, 2022 and 2021, it has otherwise incurred accumulated tax losses since inception. Based on the available objective evidence, the Company cannot conclude it is more likely than not that the net deferred tax assets will be fully realizable.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; Accordingly, the Company has provided a valuation allowance against its net deferred tax assets. For the year ended December 31, 2022, the Company recorded a valuation allowance increase of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;158.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, primarily based on the estimated 2022 taxable income. The valuation allowance is decreased by $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;114.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the year ended December 31, 2021 and increased by $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;74.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for the year ended December 31, 2020.  As of December 31, 2022, the Company has net operating loss carryforwards of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for federal purposes and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;111.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for state tax purposes. If not utilized, these carryforwards will begin to expire in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2037&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; for federal and in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2031&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; for state tax purposes. As of December 31, 2022, the Company also has net operating loss carryforwards of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for Australian tax purposes, which have an indefinite carryforward period, and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; net operating loss carryforward for Swiss tax purposes.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Under the Tax Reform Act of 1986, the amounts of and benefits from net operating loss carryforwards may be impaired or limited in certain circumstances. Events which cause limitations in the amount of net operating losses that the Company may utilize in any one year include, but are not limited to, a cumulative ownership change of more than 50% over a three-year period. The Company completed its Section 382 analysis as of December 31, 2022 and based on this analysis, it does not expect that the annual limitations will significantly impact its ability to utilize its net operating loss or tax credit carryforwards prior to expiration.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022, the Company has research tax credit carryforwards of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million for federal and state tax purposes, respectively. If not utilized, the federal carryforward will expire in various amounts beginning in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2036&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;. The California credits can be carried forward indefinitely.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Tax Cuts and Jobs Act of 2017 subjects a U.S. shareholder to current tax on global intangible low-taxed income ("GILTI") earned by certain foreign subsidiaries. The FASB &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Staff Q&amp;amp;A, Topic 740 No. 5, Accounting for Global Intangible Low-Taxed Income, states that an entity can make an accounting policy election to either recognize deferred taxes for temporary differences expected to reverse as GILTI in future years or provide for the tax expense related to GILTI in the year the tax is incurred. The Company has elected to recognize the tax on GILTI as a period expense in the period the tax is incurred.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt;Uncertain Tax Positions&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;As of December 31, 2022 and 2021, the Company had an unrecognized tax benefit balance of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; million, respectively, related to transfer pricing and research and development tax credits. A portion of the unrecognized tax benefits as of December 31, 2022, if recognized, would reduce the Company&#x2019;s effective tax rate by &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other unrecognized tax benefits as of&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;31, 2022, if recognized, would be in the form of net operating loss and tax credit carryforwards, which attract a full valuation allowance offset, and would not reduce the Company&#x2019;s effective tax rate. There are no provisions for which it is reasonably possible that the total amounts of unrecognized tax benefits will significantly increase or decrease within 12 months of the reporting date. Because the statute of limitations does not expire until after the net operating loss and credit carryforwards are actually used, the statutes are still open on calendar years ending December 31, 2017 forward for federal and state purposes.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The Company did &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;t recognize any expense for interest and penalties related to uncertain tax positions during 2022, 2021 and 2020, and the Company does &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;t have any amounts related to interest and penalties accrued at December 31, 2022. The Company files U.S. federal, state, Switzerland and Australia tax returns. The Company&#x2019;s tax years remain open for all years. As of December 31, 2022, the Company was not under examination by the Internal Revenue Service or any state or foreign tax jurisdiction.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;"&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;A reconciliation of the beginning and ending amounts of the liability for uncertain tax positions is as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.843%;"/&gt;
        &lt;td style="width:1.27%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.085%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.282%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.085%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.282%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.152999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross unrecognized tax benefits at January 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,422&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,877&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,725&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Addition for tax positions taken in the prior years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Reduction for tax positions taken in the prior years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;588&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Addition for tax positions taken in current year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,228&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,607&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,740&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross unrecognized tax benefits at December 31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,638&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,422&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,877&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_88e31b66-fc59-48f8-a423-55c776809395">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Income (loss) before provision for income taxes consists of the following (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.739%;"/&gt;
        &lt;td style="width:1.281%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.587%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.281%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.752%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.281%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.081%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Domestic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;692,445&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;535,989&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;309,697&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;61,835&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,813&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,086&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Total income (loss) before provision for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;754,280&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;549,802&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;298,611&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_22ddb718-ba83-4677-97d0-1163fd16bb9c"
      unitRef="U_USD">692445000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_355c6671-0224-418d-9c34-8bbe4c73fd00"
      unitRef="U_USD">535989000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_236c6ce0-ffd5-43fb-a9b4-7fa64005feed"
      unitRef="U_USD">-309697000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_3c17e166-1f89-4f01-b72e-d7cd95722f98"
      unitRef="U_USD">61835000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_622d4173-9b74-49ff-affa-dfb3f80ee19f"
      unitRef="U_USD">13813000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_ea9bc6d0-96f4-4639-acbe-420c1cf7f5ae"
      unitRef="U_USD">11086000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_39a6860d-2e5d-49ae-bde5-7021c9b88c9c"
      unitRef="U_USD">754280000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_8b816b34-7664-4dad-86ce-f469bcb7dac9"
      unitRef="U_USD">549802000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_20937271-399a-41eb-86b4-d95358138178"
      unitRef="U_USD">-298611000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_1da36aff-a27d-4ca5-9eb0-85e0776b4168">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The components of income tax expense consist of the following (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:37.715%;"/&gt;
        &lt;td style="width:2.141%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.708%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.141%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.456%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.141%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.697%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Current:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;238,550&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,526&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,432&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;105&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,647&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,401&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;106&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;253,629&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;6,032&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;106&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,186&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,186&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,186&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,186&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;52&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Provision for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;238,443&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21,218&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;54&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_2d5774ba-bca4-408a-89ea-bff1bec4a569"
      unitRef="U_USD">238550000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_d4fb6ad7-71e7-4dff-9b7c-4f915b3ed48c"
      unitRef="U_USD">3526000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_c704e193-ee6d-4f51-8e32-b6fa6d488653"
      unitRef="U_USD">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_ef57ffb8-e707-49ff-b61a-17c5f80900ab"
      unitRef="U_USD">2432000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_c52845d4-514f-4380-bff3-c6a13880d6d4"
      unitRef="U_USD">105000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_b8bf2123-cd42-4ae2-8433-0c28c78a9c60"
      unitRef="U_USD">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_8bd1e07c-dd8f-4263-8041-20339343ad41"
      unitRef="U_USD">12647000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_04690a59-b611-441f-a74a-3588db8f6fd3"
      unitRef="U_USD">2401000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_3c6aba07-0bf9-4cc4-9be6-3dc37f647367"
      unitRef="U_USD">106000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_78fcf687-7104-4748-8c29-d586aaa46040"
      unitRef="U_USD">253629000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_356da162-7b4a-4e31-9730-6dfb1ff81775"
      unitRef="U_USD">6032000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_0cf58def-602b-401c-a0c8-ec79a8d832e5"
      unitRef="U_USD">106000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_ae749f7a-7828-45c5-82a5-2b9272e38ea8"
      unitRef="U_USD">-15186000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_955d7dec-3516-48e3-ba46-0157eeeb6176"
      unitRef="U_USD">15186000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_66db909c-cd6e-4f28-8208-950901361b98"
      unitRef="U_USD">-21000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_91d27e81-9b74-4046-af9d-3404fbce9c87"
      unitRef="U_USD">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_2e2c18b2-8b14-4c6c-82c0-911ff623242e"
      unitRef="U_USD">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_e523422a-9b87-4ddf-8f61-c903f5d2bfec"
      unitRef="U_USD">-31000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_0bed4393-ffa1-435d-a2a2-2245f7773703"
      unitRef="U_USD">-15186000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_7936ac71-714c-4ad5-9ddf-3f6d2cdcbc69"
      unitRef="U_USD">15186000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_856a7da9-7532-41b5-8b2d-3a4cd39e16df"
      unitRef="U_USD">-52000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_5a3cd632-b4c4-4af7-aeec-4416b305e2e9"
      unitRef="U_USD">238443000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_ef31a209-d82a-4a12-a46f-79a158f7cbed"
      unitRef="U_USD">21218000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_74a7f82f-d9cd-46b0-8ba5-34ae917ac65b"
      unitRef="U_USD">54000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_8d7b8886-4852-476c-9b1e-1ad811c771d2">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;A reconciliation between the expected income tax provision at the federal statutory rate and the reported income tax expense is as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:46.221%;"/&gt;
        &lt;td style="width:1.39%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.771%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.39%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.771%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.39%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:14.07%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;U.S. federal statutory income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Foreign tax at less than federal statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Prior year tax rate adjustment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;State taxes, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development tax credit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Permanent items&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Changes in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;21.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;17.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;25.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Effective income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;31.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="INF"
      id="F_206da469-5288-49c2-8018-f06ffd7c2e23"
      unitRef="U_pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="3"
      id="F_c9537cf4-d25c-46a2-96da-d86088d2d49b"
      unitRef="U_pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="INF"
      id="F_2731fe3d-7797-4fea-bc86-6ad5359484c1"
      unitRef="U_pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="3"
      id="F_6656e810-81f4-445a-956d-e0b4cb1ba1bf"
      unitRef="U_pure">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="3"
      id="F_b0e566fa-51df-4ede-8a06-a7e87fe4f4e4"
      unitRef="U_pure">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="3"
      id="F_bcc24e01-c6f5-4f1f-83f4-a53feeae0e27"
      unitRef="U_pure">0.009</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="2"
      id="F_3dba834c-a191-44bb-98e2-01f6991f2850"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="2"
      id="F_e0c0063e-ba83-4139-a04d-1859db941301"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="3"
      id="F_7b118604-3d1a-400f-a1d2-908c92203b01"
      unitRef="U_pure">-0.019</us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="3"
      id="F_a04795c6-fe41-4ecd-bdbe-84f920cdacba"
      unitRef="U_pure">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="3"
      id="F_905fa70b-c5bd-4207-a018-56cfe5ad263e"
      unitRef="U_pure">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="3"
      id="F_68040c28-4533-40ac-b23e-d0a1fe203a96"
      unitRef="U_pure">0.027</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="3"
      id="F_22cf7147-460a-46b8-8bac-bb97b28f6e28"
      unitRef="U_pure">0.020</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="3"
      id="F_e6160158-e81b-434b-8caa-dc3a4d76c1c8"
      unitRef="U_pure">0.016</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="3"
      id="F_ac7388f4-6cec-48e1-8a31-ced9909762cb"
      unitRef="U_pure">-0.018</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <vir:EffectiveIncomeTaxRateReconciliationPermanentItemsPercent
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="3"
      id="F_fc418fa2-267a-4280-a280-cfa25ebc0958"
      unitRef="U_pure">-0.074</vir:EffectiveIncomeTaxRateReconciliationPermanentItemsPercent>
    <vir:EffectiveIncomeTaxRateReconciliationPermanentItemsPercent
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="3"
      id="F_30cf30d3-8cef-4007-b94b-eca589906d32"
      unitRef="U_pure">0.018</vir:EffectiveIncomeTaxRateReconciliationPermanentItemsPercent>
    <vir:EffectiveIncomeTaxRateReconciliationPermanentItemsPercent
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="3"
      id="F_4cf089a6-4745-4437-9aba-5ebc232dc1e8"
      unitRef="U_pure">0.013</vir:EffectiveIncomeTaxRateReconciliationPermanentItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="3"
      id="F_cd515e16-c63a-4ed2-9973-337edb601fc2"
      unitRef="U_pure">0.211</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="3"
      id="F_dc0480b6-ecba-4081-a6d1-7da82501d62c"
      unitRef="U_pure">-0.179</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="3"
      id="F_645d4f48-00e3-4c1b-9143-a15992739c92"
      unitRef="U_pure">-0.253</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="3"
      id="F_25b2127a-0f46-456f-9d87-6a03fa403051"
      unitRef="U_pure">-0.009</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="3"
      id="F_3f7510a5-b6c1-4ad3-b7b4-81ae641115a9"
      unitRef="U_pure">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="3"
      id="F_d322d900-bf3d-46bb-83a0-4d5a40261266"
      unitRef="U_pure">-0.005</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="3"
      id="F_94b50a57-c499-4139-af57-afc459de5986"
      unitRef="U_pure">0.316</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="3"
      id="F_aca2cc4f-00ec-4156-a4c6-e4e721820bb7"
      unitRef="U_pure">0.039</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="3"
      id="F_752a51d6-1ffc-4055-8bb7-d5eee17cd6fb"
      unitRef="U_pure">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_0926d2a6-5432-4c57-a1a2-f49866a5d5f3">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;The tax effects of temporary differences that give rise to significant portions of the Company&#x2019;s deferred tax assets and liabilities as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31, 2022 and 2021, are related to the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:58.692%;"/&gt;
        &lt;td style="width:2.103%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.569%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.103%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.534%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;14,793&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,030&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Research and development tax credit carryforward&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12,123&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;11,375&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Equity compensations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;24,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;15,065&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Reserves and accruals&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;85,977&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,115&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Capitalized research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;75,680&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,553&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28,612&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,348&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;19,657&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;249,724&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;96,854&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Unrealized gain on investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;5,880&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;30,170&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;ROU assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;20,834&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;28,483&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;13,151&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,422&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,511&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;8,511&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;48,376&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;69,586&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;204,601&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;45,707&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,253&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;18,439&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_60e0644e-302a-4138-a463-f6b0626e591d"
      unitRef="U_USD">14793000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_aea45f96-4e66-4651-abba-2e2787455aec"
      unitRef="U_USD">15030000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_90143095-a498-4b27-8c6a-e1c8e82a5793"
      unitRef="U_USD">12123000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_919124f5-b6a8-4d21-92e5-035cb46bf5d1"
      unitRef="U_USD">11375000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_b2e4150f-971d-4314-9547-a64bf5d185ca"
      unitRef="U_USD">24250000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_a24f6e5e-2bc7-416b-a5d0-30f620c62029"
      unitRef="U_USD">15065000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_ef9e0491-1ffd-4616-8647-b6d5e467bc16"
      unitRef="U_USD">85977000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_ef91281e-6cad-4180-898a-2c061e2db72e"
      unitRef="U_USD">7115000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_24efea2c-9b9c-497c-a43f-d33890e18322"
      unitRef="U_USD">75680000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_834d23e5-1219-459d-b581-b4396e976b21"
      unitRef="U_USD">0</us-gaap:ResearchAndDevelopmentInProcess>
    <vir:DeferredTaxAssetsLeaseLiabilities
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_de559909-ef26-41fc-a121-536c54f2a3f9"
      unitRef="U_USD">18553000</vir:DeferredTaxAssetsLeaseLiabilities>
    <vir:DeferredTaxAssetsLeaseLiabilities
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_785ff286-ca76-457f-a662-357ab8e5323d"
      unitRef="U_USD">28612000</vir:DeferredTaxAssetsLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_97dd83b0-0024-4c34-a47f-95a0e67cf33b"
      unitRef="U_USD">18348000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_92a296c5-9ec8-4eb9-a02d-1dd3d1bddb83"
      unitRef="U_USD">19657000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_50d50eb0-bb85-46a1-90fd-60d53bc636a1"
      unitRef="U_USD">249724000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_63b9d7c7-f5e2-43de-a3a0-e46a47fb9b23"
      unitRef="U_USD">96854000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_085fb317-fa19-4ceb-a478-6d6864adc43e"
      unitRef="U_USD">5880000</us-gaap:DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities>
    <us-gaap:DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_62806d81-dc2a-41b1-8e49-61c99922d7d4"
      unitRef="U_USD">30170000</us-gaap:DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities>
    <vir:DeferredTaxLiabilitiesRightOfUseAssets
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_50a1fff7-a141-4c93-ae9e-849205ea60aa"
      unitRef="U_USD">20834000</vir:DeferredTaxLiabilitiesRightOfUseAssets>
    <vir:DeferredTaxLiabilitiesRightOfUseAssets
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_3265c199-2f91-4390-aacb-a946b2cc49de"
      unitRef="U_USD">28483000</vir:DeferredTaxLiabilitiesRightOfUseAssets>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_6cbdda36-8f77-4a71-9302-93f16c98cb7c"
      unitRef="U_USD">13151000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_de1f0c8b-3691-4e42-9ac6-20990ae53179"
      unitRef="U_USD">2422000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <vir:DeferredTaxLiabilitiesInProcessResearchAndDevelopment
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_fb312d93-68b3-44b5-bacb-684ed4b69db0"
      unitRef="U_USD">8511000</vir:DeferredTaxLiabilitiesInProcessResearchAndDevelopment>
    <vir:DeferredTaxLiabilitiesInProcessResearchAndDevelopment
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_0e698373-eaf9-47ec-b7a4-e677290b9e11"
      unitRef="U_USD">8511000</vir:DeferredTaxLiabilitiesInProcessResearchAndDevelopment>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_81284f41-f083-43dd-899a-4dba292c996f"
      unitRef="U_USD">48376000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_466bb986-5249-4154-8b69-ba8946c29d23"
      unitRef="U_USD">69586000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_434716dc-3d55-4a8e-8a08-9d8a80c4d9f6"
      unitRef="U_USD">204601000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_7eaa396b-6baf-4d5c-9895-5c98a76ea77f"
      unitRef="U_USD">45707000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxLiabilities
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_6e85bd67-1837-479e-812f-7c4d84e7d254"
      unitRef="U_USD">3253000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_b861197f-7e8a-4d0d-a279-93451155e666"
      unitRef="U_USD">18439000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-5"
      id="F_8a51da04-2306-4a16-9cf6-14bc74d4014f"
      unitRef="U_USD">158900000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-5"
      id="F_34ff2fbd-bece-4446-a261-796b19181412"
      unitRef="U_USD">-114200000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-5"
      id="F_dd93f65e-495b-4c4b-aa84-1d27623b8c37"
      unitRef="U_USD">74100000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_b8ad5282-2271-4d16-8946-c9bc284a5384"
      decimals="-5"
      id="F_32f9f56c-c926-4f71-affa-c2142a4620dc"
      unitRef="U_USD">20900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_2d2b4307-0211-44cc-a6ea-58f34976c023"
      decimals="-5"
      id="F_41172bab-5140-40d5-9964-af70614c3db7"
      unitRef="U_USD">111400000</us-gaap:OperatingLossCarryforwards>
    <vir:OperatingLossCarryforwardsExpirationBeginningYear
      contextRef="C_10a388d6-6193-4e20-a608-d5203976d818"
      id="F_ba14da5d-bd42-4777-9a23-ed57fa0620fd">2037</vir:OperatingLossCarryforwardsExpirationBeginningYear>
    <vir:OperatingLossCarryforwardsExpirationBeginningYear
      contextRef="C_24ffc582-325f-493e-a4b4-111a43d7f9d9"
      id="F_a5df8296-dc11-418e-9f92-c7ba4f345749">2031</vir:OperatingLossCarryforwardsExpirationBeginningYear>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_774f1d32-810d-4510-b5e3-aaafabf8e63c"
      decimals="-5"
      id="F_5fc02f42-5a2b-4386-9fc6-db16bf4b7627"
      unitRef="U_USD">10600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_d39ab2c8-69ae-4434-87f5-e53d359487e4"
      decimals="INF"
      id="F_f65fd33c-c486-4890-a27a-14ff08477316"
      unitRef="U_USD">0</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_b8ad5282-2271-4d16-8946-c9bc284a5384"
      decimals="-5"
      id="F_6a2bd6f1-489e-4fae-b946-3371bef94363"
      unitRef="U_USD">400000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_2d2b4307-0211-44cc-a6ea-58f34976c023"
      decimals="-5"
      id="F_e1c3159f-86ca-4850-8051-9d66e0f2ec18"
      unitRef="U_USD">15900000</us-gaap:TaxCreditCarryforwardAmount>
    <vir:OperatingLossCarryforwardsExpirationBeginningYear
      contextRef="C_d8fb65c9-343c-4c85-898f-95ed557e0d7f"
      id="F_f1bb6347-8486-4738-8c51-49db52826db1">2036</vir:OperatingLossCarryforwardsExpirationBeginningYear>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-5"
      id="F_fffd2f93-ccdb-4c6c-9a54-a81eb199ca96"
      unitRef="U_USD">10600000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-5"
      id="F_bb7bde7c-bb8f-47c0-a781-33ff5830d0a5"
      unitRef="U_USD">7400000</us-gaap:UnrecognizedTaxBenefits>
    <vir:UnrecognizedTaxBenefitsIfRecognizedWouldReduceEffectiveTaxRate
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="3"
      id="F_ebc1391d-da9f-46b9-a482-40fde1c866ae"
      unitRef="U_pure">0.007</vir:UnrecognizedTaxBenefitsIfRecognizedWouldReduceEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="INF"
      id="F_7d1001c0-1478-4d58-8bb9-9d13fba68970"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="INF"
      id="F_d912ae25-e52e-4aa6-a8fe-ab2312f7b92d"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="INF"
      id="F_93ec68af-898e-4d11-b782-2dd819477ebb"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="INF"
      id="F_cc5cfa11-afa3-46fc-946d-2de08dec1215"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      id="F_2daab237-bb19-4f0b-8dda-3d42af2b9bf4">&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;A reconciliation of the beginning and ending amounts of the liability for uncertain tax positions is as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.843%;"/&gt;
        &lt;td style="width:1.27%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.085%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.282%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.085%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.282%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.152999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross unrecognized tax benefits at January 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,422&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,877&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,725&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Addition for tax positions taken in the prior years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Reduction for tax positions taken in the prior years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;62&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;588&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Addition for tax positions taken in current year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;3,228&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,607&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;2,740&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;Gross unrecognized tax benefits at December 31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;10,638&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;7,422&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;4,877&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_3e90cfd8-326b-4e24-8c5c-d0fab380e0fb"
      unitRef="U_USD">7422000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_da5feba6-e631-4bec-b33d-106ac3401870"
      decimals="-3"
      id="F_6dffdadb-eea0-410c-adca-b7bc6d0041d7"
      unitRef="U_USD">4877000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_ce64793d-668a-40e8-af07-6ebdbdd93828"
      decimals="-3"
      id="F_ef487356-c0f9-4ac1-a7be-a25e36672367"
      unitRef="U_USD">2725000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_1d0ec088-a8f1-45e3-a546-63f0cbcf4426"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_4d7a1162-0d5a-4202-9da0-70ceeba57cbb"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_871e8816-4703-4ae5-bacf-7bd07a5bc600"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_ac69dddf-3895-4e5c-8506-5c59fc542da2"
      unitRef="U_USD">12000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_78632a09-8157-4ddd-805f-de603f61e13d"
      unitRef="U_USD">62000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_55d83caa-402f-468e-b552-7e639bedab6d"
      unitRef="U_USD">588000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68"
      decimals="-3"
      id="F_2a55186e-49ea-483d-a90b-745e0df44d54"
      unitRef="U_USD">3228000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_4be62c4c-687d-4539-b972-f167d33aa2d8"
      decimals="-3"
      id="F_401c92fd-10c9-48e1-900d-0853323d9dda"
      unitRef="U_USD">2607000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_94806f35-4a90-434e-acce-cb420888cb77"
      decimals="-3"
      id="F_2943f177-1279-4f00-8cb8-a88533364586"
      unitRef="U_USD">2740000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3"
      decimals="-3"
      id="F_b7615371-f18a-434f-b74f-c1b9ce558ffa"
      unitRef="U_USD">10638000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_a7262ac3-ad3a-4279-afb3-5136951286cf"
      decimals="-3"
      id="F_617e2317-404e-48f4-834f-22d737c46526"
      unitRef="U_USD">7422000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_da5feba6-e631-4bec-b33d-106ac3401870"
      decimals="-3"
      id="F_9c678344-7f0a-48af-a742-16e423af8296"
      unitRef="U_USD">4877000</us-gaap:UnrecognizedTaxBenefits>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#F_36b8b5e2-054e-47cc-b86d-523e8cbc6e77"
          xlink:label="F_36b8b5e2-054e-47cc-b86d-523e8cbc6e77"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_95c3d196-361b-4bb9-bbfc-19a0145e77ff"
          xlink:label="F_95c3d196-361b-4bb9-bbfc-19a0145e77ff"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_f2ee8c17-9247-4204-9405-460cc56f15e9"
          xlink:label="F_f2ee8c17-9247-4204-9405-460cc56f15e9"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_e67a3f38-3954-40a0-a395-2d43a7a52199"
          xlink:label="F_e67a3f38-3954-40a0-a395-2d43a7a52199"
          xlink:type="locator"/>
        <link:footnote id="FNT_e1b04269-f99c-420d-9953-f9f240029909" xlink:label="FNT_e1b04269-f99c-420d-9953-f9f240029909" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Includes </xhtml:span><xhtml:span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</xhtml:span><xhtml:span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19.3</xhtml:span><xhtml:span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million</xhtml:span><xhtml:span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> of restricted cash equivalents.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_36b8b5e2-054e-47cc-b86d-523e8cbc6e77"
          xlink:to="FNT_e1b04269-f99c-420d-9953-f9f240029909"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_95c3d196-361b-4bb9-bbfc-19a0145e77ff"
          xlink:to="FNT_e1b04269-f99c-420d-9953-f9f240029909"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_f2ee8c17-9247-4204-9405-460cc56f15e9"
          xlink:to="FNT_e1b04269-f99c-420d-9953-f9f240029909"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_e67a3f38-3954-40a0-a395-2d43a7a52199"
          xlink:to="FNT_e1b04269-f99c-420d-9953-f9f240029909"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_549f2f58-0809-43a7-af9f-aa62d6cab632"
          xlink:label="F_549f2f58-0809-43a7-af9f-aa62d6cab632"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_e42ea656-1acd-403e-8417-882547909ce9"
          xlink:label="F_e42ea656-1acd-403e-8417-882547909ce9"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_c5e69a23-b98a-4558-b375-80f9e0916679"
          xlink:label="F_c5e69a23-b98a-4558-b375-80f9e0916679"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_69ac5583-03ad-40a0-a1ae-3d91bf3c9102"
          xlink:label="F_69ac5583-03ad-40a0-a1ae-3d91bf3c9102"
          xlink:type="locator"/>
        <link:footnote id="FNT_0c55a751-de0a-4516-8374-b7d3de9b6dd1" xlink:label="FNT_0c55a751-de0a-4516-8374-b7d3de9b6dd1" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Includes $</xhtml:span><xhtml:span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15.6</xhtml:span><xhtml:span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> million of restricted cash equivalents.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_549f2f58-0809-43a7-af9f-aa62d6cab632"
          xlink:to="FNT_0c55a751-de0a-4516-8374-b7d3de9b6dd1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_e42ea656-1acd-403e-8417-882547909ce9"
          xlink:to="FNT_0c55a751-de0a-4516-8374-b7d3de9b6dd1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_c5e69a23-b98a-4558-b375-80f9e0916679"
          xlink:to="FNT_0c55a751-de0a-4516-8374-b7d3de9b6dd1"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_69ac5583-03ad-40a0-a1ae-3d91bf3c9102"
          xlink:to="FNT_0c55a751-de0a-4516-8374-b7d3de9b6dd1"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_24f706d2-1a5c-4606-a102-532a52e31e5b"
          xlink:label="F_24f706d2-1a5c-4606-a102-532a52e31e5b"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_badce134-8528-4753-8a8b-28ca3cf397fa"
          xlink:label="F_badce134-8528-4753-8a8b-28ca3cf397fa"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_de81d354-d0b9-4919-aaaf-c3852c79312a"
          xlink:label="F_de81d354-d0b9-4919-aaaf-c3852c79312a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_94b5821e-c6b0-49b4-bd92-b25178e3d93a"
          xlink:label="F_94b5821e-c6b0-49b4-bd92-b25178e3d93a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_faed9603-c7e8-4971-b88c-45fb1a1abd5f"
          xlink:label="F_faed9603-c7e8-4971-b88c-45fb1a1abd5f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_6ed74193-b982-4779-9300-7e451bc0ef5b"
          xlink:label="F_6ed74193-b982-4779-9300-7e451bc0ef5b"
          xlink:type="locator"/>
        <link:footnote id="FNT_309d5bc3-a5ff-45a0-b9dd-16d51cf30514" xlink:label="FNT_309d5bc3-a5ff-45a0-b9dd-16d51cf30514" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unobservable inputs were weighted based on the relative fair value of the clinical and regulatory milestone payments.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_24f706d2-1a5c-4606-a102-532a52e31e5b"
          xlink:to="FNT_309d5bc3-a5ff-45a0-b9dd-16d51cf30514"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_badce134-8528-4753-8a8b-28ca3cf397fa"
          xlink:to="FNT_309d5bc3-a5ff-45a0-b9dd-16d51cf30514"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_de81d354-d0b9-4919-aaaf-c3852c79312a"
          xlink:to="FNT_309d5bc3-a5ff-45a0-b9dd-16d51cf30514"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_94b5821e-c6b0-49b4-bd92-b25178e3d93a"
          xlink:to="FNT_309d5bc3-a5ff-45a0-b9dd-16d51cf30514"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_faed9603-c7e8-4971-b88c-45fb1a1abd5f"
          xlink:to="FNT_309d5bc3-a5ff-45a0-b9dd-16d51cf30514"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_6ed74193-b982-4779-9300-7e451bc0ef5b"
          xlink:to="FNT_309d5bc3-a5ff-45a0-b9dd-16d51cf30514"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>108
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MKQ#ME/M4A6\_[]6G6>.A,4LLR)A%?]!0;FXZ5QT4DA5.(_G(=O\A18,NE%[
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MC88A_H!,XQ!OKFL-ZQ2FWZM,OW>4Z?\#6'6_)6P'PSS!@B5@I&9"I%HG=7=
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M;. ?E0WT&)]V.E-Q=T!RD5(8 BX<1PO/:D2PI5:'5T4$_ZB(4,(;JR48^Y[
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MA*=(=_X.FB0-0RN]#K.84CR MR,LXF>LUS%!)2L/&1";I*+(:@4.JQB$^D
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M3M2.%3N.XS2RRMJU \! R SEO-,Q[#6K^SUM@,X^GG]K&+%U9.+> 7 8NG<
MQGMG?N; ]0]>W^>5 AF^A)'X;0R9J+=GF-L;+=?-,>"=U%J6S>5*<-"\Q@!^
M7TJ0#[L;<[+8GB1/_@-02P,$%     @ M8)<5KCT#E/@ @  Z0D  !@   !X
M;"]W;W)K<VAE971S+W-H965T,RYX;6RMEM%NFS 4AE_%8M.T25TPD$#:)4AM
MJFF[F!0UVG8Q[<*!DV#5V,QVDFY//QLH"RU)2+5<!!O.^?W]YAA[LA/R7F4
M&CWDC*NIDVE=7+FN2C+(B1J( KAYLA(R)]ITY=I5A022EDDY<WV,0S<GE#OQ
MI+PWE_%$;#2C'.82J4V>$_G[!IC831W/>;QQ1]>9MC?<>%*0-2Q ?RWFTO3<
M1B6E.7!%!4<25E/GVKN:>=@FE!'?*.S47AM9*TLA[FWG<SIUL"4"!HFV$L1<
MMC #QJR2X?A5BSK-F#9QO_VH_K$T;\PLB8*98-]IJK.I,W90"BNR8?I.[#Y!
M;6AD]1+!5/F/=E7L*')0LE%:Y'6R(<@IKZ[DH9Z(O01O>"#!KQ/\O@E!G1"4
M1BNRTM8MT22>2+%#TD8;-=LHYZ;,-FXHMZ]QH:5Y2DV>CF>"*\%H2C2DZ(8P
MPA- "RNGT-LYD<!U!IHFA+U#[]%KY"*5F;MJXFHSNM5PDWJDFVHD_\!(MY ,
M4.!=(!_[?D?ZK'^ZUTYWC>?&N-\8]TN]X(#>0AO+IAXU$BOTD7)CG!*&YD+1
MLKY^7"^5EJ;*?G99K;2'W=IVZ5VI@B0P=<S:4B"WX,1O7GDA_M!E_#^)M:8A
M:*8A.*8>S\VJ 2G-RS>EEMQ?H()(M"5L UVV*ZVHU+(?B&V,!QAC\SZV^X9.
MAK50APWJ\#S4JA(1V>A,2/H'TB[D2G.TQ^+AZO<$ND=@"WO48(]>A$V5VG0C
MCYZ1/&4]%M&"#!O(\$60YL.O-.$IY>LNTO DZ;&(%FG4D$9'26<BS\WR[%.M
M4;]J/1G6XAPWG.,S.'N5ZOC97 6XNU;[1+:H+QOJR_.I#U?JY?,U$P1^$(;C
MZ EQ5Z3GA=X0#[N)/?QO!\/G,Y\HW%JR#WEG:#>ZN[</VT/0%R+7E"O$8&5R
M\2 R(K(Z5U0=+8IR:UX*;3;ZLIF9LQA(&V">KX30CQV[VS>GN_@O4$L#!!0
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M,.N9VPKF=R*T ;Q?<:Z>%_H+^G\$V3=02P,$%     @ M8)<5C(WZB8@"P
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MV8\_C]#)*6;=\/SQ=WK4#%X.YB$NQ2)/_Y.LJ\W=))A8:_$8[]/J4_["Q7%
MLYJWRM.R^;_U<CS6GEBK?5GEVV-CV8-MDAU^QE^/)^*L@4,O-"#'!F1H WIL
M0'L-*+G0P#TV<'L-B'^AP>S88-9KX'H7&GC'!EZ_2Y<B^,<&?K]+ETYK<&P0
M-+-[F(YF+I=Q%=_?%OF+5=1'2UK]H!%$TUI.89+5VOU<%?*WB6Q7W2_RK,S3
M9!U78FU]KN0/*<RJM/)'2_[J6115\I *ZZ-4E"B*YIA\]8<59\='FSQ=BZ+\
MFQ7^N4^J;]:;I7A,5DGUUKJQ?O^\M-[\]-;ZR4HRZ[=-OB]EL_)V6LE^U]&G
MJV,?/QSZ2"[T\;>\BE--LX6YV2+?;N5?1]--3>OE\-96E*?RC_Q&/O_U49Z'
M)'O2 $,S\.?U.JG_7./4^A@GZQMY3A;Q+M$/+7HM:UA7V17\:K7?[M-&$[]6
M&U%(+6QE:MS4.>M96/_,2]TT\N'4HTJZD*G4[DG Y"1@TE#="]0/XBG),CE,
MF<+2.%L)*ZXD?O7.HL[?+6([<YW@#DRO8=;I_?G>)73NDMOI\[G U,,<IWO(
MTMB[^LKSOMS%*W$WD>>O%,6SF-S_]2^.9_]#IR UGC^G]JP7,T+&9&K,&\_N
M1>2:@Z@7S.J3^ZR9/'J:/#IR\MY(*9>;6/;[[:")-/)'GHK% 38[GV[;]]Q@
M3F:]64>&#9&P" EC2!@'P3I"<T]"<XU"^R16:5R6B<PZ<;-FDM<W>=U*GN-Z
MZ62E2?R0I/7UJ\JM^)A<K=TAM=ZL+J;I#ZZB&#(G;D\M"V/?1I[&)1(6#NI_
MA S)D# .@G4T-3MI:F;4U"]EN6]REM32ZK!:*)O5@DQAJSS+CJOSEZ3:6/(B
M*I?IFT0\-^NKNDDLEW.ID"VR3M;3J<S8C[%);J8FN<-_O12'#!HB81$2QI P
M#H)UY.B=Y.C!Y!C+5](T?LB+0S:,GPK1"%.G/D_-$;;GS>>]).>I:Z6>HHS]
M'ZNH"[T*>JD+&9,A81P$ZVC%/VG%_]]KY5K6,G9A;-;RE>GV/.+9Q.]I#!DT
M1,(B)(PA81P$ZR@Q."DQ>)T2'_/"6L7E1EXB2TM\%<4J*9NC7N*BB*^KSQAV
MK/H"-=DXCN^[/?$A8X9(6(2$,22,@V =\<U/XIL;Q?<E3O>-I@XZ.J2V=7T/
ML-L7JTU<"IVRYHH8**'$Z8EA80P]=M$_OW9Q#9'A(C5<,T3:C<F0,3D(UA&"
M8[<VJ/VZ/'0ES9BQ8_,,E+8\TLZ5&DB=DJ!W?Q="PT90&H/2.(K65=F9V>X
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M:+8\[^A" )\WUM+!"1>,?Y#R+U!+ P04    " "U@EQ60O?7\S(,  !:.P
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M!WN$RX(D$,X+\#XW&,?;&]Z@__1U_C]02P,$%     @ M8)<5@U,LR?I)0
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MX .<Y*IX,H+]R'ISU9,X+D$Z_8>['6O XL4?O\ 5S/. ,-8Y Q*(.]<EC7F
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M[D?U(O&]\":977P D7P!OZ!2B9=[%/NP"_MT1V(2%$DR>M!"(;*@K3-OJJA
M%H -@@52@1HCJJ[='BUU=*C& >64F5Y-//AV"X<+-!0/CPV-LD4.7)$UBG8&
MX)Z,2C0R0>B398,4C2Z(W\'I?A?--;">AWXTJ^P[Q#&;(E'\&V) :62<Z<IJ
M:*+5BK4R4AHI?C"TT,,%%/B&J+$JPW9!_Q9H[P*BHK7H6T ANZF@_/$)WM_T
M4<(/N:#B7&]=]9&D,CP>[IS;)U<2,6?L4]RP'T9V]&Y&H"*9":WNPX(0!3B"
MHP9W!L7OVM7BDL/0$;UYTD?AF$?P$)(Q69- $Z]$R#DN)6B8W=Z\L990PYQV
M$# LSO!PE#"&PYXMJP"F6\]6O =C%2VP0[(!-L#M?8NCV=XK49RI:V!P%9BB
MTF+GFQX4;SQM,MU$$#0E&KS ]Z!(JV@&@@6K<-"N,],.00* >56$LL_1"Y0+
MF.T"2Q5+8FI#W!(? KMI"%.W.7OTH=AV#8EQXL='4>3"0!=4<DVP;Q0(&!E=
MCT[HG)<I08J"XIP8Q: )WX U2H)5(X*T(OQQD=MG3&PP8GV>370_-SX"HT*M
MB5W%&Q<[&;5N8!7+D5S7ZV$V#2B.OHP^DPXDFKH%VPO'GH, /$>E#&>T&@QE
MSI,\\A()LX8L?/ 0[FBO.P?6;TWV2 P_60!]-+,POC-U]Q!6,7,2LR[4OB;@
M103# ;8=*B,1W_"1;04D!;0X,$:OWK .)UV$3O#(B$CD%X?K&)2SO/L;V"A*
M5+-)]951U@&%P<X\G#$=%E,6!\SV;*>1^1O'(E+2 9%8)TNA)/W!%N!*C" $
M1CAF6;R.L3-8]0[.!B@9R8Q=V]J!D[KSHMK)#E-D MY__QE.B"(_Q]5!,!YM
M+V8SP>78]HXL2EZ)^27 9_34^MT"+,4.)-9^2S3 OB8:?<SC-2"KCZ82L_C"
M_!UD/W/B#IF)XU[BT*#++@\LT"6_<QB #0;\WT1KT:*8@B*3W$]K.=.3/@9U
MYNJ<:"4(0P<U!<C8+P8HT(3 X&VTA(\M.,8L(!^HEV)[R4*DL),AIJV$ES30
M80272*0[4:_&]$"%3/:=A)J18EDNYHR0-/##<@BT/^@L\#O5O[":1LGTX##Z
MZ3 #=(_$%OOEK=$G<R=!/*%F7>/AZ4SGL-8%R05B!8[5Z%"BU=X!)W%&"G=*
MEG8>J=N//1!G<,*Q4QVW$$M:#354H")X& JVKS!2?(A6+!R[*$,4$Q3PHT N
MI1'([D7/*NW!_AV3$H\X"Z1* '4XY%J8(<:EJ[('\4UK*^G4&117V2HWN,H;
M7.4FK3(GM#BZJ"J4MRWAM 0=K)^R-7"2%$8BW0CRA*QYLM5 Z9!&</VM1\F*
M&5>R"?X^=@@N/L"2@_.YLAQ'R#2:DE&HA$21 I?%]PK"XG%DLW*'CM5S(IU3
M)(,'P,BF"=")6$0Z Z9MBXM+G0,WOGC SN$5Z."2' I;<*S.419,3IF29, ;
MY+B&3'01*3==NSD:MRP^)$5PE!NH';BPM0G= =9;V5IOX]2!@I;P5*M6956-
MNY%3%OA#[[:8Q[]U,;. 2SQE:0L<U \$0=4Q3\UH-@XJ(\D 1F5$F8(O($+'
MG2B8"J20_H*..O,G)0;H7 _*$S[R%W%ME+X"XV]+=W#VCN$WH,-0-((3'9.B
M5?L%O<V!!#0!S%I^25(0V-@* BL,=ZY$SXJC^<;1@3V( ,@9(+$XL7Y9;4W"
M@(@L@T[D%G%:SC^%QW@3V=-HT)6U)UYFS51*V#!*$XHOW_G@%D>F_SRDO=.M
MD8PB;!+SH.+R/7M=&2%T*Q04M#*#JY8%A0X(N6B_&-%@H1#[)6 PF:T%L(N$
M6W/OP;KPOEW#]BB(U5/^I^]@A5N)3XL:@.U?)R/'' !'J1#Q)/M.;@"1$7/#
MR&&2*\QG@QT<BWQV,1ZSNB9+8X)6,XU4+_,ORPR^%U<7'HI!BR/M;QXZZ?HC
M&3..9E0NA5Z0NDCGMC58Q(T#"[VWCAX%0)@$#RG<0,)TWA%>%"M 1,$)B8ZR
M.RPRU9\#DL8"$%B+=,*F=TY$[56,MZ/Z81AC0H6]1 E&@.6MODR?T%"JRPS'
M.8J^H?0P&G-XE$75E"$ G?+#_2,PN"S>]7@TL'O\&0]@SWSV$^ Q^\WI;Q,S
M!ME4J" 7_#4>#B"0J:FM,[&]!,OBGI]%[>WVXQ"=4N)5H% ,V)YC_8K(R\1\
MR:H!_*Q'<%PHQBA\;G+CG-]=&(N$-3S@=XV_L\VZ+'[$0]R2"-]A0%XSM;W5
M6G%Y%!T<YHV'9(!0QQN#Z[B=QJ]C?HF(95G\#=U&S3W3X0\>A2%*.A6FJ-(X
M#M&MU8((&H"5(H'''H(LLNLB!5**+3-"4E9:10>E3\130-4&Q->P+X3?IURF
MA)I$?:B9L2S^@E%TUY::0<:2 -_SCD%L]1M)(:692E+4**3JW$%C'S&P<=,0
M(PGZ2 %$M4$.N<-SHL 7G8:1D'GJ&>Q15,@N.5IH.!\H7DK&/H>I>25*+D@X
M&0,-6)Q!WOU[_<!A \!3U&VK R?U8OI^.K]$QL2U1-9"UY$M&>7F-3AMP03V
M#=E$W]1D?"@3%3!^:QX\,A(98ZY>Q*2#X(]_Q@V"(J0\:KZ?8:LA&/QDT@W'
MF#/ <LB8U2VPUZ\,M=FIP8#9-" N1!T6IUL6/W6Q,,#"+M9L*F=26L)=U5)D
M0)4D-9A< ^9'4!]?,8SSP>7XE.SD#OWI4F>Y]67*3<%1K[!XBOVC7LB&GN6:
ML(#N7^U W_C!"14?KY!472[IK'$74B;)M^> 44PQ(N>".*NV$D=(:1A-U/_P
M[OT?RMW^Y9M4#Z<[03]K=BOS?.@?WL>$,<N!A!_*F78D28SY1U1F:RSOX10^
MF)V_CV^CM62(;X=Z9)9U)6=[/+IL']YA)&HT)-+A$$=A5@,Y1T.%=7?7TF$-
MUL&Q#OE\G'O!.M^0=-LQ<R?,!JK+*^+9+A"+Y7&J./?%V81]:(M9I)$#VB9)
M+=(C:C]0<YJ)3E&L150L$S3KHTF_ LBJN)$\6-MF,0RS%%8XPAI(I/CXR5VC
M2[F"3UVK\,X3R]'>%3ZCJ4XRF%;Q+=,Q1/&K' :Z#3/ZF4XQPD%4M.1&U"LR
M96!HFH"7CB%MYA2 ^L"40;&]B P5IB,!]-W]7)K (R_ 2X;3* !F,=]/O$MB
M, .^R%=K=/CP+[3L[I<^UN(+*%+P^"Z^C/;>0UBALT!1)_[G_ZF%\7W7U42-
M\8^H(X*$_$G^"Y)BG(H=S1G4YHXE%]0 >!$)[;V4\DA5@15$H=@HR/][Z@ Y
M/N+3V#JI\/8]4S<1Z75,T5'>XT= 62L^US7Z_%B-H>,^D#-HZN1OT-\L>U "
MUUV=PCNJ;Z]NKJ.F_:7;^ZKXZOE7BS@="6)=1)S1ZYB>,I/@,%-AE]?I,9^&
M6.E#*:FYR@[-?$D54D@Q#:IJVGF4,7A>7*4C@=D%G7<;+5;$L3@"(<8"T+;D
MK2>+,-:DDI$:)$'G.#:8:J(Y>X"Y(5Z:'75>&PBJ2ZHD[K WQT=1PK['J5*$
M5QP2L"[W1.&"PAQUX'5@I3%O8MUA;H1L3000]/,^?%T\\4\U<G?0O=)A/0E/
M)1 ;L?H2GIX^+DMPT=FJP2H?ZS#I;#04QJ:=XJ^F1)\Y&1^[?:H5H2<>4I?B
MT4LCOI_ M)&2<D(B.S;#6X"9PIKB>"=688,DY;[)$;=G1$2TQB#VJ=-Z\?S%
MPK(FS'!E9[#, <_.,\<:G,TA856=*->X+"Q860D@-30<#R=?Z-0NIP1P'^4Q
M1NS"TT6GV*'(0Q7=(ZX*#F/)+IIL.T:&N- PUJ0B")L1[!^$&$":I?]ROV^\
M%"K/<=:NJUTC\:\X05[FUW<'L#L.I'_VW':@JR)D5.6'&B07$?&9;&XDL]J%
MJO<K]#2QB7 1XR%QS((?H^,Q.7Z)J-CM^2PU@@)LHZ'SQQW#O:3IM8Z%S?^P
M+;5-P,ZG:,T#)%ZE)!GR4HM9@:=Z5(@RMX$HWO.EM%A49'ITM<D:7G'4D(0%
MUM +B>2U*EOA<PUDH,\,:E/*W,80B_:DB!4;;T#]B<%(&2DUTC3RM0)+:4WN
MD;H< A%5F,+GX"CF2GI\<0IYFE.ACB0U5AAM,3,ED0G!W6=A'CLAAB\U@<,Z
MAW(WQ$N4(4>2C7TY3]QRLZ2R_A%;&*@58X&A"TZ(D]& 9CFF'\HU6E:P2G!-
M0\^E(@'$AT[Z-*<(P@;:_;VI8IE%1L[!L'I#JE_#R;[EYEU2C)1Q'4Y@PG)R
MR8T7+:6"3('P0CR^,*2H'&=?"?>4EJ6$CF[S(WS[$7R27\=:NC%BNBF:B^.>
M"ZLUA(FU!-&GY 6U[#0MH/&L%/ R8VH@M[:V]=/P.,BV ]7@3DZ.GO*:2^6J
M7P,*S!_CL"N@"C=PHJ?%(BG=Z-&H6!H:\=<[6(ZC0*II"TF>F2QB/,? 8CAK
MHAFLY0-,3V)P7QX8L?5(FGX,FJ 8^WMDV2(BD.N\SUE>Z6P+3#9CMTT>^2NC
M33D-\:HW@^8U98D0'-BK@DGF%3J"J:8K@SPMAQ(._<%6XQ)SF@@6*5'^<$P%
M=1W7:35.S5&&F>H):*-2JG%'R^  #FJSZQ)#A[A6'\K&]%UQ'HW]YP=ZK5!>
M.LHD2Z.A+?]NC!LQ.9>8*'J$&42F@UTT-7B)-#UAM<N!98FI*4FA"NI:9R..
M*-: U8=3YB,!DT^*3I9M54V6=*RT/0TFF]B2!4MH XHD8SJ#8GTZ_))\%;)F
MR9A&0><KOY?:@;;XM?-4?9KF> :0V&E8-@Q.ZBZEE\!NL-/6PMCXHA"K3IV)
M(#LJ!1Q9/%":#9-QOHO27FEW5LBS6$UR0?CIR/"W$OV$X47TACU,MGLI<N!
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M"/*(#*YX?KP'VE=>:EURG'\F1QQR&WAL,=8\N6*>:L&I9J-BQ@!Z!+.UYX)
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M#C$S*:C&78L??Y@,AQ<WXA=:3 RNQ5N_EM]49W%:)DI\*4V!]7*K8VRO*Z+
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M.W@^$<-HW!]%@\FHM?]F"1HQNAI'EY-+UN"MYTN:.KCJC5",I"GA!%='3BE
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M"R6!$ W ^YE!_QV^T ;U#_M>_@=02P,$%     @ M8)<5L0^$)X="P  G!\
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M\C,9M-JU[GA3AQORS'BZ;X=F21\X:'D"C<^-\>L.+]!_,EW\!U!+ P04
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ME/.E1E*4 /2Y<,!K;VLY-QLQQQZXXQ%?@A-O@HJ'^3;/"8?D9L(@(][)6^>
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M8-??(_-E+U1=UBN5BU(S#,?[&>&V]R=H2!CHMD8("W6MB@X0X$-JZY4$Z!H
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MA^,HT:@)O8RS]8U"G\'Y!39=X^8%@*Z@\91)819*K*J:?D?%3Q?0KUN8L%5
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MYUH*$&=\ +Y?UG!0YA^XP4W=?"#PGO\O4$L#!!0    ( +6"7%;-,Y)C<00
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M0K1GLV0TG]&#>3)93-FW"?08B5C6V@7GRU5(P@'=N!.KJ <H:M5W];:L!UX
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M3T-QT-QXL^6/YDOCO2GY<J-@34L+\'YE$(GQA@YH_XOBXC]02P,$%     @
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M#TD/N</\#_X,G0PY;PF9C%K0:S(&(SLB3R<RK[;1<UG;J4H;=.UF&;7_O:V
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M41"(8[^+N6C]AFFC\A7_4HN&YV5:V)\SU4_K'X-=VM] -<OM+\E^DCD:+?3
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M(Z?3YJ/#V Y'J.*W<W,[-A\3]2@: W*7._L#)^Y,71#[O,[4P4E<=:<#W;$
M\HG..)Z.A#]4^+ND6'2^YOI^L%SZ8ZDCX-IV);+BDVJ$$C7[!]M:LURB-_>-
MB>=.^/E-=N 81P+Y(KP[5_,YZ27Q POUO:9$N[V% YUCI.CJ7,4GLKW>Y;@Y
M#]6_;A*P79^.=:BS=**)6L^O&IIP\4=Y9,J<Y;]0OF6A9_[<C(.[7W+[Y9E*
M!@$5I%U633]VQ$,'2Q\9"FY!58?@X-N4J8:S?XXA!3K2"S0"A4P6F :D;4 *
MU\3EBWB*IJ+?/]XOG+L^L@]*N>:6M.K!$=UN4<<?P$)-S$U,"[=EP>-W+YGK
M#GBX.G? D]>6)/7!WHU -,8$W<%J)X@WL:C:;GK;14./TQ%9^)R'YL3J?IKM
MZ[O4!=;WSUZ;XA10RUW]I6S!!T?XZYI^'^L*=:+<MUZ7%K3 .\>J-9_0D.O(
M>/"R?_+(]NE.^D"KN==7G^5:E\V)]I87OB,+0&_T_^BZ:X4VU-[JC$.?"'AG
M4P3TSHC_@"-<KK.FC_ORL+Q)C%W7PT="/LQZ*4EKV@.8+6MWS/'_WXGX%V>.
M/UK*HP=@M1(_273'*/@1U1T^JWHBQL%L.J7!-IC&Z> \SUDF7\_WA*S0>91=
M7>U.P]V]H^_V#/"*</%;B9T0 /'YE_]*9S/Q[%%BM3T?=Q=)$,<SZ#0)Z>4,
MFK''F*=G;*[5P229W;/4H7>/I[WWPFME;_CM-[W/0RCX5\3=W>X%^[E_K[Q;
M[M_._R(MHLJ)0BVQ%14S'0KKWWC['Y79\%OFA:DJL^;+E9*(?EJ YTMCJO8'
M,>C^[>#5_P!02P,$%     @ M8)<5B:8&\!?*   78H  !D   !X;"]W;W)K
M<VAE971S+W-H965T,C,N>&ULS3UI<]S&E7\%Q53%4M5P)-*'9,M6%7584<JQ
MM:*5;-76?L  /3.P,, $#9":_/I]9_=K# :DG$UVO]@B"72_?OWN"]_?MMU'
MOW6NSS[MZL;_<+;M^_UWCQ[Y8NMVN5^V>]? 7]9MM\M[^+';//+[SN4EO;2K
M'UT^?OS-HUU>-6?/OZ??O>N>?]\.?5TU[EV7^6&WR[O#"U>WMS^<79SI+]Y7
MFVV/OWCT_/M]OG'7KO^P?]?!3X_"*F6U<XVOVB;KW/J'LZN+[UY<?HDOT!-_
MK=RM-__.\"BKMOV(/[PM?SA[C!"YVA4]+I'#_V[<2U?7N!+ \7=9]"SLB2_:
M?^OJ/]+AX3"KW+N7;?VWJNRW/YP]/<M*M\Z'NG_?WO[)R8&^QO6*MO;TW^R6
MGWWRS5E6#+YO=_(R0+"K&OY__DD085YX^OC$"Y?RPB7!S1L1E*_R/G_^?=?>
M9AT^#:OA/^BH]#8 5S5X*]=]!W^MX+W^^37?1M:NL^MJTU3KJLB;/KLJBG9H
M^JK99._:NBHJY[,'^J^'WS_J86M<X%$AV[S@;2Y/;'-QF?VE;?JMSUXWI2O3
M!1X!S 'P2P7\Q>7LBJ]<L<R^O%ADEX\O+V?6^S(@XDM:[\L3ZTV=^+^N5K[O
M@'#^>^K$O-Y7T^LA-WWG]WGA?C@#=O&NNW%GS__XAXMO'C^;@?:K .U7<ZL_
M?Y'[RN.EO<.UFSY'$I\"<G:9:2 GU\Y^W;KL9;O;Y\WACW]X>GGQY)G/BK;Q
M@*LR[UV9K:LF;XHJKS,/KSC@W-YGV_S&92OGF@S6W^<=/%<U^![*DZH_ +7W
M6V#-@/M]5\$B^QJPOW&-Z_*Z/N#?W;[G=WN XT-3X4_7N ]!>K5S'1!N]@!!
MNWS\[,W5U3OZY\6SAUG>X(M%/90N@^6RO/P-^(KA:USAO$<& (!H[75>==G>
MGAS6[R<.'\^[;WU%3^H:>X"F+;TNX\HEH>]N="F8N(@@A<[W5X")C@$_WFY;
MP,EY>]O *GY8^:JL\@[(=9E=P>DJV*\K&%:05S5L CC"EX&2&Y^3,+07X^H*
MY K!-.S;QD )#RZS&6+].A#KU[/$"N(3A&.3O1RZSC7%88I.9U>8IM/QLH3C
M]=#0"0&OA?[^U 7*^Q:'&5 ^4=CR>IF5@.B\6Z+D<CW22.Z]ZQF9=96OJAJN
MG0EP<BT@=T9ZG3/Q]JU=&![HA53.'2SI/A7;O-FXK".RQEV:MCG?W;'[:)?Q
M'H-'MMI6H$F01>K1-LOLO;MQS>!H7?<)M+T_7A0 !7KI\@!<O^W:8;,%-4_H
M@CO9.]*O2OM \9'<L@V8!P)YZW5](7;BZA96Z? W[<YE#P2,APO@SSYKF>D3
M[C$\ ]@'&Z4C<O6S]/I-H-=O9NGU@W>XZFO?5SL\[12]SJXP3:_C98E>62PF
M@N8^8N)(A*+$@VOX^U#!?F @-'!7^##2PR[_Z#(7ML5K %H:=GL6!?T6KW>]
MA@N4R]RW'=WZ+@B@4[0'/Y>5+^!6AXY.!W"A',>=DP=Y:3S3_8])0NL$0-TQ
MU6;ET"&MQU=(H01ZC"(@<S=Y/1 R4**>1@V:C7 OS:;%I5:D&"<8"O< 2</0
M,"FO@?+;3E8DA8.(;OW<1=QN01SCB_RGHNJ*80?X( E>5@5B!H1\T0^P*UPS
M&)ZH@X>ZS'#!KB)E659PE0! U^[&.\YRQY/ '4]FN>/:;>AZIKAB]LUIKM#E
MDOMAAD84X1WH=>:KVF6>GU].&R3;R@5Q +=4NJ(B_P%9H%O0;;^D9UY_<L5
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M+;(5Z/NF[?DX9&PPF(UCRZ-=X>7"&4 1H:C7PR"^ <&T!C"(KY"3P=*N16N
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M%G5'. AS*C"F82U-X%2[D2).F5@Z:JG%/;@Q>W(83H??I,+E*&2[TO)8#:P
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MG=[ ?1S=03]P>H'[-;96V(SZ3K\?[N#:Z_2?BRLT4$>OHH[><ZGC+*'Y'(U
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MO*O(\JFO_-!B89_7ID)KD=EFPBCB8R;@^$P(O?DP"U0/KN/_ %!+ P04
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MEB:7%U?TJ8#:*=!YH93=+UR P\?']%]02P,$%     @ M8)<5L4;;,OB @
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MR#3C:%]?@@#;+PH)W9L=P-(H&K0O76;*6U7C")'BCDCQ#U5H9W-3FV)6PU.
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MT/#P,I\K>.ERB1-@?"&$WC5P@>[M//X74$L#!!0    ( +6"7%9C_<U%1@0
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M//D>#E<K:@DNEYX3-04PF#>ZM"6:\]ZO&]<N#%@%FT;G:Y(\4$P5M1!28_X
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M\:':;QWMC6G6]OO"O#&FJ>QR)05F$MJ ]XNF,?T-*1@^.)W_!5!+ P04
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M\6/"$F_0R]KNQ:#'4Q6QA-X+(-,X)N+EBD9\W?>@]]HP9O.%,@W^H+<D<_I
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MK&?& @  ;P8  !D   !X;"]W;W)K<VAE971S+W-H965T,S@N>&ULG57;3MM
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M$?'91L1G6A%_97'-2387':_#U-PGWK.=ZAIG?6VPMDB'ZA()<Y$P#PGSD;
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MY]?Z&,D<;6QIBC.HKY@O2"80A;FB="X&*C=>'.L4-Y+EYJ!CQJ1DJ;E< DZ
MZP#U?LZ8?+K1#52':^$O4$L#!!0    ( +6"7%;CB/:5R@,  &X/   9
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M/12S1SL[O!ZC;C?Q\_9KWGXC[P26YGNX,+ ?(9USP<3LR0?8J/+2S7HDL:V
MS^N SU_ST#H_9AZ.)+:5!QRM/Y_1ZQQ;E>[6N14GN[NKLMI<KKTHBOS+%6]\
M]'$C]6=7W4#6NER"--4:N@-;\E$^0P\*I@4S4SL%=/(%B%2G7OSF ;KHR;JB
M!.7NZ^V;N&:)7YVY>)V#N!%Q;,"DJ2);5Z8*W%_%WJ ;%5^Z<(^EMAW_NN[
MKUIXX*-6'L=2V\[%NO; KU1\X/W"8K.NJ()K-MIF7E<?N+G\.,(>;A[ E-[E
M)L91M8M1W$$9>?+OYD:QE\Y@N-'1Y"!GKM%3*!4%UV5S4S^MF\E+UT*%:_.R
M$_U Y(QRA1A,C6MTUC.@LFSNRALM%JX_>A3:=%ON<FX:8I#6P+R?"J&?;^P
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M2!. []="Z*>):5?#QR;] U!+ P04    " "U@EQ6;S?Q9T('   /.P  &0
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M%/)Z]V7]0;)EM5OPGDG)LNIP0;!Z\RD+J.]G3"4#_:&LH-D#._D/4$L#!!0
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M_Y??]^8J6LF$:B*J2:@FHYJ":BJJ::BFHYJ!:B:J6:AFHYJ#:BZJ>:CFHUJ
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ME?G-@+0.YGPIA-YM[ >Z'U?V#U!+ P04    " "U@EQ6=!C:'M<#   U#
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MI+CC$<NL8*^[H>D.=MAZG9VH'"=9"C=!L+\EM-KPYLL07 ,L6,;=680+V).
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MR%]!J##Y&Q&75*YXJB &EH!TCD<0G#)_R2 _T&*3/10_%UJ+)/NX9C1BTC2
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M;:[OQ.YOV!,*#%XB<E7]DMW>UK%(LE5:%'MG7$'!R_J?/>Z%.')PPQ,.=.]
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MTMWM_0F)HZ.7I^%XG!Q([(E*PG#8+W'<21R_4J*KHP'YS.B2<69^#LBLR>V
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MBJ8KH?9YG7_PM 9S79VU MTF#*51Y_24A=G5X'A+>$,I:W8U'1UM$D8U39=
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M+ZCG8\;D^D8'*$_H!_\!4$L#!!0    ( +6"7%8%5O+V]@,  $(2   9
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MPDJFM94YLDXR!A!>(=O\@BS#LAHF-'X[W&R !V^'&R?4V-6BV8K//K9H,::
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MG<P9^Z4G=_G8<K0@*"&3F@&KVQINH2PUD9+QN^6TND=JX.YXR_[9>%=>YEC
M+2N_DUPNQU9LH1P*7)?R@6V^0.LGU'P9*X6YHDT;ZU@HJX5D50M6"BI"FSM^
M;O.P W"C%P!>"_ . <$+ +\%^*\%!"T@,)EIK)@\I%CB9,39!G$=K=CTP"33
MH)5]0O6QSR17NT3A9')',U8!>L3/(-  S=1KE=<E(%:@=NO\*Q/B DU O6.
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M>:5RSYOFUDPD6YER/V=2-0\S7*K_ > Z0.T7C,GM1#^@^\-(_@)02P,$%
M  @ M8)<5G/"MQQV P  'PT  !D   !X;"]W;W)K<VAE971S+W-H965T-C,N
M>&ULK5?O;YLZ%/U7+-[TU$IK ?,C:5^"M(1-;Q\F56N[?7;A)D$#.\]VDNZ_
M?[8A) &'=5.^)!C..9QS'6XNDQWC/\0*0*+7JJ1BZJRD7-^[KLA64!%QR]9
MU94%XQ61:LF7KEAS(+DA5:6+/2]V*U)0)YF8<P\\F;"-+ L*#QR)3541_G,&
M)=M-'=_9G_A:+%=2GW"3R9HLX1'D\_J!JY7;JN1%!504C"(.BZGSP;]/?:P)
M!O&M@)TX.D8ZR@MC/_3B<SYU/.T(2LBDEB#J:PMS*$NMI'S\UX@Z[3TU\?AX
MK_[)A%=A7HB .2N_%[E<39VQ@W)8D$TIO[+=O] $BK1>QDIA/M&NP7H.RC9"
MLJHA*P=50>MO\MH4XHC@QV<(N"'@+B$\0P@:0O!60M@00E.9.HJI0THD22:<
M[1#7:*6F#TPQ#5O%+ZC>]T?)U=5"\63RF6:L O1$7D&@&S1GU9I1H%(@MD"'
MB^CCJ_JE"4!7,Z"P*.0UNDI!DJ(4UXKV_)BBJW?7Z!TJ*'I:L8T@-!<35RJ'
M^CYNUKB9U6[P&3<^1E\8E2N!/M(<\E,!5T5K\^%]OAD>5$PANT6!_QYA#V.+
MH?G;Z;Z%GKZ=[@VD"=K="HQ><$9OON%<;<Z]K;(U,[0S=?NX%VN2P=11_4$
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MZ[BN >CF]]WQ"([7U-RKXGF#\8Z%55!84A7VTE2F.HIOCJ+/]Z7<D93.+#C
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M09'](EKGBPOSH-PIJ>]R':<6MR+*4H:^T$>6H_?H*HZY$9 FZ%:4CZ&1\TW
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M^=])]7B^MUP??UE^G9RP<\$YW5;4Y[]02P,$%     @ M8)<5N(A,D+Q 0
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M;%!+ 0(4 Q0    ( +6"7%9E4BNE[0   "L"   1              "  :\
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M2P$"% ,4    " "U@EQ6N/0.4^ "  #I"0  &               @($C&
M>&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ M8)<5O_",5_6
M!@  [2,  !@              ("!.1L  'AL+W=O<FMS:&5E=',O<VAE970T
M+GAM;%!+ 0(4 Q0    ( +6"7%; X^>'E ,  !T,   8              "
M@44B  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " "U@EQ6
M,C?J)B +  !I;P  &               @($/)@  >&PO=V]R:W-H965T<R]S
M:&5E=#8N>&UL4$L! A0#%     @ M8)<5E.!37PF @  300  !@
M     ("!93$  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    (
M +6"7%9"]]?S,@P  %H[   8              " @<$S  !X;"]W;W)K<VAE
M971S+W-H965T."YX;6Q02P$"% ,4    " "U@EQ6VK<&5U$(   &$P  &
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M970Q,RYX;6Q02P$"% ,4    " "U@EQ64<,BLO@(  #<%P  &0
M    @($?C0  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    (
M +6"7%8#C4O V2(  ->&   9              " @4Z6  !X;"]W;W)K<VAE
M971S+W-H965T,34N>&UL4$L! A0#%     @ M8)<5LTSDF-Q!   O0D  !D
M             ("!7KD  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"
M% ,4    " "U@EQ6%_8C;Y,,  !1(0  &0              @($&O@  >&PO
M=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( +6"7%;_<02!\0(
M &<'   9              " @=#*  !X;"]W;W)K<VAE971S+W-H965T,3@N
M>&UL4$L! A0#%     @ M8)<5M703Q0O#0  +B<  !D              ("!
M^,T  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " "U@EQ6
MTGNB/1(%  "<#   &0              @(%>VP  >&PO=V]R:W-H965T<R]S
M:&5E=#(P+GAM;%!+ 0(4 Q0    ( +6"7%:J+$\I\0(  +0&   9
M      " @:?@  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%
M  @ M8)<5KZ4C:$@#   @B   !D              ("!S^,  'AL+W=O<FMS
M:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " "U@EQ6)I@;P%\H  !=B@
M&0              @($F\   >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+
M 0(4 Q0    ( +6"7%;&N_-W$@8  'P5   9              " @;P8 0!X
M;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ M8)<5HG( "N9
M P  B @  !D              ("!!1\! 'AL+W=O<FMS:&5E=',O<VAE970R
M-2YX;6Q02P$"% ,4    " "U@EQ6Q1MLR^("  "1!@  &0
M@('5(@$ >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( +6"
M7%9');0X5 0  )$)   9              " @>XE 0!X;"]W;W)K<VAE971S
M+W-H965T,C<N>&UL4$L! A0#%     @ M8)<5FITLEB(!0  A T  !D
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M=#,R+GAM;%!+ 0(4 Q0    ( +6"7%:1E%,".00  .\2   9
M  " @6%) 0!X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @
MM8)<5ABP"%>O!   BA4  !D              ("!T4T! 'AL+W=O<FMS:&5E
M=',O<VAE970S-"YX;6Q02P$"% ,4    " "U@EQ67.D8)J0"  "U!@  &0
M            @(&W4@$ >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4
M Q0    ( +6"7%:QT^]Y;04  /8<   9              " @9)5 0!X;"]W
M;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ M8)<5B"4.-@A!0
M;R   !D              ("!-EL! 'AL+W=O<FMS:&5E=',O<VAE970S-RYX
M;6Q02P$"% ,4    " "U@EQ6H.*L9\8"  !O!@  &0              @(&.
M8 $ >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( +6"7%:@
M^LO#;0P  (>,   9              " @8MC 0!X;"]W;W)K<VAE971S+W-H
M965T,SDN>&UL4$L! A0#%     @ M8)<5F=\+D?* P  :!,  !D
M     ("!+W ! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( +6"7%9M<7#EJ0(  #T'   9              "
M@<?6 0!X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ M8)<
M5MH*7=,$!   #10  !D              ("!I]D! 'AL+W=O<FMS:&5E=',O
M<VAE970T-BYX;6Q02P$"% ,4    " "U@EQ674 >%I "  #$!@  &0
M        @('BW0$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0
M   ( +6"7%9T&-H>UP,  #4,   9              " @:G@ 0!X;"]W;W)K
M<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ M8)<5FR?K3\B!P  ]C$
M !D              ("!M^0! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q0
M2P$"% ,4    " "U@EQ6E8>'-RD$  "A#@  &0              @($0[ $
M>&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( +6"7%;]"\:9
M&P,  ,L(   9              " @7#P 0!X;"]W;W)K<VAE971S+W-H965T
M-3$N>&UL4$L! A0#%     @ M8)<5F#0!"(] P  ?0D  !D
M ("!PO,! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4    " "U
M@EQ6TP)Z$R()  !]6P  &0              @($V]P$ >&PO=V]R:W-H965T
M<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( +6"7%: /V=,]@0  *T7   9
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M970U."YX;6Q02P$"% ,4    " "U@EQ6K5^9F68$  !5#P  &0
M    @(%Q%0( >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    (
M +6"7%;:3C,2" 0  /<2   9              " @0X: @!X;"]W;W)K<VAE
M971S+W-H965T-C N>&UL4$L! A0#%     @ M8)<5AP[63Z* @  RP8  !D
M             ("!31X" 'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6Q02P$"
M% ,4    " "U@EQ6LGI!LO<"  !M"   &0              @($.(0( >&PO
M=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4 Q0    ( +6"7%9SPK<<=@,
M !\-   9              " @3PD @!X;"]W;W)K<VAE971S+W-H965T-C,N
M>&UL4$L! A0#%     @ M8)<5I3)DPO^ P  ;0X  !D              ("!
MZ2<" 'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6Q02P$"% ,4    " "U@EQ6
M>;[+OW $   *$   &0              @($>+ ( >&PO=V]R:W-H965T<R]S
M:&5E=#8U+GAM;%!+ 0(4 Q0    ( +6"7%9KPBRBR 4  (TJ   9
M      " @<4P @!X;"]W;W)K<VAE971S+W-H965T-C8N>&UL4$L! A0#%
M  @ M8)<5J"9.,)& P  5@H  !D              ("!Q#8" 'AL+W=O<FMS
M:&5E=',O<VAE970V-RYX;6Q02P$"% ,4    " "U@EQ6N=?\]5,#  "^%0
M#0              @ %!.@( >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( +6"
M7%:7BKL<P    !,"   +              "  ;\] @!?<F5L<R\N<F5L<U!+
M 0(4 Q0    ( +6"7%9 2W]V[00  +(L   /              "  :@^ @!X
M;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " "U@EQ6R%S!4B "  #0)P  &@
M            @ '"0P( >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"
M% ,4    " "U@EQ6XB$R0O$!   9)P  $P              @ $:1@( 6T-O
F;G1E;G1?5'EP97-=+GAM;%!+!08     2P!+ (04   \2 (    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>272</ContextCount>
  <ElementCount>507</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>112</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="vir-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="vir-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="vir-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="vir-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100060 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="vir-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100070 - Statement - Consolidated Statements of Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20221231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="vir-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100080 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit</Role>
      <ShortName>Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="vir-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100090 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical</Role>
      <ShortName>Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="vir-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100100 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="vir-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureOrganization</Role>
      <ShortName>Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="vir-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="vir-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="vir-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitions</Role>
      <ShortName>Acquisitions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="vir-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Goodwill and Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssets</Role>
      <ShortName>Goodwill and Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="vir-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Grant Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGrantAgreements</Role>
      <ShortName>Grant Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="vir-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Collaboration and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreements</Role>
      <ShortName>Collaboration and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="vir-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponents</Role>
      <ShortName>Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="vir-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="vir-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="vir-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Stock-Based Awards</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwards</Role>
      <ShortName>Stock-Based Awards</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="vir-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Net Income (Loss) Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20221231/taxonomy/role/DisclosureNetIncomeLossPerShare1</Role>
      <ShortName>Net Income (Loss) Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="vir-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Defined Contribution Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20221231/taxonomy/role/DisclosureDefinedContributionPlan</Role>
      <ShortName>Defined Contribution Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="vir-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="vir-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="vir-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="vir-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Goodwill and Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssets</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="vir-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Collaboration and License Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTables</Role>
      <ShortName>Collaboration and License Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreements</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="vir-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables</Role>
      <ShortName>Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponents</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="vir-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="vir-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Stock-Based Awards (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsTables</Role>
      <ShortName>Stock-Based Awards (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwards</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="vir-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Net Income (Loss) Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20221231/taxonomy/role/DisclosureNetIncomeLossPerShareTables</Role>
      <ShortName>Net Income (Loss) Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vir.bio/20221231/taxonomy/role/DisclosureNetIncomeLossPerShare1</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="vir-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxes</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="vir-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Organization - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails</Role>
      <ShortName>Organization - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="vir-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="vir-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Fair Value Measurements - Financial Assets Measured at Fair Value on a Recurring Basis by Level Within Fair Value Hierarchy (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails</Role>
      <ShortName>Fair Value Measurements - Financial Assets Measured at Fair Value on a Recurring Basis by Level Within Fair Value Hierarchy (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="vir-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Fair Value Measurements - Financial Assets Measured at Fair Value on a Recurring Basis by Level Within Fair Value Hierarchy (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyParentheticalDetails</Role>
      <ShortName>Fair Value Measurements - Financial Assets Measured at Fair Value on a Recurring Basis by Level Within Fair Value Hierarchy (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="vir-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Fair Value Measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="vir-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Fair Value Measurements - Estimated Fair Value of Significant Unobservable Inputs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails</Role>
      <ShortName>Fair Value Measurements - Estimated Fair Value of Significant Unobservable Inputs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="vir-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Fair Value Measurements - Summary of Changes in Estimated Fair Value of Financial Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Changes in Estimated Fair Value of Financial Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="vir-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Acquisitions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails</Role>
      <ShortName>Acquisitions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="vir-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Goodwill and Intangible Assets - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="vir-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Goodwill and Intangible Assets - Schedule of Finite Lived Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Schedule of Finite Lived Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="vir-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Goodwill and Intangible Assets - Schedule of Estimated Future Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Schedule of Estimated Future Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="vir-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Grant Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails</Role>
      <ShortName>Grant Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="vir-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Collaboration and License Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails</Role>
      <ShortName>Collaboration and License Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="vir-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Collaboration and License Agreements - Collaboration Collaboration revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsCollaborationCollaborationRevenueDetails</Role>
      <ShortName>Collaboration and License Agreements - Collaboration Collaboration revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="vir-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails</Role>
      <ShortName>Balance Sheet Components - Schedule of Property and Equipment Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="vir-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Balance Sheet Components - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails</Role>
      <ShortName>Balance Sheet Components - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="vir-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100540 - Disclosure - Balance Sheet Components - Schedule of Accrued and Other Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails</Role>
      <ShortName>Balance Sheet Components - Schedule of Accrued and Other Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="vir-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="vir-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100560 - Disclosure - Commitments and Contingencies - Summary of Lease Costs and Additional Information Related to Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsAndAdditionalInformationRelatedToOperatingLeasesDetails</Role>
      <ShortName>Commitments and Contingencies - Summary of Lease Costs and Additional Information Related to Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="vir-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100570 - Disclosure - Commitments and Contingencies - Schedule of Maturities of Operating Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Maturities of Operating Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="vir-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100580 - Disclosure - Commitments and Contingencies - Schedule of Operating Lease Amounts Recorded in Condensed Consolidated Balance Sheet (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Operating Lease Amounts Recorded in Condensed Consolidated Balance Sheet (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="vir-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100630 - Disclosure - Stock-Based Awards - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Awards - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="vir-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100640 - Disclosure - Stock-Based Awards - Summary of Stock Option Plans Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails</Role>
      <ShortName>Stock-Based Awards - Summary of Stock Option Plans Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="vir-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100650 - Disclosure - Stock-Based Awards - Summary of Assumptions Used for Estimating the Fair Value of Stock Options Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails</Role>
      <ShortName>Stock-Based Awards - Summary of Assumptions Used for Estimating the Fair Value of Stock Options Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="vir-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100660 - Disclosure - Stock-Based Awards -Summary of Employees Stock Purchase Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20221231/taxonomy/role/DisclosureStockbasedAwardsSummaryOfEmployeesStockPurchasePlanDetails</Role>
      <ShortName>Stock-Based Awards -Summary of Employees Stock Purchase Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="vir-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>100670 - Disclosure - Stock-Based Awards - Summary of Restricted Stock Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityDetails</Role>
      <ShortName>Stock-Based Awards - Summary of Restricted Stock Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="vir-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>100680 - Disclosure - Stock-Based Awards - Summary of Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Awards - Summary of Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="vir-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>100690 - Disclosure - Net Income (Loss) Per Share - Schedule of Basic and Diluted Net Income (loss) Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20221231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails</Role>
      <ShortName>Net Income (Loss) Per Share - Schedule of Basic and Diluted Net Income (loss) Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vir.bio/20221231/taxonomy/role/DisclosureNetIncomeLossPerShareTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="vir-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>100700 - Disclosure - Net Income (Loss) Per Share - Schedule of Potentially Dilutive Securities Not Included in Diluted Per Share Calculations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20221231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails</Role>
      <ShortName>Net Income (Loss) Per Share - Schedule of Potentially Dilutive Securities Not Included in Diluted Per Share Calculations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vir.bio/20221231/taxonomy/role/DisclosureNetIncomeLossPerShareTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="vir-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>100720 - Disclosure - Defined Contribution Plan - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20221231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails</Role>
      <ShortName>Defined Contribution Plan - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="vir-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>100730 - Disclosure - Income Taxes - Schedule of Income (Loss) Before Provision for (Benefit from) Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeLossBeforeProvisionForBenefitFromIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Schedule of Income (Loss) Before Provision for (Benefit from) Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="vir-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>100740 - Disclosure - Income Taxes - Components of Income Tax Expense (Benefit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails</Role>
      <ShortName>Income Taxes - Components of Income Tax Expense (Benefit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="vir-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>100750 - Disclosure - Income Taxes - Reconciliation Between Expected Income Tax Provision at Federal Statutory Rate and Reported Income Tax Benefit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails</Role>
      <ShortName>Income Taxes - Reconciliation Between Expected Income Tax Provision at Federal Statutory Rate and Reported Income Tax Benefit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="vir-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>100760 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="vir-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>100770 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="vir-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>100780 - Disclosure - Income Taxes - Reconciliation of Liability for Uncertain Tax Positions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfLiabilityForUncertainTaxPositionsDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Liability for Uncertain Tax Positions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 8 fact(s) appearing in ix:hidden were eligible for transformation: dei:CurrentFiscalYearEndDate, us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife, us-gaap:FiniteLivedIntangibleAssetUsefulLife, us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend, us-gaap:LesseeOperatingLeaseRenewalTerm, us-gaap:PropertyPlantAndEquipmentUsefulLife, us-gaap:StockholdersEquityNoteStockSplitConversionRatio1, vir:RoyaltiesPaymentRangeOnNetSalesOfLicensedProduct -  vir-20221231.htm 8</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="vir-20221231.htm">vir-20221231.htm</File>
    <File>vir-20221231.xsd</File>
    <File>vir-20221231_cal.xml</File>
    <File>vir-20221231_def.xml</File>
    <File>vir-20221231_lab.xml</File>
    <File>vir-20221231_pre.xml</File>
    <File>vir-ex10_17.htm</File>
    <File>vir-ex10_8.htm</File>
    <File>vir-ex21_1.htm</File>
    <File>vir-ex23_1.htm</File>
    <File>vir-ex31_1.htm</File>
    <File>vir-ex31_2.htm</File>
    <File>vir-ex32_1.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img62602283_0.jpg</File>
    <File>img62602283_1.jpg</File>
    <File>img62602283_10.jpg</File>
    <File>img62602283_11.jpg</File>
    <File>img62602283_12.jpg</File>
    <File>img62602283_13.jpg</File>
    <File>img62602283_14.jpg</File>
    <File>img62602283_15.jpg</File>
    <File>img62602283_16.jpg</File>
    <File>img62602283_17.jpg</File>
    <File>img62602283_18.jpg</File>
    <File>img62602283_19.jpg</File>
    <File>img62602283_2.jpg</File>
    <File>img62602283_20.jpg</File>
    <File>img62602283_21.jpg</File>
    <File>img62602283_22.jpg</File>
    <File>img62602283_23.jpg</File>
    <File>img62602283_24.jpg</File>
    <File>img62602283_3.jpg</File>
    <File>img62602283_4.jpg</File>
    <File>img62602283_5.jpg</File>
    <File>img62602283_6.jpg</File>
    <File>img62602283_7.jpg</File>
    <File>img62602283_8.jpg</File>
    <File>img62602283_9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="835">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>114
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "vir-20221231.htm": {
   "axisCustom": 0,
   "axisStandard": 28,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 835,
    "http://xbrl.sec.gov/dei/2022": 38
   },
   "contextCount": 272,
   "dts": {
    "calculationLink": {
     "local": [
      "vir-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "vir-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "vir-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "vir-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "vir-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "vir-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 938,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 10,
    "http://www.vir.bio/20221231": 1,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 15
   },
   "keyCustom": 149,
   "keyStandard": 358,
   "memberCustom": 71,
   "memberStandard": 35,
   "nsprefix": "vir",
   "nsuri": "http://www.vir.bio/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.vir.bio/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Fair Value Measurements",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Acquisitions",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitions",
     "shortName": "Acquisitions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - Goodwill and Intangible Assets",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssets",
     "shortName": "Goodwill and Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vir:GrantAgreementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - Grant Agreements",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGrantAgreements",
     "shortName": "Grant Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vir:GrantAgreementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - Collaboration and License Agreements",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreements",
     "shortName": "Collaboration and License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure - Balance Sheet Components",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponents",
     "shortName": "Balance Sheet Components",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Related Party Transactions",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - Stock-Based Awards",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwards",
     "shortName": "Stock-Based Awards",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Net Income (Loss) Per Share",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.vir.bio/20221231/taxonomy/role/DisclosureNetIncomeLossPerShare1",
     "shortName": "Net Income (Loss) Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Defined Contribution Plan",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.vir.bio/20221231/taxonomy/role/DisclosureDefinedContributionPlan",
     "shortName": "Defined Contribution Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "23",
     "role": "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Goodwill and Intangible Assets (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsTables",
     "shortName": "Goodwill and Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vir:CollaborationRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Collaboration and License Agreements (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.vir.bio/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTables",
     "shortName": "Collaboration and License Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vir:CollaborationRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Balance Sheet Components (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables",
     "shortName": "Balance Sheet Components (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vir:SummaryOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - Commitments and Contingencies (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vir:SummaryOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100340 - Disclosure - Stock-Based Awards (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsTables",
     "shortName": "Stock-Based Awards (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USDollarShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USDollarShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100350 - Disclosure - Net Income (Loss) Per Share (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.vir.bio/20221231/taxonomy/role/DisclosureNetIncomeLossPerShareTables",
     "shortName": "Net Income (Loss) Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100360 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_94806f35-4a90-434e-acce-cb420888cb77",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - Organization - Additional Information (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
     "shortName": "Organization - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_ca5589eb-ea15-4baa-83f9-5cfcb0672b1d",
      "decimals": "-5",
      "lang": null,
      "name": "vir:SaleOfStockConsiderationAggregateOfferingPrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_Segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100390 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_Segment",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "vir:FinancialAssetsAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100400 - Disclosure - Fair Value Measurements - Financial Assets Measured at Fair Value on a Recurring Basis by Level Within Fair Value Hierarchy (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails",
     "shortName": "Fair Value Measurements - Financial Assets Measured at Fair Value on a Recurring Basis by Level Within Fair Value Hierarchy (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "vir:FinancialAssetsAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "link:footnote",
       "p",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_f1574fdc-3dbc-4686-99a7-37e3229c36eb",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestrictedCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100410 - Disclosure - Fair Value Measurements - Financial Assets Measured at Fair Value on a Recurring Basis by Level Within Fair Value Hierarchy (Parenthetical) (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyParentheticalDetails",
     "shortName": "Fair Value Measurements - Financial Assets Measured at Fair Value on a Recurring Basis by Level Within Fair Value Hierarchy (Parenthetical) (Details)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "link:footnote",
       "p",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_f1574fdc-3dbc-4686-99a7-37e3229c36eb",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestrictedCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100420 - Disclosure - Fair Value Measurements - Additional Information (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
     "shortName": "Fair Value Measurements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_f22a75a3-1d5c-4569-b00b-c460e4c440a5",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100430 - Disclosure - Fair Value Measurements - Estimated Fair Value of Significant Unobservable Inputs (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails",
     "shortName": "Fair Value Measurements - Estimated Fair Value of Significant Unobservable Inputs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_f22a75a3-1d5c-4569-b00b-c460e4c440a5",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_a17e8413-fa17-4363-9bcc-2c63c792146e",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100440 - Disclosure - Fair Value Measurements - Summary of Changes in Estimated Fair Value of Financial Liabilities (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails",
     "shortName": "Fair Value Measurements - Summary of Changes in Estimated Fair Value of Financial Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_a17e8413-fa17-4363-9bcc-2c63c792146e",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100450 - Disclosure - Acquisitions - Additional Information (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
     "shortName": "Acquisitions - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_11d4ba09-a5bc-40ed-9952-89cf471e26ef",
      "decimals": "-5",
      "lang": null,
      "name": "vir:PaymentMadeForAssetAcquisitionMilestone",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100060 - Statement - Consolidated Statements of Operations",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100460 - Disclosure - Goodwill and Intangible Assets - Additional Information (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
     "shortName": "Goodwill and Intangible Assets - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:GoodwillImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100470 - Disclosure - Goodwill and Intangible Assets - Schedule of Finite Lived Intangible Assets (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails",
     "shortName": "Goodwill and Intangible Assets - Schedule of Finite Lived Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100480 - Disclosure - Goodwill and Intangible Assets - Schedule of Estimated Future Amortization Expense (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails",
     "shortName": "Goodwill and Intangible Assets - Schedule of Estimated Future Amortization Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedLiabilitiesAndOtherLiabilities",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100490 - Disclosure - Grant Agreements - Additional Information (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails",
     "shortName": "Grant Agreements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "vir:GrantAgreementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:OtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_94806f35-4a90-434e-acce-cb420888cb77",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100500 - Disclosure - Collaboration and License Agreements - Additional Information (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
     "shortName": "Collaboration and License Agreements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_6cddb4e4-b247-4253-a284-b9685fd836de",
      "decimals": "-5",
      "lang": null,
      "name": "vir:ProfitSharingAmountConstrained",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "vir:CollaborationRevenueTableTextBlock",
       "div",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "vir:ProfitSharingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100510 - Disclosure - Collaboration and License Agreements - Collaboration Collaboration revenue (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.vir.bio/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsCollaborationCollaborationRevenueDetails",
     "shortName": "Collaboration and License Agreements - Collaboration Collaboration revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "vir:CollaborationRevenueTableTextBlock",
       "div",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "vir:ProfitSharingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100520 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment Net (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails",
     "shortName": "Balance Sheet Components - Schedule of Property and Equipment Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100530 - Disclosure - Balance Sheet Components - Additional Information (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails",
     "shortName": "Balance Sheet Components - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "vir:ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "vir:MilestonePayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100540 - Disclosure - Balance Sheet Components - Schedule of Accrued and Other Liabilities (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails",
     "shortName": "Balance Sheet Components - Schedule of Accrued and Other Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "vir:ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "vir:MilestonePayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vir:LeaseArrangementContractualExpirationEndingYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100550 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vir:LeaseArrangementContractualExpirationEndingYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100070 - Statement - Consolidated Statements of Comprehensive Income (Loss)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.vir.bio/20221231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss",
     "shortName": "Consolidated Statements of Comprehensive Income (Loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "vir:SummaryOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100560 - Disclosure - Commitments and Contingencies - Summary of Lease Costs and Additional Information Related to Operating Leases (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsAndAdditionalInformationRelatedToOperatingLeasesDetails",
     "shortName": "Commitments and Contingencies - Summary of Lease Costs and Additional Information Related to Operating Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "vir:SummaryOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100570 - Disclosure - Commitments and Contingencies - Schedule of Maturities of Operating Lease Liabilities (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails",
     "shortName": "Commitments and Contingencies - Schedule of Maturities of Operating Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "vir:ScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "vir:OperatingLeaseIncentiveOverLeaseLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100580 - Disclosure - Commitments and Contingencies - Schedule of Operating Lease Amounts Recorded in Condensed Consolidated Balance Sheet (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetDetails",
     "shortName": "Commitments and Contingencies - Schedule of Operating Lease Amounts Recorded in Condensed Consolidated Balance Sheet (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "vir:ScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "vir:OperatingLeaseIncentiveOverLeaseLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_2af6ea14-ac98-4568-81e0-3bef718e3542",
      "decimals": "-2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100630 - Disclosure - Stock-Based Awards - Additional Information (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails",
     "shortName": "Stock-Based Awards - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_2af6ea14-ac98-4568-81e0-3bef718e3542",
      "decimals": "-2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_63454d26-78fb-4850-a047-cf04ffc3c617",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100640 - Disclosure - Stock-Based Awards - Summary of Stock Option Plans Activity (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails",
     "shortName": "Stock-Based Awards - Summary of Stock Option Plans Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_2af6ea14-ac98-4568-81e0-3bef718e3542",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100650 - Disclosure - Stock-Based Awards - Summary of Assumptions Used for Estimating the Fair Value of Stock Options Granted (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails",
     "shortName": "Stock-Based Awards - Summary of Assumptions Used for Estimating the Fair Value of Stock Options Granted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_62304650-1cd7-4013-b062-3aa4e9d5ad9f",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100660 - Disclosure - Stock-Based Awards -Summary of Employees Stock Purchase Plan (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.vir.bio/20221231/taxonomy/role/DisclosureStockbasedAwardsSummaryOfEmployeesStockPurchasePlanDetails",
     "shortName": "Stock-Based Awards -Summary of Employees Stock Purchase Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_87139d89-e3fd-445f-b6c1-4593f57a1d30",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_c9e8dc36-972e-4533-bbcc-9f347a84b7dc",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100670 - Disclosure - Stock-Based Awards - Summary of Restricted Stock Activity (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityDetails",
     "shortName": "Stock-Based Awards - Summary of Restricted Stock Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_c9e8dc36-972e-4533-bbcc-9f347a84b7dc",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100680 - Disclosure - Stock-Based Awards - Summary of Stock-based Compensation Expense (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Awards - Summary of Stock-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100690 - Disclosure - Net Income (Loss) Per Share - Schedule of Basic and Diluted Net Income (loss) Per Share (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.vir.bio/20221231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails",
     "shortName": "Net Income (Loss) Per Share - Schedule of Basic and Diluted Net Income (loss) Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_ce64793d-668a-40e8-af07-6ebdbdd93828",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100080 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
     "shortName": "Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_ce64793d-668a-40e8-af07-6ebdbdd93828",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100700 - Disclosure - Net Income (Loss) Per Share - Schedule of Potentially Dilutive Securities Not Included in Diluted Per Share Calculations (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.vir.bio/20221231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails",
     "shortName": "Net Income (Loss) Per Share - Schedule of Potentially Dilutive Securities Not Included in Diluted Per Share Calculations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100720 - Disclosure - Defined Contribution Plan - Additional Information (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.vir.bio/20221231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails",
     "shortName": "Defined Contribution Plan - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100730 - Disclosure - Income Taxes - Schedule of Income (Loss) Before Provision for (Benefit from) Income Taxes (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.vir.bio/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeLossBeforeProvisionForBenefitFromIncomeTaxesDetails",
     "shortName": "Income Taxes - Schedule of Income (Loss) Before Provision for (Benefit from) Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100740 - Disclosure - Income Taxes - Components of Income Tax Expense (Benefit) (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails",
     "shortName": "Income Taxes - Components of Income Tax Expense (Benefit) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100750 - Disclosure - Income Taxes - Reconciliation Between Expected Income Tax Provision at Federal Statutory Rate and Reported Income Tax Benefit (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails",
     "shortName": "Income Taxes - Reconciliation Between Expected Income Tax Provision at Federal Statutory Rate and Reported Income Tax Benefit (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100760 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails",
     "shortName": "Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_9ce7b082-bf92-4b49-8498-1be7fba1c1e3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100770 - Disclosure - Income Taxes - Additional Information (Details)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_a7262ac3-ad3a-4279-afb3-5136951286cf",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100780 - Disclosure - Income Taxes - Reconciliation of Liability for Uncertain Tax Positions (Details)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfLiabilityForUncertainTaxPositionsDetails",
     "shortName": "Income Taxes - Reconciliation of Liability for Uncertain Tax Positions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_94806f35-4a90-434e-acce-cb420888cb77",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "vir:CommonStockIssuanceCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100090 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical",
     "shortName": "Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_94806f35-4a90-434e-acce-cb420888cb77",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "vir:CommonStockIssuanceCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100100 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "8",
     "role": "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Organization",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureOrganization",
     "shortName": "Organization",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20221231.htm",
      "contextRef": "C_feb329d4-6a19-48fc-a8a5-36a2ebc45d68",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 112,
   "tag": {
    "country_CN": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CHINA",
        "terseLabel": "China Territory"
       }
      }
     },
     "localname": "CN",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r750",
      "r751",
      "r752"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r750",
      "r751",
      "r752"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r750",
      "r751",
      "r752"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r750",
      "r751",
      "r752"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r753"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r748"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r747"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "verboseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r747"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Securities Act File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r747"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r754"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r747"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r747"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r747"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r747"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "verboseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r755"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "verboseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r750",
      "r751",
      "r752"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r746"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r749"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r243",
      "r244",
      "r365",
      "r370",
      "r707",
      "r709"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureManufacturingAndSupplyLetterAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r350",
      "r351",
      "r352",
      "r353",
      "r457",
      "r642",
      "r671",
      "r702",
      "r703",
      "r720",
      "r733",
      "r745",
      "r795",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r350",
      "r351",
      "r352",
      "r353",
      "r457",
      "r642",
      "r671",
      "r702",
      "r703",
      "r720",
      "r733",
      "r745",
      "r795",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]",
        "verboseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r312",
      "r643",
      "r721",
      "r743",
      "r788",
      "r789",
      "r796",
      "r924"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureManufacturingAndSupplyLetterAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r312",
      "r643",
      "r721",
      "r743",
      "r788",
      "r789",
      "r796",
      "r924"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureManufacturingAndSupplyLetterAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r350",
      "r351",
      "r352",
      "r353",
      "r405",
      "r457",
      "r492",
      "r493",
      "r494",
      "r641",
      "r642",
      "r671",
      "r702",
      "r703",
      "r720",
      "r733",
      "r745",
      "r785",
      "r795",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r350",
      "r351",
      "r352",
      "r353",
      "r405",
      "r457",
      "r492",
      "r493",
      "r494",
      "r641",
      "r642",
      "r671",
      "r702",
      "r703",
      "r720",
      "r733",
      "r745",
      "r785",
      "r795",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r243",
      "r244",
      "r365",
      "r370",
      "r708",
      "r709"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureManufacturingAndSupplyLetterAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r313",
      "r314",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r722",
      "r744",
      "r796"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r313",
      "r314",
      "r686",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r722",
      "r744",
      "r796"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r779",
      "r909"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_WeightedAverageMember": {
     "auth_ref": [
      "r702",
      "r703",
      "r913",
      "r915",
      "r918"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average [Member]",
        "terseLabel": "Weighted Average"
       }
      }
     },
     "localname": "WeightedAverageMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_OR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OREGON",
        "terseLabel": "Oregon"
       }
      }
     },
     "localname": "OR",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201409Member": {
     "auth_ref": [
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2014-09 Revenue from Contracts with Customers (Topic 606).",
        "label": "Accounting Standards Update 2014-09 [Member]",
        "terseLabel": "ASC 606"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201409Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update 2016-02 [Member]",
        "terseLabel": "ASU 2016-02"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201613Member": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-13 Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.",
        "label": "Accounting Standards Update 2016-13 [Member]",
        "terseLabel": "ASU 2016-13"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201613Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201704Member": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2017-04 Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment.",
        "label": "Accounting Standards Update 2017-04 [Member]",
        "terseLabel": "ASU 2017-04"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201704Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201814Member": {
     "auth_ref": [
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2018-14 Compensation-Retirement Benefits-Defined Benefit Plans-General (Subtopic 715-20): Disclosure Framework-Changes to the Disclosure Requirements for Defined Benefit Plans.",
        "label": "Accounting Standards Update 2018-14 [Member]",
        "terseLabel": "ASU 2018-14"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201814Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201818Member": {
     "auth_ref": [
      "r554",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2018-18 Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606.",
        "label": "Accounting Standards Update 2018-18 [Member]",
        "terseLabel": "ASU 2018-18"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201818Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r13",
      "r742"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "totalLabel": "Accounts Payable, Current, Total"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r316",
      "r317"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Receivable from collaboration",
        "totalLabel": "Accounts Receivable, after Allowance for Credit Loss, Current, Total"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "(Accretion of discounts) amortization of premiums on investments, net"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r2",
      "r172",
      "r183"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Accrued income taxes"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.",
        "label": "Accrued Liabilities and Other Liabilities",
        "terseLabel": "Accrued and other liabilities",
        "totalLabel": "Total accrued and other liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Other professional and consulting expenses"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "auth_ref": [
      "r15",
      "r706"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Royalties, Current",
        "terseLabel": "Accrued royalties"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r79",
      "r208"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less accumulated depreciation and amortization",
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r23",
      "r24",
      "r25",
      "r216",
      "r666",
      "r679",
      "r683"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r22",
      "r25",
      "r147",
      "r628",
      "r674",
      "r675",
      "r762",
      "r763",
      "r764",
      "r773",
      "r774",
      "r775"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Estimated remaining useful lives"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r8",
      "r742"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "periodEndLabel": "Additional Paid in Capital, Ending Balance",
        "periodStartLabel": "Additional Paid in Capital, Beginning Balance",
        "terseLabel": "Additional paid-in capital",
        "totalLabel": "Additional Paid in Capital, Total"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r501",
      "r502",
      "r503",
      "r773",
      "r774",
      "r775",
      "r900"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r248",
      "r249",
      "r250",
      "r251",
      "r260",
      "r318",
      "r319",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r501",
      "r502",
      "r503",
      "r529",
      "r530",
      "r531",
      "r532",
      "r546",
      "r547",
      "r548",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r599",
      "r600",
      "r602",
      "r603",
      "r604",
      "r605",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r645",
      "r646",
      "r647",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r114",
      "r115",
      "r466"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation",
        "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r496"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r48",
      "r66",
      "r73"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangible assets",
        "totalLabel": "Amortization of Intangible Assets, Total",
        "verboseLabel": "Amortization expense of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive shares excluded from calculation of diluted net loss per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionAxis": {
     "auth_ref": [
      "r894"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by asset acquisition.",
        "label": "Asset Acquisition [Axis]"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionConsiderationTransferred": {
     "auth_ref": [
      "r738",
      "r895",
      "r896",
      "r897"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.",
        "label": "Asset Acquisition, Consideration Transferred",
        "terseLabel": "Asset acquisition purchase price",
        "totalLabel": "Asset Acquisition, Consideration Transferred, Total"
       }
      }
     },
     "localname": "AssetAcquisitionConsiderationTransferred",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable": {
     "auth_ref": [
      "r895",
      "r896",
      "r897"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of acquirer's equity interest issued and issuable as part of consideration transferred in asset acquisition.",
        "label": "Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable",
        "terseLabel": "Value of common stock shares Issued for milestone payment"
       }
      }
     },
     "localname": "AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost": {
     "auth_ref": [
      "r738",
      "r895",
      "r896",
      "r897"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction cost incurred as part of consideration transferred in asset acquisition.",
        "label": "Asset Acquisition, Consideration Transferred, Transaction Cost",
        "terseLabel": "Asset acquisition, transaction costs"
       }
      }
     },
     "localname": "AssetAcquisitionConsiderationTransferredTransactionCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetAcquisitionContingentConsiderationLiability": {
     "auth_ref": [
      "r894"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized from contingent consideration in asset acquisition.",
        "label": "Asset Acquisition, Contingent Consideration, Liability",
        "terseLabel": "Estimated fair value of contingent consideration",
        "totalLabel": "Asset Acquisition, Contingent Consideration, Liability, Total"
       }
      }
     },
     "localname": "AssetAcquisitionContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetAcquisitionContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r894"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized from contingent consideration in asset acquisition, classified as current.",
        "label": "Asset Acquisition, Contingent Consideration, Liability, Current",
        "terseLabel": "Contingent consideration recognized"
       }
      }
     },
     "localname": "AssetAcquisitionContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetAcquisitionDomain": {
     "auth_ref": [
      "r894"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition.",
        "label": "Asset Acquisition [Domain]"
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r171",
      "r182",
      "r212",
      "r239",
      "r297",
      "r306",
      "r310",
      "r323",
      "r354",
      "r355",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r363",
      "r364",
      "r558",
      "r562",
      "r582",
      "r742",
      "r793",
      "r794",
      "r911"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "TOTAL ASSETS"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r203",
      "r218",
      "r239",
      "r323",
      "r354",
      "r355",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r363",
      "r364",
      "r558",
      "r562",
      "r582",
      "r742",
      "r793",
      "r794",
      "r911"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "CURRENT ASSETS:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueAdjustment": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of addition (reduction) to the amount at which an asset could be incurred (settled) in a current transaction between willing parties.",
        "label": "Assets, Fair Value Adjustment",
        "terseLabel": "Change in fair value of equity investments"
       }
      }
     },
     "localname": "AssetsFairValueAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AustralianTaxationOfficeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government of Australia.",
        "label": "Australian Taxation Office [Member]",
        "terseLabel": "Australian Taxation Office"
       }
      }
     },
     "localname": "AustralianTaxationOfficeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r151",
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Related Disclosures [Abstract]"
       }
      }
     },
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BankTimeDepositsMember": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest.",
        "label": "Bank Time Deposits [Member]",
        "terseLabel": "Bank Time Deposits"
       }
      }
     },
     "localname": "BankTimeDepositsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r544",
      "r727",
      "r730"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r128",
      "r129",
      "r544",
      "r727",
      "r730"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.",
        "label": "Business Acquisition, Transaction Costs",
        "terseLabel": "Business acquisition, transaction costs"
       }
      }
     },
     "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of equity interests issued or issuable to acquire entity.",
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares",
        "terseLabel": "Business acquisition, shares issued"
       }
      }
     },
     "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount": {
     "auth_ref": [
      "r141"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.",
        "label": "Business Acquisition, Goodwill, Expected Tax Deductible Amount",
        "terseLabel": "Goodwill expected to be deductible for income tax purposes"
       }
      }
     },
     "localname": "BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r134",
      "r135",
      "r138"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Business acquisition purchase price",
        "totalLabel": "Business Combination, Consideration Transferred, Total"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": {
     "auth_ref": [
      "r134",
      "r135"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable",
        "terseLabel": "Business acquisition, shares issued value"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r551",
      "r767"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Change in estimated fair value of contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": {
     "auth_ref": [
      "r140"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.",
        "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High",
        "terseLabel": "Milestone payments aggregate amount payable, maximum"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r133",
      "r136",
      "r550"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Contingent consideration recognized",
        "totalLabel": "Business Combination, Contingent Consideration, Liability, Total",
        "verboseLabel": "Estimated fair value of contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r133",
      "r137"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "terseLabel": "Contingent consideration, current portion"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "auth_ref": [
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure contingent consideration liability from business combination.",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "terseLabel": "Fair value contingent consideration measurement input"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r133",
      "r137"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Contingent consideration, noncurrent"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r142",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures related to transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination by type of transaction.",
        "label": "Business Combination, Separately Recognized Transactions [Axis]"
       }
      }
     },
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of transaction that is recognized separately from the acquisition of assets and assumptions of liabilities in a business combination by transaction.",
        "label": "Business Combination, Separately Recognized Transactions [Domain]"
       }
      }
     },
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r53",
      "r54",
      "r55"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Property and equipment purchases included in accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r50",
      "r205",
      "r705"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.vir.bio/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows2": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.vir.bio/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance",
        "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r51",
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r760"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "terseLabel": "Cash, cash equivalents and investments",
        "totalLabel": "Cash, Cash Equivalents, and Short-term Investments, Total"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r45",
      "r50",
      "r56"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.vir.bio/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash and cash equivalents at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash and cash equivalents at beginning of period",
        "terseLabel": "Total cash, cash equivalents and restricted cash",
        "totalLabel": "Total cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]",
        "terseLabel": "RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH TO THE CONSOLIDATED BALANCE SHEETS:"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r45",
      "r164"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash, cash equivalents and restricted cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r213",
      "r214",
      "r215",
      "r239",
      "r263",
      "r268",
      "r277",
      "r279",
      "r287",
      "r288",
      "r323",
      "r354",
      "r357",
      "r358",
      "r359",
      "r363",
      "r364",
      "r368",
      "r369",
      "r371",
      "r372",
      "r373",
      "r582",
      "r704",
      "r756",
      "r770",
      "r776"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantLiabilityAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date the warrants or rights are exercisable, in YYYY-MM-DD format.",
        "label": "Class of Warrant or Right, Date from which Warrants or Rights Exercisable",
        "verboseLabel": "Warrant, expiration date"
       }
      }
     },
     "localname": "ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Warrants issued, exercise price"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Class Of Warrant Or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Warrant to purchase of convertible preferred stock"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantLiabilityAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r90",
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]",
        "terseLabel": "Class Of Warrant Or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r552",
      "r553",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaboration and License Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r18",
      "r176",
      "r188"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 9)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r81",
      "r347",
      "r348",
      "r690",
      "r791"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r773",
      "r774",
      "r900"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantLiabilityAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value",
        "verboseLabel": "Common stock price per share"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "totalLabel": "Common Stock, Shares, Issued, Total"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r7",
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r7",
      "r742"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "terseLabel": "Common stock, $0.0001 par value; 300,000,000 shares authorized as of December 31, 2022 and 2021, respectively; 131,161,404 and 131,161,404 shares issued and outstanding as of December 31, 2022 and 2021, respectively",
        "totalLabel": "Common Stock, Value, Issued, Total"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "terseLabel": "Stock-based Compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r27",
      "r225",
      "r227",
      "r233",
      "r662",
      "r667"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income (loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer Equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in Progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of contingent consideration.",
        "label": "Contingent Consideration by Type [Axis]",
        "terseLabel": "Contingent Consideration by Type"
       }
      }
     },
     "localname": "ContingentConsiderationByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of contingent payment arrangement.",
        "label": "Contingent Consideration Type [Domain]",
        "terseLabel": "Contingent Consideration Type"
       }
      }
     },
     "localname": "ContingentConsiderationTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractBasedIntangibleAssetsMember": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right received from contract, including, but not limited to, advertising contract, broadcast rights, franchise agreement, lease agreement, licensing agreement, and use rights.",
        "label": "Contract-Based Intangible Assets [Member]",
        "terseLabel": "Contract-Based Intangible Asset"
       }
      }
     },
     "localname": "ContractBasedIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r376",
      "r377",
      "r380"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Deferred revenue",
        "totalLabel": "Contract with Customer, Liability, Total"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r376",
      "r377",
      "r380"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Contract liability"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r381"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtSecuritiesMember": {
     "auth_ref": [
      "r820"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder.",
        "label": "Convertible Debt Securities [Member]",
        "terseLabel": "Convertible Preferred Stock"
       }
      }
     },
     "localname": "ConvertibleDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [
      "r368",
      "r369",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible Preferred Stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r33",
      "r239",
      "r323",
      "r354",
      "r355",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r363",
      "r364",
      "r582",
      "r793"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "terseLabel": "Cost of revenue",
        "totalLabel": "Cost of Revenue, Total"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r772",
      "r890",
      "r892"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r772",
      "r890"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r125",
      "r526",
      "r536",
      "r772"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Current income tax expense (benefit)"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current:"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r772",
      "r890",
      "r892"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "auth_ref": [
      "r320",
      "r332",
      "r333",
      "r334"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss",
        "periodEndLabel": "Debt Securities, Available-for-sale, Allowance for Credit Loss, Ending Balance",
        "periodStartLabel": "Debt Securities, Available-for-sale, Allowance for Credit Loss, Beginning Balance",
        "totalLabel": "Debt Securities, Available-for-sale, Allowance for Credit Loss, Total",
        "verboseLabel": "Allowance for losses on available-for-sale debt securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTerm": {
     "auth_ref": [
      "r902"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Debt Securities, Available-for-Sale, Term",
        "terseLabel": "Securities contractual term"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Unrealized Gain (Loss)",
        "terseLabel": "Total unrealized gains recorded in accumulated other comprehensive income (loss)",
        "totalLabel": "Debt Securities, Available-for-sale, Unrealized Gain (Loss), Total"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r772",
      "r891",
      "r892"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncome": {
     "auth_ref": [
      "r792"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Deferred Income",
        "terseLabel": "Transaction Price Upon Option Exercise"
       }
      }
     },
     "localname": "DeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r48",
      "r125",
      "r527",
      "r535",
      "r536",
      "r772"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Deferred income tax expense (benefit)"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred:"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r3",
      "r4",
      "r173",
      "r180",
      "r520"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Deferred tax liabilities",
        "totalLabel": "Deferred Tax Liabilities, Gross, Total"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r508",
      "r509"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liability",
        "totalLabel": "Deferred Income Tax Liabilities, Net, Total"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenue": {
     "auth_ref": [
      "r758"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Deferred Revenue",
        "terseLabel": "Deferred revenue",
        "totalLabel": "Deferred Revenue, Total"
       }
      }
     },
     "localname": "DeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueArrangementTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of deferred revenue arrangement.",
        "label": "Deferred Revenue Arrangement Type [Axis]"
       }
      }
     },
     "localname": "DeferredRevenueArrangementTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredRevenueArrangementTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Category of obligation arising when an entity receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized.",
        "label": "Deferred Revenue [Domain]"
       }
      }
     },
     "localname": "DeferredRevenueArrangementTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureManufacturingAndSupplyLetterAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredRevenueCurrent": {
     "auth_ref": [
      "r757"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Deferred Revenue, Current",
        "terseLabel": "Deferred revenue, current portion",
        "totalLabel": "Deferred Revenue, Current, Total"
       }
      }
     },
     "localname": "DeferredRevenueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueNoncurrent": {
     "auth_ref": [
      "r758"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Deferred Revenue, Noncurrent",
        "terseLabel": "Deferred revenue, noncurrent",
        "totalLabel": "Deferred Revenue, Noncurrent, Total"
       }
      }
     },
     "localname": "DeferredRevenueNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r772",
      "r891",
      "r892"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r521"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsGrossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r123",
      "r889"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r121",
      "r123",
      "r889"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and development tax credit carryforward"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r123",
      "r889"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Equity compensations"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "auth_ref": [
      "r123",
      "r889"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals",
        "terseLabel": "Reserves and accruals",
        "totalLabel": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r522"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "totalLabel": "Deferred Tax Assets, Valuation Allowance, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r117",
      "r888"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Net deferred tax liabilities",
        "totalLabel": "Deferred Tax Liabilities, Net, Total"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r123",
      "r889"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Property and equipment"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities": {
     "auth_ref": [
      "r123",
      "r889"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from unrealized gains on trading securities.",
        "label": "Deferred Tax Liabilities, Unrealized Gains on Trading Securities",
        "negatedLabel": "Unrealized gain on investments"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities": {
     "auth_ref": [
      "r93",
      "r94",
      "r174",
      "r184"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension plan. Excludes other postretirement benefit plan.",
        "label": "Liability, Defined Benefit Pension Plan",
        "terseLabel": "Net liability recognized under pension plans"
       }
      }
     },
     "localname": "DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "terseLabel": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]"
       }
      }
     },
     "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r451"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Defined contribution plan, contribution expenses"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage employer matches of the employee's percentage contribution matched.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "terseLabel": "Defined contribution plan, company contribution"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "terseLabel": "Defined contribution plan, employee contribution"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r48",
      "r295"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization",
        "totalLabel": "Depreciation, Depletion and Amortization, Total",
        "verboseLabel": "Depreciation and amortization expenses"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "auth_ref": [
      "r21",
      "r152",
      "r167",
      "r219",
      "r709"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
        "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset",
        "terseLabel": "Estimated fair value of the derivative liability",
        "totalLabel": "Derivative Liability, Fair Value, Gross Liability, Total"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents derivative instrument obligations meeting the definition of a liability which are reported as of the balance sheet date. Derivative instrument obligations are generally measured at fair value, and adjustments to the carrying amount of hedged items reflect changes in their fair value (that is, losses) that are attributable to the risk being hedged and that arise while the hedge is in effect.",
        "label": "Derivative Financial Instruments, Liabilities [Member]",
        "terseLabel": "Derivative Liability"
       }
      }
     },
     "localname": "DerivativeFinancialInstrumentsLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r899"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "negatedLabel": "Change in estimated fair value of derivative liability",
        "totalLabel": "Derivative, Gain (Loss) on Derivative, Net, Total"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativesEmbeddedDerivatives": {
     "auth_ref": [
      "r149",
      "r150",
      "r156",
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for embedded derivatives, including how such derivatives are identified and analyzed for possible separation from their host contracts.",
        "label": "Derivatives, Embedded Derivatives [Policy Text Block]",
        "terseLabel": "Embedded Derivatives"
       }
      }
     },
     "localname": "DerivativesEmbeddedDerivatives",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "terseLabel": "Developed Technologies"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r469",
      "r497",
      "r498",
      "r500",
      "r504",
      "r734"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Awards"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwards"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r234",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r261",
      "r263",
      "r277",
      "r278",
      "r279",
      "r283",
      "r573",
      "r574",
      "r663",
      "r668",
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share, basic",
        "totalLabel": "Earnings Per Share, Basic, Total",
        "verboseLabel": "Net income (loss) per share, basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r234",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r263",
      "r277",
      "r278",
      "r279",
      "r283",
      "r573",
      "r574",
      "r663",
      "r668",
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share, diluted",
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "verboseLabel": "Net income (loss) per share, diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r58",
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Income (Loss) Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r280",
      "r281",
      "r282",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Income (Loss) Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureNetIncomeLossPerShare1"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r511"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r241",
      "r511",
      "r538"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "U.S. federal statutory income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r886",
      "r893"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Changes in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r886",
      "r893"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "terseLabel": "Foreign tax at less than federal statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r886",
      "r893"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes": {
     "auth_ref": [
      "r886",
      "r893"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense.",
        "label": "Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent",
        "terseLabel": "Prior year tax rate adjustment"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r886",
      "r893"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State taxes, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r886",
      "r893"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "negatedLabel": "Research and development tax credit",
        "terseLabel": "Research and development tax credit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability": {
     "auth_ref": [
      "r153"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability.",
        "label": "Embedded Derivative, Fair Value of Embedded Derivative Liability",
        "terseLabel": "Embedded derivative liability",
        "verboseLabel": "Estimated fair value of embedded derivative"
       }
      }
     },
     "localname": "EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmbeddedDerivativeLiabilityMeasurementInput": {
     "auth_ref": [
      "r902"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure embedded derivative liability.",
        "label": "Embedded Derivative Liability, Measurement Input",
        "terseLabel": "Fair value contingent consideration measurement input"
       }
      }
     },
     "localname": "EmbeddedDerivativeLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Estimated weighted average period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r885"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost related to unvested restricted stock"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r885"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unamortized stock-based compensation expense related to stock option"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Employee Stock Option [Member]",
        "verboseLabel": "Options Issued and Outstanding"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r85",
      "r199",
      "r229",
      "r230",
      "r231",
      "r245",
      "r246",
      "r247",
      "r249",
      "r257",
      "r259",
      "r286",
      "r328",
      "r375",
      "r501",
      "r502",
      "r503",
      "r531",
      "r532",
      "r572",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r628",
      "r674",
      "r675",
      "r676"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantLiabilityAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r669",
      "r780"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "terseLabel": "Change in fair value of equity investments",
        "totalLabel": "Equity Securities, FV-NI, Unrealized Gain (Loss), Total"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyParentheticalDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r576",
      "r577",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyParentheticalDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Estimated Fair Value of Significant Unobservable Inputs"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r158",
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary of Financial Assets Measured at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyParentheticalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r158",
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyParentheticalDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r366",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r577",
      "r638",
      "r639",
      "r640",
      "r718",
      "r719",
      "r723",
      "r724",
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyParentheticalDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r162",
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r366",
      "r408",
      "r413",
      "r577",
      "r638",
      "r723",
      "r724",
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyParentheticalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r366",
      "r408",
      "r413",
      "r577",
      "r639",
      "r718",
      "r719",
      "r723",
      "r724",
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r366",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r577",
      "r640",
      "r718",
      "r719",
      "r723",
      "r724",
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r161",
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r161",
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Summary of Changes in Estimated Fair Value of Financial Liabilities"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)",
        "terseLabel": "Changes in fair value",
        "totalLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease), Total"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r161"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Balance at December 31, 2021",
        "periodStartLabel": "Balance at December 31, 2020"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r366",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r638",
      "r639",
      "r640",
      "r718",
      "r719",
      "r723",
      "r724",
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyParentheticalDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r608"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Current portion of finance lease obligation",
        "verboseLabel": "Financing lease obligation, current"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r608"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Long-term portion of finance lease obligation"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r610",
      "r617"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedLabel": "Payment of principal on financing lease obligations"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis": {
     "auth_ref": [
      "r143",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by financial support arrangement provided to a nonconsolidated legal entity that is required to comply with or operate in accordance with requirements that are similar to those included in Rule 2a-7 of the Investment Company Act of 1940 for registered money market funds.",
        "label": "Financial Support to Nonconsolidated Legal Entity [Axis]",
        "terseLabel": "Financial Support to Nonconsolidated Legal Entity"
       }
      }
     },
     "localname": "FinancialSupportToNonconsolidatedLegalEntityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain": {
     "auth_ref": [
      "r143",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial support arrangement provided to a nonconsolidated legal entity that is required to comply with or operate in accordance with requirements that are similar to those included in Rule 2a-7 of the Investment Company Act of 1940 for registered money market funds.",
        "label": "Financial Support to Nonconsolidated Legal Entity [Domain]",
        "terseLabel": "Financial Support to Nonconsolidated Legal Entity"
       }
      }
     },
     "localname": "FinancialSupportToNonconsolidatedLegalEntityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancingReceivableAccruedInterestWriteoff": {
     "auth_ref": [
      "r331"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of writeoff of accrued interest on financing receivable recognized by reversing interest income.",
        "label": "Financing Receivable, Accrued Interest, Writeoff",
        "terseLabel": "Write off of accrued interest receivable"
       }
      }
     },
     "localname": "FinancingReceivableAccruedInterestWriteoff",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Finite-lived intangible asset, estimated useful life",
        "verboseLabel": "Weighted-Average Remaining Useful Life (Years)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r210",
      "r343"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Less accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails": {
       "order": 0.0,
       "parentTag": "vir_FiniteLivedIntangibleAssetsAmortizationExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails": {
       "order": 4.0,
       "parentTag": "vir_FiniteLivedIntangibleAssetsAmortizationExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails": {
       "order": 3.0,
       "parentTag": "vir_FiniteLivedIntangibleAssetsAmortizationExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails": {
       "order": 2.0,
       "parentTag": "vir_FiniteLivedIntangibleAssetsAmortizationExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails": {
       "order": 1.0,
       "parentTag": "vir_FiniteLivedIntangibleAssetsAmortizationExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationMethod": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amortization method of a major finite-lived intangible asset class. A major class is composed of intangible assets that can be grouped together because they are similar either by their nature or by their use in the operations of a company. The straight-line method is the preferred amortization method, unless another method better reflects the pattern in which the asset is consumed.",
        "label": "Finite-Lived Intangible Assets, Amortization Method",
        "terseLabel": "Finite-lived intangible assets, amortization method description"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationMethod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r341",
      "r342",
      "r343",
      "r344",
      "r644",
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r72",
      "r648"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Finite-lived intangible assets, gross",
        "totalLabel": "Finite-Lived Intangible Assets, Gross, Total"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r67",
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r72",
      "r644"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "periodEndLabel": "Finite-Lived Intangible Assets, Net, Ending Balance",
        "periodStartLabel": "Finite-Lived Intangible Assets, Net, Beginning Balance",
        "totalLabel": "Finite-lived intangible assets, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "auth_ref": [
      "r49",
      "r904",
      "r905"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), Unrealized",
        "terseLabel": "Foreign Currency Transaction Gain Loss Unrealized"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and Fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Gain Contingencies [Line Items]"
       }
      }
     },
     "localname": "GainContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureManufacturingAndSupplyLetterAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainContingenciesTable": {
     "auth_ref": [
      "r790"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sets forth the existing conditions, situations, or sets of circumstances involving uncertainties as of the balance sheet date (or before issuance of the financial statements) that might result in a gain, typically reflecting care to avoid misleading implications as to the likelihood of realization, and previously disclosed contingent gains that were recognized as income in the period.",
        "label": "Gain Contingencies [Table]"
       }
      }
     },
     "localname": "GainContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureManufacturingAndSupplyLetterAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainLossOnTerminationOfLease": {
     "auth_ref": [
      "r606"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on termination of lease before expiration of lease term.",
        "label": "Gain (Loss) on Termination of Lease",
        "negatedLabel": "Gain from a sublease termination",
        "terseLabel": "Gain from a sublease termination"
       }
      }
     },
     "localname": "GainLossOnTerminationOfLease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r209",
      "r335",
      "r661",
      "r717",
      "r742",
      "r782",
      "r783"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Goodwill, Ending Balance",
        "periodStartLabel": "Goodwill, Beginning Balance",
        "terseLabel": "Goodwill",
        "totalLabel": "Goodwill, Total",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r338",
      "r340",
      "r717"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.",
        "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Acquired Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r48",
      "r336",
      "r337",
      "r338",
      "r717"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Goodwill impairment loss"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrantMember": {
     "auth_ref": [
      "r797"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award of money not required to be repaid.",
        "label": "Grant [Member]",
        "terseLabel": "Grant Revenue [Member]",
        "verboseLabel": "Grant Member"
       }
      }
     },
     "localname": "GrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r48",
      "r75"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Impairment of intangible assets, excluding goodwill",
        "totalLabel": "Impairment of Intangible Assets (Excluding Goodwill), Total"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "auth_ref": [
      "r768",
      "r784"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.",
        "label": "Impairment of Intangible Assets, Finite-Lived",
        "negatedLabel": "Less impairment of intangible assets",
        "terseLabel": "Impairment of intangible assets",
        "verboseLabel": "Impairment of intangible assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "auth_ref": [
      "r768",
      "r784"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.",
        "label": "Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)",
        "terseLabel": "Indefinite-lived impairment of intangible assets",
        "verboseLabel": "Impairment of indefinite-lived intangible assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "In-Process Research and Development"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r240",
      "r537"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeLossBeforeProvisionForBenefitFromIncomeTaxesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Domestic"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeLossBeforeProvisionForBenefitFromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r28",
      "r168",
      "r177",
      "r192",
      "r297",
      "r305",
      "r309",
      "r311",
      "r664",
      "r716"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeLossBeforeProvisionForBenefitFromIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "terseLabel": "Income (loss) before provision for income taxes",
        "totalLabel": "Income (loss) before provision for income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeLossBeforeProvisionForBenefitFromIncomeTaxesDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r240",
      "r537"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeLossBeforeProvisionForBenefitFromIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfIncomeLossBeforeProvisionForBenefitFromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r345",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of taxing authority.",
        "label": "Income Tax Authority, Name [Axis]",
        "terseLabel": "Income Tax Authority, Name"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority, Name [Domain]",
        "terseLabel": "Income Tax Authority, Name"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r241",
      "r512",
      "r518",
      "r525",
      "r533",
      "r539",
      "r541",
      "r542",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r242",
      "r258",
      "r259",
      "r296",
      "r510",
      "r534",
      "r540",
      "r670"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Provision for income taxes",
        "negatedTotalLabel": "Provision for income taxes",
        "terseLabel": "Provision for income taxes",
        "totalLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesComponentsOfIncomeTaxExpenseBenefitDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r228",
      "r506",
      "r507",
      "r518",
      "r519",
      "r524",
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r52"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Cash paid during the period for income tax",
        "totalLabel": "Income Taxes Paid, Net, Total"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Receivable from collaboration"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r767"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued liabilities and other long-term liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "negatedLabel": "Change in deferred income taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r710"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Deferred Revenue",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi": {
     "auth_ref": [
      "r235",
      "r321"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Increase (Decrease) in Equity Securities, FV-NI",
        "terseLabel": "Increase Decrease In Equity Securities Fv Ni"
       }
      }
     },
     "localname": "IncreaseDecreaseInEquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r767",
      "r907"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets",
        "totalLabel": "Increase (Decrease) in Other Operating Assets, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares": {
     "auth_ref": [
      "r265",
      "r266",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r279"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of contingently issuable shares. Contingently issuable shares are those shares that are issuable for little or no cash contingent on certain conditions being met.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares",
        "terseLabel": "Contingently issuable shares"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToContingentlyIssuableShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r264",
      "r265",
      "r267",
      "r279",
      "r468"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "terseLabel": "Options to purchase common stock",
        "totalLabel": "Incremental Common Shares Attributable to Share-based Payment Arrangements, Total"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IndefinitelivedIntangibleAssetsAcquired": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in assets, excluding financial assets and goodwill, lacking physical substance with an indefinite life, from an acquisition.",
        "label": "Indefinite-Lived Intangible Assets Acquired",
        "terseLabel": "Indefinite-lived intangible assets IPR&amp;D"
       }
      }
     },
     "localname": "IndefinitelivedIntangibleAssetsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r65",
      "r70"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Intangible Assets, Net (Excluding Goodwill), Total"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestReceivable": {
     "auth_ref": [
      "r759"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.",
        "label": "Interest Receivable",
        "terseLabel": "Accrued interest receivable excluded from fair value and amortized cost basis of available for sale securities"
       }
      }
     },
     "localname": "InterestReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.",
        "label": "Investment Income, Net, Amortization of Discount and Premium",
        "terseLabel": "Interest income",
        "totalLabel": "Investment Income, Net, Amortization of Discount and Premium, Total"
       }
      }
     },
     "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentOwnedAtFairValue": {
     "auth_ref": [
      "r194",
      "r684",
      "r685"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of the investment at close of period. For schedules of investments that are categorized, the value would be aggregated by category. For investment in and advances to affiliates, if operations of any controlled companies are different in character from those of the company, group such affiliates within divisions and by type of activities.",
        "label": "Investment Owned, at Fair Value",
        "periodEndLabel": "Investment Owned, at Fair Value, Ending Balance",
        "periodStartLabel": "Investment Owned, at Fair Value, Beginning Balance",
        "terseLabel": "Investment Owned At Fair Value"
       }
      }
     },
     "localname": "InvestmentOwnedAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r322",
      "r923"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Investments": {
     "auth_ref": [
      "r190"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.",
        "label": "Investments",
        "terseLabel": "Carrying value of investment at cost",
        "totalLabel": "Investments, Total"
       }
      }
     },
     "localname": "Investments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LaborAndRelatedExpense": {
     "auth_ref": [
      "r766"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.",
        "label": "Labor and Related Expense",
        "terseLabel": "Changes in estimated constraint on profit-sharing amount"
       }
      }
     },
     "localname": "LaborAndRelatedExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseAgreementsMember": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual agreement that stipulates the lessee pay the lessor for use of an asset.",
        "label": "Lease Agreements [Member]",
        "terseLabel": "Lease Agreements"
       }
      }
     },
     "localname": "LeaseAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r621",
      "r741"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "terseLabel": "Total lease cost",
        "totalLabel": "Lease, Cost, Total"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsAndAdditionalInformationRelatedToOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeFinanceLeaseTermOfContract1": {
     "auth_ref": [
      "r906"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Finance Lease, Term of Contract",
        "terseLabel": "Lease, term of contract"
       }
      }
     },
     "localname": "LesseeFinanceLeaseTermOfContract1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "auth_ref": [
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease.",
        "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]",
        "terseLabel": "Lessee, operating lease, existence of option to extend [true false]"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r908"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Maturities of Operating Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r622"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r622"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r622"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r622"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r622"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r622"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r622"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r622"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "auth_ref": [
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.",
        "label": "Lessee, Operating Lease, Option to Extend",
        "terseLabel": "Lessee, operating lease, option to extend"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r906"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lessee, operating lease, renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r14",
      "r239",
      "r323",
      "r354",
      "r355",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r363",
      "r364",
      "r559",
      "r562",
      "r563",
      "r582",
      "r715",
      "r793",
      "r911",
      "r912"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "TOTAL LIABILITIES"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r12",
      "r175",
      "r186",
      "r742",
      "r771",
      "r781",
      "r903"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r16",
      "r204",
      "r239",
      "r323",
      "r354",
      "r355",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r363",
      "r364",
      "r559",
      "r562",
      "r563",
      "r582",
      "r742",
      "r793",
      "r911",
      "r912"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "CURRENT LIABILITIES:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r797"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "License"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r206"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-Term Investments",
        "terseLabel": "Long-term investments",
        "totalLabel": "Long-term Investments, Total"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r82",
      "r83",
      "r349",
      "r350",
      "r351",
      "r786",
      "r787"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Short-term investments",
        "totalLabel": "Marketable Securities, Current, Total"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r901"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Measurement Input, Discount Rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r901"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Measurement Input, Price Volatility [Member]",
        "terseLabel": "Expected Stock Price Volatility"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r901"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "terseLabel": "Measurement Input Risk Free Interest Rate"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r820"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyParentheticalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r237"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r237"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r45",
      "r46",
      "r49"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r29",
      "r49",
      "r178",
      "r191",
      "r202",
      "r223",
      "r226",
      "r231",
      "r239",
      "r248",
      "r252",
      "r253",
      "r254",
      "r255",
      "r258",
      "r259",
      "r276",
      "r297",
      "r305",
      "r309",
      "r311",
      "r323",
      "r354",
      "r355",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r363",
      "r364",
      "r574",
      "r582",
      "r716",
      "r793"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.vir.bio/20221231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net income (loss)",
        "verboseLabel": "Net income (loss)"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations",
      "http://www.vir.bio/20221231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetRentableArea": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net rentable area for properties owned.",
        "label": "Net Rentable Area"
       }
      }
     },
     "localname": "NetRentableArea",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "NONCASH INVESTING AND FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1": {
     "auth_ref": [
      "r53",
      "r54",
      "r55"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of an asset or business acquired in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash or Part Noncash Acquisition, Value of Assets Acquired",
        "terseLabel": "Issuance of preferred stock in connection with asset acquisition",
        "totalLabel": "Noncash or Part Noncash Acquisition, Value of Assets Acquired, Total"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r778"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segment"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r297",
      "r305",
      "r309",
      "r311",
      "r716"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income (loss) from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r614",
      "r741"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsAndAdditionalInformationRelatedToOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r608"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease liabilities",
        "totalLabel": "Total operating lease liabilities",
        "verboseLabel": "Present value of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r608"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      },
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities, current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r608"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, noncurrent"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r611",
      "r617"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for operating lease liabilities",
        "verboseLabel": "Cash paid for amounts included in the measurement of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsAndAdditionalInformationRelatedToOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r607"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": -1.0
      },
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating right-of-use assets",
        "verboseLabel": "Operating ROU assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r620",
      "r741"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average incremental borrowing rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsAndAdditionalInformationRelatedToOperatingLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r619",
      "r741"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsAndAdditionalInformationRelatedToOperatingLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r121"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "totalLabel": "Operating Loss Carryforwards, Total"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureOrganization"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails": {
       "order": 12.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssets": {
     "auth_ref": [
      "r170",
      "r181",
      "r211"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets classified as other.",
        "label": "Other Assets",
        "terseLabel": "Other assets",
        "totalLabel": "Other Assets, Total"
       }
      }
     },
     "localname": "OtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r217",
      "r742"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other Current Assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r144",
      "r145",
      "r146",
      "r224",
      "r227"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other comprehensive loss",
        "totalLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.vir.bio/20221231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax": {
     "auth_ref": [
      "r23",
      "r26",
      "r222",
      "r425"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan.",
        "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, after Tax",
        "negatedLabel": "Amortization of actuarial loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r220",
      "r221"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized losses on investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherExpenseMember": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other expense.",
        "label": "Other Expense [Member]",
        "terseLabel": "Other Expense"
       }
      }
     },
     "localname": "OtherExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities",
        "totalLabel": "Other Liabilities, Noncurrent, Total"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other expense, net",
        "totalLabel": "Other Nonoperating Income (Expense), Total"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).",
        "label": "Other Operating Activities, Cash Flow Statement",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r44"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Offering expenses"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r40",
      "r549"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Business acquisition, cash consideration paid"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedLabel": "Purchases of investments",
        "totalLabel": "Payments to Acquire Investments, Total"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r405",
      "r407",
      "r413",
      "r430",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r449",
      "r450",
      "r451",
      "r464",
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Defined Contribution Plan"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureDefinedContributionPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PensionAndOtherPostretirementPlansPensionsPolicy": {
     "auth_ref": [
      "r95",
      "r100",
      "r101",
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for pension plans. This accounting policy may address (1) the types of plans sponsored by the entity (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived.",
        "label": "Pension and Other Postretirement Plans, Pensions, Policy [Policy Text Block]",
        "terseLabel": "Pension Benefits"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementPlansPensionsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PensionPlansDefinedBenefitMember": {
     "auth_ref": [
      "r91",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r431",
      "r434",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r451",
      "r452",
      "r463",
      "r725",
      "r726",
      "r730",
      "r731",
      "r732"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.",
        "label": "Pension Plan [Member]",
        "terseLabel": "Pension Plan"
       }
      }
     },
     "localname": "PensionPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureStockbasedAwardsSummaryOfEmployeesStockPurchasePlanDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureStockbasedAwardsSummaryOfEmployeesStockPurchasePlanDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r6",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r6",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued",
        "totalLabel": "Preferred Stock, Shares Issued, Total"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r6",
      "r742"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance",
        "terseLabel": "Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of December 31, 2022 and 2021, respectively; no shares issued and outstanding as of December 31, 2022 and 2021",
        "totalLabel": "Preferred Stock, Value, Issued, Total"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r760"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.",
        "label": "Prepaid Expenses and Other Current Assets [Member]",
        "terseLabel": "Prepaid Expenses And Other Current Assets"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r43"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Net proceeds after deducting underwriting discounts, commissions and offering expenses"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock, net of issuance costs",
        "verboseLabel": "Proceeds from issuance of common stock in connection with a collaboration agreements"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "auth_ref": [
      "r43"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Proceeds from Issuance of Convertible Preferred Stock",
        "terseLabel": "Proceeds from issuance of convertible preferred stock, net of issuance cost",
        "verboseLabel": "Net proceeds from sale of convertible preferred stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "terseLabel": "Maturities of investments",
        "totalLabel": "Proceeds from Sale, Maturity and Collection of Investments, Total"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfMachineryAndEquipment": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sale of machinery and equipment.",
        "label": "Proceeds from Sale of Machinery and Equipment",
        "terseLabel": "Proceeds from sale of an equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfMachineryAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r43",
      "r113"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from issuance of common stock under the employee stock purchase plan"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r202",
      "r223",
      "r226",
      "r236",
      "r239",
      "r248",
      "r258",
      "r259",
      "r297",
      "r305",
      "r309",
      "r311",
      "r323",
      "r354",
      "r355",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r363",
      "r364",
      "r557",
      "r560",
      "r561",
      "r574",
      "r582",
      "r664",
      "r716",
      "r739",
      "r740",
      "r764",
      "r793"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income (loss)",
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).",
        "label": "Property, Plant and Equipment, Estimated Useful Lives",
        "terseLabel": "Property and equipment, estimated useful lives description"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r78",
      "r207"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "terseLabel": "Property and equipment, gross",
        "totalLabel": "Property, Plant and Equipment, Gross, Total"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r80",
      "r187",
      "r665",
      "r742"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r80",
      "r691",
      "r692"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property and equipment, estimated useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Quarterly Financial Information Disclosure [Abstract]"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r431",
      "r631",
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r431",
      "r631",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r910"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r629",
      "r630",
      "r632",
      "r633",
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r116",
      "r196",
      "r919"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "totalLabel": "Research and Development Expense, Total"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process",
        "terseLabel": "Capitalized research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research Tax Credit Carryforward"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r50",
      "r56",
      "r205"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.vir.bio/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows2": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.vir.bio/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Current",
        "terseLabel": "Restricted cash and cash equivalents, current",
        "totalLabel": "Restricted Cash and Cash Equivalents, Current, Total"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r50",
      "r56",
      "r688"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.vir.bio/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows2": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.vir.bio/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows3": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "terseLabel": "Restricted cash and cash equivalents, noncurrent",
        "totalLabel": "Restricted Cash and Cash Equivalents, Noncurrent, Total"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashEquivalents": {
     "auth_ref": [
      "r687",
      "r689",
      "r769",
      "r920",
      "r922"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash equivalents restricted as to withdrawal or usage. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash Equivalents",
        "terseLabel": "Restricted cash equivalents",
        "totalLabel": "Restricted Cash Equivalents, Total"
       }
      }
     },
     "localname": "RestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyParentheticalDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock",
        "verboseLabel": "Restricted Shares Subject to Future Vesting"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs) [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r9",
      "r87",
      "r185",
      "r678",
      "r683",
      "r742"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "terseLabel": "Retained earnings (Accumulated deficit)",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r199",
      "r245",
      "r246",
      "r247",
      "r249",
      "r257",
      "r259",
      "r328",
      "r501",
      "r502",
      "r503",
      "r531",
      "r532",
      "r572",
      "r674",
      "r676"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanNameAxis": {
     "auth_ref": [
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r733",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans.",
        "label": "Retirement Plan Name [Axis]",
        "terseLabel": "Retirement Plan Name"
       }
      }
     },
     "localname": "RetirementPlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanNameDomain": {
     "auth_ref": [
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r733",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans.",
        "label": "Retirement Plan Name [Domain]",
        "terseLabel": "Retirement Plan Name"
       }
      }
     },
     "localname": "RetirementPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "auth_ref": [
      "r91",
      "r92",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r431",
      "r434",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r451",
      "r452",
      "r453",
      "r463",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Axis]",
        "terseLabel": "Retirement Plan Type"
       }
      }
     },
     "localname": "RetirementPlanTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "auth_ref": [
      "r91",
      "r92",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r431",
      "r434",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r451",
      "r452",
      "r453",
      "r463",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Domain]",
        "terseLabel": "Retirement Plan Type"
       }
      }
     },
     "localname": "RetirementPlanTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r293",
      "r294",
      "r304",
      "r307",
      "r308",
      "r312",
      "r313",
      "r315",
      "r378",
      "r379",
      "r643"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenues from contract with customers",
        "totalLabel": "Revenue from Contract with Customer, Excluding Assessed Tax, Total"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r293",
      "r294",
      "r304",
      "r307",
      "r308",
      "r312",
      "r313",
      "r315",
      "r378",
      "r379",
      "r643"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "terseLabel": "Contract revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromRelatedParties": {
     "auth_ref": [
      "r32",
      "r195",
      "r356",
      "r357",
      "r358",
      "r362",
      "r363",
      "r364"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.",
        "label": "Revenue from Related Parties",
        "terseLabel": "Revenue from Related Parties"
       }
      }
     },
     "localname": "RevenueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueNotFromContractWithCustomer": {
     "auth_ref": [
      "r765"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue that is not accounted for under Topic 606.",
        "label": "Revenue Not from Contract with Customer",
        "terseLabel": "Revenues not from contract",
        "verboseLabel": "Revenue from grants"
       }
      }
     },
     "localname": "RevenueNotFromContractWithCustomer",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition [Abstract]"
       }
      }
     },
     "localname": "RevenueRecognitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r711",
      "r712"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r232",
      "r239",
      "r293",
      "r294",
      "r304",
      "r307",
      "r308",
      "r312",
      "r313",
      "r315",
      "r323",
      "r354",
      "r355",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r363",
      "r364",
      "r582",
      "r664",
      "r793"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Total revenue",
        "totalLabel": "Total revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r618",
      "r741"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "ROU assets in exchange for operating lease liabilities",
        "verboseLabel": "Operating lease liabilities obtained in exchange of right-of-use asset"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsAndAdditionalInformationRelatedToOperatingLeasesDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalariesWagesAndOfficersCompensationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Salary and Wage, Excluding Cost of Good and Service Sold [Abstract]"
       }
      }
     },
     "localname": "SalariesWagesAndOfficersCompensationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Common stock price per share"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the major classes of acquired finite-lived intangible assets showing the amount, any significant residual value, weighted average amortization period, and other characteristics. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.",
        "label": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]",
        "terseLabel": "Schedule Of Acquired Finite Lived Intangible Asset By Major Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Potentially Dilutive Securities Not Included in the Diluted Per Share Calculations"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureNetIncomeLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r128",
      "r129",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r898"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Summary of Stock-based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Components of Income Tax Expense (Benefit)"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r98",
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "terseLabel": "Schedule Of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r777"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Basic and Diluted Net Income (loss) Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureNetIncomeLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation Between Expected Income Tax Provision at Federal Statutory Rate and Reported Income Tax Benefit"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r67",
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r772"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of Income (Loss) Before Provision for (Benefit from) Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Summary of Restricted Stock Activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.",
        "label": "Quarterly Financial Information [Table Text Block]",
        "terseLabel": "Schedule of Selected Quarterly Financial Data"
       }
      }
     },
     "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureSelectedQuarterlyFinancialDataUnauditedTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r165",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r465",
      "r467",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureStockbasedAwardsSummaryOfEmployeesStockPurchasePlanDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockBasedCompensationExpenseDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r105",
      "r107",
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Plans Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Summary of Employees Stock Purchase Plan"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Summary of Assumptions Used for Estimating the Fair Value of Stock Options Granted"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r737",
      "r887"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Reconciliation of Liability for Uncertain Tax Positions"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segments"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative",
        "totalLabel": "Selling, General and Administrative Expense, Total"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, General and Administrative Expense"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation",
        "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r734"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Options vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate from fair value on offering date that participants pay for shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Offering Date",
        "terseLabel": "Purchase price as percentage of lower of fair market value on offering date"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate from fair value on purchase date that participants pay for shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date",
        "terseLabel": "Purchase price as percentage of lower of fair market value on purchase date"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Number of shares, Forfeited",
        "terseLabel": "Number of shares, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Number of Shares, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r481",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Number of Shares, Unvested, Ending Balance",
        "periodStartLabel": "Number of Shares, Unvested, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r481",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted Average Grant Date Fair Value, Ending Balance",
        "periodStartLabel": "Weighted Average Grant Date Fair Value, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Number of Shares, Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield",
        "verboseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureStockbasedAwardsSummaryOfEmployeesStockPurchasePlanDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected stock price volatility",
        "verboseLabel": "Expected stock price volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureStockbasedAwardsSummaryOfEmployeesStockPurchasePlanDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected stock price volatility,maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureStockbasedAwardsSummaryOfEmployeesStockPurchasePlanDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected stock price volatility,minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureStockbasedAwardsSummaryOfEmployeesStockPurchasePlanDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate",
        "verboseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureStockbasedAwardsSummaryOfEmployeesStockPurchasePlanDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureStockbasedAwardsSummaryOfEmployeesStockPurchasePlanDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureStockbasedAwardsSummaryOfEmployeesStockPurchasePlanDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureStockbasedAwardsSummaryOfEmployeesStockPurchasePlanDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockBasedCompensationExpenseDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate",
        "terseLabel": "Percentage of employee payroll deduction on earnings",
        "verboseLabel": "Percentage of employee payroll deduction on earnings, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r736"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Shares authorized to issue under purchase rights granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available for grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r488"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "verboseLabel": "Aggregate intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of Options,Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Number of Options,Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value of options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r112"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r473",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of Options,Outstanding, Ending Balance",
        "periodStartLabel": "Number of Options,Outstanding, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r473",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price, Ending Balance",
        "periodStartLabel": "Weighted Average Exercise Price, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r490"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Vested and exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "terseLabel": "Number of Options,Vested and exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price,Vested and exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r489"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Number of Options,Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price,Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Share purchase price per share"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r735"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Expiration period of awards from issuance date"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term of options (in years)",
        "verboseLabel": "Expected term of ESPP (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureStockbasedAwardsSummaryOfEmployeesStockPurchasePlanDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term,Vested and exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term,Vested and exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term,Vested and expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Purchase price as percentage of lower of fair market value on offering date",
        "verboseLabel": "Option price as a percentage of estimated fair value on the date of grant"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Convertible preferred stock, shares sold, price per share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r615",
      "r741"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-Term Lease, Cost",
        "terseLabel": "Short-term lease cost"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsAndAdditionalInformationRelatedToOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r57",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r213",
      "r214",
      "r215",
      "r239",
      "r263",
      "r268",
      "r277",
      "r279",
      "r287",
      "r288",
      "r323",
      "r354",
      "r357",
      "r358",
      "r359",
      "r363",
      "r364",
      "r368",
      "r369",
      "r371",
      "r372",
      "r373",
      "r582",
      "r704",
      "r756",
      "r770",
      "r776"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantLiabilityAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r20",
      "r85",
      "r199",
      "r229",
      "r230",
      "r231",
      "r245",
      "r246",
      "r247",
      "r249",
      "r257",
      "r259",
      "r286",
      "r328",
      "r375",
      "r501",
      "r502",
      "r503",
      "r531",
      "r532",
      "r572",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r628",
      "r674",
      "r675",
      "r676"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantLiabilityAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsTables",
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical",
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r245",
      "r246",
      "r247",
      "r286",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsTables",
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical",
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r19",
      "r85",
      "r86",
      "r87",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Conversion of convertible preferred stock into common stock (in shares)",
        "verboseLabel": "Number of convertible preferred stock converted to shares of common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r6",
      "r7",
      "r85",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Share issued under plan",
        "verboseLabel": "Issuance of common stock under employee stock purchase plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r6",
      "r7",
      "r85",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock (in shares)",
        "verboseLabel": "Issuance of common stock, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r85",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Vesting of restricted common stock (in shares)",
        "verboseLabel": "Vesting of restricted common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r6",
      "r7",
      "r85",
      "r87",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Number of Options,Exercised",
        "terseLabel": "Exercise of stock option (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r6",
      "r7",
      "r85",
      "r87"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock under employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r6",
      "r7",
      "r85",
      "r87"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Net proceeds from IPO",
        "verboseLabel": "Value of shares agreed to purchase"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r6",
      "r7",
      "r85",
      "r87"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "terseLabel": "Vesting of restricted common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r20",
      "r85",
      "r87"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r7",
      "r10",
      "r11",
      "r63",
      "r742",
      "r771",
      "r781",
      "r903"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "TOTAL STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "STOCKHOLDERS\u2019 EQUITY:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Reverse stock split, conversion ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.",
        "label": "Stockholders' Equity, Reverse Stock Split",
        "terseLabel": "Reverse stock split, description"
       }
      }
     },
     "localname": "StockholdersEquityReverseStockSplit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r597",
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event",
        "verboseLabel": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r597",
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r597",
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r597",
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r635",
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureSubsequentEvent1"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r761"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Components"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "SUPPLEMENTAL DISCLOSURE OF CASHFLOW INFORMATION:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SwissFederalTaxAdministrationFTAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government of Switzerland.",
        "label": "Swiss Federal Tax Administration (FTA) [Member]",
        "terseLabel": "Swiss Federal Tax Administration (FTA)"
       }
      }
     },
     "localname": "SwissFederalTaxAdministrationFTAMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r121"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforwards"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TemporaryEquityByClassOfStockTable": {
     "auth_ref": [
      "r1",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table of capital stock that is classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. This table may include a description by series, value, shares authorized, shares issued and outstanding, redemption price per share and subscription receivable.",
        "label": "Temporary Equity, by Class of Stock [Table]",
        "terseLabel": "Temporary Equity By Class Of Stock [Table]"
       }
      }
     },
     "localname": "TemporaryEquityByClassOfStockTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [
      "r354",
      "r357",
      "r358",
      "r359",
      "r363",
      "r364"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity Disclosure [Abstract]"
       }
      }
     },
     "localname": "TemporaryEquityDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Temporary Equity [Line Items]",
        "terseLabel": "Temporary Equity [Line Items]"
       }
      }
     },
     "localname": "TemporaryEquityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Issued",
        "terseLabel": "Preferred stock shares issued",
        "verboseLabel": "Issuance of convertible preferred stock, net of issuance cost (in Shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Convertible preferred stock, shares outstanding",
        "verboseLabel": "Outstanding convertible preferred stock (in shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TenantImprovements": {
     "auth_ref": [
      "r189"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.",
        "label": "Tenant Improvements",
        "terseLabel": "Tenant improvement allowance"
       }
      }
     },
     "localname": "TenantImprovements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r248",
      "r249",
      "r250",
      "r251",
      "r260",
      "r318",
      "r319",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r501",
      "r502",
      "r503",
      "r529",
      "r530",
      "r531",
      "r532",
      "r546",
      "r547",
      "r548",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r599",
      "r600",
      "r602",
      "r603",
      "r604",
      "r605",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r645",
      "r646",
      "r647",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r898"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureManufacturingAndSupplyLetterAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r713",
      "r723",
      "r725",
      "r921"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. Government Treasuries"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r505",
      "r514"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Gross unrecognized tax benefits at December 31",
        "periodStartLabel": "Gross unrecognized tax benefits at January 1",
        "terseLabel": "Unrecognized tax benefit"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfLiabilityForUncertainTaxPositionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r515"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedLabel": "Reduction for tax positions taken in the prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfLiabilityForUncertainTaxPositionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r513"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Interest and penalties accrued related to uncertain tax positions",
        "totalLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r513"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "terseLabel": "Interest and penalties expense related to uncertain tax positions",
        "totalLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r516"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Addition for tax positions taken in current year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfLiabilityForUncertainTaxPositionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r515"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Addition for tax positions taken in the prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfLiabilityForUncertainTaxPositionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r517"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits, if recognized, would reduce effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r60",
      "r61",
      "r62",
      "r289",
      "r290",
      "r291",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r523"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increase/decrease in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r616",
      "r741"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsAndAdditionalInformationRelatedToOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrant",
        "verboseLabel": "Warrants to Purchase Convertible Preferred Stock"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "auth_ref": [
      "r902"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.",
        "label": "Warrants and Rights Outstanding, Maturity Date",
        "terseLabel": "Warrant, expiration date"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract]",
        "terseLabel": "Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r262",
      "r279"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average shares outstanding, diluted",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r261",
      "r279"
     ],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average shares outstanding, basic",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "vir_AccruedLiabilitiesAndOtherLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Liabilities And Other Liabilities.",
        "label": "Accrued Liabilities And Other Liabilities [Member]",
        "terseLabel": "Accrued Liabilities And Other Liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilitiesMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_AdjustmentsToProfitSharingAmounts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Profit sharing amount constrained.",
        "label": "Adjustments To Profit Sharing Amounts",
        "terseLabel": "Profit sharing amount constrained"
       }
      }
     },
     "localname": "AdjustmentsToProfitSharingAmounts",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_AdvancedProceedsAppliedToConvertiblePreferredStockIssuance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Advanced proceeds applied to convertible preferred stock issuance.",
        "label": "Advanced Proceeds Applied To Convertible Preferred Stock Issuance",
        "terseLabel": "Advanced proceeds applied to convertible preferred stock issuance"
       }
      }
     },
     "localname": "AdvancedProceedsAppliedToConvertiblePreferredStockIssuance",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_AlnylamAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alnylam agreement.",
        "label": "Alnylam Agreement [Member]",
        "terseLabel": "Alnylam Agreement"
       }
      }
     },
     "localname": "AlnylamAgreementMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_AlnylamPharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alnylam Pharmaceuticals, Inc.",
        "label": "Alnylam Pharmaceuticals Inc [Member]",
        "terseLabel": "Alnylam Pharmaceuticals Inc"
       }
      }
     },
     "localname": "AlnylamPharmaceuticalsIncMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_AmendmentNumberOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment number one.",
        "label": "Amendment Number One [Member]",
        "terseLabel": "Amendment Number One Member"
       }
      }
     },
     "localname": "AmendmentNumberOneMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_AnnualLicenseMaintenanceFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License maintenance fees required to pay annually.",
        "label": "Annual License Maintenance Fees"
       }
      }
     },
     "localname": "AnnualLicenseMaintenanceFees",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_AnotherProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Another product.",
        "label": "Another Product [Member]",
        "terseLabel": "Another Product"
       }
      }
     },
     "localname": "AnotherProductMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_AntibodyLicenseTransactionPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction price for the Antibody License under the collaboration agreement",
        "label": "Antibody License Transaction Price",
        "terseLabel": "Antibody license transaction price"
       }
      }
     },
     "localname": "AntibodyLicenseTransactionPrice",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_AntibodyProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Antibody Program.",
        "label": "Antibody Program [Member]",
        "terseLabel": "Antibody Program"
       }
      }
     },
     "localname": "AntibodyProgramMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureManufacturingAndSupplyLetterAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_AssetAcquisitionMilestoneAchieved": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition milestone achieved during the reporting period.",
        "label": "Asset Acquisition Milestone Achieved",
        "terseLabel": "Asset acquisition milestone achieved"
       }
      }
     },
     "localname": "AssetAcquisitionMilestoneAchieved",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_AssetAcquisitionMilestonePaymentAggregate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For contingent consideration arrangements recognized in connection with an asset acquisition, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.",
        "label": "Asset Acquisition Milestone Payment Aggregate",
        "terseLabel": "Milestone payments aggregate amount payable, maximum"
       }
      }
     },
     "localname": "AssetAcquisitionMilestonePaymentAggregate",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_AssetAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition number of milestones achieved related to contingent consideration.",
        "label": "Asset Acquisition Number Of Milestones Achieved Related To Contingent Consideration",
        "terseLabel": "Number of milestones achieved"
       }
      }
     },
     "localname": "AssetAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "vir_BillAndMelindaGatesFoundationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bill &amp; Melinda Gates Foundation.",
        "label": "Bill And Melinda Gates Foundation [Member]",
        "terseLabel": "Bill &amp; Melinda Gates Foundation"
       }
      }
     },
     "localname": "BillAndMelindaGatesFoundationMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_BillMelindaGatesFoundationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bill &amp; Melinda Gates Foundation.",
        "label": "Bill &amp; Melinda Gates Foundation [Member]",
        "terseLabel": "Bill &amp; Melinda Gates Foundation"
       }
      }
     },
     "localname": "BillMelindaGatesFoundationMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_BiologicalMaterialsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Biological materials.",
        "label": "Biological Materials [Member]",
        "terseLabel": "Biological Materials"
       }
      }
     },
     "localname": "BiologicalMaterialsMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Biomedical advanced research and development authority member.",
        "label": "Biomedical Advanced Research and Development Authority [Member]",
        "terseLabel": "BARDA [Member]"
       }
      }
     },
     "localname": "BiomedicalAdvancedResearchAndDevelopmentAuthorityMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_BriiAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Brii Agreement.",
        "label": "Brii Agreement [Member]",
        "terseLabel": "Brii Agreement"
       }
      }
     },
     "localname": "BriiAgreementMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_BriiBioParentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Brii Bio Parent.",
        "label": "Brii Bio Parent [Member]",
        "terseLabel": "Brii Bio Parent"
       }
      }
     },
     "localname": "BriiBioParentMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_BriiBiosciencesOffshoreLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Brii Biosciences Offshore Limited.",
        "label": "Brii Biosciences Offshore Limited [Member]",
        "terseLabel": "Brii Bio"
       }
      }
     },
     "localname": "BriiBiosciencesOffshoreLimitedMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_BusinessAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business acquisition number of milestones achieved related to contingent consideration.",
        "label": "Business Acquisition Number Of Milestones Achieved Related To Contingent Consideration",
        "terseLabel": "Number of milestones achieved"
       }
      }
     },
     "localname": "BusinessAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "vir_BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business acquisition number of specified clinical milestones achieved.",
        "label": "Business Acquisition Number Of Specified Clinical Milestones Achieved",
        "terseLabel": "Number of specified clinical milestones achieved"
       }
      }
     },
     "localname": "BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "vir_BusinessAgreementEquityInvestmentCommitment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business agreement equity investment commitment.",
        "label": "Business Agreement Equity Investment Commitment",
        "terseLabel": "Business agreement equity investment commitment."
       }
      }
     },
     "localname": "BusinessAgreementEquityInvestmentCommitment",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_BusinessAgreementGrantAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business agreement grant amount.",
        "label": "Business Agreement Grant Amount",
        "terseLabel": "Business agreement grant amount"
       }
      }
     },
     "localname": "BusinessAgreementGrantAmount",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combinations additional consideration payable upon achievement of specified events.",
        "label": "Business Combinations Additional Consideration Payable Upon Achievement Of Specified Events",
        "terseLabel": "Additional consideration payable upon achievement of specified milestone events"
       }
      }
     },
     "localname": "BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_CashCashEquivalentsAndShortTermInvestmentsExcludingEquityInvestment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, cash equivalents and short-term investments, excluding equity investment.",
        "label": "Cash Cash Equivalents And Short Term Investments Excluding Equity Investment",
        "terseLabel": "Cash, cash equivalents and short-term investments, excluding equity investment"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestmentsExcludingEquityInvestment",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_CashGrantAwarded": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash grant awarded.",
        "label": "Cash Grant Awarded",
        "terseLabel": "Business agreement grant amount"
       }
      }
     },
     "localname": "CashGrantAwarded",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_ChangesInEstimatedConstraintOnProfitSharingAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Changes in estimated constraint on profit-sharing amount",
        "label": "Changes in estimated constraint on profit-sharing amount"
       }
      }
     },
     "localname": "ChangesInEstimatedConstraintOnProfitSharingAmount",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_ClinicalAndRegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical and regulatory milestones [Member]",
        "label": "Clinical And Regulatory Milestones [Member]",
        "terseLabel": "Clinical and Regulatory Milestones"
       }
      }
     },
     "localname": "ClinicalAndRegulatoryMilestonesMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_ClinicalDevelopmentAndManufacturingOrganizationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CLINICAL DEVELOPMENT AND MANUFACTURING ORGANIZATION [Member]",
        "label": "CLINICAL DEVELOPMENT AND MANUFACTURING ORGANIZATION [Member]",
        "terseLabel": "Clinical Development And Manufacturing Organization [Member]"
       }
      }
     },
     "localname": "ClinicalDevelopmentAndManufacturingOrganizationMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureManufacturingAndSupplyLetterAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_ClinicalDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical Development [Member]",
        "label": "Clinical Development [Member]",
        "terseLabel": "Clinical Development"
       }
      }
     },
     "localname": "ClinicalDevelopmentMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_ClosingStockPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Closing stock price",
        "label": "Closing stock price",
        "terseLabel": "Closing stock price"
       }
      }
     },
     "localname": "ClosingStockPrice",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "vir_CollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration agreement.",
        "label": "Collaboration Agreement [Member]",
        "terseLabel": "Collaboration Agreement"
       }
      }
     },
     "localname": "CollaborationAgreementMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration agreement, number of separate programs agreed to collaborate.",
        "label": "Collaboration Agreement Number Of Separate Programs Agreed To Collaborate",
        "terseLabel": "Number of separate programs"
       }
      }
     },
     "localname": "CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "vir_CollaborationAgreementNumberOfUnitsOfAccount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration agreement, number of units of account.",
        "label": "Collaboration Agreement Number Of Units Of Account",
        "terseLabel": "Number of units of account"
       }
      }
     },
     "localname": "CollaborationAgreementNumberOfUnitsOfAccount",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "vir_CollaborationAgreementRelatedCostsAndExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Costs and expenses for the period incurred under the collaboration agreements.",
        "label": "Collaboration Agreement Related Costs And Expenses",
        "terseLabel": "Expenses incurred under agreement"
       }
      }
     },
     "localname": "CollaborationAgreementRelatedCostsAndExpenses",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_CollaborationAgreementTerminationDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration agreement termination description.",
        "label": "Collaboration Agreement Termination Description",
        "terseLabel": "Termination description"
       }
      }
     },
     "localname": "CollaborationAgreementTerminationDescription",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vir_CollaborationAgreementTransactionPriceConsideration": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration agreement transaction price consideration.",
        "label": "Collaboration Agreement Transaction Price Consideration",
        "terseLabel": "Collaboration Agreement Transaction Price Consideration"
       }
      }
     },
     "localname": "CollaborationAgreementTransactionPriceConsideration",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_CollaborationAgreementTransactionPriceUpfrontFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payment received under the Collaboration agreement, which represents part of the transaction price.",
        "label": "Collaboration Agreement Transaction Price Upfront Fee",
        "verboseLabel": "Upfront fee"
       }
      }
     },
     "localname": "CollaborationAgreementTransactionPriceUpfrontFee",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_CollaborationAndLicenseAgreements": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and License Agreements",
        "label": "Collaboration and License Agreements",
        "terseLabel": "Collaboration revenue, net"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreements",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsCollaborationCollaborationRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vir_CollaborationRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration revenue.",
        "label": "Collaboration Revenue [Member]",
        "terseLabel": "Collaboration Revenue [Member]"
       }
      }
     },
     "localname": "CollaborationRevenueMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_CollaborationRevenueTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration revenue table text block",
        "label": "Collaboration revenue table text block",
        "terseLabel": "Schedule of Collaboration revenue"
       }
      }
     },
     "localname": "CollaborationRevenueTableTextBlock",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vir_CollaborationTypeAndPrograms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Type and Programs",
        "label": "Collaboration Type and Programs",
        "terseLabel": "Collaboration type and program"
       }
      }
     },
     "localname": "CollaborationTypeAndPrograms",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vir_CommercialMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial milestones.",
        "label": "Commercial Milestones [Member]",
        "terseLabel": "Commercial Milestones"
       }
      }
     },
     "localname": "CommercialMilestonesMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_CommonStockIssuanceCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock issuance cost.",
        "label": "Common Stock Issuance Cost",
        "terseLabel": "Common stock issuance cost"
       }
      }
     },
     "localname": "CommonStockIssuanceCost",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_CommonStockSharesIssuedFairMarketValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock, shares issued, fair market value",
        "label": "Common stock, shares issued, fair market value",
        "terseLabel": "Common stock, shares issued, fair market value"
       }
      }
     },
     "localname": "CommonStockSharesIssuedFairMarketValue",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_CommonStockSharesIssuedForMilestonePaymentShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares issued for milestone payment.",
        "label": "Common stock shares Issued for milestone payment| shares",
        "terseLabel": "Common stock shares Issued for milestone payment| shares"
       }
      }
     },
     "localname": "CommonStockSharesIssuedForMilestonePaymentShares",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "vir_CommonStockSharesPurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Shares Purchased",
        "label": "Common Stock, Shares Purchased",
        "terseLabel": "Common Stock, Shares Purchased"
       }
      }
     },
     "localname": "CommonStockSharesPurchased",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "vir_CommonStockSharesPurchasedAggregatePurchasePrice": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Shares Purchased , Aggregate Purchase Price",
        "label": "Common Stock, Shares Purchased , Aggregate Purchase Price",
        "terseLabel": "Common Stock, Shares Purchased , Aggregate Purchase Price"
       }
      }
     },
     "localname": "CommonStockSharesPurchasedAggregatePurchasePrice",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_CommonStockSharesPurchasedSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Shares Purchased, Share Price",
        "label": "Common Stock, Shares Purchased, Share Price",
        "terseLabel": "Common Stock, Shares Purchased, Share Price"
       }
      }
     },
     "localname": "CommonStockSharesPurchasedSharePrice",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "vir_ConcentrationOfCreditRiskCreditLossAndOtherRisksAndUncertaintiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Concentration of credit risk credit loss and other risks and uncertainties.",
        "label": "Concentration Of Credit Risk Credit Loss And Other Risks And Uncertainties Policy [Text Block]",
        "terseLabel": "Concentration of Credit Risk, Credit Loss and Other Risks and Uncertainties"
       }
      }
     },
     "localname": "ConcentrationOfCreditRiskCreditLossAndOtherRisksAndUncertaintiesPolicyTextBlock",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vir_ContingentConsiderationLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent consideration liability",
        "label": "Contingent Consideration Liability [Member]",
        "terseLabel": "Contingent Consideration",
        "verboseLabel": "Contingent Consideration Liability"
       }
      }
     },
     "localname": "ContingentConsiderationLiabilityMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_ContractRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract revenue.",
        "label": "Contract Revenue [Member]",
        "terseLabel": "Contract Revenue"
       }
      }
     },
     "localname": "ContractRevenueMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_ConversionOfPreferredStockIntoCommonStockUponCompletionOfInitialPublicOffering": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion of preferred stock into common stock upon completion of initial public offering.",
        "label": "Conversion Of Preferred Stock Into Common Stock Upon Completion Of Initial Public Offering",
        "terseLabel": "Conversion of preferred stock into common stock upon completion of initial public offering"
       }
      }
     },
     "localname": "ConversionOfPreferredStockIntoCommonStockUponCompletionOfInitialPublicOffering",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_ConvertiblePreferredStockIssuanceCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible preferred stock issuance cost.",
        "label": "Convertible Preferred Stock Issuance Cost",
        "terseLabel": "Convertible preferred stock, net of issuance cost"
       }
      }
     },
     "localname": "ConvertiblePreferredStockIssuanceCost",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_ConvertiblePreferredStockWarrantLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible preferred stock warrant liability.",
        "label": "Convertible Preferred Stock Warrant Liability [Abstract]"
       }
      }
     },
     "localname": "ConvertiblePreferredStockWarrantLiabilityAbstract",
     "nsuri": "http://www.vir.bio/20221231",
     "xbrltype": "stringItemType"
    },
    "vir_ConvertiblePreferredStockWarrantLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible preferred stock warrant liability.",
        "label": "Convertible Preferred Stock Warrant Liability [Member]",
        "verboseLabel": "Warrant to Purchase Convertible Preferred Stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockWarrantLiabilityMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_ConvertiblePreferredStockWarrantLiabilityTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of key terms of the warrant agreement and valuation assumptions.",
        "label": "Convertible Preferred Stock Warrant Liability [Text Block]",
        "terseLabel": "Convertible Preferred Stock Warrant Liability"
       }
      }
     },
     "localname": "ConvertiblePreferredStockWarrantLiabilityTextBlock",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantLiability"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vir_DeferredTaxAssetsLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease liabilities.",
        "label": "Deferred Tax Assets Lease Liabilities",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeaseLiabilities",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_DeferredTaxLiabilitiesInProcessResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities in process research and development.",
        "label": "Deferred Tax Liabilities In Process Research And Development",
        "negatedLabel": "IPR&amp;D"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesInProcessResearchAndDevelopment",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_DeferredTaxLiabilitiesRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities right of use assets.",
        "label": "Deferred Tax Liabilities Right Of Use Assets",
        "negatedLabel": "ROU assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesRightOfUseAssets",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_DefinitiveCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Definitive collaboration agreement.",
        "label": "Definitive Collaboration Agreement [Member]",
        "terseLabel": "Definitive Collaboration Agreement"
       }
      }
     },
     "localname": "DefinitiveCollaborationAgreementMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_DeterminedTransactionPrice": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Determined transaction price.",
        "label": "Determined Transaction Price",
        "terseLabel": "Determined transaction price"
       }
      }
     },
     "localname": "DeterminedTransactionPrice",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_DevelopedTechnologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Developed technology.",
        "label": "Developed Technology [Member]",
        "terseLabel": "Developed Technology"
       }
      }
     },
     "localname": "DevelopedTechnologyMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_DevelopmentAndManufacturingCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development and manufacturing collaboration agreement.",
        "label": "Development And Manufacturing Collaboration Agreement [Member]",
        "terseLabel": "Development and Manufacturing Collaboration Agreement"
       }
      }
     },
     "localname": "DevelopmentAndManufacturingCollaborationAgreementMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_DevelopmentProgramsExercisedByBriiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development Programs Exercised by Brii [Member]",
        "label": "Development Programs Exercised by Brii [Member]",
        "terseLabel": "Development Programs Exercised by Brii"
       }
      }
     },
     "localname": "DevelopmentProgramsExercisedByBriiMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_DevelopmentProgramsExercisedByVirMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development Programs Exercised by Vir [Member]",
        "label": "Development Programs Exercised by Vir [Member]",
        "terseLabel": "Development Programs Exercised by Vir"
       }
      }
     },
     "localname": "DevelopmentProgramsExercisedByVirMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_EachInfectiousDiseaseSiRNAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Each infectious disease siRNA.",
        "label": "Each Infectious Disease Si R N A [Member]",
        "terseLabel": "Each Infectious Disease siRNA"
       }
      }
     },
     "localname": "EachInfectiousDiseaseSiRNAMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_EffectiveIncomeTaxRateReconciliationPermanentItemsPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation permanent items percent.",
        "label": "Effective Income Tax Rate Reconciliation Permanent Items Percent",
        "terseLabel": "Permanent items"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationPermanentItemsPercent",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vir_EquityInvestmentCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Investment Current",
        "label": "Equity Investment Current",
        "terseLabel": "Equity Investment"
       }
      }
     },
     "localname": "EquityInvestmentCurrent",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_EsppDiscountedPurchasePricePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ESPP Discounted Purchase Price Percentage",
        "label": "ESPP Discounted Purchase Price Percentage",
        "terseLabel": "ESPP discounted purchase price percentage"
       }
      }
     },
     "localname": "EsppDiscountedPurchasePricePercentage",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureNetIncomeLossPerShareAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vir_EstimatedSharesEmployeeStockPurchasePlans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated Shares Employee Stock Purchase Plans",
        "label": "Estimated Shares Employee Stock Purchase Plans",
        "terseLabel": "Estimated shares to be issued under plan"
       }
      }
     },
     "localname": "EstimatedSharesEmployeeStockPurchasePlans",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureNetIncomeLossPerShareAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "vir_EstimatedSharesIssuableUnderTheESPPMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated Shares Issuable Under the E S P P [Member]",
        "label": "Estimated Shares Issuable Under the E S P P [Member]",
        "terseLabel": "Estimated Shares Issuable Under The E S P P [Member]"
       }
      }
     },
     "localname": "EstimatedSharesIssuableUnderTheESPPMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_ExcessFundsPayableUnderGrantAgreementsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess funds payable under grant agreements current.",
        "label": "Excess Funds Payable Under Grant Agreements Current",
        "terseLabel": "Excess funds payable under grant agreements"
       }
      }
     },
     "localname": "ExcessFundsPayableUnderGrantAgreementsCurrent",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_ExecutiveOfficerAndDirectorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Executive officer and director.",
        "label": "Executive Officer And Director [Member]",
        "terseLabel": "Executive Officer and Director"
       }
      }
     },
     "localname": "ExecutiveOfficerAndDirectorMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_FairMarketValueOfCommonStockIssued": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair market value of common stock issued.",
        "label": "Fair Market Value Of Common Stock Issued",
        "terseLabel": "Fair market value of the common stock issued"
       }
      }
     },
     "localname": "FairMarketValueOfCommonStockIssued",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_FairValueReclassificationOfContingentConsiderationToAccruedLiabilitiesUponAchievementOfMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, reclassification of contingent consideration to accrued liabilities upon achievement of milestone.",
        "label": "Fair Value Reclassification Of Contingent Consideration To Accrued Liabilities Upon Achievement Of Milestone",
        "terseLabel": "Payment of contingent consideration upon achievement of the TomegaVax milestone"
       }
      }
     },
     "localname": "FairValueReclassificationOfContingentConsiderationToAccruedLiabilitiesUponAchievementOfMilestone",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_FairValueReclassificationOfDerivativeLiabilityToAccruedLiabilitiesUponAchievementOfDevelopmentMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value reclassification of derivative liability to accrued liabilities upon achievement of development milestone.",
        "label": "Fair Value Reclassification Of Derivative Liability To Accrued Liabilities Upon Achievement Of Development Milestone",
        "terseLabel": "Reclassification of derivative liability to accrued liabilities upon achievement of development milestone"
       }
      }
     },
     "localname": "FairValueReclassificationOfDerivativeLiabilityToAccruedLiabilitiesUponAchievementOfDevelopmentMilestone",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_FinancialAssetsAmortizedCostBasis": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial assets amortized cost basis.",
        "label": "Financial Assets Amortized Cost Basis",
        "terseLabel": "Financial Assets, Amortized Cost",
        "totalLabel": "Financial Assets, Amortized Cost"
       }
      }
     },
     "localname": "FinancialAssetsAmortizedCostBasis",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_FinancialAssetsFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial assets fair value.",
        "label": "Financial Assets Fair Value",
        "terseLabel": "Financial Assets, Aggregate Fair Value"
       }
      }
     },
     "localname": "FinancialAssetsFairValue",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_FinancialAssetsGrossUnrealizedHoldingGains": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial assets gross unrealized holding gains.",
        "label": "Financial Assets Gross Unrealized Holding Gains",
        "terseLabel": "Financial Assets, Gross Unrealized Holding Gains"
       }
      }
     },
     "localname": "FinancialAssetsGrossUnrealizedHoldingGains",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_FinancialAssetsGrossUnrealizedHoldingLosses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial assets gross unrealized holding losses.",
        "label": "Financial Assets Gross Unrealized Holding Losses",
        "negatedLabel": "Financial Assets, Gross Unrealized Holding Losses"
       }
      }
     },
     "localname": "FinancialAssetsGrossUnrealizedHoldingLosses",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_FiniteLivedIntangibleAssetsAccumulatedImpairment": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite lived intangible assets accumulated impairment.",
        "label": "Finite Lived Intangible Assets Accumulated Impairment",
        "negatedLabel": "Less impairment of intangible assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedImpairment",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfFiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_FiniteLivedIntangibleAssetsAmortizationExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of total amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in the next five years following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite Lived Intangible Assets Amortization Expense",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpense",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfEstimatedFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_FiniteLivedIntangibleAssetsReclassifiedFromIndefiniteLived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-lived Intangible assets, reclassified from Indefinite-lived.",
        "label": "Finite Lived Intangible Assets Reclassified From Indefinite Lived",
        "terseLabel": "Finite-lived intangible asset, reclassified from indefinite-lived asset"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsReclassifiedFromIndefiniteLived",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_FirstAndSecondClosingsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First and second closings.",
        "label": "First And Second Closings [Member]",
        "terseLabel": "Two Closings"
       }
      }
     },
     "localname": "FirstAndSecondClosingsMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_FirstInfectiousDiseaseProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First infectious disease product.",
        "label": "First Infectious Disease Product [Member]",
        "terseLabel": "Infectious Disease Product"
       }
      }
     },
     "localname": "FirstInfectiousDiseaseProductMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_FirstPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First plan.",
        "label": "First Plan [Member]",
        "terseLabel": "First Plan"
       }
      }
     },
     "localname": "FirstPlanMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_FirstSiRNAProductHBVMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First SiRNA product HBV.",
        "label": "First Si R N A Product H B V [Member]",
        "terseLabel": "First siRNA Product HBV"
       }
      }
     },
     "localname": "FirstSiRNAProductHBVMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_FirstSiRNAProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First siRNA product member.",
        "label": "First Si R N A Product [Member]",
        "terseLabel": "First siRNA Product HBV"
       }
      }
     },
     "localname": "FirstSiRNAProductMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_FollowOnOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Follow-on offering.",
        "label": "Follow On Offering [Member]",
        "terseLabel": "Follow-on Offering"
       }
      }
     },
     "localname": "FollowOnOfferingMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_FormerBusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of former liability recognized arising from contingent consideration in a business combination.",
        "label": "Former Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Estimated fair value of former contingent consideration"
       }
      }
     },
     "localname": "FormerBusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_FundsReceivedInAdvance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funds received in advance.",
        "label": "Funds Received In Advance",
        "terseLabel": "Funds received in advance"
       }
      }
     },
     "localname": "FundsReceivedInAdvance",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_GlaxoGroupLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Glaxo Group Limited.",
        "label": "Glaxo Group Limited [Member]",
        "terseLabel": "GGL"
       }
      }
     },
     "localname": "GlaxoGroupLimitedMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GlaxoSmithKline Intellectual Property Development Limited and GlaxoSmithKline Biologicals SA.",
        "label": "Glaxo Smith Kline Intellectual Property Development Limited And Glaxo Smith Kline Biologicals S A [Member]",
        "terseLabel": "GSK"
       }
      }
     },
     "localname": "GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureManufacturingAndSupplyLetterAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_GlaxoSmithKlineTradingServiceLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Glaxo SmithKline Trading Service Limited.",
        "label": "Glaxo Smith Kline Trading Service Limited [Member]",
        "terseLabel": "GSKTSL"
       }
      }
     },
     "localname": "GlaxoSmithKlineTradingServiceLimitedMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureManufacturingAndSupplyLetterAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_GlaxoWellcomeUKLimitedAndBeechamSAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Glaxo Wellcome U K Limited And Beecham S A.",
        "label": "Glaxo Wellcome U K Limited And Beecham S A [Member]",
        "terseLabel": "GSK"
       }
      }
     },
     "localname": "GlaxoWellcomeUKLimitedAndBeechamSAMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_GrantAgreementAmendedDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant agreement amended date.",
        "label": "Grant Agreement Amended Date",
        "verboseLabel": "Grant agreement amended date"
       }
      }
     },
     "localname": "GrantAgreementAmendedDate",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "vir_GrantAgreementAmendedExpirationDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant agreement amended expiration date.",
        "label": "Grant Agreement Amended Expiration Date",
        "terseLabel": "Grant agreement amended expiration date"
       }
      }
     },
     "localname": "GrantAgreementAmendedExpirationDate",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "vir_GrantAgreementEffectiveEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant agreement effective end date.",
        "label": "Grant Agreement Effective End Date",
        "terseLabel": "Grant agreement effective end date"
       }
      }
     },
     "localname": "GrantAgreementEffectiveEndDate",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "vir_GrantAgreementExpirationDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The date the grant agreement expires.",
        "label": "Grant Agreement Expiration Date",
        "terseLabel": "Grant agreement expiration date"
       }
      }
     },
     "localname": "GrantAgreementExpirationDate",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "vir_GrantAgreementExpirationDateBeforeAmendment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant agreement expiration date before amendment.",
        "label": "Grant Agreement Expiration Date Before Amendment",
        "terseLabel": "Grant agreement expiration date before amendment"
       }
      }
     },
     "localname": "GrantAgreementExpirationDateBeforeAmendment",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "vir_GrantAgreementsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant agreements disclosure.",
        "label": "Grant Agreements Disclosure [Text Block]",
        "terseLabel": "Grant Agreements"
       }
      }
     },
     "localname": "GrantAgreementsDisclosureTextBlock",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGrantAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vir_GrantAwardedAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant awarded amount.",
        "label": "Grant Awarded Amount",
        "terseLabel": "Grant awarded amount"
       }
      }
     },
     "localname": "GrantAwardedAmount",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_GrantAwardedAmountMaximum": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum grant awarded amount.",
        "label": "Grant Awarded Amount Maximum",
        "terseLabel": "Grant awarded amount. maximum"
       }
      }
     },
     "localname": "GrantAwardedAmountMaximum",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_GrantsAgreementAmendedDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grants Agreement Amended Date",
        "label": "Grants Agreement Amended Date"
       }
      }
     },
     "localname": "GrantsAgreementAmendedDate",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "vir_HBVProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HBV program.",
        "label": "H B V Program [Member]",
        "terseLabel": "HBV Program"
       }
      }
     },
     "localname": "HBVProgramMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_HcmvVaccinePlatformGrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hcmv Vaccine Platform Grant [Member].",
        "label": "Hcmv Vaccine Platform Grant [Member]",
        "terseLabel": "HCMV-Vaccine Platform Grant"
       }
      }
     },
     "localname": "HcmvVaccinePlatformGrantMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_HepatitisBVirusProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hepatitis B Virus Product Member.",
        "label": "Hepatitis B Virus Product [Member]",
        "terseLabel": "HBV product"
       }
      }
     },
     "localname": "HepatitisBVirusProductMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_HumabsBiomedSAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Humabs Biomed SA.",
        "label": "Humabs Biomed S A [Member]",
        "terseLabel": "Humabs",
        "verboseLabel": "Humabs IP Transfer"
       }
      }
     },
     "localname": "HumabsBiomedSAMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_HumanImmunodeficiencyVirusGrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Human immunodeficiency virus grant.",
        "label": "Human Immunodeficiency Virus Grant [Member]",
        "terseLabel": "Human Immunodeficiency Virus (\"HIV\") Grant"
       }
      }
     },
     "localname": "HumanImmunodeficiencyVirusGrantMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_IncomeTaxesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes line items.",
        "label": "Income Taxes [Line Items]",
        "terseLabel": "Income Taxes [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxesLineItems",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vir_IncomeTaxesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes table.",
        "label": "Income Taxes [Table]",
        "terseLabel": "Income Taxes [Table]"
       }
      }
     },
     "localname": "IncomeTaxesTable",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vir_IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 22.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in payment of contingent consideration in excess of acquisition date fair value.",
        "label": "Increase Decrease In Payment Of Contingent Consideration In Excess Of Acquisition Date Fair Value",
        "terseLabel": "Payment of contingent consideration in excess of acquisition date fair value"
       }
      }
     },
     "localname": "IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_IncreaseDecreaseInResearchAndDevelopmentExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in research And development expense.",
        "label": "Increase Decrease In Research And Development Expense",
        "terseLabel": "Research and development expense",
        "verboseLabel": "Increase (decrease) in research and development expense"
       }
      }
     },
     "localname": "IncreaseDecreaseInResearchAndDevelopmentExpense",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of restricted shares subject to future vesting using the treasury stock method.",
        "label": "Incremental Common Shares Attributable To Dilutive Effect Of Restricted Share Subject To Future Vesting",
        "terseLabel": "Restricted shares subject to future vesting"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "vir_IncrementalCommonSharesAttributabletoShareBasedPaymentArrangementsEmployeeStockPurchasePlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to share based payment arrangements employee stock purchase plan.",
        "label": "Incremental Common Shares AttributableTo Share Based Payment Arrangements Employee Stock Purchase Plan",
        "terseLabel": "Shares to purchase under Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributabletoShareBasedPaymentArrangementsEmployeeStockPurchasePlan",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "vir_InfectiousDiseaseProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Infectious Disease Product [Member]",
        "label": "Infectious Disease Product [Member]"
       }
      }
     },
     "localname": "InfectiousDiseaseProductMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_InfluenzaAAndHBVResearchProgramsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Influenza A and HBV research programs member.",
        "label": "Influenza A And H B V Research Programs [Member]",
        "terseLabel": "Influenza A and HBV Research Programs"
       }
      }
     },
     "localname": "InfluenzaAAndHBVResearchProgramsMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_InfluenzaAAndInfluenzaBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Influenza A and Influenza B member.",
        "label": "Influenza A And Influenza B [Member]",
        "terseLabel": "Influenza A and Influenza B"
       }
      }
     },
     "localname": "InfluenzaAAndInfluenzaBMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_InfluenzaAResearchProgramsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Influenza A research programs.",
        "label": "Influenza A Research Programs [Member]",
        "terseLabel": "Influenza A Research Programs"
       }
      }
     },
     "localname": "InfluenzaAResearchProgramsMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_InitialPublicOfferingCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial public offering costs.",
        "label": "Initial Public Offering Costs",
        "terseLabel": "Initial public offering costs"
       }
      }
     },
     "localname": "InitialPublicOfferingCosts",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_IssuanceOfCommonStockInConnectionWithAGrantAgreementShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock in connection with a grant agreement, shares",
        "label": "Issuance of common stock in connection with a grant agreement, shares",
        "terseLabel": "Issuance of common stock in connection with a grant agreement (in shares)"
       }
      }
     },
     "localname": "IssuanceOfCommonStockInConnectionWithAGrantAgreementShares",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "vir_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory equipment.",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory Equipment"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_LeaseArrangementContractualExpirationBeginningYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease arrangement, contractual expiration beginning year.",
        "label": "Lease Arrangement Contractual Expiration Beginning Year",
        "terseLabel": "Lease arrangement, contractual expiration period, beginning year"
       }
      }
     },
     "localname": "LeaseArrangementContractualExpirationBeginningYear",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "vir_LeaseArrangementContractualExpirationEndingYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease arrangement, contractual expiration ending year.",
        "label": "Lease Arrangement Contractual Expiration Ending Year",
        "terseLabel": "Lease arrangement, contractual expiration period, ending year"
       }
      }
     },
     "localname": "LeaseArrangementContractualExpirationEndingYear",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "vir_LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails2": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease liability net tenant improvement allowance yet to be received.",
        "label": "Lessee Operating Lease Liability Net Tenant Improvement Allowance Yet To Be Received",
        "negatedLabel": "Less: net tenant improvement allowance yet to be received"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_LetterAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Letter agreement.",
        "label": "Letter Agreement [Member]",
        "terseLabel": "TomegaVax Letter Agreement",
        "verboseLabel": "Letter Agreement Member"
       }
      }
     },
     "localname": "LetterAgreementMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_LicenseAgreementUpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement upfront payment.",
        "label": "License Agreement Upfront Payment",
        "terseLabel": "License agreement upfront payment"
       }
      }
     },
     "localname": "LicenseAgreementUpfrontPayment",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_MaximumAggregateCommercialSalesMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum aggregate commercial sales milestone payments.",
        "label": "Maximum Aggregate Commercial Sales Milestone Payments",
        "terseLabel": "Maximum aggregate commercial sales milestone payments"
       }
      }
     },
     "localname": "MaximumAggregateCommercialSalesMilestonePayments",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_MaximumAggregateDevelopmentAndRegulatoryMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum aggregate development and regulatory milestone payments.",
        "label": "Maximum Aggregate Development And Regulatory Milestone Payments",
        "terseLabel": "Maximum aggregate development and regulatory milestone payments"
       }
      }
     },
     "localname": "MaximumAggregateDevelopmentAndRegulatoryMilestonePayments",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_MaximumAggregateMilestonePaymentForAchievementOfSpecifiedMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum aggregate milestone payment for achievement of specified milestones, including development, regulatory and commercial.",
        "label": "Maximum aggregate milestone payment for achievement of specified milestones"
       }
      }
     },
     "localname": "MaximumAggregateMilestonePaymentForAchievementOfSpecifiedMilestones",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_MaximumAggregateMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum aggregate milestone payments.",
        "label": "Maximum Aggregate Milestone Payments",
        "terseLabel": "Maximum aggregate milestone payments"
       }
      }
     },
     "localname": "MaximumAggregateMilestonePayments",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_MaximumAggregateSalesMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum aggregate milestone payment for achievement of specified annual net sales",
        "label": "Maximum Aggregate Sales Milestone Payment",
        "terseLabel": "Maximum aggregate sales milestone payment"
       }
      }
     },
     "localname": "MaximumAggregateSalesMilestonePayment",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_MaximumAggregateSalesMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum aggregate sales milestone payments.",
        "label": "Maximum Aggregate Sales Milestone Payments",
        "terseLabel": "Maximum aggregate sales milestone payments"
       }
      }
     },
     "localname": "MaximumAggregateSalesMilestonePayments",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_MaximumAmountGrantAggregate": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum Amount Grant Aggregate",
        "label": "Maximum Amount Grant Aggregate",
        "terseLabel": "Potential maximum amount of grant"
       }
      }
     },
     "localname": "MaximumAmountGrantAggregate",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_MaximumAmountGrantBasePeriod": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum Amount Grant Base Period",
        "label": "Maximum Amount Grant Base Period",
        "terseLabel": "Maximum amount of grant during the base period"
       }
      }
     },
     "localname": "MaximumAmountGrantBasePeriod",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum milestone payment for achievement of specified development and regulatory.",
        "label": "Maximum Milestone Payment For Achievement Of Specified Development And Regulatory",
        "terseLabel": "Maximum milestone payment for achievement of specified development and regulatory"
       }
      }
     },
     "localname": "MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_MaximumMilestonePaymentForAchievementOfSpecifiedMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum Milestone Payment For Achievement Of Specified Milestones",
        "label": "Maximum Milestone Payment For Achievement Of Specified Milestones",
        "terseLabel": "Maximum milestone payment for achievement of specified milestones"
       }
      }
     },
     "localname": "MaximumMilestonePaymentForAchievementOfSpecifiedMilestones",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_MaximumNumberOfDevelopmentProgramGrantedFromCounterparty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum Number of Development Program Granted from Counterparty",
        "label": "Maximum Number of Development Program Granted from Counterparty",
        "terseLabel": "Maximum number of development program granted from Brii to Vir | Program"
       }
      }
     },
     "localname": "MaximumNumberOfDevelopmentProgramGrantedFromCounterparty",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "vir_MaximumNumberOfDevelopmentProgramGrantedToCounterparty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum Number of Development Program Granted to Counterparty",
        "label": "Maximum Number of Development Program Granted to Counterparty",
        "terseLabel": "Maximum number of development program granted from Vir to Brii | Program"
       }
      }
     },
     "localname": "MaximumNumberOfDevelopmentProgramGrantedToCounterparty",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "vir_MaximumNumberOfProductsCoveredAgainstMilestonePayment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of products covered against milestone payment.",
        "label": "Maximum Number of Products Covered Against Milestone Payment",
        "terseLabel": "Maximum number of products covered against milestone payment"
       }
      }
     },
     "localname": "MaximumNumberOfProductsCoveredAgainstMilestonePayment",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "vir_MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of right to perform details in connection with antibody product.",
        "label": "Maximum Percentage Of Right To Perform Details In Connection With Antibody Product",
        "terseLabel": "Maximum percentage of right to perform details in connection with antibody product"
       }
      }
     },
     "localname": "MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vir_MaximumSalesMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum milestone payment for achievement of specified annual net sales.",
        "label": "Maximum Sales Milestone Payment",
        "terseLabel": "Maximum sales milestone payment"
       }
      }
     },
     "localname": "MaximumSalesMilestonePayment",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_MaximumSalesMilestonePaymentsToBeReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount of payment to be received by the company upon achievement of sales milestone by the counterparty",
        "label": "Maximum Sales Milestone Payments To Be Received",
        "terseLabel": "Maximum Sales Milestone Payment To Be Received"
       }
      }
     },
     "localname": "MaximumSalesMilestonePaymentsToBeReceived",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_MaximumSalesMilestoneToBeReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum sales milestone to be received.",
        "label": "Maximum Sales Milestone To Be Received",
        "terseLabel": "Maximum sales milestone to be received"
       }
      }
     },
     "localname": "MaximumSalesMilestoneToBeReceived",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_MaximumSharesToBeIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum shares to be issued.",
        "label": "Maximum Shares To Be Issued",
        "terseLabel": "Maximum shares to be issued"
       }
      }
     },
     "localname": "MaximumSharesToBeIssued",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "vir_MaximumTermOfOfferingPeriodSpecifiedUnderPlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum term of offering period specified under plan.",
        "label": "Maximum Term Of Offering Period Specified Under Plan",
        "terseLabel": "Maximum term of offering period specified under plan"
       }
      }
     },
     "localname": "MaximumTermOfOfferingPeriodSpecifiedUnderPlan",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vir_MeasurementInputExpectedRevenueVolatilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input expected revenue volatility.",
        "label": "Measurement Input Expected Revenue Volatility [Member]",
        "terseLabel": "Measurement Input Expected Revenue Volatility"
       }
      }
     },
     "localname": "MeasurementInputExpectedRevenueVolatilityMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_MeasurementInputExpectedVolatilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input expected volatility.",
        "label": "Measurement Input Expected Volatility [Member]",
        "terseLabel": "Measurement Input Expected Volatility"
       }
      }
     },
     "localname": "MeasurementInputExpectedVolatilityMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_MeasurementInputProbabilityRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input, probability rate.",
        "label": "Measurement Input Probability Rate [Member]",
        "terseLabel": "Probability of Achievement"
       }
      }
     },
     "localname": "MeasurementInputProbabilityRateMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_MedImmuneAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MedImmune agreement.",
        "label": "Med Immune Agreement [Member]",
        "terseLabel": "MedImmune Agreement"
       }
      }
     },
     "localname": "MedImmuneAgreementMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_MedImmuneLimitedLiabilityCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MedImmune, limited liability company.",
        "label": "Med Immune Limited Liability Company [Member]",
        "terseLabel": "MedImmune"
       }
      }
     },
     "localname": "MedImmuneLimitedLiabilityCompanyMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_MilestonePayable": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payable.",
        "label": "Milestone Payable",
        "terseLabel": "Milestone payable"
       }
      }
     },
     "localname": "MilestonePayable",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_MilestonePaymentDueToCompany": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment due to company under grant agreement.",
        "label": "Milestone Payment Due To Company",
        "terseLabel": "Milestone payment due to Vir"
       }
      }
     },
     "localname": "MilestonePaymentDueToCompany",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_MilestonePaymentReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment received.",
        "label": "Milestone Payment Received",
        "terseLabel": "Milestone payment received"
       }
      }
     },
     "localname": "MilestonePaymentReceived",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_MilestonePaymentsPaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments paid.",
        "label": "Milestone Payments Paid",
        "terseLabel": "Milestone payments paid"
       }
      }
     },
     "localname": "MilestonePaymentsPaid",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_MilestonePaymentsRelatedTermsDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments related terms description.",
        "label": "Milestone Payments Related Terms Description",
        "terseLabel": "Milestone payments related terms"
       }
      }
     },
     "localname": "MilestonePaymentsRelatedTermsDescription",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vir_MinimumCommonStockConversionPriceForMilestonePaymentsConsideration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum common stock conversion price for milestone payments consideration.",
        "label": "Minimum Common Stock Conversion Price For Milestone Payments Consideration",
        "terseLabel": "Minimum common stock conversion price for milestone payments consideration"
       }
      }
     },
     "localname": "MinimumCommonStockConversionPriceForMilestonePaymentsConsideration",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "vir_MinimumCommonStockPriceForMilestonePaymentsConsideration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum common stock price that triggers milestone payment.",
        "label": "Minimum Common Stock Price For Milestone Payments Consideration",
        "terseLabel": "Minimum common stock price for milestone payments consideration"
       }
      }
     },
     "localname": "MinimumCommonStockPriceForMilestonePaymentsConsideration",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "vir_NationalInstitutesOfHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "National institutes of health.",
        "label": "National Institutes Of Health [Member]",
        "terseLabel": "National Institutes of Health"
       }
      }
     },
     "localname": "NationalInstitutesOfHealthMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_NetProceedsFromIssuanceSecondaryPublicOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's follow on offering of stock to the public, net of commissions and expenses.",
        "label": "Net proceeds From Issuance Secondary Public Offering",
        "terseLabel": "Net proceeds from issuance secondary public offering"
       }
      }
     },
     "localname": "NetProceedsFromIssuanceSecondaryPublicOffering",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_NonCashCommonStockIssuedForContingentConsideration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non cash common stock issued for contingent consideration.",
        "label": "Non Cash Common Stock Issued For Contingent Consideration",
        "terseLabel": "Common stock issued for payment of contingent consideration"
       }
      }
     },
     "localname": "NonCashCommonStockIssuedForContingentConsideration",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_NoncashLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash lease expense.",
        "label": "Noncash Lease Expense",
        "terseLabel": "Noncash lease expense"
       }
      }
     },
     "localname": "NoncashLeaseExpense",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_NumberOfAntibodiesToDevelop": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of antibodies to develop.",
        "label": "Number of Antibodies to Develop",
        "verboseLabel": "Number of antibodies to develop"
       }
      }
     },
     "localname": "NumberOfAntibodiesToDevelop",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "vir_NumberOfClassOfStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of class of stock.",
        "label": "Number of Class of Stock",
        "terseLabel": "Number of class of stock"
       }
      }
     },
     "localname": "NumberOfClassOfStock",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "vir_NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of years conduct certain research and development activities under mutually agreed development plans.",
        "label": "Number Of Years Conduct Certain Research And Development Activities Under Mutually Agreed Development Plans",
        "terseLabel": "Number of years conduct certain research and development activities under mutually agreed development plans"
       }
      }
     },
     "localname": "NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vir_ObligationToPayCapacityReservation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount obligated to pay for capacity reservation under the agreement.",
        "label": "Obligation To Pay Capacity Reservation",
        "terseLabel": "Obligation to pay capacity reservation"
       }
      }
     },
     "localname": "ObligationToPayCapacityReservation",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_OfferingPeriodEmployeeStockPurchasePlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Duration of offering period under the Plan.",
        "label": "Offering Period Employee Stock Purchase Plan",
        "terseLabel": "Offering period"
       }
      }
     },
     "localname": "OfferingPeriodEmployeeStockPurchasePlan",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vir_OperatingAndFinanceRentExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating and finance rent expense.",
        "label": "Operating And Finance Rent Expense",
        "terseLabel": "Rent expense"
       }
      }
     },
     "localname": "OperatingAndFinanceRentExpense",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_OperatingLeaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease.",
        "label": "Operating Lease [Abstract]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "OperatingLeaseAbstract",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vir_OperatingLeaseIncentiveOverLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease Incentive Over Lease Liabilities",
        "label": "Operating Lease Incentive Over Lease Liabilities",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "OperatingLeaseIncentiveOverLeaseLiabilities",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_OperatingLeaseOtherInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease other information.",
        "label": "Operating Lease Other Information [Abstract]",
        "terseLabel": "Other Information"
       }
      }
     },
     "localname": "OperatingLeaseOtherInformationAbstract",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesSummaryOfLeaseCostsAndAdditionalInformationRelatedToOperatingLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vir_OperatingLossCarryforwardsExpirationBeginningYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards expiration beginning year.",
        "label": "Operating Loss Carryforwards Expiration Beginning Year",
        "verboseLabel": "Net operating loss carryforwards expiration beginning year"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpirationBeginningYear",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "vir_OperatingLossCarryforwardsLimitationOnUsePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards limitation on use percentage.",
        "label": "Operating Loss Carryforwards Limitation On Use Percentage",
        "terseLabel": "Net operating loss deduction limitation as percentage of taxable income"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLimitationOnUsePercentage",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vir_OptionExerciseFeeConsiderationToBeReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option exercise fee consideration to be received.",
        "label": "Option Exercise Fee Consideration To Be Received",
        "terseLabel": "Option exercise fee to be received"
       }
      }
     },
     "localname": "OptionExerciseFeeConsiderationToBeReceived",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_OptionExerciseFeeHighEndOfTheRange": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the high end of the range of option exercise fee upon exercise of a program.",
        "label": "Option exercise fee, high end of the range",
        "terseLabel": "Option exercise fee, high end of the range"
       }
      }
     },
     "localname": "OptionExerciseFeeHighEndOfTheRange",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_OptionExerciseFeeLowEndOfTheRange": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the low end of the range of option exercise fee upon exercise of a program.",
        "label": "Option exercise fee, low end of the range",
        "terseLabel": "Option exercise fee, low end of the range"
       }
      }
     },
     "localname": "OptionExerciseFeeLowEndOfTheRange",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vir_OptionExerciseFeeReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option exercise fee received.",
        "label": "Option Exercise Fee Received",
        "terseLabel": "Option exercise fee received"
       }
      }
     },
     "localname": "OptionExerciseFeeReceived",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_OptionsTransactionPrice": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options transaction price",
        "label": "Options Transaction Price",
        "terseLabel": "Options Transaction Price"
       }
      }
     },
     "localname": "OptionsTransactionPrice",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization consolidation and presentation of financial statements.",
        "label": "Organization Consolidation And Presentation Of Financial Statements [Line Items]",
        "terseLabel": "Organization Consolidation And Presentation Of Financial Statements [Line Items]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization consolidation and presentation of financial statements.",
        "label": "Organization Consolidation And Presentation Of Financial Statements [Table]",
        "terseLabel": "Organization Consolidation And Presentation Of Financial Statements [Table]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsTable",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vir_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentToProjectedBenefitObligationsNetOfTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other comprehensive income loss pension and other postretirement benefit plans adjustment to projected benefit obligations net of tax.",
        "label": "Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment To Projected Benefit Obligations Net Of Tax",
        "negatedLabel": "Adjustment to projected benefit obligations, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentToProjectedBenefitObligationsNetOfTax",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_PaymentCommitmentManufacturingCapacity": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment Commitment Manufacturing Capacity",
        "label": "Payment Commitment Manufacturing Capacity",
        "terseLabel": "Payment committed for manufacturing capacity"
       }
      }
     },
     "localname": "PaymentCommitmentManufacturingCapacity",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureManufacturingAndSupplyLetterAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_PaymentCommitmentRawMaterials": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment Commitment Raw Materials",
        "label": "Payment Commitment Raw Materials",
        "terseLabel": "Pre pay for raw materials"
       }
      }
     },
     "localname": "PaymentCommitmentRawMaterials",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureManufacturingAndSupplyLetterAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_PaymentMadeForAssetAcquisitionMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment made for asset acquisition milestone.",
        "label": "Payment Made For Asset Acquisition Milestone",
        "terseLabel": "Payment made for asset acquisition milestone"
       }
      }
     },
     "localname": "PaymentMadeForAssetAcquisitionMilestone",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_PaymentMadeForBusinessCombinationMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment made for business combination milestone.",
        "label": "Payment made for business combination milestone",
        "terseLabel": "Payment made for business combination milestone"
       }
      }
     },
     "localname": "PaymentMadeForBusinessCombinationMilestone",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_PaymentOfContingentConsideration": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment of contingent consideration.",
        "label": "Payment Of Contingent Consideration",
        "negatedLabel": "Payment of contingent consideration"
       }
      }
     },
     "localname": "PaymentOfContingentConsideration",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_PaymentToCollaboratorResultingFromProgramOptionExercise": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payment to a collaborator due to a program option exercise under a separate agreement.",
        "label": "Payment to collaborator resulting from program option exercise",
        "terseLabel": "Payment to collaborator resulting from program option exercise"
       }
      }
     },
     "localname": "PaymentToCollaboratorResultingFromProgramOptionExercise",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_PaymentsOfUnderwritingDiscountsAndCommissions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments of underwriting discounts and commissions.",
        "label": "Payments Of Underwriting Discounts And Commissions",
        "terseLabel": "Payments of underwriting discounts and commissions"
       }
      }
     },
     "localname": "PaymentsOfUnderwritingDiscountsAndCommissions",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_PayrollAndRelatedExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payroll and related expenses current.",
        "label": "Payroll And Related Expenses Current",
        "terseLabel": "Payroll and related expenses"
       }
      }
     },
     "localname": "PayrollAndRelatedExpensesCurrent",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_PercentageOfAggregateGrossProceedsFromSaleOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of aggregate gross proceeds from sale of shares.",
        "label": "Percentage Of Aggregate Gross Proceeds From Sale Of Shares",
        "terseLabel": "Percentage of aggregate gross proceeds from sale of shares"
       }
      }
     },
     "localname": "PercentageOfAggregateGrossProceedsFromSaleOfShares",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vir_PercentageOfCommissionRateFromSaleOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of maximum commission rate, based on aggregate gross proceeds from sale of shares.",
        "label": "Percentage of commission rate from sale of shares",
        "terseLabel": "Percentage of commission rate from sale of shares"
       }
      }
     },
     "localname": "PercentageOfCommissionRateFromSaleOfShares",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vir_PercentageOfDevelopmentCosts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of development costs.",
        "label": "Percentage Of Development Costs",
        "terseLabel": "Percentage of development costs"
       }
      }
     },
     "localname": "PercentageOfDevelopmentCosts",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vir_PercentageOfDevelopmentCostsResponsibleByCompany": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of development costs that the Company is responsible for.",
        "label": "Percentage Of Development Costs Responsible By Company",
        "terseLabel": "Percentage of development costs"
       }
      }
     },
     "localname": "PercentageOfDevelopmentCostsResponsibleByCompany",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vir_PercentageOfDevelopmentCostsResponsibleByGsk": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of development costs that GSK is responsible for.",
        "label": "Percentage Of Development Costs Responsible By GSK",
        "terseLabel": "Percentage of development costs responsible by GSK"
       }
      }
     },
     "localname": "PercentageOfDevelopmentCostsResponsibleByGsk",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureManufacturingAndSupplyLetterAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vir_PercentageOfEstimatedBatchProductionFees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of estimated batch production fees owed.",
        "label": "Percentage Of Estimated Batch Production Fees",
        "terseLabel": "Percentage of estimated batch production fees"
       }
      }
     },
     "localname": "PercentageOfEstimatedBatchProductionFees",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vir_PercentageOfOrdinaryShareEqualToOutstandingShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of ordinary share equal to outstanding share.",
        "label": "Percentage Of Ordinary Share Equal To Outstanding Share",
        "terseLabel": "Percentage of ordinary share equal to outstanding share"
       }
      }
     },
     "localname": "PercentageOfOrdinaryShareEqualToOutstandingShare",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vir_PercentageOfShareDevelopmentCosts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of share development costs.",
        "label": "Percentage Of Share Development Costs",
        "terseLabel": "Percentage of share development costs"
       }
      }
     },
     "localname": "PercentageOfShareDevelopmentCosts",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vir_PercentageOfUpfrontPaymentReceivableAtEffectiveDateOfAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of upfront payment receivable at effective date of agreement.",
        "label": "Percentage Of Upfront Payment Receivable At Effective Date Of Agreement",
        "terseLabel": "Percentage of upfront payment receivable at effective date of agreement"
       }
      }
     },
     "localname": "PercentageOfUpfrontPaymentReceivableAtEffectiveDateOfAgreement",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vir_PercentageOfUpfrontPaymentReceivableAtExecutionDateOfAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of upfront payment receivable at execution date of agreement",
        "label": "Percentage of upfront payment receivable at execution date of agreement"
       }
      }
     },
     "localname": "PercentageOfUpfrontPaymentReceivableAtExecutionDateOfAgreement",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vir_PreDefinedRegulatoryMilestoneConsiderationToBeReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consideration to be received upon achievement of a pre-defined regulatory milestone",
        "label": "Pre Defined Regulatory Milestone Consideration To Be Received",
        "terseLabel": "Pre Defined Regulatory Milestone Consideration To Be Received"
       }
      }
     },
     "localname": "PreDefinedRegulatoryMilestoneConsiderationToBeReceived",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_PreliminaryCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preliminary Collaboration Agreement.",
        "label": "Preliminary Collaboration Agreement [Member]",
        "terseLabel": "Preliminary Collaboration Agreement"
       }
      }
     },
     "localname": "PreliminaryCollaborationAgreementMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_PremiumReceivedOnSalePriceOfCommonStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Premium received on sale price of common stock.",
        "label": "Premium Received On Sale Price Of Common Stock",
        "terseLabel": "Premium received on sale price of common stock"
       }
      }
     },
     "localname": "PremiumReceivedOnSalePriceOfCommonStock",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_PrepaymentRawMaterials": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepayment Raw Materials",
        "label": "Prepayment Raw Materials",
        "terseLabel": "Non-refundable prepayment for raw materials"
       }
      }
     },
     "localname": "PrepaymentRawMaterials",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureManufacturingAndSupplyLetterAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_PresentValueOfOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails2": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, net of tenant improvement allowance yet to be received.",
        "label": "Present Value Of Operating Lease Liabilities",
        "terseLabel": "Present value of operating lease liabilities",
        "totalLabel": "Present value of operating lease liabilities"
       }
      }
     },
     "localname": "PresentValueOfOperatingLeaseLiabilities",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_ProceedsFromDisposalOfAnEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from disposal of an equipment.",
        "label": "Proceeds From Disposal of an Equipment",
        "terseLabel": "Proceeds from disposal of an asset held for sale"
       }
      }
     },
     "localname": "ProceedsFromDisposalOfAnEquipment",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_ProceedsFromIssuanceOfCommonStockInConnectionWithAGrantAgreement": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of common stock in connection with a grant agreement",
        "label": "Proceeds From Issuance of Common Stock in Connection With a Grant Agreement",
        "terseLabel": "Proceeds from issuance of common stock in connection with a grant agreement",
        "verboseLabel": "Issuance of common stock in connection with a grant agreement"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockInConnectionWithAGrantAgreement",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_ProceedsFromIssuanceOfCommonStockInConnectionWithCollaboration": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Issuance of Common Stock in Connection With Collaboration.",
        "label": "Proceeds From Issuance of Common Stock in Connection With Collaboration",
        "terseLabel": "Proceeds from issuance of common stock in connection with a collaboration agreement"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockInConnectionWithCollaboration",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_ProceedsFromIssuanceSecondaryPublicOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's follow on offering of stock to the public.",
        "label": "Proceeds From Issuance Secondary Public Offering",
        "terseLabel": "Net proceeds after deducting underwriting discounts, commissions and offering expenses"
       }
      }
     },
     "localname": "ProceedsFromIssuanceSecondaryPublicOffering",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_ProfitShareAmountConstraint": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Profit share amount constraint",
        "label": "Profit share amount constraint",
        "terseLabel": "Net profit-sharing constrained"
       }
      }
     },
     "localname": "ProfitShareAmountConstraint",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_ProfitSharingAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsCollaborationCollaborationRevenueDetails": {
       "order": 0.0,
       "parentTag": "vir_TotalcollaborationRevenue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Profit sharing amount",
        "label": "Profit sharing amount",
        "terseLabel": "Profit-sharing amount"
       }
      }
     },
     "localname": "ProfitSharingAmount",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsCollaborationCollaborationRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_ProfitSharingAmountConstrained": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsCollaborationCollaborationRevenueDetails": {
       "order": 1.0,
       "parentTag": "vir_TotalcollaborationRevenue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Profit sharing amount constrained",
        "label": "Profit sharing amount constrained",
        "terseLabel": "Profit-sharing amount constrained"
       }
      }
     },
     "localname": "ProfitSharingAmountConstrained",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsCollaborationCollaborationRevenueDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_ProfitSharingAmountPreviouslyConstrainedReleased": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsCollaborationCollaborationRevenueDetails": {
       "order": 2.0,
       "parentTag": "vir_TotalcollaborationRevenue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Profit-Sharing Amount Previously Constrained, Released",
        "label": "Profit-Sharing Amount Previously Constrained, Released",
        "terseLabel": "Profit-sharing amount previously constrained, released"
       }
      }
     },
     "localname": "ProfitSharingAmountPreviouslyConstrainedReleased",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsCollaborationCollaborationRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_ProfitsAndLossesSharingPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Profits and losses sharing percentage.",
        "label": "Profits And Losses Sharing Percentage",
        "terseLabel": "Percentage of share Profit and loss"
       }
      }
     },
     "localname": "ProfitsAndLossesSharingPercentage",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vir_RangeOfRoyaltyPaymentToBePaid": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range of royalty payment to be paid by counterparty.",
        "label": "Range of Royalty Payment to be Paid",
        "terseLabel": "Range of royalty payment to be paid"
       }
      }
     },
     "localname": "RangeOfRoyaltyPaymentToBePaid",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vir_RangeOfRoyaltyPaymentToBeReceived": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range of royalty payment to be received by the company upon exercised of the development programs by counterparty.",
        "label": "Range of Royalty Payment to be Received",
        "terseLabel": "Range of royalty payment to be received"
       }
      }
     },
     "localname": "RangeOfRoyaltyPaymentToBeReceived",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vir_RangeOfRoyaltyPaymentsToBeReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulatory Milestone Payment To Be Received.",
        "label": "Range of Royalty Payments to be Received",
        "terseLabel": "Regulatory Milestone Payment To Be Received"
       }
      }
     },
     "localname": "RangeOfRoyaltyPaymentsToBeReceived",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_RangeOfTieredRoyaltiesToPayToNetSalesOfProducts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range of tiered royalties to pay on annual net sales of products.",
        "label": "Range of Tiered Royalties to Pay to Net Sales of Products",
        "verboseLabel": "Range of tiered royalties to pay on net sales of products"
       }
      }
     },
     "localname": "RangeOfTieredRoyaltiesToPayToNetSalesOfProducts",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reclassification of derivative liability to additional paid In capital.",
        "label": "Reclassification Of Derivative Liability To Additional Paid In Capital",
        "terseLabel": "Reclassification of derivative liability to addition paid-in-capital"
       }
      }
     },
     "localname": "ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reclassification\u200b of derivative liability\u200b to additional paid-\u200bin capital upon achievement of development milestone.",
        "label": "Reclassification Of Derivative Liability To Additional Paid In Capital Upon Achievement Of Development Milestone",
        "terseLabel": "Reclassification of derivative liability to additional paid-in capital"
       }
      }
     },
     "localname": "ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_ReclassificationOfPreferredStockWarrantLiabilityToAdditionalPaidInCapital": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reclassification of preferred stock warrant liability to additional paid-in capital.",
        "label": "Reclassification Of Preferred Stock Warrant Liability To Additional Paid In Capital",
        "terseLabel": "Reclassification of preferred stock warrant liability to additional paid-in capital"
       }
      }
     },
     "localname": "ReclassificationOfPreferredStockWarrantLiabilityToAdditionalPaidInCapital",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_ReclassifiedDeferredRevenue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reclassified deferred revenue.",
        "label": "Reclassified Deferred Revenue",
        "terseLabel": "Reclassified deferred revenue"
       }
      }
     },
     "localname": "ReclassifiedDeferredRevenue",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_ReconciliationOfEffectiveIncomeTaxRateLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reconciliation of effective income tax rate.",
        "label": "Reconciliation Of Effective Income Tax Rate [Line Items]",
        "terseLabel": "Reconciliation Of Effective Income Tax Rate [Line Items]"
       }
      }
     },
     "localname": "ReconciliationOfEffectiveIncomeTaxRateLineItems",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vir_ReconciliationOfEffectiveIncomeTaxRateTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reconciliation of effective income tax rate.",
        "label": "Reconciliation Of Effective Income Tax Rate [Table]",
        "terseLabel": "Reconciliation Of Effective Income Tax Rate [Table]"
       }
      }
     },
     "localname": "ReconciliationOfEffectiveIncomeTaxRateTable",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationBetweenExpectedIncomeTaxProvisionAtFederalStatutoryRateAndReportedIncomeTaxBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vir_RegulatoryMilestoneAchieved": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulatory milestones achieved during the reporting period.",
        "label": "Regulatory Milestone Achieved",
        "terseLabel": "Regulatory milestone achieved"
       }
      }
     },
     "localname": "RegulatoryMilestoneAchieved",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_RegulatoryMilestonePaymentOnLicensedProductHighEndOfRange": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulatory milestone payment on licensed product, high end of the range.",
        "label": "Regulatory Milestone Payment On Licensed Product High End Of Range",
        "terseLabel": "Regulatory milestone payment on licensed product, high end of the range"
       }
      }
     },
     "localname": "RegulatoryMilestonePaymentOnLicensedProductHighEndOfRange",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_RegulatoryMilestonePaymentOnLicensedProductLowEndOfTheRange": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulatory milestone payment on licensed product, low end of the range.",
        "label": "Regulatory Milestone Payment On Licensed Product Low End Of The Range",
        "terseLabel": "Regulatory milestone payment on licensed product, low end of the range"
       }
      }
     },
     "localname": "RegulatoryMilestonePaymentOnLicensedProductLowEndOfTheRange",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vir_RegulatoryMilestonePaymentToBeReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulatory milestone payment to be received by the company upon exercised of the development programs by counterparty.",
        "label": "Regulatory Milestone Payment to be Received",
        "terseLabel": "Regulatory milestone payment to be received"
       }
      }
     },
     "localname": "RegulatoryMilestonePaymentToBeReceived",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_RegulatoryMilestonesAchieved": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulatory milestones achieved during the reporting period.",
        "label": "Regulatory Milestones Achieved",
        "terseLabel": "Regulatory milestones achieved"
       }
      }
     },
     "localname": "RegulatoryMilestonesAchieved",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_ReleaseOfValuationAllowanceDeferredTaxInAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Release of valuation allowance deferred tax in amount.",
        "label": "Release of Valuation Allowance Deferred Tax In Amount",
        "terseLabel": "Release of valuation allowance"
       }
      }
     },
     "localname": "ReleaseOfValuationAllowanceDeferredTaxInAmount",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_RemainingPaymentForAssetAcquisitionMilestoneAggregate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For contingent consideration arrangements recognized in connection with an asset acquisition, this element represents an estimate of the high-end of the potential range (undiscounted) of the remaining consideration which may be paid.",
        "label": "Remaining Payment For Asset Acquisition Milestone Aggregate",
        "terseLabel": "Remaining payment for asset acquisition milestone, maximum"
       }
      }
     },
     "localname": "RemainingPaymentForAssetAcquisitionMilestoneAggregate",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_RemainingPaymentMadeForAssetAcquisitionMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining payment made for asset acquisition milestone.",
        "label": "Remaining Payment Made For Asset Acquisition Milestone",
        "terseLabel": "Remaining payment made for asset acquisition milestone"
       }
      }
     },
     "localname": "RemainingPaymentMadeForAssetAcquisitionMilestone",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_RemainingPaymentMadeForBusinessCombinationMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining Payment Made For Business Combination Milestone",
        "label": "Remaining Payment Made For Business Combination Milestone",
        "terseLabel": "Remaining payment made for business combination milestone"
       }
      }
     },
     "localname": "RemainingPaymentMadeForBusinessCombinationMilestone",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_RepaymentOfOutstandingPromissoryNotesAndAccruedInterestReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repayment of outstanding promissory notes and accrued interest received.",
        "label": "Repayment Of Outstanding Promissory Notes And Accrued Interest Received",
        "terseLabel": "Repayment of outstanding promissory notes and accrued interest received"
       }
      }
     },
     "localname": "RepaymentOfOutstandingPromissoryNotesAndAccruedInterestReceived",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_ResearchAndDevelopmentExpenseUnderLicenseAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development expense under license agreement",
        "label": "Research and development expense under license agreement"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseUnderLicenseAgreement",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_ResearchAndDevelopmentExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of current obligations incurred and payable to vendors for goods and services attributable to the entity's research and development activities.",
        "label": "Research And Development Expenses Current",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensesCurrent",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_RestrictedStockAwardsRSAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted stock awards (RSA).",
        "label": "Restricted Stock Awards R S A [Member]",
        "terseLabel": "Restricted Stock Awards (RSAs)"
       }
      }
     },
     "localname": "RestrictedStockAwardsRSAMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_RestrictedStockLiabilityRecognizedForPortionOfPromissoryNoteRepayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted stock liability recognized for portion of promissory note repayment.",
        "label": "Restricted Stock Liability Recognized For Portion Of Promissory Note Repayment",
        "terseLabel": "Restricted stock liability recognized for portion of promissory note repayment"
       }
      }
     },
     "localname": "RestrictedStockLiabilityRecognizedForPortionOfPromissoryNoteRepayment",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_RestrictedStockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted stock purchase agreement.",
        "label": "Restricted Stock Purchase Agreement [Member]",
        "terseLabel": "Restricted Stock Purchase Agreement"
       }
      }
     },
     "localname": "RestrictedStockPurchaseAgreementMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_RockefellerAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rockefeller agreement.",
        "label": "Rockefeller Agreement [Member]",
        "terseLabel": "Rockefeller Agreement"
       }
      }
     },
     "localname": "RockefellerAgreementMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_RockefellerUniversityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rockefeller University.",
        "label": "Rockefeller University [Member]",
        "terseLabel": "Rockefeller"
       }
      }
     },
     "localname": "RockefellerUniversityMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_RoyaltiesBasedOnNetSalesOfLicensedProducts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalties payment based on net sales of licensed products.",
        "label": "Royalties Based on Net Sales of Licensed Products",
        "verboseLabel": "Royalties based on net sales of licensed products"
       }
      }
     },
     "localname": "RoyaltiesBasedOnNetSalesOfLicensedProducts",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vir_RoyaltiesPaymentExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of years that royalties payment expired.",
        "label": "Royalties Payment Expiration Period",
        "verboseLabel": "Royalties payment expiration period"
       }
      }
     },
     "localname": "RoyaltiesPaymentExpirationPeriod",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vir_RoyaltiesPaymentRangeOnNetSalesOfLicensedProduct": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalties payment range on net sales of licensed product.",
        "label": "Royalties Payment Range on Net Sales of Licensed Product",
        "terseLabel": "Royalties payment range on net sales of licensed product"
       }
      }
     },
     "localname": "RoyaltiesPaymentRangeOnNetSalesOfLicensedProduct",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vir_RoyaltyObligationPeriodFromDateOfFirstCommercialSale": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty obligation period from date of first commercial sale.",
        "label": "Royalty Obligation Period From Date Of First Commercial Sale",
        "terseLabel": "Royalty obligation period from date of first commercial sale"
       }
      }
     },
     "localname": "RoyaltyObligationPeriodFromDateOfFirstCommercialSale",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vir_RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty payment obligation expiration period after first commercial sales.",
        "label": "Royalty Payment Obligation Expiration Period After First Commercial Sales",
        "terseLabel": "Royalty payment obligation expiration period after first commercial sales"
       }
      }
     },
     "localname": "RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vir_SARSCoV2ProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SARS-CoV-2 product.",
        "label": "S A R S Co V2 Product [Member]",
        "terseLabel": "SARS-CoV-2 Product"
       }
      }
     },
     "localname": "SARSCoV2ProductMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_SaleLeasebackTransactionProceedsFromFinancingObligations": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "sale leaseback transaction proceeds from financing obligations.",
        "label": "Sale Leaseback Transaction Proceeds From Financing Obligations",
        "terseLabel": "Proceeds from sale leaseback of financing obligation"
       }
      }
     },
     "localname": "SaleLeasebackTransactionProceedsFromFinancingObligations",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_SaleOfStockConsiderationAggregateOfferingPrice": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the aggregate offering price for which the entity may sell shares of its common stock under the sales agreement.",
        "label": "Sale Of Stock Consideration Aggregate Offering Price",
        "terseLabel": "Aggregate offering price"
       }
      }
     },
     "localname": "SaleOfStockConsiderationAggregateOfferingPrice",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_SalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales agreement.",
        "label": "Sales Agreement [Member]",
        "terseLabel": "Sales Agreement"
       }
      }
     },
     "localname": "SalesAgreementMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_SalesMilestonesAchieved": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales milestones achieved during the reporting period",
        "label": "Sales Milestones Achieved",
        "terseLabel": "Sales milestone achieved"
       }
      }
     },
     "localname": "SalesMilestonesAchieved",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_SamsungBiologicsCompanyLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Samsung Biologics Co., Ltd.",
        "label": "Samsung Biologics Company Limited [Member]",
        "terseLabel": "Samsung Biologics Co., Ltd"
       }
      }
     },
     "localname": "SamsungBiologicsCompanyLimitedMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of accrued liabilities and other liabilities.",
        "label": "Schedule Of Accrued Liabilities And Other Liabilities Table [Text Block]",
        "terseLabel": "Schedule of Accrued and Other Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vir_ScheduleOfGoodwillAndIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and intangible assets.",
        "label": "Schedule Of Goodwill And Intangible Assets [Line Items]",
        "terseLabel": "Schedule of Goodwill and Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillAndIntangibleAssetsLineItems",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vir_ScheduleOfGoodwillAndIntangibleAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and intangible assets.",
        "label": "Schedule Of Goodwill And Intangible Assets [Table]",
        "terseLabel": "Schedule Of Goodwill And Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillAndIntangibleAssetsTable",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vir_ScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of operating lease amounts recorded in condensed consolidated balance sheet.",
        "label": "Schedule Of Operating Lease Amounts Recorded In Condensed Consolidated Balance Sheet Table [Text Block]",
        "terseLabel": "Schedule of Operating Lease Amounts Recorded in Condensed Consolidated Balance Sheet"
       }
      }
     },
     "localname": "ScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetTableTextBlock",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vir_SecondPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second plan.",
        "label": "Second Plan [Member]",
        "terseLabel": "Second Plan"
       }
      }
     },
     "localname": "SecondPlanMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_SeriesAOneConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A-1 convertible preferred stock.",
        "label": "Series A One Convertible Preferred Stock [Member]",
        "terseLabel": "Series A-1 Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesAOneConvertiblePreferredStockMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantLiabilityAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_SeriesATwoConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A -2 convertible preferred stock member.",
        "label": "Series A Two Convertible Preferred Stock [Member]",
        "terseLabel": "Series A-2 Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesATwoConvertiblePreferredStockMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_SeriesBConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B convertible preferred stock.",
        "label": "Series B Convertible Preferred Stock [Member]",
        "terseLabel": "Series B Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesBConvertiblePreferredStockMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_SpecifiedClinicalDevelopmentMilestonesPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specified clinical development milestones payment.",
        "label": "Specified Clinical Development Milestones Payment",
        "terseLabel": "Specified clinical development milestones payment"
       }
      }
     },
     "localname": "SpecifiedClinicalDevelopmentMilestonesPayment",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_SpecifiedResearchAndDevelopmentExpensesMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development expenses related to certain development milestone payments",
        "label": "Specified Research And Development Expenses Milestone Payments",
        "terseLabel": "Specified research and development expenses milestone payments"
       }
      }
     },
     "localname": "SpecifiedResearchAndDevelopmentExpensesMilestonePayments",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_SpecifiedSalesDevelopmentMilestonesPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specified sales development milestones payment.",
        "label": "Specified Sales Development Milestones Payment",
        "terseLabel": "Specified sales development milestones payment"
       }
      }
     },
     "localname": "SpecifiedSalesDevelopmentMilestonesPayment",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_StockIssuedDuringPeriodSharesAchievementOfMilestone": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares achievement of milestone.",
        "label": "Stock Issued During Period Shares Achievement Of Milestone",
        "terseLabel": "Issuance of common stock in connection with the achievement of a milestone (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAchievementOfMilestone",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "vir_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares cashless exercise of warrant.",
        "label": "Stock Issued During Period Shares Cashless Exercise Of Warrant",
        "terseLabel": "Issuance of common stock for cashless exercise of warrant (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "vir_StockIssuedDuringPeriodSharesCollaborationAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in connection with a collaboration agreement.",
        "label": "Stock Issued During Period Shares Collaboration Agreement",
        "terseLabel": "Issuance of common stock in connection with a collaboration agreement (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesCollaborationAgreement",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "vir_StockIssuedDuringPeriodSharesIssuedForSettlementOfContingentConsideration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for settlement of contingent consideration.",
        "label": "Stock Issued During Period Shares Issued For Settlement Of Contingent Consideration",
        "terseLabel": "Issuance of common stock to settle a contingent consideration (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForSettlementOfContingentConsideration",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "vir_StockIssuedDuringPeriodSharesLicenseAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common stock issued in connection with a license agreement.",
        "label": "Stock Issued During Period Shares License Agreement",
        "terseLabel": "Issuance of common stock in connection with a grant agreement (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesLicenseAgreement",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "vir_StockIssuedDuringPeriodValueCollaborationAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in connection with a collaboration agreement.",
        "label": "Stock Issued During Period Value Collaboration Agreement",
        "terseLabel": "Issuance of common stock in connection with a collaboration agreement"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueCollaborationAgreement",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_StockIssuedDuringPeriodValueIssuedForSettlementOfContingentConsideration": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued for settlement of contingent considerations.",
        "label": "Stock Issued During Period Value Issued For Settlement Of Contingent Consideration",
        "terseLabel": "Issuance of common stock to settle a contingent consideration"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForSettlementOfContingentConsideration",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_StockIssuedDuringPeriodValueLicenseAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of common stock issued in connection with a license agreement.",
        "label": "Stock Issued During Period Value License Agreement",
        "terseLabel": "Issuance of common stock in connection with a grant agreement"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueLicenseAgreement",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_StockIssuedDuringPeriodWarrantExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of new shares issued in the exercise of warrant during the period.",
        "label": "Stock Issued During Period Warrant Exercised",
        "terseLabel": "Common stock shares issued for conversion of warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodWarrantExercised",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockWarrantLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "vir_StockIssuedGrantAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total common stock issued in connection with the grant agreement.",
        "label": "Stock Issued Grant Agreement",
        "terseLabel": "Common stock issued in connection with the grant agreement"
       }
      }
     },
     "localname": "StockIssuedGrantAgreement",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "vir_SummaryOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of lease cost and other information related to operating leases.",
        "label": "Summary Of Lease Cost And Other Information Related To Operating Leases Table [Text Block]",
        "terseLabel": "Summary of Lease Costs and Additional Information Related to Operating Leases"
       }
      }
     },
     "localname": "SummaryOfLeaseCostAndOtherInformationRelatedToOperatingLeasesTableTextBlock",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vir_SummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vir_SummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vir_TaxCreditCarryforwardsExpirationBeginningYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax credit carryforwards expiration beginning year.",
        "label": "Tax Credit Carryforwards Expiration Beginning Year",
        "verboseLabel": "Tax credit carryforwards expiration beginning year"
       }
      }
     },
     "localname": "TaxCreditCarryforwardsExpirationBeginningYear",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "vir_TemporaryEquityAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity additional shares authorized.",
        "label": "Temporary Equity Additional Shares Authorized",
        "terseLabel": "Convertible preferred stock, additional shares authorized"
       }
      }
     },
     "localname": "TemporaryEquityAdditionalSharesAuthorized",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "vir_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock classified as temporary equity issued during the period.",
        "label": "Temporary Equity Stock Issued During Period Shares New Issues",
        "terseLabel": "Issuance of convertible preferred stock, net of issuance cost (in Shares)",
        "verboseLabel": "Convertible preferred stock, shares sold"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "vir_TemporaryEquityTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of key terms, rights and preferences of convertible preferred stock.",
        "label": "Temporary Equity [Text Block]",
        "terseLabel": "Convertible Preferred Stock"
       }
      }
     },
     "localname": "TemporaryEquityTextBlock",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vir_TenantImprovementAllowanceAggregate": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount of tenant improvement allowance available.",
        "label": "Tenant Improvement Allowance Aggregate",
        "terseLabel": "Tenant improvement allowance"
       }
      }
     },
     "localname": "TenantImprovementAllowanceAggregate",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_ThirdClosingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third closing.",
        "label": "Third Closing [Member]",
        "terseLabel": "Third Closing"
       }
      }
     },
     "localname": "ThirdClosingMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_TomegaVaxIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TomegaVax, Inc.",
        "label": "Tomega Vax Inc [Member]",
        "terseLabel": "TomegaVax"
       }
      }
     },
     "localname": "TomegaVaxIncMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_TotalcollaborationRevenue": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsCollaborationCollaborationRevenueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Totalcollaboration revenue",
        "label": "Totalcollaboration revenue",
        "terseLabel": "Total collaboration revenue, net",
        "totalLabel": "Total collaboration revenue, net"
       }
      }
     },
     "localname": "TotalcollaborationRevenue",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsCollaborationCollaborationRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_TuberculosisTBGrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tuberculosis (\u201cTB\u201d) grant.",
        "label": "Tuberculosis T B Grant [Member]",
        "terseLabel": "Tuberculosis (\"TB\") Grant"
       }
      }
     },
     "localname": "TuberculosisTBGrantMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_TwoThousandAndTwentyGskAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand And Twenty GSK Agreement Member",
        "label": "Two Thousand And Twenty GSK Agreement Member",
        "terseLabel": "2020 GSK Agreement"
       }
      }
     },
     "localname": "TwoThousandAndTwentyGskAgreementMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_TwoThousandAndTwentyOneGSKAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 GSK Agreement [Member]",
        "label": "Two Thousand And Twenty One G S K Agreement [Member]",
        "terseLabel": "2021 GSK Agreement"
       }
      }
     },
     "localname": "TwoThousandAndTwentyOneGSKAgreementMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_TwoThousandAndTwentyOneGSKCollaborationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 GSK Collaboration [Member]",
        "label": "Two Thousand And Twenty One G S K Collaboration [Member]",
        "terseLabel": "2021 GSK Collaboration"
       }
      }
     },
     "localname": "TwoThousandAndTwentyOneGSKCollaborationMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and twenty one preliminary collaboration agreement and stock purchase agreement.",
        "label": "Two Thousand And Twenty One Preliminary Collaboration Agreement And Stock Purchase Agreement [Member]",
        "terseLabel": "2021 Preliminary Collaboration Agreement and Stock Purchase Agreement"
       }
      }
     },
     "localname": "TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and twenty preliminary collaboration agreement and stock purchase agreement.",
        "label": "Two Thousand And Twenty Preliminary Collaboration Agreement And Stock Purchase Agreement [Member]",
        "terseLabel": "2020 Preliminary Collaboration Agreement and Stock Purchase Agreement"
       }
      }
     },
     "localname": "TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_TwoThousandNineteenAndTwoThousandTwentyXencorAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Nineteen And Two Thousand Twenty Xencor Agreement [Member]",
        "label": "Two Thousand Nineteen And Two Thousand Twenty Xencor Agreement [Member]",
        "terseLabel": "2019 and 2020 Xencor Agreement member"
       }
      }
     },
     "localname": "TwoThousandNineteenAndTwoThousandTwentyXencorAgreementMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_TwoThousandNineteenEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand nineteen employee stock purchase plan.",
        "label": "Two Thousand Nineteen Employee Stock Purchase Plan [Member]",
        "terseLabel": "2019 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "TwoThousandNineteenEmployeeStockPurchasePlanMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureStockbasedAwardsSummaryOfEmployeesStockPurchasePlanDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_TwoThousandNineteenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand nineteen equity incentive plan.",
        "label": "Two Thousand Nineteen Equity Incentive Plan [Member]",
        "terseLabel": "2019 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandNineteenEquityIncentivePlanMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_TwoThousandNineteenXencorAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand nineteen xencor agreement.",
        "label": "Two Thousand Nineteen Xencor Agreement [Member]",
        "terseLabel": "2019 Xencor Agreement"
       }
      }
     },
     "localname": "TwoThousandNineteenXencorAgreementMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_TwoThousandSeventeenGrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand seventeen grant.",
        "label": "Two Thousand Seventeen Grant [Member]",
        "terseLabel": "2017 Grant"
       }
      }
     },
     "localname": "TwoThousandSeventeenGrantMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_TwoThousandSixteenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand sixteen equity incentive plan.",
        "label": "Two Thousand Sixteen Equity Incentive Plan [Member]",
        "terseLabel": "2016 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandSixteenEquityIncentivePlanMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand wenty Glaxo Wellcome UK Limited and Beecham S.A.",
        "label": "Two Thousand Twenty Glaxo Wellcome U K Limited And Beecham S A [Member]",
        "terseLabel": "2020 GSK"
       }
      }
     },
     "localname": "TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty one Glaxo Wellcome UK Limited and Beecham S.A.",
        "label": "Two Thousand Twenty One Glaxo Wellcome U K Limited And Beecham S A [Member]",
        "terseLabel": "2021 GSK"
       }
      }
     },
     "localname": "TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_TwoThousandTwentyOneStockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty one stock purchase agreement.",
        "label": "Two Thousand Twenty One Stock Purchase Agreement [Member]",
        "terseLabel": "2021 Stock Purchase Agreement"
       }
      }
     },
     "localname": "TwoThousandTwentyOneStockPurchaseAgreementMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_TwoThousandTwentyStockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty stock purchase agreement.",
        "label": "Two Thousand Twenty Stock Purchase Agreement [Member]",
        "terseLabel": "2020 Stock Purchase Agreement"
       }
      }
     },
     "localname": "TwoThousandTwentyStockPurchaseAgreementMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_TwoThousandTwentyXencorAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty xencor agreement.",
        "label": "Two Thousand Twenty Xencor Agreement [Member]",
        "terseLabel": "2020 Xencor Agreement"
       }
      }
     },
     "localname": "TwoThousandTwentyXencorAgreementMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_UnderlyingSharesPremiumReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underlying shares, Premium received",
        "label": "Underlying shares, Premium received",
        "terseLabel": "Underlying shares, Premium received"
       }
      }
     },
     "localname": "UnderlyingSharesPremiumReceived",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_UnrecognizedTaxBenefitsIfRecognizedWouldReduceEffectiveTaxRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized tax benefits, if recognized, would reduce effective tax rate",
        "label": "Unrecognized tax benefits, if recognized, would reduce effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIfRecognizedWouldReduceEffectiveTaxRate",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vir_UnusedFundsReceivedInAdvance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unused funds received in advance.",
        "label": "Unused Funds Received In Advance",
        "terseLabel": "Unused funds received in advance"
       }
      }
     },
     "localname": "UnusedFundsReceivedInAdvance",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_UpfrontFeePaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront fee paid.",
        "label": "Upfront Fee Paid",
        "terseLabel": "Upfront fee paid"
       }
      }
     },
     "localname": "UpfrontFeePaid",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_UpfrontPaymentReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront Payment Received.",
        "label": "Upfront Payment Receivable",
        "terseLabel": "Upfront payment received"
       }
      }
     },
     "localname": "UpfrontPaymentReceivable",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_UpfrontPaymentReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront Payment Received",
        "label": "Upfront Payment Received",
        "terseLabel": "Upfront payment received"
       }
      }
     },
     "localname": "UpfrontPaymentReceived",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_VaccinalAntibodyGrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vaccinal Antibody Grant [Member]",
        "label": "Vaccinal Antibody Grant [Member]",
        "terseLabel": "Vaccinal Antibody Grant [Member]"
       }
      }
     },
     "localname": "VaccinalAntibodyGrantMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_VaccineProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vaccine Program.",
        "label": "Vaccine Program [Member]",
        "terseLabel": "Vaccine Program"
       }
      }
     },
     "localname": "VaccineProgramMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_ValueOfCommonStockSharesIssuedForMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of common shares issued for milestone payment.",
        "label": "Value of common stock shares Issued for milestone payment",
        "terseLabel": "Value of common stock shares Issued for milestone payment"
       }
      }
     },
     "localname": "ValueOfCommonStockSharesIssuedForMilestonePayment",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_ValueOfSharesTransferredToCollaborator": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares transferred to collaborator under the terms of the collaboration agreement.",
        "label": "Value of shares transferred to collaborator"
       }
      }
     },
     "localname": "ValueOfSharesTransferredToCollaborator",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_ValueStockIssuedGrantAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total value of common stock issued in connection with the grant agreement.",
        "label": "Value Stock Issued Grant Agreement",
        "terseLabel": "Value of common stock issued in connection with the grant agreement"
       }
      }
     },
     "localname": "ValueStockIssuedGrantAgreement",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_Vir2218Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "VIR-2218.",
        "label": "VIR-2218 [Member]",
        "terseLabel": "Vir 2218"
       }
      }
     },
     "localname": "Vir2218Member",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_Vir2248Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vir 2248 [Member]",
        "label": "Vir 2248 [Member]",
        "terseLabel": "Vir 2248"
       }
      }
     },
     "localname": "Vir2248Member",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_Vir3434Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "VIR-3434 [Member]",
        "label": "VIR-3434 [Member]",
        "terseLabel": "VIR-3434"
       }
      }
     },
     "localname": "Vir3434Member",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_WarrantsToPurchaseCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants to purchase common stock.",
        "label": "Warrants To Purchase Common Stock [Member]",
        "terseLabel": "Warrants to Purchase Common Stock"
       }
      }
     },
     "localname": "WarrantsToPurchaseCommonStockMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Written notice period for licensed program, uncured material breach.",
        "label": "Written Notice Period For Licensed Program Uncured Material Breach",
        "terseLabel": "Written notice period for uncured material breach"
       }
      }
     },
     "localname": "WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vir_WrittenNoticePeriodForTerminationOfLicensedProgram": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Written notice period for termination of licensed program.",
        "label": "Written Notice Period For Termination Of Licensed Program",
        "terseLabel": "Written notice period for termination of licensed program"
       }
      }
     },
     "localname": "WrittenNoticePeriodForTerminationOfLicensedProgram",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vir_WrittenNoticePeriodToTerminateAgreementByCompany": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Written notice period to terminate agreement by company.",
        "label": "Written Notice Period to Terminate Agreement by Company",
        "terseLabel": "Written notice period to terminate agreement by company"
       }
      }
     },
     "localname": "WrittenNoticePeriodToTerminateAgreementByCompany",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vir_WrittenNoticePeriodToTerminateAgreementByCounterparty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Written notice period to terminate agreement by counterparty.",
        "label": "Written Notice Period to Terminate Agreement by Counterparty",
        "terseLabel": "Written notice period to terminate agreement by counterparty"
       }
      }
     },
     "localname": "WrittenNoticePeriodToTerminateAgreementByCounterparty",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vir_WrittenNoticePeriodToTerminateLicensedProgramForFailureToMakePayment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Written notice period to terminate licensed program for failure to make payment.",
        "label": "Written notice period to terminate licensed program for failure to make payment",
        "terseLabel": "Written notice period to terminate licensed program for failure to make payment"
       }
      }
     },
     "localname": "WrittenNoticePeriodToTerminateLicensedProgramForFailureToMakePayment",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vir_WrittenNoticePeriodToTerminateLicensedProgramForPaymentBreach": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Written Notice Period To Terminate Licensed Program For Payment Breach",
        "label": "Written Notice Period To Terminate Licensed Program For Payment Breach",
        "terseLabel": "Written notice period to terminate licensed program for payment breach"
       }
      }
     },
     "localname": "WrittenNoticePeriodToTerminateLicensedProgramForPaymentBreach",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vir_WrittenNoticePeriodToTerminateLicensedProgramForUncuredMaterialBreach": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Written notice period to terminate licensed program for uncured material breach.",
        "label": "Written notice period to terminate licensed program for uncured material breach"
       }
      }
     },
     "localname": "WrittenNoticePeriodToTerminateLicensedProgramForUncuredMaterialBreach",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenge": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Written notice period to terminate licensed program if the party challenges the validity or enforceability of the patent licensed.",
        "label": "Written Notice period to terminate licensed program if under challenge"
       }
      }
     },
     "localname": "WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenge",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vir_WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenges": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Written notice period to terminate licensed program if the party challenges the validity or enforceability of the patent licensed.",
        "label": "Written Notice period to terminate licensed program if under challenges"
       }
      }
     },
     "localname": "WrittenNoticePeriodToTerminateLicensedProgramIfUnderChallenges",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vir_WrittenNoticeToTerminateLicensedProgramIfExercise": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Written notice to terminate licensed program following the exercise of an option for such program.",
        "label": "Written notice to terminate licensed program if exercise"
       }
      }
     },
     "localname": "WrittenNoticeToTerminateLicensedProgramIfExercise",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vir_WrittenNoticeToTerminateLicensedProgramIfNotExercise": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Written notice to terminate licensed program if not exercise.",
        "label": "Written notice to terminate licensed program if not exercise",
        "terseLabel": "Written notice to terminate licensed program if not exercise"
       }
      }
     },
     "localname": "WrittenNoticeToTerminateLicensedProgramIfNotExercise",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vir_WuXiBiologicsLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "WuXi Biologics Limited.",
        "label": "Wu Xi Biologics Limited [Member]",
        "terseLabel": "WuXi Biologics"
       }
      }
     },
     "localname": "WuXiBiologicsLimitedMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "WuXi biologics and Samsung letter agreement assignments and master services agreements.",
        "label": "Wuxi Biologics And Samsung Letter Agreement Assignments And Master Services Agreements [Member]",
        "terseLabel": "WuXi Biologics MSA and Samsung MSA"
       }
      }
     },
     "localname": "WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_WuxiBiologicsLetterAgreementAssignmentAndMasterServiceAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Wuxi Biologics Letter Agreement Assignment And master Service Agreements Member",
        "label": "Wuxi Biologics Letter Agreement Assignment And master Service Agreements Member",
        "terseLabel": "Wuxi Biologics Letter Agreement Assignment And Master Service Agreements Member"
       }
      }
     },
     "localname": "WuxiBiologicsLetterAgreementAssignmentAndMasterServiceAgreementsMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/DisclosureManufacturingAndSupplyLetterAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_XencorAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Xencor Agreements.",
        "label": "Xencor Agreements [Member]",
        "verboseLabel": "Xencor Agreements"
       }
      }
     },
     "localname": "XencorAgreementsMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_XencorIncorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Xencor, incorporation member.",
        "label": "Xencor Incorporation [Member]",
        "terseLabel": "Xencor"
       }
      }
     },
     "localname": "XencorIncorporationMember",
     "nsuri": "http://www.vir.bio/20221231",
     "presentation": [
      "http://www.vir.bio/20221231/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    }
   },
   "unitCount": 11
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(27)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6412939&loc=d3e15145-114933",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=d3e29149-114947",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5227-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(4)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(3)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "https://asc.fasb.org/topic&trid=2303972",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116873149&loc=d3e923-111674",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=107671284&loc=SL5844817-113951",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515679&loc=d3e40733-113955",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "15",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=123589689&loc=d3e48542-113965",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "15",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=56949186&loc=d3e50579-113967",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Subparagraph": "b.",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123398031&loc=d3e60009-112784",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(f))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(h))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=66023616&loc=SL35737432-115832",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.1(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL34724391-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3444-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e689-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1828-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "44",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2062-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "48",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2538-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "48",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2538-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "51",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2574-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2597-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2600-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "54",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2603-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900988&loc=d3e1280-108306",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1(e))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=123583714&loc=SL75117360-209713",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL82887624-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL120267969-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(i)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=128310582&loc=SL108377954-173880",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123573877&loc=SL118137113-114923",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=118645555&loc=SL118645700-161420",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=118645555&loc=SL118645700-161420",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL77916155-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123386189&loc=SL77918607-209975",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121554622&loc=d3e15372-109273",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL6242262-115580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=127002003&loc=SL6242269-115581",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r704": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6829253&loc=SL6831962-166255",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r746": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r747": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r748": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r749": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r750": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r751": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r752": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r753": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r754": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r755": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "https://asc.fasb.org/topic&trid=2144416",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "https://asc.fasb.org/topic&trid=2122208",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905813&loc=d3e1205-110223",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r775": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r780": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117546-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r781": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r782": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r783": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r784": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r785": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r786": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r787": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r788": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r789": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r790": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=6397426&loc=d3e17499-108355",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r791": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r792": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=28183603&loc=d3e692-112598",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r793": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r794": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r795": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r796": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r797": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r798": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r799": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r800": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r801": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r802": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r803": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r804": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r805": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r806": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r807": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r808": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r809": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r810": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r811": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r812": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r813": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r814": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r815": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r816": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r817": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r818": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r819": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r820": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r821": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r822": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r823": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r824": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r825": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r826": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r827": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r828": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r829": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r830": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r831": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r832": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r833": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r834": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r835": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r836": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r837": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r838": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r839": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r840": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r841": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r842": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r843": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r844": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r845": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r846": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r847": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r848": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r849": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r850": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r851": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r852": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r853": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r854": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r855": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r856": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r857": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r858": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r859": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r860": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r861": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r862": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r863": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r864": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r865": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r866": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r867": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r868": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r869": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r870": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r871": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r872": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r873": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r874": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r875": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r876": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r877": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r878": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r879": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r880": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r881": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r882": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r883": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r884": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r885": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r886": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r887": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r888": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r889": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.C)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r890": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r891": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r892": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r893": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r894": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r895": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=127000608&loc=d3e9135-128495",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r896": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9212-128498",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r897": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9215-128498",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r898": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r899": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r900": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r901": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r902": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r903": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r904": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r905": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r906": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r907": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r908": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r909": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "712",
   "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r910": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r911": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r912": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r913": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r914": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r915": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r916": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r917": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r918": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r919": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "712",
   "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r920": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r921": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r922": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r923": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r924": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>115
<FILENAME>0000950170-23-005118-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-23-005118-xbrl.zip
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M6 %D80(A,+"5#NRA(7?4M)Z6#/'M(3&KNN=0.4](%A<=J_UJVZM$$\3A%>2
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M6II<P1D+;D4/Q)9"!3PF5 WJFX\9V,)P;/E_I _5_^$U%3#+FIV=F-69:FG
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M8AY>@1[=.)2%9PVE"0]!:^SC6EV+7$F6N.]5A7@LUAAQWAC)!WJ2&<,/:31
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ML5^<OR5* 96/%<ON,836'76.Z4N9$_FONOPJ#Z,)?WF+W6MGM<=L:U1>[7%
MH[DJEF"64<Q0S;P2X$(]F,] NW1<G=#]^AC918]]<DF$8Z !R_#9(V FT./<
MZBI T\9:Q3H</U"R)^["P""O,/^,7JP-E6.# _UM<4@<K%HT(Y1!)>2_Z]3#
M^2/0782ZP9'(/5S!*,/ '<4C@%HM\0[K$2!J=19Z6@HF.1,NIGX$N"5>-;_#
M4Y)P)._YSY[]W]RQMP_%_:SI_]1)HC)T[QX!SD^.-!7W?D1I^%\^"T:Y]:'\
M*#=?4V32%P_NX]]\]3/:B!\GR)*OT^2>!GM>H/H!R8#V$5!_,[+6? G2KI0
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MR[586G '[7" -F@-T96YP"(=M-2;L>\<\A:)H)72,!H3?SN""2#Z2=:HZJ[
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M>0ZK8?5\%;<Z4 *UQL9(21WW'*WG==_@U] - V)F +^_5SVBF^++TA2?76J
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M6*"#26(B=4)-W8=-X9:CYF#AC1IY!+6P5G+$*NS782J3V ?"X]MQ@6*S68\
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MZ-VL>ZO&Q"-?,\4\N['^]4L,S;<7J)3H !'F\23U>.%R>_,:#W3*;R>$_3@
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M:T%SJ@(_1IN$I,_S\@[I_^B!)<W]75[QK[)N] B(R79Z!!AF/P)&XB>4Y-F
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M,$;; [ +*; WCX=3_K3W<S6U7+6.@@1K6.VUHJ;T.,3X!"?498?M[F&Z^VJ
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M*44#:B/HD#_9)8"&C*#3-3?Y/VD.&"4HJKXJ^5$GI?(E?H&!"=2VD:3++I(
M(U%5^XO%Z-=3BTNC%]3?AKC10ZSC*B'4XZ6>MK<>-D0_@U?\MAQ]8W".*Y=M
MWH;WR[R:$B$Y]9B7K=*KJ;^4H_^,4-A,3*1B(>&AS1&<8O J6CO&%64P+?>A
MA1M?OXC//='#8L!G&A"RM**SH#TR=1JFP3%F7"W7<6(Y!AJJQ<]'RX[.LO$R
M885-HE)#J4,G8Q?KE1 E'LTW^X(HFURM:K9*E-\V3E_NBCA5X>#L*Q-M>TB
M*0UZ:BC+RM/G*U.C/&/,)\D7W*UP+D$'B<9=O@%-;N^(&LH)>?"K& [+I84P
M\OJB)*7:Z+X9$*,%#NV-5=DRS?R-68*((\V8=H!QRP/Q&E,(P]'P3<.$ASO?
MY([8[>F7]^:5['I84H)ZYO[IOQC_-S8!T=_5O(7@7(#2H-DY /L<T$-5>[]F
MU:*EEBBW]1PP,8]YU'NY"Q98_/NQ+RX>AEGC3OI;S'KM;Z7B_THCEN\%3I#2
M_JT8KO-?W@_[I2H]*VLTT47<!M#^>^7KTE^+TJ<E71:N_VLE=7^6?_\_7OX]
M7W=%?HN@_L,C%S&FW2;:'Z"O>B4/9'HQK9BR@5XED9NYT/6$E&5'&_G<%3?^
M;A").<O+,LW;R6+*>A%*.KVE'TI/$G36\95CX$K<UQA/TTP(PH=W8'&7_\&<
M5P/TRI3(L1K:;APS:Q0JDW6=P'X\[PD>A^YU%W5R0P@FY6="&)X12Z!U.O!:
MFT/[[N0+=B\92),8O'N3M5P_5F]NM!I6Y'&"<2A;1\)Q,B:=H!K+#_'G:[C2
MW?UE@>;58*Z\V$FMQ['X\?&)W( 6&^G2V'7OYW$)_2UVL)>C5E01<JXG7>.O
M00TK>B3J%7D,ZS>: 1RA6()7SVS()7LMBA(WG@\PAMHIK.TP("*R_-=3T%"B
MG;[RQ;]&XO$G1=X12@]<MKRKBMPQ7?NO )4B\.M=H&"3+5@0"S:S;A]ZP-XY
M^Y[[@*Y!WK8#H]D3!FSL MZX_3#.;-J:H1AZ\[K2R$[XY^!\SUM-/4'#*0G-
M)G>4_;^'N3(.VI?N^KT(>]#%+])&JRC 0#<8;C&38-__K*)W:$-9$4>>U%Q.
M)?&DI ER8Z5M;K::]:(7YM=/@=FT#%)Z#]>BSP'/;H8)@#YLQJM(Q)7R)LC8
M6<@-V,^76Y0%:21UX">7^(4DH_W6;3R#.,FXC?O0'YL%/.-Y?9X.M1%G,;^^
M&^'4PM4-4PMLDI$HD/)<-!Y(GTS4$?EL4B>KOS-9)7S9Y1QYW@;$",OCZ#B.
MU,:SK*>=(BQ[ZML+I29]:!4RE9R8L-:(7F.\R.K7MFB*%B#54,K'=\'Q!ISN
MWDJ0;!Z9EQ4!@KT2(G[Z:%&3>IA:CW.(B6Q5].@Z>Y+BCFGX8QB:%B$H%KAB
M0'LQ7"^ [MZ[OP)KCHG";\NB\AI>1Y R]S.< V &!B\&5N^H]6>4^0@4M(,I
MG($)5@K>D6I"19\-K(DSX):BCQSAAC0E9J(I'K9BN%L8TE0W$&U921MGW^/7
M>=_<:)SG_ P]9M;,C0B6>;2G4MGQIP1;% 0. K,0N_G[L]1VADTL/0IY/"0P
MJE:28U_WW%R5:#<OGOAK'_8K?+1/09HV/0ODFIAVJ(J%?:\.V8^A%LO1)^NM
MV,1$A=,G6E;Z=MV!C^BV17@MZ<CU.QX7AC[.7;R!=NNK LNJE_;!@@\<WZKV
M0CZ$)=,NYGR&=>32$:MG9"POD4Y.B>AE('BVKL]K-O8- WG:31&%%R'=:&[W
MBI3.H-F0"WG5)SMZESLG.<*XW062P4)W(\5-Z-]K!VU#71<OK&D-^DOF_"]H
MU(D7TUMX3@?F8G)+YO.4]JCWOYCMK8O/ 7[G@$4"PW!#5QZ48>#@'&1]^QQ
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M,L30NZOH9?5(-$E<Q_[+>]2SZ=<U$4I J2&'=3YJ&+-6^1OJ$V<=*;TBKO;
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M>)]>5U'/G1>/M*ZBPZ UB='CFYJ729AJDL(BIJOO="KP]#;[V*;:W.!JP3D
M<&ST&XOICHU=DOX6%^'>Q%\+)74'$ JC,OORK:OR-,NG1N.LKC!=,_B&3W&[
M%2=)7>5$0.^AS=(YX"H\5MSL&EY=U=HAO?+Z/U3C7HKS%K;+&N0#M"\KMX:U
M-^Q/HQ*)Z*(2UUQF.5Y<P\W3 CB5D7A^$H,DX'%4^V 2DS8ES*W57$,_ND$.
M<0;U+F\B@SIK.M;J)(=O+KK6&_?''\P%>'!38/?L=8LZ(SQAJ4M<1QQ91@N"
M)G=SX!W5H83NJ/ P7:/1,8..S7/ &Z:X?%DAR8Z,JOJ&8__?/*8A9M_.2S6
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MU/:ZWO@C6-09XB?W7$/I/QM5:E!D!D OHO^5,&N[J(2+)Y?G#7Z,&ZLGB,K
MJ<,ZS0&K:'\P)J,R)^OAO#GFZ 3U2QSO-4^(GO[\&6J2-[E1.*'W(G 5I=SO
M2_;DBC*A?-?KFVM0'\,HUS^&-J:08%V"B@$74I#X[ >J6R.MIR7!!RUB*X_Q
MIFY;,W\Y;8A%O].@+U#?&(H.T;$;_,#$4M$\AN<V=;PNQ%"_1;KE^#R*@N-
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M+#UYZJ>W8<(('TA4,DR)0AC_PJSRB'UM#T_(CC.56()US9DQ..RRLN"]LK*
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MNJ_WM:@=*@ZC51EDH#,\66Y R$KE+(:%8'QG7CU&!)4:U."QX1DY&N303DT
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M_:;NJKQ_[>*=8K.JBBE8G]#"KN(RA&Y (,1Q=9R:8ZF"6>F%DUTQ5]0:7 4
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M''\SK 3_'4HBP"A;=E@D E$G(QW>"P/E*@"(_>OCU"3'7?/5) -4'!.-J3-
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MI_J$;Z@Q\<%#>C!@B5/K1M(:1^;4A*2K<95X)ON8IW[G=A7_0W5&?Q)4$7\
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MB\P-9CEJ=DP<]V*ASK>&>3_1BI9?TLTR]9PXA4BWL73LR]4YK6VF'.1PX6
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MZ[]TAM2(_MTAPW]KN#**(X;63PR=.$M%L<]K2,DQ*F1LO,G4*DW?^_J#*%K
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M[MU_@/M%BI\_2NC!2=$;Y7E2:$O=5[-TQC=[U8F?][9M3JYIN>.H%HF'I=W
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M?FJJ>[PN!^?5L18C_R$)9JXRW&#@>W[)</B;TH*S(]J?$V5^%%[IO/08ZQ5
M>]\.7.E@4>2G=]U?%AR0A?Y&R-]V0C6V7V*H$ &T>VW@@CX=_E9,NM]THV;:
M3RC-%_Z47"WGO"WUUU+^MA.1RX?R1TS"^Q2P%MUE0<K?2/F;3A1P)P=GZ2.
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MN">W()WDP"J2,J;9N]QF3<#P-87X)N5]Q_,:FQ;=G[V@/P*H?KH1$L:2=^F
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MN3!\NPN[#03]$U[;K;9^!#"5KKBPB@"V!_^IMW;_A%L9P]'^;L:.PK>MQQ$
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MT6);JMQ>E;EYT9D2L-UR>76+N8W4-XT_J81GU5&H$M\W056(2!.J]JG@VSY
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MBVL<,^?(P>>,"GXLC:VZOZSZOLEO+H( DFAB$8!'* +P-I,7&U/K_)MJ\MU
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M]5K#>,IF9B71<H+>'<Y1VN3D;B=7@6$S[V6<82ZHT?ZWIEE0R%9)\TV;Q)&
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M];Y ,RNV+:FJQH"D77V6S+8I)&_>]P[U83Z\C<?&Y.0",AM-,61$[SY7;IG
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M9Y^<AC18$H'O%>:UQH8$H@>0P#Z>U^+I520&HMX  6E2S6-\4K'C,+=7=F6
M!%Y&7L4%(H&@C%^-P(Z9=^O5$M5YN^&J$ILA]>Z^F[7!>6##D(@F".PLIC0
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M\$_Q2\1,G(RL7T;##EC9GU(WL/,A@4U%[;/L"P_;8=408@%I$/?YP\GON)S
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M0OA1\>OCN#<<I]82.$*'2A88=IE[B=S"-/MD.?D;1.]S _IZP?[^F9[:<ET
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MDZH%&<ZVT&NLTA;4VB+X6W229%L1<CG(\F1@T*X#L=#32?$ MBQH*4:XE,'
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MHO2.1GT"3Y>1G9HJ$+TOC'FD@1HG_;*5TL07?\@=(C=Y#GJUI!C3^RF(Q.*
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M'3)H^U+'DOP,NH+R\!ID,$IP\W"HUZ#CKO&ZYGOF,F[XB8R0PZ$V>S]*4.%
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MW'O8G8@G1I^P6BF7PE<Z[8;$_<T\,B5[]'61R:],(YRKK=*BI0;CN0J,"B@
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M5<I!>]VDG>YX2C8A.&J)Z_<+K=6*7HCUO.$Y3FJO=!*;M>J<!E5W8WJVF^R
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M@ML1E\=-;#GQJXU=P>&8TB,MNZ'RH16FLKJU1!.!2=M093$L3.D9H0B8NOE
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MM3SV))J]<&-5^)N=[\)AL0^OD?@Q7+G>S @E&J8%+UG9<-1S,9%3R_[*[0M
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MOC=6^5BOFA_TLL-UX6;C8'? :&32Q5W[4EW.F<_L:V"&L9;1@URM1V?Z?5]
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M?IKTAQN2C><7#$0C]1LRP]&8CEDUO$/$F395O9(;0KL-[MIBT;3XCDFPZ8&
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M_I':7*.9ZJ!H$$>^&OSF0?7[%DTX5?!ILH^PK#2T_"!G$]YG# :L%AF3G/X
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M$^4) T(5*]PQ#\:L\FC]3LIPM"TJA'B^X#-5"AKMR+MT0U;S/JB1DD"Q:!_
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M&\C.\)G\ARWVNMZR3>OC@:*P80=.IQLWXK.C^N?+=OS6\%,6I(=SKWF6>6!
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MC 4YC\-K>S;(PPT!P!(\A]8SD_T\&_^ $\NH#]9G?J0%S@%=CDP@+?=RSL-
M /#:R_FV3\8&QAU@KVE]&Z+F$J8UG5<1O%G4L!1?=.SZLEI0EI"%(Z?]I?:
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M/_$% _^I[WV%?85]A7V%_:_#'L3(2/G9,G$@<</OH;&>+F2!9HL7$$!@/P)
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M1@#U]1=FPB7":[!..!P!'&6!C.=!T7NZR\*6&$NW&1# _\>&?#SQ\,(( 8!
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M!<O"!SM[P:>^HW0(@'NVBX'1"8[5"W-# .V@"U?A.1($D%%_[HL 1E,N=+M
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M_Z3\$= @$2(CPD*2!N+,8AY+FN*[\FNGS9BNI SQ?.[V.]7C&J'_08@LTU'
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M!1N7;U,#(6LS9]+R\Q<@9BZ7+.J!%0; (R-5?E[0WR5&F3@L_H0]#:/+L(F
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MY-GCSI&<70/YKB;@>0XZAP.!TZUPCJV3J0GC\;)R*"S>OU.G!9[\6BB!\?D
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M@\(S>$OV'1RF"]PK8(_A#;SQO&]*EN (\$9J6RS_B=31<X'6_=Z_BCT\HWD
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MQ^ST,>5O;]G#HB'M)7_R*SF)1N3XNQ@I/N*LQK3PF@E2"QIH>N71>8D'7CP
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ML=&%X4?GSNQFM/)+#.L[3& Q-7''KGFT3\IED84U;4D[!]G>\QPC&KHA978
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MH,L3WB 27A$R#.V@V'_A.("$'\J*A>&LN0LJJV4/QNXB/7:SMG8\#@J_PV*
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M>0PUCY/@]5K/!VRNE+=G,=Y!Z,FJ&RH"%\(#AIXU"L1W"B+-_/Z?^Z>[Q'O
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M][O;VM*NN!0<.:Q/=VGVDIO=!LR5J4;S37:@H]AEG4O%(;/P592S6>,J&=<
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M95U R-?[\$:S_I9C/$6E/*@\.FO/'2,3R)&X]X7P] L&OB&6)2Z./<)<%>U
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MR-#I,2?)$_ +9PKI0!44*P)29&.+<#T2MS *01F[?$7+$!Q 8:,?Y42 C1\
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M14@"R!"_<,%(^<<O:.;I\<_Z@)*5@)8UM9'WGEUA60RHQBW:C7.JD3$D!3L
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M4, D_.]+<QOSO"8V=7DW^JUXZXX+,.'C%ZT.*^[6T&4'B8"H_Z(/S&"I$3M
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MX?%A*0S>2Z@SJ;OMH$:PER*E9Z:9: V^;BUD7?@KK24%(%+V(_QHD(TRE$@
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M$D*G(0NW@)8$S+P"4Y0;W!H_29C-BL.L2@[\F"X.;CLF2?)/D-;%&3-[F]*
M9ZGG%BB[F]?; V-Y[DYGS9XMC);TXY(PIP=8VVP)9+0D&F+7;(1WLU=:WI6P
MJ;.KSH].QS4-A'DP J_SUV6!752OZ[P%_#(01$S.)=V:W#G1 \W+B6.;#[$B
MOW%1-Y:"EKS652X<8>;)7"C8'H4WH2C:6OS(<>K@IE!=>S]'D]?[B@CM.M$P
MP'KW9):$=;B%:).GN2G?OS&6UCO+VT"]QYPYK-[8)=C+0%=Z21P2;^\7T3!9
M3)?DZKFTG-5C<5KSO!5?I[^[=[>6KPT2'&R_(S_?F6MVJ/KNPEV=].53[O(>
MXK?G[N2CXD-YL,#.+FFH@Q;WW0R*ZX:K7IU^'9>M^0&[<01Q?Z8!9W,RKZ=P
MOM/]65:B7:!5=%7+P2$*YV<N+TW864>I%6KQ@T8^5W.+I(V(MT'AC'9<(,HX
M)V?T':A4KVB\Y:@NM8%'=C0,Q"NEP"W48V$?ZN5V\[AA4<#O@]CQY=9^4;^]
M&E\<C=BECWY(@ZI/\CZ!K5AB=49]9W6J;<Y7D(,E?7R<<+7_5VX+_$.>IAT^
M.5]S+D*T'L9\VK7NTHJ/O;,Q"A'3QE-@]3(C/,D)6MW$MM=DPPR%>>YD[;ER
MJ:NR@C^F3SH-AW@-DFJNN YW#LGW-X6%,51T<^6$]7Y6NQ=\0#1C4HM]4:C)
M>"(741N6UI,.2S?D:DGCC-9IC]0/=";N1J(?=\3D2\' "J(9);7-#VXH!7B1
M-SN-%=-9.E*[[N'XMW5G,XPG'U^9-_PLLK>;<O. B5>K%!&&S>2U\7X=-EC4
MKH$&SAZ2"S I)D9OIQ+'<S#0$;@29M3H4S42,ZP+X/BPG\F.O"BPT-B^S'W&
M!W4^72JK/!0JW26T@3W":Z$W6V%Q#RI(T=LWG]2W,[2\K/=%8?CID"ZD <\;
MQQN<^[JILBXBTW<;1\OK,,OGRX6/MG?^A^W4[[F[F[1$B?QE_;> SG4K(OS+
MCRV:4\E;*B^=ZHL*)\G\>[N;5;6S-L&KH_Y(?BEA&=F)%,2F1A$D(6Y_-;"@
M;<O6B>ZU0R16T*-W.@(<)Y@;MP L.KKF>5TK222AYS9<3)OPA]A7VWS^+]E(
ME)JJD+LFTA?:2VWX">/?'&;&27YFK>81^;^U,:<D^>1?M*9$:*+DA.E[Z*"1
M*?>,$X3IC,'P(^DOBR^'EW44ZK[9:*O/8V&=O>V776ZL>1963&E<YSO)Q[CB
MLOQ^U2'TEYYX&S<>3_\KNC&O7@W[_MQE]_3+F2M&;\3)GTFVCF^ P4Q8A\2!
M'C$\;T5)O3@(_?$3ISF.ZW:_[!##BR 7,N)("V!*[CG= F:]C2_?:3M'W92X
MS$^-UO)]?NGV\?M@99F5XT>K*CCC,W_5<#ZT1O?+J<2DP,2U.9P/0[2-/;7[
M\\F;O)449BANA!),5*^==?(S2:,^/A:U=K1V)DRPYE8@MZUG0V8ZP=S\@%;"
M\F*9 $.RZ7%;@9:./GTI&NIJ[2JTE!=7QIXP*#, ?>%]60LH,V>8\>G=W*%_
M]+<C0]T;S+5:3&H#"#:1-M@U4RW&OZX9.)0\^5'5.7Y#-_YXQ )"*39^"T!$
M;0AK3^UJ('AT"U"4\7\Y)C+J6AHG1E@;MMX#/TM_#*E"P7T$JN9Y;&WY:FVV
M:)R6?0<M'(OPL[KCWXP7I2,'NQZ,/F8[QMZB.BUI!-ZZDHSC<R-/XDGSUFHC
M'UP=41$HDE==-L6T;4Q/4<OJ)/T9_&&>*:8?A>%EEH'\>/0?T>/H6P#X*]^,
M6844G:^PH,AJ,N+] D3X;JG^JOP64.L=@[7X8^?EI=^YXF\=Y[]1S/Q(OQ<Y
M2A6W@!?<3H?>IW=U_8%P QQ_OP)X4)GD;V#TQ_^+O;>,J[I;UT8GH2 -TJU,
M.I24#I%)27<K(-T=$H*B( T3I+M+NKN[)S#I;I!N.+C6([#6?O;9:[_G]WX[
M'R8?&/\QQCWJ'G5=UZ"XX_^DI?[!1=^=,.#\;8KWYBF/H#'HMY<?X!C$W&.B
M[\#X='_H.MF][%J$HK*@Y;;Y!V>,T$^M_C^.KW5SA^_0T/<'C+])6/=T'9,J
MML#$@.Z IKC[*^EG "_$#CX11FR8EO%&ULV7I_8#5Y'2%:9YT_YNNCKNJC>
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M<H:."S1$(",H@5[D]JZY-Q$LOU:+=3WU)J3*CUY\V,:E]O&B;<1P*:==/UH
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M06%!I!CY@W=F:_.WZ4@]#U&S\:2R>@S0DWK&82JG.B+WKK)81$].Q&NE%R=
M!!<YADV9'5N5R6SP[X*4B( JLY5";=Q!>1K[NK?V&-\ /OH)WUK9^?W:.>-J
MG^;^O[\[,-6+LY6$DXZ4/Z&_F^1'_6JTQ^SSH+_"?A?\/M*?4,^_3U*&]N,-
M@(?:8;IBVW\E-3M>W<-H>[SZ8^PBL2&[WO\^$YP!<:)G??@8UJ_) ]F%8FD
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MJD+Z@<?$A)LYO0O/R;X3?JN<3R^_ 8@RN 1%DKM+G1%FAE'(MZN-I-4%0FX
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MJ_&&DM\WC3)TAS4:^<>7J/-52#:6_B[UM;K&&X"4Q][L=2W9NQM >OWI[@U
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M\&#5&.^E<UO6YJM6MC>A4UR6UP#.3G&V=J;Z3.M,3M(_!L-[6M4Z9S%F2/[
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MDP(RHI!Y:[!;[DZ"!M^5([>Q;K9"$-UX0<8$8T!]!-H*-<-,>IZ<B$NX45,
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MP(<Z:LW.H7R,-ILCQFV9+?T%-^U[^>P--$0Z\4;XP%6NG&'-1LOR_GC.<OV
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M7JNY_&J&*DY+^XJ-!F&Z*0GMVG_7<-2U&61 D$<PD%=8TGC[JS$B#K()\L/
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M$!A?W35*# YVX\YGH>;1:BIYG,T=+M68BTU4DD<F\\#EN5*H^[W<CDKX_'3
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M8-NU+93WXS8!3= W@H@VS6)"J=DP!#:]N+9]$D:&?.NT#S3XD+E4BC% 2(+
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MRLO 5@)G\=9GIXR=[GS/G%=J+O?^;U[S'LCSEJ,%.=K0?#Q@9\6Z0;_/-7B
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MQ"'CSM(];@@"9?+C1_\&4$L#!!0    ( +6"7%8A(3M!8CP  &)/   2
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MY,.D96;>J-_,"!>KB(+5&D@B3#4]:HI(SY/XOICC&T@_3I!L#B1%0KXYG?C
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MW(Q9GNDQ9V8\_V,,0M$]&R0K.[_XU'#.S'L]8YM&,$E:]YVQ#OQ3F@;64#+
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M(TP'+R6?_G+/<5E\?\IF^-"D=9KL]72QRR(&^X_M>"5W@8$))8V?1+;O5*?
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MOLM]9N/&\P/50*E0..^5:?I0V)N]SK6/1K0'A"F%^V[)RI6#; Z<WVG)$^"
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M7@XW_DI1XBH]1@WN&!(I[7R#]^KS*G7X _-U[PI3$_(WQESFO*"%<$"] AS
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M8@K#A(!NX.,%B^-BWJ,+.$!1M%ET#30O*2+%O92>1_6M-$9,V9K,KHNW??F
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MQ2>P#S=@&!+3U8.MHA^&P0&2/D X "'NCAEQ>[X$N+V'=WO%?.N:=W?_' X
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MK+HW<1/E1OI3?$6C;%I$E46Z@VZ^ \6YG)S( ;%.N._PR*/B&\ ,4UI/^LT
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M5 '[/>9^C?X\&3O)?]/T]YQS#!%!))44G!/AA@6N<L*#)+$< C)..G^:(IG
M\*=>0.CMV>Z5-LXI]93VR)8ZYYW=C<AHCAQO:^QETM3 EZQ>,ALT6J:(K5C*
M0+NB3]1]PXY42MX [&WC%BJA-9HW'!\D1:)+4PT'&GDY>HV;ZG:(@]'1OB2Q
MGA^O9EU'QA#.XIW:X%N_KL6F.,A3E>7O?*KA$SXR-XC+]QE9B^HI?BJY4!W?
M8/B#VVSJB=R;E8GF\"O6KW^KRN?RC#XH9T=/)4A?,C3+^[DN HKO]B1^D8P6
MC3V:[7#$6^N\F2T] H>YC FERSMCW0,'+1X\1$63&H)U+(D)]K[)XVO18 "K
M[ ,>W%  /,%7QX8.#W_Q_G'SK\\]E;XKT^4A-%@?&R85>C<NRWM-;NK^+Y55
MD?W0IX!#<?JMH0*WNFE])K9[^B=\N?;V$*-C7'CQMYIO\XM"9\U?IM2!Y@3B
M9(CN=[4?>AY#B+)?">JD=>$=T*Q)KT /E.:-N?;'9/-DFN,Y &"4NDA?G05P
M"3+>P7B60*M6U?5V<=!*"1!C"(^QJ4;NUJS K^&-VE'9C4GRTAR:BTG77_3I
M0=@]*R:X-UY^6#\&.$TC(#;0CD=0AVQ_=!&!15"Q[K<'6"H82K4UA5W2:&]*
MV-)A-]54VCN4@ 4!UD'@"P!>! H+83XW"6#LXB-K2E!FP&RR<^4_\6X%I\L4
M@0R$=\43EC$OX>$7@!J9O**_;<+3:+Y;&5/<L;%TKZS=['VI!SWC*,F%*E3=
M#L17V7>DL5[0C\8*^S$MXM#O 9?-V\K]S'3-9DDT.QQU]Y/WJ*#VF<F$>:W"
MR8[:^9L =+>U&-ZF+.!0#3L53UF77FS6PY/SN-2+\>:^;5PZ:P P'A#Z"P7'
MWQOI!#&$,%1B#P/J>MT97S:PI>HR R77W3N> C2MNAE[&ZTL2+23F!,#(CS$
M#LW(L"Q*//GHOF110L/ZX4F/:2]WT;671]*G:-D="Y0.<&;N F".]7]' +OQ
MU:!FCZTDZ>^J@I6DZ18#$_N,9KXM%NIQ)S"UTN%$,&F]0$Z"//[WZO:VE45/
MSM4FS$25B^S98HO^XI"7^SHM]6=6;<;Z[[F,#1> E0Q0?0NTOF)GITW$>;5Z
MXG:.EO7<LO]>V.U[I^V]+=.XI\0&@I7;N76($=X!*WGHA@]]7ESX%$]AAM(&
M/:$SAJY$<B$FZW<2&2..]>B7 Z"FF*'NNI,23Z[<1O<>-0[0#GRXA9Q$EWRN
M3%#'U/>.,!!T\#I?EVU<,Y:R/5>)9B(_%T4,OSXJ."3<-P]3IL;97+)]Q+/4
M]NLMGEA%4PMQJHZ*7U_Q'APOJYIFE1+MWP;*/<>OM^7@:2X5 S_>Y%P5+][=
MM =#Z024A0@ ,TO*.N:FZ"+D(8KA=LC"$/[+,+_4%K!VN\LX%UX9^1@BG.]J
M/.=7=G\IX(/Q.'^"[N.G.8[1?SB2[R4-GO:!_%IB5XIV4K#<*,;W4&<=17?A
MGAQPE.B*F[9O08SBHMU PBN9J+=P&8V'L):[Y$<5*_X$UOR5_5U*+*>21"X^
M@ZVU@8G;W]?7XE,D11YRO*+,  LFL#&O%$6H"-5'6'0O.R<MK9A96OTL+%OY
M4K<8YYG=\0X8'O+K7#$D>!(BL7D!8"!QN5PJ75$!2\Q>1I-'89GK=8W8(BEM
MGC<_"](58Y+[E(4'VQW!O&[PZK0()3O,=#><S!?.'E!CC U=["D8N>;NYLM2
M[U7KY7%(_DJX>'<J3&4I$]>M -JM+W8Q@<B,P<)M,<NX6@53T77)4SJA#(AU
MUD9%4-FE'*&LQ+/_V)[S@+NAYBTB)L#J80WJX)J">1S+@N;28B+>9 C( J$+
M&# E-A)LRRHBRLM\SO<C]IV_WCEU%Y*YVNYD'2QCTKZX;<F0=RX>\%4/+P"+
MD JVH5F>QZ<"N1%_ZK"J<.<;HG_B+(1RU*@K@@!$"F(N=.7[,@W4<9]C%@^U
MQK)XN;$;+WL$.WN-@#T>52;B?UJ5,HZUPE;]>ZS$T4(??"X U_%>6%]Z(<.H
M7Q1_U1X?[]O$V0 O $[B?"% XC>$E8X)#,4&_QJ [,1=-]-;_>[N$)QJ(:4M
M^N=<]0T3TF4^(3*#^.!RC!F&4#?@*<^!?YOH)V%1M1< F>#8WKJI0<?=D%FZ
M]R'5)MFSJ#"5S^^- Y_6J;UX2)PZ>SEI/GO[D*6OV>\]U=*776-GLC"X[%S6
M4*TAS6F\MPU'BW4;%=ZAS'5P&SCC?ON+!(XSEY[C>$9W[#0CO.)+NB'3TP>!
M6Z%;_<V/W^0."8!O4Z-OYWPY,]E(B[ ==<"#Z>/WNX#,VFA1OP-#NQ^Z#ZYH
MI&K8.W2W^R?.M<[WP($$-<SCYV,^;!,M0F!?%P=2LEB!&.=DE,&5+QWDY!^:
M&\KD.263M,XN[ZPU/^M7+D-Y/K2=X3Z<*XH<G \91Y I$X77=[EQ-5C_[E!P
MEX))Q%$HE<ZBDUY3<U-#B^3IC:OV+]$NBQ'#&FZ"A[CJ4.^N#)ZS]>1OQ*:I
M/6TP:7CL37T"IQD=,CGGB])ZPB/EKWNA+\!Q6F4"FEQA_AYR/6SU[G?/J\7T
M**O&)TQ^09D@@B&JV-:T\/RVJM$C(G4OUZ ,VZ;'&+%:ZG5_M79R/0?G::AZ
ML GR A"= >N 43FCM:IB]:?%BV*UJQ,>^?T2*$8^4DC)_Q2R"--P-Y(%[5.G
MMMH#.T/I%2R*/@%*^P<;:=N#MVW$;2 3<!:?!B7[9)<V!L.5F;'@DOR-T[O7
M;/M!\HLCM@G"+?C@\V?+ >V]-&Z>W^9F9Y&%W-N;U?Z:=^=K&3QK2YA'E._B
MWLC#'"3[/(P?"MRUS<)V''U=PNGT-4G9=LQUU<E5?#YJ3R!)X[NPFC_S[,>.
M%J6?G67_X?ST]+?:6[O3IKCK:@37;FA=6Y50-SU#KS:!WQ-<NDWS333+S1O7
MH"U"Q;CP:SZG=8N8R>@,*_HSD=%/%1PM8/1WF'L-MKRI)YLI<'@M*?!F*/9$
MBW0<XO\MY 56?6T_@;N;IG#;7#/:M\]G46%,X_-5;\;[!7;O7R:/F.\4$(L)
M=D4$P3;L6FI:7L7[(\2I;=K@N645\D!ED+<]4&O]<W'LG,!FWD/&]'2_"X#$
M"T1W>&6.G<@BC]V-Z:$V06))B&VP;%QY+:_L8ROQ#NR3P\7ET^:LEGMBDS.>
M62#/N0+\AW,K?&Q7$RS2O73WB/>.;PECK;;WC]-"/K0?A9;=,(VUQ@YC$-RQ
M:PZH/6\IW2WB?V\F*.&8PB0"IUK5-\1-O_3Z^J.<+^6.R\@TMF4Z;LM)T;%A
MK;*XY!YX\A9#$+ B" .-A/*UF/B&%OS-8<60XNE[\PKT2JQ&(&,I[\96>EGK
MZGT["OL'UC4GYI?4T?=+%4ZHOIY[_*T7Z>=6U!+*.^D)W/C9'NN_S*K":(%/
MUD]8FEI-?2SBUWB052*);<[RM";#-*-EXPB,RAO1QM.:R6K8NN8O NF%LI3&
MDI']&V!"C7+P[YV9I\::,R"79#N/98[H1O_-FTA7GWI)M1L.3)9O..ZW!V2<
M/K:^S!;1PVE</5.90I$FVF.J^BYOTZA?-(/35,STUTZ4M3:MJ'OVY\4-,) 2
MILWZ-O::]TNS3NG2:O(9KST/*E)I/XQ@7\-K[(,?;W*4R]0-S6=ZO V*B5@Z
M'TY,L7?A4.&Y1]TO]]=MHU48!\=J=O._SF$<.^+V(PVY&QHFZQ_Z7>?YUH?C
MV5,"9B)<2+W^)R=P^F,8IVO_U&' U]V*CUK>/+8FMG1962&?O1B_G AF+UI(
M?E[L9"7Y_)GX^GZ3/VGUR3@P5;(+%+9MH^ *O\QT\=!5&TN"&DSOMQTFM/'P
M9ES:N6ZW(LY#:?=\=G/3"$+SEPO><P&8F^^V%IHH.PJ.E^TLKY-YQ@=6X*0M
MS?PYO+#:MYYVSQ(Y\5(_XS[MOW_ \]_!<!295SC$G\M(2RP'N=-3XQZU8+HA
M-ZO;)MI712;MQLO8J/37%*G^_('M9:R'0"^GGOL8^(<V%3QTM1R6M\TGCI6I
M_;'+D($%5N:_VOM414[^]F_P]  <X[F>7>:J L#K@E>;HXZ(0>@>/^QL\WL_
M>;.WSQ5-DB\ '=(K$Z"5+%#=\07@'4E"W:UTVX9Y5:>,O<?D:<_T/2XBW-]!
M-'D<'S1*O=TS$K4KZA3!'2VRNV=/]C5!6]5'J(KS%^AICI7KTMM=W@D#*0%Q
MEN>R=@N^%1T7 &#(,WP*=A\%[X7=6-!&X4-T5ULU=YK8RL#%YAWNN3UK>=>J
M^CH?/1SIYRX+KN]>G@/U+E?6=X,C+@"L+4:^H9Z%>'37;L&V<4\-1XLD(8DD
MT:MXDLLX]4OI<5$/>+WUN-0U4NQ)25@HO7DJ=*$6WIGU'A1ELA&Y$WBN8H$?
MP=U%3+<)!!R:8XZ78Z6]2[G['&]4AUDQD37J];\DC_-E/:/^:A$;RC9DEUTN
MNAI^76LC/8V<_EB*K/CJ3SOB'B1%*"AB8F\A])0O1?;?/W O"K#8C24N>+_H
M6W:(GGL6^,I)"*'K9[I\_[ &+)U6MIGLRA4Z0<<?-\1\JY+$I$F5G12KOYCN
MK>"MG[0>!U\(^7 ><-GP^E*@L":'/5A^J<*W0EI)R[#EYE@E+TGZ$-D5&%\7
MUNEGQK?6'X,9'O#[JX^2UP9GJ9VIA99JVUWA^-LF"4K\V B;ZS;X =VI'8)N
M0*=INOWA5TLVGD_4F'>ZV/8N=^I+H?:AS(=7 ]4[C'K%J]Y4?ZG+*@J];/^B
MG;7/YQ[^#<@D3T(].*J4,SW7;I9UGT0HC2!S!*="#.:4RY/!G@YY73?-LJDF
M$^5++P"Q*F0U]5@-GT4'G_,;5P/RMX:UD7GKK2.HY^G>J(JPZ\B"$I<:EP>$
M> 862U+(246TTD-LL#[\<JZRG?#9[FVK3S?ZEB0YP#XHB>0UX=Q<:GC(TV:D
M?)8!5^\@Z$=VORZ*SS>R3:%TTOV[86>":N\(UC7+B]@V3NH]U4LG2UZ39-1'
M3ETR=;=Z#%5&U693^#$BI_;FK> %=G9RZG<=)*/,<]NZ#]A]I(Y[T9:!L(O,
M^S'N&9)12L?M70JGO#UA&QP;7@USWL'EVVU]O[$^V2#Q:<_MR+6X,Q@$<8@W
M]U&I_O[+7%EOM.&#0O> 0*J;";U\K^LO(7P.".NTDE"(#>XQ,;&^T9#D-^9T
ML+MJU#G,GL6G3%-1#'6\ "3P 3!%[W:.@#>D$Q)1P@$XU\1/7O$)FI#C<8)L
M9%>&4*S N(_9&]OP"MZ"],-TB$WKL;+P9<.X \.MKXR1^(<"O\WFNYI_C-PU
M?!+PZ0)PMKWKR8+AD+OW C'2@3&%W$:%A!P$C)=$/I?5K4O,/M=W;?K6B.85
MLP',/?X>8"U]9[?LK%]+0"AQUU(:OE."Y5;%1%2AS?ZXWW2E:#&'8G=OAX:&
MNLV [$7%U3'^<3M.;H416C4\J5ZR [7D[Y4/]ZT3SY]!?I^%UI6 ;0M[P47)
M-%)6SVYFV>.08Q74R2N'9H<3U[JZ&?A7LIYXO7&7%<+9' ;"169((]8/L":=
M]$#C\"?8A6?&*!H(QBH7>SJM>RY/&LZY/1'BX)?81<R0JK;NRVF;W%MFVLT;
M#0&N9C_268]88C4)#F IABCPQ!E? #HO4Z?%9;Z8EZW1>R5U 9!C9]*-;]Q^
M%W-0E:Y"1Q>#>W/^#-8]?'NP^D=ZN )# 7H\6 PYO8QYQABC(H08%5-21KO]
M_3,1"_TJW#Z(AOVE#\UL'HQBX[;@?3C5#B $GOMNL8& !9.U%A4[DV/SUP>Y
M3SRHH%^DSRC/KT([7OL 8ZWYW$"<EET.H?;-!JNL<5[H0^FI*E-7>OWH%1W^
M88D9\&[Z^-KG$]@!'+JYEG/+E&S(S C5PK[:OGN".4$)Q;>O JNPE"6NAMXL
MCK)4SUM5K+-,&BVL.05@^1Y[PODZ?P.2NOJ3:K,) _>;=6_YYD/4;SNME]$L
M6H9J)D;P8L<*OO-6KDW_]=9BC&M_ Z61C2"):DN*S5O\354-9I<7)=Y?WK%%
M+>] @2-%?3.1!A][57)E\=,5I"D@U;Z*H(L,N C99"'K3]WL 7AU?LT$":WQ
M[QU09)P[0W9RM>VJZ*IL!=A_)C0Z4##^3(P![(*<&6DOFUT ZZ1?9^&^Z\G_
MZ;I\%W,,CG'&R:"EFMU/EL:3OLVK$2@>=$)OLZH7V6)85E[L_VW>RFJ7]H[O
ML.JFA;E_9)F/:4BS1<#N1$Y(7@Q@]-]>;UQ1?-\)2ILJB>)/#>U/K#D2,\E
MW );>@@?Y78_W-U497$8YQ>N[Z^?*VOG#N)K/!L''^%]I30"1-=G+P#*AG)\
MDP'S$0(YZ=_![I]GAQI2K;+(YUG(THJVS:T1&Z9=G@Z^HL573&\YV%W?;8"P
MNM^R8+5/F QI>7>.,**'8RKZ]M]= &JGRLXE";[$$B5W)Q99?W.>U&7'NF81
M+#QCHQJ.^EEAC*DGL#:C3CZV.&'*#Y'6E*-'[=0$/=/7=:9DY_8&VFOAG^J_
M&-I*7J&V#!ZE_MN"JS0S[[,W%44]WF#_J6[I?<BEJW(Y_!$)6K<1+?'SM[2B
M$B45#H<@[J11*.;%?JQ-K>4R9ZUX)(3YMT5'#DUESK1!2\NU:0,Y;:-!=4NR
M]_$302;DYP#(<LXM8B;( ?X^@[<<YA:DPA_P]:#_0*?:7.?MM/XW-7K2[/&F
M*K!,HU=^0..WL :#JB^EYECZG2QK5R2/.[C%OB]&@=$<CT9!":Q,X(]PQ'3W
M"-E6ACL,QQC6(LO7R/*];&.I;VI((HIG]T\YE>=TF=<%H :\NWFN'6+5C+D
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M5&AAS\ *!IH /_4RY<YK+Y\U+D.F;&AKCZMM;@18E4O-$YW31<M>1D2G<2X
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MA@]C#8L*!^@GK69E]F[<'P7DT84J+]95QH8XAP) 72-SUA;TJ6>XS7P/RN%
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MJ?EF=[N7SD=UG]=]_& WD]^]&PJL@"5D8O,-+P ?'8=W>WJ*!Q:$!M9@N,L
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M+S4 '/,\$PVFL<"/&TRG66(?FN=^?J#B4./_AZA5<:D1(FWH0EYE9/>0"BX
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M]!F@-(@/+.EOP]7S+&.T8!I1LI5SA6A63SSP(.N\&GW@W<]F?[,@7S3-]#7
MNLP3/YA^8AFD/A2D21 3-HGXXPA;>-'4F&"8@$$T>29_\+) W(3SD\\ .N17
MP>*((F25[1W.C?'PX:2[<^]\3V=[ZT"1P.OB32%BB_"'HVA1SN>7-FX\C?UT
M;1M/K%"!"_#%)-XI^C[RSY<X:I/T]@]_RYNR0!TM,]N#0]\M'\CU)A9_$HI0
M#><@!B]FI/PIV<WK?SC)Z+6>\!4U:4 6]MO(EMA G"A9.(.K9)<K8;-O6C]K
MS<Q +W?C*BTI'*>()MT":C_\P1G@XT^LK4OAH,<O9@PH1:"K7$IRF&C@>MI\
MFM Z5Y)#<XKT81#!ZLJ;-63O\;^,T7QI\4/GTIQWYZNT>>):P?8VP@2;R!*?
MJU5PU?:Z"L[V=%^M,NSPTY8*_7(=)+Z564*-9ZQ@)#[?2P9Q_UVS:--09+8S
M3[%G5@!8G@2=I^2 B&/H<$K]A>YSR.>!^!(:T'8KTWX+X&@5C=O@8?ZKDZ5=
MS\*.\?(^,GB\ZZ"T-,M(*PRRLVH[F0OO\26EN#TF6C,/WTFI6,"T7O$&,M9N
M;;!-\LK4A:RJ:W=SGP':X[TZ)T*IN"'QS--"'E.JSS!,XT"(=+>N[[1 J"+;
MX\[.TRE/,O?Q#I^B6-Y$:4S>-_6:]ZXO>'@R_0[_;!C27B;2S=F'7)8I>;#0
M "WXM/A#P8@,SG-;45WC1%(*;=7JYDSW+C",5'O]LDMB2VHHV;;U(S$=! P%
MO>#1<2YSDKOVV\Y];2^,?^$QOS/-8@AWD,)P$[-$FH_[H*6$EI$A&4Q@+YJ;
M+,@TR/ 0]$GT,]H271<#:]2,NDTH%PMDF]O12]MJDX '3KOVG\\ VLE]G^RC
MI-\_8F^Z39)_0FZ]/N::*G(8]]"\XAE5 65,/(Q$JL@78*%.USOIH;4 GT/9
MY5: VDV=^7N.S<.W#6IT)B,Z ZJU)5&<"P4 'E9FK'[.\-J];U=4K@F4294X
M_#-PM0D]6-7_'LKB=BM>V]6']0*/I=:.**M-WR>FPH#!T^P+)WFUJP;?0SG%
M%H#M35D9<(7O,8!'N7JWHI^$?XCO'SX>*OYVI?K9!M<7=MO(P?C8K(4,'U;
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M1"/>.^;8^9]6"EX1>$.4VSCQA'R;#P[G+ &CERHIE9DOJZZ^%'GUUB3;_'&
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M_*9+(P1<LHMHP]V P+O/ -QI&/@]="T"P[W7VK#[S<),D?&MUCQ6'5(/)!J
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MG3HDC3GZ%D$W_G7=';61_'N:,1[[QB@5_F9<@8J/VITX2;7>;7<(2$,!=Z&
M\'(5A);&S36_WM&ULI 5N_T1RGKS*,D:F)9G-_MCTWH[2@5"<//#SC!3QVNM
MV.J:+AO/O.Z%F\UET>/M/$Z4UBRQ'R0V?:!E+UH;W+K%".:#_%^Y#*6'FDVK
MR P$I%5'#E_+2,6FA;?B87@\=6<^\MM*1C]6+>O'6I/@X+/C-Y3^E#>L)@>6
M(-#? U'.0ZTZ;%];]R;X<6CKLQ@>WQA93JYM8Y$?;,=(SEH=+_>@39W "<;$
MN*&28DE]55'CQV6NU[Z8;37%_&0T*UF3OQY31/Y"5'7-J\MN&<7F4$):AKP1
M'S-J#Y!KXQH'OJ)OK9S--B%Q#=@._[LDA[V /[F-^N@$78=TP5_UG&^ GKA5
MB/T9H,VZY0XTY_Y?GT2F?[O6@@$NLP\$EES\><658B@4LA%1ZPQ 0"-'6PD&
M:!=N1T2#PJ9@;[<57QL6^>[DN2LRX*V[<-[[O&0[J=_Z$FS&DDC:?-M-?SY:
MRLVJME'+KG "P</S<@7JSN/Z-;FBNRT9D;^4G*+@MS \-@9"+3GC]N#;3/-9
MX+;9GZ"NIR$.H$0E:F:%AC_T.SDN_4$?ZG+/H5HLQ)LB3@I/H]QNG?@=5+]_
M__$3;(LGY$54^5)J?Z]U' 6DAD$G)-S'3J<@2C8P\QSA%) 7,"9O$+G%+D,G
M4BVB/]058DG8YV-W5KOGRE#@? :PJW2F]($EY_5U^%.8XBFO%G0-F)VIK)7H
M&"OHANKO\:,GUDD)BHJ6>TPLT QJ?!&ZLR)=:"0G(X;Q=4>XUVIB /51Y\KG
M7\M5/L!J_?66E8VQ-]F.7-9"FCN6,]K")&C;S$.2!,9&0#N!H'R_XBM6")>>
M*./VAQ;8VZ0[C]T8*: (N07,6E2:M;9DY]^4VO:O2F#-T7Y.LCW)A0]2F4DA
M<>TV=&7FU0=C);XJQ4G'?,@<F.P\J!;7Z7*7]$Y[WM\I0S>:6T'PO7SH(^%$
MR\.@^W\J%<1O905G+CEQ\#A4IAJOW;?!>JV@)D$$>8HHBA%JRY.4-[CICE3_
MP,QI(234F,/DBCA0;,0WR1)G?TE#UFIJ?"O'\S]U/-[2G/#,$>TZ [BZT1J2
M\L@>&@U-]2-!-A7/DG18NMBA+_[HB"@QHC=S:,]3&WQ]AGN$S4-%W4<UYVN$
MJ+?)R*-?G#B(*[7HRRG2;*(J /$%0U^RY)FUA-Q*'(",.QV@T2-PP=6, '*2
M![L]<]/EMIZ5F9;UVA135F-SD2NTHZT<U,M!LG];N,BSVFYW#XV&570\[ES;
M7+"9,1(&RO=CX2,GUXA;.TY$O:PTA!CN2]EM-?22(^NPC_;8VYQ75LSJ)YK?
MU[Q3!_U_E 4,IS#$]3W0=DVY[MFO9VOMHSVJ65CQ(<8EB)MFN=BN.'_JWM2]
M"\Z%1U]H^P%*$8LF]&-O3.SK7M#ZT? YTTGZO9+<M*C-N57YLS5B%%JWD+%P
M:OU@S$F@0C26O'_RZ-\9X&(3EWA1B?4#K]*?DQJ(#$<L+_S%41Y)^Z"&!$ZD
MWI.(1J+NUF;,/&^[+CD6PZ1(42)9B;A]-2W_MGD77E/MT#;37_>N#N2W;O8*
M]Z4Q82'!  EKW? @+1B2%X@-,[O&53FC:VS7'>S;I^9\3,X)+,JV(R.&9=;C
M\:^@;\=F[V*M,KK X =&SRUJU0"" 0=%PU_.<SO@_W&-/XN:])RH6SPV1-5'
M[94&4*OX(_.M;9Z5#_P*'[N0]?[1-=[?G%X-CW[=8-($G;K6.EOD]?GTH&Z0
MC4ZL_QU2:=$M)+>#[+PU\.#T5[<)0_ZGK[Y^N\7K.WF$+X;1$,P224P8T3+G
M0]U )P&IDN<WGPHR'[]X]],_:6!$D3>ZA>B&?8^8W[8^IK@1,>37>J]\H%I#
M"RFY+I?"+@Q_ J]_TE(MZU.Q.WEM"1.U@$BY*>W@S4:0Y3*S=VR6C#65XQ#3
MRI%\L+R42"G595H7H'*+[<R^G#]*&C*!^$5TO6F%0[D,6(]C&Y;87YU\\E_)
MF"""L*W7*5HCCI6#LKJ!C5&&W2^L^;HE4WEWKFCRE@=UKU4(03T%I!T\/]VO
M[-E)X>4O2Q[-5)VHOOOT\>]'6W#+'53D;+6W5Y R2:V2()CPFZP//O'(=Y;Z
M=4#E-5ZRJU]#+;/<J6+*_')0I-TP]ZY5@,D6VJ8B<6*XC@^8C=P[U="NKJT;
M_99FF%7=<15III<;R3=<0H$B!EN=<3&V@F0WOP4K,>'VT89+[Y[UX@-BM?I8
MW;MU>)B,Z]<-4I)_)Q81=WC9+M!JY+C4FRA1)M.U%&2[*7SD+[,W6WA6&_:7
M4&..C?%9'>:D" &01ERBZTXK'W705IEX-\\?:0MS,J@BQF<UVEJLV#<D!1O)
MS1UN:XLRPG(HRT_"EL:7[>A2%V0TI6JFE'X>WFZ-'6PR.,@ZK1"C7H6I3:W*
MA4QD')1<QUW^(7@DHCT;LE6LXL2W+DP ;RH3))C(A3B-O]Z;#(YNHB=:7L4V
MU<H)8&4UD\;M0*,>\;9-@:EC;K/3@5TNNP5%G+K>NXH.X=_2N]G3HI@"\AE@
MP8"7K(RIG>$D]I</KAG*'!K;]OZ=?!*U$:X1#I(4N&57X#-;M=*52FZ;ZVQI
MKJE!U[_/4$ZZ5+!P\Z(6C6?.9=YRQ:1_@1D&#;Z+AWLE#\X (Y_AN_S^J*MD
MOQ.'?PVS"4T6^>OX R5O7Z72<7-'0[JNUV:*JW\V\'X$@PF/-CC=*-!@&-W'
MXS]_2_>D+>H"X,,*Z-XBW/O=CV7M7/X4R]><P1M:S?X5RETAU2%A%)H23:=2
M*/OH;O^-;-.Z,X"9/DT.? O6#X4E=Z4V@#X6C=2*=KHQ9[?O[BPD+M];_.0E
M\.YW58KCR5B;]9[LZR:O ^AIF3<DMN7F4%Y32V5L1_*C79P+;VC*12T(ZI$R
M6#>/.M1R#=^DRY_L@K+0\Y=I>7+;_K*[X'HEH_^;BYX;SDNO?B<<Q\QMA[AX
M7#&'?=?CUW/]:]-.M9Y5F*0[ _@DP-1F]IFBS@.V!PW,<@WF(;LNDS&JSOI/
MD.>;($WJROMNRK_%M)?G>S.5KAF<.E@UQ7=.!/X+F=#UXC$_LGW[1;[7!*^6
M@ED] U37AE,L3K_)V!B/'J_]&:BX*>29;LKK;C3E%'=BU(U)]U->S.H>#*'3
MFM0RF"D+*X E;AR>O"9[$&8C]CRJUS+L _X4,">]M(@@M'V]H5W!F@6V<#@Q
M@;&? 3HJ5R771\\W5W@U\JO<[SEVD2*53Q= X?Q_;,)R5'&/O]=-HA);6*JJ
M*W/<'/\H["N'05TMU4^.+J9.M!0!$.UEZ^?6%7T(>KAH2PXS"#=;'&],UQK^
M*K[ !9K!*ASF??[O,7_68I8I%TAV&N2L-(8\6R'\N/[X(X%[P4S+HM]US#3:
M%GWX4^3L&O@T60T?_J>SJZA_M9!+0>8( 86S8H3Y1!Q@%2_?)G,.1LU/6?79
M+AX4TD5M?5.VL-].LI4]T85AC7^,>HN)#+JPTZVV3SW@_=.7_!=\-^<^7D5R
MGHE]LD]VOTGNQW95X!<ZI>R\;ZL)!@'DK+ZXW(_(C2(&)EVFE(8OAVJ?[;G,
MA+<2NNK'U(1=R@*+-:2#LZNQD[?ARC2GT/;7F6;$G/!Y&TL&L-&P.&KKA?LK
M$;F??..X11$@UTP_04R"("G]O'(\_%5U<-?.4.N"K;@#@27&MBNS<D1;1%>G
M:E55PK867TW>$BL$)WC4J1,JCDK'J ]\[K1 :U-WM8BS84W*3L6V&G;E+W7?
ME7+.I1Z]"PC9+]U/J"^!271:UD1[E/076YQ^:=@"R>AU^AHM'#_[7&+)("&V
MO3J6[J!T$G=\M2]MP6-%WX5=NDM>_C5TJ3':QPTXGY(6]0V/<ARY\X[^W4L/
MGD3 ]4PK$AR]@.-;EZOP*3QA=:WI<;EQV\HU:Y]K#<J=<PN;;?+V,*?'M<4C
M5^)^X-1QDNN+56MP&Q)J,DJY8"=74(^2VWR-N327U._[]*T2E>WPJXIIF::<
MOW%\->_I?9.M07G19PC?9AJ):C%6(W5U]55-V@* 3'#O7*NS00S-W"R&#]P1
MX@0M'+HC5?XR>.$3".GGD@66)X':S:@@HGON]^G[.SX*&5=N^[GA%$]%1" I
M8X/QS]X6%X#G6XJ6G[>B4Y-/GJQG1* )--#"FN]G *?WUQ9?1ES"(RBV9&&Q
M"!1C,?7>Y'?(T[O.\YJ35!@;X0Q0>[C!3# 8.R3$NL:6X4J<:\&7"JH4-:/]
M01@+)2Z27X>N%:SZQ,WX1/VCX-(-]J?#P(:B$JY]%%2L1,W6 H@@I3C03Y@2
M+=61^E4''62?7.I PY5,:&ZG.((@=NG:FZE?Q;7B]7,(SYP1W0/STT**?#%R
M&A&75S=$<9M7.-0KJIQTGX=-*7*MJ#8:!WF1$Q>F::RJ\&> G^[>T_S]O9/"
MXU]X-P4$%_[B60*)",QL=6MXFN'(Z_]-QY@G-C!*:_3KL;R ZC%>2_KZNHFW
MDC2VAS2\8)F)A5[=_!<@'QLR5VA9&XT2EXWEF58;G9F6=.*:;'6';4*>4+&@
M:NUH^!T*QS %C*(1ROK]+"NH\6'3WB&J;Y:/VG$&8/<N.P-(-BF7K$W8YG0&
MD>_<>I9=%7=>1YX!F,X ;PQX* ].L\6"KK<R[O_C_[N9_IMV)1'P<G<3\M%3
M.U+*Q_\?<OR4)6HA+J;&BE>.X5XU&O1(18B NAAD2BS,\Y#MRI3%?G&*SQ,I
MQQ*/P5TMBN39^9"/QX7-?@1H1(J;:;SX"$1*[[[R6T7:7!0SJ)HI 2X(O8AO
M:V&I_>N.Q(T_3S80:0F97O1#HCXB*D$=8E8$#=<9(2LHTIV6_J<KH]DEQ967
M-/0!^VS;1 ^:D3Y)D8K;TXA,Q_%"%I;(%!%C,KI*Y0R H3*1"LX <>(M=R%W
M\PJ50>D.3IX<6XMQ>SRXWTHY*0<<&QXGUAB2_OT]#CV0_JC86'KYS%*^HPI-
M=:UPT:I-4<?LAV0(Y?X'C&6$WC/==F[S\CR>IPJ_+KU,"!;MI.@1[1X1E[(R
MKL1^<^46KRS2$K]=%^N7S1-0*8;3CVA]0>WK-.Q0L2^ Z5@(M/U6"*--[)M/
M+7451]BN# /I_DL0&TPQW)$1>],W>[9ECMB- H@5J]?>/'3$OI0FXU=;VQ$L
MB;QD&KWA5%F@:Y1*[!BO+ZIM.RQ#OQ!Q4T4ZF*2A.RRC>G=GE5WBQE-+3H_3
MK \ 7"T2OA,D636P0-1* T8*)KBQ<[*Y60H_R/7L8@KIJB/YL.XY>=#/.SR.
M+3QPTG-6R5=0[,$-Y@O+V@K<$2;)33%J7:L((2 ZID'S3.%W1]$ZP(W*&U=I
MIIC6;8/1/]724B7-E&)$5V;)YR@BPI>1Y/96R@O9UKG\&8 #016"<@:?.R]2
M0,O#WFG3KG)/B&W'(/$,,/?S#'"-RK,&=!KFL#(34'F$H+SP$J#2]1!MOFG9
M$1@&64)3!W*RS@#PS#S9!B8HRV9;3]&%FB;\P<O3(F_@1.O\%_@#8N\,@[C.
MS+1>[R6WOK@]X9/V9F[P!"*0?Y\757PT4O%!(\)=D081L#L[07OP?H!Z$2;N
M9F"<;JF7KTG+D]X(+TP\MP18C0B=N9EF/%QQV^+@1\W'VG[IA?>)'>"E62QN
M@K8#" SR4,LKEM9V[XC*%3[T9,0<FPW_JWEEPOSRO%(BG5B>?E>Q4Z46R,2[
MM\HV77];*5RHZFF;?L(%[\(#.5&O1M%"R0;$YD8/J3K,LX7/K1J_UF?2#B1/
M8]!,\999W,OU]*FV')4>L@6OPI110N 1&->![+_9&J?-R@*RME9R&_]EYTVD
MF^GD5/^;*V.XZ>L@?NG1!M0 KV2S04"NW<&/T[H'5+9.IC X?_G#BL]KR?JA
MKZ[>NKP]' >NIG:&U(@E;M)]T\Z?+9TDQ_2#0JZ> 5*_ @-);:JBNY!V-;K1
M%@%R!-X 7?5YQ;@E9/]EJB,M>6S_$#4D,88]4*L\S591J:T5$<*C;O-#DW>U
MDWJI^6"UVQ8"9=>,W?4E[&9N 9L=IP_K)A.^EI2R)IY".$5$7)>4/_R_33-U
M[UZS36FG#AX<H[?;0,R6_U)W;5S![#<+FCSI&^M-0E77&[=&>'^6W]AZ1ZMJ
MX,I.2,7V01BHM#::).&GPQ[5BH6UQ#]A0G6U=9'1CEG: O#;7V+V4./R;>"9
MZV1Q,1]1BP<2%2CW_)T:NUX&Z2_8.<T 8,3^.O"FA>Q(^+"?&15Z/\4SOO>I
M@%H',WAF]'ZL.R0E8FJ%"U< O:_L;,=GL8,-^V^TT9!<6>:L5)/L"9V+9U\_
MT9<S)P\+GZPG>J2_;ULW;V$B0P@,/);$Q /<QWTH>?!@>6LU=4B43JQM1_H\
M9/8'A^WD:?/X.ZCW?AZSBW%)SPF9=G^9=1%S%;MN$:C#O?/DR-@C=.)G$$.B
M8=/?+7'T)-(!Y<,C4PMT21W@?\0,6*Q\W.29,1)IW/"#G*$F$-(.1#K#@43W
M,-D\B^#8WJ9FQWM'.[MAAT__!.('!W"L?74-0>FW=[N4J5HELRZ^R6/57B+=
MW^9N*=>R='.J>OUS7OY4WL NHV<D&\\]ZI80&WSS=V7#9M*+4)7WJQE']I0;
M)$A4B$N_U^/,IW60R(QFBA*R<_4!^WIOW.W0 XR[^VG9.IW/.#>E4-80,"59
M;9+W_ \G(^M+H*5B/FU?*Q>5GUP1P@>KLOR[I_<,.LV!&7*Q%(1KB6T=;KRY
MPM=F_5:4M@OR8RM]3B*BA6>TFD$4/(P6X]9L:AS*:\W1;&9(2Q5@W\SG4%B=
M:"DC:<<\H##/-_9;F=7I*O/(2AN(9@G>4\H: 5T/TA@,@OKY>.3/6$'ZBW[2
MI83_K%D:5@K;,@W35HGL84GX278AT!G<<&D85A,>?E"]OS,#8<(4=?Q-JH;_
MJS]*FV5;5+M"8F\FA1'2#A(3*"P+8RIE&/9TUP8GBN[&%]YK?+4,OQ9 #T$!
M+:72EZ.;6K^V7N4)-2AT4<'6)W]_8'YDPW1K1,NX);^NXSP"$%8V(A<\R.8!
MJJ-I!)Y-8[SYJ$"FH9@#C]B7"\_F>'GM:)967[3<I=P900/9R3T^N.ODV [+
M[&$=ID@?W:M35AI7G] +.MRZ/W.MBR$X77;'4D"9S=S0(5_E'C\Z,Q>6BNT(
M"&[NCZLY3-6,LG@5W,O)<NQ#<3W-#_LL_!O!@CX#<+JLSB,N],^'\.C-CS^H
M=;7,B2Z\5C]-_995_$C]SSR.?W\[AV%HPSOQ(TD.\7W6Y=-I5KGO9\S2- UN
MUOJ4X+\&DQVO=)JL@MZ853-0U]-847[S26VY#:M\V0%WI_YU4)$=$6A60[::
M4]9MOM2#=#W&J-5*8]#MRS8%"5*MXG^@[\E%<ZU\Y#Z,VKW!Y8$@F].\8*FV
MZG]&P8E]%SR7<(=C;Q4%1EOFAF6+O6-UMCP<(V9&V7;I?Q+O;"9M;NL6V&!+
MV^WCR@=^]&;M'Y^,:.6'I0IC9UF;;A,@Y&<5XC*SU\F?^0*Z.)$;B['Z'+Y*
M^5:&7U(608U'58<73M";B&I\Y'[F['C(BZ&]X+N$;5,H&^1G6_;O=_GA I\#
M2+:-6:DVC1](:'^!=0M+X3AO!+NK4@$R(9=AI"O2<Q&B%9]:E>;\BB<!"Z5)
MU #C1",?&'SU88K(V.YTD0G_KTG(0X7G-+:0N@:=#*G251E7-(K;NL0R6C_[
M$7AY_Q0.H1NK0:#&$$S=9P!G&UT]W1<1&LM>O&6IOD>1,QO030G%H )KP6<<
MPGXSELRC(\RI<I\4Y[[A*%<'-@5Y*]6 1(E?.';=@C&RXS&VZZ:-['BP_D$P
MOTRM8\^M_/&IOO@\8;:)J7-@7@+2MPBO,<SCZTC"T3Z7H*8WCCX_4'\-27EZ
M!GB9<5RX=F^+)9VM:?Z#GQW=)AFOO. 1E\-'AI:N'C0LES@53;E^]F<G=9/_
M1VGO'=14]+:+1E%1:2)(AR!%D"K2I41$FDB1+BTJ4F,(G0 A* A(%Q 0$ (B
MO0LA2$E$FDJ3#D%Z[PDE! CAX&_N/>=^WYU[SQ_GCS5[)IE9:^UW/_MYU[/7
MFN?]ZV%HM*B?K='%PCXGE1@P"PIE9[-&IAZUQ;A4<S][E-7T$M&T7(X8S8$+
MMC> P_>/#6A:J0)I^@D&9H-:U(]U-=:Z3G;]'5VI*0JIR@Z?DCMO[(^4SD.E
M-89JC\5CBF;K<6E=F$AE2&J+DG$@X0I%W R3*)>(2>-:AFLI._'-HWD&&,T0
M_7-&XX-/8,QP\*/^/?.::D)PIIV&-ZN-A=[8O1M2EZPVO5MZO!M$7J,3@'"F
M%B1#9$M#;UQP8??+X<JM,D31C"WH;V:JDPC,U@.R$A."MVEAYQ-NZ+=LLW8=
MELC?$:[;U4G'):3Q-8V^2L[]N"E6,FE$5 DT]]9-NXRB)7>2?(@=!<B;]GJS
M)Q:KM2HS4SR8.&X6T-9H=RQC'@2DWM',T@JJ*2CVK(1?1,?)+U![/JX'+L2G
M1]L41,V)!A.KYK 5D*S/"GA+CT.,/^EHR.M>0X"#RX>X&44W^X$')$_52M(+
M@GKN+*]-IR4^-4,N91B-J:\QU'XN^OH9T ,RFDO_$OJ;?7D>V"9V^T"[$6NN
M.PHR7367K"Q(@_SBB5'X>Z]-40Q8?G/CU1.SBY0WI,ZZ68>Y!TS;YX[,&RVE
MV0PWSI2V<EG7MW]5R#MT[P8Z95@F-)H<Y!7G6!\H@[D0=P>Q_*LXYZ%-[$"_
MPH*?, ?P1;W:>C*Q\_M/G^F(P([,'#P&7YDCIBBK[##(*92Q_WPDFNA-'WDE
M=N2+[SV7.3?3\6Q3P@0)TH\0843Y>CH+9:34,[Z\VRB&^?,)F3)@0 C22I>'
MW>WJIHXMK7BI3@'V]\XWBJD,F_STN%-0W. :_MC\:6-=P-@)RN>IJJK/M\V%
MU!&17?[#,0[L6YX#M359PJ/65GO@T/,!J*WMY -C61F'O5]"HU_\\YKU?WJX
M3EW3V\0\R(LM2:F ][4:C<?H#M8RR.Q+*I_=MZ173X-SBTK4@C/O^A>B\_<X
MNO:CT$D[*\RGTJJ/"RZ[IP!$HGVXEJ-^!('U\^QE<;71D.Q%55^+;6_I^W]R
M"5M9#.5-KZK;[JB5WA>GZ9LU>9(-&<_5EDN3\%.VK2P:/! %-QI^KA/Z=P3'
M58Q1S=7_*B06?7/UP53+&I- B:) /2XVY/HFE8UL ;58?!P#G.0K: B:>'.!
M?AP?K:@0?!'!? JX>/&DG@*JL#*8E>2;G1V>_52(OZN0VWFXJ5-7:*CW,^1)
MVPN/71]!O\3?R.$IX4Q2[!!B$9LT,G+?D_MA0CPV9_3UKQDF9@0] 7V,M],I
M<C/%KNL_ R1I_502NR3;LFI"IB$E!]\4&D08>%7K\DCXEYS;#> -0CYHZ(M1
MOWL*>.NF#V;6:C0>W+1R-UL P*GH_5J7 9\4:Y@IL;M+MFVPTI3A7:BA-=@F
M#U5+;G>>*[_H0,1%;-6JE$8RMY/:)K@Q/)4@ZV]SP,W*<^N$7[,HQ@EXF('9
M]<Z%@@VF)T]/ 5Q-FKD49P)[NB"Z'/>)^7,'KW<\*JHDA FA/ <,PZI6#[Y:
M2)K72+HC7)\5Q5P).G'#RUN[ZO&]JI)*N6QXW6L$G]T\VQ<5 VJ=Z/':&BZ?
MG.\>Z0U[92C34GEQE*JRQ@(/73L%6!!VZK("F(_5!3A2 OBC#_IX%3)P3)5+
M5B^P$6W.=U"I3SII=RO3D0JK^J> R^7QWSBN3=K92(]OQ #?.P_N5C *M*G*
M,P9ZFB"=1SV C*WR<_<"H 'UIG[0\A/Y/_ZM3+3DFLZ,6,4,J3>P_'&P'BDU
MQ52)HJN>,@''S:C L=N;<7-!1;Z7;PE3DA2V5)^-A&P$$\_YE$(*A@KC1U2T
MQGD<<4SK9@B;^<D7L&CVQ&)TC$;F=4Y_YH3,4T"9>/OL)T?.F6E,UAI)'=,>
MF\:BHY#%P\;[(XNI-GG8/YBAQW]>\5T3MR-L1@G*=VS1E\+3=U 7[X^,J'0)
MH9=7$S1$6:59,96[,18']I[3M10\0V./I_\42]J9%JLS4*!A^!:;VBSE?^]3
MPH>E"DS+/MGPR*[IWN9P7,9/U:7T@X#6ZF4UR)IHQY<B^])#'Q!;(;SWANN0
M25C@ 0ZFN0^<9=K8G#D%1$U_W4J>G;3H';4=6/A*X_/NG(68LHGRGAID.6@Z
M,H3U3*FE(_D5J4Q!IP!NA' BYN]J3[J47(K:8[LQIK1M1;>#;;)(0AL$Q(D0
M29VZ$MOZ*"OG*??K[Q=I#D>Q8%?BFL*N30^,/MOKU4O/CV-<AZJ.BKT;R-74
M(=)'%W1!9#:U>QJM\S;$%77>9IV/?=C2V.EDLIOQ?GWM^W,?4G2NSJN^>8JK
MH\8%5%#[ ML4JC*CPFZ:TXAPC^9[K)\"+FS^:1(YOC].WOW1D#\=D:%\!5N-
M4<(T"/'E+'_;C-Z'X;GG(BFWSY)X1D$SR64[TX@YV:GU-K\S7?(T-N1J;VR&
MWYJ/X3VWOIYILH4Z_RD@QV#TA&@0$G%O)S9+[$"9@PYH?:1)Y7.]>0I(M]2@
M9&2< @@FA\(<9R^9J:93'^!2Y8LLMRB[A[N.E\'>NZ6D;V3QN4UP^S7YRLC]
MVV:BD^\@/X7(S/,N#D_96QMJ;:X RNM5,)[@+V#NL[C6'(#IY#]@DF?/YK>5
M<?].+S<%$AY#I=OTZ>X"M@*O_OP>6V39MUM4^JY8^FMTG!"U?U^$PFSTHR$M
M#.2@8@<R0]?7-$9:-*2][$+75270\I$KD2>Y(!=>D1F14'=Y@P>.4[\?WDG>
ME0U)$E\X!83B"-8)M! @DU#SJ*J:;]X:7U )?EQ@4^V>8^GR-MZ?U%)_4DT5
M&K=>.1)*)79X\CA^; H;BDVT5>F:^K,6:QV76@#N1,7C.SLKN8V*W-CORM?&
M95IY[W3D'<TU&YTIVAB8^MUID7?H^B4TH;S1W3?%<[G!RW-SL-GJ)#GDV:;^
MG$ZT8=Y<E[)/%F//P2,.ATT5PP>[1_,\7%MG6@DU<:NOQ5H5>Y' E QS*$SX
M^K?OW"S@T$^ZF&,!9;T:FV$1U2?F=O#*: )$ZJHA^$<RO5$]WP6!O%+-+-ZL
M_IA6,+S?>UF(5)F$X)[9-)V#Q=X<+(,Z-F&;Q$!^BJ%,VB)#OG+3M&20"1DU
MMP*5%*P?\@TJ8/Y1(KN3K:@XVS<++@!78S8<"ZA]V3?BUXYN-!$O#D1D: /7
M$FR9"@P,]$0EKZ: W+;V;I[$XQS.2&:[56;*O@.#%?IF[)BJ@1("S@(?9P]O
MYU"B_[K3?"M,C/QKL_1\(/>C8AKJ@WZ2F311M(+3S"LP^ZU 'K> U0),QLL<
MX]/^R-'8J%O=W@@-9PH]!;AOTY,Q)/0PDJ'3H<05*S*PJ9U+38VNMM5N^9C"
MG_S=)-"_0G$>3+EA^OV,\+#2Y,@6;U>DX+ [1?"9O)IAD%*>R_,'92M7)!B1
MVKQBC]2K=M,X^UX-:G6_K.Q6=\_>)\(ZI,F2M*^1=&2'%O]=>%!'8/>4^FN[
MU=14-D)3NU]>8NA\3?3D229NID+]W,D7I'3+3.J?)H,SFKA^AG&;\76/3KK?
MUUYN7NVA&@""84L51CT' >I# :6Q6Q7L\T;MD^PSTJUQFFU3_ W'4FD%;0>F
MSB<.S]@NJ[R<O[&+V3@#^D4$.>A8'V$WB!!K4(QJ$@DJ?[B[FKQ&%#)>$WT-
MG(0ZB?!7&M^+!APS.%E <[^M1[]*2WS0F#ZL[4>5W\5LFI_U($ 0V4@DBOQ
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M.GM V>"-W\R/7:]-1%RU=%7?[T?V 6MLIUB)[;@H>2/&E0;@&)3:<T%AX/'
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MI^G5H4:!P9BC\$,_XA]2X8C36X$.^> 6),QVZ%VCZY#Q.2U6XW/9+GG-(H$
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M(!7W/2T]P&R:MKRIG:OD%Q_)AZN<Y[6]UPB#DWTVLBOUW6\F_&X)@A;;I&C
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M4%?*9GOHB*-;$R'A@X,?#S^)A*0OVM5KU5RF*GIO'C*E34M(J13)7DG:&CA
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M_H24$U]8,VV9 CFT-<DYS["'59,41LE"13OK1=-W4<@KPZ:\O$1IAV#N4E&
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M>A.@6 B/R1GUXS-;KN12]JJBCR@+O4NS29C1>WI1NLS.J16X8(#2G2^ZG_=
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M6A?FZ2J'DBY!RFDB\[)MA!,+'&/U)ZMP@-O)!%<_@*<WD@^H"5Z73OD"<8!
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M0=_CEH^.WKOHJJ-V%.^DNG'UEO^K\K..E[$C>U'Y#M.\R_P?U(J32(%03N8
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M>K3P9'3!"-$Z4X^QAGE+P#*Y[4GKD T>:C(+]-0OEP7J*@+F)HVNRP*]AW;
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MN%JO>3=.[SYEAT?:GUAQ3;<T>; H;<K#J#IE7"<,2"L3M&0=O>U/;HO]E=N
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M/O<1H+Z"UJ0('GS8?7?V"1+]W2'Z0!G<$<CKZU1[@HDCEXX!X1!D-??G]]Y
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MJ:E%+D73UC%_=/BFC;<AAV)I3$[8+XY%7V*8Y-$V5DR#!+AXG\)8IA8#:/$
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M$8F%86VK1TZ![^XIL)O3JD*-TNZ\;KX5]%<\9AJE2D9RY7&P@0XRX3]_A'N
M05DN)?GK\E#&S]PZ"?F6;8@S=%,)<YB3#NO29(3VUB$8SV!T-$<R1!'SUN+_
MOTE3A9FWQ>/K7>[U_]Z+_)^?W>H622(B>O('Q3=*T&-DI4AW%-3WW=B<7]66
MZ92\:IU;I2-WRELKH[A;I[E^HM29DBP-6A8GT2<?>#(YZK'7SUKY^S9DEBK\
M360-9TCHR^E?E*E\8ZRG_,K[K2,T*/-XQ:X6UEDVMDZ&9H2#D45Z'_9R2&<R
MIJ1*5\63C33D^ONQ_!S> &/J6=LVBH+RT*WD3CQ1=BGE*F;$]V2D?5N][Z*R
M_!1\M!ND+I@#$C@-#:^<T+-LJ ,PU$_Q296O_HPVS0;&70C-OKJ+M'R+>\B*
M5&X8ZDO:,Q[@MVP8P;Q1?;]77[M;Q?'(E<GF+XT0FFL<MK2-^+6"+3L(YVL[
MIRF);OD#EZH0:?4R=OJR,&<O00]FE'YE)Z-$MB$'Q.;4A4ACDW[O)MT+IT??
M?P1%74BK]H@F5;O?#T:[PZ!/$,*74%)DVV);^Z&*@?[)YA]1'2+ZJ-W-!\GU
MSEQSF$@HE[82+=&PY@N-D2Z9Z1*P)-W3NA3Y6#JE?3G% BV,[D8? O1\"DS)
M];(2FJ;V>@KD! .D1L(N.>DM'AJ&%]-X=7TY!GJDI )V&)!DS#W-C"I:O]<M
MG-R>K3/-H6U:Y;3>=".BQ3&-)B4-/"QU?$.B*5TH^N.0ZF9%90R'(ILL9)V!
M>!6?ZRDDO' 9ZAB0R! #$)1V1=M;M.)BHKV=ZN^?CUX*I7XQ%E>_'6H^ARBU
M(NH($4M=+!N$*A):>0EX0^$DCA'><_SP$XT_#5Z_,%-E@IKYSY[61K.TO#TH
MAVXPYEL4&K8BGZL^.?]AQF_QH&3E.F)QG1[2H,92*QV2[O.L^%HBM)&V6F"I
M1XJ!Y"!!]=5]'F(#5K."C:G''O^\D===$(B3W!?(X\).ICCK4CJQ=\Z#G&E9
M7OWZWHV\UQ4)%Y[;:ESZ-A]L]8E+'^+5<)&=62=&W^^2:]WSH([SW=+8M%?]
M+]>AXCA):DSS+\Q#7$2V2/]39B'TX-@5W725;G>*$=^KOWH7Q#=.6'WNN7PH
M_IKK4:MIL]";[V,@*X@XZ%[M*U18U&#-8&9!&U*@IJDTMY3=;BGS7?C$7WN-
M-=R=,L.('ZI)^.^?N=0+2J"4]>Q"M7*PP!XOB"9D]YDF*AX,?+*WT6.3^[FF
M@\"$K4&'YW.#\6$(]O9E20P]GRP4HRL#YP(P%#7\5$7TC7:)U-2ZA0OKLA;2
M: $Z(9HPE0P[JIJ%GI]E70W.U0YGM2LZQF-U?GSZQI)?1,8CA.K,:(,!4B!O
M$[-\6@N4CZU83]I^^P*]*G,?3D:HL*#L>HYR0 HE(N]!( UK.:!PG_M15JY,
M78\/R_P&16T;\BR#4?;6X&R<JP6Q\OW@-B1GAEI@]HG*@Q^8<\B@R;&.^5.4
MPED6+BC"T8^E:DNU71%^J7WC\B5]P-"O+YP?B&/4:"N.*%>K<6C<(3$X=1MR
M<J@;(0H&D_=8,902M:-#"QJQ8:-3YWYU;/+JD'+^ .5A)*V$Q$"R:]!* .EZ
MMBE\BO.5LL_P6PH\0U[5ONZHUG,,SWRGLX-;3X+2$:J;BQL"(750PD1',Y'/
M2"L[1VZQD'Z^8!L2]XR>1.4\&\5L0\1P63LW3.W)!N(IR.-V]OAF%Z3)<FU7
MQN-HTORG6D.R?2A3'SV.%=(6RK'M_,@2'ZH0$?G2BQC7\XL?>A?:#HWW11S>
MAK@KQ=@,O2CZZXG> Y1Q H\(9A\RZ#I-&I=OKT:KMH<51S>:;PW(%BMHJF](
M",SU-,.'.W54-4@1,!I\.5J7!_#PSL6UVOF;WLUU9,I4%O$WC=R[WWX**<+X
MC-D-F\K:AAS3%>Q$M]/#;'K0_2.=KXY,!&8%;7[W'JK<.78#F\HAB-:=I!HI
M@/ 9X5\C42UN2S)D%' C*.$Q0_I,5<XD3!CU)!T[BCG@FW@D,&#TZ9Q4^<@0
M;E0<--K1?N]"7FV3\4"GQXROX9JO,1ZB9[3:](<Q1!P@NPUI3MS/NE,W)$09
M+'@XM#>Z[OGI/UDK5_ZH(\XYC=82HDBEF&:"<(#B-L04F3!YAF!;S1 +CE?N
M$O[]6UPH7OUP5J$S>@![+)(UMAR/H2'S=S;JT G\:!)&Y)RNENW<4=29 86*
M39G1T:=QB4^)+I?XY3<O,U-B5N>ZC\85+RGB]J)'I=Y[YT7F_UAVT0J9$0.%
MLO$DY]1=5\M53%/(]*9RX;)MP=UT;@U(G'B0I/R [@7P%W31TBP]FMW'#)+P
M>J>U[3/MV$)KA5R3(.WKPAS51/HR8P5H(?,=FTO;PC1Y..C'^%VF(XPD^CI3
MG@OD/"G$,CYOM)+&<G=NN-;F=?)WH&'N]?R5AE2V_*:-M\C=C.9-A\8'^5X0
MWEH_/9 2/['IQ[IYJ8=H'G]=>FF(LZL-M7.9\QV4 0T1Y[XN "1YYXOYC<OA
M7W6?"CFF?Q8CNK'&3M65/;L+!&XNJB(W>U?%-H2C?F^9"!T3HZ353C&-,W&A
MV6?['R?M<EFJY+WD@/$JNRZ,5OV#$<$@P>4[*0(D(AT>T?#FO1Z.7H>*AX7X
M85\"WKYCN<7@!\O%]?+-2ISS1Q0.9Z#;>(TSU,LWLR?D%@OH%W(?_-<3L6O[
M^L"D,Q$(>PY6&QAZCK*TZ)[+S;QTI$6E6X0?T_V"H0SQ]XRL'#C)PU:?K#F#
M&'Z9OEP_@(NJ(9(BTUI\_SCVGHB*O>$4<HQ*E2VD9Z\:8\D&A8$._)?L= 6O
ME]SFCONQ/"T>+#KSS?!(CH69Z^ @NR[>6S']HL9R0V09AGAVYYQ![G-Z.N?
M/YVWOTTG<0X0Z5*4R.B+S#8 7^B&> 0Y@'R8,$!IE L/OXK'J8ZSKK._<$[/
M9O/T*Q:#A58.SQ:.E6EIS76ZZ VUM/X];OCE3X-S"H?'C3YU_5N HB0??)&9
M +.9_TZ[5- ^1+STL6+H9]OY9K,8AB\.YS!?+\8P M[DS[TD;D-X-UI^;;H*
M/701/%BX)JO-\27#CNUL00;'ILZ%RMMYI4%ZW%66W!&X<>RU-#HH-=XOL:D"
M\Q@<Q=-\K1BQ@(R_I-N [2?@^6F*I?53VKE)E6Z9_/L?@@\'X-RAE?[-8!AL
M;P#&MB'[MD#5$2]B5\G+-U=D_ E>[+GWROM5BC]^'$4E$P#IR&93,;O*&N@1
MT?'&$QAEK3<2*1)-7QI9 ;CW13#'Y>BT06]#L+G,UC/3GX1%=4*YZ!?^@"41
M40*D;D,,F%0D2VQN&\)ZD@BX+D<CUI -H% W-F!W-C^F0S.L6B\NV-[\T3I\
M3T+SP.<05)<A%;ZH1)>GP%Y(]XU1G:(J?1]S?Z\MK:R*6^.<?JD*W0M2,C(:
M=EA;2O(M04Q;_T/X0U2LL9CMZS86SQT%.R1+%=.<LPU1^]\/;D #(%KOY0-&
MR# Q8S<'VNB"0>CEEOI%@WFS;0@7*$@&^X3?VL$*S%W'%O(I3C&I9X\Q5NL9
MOQ9T89C&2V@IEL6 ^PPR-J.JVJ-5G:0OD2NG\^+L+I9;;YT.\Q3*I/>IL1L2
M0&0KXE<<]DLE&I7ZFOCMS6UGN76"QHD=PU&Y$\XA'0=TCRS8GW >W^NA:5W4
MC#'SFL(VU9MP!DC'"+,DE,<V)"P$!F9BR\ 7"WW&!^[B?/#8-P'6?:D+?83Z
M\14W+"#;W1S=H(:/)I#=Y^,ZI6",T 18Q=L9K#PR=<NJ6 ETD@MW^ !GJ AF
M*A.^#:'Z=K*LV%4<&0#Z#9^1SCK=?=SE\3@7([/S:F^ 0_O?I._W. +Q3!BH
M>_RZ9P)T*O<!2CBWUZDI2Z*^$_5%]R0S'WN-;,P92"U<BM-LOCE>6J$/'S$O
M7,P-KC=9'H5R#HR I4$:]F<A!E67RPJ@<S1]I^G5L>]7L*U?,2\P-&-XU.0N
M^@O-&)9);>]/S,KD *?G%/N8A?SF4 UL"4&7=\.TZ@+]H%M<^:?C5C])1V!3
M'S#B%4A!>]NQ@+U%#Z*_6SM5)KOP#Y>I]0%6N:\H%X9CE Y<:4M5K%KX\\3!
MA5QPQV)>#B-5 @R!AOD-2*3+MZRX'J)?95J-7YB9/.IV<H%UX;3-]$6P**1A
MS<9: )A&7S [5L;5IFM2WWB/[[Y@7T_C9XP Y:"P[FWS_802H@M^51$/>?_C
M[^2@2A_PV&L@G'D9/;$-$=:&%LV5SI'VK\<?UGC-;3SG4.,2%-+'^Y(0[Q;Y
M4V5__U:<>,B$&N*-@%>U%;2H7<<4%D.@P0G1DEI L$<NOM74Y[:UWS;D_83M
M%23/?8?(>"YL:QV3/,,Z%DM1>J'MEC]O3!=U$RQ/P6#W=%Y,HAE82/BE= =M
M(/C0(,GPXRX:NWP N*DBOY//=TH'%<<4)FL^ZW5$JU+]$;1;L/BCK">11M"#
MJGM+71A9VI_4KWET]9Q&RNNLW)0_2!"*?SK_8+9ZQ*YV;,;AGH6XYBO7_OJU
MTK^QS#,L8U "Y'91P8CI A:+9]T0(P+TB@#6=:#2Q4&,=7^PDE0N>!)93"X_
M.B-Q</^!N<FOI 08?J,5>8!UM;3\"W"WP)FQ\GK#UM[C:X9)U6%)P=,J?=FI
MBS;J2QYTY1GCYT:Z$."'Y=,]-?-5/,5M]QV_L]R>7Z0+*YK<L1FR&%HV-,F#
M'^V\0C+M%@! E]I3"\339EJ3P-'0734ZG8?N<2:YO'QR:>1L*NX^';_H0Y=O
MGN2O^P*3U+8*4)0:^=V9-Z(OGG7I7'1UB+X+AFB)N@'*> @=SSFT!LJXACV4
MLB.)T-9X=>J3N5NL\_T*[J@IPLA*J$R[\-R?PL"[&UWRS@,MCU79A6X99]E5
M*EZY+_+;BS/Q(5V/QS@'^.B""E<U,&3=L:K+8RW]>1&'?>(>-L30AA;#Z4H&
M/0I+&'((4$-JO]QP+\@T]O/]I_]4_D^T+F<2(UPG\<FE()\E.WA1_VW)>D.R
M5JXBG/;Z7C@H'2P%IAWJ)H'&+NI#[:&']R<;\!H+%CR,FI&X[*+,/8B[V$Q9
MZ DWT;,<'*QL;^S)N?DAY\;&PA-L,W883[&*JY,(S%=O@Q]WY?4*-Q$2]7A[
MH7W1YN(XC&=&%S3Q1EB##.IL3TEQ'U6M]GU@K^?*8O']6JNY=I634K3BY1A,
M%:Q%AZM1:,@2LYME\7'\ZHOBEJX<EXO>6/.D]FJ. "BE[!K.^0!\XU;J8 XM
MTF;PX[.J]L6/,8.7OL"B'WMU I;'':("SIRN;/=%;US\-'?N:OUF\8H2^A>"
M!D^,A@D^C37V!UI*W+!.+_'I(1Y[WW_T_G[^A!R]1'UJ@W5LB*).[):PG8^E
M*R\8.5ND+PD6,Z*%+LTF%^@!0WP@#C>:H+5M23]CIUY3+1[NKGRQ:#5_I6W:
M3OW;SE1B6TF" 9S)KFT(N:6K%'GJ@MJ@5V5%<=_+U?-7@*&Z+V_2H/OF"O22
MNRN[U1>$-8?#9?,Z,2KY]#86OR%%/;KAW-A")]W6O,YYPG:I_*R^5S57DJA2
MFO??L]UM,$!VN3DQ>BLM705E,^"+_?+.;JC4T/775$KXD4^'MB&[<1:@L14#
MKPQ9F1O_@<<5Z*@6@P&T3V5A3")- 'AA %JC7RCQUM,ZEP:'#9/#5[<AWPK;
MOU&]?1>N'A^MNWUCSMW_X?FU,WVO\H/5_1VL*.DL?CS%,)XCZ;)EC$(,^LJ4
M:PCBC^CM,7O*Q(ER>V8MQ ,[[_TI .*G<,*C8&6<HIHZ\VTQ TU6Y'JDS?/I
M.%>:_U(P7<^,-EVTBMI+#Q]//J%PSB;KE3.';&-*I./.$]@-NLKZ]*\7\X#;
MG_-BU5EA'2>_PAC]L-2MP=?:CS6:/HIFQJ>.U2"TE-W(M'FSPHO+>?'0V&T(
M[28R&GH$=3>?I-XR@;BC%M"\<:L%*8WX6W1#@""Z%@L;D:,\JDH1A]((=?="
M^1\W?K!63G1_O7H+"&-\!;)<R,SH7%"V> .EHLHZ9 L>SN;WAZ?(S6K@3@.\
M3!3+D1X9K[3DRQ>N^;%RSXE%?)F\FS1JP^7M&99\8OK1:**/VE<7%I;%GYN1
M>K9J<%7F%XA ;\#P<;$[SI0"!6Q&7YUS?,Q\<E:U36/FQZ.5S2VK+WPC",I]
M;?0O265P(:F!G-$ZBQBMI5AB?O\/F[4*9>WLXPEGN=(BXS.&X(!38,ZW3WPC
MR[GJYGPAM%*;S][-CWWO*.($YG*44\])BU>6H_/O,J^ 'ZF!ED;9UI8F<13G
MMV9&[L21] 3>)+ZE_S[=3;7;> %SZ(Y&2]"FB[$LI41!FZ@C2JF"J8].R?6\
M4<:(KF)'"D'0)U)C/?0K=U[U$F4BO<=#\_IB\SW,D6IO;%,A2_&?C!M&J<K)
MGT"='O"5OW1E[)%[^QXZF'&O4U0 T;&CD2TU2%YU,?.AY=5YIQN5DH]LSDP&
M239N0P[BZ.?QK+=\<:7;D/L>8#?CAUZR4& W75@&0#'E^K(8I2JOQ/UR@\>\
M3&Z"ID?X99P]M!+97(1I;PCX#PGF8XA6J!O0U?\):AV-U+-DUV ;V\W"K%0:
MK?BPT6( Z1N8QIR:$\,YTL'-0,$GY]H49*:CX%SW3;6?>:ZMX-K9,PHDY;%L
M4Q!@:BG_?+6+V3":E-M%8GS'I6]9MBT=97JQ[M$0$0^K^]"'%K8.%DV)X/[>
MK]4;BO^BX9I'X1O+IZQC&YU]KW..N-TB*?\FM5\T=6\;E<&HK^%<K-HLV6PJ
ML]L_?RT1-O)@CO.W>[Q_G0]XA(E^AFG_!G3L//Z?.'T1V#DDL><OD$2W6S1&
MW1]4[2X7_\/87WPP1#,0]*IZ*\"!Z8M"#'&.3[H*(?;[%ANL"'BD5_6V'#SP
M3+--:C.2)F#%"&;7ZUX(Z/(P\U5Z,=I0\P53*'@X+4*2$-SM7<OANE=Q/N#M
MQ6G[3*NP\H6OE3?Z"T_WI2Y)N5$,6?P+%'A<@\#HK <]\5Z_X"'LK+_@+[W=
M]X\V)^6_]EZVQ7)CP.*.1O"A^%SR<&U@!#3VK&;JE&#=?([YC$Q?G:'CN.A(
MUO%":DD61>O[ YK2B$.,I46,K<:'@-8@0<M1>#6EWHF(P,-:%K8ASU;F5U@2
M0R6J>\,"^AVRCU=R^ZG\+M^L7HI[7%/Z^IS[>7JXH>3=&UNJP81?K1%2?)HE
M9C?GT/L+Z&W_E760L>[(3,ID89&8W>N,E=-+CHG<VN?.'J=.UBM=92?KRK@$
MF=836$K=0E=/7:[E-RI]=.]?U-7=Q9G "&LCR HW%FX!^L5N*5<(C@SE%C=Q
M:W'/NV]5'$8+6$?8]0T7@/+6FOB2'!K6<O!D>(-QL)RQRZF%C6PG'E*X#\4+
M*+C]]/% 09 OJ_/TX/N/^6*33H%T'\8)()6ZO'?<I9A.;*YYE\ZQMG-AI-'Q
M ]3+1!I.@ 9"E"%%,0DW.H%I:G3S.1C*^O[7T0_N)>*%$9V_2!I;I8((*#IF
MC P/>INF%<7<G2JD8\BJ5)I&5\(9+\ "><YRIB%CI/!]#<*(63/EWT0TP>T)
M9C(T9L@/(1XB]L"YFOEC:VQ5@Z[<U,]>O\8><O@$4/]=5"KP/C(F3K3KB\+^
MD\@3$?WZ?3GANV#Q_I(\[ 2T3( /4=#/F$YM\<,XQ<FE'@:U0);[<E=F8O]0
M!X&VBDR$KLGJ@2U@)M)+^J:L6,=A5*=85/"AK VB;;WK1$]T55G4Z(]F?SZ5
M/:PYJG+<4Z_Q2O% !_]<*QYAEDIQ@%R@2^D:E*6,:^[>NJ3T'_:WM6(G-\B0
MYOR/;$.:V/07DZX"PZ/ZSPL=GTH;)@$6_V\6.UM2R;1AF53UEDC#G^DJAR<K
M-Y(LOCRZ/7\Y18Z&2\M'/W(821O%7D+L_+&CX90=PO0D?>/-GPM:&7\M%(!=
M,6, ^"][/H,6A16Q^=>B8-/U%1&!_+/)BGW $/0?7V_0U@LYJ_3<(=[BBT"1
MW$/8$6_[GL_H<9C0">"D8!&66Q58'I5Q^*3Z\Y"KD7C2$8PZUL1JE'I!I%C3
M.]_\5L5:[P0\F]C7>,/3ZR9]J&#<C5 &;>Z$7ZVN!"5F@S+"FOT1B/PP_!Y?
M*B]IV&_5-82A7<=$I<R;FZ!""#Y_)SWS#@8N/+M@_X:6R/@#U%-@X1LVX3.-
M;)\[M7$7;&OODI_O:=1Q2&J.E&RJ"UKE\"#HDPIWJ9+<^E=DU<1$.G9EO^$6
M:'OUZ^>9&WGGM.+[!AFLPW&^)A?[G2QT_$K7G;[!1AS:,+S[TMFY=)]FT:SX
M&(^0,T4>#5TL!\G'W2J)Q<&_+D%5 _@65YEPUE4@?E^*X%=:8K.FNWKTFTJ'
M0'>%EU2-E8W-US"3(<+><8T%A&K4'T;RS.16=J7\$T6[.$14M@B88&H;\5MN
M5P1Z[:\Y..<EY5IQ5TW_1@M0=?G8*2A#,DG<.2@7>/.[O$_Y4$++T5:"^H]\
M3[A]?@8#$<V/L 6DS#B=-3%=K*9K_#<.6)-*+_VIZR,+-?,=<=55["GR/:"4
MH5%!O?B'ROTTVTWQR:79O0^=@]64*T&,AA)^UZ.T9BJ[5Q/J<_WV!G0O02[0
M_VM'?(O="(:.AJ]HT!$[^]_3T+\P- L=]2FYYF#<X<YWX_9&;G'?Z_FXV+@@
M,@AN&QDP-L\&!L0G 80BN"ZN8W[/5"8"?"L"4Y\B#"W,TAR>Z9BBDYZ140TE
MH@)R$C9V\*3F&>%/%J].K<%+MS2V(7QU/=N06:N:;0B,=I:/);AA"%V5GT!C
M61:H1W1CAMT@1P@E3UN.P0DTM.&N"9^Q=W#G"MN,676NB"U\+>J\Y"D='533
M^C.77ES@U65AKOW+QJ/VU$=D?%@%=@H->A=Q^2)F2^#O-@3..?L2;"'R*9A4
ME>N'-K<AH58S,$9(:POR5$B15_X#(M0U W[8]6@)HV]Y]WI[>"FK$+%^6]ZV
MC2[%=!,AT6#7".2-FIW^(G;Z"R+$\\E9*N=1,.XGAFZQ^7/+H]GK0,;DHQ=O
MN4_[I:S/W4KCKH2MP\]QX"V1C$DEPA0Z\9_F@$;^'>>[A:'?(="8G5!.>#"N
M;QL2@TM&\3%/D (B&2&#VH$A6C:VPV]MB2QSVLWK+'D'1B [B06C\S=Z% 'E
MS6U$OU7U+<7[?L?>435X#.]Q+!IOR[2_RY/-3AA%^+S7B'@@F[HQE+.VS-)=
M-=R&Y-@O@!F*4H#Y=[[^:3^"F^5!\XN<@D,G71J@ X2J"J;?:/KE(](;(KNK
M=(]RNC9 /$-IA5!X"U^O80_/Y:K8FWPHS$;KMVE<DLKS!)!G[@P8Z>?-_]R&
M5):6H*(75G3!]!XYZ;P-69,'@S86$(#^'_WKAA]OR6O\7!=D:Z=:YU@R]UJ"
M0^7*>SQT+0"NX,I*7'[\I(ON=M-A'<EPVGECW1RA M%Z2+W);^M0R]N:Y]^;
M+&=KC^ W$O-"W! )!)HQ;%,'=A SI(5E'QM@'K=2I=TS2[_52$D]R_-C2#=3
MKN4.3K^K<)!\^7W,9N[@SITNNVL+GP$;S(L G)'<=[$0)N"R\,EV=N,A8T(,
M>N[9?<DK)9P8" TQBN$<H$]M0T8_AYRI[%@^<K?MPUB'QT%+H8:K'DD\XO'Y
MI24(,)H^-P/XB'A[_KK>2J3 7%#^BP>"5?BJFJ0$EX=-\0F-3XC[]X;HZT,"
MN",Q4]D-0C2GULQE,>>:H9B*L26S.ZZ"-%=]C^4W=TZ['%'ZZ:71&> ?MPUY
MB'AN?P@(!0LK<F-H4E$TOC5?%N<HN/0&-1-/=:_ZZ>#Y5WYYM_?.]3/WP*6L
MI_U?[R_*2R,_L/^0JYN$_*OAG9IWXZS9WZ0>'.N8'+D3%UFT=&Z99>;@F^^*
M_#Q*TONT]#7":J2.>RSKPPGAK:%>#@_M/:!"K-H*J*MO8&KN6?T[O2J3PE6H
M[F-#S!/XDW4E0^5_W+G="BQ396.G$$='YFI"']5\E9_>30CV;FMG4[1"?UD]
MV-,48'FE)\) WVL;<I2S=PYSE&7D4H P/=7I>JLMP4] 8_,FVCPXJ=_+K:KR
MA>U8FVCR5<B[E/9W!['\K&N_4"*G%$M+7$1O7U>.#?07W\O)C.KT@@D0/# 1
M&.ZUZ[AUV'&7]%L_0&;0?%3W4MPI-2YYKY_])0!&)D2K&,I^S1V>1^YO$HNR
M-,T=.S&4R;(")PG-4@$*W[<X^+P;LS846^9S?#[1WGK^QGU*S?F&ME%<$2*]
M&*]<W/V=G<U6='8FX86($C[DU8!DI>,N[0\+"#_2]!,6H.O?LS89+=XV_BR!
MX*FNW,]Z3I)X=)GIB?B[:W,6N^3$2X6Y)FL.03D'9FC=1D 02C=#HNZELCOS
MVC-5,.B&8C/72^1,P<9<89WN\[WDF48R3\IY>5W@[^]'ES0:Q4ICUL_3?["W
M(>[3A%K/22<!1$EP0Z>2RD01P3EQ%VG44!GH:)HO.WT?>B?4%GO+)@\*1?%N
M0_2PX1B:!S=8R-9^L#(Y8JV\-;AN7MS6?R :OK=82II*\C &DT0.;9D3KL.W
M#8& ND]Q:TG%Y<SB5&* S&W(7FG F(9K/O1Q7O(DT^2'LGWKOMI$#M,D9@ P
M9 :A%(!V1E@>D-'5MPA,L-_KIZ&S'XC,C7Z%1R-HQKAP++_VU=$76^Z#RN?;
MTEWD]:"_/_ , . C]Y"!![3T)>CC'H=^W9XX-IXMA;3/7$VH7.B_BQP(:5-R
M \2/;)&J-HK;@2Q8"W3,D(QKLH.XVB3&5!1^4E\<>^"5_L0).Q67,OH10#(?
ML-0!+/E[I3&?H#.#L?JD,.1I6EGB9XT]EM 6OF$^,K9%@I>I2[U<47J9S.JX
MU'S,_V^USCPB$O8EDHB(X$C&FN)IZ_&_O1*D:Z(?OV3?#55MI89O5:4STC>M
M9]G+58/C:9OC\&@"GM!$"@_JS$K+H;@9%R!%+$2;8S\-R7'YG#R)D4P=L4;W
MV'/U%^6^03TB^]Z]<YZOX%N1RCROHU4F:N=:(V^6$I!>9&-_SWGNX:![48$S
MZI6[^(H09.A1/OH[]G"1>VXXZDRN9FO.%;?KP]CFXK,=?(LYB\N=#!S^^QFF
M?:#/Z,1A[A8"[0XFC,,[Y-3WMW*AX"/>HVAP$'[1:?;'?EBX>1]AJ@BSS]<8
M**8.5NY-=MI_,./IYW=8<X.]5F"L..9$AL?ZCBQ_**O')_N=,^=-3U#=.OOR
M;#;(A'M" 7@^0N\2OO]-SOU&^Q6#VXEF-?51AM(,]"I6M<%*>U.;F*DO)KF,
M9%X%CC%&-:Q:[84L7CKN&SAAKIOK"^,(D4+OT*DP'C"SC_)QSI86;4,<,9&6
M506BP&U]CS 1M^OM,&#I.LQQ.1+,]$G&( =_N[0- 3(VVSP]U'1\_WAACQ"F
M/F+W<T2!!#M%9O.Q>_?TXNI3R\>;T0EO]N$;!,',P<M1=!%*'T5&%Q4_+.U:
M[Q>^6WO?:?KN?@7 2FCGZA K&H["%Y77G]_W]]SO]"*_\HH+B>\+=N/1@CO'
MX1N$6?*]R'-+:\ZX-%JR_>K&WS<05%Z9(=F^TWH::VG?V3'J@IYTPO(5,Q'H
M<4)T6#!8 (\ E?Q)(]X%FS!MCXI7?8\>P:YRJ\ZC#[ +.1+ *G%P*S4_MD+X
M?O6M'^E6I;;?5>;COB6VUMDS.?NW(;1LSE^C^(8/'PW.79V\_BYDW_PZ= ^G
M&7:(=90,7 3J5#].&'KF7$L_<BY9?>#U,5>?_=.3G2%F'9G%#'D>^KWNL=&)
M<[?H0ZSCO&2G9]IVR/>3 1F3;H7O=QLYZ_9 NHMB4Z'1)90^1@1-8J+B"2ZN
M3K'PQ#B7Z\LS4+.:NK8V&,T4$\[1I(<TE*J]K"JS/7)-K7/ZVO"ZQ3=85,GD
M$,,0\'=!BF-H,<Y%1QP47$3DMB$2)=I7B<&7@L560PJ7,%)!BKB+]7G%O\9
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MI>24>;.>YVZYW"1\Z1!$8'#WQ SE4U>BM&"NB87+:(.>0M[8]GO!_&">*MN
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M3KHZ>#H>GNJ=TL/_\2$QM&N8),&,X.R/O=43 J**FR509FXGTL9?8:=M7C6
M6T@: N<ZDLK;M4#K?B1,U*<'?X6H4DK ]#CF&%G_(_>0FNFX!_(76U@[6U<Y
M]X@-2F%RZP.9XS#8I+]H[D_'7D4*\;M&6)7I*>S0=V23#6\7DU8'Y=S* -G6
MYQ6048OA#VV>G)"@1L UDN?48X6G<[66]#T,KAA[5<*H0S6(:(U3$F%:4N:8
M"NL TF?[[.N$67K0PJ]@&2:.9E0'-C#S?A#=.5"_Y'#VSDVJAAL[H$G%.Z8<
M!,@-R![28>#(S:KDSW[K>U7D(2>590_?57?VP/2Q+VW^%$] '$&_/!++#^#-
M8WJ.[P8;NYGD/]1^9=90VJAOE;?+(A\M:5X=WY AW7LR_-(?=^N-DW8L=&?N
M7JY-A^4[S BP -^+!PJ"[PZWV*S%EA9A4)G3U:E6UM,IP8V_L(&')LSCO*;?
MC!.71J4^D<,0^XCNG>CG1HRY\8\/'IB,-#A[+VM0_N1<!'MJ[N#B((Q7DC5M
M3.ER64Q>3**:I%QLLA1,-M^+7LUB2G'VU]PD SVH0FL ;VVWXZ*_6DO^#8KZ
M QT!&S_O!2O3S"N)YOF4#V.UE)#&K[[.T)#TE8'6CRL6]7*/X0>!RW^4HE$Z
MY9V9K^:]_KBS#?;)#/>4O(N(8"+U;!""KA75V05B1=Y'G?B8PK\R-PU$0HQF
M,9MYT/E-*Y\&^Q<$N&._M=!C.3"[W\>*U!(,L:[?%JCY [/TUE8/=8DR+T9L
M?:7]+I"#^!F<ZRGWJ(&WO@] +S==,,%H #9O.-*=(?5O7"O6/?(O+M(N%:Y;
MQ&U ZDD8T NN2L4@&,'^H,8 GQ2! 5"\<",Q[,@Z2(EC3'P+5!<K9IMG1],[
M-1??PX]BY'_ S[A$Y\ST!Y.R[S9[1=[;^W%==%$.\&\/WX!,WMOL]6_?A#$6
M<""9[_BGTZ^^&F-^^#DFF)K?;XIG*V+$&2)1[OT#.HRV\$K4T2 ?;N>-XI^/
M>FNO6C+#XVFQIS2OFI26ND($BY;.!G$OQ+=AL'04<#*8]?]P]]YA36W=OG 4
M$ &!C51I46DJ3:6)0&(#!$1 :8H0%04A @(B+1 4*=*R!14%)2)=2D1Z#1"*
MB(@@'2$D$9&>4!>DW<7NV_V>\Y[SW?/=[[G?'WEXULK*6&..\1MC_,9BKCD+
M:2F?;=[0;$NKI3TC3Z6>>U:T'>(JX'"+,8W&P*EF#IA=TY*7TF1HMG4B=^@H
M6G!>YR']YW-CD]"(8.$<H](INOM<=IF7 ZR-\_HYH60%@[0TUZ&#9C+-2/F;
M!06'M^MN*Y&C?<0HOKEI5)BC13VB32:A&MF0+1^1A&4$H)00[I9]7)HE3\M)
MB>80&?"\-SD8^'C"%DTU?6&D'M>9#X]9P<SNG3W!;W3%^U[ ^IHG$QDE>.+^
M%V;F^LW2)5=#]\=R'>U21+3<K+E7VP8T<E[_Q4G[SS==IG<&1\3C]R*3:?YW
MZZ&L;JLV@<P4Z ,NW(%T2FH'*[1LD=B& 13$"BGJPJIM42B[UVW(-UO5_7A<
M4;31IREU=!BZ41E7*Q1\>TR!9ENFXB,X&LMO>F/[U(#SCH';MP8O!O@YO0BV
MGDV>]J6[]^3/3EB,SH<HC%L,633 =ZST]9;"^=VJ0Z9W\%R-L(DB<]T)5?Y\
MFXD@K-ENO&T:1G4_?G[&^(F=]*3^U=KS+)DE$GYCESY(&<-G\"S="S!M$**^
MWS?P$3B/67US"E=MBJ)]W/#HYY?RWC]?V\W2^D9WZ\M]<0'NU(8HB=O=*_YN
M!1T.@U"5[I)J$5R$C.82V SFS5OIBGKBC..@!"X![;H *'RIY[FWCC(AXWXZ
M_1EVE2Z0I[];,"1! QC(0O\&7/7?@:M\YO;5?"V>I2)F.T%[JNC&8GU;"=#6
MF.*%N<VS7'>Q7VJ&[WG@F_?IC]_X]M3&VC(?AFZ_8=?N$4(",]3P)9.PX@_%
M<MI!EX5L!!G"% )8 1\FM4$!V.9+YH\GH!+P\<=K8_MI<_'S#\B%G@9'=Z:Y
MCTZ?-]O/L8N@L1/.X7"]#PJ7?UUI'*+W, 93\^%E9M>U?CA(G._5R]S3Q=7J
MD5*/?)V0O1YSD'C",$B$R*>O3%[8<O)5.=8Y\.5<\ZW7^2<QGGU+T%8BH-#,
M4J,R[Q_ECO'[/G_%4D$G)7-I/ZSQZ5W SFU<'5"237H%7.PG6M%T8H<7-;>>
MW%;A\S!IEC/,AGR@PDC+H.01KKPZ,,E4+)?R+K&<V>4/H*D=IP"'##7LRZG5
M#8^4Y]'IQU[#MSBLC+NR>/[N16.&WB0!O7PX@,*&< ^@&3ZU[6?/H7K\7:VO
M)KXU6(RAPO\+,9Z(0159D-$-H%T9U^^-P7=^7PUZ>S'QJG KU,7[^;5@WD7P
M=_]>S&L_!1[?XT/KPOORE$\O>XDS5*C6:('/)_L+2BM1>CQ25ZH&W^1![@XD
M/'L-%5A@2:'V]\ :7TZG[?KLX8M5DZI\C-Z-;-U$9:.F*LIQ_)FJ)E0DX)7!
M\><_>6G%/LAH%:26/-RPBP SX'-]3P<X-;F""5;>M8.:!_N^XPO(NGXCZ&>3
M5]UM<\ZO:5:5?F%N_UR+2 ?*AP-F5U3AEI@K.Z-=+T#.Z7[DO\7B .RH;83Z
MHTF65"8NBC+PO/A.><"'(0/?!.0DYBZ<:CJRP#TRS='L=* _TXVB+#A8MC\=
M,D[1LW>EO2;N0(\_&LZ)JE?HS'4?4^XCFEP=$1NQ>J);-?7$EGLE=Z->%EL:
M?W1#(6>M-L;F0/OQ]VEU*$PEM^FAS@#HC^["_,.N 5&O@B=L^E9J'+=V%ZD7
M%<[.#82K]'!: 6G*!#B)")-B0]+_Q/E[U.8:^>Y# *XA62P(^H!Q7C9=;K]1
M3;^:0BR'[GO08+:E>WBLK5+?>MD-QB0^NOK%AN@\52C>/(Q^L'OI-GW&X7O)
M/:JIO!40@W&D>3XCQ>><ZRVXO8*N]E2T7PLYC)Q AV&I9VRHB,@48K/3/II\
MLN%;_B>%^OLQKRI%C5=!;]R[U$F)#3:D#L24 2GJ*UC//J7GLG4Z547O2&\6
M1&=?6/BN%UPYT&<CZP<-+EZ)C*=QGZ#)="7ES!SUF!W\^$[MG!$T3$LG5E\A
M!Z"<2#7O4W6N?5LID;A_VX17(<J*JL[B,2@ ]%J\_,B"8NZ)%QY!^)37KR3I
MK]ENJRM%-\+^7@P/'.J]\2G_IM;9Z\0KI&GKO+,KSJZ#RPM;4?Q4',%Q[S3A
M9/?L,MVA:Z6;(&&3-'/7$N!>15'1!'Y/"LA[]62.KBX\N!ZI8!O*^%FYLXTA
M_.^\Y=LA9#.V&+10Q,JN?\_;;V:.07%L*U[!1TL*1GG6=^4B)3WB!KN2#=ZW
M#FX(.X&J"JQ3Q]!?_^)N;!L6D&<54^ 2S'Q"O4HOI7BQSSL$K=)S32#016FE
MD"JRKR^_PPD56Y6FF'7ZQ#+E QV*O $[U(.RJJ'KG"ONU:^7FETJ2 VM5"S-
M)X.D&22=KG[CYT/8$!Z=F+)VU+=MZF_<?8_?3:!+N-)PUK^S!<3O;,':>?^Y
M+)NFN*J,+P4&)A]Y;42QSD3^JT!&RT59C&=_=7U6SK!JT\_GOOEA N +DC3B
M/XP0J#X'4AC.PGI::X:74B3#IM!8!!E%#\W2G+4H7]6RE]1\;6-5"#/\8A^3
M=%_]K'Y7\9P8XNWFKG;2TR5:Y?$D#]-%(W6EQU_?-:=E4K1FG(2I=[#C'@(R
M.B9E,1_??_%(V-?:=WR6"X6@"K-X#%\#&LV)EP)B6U)*GQ1D;KF>:\8WF?"]
M8:!4$% :B%QB0^3^@(-RAD;B^=7;T]4/YS^\\:X-G. 2"S;*H)@KG>X5ZUFP
M?E-6G22U-]'/SNNEDM:KG*#YCQ.>Y'HU8'.M]#=U-,'F&M63)C2G\A1K!51?
M56]VHG/XQUU/'ZX/O'9 -QK4'GWRO9!L(>5I Z$XU;2QXHIN&DH>O*]P%M59
M:.=\T4]IO]:1(=7:KM.?X*X6VP)<6]\",6TGBBOZ%>7K>DZ],FIOG]Q5%#/3
M=E0-FU<8MY&-Y:=(JPC>RM\#GY_4HL#_D5\7H9N3T ^L\"/($_4Y.0#N@J.8
MKL[1SMP/:Q)MKBH.*X4':1&!\(+>LB?Q,XN*^8_WL:9U!C9<AP>$C/UOTMYQ
MM!U^?&7HKH361'7.K#$5?P&?.#W9)'FJY$/+B^%1GJM!JT6V4$ )'V6KP+\Y
M+([RNE]"ZCAHC74JD;DC[<COW4>1N]_T.:\A$YP1\L M;&M1T'P4B<E!@D;*
ME94Y&$B958SO*+#*613M0B)X45MHJ8X5 THEW2L='<+TFD?[#T4SC;S[:[W(
M:PQAI[866;[*TFZ4%3EW 3LO5>CRS7Y#-OTYIJ>X'H)N/ AVR[R?YO?0H#$H
M0P5"O>7@=$E3)277>&O-_MP#:O@R]ZS5^;HS"IUSHC +_ZH%O'BH#,#7LMKO
M#301#1/UG%D)ZA=$]K,AKGY^8Z*?2YE*A-7^C8M-U:C38D("VEQS<7;M:"C8
M227[!O3K'2+A19&T4O5GH:.O+;2-972JVDB..??PX\\W8 ])L7K!"\(!+47D
M.)5(&<\IR^>^8?(0:]LX6*'XG!H;DEQLO5Z7?U;;D9X&9F9^=?/^6IU 9(%J
MS52)D>W7L\?B<D*&*-"+$_6\##@5>M?#2[SQX'=JBV9J$:SA74,%--@K] 7R
MO3YH<LYO/5K8[>YBU>@'M9<KDIILA;4K?&B1<R KPQ1Z8TNZ&#L7$1Q#[CQD
M+]& >Q<4DV\K$JS3(.(<"YS>20.%(H]@^=K3%T:#ZQ@M.NH>4D8S>.=99_,#
MK;7)I)S9P%>,@[131PN+*LBI5>F<V^=7D \HNI3'KG++N$M*H@U^N^J5RLJJ
MNET<.O)4"E<92RKU5L=9:^X4A@:UIC'%L26NW-_LEIRSPBNMX7=WJSKVK7Q=
M7BLJ:2WWE\1$SE\NNS=&=K/,-:DG;5"1!(8H_5! QTE:?=3KT8"8784J9H%/
MD+Q[6S.+AS/]9OK#8)$RRG]_4K42;]<B&7KO?47RD]4/1L<>%J?0T/%.^S^7
M+6"(@K8?%_F>6/D^E'*5;G,$MIL-^SJ8P=]--IOXC'2&NM;\[2D6Q\O-*6$:
M?YUD]I]]E*,!+%T74*9H?=615?SDH>56.'#38\]E:W3#Z94B8ATJBVZ-;K2Y
M#1T*)Z<"9P!XLZQB;\8N[YPW>FC^S/[>Z^<.URE^7OST$2<7__IFD"7S;OU/
M26S(WK.I;$A(.QO2<@[D+5L9>\#JK6S.AM1_94/(^9/J0*A".AN2HD&38C&P
M+!TS-D20 #;AKS9/,*$L'4>L?1M:'T]58KGJE("=]@$Z?AQJ)#@H3 (S[K,_
M)+U&0@<M2-K/ F6:8?R?,U+$!.)D+1XE1"W8=>*I##.+#3FX$'ZA&\3E;2R5
MH:?!AFBZDG68ZW"&)Z; &9V& (39D(.K 5X3".\UQ[+:.[93(F;E1UI%!)HR
M<??A).".,^M&6S."OH@&1H,$9SO8$"Z3"F8F[,!%P D>6:]!7;K4VA/REG5X
MCWGE.".\* 098^WNV=TM^2E(,<31T*ZN"JFW/\O:35)31;R_7F=S<BF76CV0
M6'^@(M)<R7P I2/2I88)<541YRE)W]',LT6"7C5S01)[PPK! SBS>%TIAH 9
MM:0MI?_%*P()*V6^&G+B-.EROXJ-]O-Y.:[G@DUU-2WH"MA=*L+$_'R;Y'W;
MZM \^:@S=-7G;S5I>=-W(J=Y/W'CK1!P0(/%>X6*;7L0,!Q:<IL-N5*N<VY;
M\3.'#@G.L/-*G'=;S*^#NLD!=KG?^=#;RN3'K@\,]F^?RW2[:%Y37*H6Y-L3
M9C =L^Y/%ISSHHQ"*5'AES^5IO*?;PQ5.]PFF>J?L/'EE>=.V#<IZZ^WK&]K
M-0 ++-Z3%*\(J# #06(ZF/?X06=3\X_<'.L?I=QX0@D]$_/!C'/XL-W6,-CX
MJWI;9AI^_%4[A3CTN16F0^./\\:%G\+Y>&R3>V83+15$MUUKZ!KF(W.W$*..
M6B3(6P@.!WBNIP6.WW#HJBBW)![R )3DWBP<@QIV.W$H,43P)-7Z>%^T4K34
M["KMY*W3Y3^7M&D\B@\;2>3ASO)=(U)M,)%K&Y[)VN&JJT7#V3G,E-SRGE/O
M2*N']CR2Y8>$&!BBUG+0C6=A(M,Z=I9%>:&XRX6KD1XP;^F;.5S^LR,U(P;Y
M=P'2YH2+$G!@ FQ(TX[5HUGUN8LM/FI[+U,/&\J'A]^#?6=\YY@]H#R!'OK,
MXO4GP67!UF!N+0:WYS/#,'^HS5\KJU:M8R=^5-\U[]W,<)WZ>-<<;APQS-&\
M5FT1L:".*[JI$*#HZWSX5,+]2*FA$U3C0DC0G"@5&@,F[M>L ]2*YGC?TW39
MJ-O#3E6RR5SWO76&<4)]"=;SK4:'/M?YR^X&66K<#'8'W"T7I4RN4^OI(%2W
M8%)S'%__1*9PKJOY^-SB^;Z/8]94>5)P4&FUEB8X9Q5,N=Y?2C?016D4F&<W
M/U3_0.)E-']-\$48?]IBN.L_G]KZW_]T_ODB]G_XZ8_9MR7#[TC*?C[?8](5
MF%"! "_RM>[V0K=7ZV2)<]<?'H2/R]MZ1:!=%C@!C4M1YSZ7'O%8>,DIG^TF
MG6O@715=-$L[;:=89A_S6O_UV=$BEZG&>I<R40N1TIBAK(+X/]:W_%>?N&Y#
MB(C5GY\]HE2NB5I_.-5.>>6AF"']""DR>. [%XI;AY'53V?5M2T5?O=;/E3X
MN9?>>%M*!=U6 %UKR&(U@J0/:P]?N&O;9JK,ES(D"G]S$S_9+T@?MV*&@V$'
M>X,F;BWL-FR[=I[56/+;M1;A)N5E/VO>H2D'1>P2=8F!1+(&QX9,MCOO>F@:
M"24@C@!X%L](-N,X3;[Z8W'NQ:Y\YN.Y]+J8KH[*+14A:Q\O7<% 33<LK8Y!
M=0&P?QXEU4"'U,\")OFCVGD94V]/RI^_.;1[\9F];]+ C7PL%'ZY4XD"C]#7
MR"3DF64/ RZCA>/OG_'MY]7]BKYMEXTRIW5.1J ND(+U7!#*MI5/=._*/#XN
MP9AYRQ<# 08V%Y8Z??'[G36L,RVDKZZE\WZYLHKWX=(K@X?@P</YP$G6=N;U
M\;Q"KX):!\V@SL@\9HZ7C^K'!A1>);]HX:E0&M,\1)6&ICS"\F1%R%&]XFO-
M)_=X;"BFJ"6JH /F+]FUX4NB&*+^K40AEAXR1:"8NM"\EN(8D[1#T@:##<(>
MA!Z][KV>DMM8.OS]3':2R8I!1S.TV#@&S+=QWL ;QHG*BD6/SNJ+A)OO\@D>
M^O"K:&G;K*C9\Z)CA7G(BZOI.4C9O;VJ3SIQ"(LMJ+)S&0=,VAMG4K[B;^"
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M&B7A).< -"L\R(+%I00,/$,3:C9W@^W6HK:Q.+"TC/\S @ 4^H.7Z6_'2^J
M/[H1NJ&XN:=@@R]+$TN=7[BGQ'++B0 [H%^$^$'%\3?@G P-*O]J29%[M4UK
MJON6Q_I?DW2/0-5UBUS'<^8BJ -D-($/OS/ W_*SQ^U4^,%W89E*^Y\S:H-L
MC>-!%SS%<J+<2#7Q>JR?#*#F="-XCPIEZ+ S/?-KZ..'XPA ?J!1G2/@!&5S
M8O;9$6NZT<)RS;A\I?E8'(1#IC+_4FWUO,MZ5>G@3"@7:PPN -8@5>-S99_*
M\A$:9DD=J1\?6[J.',&90X5N"VX(N,'!?$-!P!F'-Q^LH'8"2+] '3 *9M#(
M$+J6BFEQ\#[(U9H]H+NIP%YC1I+%#E!#7= 8YR;P-<56=75S76?!%!D/1L8&
M_]0OPHQ_M./2GE\0OQ?]#00,&[*E:W/11X$_0@ 00+=F9GQ&_]5=X 5\4B!/
M7);J05/WPUMK.WYP%Y0Z#RH,7S9'_8K)&QS_PP+Z+>)9NH!#0ZA(7;^Z5IW.
M;+G0^MO9*J.;KM*0D)GHOP :P^"&4ZPWY\ES]@)R9%6!;VTLT?EPU]7[(Y,.
M+>7VS-[$6VZ%*]SED?@&^(AK [S4-LD[\.6,;;U-0;;2TH3]1^,!V;+OX63U
M*)#-_OQ;"&F-X\$ 'D_"<X9*#'8*,O;>J9Y\/K$V?<RT?78[1\P,-T.8,/X
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MN_@H_6.1_]JT\B<8F(P;75C\#%6:7UJR;)XOKK#_PZA;<<$GPTK*MZL$B>D
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M-'HBO@EZ")Z@6B342S",EO#%GOK*N2'/RCLF"!*#:%'13S_8;MU_=7--(%C
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M4:7U"3!BB!-\_RR776A6_60/>-D7^X.IPY9;1-ZUW0Q9)N3-!1B04$PJI!0
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M[-N?3@N60($J_06G6F19:#SV6Z$3%#@>O0N)S@LC=A+ &5/_G!H.@&! ]1P
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M./Q)_9$QW"/G,F\5/:VTGCU1U*7([$(X6Q-G>N>4#MF8U_8Z50Q:;X92-\:
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M8+XHQ).UG<8&'I5,49:AHR36(UP;AB'<Q@;:^SB/;&%FP^<3&+J<  W@#$O
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MY>PELN[75M\\51\Y'3;R:@%>C7BHB4APZHUV'YHV.O2=;#05['NY.$Y:UMP
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MA)T/TO1P:?(2@CH!02(#A]!$4=AX[A82U?0J8#A2%Y=T49FA1(73G5Q:C=C
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M_F9#C6:$S^'Z_GNCV8!7+4H]+U#__2!/5&PHQUQ'Y*D4MJPI5]UR.EEOOAR
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M$J[%4'"#<;3UQ_CT2">_/1=+FG'&2W-W9)LJ)E2APD7,4.M=0%JOE;>!6U
M%4)3 H>HW0+'X.*-$7ELX*918)+F[645Q]VL!2\/'=GJ;2D4G9MA&$^S'6D6
M*BL8"#%K?VHM\_7"[(SL+;+GU=]'=:5'U*D9-&B_"FXZ>SU<@F*8-;; @GT0
M>#-NSK#%*[V6M6YLG,L$AA)(P\4$F!08W**'>K@B3VGSWG=V+/?@\?;LT]-!
M\Q 9?0=^-K 34T=7!YORO=F :IHG<6FX1E?_[M<3\#U\F]#8/K#-E)EAH.]6
M>L4,EOCN-[^/+KG?MEM^Z?;;.1U8)_06!VC3F?#*FB:Z0?CNYAKJY7UM1+\'
MCO5#V.?2S7NRK$X8_];@^FWW4N7N*+U[37W#\-:L7>5!QRS6 ^DGU?V1?(=S
M_W%"SQ^^_8R+BHA$,_S__HO488Y"N38?!DNG5Y?]RGR,^ <SSE%%/KY'%XY/
M/-MS3=SI>5/#\2ZYJ",,Y52*.)QR]>^;VSY,%79Y*Q<Y@(-Z4+"/2)F6"EC?
M:J&#S_*V:FK5?YIUS7.WYV\G/@% ["?4?N31\)UHDG8TXPQI5+/)_=.1PHF%
MCRU5#JD*V5-?G_$(KL>[)6)O41%C[J3>=F@"IE+*>]-5KI'JL1U7?\-3/E@K
MP1N6^NW,#M%]@F@GILH [F;OGA\,>ZI9@ER%N,/D8>>05<OVV-P79_:?BKR[
M"Y@)-AB"HC$5GM%P+[78[?A8M>6]F,+%V--7%^26*\\HZ;@=<HN26#*65>;D
MJ@><"R5"A<$&PB_LM MWFR0NQG;?S?[I)+<F 6F/B,F3<7,%$8_=0FH=?$O4
M9R.E[PLLN"K3#[,ZD8+,IU7Z=/C>"1_Q$?'57Q.+D@4#$RX3/!=W>=QU+*^5
MSAXBUQR1"$K9-=$%I8_.*4U&JO29>GWS G(3^SYR<C-AN@A\H_HB/6,W]D[-
M]\,8=T:^XB@F=0PTJ(!KU?1_F=4&*BUH5/^>>P)E7-)#,\,X"I CN97!XNT*
MY'C> LIQ5(";#>05Y$"+TX^+SW*OY>_S7'4?%SVP8 *<IM1\/6)'BEFPF[J0
MDD!.<9^8N.PY5>V:&ZD+3[C/!CQ .^+5DZH:#>@7$<2=%XR>KT\Q!$L4_4$%
M[1:M=8.F9L$/K7R[=5S9 //6MAQ)APTD6!/]Z3Q7V<!\#3;[3[-Y%,_:K4L1
MC9^TYG4\_KEEIU(8L#5.^PKBJ#$NS _(@][9@M3^$,\V')2AXE>691+E3+;-
M2K\JU&6MP_VVB'&6665T<%$2$_M>Q>#&6R_*HM.-Q-IA=>_20ROJIO)/ZQ-)
M@4)(>];1;3;0B2CGP,>'A!,)265)86M#!LY;*MEYU%V3E7_Z,98-1#G834]%
M(<4I&7'O[H7\3M O-50=5;GF\TQ<6,,+ -(E2-RX6P#C,1-75NTS-<8I>X83
MO#VQ(8H=&JN@Q4;6VSSQ3+XC60_.U$$FDO"SD)4GS%@0+O"^@#+0%NC=OU)>
M5Q[;;__Y/I>ICL&>D5Z4#&XZ#;&'9<BP:J+&E480&[2&Y4^]74B7S/_PP^=\
M_M.*3^\$:V_+/0W+W/9OR[3#Q?^V,%2=^AKWI<.6-\7AVL/#7)=3AB/U](YP
MVZ[D['BB;?-O@/"-N:M]6V\$#Z=<?/L<?@LQ6F+8D&DMV:*=%K.I\!M;_IG8
MK,?1BS@V\/D'\NL43;^-@PES8]BU4[?=3^LLI7PNTO!+UJ-GIEB+7-P)OSF)
M]$7N'/2[=D;=_M.'5E?\]E#)86ZAWD\+!3][ B3/2->>K9IU8 :Z2V<W 8S2
M6350<<U<FZQ"/U]ZXA=<R)L$G^C(VPO?WJ IX"=@3B ;8.VN@),44=Z]=(EW
M\-\I;[GU67R&1-QC/0Q>+1;)18$D.G\Z$9+IR!H-FI&/NU9XP&A->Q,]YZI,
M4!N'$^\7T ^"B*MIG1E:'[==KRYL9@1X4WOFWEUH"V6.=H8%)#_?1*'AGI;<
M1'@[5B DS]8"2_;GKXIK3;_/4BG _19TQ/'B/+ \#"@8DBW5_WM^M6JX+GV]
MNX%)V-M>*?V*$G&8>P8UYM#&P7=5$4,HRY9JEK12.%*==*RLI_KG:*WLM>:S
MB*=^D!FEDI%0^J60VA;<7I3;ZIY%EOSW>_Y"/HA1P85L6/_*&^&>!P8ID:*B
ME>M">=DQPTV!M/?,AXTPN@M#K9:27F_4E.^E_D5>*U.Q2/59LA%M_UG3U2Q(
M-K&QE AG"(X3BCHP$!!V>JAZ]5$62U:C8E[<)J1PE?P]8W2]<3Q&VM>ED=%(
M*@/">AG",=,K!70]9"<<&BY72DZS[?O=JSJ#5YQ-RC9[NM<J9"^$X$KFFC"*
M^$A[#YU&M)8B(MD U)<!=X]XOR3H;#:;OUTV/N&BT^LH?]<17:\YZ1RQT=K"
M']T<%WG,QM1KPIA'Y'9>$""ZCF"(EK(N.'0B5J_\*2TU?Q<N;F%9? .]R\HD
MM<UEU.\:28 &']UDG7.(QBWSW& #N4)/X)Y36P==.<WE!]$,UJ/SA[G+Y33\
M9)_9&._J6S#]_L#&!%#\KF_[O/?6X9R=8R>_VQ*?' ;&# ]SCMS(?6\-WXX9
M'O'*X?;ZG2<B>SB'6^0O_VW],XTYH#_\UQFW8*(Y?JNV/])(E<)KQ\'V%./<
MSP)KAO)KR H;&(DXW?QE@K-:J,9J*@R/&<T@]6209]^%(T"3( JYC&%"2% 1
M>X 2*IM:2:K\>>+YVIV[X>NOMOD&7L-OMQU9\V"^=C2%SV:7X6&K%R&C^N=6
M,)L]4N=D+K&VL(D,['@;G=/_%C'I0SBPQ. ?38"NYL8&"E&;/?H"S%DVT.Q#
M4E.F45B<0G"!#2 W_%E'T1R;#61C_LLMVK]8:VQ@2B-\:A)!_]5\8@WG#UUE
M?<-LKMJS >+;?S*YEZ>RZ!Q6#^];1X6B5C/![B_,1CB.KH>::N*TV4_R_M',
M@58B_5?5F.MF/?\-A_[>CC3"477\0=-JV,>I^0IJ(FHWI]*?3K1%=6*;=T<V
M.-.Y<+_O5>,7[7&UECV)'R9@HZ,Y+R_X5P?9'=AGMK/Z@1)#&#>M6DD_QFI'
M[67!P-3%;TM7*=G/:1;U*C&A5N.CR3_7&9>Y5A8V(?WI68(3DLQ=1P8!FU,<
M_;G+!O:/P/<TFD>MHV[\530X%6/T\5UL(-Z. >G60A$$*^EMZ'K$Z?!S%7Z!
MK=N=F#T),CT;KVJZEO-+Q$]SZ6R/M*(JIEJLQ]UIKDQ,HQR%=*H1W!U:$*)V
M(<&B.GM#$UYE(;EG5YH;?QT;J !RH-\GBH;@JYD[4B8X?\'>?V\QM5X%6<%'
M\WS"BICK"(DM1&W\)J>!LJ9OEJ*HET/_T>2B^?]UT;VV<(VXS9[P&[/(2=@4
M\S5\=9+3 W?8_*/)P1I.>S.#M97W5T!H4C.>TT-0*-H]-H +J^7T16;_9!O#
M;C+^ AKT7R$QTNGJ0"8PV<#H (NY.,6PD_U'$XAX$7R-T0VJA'/TCV=G%[,$
M=1.UD<1Y4J.A&5UH"/I/V)S+H'DQBYIUD-^G]C#,J!87P3.>.0RCX5W8VK8E
M%"TKXVIDT3=YOX-HJ["+D,FG-;,,[R&!A,<J;6H3M\T@VX.<M)J(<,G@)Q%X
M4>HJ0_A1+4-CCJR.44<1\SZP@7Y[+!8[<Z6QYG9D=CL;. I>8'V=JIIKA8X)
M$^/J*5A;T#PH!Z31QB^.$^6;Z1>LI9VUL*FG26G#D49+;3"B-?U74MDB9W.&
M>_Y["_O"_S(G#]Y:^U"S&$[B)$/_G<3=EOKK'HO[WY:)K+]N7Z._;$Z$Q+_G
MT-^0Y#,'!965>CC]_N?0;W198S90],,GZA\IHC097**HT;XR\XWV(T+@[2,(
MKN7?$_:_?KI87/N(&3MKTRV=CV]\_LU!^@E MZ9%;"%Y0X[=AJ_MJ%QB U>%
MGM12LLZA=H=(G?E>^,PR('?ANV/78KYR54!)Z@G#MSE[<_^-A?][9THS6>3B
M+I>!"F/GP-O"U+17=EFA63<#N^^&Y#X!4&-2]*D"F)?_*I(C$9#_H+7O%FQ!
M*[F")ZCSCHDF]+6N?:N=R0'WP<S#.0(*TQP,_@6'*>_4&!?2?OD>G[FM X^U
M+JR9,#JB,W4H&B]=S2E\_OQ&C/.LB#>XIFV.WL#^@Y:<50=RP_30I3ME53<<
M.-'OUN@8J[R+/R'\6;',_6\_;1/=./@"_NA.F+2=B\+.F@\-X=_>&[M_7EKB
M^.A)%F"N]J.KM#=QYSGJ]S]EO3SFH[4@<2KH4MP*1UJE\J$3G<$GPXM*A4U$
M+D+8H_\)4$L#!!0    ( +6"7%;,;K+O//T  -<  0 2    :6UG-C(V,#(R
M.#-?,38N:G!GK/EG5!-O]#8*!Q%!JHAT!!4!Z=*EQ@8(B(A(;RJ=T&N D"@(
M*"T" DJ5WD%*Z$TZT@D0>DDH4@())00(X?#[/\]SSI?SX7W?]>Z9/6O6W/?,
MNJZY]^R]KS47TQ?+@!O:&EH:  H*"D#2Y0:X6 '<4P<[V0, NKH $0  0',Y
M=A- >7E&<;G]CUW, 9X!KE!0_+?_;Z.DHOS/KEV]2DE%?8V:^C^GN4YWG8:&
MEH::FI:!EI:._M*HKS,R,= S_G?^WT/^N_V_NRYW>AIJ&OK_K^VB'<!, SBE
MC**DN >XPDQ!R4QQT07@N\1*1?$_!OC?1G&%\BK5M4M(M'27$Q W+N%34EZY
M!$MU]>KE:/#E.. J,]7-NU)/KK'HOZ>^YWE+^E-<%@W_T\H_K&_&</=E/GB%
M7*=E8^?@Y!(0%'H@+"(K)Z_P2%'IV7-U#<T76MH&;PV-C$U,S6QL[>P=')V<
MO7U\_?S! 8&AG\/"([Y\C8Q/^)Z8E/SC9TIV3FY>?D%A47%5=0VBMJZ^H;&C
MLZN[I[>O_^\X<F)R"C4],[N"QJRNK6_\V]S"[Q\<'A&.B2>G__&B %!2_!_[
M?^7%?,GKRN4:7*7^CQ?%%?__)C!?I;HK=>WF$WWJ]YXL]Z0_T=QZ&I=5^><Z
MO\P;'.L'KS%:MONR*P+X_ZC]#[/_SXB%_/_$[/\F]O_PF@704U)<+AXE,P (
M."=E1SX %.ZZ&<T\>==[GY%*RW!W?=_NZ5](\TWLC.=C)A#"E-12EN;P")U'
M?:]9[8#P9WR9^,DS_P)@!V("\5P ;$%8_/EW1=><Z-WMV$FL$?4YK633L>;"
M)O'UU=*Y6YE/4L)\K[H+K;DO^6 *II+(*ZZEN7'3]S3R?F2T^Y;+=%X .%2
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M\ !)B'H4W6Q,>'  #_4=4;*OAV'99IKJS #'VL+LNY%F@ ?9D?]_\UB=3]R
M9UXR+\W7['NXXG?L#4\-P:B;7,,W_5*3=:,^&[3T9QH^?^W7)EZ;3G4Z[SI;
MJN!0>%@A>9X#<QJA)0^0;Y(7\.K',UC;;QJ100F9SO-$=GS),^+)<@GL)MAO
M#VOFBJ)YLLS\ISBZ0DNOH?]5;IY\[/)\87"]LTMR%*=[8JN^[LQB0]MMD@[N
M O!QM<[2V[AZ?/;?)T BSI:?!YI=G+ZZX\II>M;[Q+-<W27 E'MW%:!\N&=
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MOM& :$#R_PX'V2[.V<;]C'#_56[=+<]6%ZC>L2C>[#G=N]Z!E-*GWX@M62I
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M@63=C<LT,J>*6,NLR2U9V6-SY@H[9N#-.#:2ZGLUP_,00'&",O]%/-8DRET
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M!)/I?3F/-N3P0B3F@F6&D? +@&UF!/G^I-S04PSY0;^LSA"MG2&;07"Q5A6
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MPHJHB6LT\5U50-[CJ^?JD+HS1:W\:9+5*&;JGE&-](OK[BOBW"(7 $R781N
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MVSUK^,=4L/+VWH!+^(?B-DG8;N8QW&9'&/THR5W&6_0!!OX#_E@9[CUD&$M
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MA-;6D>_7X*UG_5](E+GNWA51N@XP.$WYISA\>F;5U$BTE#MJ'M<,/O]AP?^
MGD-#BR\L@*^]S*K7!$<N(72'[[TA]^H,)'X['U^IZIQ'MRBCX5WB"CJ_DY]7
MMX;)L4ME9U'N-LQJKJ7DX"H(04@HUX)SE2;_PCPHCF/7>XPE(8S *4NQ :SN
M_5+0,$D",F;,E=;UJ^ JS[=R\EE_P'PR(B:,2R&VJ;S,Y'['C93=S1\:'SCO
M?G?KW;08*NB,45ZNB-KQU15T/PS*E4?FIG^(H;ASO OZA?>/>H?7)/'CG!3T
MYV&N\_TTF93'$OSS,&W @0Y3A-\V;DJ/64\V<^Z;[L;3<=SOI(YOP3@]MR,8
MP1[_(J%WEI!\/T%VUB9 F.*L\DE<*/PX)M"?)-($(SZ=ZZRV",ZR<(DWY-GE
MV3@LYR: B4'NN(2W>-\)9$F _V#UPLL Q]_UV^1)I]N&$9P^4D 75P/]5+WZ
MT?>)6363.S&YTJ'A3I3NF"4Z:VYHC[%2^E+/U\M*5*M5_9K!W?/^T* V8P#I
M<87.93<63D;6&9.%D8=EXCEG$DGY6\J)*JW^0D<521!5=)E!1^. E<EB<.RI
M7FH ,+#U+&)?R%JR2&#ZY*65W4ZEMF3#Z= 9T,+*FG1W?/9E:O\]QSE_HY,Y
MDF@$WB[72IB8BU+0@M1Z@G[_X_X&^90;-=2WL>=I<@'XO83E=D!G?C(++F\!
MU];1/4*$O+YF^D4<NV>9GUXZ31SI,ON,,AM*;\U\7](;#'+1+AD0Z:V1VIN/
M))I-FZY42M"?\JC:F2E\;2>9COKL?8:*P[5 ZW5(7QUA@;B9RM7?[RB9.EI2
M5UZU"%;@%GO.!NOC=]'7(J>E]ST\"@XK%,^+FKFS(<^1!1,)IG7A&-T:Q]GY
MWVK.&2^.RMNLB/V_P-Q_,F<(I[4I*->"(L271PPR5V^K*F(B>T#F*4A=MX"-
M]C+MV^X]D7)?U:<0@76N]]^<+WR5F,_\U>L\0C1'&S7@GX_^*UMK6?Q=3C@Y
MPW?ME/]5I3XJ1Z[ .V&T1,UN:6(NZ,:2I3-;UZV#1U]^<W_WWA)I;5MVIP%S
M=\U"6_*</:)*3*NFR.Z&?O/GY^I:69N9-_;8YCJ]S4Z\9/W'\QJO\DDM?9L^
M'M'&+U&3U!!XMD]H76.3,[,MI:#,:HT+P'[?G_KG>JK@:TT5G!#+,5]KIC_G
MZ46F QM6ZARNF.,W+.<,YK@YQT"W4+FTQJ&"U$+.J^-NU.O]%P"6Q[S59S?!
M'U#=BV)3Y4=TRN8CU=.;^]WW!Y*T7MK6K4\>):4UB3\]W/BF1$L<(;#@?2M"
M6A^ _TZ=6=0$R86,W5...#;G2V8]4J_H;J.?[48@SN52[Z<C 2#%1(;AJLAU
MX(H7V)H<.FM]?@&X!>O X-K.J6O:SLBB,C;^;UZ3S5:J,VC^J2%ZB,DK/7&%
MO;!BW=P9G>"UOJ89+Q-7(,;H"!:=P:G#>9\\A\S=?]M@F&97.>0)HX>!8)00
M)SSK>G+.MD=YGO.B^>S+O]6UJBQ"\,#A@F?"!@90<N\0%[!S@?M5<[/]>-D;
MX_3CKJZP:,SO<M$.LN*4&@_X^"T"-YP9@'82\J?+O3E8E?&W?B.V.=!XO*U&
M<J>A8"LE9N.+V-%]W(Y7.DKR?J_##STAZEAT<]N*4!A$81D8FS3V!UT&- &!
M;&2K<TN^=4D3CKN-E&_3>D0KI26^%>X/4H6'PUP8J#%M/4RWP4PF^(@_J4V2
M3&!O"VE7DS5N_OUIR#Q3LCAJJO7D_!NV]XN:[+R69ZZ*DMU1]H^L%-4.F;@1
M5:4/U6KW2.9U4>UQFPI<Q8N6STJ:JXI<IR,&VB\ O275Y_'-QG9H6+37W.Q@
M57!&NR* HFZC1W0"+OL[Q_?7VF[&<1#.IG//8U\\K3M_N2!C*U+5@U'T#\Q-
ME46+"%O!2KY%9"SI-",LNN)65AM68W+\K<F(8-,U-PW/R616?!N)U>BH1E22
M?K'3V:V\;.T*0$EQ@,<F+P"2@8F.38F'%.7 <4RQ$(9EZVO@T$Y"8]AZ)1JK
M_7\Q]=913?WQ__A,%!1$1)KY%@0E120D-HL2*9$NI6%TQ]@4!*1+0%I:<M+-
MZ) 8$J,9,#HW\@+;^/'YGL_W=[Y_W/]>]YY[G_>1Y]QS7Z-9(H%*WZMII0Y)
M?-9N)1QPGF%#&H6JFV?KP52R^VJ$X(X\@E4'S.2.5U'+WMNIA,3Z^_ZX1Q.,
M(/R5D1(7"2F/,#R4S2]=<:=R0BAWD2W(.CIA%1O>0,7J_F+PILZ/2FG<A');
M-/SU^"&;05\8WLJV_X&\!W7V"WSRZ?[".:B]%G[I2DEQG*%WN>M*G7UVAL\*
MXA*)J0)0^"70MS1]$A-DCWXV'PDQP[S;%$(( 9;#CGPJL/>A<I)\%\"U+7E1
M'3GE9A<GI<UR;ZW^H-,52:@E"9^#7FT+4\Y!H?\OHAF3ABJ'UC<::T3TN>Z[
MOU77^WET)4X73*B3$?G_U^]AOI^#JC+:,VX!L>-MS0_&WO)J[W-'+,2);UV_
MV9]TE=-'_?IQ%-IZVH .,M)>1%L"KV/KHZS+NB@X&XO);N/"Q6R$Q91RFAL'
MX4'0NG!?Y&D1=AMIM4NW,65XUT;"GK%I<G\Q%CQW7WN)/JZGL/YX:Y^<'"&U
M4>12%DX!;GB0/<;>ACAX!PX;E+0KL(_<F!$BF(&N<S0%^7 >U-SY<XW4^Z>%
M/T, L:Z@AAH=U='\V?@22Q1LSKSLSVIMXN(/#89D%?86#CS_>[OH88^B65P+
MXVO!A?\"$?WPV9F Z<V,]>$4*P?VRO(31XQL#1BI]NOWQ>,*XD,EL?9%D5YL
MR'D%0*U*"KO"(I!CX!L@$.K2\GLF>\*3\^"2X-]NL7E<E9["AQ><$^O ,"2,
M.<[SYU#1'HLWUP2=FD]Z;QQ&B3$[5B7C,94'=)9RC'\?J>E,;Q.ODU%/M].-
MW]Q^>4^H\KY*.;^]NH\#>>ILM=2O8$_72/%=IXRK/!7F >6M&Z//G/T>6,1R
M;]1UCP0<&W_Q':7AG?Q;;*#] K*F&0\^[#\'@?&[ZR_O;3D(L3 _"V&=>\]M
MZW/+G0J-?U\[NB.PFJQ6T8-YL/!R1:V]9D'_F7SU(W.5AH;52+\F<H$0PZ!\
M(M"P6G 1W9!T"R^9_UAKPCS59VR9J/O 4+/;W[OQXV+#UE/+QT$ZXCHCNOYX
MTV=?NT?.F@]OE3TZ2B_>\RNW."N7?UI V8$<X]77[9T7^:/*IZ<'?AM*_,T2
MPR121LSR9*4^)+2XA1#C.K##=Y/CNBLMDG5'+U3_3>@!74 &@XP6WDKOT4AF
MG!IW8%UTO) "U1<1;"'I.3G9K(H>Y^5OA4Y2M%YDY_.]P__/00;V"Q EL^Z<
MJ8Q@GX+":U]GKZM;VV<K7C[Y^O%4^&&)#B]5)^J6O\F9KXJ%XZD=GPE@B& ^
M!_TZ2CP'(3M!;DO[[_7^M=M_\C@\*M5'AB.8!:"+WGE+EU_M!U%A_\C8G"EY
M*;3.,=5BA<1\?5-@+]^'F;=I0X/D0%YTI'N\1S>J@(5\0R"NW;::PE,>L9S\
M_*RFY_I+R#>0\]=>L9-I0M^B6@C4"O6]P#N_,D$_/1E E__8?AE04R?C?V,1
M;4:A(\$)W=V[M]/>M-6',_U%8N45][DXQKY@N/+X5Z# D\0M.F<BK.68\H0@
MGEX&9+7Q_)A\YNT\!WJ&>WIUI\M)I!=5NI Z%=M!5F/*?6&#%&T9>#8Y9J(?
M&6M$QPOL+R!O(W F5'E$S_8UNU] 9KY>T0:K:?7(0S/_0M$6Z1[):]]7T()P
M>N+((M-6U-GKZB9']P+=S5/WA:"]*>>*1VK]N5+L2P$QW1H:)'YR5B/R[#'<
MQ_&.OIIW'I"B6LOO:MM1GN7O^>8A)]752 46%/IB8K(  X7F%6%CO)OS6BRF
M'7VW1/N_18X7N+X0YC^W3I;F8R<DV;YW^N6+R=1D4&G.90MJ0DP_%'U_I_PN
M9'MY]*R"<A-]#KI&0QC?QA  0]V^VZB0Y\"=C7HO.#GUX,2[US#ULK.)BE^F
M^GW+2PH?5.!4%^E_%^!$$U350L9-:-U_V_53^#3$@E"I;+W/]+(=GCXM2+UU
MB&H28AJ(LY488)F1EW2T)64\_V81XI#8YK=C//7KQ[&,X]$ZN1+.?\9,XK-W
M[6"*Z?9VKI>5FGFZ+Y1'DU8HBF&!OH2=')'SH3 <&V(*S$KW_1#6U^[+?68O
M8/^S4MQ:[3(DZ86L(D;LC./B[JD!OW/0[07B96A O:'SB38;RIU#^9/'R-)_
MB9\P;Z*;4\7@ X1\RDWR_#D(X.X*+(2K [T%>IOZ5<7A,E"K0.O5Z$M?J-@R
MV"*'Z=C'9YTBI:\$?9N.V"1G:*Y4V,GZ'++;2K^R&VPX>@EHY%"Z,VZZ[7['
ML<3.@>\:OV13'!9ZRO/LD.5->/6E^=50(MT4 W[\.]+&!"QV5, ]4.\H-#P,
MT6:4I5=@D3T'L9Z\.<HD5\F8G7V"VQDA->J3+SU/UX[/?SV='9"1(.,<N2J)
MD41AA8%'.B0&O/8_$F,N,++HD5%CG*:M;/],KC=06G'^RQOG$2I__M%N;6^5
M)Y8O,M#Z!@IEJ_,VHUU]$_;,ASN.YZ!6F8N^EW[7"S*%Z4SGTY8J,H49*+!?
MFI;M]!O/Z>B[-#/K' AV?XD'856S4;H I)<;75]3%M&LV/'M@<:ZEF"SB)?>
MI0AWLO QG'XUDG^OO_U%443!@ ;8)K#]C-&L6##T+?OX,\13P/ <U.][40[0
MBX% YT+4*9T-\IBD(V#V]]_8HY+!4-/")$12R[%8.\D)$,Z#NQ$8CX,/>[0-
M#')X1.=$ P( RU*8"2M<V#Z_@0.F'$U;R,OBF-_D KU^#K(UH2)YC H+N F^
M$VL,R8DH<6!^U'ZC5_L_%X2QU.D=F*YR;*%U<MFJ-I0?#:.;=-0GQ\$1Q'X>
M7[T4*;_YLUQ?D)_\2U06TOP<%#)$T@ X*?1 \1_,PG3UGKWP#D5O(7KIB68W
M"(^V/0M;7&W=IEE$!R^5C15_;I('%;CWAG]M?W)$AA$=*32\N7!%@ L/4Z.;
M>\.3,=\>8H>R?U;D''XG"?0IDNIZDT"?5'^%R>?$3_;,7>_V-Y)E3KT4%QZ/
M=IGBQ*J-%6Y?(%2:G";C>"8.EP^:>L6=?J^6QY[UZ-:):/XU)3C=S\OY[/LF
M;R[>&0=T'H6:U]NBL)'>CLH,0+RO^B!RW0!KH\BK=GZ0->.Z4JXC6G(=7/KL
M%5S"Y"N:/3OR['WS95DFW1\KODK@[ZTR?NT55W@]7I2>M4$)<O:N1Z;$P.ZH
MA#TH@W4S2[/RV8WJR^/J-R5$_UP)?Q@PAU8<+&.?\/ZT;^"K*.>BY(?27'XV
MPZ&CAW\:>\Q]:!0U?N;W6O:-:D3)\EV!VE@)JF#-03G6!-3MP,"QF7TYCAP1
MD>37$WMM_KJ4RW4H?_!=.\HS$O^(.UDL0=JWDZ[R,1D#^D$2#>TDYR%$UTUN
M(%@V6..7[$75V Q:+Y?J+\S87>'\]F<%S1,!/@H[@*Q."9LYY"^MDABG*=3[
MO!VS.NJ &>%8/6'ZS1]IX=UY9/)FZN,W@_+++$M.L![D_(^,<EP$TE:8Y:?C
M[4YT0*5WTJ&*4I?9W_!R?GK,JVCG+ZXF;[QJ*#>LBN&61/DX?-'V:S#=>O+!
M;L%F0F$V^3I'PU&IO-^KP:?\?1=4^04FJ MR+0C[9P.\!-G,8?BCG*ZR6=NC
M[; (C>YKKH,ZRYJUXJHJB(+$1>$ K_<)3Q9SBE'EAQ!>1KDV&'TDLJ%YSFK4
MI!JY34?7#K[2/@\..K+)!S2RI@4/>%=JP5L2W =4+U#WR-%(<WO843I1JZ%S
M91KP\T@YZV(7P5R0U8L@LJYTH:TI*9TFU>-!YH3\T$J/VG^56A_<G^;;&7[Y
MI-TRHV 8EPX[S%[H;I-EFC_^*G# <1W+IOC@5>4VM3ETFQ40H'5-G?^L\V3
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M<HE6:_D!,6O=''&6Y?O#S K()#1K/1$+21@D@]_8BKH[-T^6W)5R9)LQ@;\
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MZ[RL2Y93GX@"5'7NL5K@B)V&;[UMFHO>5/NK?D?;UXK_;)/:<))<\XJ= _:
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MZCVTMQ>J)/Q^4+R]-V_^]Z$-%N,C37X-$/XPJP^OA9'!7T4M]VF9R,O-K5\
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M6QYM'3L?*9IOD;^W0_7CQ9_TE3';QQ@=EN1_5GP&ODZ4&R<R%8FW5]9T[^R
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M070KJRH_(GU6$_OWH\+7>KME:JZVE*[BV\]KO+GE*\AWR.L>9$GRU)Q=:K5
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M^R'"227A-W;@7))^RJ)ZO?6U;-95BH3R.B(I>)2"1; 7/IO<C3*,D@F3Z+T
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M)5[9W+>1\K?ADH)MB[LE9[.-?N!+2_#YO?+1S[]L+;M0!=F$34P>L[,@5BX
MLS7 ."2/A(IAT7)]%=R?MB++6?!-,EZ I*"(7DIV5#,)R5^DT_IU])D;TOSS
M "RX>\Z2FXE>A!8WO)HH&K=VC3E[EMISP\N@N##,OM57U-UB<(L'=P$XW^U1
M8PL?E._@Q->'H49ON=6XT7O+##-K6)PY_]:5Y">-1>)-C<8X)A6A?W47;(B/
ML,??.MR"IV?M^5)O_?I*5B"*[N@]^_"&N@0 =#V[ *QD[FTA()+XM3)7%!FX
M9ZNSE?Z=QZ;Y=?L%($[VH"5<)5FZDT^P_1F93QO"?VRDH?-4/J7NO=S):*$I
MW- MVX4OU>SL\TIIWQ6TN0,'"^].]F%KU(<0N! Q%$]9]A@U6U5I_MLQI: V
MA>SP1 O:U6&&;<C'TB/=&:B(JEB*N=D@)]-:O59"2<4I!-FV=N=D$#:"?(QT
M!4:%S/3#XXR=0PSC/56D_=X<L>XL^_PJ[^=XP6 /O@%Q(<6HV*YXS=%VSA6
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MIU0M;XX!Q9\O031IN&0\=1CA45"V>F/KE'TCI@HNU#PILWI;TF_'-$T\Q_[
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M+ _!0:@\)0/M(@2W7B\1B.EW4!^( W'W[*N]>LZPI#T!A=4FA;,[A/$7,PV
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MJ"ZD)]E\Q8;*+80[0M%).O)^QDQW&@U(AE0;N?E_7+1NG50<J;U]\Z8RRPD
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MYG,O-WIG.#>1A#<.@P%"#OJGWQ['%EC<?'[V!) 603"^.H) $^[16"X2M;M
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M#(AD[8<?"7.R5"_(%H7Q4'1I"S16,F6U?KP^<!(\7#;'>JQU/)3IY*RRIC^
M>A\V<12QJ<>;2V/>)4Q119:/F>N;EDP)9EAG<OCY/,6L*!%FJ'[#TGX%I9HL
M ^NF5#,UOOXKA7P4<X\VUR#&/HW6UFG;IDW/H_++.NKI*5Q\5VX=4]RN&O*"
MPQ8GTJT3;:-YZ[Z1FY"Q)$/=H/9K.K$XG@#ZS<F7EJ)HS.2C7HS96"35 *D9
M=3 YK233F'R^TG/T;6ST.NCRQMVQ:W@]T/5YJO"$%(&MG3]YRD<MLQQ69R9
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MY$UTZ-%"Q]V[@9ZND)JJ$O< ?ZL-)TXRI&SV>V43C08Z&,GWC"9W98F*<;G
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MNC6#X\U1\*G?3/WV],7;:/C8?:;*L  V31:;Y_M9)JC5H_(+V$9 OT (NA(
M1^Y<IR@,4"00LE"6;!.?H?:'!H-)<\CF+P(#TVUKX;_*+#'UGEA$_V)(A,JE
MK>,?>JP9_UL#P_]I_[$8PB+W_X7K%P;< &N;I*<;DPB!<@=,M*8F;W(?K[:V
M...A>KGQ+Y%GG5<.)"(@0A7_"C[C[36*"$BCR7!1<EF832=-JZ5M2KU L*&2
MJE0RS#E4X1"X\+OUC99-2?@8J&8#516 Y/5HU_F.>):1AOIDXNN&=*\YCK=.
MZ.<^_41[\$QL%^/OF2U&^]Z]7>5^:#&N )+-[L9JS-\C\%C[Q2458"4@_/H6
MM!8XX"2[K+X1[:!'M'E=?ZS9QWHY5G?>/>-58([MX!MQUKI@E[<I63;UX=^6
M:J(;D)1GB(=$M\16^7+;S;]1._?(SVE_XOJ3%)91"'&'T]$VH"L#]L?<7G+.
M!H'1*L.=#PLDWC[--Q%(XT_-6GLO-@RZIP=*/@&PG0 >5L>)2AQ_H :LZ)KV
MT+1_A$NX9^C^3B_R4JUX.&9MXL,V],"[[SVU$]$9-N'4L>-% .'8T?@> K9?
M,+TGEPL>9/*=RA54X&E3U_ORFL_(N$IR$-=0J?I?%](Y3?G@*[_U4[69AL)*
MEYXDH Y]"<_!=[L.\X O3@!>P)?@RU-(GVQ-QTD=+APL%L1&O;ZR7<FY-V9F
M89!B*H74I@Y&G$*+;600()AAD@CY!0Z5!.)3![%3=8BG29B%RE<ADIT=%R_8
M5<#OM4 N,I@W5<] I34C:YX7 %:+)#$#LHM)&ALZG_* @[F8 5(HN645QGN<
MV=/!VOK82S$K1[0IY5Z=Q0_/1-B3\LM[HX'OL?)[$<!K@^MM,<O G:)R>":-
MA6^UFI\\W-4<U1\)CBT0D?&*=F&=Q\Y=^L9]%J0UI'Q8_?V>&RMXE>WQZRYM
M0]_-.\:65S0^5FD]\,\##E2SA=,I4E!="1/4$Q*5WK/+#S<R']_5T>=['R%D
M^KCYRS>5WVY/>N,TA3=$(H1MBJF,QQE4NS+::"Z7CB2N(XHF5D=^Z^6&XS_H
MX!H%SL$*6NP"C4!C@[[US[/<$FPV.^8*3@ Y'C.0H#8@3/C#@J"&(8<-_6F'
M3*%S';C^R'P$L#FS6U3'&VA"6%B*;F@#=Y\+GREI37N+K<\WP:Y]F;\NU7@6
MKO[+F>_X]:'\$EE.*>JR.I1U&X/N6>#K3IN.]44$]L$D'&H_A25 X/QLA^L=
M!JNUT>)1T=*B+P"%+[M9H8?/>D!2U$],LO0HMB%7D\2(8[$-J$1>WU]@^?&=
M0U-L<.NUT(<\L7 ?>X-'',;8([^!6UA"Q\XP,<0\8>E,J\TJ\.Q6R-I 3&4#
MJ]D=>(&H>U#MWGAPM-Z9^1, 4$!$_F#AZ8JAM$NB:8"XD=J*8&1V>6X1(-S
MCC8$Y:>*+.-!MDT$V;@&4Q$N7%)+&93LS]!Q?Z)J.9H_.]SEW2@.['+D]1WI
M43VGU#>(0YV#9R[3<V_$XY4O:I108Q]_V?M>%RM[L[#?[#YT)7#^L00R)LL?
MC%2N!H@7W!#Z)#^=LE/S 'A91XEQ3=CBK.A;1EN'_OU;'2WF&5='7?5_E912
MO;SNI);4)&9H1'UX?K>Y4L'Z66^+M=R43<2I%R\LHP#^_X4^=_^9H5P>H]I_
M:^7SO]GI)_\WQZR_J_?_J\'[M@&WQ7^4;FO_^,\[_I<QG,S]'U!+ P04
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MH:*D_EW__9#?PW^/(GPIKY)>I?R_7?#? ;17B=R)E8B)[@ NT1(1TQ+ANP!
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M7+,3VAE._; [3Y/ ZG(KBIIWD>821FF\E0F<X3CL;"Z9>!,D#/)]!CLJSJ#
M,9AAY!OC0"DLNM*&T2L,6Z.X/K\ I,G+YM0]"7@#2/ (VED5 &-);70OVMUJ
MX8,HOFH0T(OIR;UK[Z]0>CIVZ'] -[@,8N@KW&&D,]?@#%^:6A7TPSY',:Q@
M*<Q1H+R:TO&/D8Z)ABZ=5\B)H ,';!A0,\J[1#:R9X5=PNI7>.8W5*<AXHAA
M5%"@%/Y(-T?M+,0IYE#&+4)!I>8T(;$&$X&*?F>_(>&@2G67J7M^3E9C&$J,
M>16_#-M3$FU)BX"+?7HU?$.Q7R0U&3C1L@JYV-EP(8C5]R]R+ '2]>,NV7B
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M?P]EM$AAKHVXM'4<Z/ZLU_T8^*"AG6,-+ENXL$$O=,LFX45I;W6#9H*=]&A
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M/(!OQ&7_ICW'EU?.]9]SE?  \D^*N-T%%#WX"7787U&!,V*O")[=>!T7<,<
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M5^$M5XLVS20+R@;K$WM%83-MY8PWRZT-'[JP[K3&.J=.7P5"E@8LJ+:*P5;
M>.?\.W+?]'I"+*";KBK6M(*UBVT?UY,EH3<$D^2Z#^B<@[P'72\M^F'MO:+W
MH6L*#(]8E+)PNJF*_D&ZU9I$TRU,J^%D@_2:1&JZ<(MX],]F@BA>5CA"KJ!\
MZ!\Z/\G/=%J(Y*>7]08*._R0?GT)_?:=UM!E=_D[:D<S_2&L*[Q#I<K/DZ$_
MF),;HT+SD\\UMVH8W9<T(BW*H[LT+J.2CO" [[S@0GO&2F%LBO+5Z72?V\K
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M>O*W'<;/HXZO+%)DHV;ZS!^PN*U$@3?=W'P6_:C';,*_J"P2:'CVWR5._G=
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MVN/3&3E.5W5$&;M@3H3:[MN#?*"V4EO\DA= RIH-SH/<7=V(7HTVZI[:WC2
MAHC1YLVKN%P3P!=.&]/B46 &C XZ<%+&%^H%[W3U<M4)ZX)S&!GL@&REW<+
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M#GTV2OVI2&:/#<Y8=)4B*IR6L#/@RVK8&2X0L[NOHSWF^]:J%H?7%9_W>.U
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M3X:QMXL/UY*$:C2VY A^GEF4Z7D=O;L:%/5O;B/82,X3BRU8]2, AM+_YP]
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M>Z<HCKE?C:_CO)=3>UA>QZ*9F1:Z"=\6S2N&AP@CN))#KMM1NK5/;8$ZH9<
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M/2!%,XJ;3$CAOO)]\1_NV+8/??%>N^"7 >,$CJ,V2W6?/_!]%MB%H0)3O/*
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M35&NL64J8]4XH?)9KP2%T(L>!.^ = @5W6CM>IS_\[);_[9UJ<A?51+$_U%
M8?V70$I<WP+1SG*4GC.L0EM$8@,8<H1"9JSUI'G='S=LCJ/2Z',"K*$87)[^
M;I@OKM3W]:9K'?WJ):#J(-N!$H:8$*;FGJUF&OUV[1+09*H \%6HKC8?MY$L
M*F[)Q?XVR?X0=%I"!_#\&2%RE>ZQ7 UPU.@_"WM3KF3Z9 /X&63S#Y^Z\C)
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MG/R /=\,\"EU YS+*94!.=]^G*OQWCTQ\>6[_P4!PN3^M.>9:19;F9)#2,U
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MP6NI7^O&+X,S[SPZ!?@W5"\I;I$)[!B:_+#=,,5<"''QFY!'>.0N70&Y)5/
MM21@*>]O9V16:F6P/R+OCG=,E-"8K?XS5YG:(BO>X=U*ZZOFZT<0)@^/JXH&
M::OYC>][6@]-EG:O'NC&ZZ\5OFS3__X!.RQB=\N/-Y+8<IU<>.;'SC#_)9 D
MRHG<=EIPD)=D;NI;+!67L9([?E-GA;Z_,PM07D\A7_HDSOU-)$HUAW4U*9K2
M=XA\? _S]L-$N$F6R'<?@\*NZ&S&/6(1MSO9NANF<0IHEJ&I4IY1X[TDC5IA
MXB->M_$Q)7E*X\;7(S1!ZVHVO-O6QE"CLRR549:?/^_@?R_8*Q_C=3E2V?:G
MI;[_P?FF E+B+Y(^\,J,E6^PWA"LU;7)YC(KR.TCBY'U%=HH_!J%B6 VQ\]R
MGJ2)L_M,6)V<_!Z-.#+VHVSN(SAJPJ3;QH@']CQ'01NP=EPL)'X\'AG3HI.3
M3&DPOQFW5<HA^SA 6L.\M WQ0[!I;,L)F,K]H[O^NY#6A8RQ/4P84DT#;_\B
M=G'3H/:W:;B=S).AR_ %$?<#I#Z*6N)YO#V65Q&OVHEAN" !2R1U, @R*B;:
M%H-=>C\6_>AH*J'.981BMV]=;)B_JM;S%33*TI.!VD>'NK@<ZL$ZQO<>5"'%
M9!*.GD,>$MR6!%?;4K<2WV]SY[JO*$@*C<D\Q5SFHZY+K+J_"A_KN(-Q0A@&
M_35@^9RN\J<JE0@VA5TQ6P?CD9[A<J;;4QT\R<N1MM:I,UZ'9:4>GP+Q\$ED
M+YS!$<[:=*XTM/R?8_GZ'Y6FCOD_\H?JQ0<>.&2T,&'^LV>CE9!-_9?+Z#GD
MNC[+P+IQ"X9EE/9LJ9\]R=IZDS:=(>O?U+$$%*N"K:DIELH9U%"*=$Z6.,I>
MWIXM69'];#HG/"(O^7'2I&.#7Z:I9F ?6>$/9+[WDMKE<8_:IR/Q]:Q"@=OF
M#_B#:10@33R.])BB=^:+:L"[9S*S-9*,4#EYVN73,=M@GV 1]W]'R5G<$(PY
M!X(H!I+522G4&I@^-#;X MR_G Z):@JE<4IK<XSO0Y&H9K .%[=^@SSZ).V
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MR@<4:];%Y(VQ))67B]BD"7A0IZ@713TS;%RGT%Y:\(+\2TN1SO3&;VM8=S9
MWP/?\ UUOV&:H>R3YLG"&XA*[JV*8D<0/PGNCD-S6ZHW]@[-6;:+8%N4#6=]
M[M%[AZJ-0S[16"D/"(CM9'Q<NR%)Z,A@2$TJ*Y5_<KDV[D9#4*8-DA[]]';0
M[8C'=XRM-$?&X\6FY%V*:@:ZBS[49&]>^M#C4,@E-SKIJ&Q3LYJ0%F#XPKRL
ML\ZFD3-XYB";D_.=PN9.]2 VHX^&0F]F(1_5D4L/Y%<KX*5N)VM.4&5,%*-8
M7F5J $Q^PB_[QX*1>\U*YAC*/)"ON>S>[5BEE[8_$'7J>L]3,2EW^=3\OZ0D
M_GK5B5/;.P7<7!VE<<IZ/])'R.>9D+*<Y%<_H=YO+Z;X98P%:?&YBF!7K3^#
M+O@.CRRB$D?G>,<D<;&[\!^#"M() SI4J:"'@<"?/,Y_EO5A>'4PJ'+=Q;ML
MDMM#8TPG.O) 9F8,-Z+5X:YU<;#7GB]M6FX@#+V0:<W88+ $C#BQ'$_(VE#Y
M+CV1XSSTH.VJ^6  MO(L6-35A(M\A1=*QOW+$%[Y_5Z7<R^K<"K="(0E;IN-
M(^VS'$J]W.^:_.Y8O+G;R1!]!5%J7IUR^ZL&D^M,AH/AM/HI0&>JRG$#=WRY
MAR04RB2;Y*5C5JFC<;$FKR1RC;'*QYX.*PB_=ZC3VJ[B6EA@,34];][CY7@N
MGM,MS3Z?<UGKU0S9S4'^XHO\*5M\@U&]T<-9J@: >)0'2A:@O\AQ]?OSZYD?
MQ/*JS7XRO&0#)RD"?T@Y'F-HC-\6$4(D,-$FPPV  1,;DAV(>9_81;S)_+>>
M_A/87K?6NK.ZLR.(*558N;3[]KW=TW_5[JAO@Z %_\,R9V_.\9!?_GXP!:4K
M4&E)2^$%($ED'@./J" IOC+@E1R;+9IQ_1/X<'K _?-7Q7<9/C[;UC8DW:7Q
MN*4+&>,S??8%#FO]-^H,)-\Y>]M@]\IB=__RJ5._?(7;FY6\8RMO"V+E7?\*
MH6\(6\1N'630DY0+@5?GK?QH]E-J7==XKYU7O/=17R'X>*3G?G50EFAY-8_]
M( 9;')?+45?LSZG&+QH)M5X::_Q6NB,WJ^.=XJ,!K(TJ.H=A4'>:?QVJ]&C[
MRI^;7TX!GV+#"+O6LK1V!$>U;^2FAL.%)$@AM="Q;?F[]K=EA%Z]1YS_B2,O
MUU/.:E?8:I4J)-!1)^J?5M<[Y8-]'?9$O4554K5/A^SV YY?D9T'P]JF]#,I
M#R(9'NIJ\#LK3 \%4<(D]A"&3Y\KR*B\&-(D1VA(!BO_BA3[/V=?R>P(#&IJ
M_M= #N"2<^FB)%V"1M"6=+L\NYVQ=]')U8,5K\?[,LC:O+_SCHQOA-XJ=QPN
M:XWG[LWUYG;_VD$C93*J<:E2[*^Z7/R<W+SX60X_:@HH+C@I:N/!85#1[![Y
MJJC<Z5:GWE+!/YIO,8,OYY0(<ZGXS59L2E6YGQ#"-C\KWE1$:<$?\F]^&W4*
MN!A)\,%(A4N3[''II6--\:Z@_DO1$ANBU#3[8V*QJ: 9[> FHK/DGCN?T^1;
M<7)Z0O6_0%9".TIJ6I@8E?H$CTVF1N26QY15Q2"C]U3](1FT8<0?JW*RNH:3
MEZSZ6%KWY ]H=\.5 !\D$OW:X,N^+\N"74) R3J;P]S-L=)XET>\R4[FRD"9
M523G!I"=QO.*8H5/'X\K>..2[D[W6I9^&XM'=LFR7'T3TSK>M@B/35VNFM/:
MJ@5'OOAKL_8&#]\9UX',]U+ZJ!DT=GC++NE;WMJC_:Z8K'A<_T#6(5+ZC#]^
M0F\2PK:T"3VM)WG)/L3T<]Z64SH&.Y-8UW]O.I<C%DX@4T"Z,UZ.XZ8-H%&"
M):7YNAYYO2(:*7(SOQ2$!1LE9D\!+L#)QUK44A"SI:^;437]^QD+<^WJHV]U
MH2UQ-AEGL>YKG%!R(?U9/Z.QEUFNDP#HOONO#C/3ERF_4-Z!.L _W!T#5VB3
M\Q56/POU!"N)6),@IA]/',T4@'> $1>P2%_%%J(5T^"[\I$;[[?#9DS60$%-
M$M280W.I29NVXNRI:5137,&SZ_6:IX!DW9!C2&SW2_9#>>(O$EJO9I1KUHO)
M^^=7T)CK)>10A7-5C'@W2B1^#\S:Y1M;Y:%C6 SWR<H)?N>$"I;FO1T<Y&<6
M4S:DL&L;Y[Y@?UAX=4MY:MHX<K7\!(+8/EZU&?0-?[.0MM;H?W"%4IFYDG [
M44M^L'(HF2>O=CSCT5 T7%RLZ)R"F/+?3I[,>W?>9UZ8NGC1E_)^MEWL^,3K
M(#M15YM!MNJ3MD<7./TM:1K7'T,P:$WF4ZC--]WD4A1T+KMN*IRP<>DZS;A<
M6-S&Z6YZD]&K,Y""PO,H"OC E<*2?LDMY\$NB<!)X9- _\/"?/WLPJVUA!>Y
M?*S$'V$V3*W6%]4NXZ,TXET46^:X!Y/U-!/[FE(OZ/$(_/O]W(E@3AQL(MA3
MN"J(.VY7?+DXXUIHW*> )V1WH/ 3GO35:/H>_P.D#K41O%!,NT\M@AJ(?@;Q
MM_KEKU=T.@<_J*U']_N>"0$YU;1R)AMM6MN)SU8"6=5A>,Z!9AVII@VH&W.]
MQ?.]W^#AVOWBOQCY V.9DQJQ(M2!V[N/.,*$PRG@\BPP$HA_X4:Z)1H)7T#4
MA22.8IF1OFXO (\+Q?W>*@<4TEWWWIVK<2.)6F\YSE<;; O;+"C+TP]M_8M8
M;:H15MX;K>*(5UDX0*X+$W]3DRE@LCE%H!$?%H$S7ZX+_].U'!(_2[Y/)_@7
MV0.?X*==CCF[9H:S'YON\,<@R\H11I\D42%4>,%VNT7.6=@$&KCS4^BP"JA@
MG#EVJ&6_,UY"<)M:)5XR(-U6W&;)G'=HLBK-AJULC&_L72/(%58FJOY1%H%L
M@;<(2VX,M#GK/U:I"H7YDQM\@M2:JOK*=Q F\9@8E/LG&7Z>XOFJU:UOOVCC
M:(8RST"3<>7<SWIC#9_=E^OV.%@'1,\WR!)EL"5P.S>.Z??W)U.EKEKK"7YO
M_K$XC(,]>*I.)]B7LM;V-NN'[2E@3JMSA7?L6;ZLGD11/A;.2.-X?PI@:&"_
M&IPYW74UT0DA*?)U)T9;E"DC.".H[A:_$YC&5JJXW?<6>Y]:^,/E"DDF2$;A
M9&SY^VTNS5>6Z+%BH;,O]1EODAPCNK^<)+)%?A\#VZWV(O,?=BMDS"_I9C@H
MI+D"",U$T'<AD\I\0UF^CR'F(]KMF!J<EB-W+J=F.&#J3G[O)[DH5++#,W^C
M@@B%_I]NLYT3SB>C-3.7=NZI%51+E$BX<9EI"GBM@D.@JF2[]12N8L(C/9^_
MM+OXWKJVU7<GSE/QQ:H>A]?WUZ<: VB,=Y8:(2W6EST#F'C_5419H162%0T1
M*1P3YN#803 ?"8.!GZODQGL=S!FWR6IF?)SA?:56BE6MR!@[X-6_J*^%2L2-
M_O.< U(C06*P(=K-D52KD6TY]-57W?%ZR[HUG3(RD&5> :^R36(]/AK$1$+C
MYEGF.%T8]$9L0EO[77YW/A)3%KR\ #$\!5R DRI*2$M_4Y+BH,,696$2?NR5
M);LW,Q0\L#Q+FU:U9,?\5GF\&A?\V@[;Y?0,<VW.*LL;2JH/+KR+5>HSAK[+
MBB2JW]QR@5Q;BB Z98-!<,=TU<?#%&[F@_O3TQN#?>'/[M'3?-</.$]XR3Q.
M*3'(K>S,6=\,VRJ@/;BQ)IGTT3T^L'@9.#F"J]XZ7'*+^"9!2GW9U& >PD54
MJ1*&*&^'*9?5$]L(S/-Q(&EPT+;KCASRRAJQB[7JC_/ECT4/&8('QW]^":R/
MD2MQB8.-=21[U)WI_XLO4H^P^EG.[\#R$>8%:AAU,2 UP/1+C/B6*\_5;-$L
MY _0+2@$/TP!U\5MFU0KRMXP1MGS-Y\"O&MV8YI83@$AM]QM2MY#L$F$8A9E
MT9\YL8\S<!';UKH;)PPM U<H=(.PZU:^"DR[;$X%;"V<B91:D69E824, \I?
M)JAU.%H_\BO1/5H/3!+._XR*X<;=*PPHQ,@IJ'SONU7)\MWH:^W)/Y/\;44R
MLZ-)2EGQ(O*2;Q#V<=SSKP,!S'OBTT\F9[R3E'B[UB[Z21YMUQ(\%FB);@7:
MV6M)0L!J#9EUO%>(Q^>$WZP9Z4X>2_/;1J< 9BW\9HL/EZ1D;'JQ:GOA0XXP
MIZ>?F?[[$UF\TE&\YUK=#^/,65M#'NL_F!:WL!/NCA\4C25@N!DH"VD>_^V1
MZ./+-B-N?;'2S>V!>F1S7R:<QM%G3(2:9=Y4GQ,;AH/=3+?**<^VNRBQ>54P
M!@HD8'$&89[ <WV>G^7&_QB*R(;>^%F>N%JS6(^\Z$@3)U60N4D^9DULUEHX
MJM:[HFP_SZMD 3HL8R/5*5OP,W$_!"+QJJ0%(?_4T93D0W[G *ZP&+9\#V9\
M,=)*<P5AY7JQCNBY&2-OU4-D'>T<Q6_P%/ >?=Z<%/PPV5-&C(4UL$-VS6D_
M8!'1,7\%P6"A63TXX\BMNRQ98+ARIT.Z(M_QQ)YV^1R^U0)OW:)N1WX1^>K-
MV$[3V/OH^UR26>ZQ,\'#-022K]ALQ17;2P5 \Z[<Q^[N-ZM6[([=UYQ>6 >G
MN#:^#763]KGZ5,38V.3K<5$-FW;:MT&(5V[>M@HX5?1\DWY.K?&W)=SO@[QY
MY17_U2UDYH9T^H#"4%=;&,5IF1E"=&DB_22\W7PXLI"B+L0[^ZY&9(?.1^T4
M<+AYP-3YF@6*=Y+5PH<@PJ;L0WG&\K[EV-$E)*1@F7YTQ[NK]<Z'?B E_>R#
M<I%D<RC<^"\J@3$-XMWTZ^<!P\ 7_BFE9(.IK@ \2]O0](!ZVOSKKSF_=6SB
M93=X7@<?E!UG[8<&8(4)JRW^U=%-G$XJH#@!EL "LTKIGVE%=T Y=!8SE/X]
M^]^_/?$D*9M0DY$L/)#"SDT,KR.ID^E)(XM2X5(-#Q<-ME2)WV*(6?(]%V8*
M/UEDR/A#BM<0>(B$^3R;KU6'VZ5Y#'=LB1XQNKMW3_]1_1LL\'H+T&P)Q'C&
M0,H@,1(#[3*5P(^S7"1YH9 <RD[<L>M3LW _?NAVA7"(>LSC;'BS,DW< 29'
MNE4D!^/U(CGDRJ<OD,UIQ,<<A7N4M+@TKW;G;'UKUN61PJ@O'&;JYEIG89V_
MC@6>@YHN,6VS;/E8,=<KU,44]9H*JP9%*]";*R\))29GGIT?8C,.=<(U<EDS
M6+?,W1_6+,S1KCVR9.?YP&.S;%3KMUKJ%X.EL%LOH@::T5%3?!A<^"$+T-'^
M^9]3@.ZW7W&>]3] 1G')^0PI$V>?!/E##2M(B7CX2VN2EDDKCO@E)7"16MC3
M<S]4[A9,'R(6J+2M59XU YOGG#A@IJ,QEN9L6E?D1T/]%$+D/I)$GR<;C#D_
M"9/F<.#XK=1U"C )8%RCR)X9;:%AZ$-"=G,3J]YMV^2.E/>C=W/OPEX>GV.(
MK76WXETXJ\D&;4_!=O/19]0*_KTTIN959#&_WL?<4^DLN&IK"C*,.XP:Y$/A
M@XD72<WYM"$$,]0::4ZRE$-?7 _32Y?<%7%X.LL[$_QZX/*&&)%#->&P!&Y3
M2)"B< G-/SD%?*FRQ:?W2 6YM<?FD*<=[S!.-^V2=8U!TK1!?RX4V1%Z9_1F
M'59X%&4IF?^[(LHH14(U=UH6MG??NWQA[^&:Q*=1^$(R@@L)92%$Z4K@(D1(
M$86ELQ7R_Q B;X0MI">;CU4A;CYG]>68E%A$&YQG@)JJD&#JX+\IJ@XGT4X?
M^FY\%.7//@:Y'4:-QAX:QH@Y72-.K*^+6%+3T6ZG@' $JUO3'2?N#'94ZE-\
MX+_!TAR(1M[+N(OA_+)'VDC[LU4N/=93$CATJ!>50=?!Y7 SXO5>>F27H_ E
M?5QLC2LM<07\9W=K&0GK,,.VI>X*6)*\6>A\$YXG_7.4F:U.*U2X=C<2\GZ
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M\Y\0DWY5W0_C^C677#L=Z%C-/#6K$XD_<$0P!FN/,3-RNW(4$QI??6C>R,O
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M*M'9HC&[:L6,1S;O$6K:$K;=X5TPP9UZ)28]C^=CRXB:L .^X""T$@50V'T
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MU\X4!W<L[OYZNDJ*1:Z_\,S-W?(R+!)R]1(>S\K(8NOT9)0(T\YB^>?YT=+
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M%B0^%[PU-A/57XQNTT68)T;U.^=N##Q .&%#)'T"FYY@*O3"PI?D%#^USJY
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M<<=7P($#&(S<.FEV) 1M]OS![80_0R2G4^:-\I$E*=45BXY4XP9G9MVWJ,A
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M\\1GPG"-UY^T<<AH=!1:/N@I5-23/" CR/6^ODCLLB$.^;'L1.RMY\"6S9>
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M')A@677MY(VGU'JV%D=X74$/TESM)F*#%92L?9U[]9D*,5@*+$W]@RO9!-;
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M=;OS%2K2T'$^&DI6DT/V.O1^'5RWA2#XNV8DO O0F)Q"8TJP)V]T1]^TR_\
M/LQZF0&7T.%#%7Q/O?5W0=3?61(:5JHA\M.K/;YE? 7-#G*&7R9S-J0K>VWG
M)([\WC3E@74WU\W4#RK'2JQ9U5:< 2XQDARR@R2&@\Q]?DJOJ]S^]OI7_>^9
M]QTAS927HAMZ2<I'_>!=HQ*A]O1EJ,"(V.X;MV)(F)V5UU]U6)F+/N"E,./;
M1+VOKWW*';"HCK*'&/G0W9I^YZ6M '?$E71LD,/?I^-%M 7<YEZ*1^7T2V1Q
MGT7&_$\6ZMUJG+*?\"7$)KQ0%R(2!97![Z =_##;RNF*&;\6Q%N&$SD"S@!Q
MGJGG_,/0(Z+AJ"U.I\L YZF+<9-;*5T;8X +YJE&&^R(IMV()E9G7DGV3X'+
MZ#(<GUC,\N8BYK)$"TC@7.ONLCZ+"8SJM/;-9*7O<=;(&)#;&2!*A6E$Z6%P
M\6Q[X33I[ZMHC53'9/%]2<%G)\NTQR9'G]%.,%K(C<Y4%6!=G27\NK,^Y0<O
MU[2@_"<@2.X1Q^+1-AC(=^WS3&JWTB^B$N>!Z$J2Q[\=>3O"2M9"I#M9?MB#
MO8LK4+:L#9DN_<+A0O,2!M4)ND*VJ1\K\_:_X]+/\V/A-X%&O.*])O/.^T!B
MN4/'&: &WGX>=$%>(RI\FTG=MMA^3YV-6C<.%N]<7^TSP(+XL5%AF\AWL[&6
M?LFXF]\'[?Z\Z2Y3X,V'<1%V/X-K8:%0>K#S,&YRVX/RB<G(^1)L9<Y.C']W
MMH2EK1B21"22_#$?FT0FIR/^>YI?4[B>WH;EI7+RXK:=NE.%#'8N&(NCW@]X
M?AXM 6DU6S_CL#,$0<)>L XJXY[]E*ZC<ZH,GN;%EVV_\E%6G]0)#^[L>%\N
M?\MW&G"27G;P-LG)^E;[@]GEUX&3[6"\%9C%F>\NY;NX;4550TN"^Y[AY;X(
M[RW1;5%KWX']EZ?/Y4TJ_]5^D/^VA_=?RW_GPI4:7KY1H(.+D]OLAACOQ\@$
MUJWK^MG7+12_Y;<1(3YZR(3&5?,**UI1O<Y1]X8$" _'F?'"AI;/  Q$^%0N
M!O8QAV1$,!26$;=X[# 4TQ'GC,E3<=4 V":!42@NB0CL5WXS4K"?\-LRCVMN
M+=FV"7IC OC4L-@;3W]84*HN9W=\?+<[Q#2Y_FCWAJAQ07+Q=/=O3)-<_DLO
M[<!-F,(&'MDQJF+:?M+N.3VBAT?FH1>3%UAJ^MF)/?C\SAUXL<5,]R,)@=J!
MG[E>>UH<R*DY4"L?>[-Z.J^\>J*@(D.G$RN XFEDM@'E')5-B9J>U$ UJ0$;
MXSDF7O!]IW-A@GT<KS![_,:>6: ,9N2*:I^&N%IT"%MWSJ[_$/DT%C 6&B(;
M7DQ"OAA>LVL8*WMCO="T;\>(&H8IO8K#EBF[+\9YB!OJA-?*)KH^I-!#:XZK
MFU>A<9?W2K@]OW3'JZG\G&*91_7UHT(\(\DBXU*=9O=_Q-#]S^\K3_[G2LV#
M4B 7Q!#( ?$Z ^BF!W[,1>O&VP9)TI>+0@[*_;JR%$:":#"X?B.+L3L5HUN$
M-:N_DA7+<+VB;!90%26^B;?0>1XXGA>UL_0*WY^<>DM>5W[PYLM024C/[:L*
M;^OJ88N9+<QPS!B5,^JTX]:)-?&GC\.,?YI3C^_@2_J!6=/\?]11ODL3.R:B
M>FR.>U;BO] ,E5+]Q1>/OW;K9B/:$&70$;X+PQIIP5BW!ZS2G^AWN7=XWE3%
M*\ '0J3(]J?"$%@W['K3'2SNM/FM+KCU2^^E;Y;]%6R)<G&Q!2IOC3]NBB B
M07;,BIC5YB(KDH/%A+<XR.SKG-7&EUG6=X)OS>?X.2Y;)5J6ZSXEE!"'\?+M
MS?(FH]M-.C_0'[>\B8WQ;5K<WN',OY9IR<^J00[ Z0?=6(V0(#D?-QT]>$?Z
M>/H<XR,SU%]CK6Y>U-5JF@VY^5NHJB&33E5_16UTR5K]$9(?+[&EE4=6&%52
M=<HCQ7:FRK7PC^W(NA0MC5TV\E2Y^%E2(2AWKSRWZPS >9[,+Y'51L_9&JO3
MB:OIY4'9_)Z. 8!MRN))P/ B:+H1L]8Q>&-J_80^5F9.3[\Y;IK;T2SUR^U>
MGH1_^K14*6C_"4LW(H*_36&Y(:1VSU"@*0SV8$=.;5K 7/+]//5PU0)!OJ'3
M"KUC;5 39]DY';E:X\'6:-7STSUU]AGVN;<;6C3*H#]@K0,9GW6#I.>Y3(JU
MJ1SAQ$K?[=-45*?AIYTU32 M$-,(S,@NZP^J([<&UC1K\)/$LB11AX&T#X>/
M!B2SA^BJSP"_YA/*(!YJ5>-*6MC^MZ?/QN^,N_EP]^[+MBN)<4GNJ)O1'O3[
M^H*KB/ \,KB!4-)?I%OJS 4CVN'$9C![6B9WV'FN_V4!6^3C04MB\R!*Y@&:
M#2?N5C _9UYBW2 EU7E?7XLG>':MQL$)5BL4JB2$X558ZIB7'S+<6]>Y^[?O
M;^7=/[T)D=N?O;>?W)BB=K4P_L)+Q#2!>,N&1LGFGH+C2XRAJ[EU@ @W]'V.
M/WPU/1+D&[WM\@N,=GAH!5:/ S<1<JDZZ\A0VFIC,_MCZA4&ZI9(YNNK[2/-
M+!VP:F1$-BG0 \LLWZ'@UEE>YB+8E2%=(34;\6R*Q^$ *4CY=@9PW5 1@QBI
MCLLV!ZK]JAN3U9F!5<%ZM7*B/G#8<P>X=2O[WZ191UR$V95)+#K$>#2ITI5A
MF55?H6LMG5::6Z3Y?R; D^,5KE)*-+#R6ST_@EZ2D-FD!BK.(.JTO;%/]&*+
ME=<-U"Y34/O*LE_)"7B;9K'9H;VDR(R4H9?>G^]B_XVCX1M S#1AS*<4<8$,
M&[;%NZT6%D-RM<?$NPH]72[]Y2W*NW;K.@ H.:#@ETU'-J>DR4A\I*J,!!GS
M=N7_@"3IG@$TV$^"6EZ@KO&]$'O2\^Q9IO??F&@L<"LECVR %W6TZ"K&TL_=
MU2(6[?K^:>20!"P2$D9G)[E/):DS)WH=3C5?FU1+-GS3Z"T4W+]=^_ MGB?D
M$2Y2=B,-6+T;LGTP$UO<I%M0*H>2</"\[67R.$%5VGOS9EAP'."#-+0KBY-/
M88BLYN)3:N:2+I?E>FFE9F 0I1IQ43=TG^<^;M?B#,!T!GCGQOT;R"I$$+7:
M3"^HJXUJ]?!PV+=Z9K?ONR?MO_YA-&9%R?14VPH1G\4P<J 8RZS3#KT?I977
MH,'/_>(-@^?@5:^KBJ8%D!M+>E'DX&"B-="R8OQ![<.(N/A=,2EU9:GV"_=I
MHPF@+0T,D@O2V,TUUT]$\4YVB"N(2QB8N;]P(D+Z(@!2[4#9RD""F8W*&2#L
M/4D#*SU=0RS&0MS%9( D#;?Y4?T];0OJ%LWWPE7*R/XA\L=K;B/:BFZ+Q! 5
M\#C,?IR"\ YV"WI8B+.15)$T<O"[1"&N?*R,?# %_FH+@$\TAQ,]2+(.>%$,
M70*FA/O1EN'$;?NH>W0R7G2+=>OU/%?;FB_$ "*8I%$8TJNQ_[V&^Z^Q_N6H
M7"KP_ZDPEC#C)"_QL"C::2#0)"+:H^RIGRTOI4I-P$7 8XP+0$XEL)\S$59H
M'QA%'QX$6^26':N&??)C#[A7)_Y/8:;^>TSM33):S'I_XB>U*P":L>@QPT_\
M-=+98= .C)JMTKF+U:!@'JO4G!3;XU%/ADWFQ*IY'\QS",HS%+M_JC5\:?7:
MY['2Z81XX=;,HJ(;^-786[Q'])LQV171(BN80X<-GJ_DSDPJ7[<,^[8 O'..
MAJP)6OR4);9WZ,$<QZ +/?XF)S]#OVO?Q>T[Z[-M@UY2S,"!IWN).N,U&P(-
MI#>4Q++W>TP6X@,SD=SPIUTLRK@#HL24+:8?'9&'WPP"X0-(4(=YHFC^,_&Y
M>#\IN/O\VGZ9LL>B1D20&L9%^>II.Q?OQ*<"GFGS'B?.J!GD[(O7/LK*CA;7
M#F=76^Y#CEX,;T^:X\L_V2\A;VP,*YI;.!W]TA!6YW@M8%MMQ_0!##C74V]:
M1'!G@&NP=RPT"Y"2WRC$U<-+!)_ZF*Y]_;"=9U)REM[/BP9M@ET.2MI@#-Y
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M:<YYNGG4;&H&\ +CE])+,\JO[$B+148A "VB9.$QLF*Q-43.VFN:.[!$2X8
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MXS-Z8@T3L993;_Q'YN=!TN_BI.J):]E_>H[*^A_L=7=RO3*]M>*^?7BY(T>
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M/=D!,XALQ.GMO4(<<'\'=Y %+ =%7)LS=,"2=A@SR-PPELTQ?)@3C8=S,<P
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M??!M8.Z)]?GDGC@!SLR)!L2(&NCCI>SW6-M4@\$[YWCWNM!:G)\]8W-[5U+
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M0&EIBAX_+:YA"4VQP)JW$'!1'_Y;V'>G6#QKJ*HOB=.7&#AOVR@AECZ' ^;
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M6S^N]=09"/3JE6_,@(M]H!NG ]4F2?ZT+(S1 FCBX5ZSQHWJ$1E[,]FL/R<
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M1A \3W50>95?G@#0;ZD;QQ^K P(]ZM3>F.YQ,F[]RA<4X3E-:R5:X0MML##
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M6I0:;I,+,M9\_PZ:K_,3'MS,FS 3TA1@F@QY#F-([?CO"T@*VS1B=;D(.5Y
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M4R]$W&*CVEZ<JECLF->,Z*M"*K@W-,QXLF;N&(#/&^JY>NO4,+^*^K64/$Y
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MWS."+-S@:1]PP9M;IB5];X8K.-YOY0)(>[/,E/Y1% S%,KME3TFN_'Z>3^7
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MX1A(L\>$S*43VQ>*'%V>'>):0 (1GV:"G@<BSD#MJ4T],Y#GJK;?0(Q\_E[
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M_+MI\/]/__LC_G]3[G\Q@(^G_P-02P,$%     @ M8)<5@!T<B4 ^P  8/\
M !(   !I;6<V,C8P,C(X,U\Q.2YJ<&>LN@=84\'6*!I I @B2F]!05!I(DVZ
M6$! BB*]1 6D1$!Z@)!@H3<! :7W(DU*"+U#*-)[AP1!>D(-)(0;SW_._<OW
MOW?O?>_.WNO[=K)FS\SJ:\WL\ZGS)< 5+75-=0 %!04@@7P!SI<!-YY '-X"
M #HZ@#L  ("6C+L*H"(_49"O?[3S6< C "4%Q=_[GXV*FNIONWCA A4US44:
MFK] 2W>)CI:6GI:&AIZ1GOX2 [G1T%UF8F2X_/?Y[R!_7__[%OEFH*6A9?@_
M;N<M &9:"@:J2BJ*&P!*9@HJ9HKS#@"0O%9JBG\TP#\;!275!>J+Y"717R)W
M0%PA+Y^*BI*\6.H+%\A8?S(><(&9^NIU2;6+UYZ_IKGARG+O0TPFK<##\E;6
M%\-80:DW;A_IZ-G8.3BY;@H)W[I]1UI&5NZ^O,*CQT_4-9YJ:AF\-#0R-C$U
ML[:Q?6MG[^#H[N'IY0WQ\?WT.3 H."0T+#;N:WQ"XK?O25G9.;EY^06%/RHJ
MJQ#5R)K:NK;VCLXN5'=/[\CHV/C$Y-3TS#(:L_)[=>W/^@9N;__@\.@8?W+Z
MERX* !7%O]I_2Q<SF2Y*L@PNT/REBX+2^V\'Y@O4UR4O7E5[3O/:]=J->Q]H
M61[&9):WT@E(O<"ROG$;IF<3E%Z^B?M+VC\H^]\C[./_)\K^)V'_3M<,@(&*
M@BP\*F: *N",F!5UH$_QA":7UQZ0]=%5W?T!-<OS_U>@77-,SWUOI%JE$;C3
M='L><MLSW ['FG)CP]PYHIPY9I97I-&E#A9_HD-P-X=$ZYR5D00=N>YLLLDE
M<HG>?>3C<.UJ>^^KAU]H![4 9XJ3I.OK5AS#+HA+VUHC$P/]2CU"#A0FB6,8
M&9K/))$_*HI#RV-5_F8#I*X5YS#("@5H/<5XI2Q$Y2HDN5W?PC2O'&/>+]&1
MQN%7C]_1C+%Z-5S&H7M9JG6UD"B ]_9'H_"/EOWE+'"(J(\)T:X%G;3VWTV?
MY8.==>EF&OWMJ8ZD2%<OV7WI$G]E:@I[>4]\Z^P6<K+D5T29Y\7?+7<L;'5@
MMX@V^._H1JFC:&0C=K4$$W[+(_6]"8IUSD4T2%72F/\'@)VOL:@$?HGX;*SY
M;7J8BC("IQHIA)/)*WB-1#IUW1*+3FUZ'.V,5A_[H^O^ /B3K>E&=3/#J]H@
MF\]H#0UJ_5.N3EQBYSS-\CD@V-QH0B:<FU=V08VGLH?_3L<7]CR_&% DB![J
MB=-N!UZ&OI8+)MJBE1]./(XFZ,YP7_IL_S+D6"'!@FW[0UP/N@X4PL>&38]J
MMCWS5;V,3T3+UKK8B-DU53<B$[?^K-K.(Z 9FAQ;.@!8\WJ37/EXL9ASR:[3
MV^HF/5FZQS]8Q_9R[#8M=E():A [4WRA^U*]I>.,'O-Z;Z7%3( W;3?-*+!#
M!%=_] G_R4<B2-H<2#</Z1WPIU%'IDTXO/J:K9IP>6J,G__C1;6CLD+X4EHE
M_E-'<[7=4=?/I-2Q8SX^)#M[HN2](KEXVJZG/ 0_?9H)8)4&D<5E&;35C+8_
M@+-!$KB57QC$(YXN:%*>IOYP72P!0^2.MO'6F'5IYCQ(I=YWZ"-./Z$>RC?L
M-WUXF&,F)YINCZJ(X(V/M,[J87<6B1:C+E:3'?3PBAV03M+.;8&93WT/PZ8$
M@XB;G_&IV-WVYBIDAP35/$2NM>ZXO9EQ_I&G-,@VI%WI\V,.%2UB+>8C!3I
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M1YL;_<\!']S@D0"G'6EGF=!S /V:+NF0W*'G_T:':1COE.@[PS)MBB[GE7,
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MM35;@.L0F35.[QK$%X"CGBX ?*+^A'C)U5W]I.FL/8_?KXJ]*4_NSRE0C11
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MO8"N'5^#)/U&$Z;"G/U)52C,PZV<\%CVJ='KJO12A23'ZX:P9#_ZJ'TCY$]
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M3.</<YFYEMZ02A&I A3'P8IQ9Q,[]@8^'U6M8)F06*"!+BJTM73> -^F;IC
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ME@L+B%#T(KM#$^.(N*>RV<8,2J_<<E#I%R#B>-/<F_-N]7#-J9%<1!7MX3F
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MG$2R.,;G0C3F 8\Q:O"=M<-=C*:.?\GTOR$X! 6FYBB4E@:"L,"GXZAQ_,S
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M9M5R23.:V<J:SX-?PQR_)S&A^&'5GMHR W(/_L<_VF*MM0DKHEK?&2,?'A^
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MR^C"&<=L[FL,A,H8*3G"[R\#OWCV#=U5?U711G1*5(V5*>P&_^ILT:8A\*>
M*RK18M9.8^(W,7;7=G_W+OF$-DOME9Q<)/D7V<&<*9XY\C:ZB$!?R7G/E%W1
M=Z^]BZ?M'S>\GBOS=D5@WUN=V6_;1Y6? EZ2S,SKR+)36XJG@,HIO7X-&8%3
MP./ANUWJ(]C<\0_YO2'CC:4??$Z<_ O[#FY=[U8=)AI*SB@ME T[YOP-]/",
M22>? G#E!^ 13<A"??6LZ0YF"+K&N7S3=O%;V!-FD=]]*$_W:C%7@3VE1,*-
M44_4'6*SK8&DY>RE_G=1FG[#CW.T5>HI\S%*P]%\A(&N](_!F)D!R/FT90)O
M3-"E:?4]IM;@?=#'=& G>X2@-DHB%U\2YVS8.Y6(;XJ^*Z_%O]Q\S>\4$$%M
MY12DB)%;&>+]^>DF2T*=W0K#<R(EQ144!R3!D&5[\_C!Q$:?A>7.(ON'VD*1
MVU9'0$E:7N>H(?WFU)R#-?KC*<#SQ=]4UOXPAQ]OH"O(*]"1C3D)@_Q9^8?<
M'CQ;8"&O5/:IAB&1:0?#%<>(V6QFK_:6H)$G;Z !94I_[=?E>;6--QQ:^!S[
MNSS]Y[G<%4=_3,]"XE_&O#I,+2QR]T%HGOAW]I=)O7H4_VR@C3D%521.XW"A
MWX<+)%A@2(Z8K=+(U,$E$N3!HB<)*\" _CZ1A(D"_YOO\3JI=.T9KHI-GU J
MWWQ]6]E2S3( 5XSREAE>"#B$6FM:^LE<S^B+/+A]A3W?^8>[I;<N6"%'JZCE
MV5,MU;*F/Q?WA?K\A:J\K^N&U[6/B9J"YCRJ&ZE9<V.T7&O<6QG7\]TL$X:3
MB]\>O]9LR7F5&X$3JJYW?9X7Y_2;[:!QU,.++?+;4ES9W[L+A P/1-0/>2D%
M%37FY'L<%WZ5-A8;:EC+YKI>#_\F=DRL 0WGNZ[]A52ZCAJ(@9#Q?$IV;MXX
M6*A1DZ7%KNI_>O^"EG'S]HTRW]^XB$C\1NCC'9S^YO;Y%]X]_[C/JN0(]'XO
M9/;ZQ++Q%:N^-Z1=VPP(#_;D+*S8!AN%GC7NH'Z>MYN=@:1N1"5^NAD9ZXAV
M%!FQ+8(M3F=?S,G+IWTH7#MRKA!6#]ZR^B7R;G;9VSR);AR$5=[F1,T!?+JK
M)!.3EKEV/4!OF##H?W5^T2U]Z'OQYS[Q))]LL"3P\9\+WU/*E2926?S#\\ I
M'>?<BOQ+W,X'B:<2]""7^7EG]-PPD6WJ<:> F#S,)7W9'[^-9X%C6/]_ C%.
MV#YC,U#L8 /YV^6I\AC[I#3Y<M.MO/2V =^!4GR0=3K_Z\0HM:OF-;\&;V0<
MRE62Z-,EOS G4K9KZOX[7=_;:_D /Y%G''4VY8ZA2>CQ\K,*M_L$JTL-SJXH
M^D9>0^'I<;=[.@0CI\O$ZAJ^OKK%Q#Z;^:K4?EWP:1'>0YL-9. _)N;8XMR-
MW; ;O=U;3K?@'WOY6:].;K_LJZ9A2 '-043I162_9&#F]8XS^T4WZ5Y47HP8
MYH2[?2!(J3,^S'6244%6MVQXV*A'=."@GX.:NH&9<Q5ZA$-L 3EMGLPV!U&[
MM4B;'>@_3-/#7]Q=4N;SWMLO=R&@\TD';Y5>CWHAC5ML#01OC=(NF(:$2N5G
M)K*\# 0:V^0B;G<YRO?^ZA.]X._#\8#X&:I@1O!0(%A&*WE%'+D+HF*5I/DV
MC^"C<8]O::8U98G-)%:\W&7[S7HYS(T4=GD5S*'I0F'OT!9KJ*MK&7GT_<=.
MXZ;]I/'7/)%.LC$/251A]$3 8=7&/>QJ3#MR:DWRB#4PS#)YV;LSI$X<WJQ5
M4C#:9)(+.;!H,&JF9M8*F7>X)=U.%&""F.]UWTQ\HQGH0'%N+CD933=JR<7;
MSLH+A3!?F3<,8:UXK"+ZT"TPH;O%B+8;Y.M/ 3^W+C!JA5SE_QN;Y WV9#RX
M W*=9^6;O@:U8(JK$\IH#28;XV3;;.Q. ;S[ PDR_(N[)@]=[_7-KSE$7+[\
M=$153M[0PHG&1_7%[AE?*"AY@]'^YLV7B>)B&Z%DG@B4MIY=O=*O9/!R++7'
M. I9?<C,-7AR %X"OX(IM/45,?C0&*;!"PU5+)GX+SPH9C)H\UR1+:W*W$/'
M!.8WG:JAF88C[5\=#WV%64K,_-GBX)JM1S[H_'>6X#K^"-;$-N><;:*T3[-R
M;4L(M@8N.Z[)07\(5Z_#;.[10R^O8^%)CZX>6A$C)0ODM4(L%0CL-,G7W<DY
MZ[57'+3&^KMRHD2M8=U!B\M-?G!)2F0'\K*= UAI.8:UL_.",_BN7]M:=O.M
MAL3DO]VWH6:K'@A#<N0FFKRTA1*KPLK(U#\W%;V&_1Z/L-E!)LQ7E[5V;E^$
M!-C8E]A:ZPDH/.B\D%+I';Z!J1/Q_7>518F3>5J*0H-6K'1[SI6WN"/J)W(Q
MU8,J-N3]#".H4G4&I7DWTBX[V**IXO%2B '(;QQ)M!]+OY&-A"IB@<Y7PS^3
MXN\$ HB%#FA@ AQ<!$.:U*239RZ*FY\"#.2RJBQ'YGB//S,$*'J_>16L>OON
M/G,P?\*8B^3I@)O2,EN9T8T(-N,\R-&B>DC4]7GW_$A59G[M%,V_DJDN]N3M
M-B3KGEF^W?K1%^EB@TM_KGT^V;YZN2GD"/N5%F*:X4#;P[A:4!,'5Y"20\8S
M=4RQ?O_."*A;T"BUD7)9HZ0QW\KSTC?IO ^0MY_O-H=*A3RA61,,-*W$*T;]
MC7_];B3-J3A);:D>C<"V>+^M"X)B&2%E#"/L'1)I\U73-WXC >#UA(SCXMUI
MKW?8.;'D3B".+]VHODK;G?ZW=G"7HY9YPUI;L('B/YR OD!:'!?<N:=#"MA%
MHLPFJAD:"V!NW'HMUB8^K=@.4H'H6=2UT$U6ZX:MM*X8IFLQ\_<U/]E^![[P
M+Q.Y3@&0@2(H>V$,VR#?%[S%$^^_RXW#9]P:P!W@BP[V;D"**42!_59IGC?[
M%]^QR.6Z>B'C)G0#730M,&_ML#/9Z-H7U.@[>]UD,K0#<25," Q>"UX<++9-
MF'_D%S94#MOLV?])#=^Y IMO"P[L/A8</;DB>[G'D?KH%*#_1MM)DK]O^^]>
M*3@*P0R_CV=G7J/,KW:KG0&N57 DTIS2MUN8X(;@J;2VV(;J@)VVX*G8Z=X;
MGFIJ/6.6.I00Z@:93O,<W,M0]3?(%_.QR^ETH?#8#9:]D](0. '0I IHH^WI
M1OMQ#'7[3D^QU+GUYS/!*Z[$]*/ WPW_T1P?Q?>KI;N2L*XN]"E4O/9UN/Y?
M3<.B-<&EZ!^F=F<RK,X/5ZF E)D/EUMJ:6H^6 ?FBD04HEI0_X- K:?X$9<=
M&N58_&U\Y)% N5G.36Z3:,!MM<I+C/H5I%M2;E-BDK;"<,X@ #9,"B3(<L,\
M1W4:R=1*Q3H;DND"P#B]7MC;@2^$\J%;,"U69@M/B2CQ*L+-*Z'+DSQY/#RQ
M ?*OQ+Q)O5H;FVS! X9C'@OV#E*WKEK\>;!D#CC^Q1Z6\L<>9HR?IAW-K8<
M6?L(5B>NF5$M?W,05[0> 8*POY=HR(5#?Y*. X;/@BL%:@N3T#_9623Z"OOB
MJN#G2C>""]M0? [E$=*>RXF=$UCYTK>L[%OI1\Q/* '?",P-]LI'F"-#WT^F
M A^JW57;F/)A#[/%DCL0E^ >WA5-:_DO$[:.<<5@ 25M+D*CAY8_D&-JLD<X
MH);+SOEA0KC])(#=;0^)4^B0)O>TXSP3[EP=?/,=H1H_>99]HA[UWN8ZK9#H
MG$P-MXC+N@O8^)!^(#L]VH8@I],B#4;';>8F<#R<,TP)=P#-T#'/"<W>DD;@
MS34+44?%V%[;7^49>%2\$C*B8;9CK3:MQMLNC.H4<;_&JX-<++TP /JO:<)[
MG:5(3^&UI\%L[:2OI=+@?Q[_=6/6[.$#/_Z M.6;]H^A^CO#!F?K<\E?PB1I
MPR>\SC5*^H[T&X02,5Y3^'"9\_V%FYNB&J@;,A)UL1<O$IFB&WTELP1/5KLW
M#LBP8?2-Y;)K-0U<:LD#48X#FI<UQM7?Q"<J4'<1'!/SUC!HN_IR],CDG0'G
M#R3 W>L/?! _BS0=@PII'5T;6ME)#?:9'P%E[>@@!S3!R);$KI1IL6/=??^5
MN6<W\^/5S9.;>D5KU+( E/@;1J/YZP^BS!MF6S&I1NDJZI=6M:7!TM);U^2=
M?I(&O>"J%*WX<,ICM@<3 T;Q,/-R&;W>IWH.CWS8"S>RKXUS6T_+-Q7>++FX
M*W0T41Y'UZ)5=>+6JL"7U\%0H()B8F7ALEZS\%_%ZGC<]+.,'H<[#16U=:-A
MXS]['V[\*O4N5]BI4"5MV!M_1#C5P6W/%[*U1EV%DK18/S\L7/)1Z X.V$>)
MU](016OI@^-E2^7Y!>69[#CGYZ]:LYGAS\',-.*S]_,6S9BF!PU@:MCS//GM
M(,M,RN='+FHEJ^8OYE9R)=N,'-NTSXZARPQ[ZVHC[-_??.W []FW'BHUY($6
M46H"A2P;O4F/Q;Q^_E6]6^NW */X2RMO.<,VO^]?7J>L)/O->;2GR; @.)AG
MDLW2(N]'&VCWB.QA]"K5KAMEVP;WSAR)MGS/P_'TS>PCIEJ)!2EX=E:W5/6:
M!._B^W[*N;WFC*A!>]KN*> "*!K.5S#G&NP>(/T9Y<6YL,T_HW^@M/@&MN;.
MN,$=P%N6O_YD7BWSN,C.^Z]W=)HQ+5FZ^4O L@88O13_.E:W*Z&"M&9H23D?
M@P>6VB$\#,\U!5!36Q['>ERS.@XJ4F3GA+E-]!C59CP9*Y>L35/HXRZV%- >
M=VRS27AW=60Q^7E-RX32FN2?D2Z?5[&2FIYM3&C).+]MUMF-1)7PI2;,7I"8
M0+2NFKQ+;I@\Z))B3?BC6@HP#UA%6L[X";^-6<8\3QW2;WOVA[_H]U[YS/'1
MSO#D>E?U*>!M@Z;'TA8+0X2=*7U?X6!CN*Q^ROCEF,DC@YS_]?TZ*IJDWSQS
MJRJV&S$$F2VN09_E4W\T%JCGT90HWQ]$_^$[FOWE# 5$JBTOSZ5P68RB!X-'
MVR>\I^^D:E3'0 M:7N0MS5^='=M#%8%<#AJ2\1(1GF6FF)?N%\UC=>6&+IJT
M+[Y8",:^A^7A+3?G2Z"#Q[G>KKCPIA^]P]2:%U,'Q!U4?ICH]-I$]I6*A,?^
M'DK/6)SM)_T908Q5IKY3@-MVA#QMPX;L6?2J=L=^<G[9N$I_[ADX[4::JJK
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MO?<]EV@I>@T?[W_]GD[V<C._^ADDA./!L,.HFWA]W1NCB>N/7@>\64WX],*
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M!=8:8+@1AYHO??I%D7'?3/A]YTO=28K&#Y9>"K+HG_F_B\'"A3\!(K=^?7K
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ML8T1_SO?X(H19K >ORX!=QI;53HN <RB;7>-IE17!C;&+<:]#WT-!H*"[\^
MHP;$-IJ9?F:5!0RI57[+U8__T1P8+-*OO\P1!UN;Q<3.SZJYR5YXF)&2EW2B
MDV%*[>.K.-?SK5).R1>![+>"@AV#6M][B8H%=?7DUJU;!.H;LRK*K@67]J_A
ME3&",;<O 3=:EQTZ,1.'NV:GH2 RW$V+5!)8I??\ [.RY#,KHCFXQ 0<=K@7
M5,SSN%LV,$CWC3*A_$+DM\]BA*+L. CL(\@O.U'8\%'K3B07!ENV?XTH@=N/
MADG?;<<5%D$5)&^Q2,7E.,$JA0[!%==3Q5.4>3>$\D4_"[OQ/$:RXMJ[<_C\
M+;M?+1CAV_9(__@*[B1G70(DJ'D9_OYKHT_?V^X*=$F/(H8$B&QL$/#KV5E4
MR(D9Y8C>1\M?*3$EJY< WWP+@S2/#@M&R_[W5T072S3.PWO]XNZ=S'%):IL*
M&7ED"U7N]?3+86_C,28^"]?.>87=";ECN\C-"8?E3<@N;AM#:M4ZA_$FZ18Q
MHUMYK]K&]R95;]=%=P@D)P\O6]SVPXKW&EH\F/#F BG(31\[7P*>^'"^4_JD
MUI#]86\S*%"7>H+$B<^[8GE>B[G9K<"4UL&_WRO3I8=644C."L,3MVZ="MEU
MESD)+HAFT5+[="'\FC)L4O[OCESUL\2R-)[7E)U\4K][/=K)VRCQ&^JNZH,K
M P/0J^W9-V!F0A43HO9@W7LXK=^)#3,#8RT("[PIQM24]G<YT=%_D(X2 [C8
M .#&MXP7&17YB4HXX8CEI@F058"K[^I>?-/[V5I D%_Z+XD0J/ZKYXNWYB=;
MM/K:Z6 ^1?ZF!@T_<1&K:%/J3UERS AHN3$6T6W)YVS!6]/8A$O9D6/IX58?
MQN:\_$RV$]<C/O#[J'@Z#4/:-HPFJF 9>^C)NW%SCFT2;4T-SM&8ZWEXK;?9
M61&N)K 'N(+>,G&Y>'&65[E-":B#7$8#1R[#0L>"-(29[<FN!0=&_!KL^1A1
MIZ#3?F7[MZ@;@Q#L?3VROM8;>&5B[Y@3OZ XWLI*!$,T <>2@AD*%\00UIT4
ME=^8]G+_VUAXSP=\S,/97G3.M"O'39MX_%&O-V89$A^"Y@;RFEN]3N4;WE+B
M_\%[IMRXE>ZDL>'J[HLL*O<7_T#DP GKXU++WP5@:'^YNO:]]3HUL_5^?([6
M\, B^DJX?^!7]CU+'DA.D%Z3;5_?<#P+&A7867W7&N$/[+:DAFF@<W3-M7KK
M4[?I_D2;C@OSM5*Z.D'H0 %%FZ<L*ACGDL)HEM@+S)DN=17?(%'5SSM?;6MH
MMX4;NTCF3[["7KT\ZQROTF=8=THY_$OM,;%$\19,$1^5ZZ!OYI@MT=R0E<^I
M/,'8'PK^5:5\BBA_++NX+[O@C#J"1H;(M81-FB)X+ 01 +&OF_[#3ALM\&7@
M1WY@N$:R#L[G>,#"+, SM-TC8!6WJP14BFL2<1-9R&CWZ!"TSSQ'I^1<:?3M
M)0!G9E;W.I3:!E'@I2B,E>N)E^J3IR_/B16WJTNCF7_,J]9_X'\^0MW&,3R0
MG&/B[-8G)U?AW#]^!1>)TX@$L38W*NI+@$D6]A^ZCY\;'R64\^/?3Z>9(-7U
M@*''^DF2.5VA8 W>"!Y3N+7V"R>R1QI"PTWS:JTZ2E12JIS?0YE\<N.[/H\J
MT=^[AY(N*@#8*!Z14915-*?YL2EFW2,?A(A8M7KH[V[OOS!BXW"X!&R/4%G&
M@%2@R^7LP9H;0\S&W^QH&&\%HL6Q7S"J[;U:&7B#!0<>'1A_R]'):06R5Y&G
M'F<?M>_=7+Z^< :J)XO)#&(VV^@&AIW#NP@73]?'--I&2RH?N7VJQ/"1@;QS
MZ:&<_FDPGN72^5?JJTWJ 0?GUM6*3+ W]?CRW-95B=].HVU]AOQIP+':D%MX
MH<4KO$E^V93N[)__;[11__R-9220OCR$%^]%D%W0![W[FG:]6P[$V!7*&&/)
M<G3EZ0M,39.US^W"T'0_PA^BWK\_^WL)H,(7+O:% .LGRF'[0EMR]]R?4]K#
MC/%J>3!K[.=TL2K6L9E?RCU>TB[7+P&. >7B%/Z/T!TA_.':U8?L,_-/O[=$
M_ +J#P(\(=R*$$<(987WE _9NBQ2/"E7G</^%MQDUSM+ST=;EJ?X^::MTM)'
MJ<X*%8QX1S 0 TIW=I(HU2@:6'^N1N')>%31_'QLERA5H&(#L.)K E";C5!G
M$TTO"KTM(_C!HR!P(%)FJ *O/W%[@R@RBI3AW-FQ;; 1$72RY2%;M9'I(&I>
M9-0 /[8]&:\=&!D,**K;/-M"+RZTTM#:'IB0945G!.0R"O^%.)7SCRLGZR<L
M+*<O&%O-]#^_[A(89/C.%:<YV,:GL?(N<JT<$SOH?Y))NE;9HD\0Q\-[3,"]
MR/T\TQ*NN8<1GD9)'N'[YFZ)2R)\XIT#WY"RVQR?^U]JT0"6:Q=G$#KC(#FK
M'V(9 0_E$]\\5>;Q]!AF&R6JXNNML/L=J4U_CSB>\GP4B+<)9;_5"+ G7ZAJ
MT2%(.\JCIU)Y8J,-_H15GGU =0Z_6&FZ!+#Z,PSW6O"&:[4BANOC,9YDL_V\
MX;T K\#%7=J\S1"Y$6_V0]L)F<UGE<^HE7PQD-.1TIR;BI+&1.F&,9N6A&W?
M/(]5-R.NOYXW^M3X?K2U$Z3Q]CU7U2&J^4!]+LH+^@3J4L3X*)PDIWCAU\N'
M.6#2XT1[JAR^T[0[6]4!.!AJ_VU"<.!I+H.:QD5>39;-2OG&!QLCDW^3=L_M
MOZK5\U6&I+2N(&-GH.$@YT('.3W+X+PWPY]'9JJ?2R94/.9S9H=,%W7GK<2C
M8MG!]7(L7);4/)FG)#/#-ROM ,<%H;\[4"1=F+/$L[NV(O6/3T]R&:26Y78A
M^3!]?'@YWG/R"<N^6G!"EZ7$350N!JF9;'J1_[!% 4>UH=Q8U:#LRIRXT7D;
M\7CWJ!1"#[=#,A+%<:G?RAW[50=Q#WM\7 XT-I*/\R'5\?$HA(RHIW/::K)^
M'.J. OL;_HYL" T@9UD-1:L3 W>*5%"(E:NEK/0B+([/5(FV.\9>H3K3OW3H
MB7G_8$%8YW7!QWQ!'L<5X<OU'5GBR\9-!/K>U4'_ O-5ZUFOK20/=*V-*D%D
MRV.X3/PD!>OJOI_8#914HKXEZTD-+B9W7M[H$X%_Y*?),0KKWV(?[?]-1OV$
M/PHHMVPDK[-K_'TPUSDP8JV\]\N)8/;K1 DAM56ZA$>!:)VE*ZW*AM!A!1QD
M3PV!]H#0[K40K\4G8.?T\4N [3##5<P3]OB^^-LGP%D*:O?HYQ\4\A%YPQ&?
M-L OA[[%!HI9I#5UJ@N!3HLS@:QU5>(.AS?,J9RIEX?#7$A ?Y-%K4ICELDI
MUSA0Y'/R?P'E>S6 UWXL+B*_.X_XG#2?F\4 PE[_VHY *2DZK9)D\&<D7ABD
MY>^M.(T NB K.D7=:8S,5+X(-R9GJ'$_NHVJ"A^US*>BUC9_XJKLRV%P.WDS
MR#N74>KB*TEZ>Y'))\M4$R=ML!UD0YB*,YKI=Y?$&YKC!GK3T1%$%K0)[Z3L
MV!<1P=.]4E[^2X D<.@'\?I%UM%PV+6SW;T*&=I93-K=K $)_G#!E7*8#U[
M&3?<];%PWMS,.-^UY?I4*.KB6V).7^@C^+OAF'-TK_BU08^RCDJSV9<XT5^<
M,4LBS(W!"5*=^V\N 4Z+,YJH$Q^LU")D>BC/_>ELWPY &*RS;>[7!8W:QK9W
M,3O:'>X. &E E<UPLE>P5_@GN3"+,0N4Z;@K5, 6P"5 F9R)#41TA=XGLN"N
M[/0FB6M+?C66=MY)0D2S2E.V,%CR& F\*+H$.--K+5OVF@)I-G^+MHZ^SG9,
M[T5:WW,/F'T/I-Z_N6]Q?(5P'09 >I"P:_Y699GLY$ MJR_09)DD2?H3:-D+
M9:HK1B<;66@SA2UCM@7?VO ]?YS+,-S9)H#HDZ?*"%Z7W?K.\ )*J'>+RH[*
M_GN(Z%N<Y3'"!^,.9KME<66^OH<//2G&9Y;?46#2OD3+7P+8O?#HL1!&;$I.
M6 O8ILC(?J=.<L?"CR6()+.^('_QJ0;"@5\[GIP0*QO<"=,J?=L<T<F;X(52
M'A\+54!RX.L.M? ! :6.=<R+YLI.XZI,7UU_O5+UIT(2S/S["=WRX#)9DY",
M"J<NC1N>0N;%G;Z8N)N)@\&2[.\=.:*&4F-&9[^^ -P\=!'@"R3)K)$D+A)@
M4BOT8@N4+2WCZ_6^DD,5)JH&3]Y19#_R&';1I9!K!]9^O038:R%8C;;<_YE,
MYO#/QL(EGC7.Q\6%FT%Z+@$S6GTSP$B80NFL6'(AJCC?PK4FPJVP*3&#4H^,
MPO>L$JYYLBNR5)&<3Q2'WD!FGL,2SZ!"F/7'\\UWJ[/;CCOPX2<B8\=0UJW
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MWT,O=<H! ?"KLYXE[[L$T("4_<5%:^;U0*.,)ZX)@E]T&)Z6_GZPRGMSG+S
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M!<[J>/XYYH_W)4!\OQ': #"SQ77DTK:SA4B9$,5'=_>X9X(B&F;\1%P[A-%
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M;@B/C+EIMP5Y<]/(ZE4F92HY1&89+,S9)ZDPW2 Z)UPDDA[ZYZU81OF((-C
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MJOJ6RIT1O%V7>_V55$[S,+)<;!+2I1A6(*U+(7D?GO:%_N6S>XJZ#;NOK&,
M\>%R5BI4J'[)5]Y7.E*=\4IP+.2EFNUT^T]VW*CF5."CA!H7X6)@A(::"2"*
M'HC=&]YZ^09ZTI:=<M4;N.+?DTX;<Y/K]^J"@Q]HWKO&](&.B,(6??^)],JQ
MF"!=Q3&[.]H:JJP NQCMQN^A[ E'"[GCQ0"WS]R2Z?(C9*H ZSA=,HVQY"?
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M1?/K=7:>:.B$8=8F$*O%R&BTC;.<<WYE;G8WLRZIF$>%W3PW,3L7/4F9,4Q
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M W*/<D?(QOY+#C&2J@#XY?3_ %!+ P04    " "U@EQ6+3DR# -Y   /B
M$0   &EM9S8R-C R,C@S7S(N:G!GS+P'5)/=MB[\(B J0J17B8H"4D0ITHG*
M!PA\&(H4J2H@)0(B'0(1%9 : 0$!)=*D$Y$J I$: >F]"(3>2:@!4OZXS]GG
M[,^SS[[GWC'N/^Y*YA@A[UKO>N9:<\WYS)7U0AVA3@-G=+5TM  Z.CH@B?8"
MJ#C@@J:?\R, T-<'Q $ .$&[Q@[0TS[1T5Y_*]1Q0 ,X1D?WZ_WOA9Z1_E<Y
MSL! S\ATG(GIEYPXR7SRQ(E3)YB83K&<.L5\FE:83K*"6$ZS_OK\ZR:_FO]J
M17N?/L%TXO3_=J%^ ]A.T*W28>GI+@#'V.CHV>BHS0"8AI61[F\%^/="=XR>
M@?$X#=(I9EJ%BC,T^/3TQVA@&1D8:%>#:-<!!C9&]O/7;A[G,'S =,&#4R8D
M+N.$\*W2!BZC7OQ%V8=/GY\\Q<W#R\=_2414[+*XG/QU!44E98T_-+6T;^OH
M&M\U,34SOV=A9^_PR-')V<73R]O'U\\_X,7+T+#P5Q&1\0EO$I.2WZ:D9F9E
MYWS,S<LO^%Q67E%95?VEIK&IN:45^[VMO:]_8'!H>&1T##<S.S>_L+BTO$+8
MVM[9W=LG'AS^THL.H*?[>_FG>K'1]#I&FP,&IE]ZT1WS_56!C8'Q_+7C[#<-
MF1YX<%R0"3G!>2LNH[3AI+"L$9[KX=/>4]P7Y7"7"+]4^YMF_S/%GO\?:?8?
MBOVG7F/ :7HZVN31LP$0@$S*C!0#_O>$[L.QN'=B;4M*HGV?+Q'J$X0^'R+&
MU\<-8WP%[L_^(&%.'>SCF-8'I5O!$?52^)@%)#FRQB!=)3"7M?Y1E]+/;Q=W
M6I[,R)Z2,ZL=W#T:UCCU-O5)?'1ZT:$>=$A*WGK*H::J>JO-="L;5!Z+Y7I8
M;T64)AQS?S')10BNRM.]PMW%E"00-)YJ9J3S;;6;:XS2AJ@\#2F'-@5IVPP^
M-FM:SOWSTW>'B;C*FTJ,-<,I\8OXUIX8W<+X.X<^.E&K=P<&K^\&I/],%2]!
M%EFL5K+]O#>A[>E^KEU'P,V4RZ7^N8R^]5F>^CRQS,C[G(;F"';IA;Y:ID(K
MRZIDN>N?E17V;QMIWK7KO,0UT%6A>>==@7H$IGKBI]8**7H8XXJ)\!E;7W.>
MT0N]O>AM^.D)/9L)!%<=+$(%>CH\J !<*NBQ'X1]\*"76$MZTIXERJ,5$ !&
MC^?]M'T-P4] .!!+#M54H)X;2723CL#LR$P@IIBA9/UF*J L2A%.,J$"ZH[$
M_VQ@^X\-P']OH'V8%D'Q A,$/Z,/MB'?R,&_T(50@3 <,8T*:$AAR?AR1),'
M7!^\_;]7GPID),U2B!:0@0GH]@<J\&H^$=&=0F%:W5M1,)L#D11 S5.'?&Z0
MS= LBD#4C#OY=!5X_UO6O^'G(6E+%E+@W7B(;95A#>8<XA_'Y51\]]XT,>72
MFOCDQ>JQ+KH#)G1?>,/(&_2/2&2LTMWLK+5?:M\U@^"K#-/,B=Y9/ZV4XF=F
M^A1\U-H,4Y<DYAR%[BGN09PR3$QR^:.<+U+PF9'B^K<BQ3X<^Y_(B^^987R<
M=(FS8$$G*@ JUZE0\S0N[?-:=9B2:AEH%)L5RD$>^Z0J>Z1)!+4&G&W-S28V
M-=4DH1Z=3%^8/%2Z$'76]ZHBUR(";]RI/F5 !9X'P1]8OGKP5CI4^BW3C?';
M$5_XT%VVQ L*ZQ)X*H"K(G% 6BQ$ZJ6H0,65BP-F+(\%*^U<ORCN?E &%Z:?
M)F?7@TF:@3D]< =<YX,BK=409X1@_8W=QT(0_@[H.!CW)\IIG,#1L+ZG-7Y=
M_C;&*TA@838GV)X*-)3L!;B_JM4\TK8B)XWYV0^OO[2<87G5G>X3'<MT1ZV0
M-@_3Z6 >. AO.<.T_A%NB2L?7I][/UM>87E[P0F??'_MYWY K):8.';C,K$;
M=VVZ356'"IP4B:(")TC",BY@&+0LU\U6<4.E#ZY"',2!HX;Z]'&V[$[UYV)E
M3"8;UT5-A$M\$FR3P7AW][7Y0(+ GC*QP0Z]FE2#"8=[!TJ:*M_M4UW4,XUI
MW##CM6+/98YK>8!H8*N]C<%#-\<W9[!K_3,Z<1D5SMY2(@>M@WZOKRSP+;*0
MQ;B00T'"LSRAWE-\4-PXA,UIWV(W3TKJI=GM8;:0@3=,PGFD%2H0J^K^D:2,
MKU@H*[1BMH9 7W7*O71TB86>7?U.!1R@H18.^Y&J4(*R_O76LWJM"GUJA?ZG
M1"N>R\Z]D8K5D+,\W''I)Y()+QJVQVS]])JY/5>X]PF\;H; 6$&3X-R+ S-4
MRB.YJUY!Q?YYQ0F!MAE< H8^$WAI?BLB HO@6%._[,?3<MS)[9*4W.G/3-O7
MEH*7QK2/UU*!F=QU9L><U6&8(^<8-N)*LD=LGU1G.NH:/;W0#AR!__@"C\9)
M1TC!!< C7B.S4ARMS3R*]+ZV37BT<)]A, L<3!FH1JZW7D!Z;G/%K_B'I_!*
M[S]_>4Y0Z*?$5D#?88MS^Y7>NI_IR1O(^&:S]PH=93\Q6\I@QN >==%>-U'U
MJWUND#+[AW_N$=S,Z9; ?#-UOH8# K-,36G63'K#YTO[;!S>J-Y/-+C)>]X?
MJR;1A'F$CK: MH#.N'#7BZ1/:5HZU2Y=<N:_,<WQ1MQ/^&RG-5$S$QV*<'(U
M.GM]1:M77HQ_9DCR_0=WPW=>@HLY=J;(2^I^>MI96HIPC3=&[JDR_3^.FO;N
M$3.F72\Q-74R6UOK6?3:=?8]^-1U7#!?[88$T:S*[#N$ =N$>#8IFM!<F/UC
M\N* AN2V!O*UPJ2H%.F/13RZ@'1IYJLMWQ+W86*">U6-]7>$+EDB?/NQ^H74
MID:]= F<-8_&"AX^V=5?U5&:J\EIUG?VIM5F2Q85X.ZWH@+HRX@=#FLN3PPW
M9BX5AMJ=EZ8\A^E"FI$%BMN@?1<4#A%'+)YY0 6XA#*0!P<)5."6_#KB\_!:
M9Q9M@I*^^$LU[R7X!5^[>& 7X4F>\$)S$*YB7^V"#O^MZBYM0;/,(AL@;/R:
MCZ(MM:M99S VG1)WDCC2T\KZ=R"1?A!Z#9[W0;8<7&+U0>!X5R&'DN VG['%
MAD+D63]; \M.!?VT]OKRUS*=0DJ*HL!T@&G=\%H5[KW*'KR,&"(W'./H+1TO
M%=>=4BWHW2K!C$54M-F^-!-BP$]&"47E=BK!OH:^2;ER>WK.:W'5AN9@H&S.
M-CSD$+B"=Y%S?H$YMH"=(.N*W52FG(5U-#^\]B:#Y_IN8OPJ#&R2-/_EBDR%
M>:_>1(Z_0K")7%_-5IFZ,1$Y#6$=(:IC#7I*2BPVG">9HRX/UH[<;E6./5BW
M#BL^NC(*YR(Z?R2BL,FGL>8F,'WQWO8)KONW'T[D\?(M#N7!#F.0KR N,"K
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M/-C4WGGR2KA-SZ7:_N%U*7[43R_7Z:#^)1<P,W'C;+!/1:J2I/>)@T!_+=Y
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M;.;Z.$F_=7T"KVRV<B=W^KVH^1NUH32[)TVO[4/,D7W%RV/Z)7&@9)@[2TV
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M3)3I>%50N@]2O=J$Z^'JWE>\=6Y,ZDSKT"&S1(S<Z-NL..X3H.[>6XL0!9M
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M0_^_WKXSK,EM6S>(BHK*DMZC=$1 D"I(5!9-1!"$T!$!*1$BO85$04%I$5B
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M[10?3AJ/-FB!!Q55?*/.>*"FG*J_WB;6[CX.XBVU^NU/UHEHM^%*AWP)QL>
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M31KQ$T7G.#/' -J8#@GT'7W(49%Y]"O3A$0M8^'W7T/C"+/LHT0>_KV7F6-
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MD@8L6Z$C(WJ/W8M+SYB^"N3?F/IQTQ&[0*RT3$"9-&9M<Z_&AST/%D5_0..
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MKVGN4T)[$+]4S5Z,)!B1G.#/?=!P<X_T\8(E0Z\S.:PU"0X<M)Q;)/WHOY?
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M1DBG"))L*U-/",E8Z]SC<=S>_OF;$=OKQQ?EU<!(RBER^AR2O_U(E&QGW="
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MJ-X?=YB!]87FDI)I%^;WT96-T&, FU6 /LF8Z+2 ?0M5%^<=GW7C++1TB5W
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MC;7N(LOF==<S'@VZXM,-]R)+G">M/V_7 4=3<? /N9 13AI;96A[Z\"'/:F
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M J&&WDFH@01X?/?>5^Y;__?6?6_/[+4F:V:?[+W/V>4W<ZZFKA8!]S14U%4
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M37THKQ#G'*L3"Z]E,M6K7CC(JN\D"C]7D4J'<_O\#C]&?%[=4U(V__;OL\5
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MVDOS,?/>7RZ>,EA3N@?W=?\I%)E(ZN)V;Y+A3#=4WA4@-^D*L*#X@?-''MX
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M\\_K\N1Q[B_YQMV]X(EPTYY&$R'M[TZXEJ=!OOE)AXX2UIM<09J"@X="9.;
M4N81S%YJL5^>H:F]*[-\7G9#V2^(>EPOK;#-12YL2TN;)$_GT@)JD\CJ(*!@
MKCA[!6C;4! =75&J>U5[!4#TTF'78^1X*OS,Z5!O*C@6:JJ>ED7S(!+6]^<I
M!BZ63:T4DIERF*3D6AS6#*28/TU<%)^T81,^D\B$5P/-.Y(('GE=*M[\(0%!
M2P@NO-;TI>S0GU&RF8^<@449*NCD/:<(H/H.I";.\:V!OD_+=:#IOH47Z.U7
MGH:7H^94JCJV.5]*O0T83Y2^Y8$L]W?KV(\-8(O\5/ZM<5(0G72/O-I8[0K
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M'>\I7N\*LS;_E<\=HNRNQ\6\#/B\T]L9]0)INV^LG%Y32O\A;45N@+Q*3P5
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M:A6;::1SF35%3X_]16.WB!\9S=E=77*.87X*@NTHH-.D#7)RCW?4-I!2 M9
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M:@Q&2_5\_Q& .352PMKBZ3U=J3Z.X XB,0]S"?$\*5HHCFRM&)UHRZ"2ALC
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M[UJ$&-H&R)F'N ]A)UDB19%Q4;=J%;<<8U1##[\M.Q@DVGW_2E1-.5'0:\_
MOD7%++"-?D!4-$QF(9"10HIF(B\ !I?F.2B>/%PEOXP0O9=P+;*5CV"T(]T"
M#Y[A %%6PVKLI2P^(9^OO+Y:+L.ZA+81;1VBLH2M:'[(K/]R%U[4MNK3J=Y'
MSXWCZ.L<Y#K;S3Z/49MN^HA PY()2L07Y$DP@Z*,CQL[+:NY8[R)*3(EPIW^
M8>BJ7>P^. N$50+.DZZ,@QKPP<$$80\8UD!T:E:?,(!%:5=A1<,^_I.\Y4RI
M.$U'75@=&3?ONV>RB%5WF49U :O0K9.C4(/\;BM7[M,,H3X^F6L5^+*/Q:(=
MP_W6.+H-P[DCF;&8RLB=+S9*%.H, NJ.XQ@;ZW3X1MUERL0:!#"W%V*^>0JR
MU^7@1DWJ>9-!#?8U2+Z8E_-$HW98>5Z\)3QP9#=EHD3\90V2KF\]JH<A2$JV
M^X]BPIG-!>"&%,%[F4A[JWM%K9I:26=RU:62,O5*<J;*J?OGG-A#KAN!ZH0N
M!;VEC XGG6K364)+U 1O(D5-/,29*M^+DL/S82/Y061VA ';B78NUB^7RH76
ML*] JFC@G6*Z7X:.0\_R8OCB/<0>OTOCLV(>KP$6XHW?Y8W7J)[TD^B/X-*$
M[T2FS06F<ASCN":T8LNP8N"V[M6R(Z%V5Q99;H0/,#3PX8X%:Z)#=>G+[2[(
MYO??71L;,CNQQY)UI>0Q+BFTQ^/JB"%Z1V8F]\=13J:!/2T8VD'%K^@X7#6O
MB 'S";#(AB28.ES,JE/,93QSDE"][;58Z17O6V(&=I"J3T.'KM?7?7<Z]@IH
MHZ'M53_; (4$KD"9RVM'%>D=F)#,BS/Q2A^+3KYN#,KL@&,O8ZT%#PIDQ\&B
M09?:9[.02PG12G*=GM:L,Q,%RKY]#I2&&NTJ?EG6@-WR,1G2')M(')U\P";(
ML73E"]BAG<%1L&<7)G)^7_R-PD=P9<A<5MK1V#[H">CCWO--8/6_3%^6=USL
M7^X/N0'*]B_E-:C )UMYU&DW<_3CT(],;[ETUPO U=+%&6Z\ *Z[(R8F'L)4
M']#4%:_0(L(Z;OGI&?T>6,T'C&<F^)&!59I*[6S^<T+O7YOPV@X%NH++5ERG
M@%8L \_.@!N#%&&$\'>Y?@2I;%8G;Y?A4V\R%P:C?79C\P)PLH4B%(&6_RE*
M7 #^6$1=  )3_P-T94EX%L)[55)XO<OY*1B;IT&D@HJ3@7>V,D[68&V-BV4V
MWDAN8DS1!<"P=N "T&^M'??_>4CV__2R^%^=G(V@/M"&WA7=EQ?-@RTF7 #N
M), LX2'_OJ"6F49/+P!Y@F2&M8C>L<OG1J)I<!'08G;Z51>"?TP4:),Y&[9X
M.=%7"BX 8;6$,?(7/^GS,Q>R0'/]!2"4A6!U 7A9DW39K1&)'X5M!U/!-@W&
M8/N]%X 0[<D#U"KLTP5@8E#\\N4ZH&'_V:!J@[/I$*2JUTIIV]S]\"T03/)K
M3,+;3CQ"HQR!-(N#%=]%/6DE0L@<_^##459X+H*=3=Z\&C"D>N*!AO7+.@J@
M.H%Y227C9@+1VJ'<M)WC26LARPC#^RL#_KZ!W+<V#?%B?F7=;:X6M#*MZW4>
M5>_X5=/16A< F-6Q+_<LA 4/["TQ:3Y8&-!_'P=^[!OB1_7>((+_9[(4'LI&
MN,$,,;4Z"_CXT\N4U)=V@Y$Y3?6W@QGT;V)X%.^C)-<\W?% ^[P@30:SZ\DU
M<#/KE;K][\P[^3X6 0L0WXC(@D?UK#[ C?"UYD=F8*7EZ9 2?G=V_CEM1WM:
M06R)7$XZL(G-J4-GIN9-'W\[4BN9)*CW:FS/XS*L)[J.0 >(E\4=_M550XLO
M3G:^>4\7S15*5IVB96)$S\(W720YE5Y@(^4"XVTE;^D'7@ &6:= =QU;6K!-
M917>$ \/8H'3;N.O%OHG1C)\?/$+!00O<Q%JDQWBRX45_Z!^^C[=3P'G14YR
MG%PKZPZ2@L0(TPHZZ5C6!T_49N2BR1/27YV/'R,$URK*H_>,GR8;6Q=L_%X)
M%EM@KAE?;4*1A^I"Z49J5G]@*(/WMW3>F3E@3>;5BDWZ) 1"Q.XP]5G!KR8O
M[T#H_7WQQ!YA6_.!!)D%WU._B7UJQ5)(#E@J"7(ST^61&P^@?&<7\GI77X6D
M&&98AXR2>)==!4[E\NYK4CLY@EMA)R)3G&/9JDKB/1,.6Q4G,.G,\=K,]VK@
MOE(93RN>,7Y[ZSY6 +<=60O=T8K6,+0+,0( ,24V=:K/<)0O)U;'/S2-_K/\
M_KPCR!!@-?NH<:-MS&369V+AX+9(\NK2C<')XS.CXDM"T0K3'9[.JX68!\M0
ML,*%L:_0PX0R[=TI)NQ[P<9@&;/C38<_"O6#!O:,":]<8UL8/SR5KXA.L.CK
ME_J&OE/\2)9RIB1_?N7/C?_L>,B!-6@H XP\A"(:!'IAH76@R(4K+M^Y*,:K
MC?<?5=2//Q!3<N=RO[V3KI@PHZ_;77?B?37/8QPM%)YODLLJ\//D#:GN/ >T
ME'P2>!,KE>1;/+V=<1=18">VWIDRHUD:FVC9^-M.<GUR$:MY)1N"EU/8"":I
M2>++IVN:PM=F%K4L4&*4T=V%C$16'GYN:%]&6\KPK>[>B%.C**.'V?SNQN?:
M%!@N=R6:@D-I%ZE :& O"JL)9R*Q$O88XF<WD>GTH;,?D;JO,AQJW5@8[_]>
M<AUJ"EA<!E[=:J:H("JF6CG947+V/WB># IQO.\%JR\^8K1D=C$Y^C3%IF]E
MG[U2&Q%9Q7&&1'2B1&MI91@>G)\L:UU+N;J\4Z1%!()$OM/I2R_B]OB(8:?Z
M$]0G)'\U\C)9_PH&5;%!"I*$__=_9PM1(A?L+[?)!0#>1?[/V3Y=Z7F0NDDH
M>6Y^:N!.152.RO/VHCBQ% !D[QUS2GZQA6KNM+8[MT#):[6>/; 0R9JPC!F:
MFC6/UY]L?+&\3^>CJ-H]C6".T6I$L%X $GVHQKA\>EA;CLLN *;GV=4Q$:#*
MO-*54OI!4_\(_JO?QZS#.[5=WAPI=-KQN^E^;$-HJ8LG8V!7G-D[@'>A 1AB
MD(G]NI-BK](PC2H%&2!83+#+-M.$>!=JOD<NN$L+U2E 8@E*-GRA(.M2^,&\
MHY&+6_,%0#QCQV(,>VEY4Q(SEB"@JEUM<9KI7^F-Z.ZUG^2Z&&\B7V[BZ%F9
M>@7P\. 2F=>34J!L"AUQIMV>D$]#S:__"HCM"G"JS QU>3FQ;8_-F#V^ !@)
MJ<834H[@]PC M^,VAX$C=@R]B[YMA]V7WIG%1W%%EA<2L2-C:Q']!8(74M"0
M:2&=(43\_^) D1:4<=0"1*V&6)N9= \Z#,#?WV/+PIPHMS/ U>3_8=&7P84"
M]:@)TYFX56H_]F[N#9+^92JTE60WV>Q-4,NT<$!Q(8H-] X+6H[7BK>?>)8J
M9_]-3.&*PNQ_]0-UL+*]QL\L=DES/YB-MX"F/T63J>9[[(H[>0<:2%GF.9_S
M\T'J^!T8[<?Q0)<X9=8RNZYZ1GBD2_K8VWF\3^!A-&8T4MA^9]!=75H8*H5C
M+,N%N+A:5PS4/]]E_-+I?Z^Z8<+CEA-^NHB9#GADR4V#ZB2@>^N3VN<UEIMS
M1$D*GCPI7NY5\D85),'S7"/]$6;-\1KC.=%>'GG;.M=?1J)^R37,K"Q]B:J6
M93XFU'QZT8>??*R[4^_)\!PM&64Y^(G$I4A(,^O![&8J-^[5<)#-T)Q,(0%P
MDZY9JUKD+QM;CI7,,(W:VDD]94CP,[&VW^<S!P%!8*Z-ZAUI[*Z]3TC)L>8+
M5%7GZ%3W"55E@DNW)%BE/,)XG-'0M <N_H5+HZU]9S0'=S.R_E&!1X0OFT/6
MNHKC7C/-K&K.@/#4DP3E:S>NW0"-5I3RLKDDN>H$)RCW>RL"L.898=53JZ&#
MQAOQYQYC*@95YR.Q8R1(<76\;F-"=D7HPNBTRN1]VE]$(P%%GH&"(6[A^<8^
M(*DJ,LRE-Z<*-]E4Q$?2,&2.TAJ-SGJ:?P"_EC 9$:$8EJP3]U.+'I,1FMH"
MOEOMY,")E/C3W^$?0V[R9%,IJ*?HU.!/HK0K4P%R_PMMV2=,JN[=6#YWW&F-
M"BC2^,@3-9RC4VO;:42$S9*8_VQ?(YM-ZQ,O<]<=DEXD__G+H@Y5'W5A/^E]
M8-;;^(XE Z/- ,#GIMY^(^?%!!:.?Q0S>97F\.BH]$^U-XM]'$_V_)0;,Q8B
MGY"*U7SAXY^.]5=R:APD-X?B"RG58@K^@2;T$SB[SXJV>)::'\'^;OV!H;TN
M ,.08<C0_UNW!V3+Z[S8>L[:TE4IMB'+S1G%AU=H7*UZB;#J,W#SVDAQJR#O
MZ8_;U=^:#)%T]%:VS'G!/!\*ZK@#WBTPC:?R/3/X;KG /R+2<;4*KS\Z5>8
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M%2)U4?BNY&5]CELWM(;04"R</S:^) E&-66F5P=9HMR0#=?UG]V="JE.W%*
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MIUL(JI7"#] B@M3-D%?2"EG;#[O?0:M$NVF 6'C4D0\F/V$431YO*X<')A3
M>C&V3R?*GJNKS>P[#O<[+-U_JC_"?[ =$!)1X*=*2!QN-B^H"'-I!I6L/V&.
M>LGG,^?[<.TIRN2@I.+/YIH*SC:_K'!KRCQJ3N#&7?_:FCA3EHT]<^^('O#E
M>%Z3EUQDE1>5*BITRN0)O9:ANW(R?GH!J#:+Z '%3MG'!G$NE!A9!$;'WNMQ
M?2LOM2(CTU[.(>2NMXB]/JK X266.NYP;J6NG[1+&-E!1"6&])GDU75-X,8L
M3"7V[ DU7L[A+-8;Y$&C$:3U&7J,;<\04Z/ )>-*TU*?N011]P!LMNP+8I@)
MX43?0K_^Z>YCV8RN@*\&UWNG /6ZB CRH$GJM>Z(G6NX-:T([3'OWAVO<ZW?
MB'I$G!COK4T5C^"(-7U=^JCPG91/O1[%+8;D?RX OTY@2_!VC:$/<[PPK<;Z
MNH8SY<;>!!7?JZR>&WM@ V@[5ZB6[>+BX&B@^]B(F6',!:#]^4JX5K04A"Z]
MA/'3G>U$]A2G*U,M</*-7;H_\N + /@V=%U4/TT_Z569NNGEXQ(+)"X@37=K
M)VW-F&E=\)WCA^=KBNG::C>QK36&*V/()^?NCR2V(W??/-6M\WS4RT_4]!>-
M0@2&H8_XJL<6)CY%0"Y-AGP$UV*+%1G,-YDV/2:YV'@Y!CF08"FX9$MIB.?-
M+S&LE&.2S?\>:MWJX\I>>&$S-? 3)RO*N.)2:+916UWB<&EXM,4 -];L%0((
MY6,+W<OSN+A9T]XT%XS[;\4]EG+7&Y*"&H'+(V[<<2P]D_^@4EC7. 7>YV0;
MF\YKR<UL(B</NG('Z4@$,)8"9C:NR#QN4SWA=F.4/+MV_\[?WJ&>#BD4*T@X
M.GH-%)KT^8O%F&JP8'O7Z<;*3'&&A(1Y,")O7*JX._HD8L7*,^GJ1QFCH5M&
MJ@J#>QDEP1^Q2N(P_37N/#;.Y4;;\*P'E>2I\%?8%MFSJ#B,9M5'PHJW!FO>
M]W8;6TY-(UPZ\XCCL5NNF:K3==\7:UPUM/>Q3:([<E)G!KD2*>V/@*]HE[++
MEQ::.M"&&F[N:\_8+:M)]NCF"X!Z5+?=%Z>?:L%"[Q-7H#>YCOX$4374J;DN
M??"QC.OND8(%<'5S,L,03]W>NBAX/\M_U9QXCM\8QEQ;D/LN+.\T,FUZ7O7X
ML=FQS)8N,6=;=CZZO%SRAEU339U+96]HBS[N:I]H+(^I#/EW"8EF?]<D[<..
M-FDCH8S=*C_&DC(@[OKY,,UQY18ZUZ!C_/VFN.:\RBG F_%FLS:W"-T 9BJL
MV6 M/7#X[IB'4T&A>2GUI*U.$5)X^%:F1C;0 OZ[U?F\">3HQA!$-R$A,2+1
M%%@FA9.>MO_^WJB'/2YGV$!?L"=UU3XMS>XKCL4^LOA0-<L)BH!_9$0X;'LW
M:3X_4WX^-GW__M>XF??B%KY8+>)#U$>2&N[X#9ZQNX6<0@L7F13.![:DX\08
M;([/!??7%MUVJ/P7Z5B=C@,4PN+"O(/?V?@[AZ-2"O V<3F@, ]?*+N\H7\)
M^X;D^?/@YX/_WI6'2T04\&=O3;4ZU;I(ZFK"V@^ K)4,>!$&2[^<8T&L(6J(
M+L@$EQ2'*##KII;NI784=PF9>7N\VO1YEVEI98:U,8JD2@2=J2(N )$DQ5;^
M5O1J0L_RC-#PZT*.]*"87/II6%G(CY!^9.WKB+-GP8THS<K6ZD25?Q-.UMR=
M;6QNRZQ#IMM6&;;:(46GE#?Q*]3H)QY)N:=<A^R4J?%L)5V+1MHI2;;_V)4^
M[#3\00!I!)3$%;I= ):FM([I]HN*V?>(A,3S3E+QI;?>]O\=7P;%+$'5"3&&
MT604?/\&&OF?/ '* (!5]KB+\BY<GD>$+_;+6@$WHZ0D>2GX(<6!ZB*LO>)S
MXUH,_[#$_,?3[L-+B\Y[GMD@D3P_N4\G]Z[W;N3+$U6GTRA-:52(P/EW;V*0
MMRUV^E%R_\N=G</<))]K.M?/EP_&"EJ";U16QE;6N*,X!3*K?]!8:R2C7<HX
MUO7;-[1Y!]5R4ABUTNB>=OH$07 _-IJUS_B?EY&1:DU^E3,T>[ 5BUG<@6Z$
M#LX\D4*H'4 Y0$$!-,$#WZ.KB)ZH"\!M>1J_)@LUD]5!K5LYB6/D?P0+B>[E
M%L^LW0N^[W)+N4[&C7RR/5%$[,NX*$?\"OY:XSG]&U62A"9\%_WIM%_0N!,,
M>S/.):WV:LQ4R0FTEL4>L6+AN<3N1K=U"S\]I>0OK26_[$+6U^TN12?XQ_(D
M"(5ZH-SOS3;-X%,/*CC\.G5JQI9MSQ32'IYH/W!+PS.>_F82G>K6\*W$Z9<T
MR.C&>*O"R<,!CZIFK:T?5/^>#"XH@&Y8F&+I#J'T\T].\N,D(__=&%]MXE0A
M'-UKP4CR7P!4=;IN/Z:X$YOEO6>&>2]QW>410J-"C'F<3TQD12[>3SX.0?#R
MS]E%5"Z@HQ'; 92?).H75#(P:U"3]=+#IXCH1]2M-LX-W*Y/+ )+B/T8I3H5
M:<&5"H.[U&1S"+?1>4%/FM7;,8/-M5IF 362LNS73>E #J^9K^4$!;"&;7S(
M[SJZ_?2'(1%;)CZM?*8ZZ.H3C3B*^QLGF"$TD*'YV>+*>4]:L-MOX]E0$<6/
MB#*2Y&*L-UT*W^RL\?6QTU34YD_H'9 17#(352#:98#C*^'I*Q2*O$^6 @K;
M;D(9FT&*6?-N^ZY32XFAZ8;?-Y'5^65!X9"!K:(EZP,1DDNA\P7 SM]ZG/M,
M^%?<6A-HMHQ;Y:O!:0;7J' &;>42B&Z]<5HMUT+>YWS)Q@J4)*;%Z"?:/=IA
MG*(Q;NW2%WBUZJ<;] *@KWD)L_!\GWD^W2@W!>Y/^!JXYN"VS.ICK1.U$'3U
MAY_?SY<Q"CS77DY&*<OHZNBT%I22>,ZK$16A >D!P:M-P,B:S&B>]RN4RX*;
M\'!DK?0'DC>$)=EA*:GM]RZSY,D9=K'U3K/4:7ZHO1#D&.GE3MH:DV?.\]/H
MUJ:KGLY0@/%DW@;^^R055RV?GYXS2%LP;NL?JVQLN88!QQ];M#AB13DW:%Q%
MA?1%'C]3"['>^>A(U^ZB("]NG3?9>P&P_^@F]XX[T_,<<A#:4^N+ 0%)<C_6
M36I^Q<I*A,\DW5<240YF7Z";HNANY3Y';). >6 UZ0BO,H60Z?ID*K[QA;/S
M35(@(P<77XNZ89,!6"*DDERZR/U)WVH[=;4N!?J=X)-H>YYA2<V>JB7D,N/4
M:?\+K!XU[;&S)N]=E#-3+FV=:+'S5-;I=M2(:#UQUZ$L$J\]0ZVLH^<+W"QQ
MYV#N&CKAE* [W9T_I0F@\3_^/UT"&'3-"4 W$V?#!^;3STX<KCYW5_8$WU'D
M-R*)X6P)=84EPF6?7+@_]-VSN71@)XU@HI!;1[UK4')]XX&T"_> *TA]K2PZ
M1VU_<#+SM2W\[>.[VCWZ;]P:CBJ?9G%@^OC)5/=QF3)Z:M[>',[NR $K2K*<
M]@6@<R6$\42H!X(0)"F:VI"3X!C<<=V3E8'8JI=[GV%+9%6,GGWJ">L%8*$:
M=-.:^UQL+U]K%P@C^>2Y$854.R8VW#U0K(!':X?%IT=TJR]0<1XR+I_!L!.@
M"7V4^&#0%R3.6.O3[K3RQ!S^^$/D>S#*]1$=B4D5"X:O1$?GNV37QS8 DPS1
MA<B:J!1VFWAB)=4EM>#>^N@PQ+A_V;V//22!DV]F,V*%??>U]GN<]CY=]J3L
M D M;[UH*BSR>W&C7#3/R/J7LY@6UU<R0FV'1\]OC/?K5Z8'TH%N9-4)!GU!
M3E>YLVOUL&_+;S:#/P]J<:X>_1Y%HNOBBM=/7TY\*NL_YDE(?0U))T;@W92(
MX'QA=%T@38S(-$/OG[[\(!"Q^@?I]27X5&D*)S#(::@L'.CN<(>8;EH>]=]"
M3LRDR&V,S]0WGO'M#.ZO%>WLF,&BR7)^]FVRLZWP4HB4CV%*Z/'MWM<;(/6A
M\]S6^T[SU(J,FZF[B?:$K2T]70[A?O@W>V[%HQ.7,RLR9BSH)9XVJ0CL8/ 8
MDOEO3#*7?8+[N M(U$)\PXREU-EA2WCHR^)OH9ROCCIJZAB-AE->NIUYK$R(
M=-_"!"2_/FKF%P;@4D/!VJ,EL]@(# ,AACZUBD).N^,RO#K/F+1$%@U/K/DS
MOP.W4TG&:/)38J=9U;ZK_+.B/C>*J_$2G4X!5W9,YQC/<Q!E7(+1YAIOQJ>U
M6E^HH4??5#_6_C#$'9,YL:1Z:?2,MT.LP_#)=6@&)]59D(]0!7>S46ZXT;(J
MJX%2>M1H13C4JF(ZI^.4,2)"_IZI83-<9Y&])'35F150U'8,3 INX,KEU>S/
M+;KRX8CQ\"M$I50W\BQ9*P-[( ^JRQJK72E668=\1H,<H+?6%>_)FJ.+W&CV
M:SOOR*\VYI0*U>+[;IW$]XOE<B%&#,0*N!Q+N*N2Q<),SV3X73NR!CM=E[>W
M,A'[QSO59_1;\!I85"F"1E2G\J>IW\?Z>H/[C8=3=%O@-ZYOLRCFX0%W?BJZ
MJKI"G#G]+>?EI9\>Q/P(MP_S"U+Y1=J%D6\*+K'2D6),Z)8XD%@=&)$'%'-I
M8>)3G@%Q-Z'$U'-J.]3LB=,ST.RY?X6)O'*,2?<?HA%1.W[_X7CLT-"UR[7[
MG#A,*Z^954&Z"B;S?8&VWP^R :W:#JN>5Z=< IN*$0KWQ+&CK!G/L:/B"X!Q
M-=TJ/_D^/YV@229J31A#NJO5P_1.\SZ>Z;T!TQPQSGSP WDGZ!@+_I0R]YA8
MZ885E/N,;7'4K*P/.KE?]?KEUHGAMEUSS&GP",V'FH1+BHX@2L0@:VOA]?$7
M 'J[9:!=A2?OD#OC?=T2DU-@&AX%L*V7=[V5P3+YVB E83U $OFW1?K^4='/
M-1Q52[L:J(W7H>2;=Y9XP2>L$O=FR6I_7_IZ./I%](IU?US&YLH/__B@F=ON
M0P&X37<I80VE0S^B:H+^QPR'IM-SU!J4) OLT4PG)CYKW]K7&"++F?-_@BZD
M YF"*%R6UUOE1YPM+4.Y)MW_'I"= ]NCCJ$"6M5P@F)]J6T72]'>":=>D&!O
M4=!CJ/_)QB*,R*O:)7K' K%R'.U%%=WP3;RW[PD_$,=VO/<'3'@]@;1[*4D\
M$E:9?R.;&_\R'_"\?.)MP(<ML+(:Y/X7J:/I&:OT6E/5N=6J+KN)XE&"AX)0
MT_O];281EF;9:J7[[-RDP!&=8'B,ZX_FG&VG QGS^\?<7LK/I@;;%).6F5LY
M1YJ%%ZF6@H.#4MB/19/9!W8P482;X>KG$.XNBSLU>)J6+@\4NWPG>U3,Q(L_
M[3AYFFN#"[53A)T^'P[0:V7_"T"41)G4L6[KF<M$3XJ$R[>/4A.)F?#8 +?W
M0:+^6"IC85<>9J:S6M1,X7&YX.(G]%1(A4^*+,1)H(W15G/.$*3TBAI,M6D2
M5N-1#K>DZ2Z-\JDN-YF!-VMAC<DLHS4#.Q[K3FR?DGN83UXZ"\7<7,.7M+)7
M-HPKCO#6%G&ET:LT9?M.&?D,<5>HAW8R&_BD#HZ"'>>GM)J C:^*J=/OO'?\
ML&[!*YW,Q156ZG*O\;K"C^=7VE F!V52-'*Z-<UL7S%,TC(@"?M; 9CB+4*B
MF=^#)P6#!!;Y*M-!C@]QZ8O-*+46F-:HZ.AIU^:=2CF;6%_KBLJLFT'WW3T+
M.D8VF$K\:6_Z\[+*E,V'TO>!/N\V+\2_,KUF\)/TQ-*SQ.@"D+/YQ('0?_/&
MKSMP>&'9T,?:;7FE=QCJ:@G-L'C*N=/384KE\LD!+!5D0]@EI]4TTJ^.@O<I
M8P06&(Z9JHN$OVF-,7U QE]UASD=*==$VHC=&!?W>"TC<9[#^(TE)5-\Y# -
M5CU8O$$X>-C#FZ$'^S5FN$C[F7*PS&'Y&.0,@Z-SQ\D<#FR#J S?',<4L0M
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M/'ZRRQX'H15=^0UN&1ASB4;BM"\ +,2#-K;AE@A=<U ;V,IA-RC+Q.Y;. ?
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M\^D2(B2%W >N"H)6,T>4ERY.5$@:[>:+GA&$*FW6;N5^ =TZS)#&YD?;5EP
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MML0:X (@5)P8@CQ3@JD_)/G[!#NK8GX.3O/\H]]OK9W 2)==ZF]&V!2HS.[
M]!3B&]<ZUD)AL#]JM95[(P63^B+6ND@UCQ0A<@'H/L4HN8)&<J;/NBU1KH)?
MB0WGR?(*XDY5FM1.]>8-@B<&#^D>C]B."5D[' DRH<MIE]9*;2/ /4VB'U(,
MZH!.":/7$/IN]5;WHE9)=")%+K;\)&Y<NP0["TRR8PVN9 J_(:_)6Q<I4EHA
MK>JQ4/T@VW:($\68Q54CJ_T\O?!'->"_A(,N"YTZ0( US3E]+*9![AE[22:^
M#G:X=_,!*AAJ;2W1^TK0_5WE]Y>463SV!4Z%8TFJ S2_W%D^:T?4%%4VJLF
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MEUZGZPWE#Z;N^V\%![V#E18%'9DM-..B^/:G[:9_S"PL$043SE.MB4U,U45
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M94))/ 8L<,TQ9LH$#SH'/@;,Y=H!Y<2;TN"LY#0WV6A1V>TIM.<2J7P+-%<
M1RKEM<JC&=\15X551%G"]01>XRFP[ZL]Q&_)ZZV]L%W8TP('YD2543,YZKV'
M3@8SN6:8'2E;GKFYD:.^@9[IL+FL+7$$5%F+S_O$NO$DTN-B#Q/G_'VU  2(
MK,0PU2P9-8^(;V$C?9C;NLL:9M65J<=W=@[<NU@"^Y5TDREOP#!M]#3P>HPW
M].SR,<!6X4F)%%A2?#VY?A[+?:G8]%*)6(MFXBS+'U\+LGN'<F.RZI5()LD[
MG:< N)PUW'SR'WO5K<\FB]/\BQ1ZO>0[?<IX=YC>(_ G5,B!;V='TJWAD6VM
MYXR$((V.SCG88K@V^@%AQ"TSR_1 [,G!=6-?9'*A4$@EG&#H/:'XP^X+1T<<
M$L3YVZV1QZ]W17JR!_MQCGTNU&P8KAZ^78!]?ZVN9O/!UU )IIR]8T"CPK//
M!DQP7Y4/G4;"G2;=&H%M*VF4E/<,>Q?!_FHGZG::.PU3A=HEVMWN^;/Z0/\8
MQYY[%LT!R#^#Z)&;%)@G-1,ZN[-,G<>M1_:F/%X.L7Z2L%]-'5WD%1S?8_7U
M(F4WWO3;^N-P!19(7$4S8D; C!(Q)9ZJ)U;O6V&Q[@[VV@M/J)\VT.K;8LYG
MGD%4S0N)?'A)PUYUA0;S^6"E!2B;BJ K3D0;4BDG>!1<X] 8Y!K_6U',?!?K
M7Q": ^3R>.+^]<-HH)Z<N+'@5W&_9;53#KE;:* ^Y0YJ+E]MF9ZA$J_$$<US
MY/HE^UO+]7NP0_\413Q=TZ.=@*9RJMO6$^CO:R"/[#:MMN[.BS>/[(N<\DI7
MO7+IY)YF/RPU=J&O\9>_F__.I@J+,WWZ3D-( ?6B_WQ,3" P?F,>SNT6S+_7
M@L,@M1PR&J0 )YKY@"HF.;2 H3WU<($'+[$SHLGJD(Z[KXH \J?\X1SM A,0
M;=UAW +NQWIFT-JY]"X6&[0K,S/?NC3":6I]5I]JIX'50L6N1,<!FWVP=S3:
M7R6%A UK29+'*$SDD045]">B4C4N,[-H[@&TU\(\Y3G/Z?9FPGCTN#9A*ZF*
MT"DRV,U]]]6R^&0CQ+NU0MUQ9)BMV/OAGM(*KD]:7RH]5+CX^GPN]VGDNH2D
MZD;%%7I/"CU$?%F7= ^^VPO"YWS=&=H9+PA>"2LP*ST&:"T><*&^"#,8L]XQ
M #I$2P52=XPH*S54)!3I#P*U:B&,Z.'H;4FXH^XQ0".=?EA,N08Z7"HXZ+<Y
M=#UT78'!(>&V!3NZVXI6#TU _8)./!'R4AY>4A*/GCT57(TJ6E#B.=?7IUEA
M$)STF2<H?*,RQYH187*LL6DC-:^)72_UCIZ^J>GJ4KB/E;I793'$YP^^%5 4
M+Z7_/S5(AG@NOX9+8$(?BV NK!G_-EHNOKA3L6.>__9$ O$TJT6KJM2TWK+V
MJQZ:= _]\NSZ)#P6S)[JXAW"?MOM(W/03#A:?ZLUC/@(,Y!N1.]O'KUX4O&^
MUK.#-6N7SFG@$^+ITA"QE(K>TJ*"G*L9UO[=FN'KN&]A-E$C;:TR<IE5/U4
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MWYUDK_6LS#-EE]G[LV<FI%^D1>"BEKJF.D!!00&DDC\ :0G@5?-W=@  '1U
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MP/L8T)JPVK@@T;P[Y(AFT1"KCX,8$M5^0='7H<0;$81D(N@F"4CT!>%ILDC
MVVR&4]0C$C#T@ 3LYF@@<DA 9B()6+CW#8RSVXUJ/;BA2@+"#$D QAO:(1BL
M3 )R7OZSY?[_W_+_PY;ZOJG@TPU#M8,@[/' <<P2>.D]$=2]5=?Q=7^*\$>7
M7UOX((,\U"-X03\?U^P>^D[7%$\O60TB^ Y/>Y9?A9JX@_\-@?"V$R.7F\7.
ME\(^+9YE*?R;X?Y/B"6MR#]/[VNSA1F<4S&HF+'O\L\2%.YR^M>Z=E]%?H-L
MU'(LTQU6H1(I:VE,5:F<S[//A@OI'&9YQZK!L]R#1TYG#EG2Y**W4;!)A/:,
MT\X7D)BX5*3@M%?ZUZ-+)94V35^$YXX"]W?_=,&[I^H)-_[@SK=) B9S*O"#
MH_P?]L9?2>XE;VUU =:Y)1WR0GXJJG2[()^0XFY?(WIX0L7Y;%IF8[V:WF?]
M^(J>J^!"2(JA <8X_@WUQY 05Z<J[B*'C[9T(77/0F6*RM[NLCDC0F)F]:#.
M9^E4S/B_J6F<2-XNL/+?TH3OR?U&>+MZ$6$^_50>V8)9[:&R125;DIF,B0V?
M1*'^@6/\OB!?U:S&^.G=.U<V2EQ]?S:FU(G@FQ@_I)_;]S!^KE&OS84%D*$W
M](UL&SWKO^SS6>'==R1GF.OD#"RHDM3CGEK?RH3RC%/XQK2E]01:VC02)\<2
M]S2&7C2W1,*@SC5?2[O[^YFYPK-N;6B4 T[ZQ@]' V)*!F+=Y;=TI:KJ!GM>
MW)H,%=,W>CHNV?AC-E]=-_!,D-%(GW34FA,V\\-/IS-=+%S4WB&:Z\V:_Z9
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M.3\!US'84W12PN$[CZO'[8+TY86ZUSX\5PZ<"+@VX"%G.QV;=/.T]'BTZUV
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M%1/T_^UGQ8]ZD"OB/L%G,3X;!^Y<5/ @C==IQV(] )V7[,[1V]C[N9F5\&B
MR@)J\?U=:<D>9K*-;DTOEKEW<=!@*Y2C*(/I))C*FST'#D+)Y2_,6*G:-V+2
M0W<WPUM V[C]&8$6"#2,./9N1JZUS]#F^N-?2+Y[9*_$/,^2) -X140QM7'4
M3XSJ0%DB'*=1W/&;43\G,'P^%05:,(^/V-Z="00: 9I<65B)N3.SP/R%F#O5
MUSLYX318IAOPX:S&1P6=<_LMX'H*>*WB(?JX)1,H#_SZZ]V4;:^"\5*4++,1
MLOV0-D6[C)Z?^I)(@(Q138NGY6<=QC>S])$SIO?%*DE;&X&DE3;\4XJ95H/8
M$$K70GYY'EOX4%J*SEOQC66]4R?;6#+2T=K5SEA3]<OJ <]L,BFI[=&5(E,*
M4KUR:J3G=Y3GX971US9H[?)O49Y#KP;%U(>J\,X,U3X;>961!F-I":+&23B=
MT7?WP4LH@ZZ21QJL8<#^3\97Z-?,Y0^BV)[#BXJ>BC/&Z'1^762NSPSPX3[N
M3"W+Q-MLI3C=UNS"5W"U? ^:&TY@O'=<V61*6T>\\W<X+CD<65+W,J09'80+
M&*^!(&I.G"JO@26BH<!VDXQO->Y;7.F7EW2,VW<,F2$E;]O^VMIKUQSGE5AA
M&IQBSOG.)%#5E<#V?'O>'TUV[^]+A?$!MV_>;QQZESH\ U_76!S WJD%W:)U
M0YGASR+ODC)BW/K&B%9F#E1.@.RJWO/>$QPRKE35RJ G^I="\3/9J.>9\:K>
MHYCY-,3%P+R:X2UETY\SIP!&-91% ^P4 )!V+<@Y24#<]6,2.E,JT(7<G<Z&
M"!A15>2C#46K5M A#_;ORX^.9MR+D64E@_0Y/3W1H.C/*QR?3@$!F_6]9IDR
M\NU('!V^;Z&T?!YSE1+_,A*.]7GT*9085OGT-@@R6GF"@3_,NMXD.=2@->\=
MLQ28;OG7#%>^J9:XB&#="IVQY9PF;L! AJ3.U%+PXMQJU8%G-;=0B#FP/R=.
MR\9Q@91@LI6%)#49@/!SG4A&*G18'1NZ/P-Z7=WIB^L1!.:^&[(';07L/+ 4
MWKY%9B<!PTMQ:_W]ZT]&IY;-2E1]8ZSVI^K=5\WKX/<I?216Q!!^CN4)@2CW
MH"^T1KG^?4ZE/2L@#>DW]CPG?#2S"/^K7K?0 :>U/W&D-L!^+3IBE*^S09@\
M]%A6YR(03\-^%"0?%CU\=M+TCGAS30O$XYA2_6'_4I+/U")4U"6(&*+EH;(]
MWN#>#JS&?L(XGP(X_ATAPL0]YQQG^8/O]<KW>GSXSL;K-X_P[HOL>"H'KO^Z
MF!RBK%_8O;G^:\QU^CA?QV52[;_%1;-<.3!*=Z3S1(YM_]GJ'FO6I=YX8OAZ
M8KDVD!\FW]<XMZSY7V9NN4HLD\PL(4T0B\>ABV4#N?!3P/8(^7<-Q8G O)&J
MHJH8_G9SP_!XWKJ1YCLKK8B#_6T21_0>275HV[EOIFC86]2*C)4%(&0[PO.-
M D</P$P/F16+GOT[D^@+P,^(FU5C"3=,L2O-_<SC9<K"E[>AG4KK&X=?5V&+
MA:#6KFNO@>PTD!^0K$IR;4H->ENU\S+US@>=OUV\,"CYQ79TTC8#?AV6XM(M
MDQ*YL?MFY[L@\W#]JM7VC>RB,>/:L6#/7)TXLXR<Q-W0C2"5]?ZF!\4I75\:
ME'(EY^;,.7.A!X]!PXUL^G?M"<L&+2A%TH[\%X3RFCS35,E>36N6RCG!\-X$
MB2@!-K2#WK;0R@9.\'J6&#GLQ@6Z F4D9)FF1+U32ZDGR1N2.BI['63'LKXP
M31?<]6""!1JX$^<^RWT-^N=BE-Q5NTHMRG_Y^37R9N8?GU_Y>JTO/&><H;&'
M0\>LR!99N#9>*CJFB/)^%3.9(D[!Q2QSFA7T?&5X<7*][#?;@XU06:.8)<:T
M>WRMM7-A=.PI*WVG *G')- DZ_CS!Y3]TK_&5F;LDL[A[5K3@\Y3"=TS.T?6
MA6MU%R!CW[Z:/X]3NRWZ!\R@0D/_F+O_\]5%ST[EG)<[KN?7"/-A$;06?P'-
M+.<+E=*W,F^O9 T\Z=ZRC))H[0YRZT'ZWIXN?20+)B 9)BE=:HG]:\J'A#=6
M8Y>W+'WG^Q#K+29>?@[F\2X^^2?TQ)A9OLS"XCR5 ?UJ7$0;PG#Y\;R[6]"#
M\9RRNM!E5K^?T<^ZC&0%L2)<AZE-1NLFHAY+9&]OH2LBN*\RSB:.)R)M2XQC
MH9Z9+W9!K+11VDV2^^=30(4;6L,8?X0Z@-G0V%PR1">:@.BX-<5;J4VQ><B!
M7(<KVS16OK#GPG20- ']NM^!G$@>A"J.*A+."O,73IY:XCA$/AJE*&Y? 7Z!
M<*VI:JDI?[S(K&<.ZMB:'"9T\O'4C;K+BBR/\EL<6]/!8C9W0 EOX'R4<S\I
M.<WE:Y @XF88O-@Z3D-0O"54Z8$ )M=O5(2@6NOO$L":&_P:Y+N@&A*]\;1O
M6;Z'Z:'>+&8JV^\[8M.N2Z4#[GVL]9I2U)PD=^0Z\-E=JECSO( 0ZZ*RU\XY
MHN7NL9 SI /;]F?J]4.YMJH[!(H_->@1=G*T=4<MC5(LZ2E:LVIU5TO+S223
MK#"XI6QW4J32T5Z>.#MX8R?^$.OJ1-)I>]#.XAA@)O3WYO@_TYC:3FWO<V9_
M9ZBRT@"VAK5XGR4+7R72ZT<R/.D*;ZL&5+:!&X<YL/MJO T/5IM,^]\\!B6*
M_2*%?<HB(;Y6?8T7A,W4CQ=UQ1\4_E&%;!<L<;Q@M0B WEA[D>.,O0U;1$-G
M[ULT40TZ<S@C/ ]-CKMRX=O'#K!')5$SOR8'/!*[:>6WCXD08$5FB+<[AY]9
M_]B^6+>XV>?Y^"6K?86!=>@SDOND:-Q:3'K;\G;AEP2^_JY"&)"MLD25L$$>
MELOU3[M4 O[>$W0BIN3^!6[DTRW6E3U5UO.[P/_SGB@8F/ZN#AQ2_.Y2@JNK
M51BH_?EKFFR@=9*;7+5*(/:"U=9.K\WL@<N4R> .\#/P-_U' MDLHKX(A6;&
M/+">.@5<G4>P=L)O42SRJ=(G!6@)*9U(<>#DSXH;N[=V3(8?((N,!!37+87Q
MXP/$#\7("9F8$_;7:G1/#)?!C4GV$VO?12<"XAM5P?E_R7W"+IXR-E%A0(C(
MD4>K_$%%'^ND!%]8?\==ENSB"-Y"'9DK:L/!G^YQ[.6\4;8)]^;]1R?5/GMU
MF&J3I^WPZ_74'.1O")^(R=O?&>TF"51="L-\GXTER2W$&]\GZ7JG<[Z!+8I]
M<T$!\9BJ'?BXE+N+2OV_C[&,+-N[?>,K$<@?AC_,_V=\'8<S;;G8 !=TQHB>
MB.Y,/0];TE7:?GP*2/2^*Y; D5LV%F7TF\&RDO X.S@XE7\A7?O;PGM^!]=&
M6.:V5'0)'"0(=6HP"SH\9U9D7;WH'2VM\X1H>>WXB7-4$"&0-8BO?V?\/G(X
MTR24+7*;>O6AZ:[2OP!%2S;9<N5X7%>MXU$,^9MG'_=F^+.>X_$0+] U"Y,V
M.0>)7?"'XX$' 62!\']-@S4VF74>3B.^8%8(HO]GSO*?E5C\U;^]E?/G1EB[
M+.'FE37CZ&MR<YYU(];2Y3<+YSZDV:"<UX4-?;QC30E?/3AL[1L,*4C-$83$
M>I3-M<]U,#G_#(7.[9WXR)',UNX\E&!)D'&FC-_RQV-?N WEPX+V6^!EJNRC
M\<R<:1DA Z^;6[<SMQ3V9$ODB7K'SS=. 7$*4T'J&T"J3R5F/L64UK[=[D*S
M]\Z7E-L[S P_>O^=$+,)3__&E)#^2%*OOG8_N<.9PP6^"KX:9SQ,T_I[*(,8
MG:OT4S\%1,A-[!^[\)P"%B$@_"^DX];1?UCGAS+D-NYH$)R9*E&Y!WTAAVPT
MX%':'+AK_PWSCPL4<YAY]Q309D@;FMM[?C8CZ=Z< @B50%P,.?K[67#(HZ%-
M@N_4F_^XC6+'4T&S/SHPT;5%KWT#9Q).\K5H'W).X -?$'=HN%, 4)7;$8CC
MPK8>RJR;7WAX4D7_[.[[[O-/ ['>>*GW?"(G>95%O.X+X"^"-<,H5KL(]=]W
M)<[O<W_HEEC_&'W1'=FB2402>-VH%3S0IBA-VYG81M@8XB+$E:*"/P4D^$3(
M3'6AO48BTP,U_P5\CU1G2#(H?'59L]HG,3?S ER(M-7F*B0!>CKLLG?\^O/Y
M>_&1OHK*6%/ZS(MU0$E9O7^B')W#IN4U]Y=+PWJ6Z_W]?515M$=?>(VM%YX;
MR0+M]#FK5QM:9#T7F7W#T"AM]@</>FA0+[D!_=WY7"Z<;<;F^)?(U*J:?<)$
M::<FC"=,/#M]4>K :=1@V78'''AM)^FXTA^V^BH[H:OG_94'ZBQ7'VCO8$'O
M# I^B,OW0#?#E7-I__+UU#MZ0G\5\%SQN9?](53DB@A12_V<K7POW[?_BHV(
M2+AVHX"H,?YOKE5D3\\STI$5>]&IT(&K:KY(/T5D)KZ;>[9=*K]->#9*^\:$
M&N>AC9Z!GD:3 XR/\3B0-@ YZ#H%?/2%,(?:#V^@I&X0XF#?DU-A5SV>'&&7
M?8-/ ?,)<S<P-CH1"%:LX%CEC":W0<2!TUGZN]=@Y/"#.\^V6JBP,Q%&=D3'
M7$ 6'^[[J;D$U7!'^5,V[J3GQ53C)>^U6^65/0CW.*CS!5<YTC_!]P(??H'_
MG-N?@B028+(.JPV3ST 3T$6Q%U+)O8'6C<RA(L!;^B_>OMU%)M]ET7LB*._\
M-P)=M6NT,MNW\R>HN8C=D_.&YWH*BK7H;N<6_I>Q5FKAS7SBK<C*#8]3 !?&
MT9V1-F#)XVK0P?4IP/6[F\6'MX@/;YU1S9FXCRV8RM*O[@W"Q>#"I_D,;H8Q
ME,L [$=DB^$IP&: #3'2=+4*>KF;<0[2A.@5N1+/_%:#M0?9(@*R@G(CNG>=
M4\*^$-"A"Q1XXM"+XB)LC: O2O3U7RA:+U)F$Q&AP__G%# VA]*Z01MN:OG/
M33=/3B*],R.QXS2A8;<$2.?]F!M;S2M[I?%D 9)DUC'0CVU.>_O"VVZF8F.[
ME ??\7^VL..-*P3+O"@2^;@_6CV6% (696(.P)%FD]T7@.<G<3/B#R>[W=@T
MII9G+$\!Y+1?^N2;_Q .S],2'/0V'#5+IP9R5!;UP1)U[>8:4;'F[LU_Q@_
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M"Q+!H'.6)?"F*"[/=&&?_A!(KGJOV.M]DQ'BFX2\ZUWU3G=;H\86^&Z??&L
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M)\H^C0#S1;K]$B0C!&QW;#ZG=I,8KO+PB@K#YOI -R'Y:<71:'R$:I-1&:N
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M=:6MO"L6QI=^P#0_-%272#HQ8C]5#)'[.Q7CA19@-D+BEFV/2O^0WV&QC^*
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M")/>DQIC),5H/8%"H&99(,ST,XJ!S.9,H86+U?6#B=IWR'S&A618GX[BI%^
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M?[$9.8[!XR&3[B"?K(MC3(A/+MF>($$*4QV[5VHGF[)'?0%>^90+T;#1'N:
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M#]-ZKINQCCM/#9JY!@9T@C!\.J1+8 XW#Y&EMLS'SW*6/2S!>O/P3B&Q."C
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MI>.M!,0* .GA!%0:)3_--;.0:O//=(XS;Y;\4?8<H;(=EHJ$&)&9^)I/4J-
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MT6[YM97#F(%3KT^*$L"1SK-O^ -4MC?5#]'?=MB3H)$"C6_2J@_EQ1BI"XJ
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M*'( ^9SCBB"]'?YACI_GGSA@]X/<J&CWSZDP5CCWB, \."U)J]C-.M8MT6G
MTM43W.F'>I^)K53_L283<*1G>:/3%1#AL]49M&_%L&HZ^9;\7*0X30G=/OY]
M.T7O_K'/()]?X.,VPX*/L03&8=?0!OD2WU1@["::GA5B]*RN_.\+51V)4[T6
M[)5(8^G5#_T8<IL$^TZ^1[+_/NO,MH2<A7G1"A.Z.OUJME5H+#.T0JZ?"D,
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M.Z<*IJFD7S%CX;H U]U]6!C\,!,<5M ,61+#MV@_^_14[+T.RI20&56+R%D
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MT.MZ7G?]Q-.EV9C=CV:I5E%HL.OV-D=T%;5B%G(K2E&Z2=M3!GO&:,[O3=W
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MH[^FF9J\&ZY\'8;U1XL=J[#=%C8:Y!P)#2G"$?+??CG].^<"MS'I5XWY[C:
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MB/&?;KE;D0%>=R!P0_4Q=RRABHC-CP<1BHZC^Y60*0&FU&%MQ)MK#WV'MLF
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MU_ZS>%'YE2:9"92.0GB3?,*;3&!>8*OS:CGIW38K)-)UR^BP0_2YMT" _L?
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ML +JT8J?)J.*;KF+.OT:GM@"^,^G Q^S"C9Z*OB;VJB7J1"#QS[MF*8XW>6
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MI'P"32!;V<>&2Y9VN:ORI_6G<JZ;3/\Y&HEO;U/ZT3A$3Y\0?51R+D*B%0R
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M$<76_C?:WC.JJ:]M]PVB(BJ@TKM21$! Z37! @C\$40ITH+2"54ZA@1$>HF
M@-*"TH40Z1VD1D!Z";V$)CVA!E+8/.^[]QAGG_>,<?8Y>S\?[J]KS3'7G/?]
MN]::U[U:*K$A$@?3ZUF]!B,[AGMMIZ 65^DU")/5>S[Q/"((?\04#F?T#F*[
M)"Q+LHU!&BA1O"Q!\ :-+\H__P8@VG<OD-6'MR6\*5Y6(VL1^HA>=M]U$BF/
ME[;(H/C0"H(YA!-%?.8C&V5PQ6S8OLSQ<^7N:FK52JT>=OG]BK5K_,4J7]TZ
MV.1?<Q +KSA]N?+V: @(QK;8N$?.J1*#<LTWYV_='55]E#LCB&J;SC6N:+NZ
M8B5G4.+!9*0&>;* W.(7:1^@)38\'O?9W8: V-VE!<R%!-CL9Y.O GX?HG,7
M+6K$HP.NWJMY]QG] PA!'C'5CH#L>Z5HG:R$F\./^E>5]/:IA)T+-T/N;IV^
M/T0+$%$DB8WY"D0[FA4\3TS#[8!850WZQT]?23]Q9+G+$U>W$?J)?K5Y]SY-
M@29M*&9=(_I?*HH&>F>T69DH98 O@0D/0_6^;=RXF&1:7I4XMZ^?^>A*1Z6C
M.:>;M!;K0<W6"%X! [ZZ$#_?V2R;WO%I8E7E64[-LS%!#/<$0)N\.6W$&GB/
M_Y%NM+KT)7'^/],(LZ#_!V?BOSLNU^]:U>::7O N&%*_F6ZD= : */W>3-MS
MG[IV! 9'UW#!BKYOFLQQ8BMK9MU]G&&:1[:WBS;>FY2.FEAO7U> %GR/70U6
M%7Q"R7? ,W7P@EKY9$=\"MTS'V.*N[FX@]1C&>8;2'7] 1>:FJ?-P[=I'PEY
M/8G=U;Q.MV(DAZ"?A/P\\4LIFW453LZWG/;ZJZ]#L!0_@A,4MHY1FU:W\<TU
MA<0/78MFII77RCM$U\*2A,X 2Y4TNPG]?UK:LS!E++NR7ZM)/FAAHCC)P(S\
M;#B?.C=TR$2_X9MXPGX#C%DIA'F6(>8X>#W$QU#VYI&?NZ8_[Z$FPP"FW]-Y
M-N^=O#:GHV.Y'XT)56?\GN31)QF0?07IZ/QX6JOWN:"$T>$U1/DO,-U*]R^J
M6+D-5Z+O/^E_>A#+D%7$-!/UJL,":%*J\Q0<YB-AU@DU*A6%B+\/2^I9$MH5
M4US4A^M,-E"J7)8:"3P.>HV8B/W5-X$V:G Q/'A*IHW_TAG 23^Z^3HA(K:1
M21[U0XM;HF1WK^BW!_0W_LFA8O=!R8]7RUHH?>%.;2LV6,F/%KP5\D)GSF9]
M95Q!==("H<+L8=3U'VN*>Q%Z+8(^1\7L8+S% -T4),TMWJU2?K11@]9R7?+B
MW).G/RP;VT?EQ]PR'%A_H;>22(I/%J0B4X[F&:6:,45_T$6A4BDCR#EK44Q/
M8S5@">D\@3PRIZ2[JP8L<B.()@JW] HF5.45 7?;$ VBL0J7PB&@$G9*3/Q6
M\[XK?*&YA4D_?+?Q:0T7=(HO[%[%Z/>GJ=MP1R5,,O)S0<\,TKD&1&9G;DN9
M$ZC!;V&;>4,[S,+*1E$XN]H'J/(/?TJU@/;_,;(U7W"YP];(.;:'=DQY@QC=
M4Y_7CY%)P<.PDUR&NZRV72\NZ_<H+@0:'V*VVDG*Z"Y>$>.DQ;[1M/IU]XO_
M8!ZT<PN&=BG]%F'8/,C9I*'$Q&W%%8(66N",J_@D_PP]^RFFJ><9 J]2M\-7
M3+^Y[YR\3V[":YB/@19JYIB&56T\%W5[^R[S,YNV'9<7:RD%/\X1H>-_'SK/
M*]['?O28DKY %)=,IVOOTR[1K,5*)EK=H+Y)Z.YH>/=21.5A?%;R& 1</K"U
MZTEH-VA.7^Q;Z2JL]^KT$6PVT K_^P6CNJ\U3L>3RETC1F:(<2=*@8)M\92L
M&J%QCW7E3LR$B^ ;D:GK"\G"9X (^Q6WC"76MR3JM?2%;>8.Y92( +_O^>A%
M(G6L\%/%%RN^YP*[+:''M6C5&DKB&<!^E C^-J6-WSDY(%E:S+P.44K42'K/
MDSJ=62>RLF[)% VW=Y\<W\<A8J300-Y_IL*HF>4K@TQBKUI7_"F3G!MJCJ>M
M^L)=9P Q4O\')J(4>_#*B&S08VU98@G4M$WBYN]/94&=("C=HUJ^S,*&<V[:
M)(H_'ZTRYRZ>99S;;%OCJEY)MZ4B'8 +_"T6%O!R^-8\_T<HW56R4OV>MSE"
MNH,^P%ARA@VSJZ346M2H0;I'[:O/:EKJ=(]0,#%1SGA4=='Z@CP='YB_X4W6
M:) U<LL"\C>^9X!Z#;70T!#$FN)Z5X'P(?3;[JUMGG.Q&7@&J#!:.1_%D?^M
M(;FH4DEO?VM\\0E7ZQOY)=$S0!8P9].B/YDD >N79T,RFE-9MP=KACYA\MO.
M *#$V=!2H,LM1KT7+92$%ON"$;+7)4S[^^(H.=&.X]X6#Y%85A?8;N'"U=KQ
MYMQ>P0[A/@G.O_)PO$4+W?S,NG'17<01DJ7]J.DF02&%8 -JVN&^Z/T+[4>)
MA2]\S[I$J<@;.]AEV&#;V\SB3^H>=1V5'X4Q]3Q;MHX_7.6_ EI(/0-<4/7\
M[J_2R0:DA]CC*<A)E]N)_]#R#8("'^[S94*P+7;("=I%Q%9H*3'4&"\5@=4=
M5=66RH1VUMC% _]B>A[072B> G];Z8]=%-?.FF7HU>G;V[[JF;+[<O2"_+[*
M3PL?JH^:]./H>R+_:DXC7>CBMC8<*E"H>K!YGM?2A UE&J(M!B^,V"8DA+.F
MSP^G2=K<@?F<U'N-U[:PP(:R+N&1D4M#AR!6QR.SC-B;KKEUU\0?;ET"^!I:
MB?&V=.XP7%AZ1RZN;W2!S?+1-!(.YOC*FAM&Y:[!DX?'[]P=/U[-&3HO&]JJ
MNKCI/NF!7_ ;,LZ,O47>;2G[_/8SCK13*99+<0TAJ^$982[B\B.#?N@;^)IM
M]B7$C<WCE'+H?>P!"6+T">/I@>+J_^6)2&V2^M#BB.#?;)G2*X0^'*\<+8NL
M?*PW71J_!<AQ%^$9I*L)F%#=7LL71?FR'IT!GE@)+IP!IB(ZTE(003XHJ P!
M%I_R<1'6U:7]:V"6QSYW$.ZZRS"P^+[/W'08:K08$Z2:_-GYB-]AH.5^D"/M
MM&!R8Q^J\I2U2+P?R 8;Y:,AEGV3+,@FINHT5260J^TRV+2HZ\<+5*._'A88
MGUO=W,4YWG9*EX.%OJ?9&KDVU!WD4[ZK!JULUA .LNGOY4JR& [2#/]?*BRM
MK,%_.ND &?^[38(4=$I]RZ905:GC)2^A>=UG .=@160,^+*J"L&]_=UZ_0Z2
M!V_!W\*WDL!=<:&)6K5R6M"&CN2OP'Q$;5&YK=IQ5UQ[*E/,IMT^%7AKTVCP
M9:PV?R0IAY M KD\HGRW!3TV!V1I<&@2V!%VO6G$&\EK9D%T-VU\4<7%GDA[
M9TO(P.00;3KB$Q/D-BDI(6GH:,O]&2/P4R =)T7SMUDR6G;,NPED:-J\-H4:
M=I=:K^6!L2[#Q"FQ+O9$A#M.BHF([&CF^:H3Y>JZ8V6N#=A>D?D(_F5 5]WU
MW.3TL C2>G &X(3:X/4[Y$--![UY;=K,33O?.WBL;CSXX5DG3Y.H"3P.;%EP
MGW[?EB5-L)N+\DA+C3C4E8F(>!7:8X*Y6&0X2?94Y^MG9T@+7WVP654[P)J>
M31S1(SPN=CJ-0^$4?SMF*/!5Y=7E\1RMI=&ZOEAM!E&^J*HL#=S4*K1\/'BC
MXT\"SS7D<02<VO2V9LMAT3*QK'94]5"I+"EP]R<O^5L\F;(0F'8D8D_GU[N=
M%J\KF^IEXP4*FD%\R[LGZN96EHQRK,"< 19C5*7N#^ZF[3U[-.M%^V!OE\G7
MX[*?SWI(-RX1/%'3[G?C#]?^J_U<T%_LG<^ZCCD_[DP'Y]J^HU_&5K1>Z *&
M\AR2U]N$&=(0-C<I7C=G"*F4.*@0-F5GV.K:E5&A<;O@#X0S0(L(IP3V&Z_>
M8Y"-%&.N2_Z^T>OD?7<!Z3- #IJ\_P]Z]G2M:+6I"&7C>_)9H6P9]DK7I>+.
MRP:&OYY:98\._VCM\RG0;4$6#IKL[.I3^I(DK/\ !U;/  -67_=ELHC+A!?:
M) ZB9PG7S(99VYS;##9LI#\!M)9U+NFL)E>;"K;*@A5!]S GQ^A[E-RJ:W%L
MX*N4%!R._V PKOJQ0FR!50#9B<01@7VHUF- [8+=W%\%'W163,F;L?'](VT-
M(_CW[U \DX:_ZT^TMU\2?"WIPUT<[N%6*NRS[R[(O]=-?;&'M!:?=+W]&O7&
M=R7M-E.!3H*$H32W^VT;D:23X:.'M4'NYS,S 7H[0(]17>X-$FZ>/]"UM]L[
M6*62H0YJU+?.,B1.?[OQ!\=I23*>T-<C7!].=7S/%Y@?Z[8*N\@*S^$22D/X
M\[ODWR#1?IG6T].1HX=,I6]5LN1;ROS"K5\WIJ,>*TY<JKK7H_?E +&R?MA=
M8$KMLF*O&G-9>8UN&4I7\ @'2YX!:O?]N]64;PXWI2BR/=R+97K>EMIK<7Z;
MS3%-4<>0I8=,NI^W9&."^+H4)1;-_=\L"C[Z53R^7:?=)5H2*AB+R[RP4+:6
M9+SC1=J>^R<QVJ744%Z0DZ])3% &?F6VH2"[Z$*@2XYHWXMF+.J@(U$[/TXP
MS.N.1%S5BA^X6C(,I^=@/$@60.' -YV<ZK91HR<.I3!W%R]UOKINNM7[00TF
MX@1!W'$$D/FO?J%_C%%U64UD2J^BY,0:C=9]V(?&"@T\HM,=D75]M(0,]G%8
M,'5;Z?LV?-=)\A9(4_CE1<032W#;[N2UMF8:_+(\^]",?T[OIX$U2)(<J:):
M6BO#W%&1A_$2X*U_PU%C;?VP[/0N#5'+C% 9^/./2VRUYR\:09$^VI'#0JC-
M(B)VGAGE?>(]:_,8K];TNV^E*&JM,4;Q]RUQEL-MJ]D<QY0TWD3SR:GIJ>F.
M!PF='!J/_@+6C?_HF/#*S!C0A1%CCNZ-- ;ATGDA'5E"!+8\G[<T-TH6[[Q3
M4S<(.,5:.I%D_-G_P;X936J7%WU/>[]M.<6)];.U@] I-B= O)+1_T!65FSC
MD563'L!FRI$KL-\ANJM+*3U)9+*M[&"--8^WODU!0*OV<$H,? ?:-JL-L#X@
M%_VC,UL(>!3VK8Y%BS]%<0#GU&$??.?ABF_S^,N),<Z#3%!/HA+*=3G^R8?\
MVY.GXTE/2UI;&IX\SCW C$0#%J !)"5_*9Q(^.KPH3[3A+:#AQ]+W#]/_!1!
MHCQ[D! LW!:R>]U?DU=J<3[&Q_UR^I-Z16.CE#GP<>AE*$QN-_R!YQ/U6*\J
MK\UXC7]9^W'P&.0M((V3F?/&''LMH;-0+%7A]%41MQ9&J*NCCGPI$/01J$QT
M[YR*:\I0#JMJ_N;)_O6(_HN61\30YX4U?.G2;\-TWUB^1A^T+!%-$O=7P?E%
MNOH4][)7C4LP+M>79VX+N7CMR]JR8;YE,SVNG&IW+M1/7WN)Q1<G[^^$+2&C
MP'2-7D%,,1+;/O!+TZ5_?6S!DKJFP8#+-)I;@8EZ[^E"@$+K_,RRIH<,UPQJ
M1EU-[>SBFHW/B1[PM[!PX=WFO@UP5DSG_]]9Q?^%$.-$I3BL&#57R;'0T/YJ
M+^@[_%N5B?(7UR.P9AP=C\O7&,Q*=C\MO/(ID&OB>[#J\_DC#CPB]/O8,OZM
MA3^0]$H=.%30O7*BE_CNLMJFPB.B',%]$1PNI[\UP&U.+#;XFHSJ0E\# CBZ
MMA>84.\/M3Q(%U:B]R=\LIGH?Q)["2\7!X+-]KOXZ"S!AHC<0+GAZMU?=+*;
M^M,Q[?7LH3;CC7K?_-/;=<6W]G9DNV-H,^#>GKM6"[9JO@J+T0-CWKIJQH#4
M%&._%V4KDCFWEO"WHVDV/$_!VZ\7KLUR]5/A+(ZGKDWX/_QN=;IO*2I*?%7C
MTT32D\8/2F_&#B9SOMC+ZWZV7IK.@ESK@M.0[RQ1'KKXZ#,Y^;&5R2^#R[]O
M 3L &N^H\I1H*.W26 T)EB!-B:1Q/7+569W1BM>ZLO!J+V3SVCLTU\\5V[]:
M@3$OQR6\(?2EI:4"-34UEW(3M:X6TEFD$?BY8.W*3#%R,=SIKI!.KD<_7^E5
MGWXNB:L$2',.6!A+808FD@R)B+QY[7SB?H>OR:TIV9N3T+B+J$K*UH>  6<E
M]>/Y:\0!'4)UYA%*Q*!B5*);$'JK)/K**=<^:"I->H3XRH_DOTL=-@F%_8+C
MGX.Y8'].YX^JZY90CY<&ODZL^_8USQ2)<!_'(L I36M'.1]SYYAIFNU:+,X
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M&SH83P[';@R_Z$58<DSQQF9FW^"!G,/BI9!QLM.:]$DUX< =Q[K1D_:9*^T
M**88QF.63&^%64[=QN!U<3@8-K!RW)>K@^V=Q6YU[9.5R<?I\?YTCKPJ)G_I
M?NWRS>M]=PQ40\=D$U@/F](DQGYHL$U[]6NJ]P6ND5D*%K%1S6*P7IC0$)E;
M10NEQW;GXO:<?+4)[WXGS)3:>@:XU/B()$-VKQT#"LQ;0)5&>EB22VU)U^:
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M0<#A=7<;[8LO^@D!)U.,[PK<M$329O"(K; 21V0U;U=2P0;7#G*Q$S]J!MF
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M[N(N>X:,U)7FM(/+8,A%.*]C_8'R:I[P:H3-T95KWQ5Z,2XV50 H"2<U=0;
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MM2].J&Y/(Y^/;8#P>F> J0+M<6\UFP5,AWAN_)PH%Z_8>XS1T\?/.[O_JF.
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MV\P(>*QY'& CL0,E;UJ3L]<1[8V_>[#CC]ZWN(WG^$R#3S4K<6B6=\91Y_U
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M*H?AK[SH=^LE/U>]==V6,1'.L;Y2/YV*;>V 4TNRB)WGTOV1=!;60N"=;^P
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MN=\3K'^L>=/QAZ->49D=7-6J\8AIW(@]H-C?Q:61 /8+]:Z(I>8L)[.Q@PL
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MXX8*^0L?W0/(:ZB4O. [C_Z"=G9@7_.*_O<*H3G7KP?WAJ^6,+N6I 3[A^/
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MP$^*YT3&IG^4"T+KX1Q?1$B&>)R$J=8CETDVCPJVZ*\Z0>B=5RCP!:-%;/1
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MR+(D&2((\^[.Q*6KM K#U[W"0Z_2A2?>L-+1C+;K8P.W<G=ZT\=B<1:9O:J
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MNY(W-?JG,L*+T/EW_(GA_@Y4\!+P_3U7^;E#09 2[%CI2M%<^?#FO BL37@
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M<17585_[OFTY-SH0S,TZ.RZ&+>3=TSU*+#YQVBZ2;^E2)=-#W6)USFO;74O
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M]+3^UO!>#F$Y2#:(MJH(Z"F8[ARFJWF6,GQ:Q>7U/UG@C/!ZU: CQZT[7'7
M9YK_E>IY/,_JCO]M H-)V: @K6&K@H8I7J,:S#I3,-U^_9NDXW#RJ<HRN#SJ
M_.$X S8E8L?# MY[&&^FW'^2(>^;AGC9@-X86:>1N9GKK;"VTN'K6:98-Q"
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M>35W^196-!ZM31UOV ]TP*KMR9R&O!$3[]_9T?BQ$]:A88"W*MGIO)FB<:?
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M#A1J?TBBI8JO5<<3!$\S,9ON?4P5G,,_KLD_?]<MS1[9$.FD:<GWZF/;JEP
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ME^K8GD!]LF\#7U(*7V;0%90#<@JI2KX73$>HP#KB,YMQ6I'5?]8;ZJXYYH+
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MZ8=I;^7%#C6 BHHR@WQ*YU6CEOG*&)+>TA8MLTAB*D(D>+KHR'N @-#=T L
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MFO2J:6PI^0;!95$-)^N7ZL'4Z-S@;"GT&=5;L(S!(O0S>..99=P(\W:V215
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M%:R=/[U4^YE#530^F37#W[P3_[<VQ?[J;1EEH9+M@,V@[ ^=QJ40\U7*MG?
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M= ^2ZX*MD>R Q !3<6^"F98.38[,4E!SJF0SK<>,K5ZX5&X]299^<QMD2_6
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MU,_[3N;.-KHNO56AM3R$FA:N[(? BN76)QY'%_ZDXZGD7&JB+NEB#$<>-2H
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MFT=ZP*2'_!IN9%E],AL50[F<?0!RJ-;+N9P5Q1WNTOYB"Y"QHJJR9C=(XJ5
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M2/4,\_,63[YW90Z4+T>)<&VR->,\=)'CBIO=9;)9_@(1W#X^SKM/>9?P4'O
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MLHG403/ K\YZ*?9_HZYA+B[_KVC-?UE[=W.2&E[% -;FS&FLW[!%%>@^,09
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M0F3:%JP.)E1%HE2(2MNC5]J$QN\TU:JJZ-M_Q/:%%$D\-6&MV'DZ*0(Y.\
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M4;DA5T$\Y6(@ND-?0U+D/?'C4/W.T,:W^MQ/)!GA#+.6SV[&-]A/FT@7>TQ
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M82)N^[]7-?=#:S<]SDY,W&"V/&OEK7? TC?QA07'9S31!+&GIPQC %-G+!C
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MH9A*N%WQZT0PJ.$<KJ[1>/*\(YL$;_DV79BX,2,%$L/)RG$4H.FS#<()>W9
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M*8E.6>2[5&<70C@6@@TO&M)$<I#=#FP$/-JT[X6P5(5?"F>[\>YV'G_C@QL
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M;?K^'UXX*\KKP)SD3.=]Z[;H<?;U9@6:Y6I9A>M&_LY:U%(_MK^2?R+<H H
M?Y+XA[5DTLR;FC7NB/@&:LFGO]L[^Z"DVD+_<D5MN$V$.G&H;CXAD,*7"W^
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MG)!WTZ'%)5':\^-D%K@FV2,)2XGCA\2N3PR$@C^J3LT*:*^) >)0>:UEQ8N
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MSTMJ04EKSI?9-^( \O<]+G)F[U(NUENK2/HN$?K#<P^>E#O:YHT:N>JG\?I
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M:9T G8P&]P'>'ZQ2[ZW8KR@(/K*^\D/CZL;'T':]\!*8/*:E^X+HZH%W3*]
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M/6NX/^O?H:K.8ISN_7^-]$YQ>OSV_V TW"-\]A>%-YL5P)^LE#D/7!-4MLY
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ME#3U_U7\VXUU?\'^@OT%^\?"ID.U\B%PH=ZB'</;!T,<:@_D)*:<AUGB]54
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MYX!W3V_@#!I"0C: CU&4GR:GV=C9H6GU8/C!O8/8N&^(B=^JOSZ]6>1ZT5)
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MLM4!X(9Q'V:.9!R^&LI!K#44;T $'NOXJ2MLS349L">U*2B6OW4UA<5,M<5
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M?E2':\9<^4ZZY3A8]^3[. NJI+5&'YG[\TL"RNRYO=JTW*BVF3.L3*^*9UM
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M]6K*Y%DM!-BT#H]?>EQ8W>2NZQX8 GT;=R7^"JDY\O@CCL^?FH]N[@TP;V4
MHI@]D' J+;#.O23%4<'S;HB<VT++0OI$W<;\SB/_NK7:%H*[J)RE%5IE>B?
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MYX:&%I]$!B U0-+(<Z>;IM;TU[3H;,=,J&UL=-*$,S&GB6Y-;H)DU=87"LQ
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MT>V8XTU70EE7Y*J2+""+K9Y;56S\/'5J^^^>X9D(W,'$0@?21WP0Q>B:B:5
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MFXO)?$H^V^FD5['^^N;%$BN0).UV'Q [1MF6JE9EI8%56K^04'P"\[@SOH]
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M/ET_\H$^]7ING,;S:#(H[Y:WEE*/9<]L$:8L9J';^_1Q):X\CAWJA%162L^
M?@%JCHJ5G%M[N/+%U-30J9I *>Q87X#QX]P.V?H9W8K9Z@P#GLAR7V\QWRU
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M;)CU*_ZM87:;UKK4782GZJE\;U+8LX5]_5[4P-&WD ],3=MD(#I=C)C_ELL
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M:5GX;.SOQSX^R]2@D",]-()R*8+"(<YWQYX*NSD]]PH!M@^#F5I0#\5MNC*
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M7??\UOF=>W]KW3_V/UDS>V;>F7G>YWGGS1Z;AV3PM4' =7ADJ;<85\O>G$F
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M^M;,&R$]TTV$W/P72Q2XK80/$]?CJBA"$S$=%P]),$@NU?4 N9^\-XC+S!-
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MA<.'G83:5($Z-P*T-PN 6S8##48&'-FY6SA$K1EAGC@<STY@.X?CUQT1$.T
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MUCUJKP>OY2]JA&38LE!#_Z+ZF03L:@H@+_>M(#6/EL;UVL=)R$C<G;2/#"_
MW]6[N883!-M'E&AMC1-$FT<#/BM%.T8\0.:QG^MRQ%"Z^2_D3F8V)L0 ;"ES
MP_#40W&\U=?I*ZT^R^&DQP:>AI1S(<#.W'T3U]263K*%8]+GHU$7M7!J?R87
MS^<6\?I8>:2P]7NK"XFJX>D1X8:<^95XPU_+6@B.B8_WO8%#/UT\DEM\+FR9
MKF%E_$4NX^NK7'3IA^*IM]"%3G[!Q=]$7I2\U]&.TH#;H7;.@Z*]6@H>$W/L
MQVU?)D9]Z1_,(+E5#O_5@]AS<_EFN54B(C-G27RI>7NP=,"NJ?+S7/.W-;<&
MQD^O6H'#P"13-O%@]>&S]P+2!-,5H 4W ZT.*KE#$#$A(@AVCBBTJ^IA:/-Q
MS;^M4H?.:2?Y<WZH+-B*\=(J3^<MX(Q6US3C1B."*8<"DH#$+2C'(.I9DOAC
M<B/GEF$#NI;YUE%XZKXF\8[/1A3I#006\X6F-FKW?O8JF$U5+PD-O> 4##4>
M,:3NL22D&AN;6\$53I56Z%M #OKV?_3ZW?^ C*UGID R**A2M@I=]%%F#)@<
M[&9U.K8'MW6!#(1@S^S#<;+E341K_TB43/%QZ_</)K@?VO[$$-%TPT7'LXE4
M&N-M_M[7TW==&T!>YB\D3=;V"A47-G**'K?>XQ41]M6MF(X_IYA6]PL9B8E3
M#*<I*Z?XX9IU-T@=%Q=^8&1QM9:F@VF5Z\ SGJ5.&=VP'MCEH^=G,[_?\!EI
M9=&1,WMQY@4MG4=%-&H9<2QL6HF*(D_H0_)7/+!#%)!I#$.&$?"FM\[#[+_
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MG:TCO1.K'63*HRH;XK_;/EA3W'^%]=FLB+"90V3G]?G%Z$:</1C4"Y]7DW%
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MA.>(L99S[K$1T-8<<'[,E,IPE>A>?+4<9&?;!+57HR,5M?8=:H^%?=M*W_L
M[.1$3]RBR074O,@_?(3N9@BVFLC_"MZS.O\XOL/5'5C36/=#9.D<<:\%I@[Q
M80R>(7BC:7H@@@^+QP<!C2M,<,?@V^6>M(=@RU' !%I::@;;IKO=^OFP E'@
MYEH6(D]K1\W=H9U$%K+MNJ%F"YQ;]:^\E< BIM+7*SBEO"41X,)= 5!CA_,@
M5X76DZ?J9%2V_F& #_NDTM5A6PP/7M%2I/UX#GH8\!95/0TOU-]C9C4O.W@1
M0IYG2P?@#0J#HNB_OH(^N3ON9L$.;WNY0U7?6%11-N>)QD_I+?=+1C1I(XGX
M(F;@K6)& D,%F6U>)>B#.>NZ*T,1(4O.-&VVC.$,5.BZ>U..8':D3[?255+L
M0!^!>#[LLLE]<4J1^,M%_96\947(FG&'WEZ$&/9BSF14=0TU&UXE3=Y_4[,U
M8#JWPU; G_/ Y\5Y;%.R<^R7$8\HY$0K5+OXG\5HQ[$GXVM.R[>PKP16\_0=
M#Q]>-J$!$P_HI3Z\E-ERQ(35\N!TW<\)*Z=!@RPVRU@3^YC.-D<&<&YA+E<V
M&CS2--7^6AC!*HBU?D85EGY1P0(2E7PCQ8H&&#UB-)6->D.I.8E5C$EF'C =
M-'6.#UMX5,99/C#'CL,.9(T,.Q+P[LO<UF>WPDXKODX$-(%/$2UCG?(S-HR*
MM-E/'(=O+DY11,P<OJ5WQT8=:<?L1%BE4>H!C="\F*O('7+$+<FED[4?X+\-
M%)/XL,:ZJ6>S!Q?GEP?UQM:_>.06-8N,O>ZU&^K.@.=Z;E"*2@)S5X[^[,D;
MRK^_WWS546"-$)V[Z% ),8PFR&PO5,X"QZSBD'NYIIEV"T2IGG03KO[C8RBR
M&P+/\3YB/AK.D@>?-G.N[5<,Q@H0*=A^AA,^G_G(MTIX(P*^<CU':'E(R"86
M:=?^?$9;:R,&-6%6*@1_J8/L5IIDNHT)\-3BU$EK<F+M]\$_(Y?*&Q)E\(YX
MUK+79X"R)3/ Y5)N03RX#=VN7:SJCUH26AY,:3#_YV-JUP+O:U$;<KF@AVS+
MQ=#!K[OB:TN$\*QQ:0]@1A#1?A:P&WYQ.^"G;=?H^HIL#&KJ4+D0O'^J28E!
M/DA6RWC=:@>Z=0>87\JM@- 3W:T=I>I/6=;:RJ&*AWN=Y677^A6.\F'"\05B
MW))'/Y;..93'8CHKR;S9P_G<U@!O.\X)I@9EIW^KY6)%2)(8</(R8$DIX"6"
M<(M727OR#@.B?2;P]O/P5.3"62]4U*TI"NL\2*Z]1759UCF63 0+F+=&J[0"
M18+7<J*NQ/2<D*4_<,$V7.MZWA* ,RPJ;# \+F8X@4C64C/B>AU@H;B19A;G
M"I#:9S$JV7/W.3(?_+V^?-&M(*U 1N-*T8G?<(CJP81IT/_7HV5P!+&< .U=
M-7V,EQ3+BML:9[&W0.=D/B\!>]3V 1%W).O+ZG =]T-8KA%'GMG_BC-\"AAJ
M!NAB# 6Q/AGX[]R_>#*XI: Y(V^Z : U@:H03R@W![?_ZXR -!:'@9!+ZZPA
MKTJ$1OCY)!TDC')!/HRYA9=TK85)1 UX-T1_>USX\ST?YN76A\P[(\)T0(7"
MUP0#^;!MFU":O>AW!NA9D/<-F.<&\Q+U*G1D$QDNS! I6+FDP5+\#P]6Z6:N
M=2((%6ZOX,-BBRG<9\31Y'2>336@3%P'KX*M*<,@? )SEO)SHW;'H_0:3WMI
M#ZU_@)GG SI;F* R9"7WR^!"="QK)Z'\7^EWYREDQ9K-UFY5<)&-S(N@*"Z*
M#YNY3^3#B'K,;A.,!+V.J.:#,KX$3IR$X,)E.1SJ8PMRE;19ZY,AZQ,-SCT#
MEP+:<R' 'T4 P>:Q8]YO4YZE5R=TR'+*,=^Q#UW6#H3CU]UP-W$T<88]\A,>
MOX=&KM^5FEB=,)@A<6*VZP$P7H0"]Z$.0..JVGR-*(EK@ WI, %S.V>->-5@
M"VX5GA3KHU9[:$[21L@X].!+V\XKW#I=/FQ76SZ$:HG+W)T C="QV;=2@-RW
M ?P69U@#>!I2_61'T2[K[W%J2J5SN4+;N)GX@7C\ZBR2QT'3")UGH/*I?!@2
M$&$>!YM19";P&ZERBM!9;M_>X%[Q.-+>ML)Z*U2&P [@PV+X,.BMJ U(T#'E
MIZK$V-=X\8Y\F,X[@%+$APF&HT5FO84E;50[S>HOT(ZI<[. GDR 3*D!=Y$*
M**L@G&;8IH%8LP/W)\'!5ZI(IC!^S!3WJE*U-G:,=S:VFQ>N",JE\ZSP-[.7
M^+#7A@QK$M1_K5.$]@&M;6-A[[Y_D>JT$3%U.1R*9"Z:\V'!=J/+;-$U)/=0
MS>;_*?FP;"^_>RAWTD]Y;L-TCQA[BUHU?L???5;5Y>H-&V=34!,['$8PNVEB
M# Q9>/"<)_B]T@88?FAT3IK0Z4(_V'SF>8R.5%$/X:E/<65IR>&&I=3'X/7B
M14CYE#?P],+60^L]2Q8[/T![GOBC@O>1N\4#KVA0"@T\3RU&AK)X\'X)JD M
M2&[JR+7[)6A##554KQ98A&?(/30<C6%!' R&RZ#*TDBU- 02IZ.3WQ!/M4IK
MX#)N3$)S_KZW%;^H/3[_U#<A.'<$.5WTW0ZYT2@V:P[DMP9.+Q#ERD*ZV@HM
MD+$*=K;8!HT8QP7BR:+$/*UY!]QL1P(N<UJ9 ;G?7Z31D/SZ!H?-/2>G2UCT
MHL[XX.]T3,L0[V51V!?AJ:Z68']?(]")44*?)W,+*I_P80DJ#VW 1O!\4.P>
M1K1[5;YR."4:!\]]-(QM(>U3X,-Z9MUM@#Y$8P@85(US23(&T>5\6,K>I\_]
M>7W:U[L8M9T4N#-M>$*':%"MOSYWJ-@5Z8(6,'RE$D=X.KQQ14JD\S;X8768
M\HLB8S'1-)98W\"E#\F#KPWL;#&:=#,\OI#I8O92F$NV.R7M=6DH'%ET\28@
MC67R834"O70/9OQH@*L+QP"#+.7#++(-7/@PFZ>32+9@PE 1<VST5DTHU\"^
M<GPC-06RXDM"L%LA)_M076MA[[1Z;?X'T,OVLT^$V)&3NT#DE,HG,ZOOV. !
M[E5:\;=7KE0#N6<>*PT!^[4X;KF)5O,NDZU5M29O'974W9""W*%4LS._ E]?
MVFY^VR<&<(X?Y\.V).1TVCQDXE/OF4]K$\)5$F44BOSG/;HVS,^1&GN'T^O(
MD@- -OU.SM_IC1*T/!AD\+PA['1 %GJ9#WNC8O'9KY;#"&>ZD1FAS$#'E\1C
MOO?L)A,&Q=NT_SBNYR8:#J8WJ#)7X8:0>?-Z2\F\%5TOO5!WG-?)%=24\\\S
MBL_)!3.$V%S@J<@!.9VNY%EHOOL4E9")*M"D#NSY54;[*HOT0W!?K"GQ89:S
M4;ZOXE9+FA)RL$=XA%]LVW!HU0T)U"SCBI[XO=>^.%'X+,#O0VXB<K#DM[CZ
MZL[T3;OFOFK@K=27VR4\2"TR96$=LL6O\ K]3XI-Q9$*T35#!!:.I< ;<'5
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MZ9 WQ).8B\08,M4[\+*+^@&C@S;U!;X9LN_>';A/\3SGOI>Z6]I\\$,(>MQ
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MD*MKLY_CVL(1,1Y*:";,& UUML?,&C$V3]7+A0O;<T4;E%._PI8;BO@@V_9
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M>4"/\-*RVHI(._87>>?IV>UGU4XFU6R=VB6TU/>NPU$$M? #,;^S^U=0HD9
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M@X# '3Y@2YWBGPR)E2W+/_3)HMO3:VZMLJK2B/=[NTB"K^8QMWDPJ)UV1DC
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ML$W\>R&/KK0:O>=2N\2#>4"L#SE-CI25>#-C(K5Y@DB)/#L\H9W#%<H_0HA
M4=*J]H._3(4X&]8*P"=#8FY4/NXFV+-\/4-DQ(WS /,[":FKBHNGH+;D'AZ
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M2G6M?)?CYI"(C%P_P^+"=I'GK*Z(O=MF]/0W>S4HNQUU2MQOW.6:R0-*C'C
M"+\_YJ'J=P&(#'<Y,(RCB&.%P+_"9W;:?SZQ%?4;MA%K_HZ<:JB!_!\.+VY
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MP%<-6<-NQ($Z3@SG[" 9VYUX-/[@?V'OO<.:W+I]T;A8BHJ*BHA*B0H"2K.
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M%]P>KX\;YXW+1[\'(K!@SC)]<]K^6$&>AT:L391]T98"9GF3AW(,:PT%=>4
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M%+3W5>%I)![/U'@_NS,U;+$<AJ+=UA(C2:W--.JNWG3T@\&%+?-W"0I.W\J
MU;KC+YGPSGB7.NR!!:\+"Y&WI^BYE\ZR$R37A;NT]GE0W@4?5187AD#0PJN/
M4)(-=[L;22E0V72EAG7PSE1.PY'^#_8EBRL,2_)^U4G$^\U]0L^*WP,A,S]
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M-N3SF'9;C;"W1BJD&)#^J+$EZ/9+MY%<U8X2K6Z ;T\)E-^MC\N_ISQ77&_
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MZX5U0AU^Z'C.D/8)F 9OFNVZ=9*8*;7[$."ZGB]Q$">2[/.#RZ3E#><W,-&
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MQ"24!RFUM?=L4_NZ+=3?3?^:IR/-Z@@,?:SL$(DQ%+WSZ9.>-IT_G0GHTR%
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M"KZI;[>2_"2;_: 9XEPLY6"<+<CA?M8TF6W.[JJ'2, @77X30D/OVT[YRT/
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M:L#?U#368V%,_Y]_?PK;@C8Q[JB@8:LXR\3U>@#)$ISC8!L?&/IVA\>J7SA
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M="CB[VQ$?DBQ)IK$(\XMF!$^&_GQP*;O?IP,%/@>>263V/HV77?@T8C$;J9
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MR4(Z4S0LPL%3^N/R6L.Z=U9?7D[7/>:/U+D&L)Y)R3B!%(L# W>HJEX!\(=
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M)ATS.[M!'D4QXSGA=LF0+&'3"T-WV;\OTGK<U):D_5G BUA%< ("6,L+%#Y
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M)R;C6W8N$QMP;LF=/&2US5S?U/<PG<W&'<<AC;X!P^-HEE$?4+:]CL%+B&A
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MI?>$#DKOO20T*8$$-402PH_??V[.N?G>BW63/'F>O>>>>XXQUER98W&ZIG)
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MDL5C3Q*09UV+MX]?&?!XG_'R5CMG!LD&WMZL'%=+O>81;FI"5B=6Y>0V3U3
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MIJ*]/[IEWZ'/S*7]@X>N5_L*]2#8(7'>!3+_N%V-JS6+$4\7*2/U)KUA9GJ
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M6-S39>HF:NH]??9DU9Z=#E"#@(Q61RZ1K\^(X!7W,WQ7C70,WZW8&JGQZ]5
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M/BN8:DV[D^+BRM.4U)+9N;6L+ TV>+F/P/-<]_F24"G=F?C7C>J@UM8;-ZZ
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MK?;\/VI;]#=Y520P=1XB8VIND%N_^ND:?9B'3&U4<NT_7!>SOIC%Y<9QOGY
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MKT(DPE/JLYG$K_]4%,LM0^\B92=O.G@]5!^W"3#Q\?(5Z&!F+[V>S TJSW]
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M1,&?QOUA]C], *2FWNW A9H?J!\Z'3K\YR#?_LM\!/U<^,.R/XV>FC4CC5)
M;8D44#K;/TSKFY*G<*]4'J_#KL_C']R^/U@.D+)!FLY=3TLO BT%K6@A*M?;
M2"K$LZN'QM6^H64^J>4.[1BK3Y6E3[7H197F9Q^ECC=C6F;$WKZZ4J+V4GW7
MIK%Q>WQKH S?="%N0(GGUJ_)HH+F+)E?(P/#;P]"J:S% .]7@J?'[G<H3MNV
M!W#GRO;>W87*L7^R.OG%I1>G5I_.N[+92?_H2 0_W&E!WY7'IKHE. 7MUM4*
M+RXNSTH_QYB) [_ZG!+2OKO3MO,!LO<.D/0A7B#1$^"//6YVC1?<&711C705
M["6'@/4BTZX+!5EW-$>X1 Q 1'0O8/.F^K%[5]Q"/;!.USKCT3]?/8^_NV.7
ME+XFL=(DR]+^+,PRG^WYQ%B>1/@!D7,5Z:SPE>1.J+!%IK,X8/S>3R<7!C+K
MM:2"SJU^S2/>9GXE!-;01!@>O8<OC4<HPR=?O:> 5IF__SP4271#5_)9C:@.
M/*@>?4 ,P<G[8HE51@+1%T7:#,#1H3TX-PI(JIJ00>X<]*" 3._DLV514U$2
MY)>WP,)1,C+OT-S+D:K#>4?)IGR/X1MWP(?F>@_ >.,3]'M7)T!:/8E^5!+4
MZG!IA?JINKQ?!DU,%)#;.0IHQ.XG[2A5O$<EP@0 0WQ>>^:$?6[%^Y XS[TJ
M!T\;;;41JR#1>"YOW:K"D+GNX' 59P<B)[D/PJGF/QW<":\)[JH4ADF6+EB%
M!A8!X85L >F.)\X/*3\\?7%+H,*E3TN49CM, \="E%[-JRW9R$ ["=.IS\N/
MJIH[#-):PVB$*""/RYVXB?[GH,J?Y^M8O\HF46WQ)H\+9'6RG*#:NM!Y)[L'
M X_:MP\-7N&:G[GX4'AJ:8!!$/Q9T"&C/I+M<^D_<$0L60(8\3_I]3'\!<^'
M3;L7 H8O#$!]/8&]"%G_A/DS<J9CA UY# 6$\9DB0=&"T%-> [X!..:T.J#8
M,#WVU.ILF"T#!<0()A?D'9RE@*8F%DGN+P@I*BI!R@GI>[PV5TK?^JHU+"?/
M;6Y]R-2?.-OY0_4CJ;[T0]AZR,+FMS=Y)'DK;@KHZS4*2/+WMWA20-%EF+Q#
M1OA2$Y1D$92'?TL!K6E1_2GO* ?\C[_ % ]1&.GM[U1W6Z> ,D6&)SZ)4-VQ
M%4SUXOMP?*TN=4A#*U(6U1?C"\B\)0GPGU3[T@EP@MHXO)V:!TM7R)?@>P_^
M^+F"?!JN!R6)H YNA8>)X< DFM_12YH"8KK6!=FA&MH7@@*R(6COD!)R5-Z!
M(A\%Q.7D03H#/TR!+Y50%\;D'W_^PT#Z?R+[+/ +&)NWE>MGB];<I;U>) 7*
M'+_5KVQ(FW1+Y#L$IT9UJQD"E-PE[T!UJQ^5_L=)2K7X%]O.S:-0)U]9P5-[
M,K1C6.G<N7 ?Z3UJJLKP!1!4G9A)#?N%]R>VWH!CA@(^VY?DFF<C5&JG,ZZ.
M]/4Y;^Z'-0OH2ZN5/2V+7VZK,)Y[CUA*?0KQS)O,WL*@-I#X5,Q"AZ=[-? 6
MO7#2<Y^S./>21=D%GC=R18S;>W%U44_OM_HN/:7]:05(HW (+^)UDIZV3:.J
M#8KSP:D7:N:.=,3;%QB1:8BWFJP%FY]_TBJ$(_;<_\VTJ[]-RZ":=L^VE0)"
MEFR,8J!3!9AH!$X'?U6@#>?7,HIA49]B2.%SBWV33_QJGOX)X3K3H'1VKR<E
MW(FH1)WSSHA1U)Z*%P5TZ!OS&9$"X:7Z5,%>*Q[:BF"87=-GP'?M94E5OP>J
MK3ZE^)0DVYP__7C9)$5R3D#L_OO@2YJG.J@9K$TSXIP]"4:@[P&#IV_V%1M]
M\'GT .<A>^)<;P/,ZW0,.(3>N TK3D];]""/&^+ESPU,[)4^V0L&W -]T3CK
M\1ZB26>$7"/2H>3CT^Y/)W&W_-.*9"6@NJ^N+H>/)H"V(<D+W/H2Y&Y4+5L[
MBQ2;B(^^-A",7>\:_;"#XC[I)XU\9L%L;<:]*G"NM3ZY?4?BG!:=VPS$-V_Z
M]/;BP]1%%K#E=S2^:R$9=N%$HF*\GZO9-9-:B=!],>B2PMLLP5\%DG&:7;!X
M:NJA!:P*2&< '%'!J:W,Y]%\66E(INU84!Z[M_7\G.-!L/W#+YLZXC?F =,T
M[MMHGTW(=.)B20=BVKQ#.[@#*C0L64LN'(5Z(GD+B[ZH&$3JIBE9ES IGIE5
MSN@9>$&]CE0H2XL<3!'/4Q)'%B:Y$N[4UQU&OQI7/;HGAV"9>STL,"#!*?E)
M]7)Y,'NAPB  PC1+[[4>%5&SACOJR83S&?7X\O7]P.*<=UZ73?F"TVEKU%D?
MGF$>3!F(-'2!T@#1$,\M0#)Y,^=1PR'I,B QX>,MOVG75']]Y6[8S>II+9JZ
MEU/OAI09Q'S"R(Q=V*??%2%WH$(&E1I/I=-][>CB0IGOWJ%IW4W-WWL$.NPQ
M N@)>=?QS-KS",) I[9'ETX<[\;T],P4_-:T(T>:MR\L_79\!#J<."-8/=U"
MO8.B5&:]^>PG<#3JE9QMY7WEDWJSIN?*E'Q&UDY8T51#BQYJC!\6)3?_>$.8
MG78TKKZ@>IE?PAA4<5;8D(X]?'W[-9E! (YI.2J*A0.F\O =WR/0HR\+G/J2
ML$='U;H>^-Q1FW&R($P/[_=*>.PP)=F'O>F[1T;_I/XW5;_32?%"I8;I8M*Z
MI*;<QX1$C$DK&#C#&XTW<2!$4T"IL.,8G.::P(.&G7MJ1X^5AHREDMGKM^5S
M CH$;[(KLX8)LDVS=>75TN/$L/"G9)IQP58R*U[K7$ALYWB5B7I9Z+WE4X/-
MQ?AOK8WI5V[+X(A-R9]Y%B&<$<(_\QCAB^_AQU1Q,A;G;W_^FKFVMGT#E7NX
MMH:>L;X@D=[_I?-9J78DZ!3H"OT$M+8$)UT&$Z: GEYHBV"HKAZ/.!N"O>*D
M<_%3LT3;W:>/)6?1H4K%)OS\2SLV/$.P*X :(;$=SA($.47-+6"8"1S;S-MN
MOE_7-%JS\\W_LEDSFB@7<,+H5M&%T*2.AV9JB^!:C01Q?"J)IV#1^.V'/B%M
MC3V]YLJF]#?&"%WDUS+I?/W;\8#O8#B1X$$V@R:A-IC"**!W(I'Z =3E<R/Y
M$?)P-'B^3A%9POC'Z:%/\V<:D&:ZA?%B3QUFE#OC(D'YC6XH:8GLP[461NH'
MJ'RBK]0'OJ<^#U^5+PI?_V]+NULAQ*[X13C]6O92&G_7&X=,.6P@)X^A7@Q&
M-J*:9)@_!>09-8_4GB3-Z-1_L3ZCJ:G7MF&X!+YJ-W8M(+T8)^NU=AG1?Q"L
MK]YR5*PO.C>G6^5-L#/N.7WJ+EJFI;6ABC1(Y>8L8@0^<HPB*;WN-]%=W0=7
MU<C?$T,2W+H8(*?-2F)OZ3$Q&%NU'#>BDE[JK7HMEGP-0@R"T;:MV,Y# 0$*
M2&4E/$6GD4BE(+D^_V4XJHXPA5$_^#;Q-_]'466$+4FIY,@2?'"9RL?'X!T"
M\#$TE:@/D^?,UT(G0N&+\*./S=31J!D)]=\UG,G8]H=?U%$H(.*M/<W-+0KH
M&'7:0Q$DU=A.Z.$IU*]+,__!\_^\?"B^.V]7$_Y#A9H4KOYQQ>!K0XT#%! M
M]9N>3&(;420F,L,R"C\"YH#_=/VM1?S_38O\X_ 317^8](^VAEMI;RG^[I:M
M8W-+V:2*)T5 ^K>^^_/Z_  J"2?XY50Z"-]?EH=:>!W[DNPOY%=JVF?].%0X
M=,B'FEQCJ-*KK(,".IMWU%!+DB>*KT[K(WW"RM9'O,?QFAD;99YBK(:]S,'(
M@340V'XDDTL[:709KN44/N'>G:)EYDVFRC)IU,1*;BSQK">DMJ0-GBHBC/JU
MT63H3O#HXM,6^6@K[W5O!<&2<MDJ\D/+2_$7UI +LLMYDT&/1ULT(P-3$YVE
MZ*G3RXLRT(\[J" S3!!M?!988.[WB,HP]VU5%*?GZ&OA8VL'!Q(//GG\;"UC
M87K@+D:]\6S81N9UJ5,3":,RH"H5*JOXMO>=RKW;C"&NUX@70RP5!0$%\">8
M-7[)V;UB)B>US. I\MG-^Y+7,I.;[Y?$'(=)[X&/RH(0T]?V<@%??\R V3M"
MUE/2V?=>CW+&$I&XV$'DV;/.%5(\3SXH?;ZOU.@=&7Z#"(-%$%9:4;'Z(HGH
M[A3_IJL87V<]D84K8=?N"3\.,(7+'>.?7#SCIYW.>@[6L=<]&B%#[D<==P4*
MT%;)(F<G@I)Y-Z?4'!0YC+STHDGW&SHGHT4-^88&DH2BI7,FO7<1,XI[[YN.
M<GU)/&@$T^K#AIY.16%O\4M?T6-"E3F-?"DJJD1+S-OBI.-T'A)+OEIX*' &
MWOIY!SRYT"TB0\A*4D.(A(PPJ!XALX)9?$NF5>9;4^3ONLHRWRJ3_?RD+^5#
MH '8#*C8>YE!7?*J$&!>M73ZEQ63@\^]U?<] WQ<G='B$H$?S43I=J=9 E"L
M,'[L0A+XF"H\+H(;.,+P-WE\\#(K=>A;NJF?R#,@ZN;MJS]TJ3OUY8S";:<2
M.=.N!U"Z:VV'R T>_((5H34&RN =P3%2\WJIGJVJ"7B+O"$9X?XE_<R\$G+K
MMIOX$EL\M"JU>V'2/AR*H=_8PB8>.;3MM2&"V)CGV7\57E+^@1;O_\R83^KG
M--#_J3D("N_ >V"B]Z-1MU/9@"U,-(FPIOTP,HCET=HJSYUM<6;WX\8G2$G'
MA2U!"#G@V (7Y*[BR4'"A<X('0)]AQ6S]^@E715TWLGF&BN6<B7#>X&Z'WM'
M>K^4,$4;\.D$3(H8$HW(WS06:FU)G!6=SIHUHZ/F*)\*'8O[_<>^Q!&@!D+=
M5CH,2A ML9M1ELH1F;_C ?#:BF"RX8-O\=4WS?%5'?YHF0;>#3R/$XP1?OEB
MCGI7T[_EIB'$MH<K=F>SD7@.)\P(\TAP?.UK%H60T^/IWWV3=Q%[/JK*VHK]
M$I-M#IZT]^OT?-80,UQ8C\X\5I(U8($O0<]>\ZP.P0 ]I2&?=,0>C//VKTFP
M5Y2E?CGI-*"I";HW9!+GG ?,N<<>)5(UIP7">9]H'C%F3_5L?0V ;=&JH_2]
M*X$"2AS%*:_;E_-7UKQ66LY\?O'DMOL,W9=R4UK7%9UZ$&%XQKP'S 5WN;?H
M'R<B &1A%/F!1\1K G>JJ>&']RC[AX*^\7-5?R&EE_$WE\ *YQYBD\H.M['[
M/7ELY&$X?5!>G#9!T<,=Y.-SKNUV4_V]N'SG>KG.P"<U?FZM:@?[5(KG#LAZ
MX*E1GBU:;6:+?9VL1'"?B'>M^SQ>N[[W[.5@Y4!-P$SQI*A%/^MD@?,3":P:
M-02VW5YI?+UG"\#V5AZ^DHZKS+8!)2$G/S##8S3(SVFV1.@ #T(BUJIC'<P3
M,H,9;UX4]K\9K<:DR KHCPPQ64@*G4@YF^UY.Q/=GH8*C.X3955QOD#D) 4#
M;5BK:2(&WI$:GRN7V'D.T##/[E?R\A!^KS+ ,WOUJ+3\C,Z<9:BFX$<0HEZ7
M'A.NT]UR\JNN84&?4(--F<OQ'Q7M]V/.BMLX1M#9KNS_/C7RK/Y1$7P]>9B<
M:6@ +MCY7Z#'X)\-_^J)^)\&V65$3%Y53#)^:Z\5>$PHIJ_SI*9O@<G)4AV<
M7Y%6\_,DMQ6E[M8H2_>7["=4=BJY0;;I$=\66$B!A##T5IPN/SJ5_6>+X&@0
M3MU)?6_KRNB/AOJ;/YC3X_;Z$S2,9^X;=IOM]%1^,P!+1G2A/FETLDW1&Z'P
M7YRUONJ:HYTN7"6/Y#*HAK[]G&*=UKVL1?<CXG;\"7Y+QI4)*C?Q99M<P-#C
MHCT*?TXXZWR%J:$'I7XY#(3YA(MXE;R8Y#9^\671_4I:]-4!I1W:#8$SM(,M
MQP&-'C ;C*L \.^:WDS$G-Q)UA=D"IM3L<H<L;MXB</>R,LIL-;XX2)7QN.1
M)K:]W*-(::"94$U-B;QD86""S).5*G?.;_?DW23,ZM?C"8[TCIJ7NZ=FA=6C
MSK%&=+V+U%R(T8:GJC8+5Y+"*SWM]_(?V\@.<EEF]FJ"-I7%!T5G0XB%K$V,
M&Z5_89_@5^JT-'HAF2Q'TB70/VE2Q+#P=61J[[U6?QT:6NKU:\XRK?]]^H&+
MNQ%_<AS="EW&JC/""!1JLH'#;_6 &5I$ 'C;_!G"B42,#@N]1:S%IZ;1G0-?
M#T_,#=.FUI&&= X#"9ITFEV$U9@JT<F^?;E[;UIV0/9E-C]NQ8 P('B,G]_J
MN*D$>XCH=ZIWM<+=4Z<@EX]>[%K%U<V#&SE#W#KM"^U3<EQGDC)EQ*>_5H.;
MWL9//\*UZB;ER0$$(F-(3R>DYCNR!_P4SB&*5TR43M ,.K6U,=BIC(MWF2UX
MUO;NQ@EU1W?:8PQ8''5MT/!I<3+##(9*;O<B&";< 51H.$'Z?+.&RGI#9;Z#
M16'W^>GIBQ<#3DZ+MH+,TX,_+Z:: 'U$&8#8G0EGVH(I$IRQ%H2\)_Z;069-
MYA53B;&H7,_OPI?/6&MB;O'#B@3/"^>+6(1?, +!.@BVB^ NQ>EK[0]SCP-9
M[T/,S? .<PZS:UOHD,W<_6OL]4'QNAORGZIET@W36AQIQQN'I[GV[/'^."Z\
M)TQ[7"Q<P[+FYNM+#=6@@1)S3NYX[-R;R,*R:]_-^.G3-JY?H>_,HW)Y=_"T
M+=HXEN\Q%#N>W0*J[51'LE,5H^?W6\@M;OESLGQ""LO/I 6-03P:&\%$6J!Q
M[PYA)0%F$DBP_+&Q.] FWQU?/&TB,V\B] %_] Z#YA]P-6'Y4:XQ-!EQ7__[
MNTA]@>^06_"XEN-'14U7"9#%X2X?*)T]\,'.X_O[(!8Y9URH8Y_"F-LGPV7W
M"9U+FZ)"0?I4-MRF3;J!24W./0;DH/.2!%ZD)CYX</U[T)SWE*+?G8#-^;L<
M'$O&2N*BD:>[\VFC@OV(F0F@@R=[GXZB87I$2]*YKS5GU1IQ.EWZPA>.7F <
MNC6N?;X;FGC?DCGAQP4AGNE6'JP,K*,#]2FU^X@/#8VO&4X""RDT.2WB5$P:
MB(JQ-85G_-4-9H[/S9P>(B07*/F)'2J)?D+.?6\C>8_"W#^0],8?P.DF/8.S
M/Y2XZV6]0GBKV+7Y+QM?,2-6A&9?]AM:R-+L1K^)9$M#_5EXASZ:Z*5J':N%
MJ49,[$;>HH5)FXB<".?W!S[-UDXWU/0$;S3XQ+U"IZCPQYA?M.&/MMPZYW9O
M<=%C_>^'Q"["[0BQK$LSZ-?)RC/6"^1JFRBSMTQ/2$H-G(%(U.6)J BJF*L>
M[ER8(J]WL:^U:.+W$VI0G$ 4MC-XT7/4P5%RL$T$GMG^T*FR-H#Q#7OH<LL+
MJK<?K/7L&7XEJ1"=3 BHCE36+(6W17-VZX]<BWF7,1?XS5\2VJL8+Z1B-/V*
MJG?DN6FH&A371>1#XMP+0^R)Q@0Q?%X22?'^]FIVAKBJNV.WDX,7<Z&J:3]6
M@D<<K&XBC=V:S,"8]/A'"4Q$DV5)=^H)TG'+"8H;!263\IFOW&5,4Y?-F1WL
M5V=<G$8"'O==9QD,?T5UEL=OR9TM"HE[!M];.'SRN.Z,JPT,"#JICU[Q"<_4
MMJC18) QH3M;\YG&\G9@<\O59^6@]9H%$'F$%\4ZTQ9,5L&KUTIDQK0UN02Y
M/T2N"YZ](&L?HS1PCE[T%3?7_N,5B.DW Y$+^)(])[QM.VKJ$/+TG+UZ!?K5
MW>6Z,98M1=@H[8HI.3I>DW8S,O\!SS9;!]ND"M9_8P S9[^PV-/MI-[3:E^X
M[#'29%ZB-MIZ+[(--#E"$^ET.2SJ@PF(#74FG^VI/)58YE! [."]BAJ@[1ZA
MCJ"(NY7ZL#3[@35TMM_%L]@H?F(#?_[&JZOG>X]A19%?'@U/H_;X"/3=5O'.
M)X&\13:PQM,6\9 [\[)6.%EBP.J#M.J&2^UJC.# ^EM<;A58$#/XX\_\WSOA
MGE2IO96,\MQZ^K !GD16F*6R/_9*_X(&9$OV%WLO]HN\1I[BU;$@WGF&5\C>
MR]XGODOZ3$'WK)$$Y,9Z*'X $YL0I"CBM';EHJ):GXVF"'_!#0ZU]Y<:Q3@V
M' /,A;L&^.X2Y[AI#H[P%_98CO);F.; C*N0F@M><*8O[P?]2R;ELN;M;EUJ
MES9QN.,7<3LPRFSZOD_RT1-=#;?%+>#,"H[IG5>%S.3DU.P%OFFIT*);"HL'
MN2:2.?%]<IWI9A)+$ZOJ50IO6;,"I5[X^(:5EM]A"AO(1$;/?"N\N22CUZXQ
MTB(.L!%E20\ "Z)M" 6$(;]EZ\"='^X^CU9X\-KWX8%$C9V4V97"F Y6VP'&
M^Q6-$J3F,[2;V?\+;+C_T^%?K?7_1' .)1"QP=0(X.$?K;V50C+=N/M@$A7L
MRW_,_/,DY@S74?%=YAU:N9 3D7JL"8#LG@_P^T''Q(O^"120D%JS)?B$][7J
MD&#T9FJ86DJN_+>$^$W=.MN7Z:QS/<\8B.^YPW)6-E3PU5;5+TA<+J4DY0DM
M3S742>]K4[,75SY?6=8R;.WO?7\RGRV_%)%. =W*4>R9YQJ+T CQP#A7*\8U
M.;AAQNKS;#(>AW)GJF,8KM\"%9_)8*0?2$9U0.W_WX\3N*XZ"+\\7MR4:#56
MJ?CC4U9O0\IX4%I^!O\DVFQZ<B.T8A<#J49MI"XN3!5TZNN.Z\J'OG>:!=IW
M%17YKC?890I7BLN81%^+'#7;UKK3QJ][.S(LB.>'O@9 + RQQ2(Z\J*?F1^?
MB"-9^VUZ(&?-I^T,?72CK.G/_^J.^[Q&]Y)8N_8W&FX=J<2QB3:?9/PMY05&
MD*;TYN8\UV#(*P<Z/UMCFVM1H71!B+ZM25NT2!;AR5XQT+:(.K5&EAIOTD.'
M*F18U>F?;HY,5=AI;YP_>^/UDD@-#9'6"/:84+TGWX#O>1RD%[R8FDKR7U3D
M]>(=<9JZR<;E/+^Z'WT"R_QQUDPJ^-;B"LUKB7.85$!J 1?[/N+[ G-0:9.M
MD'2W_JGL4XH?< 4</:'<Y<O\":P\?0E7V@P<2T69<2#P3>]I\BOT#C+\FG7-
MJ#7F1A1O8XXKI^E"$-\]?K=)5@LH@N.H%'(;?H(\;@^-V8"YA+ZW,WKK_'K@
MX8B?#9?4(FW!I@T=>\$S6N8 8\OP6N/OH(>[6OG'_[UWL 3KT3,GCF;]O,C&
M-B#'!:1VVQ\5I[G<V@@^L)))C,=K3<>9TA>O& Y?VOU/;?RVW.?P3LRX5YFW
M>G:8LV5=W4"0=J?'JQ1>U5GC%>EW*523!E)G9-'C68NIP)F>#32\Q-&[VOS]
M.J_*G$)1N2.4YO3:20V3%9V7;70L<>=!%=%"*[LB_Q#:2C?%^-C-N%3*>XO,
MC;MNWG8333'<YZ:Q67$:O;MKKJ>,O5+[Q+J)=7S\OF6%*MK8\1U79NO2XCW;
M"FKR![/5;%'%/-Z.1<=RI&1,NJ;^FV334%GI,/Q<\.C2PJN2X+1/_0[+;LF=
MS,PTAZ'_\SOH_AGPKRZ_?QZ06BF@*'1(P]YH^P(C3(G[0T/XT?+;TED3DKP$
M ]T],(PI'JY]!$%$H18_0FF#(/%YH!W$*2\.P==Y='/F04%^Y>:OM5YP>CC"
M[Z5+039B(!T&8&<8 _X(&1W! -":5">?KJOZ*N?[S6TU&FF8!]L=ADT$0B$1
M[5#!FN&4O&IP5*VY3NGRV$[CR0?)]L<ANAI7C$MG8F\MRCV9ZFD.IS7@7AR1
MJPR2;3XO:.K:TFB*K:^_2//CYOY=YC#<_.3PY8D>,&N$M$\>DJV; HK+]LO"
M)'NT0T_J,@5DWX;BD^9KDS<;']DA+^U?)1/$KG*YN-V6$V:0?J9?-MKDY8+5
ML^W29DV5V%)/K1M9MTXV1*:L?JUZ#(6H5I4EOZ&)WF;W>+B(>D.-#\8L]YJD
M*V&N@,?[@ILAF>UK3,BJYRX]ST<<9FG)V ,#"JCE#.W'HV)=(P(7F6$!R\80
MLM7A+$^03HG@\)XHL!R'J6!RC"V,WA?.?(X8OG=666K)CG$[\AL:>0+T$(Z_
MFAHO AFA@.Z<C)"&*0(9ZD_0%2\W)#F\,GV$N^::OQVX.[R#]?Z2>!KYV!2T
M](8 (?$0*N'H% 0O5B1L/9/)6[,O(S"=OFQ28M51 Q>$%C9OA>+-+.@[ION;
M'GW(*_IYSLE(>C[!4$ZP +*9@233&@BO1+8PDFX<%:+NY,7R"2"[A</0<\_G
MN4<MBI#115*;J\F%-QN;FR3,SF9DG7MK0.OR:D:JJ6!/#"@B[&/F4CL7HB9:
M-&X&6=%[Y[DU$C;S6?8*?%D/WGFZF$'&>X=I>3)M=+CK+@A'AE<2I3[Z3[DM
M3M%#",:>'120A OB&60QFQF"+H?X5.7"T5)#$!SQ:CXK',-:1C#?XS^JC."8
M&B0$=E) G# .[/KNI^91DM4#CY"^[#/N,@PR11<)VL\9^E_H!NWZ S+0%'T9
MTEE (5<&;]+)A^_.G'XJ$#241U4NP7Z?Q',P&U6WQ9[?$WC;1IP-7%G 7[_#
M1#2-Z)=X0X/H-8/L'I1,Y%- ;2[PI>$%<C<3^(<\R-TGKWH+QT:T@,GC5^+0
MP%0I[-Q,@7U? 1!L'MHTD,DNYI!(G"RV5>[O" 5I)G'LOU12@R^^HH!J@U-(
MX1@K?M@IH$IM<"4%=D8B5W;@J_X(P>1,3,@=?TS(4@A^-I/UON5L7I4^[:SD
M!-7W8C.Z X5RA4=S(F*FE671PU-Y'1!\&KSMIKY>2-8E.];X@BF]RB^$7WD^
M&1N]KJZ:?9X?!$6JB%?H*X ,K&(<Q(MM>N8F\/OD2/8%P+PM@NVCSS"/3[;<
M._GS>TLO;E1'W>5BK##5T(Y<ZA$]'J#219[0YP(2B?R WRB& FK/$P$0]M]4
M!WH+"&S1NG85PQ53@W2IR*%K.BIOE94K>+0..HZIOSF ;^B4F^-[R(P>!&Q;
M[FE%W[*0*.RUW.&A4SZ9?'#OI-1]W-R22'M+#S68/-8KA%?E=04^,H@EBD;/
M&ARAT^C"X3,S!D)L. ZB5TL6D>DFZ0Z>=ST,P2%965N(8W^S^FE +.7^C9B)
MD%>2AGG/&Q!7VZ"G8 S^ N2AP]1X,B/,C;#\%A.6K&P^IV-/ 3VM6R/+VQ@\
M/5 ^O_G-&/I<Q-K8S172</W70M5PI*Z*!P5$=PB$+N8E\LH&%80L_S+WO*OP
M(FIY#6-7"7*)BHZ22.AX-E2_W"2+!6_ "3YDAGV1"H+YHF(J J'+=[M]_?I7
MQ5Z/%*%(^YNH[X[YPE!OT\BE!W(@B.F#.>G.0V3;(&.'U?@2?CA>8@3'ZV2\
MUX,+-)1^GGO'->TYOTK:]@J]UHD6'>I,.)&,@<<$KBX*")P//,:RF'<)U+TH
MF[I9V37V.877ILGD7!?Y@Z0DS70Y/>T3J -Y$'7J_VKOS,.A_-^^/Y*=!ME"
MID*R+R%;1DE(HN5K9Y*=$,+(F DQ9 M%=H4D)!G[,C&VDF3?LLQ,L@XS:%R8
M&;?O\SS'<SS/?_=QW[_[N'^_^^@ZCM>_UW5<G\_Y.<_W>5WGY_Q \4@:-SDT
MI3]R:&%LK66Y8O-:EURS\:E;8;*M(F47[SP%AAD<5W$,H5+2U?,#-*GOXJCI
MB,N/]9H["Y@4MP] @#P;ND46G*SG*3V*B:\52^%#^3"]B^?)^RR7'O?I2J=W
MSN5YI3MW72#.C.\%0BEKX60T3N+D<(N]9@FAX+B/;-$R\A2%!#28037-AYT<
MOX0P"[!/]IRT##SO=()H*HB:Q[0=X390Q)<=V2_XX%3PD^?OSN/WQI7:3L+[
MJ(% @G3%^!1;+,)4?7QL6<3M^4;M\ZNFNX&4Z6^%$)2A <?^%1A<=!SO7DU(
M.8*<"$U#7!N\7X*M[^D4\[H[ZIH4BH'<3;[$J^8KER#*U/#V]..N\ ':\45J
MX0C4N^!Q@,_>]DUC0M+9/7.9.W !J5!^.:EXG<+]5VE&O<N-,! W)[6 M6^^
M($Y?>%C/&#^A'@&[,O+*/L&^ST;R82JXX>2E7LFWIZ)[BX%P(A@,?[?:29T5
MJTM2?&A^$U.>4 X?O)N_<";I)]\+J";N5%*RUL/@E3>/=?]]432"'J<O/4L[
M3Z_5ASI. F*=#.U]\_577--P)_:SV2 -H=,S;AFJF-1D,>V+\E1.K.*AQT!M
M(@HP_O00[ %H.*L0;$*OP?JG",.5\58E;Y8.0*PM 7B.VK=B%BA^ &MA<K]"
MR-+%@\=?JKVX7??.QZWHV.[A"52[ I(5L,?+?"(96@WJN13#IVTHTD-F[V">
MZ<+U=9O/XRK;[HJK^8?HCIJJ/?QTE(XB^$J:4MC0P1<O.-;5M0SZD8ICJ;.4
M2[$FMB8/YBGU?D'9M-1#TS5P@GG-U1IW]HOA0B\(.QUA]#6$N-^[AU):U\ \
MHVYQJC?\YF8\9UH[#(UW"D1I=@ L8EZ^]3C!?#T+;XZRU@Q<FC)J^ BGAMUO
M?B^8^)&598?['5G?;F^1^I'^:@WE=@"*W-M(?E\YMK?)4]?DFU W&!1Z]HJG
MA6,12XXXZ6J/QB:,)F0:!5C/XV5 \*QX&49CY?U#1^U!4WWG ZV1B"R;-%88
MTS&./Y6]Z^)0$=!R_,K'ZC7F)IFQFP821>0#$-6/ ND:B'D$C6\[0[M%^5V?
M_'M:Y+<PB@>(]54:,$F[HY!J;W_9"CI3_D3Q5&"G>*[HU@%H8IJ:2QE+V#>
M8ZF^0$]94E"7G>27/9FXXA37J43VUP8?F=H5F16^].2]BN8WJ'I[&+#G3MHB
MK@',Y/W.)D2'I_*VF=4]:.Q?B5)O(\:,@O57?/ DZXY0";G#(1V>G/7$UWGJ
MZ'B+M@P>@/HT&-\\#;26F[]%AJV-,/4@IPI8"H=1\X4%S&B:-$.^H97B1C/7
M+U)Z_9IH<61)3CK+YE.DI:H<2$MOTW1@ GM"+\A_GXOQ;?8,A0N> J.TE6I,
MX4H@(BLH[Y"6EW)&?.D<=8(30RJ]>!B;E/7 7/WU! A-0)YJI7 YI?ZR]N\+
M;]E6'8UI0FH]?T%K(.C@"'630<\VA9K61LZ8%\*?&Y).TD&I1">X= _"DEG/
M#PNF>9$9MHOTFGO50!XU2.]173J%<ZK/W*R_D:_R^:T*E ?/YN.K]%:'W/0@
M!D??OK\W1%R?$_B&BA>NSG/YI*KXK:@RS)FE*\%8LN);.<W[U'/5FU&:^<7C
MA[*'1<]G'I("Y=Z&BL'O]9@U#M?J!J>^MKD76IOCJ79)B8W_M*X)=>"R? S]
ME3(&*X8X">S/6[#9RHX_'."X7A_H]?WL6'ZX3ZP9-#-=J7?D10]7P F&'&@>
MZ[';8K;_ &Y\&\@D% C 4SJ0'"-52O=IY_$%G"MIRS&^9U)?7Q"^W7$E[>NW
M1,V-S4^&FWD] BBWERA/2"P4TY/$$ .^KC)4 5.!(,<EI *%F?[:<_S1R]ND
M*^GR@O<J$DU9F$&%SX*P\\\.0"+JJ!.,OA GSJ?K&N,TR= @GJX<K:WKQV]L
M]:@X-7.\&-:O+O#>V[(#8MXL,73(BT^"J'G^=F8),77QL:OA-I:9#0$C,B^_
M=^63Y/;$04C$W\5%2AIB%M-%5)<<DYH$RU')EGH?>]-?FR[9-U$2G5XJTP*Y
M1R:TQ.>WWZ.IPX VI1F_T='O0E0L)3$3H("I.ELR-8+K&BO.V,;NBJ&XBGSN
MDYG<?BR<+?1L#<J_8-<$\O>I&,ZZ%G2M'MBUP\<98G_V(0]-=4(5M8VXPY1>
MA+A.V>A!3208 =%X?P'<?)7 #R#$]_+*YD4U7:S:+Y$\1Q?;8Q.C)4G)UZI!
M\P_[$>/[1TTI6&H)/?_WDA]#=B7_Q-!/BN!@&^5Z4.VO^I!NKOMVTS6Y=IW1
MOV:+JY6.O'MLNF,Q,<>X680_ .T+!</H)X(=K&E\:(:YH?T!J+KN<$V:^IYC
MSJ=G(((I,O,PTB0!.KG1Q= ?;3L#>!/-+S0YO7K_=>A']^PU!]EC:U]9A^74
MUMOE1)B&6K'4;GH1[=(\2@2A!T#)F[^XE..<H*WV#T<]DMP<S_0A)Y6>^.*@
M<U/LDCO^[:<XR>$#N^;_MZ[%89S47F9.SF%P^I(O]$P-FX)CE10K*F.V$_;?
M1OT8$%@MH H]3&T]&O58/QWXO"\-5)D!X64^*&ZD LTDFG CQV\\)-W;23J?
MRG/K"C=AUL<+G([N8^%\^N[K,?9>'139X@ T=?C2/LI/CL_Y\.*\B.:LP=5C
M=^MO5??:FC[%6P-7'FM:ZZE!+SW="]7Z29;?@C'8M_#R<<%SR0RY6BL+[KE5
MWF4JM_[/?JX?)A-K(<64AXS=0AYS%\9MTU>HB8]S>X8:X:&DI'UC(/H30P4(
M(Z/P"U^%8+PMJ$=UR^\&1+\T&670/SJR3\>BL!A>X_6Y* -!@LXPT^%J+/Y^
M26L@U@9,8\IN!$]'W\K!7Z )3,_[I]2^28-P.]C;VG,M"^_<9&G,EQV'KBDL
M2S[B8 %%R%#2J684ITSRSJTQA@C-%DAEZ\S3G'E/.CO28G9Q3;0X[D17R]@0
M1 :<P2DH^-=+<;YG#P] \P6'PAG'&(.QR[2-G8X=[L[F7G6I:/<K<7GV,5VP
MHXH<#[K_'NZ*C!;<7@_X/&_]"TOC6^RPYEW%GJ3]Y5V1?P([=GIX323B<[9P
M0VKU!,F4L$S?,I!(GY]+S%XD.>][(BX#X?36=T 0'HMK**[/M/A>5?RA:;0J
MS5]ZUN>EK;O-Z)-"*;]"TN7)SX(+T%J+.*0<\LL!").)VV #P$1(7(ON/#3N
MO*%?P71J:=R<Z<OK'[ 9_@F-<1SW?-ONZM4[G'L_; $XOT=('?KX&/AP5P$;
M_US/ ^_L($<X$7=V1==JZ&=C@)2S!^I9OWSW9H7'T7,178;RUL6',<:/$DI2
MW#<%F DRG3QR<^VSQ\@<PCI6D=21EC9LB]+'W73UL*?G1HGH!>Z%EII<UGGF
M*'I]FP#-APQ9(^M%X#>2],^-Z+G@W[;T1VSWZ/B^*?%I^>5).G/O6<LUR[KA
MV#LA>N-M#)R3;"UE8*U]/H4/1^"Q[ZR?RLON*YM=U4G,3$]8N'FRPVV@][7)
M-'LAZ%C %G\$[LZPKT:EYH8%MCYYO7M=."H\+#/03$S6RNID^]&HBZN;X7AH
MM[DU@Z.?<IZ(;O>]+)^S*A]7/-K"<<)0>4I9FDG1A1F;72G:N"0Z@[[ER;P*
MGMS!Z8RGH+S\$_3/)O2TJ34#P?@(9W5SB''C^-FTH8C+6B^J)I_G8@)ZIP4#
MK:6Q3:"]]99AJC]P39^-=IQ<%?TSG:23E%>54^8H]&/\PE!UQJ];,S>6'7ME
MZMB\MYO^VRM:_AGYTYWB7XH[0>TG1]0,U7T4U&2-DXVX*XKO1H$MC4R-0 BW
M=ZAV[=-D2*?8@"B-!4@O1YP85=9N&IK'F!N:Y;"=UD.[=:Q_GNH:#0QY*VY=
M[(D]RM#TT5SV(*:D*&N^[/M(@'# _>;,FE\&'("4KV^^W)KKN^('=X9='C00
MR><A.\63=W A=FQHS-+#UK/]U[K\V2^:2F>]_%E3P_]US>P\OZE4.DP'X4R/
M543<I.1/$\$X"Q$'FC*0*8$<#F?)GK7UAB@-R=2[.V0XR/-.:!TM<\[>RWX*
MVIV"3/K; V@BF!N>0C1.PE-V:)*W$V;D<7ONS]3[E>0_@(3Y7V58YQLQ3GY]
MIX:\<<./,0ZIT:_9OP-7@*L#RWHR>"\)V742:3LR*"!(P<\V2/YZH7$>VO/Z
M@II-=.3&<TNV%-I)P) (BSX L:TAN/R)K>=M?"6&N'@@=UK)6_+MW&%B[E>:
MCMP[[EW&HEJOB-58@-14K>D>2H@!0L%3/=]2Q%^.CXA=H1#/<5\-Y6.%9F_.
MJU<L#?Z03=J2>BDI=V&S\K'\ZJ-SS#]A4SY4(0H;29L"QC'.C;8=:B3GJMCW
M$K['^FZ0-_F\LOC:0\,^OS@ !4O8/"[UYRPD-*  >9;WE2[[?-/M[U<TF^K*
M)5I=95IK:C13KZ$BHLZHF6)(W<A['$<3F2-W7B!J]_V1_5#> Y#W!FMIU,.\
M4!Q2G-SAA$.."S\8T/A9):K"&8(7#-76<\TK[_UI>13*K ^F.9#G/AV V)?:
M!('F4GNX-]&H-OSJN)XJE6YAEC1_=?-5GM_K9*-;G3(Y7(*61;^Z'BVNT?<O
M A[4(/+]/1ET?S]I@3Z\(EI7\Q::%5KFB)W+MOI]\?E=<)G4),"!AXH ;/BV
M>'R*B*-G4TQW@K-OJ?V<YZH<!_&IJH@7OT73Q%]+)C(7=:R++-GZL9CZ->-"
M&H(2&T.<$>L4G@,C93Q]Q6R (K-X-ZG37Q2^I[TV*,Y%?'EP+<WZ:;0-_07-
MAY+6<VU(7Y-VO9Z"CKGO)]F<@VMBC55_&RSK<K]T:F&KV.NXEKX=>[?!:F3*
M&\]"L"B]%.JA=0#RK(K50457MAA!HX9Z;M>.5&YL3S_8O'R79Z'BKMK:J1>G
MT>8MX!NWNR U<UW8N-DCC0"*"$ZT\ST /:F:%VK*8V3A81]]K,<6SYA<[UZ>
M-U_%Z;2GIS^67^8\QYP\C(0<@#JXR.,69#1N^3Y"F37+YV1^_HZ5;[@ WUOF
MEYW5F?==UY5WDF^L7]K=HMK3T<$;D_X]3M*48UD4,P:_".*F>I!/QJ.,Q^_\
M;"6,CZ5)?U)M<\_,5:,MRCU0_5TBP+2Y2#J_SV-((1(&8MIDX*$]354XE/B2
M9>6[E6S?AH+^&-L)4,FP#\'6.L1$;D+.H.N14,V^ B#?5<"\H2\"S_.GF9?
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M*:< RU^?/YTTE7H&MOY/];SZ'\Q_P1E,?_BO0A!_ *K=Z0"ST,R X\3I*G[
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M8]JN9?^:8??^(\M^-^P?=J$!=CH:T'ETW  4().RHJ6!K&@E;0;>V"^Y3,J
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M$2V;_T0SGR:T>+MNAYKHDV*X>EV?^UK1JQORTX/[=+C1MNJG'375KEF6T26
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MSWM+&BSY#C;C\]7HY:Y;#@(>7U<.11W5.N^_-7R1TP7(C.W3 U1>RD80W:B
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MX1PO:#HT%2\8$X8O!9U&ER9E%RA\C>)\0R.;H51=AG&0VCY*Z<\X0)A<, [
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M**MPO]C[ P8D>HMQX!9"A&M+/A3TD3]T_<8@,1N_"(F>Y%!1X+([VZM39!O
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MC914;4DVX4WS-!5X]R$;L0,H'6[7GFM]33OVA)R$" 5WI4E%:]@&O;#=/(Y
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MKM_O%'#)^1ND83D#U'PBZR44XS0+==PV0$/]GCJ[^9(*^T$9C*)'#=A ;NS
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M>"&'&)?;?L1H ).WC3K\?3638TZ60TO,U=M>0Q:Z) XZ&;>:9T"0-4R9,+3
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M4@E;[?[U*>FE'CV+;0LHU(\"Y<$[.2)/UO4"UZ(!NQ\O,OY]6#.=R2:'%]$
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M' 60SY$$B-DM5&$B)+XZF-,N'KKHH?XR]?MDZVGXP[,+7+,A6NFB%S\>ZI5
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MGDN D:VH;,)#&N!58D)((O2!SL"/+Z2N @/U@N_.+S/PUS@V!6&A!2MCQT)
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MS<K6"B]9*?,KE8V22/I66K.#SK+]+>3ZM.]0X?7RY+E:,N]4,YBO\8KK+-]
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M](E $2;#<N)?J@>?L39P6Z:><MI!LO>2$^YNM &"O)./[I%<;,.6IS+O*'H
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M-<,"WNFJ1Y$_+<2/U#E)E8= BB^"<F;/W/@E_'*:BCDIM/BM0QBH*N='/0)
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MFIMG61R8@*:6M)SZL;HY775%ACT5&4G]=,:9I#80E;=U:75].GUG6^$0*2.
MH!# %AO\FK+I6B4+O!=#+"HTEA&R'*O]C45)A&(I3 \@9>C&#-0=P0PJ3HX&
MS;@ 7Y7JPA'@GR"[_+D[1MU_=W]E^PW]7OA>@#PH]ZZP/<A]!,T@22&U!D-
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M<\ ,P-7]\_]E?\\0JJ5/72 >M3KP7<X\1(GI!3:%4(]:0IXZW7AFM>W><SY
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M=]6NVK-V=Z_NM?KKM==L_"1^$;CQ1$5=!2 @( !2K@X OP3<5O:VLP8 34U
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MDG&)ZR+I+5R'R!FX)99X4']-^Q?+_FN&A?QO6?9_&_8_[9H&* D)KIQ'2 -
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MXL@-45S/)SB6>QU%-2MGNV0?5QKI&\H),JS%/<B\/\!/>&SB)6$8A>M"5$M
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M%TZWVMC8!]\*H2-C^QOE= 3M@XM9$3J6/:CJF.YA1^:KF>*A?;%"*,IX-O#
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MH;V4Q?"8AYB3N#M35T6ZN%BRLD;JO.-.F,MHKA5273(=O\M/>!7C4?>N]/M
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M!MG/Z1,%Z<<A>5,*7^:8TL_G-2/LJZ&;-3%$MM@^<IO* A-G8YF)H4/ZB$O
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M5F3U]2RRC'X7))N;;-5TKX.BC\7@NK@SF/+&VN_E]>\\JH8VKNS(2VR\C6;
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MF.B3?8Z2A+=\O0OFA7:Q%R[O3_Z^:#]ST.<4^>Q^*^KC_!>OG>^77\'182<
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M>@-)D2!X8'1SI0/1OKRP1]#1JIK%K[K&)$!CC@Y6D2+FHT)]L%)WB/@P%JK
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M!65D76(7-'>D#U\]!K!BWQT#7G\DZ2/0O>W' 'X0>B$$^,L.Y%U#5@O-Q^H
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MGE^19&VB_<4$,, >[4![#]R*WVRE;K=E;3(>YH%8,\7DF5:. 3[Y"6VKW<>
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M9$F./$O>;E@/2T$LV8<1%0^[2;B%R//3E'M$QQL].^H-'NF;_7L/@XMW;^]
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M6?>%^&($>MO$U;;L S59HI+B[8Y-CY[._%+3L&WJ]ZLE.+R&S1;:K(.-B\7
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M'1UB2,D$Q<Z&VK0%\J!A9V!0%@?"+'&[ !+AY.\8\WG;<Y:]EN7A 7RR$%>
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M4H8PQ"CYFWU8Q2^&5.?JL'56P"5&EZWBVE(&W//M;KTW6E"9>]1YR5]A#-Y
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M5+^$+G$ZSON>H"0JZ2>S$M*ZNV'%"SD2+L EI?OG%R,E._+U)0J^Y1>#/3>
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MC((Y;M T\#^SF+D<WB193+G(R0W<,%E/H=SRKD9T9LG!2B:]5H"@S32:KG3
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MV_1_0EZD4U!< _PB_S@V?]QG56P$J_] +.<TQZC@.<O-FJUG1\D2 ?1GJ.U
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MU-MK4N@:</<"%K%GY\@O'?3A4YZAR1KQ?$.R@FJTO6[DAR-5@>\3A:YUV.0
M'Z[)=_4-,>+PAG/?#Z<E3NT43H6VI^5&12-MP/E7Z[?&PVW>F#FT'>Q4Q:CY
M)!DX[QJZIP)96;ZF&UF:+;P,XT2LFOMR97]Z.SZHFI7RXX.CCHG"R.J8'%*<
M]K;>JE'3B6_=-:#E=RISK%H35K=H.Q!<(QL.CF9E/1A#^R<?G<\;_! 4X]07
MN<!> ^YTV5=3V<OR5B1^X"8-+R'YZWNF@]Q(42Z E\UBA6 26BX173O?V2B/
MNT92U+]=:8\6#LK*?+H!<_]+8>M_E=RX^<7_R_Z5!7^.ZUYD1-$X3MVCIWE?
MTP-?O&_0>0VH4,)3@SK2RJMW\Y> @5[[@6[>3F2P87R]C!:*R?.3&/UTA/LR
MRNN2:VO,-%!?[U,$T3[XR8T"WB,LR>5/?^"(G3R7\F8(5(.DLVV>.6I4:V^<
MG\;(.(>M?9%1ZP+2X8T^+,^I=BF7CE@-'Z?(E*1B<\2#OY@^GY-Q\3Y%I5P#
M;-)PG)/AOB*$P33*!LCS@ H'(SC%.OMGGTJ_ 0NS:5#]/FZR O[DH+-Q$3Q5
MN8+5JY@TYQ@3AGH?5P?GV+$?=A'1\<YBP92$MGDZ+$G -> C.!RID;T$IIFY
MX=']L_'!KIFSKX\*%45W%%_UQZ8FIE-H5-Y TS;8I>)5,EX,*Z1_  Y<'8+>
MH.3?IL^:,CHQ_(D!>O!?-?A&0>Y]S3LX-"A(EG(4VF?BJ3^H7:'6;?'\TVYT
M2E'SE1=>\R!P)Q?[J.4: &@@QCZ=;&OBF2R2YBR41C9_AY+S08\>]G"PAU#]
MZKL?H0CC:%:N:&3#='5X"@\RX<"=.C"EEFW[!&W8QZ,W-1%8:GCGPP>CR<[A
M%40#>(>K.EDA^+VK CC;4KC:TGJ@8P,-9CNMO$-:LKS'AV)>"BET%]@V"G6_
M!E2+X:EI@=,.[:R40\?]LNHZ^EB.G'@;>S_>J"CZY3%+@X'F2OZV/LV9<HS8
MMP:C@S,U;&X @1VFI$W9YYEG9R J0$W:.P ?>]?&OOAME&9UH7I_)_-2U:Y)
M_ ">8)P; #>R<D8]FX7DVM)INH4!09M4P4;N1QN-&\1;@S,FIU.XEDL!AU3F
M<;<T  YA?"";ZWR[L/NB(7K+1;HHO3IVE=)_EF)A@]P#7-6\NT^QDW@I.X4K
MK3BM&4<M?[F*E#B$M\\-CFZ")7TGZT33+IUQC]0/8FQEA4=\V6%\WM8!I[RT
M6_,#*GI1^)BZ3]S;1ZSXR61$R^MK@*4FVH3 L"9_#;A'X@\WRC&5=WBT.6R;
M0,=81/64J+V0[^]GQ+>1+R"M)G+<"#BHF>Q8Q@6F/P_1'N9C%, _JS=0-P=?
MTF^F/AYNMHZ\9P)+@2Q/_/H=;A/QXN]'ML@Z.?85@[Q_]0'I<B'ZLZFZ"$O#
M4]MK4>S8+%=!9NW*W*X!;I.'9LL^;^<=JEFA1<&, ]< 6<E#AXN)&^?ZKG":
M-G4-Z-SRW;8KLR&<B^!S\')UD9HA.,_H_J>SDM^G?&Q7G,P#ARWS*\::'HG)
M'0P&[!\W5]N/F!HK)E-PXYH:0E"NQ=.VDR%U3#RG9<#DYOD_F]L&#4098+CN
M2)KFG).-8^[5A_-7^'[75%Z<5AY,21>V[ QEC+H?];M-WS6RWC?03-:VIX")
M#C^(4VU0#A>VCTKO=)!714ZJF-2+A".7FL?*KP'D"K*Y-DMF=YB\^]0B*U5K
M#>1&MYS?'C")!:GOH^.ZIXP,@3_U)='[%EY0)O<\K6_Z#>6-$?,8^L,=N?>2
M$Y/3)8_D:ZK]+?03:V3C$FSRNPKFE"BF<=4?ZZ=V/_H<F1BXE\L_6+4ROXSK
MZM-C#.8EM]-Q28WCL9%?5C=>4(/(RHA*I(+.;=F 2\;F]VO'3B#/]OA"7_?B
MWMZWH,F&+"OAO+.8?F;Y':K +!/(.RSL%RB?30JGG+J+#<=#CF[[AZ"&OH9@
M4EGUK$JZLOM4.@K*7,[IDMH2C--"C$V2<KSCPX(\6(EV'*JP=(%PL:5]_]]7
M9>N[LAPQFBGO5U^=H7@;L<)-G+75$6T#(5;@E-GC#K6,K8<P8R,(&LO'QZ=A
M*/97KB1$,$S8)EA:,LDEMSH1A:#[^=&!7D[@8,5=9IND@Y6F;E+DF5,5YSL0
M+/$RHRZWP6 8.4^Y*MSV[.A;S61:7[:YG?&Q-<8:#>0_\ED5&8\H0IH&'+85
M")\_'VM<NN*6;\3^8RQ<_4B%XA;_#7&O3Z,9V/W(LU1NXNW[O>>L(#LG.KM"
MD.\GK8Q6E&0U,MU7)-%YJ>\:\- X:Q)=E^JU5Z)\I,(QJ!AFQJ4BG^_2UWIZ
M*ODVS0JYFO,A=H.B6F30:/-B'N5X*J0>Y/$^7OJK\82!02I3HL6ERZQ1ZCW#
MGL=7#DIM=9:CV]KF/AES16-.4$^ B]2BS866?L6IXK&M7/W?-S@KJ$5F4:A;
MF6+FFNF8ET+XCU_7@!'&6=2M@A6]I%TO=5;"J^&U@0^'8<PA_:.5?:'<:@&5
M7U?U/[ZVB'! QBDQ,&&X7I/%WZI"A\QT8^@"SM:F [226;D5KP%M9#E*U!.E
M05E.B56D'<,<-7R62/HE\B/!ERW+R,D .WZ_<S'R^[')BNP2I@856YT9[P*[
M<*P^] -4T&>E2GJ58,JWA7FFJA9A2W*[YCV7]XUNPK_O!.B!;Q][C#Q'*>/[
M8V(' ^(B'*T,F4)U34V-IZ5U6]1W/_%-\Y3+^PY#9KX3J425(0S2-5!8;_T3
MAG.31B]#>./KI'@VS"9$\SE-1$S8$DOBE<8TQ;%A L[]2#NR^=WF@@SR_LW-
MT8C&CZ]IJ@#9"F)KCB5X-7*ZYE.4@W;^/7FG#Y$07VH8]>?!2;"6HEO]PFC3
M3<;T\^F0* !JC:QUH2RA8]NTRWFQ$7:W.PPSNT<R-'EB _OF52[$E;>>K,/&
M_6(VO)9^>94 W; ZK_S$O'_+@,M!YURW^2I&E@/A /FVM!_"RU#KB::(:]8Q
MX$5\O 8PF:*ES&!*[=JF3\2O 4J?1!"ZJ<8H-FD=OWR&+I%=M5!G_GG;CI%0
M+V O!^J2&BY?$3I8?A 93 SEBN^"RF7Y=J=15\[<8R(\-+._A[E$/?LUZW#Q
MY\/7/SD-$BB.'*CD2+T2E'0 .430/$%,4V"JRI>F=AP;Z%!2%CS;]JY(%,5.
M(5:MM>YC@RP1]MD*%E^ <G3&;U]T&9XFD^KK()=^H/@LAN(]M$DG0/% 4L)?
M,%7Z;S/%[3\7#:XJ?2VGUMU%/N!37>S5<3_[P@.1]8]==[C=@6,&)Y\,0+SB
M?[+TXTHUBG3!KS)35*1JTGIF;Y _?[OMD$_:'U]V!413L:/F2;X(_S00\RP@
MB=F=0(Q5:%-V+\LN/7?M<@5/ ((-LN_G$HA-<^)J_*K?(#@N@#LD6,8)M$.^
M-!E*A2V5371&<U.SZ2JRB<VXKHND#4%)WBM&Z6A(C$,22HVH;XQ^"\*L'X.Z
M+'PS8#2N6 6*-4)\W ]6UOMP0!(TE[5=-9.[K6-W#2@%M2]S?S^(:'9X0D]4
M+#5Y$AP682?*":E9GZAC"TMX&A9AD*C[XWPB\/ 'Z,,U(!2I[[]V#6@%%JH(
M?78WB=F1:<$4VC>7H=KG^-6J_8" [1P5=@KV8,>9EF.V;(1!\3_?%H1O4Z;^
MF.".%U4>,2I*JL6G3A&Z@-10IC9!G$'[1-G7P](J*?OU4(05*J@*G9+2@6J[
M!E"J"W,1E\T ?W[MP:LC#!CFQ=/Q;2$.+V,B.9-=N0I,)T"Q5^!3&USVLKH<
MK5, X:F_KL6 **YK^YTIH;OY4?'QJ'73/:R052>I41BKSXU5K7JR7JX%K5&%
M>7[Z=&37<U1^KAYZ*H>K=75U<')=XO6:[P0UT4Z-5H*GGV,L!4Q%DQ9W/5Q2
M"IY5\ QV:25CP>/!_CZ;A8SYLU+>^BZ=*L?\E];NI?CHS;0R1.=,82WM?HLY
M1[CA(J6#O\C%Z@V:7L238L&MO$KMH[A8A3'AYLKTP_"_WAX'XQ<C_>ML_-79
M@G?A7UMT3\Z])@031->%RSGULC!]+YG;*RXLB=X@^#7M?:P]AZ=>9(3<^=^_
M1)7;?,4P_Z3FS1#T?C7^M_,U( )YY#1=WL'H&+U8'\2'*MI=,ZDUS(HIB"(K
M9=D>8_=GO:/]-3.*QJU3;O!.C4/S=.@2H=:3YRR5?.AY7-*S^6FS)) _ -I\
MD++1?$P[>@TX>(+H3" \2J$C^-4AKJX!8&R).*$'3/[J&A -;$O#W4E;NL'Q
M 9HXAVO :U @XH <U/I%B@[;%(98X\Z]!BS> )]P(<(C"$T+".WEM;>=Y'\-
M8%Q!+,42&*\!0Y%+"WABS8-, @-H"75UE\!R#?@C? T@!6PKA;EI-Q]2C7;1
M8Z#,OE J6+,2;\66E_N"8LH#D/&-<O_?5M@"=EZH<>V.\?A:A#%]7UY J88W
M@+-_ZBGFYYY_56FI,<MNJAW@3OJ?#Q^)L[P9:CYFPWG<@.11_ OBK&JL>?0C
M42@Y)VPI'LJGZ>LZDDS@&6&TBKW4T9QMYHJL*!'8#OL7W;N?=C!#^(YX</.U
M&1'^P(.>FPN(V% ZV"<0Y>+>D:B+A;HYN[&;R6L8 5?GGX,39H\T0CL990\U
MLG,A'P+^;A\!36UH;I)EVW.\R#7@%["M^5_Z5<(+(MK %Y1XJ6O %SL"-=&4
M_#*$4:3K-"<%I]% J%C##H0HX?UO -XEH7G9U.E_FH[XCZN]8@G$<UR KF[?
M* E_%XS-*X%[9LQTL*>AX\E7?KG<;CT&AKND_<>CZ]+=Q"UPFT/-:?57O+C&
M??NU86+%NSO.^P:PKYB%2M2NPR(X#%BNV4Y.)X^]'3Y1:6/%)9)1NA!U5T:1
M^SP%.U#N+(WT;SPI;N!EWIOE[P\[06ULGZ*NOOHRX.]=)1,>P[ZU$5BJS.Q]
M9&TNY6GF6.6DG4>:D\*)M1K'H>HJ)[R3T>S9KL #\K4XTS<6K+K>T^Q6G")#
MF1GF"!N[XI7S;>' 5=L!.NQ:KNS32"68_DENC%WD_AU?/9;(H[S]$C:($6&
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M;PX%_?E/$WH8^YM7"5EMQ@GTJ#9JOMM9@9-S8FWKPW]/!&8[TW\#4$L#!!0
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M6DRM?!U2)856O_I>(G3BZL&A^?5%4B=L[>&J+$2L=4MN[/QG@0^4ZX/P-^2
MM2,QBA/99PZ7D5:HES? :;KAZSVW=C"B,DAZ+/!=&GBEYW]'>WRLFM7'6FU+
M_H]!UL>3EKJ]]H^*FUQSURTWH)X!G!BN1M9\F3]JGOUH=<ISL@FI3'_4'??Z
M39/YXMIK-=.EFO*'#8&D:=;VIS63FVPGF 9-\9:Q%/>\N34_,?AT2?!D5M8Z
MYJ&)@'%QPM;#8K6->*^;H+SZE22T%AQ)<%ZN[3!BLOX>U&5WJ;GVR6L]]<0^
M1:WO=1^:VNZ5W4?=B6(_ND-E.\ B>4D;BS-SL%";M$Z^DDU"UYMKZOV]YYXR
M>0#X*^K/WFJM_]_L]0+I[+NH"!I0A8C#SWM^G^FY4%ZL.E=1(XU<-ADXFH3@
M! D9&QV>/*&O^1NMQEF&3M. 9/V?".]#7CN?)1#S#,E)Z&-277.=QFI]0LH%
M3S.KVU_V'?LM%-U _-0SL/$4[0GG3"OTG/X=CF"IU<1!)\.OL(J_5Q.6A2.&
MO__6N^9.1[O0S,R]DD\/KZ\X]S=@*/QE5F ^GS(^5S!?DT[N C3A3>TUO2L\
M%UM!JGV;EY D>T\0<N0YP9-Z@H=ZMB6+8TAIG9B-<N SJ,Y+DQZ@]G78K8&;
M40K(#G82F1JI&(G$GT82!/[C5\%]4;5,<Z3G,W(9A9F%: RJ)$_MK%*NE,6B
M_U:0Z'"0D9Y+\^I1KM3^AQL0T^&(420'XM%_[$E ]GC^ZNFF2I!4EPW)99%V
MLN/RN,OGX@U=99@O (%C.Z^5IY%M*DHFI\";!5^/$[HSSH_9\_T\(31VMAO=
M[*%KV1S(3%!<:N[IW ZUF@P"I8"(U44SGM,(HP[18M14+-%AO(61(E..'PU7
M1'3O@%-9YF?_-&(G:SJ=%AZWJBNGKJP8N;I??JXG3U3KLH@_>#&Y N[6WQ_B
MH2A-RK20PI>S/=SGV >NN;^Z=6@LW/R4^L-[G7J6Y.PQ38_?_'<D7K3V>%YC
MOI.P7KVQP*]]P@W$U\3US04C!@]6_.K(Z;5S580+4P.56=3;K W$@UOQ?XDU
MUWJEG9P2HLK/H38@&EL9D]ETJR28' N8B" 7]FC L@L-^(#L N^9:MK3 .08
M#0@O[3=A<8L#I?ZT-W<>]2BA4O@4EW2^RE4F_U]:9E/I^;T #1BY2P@]I@$F
MU L-TN**YO;[ K/+,8\D?JS2@/_'A[WUUM'^KS4MV?$>_?0Z.Y$CY7.--VSA
MCOMDQO7QLL^OA(X/+A[A&!L4>1#C1Y@/'J,+7=,/FQM/Y9M6B 1K9\8O?-PV
M;^U2<;%8.1M_J>%[VPF?@D2E[IR1K7EQ@@IJ>5!!8TYE1:/(-?E5@Q1KT:)#
M,[PR:\-R :#<5I97_9%\J^XCQ\!IQ.,*Q!%YY_JFW!J*>X/8<F$$MUV\\J1D
MZY2F1W[(R>^?K)2B2NV^OO^5*3'^Z3_]X>"!L2R+$F"JZZ4#L,1!A.C9DA7\
MC&12; [LZ[.X)],))T;K12R>9>FJ[P9!7)U:7M#1? RBGP\QAN+&]1 Q1+CZ
M155%#QRY\2WZ:F^W'Z?7?JE$CWQN;,< VY-J4=_9S=95D:B*ANZE>.^8?FOX
M4) V#XP&M*K__ *>OD"XD 67^!9D8-2(-_&U053/6<$4[0C9V'8D:\OYV6Z8
ML%CT!"IQO_6E%\25VHZJV$H@J\//U9:7-[G?GB=Q-%<$>U[\??B9DSM%>:O\
M9EQLHKG>]X)V1U%CH4\NA<;P0LPGU.\H+YM;G2)'%9V/.@O=C(D?I ^;30:C
M98C,) Q!@EEE7A#_27Y^YT:J_;YLIU,##6"CBT"\>B EB)2PK'.T]2?YON\M
MDN<=",(T8OTHCP_<D<6\@UYYM>MPON2%D0%R9I)2#"];0I+.@]_#E>W/SKDU
M$.L5D]J,]@H75-0T9<M.>?YB>@2)C,WI\!;^Y?X\9@D[M_M&AP2ZS2!X)*.I
M_>)^_>DKTM(UT/X%HNG80H\WE ;,-$S/&9N]8K']_% ?Y)>OW!/1]_)Q8X"+
MHL]<0)'W<-OJ8PK7I-@K>/_0? !\T(0;,4!E'GEQ1@?_\U.%;J80[[[RF.L"
M9Y7DQ=MM.5.ZPGGC)=^6=S[*KC*)*E^0:U!Z6F40V*-1I%KDN7VI(]=JNE2Z
M-EBO@CW%/9LIC)YTMN@81%RUDE>Y[K_U!H6[<QPNW+'3,!DDU>QYYNEWD0-W
MM0W(>1)+MR%>H\M*,:)*Z^2JP>B%:'<?%U_W_M]?%E(@_2W41"&=CDNUXY;*
M!).EP=A.%(.;NO*/JU5^'S^UFK:M@Q_(#0Q>N=2DE2.^&E-. Q13UI_?^/!]
M7_+BS-20@1^FK'=LI'H + !ST]B **S/KTBN58*:1/YJ5^]Z)"]Q!)'U[I30
M@/8OF))BQ.#O\&EK;XF'VS(_NBE8=\OC,.W+<W PH;0$7]29\,;/2@/969].
M*9.ZR:IUE'I4J7F\OG=%I'?\:V$N0;&Q?M7A2FFBJZGG$A+IO'OWP=T0YA^7
MT@-'U<VH _P\^ZZ'9C6_]W.[602S6-["/8Y1KP.MEUO"SQKY.'L6V)QLJ UU
MB?'N/:S0"O8/HK#CH^<^^!Z("4:-?,4QQ-=!(L GM<_"&I<%2POR8+%Z5>45
MGS1-[U5XFN\M.M27V8Z<KJL973+LXX,&/Y <EBR&?BTZ<'!R,%GV!RDA,*AR
MEF#E6,8Y-W7CR+SVR8_E\;-E?-Q-CL?K/<?):'M;[;$.7(%X430/3F0'6_[<
MTG3![P3"?!M5]:AF&[]^Q/9ZRN>BPMF+ JX8O]4'B)\'*L[M4$[U^],OOB_J
M5R!Y*>OC^9OR@0HFEP-+<,.K?X[CG6IH0"Q8G)0G/7,M"W3$]<82%TAFV("(
MM7#-NUC.*V!\(EGBGL?/O/)XRK"V@]7$8-ZNI'UI)3P>+5-_9194J9MX4=?K
M3_PPY3KI!OG</*)] :1Y'GO,MV%1CB=F>:F$?W,S?H1T;HH/MOTE>27*F&$-
M4C2MV+8@#HO4KVVJ)246]'GZB V(]\APYCCR[I GQ!7?J5OB1,F7-^;Y)IY%
MS:PGS.O&6'Z6Z#O-K=4-?4=W1&YPKPFEH%+X&4).F7!$D^"-D%\_$-"!.W6=
M YO2O\!BQ/+]_.C0ZH2FI>Q=VR%5%F,UUP!E_("G7;== =ZY>YH3,R^9\( @
MV'GTH93PV3&VK^Y$>GWOD'C]$:84!B7:$OA<?./FZ.ZJ\V/%W<PNB4)!;A:F
M/[C19FF;<9S9LG:\V/+<8^L?5QQM]JW6@^3R=-GW>\O89O<%8R5I0,C]5&\R
M#9"$E1\CX2B*T1MT)V0*06Y%G*YK"-GM%/N3E/6GO3B^9T4N0QO^EK4/-]U2
MN(B)I8Y+R1+T0EZ3GRA%EG&=3T\-SKFM,73])^=/!AD6D<)<EANOOCJ-FT_%
MX3N(9_&XD"!QZ&3V@Z:XJ.)S?S-W:_%KMN PM".(:=U*W'KJ;TW#B_Z[X9H<
MH0]O2'JOV1Y\R&M)TPFN9GOAU""] KU_Z+R6 =4UW2DG%OC=_S:5W=[$3#X/
M\[--W=FU>:=L8#X])]@S(&*GRN-M54GM$3,*7_BZ(=8==.'5UTD=<]!GY;\0
M'C3VYRZUY0_59Y@_[MZF[_#A[K)JQU#X C=%^)N=*T(A[8G^69G>NLMCU[#I
M3QE&6UZ2C C0'BDUPA8J;\WJ];1"EMRG^N:P9P:DWVB9?)G,E99-4CU!PX1T
M"[]M1A J+":JO]!]DNB?R(B^T42/Z\R5) =7;/1+DE[[=$;YLI';P]3 8FV[
MM9S+OJOGO!*&E-<67PJ6G_I4T$Y<]WI6_OIOW\7^G@F4 %62!%J,_>!$ '?Q
M"-BX%7CD]D/T11T]^@NS;\@P$<JZ%V;DB&:D%+(-'-9 2.Y8"&[81P?#]32B
M3PN%:P]GR[<JL![J;T0<&Y/.DT_!BH@IA)+\SMA82RZ_*_9>>21KF<T&B%<=
M$N9<R;L3<1 ;)51KI1A#X7#/GYKI@7+];C_/\98E<;3Y,AK$65.V57)CQG+D
MC72H<'"2"JCIP&&L45OM.)P&/"N;3EA";2XLI6F!>]050\[55.I0NR:ED^XX
MOSO@26+%_DK=?Z*(?N$)<$5#\9@NWGS"+>BK"O#R3^; Q#S-T:GN,=F8V^@K
MDM&/R[1+W=4KO0M8&P\E/^V0VB]=31C[01&GVTT'8A(-JD*''2G'AN.VFMB[
M^_1KOC_]/AL]N+OO0 /6RZSHC?3H<5!7^S(,LAA3((GI*). /XHEWXS[-CWT
M@KGN%[KQ&%MPL#:/O@OVX)FZL[3=P\,X#[6[A"]-+G%+A9OV>'J]#,XXORO\
M;HBLMUNZN\BS25@<FCIHZS#"^X7N'9_L7ONPT_'BLR6<(2'^3:O@QJ.?WU^U
M%BJ\7Z&V.*-,Y#OU!-8#]!R68Z<CJ>P'6#0WG(%PEXABHIXA&3X*&;OB5IM@
MI=R<Y@%):=>WEM1C:H8KD[GI,W;4/OT77/4EG7JA*75;9U*QZ=A8W$?^7+:'
M.H(1[:-]D2([3+T&8S'##X4ID12K I\IGEUG@20]ZE4#APGN"F]6TH 3PR0-
M? ?6.<RG!-1V]+PT>VG.VCVJ"'0E5MY$@I[GN+0ZO7E]9>+,PYBRGS0@DM."
M1?32R"<WEQ<P")6#'P^VF6Y(#LL=_JUEL=6-#2+I0BN0)%G5-A"_B["))U9>
MBJ@HFR :HS\0:Y+"[(\*H_+ ++O^6CX<KIKITCR%C]BA 6$T &_,$X0\]=JZ
MUT,;1/(IS8\JO$= ]_:@N>PN/W_WJ70\>?#ZJ%=7;O9]"@6_0!%T7C*N)>L_
M7DNJH<JY2UD$@"I3LG9^.UQX"2.'[I9-EG'.=R"79N0B?2Z>&,[NSJ_X>!42
MAQ"D 4$^/K$L<+_RYM#NU&LES7WC9\,?VA:)/&,,_-F$V4 %[R4-:]YP>/:C
M=/+C.9W0.U4,J1CEDN2AY'75,;V7;2-=8^C)DM+"KBT)9/0=][R9*?UN-0==
M[_B;W= ^Q#7J')*KA0&6:B33.;WCBOD>_;.$,PK UCW4.,)$4D!T'1N&*Q+F
MBXKO%+F9KLDY:P_<=O!3-<4F,]S":M>5WGN#N)"CE7-ZT_O9]4UF]L)@JP*#
M/>U^0>:Y*.$7FG\=$CR-!M(M%#M X=/@KFU6:VB#Y-!TU4S3Y]QI2U]N]2LL
MU6_HMCYM1UZ$=',Y==B8IQG4C5Z85)IK-I>?N!OF/5OI%?'[DY6O<Y&Q5_JC
M[$+GNIJT%SMR2E>23-_ZQERZY<I* Y),CP)'(+RD56(G8?5]E>'*N**\^_VD
ME:V+K<C9NUA_"?]@Z=P7U$%PC53N,BJ2V/ "(5M#L PQ,X*6.!W'WW6_%%@X
MTA-BKO;4!L\SMZ&?O2GJ?N;+$RNU7@_62S>^SK/B/EUV^Y9=$64Y!*XRZ4;R
MP7RW)*$W"4+Q#?<3[IQ,<XP\D_8PKNZY?53@%L.B]^"S=;28]CF89P]"PGJ@
M1&'#8O)W%#BTQ,)H>.8/O,]:D['0^Z#E[3#+^#@_1'Z..HY0'X9;$YX-/:X>
M>]$37%RR.HI],),V&*/+7+_N&Y/H1Q0[SFG2(^1MVWR?/!?C-(9[6A]CP,3&
MU%_<94(^'<7C!AP]CCK(%=SU"T$HPWK:%ZI]48MSW@_'?#@"O11*&5M!SYN\
M2O^VKY*^(SR:+R&GF:CL@LYXT+)=]E(-'AQ>C<TMB4O=Z=<7.H6Y__#<X2^)
M))&UFR =TW3,X%6ZN>I?WE*Z"Z,P+1<H9WN_\3BZF<13U2G_Z7J]!A$GK<4-
M*U7$8B@"T@],0E6DI/&XIFD)==?*ILDSS6<RQ /"!5_Z\ET[N962R5/QK2S=
M [GXU>I%!G_5^)XG*RFT,Q(FDW2N,E[051YKM(Q=M?]@G\ZTZ]4KN EA:KEL
M3?$BF621*B;[-TQJ,?)\./E2]A1[SNO5-?'7M+XQ%?_K_R4Z@*!)IUB%B[_D
MQ.\/S+7A*)2]I=R[XWP?F5$$&]1,K^-2-SH] EP"P)#O%)P(P?L'$0H'RMW5
M9U*OS-E'85FU0I4GN!-12W-:KYN%YN?!B0XW <',DW*EZM+ILE\CG@J8VJJ^
M;Q&;A7T,SY/G:H%IS:P9],EW>'^IKD@Z,M?/=A5)!YA]Q$#M6G<>,N3-N+5$
M3S:+W\5W9;SSK&$U-?'MN5 JOU]O(:>D81ERI@=DU6T.N:-C4M^_AF11(FL[
MN2J(UWDD-C]?XE(U8>JO#/::9:_S7&0M6=6I;I#$HG)A0^'(Q4P()T44"SGE
M8E73R!R]&NQU7++B+ 1\>PD!"%5!W?[CWBJ02UI9[M*W@G4@[>F\>OC8_J;8
M3G MN,.$G;3;H2TUKFGH  W RE+F1!HED[&GX:$BZS=7!>=AWLL>J&43').H
MBYG1Z?L_=8=9>V_L=>G_C!1X5D\#0D$"2N!(.Q!U'$_-\BQX_&;TUNKM5XTC
M$=\IK-+XTO=OQ:-0C4</AJ5]S"E%B:1H0O8MDO6W-=^&KN49DV+C&F*A-[G[
M',-1ZAJ_9;7/\C)W6NPV"^-;N7D8Q&0<C+'JDAFWD"K AQJB60:X/.9J+"\2
MK(G#>)XVLI$ZUAPC?U>L9)OH4YGM:.#5I"LM$8CK$7RX3=PD09\O?G&PHR?Z
M[R>**>I4N[R3.*+>.3@6M%E[?Z_PH8N%;D@UWF.G][I5;Z7L7W2730DUT2OO
MWL-EX?#0!SI^".;CW"8Y@G;'K28Z\)4J=UZ6G;:^4?+3?.*1T,9?UA*-!1#,
MLE-;LQX?A:EY!9W$G^],<J3NF[9=6LBB%&)-]\]WE/\Y_>R=;7XT0M @5\[F
M\5:25*Y&B==]]MJ]DD\)OP:+.'2 WZ;W[_HEA0>ZGKNF\#ON7MPFU)IH0I!S
M.4HJ6;KX.7$L;:B*A71:QBUV>!+J+)BVJ)'PE3J<^J(HD3KZP;H%'";KM%+Y
MK30BLE([4:[A$R>[<*[@SQ?_Z0[!N(_73J+])E1X60%5O-YRJJEVV".S8N+"
M[8]#"KZ=^N19/\$=O\TE K8+S0Y^JD$#A-P:<A#G)O<"GU%,SE.7,2[)UWD4
MM-["?ST0UO0:! )3]90ZO,2Z'S>XV^5KLA^F$0..\^"VY.>((?7NVARD,\F.
MZGSE9DR%_&!\=/_/.=W-MY:B4M78>692Y/("+^)GBS!^*VM9ZU9I-5)PU@KB
M]C16Q26[R>7'7:R(?8_Q.,-!;T-T-N>YJ (UEI=MI2!B"-ZG++Q%9./AK,<"
MU%[CC&1,!U5PQR(M'_ZHD9"+>=>D6&SC-JT8[#,@-Q 9_M/#2L;[3-13]U^9
M@EIXYL [Y#OP.VGM(,ZR$J?1LC*I79,XJ<<J84OGK_Y<YO'W2C#^FZ)C\&K
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M?%_Y70;B3HC%5;_=KK]%XC1L8<@!]GK8SLGSM43>B(#HT;+-O==;'4V)E7=
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MLICF*2,0H"5.L>G?Y%I@ LYT+2 %W='2]4V5,)!Y90-5IQUXOC QJU "W)M
M";-M\)P5(7"^WNLU;3_KNU8KA)".D \KZ7RSU:!?Z"+2+\P9<26D%!E#N=2*
M>NDLQ6@?6!K:R[%ZD.BPN8)?REA6V:4OF%\)7FT&A)R-(NF:_@360&*JIKQ/
M>]JCDQ=N8G(=L@*?U3\Q:]7C/*KJHY+4M/*97H2$H5X#N?04H=G*,7 0/HPE
MK1D]R?WH[(!LX^:WV,'@UESH!%R#H(;'O$#+EA<6K=4$HB\U_'6]I7E&)P:I
M9/W@M4C_(WM)/;+UO).I=383T"X:'MLP*EW#*SVDFI5[=H87B7=)T0?J33%F
M@:>WP?O&-"D&7W*[[_3ZY<LAJT((IZ_>[.#9:1\_E.=?#$YYOY'HELP0,*PP
M9!DLQ[!UT6RD_.'0NX;9\$_WRL[L+-&'.,VK-Y!5.RW*,1@!TA2$>ZVA+_GS
M1MG%]LH)D1E)/^TMMU^K/DLO>+@V.D+!K>")_A8,#T+0+MAUT2S9ZO:C6I.5
MK/<!;3<,I23#KO0"0GARJ.'DG@X&?\U[@P&:IE#>H.-T#T>A^N![]T_QO^WF
M/!:\CC_4$G^,CJ!GZ<E!X# R+QXIZ&E3DQ&$6WX59&7H^7N@\W?>F\)Z[%C3
M^'XB_94Z)&[_37DR>TVN=&Z(5_Y?28V4S_=*#SFO[22E_P&>T)'_R.B>8Z=I
MX!T2K:5^#)99=G*5BWED/F3[F\=[Z]/';R,/1S87ZVK39:(MZB7 W'+/5OY-
MHU@2N_]_2VS; MOWC#'4KD$ ANK"!.1;OM Y,&<"DF69@!E!#<,B)@#[%KD=
ME]W(X_,/]<NO%KAW%/C6.@=DUS ,@:O=3N!UL:8,R+(5#Z&5/&W.<45,NU!7
M@=VUFWI7I[X!W6L"2!-JSMX&2_>U?9_ZJ8W#T/)KFH8K*?E, /)H61N1\U8:
M Y)G]<>^R=%'MO-RF+1>8-C3\>0]!_D',IF6U4G"F7[?$0*A(Z'>[8F<=I4.
M\4Z6?0M"?_X<<J"#R252RFWAWMS&%/$<>@G;OD_6'#X@]T'R;SJ8>JMH\B/U
M5KBU<G)5,'*9,4?P+/0CVIK4@C::^@_DL:.U)WC\K#??U$^NU6+$%$\C%F9O
M@;82D/8M(VC5];,H!16L]Y_[2XSJ7X,)UG*^-U:>]AJWG\TN\:JK2P5C!>]^
MR);]*JV2S3(GS]M_CJ>D?V("NH((_=0=)B!/PW/,)IX)N#C7!MK!,%Z,:NCQ
M8?W64H;B..^H.7[&_^<BDO=)ASN*56&QZF1\-O'>.TM+:Y'&H\8:S[\CSJ^I
M;<P>'U78"N!2;XQ_+2+5J'_2(8VF+ZEUD,>;R9"!JXTVF1!!ED3VU22:&Z%3
M;.&3H23JV;.9B)=M=0JA014(^H<F5;0 V?:1&S#6E?CX8R!C.-W:?E$!?%Y?
MW$W<5H\) ,"MPS\K/*?='7.]EW]D;\,-,@KUVX<2/Z"UR$ZP$-6ITEB%;RJO
MX.66M^[2S:>S 3MO_<P+7%L*_RU?ZBIPO.T49!2:;Z/2\^R;2:S&AV_YMWU$
M)H];2RZ-0QV+.GOLO-'\Y)>N<=<$G\D\E#!\^$I+_<BEELQ3A,HVLNZS\U@Z
MU7YMXQWY*H8(A8.8 .?3+,5479[[WQ?2A%Z]/#)3[PE8I%D\K9@E1^"@#J9"
MM37PB.V6US3V@(Q$>?W/1M9IXB^'/DMXG'Q4<L(_1'HY;!I7Z!7\9=+=-;B?
M803=H2RY$UCT+E800ZWF3):I8_S,%0OS4)+.NO,B4NM+$U> /\Z^PQ>J6&F$
M[5/)[G]_L+^KL8RTQ60-6+F"SE,LMWMM1G>24$^&CKO6G0O_%6W'$!R62;WF
M(C23\M<[=D%/D#PYW_L<E.)UL>[;&TJ6C"/RC\9>NS=:P_O9>!\$.+0PC(?E
MC#0X?X3J)7\M.W@O'69]3TW3D1IW,,>^CL0Q!(:W*U%Z,]*T$='#Z>P[N3)E
M%\>&J'MNPZNQ(ZV#I11G4. 7(D88T46IC=.3<2#'P@T"3MK'GM%Z*7QBB7\*
MU]QH7!D.,JV-N*6JH_)5"-2NSZ;A&4?)3B]4?]L E#+E%875D=@<-;%SAP*E
MR$UY#]:Z9P^2:<+NOR::&GW&31@6K9]-,T+"K@M+31_E/);;'"7P>'HT@9AJ
M\6D[U.D_\])B<I"M$_1.G'_2[=&8F3>/HAQ1=%;(;?"\ZG93U-=,G'.3Q 2<
M4W1AM(Z#*!*AIT(._G5#XI\;$-:-(\^LQ\B3ZF@^:!0Y@ F00C<S 4[)C%?0
M.IM>GSF>9)H-Y8 >!*+P%8)=71S(;TC7&_*#\(VG;B!5PZZ'%(A'![?QV7[Y
M8E:6%&MD>NOU%BQU2#!)X[Z1\ D.0/$I00>;)BK/>U]-&C$1M7MLY(Z-X^^Z
MSBTCH"KM 80,1F@&9^,9[G"0"[=L&)?>@!I%(URM$$C.-$S>YFU%P\CG"=T[
MB[J8.%+%5D^OJH3?/:5C*E([!M^2'*9M!W*Y":35Z"I,Y:QGIFAE9'OEK2\_
M0^'Y@BM+*> 3&Y '73VT9+#>\Z3K$X7;K2K)O8IF#WV:QB_-<W"V,Z27D-@#
MQJ_J$<BD\9?)+NZ?5<^YKW"*"*XP 9PT*1>W18R0B?ASCMJ1&FR6W9:D?>[J
M;.-7JP\%A1(IJZW56D:MMDU5$$6P.>?1N!OUA5L.(E$"%OJG@L>,Y+I+B[Y(
ME=E4#FSNK3W8VH+A7=<MKQ0PK+WB,H_7!L99I=K</5Z!PD"9 "ZX%5&H'C]&
MN#N@F*!=P.O3^/JIOOG"!.<RJ2+/O=,S5@>Z7T:P9E03S/OO3V-M"(7MHFVO
M8W\S]!4&DUTU_B;5%FU@^-%\:TS :8V38E,2+NVSZD,W,V+.M7"?T7FX.%#.
M5=$D\U))ZFF*]6#TB6^_I-8LD$_MZ3F/J1J83#&.^[N=HU(?V<9>@-3A@H0V
M[&DROTG3Z$<[^(7<Z[EAL:6+IY#\)U=5MG\!&Z2N)P4+DLYV0$3ZX.>?S_&I
MTY6-!PWX_N ZFBHN&.;R+?/N1E,+N/G&T/&B9A4I2_2,N:Z91K>,JVD;R?8.
M6Q>&K:JINKUES>TZB.W;;<J2[8]?@%1(5,CKW MD=@]/'<U23TF1;^-%]28*
M!WS%0)"_%7]*E-;TT3=79E2<8ZFWH36:"$G"6U&SPM[DI,?U@ZN-0RO=O4AA
M?REOZ1>1USK5<OT@H<:%]FWN-6O>)UJ;I?A>Y!/6+$SQO7H+:U[2WRM3_7\^
M$&57RO-OZ71G6U"..KG826^H,G/HD!0;RZO#Q.U>K0O0NZ%?3"T47WP1NJBQ
M":S!M,D&])\)-G2V\RH<4:B6M=%-52WU?*+?_L(GF"2XIV9_\Z]"HCCL J'T
MOA?0T$3C0Y#67ZDDLZ;$=9Y3 /CU)[O!G(M[M?; V(!3D/:@ANE6[U/.#C>/
MORP02;<[2A4TO7*-(<KZZ3QAI@M"]41,>XTV,$XCF7>M02^MR'$*ZW'LN4)J
MEU3LM8=@(T%2'H$4,4<OV;SZ3[.CW-D[AZB#,35+DR)#]80M[Y/77XC$';7C
MR<KC?4E2C@6=@0LN0IU.VA"3JCFCMF$7FD<UZA47>!_N? !<W5I^(4X9XWF_
MB#G-&$"?':_:,'N^T]X[[^2Z#35=:\UKC&K%GLF)%#[F1JQHU%. <Q%V.IV.
MVT&OJC1Y/B]%708ZNNA>'T&=U#M.]IZ?B\;\V-.].HN;>0]'*=G;:'5)TV79
M\!5'X"[DJ#R:SL#>G! 4%Q,M?7:<S39;:Z"MZ,'KER_S%50M"KHCIK,ID?N<
M1-)!.S!*.WUTI=EWX?86Z<'#&DP6G[U[1/EP%"!(8Y;F2$<UJ1%+C*/[[8<7
M VH?NSP1N[,:P7/\%]9EJ HM2),=U.,FWY@S'% 8ZP?7 N4N7[KTV1SQ]LC0
M/QE1_U K)(M:5?R;6C5?:)K;KV("4D^6,0%30+KHVR.K#4A:B#'C3W'BOZA6
M N0_J-:I_W7T[S[<I$PYQE^L9$W@!Z[3\>7L"V4+YXO*6_F%-S<QCU'+TN%S
MC&8-),Q)F@GHR<'2_S(!XV7A"51A:G"0+CJ.R$N&*<K^[[<*F(#HH2',:M\B
MXY )V!C<=)M X"3Z_NY'$R\3BEKHSW<V=Z>_3C7\Z%2]+W@-9.!8L>FV&,52
M6Z8A^=5UM5%/ FQ2?#$KU[#+=MGC6T$?R3&WZ[XW#*^DSJYQ/[]LGD?:L6ZZ
M3+4B>[=HJP=J(S(O-I<^23<RYP@]*&1]E6[3=92!!:[)F"%F9<H$H"XS 3LH
MUO Q,$4%UAC3_SW&K_O\FY*S$OT^GYI ##%;4\BA;QT3@$922-\]J/?7#IRY
M1@(*JS*[AB>M,[TO!8;3OR1)%A1V9WRV)E:Y#Z?;)PW&-2*,2RT>H$\318,K
MVP+M$Z UUW_9/#WVG V +'L*=R:G<;8BV::AMGQ5@PX-EZU%+OEVR Y^^!HF
M6^;]R!I[KR@ZN+YG^L[![K;_GFVO"^.$QD?48?0,<@Y$#^6D";@8<3(,:D$'
M_2S&T@PA!5UA3>79(2\YUO$:$V @3]1[^PD-!1(LFEETYO?5U7]9>@ YGQ\J
MS 2\@_73B:Q)YM.=?H-6I_[SATK+SC),,='(.23]2,E/$'XQ5!BX>ZJ>-740
MA63>QCC!GX^#WQP*B![VX@X-4U.-6OY1$$H=Z8GQXRC;G#!N+Q?'4+MIX"&#
M 0N("+)MGJ;)!.B'[5 7F8 *Y^]4.<14 V3+<$'"$#R\Z:7H 'YUM].HTP"&
MKFY[_8M8=;FA^N&0<5$F<<4XJ=WX9%1YX;5GU2,'%F-Q^M<**Z0IA/_H8E=^
M=C^+>I[,MM!?J[$4B)P<"NGU5+OB3+TFSM"8L0;RNV,(*>Z:-C)@Y2V+=P<"
MO+5ZV$CR .=*J2BP9>J5=6,-N=E/C'<V[XP<IN+"LSAJY;[)*$VW#,XSY$HH
M?Q]2Z)ZG;>CM?SS=IUUB4GKI#=B9M(R^0ASOY(VAM-FUL)R4LIP;.#7C\'NS
MKSGAA7$4Z Y)^47-[-6FX8[5^*IFL;:*B O#_O5W!UZ$="E\-0QSJ<_C&<;F
M:E:20_ .9?;DVP/VYY^GG!JZC6S(K]=8 1U!PGAYX0_)9WF3-7C)G_T;$V_
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M5$.BJTEI9BG>MJ8-0XO5J0&U)W54"^Y$BB\57^O7C;JLG6%S?!?JU^<_-[D
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M NN!4;X3O6XA%QNF*D_6GWU^Y.?,SU_E_P]KWQG65+>M&T2*(D24WH*"(DU
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M\!0>^2HH^H<O,O4^J7)IR-31X".X4"UBGS.U?\0JD-A=NL\!AW)&YX"ENG,
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MY^Z4P/^A)_]H^<A_3V_O[O^C05$%_ZC+!YR ?]0Q?AR"T@DW^]" B^SV>QO
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M(O/QOGF;Q;/?<+%SH$=VF1Q$&902)4%O0-<T2JPJ5>7F#=F/TF-UVQ]\BE*
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M#G9GD/<N(FWY,387/58^]N?.#P?;@X!0<D#=&K[U%2E_DJ NE-ZC^+;);5R
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MZ9VL\1X*E\R.R)(=V9;2:%:3RG\C5/%1)DDHZ8JLM^S@TF2J8N5(0S;+>OI
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MY^ZR.1162XZ[:8[H[WHANK8QHSLF&K.LZ;I?7[>I),$*_!W",:GOB^T"2?Q
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M?K<"\K>;(7^W+ R8]3<@)6+=K"MR6UG6/H!EH.)E90BJ7Z+QGH4(L[V45OA
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MS46_H7_D%,7O*@.0:TAJP99:R('9;9TO"/GT]J_.-[O)X(/JSD:J+":_IH%
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MA)U&54)/E #>?R^4_1?]WT.,;;^*5<F:A$YSE=.,N@@D@>\,\"/[#& MDDE
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ME);#$.V\:$V=:JG);U^!5WOC0(KBY\L_Q\1GVTTROIE8]7HW.75-F%<_6<E
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M>&6S:TRRKE]B6+4>+,\UD1^7 $P:&RN&7[UL:,B0$\FZO:-[N;6 L\\GZ@S
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M?K=M$?WOJ<G_<,KK]YV_OYDBWOMCA[OAO\^#D?2"A[N.90.1WY),S//,*U_
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M1_>("4#3( 6S[\'Y8&6;N]K8G!*3QB;U.NHI.!+'>;^3-)/$[.ZDI:4M"S8
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MQ>),7=^8ILIST&WV ]524P**X&#!+B8NCG$9S='RAOMT-MZ2J$<+'([6<W%
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MO#5@)TMC[? ,I8F@^MM-U4LC#-R1]S[$7ZDG4.",_?<.;LV</)#AXQQZRS@
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M)0=Y&K3.Y/;UI:C=K>?@AI#U^4;[K3C)0_'9(87+'J9L&N/[O6);2L,RT:H
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MWTHZW*7PK'_W-$@-_O"SA**Y3L"-RDAQVRIA&C,[O4-Z._IO.=WVU%[?.\*
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M;5QFJS794>-Y\N0'N[$2R:]>THT$Z@"?RLMC!Q3%+2^$*:=X8R+_#C!F_RW
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M82>B8\ND_\7>>X<UV6W[HB]%BC21WE&J@B*]$Q"EB( @3:I(!^DMU%"D2D=
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MVA^[Y\];<Y#&5OU0MO)GCFN5BDY^,AH1U$+HZ6#C=@)Y%6X'=PCN<S&BIT>
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MF/5&V8;!SGX:OVXL7F,MB@W#F7U[BDU_<E2F@>DK93]N@L)L[E: 5+;PT&\
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MOST<<LASY3&%V+;W!<D*=)L^&&DQ<Y;M"PLX;LAQ21)/0NUP6E)\4')P:Q3
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M]-9W/6LMZ/Z&[VXF7)V;15.U22U3-7"[ I]U.72 8V0JUH>BXQ'MF4U4F<5
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MU! 9O,J]DY-UEH75_<D9Q:EV5TSKW0.YOA9WA;$TN&:DC%WI<*B-B+)ZE?L
M?2>I7*96^[)2D&P<0VY#B"3,!:7R<31""=^2,<!GK_/"S42Q2SUOT=)L8S_S
MA593&,/<Z<L*#$$%>+KOA)'L(B[BDP&9HFG[&CT]C-+G-#.QG[!A0Y6#&F=6
MRU2W##S7GTTQMM(\?>@H9)NG73G_HIHF^OG)HV@C3J\!CNWM);3%<Z@ALBV]
M>+[43G;RRY-M^EL*'#P,G A4#IFD51Q1]@L3;1'M[]]=J,E51>;\(N\OJ^X4
MQ-D:6UG&AO)1O)(:&R;U%MM7$(J(UN7=\@MY\-CG^Y45<?)X,7O0R7@QE7A'
M.K;TNU7P\$="G@,R>=:4QS[6*2AIG?$630=8/(W=\5" S""N\>9!2?G:RY)&
MX925@P'0K^GB$0**:'^S//3#WON>DF8>I7KTMTW&GBQ&@XH[5GRG058H(PW'
MAR3J-LJ3-9HU=>P9V/D\Y\UAY]4]H]GXT,.=Y[V^WI%.V=Z-XQ.E#W99]2'O
M8VS8L]9E(_)=S*ADU/+!]>IONWQ)R#3U&YI,WC)B*E-^J%H$D0O)I5^=WMJ=
MG;H/5J*K*X-D-;RFJLS+O#3KA0CNS)J%@M"RM@0FY^/HN< ]R3[?0XS[CD[@
M?=F%M" 1=:+OAD;-D8Z%"6SMM3Z8F3L8OG'S\=>PL>2G!E2_5(F"'BKI% B&
MR+T#F@(_VGV>40RPD-)TD-J->R1)RO=V GMW<VHVOP^:;V>87<M5W/L]]<:>
MRH7/7@R;D]0TUW*K(:(;2XA:A)(68CFKG]Z+\WGHS7L)]*>!HLK[8;0?:"*Z
M8R5'@=1M__TZR5<&P9= 7!A;&."$-NO-T'];L]8RSODZUS&#6.GG;6<E!A#T
MR4=X/-MF('UKA,8#$WO&O&ZW%R^4VY[Z0C4BEF8;_5Z*",P2&!F]Y @UJ#S(
MCP5?Z^#QDG5[<PETQ/)T,SNPBJ-2VUW$AX_;JQ_V)R6&S.,=ZEP]S6.1'AU6
M ([72E;S,VH5UHUQ$O,>_>5%/SBW'=]QKF]B^@(%)N,^[V;EKL>YO^,\=1,1
M,J#@6#CA7W8)!+ 9'DD!?YZ#:@5V[G4!)W>%FH7/JKRZK;@JC;MTBWU?+L6B
MMWV?VZ']F.+*\1AU-/;N&C[E*,;N7)F@"9QQM'!O)7A8T5%[<4K-DDI$FO.E
MACRA3("#F4Z;B8!JZP0+27XIA?3M+-KK^96@NP=+P6;[FBN70,4FZ)"Z?/H/
M,\N3(M.B;J&<(W*FV.N3%B5?3"C?PH\M57;.%SKI&71 L(AW)\[6C)LJ<O4D
M172$T4EP6F0E*-NOMY%"!H4K+X'R:LA&7QXR#:/1Q@4N,06)B(6)-%MOG_@D
M7P*L %;D-]Y$X@;;31DS>-$N?XTC;9>)$O&,NBOW2GWX?5R;-<Y&Z2;6T(_K
M5 ;^3U%D;;D^L#(C!=46C=(2.YKBGN>6-NXW-0 V,??Q<6J<K<GOVX'"]:,R
MNKD;0H9J_$WI74]*<0LE5O3O70+$[6\QLG!'H?[>)M.L5,9WGWC+^=/;O?KQ
M"#G7&1B6O=FS7I6@S[%JA"&0Q;\ ;DUNX_6T(Y.>OO[5(F->=[#0-E[TY#/\
M)X!X;1G[75-CWGW;Z"@6KDG9"9NC7[&U:FIN2!ZLJ7ECM9YPB#?BS5.)*<+#
M4YZ0>?P)W;?4/7M<2%Y!<]0\[.R1VD5,F<R4D@+NHR!HCE[%B,/.-XX8,(H5
M7Y.VQ>^LEFIE]=K1NG%H/A])W868_@?A*/U/-':>7JX+_8R&=#>U,-;&U"4-
M%0_R.[!W6O(&4>YT5CRY"OJG>WS)2[Q1W[J:OM,*#18:SJHDS^/L]_5:=8!.
M1C#;8T7__?DR3O<$>ME(6DQ*%C?.F)M.(CSM_(_#9[!G"_L:N A.-V7%Q#B%
MO(E2?RV4C>'8QPD1DEC";CVJLN]=2+C=/#E@;.F:.!Z3G+6L_^7/B\K_[BW[
M'T.B_[$<ZS\XRA5]'PAU4801'I$BF0Q.JQ'/XU[0"B8547;RS"6:QC^XAQ]$
MFI1'\15Z]=/^SGLD.LB3H)4OD[_RJQO%OZAPO'NY<[<!]+%"^:\Y6<GHV.4#
M!(1@?E/P:Y5Q.)51<\#H[76<UDA./^NFK[QX@QY[;.!UY?';8T=F$;,?U@IQ
M?1ZNS:PQ1",9WN/2R=@D9_MZ,"Z1MMPJV10W'([R5UTMJ"U[P@GF8(^\81DV
ML)>\UQ7G._WISVM362'PI5.^)?+V79Y+(&_[=\^UOQOX0QGKF_:K>.#Q53Q@
M@TVN]?TW(_\V8&0-0&4^GJB]!"+&9C;UW$P6F-Z_?TR_#F1E[!S.+-Z[/R9)
M79)'5$KQBMJZ[.K7=LA0A4D/7ADE434&1_4?!?O=:Q1M;SQ_OX#YESE?HH>[
MM=#M75+A$9S96HTQKY,99K84[YQ9DIY;UQ?E4+"-^!LA((0;QUBV20QQT=9S
M@S[VD#U-:40*M;F0O,0R.>0!F3U&%EG7L,@WB7&'1VI/:T_DWNBTC&$:B'0\
M[Y\FRCT8YL$;V_C3>RD*$+KP$A#2OXCU IW+_H4!?VAH^P]%B\/+0ET"F.0+
M"+;%ZA(847=G(Y41A%THPJ82/?T^VJ6)W^3/7,T8$_?J*2=099#!,6F/]"B8
MEI$NLG/@#2M?!C\*<Z/C8.CW+5N^P&D1@!FQ,.Q>ZS8B)- U^?CEUX)0@"U>
M(AH*BZ?8O 3(:_U*[I$\K6N(M?C)+Y:86VXE[R(_L)QAM83)O#HS,[=!*WQ5
MJ/"@15YDV7%,&NY"^4,<OOO+#9Y.Z:PI3YR)506Z76&:=;RNUG7MMOOH@7YI
M]YWMW_>(W4L$: <M)'F\M\_'&4U7?LZ6+P_SW^_*JKM#J5I !6@RCV%*M(64
M]:?[;TQU^+V>-*M*FG7@2MWP*?.C"&\3'N=_]>4+ZE>"T4.Q?D8CE]R*D\_'
M'Y#%>5,[1\[4X/ ]TXR9\/ [SRWM??=)Q)1\.OI<?]@R^/5AV<9:]&9U\_LJ
MFS3:6:VJ[K ?*'#<VU^Y*6>:$T,YU?CAX0G<)N@>(_9L]YOI&#O'D#5]HDZ"
MI 2AS-%I5<:.C-UR9(M!JO>-Q6^%6ZD";5/[MY(BRHD&!@8(YPY*F: XX/J>
M&UP14?XO><;Q[J22&.G&%@#KU\(%3]GR<>^A$7TN<_YW':U'HU4_&^5Y=4#3
MG[X=AI<T7#QV;Z-&UO>T$G;73?E:[08[.W7_V%_7%\*=3UCBT1I'EA?V0"B2
M3=J1AW:>+&VQN2FW>Y0TTV-<LPZ[@I>*C\H7@V3$E1B7@K#WY;&WDH;2>FZE
MON ?W(\):Y )#E^(.9=UQF6_R*68C60-3']KLK1[$'^^NEUP)40A='VS)J7$
M7OR[.]8'KZ#6OTA?QN56$")IDN%#PH^F:]79'D[41O'[OZ#F$\U?;7F='R\=
MN1.B%4>,[W5"8(?122+",FZ;V=ZE^:3[S*_M:"Z^KP*,AU7%7OE9IH*0C=LM
MTW">,&>//8(%,W1F[[14:16-&I/[C3#2L*!!X$._$V)GV/"([=J<JLUR+/FB
M+M]M@RX&S6=>I-'X]HM#7*UA/2/]:]^8GVZRNC8&#;#%^H!',78(-FA/X.WZ
MD<.3;?-"%9D^UIB.JY.WI&":[^G(LIHW]27$(D,L%NGBHD1Q4"%W9<HXEI=.
M85<',I@[2 PCOKQ'C+8L/+:JK6K:/(XR5N5C>^4;0,!74DZBB0;!9(6U:]OK
MPG]I.@BI,SB$**VRQ\07E1\'"7&CY)()HW*0O^JO>4K"A?HI8RN_#<*JXF%.
M%R7)Z,3E/0KQD%J^C<-M-;YFB1CDO%%/E82+&X&.>W(?1469 WJX8P1<7";@
MN,<Y7NO'T31[?"NI99U48F"XG?DLP>6^'!NXL.<5GQDMN'Y'ZM4#F[KJ>H.8
MF<V&(%#B<;\AL(+1#P@HPG CK=LA3:J.>W0_W).>A'0(GKUA/LLXT4GDC+54
M(HT1)R ,D740T$(NIA6C70^)=U(\UB(?514R 7T+;6]>6FP:"V#XVND?%UP"
MYD9H6'BTTE#9:YG5^//@ZBR+N!P_G%[ /9NA)L"B<^GFWDZ:OW?U]Q'$AW/O
M-L(*4I#4H4"8M]8"1G0T0XSP6^RGE](TKR2QD%@GL%_W%"OC2,X8_XV+;"Y)
M@<'$^$7K$^Z&=K2^U%JHCQ>6%"4XSE^>Z?=3$TCAL%@@_B'M-8R7+$^3W_?Q
M_+'1>Y>EG[/F5)08SO!+ %&BW&5V>,^OSU>GG1^YQ76<G:_JFKC3@>GUP)(@
M'\E1JS6G5W!-B!I-+7GZ\'9"7@JY"$,K5JX)4*()X <]'#V!+%-LRE/7?Z7W
MF".R+/#<L'@3+A(#0\ KC'WO:F&$2"1RFLXW@UIC!:<&6\XW41(ZXH_CF\VE
M28G.-91JR[^>4J<;_RV:S84P4--\6B;;H26'%$)["0RDEU\I.SG$)?"XU@U"
M].D 2VVD> G(DG5AG;J: U[U;&5P8;._$ U-UB00<DA[WS%&H$K;\<%V& Z8
M0P"K6GZC;?K<D,XL^1I/@689X-J.>Y\0<ULJ+/1#/>WT7IOPI()N'X3&'*UO
M@\AL*&TA+!\2#C.K_!J4/)G^I BCBH<JMS!!F[F<'9ZMAWG^K#&:2TY'R#]U
MN^FF21AO?$,IX&X6E 2C4*')B*[N/5@RZ.N,K2&NE#S9(%R!7"=X@7:_DGZB
M2Z#3X$@Z."R$Z6U"V3RA&R$B^'1JN&M'\' /F)$Y%1=OKK"VF,Q03-#$$#H:
MHO3#C R1=LBU='X]L9U5I4#MASUO6'+9Y/GRPNEWEN.(WO&[%CW2FL$)XJ5<
MO03P++1R'+1Q#L0*MC0K=?L/1&9TQ'=87%0&340H?WD586LGP11=-\'B3UNK
MDU!.L4-SQN$&QX[7="R*#_/B.[_P]#3Z&QU/"K96_,0.K>Y+X$E7[VS*,R_U
M.1^Q,EP"E9\A=T/[E_8-9*BP)]AA$YO8EEL\;W/'IJ1[Z\[)9N<_C.XN$CKE
MTD 1\< 2NM!X7-0$](+1L3?D1NQ*FG1U5IP2+\/"%%VD/TL.NKALSK!*7&G^
MP=N3,>YY!,@SW)>\MO\2Z")&+)WQND.6Q2\!*Y/V")$=9;715S63GF(3Y9/O
M:[_='^M(DN^OA <S9(AW0Z^#(<_CM<<.*V[OLC]4/8XR8J"7$:8<.=-__I]5
M\(?5?',,F94*6X5&M^@77K3MJ@U^K)K USJ-<^OAU<Q9YP'<_PK\=W?X#.KO
M?@F$QF.[XM&ZT",Y]/HE0,AV$?97^, 2T%8 :AA+#CJ_#H+I02;.$5 ,,^28
M^J^ ?Z670/%)/P@M<0G\^HT*^.(2>+X7!T&Z7IV*?X4.K,86+EU9]N6K4U*9
MBZ6QN=!LD[P2NBO>FO]S)?\1*P$@?WN5TX]VAJU"(V04N1LOZLOMTX9M7Y]L
M>;\*J$JC"/(*D61M6$$->?U3H/ZYDG]'H,!_E]Q$D8<1JAZ742[<3@;']_CF
M3T:D'WM,5+S9:'M%[73=TI*UQX,U9?YOKY%A E=!(B5D]TIKY^V8!AO+E2&_
M#C]'L7XL5X2#*#>]];%FLU3J;3<X?&PIP<3)0=+)$V<CA*[_Q[#PGROY$['R
M_V,R%A;T%TT3L+I^I6F* D)VI0?,VR;PJTXCW?**-8L0A/@'?_MZX3^*W-ON
M(/7BX>B/V-$XG8:@-:9,[Y_\$,6!G7G&C:(<<O)AF%P$[4>RM=R S]L4>$Y1
MHDQ00;IL"<"FWI0BW_O=?Q%FV#_IG_1/^B?];TC4M0%Z<X_&G#REN[IF?XH/
M:+FY_N*[BOK#%I:73O>N;$Q07[T<YR4P*#D-V9ZY! 1-'9$67;[D[;"AAPC=
ML>7F5.G6R'U<%9-HU],, E_N8)1X5QMGFQ$3WWZ:ABOS\SX+ >RF#-5.UK29
MF2#FQ:B()BFZ[J>,W#>\]V^J%:C?G H1+,>YY<4P>_6W^IZ\#>0R0HNKC#\>
M*EG8FG;AAUJ353LSITI(K'/0_[*E7-(R%;X$2)J?CY??DEI_<__>/6L0WZ[5
MJ[;/#/+.W_5=X<.L1FCWSN,VCMH:[$A]DVV/P]KI"WWMCG6[P\UH8/MS:F[)
MYMF3+N>]V_4'*P:?R.<'5I:OL:BNU_K(M+.2'OQ\7(#V*6=]%F(ECN_H)3%3
MZ"S;*'ON74[2S\K;-!'(U5VLEO\-/U58*>JU);_E_@KG#:\8IS.VON"9L^CH
M'F1JNWA4BRQ!L=P';BAGZ9;CRJM>EQX;3O*&X2=S.<I08W\;9%C9][I]=9^U
M1ZM,M"O[Y&2J5JCX3N\T/N()KGI^%U8P@SY*!H&JN(/VS+6;W>N]ISVN4Q.W
M-7^O.W*%V>DF*=O$]$?P 4P_@A/9>K2;\K).?"I!9L#\%4U7;.^3;$G@8%M^
M6#/N489HDKA^;(>5E20IQ4,RJ9;D9;%6V4L@8N_P;<1]D5.:C_R^'.NK9[AY
MET!'R=0&911<DW:CC:I6]<BODR(]D=F>1.;]=AC;<+Z;V"7 W,(F@S6Z!&SE
M&_O3N1KXCDX-H&,MEP "E\DY6LS;MX5*,U_$)>6QQ-)-Z ?JLW7OBT.^H@^!
MM.!O"LF:XTQJ8WL_!?$&B>H3.7>27-NS<[F#LZO-(7:?#7K]+%Q9>FMR[_ [
MIIBK3QPQ.7(\;9QPYOSIZ,B0I-0'QJLO/BZW@"V%.F%H\N9G-(O+#H6^<KU]
M;?7(,H8U[ZBCW C1'AG8"YLS(:?KJ=_W20J^!&02U@FWKL2T31U7ZA(@]7^$
M/'E;2_S:HW%-G+)_+27U=OHS>8FC+;["A@_W'/,;DN6,54PJI7&2S005;?R0
M]7V+;!/WU7S<%:@/2#V4F:PTW5JP*8>IY=L\$7L+]$*BI6$&S"%BK+9XD7\X
M(16;(-H6MI)%KE+?9 6^+)[95X(E;"=-%#W3J?[4R-UX.-.0N:BC'%-MN$3,
M*ZT/>:D_0+=,Z'HUPWUIH3"_6'>E&EKWV7="RDPL2;=>%H:.Q(3V?\RQJ=$R
M)NQ<\ UP[W"]-Y[.4Y52IE8U: 4()1^2$L),+G#_J_NZ_/^G"C;D='B%C$41
MNGS_H$^.K_I<(/+^+UAX_W/!OJKB:_+:Y((-<1(=S,\(*_^O<L[_;UW)ROJC
M%F1\KP#!SVXXE')+K"EM+G"4/+^((>'4Q2KP&;#U<UWVVA][*6B(J W3^6NC
M4K(6[Z!8/S@47+S]A=QL"@XC3"<P6F6/*\D6G!@A+/T_CE7_7,F_70D"RX6<
M7 ^M9;N^^ +=W^L-M4==R\\:6;*W5ID5XZR\"_SP"AZFYXD^_N\@*_\(6@W\
M@W]$N0P*%P8CU!K;XG7B1A1 25H?!:#OF-<YIMHB4%Z)KA5H3>VQ,E/.["TJ
M1I&\,$*.8@ Z5BE'#Q;60NI%^5@5JSOP)QN??G9,?X]30^[-NQY-8 XV6_9*
MS[5_MK25$6JO24*HXI_([!>AWLU9#]+TA<+%8PX7>$R_C#FV2-N5;O]XUGL<
M&>KS")J %Y/*4\FQ;0HU-4(QP;+SX10WC, 1\BW1+ \?!(_I\1W<^MI429B=
MQ:8@'\<!#P7O([J/TTSOFDC-CBS@L.37D1"+B7,>=#"P^;4Z@ >2S^7 WCP@
MT79LR)&W,=H& :6SZS*!](AIFW;)U]4]TZ,AW*.]"_5#@@Q_3F+9'#(*NSX(
M=ZTA-$T>CNG>XWF/U7H\3T#^?1W?ZRC'.JV+A-ZQC6$SIJK(+SS)CESNP"<&
M!Q2DA=;/PJCA^SN/[DO5%H#V5OW80FK4H.1@D,:8 "M/0YV2OJTJKUL/4H6P
M/=_5C$J.R1[+-?WK:(A\BVCW8ZR%9<K7&[IO^>X !\/U"O*LA8]?@J6Z3<=K
M\$-[O$<7[>4LA)_$&3C*$JBPR*6TR\=G8V]"!DTG0=LIP]@8PV,(P]:-S6R2
M*:="E\]U;G=7$/Q?'\;W)/ -S"VOQSK6EK0JJTW]XL_+4+X%:\X0GQW*NEE\
M""]P#LT6GK** U&"RWCJ%!,SH\J?G,&, 0J$_&"[S;<[CWQWSN_<J(JF=NH-
MAW<C2=L_^#E:@;V[IUCI1MG':C:^=M)Q9:9ZR;Z(=W/0"V;UJ4!7=#8M1:5U
M^NYFBDP3.//*C'[^) D4DS.Y+"3@L-;^0$.739-9H9Y^N?94LX/4CNS1*Q$Q
MRS9,5ZZ99-E29/OU\=X3A\^;:5H_MSY_-!X@'ZPZ4>5(X9@FC"&?[!]&KL/#
M\YTO,@/@U_QNXU8FG?XT\*6,@?8%9T!P6A0A?@Y%&]/:+77'T4E&N^O?\!/T
MY3X0L316@%#M44K-*"E'5<>AG0_OOC$_P^M)[)N/"0);ST.6=7=8F=$0\5 ,
M0]&,[8F6:MEBGZ+)T#MY]"W7(!62)&5CZ%AAUUX$72!Q\K.FB;7:C-UE?M=,
M+VNBT.1OO"M9D*7;03+0?JQT(ZKWPZ=Y6X*O:LK6+T*K_4LE">]*AX'"?"NZ
M*R@ASOX\#='Z"^Z%<X,.W)I<#UDBL*<=9\45BFU?0K7&=U\[Z?O348IH"WRN
M[,1ZKF9?0]O!-8E-MD:'_ K5S"'VR)0X57'G=8L;SYDM0X?=IX($03;MZ$M@
MNGW['6AHNPW=7*1H@9Q[_H*9^+Z7XLWD;X(N&B! $V;J7NC/A-I-&!-+AS/Q
M<2< :[/'X!.+ J^<8<-6BD[GFPYTHVKP"JJ+3[SHK^J<^XZ'!/)BV/8GP"*:
MPNI>>_"NDZ4V[=K1K,S)L\^-F&Z*KM8GGS>;/,L3"^8VCQ]$.I:-<-I*XV"&
M6PUS%/ZC:XK^UZE9,JZ/E;E3A"Y@$AG'J!=M6!.\VK'\3MK8AV>>5@ R/ #1
MH<5UD<[ANYYO?W?>X^2CGZ-^:(>G=NN\".2S= AD3^#LUNAG8[C&6Q0*P*(5
M&*W/BR;&II0NQ=[" U,HQ^6;/<N)@RP->\9LP1A).#0R0W<]TA*UUEJ@+'I8
M0M8B/*##0QB?!0BI=!SF4 1^:A@F0//I7D550[V7P-LC=5>NR-N]OK_TA+-V
M&;S6:[T\ "W=I6=?X@Y^.7L[U9N:9:ZD P'0Q;DLQ&*Q 1@J/^G,.*PY=;C=
MG/+#/&23!;W=(9E#9LAW=[OG[%HLLJKYZBN_.HD;:A[1I[_KF?6"KO-Q8&]6
M4+ HGTLX--G,>3N>@V;'OR]LUDL.UYK5MU4WIX++RI<S5)@L!YF#8QPW.CQD
M6,D @T_1^^U13<?-GO =DHXF@AR/1L_'0O-F N15L?-WML@IX_%O>L7$V>)-
M\E9P)"_;QG'(IL7**) 7QKQ-A7)X6P2';T/A>Z>__.^@""-K21SU'Z$>N8GE
MYVFN7!0G%#4\K1R0P*G4.9BG7/H+;/] BS)<DQ(]W9_&>AT9>SI^CU]?*K4@
M=_WYR.?L&4[R!ZJ$"=?DG$/N47,C-% 5D;<FY;_.J[JFW)NP)!43TD1YYU 8
M?FK9@SE'>^[HV&=01.TLG>NKI'UUR'G#U;42LP[<%)QN8/];W/E_6\O]]P/_
MSL7&WPW\2Z^&QS1=_NJ3,IJ.YH5V@31U#>?6A6[L26<2:F6?+,F^NSQ<]WX^
M@G?%L>9/+38];?C3,DRPS/B;=G*2T]83I1P':T9SL<@?A/QBK-D-TJVRVY5O
M^S?:B>GZZF_<;9_!=!/!GOZ<H?:CNR #O";T8]&0CC9N5& H191H/).#GN$'
M#,2V+ORK!;/8QGP.KQ0J-#BN]6Q:$=G>*U50T-0>(:-X5[7,UOU4Z*G$ 6*%
M[SR;0NZ-3;(\:\1C<%L\:S4J],6D)S>*(#</;?]U>?9G=Z'JJDR/FTGFAL(Z
MR ^/?EVQ.R.[<1D:10D6-IE<FZQ9>$(E]L''0S7%P&;%6C9PD\VDH4\EA^)*
M;"I\ FP*N[A;FT-F;W<J#K$_YCQDD-W [:5)]H/'4VS6=_6=&X\[.OT0Q)]6
MB1_6(!X6M=":JFEEO09]/E'ZZY-STPE5J7G;FVQ;W".::Q^."G+MT_3$GYD8
MM=_AOTFH=$;9^3D#&EFC3IDH:F+:U9MW_M;=+3'UC(!#!"?_L;:ZQ=,D-5O$
MA"/+;K MC8VV%5ZQ%C2ST+Y9_AK-($85]11+CA3%EMD'ET^_?N;$</V7"_V%
M)"C,I4FYBV_XIIU81G^4C%69)L2;<1['48*8%I9 X#XN6RG+B_>SJ((%>8K2
M[]Z+K#-E:)L0$&VGL%?Q?YN>F%XVEX4[CTC 8>@CXF#ART5_1)2T$_\TV)SE
MYY-K+5%;^9E+UBD)U$EG50*LPH>W@Z3/^ ;O8<G,[%.W/>'QC YIC)FQ0\=&
ML55]B]%$,N2^CF?7*SZ9@DM@2_&_9 1+EN:W,\@+B&J:$E_D!5?':?( "40\
M].PQ;KQX,_\ED%K7^:3UIP_+<'GS)YT_U<3IS<3>Z> 9%\V]XK$I%CNM5I5Z
M?.81,DO9I&J\S+NI([)$;9O1NEQ=.?&QH4'0!R[RP[]-SKF0XR"'S/</,W]F
MU*LMV$Y0$TOW89EP57GE%8,L!3@#/P4)_"L"@<Z]HS*Y;8.FL9<-!P*.E*;@
M22;*\//&UXZ#AS_L1!:\U2;7FR,T6Z/A:LK[NS04@G4JG9CX57E&:JT79TK-
M^=LCJF)I?C03KJ#4'0:8$4/_]M57^H("/69$BGR]W.W67SAHK/C!'$6;>C7#
MC& '@R;:V<!Z*]GN@)DW.<(!.-OH9P0[-!]*ML_T@JFUM^I'#97Y7BN]6Z;:
MS!C-P8VN@$ <\F>^^05(*3@2+7"6NU![?.H[F]/^$GW\PRICUFJ!^>UH1%$.
M"?5S2\]HL<29N[S\/<>XC1#T"SFR2^!C^##V# 239]&EB<T'5W>?K?2Q".M7
M-[XG/;5C7XHW:74P53;(M6,)^13R7?,E+\Z$GE-\Q:8<>XAJ32;:"1%;)QE5
M78.0F=Q<CYY:-(J:Y]2ZY>T^JD.:?/H,_YVNK+!NU=1K[1.-QKBUGX,D_#8A
M"IT7=IZRVOU*E7X[2EO2#I;L(DG,@&K'A3I@].GSYEEL=IDYS5%8E['A5V)5
M"TFRT-"S4+VB/^:C%LUM2P5,E7CF=WHDF<[>K4&6N],[I>_H<R;>CLU+G*3$
ML;:6 ,CS,@!/FF [!(1D:?&MM(EOEUJXX^<0\P.VQT>@)TM7C.ML156$>VP?
M6/B4SW2[%9(Q?2<8W^C/P3@X,7QJ".,.?Y1ZA_IW+YF7OC>4M7Y#D=?&4]EF
MX"A\WDJ=BF7_RE^.]^ (KUQVZT?FU;I[*V8]YN;\&H3KOX?(+[,IQD7,!MW7
M>OS8U94LO[1>_"81+(PT2=I#%X\3VA7$]:EH\ZSOP^?-7*VJYC@_X8;3@4"S
MM(K54*7DTLW9G?3FL5U$4SWYLT$&A$N?\A;OE5*BZ>T12_TR/Z_"$4XMI+)S
MQ>$DR/70IY.O/3.I6\?++1KKW!Y^8UA.<($8 HV/;18<,CRSJZSRAEWKSM"2
M]6\X!%UR^=T(" C+^1[^RW&2.S 9^R7*9R*U=<Q;<1\=0@L2R4)$CUPQ)K=D
M6XR1)JIUHG#_7NAGD7R&D%0)A@X)AEUP24X(#B'[E3:A_<_N<OK_'86G@F7:
M_,HQBT#5C2M:K-FV,<48+WQ<M7R_O",;KTLOFW+A,%V8[KBSDHY=L3=I"[)N
MB5_&=S/=P+*C: :&?A06"WK)JN!YKZ8S!LD*]Z2FI6'I)_EKX"'[\#$5<R$Q
M:N$[0'+HN&3%7>1PYS!E-ZS93U:SSS<NRYS_5<TX)Q^SSRNW'LJ6K.2=+)OH
M(Q!5;\DWV <%$9)@@K*59/M5'0PBX4%'G&N<LN_!$C'&>A0QHC?7I_]E<_8H
MV^)*%*Q)?X$B[PHPT ]T=.[$/,/UET/118I F)?0>#TG0T5#I*8!*0=N8]PX
MW52# Y+KG#>4-&FV11&+UT(.^MJIG;'LK5EU&3)>EX#5>,MJMWK?0O<<4_M>
MCF1GA7D.!2EJ\<K=)&;;N99GNV^L3I8_]8YV>_!5@4I*OELZ2Z8MX;9NFR 8
MI(Q4BLIU6*2MP7Z;,)^XB9^T,,=)[86_DI55N.6>L2%J=BJY0('MV,$4Y!Y'
M7 *)=&J70&6/V=E=0R"M!T+L?\\.>:*;:B26J1ORU2AMPC(EPXY'A]\XR><;
MN;*&P_LV5'BQQ;GHAK;1O(HHV4/%0O[/2U)]%;>1 5Y]=')'OTQ%?L_9 SHF
M;;P$1M5-0>8PZ0JZP.^SC^NR\_=VN%-W%P6#+*VRG^G+-1L@YJ\#NZ6!)&BA
MI6[736]&8_?AU6"N797W;9(N"XT;4A[+TY+(NS\"I'51K;$3>ZZR=3F5@R)O
M4A/?#9 PGR%$<RU0PP\#[G&T5$\\[[G^27PL:?)[O+CZ9]<8JNWA6FL,4?;^
M]G-4;=]'NF2_^Y\J7.FQQ,0)7["$MX-D,QKB(T'D99C7J6DN9FH%V[0\8O6)
MGLSKA/BLN>RA"9"[.]O]6'9-. 4^YE$UJK;%.R,\:,1'O*Y*124BAJH^A\TS
M>#-!@>-V$%]ZFQA8/1!<<PG<G.U?D!>H1\[T8,G0TU;($[AH85S9[D<'59$+
MO8&PINIW*Q6O0X,3$Q3P+5E;J^/DY,#4/].QD[Z<_1B_BY1Z+,3[J'0IC#$
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M?Y):5(V#/RQ_=OJ'-;UR RMM!8,MH2K),V*J<DR=UY/<+:P;?"P"^<V77HC
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M7XL+A+'0F,QR4H86J^+[9+5[ A+2"_U,'S1/(7W>)$G-7I&RLEB>IBFSHSA
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M(L 2Y""_2CCX23!&0JI#F+5AC_LVCR/:'T7T:^X])O)164=_=$J"FLNN9+V
M>'K3W^KCD9),WE8BLJT0V; ^'T@ DS>$SN\+=568'>1IPUYR^\ L;9='-&='
MK^^34%60^N?:"8)R\<]I_O)FD[42 ".)Q&W@D;E!TE_J)EH%\(OC8S<U+O4S
M7WP?/OQ<+:O'; *"<G3,=@FX9/XL*RCI1OK90J%V@ ^E>]WW$LCMUX8\BCIW
MJ#B.X,#V"TF^BRP6)URBE-ZN'?'QJ,"/O^66[W^4D4D+.^S;QA_.<D0<(#-:
M=U#7")M3=D*E7#1Z?G/#2M<P^[2<!'Q>? OM?Q'BX)(#T+CEBE"-BU1"_K+@
M!7S*2@((" L2$ _&O@[2) 'OX20@C1Z&^[,_@%R/B<PW7L'V'Y" W3!WH@RL
M4P@'(L; B(;B?V&1E#'D,H*_U7J9!(P9D(!!ZC;\& F@S>R&')/)U&_U.A+
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MWI"I.3'##6=3UJQ69^6L'HWK!K^AAH!Z!=BI=S.<HN,B(9WTZV93<T-]57T
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MQ*Y;<AT".$J6+&B]G+#R7J$\!M5Y5FJ)^6TI-#\;6I##;=O5:,=</+P>OX4
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MI9^(%T:@!H &WSGA#;LCGRDR>GI^ ;+I"UENF\$9==%AN5_W5]@/'YS^6X%
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M!7E2S)K2EV9GFQ%F3</GVQ.*;/'6:C=1R1,;5I.,P\E6PV22"TX3/8O=ZZ$
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M5'@ZUTO@&4FFX/)0OMS C;3Q??UZ=;"(W8CW/B]M00QY F5(I[+?XZ(X>^S
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M/C)SC&0?Q>8>":P$Z6*!M;4$"JWL8RZ86%0N+ -)X_UDGB>=?/(10"0PJAG
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MM!A1S7I[1*0;$+K6@PA=>LT?*8*AM/P"Y'@B?BK3SFUEV='?]>?\5,-#5%%
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M("H+]SS_68K9*3H2T6C]XWHS$6*17AJ3:'G"SLRXZ]6+\CIV0W?$Y)[N0K#
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M4\@09%PJI/@J W,IW-S"@1*^P5K*362*)=5II%S<$JI]+E,LG^V@=9F<>%@
MWATIE74T8%US(2GK_L[HQVV)XI&NGMF(3$K.<[LON_KCVMX(E:?V9!4^DR8=
MM:Z)-M9KNRXUHC/CQ!K*Z*+]A/!Z=GF?\#'#83W*P%<"+;&YY(J.V2FG!L53
MX>7*6\BFZ4[80/-:':3ZNKKDC+OZH\=Z-SO7VR1)3-U:+J;IL1><9I5X\1+3
M3!Q\[])C!:VBUD]$^\Y_OV=IF1#.2-UQQCO,9C:)<1N':M^\IXI %W9>@VPP
M^-*"]CI]>IOLN?20W'K[\D-7%]3T_+GM5.^ZOMQHE78!68@OFJ6<J@+6_7KQ
MGHRTB7[&(B.9C*]0%TGW\NG;WET8]\:@ZVF/P+<#Q@WKES.)KP>,.7B E1R5
MES1G4SS[+H3Z/K #;9IN'JG]L2?]AL$G-J'@J_6[M\O'CU"F 4!EC=70J<SL
MJ55=O\\,=4UE.L+NB6K#5]0%_JG;1WMII/K<8H\&I&:H+IYFYAEXL(2-[-KQ
M#<;-HG-7K>H&]#<'IL\/[1/#B/"[_;3(.>B^!VNDZ@-)ZL,WA9,T8!Z\S3T
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MGM.\+ZI@()ZR&4 KEP9^EGAEL%]%[&*> IF*.S=KMF2J(,,#Z=,I4WLX7[I
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MYZ]0>=9BI'D!6H]B!@H8?L;0_PL%X+&&HP#IVQ!^0S591Q102 Z)I --Q:"
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M(UWL8>;?GTGI.@2PX6;).#4)OT4!O-9-.5N.,- GK6,9'SNM<::1DUVDOJ.
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M]ONCI]U4** 1 EXJR(Y5<=ZOM?'I$@1[A^J]B[[#GE[.=^?//J_OSS8P+^\
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M0J'E!:.EJX?K,FM_&\50("WV\>A%L2>  6AW!0N&']_N,B3,(T2^WP$^@ 4
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MXMO5AQP=I72'NF^Y]Y*G&-.]C+: ?19H3FVK\S=YTL=4NDYH6._P\?2TF\#
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MK_!,@_X;)OCWZ,J_T=')\/W/9XKR8O]%VO%4KI@Z-S]>FB-P&9)X0W$'V-H
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M"QU/>N^/\3)ZA49ET!M DLO,BS_I3=B]L)NXM\+5(A<<>JE1'V' W.MG8D!
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M3\PNP)Z6VGD3R>:(\J]NC7;Z'/+U(PKH9=ET-L&$WB.O)V]5<RVUO5,G5]U
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M2'E?CZ@4IL4^Q=#NKRX0=(H0*A'=2P8S)'UON@-$,4;!-I?[_Q2C>9U'55!
M/';_]R2V#GOT[S0E#"WY>2^_&DW$<\C(R&3H5?"OO/>6=](CKTH;Z=;^UO!Y
MP(6Y2&5PL1;?$;WL)ZZAQ%+;A2"I7RFSRMR!]B:A'P>IRD^&GS_7SWX>:R%>
M-B=TB-?%+M:,O)PULI-R)*#JX,]9O/+Y 6*D-P^5M2E"VZ@A9GR%Y5>'=TJU
M:XF4;^-BY_$P:=H]]].9>PI'>N=[92O7IT_E08_.JQ*Q+C-DW]?!?)UTR)]&
M:W>M AO)M+A:S]A4?L@,*N#2#,V'XWQS2*HOW$YRC5N18Y;H'Z8O@9)B$)GH
M"%+TXRBJIJ0]XFY=O/);5#/,UTP>*0^;=W(6W0A.:KP#'*9LYMH:B_(L"< T
MXC\:PP,I,G8<F0_3T"^V8FY2E\P^C B6GOVQ/*J0!!M?<O^6MOLP)_'3F@=R
M)1QI3Z5I[$UOA<RG<9Y)[#8BOF'T_#;NGCUU#;,]G:C]TP6>[S8$KI$Q1&J&
MT>(&;%_H7!48)K7CRZ90%\\&C:O5:VL>1CR+::.T_J*D@+XX(OYQ3P+WUVP<
M!:<<J4Q,U2?:#U 5#VN7MD/%(E9\F>*5M0)MCD8(M-%O<OTQOQ",D-:'NQJ[
M4 BOO]5ED@V&EP3P_C53RG8'Z)DJA3N+PE!4=X(1(L7@O>]_."AR_9(;C!S/
MWSA&<[RI,/"\W:S:X\%MI(.[Q-T!7G,A;5V(XI)I>36_[I1WL?,2VO_!9RJ!
M?-'7 1:9O!%%W]4&[C7(9W#NN-7,^GN8Z(0 ?C[F/Y!RV-$+E&1DU'2;WJ0*
M6)VTJ2)F.B?# [VH^)1X.4#W!7"SX Q3U^_$Q5T&)1!%Y/PP;?!7;;,/-L;Q
MH/7$W*?/9?5R8.;A6_3Z<<EY13F@4![E DU,&/-M=^P(6D]QHRM^G]Z>Z.C.
M^+8RDL]GV90N;;1?7)HVMM>+LE6!L3DCN/BVW?F$GX+F;6/:^=)>A[9"G,T&
M :5*YK!F.#X)&Z!=Y#S">*587\YWIW"EF?(J!"-*N?ZAU ]PB,^QJ.)T,V4H
M8/5<%$LVS[U1/@%$;#*^4L$V4&N544,&8'$4"#?.MG17Z%$=M['E:MP>  )[
M);-N)@_#+ZC)_85[/+?SOEO@JJ*\/\HB32N$9\*S\R$Z'A),$ 4:,O%A ?/S
M$F/9(Y[,.\##X6)3%ZXC1:=G)YD>'Z7$&-H_Z9S(M(ND%H[E91LN_)R0/D8K
M=<J8WQ7XP*,. 196#? YL>L86Y!'?BPM7='=(%#324;]+X"RFJ0;.=E$A>9%
MENKEBT/8=M@U4.KP!G;T("'DAX? ,R4TM(^F>112-QI3U)&0U6U:2]M(J@')
M$75R?-G,3H=KC0:1')^-[.DYW$MU\4K1KX2MRB,/--1/Q 700R49=CT?6^RC
MB^;-[\)LFU_F9VM*@RD&&0E&23K?D<AV(+MWXS#,!'/M-?*Q'+B@1MBQFG/V
MQJ04V -T+ML(RW]Y_.E E0!]M&N[GA-YVFA;PBZ9"[LQ5H?V#SAUWDS7M*7L
M1TVNW0SU72 GRI4W>YL)WA2:56LR)4S2R!296*_7]BL.])"TKQ\Q?LLRQ<Y6
ML)?BX_MN"0?KMN_=_X13H(F*JD]7"WV(6WAHS+=;'I$%Y[6]+?3)J*D)&H<(
MNC^F52Z94IY]7_7'-6WO_Q4?Q9[\XR:W7^MR(?FSNCKNZ6^:0IFG+W[8<5\B
MU3KZ\@TKBL17M7%$>^*%:M/O&/ +,[X%+J/KN7NJS]'B,M?372E >Y=C5-]Y
M*3X&X0$M/2.34:NK.*1.=;/;'-@D< C%>OM0BEU>@3!U99WS0[*42MK2OV"O
MT>0Z#<E+ S_NJX5ZY4ZR/(L=&:@1RV&,XJ+B2LNT4X[RJ4Y=V<,JU.*6"YNM
MD7=Q/V&E1NP#GN26%3?0(T>6U,;N0%$_=4[@D<11>[SU.3U=P%Y;)HQQRUK0
MM,(2236SI1;PJ-!4F_I0@2,N^*GWO$>DNT'[E:8;O["&@A?XH24$"<QA"2$S
MDA9")HD:1>6>\@4 G F?:/^X=%CD,+.8S&"GVT G:=N9=5)5TUO_M0CP-T?"
MP-:U"U;8YAU@R,KJS^>_0Y3[0,(E)_3K;AY720:? *.ZN-RK!%W"#UPP[P:(
M[S,;:2C@XV/AN))]#2=)(J0PTJSGU")*C6(7)<"W$R(S/^>7<1L?)*$ES,;-
MKE?P3J#*N\1C:O](5-%E,+(D8"RCVT3AZ]U9.'T]_;-J=D.^]5-UG+%AOF6T
MMO;\8.R0/<N#--=A,37R\&B!&?$B21<GXPN@F'AJ@*,,,2X+Y^47KS6_R,TJ
M^F]$P>QYEKRN,[6*AF9T_IMM6AF,!9]DAC'ZJ%C(:A0I7G&'$>D^D1YU^VH2
MJVEL)K1!T\$)7FO-*\GXSE.6W-7XZNL4ME5G&D%*-+IX"FY_U-XY[M[9GRK8
MX Z@ZW0?T!&^U=ROT6%[Z;!MT3/4;QB_8!XCC::W%625K)B%MBGD?5&-]1Z)
MD2='/3G>CO;]8,6), :_+'0IVG4]AHP(R6("L]+,.E44!Q<Q^J [LJM\MX6+
M5*JBCN-[UL$WA=1SZ8.ARWE;_HR%'M2I*%W/XUV$'W*Y(C-+T*7+-P2QUR\]
M52/IEGV V6:#?+#6KD[T@%8@,$.2UG!8S43!7@8ZZ;"GRV5!$Z'L5"V&0AL7
ME;^GD F[\=VDJ9UV*5;OME&5#U.L+8_N9[=_P2G"QN[7MIX&<AWWJD];UYGS
M3C6.+I(>PMTL-5L[@#_2SO!E_\!JZ&2<+3IOA+<XXL!T4B*^\64MIN?=>]A0
M<=>MTFQW^O:$"$NZ/7&XH\;,YD]OC&(!>I2X*2[01;JF/V1^*.Q]))>66YXF
M3T2N/1U?#PT 06BG[[M 0?9613=MA];1 [[PVH'N&")*NFV%!WK8Q.LEZJ,Z
ML"3+I[,%<"9'?/!4:BV-_F,LO^=-/]YP^.-NT/=3C[9N/73 ,SR(]TC<?U]R
M)!&8]B.JL4F2&YC7J#7JO8@-X*>AL/<"<VI"% -MG>\ 1$.>E[#/TP.8 ;%>
MT9OJZX0.DWXID2DS^I)8TO:>A<1I3-6Q>QT37]Y7E7'H,$3F&J/1G*"EYRL6
MR-J9YUGD"'Y&\9KG1'V2B<.V;B^] 21\5%S$X[J'VF =(@NII\5..4Y;6LQ#
M^4HJDEFJLZAG-1TS^[3"2^:;5D 1+WF"&;FG 6:)]:UL 43; A*4C-I<I$B5
M[LZ"<ET00!7OZ6\O,&/Y:^7S,]U3WCC=65D+XTIWGN+1S_B#"WBU>3W%3B\'
M.NTRP#]XG!M-:T\DZR=%QGGV=])9R2JCIAOOQS^+^5*7&T[4A8T04;I19V3G
MAX^^.ELEZ-R)/#$B7\&F3KF0ZD$VK>;<V)*"MMB'=E]\/<A/T[QF9"5Y\YBY
M^.7F7U65 E@^ P<;$EY4*_$/U'>CE_7=HCI/CS)7%[&Q+H8@XWXCSDJ8)MD*
MLGSBU"8G)<NG(L49^;7G-#^O9?\/L_$+>&UW!M% !4?*/^NX%\3JK>>C=X#M
M1V*D!+]V>$I!QB&:B^NU(;,#+[6B\7V<- JJ\UY.B^6"2%ZTGUU#?)_N$X%/
M=]#A-P3>_B,(;^H[0*M1G3=O5T. #_IT*3>6+RP^8 3@'2IBBWS[#6D2YIJS
MK<<\N=S>L-B=RR:0EM[X("/<U$<!T*-SD>V];.HP;P>DF)EEN@-LC>/>7-#?
MH*;?PNXM,)\NQX:7Q>XG%L8J,U$06VN(!]/0-_B1X">;78 .ML,RH9SB,6RW
M0U\F1V;#_Q5E&Y.U'$,AQ7I,^!D?'TS54W_@#'^ZQ^X"2_3Z[","'BK2;GX'
M$(D&+Y?K) 8+>>3PA.665!9VP;/Y!$_JVA?$%JML]-AG""$?8V+&D]7QW1CA
M_ZQ<5)G6'6 DB^IR7P-CS8X I*X]5SFZ@5FCOFS9>$U8P<&W3NX0F58]P_O)
M>?N#*$ZU$V^<.:W%S45"][Z! ;)GBHK"[IK7;.-?%$4K <%V!%_*2/I FL+J
M> 7Q)7^RTT@\4N.D123"7]MTW#4</IX!I#[Y]HRXJM+$]L%:N*,PW^X?[L4%
M?_*)RJ#R#I N(WHX6[2,HP>O$5R#E\*S-Q8%S/>7%..B?MX!0)35Z6OR1G<
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M@TGMP*E^FBSH4+?H<N.#G$53-T=(3&=:J((#<_MT/1V^XXY2WRO.W34NGK9
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MN0%<G_30O T7V%K1NS((O*G*1&>4O9@]<@$R@8Y@I1"]C<VMM![SEKQXZ_2
MWN@)7@I0(A1SGJ*WCGI(2ZV8-M('Z1#0]*\A\)UD@B[^%+.$CE\3)\<TW/9U
M[8[U/[+*\_%P.'[_>O2ZH@>'KN*]1%:\%EZ=0#T34-EHZ2UB88'N%%H9[426
M4FZBGKGGXQ;.V9Q/)BC<:I:ZR-Q$'UB)WC$=E4!><!2552YKBP!0]B[8L\T.
M^RI-<[X<X9J<WO-+;Y5[Z&SA!M&L0-^;:0B914![E9,6A6M7 E^YUWU38WTA
ME^I6-6[)QB 537^4@' N*!8JOGQ0B5LKO.1Y@T(.:\J978^%=$Y7@:J/><&I
M@P[UM3<T\#S&&E/U8%5O.V=^GHO^43^>@:Q9.YW$81-'N.ZDL+@BJ9>E"*_+
MAW\^GD"S/]JP/N5152MSM,S0Z$?MDV8>1& .0BJJ*N^A=[;RANA[%Z:Q&4$Y
MK3*_E]+M0XY25<- R$P] B)+0"4O2AH157!0MDFN"P;:_@XT) KAU#N8Q/WM
MR+U-T64:K$PV:Z9R01]0TT%^=HX%HRN5YJNPF6U2^]DLZL9\C_HYH;- #+@'
M>',4WN'Q+N3Q_JCY)Y2W^.IM["K(SIWE_=%,E%9Z]3I[#8VK1!92A\29B7-^
MS13YDBP0N$:>+<GVM@9Z$]*%>I 1IA/JI*PSL]X1Z%:!I> DJ\+2()@895DY
MO+KI3JVGI$](2.B8"%395 Y!'G40+K "SN*[04'GLJ_"L" 076F+HG.AM+ \
MDYJ<$#PG8"I$3:G5D7KQ%B:B=DGR6C/OK8KJ1U@5#9B4PO?';M\6KEV86G:K
M8_E$=4[@62K!,S2$B-2<M@Q<!N<5T%R"OO+6U_5Y/@DO+;_=\[9";R755\%G
MF6)FPHC*= 3!0@"#-]!<0*6,G=Z=*5T7[)P#L/O<&R#[6JFRDE6@"4$RHLE2
MZ IJ;X5WR4H!IF]4^ZKFEO,6BC Y6[0I"?=:50]&>&9#H"PX8UD2$9%Q%=$I
M:VWAFW[B?T=0;YE4J;CWWMO*(- 8H& MBS48!A81>"X^Y]R[XI4-F1G9I0C=
M:CK<9GJ_/";C3=7,!269KKG.V[U%G[)"[\['U-ON[3U6Q4N$.$DK61(U2R]T
M; #1L"1S1-LIC52)!^5[EZ1Y=N#W/D[*Y[3816 [:0ANKU[]+I$2$+UW:/]0
M0@*-@=**^9 4"UI3\Q(E^89VC_VV3C9ZH'55R)1HC:S#Z:"?9_2P%=!\5>YX
ML#$7U]O*HEZWUES/R6[0)<82"U.%JGR,CLR#(E<T:B<@H)+H;=5Z/T_HU]2S
M3B,6\M2\I4I%IE:QZ(#*(V(.L2:K8F_%LN]=Q=9 3EZ"*M$))E6@AC.^,F_
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MGCY\\G @$6B'E7'"4I_]2DXX(1VA@,>Z8X5^6%R!YK;+UC]=.^DVZ=PCWL(
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MJ8 >^JK3#5;Y"MM<@TW0D2N*-)Q[\:]Z\RLT20T<0;Y6S.DH42O8P+SGJ!5
M5F>R4E!A.9ID%_:[IGRC*?4%N'MM\G7;=A7#_-%,!K\TXRGD@Q$^W/[Q7P8O
M1OGA*D-86^,[3V-Y]B'FZ8"8:#"N@X]L-8CM8.\(,E58ET$S&C33=O#D($[P
MI5>6\K)5\-^<@E^)0["<W,:E5@0-K@\^GN?+.)N.?UA>-/("0W77OE5\TO!K
M Y2?+?E"@#*L/#[Y21AFSDN71V(N8:UUY69<AUV6Z039"+7X7)F)5+II?&$!
MG,4+ZR!CBD+&)3E!%^:I=HTP3]IK/!D7^#Q4V=**H\GX'5WG'IRP#N/[2,TC
MUARLW$K$=1)A#-1DBV7&&L5TD8D%'P-S)AJ?;1+<Q.5(Q-OXX<5)-YMY,^Y[
M$2.@Z:U.<67##9C]"U;"W0<KX>Z/'^*6ZH=TAF PG@RZX1.#\Z.CT#$YSRK;
M?;[%/E\POMUV3_;CJ/EG]_OW]\K\;%G@"E%[\7#WX=[#P;/#H^'XF)J+;65K
M.;)UP88/7HT?7BI0V\.T&R3D;'WB35;!&^X!.*%]Y#PACG6)#@8-BT48QG.0
M)KC(U>TKD.<>P$XI-(/EY#^_-2,0&X[^=0B#%\-A,QHW[6!O.@&8WN"T<-/>
M]BZSI5T,4N6H6<JI4/<LP;P5EEDC?*A&\5*7Y)=^SI5RP[ER;X8W'QC.[\O)
M]3>AA[D02FH9F0!OD>,3L)!%8D5XI;TUW/);YTY>X/@G^./KR=OQ^TT/-^[A
MHS^?T-35-H^W^G<YW)A"D=8C#]H,3%?E6(),O1 K<J,TJ<KE<F,7&GD]>3,9
MOVM&^=Z'R)^@@L$W'#7QWBCIC8^E;+@!23H)[G)BKE C65M09(ODK'*>J]#%
M"J>7*K)OQBB3P_^_.>K.M#9;'H,6QF]#^-OPUW5QQ1/>ISRB-Q.T5,U1' Z>
M?8#<S<@8O*ZUR=!N@\S?!#.@[AN0\EMQ"'1S*U&7JJ,_YNW]^[]^D%R$']K!
M%(9P=# >P6#4'2?_98 R.9P1[P\B2@[:NP*/!]_='7).196<$#278LB/RX%Y
M:@,?:O'*!YUMO76=-[EN._AV]\#PHMV]QR[;]W?HLMG,(9B"C&=+95K60//:
M*RM!NAJR,/GVC$>#U(=O2-[N1?9&X"BA2NKK@=\VM[:ON;4;4QKZ6>KM4GL?
M?IS.-IAT=A(F4 9'LTD[HT3WZ7B *[HC6R&_2]\3?J4&-SMY^GAUC5.WW1V_
MX?X.RE][5BRO7W']@?/U%_GL2;[@O?LU>>\7-3E_:,YT^==Z;?[^>&U+U2-O
MF^FPJP."F \&>1C;=MW>^I7$'W0WDL;\Y?3_R97_OO<\<8U"7"H]/U.(_2)A
M[VFU<?([B02M;WP^O-W/*Y#C\2%>_KOUQRRW6G"K!;=2NR"]3XN9.Q #'_(!
M360?H'N'3X5_^>@#WO#TZ@[ZJ%W2+FJ#CFR7VC#->V>]UH4)+0M-?Y0L"!F9
MM;5$SQU4?>N8W4EDX%C(U$'?=80ZEMY+!QF]FS;_E[N*$G\^%.:K^.#:X,9F
MD^;?<%,X%X.C.!F\B\-97TM OU;?A'X@AZ72K!_(88,LP%+K;Y5/4FI@3H7*
M="F5&G0!X[;DF+RVDM]Z7L:)PS3'^1NO_?]XL;M5*ENELE4J5RL5T$%9[CG+
M4!)-2$=4"1%_ AV]SM%F?NLV%Z>H\MF)Z]%UZ/HL:9<<DSO+UUVMWGD5VQ+_
M9_#K<)SB<+ '0\C3 <U'N[;F9UL7N9']E>[Y&?#^A3/@P:OQ"+ZI@^!MWL!)
MKX1"M=PP2,>#? #YS\$AS7QLYJQQKE5>TP[BX#T,A^S/T?@]OC'$%GFFX ?M
MC!+O8CLH4)O1O)/>[FP( \W-*9.=XTWDMX?7Y$5]U2M>-9+.FYR4\LQY*B7T
MWK"H768U>56]%D'8)96R_!UWYV^T.7LG>_.BVYJ-YY'_@G;-.7HK5B@GX_50
M"0X^[;._53%WJF)&XRG:KO^9-62YT&!5:I8]Z08\M)=;,D4-7N;=[C_:LX>#
M 3+M*3'O4-EX'X+5X"CKDG(+O6 IY\AXY<E&DRRX)573_S$>SD;3..GZ;4_N
M8L;3:KGDU;I+-^]&QVP5R\H5R_L#Z-IK7=0NCP??B>\'!XA22*>401P.SQ3+
M>8V3X&0!7O0+2N8<GCEU@4GQT,?=2(V"GX[VNZ6X,^B(TV]"#KI1>NW@.[P>
M.LN#=I8/!NW!F#H.#XZZ*7SXG3C]5#6^C^WG>K'[\LD[?(\ ;%0&W\GY.R9T
MN?'S]-_DI>+Z;BE^B9[BY#HT1*?M'J)[R-A.!X$/2CQN'P[N4&,JSX,TX)GW
MFC,=4&/&K"5+.M7H+' %2VHG_F0VF> [S\<%44!T&J=W,AQOB\ZVZ*RWVWLC
M)=KI%E0KA\UTBHJH"X)-QB.*O Z/!_ .)L>#%Q3HC+DKAWP:IW$^\.03%?OQ
M&N=!W7FG$6\Z&\Z;C.VQMX/O*%SD?I!*/CSS*A$OHN8]HF;MJ]:W\^<]4Z/0
M?G^G2E(+J;PUB7&M4.'E6EC04C >N-4\5EW@UGD"IXV+SZA'Q#O1F1O/Y5LE
MN562=Z8DNU#9$/<%!C%G5))43%$ZO4%QLM&E?T77=\0N^:#%U\(?3G >:;4\
M/L3-//X+85*\& (YHL#^ +?T_?3@]..'"%&A>[(N*M=-2NS*UN?%L_F'JQYP
M_GGYX6SA DNN?LBSI81.3Y=?\<AG:T_CAT(F)D\1]WF8_;"_QP9K/T+9T-:2
M(CST6EU3R2.N;S^I'PKCKKV,D-<7'CDM;OTX\J%08<6U1Z>UIB<L39T>;I>-
MN<9C\B\/JUTFI,HR0?&R,*,=(#S2@<6BT --RD T6>9JEC<0;_($169_/#F^
MY(R\6]0IUGRR:#W'Y4NUF+]=;EU6D[JS-@E8?G;ZZB;]+!MO+B'!YY[3;?.D
M]O,@]9:L&R&.6WF\E_*X<Z7]W!)X0R1S*YCW43 _C[%=ZN!M#)U5'V(C2YU%
M>8W<X>[3)S\]D ^VM-G29DN;+6TVF3;W**JXA1Q7)<A=<CZTQ95;?^#^T6WS
MA/,+_L"6K'T6QZT\WDMYW+LJ(6%+Z$V3T,T6T(T^(Z_<1*^48BK22)FL/(LI
M6P;.FBH#F!K4<L[(.WG]9=8V(VC;S\_(TW@\3+AB/$WC#QNOG#X%"S<;-[,Q
MK/\M^=];>FSIL:7'EAY;>FSIL:7'EAY;>FS/-[8AFQL1_]GE12&;*IUW0^:-
M:S&^#<1\32!&!%/!F\J<K9%Z&'&6C#!,5Y 9BO0>EC3;]U0*?^V$\,E<!K<!
MF4WD^*T&VM)C2X\M/;;TZ!\]MGU@K]ZDGNW%YL&9%_4+?0%H0O:"_?BHV4O7
MX@5*UYAO.A[,VGE/ =PR0**4 :ULN^8"I^U4J,T*W6MX3#=_W^"M\;:#$;[#
MF [DWS5ME[TVBJ/<Q"'5B.+F=F?T[32.2IR4=G T&;]KRE7=:]5W\?M+VP(,
MMLTOUMW\XER'M9/L"YI*1-T?XG0*2.&.A$C-9MKBA49QO^M$]K_;06Q;:%OZ
MY92V4"MTK6CH5)C^2-]IJ$/-"!F'GG R'@[&:'/.\=/'E _<8_SDE&LTU^<&
MW^[%28IX6?;ZPQ".N]9MWPDS^/WAWL,G#P=.6IJ2^SV],JV^T$XY#=$O.\>U
MM9D<SIL((7&.(BU"1N_:XI;NB>.L--.3Y[K+SK=2&VESB$P6=!@U6,&"=ISY
MXI,-)A2G;MWY]D6NDQUZO_%DYR-]GP_C_C?A--H%G,:M KJ]/6L_MEM$ ;OI
MB.LK;=YY'?91@Q 3G[1'/+G&Y%QSGU$>SLJ\R?7\:R=-%6LW$8#^E,>3R<F3
MC.>F>#*A-HMC4A#OFO&L'1Z?ZH?+[OIP:\7NW(H11.F(/4:$,Z?71S*>,MTY
MQNCT_5F'.#)U>=RUOT.+-CQNF[FY&M'8#[1?+$4"/02+8-3.32!UJ<./ND:C
M9W<_SVKS=DCA!P1A'Y#]NX9Z8_QC35S]D&'2GF]Z-T&@]H[X\^Q!3N#8>?DX
MZ:&G^4/!GS*!0K)EM;4#IJY;6'L P^$I1!]\=TDO_2M[87U_TNSZ[G %S]RI
M8!7C/""N*%FR:$1B2B%@R]P8X^22T@)I6[9!Z/O3IO"T/>%'W-3W]..M8ES>
M9KY%U17W]]'$D78\[(8GS>=$GBJV=^/.I2)WD?HAGOR:YQ,_R=I.CP>H$SJC
MV35,K(2_\&IG4.V<9HW='_]C-H*!XG\92"YEU]@U'AU-QA\:U"6 0.S?5J X
M-X\T)XK^>=?[%?=ZKNF3]%9;X5E-D%#3.\D\CQR5N+&F*@\R?M:<NSA;N,'E
M(CJ#7F= 30]:L9RT*%R[$CC_7-._Z=SJY\-QG#Y Q[V97^WW?_R^]_3!H,V1
MB!(>H%7,2+=A^],#YB\8A,>CV6$93T\^?_ S2MRI"CU]I_NB0U,S'!*)YIAR
M=C2>.R)Y.&Y)6([07,!IL.3\K%R*PUP4!EST;](\U([ (F(01+G=')]YJ&(.
M34EFOS#[[.%6CW^;>ASE+2'3( MU?'.)_OWHOUSDPMFTB_-V>K[[VG-(DUE$
MET6*CC%5IZ6W:OE*M2P$2(FJEX%4E6EI"DO*1,:E-KR 4/^/O3=A;EL[UD7_
M"BKW)L>^A^0624VVZKPJ69)M97O0E60GJ5>O7""X2&(;!!@,DIE?__KK7A,X
MR/*V)&M ZIS$DDA@C3U^_?6+P9(!KC;#K?Y [;;)0-]N;VZ.NNW!%MGPFV3*
M;T11KSL,ARMZ)O#.\<:=\39_=+M7D]-R"'P!O7&E?.[V^ZVM?K?5WWGQ2.5T
M(QE_2#*N;I#Z\/J$'GX\^/3^Z,/Y67#\X>#CZ<G'T_WSH\/@U;^"TZ/71Z='
M'PZ.%A9\&%^L:28UVMH8[6[LM#>&(_*S-Z+-]F!SV&^/=@:[@\'@!0G7GVXF
M=9A%%4>TCM,HRTGM@UOBU9R>IG*51NJ<'OTJH>O_ET"1&3;#N<@K=45.O]&@
MUS@E)TA1:4)VGZ/] NTKLF]S%PUFFG=\Y(1_?^9^;UKWK-*XK$7WT[0B>^V]
M4NQ%T:M8D$^R9(CH(6*:L;?KL/9RL^](LV7!29B7P?'QL>VWH1]Y:A-[KVF9
M@NY&^_<.6XH+@PPNR59U+94X&;S0/0FNG@UG0=W$10%-A\_&".5+3Z*KS(M1
M# <AF*LP#R0K?:@BQ>9)7RR*7J<&PE@,K> &WB1U^HNMNV1.[[WH;.U\CZJ\
MO]7I=;=^_$,/ 'AO'BCKJ1]YSV#!#T]"Z:1N<'*P__%5<'SX\BY[@H6;H]T7
M6UOM+=55[<WA[G;[Q5:WAP#SSHOMW<UP.^K^K.+3\WL=Y]/CX8/?K<W> P$O
M_]1E;4IGKKRK=WE%7Y#GN37LOVCO] 9T1;<WZ8IN;VVV-[J][LYHV(W(=+VA
M*_J!?O'@M^@H3XLR^%LXG>T%_Z*!CX-W[TZ>PIUM%.RZ2SL<YJHH[O+2*M7?
MV.SW5+N_ 3Z73;7;#KN[O7;4W1I%.QN]C<W!3SN4^M*^RR*&.3SX;3JCP;\G
MJSUK!0=T_,CI2N/P3U"W7 _I;:Z:/OK=6[I,VC71O^MU>ENS,AAF%0WP^S&9
MIPH._U.KT5U^[2-9CC]1-W 'BS&Q7NHL'"O1>>UP1!OW,DPNPWFQ]Y?@MV;9
M[LD9NKN@[R!+AK>VI.<<-\I&P8'\JK@?J_MGCEK3GW!=K[^-[S;[V]WL]%_L
M?J]!86=[HW<[(;;>UE;+_'_WAOV :3P<DG'P -SW>VA#_A2'Y6WNJJQKLZNP
M[ =Y;'<S3(OVP][2NH6_(19^D27Q,*@OXLJ]7[$9O^@L_#(+X6;3?62+_B"M
MD;8'[H/L?\HQ(#X5_-ZABI GC;/T)1<6)G&J;LVB/-D_/0^.[Y]T>2A'X6;4
MQ<WNZ7U7&=_3!$X4_ZJ=YI'=+^>Y$>4/1I3?\O4^+M4TZ';NW_6^SWL>!I,<
M>8;_1=.8?NE^&1@*^)\Y#GH1KWL@[EZ[&Z)[>U;"^W1>'K8Z>("28[/1)XT^
M6:-/]AN%\C,*)?R2Q\77+Z,P*K/\D6N54YII\%IFVFB61K/0^'>V&]72J)8U
MJN55HUI^1K4,OE1IKHHLN5##+T49CD9?4*>.]._CUC.?[+11Z#$:<=5&+>O=
M*)VGK'2ZO8U&ZS1:9[76Z35*YR>43N_++,]F&+UZY$KFQ,ZST2J-5F&MTFVT
M2J-55FN5?J-5?D*K]+\D:APFT"V14ACP(U<N[S!=U*J;Z38ZIM$QC8YI=,Q5
M.F:ST3$_H6,VO]#BJB]%.%+E_,LP+D!75^6/W8UY3P\/SGC2P:&;=*-O&GWS
MY/7-]@-"@FX_"2#H?58G#;KW7DGUF[^\?P;<>Z/7LL'VWH$Q. OS\DL</_;*
MC>/[:>'=YR/2"/A[)>";\HU&Q#^Y&,]6$^/YB1C/UA=IZ?%EE.5?7!^KXHOT
M[_BB_ET]\FB/=#0!,>\5-/A'W,:D11])F';7(^4%TU3)W+SI,#A&A[@\.*GR
M:!(6PK OW_7X<^^GG?&P5=(#E%[=7J_1:HU66ZW5MANM]N>T6JYH=2_4S]$#
MWWNM]?^>ZFG^?XTR:90)*Y-^HTP:9;):F>PTRN0G7*2=+Z[E?<%I\(K;77PQ
M;8._C!ZWLGEOI^_\HD.[#.SW['L=E%_;]M@'63J,2_,94EE5(OVY/\Z4C+[Q
MA1KU)>JK*:AOU-<Z]=44U/^4_@J__!O=Y.,R1+,J_)"8?VM0U^/67__7FSUK
MHO_K5L!'> 7[@ZPR35(#E.8WVJG13M!._9U&.S7::;5VVFV4TT\HI]TO(^,N
M?+']$Q^Y/G(.DFVZ*-FCLVHV2_AG=%8^#,NP44"- F(%M-LHH$8!K59 +QH%
M]!,*Z,47Z6-;?(E3N$/A.%<ZU(=VME_"*'K<VNA IA_$$J4[])<@^ >Z_^Y'
M$<VV!"P$[8/UCVA/C"\X;>9<J49M-6H+:FOW*=?*-&KK:K751/5^2F^%7["@
M>9840@(P?/R5F0=ZPJQW3NRD&VW3:)M&VS3:YDIMTS!G_I2V&7S)<O*01MBJ
MG^X1?.\5S<=RHO+@V$VW43&-BF$5TZ#L&A6S3L4<-"KF9U1,Q&B$+[E"+1)M
M6_KECRJ/BV$</7Z%XT)GJ$(*<^Q7\%J6(?B[MPQ!.0E+\GW4!7V1-%0Q4U$#
MI&LT5*.A&GJ:^UCH?I_U3\-><*^D>D-/\_@$\AW2TSQ^?IJ&H*81\0];Q#<$
M-8V0?W)Q(7KD_;O?]WG3%YIV;7P9QKGB%HE?U#<555RY,HHCE8.F)I]ECSTV
MI&??"H[,](./(UD 3H4?8!%H/"IXD]$^ X_50+":>)#$@YK"RD8SK=-,W48S
M_8QFZGKZ*,JF,Y463R Y[I30@3?G1M\T^J;1-XV^N5+?-)TD?TK?]+X40B(Y
M_Y)=IF3]3^+9%_("RC!.OPQ4JAXY$8VFT)P''\WL029S( L0O,("Q%R)(G]G
MW\B1UV@2FK4$GHT&:S18H\$:#7:E!FNZ5OZ4!NM;=95#$ .X1%*\D)_4\$N9
M/VX-9G35J3_[FF(ZST/RJ 33U=(5F1+_"XYI>.1OT18VX;U&637*JE%6WU%6
M3?O+GU)6FU]F>9Q&\2Q,0 .@B]Z_C)0JOH!].7[DS  G9O9^R?]KFKV0U? *
M--67C29J-%$#/&[T3(-*>ZA2O0$>/SZ!?'? XXO'CCO^?#\MO/M\1!H!?Z\$
M? ,[;D3\TXO^-(TQ?RKZL_5%?9O$@[@L5E$4?RFBR>.._ASIV;>"%7S%P5DT
M4<,J:<(_3?A'AW^V&E74J*(UJFB[T40_H8FV08B"0IBO7XIJ2L^8/V[-\YI>
M''0WVK\'9S+=1L<T.@8ZYL65!(_TO^$@4?S/=4O]U[L7VK_6*?SSB[$<C_S!
MQ7 '_X&?NWAA/2?6E)F%8R7"HQV.:+(OP^0RG!=[?PE^:X[AS1S#GUZ,NSN&
M'*6]->38_J?SXX\?]D__%7SX>'X4G!Z]V3\]//[P)GC]\?0?],_VNX\??\?/
M9^?[YT?OCSZ<GP7['PZ#XP^'G\[.Z6N'^^?[U]F2S<Y6OW_UIG1[C7G+NW(^
MB8M@/TTK<HY/U2S+2W1(< 8,/AG&:1&0!7<9DJ619-E7P"@*K_,/=YVK!%61
M57E ^U 593X7KK<XO<B2"Q44U:! #P;XX7E<?)7/5ZD&5):Q*CK!?I+XC\Z8
MQY0>D]9^.PIHV&66PY@)1F%$O],#54/T@2BOGE6+/A,EU7!A'KDEKL,D: +T
ME_&\%8RJ$KQV-HB"=TE;6/NWS/:#;05HX![FT82G-U07*LEF>$$KF&58=3PA
M&PDT4GT#_9U\$TO<XE?/XIF"@4K?2,(4<XKH1YYLF=/79>7HN-A?%R7-1M'+
M2Q5-4CIGXSF^6\+NQF\G*BCCJ>EXD<1?Z?F3+!MB*6G:%7TTH_T:Q?3 L3P^
MG,WR[ (OHX?(L/)L6$5E$-&?XR$M3B'##0?TM9)V.Z.5F4Y5CD6BH[KV2QB.
M6PNN^XAE6^F*)'2<[%K2M_^@!<(*9$4IOV#&P$+6!B,8X!/QA>('N$['+;VX
M]-VI-$2DJWE93FJK0=\(+\(X,5/ $,R:TF!#?N$X#Z=!->/!RZ;27X*AZ[LH
MC_2>460EK5T\#0=8E)+T*Q=O_)9A/83Y\.#CY^/#=O>%WG',A1?:?;5E[Y/[
M*WZ:J!DM3TDG_%5P$><5O=[]ZM#\*DY'2:72_] 4S*OX>9.*EBB(I],JS89<
M;J+2:"[?"G!31ED29T#NXLBOO?2=X)BN9#95M+$%5F">5=CC((8(CD?SJP3&
M@,Z*RFD#Y* 6%2Y+$4ASYF@OC*<M^?=PS_V2G@HL5ZE6_*T@MW+%[P=TRFFU
ME__ \F^*"[+FCW%:K?Q+E0R7?SU4!6F$%;]?]0Q5T-%;^5XYKLN_'V=ALOS;
M&!)\Q6"FX7SYE_:.+/\)9VO%;[."!9Q:\09[<U?\*5>@^5S^0Z'4UQ6_G:Q>
MT))4KUKQE,LX6?'22SS$_I;O#&N-@JYX$N80 W1'"Q:QK)!PLO5(^9=T83-6
M6G3M2V5$.E]3N>_Z-W2/TR$D3L[W/25UP57$]'WZN5!\J O\60: BNHPATOG
M'_=.8\+<K GS#Q5,0MJ& 0FBH=Z)*X1/@L.5S&$00)I&59Y#'M<TL:A75CWR
M,ULX*PZ&-0GD;,CYNJ2QB.0AS3,/PM&(GL,O6VE"Y*ZMO&]&#*J"3("BL(;(
MPAM3I88DAL^_-U^<=C*],!<HHS!(J^F 3B>][FN:7:;:"I-_LUW6JAME8@U
MQ,YD-4C>17D\,*86/=ZL$^F@A'YM;B8Z$ >O0^9^J5U0\P%7VRB_>;%7<!.N
MBJ\K?W0_#9-Y$?/RN#S.@5D^77IB5_"C7<':"U52J$NZD\I:ASF;A9U F/+M
M#/@NVS_S_HFM2/I]**_4)B?-2;:;M0(=03(NL<=VW^K;1>-B,GY:V4YPF%=C
MWS3DS_JV$T_!6LXAF;OC"7T!?<W89*.%U>9!2D<Y# JZ8(FWL^ML4&/.%/K4
M83F6WPNKR!AN';NZ]%%Z9C)OT^$:JR63%$N59B4=?2-*M6P<530T>\AS^\]1
MGDT#J&#8VG@B_8TO)_U,SUU^ \\EXY>HE*FF/=/5F*N=X%]DB8AFX8^2@HL4
MG6C2QO3Y),8.!,Q#C8OC+HJ5ZP5,(C)AXD@,/6@/N.##3O ^RQ4(BEJXXW)9
M^42% ?URS@)?P0[3;;I)$,9#VA]NT(=KJ5*RL[(4[^NPF,-&VM-$XZ#9R[J0
MD:#8=J3_E9V.:;,*F5%&UP-:Q5B$SNC%5[1J"W B:L\G.<PF&HV=KC..**8;
MDY*">!KQ%\QGM72TAUFO#2D/_1:2^GR\YOHKO'RT  ,Z\>80Z8>U^&Q$847K
M3;^!4V;. #UH&)-\Q!SH(- VTW+) DPR^KCOU?$;:+0D68=D0K;DY>LMU$;/
MWG F+"7'D=ZC[9T 1B]N"5GF"PHC3K^KAL5A\*YI#IU<S>C@7*7+BD7#K::3
M$3Z@<U.1K/1TL-');"2$]**P("&.^T,60RQ^E0KI,*]]\8K@@N@'E@.T )C
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M]Q8/%VT-W;E.< 0A*_M4K.+;X?-9;Q//=$7Q%-Q]W/7$2=K%B"QK97#U,!S
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MY@D"^!'+4[^1CPT56? RO.4,U5VY)!.6FFQYDK(P3J9'O5)K2X7T,8UM5"$
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MNW:5N9T$*6KW,!?RZ)@1PJ]QL047*5J>,(;H+$6]@<Y-?4^FRB0[FQ=LX(7
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M.?M-0VW"^2HW#-_FTC2?L/ BC!.#_)[1$3*X"S3+<K8?"1K]WXT&:C30D]!
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M/.)T$@]BDU5UO1G(D77H.*];LO$4'DGEYIU5H-[Q3C\T6O#KSVP_SY$N)U'
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M2 !_8.6D*FK-HLGFRK-PR/7J)>,XY*^.G*LQP&_! #?QT & 9\J/8W)(5.C
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M27?Y<#,*T^$1S]*BK)H.,9L/:S-BBRG&'8OK7)+LJ/PANRLN_%_E-$:+&,G
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MY&N'>+>W-7_62^I57<!31>1\H)AUTF-F[IVA>(*6Y D:5.5+-KJXMT>\*+F
MR\0%Z7$ZSHY_AJ9OBHL8T-@('5&E*$KZL,-?0ZS 2RF9M=BT="9Z@3R@HEZ*
M^7?&.4W%T]()0J-X&(&X2W""IM,I\\]BA027QXA;UQ!2.\)Z</ TK^=)T,0U
M=A8KNZL,).:*+>E=EJFN1+K!U'3*K8TL^A,]NPIV_S%#M:+=Q+"6A7&1KV#]
MN'-\J2UHS)<8([ 6@L<G0V_RKT43<EJGKI9UI36V>"?7FU5F>I:19)WZ52VE
M(!$/_N*T7,WNI2$+Y(8@Q#WAXH8S=:1WC'=36&)??+HC6(F' ]IYVH-V?AP4
MX898/A_<\3^I%PBEWBTNU7M_UG$U%\X.L>30'=A4C5Y90]]'L81K0H+OZI23
M3A[9%N[,0%JDW 6&+\\\P[>:9@>>3%^*YBE=JJOI7')BS)&PH:2):XP2LS2\
MXUPP9',2_+0@BJ\C L"WHCTUE6\E$KI\_%T7E ](_V4BC6_'4O_/P2"X63X6
M =/FU&3YPI8SNLJGYD,1/PKKFH*2]V!H/%<R4Q(V/;K?RA^W5AD'K(S,0IN?
MZNRE\$K[[!4:RL?' A[,F1"=Y=-596Q;4VSEQK(RH/XM;H2-N^:>-)#!/I;F
M,,;TPD[>#5FYP!V[.#/9IE&@OIX\0/+!<MH=I(=X)$U4LNW(0'\@FYKF*WO
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MU:9A'#?9+LJJ%C/OPG04.6*@ R&C:@*:V"D1I\WU;+XFA@GX)8NMJ3/,K&4
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M?CX*>WU@DM]0O4P/HW4PVNT>1OLCS:<^Z?E0+KBO&8+#G:VM;8D_VMI::3M
MTC(\J^EY T#^DGP!8"D -#5==\/)',)$/R_G-(-)SD^6-F4V>!&7I(XX6LI(
M'"6)R5QU+S=["&M\.8#L"5L0<^WH7B>(I.593,LSS3^GF4'*>8#6#>__,0AX
M/6U:11% '*H[?L- (]2")NEL9CAHA^&5OT9/MJ+%Z2"B]>#_W1[K/_"Z[0/^
M04,Y=BJ6OH<>>5B?UDSGN?W4=DG-\@O'6A_RY( #P"275D;72]@,^E+7=36L
MH)%\6A!4HM7:.X@2TH210*)R3O2Y_L.>WQZY^ <%G>DCUS?'1.74PN[6UN[
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MS$[=N]8+<\ZKND%;NYIO$%0Y2'/&_O#<PN%IQ'NLJ%IU"\W)VC9L[.<[Q(Q
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M8,,"ZMCR6'M#\<9/J_3Z$"N&74DA56<HG7+:)+$D<-$BW1\YG /]&\LU'UO
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M9J<C+3Z)</U:.K_RC#39$/[[/$<1&9GL]*(OW)J">SA?YIEK V8L!=!;'!F
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M)$0F5 K"_;";MKZNTM\KK]"]91%/HD<0\5028,@+[!_L\-8F]J?Q78/%.+#
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ML0E%&!"ZA#@W)C]9&CZ]Y/<%5QSK<-I?4;>A*D<& _I8KLHI.=R7Q>M;\?U
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M"Q%ER_S'MG>2RU6B3XBO5H\OW2J3H#K5PE79H1OTV$(]<LZ6<;XS.#3SFR"
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M8D9=G$G6\6Q>W,SADU9H/;+50W"!KK+'B&0R* DG!^,?6,: ZHMQ]?C0FMN
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M%E$7Z7XE/:9Z F)??&C<P^D<D>U.B+O(O+)@Y;FQ-H9]==J 2<?E3M<0YC1
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M2?8-2?JC^,'G+S*,G.<UYXK3B:0BG+Q&S#K! ^B>9_P&ML(LX;2PWZ[&B=,
MJRZYN;1MKS1#R*1$>R]TM5P/6<LBU;5/,8/PRLQ00(IN,6*TN[5V77I37.57
M-U/G?IG?.%(V&;VL<DHO)\2,#6("A-3K#!33Y02'_:J$+__13.%_?=/@0T;M
M<.#3[[UMJF57@Y$':[AV^.>7,)#R(I?AJTGV/JW 9,/Q4O"6@MW\B5\*3'+U
M#(;,!5S^NC.PN$6Z;GC>$OYV_GM"H"ZX<\X+S].BG.6C\\.S ,_;3>^89@&U
MU [5E+V7( L%?3CKPT/+X-_9(K<-$"@'24%3 5E@LD>U+AI\Q+)BJZDX>052
M$N\GJ8H9-K.E$%DYKLMYUH3)K"%*<I=1DM<O_Q[\TMTB-80 M,\;I53,)<@O
MN/;8W1JO@!;IB03]]<\#T.VGX^.??/_P0SE!8GHX(40&^1M)5_JEH!1]^P>S
MV]A@'($_H(G__/#Q31US..F[(([KIIP?O+W!_,?Y_[;Y>*QNF*:_G%E,2_(0
MN/]3:3**2"D_D5P*%2MR^J@A7E1SLZ_06UJD_P)[L;EQ./5K18 R#BIE6(.,
MV[0^RV?9 >DRMN]@=.?BM:_1XSO0VHE$>EONN2[Y4T)!+<92D)I8?-A%*>A\
M:N[-V3W:='^9O$7J*(H/?Y[ENI=KU4,%IGU+>HHG#P\3B@$<&"D,-8:B&HN.
ME'[B$>;;"!I:7A8UG% VGN5?Y/!)?Q?LM<>C/:NJ$JS]=!I__F/>8C[)CV(/
M^#F?H)G9\W5?H6FXIG=G';M%O41P, B)@G^"176LL-]>R4O!.)FWV;] 5WVD
M(T9CJ&7VK]OTLLW%5+%GST&>.$\4Z\%==UZ OU'AHT6)OBCGBAK[+L\>H(:?
M;OK;)%.C;!2#OKQ+??FFF,'1*/Z=#EKSCJ*YA7IE1GEB,(-$)2R]XQTYD0"$
M:\TSZ3\[M?_" -K!M*Q%/R*YWQ43.6AV,]"'>$_%?'Z/R/NV$J*U['^)B_]1
M>5WP1U^=_Z&T;(\#,]O&6)U 9Z"4$6N,VA35/Q^HQ"CJ_RGA5_].A59@D<._
M(G: A]_@>$L!XTTQY#Q-"5USF8\9=3!Z!;^J4D^<B<,0E<$BJAZCIZU=C9$N
MUV3%G0G!'OZKQ;(T+^N+#2S!0H#/@QYM+DN.]J#:/D@YP>K$>/8-%?'@;Q,#
M2#O:T;TSJN/I=)^]I-!(YW0(BL%A5@K:7MCZ">7B[T3?G0..Y:-M9=&C03J"
M#['G%SL/MR'''B/H4 ,-U(>C;H1I!N\8]T<JIK5[BOM>Q-$I&?1P-'=\--5>
M,A9.RGY!U*QE%I5-K7K'[CK_/2[8P#G+P/0:_7GX-YJB7D@S"*4D)O@;>Q!<
MES\_HOEV_LOC3M E^HV/6 J'MAQ^%U3&.2%X\P4>2>T"I@ 2=@H,=(3#_@8_
M:_2AU84VSL04,EC2PJB:MLCAR[6O/5DQ8?T'U^O"S]P.D3P9W"!9<9/;0D^'
M2&:Y#T7#+NN.C,T!7*&WX^G1 *ZXOX9:N^](\NS;\X!>OQDBAKN]]'^6?K#0
M27-9H\<FO$Q/2F1Z*[0\'[;%!B/Z5&3BZTBC $7A40%XB6AF!%?"$SE,H4 7
M26MB!TTXVQ2GTZ'VP?@YEI>35DHUC&B457_<QE@'+94*L:=QE4TXZ56 KF4H
M.&'G?_[S+,$H&<6N'&+/.A*)0_(*^C,\E3N&'BPHT\X@&FQ@#UX4:$)IQ6;*
M?J5DTPDDT8I_[)BT12GKQ4-/1Z_>_GW 7/(\ 2?Q&#&GN>N29QUI[Q;F@]?>
MOV@:X<S^?//:;-,'W897I!"33?MZ)A;XLZ ^T)74E[TI!"="]L;9FY_/S;O>
M$$DJ8YTI%=^"/8T<^7T?."];C _.*@3V\[/<CT@Z"?/K6KG%P6"I7%*#*G"V
M%U+DPNOFUWHY#G*OT8@ 7C<._G>>7[EY2)=Z'?\F.7W$5==-.[U1),(2>0\(
M3<.,!\0#@W85E4AT3U3NGR1%^+@>R=0+":9+AC!O7%H[>"5;-:8SE2A>30^E
M5(+(!>Y@E5%.,X"9K('ZL,2HVJMTFO8B_Y"G<Y(=3$'<WVB*P\?,D$!%_,1$
MFO+2F67T$R%R)EE^Q7A('YR_=A*(6$]AJ[,+1KIL-"$=NXEO,]#&7"9NKFQK
M;-Q1N-)ZY'-W#8'LG7+%-" (0?U@CY/W**BKYF8PXW9>?I2[Z[R4=29#KLI9
M\T@,;(S6@9*18]TPQK )="'>]2CWP&[C&Z>^D4L$X5WR[V7:")"G,:GD""C*
ML.NH0I_?&!:\9:>D.7&*CXT&HJ"!%AJ:^BHKB]Q0!))FL7WJ%$OE"[1>A&W#
M70BN75J6H.-HP0CAFGUR5Z1+*S_M67!;/'3CL\MP+!I&.0,S!WY+)H_PP<,A
M*70I764+ M4P=H5#<.OQG>G2R#BF([WFNO-7,SXDL\E-O:5+IV^7Z9^9=I='
M_AK>Y_H3V'@P*UN7SP77IGY?GN*4\)-Y@:.G4^E4F3I&$],.\%?3Z55>D_6-
M)-#M'.=0>Z8\]QFE= -8Q9?9?-F[<SC.@\OR6L*S-6$)>.FYA]5U9N8'#Y[E
M4SYIC/9U._BY;U!:)UXDQ0L0*P*L:7F399'1Z[QL41DQSZQX*[R2$BN&/2VO
M)W-6C[!6[A<QC(PRQW! \)CPB\Z7:!26J(MHNY67!9Z4^JP,^"_X+@;I<G.G
MS<'KOUZ#Q;A[::]R%QMM@> J%891RU],079'I!AY( SS4_;G4H=$TJO$=RZ:
MUWO-51'2-3@9O7M]_A=:8=,W"!>%V_3FP\L$DX:?LEE&Y=CXM/_)L/U$X@QQ
M@^&:]&>K OO+EH#.<8\"<G&#CQR8/79[?O;\]/AQHC^>)*8%-/]T^N3TB?SN
MR7/YZS'\'QNE^(_3Y\^-RTF%+L:%= 8@(MHHP&5;@6;)=.I1/6";P-M6)_ Q
MN!2Y4[/NUI8GK&#PQ\M\J8!;]8%-9(5CW+54D4I39_/7LKH ?_;?@WMX)Y?]
MUQ56DE!\$1J*D,DI_9P+/0*E8K*(B<8B7'AP2N49P'*EE-N H9''Y@K^%LXH
MQL_H^)1MTS$=;'%R;(1J2K%FFMVX_M@B2_G%UL#LCI:KS2FU[Y(_9,6E,)LZ
MS'I4->17:LBI=U_JSLSVYJ'Y?Z)B*+=%#X45RUK(/6 +BP.URB;S-%\,1_X.
MV$6)7%@8/0(Q[Q4OB*#W59E/!+M2A>$%J'(,K9(V.#XZ<EB@Y,TT(3)XZ(S\
MG$VXSDPZ[9V01:\Q:<9O_JN%AX)CPA?+MAI:H[?R&N[K>I6XPL/BF*3G:=E2
MJ)[7]_MAUE)G_8+TP4QXCC&8ML$^5XBWF9?7WUN?ZJ^<^7K/F_;>;!K804H%
M]DKW:R=;<,\AE:VZNG_E33@W1N%WM])?OR>,2G0^^4,KR-V[D%ZGJ7@HZW:>
M%?5NN,J(3MJV  23S5?3[ 4>CL[ZU"H[1>XK S7(A0<SC%X&JC.J(KGZG:-I
MCN7K&+YLT"6NB0A;GW&C#)./A:5M%S#%^>P *T+,MR*)/GT%?T3I(,C<?.2\
MA%4OO.2QVI1$%71R=$# )VJR9;Q$,\=:>.XP\V);(V PZ?,R9V@;+.13<#;'
M-8?XW%P^/^8[:\(UP+T,W.MX@'O=']QK1WK(HKV>/_P3R:T$I_]J:RGT(T87
M9#1FZEN?AZ#7&=M0:[PXBNB,,\1[P *G"?^(/[S,YA=YN\"J\?3?.3BE+]OY
M14I_ LN;TNG2G/%55<)+TB0F4Q_@?HQ>W2PK+*)^]6]P 7&^/V<%(@>2T2]U
M4Q;XFU^Y/27\4'&#I=\R9+V'_?FMRC+\Q>NVN"!,SYM)QA]] ^H4<<^5_KNN
M4LS^O &+\"9A0HU$(#N_ER"&DM$?:7.%W_DC;R[;E-[\1_L9=A[\5FJ%.6]2
M1)05Z:1,8)[HZA.], *K*Q!>";A._#9TH=H+#"[04N"C/K1UC?\]GY=7Z2?]
M*:._G2]3;+IQ?IU-,_IOWOR;GYV,/K85DOEI*/>OP]\/M[ QW+\JY1&:+::
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M%NR3T\&"W2.EI##"27F ZLB1;V:7!:&SM:[1LP0RRJ]:T/J?6"A@;R]&WX6
M.\"[L*DR.QG.__Z>?\>_DEUE:*KD7-9Y9O$3CT<M])4TB;.M_30<T.& [OR
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M9T!-/P#4]+Z[02=*B37 GO=*UWQ3L.>MD<QA$Z7ZS@3U-Y&QV.]@^@!4_II
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MF$TN"QC[Q<WH_3R%WU>+[RZW]I6WH<X__'GV_:[VD,G\M@P'S&3RD5[')QE
M8U-C<'QY+O-L7MS,*<YHLEA?B),\CH'T'GP&RPF)&H;6X[U$23Y[L2$#BL%"
M]B$@#>"Q'][8S_T8:2%X.SCC1H0E,>KB'@1B%WIX6W['^X^$W.\)_J:LX\'E
MO0V8?D<PS6U#L74&5[OO*RK.^FD+1!"Y*,H'=>V#',+J^.?:WG:W30WN6(H,
MEW-G62JR^>@BKC7\OD<TDG.&3P8&Y#T]PW1\^2 7]ACK(<;==-P@.<RCI<0&
M8+],= 8%[.N7?]OCSY1/S3<"2MC;H-F9<O\/ 9LA8/.M2*4UT90/Y>13-L-8
M3G5KC,A6?;I=[K!M2 1/C[=N7AQC%KL%E@_'LVL\7QPEL9IY;(>X/1='L4'/
MXN^,(;%90Z>V&?ABL,\>EB1\\^&EZ];[86D,"#9DPR%\V30)BEAOAZ-W169-
M_+"YV*YYJS<Z_QPX.(F6"VB=>33,VBDDWR2NVE,:[H5%8X7:C@S[@@8W6P@$
MKU_>K:- :Z,5.]@];*(RG]- MN7>?7%G70]6TVGNN/G!UGV][ILA>S7D+T*7
M=?=1K[O72 ,<< LX8%C9/, !!SC@O9.PKFW6E8YP>DL2AJYH<^753CL_[CP[
M?T=]']?F4.ZE8=ZIAHM_W*<.D<?'T93_G=,?#:TA;]T:\F'X]#NX*(/?OD_*
MZ:MWENS+[.^DM>3FQYM=]O5M+DDZ;1_?JGL*IV]S8?:ARFBHLQWJ;/<@^UM>
MHPF-;>MZFACLIM]EK-ZF/S#D=#\:ND?>9<W-@Q9A>YN5_SAZA;'/(2<_Y.2_
M%5VQ 5L;ACWZ2R4X'375?-3'T02OB"F_&+R0'>_9+_@2#>S#SMRZTN3I)K&L
MKUL/N]LTQQ>E*BR=][,OBU9Y(<TB-PG9+]F[DZ>KRU2^%I>W"5EM0NI]]US>
MO>3=/FG<RF"7ER,,V:KNB]J[R&E-5W)\[T7X#.WA_;S/EHCOR^[SH,YV'U0[
M/NI8%;>!0)!PW13[D(P8DW#4SUAN,'N[Y>/;%PQ?G)//0/ON$-OWK<FJ>R@?
MVB=FP1TE\T?YE.$&/S[]1KW9NPM^#NJD!T" ;$*]2,KM4'5!I+,6\VM%CXP8
MP=!#D'VW$GU&\MU"L V1SWV/?+XI"@0=OUDLP!EI=ER6-"#Q+!+OQ8#$NT\D
MWA 9]B/#GXKR^N"RO.8P+XIWB?/F+!!R%0BF_("0$17F\5#UM=S)(P,7KESB
MU_F[,<8>39>EY$0X.//L*IVW_'*4]Q76K)HBAUS Y6E=9XWH]44J=+67V7R)
M&,%K8>^5,0Y._.Y/R[0<%248'VU5L9[76F/0TD3IZ/A(0<J@[R@-*OUK\/)]
MS.32T@^_&(-J$*@[=DRF^54^)8DGUX $+%JU-=GG5VEU0\$"> [&'Z:9>AXE
MQZ^F>$O YIZ!58V_G?7U-H>'N9]W[',,Q9NP\3R[($G*EGR0!9K ZC855XN-
M8/$FE_CK&Q+MY;C!D,[T</2;-FM*1N"ES//&#X1@%A'A;AX@.Y_#K^-%0MC^
MJ4J+AK#=.K"3HQ&Z'+6M3X%_H5_1C++9C..#NB8ZY91P>*!:KO*:20ZZRQ2D
M9F!$$]!#,#'XL6YPI6HA%E-?9_37X?FA/@F#=^-,8-LLS,"Q2Y=-"[-(*0$J
M;AV'Z.&;[RWCS,<JG6:81!F]F\U 4O[G__WYY.CXQ4^(R^'=^^O\_<=W"9R"
M>4JZ4=TK=\^MCNR\D 9MU@?E<5DW,<ZIKW*77O1<I;,J3^?F J5%?; A&=4#
MEP:T8^ 2MW.3ROWUYS/XS44+RJ^L;N#'JQR>R<+@</2ZO 8;JB*["$Z:?H%\
M_ *>R2<5G@A?5F F?A./*>IE.*GSLKC(\&S!RE&[&KY5*@WZO\M'W#UX=+C&
MV4V)$?0G[O7$0<$=@XN7SH,+5A9P"KO0,/3PD8^DD._!59I6[04&#3)0 #G^
M?29WPKC["DDET%I9:VD$K <LDMX2[WG($2W1#0Z&4*BBH>N6.G$4V,)VEH)I
M2H]!2]*YY!P#F;:R3"B+RPH.3&&D'@AQD9GI9%)64Q*XA,(SPHAB3<[DYR5&
M=^;I=3(:M["V-TL,]S!@C*S8;07@X>@,A$*3?B807U&TL $9A4L6*9K>!0UJ
MEF6L=Y1J@<Y6E?UOFU<<G312B!8;9U:VM9GQOV"%ZFD^(:F>C!9M3:>L@>LP
M1RV0DY"')8 SI_NGQP=%Y8(E+?YM0FO*VX9F.I\^O!?PL,%8OX.,6VI\KR:;
M,&YS-L.]HHTWY!MX_-$L00LD5>H?_(3Y,:USV'PZF&PQW'!<DW[D6XJ*DFV9
M40O""F_8S0BO6%G5B<1@]<K"X7=,%A9J]:3D7^:-7/#T(N,_28R0#0_XA)6?
M!^ICV BAD73AM]@.@A.93?7NP@! FT[@8969EWX=)%L^Q:_B+[*"SJ_S-'O.
MAY-[!YR_;@%&+.PN$KMNQ_^"DVT*VU%FSU$$\F9/+D'"9J /:SS-)>) ZL,1
MN+'R];90O<2V;L*B$T66Q,L;>CJ"%*+!C K7HQX5&<;54[T5!5T:]'G'J(#@
M3WQ%KK/(N$6E*15Q7LQ01+)#C0.^SD'O7>4ELT&L&PF<3)YF(M8\'.OY%%,.
MF 1&=8/9!F]LAZ-?46>4%*!'ASQE15YG_+Y:1$>3-VC2LPD[^>E#7G\:_<KW
MFW_WA'Y7CSY8OQ^W\HT[WO<RWD/^RG2C@-[@_-\:R:S^!]^DWS',!S;FX/3O
M.AL)_RCDGI 9B!<'#/&2C#4.BR[4*4RG5VB:T;_QOJ*X$[H](6ZMKL!77$'M
MJD8:BH*J2(7@+S#5KO'J9I](QF R,'/M #35\,7V;&3%)1F,\,8<HQ3S-B,3
MH*W$(?6/D@Q2'G -(B=S<GDD[2XS,?:7('K07G7\!)+8UD\V#W?&2#.HT,HD
M>\*$J+FZ@Z+.-"X3(D;[.@=7YBK5-\C*,U^F2G:<-CI4&0@T:N<IV5-2#+IB
M*OIE<V &68/RW9.0>4$&1(+KQ)X&C&N6X_4!64NVPT6599S&-#4Z\.Y%5DUR
MBE9434'"&C%0Z1@=,S*7LL5R7MYDF=:R%.A"IO 85B1Y<87O0'.MKN$B\=&*
MO*OW.:8VQWX)PS+3#!]GF&+6+<&(X#\:2DIK WI=,\ $GT\A(%@WC!O#&ESF
M5.'O1?Q)*?*X:"/9;NU.K+D$@7%Q*=D+F"4\K-:+F%=3MO.RV*Q%(6/";7*9
M33U%C5XQLVM.P5_"&V2L1_*HP,#E[X4N, R03C3JSBJ3MUAM/L[@#'#2A:)X
M8UPPMITYJ#[-:[* >;YZ6$LT7CZ6UD5N>('X4('QJL;V5B<L"8^&( AB1D:I
MB!:V,63G05Q<EW!UV>%&*'F];%%448*FPAG;<(;8*?!--=WA6QPBP0ODW7)S
MB@8;Y<'9*'VZ\C<\URP//K ;I^6$[\79/).XTGX9*1:V]N/#-U@^2ER1HFMX
ME=V09-HVEV7%P220+K-LBK%_>"3:'_05"66A3/:IPCC.0W$CDUA(U#>G\+2\
M!\%8"\2X\MM!2!<7M0EN9FDUN4Q<NPG^A( BQ,/:R!T\!*0RZ5D2?R4,,E]@
M@!S?R?^MTUG6W"3?2#S9!@+9J02!GLUI56!(G](+^I'BNQ@Z 3D,.S!N6516
M&08J1Y^R;$D?T_!M@O8HB+N\Y@=5Y:+D;Z ]EO&B@XT$UT&^ 7*X0&W$)#;3
MX(]51BD*SEQA2)95]#AG&ZT&WQ?<4E0(%-$%5>LH>/C:$$[9O7<2@<5K:D&B
MY[Q)>CMKV3B89L8AW5]9"H :+L%&^IDC[?"-5V6]@#,R&9U-&I/3^O7G5V>'
MHY>YL<K5O:%/F).0T,[;0L2RLD?.>?5[ LZ/7F?I'.RY<_$[W/>]?WU^EG@3
MF+I#I]%P$H6JF##OES=R+= /JB[2(O\W:R+)@::?J.:Q!L^CSB7JI^'M'%8R
MMWH+-@*NFWISZ6@R)\S_W//[8 7 WEW0,^@"&(\OKYU<0)7-LJIBNX221S0
MY+3Z)XI,S.TX9NT!6G<WONUWG8,H'F<VP@]/*M*K_$+#1^H[PE'4D29VS%(Z
MK^:C<ZOI<8+(9"/_@E0Y;I:K/2ZR8D)YB%E?@OD:4R7UI1LKJYMV*LD+K%N;
MTT_DBYD18%"/C@HF7GVW&6//TQQS(@-GX*ZEQX]' U+QSI"*@]-PV\ F 2U
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MJ?Y5?MX667<X.L]A<S$[)/C47IC@A##>/"6R19@N(_,+>2-S96BI>2XFJ&*
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M&W$SN,9@D:&RO**!I8MQ?M&B6Z8+['31Y8;T5YFZT-0N_8+KJ&@#N5"7+-!
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M<X9T_?F/O[SZ]FCQE!H;9]_ERP9W/-,;TO4]=E\"6/T)5?B(:PN\-LE[X2=
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MX=34,X=A"7F/U.:E]B8P"$A/?;DPZ&QXN4&.9BVG0+D?'6Z)H01)4[!R[OG
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M2HWZ]<"$4U?$MG<%'"&@HA%V-M;O 1/CG!"^2JF(>JWRG9!]]VFX <21 )W
MN 6\@)AFK6\'O5)3WSZ>O:QOJ/8^EY$7TLK47J'5N.F[JTW/>$? "HK6G2,B
M^A;. NW#PF%Q0^1$X,MKZ14,4 &!E2H #TVU_7CV0]WD-4;$:O9!:(.&_]JM
M( ]*?V6&\.*=< J"O,!ML=>O7O"_Q\H<GFC$I$RT4]<V700&YPP0[0S.:;DW
M1R>S&&5[NIKB1,>GI+])447$]Z2ZD9>[P(SO.S%)#J$5\.,P=TH28 K"$,3R
MX"R_(70QYXK(/V=$ !KPA6YE#E)^;@*-!4/<4,IB51#0=*<2O\+2)(0/?O9N
MKFIMC_]5C\[39F$B$X3:0XCV9T<I_=482(,%4X2T7_ YO=<5]QZ7V4TKNI !
M#NS>SE6Q+#QI<F0RZ\WF"!L<;Y74Q2<A.QTD'")L$ZN7"EAGNB]!H45,\8#V
M-RT:>A_81)8CVQX0,3B< 5X>G\ZSUU?[UET^$W$T\JI9@DJ)0 .SAU_R&^X1
M:X/Y)M.BXE5K1?.-+.,@2B:.#C0M*VJ #I-."#CV'AL]/AF$=SB>?FDXV&YI
MBZZ:F@2*A%4*8NV)!Z81Y=?2<MLF+LLT%M 840W5#6,E]L&T$:$PT1P/6O(#
M\[1O%M>C6J[KC'/!^D&[,#:>P\*Y5%=U(7AWHVAFKSF?7>EAI_"." MN5'=B
M<ZJX>NE &*YH.9N*QG@"B5Y="%VR- \U,F.1V6W$?0>1O)D7R;0$X:&!7AOT
M6 N^J$:-HIZ,1T8ZIICY7)OJ3KZ^IKIO"A<-N,MFTDCS)J 47X0^R4.#W9T?
M<*_9^E!^1%T9FO]S@E6O8;6?DP&#PTCM7UO>,V)+14T$7Z&?O7"[G)V<-SGU
M(!<EM[9XYW-%HH9Z>-(5SI^?S]&88WIX:;<Z@_- /2#P/SDC YC+C$!@HMKV
MC2IDD_;KBCK^M[N\"U*/KZK*^84Z -KD)P\>/,5 OGG]_-6Y)YR'9 /4H+/E
MLD%#3B12R'RP+$4>5$)B%YGF8.F7,?/(<'LW.^"83/;Y*[)01VX_Y!61,#4Y
MB#=6^<3%@Z6^,NV^;CZJ'B:4 Z]H[P2.G.'=S? \:XN]*K'Y]>[%G#Z8BVUF
MRJ267J;W-"W4.0R(WI&Y?DR  A;%P6#<2_YQU=5Z#AS<USO>W<&DLN^'E6Y4
M\?BL1%,;T;<937AB'G"G),6W2@I#8.AEWMWDPNHU7JA^Z875[/LKJT"PR8']
M5"P_5V5:)?AAU35(8'211H,(,72A?)(-Y1BA54(?D\=AUAT3 \6S$$BIB#$E
MVL'3SZ-/JO\-^K=U[AQ'YSRQ6Q;(B99*A\?-G_R;/+#Q^(&K5(4(2$Q.(_F+
MEZ0QHEXC=SH:;1-CC+(U>3O4:4J1NKMVL2M9D8V!2Y5A^IM';W7B7?J/A,]%
MI6.XCZ)U=FU%GANW3Q#?MF<^M=;"CHA,(07"SL83=2 $F0W@'U@/_@=!_?'#
MJSRD@R1=="W-04I*$]S.B<'38CBT-/Y16QH?'5H:#WH$O_LR3(DA$STS<Q#H
MR<<ZMB,^0<6G>HO^7E]ORF5MF;->3QO_=QP<)&-D?,+@4*[=_8F*"[Z$B-::
MP]-Z@Y.>[^3!=O#\/AEYL40Y3&E16N:W;"H84.JYI6>N%:YB67ZL$0UY/-!)
M&LT\,&)YWV?:@:&8@->1#WUL3FXD+1_I1[]GO-ML;83F;!6(![TXT2%K@]%:
M1)X"=\B'C/AX]JT2R[L%OS@YHJNJPBV W89N+*L\H@#%+Q20.DI,27=3AH^X
M=XJRM8:O9<+_"XA7V6BMTH42?:URHX4K>KF[@&!@YY#70F4RJ]RNFGMG%*IG
M(/,(\F<B<,D*I7E9'DD[-47C$XV<L4.<W^+YTR.#K]B&O%BZS*:AX;D64RQS
M%L]\JZ%Y"(1O,44A&WE18(+C4IIL&B1G6R8Q1/F+OH:*W W+!E(JQ+<!X*\\
MN^LU#+H40RDE3N4";B>]KDOP>8X7\X?5;PZ\^;\VP_AGH<\F(O=#CO$W.XLN
M)*GX\,'# -E_?NY3^;1IFMQD\T,S:=1X@ZTEL>?DV=35GCG47"*2\N!SCPJ[
ME.DG5((9W;WE?=+W(\:GHAV>F,(#"#/:LLEE5AX,.6+Y:2T8S< 7Z'9RFY-/
M>!O4KV^81<N=6CD)V[?UUALW6XCVI%21*OV*=#+9Y _N*#Q"4JZCE&"_DEH;
M\0W(^>-/%Q7:-"=L^$S9G%G'!!E-L,@RSX8>?5PG#&>VL_8ML[/)#6^NY)/!
M4#%*/T(Z48K64A]H1C>'8$$[&!S6$F$(B-PJ:RAU7>E""V<FTT01ES5C J??
M!^:V&C5\(0D=*EXEZ4ME5&W#3:G'3%I7Z& T:^0X6K/_N!_HPX3O;#)_+719
MO %42, X'/ZT1 G,I)(:)>[D3=?Z'U2S<W,G,@JLD!%&BB<\=PO]X-_?.3$B
MYC7@4+B6[)OP-^8EVQ<Z\Z3[/ON8*:S\DH03I.FCAC=$=F).[&IY==E=S6=N
MCCHNE$H6KY'7'/!A;GO"NM#6=?X6^3UN$"2Z*X1FIN0Z#5J ;LI4?2'0%[HG
MEZ)ZWFP-^:Y9^9Y[=IE#]GT&XECZ31!ZY3IZ8.53)6'K!=_C3/-]!C_XOU[U
M[A'OLVM,R4?=@=-F_Y5S@O-L/?>OQ-L9YE@S,LI";#U()$<E=,E1T\#=SF;
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MW_110L#G*;#G.3] -QAXL;Y\C/Q4[FQSO<]SJ&>6I?M50P>[27NT(/0&6B5
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MYI"4P=60>6M\^1'#<O^)4KS^_IJ9)_%J)O"9/$-Y8P+/J%C&%JT2,V-DY<6
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MVH?M.AH&6*A<Q X, *[=T=CG7I7$CE=&2)$!VX%@*_1()_IC>OY,2'Q@8Q1
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M^;[^Q$BX 62KFMRA)0S \+:!6H:=1=F#1E;E=ZA[/E]%-P"4>*NNSU1:;NF
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M#^?<<8:JT- Y8'RW0YF/LJ98G<LFV]0K,)>,:W=819KY>:53_4E:1="(1%L
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MW_]\)@^$LE*862>[$TL)E:3.W8#T!81[&>Q?8M:C+T^,>4R.3SB9]XF3F4]
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M4LO9]'W.OI-LG 5=$)- 0WHH.9/(0;/-VC8350K&[( 48Q<=5PZT8F$13UO
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M$R"V0'A)LQ(=YWWVHUX]\B+RF.P+A,KPHFM68N?]J@%O>_@"0(-%8,N14E)
M$6)+<+,P)^C0-4<FHM Z%UM;\4*+RAIV*738BS;H7.MX?#1CZ\&IP=2G>\_:
MU^9"%MI+I8HX2?#BS?&7TJ%U%',(', VDR']@+H2(N MHMU1&=H84DV-E9>M
MI<TES=BI0.=0^QE4 -I\MA=HDF(>D*O63#G[MX[Y3@,_3<YCC=#RXF3G@B)
MD630PK$L([IDK1*K@4!QQ]8"^.-8@TYZTZW#+%9\I;V[EVT?PL"\6S8?*Q!H
M*UN4H4W!'8=Q'".PC]/_?]',_O)_/A$QSJD*]B%F]5JT3D/2C,-8I3^!1MV!
MIE[BYA,!\@=:':\N8)2N<I7KX(Z':_>.7:4%5@FC1^E@^H75P(ERJ+C:H\N%
MU6Z*\QH<R,%_(W\+TI*J->#7^:J^JJZR9A6YSY->;HO9C;G9$+8AR:(V?#[T
M2$;;D7MEUS$^Y[-J'\M8<H@DAP?G9F*,T@QH90(3P4!@T_A/DJO'A+TF?="Q
M)BAHZ5()U8/0RPV/5IU.P??:"QLCUK&#F(=CP*M.[R=*QI8$D18-E/'H4QTW
M*NVD@*!@*?$J>Q3(/:&G3RJ<GP!%-P 4?3T!BB9QYCN'2OXC'VCT,.DM14Q-
MMY5$#WZQX':W9J\_4;2?[V=E!J4)L'6@@J46/-)U5W5UTJ?("?3:TJ>7</IZ
MGK"_L"$%PRY]V_'?@KK*AQL3(OQC6=L?'BK76\L!;?6CPL&?R+HFGUU9 B-_
M\C??I-">\-U5O>%LZG*F>\!H_LS'$*_O_K?X])/3&9NM;QXS=L9=Y!]-QJU*
M9TH+(&Z(WUE!:F*PN62SJ&,9< 6Q6= Q[7I*G+-T'\?KVPUQV5A-R3FF6AI>
MJ6U5YZ."=TE.4:PN9HWB..@E0TBQJ;.5])+&-E;R>"Z*1;'STAW2@%8TLYQ,
M0KW/P^]B@QNN"T4>/"3<,"LOP]#47!E1.J#05'E8?0 ([ZWTG6M2I(F"PX"'
M+XNM-,;J%"L75!T9$CA$K!MTP6%\F>5]:N8U*3@I"=Z#\%2]BN Y"S'IPSJ:
MKFR]!NB.VW7K=LO6@NQF5Q6@$PP(_5K;Q1V+0R\5K]U?>77.\<21Z12 V:;>
MB5?*0O8H=1D!<](<@->*#KC0:5WEW$_&/>-;;MOFY)!6E/U01WAI0@LAQTH7
M.2"FH2E0UK5LS,BG54H5P2>OC+?R\!/.\5SA18#UD!\.X<%E[K@1E7^^++,%
MTS+6MK8YH<:IW$A#HC@""A(9=,%K+. =E#XR[KI/RKV?4A W.'N05[[*+=^O
M^!QM!9+^[E8P.2O%ZAQRBPZF*33SK)P:^[I3*'!96H4]M:NREI4Z@5D+F38A
M6P9RDX08%E&J'W9*93A/>WTTZ\%0K8UHIV%3!](]!I3]D&N5?^YD'V+MHS4B
M7.$IY=0%;WEZY# N<1$UI=WC%%@5*KYL\M]SSS+'X]^AYA+DYO*J0'>_L0?V
M;.@(I>I13UC Z >/ZT"9Y[Q;FKUV5^8+J3GA;EPT:)/Y =;$$3XR XTD.""D
M4;< L?%H%'XHQ[:#GO2(<[55; UK[6?02':-(%:N-R)J$1AZY7#]9Q<'U[5<
M^U+WXB]H6%N0?QY2069M>5Y\I42I&[5*R*2!/$PRL74#E"6-(1]GK9V'O!6,
M?MI9K8_ 5GTG$AV)*."S_\?>FRY';EQ;HZ]2<>.>+Z0(D-;@8_M8$3>BW1I]
M+$M'@W7_@E59)-150!T,I,I/_^5>>\B=&$AVJUL]"']L-5E$ 8G,/:Z]%E-!
MQ;=R:N(S.>)%7?H-4_G%)[P)W-/-1@+,.]D+XF (S1G^?.8SJ*!45@<%?MG<
M 2\R)3BZQ@DR6[RD0=F$$:(3VG*#GE:0^%VRK<^G=J?TAE1 Y *<Y^OVI3IW
MP<4CF0Y:0F"F(ZDF(!W7[$)A3S&%&]0S1D:3E=GL [W2SZ;;7[B_] 6)@),"
MG\;9H]]B;\)4\IO@^-=RRN,6<R*Z1UI)GX([#I"4N-%!W@$P2[2?;U:AXM5N
MD;>F*/';%]PRAB?35.#<#+/*EI<QFD6;"=%Q"4)X67#SS=IB:RWL-=?"$L1%
M2D2BR$EIO&=?5F;M1,!L3E[IJR:SEGN@WQ)8M=\<FUW);-M_W1R?7$7?^N73
MK_]U<85)"M5=%6__W3^?D/O^A1@[&8DE:/NEN]/Y?&4ZZBEL(WZC\E0JR3?@
M?SEE6'P@^67A C-B<FR4MSJX#^%6 %V>NP^W$F.VZKZQ*-2S5#.%$-\J:B"L
M7\LNHI^U DK=F#/[^1>7ORP!@:O-&!L)K]UW[_0L;@_IJ\'EPUCC*Y_0T>C^
M@9V4E:YXCNG3K[]![*\C!F+Y=FG7@;[HA'R 35W0)RPVW][0B,"'Q>8C;C-\
MG)Z^IS]VCZ*[R@%%1S<W3RL'SD-O>N/%@]&%R"XZ![G];D A$$Q5#IJ"\B(*
M76<#Y(Y!E_Y+1G<F&WCY?3U]D!W/&'D<NSC>(<A4-1G/OV*DB"B8Q_UAT".L
M<]A3 1R;AY9/%@DC(;Q ;NHGID,5I>'4Q9<B -8%!(]I<R\\F3),6R;"S%HC
M6-IH@6^MD_0;>-!7'<FO-;Q7@+AWGH!8%WEX?L% C\WPTADDV+4CAM6!_,\_
M?9(*"KYF[M2N,,M7UH*<1ZZ9Y)@4H2JNG5HWP/+?H0=&H'"ZHW_RUQ 22CIB
M\L5*D901]B@,63^+FX['E7$ODWL\P]**.33/O.BXF$&/.TBH?P74#KT_S*F<
M/;.M3 E.=8\VVR^^_C9#OIHRUO*UI)B:4>3YEYD<$<];U0P3HEX(R9?$-X%J
M1:H% $O(Y$N+>-S]Y,7+8)F6:#UY'PF%!*VK$>G!(NG_?8"M<:-(M*_M98&N
M%6\ZMXS+*P?[+'=C5(:CZ*RP'Z!:;=!\_'1?49BGVBUX5VY92NX8MMH>PAZ=
MVWJ.9?ID-$[=))C+=V.XQUER]:[BWMZN94&/LSC#$8A0V5.4>%&8B?<5[>X#
MY/4 .\W/01:,NEEU5_PZ&!?EB))+K$YQG_H#-D*K$W'SCSD23"5 7UY[(\8Q
M>4K$DM@2Y?1*QHX95RH=%WIY3<UT%C1>1$>><8GQ<%\WB-BS8&VS&XQ/19>Q
M#2"B'M%Y9S37[/^IODMT&0BQ^-;%KKBVQB@X+!(#:4@Q4!K1F%O8-5Q8PX6Y
M%)OF\J@#7<NVG5)W3VRGG*FAT[Z?I0[_2Y[>6MT+1HKI\0:T&]Q!+M0Y&O!4
MIJ)_ -=>%7?]C8H21.N?K+(I:"[?-+S3,8A%N6O:9S@T\1+'DTD2YH:N)T@S
MSM6YHL8@(3"NRI['HY;-+XYSUW/%PAMMR[I#L+EA]3"YXY\ E&E-,6,8QGDI
M;K*8WJ'^A\0&F.KE5"KE%VRCWYK#OZ)Y7S*:]\\KFG?5D'[MVW 4(L)&2_#G
M9CGF1D*, N8(S1?N6AL#N:0@VH\0ET54(\W=)M3@_Y+16@J7F3)"&)\7 ]CI
M_(0U8WT+MC01R/MU\]XD*NDWP7ROH=MS<4=G27%JDV@(![ZK0*1"4XR@)J52
MQ4Y<>B5^1$''TYNX)RW'"X5*B17V!09\U.3D/BW,O \HL9T+I4[$%U4"1-Q7
M5\V.0DBYGC#V?/_DN^\OGC;_NI"2N8=V>.IE=WOI&?.DUZ&I\<NINFU<NUTP
M+NJ1[-A,2I\52?RHFHF,IJ)YZW5%4WYJ^6?22A"-<LX*>6BNH9**@J*0U]O?
M$6OI8W4ZI323B?C&MU/U;E8MX8:XM3NTVQN52TVY9J]2:JLM^KW:HIQ)D?;I
M5=6,J(CBL@[Q,)W-M!!] 9\NV"PF>K?*,GV$*F%I#U[&GS&=0-R+^FNO5-OD
M0YH&!,41(-LVO2D'[(>BE# BX.QQ:=RZ/NETSAZMW,3:,SYN:/4EQ0*;SVX%
MD*K$"WH?";\FDP$\/5H8\V.!]>JY-\D*!/D=I +Q4">JB!+[=/P=OM\J0P:C
M$=I1?VXJ@,!#)_]]62A9 U4I'@S/'M')L#KSH:QI[&546'L1&^K)KX::9SD>
M))J8><GL(IW,.)O]K/SGN]0ZAKS.XK]LI@9EEN2X7EHUHZ*88!3:"92A!8MT
M]."=T$>9V.J8FHZPPAU7BQ%)I5%\I37AG"8UQQ8 '>[;=[-E*1IN/V!VQ"*]
MO[ZMWGI7W>KMRG:D;??7/UW^Z4]__H]/)DGXKNKB63__=7\(OTQ15C]'GU3M
MS_IU^-1%%^/0_A-LZ8OX[,?NKP3_(2;4V0.0;OSCRX_ID+UK)R);4UO0JJ85
MN<"ZWON]8R-RSYK[I?S//W_XP5_^^.%?/OKC'S_^SP_^ZS]0?_F%:%NM N.V
M0GY7;_V2_S__GQA_0O?GHC;P.6#H/\%1I^)[7AHF4-DV_EFJ5\7EDO]=S]%Z
MCGY/YT@8<2?.\Y/->CC>D#>U'H[7<#BJKAN")&P<B (D>C&<)OW0]:B\,>]M
M/2JOX:@0D6W7+<18"@ B$E<7CHV[6$OZW[4;.TZ\KGTNAXYFU1K,O2D[8CV$
MK^$0IFG:V[B5=M9#(DY9:L"D\0V'H#3N;"@TB'];W=D;\UK7D_0Z(K_Z><#2
MK#L4YE*H2:.W#]N;FA18SM1$K;L]$.(S8'KF$TE=51)MZ7H; *.QJ:RKZG#\
M3)*$ 2?BS8C_C$>HZM9#_<;LL/50O]9#G<E4W3_:6%ZW07$+/(WB9X5 ">.
M&^C5EEU3,SZ!-*48Q L2GW0 ?_N5?#4]A]6.K';D=V='KB"54N!X5[5$V2WQ
M2[4AAMH\3/)KK(I0\-0U6 %A/.#(1<>J0[++3A[<3L+K,ZP>_LW9)NO)? TG
MTZ,11+]0&:@\QX4?9Y.I%!UI6T_0&_,ZUQ/T&D[0@60+H_M*8[ST$,/) 7JX
M^$I:1?><(R&NS AJ%"$K I]E/)L'].ISU5?]IO4HOC'[8CV*K_$H-G<Q#@18
M5&:H:1SU< A,J,+DUS0D2??4*;\C6+%O)<0\$EC_ZIP*63[27.9R6.[)K$?S
MC=DGZ]%\#4>3V8UT=@6N;Q?X'SN=3['R\6.BSO4XO2'O=CU.KP.$5G7"P,WT
M.VF"X\'N"U3E-3*].ON)C*%VP!T_0Y)X 9FN+HWWR;19C%(K$JTG]$^14 S$
M7="W0NB-Y@UU89),("9<-NYABLWUH;F209K0\QC#GA4Z.2V5<:"R?D9_LSTK
M@5!&A"($0:*\84,I[ED+DWN'5(E)DT,Z(70]RY9C@ +1^/;,/]D?!@B?\C6@
M<*$7[P[-W4Y(%%N(0L0/K7[_C3DUJZ%ZS88*HT@8R+L.C8V'05:DSXR*4<&G
M#Y%IBJ?R/3_EI=Q)=R7)U_1WI-CSXS,R-WQROQOB$2S?1]FY;=JJ.Q8 5+6M
MR)N2>D/9HI=\@8B?:M)E-"$T&%5U9=>+P<R&W#8$DP_QQ.-7X53Q/]P#,/%,
M^*4DUB4V6,8"J7_\"=WB:AO>D(VZVH;7 ;XJVS9&(=[_\WR*Y@6,SK*ZV%4X
M-P3NP'2L4.HEHY%R"Y*5E:RAD!##."6SO/U"PQW^(AK5C,\=VCRJ41@)-Y&Z
MRR6/OA((_5H"H;^L!$*KLOH;L!%_2F).M=)F",/D(TH32NU("Z\-[T!<:E6S
M4V$F(%QJ25X>-P-\1YQU1%D-\@_828IK2"!.;DI"&ABZNPJLG]7!T>LQ%>AB
M^Z&!QK-P(S$FQ]O7G9*A+/"XMJ8U\U[ZHQAIE8=#]WY2*$ISZJ[?3S(XN()1
M*QB3217:T41R#-CHP6AJ4;@=ECZH#-_QV5EHZ8NOOQ6YNU)Q"/'?EN7:BAHI
M.WN/[H:RUFLI6T4W/(!&]GM[6U :_ 64AX=0[O"*H0-(A,.)?#[Y-F;[[G11
MYQ+FY+/V+,TWX_]405#FOSLFOH]KF;5R1YTH7Z"^;QN##B>^7F3V=58+4%7X
M<\;2F[I55#FOC596<_F&@^FR5DDJXLHX&T2#KJ+I-^N'"@F/@#64>8NW\4,'
MD+Z862AIA'UH:3)^Q/P+F2U]7>!9Y<J'4?UORAGJB1+@<-MRHM]X"/5U?W-6
M,GS>$$:OGV8&E:Q1ACBDF\ 2Z_1WQ(O=Q>^)60[U);+O8EIXW"P*#_L]05KC
MQ[CU>)[<&K@!DDA5WK/@>RIL/81J'DII3K,J*5(9S= 8F@.R2%1#8- \B>\\
MPX:4DF ?P$*R,OW\7EUMQK@'<F2$^J6)5-3#\8HL^_Y>Y\A&C]U<=Z[CA4B<
M6!55?IIC,WOX*YC*2XU)XM6:?L$/=N/,T%'5-ZS^0A%#SA THEME(G6PNB1U
MAA&2GN]#N0SI)_'LTAD]LS$8^V&6  Z)B+P\DD)R-W?OV67)!((>G=QW4.O4
MZ5/1\R6:+O9W(?=X8NARG[D?&6MA;F-K[:GB.AA<F"NIZD[*)H4\05<)65%<
M1^6<U["@,ZET[^BCKVTULICMWD+J^BY$?T8JB"RXR^.L1JI/;R+1$LE(D,AL
M)*"T#SE$+T!50_,O]B\NJW^-N?LS^I]DT(=ZZ'!9([#\X2:N"YM>)OY)GH=>
M\)CK]XB2#Z^DTRV=X0GJTZNS+0" 2D^A&^V/B2C7.5M0IY68' ZY2!(U1.P9
M[[XAF:$]A10X<;1#]=SE:S6BF%== $<RGX[RW*Z7#?(LG._;FU+AYYKC[+4A
MC2EF1/F])!J*<=ZN(HXF)=]#0'DWDUH@?Z=@I9E!N88C&:LQ1'XCP8.-JS#V
M=?6COU<_F@6VN6\TSKEHGWJ&C]6-CTZQTVXKJGK?0M7=5(^4.JT-Q%")*\TK
M#[.'41=*82D :P-;GG;'N5A%]7"'[Q;!#$;H[-LRICX#DZV91G37^8'+&4HV
M4E.3VQ91M3G%#PJ<8VYRH#"="?^F*FPCZ\CFF#DU#W$/$;?EOX,ZIKA<@PE6
M0(@K?K93@'NT@&102*RC.O2M8_'E0*6)7IOON5,Z0&4&C?<3M]X=M1EN0C0E
MYU-@!;>81O-?<Q#>2=BM;BV[>9A25=5F%YZ>/DF>H.?A7R/2KQKDBJ0 S(9H
MGNF$+:,,OQ:\0H<S".NDQ].61OQ)*_8W,NO_ISR>/ME\36YG5VZ^P+3ZYW30
MA)E_3FVM9'^H]Q!OQT30]BI[AKOA__YHXK1$4HT2Z%#GZC8Z4-B*_9:YQ!U/
M$("Y%K(V1##+FV)#D=?\EKG<?*ER DCJ5$Y,[UP2:CD_R0L^M+HL!4@N*FXK
M#:EF&?SFM#'/$[^*(_,RW.JBS7@IOE5]*6NU3:(V9\ HU-,*2C:<_= A7UWR
MZI)?V8(^T?HNF5]N<DL$SQE3,Q']L>1)ZYNI[CPKP-,NT)9F)LYS9(=,_5)*
MO8MBBG&7;X.31?J>W-;\$UT%@>507D8GCX2KN!Z<]^A^'NJM$M#^[T M?4;W
M4)F8%K3ZM[#1]8V(RP-X"V/64;(@9:E4\A:Y)K(C,Y=Q?S4F3W5KYRK \?S>
MED0=SK4LE,C2 T1;I)+P5UW37AG3T6A8C<JT\7MNZ$4+QT1*A5(.36ZVQDN]
M:VFS-OO]X]A7'VXK_K[4R/GO'R.J_#0Q&?]X^?VE6&WQ/W#'S-2N=,\%;\!M
M/'VM)O7$K2.T[D)J/R>$D^\L;(G%NN>J\/Q23.X/8'F.;]51*%/@QX$NL4%+
MMXDB\?)9C 9++Q[)61+'/BJ9K,S7FMVK[?9E\T0C_L@MY2QB#(<Z "DI<"2E
M-5IPED6,9BC: ]<4TWNR4"OCZ55N[IDNQY3\/-YL\\PN**O@;TR^75,<J4X^
M> >]OH&OT-,9ZF<U02+O;@(*:B6+@MW1:J. V*-EH8_ZGO6\Z*<'4AML3 >4
M[O!]$_@L=\VI)XTO(;8*6CZER-T4"N7MWB6^].@(!NZMH4'$'/+L0X9Z7]XV
M++(X1_P.[:S):TW,XT2_W)KD)^-@R1K93W"ONJXP&:GF^R"K5Z'"O8R+)8'H
MN'-&HA>3O\%>/'*VU.H=SE9D]:^!T9-ZX:X=KO,$(R[H+;,@C7*-45Q]K]%<
M_G+6< UZRT@>Q<2FK>D%8+D:?N_@>-O2\701_$_#_U_%=)0H9:HMZZ+2CG$;
ML9B^RT.XKKJ#09?_D.]+% *MO"';LMJG') M@,LET"P(QJFQDS_H9RP862HJ
M@I!CXQ!0KB:[VXE%$NXX_@5=X8(% _BC/<= LE?58/UJ&0%EFILJ";RD*&8%
M1QDXZK]6<-1K5%=;P^GY-?XFSYY(+R0P.INZ3]$DW)3_+MM=,W0CBW_'1=[[
M9U6X0F0%(0)'^.9:J&^KMH&1)*BGP+/Q1^6>,K@#ZQ7OO*DV+0T&;G +JKH-
M:LM8KOJFN:-;W#5%#K6*]YL 0R^OMO,;O[675>M9\XYT"N+6"66[Y?UW3\R$
MCG#ZT8/S6OD9D".&JXAX(/OU&!=$-U#@V.$.JB[&A\RL,W,&LU!?XDI!3RVK
MT29JO71%_"%2%IQJFIE@Q(6>[ON>AH(@IY'V0N=9(B76A#LV)(0K2.^^!U.@
M&*.L+5;,+UZ,BW8')AW,AM4($]7%J(FZ0./%Y6K8HIG#@O!_-NTS6KKQ4R%?
M0TMH2_#UXH$K4G6*?BI7YN@+0NK2::E:W@2TMO'!N)F!"N'<&U$X@R<XC191
M-X9>S#VT!QT&:GX#WXKHDV  U)O(<!>PGS\/[;E8@#&4=8:\=+#!D;@?(]ZZ
M8OFLR2?P\P18=).+8'^2%Y)IU<6\OAY.FT0(&V/M*UT0)JUS.(X7VJE\+$AX
M2E;O>BBI21:" 2KUSQV?Y=!75+G=970$LY9B#ZTIWL'NC4$;6O?I[.Z4.<G#
M>0)=Z?KXL;@-.^IQ=MNVNC)%M2XL/Z3T4VY(1)K6D1JA!BS6_:JOPH8OW(KG
M6X6HLL-.U)-L#A2K334=5,S##N43*R"XEU4._4W3\IND.]L.5,3@7IA$*5K7
MR);G#V///[>E1J*Q+V;"P/I"2Q]^*20[B\>9"N2 K-''N0O&B"OHG6_)8M"7
M0O0N_@4IVJ63*<ISW%R7>N0^3_]8'DS!P[H$<OJD*X"[ D-4?-#4E1CMD^X%
M3X0@"M001%= &PZE\3TM=$&F*%Y(T-/\9KN26PB\U78-FH0)WT=316=G/;''
M>>X/1%=;<A=QX[U;C;DU@WG16/BG8)#0G.D%VQQ":50VB0?^MA)/&*,,0K-+
MF!2LC=?UP\Y*8SD(02IQ>^&!RK\I7CN:QZ/XPJ'NXNGH&/6O;62(2C.21_2A
MUR1D34*6-O+3[[Z9VX4QXNEY8X=:9D6"T"%Q:L+ !=GU*1%XCAU^QQDUQ_."
M.F-X))$L# S7N VMQ):E4#+Q 6 W,WX. GW)@9/J;K3>,7KH2ZN6VZVHA&4&
M/64P#@%[)+JTCO?DP?#MZ0&D_!MOA99%FR6LCFKH['B/%D2GQ.XROK[XG/&[
M#ZB>DE:CM"Y,FD/"(KP,0X,34^IS+CT3G*JF(_HYVZ;=E0;N&Z&0XRKUS9;&
M9P_AFKRU1Q< >$1Z(Q0:IP"PL/0A%[ ,_))V3> )'OIM?' T6?;R>3<QYD1)
M5H7GW[>QTOW$QJJU.8;='(;^NFF$+H9WTJFEHX8\()Z@+_[QK6S0+YY^FWJ6
M;:[G3+^_'JJ=@-Y#'0_?-BE$ [(B$+6RU:1EK,ONDPF5@"??'3?[5UES\&E3
M[VD(A _*E]%M1R,FB:R["\V+EJLN-O^.OFLR")DA<$DPHUT7;ED>&NL4KQPW
MS?6-S*;&TQZCY%/8&I&0. TZL@U54D[12FVKD^%#JVM6IU[R-)>;)S$)P%?<
M38VZNIEX*Q>:9O13KX*_/#(&ZK%V,^Z'EV8[*T!@]7$%L7DH:^U;PI+R"$BR
ML/.9\5=0WQ6?A670"5V_W7D+HRAG;Y><G52L4G=V_"22=>^HQ;AC,J>*!P^T
M[DA;7$8E'[?#/>*;-:0U5O7XA]%]7#%:G(%CJ#Z@Z$3B5:A,\#+)FCS!<M.X
MZAF\__<NC4PCY1KM^L'XOMNA(MRNT\SRLUVH,R:4ZU5N<=IP"N7<_G/CC#P8
MTX^.E^+Q!,?[]CBUU:N]DC[ 2-][)J&<'!F!AFLAY  X>-4"<J,QJ$3-$@"S
M5/>>38-8?]K(8M)G,/"U;&+!:E*Q6?3 02U YAFXZACYP50/)X$ $( GQH'[
M_65T:L?C4./T$O$2G4G+-;@ZDS^R--ET^("A(6Y^C-!4 J@\5AT#'5SDOJOH
M( \'];;;!K:"O]W'VE\YPR$5H1P$BZ)0,_22=V!1)?G8#59?NCJ(C>\*,RN8
MCN24() %*'?LN)WE\29J@1^A</@.C&OW9Z9,V [Q/HS%+K?XF+ 7 '#%K9:V
MB>M$]Y$P'PXL7.YNA"5BG!7!2WDTU1R!@\4B>),,<.^*^WR-#H'*Y"?#6(ST
M8F<YH9N+&Q%JS!G2>!\%@W>7<,P\;#X)E@P_) <BNI<T4\H/DE LBEM1Y^C
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MN/U*1QL([!D$]QJ?#6P#;6W$D>AJ8X2&_KZ6T!,'$Z@4^E(JZ%]N?F2)4!W
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M[N?R_250#.52KK*X_-AH/]!PFVM?<V$]T4;E&)=2D 3 ]91\!3G!]W&Q..V
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M3"P#5<8M&W\;5RB^PW^S%Y3"X&WP[)/.-[J0T,,9N?)YG^VYW/QSB-N >J3
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M-@:?].62+FW#29W'J*,V;Z-8)8-DGIV\CO1$'6/YPI_FKF>H<VO&%[:K4(%
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MDBV 0#'.53CLDJQV&ZC$G@@]\CQ@1.^![A7!GZ^#J==,TDTF<1;ANBZ[43R
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MT$  ^%T7HA3II^.NX9/X/CF9!6BA>TS^N911XPO$5=&,*-P ;;H<[F5MS2Z
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M]/^7O3=Q;MO(]D;_%51N,L^N@AANVNP[4R7+=J([2>QG.9GOUJM7+I!HBIB
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MQ;1@(^YU5;U;O?&5DL0-XF&F,%!37ICB<@-8>G?^12G'H9F7TY@'/<(1@MW
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MF\?!6,.%S-)+W=I2YXU6&K-(S6TAB<=V<]Z!!"Q2ZP(A_C@A(,HQPPAND]^
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M! \46=2.<]BFBR^R2&21R*)6D>1.\$"11>TXAVVZ^"*+1!:)+&H523X]#WQ
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MG.;%GL,'4>"S3XH-!UCS2,$+,?P64W+@9SG8I.H1^>2JQM\&-KDU=LB3>WB
MLXB^_Z"B"$5*O]\[0K62F,ZERHOH(M"V/FSX7L7N-:=#=H'O#8:#X0WO):HL
M,F0G^.KL9,1D[F0"YR!T\%^5Y^;_P*Q"1_B\']=TL,?4F![5*@5%T4Q77RN\
M/G1/#W]XO>*E )8*HFOQ:A*KZ]5+^V\0"Z!BF\_14VBC9<5KNII[& +,7XV
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M!K8KHB1C^"4N]TLN)D82\Y5%S0NX%\A<Q3GK/:YSX=O<G5B@>F>LIQ  -ER
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MMT\$J[EL!41G"]%Z0)3O1N_C"#9'K0>N#QW9UH+^Q465;0HLJIYQ6_4?$.*
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MOO(\C-?C,<U*I[QZ>-;UFLV](5O&N:NUN W9VC>KN*,L?QQ'41ADQ/$H)T&
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M:0%4KN"$TB(ES E<Q_>"P@LGZ3"\WL]PXH!5;">1GO$J4_M>=YNFE\ -X!O
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M<?V4)QGGL>OQ>_FFNX<E-[)*?-_V_,B.DOAI&0%48:.NNUT7C$8)2QWBIQG
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M/L4?KWX5)6L+7C^A+(NINUBFY\M4MA0%2V^,LS["NWKM'[ZLA7TW64[\9%H
MZ?G-\^^HB+WZ=9P]TUS]J;/G74<GU^_I&;7FJX\A7WF$?B8M?_*KE$=P^N17
M,<\8L[?_A^_K:^]+Z%[>R],_45WOA7_W>WF@?%U_7_5Z7RU/7Y:J/W0:J6O
M<UU-LG!/;9D'YX5B\^XG__6#^J'Z/L ;4^[)DWL3UKVNA^/Y^?E\-EKOMNJ(
MS>_N]*I]2504W@BR-7CA(\@R!-F# -FC&"=="MU-_S^_&/WG?[]RDP@GLZN_
M'+N+[D"@CIA%\$7P1?!%\!T2^(9P>7XY7>=)KA!W/7#A&GQO%U5=?:L;NU!'
M#",8(Q@C&",8#Q.,K]#VYY0G8;*J(TX1<!%P$7 1< <$N&_FJYM3A[LJ:JY^
M\GE9#6+P #&XOVQH7[U=]65#6XOMG]S4S4(:N=7HYQ32N4^+$:?C41?9=33N
MU>7?.B)QURU3=?E@".;^RJ*OOP?UB4[82;='K\OCGFN]N27$6PG6)@&"I0S&
M\P!":2H"T]S0]&7G)F7)4Q(IF.#+(Y/@8*FV$)-6FJ@4J6%W=&Z>SV=K^?6Z
M*T]=GEZNEBLWBY/9V\]:-]?%J\O;/9LG+W]Y>#9]6;M*F+%ELLI^300?9%QD
MW-94[>Z N9(!$TC9C5"VC2D+%C((3LL?63EPB2J0A@7'O<Y2;LR=>@QEWSXK
MN3H=Z><J&8HLC2Q=F\&1I??O V1I9.G!L+3BWMJH"9"04J'JQ,O&6C%PQ$5!
M96!1Y0V6YDJ$2!RP\E% N%36"O,>E&/$$Y9STFE'+*TM'Q.)5(U479W!D:KW
M[P.DZB%0=7M<^Y4QC >M.&QB3AB1P0K)0,1(P!##NYF,G&NK TMV8PBCC#1(
M0XOBR!:$90*\51*T\2Y+31CK5$I_BN.;KE\C*#L:1^#&;L="W8)14T'4H&Y!
MW7* NB4$PXWF172D[BHN*SUXPR@0F0++3@6MZ9>Z)?)<5$[20)E5(((F8%.(
M0(SGCE#M1-RY;N'*C&57=8;:I6441NV"VJ5*'U0=-:A=,#WR/:2?K6),.04Q
MYD+@D4JP,3(@E$6E=%#&AB])/R0EM.41E#)%*)!DP&6B024??8R6&[9Q>=:6
MTB."\;&M]'Z(NE!KYR2!,^^V0B5[1I'?4IBZY7*2BUW7,#+/)5H7DW?E;^_2
M:#IQ5V-(1ZOYR%V/FAE==#-FR@N&FL;+U+42FA%VW^L%A,B:FI$?K\OZ=\%
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M!T,P-S+O0)C76*EUV38Q8\NFBT8)1KGR5=(F%6)E)I@M,N^Z>_ANXL4!OHA
M2+NU>P$7?4V+'FFW$=J5(7.I. ?)"05AL@1K28;(I,^1)9_DQEDGB3&I0!AH
MDWVA71?!L>ZD5!;N9MH01OW^:)<S7O:]',D7<:@V@R/Y[M\'0S WUCHT5NN
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M>EOKG;S\Y4&-1YD>"ZK&6O1VEPF"3\O@4Y?!D7'W[X,AF!L9=R",JPK!\AA
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M=G^_T: ?^LT,R;$D#&NB#C,QA/ID"(394!0-P=RH3U"?5*1/%->2$B* 12U
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MG(X1MIHJ.*EAG\-/-Z*4.)[9T30+JZ<EG_>O%X%!.0;E3.T4'<)T[SW*,?!
MM35,?)\'7! ;$UI\VW5([$4V<1+'#UCH1IX]"H_>5.'!3;FR;CP+H]$R8XQ
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MSHAC_?PNGPOK0WED>9Y'7"\)XT2AWSM]/<L1(?:?^GD%]_-#]V?V2P]GGPF
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M%GA?HZEN+. -$\_/D"T$5!+QXR@#9,8$28*()ZGM.SS@ZYHJI4$0)X(109T
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M/Z'UA?6VEVF$V^VXJ0TG@!#(&7QBO1%L:9V)5.^>J6V>>V8Z/#X-H1"V[[.
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MKYGKV[:;)';RD_7]<OYJ3HOSO_TD"O+U;.]GY;1(YRL.WQNI9^XS#^<_;G:
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M-)N/W:OOELU0;1L+,HUK,0P&S&D-]B$H@C0BY\&>[VSKI #C\098K%4;W3(
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MGQ_@UO\^/PU-0:#-@6-DHOUQUNS9+A^6%;;CO>BML/WCX?6JVGF)'>4,N=R
MVE58(:UU "T,9IDM%,5D157[P+!S&B[G%G!I$6*RDO9(PN>6Z,"9M/N+2]GQ
MUN7KK; ;J%UX5S"L*#)*$J#<0B%%\QP5GG%L;.X#-RO47N0&6X"CE.0!,2<T
M6&$AH"(&)S!& *GNKQ4F8%&/E]I[*VP;L1,6BEPX@K".SC*1"Z1Q3A"G1'/B
M*?:KQ"Z5U80&CCPF<(\S&AF?2Y13,-TT585W>O^M,$;WJ6O/4UAA?1NY!ZK/
MLQA4M;63T%ZTE_NJ.#!R\-W8;NI1![-TW,1F'!P4.N,Z!V  RX"%X]@&FG/,
MCJ]'W6JP3%LR8Q;GO!2PG"(C8X;8F@CLF^(J9S'0M^@B=G@+N13K>4TPW!3M
MV6<'?.7B=T48UH7>U\LQP]-(S3K[+=Z;O='C004H(A5TCA+1>*OABFM]QV:^
MKI@>-/:3R >?_'#J4Q:HU77J!79SO'UPQCK-!"+$R=@&,T>2T1R1W( I8G P
M;"59WN:YQP9S &XVYO[&0K<>[K;$:BF)*7*^TNMP'^+M;S/78XBWWU8O; .1
MZ;H&LG"I0M6,7D?CRDWM)!OHZ=!>-!WQZKJ"[Z(0WDQX*='W<RPAW2;\WCH\
M/0M'@H);YE\(\5\G!M9%]>]YA/ZM>6B/0NV?MFQF'T+?A]#W,;=]"'T?0K^/
M)X$].S\-.R=;H(^4?Z;&\1]5M#LB^-B?R.P]V]7#BL_HH^2?Z2&>$YAB'#P2
M)+>(V<"BL]HC)G,2E)'PAUQIE&0H(<K+&'098XU-@50!)J4OK"\D]3*G>&]/
MK.4QGUCW 93/5"$OI:[M#SK?LXT]+)W<QTP^4YW,F+4\EP8)PPABV@6DO,>(
M%SS/"3:%""N!-4X[GENLD5:2@QYW"DGJ..(Q:PUKHKAYXL":;3&3I-?)O9%\
M;#KY09(:>J-Y?Q1T;S0_4P4MF2'.%Q@1"C^8X3DRFFJ$C2,V]V!):[:2?QBT
MB-4,41&T0XR"/H?'.$1P+KC"6FJVOPJ:\./MNW(K!3V+=[U3C&8?;W6W:JQN
MT8K-K![%7NEMT=VQ=R5\4=9_+@:QS(H[MX& -]9N_7SAAYG7XZ%OJJ&ZZ>;>
M6LN-Z1^R5FS?WV*;N/4%%2HXB0H9&[,'KI%4 GZCVBB!):-RI;:!9X2$G 2P
MH2A#S.5P#Q4@L8N<%F -<;-:4_8>XG8G;2X(/=Z4L7ES&."EGLRWEO"PRL>H
M<(0=P 0FL$$2RP(5AMJ",>8)YJNIDIR&$ !5$!G)7!.DG<^1R"7V.=.:N%TD
MC^VF"5)QO!4[.C*/E;OKD4\M3P97)XU^:II?UET_I+5Z)/8,&Z>FHU%GU#X6
MA&\45*PH7XV2<O-?1K&E9WUR+/W@4EM,G]JIGF1 ?D!W3;"_=G!+64_&36I
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MBT'CP%_(@;7C7*$(#4M9/BM,\<,\"FO.'VT\S4Z T0;9@'/*#%'("K#(X+>
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M:):8D+Z:Z;3@EP+:DMXT_CP^OQE2@I>GV=GLHDY#@]T!A& O%B,!TXFS#\
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M%,X*KC@GU[6S+H@@VE*D'=6@T0N%=# 4<4R%XIA(8>_@'MIIFLN.STYZ873
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M2!KAD-&Y%+J0N&"K?=3 !G:ZP(A0!;8SE@%)[B521IB<!&;P<I^"WV$?80S
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MS /KAI^\>H.KQ*DI(SHUZIH.)FU(H^XY=GN(#E=2%(H@K&ALDBL%DJZ(;KS
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MY^\P'*3)W-;%M]*V9!N.5X@;L/CG#DPXL!&!(]$LG&VG9VL[V>HY)(^ADW_
M0316^\ARVN?5I5Y:5[&/<.[@.;#)5];#4*UGX1H\OA5"P?B2I;+05W:A73>J
MS*O?*P?V]X65T@';,?-U&V4HJDG/-N]!/2/,C$17X=^^K_Y-.^3E AQ[,]?Q
MNM%TPTUHW:D&D:/S,MMZT71>-,VPG7>T7E;M-MJQB=7.P 9:\*^FR:8+V5L!
M7;GG-1 ?F XSD"&[^O>33N'%X@=7&%*?L2S@+O3EW)C,6OLVLS_<M$BSY#IL
MT=^2J0#",,"1X/#'?8/%EQ8^$C%7P1-PH(D,G./B$T(C(B!Z+^F^9MM=V2D_
MZ6Q(I\UF?TZ@9R5=6>';#1%OV(UUPK$[J6RGL=I?&K,)']@?6EJAG+;#S&V)
M*Z8N>D&0>ERF*.V 9/=P PAC$ZI[??D:A&-9UP("WZTP<-",,\682_=0P/1"
M$W*[:I!]3/S)356?^(1;D&PO9-<TT+PTN@M^A0O=;?#Q.W,^34?--##(*$#6
M/0+\57,,>W;\5EQVNQ4?Q#5IX/V:8ZU)TZRDCM\-[>/ZZHXY^^7*08[6'^*V
M2(A=.7>]WY?&!!=W[GJ?N][/<8/GKO?'4<@]=[T_(7WPI@&;\ZW-].O%!VQ*
M+FQE](_E[A,85G!W7FV=S=+@";[^\;*=0U/G3V$W?OKU<K*AU/:?%ELT2Z\9
MM^_3>5EM]S0K[<]XFC%(S6 FA^S]VDPF;RPGM=C91I3VE::\#2P1\Y&E^F1L
MXT[=G#6%L+@'S>^V)[A&"#>]+5UP\1H<\NUU+DH,0.[X9["[T/LS ;U^)Y6U
M?%<CU,0C3N#2PAEBHTQE;G>V6.\I2V<_&3?%%"#AHWL#A5WS,^S:&IVU%;H0
M]J9._J&J(>KR4K9H\)==&$+X7I2UB\">/OW^P^[Z&LL=85T?.LZI*TO =;P#
M>2S,IW3L\M:/8^V5&[SR9MJZ);:?/Z^Z5KSU5TTG#S'V:S.897"CV>IK?$]E
MG<DZAF1: +!:R_B:3>]X@<%?=ST^L0-$T*!-U^8]DS@ZTUKH/?<,OP+HFWUF
M^<JTT.NF$V(PR_YN. <-=75\'+L1:@C)W]C<E<.4L,&U&I?JV%:A7];@ [S
M[@C7W]6B-;Y$=\[%ZCKNJ:4MQ!. JY$MBAWL?+4UHT30IW/>7HL34"IN.\_K
MDE?X45PA-#B*5OP'N(@UC$.I8.L1#6.%H0ST? VS-US $&W3['G#!1T':, \
MF*PUE74F[7 -;\$*#*:QH \/1ZU6YKII]GK9S*$S8S@ZJ0GT9H!_?IZ EK1K
MP:@ SC8H2CPI2X6&_5N*@B\LOMA8I_W*IL2PO;5W>?OK+]B20V3QQ8'.VG\7
M6CL0$9Y;_(X&C-1FOCNS-9D5!:0&&:F_ _GFNFCFF4]@9_9\VF[,YF[TAWF3
M6W(>1DI&AUY/Y6A22:9  M$*'%4Z9(M.3 "8:VM%!-R$6@!WR)SL8*Z;$QK5
MG5A]6-QBY8UQ\EN-LV<SNDU/:]3(&&F:@]_/TG2[G)ZB;JV%*[5J)UIVAR.
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MVGGC6#[5O$T  =I2J^T($ZT^G2W0!J[:IJF<8=RMOJHCXGMV#KZ]@I\JXPK
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M:2'C)"5>B.#% >4D#2DCB9?$&0\$3RB?XT!S#O9/)^Z,AU2%PB?4"Q@0=QB
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MR/-STO64-'!I<AT3+E\/JQ%'"YFY=4W0!R2P#1S=S.B+1TN9?,IDFDEL3DO
M\\-9X]R+2!!F@D7:UU$J1[UJ8415%FG"L@SNB:*,I-KSB!=G?@K&=$8E/Q)*
M_J7 B4$(GGD:27@1G;L@K'/HZV;G1O'EJDX5EFJ#D@I#@LTU_4KV&F/1#DHU
MALB7HAF%VL21:R:;K#[XV UQ]Q]O8GY<]6*$"/@Z*O:O3-RV744[C'6PO/H/
M=EKYTPP*SM,,3CK-()ZG&<S3#,YQ@^=I!O,T@W.# #X)@=G[;P, [)R\Q\4?
MMU_^27*),TAQTV_Z5FP+="$#ST_Z[J/1&-ASNG8E&:([7=[X^4T=0!,P,#$%
M1V(FY,=<; 'L\\9=Q=Y0<__/&#%8+BXW9;XRO^A<$GB+%_C6>@+9WB!%.Y>L
M-MV[X0=P<ZO\_2^7;:=K?=463*!M?<U??_C-=CKLG^XK5&G:;>NQN,[N7HY>
M.>RY;3ID[4*P,(%MU&Z;BW91=J*9]2-LGY$N=J6K8LC7VH1L=GA=I1C6+0!]
M*KBO4BM['[_I'IXK!%;B:@UD]^FF/BG9J2C>'_5!=](6FMC1O_N:>]WWM&_9
MK-@6;WZ:3L@<E?K&W?SU.&WU18QM8#?U5U^*<B7AH6HYT1O>EC@M%[":G6;"
MU/R,N]OQZ<#+?9['RAYI;$7@UMQ4]R"#US ?2R,2L*AH5[GJH<VNW!3XC[HX
M"LX%A%PN=BMX,5LM%U=8BM/^$TN=JBWVIK-_[IC]O>H4(L%?;9\#&*ELLX$/
M<_7_+\R8<&?L@/C)U4HZF5)+OI_J/[XV?VSDW6#43;W7342B&PKL=MQ;P66_
MVD[IUJZV;B1FFFU$B=>74M,2H19'3CXM.S %)SOC@3P?+LJ^&C_*?%QW#/OM
M#AH?,MCSB\5;-QP=W^F&HQO2:H>CF[?5O^[!*=1$6:_"5,CU%<UH)P?Q_.6^
M$W+/;(_?!'RGCML]RM2R29MB8XO*EBK:TKR\0$"(SCB@? VTU:@OMGAWA:\,
M%V(%?\'Q(ULS[+WY^GJO<0O,T:_5IP*?8(_16!36GC![B=(#QRB9I72U3^]!
M<^;@OMJU\$QJLC&C8?^!59=FX%2_+TK#%]:4:FGB=LU1>&^+PWD%._7IRIF2
MUYN5J@D+#KK0!/X_EEZJS=:253683=6UQ0ZQ3$N-7>'5$Q/89[;7J*E%V'ZK
MJV6VB1XR^ :DVKJ';'IGEHM^&+E]O4N7H9XRP[9*:8IEC5UME9!2DNS@E;U'
M@^6UOEB\/BQ3NCO(UMW]8EW95%?-UEO4-WC''0E&D^^VU999*JFOQ_%(53TL
MN/$)!N@45;%2?8H[NC>H,_D_< !P^]P]'SF4,O837BZ/G-1A#>3\GSZ93P/I
MC#00Z&S=4$\;ZM^ST/9LG$0=%@^W\M5H/H5V.SH:[HV3 K9.A9@'Y*[6N;Y*
M@?6R6MWT_#BS.^U .G>NK*H*D9OX6Y-('CI>/74 >NF+@B>Y&G:[/*N%5T55
MV;%7P_1T_Q&=<R]5?LUW965U!G@_]6+ML:-UYIRN1L-U5V>_ 5_HO#J1EV)W
MC30L5#7[+\]2-_Z*4M74\8LK;-.HZ9@U5-(EH:;AP)"VWI7&@@15(7955==+
M#'@6+G1M#U81F=%L]2C)?1H)94^!^UJ(WRV#UBH11\]ACX=>O,A?SN6O!\M?
M([#F?1$21;%N4+"89*%,2>I'7 >I1V,]FB^@M0ABO%S**(9[%"<\BQ717$<B
ME#R,O7@*F,0<)T)%O,'C[?<\VK,^5/$ZRN O?=_\W]GF\6OZ+X&,@8Y;=H.=
MX):^ZVFK!J7$<>G8=#,<8IMFNJU)1HFTT";8Q&497/9#C V8S,(>8<?3'K7M
MF!3^/W>Y&\H*)E.C@6:<H./L*$0*=FQ$@:%X@L6$G# 5:^*%+,Q"SZ/9&.&<
MI:GD:1R2!%%U:9+%A(786Q'Y(?=5D'$_FF#'(336ZZ*\;.7[6_VA-A":"T]3
MX^MGSZ (L>E\^P3F):JU)KP^T*'39IC!%IH W:KJ>+;.RVH[B.9U/;DF;C\S
MW2UZF3S._4 $A'LZ)%3JA' ?]%DB/9W),*:AHD.FR\+,$SYBKDOE$4J%)%QQ
M4(FIQZ)0QD'F3TUT^M.8SG\.J%WWP6-3W#413CT6)#9KLPYF+YDX 6';C5>,
M_.L)9W="Y79JFV<!<(N2UC#-6))E)! 9 M2 &DU]/T$<6(^G09)DC)U(ZU[6
M"F%RMMMIFFBB6<%.,?\*F=^XDRU2'[#Z@;0))B=F)7I+8"B>^9Y&5S!(-0&5
M">R393[1'@LU2WB<GDR)WA_K^-YS8)VOY93;IA9/J@L?$#[3YZ&O RF)"I1$
MI)P4+,*$D4AFG'M1RA@==39D09@JS03!9F&<!LI)RJDD'I<QC^.$"^5/P&=^
MS+&&Z'T-'_JQ "K^6/RBMH:VW^IW;JN??O"P&R&X9J[[YD"48&MVIH.LR@R@
M#!;JLD]#;%4DGP<D$!EI/P&GG*1>J@C5$G0^ []!>XK&F>91*D=0\7>U$YX=
M@8"ENY#%CJ\4D?FG?-NBKB($ZWE#KBY,P> :0]>MI+5E=XVTM7[\8V8+G."4
MR"@BP + %BEVS2H)%.]KD)]*"L9&<\#OJOJ?'5O@C-H%9DQ[?($G6^VXX8T^
MUSQ/1FGJ-Z=+@!P#U4A1PI@B;;*TM7B J';"5IZ9XC2M*[6M6NOC/'<5=7-'
MHI0&WMP"KNTIZ[(Y_]UZ6][@K]V/KMH+?LY7-@''MC8_80M4-GD[#@>3YI_9
M*H?GK%CN\O)MM17;FB9$47Q6)O'>370;5/:= 3:UK\75/*"<B^(P2\(T(,SG
M'%P<K0D8AAG1&>A]G24Z4!.SN'T>J] CL:\0Q)]%A&DP!!*J,AI+C_IQ7_WW
M<-7?-EAP/S6;^,X4I%UBB]IKC%"]:D)$1@:.46+DKD2\B*<O$GWOO-G1X9:U
M,-8V MG& (W<&U:0#+EB+M)XED4:;]:V;60" Z;)ZAKK83(8WF:!#>B,*96S
MUL8P^=N426$]K3 TA_796)!E"VROP?:3YO%E_IDARLV%:4NT55)#Y,]278.R
MWAFP41.0!ZU057:!MG2J?DH'HP$+91OD2X-K0[!4B6VP2:J?#(>UY]>FK$2S
MO$3-LU,SQL-1-"EP;;FO!=&4I^#H^AX!'<=((D.6*.7)-!D'Q#W!DM37)(@5
MW,-I1C*J* FUY[,L#;2*@C'&0WVZK^%T?L/#>:O;7_ZM/O'3Q,6SB^#<8WO]
MB@Q31M76,L\D?V@N&4T\K3Q->)8H!V@IJ0+_5.@XT!Q,MQ'T4X*H:PDPA\\1
M55OX/F%QJ$@ MP=9S*@?C@#4/F QCBV LH!>UIZSPA6^Q/RIFFNC;ED;I4VP
MN%<*:$NU\Y;N9UE_L/HA$3*(0-:G7@8>BA?'A$5^1F(:"AW).,[8J.2(>D$4
M9R(#<D]B9!:)(*Z"\$2'?LAX',3]"L!!LJ9Z!^=SFHS-<ZAK<+E.<.8*H.U_
M[ECIW&NT]7I]0#-@S$D!8Y(9,&8&C#G'#9X!8V; F#G$\A7A<NPEJP/;^Y$B
M3%T>WIBO=VKY5='T92></HZ@VZC]3=N2V!F==PLH"]-N-SF>KVD3;&LP;'!G
M?:#+>JJ)--].MKT?WS:+U[?8U4U'_8\W=2L6*,#D*>P*79.V:8USZ,HFO]/K
M,/QK\07GDBP7^52K(:[W0+/A^J;?;O@5=+#W0-NVO[8KL3/6<-3XO1C65-AQ
M/G6[X_[EU'2(^^'HT!R?@S/!'G2S#PC(4"H@K_K3P<BI<*WK!ZVV4$JP+*:$
M!Q*<#$]+DF82:R@H%X$7,1-0&H QI[[F6> 3:E(T<4 1EAE\<QJR1("GH_V>
M8_+W,M\"=X,ZS(6RGOCKHOSH]A/.YZW^FTLQ.E3FR?R*9#=/7[QEYYY>@5.J
MZJZHQ1=[\BCTX( O%C_E;C(2#K4:,U4?A\$.2:KKZ(KVSK;I:H>@JS@Z&E.A
M:%*AIX"@(@_*0YS%&'YE) C]E% F$,M<8:6&)SEEL1^(457F"7CH8U&SD!JP
M#W#7KW9G?G8;\X/9E_-EJ_@9L]7B!;#( Y)['"?"3^.(J @'H/LZ)MP+0X)S
MS+TDY#*:F()QS^3N0E[G3N;ALR)S1]X&X<*9X%:^OUP:.TH/%<-"7('=KM98
MJX=_,B4P!F\>!WG <X3J(- ;<].4PK053M@6O[T53MW#JI@P\7B@:$H$Z!-0
M,8G EE5&/#_U@C .?.W=AYFVG^?>: .X]JK>\$F>:^8F/76Z##U#F>?-? .^
MFZ&O[JM"/[>C F2-*72K: )*K#,AM#E5>"A5R!+P%Y1&.<W #]=Q1E(?#"T1
MLRA./"6#B5EY01)[00H>B RP.!P')2F6$A93FB91!"99KT'F51=-MR$Q-VOL
M%<(37:[E3XXZ3S0*A)Y[!O%</F>> WBTC$7+-(P5CN,!0PSL*4FRT)>$\HAZ
M,O2T'XPJM^Y:H_PGL*A__J5;-?CHP0'&9_+-.)2KGL#L]P<B3G=\/L%O?.VB
M@X=G->8M5/'^BMM9Y!W$3 IC7X9I2A*N*18P47! 94:R. U]%; L"D?M9S2A
MX)RR@&1<P3V2^R3SPXA$:9I2ZBF?>NE<P'0RT=:6E]?1DB[TJ>EO!,*?R?P@
M4E_J:05ZF7C: ^-;)"GA2B=$4Y'IU ?;/!F%\E.:!()Y/I$4P_^1#DA*,R#X
M2&5AQ#D7:3C/)GU 1JC)OZSWU#;LUE/N]N*<UR6 MB.H'G Z;O48^^]SK\,1
MO@(>8A);%GRN%<ZFC$C*4DJTSVD6RQ24P:CP&\QB+EC$"4O]C-!,"\(RQ4DH
M%5-1*M,TH'^ZQ7S^ RYO4^GR[85A\\BL/>?P]]W_&JFU*C[EHCI%3'8>0-4T
M\[U6O-RQ\F9"R*ON!"HV K5K,=HM@EQO.E5_(E7_!/NHKX._]438H2E3S1",
M/<#QL*CE_EE0DP"VF[+8E+G:,M/SO<UY(;%AW;W M1]^N'S_@;PJ?B/!Q:*=
MN'.[KU@.KW,8^#BF5JU6!#Y)];_'S!&O*C<;J[Q&&,&\/WS ?F4]%Z)_*J:(
M9&*CS"U7S-K#)9(:6LK].2\-#!,H^Z+<F(^I.^7;3>AN%!@/.!5WA0]_=96O
MV7+QUP)N^9\"S^)G)MC.O/@CR[^P6JSVAJ74TVCJ(3KU83<5?M,OMD/1<81&
M<U;/K#WYR>B.$^WF[;5'I\BN9OS;,>NL:$Y'Y&^Q:_QFX<<F'A4,^L9!) R.
M9*!ZNF?8I@-[:F3RDE9K;'9EM6,V(#"&A)M805.6)^] ,A>+MZ840_V15]O>
MU(]JP=7V"Z+I''FO'2QNH&0TUD'/.>C[&9'7#&O!?TP2S])4P#N-5#4J:7='
MG6_U4H><S,P>K*W'#V[0EL:*[::K@>^D6$NL/Q_/B1L6=$L%K%6L%3$H_=O.
M'G2B9X./1#<_N? :U\A\3 ^>P529N_LM5 ,3_]SE5=[T%:P7;]Z]_W_9]>;[
M'W&,C=K:B6S(.0H'^6&@7A2?UG#\<O^<JWH:T7!%G?3&9"-CSVR[#15, 2'W
MIH@@K.!0>@QAU."1/4"IJMB6Q6?PH?F=#[>+P(:@=A:\:]&"=[5(=^Z7%XOW
MD^A+X^.U X\Z>%6N_\.T(9BS+E5_#)##LSH^RV=VC$]NVKPOQ.]*@^, U/SK
M&NSG$KCLYG%UTMW^:^;1TJ?U[/][MT*O'@>L[O?JIYRO@?..2F.:TA8O:NNK
M\_?&YNHA^+1CJ-$.1'_;Y"0_J,VVG3A=>[(MPI"_>-'>W1_+VEW2V.#K"OG)
M*Y>]7T\.;6T'IDYLDC4#FJ'4MHC6JG3[&=W;U\6:''M$W<!A??W?U\47<@6"
MO$&HJZ]KK(//#"Y'R[(+I=05WM>[K55F*\6D^[M:7Z%8ENUC]&XMFHGBNZVI
M#5[>81SL 41$N_AV.G938^S@]TP-L_'=\_7G8O79ML!@RXOI$6NB#JWGUCQA
M>K<&$(S[Q\WJ8FJL=]6WD,QMAX=X3Y)6G409Q9=:P\X-ZJ[I?5\TJC\]V<SR
M#&E(GUEL8W9>)@IHJQ&RM<,MK:4+VI1PHQE?JM6<H3N>H8MCQI,$(;2YGQ J
M4D:8S"+B)8H'5 61GXXZ#$2JHR1+!5P99H1Z%$=ZQ!Y)F*:AQP5/PEZ&[M(<
MDNLD^+D]HM?J9%6F9Y_=/I//J>TCD._H4@I@9;"0T2]CGX PJFW'?=3[)_6<
M32';F[9$;6G;\F\S7VG9':[4MTXP56&2)VU9$-RWKO$!#HC2>1#+<6D9T)BG
MB8A(XJ&T# 0'R4<#D@9!$"92<<5'0PJ\,/8R01,BO S;A$%09@F7Q(M"%7 =
M^AG7AX89_5ECS5+O(CQWJ;H<C3JR8[HM+\RL<( 5PBBF?N9I$FL/C(  R)K[
M7DR8#J5*_(QEZ0BP&XQ\/_)\O#*("(TR3A@']A&A3BG+6!1$V00K_&)&LK8#
M"%Y9#^O2:HR#PXK<+8?P'4W7(M!^T[58Y7^<+=UW_+\S^:2A_WVQN%S?.-N!
M8%B_]LNYNL' .)QN^SO$HK#E@MUB<:PHZ&O/.KA?34SEW3=T!_ZGZRFS)JX,
MKC_K!+'MC(G.P)%%B7[O,'C>QA&:T0N=F'03*)'_V%7;\5([Q8\-FE&]T-;B
M&BS9?%Z3Q#D,M?2/79E7,C?<@G_K_MN!+CU)!WX&?3PIZ&,Z@S[.H(_GN,$S
MZ.,,^OA0^N!,0KLFW'$F5F@]F*G:3D]FLG^'OW;&,YFZD&%^J)DXTS6@EON0
M*MLH4)UIPPSEU",6#PL6%7DJD;'D) FC /$%/9)F(?PGCH/,BY(L]$>!DKN&
ME=TXIW:.D\,8+(OK'V$OW^J)$4[G/,$I.&^<&M>XW4:%#TYQ&F"9#KVG21YY
M>BG&)[/0)V9%G!A@:6A%?&U6>+8<AA6M>\I<^E.PFKI*!@8Z3K&:L\)'@KL\
MDA&-0T:T3!-"8Q:2+/$EB=)$LY0%/O>BT8PJ7^LT%A$)0P7J.PQBPGT=$$9U
M L\+1-+'G7OOBEPOU_+'-K7E&C7-";N,<7.N)\H5/X.LQDS=AZ@["E24!KXB
M7A0#=6?*)YD7:N+S6&0>EYR&HVY_2ID(,RU)''"X)_08R7B4$!$(K7BH?<][
M#-1-+Y+SI^X9J>HHF!R0L8Z9("![/4*C1)%4!Y0HFF69[\DDCK,AA4NJPU2$
MDBB0UH2F*@%O+:-$:"EB&D5I)))'0.'/0'[?"JW*MI29<F$']N3UP9Z6V(ER
MK)/$%=+:K%6=1)H>7EJGP);'BNXL@[;#0:L=KR_%/S\]+VLNY#Q1(>=TY;!)
M,[8M@ :O&6B(5X9.6;G*T=AO^Y0.3V_9U^?>G>)R+/&)B51X5#<V4$V7G-U3
M^$SS,*5!A.B?,B144K"_J4P)52GC7IQP[LMO#9]-XZ9T^L%^5)4H<X.5<Q[D
M5WN$5ZSJ8P#TQU'LK6_OCF]9NI$N"$"^_'-GN:B ,<H]CZ04[%.J=4:XYIS$
M(<UB/TX#04?(L7<EEL,@X<TN_7#C]OB\<<'C9X4+/A@[T9>5%SUV&<]VF6:F
MAV60+.!I%E!!$JX\A,6/2":CB,1*B(BE0:;B;TY&W(%!L&VX-(,+SIM+LN?,
M)757^,@.V3.[J#O:HM93=QYK,6P8Z[:<Y=?72N;PB]5-7?1J2]OV&4PYUC'
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M*-!,(UJ];.4.HH3/F]-4W#"L1W[K++F26(HLBA\.MCW@]JFW-J++X:Q':3Q
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MVJV[NTN_6#Q"?(9E-[PO=5-W#LCIXAHK!\8CW7+TVKMR?B)HRQ_^\N>IN^%
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MX?5\\7<=Q^NO"R&_FYW'*]OXMZN_[!ZL'YY^K&[C ?AQ!W#K2- 31L@>QN(
M3>7/-Y445O[;A1\U\:I?_<17V_(Y!_C*_U[R4C<U&^!(^, I"!C"U% RU?A
M#P1C2FJGI ]AHPFE-P1'%QYPC2*RRF"!EIH!PC7VQE+FN+R.DG=)1NU$2[Z&
MENQ&M.0GNRMX#GPF5_$"PY72WP-_G4%55//&_K#,*60P ZD?"*">,F"B:@&F
MD!;4>.FHN:Z:\6..([L%7 H'*",*F-3&/2 N'"%:8[<_U63'KYHMII9I?=.T
MAECK.(,5$!%'XA1% 6@(18001WW:H5O2C<YWBDK( TF[.B95(-0#;:T'UE ,
MI936"+&W:4U/=CMGQS*MX^M7TS-?77H]:2H?>;>K?O;6GQL_J0@:5!ABW/Y$
MK0K$7^"@FOCFPL<!^>*'ER?;AB3+=U[U-Z)8_3<[G#E_7R]LBT?TG:['5:#I
MP&<3$G!E;#O7]R]GR_J/"_W9=W$(H$-\XU,]_*HOFY<OJC_OS05^NK$WXZ%[
MM)'_X^V'ZJ>W[S^]>?V?[][_]O[7?PRJM^]>G]SJ6=\ZP+P,<#O [\;3>-)T
M7*4NW*F$K%W ]TL]TJ,(0</JXS1^L+:QV8/-X*.^3_7PJ7&,X:<_]X '\E!"
M4;U,L.[\])"G]30^O]TYVJ^LG<RBTB3Z\#YRC4GU6ZU-/:RGM<],:^[^4FMZ
MY.HO6[R!>TW9);F>1XH7+0DP#U1C#QQ$D5NG0(Z2 0%BC=688"3EYI8BWQ'-
M^5)/3C_:,^]F0_\^S"6V(J9(KUO1K7ST*06V/\7;_30<VW^^J'QDV!=):>*I
MN_( =PCH/AAXCB2@NZHUXU9KAE=CGR3=U,VT&H>6O8?Q<#C^6H\^GQXD&2\X
MM$:=J[^T2:-MA<EZ-ATO$G/I(9/(X<OV<##4E^/9--[BFW<ON]N)=A#GQ\=I
M,-07C3]M_(6>1-JR&)\VW=Q=^L6V^NTO=5.W,^_R='&-'57<W5TY/T'XAS2R
MN]*7W7'HA#-VI^/@78XB)YCR_B[7]\,13.]YN5OJZN5#R^J?IC^(S$%_-SG:
M(54S/4ZE6?^"N4^AV5-+)LHA?=M&!/=8DW2GM8R+B;XG<>[-E>]U3JQ&-3/0
MV?LN5<M]6N2CY@4V"VP6V'PLV,0%-I\%;*;\7P:Z6N"R&-YB>(OA?5:&%V6@
MJ\7P%C^E^"D%+@\5+I\ZO)>[W3LT&/RQ'E73L_&LT2/7/*27XS.3<S[Z6/K;
M'WFIPM_JH6^FXY&O+O1E2D5GT#BR-%_8?U//0]KZXWA;*O3<BC5_I7JH$ [0
M N_899!1KI$A0*@  16* FVP C(X$FBP1$ORD&9,J6AP:?M_[TS__1HC_(^?
MC)UNSI*1^H8AHB^S[2V:F=TZ&K H0)ZO; Y)(0J0%R _-B"G5%.,# /&)2"W
M! '-E0*!0"XA99IQ])".1_T!^;45M(H-((0%RW/&\D?OVEW",_NU*>_\-'7C
M3A\V9WI2CSZWRT>F$UV/O,L@HEHHWOYS3\5.9I3P*PPM7VNZH^]U@,*CMI&/
M5H 2YX!DP0'.F<'$"8;=QBXPWQMJ^;VUX1^C"?>OSN.835\OK'@_[2@)$P/!
M>]W5I5BA [9"!9;W+YM#4HCCC;P\.UP_0%R^2AP4Y<P&K4KIQY''%A9=*B;C
M2SU<[>=2,D9'Q5M*V/4 !OW@:4<))RPJ-[0C$#(-G+ 64*\%D(YJ8(TS&'IM
MO-KH$'R?;;3FYOO#PGJ_GDTFOJ\]8N& 4E%R/\4(%53.1#9%(3)2B(+*AX;*
M E%)!7< 21A2LW(&I"(!&(0IIAXAAG1/6[T_&BHS.> BWYW;BQ$J%1G''S7Y
MX!NO)_:L;>[I_!<_'+<;RRWW:<H@5EWX6LG^Y&\J2_*F\+7=9;,>&D,8!M*2
M%$5Q&!@F%<!2:6D%#1H^:#/R5)2Q,.6O1N[G*T/^9F['^V1N5 ZD[+66MIBC
M S9'!9_W+YNB$!DI1,'G0\-GB"02@2@@5,):11W02!- G#=8!:NAV5B?^KW+
M6IX.G[$<0+%['\1BCC(P1Z4>Y<@C*[_KR\EX.&P#*Q,_;#?KZB&H4I)@^9*V
M$G\^@$$OI.WP;.F.S:N=Q9&W!: ))I& 60\4]0&(2(0@U=#['E:Z=%8\<K8/
MG0U_)+X6V6+)A!5+5* Y$]D4A<A((0HT'QHT"QF!65,**,,*4.<"4$(D:#8,
M$48T%N*A\92G@68U$*S74$JQ1 <02BE%*CG9F,72GGIDQ^>^FNIOI2[E2'E:
M"30?P* 7GG9X-G0[3\->6ZFX!]9: ZB7%&BD+) \(&ZAQ8AM\+0'K.YYVQKP
M3\E^][J^)\Y=+$N^JYBA@LN9R*8H1$8*47#YT'!9>RFU%3PBJX: (H&!@@$"
M;[B 2# GU$9JXP'K>QX)E_D HUZ7W18K= "QDU*&DI-]>?/-^J:I0GSF9K$I
M3M1MYR?5YXD>32O]>>)]JD0K52G'2=U*P/D !KU0M\,SK3M27\Y(%;P$2$0&
M1@T*P-C  *30(R*"M.Q!#5-2ZJLSZK\DFS[OD?_W9-%_30;]U=*>]TGEQ("S
MLE:[6*4"T[G(IBA$1@I18/K08)HP;0P5"%AE#*#(<B"Q-D!+1Y$*P@:ZL2+W
M>RM4GAZFT4!B5F Z9ZM4JE6./.+R_L)/]#3M;3/TNO'5L-:F'M:I?=*@LIVR
M9Y 4*!QN_PF;8BU+EJQPN'MS..0-U(2FM!CD@!*/@1($ RB<)41Q8O5&%[S[
M5*\L+?IOR:#_-K?GE[VV5!D@4E)EQ105;,Y%-D4A,E*(@LV'ALT&<Z5UD$ &
MB@"E$9:-IP$@AJ31Q&*O8!\5+$^ S62@<,'FK$U1*6,Y]J#*],Q/VKV#?=-$
M]=-=8Y6T>_!LV 9;2F^5HZ9O)1!] (->Z-OA6=;M]$T29;@P%)" +*"1? 'M
M+0=::Z^]Y 8+WN/"H-]7#/LOOM\JY$C?9-G\IYBB@LVYR*8H1$8*4;#YT+"9
M0"D<I 9 X16@T@>@&>; <"IT4#K^E#TN#GI,;,8#H5#!YIQ-4:E7>1:A%3WO
ML5+V_3EJJM9KZ-G$H_WD:KC8Q;1JQL/:5>LS/#,=/1KAW$+I[BJ>_'6L4+]%
M5HTPPJ3VP.%  +6$ D,I Q8J+R"B+)@-ZG>OBI>$"7/^]]M5_6*OI<J1^Z%>
MN=]3VK;5FT6Y%R-7V$%A!X4=Y"2<P@Z>&SOPGDN$4Q6L$1Y0CB!0WC'@H!'!
M<V*$0[W4W#P!.T@Q'%K8P5$9N4>OTED=6=Q=K;_HTGR8TW N+IZ!) _0>'T:
M3U/YSCS@E,IXQFT(:F6A5 9YD<(O]Y^S^@X;C$]P,L)N/$L-CK)FF/=0V2?4
MSG_/0/>^6\+Y*VHAJ7.2RA2"U%,+4#"1I"(I@)8J3I34<%CKX#"S/586K?#3
M5R/7,M>5CWK:#EL-H.IU/^RG-92%KN[;X!6RL7_9%+)1R$8A&\=%-HS%$'%!
M@,$L ,HM!=(I!A@*E#C+K1 /ZO+S]&0#$SZ(#U'(QI&1C=786/P]-8OZZT+(
M[V;G\<HV_NWJ+SL^C:?N',4?;AQ$^1B#N%^JD 8C#LH6B>+[W'=I7>9#/C<N
MT <DF4! >68 55P J8D!RCIG92 J_KMN7((W!"M' =<HU6X&&[T?S0#A&GMC
M*7-<7C<NK\?GY_6T[146K<KK>+UZ]-F/;#0I/]>-'8Z;V<1_BO?X:3BV_WQ1
M^6A6+M(LB":INW\]BL;IU?2N#_U?*+[QROAM3"=7-Q=#?7D:AO[;IC[^]ZR9
MUN%R(:#V*-!,]63ZLITP($Z-\^;4Z,8/ZY'?.KVN1$U/&!$_[",,:L9#]TAS
M=FU$E\-9C])X@'94;[SO=06]8<0W!O+%7]7)0E569+S^# <^O"_^NJ(S;81Y
M36NJI:GH[&G[\W[&DV?"V9]FM+OSTT.>UM/X_';G^+>K\:M76WO+;QWI-#O)
MD8SU8^=/SGR<S^?Q)2ZK,]U47_2D'L^::GRM\9R>3'2<\IT21$I9C4.HK6_U
M8:@C4=/3\>2R:E^DJ2)VI$U4JWI4O8[#%8\?U7I0O9_XS^/1H/I;W33CV:0>
MM*=__%I/_\=/ANGW^.M9BS*)BL[T<'[W^##UV#6IH+B>I(?2T^63NGBGIIJ>
MQ7'_?+;4QCY)V"[(Q@H);B+<>>D 93JR_ BZ\<(P($J58GIC6>/W0';J^ME.
M_5=78__Z:FC>I+'0B:^_&;DX)O_P>G+X\Q%#0I;Z?9V;;HKV -_PY"GG*'5"
M:^8L\-I'AB:YBW/4*6 0(L9R[+G:J.*X#ZW\S3>-]^O]4]Y?I,GY:?SF6WQS
M=_A3,YK*U($SO5I33?R_9O7$5^?QZ[/AY<).Z<O.0D[/HH4ZUY>5\54S,__M
M[;2:CJ.Y&R6C5H_LI+O,W&R-9_'KL_G%JZF?G)]4KZ-+K*,!G=O?)?I5T;,?
MI^X57VKGV[,6]KLUGNF#<3ORZ883/XHOF>RU=JZ>=LTN%M8T695D3,-D?/Y8
MDW+U<J#Q%M3?P%GM(DR?_O)?W!,3N+% ^+0PW%$+)'("($$D#T([;N018.QX
MY)<F;>T_!_Y>:8(]H2T3@4FAJ0(,AI#V%XU^IU$,&".\$Q2B@#;V%\5<6FRY
M!=A3'CU4'X TA +)+/%IC2.W^"ZV[$/2(SW\%#5S+:*6IO2IFTU27*OQH\.?
MJZ'^XJO+2"6:(T?AXWZ]J@.K23=MYX 0H2,BUF@\;5L=1?28=!0]0<;$GT>P
MN>+["8.JV6B8]ONJIU6=$$\W$3Y,!#L[AZ86Y=81:#B,)-U/;-TDX+-GBUN?
M;!O8+$>N#^]R2VCP>;J7;T?5>SL=&S^I,,1HL#9;VGQ7.P43-:H24VE2;'^-
M[]SN;,:)N' HNQDYGX47B9_%+W_VUI_/GT ..I8T&E\G22=5NY]"O$*<ZU>/
M<>5ZK3][/"A^5D^'\?GC)>+KIOWOZO/$R[KGUL/A^*L>Q<<>AVIVD8[Z]\=
MRP.<%3LVN[)6T[0QJ;4D^AV!$2 I0B!^9)7%'EN[L=D59Q3BH"3@@4=\1R@
M)94%SBO/*/.&2KWJ3W]JY?3V2DRO%E)Z]3G.N,]ZZG=FUOA:9HW=7').3W:W
M"3IPG:[B!89);$?R/A,_;(-528VCACO?1 .\[ @XG<RZ21JU>(%[2R-P-8\*
MP#U;@%O%EYL1[CJT+1WV!'WCKR.?D*[]P,SJH9L'.I&$L'K_U4?^]G$:3YTF
M4/L81RT:EE$D6G;<8N15_"!>0U_$F?DMVJ*ICWRMP,Y-91T,2BZ9 ,)("*CC
M$4*$I$ 33S@+3$F\4=8A$5,>*PZL<3"5@B0O5$;0HA0'AAD)$%UW*]_Y>/:H
M3<:_BEQZ#6::?X7I*KJ\???+S?!"R$ J?K0(,YD/5-7\:Y9\EI!F?9S6-_#
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MH01YZDZA!$='"8*UEAE$ )'8 *HP BI..B!9L$R0 )' ?>1_'H<2X %6O2:
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M6>_Y;G8>/[#S<D^C%:&8(>!3U285P0!)H(Y_0BV(<!HZOU'N:;TP4&)@@L*
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M(X1TGWWAUGGF[_HR04+3SSXO>"!0KYO$';,1.QKD.'@;5( ]%YTHP'XT2E6
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M'N?+*VZ>MXX6:9SJT:RC[VT<H[F(#U2G<'*RN=MTIN0[YOF.P CUA"/@A ^
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M#"A!.-#." N9]<&XQRIA68KYH;4K RRC8([7!UV4KNRRGK9UZ^>IW2X0>K&
MV/F:D:4K.FYM^3+IF[JHK/P1JL2G=MW'M<NO6Q]8AU /Z_CK?/G':+98-/T]
MSQH/[%:5IZ3V4L_K9K577I1<- AQL*;)G1W92;O]BYY67J>.>WKH1TY/VO#7
MHJ?3 ILVFSDE'IA:^RR6E\Q["47/\JIU; J!G7=;Q#QMN%@HJX-S&%"=_&Q%
M)%",>2!A( P*[C39*$$3AAF%C8B>/;> LNBO:T<44 A+J:U@UJYU?GP_?_'.
MR5[PLBXBM(@515*VU?EN-]$Y?,3!XLA][FZSHWG_]ZLYWT1K.UTU#9UOWJE
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M+/.--$&>0%$H0J$(&0][;A0AAW57F0)/;J(JXBGB*5:M6+6B-D4\!YJ-*^M
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M-UW(O"DQ\Z8$S9LN:MZ\B\NFFS[U0/MW]]ZH?>K4TXVC>GT%IAR^Y'J4+6Z
M7Q\9O_[Q_L]Z7!,H<T0X.Q:/KLR&@-" T-4Z-2#TO;W4P$+:H2<!_SS-PYZ6
MKG]=(7UMUT%843OJQ67SQ7 L,9I!OWW\YIPV]F6(;K4%+.F[I@Y<*EPJ9P3R
M0FO$I3;(*H\14X1[ZP+%NSN1>!-U\$PBHVA$7#"&G/,>F<2XLIH[%7QO=>"O
M_K6>KDY>S]O5<MW5%KY='<;EAT,[/ZT0/RO0>;,N?'"I KRK?&XO%GR_?O/[
MS3L%3Z@B$\:NWZ(', TPK4I, YZOQ2?NP X/2 1_ :<"H?#]FQ)+[X,@J6SA
M)Q!GAB.K'4:$$V^(I<%B/1"A\, K+84Y, SD1,URXMX[)5P<V=.S]1=/.AWF
M,IS;DU=@R0$BWU\W*_+KB1=7YIS#4IC?:PN R?JRH" 0*X3)JP6B8-9R*P5*
MSA#$C:;(26T1<XQB*HBR86=IEH]46H4=BC9YQ)732#,LD3,R:T=FJ0C\X03B
MY;T&?C"01"?8J FAND_E!Y &D :!I,?C$^,-)#TZIP*=<*H3(J8F6NF1CR0A
M;@-!5EI:PD.2<BQXH#O]6VO6"0\<3:+J0"O0%#5KBGLO18)HTA#@[^]=L+F>
M9$MEOCDLE0DQ]P$,^N!%X@!1[F?89O.FH%AD43GND(U=QTH1\J?@D-&$$^==
M5"K4+78W+-934(QQ,^%&0C)T#*__OP"RCS6F!DXUQ)C:HW,JD!E;F2&9EIQY
M1"T)B#LBD0Y>(>M(\EP+YK$9DLQXZ HM?4!!E%3]M@@56E4PX;[A[_?%,L4I
MU&B-):S6:_+AMDOL*[/8:(S3_PX(E>K. 0(GA.ENTL\<>TP8#P@GF;4P35D_
MD\21#YP[ER5T9)7KYS-B[#%2IW2]Q6O?O9-&9:!?=Q3B1T)[CZZRYQ$K+G J
M*)>#T-Z]2A-,L/<DD2)($N(^!&1"EAE$2R:IH]@Q-PAILLX*Y('C>AP?Z%[C
M>F,&S]'$]6#;KII0[1O;=M%Z\EV5V7I8LK+7C,?EESMZ0,O;75BL2P<@".55
MX"JW-Q HS0HQ^9JVZ=H1&8U 3+!0VJ8+9+0H/Q)#C)22N)T@&+56.&$=HBS_
MPT/6G#H+5<2<]YY3I7ATM6X%AK^Q?E-*,R&JUQ#8PZ)D]4&PQP*7]8/@(Q8;
ME?G$>&-8C\ZI0%EL-QF56&%9>O5&JQ&W6")+*4,Z6<^49T%X-1!E\< 1+*8.
M.%2F52TG+D:P\N?2B/;7K<5.FU?GG\/T$S3U/1_ NW;$KH5R]XVSI2/V>AM9
MV[S:E.A:UPK[T'Z*S7RQ:ER,&8'G?K8.^:CIO,F@MCUXVK;K$I2;AV:Q7K6K
M_&$Z_W@PGE[9MYA,5TSRQSF;GE\=FIV4";.,S6?;-G^!^J$;!4Y,.@F,B"[+
M_ PMFZ-Z@1*)D3 5H\/B:X'C.*/!,9RU#?6(1RN0H]ZB%#,Y,X<-T_)K@?/J
MZ'BV.(GQ?5Q^FOIXM=XYTRJ=M&D_+%9V=O'O+Q;MZLUB]8^8[\0O/L[S((7S
M,VV^]+7^^5K5G&D9>5'+('&CF%'J %^K90;N0DT^P:Q,B.Q(JS+B><"69\.;
M37\^_OF'=M4LX\P6\%XMSH$\ _,JRX4.TU<+_\]NT-M)8V>S<M[\C/XP(W<3
MOQQ'?_IE%YL+UUEDH=;8_)LC.YUG0&\^G^I59$\;P!YWU6'E=/?AT6<.<JI\
M3OU#A^0-)@KA+ 005Q@CFQA#0D4;DB/,RITDMHV*^A0)BDH9Q+%3R&A#4=1!
M&F]%E,D\F']L:NI^7RQ/?U6.(Y<F.VJC?QK6RY-HE\-G!'J@SQCV:RD[#G\M
M=FH/OBDCOJG.R6Z/JTI%Q%==UNXVGIOOEYM\.LU^,_77MR,O"(8Z[VLNNE?S
MZDOY''N3F@_\7+U(3SF427//;KB9)*Z;))<X,K/<15J;9U++W&C+/:'9=!Z;
M_)U\3,=WY;5F&?^UGK;Y8<H%"_:?$MWDG#4_QGFFP-GLI/M"H8!"D)O##AZ2
M#5U45K,4D,"ZR#_BD5&9%Q.AE,KHM)4[.Z"EZ!@U@2-I269#G7Q6F%DR,FEI
M=)Z+(/5..,P?QK">Q;?I:WK+1+8;"#L/D[7/9[.%[XY^FZXFT7*6]K>3=S,[
M_U!"'A_RK?Z6O_3/)TW,TO"XN,1R?;KAZW2>WS6?KV[[[/^7#']BEQ?TM,C#
M^+E,LBXJE+^Q:HMD6!UV,W C$]OK/"!N8+)\H1. ME,KS<?-'N5%^L53M=-V
MK_'EE*_>OWNW?='/]](5Q-N-G,S_Z4Q;E-\B3_KN(NW3YCMH_LFEP&.8?KK"
M3^X4-]KXR>E,L1?>JVX]6R"R=FJ6;2#R=,;M+C^UZ]5BFSHN-YFGYU/\K#L<
MS>S)8KW*E_@2P[/-Y70WB*?'^Q+,/F[CTS8>VSR#XG9\NO3'YM1/KJKF^Y2A
MV4UGT]7)T^TYKJGIVUQ5J /"Y$]E:*^+;V\.) =,Z%L=AV]S%#[0E/1WN@,F
M3:\W5V1%G3='#@BA=SS=-VI ]?>7@-Y?N3QTX:UL52G8YF[]SPF&!NB/H@'Z
M/Z)=-J_F)05T,<)?CP=#4_1]K:X 9AV.*<$VE=OFC%DI$.NC(-8?7+T$+#HH
M]P;HK=<V +V/#WI)/=X*T O0^UAM ]#[^* 7U^.M +T0.P)3 HL.W#;[R\K4
M;JBAT>//7?7-8MW:>6CKW$:Q2CO7XY"P(]7(:T[_B&VT2W_85<V%^"G.%L>E
M-*Z>I>V5V1@VAZC%$K Y!&P.,;:UDRI:3(T22!J?$"?<((N90;$LFPS)X.#L
MS@:GEC#L$D>:E;I@3@PRB3*D%%>!.>6N6!MV6M-^<:WCQ8+VTU4IURYT9)<6
M.K*;^PFQ"1$,MFVH>=L&8'5@]4HL :P.K#XV5G?2>N*T1H09AK@R#FEA!*))
MQHAY$!J3KUD]!IJ\<10%+K,2$"ED)2 ,2B:+ ")B2IKLD=4YG0C!@=6!U2L>
M=F#U6BP!K ZL/C965XXGJ0Q& @=<&#JSNLIOX#3Z(!()WH6==_64B+;Y91XQ
ME@SB)F+DE V(*,DEYC00&O?(ZH1-I(1W]:I9_=Z;_T)*9L_;@,39;#K_.-GN
MT=&E9FS(AT_+KA^KZ:=83RJU,G,/2_%!P]\Q*\/]UWB"@JP%TZ]6D(3II W.
M"M(2FA6DELB8J!&5EB:-'7&)[6P%GO^8DA?(Y@^(2RV0,\R@D+#E(5(6B-AG
M7$A/##75MID;>J?<T5 9R(IZ; &R F0%R(KQR JM@V8<:T2LDHC'K"T<CQPE
MP2V3F@FE=F6%5=@*G56(]@3E+[O\'2J1B\H9$5G^WSX#4YQ,*+M^O^S*01)D
M125@5]FP@ZP8FJP8C7% %3PV58"5M8Q8C"2Q(3-\(,BP:)#$/D:B9=3<[[3E
M2$9C;#3RDJM2CLJ15I8C*U)T%AMF--UONLHP!:I@5&!W[TN.+H[LZ=GZ2WE=
MW%V87!CEP;T-[QO$/MRX(7@]!1N5^>RP).7#MH"N552.-U;5LZ_=WL*@2RN$
M]*MU*=.*4A,8<B)+4AZD1L9SB@1FA# NO=*ICP8@#ZE+,9U@3:NMH_JF'X$T
MK03Q*AMV4!>@+D!=@+H8CKJ@V!&K(T.)*XZXC+0TSL2(8!,%HRIYQK]6%]Q%
M23WW2&H5$!?,(&<418E(%1BSEH9]J@O-)DK7N_0*Q$4UA ;BHAY;@+@ <0'B
M8ESB(K(@K"$,2>8-XBE$Y+C/0B$K!(.E)5[(K\6%X1K+Q 3B-LL0SGA$UON(
MO.,4:ZV]4VJ/XH*JB<2]%MJ N*A 7%Q,JN7/I<'EKYV1+_89S;\)TT^_[G8_
M+;_-7X;&HA<:BU[3\O5.-GUR=6MDZRVWR0I$ R,9+T)^#Z'*(>Q5E,8KF_P.
MO-PE,OK*+N?3^<?V7=PT0OX0KVY??*G-[<X4"-/V>&9/GJ99_++;W?M_UNUJ
MFDZV@]H=A=J57:Z>=49&V9Q'[=.2Z2L=K:^<$N?F*4W%U4^#[1M_]3R[-*)G
MPSF=E_% W:C>>-VOG>J&$=\9R">_9H?9SN\+1KY\$P,?WR>_OHFKYO7<+XYB
M\_/?%FW[2Y.G?-/-^:M:/ ]0IYQWL-X@>??OE;!=+,]N!FY9R1O#O@<U"ZZ,
MR?,\>::GDV?639[C/'GRST=9#[9E#C73MBM26)<FX^ZDR8,_#5W'\\-XQ=?S
M$>4/FV>( =DL>>S'?.2Z:TNY2)=.WC:+]2J[[[P[8U@OMR?.=S%=A$GS>5JV
M6EYUK<ZGX;2G^<6SE%**)OYK/?V45>%\U1XT+Z>S[E[OZ]':]5&Y@?Z>LCF>
MK4N#]Y/F>%&,,[6S?"OY(::?8A-3BG[3T_VZ1_[&V;/<].M9UR-^.F^R+,]J
MT\Y][,9VTZ8^:]9VO3PY/?51S&,>#IK?%\O3<[3Y,+OJCBT2O=SJ9]MVI^O&
MJ8Q/OOEV6JPS:=S9U-K\(8_(V7AW(YB)NLG?#Q<L]=61=G-D-D >FU.3V]GL
MP@AM1R/Z_,2KZ5>#_'FQGH7F,-NE<3'F^\Q?0MM!/6@^Y'.G17X!^5P.SK=E
MSX;I]&+EZIOGZ/80WIU3Y_=Z:4/P21._^%AJXC;/D;]\?F2P*_O+TXMR]FJ]
M=2>==XW>8BY$&KU"#H>$."8<.>T2$I&1/+4T)W@G5GP7O?7>'\:PGL6WZ6OE
MU2'-\WDX=<P/1:=?K\;V*\>WHOCX[+VB>ZVXJA#.KE>+[:M;@?'\R%GA=(>C
M+"_R;,R(^R7F]\#3YN[=0YQ^(3/"S!ZW\6D;CVU&M3-MV,4F-N=^<E7!X*=I
M.W73V71U\G1[CFO*!C>7%>J R=LUO!=8]MG*7BC>8RO[QW1SYLXW5WU'EUO'
M+4@5+]SD&B!^D4_IEM,S +;S%@UK+008HL9>+=#R;#\]7?X1[;*)><Q"\S+Z
MV(EX1B;UN"MT07N\7=  JBMQ0C $= D%RCSO$DKK<4W@QQ&MT]Z?+>X L]".
M&8#VOH&6U..; +2/$&A!T-;C88"S]X>ST/;^,> L[#4_\M*6-U^7;DQV4_GU
M>'IE]A[6@I5>MS:JS!+C78;2LP?!XI(*0?B:S>%IEEDF*D28E8@KJI&)(B!,
MK'.1XABEZ*,:*5/ IB:V5,3VT_&7B(FN>%^VRL!K-(P![%V/+8;D ,#>P-YC
M8V_/B0N:$T1U+&L]M48:"X),\(1($G7$KH]])^Z!O:F>B'[WEQ@S>(V&,8"]
MZ['%D!P V'LT[#U ]OWYJH6;H$*V*YJ$L:5;'!+::<2-3,BE@!$S)I:U3H;N
M[GYUEPTJ[JA"VCP3\Z>;-Z0P>B*E #DR!C3^Y;:))L@H/0*5 XISD%47]>N8
MVDP%Y@'S *H!JH';@'G&:1Y -4 U<!LPS\"*4?O:Y+?"T,$ 8YC__?4>8;M;
M@IV6I]:SKW-E5J_(71]Z:^#*+#&:01\\A4$V:+N?,'?66&%12HXBSH)"-N9/
M6 F9IP,3PN(^*DJW./Y\ ^-ONIT>WZ9NA[OV[3F8=[O=7<H6;0#_8IH(?Z,!
M,)U(+"=*]EIM"K@T?%RJ;-B!F&NQQ&@&'8AY+,0LK9",X8BLB3(3LU/(!<H1
MMT3H)# 5Q/11+/J Q$S-1&L^,4#,@$M5#SL0<RV6&,V@ S&/A9B]3<9SE9 7
MS"/NE4!:V( P"XP[EAF.D#[J)Q^0F(F9$&$FG-;;011PZ7ZR'2,NE!P@XNQD
M.S;]2TI'C;.6)N<M.Y[6D[2LS/2U"3C(]0\AF0RY?C /H!J@&K@-F&?$Y@%4
M U0#MP'S#"Q2<3F<='&\3\_67_#B8I]"<F'L(9[QG9/D[7$)(K;-:M$<KY?^
MT+;Q4A_6>@+P0(H0Z:THT@L9*,A 79N!2DP&K:Q%--E0,E 8:2DIHH*Y_)!$
M..+[J-E\/??+>)3OQ,Y>=*"]R3T]7ZV64[?N6O5^6&Q[%,?PSIZ4@Y\OEW;^
ML?M>^T-IJ3RO69[?A$)2"J"JXF$'KJ[%$J,9=.#JL7"U$ %+'CR2E"7$N5)(
M8ZXS W/+--5,\9W=MNY2QKEGKF830=B$,PU<#5!5\; #5]=BB=$,.G#U:+C:
M8AH]C2A@+C)79P9V-%"DHHU:)F5PZF5GS(?FZG_'Y2+8]K XQQ>*"7\&+%TS
M2-U[F2<D3X8 4G_$-@."7\6PW?2B7;O_*>6@JT63UJOU,C:?\C'3^<=ZLJ25
M.?"P]-Z8-R$>S:"#WAL>E%ZM]Z(QUO*20F&6(IZ"0Z;D1(0QT6-,3,(_E$?Y
M-%W>3NN]/*WM?]55^[]-Y\C?'?U^ _L?%K]WH/_W#>;_4+Q&L8D6!#90!^RJ
M>-B!O&NQQ&@&'<A[+.1-B2,^90XVQ)0B"$J18ZE\$IF@HTA4_M#^&!63-Q,3
MKGO-M !V#1^[*AMV(.]:+#&:00?R'@MY>X>CTH&A:(E%/$B"7+(84>N"#\P)
MZ_6/9%IJ(N_[S;X < T@^P)+5X8'7!NTN+1R)=]^7#:OCHYGBY,8F_=E!4OS
M;OO7=S,[KZ?LH#)7'I8:A)3V  8=U.#P0/5J-:@BB<$)A9RT&G&J(G+$4,2B
MCRP1$66T#Y"'6=U<<[/%_0[VMZA?0/_'$C%0,0O 5?.P W/78HG1##HP]UB8
M.S)MC50)!9UP9N$8D<W_HAB2%MXK)W!\@"3,PS WE-$"<@%U5V,+<(#Z' "H
M>S#4G:F9*R(8TM&7XD?FD,7"(V:4PH19K'8;?]U#"@:H&Y +5L! #N;*2?(B
M?YIF*)BO9B?-M&W7!3%.%\/44W=0F<<.2_7UFK]V^>BX/!\M<;QJVL5L&IK+
M\[HRBXW&.-]PE-N:!U1DA5A\30!(&1N=-4AER8BXD!PY2?,G:PWQ7"KBPH-M
M17:1+EZ?LL7[4VE8CUI\2,2[>+$\&P#Z0". 1@"-4+&C@$88G4:0&G,LK42)
M.(<XM@EI'"BB6&K%: @4[VB$>]L"K2^-L+/_&64,5 * 'ZB$H=@"5$+%Q@&5
M\-A40O!!2.&R2DA4(1X$1XYSC'RD"3/G'&/IP39?@T@":(0Z%@M!1][*.O*>
M;L6V.&_ /=GTYHVAGCJ,RNP^+"$)Z?P!##H4(@T/2Z\6?IHD$BS7*!FO$7<Q
M(:T=1<0KQARW0H2=M>!W22%MD?SY!LC?K(]<7+Y-+S?8O5%W;\]1_1M"[_6;
MWV\,"!'&)YK@B<&PP >PJ>9A!W*NQ1*C&70@Y[&0,R%!9_,3A#VGF6B91SI(
M@227RHO(@_2TC]S-0Y-SZ56C)H1*(&? IHJ''<BY%DN,9M"!G,="SC+3K%0,
M(^:,1=P(FM^<@T6,\&22H)(%T4?*Y(')F9@)$6;"*0=RKAF;OLY][",?7&&2
M8UB4#14L#VF+//+EK__Y)+\T/:A=ZF?UVDP%Y@'S *H!JH';@'G&:1Y -4 U
M<!LPS\#J(T<<.AA@9/)-7#73N5\<Q>;GV:)M?VF.XW)3)#EIG&VGOA[/K<S:
M%;GI?HO-Z0$MU>9AL2[;NU2]P.8.'OJ SOB7>GSM]A:NGT\AX72:<!*&>*ML
M6;K+(^*4!J2EYT@3P['UGB2L^BC5?&67\^G\8_LN+K>[PTW]I;32G^]?+F8S
MN_ESUN=Y_L5N]<UYGHG>O&#W0)N!K,6YPGE@-4XE,%?9L(.D $D!D@(DQ7 D
M1=)<&^T3LC%D24$L0Y8&@Z36ECE*%)&^CP+3!Y 4_  KD!0@*4!2#,<6("E
M4HQ$4@Q0$OR\G0D@C:YJDAR"9#@$)(EAB"NED98X(D^S7L+&>V)[*>_M2QJU
M>6K^YQ-THT:B!X* 1GJDP/\+[*("6<+=+"'LGC(F!=[K.@M0X-4I\)Y];4P*
M')3KJ7+%1;AR19%(B2..I4(F)8Q(U,YJJ;3A.WOY]9$G/%V1UGNFL->=?1\6
M(*N7K*,A,A 5]=@"1 6("A 5XQ(5S&/&',YZPI"8147T2"O-D35$:L.<(6:G
M864?F<)[$A6FWJUG0%140V0@*NJQ!8@*$!4C$14#% 60*[RQC(I[*2UWB'*1
MA8ZE#MF499)Q).&8A'!\9Q/=/G*%=Q='^\@6@DH:$/3?*EN8/Y?>'->/ZT^/
M3@5E=XE?_&P=[CPJA/[HL)S3WL!9ARAY86S/9N#A68KZV'Z,&Q#)@)N?^:F=
M?;8G[;,GS7_L;5(^W.B[Q2S<V]C__?4?S6^OWWYX]>*_WKS]V]N__F/2O'[S
MXN#B7+_; $L8X$U6?K'*7UHMFA>+>=?JQV8J;WZ?SNW<3^VL>;_*ORBMDMJK
MM%=]S]/\^-38"R'LPFV_K\47&>%43;U9'^6S^/QSF'[Z]?_D?ZZ0U'>ZKS.%
M>GJ)[=)!IVPR5"*.M4>\) <-]A0Y;#QU-!DK91\IP??^,(;U++Y-S^>K:5=:
M,OT4WT>_7DY7T]B^V@Q$^'VY.'JQ.#I>YSF>5>7;]+6R_9#OX[?9PO_S21.S
MA#TN,VFYCM=).'X@&+MO6AU)-="[1?F0$69VTFPME+^R-5&S.K2KYG-<QF:^
MZ.J&.HOE#_DO<5LN=%Y!U&1I[M>SSHYMXZ*WZS:60T^:SXOU+.1?-39?#YU=
MJSNW;?.KQVRV^-P^[0W>[GG@ ."N KCMJT#W)K"]I=.G*'?[U*Y7B^WK6KG)
M[.9/\;/N<#2S)XOU*E_B2\SO?MWE".Y&\?0+OKS+'K?Q:1N/[3(3XG: NL#*
MYMQ/KBI>_#1MIVXZFZY.GF[/<4T)X^:R0A]0+'XJ8WO=:^WI_1U@J6]WW&V.
MP@>*W?*RMSM*/):;(P>$DSN>[ALEK_K[*U[O;YNCK<O?*G:A'^AUYAN8HZM*
M->QIB5C_MK@#^C^T)<[V;2/X@3=NNT-7XBI=ZP%>9'N=%,_;9I&:E]''LC%]
MP\BD'E?][K:ZM4^.>KP=*'0TI@0*K<H2>]OZ%!AT/PQ*,:7U^"9P)@ M "T
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M!-4F&;);=&LTB21X@Y0LZB)%CJR,"868B//!>1)W.J"!4@"E,'P K&S802F
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MM&7.&K03_, =VN]0%%VEJ]V'KG2+6;BO2?&/:)?-JSQFH7D9?3QR<=DP,JG
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MV$ EBP^54+IOXE9 W(!30-R5V 8<HB*' .(>&G%+C3GV5!?^98ACZY&C+**
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MV AD2Y2&.ZJ0]M*B2+R.FEJAS,[^/;W$>/*'%QVH7Q)]6Q+H1_SEV4Q[C?,
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M$FG)%7(RB,BE<I[(!XKL;%$^2\#GIQC?B]#38F*4@@P>8!20=B6V 8>HR"&
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MLD!D@<CZMLAR6A)B5%9549?5'S@@6R*<AG%!B!!1RIWL<7_;,?:S6;2><&9
M93U2I+]5%#1_MGG ?]W.DC?KHWQ2GW\.TT_7C#8_$(S]=.-P$UK)>.\;7)[/
M5H>+]<?#9G48FQ>+H_PT)\VA;4O8L0Q\,^UJJXL;=X><1+ML8A[GT+R,/AZY
MN&P8F3044]HU/<D?\H_357>21?[*\O.T[4ZS[L*9UOOUT7IF5]O0YJ)M\VVW
M^8#NJ'A<0."@^<VV^8@,=^6J]I.=SKK;6;C_B1DF/L4F?IIF:_LXN73KWL[G
MBU7!/3];AUAN9-HV1XME;&;3?\;923XZ&ZP<DS^LNN_.OPZW;MHG-Y^GLUGC
M\K.O9_E[FT;MY28.KB*F =J^>>Y]QKCI_./L9+(S 8Z7BS+"V6+-I]W2V,9^
M+ WK\^CF@;IF  ^:WV\Q:RY?>1G++5U[U3Q!LAWR?%JDYB^@#VY:)VH%"19S
M1!F6B%LBD?%)(L*=5SQP3/A.PC1%QZ@)'$E+#.(Z>63S>1"3ED;GN0A2?ZT/
M=O.C7Z=07V2'^QA?SY\?Y6&]?AL5>4DYB)N5@] 'UPN'H;ME/L$L/\\DNV!^
MW&4^7>,NHF%L5_GW!4 [U+V,U ?-AWS(E;[3E@'NW"<T[@3\Y^8FA#PEFEP6
MD!FP$.=<9GTM"5)&.F*()IS0K_V'NRBIYQY)K0+B@AGDC*(H$:D"8];2\(#^
MTV:9DC_=[$B$'UR_\?E('.DVXH5TXF5++^ ?WVX'$ Q+4F37,,(A[KE#UFJ.
M2*!*4N:T9VHGR,\UEHF58F>#$6<\HBP'(_*.4ZQUZ7RDJN 7Q0^NKV-^1%Z!
M#YKF>5O$UC=D6Q&,1066)@W96O./G:[__]L[\^:VD63!_[^? N&W/6//DC1.
M I3F380LVVUW^]!([NXWL;&A* )%"=,@P(=#$M^GW\PJ@ 0O'10IXLB)Z+$D
M@D AJS+KEUE964#C<3R%Y]RRV$N(V1X^^'8T&%E]M^L.=&"VD:UUV6C$NJZN
MF3HS^[KJK9P,-G289^F.WM5UN-ST@/-PDRW<8NCJCLDLPS&7=>I[T4M?H)-.
MRWVT$^V!8=-X.!/:,^(>"#)0)ED\B="+Q3F$AOB]FUXTS=:';-BU-!.F -6S
MNH-!WX1Q;JM]S70-;[@R;>B>/C0-U>["- U#W'3!+>ESUK6<D6$.[+ZKZBMK
MPWL>XIJF]<Q6C/$D!4]#./7%*.\IGT<B@)*E?@!/]\14 #[YHK7/HR=7/C@M
MD<+O)GZ,/HJR#_68C;8\/%C$R)EF>LP"AO=,O6O:MMT=,-WH<L^R1TP%>SKR
ME@>;IC+#<;Q^MZ\-C*[)=14&F^ITP<BJ!@PVS]&<<BW1S0/M [ZR0)=W*(40
MKOD73+7UCQF"(.Q9['8Y+-L,#2A;=^D8O.2XA2$[<O1!O^NY:/ TAW<'F!;C
MVD-F@LVS;'/EJ"T=_%77 @XP=&L$4&X 6YM#X'%-8Z;AV:.!-Z!QJ[5@W*ZS
MV(^">)CX(B+YG6".-0(H&<&D8S$=O&/#Z8,&NZ#00ZT_')E#<)%7,,>VS9'F
M&7K7T52,'FEJ=VAQ ]QJ-F+#D</[AOO2F*/V-E>_J;NNE"GG)$M2L/4^O%%9
M<3H*M-*]!J6XX3 /*+C ./)!KHNPHT O^!%P$$X5I!?W'8O3MT:>88"':X)*
MF,Y Q:P%UM5@]E(=(#1#6\E:\(P!&^JNT^T/&$9B#;/KV".KRRW#,ZR!Z=C\
M61[N7!L^?_NXH [=A+NH$I@WD/#PU3_"J+':\(#-%UIR<>LGR>+,LN[U*_E^
MY60#RAIXIC1_ Y')X.$/& R@3/ XY<1-$0RT@=.77,%$0%;0 AK&(0_!>,+O
MHS@:/\P88S;%Q7<?V,3'=648?X$_]G'9"VC<Y7'*\%\_=K,Q($_H(N=\N.'X
M1&FU798E7'Y)X&R"7YPW#-NUV@H0QBPQH  C;$KN[.(M\$]1F =.?9EHT%&&
M6:HP<''1,RX:FD8P)RAYP@,F+42W(8^3:W^BN")JC6T0R0DB*\%2?U*B&Y L
M@]]CSKOB"7)RD>MZLS0'^#?@0A;PNA=<VEC#P1P,%DP3/U'8>N2373%?3L0K
M\Z^(M TO @G@.X#'#K>="X.%80;>4%F<PL7'929_Y+LL3(.IZ"Y79@7(9+$I
M>O\SX:5KX1(#T3".7.AF:,'B,)C R\>S"()X<(]T>9<90(^-[\?YL2B;^XK<
M@@?PIP_>@-<?:4@^@#(CX)DA!NL-P]:&?#0PC?Y*8<QM OQ@E4]%!Y719X?K
M8VH+@I\4RW]H-'/--31K,.HZ?9?!D+;4KJ-:6G?@]?M<'>G<Q5#I\V/Y^Q[-
MFM6R]2H<VJM1H@Y:^(G,K@RFZZ/\LULL^ :" ^81_AL&<W:6S/AO6(017SB,
M.M*&P[YAVEU'.)NVX70=%\:G.?"&:%'[WG#E*#'/&0W[ECOH&B9XJ:;K6&!M
MG5%W8''/LFRN>O:(PJC]9H=1<]8&S(/.#'V6TPYZ*"'Z)#CX?2Y\8C'^YV$A
MT)O:>,0++K'GW^Q6&_%!?I@G(4I]U >Z8]O, +7R;-!"K'4X8G:7>?: L9'*
M!D/S4MNTAX*8_O%]B\.W(;J( 8;3+)6Y%;]$PZ2(,^BJ9BM))O8#P*?*;[V+
MGI)<@PM^'04B/!$I8L\!>/HXS<$PO JB(<Q=?IB"[^UCSFP0W7;A0Q%3$/L<
M7O_E/PSS^.?/7WY\%C^]4<!FAS(AL(@Y@-K#JX?X\,3W?)CM,/2 ,O]X<O&N
M*8*_2-EHI/SS+VP\.3[I*#^B"4RLMJDJWZ*>8G7$YH$L%$X\LL7/4K:?Y[+]
M K+](60KZ_-W)'/D\160#3P'XP-H5,?L3Q%@9_.;3J+ =Z<*#_+@!H8 ?-Q/
M(O8(7(483RAO.H ;BXPV/IY$,8NGBN>/X%/<(I+DP0P1D8&OW_ XX1@@$?V,
M5#+*TBR6$1T1CL@W/\QRY'  X3U"^%[,\]TKT?S[LSRZXF(_F6UY68S<H"<M
MWJEH3/$NQ3?A5>5M&8YJ&?R9/3M_5/[7=0];V%2U9(?OW34%@^<!Z^K4Q;H.
MP0 \6R_D][&11WX*[7?OB886E@&-U5F4^"(\MC,0>.'7V4FHO%^7L7*8Z%II
MJ]QBF,U#*YB%,[,@]U/EH7,%+*S8RD&!MH?6&4<C3Q\-C*[K>IB=WG>[ V:9
M7>9H?*@-!BX;[*2V]F^EG@+E?Y<O<=#B.T79=K;1?V@//6Z[W>'0&75-VU6[
MS':TKF&,1I9CJ)[*K%UL]-_G4+:;'R]>C)YURI28QBQ, $5Q+<M%M,5!/UM-
MP5^\^3'SI=45S-L"#([%8 "3CS/%IJEAXWI?1_%'<\KT.LIME 7X>"]S>7GR
M^<M_W(%+-3@&/ 5NEGNL\0$QQ@G!^R$EO2\4/G0U8Z!Y78\-0$G[0U X$Z82
M4QUY7'.=?I_QY\PW&&K<H*"?1^>S/_^!?7LNNO9#T8EPZ3ETX8(>3\#9F2ER
M5R]K\OTE.]3>YIK%-5?DGWI-\=R_"R_Y 4M1FS!EV1N!D<?O1+[%UD[LLT.$
M\P)/-1\FFCTHR5;66_G[]:SF](1=<5D]!]@!WOB(!;=LFAR_4MYN*_QG%[EY
M.=GOQ.?>>-3<YW/EW>?O/SZ<?OKV_<OWG__543Y_.WTXK>5! 3_;ZVZ(@+]%
M(LX8 =N$HFR]0+&/?@C>L\\"Y0(#D4A;%0O2;!^2V;_NK0O(/%3^<=78/D,(
M:\H_/G\^H#B5%.[,;V@( SW@_@QGH721NKHV$U1X9IMRW8J= 2Q-D8,5)JI$
MK:V[$HU&"4_EY@#Y=$RK>)H#)M808IXGF,KEB43D8.(*A6R*+'6%]2NBD V#
M*;B.22)68F8YG&F48OK'/"]W,R2NR^V<%5^*9Y5DX+KT&D2IZ<H8A'^=%(YJ
MS(7G"K+T1/O?<9F.BY_A.E"6BC!F.9VTG'J*J22X$ 2M1?B8U>E:TT5K4Q%1
M4- O&</27?#</'TE?[+\/$GQ'>&.(2ZZH#,4>BS.%X'@9WS*DC^MV4HY(7XU
MH882XUMM1LLK?9Y/FX'N/]/)TU15<]6N9MH.GNGD=)WA<- =>)HQ&K*^,[#5
M790HVQ0X*4Z-/^,A"["JZ4GH?4;^Y4GZ02ZX/FNWT(;".0--9US'_4LZ[YJ,
M]>$-1KS+AKJAZ2-[.-!7-J5O4UBJ6F\],+C;=]@(L^DX9C%KW:&-2<V>YV@#
MT[;Y<+B+<D&'>NNU.\,>_D,C6"LM93&@X2N2%7"&]',9BRER4@B_'!W/9JOG
M(AFU6#U7O"S&"5A"W*Q"%Q8EDBA57C<5Y$"V]AY;Z[J6.V(:%A3"!+P^V,V!
MV?= _[CJP#C7=&UE%6F'"Z+WZM^)Z\89]VAGY@;MRG<?3V?@7M*>#?K%I$C!
M/5E=$5K,1QKY 5PODN=RFLWSM#JXW3/]'QX'>&O\;[9)6KHE/,WB,%FXV]R%
MP2LD2,=\C,HM,!LM A"Y_.2150ENF70*,K'GD-^!0$/I8@VGXD(QC.#%E7-^
MP\.,*Q<\OO%=X:;@#228(ZWG>7O8MG^#=4D\WUW83U8K5E^?L;M5Q&5#_KSN
M,802NSL<(FN-U&'7\3S6-3Q39R-].!B.5L[QV8;/+MQK<(8#_GVTP7J<1T'P
M4;I=/[#4Z0]XWKL@<O]\I?#$91-T6&"X4^;P#O*5Q%P>NCZH>7G=>;Z' RU!
M[AR7 @EX37%*X53H^:9Y76Y-'448'TF.:JEZ%(%=6#12_BYJ]*\[!I1E:50<
MI("-A%%SI!Z+R[L!FT99"H^XX]ZQ?)PCA)A?#\,@8).$'R5\PC (5LA''' B
M;_UJW6FI&!J3 _&HN,>&,U/E4ZU^SS'!0+S:?-Z$O%#KZ?:C+E,?<Q5<YEB[
MNUU/=_36-$ZS]$'I?UO>^H'C=F6^\Y-.V]W5@>S+1^O>=YB(4P5#LYH;OMN5
MGOV>A;V?0]AVWS';G,'VTCT#_8"?_N<K37WU0MWTN$/+9RRQ9J0?J#\/MMR^
MTT&!VUJ5#RL%I"N@O]N>9E_U$5(=E:<IE*90FD+W-87J-(.V8@;%J&<%=)6F
M2S*\9'C)\+;*\&H5T%4RO&1XR?"2X6V5X54KH*MD>"E 1 $BFB[K.EV^^!I+
MU0U?W>;!UV(;4I0E+/22-Q50QYKT<W44\H$)+L\#>M(,I]H=W52A+_67F^%>
M*%^IABEQ/\>XT^R><@JI\@L+,RPY^)Q8PBX[??OY= _#8)L)=;<]^&S6>6K?
MA-$]IK7^&OF"RO>_*Z!1JU-B196*=KL4!VGS@>J./*=KZ/TA'N)J8N5WM^NI
M(S8T')6KHY7=9B]1,\U8J)EV?ZDENV/BHN"&32UDQ'8Z\BLS<]"L7MV^J9-"
MT*Q.LWK39O6^-QIYS!MV.6=JU]14%^9JEW6']M#M>ZIJ:M[*H;H>LT9\R/I=
MWC>TKCGD;G=H&%Y74_LPUYNJYF"-@9>;U<V.8V\NH4A&C&;UZAD@FM6KHA T
MJ].LWK19G8],QS:L?M=51X.NR5RMR^PA[S+=XD:_;^M&?V56=WG?M <PC??[
M#OCJ*G? 5U?M;I\/O:'G#0Q'?VP]G)W,ZGK'UBV:U:L\J^]AF>80B0C5G6@.
M;5U./$]4&)!G-BV4'$C9GSR<G9TD#I06%4@JL-Q*!'CXS!0RGA5*!R* JZZ)
M70]PFJ=R5W4<+&.H=4V@MBZSS'ZW;XQ4=^B.3%-?.6MIMV4<127:Y)PG68"E
M83_&T?@,K?R9."8/JXX54\%VM/<_/(X\EERCFF"!*_-XEZQ'YJK&YHKF[\/W
M#2E$A12"YN^ZS=^F9S--Z^M=U;,P\4'5NP./J5U;=3D?,LMV5TOS[K8@,<W?
M9*YH_J;YFQ3B\ I!\W?=YF_'UKCC:/VN::M&UV3<ZL*[C;KVT%-M9@W=OKIR
MC,)N2^O3_$WFBK;$M&BM11PQ^W*++91N4UW8HY7J&@B]]K!70QOYFLZCN0=:
MF=L?>)XWZAK. "B46V[7L=1^UW*MP<BU3-UC^AX7C=[SO4/K4HJ01GMY&I'D
M^)P]^L0QQ#'$,<0QM9J_B6/NXQC;Z1LZ4P==1[/LK@E(TW54:]3U>%\U1GV-
M:\8^3_-\>8[I$\<0QQ#'-&9*K9-&-4;HQ#'$,=7B&,OR',-EN)E*'W7-OL.[
M0\O2NS;O&X,A]]BPO\(Q.UQ$?'F.L1R'0*;1($,[OAJ^"OF8'5]N%L=PM5B"
MK$!V#1'OX3.?[C6]CZT'7S'M;4SG[+Y<?T5UC,BS.&6>69;F]'G7''# 3\?P
MNH"3PZYM6ESU1J;I63LY9?Y)Z6NG<MK8$WL:'5W?*7V^I E</0R!;"%!!$$$
M041E.H<@HFT08:J:.]!'6-?/12#@6G>@JEY7=2S#T UOX'GLQ?>P[1<B]$Y?
MW6DE08*(-ME"@HC#]PU!1(4[AR"B;1"A#TQCI-EV5\/B_^9(5;N..\2Z-D@1
M1M^TG)5"-GO?2+=OB+!-E2"B4;:0=M\U?-WK$0=2O><N'P]YK!AT)%4S67.G
M"0>+AE;OZ6AIO2@;!KS:M%GMU(0*%<1^? ]77U$)6'-@'=I]S3)LK3O2L RV
M88ZZ0QO^S]6& Y=;EC,:K42]X -[J#IZ=S@:Z%US: ZZCCEPNMJ0VZ,ATUR-
M&R]9.EM3.WVCNJE8#^H-0>BA+1S1Q>'[ANB"Z(+HHEETT==LKAN:W355DV.2
MC=EU$#%TW;,-VS7[UFI=9SI$D^"BEA,8P45U^X;@@N""X*)9<#%P^S;0A-FU
M1RIF_;)1E]FFWM7ZW-0--G+TP0I<T%F>!!<ONWP&/S.0US^*3OZ6C>'.+OSN
M^3<;_@I?W2C%GUY>B(=%@^V%H>G/E<9\"JCY>I_FJ$LBO9XMZD[8%9=& APM
M>-TC%MRR:7+\2GE+(W$W(W%'PA 3'TA@?#FX=*]9>,632S^\]/R$7<6<CZ$M
MR>6MGUY?,M=]@4$[C )O;^+_#.^I#'K*J7Q1W(G)0D]Y7WY9Y0]X6>7$=:-L
MW=;\VKUSF#)\*T <\4XA9O"(M_[HARQT?1;@^[M!E&0Q[SUF:)H]RS#N'YS]
MBK@FA[:1WZ+P<3)]>.)Q=J[O[!(;&D=!<CF)(Y=[, "29JCX">AX_FY*([08
M%?9LUDF]=>]4O48K.QGYM;$E.Y&E_#XV\LA/H?WN1NE^N&%!QH3S&HU*-GP^
M\C<,&K+M.QG=W[-8@8N!=)$;.@I"DJPNS]#Q]2>R;[ 3DFS"XQL_R?LJ@F^>
M7OM\I'RXXVZ6^C=<^3X:^2Z/Q>7SS^=S=/YY1[EF<#67?<_EM=Z\[]URW\^M
MNO*:)8K'1WX(7P'J.<\"^*-FL*YFO>9OQ-6:Y<G?WBC0#= 4?)</=Q(* 1Y2
M!>X!K<<_<VRE_'$B4H#AP>#OP\V'4_BKGR@G89A!L\_Y)(I3I(^/T!N*IG9_
M[2GO6((MQUK\+"W>!633>8YDI&#@_=T@\S#W$.[=V5&3.X\5\RW<4.&C$7=%
MT],(/[SQ/:Y@#G44HML.;8)[0..Y?'\_E,$<'!RW\&F,%_]WYF/3X ;Y4SEV
M6RR:ELCOP;4C'VX7@=>5#<=^NJG;X-4PVA2#5#JRL4F"/R;9&#050U =\1[R
M[O!4',GY20DI:$8NKT1))MSU1[X<0A<?3I58#"/\+KY"(F\C&I=D[O7"FT$C
MP('(QED@ABU>Z$;C<1;ZKO@#O&FTI%"^Z$K$U8>&Q49E@>YG$WCE2>S#4SKX
M%!8$T:UXKV J@FJ)*,T2\RL6BX?-A#_O[Y[R==8N91:YR_N!A=--XZ&CA!&\
M4IKB\(2GWO(@@&<F8 5S&40@6WS_CN*",2P&2Q1"V]:.&!C!S(6WO<&60@?Y
ML1(-_RV'6R[_N0B5D&-?0Q_#[4 .@8\^#XR??V?>E;@ ^K%0/WD_>),D[>8Y
MN]"$0/1><NU/\-&3*$E\;-"&]ZT6ZC9NQI\/0GG@T. X*5FKSQA7"F'TY_._
M\AW,6TDIY)70S\0!.^6 DFD0EC:9@,((+<$"4#S!6*T/&I2[W6/F@TONA^)W
M#VP-J#_H8=YWN6(I.#6!>2_Z+B[Z[MZ)?+1IYG[34Y!6'O\4/YF;J?DMGX@Q
MFR;JAV;%N2G&AX(-\MG0#_QTB@]=UUHYZ^"Q/AS8:X;$\)9B6XZ87^;?@PY)
M\U"/Z*"[7"B3+ ;[ED>%7)PO16L$UEV!08QAYICB)WPB9K!Y- 5F%[CU!'H"
MV(:[+$N$H49+ZX?77%3Z"GR8H:4Q[3RA(\9L"G-(BJ]V@[>!!GL\!7NOC/UD
M_B8]Y21((C&[B\D 9S2<*F!JX@MNPHQ-0I@8L"=&68I 4TSQ2!] $W@3_%1T
M@)_\*6>ZF=7'5@UA&ASCR)T-XN'\U=UY@ V^).NAP7MC032\$=[6XQARD_TT
MAJEI+FS1E=!Q+DY7\)427^&#\?VQ B,\<E<NS?.C^LVS9:"/@A,E/"\,FUSW
M'S^*AW/@!ZL8LS&_C>(_H2TIJB!TN4!P]%S'H"6I'!87:$>C&+__/;YB0%QL
M-K#QXA]@/+Q;&!#B6XFP2J_EQ.@>GWZ_^"Y_]H[?X#!<GAV+(_OP[U<"P92/
MLX:]AH^,^>]O2BX+OK@43>[U+?L<3Q3-+=CSN<,@W972-JF.HJNZ3N-\Q^/\
MQ_/']#7TU9!SF"O 1TFE&_DA#I-4^0L;3XZ5?X% KI0O7\Z0RA7LHPD7'87S
MFY^DPO6<9, &;GDN&?GQ6/@MPKA[^8EU@/GH121R!LE;H>#4XH/7#-($;XO?
M@21Q9.+SLA!L<B"=M6@"M(%#-]R%+C\T1)\=DMQSU^\F*$D^R@;QEI;6=NJ0
M-"=,O*/Q_?@N.8<)W?-G"'@&*.E'60(P>UY$?+XR9"KHDS\X^Q/M OF(.S4Z
M)Q@%DA*^S24LC/R2)Z=H^K"K;W#B.B*&)KX"9!RZ4\'3 ,]#T*BB<V>?^ESX
M&4\P[")D5^ YN 'B:24'309_I",F U_SERH[(]+Q$*'4*)]8_/%Z_^O6#P+A
MW@QYX>'@?%7X.)*X6!&L XKT=[:*02A4+)@*%RV47J-TP! (EGQI_-/:+F2Y
MH^G)<M<P9@$\8@QX(NUXRB]9R!5#E9 @<-G'+I)DPE;5 L?LDX"D)Q,V,.Y2
M<EJ%DS@N*88@GP1&DJ J<"E1"LDU$_X%&R-^X7>' N>3-&;^8NQ#:*HO(!UZ
M,6##*!?.+'-$D8$&\<(#\;YJ[O%R\8OR\\6ORDEQ=0<>E=XB/^:.SP2==93C
MSP&[B\ 0!X%PL'_[5?F"L8,\8"P^O8#?KW\-H(G*.Q_&U!7F62;*1>^DI[P&
M'?!O?"^3X0H19P\"27PBJCSB<;ZT 'T';7K368J\*SA!P" J)+^\OH$*.XL.
M8; $OQORW+>_C;+ @\X7ZR0Q#_@-"Q<7.;!-?_+I+ HMHP[1,)4RQX^A+<$4
M*TCDP8)2$%^!._) 1*/C/'K?6343<_&&4=B=#YL)CQ,<[4$>-(H2WC)PI03&
M>0*C1@F,=4ZE;<@,O+QDL-GK7IA,%Q8EEV)0<B5/FN\Y,.+]X&&2LM;-O>N>
M0KRUV][^&.$"=+&Z4<"0NP JCZ:BY*$XS2I^2; 3 R N.8;Y-IA)P.0$[8\G
M@1A:Q9 2GP TP =QA+D-UZ5E8+%0+*%B+_2UCI]DU,N?CWO4GD*V\G62HZ71
M"V14#)U\M.&H$N/7_NEXQ7QY?@*O/3T:!?QNU:W]=P9O-)H6?2NN H\<Z/=8
MC-@NIEDF1QC\1E1;.[[GH\3H&:A#31OP"S*="=0/42)=(==[G[ML(^Z1>5F4
MYD S54LU^P-'LRP0*\Y<=Z@#L[FK-!066U5[D;_ZQQ^8[G2-*VKE+!NAWW.6
M+U9-!3;[13!8(''YLD=S],K2]SJK5#(4,]]@F"5^;N1F3D+OQ=)V5[MB/] N
MMV856['($)$A:H<AFD4*\NQ!=R$_[I'^O3 7(BB!YB8/+D@"04Y)^=Q\S8(I
M\QPI$4T008%Y2J%X:OYW_.(,N3 /93S)$Q;BHN:MS&0 ].'7\'2, GF1FR&(
M2+N:9)-YRL9JEE8IU%&T?YYP5WJ#PB9CJF3,W&GQ2H*$@JEL2&N,)/D:SQ3L
M^_DP&X'[D%[/@K,PKF8>09*YF"8ZRC!@6 S'G T0VN$.12+I%#6Q\#7GKN:J
MOS);'2]\#.[UE!\;+O4P31;\"H!V$<G#0*CP"9)Y3G*>C[PQC4M^B-OEQ:&*
M>?1Y99D: [)X.3YCDB^$Y<E/Y.GN/LD"K+1(RQ]*@BSGA3TMZT!FUKCBW$Q/
M\>2X%HL2<ESG7;^X]K#:^^(VQ1#$\+C(A<#T:QP3<2DA<:H$_I\83DZCU2]T
MGKA$4>75U+J&#Y\=2WVY./9>-]D5"> CY7,IQ^A\GF-T)G.,2KM_/_KQF$*X
M.S5U,NYU<0TVY!IZ&[SC&<N]BUCLR2UZ +1I% O>_-V/<>TNY>YUB"MXTP[T
MG]NR+*J])%&UUJ#5*J-LXZ[*>;(B;6@YF-,NH*U(;-U@JN;>[;.31SOS#'$W
M]@5LS3?.2/A_4OZV#SY\L;%S%UGE(AU\EK?^1GDM;OO]XONLN6]ZT$)!A7FV
M;6>3V/(ORQC%F]EV(&10S*4(@KF+E.>T))U2AO@N9;WR%N0"[5Z56)!$"_K4
M6;?!2&RO2@$9@!5F8S$GMR(YJ$1P: D3?(&<+E[_%@I5O4"G.($!>G9Z\OW=
MFTZQ2C??!S5D@7@JZ!5/ET-FF\:,8!GX0>L46[+$O19N7/+',5],[&N50;1[
M+EL,J?FAR'AZ'41) FV_[XM)&KE_YJ15&"(%-^ZF><X32\ I#*+;?),7<Z^+
M=TVO<=\1!@F2(JJ0;PC?X#5V9BA7O'@(6IW,-J3GV?BRF1_Y,,XP4*([XMO&
M+"_?VY27+](MH[!E[->R#/I-PGR'V6IBC.;D0S"S\YT^*PL"XWNW[)9WZ&XU
M\>;)L.+0J]E6L5D:Q/+VFR?LRBUR'7*SA9.(>#/\<$>;P^5.X9E(9+JW+[:*
MYH8,S=C2EJ(5 6^Q-5!LK,,9LJ?\(:M@L W;H\H;J&:3IYCP9.[H4@&-(5_8
M?76[)ENXF/XV3,R_]2YZRHA[N 48AIN; 2[AWM2 W9:6;+"^@BLRY>=E,:"E
M6; (F!?S[^,5LPS_$F\6MQ3O1$RV>R;#/<F96Y3/$:/N\5 F.D7Y(5(>YI_F
M(VY6FF662 5L@0MV<HR()V&I$Y'LO'[[.QM&&=SBFB,7;&6 <$_IW*_8Z%8T
M"SA(!9Y6NJH8]?F4(D>DG+[D<K,8VV*9Y0ES5">?\6;5&V;% ];EF_([L./@
M(13+C&)Q?+$>C4P?*-7*69B5-\ZA"S[N;"L[MJ93ULK9OJ=(*%LY.RK)MW8G
MOB=FFOD2:#[[NG[L9F.4DHN%'_[ 5:[ YS=\O@U<RC@O=K&TG6HX []2U*!9
M*DF;$9ZR&4&GS0@'W(Q WJA(&,EWN>40^F5>M$8N,%) _C"[A]WM'2RQC3>O
M^C=/QGNI&DPO57;I>2*2$)04R<]%[:&EXHYB6G^MO4%X$/B>>X\"M7E8U.>3
MM1:3O #E(N5['+X8=/+\OI3G.S1'S(_EWLQ >*48I81^2/)=#.(:S V-$G_!
MET2PF0=Q<PD<*Z_U-X^H.[GX!.$TRR*1R#X+"5\3W,R1/JIKG]&)I>J1T!+N
M3XILR3MTW?U4],'BJXIF#[G,NBSJ)JYI LN@9^/R4D\I B2%6UJ:7Y E?OK:
M>$"><VW)=[$+$<7S*I-IOKT:[IZ%16N$(,!KE)W:4;*$BSRD4D\O-:>4TBI[
M/B_+A3MNY1+#'+(E(\^*+JWI+(HL[#J62[7?*E;[K=_K]^T*8O"JQE0#@VN3
M@[)G37Z;O%U?S*NZ4JZB&)4=#DV:9*1,+Z#U6*X)+/XIKB1'<>BSZ@[+&DIX
M90F_4A&&T@$NP\LHOBSM!ZI[]$&>W?*NIWS':&PCSFU1/I>V:S7HU!:*WC3C
M#"@73WIS+V-^"<,4Q!%>_CL#Z/=\MSD&Y;0W.QVG$38%W+3S6<#AH^PVY9=2
MM^5Q@;/<;_P<BO5>_*#2.Y%JJ=MI*?%C1UI.BV+S1;%E]J)%L=U% QZAYSO;
M9">F'#P8Z]+W_;I/*V<GYS\:,9,HGS]_;A"4OMA^Q3E :>KE;.W@DA?'H%R*
M@TZ22S>*)U'=1[N *+CE?/]B9_' ET:H@N@P>6P-=AI&F)6?,30OUO7(=6LE
MWF'R>+ER[2RMN#@R$&T KK#CSI5\U(@/195=+I9:Y4)*^2[S8T_R3+*D6+9)
M_32 &Q2'F)S%T21*6*!HQ6ZW#\%\(7&NCL5!)[,OEH(.)5=APV;D36.^>.9I
MY(FEFG=%F:Y3F3TKTY=!#.Z:%KS'2E/_G:'[<9$W6>N_9F_R')%]M_E;)*L/
MYHD)ZRZ=;PN<-04OW4MS3D0>X.H#\S(8I=K2DSBZF\[7:&?Y@6(G47Y Y5?.
MTSPO\Z*T#6I6;/I,W..BN$?;<@IW'B31M-+,C@N6/$R:$V_5M-YL.F_$3"ZW
M<Q1]1#,WS=PO/W//^;@\%F=V_S6_PTRH6>&J_#9/N8MY?,:FRN]@][-$.9/9
M[/,I)S_T#&<.F@UV/!OHE_D6L.EE=!M"!US[DTM7I@1>BI-SFS$OZ+UBK]I4
M^5Z\*$+':9[^^$Z<$BR/]KP-FS%WY##W=3$]\#S?]UW"+5R#3^%RFE]H?GGY
M^>4IBKDZIM<Z//=/-A]D:87R1\H9;G$L^4G+;@W-/#N>>8S9-%,^F#VYS,M2
M7*9Q,V8>HS<;RN?E%UVPQ8V8;WZ4<O!E_GL15"A5\Z/P(TTRAYAD=AH"*P_G
M8E?#ZFW6SDQE)9%9XH4-.!.G$"0T\>QYXC$O\VTZ++B<[]VY''&>@#,4W_AN
M,R8>LP=C)W_1O-Q6(Z896?65YUO:+D2/<7)=:%;9_ZRR<4W+*&:&<[9X -8%
M+RUR/:FF,<T#E$>V(8_,I#RR&N\J6Y-%=E-WXFA0$MGO#0*)0^2069?\[MH?
M^FER.=L'?#G+ ;A,W.NZ#W:)UQ:N-,L7[>1E0QJA 1AHG5&&<N%><P\K !)?
MMY:OUY5;Z*S[JY(4HR6O=2'5 RX-9"$.G.UDO 2(/$\ FI?U_(B5!36U^ZLL
MF)GD)Z"NG'M*19&>T:&OV1NL^C*O<S33]8149Z>2/I]YF'XB*[KDGN:&6C/S
M<KAB@G%04<Y083Y_5D11[5&U-MXU0!'TM8HPG_1((W8J\I,@6#_X2_,&6/Y(
M))9ZLS(LLFA7'M<IAVG\1;59.1Y@[;/R+"59]5Y4J\=SP$G[7E[[C#<S@J[*
M#J]JEK])186NO#GE$Y99ED;'0ZQS%HL&^N'5D7HL+N\&;!IE*=S^CGO'\E&:
M*H9G_@48% &;)/PHD9709D<IQZ+[Q;U?X?.A ;, TXU?U%$_*KZ?7P17>3.1
MB<?I6D^W'3PE^.]O4V_#11JVZ-XK;+MGZ_K"1?!#O-RR:SEJI7JM-ND!#;D%
MF<C V9$,G^$?UNO(#8]3WV5!/F3D4"J$.AM8U@1P&"W1NN&UR704XT@,+&=O
MD:<7MQVK-N\9*I+;C)*.D#R?M>T[PP-BRN)<IXM[TQ_HB<W*HXBGZ);5*?Z#
M3@"!55VG'I@S=MI_*U/&R_8?V;\7UM?W/'%C7QSJOJ[3[YD;K9YMO>SD./8]
M+^"/[O)^%8!NU5NKKW*B<27A'TCX-/@WRO\>(Y5[=2]HI%!)MIVD:GV4]Y[#
M/49/JX7AJT@<8;\)#ZT4/U.N8SX"TY*FD^3H[=O;V]M>PMW>573S]B1VK_T;
MGKSEWA6+WWHL96]55=5LM6\:FOA1&QB:;FD#O>^8?>NMY^AJ7]4\?F=HO>MT
M_"P-15_F"3HJ7L[#FO8B]'DD#C4*_)#O+U@[EB>(RFT*(H#JB9T,,K^-RX2V
M(JFN5-Z].'_N]4+*'<90_7 E\RYWYA6P%4OGU\W+PY]F<2Q3YA96"IWNK\KK
MCW[ E6]13X'NZAH#U3'>=/+UQED)[HL/I_BE[VX:X4FH6A\+H6J#-S5,H6/5
M9_UM9]+=X\]6KGF3 )3HG^B_BO(G^F\%_>NU,'Q$_TT5_][H7V\I_;^;BD.B
MG\?Y^N$XG_"9\)GPN1[")WPF?&XS/IL4/"=\;@0^6_; T=YZMF7IF@WX;+8@
M>"[ %8M81>,Q(*DHM;8</-^:H<U[8N5R6WD>D)]GM!<L?='52BQM&$97-XR^
M:FZ$Z0L\XQ;SPQ1#)9PFG":<KJ?P":<)I]N-TQ2-)IRN$TZO96FC;PWT,DNW
M-13].01QS8OL#8Z5<VQEHIS@8>S(O!WD9_P. P*_6J!M_&M>?+0XWCY9.'M"
M;A_\%MU(]-4' GWMIV+ZYE#W'C']*91>CWF-6)Q8G(3??.$3B+<"Q(U:*!Z!
M>%/%_\RXMM4WK8&JPT^&-C#?WOAQ%SC<O-34_J#Y,%[:?"CBVVSBIZ)V"@:X
MGXC'YD8\GE>">DKBQU<&O:?H(NU#5RE.36Q,>%8WX5.<FO"XS7@,=]/^3RU,
M'P%R4\6_L[QIVS8&;SU''3A6'X/53O/Y^'<_5M[Y4<K=ZQ":?C7MX";)GHC)
M*OFY8_ 'N!@/)\-#QSI/Q6;G?FR^Z#HKL6-3U_2'\Z4M2O @<"9PKJ?P"9P)
MG%L.SCJ!,X%S(\%9:T'*M"3D\22(IISG >6S#*3&$@G*3TZ2WIPEO1:4]\/)
M]9A9B(:)ADGXS1<^H7 [4-@@%"84;@(*+R<\:VH+4+C8/8CGQ8Y##!G/LIJ+
MI.8A3V\Y#U?2FC&7V5LXQYS?<3<3T>9H-/)=#G]^$DCCBM0!\YA?ZDR]/=MD
MBJF3%T$@6S/A4TR='(F6.Q(F.1+D2#33D3#:X4B(>GW?9<;VSS$#.O\603]S
MX1SD?Y^[%Z)-RMZS6#!$487-D>6^?U[G[JL+J?8W.0[D.-1,^.0XD./0<L?!
M(L>!'(<Z.0YK]GAJJNH,-"O?XZFIUJ7>'ZC";2A>K@NWA,^ 5MWTB$NZ;;Y/
M@2X%EF*)?1=A7R;K_!8"V*]X&.*O)[<L]G;@93S9R;"6G(R_;KNW]",?QAF+
MIXHNLG]TC;+D"<P)S.LF? +S;<#\Y<T6@?G>P+Q_.##/CPJO !S>$_>K1#\I
M2HUFJ0I!_..C_U;SH__W\'5_4Q2?)0K+ZRT^E[4K5^WPX+,:P7C5>)!@G&"\
MBO(OS!;\RX8!%S]N$M)/]T[%FD[P6\"O8Y5DC2*]GLT)$W;%Y2CNLA&\[A$+
M;MDT.7ZEO'V&\!L82T9AB#%9-"=_ VSI$<O2Z'@(^L]CT4 _O#I2C\7EW8!-
MHRR%V]]Q, _B49HJ))A_ 89,P"8)/TKXA"%T%,*)Q> 0]WZU/)??^ GP1P H
M<U1\?\V,+A^G:SW==GY">:ZS<WF;L$7W7F';/5O7%R[:W:(60F7QGT8>= 6-
MB-JSM_2@=]:WN1]=^>ZMS:K73K6NT6YSO_EN\RQI;NX;RP6N/%FNM+A5.FS@
M6Q1V_YE!-XS\V8K8O5]863][U&>S4Q 6/I[MDU]>8D.G^87# 'T* Y#?4VF_
MDYQ^<OJK*']*C6N'_^!0:EP=G83FB+]P#XJ\MLL6%&9%/I]5EWJ?[Y 7C,K#
M1"+I613X[I3VAM"J5\,9C "8 +B*\B< ;@< #PB "8"K ,"[CX^WX BPM>?Q
M2K06\=PO/ 5+52Y9M:%6U<\\BJ^X<N&R\"J:G;I[DEUE2:KHMHSI/CG^/*A"
M_)E\!_(=FHFOY#N0[U!%^9/OT [?05/)>2#GH9G.@Z:2]_!H[^%3)#:5?XKB
M<%>N@Z96P7<@("<@)R"OA_ )R G(VP[D=%XQ 7E3@5PG('\TD)]=^X%RQL*K
MG>&X3CA..-Y@F]@F'"0<)QPG''\!'*=3D G'FXKC)N'XX^/C/ :>37'[)_1:
MP>0KH/MT*C>)RHG*&VP:VT2%1.5$Y43E+T#E=" S47FMJ'S-<0BJ:NF#?G]V
M'()QJ5DMR%C9!KXO4GX#?S[W7;X<#=>WY.[-YZ45)QK\\TDG&GR+;B1;:ZHX
MT4"E['7R YJ.HN0'D!]01?F3'] 2/X#.4R8_H&E^@'FIF2W8]WH61^-(A+:?
MXP;\D@53Q<B1^\E.P.;8.SD!Y 20$T!.0-6%3TX .0%M=P+H;.2V.@%/M'[5
M]@,T53<'IC/S _J7AFJW_'3DG:7OG(2A\OH$FOI&^=I3/K$PF!8NQ%<V54QY
M"O$.J[-OYT!@6_I/.1&9P+N2[%&YR:=-X%?%J:=-\B?P;@EX'_#L8[)]];%]
MU<1N=6!AHKRNJZKM:-H,NR^UYL?>2P2]BLZ?LC$;)GC&T5?,<#]17H_>_OF6
M%7__% 6>'UXI/X^'G]X(MOXENF9AR)2/L<^]H/N-0?-Y7.#U>^[F,?'^EI"M
M+4'V7^^C:T>]GZXMT0A]D:[O"<Y7PM@J#TVSY :TUQK35%B?J;!-\B<WH"5N
MP+8'N%+\O>[6KR+B7SF 2;.;S_!S< >R_1&S, %ZQG-62W O(M\80I?7+7SV
M,/AW5L\Z53ZCW0K%.[) ^ !/<@$&DKZ;EA5#\QB90)J!2/Q5$C_A=TOPF\X_
MK:#VM4G\>ZQ08S6?XU<8NP.0[?:44R#J*Z[XH7(*U\91(%/@.8P!AC'R=SSD
M<"?E+ #1/#FD;E6AZDQ]PNZ4$4\1>8K(UT+X%)'?QB5X>;-%+L'^7((!C '#
M/)P.2B%7@4TKCQA*C>:J>OH0_>;[$*=1$+!A_KR.\GTB_T6'X8L/EBWACTB1
M?Q?[/GHBB>NCQY# 5\<^NA.OX65O_"A+@JD2LC'\Y9WO_ZS\ #>#37@&HVEV
M[9MR4KTN@=]YNG>R.:V>:F(2]%>3.PGZ"?JK*/]*F2V"_KU!OZX2]!/T$_1+
MZ&]! M "]#^1]4^"<!JPL7)VS:#UKH!X%B1RZ:%@^.]N&LT3]S7[Z1QO$\?O
M<4(DB#_T'-8FCJS<Q-0FX=]CLTRMI];(:!'%WT_Q&E$\9?540?P[J6RI&=K
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M[(I+U>^R$;SN$0MNV30Y?J6\A2O__G88>=-__*^_O[U.Q\$__C]02P,$%
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M?']X*+%%ZPWQ%\O8>>-^YP 7^W88XB#8..=^B$+71X%SEWWT?YV+T'WK3(+
MN04NZMQBBLDC]MZF,I^I]YZF&&)$%CB^1BM,U\C%'_8D)(\^>?O@1P?L@T?O
MCH[?[3DHCHG_D,3X/"*K,SQ'21!_V$O"/Q,4^',?>TRU 0:=E BDU\P6(7WO
M1DD8DTW^M><'$KREV'V[B!X/Q$O^V8S!B\E^O%EC6BH@9XO(XH"]/H#7P'.X
M?_AN_^A=QLFPEGB>CCG'T>'ANX,_KBY34V;$@1]^:?X"HS\^@-</B.*\5-AO
MAL!>E(H/+[VX3"ND_G"0OI1)_98R,.>*F<'S,N P61TU23XZ/,#/,0ZI_Q#@
M?2##A#L?W3^".I"R4U(4:X[H V=F#TO%I_&:- .%-R72A.XO$%K798H7)6+F
M8!J'$SJIV458\=W//_]\P-_N_?H7Q^&.[:_6$8F=U+\O(Y=C;E$H_-K/M+H/
MC_;?'>T?OWO+A.TY86/-4)CD8+M"9.[5JQ"Y;_8M1.:(\/4?5-]M]%RC+U*E
MZ_"_]N&OUJ_67<[XNQ6H[37# +JF:O731]9FP!_FVLA;FFX?;:R6!SB(:?:D
MM0C-M;H?;KFYSWZ8XR]U%OT<HJ'SX+^I4>5KZGIZVB)K=E,[L%]F-LA;Z^*S
M* RCF'\+'F4/UVL_G$?I$_8,6HSW6;-QB^<.;TC?(^*2*,#MS>W!FD1K3&(?
M4[E7Y *6!,\_[+&V?#]KQ_\9H(>WK"G/*&KRRTT9O#Y@+#BX+$J7\<9^#,R7
M\)HZO.G/WC K?-BC3.6!: 5?&^::X*XP&0MEPR5N*S7:&XG*,LP>GG?%S%C\
MT&]'?);36(;714%7O(S%30*-B4\+(F/$('W&WCOPQ_WM1>M@ZB!&SU$8K39I
MH6[9?_Z9S6"R?R>A]S%D!=I<L(:"K'AI]AR?C:#-R;,B9H4LK/WKNT/X'YLN
M23.G_$\4>DXJS9'$_7)0%5(1GU#L3<-?^=_5RB28!4D+8\5"QGQE3VYD$P\S
M4^W8@'<,+)]OG48PZ?0]]M,[00$,1^^6&,=4,I\!L<9X[\!XN1@'9J:%)$>(
M<E)9H^54EBMB"J?1:N7'H$O*ZA)39NR'"\RF\YC"Q-1+ CR=7Z$X(3ZT3]/Y
M=,U'FN'B$K-6Y-)'#W[ 7YWA&/D!/4K-_:)?T/C($:_@1=@$G"0O Z_EI5*
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M>4GJ'(]OV61W*K,I^3;'51[+)7MR>=JB2<C&+D4X(&E;^^M/ Z3$"P 2O$@
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MW%_VCO8F:0S#),]L"%Z8<=X2K&<IB$^4R-"!8\O]B%MOY<%N<M/2!8398F@
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MQE_(#QQN_NM=&IB=YH0UZ>PTDM@@8 TI9WKBIN[  +R6%#(IHF8:,[6#=++
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M""UPPA\?*&AM\3J+D;,!9E.0PBSDNP 2Y8A*0[]X2Z@'E@I''EU=0<\QVQL
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MIJM(#],2$>AH_#JAK?F2\3AU'Y?I)&N@?]Z0)W6:(H%F_UNRDO$P[ONQOFR
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M:8X6\X3\+WE,O\Z)^#)?WJT\_'OQJ[J$T&5P:]@64YQDK@BK6-62^@NLTB\
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M'!:.G^V#HW^(.BQ$O]@+4:=0=EAT?K47G<YQ[\!&%[?>\T:EGO<6V^SD(?7
M6#A@?.@;DP^,F /:*$BX/C!L%JI<0P7[ R-GJ:;1-T\ ,$J6RMB::0> 0;%0
MTI:G-0#&P$)16IA' 7CY-LO*O;(R +\V6"PP:Z9N  ;&8FF9T;Y/N@=@X"P4
MK0=(%0$,FH72-72J"6#$+!6L=6+7@1&Q5&!6#H8'AL-2R5@_[08P+I8*QQUR
M>@ #8Z'$#)X'!!@R"Z7LSIE$@)TW+!2LN^4H <;%0KFZ1P(48' LE9TA$JL
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M,-:;A(LP,ZYG$T#K3L-&J'M?X098=,])36<;:M>]/=N@.BF7R@%(98-;1&Q
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MSKKR#XZUI\U:O8=[VOC=);]*$<1_Q*0:%\T617.DPO)TC2]/$]"2$9C#M9K
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M89%;5G*FEF ]YMY@BOO$9\QW(:-%=J$H[VWQKE9L,AJG1@"]#A7?Y?47!ZO
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MBR(5OOH0TI2+YB'&'TH$^9G+-7Z:1CYR_WK"K'#AD8QSYK75PJ:EXB$T^XQ
M 'ID0#O"B8S"EX3U;'AEF64C,J=LCP2YK %OH"Z?;,G\?:05$)9!":\1<]X
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ML#25U:Q'?QRRX\Z\#9V2S8#7_1+6#/G\'^. IG25N7U!_52XBIL,U>MRSX[
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M&@<+6NV'EYE&ZTH_J?-D7I*':FPR?CM:RUXXE45$*%Z\TPK>,T5WN@5$DQ8
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M!<0C @IE_8%CX(RKT5M/8[%QR( J4=$EO#(Q3<4-O("<OL$"WYY_#P,PKPQ
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M!]D9%.7N&$Z>V\E.V6&< //TW%11Z5\K69H'PW@));3_P#]OU\''R]<GE=6
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M,Y-IE):3I?[43.]G%PMP+:M;?M"N__02P@]8&8LZ1>*5BLA%("+KWF+ZXAD
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ML@'*X%T.3(4593WD>O(!KX78/!4-,C+.0]F#!*CVG-0^2-,N,HS98\^#,D^
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M1;U>H ")AVN[ZM=L1UP8%=!B%?X#W!#Z[881AA*=H'K?W(OI?H7!Z]/4$>U
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M'_7;*REDZ[CS1I#'2J;WQ>L%[ 8SG(<5I*O.'T\M*+4#?OKT^7:6E"V/21
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M\7W;S+NPWGY>J;=_=Y&54OR).;6K(UBJ&5%%)N?^1G''\;J\SZ <#+J9G&3
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MQI]IF_K97,L;:&@EXZ_Z+_,D4IWF7/YL;N[:V"*69 PEZ;ZED:*5W?$(=3]
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MUQL<"/0J,SURQ!<=,IP:@8,P6UF+#7&^D=DO(^DX_MN:<LW/LGP',VO;9VO
MQ'H-O('0VE?<K&*]HPX4G7H6&-M;UN)S-#V8Z[\P)/IM9\K3$HE0[ !0J)T
MV&8#/5LFI@+>^KF4<3%>K50BXUD6= %P30!<,E/;V)K5"L\\5"LBHQ<\^?.@
M_\#*]1_PN4Q\<:S^!D/5QL%J%*02TBIW]&$0DS<R#G7O9]MUP?C<JI$-!??T
MF?[GK3+GZ]1#C/GR6$ 3S>\G*9*IZ0O425+ ^7V=7%V,.ZARTK*%%RY(NBA
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M=.]Q8CI\7V.@U$ 6DFM_*V_+:SE?YX81(VA^#(?V&,H"P0FL?V]<%.<=))^
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M=6#,1$Q&5?YX%@8@%U>5VND#?R;BKX$:4UO'B"GQ_V>FAPTGKU'XYJN4 +[
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MQ".;NQ39R<W38S&@7)2!)V9^*DOD6!Q4O//J^T]H/%;7!BM$PTH5Z)8PGJ;
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MKC!G1\./BPVD9H.^=^7O_75M$;OW.M?\DSJW@XC--D9+PL1MC,)-EW[H+U<
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M>J44&\#W_,5/?R,YDX>E2?IZ;#VVPWCX%JQ:"AL/R2AA7V_?'T*+/:M#SSD
M1[O<994&Z'8%2V%WHT6J>Z^9.0"7,:3 1"$D3T!<G,G2+H-(Y4DYPF,XPC"H
ME<_**!D&@$=;/T.]N8 R\UB\TD=,JO3UC]&CZ\Q*2-7%'U>[F=9T:;S!CK;(
MUTU-I:XBF&LH+" ]KDTW3R\"B.HY5.=<T#?*%+6K_W:N4HV()=6^.!7UZ/&F
M7WU\)(:VP>8C6:NR:RQWMAT[N%-/1/8NJ8+SA3YH]![_3&^/[)9*EMS_9&:J
MK?V9;_?;)-T06:Z"FX.GV.B&8;#]-2KXEQN&3>82QM*KQI*[0MX@BJA%A]:
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M8$".7.JV3N@;L7/.QSQS/9JU2WI 7'?NC.]&915SNVA.;>TQ(T4J%N<%_1_
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M)@3&B^J1S(5,3'6TNK1'54/+.!YZ4>^3S(\@*MD8_-.I [J$[,JP?HGIAHI
M7I)I269IN1\-='MV(P9[6>09Y&O4\)NZ]4!?08F%K"&<'6'O[M(?\>0QG1@
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MO;^F[Q,\RNF[\02U]T!WX5\1>(8B< E\_X58ZG[5&J&&<K98T,P'OF,WY O
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M$)QEB1^"A,;=:*U&FMKE%L1KR+X^Q=%+ND$:M!.RT:.W'NN01-MM%&*C,S:
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M!5"%>[6?]BV'1WP%RKD06 Y3GQN1X[!@.6K2%R+7+<)RD)2O01G_"\LQ4SN
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M3,_=V2%G5#,IT)JS%1PW7@_3HJ2"^R1=J]4J+$Y*,]$G [2>5P:Y2BUU%.M
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M(1Z8E[SEL-W%2 70W2Z/:7 ",J'K<!7%V_R>%*Q&LK>)8K+XH??1>04)<D>
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M^<ZIWUX<M=QRK,;F*\.?*LL#B(RR):VVGS$V:GJ%Z(_K<?LDRM$_N!O@90'
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M,>S0EB.GRM34@@PM!4^)DS'B&RV%1L>)9+\L6IY9L^MA5(Y$M1Q''=>!TJ/
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M535 ]=UB#33\8U_ERZ7<J_;$1Q]B6CMU"UCL3M!I4LNH!BTK+J;2U;0M68L
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M1.SLS<*.FA N1*I<OBKP.Q11:0',:SW8A)!/_AV(_8AVNKC-1Z#",P!O:+"
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M"! F=<+&%8P/KE&6$M<X\C%;U+$<UIZBL:1WG.4@#GGB>:Y]EL=T#W_D*V9
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M3?4>H@&U["  \9<07C-QPBL*S6NMMS1LE5[O_?4F?8S@/R'/XL*I^!K9<$.
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M*[Y]%<5?0C>#QYT8KL]B -41Y<M>=EQ==QM89P%JNV_R)]$%)]=1F[H=9DY
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M8V$*=7OO)3R<*>0E4/-=8LO08W2)S1_<D 79,8;9$R@H@2  F!1(Y%?EI:[
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M!95?M/$H0]ERQ9PH8V&JHPS#PTN=,B?D199NH#K]'VI^<OF^1H0LSBV2PYK
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M^M/Y(<66BD>@Y4$N7 ?"JD.SLM.>Y<#I\>VC5VKN[29G*?94WSD$8<N/S78
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M9.;]06 Y,MAK<9D,PM210X.O538FI6J8/%#3L5]4.=<?Q3Q:L\M[D@;07PZ
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MIIS3=D[63!R]00]\-U[M1-[OOGLX5*ZT(5T_&=E/1GY LG%F1W,,MW]+QM:
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MCB_0KH:)U86AU#5P71<;@J9C.]7E=:=I-Y;7+;?5[  1T6+8=AO=;@4RBNT
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MSD6B5E R,J56H"BYL4B,C8E'^)SDNGP1H5<O7E\X?=>KEZ\]_ M02P,$%
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M 2H/\ _B<%DO71=)A%I: ?V())09@SX!N$L(\@#T0LLI@4D:I RD$BD7G%#
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MBW2[!_A#C">_=0_<#SC^'U!+ P04    " "U@EQ6R:EQC?<&  !R.@  #@
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MYV[7;86UK;#6WB7_.8V6VV3Z=9+IC1D,_/THPH-I),&#N;4N@O'5?'7[U+X
MWS;7;/;]<-T)/DJ9JIJJ,5B7'6!19'N\3#.FZ9ZY:5G7 E#O* 6F0=*,:&I:
MS!1PH2&F-*?Q?^A5-\^K/7#_T#2Z14(6PG0?Q!#.4%)")>61&3%M/7QFI!C^
M/-"(;YN$[JIPTU':*;O#<]MUWP"Q-'55%^KB&MB9IA372,A)3%'M1$AJ]B&)
MK@3;[ONJ VF.X2X")JLN/%->X[@YT)AR*C% W)S=0).A!A."2MSJ][.-Z"4"
M;MW"O[G<>/Q.F71^B5 @EF7UXE@S^22;DIFRUPF]IOF=T:/O>DW[NZ;_ %!+
M 0(4 Q0    ( +6"7%;$F!_P[44! %%6 @ 1              "  0    !I
M;6<V,C8P,C(X,U\P+FIP9U!+ 0(4 Q0    ( +6"7%;$F!_P[44! %%6 @ 1
M              "  1Q& 0!I;6<V,C8P,C(X,U\Q+FIP9U!+ 0(4 Q0    (
M +6"7%;"$?)%/9T! #?[ 0 2              "  3B, @!I;6<V,C8P,C(X
M,U\Q,"YJ<&=02P$"% ,4    " "U@EQ6(2$[06(\  !B3P  $@
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M-C R,C@S7S$U+FIP9U!+ 0(4 Q0    ( +6"7%;,;K+O//T  -<  0 2
M          "  35"!P!I;6<V,C8P,C(X,U\Q-BYJ<&=02P$"% ,4    " "U
M@EQ6.U#I2"S,  #]W0  $@              @ &A/P@ :6UG-C(V,#(R.#-?
M,3<N:G!G4$L! A0#%     @ M8)<5L)\0*L"W@  &>4  !(
M ( !_0L) &EM9S8R-C R,C@S7S$X+FIP9U!+ 0(4 Q0    ( +6"7%8 ='(E
M /L  &#_   2              "  2_J"0!I;6<V,C8P,C(X,U\Q.2YJ<&=0
M2P$"% ,4    " "U@EQ6+3DR# -Y   /B   $0              @ %?Y0H
M:6UG-C(V,#(R.#-?,BYJ<&=02P$"% ,4    " "U@EQ6Q>>]0<7>  !TY
M$@              @ &17@L :6UG-C(V,#(R.#-?,C N:G!G4$L! A0#%
M  @ M8)<5@DD[&_4[@  X?H  !(              ( !ACT, &EM9S8R-C R
M,C@S7S(Q+FIP9U!+ 0(4 Q0    ( +6"7%;*<YSK1:D  #>T   2
M      "  8HL#0!I;6<V,C8P,C(X,U\R,BYJ<&=02P$"% ,4    " "U@EQ6
M2< HD_:R   CNP  $@              @ '_U0T :6UG-C(V,#(R.#-?,C,N
M:G!G4$L! A0#%     @ M8)<5B6*X>HT^ (  J8$ !(              ( !
M)8D. &EM9S8R-C R,C@S7S(T+FIP9U!+ 0(4 Q0    ( +6"7%:=98N(9;0
M )#6   1              "  8F!$0!I;6<V,C8P,C(X,U\S+FIP9U!+ 0(4
M Q0    ( +6"7%;&_:J_$OL  (P6 0 1              "  1TV$@!I;6<V
M,C8P,C(X,U\T+FIP9U!+ 0(4 Q0    ( +6"7%8#^UR+Q<L  %/5   1
M          "  5XQ$P!I;6<V,C8P,C(X,U\U+FIP9U!+ 0(4 Q0    ( +6"
M7%;J<>MW.LP  'S:   1              "  5+]$P!I;6<V,C8P,C(X,U\V
M+FIP9U!+ 0(4 Q0    ( +6"7%9O2EWB,RT! !2> 0 1              "
M ;O)% !I;6<V,C8P,C(X,U\W+FIP9U!+ 0(4 Q0    ( +6"7%;7#!MJ]J0
M $"]   1              "  1WW%0!I;6<V,C8P,C(X,U\X+FIP9U!+ 0(4
M Q0    ( +6"7%85E8V6O)L  &6^   1              "  4*<%@!I;6<V
M,C8P,C(X,U\Y+FIP9U!+ 0(4 Q0    ( +6"7%8&G6;L5%T& %PD4  0
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M2P$"% ,4    " "U@EQ6]]C7_ %3 0#1G@X %               @ &]0!X
M=FER+3(P,C(Q,C,Q7VQA8BYX;6Q02P$"% ,4    " "U@EQ6'-<04R&-  #=
MO0H %               @ 'PDQ\ =FER+3(P,C(Q,C,Q7W!R92YX;6Q02P$"
M% ,4    " "U@EQ6L@\43C$,   LLP  #P              @ %#(2  =FER
M+65X,3!?,3<N:'1M4$L! A0#%     @ M8)<5M*$L;$1#@  4Y\   X
M         ( !H2T@ '9I<BUE>#$P7S@N:'1M4$L! A0#%     @ M8)<5N&)
MS4F( P  2"H   X              ( !WCL@ '9I<BUE>#(Q7S$N:'1M4$L!
M A0#%     @ M8)<5KX<]?L$!   _2    X              ( !DC\@ '9I
M<BUE>#(S7S$N:'1M4$L! A0#%     @ M8)<5D4AE3<C"0  WU$   X
M         ( !PD,@ '9I<BUE>#,Q7S$N:'1M4$L! A0#%     @ M8)<5A,V
M5C<1"0  QU$   X              ( !$4T@ '9I<BUE>#,Q7S(N:'1M4$L!
M A0#%     @ M8)<5LFI<8WW!@  <CH   X              ( !3E8@ '9I
B<BUE>#,R7S$N:'1M4$L%!@     F "8 7PD  '%=(     $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
